BackgroundUsing	O
antibodies	O
to	O
specific	O
protein	O
antigens	O
is	O
the	O
method	O
of	O
choice	O
to	O
assign	O
and	O
identify	O
cell	O
lineage	O
through	O
simultaneous	O
analysis	O
of	O
surface	O
molecules	O
and	O
intracellular	O
markers	O
.	O

Embryonic	O
stem	O
cell	O
research	O
can	O
be	O
benefited	O
from	O
using	O
antibodies	O
specific	O
to	O
transcriptional	O
factors	O
/	O
markers	O
that	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
or	O
critical	O
for	O
cell	O
lineage	O
.	O

ResultsIn	O
this	O
report	O
,	O
we	O
have	O
developed	O
and	O
validated	O
antibodies	O
(	O
either	O
monoclonal	O
or	O
polyclonal	O
)	O
specific	O
to	O
human	B
embryonic	O
stem	O
cell	O
antigens	O
and	O
early	O
differentiation	O
transcriptional	O
factors	O
/	O
markers	O
that	O
are	O
critical	O
for	O
cell	O
differentiation	O
into	O
definite	O
lineage	O
.	O

ConclusionThese	O
antibodies	O
enable	O
stem	O
cell	O
biologists	O
to	O
conveniently	O
identify	O
stem	O
cell	O
characteristics	O
and	O
to	O
quantitatively	O
assess	O
differentiation	O
.	O

Although	O
the	O
stem	O
cell	O
concept	O
was	O
introduced	O
decades	O
ago	O
,	O
to	O
date	O
,	O
stem	O
cells	O
can	O
only	O
be	O
defined	O
functionally	O
,	O
not	O
morphologically	O
or	O
phenotypically	O
.	O

Two	O
functions	O
define	O
stem	O
cells	O
.	O

Firstly	O
,	O
they	O
are	O
self	O
-	O
renewing	O
,	O
thus	O
able	O
to	O
propagate	O
to	O
generate	O
additional	O
stem	O
cells	O
.	O

Secondly	O
they	O
can	O
differentiate	O
into	O
various	O
progenitor	O
cells	O
,	O
which	O
commit	O
to	O
further	O
maturation	O
along	O
a	O
specific	O
lineage	O
.	O

While	O
stem	O
cells	O
can	O
be	O
best	O
defined	O
functionally	O
,	O
a	O
good	O
number	O
of	O
molecular	O
markers	O
have	O
been	O
used	O
to	O
prospectively	O
identify	O
various	O
stem	O
cell	O
populations	O
.	O

Although	O
the	O
functional	O
importance	O
of	O
many	O
of	O
these	O
antigens	O
remains	O
unknown	O
,	O
their	O
unique	O
expression	O
pattern	O
and	O
timing	O
of	O
expression	O
provide	O
a	O
useful	O
tool	O
for	O
scientists	O
to	O
identify	O
as	O
well	O
as	O
isolate	O
stem	O
cells	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESC	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
earliest	O
stem	O
cell	O
population	O
[	O
1,2	O
]	O
.	O

This	O
pluripotent	O
population	O
can	O
differentiate	O
into	O
all	O
somatic	O
tissue	O
including	O
germ	O
cells	O
.	O

In	O
the	O
case	O
of	O
human	B
ESC	O
,	O
they	O
can	O
differentiate	O
into	O
some	O
extra	O
-	O
embryonic	O
derivatives	O
as	O
well	O
.	O

Like	O
mouse	B
ESC	O
,	O
human	B
ES	O
cells	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	B
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
3	O
]	O
.	O

Gene	O
expression	O
of	O
undifferentiated	O
human	B
ES	O
cells	O
has	O
been	O
investigated	O
among	O
several	O
ES	O
cell	O
lines	O
by	O
a	O
variety	O
of	O
techniques	O
.	O

They	O
include	O
comparison	O
with	O
databases	O
,	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
.	O

A	O
list	O
of	O
molecules	O
comprised	O
of	O
known	O
ES	O
-	O
specific	O
or	O
-highly	O
expressed	O
genes	O
and	O
candidates	O
that	O
can	O
serve	O
as	O
markers	O
for	O
human	B
ESCs	O
and	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
has	O
been	O
established	O
[	O
3	O
-	O
11	O
]	O
.	O

For	O
example	O
,	O
pluripotent	O
ESC	O
can	O
be	O
characterized	O
by	O
high	O
level	O
expression	O
of	O
Oct3	O
/	O
4	O
(	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
,	O
Pou5f1	O
)	O
and	O
Nanog	O
,	O
which	O
are	O
a	O
member	O
of	O
POU	O
domain	O
and	O
homeobox	O
transcription	O
factors	O
respectively	O
.	O

A	O
critical	O
amount	O
of	O
Oct3	O
/	O
4	O
and	O
Nanog	O
expression	O
is	O
required	O
to	O
sustain	O
stem	O
-	O
cell	O
pluripotency	O
and	O
both	O
of	O
these	O
markers	O
are	O
downregulated	O
as	O
cells	O
differentiate	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
4	O
-	O
9	O
]	O
.	O

Antibodies	O
to	O
Oct3	O
/	O
4	O
which	O
cross	O
react	O
with	O
human	B
Oct	O
3	O
/	O
4	O
have	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
presence	O
of	O
undifferentiated	O
ESC	O
.	O

No	O
single	O
marker	O
however	O
is	O
sufficient	O
or	O
unique	O
for	O
identifying	O
ESCs	O
.	O

Oct3	O
/	O
4	O
for	O
example	O
is	O
expressed	O
by	O
germ	O
cells	O
and	O
may	O
be	O
expressed	O
by	O
specific	O
populations	O
later	O
in	O
development	O
.	O

Likewise	O
,	O
Nanog	O
has	O
been	O
shown	O
to	O
express	O
in	O
other	O
tissues	O
.	O

We	O
and	O
other	O
have	O
noted	O
however	O
,	O
that	O
while	O
no	O
single	O
marker	O
is	O
sufficient	O
a	O
constellation	O
of	O
positive	O
and	O
negative	O
markers	O
can	O
in	O
concert	O
unambiguously	O
allow	O
one	O
to	O
define	O
the	O
state	O
of	O
ESC	O
cultures	O
and	O
that	O
surface	O
markers	O
in	O
combination	O
can	O
be	O
used	O
to	O
prospectively	O
sort	O
for	O
ESC	O
.	O

Based	O
on	O
published	O
data	O
at	O
the	O
level	O
of	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
a	O
number	O
of	O
candidate	O
marker	O
genes	O
.	O

We	O
have	O
also	O
expressed	O
the	O
recombinant	O
protein	O
and	O
generated	O
a	O
panel	O
of	O
monoclonal	O
or	O
polyclonal	O
antibodies	O
to	O
these	O
proteins	O
.	O

Using	O
these	O
antibodies	O
we	O
have	O
confirmed	O
the	O
specificity	O
and	O
selectivity	O
of	O
these	O
antibodies	O
on	O
several	O
ESC	O
lines	O
and	O
established	O
their	O
utility	O
as	O
stem	O
cells	O
markers	O
.	O

Our	O
results	O
confirm	O
the	O
expression	O
pattern	O
and	O
timing	O
of	O
these	O
cell	O
markers	O
at	O
the	O
protein	O
level	O
,	O
whereas	O
previous	O
data	O
reported	O
at	O
the	O
level	O
of	O
gene	O
expression	O
.	O

Characterization	O
of	O
undifferentiated	O
human	B
ES	O
cells	O
and	O
differentiated	O
EBs	O
by	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
initially	O
selected	O
for	O
their	O
abilities	O
to	O
recognize	O
recombinant	O
proteins	O
in	O
direct	O
ELISAs	O
.	O

A	O
subset	O
were	O
also	O
tested	O
by	O
Western	O
Blot	O
analysis	O
using	O
recombinant	O
proteins	O
and	O
cell	O
lysate	O
to	O
confirm	O
binding	O
to	O
a	O
single	O
epitope	O
.	O

The	O
best	O
clone	O
was	O
later	O
screened	O
for	O
its	O
applications	O
for	O
immunocytochemistry	O
and	O
flow	O
cytometry	O
using	O
various	O
cell	O
lines	O
.	O

Human	B
peripheral	O
blood	O
platelets	O
were	O
used	O
for	O
screening	O
mouse	B
anti	O
-	O
human	B
CD9	O
antibody	O
.	O

MCF-7	O
cells	O
were	O
used	O
for	O
screening	O
mouse	B
anti	O
-	O
human	B
E	O
-	O
Cadherin	O
and	O
PODXL	O
(	O
podocalyxin	O
-	O
like	O
)	O
antibodies	O
.	O

MG-63	O
cells	O
were	O
used	O
for	O
screening	O
mouse	B
anti	O
-	O
human	B
GATA1	O
(	O
GATA	O
binding	O
protein	O
1	O
)	O
antibody	O
.	O

Beta	O
-	O
TC6	O
cells	O
were	O
used	O
for	O
screening	O
for	O
mouse	B
anti	O
-	O
human	B
/	O
mouse	B
PDX-1	O
(	O
pancreatic	O
duodenal	O
homeobox-1	O
)	O
antibody	O
.	O

NTERA-2	O
cells	O
were	O
used	O
for	O
screening	O
mouse	B
anti	O
-	O
human	B
Oct3	O
/	O
4	O
and	O
SOX2	O
(	O
sex	O
-	O
determining	O
region	O
Y	O
-	O
box	O
2	O
)	O
antibodies	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
affinity	O
-	O
purified	O
using	O
recombinant	O
proteins	O
and	O
validated	O
by	O
direct	O
ELISAs	O
and	O
Western	O
.	O

Caco-2	O
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	B
GATA6	O
antibody	O
and	O
NTERA-2	O
cells	O
were	O
used	O
for	O
validation	O
of	O
goat	O
anti	O
-	O
human	B
Nanog	O
and	O
anti	O
-	O
human	B
Oct3	O
/	O
4	O
antibodies	O
(	O
Summarized	O
in	O
Table	O
1	O
)	O
.Table	O
1Summary	O
list	O
of	O
antibody	O
verification	O
by	O
western	O
blot	O
.	O

AntibodySample	O
used	O
for	O
analysisMol	O
.	O

Wt	O
.	O

(	O
KD	O
)	O
Gt	O
×	O
hBrachyurymouse	O
ES	O
-	O
derived	O
EB	O
lysate48Ms	O
×	O
hDPPA5N	O
/	O
AN	O
/	O
AGt	O
×	O
hGATA6Caco2	O
cell	O
lysate65Gt	O
×	O
hNanogNTERA-2	O
cell	O
lysate33Gt	O
×	O
hOct	O
3	O
/	O
4NTERA-2	O
cell	O
lysate39Gt	O
×	O
hPDX1beta	O
-	O
TC	O
6	O
cell	O
lysate32Gt	O
×	O
hSOX17mouse	O
ES	O
-	O
derived	O
EB	O
lysate45Ms	O
×	O
hCD9PBMC25Rt	O
×	O
hGATA-1N	O
/	O
AN	O
/	O
AMs	O
×	O
hE	O
-	O
CadherinMCF-7	O
cell	O
lysate97Ms	O
×	O
hPODXLMCF-7	O
cell	O
lysate57Ms	O
×	O
hSOX2NTERA-2	O
cell	O
lysate36N	O
/	O
A	O
:	O
1	O
.	O

DPPA5	O
is	O
still	O
being	O
subcloned	O
.	O

Only	O
Elisa	O
verification	O
is	O
available.2	O
.	O

The	O
clone	O
for	O
GATA-1	O
(	O
MAB1779	O
)	O
does	O
not	O
work	O
for	O
Western	O
blot	O
application	O
but	O
is	O
useful	O
for	O
IHC	O
,	O
The	O
clone	O
picked	O
for	O
Western	O
blot	O
analysis	O
does	O
not	O
work	O
for	O
IHC	O
(	O
MAB17791	O
,	O
see	O
data	O
in	O
)	O
.After	O

antibodies	O
were	O
validated	O
in	O
direct	O
ELISAs	O
,	O
Western	O
blot	O
or	O
cell	O
lines	O
(	O
Fig.	O
1	O
and	O
data	O
not	O
shown	O
)	O
,	O
they	O
were	O
used	O
to	O
examine	O
the	O
expression	O
of	O
individual	O
molecules	O
in	O
undifferentiated	O
human	B
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

When	O
examined	O
by	O
immunohistochemistry	O
,	O
high	O
level	O
of	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
SOX2	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
observed	O
in	O
undifferentiated	O
human	B
ES	O
cells	O
(	O
Fig.	O
2A	O
,	O
2B	O
and	O
2C	O
)	O
.	O

DPPA5	O
(	O
developmental	O
pluripotency	O
associated	O
5	O
)	O
expression	O
was	O
also	O
observed	O
in	O
undifferentiated	O
human	B
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
noted	O
that	O
a	O
subset	O
of	O
the	O
proteins	O
used	O
were	O
membrane	O
bound	O
proteins	O
.	O

To	O
test	O
if	O
any	O
of	O
the	O
antibodies	O
generated	O
could	O
recognize	O
an	O
extracellular	O
epitope	O
and	O
thus	O
be	O
used	O
for	O
live	O
cell	O
sorting	O
,	O
we	O
repeated	O
staining	O
of	O
live	O
cells	O
as	O
previously	O
described	O
.	O

The	O
CD9	O
,	O
E	O
-	O
Cadherin	O
and	O
PODXL	O
antibodies	O
recognized	O
an	O
extracellular	O
epitope	O
and	O
their	O
ability	O
to	O
select	O
cells	O
by	O
FACS	O
was	O
confirmed	O
(	O
Fig.	O
3	O
)	O
.	O

Minimal	O
or	O
no	O
expressions	O
of	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
and	O
Nanog	O
were	O
detected	O
in	O
the	O
differentiated	O
EBs	O
(	O
Fig.	O
2D	O
,	O
2E	O
and	O
2F	O
)	O
.	O

However	O
,	O
SOX2	O
expression	O
,	O
which	O
is	O
observed	O
in	O
neural	O
progenitor	O
cells	O
,	O
is	O
persistent	O
in	O
subsets	O
of	O
EBs	O
.	O

Figure	O
1Western	O
blot	O
analysis	O
for	O
Gt	O
×	O
hOct3	O
/	O
4	O
(	O
A	O
)	O
,	O
Gt	O
×	O
hNanog	O
(	O
B	O
)	O
and	O
Ms	O
×	O
hSOX2	O
(	O
C	O
)	O
in	O
NTERA-2	O
cell	O
lysate	O
,	O
Ms	O
×	O
hE	O
-	O
Cadherin	O
(	O
D	O
)	O
in	O
MCF-7	O
cell	O
lysate	O
,	O
Ms	O
×	O
hCD9	O
(	O
E	O
)	O
in	O
PBMC	O
lysate	O
and	O
Ms	O
×	O
hPDX-1	O
(	O
F	O
)	O
in	O
β	O
-	O
TC-6	O
cell	O
lysate	O
.	O

Numbers	O
indicate	O
the	O
positions	O
of	O
molecular	O
weight	O
markers	O
.	O

Figure	O
2Undifferentiated	O
human	B
ES	O
cells	O
(	O
A	O
,	O
B	O
,	O
and	O
C	O
)	O
and	O
differentiated	O
EBs	O
(	O
D	O
,	O
E	O
and	O
F	O
)	O
were	O
analyzed	O
using	O
antibodies	O
to	O
indicated	O
molecular	O
markers	O
.	O

Immunostaining	O
with	O
goat	O
anti	O
-	O
human	B
Oct3	O
/	O
4	O
(	O
Red	O
in	O
A	O
and	O
D	O
)	O
,	O
mouse	B
anti	O
-	O
human	B
SOX2	O
(	O
Green	O
in	O
A	O
and	O
D	O
)	O
,	O
goat	O
anti	O
-	O
human	B
E	O
-	O
Cadherin	O
(	O
Red	O
in	O
B	O
and	O
E	O
)	O
,	O
mouse	B
anti	O
-	O
human	B
PODXL	O
(	O
Green	O
in	O
B	O
and	O
E	O
)	O
,	O
and	O
goat	O
anti	O
-	O
human	B
Nanog	O
(	O
Red	O
in	O
C	O
and	O
F	O
)	O
,	O
are	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
in	O
C	O
-	O
F	O
)	O
.	O

Note	O
the	O
dramatic	O
downregulation	O
of	O
ESC	O
specific	O
markers	O
(	O
Oct3	O
/	O
4	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
,	O
and	O
Nanog	O
)	O
in	O
EBs	O
.	O

However	O
,	O
SOX2	O
expression	O
is	O
persistent	O
in	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

Figure	O
3Human	O
embryonic	O
stem	O
cells	O
stained	O
with	O
anti	O
-	O
CD9	O
(	O
A	O
)	O
,	O
anti	O
-	O
E	O
-	O
Cadherin	O
(	O
B	O
)	O
,	O
and	O
anti	O
-	O
PODXL	O
(	O
C	O
)	O
and	O
antigen	O
expression	O
detected	O
by	O
a	O
flow	O
cytometer	O
.	O

The	O
specific	O
staining	O
is	O
indicated	O
by	O
green	O
histogram	O
and	O
corresponding	O
isotype	O
control	O
is	O
indicated	O
by	O
black	O
histogram	O
.	O

Suspension	O
culture	O
with	O
FGF	O
withdrawal	O
is	O
known	O
to	O
induce	O
differentiation	O
of	O
ES	O
cells	O
to	O
all	O
three	O
germ	O
layer	O
precursors	O
[	O
12	O
]	O
.	O

The	O
differentiation	O
status	O
of	O
the	O
EB	O
used	O
here	O
was	O
detected	O
to	O
contain	O
all	O
germ	O
cell	O
markers	O
by	O
RT	O
-	O
PCR	O
(	O
Fig.	O
4	O
)	O
.	O

In	O
order	O
to	O
examine	O
how	O
more	O
antibodies	O
can	O
be	O
used	O
for	O
characterization	O
of	O
early	O
differentiation	O
events	O
from	O
human	B
ES	O
cells	O
,	O
we	O
examined	O
the	O
expressions	O
of	O
endodermal	O
markers	O
,	O
SOX17	O
,	O
GATA6	O
and	O
PDX-1	O
,	O
and	O
mesodermal	O
markers	O
,	O
Brachyury	O
and	O
GATA1	O
,	O
in	O
the	O
undifferentiated	O
human	B
ES	O
cells	O
and	O
differentiated	O
EBs	O
.	O

Expressions	O
of	O
SOX17	O
,	O
GATA6	O
,	O
PDX-1	O
,	O
Brachyury	O
and	O
GATA1	O
were	O
not	O
detected	O
in	O
undifferentiated	O
human	B
ES	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
contrast	O
to	O
the	O
undifferentiated	O
ES	O
cells	O
,	O
subpopulations	O
of	O
SOX17-	O
,	O
GATA6-	O
,	O
Brachyury-	O
and	O
GATA1-positive	O
cells	O
were	O
observed	O
(	O
Fig	O
4	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
endodermal	O
and	O
mesodermal	O
precursors	O
exist	O
in	O
EBs	O
with	O
FGF	O
withdrawal	O
for	O
8	O
days	O
.	O

However	O
,	O
no	O
PDX-1-positive	O
cells	O
were	O
seen	O
in	O
EBs	O
differentiated	O
with	O
the	O
same	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.Figure	O
4Differentiated	O
EBs	O
were	O
analyzed	O
by	O
either	O
immunocytochemistry	O
or	O
RT	O
-	O
PCR	O
to	O
the	O
indicated	O
molecular	O
markers	O
.	O

(	O
A	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	B
SOX17	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
Fluoro	O
Nissl	O
nuclear	O
staining	O
(	O
Green	O
)	O
.	O

(	O
B	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	B
GATA6	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
C	O
)	O
Immunostaining	O
with	O
goat	O
anti	O
-	O
human	B
brachyury	O
(	O
Red	O
)	O
,	O
is	O
contrasted	O
with	O
DAPI	O
nuclear	O
staining	O
(	O
Blue	O
)	O
.	O

(	O
D	O
)	O
Immunostaining	O
with	O
mouse	B
anti	O
-	O
human	B
GATA1	O
(	O
Red	O
)	O
.	O

Note	O
that	O
each	O
antibody	O
recognizes	O
subsets	O
of	O
EB	O
cells	O
.	O

Scale	O
bars	O
=	O
100	O
μm	O
.	O

(	O
E	O
)	O
The	O
differentiation	O
status	O
of	O
EB	O
is	O
detected	O
by	O
RT	O
-	O
PCR	O
using	O
different	O
germ	O
layer	O
cell	O
markers	O
.	O

Selected	O
endoderm	O
markers	O
AFP	O
,	O
FoxA2	O
;	O
mesoderm	O
markers	O
Hand1	O
,	O
MSX1	O
and	O
ectoderm	O
marker	O
Msl1	O
were	O
all	O
highly	O
expressed	O
in	O
the	O
EB	O
samples	O
while	O
their	O
expression	O
was	O
either	O
undetectable	O
or	O
at	O
low	O
level	O
in	O
the	O
ES	O
samples	O
.	O

G3PDH	O
was	O
a	O
positive	O
control	O
showing	O
similar	O
amount	O
of	O
RNA	O
samples	O
were	O
used	O
for	O
analysis	O
.	O

Examination	O
of	O
cross	O
-	O
reactivity	O
of	O
antibodies	O
on	O
mouse	B
ES	O
and	O
differentiated	O
cellsWe	O
have	O
also	O
examined	O
the	O
cross	O
-	O
reactivities	O
of	O
these	O
antibodies	O
to	O
mouse	B
ES	O
cells	O
using	O
mouse	B
D3	O
ES	O
cell	O
line	O
and	O
mouse	B
fetal	O
endodermal	O
tissue	O
.	O

Cross	O
-	O
reactivity	O
to	O
mouse	B
of	O
goat	O
anti	O
-	O
Oct3	O
/	O
4	O
,	O
goat	O
anti	O
-	O
PDX-1	O
,	O
goat	O
anti	O
-	O
SOX17	O
and	O
mouse	B
anti	O
-	O
SOX2	O
was	O
detected	O
.	O

Minimal	O
cross	O
-	O
reactivity	O
to	O
mouse	B
,	O
measured	O
by	O
10	O
%	O
intensity	O
to	O
human	B
by	O
higher	O
than	O
control	O
cells	O
,	O
was	O
observed	O
in	O
mouse	B
anti	O
-	O
CD9	O
and	O
mouse	B
anti	O
-	O
E	O
-	O
cadherin	O
antibodies	O
.	O

Goat	B
anti	O
-	O
Nanog	O
and	O
mouse	B
anti	O
-	O
PODXL	O
antibodies	O
appear	O
to	O
be	O
human	B
-	O
specific	O
as	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
subtypes	O
of	O
monoclonal	O
antibodies	O
were	O
also	O
identified	O
in	O
the	O
best	O
clones	O
.	O

These	O
results	O
are	O
summarized	O
in	O
Table	O
2.Table	O
2Summary	O
of	O
antibodies	O
detection	O
in	O
ES	O
and	O
EB	O
samples	O
.	O

AntibodyESEBReactivity	O
to	O
mouseIsotype	B
of	O
monoclonal	O
antibody	O
(	O
Clone	O
No.	O
)	O
Gt	O
×	O
hBrachyuryNoYesNT*Ms	O
×	O
hDPPA5YesNT*NT*ND*Gt	O
×	O
hGATA6NoYesNT*Gt	O
×	O
hNanogYesDownNoGt	O
×	O
hOct	O
3	O
/	O
4YesDownYesGt	O
×	O
hPDX-1NoNoYesGt	O
×	O
hSOX17NoYesYesMs	O
×	O
hCD9YesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
209306	O
)	O
Ms	O
×	O
hE	O
-	O
cadherinYesNoMinimalMouse	O
IgG2B	O
(	O
clone	O
180224	O
)	O
Ms	O
×	O
hGATA1NoYesNT*Rat	O
IgG2B	O
(	O
clone	O
234732	O
)	O
Ms	O
×	O
hPODXLYesNoNoMouse	O
IgG2A	O
(	O
clone	O
222328	O
)	O
Ms	O
×	O
hSOX2YesYesYesMouse	O
IgG2A	O
(	O
clone	O
245610	O
)	O
*NT	O
,	O
Not	O
tested	O
;	O
ND	O
,	O
Not	O
determined	O
.	O

The	O
expression	O
patterns	O
detected	O
using	O
antibodies	O
developed	O
in	O
our	O
facility	O
are	O
consistent	O
with	O
data	O
reported	O
using	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
or	O
cDNA	O
microarrays	O
.	O

Moreover	O
several	O
of	O
the	O
monoclonal	O
antibodies	O
have	O
differing	O
heavy	O
chain	O
subunits	O
allowing	O
double	O
labeling	O
using	O
subtype	O
specific	O
markers	O
to	O
be	O
performed	O
.	O

In	O
summary	O
,	O
we	O
have	O
developed	O
a	O
useful	O
collection	O
of	O
antibodies	O
that	O
would	O
be	O
useful	O
for	O
identification	O
of	O
stem	O
cell	O
characteristics	O
and	O
assessment	O
of	O
differentiation	O
.	O

Several	O
additional	O
antibodies	O
to	O
the	O
molecules	O
that	O
have	O
been	O
identified	O
as	O
potential	O
cell	O
lineage	O
markers	O
[	O
13	O
]	O
are	O
currently	O
under	O
development	O
using	O
the	O
same	O
approach	O
.	O

Cloning	O
and	O
expression	O
of	O
Brachyury	O
,	O
DPPA5	O
,	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
GATA1	O
,	O
GATA6	O
,	O
Nanog	O
,	O
Oct3	O
/	O
4	O
,	O
PDX-1	O
,	O
PODXL	O
,	O
SOX2	O
and	O
SOX17Brachyury	O
(	O
aa	O
.	O

1–202	O
)	O
,	O
DPPA5	O
(	O
a.a	O
.	O

1–116	O
)	O
,	O
GATA1	O
(	O
a.a	O
.	O
1–413	O
)	O
,	O
GATA6	O
(	O
aa	O
.	O

1–449	O
)	O
,	O
Nanog	O
(	O
aa	O
.	O

153–305	O
)	O
,	O
Oct3	O
/	O
4	O
(	O
aa	O
.	O
1–265	O
)	O
,	O
PDX-1	O
(	O
aa	O
.	O

1–283	O
)	O
,	O
SOX2	O
(	O
aa	O
.	O
135–317	O
)	O
and	O
SOX17	O
(	O
aa	O
.	O
177–414	O
)	O
were	O
expressed	O
in	O
E.	O
Coli	O
and	O
extracellular	O
domains	O
of	O
CD9	O
,	O
E	O
-	O
Cadherin	O
,	O
PODXL	O
were	O
expressed	O
in	O
mouse	B
NSO	O
cells	O
.	O

All	O
proteins	O
were	O
purified	O
and	O
sequenced	O
before	O
they	O
were	O
used	O
as	O
antigens	O
for	O
immunizations	O
and	O
as	O
substrate	O
for	O
antibody	O
screening	O
and	O
subcloning	O
.	O

Production	O
and	O
purification	O
of	O
antibodiesAll	O
monoclonal	O
antibodies	O
were	O
derived	O
from	O
fusions	O
of	O
mouse	B
myeloma	O
with	O
B	O
cells	O
obtained	O
from	O
BALB	B
/	I
c	I
mice	I
which	O
had	O
been	O
immunized	O
with	O
purified	O
antigen	O
.	O

The	O
IgG	O
fraction	O
of	O
the	O
culture	O
supernatant	O
was	O
purified	O
by	O
Protein	O
G	O
affinity	O
chromatography	O
(	O
Sigma	O
)	O
.	O

Each	O
panel	O
of	O
antibodies	O
was	O
screened	O
and	O
selected	O
for	O
their	O
abilities	O
to	O
detect	O
purified	O
recombinant	O
antigen	O
in	O
direct	O
ELISA	O
and	O
Western	O
blot	O
.	O

All	O
polyclonal	O
antibodies	O
were	O
derived	O
from	O
sera	O
of	O
goats	B
which	O
had	O
been	O
immunized	O
and	O
boost	O
it	O
with	O
purified	O
antigen	O
.	O

Antibody	O
was	O
purified	O
from	O
the	O
sera	O
by	O
an	O
antigen	O
-	O
affinity	O
chromatography	O
.	O

Cells	O
and	O
cell	O
cultureHuman	O
Caco-2	O
,	O
MG-63	O
,	O
MCF-7	O
,	O
NTERA-2	O
and	O
mouse	B
D3	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
ATCC	O
)	O
.	O

Cells	O
were	O
cultured	O
according	O
to	O
the	O
ATCC	O
instructions	O
.	O

Information	O
regarding	O
human	B
ES	O
cell	O
line	O
HSF-6	O
(	O
NIH	O
code	O
UC06	O
)	O
can	O
be	O
obtained	O
at	O
the	O
website	O
[	O
14	O
]	O
.	O

Undifferentiated	O
human	B
ES	O
cells	O
were	O
cultured	O
according	O
to	O
the	O
protocol	O
provided	O
by	O
the	O
University	O
of	O
California	O
,	O
San	O
Francisco	O
in	O
human	B
ES	O
culture	O
medium	O
[	O
DMEM	O
supplemented	O
with	O
20	O
%	O
KnockOut	O
Serum	O
Replacement	O
(	O
Invitrogen	O
)	O
and	O
5	O
ng	O
/	O
mL	O
of	O
bFGF	O
(	O
R&D	O
Systems	O
)	O
]	O
.	O

To	O
induce	O
formation	O
of	O
embryoid	O
bodies	O
(	O
EBs	O
)	O
,	O
ES	O
colonies	O
were	O
harvested	O
,	O
separated	O
from	O
the	O
MEF	O
feeder	O
cells	O
by	O
gravity	O
,	O
gently	O
resuspended	O
in	O
ES	O
culture	O
medium	O
and	O
transferred	O
to	O
non	O
-	O
adherent	O
suspension	O
culture	O
dishes	O
(	O
Corning	O
)	O
.	O

Unless	O
otherwise	O
noted	O
,	O
EBs	O
derived	O
from	O
human	B
ES	O
cell	O
aggregates	O
were	O
cultured	O
for	O
8	O
days	O
in	O
ES	O
culture	O
medium	O
deprived	O
of	O
bFGF	O
and	O
used	O
for	O
analysis	O
by	O
immunohistochemistry	O
as	O
described	O
.	O

Western	O
blotCells	O
are	O
solubilized	O
in	O
hot	O
2	O
×	O
SDS	O
gel	O
sample	O
buffer	O
(	O
20	O
mM	O
dithiothreitol	O
,	O
6	O
%	O
SDS	O
,	O
0.25	O
M	O
Tris	O
,	O
pH	O
6.8	O
,	O
10	O
%	O
glycerol	O
,	O
10	O
mM	O
NaF	O
and	O
bromophenyl	O
blue	O
)	O
at	O
2	O
×	O
106	O
per	O
mL.	O
The	O
extracts	O
are	O
heated	O
in	O
a	O
boiling	O
water	O
bath	O
for	O
5	O
minutes	O
and	O
sonicated	O
with	O
a	O
probe	O
sonicator	O
with	O
3–4	O
bursts	O
of	O
5–10	O
seconds	O
each	O
.	O

Samples	O
are	O
diluted	O
with	O
1	O
×	O
SDS	O
sample	O
buffer	O
to	O
the	O
desired	O
loading	O
of	O
1–5	O
×	O
103	O
per	O
lane	O
.	O

Lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
,	O
transferred	O
to	O
Immobilon	O
-	O
P	O
membrane	O
,	O
and	O
immunoblotted	O
with	O
0.5	O
μg	O
/	O
mL	O
primary	O
Abs	O
as	O
described	O
in	O
R&D	O
Systems	O
Website	O
[	O
15	O
]	O
.	O

ImmunohistochemistryAntibodies	O
were	O
used	O
with	O
the	O
appropriate	O
secondary	O
reagents	O
at	O
a	O
concentration	O
of	O
5	O
to	O
10	O
μg	O
/	O
ml	O
.	O

Cells	O
or	O
sections	O
of	O
EBs	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
20	O
min	O
,	O
then	O
blocked	O
and	O
permeabilized	O
with	O
0.1	O
%	O
Triton	O
X-100	O
,	O
1	O
%	O
BSA	O
,	O
10	O
%	O
normal	O
donkey	B
serum	O
in	O
PBS	O
at	O
room	O
temperature	O
for	O
45	O
min	O
.	O

After	O
blocking	O
,	O
cells	O
were	O
incubated	O
with	O
diluted	O
primary	O
antibody	O
overnight	O
at	O
4	O
°	O
C	O
followed	O
by	O
coupled	O
anti	O
-	O
mouse	B
or	O
anti	O
-	O
goat	O
IgG	O
(	O
Molecular	O
Probes	O
)	O
at	O
room	O
temperature	O
in	O
the	O
dark	O
for	O
an	O
hour	O
.	O

Between	O
each	O
step	O
cells	O
were	O
washed	O
with	O
PBS	O
with	O
0.1	O
%	O
BSA	O
.	O

RT	O
-	O
PCRTotal	O
RNA	O
was	O
extracted	O
from	O
EBs	O
using	O
Trizol	O
LS	O
(	O
Invitrogen	O
)	O
.	O

cDNA	O
was	O
synthesized	O
by	O
using	O
Superscript	O
II	O
reverse	O
transcriptase	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

The	O
PCR	O
primers	O
are	O
available	O
upon	O
request	O
.	O

Flow	O
cytometryAntibodies	O
were	O
prepared	O
at	O
the	O
concentration	O
of	O
0.1	O
mg	O
/	O
mL.	O
10	O
μL	O
of	O
the	O
stock	O
solution	O
was	O
added	O
to	O
1	O
–	O
2.5	O
×	O
105	O
cells	O
in	O
a	O
total	O
reaction	O
volume	O
not	O
exceeding	O
200	O
μL.	O
The	O
sample	O
was	O
then	O
incubated	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
excess	O
antibody	O
was	O
removed	O
by	O
washing	O
cells	O
twice	O
with	O
FACS	O
buffer	O
(	O
2	O
%	O
FCS	O
and	O
0.1	O
%	O
sodium	O
azide	O
in	O
Hank	O
's	O
buffer	O
)	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
200	O
μL	O
of	O
FACS	O
buffer	O
and	O
the	O
binding	O
of	O
unlabeled	O
monoclonal	O
antibodies	O
was	O
visualized	O
by	O
adding	O
10	O
μL	O
of	O
a	O
25	O
μg	O
/	O
mL	O
stock	O
solution	O
of	O
a	O
secondary	O
developing	O
reagent	O
such	O
as	O
goat	O
anti	O
-	O
mouse	B
IgG	O
conjugated	O
to	O
a	O
fluorochrome	O
for	O
20	O
min	O
at	O
2–8	O
°	O
C	O
.	O

Following	O
incubation	O
,	O
cells	O
were	O
washed	O
once	O
with	O
FACS	O
buffer	O
,	O
once	O
with	O
PBS	O
.	O

After	O
wash	O
,	O
cells	O
were	O
resuspend	O
in	O
400	O
μL	O
of	O
PBS	O
and	O
analyzed	O
on	O
a	O
FACScant	O
flow	O
cytometer	O
(	O
Becton	O
-	O
Dickinson	O
,	O
Mountain	O
View	O
,	O
CA	O
)	O
.	O

Five	O
thousand	O
events	O
were	O
collected	O
and	O
analyzed	O
using	O
CELL	O
Quest	O
software	O
.	O

BackgroundIn	O
order	O
to	O
compare	O
the	O
gene	O
expression	O
profiles	O
of	O
human	B
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
lines	O
and	O
their	O
differentiated	O
progeny	O
and	O
to	O
monitor	O
feeder	O
contaminations	O
,	O
we	O
have	O
examined	O
gene	O
expression	O
in	O
seven	O
hESC	O
lines	O
and	O
human	B
fibroblast	O
feeder	O
cells	O
using	O
Illumina	O
®	O
bead	O
arrays	O
that	O
contain	O
probes	O
for	O
24,131	O
transcript	O
probes	O
.	O

ResultsA	O
total	O
of	O
48	O
different	O
samples	O
(	O
including	O
duplicates	O
)	O
grown	O
in	O
multiple	O
laboratories	O
under	O
different	O
conditions	O
were	O
analyzed	O
and	O
pairwise	O
comparisons	O
were	O
performed	O
in	O
all	O
groups	O
.	O

Hierarchical	O
clustering	O
showed	O
that	O
blinded	O
duplicates	O
were	O
correctly	O
identified	O
as	O
the	O
closest	O
related	O
samples	O
.	O

hESC	O
lines	O
clustered	O
together	O
irrespective	O
of	O
the	O
laboratory	O
in	O
which	O
they	O
were	O
maintained	O
.	O

hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
differentiated	O
from	O
them	O
and	O
the	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	O
.	O

The	O
embryonal	O
carcinoma	O
(	O
EC	O
)	O
line	O
NTera2	O
is	O
a	O
useful	O
model	O
for	O
evaluating	O
characteristics	O
of	O
hESCs	O
.	O

Expression	O
of	O
subsets	O
of	O
individual	O
genes	O
was	O
validated	O
by	O
comparing	O
with	O
published	O
databases	O
,	O
MPSS	O
(	O
Massively	O
Parallel	O
Signature	O
Sequencing	O
)	O
libraries	O
,	O
and	O
parallel	O
analysis	O
by	O
microarray	O
and	O
RT	O
-	O
PCR.Conclusionwe	O
show	O
that	O
Illumina	O
's	O
bead	O
array	O
platform	O
is	O
a	O
reliable	O
,	O
reproducible	O
and	O
robust	O
method	O
for	O
developing	O
base	O
global	O
profiles	O
of	O
cells	O
and	O
identifying	O
similarities	O
and	O
differences	O
in	O
large	O
number	O
of	O
samples	O
.	O

Embryonic	O
stem	O
cells	O
(	O
ESCs	O
)	O
,	O
derived	O
from	O
the	O
inner	O
cell	O
mass	O
of	O
pre	O
-	O
implantation	O
embryos	O
,	O
have	O
been	O
recognized	O
as	O
the	O
most	O
pluripotent	O
stem	O
cell	O
population	O
.	O

Human	B
ES	O
cells	O
(	O
hESCs	O
)	O
can	O
be	O
maintained	O
and	O
propagated	O
on	O
mouse	B
or	O
human	B
fibroblast	O
feeders	O
for	O
extended	O
periods	O
in	O
media	O
containing	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
[	O
1	O
-	O
4	O
]	O
while	O
retaining	O
the	O
ability	O
to	O
differentiate	O
into	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
as	O
well	O
as	O
trophoectoderm	O
and	O
germ	O
cells	O
.	O

Gene	O
expression	O
in	O
hESC	O
has	O
been	O
investigated	O
by	O
a	O
variety	O
of	O
techniques	O
including	O
massively	O
parallel	O
signature	O
sequencing	O
(	O
MPSS	O
)	O
,	O
serial	O
analysis	O
of	O
gene	O
expression	O
(	O
SAGE	O
)	O
,	O
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
scan	O
,	O
large	O
scale	O
microarrays	O
,	O
focused	O
cDNA	O
microarrays	O
,	O
and	O
immunocytochemistry	O
[	O
5	O
-	O
7	O
]	O
.	O

Markers	O
for	O
hESCs	O
that	O
may	O
also	O
contribute	O
to	O
the	O
""""	O
stemness	O
""""	O
phenotype	O
have	O
been	O
established	O
and	O
markers	O
that	O
distinguish	O
ESCs	O
from	O
embryoid	O
bodies	O
(	O
EB	O
)	O
have	O
been	O
developed	O
.	O

Novel	O
stage	O
-	O
specific	O
genes	O
that	O
distinguish	O
between	O
hESCs	O
and	O
EBs	O
have	O
been	O
identified	O
and	O
allelic	O
differences	O
between	O
ESC	O
have	O
begun	O
to	O
be	O
recognized	O
[	O
8	O
-	O
10	O
]	O
.	O

As	O
the	O
potential	O
of	O
hESCs	O
and	O
their	O
derivatives	O
for	O
regenerative	O
medicine	O
is	O
being	O
evaluated	O
,	O
it	O
has	O
become	O
clear	O
that	O
the	O
overall	O
state	O
of	O
the	O
cells	O
,	O
degree	O
of	O
contamination	O
and	O
comparisons	O
of	O
the	O
more	O
than	O
a	O
hundred	O
different	O
newly	O
derived	O
lines	O
will	O
need	O
to	O
be	O
performed	O
.	O

It	O
will	O
be	O
necessary	O
to	O
develop	O
methods	O
to	O
monitor	O
and	O
assess	O
hESC	O
and	O
their	O
derivatives	O
on	O
a	O
routine	O
basis	O
.	O

Since	O
differentiated	O
cells	O
are	O
often	O
scattered	O
within	O
or	O
at	O
the	O
edge	O
of	O
colonies	O
[	O
11	O
]	O
and	O
the	O
differentiation	O
is	O
so	O
subtle	O
that	O
morphological	O
characteristics	O
and	O
even	O
immunohistochemistry	O
are	O
insufficient	O
to	O
detect	O
it	O
,	O
larger	O
scale	O
methods	O
of	O
analysis	O
need	O
to	O
be	O
developed	O
.	O

Our	O
strategy	O
was	O
to	O
compare	O
a	O
variety	O
of	O
different	O
hESC	O
lines	O
that	O
were	O
derived	O
and	O
expanded	O
by	O
three	O
different	O
institutions	O
(	O
WiCell	O
Research	O
Institute	O
,	O
BresaGen	O
,	O
Inc.	O
,	O
and	O
Technion	O
-	O
Israel	O
Institute	O
of	O
Technology	O
)	O
,	O
and	O
cultured	O
in	O
two	O
separate	O
laboratories	O
(	O
Burnham	O
Institute	O
and	O
NIA	O
)	O
to	O
a	O
baseline	O
set	O
of	O
data	O
against	O
which	O
cell	O
samples	O
can	O
be	O
compared	O
.	O

By	O
using	O
cells	O
grown	O
in	O
different	O
conditions	O
we	O
expected	O
to	O
be	O
able	O
to	O
identify	O
core	O
commonalities	O
and	O
by	O
comparing	O
feeders	O
and	O
embryoid	O
bodies	O
(	O
EB	O
)	O
with	O
hESC	O
identify	O
measures	O
of	O
contamination	O
and	O
early	O
markers	O
of	O
differentiation	O
.	O

Further	O
,	O
by	O
comparing	O
embryonal	O
carcinoma	O
cell	O
(	O
EC	O
)	O
and	O
karyotypically	O
variant	O
lines	O
with	O
hESC	O
,	O
we	O
would	O
be	O
able	O
to	O
directly	O
assess	O
their	O
utility	O
as	O
surrogates	O
(	O
for	O
quality	O
control	O
purposes	O
)	O
for	O
hESC	O
.	O

We	O
employed	O
a	O
pre	O
-	O
commercial	O
prototype	O
of	O
the	O
Illumina	O
HumanRef-8	B
BeadChip	O
[	O
12	O
]	O
,	O
a	O
genome	O
-	O
scale	O
bead	O
based	O
array	O
technology	O
that	O
combines	O
the	O
sensitivity	O
and	O
low	O
cost	O
of	O
a	O
focused	O
array	O
with	O
the	O
coverage	O
of	O
a	O
large	O
scale	O
array	O
,	O
while	O
requiring	O
much	O
smaller	O
sample	O
sizes	O
than	O
MPSS	O
,	O
EST	O
scan	O
or	O
SAGE	O
.	O

We	O
show	O
that	O
the	O
Illumina	O
bead	O
based	O
array	O
correctly	O
identified	O
blinded	O
duplicates	O
as	O
the	O
closest	O
related	O
samples	O
and	O
readily	O
distinguished	O
between	O
hESC	O
lines	O
,	O
as	O
well	O
as	O
between	O
ESCs	O
and	O
EBs	O
derived	O
from	O
them	O
.	O

This	O
array	O
allowed	O
us	O
to	O
estimate	O
the	O
degree	O
of	O
feeder	O
contamination	O
present	O
in	O
the	O
cultures	O
.	O

Similarities	O
and	O
differences	O
between	O
EC	O
line	O
NTera2	O
and	O
hESC	O
lines	O
could	O
be	O
determined	O
and	O
verified	O
,	O
and	O
the	O
database	O
comparisons	O
allowed	O
us	O
to	O
identify	O
core	O
self	O
-	O
renewal	O
pathways	O
that	O
regulate	O
hESC	O
propagation	O
.	O

Multiple	O
hESC	O
lines	O
can	O
be	O
assessed	O
by	O
Illumina	O
bead	O
arrayForty	O
-	O
eight	O
samples	O
were	O
selected	O
from	O
multiple	O
laboratories	O
and	O
gene	O
expression	O
profiles	O
were	O
examined	O
using	O
a	O
bead	O
array	O
containing	O
24,131	O
transcripts	O
derived	O
from	O
the	O
Human	B
RefSeq	O
database	O
that	O
included	O
full	O
length	O
and	O
splice	O
variants	O
.	O

Each	O
gene	O
was	O
represented	O
by	O
sequences	O
containing	O
an	O
average	O
of	O
thirty	O
beads	O
to	O
provide	O
an	O
internal	O
measure	O
of	O
reliability	O
.	O

Samples	O
included	O
7	O
hESC	O
lines	O
BG01	O
,	O
BG02	O
,	O
BG03	O
,	O
I6	O
,	O
H1	O
,	O
H7	O
and	O
H9	O
,	O
EBs	O
that	O
were	O
differentiated	O
from	O
hESCs	O
of	O
the	O
three	O
BG	O
lines	O
,	O
human	B
fibroblast	O
feeder	O
HS27	O
(	O
ATCC	O
)	O
,	O
hESC	O
-	O
derived	O
fibroblasts	O
,	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01	O
Variant	O
(	O
BG01V	O
)	O
[	O
13	O
]	O
and	O
EC	O
line	O
NTera2	O
[	O
14	O
]	O
.	O

Samples	O
were	O
blinded	O
and	O
biological	O
and	O
technical	O
repeats	O
were	O
examined	O
at	O
the	O
same	O
time	O
.	O

A	O
single	O
slide	O
contained	O
eight	O
replicates	O
and	O
six	O
such	O
slides	O
were	O
used	O
for	O
the	O
present	O
set	O
of	O
samples	O
.	O

Results	O
were	O
normalized	O
to	O
average	O
following	O
Illumina	O
Beadstudio	O
manual	O
and	O
the	O
quality	O
of	O
each	O
sample	O
was	O
assessed	O
by	O
immunocytochemitsry	O
and	O
RT	O
-	O
PCR	O
prior	O
to	O
subjecting	O
them	O
for	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Results	O
from	O
the	O
entire	O
sample	O
set	O
are	O
available	O
for	O
download	O
as	O
an	O
excel	O
spreadsheet	O
(	O
Additional	O
file	O
1	O
)	O
and	O
a	O
CD	O
of	O
the	O
results	O
is	O
available	O
upon	O
request	O
.	O

The	O
total	O
number	O
of	O
genes	O
identified	O
as	O
expressed	O
at	O
>	O
0.99	O
confidence	O
is	O
summarized	O
in	O
Table	O
1	O
.	O

Intensity	O
results	O
are	O
reported	O
in	O
arbitrary	O
units	O
and	O
ranged	O
from	O
10	O
to	O
20,000	O
(	O
a	O
two	O
thousand	O
fold	O
range	O
)	O
.	O

Although	O
the	O
sensitivity	O
of	O
the	O
array	O
has	O
been	O
reported	O
to	O
be	O
high	O
,	O
in	O
the	O
present	O
report	O
we	O
have	O
restricted	O
our	O
analysis	O
to	O
expression	O
of	O
at	O
least	O
100	O
units	O
in	O
any	O
one	O
sample	O
.	O

Using	O
this	O
cutoff	O
,	O
on	O
average	O
cells	O
expressed	O
approximately	O
8,000	O
transcripts	O
(	O
Table	O
1	O
,	O
2	O
)	O
,	O
a	O
number	O
similar	O
to	O
the	O
number	O
detected	O
by	O
SAGE	O
,	O
MPSS	O
and	O
EST	O
analysis	O
[	O
5	O
-	O
7,10,15,16	O
]	O
.	O

As	O
with	O
other	O
analysis	O
,	O
genes	O
with	O
the	O
highest	O
abundance	O
were	O
housekeeping	O
genes	O
,	O
ribosomal	O
genes	O
and	O
structural	O
genes	O
(	O
Table	O
2	O
and	O
Additional	O
file	O
1	O
)	O
.	O

These	O
genes	O
were	O
similar	O
in	O
most	O
samples	O
though	O
relative	O
levels	O
varied	O
.	O

Table	O
1Correlation	O
coefficients	O
of	O
paired	O
samples	O
in	O
this	O
bead	O
array	O
In	O
order	O
to	O
test	O
the	O
reproducibility	O
and	O
reliability	O
of	O
the	O
bead	O
array	O
,	O
duplicate	O
samples	O
of	O
hESC	O
lines	O
H9	O
,	O
I6	O
,	O
and	O
EC	O
line	O
NTera2	O
and	O
human	B
fibroblast	O
feeders	O
(	O
HS27	O
)	O
were	O
run	O
at	O
the	O
same	O
time	O
and	O
correlation	O
coefficients	O
(	O
R2	O
)	O
of	O
duplicates	O
were	O
generated	O
using	O
the	O
entire	O
data	O
of	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
§	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
*	O
)	O
,	O
or	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
and	O
expression	O
level	O
>	O
100	O
arbitrary	O
units	O
(	O
#	O
)	O
.	O

Note	O
that	O
the	O
correlation	O
coefficients	O
are	O
in	O
the	O
range	O
of	O
0.9382–0.9761	O
and	O
the	O
number	O
of	O
genes	O
was	O
in	O
the	O
range	O
of	O
10,000–14,000.Duplicate	O
SamplesNo	O
.	O
of	O
all	O
genes	O
(	O
expr.>0	O
)	O
§R2of	O
all	O
genes	O
(	O
expr	O
.	O

>	O
0	O
)	O
No	O
.	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*R2	O
of	O
genes	O
(	O
>	O
0.99	O
)	O
*No	O
.	O
(	O
>	O
0.99	O
,	O
level>100	O
)	O
#H918,8990.868113,6720.97087,408I619,1390.866312,5700.97616,826NTera219,1620.874114,0360.93827,147Feeder18,1570.872410,6060.97517,021Table	O
2Distribution	O
of	O
genes	O
with	O
expression	O
levels	O
<	O
50	O
and	O
>	O
50–10,000	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
in	O
8	O
hESC	O
populations	O
All	O
human	B
ESC	O
samples	O
were	O
hybridized	O
in	O
one	O
experiment	O
and	O
the	O
relative	O
detection	O
levels	O
of	O
genes	O
were	O
binned	O
to	O
obtain	O
a	O
global	O
overview	O
of	O
transcription	O
,	O
approximately	O
8	O
,	O
000	O
genes	O
(	O
~50	O
%	O
)	O
were	O
greater	O
than	O
100	O
arbitrary	O
units	O
.	O

The	O
numbers	O
are	O
similar	O
to	O
results	O
obtained	O
by	O
other	O
large	O
scale	O
analysis	O
such	O
as	O
MPSS.Abundance	O
(	O
relative	O
detection	O
levels	O
)	O
H9H9	O
on	O
human	B
feedersI6BG01BG02BG03BG01VPooled	O
(	O
H1	O
,	O
H7	O
,	O
H9	O
)	O
No.%No.%No.%No.%No.%No.%No.%No.%<502,90921.26,06738.43,55925.34,52830.74,25630.54,70632.24194.35,80334.4>5010,81778.89,74761.610,48474.710,23269.39,69469.59,91567.89,43895.711,08565.6>1008,12659.27,53947.77,40952.87,70352.27,49653.77,43050.87,23073.38,21748.7>5003,07722.42,94718.62,62618.73,06520.82,95021.12,85219.52,85128.92,94117.4>10001,62911.91,62510.31,49010.61,63811.11,58911.41,51710.41,56615.91,5549.2>50002481.82571.62561.82561.72631.92621.82752.82511.5>10000900.7940.61120.8920.61000.71070.71011.0940.6Total	O
No.	O
of	O
genes	O
detected	O
at	O
>	O
0.99	O
confidence13,72615,81414,04314,76013,95014,6219,85716,888One	O
of	O
the	O
advantages	O
of	O
the	O
Illumina	O
arrays	O
is	O
the	O
ability	O
of	O
running	O
multiple	O
samples	O
simultaneously	O
thus	O
allowing	O
multiple	O
pairwise	O
comparisons	O
to	O
be	O
performed	O
readily	O
.	O

To	O
show	O
the	O
similarity	O
of	O
relative	O
gene	O
expression	O
between	O
samples	O
,	O
we	O
have	O
used	O
Illumina	O
Beadstudio	O
and	O
clustering	O
software	O
packages	O
Pcluster	O
[	O
17	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
to	O
generate	O
a	O
heat	O
-	O
map	O
(	O
Figure	O
1	O
)	O
and	O
a	O
dendrogram	O
(	O
Figure	O
2	O
)	O
.	O

Based	O
on	O
their	O
properties	O
,	O
we	O
classified	O
some	O
of	O
our	O
samples	O
into	O
four	O
groups	O
,	O
(	O
A	O
)	O
undifferentiated	O
hESCs	O
(	O
including	O
a	O
sample	O
from	O
karyotypically	O
abnormal	O
variant	O
,	O
designated	O
as	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
;	O
(	O
B	O
)	O
differentiated	O
ES	O
cells	O
and	O
EBs	O
(	O
designated	O
as	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
;	O
(	O
C	O
)	O
hESC	O
derived	O
neural	O
cells	O
(	O
designated	O
as	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
;	O
and	O
(	O
D	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	B
fibroblast	O
feeder	O
cells	O
(	O
designated	O
as	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
and	O
these	O
groups	O
were	O
shown	O
in	O
the	O
heat	O
-	O
map	O
.	O

Comparing	O
the	O
overall	O
pattern	O
of	O
expression	O
,	O
we	O
made	O
several	O
important	O
observations	O
:	O
1	O
)	O
Duplicates	O
clustered	O
close	O
to	O
each	O
other	O
and	O
were	O
more	O
related	O
to	O
each	O
other	O
than	O
to	O
any	O
other	O
sample	O
;	O
2	O
)	O
ESCs	O
appeared	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
EBs	O
;	O
3	O
)	O
NTera2	O
cells	O
appeared	O
more	O
similar	O
to	O
ESCs	O
while	O
differentiated	O
NTera2	O
and	O
EBs	O
can	O
be	O
readily	O
distinguished	O
from	O
their	O
parent	O
populations	O
(	O
Figure	O
2	O
)	O
;	O
4	O
)	O
BG01V	O
appeared	O
similar	O
to	O
undifferentiated	O
BG01	O
cells	O
;	O
5	O
)	O
In	O
general	O
ESC	O
lines	O
grown	O
in	O
one	O
laboratory	O
appeared	O
more	O
similar	O
than	O
samples	O
grown	O
in	O
other	O
laboratories	O
,	O
suggesting	O
that	O
culture	O
conditions	O
affected	O
gene	O
expression	O
but	O
that	O
this	O
effect	O
was	O
much	O
smaller	O
than	O
the	O
effect	O
of	O
differentiation	O
.	O

Figure	O
1Unsupervised	O
two	O
-	O
way	O
hierarchical	O
cluster	O
analysis	O
of	O
differentially	O
expressed	O
genes	O
illustrated	O
in	O
a	O
heat	O
-	O
map	O
.	O

Each	O
row	O
represents	O
the	O
relative	O
levels	O
of	O
expression	O
of	O
a	O
single	O
gene	O
.	O

Each	O
column	O
represents	O
a	O
sample	O
.	O

The	O
samples	O
include	O
four	O
groups	O
of	O
cells	O
,	O
ES	O
designates	O
11	O
samples	O
of	O
hESCs	O
,	O
EB	O
contains	O
6	O
samples	O
of	O
differentiated	O
ESCs	O
and	O
EBs	O
,	O
NS	O
consists	O
of	O
3	O
hESC	O
derived	O
neural	O
cells	O
and	O
FB	O
is	O
a	O
collection	O
of	O
hESC	O
derived	O
mesenchyme	O
and	O
fibroblasts	O
.	O

High	O
expressions	O
relative	O
to	O
mean	O
are	O
colored	O
red	O
.	O

Low	O
expressions	O
are	O
colored	O
green	O
.	O

Black	O
represents	O
no	O
significant	O
change	O
in	O
expression	O
level	O
between	O
mean	O
and	O
sample	O
.	O

Samples	O
cluster	O
closer	O
within	O
their	O
own	O
group	O
than	O
samples	O
from	O
other	O
groups	O
.	O

Figure	O
2Dendrogram	O
of	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
of	O
relative	O
expression	O
of	O
genes	O
in	O
selected	O
samples	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
p	O
<	O
0.05	O
)	O
.	O

hESCs	O
clustered	O
together	O
and	O
BG	O
lines	O
cultured	O
in	O
the	O
same	O
laboratory	O
shared	O
the	O
largest	O
similarities	O
.	O

EBs	O
were	O
separated	O
from	O
hESCs	O
from	O
which	O
they	O
were	O
derived	O
.	O

EC	O
line	O
NTera2	O
and	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
respectively	O
.	O

The	O
global	O
analysis	O
suggested	O
that	O
the	O
bead	O
arrays	O
used	O
were	O
sufficiently	O
sensitive	O
such	O
that	O
individual	O
subsets	O
of	O
genes	O
could	O
be	O
analyzed	O
,	O
different	O
populations	O
of	O
cells	O
could	O
be	O
readily	O
distinguished	O
and	O
that	O
a	O
subset	O
of	O
candidate	O
genes	O
could	O
be	O
sufficient	O
to	O
distinguish	O
between	O
groups	O
of	O
cells	O
.	O

The	O
comparison	O
across	O
multiple	O
samples	O
will	O
allow	O
a	O
set	O
of	O
core	O
stem	O
cell	O
markers	O
to	O
be	O
identified	O
.	O

In	O
subsequent	O
sections	O
we	O
have	O
performed	O
such	O
analysis	O
.	O

Readers	O
are	O
urged	O
to	O
analyze	O
the	O
expression	O
of	O
desired	O
genes	O
directly	O
as	O
it	O
is	O
impossible	O
to	O
test	O
every	O
gene	O
given	O
the	O
large	O
body	O
of	O
data	O
generated	O
.	O

Comparison	O
between	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
resultsWe	O
have	O
previously	O
used	O
EST	O
scan	O
and	O
MPSS	O
to	O
analyze	O
pooled	O
samples	O
of	O
ESCs	O
and	O
EBs	O
from	O
three	O
different	O
WiCell	O
lines	O
(	O
H1	O
,	O
H7	O
and	O
H9	O
)	O
[	O
5	O
]	O
.	O

Comparison	O
between	O
the	O
two	O
methodologies	O
indicated	O
that	O
while	O
there	O
is	O
good	O
concordance	O
for	O
genes	O
expressed	O
at	O
high	O
levels	O
,	O
this	O
does	O
not	O
hold	O
for	O
genes	O
expressed	O
at	O
lower	O
levels	O
.	O

As	O
a	O
test	O
of	O
the	O
quality	O
of	O
the	O
data	O
generated	O
in	O
these	O
experiments	O
and	O
to	O
evaluate	O
whether	O
comparisons	O
can	O
be	O
made	O
across	O
different	O
methodologies	O
,	O
we	O
re	O
-	O
ran	O
the	O
identical	O
samples	O
on	O
the	O
bead	O
array	O
platform	O
.	O

The	O
complete	O
comparison	O
of	O
gene	O
expression	O
is	O
shown	O
in	O
Additional	O
file	O
2	O
and	O
is	O
summarized	O
in	O
Tables	O
3	O
and	O
Table	O
4	O
.	O

Overall	O
,	O
concordance	O
in	O
Illumina	O
array	O
was	O
better	O
than	O
that	O
evident	O
between	O
EST	O
scan	O
and	O
MPSS	O
datasets	O
[	O
9	O
]	O
,	O
but	O
clearly	O
showed	O
much	O
wider	O
differences	O
than	O
that	O
seen	O
with	O
running	O
duplicates	O
in	O
the	O
same	O
assay	O
format	O
.	O

Nevertheless	O
,	O
this	O
comparison	O
provides	O
an	O
independent	O
verification	O
of	O
the	O
data	O
and	O
suggests	O
that	O
if	O
a	O
sample	O
is	O
detected	O
in	O
more	O
than	O
one	O
large	O
-	O
scale	O
analysis	O
,	O
the	O
reliability	O
of	O
the	O
gene	O
expression	O
detection	O
is	O
high	O
,	O
which	O
also	O
reduces	O
the	O
number	O
of	O
individual	O
genes	O
needed	O
to	O
be	O
verified	O
.	O

Caution	O
should	O
be	O
observed	O
in	O
comparing	O
different	O
samples	O
run	O
on	O
different	O
platforms	O
,	O
especially	O
when	O
there	O
has	O
not	O
been	O
rigorous	O
bioinformatic	O
matching	O
of	O
the	O
source	O
sequences	O
used	O
to	O
identify	O
genes	O
in	O
the	O
platforms	O
.	O

Often	O
genes	O
called	O
by	O
the	O
same	O
symbol	O
originate	O
from	O
different	O
database	O
records	O
,	O
which	O
may	O
originate	O
from	O
different	O
splice	O
variants	O
or	O
contain	O
sequence	O
differences	O
due	O
to	O
polymorphisms	O
or	O
outright	O
error	O
[	O
19	O
]	O
.Table	O
3Expression	O
of	O
hESC	O
specific	O
markers	O
in	O
pooled	O
hESC	O
sample	O
as	O
detected	O
by	O
Illumina	O
bead	O
array	O
The	O
expression	O
of	O
previously	O
identified	O
hESC	O
markers	O
was	O
examined	O
in	O
all	O
hESC	O
samples	O
(	O
the	O
values	O
displayed	O
represent	O
the	O
expression	O
level	O
of	O
pooled	O
H1	O
,	O
H7	O
and	O
H9	O
)	O
.	O

Most	O
of	O
the	O
genes	O
were	O
also	O
identified	O
using	O
Illumina	O
bead	O
array	O
in	O
all	O
8	O
hESC	O
populations	O
in	O
this	O
study	O
(	O
1	O
*	O
)	O
,	O
the	O
gene	O
CER1	O
was	O
detected	O
in	O
all	O
except	O
one	O
duplicate	O
of	O
H9	O
(	O
2	O
*	O
)	O
,	O
Nanog	O
was	O
not	O
detected	O
in	O
all	O
populations	O
(	O
3	O
*	O
)	O
and	O
Sox2	O
,	O
Lin41	O
,	O
NR6A1	O
and	O
FoxD3	O
were	O
not	O
detected	O
in	O
the	O
array	O
although	O
they	O
were	O
present	O
in	O
the	O
chips	O
for	O
hybridization	O
(	O
4*	O
)	O
.AccessionSymbolPooled	O
ES	O
(	O
H1	O
,	O
7	O
,	O
9	O
)	O
CommentsNM_003641.1IFITM188441*NM_020997.2LEFTB6579.61*NM_024674.3LIN283944.11*NM_175849.1DNMT3B33911*NM_003212.1TDGF131691*NM_001769.2CD92930.81*NM_000165.2GJA12404.41*NM_021195.2CLDN62247.21*NM_004360.2CDH11972.91*NM_021127.1PMAIP11601.51*NM_032805.1ZNF2061504.51*NM_003577.1UTF11444.11*XM_050625.2SFRP21353.91*NM_006548.3IMP-212061*NM_152312.2GYLTL1B1066.61*NM_015973.2GAL1043.31*NM_003240.2EBAF944.11*NM_054023.2SCGB3A2890.51*NM_020990.2CKMT1742.41*NM_033668.1ITGB1694.71*NM_003744.3NUMB618.31*NM_007015.1LECT1597.41*NM_021912.2GABRB3482.71*NM_006729.2DIAPH2467.11*NM_000222.1KIT188.91*NM_005454.1CER1151.52*NM_024865.1NANOG56.93*NM_002701.1POU5F1694.41*NM_003106SOX2ND4*NM_006458.2LIN41ND4*NM_001489.3NR6A1ND4*NM_012183FOXD3ND4*Table	O
4Comparison	O
of	O
MPSS	O
and	O
Illumina	O
bead	O
array	O
results	O
The	O
samples	O
were	O
analyzed	O
by	O
MPSS	O
and	O
bead	O
array	O
.	O

The	O
number	O
of	O
genes	O
detected	O
by	O
each	O
method	O
and	O
the	O
degree	O
of	O
overlap	O
is	O
summarized	O
.	O

Note	O
much	O
higher	O
degree	O
of	O
overlap	O
when	O
the	O
top	O
2000	O
hits	O
were	O
compared	O
.	O

*	O
:	O
Most	O
of	O
the	O
genes	O
detected	O
by	O
MPSS	O
were	O
novel	O
genes	O
not	O
included	O
in	O
the	O
bead	O
array	O
.	O

ESNo.%Common	O
in	O
both	O
(	O
Top	O
2000	O
hits	O
)	O
1,62281.1Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,07146.0By	O
bead	O
array	O
only3,46231.4By	O
MPSS	O
only	O
*	O
2,50422.7Total11,037100EBNo.%Common	O
in	O
both	O
(	O
All	O
hits	O
)	O
5,16843.1By	O
bead	O
array	O
only4,13134.4By	O
MPSS	O
only	O
*	O
2,69422.5Total11,993100	O
Human	B
feeders	O
and	O
hESCs	O
can	O
be	O
readily	O
distinguished	O
and	O
contamination	O
can	O
be	O
readily	O
assessedFor	O
all	O
samples	O
,	O
we	O
conducted	O
an	O
unsupervised	O
one	O
-	O
way	O
hierarchical	O
clustering	O
analysis	O
.	O

The	O
clustering	O
analysis	O
was	O
based	O
on	O
the	O
average	O
linkage	O
and	O
Euclidean	O
distances	O
as	O
the	O
similarity	O
metric	O
using	O
differentially	O
expressed	O
genes	O
identified	O
by	O
ANOVA	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
analysis	O
revealed	O
the	O
underlying	O
features	O
and	O
variation	O
patterns	O
of	O
gene	O
expression	O
in	O
each	O
cell	O
types	O
.	O

Figure	O
2	O
shows	O
results	O
of	O
the	O
cluster	O
analysis	O
of	O
relative	O
gene	O
expression	O
in	O
selected	O
samples	O
.	O

As	O
one	O
of	O
our	O
purposes	O
of	O
this	O
study	O
was	O
to	O
distinguish	O
between	O
human	B
fibroblast	O
feeders	O
cells	O
and	O
hESCs	O
and	O
hEBs	O
,	O
wishing	O
to	O
readily	O
detect	O
feeder	O
contamination	O
in	O
hESCs	O
,	O
we	O
included	O
one	O
of	O
the	O
human	B
feeder	O
cells	O
HS27	O
(	O
ATCC	O
)	O
in	O
this	O
study	O
.	O

We	O
have	O
been	O
using	O
HS27	O
as	O
feeder	O
cells	O
for	O
H9	O
hESCs	O
for	O
more	O
than	O
two	O
years	O
and	O
all	O
hESCs	O
grown	O
on	O
HS27	O
had	O
normal	O
karyotype	O
,	O
expressed	O
all	O
undifferentiated	O
markers	O
,	O
and	O
made	O
teratomas	O
with	O
all	O
germ	O
layers	O
(	O
data	O
not	O
show	O
)	O
.	O

The	O
global	O
pairwise	O
comparison	O
clearly	O
showed	O
that	O
human	B
feeders	O
were	O
far	O
more	O
dissimilar	O
to	O
hESCs	O
than	O
hESCs	O
grown	O
in	O
different	O
laboratories	O
,	O
hESCs	O
compared	O
to	O
their	O
differentiated	O
EBs	O
that	O
contained	O
mesodermal	O
tissue	O
,	O
and	O
hESCs	O
compared	O
to	O
the	O
karyotypically	O
variant	O
hESC	O
line	O
BG01V	O
.	O

Pairwise	O
comparisons	O
of	O
human	B
feeders	O
with	O
hESCs	O
resulted	O
in	O
a	O
correlation	O
coefficient	O
of	O
0.66	O
,	O
which	O
was	O
less	O
than	O
the	O
correlation	O
coefficient	O
of	O
0.71–0.74	O
observed	O
between	O
hESCs	O
and	O
their	O
corresponding	O
EBs	O
.	O

The	O
large	O
difference	O
between	O
human	B
feeders	O
and	O
hESCs	O
suggested	O
that	O
it	O
would	O
be	O
possible	O
to	O
identify	O
markers	O
that	O
were	O
robust	O
and	O
reliable	O
in	O
distinguishing	O
the	O
two	O
populations	O
,	O
and	O
these	O
markers	O
would	O
be	O
sufficiently	O
sensitive	O
in	O
detecting	O
contamination	O
of	O
feeders	O
.	O

We	O
examined	O
the	O
data	O
to	O
develop	O
a	O
list	O
of	O
genes	O
that	O
had	O
high	O
levels	O
of	O
expression	O
in	O
human	B
feeder	O
cells	O
maintained	O
in	O
hESC	O
medium	O
but	O
whose	O
expression	O
was	O
low	O
or	O
absent	O
in	O
either	O
ESCs	O
or	O
EBs	O
.	O

The	O
absence	O
of	O
expression	O
in	O
EBs	O
was	O
used	O
as	O
a	O
control	O
for	O
spontaneous	O
differentiation	O
of	O
ESC	O
colonies	O
(	O
including	O
mesodermal	O
differentiation	O
)	O
which	O
may	O
occur	O
and	O
the	O
markers	O
selected	O
should	O
be	O
able	O
to	O
distinguish	O
between	O
these	O
two	O
events	O
.	O

A	O
complete	O
list	O
of	O
genes	O
expressed	O
at	O
least	O
ten	O
-	O
fold	O
higher	O
in	O
human	B
feeders	O
is	O
provided	O
in	O
Figure	O
3	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
(	O
qPCR	O
)	O
was	O
used	O
to	O
verify	O
the	O
fold	O
change	O
of	O
the	O
expression	O
of	O
4	O
genes	O
,	O
including	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTHA4	O
(	O
Figure	O
3C	O
)	O
.	O

Further	O
confirmation	O
can	O
also	O
be	O
done	O
using	O
immunocytochemistry	O
,	O
as	O
antibodies	O
against	O
these	O
genes	O
are	O
commercially	O
available	O
.	O

Figure	O
3Human	O
fibroblast	O
feeder	O
cells	O
can	O
be	O
distinguished	O
from	O
hESCs	O
and	O
EBs	O
.	O

Bead	O
array	O
identified	O
lists	O
of	O
genes	O
that	O
were	O
uniquely	O
expressed	O
in	O
human	B
fibroblast	O
feeders	O
as	O
compared	O
to	O
hESCs	O
(	O
A	O
)	O
and	O
hEBs	O
(	O
B	O
)	O
.	O

The	O
four	O
genes	O
whose	O
expression	O
was	O
confirmed	O
by	O
qPCR	O
(	O
C	O
)	O
were	O
in	O
bold	O
.	O

In	O
the	O
graph	O
(	O
C	O
)	O
,	O
gene	O
expression	O
of	O
each	O
gene	O
in	O
feeder	O
cells	O
was	O
designated	O
as	O
1	O
fold	O
and	O
the	O
bars	O
represented	O
fold	O
decrease	O
for	O
each	O
gene	O
.	O

Thus	O
this	O
comparison	O
allowed	O
us	O
to	O
distinguish	O
between	O
hESCs	O
and	O
human	B
feeders	O
and	O
identify	O
candidate	O
markers	O
that	O
could	O
detect	O
feeder	O
cell	O
contamination	O
should	O
human	B
feeders	O
be	O
used	O
in	O
the	O
propagation	O
of	O
hESCs	O
.	O

hESCs	O
and	O
EBs	O
can	O
be	O
distinguished	O
from	O
each	O
otherIllumina	O
bead	O
array	O
analysis	O
confirmed	O
that	O
hESCs	O
could	O
be	O
readily	O
distinguished	O
from	O
EBs	O
by	O
global	O
analysis	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
specific	O
subsets	O
of	O
markers	O
could	O
be	O
identified	O
.	O

We	O
and	O
others	O
have	O
used	O
MPSS	O
and	O
EST	O
scan	O
and	O
generated	O
array	O
data	O
to	O
make	O
lists	O
of	O
hESC	O
-	O
specific	O
genes	O
[	O
5,9,10,20	O
]	O
.	O

As	O
discussed	O
above	O
,	O
most	O
hESC	O
markers	O
identified	O
by	O
MPSS	O
have	O
been	O
detected	O
in	O
the	O
present	O
bead	O
array	O
analysis	O
(	O
Table	O
3	O
)	O
,	O
confirming	O
the	O
utility	O
of	O
these	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
assessing	O
undifferentiated	O
status	O
of	O
hESCs	O
.	O

In	O
addition	O
,	O
we	O
have	O
generated	O
a	O
list	O
of	O
genes	O
differentially	O
expressed	O
at	O
higher	O
level	O
in	O
EBs	O
than	O
in	O
hESCs	O
,	O
a	O
subset	O
of	O
which	O
is	O
shown	O
in	O
Table	O
5	O
.	O

These	O
markers	O
were	O
common	O
to	O
all	O
EB	O
samples	O
tested	O
and	O
included	O
genes	O
known	O
to	O
be	O
expressed	O
in	O
ectoderm	O
,	O
endoderm	O
and	O
mesoderm	O
.	O

The	O
entire	O
set	O
of	O
differentially	O
expressed	O
genes	O
is	O
provided	O
in	O
Additional	O
file	O
3	O
.	O

Thus	O
,	O
the	O
bead	O
array	O
format	O
,	O
which	O
allows	O
multiple	O
pairwise	O
comparisons	O
,	O
can	O
be	O
used	O
to	O
identify	O
genes	O
that	O
are	O
expressed	O
by	O
all	O
differentiating	O
EB	O
samples	O
in	O
the	O
present	O
study	O
.	O

Our	O
data	O
suggested	O
that	O
a	O
core	O
set	O
of	O
limited	O
markers	O
might	O
be	O
sufficient	O
to	O
monitor	O
the	O
process	O
of	O
differentiation	O
.	O

By	O
suitable	O
selection	O
of	O
different	O
germ	O
cell	O
layer	O
specific	O
markers	O
one	O
may	O
also	O
assess	O
the	O
overall	O
quality	O
of	O
differentiation	O
toward	O
germ	O
cells	O
.	O

Table	O
5Genes	O
which	O
are	O
differentially	O
expressed	O
at	O
higher	O
levels	O
in	O
EBs	O
than	O
in	O
hESCsSymbolAll	O
EBAll	O
ESEB	O
/	O
ESRELN11120.52224.0SST1394.25.5253.5SLC40A11210.19.1133.0IGF24896.938.4127.5SLN2017.817118.7DCN7588.176.299.6ANXA84048.941.996.6AQP11665.420.581.2APOB1256.415.879.5AHSG1414.320.868.0NID21476.731.447.0FGB221052.442.2LUM8439.4205.441.1MGP2772.469.839.7THBD1206.434.435.1SERPINA11255.643.728.7HAND112294437.428.1HBE11106.542.626.0TTR7661.2347.122.1HBG21601.185.618.7COL2A11636.291.817.8KIAA09771370.87817.6AFP8941552.316.2COL3A11355796714.0IGFBP38446.3603.414.0PAX61577.8118.213.3APOA19398.1709.813.2FRZB3523.7315.711.2SPON21548.7159.49.7CEBPD1100.2122.79.0DLK13355.8374.89.0RDC11589.7192.18.3BMP41851.5227.38.1PITX21057.9131.28.1ACTA25045629.88.0GAS11215.61547.9AGTRL11053.8135.17.8COL5A15876.4765.47.7CDKN1C3134.1412.97.6CXCL142220.5312.67.1DOK41011.1145.27.0ARHGDIB1635.3246.56.6FLRT21879.5314.36.0MSX12771.8499.75.5	O
Smaller	O
but	O
distinct	O
differences	O
among	O
undifferentiated	O
hESC	O
linesOur	O
cluster	O
analysis	O
indicated	O
that	O
BG01	O
,	O
BG02	O
and	O
BG03	O
cell	O
lines	O
were	O
overall	O
more	O
similar	O
to	O
each	O
other	O
than	O
to	O
other	O
lines	O
(	O
Figure	O
1	O
and	O
2	O
)	O
,	O
but	O
nevertheless	O
showed	O
additional	O
differences	O
than	O
technical	O
or	O
biological	O
repeats	O
of	O
the	O
same	O
sample	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
this	O
microarray	O
strategy	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
identify	O
relatively	O
cell	O
type	O
specific	O
candidate	O
genes	O
that	O
could	O
be	O
used	O
to	O
distinguish	O
one	O
hESC	O
population	O
from	O
another	O
or	O
to	O
identify	O
differences	O
that	O
were	O
due	O
to	O
varied	O
isolation	O
and	O
growth	O
conditions	O
.	O

As	O
a	O
test	O
we	O
looked	O
for	O
differences	O
between	O
BG01	O
,	O
BG02	O
and	O
BG03	O
,	O
which	O
were	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
the	O
same	O
conditions	O
.	O

Lists	O
of	O
candidate	O
genes	O
are	O
shown	O
in	O
Figure	O
4A	O
,	O
C	O
and	O
4E	O
and	O
the	O
comparison	O
of	O
these	O
three	O
lines	O
are	O
shown	O
in	O
scatter	O
plots	O
in	O
Figure	O
4B	O
,	O
D	O
and	O
4F.Figure	O
4BG	O
lines	O
show	O
small	O
but	O
distinct	O
differences	O
as	O
assessed	O
by	O
bead	O
array	O
.	O

These	O
three	O
hESC	O
lines	O
share	O
high	O
similarities	O
as	O
shown	O
by	O
the	O
scatterplots	O
of	O
BG01	O
vs	O
BG02	O
(	O
B	O
)	O
,	O
BG01	O
vs	O
BG03	O
(	O
D	O
)	O
and	O
BG02	O
vs	O
BG03	O
(	O
F	O
)	O
.	O

Comparisons	O
of	O
all	O
three	O
lines	O
were	O
made	O
and	O
lists	O
of	O
selected	O
genes	O
that	O
were	O
specifically	O
expressed	O
in	O
BG01	O
(	O
A	O
)	O
,	O
BG02	O
(	O
C	O
)	O
and	O
BG03	O
(	O
F	O
)	O
are	O
shown	O
.	O

Correlation	O
coefficients	O
(	O
R2	O
)	O
were	O
generated	O
using	O
all	O
genes	O
with	O
expression	O
level	O
>	O
0	O
(	O
black	O
and	O
blue	O
dots	O
)	O
,	O
or	O
all	O
genes	O
with	O
detection	O
confidence	O
>	O
0.99	O
(	O
blue	O
dots	O
)	O
.	O

Genes	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

We	O
reasoned	O
as	O
well	O
that	O
such	O
a	O
global	O
comparison	O
should	O
allow	O
us	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
if	O
genes	O
present	O
on	O
the	O
Y	O
chromosome	O
were	O
expressed	O
at	O
high	O
levels	O
in	O
the	O
undifferentiated	O
state	O
and	O
were	O
detected	O
by	O
the	O
bead	O
array	O
.	O

Several	O
such	O
candidate	O
genes	O
were	O
identified	O
.	O

The	O
most	O
robust	O
were	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
and	O
EIF1AY	O
(	O
Figure	O
5	O
)	O
.	O

To	O
confirm	O
that	O
these	O
were	O
useful	O
markers	O
,	O
we	O
designed	O
RT	O
-	O
PCR	O
primers	O
and	O
tested	O
their	O
expression	O
in	O
a	O
male	O
(	O
BG01	O
)	O
and	O
a	O
female	O
(	O
BG03	O
)	O
line	O
(	O
Figure	O
5B	O
)	O
.	O

We	O
noted	O
that	O
several	O
of	O
these	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
as	O
ESCs	O
differentiated	O
to	O
form	O
EBs	O
and	O
upon	O
further	O
differentiation	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
markers	O
might	O
be	O
used	O
in	O
adult	O
stem	O
cell	O
and	O
germ	O
cell	O
populations	O
as	O
well	O
.	O

Figure	O
5Male	O
and	O
female	O
hESC	O
lines	O
can	O
be	O
distinguished	O
by	O
genes	O
identified	O
by	O
bead	O
array	O
.	O

Five	O
potential	O
genes	O
RPS4Y	O
,	O
RPS4Y2	O
,	O
EIF1AY	O
,	O
VCY	O
,	O
and	O
AMELY	O
are	O
located	O
in	O
the	O
Y	O
chromosome	O
.	O

By	O
comparing	O
the	O
expression	O
level	O
of	O
these	O
genes	O
in	O
all	O
hESC	O
lines	O
,	O
we	O
have	O
found	O
that	O
3	O
out	O
of	O
5	O
were	O
specifically	O
expressed	O
in	O
male	O
hESC	O
lines	O
I6	O
,	O
BG01	O
and	O
BG02	O
(	O
A	O
)	O
and	O
this	O
was	O
verified	O
by	O
RT	O
-	O
PCR	O
in	O
male	O
line	O
BG01	O
and	O
female	O
line	O
BG03	O
(	O
B	O
)	O
.	O

G3PDH	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

*	O
:	O
represents	O
the	O
gene	O
expression	O
level	O
is	O
detected	O
at	O
<	O
0.99	O
confidence	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
the	O
bead	O
array	O
format	O
is	O
sufficiently	O
sensitive	O
and	O
global	O
that	O
it	O
can	O
distinguish	O
one	O
cell	O
line	O
from	O
another	O
even	O
if	O
those	O
two	O
cell	O
lines	O
are	O
grown	O
in	O
the	O
same	O
laboratory	O
under	O
virtually	O
identical	O
conditions	O
.	O

Bead	O
array	O
can	O
also	O
be	O
used	O
to	O
distinguish	O
between	O
male	O
and	O
female	O
lines	O
.	O

Comparison	O
of	O
diploid	O
pluripotent	O
cells	O
with	O
NTera2	O
and	O
BG01	O
variantOur	O
previous	O
results	O
have	O
suggested	O
that	O
EC	O
lines	O
share	O
many	O
of	O
the	O
properties	O
of	O
hESCs	O
and	O
can	O
be	O
used	O
as	O
a	O
useful	O
model	O
for	O
initial	O
testing	O
of	O
biological	O
questions	O
[	O
21	O
]	O
.	O

More	O
recently	O
we	O
have	O
identified	O
BG01V	O
as	O
a	O
karyotypically	O
abnormal	O
variant	O
that	O
behaves	O
much	O
like	O
its	O
normal	O
counterpart	O
BG01	O
,	O
but	O
is	O
not	O
subject	O
to	O
the	O
same	O
constraints	O
of	O
use	O
as	O
karyotypically	O
normal	O
hESCs	O
[	O
13	O
]	O
.	O

Given	O
the	O
sensitivity	O
of	O
the	O
bead	O
array	O
analysis	O
,	O
we	O
tested	O
its	O
ability	O
to	O
detect	O
the	O
overall	O
similarities	O
and	O
differences	O
between	O
NTera2	O
and	O
a	O
pooled	O
ESC	O
sample	O
or	O
between	O
the	O
karyotypically	O
abnormal	O
BG01V	O
and	O
its	O
normal	O
parent	O
line	O
(	O
Figure	O
6	O
)	O
.Figure	O
6Diploid	O
pluripotent	O
EC	O
cell	O
line	O
NTera2	O
and	O
karyotypically	O
abnormal	O
hESC	O
line	O
BG01V	O
can	O
be	O
distinguished	O
from	O
normal	O
hESCs	O
using	O
Illumina	O
array	O
.	O

Comparison	O
of	O
NTera2	O
and	O
pooled	O
hESC	O
sample	O
resulted	O
a	O
correlation	O
coefficient	O
of	O
0.8997	O
.	O

Two	O
lists	O
of	O
genes	O
,	O
which	O
were	O
specifically	O
expressed	O
in	O
NTera2	O
(	O
C	O
)	O
or	O
in	O
hESCs	O
(	O
E	O
)	O
were	O
identified	O
.	O

Likewise	O
,	O
while	O
sharing	O
similarities	O
with	O
BG01	O
(	O
B	O
,	O
correlation	O
coefficient=	O
0.9043	O
)	O
,	O
BG01V	O
was	O
different	O
from	O
BG01	O
in	O
expression	O
for	O
many	O
genes	O
,	O
particularly	O
genes	O
from	O
the	O
TGFβ	O
pathway	O
(	O
D	O
,	O
F	O
)	O
.	O

Black	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
at	O
>	O
0	O
expression	O
level	O
,	O
blue	O
dots	O
represent	O
genes	O
that	O
were	O
detected	O
both	O
at	O
>	O
0	O
expression	O
level	O
and	O
at	O
>	O
0.99	O
confidence	O
.	O

Genes	O
plotted	O
outside	O
the	O
two	O
thin	O
red	O
lines	O
were	O
detected	O
at	O
>	O
2.5-	O
fold	O
difference	O
.	O

Our	O
results	O
showed	O
that	O
,	O
while	O
NTera2	O
shared	O
a	O
high	O
similarity	O
with	O
hESCs	O
[	O
21	O
]	O
,	O
it	O
did	O
have	O
important	O
differences	O
with	O
hESC	O
lines	O
.	O

Examining	O
these	O
differences	O
(	O
summarized	O
in	O
Figure	O
6C	O
and	O
6E	O
)	O
,	O
we	O
noted	O
that	O
some	O
reflected	O
the	O
origin	O
of	O
the	O
tumor	O
cells	O
from	O
which	O
this	O
line	O
was	O
derived	O
[	O
14	O
]	O
.	O

Several	O
germ	O
cell	O
markers	O
such	O
as	O
GAGE2	O
,	O
GAGE7	O
and	O
GAGE8	O
were	O
highly	O
expressed	O
in	O
NTera2	O
but	O
were	O
absent	O
(	O
or	O
present	O
at	O
low	O
levels	O
)	O
in	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
(	O
See	O
Figure	O
6C	O
and	O
Additional	O
file	O
1	O
.	O

Note	O
that	O
the	O
GAGE	O
genes	O
are	O
highly	O
similar	O
in	O
sequence	O
,	O
making	O
it	O
difficult	O
to	O
distinguish	O
one	O
family	O
member	O
from	O
another	O
through	O
hybridization	O
;	O
thus	O
,	O
while	O
all	O
of	O
these	O
GAGE	O
gene	O
probes	O
gave	O
positive	O
signal	O
,	O
it	O
is	O
difficult	O
to	O
say	O
if	O
the	O
signal	O
came	O
from	O
the	O
specific	O
gene	O
itself	O
or	O
from	O
cross	O
-	O
hybridization	O
from	O
one	O
of	O
the	O
other	O
family	O
members	O
)	O
.	O

None	O
of	O
these	O
were	O
present	O
in	O
BG01V	O
,	O
indicating	O
that	O
the	O
karyotypically	O
abnormal	O
variant	O
is	O
not	O
the	O
equivalent	O
of	O
a	O
teratocarcinoma	O
line	O
such	O
as	O
NTera2	O
.	O

In	O
addition	O
to	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
,	O
we	O
noticed	O
a	O
significant	O
difference	O
in	O
the	O
expression	O
of	O
genes	O
in	O
the	O
TGFβ	O
pathway	O
,	O
such	O
as	O
GDF3	O
(	O
Figure	O
6C	O
)	O
,	O
TGFBI	O
,	O
CDKN1A	O
,	O
IGFBP7	O
,	O
IGFBP3	O
,	O
NODAL	O
,	O
CER1	O
and	O
BMP2	O
(	O
Figure	O
6E	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
postulated	O
role	O
of	O
this	O
pathway	O
in	O
germ	O
cell	O
differentiation	O
[	O
22,23	O
]	O
and	O
suggests	O
that	O
TGFβ	O
pathway	O
can	O
not	O
be	O
reliably	O
tested	O
using	O
NTera2	O
as	O
a	O
model	O
for	O
hESC.The	O
BG01V	O
showed	O
clear	O
differences	O
from	O
its	O
normal	O
counterpart	O
and	O
some	O
major	O
changes	O
are	O
summarized	O
in	O
Figure	O
6D	O
and	O
6F	O
.	O

Early	O
markers	O
of	O
differentiation	O
appeared	O
to	O
be	O
present	O
at	O
higher	O
levels	O
in	O
BG01V	O
as	O
compared	O
to	O
any	O
of	O
the	O
hESC	O
lines	O
examined	O
,	O
although	O
hESC	O
specific	O
genes	O
continued	O
to	O
be	O
expressed	O
at	O
high	O
levels	O
(	O
see	O
Additional	O
file	O
4	O
)	O
.	O

In	O
particular	O
,	O
the	O
Wnt	O
pathway	O
and	O
the	O
TGFβ	O
signaling	O
pathway	O
(	O
Figure	O
6D	O
)	O
,	O
both	O
of	O
which	O
involved	O
in	O
the	O
early	O
process	O
of	O
differentiation	O
[	O
24,25	O
]	O
,	O
appeared	O
to	O
be	O
activated	O
(	O
Additional	O
file	O
4	O
)	O
,	O
suggesting	O
that	O
the	O
role	O
of	O
growth	O
factors	O
and	O
signaling	O
in	O
these	O
early	O
events	O
can	O
not	O
be	O
readily	O
studied	O
in	O
this	O
cell	O
line	O
.	O

In	O
summary	O
,	O
the	O
analysis	O
highlighted	O
the	O
utility	O
of	O
the	O
potential	O
reference	O
standards	O
NTera2	O
and	O
BG01V	O
,	O
demonstrated	O
their	O
general	O
similarity	O
and	O
provided	O
detail	O
on	O
potential	O
caveats	O
to	O
their	O
application	O
.	O

Global	O
arrays	O
provide	O
a	O
snapshot	O
of	O
the	O
state	O
of	O
the	O
cells	O
and	O
identify	O
core	O
self	O
-	O
renewal	O
pathwaysWe	O
have	O
utilized	O
a	O
small	O
fraction	O
of	O
the	O
data	O
to	O
demonstrate	O
the	O
overall	O
utility	O
of	O
this	O
approach	O
and	O
its	O
sensitivity	O
in	O
identifying	O
small	O
differences	O
in	O
cell	O
populations	O
.	O

An	O
additional	O
potential	O
application	O
of	O
such	O
an	O
analysis	O
is	O
the	O
ability	O
to	O
examine	O
the	O
general	O
state	O
of	O
a	O
particular	O
signaling	O
pathway	O
and	O
determine	O
whether	O
it	O
is	O
active	O
.	O

By	O
comparing	O
across	O
many	O
samples	O
,	O
a	O
procedure	O
previously	O
expensive	O
and	O
difficult	O
in	O
terms	O
of	O
the	O
RNA	O
and	O
replicate	O
requirement	O
,	O
one	O
can	O
rapidly	O
identify	O
key	O
regulatory	O
pathways	O
.	O

To	O
test	O
whether	O
we	O
could	O
use	O
such	O
multiple	O
pairwise	O
comparisons	O
to	O
elucidate	O
the	O
major	O
regulatory	O
pathways	O
that	O
may	O
be	O
required	O
for	O
hESC	O
self	O
-	O
renewal	O
,	O
we	O
examined	O
several	O
metabolic	O
pathways	O
.	O

The	O
results	O
of	O
the	O
analysis	O
of	O
the	O
insulin	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
signaling	O
pathway	O
are	O
shown	O
in	O
Figure	O
7	O
.	O

Using	O
the	O
same	O
4	O
groups	O
of	O
samples	O
as	O
in	O
Figure	O
1	O
,	O
we	O
conducted	O
PAM	O
(	O
Prediction	O
Analysis	O
of	O
Microarray	O
)	O
[	O
26	O
]	O
,	O
in	O
search	O
for	O
biomarkers	O
used	O
in	O
diagnostic	O
identification	O
of	O
these	O
four	O
groups	O
,	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
.	O

In	O
PAM	O
,	O
a	O
list	O
of	O
significant	O
IGF	O
pathway	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
was	O
obtained	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
each	O
class	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
took	O
the	O
gene	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
and	O
compared	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
.	O

For	O
cross	O
-	O
validation	O
of	O
prediction	O
results	O
,	O
multiple	O
classification	O
processes	O
were	O
performed	O
on	O
two	O
data	O
sets	O
randomly	O
constructed	O
each	O
time	O
from	O
the	O
entire	O
gene	O
expression	O
dataset	O
.	O

The	O
first	O
dataset	O
,	O
consisting	O
of	O
70	O
%	O
of	O
the	O
total	O
data	O
,	O
was	O
used	O
as	O
the	O
training	O
dataset	O
,	O
and	O
the	O
other	O
dataset	O
,	O
containing	O
the	O
remaining	O
30	O
%	O
of	O
data	O
,	O
was	O
used	O
for	O
the	O
data	O
prediction	O
and	O
verification	O
process	O
.	O

The	O
final	O
biomarkers	O
were	O
determined	O
in	O
such	O
a	O
way	O
that	O
the	O
misclassification	O
error	O
rate	O
was	O
minimal	O
.	O

The	O
resulting	O
graph	O
(	O
Figure	O
7	O
)	O
showed	O
the	O
shrunken	O
class	O
centroids	O
for	O
genes	O
that	O
had	O
at	O
least	O
one	O
nonzero	O
difference	O
in	O
each	O
diagnostic	O
class	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
represented	O
candidate	O
biomarkers	O
for	O
the	O
diagnosis	O
of	O
each	O
class	O
.	O

All	O
data	O
analyses	O
were	O
performed	O
using	O
the	O
bioconductor	O
package	O
[	O
17	O
]	O
.Figure	O
7Identification	O
of	O
diagnostic	O
markers	O
by	O
PAM	O
.	O

The	O
shrunken	O
class	O
centroids	O
for	O
genes	O
which	O
have	O
at	O
least	O
one	O
nonzero	O
difference	O
are	O
shown	O
.	O

The	O
genes	O
with	O
nonzero	O
components	O
in	O
each	O
class	O
were	O
almost	O
mutually	O
exclusive	O
and	O
were	O
the	O
candidate	O
molecular	O
markers	O
for	O
the	O
diagnosis	O
of	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
,	O
including	O
,	O
(	O
from	O
left	O
to	O
right	O
)	O
hESC	O
derived	O
mesenchyme	O
and	O
human	B
fibroblast	O
feeder	O
cells	O
(	O
""""	O
FB	O
""""	O
,	O
n	O
=	O
5	O
)	O
,	O
undifferentiated	O
hESCs	O
(	O
""""	O
ES	O
""""	O
,	O
n	O
=	O
11	O
)	O
,	O
hESC	O
derived	O
neural	O
cells	O
(	O
""""	O
NS	O
""""	O
,	O
n	O
=	O
3	O
)	O
,	O
and	O
differentiated	O
ES	O
cells	O
and	O
EB	O
,	O
(	O
""""	O
EB	O
""""	O
,	O
n	O
=	O
6	O
)	O
.	O

The	O
identified	O
biomarkers	O
can	O
be	O
used	O
to	O
distinguish	O
the	O
four	O
groups	O
of	O
cell	O
populations	O
.	O

Undifferentiated	O
hESCs	O
have	O
been	O
analyzed	O
by	O
EST	O
scan	O
,	O
MPSS	O
,	O
SAGE	O
and	O
microarray	O
[	O
5,10,16	O
]	O
.	O

The	O
goal	O
of	O
these	O
experiments	O
including	O
our	O
own	O
is	O
to	O
develop	O
a	O
low	O
cost	O
reliable	O
method	O
to	O
assess	O
multiple	O
samples	O
to	O
generate	O
a	O
global	O
database	O
of	O
markers	O
and	O
to	O
provide	O
a	O
method	O
of	O
identifying	O
core	O
measures	O
of	O
similarities	O
and	O
differences	O
across	O
multiple	O
laboratories	O
.	O

We	O
and	O
others	O
have	O
proposed	O
three	O
alternative	O
methods	O
of	O
assessment	O
:	O
Quantitative	O
RT	O
-	O
PCR	O
[	O
9,20	O
]	O
,	O
focused	O
arrays	O
[	O
27	O
]	O
or	O
a	O
large	O
scale	O
array	O
with	O
bioinformatics	O
tools	O
being	O
utilized	O
to	O
focus	O
on	O
appropriate	O
subsets	O
of	O
genes	O
[	O
5,7,15,16,28	O
]	O
.	O

Each	O
of	O
these	O
methods	O
has	O
its	O
advantages	O
and	O
disadvantages	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
global	O
Illumina	O
bead	O
array	O
retains	O
the	O
advantages	O
of	O
low	O
cost	O
per	O
sample	O
associated	O
with	O
focused	O
arrays	O
yet	O
still	O
has	O
the	O
strength	O
of	O
the	O
global	O
attributes	O
of	O
MPSS	O
or	O
EST	O
scan	O
while	O
requiring	O
much	O
less	O
RNA	O
and	O
turnaround	O
time	O
.	O

To	O
test	O
this	O
array	O
format	O
we	O
examined	O
samples	O
from	O
a	O
variety	O
of	O
laboratories	O
in	O
a	O
blinded	O
fashion	O
to	O
determine	O
whether	O
the	O
array	O
was	O
sufficiently	O
sensitive	O
and	O
rapid	O
for	O
routine	O
assessment	O
.	O

Duplicates	O
using	O
100	O
ng	O
of	O
RNA	O
were	O
run	O
and	O
results	O
obtained	O
forty	O
-	O
eight	O
hours	O
later	O
.	O

The	O
resolution	O
was	O
sufficient	O
that	O
ESC	O
samples	O
could	O
be	O
distinguished	O
from	O
one	O
another	O
and	O
a	O
variant	O
karyotypically	O
abnormal	O
subclone	O
could	O
be	O
distinguished	O
from	O
the	O
parent	O
population	O
(	O
correlation	O
coefficient	O
=	O
0.9043	O
)	O
.	O

Aliquots	O
of	O
the	O
pooled	O
ES	O
and	O
pooled	O
EB	O
samples	O
,	O
which	O
we	O
had	O
prepared	O
for	O
MPSS	O
,	O
were	O
included	O
in	O
this	O
run	O
to	O
compare	O
these	O
two	O
methods	O
directly	O
.	O

The	O
current	O
analysis	O
confirms	O
that	O
comparison	O
across	O
platforms	O
is	O
difficult	O
and	O
that	O
only	O
positive	O
results	O
can	O
be	O
treated	O
with	O
any	O
reliability	O
.	O

The	O
absence	O
of	O
expression	O
can	O
not	O
be	O
readily	O
interpreted	O
.	O

In	O
particular	O
,	O
genes	O
expressed	O
at	O
low	O
levels	O
(	O
greater	O
than	O
70	O
%	O
of	O
all	O
genes	O
detected	O
)	O
should	O
not	O
be	O
assessed	O
in	O
cross	O
platform	O
comparisons	O
.	O

The	O
limited	O
concordance	O
at	O
low	O
levels	O
raises	O
a	O
question	O
as	O
to	O
how	O
many	O
genes	O
are	O
actually	O
expressed	O
by	O
any	O
one	O
cell	O
line	O
and	O
whether	O
the	O
cutoff	O
of	O
3	O
tpm	O
used	O
for	O
MPSS	O
or	O
100	O
intensity	O
units	O
for	O
bead	O
arrays	O
is	O
a	O
reasonable	O
cutoff	O
.	O

We	O
used	O
100	O
units	O
for	O
our	O
analysis	O
and	O
we	O
would	O
suggest	O
that	O
readers	O
exercise	O
similar	O
caution	O
.	O

Nevertheless	O
even	O
at	O
this	O
higher	O
cutoff	O
the	O
arrays	O
were	O
remarkably	O
sensitive	O
and	O
allowed	O
us	O
to	O
readily	O
distinguish	O
between	O
samples	O
including	O
cells	O
grown	O
in	O
the	O
same	O
laboratory	O
.	O

The	O
basis	O
of	O
the	O
sensitivity	O
could	O
be	O
attributed	O
to	O
a	O
limited	O
set	O
of	O
genes	O
and	O
those	O
genes	O
could	O
be	O
identified	O
for	O
future	O
use	O
.	O

For	O
example	O
BG01V	O
,	O
while	O
much	O
more	O
similar	O
to	O
BG01	O
than	O
to	O
any	O
other	O
cell	O
type	O
,	O
could	O
still	O
be	O
distinguished	O
from	O
a	O
biological	O
replicate	O
of	O
BG01	O
by	O
the	O
expression	O
of	O
a	O
particular	O
subset	O
of	O
differentiation	O
markers	O
(	O
Figure	O
6	O
)	O
.	O

EC	O
cells	O
such	O
as	O
NTera2	O
could	O
be	O
distinguished	O
from	O
hESCs	O
by	O
the	O
expression	O
of	O
germ	O
cell	O
markers	O
and	O
the	O
presence	O
of	O
a	O
partially	O
inactivated	O
TGFβ	O
(	O
BMP	O
)	O
signaling	O
pathway	O
(	O
Figure	O
6	O
)	O
.	O

Distinguishing	O
ESCs	O
from	O
EBs	O
was	O
relatively	O
straightforward	O
.	O

We	O
have	O
confirmed	O
the	O
utility	O
of	O
previously	O
identified	O
markers	O
for	O
use	O
in	O
this	O
platform	O
as	O
well	O
as	O
identified	O
an	O
additional	O
set	O
of	O
markers	O
that	O
can	O
serve	O
as	O
biomarkers	O
to	O
distinguish	O
between	O
the	O
hESC	O
and	O
EB	O
states	O
.	O

A	O
subset	O
of	O
these	O
markers	O
have	O
been	O
used	O
to	O
develop	O
a	O
qPCR	O
assay	O
that	O
shows	O
such	O
a	O
high	O
sensitivity	O
that	O
changes	O
in	O
cell	O
behavior	O
can	O
be	O
detected	O
after	O
as	O
little	O
as	O
twenty	O
-	O
four	O
hours	O
and	O
the	O
development	O
of	O
EBs	O
can	O
be	O
reliably	O
staged	O
[	O
10,20	O
]	O
.	O

During	O
the	O
identification	O
of	O
ES	O
and	O
EB	O
specific	O
markers	O
,	O
we	O
have	O
noticed	O
that	O
some	O
known	O
hESC	O
markers	O
,	O
such	O
as	O
Nanog	O
,	O
was	O
not	O
detected	O
in	O
all	O
populations	O
of	O
hESCs	O
that	O
were	O
included	O
in	O
this	O
analysis	O
.	O

Several	O
ESC	O
-	O
specific	O
gene	O
,	O
including	O
Lin41	O
,	O
Sox2	O
and	O
FoxD3	O
,	O
were	O
not	O
detected	O
in	O
the	O
array	O
either	O
(	O
Table	O
3	O
)	O
.	O

We	O
believe	O
that	O
the	O
problem	O
with	O
Lin	O
41	O
,	O
Sox2	O
and	O
FoxD3	O
is	O
a	O
technical	O
one	O
as	O
we	O
were	O
able	O
to	O
confirm	O
expression	O
using	O
alternate	O
methods	O
.	O

We	O
are	O
in	O
progress	O
of	O
redesigning	O
appropriate	O
probes	O
for	O
these	O
genes	O
.	O

In	O
the	O
case	O
of	O
the	O
gene	O
Nanog	O
,	O
there	O
are	O
several	O
pseudo	O
genes	O
in	O
the	O
genome	O
for	O
Nanog	O
and	O
it	O
has	O
been	O
a	O
major	O
technical	O
challenge	O
designing	O
primers	O
or	O
probes	O
that	O
are	O
specific	O
and	O
sensitive	O
.	O

We	O
believe	O
that	O
a	O
partial	O
explanation	O
for	O
the	O
variability	O
in	O
Nanog	O
expression	O
is	O
due	O
to	O
the	O
lack	O
of	O
sensitivity	O
to	O
this	O
gene	O
.	O

However	O
,	O
immunocytochemistry	O
while	O
not	O
strictly	O
quantitative	O
shows	O
similar	O
variability	O
when	O
used	O
to	O
assess	O
Nanog	O
expression	O
in	O
different	O
cell	O
lines	O
[	O
9,27,28	O
]	O
.	O

This	O
large	O
comparison	O
between	O
samples	O
allowed	O
us	O
to	O
identify	O
markers	O
that	O
distinguish	O
human	B
feeder	O
cells	O
from	O
hESC	O
.	O

While	O
we	O
have	O
listed	O
19	O
potential	O
markers	O
(	O
Figure	O
3	O
)	O
and	O
identified	O
several	O
hundred	O
potential	O
markers	O
as	O
shown	O
in	O
Additional	O
file	O
5	O
,	O
we	O
suggest	O
that	O
as	O
few	O
as	O
3–4	O
genes	O
may	O
be	O
sufficient	O
.	O

Previously	O
we	O
found	O
that	O
as	O
few	O
as	O
four	O
were	O
satisfactory	O
to	O
distinguish	O
between	O
hESCs	O
and	O
hEBs	O
,	O
which	O
are	O
two	O
much	O
more	O
closely	O
related	O
samples	O
[	O
9	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
confirmed	O
by	O
qPCR	O
the	O
differential	O
expression	O
of	O
four	O
genes	O
,	O
THBS1	O
,	O
MMP3	O
,	O
TNFRSF11B	O
and	O
KRTH4	O
,	O
to	O
separate	O
human	B
fibroblast	O
feeders	O
and	O
hESCs	O
(	O
Figure	O
3	O
)	O
.	O

Several	O
markers	O
such	O
as	O
MMP3	O
and	O
TNFRSF11B	O
have	O
commercially	O
available	O
antibodies	O
(	O
R&D	O
systems	O
)	O
that	O
may	O
be	O
used	O
to	O
further	O
confirm	O
contamination	O
of	O
feeder	O
cells	O
by	O
immunocytochemistry	O
.	O

Efforts	O
to	O
identify	O
other	O
useful	O
antibodies	O
based	O
on	O
these	O
results	O
continue	O
[	O
29	O
]	O
.	O

While	O
we	O
have	O
focused	O
on	O
the	O
immediate	O
utility	O
of	O
the	O
Illumina	O
array	O
platform	O
,	O
it	O
is	O
important	O
to	O
remember	O
that	O
this	O
array	O
provides	O
a	O
global	O
snapshot	O
of	O
cell	O
state	O
and	O
the	O
data	O
obtained	O
can	O
be	O
readily	O
compared	O
in	O
order	O
to	O
determine	O
key	O
signaling	O
pathways	O
.	O

The	O
ability	O
to	O
compare	O
multiple	O
samples	O
in	O
one	O
run	O
enhances	O
data	O
selectivity	O
and	O
reliability	O
.	O

To	O
make	O
such	O
analysis	O
more	O
readily	O
available	O
,	O
we	O
utilized	O
several	O
software	O
tools	O
including	O
the	O
software	O
package	O
available	O
through	O
Illumina	O
.	O

The	O
BeadStudio	O
software	O
provided	O
with	O
the	O
BeadLab	O
and	O
BeadStudio	O
genetic	O
analysis	O
systems	O
for	O
use	O
with	O
the	O
bead	O
array	O
datasets	O
provides	O
a	O
useful	O
set	O
of	O
analytical	O
and	O
presentation	O
tools	O
that	O
allow	O
straightforward	O
comparisons	O
,	O
which	O
are	O
sufficient	O
for	O
average	O
users	O
.	O

For	O
detailed	O
analysis	O
we	O
recommend	O
using	O
more	O
specific	O
commercial	O
tools	O
or	O
software	O
packages	O
developed	O
by	O
NCBI	O
.	O

In	O
summary	O
,	O
the	O
Illumina	O
bead	O
array	O
has	O
several	O
key	O
strengths	O
including	O
high	O
throughput	O
,	O
low	O
cost	O
and	O
high	O
sensitivity	O
.	O

By	O
using	O
this	O
array	O
,	O
we	O
can	O
readily	O
detect	O
contaminating	O
feeders	O
and	O
spontaneous	O
differentiation	O
,	O
differentiate	O
male	O
and	O
female	O
lines	O
and	O
distinguish	O
between	O
one	O
undifferentiated	O
population	O
and	O
another	O
.	O

Such	O
a	O
global	O
analysis	O
allows	O
us	O
to	O
assess	O
context	O
dependent	O
signaling	O
and	O
identify	O
biomarkers	O
of	O
particular	O
states	O
of	O
cells	O
.	O

Our	O
future	O
efforts	O
will	O
focus	O
on	O
data	O
mining	O
and	O
developing	O
better	O
cross	O
platform	O
comparison	O
tools	O
and	O
generating	O
focused	O
high	O
throughput	O
arrays	O
for	O
quality	O
control	O
in	O
clinical	O
and	O
research	O
settings	O
.	O

hESC	O
cultureThe	O
hESC	O
lines	O
H1	O
,	O
H7	O
and	O
H9	O
(	O
WiCell	O
,	O
Madison	O
,	O
WI	O
)	O
were	O
cultured	O
on	O
feeder	O
layers	O
derived	O
from	O
mitotically	O
inactivated	O
HS27	O
human	B
fibroblast	O
cells	O
(	O
HS27	O
,	O
ATCC	O
)	O
,	O
or	O
mouse	B
embryonic	O
fibroblsts	O
or	O
under	O
feeder	O
-	O
free	O
conditions	O
on	O
Matrigel	O
(	O
BD	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
)	O
coated	O
plates	O
for	O
at	O
least	O
10	O
passages	O
.	O

Culture	O
medium	O
for	O
all	O
cultures	O
was	O
composed	O
of	O
DMEM	O
/	O
F12-Glutamax	O
1:1	O
,	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
nonessential	O
amino	O
acids	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
(	O
all	O
from	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
,	O
and	O
4	O
ng	O
/	O
ml	O
human	B
recombinant	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
/	O
FGF2	O
;	O
PeproTech	O
Inc.	O
,	O
Rocky	O
Hill	O
,	O
NJ	O
.	O
)	O

Feeder	O
-	O
free	O
cultures	O
were	O
prepared	O
for	O
gene	O
expression	O
analysis	O
by	O
manually	O
harvesting	O
individual	O
colonies	O
with	O
uniform	O
typical	O
undifferentiated	O
ESC	O
morphology	O
.	O

BG01	O
(	O
46	O
,	O
XY	O
)	O
,	O
BG02	O
(	O
46	O
,	O
XY	O
)	O
,	O
BG03	O
(	O
46	O
,	O
XX	O
)	O
,	O
I6	O
(	O
46	O
,	O
XY	O
)	O
and	O
BG01V	O
(	O
BG01	O
karyotypic	O
variant	O
:	O
49	O
,	O
XXY	O
,	O
+	O
12	O
,	O
+	O
17	O
)	O
:	O
Cells	O
were	O
maintained	O
for	O
3	O
(	O
BG01V	O
)	O
,	O
7	O
(	O
BG02	O
)	O
,	O
8	O
(	O
BG01	O
)	O
,	O
or	O
21	O
(	O
BG03	O
)	O
passages	O
under	O
feeder	O
-	O
free	O
condition	O
on	O
fibronectin	O
-	O
coated	O
plates	O
in	O
medium	O
that	O
had	O
been	O
conditioned	O
by	O
mouse	B
embryonic	O
fibroblasts	O
for	O
24	O
hours	O
.	O

Culture	O
medium	O
was	O
DMEM	O
/	O
F12	O
,	O
1:1	O
supplemented	O
with	O
20	O
%	O
Knockout	O
Serum	O
Replacement	O
,	O
2	O
mM	O
non	O
-	O
essential	O
amino	O
acids	O
,	O
2	O
mM	O
L	O
-	O
glutamine	O
,	O
50	O
μg	O
/	O
ml	O
Pen	O
-	O
Strep	O
,	O
100	O
μM	O
beta	O
-	O
mercaptoethanol	O
,	O
and	O
4	O
ng	O
/	O
ml	O
of	O
bFGF.Different	O
hESC	O
lines	O
were	O
grown	O
in	O
slightly	O
different	O
culture	O
conditions	O
as	O
described	O
above	O
.	O

H	O
lines	O
were	O
grown	O
on	O
Matrigel	O
coated	O
dishes	O
,	O
while	O
BG	O
lines	O
on	O
fibronectin	O
treated	O
dishes	O
.	O

These	O
coating	O
substrata	O
supported	O
the	O
growth	O
of	O
hESCs	O
similarly	O
,	O
as	O
evaluated	O
by	O
colony	O
morphology	O
,	O
immunocytochemistry	O
and	O
proliferation	O
rate	O
(	O
data	O
not	O
shown	O
)	O
.Embryoid	O
bodies	O
(	O
EBs	O
)	O
were	O
prepared	O
from	O
BG	O
lines	O
as	O
described	O
in	O
[	O
5	O
]	O
.	O

Cells	O
were	O
aggregated	O
and	O
cultured	O
on	O
non	O
-	O
adherent	O
substrata	O
for	O
fourteen	O
days	O
.	O

Other	O
cellsNTera2	O
cells	O
were	O
purchased	O
from	O
ATCC	O
and	O
cultured	O
in	O
parallel	O
with	O
hESCssamples	O
using	O
protocols	O
described	O
previously	O
[	O
21	O
]	O
.	O

HS27	O
embryonic	O
human	B
newborn	O
foreskin	O
cells	O
(	O
ATCC	O
CRL-1634	O
)	O
were	O
grown	O
in	O
DMEM	O
with	O
10%FBS.All	O
samples	O
included	O
in	O
this	O
study	O
can	O
be	O
found	O
in	O
Additional	O
file	O
6.Bead	O
array	O
gene	O
expression	O
analysisRNA	O
was	O
isolated	O
from	O
cultured	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
(	O
Qiagen	O
,	O
Inc	O
,	O
Valencia	O
,	O
CA	O
)	O
.	O

Sample	O
amplification	O
was	O
performed	O
using	O
100	O
ng	O
of	O
total	O
RNA	O
as	O
input	O
material	O
by	O
the	O
method	O
of	O
Van	O
Gelder	O
et	O
al	O
[	O
30	O
]	O
.	O

Amplified	O
RNA	O
synthesized	O
from	O
limited	O
quantities	O
of	O
heterogenous	O
cDNA	O
[	O
30	O
]	O
was	O
performed	O
using	O
the	O
Illumina	O
RNA	O
Amplification	O
kit	O
(	O
Ambion	O
,	O
Inc.	O
,	O
Austin	O
,	O
TX	O
)	O
following	O
the	O
Manufacturer	O
instructions	O
.	O

Labeling	O
was	O
achieved	O
by	O
use	O
of	O
the	O
incorporation	O
of	O
biotin-16-UTP	O
(	O
Perkin	O
Elmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Boston	O
,	O
MA	O
)	O
present	O
at	O
a	O
ratio	O
of	O
1:1	O
with	O
unlabeled	O
UTP	O
.	O

Labeled	O
,	O
amplified	O
material	O
(	O
700	O
ng	O
per	O
array	O
)	O
was	O
hybridized	O
to	O
a	O
pilot	O
version	O
of	O
the	O
Illumina	O
HumanRef-8	B
BeadChip	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
(	O
Illumina	O
,	O
Inc.	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Amersham	O
fluorolink	O
streptavidin	O
-	O
Cy3	O
(	O
GE	O
Healthcare	O
Bio	O
-	O
Sciences	O
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
following	O
the	O
BeadChip	O
manual	O
.	O

Arrays	O
were	O
scanned	O
with	O
an	O
Illumina	O
Bead	O
array	O
Reader	O
confocal	O
scanner	O
according	O
to	O
the	O
Manufacturer	O
's	O
instructions	O
.	O

Array	O
data	O
processing	O
and	O
analysis	O
was	O
performed	O
using	O
Illumina	O
BeadStudio	O
software	O
.	O

Identification	O
of	O
differentially	O
expressed	O
genes	O
and	O
clustering	O
analysisDifferentially	O
expressed	O
genes	O
between	O
ES	O
and	O
EB	O
were	O
identified	O
by	O
ANOVA	O
at	O
p	O
value	O
0.05	O
using	O
bioconductor	O
[	O
17	O
]	O
.	O

Unsupervised	O
hierarchical	O
clustering	O
analysis	O
and	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
were	O
conducted	O
using	O
software	O
Pcluster	O
[	O
31	O
]	O
and	O
TreeView	O
[	O
18	O
]	O
.Identification	O
of	O
diagnostic	O
markersPAM	O
(	O
prediction	O
analysis	O
of	O
microarray	O
)	O
was	O
employed	O
for	O
the	O
identification	O
of	O
diagnostic	O
markers	O
from	O
insulin	O
pathway	O
genes	O
by	O
using	O
the	O
software	O
package	O
bioconductor	O
[	O
17	O
]	O
.	O

PAM	O
is	O
a	O
class	O
prediction	O
method	O
for	O
expression	O
data	O
mining	O
.	O

It	O
can	O
provide	O
a	O
list	O
of	O
significant	O
genes	O
whose	O
expression	O
characterizes	O
each	O
diagnostic	O
class	O
.	O

The	O
average	O
gene	O
expression	O
level	O
in	O
multiple	O
classes	O
,	O
such	O
as	O
ES	O
,	O
EB	O
,	O
NS	O
,	O
and	O
FB	O
,	O
was	O
divided	O
by	O
the	O
within	O
-	O
class	O
standard	O
deviation	O
for	O
that	O
gene	O
.	O

The	O
nearest	O
centroid	O
classification	O
computed	O
by	O
PAM	O
takes	O
the	O
protein	O
expression	O
profile	O
from	O
a	O
new	O
sample	O
,	O
and	O
compares	O
it	O
to	O
each	O
of	O
these	O
class	O
centroids	O
[	O
26	O
]	O
.RT	O
-	O
PCR	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
analysisTotal	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
(	O
Invitrogen	O
.	O

cDNA	O
was	O
synthesized	O
using	O
2.5	O
μg	O
total	O
RNA	O
in	O
a	O
20-μl	O
reaction	O
with	O
Superscript	O
II	O
(	O
Invitrogen	O
)	O
and	O
oligo	O
(	O
dT	O
)	O
12–18	O
(	O
Promega	O
;	O
Madison	O
,	O
WI	O
)	O
.	O

One	O
microliter	O
RNase	O
H	O
(	O
Invitrogen	O
)	O
was	O
added	O
to	O
each	O
tube	O
and	O
incubated	O
for	O
20	O
minutes	O
at	O
37	O
°	O
C	O
before	O
proceeding	O
to	O
the	O
RT	O
-	O
PCR	O
analysis	O
.	O

The	O
PCR	O
primers	O
are	O
:	O
RPS4Y	O
-	O
forward	O
:	O
5	O
'	O
AGATTCTCTTCCGTCGCAG	O
3	O
'	O
,	O
RPS4Y	O
-	O
reverse	O
,	O
5	O
'	O
CTCCACCAATCACCATACAC	O
3	O
'	O
;	O
EIFAY	O
-	O
forward	O
,	O
5	O
'	O
CTGCTGCATCTTAGTTCAGTC	O
3	O
'	O
;	O
EIFAY	O
-	O
reverse	O
5	O
'	O
CTTCCAATCGTCCATTTCCC	O
3	O
'	O
.	O

Quantitative	O
real	O
time	O
PCR	O
gene	O
specific	O
primer	O
pairs	O
and	O
probes	O
were	O
purchased	O
from	O
Applied	O
Biosystems	O
(	O
Foster	O
City	O
,	O
CA	O
)	O
for	O
the	O
following	O
genes	O
:	O
MMP3	O
(	O
Hs00233962_m1	O
)	O
,	O
TFRSF11B	O
(	O
Hs00171068_m1	O
)	O
,	O
THBS1	O
(	O
Hs00170236_m1	O
)	O
,	O
KRTHA4	O
(	O
Hs00606019_gH	O
)	O
,	O
and	O
for	O
internal	O
control	O
β	O
-	O
actin	O
(	O
ACTB	O
,	O
Hs99999903_m1	O
)	O
.	O

BackgroundHuman	O
stem	O
cells	O
are	O
viewed	O
as	O
a	O
possible	O
source	O
of	O
neurons	O
for	O
a	O
cell	O
-	O
based	O
therapy	O
of	O
neurodegenerative	O
disorders	O
,	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Several	O
protocols	O
that	O
generate	O
different	O
types	O
of	O
neurons	O
from	O
human	B
stem	O
cells	O
(	O
hSCs	O
)	O
have	O
been	O
developed	O
.	O

Nevertheless	O
,	O
the	O
cellular	O
mechanisms	O
that	O
underlie	O
the	O
development	O
of	O
neurons	O
in	O
vitro	O
as	O
they	O
are	O
subjected	O
to	O
the	O
specific	O
differentiation	O
protocols	O
are	O
often	O
poorly	O
understood	O
.	O

ResultsWe	O
have	O
designed	O
a	O
focused	O
DNA	O
(	O
oligonucleotide	O
-	O
based	O
)	O
large	O
-	O
scale	O
microarray	O
platform	O
(	O
named	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
and	O
used	O
it	O
to	O
study	O
gene	O
expression	O
patterns	O
in	O
hSCs	O
as	O
they	O
differentiate	O
into	O
neurons	O
.	O

We	O
have	O
selected	O
genes	O
that	O
are	O
relevant	O
to	O
cells	O
(	O
i	O
)	O
being	O
stem	O
cells	O
,	O
(	O
ii	O
)	O
becoming	O
neurons	O
,	O
and	O
(	O
iii	O
)	O
being	O
neurons	O
.	O

The	O
NeuroStem	O
Chip	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
the	O
NeuroStem	O
Chip	O
in	O
detail	O
and	O
describe	O
the	O
special	O
advantages	O
it	O
offers	O
to	O
the	O
fields	O
of	O
experimental	O
neurology	O
and	O
stem	O
cell	O
biology	O
.	O

To	O
illustrate	O
the	O
utility	O
of	O
NeuroStem	O
Chip	O
platform	O
,	O
we	O
have	O
characterized	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
human	B
embryonic	O
stem	O
cells	O
(	O
hESCs	O
,	O
cell	O
line	O
SA02	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
performed	O
a	O
comparative	O
gene	O
expression	O
analysis	O
of	O
those	O
cells	O
versus	O
a	O
heterogeneous	O
population	O
of	O
hESC	O
-	O
derived	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	O
stromal	O
cells	O
for	O
16	O
days	O
and	O
containing	O
a	O
few	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

ConclusionWe	O
characterized	O
the	O
gene	O
expression	O
profiles	O
of	O
undifferentiated	O
and	O
dopaminergic	O
lineage	O
-	O
committed	O
hESC	O
-	O
derived	O
cells	O
using	O
a	O
highly	O
focused	O
custom	O
microarray	O
platform	O
(	O
NeuroStem	O
Chip	O
)	O
that	O
can	O
become	O
an	O
important	O
research	O
tool	O
in	O
human	B
stem	O
cell	O
biology	O
.	O

We	O
propose	O
that	O
the	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
hSC	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

Modern	O
DNA	O
microarrays	O
permit	O
a	O
comprehensive	O
analysis	O
of	O
quantitative	O
and	O
qualitative	O
changes	O
in	O
RNA	O
transcript	O
abundance	O
,	O
outlining	O
the	O
cross	O
-	O
sections	O
of	O
gene	O
expression	O
and	O
alterations	O
of	O
these	O
in	O
response	O
to	O
genetic	O
or	O
environmental	O
stimuli	O
.	O

Genome	O
-	O
scale	O
microarrays	O
(	O
cDNA-	O
or	O
oligonucleotide	O
-	O
based	O
)	O
are	O
most	O
valuable	O
when	O
screening	O
populations	O
of	O
cells	O
for	O
the	O
novel	O
genes	O
reflecting	O
potential	O
diagnostic	O
and	O
prognostic	O
markers	O
or	O
for	O
an	O
identification	O
of	O
novel	O
therapeutic	O
targets	O
.	O

On	O
the	O
other	O
hand	O
,	O
custom	O
microarray	O
platforms	O
that	O
focus	O
on	O
specific	O
pre	O
-	O
selected	O
subset	O
of	O
genes	O
relevant	O
to	O
a	O
particular	O
field	O
of	O
investigation	O
can	O
be	O
less	O
costly	O
and	O
more	O
suitable	O
for	O
detection	O
of	O
smaller	O
gene	O
expression	O
changes	O
.	O

Microarray	O
technology	O
has	O
added	O
important	O
information	O
on	O
both	O
normal	O
development	O
and	O
pathological	O
changes	O
in	O
neurons	O
.	O

This	O
is	O
well	O
illustrated	O
by	O
multiple	O
studies	O
on	O
substantia	O
nigra	O
dopaminergic	O
neurons	O
,	O
which	O
degenerate	O
in	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
[	O
1	O
-	O
5	O
]	O
.	O

The	O
shortcomings	O
of	O
pharmacological	O
therapies	O
in	O
PD	O
have	O
stimulated	O
a	O
search	O
for	O
alternative	O
treatment	O
strategies	O
.	O

In	O
successful	O
cases	O
,	O
transplants	O
of	O
human	B
embryonic	O
mesencephalic	O
dopaminergic	O
neurons	O
can	O
both	O
restore	O
dopaminergic	O
neurotransmission	O
and	O
provide	O
some	O
symptomatic	O
relief	O
[	O
6	O
-	O
8	O
]	O
.	O

A	O
wider	O
application	O
of	O
neural	O
transplantation	O
in	O
PD	O
is	O
,	O
however	O
,	O
currently	O
not	O
feasible	O
due	O
to	O
the	O
unpredictable	O
and	O
variable	O
outcome	O
,	O
the	O
risks	O
of	O
unwanted	O
side	O
-	O
effects	O
(	O
dyskinesias	O
)	O
[	O
9,10	O
]	O
and	O
ethical	O
and	O
practical	O
problems	O
associated	O
with	O
using	O
donor	O
cells	O
obtained	O
from	O
aborted	O
embryos	O
and	O
fetuses	O
[	O
11,12	O
]	O
.	O

Human	B
embryonic	O
stem	O
cells	O
(	O
hESCs	O
)	O
are	O
considered	O
a	O
promising	O
future	O
source	O
of	O
cells	O
for	O
cell	O
replacement	O
therapy	O
in	O
PD	O
and	O
other	O
neurological	O
conditions	O
[	O
13	O
]	O
.	O

They	O
could	O
constitute	O
a	O
virtually	O
infinite	O
source	O
of	O
self	O
-	O
renewing	O
cells	O
that	O
can	O
be	O
persuaded	O
to	O
differentiate	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
,	O
including	O
dopaminergic	O
neurons	O
[	O
14	O
-	O
16	O
]	O
.	O

The	O
molecular	O
mechanisms	O
that	O
govern	O
development	O
of	O
cultured	O
hESCs	O
into	O
specific	O
types	O
of	O
neural	O
cells	O
are	O
not	O
fully	O
understood	O
.	O

To	O
promote	O
our	O
understanding	O
of	O
such	O
mechanisms	O
,	O
it	O
would	O
be	O
valuable	O
to	O
have	O
tools	O
that	O
readily	O
and	O
reproducibly	O
can	O
help	O
to	O
characterize	O
the	O
cells	O
as	O
they	O
differentiate	O
from	O
pluripotent	O
stem	O
cells	O
into	O
post	O
-	O
mitotic	O
neurons	O
.	O

This	O
important	O
issue	O
was	O
addressed	O
in	O
earlier	O
studies	O
by	O
Luo	O
et	O
al.	O
and	O
Yang	O
et	O
al.	O
,	O
who	O
designed	O
small	O
-	O
to	O
-	O
moderate	O
scale	O
custom	O
microarray	O
platforms	O
(	O
281	O
and	O
755	O
gene	O
targets	O
,	O
respectively	O
)	O
[	O
17,18	O
]	O
.	O

In	O
addition	O
SuperArray	O
Bioscience	O
Corporation	O
(	O
Frederick	O
,	O
MD	O
,	O
USA	O
)	O
have	O
manufactured	O
a	O
range	O
of	O
small	O
-	O
scale	O
arrays	O
(	O
263	O
gene	O
targets	O
for	O
human	O
array	O
;	O
[	O
19	O
]	O
)	O
.	O

We	O
sought	O
to	O
create	O
an	O
improved	O
and	O
updated	O
microarray	O
platform	O
for	O
hESC	O
/	O
neuronal	O
differentiation	O
-	O
oriented	O
gene	O
expression	O
studies	O
.	O

Therefore	O
,	O
we	O
generated	O
a	O
specialized	O
large	O
-	O
scale	O
DNA	O
microarray	O
platform	O
(	O
the	O
""""	O
NeuroStem	O
Chip	O
""""	O
)	O
that	O
has	O
over	O
1,300	O
pre	O
-	O
selected	O
gene	O
targets	O
and	O
multiple	O
controls	O
spotted	O
in	O
quadruplicates	O
(	O
~46,000	O
spots	O
total	O
)	O
.	O

Here	O
we	O
introduce	O
the	O
platform	O
and	O
the	O
advantages	O
it	O
can	O
offers	O
to	O
neuroscientists	O
and	O
stem	O
cell	O
biologists	O
:	O
particularly	O
,	O
in	O
the	O
niche	O
of	O
gene	O
expression	O
-	O
oriented	O
characterization	O
of	O
the	O
samples	O
using	O
an	O
assay	O
of	O
pre	O
-	O
selected	O
,	O
already	O
established	O
gene	O
targets	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
use	O
the	O
NeuroStem	O
Chip	O
to	O
characterize	O
an	O
undifferentiated	O
population	O
of	O
pluripotent	O
hESCs	O
(	O
cell	O
line	O
SA02	O
,	O
Cellartis	O
AB	O
,	O
Göteborg	O
,	O
Sweden	O
)	O
and	O
compare	O
the	O
gene	O
expression	O
in	O
those	O
cells	O
with	O
that	O
of	O
a	O
hESC	O
-	O
derived	O
cell	O
population	O
rich	O
in	O
neurons	O
,	O
including	O
tyrosine	O
hydroxylase	O
-	O
positive	O
dopaminergic	O
neurons	O
.	O

Stem	O
cells	O
have	O
unique	O
biological	O
characteristics	O
,	O
but	O
only	O
a	O
limited	O
number	O
of	O
genes	O
are	O
currently	O
recognized	O
as	O
established	O
stem	O
cell	O
markers	O
.	O

Examples	O
include	O
POU	O
domain	O
,	O
class	O
5	O
,	O
transcription	O
factor	O
1	O
(	O
Oct3	O
/	O
4	O
)	O
,	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
,	O
teratocarcinoma	O
-	O
derived	O
growth	O
factor	O
(	O
Tdgf1	O
)	O
,	O
Enk	O
-	O
pending	O
(	O
Nanog	O
)	O
,	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
and	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
[	O
20	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
hundreds	O
of	O
genes	O
are	O
suggested	O
as	O
candidate	O
markers	O
for	O
""""	O
stemness	O
""""	O
,	O
but	O
their	O
coupling	O
to	O
the	O
undifferentiated	O
stem	O
cell	O
state	O
is	O
not	O
yet	O
fully	O
verified	O
[	O
21	O
]	O
.	O

The	O
concept	O
of	O
""""	O
stemness	O
""""	O
(	O
term	O
introduced	O
in	O
1986	O
by	O
Grossman	O
&	O
Levine	O
)	O
is	O
defined	O
as	O
""""	O
core	O
stem	O
cell	O
properties	O
that	O
underlie	O
self	O
-	O
renewal	O
and	O
the	O
ability	O
to	O
generate	O
differentiated	O
progeny	O
""""	O
[	O
22	O
]	O
.	O

Considering	O
the	O
complexity	O
of	O
the	O
processes	O
involved	O
,	O
stemness	O
can	O
hardly	O
be	O
ensured	O
by	O
co	O
-	O
operation	O
of	O
just	O
a	O
few	O
genes	O
.	O

Nevertheless	O
,	O
three	O
stemness	O
genes	O
(	O
namely	O
,	O
Oct3	O
/	O
4	O
,	O
Stat3	O
and	O
Nanog	O
)	O
are	O
considered	O
""""	O
master	O
"""-"	O
genes	O
that	O
control	O
the	O
self	O
-	O
renewing	O
process	O
[	O
23,24	O
]	O
.	O

Various	O
types	O
of	O
stem	O
cells	O
,	O
such	O
as	O
hematopoietic	O
,	O
mesenchymal	O
and	O
neural	O
(	O
HSCs	O
,	O
MSCs	O
and	O
NSCs	O
,	O
respectively	O
)	O
,	O
embryonic	O
germ	O
and	O
embryonic	O
carcinoma	O
cells	O
(	O
EGCs	O
and	O
ECCs	O
,	O
respectively	O
)	O
are	O
all	O
characterized	O
by	O
variations	O
in	O
gene	O
expression	O
profiles	O
,	O
and	O
only	O
a	O
few	O
gene	O
markers	O
are	O
associated	O
with	O
all	O
these	O
cell	O
types	O
[	O
25,26	O
]	O
.	O

We	O
have	O
aimed	O
to	O
embrace	O
the	O
most	O
comprehensive	O
set	O
of	O
those	O
genes	O
into	O
a	O
solitary	O
array	O
,	O
the	O
NeuroStem	O
Chip	O
.	O

Thereby	O
,	O
it	O
is	O
possible	O
to	O
employ	O
it	O
to	O
monitor	O
the	O
relative	O
expression	O
levels	O
of	O
numerous	O
known	O
and	O
candidate	O
stemness	O
genes	O
in	O
a	O
single	O
experiment	O
.	O

Similar	O
to	O
the	O
genetic	O
bases	O
underlying	O
stemness	O
,	O
cell	O
differentiation	O
is	O
associated	O
with	O
altered	O
expression	O
levels	O
of	O
certain	O
recognized	O
or	O
candidate	O
genes	O
[	O
25	O
]	O
.	O

We	O
therefore	O
incorporated	O
gene	O
markers	O
of	O
development	O
and	O
differentiation	O
in	O
general	O
,	O
and	O
that	O
of	O
neuronal	O
and	O
dopaminergic	O
differentiation	O
in	O
particular	O
,	O
into	O
the	O
NeuroStem	O
Chip	O
.	O

Examples	O
include	O
markers	O
for	O
the	O
processes	O
of	O
neuronal	O
maturation	O
,	O
axonal	O
branching	O
,	O
neural	O
/	O
neuronal	O
survival	O
,	O
etc	O
.	O

Finally	O
,	O
we	O
ensured	O
that	O
known	O
markers	O
for	O
specific	O
types	O
of	O
neurons	O
,	O
allowing	O
identification	O
of	O
individual	O
cell	O
types	O
,	O
were	O
present	O
on	O
the	O
chip	O
.	O

We	O
paid	O
special	O
attention	O
to	O
genes	O
associated	O
with	O
the	O
differentiation	O
and	O
maturation	O
of	O
dopaminergic	O
neurons	O
.	O

In	O
many	O
published	O
studies	O
,	O
the	O
expression	O
of	O
only	O
a	O
single	O
(	O
tyrosine	O
hydroxylase	O
,	O
TH	O
)	O
or	O
2–3	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
e.g.	O
amino	O
acid	O
decarboxylase	O
(	O
AADC	O
)	O
,	O
dopamine	O
transporter	O
(	O
DAT	O
)	O
,	O
vesicular	O
monoamine	O
transporter	O
2	O
(	O
VMAT2	O
)	O
)	O
have	O
been	O
used	O
to	O
indicate	O
dopaminergic	O
identity	O
of	O
neurons	O
.	O

In	O
contrast	O
,	O
the	O
NeuroStem	O
Chip	O
includes	O
oligonucleotide	O
probes	O
for	O
88	O
genes	O
related	O
to	O
dopaminergic	O
neurons	O
,	O
thus	O
being	O
more	O
comprehensive	O
in	O
this	O
sense	O
,	O
compared	O
to	O
other	O
existing	O
microarray	O
platforms	O
,	O
including	O
focused	O
ones	O
[	O
17,18	O
]	O
.	O

Those	O
entries	O
encompass	O
recognized	O
and	O
candidate	O
markers	O
for	O
dopaminergic	O
neurons	O
(	O
mature	O
and	O
early	O
)	O
and	O
progenitors	O
,	O
as	O
well	O
as	O
markers	O
for	O
the	O
maturation	O
and	O
differentiation	O
of	O
the	O
latter	O
(	O
Table	O
1	O
)	O
.	O

Table	O
2	O
represents	O
conditional	O
functional	O
breakdown	O
of	O
genes	O
targeted	O
by	O
the	O
NeuroStem	O
microarray	O
platform	O
.	O

A	O
number	O
of	O
important	O
gene	O
groups	O
that	O
are	O
included	O
in	O
the	O
chip	O
are	O
not	O
mentioned	O
in	O
Table	O
2	O
.	O

Among	O
these	O
,	O
entries	O
related	O
to	O
Dickkopf	O
gene	O
family	O
,	O
galanin-	O
,	O
melatonin-	O
,	O
vasoactive	O
intestinal	O
peptide	O
(	O
VIP	O
)	O
-	O
,	O
cAMP	O
response	O
element	O
-	O
binding	O
protein	O
(	O
CREB	O
)	O
-	O
and	O
B	O
cell	O
leukemia	O
2	O
(	O
Bcl2	O
)	O
oncogene	O
-	O
related	O
are	O
present	O
.	O

Many	O
of	O
them	O
play	O
potentially	O
important	O
,	O
yet	O
undefined	O
,	O
roles	O
in	O
the	O
biology	O
of	O
stem	O
cells	O
.	O

Additionally	O
,	O
we	O
included	O
some	O
genes	O
implicated	O
in	O
disease	O
mechanisms	O
of	O
neurodegenerative	O
disorders	O
(	O
most	O
importantly	O
,	O
Parkinson	O
's	O
disease	O
and	O
Alzheimer	O
's	O
disease	O
)	O
in	O
the	O
chip	O
.	O

Furthermore	O
,	O
we	O
incorporated	O
a	O
number	O
of	O
markers	O
for	O
distinct	O
differentiation	O
pathways	O
(	O
e.g.	O
hematopoietic	O
and	O
pancreatic	O
)	O
and	O
cell	O
types	O
(	O
e.g.	O
cancer	O
subtypes	O
and	O
a	O
range	O
of	O
normal	O
cell	O
types	O
)	O
to	O
serve	O
as	O
essential	O
controls	O
.	O

Taken	O
together	O
,	O
we	O
believe	O
that	O
in	O
its	O
present	O
form	O
NeuroStem	O
Chip	O
represents	O
currently	O
most	O
comprehensive	O
gene	O
expression	O
platform	O
for	O
studies	O
on	O
stem	O
cells	O
,	O
neural	O
/	O
neuronal	O
differentiation	O
,	O
human	B
neurodegeneration	O
and	O
neuronal	O
survival	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
complete	O
layout	O
of	O
NeuroStem	O
Chip	O
will	O
be	O
disclosed	O
to	O
the	O
academic	O
community	O
,	O
upon	O
request	O
.	O

The	O
microarray	O
format	O
we	O
selected	O
relies	O
on	O
long	O
oligonucleotide	O
molecules	O
(	O
69–71	O
nucleotides	O
)	O
printed	O
over	O
a	O
solid	O
surface	O
.	O

We	O
spotted	O
the	O
synthesized	O
oligonucleotides	O
(	O
Operon	O
Biotechnologies	O
)	O
with	O
a	O
constant	O
concentration	O
across	O
the	O
slides	O
,	O
and	O
evaluated	O
the	O
quality	O
and	O
consistency	O
of	O
spotting	O
in	O
a	O
series	O
of	O
control	O
experiments	O
.	O

We	O
then	O
illustrated	O
the	O
utility	O
and	O
technical	O
reliability	O
of	O
the	O
NeuroStem	O
Chip	O
by	O
characterizing	O
the	O
gene	O
expression	O
profile	O
of	O
commonly	O
utilized	O
hESC	O
line	O
SA02	O
(	O
Sahlgrenska	O
2	O
;	O
[	O
27	O
]	O
)	O
,	O
including	O
(	O
i	O
)	O
undifferentiated	O
cells	O
and	O
(	O
ii	O
)	O
cells	O
committed	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
.	O

For	O
the	O
first	O
of	O
these	O
,	O
we	O
used	O
total	O
RNA	O
sample	O
purified	O
from	O
hESC	O
colonies	O
that	O
exhibited	O
morphology	O
consistent	O
with	O
cell	O
proliferation	O
and	O
the	O
absence	O
of	O
spontaneous	O
differentiation	O
(	O
Figure	O
1A	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
expression	O
of	O
the	O
cell	O
cycle	O
marker	O
Ki67	O
and	O
the	O
pluripotency	O
marker	O
OCT3	O
/	O
4	O
in	O
the	O
sample	O
by	O
immunocytochemistry	O
(	O
Figure	O
1B	O
–	O
E	O
)	O
.	O

Co	O
-	O
culturing	O
of	O
ESCs	O
with	O
murine	B
stromal	O
cells	O
(	O
including	O
PA6	O
cell	O
line	O
)	O
rapidly	O
generates	O
dopaminergic	O
neurons	O
from	O
ESCs	O
by	O
an	O
unexplained	O
mechanism	O
termed	O
stromal	O
cell	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

We	O
therefore	O
committed	O
hESCs	O
toward	O
the	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
PA6	O
cells	O
for	O
16	O
days	O
,	O
resulting	O
in	O
appearance	O
of	O
cells	O
positive	O
for	O
early	O
and	O
late	O
neuronal	O
markers	O
,	O
including	O
nestin	O
,	O
β	O
-	O
III	O
-	O
tubulin	O
,	O
and	O
TH	O
,	O
the	O
established	O
marker	O
of	O
dopaminergic	O
neurons	O
(	O
Figure	O
2	O
)	O
.	O

To	O
verify	O
the	O
expression	O
of	O
some	O
key	O
stem	O
cell-	O
and	O
neural	O
phenotype	O
-	O
associated	O
genes	O
we	O
performed	O
RT	O
-	O
PCR	O
comparing	O
RNA	O
samples	O
from	O
the	O
undifferentiated	O
hESCs	O
with	O
hESCs	O
of	O
the	O
same	O
line	O
differentiated	O
toward	O
neuronal	O
/	O
dopaminergic	O
pathway	O
,	O
as	O
described	O
above	O
.	O

The	O
expression	O
profile	O
outlined	O
by	O
RT	O
-	O
PCR	O
confirmed	O
the	O
identity	O
of	O
the	O
sample	O
used	O
(	O
Figure	O
3	O
)	O
.	O

After	O
performing	O
RNA	O
integrity	O
tests	O
,	O
we	O
incorporated	O
fluorescent	O
labels	O
to	O
the	O
amplified	O
RNA	O
samples	O
from	O
hESCs	O
(	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
and	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
)	O
)	O
,	O
hESC	O
-	O
derived	O
cells	O
containing	O
TH	O
-	O
positive	O
neurons	O
(	O
Cy3	O
and	O
Cy5	O
)	O
and	O
human	O
universal	O
reference	O
RNA	O
(	O
Cy5	O
)	O
,	O
and	O
hybridized	O
aliquots	O
with	O
NeuroStem	O
microarray	O
slides	O
using	O
the	O
following	O
conditions	O
:	O
hESC	O
vs.	O
reference	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
i	O
)	O
20:10	O
pmol	O
,	O
and	O
(	O
ii	O
)	O
10:5	O
pmol	O
;	O
and	O
hESC	O
vs.	O
hESC	O
-	O
derived	O
cells	O
,	O
Cy3	O
:	O
Cy5	O
=	O
(	O
iii	O
)	O
30:20	O
pmol	O
,	O
respectively	O
.	O

Universal	O
reference	O
RNA	O
has	O
been	O
previously	O
established	O
as	O
a	O
standard	O
reference	O
material	O
for	O
microarray	O
experiments	O
,	O
proving	O
an	O
ability	O
to	O
effectively	O
hybridize	O
to	O
a	O
large	O
fraction	O
of	O
microarray	O
spots	O
[	O
30	O
]	O
.	O

We	O
performed	O
two	O
-	O
color	O
hybridizations	O
(	O
e.g.	O
for	O
the	O
experiment	O
vs.	O
reference	O
)	O
following	O
an	O
established	O
protocol	O
[	O
31	O
]	O
,	O
and	O
included	O
dye	O
-	O
flip	O
technical	O
replicates	O
in	O
the	O
analysis	O
(	O
Figure	O
4	O
)	O
.	O

Using	O
the	O
online	O
software	O
program	O
BASE	O
[	O
32	O
]	O
we	O
sequentially	O
filtered	O
the	O
data	O
by	O
background	O
subtraction	O
,	O
negative	O
flagging	O
,	O
negative	O
intensities	O
and	O
for	O
inconsistent	O
data	O
amongst	O
replicates	O
[	O
33	O
]	O
.	O

Figure	O
5A	O
shows	O
a	O
comparison	O
of	O
the	O
spot	O
intensities	O
prior	O
to	O
normalization	O
(	O
M	O
versus	O
A	O
plot	O
)	O
,	O
with	O
the	O
Log2	O
of	O
the	O
expression	O
ratio	O
between	O
Cy3	O
/	O
Cy5	O
being	O
plotted	O
as	O
a	O
function	O
of	O
the	O
log10	O
of	O
the	O
mean	O
of	O
the	O
total	O
expression	O
intensities	O
for	O
Cy3	O
and	O
Cy5	O
channels	O
.	O

The	O
deviation	O
of	O
the	O
line	O
from	O
zero	O
revealed	O
a	O
need	O
for	O
normalization	O
,	O
so	O
prior	O
to	O
data	O
analyses	O
we	O
normalized	O
signals	O
using	O
a	O
locally	O
weighted	O
scatterplot	O
-	O
smoothing	O
regression	O
(	O
LOWESS	O
)	O
algorithm	O
(	O
Figure	O
5A	O
–	O
B	O
;	O
fitted	O
line	O
)	O
implemented	O
in	O
BASE	O
.	O

Since	O
the	O
reproducibility	O
of	O
two	O
-	O
color	O
microarray	O
gene	O
expression	O
data	O
is	O
critically	O
important	O
,	O
we	O
calculated	O
Pearson	O
correlation	O
coefficients	O
of	O
the	O
reporters	O
present	O
in	O
the	O
filtered	O
database	O
comparing	O
the	O
average	O
expression	O
ratios	O
(	O
7005	O
for	O
hESCs	O
vs.	O
universal	O
reference	O
;	O
6947	O
for	O
undifferentiated	O
vs.	O
neuronal	O
/	O
dopaminergic	O
lineage	O
-	O
committed	O
hESCs	O
)	O
.	O

Results	O
obtained	O
revealed	O
that	O
data	O
were	O
consistent	O
across	O
technical	O
replicates	O
(	O
dye	O
-	O
swap	O
and	O
amount	O
of	O
loaded	O
material	O
)	O
,	O
showing	O
general	O
high	O
reproducibility	O
:	O
e.g.	O
,	O
correlation	O
coefficients	O
were	O
greater	O
than	O
0.96	O
for	O
technical	O
replicates	O
and	O
0.78	O
for	O
dye	O
-	O
swapping	O
samples	O
in	O
hESCs	O
vs.	O
universal	O
reference	O
hybridizations	O
(	O
Table	O
3	O
)	O
.	O

To	O
detect	O
genes	O
with	O
high	O
expression	O
levels	O
in	O
hESC	O
samples	O
,	O
we	O
filtered	O
data	O
for	O
intensity	O
values	O
>	O
100	O
in	O
the	O
hESC	O
sample	O
and	O
performed	O
clustering	O
analysis	O
using	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

To	O
visualize	O
variations	O
of	O
spot	O
/	O
reporter	O
per	O
technical	O
replicate	O
,	O
hierarchical	O
clustering	O
was	O
performed	O
by	O
K	O
-	O
means	O
classifier	O
based	O
on	O
the	O
linear	O
-	O
correlation	O
-	O
based	O
distance	O
(	O
Pearson	O
,	O
centred	O
)	O
method	O
.	O

The	O
optimal	O
number	O
of	O
clusters	O
was	O
determined	O
empirically	O
to	O
produce	O
the	O
most	O
balanced	O
ratio	O
of	O
entries	O
to	O
cluster	O
of	O
highly	O
expressed	O
genes	O
.	O

A	O
cluster	O
of	O
101	O
genes	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
[	O
see	O
Additional	O
file	O
1	O
]	O
,	O
was	O
plotted	O
in	O
a	O
centroid	O
graph	O
(	O
Figure	O
5C	O
)	O
;	O
the	O
variation	O
across	O
technical	O
replicates	O
was	O
low	O
.	O

We	O
merged	O
technical	O
replicates	O
to	O
generate	O
a	O
list	O
of	O
the	O
most	O
up	O
-	O
regulated	O
genes	O
expressed	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
(	O
Table	O
4	O
)	O
.	O

Standard	O
error	O
of	O
the	O
mean	O
expressed	O
as	O
percentage	O
was	O
calculated	O
for	O
the	O
4	O
technical	O
replicates	O
,	O
and	O
was	O
6.7	O
%	O
for	O
the	O
top	O
25	O
genes	O
up	O
-	O
regulated	O
in	O
hESC	O
samples	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

We	O
performed	O
the	O
analysis	O
of	O
microarray	O
data	O
,	O
as	O
described	O
in	O
the	O
Methods	O
,	O
and	O
spot	O
error	O
values	O
were	O
generally	O
in	O
the	O
lower	O
range	O
,	O
indicating	O
high	O
stringency	O
of	O
the	O
signals	O
and	O
low	O
variance	O
.	O

As	O
seen	O
in	O
Table	O
4	O
and	O
Table	O
5	O
,	O
the	O
NeuroStem	O
Chip	O
identified	O
numerous	O
genes	O
associated	O
with	O
stem	O
cells	O
.	O

In	O
particular	O
,	O
homeo	O
box	O
expressed	O
in	O
ES	O
cells	O
1	O
(	O
Hesx1	O
)	O
gene	O
was	O
identified	O
as	O
the	O
most	O
up	O
-	O
regulated	O
in	O
the	O
ES	O
cell	O
preparation	O
,	O
compared	O
to	O
universal	O
reference	O
RNA	O
.	O

Highly	O
expressed	O
in	O
pluripotent	O
ESCs	O
,	O
Hesx1	O
expression	O
is	O
down	O
-	O
regulated	O
upon	O
embryonic	O
stem	O
cell	O
differentiation	O
[	O
35,36	O
]	O
,	O
as	O
also	O
clearly	O
seen	O
in	O
differentiation	O
experiment	O
of	O
our	O
own	O
(	O
Table	O
4	O
)	O
.	O

Similarly	O
,	O
Gremlin	O
1	O
homolog	O
,	O
cysteine	O
knot	O
superfamily	O
gene	O
(	O
Grem1	O
,	O
also	O
known	O
as	O
Cktsf1b1	O
and	O
Dand2	O
)	O
is	O
a	O
recognized	O
factor	O
of	O
cell	O
-	O
fate	O
determination	O
of	O
ESCs	O
[	O
37	O
]	O
.	O

Many	O
more	O
genes	O
highly	O
up	O
-	O
regulated	O
in	O
the	O
hESC	O
sample	O
in	O
comparison	O
with	O
universal	O
reference	O
RNA	O
are	O
associated	O
with	O
stem	O
cells	O
:	O
further	O
examples	O
include	O
Gap	O
junction	O
protein	O
α1	O
(	O
Gja1	O
)	O
and	O
Zic	O
family	O
member	O
3	O
heterotaxy	O
1	O
(	O
Zic3	O
)	O
(	O
Table	O
4	O
)	O
[	O
20	O
]	O
.	O

The	O
expression	O
of	O
fibroblast	O
growth	O
factor	O
receptor	O
2	O
(	O
Fgfr2	O
)	O
is	O
of	O
particular	O
interest	O
.	O

Basic	O
fibroblast	O
growth	O
factor	O
(	O
FGF2	O
,	O
bFGF	O
)	O
supports	O
hESC	O
proliferation	O
and	O
their	O
ability	O
to	O
maintain	O
undifferentiated	O
phenotype	O
when	O
cultured	O
in	O
vitro	O
[	O
38,39	O
]	O
.	O

Moreover	O
,	O
in	O
some	O
hESC	O
lines	O
a	O
very	O
high	O
concentration	O
of	O
FGF2	O
could	O
substitute	O
for	O
the	O
need	O
of	O
feeder	O
cells	O
[	O
40	O
]	O
.	O

At	O
the	O
same	O
time	O
,	O
genes	O
listed	O
in	O
Table	O
4	O
represent	O
the	O
most	O
highly	O
up	O
-	O
regulated	O
entries	O
in	O
a	O
relatively	O
limited	O
group	O
of	O
genes	O
(	O
Figure	O
5C	O
)	O
.	O

Many	O
other	O
genes	O
involved	O
in	O
maintenance	O
of	O
ESC	O
phenotype	O
(	O
i.e.	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
)	O
have	O
lower	O
levels	O
of	O
expression	O
(	O
Table	O
5	O
)	O
.	O

Examples	O
include	O
undifferentiated	O
embryonic	O
cell	O
transcription	O
factor	O
1	O
(	O
Utf1	O
)	O
,	O
DNA	O
methyltransferase	O
3B	O
(	O
Dnmt3b	O
)	O
,	O
developmental	O
pluripotency	O
associated	O
4	O
(	O
Dppa4	O
,	O
a	O
newly	O
established	O
pluripotency	O
marker	O
[	O
41	O
]	O
)	O
and	O
numerous	O
candidate	O
markers	O
of	O
""""	O
stemness	O
""""	O
:	O
e.g.	O
genes	O
for	O
KIAA1573	O
protein	O
,	O
forkhead	O
box	O
O1A	O
(	O
Foxo1a	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
1	O
(	O
Hmgb1	O
)	O
,	O
C	O
-	O
terminal	O
binding	O
protein	O
2	O
(	O
Ctbp2	O
)	O
and	O
left	O
-	O
right	O
determination	O
factor	O
1	O
(	O
Lefty1	O
)	O
,	O
as	O
well	O
as	O
others	O
.	O

For	O
numerous	O
established	O
or	O
candidate	O
markers	O
of	O
stem	O
cells	O
the	O
expression	O
levels	O
were	O
not	O
considerably	O
higher	O
(	O
Log2	O
ratio	O
<	O
1	O
)	O
in	O
the	O
hESC	O
sample	O
compared	O
to	O
the	O
universal	O
reference	O
RNA	O
.	O

For	O
example	O
,	O
the	O
expression	O
of	O
Nanog	O
,	O
DNA	O
(	O
cytosine-5-	O
)	O
-methyltransferase	O
3α	O
(	O
Dnmt3a	O
)	O
,	O
MutS	O
homolog	O
2	O
,	O
colon	O
cancer	O
,	O
nonpolyposis	O
type	O
1	O
(	O
E.	O
coli	O
)	O
(	O
Msh2	O
)	O
,	O
Thy-1	O
cell	O
surface	O
antigen	O
(	O
Thy1	O
)	O
,	O
high	O
-	O
mobility	O
group	O
box	O
2	O
(	O
Hmgb2	O
)	O
,	O
transcription	O
factor	O
3	O
(	O
Tcf3	O
)	O
,	O
Nanos	O
homolog	O
1	O
(	O
Nanos1	O
)	O
,	O
MyoD	O
family	O
inhibitor	O
(	O
Mdfi	O
)	O
,	O
Calumenin	O
(	O
Calu	O
)	O
and	O
soluble	O
thymidine	O
kinase	O
1	O
(	O
Tk1	O
)	O
was	O
detected	O
in	O
hES	O
SA02	O
cells	O
with	O
Log2	O
ratio	O
value	O
<	O
1	O
.	O

Expression	O
levels	O
of	O
those	O
genes	O
range	O
from	O
being	O
inconsiderably	O
higher	O
to	O
nearly	O
equal	O
to	O
that	O
in	O
universal	O
reference	O
RNA	O
sample	O
.	O

We	O
believe	O
that	O
those	O
findings	O
could	O
be	O
explained	O
by	O
cellular	O
composition	O
of	O
human	O
universal	O
reference	O
RNA	O
sample	O
[	O
42	O
]	O
,	O
which	O
includes	O
pooled	O
RNA	O
samples	O
from	O
proliferating	O
cells	O
(	O
e.g.	O
,	O
skin	O
and	O
testis	O
cell	O
lines	O
)	O
.	O

Thus	O
,	O
the	O
relative	O
difference	O
between	O
gene	O
expression	O
of	O
certain	O
markers	O
of	O
stem	O
cells	O
in	O
undifferentiated	O
hESCs	O
and	O
universal	O
reference	O
RNA	O
is	O
naturally	O
decreased	O
.	O

Taken	O
together	O
,	O
the	O
gene	O
expression	O
signature	O
of	O
hES	O
SA02	O
cell	O
line	O
profiled	O
by	O
NeuroStem	O
Chip	O
is	O
indeed	O
characteristic	O
for	O
pluripotent	O
stem	O
cells	O
,	O
providing	O
proof	O
-	O
of	O
-	O
concept	O
.	O

Notably	O
,	O
comparison	O
of	O
expression	O
profiles	O
of	O
undifferentiated	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
committed	O
toward	O
dopaminergic	O
differentiation	O
pathway	O
by	O
co	O
-	O
culturing	O
with	O
SDIA	O
for	O
16	O
days	O
have	O
revealed	O
that	O
many	O
of	O
the	O
stem	O
cell	O
marker	O
genes	O
mentioned	O
above	O
were	O
down	O
-	O
regulated	O
in	O
differentiation	O
(	O
Table	O
5	O
)	O
.	O

Expectedly	O
,	O
Hesx1	O
,	O
Grem1	O
,	O
Dnmt3b	O
,	O
Utf1	O
and	O
Nanog	O
could	O
be	O
listed	O
among	O
these	O
.	O

At	O
the	O
same	O
time	O
,	O
numerous	O
other	O
genes	O
,	O
including	O
Pitx2	O
,	O
Dlk1	O
and	O
Msx1	O
were	O
up	O
-	O
regulated	O
in	O
the	O
latter	O
sample	O
(	O
[	O
see	O
Additional	O
file	O
2	O
]	O
,	O
Figure	O
3	O
)	O
.	O

Table	O
1	O
lists	O
24	O
dopaminergic	O
system	O
-	O
related	O
entries	O
(	O
e.g.	O
,	O
Ptx3	O
,	O
Th	O
,	O
Lhx1	O
)	O
with	O
gene	O
expression	O
up	O
-	O
regulated	O
by	O
Day	O
16	O
of	O
hESC	O
differentiation	O
protocol	O
;	O
few	O
more	O
genes	O
have	O
demonstrated	O
less	O
prominent	O
up	O
-	O
regulation	O
(	O
Log2	O
ratio	O
values	O
in	O
the	O
range	O
of	O
0.7	O
/	O
0.97–1.0	O
)	O
.	O

The	O
gene	O
expression	O
profiles	O
generated	O
are	O
therefore	O
consistent	O
with	O
the	O
results	O
of	O
earlier	O
studies	O
utilizing	O
hSC	O
-	O
derived	O
samples	O
with	O
similar	O
characteristics	O
[	O
43,44	O
]	O
.	O

Diversity	O
of	O
NeuroStem	O
Chip	O
entries	O
responsive	O
to	O
hESC	O
commitment	O
toward	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathway	O
clearly	O
illustrates	O
the	O
complexity	O
of	O
that	O
pathway	O
.	O

The	O
cell	O
population	O
obtained	O
after	O
16	O
day	O
exposure	O
to	O
SDIA	O
is	O
highly	O
heterogeneous	O
.	O

Only	O
around	O
0.2	O
%	O
of	O
the	O
cells	O
are	O
TH	O
-	O
positive	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

This	O
heterogeneity	O
,	O
with	O
an	O
apparent	O
presence	O
of	O
residual	O
pluripotent	O
cells	O
explains	O
the	O
presence	O
of	O
stem	O
cell	O
marker	O
genes	O
,	O
including	O
homeobox	O
transcription	O
factor	O
Nanog	O
,	O
as	O
revealed	O
by	O
RT	O
-	O
PCR	O
data	O
(	O
Figure	O
3	O
)	O
.	O

It	O
would	O
be	O
therefore	O
impossible	O
to	O
apply	O
the	O
platform	O
to	O
identify	O
novel	O
genes	O
associated	O
with	O
the	O
process	O
of	O
differentiation	O
;	O
for	O
that	O
application	O
,	O
the	O
genome	O
-	O
scale	O
microarray	O
platforms	O
(	O
e.g.	O
,	O
Affymetrix	O
)	O
are	O
clearly	O
superior	O
.	O

Nevertheless	O
,	O
being	O
based	O
upon	O
a	O
moderate	O
assay	O
of	O
pre	O
-	O
selected	O
specific	O
gene	O
targets	O
,	O
the	O
comparative	O
analysis	O
of	O
microarray	O
data	O
derived	O
from	O
undifferentiated	O
and	O
dopaminergic	O
differentiate	O
pathway	O
-	O
committed	O
hESCs	O
provides	O
a	O
valuable	O
cross	O
-	O
cut	O
of	O
complex	O
relationship	O
between	O
factors	O
driving	O
or	O
indicative	O
to	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

RT	O
-	O
PCR	O
analyses	O
have	O
validated	O
the	O
overall	O
reliability	O
of	O
NeuroStem	O
microarray	O
platform	O
:	O
all	O
of	O
the	O
entries	O
detected	O
in	O
the	O
hybridization	O
experiments	O
have	O
demonstrated	O
similar	O
trends	O
when	O
analyzed	O
by	O
RT	O
-	O
PCR	O
means	O
(	O
Figure	O
3	O
)	O
.	O

Those	O
entries	O
include	O
Sox2	O
,	O
En1	O
and	O
Nanog	O
(	O
ratio	O
of	O
differentiated	O
/	O
undifferentiated	O
hESC	O
sample	O
normalized	O
spot	O
intensity	O
<	O
0.75	O
,	O
down	O
-	O
regulated	O
)	O
,	O
Gadph	O
,	O
Aldh1a1	O
,	O
Sdha	O
,	O
Tubb	O
and	O
Nestin	O
(	O
ratio	O
.1.0	O
,	O
unchanged	O
)	O
,	O
Actb	O
,	O
Th	O
,	O
Msx1	O
and	O
Pitx2	O
(	O
ratio	O
>	O
1.25	O
,	O
up	O
-	O
regulated	O
)	O
.	O

Some	O
of	O
the	O
housekeeping	O
genes	O
(	O
Gapdh	O
,	O
Sdha	O
,	O
Tubb	O
,	O
Actb	O
)	O
have	O
somewhat	O
different	O
expression	O
in	O
undifferentiated	O
vs.	O
differentiated	O
cells	O
,	O
consistent	O
with	O
previous	O
reports	O
on	O
certain	O
established	O
housekeeping	O
genes	O
(	O
including	O
Gapdh	O
)	O
being	O
variable	O
in	O
human	B
samples	O
[	O
45	O
]	O
.	O

Importantly	O
,	O
all	O
the	O
observed	O
gene	O
expression	O
trends	O
were	O
similar	O
in	O
both	O
microarray	O
and	O
RT	O
-	O
PCR	O
.	O

Our	O
experiment	O
therefore	O
confirms	O
that	O
the	O
NeuroStem	O
Chip	O
microarray	O
platform	O
can	O
still	O
identify	O
gene	O
expression	O
changes	O
related	O
to	O
early	O
stages	O
of	O
differentiation	O
of	O
hESC	O
into	O
dopaminergic	O
neurons	O
.	O

Recent	O
technological	O
advances	O
have	O
led	O
to	O
DNA	O
microarrays	O
which	O
contain	O
over	O
hundred	O
thousand	O
of	O
spots	O
of	O
DNA	O
material	O
,	O
reaching	O
a	O
truly	O
genomic	O
scale	O
.	O

Highly	O
specialized	O
DNA	O
microarrays	O
of	O
smaller	O
scale	O
(	O
e.g.	O
the	O
NeuroStem	O
Chip	O
)	O
still	O
have	O
an	O
important	O
role	O
in	O
the	O
directed	O
studies	O
in	O
particular	O
fields	O
.	O

Since	O
they	O
are	O
significantly	O
less	O
expensive	O
,	O
compared	O
to	O
many	O
recognized	O
large	O
-	O
scale	O
platforms	O
(	O
e.g.	O
Affymetrix	O
Human	B
Genome	O
platforms	O
)	O
,	O
they	O
have	O
a	O
clear	O
advantage	O
in	O
routine	O
work	O
involving	O
samples	O
from	O
,	O
e.g.	O
,	O
multiple	O
cell	O
culture	O
conditions	O
.	O

While	O
there	O
is	O
a	O
risk	O
that	O
one	O
will	O
miss	O
out	O
on	O
changes	O
in	O
genes	O
previously	O
not	O
believed	O
to	O
be	O
relevant	O
to	O
neural	O
differentiation	O
,	O
the	O
restricted	O
number	O
of	O
genes	O
in	O
the	O
NeuroStem	O
Chip	O
also	O
simplifies	O
analysis	O
and	O
adds	O
power	O
.	O

NeuroStem	O
Chip	O
is	O
comparable	O
to	O
other	O
stem	O
cell	O
-	O
related	O
focused	O
microarray	O
platforms	O
in	O
regards	O
to	O
manufacturing	O
costs	O
and	O
technical	O
simplicity	O
of	O
the	O
recommended	O
hybridization	O
protocols	O
.	O

At	O
the	O
same	O
time	O
,	O
it	O
currently	O
implies	O
an	O
advantage	O
in	O
both	O
the	O
scale	O
and	O
the	O
spectrum	O
of	O
pre	O
-	O
selected	O
,	O
specific	O
gene	O
targets	O
assayed	O
.	O

Some	O
suggested	O
areas	O
of	O
application	O
for	O
NeuroStem	O
microarray	O
platform	O
could	O
be	O
the	O
following	O
:	O
(	O
i	O
)	O
characterization	O
of	O
the	O
expression	O
of	O
established	O
,	O
pre	O
-	O
selected	O
gene	O
targets	O
in	O
human	B
stem	O
cell	O
(	O
hSC	O
)	O
lines	O
,	O
including	O
newly	O
derived	O
ones	O
,	O
(	O
ii	O
)	O
longitudinal	O
quality	O
control	O
for	O
maintained	O
hSC	O
populations	O
,	O
(	O
iii	O
)	O
following	O
gene	O
expression	O
changes	O
during	O
differentiation	O
under	O
defined	O
cell	O
culture	O
conditions	O
,	O
and	O
(	O
iv	O
)	O
confirming	O
the	O
success	O
of	O
differentiation	O
into	O
specific	O
neuronal	O
subtypes	O
.	O

In	O
addition	O
,	O
the	O
NeuroStem	O
Chip	O
can	O
be	O
used	O
to	O
characterize	O
gene	O
changes	O
in	O
intracerebral	O
grafts	O
of	O
human	B
cells	O
,	O
even	O
when	O
they	O
are	O
transplanted	O
into	O
experimental	O
animals	O
.	O

We	O
specifically	O
wish	O
to	O
stress	O
that	O
we	O
are	O
about	O
to	O
make	O
the	O
NeuroStem	O
Chip	O
available	O
at	O
a	O
non	O
-	O
profit	O
cost	O
to	O
the	O
research	O
community	O
.	O

We	O
believe	O
it	O
has	O
the	O
potential	O
to	O
become	O
an	O
important	O
screening	O
tool	O
in	O
the	O
expanding	O
field	O
of	O
hSC	O
studies	O
in	O
application	O
to	O
neurological	O
/	O
neurodegenerative	O
disorders	O
.	O

Human	B
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
culturesUndifferentiated	O
hESCs	O
of	O
SA02	O
(	O
Sahlgrenska	O
2	O
)	O
line	O
(	O
Cellartis	O
AB	O
,	O
Göteborg	O
,	O
Sweden	O
;	O
see	O
NIH	O
Human	O
Embryonic	O
Stem	O
Cell	O
Registry	O
at	O
[	O
46	O
]	O
)	O
were	O
maintained	O
over	O
a	O
monolayer	O
of	O
human	B
""""	O
feeder	O
cells	O
""""	O
(	O
hFCs	B
;	O
human	B
foreskin	O
fibroblasts	O
,	O
ATCC	O
;	O
cell	O
line	O
CCD-1112Sk	O
)	O
.	O

Feeder	O
cells	O
were	O
grown	O
in	O
hFC	O
medium	O
(	O
Iscove	O
's	O
modified	O
Dulbecco	O
's	O
medium	O
(	O
IMDM	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
FCS	O
(	O
Stem	O
Cell	O
Technologies	O
,	O
USA	O
)	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
)	O
for	O
11	O
passages	O
.	O

One	O
day	O
prior	O
to	O
hESC	O
plating	O
,	O
hFC	O
medium	O
was	O
washed	O
away	O
from	O
the	O
hFCs	O
,	O
the	O
latter	O
were	O
resuspended	O
in	O
a	O
hESC	O
proliferation	O
medium	O
(	O
VitroHES	O
media	O
(	O
Vitrolife	O
AB	O
,	O
Sweden	O
)	O
supplemented	O
with	O
4	O
ng	O
/	O
ml	O
human	B
recombinant	O
basic	O
FGF	O
(	O
hrbFGF	O
,	O
Biosource	O
International	O
,	O
USA	O
)	O
and	O
plated	O
in	O
a	O
central	O
ring	O
of	O
gelatinized	O
in	O
vitro	O
fertilization	O
(	O
IVF	O
)	O
dishes	O
with	O
a	O
cell	O
density	O
of	O
120,000	O
cells	O
/	O
dish	O
.	O

The	O
outer	O
rings	O
of	O
the	O
IVF	O
dishes	O
were	O
filled	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
mix	O
.	O

One	O
half	O
of	O
the	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

Every	O
6	O
days	O
,	O
fragments	O
of	O
the	O
hESC	O
colonies	O
(	O
around	O
10–14	O
colonies	O
per	O
dish	O
,	O
measuring	O
around	O
0.015	O
×	O
0.015	O
mm	O
)	O
that	O
had	O
an	O
unaltered	O
morphology	O
(	O
indicating	O
lack	O
of	O
spontaneous	O
differentiation	O
)	O
were	O
mechanically	O
cut	O
from	O
dishes	O
using	O
stem	O
cell	O
knives	O
/	O
transfer	O
pipettes	O
(	O
SweMed	O
Lab	O
International	O
AB	O
,	O
Sweden	O
)	O
and	O
then	O
plated	O
on	O
fresh	O
hFCs	O
.	O

Commitment	O
of	O
hESCs	O
towards	O
neuronal	O
/	O
dopaminergic	O
differentiation	O
pathwayCo	O
-	O
culturing	O
with	O
the	O
PA6	O
stromal	O
cell	O
line	O
(	O
MC3T3-G2	O
/	O
Pa6	O
,	O
from	O
RIKEN	O
Cell	O
Bank	O
Japan	O
(	O
RCB	O
1127	O
)	O
,	O
derived	O
from	O
newborn	O
mouse	B
calvaria	O
rapidly	O
generates	O
high	O
numbers	O
of	O
DA	O
neurons	O
from	O
mouse	B
and	O
monkey	B
ESCs	O
by	O
an	O
unknown	O
mechanism	O
named	O
stromal	O
-	O
derived	O
inducing	O
activity	O
(	O
SDIA	O
;	O
[	O
28,29	O
]	O
)	O
.	O

For	O
differentiation	O
experiments	O
,	O
PA6	O
cells	O
were	O
plated	O
on	O
gelatine	O
-	O
coated	O
T25	O
flasks	O
at	O
16	O
×	O
103	O
cells	O
/	O
cm2	O
(	O
400,000	O
cells	O
/	O
flask	O
)	O
density	O
2	O
days	O
prior	O
to	O
introducing	O
hESCs	O
into	O
the	O
co	O
-	O
culture	O
and	O
cultured	O
at	O
PA6	O
culturing	O
media	O
(	O
containing	O
minimum	O
essential	O
medium	O
alpha	O
(	O
α	O
-	O
MEM	O
)	O
supplemented	O
with	O
10	O
%	O
FCS	O
and	O
0.5	O
%	O
Penicillin	O
/	O
Streptomycin	O
)	O
.	O

Alternatively	O
,	O
PA6	O
cells	O
were	O
plated	O
over	O
Type	O
I	O
collagen	O
-	O
coated	O
glass	O
cover	O
-	O
slips	O
placed	O
in	O
wells	O
of	O
4-well	O
-	O
plates	O
(	O
50,000	O
cells	O
/	O
well	O
,	O
for	O
immunocytochemical	O
(	O
ICC	O
)	O
analysis	O
)	O
.	O

Three	O
hours	O
prior	O
to	O
initiation	O
of	O
co	O
-	O
culture	O
,	O
PA6	O
cells	O
were	O
rinsed	O
3	O
times	O
with	O
PBS	O
and	O
media	O
was	O
replaced	O
with	O
co	O
-	O
culture	O
media	O
(	O
Glasgow	O
's	O
modified	O
Eagle	O
's	O
media	O
(	O
G	O
-	O
MEM	O
)	O
supplemented	O
with	O
8	O
%	O
knock	O
-	O
out	O
serum	O
replacement	O
(	O
KSR	O
)	O
,	O
2	O
mM	O
glutamine	O
,	O
0.1	O
mM	O
non	O
-	O
essential	O
amino	O
-	O
acids	O
(	O
NEAA	O
)	O
,	O
1	O
mM	O
pyruvate	O
,	O
0.1	O
mM	O
β	O
-	O
mercaptoethanol	O
(	O
βME	O
)	O
and	O
4	O
ng	O
/	O
μl	O
bFGF	O
)	O
.	O

Fragments	O
of	O
hESC	O
colonies	O
(	O
80–90	O
per	O
flask	O
;	O
4–5	O
per	O
well	O
of	O
4-well	O
-	O
plate	O
)	O
presenting	O
undifferentiated	O
morphology	O
were	O
manually	O
passaged	O
onto	O
the	O
confluent	O
PA6	O
monolayer	O
and	O
cell	O
co	O
-	O
cultures	O
were	O
maintained	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
,	O
95	O
%	O
humidity	O
settings	O
.	O

One	O
half	O
of	O
the	O
co	O
-	O
culture	O
medium	O
was	O
replaced	O
every	O
other	O
day	O
for	O
first	O
10	O
days	O
,	O
and	O
daily	O
onwards	O
.	O

Characterization	O
of	O
hESCs	O
and	O
hESC	O
-	O
derived	O
cells	O
by	O
immunocytochemistry	O
(	O
ICC	O
)	O
and	O
RT	O
-	O
PCRIVF	O
dishes	O
with	O
hESCs	O
grown	O
atop	O
hFCs	O
and	O
4-well	O
plate	O
dishes	O
with	O
hESCs	O
growing	O
atop	O
PA6	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
15	O
minutes	O
at	O
the	O
day	O
of	O
passage	O
/	O
harvest	O
(	O
Day	O
6	O
of	O
hESC	O
/	O
hFC	O
co	O
-	O
culturing	O
)	O
and	O
Day	O
16	O
of	O
co	O
-	O
culturing	O
with	O
PA6	O
cells	O
,	O
respectively	O
.	O

Cells	O
were	O
pre	O
-	O
incubated	O
with	O
blocking	O
solution	O
containing	O
PBS	O
,	O
0.5	O
%	O
Triton	O
X-100	O
and	O
5	O
%	O
of	O
donkey	B
serum	O
.	O

They	O
were	O
then	O
incubated	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
overnight	O
at	O
room	O
temperature	O
.	O

After	O
three	O
washes	O
with	O
PBS	O
,	O
cells	O
were	O
incubated	O
with	O
the	O
donkey	B
anti	O
-	O
rabbit	B
IgG	O
conjugated	O
with	O
FITC	O
or	O
anti	O
-	O
mouse	B
Cy3	O
(	O
1:200	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
.	O

Cells	O
were	O
then	O
washed	O
once	O
with	O
PBS	O
,	O
incubated	O
with	O
1:1000	O
DAPI	O
in	O
PBS	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
another	O
wash	O
with	O
PBS	O
.	O

Coverslips	O
were	O
mounted	O
onto	O
glass	O
slides	O
with	O
PVA	O
mounting	O
medium	O
containing	O
anti	O
-	O
fading	O
reagent	O
DABCO	O
.	O

The	O
following	O
primary	O
antibodies	O
were	O
used	O
:	O
mouse	B
anti	O
-	O
Oct3	O
/	O
4	O
(	O
1:500	O
,	O
Santa	O
Cruz	O
Biotechnology	O
Inc.	O
)	O
;	O
rabbit	B
anti	O
-	O
Ki67	O
(	O
1:200	O
,	O
Novocastra	O
Ltd.	O
)	O
;	O
rabbit	B
anti	O
-	O
TH	O
(	O
1:500	O
,	O
Chemicon	O
)	O
.	O

Immunostained	O
cell	O
cultures	O
were	O
visualized	O
using	O
a	O
Zeiss	O
fluorescent	O
microscope	O
attached	O
to	O
a	O
Nikon	O
digital	O
camera	O
.	O

Using	O
RT	O
-	O
PCR	O
,	O
all	O
RNA	O
samples	O
used	O
in	O
this	O
study	O
were	O
tested	O
negative	O
for	O
the	O
presence	O
of	O
gDNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
intron	O
-	O
spanning	O
primers	O
for	O
RT	O
-	O
PCR	O
were	O
selected	O
from	O
published	O
works	O
or	O
designed	O
using	O
Oligo	O
4.0	O
software	O
(	O
Molecular	O
Biology	O
Insight	O
)	O
or	O
Clone	O
Manager	O
Suite	O
7.1	O
(	O
Sci	O
Ed	O
Software	O
,	O
NC	O
,	O
USA	O
)	O
and	O
ordered	O
from	O
TAG	O
Copenhagen	O
A	O
/	O
S	O
,	O
Denmark	O
,	O
as	O
the	O
following	O
:	O
Sox2	O
,	O
SRY	O
-	O
box	O
2	O
:	O
5'-TAC	O
CTC	O
TTC	O
CTC	O
CC	O
CTC	O
CA-3	O
'	O
,	O
5'-ACT	O
CTC	O
CTC	O
TTT	O
TGC	O
ACC	O
CC-3	O
'	O
;	O
En1	O
,	O
Engrailed	O
1	O
:	O
5'-AAG	O
GGA	O
CGA	O
AAC	O
TGC	O
GAA	O
CTC	O
C-3	O
'	O
,	O
5'-GAC	O
ACG	O
AAA	O
GGA	O
AAC	O
ACA	O
CAC	O
TCT	O
CG-3	O
'	O
[	O
47	O
]	O
;	O
Nanog	O
:	O
5'-TGC	O
TTA	O
TTC	O
AGG	O
ACA	O
GCC	O
T-3	O
'	O
,	O
5'-TCT	O
GGT	O
CTT	O
CTG	O
TTT	O
CTT	O
GAC	O
T-3	O
'	O
[	O
48	O
]	O
;	O
Gapdh	O
,	O
glyceraldehydes-3-phosphate	O
dehydrogenase	O
:	O
5'-GGA	O
AGG	O
TGA	O
AGG	O
TCG	O
GAG	O
TCA	O
A-3	O
'	O
,	O
5'-GAT	O
CTC	O
GCT	O
CCT	O
GGA	O
AGA	O
TGG	O
T-3	O
'	O
;	O
Aldh1A1	O
,	O
aldehyde	O
dehydrogenase	O
1	O
family	O
,	O
member	O
A1	O
:	O
5'-GGG	O
CAG	O
CCA	O
TTT	O
CTT	O
CTC	O
AC-3	O
'	O
,	O
5'-CTT	O
CTT	O
AGC	O
CCG	O
CTC	O
AAC	O
AC-3	O
'	O
[	O
49	O
]	O
;	O
Sdha	O
,	O
succinate	O
dehydrogenase	O
:	O
5'-TGG	O
GAA	O
CAA	O
GAG	O
GGC	O
ATC	O
TG-3	O
'	O
,	O
5'-CCA	O
CCA	O
CTG	O
CAT	O
CAA	O
ATT	O
CAT	O
G-3	O
'	O
[	O
50	O
]	O
;	O
Tubb	O
,	O
β	O
-	O
tubulin	O
:	O
5'-CTC	O
ACA	O
AGT	O
ACG	O
TGC	O
CTC	O
GAG-3	O
'	O
,	O
5'-GCA	O
CGA	O
CGC	O
TGA	O
AGG	O
TGT	O
TCA-3	O
'	O
;	O
Nestin	O
:	O
5'-AGA	O
GGG	O
GAA	O
TTC	O
CTG	O
CT	O
GAG-3	O
'	O
,	O
5'-CTG	O
AGG	O
ACC	O
AGG	O
ACT	O
CTC	O
TA-3	O
'	O
[	O
47	O
]	O
;	O
Actb	O
,	O
β	O
-	O
actin	O
:	O
5'-CAT	O
CGA	O
GCA	O
CGG	O
CAT	O
CGT	O
CA-3	O
'	O
,	O
5'-TAG	O
CAC	O
AGC	O
CTG	O
GAT	O
AGC	O
AAC-3	O
'	O
[	O
51	O
]	O
;	O
Th	O
,	O
Tyrosine	O
hydroxylase	O
:	O
5'-CGA	O
GCT	O
GTG	O
AAG	O
GTG	O
TTT	O
G-3	O
'	O
,	O
5'-TTG	O
GTG	O
ACC	O
AGG	O
TGA	O
TGA	O
C-3	O
'	O
;	O
Msx1	O
,	O
homolog	O
of	O
Drosophila	O
muscle	O
segment	O
homolog	O
1	O
:	O
5'-CTC	O
AAG	O
CTG	O
CCA	O
GAA	O
GAT	O
GC-3	O
'	O
,	O
5'-TCC	O
AGC	O
TCT	O
GCC	O
TCT	O
TGT	O
AG-3	O
'	O
;	O
Pitx2	O
,	O
paired	O
-	O
like	O
homeodomain	O
transcription	O
factor	O
2	O
:	O
5'-ACC	O
TTA	O
CGG	O
AAG	O
CCC	O
GAG	O
TC-3	O
'	O
,	O
5'-TGG	O
ATA	O
GGG	O
AGG	O
CGG	O
ATG	O
TA-3	O
'	O
[	O
49	O
]	O
.	O

cDNA	O
was	O
synthesized	O
from	O
1	O
mg	O
of	O
total	O
RNA	O
using	O
SuperScript	O
II	O
(	O
Invitrogen	O
)	O
,	O
and	O
RT	O
-	O
PCR	O
amplifications	O
were	O
performed	O
using	O
the	O
MiniOpticon	O
system	O
(	O
Bio	O
-	O
Rad	O
)	O
with	O
REDTaq	O
Polymerase	O
(	O
Sigma	O
-	O
Aldrich	O
)	O
essentially	O
as	O
described	O
by	O
the	O
manufacturer	O
.	O

Following	O
initial	O
denaturation	O
for	O
5	O
min	O
at	O
95	O
°	O
C	O
,	O
DNA	O
amplifications	O
were	O
performed	O
for	O
35	O
(	O
En1	O
,	O
Nanog	O
,	O
Aldh1a1	O
)	O
,	O
33	O
(	O
Sox2	O
,	O
Nestin	O
,	O
Th	O
,	O
Msx1	O
)	O
,	O
32	O
(	O
Tubb	O
,	O
Pitx2	O
)	O
,	O
27	O
(	O
Sdha	O
)	O
,	O
25	O
(	O
Actb	O
)	O
or	O
22	O
(	O
Gapdh	O
)	O
cycles	O
of	O
1	O
min	O
at	O
95	O
°	O
C	O
,	O
1	O
min	O
at	O
55	O
°	O
C	O
(	O
En1	O
,	O
Pitx2	O
)	O
,	O
57	O
°	O
C	O
(	O
Sox2	O
,	O
Nanog	O
,	O
Sdha	O
,	O
Nestin	O
)	O
,	O
58	O
°	O
C	O
(	O
Tubb	O
)	O
,	O
58.5	O
°	O
C	O
(	O
Aldh1a1	O
,	O
Th	O
)	O
or	O
59	O
°	O
C	O
(	O
Gapdh	O
,	O
Actb	O
,	O
Msx1	O
)	O
,	O
and	O
1	O
min	O
at	O
72	O
°	O
C	O
.	O

The	O
final	O
extension	O
was	O
5	O
min	O
at	O
72	O
°	O
C	O
.	O

Twenty	O
μl	O
volumes	O
of	O
RT	O
-	O
PCR	O
products	O
were	O
analyzed	O
by	O
electrophoresis	O
at	O
1	O
%	O
agarose	O
gels	O
and	O
visualized	O
by	O
ethidium	O
bromide	O
staining	O
.	O

RNA	O
purification	O
and	O
fluorescent	O
dye	O
incorporationFor	O
RNA	O
purification	O
of	O
undifferentiated	O
hESCs	O
,	O
the	O
latter	O
were	O
mechanically	O
separated	O
from	O
hFCs	O
,	O
collected	O
in	O
a	O
500	O
μl	O
volume	O
of	O
VitroHES	O
media	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
at	O
300	O
rcf	O
for	O
5	O
min	O
.	O

hESC	O
-	O
derived	O
cells	O
grown	O
atop	O
PA6	O
cells	O
were	O
harvested	O
using	O
a	O
papain	O
dissociation	O
kit	O
(	O
Worthington	O
Biochemical	O
Corporation	O
)	O
,	O
rinsed	O
in	O
PBS	O
buffer	O
and	O
spun	O
down	O
as	O
described	O
above	O
.	O

The	O
resulting	O
cell	O
pellets	O
were	O
resuspended	O
in	O
RLT	O
buffer	O
(	O
Qiagen	O
,	O
USA	O
)	O
,	O
passed	O
through	O
the	O
shredder	O
column	O
(	O
Qiagen	O
)	O
and	O
stored	O
at	O
-80	O
°	O
C	O
until	O
the	O
RNA	O
sample	O
was	O
purified	O
following	O
the	O
RNeasy	O
Micro	O
Kit	O
(	O
Qiagen	O
)	O
protocol	O
(	O
without	O
carrier	O
RNA	O
)	O
;	O
with	O
DNase	O
I	O
(	O
Quiagen	O
)	O
treatment	O
incorporated	O
to	O
the	O
latter	O
.	O

RNA	O
integrity	O
was	O
tested	O
using	O
both	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
,	O
USA	O
)	O
and	O
RNA	O
Nano	O
LabChip	O
/	O
2100	O
Bioanalyzer	O
system	O
(	O
Agilent	O
Technologies	O
,	O
USA	O
)	O
.Fluorescent	O
label	O
(	O
24	O
nmol	O
of	O
the	O
Cyanine	O
3-CTP	O
(	O
Cy3	O
)	O
;	O
PerkinElmer	O
,	O
USA	O
)	O
was	O
incorporated	O
to	O
350–500	O
ng	O
of	O
total	O
RNA	O
amplified	O
using	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
Kit	O
(	O
Agilent	O
Technologies	O
)	O
,	O
generally	O
following	O
the	O
kit	O
manufacturer	O
's	O
protocol	O
.	O

Similarly	O
,	O
24	O
nmols	O
of	O
the	O
Cyanine	O
5-CTP	O
(	O
Cy5	O
;	O
PerkinElmer	O
)	O
fluorescent	O
label	O
were	O
incorporated	O
to	O
400	O
ng	O
sample	O
of	O
Human	B
Universal	O
Reference	O
RNA	O
(	O
Stratagene	O
,	O
USA	O
)	O
;	O
in	O
addition	O
,	O
dye	O
-	O
swap	O
replicate	O
amplification	O
were	O
performed	O
.	O

Amplified	O
fluorescent	O
cRNA	O
samples	O
were	O
purified	O
using	O
RNeasy	O
mini	O
-	O
columns	O
(	O
Quiagen	O
)	O
,	O
and	O
fluorescence	O
of	O
the	O
eluted	O
products	O
was	O
measured	O
using	O
ND-1000	O
specrophotometer	O
(	O
NanoDrop	O
)	O
.	O

Microarray	O
technologyLong	O
oligonucleotide	O
probes	O
(	O
69–71	O
nucleotides	O
)	O
matching	O
gene	O
targets	O
of	O
interest	O
were	O
selected	O
from	O
Operon	O
V2	O
and	O
V3	O
human	O
AROS	O
sets	O
(	O
Operon	O
Biotechnologies	O
Inc.	O
,	O
USA	O
)	O
.	O

Arrays	O
were	O
produced	O
by	O
the	O
SweGene	O
DNA	O
Microarray	O
Resource	O
Centre	O
,	O
Department	O
of	O
Oncology	O
at	O
Lund	O
University	O
(	O
Sweden	O
)	O
using	O
a	O
MicroGrid	O
II	O
600R	O
arrayer	O
fitted	O
with	O
MicroSpot	O
10	O
K	O
pins	O
(	O
Harvard	O
BioRobotics	O
,	O
USA	O
)	O
.	O

Printing	O
was	O
performed	O
in	O
a	O
temperature-	O
(	O
18–20	O
°	O
C	O
)	O
and	O
humidity-	O
(	O
44–49	O
%	O
RH	O
)	O
controlled	O
area	O
on	O
Corning	O
UltraGAPS	O
aminosilane	O
slides	O
(	O
Corning	O
Inc.	O
,	O
USA	O
)	O
with	O
140	O
μm	O
spot	O
-	O
to	O
-	O
spot	O
centerdistance	O
and	O
90–110	O
μm	O
average	O
spot	O
size	O
.	O

Following	O
printing	O
,	O
arrays	O
were	O
dried	O
for	O
48	O
hours	O
andstored	O
in	O
a	O
dessicator	O
until	O
used	O
.	O

Microarray	O
slides	O
were	O
UV	O
-	O
cross	O
-	O
linked	O
(	O
800	O
mJ	O
/	O
cm2	O
)	O
,	O
pre	O
-	O
hybridizedwith	O
fluorescently	O
labeled	O
samples	O
using	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
(	O
Corning	O
)	O
and	O
subsequently	O
hybridized	O
with	O
test	O
(	O
Cy3-labeled	O
)	O
/	O
reference	O
(	O
Cy5-labeled	O
)	O
RNA	O
samples	O
(	O
or	O
in	O
reverse	O
dye	O
-	O
labeling	O
order	O
)	O
at	O
42	O
°	O
C	O
for	O
17	O
h	O
using	O
a	O
MAUI	O
hybridization	O
station	O
(	O
BioMicro	O
Systems	O
Inc.	O
,	O
USA	O
)	O
and	O
the	O
Pronto	O
!	O

Universal	O
Microarray	O
Hybridization	O
Kit	O
,	O
generally	O
following	O
manufacturer	O
's	O
instructions	O
,	O
with	O
several	O
minor	O
adaptations	O
[	O
31	O
]	O
.	O

Data	O
acquisition	O
and	O
statistical	O
analysisImmediately	O
following	O
the	O
washing	O
steps	O
,	O
the	O
fluorescence	O
intensities	O
were	O
measured	O
using	O
a	O
confocal	O
laser	O
scanner	O
(	O
G2505B	O
,	O
Agilent	O
Technologies	O
)	O
.	O

After	O
image	O
formatting	O
by	O
Tiff	O
Image	O
Channel	O
Splitter	O
Utility	O
(	O
Agilent	O
Technologies	O
)	O
and	O
grid	O
annotation	O
,	O
a	O
complete	O
set	O
of	O
spots	O
was	O
visually	O
inspected	O
for	O
each	O
slide	O
.	O

Using	O
GenePix	O
Pro	O
(	O
Molecular	O
Devices	O
Corp.	O
USA	O
)	O
flags	O
for	O
artifactual	O
spots	O
were	O
annotated	O
for	O
each	O
spot	O
.	O

Median	O
pixel	O
intensity	O
minus	O
the	O
median	O
local	O
background	O
for	O
both	O
dyes	O
was	O
used	O
to	O
obtain	O
a	O
test	O
over	O
reference	O
intensity	O
ratio	O
.	O

Data	O
normalization	O
was	O
performed	O
per	O
array	O
subgrid	O
using	O
LOWESS	O
curve	O
fitting	O
with	O
a	O
smoothing	O
factor	O
of	O
0.33	O
[	O
52,53	O
]	O
.	O

All	O
normalizations	O
,	O
filtering	O
,	O
merging	O
of	O
technical	O
replicates	O
and	O
analyses	O
were	O
performed	O
in	O
the	O
BioArray	O
Software	O
Environment	O
database	O
[	O
32	O
]	O
.	O

To	O
visualize	O
sample	O
-	O
dependent	O
variation	O
of	O
spot	O
intensities	O
,	O
data	O
was	O
uploaded	O
to	O
the	O
TIGR	O
MultiExperiment	O
Viewer	O
(	O
MEV	O
;	O
[	O
34	O
]	O
)	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
diclofenac	O
was	O
metabolized	O
in	O
rats	B
to	O
reactive	O
benzoquinone	O
imines	O
via	O
cytochrome	O
P450-catalyzed	O
oxidation	O
.	O

These	O
metabolites	O
also	O
were	O
detected	O
in	O
human	B
hepatocyte	O
cultures	O
in	O
the	O
form	O
of	O
glutathione	O
(	O
GSH	O
)	O
adducts	O
.	O

This	O
report	O
describes	O
the	O
results	O
of	O
further	O
studies	O
aimed	O
at	O
characterizing	O
the	O
human	B
hepatic	O
P450-mediated	O
bioactivation	O
of	O
diclofenac	O
.	O

The	O
reactive	O
metabolites	O
formed	O
in	O
vitro	O
were	O
trapped	O
by	O
GSH	O
and	O
analyzed	O
by	O
LC	O
/	O
MS	O
/	O
MS	O
.	O

Thus	O
,	O
three	O
GSH	O
adducts	O
,	O
namely	O
,	O
5-hydroxy-4-	O
(	O
glutathion	O
-	O
S	O
-	O
yl	O
)	O
diclofenac	O
(	O
M1	O
)	O
,	O
4'-hydroxy-3'-	O
(	O
glutathion	O
-	O
S	O
-	O
yl	O
)	O
diclofenac	O
(	O
M2	O
)	O
,	O
and	O
5-hydroxy-6-	O
(	O
glutathion	O
-	O
S	O
-	O
yl	O
)	O
diclofenac	O
(	O
M3	O
)	O
,	O
were	O
identified	O
in	O
incubations	O
of	O
diclofenac	O
with	O
human	B
liver	O
microsomes	O
in	O
the	O
presence	O
of	O
NADPH	O
and	O
GSH	O
.	O

The	O
formation	O
of	O
the	O
adducts	O
was	O
taken	O
to	O
reflect	O
the	O
intermediacy	O
of	O
the	O
corresponding	O
putative	O
benzoquinone	O
imines	O
.	O

While	O
M2	O
was	O
the	O
dominant	O
metabolite	O
over	O
a	O
substrate	O
concentration	O
range	O
of	O
10	O
-	O
50	O
microM	O
,	O
M1	O
and	O
M3	O
became	O
equally	O
important	O
products	O
at	O
>	O
/=100	O
microM	O
diclofenac	O
.	O

The	O
formation	O
of	O
M2	O
was	O
inhibited	O
by	O
sulfaphenazole	O
or	O
an	O
anti	O
-	O
P450	O
2C9	O
antibody	O
(	O
5	O
-	O
10	O
%	O
of	O
control	O
values	O
)	O
.	O

The	O
formation	O
of	O
M1	O
and	O
M3	O
was	O
inhibited	O
by	O
troleandomycin	O
,	O
ketoconazole	O
,	O
or	O
an	O
anti	O
-	O
P450	O
3A4	O
antibody	O
(	O
30	O
-	O
50	O
%	O
of	O
control	O
values	O
)	O
.	O

In	O
studies	O
in	O
which	O
recombinant	O
P450	O
isoforms	O
were	O
used	O
,	O
M2	O
was	O
generated	O
only	O
by	O
P450	O
2C9-catalyzed	O
reaction	O
,	O
while	O
M1	O
and	O
M3	O
were	O
produced	O
by	O
P450	O
3A4-catalyzed	O
reaction	O
.	O

Good	O
correlations	O
were	O
established	O
between	O
the	O
extent	O
of	O
formation	O
of	O
M2	O
and	O
P450	O
2C9	O
activities	O
(	O
r	O
=	O
0.93	O
,	O
n	O
=	O
10	O
)	O
and	O
between	O
the	O
extent	O
of	O
formation	O
of	O
M1	O
and	O
M3	O
and	O
P450	O
3A4	O
activities	O
(	O
r	O
=	O
0.98	O
,	O
n	O
=	O
10	O
)	O
in	O
human	B
liver	O
microsomal	O
incubations	O
.	O

Taken	O
together	O
,	O
the	O
data	O
suggest	O
that	O
the	O
biotransformation	O
of	O
diclofenac	O
to	O
M2	O
is	O
P450	O
2C9-dependent	O
,	O
whereas	O
metabolism	O
of	O
the	O
drug	O
to	O
M1	O
and	O
M3	O
involves	O
mainly	O
P450	O
3A4	O
.	O

Although	O
P450s	O
2C9	O
and	O
3A4	O
both	O
catalyze	O
the	O
bioactivation	O
of	O
diclofenac	O
,	O
P450	O
2C9	O
is	O
capable	O
of	O
producing	O
the	O
benzoquinone	O
imine	O
intermediate	O
at	O
lower	O
drug	O
concentrations	O
which	O
may	O
be	O
more	O
clinically	O
relevant	O
.	O

Cytochrome	O
P450	O
2C11	O
in	O
rats	B
was	O
recently	O
found	O
to	O
metabolize	O
diclofenac	O
into	O
a	O
highly	O
reactive	O
product	O
that	O
covalently	O
bound	O
to	O
this	O
enzyme	O
before	O
it	O
could	O
diffuse	O
away	O
and	O
react	O
with	O
other	O
proteins	O
.	O

To	O
determine	O
whether	O
cytochromes	O
P450	O
in	O
human	B
liver	O
could	O
catalyze	O
a	O
similar	O
reaction	O
,	O
we	O
have	O
studied	O
the	O
covalent	O
binding	O
of	O
diclofenac	O
in	O
vitro	O
to	O
liver	O
microsomes	O
of	O
16	O
individuals	B
.	O

Only	O
three	O
of	O
16	O
samples	O
were	O
found	O
by	O
immunoblot	O
analysis	O
to	O
activate	O
diclofenac	O
appreciably	O
to	O
form	O
protein	O
adducts	O
in	O
a	O
NADPH	O
-	O
dependent	O
pathway	O
.	O

Cytochrome	O
P450	O
2C9	O
,	O
which	O
catalyzes	O
the	O
major	O
route	O
of	O
oxidative	O
metabolism	O
of	O
diclofenac	O
to	O
produce	O
4'-hydroxydiclofenac	O
,	O
did	O
not	O
appear	O
to	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
the	O
protein	O
adducts	O
,	O
because	O
sulfaphenazole	O
,	O
an	O
inhibitor	O
of	O
this	O
enzyme	O
,	O
did	O
not	O
affect	O
protein	O
adduct	O
formation	O
.	O

In	O
contrast	O
,	O
troleandomycin	O
,	O
an	O
inhibitor	O
of	O
P450	O
3A4	O
,	O
inhibited	O
both	O
protein	O
adduct	O
formation	O
and	O
5-hydroxylation	O
of	O
diclofenac	O
.	O

These	O
findings	O
were	O
confirmed	O
with	O
the	O
use	O
of	O
baculovirus	O
-	O
expressed	O
human	B
P450	O
2C9	O
and	O
P450	O
3A4	O
.	O

One	O
possible	O
reactive	O
intermediate	O
that	O
would	O
be	O
expected	O
to	O
bind	O
covalently	O
to	O
liver	O
proteins	O
was	O
the	O
p	O
-	O
benzoquinone	O
imine	O
derivative	O
of	O
5-hydroxydiclofenac	O
.	O

This	O
product	O
was	O
formed	O
by	O
an	O
apparent	O
metal	O
-	O
catalyzed	O
oxidation	O
of	O
5-hydroxydiclofenac	O
that	O
was	O
inhibited	O
by	O
EDTA	O
,	O
glutathione	O
,	O
and	O
NADPH	O
.	O

The	O
p	O
-	O
benzoquinone	O
imine	O
decomposition	O
product	O
bound	O
covalently	O
to	O
human	B
liver	O
microsomes	O
in	O
vitro	O
in	O
a	O
reaction	O
that	O
was	O
inhibited	O
by	O
GSH	O
.	O

In	O
contrast	O
,	O
GSH	O
did	O
not	O
prevent	O
the	O
covalent	O
binding	O
of	O
diclofenac	O
to	O
human	B
liver	O
microsomes	O
.	O

These	O
results	O
suggest	O
that	O
for	O
appreciable	O
P450-mediated	O
bioactivation	O
of	O
diclofenac	O
to	O
occur	O
in	O
vivo	O
,	O
an	O
individual	O
may	O
have	O
to	O
have	O
both	O
high	O
activities	O
of	O
P450	O
3A4	O
and	O
perhaps	O
low	O
activities	O
of	O
other	O
enzymes	O
that	O
catalyze	O
competing	O
pathways	O
of	O
metabolism	O
of	O
diclofenac	O
.	O

Moreover	O
,	O
the	O
p	O
-	O
benzoquinone	O
imine	O
derivative	O
of	O
5-hydroxydiclofenac	O
probably	O
has	O
a	O
role	O
in	O
covalent	O
binding	O
in	O
the	O
liver	O
only	O
under	O
the	O
conditions	O
where	O
levels	O
of	O
NADPH	O
,	O
GSH	O
,	O
and	O
other	O
reducing	O
agents	O
would	O
be	O
expected	O
to	O
be	O
low	O
.	O

The	O
marked	O
analgesic	O
efficacy	O
of	O
ketorolac	O
in	O
humans	B
,	O
relative	O
to	O
other	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
has	O
lead	O
to	O
speculation	O
as	O
to	O
whether	O
additional	O
non	O
-	O
NSAID	O
mechanism	O
(	O
s	O
)	O
contribute	O
to	O
its	O
analgesic	O
actions	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
characterized	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
's	O
pharmacological	O
properties	O
in	O
vivo	O
and	O
in	O
vitro	O
using	O
the	O
nonselective	O
cyclooxygenase	O
(	O
COX	O
)	O
inhibitors	O
[	O
indomethacin	O
(	O
INDO	O
)	O
and	O
diclofenac	O
sodium	O
(	O
DS	O
)	O
]	O
as	O
well	O
as	O
the	O
selective	O
COX-2	O
inhibitor	O
,	O
celecoxib	O
,	O
as	O
references	O
.	O

The	O
potency	O
of	O
racemic	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
was	O
similar	O
in	O
tests	O
of	O
acetic	O
acid	O
-	O
induced	O
writhing	O
,	O
carrageenan	O
-	O
induced	O
paw	O
hyperalgesia	O
,	O
and	O
carrageenan	O
-	O
induced	O
edema	O
formation	O
in	O
rats	B
;	O
ID50	O
values	O
=	O
0.24	O
,	O
0	O
.	O
29	O
,	O
and	O
0.08	O
mg	O
/	O
kg	O
,	O
respectively	O
.	O

(	O
R	O
,	O
S	O
)	O
-ketorolac	O
's	O
actions	O
were	O
stereospecific	O
,	O
with	O
(	O
S	O
)	O
-ketorolac	O
possessing	O
the	O
biological	O
activity	O
of	O
the	O
racemate	O
in	O
the	O
above	O
tests	O
.	O

The	O
analgesic	O
potencies	O
for	O
(	O
R	O
,	O
S	O
)	O
-	O
,	O
(	O
S	O
)	O
-	O
,	O
and	O
(	O
R	O
)	O
-ketorolac	O
,	O
INDO	O
,	O
and	O
DS	O
were	O
highly	O
correlated	O
with	O
their	O
anti	O
-	O
inflammatory	O
potencies	O
,	O
suggesting	O
a	O
common	O
mechanism	O
.	O

(	O
R	O
,	O
S	O
)	O
-ketorolac	O
was	O
significantly	O
more	O
potent	O
than	O
INDO	O
or	O
DS	O
in	O
vivo	O
.	O

Neither	O
difference	O
in	O
relative	O
potency	O
of	O
COX	O
inhibition	O
for	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
over	O
INDO	O
and	O
DS	O
nor	O
activity	O
of	O
(	O
S	O
)	O
-ketorolac	O
at	O
a	O
number	O
of	O
other	O
enzymes	O
,	O
channels	O
,	O
or	O
receptors	O
could	O
account	O
for	O
the	O
differences	O
in	O
observed	O
potency	O
.	O

The	O
distribution	O
coefficient	O
for	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
was	O
approximately	O
30-fold	O
less	O
than	O
for	O
DS	O
or	O
INDO	O
,	O
indicating	O
that	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
is	O
much	O
less	O
lipophilic	O
than	O
these	O
NSAIDs	O
.	O

Therefore	O
,	O
the	O
physicochemical	O
and	O
pharmacokinetics	O
properties	O
of	O
(	O
R	O
,	O
S	O
)	O
-ketorolac	O
may	O
optimize	O
the	O
concentrations	O
of	O
(	O
S	O
)	O
-ketorolac	O
at	O
its	O
biological	O
target	O
(	O
s	O
)	O
,	O
resulting	O
in	O
greater	O
efficacy	O
and	O
potency	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
distribution	O
,	O
excretion	O
and	O
metabolism	O
of	O
1,2-dimethylnaphthalene-	O
[	O
ring	O
-	O
U-3H	O
]	O
in	O
rats	B
.	O

The	O
experiments	O
were	O
performed	O
on	O
54	O
male	O
outbred	O
IMP	O
:	O

Wist	O
rats	B
with	O
body	O
weight	O
of	O
200	O
g	O
+	O
/-	O

20	O
%	O
.	O

The	O
compound	O
was	O
given	O
i.p	O
.	O

in	O
olive	O
oil	O
in	O
a	O
single	O
dose	O
of	O
28	O
mg	O
/	O
kg	O
(	O
about	O
6.2	O
MBq	O
per	O
animal	O
)	O
.	O

3H	O
radioactivity	O
was	O
traced	O
in	O
selected	O
organs	O
and	O
tissues	O
,	O
blood	O
,	O
urine	O
and	O
faeces	O
,	O
1	O
-	O
72	O
h	O
following	O
the	O
administration	O
.	O

The	O
main	O
metabolites	O
were	O
isolated	O
from	O
urine	O
and	O
identified	O
by	O
the	O
GC	O
-	O
MS	O
method	O
.	O

Faeces	O
and	O
urine	O
proved	O
to	O
be	O
the	O
main	O
route	O
of	O
tritium	O
elimination	O
.	O

Over	O
93	O
%	O
of	O
the	O
given	O
compound	O
was	O
excreted	O
during	O
the	O
first	O
72	O
h.	O
Maximum	O
level	O
of	O
tritium	O
in	O
plasma	O
was	O
observed	O
during	O
the	O
4th	O
h	O
after	O
the	O
compound	O
administration	O
.	O

The	O
accretion	O
of	O
3H	O
proceeded	O
with	O
kinetic	O
constant	O
of	O
0.7	O
h	O
,	O
followed	O
by	O
monophasic	O
decline	O
with	O
the	O
half	O
-	O
life	O
of	O
about	O
19h	O
.	O

In	O
organs	O
and	O
tissue	O
,	O
the	O
highest	O
concentration	O
during	O
the	O
first	O
hours	O
after	O
administration	O
were	O
detected	O
in	O
the	O
fat	O
,	O
adrenals	O
,	O
liver	O
,	O
spleen	O
and	O
kidneys	O
.	O

Then	O
gradual	O
decline	O
of	O
tritium	O
was	O
noticed	O
in	O
all	O
examined	O
tissues	O
.	O

The	O
following	O
urinary	O
metabolites	O
were	O
identified	O
:	O
1	O
.	O

1,2-dimethylthionaphthalene	O
,	O
2	O
.	O

1,2-dimethylnaphthol	O
,	O
3	O
.	O
1-methylnaphthalene-2-methanol	O
,	O
4	O
.	O
1-methyl-2-naphthoic	O
acid	O
and	O
5	O
.	O

1,2-dimethylmethylthionaphthalene	O
.	O

In	O
conclusion	O
,	O
1,2-dimethylnaphthalene	O
has	O
a	O
relatively	O
rapid	O
turnover	O
rate	O
in	O
the	O
rat	B
organism	O
and	O
does	O
not	O
form	O
deposits	O
in	O
the	O
tissue	O
.	O

The	O
metabolism	O
encompasses	O
ring	O
hydroxylation	O
and	O
glutathione	O
conjugation	O
leading	O
to	O
thionaphthol	O
and	O
oxygenation	O
,	O
and	O
then	O
to	O
naphthoic	O
acid	O
.	O

Trimethylbenzene	O
isomers	O
(	O
TMBs	O
)	O
:	O
1,2,4-TMB	O
(	O
pseudocumene	O
--	O
PS	O
)	O
,	O
1,2,3-TMB	O
(	O
hemimellitene	O
--	O
HM	O
)	O
and	O
1,3,5-TMB	O
(	O
mesitylene	O
--	O
MES	O
)	O
are	O
important	O
constituents	O
of	O
solvent	O
mixtures	O
.	O

In	O
the	O
US	O
,	O
the	O
adopted	O
TLV	O
-	O
TWA	O
value	O
for	O
TMBs	O
is	O
125	O
mg	O
/	O
m3	O
or	O
25	O
ppm	O
(	O
ACGIH	O
1996	O
)	O
.	O

Recent	O
experiments	O
at	O
our	O
laboratory	O
have	O
revealed	O
an	O
impaired	O
learning	O
of	O
passive	O
and	O
active	O
avoidance	O
responses	O
and	O
a	O
longer	O
persistence	O
of	O
an	O
effect	O
of	O
footshock	O
(	O
increase	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
)	O
in	O
rats	B
tested	O
several	O
weeks	O
after	O
a	O
four	O
-	O
week	O
inhalation	O
exposure	O
(	O
6h	O
/	O
day	O
,	O
five	O
days	O
/	O
week	O
)	O
to	O
PS	O
at	O
a	O
concentration	O
of	O
100	O
or	O
250	O
ppm	O
(	O
15	O
)	O
.	O

The	O
concentration	O
-	O
effect	O
relationship	O
appeared	O
to	O
be	O
nonlinear	O
;	O
the	O
effect	O
of	O
100	O
ppm	O
HM	O
was	O
more	O
pronounced	O
than	O
that	O
of	O
250	O
ppm	O
.	O

In	O
the	O
present	O
experiment	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
repeated	O
four	O
-	O
week	O
(	O
6h	O
/	O
day	O
,	O
5	O
days	O
/	O
week	O
)	O
inhalation	O
exposure	O
to	O
HM	O
at	O
concentrations	O
of	O
0	O
,	O
25	O
,	O
100	O
or	O
250	O
ppm	O
on	O
radial	O
-	O
maze	O
performance	O
,	O
open	O
-	O
field	O
activity	O
,	O
passive	O
and	O
active	O
avoidance	O
learning	O
,	O
and	O
on	O
the	O
shock	O
-	O
induced	O
changes	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
(	O
hot	O
-	O
plate	O
test	O
)	O
.	O

The	O
tests	O
were	O
performed	O
between	O
days	O
14	O
and	O
61	O
after	O
the	O
last	O
exposure	O
.	O

No	O
significant	O
effects	O
on	O
radial	O
-	O
maze	O
performance	O
and	O
open	O
-	O
field	O
activity	O
were	O
noted	O
in	O
any	O
of	O
the	O
dose	O
groups	O
.	O

In	O
the	O
remaining	O
tests	O
effects	O
of	O
exposure	O
were	O
noted	O
but	O
,	O
similarly	O
as	O
in	O
the	O
case	O
of	O
PS	O
exposure	O
,	O
the	O
concentration	O
-	O
effect	O
relationship	O
was	O
not	O
linear	O
.	O

In	O
rats	B
exposed	O
to	O
HM	O
at	O
25	O
or	O
100	O
ppm	O
,	O
but	O
not	O
250	O
ppm	O
,	O
learning	O
of	O
the	O
passive	O
avoidance	O
,	O
i.e.	O
refraining	O
from	O
performance	O
of	O
a	O
punished	O
response	O
(	O
stepping	O
off	O
an	O
elevated	O
platform	O
)	O
was	O
significantly	O
impaired	O
.	O

Moreover	O
,	O
in	O
rats	B
exposed	O
to	O
100	O
,	O
but	O
not	O
250	O
ppm	O
of	O
HM	O
,	O
acquisition	O
of	O
the	O
two	O
-	O
way	O
active	O
avoidance	O
in	O
the	O
shuttle	O
-	O
box	O
was	O
slower	O
and	O
the	O
footshock	O
-	O
induced	O
increase	O
in	O
latency	O
of	O
the	O
paw	O
-	O
lick	O
response	O
to	O
heat	O
persisted	O
longer	O
than	O
in	O
the	O
unexposed	O
animals	O
.	O

The	O
results	O
suggest	O
that	O
a	O
low	O
-	O
level	O
inhalation	O
exposure	O
to	O
HM	O
,	O
just	O
like	O
low	O
-	O
level	O
exposure	O
to	O
PS	O
,	O
may	O
lead	O
to	O
long	O
-	O
lasting	O
disturbances	O
in	O
the	O
CNS	O
functions	O
.	O

The	O
nonlinear	O
concentration	O
-	O
effect	O
relationship	O
observed	O
in	O
the	O
case	O
of	O
both	O
TMB	O
-	O
s	O
requires	O
clarification	O
in	O
further	O
studies	O
.	O

All	O
the	O
benzodiazepines	O
(	O
BZDs	O
)	O
in	O
clinical	O
use	O
have	O
the	O
capacity	O
to	O
promote	O
the	O
binding	O
of	O
the	O
major	O
inhibitory	O
neurotransmitter	O
,	O
gamma	O
-	O
amino	O
-	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
to	O
sub	O
-	O
types	O
of	O
GABA	O
receptors	O
which	O
exist	O
as	O
multi	O
-	O
subunit	O
ligand	O
-	O
gated	O
chloride	O
channels	O
.	O

Thus	O
,	O
the	O
BZDs	O
facilitate	O
the	O
actions	O
of	O
GABA	O
in	O
the	O
brain	O
.	O

The	O
BZDs	O
in	O
use	O
as	O
antiepileptic	O
drugs	O
are	O
diazepam	O
,	O
clonazepam	O
,	O
clobazam	O
,	O
nitrazepam	O
,	O
and	O
lately	O
,	O
also	O
lorazepam	O
and	O
midazolam	O
as	O
emergency	O
therapy	O
.	O

The	O
BZDs	O
have	O
a	O
wide	O
-	O
spectrum	O
of	O
proven	O
clinical	O
efficacy	O
in	O
the	O
prevention	O
of	O
different	O
kind	O
of	O
seizures	O
.	O

Clonazepam	O
and	O
clobazam	O
,	O
as	O
well	O
as	O
nitrazepam	O
in	O
some	O
cases	O
,	O
can	O
be	O
useful	O
as	O
an	O
adjunct	O
treatment	O
in	O
refractory	O
epilepsies	O
.	O

However	O
,	O
the	O
clinical	O
use	O
of	O
BZDs	O
for	O
the	O
prophylactic	O
treatment	O
of	O
epilepsy	O
is	O
associated	O
with	O
two	O
major	O
problems	O
which	O
have	O
limited	O
the	O
long	O
-	O
term	O
use	O
of	O
these	O
drugs	O
:	O
the	O
potential	O
for	O
side	O
-	O
effects	O
,	O
especially	O
sedative	O
effects	O
,	O
and	O
the	O
high	O
risk	O
of	O
development	O
of	O
tolerance	O
.	O

Despite	O
the	O
limitations	O
of	O
BZDs	O
in	O
the	O
prophylactic	O
treatment	O
of	O
epilepsies	O
,	O
these	O
drugs	O
play	O
a	O
prominent	O
role	O
in	O
clinical	O
practice	O
in	O
the	O
emergency	O
management	O
of	O
acute	O
seizures	O
and	O
status	O
epilepticus	O
.	O

Diazepam	O
,	O
clonazepam	O
and	O
lorazepam	O
are	O
all	O
considered	O
first	O
-	O
line	O
agents	O
in	O
the	O
emergency	O
management	O
of	O
acute	O
seizures	O
and	O
status	O
epilepticus	O
.	O

Furthermore	O
,	O
the	O
value	O
of	O
midazolam	O
as	O
an	O
emergency	O
therapy	O
in	O
epilepsy	O
has	O
been	O
increasingly	O
recognized	O
in	O
recent	O
years	O
.	O

Anti	O
-	O
ulcer	O
effects	O
of	O
cetraxate	O
,	O
a	O
new	O
compound	O
possessing	O
anti	O
-	O
plasmin	O
,	O
anti	O
-	O
casein	O
and	O
anti	O
-	O
trypsin	O
actions	O
were	O
investigated	O
by	O
using	O
experimental	O
gastric	O
ulcer	O
models	O
in	O
rats	B
.	O

Cetraxate	O
,	O
300	O
mg	O
/	O
kg	O
p.o	O
.	O
showed	O
significant	O
inhibitory	O
effects	O
of	O
65.3	O
%	O
,	O
70.0	O
%	O
,	O
30.2	O
%	O
,	O
and	O
67.1	O
%	O
against	O
aucte	O
types	O
of	O
ulcers	O
producing	O
by	O
aspirin	O
,	O
phenylbutazone	O
,	O
indomethacin	O
,	O
and	O
pyloric	O
ligature	O
(	O
Shay	O
's	O
ulcer	O
)	O
,	O
respectively	O
.	O

These	O
effects	O
were	O
greater	O
than	O
those	O
obtained	O
by	O
gefarnate	O
and	O
aluminum	O
sucrose	O
sulfate	O
may	O
be	O
mainly	O
attributed	O
to	O
the	O
protecting	O
action	O
of	O
this	O
drug	O
on	O
gastric	O
mucosa	O
.	O

Ctraxate	O
further	O
revealed	O
remarkable	O
inhibitory	O
effects	O
on	O
chronic	O
types	O
of	O
ulcers	O
produced	O
by	O
acetic	O
acid	O
,	O
clamping	O
,	O
and	O
clamping	O
-	O
cortisone	O
.	O

In	O
acetic	O
acid	O
ulcer	O
in	O
particular	O
,	O
cetraxate	O
was	O
found	O
to	O
have	O
a	O
dose	O
-	O
dependent	O
inhibitory	O
effect	O
at	O
doses	O
over	O
50	O
mg	O
/	O
kg	O
.	O

Of	O
test	O
drugs	O
including	O
L	O
-	O
glutamine	O
and	O
methylmethionine	O
sulfonium	O
chloride	O
,	O
cetraxate	O
showed	O
the	O
most	O
remarkable	O
inhibitory	O
effect	O
on	O
beta	O
-	O
glucuronidase	O
activity	O
in	O
ulcer	O
tissue	O
of	O
these	O
three	O
types	O
of	O
ulcers	O
.	O

These	O
findings	O
suggest	O
that	O
cetraxate	O
may	O
prevent	O
the	O
connective	O
tissue	O
in	O
the	O
ulcer	O
location	O
from	O
decomposition	O
due	O
to	O
lysosomal	O
enzymes	O
such	O
as	O
beta	O
-	O
glucuronidase	O
,	O
thereby	O
accelerating	O
the	O
recovery	O
from	O
ulcer	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
the	O
Bacillus	B
subtilis	I
168	O
tuaABCDEFGH	O
operon	O
encodes	O
enzymes	O
required	O
for	O
the	O
polymerization	O
of	O
teichuronic	O
acid	O
as	O
well	O
as	O
for	O
the	O
synthesis	O
of	O
one	O
of	O
its	O
precursors	O
,	O
the	O
UDP	O
-	O
glucuronate	O
.	O

Mutants	O
deficient	O
in	O
any	O
of	O
the	O
tua	O
genes	O
,	O
grown	O
in	O
batch	O
cultures	O
under	O
conditions	O
of	O
phosphate	O
limitation	O
,	O
were	O
characterized	O
by	O
reduced	O
amounts	O
of	O
uronate	O
in	O
their	O
cell	O
walls	O
.	O

The	O
teichuronic	O
acid	O
operon	O
belongs	O
to	O
the	O
Pho	O
regulon	O
,	O
as	O
phosphate	O
limitation	O
induces	O
its	O
transcription	O
.	O

Placing	O
the	O
tuaABCDEFGH	O
operon	O
under	O
the	O
control	O
of	O
the	O
inducible	O
Pspac	O
promoter	O
allowed	O
its	O
constitutive	O
expression	O
independently	O
of	O
the	O
phosphate	O
concentration	O
in	O
the	O
medium	O
;	O
the	O
level	O
of	O
uronic	O
acid	O
in	O
cell	O
walls	O
was	O
dependent	O
on	O
the	O
concentration	O
of	O
the	O
inducer	O
.	O

Apparently	O
,	O
owing	O
to	O
an	O
interdependence	O
between	O
teichoic	O
and	O
teichuronic	O
acid	O
incorporation	O
into	O
the	O
cell	O
wall	O
,	O
in	O
examined	O
growth	O
conditions	O
,	O
the	O
balance	O
between	O
the	O
two	O
polymers	O
is	O
maintained	O
in	O
order	O
to	O
insure	O
a	O
constant	O
level	O
of	O
the	O
wall	O
negative	O
charge	O
.	O

Evidence	O
has	O
accumulated	O
supporting	O
the	O
concept	O
that	O
reactive	O
oxygen	O
metabolites	O
,	O
including	O
free	O
radical	O
spe­cies	O
(	O
such	O
as	O
superoxide	O
and	O
hydroxyl	O
)	O
,	O
and	O
other	O
oxygen	O
metabolites	O
(	O
such	O
as	O
hydrogen	O
peroxide	O
and	O
hypochlo­rous	O
acid	O
)	O
play	O
an	O
important	O
role	O
in	O
tissue	O
injury	O
(	O
BAUD	O
and	O
ARDALILLOU	O
1986	O
)	O
.	O

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
studies	O
have	O
implicated	O
reactive	O
oxygen	O
metabolites	O
in	O
various	O
forms	O
of	O
toxic	O
nephropathy	O
(	O
PALLER	O
et	O
al.	O
1984	O
;	O
WALKER	O
and	O
SHAH	O
1987	O
,	O
1988	O
;	O
PALLER	O
1988	O
;	O
SHAH	O
1989	O
)	O
.	O

The	O
putative	O
site	O
of	O
injury	O
in	O
most	O
forms	O
of	O
toxic	O
nephropathy	O
is	O
the	O
epithelial	O
cells	O
lining	O
the	O
tubules	O
(	O
BREZIS	O
et	O
al.	O
1991	O
)	O
.	O

From	O
this	O
viewpoint	O
,	O
therefore	O
,	O
protecting	O
these	O
cells	O
from	O
toxic	O
oxygen	O
metabolites	O
may	O
reduce	O
the	O
risk	O
of	O
renal	O
disorders	O
.	O

Although	O
a	O
native	O
scavenger	O
system	O
is	O
capable	O
ofdoing	O
this	O
,	O
it	O
may	O
lose	O
its	O
activity	O
under	O
pathogenic	O
conditions	O
due	O
to	O
organ	O
dysfunction	O
and	O
an	O
excess	O
of	O
free	O
radicals	O
.	O

Therefore	O
,	O
supplementation	O
with	O
chemical	O
scavengers	O
would	O
be	O
necessary	O
in	O
order	O
to	O
decompose	O
these	O
excess	O
pathogenic	O
metabolites	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
membrane	O
protective	O
effects	O
of	O
some	O
flavonoids	O
on	O
the	O
LLC	B
-	I
PKj	I
cell	O
line	O
,	O
which	O
maintains	O
the	O
differentiated	O
characteristics	O
of	O
renal	O
proximal	O
tubular	O
cells	O
(	O
CANTIELLO	O
et	O
al.	O
1987	O
)	O
.	O

This	O
cell	O
line	O
has	O
been	O
used	O
extensively	O
in	O
in	O
vitro	O
studies	O
to	O
examine	O
both	O
physiologic	O
and	O
pathophysiologic	O
mecha­nisms	O
in	O
renal	O
tubules	O
(	O
CANTIELLO	O
et	O
al.	O
1987	O
;	O
MULLIN	O
and	O
McGINN	O
1988	O
;	O
ANDREOLI	O
and	O
McATEER	O
1990	O
;	O
ER­COLANI	O
et	O
al.	O
1990	O
;	O
YOKOZAWA	O
et	O
al.	O
1997a	O
,	O
1997b	O
)	O
.	O

The	O
purposes	O
of	O
this	O
study	O
were	O
to	O
screen	O
out	O
a	O
potentially	O
useful	O
agent	O
for	O
cell	O
membrane	O
protection	O
,	O
and	O
to	O
shed	O
light	O
on	O
the	O
possible	O
mechanism	O
of	O
this	O
process	O
.	O

Material	O
and	O
methods	O
Compounds	O
:	O
Flavones	O
(	O
acacetin	O
,	O
apigenin	O
,	O
apiin	O
,	O
bai­calein	O
,	O
baicalin	O
,	O
chrysoeriol	O
,	O
cirsilineol	O
,	O
cirsiliol	O
,	O
cirsimarin	O
,	O
cirsimaritin	O
,	O
cosmosiin	O
,	O
genkwanin	O
,	O
6-hydroxyluteolin	O
,	O
linarin	O
,	O
luteolin	O
,	O
luteolin	O
7	O
-glucoside	O
,	O
pectolinarigenin	O
,	O
pec­tolinarin	O
,	O
plantaginin	O
,	O
rhoifolin	O
,	O
scutellarein	O
,	O
sorbarin	O
,	O
tecto­chrysin	O
and	O
toringin	O
)	O
and	O
flavonols	O
(	O
afzelin	O
,	O
chrysosplenol	O
B	O
,	O
chrysosplenol	O
C	O
,	O
chrysosplenol	O
D	O
,	O
hyperin	O
,	O
isoquercitrin	O
,	O
isorhamnetin	O
,	O
kaempferitrin	O
,	O
kaempferol	O
,	O
kaempferol-7­glucoside	O
,	O
oxyayanin	O
A	O
,	O
quercetin	O
,	O
quercimeritrin	O
,	O
quer­citrin	O
,	O
rhamnetin	O
,	O
rutin	O
and	O
tetramethylquercitin	O
)	O
used	O
in	O
this	O
experiment	O
were	O
isolated	O
from	O
natural	O
sources	O
.	O

Medium	O
and	O
reagents	O
:	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
/	O
nutrient	O
mixture	O
F-12	O
(	O
D	O
-	O
MEMIF-12	O
)	O
and	O
fetal	B
calf	O
serum	O
(	O
FCS	O
)	O
were	O
purchased	O
from	O
Life	O
Technologies	O
,	O
Exp	O
Toxic	O
Patho151	O
(	O
1999	O
)	O
1	O
ries	O
(	O
Cleveland	O
,	O
OH	O
,	O
USA	O
)	O
,	O
respectively	O
.	O

A	O
commercial	O
kit	O
(	O
lactate	O
dehydrogenase	O
ClI	O
-	O
Test	O
Wako	O
)	O
for	O
assaying	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
was	O
obtained	O
from	O
Wako	O
Pure	O
Chemical	O
Industries	O
,	O
Ltd.	O
,	O
Osaka	O
,	O
Japan	O
.	O

Cultured	O
cell	O
experiments	O
:	O
Commercially	O
available	O
LLC	B
-	I
PK1	I
cells	O
were	O
maintained	O
at	O
37	O
°	O
C	O
in	O
a	O
humidified	O
at­mosphere	O
of	O
5	O
%	O
CO2	O
in	O
air	O
(	O
routine	O
conditions	O
)	O
on	O
culture	O
plates	O
with	O
5	O
%	O
FCS	O
-	O
supplemented	O
D	O
-	O
MEM	O
/	O
F-12	O
medium	O
.	O

After	O
confluence	O
had	O
been	O
reached	O
,	O
the	O
cells	O
were	O
seeded	O
on	O
fresh	O
96-well	O
culture	O
plates	O
at	O
104	O
per	O
well	O
.	O

Each	O
flavonoid	O
compound	O
was	O
added	O
to	O
the	O
culture	O
2	O
h	O
later	O
,	O
and	O
the	O
plates	O
were	O
incubated	O
under	O
routine	O
conditions	O
for	O
48	O
h.	O
Leakage	O
of	O
LDH	O
into	O
the	O
culture	O
medium	O
was	O
assayed	O
using	O
a	O
com­mercial	O
kit	O
.	O

The	O
level	O
of	O
lipid	O
peroxidant	O
released	O
from	O
the	O
cultured	O
cells	O
was	O
estimated	O
by	O
measuring	O
the	O
amount	O
of	O
malondialdehyde	O
(	O
MDA	O
)	O
as	O
described	O
by	O
YAGI	O
(	O
1976	O
)	O
.	O

All	O
assays	O
were	O
performed	O
5	O
times	O
.	O

Statistics	O
:	O
Data	O
are	O
presented	O
as	O
mean	O
±	O
S.E.	O
Differences	O
among	O
groups	O
were	O
analyzed	O
by	O
Dunnett	O
's	O
test	O
.	O

Signifi­cance	O
was	O
accepted	O
at	O
p	O
<	O
0.05	O
.	O

Results	O
Flavone	O
-	O
type	O
compounds	O
:	O
Eighteen	O
of	O
24	O
flavones	O
(	O
75	O
%	O
)	O
demonstrated	O
different	O
degrees	O
of	O
membrane	O
pro­tective	O
activity	O
.	O

Baicalin	O
,	O
cirsimaritin	O
,	O
6-hydroxyluteolin	O
,	O
luteolin	O
,	O
plantaginin	O
,	O
rhoifolin	O
and	O
sorbarin	O
appeared	O
to	O
be	O
the	O
most	O
effective	O
compounds	O
for	O
preventing	O
LDH	O
leakage	O
,	O
since	O
only	O
a	O
very	O
low	O
concentration	O
of	O
0.25	O
Ilg	O
/	O
ml	O
was	O
needed	O
for	O
coculture	O
with	O
the	O
cells	O
,	O
as	O
shown	O
in	O
table	O
1	O
.	O

Cirsimarin	O
,	O
luteolin	O
7	O
-glucoside	O
,	O
pectolinarigenin	O
,	O
tec­tochrysin	O
and	O
toringin	O
showed	O
significant	O
inhibition	O
at	O
a	O
concentration	O
of	O
0.5	O
Ilg	O
/	O
ml	O
.	O

Five	O
compounds	O
,	O
baicalein	O
,	O
chrysoeriol	O
,	O
cirsiliol	O
,	O
linarin	O
and	O
scutellarein	O
,	O
suppressed	O
the	O
leakage	O
significantly	O
at	O
a	O
minimum	O
concentration	O
of	O
2.5	O
Ilg	O
/	O
ml	O
.	O

However	O
,	O
the	O
other	O
flavone	O
compounds	O
acted	O
only	O
weakly	O
in	O
comparison	O
with	O
those	O
described	O
above	O
.	O

In	O
addition	O
,	O
LDH	O
efflux	O
was	O
apparently	O
associated	O
with	O
the	O
MDA	O
level	O
.	O

The	O
amount	O
ofthis	O
lipid	O
peroxidant	O
form­ed	O
declined	O
markedly	O
when	O
the	O
cells	O
were	O
cultured	O
in	O
the	O
presence	O
of	O
baicalin	O
,	O
cirsimarin	O
,	O
cirsimaritin	O
,	O
6-hydroxy­luteolin	O
,	O
luteolin	O
,	O
luteolin	O
7-glucoside	O
,	O
pectolinarigenin	O
,	O
plantaginin	O
,	O
rhoifolin	O
,	O
sorbarin	O
and	O
tectochrysin	O
.	O

The	O
in­hibition	O
ofMDA	O
formation	O
by	O
these	O
compounds	O
was	O
con­centration	O
-	O
dependent	O
.	O

Flavonol	O
-	O
type	O
compounds	O
:	O
As	O
shown	O
in	O
table	O
2	O
,	O
most	O
flavonol	O
compounds	O
tested	O
(	O
14	O
out	O
of	O
17	O
)	O
revealed	O
much	O
higher	O
activity	O
in	O
preventing	O
enzyme	O
efflux	O
.	O

Afzelin	O
,	O
hy­perin	O
,	O
isoquercitrin	O
,	O
isorhamnetin	O
,	O
kaempferitrin	O
,	O
kaemp­ferol-7	O
-glucoside	O
,	O
oxyayanin	O
A	O
,	O
quercetin	O
,	O
quercitrin	O
,	O
rhamnetin	O
and	O
rutin	O
were	O
markedly	O
effective	O
because	O
the	O
released	O
LDH	O
was	O
significantly	O
decreased	O
when	O
they	O
were	O
cocultured	O
with	O
the	O
cells	O
even	O
at	O
a	O
concentration	O
of	O
0.25	O
Ilg	O
/	O
ml	O
,	O
isoquercitrin	O
and	O
isorhamnetin	O
exerting	O
the	O
strongest	O
effect	O
.	O

Higher	O
concentrations	O
of	O
chrysosplenol	O
B	O
and	O
chrysosplenol	O
C	O
(	O
20	O
times	O
those	O
of	O
the	O
above	O
com­pounds	O
)	O
were	O
required	O
to	O
inhibit	O
LDH	O
release	O
to	O
the	O
same	O
extent	O
,	O
but	O
tetramethylquercitin	O
did	O
not	O
affect	O
LDH	O
re-	O
Exp	O
Toxic	O
Pathol	O
51	O
(	O
1999	O
)	O
1	O
MDA	O
leakage	O
from	O
LLC	B
-	I
PK1	I
Compound	O
Con­	O
centration	O
(	O
Ilg	O
/	O
ml	O
)	O
Acacetin	O
0.25	O
0.5	O
2.5	O
5	O
Apigenin	O
0.25	O
0.5	O
2.5	O
5	O
Apiin	O
0.25	O
0.5	O
2.5	O
5	O
Baicalein	O
0.25	O
0.5	O
2.5	O
5	O
Baicalin	O
0.25	O
0.5	O
2.5	O
5	O
Chrysoeriol	O
0.25	O
0.5	O
2.5	O
5	O
Cirsilineol	O
0.25	O
0.5	O
2.5	O
5	O
Cirsiliol	O
0.25	O
0.5	O
2.5	O
5	O
Cirsimarin	O
0.25	O
0.5	O
2.5	O
5	O
Cirsimaritin	O
0.25	O
0.5	O
2.5	O
5	O
Cosmosiin	O
0.25	O
0.5	O
2.5	O
5	O
cells	O
.	O

LDH	O
leakage	O
rate	O
(	O
%	O
)	O
92.8	O
±	O
6.2	O
90.2	O
±	O
6.3	O
89.8	O
±	O
5.9	O
89.2	O
±	O
9.5	O
96.7	O
±6.7	O
94.9	O
±	O
5.6	O
95.5	O
±	O
7.5	O
91.8	O
±	O
5.2	O
98.3	O
±	O
6.3	O
89.2	O
±	O
7.0	O
88.9	O
±	O
6.2	O
87.9±7.1	O
96.5	O
±	O
2.8	O
91.3	O
±	O
4.2	O
82.9	O
±	O
9.4b	O
81.4	O
±	O
6.lb	O
80.0	O
±	O
6.5	O
""""	O
80.3	O
±	O
5.ge	O
80.7	O
±	O
5.8e	O
76.2	O
±	O
3.4	O
<	O
101.1	O
±	O
5.7	O
89.3	O
±	O
4.3	O
84.6	O
±	O
8.9b	O
85.2	O
±	O
8.0	O
""""	O
99.9	O
±	O
5.9	O
96.5	O
±	O
8.9	O
93.9	O
±	O
9.5	O
88.1	O
±	O
7.6	O
94.0	O
±7.9	O
88.4	O
±	O
7.0	O
82.9	O
±	O
6.4	O
""""	O
71.6	O
±	O
6.3c	O
89.3	O
±	O
6.4	O
82.9	O
±	O
6.1b	O
77.3	O
±	O
5.7e	O
67.6	O
±	O
6.7e	O
80.5	O
±	O
5.1e	O
71.1	O
±5.9c	O
59.9	O
±	O
6.7c	O
52.8	O
±	O
7.4c	O
97.5	O
±	O
6.1	O
88.6	O
±	O
6.5	O
85.5	O
±	O
6.7	O
79.1	O
±7.5	O
""""	O
MDA	O
leakage	O
rate	O
(	O
%	O
)	O
89.5	O
±	O
8.4	O
85.7	O
±	O
8.5	O
86.4	O
±	O
8.2	O
79.9	O
±	O
6.8b	O
97.3	O
±	O
9.7	O
95.6	O
±	O
8.3	O
88.5	O
±	O
5.4	O
85.7	O
±	O
6.6	O
93.2	O
±	O
5.1	O
94.2	O
±	O
5.7	O
94.2	O
±	O
5.7	O
92.4	O
±	O
4.4	O
95.5	O
±	O
4.7	O
93.2	O
±	O
6.1	O
91.7	O
±	O
4.2	O
89.1	O
±4.4	O
""""	O
81.9	O
±	O
7.8b	O
79.0	O
±	O
5.2b	O
75.4	O
±	O
6.3e	O
72.1	O
±	O
6.1c	O
97.9	O
±	O
8.7	O
95.8	O
±	O
8.7	O
93.7	O
±	O
7.6	O
89.4	O
±	O
7.8	O
95.6	O
±	O
5.7	O
94.2	O
±	O
8.7	O
90.5	O
±	O
7.8	O
92.6	O
±	O
6.4	O
97.8±7.1	O
91.6	O
±	O
5.8	O
80.0	O
±	O
7.8b	O
76.1	O
±	O
5.9c	O
85.7	O
±	O
6.7	O
""""	O
83.2	O
±	O
7.2b	O
76.6	O
±	O
5.7e	O
69.5	O
±	O
5.8c	O
85.2	O
±	O
6.7	O
""""	O
75.7	O
±	O
5.7c	O
63.7	O
±	O
6.1e	O
57.3	O
±	O
6.0e	O
93.1	O
±	O
7.1	O
89.6	O
±	O
7.1	O
82.6	O
±	O
6.8	O
""""	O
77.2	O
±	O
6.3b	O
Compound	O
Con-	O
LDH	O
leakage	O
MDA	O
leakage	O

Compound	O
Con-	O
LDH	O
leakage	O
MDAleakage	O
centration	O
rate	O
rate	O
centration	O
rate	O
rate	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
Genkwanin	O
0.25	O
0.5	O
116.4	O
±	O
18.1	O
108.1	O
±	O
11.9	O
110.5	O
±	O
13.6	O
106.8	O
±	O
7.1	O
Tectochrysin	O
0.25	O
0.5	O
93.6	O
±	O

6.0	O
84.5	O
±	O
6.7a	O
95.0	O
±	O
7.5	O
85.2	O
±	O
7.7b	O
2.5	O
101.9	O
±	O
10.9	O
103.7	O
±	O
6.5	O
2.5	O
82.2	O
±	O
7.5b	O
85.8	O
±	O
6.9a	O
5	O
100.2	O
±	O
9.2	O
103.4	O
±	O
6.2	O
5	O
71.2	O
±	O
5.ge	O
68.4	O
±	O
7.6e	O
6-Hydro­	O
xyluteolin	O
0.25	O
n.3	O
±	O
7.2e	O
78.6	O
±	O
5.2e	O
Toringin	O
0.25	O
88.9	O
±	O
6.5	O
91.0	O
±	O
6.9	O
0.5	O
69.1	O
±5.7e	O
n.6	O
±	O
6.8c	O
0.5	O
86.9	O
±	O
7.8a	O
89.3	O
±	O
6.3	O
2.5	O
53.8	O
±	O
5.8c	O
59.4±6.1c	O
2.5	O
83.4	O
±	O
6.1b	O
78.4	O
±	O
5.7e	O
5	O
50.9	O
±	O
5.6e	O
54.7	O
±	O
7.2e	O
5	O
76.5	O
±	O
5.4e	O
73.9	O
±	O
4.ge	O
Linarin	O
0.25	O
97.4	O
±	O
5.6	O
95.3	O
±	O
7.6	O
Control	O
100.0	O
±	O
6.1	O
100.0	O
±	O
6.9	O
0.5	O
94.5	O
±	O
5.1	O
'	O
91.4	O
±	O
7.1	O
2.5	O
79.3	O
±	O
7.3e	O
82.1	O
±	O
6.2b	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
:	O
ap	O
<	O
0.05	O
,	O
5	O
68.2	O
±	O
8.2e	O
69.5	O
±	O
7.6e	O
bp	O
<	O
0.01	O
,	O
ep	O
<	O
0.001	O
.	O

Luteolin	O
0.25	O
78.9±4.1e	O
83.5	O
±	O
6.2b	O
Table	O
2	O
.	O

Effect	O
of	O
flavonol	O
-	O
type	O
compounds	O
on	O
LDH	O
and	O
0.5	O
76.6	O
±	O
5.7e	O
81.7±6.1b	O
MDA	O
leakage	O
from	O
LLC	B
-	I
PK1	I
cells	O
.	O

2.5	O
74.6	O
±	O
5.8e	O
78.0	O
±	O
5.4e	O
5	O
67.8	O
±	O
5.2e	O
66.8	O
±	O
6.ge	O
Compound	O
Con-	O
LDH	O
leakage	O
MDA	O
leakage	O
Luteolin	O
centration	O
rate	O
rate	O
7	O
-glucoside	O
0.25	O
97.5	O
±	O
5.6	O
96.3	O
±	O
4.9	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
0.5	O
83.2±7.1b	O
86.3	O
±	O
6.2a	O
2.5	O
5	O
70.3	O
±	O
7.ge	O
63.2	O
±	O
7.4e	O
75.2	O
±	O
6.2e	O
65.7	O
±	O
5.8e	O
Afzelin	O
0.25	O
0.5	O
67.8	O
±	O
3.5b	O
63.2±3.1b	O
73.9	O
±	O
5.9b	O
70.8	O
±	O
6.4b	O
Pecto­	O
2.5	O
59.7	O
±	O
6.9b	O
65.3	O
±	O
6.7b	O
linarigenin	O
0.25	O
93.2	O
±	O
7.7	O
96.8	O
±4.7	O
5	O
56.1	O
±	O
4.5b	O
53.7	O
±	O
4.6b	O
0.5	O
69.2	O
±	O
5.2e	O
n.6±7.1e	O
Chryso­	O
2.5	O
57.4	O
±	O
6.1c	O
62.6	O
±	O
6.4e	O
splenol	O
B	O
0.25	O
107.7	O
±	O
7.0	O
100.2	O
±	O
9.1	O
5	O
48.0	O
±	O
6.5	O
<	O
54.1	O
±	O
5.3e	O
0.5	O
100.3	O
±	O
6.7	O
95.8	O
±	O
7.6	O
2.5	O
89.8	O
±	O
6.4	O
92.7	O
±	O
6.7	O
Pectolinarin	O
0.25	O
103.8	O
±	O
5.7	O
103.1	O
±	O
5.1	O
5	O
70.4	O
±	O
5.3b	O
76.2	O
±	O
6.8b	O
0.5	O
100.5	O
±	O
7.1	O
100.3	O
±	O
6.2	O
Chryso­	O
2.5	O
99.2	O
±	O
5.1	O
96.3	O
±	O
4.8	O
splenol	O
C	O
0.25	O
100.7	O
±	O
6.9	O
94.8	O
±	O
5.8	O
5	O
89.3	O
±	O
6.2	O
92.0	O
±	O
5.7	O
0.5	O
98.2	O
±	O
6.6	O
94.2	O
±4.5	O

2.5	O
94.6	O
±	O
6.5	O
90.5	O
±	O
7.7	O
Plantaginin	O
0.25	O
80.0	O
±	O
4.2c	O
83.2	O
±	O
4.4b	O
5	O
84.2	O
±	O
4.7a	O
81.1	O
±6.4b	O
0.5	O
71.3	O
±	O
5.2e	O
76.8	O
±	O
4.7e	O
Chryso­	O
2.5	O
67.5	O
±	O
5.7e	O
67.8	O
±	O
6.2e	O
splenol	O
D	O
0.25	O
91.6	O
±	O
6.8	O
95.2	O
±	O
4.2	O
5	O
63.0	O
±	O
6.3e	O
59.5	O
±	O
5.0e	O
0.5	O
84.7	O
±	O
5.3a	O
90.5	O
±	O
7.4	O
2.5	O
80.8	O
±	O
4.4b	O
81.1	O
±	O
5.8b	O
Rhoifolin	O
0.25	O
82.4	O
±	O
5.7e	O
85.3±6.1b	O
5	O
75.6	O
±	O
5.4b	O
73.7±5.1b	O
0.5	O
2.5	O
5	O
79.5	O
±	O
5.1e	O
71.9±6.1e	O
71.3	O
±	O
4.4e	O
81.5	O
±	O
5.ge	O
73.9	O
±	O
6.3e	O
n.l	O
±	O
6.ge	O
Hyperin	O
0.25	O
0.5	O
2.5	O
86.9	O
±	O
6.8a	O
63.7	O
±	O
5.6b	O
50.2	O
±	O
3.9b	O
94.6	O
±	O
6.1	O
71.7	O
±	O
6.9b	O
59.5	O
±	O
4.4b	O
Scutellarein	O
0.25	O
95.9	O
±	O
7.4	O
93.7	O
±	O
4.2	O
5	O
41.9	O
±	O
4.0b	O
48.2	O
±	O
4.3b	O
0.5	O
2.5	O
5	O
90.6	O
±	O
6.9	O
80.6	O
±	O
7.7b	O
63.5	O
±	O
6.4e	O
91.4	O
±	O
5.9	O
84.3	O
±	O
7.4b	O
60.0	O
±	O
5.3e	O
Isoquercitrin	O
0.25	O
0.5	O
2.5	O
47.6	O
±	O
4.9b	O
46.5	O
±	O
3.5b	O
42.2	O
±	O
4.7b	O
57.1	O
±4.9b	O
52.0	O
±	O
4.9b	O
50.5	O
±	O
5.8b	O
Sorbarin	O
0.25	O
60.0	O
±	O
4.4e	O
63.3	O
±	O
6.7e	O
5	O
39.1	O
±	O
3.5b	O
45.6	O
±	O
4.0b	O
0.5	O
2.5	O
5	O
54.9	O
±	O
5.5	O
<	O
50.1	O
±	O
7.8e	O
47.0	O
±	O
5.2e	O
59.2	O
±	O
5.5	O
<	O
53.3	O
±	O
5.8e	O
42.6	O
±	O
4.8e	O
Isorhamnetin	O
0.25	O
0.5	O
2.5	O
63.0	O
±	O
5.4b	O
51.4	O
±	O
4.8b	O
32.2	O
±	O
3.7b	O
74.2	O
±	O
6.8b	O
62.8	O
±	O
6.2b	O
40.1	O
±	O
3.6b	O
5	O
21.6	O
±	O
3.7b	O
32.3	O
±	O
3.0b	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O

I	O
Discussion	O
Compound	O
Con	O
-	O
LDH	O
leakage	O
MDAleakage	O
centration	O
rate	O
rate	O
(	O
Ilg	O
/	O
ml	O
)	O
(	O
%	O
)	O
(	O
%	O
)	O
Kaempferitrin	O
0.25	O
78.5	O
±	O
5.4b	O
82.2	O
±	O
6.1b	O
0.5	O
75.9	O
±	O
3.2b	O
78.9	O
±	O
6.8b	O
2.5	O
74.3	O
±	O
5.6b	O
71.6	O
±	O
4.3b	O
5	O
72.3	O
±	O
6.1b	O
68.4	O
±	O
4.9b	O
Kaempferol	O
0.25	O
99.3	O
±	O
5.4	O
92.6	O
±	O
7.1	O
0.5	O
79.4	O
±	O
6.5b	O
84.1	O
±	O
4.7a	O
2.5	O
73.3	O
±	O
5.7b	O
78.9	O
±	O
4.9b	O
5	O
66.9	O
±4.4b	O
62.1	O
±4.6b	O
Kaempferol-	O
0.25	O
77.2	O
±	O
5.7b	O
81.5	O
±	O
6.9b	O
7-glucoside	O
0.5	O
72.2	O
±4.1b	O
77.9±5.1b	O
2.5	O
61.4	O
±	O
5.7b	O
66.3	O
±	O
6.2b	O
5	O
53.7	O
±	O
4.8b	O
60.2	O
±	O
4.2b	O
Oxyayanin	O
A	O
0.25	O
86.0	O
±	O
5.78	O
83.7	O
±	O
4.3a	O
0.5	O
83.3	O
±	O
4.8b	O
77.3±7.1b	O
2.5	O
73.5	O
±	O
4.7b	O
68.9	O
±	O
6.9b	O
5	O
67.6	O
±	O
4.8b	O
60.2	O
±	O
5.2b	O
Quercetin	O
0.25	O
77.2	O
±	O
5.8b	O
81.5	O
±	O
5.6b	O
0.5	O
76.5	O
±4.8b	O
79.7	O
±	O
6.2b	O
2.5	O
75.6	O
±	O
3.3b	O
72.1	O
±	O
5.0b	O
5	O
73.5	O
±	O
4.3b	O
69.5	O
±4.6b	O
Quercimeritrin	O
0.25	O
107.0	O
±	O
7.1	O
99.9	O
±4.0	O
0.5	O
98.7	O
±4.7	O
94.7	O
±	O
6.9	O
2.5	O
86.3	O
±	O
5.7a	O
89.4	O
±	O
6.1	O
5	O
74.6	O
±	O
4.4b	O
77.4	O
±4.9b	O
Quercitrin	O
0.25	O
79.1	O
±	O
3.1b	O
81.4	O
±	O
5.5b	O
0.5	O
75.5	O
±	O
4.2b	O
82.1	O
±	O
4.8b	O
2.5	O
70.5	O
±4.9b	O
74.2	O
±	O
4.2b	O
5	O
63.5	O
±	O
4.5b	O
58.1	O
±	O
5.3b	O
Rhamnetin	O
0.25	O
70.4	O
±	O
4.1	O
b	O
80.2	O
±	O
5.2b	O
0.5	O
66.3	O
±	O
4.2b	O
71.0	O
±	O
5.6b	O
2.5	O
51.3±3.1b	O
56.5	O
±	O
4.8b	O
5	O
32.3	O
±	O
3.2b	O
38.4	O
±	O
2.5b	O
Rutin	O
0.25	O
73.2	O
±	O
5.1b	O
79.5	O
±	O
5.5b	O
0.5	O
68.4	O
±	O
4.4b	O
73.4	O
±	O
6.2b	O
2.5	O
62.5	O
±	O
4.2b	O
69.7	O
±	O
5.5b	O
5	O
57.2	O
±	O
4.6b	O
62.6	O
±	O
6.8b	O
Tetramethyl-0.25	O
99.6	O
±	O
7.4	O
97.1	O
±	O
4.9	O
quercitin	O
0.5	O
94.1	O
±	O
7.7	O
96.3	O
±	O
5.3	O
2.5	O
94.3±7.1	O
91.5	O
±	O
7.7	O
5	O
93.4	O
±	O
6.8	O
90.5	O
±	O
8.0	O
Control	O
100.0±	O
5.8	O
100.0	O
±	O
7.1	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
:	O
ap	O
<	O
0.01	O
,	O
bp	O
<	O
0.001	O
.	O

lease	O
.	O

The	O
generation	O
of	O
MDA	O
was	O
found	O
to	O
be	O
markedly	O
decreased	O
in	O
the	O
groups	O
with	O
decreased	O
LDH	O
efflux	O
,	O
which	O
indicated	O
a	O
possible	O
cause	O
and	O
effect	O
relationship	O
between	O
them	O
.	O

Exp	O
Toxic	O
Patho151	O
(	O
1999	O
)	O
1	O
One	O
ofremarkable	O
features	O
ofcellular	O
injury	O
is	O
leakage	O
ofLDH	O
,	O
a	O
soluble	O
cytosolic	O
enzyme	O
,	O
from	O
inside	O
the	O
cells	O
.	O

This	O
leakage	O
is	O
due	O
largely	O
to	O
increased	O
membrane	O
per­meability	O
,	O
which	O
is	O
probably	O
modified	O
by	O
certain	O
factors	O
such	O
as	O
antineoplastic	O
drugs	O
,	O
radiation	O
,	O
and	O
attack	O
by	O
oxy­gen	O
free	O
radical	O
species	O
.	O

It	O
is	O
therefore	O
a	O
useful	O
indicator	O
of	O
membrane	O
integrity	O
and	O
provides	O
a	O
convenient	O
ap­proach	O
for	O
cytotoxicity	O
evaluation	O
.	O

On	O
the	O
other	O
hand	O
,	O
ANDREOLI	O
and	O
McATEER	O
(	O
1990	O
)	O
,	O
RaVIN	O
et	O
al.	O
(	O
1990	O
)	O
and	O
WALKER	O
and	O
SHAH	O
(	O
1991	O
)	O
have	O
reported	O
that	O
renal	O
tubule	O
cells	O
have	O
the	O
potential	O
to	O
produce	O
reactive	O
oxygen	O
meta­bolites	O
in	O
response	O
to	O
various	O
stimuli	O
,	O
and	O
are	O
the	O
major	O
site	O
affected	O
in	O
renal	O
failure	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
we	O
used	O
LDH	O
leakage	O
from	O
LLC	B
-	I
PK1	I
cells	O
as	O
an	O
indicator	O
to	O
evaluate	O
cellular	O
membrane	O
permeability	O
upon	O
incubation	O
with	O
41	O
flavonoids	O
under	O
normal	O
culture	O
conditions	O
.	O

Flavonoids	O
are	O
phenolic	O
compounds	O
widely	O
distributed	O
in	O
plants	B
,	O
with	O
thousands	O
of	O
individual	O
substances	O
known	O
,	O
and	O
the	O
list	O
is	O
constantly	O
expanding	O
.	O

These	O
important	O
bio­active	O
compounds	O
have	O
been	O
shown	O
to	O
have	O
many	O
medi­cal	O
uses	O
,	O
such	O
as	O
diuresis	O
,	O
laxation	O
,	O
and	O
antispasmodic	O
,	O
antihypertensive	O
and	O
anti	O
-	O
inflammatory	O
actions	O
(	O
MITsv­HASHI	O
et	O
al.	O
1989	O
)	O
.	O

Most	O
of	O
the	O
compounds	O
we	O
tested	O
in	O
this	O
study	O
also	O
showed	O
significant	O
effectiveness	O
in	O
in­hibiting	O
the	O
efflux	O
of	O
LDH	O
from	O
LLC	B
-	I
PK1	I
cells	O
,	O
and	O
thus	O
appeared	O
to	O
change	O
the	O
permeability	O
of	O
the	O
cellular	O
mem­brane	O
.	O

To	O
determine	O
the	O
nature	O
of	O
their	O
effect	O
,	O
we	O
measur­ed	O
the	O
MDA	O
content	O
in	O
the	O
culture	O
medium	O
,	O
and	O
found	O
that	O
under	O
routine	O
culture	O
conditions	O
such	O
as	O
5	O
%	O
CO2	O
,	O
95	O
%	O
air	O
and	O
37	O
DC	O
for	O
48	O
h	O
,	O
a	O
certain	O
amount	O
of	O
MDA	O
was	O
generated	O
.	O

This	O
suggests	O
that	O
LDH	O
efflux	O
from	O
the	O
cells	O
may	O
be	O
due	O
largely	O
to	O
lipid	O
peroxidation	O
of	O
the	O
mem­brane	O
,	O
although	O
this	O
may	O
occur	O
slowly	O
under	O
normal	O
con­ditions	O
.	O

Interestingly	O
,	O
when	O
the	O
cells	O
were	O
cocultured	O
with	O
different	O
types	O
of	O
flavones	O
and	O
flavonols	O
,	O
the	O
levels	O
of	O
both	O
LDH	O
and	O
MDA	O
in	O
the	O
medium	O
showed	O
an	O
obvious	O
de­crease	O
,	O
indicating	O
a	O
possible	O
link	O
between	O
them	O
.	O

Itis	O
there­fore	O
reasonable	O
to	O
infer	O
that	O
an	O
antiperoxidation	O
or	O
free	O
ra­dical	O
scavenging	O
mechanism	O
is	O
involved	O
in	O
this	O
process	O
because	O
of	O
the	O
reducing	O
property	O
of	O
these	O
compounds	O
.	O

Much	O
attention	O
has	O
been	O
drawn	O
to	O
the	O
antioxidative	O
ac­tivity	O
of	O
flavonoids	O
due	O
to	O
their	O
structure	O
,	O
especially	O
since	O
a	O
superoxidation	O
injury	O
hypothesis	O
has	O
been	O
put	O
forward	O
to	O
explain	O
the	O
etiology	O
and	O
pathology	O
of	O
some	O
diseases	O
,	O
and	O
this	O
has	O
prompted	O
extensive	O
studies	O
on	O
their	O
antioxi­dative	O
and	O
lipid	O
peroxidation	O
-	O
inhibiting	O
potential	O
.	O

Our	O
data	O
revealed	O
that	O
the	O
action	O
of	O
flavonoids	O
was	O
closely	O
re­lated	O
to	O
their	O
chemical	O
structures	O
.	O

First	O
,	O
as	O
shown	O
in	O
table	O
3	O
,	O
those	O
that	O
demonstrated	O
marked	O
inhibition	O
of	O
LDH	O
efflux	O
activity	O
possess	O
more	O
phenolic	O
hydroxyl	O
groups	O
linked	O
to	O
the	O
backbone	O
.	O

For	O
example	O
,	O
having	O
an	O
extra	O
OH	O
at	O
the	O
3-position	O
made	O
10	O
of	O
the	O
17	O
flavonols	O
tested	O
here	O
exhibit	O
a	O
significant	O
effect	O
at	O
a	O
concentration	O
as	O
low	O
as	O
0.25	O
Ilg	O
in	O
the	O
medium	O
;	O
in	O
contrast	O
,	O
among	O
flavone	O
types	O
,	O
only	O
7	O
out	O
of	O
24	O
(	O
about	O
29	O
%	O
)	O
showed	O
such	O
activity	O
at	O
the	O
same	O
concentration	O
,	O
suggesting	O
that	O
hydroxyl	O
groups	O
are	O
of	O
prime	O
importance	O
for	O
their	O
effects	O
.	O

Compound	O
5	O
6	O
7	O
8	O
3	O
2	O
'	O
3	O
'	O
4	O
'	O
5	O
'	O
6	O
'	O
*	O
Aeaeetin	O
OH	O

OH	O
OMe	O
Apigenin	O
OH	O
OH	O
OH	O
Apiin	O
OH	O

OH	O
*	O
OH	O
apioglue	O
Baicalein	O
OH	O
OH	O
OH	O
Baiealin	O
OH	O
OH	O

OH	O

*	O
glueur	O
Chrysoeriol	O
OH	O
OH	O
OMe	O
OH	O
Cirsilineol	O
OH	O
OMe	O
OMe	O
OMe	O
OH	O
Cirsiliol	O
OH	O
OMe	O
OMe	O
OH	O

OH	O
Cirsimarin	O
OH	O
OMe	O
OMe	O
OH	O

*	O
glue	O
Cirsimaritin	O
OH	O
OMe	O
OMe	O
OH	O
Cosmosiin	O
OH	O

OH	O

*	O
OH	O
glue	O
Genkwanin	O
OH	O
OMe	O
OH	O
6-Hydroxyluteolin	O
OH	O
OH	O
OH	O
OH	O
OH	O
Linarin	O
OH	O

OH	O
*	O
OMe	O
rham	O
,	O
glue	O
Luteolin	O
OH	O
OH	O
OH	O
OH	O
Luteolin	O
7-glueoside	O
OH	O

OH	O

*	O
OH	O
OH	O
glue	O
Peetolinarigenin	O
OH	O
OMe	O
OMe	O
OMe	O
rham	O
,	O
glue	O
Peetolinarin	O
OH	O
OMe	O
OH	O
*	O
OMe	O
rham	O
,	O
glue	O
Plantaginin	O

OH	O
OH	O

OH	O

*	O
OH	O
glue	O
Rhoifolin	O
OH	O

OH	O
*	O
OH	O
rham	O
,	O
glue	O
Scutellarein	O
OR	O
OH	O
OH	O
OH	O
Sorbarin	O

OH	O
OH	O

OH	O
*	O
OH	O
rham	O
Tectochrysin	O
OH	O
OMe	O

Toringin	O
OH	O

*	O
OH	O
gluc	O
Afzelin	O
OH	O
OH	O

OH	O
*	O
OH	O
rham	O
Chrysosplenol	O
B	O
OH	O
OMe	O
OMe	O
OMe	O
OH	O
OH	O
Chrysosplenol	O
C	O
OH	O
OH	O
OMe	O
OMe	O
OMe	O
OH	O
Chrysosplenol	O
D	O
OH	O
OMe	O
OMe	O
OMe	O
OH	O
OH	O
Hyperin	O

OH	O
OH	O

OH	O

*	O
OH	O
OH	O
galac	O
Isoquercitrin	O
OH	O
OR	O
OH	O

*	O
OH	O
OH	O
gluc	O
Isorhamnetin	O
OR	O
OH	O
OH	O
OMe	O
OH	O
Kaempferitrin	O
OH	O

OH	O

*	O
OH	O
*	O
OH	O
rham	O
Kaempferol	O
OH	O
OH	O
OH	O
OH	O
Kaempferol-7	O
-glucoside	O
OH	O

OR	O
*	O
OH	O
OH	O
gluc	O
Oxyayanin	O
A	O
OH	O
OMe	O
OMe	O
OH	O
OMe	O
OH	O
Quercetin	O
OH	O
OH	O
OH	O
OH	O
OH	O
Quercimeritrin	O
OH	O
OR	O
*	O
OH	O
OH	O
OH	O
gluc	O
Quercitrin	O
OH	O
OH	O

OH	O
*	O
OH	O
OH	O
rham	O
Rhamnetin	O
OH	O
OMe	O
OH	O
OH	O
OH	O
Rutin	O

OH	O
OH	O

OH	O
*	O
OH	O
OH	O
rham	O
,	O
gluc	O
Tetramethylquercitin	O
OMe	O
OMe	O
OH	O
OMe	O
OMe	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O
1	O
On	O
the	O
other	O
hand	O
,	O
different	O
capabilities	O
of	O
cell	O
mem­brane	O
protection	O
were	O
observed	O
in	O
compounds	O
ofthe	O
same	O
type	O
,	O
due	O
mainly	O
to	O
the	O
hydroxyl	O
group	O
position	O
on	O
the	O
fla­vonoid	O
backbone	O
.	O

Most	O
flavone	O
-	O
type	O
compounds	O
gener­ally	O
possessing	O
6-or	O
3'-OH	O
in	O
their	O
structure	O
demonstrat­ed	O
marked	O
LDH	O
leakage	O
inhibition	O
and	O
antioxidation	O
activity	O
.	O

For	O
example	O
,	O
baicalin	O
,	O
plantaginin	O
and	O
sorbarin	O
belonged	O
to	O
the	O
former	O
,	O
while	O
luteolin	O
and	O
luteolin	O
7-glu­coside	O
were	O
ofthe	O
latter	O
type	O
;	O
6-hydroxyluteolin	O
had	O
both	O
.	O

However	O
,	O
there	O
were	O
some	O
exceptions	O
.	O

Although	O
lacking	O
6-and	O
3'-OH	O
,	O
cirsimaritin	O
and	O
rhoifolin	O
still	O
showed	O
membrane	O
protection	O
and	O
banding	O
MDA	O
production	O
;	O
in	O
contrast	O
,	O
baicalein	O
,	O
cirsiliol	O
and	O
scutellarein	O
showed	O
a	O
weak	O
effect	O
,	O
even	O
though	O
they	O
possess	O
either	O
6	O
-	O
0H	O
or	O
3'­OH	O
.	O

The	O
reason	O
for	O
this	O
remains	O
unclear	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
observed	O
that	O
linked	O
sugar	O
might	O
contribute	O
to	O
membrane	O
protection	O
.	O

Among	O
the	O
most	O
effective	O
com­pounds	O
in	O
this	O
study	O
-baicalin	O
,	O
cirsimaritin	O
,	O
6-hydroxy­luteolin	O
,	O
luteolin	O
,	O
plantaginin	O
,	O
rhoifolin	O
and	O
sorbarin	O
­four	O
possess	O
glucuronic	O
acid	O
,	O
glucose	O
or	O
rhamnose	O
.	O

This	O
implies	O
that	O
sugar	O
may	O
account	O
for	O
the	O
varying	O
radical	O
scavenger	O
activity	O
through	O
changing	O
the	O
electron	O
distri­bution	O
and	O
participating	O
in	O
electron	O
delocalization	O
on	O
the	O
structural	O
backbone	O
,	O
or	O
through	O
some	O
other	O
unknown	O
mechanisms	O
.	O

Similarly	O
,	O
flavonol	O
-	O
type	O
compounds	O
,	O
having	O
an	O
addi­tional	O
-OH	O
at	O
C-3	O
,	O
performed	O
more	O
effectively	O
than	O
the	O
previous	O
type	O
.	O

Chemically	O
,	O
their	O
actions	O
were	O
probably	O
dependent	O
on	O
C-7	O
,	O
3	O
'	O
or	O
4	O
'	O
,	O
as	O
well	O
as	O
3	O
-	O
0H	O
,	O
such	O
as	O
af­zelin	O
,	O
hyperin	O
,	O
isoquercitrin	O
,	O
isorhamnetin	O
,	O
kaempferitrin	O
,	O
kaempferol-7-glucoside	O
,	O
quercetin	O
,	O
quercitrin	O
,	O
rhamnetin	O
and	O
rutin	O
.	O

Sugar	O
linked	O
at	O
C-3	O
would	O
also	O
affect	O
antioxi­dation	O
capability	O
.	O

For	O
example	O
,	O
a	O
lack	O
of	O
3'-OH	O
,	O
but	O
pos­session	O
of	O
rhamnoses	O
at	O
C-3	O
and	O
7	O
,	O
made	O
kaempferitrin	O
act	O
powerfully	O
in	O
both	O
membrane	O
protection	O
and	O
anti­peroxidation	O
,	O
similarly	O
to	O
afzelin	O
,	O
hyperin	O
,	O
isoquercitrin	O
,	O
kaempferol-7	O
-glucoside	O
,	O
quercitrin	O
and	O
rutin	O
.	O

In	O
terms	O
of	O
results	O
,	O
we	O
attempted	O
to	O
draw	O
a	O
general	O
con­cept	O
about	O
the	O
structural	O
principles	O
necessary	O
for	O
optimal	O
cellular	O
membrane	O
protection	O
and	O
antioxidative	O
capacity	O
.	O

It	O
is	O
assumed	O
that	O
the	O
bioactivity	O
of	O
both	O
types	O
of	O
com­pounds	O
is	O
decided	O
mainly	O
by	O
the	O
following	O
three	O
impor­tant	O
structural	O
groups	O
:	O
(	O
a	O
)	O
the	O
o	O
-	O
dihydroxy	O
(	O
catechol	O
)	O
structure	O
in	O
the	O
B	O
ring	O
,	O
which	O
is	O
the	O
obvious	O
radical	O
target	O
site	O
for	O
all	O
flavonoids	O
with	O
a	O
saturated	O
2,3-bond	O
(	O
flavan­3-ols	O
,	O
flavanones	O
)	O
;	O
(	O
b	O
)	O
the	O
2,3-double	O
bond	O
in	O
conjugation	O
with	O
a	O
4-oxo	O
function	O
,	O
which	O
are	O
responsible	O
for	O
electron	O
delocalization	O
from	O
the	O
B	O
ring	O
;	O
and	O
(	O
c	O
)	O
the	O
additional	O
pre­sence	O
of	O
both	O
3-and	O
5-hydroxyl	O
groups	O
for	O
maximal	O
radical	O
-	O
scavenging	O
potential	O
and	O
strongest	O
radical	O
absorp­tion	O
;	O
in	O
fact	O
,	O
the	O
3-and	O
5-hydroxyl	O
groups	O
are	O
equivalent	O
owing	O
to	O
their	O
hydrogen	O
bonds	O
with	O
the	O
keto	O
group	O
,	O
from	O
a	O
kinetic	O
standpoint	O
(	O
SLABBERT	O
1977	O
)	O
.	O

These	O
sites	O
can	O
be	O
considered	O
as	O
the	O
active	O
centers	O
on	O
the	O
compounds	O
,	O
or	O
as	O
a	O
prerequisite	O
factor	O
for	O
the	O
scavenging	O
of	O
oxygen	O
free	O
radicals	O
.	O

Here	O
,	O
we	O
should	O
note	O
that	O
from	O
tables	O
1	O
and	O
2	O
,	O
the	O
po­tentials	O
of	O
the	O
two	O
types	O
of	O
compounds	O
are	O
not	O
absolutely	O
Exp	O
Toxic	O
Pathol51	O
(	O
1999	O
)	O
1	O
affected	O
by	O
whether	O
they	O
are	O
flavonoids	O
or	O
aglycones	O
.	O

It	O
is	O
thought	O
that	O
the	O
configuration	O
of	O
functional	O
groups	O
may	O
also	O
playa	O
crucial	O
role	O
in	O
determining	O
their	O
bioactivity	O
.	O

The	O
FM4	O
-	O
64	O
,	O
a	O
member	O
of	O
the	O
family	O
of	O
fluorescent	O
dyes	O
,	O
has	O
been	O
applied	O
to	O
the	O
cerebellar	O
cortex	O
to	O
evaluate	O
its	O
properties	O
as	O
an	O
intracellular	O
stain	O
and	O
intracortical	O
tracer	O
.	O

Slabs	O
of	O
hamster	B
cerebellum	O
,	O
1	O
-	O
2	O
mm	O
thick	O
,	O
were	O
incubated	O
in	O
10	O
,	O
30	O
,	O
and	O
100	O
microns	O
solutions	O
of	O
FM4	O
-	O
64	O
in	O
sodium	O
phosphate	O
buffer	O
and	O
observed	O
in	O
a	O
slow	O
scan	O
confocal	O
laser	O
scanning	O
microscope	O
.	O

Mossy	O
and	O
climbing	O
fibers	O
were	O
traced	O
in	O
the	O
cerebellar	O
white	O
and	O
gray	O
substances	O
.	O

They	O
exhibited	O
a	O
high	O
fluorescence	O
signal	O
at	O
the	O
level	O
of	O
the	O
myelin	O
sheath	O
.	O

Mossy	O
fibers	O
were	O
identified	O
in	O
the	O
granular	O
layer	O
by	O
their	O
typical	O
rosette	O
formation	O
and	O
dichotomous	O
bifurcation	O
pattern	O
.	O

Climbing	O
fiber	O
bundles	O
were	O
observed	O
crossing	O
the	O
granular	O
layer	O
and	O
giving	O
collateral	O
branches	O
around	O
Golgi	O
cell	O
bodies	O
.	O

They	O
ascend	O
to	O
the	O
Purkinje	O
cell	O
layer	O
on	O
their	O
way	O
to	O
the	O
molecular	O
layer	O
.	O

Cerebellar	O
macroneurons	O
(	O
Golgi	O
and	O
Purkinje	O
cells	O
)	O
and	O
microneurons	O
(	O
granule	O
,	O
basket	O
,	O
and	O
stellate	O
cells	O
)	O
showed	O
optimal	O
intracellular	O
staining	O
of	O
cell	O
soma	O
,	O
axonal	O
,	O
and	O
dendritic	O
processes	O
.	O

The	O
z	O
-	O
series	O
of	O
stacks	O
of	O
optodigital	O
sections	O
allowed	O
us	O
to	O
explore	O
in	O
depth	O
the	O
cytoarchitectonic	O
arrangement	O
,	O
nerve	O
and	O
glial	O
cell	O
morphology	O
,	O
and	O
the	O
topographic	O
relationship	O
with	O
the	O
afferent	O
fibers	O
.	O

AIMS	O
:	O
Cysteamine	O
,	O
the	O
only	O
drug	O
available	O
for	O
the	O
treatment	O
of	O
cystinosis	O
in	O
paediatric	O
patients	B
,	O
is	O
available	O
as	O
the	O
hydrochloride	O
,	O
the	O
bitartrate	O
and	O
as	O
sodium	O
phosphocysteamine	O
salts	O
.	O

It	O
has	O
been	O
suggested	O
that	O
cysteamine	O
bitartrate	O
and	O
phosphocysteamine	O
are	O
better	O
tolerated	O
and	O
may	O
have	O
a	O
better	O
bioavailability	O
than	O
cysteamine	O
hydrochloride	O
.	O

This	O
has	O
,	O
however	O
,	O
never	O
been	O
demonstrated	O
.	O

METHODS	O
:	O
We	O
compared	O
the	O
pharmacokinetics	O
and	O
tolerance	O
of	O
these	O
three	O
formulations	O
of	O
cysteamine	O
in	O
18	O
healthy	O
adult	B
male	I
volunteers	I
in	O
a	O
double	O
-	O
blind	O
,	O
latin	O
-	O
square	O
,	O
three	O
-	O
period	O
,	O
single	O
oral	O
dose	O
cross	O
-	O
over	O
relative	O
bioavailability	O
study	O
.	O

RESULTS	O
:	O
No	O
statistical	O
difference	O
was	O
found	O
between	O
relative	O
bioavailabilities	O
,	O
AUC	O
(	O
0	O
,	O
infinity	O
)	O
(	O
geometric	O
mean	O
and	O
s.d	O
.	O

in	O
micromol	O
l	O
(	O
-1	O
)	O
h	O
:	O
169+	O
/	O
-51	O
,	O
158+	O
/	O
-46	O
,	O
173+	O
/	O
-49	O
with	O
cysteamine	O
hydrochloride	O
,	O
phosphocysteamine	O
and	O
cysteamine	O
bitartrate	O
respectively	O
)	O
,	O
Cmax	O
(	O
geometric	O
mean	O
and	O
s.d	O
.	O

in	O
micromol	O
l	O
(	O
-1	O
)	O
;	O
66+	O
/	O
-25.5	O
,	O
59+	O
/	O
-12	O
,	O
63+	O
/	O
-20	O
)	O
and	O
tmax	O
(	O
median	O
and	O
range	O
in	O
h	O
:	O
0.88	O
(	O
0.25	O
-	O
2	O
)	O
,	O
1.25	O
(	O
0.25	O
-	O
2	O
)	O
,	O
0.88	O
(	O
0.25	O
-	O
2	O
)	O
)	O
with	O
each	O
of	O
the	O
three	O
forms	O
of	O
cysteamine	O
tested	O
.	O

Bioequivalence	O
statistics	O
(	O
90	O
%	O
confidence	O
intervals	O
)	O
showed	O
non	O
equivalence	O
of	O
Cmax	O
of	O
cysteamine	O
base	O
as	O
the	O
only	O
non	O
equivalence	O
of	O
pharmacokinetics	O
between	O
the	O
three	O
formulations	O
:	O
90	O
%	O
CI	O
for	O
Cmax	O
relative	O
ratios	O
to	O
cysteamine	O
hydrochloride	O
were	O
[	O
75.6	O
-	O
105.81	O
for	O
phosphocysteamine	O
and	O
[	O
74.2	O
-	O
124.2	O
]	O
for	O
cysteamine	O
bitartrate	O
.	O

The	O
only	O
significant	O
adverse	O
event	O
was	O
vomiting	O
whose	O
frequency	O
was	O
inversely	O
correlated	O
with	O
body	O
weight	O
(	O
Spearman	O
's	O
r=-0.76	O
,	O
P<0.001	O
)	O
.	O

The	O
nature	O
of	O
the	O
salt	O
tested	O
did	O
not	O
influence	O
vomiting	O
.	O

CONCLUSIONS	O
:	O
While	O
none	O
of	O
the	O
three	O
forms	O
of	O
cysteamine	O
tested	O
has	O
a	O
clear	O
advantage	O
over	O
the	O
others	O
in	O
terms	O
of	O
pharmacokinetics	O
and	O
tolerance	O
profile	O
,	O
this	O
should	O
now	O
however	O
be	O
addressed	O
in	O
patients	B
treated	O
for	O
cystinosis	O
during	O
repeat	O
administrations	O
.	O

Both	O
alpha-	O
and	O
beta	O
-	O
D	O
-	O
glucose	O
pentaacetate	O
(	O
1.7	O
mM	O
each	O
)	O
augmented	O
,	O
to	O
almost	O
the	O
same	O
extent	O
,	O
insulin	O
release	O
caused	O
by	O
succinic	O
acid	O
dimethyl	O
ester	O
(	O
10.0	O
mM	O
)	O
in	O
rat	B
pancreatic	O
islets	O
.	O

The	O
secretory	O
response	O
to	O
these	O
hexose	O
esters	O
largely	O
exceeded	O
that	O
evoked	O
by	O
unesterified	O
D	O
-	O
glucose	O
tested	O
at	O
the	O
same	O
concentration	O
(	O
1.7	O
mM	O
)	O
.	O

The	O
release	O
of	O
insulin	O
provoked	O
by	O
succinic	O
acid	O
dimethyl	O
ester	O
was	O
inhibited	O
,	O
however	O
,	O
by	O
alpha	O
-	O
D	O
-	O
galactose	O
pentaacetate	O
,	O
whilst	O
being	O
unaffected	O
by	O
beta	O
-	O
D	O
-	O
galactose	O
pentaacetate	O
(	O
each	O
also	O
1.7	O
mM	O
)	O
.	O

It	O
appears	O
,	O
therefore	O
,	O
that	O
the	O
insulinotropic	O
action	O
of	O
hexose	O
esters	O
is	O
not	O
attributable	O
solely	O
to	O
the	O
catabolism	O
of	O
their	O
carbohydrate	O
moiety	O
,	O
but	O
may	O
also	O
involve	O
a	O
receptor	O
system	O
that	O
displays	O
anomeric	O
specificity	O
and	O
can	O
be	O
directly	O
activated	O
or	O
inhibited	O
by	O
the	O
esters	O
themselves	O
.	O

Hence	O
,	O
it	O
is	O
proposed	O
that	O
selected	O
esters	O
of	O
non	O
-	O
nutrient	O
monosaccharides	O
may	O
represent	O
new	O
tools	O
to	O
either	O
stimulate	O
insulin	O
release	O
in	O
diabetes	O
or	O
prevent	O
excessive	O
hormonal	O
secretion	O
in	O
situations	O
of	O
hyperinsulinemia	O
.	O

Bioassay	O
-	O
directed	O
fractionation	O
of	O
the	O
methanolic	O
extract	O
of	O
seeds	O
of	O
Casimiroa	B
edulis	I
led	O
to	O
the	O
isolation	O
of	O
seven	O
constituents	O
with	O
cardiovascular	O
activity	O
,	O
namely	O
the	O
new	O
compound	O
synephrine	O
acetonide	O
and	O
the	O
known	O
compounds	O
N	O
-	O
monomethylhistamine	O
,	O
N	O
,	O
N	O
-	O
dimethylhistamine	O
,	O
proline	O
,	O
N	O
-	O
methylproline	O
,	O
gamma	O
-	O
aminobutyric	O
acid	O
and	O
casimiroedine	O
.	O

In	O
anesthetized	O
rats	B
,	O
both	O
histamine	O
derivatives	O
produced	O
transient	O
hypotension	O
mediated	O
via	O
H1-histaminergic	O
receptors	O
and	O
in	O
the	O
case	O
of	O
N	O
,	O
N	O
-	O
dimethylhistamine	O
,	O
via	O
nitric	O
oxide	O
release	O
.	O

Synephrine	O
acetonide	O
produced	O
transient	O
hypertension	O
and	O
tachycardia	O
,	O
mediated	O
via	O
alpha-	O
and	O
alpha-	O
and	O
beta	O
-	O
adrenergic	O
receptores	O
,	O
respectively	O
.	O

The	O
chromatographic	O
zone	O
containing	O
N	O
-	O
methyproline	O
,	O
proline	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
elicited	O
marked	O
and	O
prolonged	O
hypotension	O
.	O

Finally	O
,	O
casimiroedine	O
did	O
not	O
modify	O
the	O
blood	O
pressure	O
of	O
anesthetized	O
rats	B
,	O
but	O
lowered	O
it	O
persistently	O
in	O
anesthetized	O
guinea	B
pigs	I
.	O

It	O
was	O
concluded	O
that	O
hypotension	O
produced	O
by	O
C.	B
edulis	I
is	O
due	O
to	O
several	O
active	O
components	O
.	O

The	O
immediate	O
effect	O
can	O
be	O
attributed	O
to	O
the	O
histamine	O
derivatives	O
acting	O
on	O
H1-receptors	O
.	O

More	O
prolonged	O
hypotension	O
would	O
be	O
produced	O
by	O
the	O
mixture	O
of	O
amino	O
acids	O
through	O
an	O
unknown	O
mechanism	O
,	O
as	O
well	O
as	O
by	O
casimiroedine	O
,	O
possibly	O
by	O
activation	O
of	O
H3-receptors	O
.	O

Hypotension	O
is	O
partially	O
offset	O
by	O
synephrine	O
acetonide	O
through	O
adrenergic	O
mechanisms	O
.	O

Fractionation	O
of	O
cube	O
resin	O
from	O
Lonchocarpus	B
utilus	I
and	O
L.	B
urucu	I
roots	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
11	O
minor	O
flavonoids	O
and	O
stilbenes	O
containing	O
the	O
gem	O
-	O
dimethylpyran	O
moiety	O
or	O
a	O
dihydrodiol	O
derivative	O
thereof	O
.	O

The	O
eight	O
new	O
compounds	O
were	O
as	O
follows	O
:	O
the	O
isoflavonoid	O
cis-4'',5''-dihydro-4'',5	O
'	O
'	O
-dihydroxylonchocarpusone	O
(	O
2	O
)	O
;	O
four	O
(	O
2S	O
)	O
-6-	O
(	O
gamma	O
,	O
gamma	O
-	O
dimethylallyl	O
)	O
-6'',6''-dimethylpyran	O
[	O
2'',3'':7	O
,	O
8	O
]	O
flavanones	O
with	O
substituents	O
of	O
5-hydroxy-3',4'-dimethoxy	O
(	O
3	O
)	O
,	O
5	O
,	O
3'-dihydroxy-4'-methoxy	O
(	O
4	O
)	O
,	O
5,4'-dihydroxy-3'-methoxy	O
(	O
5	O
)	O
,	O
and	O
3	O
'	O
,	O
4'-dimethoxy	O
(	O
6	O
)	O
;	O
and	O
three	O
6'',6''-dimethylpyran	O
[	O
2'',3'':3	O
'	O
,	O
4'	O
]	O
stilbenes	O
with	O
4-hydroxy-5'-methoxy	O
(	O
9	O
)	O
,	O
3,5'-dimethoxy-4-hydroxy	O
(	O
10	O
)	O
and	O
3,4,5-trimethoxy	O
(	O
11	O
)	O
substitution	O
patterns	O
.	O

Structure	O
-	O
activity	O
relationships	O
for	O
inhibition	O
of	O
NADH	O
:	O
ubiquinone	O
oxidoreductase	O
activity	O
(	O
bovine	B
heart	O
electron	O
transport	O
particles	O
)	O
and	O
phorbol	O
ester	O
-	O
induced	O
ornithine	O
decarboxylase	O
activity	O
(	O
cultured	O
MCF-7	O
cells	O
)	O
generally	O
parallel	O
those	O
for	O
cytotoxicity	O
(	O
MCF-7	O
and	O
Hepa	O
1clc7	O
cells	O
)	O
.	O

Reinvestigation	O
of	O
fractions	O
derived	O
from	O
large	O
-	O
scale	O
fractionation	O
of	O
Maytenus	B
buchananii	I
led	O
to	O
the	O
isolation	O
of	O
two	O
new	O
maytansinoids	O
.	O

The	O
structures	O
of	O
these	O
principles	O
were	O
determined	O
using	O
electrospray	O
MS	O
,	O
1H	O
NMR	O
,	O
13C	O
NMR	O
,	O
and	O
2D	O
NMR	O
techniques	O
.	O

One	O
principle	O
was	O
found	O
to	O
be	O
2'-N	O
-	O
demethylmaytanbutine	O
(	O
2	O
)	O
,	O
while	O
the	O
other	O
was	O
found	O
to	O
be	O
maytanbicyclinol	O
(	O
3	O
)	O
,	O
the	O
first	O
maytansinoid	O
with	O
two	O
macrocyclic	O
rings	O
to	O
be	O
isolated	O
from	O
a	O
Maytenus	B
species	O
.	O

Previous	O
studies	O
have	O
indicated	O
that	O
part	O
of	O
the	O
binding	O
of	O
[	O
3H	O
]	O
[	O
1-	O
[	O
2-	O
(	O
diphenylmethoxy	O
)	O
ethyl	O
]	O
-4-	O
(	O
3-phenylpropyl	O
)	O
piperazine	O
dihydrochloride	O
]	O
(	O
[	O
3H	O
]	O
GBR	O
12935	O
)	O
to	O
human	B
platelets	O
is	O
to	O
a	O
piperazine	O
acceptor	O
site	O
,	O
which	O
might	O
be	O
associated	O
with	O
cytochrome	O
P-450IID6	O
(	O
CYP4502D6	O
,	O
debrisoquine-4-hydroxylase	O
)	O
.	O

Due	O
to	O
mutant	O
CYP4502D6	O
alleles	O
,	O
5	O
-	O
10	O
%	O
of	O
Caucasians	B
are	O
poor	O
metabolizers	O
of	O
CYP4502D6	O
substrates	O
such	O
as	O
debrisoquine	O
and	O
dextromethorphan	O
.	O

In	O
the	O
present	O
study	O
,	O
possible	O
differences	O
in	O
binding	O
characteristics	O
of	O
[	O
3H	O
]	O
GBR	O
12935	O
in	O
platelets	O
from	O
CYP4502D6	O
poor	O
and	O
extensive	O
metabolizers	O
were	O
investigated	O
.	O

The	O
most	O
prominent	O
finding	O
was	O
a	O
gender	O
difference	O
,	O
with	O
males	B
having	O
significantly	O
higher	O
Kd	O
values	O
than	O
females	B
.	O

There	O
were	O
no	O
differences	O
in	O
Bmax	O
.	O

After	O
correction	O
for	O
gender	O
,	O
there	O
was	O
a	O
tendency	O
towards	O
higher	O
Kd	O
values	O
in	O
poor	O
metabolizers	O
than	O
in	O
extensive	O
metabolizers	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Whether	O
this	O
finding	O
corresponds	O
to	O
reduced	O
CYP4502D6	O
activity	O
is	O
a	O
matter	O
of	O
further	O
investigation	O
.	O

Rhus	B
javanica	I
,	O
a	O
medicinal	O
herb	O
,	O
has	O
been	O
shown	O
to	O
exhibit	O
oral	O
therapeutic	O
anti	O
-	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
activity	O
in	O
mice	B
.	O

We	O
purified	O
two	O
major	O
anti	O
-	O
HSV	O
compounds	O
,	O
moronic	O
acid	O
and	O
betulonic	O
acid	O
,	O
from	O
the	O
herbal	O
extract	O
by	O
extraction	O
with	O
ethyl	O
acetate	O
at	O
pH	O
10	O
followed	O
by	O
chromatographic	O
separations	O
and	O
examined	O
their	O
anti	O
-	O
HSV	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moronic	O
acid	O
was	O
quantitatively	O
a	O
major	O
anti	O
-	O
HSV	O
compound	O
in	O
the	O
ethyl	O
acetate	O
-	O
soluble	O
fraction	O
.	O

The	O
effective	O
concentrations	O
for	O
50	O
%	O
plaque	O
reduction	O
of	O
moronic	O
acid	O
and	O
betulonic	O
acid	O
for	O
wild	O
-	O
type	O
HSV	O
type	O
1	O
(	O
HSV-1	O
)	O
were	O
3.9	O
and	O
2.6	O
microgram	O
/	O
ml	O
,	O
respectively	O
.	O

The	O
therapeutic	O
index	O
of	O
moronic	O
acid	O
(	O
10.3	O
-	O
16.3	O
)	O
was	O
larger	O
than	O
that	O
of	O
betulonic	O
acid	O
(	O
6.2	O
)	O
.	O

Susceptibility	O
of	O
acyclovir	O
-	O
phosphonoacetic	O
acid	O
-	O
resistant	O
HSV-1	O
,	O
thymidine	O
kinase	O
-	O
deficient	O
HSV-1	O
,	O
and	O
wild	O
-	O
type	O
HSV	O
type	O
2	O
to	O
moronic	O
acid	O
was	O
similar	O
to	O
that	O
of	O
the	O
wild	O
-	O
type	O
HSV-1	O
.	O

When	O
this	O
compound	O
was	O
administered	O
orally	O
to	O
mice	B
infected	O
cutaneously	O
with	O
HSV-1	O
three	O
times	O
daily	O
,	O
it	O
significantly	O
retarded	O
the	O
development	O
of	O
skin	O
lesions	O
and/or	O
prolonged	O
the	O
mean	O
survival	O
times	O
of	O
infected	O
mice	B
without	O
toxicity	O
compared	O
with	O
the	O
control	O
.	O

Moronic	O
acid	O
suppressed	O
virus	O
yields	O
in	O
the	O
brain	O
more	O
efficiently	O
than	O
those	O
in	O
the	O
skin	O
.	O

This	O
was	O
consistent	O
with	O
the	O
prolongation	O
of	O
mean	O
survival	O
times	O
.	O

Thus	O
,	O
moronic	O
acid	O
was	O
purified	O
as	O
a	O
major	O
anti	O
-	O
HSV	O
compound	O
from	O
the	O
herbal	O
extract	O
of	O
Rhus	B
javanica	I
.	O

Mode	O
of	O
the	O
anti	O
-	O
HSV	O
activity	O
was	O
different	O
from	O
that	O
of	O
ACV	O
.	O

Moronic	O
acid	O
showed	O
oral	O
therapeutic	O
efficacy	O
in	O
HSV	O
-	O
infected	O
mice	B
and	O
possessed	O
novel	O
anti	O
-	O
HSV	O
activity	O
that	O
was	O
consistent	O
with	O
that	O
of	O
the	O
extract	O
.	O

IC202A	O
(	O
1	O
)	O
was	O
isolated	O
from	O
the	O
culture	O
filtrate	O
of	O
Streptoalloteichus	B
sp.	I
1454	I
-	I
19	I
.	O

The	O
structure	O
of	O
1	O
was	O
determined	O
by	O
spectral	O
analysis	O
including	O
a	O
variety	O
of	O
two	O
-	O
dimentional	O
NMR	O
and	O
FAB	O
-	O
MS	O
experiments	O
.	O

IC202A	O
is	O
a	O
ferrioxamine	O
-	O
related	O
compound	O
containing	O
a	O
butylidene	O
N	O
-	O
oxide	O
function	O
.	O

It	O
is	O
suspected	O
that	O
not	O
only	O
fibrinogen	O
concentration	O
but	O
also	O
the	O
quality	O
of	O
fibrin	O
networks	O
may	O
contribute	O
to	O
cardiovascular	O
risk	O
.	O

Evidence	O
is	O
accumulating	O
that	O
a	O
""""	O
prudent	O
""""	O
diet	O
may	O
protect	O
against	O
diseases	O
associated	O
with	O
raised	O
clotting	O
factors	O
.	O

The	O
effect	O
of	O
diet	O
on	O
fibrinogen	O
is	O
,	O
however	O
,	O
still	O
controversial	O
.	O

In	O
a	O
previous	O
study	O
performed	O
in	O
our	O
laboratory	O
,	O
it	O
was	O
shown	O
that	O
dietary	O
pectin	O
influences	O
fibrin	O
network	O
architecture	O
in	O
hypercholesterolaemic	O
men	B
without	O
causing	O
any	O
changes	O
in	O
fibrinogen	O
concentration	O
.	O

To	O
elucidate	O
the	O
possible	O
mechanisms	O
,	O
it	O
was	O
necessary	O
to	O
study	O
the	O
possibility	O
that	O
pectin	O
may	O
itself	O
have	O
indirect	O
effects	O
on	O
fibrin	O
network	O
architecture	O
.	O

Pectin	O
is	O
fermented	O
in	O
the	O
gastrointestinal	O
tract	O
to	O
acetate	O
,	O
propionate	O
,	O
and	O
butyrate	O
.	O

In	O
humans	B
,	O
only	O
acetate	O
reaches	O
the	O
circulation	O
beyond	O
the	O
liver	O
.	O

This	O
investigation	O
primarily	O
examined	O
the	O
possibility	O
that	O
pectin	O
may	O
,	O
through	O
acetate	O
,	O
influence	O
fibrin	O
network	O
architecture	O
in	O
vivo	O
.	O

The	O
effects	O
of	O
pectin	O
and	O
acetate	O
supplementation	O
in	O
hypercholesterolaemic	O
subjects	O
were	O
compared	O
.	O

Furthermore	O
,	O
this	O
study	O
also	O
aimed	O
at	O
describing	O
the	O
possible	O
in	O
vitro	O
effects	O
of	O
acetate	O
on	O
fibrin	O
network	O
architecture	O
.	O

Two	O
groups	O
of	O
10	O
male	O
hyperlipidaemic	O
volunteers	O
each	O
received	O
a	O
pectin	O
(	O
15	O
g	O
/	O
day	O
)	O
or	O
acetate	O
(	O
6.8	O
g	O
/	O
day	O
)	O
supplement	O
for	O
4	O
weeks	O
.	O

Acetate	O
supplementation	O
did	O
not	O
cause	O
a	O
significant	O
change	O
in	O
plasma	O
fibrinogen	O
levels	O
.	O

As	O
in	O
the	O
pectin	O
group	O
,	O
significant	O
differences	O
were	O
found	O
in	O
the	O
characteristics	O
of	O
fibrin	O
networks	O
developed	O
in	O
plasma	O
after	O
4	O
weeks	O
of	O
acetate	O
supplementation	O
.	O

Fibrin	O
networks	O
were	O
more	O
permeable	O
(	O
from	O
213+	O
/	O
-76	O
to	O
307+	O
/	O
-81	O
x	O
10	O
(	O
11	O
)	O
cm2	O
)	O
,	O
had	O
lower	O
tensile	O
strength	O
(	O
from	O
23+	O
/	O
-3	O
to	O
32+	O
/	O
-9	O
%	O
compaction	O
)	O
,	O
and	O
were	O
more	O
lyseable	O
(	O
from	O
252+	O
/	O
-11	O
to	O
130+	O
/	O
-15	O
minutes	O
)	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
effect	O
of	O
pectin	O
on	O
network	O
architecture	O
could	O
partially	O
be	O
mediated	O
by	O
acetate	O
.	O

Progressive	O
amounts	O
of	O
acetate	O
were	O
used	O
in	O
vitro	O
to	O
investigate	O
the	O
possibility	O
that	O
acetate	O
may	O
be	O
directly	O
responsible	O
for	O
changes	O
that	O
occurred	O
in	O
fibrin	O
network	O
architecture	O
in	O
the	O
plasma	O
medium	O
.	O

Results	O
indicated	O
that	O
acetate	O
influenced	O
fibrin	O
network	O
architecture	O
directly	O
.	O

From	O
the	O
results	O
,	O
it	O
seems	O
highly	O
possible	O
that	O
acetate	O
may	O
be	O
responsible	O
in	O
part	O
for	O
the	O
beneficial	O
effects	O
of	O
pectin	O
supplementation	O
in	O
vivo	O
.	O

It	O
is	O
evident	O
that	O
pectin	O
or	O
acetate	O
supplementation	O
can	O
be	O
useful	O
during	O
the	O
treatment	O
or	O
prevention	O
of	O
some	O
clinical	O
manifestations	O
,	O
especially	O
those	O
associated	O
with	O
raised	O
total	O
cholesterol	O
and	O
possibly	O
also	O
plasma	O
fibrinogen	O
.	O

INTRODUCTION	O
Chemical	O
substitution	O
of	O
ribosomal	O
proteins	O
by	O
dansyl	O
chloride	O
[	O
I	O
]	O
and	O
iodoacetamide	O
[	O
2	O
]	O
has	O
yielded	O
first	O
results	O
concerning	O
the	O
localisation	O
of	O
proteins	O
in	O
rat	B
liver	O
ribosomes	O
.	O

The	O
accessibility	O
of	O
proteins	O
can	O
be	O
further	O
Abbreviations	O
:	O
MAI	O
,	O
methyl	O
acetimidate	O
;	O
NPA	O
,	O
p	O
-	O
nitrophenyl	O
acetate	O
;	O
TEA	O
,	O
triethanol-	O
amine	O
.	O

310	O
studied	O
by	O
substitution	O
of	O
their	O
amino	O
groups	O
by	O
NPA	O
or	O
by	O
MAI	O
as	O
will	O
be	O
demonstrated	O
in	O
this	O
paper	O
.	O

These	O
new	O
results	O
agree	O
in	O
general	O
with	O
those	O
ob-	O
tained	O
earlier	O
,	O
but	O
give	O
more	O
precise	O
data	O
as	O
to	O
the	O
localisation	O
of	O
proteins	O
in	O
the	O
ribosomal	O
subunit	O
.	O

MATERIAL	O
AND	O
METHODS	O
[	O
~4C	O
]	O
MAI	O
was	O
prepared	O
immediately	O
before	O
use	O
according	O
to	O
Hunter	O
and	O
Ludwig	O
[	O
3	O
]	O
using	O
[	O
~4C	O
]	O
acetonitrile	O
(	O
1.85	O
mCi	O
/	O
mmole	O
;	O
Institute	O
for	O
Isotopes	O
,	O
Budapest	O
)	O
.	O

[	O
3H	O
]	O
NPA	O
,	O
synthesized	O
as	O
described	O
elsewhere	O
[	O
4	O
]	O
was	O
a	O
gift	O
from	O
Dr.	O
B.	O
Mehlis	O
.	O

Preparation	O
of	O
ribosomal	O
subunits	O
Polysomes	O
isolated	O
from	O
rat	B
livers	O
according	O
to	O
Noll	O
et	O
al.	O
[	O
5	O
]	O
were	O
in-	O
cubated	O
in	O
500	O
mM	O
KCI	O
,	O
50	O
mM	O
TEA	O
HC1	O
,	O
pH	O
7.8	O
,	O
1.5	O
mM	O
MgC12	O
,	O
5	O
mM	O
fi	O
-	O
mercaptoethanol	O
and	O
0.1	O
mM	O
puromycin	O
for	O
30	O
min	O
at	O
0	O
and	O
then	O
for	O
10	O
min	O
at	O
37	O
[	O
6	O
]	O
.	O

The	O
ribosomal	O
subunits	O
were	O
separated	O
according	O
to	O
Eikenberry	O
et	O
al.	O
[	O
7	O
]	O
and	O
pelleted	O
after	O
dilution	O
of	O
the	O
gradient	O
fractions	O
with	O
2	O
vol	O
.	O
of	O
50	O
mM	O
TEA	O
HC1	O
,	O
pH	O
7.8	O
,	O
30	O
mM	O
MgC12	O
.	O

Thereafter	O
the	O
sub-	O
units	O
were	O
dialysed	O
against	O
a	O
buffer	O
of	O
50	O
mM	O
TEA	O
HC1	O
,	O
pH	O
7.8	O
,	O
50	O
mM	O
KC1	O
and	O
5	O
mM	O
MgC12	O
(	O
buffer	O
A	O
)	O
and	O
clarified	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
10	O
000	O
g.	O
Isolation	O
of	O
proteins	O
of	O
ribosomal	O
subunits	O
To	O
the	O
solution	O
of	O
ribosomal	O
subunits	O
(	O
5	O
mg	O
/	O
ml	O
)	O
1	O
/	O
3	O
vol	O
.	O
of	O
1	O
N	O
HC1	O
was	O
added	O
[	O
8	O
]	O
,	O
the	O
RNA	O
was	O
pelleted	O
by	O
centrifugation	O
for	O
10	O
min	O
at	O
10	O
000	O
g	O
and	O
the	O
supernatant	O
dialysed	O
against	O
50	O
mM	O
KC1	O
,	O
50	O
mM	O
TEA	O
HC1	O
,	O
pH	O
7.8	O
,	O
1	O
mM	O
MgC12	O
,	O
4	O
M	O
urea	O
(	O
buffer	O
B	O
)	O
.	O

Substitution	O
of	O
proteins	O
or	O
ribosomal	O
subunits	O
by	O
[	O
~4C	O
]	O
methyl	O
acetimidate	O
To	O
3	O
mg	O
of	O
total	O
ribosomal	B
protein	I
mixture	O
in	O
1	O
ml	O
buffer	O
B	O
or	O
to	O
5	O
mg	O
ribosomal	O
subunits	O
in	O
1	O
ml	O
buffer	O
A	O
,	O
3	O
pmoles	O
MAI	O
were	O
added	O
and	O
incu-	O
bated	O
for	O
30	O
min	O
at	O
37	O
.	O

Thereafter	O
4	O
M	O
NH4C1	O
was	O
added	O
to	O
give	O
a	O
final	O
concentration	O
of	O
50	O
mM.	O
The	O
proteins	O
were	O
isolated	O
as	O
described	O
and	O
dial-	O
ysed	O
against	O
6	O
M	O
urea	O
,	O
5	O
mM	O
methylamine	O
acetate	O
,	O
pH	O
5.0	O
,	O
5	O
mM	O
fi	O
-	O
mercap-	O
toethanol	O
.	O

A	O
label	O
of	O
4.9	O
10s	O
dpm	O
with	O
an	O
average	O
error	O
of	O
+	O
10	O
%	O
was	O
counted	O
per	O
mg	O
protein	O
of	O
the	O
small	O
ribosomal	O
subunit	O
after	O
dialysis	O
against	O
0.1	O
M	O
sodium	O
acetate	O
(	O
pH	O
5.5	O
)	O
and	O
solubilization	O
in	O
a	O
hyamine	O
hydroxide	O
containing	O
scin-	O
tillation	O
mixture	O
as	O
described	O
below	O
.	O

Protein	O
was	O
estimated	O
by	O
the	O
Lowry	O
method	O
using	O
ribosomal	O
protein	O
as	O
a	O
standard	O
.	O

The	O
labelling	O
value	O
corre-	O
sponds	O
to	O
2.4	O
acetimidoyl	O
groups	O
per	O
20	O
000	O
daltons	O
which	O
is	O
the	O
mean	O
molecular	O
weight	O
of	O
the	O
proteins	O
of	O
the	O
small	O
ribosomal	O
subunit	O
(	O
see	O
also	O
ref	O
.	O

5	O
)	O
.	O

For	O
the	O
proteins	O
of	O
the	O
large	O
ribosomal	O
subunit	O
3.9	O
acetimidoyl	O
groups	O
per	O
20	O
000	O
daltons	O
were	O
calculated	O
.	O

Substitution	O
of	O
proteins	O
or	O
ribosomal	O
subunits	O
by	O
[	O
3	O
H	O
]	O
p	O
-	O
nitrophenyl	O
acetate	O
The	O
substitution	O
was	O
performed	O
using	O
1.5	O
pmoles	O
NPA	O
(	O
10	O
mCi	O
/	O
mmole	O
)	O
311	O
per	O
1.0	O
ml	O
by	O
incubation	O
for	O
60	O
min	O
at	O
37	O
in	O
analogy	O
to	O
the	O
reaction	O
de-	O
scribed	O
before	O
.	O

The	O
excess	O
of	O
reagent	O
was	O
destroyed	O
by	O
incubation	O
with	O
0.25	O
N	O
HC1	O
for	O
1	O
h	O
at	O
0	O
.	O

TABLE	O
I	O
SUBSTITUTION	O
OF	O
PROTEINS	O
ISOLATED	O
FROM	O
SMALL	O
RIBOSOME	O
SUBUNITS	O
OF	O
RAT	B
LIVER	O
AND	O
OF	O
SMALL	O
RIBOSOMAL	O
SUBUNITS	O
BY	O
[	O
14C	O
]	O
METHYL	O
ACETIMIDATE	O
OR	O
BY	O
[	O
3H	O
]	O
ao	O
-	O
NITROPHENYL	O
ACETATE	O
Average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
;	O
the	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

Small	O
subunit	O
protein	O
Label	O
of	O
proteins	O
obtained	O
by	O
[	O
14C	O
]	O
methyl	O
acetimidate	O
Label	O
of	O
proteins	O
obtained	O

by	O
[	O
3H	O
]	O
p	O
-	O
nitrophenyl	O
acetate	O
1	O
2	O
3	O
4	O
1	O
2	O
3	O
Protein	O
Par-	O
Ratio	O
Classifi-	O
Protein	O
Par-	O

Ratio	O
mixture	O
ticle	O
of	O
2	O
:	O
1	O
cation	O
mixture	O
ticle	O
of	O
6	O
:	O
5	O
dpm	O
/	O
"AsT8""10"	O
-	O
3	O
%	O
dpm	O
/	O
AsTs	O
""""	O
10	O
-	O
3	O
%	O
4	O
Classifi-	O
cation	O
$	O
1	O
3.4	O
4.3	O
126	O
23.2	O
5.4	O
23	O
2	O
4.4	O

5.4	O
123	O
32.5	O
15.4	O
47	O
+	O
3	O
n.d	O
.	O

3.8	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

4	O
7.5	O
4.2	O
56	O
--	O
19.8	O
8.3	O
42	O
+	O
5	O
2.2	O
6.1	O
277	O
+	O
29.8	O
7.4	O
25	O
6	O
n.d	O
.	O

5.2	O
n.d	O
.	O

36.1	O
23.7	O
66	O
+	O
7	O
3.2	O
5.8	O
181	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

8	O
4.1	O
4.2	O
102	O
37.1	O
13.9	O
37	O
+	O
9	O
6.1	O
4.8	O
79	O
26.2	O
4.1	O
16	O
--	O
10	O
5.0	O
7.1	O
142	O
+	O
33.6	O
10.7	O
32	O
+	O
11	O
5.6	O
3.8	O
68	O
--	O
21.3	O
6.9	O
32	O
+	O
12	O
5.4	O
3.2	O
59	O
--	O
27.4	O
16.2	O
59	O
+	O
13	O
3.7	O
2.9	O
78	O
15.6	O
4.4	O
28	O
14	O
6.1	O
4.3	O
70	O
--	O
34.1	O
7.5	O
22	O
--	O
15	O
6.8	O
6.8	O
100	O

26.7	O
11.4	O
43	O
+	O
16	O
3.3	O
4.4	O
133	O
+	O
30.2	O
7.1	O
24	O
17	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

31.0	O
7.2	O
23	O
18	O
3.4	O
4.3	O
126	O
22.5	O
6.8	O
30	O
-+	O
19	O
3.8	O
3.4	O
89	O
27.3	O
5.5	O
20	O
--	O
20	O
5.2	O
4.2	O
81	O
-+	O
21.1	O
3.9	O
18	O
--	O
21	O
3.9	O
2.7	O
69	O
--	O
17.3	O
4.2	O
24	O
22	O
4.4	O
4.2	O
95	O
27.3	O
9.1	O
33	O
+	O
23	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

25.4	O
5.1	O
20	O
--	O
24	O
7.9	O
5.2	O
66	O
--	O
35.3	O
7.3	O
21	O
--	O
25	O
7.9	O
5.2	O
66	O
--	O
33.3	O
7.3	O
22	O
--	O
26	O
8.3	O
9.0	O
108	O
24.7	O
6.9	O
28	O
27	O
4.4	O
2.0	O
45	O
--	O
15.1	O
5.9	O
39	O
+	O
28	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

26.3	O
3.0	O
11	O
--	O
29	O
4.3	O
2.0	O
46	O
--	O
10.6	O
2.9	O
27	O
30	O
n.d	O
.	O

4.7	O
n.d	O
.	O

12.5	O
2.7	O
22	O
--	O
31	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

TABLE	O
II	O
SUBSTITUTION	O
OF	O
PROTEINS	O
ISOLATED	O
FROM	O
LARGE	O
RIBOSOMAL	O
SUBUNITS	O
OF	O
RAT	B
LIVER	O
AND	O
OF	O
LARGE	O
RIBO-	O
SOMAL	O
SUBUNITS	O
BY	O
[	O
14C	O
]	O
METHYL	O
ACETIMIDATE	O
Average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
;	O
the	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

b.a	O
b~	O
Large	O
Labelling	O
coefficients	O
Large	O
subunit	O
subunit	O
protein	O
1	O
2	O
3	O
4	O
protein	O
Protein	O
Particle	O
Ratio	O
Classifi-	O
mixture	O
of	O
2	O
:	O
1	O
cation	O
dpm	O
/	O
AsT8	O
10	O
-	O
3	O
%	O
Labelling	O
coefficients	O
1	O
2	O
3	O
4	O
Protein	O
Particle	O
Ratio	O
Classifi-	O
mixture	O
of	O
2	O
:	O
1	O
cation	O
dpm	O
/	O
AsTs	O
10	O
-	O
3	O
%	O
L	O
1	O
n.d	O
.	O

5.8	O
n.d	O
.	O

L	O
21	O
2	O
9.3	O
.	O

1.1	O
12	O
--	O
22	O
3	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

23	O
4	O
11.0	O
3.0	O
27	O
+	O
24	O
5	O
13.0	O
4.6	O
35	O
+	O
25	O
6	O
14.2	O
5.1	O
36	O
+	O
26	O
7	O
13.9	O
3.0	O
22	O
+	O
27	O
8	O
12.4	O
2.2	O
18	O
--	O
28	O
9	O
9.6	O
1.9	O
20	O
--	O
29	O
10	O
9.0	O
1.8	O
20	O
--	O
30	O
11	O
9.0	O
1.8	O
20	O
--	O
31	O
12	O
9.7	O
n.d	O
.	O

n.d	O
.	O

32	O
13	O
6.9	O
2.5	O
36	O
+	O
33	O
14	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

34	O
15	O
8.1	O
2.4	O
30	O
+	O
35	O
16	O
n.d	O
.	O

3.5	O
n.d	O
.	O

36	O
17	O
6.6	O
3.0	O
45	O
+	O
37	O
18	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

38	O
19	O
6.1	O
1.0	O
16	O
--	O
39	O
20	O
5.9	O
1.4	O
24	O
-+	O
10.1	O
2.3	O
23	O
+	O
12.3	O
1.9	O
15	O
--	O
5.9	O
3.6	O
61	O
+	O
4.8	O
2.1	O
44	O
+	O
8.3	O
2.4	O
29	O
+	O
6.2	O
1.8	O
29	O
+	O
8.2	O
2.3	O
28	O
+	O
6.6	O
1.6	O
24	O
-+	O
7.5	O
2.3	O
31	O
+	O
6.1	O
1.9	O
31	O
+	O
9.3	O
1.3	O
14	O
--	O
7.9	O
1.3	O
16	O
--	O
4.8	O
1.5	O
31	O
+	O
6.0	O
2.4	O
40	O
+	O
7.0	O
2.0	O
28	O
+	O
-	O
7.3	O
1.7	O
23	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

5.5	O
3.1	O
56	O
+	O
n.d	O
.	O

n.d	O
.	O

n.d	O
.	O

313	O
For	O
the	O
proteins	O
of	O
the	O
small	O
ribosomal	O
subunit	O
1.9	O
106	O
dpm	O
per	O
mg	O
protein	O
were	O
measured	O
by	O
the	O
method	O
described	O
above	O
,	O
corresponding	O
to	O
1.7	O
acetyl	O
groups	O
per	O
20	O
000	O
daltons	O
protein	O
.	O

TABLE	O
III	O
TENTATIVE	O
LOCALIZATION	O
OF	O
PROTEINS	O
IN	O
RIBOSOMAL	O
SUBUNITS	O
OF	O
RAT	B
LIVER	O
ESTIMATED	O
BY	O
USING	O
CHEMICAL	O
SUBSTITUTIONS	O
Small	O
Substitution	O
""""	O
by	O
Preponderant	O
subunit	O
localization	O
protein	O
Methyl	O
p	O
-	O
Nitrophenyl	O
Iodo-	O
acetimidate	O
acetate	O
acetamide	O
S	O
2	O
+	O
+	O
+	O
exposed	O
5	O
+	O
-+	O
+	O
exposed	O
7	O
+	O
n.d	O
.	O

+	O
exposed	O
8	O
-+	O
+	O
+	O
exposed	O
9	O
+	O
--	O
--	O
buried	O
10	O
+	O
+	O

-+	O
exposed	O
13	O
+	O
+	O
+	O
exposed	O
14	O
--	O
--	O
--	O
buried	O
19	O
+	O
--	O
--	O
buried	O
20	O
+	O
--	O
--	O

buried	O
24	O
--	O
--	O
+	O
buried	O
25	O
--	O
--	O
--	O
buried	O
27	O
--	O
+	O
--	O

buried	O
29	O
--	O
+	O
--	O
buried	O
30	O
n.d	O
.	O

--	O
--	O
buried	O
Large	O
subunit	O
protein	O
L	O
1	O
n.d	O
.	O

--	O
buried	O
7	O
+	O
--	O
buried	O
--	O
buried	O
8	O
--	O
buried	O
10	O
+	O
11	O
15	O
+	O
+	O
exposed	O
17	O
+	O
+	O
exposed	O
--	O
buried	O
19	O
20	O
+	O
-	O
+	O
exposed	O
24	O
+	O
+	O
exposed	O
25	O
+	O
+	O
exposed	O
27	O
+	O
+	O
exposed	O
28	O
+	O
--	O
buried	O
29	O
+	O
+	O
exposed	O
--	O

buried	O
31	O
--	O
buried	O
32	O
33	O
+	O
+	O
exposed	O
34	O
+	O
+	O
exposed	O
35	O
-+	O
+	O
exposed	O
38	O
+	O
+	O
exposed	O
314	O
Two	O
-	O
dimensional	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
estimation	O
of	O
the	O
labelling	O
of	O
the	O
proteins	O
Electrophoresis	O
and	O
numbering	O
of	O
the	O
protein	O
spots	O
were	O
performed	O
as	O
de-	O
scribed	O
by	O
Welfle	O
et	O
al.	O
[	O
9	O
]	O
.	O

The	O
gel	O
slabs	O
were	O
stained	O
with	O
0.0005	O
%	O
Coo-	O
massie	O
Brillant	O
Blue	O
G	O
250	O
in	O
3	O
%	O
trichloroacetic	O
acid	O
for	O
24	O
h.	O
Thereafter	O
the	O
gel	O
pieces	O
containing	O
the	O
stained	O
proteins	O
were	O
cut	O
and	O
their	O
staining	O
intensi-	O
ties	O
measured	O
in	O
10	O
mm	O
glass	O
cuvettes	O
at	O
578	O
nm	O
.	O

For	O
the	O
estimation	O
of	O
the	O
labelling	O
the	O
gel	O
pieces	O
were	O
squashed	O
using	O
a	O
1	O
ml	O
syringe	O
with	O
a	O
I	O
mm	O
aperture	O
and	O
incubated	O
for	O
16	O
h	O
with	O
1	O
ml	O
of	O
0.5	O
N	O
hyamine	O
hydroxide	O
(	O
Packard	O
Instruments	O
,	O
Ill.	O
)	O
in	O
toluene	O
.	O

The	O
counting	O
efficiency	O
against	O
an	O
ex-	O
ternal	O
standard	O
was	O
about	O
80	O
%	O
using	O
a	O
scintillation	O
mixture	O
with	O
0.4	O
%	O
2,5-	O
diphenyloxazole	O
,	O
0.01	O
%	O
1,4-bis-	O
(	O
5-phenyloxazol-2-yl	O
)	O
benzene	O
,	O
10	O
%	O
Triton	O
X-	O
100	O
,	O
0.3	O
%	O
acetic	O
acid	O
in	O
toluene	O
.	O

After	O
measuring	O
the	O
label	O
for	O
10	O
min	O
the	O
disin-	O
tegrations	O
per	O
min	O
(	O
dpm	O
)	O
were	O
correlated	O
for	O
each	O
spot	O
to	O
1.0	O
A	O
s78	O
.	O

The	O
average	O
values	O
of	O
5	O
-	O
-10	O
independent	O
experiments	O
are	O
given	O
in	O
Tables	O
I	O
and	O
II	O
.	O

The	O
average	O
errors	O
of	O
the	O
mean	O
values	O
not	O
specified	O
for	O
the	O
individual	O
proteins	O
did	O
not	O
exceed	O
10	O
%	O
.	O

RESULTS	O
MAI	O
reacts	O
exclusively	O
with	O
the	O
amino	O
groups	O
of	O
proteins	O
[	O
3	O
]	O
,	O
whereas	O
NPA	O
also	O
substitutes	O
tyrosine	O
and	O
cysteine	O
residues	O
[	O
10	O
]	O
.	O

Because	O
of	O
the	O
relatively	O
high	O
lysine	O
content	O
,	O
the	O
low	O
portion	O
of	O
tyrosine	O
and	O
cysteine	O
in	O
ribosomal	O
proteins	O
of	O
rat	B
liver	O
[	O
11	O
]	O
and	O
the	O
lower	O
reactivity	O
of	O
tyrosine	O
OH-	O
groups	O
[	O
12	O
]	O
,	O
it	O
can	O
be	O
expected	O
that	O
both	O
reagents	O
predominantly	O
react	O
with	O
amino	O
groups	O
.	O

The	O
substitution	O
of	O
ribosomal	O
protein	O
mixtures	O
by	O
both	O
reagents	O
is	O
com-	O
pleted	O
after	O
30	O
min	O
at	O
37	O
to	O
more	O
than	O
90	O
%	O
.	O

The	O
proteins	O
isolated	O
from	O
the	O
small	O
ribosomal	O
subunit	O
incorporate	O
on	O
the	O
average	O
1,7-acetyl	O
and	O
2,4-	O
acetimidoyl	O
groups	O
,	O
respectively	O
,	O
per	O
20	O
000	O
dalton	O
,	O
and	O
the	O
proteins	O
of	O
the	O
large	O
subunit	O
bind	O
3,9-acetimidoyl	O
groups	O
per	O
20	O
000	O
dalton	O
.	O

The	O
labelling	O
values	O
for	O
the	O
proteins	O
of	O
the	O
small	O
subunit	O
are	O
presented	O
in	O
Table	O
I.	O
The	O
values	O
for	O
labelling	O
of	O
the	O
protein	O
mixture	O
with	O
NPA	O
vary	O
from	O
10	O
600	O
to	O
37	O
100	O
dpm	O
per	O
1.0	O
As78	O
.	O

When	O
using	O
the	O
subunits	O
,	O
values	O
between	O
2700	O
and	O
23	O
700	O
dpm	O
per	O
1.0	O
AsTa	O
are	O
measured	O
.	O

It	O
is	O
obvious	O
from	O
these	O
results	O
that	O
the	O
reactive	O
groups	O
of	O
the	O
proteins	O
in	O
the	O
subunit	O
structure	O
are	O
only	O
available	O
to	O
about	O
10	O
to	O
65	O
%	O
.	O

28	O
proteins	O
can	O
be	O
classified	O
into	O
3	O
groups	O
with	O
10	O
-	O
-22	O
%	O
,	O
23	O
-	O
-30	O
%	O
and	O
31	O
-	O
-66	O
%	O
remaining	O
reactivity	O
:	O
Proteins	O
$	O
9	O
,	O
14	O
,	O
19	O
,	O
20	O
,	O
23	O
,	O
24	O
,	O
25	O
,	O
28	O
and	O
30	O
{	O
marked	O
by--	O
)	O
are	O
strongly	O
protected	O
,	O
the	O
reactivity	O
of	O
9	O
other	O
proteins	O
is	O
diminished	O
moderately	O
(	O
$	O
1	O
,	O
5	O
,	O
13	O
,	O
16	O
,	O
17	O
,	O
18	O
,	O
21	O
,	O
26	O
and	O
29	O
(	O
marked	O
by	O
+	O
)	O
,	O
and	O
the	O
proteins	O
$	O
2	O
,	O
4	O
,	O
6	O
,	O
8	O
,	O
10	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
22	O
and	O
27	O
(	O
marked	O
by	O
+	O
)	O
are	O
exposed	O
to	O
a	O
relatively	O
high	O
extent	O
.	O

The	O
reaction	O
of	O
proteins	O
with	O
MAI	O
in	O
the	O
small	O
ribosomal	O
subunit	O
is	O
on	O
the	O
average	O
only	O
little	O
decreased	O
in	O
comparison	O
to	O
the	O
free	O
proteins	O
.	O

As	O
demon-	O
strated	O
in	O
Table	O
I	O
,	O
the	O
reactivity	O
of	O
proteins	O
$	O
4	O
,	O
11	O
,	O
12	O
,	O
14	O
,	O
21	O
,	O
24	O
,	O
25	O
,	O
27	O
and	O
29	O
(	O
marked	O
by	O
--	O
}	O
is	O
inhibited	O
by	O
30	O
%	O
or	O
more	O
if	O
the	O
subunit	O
is	O
com-	O
315	O
pared	O
with	O
the	O
protein	O
mixture	O
.	O

The	O
proteins	O
$	O
5	O
,	O
7	O
,	O
10	O
and	O
16	O
(	O
marked	O
by	O
+	O
}	O
are	O
labelled	O
more	O
strongly	O
in	O
the	O
subunit	O
than	O
in	O
the	O
isolated	O
protein	O
mixture	O
,	O
showing	O
values	O
of	O
more	O
than	O
130	O
%	O
.	O

For	O
11	O
proteins	O
(	O
S1	O
,	O
2	O
,	O
8	O
,	O
9	O
,	O
13	O
,	O
15	O
,	O
18	O
,	O
19	O
,	O
20	O
,	O
22	O
and	O
26	O
;	O
marked	O
by	O
-+	O
)	O
,	O
the	O
labelling	O
is	O
about	O
the	O
same	O
both	O
in	O
the	O
subunit	O
and	O
in	O
the	O
protein	O
mixture	O
{	O
70	O
-	O
-130%	O
}	O
.	O
A	O
stronger	O
inhibition	O
of	O
the	O
reaction	O
of	O
MAI	O
with	O
proteins	O
is	O
observed	O
in	O
the	O
large	O
ribosomal	O
subunit	O
(	O
Table	O
II	O
)	O
.	O

On	O
the	O
average	O
a	O
value	O
of	O
30	O
%	O
is	O
es-	O
timated	O
in	O
comparison	O
ta	O
the	O
protein	O
mixture	O
.	O

Proteins	O
L2	O
,	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
19	O
,	O
22	O
,	O
31	O
and	O
32	O
(	O
marked	O
by	O
--	O
)	O
in	O
the	O
subunit	O
structure	O
take	O
up	O
only	O
20	O
%	O
or	O
even	O
less	O
of	O
the	O
label	O
taken	O
up	O
by	O
the	O
isolated	O
protein	O
mixture	O
.	O

When	O
la-	O
belled	O
in	O
the	O
subunit	O
a	O
second	O
group	O
of	O
proteins	O
(	O
L4	O
,	O
7	O
,	O
20	O
,	O
21	O
,	O
27	O
,	O
28	O
,	O
35	O
and	O
36	O
;	O
marked	O
by	O
+	O
)	O
show	O
21	O
-	O
-28	O
%	O
and	O
a	O
third	O
group	O
{	O
L5	O
,	O
6	O
,	O
13	O
,	O
15	O
,	O
17	O
;	O
23	O
,	O
24	O
,	O
25	O
,	O
26	O
,	O
29	O
,	O
30	O
,	O
33	O
,	O
34	O
and	O
38	O
;	O
marked	O
by	O
+	O
)	O
more	O
than	O
29	O
%	O
of	O
the	O
label	O
of	O
the	O
protein	O
mixture	O
.	O

DISCUSSION	O
Chemical	O
substitutions	O
of	O
ribosomal	O
proteins	O
by	O
iodoacetate	O
and	O
2-	O
methoxy-5-nitrotropone	O
[	O
13	O
]	O
,	O
fluorescein	O
isothiocyanate	O
[	O
14	O
]	O
,	O
acetanhy-	O
dride	O
[	O
15	O
]	O
,	O
iodine	O
[	O
16,17	O
]	O
,	O
5,5-dithiobis-	O
(	O
2-nitro	O
-	O
benzoic	O
acid	O
)	O
[	O
18	O
]	O
,	O
N-	O
ethyl	O
-	O
maleimide	O
and	O
iodoacetamide	O
[	O
19	O
]	O
,	O
aldehydes	O
[	O
20	O
]	O
and	O
kethoxal	O
[	O
21	O
]	O
have	O
been	O
successfully	O
used	O
to	O
elucidate	O
the	O
topography	O
of	O
proteins	O
in	O
ribo-	O
somal	O
subunits	O
of	O
E.	B
coli	I
.	O

As	O
was	O
demonstrated	O
before	O
,	O
all	O
proteins	O
organized	O
in	O
the	O
ribosomal	O
sub-	O
units	O
of	O
rat	B
liver	O
are	O
accessible	O
to	O
the	O
reaction	O
with	O
MAI	O
and	O
with	O
NPA	O
.	O

The	O
extent	O
of	O
reaction	O
,	O
however	O
,	O
is	O
less	O
than	O
with	O
the	O
isolated	O
protein	O
mixture	O
.	O

Both	O
findings	O
are	O
in	O
good	O
agreement	O
with	O
results	O
obtained	O
with	O
iodoacet-	O
amide	O
[	O
2	O
]	O
,	O
2-methoxy-5-nitrotropone	O
[	O
22	O
]	O
and	O
also	O
with	O
conclusions	O
drawn	O
from	O
iodination	O
experiments	O
[	O
23	O
]	O
.	O

When	O
comparing	O
experiments	O
with	O
MAI	O
and	O
NPA	O
it	O
is	O
remarkable	O
that	O
the	O
reactivity	O
to	O
NPA	O
of	O
the	O
proteins	O
organized	O
in	O
the	O
small	O
ribosomal	O
subunit	O
is	O
inhibited	O
more	O
strongly	O
than	O
the	O
reactivity	O
to	O
MAI	O
in	O
comparison	O
to	O
the	O
free	O
protein	O
mixture	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
less	O
hydrophilic	O
properties	O
of	O
NPA	O
which	O
prevent	O
this	O
reagent	O
from	O
penetrating	O
the	O
ribosomal	O
subunit	O
structure	O
as	O
readily	O
as	O
the	O
more	O
hydrophilic	O
MAI	O
obviously	O
can	O
.	O

The	O
reaction	O
of	O
the	O
proteins	O
in	O
the	O
small	O
ribosomal	O
subunit	O
to	O
MAI	O
,	O
on	O
the	O
whole	O
,	O
occurs	O
more	O
readily	O
than	O
those	O
in	O
the	O
large	O
ribosomal	O
subunit	O
in	O
com-	O
parison	O
to	O
the	O
corresponding	O
free	O
protein	O
mixtures	O
.	O

This	O
finding	O
favours	O
a	O
more	O
dense	O
structure	O
of	O
the	O
large	O
ribosomal	O
subunit	O
.	O

The	O
explanation	O
that	O
more	O
reactive	O
protein	O
groups	O
are	O
localized	O
on	O
the	O
surface	O
of	O
the	O
small	O
ribo-	O
somal	O
subunit	O
in	O
comparison	O
to	O
their	O
total	O
number	O
than	O
in	O
the	O
large	O
ribo-	O
somal	O
subunit	O
is	O
unlikely	O
,	O
because	O
the	O
reaction	O
of	O
small	O
and	O
large	O
subunit	O
proteins	O
with	O
NPA	O
is	O
inhibited	O
to	O
the	O
same	O
extent	O
in	O
the	O
subunit	O
structures	O
.	O

Different	O
proportions	O
of	O
reactive	O
amino	O
groups	O
in	O
small	O
and	O
large	O
ribosomal	O
subunits	O
from	O
E.	B
coli	I
have	O
also	O
been	O
reported	O
by	O
Slobin	O
[	O
24	O
]	O
using	O
methyl	O
picolinimidate	O
.	O

316	O
If	O
the	O
proteins	O
are	O
classified	O
as	O
weakly	O
exposed	O
(	O
--	O
)	O
,	O
moderately	O
exposed	O
(	O
-+	O
)	O
and	O
strongly	O
exposed	O
(	O
+	O
)	O
proteins	O
,	O
it	O
can	O
be	O
demonstrated	O
that	O
the	O
re-	O
sults	O
obtained	O
with	O
different	O
reagents	O
agree	O
for	O
the	O
preponderantly	O
buried	O
proteins	O
$	O
14	O
,	O
25	O
,	O
L8	O
,	O
10	O
,	O
11	O
,	O
19	O
,	O
31	O
and	O
32	O
and	O
for	O
the	O
mainly	O
exposed	O
pro-	O
teins	O
L15	O
,	O
17	O
,	O
25	O
,	O
29	O
,	O
33	O
,	O
34	O
and	O
38	O
(	O
see	O
Table	O
III	O
)	O
.	O

For	O
the	O
other	O
proteins	O
also	O
listed	O
in	O
Table	O
III	O
,	O
the	O
results	O
obtained	O
with	O
different	O
reagents	O
are	O
not	O
in	O
full	O
agreement	O
.	O

However	O
,	O
the	O
accessibility	O
of	O
proteins	O
in	O
the	O
subunit	O
struc-	O
ture	O
to	O
trypsin	O
[	O
25	O
]	O
and	O
their	O
tendency	O
to	O
be	O
split	O
from	O
the	O
subunits	O
by	O
dif-	O
ferent	O
LiC1	O
concentrations	O
[	O
26	O
]	O
argue	O
in	O
favour	O
of	O
a	O
relatively	O
buried	O
locali-	O
zation	O
of	O
the	O
proteins	O
$	O
9	O
,	O
19	O
,	O
20	O
,	O
24	O
,	O
27	O
,	O
29	O
,	O
30	O
,	O
L1	O
,	O
7	O
and	O
28	O
and	O
an	O
ex-	O
posed	O
arrangement	O
of	O
the	O
proteins	O
$	O
2,5	O
,	O
7	O
,	O
8	O
,	O
10	O
,	O
13	O
,	O
L20	O
,	O
24	O
,	O
27	O
and	O
35	O
.	O

Exposed	O
positions	O
were	O
also	O
reported	O
for	O
proteins	O
moving	O
electrophoreti-	O
cally	O
like	O
L17	O
,	O
24	O
and	O
29	O
by	O
Reboud	O
,	O
studying	O
the	O
reaction	O
of	O
large	O
subunits	O
of	O
rat	B
liver	O
ribosomes	O
with	O
2-methoxy-5-nitrotropone	O
and	O
glutaraldehyde	O
[	O
22	O
]	O
,	O
respectively	O
.	O

Glutamate	O
contributes	O
to	O
secondary	O
brain	O
damage	O
,	O
resulting	O
in	O
cell	O
swelling	O
and	O
brain	O
edema	O
.	O

Under	O
in	O
vitro	O
conditions	O
,	O
increased	O
extracellular	O
levels	O
of	O
the	O
amino	O
acid	O
taurine	O
reflect	O
glutamate	O
-	O
induced	O
osmotic	O
cell	O
swelling	O
.	O

In	O
vivo	O
,	O
increases	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
taurine	O
could	O
,	O
therefore	O
,	O
unmask	O
glutamate	O
-	O
mediated	O
cytotoxic	O
edema	O
formation	O
and	O
possibly	O
differentiate	O
it	O
from	O
vasogenic	O
edema	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
ventricular	O
CSF	O
glutamate	O
and	O
taurine	O
levels	O
were	O
measured	O
in	O
28	O
severely	O
brain	O
-	O
injured	O
patients	B
on	O
days	O
1	O
,	O
5	O
,	O
and	O
14	O
after	O
trauma	O
.	O

Posttraumatic	O
changes	O
in	O
CSF	O
amino	O
acids	O
were	O
investigated	O
in	O
regard	O
to	O
extent	O
of	O
tissue	O
damage	O
and	O
alterations	O
in	O
brain	O
edema	O
as	O
estimated	O
by	O
computerized	O
tomography	O
.	O

On	O
day	O
1	O
,	O
CSF	O
glutamate	O
and	O
taurine	O
levels	O
were	O
significantly	O
increased	O
in	O
patients	O
with	O
subdural	O
or	O
epidural	O
hematomas	O
(	O
8+	O
/	O
-0.8	O
/	O
71+	O
/	O
-12	O
microM	O
)	O
,	O
contusions	O
(	O
21+	O
/	O
-4.1	O
/	O
122+	O
/	O
-18	O
microM	O
)	O
,	O
and	O
generalized	O
brain	O
edema	O
(	O
13+	O
/	O
-3.2	O
/	O
80+	O
/	O
-15	O
microM	O
)	O
compared	O
to	O
lumbar	O
control	O
CSF	O
(	O
1.3+	O
/	O
-0.1	O
/	O
12+	O
/	O
-1	O
microM	O
;	O
p	O
<	O
0.001	O
)	O
.	O

CSF	O
amino	O
acids	O
,	O
however	O
,	O
did	O
not	O
reflect	O
edema	O
formation	O
and	O
resolution	O
as	O
estimated	O
by	O
computerized	O
tomography	O
.	O

CSF	O
taurine	O
correlated	O
positively	O
with	O
glutamate	O
,	O
eventually	O
depicting	O
glutamate	O
-	O
induced	O
cell	O
swelling	O
.	O

However	O
,	O
parallel	O
neuronal	O
release	O
of	O
taurine	O
with	O
its	O
inhibitory	O
function	O
can	O
not	O
be	O
excluded	O
.	O

Thus	O
,	O
the	O
sensitivity	O
of	O
taurine	O
in	O
unmasking	O
cytotoxic	O
edema	O
formation	O
is	O
weakened	O
by	O
the	O
inability	O
in	O
defining	O
its	O
origin	O
and	O
function	O
under	O
the	O
conditions	O
chosen	O
in	O
the	O
present	O
study	O
.	O

Overall	O
,	O
persisting	O
pathologic	O
ventricular	O
CSF	O
glutamate	O
and	O
taurine	O
levels	O
are	O
highly	O
suggestive	O
of	O
ongoing	O
glial	O
and	O
neuronal	O
impairment	O
in	O
humans	B
following	O
severe	O
traumatic	O
brain	O
injury	O
.	O

Dopamine	O
is	O
a	O
biogenic	O
amine	O
synthesized	O
in	O
the	O
hypothalamus	O
,	O
in	O
the	O
arcuate	O
nucleus	O
,	O
the	O
caudad	O
,	O
and	O
various	O
areas	O
of	O
the	O
central	O
and	O
peripheral	O
nervous	O
system	O
.	O

It	O
has	O
been	O
widely	O
established	O
that	O
dopamine	O
and	O
its	O
agonists	O
play	O
an	O
important	O
role	O
in	O
cardiovascular	O
,	O
renal	O
,	O
hormonal	O
,	O
and	O
central	O
nervous	O
system	O
regulation	O
through	O
stimulation	O
of	O
alpha	O
and	O
beta	O
adrenergic	O
and	O
dopaminergic	O
receptors	O
.	O

There	O
are	O
several	O
agonists	O
of	O
dopamine-2	O
(	O
DA	O
2	O
)	O
dopaminergic	O
receptors	O
,	O
such	O
as	O
bromocriptine	O
,	O
pergolide	O
,	O
lisuride	O
,	O
quinpirole	O
,	O
and	O
carmoxirole	O
,	O
which	O
inhibit	O
norepinephrine	O
release	O
and	O
produce	O
a	O
decrease	O
in	O
arterial	O
blood	O
pressure	O
;	O
in	O
some	O
cases	O
,	O
bromocriptine	O
and	O
pergolide	O
also	O
reduce	O
heart	O
rate	O
.	O

From	O
a	O
therapeutic	O
point	O
of	O
view	O
,	O
the	O
above	O
-	O
mentioned	O
agonists	O
are	O
used	O
for	O
treating	O
Parkinson	O
's	O
disease	O
,	O
acting	O
over	O
DA	O
2	O
dopaminergic	O
receptors	O
of	O
the	O
nigrostriatal	O
system	O
.	O

Bromocriptine	O
and	O
the	O
other	O
dopaminergic	O
agonists	O
mentioned	O
act	O
over	O
DA	O
2	O
receptors	O
of	O
the	O
tuberoinfundibular	O
system	O
,	O
inhibiting	O
prolactin	O
release	O
and	O
decreasing	O
hyperprolactinemia	O
and	O
tumor	O
size	O
.	O

Among	O
DA	O
1	O
receptor	O
agonists	O
,	O
we	O
can	O
mention	O
fenoldopam	O
,	O
piribedil	O
,	O
ibopamine	O
,	O
SKF	O
3893	O
,	O
and	O
apomorphine	O
(	O
nonspecific	O
)	O
.	O

Activation	O
of	O
these	O
receptors	O
decreases	O
peripheral	O
resistance	O
,	O
inducing	O
lowering	O
of	O
arterial	O
blood	O
pressure	O
and	O
increases	O
in	O
heart	O
rate	O
,	O
sympathetic	O
tone	O
,	O
and	O
activity	O
of	O
the	O
renin	O
aldosterone	O
system	O
.	O

Among	O
DA	O
2	O
receptor	O
antagonists	O
,	O
we	O
can	O
mention	O
metoclopramide	O
,	O
domperidone	O
,	O
sulpiride	O
,	O
and	O
haloperidol	O
.	O

From	O
a	O
therapeutic	O
point	O
of	O
view	O
,	O
metoclopramide	O
and	O
domperidone	O
are	O
used	O
in	O
gastric	O
motility	O
disorders	O
,	O
and	O
haloperidol	O
is	O
used	O
in	O
psychotic	O
alterations	O
.	O

Antagonists	O
of	O
DA	O
1	O
receptors	O
are	O
SCH23390	O
and	O
clozapine	O
.	O

Clozapine	O
is	O
used	O
for	O
treating	O
schizophrenia	O
.	O

Administered	O
to	O
rats	B
by	O
stomach	O
tubing	O
oxythioquinox	O
(	O
Morestan	O
)	O
toxicity	O
is	O
very	O
strongly	O
increased	O
after	O
solubilisation	O
in	O
olive	O
oil	O
.	O

The	O
oxythioquinox	O
DL50	O
,	O
in	O
this	O
case	O
,	O
is	O
500	O
mg	O
/	O
kg	O
although	O
we	O
can	O
reach	O
2.8	O
g	O
/	O
kg	O
in	O
aqueous	O
suspensions	O
.	O

When	O
it	O
is	O
administered	O
(	O
1	O
g	O
/	O
kg	O
)	O
in	O
aqueous	O
suspension	O
,	O
the	O
decrease	O
in	O
body	O
weight	O
is	O
the	O
same	O
as	O
these	O
observed	O
with	O
a	O
5	O
fold	O
lower	O
dose	O
in	O
oil	O
.	O

Conversion	O
rate	O
feed	O
and	O
weight	O
of	O
differents	O
organs	O
decrease	O
when	O
animals	O
are	O
daily	O
submitted	O
to	O
oxythioquinox	O
in	O
oil	O
,	O
during	O
16	O
days	O
,	O
compared	O
with	O
animals	O
treated	O
with	O
an	O
equivalent	O
dose	O
in	O
aqueous	O
suspension	O
.	O

Potentiation	O
,	O
in	O
oil	O
solutions	O
,	O
of	O
the	O
decrease	O
of	O
oxythioquinox	O
intestinal	O
transit	O
,	O
promoting	O
its	O
absorption	O
,	O
could	O
explain	O
the	O
increase	O
of	O
oxythioquinox	O
toxicity	O
in	O
oil	O
solution	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
methyl	O
ester	O
of	O
hepoxilin	O
A3	O
causes	O
a	O
receptor	O
-	O
induced	O
rise	O
in	O
intracellular	O
calcium	O
through	O
the	O
release	O
from	O
intracellular	O
stores	O
in	O
suspended	O
human	B
neutrophils	O
.	O

The	O
corresponding	O
free	O
acid	O
was	O
devoid	O
of	O
activity	O
.	O

We	O
now	O
report	O
that	O
the	O
action	O
of	O
the	O
free	O
acid	O
form	O
of	O
hepoxilin	O
A3	O
is	O
dependent	O
on	O
the	O
type	O
of	O
vehicle	O
used	O
,	O
i.e.	O
it	O
is	O
active	O
in	O
releasing	O
calcium	O
when	O
used	O
in	O
an	O
ethanol	O
vehicle	O
but	O
not	O
in	O
DMSO	O
.	O

The	O
methyl	O
ester	O
is	O
equally	O
active	O
in	O
either	O
vehicle	O
.	O

The	O
pattern	O
of	O
calcium	O
release	O
between	O
the	O
free	O
acid	O
and	O
the	O
methyl	O
ester	O
is	O
qualitatively	O
different	O
.	O

Both	O
compounds	O
show	O
a	O
biphasic	O
pattern	O
,	O
i.e.	O
an	O
initial	O
rapid	O
phase	O
followed	O
by	O
a	O
slow	O
decline	O
in	O
calcium	O
levels	O
but	O
never	O
reaching	O
pre	O
-	O
hepoxilin	O
A3	O
baseline	O
levels	O
.	O

The	O
methyl	O
ester	O
appears	O
slightly	O
more	O
potent	O
in	O
the	O
initial	O
phase	O
of	O
calcium	O
release	O
than	O
the	O
free	O
acid	O
(	O
methyl	O
=	O
188+	O
/	O
-14	O
S.D.	O
,	O
free	O
acid	O
=	O
135+	O
/	O
-11	O
S.D.	O
nM	O
,	O
P	O
<	O
0.0005	O
)	O
.	O

Both	O
compounds	O
appear	O
to	O
reach	O
the	O
same	O
calcium	O
levels	O
at	O
the	O
plateau	O
of	O
the	O
second	O
prolonged	O
phase	O
(	O
methyl	O
=	O
88+	O
/	O
-8	O
S.D.	O
,	O
free	O
acid	O
=	O
107+	O
/	O
-15	O
S.D.	O
nM	O
,	O
not	O
significant	O
)	O
.	O

Lanthanum	O
chloride	O
(	O
an	O
inhibitor	O
of	O
calcium	O
influx	O
)	O
interfered	O
with	O
the	O
second	O
phase	O
of	O
the	O
curve	O
causing	O
calcium	O
levels	O
to	O
return	O
to	O
normal	O
pre	O
-	O
hepoxilin	O
levels	O
for	O
both	O
compounds	O
.	O

Addition	O
of	O
lanthanum	O
chloride	O
prior	O
to	O
the	O
hepoxilin	O
addition	O
or	O
carrying	O
out	O
the	O
experiments	O
in	O
calcium	O
-	O
free	O
medium	O
,	O
eliminated	O
the	O
second	O
phase	O
completely	O
,	O
with	O
the	O
calcium	O
peak	O
returning	O
rapidly	O
to	O
normal	O
baseline	O
levels	O
,	O
suggesting	O
that	O
the	O
second	O
phase	O
is	O
due	O
to	O
calcium	O
influx	O
.	O

Again	O
the	O
methyl	O
ester	O
is	O
more	O
active	O
than	O
the	O
free	O
acid	O
(	O
methyl	O
,	O
189+	O
/	O
-12	O
;	O
free	O
acid	O
,	O
145+	O
/	O
-6	O
S.D.	O
nM	O
,	O
P<0.005	O
)	O
.	O

Additional	O
experiments	O
with	O
tritium	O
-	O
labelled	O
methyl	O
ester	O
of	O
hepoxilin	O
A3	O
demonstrated	O
that	O
the	O
compound	O
is	O
hydrolyzed	O
into	O
the	O
free	O
acid	O
intracellularly	O
.	O

These	O
experiments	O
demonstrate	O
that	O
DMSO	O
interacts	O
with	O
hepoxilin	O
free	O
acid	O
,	O
interfering	O
with	O
its	O
entry	O
into	O
the	O
cell	O
while	O
ethanol	O
does	O
not	O
.	O

Once	O
inside	O
the	O
cell	O
,	O
hepoxilin	O
interacts	O
with	O
its	O
own	O
receptor	O
to	O
release	O
calcium	O
rapidly	O
from	O
stores	O
,	O
but	O
it	O
also	O
causes	O
a	O
more	O
prolonged	O
influx	O
of	O
calcium	O
from	O
the	O
extracellular	O
milieu	O
.	O

We	O
have	O
recently	O
shown	O
that	O
hepoxilin	O
(	O
Hx	O
)	O
A3	O
interacts	O
with	O
a	O
specific	O
binding	O
protein	O
in	O
the	O
intact	O
human	B
neutrophil	O
resulting	O
in	O
the	O
release	O
of	O
intracellular	O
calcium	O
[	O
1	O
]	O
.	O

In	O
those	O
studies	O
we	O
used	O
the	O
methyl	O
(	O
Me	O
)	O
ester	O
form	O
in	O
DMSO	O
because	O
we	O
found	O
that	O
the	O
free	O
acid	O
(	O
FA	O
)	O
was	O
without	O
effect	O
in	O
intact	O
cells	O
both	O
in	O
terms	O
of	O
binding	O
and	O
calcium	O
release	O
[	O
2	O
]	O
.	O

We	O
also	O
found	O
that	O
both	O
the	O
FA	O
and	O
Me	O
ester	O
(	O
in	O
DMSO	O
)	O
were	O
active	O
in	O
specific	O
binding	O
to	O
disrupted	O
neutrophil	O
membranes	O
[	O
3	O
]	O
.	O

This	O
suggested	O
that	O
the	O
FA	O
did	O
not	O
penetrate	O
into	O
the	O
intact	O
cell	O
and	O
that	O
the	O
binding	O
protein	O
was	O
intracellular	O
and	O
not	O
at	O
the	O
outside	O
surface	O
of	O
the	O
plasma	O
membrane	O
.	O

We	O
now	O
describe	O
new	O
findings	O
which	O
support	O
a	O
binding	O
/	O
calcium	O
release	O
coupling	O
where	O
both	O
the	O
FA	O
and	O
the	O
Me	O
ester	O
are	O
found	O
active	O
(	O
in	O
ethanol	O
vehicle	O
)	O
in	O
the	O
intact	O
neutrophil	O
and	O
demonstrate	O
a	O
biphasic	O
action	O
of	O
HxA3	O
,	O
one	O
in	O
releasing	O
calcium	O
from	O
intracellular	O
stores	O
,	O
a	O
second	O
in	O
increasing	O
calcium	O
influx	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Pure	O
8	O
(	O
R	O
)	O
-HxA3	O
Me	O
ester	O
was	O
prepared	O
in	O
our	O
laboratory	O
as	O
previously	O
reported	O
[	O
4	O
]	O
.	O

The	O
FA	O
was	O
prepared	O
by	O
hydrolysis	O
of	O
the	O
Me	O
ester	O
with	O
1	O
N	O
KOH	O
/	O
ethanol	O
followed	O
by	O
mild	O
acidification	O
,	O
extraction	O
and	O
further	O
purification	O
by	O
chromatography	O
[	O
5	O
]	O
.	O

[	O
3	O
H6	O
]	O
(	O
8R	O
)	O
-HxA3	O
Me	O
ester	O
was	O
prepared	O
as	O
previously	O
reported	O
[	O
5	O
]	O
.	O

Lanthanum	O
chloride	O
was	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

2.2	O
Preparation	O
of	O
human	B
neutrophils	O
Human	B
neutrophils	O
were	O
prepared	O
essentially	O
as	O
described	O
previously	O
[	O
3	O
]	O
.	O

Typically	O
,	O
neutrophils	O
were	O
obtained	O
from	O
40	O
ml	O
venous	O
blood	O
from	O
volunteers	B
that	O
had	O
not	O
taken	O
any	O
medication	O
.	O

The	O
blood	O
was	O
anti	O
-	O
coagulated	O
with	O
heparin	O
sodium	O
(	O
Organon	O
Tecknica	O
,	O
Durham	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Erythrocytes	O
were	O
removed	O
by	O
4.5	O
%	O
dextran	O
sedimentation	O
.	O

Neutrophils	O
were	O
collected	O
and	O
pelleted	O
after	O
Ficoll	O
-	O
Paque	O
gradient	O
centrifugation	O
.	O

Further	O
removal	O
of	O
contaminating	O
erythrocytes	O
was	O
carried	O
out	O
by	O
ammonium	O
chloride	O
lysis	O
.	O

After	O
washing	O
twice	O
with	O
centrifugation	O
,	O
neutrophils	O
were	O
resuspended	O
in	O
RPMI	O
1640	O
medium	O
and	O
were	O
counted	O
in	O
a	O
Coulter	O
counter	O
(	O
Model	O
901	O
)	O
.	O

The	O
cells	O
were	O
adjusted	O
to	O
a	O
concentration	O
of	O
107	O
cells	O
/	O
ml	O
in	O
RPMI	O
1640	O
medium	O
.	O

2.3	O
Intracellular	O
calcium	O
release	O
Freshly	O
prepared	O
neutrophil	O
suspensions	O
(	O
1	O
ml	O
:	O
1	O
×	O
107	O
cells	O
)	O
were	O
loaded	O
with	O
3	O
mM	O
(	O
final	O
concentration	O
3	O
μM	O
)	O
of	O
the	O
acetoxymethyl	O
ester	O
precursor	O
of	O
the	O
calcium	O
indicator	O
(	O
Indo-1-AM	O
,	O
Calbiochem	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
during	O
30	O
min	O
at	O
37	O
°	O
C	O
.	O

Excess	O
dye	O
was	O
removed	O
by	O
centrifugation	O
and	O
the	O
cells	O
were	O
suspended	O
in	O
fresh	O
RPMI	O
1640	O
medium	O
.	O

Dye	O
-	O
loaded	O
cells	O
were	O
kept	O
at	O
room	O
temperature	O
on	O
a	O
rotator	O
.	O

Each	O
measurement	O
consisted	O
of	O
the	O
following	O
:	O
2	O
×	O
106	O
cells	O
were	O
suspended	O
in	O
1	O
ml	O
of	O
assay	O
medium	O
of	O
the	O
following	O
composition	O
in	O
mM	O
:	O
NaCl	O
140	O
,	O
KCl	O
5	O
,	O
MgCl2	O
1	O
,	O
CaCl2	O
1	O
,	O
HEPES	O
sodium	O
-	O
free	O
10	O
and	O
glucose	O
10	O
,	O
pH	O
7.3	O
and	O
placed	O
in	O
a	O
plastic	O
cuvette	O
(	O
Diamed	O
Lab	O
.	O
,	O
Toronto	O
,	O
Canada	O
)	O
whose	O
temperature	O
was	O
controlled	O
at	O
37	O
°	O
C	O
.	O

Calcium	O
-	O
free	O
media	O
contained	O
no	O
calcium	O
and	O
1	O
mM	O
EGTA	O
was	O
added	O
.	O

The	O
cell	O
suspension	O
was	O
continuously	O
stirred	O
magnetically	O
.	O

Fluorescence	O
was	O
continuously	O
monitored	O
with	O
a	O
Perkin	O
-	O
Elmer	O
fluorescence	O
spectrophotometer	O
(	O
model	O
650	O
-	O
40	O
)	O
and	O
recorded	O
on	O
a	O
chart	O
recorder	O
(	O
LKB	O
model	O
2210	O
)	O
set	O
at	O
1	O
cm	O
/	O
min	O
.	O

The	O
excitation	O
wavelength	O
was	O
set	O
at	O
331	O
nm	O
,	O
the	O
emission	O
wavelength	O
at	O
410	O
nm	O
,	O
with	O
slits	O
of	O
excitation	O
and	O
emission	O
set	O
at	O
3	O
and	O
15	O
nm	O
respectively	O
.	O

At	O
the	O
end	O
of	O
each	O
test	O
,	O
a	O
calibration	O
was	O
carried	O
out	O
to	O
determine	O
the	O
maximal	O
fluorescence	O
by	O
adding	O
ionomycin	O
(	O
Sigma	O
)	O
at	O
1	O
mM	O
(	O
final	O
concentration	O
1	O
μM	O
)	O
and	O
minimal	O
fluorescence	O
by	O
adding	O
MnCl2	O
(	O
final	O
concentration	O
3	O
mM	O
)	O
as	O
previously	O
described	O
[	O
6	O
]	O
.	O

Test	O
compounds	O
were	O
prepared	O
in	O
DMSO	O
(	O
Caledon	O
,	O
Georgetown	O
,	O
OR	O
,	O
USA	O
)	O
or	O
glass	O
-	O
distilled	O
ethanol	O
(	O
100	O
%	O
)	O
at	O
a	O
stock	O
solution	O
of	O
1	O
μg	O
/	O
μl	O
or	O
5	O
μg	O
/	O
μl	O
and	O
1	O
μl	O
of	O
this	O
solution	O
was	O
added	O
to	O
2	O
×	O
106	O
cells	O
in	O
1	O
ml	O
.	O

2.4	O
Metabolism	O
of	O
[	O
3	O
H6	O
]	O
HxA3	O
Me	O
ester	O
Freshly	O
prepared	O
human	B
neutrophils	O
were	O
incubated	O
in	O
the	O
above	O
assay	O
medium	O
in	O
a	O
siliconized	O
glass	O
tube	O
to	O
which	O
had	O
been	O
added	O
[	O
3	O
H	O
]	O
(	O
8R	O
)	O
-HxA3	O
Me	O
ester	O
(	O
5	O
×	O
106	O
cpm	O
)	O
diluted	O
with	O
3	O
μg	O
of	O
the	O
unlabelled	O
compound	O
.	O

The	O
mixture	O
was	O
incubated	O
for	O
1	O
or	O
5	O
minutes	O
and	O
the	O
incubation	O
mixture	O
was	O
extracted	O
with	O
ethyl	O
acetate	O
without	O
prior	O
acidification	O
to	O
extract	O
the	O
intact	O
Hx	O
structure	O
and	O
its	O
products	O
(	O
which	O
are	O
acid	O
sensitive	O
)	O
.	O

The	O
solvent	O
was	O
evaporated	O
to	O
dryness	O
with	O
N2	O
gas	O
and	O
the	O
residue	O
was	O
dissolved	O
in	O
a	O
small	O
amount	O
of	O
ethyl	O
acetate	O
and	O
spotted	O
on	O
TLC	O
(	O
silica	O
gel	O
G	O
,	O
ethyl	O
acetate	O
/	O
acetic	O
acid	O
99.5	O
/	O
0.5	O
(	O
v	O
/	O
v	O
)	O
)	O
.	O

The	O
plate	O
was	O
developed	O
for	O
60	O
min	O
,	O
then	O
the	O
solvent	O
was	O
dried	O
with	O
cold	O
air	O
and	O
scanned	O
for	O
radioactivity	O
on	O
a	O
TLC	O
radiochromatogram	O
scanner	O
(	O
Berthold	O
)	O
.	O

Authentic	O
standards	O
of	O
HxA3	O
Me	O
ester	O
and	O
FA	O
as	O
well	O
as	O
the	O
ω	O
-	O
hydroxy	O
(	O
ωH	O
)	O
metabolite	O
FA	O
(	O
product	O
of	O
ω	O
-	O
oxidation	O
[	O
7	O
]	O
)	O
and	O
the	O
trihydroxy	O
metabolite	O
FA	O
(	O
product	O
of	O
epoxide	O
hydrolase	O
)	O
were	O
spotted	O
as	O
reference	O
compounds	O
.	O

3	O
Results	O
and	O
discussion	O
We	O
show	O
herein	O
that	O
HxA3	O
FA	O
but	O
not	O
the	O
Me	O
ester	O
is	O
vehicle	O
sensitive	O
in	O
evoking	O
a	O
rise	O
in	O
intracellular	O
calcium	O
in	O
suspensions	O
of	O
human	B
neutrophils	O
.	O

Fig.	O
1	O
A	O
shows	O
a	O
typical	O
pattern	O
of	O
intracellular	O
calcium	O
resulting	O
from	O
the	O
addition	O
of	O
HxA3	O
Me	O
ester	O
(	O
upper	O
trace	O
)	O
and	O
FA	O
(	O
lower	O
trace	O
)	O
in	O
DMSO	O
as	O
vehicle	O
.	O

This	O
is	O
compared	O
with	O
the	O
same	O
two	O
compounds	O
added	O
in	O
ethanol	O
as	O
vehicle	O
(	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
following	O
three	O
points	O
are	O
apparent	O
.	O

First	O
,	O
the	O
pattern	O
for	O
the	O
Me	O
ester	O
is	O
similar	O
and	O
independent	O
of	O
the	O
vehicle	O
used	O
(	O
compare	O
upper	O
traces	O
in	O
Fig.	O
1	O
A	O
and	O
B	O
)	O
.	O

Second	O
,	O
the	O
FA	O
is	O
inactive	O
when	O
made	O
up	O
in	O
DMSO	O
but	O
is	O
active	O
when	O
added	O
in	O
ethanol	O
vehicle	O
(	O
compare	O
lower	O
traces	O
in	O
Fig.	O
1	O
A	O
and	O
B	O
)	O
.	O

Third	O
,	O
both	O
compounds	O
added	O
in	O
ethanol	O
show	O
a	O
rapid	O
action	O
(	O
rise	O
in	O
intracellular	O
calcium	O
)	O
and	O
a	O
slower	O
more	O
prolonged	O
decrease	O
in	O
calcium	O
levels	O
but	O
never	O
decreasing	O
to	O
pre	O
-	O
HxA3	O
levels	O
(	O
see	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
Me	O
ester	O
appears	O
more	O
potent	O
in	O
the	O
rapid	O
initial	O
phase	O
of	O
calcium	O
release	O
than	O
the	O
FA	O
(	O
Me	O
,	O
188±14	O
S.D.	O
;	O
FA	O
,	O
135±11	O
S.D.	O
nM	O
,	O
P	O
<	O
0.0005	O
,	O
n	O
=3	O
)	O
and	O
decreases	O
to	O
a	O
similar	O
plateau	O
level	O
as	O
with	O
the	O
FA	O
(	O
Me	O
,	O
88±8	O
S.D.	O
;	O
FA	O
,	O
107±15	O
S.D.	O
nM	O
,	O
not	O
significant	O
,	O
n	O
=	O
3	O
)	O
.	O

Hence	O
,	O
the	O
decrease	O
to	O
the	O
second	O
phase	O
(	O
prolonged	O
calcium	O
rise	O
)	O
is	O
greater	O
with	O
the	O
Me	O
ester	O
(	O
from	O
188	O
to	O
88	O
nM=53	O
%	O
)	O
than	O
with	O
the	O
FA	O
(	O
from	O
135	O
to	O
107	O
nM=20	O
%	O
)	O
.	O

In	O
order	O
to	O
address	O
this	O
second	O
phase	O
of	O
calcium	O
`	O
retention	O
'	O
,	O
we	O
administered	O
lanthanum	O
chloride	O
(	O
1	O
μM	O
final	O
concentration	O
)	O
at	O
the	O
plateau	O
of	O
the	O
profile	O
(	O
about	O
5	O
min	O
after	O
the	O
addition	O
of	O
HxA3	O
)	O
.	O

Lanthanum	O
chloride	O
blocks	O
the	O
entry	O
of	O
calcium	O
by	O
inhibiting	O
calcium	O
channels	O
[	O
8	O
,	O
9	O
]	O
.	O

Lanthanum	O
caused	O
an	O
immediate	O
decrease	O
in	O
intracellular	O
calcium	O
levels	O
towards	O
the	O
baseline	O
for	O
both	O
the	O
Me	O
ester	O
as	O
well	O
as	O
the	O
FA	O
(	O
Fig.	O
1	O
B	O
,	O
upper	O
and	O
lower	O
traces	O
)	O
.	O

In	O
separate	O
experiments	O
(	O
Fig.	O
1	O
C	O
)	O
carried	O
out	O
in	O
medium	O
devoid	O
of	O
extracellular	O
calcium	O
(	O
containing	O
EGTA	O
)	O
,	O
the	O
Me	O
ester	O
(	O
tested	O
in	O
DMSO	O
or	O
ethanol	O
)	O
effected	O
the	O
same	O
rapid	O
initial	O
phase	O
of	O
intracellular	O
calcium	O
rise	O
but	O
the	O
peak	O
response	O
quickly	O
returned	O
to	O
baseline	O
(	O
Fig.	O
1	O
C	O
,	O
upper	O
trace	O
)	O
,	O
suggesting	O
that	O
the	O
second	O
(	O
longer	O
)	O
phase	O
of	O
the	O
normal	O
HxA3	O
response	O
was	O
due	O
to	O
the	O
entry	O
of	O
extracellular	O
calcium	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
the	O
FA	O
of	O
HxA3	O
(	O
Fig.	O
1	O
C	O
,	O
lower	O
trace	O
)	O
.	O

Again	O
the	O
Me	O
ester	O
is	O
slightly	O
more	O
potent	O
than	O
the	O
FA	O
(	O
Me	O
,	O
189±12	O
S.D.	O
;	O
FA	O
,	O
145±6	O
S.D.	O
nM	O
,	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
)	O
.	O

Similar	O
results	O
to	O
the	O
extracellular	O
calcium	O
-	O
free	O
experiments	O
were	O
observed	O
when	O
lanthanum	O
chloride	O
was	O
added	O
to	O
the	O
cells	O
prior	O
to	O
HxA3	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
order	O
to	O
investigate	O
further	O
whether	O
the	O
calcium	O
releasing	O
action	O
of	O
HxA3	O
on	O
neutrophils	O
was	O
mediated	O
via	O
its	O
conversion	O
into	O
other	O
compounds	O
,	O
we	O
incubated	O
tritiated	O
HxA3	O
Me	O
ester	O
with	O
human	B
neutrophils	O
and	O
analyzed	O
the	O
products	O
after	O
1	O
and	O
5	O
min	O
incubation	O
,	O
the	O
periods	O
of	O
maximal	O
change	O
in	O
intracellular	O
calcium	O
.	O

The	O
ethyl	O
acetate	O
extract	O
of	O
the	O
incubation	O
was	O
analyzed	O
by	O
TLC	O
.	O

Fig.	O
2	O
shows	O
that	O
within	O
a	O
1	O
min	O
incubation	O
(	O
the	O
period	O
of	O
sharp	O
initial	O
calcium	O
rise	O
)	O
the	O
Me	O
ester	O
is	O
only	O
partially	O
hydrolyzed	O
(	O
about	O
10	O
%	O
)	O
into	O
the	O
FA	O
by	O
intracellular	O
esterases	O
,	O
demonstrating	O
that	O
the	O
Me	O
ester	O
penetrates	O
into	O
the	O
cell	O
where	O
it	O
acts	O
to	O
release	O
calcium	O
from	O
calcium	O
stores	O
(	O
rapid	O
initial	O
phase	O
)	O
.	O

About	O
50	O
%	O
of	O
the	O
Me	O
ester	O
is	O
converted	O
into	O
the	O
FA	O
as	O
the	O
sole	O
metabolite	O
within	O
5	O
min	O
of	O
incubation	O
.	O

Hence	O
,	O
the	O
rapid	O
initial	O
phase	O
of	O
the	O
calcium	O
profile	O
of	O
the	O
Me	O
ester	O
of	O
HxA3	O
is	O
due	O
to	O
a	O
large	O
part	O
to	O
the	O
Me	O
ester	O
form	O
itself	O
while	O
the	O
prolonged	O
phase	O
occurs	O
during	O
and	O
subsequent	O
to	O
the	O
formation	O
of	O
the	O
FA	O
.	O

The	O
important	O
experiment	O
in	O
Fig.	O
1	O
C	O
(	O
bottom	O
trace	O
)	O
demonstrates	O
that	O
the	O
FA	O
is	O
also	O
active	O
on	O
intracellular	O
stores	O
to	O
cause	O
the	O
release	O
of	O
intracellular	O
calcium	O
,	O
i.e.	O
it	O
has	O
dual	O
actions	O
.	O

These	O
experiments	O
demonstrate	O
that	O
HxA3	O
,	O
both	O
as	O
the	O
FA	O
as	O
well	O
as	O
the	O
Me	O
ester	O
,	O
are	O
taken	O
up	O
into	O
the	O
cell	O
and	O
act	O
to	O
release	O
calcium	O
from	O
intracellular	O
stores	O
.	O

Within	O
the	O
time	O
frame	O
of	O
initial	O
action	O
(	O
rapid	O
phase	O
,	O
1	O
min	O
)	O
,	O
studies	O
with	O
tritiated	O
HxA3	O
show	O
that	O
the	O
Me	O
ester	O
is	O
not	O
substantially	O
hydrolyzed	O
into	O
the	O
FA	O
,	O
although	O
this	O
takes	O
place	O
subsequently	O
and	O
is	O
likely	O
involved	O
in	O
calcium	O
influx	O
.	O

Supporting	O
this	O
is	O
the	O
finding	O
that	O
the	O
second	O
phase	O
of	O
calcium	O
response	O
is	O
equally	O
pronounced	O
when	O
the	O
FA	O
is	O
used	O
(	O
Fig.	O
1	O
B	O
)	O
and	O
is	O
absent	O
in	O
calcium	O
-	O
free	O
medium	O
(	O
Fig.	O
1	O
C	O
)	O
.	O

Finally	O
,	O
caution	O
should	O
be	O
exerted	O
in	O
the	O
choice	O
of	O
vehicle	O
as	O
we	O
show	O
that	O
DMSO	O
interacts	O
with	O
the	O
FA	O
form	O
of	O
HxA3	O
(	O
likely	O
through	O
formation	O
of	O
a	O
polar	O
hydrogen	O
-	O
bonded	O
DMSO	O
-	O
HxA3	O
adduct	O
[	O
10	O
]	O
)	O
making	O
the	O
adduct	O
incapable	O
of	O
entering	O
the	O
cell	O
and	O
rendering	O
HxA3	O
inactive	O
.	O

In	O
ethanol	O
as	O
vehicle	O
,	O
the	O
FA	O
enters	O
the	O
cell	O
where	O
it	O
is	O
capable	O
both	O
of	O
releasing	O
calcium	O
from	O
intracellular	O
stores	O
(	O
see	O
Fig.	O
1	O
C	O
)	O
and	O
causing	O
influx	O
of	O
extracellular	O
calcium	O
(	O
compare	O
Fig.	O
1	O
B	O
and	O
C	O
)	O
.	O

Similar	O
findings	O
were	O
observed	O
with	O
Hx	O
binding	O
studies	O
.	O

The	O
FA	O
dissolved	O
in	O
DMSO	O
did	O
not	O
bind	O
to	O
intact	O
neutrophils	O
but	O
did	O
bind	O
to	O
membranes	O
from	O
disrupted	O
cells	O
,	O
while	O
the	O
Me	O
ester	O
was	O
equally	O
well	O
bound	O
to	O
the	O
intact	O
cell	O
as	O
well	O
as	O
disrupted	O
cells	O
[	O
3	O
]	O
.	O

Acknowledgements	O
This	O
study	O
was	O
supported	O
by	O
a	O
Grant	O
(	O
MT-4181	O
)	O
to	O
CRP	O
-	O
A	O
from	O
the	O
Medical	O
Research	O
Council	O
of	O
Canada	O
and	O
from	O
FO	O
/	O
FUB	O
to	O
SN	O
.	O

Manoalide	O
is	O
a	O
potent	O
analgesic	O
and	O
antiinflammatory	O
sesterterpene	O
isolated	O
in	O
1980	O
from	O
a	O
marine	B
sponge	I
.	O

The	O
antiinflammatory	O
activity	O
of	O
manoalide	O
is	O
due	O
to	O
inhibition	O
of	O
PLA2	O
,	O
through	O
irreversible	O
binding	O
to	O
several	O
lysine	O
residues	O
.	O

The	O
binding	O
is	O
realized	O
by	O
means	O
of	O
the	O
two	O
masked	O
aldehyde	O
functions	O
present	O
in	O
the	O
polar	O
part	O
of	O
manoalide	O
.	O

Of	O
the	O
two	O
aldehyde	O
groups	O
,	O
only	O
that	O
present	O
in	O
the	O
g	O
-	O
hydroxybutenolide	O
ring	O
seems	O
to	O
be	O
essential	O
,	O
since	O
cacospongionolides	O
,	O
naturally	O
occurring	O
analogues	O
lacking	O
the	O
second	O
masked	O
aldehyde	O
group	O
,	O
were	O
also	O
shown	O
to	O
be	O
irreversible	O
PLA2	O
inhibitors	O
.	O

It	O
appears	O
that	O
the	O
minimum	O
structural	O
requirement	O
for	O
exhibiting	O
manoalide	O
-	O
like	O
PLA2	O
inhibition	O
would	O
be	O
the	O
presence	O
in	O
the	O
inhibitor	O
of	O
functional	O
groups	O
able	O
to	O
seize	O
the	O
amino	O
groups	O
of	O
PLA2	O
lysine	O
residues	O
with	O
formation	O
of	O
stable	O
covalent	O
bonds	O
.	O

Many	O
manoalide	O
analogues	O
have	O
been	O
isolated	O
from	O
marine	B
sponges	I
,	I
most	O
of	O
them	O
sharing	O
PLA2	O
inhibitory	O
properties	O
.	O

Other	O
interesting	O
bioactivities	O
have	O
also	O
been	O
reported	O
for	O
some	O
of	O
these	O
compounds	O
.	O

Bis	O
(	O
monoacylglycerol	O
)	O
phosphate	O
(	O
BMP	O
)	O
was	O
first	O
described	O
in	O
1967	O
by	O
Body	O
and	O
Gray	O
[	O
1	O
]	O
,	O
and	O
was	O
shown	O
by	O
Waite	O
et	O
al.	O
[	O
2	O
]	O
to	O
be	O
synthesized	O
in	O
alveolar	O
macrophages	O
from	O
exogenous	O
phosphatidylglycerol	O
(	O
PG	O
)	O
.	O

BMP	O
is	O
a	O
unique	O
phospholipid	O
having	O
a	O
sn	O
-1	O
rather	O
than	O
sn	O
-3	O
glycerol	O
phosphate	O
ester	O
[	O
3	O
]	O
and	O
one	O
acyl	O
group	O
attached	O
to	O
each	O
of	O
the	O
glycerol	O
moieties	O
.	O

While	O
it	O
is	O
unclear	O
whether	O
the	O
acyl	O
esters	O
are	O
at	O
the	O
primary	O
or	O
secondary	O
hydroxyl	O
[	O
4,5	O
]	O
,	O
the	O
acyl	O
groups	O
of	O
BMP	O
are	O
unusually	O
rich	O
in	O
polyunsaturated	O
species	O
[	O
5–7	O
]	O
which	O
implies	O
acyl	O
linkage	O
at	O
the	O
sn	O
-2	O
and	O
sn	O
-2′	O
positions	O
.	O

We	O
proposed	O
a	O
biochemical	O
pathway	O
by	O
which	O
BMP	O
is	O
synthesized	O
but	O
this	O
remains	O
to	O
be	O
proven	O
(	O
Scheme	O
1	O
)	O
[	O
8	O
]	O
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
characterizing	O
the	O
enzymes	O
that	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
BMP	O
from	O
PG	O
.	O

In	O
this	O
proposed	O
pathway	O
,	O
PG	O
,	O
presumably	O
from	O
lung	O
surfactant	O
,	O
is	O
taken	O
into	O
the	O
cell	O
and	O
metabolized	O
to	O
BMP	O
.	O

There	O
is	O
reason	O
to	O
suggest	O
that	O
BMP	O
synthesis	O
occurs	O
in	O
the	O
endosomal	O
system	O
since	O
a	O
role	O
for	O
BMP	O
in	O
the	O
endosomal	O
function	O
has	O
recently	O
been	O
proposed	O
[	O
9	O
]	O
.	O

The	O
first	O
proposed	O
step	O
in	O
conversion	O
to	O
BMP	O
is	O
the	O
hydrolysis	O
of	O
PG	O
catalyzed	O
by	O
a	O
lysosomal	O
PLA2	O
to	O
form	O
1-acyl	O
-	O
sn	O
-glycero-3-phospho	O
-	O
rac	O
-glycerol	O
(	O
LPG	O
)	O
.	O

In	O
the	O
second	O
step	O
,	O
sn	O
-3	O
:	O
sn	O
-1′	O
LPG	O
is	O
acylated	O
on	O
the	O
head	O
group	O
(	O
prime	O
designation	O
)	O
glycerol	O
with	O
an	O
acyl	O
group	O
from	O
a	O
donor	O
phospholipid	O
.	O

The	O
next	O
step	O
proposed	O
is	O
the	O
reorientation	O
of	O
the	O
phosphoryl	O
ester	O
from	O
the	O
sn	O
-3	O
to	O
the	O
sn	O
-1	O
position	O
,	O
with	O
liberation	O
of	O
the	O
sn	O
-1	O
linked	O
acyl	O
chain	O
concomitant	O
to	O
the	O
phosphoryl	O
migration	O
[	O
10	O
]	O
.	O

While	O
this	O
proposal	O
provides	O
the	O
energy	O
and	O
specificity	O
for	O
the	O
transfer	O
of	O
the	O
phosphate	O
to	O
the	O
sn	O
-1	O
position	O
,	O
it	O
has	O
yet	O
to	O
be	O
demonstrated	O
in	O
a	O
cell	O
homogenate	O
.	O

The	O
final	O
proposed	O
step	O
is	O
a	O
second	O
transacylation	O
to	O
incorporate	O
an	O
acyl	O
chain	O
into	O
the	O
original	O
backbone	O
glycerol	O
(	O
non	O
-	O
prime	O
designation	O
)	O
of	O
sn	O
-1	O
:	O
sn	O
-1′	O
LPG	O
.	O

If	O
the	O
sn	O
-2	O
chain	O
of	O
a	O
phospholipid	O
were	O
the	O
substrate	O
for	O
the	O
transacylation	O
steps	O
,	O
the	O
final	O
BMP	O
structure	O
would	O
contain	O
the	O
expected	O
polyunsaturated	O
fatty	O
acid	O
.	O

Various	O
groups	O
have	O
shown	O
that	O
diacyl	O
phospholipid	O
stimulates	O
the	O
conversion	O
of	O
sn	O
-3	O
:	O
sn	O
-1′	O
LPG	O
to	O
sn	O
-3	O
:	O
sn	O
-1′	O
BMP	O
(	O
Scheme	O
1	O
step	O
2	O
)	O
.	O

Our	O
studies	O
[	O
8	O
]	O
showed	O
that	O
the	O
lipid	O
product	O
of	O
the	O
reaction	O
catalyzed	O
by	O
the	O
partially	O
purified	O
transacylase	O
was	O
BMP	O
,	O
as	O
predicted	O
in	O
Scheme	O
1	O
.	O

Matsuzawa	O
et	O
al.	O
[	O
11	O
]	O
earlier	O
reported	O
that	O
PI	O
was	O
preferentially	O
used	O
by	O
a	O
rat	B
liver	O
lysosomal	O
transacylase	O
to	O
form	O
BMP	O
,	O
whereas	O
the	O
work	O
of	O
Huterer	O
and	O
Wherett	O
[	O
12	O
]	O
indicated	O
that	O
the	O
acyl	O
moiety	O
from	O
either	O
the	O
sn	O
-1	O
or	O
sn	O
-2	O
position	O
of	O
PC	O
was	O
incorporated	O
into	O
BMP	O
.	O

Huterer	O
et	O
al.	O
[	O
13	O
]	O
proposed	O
that	O
the	O
lysosomal	O
PLA1	O
is	O
also	O
a	O
transacylase	O
and	O
could	O
be	O
responsible	O
for	O
the	O
formation	O
of	O
BMP	O
and	O
acylphosphatidylglycerol	O
(	O
APG	O
)	O
.	O

The	O
stereoconfiguration	O
of	O
the	O
BMP	O
formed	O
was	O
not	O
determined	O
in	O
the	O
later	O
reports	O
.	O

Considering	O
the	O
differences	O
in	O
these	O
reports	O
,	O
we	O
felt	O
it	O
necessary	O
to	O
more	O
clearly	O
define	O
the	O
transacylation	O
step	O
(	O
Scheme	O
1	O
step	O
2	O
)	O
.	O

In	O
particular	O
,	O
we	O
set	O
out	O
to	O
establish	O
what	O
the	O
substrate	O
(	O
s	O
)	O
for	O
the	O
reaction	O
are	O
and	O
if	O
indeed	O
the	O
presence	O
of	O
polyunsaturated	O
fatty	O
acids	O
in	O
BMP	O
was	O
accounted	O
for	O
by	O
this	O
transacylation	O
.	O

To	O
our	O
surprise	O
LPG	O
served	O
as	O
both	O
the	O
acyl	O
donor	O
and	O
acyl	O
acceptor	O
,	O
even	O
though	O
diradyl	O
phospholipid	O
enhanced	O
activity	O
several	O
-	O
fold	O
.	O

The	O
data	O
supporting	O
this	O
conclusion	O
are	O
reported	O
herein	O
.	O

2	O
Methods	O
and	O
materials	O
2.1	O

Materials	O
RAW	B
264.7	I
(	O
murine	B
monocytic	I
,	I
macrophage	I
like	I
,	I
Abelson	I
leukemia	I
virus	I
transformed	I
BALB	I
/	I
c	I
)	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Tissue	O
Culture	O
.	O

Tissue	O
culture	O
medium	O
was	O
from	O
Gibco	O
.	O

Phospholipids	O
(	O
except	O
for	O
RAW	B
264.7	I
lipid	O
)	O
were	O
from	O
Avanti	O
Polar	O
Lipids	O
.	O

Salts	O
,	O
buffers	O
,	O
and	O
organic	O
solvents	O
were	O
from	O
Fisher	O
.	O

Protein	O
assay	O
reagents	O
were	O
from	O
Pierce	O
and	O
microconcentrators	O
were	O
from	O
Amicon	O
.	O

S-300	O
column	O
matrix	O
was	O
from	O
Pharmacia	O
.	O

Silica	O
gel	O
G	O
plates	O
were	O
from	O
Analtech	O
.	O

Preparative	O
enzymes	O
were	O
from	O
Sigma	O
.	O

The	O
1-acyl	O
[	O
1,2,3	O
-	O
3	O
H	O
]	O
-sn	O
-glycero-3-phospho	O
-	O
rac	O
-glycerol	O
(	O
[	O
3	O
H	O
]	O
LPG	O
)	O
was	O
synthesized	O
as	O
described	O
earlier	O
[	O
14	O
]	O
.	O

2.2	O
Cell	O
culture	O
RAW	B
264.7	I
cells	O
were	O
grown	O
in	O
Dulbecco	O
's	O
minimum	O
essential	O
medium	O
with	O
10	O
mM	O
HEPES	O
,	O
pH	O
7.4	O
,	O
4.5	O
g	O
/	O
l	O
of	O
d	O
-glucose	O
,	O
584	O
mg	O
/	O
l	O
of	O
l	O
-glutamine	O
,	O
110	O
mg	O
/	O
l	O
of	O
sodium	O
pyruvate	O
,	O
4	O
mg	O
/	O
l	O
of	O
pyridoxal	O
HCl	O
,	O
10	O
%	O
heat	O
inactivated	O
FBS	O
(	O
by	O
volume	O
)	O
in	O
an	O
atmosphere	O
supplemented	O
with	O
5	O
%	O
CO2	O
.	O

These	O
cells	O
were	O
grown	O
to	O
confluence	O
in	O
15	O
ml	O
of	O
medium	O
in	O
a	O
75	O
cm2	O
flask	O
,	O
then	O
passaged	O
into	O
150	O
ml	O
of	O
medium	O
in	O
225	O
cm2	O
plates	O
.	O

Once	O
the	O
population	O
reached	O
1	O
×	O
108	O
total	O
cells	O
,	O
the	O
cells	O
were	O
passed	O
into	O
200	O
ml	O
of	O
medium	O
and	O
transferred	O
to	O
a	O
500	O
ml	O
cell	O
culture	O
stir	O
bottle	O
and	O
placed	O
in	O
a	O
second	O
incubator	O
.	O

Since	O
this	O
incubator	O
did	O
not	O
have	O
a	O
CO2	O
atmosphere	O
supplementation	O
system	O
,	O
the	O
medium	O
buffering	O
capacity	O
was	O
increased	O
with	O
additional	O
HEPES	O
(	O
pH	O
7.4	O
,	O
20	O
mM	O
)	O
.	O

Suspension	O
cultures	O
were	O
initiated	O
with	O
5	O
×	O
105	O
cells	O
/	O
ml	O
and	O
allowed	O
to	O
proliferate	O
until	O
reaching	O
approx	O
.	O

2	O
×	O
106	O
/ml	O
.	O

They	O
were	O
then	O
passed	O
into	O
600	O
ml	O
of	O
medium	O
in	O
a	O
1	O
l	O
culture	O
bottle	O
and	O
allowed	O
to	O
grow	O
until	O
the	O
population	O
reached	O
6	O
×	O
108	O
cells	O
at	O
which	O
time	O
the	O
cells	O
were	O
taken	O
for	O
LPG	O
transacylase	O
(	O
TA	O
)	O
isolation	O
.	O

2.3	O
Transacylase	O
isolation	O
RAW	B
264.7	I
(	O
6	O
×	O
108	O
)	O
cells	O
were	O
pelleted	O
from	O
medium	O
by	O
centrifugation	O
at	O
1000	O
×	O
g	O
,	O
resuspended	O
,	O
then	O
washed	O
twice	O
by	O
centrifugation	O
in	O
ice	O
cold	O
0.9	O
%	O
saline	O
.	O

Cells	O
were	O
resuspended	O
in	O
5	O
ml	O
of	O
1	O
mM	O
NaHCO3	O
and	O
lipids	O
were	O
removed	O
by	O
adding	O
an	O
equal	O
volume	O
of	O
water	O
-	O
saturated	O
1-butanol	O
.	O

The	O
mixture	O
was	O
vortexed	O
for	O
15	O
s	O
,	O
placed	O
on	O
ice	O
for	O
2	O
min	O
,	O
then	O
the	O
phases	O
were	O
separated	O
by	O
centrifugation	O
at	O
20	O
000	O
×	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
.	O

The	O
aqueous	O
(	O
lower	O
)	O
layer	O
was	O
applied	O
to	O
an	O
S-300	O
column	O
(	O
1.5	O
cm	O
×	O
84	O
cm	O
)	O
which	O
had	O
been	O
previously	O
equilibrated	O
in	O
10	O
mM	O
Tris	O
,	O
pH	O
7.4	O
,	O
and	O
eluted	O
with	O
the	O
same	O
buffer	O
at	O
a	O
flow	O
rate	O
of	O
0.55	O
ml	O
/	O
min	O
.	O

Fifty	O
fractions	O
of	O
2.2	O
ml	O
were	O
collected	O
from	O
the	O
S-300	O
column	O
,	O
assayed	O
for	O
TA	O
activity	O
,	O
and	O
those	O
fractions	O
exhibiting	O
TA	O
activity	O
were	O
pooled	O
.	O

Pooled	O
TA	O
intended	O
for	O
experiments	O
utilizing	O
gas	O
chromatography	O
(	O
GC	O
)	O
or	O
mass	O
spectrometry	O
(	O
MS	O
)	O
analysis	O
were	O
concentrated	O
using	O
an	O
Amicon	O
filtration	O
system	O
.	O

Pooled	O
fractions	O
were	O
then	O
assayed	O
for	O
total	O
protein	O
concentration	O
.	O

2.4	O
Transacylase	O
assay	O
For	O
each	O
assay	O
,	O
10	O
nmol	O
of	O
diradyl	O
lipid	O
,	O
[	O
3	O
H	O
]	O
LPG	O
(	O
5	O
×	O
104	O
DPM	O
,	O
200	O
pmol	O
)	O
and	O
10	O
nmol	O
of	O
1-myristoyl	O
LPG	O
were	O
dried	O
under	O
a	O
stream	O
of	O
N2	O
and	O
0.1	O
ml	O
of	O
1	O
M	O
Na	O
acetate	O
,	O
pH	O
4.5	O
was	O
added	O
.	O

The	O
lipids	O
were	O
sonically	O
dispersed	O
and	O
0.1	O
ml	O
of	O
the	O
solution	O
was	O
aliquoted	O
to	O
the	O
various	O
tubes	O
.	O

Seventy	O
-	O
five	O
μg	O
of	O
the	O
TA	O
were	O
added	O
to	O
each	O
tube	O
,	O
the	O
reaction	O
volume	O
was	O
adjusted	O
to	O
1	O
ml	O
with	O
water	O
,	O
and	O
samples	O
were	O
incubated	O
for	O
1	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
reactions	O
were	O
stopped	O
and	O
the	O
lipids	O
extracted	O
by	O
the	O
method	O
of	O
Bligh	O
and	O
Dyer	O
[	O
15	O
]	O
.	O

The	O
organic	O
phase	O
was	O
evaporated	O
under	O
N2	O
,	O
and	O
lipids	O
were	O
spotted	O
on	O
a	O
silica	O
G	O
plate	O
in	O
methanol	O
and	O
separated	O
by	O
a	O
thin	O
layer	O
chromatography	O
(	O
TLC	O
)	O
system	O
containing	O
chloroform	O
/	O
methanol	O
/	O
ammonium	O
hydroxide	O
(	O
130:70:10	O
v	O
/	O
v	O
/	O
v	O
)	O
(	O
R	O
f	O
values	O
:	O
LPG	O
0.27	O
,	O
PG	O
0.40	O
,	O
BMP	O
0.53	O
)	O
.	O

Radioactive	O
lipids	O
were	O
visualized	O
by	O
scanning	O
the	O
TLC	O
plate	O
using	O
a	O
Bioscanner	O
detector	O
and	O
compared	O
to	O
authentic	O
standards	O
.	O

Silica	O
,	O
containing	O
the	O
radioactive	O
products	O
,	O
was	O
scraped	O
from	O
the	O
plate	O
into	O
a	O
scintillation	O
vial	O
and	O
then	O
counted	O
in	O
a	O
liquid	O
scintillation	O
counter	O
and	O
TA	O
activity	O
was	O
determined	O
as	O
the	O
percentage	O
of	O
the	O
radiolabeled	O
BMP	O
formed	O
compared	O
to	O
the	O
sum	O
of	O
radioactivity	O
from	O
the	O
silica	O
plate	O
plus	O
the	O
methanol	O
/	O
water	O
phase	O
of	O
the	O
extract	O
.	O

This	O
percentage	O
was	O
converted	O
to	O
mass	O
based	O
on	O
the	O
specific	O
radioactivity	O
of	O
the	O
substrate	O
.	O

Due	O
to	O
enzyme	O
instability	O
,	O
experiments	O
were	O
completed	O
within	O
1–2	O
days	O
of	O
preparation	O
.	O

Even	O
so	O
,	O
considerable	O
variability	O
in	O
specific	O
enzymatic	O
activity	O
existed	O
between	O
preparations	O
.	O

2.5	O
Gas	O
chromatographic	O
analysis	O
Fatty	O
acid	O
methyl	O
esters	O
were	O
prepared	O
and	O
examined	O
by	O
the	O
method	O
of	O
Wang	O
and	O
Peter	O
[	O
16	O
]	O
.	O

The	O
lipids	O
were	O
separated	O
by	O
TLC	O
and	O
5	O
μg	O
of	O
pentadecanoic	O
acid	O
(	O
C15:0	O
)	O
in	O
hexane	O
was	O
pipetted	O
onto	O
each	O
zone	O
of	O
the	O
silica	O
plate	O
to	O
be	O
scraped	O
.	O

In	O
these	O
and	O
experiments	O
employing	O
MS	O
,	O
a	O
trace	O
amount	O
of	O
[	O
3	O
H	O
]	O
LPG	O
was	O
included	O
to	O
localize	O
BMP	O
on	O
the	O
TLC	O
plate	O
.	O

One	O
ml	O
of	O
7	O
%	O
HCl	O
in	O
MeOH	O
was	O
added	O
to	O
the	O
scraped	O
silica	O
,	O
vortexed	O
,	O
and	O
heated	O
to	O
100	O
°	O
C	O
for	O
15	O
min	O
.	O

After	O
cooling	O
to	O
0	O
°	O
C	O
,	O
2	O
ml	O
of	O
hexane	O
were	O
added	O
followed	O
by	O
the	O
addition	O
of	O
1	O
ml	O
of	O
2.5	O
N	O
NaOH	O
.	O

The	O
hexane	O
was	O
collected	O
,	O
the	O
samples	O
were	O
extracted	O
again	O
with	O
2	O
ml	O
of	O
hexane	O
and	O
the	O
hexane	O
was	O
dried	O
under	O
N2	O
.	O

The	O
fatty	O
acid	O
methyl	O
esters	O
were	O
dissolved	O
in	O
100	O
μl	O
of	O
undecane	O
and	O
analyzed	O
by	O
gas	O
chromatography	O
/	O
flame	O
ionization	O
detection	O
(	O
GC	O
/	O
FID	O
)	O
.	O

2.6	O
MS	O
analysis	O
MS	O
analysis	O
was	O
conducted	O
by	O
the	O
method	O
of	O
Lehmann	O
[	O
17	O
]	O
.	O

BMP	O
was	O
isolated	O
by	O
TLC	O
,	O
dissolved	O
in	O
250	O
μl	O
of	O
MeOH	O
:	O
MeCl2	O
1:1	O
,	O
injected	O
into	O
a	O
VG	O
Quattro	O
II	O
triple	O
quadrupole	O
mass	O
spectrometer	O
,	O
and	O
resultant	O
data	O
analyzed	O
using	O
Masslynx	O
software	O
.	O

Both	O
parent	O
and	O
daughter	O
ions	O
were	O
detected	O
over	O
a	O
range	O
from	O
200	O
to	O
900	O
m	O
/	O
z	O
.	O

Ion	O
spectra	O
were	O
assigned	O
acyl	O
compositions	O
based	O
on	O
detected	O
ion	O
molecular	O
weight	O
and	O
previously	O
determined	O
standards	O
.	O

Parent	O
ions	O
were	O
detected	O
in	O
the	O
first	O
quadrupole	O
,	O
ionized	O
in	O
the	O
second	O
quadrupole	O
and	O
daughter	O
ions	O
corresponding	O
to	O
acyl	O
chains	O
esterified	O
on	O
BMP	O
detected	O
in	O
the	O
third	O
quadrupole	O
.	O

3	O
Results	O
Studies	O
reported	O
thus	O
far	O
have	O
not	O
established	O
systematically	O
the	O
optimal	O
conditions	O
for	O
the	O
TA	O
.	O

For	O
these	O
studies	O
,	O
it	O
is	O
important	O
to	O
remove	O
contaminating	O
phospholipases	O
that	O
may	O
hydrolyze	O
substrates	O
and/or	O
products	O
.	O

Previous	O
work	O
from	O
our	O
lab	O
demonstrates	O
that	O
lysosomal	O
PLA	O
activity	O
was	O
minimal	O
in	O
our	O
transacylase	O
preparation	O
and	O
that	O
no	O
ATP	O
and	O
CoA	O
dependent	O
transacylases	O
were	O
present	O
[	O
8	O
]	O
.	O

We	O
first	O
demonstrated	O
that	O
the	O
reaction	O
was	O
linear	O
for	O
30	O
min	O
using	O
our	O
standard	O
assay	O
conditions	O
,	O
and	O
although	O
at	O
a	O
somewhat	O
decreased	O
rate	O
,	O
the	O
enzyme	O
was	O
active	O
up	O
to	O
90	O
min	O
(	O
data	O
not	O
shown	O
)	O
.	O

Optimal	O
activity	O
was	O
observed	O
between	O
pH	O
4.0	O
and	O
5.5	O
,	O
as	O
previously	O
reported	O
with	O
lower	O
concentrations	O
of	O
substrate	O
[	O
8	O
]	O
.	O

We	O
also	O
showed	O
using	O
10	O
or	O
30	O
μM	O
LPG	O
that	O
lipids	O
extracted	O
from	O
the	O
RAW	B
264.7	I
cells	O
stimulated	O
the	O
TA	O
in	O
concentrations	O
up	O
to	O
50	O
μM.	O
Since	O
it	O
would	O
be	O
difficult	O
to	O
define	O
the	O
substrates	O
involved	O
in	O
transacylation	O
using	O
total	O
lipid	O
extracts	O
,	O
we	O
used	O
synthetic	O
substrates	O
with	O
defined	O
acyl	O
groups	O
,	O
with	O
the	O
exception	O
of	O
the	O
[	O
3	O
H	O
]	O
LPG	O
which	O
contained	O
mainly	O
palmitate	O
.	O

The	O
[	O
3	O
H	O
]	O
LPG	O
used	O
was	O
present	O
in	O
trace	O
amounts	O
,	O
being	O
diluted	O
approx	O
.	O

100-fold	O
with	O
synthetic	O
1-myristoyl	O
LPG	O
.	O

Using	O
LPG	O
and	O
either	O
1-palmitoyl-2-oleoyl	O
-	O
sn	O
-glycero-3-phosphocholine	O
(	O
POPC	O
)	O
or	O
1-palmitoyl-2-oleoyl	O
-	O
sn	O
-glycero-3-phosphoethanolamine	O
(	O
POPE	O
)	O
,	O
we	O
find	O
a	O
concentration	O
dependence	O
of	O
both	O
the	O
LPG	O
and	O
the	O
POPC	O
(	O
Fig.	O
1A	O
,	O
B	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
POPE	O
did	O
not	O
stimulate	O
the	O
transacylase	O
(	O
Fig.	O
1B	O
)	O
.	O

The	O
concentration	O
dependence	O
of	O
LPG	O
and	O
POPC	O
showed	O
that	O
both	O
were	O
required	O
in	O
concentrations	O
above	O
1–3	O
μM	O
before	O
stimulation	O
was	O
seen	O
.	O

The	O
complexity	O
of	O
substrate	O
dependence	O
suggests	O
that	O
the	O
physical	O
state	O
of	O
the	O
substrate	O
may	O
regulate	O
the	O
TA	O
.	O

In	O
order	O
to	O
better	O
define	O
the	O
properties	O
of	O
the	O
reaction	O
we	O
investigated	O
the	O
effects	O
of	O
detergents	O
on	O
transacylation	O
(	O
Fig.	O
2A	O
)	O
.	O

Only	O
the	O
bile	O
acids	O
deoxycholic	O
acid	O
(	O
DOC	O
)	O
or	O
cholic	O
acid	O
(	O
CHO	O
)	O
were	O
seen	O
to	O
stimulate	O
activity	O
and	O
both	O
Tween	O
20	O
and	O
cetyltrimethylammonium	O
bromide	O
markedly	O
inhibited	O
at	O
20	O
μM.	O
The	O
stimulation	O
by	O
DOC	O
was	O
optimal	O
between	O
10	O
and	O
500	O
μM	O
while	O
it	O
became	O
inhibitory	O
above	O
that	O
concentration	O
(	O
Fig.	O
2B	O
)	O
.	O

At	O
pH	O
4.5	O
DOC	O
and	O
CHO	O
are	O
protonated	O
.	O

This	O
reduces	O
their	O
critical	O
micellar	O
concentration	O
and	O
may	O
account	O
for	O
their	O
stimulatory	O
properties	O
.	O

We	O
next	O
sought	O
to	O
determine	O
the	O
effects	O
on	O
transacylation	O
of	O
various	O
phospholipids	O
in	O
the	O
presence	O
of	O
20	O
μM	O
DOC	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
purpose	O
of	O
these	O
experiments	O
was	O
to	O
determine	O
whether	O
phospholipid	O
had	O
an	O
additional	O
stimulatory	O
effect	O
beyond	O
that	O
of	O
DOC	O
and	O
to	O
determine	O
whether	O
phospholipid	O
that	O
lacked	O
an	O
acyl	O
group	O
in	O
sn	O
-1	O
and	O
sn	O
-2	O
positions	O
would	O
stimulate	O
the	O
TA	O
.	O

In	O
this	O
case	O
a	O
plasmalogen	O
rich	O
PE	O
from	O
brain	O
was	O
stimulatory	O
.	O

Perhaps	O
the	O
most	O
striking	O
feature	O
of	O
Fig.	O
3	O
is	O
the	O
stimulation	O
by	O
1,2-dihexadecyl	O
-	O
sn	O
-glycero-3-phosphocholine	O
(	O
dialkyl	O
PC	O
)	O
,	O
a	O
phospholipid	O
with	O
ether	O
rather	O
than	O
ester	O
bonds	O
that	O
can	O
not	O
undergo	O
transacylation	O
.	O

This	O
indicates	O
that	O
the	O
stimulatory	O
effect	O
of	O
diradyl	O
phospholipids	O
on	O
transacylation	O
may	O
not	O
be	O
as	O
a	O
substrate	O
but	O
provides	O
a	O
favorable	O
lipid	O
milieu	O
.	O

Since	O
the	O
lipids	O
used	O
in	O
these	O
studies	O
have	O
defined	O
acyl	O
groups	O
,	O
we	O
determined	O
whether	O
an	O
acyl	O
group	O
is	O
transferred	O
from	O
PC	O
by	O
fatty	O
acid	O
analysis	O
of	O
the	O
product	O
BMP	O
.	O

Fig.	O
4	O
shows	O
the	O
acyl	O
composition	O
of	O
the	O
BMP	O
in	O
which	O
1-myristoyl	O
LPG	O
and	O
POPC	O
were	O
used	O
as	O
substrates	O
(	O
from	O
Fig.	O
1	O
)	O
.	O

As	O
determined	O
by	O
the	O
GC	O
,	O
myristate	O
was	O
the	O
predominant	O
fatty	O
acid	O
present	O
in	O
BMP	O
with	O
only	O
a	O
trace	O
of	O
the	O
acyl	O
groups	O
,	O
palmitate	O
and	O
oleate	O
,	O
from	O
the	O
POPC	O
being	O
used	O
in	O
the	O
biosynthesis	O
of	O
BMP	O
.	O

These	O
data	O
show	O
that	O
PC	O
does	O
not	O
participate	O
significantly	O
as	O
substrate	O
in	O
transacylation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
finding	O
that	O
dialkyl	O
PC	O
can	O
stimulate	O
transacylation	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
results	O
of	O
Fig.	O
4	O
were	O
verified	O
using	O
lipids	O
with	O
different	O
acyl	O
chains	O
to	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
TA	O
was	O
selecting	O
only	O
myristate	O
.	O

When	O
1-palmitoyl	O
LPG	O
and	O
1-myristoyl-2-stearoyl	O
-	O
sn	O
-glycero-3-phosphocholine	O
(	O
MSPC	O
)	O
were	O
used	O
in	O
combination	O
and	O
the	O
product	O
BMP	O
analyzed	O
by	O
electrospray	O
tandem	O
MS	O
,	O
the	O
mass	O
was	O
721	O
,	O
showing	O
that	O
BMP	O
contained	O
two	O
palmitate	O
chains	O
(	O
Fig.	O
5	O
)	O
.	O

In	O
this	O
experiment	O
MSPC	O
increased	O
transacylation	O
3-fold	O
which	O
indicates	O
that	O
MSPC	O
was	O
capable	O
of	O
stimulation	O
,	O
but	O
not	O
acyl	O
donation	O
.	O

Using	O
MS	O
we	O
could	O
also	O
determine	O
whether	O
the	O
TA	O
has	O
substrate	O
specificity	O
for	O
the	O
acyl	O
chains	O
.	O

We	O
analyzed	O
BMP	O
synthesized	O
from	O
reactions	O
that	O
contained	O
dialkyl	O
PC	O
and	O
mixed	O
LPGs	O
,	O
in	O
which	O
the	O
LPG	O
contained	O
either	O
myristate	O
,	O
palmitate	O
,	O
stearate	O
,	O
or	O
oleate	O
on	O
the	O
sn	O
-1	O
position	O
.	O

Fig.	O
6A	O
shows	O
that	O
all	O
of	O
the	O
saturated	O
fatty	O
acyl	O
moieties	O
on	O
LPG	O
were	O
present	O
in	O
BMP	O
synthesized	O
whereas	O
monounsaturated	O
oleate	O
was	O
not	O
.	O

(	O
In	O
other	O
experiments	O
,	O
not	O
shown	O
,	O
where	O
a	O
single	O
species	O
of	O
LPG	O
was	O
used	O
,	O
1-oleoyl	O
LPG	O
was	O
transacylated	O
to	O
a	O
low	O
extent	O
only	O
.	O
)	O

The	O
major	O
BMP	O
ion	O
at	O
721	O
m	O
/	O
z	O
could	O
be	O
a	O
mixture	O
of	O
myristoyl	O
/	O
stearoyl	O
BMP	O
and	O
dipalmitoyl	O
BMP	O
so	O
the	O
daughter	O
ions	O
were	O
determined	O
(	O
Fig.	O
6B	O
)	O
.	O

Although	O
the	O
daughter	O
ion	O
analysis	O
is	O
not	O
strictly	O
qualitative	O
,	O
it	O
appears	O
that	O
the	O
721	O
m	O
/	O
z	O
peak	O
contains	O
approximately	O
equimolar	O
amounts	O
of	O
myristate	O
,	O
palmitate	O
,	O
and	O
stearate	O
.	O

Table	O
1	O
has	O
the	O
quantitative	O
analysis	O
of	O
the	O
data	O
in	O
Fig.	O
6A	O
and	O
indicates	O
that	O
,	O
assuming	O
equal	O
amounts	O
of	O
dipalmitoyl	O
and	O
myristoyl	O
/	O
stearoyl	O
BMP	O
are	O
present	O
in	O
the	O
721	O
m	O
/	O
z	O
peak	O
,	O
the	O
TA	O
has	O
a	O
slight	O
preference	O
for	O
the	O
longer	O
chain	O
species	O
of	O
LPG	O
.	O

We	O
then	O
examined	O
the	O
relative	O
activity	O
of	O
1-palmitoyl	O
LPG	O
vs.	O
2-oleoyl	O
LPG	O
(	O
Fig.	O
7	O
)	O
.	O

We	O
had	O
studied	O
their	O
metabolism	O
earlier	O
with	O
low	O
concentrations	O
of	O
LPGs	O
but	O
without	O
stimulatory	O
diradyl	O
phospholipid	O
.	O

In	O
that	O
case	O
we	O
found	O
that	O
the	O
TA	O
had	O
approximately	O
equal	O
activity	O
on	O
the	O
two	O
LPG	O
species	O
[	O
8	O
]	O
.	O

For	O
the	O
study	O
reported	O
here	O
,	O
1-palmitoyl-2-oleoyl	O
-	O
sn	O
-glycero-3-phospho	O
-	O
rac	O
-glycerol	O
(	O
POPG	O
)	O
was	O
hydrolyzed	O
by	O
either	O
a	O
lipase	O
from	O
Rhizopus	B
arrhizus	I
var	I
.	I

delemer	B
,	O
which	O
yields	O
2-oleoyl	O
LPG	O
[	O
18	O
]	O
or	O
porcine	B
pancreatic	O
PLA2	O
,	O
which	O
yields	O
1-palmitoyl	O
LPG	O
[	O
19	O
]	O
.	O

When	O
used	O
as	O
substrates	O
singly	O
or	O
in	O
combination	O
,	O
the	O
1-palmitoyl	O
LPG	O
was	O
the	O
better	O
substrate	O
(	O
Fig.	O
6	O
)	O
.	O

Ideally	O
,	O
the	O
experiment	O
should	O
be	O
conducted	O
with	O
the	O
same	O
acyl	O
chain	O
present	O
in	O
either	O
the	O
sn	O
-1	O
or	O
sn	O
-2	O
position	O
.	O

Technically	O
this	O
was	O
not	O
possible	O
.	O

We	O
can	O
not	O
conclude	O
,	O
therefore	O
,	O
that	O
the	O
difference	O
in	O
transacylation	O
using	O
these	O
two	O
substrates	O
is	O
the	O
sole	O
result	O
of	O
the	O
position	O
of	O
the	O
acyl	O
group	O
.	O

Since	O
some	O
1-oleoyl	O
LPG	O
was	O
transacylated	O
in	O
samples	O
containing	O
1-oleoyl	O
LPG	O
and	O
dialkyl	O
PC	O
(	O
data	O
not	O
shown	O
)	O
it	O
appears	O
that	O
the	O
TA	O
does	O
not	O
exclude	O
naturally	O
occurring	O
2-acyl	O
LPG	O
that	O
has	O
an	O
unsaturated	O
acyl	O
chain	O
as	O
substrate	O
.	O

The	O
question	O
then	O
arose	O
,	O
is	O
the	O
TA	O
specific	O
for	O
LPG	O
or	O
can	O
other	O
lysolipids	O
serve	O
as	O
substrates	O
.	O

Fig.	O
8	O
shows	O
that	O
none	O
of	O
the	O
1-acyl	O
lysolipids	O
examined	O
were	O
substrates	O
at	O
10	O
or	O
100	O
μM	O
concentrations	O
.	O

Further	O
,	O
when	O
these	O
lysolipids	O
were	O
mixed	O
at	O
a	O
concentration	O
equal	O
to	O
LPG	O
,	O
inhibition	O
was	O
seen	O
.	O

While	O
not	O
studied	O
further	O
,	O
this	O
could	O
be	O
a	O
competitive	O
type	O
inhibition	O
or	O
the	O
result	O
of	O
surface	O
dilution	O
of	O
LPG	O
in	O
the	O
lipid	O
aggregate	O
.	O

4	O
Discussion	O
The	O
results	O
presented	O
here	O
show	O
that	O
the	O
TA	O
that	O
converts	O
LPG	O
to	O
BMP	O
is	O
intramolecular	O
involving	O
the	O
transfer	O
of	O
the	O
acyl	O
group	O
from	O
one	O
LPG	O
to	O
another	O
.	O

The	O
enzyme	O
,	O
previously	O
shown	O
to	O
be	O
independent	O
of	O
ATP	O
and	O
CoA	O
[	O
8	O
]	O
,	O
most	O
likely	O
involves	O
an	O
acyl	B
enzyme	O
intermediate	O
,	O
although	O
this	O
point	O
can	O
not	O
be	O
proven	O
since	O
both	O
acceptor	O
and	O
donor	O
are	O
always	O
present	O
.	O

The	O
physical	O
state	O
of	O
the	O
substrate	O
appears	O
to	O
play	O
a	O
significant	O
role	O
in	O
the	O
reaction	O
.	O

The	O
1-myristoyl	O
LPG	O
is	O
reported	O
to	O
have	O
a	O
high	O
critical	O
micellar	O
concentration	O
(	O
CMC	O
)	O
ranging	O
from	O
160	O
to	O
3000	O
μM	O
,	O
depending	O
on	O
the	O
presence	O
of	O
salt	O
[	O
20	O
]	O
.	O

Under	O
the	O
conditions	O
used	O
in	O
our	O
standard	O
assay	O
,	O
10	O
μM	O
LPG	O
,	O
most	O
substrate	O
,	O
if	O
not	O
all	O
,	O
is	O
monomeric	O
.	O

The	O
presence	O
of	O
diradyl	O
lipid	O
or	O
bile	O
acid	O
would	O
lead	O
to	O
partitioning	O
of	O
the	O
LPG	O
into	O
a	O
lipid	O
aggregate	O
such	O
as	O
a	O
bilayer	O
vesicle	O
or	O
a	O
mixed	O
micelle	O
.	O

If	O
so	O
,	O
the	O
enzyme	O
appears	O
to	O
prefer	O
a	O
lipid	O
/	O
H2	O
O	O
interface	O
over	O
monomolecular	O
dispersions	O
of	O
LPG	O
.	O

The	O
unusual	O
dependence	O
of	O
transacylation	O
on	O
both	O
the	O
LPG	O
and	O
PC	O
concentration	O
is	O
consistent	O
with	O
this	O
interpretation	O
(	O
Fig.	O
1	O
)	O
.	O

Where	O
increasing	O
amounts	O
of	O
POPC	O
(	O
1–100	O
μM	O
)	O
are	O
added	O
to	O
a	O
fixed	O
amount	O
of	O
LPG	O
(	O
30	O
μM	O
;	O
Fig.	O
1B	O
)	O
,	O
two	O
considerations	O
must	O
be	O
made	O
,	O
first	O
the	O
intermicellar	O
concentration	O
(	O
IMC	O
)	O
of	O
LPG	O
partitioning	O
into	O
POPC	O
,	O
and	O
second	O
the	O
surface	O
dilution	O
of	O
1-myristoyl	O
LPG	O
in	O
POPC	O
.	O

The	O
fact	O
that	O
POPC	O
does	O
not	O
increase	O
transacylation	O
until	O
the	O
threshold	O
of	O
10	O
μM	O
is	O
reached	O
,	O
but	O
continues	O
to	O
stimulate	O
to	O
100	O
μM	O
,	O
suggests	O
that	O
the	O
partitioning	O
of	O
LPG	O
into	O
the	O
lipid	O
interface	O
,	O
the	O
IMC	O
,	O
has	O
more	O
influence	O
on	O
transacylation	O
than	O
does	O
substrate	O
dilution	O
.	O

Comparison	O
of	O
POPC	O
and	O
POPE	O
(	O
Fig.	O
1B	O
)	O
also	O
suggests	O
that	O
not	O
all	O
lipid	O
/	O
H2	O
O	O
interfaces	O
support	O
transacylation	O
.	O

POPE	O
,	O
a	O
lipid	O
known	O
to	O
form	O
a	O
Hex	O
II	O
phase	O
[	O
21	O
]	O
,	O
was	O
without	O
effect	O
,	O
either	O
the	O
result	O
of	O
little	O
LPG	O
partitioning	O
into	O
the	O
POPE	O
or	O
a	O
lipid	O
polymorphic	O
structure	O
,	O
presumably	O
Hex	O
II	O
,	O
that	O
the	O
TA	O
is	O
unable	O
to	O
productively	O
bind	O
.	O

When	O
a	O
different	O
matrix	O
is	O
present	O
and	O
PE	O
is	O
added	O
with	O
DOC	O
,	O
stimulation	O
is	O
observed	O
(	O
Fig.	O
3	O
)	O
.	O

We	O
recognize	O
that	O
these	O
interpretations	O
are	O
speculative	O
without	O
data	O
on	O
the	O
lipid	O
structures	O
involved	O
.	O

They	O
do	O
provide	O
,	O
however	O
,	O
a	O
reasonable	O
approach	O
to	O
the	O
understanding	O
of	O
the	O
nature	O
of	O
the	O
lipid	O
mixtures	O
used	O
.	O

Previous	O
work	O
by	O
us	O
and	O
others	O
suggested	O
that	O
the	O
conversion	O
of	O
LPG	O
to	O
BMP	O
involves	O
transferring	O
an	O
acyl	O
chain	O
from	O
a	O
diacyl	O
phospholipid	O
[	O
8,11–13	O
]	O
.	O

Those	O
results	O
were	O
obtained	O
with	O
sub	O
-	O
μM	O
concentrations	O
of	O
LPG	O
and	O
transacylation	O
was	O
dependent	O
on	O
added	O
phospholipid	O
.	O

No	O
attempt	O
was	O
made	O
in	O
those	O
experiments	O
,	O
however	O
,	O
to	O
demonstrate	O
the	O
transfer	O
of	O
a	O
radiolabeled	O
fatty	O
acid	O
to	O
BMP	O
.	O

In	O
unpublished	O
experiments	O
we	O
found	O
that	O
a	O
few	O
percent	O
of	O
radiolabeled	O
fatty	O
acid	O
are	O
transferred	O
to	O
BMP	O
from	O
diradyl	O
phospholipids	O
,	O
relative	O
to	O
the	O
total	O
amount	O
of	O
BMP	O
synthesized	O
.	O

How	O
do	O
the	O
results	O
presented	O
here	O
reconcile	O
with	O
those	O
of	O
others	O
?	O

One	O
possible	O
explanation	O
is	O
that	O
multiple	O
transacylases	O
were	O
present	O
in	O
the	O
lysosomal	O
preparation	O
used	O
by	O
others	O
,	O
but	O
not	O
in	O
our	O
partially	O
purified	O
TA	O
.	O

For	O
example	O
,	O
Huterer	O
and	O
Wherett	O
showed	O
that	O
a	O
preparation	O
of	O
rat	B
liver	O
lysosomes	O
transferred	O
[	O
3	O
H	O
]	O
oleate	O
from	O
PC	O
to	O
form	O
BMP	O
[	O
22	O
]	O
.	O

However	O
,	O
the	O
vast	O
majority	O
of	O
the	O
oleate	O
was	O
released	O
as	O
a	O
free	O
oleate	O
and	O
less	O
than	O
1	O
%	O
was	O
recovered	O
in	O
BMP	O
.	O

Further	O
,	O
the	O
amount	O
of	O
BMP	O
formed	O
from	O
LPG	O
was	O
far	O
in	O
excess	O
of	O
the	O
amount	O
of	O
oleate	O
incorporated	O
.	O

These	O
data	O
are	O
consistent	O
with	O
our	O
results	O
here	O
that	O
show	O
little	O
,	O
if	O
any	O
,	O
BMP	O
is	O
formed	O
by	O
the	O
transfer	O
of	O
an	O
acyl	O
group	O
from	O
diradyl	O
lipids	O
.	O

The	O
different	O
transacylases	O
described	O
can	O
be	O
classified	O
as	O
follows:1	O
.	O

acyl	O
-	O
CoA	O
acyltransferases	O
;	O
2	O
.	O

CoA	O
independent	O
transacylases	O
;	O
3	O
.	O
lysophospholipases	O
;	O
4	O
.	O

LPG	O
transacylases	O
(	O
TA	O
)	O
.	O

The	O
acyl	O
-	O
CoA	O
acyltransferase	O
employs	O
an	O
acyl	O
-	O
CoA	O
formed	O
by	O
acyl	O
-	O
CoA	O
synthetase	O
in	O
microsomes	O
and	O
is	O
optimal	O
at	O
pH	O
7.5	O
[	O
23	O
]	O
.	O

These	O
characteristics	O
make	O
it	O
clearly	O
different	O
from	O
the	O
activity	O
described	O
here	O
.	O

The	O
CoA	O
independent	O
transacylase	O
is	O
an	O
enzyme	O
that	O
transfers	O
an	O
acyl	O
group	O
from	O
the	O
sn	O
-2	O
position	O
of	O
a	O
diradyl	O
phospholipid	O
to	O
a	O
lysolipid	O
[	O
24	O
]	O
.	O

If	O
that	O
were	O
the	O
enzyme	O
involved	O
we	O
would	O
expect	O
that	O
PG	O
would	O
be	O
formed	O
from	O
LPG	O
yet	O
none	O
was	O
detected	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
transfer	O
of	O
the	O
acyl	O
group	O
only	O
to	O
the	O
head	O
group	O
(	O
prime	O
)	O
glycerol	O
is	O
different	O
from	O
other	O
CoA	O
independent	O
transacylases	O
.	O

The	O
third	O
,	O
lysophospholipase	O
,	O
has	O
one	O
similarity	O
to	O
the	O
activity	O
reported	O
here	O
;	O
two	O
molecules	O
of	O
the	O
same	O
lysolipid	O
are	O
used	O
to	O
form	O
one	O
diradyl	O
phospholipid	O
[	O
25	O
]	O
.	O

This	O
enzyme	O
is	O
different	O
from	O
the	O
TA	O
in	O
two	O
important	O
respects	O
,	O
however	O
.	O

First	O
,	O
we	O
find	O
no	O
evidence	O
for	O
lysophospholipase	O
activity	O
in	O
the	O
TA	O
,	O
based	O
on	O
the	O
lack	O
of	O
fatty	O
acid	O
released	O
(	O
data	O
not	O
shown	O
)	O
.	O

Second	O
,	O
the	O
LPC	O
:	O
LPC	O
transacylase	O
has	O
a	O
broad	O
substrate	O
specificity	O
and	O
can	O
use	O
LPG	O
,	O
but	O
in	O
that	O
case	O
PG	O
,	O
not	O
BMP	O
,	O
is	O
formed	O
[	O
26	O
]	O
.	O

The	O
TA	O
described	O
here	O
,	O
therefore	O
,	O
appears	O
to	O
be	O
unique	O
.	O

How	O
do	O
the	O
findings	O
reported	O
here	O
fit	O
with	O
the	O
proposed	O
role	O
of	O
the	O
LPG	O
transacylase	O
in	O
Scheme	O
1	O
?	O

Scheme	O
2	O
provides	O
a	O
modification	O
of	O
the	O
TA	O
reaction	O
proposed	O
in	O
step	O
2	O
of	O
Scheme	O
1	O
.	O

Rather	O
than	O
utilizing	O
a	O
diacyl	O
phospholipid	O
in	O
transacylation	O
,	O
a	O
second	O
molecule	O
of	O
LPG	O
is	O
the	O
acyl	O
donor	O
with	O
the	O
production	O
of	O
glycerophosphoglycerol	O
(	O
GPG	O
)	O
in	O
addition	O
to	O
BMP	O
.	O

The	O
major	O
factor	O
that	O
can	O
not	O
be	O
accommodated	O
is	O
the	O
failure	O
of	O
the	O
TA	O
to	O
use	O
unsaturated	O
fatty	O
acids	O
significantly	O
.	O

We	O
must	O
conclude	O
that	O
polyunsaturated	O
fatty	O
acids	O
such	O
as	O
arachidonate	O
[	O
7	O
]	O
or	O
,	O
in	O
particular	O
,	O
docosahexanoate	O
[	O
27	O
]	O
are	O
incorporated	O
by	O
some	O
other	O
mechanism	O
.	O

Until	O
the	O
mechanism	O
of	O
stereochemical	O
rearrangement	O
is	O
defined	O
,	O
this	O
question	O
of	O
polyunsaturated	O
fatty	O
acid	O
incorporation	O
remains	O
open	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
National	O
Institutes	O
of	O
Health	O
HL-50395	O
and	O
National	O
Cancer	O
Institute	O
Comprehensive	O
Cancer	O
Center	O
of	O
Wake	O
Forest	O
Grant	O
CA-12197	O
.	O

Use	O
of	O
the	O
Tissue	O
Culture	O
Core	O
Laboratory	O
is	O
gratefully	O
acknowledged	O
.	O

We	O
especially	O
thank	O
Dr.	O
Mike	O
Thomas	O
and	O
Mike	O
Samuel	O
from	O
Wake	O
Forest	O
University	O
for	O
their	O
technical	O
support	O
in	O
examining	O
the	O
MS	O
samples	O
,	O
and	O
Dr.	O
Nick	O
Ralston	O
and	O
Dr.	O
Koji	O
Shinozaki	O
for	O
their	O
advice	O
and	O
assistance	O
in	O
the	O
laboratory	O
.	O

The	O
authors	O
attempted	O
to	O
evaluate	O
different	O
reagents	O
in	O
order	O
to	O
quantify	O
the	O
amino	O
groups	O
of	O
the	O
platelet	O
membrane	O
.	O

The	O
study	O
was	O
carried	O
out	O
by	O
the	O
action	O
of	O
different	O
aldehydes	O
and	O
acid	O
anhydrides	O
.	O

The	O
use	O
of	O
2,4,6-trinitrobenzenesulfonic	O
acid	O
made	O
possible	O
an	O
approach	O
by	O
electrophoresis	O
and	O
chemical	O
assay	O
.	O

The	O
results	O
showed	O
an	O
increase	O
in	O
the	O
surface	O
charge	O
corresponding	O
to	O
a	O
mean	O
number	O
of	O
amino	O
groups	O
varying	O
from	O
1.86.10	O
(	O
5	O
)	O
groups	O
with	O
citraconic	O
acid	O
to	O
3.94.10	O
(	O
5	O
)	O
groups	O
with	O
acetaldehyde	O
.	O

The	O
study	O
on	O
the	O
metabolism	O
after	O
oral	O
administration	O
of	O
chenodeoxycholic	O
acid-24	O
-	O
14C	O
was	O
performed	O
by	O
analysis	O
of	O
radioactivity	O
that	O
had	O
appeared	O
in	O
bile	O
and	O
feces	O
of	O
male	O
hamsters	B
.	O

The	O
radioactive	O
bile	O
acids	O
were	O
analyzed	O
by	O
thin	O
layer	O
chromatography	O
and	O
identified	O
by	O
the	O
isotope	O
dilution	O
method	O
.	O

In	O
the	O
bile	O
of	O
the	O
hamsters	B
with	O
bile	O
fistula	O
,	O
radioactivity	O
was	O
originated	O
from	O
unchanged	O
chenodeoxycholic	O
acid	O
for	O
the	O
most	O
part	O
,	O
and	O
7-ketolithocholic	O
acid	O
,	O
lithocholic	O
acid	O
,	O
and	O
beta	O
-	O
muricholic	O
acid	O
for	O
the	O
remainder	O
.	O

In	O
the	O
feces	O
lithocholic	O
acid	O
,	O
dehydrolithocholic	O
acid	O
,	O
isolithocholic	O
acid	O
,	O
and	O
unchanged	O
form	O
were	O
identified	O
.	O

After	O
the	O
multiple	O
dosing	O
of	O
chenodeoxycholic	O
acid-24	O
-	O
14C	O
for	O
6	O
days	O
,	O
beta	O
-	O
muricholic	O
acid	O
was	O
also	O
identified	O
in	O
the	O
feces	O
.	O

1	O
.	O

Normal	O
human	B
urine	O
contains	O
small	O
amounts	O
(	O
less	O
than	O
4	O
mg	O
/	O
g	O
of	O
creatinine	O
)	O
of	O
2-ethylhydracrylic	O
acid	O
,	O
formed	O
,	O
we	O
believe	O
,	O
by	O
a	O
previously	O
undisclosed	O
endogenous	O
catabolic	O
pathway	O
for	O
the	O
oxidation	O
of	O
a	O
newly	O
described	O
series	O
of	O
R	O
metabolites	O
of	O
isoleucine	O
.	O

2	O
.	O

Urinary	O
excretion	O
of	O
2-ethylhydracrylic	O
acid	O
is	O
variably	O
increased	O
in	O
defects	O
of	O
isoleucine	O
oxidation	O
at	O
distal	O
steps	O
in	O
the	O
catabolic	O
pathway	O
(	O
3-oxoacyl	O
-	O
CoA	O
thiolase	O
deficiency	O
and	O
methylmalonyl	O
-	O
CoA	O
mutase	O
deficiency	O
)	O
and	O
is	O
diminished	O
when	O
proximal	O
steps	O
of	O
the	O
oxidative	O
pathway	O
are	O
blocked	O
as	O
in	O
branched	O
-	O
chain	O
oxo	O
acid	O
decarboxylase	O
deficiency	O
(	O
'	O
maple	O
-	O
syrup	O
-	O
urine	O
'	O
disease	O
)	O
.	O

3	O
.	O
Precursors	O
of	O
R	O
-	O
pathway	O
metabolites	O
[	O
R	O
(	O
-	O
)	O
-2-methylbutyrate	O
and	O
2-ethylacrylate	O
]	O
lead	O
to	O
increased	O
2-ethylhydracrylate	O
excretion	O
in	O
the	O
mammal	B
(	O
rat	B
,	O
rabbit	B
and	O
dog	B
)	O
;	O
the	O
corresponding	O
S	O
metabolites	O
[	O
S	O
(	O
+	O
)	O
-2-methylbutyric	O
acid	O
and	O
tiglic	O
acid	O
]	O
,	O
when	O
given	O
in	O
equimolar	O
amounts	O
,	O
have	O
little	O
effect	O
on	O
its	O
excretion	O
,	O
suggesting	O
that	O
little	O
or	O
no	O
interconversion	O
between	O
S	O
and	O
R	O
metabolites	O
occurs	O
in	O
vivo	O
.	O

4	O
.	O
Studies	O
with	O
2H	O
-	O
labelled	O
precursors	O
indicate	O
that	O
conversion	O
of	O
R	O
2-methylbutyrate	O
into	O
2-ethylhydracrylic	O
acid	O
occurs	O
by	O
a	O
direct	O
pathway	O
(	O
apparently	O
via	O
2-ethylacrylic	O
acid	O
)	O
.	O

5	O
.	O

The	O
further	O
oxidation	O
of	O
2-ethylhydracrylic	O
acid	O
to	O
ethylmalonic	O
acid	O
was	O
demonstrated	O
,	O
and	O
may	O
be	O
analogous	O
to	O
S	O
-	O
metabolite	O
oxidation	O
via	O
methyl	O
malonate	O
.	O

6	O
.	O

Valine	O
metabolites	O
do	O
not	O
interact	O
with	O
the	O
R	O
=	O
isoleucine	O
pathway	O
under	O
the	O
conditions	O
of	O
these	O
experiments	O
in	O
vivo	O
.	O

In	O
six	O
persons	B
with	O
contact	O
allergy	O
to	O
chrysanthemum	B
of	O
florists	B
,	O
patch	O
tests	O
were	O
performed	O
with	O
25	O
sequiterpene	O
lactones	O
.	O

Positive	O
responses	O
were	O
observed	O
to	O
15	O
lactones	O
.	O

The	O
most	O
frequently	O
encountered	O
positive	O
responses	O
were	O
to	O
alantolactone	O
(	O
positive	O
in	O
all	O
cases	O
)	O
and	O
to	O
arbusculin	O
A	O
,	O
8-deoxycumambrin	O
,	O
ambrosin	O
,	O
damsin	O
and	O
psilostachynin	O
.	O

The	O
findings	O
corroborate	O
the	O
assumption	O
that	O
an	O
alpha	O
-	O
methylene	O
group	O
attached	O
to	O
the	O
gamma	O
-	O
lactone	O
ring	O
is	O
an	O
essential	O
prerequisite	O
for	O
allergenic	O
activity	O
of	O
sesquiterpene	O
lactones	O
.	O

Pyrethrum	B
produced	O
a	O
positive	O
reaction	O
in	O
one	O
of	O
the	O
patients	B
,	O
pyrethrins	O
gave	O
negative	O
reactions	O
in	O
all	O
.	O

Some	O
of	O
the	O
chrysanthemum	B
patients	B
were	O
also	O
hypersensitive	O
to	O
turpentine	O
and	O
colophony	O
and	O
to	O
garlic	B
,	O
primin	O
and	O
tars	O
.	O

Depression	O
is	O
a	O
common	O
condition	O
that	O
is	O
often	O
unrecognised	O
,	O
misdiagnosed	O
and/or	O
undertreated	O
.	O

It	O
is	O
associated	O
with	O
substantial	O
direct	O
,	O
indirect	O
and	O
intangible	O
costs	O
.	O

The	O
indirect	O
costs	O
of	O
lost	O
earnings	O
/	O
productivity	O
and	O
premature	O
death	O
account	O
for	O
the	O
majority	O
of	O
these	O
costs	O
;	O
drug	O
costs	O
account	O
for	O
only	O
about	O
1	O
to	O
2	O
%	O
of	O
total	O
costs	O
and	O
about	O
10	O
to	O
12	O
%	O
of	O
direct	O
costs	O
.	O

Thus	O
,	O
better	O
recognition	O
and	O
appropriate	O
treatment	O
of	O
depression	O
would	O
increase	O
the	O
direct	O
costs	O
associated	O
with	O
this	O
illness	O
,	O
but	O
would	O
also	O
have	O
the	O
potential	O
to	O
greatly	O
reduce	O
indirect	O
costs	O
and	O
consequently	O
the	O
overall	O
cost	O
of	O
depression	O
.	O

Because	O
of	O
their	O
higher	O
acquisition	O
costs	O
relative	O
to	O
tricyclic	O
antidepressants	O
(	O
TCAs	O
)	O
,	O
there	O
has	O
been	O
much	O
debate	O
about	O
whether	O
the	O
use	O
of	O
sertraline	O
or	O
other	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
for	O
first	O
-	O
line	O
treatment	O
of	O
depression	O
can	O
be	O
justified	O
.	O

While	O
these	O
agents	O
have	O
similar	O
efficacy	O
to	O
TCAs	O
,	O
they	O
are	O
better	O
tolerated	O
and	O
have	O
a	O
lower	O
risk	O
of	O
death	O
on	O
overdosage	O
.	O

Despite	O
the	O
large	O
economic	O
burden	O
of	O
depression	O
on	O
society	O
,	O
pharmacoeconomic	O
data	O
on	O
sertraline	O
and	O
antidepressant	O
drugs	O
in	O
general	O
are	O
scarce	O
.	O

Most	O
of	O
the	O
available	O
studies	O
on	O
sertraline	O
are	O
limited	O
to	O
considerations	O
of	O
direct	O
costs	O
and	O
do	O
not	O
assess	O
costs	O
from	O
a	O
societal	O
perspective	O
.	O

In	O
addition	O
,	O
a	O
number	O
of	O
studies	O
have	O
significant	O
methodological	O
problems	O
which	O
limit	O
determination	O
of	O
meaningful	O
conclusions	O
.	O

Nonetheless	O
,	O
data	O
from	O
2	O
more	O
recent	O
studies	O
with	O
fewer	O
methodological	O
problems	O
than	O
earlier	O
studies	O
indicated	O
that	O
sertraline	O
was	O
more	O
cost	O
-	O
effective	O
than	O
TCAs	O
because	O
of	O
fewer	O
psychiatrist	O
consultations	O
,	O
and	O
less	O
costly	O
than	O
fluoxetine	O
because	O
of	O
fewer	O
absences	O
from	O
work	O
and	O
fewer	O
medical	O
consultations	O
.	O

The	O
cost	O
-	O
utility	O
ratio	O
of	O
maintenance	O
therapy	O
of	O
depression	O
with	O
sertraline	O
appears	O
to	O
fall	O
within	O
the	O
range	O
of	O
accepted	O
cost	O
-	O
utility	O
ratios	O
of	O
common	O
healthcare	O
interventions	O
.	O

Thus	O
,	O
studies	O
to	O
date	O
have	O
generally	O
shown	O
that	O
overall	O
treatment	O
costs	O
with	O
sertraline	O
and	O
other	O
SSRIs	O
are	O
no	O
greater	O
than	O
those	O
for	O
TCAs	O
;	O
this	O
is	O
despite	O
the	O
lower	O
acquisition	O
costs	O
of	O
the	O
latter	O
agents	O
.	O

Therefore	O
,	O
it	O
is	O
clear	O
from	O
these	O
data	O
that	O
it	O
is	O
misleading	O
to	O
classify	O
antidepressant	O
agents	O
as	O
expensive	O
or	O
inexpensive	O
based	O
solely	O
on	O
their	O
acquisition	O
costs	O
.	O

Sertraline	O
,	O
therefore	O
,	O
can	O
be	O
considered	O
as	O
a	O
first	O
-	O
line	O
alternative	O
to	O
TCAs	O
and	O
other	O
SSRIs	O
for	O
the	O
treatment	O
of	O
depression	O
on	O
both	O
clinical	O
and	O
pharmacoeconomic	O
grounds	O
.	O

The	O
55-kDa	O
receptor	O
for	O
tumor	O
necrosis	O
factor	O
(	O
TR55	O
)	O
triggers	O
multiple	O
signaling	O
cascades	O
initiated	O
by	O
adapter	O
proteins	O
like	O
TRADD	O
and	O
FAN	O
.	O

By	O
use	O
of	O
the	O
primary	O
amine	O
monodansylcadaverine	O
(	O
MDC	O
)	O
,	O
we	O
addressed	O
the	O
functional	O
role	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
internalization	O
for	O
intracellular	O
signal	O
distribution	O
.	O

We	O
show	O
that	O
MDC	O
does	O
not	O
prevent	O
the	O
interaction	O
of	O
the	O
p55	O
TNF	O
receptor	O
(	O
TR55	O
)	O
with	O
FAN	O
and	O
TRADD	O
.	O

Furthermore	O
,	O
the	O
activation	O
of	O
plasmamembrane	O
-	O
associated	O
neutral	O
sphingomyelinase	O
activation	O
as	O
well	O
as	O
the	O
stimulation	O
of	O
proline	O
-	O
directed	O
protein	O
kinases	O
were	O
not	O
affected	O
in	O
MDC	O
-	O
treated	O
cells	O
.	O

In	O
contrast	O
,	O
activation	O
of	O
signaling	O
enzymes	O
that	O
are	O
linked	O
to	O
the	O
""""	O
death	O
domain	O
""""	O
of	O
TR55	O
,	O
like	O
acid	O
sphingomyelinase	O
and	O
c	O
-	O
Jun	O
-	O
N	O
-	O
terminal	O
protein	O
kinase	O
as	O
well	O
as	O
TNF	O
signaling	O
of	O
apoptosis	O
in	O
U937	O
and	O
L929	O
cells	O
,	O
are	O
blocked	O
in	O
the	O
presence	O
of	O
MDC	O
.	O

The	O
results	O
of	O
our	O
study	O
suggest	O
a	O
role	O
of	O
TR55	O
internalization	O
for	O
the	O
activation	O
of	O
select	O
TR55	O
death	O
domain	O
signaling	O
pathways	O
including	O
those	O
leading	O
to	O
apoptosis	O
.	O

Amiodarone	O
(	O
AD	O
)	O
is	O
an	O
effective	O
antidysrythmic	O
drug	O
,	O
however	O
,	O
there	O
can	O
be	O
serious	O
side	O
effects	O
,	O
such	O
as	O
hepatic	O
and	O
neurological	O
alterations	O
,	O
as	O
well	O
as	O
skin	O
photosensitization	O
,	O
as	O
seen	O
in	O
porphyrias	O
.	O

Clinical	O
signs	O
in	O
porphyrias	O
might	O
be	O
triggered	O
by	O
the	O
so	O
-	O
called	O
porphyrinogenic	O
drugs	O
.	O

Without	O
sound	O
basis	O
,	O
Amiodarone	O
has	O
been	O
classified	O
as	O
an	O
unsafe	O
drug	O
for	O
porphyric	O
patients	B
.	O

The	O
aim	O
of	O
this	O
work	O
has	O
been	O
to	O
study	O
the	O
effect	O
of	O
AD	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
on	O
heme	O
metabolism	O
.	O

In	O
the	O
in	O
vivo	O
assays	O
,	O
the	O
activities	O
of	O
5-aminolevulinate	O
synthetase	O
(	O
ALA	O
-	O
S	O
)	O
,	O
ALA	O
dehydratase	O
(	O
ALA	O
-	O
D	O
)	O
,	O
porphobilinogenase	O
(	O
PBGase	O
)	O
and	O
PBG	O
-	O
deaminase	O
(	O
PBG	O
-	O
D	O
)	O
in	O
blood	O
,	O
liver	O
,	O
and	O
kidney	O
;	O
hepatic	O
and	O
fecal	O
porphyrins	O
,	O
urinary	O
ALA	O
,	O
PBG	O
and	O
porphyrins	O
in	O
male	O
mice	B
strain	I
CF1	I
treated	O
with	O
AD	O
(	O
100	O
mg	O
i.p	O
.	O

daily	O
)	O
for	O
1	O
week	O
and	O
1	O
month	O
,	O
were	O
measured	O
.	O

No	O
significanat	O
differences	O
were	O
found	O
for	O
any	O
of	O
these	O
parameters	O
in	O
the	O
AD	O
treated	O
animals	B
as	O
compared	O
to	O
controls	O
.	O

In	O
the	O
in	O
vitro	O
experiments	O
human	B
blood	O
,	O
and	O
mice	B
blood	O
,	O
liver	O
,	O
and	O
kidney	O
,	O
were	O
used	O
to	O
measure	O
the	O
activities	O
of	O
ALA	O
-	O
S	O
,	O
ALA	O
-	O
D	O
,	O
PBGase	O
,	O
PBG	O
-	O
D	O
and	O
uroporphyrinogen	O
decarboxylase	O
,	O
in	O
the	O
presence	O
of	O
varying	O
concentrations	O
of	O
AD	O
(	O
0.0172	O
-	O
4.304	O
mM	O
)	O
.	O

AD	O
did	O
not	O
modify	O
any	O
of	O
the	O
enzyme	O
activities	O
.	O

All	O
of	O
the	O
above	O
biochemical	O
parameters	O
were	O
studied	O
in	O
17	O
cardiac	O
patients	B
under	O
AD	O
treatment	O
for	O
3	O
to	O
20	O
years	O
.	O

Neither	O
the	O
activities	O
of	O
the	O
heme	O
enzymes	O
,	O
nor	O
the	O
levels	O
of	O
precursors	O
and	O
porphyrins	O
in	O
urine	O
and	O
plasma	O
were	O
altered	O
.	O

These	O
findings	O
clearly	O
demonstrate	O
that	O
AD	O
is	O
a	O
pharmacologically	O
safe	O
drug	O
and	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
associated	O
pathologies	O
in	O
porphyrias	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
antimutagenicity	O
of	O
WR-1065	O
added	O
after	O
irradiation	O
of	O
cells	O
of	O
cell	O
lines	O
differing	O
in	O
their	O
ability	O
to	O
rejoin	O
radiation	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
(	O
DSBs	O
)	O
.	O

The	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	O
at	O
the	O
thymidine	O
kinase	O
locus	O
was	O
demonstrated	O
for	O
L5178Y	O
(	O
LY	O
)	O
-S1	O
cells	O
that	O
are	O
deficient	O
in	O
repair	O
of	O
DNA	O
DSBs	O
.	O

Less	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	O
was	O
observed	O
in	O
LY	O
-	O
R16	O
and	O
LY	O
-	O
SR1	O
cells	O
,	O
which	O
are	O
relatively	O
efficient	O
in	O
DSB	O
repair	O
.	O

Postirradiation	O
treatment	O
with	O
WR-1065	O
had	O
only	O
a	O
small	O
stimulatory	O
effect	O
on	O
DSB	O
rejoining	O
.	O

A	O
3-h	O
incubation	O
of	O
irradiated	O
LY	O
cells	O
with	O
WR-1065	O
caused	O
slight	O
changes	O
in	O
the	O
distribution	O
of	O
cells	O
in	O
the	O
phases	O
of	O
the	O
cell	O
cycle	O
that	O
differed	O
between	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
.	O

Both	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
were	O
protected	O
against	O
the	O
cytotoxic	O
and	O
mutagenic	O
effects	O
of	O
radiation	O
when	O
WR-1065	O
was	O
present	O
30	O
min	O
before	O
and	O
during	O
the	O
irradiation	O
.	O

We	O
conclude	O
that	O
the	O
differential	O
postirradiation	O
effects	O
of	O
WR-1065	O
in	O
the	O
LY	O
-	O
S1	O
and	O
LY	O
-	O
SR1	O
cells	O
are	O
not	O
caused	O
by	O
differences	O
in	O
cellular	O
uptake	O
of	O
the	O
radioprotector	O
or	O
in	O
its	O
radical	O
scavenging	O
activity	O
.	O

Possible	O
mechanisms	O
for	O
the	O
postirradiation	O
antimutagenicity	O
of	O
WR-1065	O
are	O
discussed	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
are	O
the	O
major	O
mediators	O
produced	O
in	O
activated	O
macrophages	O
which	O
contribute	O
to	O
the	O
circulatory	O
failure	O
associated	O
with	O
septic	O
shock	O
.	O

A	O
sesquiterpene	O
lactone	O
compound	O
(	O
dehydrocostus	O
lactone	O
)	O
isolated	O
from	O
the	O
medicinal	O
plant	O
,	O
Saussurea	B
lappa	I
,	O
inhibited	O
the	O
production	O
of	O
NO	O
in	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-activated	O
RAW	B
264.7	I
cells	O
by	O
suppressing	O
inducible	O
nitric	O
oxide	O
synthase	O
enzyme	O
expression	O
.	O

This	O
compound	O
also	O
decreased	O
the	O
TNF	O
-	O
alpha	O
level	O
in	O
LPS	O
-	O
activated	O
systems	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
dehydrocostus	O
lactone	O
may	O
be	O
a	O
possible	O
candidate	O
for	O
the	O
development	O
of	O
new	O
drugs	O
to	O
treat	O
endotoxemia	O
accompanied	O
by	O
the	O
overproduction	O
of	O
NO	O
and	O
TNF	O
-	O
alpha	O
.	O

The	O
putative	O
biosynthetic	O
gene	O
cluster	O
for	O
the	O
alpha	O
-	O
glucosidase	O
inhibitor	O
acarbose	O
was	O
identified	O
in	O
the	O
producer	O
Actinoplanes	B
sp.	I
50	I
/	I
110	I
by	O
cloning	O
a	O
DNA	O
segment	O
containing	O
the	O
conserved	O
gene	O
for	O
dTDP	O
-	O
D	O
-	O
glucose	O
4,6-dehydratase	O
,	O
acbB.	O
The	O
two	O
flanking	O
genes	O
were	O
acbA	O
(	O
dTDP	O
-	O
D	O
-	O
glucose	O
synthase	O
)	O
and	O
acbC	O
,	O
encoding	O
a	O
protein	O
with	O
significant	O
similarity	O
to	O
3-dehydroquinate	O
synthases	O
(	O
AroB	O
proteins	O
)	O
.	O

The	O
acbC	O
gene	O
was	O
overexpressed	O
heterologously	O
in	O
Streptomyces	B
lividans	I
66	I
,	O
and	O
the	O
product	O
was	O
shown	O
to	O
be	O
a	O
C7-cyclitol	O
synthase	O
using	O
sedo	O
-	O
heptulose	O
7-phosphate	O
,	O
but	O
not	O
ido	O
-	O
heptulose	O
7-phosphate	O
,	O
as	O
its	O
substrate	O
.	O

The	O
cyclization	O
product	O
,	O
2-epi-5-epi	O
-	O
valiolone	O
(	O
(	O
2S,3S,4S,5R	O
)	O
-5-	O
(	O
hydroxymethyl	O
)	O
cyclohexanon-2,3,4,5-tetrol	O
)	O
,	O
is	O
a	O
precursor	O
of	O
the	O
valienamine	O
moiety	O
of	O
acarbose	O
.	O

A	O
possible	O
five	O
-	O
step	O
reaction	O
mechanism	O
is	O
proposed	O
for	O
the	O
cyclization	O
reaction	O
catalyzed	O
by	O
AcbC	O
based	O
on	O
the	O
recent	O
analysis	O
of	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
a	O
eukaryotic	O
3-dehydroquinate	O
synthase	O
domain	O
(	O
Carpenter	O
,	O
E.	O
P.	O
,	O
Hawkins	O
,	O
A.	O
R.	O
,	O
Frost	O
,	O
J.	O
W.	O
,	O
and	O
Brown	O
,	O
K.	O
A.	O
(	O
1998	O
)	O
Nature	O
394	O
,	O
299	O
-	O
302	O
)	O
.	O

The	O
mechanism	O
of	O
DNA	O
damage	O
induced	O
by	O
metabolites	O
of	O
nitrobenzene	O
was	O
investigated	O
in	O
relation	O
to	O
the	O
carcinogenicity	O
and	O
reproductive	O
toxicity	O
of	O
nitrobenzene	O
.	O

Nitrosobenzene	O
,	O
a	O
nitrobenzene	O
metabolite	O
,	O
induced	O
NADH	O
plus	O
Cu	O
(	O
II	O
)	O
-mediated	O
DNA	O
cleavage	O
frequently	O
at	O
thymine	O
and	O
cytosine	O
residues	O
.	O

Catalase	O
and	O
bathocuproine	O
inhibited	O
the	O
DNA	O
damage	O
,	O
suggesting	O
the	O
involvement	O
of	O
H2O2	O
and	O
Cu	O
(	O
I	O
)	O
.	O

Typical	O
free	O
hydroxyl	O
radical	O
scavengers	O
showed	O
no	O
inhibitory	O
effects	O
on	O
DNA	O
damage	O
.	O

Nitrosobenzene	O
caused	O
the	O
formation	O
of	O
8-oxo-7	O
,	O
8-dihydro-2'-deoxyguanosine	O
in	O
calf	B
thymus	O
DNA	O
in	O
the	O
presence	O
of	O
NADH	O
and	O
Cu	O
(	O
II	O
)	O
.	O

ESR	O
spectroscopic	O
study	O
has	O
confirmed	O
that	O
nitrosobenzene	O
is	O
reduced	O
by	O
NADH	O
to	O
the	O
phenylhydronitroxide	O
radical	O
even	O
in	O
the	O
absence	O
of	O
Cu	O
(	O
II	O
)	O
.	O

These	O
results	O
suggest	O
that	O
nitrosobenzene	O
can	O
be	O
reduced	O
non	O
-	O
enzymatically	O
by	O
NADH	O
,	O
and	O
the	O
redox	O
cycle	O
reaction	O
resulted	O
in	O
oxidative	O
DNA	O
damage	O
due	O
to	O
the	O
copper	O
-	O
oxygen	O
complex	O
,	O
derived	O
from	O
the	O
reaction	O
of	O
Cu	O
(	O
I	O
)	O
with	O
H2O2	O
.	O

1	O
.	O

The	O
urinary	O
metabolic	O
fate	O
of	O
4-fluoroaniline	O
(	O
4-FA	O
)	O
and	O
1-	O
[	O
13C	O
]	O
-4-fluoroacetanilide	O
(	O
4-FAA	O
)	O
has	O
been	O
studied	O
using	O
NMR	O
-	O
based	O
methods	O
after	O
50	O
and	O
100	O
mg	O
kg	O
(	O
-1	O
)	O
i.p	O
.	O

doses	O
respectively	O
to	O
the	O
male	O
Sprague	B
-	I
Dawley	I
rat	I
.	O

2	O
.	O
4-FA	O
was	O
both	O
ortho-	O
and	O
para	O
-	O
hydroxylated	O
.	O

The	O
major	O
metabolite	O
produced	O
by	O
ortho	O
-	O
hydroxylation	O
was	O
2-amino-5-fluorophenylsulphate	O
accounting	O
for	O
approximately	O
30	O
%	O
of	O
the	O
dose	O
.	O

Of	O
the	O
dose	O
,	O
approximately	O
10	O
%	O
was	O
excreted	O
via	O
para	O
-	O
hydroxylation	O
and	O
the	O
resulting	O
defluorinated	O
metabolites	O
were	O
N	O
-	O
acetylated	O
and	O
excreted	O
as	O
sulphate	O
(	O
major	O
)	O
,	O
glucuronide	O
(	O
minor	O
)	O
and	O
N	O
-	O
acetyl	O
-	O
cysteinyl	O
(	O
minor	O
)	O
conjugates	O
of	O
4-acetamidophenol	O
(	O
paracetamol	O
)	O
.	O

3	O
.	O

The	O
major	O
route	O
of	O
metabolism	O
of	O
1-	O
[	O
13C	O
]	O
-4-FAA	O
was	O
N	O
-	O
deacetylation	O
and	O
the	O
metabolites	O
excreted	O
in	O
the	O
urine	O
were	O
qualitatively	O
identical	O
to	O
4-FA	O
.	O

The	O
paracetamol	O
metabolites	O
produced	O
via	O
para	O
-	O
hydroxylation	O
were	O
also	O
a	O
product	O
of	O
N	O
-	O
deacetylation	O
and	O
reacetylation	O
,	O
as	O
the	O
[	O
13C	O
]	O
-label	O
was	O
not	O
retained	O
.	O

4	O
.	O

These	O
studies	O
demonstrate	O
the	O
value	O
of	O
[	O
13C	O
]	O
-labelling	O
in	O
understanding	O
the	O
contribution	O
of	O
N	O
-	O
acetylation	O
,	O
and	O
futile	O
deacetylation	O
-	O
reacetylation	O
reactions	O
,	O
in	O
aniline	O
metabolism	O
.	O

In	O
addition	O
,	O
this	O
work	O
sheds	O
new	O
light	O
on	O
the	O
metabolic	O
lability	O
of	O
certain	O
aromatic	O
fluorine	O
substituents	O
.	O

Masoprocol	O
(	O
nordihydroguaiaretic	O
acid	O
)	O
is	O
a	O
lipoxygenase	O
inhibitor	O
isolated	O
from	O
the	O
creosote	B
bush	I
and	O
used	O
by	O
native	O
healers	O
to	O
treat	O
type	O
2	O
diabetes	O
.	O

It	O
has	O
been	O
recently	O
shown	O
to	O
decrease	O
serum	O
glucose	O
,	O
free	O
fatty	O
acid	O
(	O
FFA	O
)	O
,	O
and	O
triglyceride	O
(	O
TG	O
)	O
concentrations	O
in	O
rodent	B
models	O
of	O
type	O
2	O
diabetes	O
.	O

The	O
current	O
study	O
was	O
initiated	O
to	O
quantify	O
the	O
effects	O
of	O
masoprocol	O
incubation	O
of	O
adipocytes	O
isolated	O
from	O
normal	O
rats	B
.	O

The	O
results	O
indicate	O
that	O
masoprocol	O
significantly	O
increased	O
glucose	O
uptake	O
by	O
adipocytes	O
in	O
both	O
the	O
absence	O
and	O
presence	O
of	O
insulin	O
.	O

In	O
addition	O
,	O
the	O
maximal	O
rate	O
of	O
insulin	O
-	O
stimulated	O
glucose	O
transport	O
was	O
increased	O
in	O
adipocytes	O
incubated	O
with	O
masoprocol	O
and	O
the	O
insulin	O
concentration	O
resulting	O
in	O
a	O
half	O
-	O
maximal	O
glucose	O
transport	O
rate	O
(	O
ED50	O
)	O
decreased	O
.	O

Finally	O
,	O
isoproterenol	O
-	O
stimulated	O
increases	O
in	O
FFA	O
and	O
glycerol	O
release	O
were	O
significantly	O
decreased	O
in	O
the	O
presence	O
of	O
masoprocol	O
.	O

These	O
results	O
provide	O
an	O
explanation	O
at	O
the	O
cellular	O
level	O
for	O
the	O
observation	O
that	O
masoprocol	O
decreases	O
serum	O
glucose	O
,	O
insulin	O
,	O
and	O
FFA	O
concentrations	O
in	O
rodent	B
models	O
of	O
type	O
2	O
diabetes	O
.	O

Free	O
d	O
-amino	O
acids	O
have	O
been	O
shown	O
to	O
be	O
present	O
in	O
a	O
large	O
variety	O
of	O
species	O
,	O
including	O
mammals	B
and	O
,	O
more	O
specifically	O
,	O
humans	B
[	O
1,2	O
]	O
.	O

In	O
particular	O
,	O
d	O
-aspartate	O
has	O
drawn	O
special	O
interest	O
since	O
(	O
a	O
)	O
its	O
levels	O
are	O
often	O
found	O
to	O
be	O
the	O
highest	O
amongst	O
d	O
-amino	O
acids	O
[	O
3	O
]	O
,	O
(	O
b	O
)	O
recent	O
reports	O
propose	O
some	O
yet	O
unknown	O
neuronal	O
and	O
neuroendocrine	O
roles	O
of	O
d	O
-aspartate	O
[	O
4,5	O
]	O
,	O
(	O
c	O
)	O
high	O
levels	O
of	O
d	O
-aspartate	O
in	O
the	O
brain	O
and	O
other	O
tissues	O
of	O
mammals	B
were	O
discovered	O
by	O
several	O
authors	O
[	O
6–8	O
]	O
,	O
(	O
d	O
)	O
abnormal	O
levels	O
of	O
d	O
-aspartate	O
have	O
been	O
reported	O
in	O
relation	O
to	O
Alzheimer	O
,	O
senescence	O
and	O
renal	O
diseases	O
[	O
9,10	O
]	O
,	O
(	O
e	O
)	O
various	O
levels	O
of	O
d	O
-amino	O
acids	O
are	O
produced	O
during	O
food	O
processing	O
[	O
11	O
]	O
,	O
(	O
f	O
)	O
d	O
-aspartate	O
and	O
other	O
chemically	O
related	O
molecules	O
(	O
such	O
as	O
N	O
-methyl	O
-	O
d	O
-aspartate	O
)	O
are	O
widely	O
used	O
as	O
agonists	O
or	O
antagonists	O
of	O
neurochemical	O
transmitters	O
both	O
in	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
and	O
(	O
h	O
)	O
some	O
of	O
them	O
might	O
play	O
such	O
a	O
role	O
also	O
in	O
vivo	O
[	O
4,12,13	O
]	O
.	O

Despite	O
the	O
growing	O
interest	O
in	O
the	O
biological	O
functions	O
of	O
d	O
-aspartate	O
,	O
little	O
is	O
known	O
about	O
its	O
origin	O
and	O
metabolism	O
in	O
mammals	B
.	O

In	O
this	O
regard	O
,	O
a	O
flavoprotein	O
with	O
d	O
-aspartate	O
oxidase	O
activity	O
has	O
been	O
purified	O
,	O
characterized	O
and	O
cloned	O
from	O
beef	B
kidney	O
cortex	O
[	O
14–17	O
]	O
and	O
,	O
more	O
recently	O
,	O
from	O
human	B
brain	O
[	O
18	O
]	O
.	O

The	O
enzyme	O
from	O
beef	B
kidney	O
cortex	O
(	O
bDASPO	O
)	O
has	O
been	O
thoroughly	O
investigated	O
as	O
far	O
as	O
primary	O
structure	O
,	O
kinetic	O
mechanism	O
,	O
FAD	O
binding	O
and	O
spectroscopic	O
properties	O
of	O
the	O
free	O
and	O
ligand	O
-	O
bound	O
enzyme	O
are	O
concerned	O
[	O
14–16	O
]	O
.	O

It	O
is	O
a	O
monomer	O
with	O
a	O
molecular	O
weight	O
of	O
37	O
659	O
(	O
apo	O
-	O
protein	O
)	O
containing	O
one	O
molecule	O
of	O
flavin	O
.	O

It	O
is	O
isolated	O
as	O
a	O
mixture	O
of	O
an	O
active	O
form	O
containing	O
FAD	O
(	O
FAD	O
-	O
bDASPO	O
)	O
and	O
an	O
inactive	O
form	O
(	O
9–20	O
%	O
depending	O
on	O
the	O
purification	O
)	O
containing	O
6-OH	O
-	O
FAD	O
(	O
6-OH	O
-	O
FAD	O
-	O
bDASPO	O
)	O
.	O

The	O
enzyme	O
catalyzes	O
the	O
oxidative	O
deamination	O
of	O
dicarboxylic	O
d	O
-amino	O
acids	O
by	O
O2	O
with	O
the	O
production	O
of	O
H2	O
O2	O
,	O
NH3	O
and	O
the	O
corresponding	O
α	O
-	O
keto	O
acids	O
.	O

The	O
relatively	O
low	O
abundance	O
of	O
the	O
enzyme	O
,	O
and	O
the	O
consequently	O
long	O
purification	O
procedure	O
,	O
hampered	O
so	O
far	O
the	O
use	O
of	O
this	O
protein	O
as	O
a	O
tool	O
to	O
study	O
the	O
presence	O
and	O
biological	O
significance	O
of	O
dicarboxylic	O
d	O
-amino	O
acids	O
in	O
organisms	O
.	O

In	O
order	O
to	O
overcome	O
this	O
problem	O
,	O
a	O
procedure	O
to	O
overexpress	O
recombinant	O
d	O
-aspartate	O
oxidase	O
(	O
rDASPO	O
)	O
in	O
Escherichia	B
coli	I
has	O
been	O
set	O
up	O
[	O
17	O
]	O
.	O

Starting	O
from	O
the	O
latter	O
study	O
,	O
the	O
present	O
paper	O
reports	O
overexpression	O
and	O
purification	O
protocols	O
leading	O
to	O
large	O
amounts	O
of	O
homogeneous	O
and	O
catalytically	O
active	O
rDASPO	O
.	O

The	O
biochemical	O
characterization	O
of	O
the	O
recombinant	O
enzyme	O
shows	O
that	O
rDASPO	O
possesses	O
the	O
same	O
catalytic	O
properties	O
of	O
bDASPO	O
and	O
,	O
therefore	O
,	O
can	O
be	O
used	O
to	O
extend	O
the	O
study	O
of	O
the	O
properties	O
of	O
DASPO	O
.	O

In	O
particular	O
,	O
in	O
this	O
paper	O
we	O
focused	O
our	O
attention	O
on	O
the	O
determination	O
of	O
the	O
redox	O
potential	O
of	O
DASPO	O
and	O
to	O
possible	O
interactions	O
between	O
the	O
enzyme	O
and	O
a	O
variety	O
of	O
molecules	O
used	O
as	O
agonists	O
or	O
antagonists	O
of	O
neurotransmitters	O
[	O
12	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Overexpression	O
and	O
purification	O
of	O
rDASPO	O
E.	B
coli	I
GI724	I
cells	O
,	O
carrying	O
the	O
cI	O
repressor	O
gene	O
engineered	O
into	O
bacterial	O
chromosome	O
under	O
the	O
control	O
of	O
the	O
Trp	O
promoter	O
,	O
were	O
freshly	O
transformed	O
with	O
the	O
recombinant	O
plasmid	O
pED	O
carrying	O
the	O
gene	O
for	O
bovine	B
kidney	O
d	O
-aspartate	O
oxidase	O
under	O
the	O
control	O
of	O
the	O
λ	O
PL	O
promoter	O
[	O
17	O
]	O
.	O

200	O
ml	O
RM	O
medium	O
(	O
6	O
g	O
Na2	O
HPO4	O
,	O
3	O
g	O
KH2	O
PO4	O
,	O
0.5	O
g	O
NaCl	O
,	O
1	O
g	O
NH4	O
Cl	O
,	O
95.21	O
mg	O
MgCl2	O
,	O
20	O
g	O
casamino	O
acids	O
,	O
10	O
ml	O
glycerol	O
in	O
1	O
l	O
)	O
containing	O
100	O
μg	O
ampicillin	O
ml−1	O
were	O
inoculated	O
with	O
20	O
ml	O
overnight	O
precultures	O
of	O
GI724	B
(	O
pED	O
)	O
and	O
the	O
cells	O
grown	O
at	O
30	O
°	O
C	O
up	O
to	O
A	O
550	O
0.5	O
.	O

The	O
material	O
was	O
used	O
to	O
inoculate	O
6	O
l	O
of	O
induction	O
medium	O
(	O
6	O
g	O
Na2	O
HPO4	O
,	O
3	O
g	O
KH2	O
PO4	O
,	O
0.5	O
g	O
NaCl	O
,	O
1	O
g	O
NH4	O
Cl	O
,	O
95.21	O
mg	O
MgCl2	O
,	O
2	O
g	O
casamino	O
acids	O
,	O
5	O
g	O
glucose	O
for	O
1	O
l	O
)	O
containing	O
100	O
μg	O
ampicillin	O
ml−1	O
in	O
a	O
fermenter	O
(	O
BioIndustrie	O
Mantovane	O
,	O
Italy	O
)	O
and	O
the	O
cells	O
grown	O
at	O
30	O
°	O
C	O
until	O
A	O
550	O
reached	O
0.5	O
.	O

Expression	O
was	O
induced	O
by	O
adding	O
tryptophan	O
to	O
a	O
final	O
concentration	O
of	O
100	O
μg	O
ml−1	O
and	O
raising	O
the	O
temperature	O
to	O
37	O
°	O
C	O
.	O

The	O
cells	O
were	O
harvested	O
after	O
16	O
h	O
,	O
centrifuged	O
at	O
14	O
000	O
×	O
g	O
for	O
25	O
min	O
,	O
resuspended	O
in	O
cold	O
0.9	O
%	O
NaCl	O
,	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
and	O
the	O
pellet	O
stored	O
at	O
−80	O
°	O
C	O
.	O

All	O
purification	O
steps	O
were	O
performed	O
at	O
4	O
°	O
C	O
and	O
all	O
buffers	O
contained	O
0.3	O
mM	O
EDTA	O
and	O
5	O
mM	O
sodium	O
potassium	O
tartrate	O
,	O
unless	O
otherwise	O
indicated	O
.	O

Cells	O
were	O
resuspended	O
in	O
2	O
vols	O
.	O

of	O
50	O
mM	O
NaPi	O
,	O
pH	O
8.0	O
,	O
1	O
mM	O
phenylmethylsulfonyl	O
fluoride	O
,	O
20	O
μM	O
FAD	O
,	O
sonicated	O
and	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
for	O
30	O
min	O
.	O

Protamine	O
sulfate	O
was	O
slowly	O
added	O
to	O
a	O
final	O
concentration	O
of	O
0.2	O
%	O
at	O
0	O
°	O
C	O
,	O
the	O
material	O
was	O
left	O
at	O
the	O
same	O
temperature	O
for	O
an	O
additional	O
15	O
min	O
and	O
then	O
centrifuged	O
at	O
27	O
000	O
×	O
g	O
for	O
1	O
h.	O
The	O
supernatant	O
was	O
adjusted	O
to	O
0	O
.	O
15	O
M	O
NaPi	O
,	O
pH	O
6.75	O
and	O
loaded	O
on	O
a	O
Phenyl	B
-	I
Sepharose	I
CL-4B	I
column	O
(	O
13	O
×	O
2.6	O
cm	O
)	O
equilibrated	O
in	O
the	O
same	O
buffer	O
.	O

The	O
column	O
was	O
washed	O
with	O
2	O
vols	O
.	O

of	O
starting	O
buffer	O
and	O
the	O
enzyme	O
eluted	O
with	O
10	O
mM	O
NaPi	O
,	O
pH	O
8.0	O
.	O

The	O
active	O
fractions	O
(	O
total	O
volume	O
about	O
2.5	O
l	O
)	O
were	O
brought	O
to	O
20	O
μM	O
FAD	O
,	O
50	O
mM	O
MES	O
pH	O
5.5	O
using	O
a	O
concentrated	O
solution	O
of	O
this	O
buffer	O
,	O
divided	O
in	O
300	O
ml	O
aliquots	O
and	O
directly	O
loaded	O
on	O
a	O
S15	O
strong	O
cationic	O
exchanger	O
membrane	O
adsorber	O
(	O
Sartorius	O
AG	O
,	O
Germany	O
)	O
equilibrated	O
in	O
50	O
mM	O
MES	O
,	O
pH	O
5.5	O
.	O

The	O
membrane	O
was	O
washed	O
with	O
10	O
ml	O
of	O
the	O
starting	O
buffer	O
and	O
eluted	O
with	O
the	O
same	O
buffer	O
containing	O
1	O
M	O
NaCl	O
in	O
2	O
ml	O
fractions	O
.	O

The	O
active	O
fractions	O
were	O
pooled	O
and	O
equilibrated	O
in	O
50	O
mM	O
HEPES	O
,	O
pH	O
8.0	O
,	O
5	O
mM	O
sodium	O
potassium	O
tartrate	O
,	O
0.3	O
mM	O
EDTA	O
,	O
20	O
μM	O
FAD	O
using	O
an	O
Amicon	O
-	O
PM	O
10	O
membrane	O
.	O

The	O
pure	O
enzyme	O
was	O
stored	O
under	O
these	O
conditions	O
at	O
−80	O
°	O
C	O
.	O

If	O
necessary	O
,	O
excess	O
FAD	O
and	O
tartrate	O
were	O
removed	O
prior	O
to	O
experiments	O
by	O
gel	O
filtration	O
on	O
a	O
PD-10	O
column	O
(	O
Pharmacia	O
)	O
equilibrated	O
either	O
in	O
50	O
mM	O
HEPES	O
,	O
pH	O
8.0	O
or	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
.	O

In	O
conclusion	O
,	O
the	O
recombinant	O
protein	O
was	O
purified	O
following	O
a	O
new	O
procedure	O
greatly	O
simplified	O
as	O
compared	O
to	O
the	O
one	O
used	O
for	O
the	O
enzyme	O
from	O
beef	B
kidney	O
cortex	O
[	O
14	O
]	O
,	O
omitting	O
the	O
heat	O
,	O
gel	O
filtration	O
and	O
Mono	O
Q	O
ion	O
-	O
exchange	O
steps	O
and	O
performing	O
the	O
final	O
ion	O
-	O
exchange	O
step	O
on	O
a	O
S15	O
strong	O
cationic	O
exchanger	O
membrane	O
adsorber	O
instead	O
of	O
the	O
original	O
Mono	O
S	O
column	O
.	O

The	O
latter	O
modification	O
has	O
the	O
main	O
advantages	O
of	O
avoiding	O
time	O
consuming	O
concentration	O
and	O
equilibration	O
steps	O
and	O
exposure	O
of	O
the	O
enzyme	O
to	O
room	O
temperature	O
during	O
FPLC	O
chromatography	O
.	O

2.2	O
Activity	O
assay	O
The	O
oxidase	O
activity	O
was	O
determined	O
by	O
the	O
spectrophotometric	O
method	O
set	O
up	O
in	O
[	O
14	O
]	O
which	O
couples	O
the	O
production	O
of	O
hydrogen	O
peroxide	O
in	O
the	O
DASPO	O
-	O
catalyzed	O
reaction	O
with	O
the	O
oxidation	O
of	O
o	O
-dianisidine	O
by	O
horseradish	O
peroxidase	O
(	O
ϵ436	O
=	O
11	O
610	O
M−1	O
cm−1	O
)	O
.	O

The	O
reaction	O
mixture	O
contained	O
90	O
μg	O
o	O
-dianisidine-2	O
HCl	O
,	O
20	O
nmol	O
FAD	O
,	O
64	O
μg	O
horseradish	O
peroxidase	O
and	O
variable	O
amounts	O
of	O
substrate	O
(	O
routinely	O
10	O
mM	O
d	O
-aspartate	O
)	O
in	O
1	O
ml	O
of	O
50	O
mM	O
KPi	O
,	O
pH	O
7.4	O
,	O
at	O
25	O
°	O
C	O
.	O

The	O
reaction	O
was	O
started	O
by	O
addition	O
of	O
variable	O
amounts	O
of	O
rDASPO	O
(	O
20	O
ng–4	O
μg	O
)	O
depending	O
on	O
the	O
substrate	O
tested	O
.	O

1	O
U	O
of	O
enzyme	O
is	O
defined	O
as	O
the	O
amount	O
which	O
oxidizes	O
1	O
μmol	O
substrate	O
min−1	O
.	O

When	O
a	O
compound	O
was	O
not	O
used	O
as	O
substrate	O
by	O
rDASPO	O
it	O
was	O
tested	O
as	O
an	O
inhibitor	O
by	O
determining	O
its	O
effect	O
on	O
the	O
rate	O
of	O
oxidation	O
of	O
d	O
-aspartate	O
(	O
using	O
10	O
mM	O
of	O
both	O
substrate	O
and	O
inhibitor	O
)	O
.	O

2.3	O
Protein	O
content	O
Protein	O
content	O
during	O
the	O
purification	O
steps	O
was	O
estimated	O
using	O
an	O
extinction	O
coefficient	O
of	O
1	O
for	O
a	O
1	O
mg	O
ml	O
−1	O
protein	O
solution	O
.	O

The	O
purified	O
enzyme	O
was	O
quantitated	O
using	O
the	O
extinction	O
coefficients	O
previously	O
determined	O
for	O
the	O
various	O
enzyme	O
forms	O
:	O
ϵ454	O
=	O
11	O
810	O
M−1	O
cm−1	O
for	O
holo	O
-	O
FAD	O
-	O
bDASPO	O
and	O
ϵ458	O
=	O
12	O
300	O
M−1	O
cm−1	O
for	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
bDASPO	O
complex	O
[	O
14	O
]	O
.	O

2.4	O
Apo	O
-	O
enzyme	O
preparation	O
Apo	O
-	O
rDASPO	O
was	O
prepared	O
according	O
to	O
the	O
procedure	O
for	O
the	O
selective	O
removal	O
of	O
FAD	O
from	O
bDASPO	O
described	O
in	O
[	O
14	O
]	O
.	O

Briefly	O
,	O
2	O
mg	O
holo	O
-	O
enzyme	O
were	O
dialyzed	O
at	O
4	O
°	O
C	O
for	O
3	O
days	O
against	O
500	O
ml	O
of	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
,	O
0.3	O
mM	O
EDTA	O
containing	O
3	O
M	O
KBr	O
and	O
0.5	O
%	O
charcoal	O
,	O
followed	O
by	O
24	O
h	O
dialysis	O
against	O
2	O
l	O
of	O
the	O
same	O
buffer	O
without	O
KBr	O
and	O
charcoal	O
.	O

2.5	O
Anaerobic	O
reduction	O
of	O
d	O
-aspartate	O
oxidase	O
Anaerobic	O
reduction	O
of	O
rDASPO	O
was	O
conducted	O
at	O
25	O
°	O
C	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
either	O
in	O
the	O
absence	O
or	O
presence	O
of	O
4	O
mM	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
.	O

Anaerobiosis	O
was	O
achieved	O
by	O
alternate	O
evacuation	O
and	O
flushing	O
with	O
argon	O
freed	O
from	O
any	O
residual	O
oxygen	O
using	O
High	O
Capacity	O
Gas	O
Purifier	O
and	O
OMI	O
Indicating	O
Purifier	O
devices	O
(	O
Supelco	O
,	O
USA	O
)	O
.	O

Photoreduction	O
was	O
achieved	O
by	O
irradiating	O
the	O
protein	O
with	O
a	O
slide	O
projector	O
at	O
0	O
°	O
C	O
in	O
the	O
presence	O
of	O
10	O
mM	O
EDTA	O
,	O
0.5	O
μM	O
5-deazaflavin-3-sulfonate	O
as	O
catalyst	O
and	O
5	O
μM	O
benzylviologen	O
[	O
19	O
]	O
.	O

Following	O
each	O
irradiation	O
,	O
measurements	O
were	O
started	O
when	O
spectral	O
changes	O
in	O
the	O
dark	O
were	O
complete	O
(	O
5–15	O
min	O
at	O
25	O
°	O
C	O
)	O
.	O

Alternatively	O
,	O
rDASPO	O
was	O
reduced	O
by	O
mixing	O
the	O
enzyme	O
(	O
2	O
ml	O
)	O
in	O
the	O
main	O
compartment	O
of	O
an	O
anaerobic	O
cuvette	O
with	O
10	O
mU	O
of	O
xanthine	O
oxidase	O
[	O
20	O
]	O
.	O

After	O
anaerobiosis	O
,	O
xanthine	O
and	O
benzylviologen	O
were	O
added	O
from	O
a	O
side	O
arm	O
to	O
a	O
final	O
concentration	O
of	O
250	O
μM	O
and	O
5	O
μM	O
,	O
respectively	O
,	O
to	O
start	O
the	O
reaction	O
.	O

The	O
concentrations	O
of	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
enzyme	O
at	O
each	O
point	O
of	O
the	O
reduction	O
were	O
calculated	O
from	O
the	O
total	O
enzyme	O
present	O
and	O
from	O
the	O
absorbance	O
at	O
suitable	O
wavelengths	O
(	O
454	O
and	O
374	O
nm	O
for	O
the	O
free	O
enzyme	O
and	O
458	O
and	O
374	O
nm	O
for	O
the	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
complex	O
)	O
using	O
the	O
following	O
equation:	O
(	O
1	O
)	O
ΔA	O
(	O
ox	O
−x	O
)	O
=	O
[	O
red	O
]	O
(	O
ϵox	O
−ϵred	O
)	O
+	O
[	O
sq	O
]	O
(	O
ϵox	O
−ϵsq	O
)	O
were	O
ΔA	O
(	O
ox−x	O
)	O
is	O
the	O
decrease	O
in	O
absorbance	O
in	O
comparison	O
to	O
the	O
spectrum	O
of	O
the	O
oxidized	O
enzyme	O
,	O
ϵox	O
,	O
ϵsq	O
and	O
ϵred	O
are	O
the	O
extinction	O
coefficients	O
for	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
form	O
of	O
the	O
enzyme	O
and	O
[	O
red	O
]	O
and	O
[	O
sq	O
]	O
are	O
the	O
molar	O
concentrations	O
of	O
reduced	O
and	O
semiquinone	O
rDASPO	O
,	O
respectively	O
.	O

In	O
order	O
to	O
determine	O
the	O
amount	O
of	O
semiquinone	O
thermodynamically	O
stabilized	O
,	O
7.7	O
μM	O
rDASPO	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
,	O
0.5	O
μM	O
5-deazaflavin-3-sulfonate	O
,	O
10	O
mM	O
EDTA	O
and	O
5	O
μM	O
benzylviologen	O
was	O
completely	O
photoreduced	O
anaerobically	O
as	O
described	O
above	O
and	O
mixed	O
with	O
an	O
equimolar	O
amount	O
of	O
concentrated	O
oxidized	O
enzyme	O
previously	O
stored	O
in	O
the	O
side	O
arm	O
of	O
the	O
cell	O
.	O

The	O
reaction	O
was	O
followed	O
at	O
25	O
°	O
C	O
in	O
the	O
dark	O
until	O
no	O
further	O
absorbance	O
changes	O
could	O
be	O
detected	O
(	O
24	O
h	O
)	O
and	O
the	O
amount	O
of	O
oxidized	O
,	O
semiquinone	O
and	O
reduced	O
enzyme	O
at	O
equilibrium	O
was	O
calculated	O
as	O
described	O
above	O
.	O

2.6	O
Determination	O
of	O
redox	O
potentials	O
The	O
redox	O
potential	O
of	O
rDASPO	O
was	O
determined	O
by	O
a	O
spectrophotometric	O
method	O
employing	O
a	O
reducing	O
system	O
of	O
xanthine	O
,	O
xanthine	O
oxidase	O
and	O
a	O
suitable	O
mediator	O
such	O
as	O
benzylviologen	O
[	O
20	O
]	O
.	O

Data	O
were	O
plotted	O
according	O
to	O
[	O
21	O
]	O
.	O

The	O
amount	O
of	O
oxidized	O
and	O
reduced	O
indicator	O
dye	O
and	O
enzyme	O
was	O
calculated	O
from	O
the	O
experimentally	O
determined	O
extinction	O
coefficients	O
and	O
isosbestic	O
points	O
at	O
the	O
following	O
wavelengths	O
,	O
depending	O
on	O
the	O
experiment	O
:	O
(	O
a	O
)	O
ITS	O
(	O
600	O
nm	O
)	O
+rDASPO	O
(	O
486	O
nm	O
,	O
isosbestic	O
for	O
ITS	O
)	O
;	O
(	O
b	O
)	O
IDS	O
(	O
610	O
nm	O
)	O
+rDASPO	O
(	O
374	O
and	O
458	O
nm	O
,	O
the	O
latter	O
being	O
an	O
isosbestic	O
for	O
IDS	O
)	O
;	O
(	O
c	O
)	O
IDS	O
(	O
610	O
nm	O
)	O
+l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
(	O
458	O
nm	O
)	O
;	O
(	O
d	O
)	O
HNQ	O
(	O
458	O
nm	O
)	O
+l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
(	O
364	O
nm	O
)	O
.	O

2.7	O
Miscellaneous	O
methods	O
Absorption	O
spectra	O
were	O
measured	O
with	O
a	O
Hewlett	O
Packard	O
HP8452	O
diode	O
-	O
array	O
spectrophotometer	O
.	O

Fluorescence	O
spectra	O
were	O
recorded	O
on	O
a	O
Jasco	O
(	O
Japan	O
Spectroscopy	O
,	O
Japan	O
)	O
FP	O
750	O
spectrofluorimeter	O
.	O

SDS	O
-	O
PAGE	O
was	O
performed	O
according	O
to	O
[	O
22	O
]	O
.	O

N	O
-	O
Terminal	O
amino	O
acid	O
sequence	O
was	O
determined	O
using	O
an	O
Applied	O
BioSystems	O
(	O
Foster	O
City	O
,	O
USA	O
)	O
model	O
477	O
/	O
A	O
automatic	O
protein	O
sequencer	O
.	O

Commercial	O
FAD	O
was	O
purified	O
by	O
HPLC	O
as	O
reported	O
in	O
[	O
14	O
]	O
.	O

2.8	O
Materials	O
Xanthine	O
oxidase	O
was	O
purchased	O
from	O
Sigma	O
.	O

bDASPO	O
was	O
purified	O
from	O
beef	B
kidney	O
cortex	O
as	O
described	O
in	O
[	O
14	O
]	O
.	O

5-Deazaflavin-3-sulfonate	O
was	O
a	O
generous	O
gift	O
of	O
V.	O
Massey	O
(	O
University	O
of	O
Michigan	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

All	O
the	O
other	O
chemicals	O
were	O
of	O
the	O
highest	O
purity	O
commercially	O
available	O
.	O

3	O
Results	O
3.1	O
Comparison	O
between	O
the	O
properties	O
of	O
rDASPO	O
and	O
bDASPO	O
Table	O
1	O
summarizes	O
the	O
purification	O
protocol	O
of	O
rDASPO	O
starting	O
from	O
38	O
g	O
of	O
wet	O
E.	B
coli	I
paste	O
.	O

Since	O
rDASPO	O
is	O
homogeneous	O
as	O
far	O
as	O
the	O
coenzyme	O
content	O
is	O
concerned	O
(	O
FAD	O
,	O
see	O
below	O
)	O
,	O
while	O
bDASPO	O
is	O
purified	O
as	O
a	O
mixture	O
of	O
an	O
active	O
FAD	O
-	O
containing	O
and	O
an	O
inactive	O
6-OH	O
-	O
FAD	O
-	O
containing	O
form	O
,	O
the	O
specific	O
activity	O
of	O
rDASPO	O
(	O
29.1	O
U	O
mg−1	O
)	O
is	O
slightly	O
higher	O
than	O
that	O
of	O
bDASPO	O
(	O
25.3	O
U	O
mg−1	O
[	O
14	O
]	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
1	O
,	O
the	O
molecular	O
mass	O
of	O
rDASPO	O
is	O
38	O
kDa	O
,	O
in	O
agreement	O
with	O
that	O
of	O
bDASPO	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
20	O
N	O
-	O
terminal	O
residues	O
of	O
purified	O
rDASPO	O
is	O
identical	O
to	O
the	O
one	O
expected	O
from	O
the	O
sequence	O
of	O
bDASPO	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
the	O
N	O
-	O
terminal	O
Met	O
residue	O
in	O
rDASPO	O
is	O
free	O
and	O
not	O
blocked	O
as	O
it	O
is	O
in	O
bDASPO	O
[	O
16	O
]	O
.	O

The	O
visible	O
absorption	O
spectra	O
of	O
rDASPO	O
and	O
bDASPO	O
at	O
the	O
end	O
of	O
the	O
respective	O
purification	O
procedures	O
are	O
clearly	O
different	O
,	O
since	O
the	O
former	O
lacks	O
both	O
the	O
long	O
wavelength	O
absorption	O
(	O
centered	O
around	O
610	O
nm	O
)	O
and	O
the	O
pronounced	O
shoulders	O
around	O
440	O
,	O
360	O
and	O
340	O
nm	O
typically	O
observed	O
with	O
bDASPO	O
(	O
Fig.	O
2	O
in	O
this	O
paper	O
and	O
Fig.	O
1	O
of	O
[	O
14	O
]	O
)	O
.	O

As	O
reported	O
in	O
[	O
14	O
]	O
,	O
such	O
absorption	O
features	O
are	O
due	O
to	O
the	O
presence	O
of	O
variable	O
amounts	O
of	O
6-OH	O
-	O
FAD	O
in	O
bDASPO	O
.	O

In	O
accordance	O
,	O
the	O
visible	O
absorption	O
spectrum	O
of	O
rDASPO	O
resembles	O
that	O
of	O
apo	O
-	O
bDASPO	O
reconstituted	O
with	O
FAD	O
(	O
see	O
Fig.	O
6	O
of	O
[	O
14	O
]	O
)	O
,	O
although	O
the	O
latter	O
showed	O
higher	O
absorbance	O
below	O
400	O
nm	O
,	O
probably	O
a	O
consequence	O
of	O
the	O
harsh	O
conditions	O
used	O
to	O
obtain	O
the	O
complete	O
apo	O
-	O
protein	O
[	O
14	O
]	O
.	O

In	O
order	O
to	O
confirm	O
the	O
absence	O
of	O
6-OH	O
-	O
FAD	O
from	O
preparations	O
of	O
rDASPO	O
,	O
the	O
coenzyme	O
was	O
removed	O
under	O
conditions	O
which	O
allowed	O
the	O
selective	O
removal	O
of	O
FAD	O
(	O
but	O
not	O
of	O
6-OH	O
-	O
FAD	O
)	O
from	O
bDASPO	O
[	O
14	O
]	O
.	O

As	O
expected	O
,	O
no	O
visible	O
absorption	O
was	O
present	O
after	O
removal	O
of	O
FAD	O
(	O
not	O
shown	O
)	O
.	O

The	O
absence	O
of	O
the	O
6-OH	O
-	O
FAD	O
form	O
in	O
rDASPO	O
strengthens	O
the	O
hypothesis	O
that	O
such	O
a	O
form	O
has	O
no	O
biological	O
significance	O
and	O
is	O
an	O
artifact	O
of	O
the	O
long	O
lasting	O
purification	O
procedure	O
of	O
the	O
enzyme	O
from	O
the	O
natural	O
source	O
.	O

As	O
it	O
was	O
the	O
case	O
for	O
FAD	O
-	O
bDASPO	O
,	O
rDASPO	O
shows	O
flavin	O
fluorescence	O
.	O

Binding	O
of	O
apo	O
-	O
rDASPO	O
to	O
FAD	O
quenches	O
its	O
fluorescence	O
to	O
a	O
final	O
86	O
%	O
intensity	O
,	O
a	O
value	O
only	O
slightly	O
higher	O
than	O
the	O
one	O
observed	O
for	O
FAD	O
-	O
bDASPO	O
(	O
70	O
%	O
[	O
14	O
]	O
)	O
.	O

Titration	O
of	O
rDASPO	O
with	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
(	O
Fig.	O
2	O
)	O
and	O
sulfite	O
[	O
23	O
]	O
(	O
data	O
not	O
shown	O
)	O
,	O
two	O
ligands	O
whose	O
complexes	O
with	O
FAD	O
-	O
bDASPO	O
have	O
been	O
thoroughly	O
characterized	O
,	O
further	O
confirmed	O
that	O
the	O
recombinant	O
protein	O
shares	O
the	O
same	O
properties	O
as	O
the	O
FAD	O
-	O
containing	O
form	O
of	O
the	O
enzyme	O
from	O
the	O
natural	O
source	O
.	O

In	O
fact	O
,	O
the	O
dissociation	O
constants	O
determined	O
for	O
the	O
complexes	O
between	O
rDASPO	O
and	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
or	O
sulfite	O
(	O
4.10	O
×	O
10−5	O
M	O
and	O
7.5	O
×	O
10−6	O
M	O
,	O
respectively	O
)	O
are	O
very	O
similar	O
to	O
those	O
determined	O
in	O
the	O
case	O
of	O
FAD	O
-	O
bDASPO	O
(	O
2.65	O
×	O
10−5	O
M	O
and	O
7.4	O
×	O
10	O
−6	O
M	O
,	O
respectively	O
[	O
14	O
]	O
)	O
.	O

3.2	O
Apo	O
-	O
protein	O
preparation	O
and	O
holo	O
-	O
enzyme	O
reconstitution	O
As	O
reported	O
above	O
,	O
the	O
mild	O
conditions	O
used	O
to	O
remove	O
FAD	O
from	O
rDASPO	O
produced	O
a	O
complete	O
apo	O
-	O
protein	O
with	O
no	O
residual	O
visible	O
absorption	O
and	O
activity	O
.	O

Reconstitution	O
of	O
holo	O
-	O
enzyme	O
by	O
addition	O
of	O
FAD	O
resulted	O
in	O
a	O
species	O
with	O
a	O
specific	O
activity	O
of	O
90	O
%	O
as	O
compared	O
to	O
rDASPO	O
,	O
with	O
a	O
yield	O
of	O
53	O
%	O
.	O

Such	O
a	O
value	O
is	O
significantly	O
higher	O
than	O
the	O
one	O
obtained	O
in	O
the	O
case	O
of	O
bDASPO	O
(	O
24	O
%	O
)	O
,	O
due	O
to	O
the	O
harsher	O
conditions	O
necessary	O
to	O
remove	O
6-OH	O
-	O
FAD	O
from	O
bDASPO	O
[	O
14	O
]	O
.	O

3.3	O
Redox	O
potential	O
of	O
rDASPO	O
In	O
order	O
to	O
determine	O
the	O
redox	O
potential	O
of	O
the	O
enzyme	O
by	O
the	O
spectrophotometric	O
method	O
described	O
by	O
Massey	O
[	O
20	O
]	O
it	O
was	O
first	O
necessary	O
to	O
determine	O
the	O
extinction	O
coefficients	O
of	O
the	O
oxidized	O
(	O
EFAD	O
)	O
,	O
one	O
-	O
electron	O
reduced	O
(	O
semiquinone	O
,	O
EFAD−⋅	O
)	O
and	O
two	O
-	O
electron	O
reduced	O
rDASPO	O
(	O
EFADH−	O
)	O
both	O
free	O
and	O
in	O
complex	O
with	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
.	O

Fig.	O
3	O
shows	O
the	O
reduction	O
of	O
free	O
rDASPO	O
using	O
the	O
xanthine	O
/	O
xanthine	O
oxidase	O
reducing	O
system	O
.	O

Almost	O
quantitative	O
formation	O
of	O
red	O
anionic	O
semiquinone	O
(	O
91	O
%	O
)	O
was	O
observed	O
in	O
the	O
first	O
part	O
of	O
the	O
experiment	O
,	O
followed	O
by	O
complete	O
reduction	O
of	O
the	O
enzyme	O
.	O

Extinction	O
coefficients	O
at	O
any	O
wavelength	O
could	O
be	O
obtained	O
for	O
the	O
oxidized	O
and	O
fully	O
reduced	O
form	O
from	O
the	O
initial	O
and	O
the	O
final	O
spectrum	O
,	O
respectively	O
,	O
and	O
for	O
the	O
semiquinone	O
by	O
means	O
of	O
plots	O
such	O
as	O
that	O
shown	O
in	O
the	O
inset	O
of	O
Fig.	O
3	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
when	O
the	O
enzyme	O
was	O
photoreduced	O
,	O
under	O
the	O
same	O
experimental	O
conditions	O
,	O
a	O
much	O
lower	O
amount	O
of	O
semiquinone	O
was	O
detected	O
(	O
about	O
26	O
%	O
at	O
maximum	O
formation	O
,	O
data	O
not	O
shown	O
)	O
.	O

The	O
significant	O
difference	O
in	O
the	O
percentage	O
of	O
semiquinone	O
observed	O
during	O
the	O
experiments	O
using	O
different	O
reduction	O
systems	O
suggests	O
that	O
the	O
stabilization	O
of	O
the	O
radical	O
was	O
at	O
least	O
in	O
part	O
kinetic	O
rather	O
than	O
thermodynamic	O
.	O

This	O
was	O
experimentally	O
proved	O
(	O
for	O
the	O
free	O
enzyme	O
)	O
by	O
mixing	O
equimolar	O
amounts	O
of	O
EFADH−	O
and	O
EFAD	O
in	O
the	O
presence	O
of	O
benzylviologen	O
as	O
mediator	O
and	O
allowing	O
the	O
system	O
to	O
reach	O
complete	O
equilibrium	O
;	O
32	O
%	O
of	O
red	O
semiquinone	O
was	O
observed	O
after	O
24	O
h.	O
This	O
value	O
corresponds	O
to	O
a	O
semiquinone	O
formation	O
constant	O
K	O
of	O
0.89	O
,	O
where	O
[	O
24,25	O
]	O
(	O
2	O
)	O
K=	O
{	O
2	O
[	O
semiquinonemax	O
]	O
/	O
(	O
1−	O
[	O
semiquinonemax	O
]	O
)	O

}	O
2	O
From	O
the	O
relation	O
[	O
24	O
]	O
(	O
3	O
)	O
(	O
E2	O
°	O
′−E1	O
°	O
′	O
)	O
=−	O
(	O
RT	O
/	O
F	O
)	O
ln	O
K	O

it	O
can	O
be	O
predicted	O
that	O
for	O
the	O
free	O
enzyme	O
E	O
2	O
°	O
′	O
(	O
EFAD−⋅	O
/EFADH−	O
)	O
is	O
3	O
mV	O
more	O
positive	O
than	O
E	O
1	O
°	O
′	O
(	O
EFAD	O
/	O
EFAD−⋅	O
)	O
.	O

When	O
the	O
reduction	O
was	O
performed	O
in	O
the	O
presence	O
of	O
4	O
mM	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
a	O
maximum	O
amount	O
of	O
83	O
%	O
and	O
46	O
%	O
was	O
observed	O
using	O
the	O
xanthine	O
/	O
xanthine	O
oxidase	O
or	O
the	O
EDTA	O
/	O
light	O
reduction	O
method	O
,	O
respectively	O
.	O

Again	O
,	O
extinction	O
coefficients	O
for	O
oxidized	O
,	O
one	O
-	O
electron	O
and	O
two	O
-	O
electron	O
reduced	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
were	O
calculated	O
from	O
the	O
experiment	O
using	O
xanthine	O
/	O
xanthine	O
oxidase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Table	O
2	O
shows	O
the	O
experimentally	O
determined	O
redox	O
potential	O
of	O
rDASPO	O
and	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
complex	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
,	O
25	O
°	O
C	O
.	O

The	O
redox	O
potential	O
of	O
the	O
free	O
enzyme	O
was	O
determined	O
using	O
ITS	O
and	O
IDS	O
as	O
indicator	O
dyes	O
.	O

In	O
the	O
case	O
of	O
ITS	O
(	O
Fig.	O
4	O
)	O
no	O
semiquinone	O
formation	O
was	O
detected	O
and	O
a	O
midpoint	O
potential	O
of	O
−97	O
mV	O
(	O
slope=1.1	O
)	O
was	O
calculated	O
from	O
the	O
Minnaert	O
plot	O
shown	O
in	O
inset	O
of	O
Fig.	O
4	O
.	O

On	O
the	O
contrary	O
,	O
using	O
IDS	O
a	O
significant	O
amount	O
of	O
semiquinone	O
(	O
up	O
to	O
58	O
%	O
)	O
was	O
detected	O
.	O

This	O
allowed	O
to	O
calculate	O
the	O
redox	O
potentials	O
for	O
each	O
electron	O
using	O
data	O
from	O
the	O
first	O
part	O
of	O
the	O
experiment	O
for	O
E	O
1	O
°	O
′	O
(	O
−96	O
mV	O
,	O
slope=1.9	O
)	O
and	O
from	O
the	O
second	O
part	O
of	O
the	O
reaction	O
for	O
E	O
2	O
°	O
′	O
(	O
−95	O
mV	O
,	O
slope=2.0	O
)	O
(	O
Fig.	O
5	O
and	O
Table	O
2	O
)	O
.	O

The	O
calculated	O
E	O
m	O
°	O
′	O
(	O
−95.5	O
mV	O
)	O
agrees	O
well	O
with	O
the	O
midpoint	O
potential	O
determined	O
with	O
ITS	O
,	O
as	O
does	O
the	O
difference	O
between	O
E	O
2	O
°	O
′	O
and	O
E	O
1	O
°	O
′	O
(	O
determined	O
+	O
1	O
mV	O
,	O
predicted	O
from	O
the	O
semiquinone	O
formation	O
constant	O
+	O
3	O
mV	O
)	O
.	O

From	O
the	O
shift	O
in	O
the	O
midpoint	O
potential	O
of	O
FAD	O
(	O
−207	O
mV	O
,	O
Massey	O
)	O
upon	O
binding	O
to	O
rDASPO	O
(	O
−97	O
mV	O
)	O
and	O
the	O
known	O
dissociation	O
constant	O
of	O
FAD	O
for	O
the	O
oxidized	O
protein	O
(	O
5	O
×	O
10−8	O
M	O
[	O
14	O
]	O
)	O
a	O
value	O
of	O
1.0	O
×	O
10−11	O
M	O
for	O
K	O
red	O
(	O
the	O
dissociation	O
constant	O
of	O
the	O
reduced	O
coenzyme	O
)	O
can	O
be	O
calculated	O
using	O
the	O
following	O
equation	O
[	O
24	O
]	O
:	O
(	O
4	O
)	O
ΔE	O
°	O
′=RT	O
/	O
nF	O
×	O
ln	O
(	O
Kox	O
/Kred	O
)	O
In	O
the	O
presence	O
of	O
4	O
mM	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
,	O
a	O
concentration	O
100-fold	O
higher	O
than	O
the	O
dissociation	O
constant	O
of	O
the	O
ligand	O
for	O
the	O
oxidized	O
enzyme	O
,	O
a	O
midpoint	O
potential	O
of	O
−157	O
(	O
slope=1.1	O
)	O
and	O
−156	O
mV	O
(	O
slope=1.1	O
)	O
was	O
determined	O
for	O
the	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
-	O
rDASPO	O
complex	O
using	O
IDS	O
and	O
HNQ	O
(	O
Table	O
2	O
and	O
Fig.	O
6	O
)	O
as	O
indicator	O
dyes	O
,	O
respectively	O
.	O

No	O
detectable	O
formation	O
of	O
semiquinone	O
was	O
observed	O
.	O

Eq.	O
5	O
[	O
26	O
]	O
allows	O
to	O
calculate	O
the	O
dissociation	O
constant	O
of	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
for	O
reduced	O
rDASPO	O
(	O
K	O
red	O
′=3.6	O
×	O
10−2	O
M	O
)	O
:	O
(	O
5	O
)	O
ΔE	O
°	O
′=RT	O
/	O
nF	O
×	O
ln	O
{	O
(	O
1+	O
[	O
L	O
]	O
/Kred	O
′	O
)	O
/	O
(	O
1+	O
[	O
L	O
]	O
/Kox	O
′	O
)	O
}	O
where	O
ΔE	O
°	O
′	O
is	O
the	O
difference	O
between	O
the	O
redox	O
potential	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
the	O
ligand	O
,	O
K	O
red	O
′	O
is	O
the	O
dissociation	O
constant	O
of	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
from	O
reduced	O
rDASPO	O
and	O
K	O
ox	O
′	O
is	O
the	O
known	O
dissociation	O
constant	O
for	O
the	O
same	O
ligand	O
from	O
the	O
oxidized	O
enzyme	O
(	O
K	O
ox	O
′	O
,	O
4.1	O
×	O
10−5	O
M	O
,	O
see	O
above	O
)	O
,	O
and	O
[	O
L	O
]	O
the	O
concentration	O
of	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
used	O
.	O

It	O
can	O
be	O
concluded	O
that	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
binds	O
also	O
to	O
EFADH−	O
,	O
although	O
with	O
a	O
much	O
lower	O
affinity	O
as	O
compared	O
to	O
EFAD	O
.	O

This	O
result	O
confirms	O
those	O
obtained	O
for	O
another	O
ligand	O
(	O
oxaloacetate	O
)	O
and	O
for	O
the	O
substrate	O
(	O
d	O
-aspartate	O
)	O
,	O
based	O
on	O
kinetic	O
data	O
[	O
15	O
]	O
.	O

3.4	O
Oxidase	O
activity	O
towards	O
neurotransmitter	O
agonists	O
DASPO	O
is	O
strictly	O
specific	O
for	O
d	O
-amino	O
acids	O
since	O
l	O
-amino	O
acids	O
do	O
not	O
act	O
as	O
substrates	O
or	O
inhibitors	O
.	O

However	O
,	O
it	O
is	O
not	O
strictly	O
specific	O
for	O
d	O
-aspartate	O
,	O
being	O
active	O
also	O
against	O
a	O
variety	O
of	O
other	O
d	O
-amino	O
acids	O
,	O
with	O
a	O
strong	O
preference	O
for	O
dicarboxylic	O
ones	O
[	O
27,28	O
]	O
.	O

The	O
availability	O
of	O
large	O
amounts	O
of	O
pure	O
active	O
enzyme	O
allows	O
to	O
extend	O
the	O
characterization	O
of	O
the	O
substrate	O
specificity	O
of	O
DASPO	O
to	O
a	O
series	O
of	O
other	O
d	O
-amino	O
acids	O
which	O
are	O
known	O
to	O
possess	O
pharmacological	O
activity	O
as	O
neurotransmitter	O
agonists	O
[	O
12	O
]	O
.	O

The	O
apparent	O
kinetic	O
parameters	O
have	O
been	O
obtained	O
under	O
conditions	O
in	O
which	O
DASPO	O
was	O
shown	O
to	O
follow	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
d	O
-aspartate	O
(	O
from	O
2	O
mM	O
to	O
30	O
mM	O
[	O
15	O
]	O
)	O
.	O

Linear	O
double	O
reciprocal	O
plots	O
were	O
obtained	O
for	O
all	O
substrates	O
in	O
this	O
range	O
.	O

The	O
results	O
obtained	O
are	O
listed	O
in	O
Table	O
3	O
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
many	O
of	O
the	O
compounds	O
listed	O
are	O
indeed	O
oxidized	O
at	O
a	O
significant	O
rate	O
by	O
DASPO	O
.	O

Analysis	O
of	O
the	O
data	O
of	O
Table	O
3	O
suggests	O
that	O
the	O
compounds	O
can	O
be	O
divided	O
into	O
three	O
groups	O
:	O
the	O
first	O
comprises	O
those	O
which	O
do	O
not	O
seem	O
to	O
interact	O
with	O
DASPO	O
,	O
since	O
they	O
are	O
neither	O
substrates	O
nor	O
inhibitors	O
;	O
the	O
second	O
contains	O
d	O
-aspartate	O
and	O
N	O
-methyl	O
-	O
d	O
-aspartate	O
,	O
which	O
are	O
by	O
far	O
the	O
best	O
substrates	O
;	O
the	O
third	O
comprises	O
the	O
remaining	O
substrates	O
,	O
which	O
are	O
oxidized	O
at	O
similar	O
rates	O
(	O
apparent	O
turnover	O
number	O
ranging	O
between	O
0.22	O
and	O
2.2	O
s−1	O
)	O
.	O

As	O
regards	O
the	O
latter	O
group	O
,	O
the	O
results	O
suggest	O
that	O
substitution	O
of	O
a	O
sulfonic	O
(	O
d	O
,	O
l	O
-cysteic	O
acid	O
)	O
or	O
phosphonic	O
(	O
d	O
,	O
l	O
-2-amino-3-phosphonopropanoic	O
acid	O
)	O
group	O
for	O
the	O
β	O
-	O
carboxylic	O
group	O
of	O
d	O
-aspartate	O
causes	O
a	O
dramatic	O
decrease	O
in	O
the	O
turnover	O
number	O
.	O

The	O
presence	O
of	O
a	O
second	O
acidic	O
group	O
,	O
however	O
,	O
is	O
not	O
an	O
absolute	O
requirement	O
,	O
since	O
d	O
-aspartate	O
-	O
β	O
-	O
hydroxamate	O
is	O
a	O
substrate	O
.	O

In	O
accordance	O
,	O
d	O
-proline	O
was	O
shown	O
to	O
be	O
a	O
substrate	O
for	O
bDASPO	O
(	O
apparent	O
turnover	O
number	O
0.4	O
s−1	O
,	O
K	O
m	O
9	O
×	O
10−4	O
M	O
[	O
28	O
]	O
)	O
and	O
d	O
-asparagine	O
and	O
d	O
-glutamine	O
for	O
DASPO	O
from	O
Octopus	B
but	O
not	O
for	O
bDASPO	O
[	O
28	O
]	O
.	O

An	O
increase	O
in	O
the	O
length	O
of	O
the	O
carbon	O
chain	O
also	O
causes	O
a	O
drop	O
in	O
the	O
oxidation	O
rate	O
,	O
as	O
observed	O
with	O
d	O
-glutamate	O
,	O
d	O
-homocysteic	O
acid	O
and	O
,	O
more	O
dramatically	O
,	O
with	O
d	O
,	O
l	O
-2-amino-4-phosphonobutanoic	O
acid	O
,	O
which	O
is	O
neither	O
a	O
substrate	O
nor	O
an	O
inhibitor	O
.	O

A	O
further	O
decrease	O
in	O
the	O
rate	O
of	O
oxidation	O
is	O
observed	O
with	O
the	O
C6-dicarboxylic	O
compound	O
d	O
-α	O
-	O
aminoadipic	O
acid	O
.	O

As	O
expected	O
from	O
previous	O
studies	O
on	O
a	O
related	O
compound	O
(	O
2,3-diaminosuccinic	O
acid	O
[	O
29	O
]	O
)	O
,	O
threo	O
-β	O
-	O
hydroxy	O
-	O
d	O
-aspartate	O
does	O
not	O
interact	O
with	O
DASPO	O
either	O
as	O
a	O
substrate	O
or	O
an	O
inhibitor	O
.	O

The	O
oxidative	O
activity	O
of	O
DASPO	O
towards	O
glycyl	O
-	O
d	O
-aspartate	O
is	O
of	O
particular	O
relevance	O
since	O
this	O
compound	O
has	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
synaptic	O
transmission	O
in	O
prefrontal	O
cortex	O
in	O
vivo	O
[	O
13	O
]	O
.	O

4	O
Discussion	O
4.1	O
Purification	O
and	O
properties	O
of	O
rDASPO	O
This	O
paper	O
reports	O
overexpression	O
and	O
purification	O
conditions	O
leading	O
to	O
about	O
2	O
mg	O
pure	O
rDASPO	O
each	O
g	O
of	O
wet	O
E.	B
coli	I
paste	O
.	O

rDASPO	O
has	O
been	O
shown	O
to	O
possess	O
the	O
same	O
general	O
biochemical	O
properties	O
of	O
bDASPO	O
,	O
except	O
that	O
the	O
former	O
contains	O
only	O
FAD	O
,	O
while	O
the	O
latter	O
is	O
a	O
mixture	O
of	O
two	O
forms	O
,	O
an	O
active	O
one	O
containing	O
FAD	O
and	O
an	O
inactive	O
one	O
containing	O
6-OH	O
-	O
FAD	O
(	O
9–20	O
%	O
depending	O
on	O
the	O
preparation	O
)	O
[	O
14	O
]	O
.	O

For	O
such	O
reason	O
,	O
apart	O
from	O
the	O
amount	O
of	O
enzyme	O
obtained	O
and	O
the	O
ease	O
and	O
quickness	O
of	O
the	O
purification	O
protocol	O
,	O
the	O
procedure	O
reported	O
has	O
the	O
following	O
advantages	O
over	O
the	O
one	O
previously	O
used	O
to	O
obtain	O
bDASPO	O
from	O
the	O
natural	O
source	O
(	O
beef	B
kidney	O
cortex	O
)	O
:	O
rDASPO	O
possesses	O
a	O
specific	O
activity	O
higher	O
than	O
bDASPO	O
,	O
apo	O
-	O
protein	O
preparation	O
requires	O
milder	O
conditions	O
,	O
resulting	O
in	O
a	O
higher	O
yield	O
of	O
reconstitutable	O
holo	O
-	O
enzyme	O
,	O
and	O
spectroscopic	O
studies	O
are	O
facilitated	O
by	O
the	O
absence	O
of	O
a	O
second	O
compound	O
with	O
visible	O
absorption	O
properties	O
which	O
partially	O
overlap	O
those	O
of	O
FAD	O
.	O

The	O
latter	O
feature	O
has	O
been	O
used	O
to	O
determine	O
the	O
redox	O
potential	O
of	O
the	O
enzyme	O
by	O
the	O
spectrophotometric	O
method	O
set	O
up	O
by	O
Massey	O
[	O
20	O
]	O
.	O

4.2	O
Redox	O
potentials	O
of	O
DASPO	O
The	O
midpoint	O
potential	O
of	O
DASPO	O
in	O
0.1	O
M	O
KPi	O
,	O
pH	O
7.0	O
,	O
25	O
°	O
C	O
is	O
−97	O
mV.	O
Thus	O
,	O
the	O
binding	O
to	O
the	O
apo	O
-	O
enzyme	O
increases	O
the	O
redox	O
potential	O
of	O
the	O
flavin	O
by	O
110	O
mV	O
as	O
compared	O
to	O
free	O
FAD	O
,	O
a	O
shift	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
the	O
enzyme	O
as	O
a	O
dehydrogenase	O
/	O
oxidase	O
.	O

Useful	O
comparisons	O
can	O
be	O
made	O
with	O
the	O
redox	O
properties	O
of	O
the	O
closely	O
related	O
well	O
known	O
enzyme	O
d	O
-amino	O
acid	O
oxidase	O
,	O
which	O
catalyzes	O
the	O
same	O
reaction	O
catalyzed	O
by	O
DASPO	O
but	O
with	O
different	O
substrate	O
specificity	O
,	O
being	O
active	O
only	O
towards	O
neutral	O
and	O
basic	O
d	O
-amino	O
acids	O
[	O
30	O
]	O
.	O

The	O
general	O
properties	O
of	O
the	O
two	O
enzymes	O
have	O
been	O
shown	O
to	O
be	O
similar	O
,	O
although	O
their	O
kinetic	O
mechanism	O
is	O
slightly	O
different	O
[	O
15,30	O
]	O
.	O

Van	O
den	O
Berghe	O
and	O
Stankovich	O
determined	O
E	O
1	O
°	O
′	O
of	O
–98	O
mV	O
and	O
E	O
2	O
°	O
′	O
of	O
117	O
mV	O
in	O
50	O
mM	O
KPi	O
,	O
pH	O
7.0	O
,	O
18	O
°	O
C	O
for	O
d	O
-amino	O
acid	O
oxidase	O
[	O
31	O
]	O
.	O

Thus	O
,	O
the	O
calculated	O
midpoint	O
potential	O
and	O
the	O
amount	O
of	O
semiquinone	O
stabilized	O
(	O
–108	O
mV	O
and	O
40	O
%	O
,	O
respectively	O
)	O
are	O
only	O
slightly	O
different	O
from	O
the	O
ones	O
determined	O
for	O
DASPO	O
(	O
–97	O
mV	O
and	O
32	O
%	O
)	O
.	O

In	O
accordance	O
,	O
the	O
presence	O
of	O
a	O
specific	O
inhibitor	O
causes	O
similar	O
negative	O
shifts	O
in	O
the	O
redox	O
potential	O
of	O
the	O
two	O
enzymes	O
(	O
39	O
mV	O
in	O
the	O
case	O
of	O
d	O
-amino	O
acid	O
oxidase	O
with	O
benzoate	O
,	O
58	O
mV	O
for	O
DASPO	O
in	O
the	O
presence	O
of	O
l	O
-	O
(	O
+	O
)	O
-tartrate	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
redox	O
properties	O
of	O
DASPO	O
conform	O
to	O
those	O
expected	O
for	O
a	O
typical	O
flavoprotein	O
oxidase	O
[	O
32	O
]	O
.	O

This	O
is	O
in	O
marked	O
contrast	O
with	O
what	O
has	O
been	O
observed	O
for	O
E.	B
coli	I
l	O
-aspartate	O
oxidase	O
,	O
a	O
flavoenzyme	O
which	O
catalyzes	O
the	O
oxidation	O
of	O
l	O
-aspartate	O
by	O
O2	O
and	O
can	O
not	O
use	O
d	O
-aspartate	O
as	O
a	O
substrate	O
,	O
whose	O
redox	O
potential	O
(	O
–216	O
mV	O
)	O
is	O
actually	O
lower	O
than	O
that	O
of	O
free	O
FAD	O
[	O
33	O
]	O
.	O

Thus	O
,	O
the	O
redox	O
potential	O
data	O
confirm	O
other	O
experimental	O
evidence	O
which	O
suggests	O
that	O
,	O
although	O
DASPO	O
and	O
l	O
-aspartate	O
oxidase	O
catalyze	O
the	O
same	O
reaction	O
but	O
with	O
different	O
enantio	O
-	O
specificity	O
,	O
their	O
properties	O
are	O
largely	O
different	O
[	O
33–35	O
]	O
.	O

This	O
fact	O
can	O
be	O
ascribed	O
both	O
to	O
the	O
need	O
to	O
assure	O
absolute	O
stereospecificity	O
and	O
to	O
respond	O
to	O
totally	O
different	O
metabolic	O
demands	O
and	O
controls	O
.	O

In	O
fact	O
,	O
the	O
biological	O
role	O
of	O
DASPO	O
is	O
likely	O
to	O
be	O
mainly	O
catabolic	O
[	O
36	O
]	O
,	O
while	O
that	O
of	O
l	O
-aspartate	O
oxidase	O
is	O
exclusively	O
anabolic	O
,	O
since	O
it	O
catalyzes	O
the	O
first	O
step	O
in	O
the	O
de	O
novo	O
biosynthesis	O
of	O
pyridinic	O
nucleotides	O
in	O
several	O
microorganisms	B
and	O
plants	B
[	O
37	O
]	O
.	O

4.3	O
Substrate	O
specificity	O
of	O
DASPO	O
The	O
investigation	O
of	O
the	O
interaction	O
between	O
DASPO	O
and	O
dicarboxylic	O
compounds	O
which	O
are	O
known	O
to	O
possess	O
pharmacological	O
activities	O
as	O
agonists	O
/	O
antagonists	O
for	O
excitatory	O
amino	O
acid	O
receptors	O
has	O
allowed	O
to	O
identify	O
two	O
new	O
substrates	O
for	O
the	O
enzyme	O
,	O
i.e.	O
d	O
-aspartate	O
-	O
β	O
-	O
hydroxamate	O
and	O
glycyl	O
-	O
d	O
-aspartate	O
,	O
and	O
to	O
determine	O
the	O
kinetic	O
parameters	O
for	O
these	O
and	O
a	O
number	O
of	O
other	O
substrates	O
.	O

The	O
results	O
are	O
of	O
particular	O
interest	O
for	O
two	O
reasons	O
:	O
first	O
of	O
all	O
,	O
the	O
presence	O
of	O
d	O
-aspartate	O
,	O
d	O
-glutamate	O
,	O
N	O
-methyl	O
-	O
d	O
-aspartate	O
and	O
glycyl	O
-	O
d	O
-aspartate	O
have	O
been	O
reported	O
in	O
several	O
organisms	O
[	O
4–10,13,38	O
]	O
;	O
secondly	O
,	O
all	O
of	O
the	O
compounds	O
listed	O
in	O
Table	O
3	O
are	O
used	O
for	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
as	O
agonists	O
/	O
antagonists	O
for	O
excitatory	O
amino	O
acid	O
receptors	O
but	O
the	O
metabolic	O
fate	O
of	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
them	O
is	O
still	O
unknown	O
.	O

Since	O
DASPO	O
has	O
been	O
shown	O
to	O
be	O
present	O
in	O
a	O
number	O
of	O
tissues	O
,	O
the	O
possibility	O
exists	O
that	O
the	O
effect	O
of	O
such	O
compounds	O
can	O
be	O
influenced	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
the	O
amount	O
of	O
DASPO	O
present	O
.	O

Acknowledgements	O
We	O
wish	O
to	O
thank	O
Prof.	O
Tatjana	O
Simonic	O
for	O
providing	O
E.	O
coli	O
GI724	O
(	O
pED	O
)	O
cells	O
.	O

This	O
paper	O
was	O
supported	O
by	O
grants	O
from	O
the	O
Ministero	O
della	O
Università	O
e	O
della	O
Ricerca	O
Scientifica	O
and	O
from	O
the	O
Consiglio	O
Nazionale	O
delle	O
Ricerche	O
(	O
Italy	O
)	O
.	O

The	O
cardiotoxic	O
effect	O
of	O
karminomycin	O
and	O
adriamycin	O
administered	O
intravenously	O
for	O
5	O
times	O
in	O
equitoxic	O
doses	O
constituting	O
equal	O
portions	O
of	O
LD50	O
of	O
the	O
respective	O
antibiotic	O
on	O
its	O
single	O
intravenous	O
administration	O
was	O
studied	O
on	O
albino	B
mice	I
.	O

Histological	O
examination	O
of	O
the	O
heart	O
showed	O
that	O
almost	O
identical	O
damages	O
of	O
the	O
myocardium	O
occured	O
after	O
administration	O
of	O
karminomycin	O
and	O
adriamycin	O
in	O
doses	O
of	O
0.45	O
of	O
LD50	O
(	O
1.5	O
mg	O
/	O
kg	O
)	O
and	O
0.3	O
of	O
LD50	O
(	O
6.3	O
mg	O
/	O
kg	O
)	O
respectively	O
.	O

The	O
character	O
of	O
the	O
damages	O
due	O
to	O
the	O
antibiotics	O
was	O
close	O
,	O
the	O
most	O
significant	O
changes	O
were	O
observed	O
when	O
the	O
animals	O
were	O
sacrificed	O
1	O
month	O
after	O
the	O
last	O
administration	O
of	O
the	O
drug	O
.	O

The	O
histological	O
method	O
is	O
of	O
value	O
in	O
estimation	O
of	O
the	O
cardiotoxic	O
effect	O
of	O
the	O
drugs	O
,	O
using	O
mice	B
as	O
the	O
model	O
suitable	O
for	O
the	O
investigation	O
.	O

Adriamycin	O
had	O
more	O
pronounced	O
cumulative	O
properties	O
as	O
compared	O
to	O
karminomycin	O
:	O
suppression	O
of	O
the	O
weight	O
gain	O
in	O
the	O
mice	B
and	O
their	O
death	O
rate	O
were	O
higher	O
with	O
the	O
use	O
of	O
adriamycin	O
.	O

Three	O
sialosylated	O
and	O
three	O
neutral	O
glycosphingolipids	O
sharing	O
a	O
common	O
iso	O
-	O
neolacto	O
core	O
were	O
isolated	O
from	O
porcine	B
kidney	O
cortex	O
.	O

They	O
were	O
purified	O
by	O
preparative	O
HPTLC	O
,	O
and	O
were	O
characterized	O
by	O
partial	O
exoglycosidase	O
hydrolysis	O
followed	O
by	O
thin	O
layer	O
chromatography	O
and	O
immunostaining	O
with	O
anti	O
-	O
Galalpha1	O
-	O
->3Gal	O
,	O
anti	O
-	O
type	O
2	O
lactosamine	O
and	O
anti	O
-	O
Lewis	O
(	O
x	O
)	O
antibodies	O
,	O
methylation	O
analysis	O
,	O
MALDI	O
-	O
TOF	O
mass	O
spectrometry	O
and	O
1H	O
-	O
NMR	O
spectroscopy	O
.	O

Among	O
neutral	O
glycolipids	O
,	O
one	O
was	O
a	O
known	O
structure	O
,	O
VI3VI'3	O
(	O
alphaGal	O
)	O
2-iso	O
-	O
nLc8Cer	O
,	O
and	O
two	O
were	O
novel	O
structures	O
differing	O
by	O
the	O
number	O
of	O
Galalpha3Lewis	O
(	O
x	O
)	O
determinants	O
:	O
VI3VI'3	O
(	O
alphaGal	O
)	O
2V'3alphaFuc	O
-	O
iso	O
-	O
nLc8	O
,	O
and	O
VI3VI'3	O
(	O
alphaGal	O
)	O
2	O
V3V'3	O
(	O
alphaFuc	O
)	O
2-iso	O
-	O
nLc8	O
.	O

The	O
single	O
Galalpha3Lewis	O
(	O
x	O
)	O
determinant	O
was	O
found	O
on	O
the	O
6-linked	O
antenna	O
.	O

Among	O
sialosylated	O
glycolipids	O
,	O
two	O
had	O
been	O
previously	O
found	O
in	O
other	O
species	O
and	O
tissues	O
,	O
VI3VI'3	O
(	O
NeuAc	O
)	O
2-iso	O
-	O
nLc8	O
,	O
and	O
VI3NeuAcVI'3alphaGal	O
-	O
iso	O
-	O
nLc8	O
.	O

A	O
novel	O
structure	O
was	O
discovered	O
presenting	O
a	O
Galalpha3Lewis	O
(	O
x	O
)	O
determinant	O
on	O
the	O
6-linked	O
antenna	O
and	O
a	O
N	O
-	O
acetylneuraminic	O
acid	O
on	O
the	O
3-linked	O
antenna	O
,	O
VI3NeuAcVI'3alphaGalV'3alphaFuc	O
-	O
iso	O
-	O
nLc8	O
.	O

These	O
results	O
indicate	O
that	O
,	O
in	O
vivo	O
,	O
the	O
porcine	B
kidney	O
alpha3fucosyltransferase	O
synthesizes	O
the	O
Gala3Lewis	O
(	O
x	O
)	O
determinant	O
,	O
acting	O
on	O
the	O
6-linked	O
before	O
the	O
3-linked	O
Galalpha3neolactosamine	O
,	O
and	O
appears	O
unable	O
to	O
synthesize	O
the	O
sialosylated	O
Lewis	O
(	O
x	O
)	O
determinant	O
on	O
neolactoseries	O
glycolipids	O
.	O

A	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
was	O
produced	O
against	O
the	O
p	O
-	O
nitrophenylphosphate	O
derivative	O
of	O
3	O
alpha	O
,	O
5	O
beta	O
-	O
lithocholic	O
acid	O
,	O
a	O
transition	O
-	O
state	O
analog	O
for	O
hydrolysis	O
of	O
a	O
steroidal	O
p	O
-	O
nitrophenylcarbonate	O
.	O

The	O
indicated	O
reaction	O
was	O
catalyzed	O
by	O
this	O
Ab	O
with	O
kinetic	O
constants	O
kcat	O
=	O
4.0	O
x	O
10	O
(	O
-2	O
)	O
/	O
min	O
and	O
K	O
(	O
m	O
)	O
=	O
3.3	O
microM	O
at	O
pH	O
9.0	O
and	O
35	O
degrees	O
C.	O
The	O
Ab	O
also	O
hydrolyzed	O
the	O
isomeric	O
p	O
-	O
nitrophenylcarbonate	O
of	O
3	O
beta	O
,	O
5	O
beta	O
-	O
lithocholic	O
acid	O
with	O
kcat	O
=	O
8.4	O
x	O
10	O
(	O
-2	O
)	O
/	O
min	O
and	O
K	O
(	O
m	O
)	O
=	O
1.0	O
microM.	O
Bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
was	O
found	O
to	O
catalyze	O
the	O
same	O
reactions	O
with	O
similar	O
turnover	O
rates	O
and	O
Michaelis	O
constants	O
of	O
15	O
and	O
14	O
microM	O
,	O
respectively	O
.	O

Although	O
the	O
BSA	O
-	O
catalyzed	O
reaction	O
was	O
only	O
weakly	O
inhibited	O
by	O
the	O
phosphate	O
ester	O
TSA	O
(	O
IC50	O
ca	O
.	O

40	O
microM	O
)	O
,	O
the	O
Ab	O
-	O
catalyzed	O
reaction	O
was	O
completely	O
inhibited	O
at	O
less	O
than	O
1	O
microM	O
of	O
the	O
TSA	O
.	O

The	O
relative	O
rates	O
and	O
efficiencies	O
of	O
the	O
MAb	O
-	O
catalyzed	O
and	O
BSA	O
-	O
catalyzed	O
reactions	O
are	O
discussed	O
in	O
the	O
context	O
of	O
the	O
hydrophobic	O
sites	O
and	O
intrinsic	O
reactivity	O
of	O
the	O
protein	O
surfaces	O
,	O
and	O
the	O
induction	O
of	O
groups	O
on	O
the	O
Ab	O
to	O
enhance	O
the	O
enzymatic	O
function	O
.	O

To	O
clarify	O
the	O
relationship	O
between	O
the	O
occurrence	O
of	O
unusual	O
trihydroxy	O
bile	O
acids	O
,	O
namely	O
hyocholic	O
acid	O
,	O
ursocholic	O
acid	O
(	O
UCA	O
)	O
,	O
and	O
omega	O
-	O
muricholic	O
acid	O
(	O
omega	O
-	O
MCA	O
)	O
in	O
urine	O
and	O
liver	O
disease	O
severity	O
,	O
urinary	O
bile	O
acids	O
were	O
analyzed	O
by	O
gas	O
-	O
liquid	O
chromatography	O
in	O
acute	O
and	O
late	O
phases	O
of	O
acute	O
hepatitis	O
and	O
before	O
and	O
after	O
ursodeoxycholic	O
acid	O
(	O
UDCA	O
)	O
loading	O
in	O
healthy	O
adults	B
and	O
liver	O
cirrhosis	O
patients	B
.	O

In	O
11	O
patients	B
with	O
acute	O
hepatitis	O
,	O
the	O
occurrence	O
rates	O
and	O
amounts	O
of	O
unusual	O
trihydroxy	O
bile	O
acids	O
were	O
increased	O
in	O
the	O
late	O
(	O
recovery	O
)	O
phase	O
,	O
as	O
compared	O
with	O
those	O
in	O
the	O
early	O
phase	O
.	O

In	O
10	O
patients	B
with	O
severe	O
acute	O
hepatitis	O
who	O
had	O
prothrombin	O
times	O
exceeding	O
16	O
seconds	O
,	O
these	O
bile	O
acids	O
had	O
completely	O
disappeared	O
from	O
the	O
urine	O
in	O
the	O
early	O
phase	O
but	O
reappeared	O
in	O
the	O
late	O
phase	O
in	O
those	O
who	O
had	O
a	O
good	O
outcome	O
,	O
though	O
never	O
in	O
a	O
patient	B
who	O
died	O
.	O

After	O
UDCA	O
administration	O
for	O
a	O
week	O
,	O
the	O
amounts	O
of	O
unusual	O
bile	O
acids	O
,	O
especially	O
UCA	O
and	O
omega	O
-	O
MCA	O
,	O
which	O
are	O
thought	O
to	O
be	O
synthesized	O
through	O
12	O
alpha-	O
and	O
6	O
alpha	O
-	O
hydroxylations	O
,	O
respectively	O
,	O
from	O
UDCA	O
,	O
were	O
clearly	O
increased	O
in	O
10	O
healthy	O
adults	B
but	O
only	O
slightly	O
changed	O
in	O
10	O
patients	B
with	O
liver	O
cirrhosis	O
.	O

In	O
conclusion	O
,	O
hepatic	O
hydroxylations	O
of	O
dihydroxy	O
bile	O
acids	O
as	O
a	O
detoxification	O
reaction	O
were	O
impaired	O
in	O
severe	O
liver	O
diseases	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
intensification	O
and	O
perpetuation	O
of	O
hepatocellular	O
injuries	O
.	O

1	O
.	O

Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically	O
-	O
reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2	O
.	O

Flow	O
cytometry	O
revealed	O
binding	O
of	O
N	O
-	O
hydroxy	O
(	O
SMX	O
-	O
NHOH	O
)	O
and	O
nitroso	O
(	O
SMX	O
-	O
NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	O
of	O
SMX	O
itself	O
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O

Cellular	O
haptenation	O
by	O
SMX	O
-	O
NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3	O
.	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	O
bioinactivation	O
mechanism	O
.	O

4	O
.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5	O
.	O

Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX	O
-	O
NHOH	O
and	O
SMX	O
-	O
NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	O
effect	O
.	O

Lymphocytes	O
were	O
significantly	O
(	O
P<0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX	O
-	O
NO	O
than	O
neutrophils	O
.	O

6	O
.	O

Partitioning	O
of	O
SMX	O
-	O
NHOH	O
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P<0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

Proline	O
(	O
Pro	O
)	O
and	O
hydroxyproline	O
(	O
Hyp	O
)	O
formed	O
by	O
hydroxylation	O
of	O
Pro	O
during	O
collagen	O
biosynthesis	O
are	O
commonly	O
found	O
in	O
connective	O
tissue	O
proteins	O
such	O
as	O
collagen	O
at	O
high	O
concentrations	O
.	O

These	O
amino	O
acids	O
are	O
released	O
after	O
degradation	O
of	O
collagen	O
and	O
excreted	O
into	O
urine	O
as	O
amino	O
acids	O
,	O
small	O
peptides	O
and	O
large	O
peptides	O
.	O

According	O
to	O
previous	O
reports	O
[	O
1–4	O
]	O
,	O
total	O
Hyp	O
excreted	O
in	O
urine	O
is	O
comprised	O
of	O
∼85	O
%	O
small	O
peptides	O
and	O
1–5	O
%	O
free	O
Hyp	O
.	O

The	O
main	O
peptide	O
containing	O
Hyp	O
was	O
prolylhydroxyproline	O
(	O
Pro	O
–	O
Hyp	O
)	O
which	O
accounted	O
for	O
about	O
60	O
%	O
of	O
peptide	O
Hyp	O
or	O
44	O
%	O
of	O
total	O
urinary	O
Hyp	O
[	O
2,4	O
]	O
.	O

The	O
concentration	O
of	O
total	O
urinary	O
Pro	O
and	O
Hyp	O
varied	O
in	O
association	O
with	O
various	O
diseases	O
including	O
bone	O
diseases	O
[	O
1,5–7	O
]	O
and	O
tumor	O
[	O
8–10	O
]	O
and	O
excretion	O
of	O
dipeptides	O
containing	O
Pro	O
or	O
Hyp	O
increases	O
in	O
patients	B
with	O
disorders	O
involving	O
collagen	O
metabolism	O
[	O
11–13	O
]	O
.	O

Therefore	O
,	O
sensitive	O
and	O
reliable	O
determinations	O
of	O
these	O
metabolites	O
in	O
human	B
urine	O
are	O
useful	O
for	O
understanding	O
of	O
various	O
disorders	O
.	O

Currently	O
,	O
a	O
few	O
methods	O
for	O
the	O
determination	O
of	O
dipeptides	O
that	O
contain	O
Pro	O
or	O
Hyp	O
in	O
urine	O
by	O
gas	O
chromatograpgy	O
–	O
mass	O
spectrometry	O
(	O
GC	O
–	O
MS	O
)	O
[	O
11–14	O
]	O
,	O
liquid	O
chromatography	O
(	O
LC	O
)	O
–MS	O
[	O
15–17	O
]	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
[	O
18	O
]	O
have	O
been	O
reported	O
.	O

However	O
,	O
the	O
GC	O
–	O
MS	O
and	O
LC	O
–	O
MS	O
methods	O
require	O
tedious	O
procedures	O
including	O
a	O
two	O
-	O
step	O
column	O
separation	O
for	O
pre	O
-	O
treatment	O
of	O
urine	O
and	O
further	O
,	O
the	O
GC	O
–	O
MS	O
methods	O
require	O
a	O
two	O
-	O
step	O
derivatization	O
procedure	O
to	O
convert	O
dipeptides	O
into	O
volatile	O
derivatives	O
after	O
pre	O
-	O
treatment	O
.	O

In	O
the	O
HPLC	O
method	O
employing	O
a	O
pre	O
-	O
column	O
derivatization	O
technique	O
with	O
4-chloro-7-nitrobenzofurazan	O
as	O
a	O
fluorescent	O
labelling	O
reagent	O
,	O
a	O
relatively	O
large	O
sample	O
volume	O
(	O
5	O
ml	O
)	O
is	O
required	O
because	O
of	O
low	O
sensitivity	O
to	O
prolyl	B
dipeptides	I
.	O

Recently	O
,	O
we	O
developed	O
an	O
extremely	O
sensitive	O
fluorescent	O
labelling	O
reagent	O
,	O
4-	O
(	O
5,6-dimethoxy-2-phthalimidinyl	O
)	O
-2-methoxyphenylsulfonyl	O
chloride	O
(	O
DMS	O
-	O
Cl	O
)	O
,	O
which	O
reacts	O
quantitatively	O
with	O
amino	O
acids	O
to	O
form	O
fluorescent	O
sulfonamides	O
(	O
maximum	O
wavelength	O
:	O
318	O
nm	O
for	O
excitation	O
and	O
392	O
nm	O
for	O
emission	O
)	O
,	O
and	O
applied	O
the	O
reagent	O
for	O
determination	O
of	O
urinary	O
free	O
Hyp	O
by	O
a	O
pre	O
-	O
column	O
HPLC	O
method	O
[	O
19	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
DMS	O
-	O
Cl	O
reacted	O
with	O
prolyl	O
dipeptides	O
to	O
give	O
fluorescent	O
derivatives	O
.	O

In	O
addition	O
,	O
a	O
highly	O
sensitive	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
in	O
urine	O
by	O
fluorescence	O
detection	O
after	O
pre	O
-	O
column	O
derivatization	O
with	O
DMS	O
-	O
Cl	O
was	O
established	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
solvents	O
All	O
chemicals	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
unless	O
stated	O
otherwise	O
.	O

DMS	O
-	O
Cl	O
was	O
prepared	O
as	O
described	O
previously	O
[	O
19	O
]	O
.	O

o	O
-Phthalaldehyde	O
(	O
OPA	O
)	O
,	O
acetonitrile	O
(	O
HPLC	O
-	O
grade	O
)	O
and	O
Creatinine	O
Test	O
Wako	O
were	O
obtained	O
from	O
Wako	O
Pure	O
Chemicals	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Pro	O
–	O
Asp	O
,	O
Pro	O
–	O
Gln	O
,	O
Pro	O
–	O
Glu	O
,	O
Pro	O
–	O
Leu	O
,	O
Pro	O
–	O
Pro	O
and	O
Pro	O
–	O
Ser	O
were	O
purchased	O
from	O
Kokusan	O
Chemical	O
Works	O
(	O
Tokyo	O
,	O
Japan	O
)	O
and	O
Pro	O
–	O
Ala	O
,	O
Pro	O
–	O
Asn	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Hyp	O
,	O

Pro	O
–	O
Ile	O
,	O
Pro	O
–	O
Met	O
,	O
Pro	O
–	O
Phe	O
,	O
Pro	O
–	O
Trp	O
,	O
Pro	O
–	O
Tyr	O
,	O
Pro	O
–	O
Val	O
and	O
3,4-dehydro	O
-	O
dl	O
-proline	O
(	O
internal	O
standard	O
,	O
I.S.	O
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

l	O
-Amino	O
acids	O
except	O
Asn	O
,	O
Hyp	O
and	O
Ser	O
(	O
Nacalai	O
Tesque	O
,	O
Kyoto	O
,	O
Japan	O
)	O
were	O
purchased	O
from	O
Kyowa	O
Hakko	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Organic	O
solvents	O
except	O
acetonitrile	O
were	O
of	O
highest	O
purity	O
available	O
and	O
used	O
as	O
received	O
.	O

Bond	O
Elut	O
C18	O
(	O
100	O
mg	O
/	O
1	O
ml	O
,	O
Varian	O
,	O
CA	O
,	O
USA	O
)	O
was	O
conditioned	O
with	O
2	O
ml	O
of	O
methanol	O
followed	O
by	O
2	O
ml	O
of	O
water	O
and	O
1	O
ml	O
of	O
Na2	O
HPO4	O
(	O
50	O
mM	O
)	O
prior	O
to	O
use	O
.	O

2.2	O
Instrumental	O
conditions	O
The	O
HPLC	O
system	O
consisted	O
of	O
two	O
LC-10AD	O
HPLC	O
pumps	O
(	O
Shimadzu	O
,	O
Kyoto	O
,	O
Japan	O
)	O
,	O
a	O
CTO-10AC	O
column	O
oven	O
(	O
Shimadzu	O
)	O
,	O
a	O
DGU-14A	O
on	O
-	O
line	O
degasser	O
(	O
Shimadzu	O
)	O
,	O
an	O
SIL-10Axl	O
auto	O
injector	O
(	O
Shimadzu	O
)	O
,	O
an	O
L-7480	O
fluorescence	O
detector	O
(	O
Hitachi	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
a	O
CLASS	O
-	O
LC10	O
LC	O
work	O
-	O
station	O
(	O
Shimadzu	O
)	O
with	O
a	O
CBM-10A	O
communications	O
bus	O
module	O
(	O
Shimadzu	O
)	O
.	O

A	O
TSK	O
-	O
guard	O
gel	O
ODS-80Ts	O
(	O
15	O
×	O
3.2	O
mm	O
I.D.	O
,	O
Tosoh	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
tandem	O
Nova	O
Pak	O
C18	O
columns	O
(	O
150	O
×	O
3.9	O
mm	O
I.D.	O
,	O
4	O
μm	O
,	O
Waters	O
,	O
Milford	O
,	O
MA	O
,	O
USA	O
)	O
were	O
used	O
at	O
55	O
°	O
C	O
with	O
a	O
gradient	O
system	O
of	O
(	O
A	O
)	O
aqueous	O
acetic	O
acid	O
(	O
10	O
mM	O
)	O
–	O
(	O
B	O
)	O
acetonitrile	O
–	O
aqueous	O
acetic	O
acid	O
(	O
50	O
mM	O
)	O
(	O
8:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
elution	O
program	O
consisted	O
of	O
an	O
isocratic	O
elution	O
of	O
25	O
%	O
B	O
for	O
20	O
min	O
,	O
followed	O
by	O
a	O
linear	O
gradient	O
elution	O
from	O
25	O
to	O
55	O
%	O
of	O
B	O
for	O
30	O
min	O
,	O
and	O
finally	O
a	O
stepwise	O
decrease	O
to	O
25	O
%	O
of	O
B	O
to	O
re	O
-	O
equilibrate	O
the	O
column	O
for	O
10	O
min	O
.	O

The	O
flow	O
-	O
rate	O
was	O
1	O
ml	O
/	O
min	O
.	O

The	O
fluorescence	O
intensities	O
were	O
monitored	O
at	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
318	O
nm	O
and	O
392	O
nm	O
,	O
respectively	O
.	O

2.3	O
Derivatization	O
procedure	O
To	O
a	O
test	O
solution	O
(	O
20	O
μl	O
)	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
,	O
Hyp	O
and	O
the	O
I.S.	O
were	O
placed	O
in	O
a	O
screw	O
-	O
capped	O
glass	O
vial	O
,	O
Na2	O
HPO4	O
(	O
50	O
mM	O
,	O
280	O
μl	O
)	O
and	O
DMS	O
-	O
Cl	O
(	O
2	O
mM	O
in	O
acetone	O
,	O
500	O
μl	O
)	O
were	O
successively	O
added	O
and	O
mixed	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
stand	O
for	O
20	O
min	O
at	O
70	O
°	O
C	O
.	O

After	O
cooling	O
,	O
the	O
reaction	O
mixture	O
was	O
mixed	O
with	O
dichloromethane	O
(	O
0.8	O
ml	O
)	O
and	O
Na2	O
CO3	O
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

An	O
aliquot	O
(	O
10	O
μl	O
)	O
of	O
the	O
aqueous	O
layer	O
was	O
subjected	O
to	O
HPLC	O
.	O

2.4	O
Procedure	O
for	O
determination	O
of	O
urinary	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
2.4.1	O
Method	O
A	O
(	O
recommended	O
method	O
)	O
:	O
solid	O
-	O
phase	O
extraction	O
method	O
To	O
human	B
urine	O
(	O
25	O
μl	O
)	O
were	O
added	O
I.S.	O
(	O
10	O
μM	O
,	O
25	O
μl	O
)	O
,	O
Na2	O
HPO4	O
(	O
50	O
mM	O
,	O
150	O
μl	O
)	O
and	O
OPA	O
[	O
4	O
%	O
,	O
w	O
/	O
v	O
,	O
in	O
acetonitrile	O
–	O
Na2	O
HPO4	O
(	O
50	O
mM	O
)	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
,	O
50	O
μl	O
]	O
.	O

After	O
standing	O
for	O
3	O
min	O
,	O
the	O
OPA	O
-	O
treated	O
mixture	O
(	O
200	O
μl	O
)	O
was	O
passed	O
through	O
a	O
Bond	O
Elut	O
C18	O
column	O
and	O
then	O
the	O
column	O
was	O
washed	O
with	O
acetonitrile	O
–	O
Na2	O
HPO4	O
(	O
50	O
mM	O
)	O
(	O
1:9	O
,	O
v	O
/	O
v	O
,	O
800	O
μl	O
)	O
.	O

The	O
effluent	O
with	O
the	O
OPA	O
-	O
treated	O
mixture	O
and	O
the	O
washings	O
were	O
mixed	O
.	O

The	O
mixture	O
(	O
300	O
μl	O
)	O
was	O
reacted	O
with	O
DMS	O
-	O
Cl	O
(	O
2	O
mM	O
in	O
acetone	O
,	O
500	O
μl	O
)	O
at	O
70	O
°	O
C	O
for	O
20	O
min	O
.	O

The	O
reaction	O
mixture	O
was	O
mixed	O
with	O
dichloromethane	O
(	O
0.8	O
ml	O
)	O
and	O
Na2	O
CO3	O
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

The	O
aqueous	O
layer	O
(	O
10	O
μl	O
)	O
was	O
subjected	O
to	O
HPLC	O
.	O

The	O
Bond	O
Elut	O
C18	O
column	O
was	O
used	O
at	O
least	O
20	O
times	O
by	O
washing	O
twice	O
sequentially	O
with	O
methanol	O
and	O
water	O
(	O
2	O
ml	O
each	O
)	O
after	O
each	O
use	O
.	O

2.4.2	O
Method	O
B	O
:	O
solvent	O
extraction	O
-	O
stripping	O
method	O
To	O
human	B
urine	O
(	O
20	O
μl	O
)	O
were	O
added	O
I.S.	O
(	O
10	O
μM	O
,	O
20	O
μl	O
)	O
,	O
Na2	O
HPO4	O
(	O
50	O
mM	O
,	O
260	O
μl	O
)	O
and	O
OPA	O
(	O
4	O
%	O
,	O
w	O
/	O
v	O
,	O
in	O
acetone	O
,	O
50	O
μl	O
)	O
.	O

After	O
standing	O
for	O
3	O
min	O
,	O
DMS	O
-	O
Cl	O
(	O
2	O
mM	O
in	O
acetone	O
,	O
450	O
μl	O
)	O
was	O
successively	O
added	O
and	O
mixed	O
.	O

The	O
mixture	O
was	O
allowed	O
to	O
stand	O
for	O
20	O
min	O
at	O
70	O
°	O
C	O
.	O

After	O
cooling	O
,	O
the	O
reaction	O
mixture	O
was	O
acidified	O
with	O
HCl	O
(	O
5	O
M	O
,	O
50	O
μl	O
)	O
,	O
saturated	O
with	O
NaCl	O
(	O
ca	O
.	O
150	O
mg	O
)	O
and	O
then	O
extracted	O
with	O
dichloromethane	O
(	O
1	O
ml	O
)	O
.	O

The	O
organic	O
layer	O
(	O
1	O
ml	O
)	O
was	O
mixed	O
with	O
Na2	O
CO3	O
(	O
10	O
mM	O
,	O
300	O
μl	O
)	O
and	O
then	O
centrifuged	O
(	O
500	O
g	O
)	O
for	O
10	O
min	O
.	O

The	O
aqueous	O
layer	O
(	O
10	O
μl	O
)	O
was	O
subjected	O
to	O
HPLC	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Chromatographic	O
separation	O
DMS	O
-	O
Cl	O
reacted	O
with	O
prolyl	O
dipeptides	O
in	O
a	O
basic	O
medium	O
to	O
give	O
the	O
corresponding	O
fluorescent	O
derivatives	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
separation	O
of	O
the	O
derivatives	O
of	O
prolyl	O
dipeptides	O
(	O
16	O
species	O
)	O
,	O
Pro	O
,	O
Hyp	O
and	O
I.S.	O
labelled	O
with	O
DMS	O
-	O
Cl	O
were	O
examined	O
by	O
use	O
of	O
tandem	O
reversed	O
-	O
phase	O
columns	O
and	O
gradient	O
elution	O
.	O

A	O
typical	O
chromatogram	O
of	O
the	O
reaction	O
mixture	O
of	O
a	O
standard	O
solution	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

The	O
peaks	O
due	O
to	O
12	O
species	O
of	O
prolyl	O
dipeptides	O
(	O
retention	O
time	O
:	O
Pro	O
–	O
Asn	O
,	O
14.8	O
;	O
–Gln	O
,	O
16.2	O
;	O
–Hyp	O
,	O
17.1	O
;	O
–Glu	O
,	O
23.9	O
;	O
–Gly	O
,	O
27.0	O
;	O
–Ala	O
,	O
33.8	O
;	O
–Pro	O
,	O
35.0	O
;	O
–Tyr	O
,	O
37.7	O
;	O
–Met	O
,	O
42.1	O
;	O
–Val	O
,	O
43.7	O
;	O
–Trp	O
,	O
47.3	O
;	O
–Phe	O
,	O
49.1	O
min	O
)	O
,	O
Pro	O
(	O
34.4	O
min	O
)	O
,	O
Hyp	O
(	O
12.2	O
min	O
)	O
and	O
I.S.	O
(	O
31.0	O
min	O
)	O
were	O
separate	O
from	O
each	O
other	O
and	O
the	O
reagent	O
blank	O
components	O
,	O
although	O
the	O
peaks	O
due	O
to	O
Pro	O
–	O
Asp	O
(	O
18.6	O
min	O
)	O
and	O
Pro	O
–	O
Ser	O
(	O
18.7	O
min	O
)	O
and	O
those	O
due	O
to	O
Pro	O
–	O
Ile	O
(	O
47.9	O
min	O
)	O
and	O
Pro	O
–	O
Leu	O
(	O
48.0	O
min	O
)	O
overlapped	O
.	O

As	O
the	O
chromatographic	O
separation	O
of	O
DMS	O
derivatives	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
,	O
Hyp	O
and	O
I.S.	O
was	O
affected	O
by	O
the	O
pH	O
in	O
the	O
mobile	O
phase	O
,	O
the	O
effect	O
of	O
the	O
pH	O
was	O
examined	O
using	O
acetate	O
buffer	O
[	O
10	O
mM	O
for	O
mobile	O
phase	O
(	O
A	O
)	O
and	O
50	O
mM	O
for	O
mobile	O
phase	O
(	O
B	O
)	O
,	O
pH	O
4.0–6.0	O
]	O
instead	O
of	O
acetic	O
acid	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
the	O
retention	O
times	O
of	O
all	O
peaks	O
became	O
shorter	O
with	O
increased	O
pH	O
and	O
the	O
prolyl	O
dipeptide	O
peaks	O
overlapped	O
at	O
pH	O
greater	O
than	O
pH	O
4.5	O
.	O

The	O
pH	O
of	O
acetic	O
acid	O
(	O
10	O
mM	O
)	O
in	O
mobile	O
phase	O
was	O
about	O
3.4	O
.	O

3.2	O
Labelling	O
reaction	O
conditions	O
A	O
standard	O
solution	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
(	O
10	O
μM	O
each	O
)	O
was	O
used	O
to	O
determine	O
the	O
optimum	O
labelling	O
conditions	O
.	O

The	O
reaction	O
of	O
Hyp	O
with	O
DMS	O
-	O
Cl	O
was	O
complete	O
within	O
5	O
min	O
regardless	O
of	O
the	O
temperature	O
(	O
labelling	O
yield	O
:	O
99.7	O
%	O
)	O
[	O
19	O
]	O
.	O

However	O
,	O
the	O
labelling	O
reactions	O
of	O
prolyl	O
dipeptides	O
with	O
DMS	O
-	O
Cl	O
were	O
incomplete	O
under	O
the	O
above	O
conditions	O
,	O
while	O
the	O
reactions	O
of	O
Pro	O
and	O
I.S.	O
with	O
DMS	O
-	O
Cl	O
were	O
similar	O
to	O
that	O
of	O
Hyp	O
.	O

Therefore	O
,	O
the	O
effect	O
of	O
the	O
reaction	O
time	O
on	O
the	O
labelling	O
reaction	O
was	O
examined	O
at	O
various	O
temperatures	O
.	O

The	O
results	O
obtained	O
for	O
Pro	O
–	O
Hyp	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

The	O
maximum	O
peak	O
area	O
was	O
obtained	O
from	O
the	O
reactions	O
performed	O
at	O
above	O
70	O
°	O
C	O
,	O
for	O
10	O
min	O
.	O

Similar	O
results	O
were	O
obtained	O
from	O
other	O
prolyl	O
dipeptides	O
.	O

Consequently	O
,	O
subsequent	O
labelling	O
reactions	O
for	O
prolyl	O
dipeptides	O
,	O
Pro	O
,	O
Hyp	O
and	O
I.S.	O
with	O
DMS	O
-	O
Cl	O
were	O
carried	O
out	O
at	O
70	O
°	O
C	O
for	O
20	O
min	O
.	O

The	O
reaction	O
mixture	O
was	O
stable	O
for	O
at	O
least	O
48	O
h	O
at	O
room	O
temperature	O
.	O

As	O
the	O
labelling	O
reaction	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
,	O
Hyp	O
and	O
I.S.	O
with	O
DMS	O
-	O
Cl	O
proceeded	O
in	O
a	O
basic	O
medium	O
,	O
the	O
effect	O
of	O
the	O
pH	O
of	O
phosphate	O
buffer	O
(	O
50	O
mM	O
)	O
on	O
the	O
labelling	O
reaction	O
was	O
examined	O
.	O

The	O
results	O
for	O
Pro	O
–	O
Hyp	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
and	O
I.S.	O
are	O
shown	O
in	O
Fig.	O
5	O
.	O

Each	O
peak	O
exhibited	O
a	O
maximum	O
and	O
constant	O
area	O
in	O
the	O
range	O
of	O
pH	O
8–10	O
.	O

Similar	O
results	O
were	O
obtained	O
from	O
other	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
.	O

The	O
effect	O
of	O
the	O
anionic	O
component	O
of	O
the	O
buffer	O
solution	O
was	O
also	O
examined	O
using	O
acetate	O
,	O
borate	O
and	O
phosphate	O
buffer	O
(	O
50	O
mM	O
,	O
pH	O
8)	O
.	O

The	O
maximum	O
peak	O
areas	O
of	O
prolyl	O
dipeptides	O
were	O
obtained	O
in	O
phosphate	O
buffer	O
(	O
peak	O
area	O
relative	O
to	O
phosphate	O
buffer	O
:	O
acetate	O
buffer	O
,	O
75–98	O
%	O
;	O
borate	O
buffer	O
,	O
91–100	O
%	O
except	O
61	O
%	O
for	O
Pro	O
–	O
Tyr	O
)	O
.	O

Therefore	O
,	O
Na2	O
HPO4	O
(	O
50	O
mM	O
,	O
pH	O
ca	O
.	O

9.3	O
)	O
was	O
adopted	O
.	O

When	O
the	O
effect	O
of	O
the	O
concentration	O
of	O
Na2	O
HPO4	O
(	O
10–100	O
mM	O
)	O
was	O
examined	O
,	O
the	O
maximum	O
and	O
constant	O
peak	O
areas	O
were	O
obtained	O
at	O
a	O
concentration	O
of	O
more	O
than	O
25	O
mM	O
.	O

The	O
concentration	O
of	O
DMS	O
-	O
Cl	O
was	O
determined	O
by	O
the	O
peak	O
areas	O
due	O
to	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
(	O
100	O
μM	O
each	O
)	O
.	O

The	O
maximum	O
peak	O
areas	O
were	O
obtained	O
at	O
more	O
than	O
1.5	O
mM	O
DMS	O
-	O
Cl	O
.	O

Dichloromethane	O
extraction	O
was	O
carried	O
out	O
to	O
remove	O
excess	O
DMS	O
-	O
Cl	O
,	O
which	O
was	O
suspected	O
of	O
causing	O
the	O
guard	O
column	O
to	O
degrade	O
.	O

The	O
extraction	O
was	O
achieved	O
after	O
addition	O
of	O
Na2	O
CO3	O
(	O
0.1	O
M	O
,	O
30	O
μl	O
)	O
because	O
parts	O
of	O
the	O
derivatives	O
of	O
prolyl	O
dipeptides	O
that	O
eluted	O
after	O
the	O
derivatives	O
of	O
Pro	O
–	O
Ala	O
on	O
the	O
HPLC	O
column	O
were	O
lost	O
with	O
dichloromethane	O
extraction	O
without	O
Na2	O
CO3	O
.	O

3.3	O
Linearity	O
and	O
detection	O
limit	O
Linearity	O
was	O
studied	O
over	O
wide	O
ranges	O
of	O
concentration	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
(	O
between	O
0.1	O
and	O
100	O
μM	O
each	O
)	O
.	O

The	O
peak	O
-	O
area	O
ratios	O
of	O
analytes	O
to	O
I.S.	O
were	O
linear	O
in	O
the	O
concentration	O
ranges	O
investigated	O
(	O
r	O
>	O
0.999	O
each	O
)	O
.	O

When	O
the	O
precision	O
was	O
tested	O
using	O
standard	O
solutions	O
(	O
1	O
,	O
10	O
and	O
100	O
μM	O
each	O
)	O
,	O
the	O
relative	O
standard	O
deviations	O
(	O
RSDs	O
,	O
n	O
=	O
10	O
)	O
were	O
less	O
than	O
4.1	O
%	O
.	O

The	O
detection	O
limits	O
(	O
S	O
/	O
N=3	O
)	O
for	O
prolyl	O
dipeptides	O
were	O
1–5	O
fmol	O
/	O
injection	O
.	O

3.4	O
Pretreatment	O
of	O
urine	O
and	O
HPLC	O
chromatograms	O
For	O
determination	O
of	O
urinary	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
by	O
pre	O
-	O
column	O
HPLC	O
,	O
OPA	O
treatment	O
[	O
20	O
]	O
was	O
employed	O
to	O
eliminate	O
primary	O
amino	O
compounds	O
coexisting	O
with	O
analytes	O
in	O
urine	O
.	O

However	O
,	O
the	O
reaction	O
mixture	O
of	O
urine	O
with	O
OPA	O
was	O
colored	O
darkly	O
.	O

Therefore	O
,	O
two	O
methods	O
,	O
method	O
A	O
(	O
solid	O
-	O
phase	O
extraction	O
)	O
and	O
method	O
B	O
(	O
solvent	O
extraction	O
-	O
stripping	O
)	O
described	O
in	O
Section	O
2.4	O
were	O
tested	O
to	O
remove	O
the	O
colored	O
products	O
.	O

The	O
colored	O
products	O
were	O
retained	O
on	O
the	O
Bond	O
Elut	O
C18	O
column	O
in	O
method	O
A	O
and	O
were	O
not	O
extracted	O
with	O
dichloromethane	O
at	O
acidic	O
pH	O
in	O
method	O
B.	O
The	O
typical	O
chromatograms	O
of	O
a	O
standard	O
solution	O
and	O
urine	O
obtained	O
according	O
to	O
the	O
procedures	O
of	O
methods	O
A	O
and	O
B	O
are	O
shown	O
in	O
Fig.	O
6A	O
and	O
B	O
and	O
Fig.	O
7A	O
and	O
B	O
,	O
respectively	O
.	O

As	O
shown	O
in	O
Fig.	O
6A	O
,	O
some	O
prolyldipeptides	O
(	O
Pro	O
–	O
Tyr	O
,	O
–Val	O
,	O
–Met	O
,	O
–Trp	O
,	O
–Ile	O
,	O
–Leu	O
and	O
–Phe	O
)	O
were	O
unable	O
to	O
be	O
measured	O
by	O
method	O
A	O
,	O
because	O
these	O
peptides	O
were	O
retained	O
on	O
the	O
Bond	O
Elut	O
C18	O
column	O
under	O
the	O
conditions	O
used	O
.	O

When	O
urine	O
was	O
analyzed	O
by	O
method	O
A	O
,	O
peaks	O
due	O
to	O
Pro	O
–	O
Hyp	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
,	O
Pro	O
and	O
Hyp	O
at	O
retention	O
times	O
of	O
17.1	O
,	O
27.0	O
,	O
35.0	O
,	O
34.3	O
and	O
12.2	O
min	O
,	O
respectively	O
,	O
were	O
observed	O
(	O
Fig.	O
6B	O
)	O
.	O

In	O
contrast	O
,	O
for	O
method	O
B	O
,	O
all	O
prolyl	O
dipeptides	O
in	O
a	O
standard	O
solution	O
were	O
detected	O
(	O
Fig.	O
7A	O
)	O
.	O

However	O
,	O
the	O
seven	O
prolyl	O
dipeptides	O
that	O
could	O
not	O
be	O
measured	O
by	O
method	O
A	O
were	O
not	O
recognized	O
in	O
urine	O
(	O
Fig.	O
7B	O
)	O
,	O
although	O
the	O
three	O
prolyl	O
dipeptides	O
mentioned	O
above	O
were	O
recognized	O
in	O
urine	O
.	O

Despite	O
these	O
issues	O
,	O
urinary	O
Pro	O
–	O
Hyp	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
,	O
Pro	O
,	O
Hyp	O
and	O
I.S.	O
were	O
separated	O
from	O
the	O
reagent	O
blank	O
and	O
other	O
urinary	O
components	O
(	O
Figs.	O
6B	O
and	O
7B	O
)	O
.	O

These	O
urinary	O
analytes	O
were	O
identified	O
by	O
comparing	O
the	O
retention	O
times	O
with	O
those	O
of	O
standard	O
solutions	O
and	O
also	O
by	O
co	O
-	O
chromatography	O
of	O
a	O
standard	O
solution	O
and	O
urine	O
.	O

3.5	O
Recovery	O
and	O
precision	O
Recovery	O
tests	O
were	O
examined	O
by	O
means	O
of	O
both	O
methods	O
using	O
three	O
urine	O
samples	O
spiked	O
with	O
various	O
amounts	O
of	O
standard	O
Pro	O
–	O
Hyp	O
(	O
urinary	O
concentration	O
:	O
25	O
,	O
50	O
,	O
100	O
,	O
250	O
and	O
500	O
μM	O
)	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
,	O
Hyp	O
(	O
0.5	O
,	O
1	O
,	O
2	O
,	O
5	O
and	O
10	O
μM	O
each	O
)	O
and	O
Pro	O
(	O
1	O
,	O
2	O
,	O
4	O
,	O
10	O
and	O
20	O
μM	O
)	O
.	O

The	O
relationships	O
between	O
the	O
peak	O
-	O
area	O
ratios	O
of	O
analytes	O
to	O
I.S.	O
and	O
the	O
concentrations	O
of	O
analytes	O
were	O
linear	O
.	O

According	O
to	O
method	O
A	O
,	O
the	O
regression	O
equations	O
for	O
standard	O
solutions	O
without	O
urine	O
were	O
y	O
=	O
0.1300x	O
+	O
0.1183	O
(	O
r	O
=	O
0.9999	O
)	O
for	O
Pro	O
–	O
Hyp	O
,	O
y	O
=	O
0.1384x	O
−0.0001	O
(	O
r	O
=	O
0.9999	O
)	O
for	O
Pro	O
–	O
Gly	O
,	O
y	O
=	O
0.1069x	O
+	O
0.0020	O
(	O
r	O
=	O
0.9998	O
)	O
for	O
Pro	O
–	O
Pro	O
,	O
y	O
=	O
0.1135x	O
+	O
0.0735	O
(	O
r	O
=	O
0.9994	O
)	O
for	O
Pro	O
and	O
y	O
=	O
0.1140x	O
+	O
0.0066	O
(	O
r	O
=	O
0.9996	O
)	O
for	O
Hyp	O
,	O
where	O
y	O
is	O
the	O
peak	O
-	O
area	O
ratio	O
of	O
analyte	O
to	O
I.S.	O
and	O
x	O
is	O
the	O
concentration	O
of	O
analyte	O
(	O
μM	O
)	O
.	O

The	O
recoveries	O
were	O
obtained	O
from	O
the	O
slope	O
ratios	O
of	O
regression	O
equations	O
of	O
analytes	O
with	O
/	O
without	O
urine	O
.	O

The	O
slopes	O
of	O
regression	O
equations	O
and	O
the	O
recoveries	O
by	O
methods	O
A	O
and	O
B	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
recoveries	O
of	O
the	O
analytes	O
except	O
Pro	O
–	O
Gly	O
by	O
method	O
A	O
were	O
almost	O
100	O
%	O
,	O
while	O
those	O
by	O
method	O
B	O
were	O
very	O
low	O
.	O

In	O
method	O
B	O
,	O
some	O
organic	O
solvents	O
such	O
as	O
chloroform	O
,	O
benzene	O
,	O
ethyl	O
acetate	O
and	O
diethyl	O
ether	O
instead	O
of	O
dichloromethane	O
were	O
also	O
used	O
.	O

However	O
,	O
the	O
maximum	O
peak	O
areas	O
of	O
DMS	O
-	O
derivatives	O
were	O
obtained	O
with	O
use	O
of	O
dichloromethane	O
.	O

In	O
addition	O
,	O
when	O
the	O
concentration	O
of	O
Na2	O
CO3	O
(	O
1	O
,	O
5	O
,	O
10	O
and	O
20	O
mM	O
)	O
for	O
stripping	O
of	O
the	O
derivatives	O
of	O
prolyl	O
dipeptides	O
was	O
examined	O
,	O
maximum	O
peak	O
areas	O
were	O
obtained	O
by	O
use	O
of	O
more	O
than	O
5	O
mM	O
Na2	O
CO3	O
.	O

These	O
results	O
suggest	O
that	O
method	O
A	O
is	O
appropriate	O
for	O
the	O
determination	O
of	O
urinary	O
prolyl	O
dipeptides	O
.	O

Incidentally	O
,	O
when	O
the	O
recoveries	O
of	O
standard	O
prolyl	O
dipeptides	O
,	O
Pro	O
,	O
Hyp	O
(	O
0.02	O
,	O
0.2	O
,	O
2	O
and	O
10	O
nmol	O
each	O
)	O
and	O
I.S.	O
from	O
Bond	O
Elut	O
C18	O
were	O
examined	O
,	O
the	O
recoveries	O
were	O
96.1–101.1	O
%	O
(	O
except	O
the	O
seven	O
species	O
prolyl	O
dipeptides	O
mentioned	O
above	O
)	O
.	O

Therefore	O
,	O
for	O
determination	O
of	O
urinary	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
,	O
method	O
A	O
was	O
employed	O
and	O
the	O
regression	O
equations	O
in	O
water	O
described	O
above	O
were	O
used	O
.	O

However	O
,	O
the	O
estimated	O
values	O
of	O
urinary	O
Pro	O
–	O
Gly	O
were	O
corrected	O
using	O
the	O
mean	O
value	O
(	O
0.866	O
,	O
n	O
=	O
6	O
)	O
of	O
recovery	O
derived	O
from	O
additional	O
experiments	O
using	O
another	O
three	O
urine	O
samples	O
(	O
the	O
recoveries	O
:	O
85.8	O
,	O
85.9	O
and	O
86.8	O
%	O
)	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
precisions	O
of	O
method	O
A	O
were	O
evaluated	O
using	O
three	O
urine	O
samples	O
.	O

The	O
within	O
-	O
day	O
precision	O
was	O
examined	O
with	O
ten	O
replicate	O
assays	O
in	O
each	O
one	O
day	O
and	O
the	O
between	O
-	O
day	O
precision	O
by	O
assays	O
on	O
five	O
different	O
days	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
RSDs	O
of	O
the	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
precisions	O
were	O
1.5–4.8	O
and	O
1.7–5.8	O
%	O
,	O
respectively	O
.	O

3.6	O
Selection	O
of	O
I.S.	O
Some	O
secondary	O
amino	O
acids	O
(	O
10	O
μM	O
each	O
)	O
were	O
examined	O
to	O
select	O
I.S.	O
Although	O
the	O
peaks	O
due	O
to	O
l	O
-azetidine-2-calboxylic	O
acid	O
,	O
l	O
-thioproline	O
,	O
isonipecotic	O
acid	O
,	O
nipecotic	O
acid	O
and	O
dl	O
-pipecolic	O
acid	O
were	O
eluted	O
at	O
23.0	O
,	O
34.7	O
,	O
36.9	O
,	O
39.9	O
and	O
42.0	O
min	O
,	O
respectively	O
,	O
those	O
peaks	O
overlapped	O
with	O
peaks	O
due	O
to	O
urinary	O
components	O
.	O

The	O
peak	O
due	O
to	O
3,4-dehydro	O
-	O
dl	O
-proline	O
(	O
31.0	O
min	O
)	O
was	O
successfully	O
separated	O
from	O
those	O
of	O
urinary	O
components	O
.	O

3.7	O
Influence	O
of	O
amino	O
acids	O
The	O
influence	O
of	O
amino	O
acids	O
on	O
determination	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
by	O
method	O
A	O
was	O
examined	O
with	O
urine	O
spiked	O
with	O
25	O
species	O
of	O
primary	O
amino	O
acids	O
(	O
Ala	O
,	O
Arg	O
,	O
Asp	O
,	O
Asn	O
,	O
Cit	O
,	O
Cys	O
,	O
Cys	O
–	O
Cys	O
,	O
Glu	O
,	O
Gln	O
,	O
Gly	O
,	O
His	O
,	O
Hse	O
,	O
Ile	O
,	O
Leu	O
,	O
Lys	O
,	O
Met	O
,	O
Orn	O
,	O
Phe	O
,	O
Ser	O
,	O
Thr	O
,	O
Trp	O
,	O
Tyr	O
,	O
Val	O
,	O
γ	O
-	O
aminobutyric	O
acid	O
and	O
ϵ-aminocaproic	O
acid	O
,	O
5	O
nmol	O
each	O
)	O
.	O

These	O
amino	O
acids	O
did	O
not	O
interfere	O
with	O
the	O
determination	O
of	O
Pro	O
–	O
Hyp	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
,	O
Pro	O
and	O
Hyp	O
.	O

3.8	O
Determination	O
of	O
urinary	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
The	O
concentrations	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
in	O
urine	O
from	O
ten	O
healthy	O
volunteers	B
(	O
Japanese	O
staff	B
and	O
students	B
in	O
our	O
laboratory	O
)	O
who	O
were	O
eating	O
self	O
-	O
selected	O
diets	O
were	O
measured	O
by	O
method	O
A.	O
Overnight	O
urine	O
was	O
collected	O
in	O
the	O
early	O
morning	O
and	O
stored	O
at	O
−20	O
°	O
C	O
until	O
use	O
.	O

The	O
concentrations	O
of	O
urinary	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
are	O
given	O
in	O
Table	O
3	O
.	O

The	O
mean	O
values	O
(	O
mean±SD	O
)	O
of	O
urinary	O
Pro	O
–	O
Hyp	O
,	O
Pro	O
–	O
Gly	O
,	O
Pro	O
–	O
Pro	O
,	O
Pro	O
and	O
Hyp	O
were	O
97.6±28.2	O
,	O
2.74±1.48	O
,	O
2.08±1.13	O
,	O
6.71±3.34	O
and	O
2.30±1.59	O
nmol	O
/	O
mg	O
creatinine	O
,	O
respectively	O
.	O

When	O
the	O
concentration	O
of	O
Hyp	O
in	O
hydrolysed	O
urine	O
(	O
total	O
Hyp	O
)	O
was	O
measured	O
according	O
to	O
the	O
method	O
reported	O
previously	O
[	O
20	O
]	O
,	O
the	O
concentration	O
ratios	O
(	O
%	O
,	O
mean±SD	O
)	O
of	O
Pro	O
–	O
Hyp	O
and	O
free	O
Hyp	O
to	O
total	O
Hyp	O
were	O
45.7–64.5	O
%	O
(	O
53.1±6.7	O
%	O
)	O
and	O
0.4–2.2	O
%	O
(	O
1.3±0.7	O
%	O
)	O
,	O
respectively	O
.	O

These	O
values	O
were	O
similar	O
to	O
the	O
values	O
reported	O
previously	O
[	O
2,3,19	O
]	O
.	O

The	O
proposed	O
method	O
for	O
the	O
determination	O
of	O
prolyl	O
dipeptides	O
,	O
Pro	O
and	O
Hyp	O
in	O
urine	O
is	O
highly	O
sensitive	O
and	O
reliable	O
.	O

As	O
the	O
sensitive	O
and	O
reliable	O
determination	O
of	O
these	O
components	O
can	O
provide	O
useful	O
information	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
diseases	O
,	O
the	O
proposed	O
method	O
may	O
be	O
useful	O
for	O
biochemical	O
and	O
clinical	O
research	O
.	O

Further	O
clinical	O
research	O
including	O
a	O
determination	O
of	O
bone	O
metastasis	O
stages	O
in	O
cancer	O
patients	B
is	O
now	O
progressing	O
in	O
our	O
laboratories	O
.	O

The	O
eight	O
enzymes	O
of	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
are	O
encoded	O
by	O
at	O
least	O
15	O
different	O
nuclear	O
genes	O
in	O
Saccharomyces	B
cerevisiae	I
.	O

We	O
have	O
constructed	O
a	O
set	O
of	O
yeast	B
strains	O
defective	O
in	O
these	O
genes	O
as	O
part	O
of	O
a	O
comprehensive	O
analysis	O
of	O
the	O
interactions	O
among	O
the	O
TCA	O
cycle	O
proteins	O
.	O

The	O
15	O
major	O
TCA	O
cycle	O
genes	O
can	O
be	O
sorted	O
into	O
five	O
phenotypic	O
categories	O
on	O
the	O
basis	O
of	O
their	O
growth	O
on	O
nonfermentable	O
carbon	O
sources	O
.	O

We	O
have	O
previously	O
reported	O
a	O
novel	O
phenotype	O
associated	O
with	O
mutants	O
defective	O
in	O
the	O
IDH2	O
gene	O
encoding	O
the	O
Idh2p	O
subunit	O
of	O
the	O
NAD+-dependent	O
isocitrate	O
dehydrogenase	O
(	O
NAD	O
-	O
IDH	O
)	O
.	O

Null	O
and	O
nonsense	O
idh2	O
mutants	O
grow	O
poorly	O
on	O
glycerol	O
,	O
but	O
growth	O
can	O
be	O
enhanced	O
by	O
extragenic	O
mutations	O
,	O
termed	O
glycerol	O
suppressors	O
,	O
in	O
the	O
CIT1	O
gene	O
encoding	O
the	O
TCA	O
cycle	O
citrate	O
synthase	O
and	O
in	O
other	O
genes	O
of	O
oxidative	O
metabolism	O
.	O

The	O
TCA	O
cycle	O
mutant	O
collection	O
was	O
utilized	O
to	O
search	O
for	O
other	O
genes	O
that	O
can	O
suppress	O
idh2	O
mutants	O
and	O
to	O
identify	O
TCA	O
cycle	O
genes	O
that	O
display	O
a	O
similar	O
suppressible	O
growth	O
phenotype	O
on	O
glycerol	O
.	O

Mutations	O
in	O
7	O
TCA	O
cycle	O
genes	O
were	O
capable	O
of	O
functioning	O
as	O
suppressors	O
for	O
growth	O
of	O
idh2	O
mutants	O
on	O
glycerol	O
.	O

The	O
only	O
other	O
TCA	O
cycle	O
gene	O
to	O
display	O
the	O
glycerol	O
-	O
suppressor	O
-	O
accumulation	O
phenotype	O
was	O
IDH1	O
,	O
which	O
encodes	O
the	O
companion	O
Idh1p	O
subunit	O
of	O
NAD	O
-	O
IDH	O
.	O

These	O
results	O
provide	O
genetic	O
evidence	O
that	O
NAD	O
-	O
IDH	O
plays	O
a	O
unique	O
role	O
in	O
TCA	O
cycle	O
function	O
.	O

A	O
mixture	O
of	O
oligosaccharides	O
produced	O
by	O
beta	O
-	O
galactosidase	O
using	O
lactose	O
as	O
a	O
substrate	O
was	O
fractionated	O
according	O
to	O
degree	O
of	O
polymerization	O
using	O
gel	O
filtration	O
,	O
followed	O
by	O
high	O
-	O
pH	O
anion	O
-	O
exchange	O
chromatography	O
.	O

The	O
fractions	O
obtained	O
were	O
analyzed	O
using	O
monosaccharide	O
analysis	O
,	O
methylation	O
analysis	O
,	O
mass	O
spectrometry	O
,	O
and	O
NMR	O
spectroscopy	O
.	O

Twelve	O
novel	O
non	O
-	O
reducing	O
oligosaccharides	O
were	O
characterized	O
,	O
namely	O
,	O
[	O
beta	O
-	O
D	O
-	O
Galp-	O
(	O
1	O
-	O
->4	O
)	O
]	O
n	O
-	O
alpha	O
-	O
D	O
-	O
Glcp-	O
(	O
1<-->1	O
)	O
-beta	O
-	O
D	O
-	O
Galp	O
[	O
-	O
(	O
4<--1	O
)	O
-beta	O
-	O
D	O
-	O
Galp	O
]	O
m	O
,	O
with	O
n	O
,	O
m	O
=	O
(	O
1	O
,	O
2	O
,	O
3	O
,	O
or	O
4	O
)	O
and	O
beta	O
-	O
D	O
-	O
Galp-	O
(	O
1	O
-	O
->2	O
)	O
-alpha	O
-	O
D	O
-	O
Glcp-	O
(	O
1<-->1	O
)	O
-beta	O
-	O
D	O
-	O
Galp	O
.	O

Concentration	O
of	O
L	O
-	O
cystathionine	O
was	O
distinctly	O
increased	O
in	O
rabbit	B
brain	O
within	O
the	O
period	O
of	O
maximal	O
action	O
of	O
drugs	O
,	O
stimulating	O
the	O
central	O
nervous	O
system	O
(	O
phenamine	O
,	O
strychnine	O
corasole	O
)	O
.	O

A	O
distinct	O
decrease	O
in	O
content	O
of	O
L	O
-	O
cystathionine	O
was	O
observed	O
within	O
one	O
hour	O
after	O
the	O
administration	O
of	O
strychnine	O
and	O
corasole	O
.	O

Lactosylceramide	O
synthase	O
is	O
an	O
enzyme	O
that	O
catalyzes	O
the	O
transfer	O
of	O
galactose	O
from	O
UDP	O
-	O
Gal	O
to	O
glucosylceramide	O
,	O
and	O
thus	O
participates	O
in	O
the	O
biosynthesis	O
of	O
most	O
glycolipids	O
in	O
mammals	B
.	O

We	O
have	O
isolated	O
and	O
sequenced	O
the	O
cDNA	O
clone	O
encoding	O
human	B
lactosylceramide	O
synthase	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
the	O
human	B
lactosylceramide	O
synthase	O
showed	O
94.2	O
%	O
identity	O
with	O
rat	B
lactosylceramide	O
synthase	O
.	O

Northern	O
blotting	O
analysis	O
revealed	O
that	O
lactosylceramide	O
synthase	O
mRNA	O
was	O
expressed	O
in	O
various	O
tissues	O
,	O
with	O
the	O
highest	O
level	O
in	O
brain	O
and	O
adrenal	O
gland	O
.	O

Microsomal	O
cytochrome	O
P450-dependent	O
lauric	O
acid	O
hydroxylase	O
activities	O
were	O
characterized	O
in	O
liver	O
,	O
kidney	O
,	O
and	O
intestinal	O
mucosa	O
of	O
the	O
sea	B
bass	I
(	O
Dicentrarchus	B
labrax	I
)	O
.	O

Microsomes	O
from	O
these	O
organs	O
generated	O
(	O
omega-1	O
)	O
-hydroxylauric	O
acid	O
and	O
a	O
mixture	O
of	O
positional	O
isomers	O
including	O
(	O
omega	O
)	O
-	O
,	O
(	O
omega-2	O
)	O
-	O
,	O
(	O
omega-3	O
)	O
-	O
and	O
(	O
omega-4	O
)	O
-hydroxylauric	O
acids	O
,	O
which	O
were	O
identified	O
by	O
RP	O
-	O
HPLC	O
and	O
GC	O
-	O
MS	O
analysis	O
.	O

Peroxisome	O
proliferators	O
,	O
such	O
as	O
clofibrate	O
and	O
especially	O
di	O
(	O
2-ethylhexyl	O
)	O
phthalate	O
,	O
increased	O
kidney	O
microsomal	O
lauric	O
acid	O
hydroxylase	O
activities	O
.	O

The	O
synthesis	O
of	O
11-hydroxylauric	O
acid	O
was	O
enhanced	O
5.3-fold	O
in	O
kidney	O
microsomes	O
.	O

Liver	O
microsomal	O
lauric	O
acid	O
hydroxylase	O
activities	O
were	O
weakly	O
affected	O
and	O
no	O
significant	O
induction	O
was	O
found	O
in	O
small	O
intestine	O
microsomes	O
from	O
clofibrate	O
or	O
di	O
(	O
2-ethylhexyl	O
)	O
phthalate	O
-	O
treated	O
fish	B
.	O

The	O
differences	O
in	O
lauric	O
acid	O
metabolisation	O
and	O
the	O
tissue	O
-	O
specific	O
induction	O
by	O
peroxisome	O
proliferators	O
suggest	O
the	O
involvement	O
of	O
several	O
P450s	O
in	O
this	O
reaction	O
.	O

Incubations	O
of	O
liver	O
and	O
kidney	O
microsomes	O
with	O
lauric	O
acid	O
analogues	O
(	O
11-	O
or	O
10-dodecynoic	O
acids	O
)	O
resulted	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
loss	O
of	O
lauric	O
acid	O
hydroxylase	O
activities	O
.	O

The	O
induction	O
of	O
these	O
activities	O
in	O
fish	B
by	O
phthalates	O
,	O
which	O
are	O
widely	O
-	O
distributed	O
environmental	O
pollutants	O
,	O
may	O
be	O
taken	O
into	O
consideration	O
for	O
the	O
development	O
of	O
new	O
biomarkers	O
.	O

6-Chloro-7-arylamino-5,8-isoquinolinediones	O
were	O
newly	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
cytotoxic	O
activities	O
against	O
five	O
human	B
solid	O
tumor	O
cell	O
lines	O
.	O

Among	O
them	O
,	O
5b	O
,	O
5c	O
and	O
5d	O
exhibited	O
potent	O
activities	O
against	O
the	O
cell	O
lines	O
HCT-15	O
and	O
SK	O
-	O
MEL-2	O
.	O

We	O
developed	O
a	O
novel	O
fluorometric	O
assay	O
method	O
for	O
the	O
measurement	O
of	O
glycosyltransferase	O
activities	O
using	O
mono-	O
and	O
di	O
-	O
saccharides	O
aminated	O
and	O
tagged	O
with	O
7-hydroxycoumarin-3-carboxylic	O
acid	O
(	O
coumarin	O
)	O
as	O
substrates	O
,	O
N	O
-	O
acetylglucosamine	O
(	O
GlcNAc	O
)	O
-coumarin	O
for	O
beta1,4-galactosyltransferase	O
from	O
bovine	B
milk	O
and	O
Gal	O
beta1	O
-	O
4GlcNAc	O
-	O
coumarin	O
for	O
alpha2,3-	O
and	O
alpha2,6-sialyltransferases	O
from	O
rat	B
liver	O
.	O

Using	O
Gal	O
beta1	O
-	O
3GlcNAc	O
and	O
Gal	O
beta1	O
-	O
4Glc	O
-	O
NAc	O
-	O
coumarin	O
,	O
alpha1,3	O
/	O
4-	O
and	O
alpha1,3-fucosyltransferase	O
activities	O
were	O
also	O
determined	O
,	O
respectively	O
.	O

These	O
enzymatic	O
products	O
liberated	O
by	O
the	O
reactions	O
of	O
glycosyltransferases	O
in	O
the	O
presence	O
of	O
sugar	O
nucleotides	O
,	O
were	O
separated	O
by	O
a	O
normal	O
phase	O
or	O
an	O
ion	O
-	O
pair	O
reversed	O
phase	O
HPLC	O
with	O
an	O
isocratic	O
elution	O
and	O
fluorescence	O
detection	O
.	O

We	O
applied	O
this	O
assay	O
method	O
to	O
determine	O
the	O
glycosyltransferase	O
activities	O
in	O
8	O
kinds	O
of	O
human	B
tumor	O
cell	O
lines	O
,	O
including	O
the	O
cell	O
lines	O
derived	O
from	O
hepatocytes	O
(	O
HuH-7	O
,	O
HepG2	O
)	O
,	O
colonic	O
cells	O
(	O
Colo205	O
,	O
HT-29	O
)	O
,	O
myelocytes	O
(	O
HL-60	O
,	O
U-937	O
)	O
,	O
B	O
-	O
lymphocytes	O
(	O
Daudi	O
)	O
and	O
T	O
-	O
lymphocytes	O
(	O
Jurkat	O
)	O
.	O

This	O
assay	O
method	O
is	O
accurate	O
and	O
easy	O
compared	O
with	O
other	O
isotopic	O
and	O
non	O
-	O
isotopic	O
assay	O
methods	O
,	O
and	O
is	O
sensitive	O
enough	O
to	O
measure	O
glycosyltransferase	O
activities	O
in	O
cell	O
homogenates	O
.	O

Anandamide	O
(	O
N	O
-	O
arachidonoylethanolamine	O
)	O
and	O
six	O
fatty	O
acid	O
ethanolamides	O
were	O
synthesized	O
and	O
their	O
pharmacological	O
effects	O
in	O
mice	B
were	O
assessed	O
using	O
catalepsy	O
,	O
hypothermia	O
and	O
pentobarbital	O
-	O
induced	O
sleep	O
prolongation	O
as	O
indices	O
.	O

The	O
effects	O
of	O
phenylmethylsulfonyl	O
fluoride	O
(	O
PMSF	O
)	O
pretreatment	O
on	O
anandamide	O
effects	O
were	O
also	O
evaluated	O
and	O
discussed	O
in	O
relation	O
to	O
inhibition	O
of	O
anandamide	O
amidohydrolase	O
in	O
mouse	B
brain	O
and	O
liver	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
anandamide	O
(	O
ED50=6.0	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
was	O
4	O
to	O
6	O
times	O
more	O
active	O
than	O
those	O
of	O
N	O
-	O
oleoyl-	O
(	O
ED50=26.5	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
and	O
N	O
-	O
linoleoylethanolamine	O
(	O
ED50=37.5	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
,	O
although	O
the	O
peak	O
time	O
in	O
the	O
effect	O
was	O
observed	O
within	O
1	O
min	O
after	O
i.v	O
.	O

administration	O
.	O

None	O
of	O
the	O
saturated	O
fatty	O
acid	O
ethanolamides	O
(	O
N	O
-	O
myristoyl-	O
,	O
N	O
-	O
palmitoyl-	O
,	O
N	O
-	O
stearoyl-	O
and	O
N	O
-	O
arachidoylethanolamine	O
)	O
showed	O
a	O
positive	O
response	O
in	O
the	O
cataleptogenic	O
effect	O
even	O
at	O
a	O
dose	O
up	O
to	O
40	O
mg	O
/	O
kg	O
i.v	O
.	O

Anandamide	O
,	O
N	O
-	O
linoleoyl-	O
,	O
N	O
-	O
oleoyl-	O
and	O
N	O
-	O
myristoylethanolamine	O
(	O
10	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
produced	O
a	O
significant	O
hypothermia	O
(	O
0.19	O
to	O
0.59	O
degrees	O
C	O
)	O
at	O
5	O
to	O
15	O
min	O
after	O
administration	O
.	O

The	O
duration	O
of	O
the	O
effects	O
of	O
these	O
ethanolamides	O
was	O
also	O
relatively	O
short	O
.	O

Anandamide	O
,	O
N	O
-	O
linoleoyl-	O
,	O
N	O
-	O
oleoyl-	O
and	O
N	O
-	O
palmitoylethanolamine	O
(	O
5	O
or	O
10	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
significantly	O
prolonged	O
pentobarbital	O
-	O
induced	O
sleeping	O
time	O
by	O
148	O
-	O
207	O
%	O
of	O
control	O
sleeping	O
time	O
.	O

The	O
cataleptogenic	O
effect	O
of	O
anandamide	O
was	O
markedly	O
potentiated	O
by	O
pretreatment	O
of	O
mice	B
with	O
PMSF	O
(	O
100	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

The	O
ED50	O
(	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
of	O
anandamide	O
was	O
0.48	O
(	O
0.24	O
-	O
0.96	O
)	O
in	O
PMSF	O
-	O
pretreated	O
mice	B
.	O

The	O
pretreatment	O
of	O
mice	B
with	O
PMSF	O
significantly	O
decreased	O
the	O
metabolic	O
clearance	O
rate	O
of	O
anandamide	O
in	O
microsomal	O
fractions	O
of	O
liver	O
and	O
brain	O
.	O

Thus	O
,	O
the	O
Vmax	O
/	O
Km	O
values	O
of	O
brain	O
and	O
hepatic	O
microsomes	O
were	O
26	O
and	O
10	O
%	O
,	O
respectively	O
,	O
as	O
compared	O
with	O
those	O
of	O
control	O
mice	B
.	O

The	O
present	O
study	O
demonstrated	O
that	O
anandamide	O
and	O
N	O
-	O
acylethanolamines	O
of	O
unsaturated	O
fatty	O
acids	O
exhibited	O
cannabinoid	O
-	O
like	O
effects	O
in	O
mice	O
,	O
and	O
that	O
anandamide	O
amidohydrolase	O
has	O
an	O
important	O
role	O
in	O
the	O
pharmacological	O
effects	O
of	O
anandamide	O
in	O
vivo	O
.	O

Localized	O
1H	O
NMR	O
homonuclear	O
J	O
editing	O
spectroscopy	O
was	O
used	O
to	O
measure	O
the	O
concentration	O
of	O
2-pyrrolidinone	O
(	O
PRDN	O
)	O
in	O
the	O
human	B
occipital	O
lobe	O
of	O
five	O
normal	O
and	O
six	O
epileptic	O
subjects	B
taking	O
vigabatrin	O
.	O

PRDN	O
is	O
a	O
lactam	O
cyclization	O
product	O
of	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
GABA	O
)	O
.	O

From	O
a	O
localized	O
volume	O
of	O
13.5	O
cm3	O
in	O
the	O
occipital	O
cortex	O
,	O
the	O
concentration	O
of	O
PRDN	O
ranged	O
from	O
0.2	O
to	O
0.3	O
micromol	O
/	O
g	O
in	O
normal	O
subjects	B
,	O
whereas	O
in	O
epileptic	O
subjects	B
on	O
vigabatrin	O
PRDN	O
was	O
elevated	O
to	O
0.6	O
+	O
/-	O

0.1	O
micromol	O
/	O
g	O
.	O

The	O
elevated	O
PRDN	O
in	O
patients	B
on	O
vigabatrin	O
was	O
in	O
accord	O
with	O
raised	O
GABA	O
levels	O
compared	O
with	O
normals	O
.	O

1H	O
NMR	O
measurements	O
of	O
PRDN	O
will	O
be	O
important	O
in	O
assessment	O
of	O
the	O
role	O
of	O
this	O
metabolite	O
for	O
improved	O
seizure	O
control	O
.	O

Phosphatoquinones	O
A	O
and	O
B	O
were	O
isolated	O
from	O
the	O
cultured	O
broth	O
of	O
Streptomyces	B
sp.	I
TA-0363	I
and	O
their	O
structures	O
were	O
elucidated	O
by	O
spectroscopic	O
analyses	O
.	O

Phosphatoquinones	O
A	O
and	O
B	O
inhibited	O
the	O
protein	O
tyrosine	O
phosphatase	O
activity	O
prepared	O
from	O
human	B
Ball-1	O
cells	O
with	O
IC50	O
of	O
28	O
microM	O
and	O
2.9	O
microM	O
,	O
respectively	O
.	O

The	O
biosynthesis	O
of	O
polyketomycin	O
was	O
investigated	O
by	O
feeding	O
13C	O
-	O
labeled	O
acetate	O
and	O
propionate	O
to	O
the	O
growing	O
cultures	O
of	O
Streptomyces	B
diastatochromogenes	I
Tu	I
6028	I
.	O

13C	O
NMR	O
spectral	O
analysis	O
demonstrated	O
the	O
polyketide	O
origin	O
of	O
the	O
aglycone	O
and	O
the	O
dimethylsalicyloyl	O
moieties	O
.	O

The	O
O	O
-	O
methyl	O
group	O
and	O
6-CH3	O
of	O
the	O
aglycone	O
as	O
well	O
as	O
3B	O
-	O
CH3	O
of	O
L	O
-	O
axenose	O
and	O
3C	O
-	O
CH3	O
of	O
the	O
salicyloyl	O
residue	O
were	O
labeled	O
by	O
feeding	O
L-	O
[	O
methyl-13C	O
]	O
methionine	O
.	O

Both	O
deoxysugars	O
emerged	O
from	O
D	O
-	O
glucose	O
.	O

The	O
biosynthesis	O
of	O
the	O
aglycone	O
and	O
the	O
assembly	O
of	O
the	O
glycoside	O
are	O
discussed	O
.	O

The	O
polyketomycin	O
producing	O
strain	O
may	O
be	O
a	O
candidate	O
for	O
further	O
exploration	O
in	O
combinatorial	O
biosynthesis	O
.	O

The	O
effect	O
of	O
thirteen	O
different	O
fungal	B
azaphilones	O
,	O
which	O
have	O
a	O
common	O
6-iso	O
-	O
chromane	O
-	O
like	O
ring	O
,	O
was	O
tested	O
on	O
cholesteryl	O
ester	O
transfer	O
protein	O
(	O
CETP	O
)	O
activity	O
in	O
vitro	O
.	O

Chaetoviridin	O
B	O
showed	O
the	O
most	O
potent	O
inhibitory	O
activity	O
with	O
an	O
IC50	O
value	O
of	O
<	O
6.2	O
microM	O
,	O
followed	O
by	O
sclerotiorin	O
with	O
an	O
IC50	O
value	O
of	O
19.4	O
microM.	O
Rotiorin	O
,	O
chaetoviridin	O
A	O
and	O
rubrorotiorin	O
had	O
moderate	O
inhibitory	O
activity	O
(	O
IC50	O
;	O
30	O
approximately	O
40	O
microM	O
)	O
,	O
but	O
others	O
showed	O
very	O
weak	O
or	O
no	O
inhibitory	O
activity	O
.	O

The	O
relationship	O
between	O
the	O
structures	O
and	O
their	O
inhibitory	O
activity	O
indicated	O
that	O
the	O
presence	O
of	O
an	O
electrophilic	O
ketone	O
(	O
s	O
)	O
and/or	O
enone	O
(	O
s	O
)	O
at	O
both	O
C-6	O
and	O
C-8	O
positions	O
in	O
the	O
isochromane	O
-	O
like	O
ring	O
is	O
essential	O
for	O
eliciting	O
CETP	O
inhibitory	O
activity	O
.	O

The	O
transfer	O
activity	O
of	O
both	O
CE	O
and	O
TG	O
was	O
inhibited	O
by	O
sclerotiorin	O
to	O
approximately	O
the	O
same	O
extent	O
(	O
IC50	O
:	O
14.4	O
and	O
10.3	O
microM	O
,	O
respectively	O
)	O
.	O

A	O
model	O
of	O
the	O
reaction	O
suggested	O
that	O
sclerotiorin	O
reacts	O
with	O
a	O
primary	O
amine	O
of	O
amino	O
acids	O
such	O
as	O
lysine	O
in	O
the	O
protein	O
to	O
form	O
a	O
covalent	O
bond	O
.	O

Six	O
new	O
(	O
1	O
-	O
6	O
)	O
and	O
three	O
known	O
(	O
7	O
-	O
9	O
)	O
sesquiterpene	O
esters	O
were	O
isolated	O
from	O
the	O
roots	O
of	O
Celastrus	B
orbiculatus	I
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
were	O
elucidated	O
as	O
1beta	O
-	O
acetoxy-6alpha	O
-	O
furoyloxy-9alpha	O
-	O
benzoyl	O
oxydihydro	O
-	O
beta	O
-	O
agarofur	O
an	O
(	O
1	O
)	O
,	O
1beta	O
-	O
acetoxy-6alpha	O
-	O
benzoyloxy-9alpha	O
-	O
furoyloxydih	O
ydro	O
-	O
beta	O
-	O
agarofur	O
an	O
(	O
2	O
)	O
,	O
1beta	O
-	O
acetoxy-6alpha	O
,	O
9alpha	O
-	O
difuroyloxydihydro	O
-	O
beta	O
-	O
agarofuran	O
(	O
3	O
)	O
,	O
1beta	O
,	O
2beta	O
-	O
diacetoxy-6alpha	O
-	O
furoyloxy-9alpha	O
-	O
benzo	O
yloxydihydro	O
-	O
beta	O
-	O
agarof	O
uran	O
(	O
4	O
)	O
,	O
1beta	O
-	O
acetoxy-2beta	O
,	O
6alpha	O
-	O
difuroyloxy-9alpha	O
-	O
benzoyloxydihydro	O
-	O
beta	O
-agarofuran	O
(	O
5	O
)	O
,	O
and	O
1beta	O
-	O
acetoxy-2beta,6alpha	O
,	O
9alpha	O
-	O
tribenzoyloxydihydro	O
-	O
beta	O
-	O
agarofuran	O
(	O
6	O
)	O
.	O

Compounds	O
4	O
,	O
5	O
,	O
and	O
7	O
-	O
9	O
were	O
shown	O
to	O
be	O
more	O
active	O
than	O
verapamil	O
in	O
reversing	O
vinblastine	O
resistance	O
in	O
multidrug	O
-	O
resistant	O
KB	O
-	O
V1	O
cells	O
.	O

Late	O
-	O
onset	O
drinking	O
is	O
a	O
common	O
problem	O
in	O
elderly	O
people	B
related	O
to	O
stress	O
induced	O
by	O
social	O
isolation	O
.	O

Experiments	O
were	O
performed	O
in	O
order	O
to	O
evaluate	O
the	O
effects	O
of	O
alprazolam	O
,	O
a	O
benzodiazepine	O
agonist	O
anxiolytic	O
,	O
on	O
the	O
free	O
-	O
choice	O
ethanol	O
consumption	O
in	O
aged	O
rats	B
subjected	O
to	O
isolation	O
stress	O
.	O

The	O
animals	O
we	O
offered	O
a	O
two	O
-	O
bottle	O
choice	O
consumption	O
(	O
one	O
of	O
0.2	O
%	O
saccharin	O
and	O
the	O
other	O
with	O
10	O
%	O
ethanol	O
/	O
0.2	O
%	O
saccharin	O
)	O
and	O
then	O
exposed	O
to	O
4	O
days	O
of	O
isolation	O
stress	O
on	O
an	O
irregular	O
,	O
unpredictable	O
schedule	O
.	O

Stress	O
resulted	O
in	O
significant	O
increase	O
in	O
ethanol	O
consumption	O
.	O

Treatment	O
with	O
alprazolam	O
(	O
1	O
mg	O
/	O
Kg	O
)	O
partially	O
reversed	O
this	O
adverse	O
effect	O
of	O
stress	O
.	O

The	O
elucidation	O
of	O
N	O
-glycans	O
in	O
plants	B
has	O
raised	O
increasing	O
interest	O
in	O
the	O
past	O
years	O
due	O
to	O
several	O
physiological	O
roles	O
which	O
could	O
be	O
attributed	O
to	O
these	O
structures	O
:	O
correct	O
folding	O
,	O
biological	O
activity	O
and	O
stability	O
of	O
proteins	O
can	O
be	O
affected	O
by	O
the	O
presence	O
of	O
N	O
-glycans	O
(	O
Driouich	O
,	O
Gonnet	O
,	O
Makkie	O
,	O
Laine	O
,	O
&	O
Faye	O
,	O
1989	O
;	O
Sheldon	O
,	O
&	O
Bowles	O
,	O
1992	O
;	O
Nagai	O
,	O
&	O
Yamaguchi	O
,	O
1993	O
)	O
.	O

Moreover	O
,	O
the	O
involvement	O
of	O
N	O
-linked	O
oligosaccharides	O
in	O
plant	B
development	O
was	O
demonstrated	O
(	O
Ettlinger	O
,	O
Schindler	O
,	O
&	O
Lehle	O
,	O
1986	O
)	O
.	O

Besides	O
these	O
physiological	O
roles	O
,	O
N	O
-glycans	O
can	O
influence	O
the	O
immunogenicity	O
of	O
glycoproteins	O
,	O
representing	O
antigenic	O
epitopes	O
by	O
themselves:	O
(	O
i	O
)	O
The	O
injection	O
of	O
horseradish	O
peroxidase	O
(	O
HRP	O
)	O
into	O
rabbits	B
resulted	O
in	O
polyclonal	O
anti	O
-	O
HRP	O
antiserum	O
which	O
also	O
reacted	O
with	O
many	O
other	O
plant	B
glycoproteins	O
carrying	O
glycans	O
similar	O
to	O
those	O
from	O
horseradish	O
peroxidase	O
.	O

β1,2-xylose	O
,	O
present	O
in	O
all	O
the	O
glycoprotein	O
–	O
glycans	O
of	O
the	O
study	O
,	O
but	O
absent	O
in	O
mammalian	B
organisms	O
,	O
was	O
supposed	O
to	O
be	O
responsible	O
for	O
the	O
observed	O
cross	O
-	O
reactivity	O
(	O
Faye	O
,	O
Johnson	O
,	O
Sturm	O
,	O
&	O
Chrispeels	O
,	O
1993	O
)	O
.	O

(	O
ii	O
)	O
The	O
crossreactivity	O
of	O
a	O
polyclonal	O
antiserum	O
against	O
HRP	O
with	O
other	O
plant	B
glycoproteins	O
and	O
with	O
bee	B
-	O
venom	O
phospholipase	O
A2	O
,	O
due	O
to	O
a	O
common	O
carbohydrate	O
epitope	O
could	O
be	O
demonstrated	O
.	O

(	O
Prenner	O
,	O
Mach	O
,	O
Glössl	O
,	O
&	O
März	O
,	O
1992	O
;	O
Wilson	O
,	O
Harthill	O
,	O
Mullin	O
,	O
Ashford	O
,	O
&	O
Altmann	O
,	O
1998	O
)	O
.	O

Chemical	O
defucosylation	O
as	O
well	O
as	O
ELISA	O
inhibition	O
experiments	O
indicated	O
that	O
α1,3-fucose	O
is	O
sufficient	O
to	O
create	O
an	O
immunogenic	O
epitope	O
.	O

The	O
assumption	O
that	O
N	O
-glycans	O
or	O
parts	O
of	O
these	O
structures	O
can	O
not	O
only	O
represent	O
antigenic	O
,	O
but	O
also	O
allergenic	O
epitopes	O
was	O
confirmed	O
by	O
Tretter	O
,	O
Altmann	O
,	O
Kubelka	O
,	O
März	O
,	O
and	O
Becker	O
(	O
1993	O
)	O
;	O
in	O
the	O
case	O
of	O
bee	B
-	O
venom	O
allergic	O
patients	O
,	O
the	O
reactivity	O
of	O
IgE	O
antibodies	O
to	O
glycopeptides	O
of	O
phospholipase	O
A2	O
was	O
demonstrated	O
;	O
the	O
proximal	O
α1,3-fucose	O
residue	O
was	O
identified	O
as	O
the	O
IgE	O
-	O
reactive	O
determinant	O
.	O

The	O
involvement	O
of	O
carbohydrate	O
structures	O
in	O
food	O
allergies	O
is	O
presently	O
discussed	O
quite	O
controversial	O
.	O

However	O
,	O
there	O
is	O
increasing	O
evidence	O
that	O
certain	O
carbohydrates	O
,	O
especially	O
N	O
-glycans	O
,	O
might	O
play	O
a	O
role	O
in	O
these	O
adverse	O
food	O
reactions	O
(	O
Aalberse	O
,	O
Koshte	O
,	O
&	O
Clemens	O
,	O
1981	O
)	O
,	O
deduced	O
from	O
the	O
following	O
observations	O
:	O
many	O
proteins	O
which	O
are	O
of	O
allergological	O
importance	O
are	O
glycosylated	O
;	O
many	O
allergic	O
individuals	O
show	O
hypersensitivity	O
to	O
various	O
types	O
of	O
allergens	O
which	O
are	O
not	O
taxonomically	O
related	O
,	O
thus	O
suggesting	O
common	O
,	O
ubiquitous	O
structures	O
as	O
glycans	O
;	O
and	O
finally	O
,	O
many	O
pollen	O
allergic	O
patients	O
are	O
also	O
sensitive	O
to	O
certain	O
food	O
stuffs	O
,	O
which	O
also	O
implies	O
common	O
structural	O
epitopes	O
(	O
Möller	O
et	O
al.	O
,	O
1997	O
)	O
.	O

In	O
immunological	O
investigations	O
,	O
mostly	O
indirect	O
methods	O
are	O
applied	O
which	O
shall	O
prove	O
the	O
involvement	O
of	O
glycans	O
in	O
allergic	O
reactions	O
,	O
such	O
as	O
deglycosylation	O
,	O
lectin	O
binding	O
and	O
compositional	O
analysis	O
(	O
Petersen	O
,	O
Becker	O
,	O
Moll	O
,	O
Blümke	O
,	O
&	O
Schlaak	O
,	O
1995	O
;	O
Batanero	O
,	O
Villalba	O
,	O
Monsalve	O
,	O
&	O
Rodriguez	O
,	O
1996	O
;	O
Tsuji	O
et	O
al.	O
,	O
1997	O
)	O
;	O
however	O
,	O
structural	O
information	O
is	O
a	O
prerequisite	O
for	O
making	O
correct	O
conclusions	O
about	O
the	O
allergenicity	O
of	O
N	O
-glycans	O
or	O
epitopes	O
,	O
respectively	O
.	O

We	O
report	O
here	O
on	O
the	O
structural	O
elucidation	O
of	O
the	O
N	O
-linked	O
oligosaccharides	O
in	O
tomato	B
fruit	O
,	O
which	O
shall	O
help	O
to	O
understand	O
some	O
observed	O
cross	O
-	O
reactivities	O
reported	O
recently	O
by	O
Petersen	O
,	O
Vieths	O
,	O
Aulepp	O
,	O
Schlaak	O
,	O
and	O
Becker	O
(	O
1996	O
)	O
.	O

2	O
Results	O
2.1	O
Preparation	O
of	O
N	O
-glycans	O
from	O
tomato	B
fruit	O
To	O
isolate	O
the	O
protein	O
fraction	O
from	O
tomato	B
fruit	O
,	O
two	O
procedures	O
were	O
carried	O
out	O
alternatively	O
:	O
on	O
the	O
one	O
hand	O
,	O
the	O
tomatoes	B
were	O
homogenized	O
in	O
an	O
appropriate	O
extraction	O
buffer	O
and	O
the	O
proteins	O
were	O
precipitated	O
by	O
addition	O
of	O
ammonium	O
sulfate	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
low	O
-	O
temperature	O
acetone	O
powder	O
method	O
,	O
first	O
described	O
by	O
Clements	O
(	O
1965	O
)	O
,	O
was	O
employed	O
;	O
the	O
proteins	O
precipitated	O
in	O
acetone	O
,	O
whereas	O
small	O
hydrophobic	O
compounds	O
(	O
flavonoids	O
,	O
carotinoids	O
)	O
as	O
well	O
as	O
most	O
of	O
the	O
salts	O
were	O
effectively	O
removed	O
;	O
the	O
proteins	O
were	O
extracted	O
from	O
the	O
resulting	O
powder	O
,	O
yielding	O
concentrations	O
of	O
180–310	O
μg	O
/	O
ml	O
as	O
determined	O
according	O
to	O
Bradford	O
(	O
1976	O
)	O
;	O
these	O
values	O
are	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
with	O
those	O
reported	O
by	O
Vieths	O
,	O
Schöning	O
,	O
Brockmann	O
,	O
and	O
Aulepp	O
(	O
1992	O
)	O
,	O
who	O
used	O
this	O
procedure	O
for	O
the	O
preparation	O
of	O
several	O
fruit	B
and	O
vegetable	B
extracts	O
.	O

A	O
cation	O
-	O
exchange	O
chromatography	O
eliminated	O
most	O
of	O
the	O
by	O
-	O
products	O
in	O
the	O
sample	O
.	O

The	O
binding	O
fraction	O
was	O
assayed	O
for	O
the	O
amount	O
of	O
N	O
-acetylglucosamine	O
by	O
OPA	O
-	O
aminosugar	O
analysis	O
,	O
yielding	O
170–260	O
nmol	O
GlcNAc	O
,	O
dependent	O
on	O
the	O
sample	O
.	O

From	O
these	O
values	O
it	O
could	O
be	O
deduced	O
that	O
about	O
85–130	O
nmol	O
of	O
N	O
-glycans	O
are	O
present	O
in	O
the	O
glycopeptide	O
fractions	O
(	O
assuming	O
2	O
moles	O
of	O
GlcNAc	O
/	O
mol	O
of	O
oligosaccharide	O
)	O
.	O

The	O
oligosaccharides	O
were	O
released	O
from	O
the	O
glycopeptides	O
using	O
N	O
-glycosidase	O
A	O
,	O
separated	O
from	O
peptides	O
and	O
residual	O
glycopeptides	O
by	O
reverse	O
-	O
phase	O
chromatography	O
and	O
derivatized	O
with	O
the	O
fluorescent	O
tag	O
2-aminopyridine	O
.	O

2.2	O
Separation	O
and	O
structural	O
elucidation	O
of	O
the	O
N	O
-linked	O
oligosaccharides	O
The	O
pyridylaminated	O
oligosaccharides	O
were	O
first	O
size	O
-	O
fractionated	O
on	O
MicroPak	O
AX-5	O
(	O
Fig.	O
1	O
Fig.	O
1	O
A	O
)	O
;	O
11	O
fractions	O
were	O
manually	O
collected	O
and	O
rechromatographed	O
if	O
necessary	O
.	O

Individual	O
fractions	O
were	O
subjected	O
to	O
reverse	O
-	O
phase	O
HPLC	O
,	O
yielding	O
a	O
total	O
of	O
sixteen	O
subfractions	O
(	O
additionally	O
,	O
an	O
aliquot	O
of	O
the	O
total	O
glycan	O
pool	O
was	O
applied	O
to	O
the	O
reverse	O
-	O
phase	O
system	O
,	O
see	O
Fig.	O
1	O
B	O
)	O
.	O

The	O
elution	O
position	O
of	O
each	O
isolated	O
oligosaccharides	O
was	O
determined	O
on	O
both	O
columns	O
and	O
compared	O
to	O
those	O
from	O
reference	O
oligosaccharides	O
.	O

The	O
individual	O
peaks	O
were	O
then	O
subjected	O
to	O
exoglycosidase	O
treatment	O
using	O
α	O
-	O
mannosidase	O
,	O
β	O
-	O
N	O
-acetylhexosaminidase	O
and	O
endoglycosidase	O
H.	O
The	O
digests	O
were	O
again	O
chromatographed	O
on	O
reverse	O
-	O
phase	O
and	O
MicroPak	O
to	O
monitor	O
the	O
change	O
in	O
the	O
elution	O
behavior	O
(	O
Tables	O
1	O
and	O
2	O
)	O
.	O

Whenever	O
possible	O
,	O
a	O
tentatively	O
identified	O
peak	O
was	O
coinjected	O
with	O
the	O
corresponding	O
reference	O
oligosaccharide	O
to	O
verify	O
the	O
identical	O
elution	O
behavior	O
.	O

In	O
the	O
following	O
,	O
the	O
structural	O
assignment	O
of	O
each	O
peak	O
is	O
described	O
;	O
the	O
proposed	O
structures	O
are	O
depicted	O
in	O
Table	O
3	O
.	O

2.3	O
Complex	O
and	O
truncated	O
complex	O
glycans	O
The	O
retention	O
data	O
of	O
oligosaccharide	O
1-A	O
,	O
a	O
minor	O
component	O
present	O
in	O
all	O
the	O
tomato	B
samples	O
,	O
did	O
not	O
fit	O
with	O
any	O
of	O
the	O
available	O
reference	O
compounds	O
.	O

However	O
,	O
the	O
glycan	O
exhibited	O
resistance	O
to	O
α	O
-	O
mannosidase	O
treatment	O
.	O

The	O
identity	O
could	O
be	O
presumed	O
from	O
complete	O
digestion	O
of	O
MMF3	O
from	O
phospholipase	O
A2	O
with	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
a	O
peak	O
with	O
the	O
same	O
retention	O
behavior	O
as	O
oligosaccharide	O
1-A	O
on	O
both	O
columns	O
.	O

1-A	O
is	O
therefore	O
presumed	O
to	O
be	O
00F3	O
.	O

Oligosaccharide	O
1-B	O
also	O
was	O
resistant	O
to	O
α	O
-	O
mannosidase	O
.	O

Together	O
with	O
its	O
size	O
and	O
having	O
the	O
same	O
retention	O
time	O
on	O
reverse	O
-	O
phase	O
HPLC	O
as	O
the	O
product	O
of	O
α	O
-	O
mannosidase	O
digestion	O
of	O
the	O
major	O
structure	O
of	O
horseradish	O
peroxidase	O
(	O
MMXF3	O
)	O
,	O
1-B	O
was	O
deduced	O
to	O
be	O
00XF3	O
.	O

The	O
third	O
peak	O
present	O
in	O
the	O
first	O
MicroPak	O
fraction	O
,	O
1-C	O
,	O
showed	O
a	O
remarkably	O
high	O
retention	O
time	O
on	O
reverse	O
-	O
phase	O
(	O
11.0	O
glucose	O
units	O
)	O
and	O
sensitivity	O
to	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
a	O
reduction	O
of	O
the	O
retention	O
time	O
to	O
8.5	O
glucose	O
units	O
.	O

This	O
corresponds	O
to	O
the	O
retention	O
time	O
of	O
completely	O
digested	O
MMX	O
from	O
zucchini	B
ascorbate	O
–	O
oxidase	O
(	O
Altmann	O
,	O
1998	O
)	O
.	O

Coelution	O
of	O
the	O
limited	O
digestion	O
product	O
from	O
the	O
reference	O
oligosaccharide	O
with	O
1-C	O
yields	O
a	O
single	O
,	O
homogenous	O
peak	O
as	O
calculated	O
from	O
addition	O
of	O
the	O
peak	O
areas	O
;	O
1-C	O
was	O
therefore	O
found	O
to	O
be	O
M0X	O
.	O

Peak	O
2	O
from	O
MicroPak	O
gave	O
a	O
single	O
peak	O
on	O
reverse	O
-	O
phase	O
,	O
which	O
was	O
sensitive	O
to	O
α	O
-	O
mannosidase	O
;	O
two	O
peaks	O
,	O
lacking	O
one	O
and	O
two	O
mannose	O
residues	O
as	O
deduced	O
from	O
the	O
retention	O
behavior	O
on	O
MicroPak	O
HPLC	O
,	O
were	O
obtained	O
.	O

The	O
second	O
peak	O
on	O
the	O
size	O
fractionation	O
column	O
exhibited	O
the	O
same	O
retention	O
time	O
as	O
fraction	O
1	O
of	O
phospholipase	O
A2	O
.	O

Therefore	O
,	O
the	O
structure	O
of	O
peak	O
2	O
was	O
assumed	O
to	O
be	O
MM	O
.	O

This	O
was	O
confirmed	O
by	O
coinjection	O
of	O
MM	O
(	O
prepared	O
from	O
bovine	O
fibrin	O
)	O
,	O
resulting	O
in	O
a	O
single	O
peak	O
.	O

Furthermore	O
,	O
the	O
α	O
-	O
mannosidase	O
digest	O
of	O
fibrin	O
MM	O
behaved	O
exactly	O
the	O
same	O
way	O
as	O
the	O
digest	O
of	O
peak	O
2	O
on	O
both	O
HPLC	O
columns	O
.	O

Oligosaccharide	O
3-A	O
exhibited	O
the	O
same	O
elution	O
behavior	O
in	O
both	O
HPLC	O
systems	O
as	O
the	O
reference	O
oligosaccharide	O
from	O
pineapple	B
stem	O
bromelain	O
,	O
M0XF3	O
.	O

α	O
-	O
mannosidase	O
digestion	O
of	O
3-A	O
resulted	O
in	O
a	O
single	O
peak	O
,	O
which	O
coeluted	O
with	O
compound	O
1-B	O
(	O
5.2	O
glucose	O
units	O
on	O
reverse	O
-	O
phase	O
HPLC	O
)	O
.	O

Peak	O
3-B	O
was	O
identified	O
based	O
on	O
its	O
size	O
and	O
retention	O
times	O
before	O
and	O
after	O
α	O
-	O
mannosidase	O
digestions	O
in	O
comparison	O
with	O
the	O
standard	O
MMX	O
from	O
fraction	O
1	O
of	O
ascorbate	O
oxidase	O
.	O

Partial	O
digestion	O
with	O
α	O
-	O
mannosidase	O
resulted	O
in	O
a	O
peak	O
which	O
coeluted	O
with	O
compound	O
1-C.	O
The	O
final	O
proof	O
of	O
peak	O
identity	O
was	O
again	O
provided	O
by	O
coinjection	O
of	O
the	O
MMX	O
reference	O
compound	O
.	O

Peak	O
4	O
,	O
which	O
appeared	O
to	O
be	O
non	O
-	O
homogenous	O
on	O
MicroPak	O
eluted	O
as	O
one	O
major	O
peak	O
(	O
>	O
85	O
%	O
)	O
on	O
the	O
reverse	O
-	O
phase	O
column	O
.	O

The	O
minor	O
components	O
(	O
at	O
least	O
five	O
peaks	O
)	O
were	O
present	O
in	O
minute	O
quantities	O
and	O
could	O
not	O
be	O
analyzed	O
further	O
.	O

The	O
major	O
peak	O
was	O
subjected	O
to	O
α	O
-	O
mannosidase	O
digestion	O
,	O
yielding	O
two	O
signals	O
on	O
reverse	O
-	O
phase	O
HPLC	O
with	O
retention	O
times	O
of	O
5.1	O
and	O
4.4	O
glucose	O
units	O
,	O
thus	O
indicating	O
the	O
presence	O
of	O
two	O
mannose	O
residues	O
in	O
the	O
structure	O
.	O

The	O
first	O
peak	O
on	O
reverse	O
-	O
phase	O
coeluted	O
with	O
compound	O
1-A	O
,	O
thus	O
indicating	O
peak	O
4	O
to	O
represent	O
MMF3	O
.	O

This	O
assumption	O
could	O
be	O
proved	O
by	O
(	O
i	O
)	O
coinjection	O
of	O
phospholipase	O
A2	O
-compound	O
5A	O
(	O
MMF3	O
)	O
,	O
resulting	O
in	O
a	O
single	O
peak	O
and	O
(	O
ii	O
)	O
by	O
digesting	O
the	O
reference	O
compound	O
with	O
α	O
-	O
mannosidase	O
,	O
yielding	O
the	O
same	O
two	O
degradation	O
products	O
as	O
for	O
peak	O
4	O
.	O

The	O
major	O
oligosaccharide	O
(	O
5	O
)	O
in	O
all	O
the	O
samples	O
,	O
representing	O
47–59	O
%	O
of	O
the	O
total	O
N	O
-glycan	O
amount	O
,	O
was	O
shown	O
to	O
be	O
susceptible	O
to	O
α	O
-	O
mannosidase	O
digestion	O
,	O
resulting	O
in	O
two	O
peaks	O
:	O
the	O
first	O
eluted	O
at	O
retention	O
times	O
identical	O
to	O
those	O
from	O
oligosaccharide	O
3-A	O
and	O
the	O
M0XF3	O
reference	O
compound	O
,	O
the	O
second	O
coeluted	O
with	O
oligosaccharide	O
1-B	O
,	O
already	O
being	O
elucidated	O
as	O
00XF3	O
.	O

Furthermore	O
,	O
additional	O
evidence	O
for	O
the	O
peak	O
being	O
MMXF3	O
was	O
obtained	O
from	O
coinjection	O
of	O
the	O
reference	O
oligosaccharide	O
from	O
horseradish	O
peroxidase	O
,	O
yielding	O
a	O
single	O
peak	O
.	O

Fraction	O
6	O
from	O
MicroPak	O
gave	O
two	O
peaks	O
on	O
the	O
reverse	O
-	O
phase	O
column	O
with	O
relative	O
retention	O
times	O
of	O
4.7	O
and	O
5.8	O
glucose	O
units	O
,	O
respectively	O
.	O

These	O
peaks	O
were	O
digestible	O
by	O
β	O
-	O
N	O
-acetyl	O
-	O
hexosaminidase	O
to	O
a	O
common	O
new	O
compound	O
,	O
exhibiting	O
the	O
same	O
elution	O
behavior	O
as	O
compound	O
5	O
.	O

Furthermore	O
,	O
hornbeam	B
GnGnXF3	O
digestion	O
with	O
the	O
same	O
enzyme	O
resulted	O
in	O
formation	O
of	O
the	O
two	O
peaks	O
mentioned	O
above	O
.	O

Again	O
,	O
the	O
final	O
proof	O
,	O
that	O
the	O
two	O
peaks	O
represent	O
MGnXF3	O
and	O
GnMXF3	O
was	O
accomplished	O
by	O
coinjection	O
of	O
the	O
corresponding	O
oligosaccharides	O
obtained	O
from	O
limited	O
β	O
-	O
N	O
-acetylglucosaminidase	O
digestion	O
of	O
hornbeam	B
pollen	O
GnGnXF3	O
.	O

Oligosaccharide	O
8	O
also	O
gave	O
one	O
major	O
peak	O
on	O
reverse	O
-	O
phase	O
HPLC	O
.	O

An	O
initial	O
hexosaminidase	O
digestion	O
resulted	O
in	O
the	O
presence	O
of	O
the	O
peaks	O
with	O
4.8	O
and	O
5.8	O
glucose	O
units	O
on	O
reverse	O
-	O
phase	O
,	O
thus	O
presumably	O
representing	O
the	O
above	O
mentioned	O
components	O
MGnXF3	O
and	O
GnMXF3	O
.	O

Complete	O
digestion	O
with	O
β	O
-	O
N	O
-acetyl	O
-	O
hexosaminidase	O
yielded	O
a	O
single	O
peak	O
,	O
coeluting	O
with	O
compound	O
5	O
and	O
the	O
reference	O
compound	O
MMXF3	O
.	O

Hence	O
,	O
oligosaccharide	O
8	O
can	O
be	O
designated	O
to	O
be	O
GnGnXF3	O
.	O

2.4	O
Oligomannosidic	O
glycans	O
From	O
the	O
relative	O
retention	O
times	O
on	O
MicroPak	O
of	O
7.7	O
,	O
8.7	O
,	O
9.7	O
and	O
10.6	O
glucose	O
units	O
,	O
oligomannosidic	O
glycans	O
were	O
predicted	O
.	O

This	O
surmise	O
was	O
verified	O
by	O
performing	O
α	O
-	O
mannosidase	O
digestions	O
of	O
these	O
compounds	O
:	O
each	O
fraction	O
was	O
accessible	O
to	O
α	O
-	O
mannosidase	O
,	O
resulting	O
in	O
the	O
same	O
two	O
peaks	O
(	O
exhibiting	O
relative	O
retention	O
times	O
of	O
3.7	O
/	O
8.7	O
and	O
2.9	O
/	O
7.2	O
glucose	O
units	O
on	O
MicroPak	O
and	O
Hypersil	O
ODS	O
,	O
respectively	O
;	O
Table	O
1	O
)	O
for	O
all	O
four	O
fractions	O
.	O

The	O
assumption	O
of	O
these	O
peaks	O
being	O
Manα1–6Manβ1–4GlcNAcβ1–4GlcNAc	O
–	O
pyridylamine	O
and	O
Manβ1–4GlcNAcβ1–4GlcNAc	O
–	O
pyridylamine	O
was	O
confirmed	O
by	O
a	O
limited	O
α	O
-	O
mannosidase	O
digest	O
of	O
MM	O
,	O
which	O
yielded	O
the	O
same	O
two	O
peaks	O
.	O

Furthermore	O
,	O
endoglycosidase	O
H	O
-	O
digests	O
of	O
the	O
peaks	O
7	O
and	O
9–11	O
resulted	O
in	O
the	O
formation	O
of	O
pyridylamino	O
–	O
GlcNAc	O
(	O
3.5	O
glucose	O
units	O
on	O
reverse	O
-	O
phase	O
column	O
)	O
,	O
also	O
proving	O
the	O
presence	O
of	O
oligomannosidic	O
structures	O
.	O

Additionally	O
,	O
the	O
authentic	O
oligosaccharides	O
from	O
soybean	B
7S	I
-glycoprotein	O
were	O
used	O
to	O
confirm	O
the	O
identities	O
of	O
the	O
four	O
above	O
-	O
mentioned	O
peaks	O
.	O

Coelution	O
of	O
peaks	O
7	O
,	O
9	O
and	O
10	O
was	O
observed	O
with	O
the	O
corresponding	O
reference	O
compounds	O
Man6	O
GlcNAc2	O
–Man8	O
GlcNAc2	O
.	O

Peak	O
9	O
consisted	O
of	O
two	O
structural	O
isomers	O
(	O
M7.1	O
and	O
M7.2	O
)	O
,	O
occurring	O
in	O
relative	O
amounts	O
of	O
45	O
and	O
55	O
%	O
(	O
for	O
sample	O
NotAP2	O
(	O
Table	O
4	O
)	O
)	O
,	O
respectively	O
.	O

Man8	O
GlcNAc2	O
is	O
a	O
homogenous	O
peak	O
on	O
reverse	O
-	O
phase	O
(	O
4.7	O
GcU	O
)	O
,	O
which	O
can	O
be	O
therefore	O
assigned	O
to	O
be	O
the	O
M8.1	O
-isomer	O
.	O

The	O
elution	O
behavior	O
of	O
peak	O
11	O
corresponds	O
to	O
published	O
data	O
(	O
Tomiya	O
et	O
al.	O
,	O
1991	O
;	O
Kubelka	O
,	O
Altmann	O
,	O
Kornfeld	O
,	O
&	O
März	O
,	O
1994	O
)	O
and	O
can	O
therefore	O
assigned	O
to	O
be	O
the	O
Man9	O
-isomer	O
M9.1	O
.	O

Additional	O
confirmation	O
of	O
the	O
results	O
was	O
obtained	O
by	O
MALDI	O
–	O
TOF	O
analysis	O
of	O
individual	O
HPLC	O
fractions	O
.	O

Fig.	O
2	O
Fig.	O
2	O
shows	O
the	O
mass	O
spectrum	O
of	O
fraction	O
5	O
,	O
identified	O
as	O
MMXF3	O
;	O
Table	O
5	O
summarizes	O
the	O
results	O
,	O
which	O
corroborate	O
the	O
assignments	O
based	O
upon	O
two	O
-	O
dimensional	O
mapping	O
.	O

2.5	O
Analysis	O
of	O
tomatoes	B
from	O
two	O
varieties	O
.	O

Analysis	O
of	O
red	B
and	O
green	B
tomatoes	I
Red	B
Notoro	I
-	I
type	I
tomatoes	I
were	O
subjected	O
to	O
the	O
two	O
different	O
isolation	O
procedures	O
in	O
order	O
to	O
monitor	O
the	O
impact	O
of	O
sample	O
preparation	O
on	O
the	O
glycan	O
pattern	O
in	O
terms	O
of	O
quality	O
and	O
quantity	O
.	O

Furthermore	O
,	O
red	B
and	O
green	B
San	I
Marzano	I
-	I
type	I
fruits	I
were	O
analyzed	O
to	O
distinguish	O
differences	O
in	O
the	O
glycan	O
pattern	O
due	O
to	O
the	O
variety	O
and	O
the	O
stage	O
of	O
ripening	O
,	O
respectively	O
.	O

Table	O
4	O
shows	O
the	O
condensed	O
results	O
in	O
terms	O
of	O
relative	O
abundances	O
of	O
individual	O
fractions	O
on	O
the	O
total	O
N	O
-glycan	O
amounts	O
.	O

It	O
could	O
be	O
demonstrated	O
that	O
irrespective	O
of	O
the	O
preparation	O
method	O
very	O
similar	O
results	O
were	O
obtained	O
;	O
San	B
Marzano	I
-	I
type	I
tomatoes	I
contain	O
the	O
same	O
sixteen	O
structures	O
and	O
also	O
the	O
relative	O
quantities	O
were	O
rather	O
similar	O
in	O
the	O
examined	O
varieties	O
.	O

Interestingly	O
,	O
also	O
the	O
state	O
of	O
ripening	O
does	O
not	O
seem	O
to	O
have	O
a	O
significant	O
impact	O
on	O
the	O
appearance	O
of	O
the	O
glycan	O
pattern	O
in	O
terms	O
of	O
quality	O
and	O
quantity	O
although	O
it	O
has	O
to	O
be	O
stated	O
that	O
more	O
samples	O
have	O
to	O
be	O
analyzed	O
for	O
a	O
statistical	O
interpretation	O
.	O

3	O
Discussion	O
The	O
N	O
-glycans	O
of	O
tomato	B
fruit	O
were	O
structurally	O
elucidated	O
,	O
thereby	O
comparing	O
two	O
varieties	O
as	O
well	O
as	O
two	O
stages	O
of	O
ripening	O
.	O

The	O
low	O
protein	O
content	O
of	O
tomatoes	B
and	O
the	O
high	O
amount	O
of	O
free	O
sugars	O
and	O
polysaccharides	O
(	O
Seymour	O
,	O
Colquhoun	O
,	O
DuPont	O
,	O
Parsely	O
,	O
&	O
Selvendran	O
,	O
1990	O
;	O
York	O
,	O
Kumar	O
Kolli	O
,	O
Orlando	O
,	O
Albersheim	O
,	O
&	O
Darvill	O
,	O
1997	O
)	O
complicated	O
the	O
effective	O
isolation	O
of	O
the	O
protein	O
fraction	O
.	O

However	O
,	O
the	O
employed	O
low	O
-	O
temperature	O
acetone	O
powder	O
method	O
proved	O
to	O
be	O
very	O
efficient	O
for	O
this	O
application	O
:	O
several	O
by	O
-	O
products	O
are	O
effectively	O
removed	O
,	O
the	O
resulting	O
powder	O
can	O
be	O
stored	O
for	O
several	O
months	O
at	O
−20	O
°	O
C	O
and	O
,	O
although	O
not	O
of	O
relevance	O
in	O
the	O
present	O
study	O
,	O
protein	O
denaturation	O
is	O
minimized	O
due	O
to	O
the	O
extremely	O
low	O
temperature	O
during	O
isolation	O
,	O
yielding	O
extracts	O
of	O
high	O
immunochemical	O
activity	O
(	O
Vieths	O
,	O
Schöning	O
,	O
&	O
Baltes	O
,	O
1992	O
)	O
.	O

In	O
the	O
further	O
sample	O
preparation	O
,	O
two	O
steps	O
shall	O
be	O
briefly	O
addressed	O
:	O
borohydride	O
reduction	O
,	O
which	O
was	O
employed	O
in	O
order	O
to	O
prevent	O
residual	O
free	O
sugars	O
from	O
subsequent	O
derivatization	O
which	O
proved	O
its	O
necessity	O
in	O
the	O
case	O
of	O
grass	B
pollen	O
extracts	O
where	O
several	O
artefactic	O
peaks	O
appeared	O
on	O
the	O
chromatogramms	O
without	O
this	O
step	O
(	O
F.	O
Altmann	O
,	O
personal	O
communication	O
)	O
.	O

Second	O
,	O
N	O
-glycosidase	O
A	O
from	O
almonds	B
was	O
used	O
for	O
the	O
deglycosylation	O
of	O
the	O
glycopeptides	O
,	O
which	O
is	O
important	O
,	O
since	O
the	O
(	O
more	O
)	O
frequently	O
used	O
N	O
-glycosidase	O
F	O
from	O
Flavobacterium	B
meningosepticum	I
can	O
not	O
cleave	O
glycans	O
containing	O
fucose	O
linked	O
α1–3	O
to	O
Asn	O
–	O
GlcNAc	O
(	O
Tretter	O
,	O
Altmann	O
,	O
&	O
März	O
,	O
1991	O
;	O
Altmann	O
,	O
Schweiszer	O
,	O
&	O
Weber	O
,	O
1995	O
)	O
.	O

The	O
methodology	O
for	O
the	O
structural	O
characterization	O
,	O
using	O
two	O
-	O
dimensional	O
HPLC	O
in	O
combination	O
with	O
exoglycosidase	O
digestions	O
,	O
was	O
first	O
introduced	O
by	O
Tomiya	O
et	O
al.	O
(	O
1988	O
)	O
and	O
has	O
been	O
employed	O
for	O
glycoprotein	O
–	O
glycans	O
from	O
various	O
sources	O
(	O
Takahashi	O
et	O
al.	O
,	O
1986	O
;	O
Kubelka	O
et	O
al.	O
,	O
1994	O
;	O
Ohsuga	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Complex	O
-	O
type	O
structures	O
,	O
most	O
of	O
them	O
truncated	O
and	O
exhibiting	O
α1–3	O
linked	O
fucose	O
and/or	O
β1–2	O
linked	O
xylose	O
,	O
as	O
well	O
as	O
oligomannosidic	O
glycans	O
were	O
detected	O
.	O

Most	O
of	O
these	O
structures	O
have	O
been	O
reported	O
to	O
occur	O
in	O
other	O
plant	B
glycoproteins	O
;	O
MMXF3	O
,	O
addressed	O
to	O
be	O
the	O
typical	O
vacuole	O
-	O
type	O
plant	B
N	O
-glycan	O
(	O
Sturm	O
,	O
1995	O
)	O
and	O
the	O
most	O
abundant	O
oligosaccharide	O
in	O
tomato	B
fruit	O
,	O
has	O
also	O
been	O
found	O
in	O
horseradish	O
peroxidase	O
(	O
Kurosaka	O
et	O
al.	O
,	O
1991	O
)	O
,	O
a	O
protease	O
inhibitor	O
from	O
barbados	B
pride	I
(	O
Caesalpinia	B
Pulcherrima	I
Sw	O
.	O
)	O
seeds	O
(	O
Hase	O
et	O
al.	O
,	O
1986	O
)	O
,	O
Sophora	B
japonica	I
lectin	O
(	O
Fournet	O
et	O
al.	O
,	O
1987	O
)	O
and	O
ricin	O
D	O
from	O
the	O
seeds	O
of	O
castor	B
plants	I
(	O
Ricinus	B
communis	I
)	O
(	O
Kimura	O
et	O
al.	O
,	O
1988	O
)	O
.	O

M0XF3	O
,	O
another	O
structure	O
which	O
occurs	O
in	O
relatively	O
high	O
amounts	O
in	O
tomato	B
(	O
17–22	O
%	O
)	O
,	O
has	O
been	O
reported	O
for	O
both	O
pineapple	B
stem	O
bromelain	O
(	O
Van	O
Kuik	O
et	O
al.	O
,	O
1986	O
)	O
and	O
barley	B
peroxidase	O
(	O
Johannson	O
,	O
Rasmussen	O
,	O
Harthill	O
,	O
&	O
Welinder	O
,	O
1992	O
)	O
.	O

Small	O
α1,3-fucosylated	O
and/or	O
β1,2-xylosylated	O
glycans	O
that	O
are	O
minor	O
fractions	O
in	O
tomato	B
,	O
have	O
recently	O
also	O
been	O
found	O
in	O
other	O
plants	B
;	O
MMX	O
was	O
found	O
to	O
be	O
the	O
most	O
abundant	O
N	O
-glycan	O
in	O
rice	B
α	O
-	O
amylase	O
from	O
germinated	O
seedlings	O
(	O
Hayashi	O
et	O
al.	O
,	O
1990	O
)	O
and	O
also	O
represents	O
the	O
complex	O
oligosaccharide	O
side	O
chain	O
of	O
the	O
bean	B
storage	O
protein	O
phaseolin	O
(	O
Sturm	O
,	O
van	O
Kuik	O
,	O
Vliegenthart	O
,	O
&	O
Chrispeels	O
,	O
1987	O
)	O
.	O

M0X	O
accounts	O
for	O
15	O
%	O
of	O
the	O
N	O
-glycans	O
of	O
barley	B
(	O
1–3,1–4	O
)	O
-β	O
-	O
d	O
-glucan	O
4-glucanohydrolase	O
isoenzyme	O
EII	O
(	O
Harthill	O
,	O
&	O
Thomsen	O
,	O
1995	O
)	O
,	O
whereas	O
MMF3	O
was	O
found	O
to	O
be	O
a	O
minor	O
fraction	O
of	O
soybean	B
peroxidase	O
(	O
Gray	O
,	O
Yun	O
Yang	O
,	O
Hull	O
,	O
Venzke	O
,	O
&	O
Montgomery	O
,	O
1996	O
)	O
.	O

Three	O
structures	O
that	O
exhibit	O
outer	O
-	O
arm	O
GlcNAc	O
residues	O
and	O
represent	O
6–14	O
%	O
of	O
the	O
N	O
-glycans	O
in	O
tomato	B
fruit	O
,	O
have	O
been	O
previously	O
reported	O
for	O
lactase	O
from	O
sycamore	B
cells	O
(	O
Harthill	O
,	O
&	O
Thomsen	O
,	O
1995	O
)	O
.	O

GnMXF3	O
and	O
MGnXF3	O
were	O
also	O
found	O
to	O
be	O
present	O
in	O
red	B
kidney	I
bean	I
Fe	O
(	O
III	O
)	O
–Zn	O
(	O
II	O
)	O
purple	O
acid	O
phosphatase	O
(	O
Stahl	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Oligomannosidic	O
structures	O
,	O
accounting	O
for	O
only	O
3–9	O
%	O
of	O
the	O
N	O
-glycans	O
in	O
tomato	B
fruit	O
,	O
are	O
wide	O
-	O
spread	O
among	O
plants	B
(	O
e.g.	O
soybean	B
agglutinin	O
(	O
Dorland	O
,	O
van	O
Halbeek	O
,	O
Vliegenthart	O
,	O
Lis	O
,	O
&	O
Sharon	O
,	O
1981	O
)	O
,	O
phaseolin	O
of	O
the	O
common	O
bean	B
(	O
Sturm	O
et	O
al.	O
,	O
1987	O
)	O
,	O
rice	B
α	O
-	O
amylase	O
(	O
Hayashi	O
et	O
al.	O
,	O
1990	O
)	O
,	O
α	O
-	O
amylase	O
inhibitor	O
from	O
white	B
kidney	I
bean	I
(	O
Phasolus	B
vulgaris	I
)	O
(	O
Yamaguchi	O
,	O
Funaoka	O
,	O
&	O
Iwamoto	O
,	O
1992	O
)	O
,	O
but	O
are	O
also	O
found	O
in	O
insect	B
,	O
yeast	B
and	O
mammalian	B
glycoproteins	O
.	O

α-1,3-Fucosylation	O
of	O
the	O
innermost	O
N	O
-acetylglucosamine	O
residue	O
,	O
a	O
typical	O
feature	O
of	O
N	O
-glycans	O
from	O
plants	B
but	O
also	O
from	O
insects	B
,	O
was	O
found	O
in	O
8	O
of	O
the	O
16	O
tomato	B
N	O
-linked	O
oligosaccharides	O
,	O
accounting	O
for	O
86–90	O
%	O
of	O
the	O
N	O
-glycan	O
pool	O
in	O
tomato	B
fruits	O
.	O

Such	O
fucosyl	O
residues	O
as	O
well	O
as	O
β1,2-linked	O
xylosyl	O
residues	O
are	O
not	O
present	O
in	O
mammalian	B
glycoproteins	O
and	O
therefore	O
render	O
plant	B
glycoproteins	O
immunogenic	O
(	O
Wilson	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
fact	O
,	O
even	O
IgE	O
antibodies	O
may	O
be	O
directed	O
against	O
this	O
epitope	O
.	O

Owing	O
to	O
their	O
widespread	O
occurrence	O
,	O
α1,3-fucosylated	O
N	O
-glycans	O
(	O
with	O
or	O
without	O
xylose	O
)	O
constitute	O
a	O
highly	O
cross	O
-	O
reactive	O
carbohydrate	O
determinant	O
detected	O
in	O
a	O
wide	O
variety	O
of	O
plant	B
as	O
well	O
as	O
insect	B
allergens	O
(	O
Tretter	O
et	O
al.	O
,	O
1993	O
;	O
Garcia	O
-	O
Casado	O
et	O
al.	O
,	O
1996	O
;	O
Jankiewicz	O
,	O
Aulepp	O
,	O
Altmann	O
,	O
Foetisch	O
,	O
&	O
Vieths	O
,	O
1998	O
)	O
.	O

As	O
far	O
as	O
tomatoes	B
are	O
concerned	O
,	O
Petersen	O
et	O
al.	O
(	O
1996	O
)	O
reported	O
the	O
reactivity	O
of	O
IgE	O
antibodies	O
of	O
grass	B
pollen	O
allergic	O
individuals	O
to	O
tomato	B
extracts	O
.	O

Lectin	O
blotting	O
of	O
proteins	O
and	O
ELISA	O
inhibition	O
experiments	O
using	O
glycopeptides	O
of	O
known	O
glycan	O
structures	O
suggested	O
the	O
presence	O
of	O
carbohydrate	O
IgE	O
epitopes	O
with	O
an	O
α1,3-fucose	O
residue	O
.	O

The	O
characterization	O
of	O
the	O
tomato	B
N	O
-glycans	O
presented	O
in	O
this	O
work	O
,	O
revealing	O
a	O
high	O
degree	O
of	O
α1,3-fucosylated	O
structures	O
in	O
the	O
fruit	B
,	O
offers	O
the	O
structural	O
explanation	O
for	O
these	O
findings	O
.	O

4	O
Experimental	O
4.1	O
Materials	O
Red	B
tomatoes	I
(	O
variety	O
Notoro	B
)	O
were	O
bought	O
in	O
a	O
retail	O
shop	O
;	O
red	B
and	O
green	O
tomatoes	B
(	O
variety	O
San	B
Marzano	I
)	O
were	O
obtained	O
from	O
RIKILT	O
-	O
DLO	O
,	O
Netherlands	O
.	O

N	O
-glycosidase	O
A	O
from	O
almonds	B
and	O
endoglycosidase	O
H	O
from	O
Streptomyces	B
plicatus	I
were	O
purchased	O
from	O
Boehringer	O
Mannheim	O
.	O

β	O
-	O
N	O
-acetylglucosaminidase	O
(	O
jack	B
bean	I
)	O
,	O
α	O
-	O
mannosidase	O
(	O
jack	B
bean	I
)	O
and	O
pepsin	O
(	O
from	O
porcine	B
stomach	O
mucosa	O
)	O
were	O
obtained	O
from	O
Sigma	O
.	O

2-aminopyridine	O
,	O
sodium	O
cyanoborohydride	O
,	O
dithioerythritol	O
,	O
benzamidine	O
and	O
PMSF	O
were	O
obtained	O
from	O
Sigma	O
.	O

4.2	O
Precipitation	O
of	O
proteins	O
using	O
a	O
low	O
-	O
temperature	O
acetone	O
powder	O
method	O
The	O
extracts	O
were	O
prepared	O
in	O
a	O
similar	O
manner	O
to	O
that	O
described	O
by	O
Vieths	O
,	O
Schöning	O
,	O
and	O
Petersen	O
(	O
1994	O
)	O
:	O
200	O
g	O
of	O
tomato	B
fruit	O
were	O
homogenized	O
in	O
400	O
ml	O
of	O
ice	O
-	O
cold	O
acetone	O
on	O
dry	O
ice	O
.	O

Another	O
400	O
ml	O
of	O
ice	O
-	O
cold	O
acetone	O
were	O
added	O
and	O
the	O
sample	O
was	O
kept	O
on	O
dry	O
ice	O
overnight	O
with	O
occasional	O
stirring	O
during	O
the	O
first	O
few	O
hours	O
.	O

The	O
resulting	O
precipitate	O
was	O
filtered	O
through	O
sintered	O
glass	O
and	O
washed	O
twice	O
with	O
acetone	O
and	O
once	O
with	O
acetone	O
/	O
diethylether	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
−20	O
°	O
C	O
.	O

The	O
sediment	O
was	O
lyophilized	O
.	O

4	O
g	O
of	O
acetone	O
powder	O
were	O
taken	O
up	O
in	O
150	O
ml	O
phosphate	O
buffered	O
saline	O
(	O
10	O
mM	O
phosphate	O
pH	O
7.4	O
;	O
0.15	O
M	O
NaCl	O
)	O
and	O
stirred	O
at	O
4	O
°	O
C	O
for	O
60	O
min	O
.	O

After	O
centrifugation	O
(	O
20000	O
rpm	O
,	O
20	O
min	O
,	O
0	O
°	O
C	O
)	O
,	O
the	O
supernatant	O
was	O
filtered	O
(	O
0.45	O
μm	O
)	O
,	O
extensively	O
dialyzed	O
against	O
double	O
-	O
distilled	O
water	O
(	O
membrane	O
3.5	O
kD	O
cut	O
-	O
off	O
)	O
overnight	O
and	O
lyophilized	O
.	O

4.3	O
Ammonium	O
sulfate	O
precipitation	O
As	O
an	O
alternative	O
to	O
the	O
above	O
-	O
mentioned	O
procedure	O
,	O
ammonium	O
sulfate	O
precipitation	O
was	O
per	O
-	O
formed	O
:	O
to	O
200	O
g	O
of	O
tomato	B
fruit	O
400	O
ml	O
of	O
extraction	O
buffer	O
(	O
10	O
mM	O
phosphate	O
pH	O
7.4	O
,	O
150	O
mM	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
,	O
1	O
mM	O
benzamidine	O
,	O
1	O
mM	O
DTE	O
,	O
0.1	O
mM	O
PMSF	O
)	O
was	O
added	O
and	O
the	O
sample	O
was	O
homogenized	O
.	O

Centrifugation	O
was	O
carried	O
out	O
at	O
20000	O
rpm	O
(	O
20	O
min	O
,	O
4	O
°	O
C	O
)	O
.	O

Solid	O
ammonium	O
sulfate	O
was	O
added	O
to	O
the	O
supernatant	O
to	O
a	O
final	O
concentration	O
of	O
80	O
%	O
saturation	O
.	O

The	O
mixture	O
was	O
stirred	O
at	O
4	O
°	O
C	O
for	O
3	O
h	O
,	O
centrifuged	O
(	O
20000	O
rpm	O
,	O
20	O
min	O
,	O
4	O
°	O
C	O
)	O
and	O
the	O
pellet	O
was	O
dialyzed	O
against	O
double	O
-	O
distilled	O
water	O
and	O
lyophilized	O
.	O

4.4	O
Purification	O
of	O
N	O
-glycans	O
The	O
lyophilisate	O
was	O
dissolved	O
in	O
5	O
%	O
v	O
/	O
v	O
formic	O
acid	O
and	O
digested	O
with	O
pepsin	O
(	O
2	O
%	O
,	O
w	O
/	O
w	O
)	O
for	O
48	O
h	O
at	O
37	O
°	O
C	O
.	O

(	O
Another	O
1	O
%	O
w	O
/	O
w	O
pepsin	O
was	O
added	O
after	O
24	O
h	O
)	O
.	O

After	O
centrifugation	O
(	O
10000	O
rpm	O
,	O
10	O
min	O
)	O
,	O
the	O
supernatant	O
was	O
adjusted	O
to	O
pH	O
2.5	O
and	O
chromatographed	O
on	O
an	O
ion	O
-	O
exchange	O
SP650-M	O
column	O
,	O
1	O
×	O
5	O
cm	O
(	O
Toso	O
Haas	O
)	O
,	O
equilibrated	O
with	O
5	O
%	O
acetic	O
acid	O
.	O

After	O
application	O
of	O
the	O
sample	O
,	O
the	O
column	O
was	O
rinsed	O
with	O
40	O
ml	O
5	O
%	O
acetic	O
acid	O
.	O

The	O
glycopeptide	O
fraction	O
was	O
eluted	O
with	O
1	O
M	O
ammonia	O
(	O
collection	O
of	O
2	O
ml	O
fractions	O
)	O
.	O

Carbohydrate	O
-	O
positive	O
fractions	O
,	O
detected	O
using	O
the	O
orcinol	O
–	O
sulfuric	O
acid	O
reagent	O
according	O
to	O
Winzler	O
(	O
1955	O
)	O
,	O
were	O
pooled	O
and	O
lyophilized	O
.	O

The	O
sample	O
was	O
taken	O
up	O
in	O
1	O
ml	O
water	O
;	O
the	O
pH	O
was	O
adjusted	O
to	O
9	O
with	O
ammonia	O
.	O

100	O
μl	O
of	O
a	O
2	O
%	O
w	O
/	O
v	O
sodium	O
borohydride	O
solution	O
was	O
added	O
and	O
the	O
sample	O
was	O
incubated	O
at	O
room	O
temperature	O
overnight	O
.	O

After	O
addition	O
of	O
acetic	O
acid	O
and	O
evaporation	O
,	O
this	O
step	O
was	O
repeated	O
twice	O
with	O
1	O
%	O
v	O
/	O
v	O
acetic	O
acid	O
in	O
methanol	O
and	O
twice	O
with	O
MeOH	O
.	O

The	O
sample	O
was	O
dissolved	O
in	O
100	O
μl	O
citrate	O
/	O
phosphate	O
pH	O
5.0	O
and	O
digested	O
with	O
0.5	O
mU	O
of	O
N	O
-glycosidase	O
A	O
for	O
37	O
°	O
C	O
for	O
48	O
h.	O
Oligosaccharides	O
were	O
separated	O
from	O
residual	O
glycopeptides	O
and	O
peptides	O
using	O
a	O
reverse	O
-	O
phase	O
cartridge	O
as	O
described	O
by	O
Dell	O
et	O
al.	O
(	O
Dell	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
glycans	O
were	O
labelled	O
with	O
2-aminopyridine	O
according	O
to	O
Hase	O
,	O
Ibuki	O
,	O
and	O
Ikenaka	O
(	O
1984	O
)	O
.	O

To	O
remove	O
the	O
excess	O
of	O
reagent	O
,	O
a	O
gelfiltration	O
step	O
was	O
performed	O
using	O
a	O
1	O
×	O
40	O
cm	O
Sephadex	O
G15	O
column	O
,	O
equilibrated	O
with	O
1	O
%	O
w	O
/	O
v	O
acetic	O
acid	O
.	O

4.5	O
Fractionation	O
of	O
pyridylaminated	O
oligosaccharides	O
by	O
two	O
-	O
dimensional	O
HPLC	O
A	O
Shimadzu	O
module	O
system	O
,	O
consisting	O
of	O
a	O
system	O
controller	O
,	O
a	O
pump	O
and	O
a	O
fluorescence	O
detector	O
was	O
used	O
.	O

Separations	O
of	O
the	O
pyridylamino	O
-	O
oligosaccharides	O
using	O
two	O
different	O
HPLC	O
columns	O
were	O
performed	O
at	O
room	O
temperature	O
.	O

Glucose	O
oligomers	O
were	O
used	O
in	O
both	O
systems	O
for	O
calibration	O
and	O
as	O
internal	O
standards	O
.	O

Elution	O
volumes	O
of	O
the	O
samples	O
were	O
expressed	O
in	O
glucose	O
units	O
according	O
to	O
Lee	O
,	O
Lee	O
,	O
Tomiya	O
,	O
and	O
Takahashi	O
(	O
1990	O
)	O
.	O

Fractionation	O
according	O
to	O
size	O
was	O
accomplished	O
on	O
a	O
MicroPak	O
AX-5	O
column	O
(	O
4	O
×	O
300	O
mm	O
,	O
VARIAN	O
)	O
;	O
the	O
eluents	O
were	O
as	O
follows	O
:	O
(	O
A	O
)	O
3	O
%	O
w	O
/	O
v	O
acetic	O
acid	O
,	O
triethylamine	O
pH	O
7.3	O
:	O
acetonitrile	O
35:65	O
,	O
v	O
/	O
v	O
and	O
(	O
B	O
)	O
3	O
%	O
w	O
/	O
v	O
acetic	O
acid	O
,	O
triethylamine	O
pH	O
7.3	O
:	O
acetonitrile	O
50:50	O
,	O
v	O
/	O
v	O
.	O

A	O
linear	O
gradient	O
of	O
0–60%B	O
in	O
30	O
min	O
at	O
a	O
flow	O
rate	O
of	O
1	O
ml	O
/	O
min	O
was	O
applied	O
.	O

Further	O
separation	O
was	O
achieved	O
by	O
reverse	O
-	O
phase	O
HPLC	O
on	O
a	O
5	O
μm	O
hypersil	O
ODS	O
column	O
(	O
Shandon	O
)	O
.	O

The	O
column	O
was	O
equilibrated	O
with	O
0.1	O
M	O
ammonium	O
acetate	O
pH	O
4.0	O
and	O
eluted	O
with	O
a	O
linear	O
gradient	O
of	O
0–7.5	O
%	O
(	O
by	O
vol	O
.	O
)	O
methanol	O
in	O
25	O
min	O
at	O
a	O
flow	O
rate	O
of	O
1.5	O
ml	O
/	O
min	O
.	O

In	O
both	O
systems	O
,	O
pyridylaminated	O
oligosaccharides	O
were	O
detected	O
by	O
fluorescence	O
using	O
excitation	O
and	O
emission	O
wavelengths	O
of	O
320	O
and	O
400	O
nm	O
,	O
respectively	O
.	O

4.6	O
Exoglycosidase	O
digestions	O
Generally	O
,	O
about	O
50–100	O
pmol	O
of	O
oligosaccharide	O
were	O
incubated	O
for	O
20	O
h	O
at	O
37	O
°	O
C	O
.	O

The	O
following	O
buffers	O
and	O
enzyme	O
quantities	O
were	O
used	O
:	O
50	O
mU	O
α	O
-	O
mannosidase	O
in	O
50	O
mM	O
sodium	O
acetate	O
,	O
pH	O
4.2	O
containing	O
0.1	O
mM	O
ZnCl2	O
to	O
achieve	O
complete	O
removal	O
of	O
α	O
-	O
linked	O
mannose	O
residues	O
;	O
5	O
mU	O
of	O
α	O
-	O
mannosidase	O
to	O
selectively	O
remove	O
α1,3-linked	O
mannose	O
residues	O
;	O
2	O
mU	O
β	O
-	O
N	O
-acetylhexosaminidase	O
(	O
for	O
partial	O
hydrolysis	O
)	O
or	O
10	O
mU	O
of	O
the	O
enzyme	O
for	O
complete	O
hydrolysis	O
,	O
using	O
0.1	O
M	O
sodium	O
citrate	O
,	O
pH	O
5.0	O
;	O
1	O
mU	O
endoglycosidase	O
H	O
in	O
0.1	O
M	O
sodium	O
citrate	O
/	O
phosphate	O
,	O
pH	O
5.0	O
.	O

4.7	O
Preparation	O
of	O
reference	O
oligosaccharides	O
Pyridylaminated	O
oligosaccharides	O
used	O
as	O
reference	O
substances	O
were	O
prepared	O
from	O
the	O
following	O
sources	O
:	O
Manα1–6	O
(	O
Manα1–3	O
)	O
Manβ1–4GlcNAcβ1–4GlcNAc	O
(	O
MM	O
)	O
from	O
bovine	B
fibrin	O
(	O
Staudacher	O
,	O
Kubelka	O
,	O
&	O
März	O
,	O
1992	O
)	O
;	O
Manα1–6	O
(	O
Manα1–3	O
)	O
(	O
Xylβ1–2	O
)	O
Manβ1–4GlcNAcβ1–4GlcNAc	O
(	O
MMX	O
)	O
from	O
zucchini	B
ascorbate	O
oxidase	O
(	O
Altmann	O
,	O
1998	O
)	O
;	O
Manα1–6	O
(	O
Manα1–3	O
)	O
Manβ1–4GlcNAcβ1–4	O
(	O
Fucα1–3	O
)	O
GlcNAc	O
(	O
MMF3	O
)	O
from	O
honeybee	B
venom	O
phospholipase	O
A2	O
(	O
Kubelka	O
et	O
al.	O
,	O
1993	O
)	O
;	O
Manα1–6	O
(	O
Xylβ1–2	O
)	O
Manβ1–4GlcNAcβ1–4	O
(	O
Fucα1–3	O
)	O
GlcNAc	O
(	O
M0XF3	O
)	O
from	O
pineapple	B
stem	O
bromelain	O
(	O
Van	O
Kuik	O
et	O
al.	O
,	O
1986	O
)	O
;	O
Manα1–6	O
(	O
Manα1–3	O
)	O
(	O
Xylβ1–2	O
)	O
Manβ1–4GlcNAcβ1–4	O
(	O
Fucα1–3	O
)	O
GlcNAc	O
(	O
MMXF3	O
)	O
from	O
horseradish	B
peroxidase	O
(	O
Kurosaka	O
et	O
al.	O
,	O
1991	O
)	O
;	O
GlcNAcβ1–2Manα1–6	O
(	O
GlcNAcβ1–2Manα1–3	O
)	O
(	O
Xylβ1–2	O
)	O
Manβ1–4GlcNAcβ1–4	O
(	O
Fucα1–3	O
)	O
GlcNAc	O
(	O
GnGnXF3	O
)	O
from	O
hornbeam	B
pollen	O
(	O
Wilson	O
,	O
&	O
Altmann	O
,	O
1998	O
)	O
;	O
Man6	O
GlcNAc2	O
[	O
M6.1	O
]	O
1	O
Codes	O
for	O
oligomannose	O
structures	O
according	O
to	O
Tomiya	O
et	O
al.	O
(	O
1991	O
)	O
.	O

1	O
,	O
Man7	O
GlcNAc2	O
[	O
M7.1	O
]	O
1	O
,	O
[	O
M7.2	O
]	O
1	O
,	O
and	O
Man8	O
GlcNAc2	O
[	O
M8.1	O
]	O
1	O
from	O
soybean	B
7S	O
-glycoprotein	O
(	O
Neeser	O
,	O
Vedovo	O
,	O
Mutsaers	O
,	O
&	O
Vliegenthart	O
,	O
1985	O
)	O
.	O

The	O
structures	O
of	O
the	O
reference	O
oligosaccharides	O
were	O
confirmed	O
by	O
methylation	O
analysis	O
(	O
data	O
not	O
shown	O
)	O
.	O

For	O
column	O
calibration	O
,	O
pyridylaminated	O
isomaltooligosaccharides	O
were	O
prepared	O
from	O
partially	O
hydrolyzed	O
dextran	O
.	O

4.8	O
Matrix	O
-	O
assisted	O
laser	O
desorption	O
/	O
ionization	O
–	O
time	O
of	O
flight	O
–	O
mass	O
spectrometry	O
MALDI	O
–	O
TOF	O
–	O
MS	O
data	O
was	O
obtained	O
using	O
a	O
Dynamo	O
instrument	O
(	O
Thermo	O
Bioanalysis	O
,	O
UK	O
)	O
,	O
operating	O
in	O
the	O
positiv	O
-	O
ion	O
linear	O
mode	O
.	O

About	O
5–10	O
pmol	O
of	O
pyridylaminated	O
tomato	B
N	O
-glycans	O
(	O
individual	O
reverse	O
-	O
phase	O
HPLC	O
fractions	O
)	O
were	O
repeatedly	O
dried	O
under	O
nitrogen	O
to	O
remove	O
buffer	O
components	O
;	O
the	O
samples	O
were	O
finally	O
dissolved	O
in	O
6	O
μl	O
water	O
and	O
3	O
μl	O
matrix	O
solution	O
(	O
2	O
%	O
2,5-dihydroxybenzoic	O
acid	O
in	O
water	O
containing	O
30	O
%	O
acetonitrile	O
and	O
0,5	O
mM	O
NaCl	O
)	O
.	O

Aliquots	O
of	O
1	O
μl	O
were	O
applied	O
on	O
the	O
target	O
and	O
allowed	O
to	O
dry	O
.	O

Mass	O
spectra	O
were	O
obtained	O
by	O
averaging	O
20	O
single	O
spectra	O
.	O

External	O
mass	O
calibration	O
was	O
performed	O
with	O
pyridylaminated	O
GlcNAc2	O
Man3	O
GlcNAc2	O
(	O
MNa+	O
=	O
1418,2	O
Da	O
)	O
which	O
was	O
prepared	O
from	O
bovine	B
fibrin	O
as	O
described	O
(	O
Altmann	O
,	O
Schwihla	O
,	O
Staudacher	O
,	O
Glössl	O
,	O
&	O
März	O
,	O
1995	O
)	O
.	O

4.9	O
HPLC	O
-	O
analysis	O
of	O
OPA	O
-	O
aminosugars	O
An	O
aliquot	O
of	O
the	O
glycopeptide	O
fraction	O
was	O
hydrolyzed	O
with	O
4	O
M	O
TFA	O
and	O
aminosugar	O
analysis	O
by	O
reverse	O
-	O
phase	O
chromatography	O
was	O
performed	O
as	O
described	O
by	O
Altmann	O
(	O
1992	O
)	O
.	O

Acknowledgements	O

We	O
thank	O
Hubert	O
Noteborn	O
,	O
RILILT	O
-	O
DLO	O
for	O
supplying	O
us	O
with	O
the	O
tomato	B
samples	O
and	O
Thomas	O
Dalik	O
for	O
performing	O
the	O
aminosugar	O
analyses	O
.	O

This	O
work	O
was	O
financed	O
by	O
the	O
EU	O
-	O
project	O
AIR3-CT94	O
-	O
2311	O
.	O

2-Nitrofluorene	O
(	O
NF	O
)	O
is	O
an	O
air	O
pollutant	O
which	O
has	O
been	O
used	O
as	O
a	O
model	O
substance	O
of	O
nitrated	O
polycyclic	O
aromatic	O
hydrocarbons	O
(	O
nitro	O
-	O
PAHs	O
)	O
[	O
1	O
,	O
2	O
]	O
.	O

NF	O
enters	O
in	O
vivo	O
into	O
an	O
oxidative	O
or	O
a	O
reductive	O
metabolic	O
pathway	O
,	O
depending	O
on	O
the	O
route	O
of	O
administration	O
[	O
3–5	O
]	O
.	O

Oral	O
administration	O
results	O
mainly	O
in	O
reduced	O
metabolites	O
[	O
5	O
]	O
,	O
e.g.	O
,	O
2-aminofluorene	O
(	O
AF	O
)	O
and	O
2-acetylaminofluorene	O
(	O
AAF	O
)	O
,	O
both	O
are	O
carcinogens	O
.	O

It	O
is	O
reported	O
that	O
NF	O
induces	O
DNA	O
adduct	O
formation	O
in	O
vivo	O
with	O
dG	O
-	O
C8-AF	O
as	O
one	O
of	O
the	O
characterized	O
DNA	O
adducts	O
[	O
6	O
,	O
7	O
]	O
.	O

dG	O
-	O
C8-AF	O
,	O
together	O
with	O
other	O
known	O
AF-	O
and	O
AAF	O
-	O
related	O
DNA	O
adducts	O
(	O
i.e.	O
,	O
dG	O
-	O
C8-AAF	O
,	O
dG	O
-	O
N	O
2	O
-AAF	O
,	O
etc	O
.	O
)	O
have	O
been	O
suspected	O
to	O
be	O
pre	O
-	O
mutagenic	O
or	O
toxic	O
[	O
8	O
]	O
.	O

Carcinogens	O
have	O
been	O
shown	O
to	O
induce	O
DNA	O
adducts	O
[	O
6	O
,	O
7	O
,	O
9	O
,	O
10	O
]	O
.	O

Exposures	O
of	O
human	B
populations	O
to	O
complex	O
mixtures	O
with	O
known	O
or	O
suspected	O
risk	O
of	O
inducing	O
cancer	O
is	O
also	O
associated	O
with	O
formation	O
of	O
DNA	O
adducts	O
[	O
11–13	O
]	O
.	O

High	O
levels	O
of	O
DNA	O
adducts	O
in	O
normal	O
human	B
colonic	O
mucosa	O
is	O
significantly	O
associated	O
with	O
colorectal	O
cancer	O
[	O
14	O
]	O
.	O

In	O
polluted	O
areas	O
,	O
the	O
seasonal	O
change	O
of	O
DNA	O
adducts	O
in	O
human	B
lymphocytes	O
varies	O
with	O
the	O
seasonal	O
changes	O
of	O
air	O
pollutants	O
[	O
15	O
]	O
.	O

Thus	O
,	O
DNA	O
adducts	O
may	O
be	O
used	O
as	O
biomarkers	O
for	O
genotoxic	O
risk	O
.	O

DNA	O
adducts	O
have	O
different	O
stabilities	O
owing	O
to	O
factors	O
such	O
as	O
DNA	O
repair	O
and	O
chemical	O
instability	O
.	O

No	O
uniform	O
correlation	O
is	O
found	O
between	O
adduct	O
persistence	O
and	O
tumor	O
induction	O
.	O

However	O
,	O
it	O
is	O
postulated	O
that	O
the	O
persistent	O
DNA	O
adducts	O
represent	O
dormant	O
lesions	O
that	O
may	O
become	O
fixed	O
as	O
mutations	O
long	O
after	O
exposure	O
to	O
the	O
carcinogen	O
and	O
contribute	O
to	O
the	O
malignant	O
transformation	O
as	O
a	O
result	O
of	O
cell	O
division	O
[	O
16	O
]	O
.	O

Measurement	O
of	O
DNA	O
adducts	O
from	O
carcinogenic	O
alkenylbenzenes	O
in	O
preweanling	O
male	O
B6C3F1	B
mice	I
suggests	O
the	O
virtual	O
absence	O
of	O
DNA	O
repair	O
for	O
these	O
adducts	O
[	O
17	O
]	O
.	O

This	O
has	O
been	O
postulated	O
to	O
play	O
a	O
role	O
in	O
the	O
carcinogenicity	O
of	O
safrole	O
and	O
related	O
alkenylbenzenes	O
in	O
newborn	O
mice	B
[	O
17–20	O
]	O
.	O

Further	O
experiments	O
show	O
that	O
rapid	O
repair	O
of	O
O	O
6	O
-methylguanine	O
-	O
DNA	O
adducts	O
protects	O
transgenic	O
mice	B
from	O
N	O
-methylnitrosourea	O
-	O
induced	O
thymic	O
lymphomas	O
[	O
21	O
]	O
.	O

It	O
has	O
also	O
been	O
reported	O
that	O
increased	O
platinum	O
removal	O
from	O
total	O
genomic	O
DNA	O
was	O
associated	O
with	O
increased	O
cisplatin	O
resistance	O
in	O
human	B
ovarian	O
cancer	O
cell	O
lines	O
[	O
22	O
]	O
.	O

A	O
recently	O
published	O
long	O
-	O
term	O
tumor	O
study	O
on	O
Wistar	B
rats	I
showed	O
that	O
NF	O
induces	O
tumors	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
forestomach	O
.	O

DNA	O
adducts	O
are	O
formed	O
at	O
higher	O
levels	O
during	O
the	O
early	O
stage	O
of	O
NF	O
administration	O
in	O
these	O
tumor	O
-	O
target	O
organs	O
compared	O
with	O
some	O
non	O
-	O
tumor	O
target	O
organs	O
(	O
heart	O
,	O
spleen	O
and	O
glandular	O
stomach	O
)	O
[	O
23	O
]	O
.	O

However	O
,	O
NF	O
and	O
also	O
a	O
lot	O
of	O
other	O
carcinogens	O
induce	O
DNA	O
adducts	O
in	O
both	O
tumor	O
-	O
target	O
and	O
non	O
-	O
tumor	O
target	O
tissues	O
.	O

It	O
is	O
thus	O
of	O
significance	O
to	O
know	O
the	O
biochemical	O
characteristics	O
and	O
mutagenic	O
effects	O
of	O
the	O
individual	O
DNA	O
adduct	O
induced	O
by	O
carcinogens	O
.	O

Better	O
correlation	O
may	O
be	O
achieved	O
when	O
an	O
individual	O
DNA	O
adduct	O
is	O
compared	O
with	O
tumor	O
formation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
formation	O
and	O
persistence	O
and	O
the	O
characterization	O
of	O
DNA	O
adducts	O
during	O
and	O
after	O
a	O
long	O
-	O
term	O
administration	O
of	O
NF	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Animal	B
experiment	O
Male	O
Wistar	B
rats	I
from	O
Möllegaard	O
Breeding	O
Center	O
(	O
Skensved	O
,	O
Denmark	O
)	O
with	O
a	O
body	O
weight	O
of	O
approximately	O
90	O
g	O
,	O
were	O
used	O
for	O
the	O
experiment	O
.	O

The	O
rats	B
were	O
housed	O
in	O
wire	O
-	O
bottomed	O
cages	O
under	O
standardized	O
conditions	O
of	O
light	O
(	O
12	O
h	O
light	O
and	O
dark	O
cycle	O
)	O
,	O
humidity	O
(	O
55–60	O
%	O
)	O
and	O
temperature	O
(	O
21±1	O
°	O
C	O
)	O
.	O

The	O
rats	B
were	O
acclimatized	O
for	O
1	O
week	O
before	O
the	O
start	O
of	O
the	O
experiment	O
.	O

During	O
the	O
entire	O
experiment	O
,	O
the	O
rats	B
had	O
access	O
to	O
food	O
and	O
water	O
ad	O
libitum	O
.	O

The	O
rats	B
were	O
randomly	O
divided	O
into	O
four	O
groups	O
.	O

Three	O
groups	O
were	O
fed	O
diets	O
supplemented	O
with	O
different	O
concentrations	O
of	O
NF	O
which	O
were	O
0.24	O
mmol	O
(	O
LD	O
=	O
low	O
dose	O
)	O
,	O
0.95	O
mmol	O
(	O
MD	O
=	O
medium	O
dose	O
)	O
and	O
2.37	O
mmol	O
(	O
HD	O
=	O
high	O
dose	O
)	O
per	O
kg	O
diet	O
,	O
respectively	O
.	O

One	O
group	O
was	O
fed	O
basal	O
diet	O
(	O
R3	O
,	O
Ewos	O
,	O
Södertälje	O
,	O
Sweden	O
)	O
as	O
a	O
control	O
group	O
.	O

The	O
rats	B
were	O
fed	O
NF	O
-	O
supplemented	O
diets	O
continuously	O
for	O
11	O
months	O
,	O
thereafter	O
,	O
all	O
groups	O
were	O
fed	O
basal	O
diet	O
for	O
a	O
further	O
13	O
months	O
.	O

The	O
tumor	O
results	O
of	O
this	O
study	O
were	O
previously	O
reported	O
[	O
23	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
DNA	O
adducts	O
were	O
not	O
detected	O
in	O
the	O
LD	O
group	O
.	O

Different	O
tissues	O
,	O
i.e.	O
,	O
liver	O
,	O
kidney	O
,	O
forestomach	O
,	O
glandular	O
stomach	O
and	O
spleen	O
,	O
were	O
collected	O
for	O
DNA	O
adduct	O
analysis	O
.	O

The	O
early	O
stage	O
DNA	O
adduct	O
levels	O
were	O
obtained	O
from	O
three	O
rats	B
after	O
10	O
days	O
of	O
HD	O
NF	O
administration	O
.	O

The	O
later	O
stage	O
DNA	O
adduct	O
analysis	O
was	O
focused	O
on	O
the	O
samples	O
which	O
were	O
obtained	O
from	O
three	O
rats	B
that	O
were	O
killed	O
shortly	O
before	O
the	O
cessation	O
of	O
the	O
HD	O
NF	O
diet	O
(	O
11	O
months	O
)	O
.	O

The	O
persistence	O
of	O
DNA	O
adduct	O
levels	O
in	O
the	O
liver	O
after	O
the	O
termination	O
of	O
NF	O
administration	O
was	O
monitored	O
in	O
the	O
MD	O
group	O
.	O

2.2	O
DNA	O
adduct	O
analyses	O
Tissues	O
from	O
the	O
rat	B
were	O
homogenized	O
in	O
a	O
buffer	O
of	O
1	O
%	O
SDS	O
,	O
1	O
mM	O
EDTA	O
and	O
10	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
7.4	O
)	O
while	O
kept	O
cold	O
on	O
an	O
ice	O
bed	O
.	O

After	O
RNAse	O
and	O
proteinase	O
K	O
digestion	O
,	O
DNA	O
was	O
extracted	O
by	O
the	O
phenol	O
and	O
chloroform	O
and	O
then	O
hydrolyzed	O
by	O
micrococcal	O
nuclease	O
and	O
spleen	O
phosphodiesterase	O
.	O

DNA	O
adducts	O
were	O
enriched	O
by	O
butanol	O
extraction	O
in	O
the	O
presence	O
of	O
tetrabutylammonium	O
chloride	O
.	O

DNA	O
adducts	O
were	O
then	O
labeled	O
with	O
[	O
γ-32	O
P	O
]	O
ATP	O
by	O
polynucleotide	O
kinase	O
.	O

The	O
method	O
used	O
was	O
originally	O
from	O
Beach	O
and	O
Gupta	O
[	O
24	O
]	O
with	O
small	O
modifications	O
in	O
different	O
steps	O
[	O
25	O
,	O
26	O
]	O
.	O

32	O
P	O
-HPLC	O
-	O
analyses	O
of	O
postlabeled	O
DNA	O
adducts	O
were	O
performed	O
by	O
injecting	O
the	O
total	O
unrefined	O
32	O
P	O
-labeling	O
mixture	O
into	O
the	O
32	O
P	O
-HPLC	O
.	O

In	O
each	O
analysis	O
,	O
2.8	O
μg	O
of	O
DNA	O
(	O
5	O
μCi	O
)	O
was	O
injected	O
.	O

A	O
DeltaPak	O
™	O
5	O
μm	O
C18–100	O
Å	O
column	O
,	O
with	O
a	O
0.5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
2	O
M	O
ammonium	O
formate	O
,	O
0.4	O
M	O
formic	O
acid	O
(	O
pH	O
4.5	O
)	O
with	O
a	O
linear	O
gradient	O
of	O
0–35	O
%	O
acetonitrile	O
(	O
0–70	O
min	O
)	O
was	O
used	O
for	O
the	O
separation	O
of	O
phosphorylated	O
nucleotides	O
and	O
adducts	O
.	O

The	O
32	O
P	O
-HPLC	O
method	O
for	O
analyses	O
of	O
postlabeled	O
DNA	O
adducts	O
is	O
described	O
in	O
detail	O
elsewhere	O
[	O
25	O
,	O
26	O
]	O
.	O

2.3	O
Detection	O
of	O
NF	O
-	O
DNA	O
adducts	O
after	O
different	O
enrichment	O
procedures	O
Butanol	O
extraction	O
and	O
nuclease	O
P1	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
)	O
treatment	O
were	O
run	O
in	O
parallel	O
for	O
the	O
comparison	O
of	O
enrichment	O
efficiency	O
of	O
the	O
NF	O
-	O
DNA	O
adducts	O
.	O

Liver	O
samples	O
were	O
collected	O
from	O
rats	B
receiving	O
11	O
months	O
of	O
HD	O
NF	O
feeding	O
.	O

In	O
the	O
nuclease	O
P1	O
enrichment	O
procedure	O
,	O
normal	O
nucleotides	O
were	O
dephosphorylated	O
by	O
40	O
min	O
37	O
°	O
C	O
incubation	O
with	O
nuclease	O
P1	O
(	O
in	O
1	O
mM	O
ZnCI2	O
)	O
in	O
1	O
μg	O
/	O
μg	O
DNA	O
level	O
.	O

The	O
hydrolysates	O
were	O
thereafter	O
evaporated	O
to	O
dryness	O
and	O
redissolved	O
in	O
water	O
for	O
32	O
P	O
-labeling	O
as	O
described	O
above	O
.	O

2.4	O
Identification	O
of	O
NF	O
-	O
DNA	O
adducts	O
DNA	O
adducts	O
formed	O
in	O
the	O
liver	O
after	O
11-month	O
HD	O
NF	O
administration	O
were	O
co	O
-	O
chromatographed	O
with	O
DNA	O
adduct	O
standards	O
:	O
dGp	O
-	O
C8-AF	O
,	O
dGp	O
-	O
C8-AAF	O
and	O
dGp	O
-	O
N	O
2	O
-AAF	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
DNA	O
adduct	O
standards	O
were	O
kindly	O
supplied	O
by	O
Dr.	O
F.A.	O
Beland	O
,	O
National	O
Center	O
for	O
Toxicological	O
Research	O
,	O
Jefferson	O
,	O
AR	O
,	O
USA	O
.	O

3	O
Results	O
Four	O
DNA	O
adducts	O
(	O
DNA	O
adduct	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
)	O
were	O
found	O
in	O
rat	B
tissues	O
after	O
10	O
days	O
as	O
well	O
as	O
11	O
months	O
of	O
HD	O
NF	O
feeding	O
.	O

Fig.	O
2	O
shows	O
representative	O
32	O
P	O
-HPLC	O
chromatograms	O
of	O
DNA	O
adducts	O
formed	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
spleen	O
after	O
10	O
days	O
(	O
Fig.	O
2	O
a	O
–	O
c	O
)	O
and	O
11	O
months	O
(	O
Fig.	O
2	O
d	O
–	O
f	O
)	O
of	O
HD	O
NF	O
feeding	O
.	O

DNA	O
adducts	O
A	O
and	O
B	O
increased	O
dramatically	O
in	O
the	O
liver	O
and	O
kidney	O
during	O
the	O
period	O
of	O
NF	O
administration	O
.	O

Adducts	O
C	O
and	O
D	O
showed	O
less	O
marked	O
changes	O
over	O
time	O
.	O

Fig.	O
3	O
shows	O
representative	O
chromatograms	O
of	O
DNA	O
adducts	O
formed	O
in	O
forestomach	O
and	O
glandular	O
stomach	O
after	O
10	O
days	O
of	O
HD	O
NF	O
administration	O
.	O

A	O
dramatic	O
difference	O
was	O
seen	O
between	O
these	O
two	O
tissues	O
regarding	O
DNA	O
adduct	O
levels	O
which	O
was	O
mainly	O
caused	O
by	O
high	O
DNA	O
adduct	O
D	O
level	O
in	O
the	O
forestomach	O
.	O

DNA	O
adducts	O
A	O
and	O
C	O
were	O
not	O
detectable	O
either	O
in	O
the	O
forestomach	O
or	O
the	O
glandular	O
stomach	O
.	O

Fig.	O
4	O
displays	O
the	O
DNA	O
adduct	O
levels	O
in	O
different	O
tissues	O
after	O
10	O
days	O
(	O
upper	O
)	O
and	O
11	O
months	O
(	O
lower	O
)	O
of	O
HD	O
NF	O
feeding	O
,	O
respectively	O
.	O

After	O
10	O
days	O
of	O
NF	O
feeding	O
,	O
the	O
levels	O
of	O
DNA	O
adducts	O
A	O
,	O
B	O
and	O
C	O
were	O
much	O
lower	O
compared	O
to	O
11	O
months	O
of	O
NF	O
feeding	O
.	O

Adduct	O
D	O
,	O
which	O
was	O
a	O
major	O
DNA	O
adduct	O
especially	O
in	O
the	O
liver	O
at	O
early	O
stage	O
(	O
10	O
days	O
)	O
of	O
NF	O
feeding	O
,	O
did	O
not	O
increase	O
significantly	O
over	O
time	O
(	O
10	O
days	O
to	O
11	O
months	O
)	O
.	O

Adducts	O
A	O
and	O
B	O
,	O
on	O
the	O
other	O
hand	O
,	O
increased	O
dramatically	O
during	O
the	O
NF	O
feeding	O
and	O
consequently	O
,	O
became	O
dominant	O
adducts	O
in	O
the	O
liver	O
and	O
kidney	O
after	O
11	O
months	O
of	O
NF	O
feeding	O
.	O

Compared	O
to	O
the	O
liver	O
and	O
kidney	O
,	O
spleen	O
showed	O
a	O
different	O
adduct	O
pattern	O
in	O
which	O
adduct	O
A	O
was	O
not	O
detectable	O
.	O

Fig.	O
5	O
shows	O
the	O
DNA	O
adduct	O
levels	O
formed	O
in	O
the	O
forestomach	O
and	O
glandular	O
stomach	O
after	O
10	O
days	O
of	O
HD	O
NF	O
feeding	O
.	O

A	O
significant	O
difference	O
was	O
seen	O
with	O
respect	O
to	O
the	O
level	O
of	O
adduct	O
D	O
in	O
these	O
two	O
tissues	O
.	O

DNA	O
adducts	O
A	O
and	O
C	O
were	O
not	O
found	O
in	O
these	O
tissues	O
.	O

To	O
characterize	O
the	O
four	O
major	O
DNA	O
adducts	O
induced	O
by	O
NF	O
,	O
32	O
P	O
-HPLC	O
co	O
-	O
chromatography	O
was	O
performed	O
.	O

DNA	O
adduct	O
D	O
co	O
-	O
migrated	O
with	O
dG	O
-	O
C8-AF	O
and	O
DNA	O
adduct	O
C	O
co	O
-	O
migrated	O
with	O
dG	O
-	O
N	O
2	O
-AAF	O
.	O

Neither	O
DNA	O
adduct	O
A	O
nor	O
B	O
co	O
-	O
migrated	O
with	O
any	O
of	O
the	O
three	O
adduct	O
standards	O
(	O
Fig.	O
6	O
)	O
.	O

Higher	O
levels	O
of	O
DNA	O
adduct	O
A	O
and	O
C	O
were	O
detected	O
after	O
nuclease	O
P1	O
treatment	O
compared	O
to	O
the	O
butanol	O
extraction	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	O
adducts	O
B	O
and	O
D	O
were	O
not	O
detectable	O
after	O
nuclease	O
P1	O
treatment	O
(	O
Fig.	O
7	O
)	O
.	O

The	O
decline	O
of	O
total	O
NF	O
-	O
DNA	O
adducts	O
in	O
the	O
rat	B
liver	O
after	O
the	O
withdrawal	O
of	O
MD	O
NF	O
administration	O
showed	O
a	O
biphasic	O
manner	O
(	O
Fig.	O
8	O
)	O
.	O

The	O
pattern	O
of	O
DNA	O
adduct	O
removal	O
for	O
different	O
DNA	O
adducts	O
varied	O
.	O

Adducts	O
B	O
and	O
D	O
showed	O
a	O
sharp	O
drop	O
1	O
month	O
after	O
the	O
withdrawal	O
of	O
NF	O
feeding	O
.	O

DNA	O
adduct	O
D	O
,	O
in	O
the	O
later	O
stage	O
of	O
the	O
period	O
,	O
reached	O
an	O
undetectable	O
level	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	O
adducts	O
A	O
and	O
C	O
showed	O
a	O
slow	O
decline	O
.	O

DNA	O
adduct	O
A	O
maintained	O
a	O
high	O
level	O
after	O
11	O
months	O
on	O
the	O
basal	O
diet	O
(	O
Fig.	O
8	O
)	O
.	O

4	O
Discussion	O
A	O
long	O
-	O
term	O
NF	O
feeding	O
to	O
rats	B
induces	O
tumors	O
in	O
the	O
liver	O
,	O
kidney	O
and	O
forestomach	O
[	O
23	O
]	O
.	O

Both	O
DNA	O
adduct	O
levels	O
and	O
tumor	O
formation	O
showed	O
a	O
dose	O
-	O
dependent	O
manner	O
[	O
23	O
]	O
.	O

DNA	O
adduct	O
levels	O
after	O
short	O
-	O
term	O
(	O
days	O
)	O
NF	O
administration	O
were	O
associated	O
with	O
the	O
locations	O
of	O
tumors	O
up	O
to	O
2	O
years	O
later	O
[	O
23	O
]	O
.	O

In	O
the	O
present	O
experiment	O
,	O
four	O
major	O
DNA	O
adducts	O
,	O
named	O
as	O
DNA	O
adduct	O
A	O
,	O
B	O
,	O
C	O
and	O
D	O
,	O
were	O
found	O
in	O
the	O
liver	O
and	O
kidney	O
after	O
10	O
days	O
and	O
11	O
months	O
of	O
NF	O
feeding	O
.	O

The	O
levels	O
of	O
different	O
NF	O
-	O
DNA	O
adducts	O
increased	O
with	O
varied	O
rates	O
during	O
the	O
period	O
of	O
NF	O
feeding	O
.	O

In	O
one	O
of	O
the	O
non	O
-	O
tumor	O
target	O
tissues	O
,	O
spleen	O
,	O
adducts	O
B	O
,	O
C	O
,	O
and	O
D	O
were	O
detected	O
at	O
low	O
levels	O
after	O
short-	O
or	O
long	O
-	O
term	O
of	O
NF	O
feeding	O
.	O

Glandular	O
stomach	O
,	O
as	O
another	O
non	O
-	O
tumor	O
target	O
tissue	O
,	O
showed	O
only	O
low	O
levels	O
of	O
DNA	O
adducts	O
B	O
and	O
D	O
after	O
10	O
days	O
of	O
NF	O
feeding	O
.	O

DNA	O
adduct	O
formation	O
in	O
forestomach	O
after	O
11-month	O
NF	O
administration	O
could	O
not	O
be	O
analysed	O
since	O
multiple	O
tumors	O
which	O
generally	O
covered	O
the	O
forestomach	O
membrane	O
were	O
formed	O
in	O
this	O
tissue	O
in	O
almost	O
all	O
the	O
NF	O
-	O
dosed	O
rats	B
(	O
HD	O
,	O
MD	O
and	O
LD	O
group	O
)	O
.	O

At	O
the	O
early	O
stage	O
,	O
DNA	O
adduct	O
D	O
,	O
which	O
co	O
-	O
migrated	O
with	O
dG	O
-	O
C8-AF	O
,	O
constituted	O
a	O
large	O
part	O
of	O
total	O
NF	O
-	O
DNA	O
adducts	O
,	O
especially	O
in	O
the	O
liver	O
.	O

At	O
the	O
later	O
stage	O
of	O
NF	O
feeding	O
,	O
DNA	O
adducts	O
A	O
and	O
B	O
increased	O
,	O
becoming	O
the	O
major	O
part	O
of	O
total	O
DNA	O
adducts	O
,	O
while	O
DNA	O
adduct	O
D	O
(	O
dG	O
-	O
C8-AF	O
)	O
did	O
not	O
increase	O
significantly	O
compared	O
to	O
the	O
level	O
at	O
the	O
early	O
stage	O
.	O

Expressed	O
as	O
a	O
percentage	O
of	O
total	O
DNA	O
adducts	O
,	O
DNA	O
adduct	O
D	O
(	O
dG	O
-	O
C8-AF	O
)	O
decreased	O
from	O
42	O
(	O
10-day	O
NF	O
administration	O
)	O
to	O
10	O
%	O
of	O
total	O
DNA	O
adducts	O
(	O
11-month	O
NF	O
administration	O
)	O
in	O
the	O
liver	O
during	O
the	O
feeding	O
period	O
.	O

The	O
rat	B
stomach	O
consists	O
of	O
two	O
parts	O
,	O
i.e.	O
,	O
the	O
forestomach	O
and	O
the	O
glandular	O
stomach	O
.	O

A	O
dramatically	O
higher	O
DNA	O
adduct	O
level	O
was	O
detected	O
in	O
the	O
forestomach	O
,	O
corresponding	O
to	O
the	O
high	O
tumor	O
incidence	O
in	O
this	O
tissue	O
,	O
compared	O
to	O
the	O
level	O
of	O
DNA	O
adducts	O
in	O
the	O
glandular	O
stomach	O
,	O
a	O
non	O
-	O
tumor	O
target	O
tissue	O
of	O
NF	O
[	O
23	O
]	O
.	O

In	O
the	O
high	O
dose	O
group	O
,	O
most	O
of	O
the	O
rats	B
grew	O
liver	O
tumors	O
while	O
they	O
were	O
still	O
on	O
NF	O
diet	O
or	O
not	O
long	O
after	O
the	O
termination	O
of	O
NF	O
diet	O
.	O

Samples	O
were	O
unable	O
to	O
be	O
collected	O
for	O
certain	O
period	O
after	O
the	O
termination	O
of	O
NF	O
diet	O
.	O

MD	O
group	O
of	O
rats	B
grew	O
tumors	O
in	O
a	O
scattered	O
time	O
points	O
generally	O
after	O
the	O
termination	O
of	O
NF	O
diet	O
.	O

Liver	O
samples	O
from	O
the	O
MD	O
group	O
were	O
therefore	O
chosen	O
for	O
the	O
study	O
of	O
DNA	O
adduct	O
persistence	O
.	O

The	O
use	O
of	O
mature	O
rats	B
minimizes	O
the	O
significance	O
of	O
DNA	O
adduct	O
dilution	O
through	O
cell	O
proliferation	O
in	O
the	O
liver	O
.	O

The	O
early	O
rapid	O
diminution	O
of	O
DNA	O
adducts	O
followed	O
by	O
a	O
slower	O
rate	O
of	O
elimination	O
was	O
seen	O
for	O
adducts	O
B	O
and	O
D	O
(	O
but	O
not	O
for	O
adducts	O
A	O
and	O
C	O
)	O
.	O

The	O
biphasic	O
removal	O
is	O
consistent	O
with	O
what	O
observed	O
in	O
rat	B
tissues	O
after	O
in	O
vivo	O
administration	O
of	O
substances	O
that	O
form	O
bulky	O
adducts	O
[	O
16	O
,	O
27–30	O
]	O
.	O

The	O
two	O
-	O
step	O
removal	O
process	O
may	O
be	O
attributed	O
to	O
the	O
heterogeneity	O
in	O
efficiency	O
of	O
DNA	O
repair	O
,	O
with	O
adducts	O
in	O
some	O
genomic	O
regions	O
being	O
more	O
accessible	O
to	O
DNA	O
repair	O
than	O
these	O
in	O
others	O
[	O
31	O
,	O
32	O
]	O
.	O

Among	O
the	O
four	O
major	O
DNA	O
adducts	O
induced	O
by	O
NF	O
,	O
adduct	O
D	O
and	O
C	O
co	O
-	O
migrated	O
with	O
dG	O
-	O
C8-AF	O
and	O
dG	O
-	O
N	O
2	O
-AAF	O
,	O
respectively	O
.	O

DNA	O
adducts	O
A	O
and	O
B	O
did	O
not	O
co	O
-	O
migrate	O
with	O
any	O
of	O
the	O
adduct	O
standards	O
used	O
.	O

Some	O
characteristics	O
of	O
the	O
four	O
NF	O
-	O
DNA	O
adducts	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

For	O
DNA	O
adduct	O
enrichment	O
,	O
generally	O
,	O
butanol	O
extraction	O
is	O
used	O
for	O
aromatic	O
amines	O
-	O
DNA	O
adducts	O
and	O
nuclease	O
P1	O
is	O
used	O
for	O
PAHs	O
-	O
DNA	O
adducts	O
.	O

The	O
values	O
of	O
DNA	O
adduct	O
A	O
and	O
C	O
were	O
much	O
higher	O
after	O
nuclease	O
P1	O
treatment	O
compared	O
to	O
that	O
of	O
butanol	O
extraction	O
.	O

On	O
the	O
other	O
hand	O
,	O
DNA	O
adducts	O
B	O
and	O
D	O
were	O
undetectable	O
when	O
the	O
nuclease	O
P1	O
enrichment	O
procedure	O
was	O
used	O
.	O

DNA	O
adduct	O
A	O
as	O
an	O
unknown	O
major	O
NF	O
adduct	O
may	O
be	O
the	O
same	O
DNA	O
adduct	O
as	O
that	O
described	O
by	O
Wierckx	O
et	O
al.	O
[	O
7	O
]	O
.	O

This	O
DNA	O
adduct	O
could	O
possibly	O
represent	O
an	O
oxidative	O
NF	O
metabolite	O
reacted	O
with	O
DNA	O
,	O
either	O
via	O
a	O
ring	O
epoxide	O
or	O
via	O
a	O
reaction	O
with	O
the	O
hydroxyl	O
group	O
.	O

It	O
was	O
reported	O
that	O
OH	O
-	O
NFs	O
are	O
potent	O
genotoxins	O
with	O
a	O
hydroxy	O
function	O
at	O
position	O
7	O
or	O
9	O
of	O
NF	O
,	O
while	O
hydroxylization	O
at	O
position	O
5	O
makes	O
a	O
detoxification	O
product	O
[	O
33	O
]	O
.	O

DNA	O
adduct	O
B	O
,	O
which	O
was	O
sensitive	O
to	O
nuclease	O
P1	O
hydrolyzation	O
,	O
could	O
possibly	O
be	O
an	O
arylamine	O
DNA	O
adduct	O
[	O
34	O
,	O
35	O
]	O
.	O

Another	O
possibility	O
is	O
that	O
DNA	O
adduct	O
B	O
is	O
the	O
bis	O
-	O
phosphate	O
of	O
DNA	O
adduct	O
A.	O
Upon	O
nuclease	O
P1	O
treatment	O
,	O
DNA	O
adduct	O
B	O
is	O
converted	O
to	O
DNA	O
adduct	O
A.	O
Since	O
DNA	O
adduct	O
levels	O
varied	O
after	O
different	O
enrichment	O
procedures	O
(	O
Fig.	O
7	O
)	O
,	O
it	O
is	O
therefore	O
of	O
importance	O
to	O
relate	O
DNA	O
adduct	O
levels	O
to	O
specific	O
enrichment	O
procedures	O
.	O

Culp	O
et	O
al.	O
[	O
36	O
]	O
demonstrates	O
a	O
biphasic	O
removal	O
of	O
DNA	O
adducts	O
in	O
the	O
rat	B
liver	O
after	O
administration	O
of	O
AAF	O
.	O

The	O
present	O
study	O
dealt	O
with	O
NF	O
,	O
which	O
is	O
mainly	O
but	O
not	O
completely	O
metabolized	O
to	O
AF	O
and	O
AAF	O
in	O
rats	B
[	O
2	O
,	O
3	O
,	O
5	O
]	O
.	O

Two	O
DNA	O
adducts	O
,	O
i.e.	O
,	O
dG	O
-	O
C8-AF	O
and	O
dG	O
-	O
N	O
2	O
-AAF	O
,	O
were	O
induced	O
in	O
the	O
rat	B
liver	O
both	O
by	O
NF	O
(	O
present	O
study	O
)	O
and	O
AAF	O
[	O
36	O
]	O
.	O

Although	O
the	O
strain	O
of	O
the	O
rats	B
and	O
length	O
of	O
administration	O
are	O
different	O
between	O
the	O
present	O
study	O
and	O
the	O
AAF	O
study	O
[	O
36	O
]	O
,	O
the	O
persistence	O
of	O
the	O
two	O
common	O
DNA	O
adducts	O
is	O
rather	O
consistent	O
.	O

Three	O
out	O
of	O
the	O
four	O
NF	O
-	O
DNA	O
adducts	O
were	O
still	O
detectable	O
in	O
rat	B
liver	O
after	O
the	O
rats	O
were	O
on	O
basal	O
diet	O
for	O
11	O
months	O
.	O

The	O
long	O
persistence	O
of	O
NF	O
-	O
DNA	O
adducts	O
may	O
increase	O
their	O
chances	O
to	O
be	O
fixed	O
as	O
mutations	O
.	O

In	O
conclusion	O
,	O
the	O
air	O
pollutant	O
NF	O
induces	O
mainly	O
four	O
DNA	O
adducts	O
.	O

Two	O
DNA	O
adducts	O
,	O
i.e.	O
,	O
adducts	O
C	O
and	O
D	O
,	O
are	O
characterized	O
as	O
dG	O
-	O
N	O
2	O
-AAF	O
and	O
dG	O
-	O
C8-AF	O
,	O
respectively	O
.	O

DNA	O
adducts	O
A	O
and	O
B	O
,	O
with	O
structures	O
unknown	O
,	O
are	O
the	O
major	O
NF	O
-	O
DNA	O
adducts	O
after	O
11	O
months	O
of	O
NF	O
feeding	O
.	O

NF	O
-	O
DNA	O
adducts	O
persist	O
long	O
after	O
the	O
withdrawal	O
of	O
NF	O
,	O
especially	O
DNA	O
adducts	O
A	O
and	O
C	O
which	O
are	O
repaired	O
only	O
to	O
a	O
minor	O
extent	O
over	O
a	O
period	O
that	O
corresponds	O
to	O
approximately	O
half	O
the	O
life	O
time	O
of	O
the	O
rats	B
.	O

Three	O
out	O
of	O
the	O
four	O
NF	O
-	O
DNA	O
adducts	O
are	O
still	O
detectable	O
in	O
the	O
rat	B
liver	O
11	O
months	O
after	O
the	O
withdrawal	O
of	O
NF	O
feeding	O
.	O

Further	O
characterization	O
of	O
individual	O
NF	O
-	O
DNA	O
adducts	O
may	O
help	O
to	O
elucidate	O
the	O
mechanism	O
of	O
NF	O
-	O
induced	O
carcinogenesis	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
express	O
their	O
gratitude	O
to	O
Mary	O
-	O
Ann	O
Zetterqvist	O
for	O
skillful	O
technical	O
assistance	O
.	O

This	O
study	O
was	O
supported	O
by	O
grants	O
from	O
Swedish	O
Environmental	O
Protection	O
Agency	O
and	O
Swedish	O
Cancer	O
Society	O
.	O

Nausea	O
and	O
vomiting	O
are	O
frequent	O
side	O
effects	O
caused	O
by	O
cancer	O
chemotherapeutic	O
agents	O
.	O

Traditional	O
Chinese	O
herbal	O
drugs	O
with	O
anti	O
-	O
emetic	O
potential	O
can	O
be	O
used	O
to	O
prevent	O
them	O
.	O

However	O
,	O
the	O
effects	O
of	O
anti	O
-	O
emetic	O
active	O
principles	O
of	O
these	O
crude	O
drugs	O
need	O
to	O
be	O
studied	O
using	O
modern	O
pharmacological	O
methods	O
.	O

One	O
of	O
the	O
difficul­ties	O
in	O
testing	O
for	O
anti	O
-	O
emetic	O
activity	O
of	O
natural	O
prod­ucts	O
is	O
the	O
selection	O
of	O
adequate	O
animal	B
models	O
.	O

We	O
previously	O
reported	O
anti	O
-	O
emetic	O
principles	O
from	O
Magnolia	B
obovata	I
bark	O
,	O
Zingiber	B
officinale	I
rhizome	O
(	O
Kawai	O
et	O
al.	O
,	O
1994	O
)	O
,	O
Inula	B
linariaefolia	I
flowers	O
and	O
Forsythia	B
suspensa	I
fruits	O
(	O
Kinoshita	O
et	O
al.	O
,	O
1996	O
)	O
,	O
and	O
Poria	B
cocos	I
(	O
Tai	O
et	O
al.	O
,	O
1995	O
)	O
using	O
frogs	B
as	O
test	O
sub­jects	O
.	O

The	O
long	O
emetic	O
latency	O
of	O
frogs	B
induced	O
by	O
the	O
emetic	O
agent	O
was	O
not	O
suitable	O
for	O
testing	O
many	O
samples	O
within	O
a	O
short	O
period	O
of	O
time	O
.	O

Therefore	O
,	O
we	O
studied	O
a	O
new	O
screening	O
method	O
using	O
chicks	B
for	O
anti	O
-	O
emetic	O
ac­tivity	O
(	O
Akita	O
et	O
al.	O
,	O
1998	O
)	O
to	O
overcome	O
these	O
difficulties	O
.	O

The	O
present	O
paper	O
describes	O
the	O
screening	O
of	O
31	O
ex­tracts	O
from	O
8	O
traditional	O
Chinese	O
herbal	O
drugs	O
for	O
anti­emetic	O
activities	O
,	O
using	O
young	O
chicks	B
,	O
and	O
the	O
identifica­tion	O
of	O
some	O
of	O
the	O
active	O
principles	O
contained	O
in	O
Po­gostemon	B
cablin	I
(	I
Blanco	I
)	I
Benth	I
.	O

Materials	O
and	O
Methods	O
Materials	O

The	O
dry	O
plant	B
materials	O
used	O
here	O
were	O
commercial	O
products	O
.	O

Alpinia	B
katsumadai	I
seeds	O
,	O
Alpinia	B
officina­rum	I
rhizome	O
,	O
Amomum	B
kravanh	I
fruits	O
,	O
Amomum	B
tsao	I
-	I
ko	I
fruits	O
,	O
Amomum	B
xanthioides	I
fruits	O
,	O
Eupato­rium	B
fortunei	I
leaves	O
and	O
stem	O
,	O
and	O
Nelumbo	B
nucifera	I
seeds	O
were	O
purchased	O
from	O
Kotaro	O
Pharmaceutical	O
Co.	O
,	O
Ltd.	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Pogostemon	B
cab	I
/	I
in	I
leaves	O
were	O
purchased	O
from	O
Kinokuniya	O
Kanyakkyoku	O
(	O
To­kyo	O
,	O
Japan	O
)	O
.	O

Spectrometry	O
and	O
chromatography	O
lH_and13C	O
-	O
NMRspectrawererecorded	O
usingaJEOL	O
GSX-400	O
spectrometer	O
in	O
CDCl3	O
or	O
DMSO	O
-	O
d6	O
with	O
tet­ramethylsilane	O
as	O
an	O
internal	O
standard	O
.	O

Kieselgel	O
60	O
F254-precoated	O
plates	O
were	O
employed	O
for	O
thin	O
-	O
layer	O
chromatography	O
(	O
TLC	O
)	O
.	O

Column	O
chromatography	O
was	O
carried	O
out	O
on	O
70	O
-	O
230	O
mesh	O
silica	O
gel	O
.	O

HPLC	O
was	O
per­formed	O
using	O
an	O
SSC-3100-J	O
pump	O
with	O
an	O
Oyo	O
-	O
Bunko	O
Uvilog	O
7	O
UV	O
detector	O
.	O

HR	O
-	O
MS	O
and	O
EI	O
-	O
MS	O
were	O
ob­tained	O
using	O
a	O
JEOL	O
JMX	O
-	O
DX	O
302	O
.	O

0944	O
-	O
7113	O
/	O
99106	O
/	O
02	O
-	O
089	O
$	O
12.0010	O
Y.	O
Yang	O
et	O
al.	O

Animals	B
nally	O
at	O
a	O
volume	O
of	O
10	O
rnl	O
/	O
kg	O
.	O

After	O
10	O
min	O
,	O
copper	O
sul­	O
Young	O
male	O
chicks	B
(	O
4	O
days	O
of	O
age	O
)	O
weighing	O
25	O
-	O
35	O
g	O
fate	O
anhydride	O
was	O
administered	O
orally	O
at	O
50	O
mg	O
/	O
kg	O
,	O
each	O
were	O
purchased	O
from	O
Goto	O
Furanjo	O
Co.	O
,	O
Ltd.	O
(	O
Sai­then	O
the	O
number	O
of	O
retching	O
(	O
an	O
emetic	O
action	O
without	O
tama	O
,	O
Japan	O
)	O
.	O

vomiting	O
gastric	O
materials	O
)	O
was	O
recorded	O
during	O
the	O
next	O
10	O
min	O
.	O

The	O
results	O
were	O
judged	O
by	O
the	O
decrease	O
in	O
Bioassay	O
of	O
anti	O
-	O
emetic	O
activity	O
number	O
of	O
retching	O
in	O
contrast	O
with	O
those	O
of	O
control	O
.	O

The	O
young	O
chicks	B
were	O
divided	O
into	O
1	O
-	O
3	O
groups	O
con	O
­The	O
inhibition	O
(	O
%	O
)	O
was	O
calculated	O
as	O
follows	O
:	O
sisting	O
of	O
six	O
each	O
,	O
and	O
each	O
young	O
chick	B
was	O
set	O
asi­de	O
for	O
10	O
min	O
to	O
stabilize	O
in	O
large	O
beakers	O
at	O
25	O
°	O
C	O
.	O

The	O
Inhibition	O
(	O
%	O
)	O
=	O
[	O
(	O
A	O
-	O
B	O
)	O
A	O
]	O
X	O
100	O
sample	O
was	O
dissolved	O
in	O
0.9	O
%	O
saline	O
containing	O
5	O
%	O
A	O
:	O
control	O
frequency	O
of	O
retching	O
DMSO	O
and	O
1	O
%	O
Tween	O
80	O
and	O
administered	O
abdomi	O
-	O
B	O
:	O
frequency	O
retching	O
after	O
sample	O
treatment	O
Table1	O
.	O

Screeningtestofmedicinalplantsforanti	O
-	O
emeticeffectagainstcoppersulfate	O
-	O
inducedemesisinyoungchicks	O
.	O

Crude	O
drugs	O
Extracts	O
No.	O
of	O
young	O
chicks	B
No.	O
of	O
retches	O
Inhibition	O
(	O
mean	O
±	O
S.E.M.	O
)	O
(	O
%	O
)	O
control	O

6	O
69.8	O
±	O
3.19	O
Pogostemon	B
cab	I
/	I
in	I
n	O
-	O
hexane	O
6	O
28.9	O
±	O
4.31	O

*	O
*	O
*	O
58.6	O
CHCl3	O
6	O
45.8	O
±	O
6.75	O
""""	O
'	O
34.4	O
MeOH	O
6	O
47.8	O
±	O
6.39	O
""""	O
31.5	O
control	O
6	O
70.6	O
±	O
1.25	O
Alpinia	B
katsumadai	I
n	O
-	O
hexane	O
6	O
52.4	O
±3.39	O
*	O
*	O
25.8	O
CHCl3	O
6	O
28.0	O
±	O
5.09	O

*	O

*	O

*	O
60.3	O
MeOH	O
6	O
18.4	O
±	O
0.93	O

*	O
*	O
*	O
73.9	O
H2O	O
6	O
46.2	O
±	O
8.12	O
34.6	O
control	O
6	O
48.8	O
±	O
4.34	O
Amomum	B
tsao	I
-	I
ko	I
n	O
-	O
hexane	O
6	O
46.6	O
±	O
3.29	O
4.5	O
CHCl3	O
6	O
36.6	O
±	O
5.39	O
25.6	O
MeOH	O
6	O
22.2	O
±	O
3.28	O

*	O

*	O
*	O
54.5	O
H2O	O
6	O
39.3	O
±	O
7.23	O
19.5	O
control	O
6	O
75.9	O
±	O
1.38	O
Amomum	B
kravanh	I
n	O
-	O
hexane	O
6	O
78.6	O
±	O
3.14	O
-3.6	O
CHCl3	O
6	O
36.0	O
±	O
5.96	O
*	O
*	O
52.6	O
MeOH	O
6	O
70.0	O
±	O
11.0	O
7.8	O
H2O	O
6	O
52.0	O
±2.98	O
""""	O
31.5	O
control	O
6	O
64.5	O
±	O
4.46	O
Amomum	B
xanthioides	I
n	O
-	O
hexane	O
6	O
41.8	O
±	O
9.05	O
*	O
35.2	O
CHCI3	O
6	O
29.8	O
±	O
3.94	O

*	O

*	O
*	O

53.8	O
MeOH	O
6	O
34.8	O
±	O
8.47	O
*	O
46.0	O
H2O	O
6	O
43.5	O
±	O
7.70	O
'	O
:	O
'	O
32.6	O
control	O
6	O
68.2±2.31	O
Eupatorium	B
[	I
ortunei	I
n	O
-	O
hexane	O
6	O
61.3	O
±	O
6.68	O
10.1	O
CHCI3	O
6	O
46.3	O
±	O
7.32	O
32.1	O
MeOH	O
6	O
50.8	O
±	O
2.42	O

*	O
*	O
*	O
25.5	O
H2O	O
6	O
54.2	O
±	O
3.16	O
*	O
20.5	O
control	O
6	O
86.8	O
±	O
3.69	O
Nelumbo	B
nucifera	I
n	O
-	O
hexane	O
6	O
75.3	O
±	O
9.81	O
13.2	O
CHCl3	O
6	O
63.2	O
±3.06	O
*	O
""""	O
27.2	O
MeOH	O
6	O
77.6	O
±	O
2.98	O
10.6	O
H2O	O
6	O
71.6	O
±	O
5.83	O
17.6	O
control	O
6	O
44.5	O
±	O
2.33	O
Alpinia	B
officinarum	I
n	O
-	O
hexane	O
6	O
37.5	O
±	O
4.19	O
15.7	O
CHel3	O
6	O
24.2	O
±	O
3.23	O

*	O

*	O
*	O
45.6	O
MeOH	O
6	O
32.7	O
±	O
3.74	O
*	O
26.5	O
H2O	O
6	O
31.2	O
±	O
4.26	O
*	O
29.9	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
""""	O
p	O
<	O
0.05	O
,	O
""""	O
""""	O
p	O
<	O
0.01	O
,	O
*	O
,	O
'	O
""""	O
p	O
<	O
0.001	O
.	O

fate	O
-	O
induced	O
emesis	O
in	O
young	O
chicks	B
.	O

Drugs	O
Dose	O
No.	O
of	O
young	O
chicks	B
No	O
.	O

of	O
retches	O
Inhibition	O
(	O
mg	O
/	O
kg	O
)	O
(	O
rnean	O
e	O
SEM	O
)	O
(	O
%	O
)	O
control	O
6	O
47	O
.8	O
:	O
!	O
:	O
6.14	O
Fr	O
.	O

1	O
150	O
6	O
37.4:!:5.17	O
21.8	O
Fr	O
.	O

2	O
150	O
6	O
11.6	O
:	O
!	O

:	O

7.08	O
·	O
·	O
·	O
·	O
75	O
.	O
7	O
Fr	O
.	O

3	O
150	O
6	O
7.6	O
:	O
!	O

:	O
1.25	O

*	O
*	O
""""	O
84.1	O
control	O
6	O
45	O
.0	O
:	O
!	O
:	O
8.45	O
Fr	O
.	O

4	O
150	O
6	O
31.2:!:3.36	O
30.7	O
Fr	O
.	O

5	O
150	O
6	O
25	O
.	O
7	O
:	O
!	O

:	O
6.92	O
42.9	O
Fr	O
.	O

6	O
150	O
6	O
28.4	O
:	O
!	O

:	O
6.95	O
36.9	O
control	O
6	O
47.8	O
:	O
!	O
:	O
6.14	O
Fr	O
.	O

7	O
150	O
6	O
21	O
.	O
6	O
:	O
!	O

:	O
4.25	O
""""	O
*	O
54.8	O
Fr	O
.	O

8	O
150	O
6	O
38.2	O
:	O
!	O

:	O

7.87	O
20.1	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
*	O
p	O
<	O
0.05	O
,	O

*	O
*	O
p	O
<	O
0.01	O
,	O
""""	O

*	O
*	O
p	O
<	O
0.001	O
.	O

Table	O
3	O
.	O

Anti	O
-	O
emetic	O
effects	O
of	O
compounds	O
1	O
-	O
5	O
against	O
sulfate	O
-	O
induced	O
emesis	O
in	O
young	O
chicks	B
.	O

Drugs	O
Dose	O
No.	O
of	O
young	O
chicks	B
No.	O
of	O
retches	O
Inhibition	O
(	O
mg	O
/	O
kg	O
)	O
(	O
mean	O
a	O
SEM	O
)	O
(	O
%	O
)	O
control	O
6	O
60.0	O
:	O
!	O

:	O
4.73	O
patchouli	O
alcohol	O
(	O
1	O
)	O
10	O
6	O
54.5	O
:	O
!	O
:	O
7.58	O
9.2	O
20	O
6	O
50.3	O
:	O
!	O

:	O
6.90	O
16.2	O
50	O
6	O
36.0	O
:	O
!	O

:	O
3.69	O

*	O
""""	O
40.0	O
70	O
6	O
25.4	O
:	O
!	O

:	O

2.80	O

*	O

*	O
""""	O
57.7	O
control	O
5	O
67.2	O
:	O
!	O
:	O
2.81	O
pogostol	O
(	O
2	O
)	O
10	O
5	O
40.8	O
:	O
!	O

:	O
4.79	O

*	O

*	O
39.3	O
20	O
5	O
38.8	O
:	O
!	O

:	O
8.73	O
*	O
42.3	O
50	O
5	O
38.2	O
:	O
!	O

:	O
6.13	O
""""	O
*	O
43.2	O
control	O
6	O
55.7	O
:	O
!	O
:	O
4.6	O
stigmast-4-en-10	O
6	O
54.9	O
:	O
!	O
:	O
8.80	O
1.4	O
3-one	O
(	O
3	O
)	O
20	O
6	O
39.6	O
:	O
!	O
:	O

7.48	O
28.9	O
50	O
6	O
24.7	O
:	O
!	O

:	O
1.21	O
""""	O
>	O
'	O
*	O
55.7	O
control	O
6	O
67.5	O
:	O
!	O
:	O
6.63	O
retusin	O
(	O
4	O
)	O
10	O
6	O
49.0	O
:	O
!	O
:	O
6.97	O
27.4	O
20	O
6	O
48.0	O
:	O
!	O
:	O

4.97	O
*	O
28.9	O
50	O
6	O
36.7:!:3.21	O
*	O
*	O
45.6	O
control	O
5	O
56.6	O
:	O
!	O
:	O
3.93	O
pachypodol	O
(	O
5	O
)	O
10	O
5	O
53.4	O
:	O
!	O
:	O
3.93	O
5.7	O
20	O
5	O
44.6	O
:	O
!	O

:	O
7.27	O
21.2	O
50	O
5	O
28.0	O
:	O
!	O

:	O
3.09	O
'	O
'	O
'	O
'	O
*	O
50.5	O
Significantly	O
different	O
from	O
the	O
control	O
value	O
,	O
""""	O
p	O
<	O
0.05	O
,	O
*	O
""""	O
p	O
<	O
0.01	O
,	O
*	O

*	O
""""	O
p	O
<	O
0.001	O
.	O

Statistical	O
analysis	O
was	O
concentrated	O
to	O
yield	O
n	O
-	O
hexane	O
,	O
CHCI3	O
,	O
MeOH	O
,	O
All	O
numerical	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
:	O
t	O
and	O
water	O
extracts	O
,	O
respectively	O
.	O

S.E.M.	O
The	O
statistical	O
significance	O
of	O
the	O
difference	O
was	O
determined	O
by	O
an	O
unpaired	O
student	O
's	O
z	O
-	O
test	O
,	O
Isolation	O
and	O
purification	O
of	O
the	O
anti	O
-	O
emetic	O
principles	O
from	O
Pogostemon	B
cablin	I
Preparation	O
of	O
extract	O
The	O
crushed	O
dry	O
leaves	O
of	O
Pogostemon	B
cablin	I
(	O
1	O
kg	O
)	O
Crusheddryplantmaterials	O
(	O
1kg	O
)	O
wereextractedthree	O
wereextractedsuccessivelywithn	O
-	O
hexane	O
,	O
CHCI3,and	O
timessuccessively	O
with4In	O
-	O
hexane	O
,	O
CHCI3,MeOH	O
MeOH	O
,	O
andeach	O
extractwasexaminedforanti	O
-	O
emetic	O
and	O
water	O
at	O
room	O
temperature	O
for	O
24	O
h.	O

Each	O
extract	O
activity	O
using	O
young	O
chicks	B
.	O

The	O
n	O
-	O
hexane	O
extract	O
Y.	O
Yang	O
et	O
al.	O
patchouli	O
alcohol	O
(	O
1	O
)	O
pogostol	O
(	O
2	O
)	O
sigmast-4-en-3-one	O
(	O
3	O
)	O
OCHa	O
OH	O
HaCO	O
HaCO	O
OCHa	O
OCH3	O
OH0	O
OH0	O
pachypodol	O
(	O
5	O
)	O
retusin	O
(	O
4	O
)	O
Fig.	O
1	O
.	O

The	O
structures	O
of	O
active	O
compounds	O
isolated	O
from	O
Pogostemon	B
cab	I
/	I
in	I
Benth	I
which	O
showed	O
the	O
highest	O
anti	O
-	O
emetic	O
activity	O
(	O
58.6	O
%	O
)	O
was	O
chromatographed	O
on	O
a	O
silica	O
gel	O
column	O
(	O
n	O
-	O
hex­ane	O
:	O
EtOAc	O
)	O
,	O
and	O
8	O
fractions	O
(	O
fr	O
,	O
1	O
-	O
8	O
)	O
obtained	O
.	O

Each	O
fraction	O
was	O
tested	O
for	O
anti	O
-	O
emetic	O
activity	O
,	O
and	O
fro	O
2	O
,	O
fro	O
3	O
,	O
fro	O
7	O
showed	O
positive	O
activity	O
(	O
Table	O
2	O
)	O
.	O

Fraction	O
2	O
was	O
subjected	O
to	O
HPLC	O
using	O
a	O
silica	O
gel	O
co­lumn	O
[	O
Silica-4251-N	O
10	O
0	O
X	O
250	O
mm	O
,	O
n	O
-	O
Hexane­EtOAc	O
(	O
11:1	O
)	O
]	O
,	O
and	O
compound	O
1	O
(	O
l.72	O
g	O
)	O
was	O
obtained	O
and	O
identified	O
as	O
patchouli	O
alcohol	O
by	O
comparison	O
with	O
published	O
spectral	O
data	O
(	O
Barton	O
et	O
al.	O
,	O
1987	O
)	O
.	O

An	O
active	O
fraction	O
,	O
fro	O
3	O
,	O
was	O
chromatographed	O
on	O
a	O
silica	O
gel	O
column	O
(	O
n	O
-	O
hexane	O
:	O
acetone	O
)	O
and	O
HPLC	O
using	O
a	O
silica	O
gel	O
column	O
[	O
Silica-4251-N	O
100	O
X	O
250	O
mm	O
,	O
n­Hexane	O
-	O
EtOAc	O
(	O
5:1	O
)	O
]	O
.	O

Compounds	O
2	O
(	O
79.7	O
mg	O
)	O
and	O
3	O
(	O
41.3	O
mg	O
)	O
were	O
identified	O
as	O
pogostol	O
and	O
stigmast-4­en	O
-	O
S	O
-	O
one	O
by	O
comparison	O
with	O
published	O
spectral	O
data	O
(	O
Hikino	O
et	O
al.	O
,	O
1968	O
;	O
Greca	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Fraction	O
7	O
was	O
subjected	O
to	O
on	O
HPLC	O
using	O
a	O
silica	O
gel	O
column	O
[	O
Silica-4251-N	O
100	O
X	O
250	O
mm	O
,	O
n	O
-	O
Hexane­acetone	O
(	O
75:25	O
)	O
]	O
,	O
and	O
compounds	O
4	O
(	O
62.6	O
mg	O
)	O
and	O
5	O
(	O
48.0	O
mg	O
)	O
were	O
obtained	O
and	O
examined	O
by	O
MS	O
,	O
lH	O
_	O
and	O
13C	O
-	O
NMR	O
,	O
DEPT	O
experiment	O
,	O
IH_13C	O
COSY	O
,	O
IH_13C	O
long	O
range	O
COSY	O
(	O
COLOq	O
and	O
the	O
difference	O
of	O
Overhauser	O
enhancement	O
(	O
nOe	O
)	O
spectra	O
.	O

These	O
obser­	O
vations	O
suggested	O
that	O
compounds	O
4	O
and	O
5	O
were	O
retusin	O
and	O
pachypodol	O
,	O
respectively	O
.	O

Results	O
and	O
Discussion	O
As	O
shown	O
in	O
Table	O
1,20	O
extracts	O
significantly	O
inhibited	O
emetic	O
action	O
induced	O
by	O
CUS04	O
in	O
young	O
chicks	B
.	O

The	O
n	O
-	O
hexane	O
,	O
CHCl3	O
and	O
MeOH	O
extracts	O
of	O
Pogostemon	B
cablin	I
showed	O
significant	O
inhibition	O
at	O
a	O
dose	O
of	O
300	O
mg	O
/	O
kg	O
.	O

Patchouli	O
alcohol	O
(	O
1	O
)	O
,	O
pogostol	O
(	O
2	O
)	O
,	O
stigmast-4­en-3-one	O
(	O
3	O
)	O
,	O
retusin	O
(	O
4	O
)	O
and	O
pachypodol	O
(	O
5	O
)	O
previously	O
isolated	O
from	O
the	O
n	O
-	O
hexane	O
extract	O
(	O
Barton	O
et	O
al.	O
,	O
1987	O
;	O
Hinoki	O
et	O
al.	O
,	O
1968	O
;	O
Greca	O
et	O
al.	O
,	O
1990	O
;	O
Dominquez	O
et	O
al.	O
,	O
1968	O
;	O
Valesi	O
et	O
al.	O
,	O
1972	O
)	O
also	O
showed	O
anti	O
-	O
emetic	O
activity	O
Patchouli	O
alcohol	O
(	O
1	O
)	O
was	O
active	O
at	O
two	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
and	O
70	O
mg	O
/	O
kg	O
.	O

Pogostol	O
(	O
2	O
)	O
significantly	O
inhibit­ed	O
emetic	O
action	O
at	O
three	O
doses	O
of	O
10	O
mg	O
/	O
kg-50	O
mg	O
/	O
kg	O
.	O

Stigmast-4-en-3-one	O
(	O
3	O
)	O
and	O
pachypodol	O
(	O
5	O
)	O
showed	O
anti	O
-	O
emetic	O
activity	O
at	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
.	O

Retusin	O
(	O
4	O
)	O
inhibited	O
emetic	O
action	O
at	O
two	O
doses	O
of	O
20	O
mg	O
/	O
kg	O
and	O
50	O
mg	O
/	O
kg	O
.	O

Pogostemon	B
cablin	I
is	O
one	O
of	O
the	O
traditional	O
Chinese	O
medicines	O
used	O
mainly	O
for	O
the	O
treatment	O
of	O
dyspepsia	O
,	O
vomiting	O
,	O
diarrhea	O
and	O
poor	O
appetite	O
.	O

It	O
is	O
also	O
known	O
that	O
inward	O
Ca2	O
+	O
influx	O
through	O
the	O
cell	O
membranes	O
may	O
induce	O
excessive	O
excitation	O
of	O
smooth	O
muscles	O
,	O
and	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
may	O
cause	O
vomiting	O
and	O
diarrhea	O
.	O

Therefore	O
,	O
the	O
Ca2	O
+	O
antagonist	O
is	O
expected	O
to	O
alleviate	O
those	O
symptoms	O
by	O
depressing	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
.	O

It	O
has	O
been	O
reported	O
that	O
patchouli	O
alcohol	O
showed	O
Ca2	O
+	O
antagonist	O
activity	O
in	O
vitro	O
(	O
Ichikawa	O
et	O
al.	O
,	O
1989	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
anti	O
-	O
emetic	O
activity	O
of	O
patchouli	O
alcohol	O
may	O
be	O
due	O
to	O
depressing	O
excessive	O
contraction	O
of	O
digestive	O
organ	O
muscles	O
by	O
in­hibition	O
of	O
inward	O
Ca2	O
+	O
influx	O
through	O
the	O
cell	O
embra­nes	O
.	O

Patchouli	O
alcohol	O
contained	O
abundantly	O
in	O
Po­gostemon	B
cablin	I
(	O
>	O
0.1	O
%	O
)	O
may	O
playa	O
main	O
role	O
in	O
anti	O
-	O
emetic	O
effect	O
clinically	O
in	O
view	O
of	O
its	O
traditional	O
use	O
in	O
Chinese	O
medicine	O
.	O

Acknowledgements	O
The	O
authors	O
would	O
like	O
to	O
thank	O
Professor	O
emeritus	O
Shoji	O
Shibata	O
,	O
University	O
of	O
Tokyo	O
,	O
for	O
his	O
encouragement	O
.	O

This	O
study	O
was	O
partly	O
supported	O
by	O
a	O
Sasakawa	O
Scientific	O
Research	O
Grant	O
from	O
the	O
Japan	O
Science	O
Society	O
(	O
1996	O
-	O
7	O
)	O
.	O

Anti	O
-	O
emetic	O
principles	O
of	O
Pogostemon	B
cablin	I

SCH66336	O
,	O
(	O
+	O
)	O
4-	O
{	O
2-	O
[	O
4-	O
(	O
8-chloro-3	O
,	O
10-dibromo-6	O
,	O
11-dihydro-5H	O
-	O
benzo	O
[	O
5,6	O
]	O
cyclohepta	O
[	O
1,2-b	O
]	O
pyridin-11-yl	O
)	O
-1-piperidinyl	O
]	O
-2-oxoethyl	O
}	O
-1-piperidinecarboxamide	O
(	O
Fig.	O
1	O
)	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
farnesyl	O
protein	O
transferase	O
(	O
FPT	O
)	O
.	O

FPT	O
catalyzes	O
the	O
initial	O
step	O
in	O
the	O
post	O
-	O
translational	O
processing	O
of	O
the	O
ras	O
gene	O
,	O
that	O
is	O
,	O
the	O
transfer	O
of	O
the	O
15-carbon	O
farnesyl	O
group	O
onto	O
a	O
cysteine	O
residue	O
in	O
the	O
carboxy	O
terminal	O
of	O
all	O
Ras	O
proteins	O
[	O
1–6	O
]	O
.	O

The	O
farnesylation	O
step	O
appears	O
to	O
be	O
essential	O
for	O
Ras	O
proteins	O
to	O
become	O
membrane	O
-	O
associated	O
and	O
induces	O
cell	O
transformation	O
[	O
4	O
]	O
.	O

In	O
normal	O
cells	O
,	O
Ras	O
protein	O
in	O
its	O
active	O
GTP	O
-	O
bound	O
state	O
initiates	O
several	O
intracellular	O
signaling	O
pathways	O
that	O
lead	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
signal	O
is	O
terminated	O
by	O
the	O
hydrolysis	O
of	O
GTP	O
to	O
the	O
inactive	O
GDP	O
-	O
bound	O
form	O
of	O
the	O
Ras	O
protein	O
[	O
7	O
]	O
.	O

The	O
capacity	O
of	O
certain	O
oncogenic	O
forms	O
of	O
Ras	O
to	O
hydrolyze	O
GTP	O
to	O
GDP	O
is	O
greatly	O
reduced	O
,	O
leading	O
to	O
continuous	O
intracellular	O
signaling	O
which	O
results	O
in	O
alteration	O
of	O
cellular	O
proliferation	O
and	O
differentiation	O
[	O
4,8	O
]	O
.	O

Oncogenic	O
forms	O
of	O
Ras	O
proteins	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
nearly	O
one	O
-	O
third	O
of	O
all	O
human	B
cancers	O
,	O
including	O
50	O
%	O
of	O
colon	O
cancers	O
and	O
90	O
%	O
of	O
pancreatic	O
cancers	O
[	O
4	O
]	O
.	O

Blocking	O
the	O
farnesylation	O
step	O
by	O
inhibiting	O
FPT	O
is	O
an	O
attractive	O
target	O
for	O
the	O
discovery	O
of	O
compounds	O
with	O
anti	O
-	O
tumor	O
activity	O
[	O
9	O
]	O
.	O

This	O
form	O
of	O
therapy	O
has	O
enormous	O
potential	O
because	O
of	O
the	O
prevalance	O
of	O
mutated	O
ras	O
gene	O
in	O
human	B
cancers	O
[	O
4,10	O
]	O
.	O

In	O
vivo	O
studies	O
in	O
nude	O
mice	B
demonstrated	O
that	O
SCH	O
66336	O
has	O
a	O
potent	O
oral	O
activity	O
profile	O
in	O
a	O
wide	O
array	O
of	O
human	B
tumor	O
xenograft	O
models	O
including	O
tumors	O
of	O
colon	O
,	O
lung	O
,	O
pancreas	O
,	O
prostate	O
,	O
and	O
urinary	O
bladder	O
origin	O
[	O
11	O
]	O
.	O

When	O
used	O
to	O
treat	O
Ha	O
-	O
Ras	O
transgenic	O
mice	B
with	O
spontaneously	O
occurring	O
tumors	O
prior	O
to	O
tumor	O
onset	O
,	O
SCH	O
66336	O
delayed	O
tumor	O
onset	O
,	O
reduced	O
the	O
average	O
number	O
of	O
tumors	O
per	O
mouse	B
and	O
reduced	O
the	O
average	O
tumor	O
weight	O
per	O
animal	B
[	O
11	O
]	O
.	O

In	O
a	O
therapeutic	O
mode	O
,	O
where	O
gavage	O
treatment	O
was	O
initiated	O
after	O
the	O
transgenic	O
mice	B
had	O
developed	O
palpable	O
tumors	O
,	O
significant	O
tumor	O
regression	O
was	O
induced	O
by	O
SCH	O
66336	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
[	O
11	O
]	O
.	O

The	O
issue	O
of	O
chirality	O
has	O
emerged	O
as	O
a	O
major	O
theme	O
in	O
drug	O
design	O
and	O
discovery	O
[	O
12,13	O
]	O
.	O

Since	O
enantiomers	O
often	O
differ	O
in	O
pharmacological	O
activity	O
,	O
toxicity	O
and	O
pharmacokinetics	O
characteristics	O
,	O
it	O
is	O
important	O
that	O
enantiomeric	O
drug	O
candidates	O
be	O
evaluated	O
in	O
an	O
optically	O
pure	O
form	O
.	O

SCH	O
66336	O
is	O
a	O
single	O
enantiomer	O
which	O
contains	O
one	O
chiral	O
center	O
.	O

During	O
the	O
discovery	O
stage	O
of	O
this	O
compound	O
,	O
it	O
was	O
of	O
interest	O
to	O
determine	O
its	O
pharmacokinetics	O
and	O
possible	O
chiral	O
inversion	O
in	O
animals	B
prior	O
to	O
administration	O
in	O
humans	B
.	O

Therefore	O
,	O
these	O
studies	O
were	O
initiated	O
to	O
develop	O
HPLC	O
methods	O
for	O
its	O
determination	O
in	O
cynomolgus	B
monkey	I
plasma	O
and	O
for	O
the	O
evaluation	O
of	O
its	O
chiral	O
inversion	O
in	O
rat	B
and	O
cynomolgus	B
monkey	I
plasma	O
that	O
had	O
been	O
dosed	O
with	O
SCH	O
66336	O
.	O

2	O
Experimental	O
2.1	O
Reagents	O
Hexane	O
,	O
methanol	O
,	O
acetonitrile	O
,	O
methylene	O
chloride	O
,	O
ethanol	O
,	O
diethyl	O
amine	O
and	O
sodium	O
bicarbonate	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Fair	O
Lawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

SCH	O
66336	O
,	O
SCH	O
66337	O
(	O
enantiomer	O
of	O
SCH	O
66336	O
)	O
and	O
SCH	O
66347	O
(	O
internal	O
standard	O
for	O
the	O
chiral	O
assay	O
)	O
were	O
provided	O
by	O
Schering	O
-	O
Plough	O
Research	O
Institute	O
(	O
Kenilworth	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Azatadine	O
maleate	O
(	O
internal	O
standard	O
for	O
the	O
achiral	O
assay	O
)	O
was	O
obtained	O
from	O
U.S.	O
Pharmacopeial	O
Convention	O
,	O
Inc.	O
(	O
Rockville	O
,	O
MD	O
,	O
USA	O
)	O
.	O

2.2	O
Calibration	O
standards	O
For	O
the	O
achiral	O
HPLC	O
analysis	O
,	O
stock	O
solution	O
of	O
SCH	O
66336	O
was	O
prepared	O
in	O
methanol	O
at	O
200	O
μg	O
/	O
ml	O
;	O
the	O
internal	O
standard	O
was	O
prepared	O
in	O
water	O
at	O
100	O
μg	O
/	O
ml	O
.	O

The	O
stock	O
solutions	O
were	O
stored	O
at	O
−20	O
°	O
C	O
.	O

Eight	O
calibration	O
standards	O
(	O
at	O
0.1	O
,	O
0.2	O
,	O
0.5	O
,	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
and	O
20	O
μg	O
/	O
ml	O
)	O
were	O
prepared	O
in	O
triplicate	O
on	O
each	O
of	O
three	O
validation	O
days	O
.	O

Three	O
sets	O
of	O
quality	O
control	O
samples	O
(	O
QC	O
samples	O
)	O
at	O
concentration	O
of	O
0.2	O
(	O
low	O
)	O
,	O
1.5	O
(	O
medium	O
)	O
and	O
15	O
μg	O
/	O
ml	O
(	O
high	O
)	O
were	O
prepared	O
in	O
bulk	O
from	O
separate	O
weighing	O
,	O
aliquotted	O
and	O
stored	O
at	O
−20	O
°	O
C	O
for	O
use	O
during	O
the	O
entire	O
validation	O
and	O
sample	O
analysis	O
.	O

For	O
the	O
chiral	O
HPLC	O
assay	O
,	O
stock	O
solutions	O
of	O
SCH	O
66336	O
,	O
SCH	O
66337	O
and	O
SCH	O
66347	O
were	O
prepared	O
in	O
methanol	O
at	O
100	O
μg	O
/	O
ml	O
and	O
stored	O
at	O
−20	O
°	O
C	O
.	O

Three	O
sets	O
of	O
quality	O
control	O
samples	O
at	O
concentration	O
of	O
0.4	O
(	O
low	O
)	O
,	O
2.5	O
(	O
medium	O
)	O
and	O
8.0	O
μg	O
/	O
ml	O
(	O
high	O
)	O
were	O
prepared	O
in	O
bulk	O
from	O
separate	O
weighings	O
,	O
aliquotted	O
and	O
stored	O
at	O
−20	O
°	O
C	O
for	O
use	O
during	O
the	O
entire	O
validation	O
and	O
sample	O
analysis	O
.	O

2.3	O
Sample	O
preparation	O
For	O
the	O
achiral	O
assay	O
,	O
a	O
0.2-ml	O
volume	O
of	O
monkey	B
plasma	O
standard	O
,	O
QC	O
sample	O
or	O
unknown	O
was	O
placed	O
into	O
a	O
15-ml	O
screw	O
-	O
capped	O
test	O
tube	O
containing	O
0.2	O
ml	O
of	O
internal	O
standard	O
solution	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

Saturated	O
sodium	O
bicarbonate	O
solution	O
(	O
0.3	O
ml	O
)	O
was	O
added	O
followed	O
by	O
4.0	O
ml	O
of	O
30	O
%	O
(	O
v	O
/	O
v	O
)	O
methylene	O
chloride	O
in	O
hexane	O
,	O
mixed	O
on	O
a	O
mechanical	O
vortexer	O
for	O
10	O
min	O
and	O
centrifuged	O
.	O

The	O
organic	O
layer	O
was	O
transferred	O
into	O
15-ml	O
conical	O
test	O
tubes	O
and	O
20	O
μl	O
of	O
0.8	O
M	O
HCl	O
in	O
methanol	O
was	O
added	O
.	O

The	O
samples	O
were	O
evaporated	O
to	O
dryness	O
at	O
40	O
°	O
C	O
under	O
a	O
gentle	O
stream	O
of	O
nitrogen	O
,	O
the	O
residue	O
was	O
reconstituted	O
in	O
0.2	O
ml	O
of	O
mobile	O
phase	O
and	O
50	O
μl	O
was	O
injected	O
onto	O
the	O
HPLC	O
column	O
for	O
analysis	O
.	O

For	O
the	O
chiral	O
analysis	O
,	O
a	O
0.2-ml	O
volume	O
of	O
rat	B
or	O
monkey	B
plasma	O
standard	O
,	O
QC	O
sample	O
,	O
or	O
unknown	O
was	O
applied	O
onto100	O
mg	O
of	O
the	O
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
cartridge	O
ethyl	O
Bond	O
Elute	O
cartridge	O
which	O
has	O
been	O
pre	O
-	O
washed	O
with	O
3	O
ml	O
of	O
methanol	O
and	O
3	O
ml	O
of	O
water	O
.	O

The	O
SPE	O
cartridge	O
was	O
washed	O
with	O
2	O
ml	O
of	O
water	O
and	O
2	O
ml	O
of	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
acetonitrile	O
in	O
water	B
.	O

The	O
compounds	O
were	O
eluted	O
with	O
3	O
ml	O
of	O
acetonitrile	O
.	O

The	O
eluate	O
was	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	O
and	O
the	O
residue	O
was	O
reconstituted	O
with	O
0.5	O
ml	O
of	O
mobile	O
phase	O
;	O
a	O
0.1	O
ml	O
aliquot	O
was	O
injected	O
onto	O
the	O
HPLC	O
column	O
for	O
analysis	O
.	O

2.4	O
Chromatographic	O
conditions	O
The	O
HPLC	O
system	O
consisted	O
of	O
a	O
Shimadzu	O
LC-10	O
AD	O
pump	O
and	O
a	O
Waters	O
486	O
absorbance	O
detector	O
set	O
at	O
280	O
nm	O
.	O

The	O
achiral	O
separation	O
was	O
accomplished	O
on	O
a	O
Spherisorb	O
CN	O
,	O
5	O
μm	O
,	O
150	O
×	O
4.6	O
mm	O
column	O
which	O
was	O
preceded	O
by	O
an	O
on	O
-	O
line	O
filter	O
.	O

The	O
Millennium	O
2020	O
Chromatography	O
Manager	O
Soft	O
System	O
was	O
used	O
for	O
data	O
handling	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
0.02	O
M	O
potassium	O
phosphate	O
(	O
pH	O
4	O
)	O
–acetonitrile	O
(	O
65:35	O
,	O
v	O
/	O
v	O
)	O
,	O
and	O
was	O
delivered	O
at	O
0.9	O
ml	O
/	O
min	O
.	O

The	O
chiral	O
HPLC	O
method	O
involved	O
the	O
use	O
of	O
a	O
Chiral	O
Pak	O
AD	O
column	O
(	O
Chiral	O
Technologies	O
,	O
Eaton	O
,	O
PA	O
)	O
set	O
at	O
39	O
°	O
C	O
and	O
a	O
mobile	O
phase	O
of	O
hexane	O
–	O
ethanol	O
–	O
diethylamine	O
(	O
30:70:0.2	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
at	O
a	O
flow	O
of	O
0.8	O
ml	O
/	O
min	O
.	O

2.5	O
Administration	O
of	O
SCH	O
66336	O
Six	O
male	O
cynomolgus	B
monkeys	I
were	O
dosed	O
orally	O
with	O
a	O
100-mg	O
experimental	O
tablet	O
of	O
SCH	O
66336	O
(	O
approximately	O
15	O
mg	O
/	O
kg	O
)	O
for	O
pharmacokinetic	O
evaluation	O
.	O

Also	O
,	O
rats	B
and	O
cynomolgus	B
monkeys	I
were	O
given	O
SCH	O
66336	O
at	O
a	O
single	O
oral	O
dose	O
of	O
300	O
and	O
120	O
mg	O
/	O
kg	O
,	O
respectively	O
,	O
as	O
a	O
suspension	O
in	O
0.4	O
%	O
methylcellulose	O
for	O
the	O
evaluation	O
of	O
chiral	O
inversion	O
of	O
SCH	O
66336	O
.	O

Blood	O
samples	O
were	O
collected	O
at	O
intervals	O
after	O
dosing	O
,	O
centrifuged	O
and	O
plasma	O
stored	O
at	O
−20	O
°	O
C	O
pending	O
analysis	O
.	O

Plasma	O
concentrations	O
equal	O
to	O
or	O
above	O
the	O
limit	O
of	O
quantitation	O
(	O
LOQ	O
,	O
0.1	O
μg	O
/	O
ml	O
)	O
were	O
used	O
for	O
pharmacokinetic	O
analysis	O
using	O
model	O
-	O
independent	O
methods	O
[	O
14	O
]	O
.	O

The	O
maximum	O
plasma	O
concentration	O
(	O
C	O
max	O
)	O
and	O
time	O
of	O
maximum	O
plasma	O
concentration	O
(	O
T	O
max	O
)	O
were	O
the	O
observed	O
values	O
.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
–	O
time	O
curve	O
from	O
time	O
zero	O
to	O
the	O
time	O
of	O
the	O
final	O
measurable	O
sample	O
[	O
AUC	O
(	O
tf	O
)	O
]	O
was	O
calculated	O
using	O
the	O
linear	O
trapezoidal	O
method	O
,	O
and	O
was	O
extrapolated	O
to	O
infinity	O
(	O
I	O
)	O
according	O
to	O
the	O
following	O
equation	O
:	O
AUC	O
(	O
I	O
)	O
=	O
AUC	O
(	O
tf	O
)	O
+C	O
(	O
tf	O
)	O
/	O
k	O
where	O
C	O
(	O
tf	O
)	O
is	O
the	O
estimated	O
concentration	O
at	O
tf	O
using	O
the	O
above	O
regression	O
.	O

3	O
Results	O
3.1	O
Achiral	O
HPLC	O
Typical	O
chromatograms	O
of	O
drug	O
-	O
free	O
monkey	B
plasma	O
and	O
plasma	O
spiked	O
with	O
SCH	O
66336	O
and	O
the	O
internal	O
standard	O
azatadine	O
maleate	O
are	O
illustrated	O
in	O
Fig.	O
2	O
.	O

The	O
retention	O
times	O
of	O
SCH	O
66336	O
and	O
the	O
internal	O
standard	O
were	O
approximately	O
7.2	O
and	O
10.5	O
min	O
,	O
respectively	O
.	O

There	O
were	O
no	O
endogenous	O
peaks	O
in	O
plasma	O
of	O
six	O
undosed	O
monkeys	B
that	O
coeluted	O
with	O
SCH	O
66336	O
or	O
the	O
internal	O
standard	O
,	O
indicating	O
that	O
the	O
method	O
was	O
selective	O
.	O

The	O
linearity	O
of	O
the	O
assay	O
was	O
evaluated	O
over	O
a	O
concentration	O
range	O
of	O
0.1–20	O
μg	O
/	O
ml	O
.	O

Linear	O
regression	O
parameters	O
of	O
the	O
peak	O
height	O
ratios	O
versus	O
concentrations	O
along	O
with	O
back	O
-	O
calculated	O
concentrations	O
of	O
nine	O
calibration	O
curves	O
are	O
presented	O
in	O
Table	O
1	O
.	O

The	O
results	O
showed	O
highly	O
reproducible	O
calibration	O
curves	O
with	O
correlation	O
coefficients	O
of	O
>	O
0.99	O
,	O
indicating	O
that	O
the	O
response	O
was	O
linear	O
over	O
the	O
concentration	O
range	O
studied	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
SCH	O
66336	O
concentrations	O
of	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
.	O

Six	O
samples	O
were	O
analyzed	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
results	O
showed	O
satisfactory	O
intra	O
-	O
day	O
precision	O
and	O
accuracy	O
as	O
indicated	O
by	O
a	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
of	O
<	O
2.5	O
%	O
and	O
a	O
bias	O
of	O
<	O
5.1	O
%	O
(	O
Table	O
2	O
)	O
.	O

Inter	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
the	O
same	O
concentrations	O
as	O
above	O
and	O
the	O
samples	O
were	O
analyzed	O
on	O
three	O
separate	O
days	O
.	O

The	O
results	O
demonstrated	O
satisfactory	O
inter	O
-	O
day	O
precision	O
and	O
accuracy	O
as	O
shown	O
by	O
CV	O
and	O
bias	O
values	O
of	O
<	O
3.4	O
%	O
and	O
<	O
6.1	O
%	O
,	O
respectively	O
(	O
Table	O
3	O
)	O
.	O

The	O
LOQ	O
,	O
defined	O
as	O
the	O
lowest	O
concentration	O
in	O
the	O
calibration	O
curve	O
that	O
could	O
be	O
determined	O
with	O
acceptable	O
precision	O
and	O
accuracy	O
,	O
was	O
0.1	O
μg	O
/	O
ml	O
.	O

At	O
this	O
concentration	O
,	O
the	O
precision	O
and	O
accuracy	O
from	O
the	O
back	O
-	O
calculated	O
concentrations	O
were	O
satisfactory	O
(	O
CV=5	O
%	O
,	O
bias	O
0	O
%	O
;	O
Table	O
1	O
)	O
.	O

The	O
recovery	O
was	O
consistent	O
over	O
a	O
concentration	O
range	O
of	O
0.2–15	O
μg	O
/	O
ml	O
(	O
>	O
83	O
%	O
)	O
.	O

The	O
recovery	O
of	O
the	O
internal	O
standard	O
at	O
the	O
concentration	O
used	O
(	O
2.0	O
μg	O
/	O
ml	O
)	O
was	O
88.7	O
%	O
.	O

The	O
stability	O
of	O
SCH	O
66336	O
in	O
plasma	O
was	O
evaluated	O
through	O
three	O
freeze	O
–	O
thaw	O
cycles	O
at	O
concentrations	O
of	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
.	O

The	O
samples	O
were	O
thawed	O
in	O
a	O
water	O
bath	O
at	O
room	O
temperature	O
and	O
frozen	O
within	O
5	O
min	O
of	O
thawing	O
in	O
each	O
cycle	O
.	O

After	O
three	O
cycles	O
,	O
the	O
changes	O
from	O
nominal	O
concentrations	O
were	O
−5.0	O
,	O
+	O
13.3	O
and	O
+	O
12.7	O
%	O
for	O
the	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
,	O
respectively	O
,	O
demonstrating	O
that	O
SCH	O
66336	O
was	O
stable	O
in	O
plasma	O
through	O
three	O
freeze	O
–	O
thaw	O
cycles	O
.	O

Long	O
-	O
term	O
stability	O
was	O
determined	O
following	O
316	O
days	O
of	O
storage	O
at	O
−20	O
°	O
C	O
at	O
the	O
concentrations	O
above	O
.	O

The	O
changes	O
from	O
the	O
nominal	O
concentrations	O
ranged	O
from	O
0.7–5.0	O
%	O
indicating	O
that	O
SCH	O
66336	O
was	O
stable	O
in	O
plasma	O
for	O
at	O
least	O
316	O
days	O
.	O

In	O
-	O
process	O
stability	O
was	O
performed	O
for	O
up	O
to	O
72	O
h	O
after	O
sample	O
processing	O
.	O

Three	O
sets	O
of	O
processed	O
plasma	O
samples	O
at	O
the	O
above	O
SCH	O
66336	O
concentrations	O
were	O
analyzed	O
after	O
storage	O
at	O
room	O
temperature	O
for	O
72	O
h.	O
The	O
changes	O
from	O
nominal	O
concentrations	O
were	O
−5.0	O
,	O
2.0	O
and	O
3.3	O
%	O
for	O
the	O
0.2	O
,	O
1.5	O
and	O
15	O
μg	O
/	O
ml	O
,	O
respectively	O
,	O
demonstrating	O
that	O
SCH	O
66336	O
was	O
stable	O
under	O
the	O
conditions	O
evaluated	O
.	O

3.2	O
Chiral	O
HPLC	O
Typical	O
chromatograms	O
of	O
drug	O
-	O
free	O
rat	B
and	O
cynomolgus	B
monkey	I
plasma	O
and	O
plasma	O
spiked	O
with	O
the	O
internal	O
standard	O
,	O
SCH	O
66336	O
and	O
its	O
enantiomer	O
SCH	O
66337	O
are	O
illustrated	O
in	O
Figs.	O
3	O
and	O
4	O
,	O
respectively	O
.	O

The	O
retention	O
times	O
of	O
SCH	O
66337	O
,	O
SCH	O
66336	O
and	O
the	O
internal	O
standard	O
were	O
approximately	O
5.7	O
,	O
8.3	O
and	O
13.4	O
min	O
,	O
respectively	O
.	O

There	O
were	O
no	O
endogenous	O
peaks	O
in	O
plasma	O
of	O
undosed	O
rats	B
or	O
monkeys	B
that	O
coeluted	O
with	O
SCH	O
66337	O
,	O
SCH	O
66336	O
or	O
the	O
internal	O
standard	O
,	O
indicating	O
that	O
the	O
method	O
was	O
selective	O
.	O

The	O
linearity	O
was	O
evaluated	O
over	O
a	O
concentration	O
range	O
of	O
0.25–10	O
μg	O
/	O
ml	O
,	O
the	O
correlation	O
coefficients	O
were	O
>	O
0.99	O
indicating	O
that	O
the	O
response	O
was	O
linear	O
over	O
the	O
concentration	O
range	O
studied	O
(	O
Tables	O
4	O
and	O
5	O
)	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
evaluated	O
at	O
plasma	O
SCH	O
66337	O
and	O
SCH	O
66336	O
concentrations	O
of	O
0.4	O
,	O
2.5	O
and	O
8.0	O
μg	O
/	O
ml	O
.	O

Three	O
samples	O
were	O
analyzed	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
;	O
the	O
results	O
are	O
shown	O
in	O
Table	O
6	O
.	O

Intra	O
-	O
day	O
precision	O
and	O
accuracy	O
were	O
satisfactory	O
as	O
indicated	O
by	O
a	O
CV	O
of	O
<	O
13	O
%	O
and	O
a	O
bias	O
of	O
<	O
12	O
%	O
for	O
both	O
enantiomers	O
.	O

The	O
LOQ	O
was	O
0.25	O
μg	O
/	O
ml	O
;	O
at	O
this	O
concentration	O
,	O
the	O
precision	O
and	O
accuracy	O
from	O
the	O
back	O
-	O
calculated	O
concentrations	O
were	O
satisfactory	O
(	O
CV	O
<	O
14	O
%	O
,	O
bias=6	O
%	O
)	O
.	O

The	O
recovery	O
values	O
at	O
10	O
μg	O
/	O
ml	O
for	O
SCH	O
66337	O
,	O
SCH	O
66336	O
and	O
the	O
internal	O
standard	O
were	O
83	O
,	O
80	O
and	O
79	O
%	O
,	O
respectively	O
.	O

4	O
Discussion	O
SCH	B
66336	I
belongs	O
to	O
the	O
tricyclic	O
class	O
of	O
FPT	O
inhibitors	O
which	O
are	O
structurally	O
distinct	O
from	O
other	O
reported	O
FPT	O
inhibitors	O
,	O
many	O
of	O
which	O
were	O
derived	O
from	O
peptidomimetic	O
approaches	O
[	O
15,16	O
]	O
.	O

These	O
differences	O
,	O
including	O
the	O
absence	O
of	O
a	O
sulfhydryl	O
function	O
,	O
are	O
likely	O
to	O
contribute	O
to	O
the	O
favorable	O
oral	O
pharmacokinetic	O
properties	O
of	O
the	O
tricyclic	O
class	O
.	O

Initial	O
compounds	O
in	O
this	O
series	O
,	O
such	O
as	O
SCH	O
44342	O
(	O
IC50	O
=	O
250	O
nM	O
)	O
,	O
displayed	O
less	O
than	O
optimal	O
pharmacokinetic	O
properties	O
in	O
the	O
mouse	B
,	O
including	O
a	O
very	O
rapid	O
oxidative	O
metabolism	O
[	O
15	O
]	O
.	O

Blocking	O
the	O
susceptible	O
metabolic	O
sites	O
on	O
SCH	O
44342	O
greatly	O
improved	O
the	O
pharmacokinetic	O
properties	O
of	O
compounds	O
in	O
this	O
series	O
.	O

SCH	O
66336	O
was	O
the	O
lead	O
compound	O
that	O
emerged	O
from	O
these	O
efforts	O
.	O

In	O
addition	O
to	O
improved	O
metabolic	O
stability	O
,	O
its	O
intrinsic	O
potency	O
was	O
also	O
improved	O
as	O
indicated	O
by	O
an	O
FPT	O
IC50	O
of	O
1.9	O
nM	O
.	O

Due	O
to	O
these	O
improvements	O
,	O
SCH	O
66336	O
persisted	O
in	O
mouse	B
serum	O
at	O
concentrations	O
greater	O
than	O
its	O
IC50	O
for	O
Ha	O
-	O
Ras	O
processing	O
in	O
Cos	O
cells	O
for	O
over	O
16	O
h	O
following	O
a	O
single	O
oral	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
[	O
11	O
]	O
.	O

We	O
have	O
attempted	O
to	O
improve	O
the	O
sensitivity	O
of	O
the	O
achiral	O
HPLC	O
method	O
by	O
solid	O
-	O
phase	O
extraction	O
on	O
ethyl	O
column	O
.	O

However	O
,	O
because	O
of	O
the	O
high	O
plasma	O
background	O
,	O
the	O
sensitivity	O
was	O
reduced	O
(	O
LOQ	O
was	O
0.25	O
μg	O
/	O
ml	O
)	O
.	O

Gas	O
chromatography	O
(	O
GC	O
)	O
with	O
electron	O
capture	O
detection	O
(	O
ECD	O
)	O
appeared	O
to	O
be	O
a	O
suitable	O
mean	O
for	O
developing	O
a	O
sensitive	O
assay	O
,	O
since	O
the	O
compound	O
contains	O
three	O
halogens	O
(	O
Fig.	O
1	O
)	O
.	O

Because	O
SCH	O
66336	O
was	O
non	O
-	O
volatile	O
,	O
the	O
GC	O
column	O
temperature	O
needed	O
to	O
be	O
kept	O
above	O
320	O
°	O
C	O
to	O
observe	O
a	O
signal	O
.	O

However	O
,	O
the	O
compound	O
was	O
thermally	O
unstable	O
at	O
this	O
high	O
temperature	O
.	O

The	O
achiral	O
analytical	O
method	O
was	O
used	O
to	O
characterize	O
the	O
pharmacokinetic	O
profile	O
of	O
SCH	O
66336	O
in	O
the	O
cynomolgus	B
monkey	I
treated	O
orally	O
with	O
a	O
100-mg	O
experimental	O
capsule	O
of	O
SCH	O
66336	O
.	O

SCH	O
66336	O
was	O
quantifiable	O
in	O
plasma	O
between	O
2	O
and	O
24	O
h	O
after	O
oral	O
administration	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
mean	O
C	O
max	O
of	O
SCH	O
66336	O
was	O
6.82	O
μg	O
/	O
ml	O
which	O
was	O
attained	O
at	O
a	O
mean	O
T	O
max	O
of	O
7.67	O
h.	O

The	O
area	O
under	O
the	O
plasma	O
concentration	O
–	O
time	O
curve	O
(	O
AUC0–24	O
h	O
)	O
was	O
84.5	O
μg	O
h	O
/	O
ml	O
(	O
Table	O
7	O
)	O
.	O

Enantiomers	O
of	O
biologically	O
active	O
molecules	O
may	O
differ	O
in	O
potency	O
,	O
pharmacological	O
action	O
,	O
metabolism	O
,	O
toxicity	O
and	O
pharmacokinetics	O
[	O
12	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
highly	O
desirable	O
that	O
only	O
the	O
active	O
enantiomer	O
be	O
the	O
drug	O
candidate	O
.	O

The	O
tools	O
for	O
chiral	O
resolution	O
have	O
been	O
progressively	O
improving	O
by	O
the	O
development	O
of	O
a	O
great	O
variety	O
of	O
chiral	O
HPLC	O
-	O
stationary	O
phases	O
.	O

Chiral	O
phases	O
containing	O
cavities	O
such	O
as	O
cyclodextrins	O
or	O
cellulose	O
derivatives	O
have	O
played	O
a	O
significant	O
role	O
in	O
the	O
area	O
of	O
chiral	O
resolution	O
[	O
13	O
]	O
.	O

The	O
chiral	O
recognition	O
of	O
cavity	O
-	O
containing	O
stationary	O
phases	O
is	O
believed	O
to	O
be	O
a	O
result	O
of	O
the	O
insertion	O
of	O
the	O
aromatic	O
portion	O
of	O
the	O
solute	O
into	O
the	O
chiral	O
cavity	O
,	O
in	O
addition	O
to	O
hydrogen	O
bonding	O
interactions	O
.	O

A	O
great	O
number	O
of	O
chiral	O
drugs	O
have	O
been	O
resolved	O
on	O
cyclodextrin	O
(	O
cyclobond	O
)	O
,	O
cellulose	O
(	O
chiralcel	O
)	O
or	O
amylose	O
(	O
chiralpak	O
)	O
based	O
columns	O
.	O

Several	O
chiral	O
HPLC	O
columns	O
were	O
evaluated	O
for	O
the	O
separation	O
of	O
SCH	O
66336	O
and	O
SCH	O
66336	O
including	O
Cyclobond	O
1	O
,	O
Chiralcel	O
OD	O
(	O
cellulose	O
carbamate	O
derivative	O
)	O
and	O
Chiralpak	O
AD	O
(	O
amylose	O
carbamate	O
derivative	O
)	O
.	O

The	O
Cyclobond	O
1	O
and	O
Chiralcel	O
OD	O
columns	O
gave	O
broad	O
peaks	O
with	O
asymmetric	O
peak	O
shape	O
(	O
tailing	O
)	O
without	O
baseline	O
separations	O
.	O

The	O
Chiralpak	O
AD	O
column	O
was	O
selected	O
because	O
of	O
symmetrical	O
peaks	O
and	O
baseline	O
separation	O
resulting	O
in	O
a	O
better	O
sensitivity	O
.	O

The	O
chiral	O
HPLC	O
method	O
was	O
used	O
to	O
evaluate	O
the	O
possible	O
chiral	O
inversion	O
of	O
SCH	O
66336	O
in	O
animals	B
.	O

It	O
should	O
be	O
pointed	O
out	O
that	O
SCH	O
66336	O
administered	O
to	O
animals	B
contained	O
approximately	O
1.5–2.0	O
%	O
SCH	O
66337	O
as	O
an	O
impurity	O
.	O

In	O
rat	B
plasma	O
,	O
SCH	O
66337	O
concentrations	O
were	O
below	O
the	O
LOQ	O
,	O
while	O
the	O
concentrations	O
of	O
SCH	O
66336	O
ranged	O
from	O
5.5–25.0	O
μg	O
/	O
ml	O
.	O

In	O
cynomolgus	B
monkey	I
plasma	O
,	O
the	O
concentrations	O
of	O
SCH	O
66336	O
were	O
within	O
the	O
range	O
of	O
0.32–	O
28.9	O
μg	O
/	O
ml	O
,	O
while	O
those	O
for	O
SCH	O
66337	O
were	O
within	O
the	O
range	O
of	O
below	O
the	O
LOQ	O
to	O
0.9	O
μg	O
/	O
ml	O
.	O

The	O
ratios	O
of	O
the	O
concentrations	O
of	O
SCH	O
66337	O
to	O
SCH	O
66337	O
in	O
the	O
samples	O
that	O
contained	O
quantifiable	O
levels	O
of	O
both	O
analytes	O
were	O
within	O
the	O
range	O
of	O
2.5–3	O
%	O
,	O
which	O
is	O
similar	O
to	O
the	O
ratio	O
seen	O
as	O
an	O
impurity	O
in	O
SCH	O
66336	O
.	O

Therefore	O
,	O
it	O
is	O
concluded	O
that	O
SCH	O
66336	O
is	O
not	O
subjected	O
to	O
chiral	O
inversion	O
in	O
rats	B
and	O
cynomolgus	B
monkeys	I
.	O

In	O
conclusion	O
,	O
the	O
HPLC	O
assay	O
for	O
the	O
determination	O
of	O
SCH	O
66336	O
in	O
cynomolgus	B
monkey	I
plasma	O
was	O
shown	O
to	O
be	O
accurate	O
and	O
reliable	O
over	O
a	O
concentration	O
range	O
of	O
0.1	O
to	O
20	O
μg	O
/	O
ml	O
with	O
an	O
average	O
CV	O
of	O
6	O
%	O
and	O
an	O
average	O
bias	O
of	O
7	O
%	O
.	O

The	O
assay	O
was	O
used	O
successfully	O
to	O
monitor	O
plasma	O
concentrations	O
of	O
SCH	O
66336	O
in	O
cynomolgus	B
monkey	I
.	O

A	O
reliable	O
chiral	O
HPLC	O
method	O
was	O
also	O
developed	O
to	O
separate	O
SCH	O
66336	O
from	O
its	O
enantiomer	O
SCH	O
66337	O
in	O
monkey	B
and	O
rat	B
plasma	O
.	O

Chiral	O
HPLC	O
analysis	O
indicated	O
that	O
SCH	O
66336	O
was	O
not	O
subjected	O
to	O
chiral	O
inversion	O
in	O
rats	B
and	O
cynomolgus	B
monkeys	I
.	I

The	O
growing	O
demand	O
for	O
peptides	O
with	O
biological	O
,	O
pharmaceutical	O
and	O
food	O
ingredients	O
applications	O
requires	O
the	O
development	O
of	O
efficient	O
synthetic	O
methods	O
[	O
1	O
]	O
.	O

Recently	O
,	O
the	O
successful	O
performance	O
of	O
enzymatic	O
peptide	O
synthesis	O
in	O
heterogenous	O
substrate	O
mixtures	O
[	O
2–5	O
]	O
has	O
provided	O
a	O
new	O
and	O
efficient	O
route	O
to	O
peptide	O
syntheses	O
.	O

It	O
was	O
found	O
that	O
some	O
amino	O
acid	O
amides	O
can	O
form	O
supercooled	O
liquid	O
mixtures	O
with	O
N	O
-carbobenzyloxy	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
CBZ	O
-	O
Tyroet	O
)	O
and	O
acetyl	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
Ac	O
-	O
Tyroet	O
)	O
,	O
in	O
which	O
enzymic	O
catalysis	O
of	O
transesterfication	O
reactions	O
can	O
take	O
place	O
.	O

For	O
example	O
,	O
the	O
dipeptide	O
(	O
N	O
-CBZ	O
-	O
Tyr	O
-	O
leuNH	O
)	O
was	O
obtained	O
in	O
the	O
supercooled	O
liquid	O
mixtures	O
of	O
l	O
-leucinamide	O
with	O
CBZ	O
-	O
Tyroet	O
when	O
subtilisin	O
or	O
α	O
-	O
chymotrypsin	O
were	O
used	O
.	O

However	O
,	O
the	O
enzymatic	O
peptide	O
synthesis	O
in	O
the	O
absence	O
of	O
solvent	O
depends	O
on	O
the	O
ability	O
of	O
the	O
mixtures	O
to	O
form	O
supercooled	O
liquid	O
mixtures	O
[	O
2–5	O
]	O
.	O

For	O
instance	O
,	O
supercooled	O
-	O
liquid	O
mixtures	O
can	O
not	O
be	O
formed	O
on	O
mixing	O
l	O
-leucinamide	O
and	O
N	O
-trifluoroacetyl	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
TFAc	O
-	O
Tyroet	O
)	O
and	O
no	O
dipeptide	O
can	O
be	O
obtained	O
.	O

It	O
is	O
therefore	O
important	O
to	O
understand	O
the	O
mechanism	O
of	O
the	O
formation	O
of	O
supercooled	O
liquid	O
in	O
the	O
mixtures	O
of	O
amino	O
acid	O
amides	O
and	O
tyrosine	O
derivatives	O
.	O

As	O
part	O
of	O
the	O
systematic	O
study	O
of	O
amino	O
acid	O
derivatives	O
,	O
the	O
proton	O
relaxation	O
behaviour	O
and	O
crystal	O
structure	O
of	O
l	O
-leucinamide	O
[	O
6	O
,	O
7	O
]	O
and	O
the	O
proton	O
relaxation	O
of	O
l	O
-alaninamide	O
[	O
8	O
]	O
has	O
been	O
studied	O
.	O

It	O
was	O
found	O
that	O
methyl	O
group	O
and	O
amino	O
group	O
rotations	O
are	O
the	O
main	O
spin	O
-	O
lattice	O
relaxation	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
examine	O
the	O
NMR	O
proton	O
relaxation	O
behaviours	O
of	O
three	O
tyrosine	O
derivatives	O
,	O
namely	O
,	O
Ac	O
-	O
Tyroet	O
,	O
CBZ	O
-	O
Tyroet	O
,	O
TFAc	O
-	O
Tyroet	O
(	O
Fig.	O
1	O
)	O
,	O
and	O
their	O
mixtures	O
with	O
l	O
-leucinamide	O
in	O
order	O
to	O
understand	O
the	O
molecular	O
dynamics	O
of	O
these	O
compounds	O
and	O
the	O
contributions	O
of	O
molecular	O
motions	O
in	O
the	O
formation	O
of	O
supercooled	O
liquids	O
.	O

2	O
Experimental	O
2.1	O
Sample	O
preparation	O
2.1.1	O
N	O
-	O
carbobenzyloxy	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
CBZ	O
-	O
Tyroet	O
)	O
CBZ	O
-	O
Tyroet	O
was	O
prepared	O
from	O
the	O
corresponding	O
free	O
acid	O
using	O
the	O
thionyl	O
chloride	O
method	O
[	O
9	O
]	O
.	O

A	O
10	O
g	O
N	O
-carbobenzyloxy	O
-	O
l	O
-tyrosine	O
(	O
Sigma	O
)	O
was	O
dissolved	O
in	O
absolute	O
ethanol	O
(	O
BDH	O
)	O
and	O
2.8	O
ml	O
of	O
thionyl	O
chloride	O
(	O
Sigma	O
)	O
was	O
slowly	O
added	O
in	O
.	O

The	O
reaction	O
was	O
carried	O
out	O
at	O
40	O
°	O
C	O
for	O
2	O
h	O
in	O
a	O
water	O
bath	O
located	O
in	O
a	O
fume	O
cupboard	O
,	O
followed	O
by	O
rotary	O
evaporation	O
.	O

The	O
products	O
were	O
then	O
dissolved	O
in	O
ethyl	O
acetate	O
(	O
BDH	O
)	O
and	O
washed	O
by	O
0.1	O
M	O
aqueous	O
sodium	O
hydrogen	O
carbonate	O
(	O
Sigma	O
)	O
solution	O
3	O
or	O
4	O
times	O
to	O
remove	O
non	O
-	O
reacted	O
N	O
-carbobenzyloxy	O
-	O
l	O
-tyrosine	O
.	O

To	O
dry	O
the	O
ethyl	O
acetate	O
solution	O
,	O
an	O
excess	O
of	O
magnesium	O
sulphate	O
(	O
BDH	O
)	O
was	O
added	O
,	O
followed	O
by	O
filtration	O
and	O
rotary	O
evaporation	O
.	O

The	O
CBZ	O
-	O
Tyroet	O
was	O
then	O
crystallised	O
from	O
hot	O
ethyl	O
acetate	O
and	O
petroleum	O
ether	O
(	O
BDH	O
)	O
.	O

A	O
deuterated	O
sample	O
(	O
D2-CBZ	O
-	O
Tyroet	O
)	O
was	O
prepared	O
by	O
stirring	O
the	O
CBZ	O
-	O
Tyroet	O
in	O
D2	O
O	O
(	O
Fluorochem	O
)	O
for	O
ca	O
.	O

2	O
h	O
,	O
followed	O
by	O
freeze	O
-	O
drying	O
.	O

This	O
process	O
was	O
repeated	O
3	O
times	O
to	O
ensure	O
that	O
all	O
the	O
exchangeable	O
protons	O
are	O
replaced	O
by	O
deuterium	O
.	O

The	O
samples	O
were	O
stored	O
in	O
a	O
desiccator	O
over	O
di	O
-	O
phosphorus	O
pentoxide	O
at	O
room	O
temperature	O
.	O

The	O
moisture	O
content	O
was	O
0.1	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

2.1.2	O
N	O
-	O
trifluoroacetyl	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
TFAc	O
-	O
Tyroet	O
)	O
TFAc	O
-	O
Tyroet	O
was	O
prepared	O
by	O
trifluoroacetylation	O
of	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
Sigma	O
)	O
with	O
ethyl	O
trifluoroacetate	O
(	O
Sigma	O
)	O
,	O
in	O
the	O
presence	O
of	O
tetramethyl	O
guanidine	O
(	O
Sigma	O
)	O
[	O
10	O
]	O
.	O

A	O
20	O
g	O
l	O
-tyrosine	O
ethyl	O
ester	O
was	O
dissolved	O
in	O
120	O
ml	O
of	O
absolute	O
ethanol	O
,	O
1.2	O
ml	O
of	O
tetramethyl	O
guanidine	O
followed	O
by	O
12.5	O
ml	O
of	O
ethyl	O
trifluoroacetate	O
was	O
added	O
.	O

The	O
mixture	O
was	O
stirred	O
at	O
room	O
temperature	O
for	O
5	O
h	O
in	O
a	O
fume	O
cupboard	O
.	O

When	O
the	O
synthesis	O
had	O
been	O
completed	O
,	O
15	O
g	O
Dowex	O
50X2	O
-	O
400	O
(	O
Sigma	O
)	O
followed	O
by	O
2	O
g	O
Norit	O
-	O
A	O
activated	O
carbon	O
(	O
Sigma	O
)	O
was	O
added	O
.	O

The	O
mixture	O
was	O
stirred	O
for	O
a	O
further	O
15	O
min	O
.	O

The	O
mixture	O
was	O
filtered	O
through	O
diatomaceous	O
earth	O
(	O
Sigma	O
)	O
and	O
followed	O
by	O
rotary	O
evaporation	O
.	O

The	O
TFAc	O
-	O
Tyroet	O
was	O
recrystallised	O
from	O
hot	O
dichloromethane	O
(	O
BDH	O
)	O
and	O
ethanol	O
.	O

The	O
moisture	O
content	O
was	O
0.18	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

The	O
deuterated	O
TFAc	O
-	O
Tyroet	O
(	O
D2-TFAc	O
-	O
Tyroet	O
)	O
was	O
prepared	O
in	O
the	O
same	O
way	O
as	O
the	O
D2-CBZ	O
-	O
Tyroet	O
.	O

2.1.3	O
Acetyl	O
-	O
l	O
-tyrosine	O
ethyl	O
ester	O
(	O
Ac	O
-	O
Tyroet	O
)	O
Ac	O
-	O
Tyroet	O
was	O
purchased	O
from	O
Sigma	O
and	O
used	O
without	O
any	O
further	O
treatment	O
.	O

The	O
moisture	O
content	O
was	O
6.5	O
wt.%	O
as	O
measured	O
by	O
Karl	O
–	O
Fischer	O
titration	O
.	O

The	O
deuterated	O
Ac	O
-	O
Tyroet	O
(	O
D2-Ac	O
-	O
Tyroet	O
)	O
was	O
prepared	O
in	O
the	O
same	O
way	O
as	O
the	O
D2-CBZ	O
-	O
Tyroet	O
.	O

2.2	O
Solid	O
state	O
NMR	O
measurements	O
All	O
the	O
proton	O
NMR	O
relaxation	O
measurements	O
were	O
carried	O
out	O
on	O
a	O
Bruker	O
MSL-100	O
spectrometer	O
operating	O
at	O
a	O
proton	O
frequency	O
of	O
100.13	O
MHz	O
over	O
the	O
temperature	O
range	O
between	O
110	O
and	O
350	O
K.	O
Experiments	O
were	O
always	O
started	O
from	O
the	O
lowest	O
temperature	O
.	O

T	O
2	O
was	O
measured	O
directly	O
from	O
the	O
free	O
induction	O
decay	O
(	O
FID	O
)	O
following	O
a	O
90	O
°	O
pulse	O
.	O

A	O
90	O
°	O
pulse	O
length	O
of	O
1	O
μs	O
was	O
used	O
and	O
the	O
receiver	O
deadtime	O
following	O
the	O
pulse	O
was	O
5	O
μs	O
.	O

The	O
proton	O
second	O
moment	O
was	O
calculated	O
from	O
the	O
FID	O
assuming	O
Gaussian	O
line	O
shapes	O
[	O
11	O
]	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
time	O
(	O
T	O
1	O
)	O
was	O
measured	O
via	O
the	O
inversion	O
recovery	O
(	O
180x	O
°	O
-τ	O
-90x	O
°	O
-detect	O
)	O
method	O
[	O
12	O
]	O
.	O

The	O
signal	O
intensity	O
at	O
the	O
beginning	O
of	O
each	O
FID	O
was	O
recorded	O
,	O
a	O
total	O
of	O
48	O
data	O
points	O
were	O
collected	O
.	O

In	O
order	O
to	O
ensure	O
that	O
the	O
spread	O
of	O
τ	O
values	O
was	O
sufficient	O
to	O
test	O
for	O
the	O
existence	O
of	O
multi	O
-	O
exponential	O
relaxation	O
,	O
the	O
values	O
of	O
τ	O
were	O
chosen	O
according	O
to	O
τ	O
=	O
A	O
×10	O
(	O
n	O
−1	O
)	O
/	O
12	O
,	O
where	O
A	O
is	O
a	O
constant	O
varying	O
between	O
1–4	O
ms	O
,	O
depending	O
on	O
the	O
estimate	O
of	O
T	O
1	O
,	O
and	O
n	O
is	O
the	O
number	O
of	O
data	O
points	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
times	O
in	O
the	O
rotating	O
frame	O
,	O
T	O
1ρ	O
,	O
were	O
determined	O
by	O
spin	O
-	O
locking	O
the	O
magnetization	O
in	O
the	O
rotating	O
frame	O
for	O
a	O
suitable	O
period	O
and	O
monitoring	O
the	O
intensity	O
of	O
the	O
resulting	O
FID	O
(	O
90	O
°	O
-spin	O
-	O
lock	O
-	O
acquire	O
)	O
[	O
13	O
]	O
.	O

The	O
spin	O
-	O
locking	O
field	O
strength	O
were	O
40	O
kHz	O
equivalent	O
to	O
a	O
90	O
°	O
pulse	O
length	O
of	O
6.25	O
μs	O
.	O

The	O
spin	O
-	O
locking	O
time	O
varied	O
from	O
400	O
μs	O
to	O
51.2	O
ms	O
.	O

Single	O
point	O
sampling	O
was	O
used	O
,	O
10	O
μs	O
after	O
spin	O
-	O
locking	O
pulse	O
.	O

Dependent	O
on	O
the	O
length	O
of	O
the	O
T	O
1ρ	O
,	O
48–128	O
data	O
points	O
were	O
collected	O
for	O
each	O
experiment	O
.	O

Co	O
-	O
added	O
were	O
2–4	O
scans	O
to	O
improve	O
the	O
signal	O
to	O
noise	O
ratio	O
in	O
both	O
T	O
1	O
and	O
T	O
1ρ	O
measurements	O
.	O

All	O
data	O
were	O
analyzed	O
using	O
TableCurve	O
(	O
Jandel	O
Scientific	O
)	O
which	O
is	O
a	O
simultaneous	O
multiple	O
non	O
-	O
linear	O
curve	O
-	O
fitting	O
program	O
and	O
uses	O
the	O
Levenburg	O
–	O
Marquardt	O
algorithm	O
to	O
minimize	O
the	O
sum	O
of	O
squares	O
of	O
the	O
deviations	O
between	O
a	O
calculated	O
summation	O
curve	O
and	O
the	O
observed	O
data	O
points	O
[	O
14	O
]	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Pure	O
tyrosine	O
derivatives	O
3.1.1	O
Second	O
moment	O
The	O
transverse	O
relaxation	O
processes	O
of	O
the	O
three	O
tyrosine	O
derivatives	O
can	O
be	O
fitted	O
by	O
a	O
single	O
Gaussian	O
process	O
.	O

Fig.	O
2	O
shows	O
the	O
temperature	O
dependence	O
of	O
the	O
second	O
moments	O
for	O
the	O
three	O
tyrosine	O
derivatives	O
.	O

Generally	O
,	O
the	O
second	O
moments	O
(	O
M	O
2	O
)	O
reflect	O
the	O
strength	O
of	O
static	O
dipolar	O
interactions	O
in	O
the	O
system	O
.	O

The	O
general	O
decrease	O
in	O
second	O
moment	O
with	O
increasing	O
temperature	O
is	O
probably	O
due	O
to	O
lattice	O
expansion	O
rather	O
than	O
motional	O
averaging	O
since	O
no	O
clear	O
transition	O
is	O
observed	O
.	O

The	O
lower	O
average	O
value	O
of	O
second	O
moment	O
observed	O
for	O
TFAc	O
-	O
Tyroet	O
compared	O
to	O
Ac	O
-	O
Tyroet	O
is	O
due	O
to	O
the	O
lower	O
density	O
of	O
protons	O
in	O
the	O
sample	O
.	O

The	O
lowest	O
second	O
moments	O
are	O
shown	O
by	O
CBZ	O
-	O
Tyroet	O
,	O
these	O
may	O
be	O
due	O
to	O
the	O
bulky	O
benzene	O
ring	O
substituent	O
causing	O
poor	O
crystal	O
packing	O
and	O
reducing	O
the	O
intermolecular	O
contribution	O
to	O
the	O
second	O
moment	O
.	O

3.1.2	O
Spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
laboratory	O
frame	O
The	O
T	O
1	O
s	O
of	O
tyrosine	O
derivatives	O
were	O
measured	O
over	O
the	O
temperature	O
range	O
130–360	O
K.	O
The	O
relaxation	O
time	O
can	O
be	O
fitted	O
to	O
a	O
single	O
exponential	O
in	O
all	O
cases	O
.	O

The	O
variation	O
of	O
R	O
1	O
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

R	O
1	O
of	O
Ac	O
-	O
Tyroet	O
shows	O
two	O
well	O
-	O
resolved	O
R	O
1	O
maxima	O
at	O
170	O
and	O
320	O
K.	O
This	O
indicates	O
that	O
the	O
spin	O
-	O
lattice	O
relaxation	O
is	O
mainly	O
driven	O
by	O
two	O
independent	O
motions	O
,	O
one	O
of	O
which	O
is	O
effective	O
below	O
250	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
that	O
temperature	O
.	O

Previous	O
studies	O
on	O
the	O
proton	O
relaxation	O
of	O
amino	O
acid	O
amides	O
suggest	O
that	O
methyl	O
groups	O
and	O
their	O
reorientations	O
are	O
expected	O
to	O
be	O
important	O
in	O
relaxing	O
the	O
system	O
[	O
6	O
,	O
8	O
]	O
.	O

The	O
low	O
-	O
temperature	O
relaxation	O
rate	O
maximum	O
of	O
Ac	O
-	O
Tyroet	O
occurs	O
at	O
within	O
about	O
30	O
°	O
C	O
of	O
temperature	O
as	O
in	O
l	O
-leucinamide	O
(	O
200	O
K	O
)	O
[	O
6	O
]	O
.	O

Therefore	O
,	O
the	O
effective	O
motion	O
that	O
occurs	O
below	O
250	O
K	O
is	O
likely	O
to	O
be	O
the	O
methyl	O
group	O
rotation	O
.	O

To	O
identify	O
the	O
relaxation	O
process	O
at	O
high	O
temperature	O
,	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
deuterated	O
Ac	O
-	O
Tyroet	O
were	O
measured	O
.	O

The	O
temperature	O
dependence	O
of	O
relaxation	O
is	O
similar	O
for	O
both	O
protonated	O
and	O
deuterated	O
Ac	O
-	O
Tyroet	O
and	O
shown	O
in	O
Fig.	O
4	O
.	O

This	O
phenomenon	O
is	O
also	O
observed	O
in	O
the	O
T	O
1	O
of	O
deuterated	O
CBZ	O
-	O
Tyroet	O
and	O
TFAc	O
-	O
Tyroet	O
.	O

This	O
implies	O
that	O
motions	O
closely	O
related	O
to	O
NH	O
or	O
OH	O
or	O
residual	O
H2	O
O	O
can	O
be	O
eliminated	O
(	O
see	O
Section	O
2.1	O
)	O
.	O

The	O
most	O
likely	O
motion	O
left	O
for	O
relaxing	O
the	O
system	O
is	O
a	O
benzene	O
ring	O
flip	O
motion	O
.	O

Therefore	O
the	O
methyl	O
group	O
reorientation	O
and	O
benzene	O
ring	O
flip	O
are	O
assumed	O
to	O
be	O
the	O
major	O
relaxation	O
mechanisms	O
for	O
Ac	O
-	O
Tyroet	O
.	O

The	O
data	O
were	O
fitted	O
to	O
an	O
expression	O
which	O
was	O
found	O
to	O
be	O
very	O
useful	O
in	O
the	O
previous	O
studies	O
[	O
6	O
,	O
8	O
]	O
:	O
(	O
1	O
)	O
R1obs	O
=	O
1	O
T1	O
=	O
2	O
3	O
Pa	O
M2a	O
τa	O
1+ω2	O
τ2	O
a	O
+	O
4τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
2	O
3	O
Pb	O
M2b	O
τb	O
1+ω2	O
τ2	O
b	O
+	O
4τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
.	O

This	O
is	O
an	O
extension	O
of	O
the	O
well	O
-	O
known	O
relaxation	O
expression	O
of	O
Kubo	O
and	O
Tomita	O
[	O
15	O
]	O
to	O
two	O
independent	O
relaxation	O
processes	O
.	O

ω	O
/2π	O
is	O
the	O
frequency	O
of	O
measurement	O
in	O
Hertz	O
;	O
τ	O
is	O
the	O
correlation	O
time	O
of	O
the	O
molecular	O
motion	O
responsible	O
for	O
spin	O
-	O
lattice	O
relaxation	O
and	O
M	O
2	O
is	O
the	O
second	O
moment	O
modulated	O
by	O
the	O
corresponding	O
motion	O
.	O

P	O
a	O
and	O
P	O
b	O
are	O
the	O
relative	O
populations	O
of	O
methyl	O
protons	O
and	O
protons	O
on	O
the	O
aromatic	O
ring	O
.	O

They	O
are	O
6	O
/	O
17	O
and	O
4	O
/	O
17	O
for	O
Ac	O
-	O
Tyroet	O
.	O

It	O
is	O
also	O
assumed	O
that	O
the	O
temperature	O
dependence	O
of	O
the	O
correlation	O
time	O
is	O
exponential	O
,	O
hence:	O
(	O
2	O
)	O
τ	O
=	O
τ0	O
exp	O
Ea	O
RT	O
.	O

Fig.	O
3	O
shows	O
the	O
good	O
agreement	O
between	O
the	O
calculated	O
curve	O
and	O
experimental	O
data	O
for	O
Ac	O
-	O
Tyroet	O
.	O

The	O
optimized	O
motional	O
parameters	O
of	O
M	O
2	O
,	O
τ	O
0	O
and	O
E	O
a	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
activation	O
energy	O
E	O
a	O
,	O
corresponding	O
to	O
the	O
low	O
temperature	O
motion	O
,	O
is	O
11.8	O
kJ	O
/	O
mol	O
which	O
is	O
in	O
good	O
agreement	O
with	O
that	O
found	O
for	O
methyl	O
groups	O
in	O
l	O
-leucinamide	O
(	O
10.9	O
kJ	O
/	O
mol	O
)	O
[	O
6	O
]	O
.	O

However	O
,	O
the	O
second	O
moment	O
obtained	O
is	O
about	O
1.0	O
×	O
108	O
s−2	O
which	O
is	O
smaller	O
than	O
that	O
from	O
l	O
-leucinamide	O
(	O
2.7	O
×	O
108	O
s−2	O
)	O
.	O

Examination	O
of	O
the	O
chemical	O
formula	O
of	O
Ac	O
-	O
Tyroet	O
shows	O
two	O
methyl	O
groups	O
;	O
one	O
of	O
which	O
is	O
bonded	O
to	O
a	O
carbonyl	O
carbon	O
and	O
the	O
other	O
one	O
is	O
next	O
to	O
a	O
CH2	O
group	O
.	O

The	O
rotations	O
of	O
the	O
two	O
methyl	O
groups	O
are	O
expected	O
to	O
behave	O
differently	O
;	O
the	O
one	O
bonded	O
to	O
a	O
carbonyl	O
carbon	O
has	O
a	O
larger	O
distance	O
between	O
methyl	O
group	O
and	O
other	O
protons	O
.	O

The	O
behaviour	O
of	O
this	O
methyl	O
group	O
is	O
expected	O
to	O
be	O
similar	O
to	O
those	O
in	O
methionine	O
methyl	O
d	O
-α	O
-	O
galacturonic	O
acid	O
methyl	O
ester	O
[	O
16	O
]	O
or	O
methylpyranisides	O
[	O
17	O
,	O
18	O
]	O
.	O

This	O
type	O
of	O
methyl	O
group	O
is	O
less	O
hindered	O
,	O
with	O
a	O
estimated	O
activation	O
energy	O
of	O
6	O
kJ	O
/	O
mol	O
and	O
pre	O
-	O
exponential	O
term	O
of	O
2	O
×	O
10−13	O
s	O
[	O
16	O
]	O
.	O

At	O
100	O
MHz	O
,	O
this	O
type	O
of	O
methyl	O
group	O
has	O
a	O
relaxation	O
maximum	O
at	O
about	O
80	O
K.	O
The	O
maximum	O
observed	O
at	O
170	O
K	O
is	O
therefore	O
likely	O
to	O
be	O
due	O
to	O
the	O
motion	O
of	O
the	O
more	O
hindered	O
group	O
,	O
CH2	O
–CH3	O
.	O

In	O
this	O
case	O
,	O
the	O
value	O
of	O
P	O
a	O
in	O
Eq.	O
(	O
1	O
)	O
should	O
be	O
3	O
/	O
17	O
instead	O
of	O
6	O
/	O
17	O
,	O
and	O
M	O
2a	O
should	O
be	O
2.0	O
×	O
108	O
s−2	O
which	O
is	O
much	O
more	O
consistent	O
with	O
other	O
data	O
.	O

The	O
second	O
motion	O
controlling	O
the	O
relaxation	O
at	O
high	O
temperature	O
(	O
maximum	O
at	O
320	O
K	O
)	O
was	O
assumed	O
to	O
be	O
a	O
benzene	O
ring	O
flip	O
.	O

The	O
second	O
moment	O
obtained	O
from	O
the	O
curve	O
fitting	O
(	O
2.7	O
×	O
107	O
s−2	O
)	O
is	O
an	O
order	O
of	O
magnitude	O
smaller	O
than	O
that	O
from	O
the	O
methyl	O
group	O
rotation	O
,	O
but	O
is	O
in	O
broad	O
agreement	O
with	O
that	O
found	O
in	O
phenylalanine	O
(	O
M	O
2	O
:	O
1.3	O
×	O
107	O
s−2	O
)	O
[	O
19	O
]	O
.	O

The	O
maximum	O
of	O
relaxation	O
rate	O
occurs	O
at	O
255	O
K	O
for	O
benzene	O
ring	O
flipping	O
motion	O
in	O
phenylalanine	O
[	O
19	O
]	O
.	O

In	O
Ac	O
-	O
Tyroet	O
,	O
there	O
is	O
a	O
hydroxyl	O
group	O
on	O
the	O
end	O
of	O
benzene	O
ring	O
,	O
which	O
is	O
hydrogen	O
-	O
bonded	O
to	O
a	O
amide	O
group	O
in	O
a	O
neighbouring	O
molecule	O
[	O
20	O
]	O
and	O
thus	O
,	O
restricting	O
the	O
motion	O
of	O
the	O
ring	O
.	O

Since	O
the	O
rotation	O
is	O
more	O
restricted	O
,	O
the	O
rate	O
maximum	O
is	O
likely	O
to	O
occur	O
at	O
a	O
higher	O
temperature	O
.	O

Fig.	O
3	O
also	O
shows	O
the	O
temperature	O
dependence	O
of	O
spin	O
-	O
lattice	O
relaxation	O
rate	O
of	O
CBZ	O
-	O
Tyroet	O
.	O

Following	O
the	O
results	O
obtained	O
in	O
Ac	O
-	O
Tyroet	O
,	O
the	O
rotational	O
motion	O
of	O
the	O
methyl	O
group	O
as	O
the	O
origin	O
of	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
laboratory	O
frame	O
at	O
low	O
temperature	O
is	O
also	O
assumed	O
.	O

The	O
data	O
suggest	O
that	O
the	O
relaxation	O
at	O
high	O
temperature	O
is	O
relatively	O
efficient	O
(	O
Fig.	O
3	O
insert	O
)	O
,	O
indicating	O
a	O
second	O
effective	O
motion	O
occurring	O
above	O
220	O
K	O
,	O
although	O
no	O
obvious	O
relaxation	O
rate	O
maximum	O
was	O
seen	O
.	O

The	O
second	O
motion	O
is	O
also	O
assumed	O
to	O
be	O
the	O
benzene	O
ring	O
flipping	O
.	O

The	O
observed	O
temperature	O
dependence	O
of	O
R	O
1	O
was	O
therefore	O
fitted	O
to	O
Eqs.	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
with	O
a	O
P	O
a	O
value	O
of	O
3	O
/	O
21	O
and	O
a	O
P	O
b	O
value	O
of	O
9	O
/	O
21	O
.	O

Good	O
agreement	O
between	O
the	O
fitted	O
curve	O
and	O
experimental	O
data	O
was	O
obtained	O
.	O

Examination	O
of	O
the	O
activation	O
energy	O
and	O
pre	O
-	O
exponential	O
term	O
of	O
methyl	O
group	O
rotation	O
shows	O
good	O
agreement	O
between	O
CBZ	O
-	O
Tyroet	O
and	O
Ac	O
-	O
Tyroet	O
(	O
Table	O
1	O
)	O
.	O

However	O
,	O
the	O
second	O
moment	O
obtained	O
from	O
assuming	O
both	O
methyl	O
groups	O
were	O
active	O
in	O
Ac	O
-	O
Tyroet	O
is	O
about	O
half	O
of	O
that	O
from	O
CBZ	O
-	O
Tyroet	O
.	O

This	O
further	O
suggests	O
that	O
the	O
methyl	O
group	O
bonded	O
to	O
the	O
carbonyl	O
carbon	O
in	O
Ac	O
-	O
Tyroet	O
is	O
less	O
hindered	O
and	O
does	O
not	O
have	O
contribution	O
to	O
the	O
relaxation	O
at	O
170	O
K.	O
Effectively	O
,	O
the	O
system	O
is	O
relaxed	O
by	O
only	O
one	O
methyl	O
group	O
.	O

In	O
contrast	O
to	O
Ac	O
-	O
Tyroet	O
where	O
there	O
is	O
an	O
R	O
1	O
maximum	O
at	O
320	O
K	O
,	O
there	O
are	O
no	O
obvious	O
high	O
temperature	O
R	O
1	O
maxima	O
in	O
CBZ	O
-	O
Tyroet	O
.	O

Inspection	O
of	O
the	O
chemical	O
structure	O
of	O
the	O
two	O
molecules	O
shows	O
the	O
presence	O
of	O
two	O
benzene	O
rings	O
in	O
CBZ	O
-	O
Tyroet	O
,	O
one	O
of	O
which	O
is	O
restricted	O
by	O
a	O
hydroxyl	O
group	O
and	O
the	O
other	O
one	O
is	O
not	O
.	O

The	O
relatively	O
free	O
benzene	O
ring	O
motion	O
is	O
expected	O
to	O
relax	O
the	O
system	O
efficiently	O
at	O
the	O
temperature	O
below	O
320	O
K.	O
It	O
is	O
very	O
likely	O
that	O
the	O
relaxation	O
mechanism	O
occurring	O
at	O
higher	O
temperature	O
comprises	O
two	O
ring	O
flip	O
motions	O
having	O
different	O
activation	O
energies	O
,	O
the	O
non	O
-	O
hydrogen	O
-	O
bonded	O
benzene	O
ring	O
flipping	O
at	O
lower	O
temperature	O
.	O

The	O
presence	O
of	O
unrestricted	O
benzene	O
ring	O
motion	O
is	O
manifest	O
in	O
the	O
differences	O
in	O
proton	O
T	O
1	O
value	O
of	O
CBZ	O
-	O
Tyroet	O
(	O
1.75	O
s	O
)	O
and	O
Ac	O
-	O
Tyroet	O
(	O
3.56	O
s	O
)	O
at	O
250	O
K.	O
However	O
,	O
the	O
fitting	O
procedure	O
was	O
unable	O
to	O
discriminate	O
two	O
motions	O
and	O
only	O
one	O
motion	O
was	O
assumed	O
in	O
the	O
fit	O
.	O

T	O
1	O
s	O
of	O
TFAc	O
-	O
Tyroet	O
were	O
measured	O
over	O
the	O
temperature	O
range	O
of	O
150–360	O
K.	O
The	O
variation	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
rate	O
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
contrast	O
to	O
the	O
Ac	O
-	O
Tyroet	O
and	O
CBZ	O
-	O
Tyroet	O
,	O
it	O
shows	O
only	O
one	O
maximum	O
at	O
around	O
170	O
K.	O
This	O
indicates	O
the	O
presence	O
of	O
a	O
motion	O
whose	O
correlation	O
time	O
is	O
about	O
10−9	O
s	O
at	O
170	O
K.	O
Following	O
the	O
previous	O
study	O
,	O
the	O
motion	O
occurring	O
at	O
170	O
K	O
is	O
likely	O
to	O
be	O
the	O
methyl	O
group	O
rotation	O
.	O

The	O
observed	O
R	O
1	O
is	O
therefore	O
fitted	O
to	O
the	O
Eqs.	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
assuming	O
that	O
only	O
methyl	O
rotation	O
is	O
present	O
.	O

In	O
this	O
case	O
,	O
P	O
a	O
in	O
the	O
Eq.	O
(	O
1	O
)	O
is	O
3	O
/	O
14	O
for	O
the	O
TFAc	O
-	O
Tyroet	O
.	O

Good	O
agreement	O
was	O
found	O
between	O
the	O
experimental	O
data	O
and	O
the	O
fitted	O
curve	O
.	O

The	O
calculated	O
relaxation	O
parameters	O
for	O
methyl	O
group	O
reorientation	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
calculated	O
relaxation	O
parameters	O
for	O
methyl	O
group	O
rotation	O
in	O
TFAc	O
-	O
Tyroet	O
are	O
in	O
good	O
agreement	O
with	O
those	O
of	O
CBZ	O
-	O
Tyroet	O
and	O
Ac	B
-	I
Tyroet	I
,	O
confirming	O
the	O
assumption	O
made	O
as	O
to	O
the	O
origin	O
of	O
the	O
relaxation	O
.	O

However	O
,	O
the	O
flipping	O
motion	O
of	O
benzene	O
ring	O
in	O
the	O
TFAc	O
-	O
Tyroet	O
is	O
not	O
observed	O
in	O
the	O
temperature	O
range	O
studied	O
,	O
indicating	O
that	O
the	O
motion	O
is	O
significantly	O
hindered	O
.	O

The	O
hindered	O
motion	O
is	O
presumably	O
due	O
to	O
the	O
presence	O
of	O
the	O
perfluorinated	O
group	O
.	O

This	O
lack	O
of	O
motion	O
may	O
have	O
a	O
role	O
in	O
the	O
failure	O
of	O
this	O
compound	O
to	O
form	O
mixtures	O
with	O
amino	O
acid	O
amides	O
.	O

3.1.3	O
Spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
T	O
1ρ	O
of	O
protonated	O
and	O
deuterated	O
Ac	O
-	O
Tyroet	O
were	O
measured	O
at	O
spin	O
-	O
locking	O
field	O
of	O
40	O
kHz	O
in	O
the	O
temperature	O
range	O
130–290	O
K	O
,	O
single	O
-	O
exponential	O
T	O
1ρ	O
relaxation	O
was	O
observed	O
.	O

The	O
dependence	O
of	O
R	O
1ρ	O
on	O
temperature	O
shown	O
in	O
Fig.	O
5	O
clearly	O
illustrates	O
that	O
the	O
system	O
is	O
mainly	O
relaxed	O
by	O
two	O
motions	O
,	O
one	O
motion	O
is	O
effective	O
below	O
240	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
it	O
.	O

Furthermore	O
,	O
the	O
curves	O
for	O
Ac	O
-	O
Tyroet	O
and	O
D2-Ac	O
-	O
Tyroet	O
are	O
similar	O
at	O
temperatures	O
below	O
240	O
K	O
,	O
however	O
,	O
the	O
higher	O
temperature	O
motion	O
is	O
affected	O
by	O
replacing	O
exchangeable	O
protons	O
with	O
deuterium	O
.	O

The	O
data	O
can	O
be	O
fitted	O
to	O
equations	O
similar	O
to	O
those	O
used	O
in	O
the	O
T	O
1	O
analysis	O
[	O
21	O
]	O
:	O
(	O
3	O
)	O
R1ρ	O
=	O
1	O
T1ρ	O
=	O
Pa	O
M2a	O
τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
Pb	O
M2b	O
τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
.	O

This	O
equation	O
is	O
generally	O
valid	O
when	O
τ	O
a	O
,	O
b	O
<	O
T	O
2	O
and	O
B	O
1	O
≫B	O
L	O
[	O
22	O
]	O
;	O
B	O
1	O
is	O
the	O
spin	O
-	O
locking	O
field	O
and	O
B	O
L	O
,	O
the	O
local	O
dipolar	O
field	O
.	O

In	O
the	O
experiments	O
,	O
B	O
1	O
of	O
40	O
kHz	O
was	O
used	O
and	O
the	O
averaged	O
local	O
dipolar	O
field	O
for	O
Ac	O
-	O
Tyroet	O
was	O
52	O
kHz	O
,	O
thus	O
,	O
B	O
1	O
<	O
B	O
L	O
which	O
does	O
not	O
meet	O
the	O
requirement	O
.	O

Therefore	O
,	O
account	O
must	O
be	O
taken	O
for	O
the	O
effects	O
of	O
the	O
local	O
dipolar	O
field	O
.	O

McCall	O
and	O
Douglass	O
[	O
23	O
]	O
have	O
suggested	O
using	O
an	O
equation	O
of	O
the	O
form	O
ω	O
2	O
=	O
ω	O
1	O
2	O
+	O
ω	O
L	O
2	O
,	O
where	O
ω	O
L	O
/2π	O
is	O
the	O
local	O
dipolar	O
field	O
which	O
equals	O
to	O
square	O
root	O
of	O
one	O
third	O
of	O
second	O
moment	O
.	O

From	O
the	O
T	O
1	O
of	O
Ac	O
-	O
Tyroet	O
,	O
the	O
effect	O
of	O
benzene	O
ring	O
motion	O
was	O
detected	O
at	O
320	O
K	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
the	O
motion	O
below	O
240	O
K	O
is	O
benzene	O
ring	O
motion	O
since	O
the	O
measurement	O
of	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
has	O
the	O
effect	O
of	O
shifting	O
the	O
relaxation	O
maxima	O
into	O
a	O
lower	O
temperature	O
range	O
.	O

Therefore	O
,	O
P	O
a	O
in	O
Eq.	O
(	O
3	O
)	O
is	O
4	O
/	O
17	O
for	O
Ac	O
-	O
Tyroet	O
and	O
4	O
/	O
15	O
for	O
D2-Ac	O
-	O
Tyroet	O
.	O

Since	O
the	O
second	O
motion	O
is	O
difficult	O
to	O
identify	O
positively	O
,	O
a	O
P	O
b	O
value	O
of	O
13	O
/	O
17	O
for	O
Ac	O
-	O
Tyroet	O
and	O
11	O
/	O
15	O
for	O
D2-Ac	O
-	O
Tyroet	O
is	O
assumed	O
for	O
the	O
curve	O
fitting	O
.	O

Fig.	O
5	O
shows	O
the	O
quality	O
of	O
the	O
fitting	O
.	O

The	O
results	O
of	O
the	O
fitting	O
are	O
summarised	O
in	O
Table	O
1	O
.	O

The	O
values	O
of	O
M	O
2	O
,	O
E	O
a	O
and	O
τ	O
0	O
are	O
the	O
same	O
within	O
experimental	O
error	O
for	O
both	O
protonated	O
and	O
deuterated	O
samples	O
in	O
the	O
temperature	O
range	O
below	O
240	O
K	O
,	O
indicating	O
that	O
deuteration	O
has	O
little	O
effect	O
on	O
this	O
motion	O
.	O

Supposing	O
that	O
the	O
benzene	O
ring	O
flip	O
is	O
responsible	O
for	O
the	O
T	O
1ρ	O
relaxation	O
in	O
this	O
temperature	O
range	O
,	O
therefore	O
,	O
the	O
temperature	O
dependence	O
of	O
R	O
1ρ	O
curve	O
can	O
be	O
predicted	O
from	O
the	O
relaxation	O
parameters	O
(	O
within	O
the	O
error	O
range	O
)	O
of	O
benzene	O
flipping	O
motion	O
obtained	O
from	O
T	O
1	O
.	O

Fig.	O
5	O
shows	O
the	O
predicted	O
curve	O
.	O

Clearly	O
,	O
the	O
fitted	O
curve	O
does	O
not	O
agree	O
very	O
well	O
with	O
the	O
predicted	O
one	O
;	O
the	O
fitted	O
curve	O
is	O
wider	O
than	O
the	O
predicted	O
one	O
.	O

This	O
may	O
arise	O
because	O
the	O
fitting	O
of	O
the	O
T	O
1	O
data	O
is	O
rather	O
poor	O
,	O
the	O
peak	O
is	O
rather	O
weak	O
and	O
is	O
at	O
the	O
end	O
of	O
the	O
temperature	O
range	O
.	O

The	O
pre	O
-	O
exponential	O
factor	O
found	O
for	O
the	O
T	O
1	O
data	O
is	O
also	O
very	O
small	O
.	O

This	O
suggests	O
that	O
the	O
T	O
1ρ	O
data	O
are	O
more	O
reliable	O
.	O

In	O
contrast	O
to	O
the	O
motion	O
at	O
lower	O
temperature	O
,	O
the	O
higher	O
temperature	O
motion	O
is	O
affected	O
by	O
replacing	O
exchangeable	O
protons	O
with	O
deuterium	O
.	O

Fig.	O
5	O
shows	O
that	O
deuterated	O
sample	O
is	O
relaxed	O
more	O
efficiently	O
in	O
this	O
temperature	O
region	O
.	O

This	O
must	O
be	O
due	O
to	O
the	O
decrease	O
in	O
the	O
number	O
of	O
protons	O
to	O
be	O
relaxed	O
by	O
the	O
motion	O
[	O
6	O
,	O
15	O
]	O
.	O

The	O
motion	O
that	O
becomes	O
apparent	O
may	O
be	O
a	O
motion	O
involving	O
a	O
large	O
part	O
of	O
the	O
molecule	O
.	O

However	O
,	O
its	O
origin	O
is	O
not	O
certain	O
so	O
the	O
motion	O
will	O
be	O
referred	O
to	O
simply	O
as	O
the	O
third	O
motion	O
.	O

T	O
1ρ	O
of	O
solid	O
CBZ	O
-	O
Tyroet	O
was	O
measured	O
over	O
the	O
temperature	O
range	O
150–340	O
K	O
and	O
the	O
dependence	O
of	O
R	O
1ρ	O
on	O
temperature	O
is	O
shown	O
in	O
Fig.	O
6	O
.	O

Relaxation	O
of	O
CBZ	O
-	O
Tyroet	O
(	O
Fig.	O
6	O
)	O
is	O
similar	O
to	O
that	O
of	O
Ac	O
-	O
Tyroet	O
(	O
Fig.	O
5	O
)	O
.	O

One	O
motion	O
occurs	O
below	O
270	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
at	O
higher	O
temperature	O
.	O

As	O
with	O
Ac	O
-	O
Tyroet	O
,	O
benzene	O
ring	O
flipping	O
and	O
the	O
third	O
mode	O
of	O
motion	O
are	O
assumed	O
to	O
account	O
for	O
the	O
R	O
1ρ	O
of	O
CBZ	O
-	O
Tyroet	O
.	O

The	O
data	O
are	O
therefore	O
fitted	O
to	O
Eq.	O
(	O
3	O
)	O
with	O
a	O
P	O
a	O
value	O
of	O
9	O
/	O
21	O
and	O
a	O
P	O
b	O
of	O
12	O
/	O
21	O
for	O
CBZ	O
-	O
Tyroet	O
.	O

The	O
local	O
dipolar	O
field	O
,	O
ω	O
L	O
,	O
(	O
44	O
kHz	O
)	O
has	O
also	O
been	O
taken	O
into	O
account	O
.	O

A	O
fit	O
of	O
Eq.	O
(	O
3	O
)	O
to	O
the	O
temperature	O
dependence	O
of	O
R	O
1ρ	O
of	O
CBZ	O
-	O
Tyroet	O
gives	O
a	O
pre	O
-	O
exponential	O
factor	O
of	O
7.0	O
×	O
10−10	O
for	O
the	O
motion	O
effective	O
below	O
270	O
K.	O
This	O
value	O
is	O
too	O
high	O
for	O
the	O
motion	O
at	O
low	O
temperature	O
.	O

Usually	O
,	O
this	O
is	O
indicative	O
of	O
a	O
distribution	O
of	O
correlation	O
time	O
[	O
24	O
,	O
25	O
]	O
.	O

From	O
the	O
discussion	O
of	O
T	O
1	O
of	O
CBZ	O
-	O
Tyroet	O
,	O
two	O
benzene	O
rings	O
are	O
present	O
in	O
the	O
CBZ	O
-	O
Tyroet	O
.	O

Therefore	O
,	O
the	O
relaxation	O
below	O
270	O
K	O
can	O
be	O
treated	O
simply	O
as	O
the	O
sum	O
of	O
two	O
individual	O
motions	O
corresponding	O
to	O
restricted	O
and	O
unrestricted	O
benzene	O
ring	O
flipping	O
motions	O
and	O
thus	O
,	O
the	O
R	O
1ρ	O
below	O
290	O
K	O
may	O
be	O
written	O
as:	O
(	O
4	O
)	O
R1ρ	O
=	O
1	O
T1ρ	O
=	O
Pa	O
M2a	O
τa	O
1	O
+	O
4ω2	O
τ2	O
a	O
+	O
τb	O
1	O
+	O
4ω2	O
τ2	O
b	O
where	O
τ	O
a	O
and	O
τ	O
b	O
correspond	O
to	O
correlation	O
times	O
of	O
the	O
unrestricted	O
and	O
restricted	O
benzene	O
ring	O
flipping	O
motions	O
.	O

The	O
fitted	O
results	O
are	O
listed	O
in	O
Table	O
1	O
.	O

Fig.	O
6	O
shows	O
the	O
good	O
agreement	O
between	O
the	O
fitted	O
curve	O
and	O
the	O
experimental	O
data	O
.	O

The	O
calculated	O
activation	O
energy	O
and	O
the	O
pre	O
-	O
exponential	O
term	O
for	O
the	O
restricted	O
benzene	O
ring	O
motion	O
in	O
CBZ	O
-	O
Tyroet	O
is	O
in	O
good	O
agreement	O
with	O
those	O
in	O
Ac	O
-	O
Tyroet	O
although	O
large	O
uncertainties	O
occurred	O
in	O
the	O
curve	O
fitting	O
(	O
Table	O
1	O
)	O
.	O

The	O
activation	O
energy	O
obtained	O
for	O
the	O
unrestricted	O
motion	O
is	O
lower	O
than	O
that	O
of	O
restricted	O
one	O
,	O
which	O
is	O
expected	O
.	O

The	O
third	O
motion	O
appearing	O
at	O
higher	O
temperatures	O
is	O
affected	O
by	O
deuterium	O
replacement	O
of	O
exchangeable	O
proton	O
,	O
which	O
is	O
similar	O
to	O
the	O
observation	O
made	O
for	O
Ac	O
-	O
Tyroet	O
.	O

However	O
,	O
since	O
such	O
a	O
small	O
part	O
of	O
the	O
curve	O
was	O
observable	O
no	O
reliable	O
fitted	O
data	O
could	O
be	O
obtained	O
.	O

The	O
variation	O
of	O
R	O
1ρ	O
of	O
TFAc	O
-	O
Tyroet	O
and	O
D2-TFAc	O
-	O
Tyroet	O
with	O
temperature	O
is	O
shown	O
in	O
Fig.	O
7	O
.	O

The	O
proton	O
spin	O
-	O
lattice	O
relaxation	O
in	O
the	O
rotating	O
frame	O
of	O
both	O
protonated	O
and	O
deuterated	O
samples	O
is	O
increasingly	O
efficient	O
below	O
240	O
K	O
and	O
no	O
relaxation	O
rate	O
maximum	O
was	O
seen	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
results	O
from	O
Ac	O
-	O
Tyroet	O
and	O
CBZ	O
-	O
Tyroet	O
where	O
benzene	O
ring	O
motion	O
was	O
observed	O
at	O
200	O
K.	O
In	O
the	O
T	O
1	O
of	O
TFAc	O
-	O
Tyroet	O
analysis	O
,	O
methyl	O
group	O
reorientation	O
was	O
found	O
to	O
be	O
the	O
only	O
relaxation	O
mechanism	O
.	O

It	O
is	O
expected	O
that	O
it	O
is	O
also	O
responsible	O
for	O
T	O
1ρ	O
relaxation	O
at	O
very	O
low	O
temperature	O
.	O

The	O
temperature	O
at	O
which	O
the	O
maximum	O
occurs	O
is	O
predicted	O
to	O
be	O
around	O
92	O
K	O
using	O
the	O
relaxation	O
parameters	O
for	O
methyl	O
group	O
rotation	O
found	O
in	O
the	O
T	O
1	O
analysis	O
.	O

To	O
confirm	O
this	O
,	O
T	O
1ρ	O
of	O
TFAc	O
-	O
Tyroet	O
was	O
measured	O
between	O
110	O
to	O
140	O
K	O
and	O
it	O
was	O
found	O
that	O
the	O
relaxation	O
becomes	O
more	O
efficient	O
as	O
the	O
temperature	O
is	O
decreased	O
(	O
see	O
the	O
insert	O
Fig.	O
7	O
)	O
.	O

Therefore	O
,	O
the	O
only	O
relaxation	O
mechanism	O
for	O
the	O
T	O
1ρ	O
of	O
TFAc	O
-	O
Tyroet	O
can	O
be	O
reasonably	O
assigned	O
to	O
methyl	O
group	O
rotation	O
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
made	O
in	O
the	O
T	O
1	O
analysis	O
and	O
suggests	O
that	O
the	O
crystal	O
structure	O
results	O
in	O
a	O
more	O
rigid	O
molecule	O
than	O
in	O
the	O
other	O
compounds	O
.	O

This	O
may	O
be	O
the	O
cause	O
of	O
the	O
failure	O
to	O
form	O
a	O
supercooled	O
liquid	O
mixture	O
with	O
l	O
-leucinamide	O
.	O

3.2	O
Mixtures	O
of	O
l	O
-leucinamide	O
/	O
tyrosine	O
derivatives	O
l	O
-leucinamide	O
can	O
spontaneously	O
form	O
supercooled	O
liquid	O
mixtures	O
with	O
CBZ	O
-	O
Tyroet	O
and	O
Ac	O
-	O
Tyroet	O
.	O

However	O
,	O
the	O
melts	O
of	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
do	O
not	O
supercool	O
but	O
rather	O
crystallise	O
into	O
separated	O
phases	O
.	O

The	O
mixtures	O
containing	O
1:1	O
l	O
-leucinamide	O
/	O
tyrosine	O
derivatives	O
were	O
studied	O
by	O
the	O
temperature	O
dependence	O
of	O
proton	O
spin	O
-	O
lattice	O
relaxation	O
time	O
in	O
the	O
laboratory	O
frame	O
.	O

For	O
the	O
supercooled	O
liquid	O
mixture	O
of	O
l	O
-leuNH	O
/	O
CBZ	O
-	O
Tyroet	O
,	O
a	O
single	O
exponential	O
T	O
1	O
relaxation	O
was	O
found	O
in	O
the	O
temperature	O
range	O
below	O
330	O
K	O
,	O
above	O
that	O
temperature	O
,	O
a	O
slightly	O
double	O
exponential	O
recovery	O
of	O
magnetization	O
was	O
detected	O
.	O

For	O
the	O
supercooled	O
liquid	O
mixture	O
of	O
l	O
-leuNH	O
/	O
Ac	O
-	O
Tyroet	O
,	O
a	O
slightly	O
double	O
exponential	O
recovery	O
of	O
magnetization	O
was	O
detected	O
above	O
345	O
K.	O
The	O
behaviour	O
of	O
spin	O
-	O
lattice	O
relaxation	O
of	O
a	O
two	O
-	O
component	O
system	O
depends	O
on	O
the	O
spin	O
diffusion	O
rate	O
between	O
the	O
components	O
.	O

When	O
the	O
spin	O
diffusion	O
rate	O
is	O
faster	O
than	O
the	O
rate	O
at	O
which	O
spin	O
energy	O
flows	O
from	O
the	O
spin	O
to	O
lattice	O
,	O
averaging	O
of	O
the	O
spatial	O
inhomogeneities	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
occurs	O
and	O
results	O
in	O
an	O
observed	O
single	O
relaxation	O
time	O
.	O

The	O
spin	O
diffusion	O
rate	O
is	O
dependent	O
on	O
the	O
strength	O
of	O
homonuclear	O
dipolar	O
interactions	O
which	O
,	O
in	O
turn	O
,	O
depends	O
on	O
both	O
the	O
distance	O
between	O
nuclei	O
and	O
molecular	O
mobilities	O
.	O

At	O
below	O
300	O
K	O
,	O
the	O
transverse	O
relaxation	O
of	O
the	O
mixture	O
comprises	O
a	O
Gaussian	O
and	O
an	O
exponential	O
process	O
,	O
above	O
300	O
K	O
it	O
is	O
exponential	O
.	O

A	O
single	O
exponential	O
spin	O
-	O
lattice	O
relaxation	O
is	O
observed	O
below	O
300	O
K.	O
This	O
is	O
due	O
to	O
the	O
strong	O
static	O
dipolar	O
interactions	O
,	O
which	O
exist	O
in	O
this	O
temperature	O
regime	O
.	O

When	O
the	O
temperature	O
is	O
above	O
330	O
K	O
,	O
the	O
dipolar	O
interactions	O
are	O
weakened	O
as	O
the	O
result	O
of	O
molecular	O
motion	O
,	O
consequently	O
,	O
the	O
spin	O
diffusion	O
rate	O
is	O
slow	O
,	O
resulting	O
in	O
non	O
-	O
exponential	O
recovery	O
of	O
T	O
1	O
.	O

However	O
,	O
in	O
the	O
temperature	O
range	O
between	O
300	O
to	O
330	O
K	O
,	O
the	O
single	O
exponential	O
T	O
1	O
relaxation	O
observed	O
in	O
the	O
mixture	O
of	O
LeuNH	O
/	O
CBZ	O
-	O
Tyroet	O
is	O
not	O
the	O
result	O
of	O
strong	O
static	O
interactions	O
since	O
the	O
transverse	O
relaxation	O
of	O
the	O
mixture	O
LeuNH	O
/	O
CBZ	O
-	O
Tyroet	O
is	O
an	O
exponential	O
process	O
.	O

The	O
single	O
exponential	O
T	O
1	O
observed	O
in	O
this	O
case	O
may	O
be	O
due	O
to	O
the	O
strong	O
intra-	O
and	O
intermolecular	O
interactions	O
resulting	O
from	O
the	O
fact	O
that	O
molecules	O
in	O
the	O
mixtures	O
are	O
in	O
close	O
contact	O
to	O
each	O
other	O
.	O

The	O
spin	O
-	O
lattice	O
relaxation	O
behaviour	O
of	O
both	O
the	O
mixtures	O
was	O
treated	O
as	O
a	O
single	O
exponential	O
process	O
in	O
the	O
temperature	O
range	O
150–360	O
K	O
since	O
only	O
a	O
few	O
data	O
show	O
the	O
double	O
-	O
exponential	O
behaviour	O
,	O
and	O
fitting	O
our	O
data	O
to	O
a	O
single	O
exponential	O
function	O
does	O
not	O
affect	O
the	O
analysis	O
drastically	O
.	O

Fig.	O
8	O
Fig.	O
9	O
show	O
the	O
spin	O
-	O
lattice	O
relaxation	O
rates	O
of	O
the	O
mixtures	O
LeuNH	O
/	O
Ac	O
-	O
Tyroet	O
and	O
LeuNH	O
/	O
CBZ	O
-	O
Tyroet	O
plotted	O
against	O
temperature	O
.	O

Clearly	O
,	O
two	O
independent	O
dominant	O
relaxation	O
mechanisms	O
were	O
detected	O
,	O
one	O
of	O
which	O
is	O
effective	O
below	O
250	O
K	O
and	O
the	O
other	O
one	O
is	O
effective	O
above	O
that	O
temperature	O
.	O

The	O
methyl	O
group	O
rotation	O
is	O
expected	O
to	O
be	O
responsible	O
for	O
the	O
relaxation	O
at	O
low	O
temperature	O
[	O
6	O
]	O
.	O

To	O
clarify	O
the	O
high	O
temperature	O
relaxation	O
mechanism	O
,	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
a	O
deuterated	O
supercooled	O
liquid	O
mixture	O
of	O
l	O
-leuND	O
/	O
D2-CBZ	O
-	O
Tyroet	O
(	O
Fig.	O
9	O
)	O
were	O
measured	O
in	O
the	O
temperature	O
range	O
140–360	O
K	O
and	O
plotted	O
against	O
temperature	O
.	O

Relatively	O
efficient	O
relaxation	O
was	O
still	O
found	O
at	O
high	O
temperature	O
.	O

This	O
suggests	O
that	O
the	O
spin	O
-	O
lattice	O
relaxation	O
at	O
high	O
temperature	O
is	O
not	O
only	O
due	O
to	O
the	O
motions	O
of	O
NH2	O
or	O
OH	O
,	O
but	O
also	O
some	O
other	O
contributions	O
.	O

Inspection	O
of	O
the	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
the	O
pure	O
CBZ	O
-	O
Tyroet	O
and	O
Ac	O
-	O
Tyroet	O
shows	O
that	O
the	O
benzene	O
ring	O
flipping	O
motion	O
is	O
expected	O
in	O
this	O
temperature	O
range	O
.	O

However	O
,	O
the	O
strength	O
of	O
the	O
relaxation	O
in	O
the	O
mixtures	O
is	O
much	O
larger	O
than	O
that	O
could	O
be	O
generated	O
by	O
the	O
benzene	O
ring	O
flipping	O
,	O
since	O
this	O
is	O
a	O
weaker	O
relaxation	O
source	O
than	O
the	O
methyl	O
group	O
rotation	O
(	O
Fig.	O
4	O
)	O
.	O

The	O
system	O
is	O
likely	O
,	O
in	O
this	O
case	O
,	O
to	O
be	O
relaxed	O
by	O
the	O
molecular	O
tumbling	O
motion	O
since	O
considerable	O
line	O
narrowing	O
was	O
observed	O
in	O
the	O
FID	O
in	O
this	O
temperature	O
range	O
.	O

Therefore	O
,	O
it	O
is	O
reasonable	O
to	O
assume	O
that	O
rapid	O
molecule	O
tumbling	O
is	O
the	O
major	O
relaxation	O
mechanism	O
for	O
the	O
spin	O
-	O
lattice	O
relaxation	O
of	O
the	O
system	O
at	O
high	O
temperature	O
.	O

The	O
experimental	O
data	O
were	O
then	O
fitted	O
in	O
Eq.	O
(	O
1	O
)	O
.	O

P	O
a	O
is	O
the	O
methyl	O
group	O
proton	O
population	O
,	O
the	O
value	O
is	O
9	O
/	O
35	O
for	O
the	O
mixture	O
of	O
l	O
-leuNH	O
/	O
CBZ	O
-	O
Tyroet	O
and	O
9	O
/	O
31	O
for	O
l	O
-leuNH	O
/	O
Ac	O
-	O
Tyroet	O
.	O

P	O
b	O
is	O
set	O
to	O
unity	O
since	O
all	O
the	O
protons	O
in	O
the	O
mixture	O
contribute	O
to	O
the	O
relaxation	O
.	O

Figs.	O
8	O
and	O
9	O
show	O
the	O
good	O
agreement	O
between	O
the	O
fitted	O
curves	O
and	O
experimental	O
data	O
.	O

The	O
results	O
are	O
given	O
in	O
Table	O
2	O
.	O

The	O
second	O
moment	O
calculated	O
for	O
methyl	O
group	O
rotation	O
is	O
in	O
the	O
same	O
order	O
of	O
magnitude	O
as	O
those	O
in	O
pure	O
solids	O
.	O

However	O
,	O
the	O
activation	O
energy	O
of	O
the	O
methyl	O
group	O
rotation	O
in	O
the	O
mixture	O
is	O
smaller	O
than	O
those	O
found	O
for	O
the	O
pure	O
solids	O
.	O

The	O
molecules	O
in	O
supercooled	O
liquid	O
mixtures	O
are	O
loosely	O
packed	O
.	O

As	O
a	O
consequence	O
,	O
rotation	O
of	O
methyl	O
group	O
might	O
be	O
less	O
hindered	O
compared	O
to	O
the	O
corresponding	O
crystal	O
state	O
.	O

This	O
might	O
be	O
the	O
reason	O
for	O
the	O
low	O
activation	O
energy	O
observed	O
.	O

The	O
relaxation	O
rates	O
of	O
these	O
mixtures	O
at	O
low	O
temperature	O
can	O
be	O
predicted	O
from	O
the	O
corresponding	O
crystals	O
assuming	O
that	O
methyl	O
group	O
rotation	O
is	O
the	O
relaxation	O
mechanism	O
.	O

The	O
predictions	O
shown	O
in	O
Figs.	O
8	O
and	O
9	O
differ	O
from	O
the	O
experimental	O
values	O
.	O

This	O
indicates	O
the	O
effects	O
of	O
molecular	O
arrangement	O
on	O
the	O
methyl	O
group	O
rotation	O
.	O

In	O
contrast	O
to	O
the	O
mixtures	O
of	O
l	O
-leuNH	O
/	O
CBZ	O
-	O
Tyroet	O
and	O
l	O
-leuNH	O
/	O
Ac	O
-	O
Tyroet	O
,	O
the	O
mixture	O
of	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
does	O
not	O
form	O
a	O
supercooled	O
liquid	O
.	O

The	O
T	O
1	O
of	O
a	O
mixture	O
of	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
(	O
1:1	O
)	O
were	O
measured	O
over	O
the	O
temperature	O
range	O
150–360	O
K.	O
Unlike	O
the	O
liquid	O
mixtures	O
,	O
double	O
exponential	O
relaxation	O
times	O
were	O
found	O
for	O
the	O
temperature	O
range	O
studied	O
.	O

The	O
short	O
T	O
1	O
component	O
varied	O
between	O
0.08	O
to	O
0.69	O
s	O
and	O
the	O
long	O
T	O
1	O
component	O
varied	O
between	O
0.3	O
to	O
10	O
s.	O
The	O
double	O
exponential	O
behaviour	O
of	O
spin	O
-	O
lattice	O
relaxation	O
indicates	O
that	O
the	O
mixture	O
of	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
is	O
a	O
two	O
phase	O
system	O
and	O
that	O
the	O
spin	O
diffusion	O
between	O
the	O
two	O
components	O
is	O
slow	O
on	O
the	O
time	O
scale	O
of	O
T	O
1	O
.	O

The	O
temperature	O
dependence	O
of	O
relaxation	O
rate	O
of	O
both	O
components	O
is	O
shown	O
in	O
Fig.	O
10	O
.	O

A	O
comparison	O
of	O
both	O
the	O
relaxation	O
times	O
with	O
the	O
pure	O
components	O
of	O
l	O
-leuNH	O
and	O
TFAc	O
-	O
Tyroet	O
shows	O
that	O
the	O
long	O
relaxation	O
component	O
coincides	O
well	O
with	O
the	O
R	O
1	O
of	O
TFAc	O
-	O
Tyroet	O
and	O
that	O
the	O
short	O
component	O
is	O
close	O
to	O
the	O
R	O
1	O
of	O
l	O
-leuNH	O
.	O

From	O
this	O
observation	O
,	O
it	O
can	O
be	O
inferred	O
that	O
the	O
mixture	O
of	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
behaves	O
as	O
if	O
both	O
components	O
were	O
in	O
their	O
pure	O
states	O
.	O

This	O
suggestion	O
is	O
confirmed	O
by	O
the	O
proportion	O
of	O
the	O
two	O
components	O
.	O

At	O
temperatures	O
above	O
260	O
K	O
,	O
the	O
proportion	O
of	O
short	O
T	O
1	O
component	O
comprises	O
about	O
50	O
%	O
.	O

This	O
agrees	O
very	O
well	O
with	O
the	O
proton	O
population	O
of	O
l	O
-leuNH	O
.	O

The	O
short	O
T	O
1	O
represents	O
the	O
population	O
of	O
l	O
-leuNH	O
protons	O
,	O
and	O
the	O
long	O
T	O
1	O
represents	O
that	O
of	O
the	O
TFAc	O
-	O
Tyroet	O
protons	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
liquid	O
mixtures	O
where	O
the	O
mixtures	O
act	O
differently	O
from	O
their	O
pure	O
states	O
.	O

At	O
low	O
temperature	O
(	O
below	O
210	O
K	O
)	O
there	O
is	O
significant	O
deviation	O
of	O
the	O
LeuNH	O
data	O
in	O
the	O
mixture	O
from	O
the	O
pure	O
state	O
,	O
both	O
apparent	O
population	O
and	O
relaxation	O
rate	O
deviate	O
.	O

This	O
may	O
be	O
due	O
to	O
long	O
range	O
spin	O
diffusion	O
effects	O
at	O
this	O
temperature	O
.	O

The	O
ability	O
to	O
form	O
supercooled	O
liquid	O
mixture	O
can	O
be	O
related	O
to	O
the	O
molecular	O
dynamics	O
of	O
the	O
pure	O
substrates	O
.	O

A	O
comparison	O
of	O
the	O
dynamics	O
of	O
these	O
tyrosine	O
derivatives	O
shows	O
that	O
the	O
benzene	O
ring	O
flipping	O
motion	O
and	O
the	O
third	O
motion	O
are	O
absent	O
in	O
the	O
fluorine	O
substituted	O
compound	O
.	O

The	O
reason	O
remains	O
unclear	O
.	O

The	O
preliminary	O
X	O
-	O
ray	O
data	O
did	O
not	O
show	O
strong	O
interactions	O
between	O
the	O
fluorine	O
atoms	O
and	O
the	O
benzene	O
ring	O
,	O
which	O
agrees	O
with	O
the	O
conclusions	O
from	O
UV	O
and	O
Raman	O
spectra	O
.	O

The	O
absence	O
of	O
benzene	O
ring	O
flipping	O
and	O
the	O
third	O
motion	O
in	O
the	O
fluorinated	O
compound	O
implies	O
that	O
the	O
level	O
of	O
order	O
in	O
this	O
crystal	O
is	O
higher	O
than	O
those	O
in	O
the	O
other	O
compounds	O
studied	O
.	O

On	O
crystallisation	O
there	O
will	O
be	O
only	O
one	O
molecular	O
conformation	O
(	O
with	O
respect	O
to	O
the	O
benzene	O
ring	O
)	O
that	O
is	O
possible	O
.	O

Formation	O
of	O
a	O
crystal	O
is	O
therefore	O
only	O
a	O
matter	O
of	O
the	O
whole	O
molecule	O
assuming	O
the	O
correct	O
orientation	O
with	O
respect	O
to	O
its	O
neighbours	O
and	O
packing	O
closely	O
.	O

In	O
the	O
case	O
of	O
Ac	O
-	O
Tyroet	O
there	O
is	O
variability	O
in	O
the	O
conformation	O
with	O
respect	O
to	O
the	O
benzene	O
ring	O
in	O
molecules	O
in	O
the	O
crystal	O
.	O

This	O
will	O
mean	O
that	O
,	O
in	O
effect	O
,	O
the	O
benzene	O
rings	O
will	O
occupy	O
a	O
greater	O
volume	O
than	O
if	O
they	O
were	O
static	O
(	O
in	O
the	O
case	O
of	O
TFAc	O
-	O
Tyroet	O
)	O
and	O
therefore	O
,	O
the	O
intermolecular	O
distances	O
will	O
be	O
greater	O
than	O
in	O
the	O
fluorinated	O
analogue	O
.	O

This	O
in	O
turn	O
implies	O
a	O
weaker	O
intermolecular	O
interactions	O
.	O

This	O
suggestion	O
is	O
supported	O
by	O
the	O
fact	O
that	O
fluorine	O
substitution	O
increases	O
the	O
melting	O
point	O
of	O
the	O
crystal	O
from	O
about	O
78	O
°	O
C	O
to	O
175	O
°	O
C	O
.	O

The	O
presence	O
of	O
highly	O
mobile	O
,	O
non	O
-	O
rigid	O
molecules	O
are	O
also	O
likely	O
to	O
inhibit	O
crystal	O
formation	O
.	O

In	O
the	O
presence	O
of	O
another	O
solute	O
,	O
this	O
is	O
likely	O
to	O
lead	O
to	O
the	O
formation	O
of	O
supercooling	O
systems	O
since	O
only	O
weak	O
interactions	O
in	O
solute	O
will	O
be	O
enough	O
to	O
prevent	O
crystallisation	O
.	O

Similar	O
observations	O
of	O
the	O
effects	O
of	O
fluorination	O
have	O
been	O
made	O
by	O
Dow	O
et	O
al.	O
[	O
26	O
]	O
.	O

It	O
was	O
found	O
that	O
fluorine	O
-	O
substituted	O
lipids	O
form	O
solids	O
on	O
cooling	O
in	O
30–60	O
min	O
,	O
whereas	O
unsubstituted	O
lipids	O
require	O
a	O
cooling	O
period	O
of	O
hours	O
or	O
days	O
.	O

It	O
was	O
also	O
shown	O
that	O
less	O
mobility	O
was	O
associated	O
with	O
fluorine	O
-	O
substituted	O
lipids	O
[	O
26	O
]	O
.	O

4	O
Conclusions	O
The	O
proton	O
relaxation	O
behaviour	O
of	O
three	O
tyrosine	O
derivatives	O
:	O
Ac	O
-	O
Tyroet	O
,	O
CBZ	O
-	O
Tyroet	O
,	O
TFAc	O
-	O
Tyroet	O
and	O
their	O
mixtures	O
with	O
l	O
-leucinamide	O
was	O
studied	O
.	O

The	O
extension	O
of	O
the	O
well	O
-	O
known	O
relaxation	O
expression	O
of	O
Kubo	O
and	O
Tomita	O
to	O
several	O
independent	O
relaxation	O
processes	O
was	O
used	O
to	O
identify	O
the	O
relaxation	O
mechanisms	O
and	O
estimate	O
the	O
relaxation	O
parameters	O
.	O

It	O
was	O
found	O
that	O
methyl	O
group	O
rotation	O
is	O
important	O
for	O
relaxing	O
the	O
system	O
at	O
low	O
temperature	O
in	O
both	O
the	O
pure	O
state	O
and	O
mixtures	O
.	O

In	O
addition	O
,	O
both	O
benzene	O
ring	O
flipping	O
and	O
a	O
third	O
motion	O
were	O
found	O
to	O
be	O
the	O
relaxation	O
mechanisms	O
for	O
Ac	O
-	O
Tyroet	O
and	O
CBZ	O
-	O
Tyroet	O
,	O
however	O
,	O
these	O
motions	O
are	O
absent	O
in	O
TFAc	O
-	O
Tyroet	O
.	O

In	O
the	O
mixtures	O
,	O
molecular	O
tumbling	O
motion	O
is	O
responsible	O
for	O
relaxing	O
the	O
supercooled	O
liquids	O
l	O
-leuNH	O
/	O
CBZ	O
-	O
Tyroet	O
and	O
l	O
-leuNH	O
/	O
Ac	O
-	O
Tyroet	O
.	O

However	O
,	O
this	O
motion	O
is	O
absent	O
in	O
the	O
mixture	O
l	O
-leuNH	O
/	O
TFAc	O
-	O
Tyroet	O
.	O

The	O
absence	O
of	O
benzene	O
ring	O
flipping	O
motion	O
and	O
the	O
third	O
motion	O
in	O
the	O
pure	O
tyrosine	O
derivatives	O
may	O
affect	O
its	O
ability	O
to	O
form	O
a	O
supercooled	O
liquid	O
with	O
l	O
-leucinamide	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
acknowledge	O
funding	O
from	O
the	O
BBSRC	O
competitive	O
strategic	O
grant	O
.	O

Y.L.	O
Wang	O
wishes	O
to	O
thank	O
the	O
BBSRC	O
for	O
provision	O
of	O
a	O
studentship	O
.	O

d	O
-Penicillamine	O
(	O
d	O
-pen	O
)	O
is	O
a	O
drug	O
used	O
in	O
the	O
treatment	O
of	O
patients	B
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
,	O
cystinuria	O
and	O
Wilson	O
's	O
disease	O
.	O

A	O
small	O
molecule	O
,	O
similar	O
in	O
structure	O
to	O
cysteine	O
(	O
see	O
Fig.	O
2	O
)	O
,	O
it	O
has	O
a	O
sulfhydryl	O
group	O
that	O
allows	O
it	O
to	O
couple	O
covalently	O
to	O
proteins	O
(	O
Coleman	O
et	O
al.	O
,	O
1988	O
)	O
,	O
resulting	O
in	O
slow	O
elimination	O
from	O
the	O
body	O
.	O

Its	O
mechanism	O
of	O
action	O
in	O
RA	O
remains	O
unclear	O
,	O
but	O
its	O
variable	O
and	O
unpredictable	O
efficacy	O
,	O
coupled	O
with	O
a	O
relatively	O
high	O
incidence	O
of	O
side	O
-	O
effects	O
,	O
has	O
led	O
to	O
a	O
decline	O
in	O
its	O
use	O
in	O
recent	O
years	O
.	O

Such	O
side	O
-	O
effects	O
include	O
the	O
development	O
of	O
a	O
number	O
of	O
autoimmune	O
disorders	O
including	O
lupus	O
erythematosus	O
,	O
pemphigus	O
,	O
Goodpasture	O
's	O
syndrome	O
,	O
neuromyotonia	O
and	O
myasthenia	O
gravis	O
(	O
MG	O
;	O
Fernandes	O
et	O
al.	O
,	O
1980	O
)	O
.	O

d	O
-Pen	O
is	O
not	O
the	O
only	O
drug	O
capable	O
of	O
inducing	O
autoimmune	O
disease	O
,	O
but	O
it	O
is	O
almost	O
alone	O
in	O
its	O
ability	O
to	O
cause	O
autoimmune	O
MG	O
.	O

As	O
with	O
other	O
drug	O
-	O
induced	O
disorders	O
,	O
d	O
-pen	O
-	O
induced	O
MG	O
is	O
associated	O
with	O
the	O
development	O
of	O
autoantibodies	O
,	O
in	O
this	O
case	O
to	O
the	O
acetylcholine	O
receptor	O
(	O
AChR	O
)	O
(	O
Russell	O
and	O
Lindstrom	O
,	O
1978	O
)	O
.	O

The	O
avidity	O
and	O
specificities	O
of	O
these	O
autoantibodies	O
in	O
d	O
-pen	O
-	O
induced	O
MG	O
are	O
similar	O
to	O
those	O
found	O
in	O
early	O
-	O
onset	O
patients	B
(	O
EOMG	O
)	O
,	O
particularly	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
(	O
Vincent	O
and	O
Newsom	O
-	O
Davis	O
,	O
1982	O
;	O
Heidenreich	O
et	O
al.	O
,	O
1988	O
)	O
;	O
however	O
,	O
the	O
MG	O
normally	O
remits	O
within	O
6	O
months	O
of	O
stopping	O
the	O
drug	O
,	O
with	O
a	O
concomitant	O
fall	O
in	O
the	O
anti	O
-	O
AChR	O
antibody	O
titer	O
(	O
Vincent	O
et	O
al.	O
,	O
1978	O
;	O
Kuncl	O
et	O
al.	O
,	O
1986	O
)	O
,	O
whereas	O
idiopathic	O
MG	O
is	O
usually	O
long	O
-	O
lasting	O
.	O

Delamere	O
et	O
al.	O
(	O
1983	O
)	O
and	O
Garlepp	O
et	O
al.	O
(	O
1983	O
)	O
reported	O
that	O
,	O
in	O
contrast	O
with	O
other	O
MG	O
subgroups	O
,	O
the	O
condition	O
is	O
associated	O
with	O
HLA	O
-	O
DR1	O
,	O
though	O
its	O
rarity	O
means	O
that	O
the	O
numbers	O
of	O
patients	B
studied	O
are	O
small	O
.	O

How	O
d	O
-pen	O
induces	O
MG	O
is	O
unclear	O
.	O

Administration	O
of	O
the	O
drug	O
to	O
experimental	O
animals	B
did	O
not	O
result	O
in	O
the	O
production	O
of	O
anti	O
-	O
AChR	O
antibodies	O
,	O
although	O
they	O
showed	O
an	O
augmented	O
antibody	O
response	O
to	O
immunization	O
with	O
AChR	O
and	O
the	O
resulting	O
MG	O
signs	O
were	O
sometimes	O
more	O
severe	O
(	O
Bever	O
et	O
al.	O
,	O
1984	O
)	O
.	O

The	O
size	O
of	O
the	O
molecule	O
and	O
its	O
reactive	O
sulfhydryl	O
group	O
suggest	O
that	O
the	O
drug	O
is	O
acting	O
as	O
a	O
hapten	O
and/or	O
modifying	O
self	O
protein	O
(	O
s	O
)	O
/	O
peptide	O
(	O
s	O
)	O
,	O
thereby	O
creating	O
neo	O
-	O
epitope	O
(	O
s	O
)	O
.	O

Indeed	O
,	O
coupling	O
of	O
d	O
-pen	O
to	O
an	O
unidentified	O
serum	O
protein	O
has	O
been	O
demonstrated	O
in	O
patients	B
on	O
d	O
-pen	O
therapy	O
(	O
Laycock	O
et	O
al.	O
,	O
1994	O
)	O
,	O
though	O
its	O
significance	O
for	O
autoimmunity	O
is	O
not	O
clear	O
.	O

To	O
examine	O
the	O
role	O
of	O
d	O
-pen	O
in	O
MG	O
,	O
we	O
have	O
isolated	O
a	O
number	O
of	O
CD3	O
+	O
,	O
CD4	O
+	O
T	O
cell	O
clones	O
from	O
the	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
a	O
patient	B
with	O
d	O
-pen	O
-	O
induced	O
MG	O
that	O
respond	O
to	O
the	O
drug	O
in	O
vitro	O
together	O
with	O
HLA	O
-	O
DR1	O
+	O
PBMC	O
.	O

We	O
provide	O
evidence	O
that	O
the	O
drug	O
is	O
acting	O
by	O
coupling	O
directly	O
to	O
the	O
MHC	O
class	O
II	O
/	O
peptide	O
complex	O
,	O
and	O
discuss	O
how	O
this	O
might	O
result	O
in	O
the	O
development	O
of	O
MG	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Patient	B
details	O
We	O
studied	O
a	O
68-year	O
old	O
woman	B
(	O
D	B
-	I
P1	I
)	O
with	O
erosive	O
seropositive	O
RA	O
(	O
HLA	O
A1,32	O
;	O
B8,35	O
;	O
C4,701	O
;	O
DR1,3,DR52a	O
;	O
DQ2,5	O
)	O
who	O
had	O
been	O
on	O
d	O
-pen	O
treatment	O
for	O
9	O
months	O
before	O
she	O
developed	O
right	O
-	O
sided	O
ptosis	O
.	O

Six	O
months	O
later	O
,	O
single	O
fiber	O
electromyography	O
in	O
the	O
affected	O
orbicularis	O
oculi	O
muscle	O
showed	O
markedly	O
increased	O
jitter	O
,	O
consistent	O
with	O
a	O
defect	O
in	O
neuromuscular	O
transmission	O
.	O

Her	O
anti	O
-	O
AChR	O
antibody	O
titer	O
was	O
3.2	O
nM	O
,	O
confirming	O
the	O
diagnosis	O
of	O
MG	O
:	O
the	O
d	O
-pen	O
treatment	O
was	O
therefore	O
stopped	O
.	O

At	O
this	O
time	O
,	O
we	O
took	O
a	O
blood	O
sample	O
from	O
which	O
d	O
-pen	O
-	O
specific	O
lines	O
and	O
clones	O
were	O
obtained	O
.	O

The	O
recovery	O
of	O
her	O
mainly	O
ocular	O
symptoms	O
was	O
slow	O
;	O
about	O
two	O
years	O
after	O
d	O
-pen	O
treatment	O
started	O
,	O
she	O
was	O
given	O
a	O
short	O
course	O
of	O
oral	O
corticosteroids	O
before	O
they	O
resolved	O
completely	O
within	O
9	O
further	O
months	O
.	O

2.2	O
Generation	O
of	O
primary	O
T	O
cell	O
lines	O
d	O
-Pen	O
HCl	O
(	O
Sigma	O
,	O
Poole	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
sterile	O
water	O
and	O
aliquots	O
stored	O
at	O
−70	O
°	O
C	O
.	O

The	O
cellular	O
toxicity	O
of	O
the	O
drug	O
was	O
determined	O
by	O
inhibition	O
of	O
PHA	O
(	O
Difco	O
Laboratories	O
,	O
Detroit	O
,	O
USA	O
)	O
-induced	O
proliferation	O
of	O
PBMCs	O
from	O
healthy	O
controls	O
by	O
increasing	O
concentrations	O
of	O
d	O
-pen	O
;	O
doses	O
of	O
100–500	O
μg	O
/	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
,	O
and	O
toxicity	O
was	O
seen	O
at	O
doses	O
of	O
1	O
mg	O
/	O
ml	O
and	O
above	O
.	O

PBMCs	O
were	O
separated	O
from	O
heparinized	O
blood	O
on	O
Lymphoprep	O
(	O
Nycomed	O
,	O
Oslo	O
,	O
Norway	O
)	O
,	O
washed	O
and	O
cultured	O
at	O
2	O
×	O
106	O
/1	O
ml	O
well	O
(	O
Nunc	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
with	O
100–500	O
μg	O
/	O
ml	O
d	O
-pen	O
in	O
RPMI	O
(	O
Hyclone	O
,	O
Cramlington	O
,	O
UK	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
human	O
serum	O
(	O
Blood	O
Transfusion	O
Service	O
,	O
Oxford	O
,	O
UK	O
)	O
,	O
l	O
-glutamine	O
(	O
Gibco	O
Life	O
Technologies	O
,	O
Paisley	O
,	O
Scotland	O
)	O
and	O
50	O
μg	O
/	O
ml	O
gentamycin	O
(	O
Gibco	O
)	O
,	O
i.e.	O
,	O
without	O
penicillin	O
.	O

After	O
7	O
days	O
,	O
stimulation	O
was	O
assessed	O
by	O
culturing	O
triplicate	O
samples	O
(	O
5	O
%	O
)	O
from	O
each	O
well	O
with	O
1	O
μCi	O
of	O
3	O
H	O
thymidine	O
(	O
Amersham	O
International	O
,	O
Amersham	O
,	O
UK	O
)	O
for	O
18	O
h	O
,	O
followed	O
by	O
harvesting	O
onto	O
filter	O
mats	O
(	O
Wallac	O
,	O
Turku	O
,	O
Finland	O
)	O
and	O
counting	O
on	O
a	O
Betaplate	O
flatbed	O
liquid	O
scintillation	O
counter	O
(	O
Wallac	O
)	O
.	O

A	O
response	O
was	O
considered	O
positive	O
when	O
the	O
activity	O
was	O
greater	O
than	O
twice	O
the	O
control	O
value	O
,	O
i.e.	O
,	O
the	O
stimulation	O
index	O
(	O
SI	O
)	O
was	O
>	O
2	O
.	O

We	O
expanded	O
positive	O
wells	O
into	O
lines	O
using	O
a	O
cycle	O
of	O
fortnightly	O
restimulation	O
with	O
autologous	O
30	O
Gy	O
-	O
irradiated	O
PBMC	O
(	O
PBMCx	O
)	O
and	O
d	O
-pen	O
,	O
and	O
supplementing	O
with	O
20U	O
IL-2	O
(	O
Biotest	O
(	O
UK	O
)	O
,	O
Solihull	O
,	O
UK	O
)	O
approximately	O
every	O
72	O
h	O
thereafter	O
.	O

Specificity	O
of	O
the	O
lines	O
for	O
the	O
drug	O
was	O
confirmed	O
by	O
culturing	O
3	O
×	O
104	O
T	O
cells	O
with	O
1	O
×	O
105	O
PBMCx	O
pretreated	O
with	O
500	O
μg	O
/	O
ml	O
d	O
-pen	O
for	O
4	O
h	O
at	O
37	O
°	O
C	O
in	O
RPMI	O
/	O
5	O
%	O
human	O
serum	O
and	O
then	O
washed	O
twice	O
before	O
being	O
used	O
in	O
the	O
assay	O
.	O

2.3	O
Isolation	O
of	O
d	O
-pen	O
-	O
specific	O
T	O
cell	O
clones	O
One	O
of	O
the	O
d	O
-pen	O
-	O
specific	O
lines	O
derived	O
from	O
patient	B
D	I
-	I
P1	I
was	O
cloned	O
by	O
limiting	O
dilution	O
in	O
Terasaki	O
wells	O
(	O
Nunc	O
)	O
using	O
PBMCx	O
prepulsed	O
with	O
500	O
μg	O
/	O
ml	O
d	O
-pen	O
as	O
the	O
stimulus	O
.	O

Proliferating	O
clones	O
were	O
expanded	O
with	O
IL-2	O
and	O
fortnightly	O
restimulation	O
with	O
PHA	O
and	O
allogeneic	O
PBMCx	O
,	O
and	O
then	O
assayed	O
for	O
a	O
response	O
to	O
d	O
-pen	O
,	O
as	O
described	O
above	O
.	O

Specificity	O
was	O
confirmed	O
by	O
comparing	O
the	O
response	O
to	O
d	O
-pen	O
with	O
that	O
to	O
the	O
isomer	O
,	O
l	O
-penicillamine	O
,	O
and	O
the	O
analogue	O
,	O
d	O
-cysteine	O
(	O
both	O
at	O
500	O
μg	O
/	O
ml	O
;	O
Sigma	O
)	O
.	O

Surface	O
phenotype	O
was	O
determined	O
by	O
FACS	O
analysis	O
(	O
Becton	O
Dickinson	O
,	O
Oxford	O
,	O
UK	O
)	O
using	O
conventional	O
two	O
color	O
staining	O
with	O
anti	O
-	O
CD3	O
(	O
OKT3	O
)	O
directly	O
conjugated	O
to	O
fluorescein	O
isothiocyanate	O
(	O
FITC	O
;	O
gift	O
of	O
S.J.	O
Curnow	O
)	O
and	O
anti	O
-	O
CD4	O
and	O
-CD8	O
conjugated	O
to	O
phycoerythrin	O
(	O
Dako	O
,	O
High	O
Wycombe	O
,	O
UK	O
)	O
.	O

2.4	O
Class	O
II	O
restriction	O
The	O
restricting	O
class	O
II	O
isotype	O
was	O
determined	O
by	O
adding	O
the	O
following	O
class	O
II	O
-	O
blocking	O
mAbs	O
to	O
the	O
presenting	O
cells	O
in	O
the	O
standard	O
assay	O
:	O
mouse	B
anti	O
-	O
human	B
DR	O
(	O
L243	O
;	O
gift	O
of	O
H.	O
McDevitt	O
)	O
,	O
anti	O
-	O
human	B
DP	O
(	O
gift	O
of	O
F.	O
Brodsky	O
)	O
or	O
anti	O
-	O
human	B
DQ	O
(	O
L2	O
;	O
gift	O
of	O
D.	O
Altmann	O
)	O
.	O

Comparing	O
the	O
ability	O
of	O
HLA	O
-	O
sharing	O
PBMCx	O
to	O
present	O
d	O
-pen	O
to	O
the	O
clones	O
then	O
identified	O
the	O
allele	O
.	O

2.5	O
Cytokine	O
profile	O
The	O
supernatant	O
from	O
T	O
cell	O
clones	O
cultured	O
with	O
PBMCx's±d	O
-pen	O
was	O
analyzed	O
for	O
interferon	O
-	O
γ	O
(	O
IFN	O
-	O
γ	O
)	O
and	O
interleukin-4	O
(	O
IL-4	O
)	O
by	O
ELISA	O
(	O
Pharmingen	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

2.6	O
TCR	O
gene	O
usage	O
T	O
cell	O
receptors	O
were	O
cloned	O
using	O
the	O
anchored	O
polymerase	O
chain	O
reaction	O
(	O
Moss	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Briefly	O
,	O
cDNA	O
was	O
synthesized	O
from	O
5	O
μg	O
of	O
RNA	O
using	O
AMV	O
-	O
RT	O
and	O
an	O
oligo	O
dT	O
primer	O
.	O

cDNA	O
was	O
precipitated	O
three	O
times	O
using	O
4	O
M	O
ammonium	O
acetate	O
and	O
an	O
oligo	O
dG	O
homopolymer	O
tail	O
added	O
using	O
TdT.	O
cDNA	O
was	O
then	O
amplified	O
using	O
an	O
anchor	O
primer	O
and	O
primers	O
complementary	O
to	O
TCRA	O
and	O
TCRB	O
constant	O
regions	O
.	O

PCR	O
products	O
were	O
then	O
cloned	O
into	O
M13mp18	O
and	O
sequenced	O
.	O

2.7	O
Requirement	O
for	O
human	O
serum	O
and	O
antigen	O
processing	O
for	O
antigenicity	O
Fresh	O
PBMCs	O
were	O
washed	O
and	O
kept	O
in	O
serum	O
-	O
free	O
medium	O
before	O
irradiation	O
and	O
pulsing	O
in	O
plain	O
RPMI	O
,	O
in	O
5	O
%	O
human	B
or	O
fetal	O
calf	B
serum	O
(	O
Tissue	O
Culture	O
Services	O
,	O
Buckingham	O
,	O
UK	O
)	O
or	O
in	O
serum	O
-	O
free	O
AIM	O
V	O
®	O
medium	O
(	O
Gibco	O
)	O
which	O
contains	O
human	B
albumin	O
,	O
transferrin	O
and	O
insulin	O
.	O

The	O
PBMCx	O
were	O
then	O
counted	O
so	O
that	O
any	O
cell	O
losses	O
could	O
be	O
corrected	O
.	O

We	O
also	O
tested	O
B	O
cell	O
lines	O
,	O
including	O
the	O
homozygous	O
DR1	O
line	O
EHM	O
and	O
one	O
raised	O
from	O
the	O
patient	B
herself	O
;	O
they	O
were	O
pretreated	O
with	O
50	O
μg	O
/	O
ml	O
of	O
mitomycin	O
C	O
(	O
Sigma	O
)	O
and	O
washed	O
before	O
co	O
-	O
culture	O
with	O
the	O
T	O
cells	O
.	O

The	O
requirement	O
for	O
antigen	O
processing	O
was	O
determined	O
by	O
preincubating	O
the	O
presenting	O
cells	O
with	O
chloroquine	O
(	O
Sigma	O
)	O
for	O
30	O
min	O
before	O
pulsing	O
with	O
500	O
μg	O
/	O
ml	O
d	O
-pen	O
for	O
4	O
h	O
,	O
after	O
which	O
the	O
cells	O
were	O
washed	O
and	O
plated	O
routinely	O
.	O

To	O
confirm	O
their	O
subsequent	O
viability	O
,	O
we	O
checked	O
their	O
capacity	O
to	O
present	O
peptide	O
antigen	O
to	O
a	O
well	O
characterized	O
T	O
cell	O
clone	O
,	O
TB-2	O
,	O
that	O
recognizes	O
a	O
fragment	O
of	O
the	O
α	O
subunit	O
of	O
the	O
AChR	O
,	O
α:144–163	O
,	O
presented	O
by	O
DR52a	O
(	O
Nagvekar	O
et	O
al.	O
,	O
1998	O
)	O
.	O

3	O
Results	O
3.1	O
Initial	O
T	O
cell	O
responses	O
to	O
d	O
-pen	O
In	O
a	O
preliminary	O
screen	O
using	O
d	O
-pen	O
at	O
500	O
μg	O
/	O
ml	O
,	O
we	O
found	O
positive	O
responses	O
by	O
PBL	O
T	O
cells	O
(	O
SI>2	O
)	O
in	O
four	O
of	O
five	O
RA	O
patients	B
with	O
recent	O
onset	O
d	O
-pen	O
MG	O
(	O
SIs	O
3–12	O
)	O
;	O
in	O
one	O
of	O
four	O
RA	O
patients	B
without	O
MG	O
or	O
anti	O
-	O
AChR	O
antibodies	O
despite	O
d	O
-pen	O
treatment	O
(	O
SI	O
4.1	O
)	O
;	O
in	O
zero	O
of	O
three	O
patients	B
with	O
idiopathic	O
EOMG	O
and	O
in	O
4	O
of	O
11	O
healthy	O
controls	O
(	O
SI	O
2.3	O
,	O
4.5	O
,	O
4.8	O
and	O
15.0	O
)	O
.	O

All	O
of	O
the	O
d	O
-pen	O
MG	O
patients	B
had	O
HLA	O
-	O
DR1	O
,	O
as	O
did	O
the	O
one	O
other	O
responder	O
with	O
RA	O
.	O

However	O
,	O
none	O
of	O
the	O
healthy	O
responders	O
was	O
DR1	O
+	O
;	O
some	O
of	O
their	O
responses	O
might	O
conceivably	O
be	O
related	O
to	O
prior	O
exposure	O
to	O
penicillin	O
.	O

Only	O
one	O
of	O
the	O
responder	O
d	O
-pen	O
MG	O
patients	B
(	O
D	B
-	I
P1	I
;	O
SI	O
4.3	O
)	O
was	O
tested	O
before	O
taking	O
corticosteroids	O
;	O
as	O
she	O
was	O
readily	O
available	O
for	O
further	O
sampling	O
,	O
T	O
cell	O
lines	O
were	O
initiated	O
from	O
her	O
for	O
detailed	O
characterization	O
of	O
this	O
response	O
.	O

3.2	O
Selecting	O
d	O
-pen	O
-	O
responsive	O
T	O
cell	O
lines	O
and	O
clones	O
from	O
patient	B
D	I
-	I
P1	I
Several	O
T	O
cell	O
lines	O
were	O
successfully	O
raised	O
and	O
maintained	O
by	O
culturing	O
with	O
d	O
-pen	O
at	O
500	O
μg	O
/	O
ml	O
.	O

Three	O
findings	O
established	O
that	O
this	O
drug	O
was	O
not	O
merely	O
acting	O
as	O
a	O
non	O
-	O
specific	O
mitogen	O
.	O

Firstly	O
,	O
two	O
well	O
-	O
characterized	O
AChR	O
-	O
specific	O
T	O
cell	O
clones	O
,	O
TB-2	O
and	O
PM	O
-	O
A1	O
,	O
failed	O
to	O
show	O
any	O
proliferative	O
response	O
to	O
d	O
-pen	O
at	O
50–500	O
μg	O
/	O
ml	O
(	O
not	O
shown	O
)	O
.	O

Secondly	O
,	O
the	O
drug	O
-	O
specific	O
lines	O
also	O
responded	O
optimally	O
to	O
autologous	O
APC	O
preincubated	O
with	O
the	O
drug	O
for	O
4	O
h	O
and	O
then	O
washed	O
thoroughly	O
,	O
while	O
unpulsed	O
autologous	O
APC	O
failed	O
to	O
stimulate	O
.	O

Thirdly	O
,	O
there	O
was	O
no	O
response	O
when	O
the	O
APC	O
were	O
HLA	O
-	O
mismatched	O
(	O
see	O
below	O
)	O
.	O

3.3	O
Characteristics	O
of	O
d	O
-pen	O
-	O
specific	O
T	O
cell	O
clones	O
The	O
d	O
-pen	O
-	O
specific	O
line	O
that	O
showed	O
the	O
greatest	O
response	O
to	O
the	O
drug	O
was	O
cloned	O
by	O
limiting	O
dilution	O
in	O
the	O
presence	O
of	O
d	O
-pen	O
-	O
prepulsed	O
autologous	O
PBMCx	O
.	O

Among	O
the	O
175	O
clones	O
grown	O
,	O
40	O
%	O
(	O
70	O
)	O
responded	O
to	O
d	O
-pen	O
(	O
SI>5	O
)	O
,	O
showing	O
that	O
there	O
was	O
a	O
high	O
precursor	O
frequency	O
of	O
d	O
-pen	O
-	O
specific	O
T	O
cells	O
in	O
the	O
line	O
.	O

Some	O
10	O
clones	O
were	O
chosen	O
for	O
further	O
study	O
;	O
they	O
were	O
all	O
CD3	O
+	O
CD4	O
+	O
and	O
behaved	O
identically	O
in	O
all	O
experiments	O
,	O
responding	O
to	O
autologous	O
PBMCx	O
preincubated	O
with	O
d	O
-pen	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
)	O
.	O

Moreover	O
,	O
the	O
clones	O
were	O
highly	O
specific	O
for	O
l	O
-pen	O
,	O
as	O
shown	O
by	O
their	O
failure	O
to	O
respond	O
to	O
the	O
analogues	O
d	O
-pen	O
and	O
d	O
-cysteine	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
10	O
clones	O
tested	O
all	O
proved	O
to	O
be	O
restricted	O
to	O
HLA	O
-	O
DR1	O
.	O

An	O
isotype	O
-	O
specific	O
anti	O
-	O
HLA	O
-	O
DR	O
mAb	O
almost	O
completely	O
blocked	O
the	O
responses	O
of	O
these	O
clones	O
(	O
Fig.	O
3	O
a	O
)	O
;	O
furthermore	O
,	O
they	O
all	O
recognized	O
d	O
-pen	O
-	O
pulsed	O
PBMCx	O
from	O
a	O
number	O
of	O
healthy	O
DR1	O
+	O
individuals	O
(	O
Fig.	O
3	O
b	O
)	O
.	O

The	O
two	O
clones	O
tested	O
were	O
both	O
phenotypically	O
Th1	O
,	O
producing	O
large	O
amounts	O
of	O
IFN	O
-	O
γ	O
(	O
2	O
×	O
104	O
pg	O
/	O
ml	O
)	O
,	O
but	O
no	O
detectable	O
IL-4	O
(	O
not	O
shown	O
)	O
.	O

They	O
proved	O
to	O
have	O
identical	O
TCR	O
gene	O
usage	O
,	O
namely	O
Vα4.1	O
,	O
Jα1.3	O
,	O
Vβ6.1	O
,	O
Jβ2.3	O
,	O
suggesting	O
that	O
they	O
are	O
sister	O
clones	O
.	O

Intriguingly	O
,	O
this	O
β	O
chain	O
sequence	O
shares	O
a	O
PG	O
motif	O
in	O
the	O
CDR3	O
region	O
(	O
Fig.	O
4	O
)	O
with	O
a	O
previously	O
characterized	O
AChR	O
ε	O
-	O
specific	O
T	O
cell	O
clone	O
isolated	O
from	O
a	O
patient	B
with	O
EOMG	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

3.4	O
Potential	O
`	O
carrier	O
'	O
molecules	O
for	O
d	O
-pen	O
To	O
determine	O
whether	O
the	O
d	O
-pen	O
was	O
coupling	O
to	O
a	O
serum	O
protein	O
,	O
PBMCx	O
were	O
pulsed	O
with	O
d	O
-pen	O
in	O
the	O
presence	O
or	O
absence	O
of	O
serum	O
.	O

Regardless	O
of	O
whether	O
we	O
used	O
5	O
%	O
human	B
or	O
fetal	O
calf	B
serum	O
,	O
serum	O
-	O
free	O
AIM	O
V	O
®	O
medium	O
(	O
containing	O
human	B
albumin	O
,	O
transferrin	O
and	O
insulin	O
)	O
or	O
even	O
plain	O
RPMI	O
,	O
the	O
PBMCx	O
all	O
stimulated	O
the	O
two	O
T	O
cell	O
clones	O
tested	O
very	O
efficiently	O
(	O
Fig.	O
5	O
)	O
.	O

This	O
result	O
suggested	O
that	O
the	O
drug	O
was	O
coupling	O
to	O
pre	O
-	O
existing	O
cellular	O
proteins	O
,	O
whether	O
internal	O
or	O
on	O
the	O
surface	O
.	O

To	O
determine	O
whether	O
these	O
require	O
further	O
processing	O
,	O
we	O
tested	O
the	O
effects	O
of	O
chloroquine	O
,	O
a	O
potent	O
lysosomotropic	O
inhibitor	O
of	O
antigen	O
processing	O
(	O
Ziegler	O
and	O
Unanue	O
,	O
1982	O
)	O
.	O

As	O
a	O
standard	O
,	O
we	O
used	O
the	O
response	O
of	O
clone	O
TB-2	O
to	O
both	O
the	O
full	O
-	O
length	O
AChR	O
α	O
subunit	O
(	O
α:1–437	O
)	O
,	O
which	O
requires	O
processing	O
,	O
and	O
its	O
peptide	O
,	O
α:144–163	O
,	O
which	O
does	O
not	O
(	O
Fig.	O
6	O
)	O
.	O

Pretreatment	O
of	O
PBMCx	O
with	O
chloroquine	O
had	O
no	O
detectable	O
effect	O
on	O
the	O
responses	O
to	O
d	O
-pen	O
or	O
α:144–163	O
at	O
doses	O
that	O
almost	O
completely	O
abolished	O
those	O
to	O
the	O
full	O
-	O
length	O
α:1–437	O
(	O
Fig.	O
6	O
b	O
)	O
,	O
clearly	O
showing	O
that	O
the	O
key	O
molecules	O
modified	O
by	O
d	O
-pen	O
do	O
not	O
require	O
subsequent	O
processing	O
.	O

Thus	O
,	O
these	O
data	O
strongly	O
suggest	O
that	O
d	O
-pen	O
is	O
acting	O
by	O
directly	O
coupling	O
to	O
a	O
component	O
of	O
the	O
MHC	O
/	O
peptide	O
complex	O
.	O

It	O
was	O
therefore	O
intriguing	O
that	O
two	O
different	O
DR1	O
+	O
EBV	O
-	O
B	O
cell	O
lines	O
(	O
one	O
of	O
them	O
autologous	O
)	O
consistently	O
failed	O
to	O
`	O
present	O
'	O
d	O
-pen	O
to	O
the	O
clones	O
;	O
this	O
deficiency	O
was	O
not	O
corrected	O
by	O
pre	O
-	O
culturing	O
the	O
EBV	O
-	O
B	O
cells	O
in	O
human	B
serum	O
rather	O
than	O
the	O
FCS	O
in	O
which	O
these	O
cells	O
were	O
normally	O
maintained	O
(	O
Fig.	O
7	O
)	O
.	O

The	O
autologous	O
B	O
cell	O
line	O
,	O
which	O
also	O
has	O
HLA	O
-	O
DR52a	O
,	O
presented	O
specific	O
peptides	O
very	O
well	O
to	O
the	O
DR52a	O
-	O
restricted	O
clone	O
TB-2	O
when	O
tested	O
in	O
parallel	O
,	O
confirming	O
its	O
efficient	O
antigen	O
-	O
presenting	O
ability	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
these	O
T	O
cells	O
are	O
recognizing	O
a	O
modification	O
of	O
some	O
resident	O
peptide	O
,	O
rather	O
than	O
of	O
the	O
DR1	O
itself	O
,	O
and	O
that	O
this	O
peptide	O
differs	O
in	O
the	O
PBMC	O
and	O
the	O
B	O
cell	O
lines	O
.	O

4	O
Discussion	O
In	O
this	O
study	O
on	O
d	O
-pen	O
-	O
induced	O
MG	O
,	O
we	O
report	O
the	O
isolation	O
and	O
characterization	O
of	O
CD4	O
+	O
Th1	O
cell	O
clones	O
specific	O
for	O
d	O
-pen	O
,	O
which	O
recognized	O
DR1	O
+	O
APC	O
preincubated	O
with	O
the	O
drug	O
.	O

Our	O
evidence	O
suggests	O
that	O
it	O
is	O
acting	O
by	O
directly	O
modifying	O
pre	O
-	O
existing	O
MHC	O
molecules	O
and/or	O
resident	O
peptides	O
on	O
the	O
APC	O
surface	O
,	O
though	O
the	O
nature	O
of	O
this	O
modification	O
still	O
requires	O
elucidation	O
.	O

Responses	O
of	O
these	O
T	O
cells	O
became	O
significant	O
at	O
approximately	O
50	O
μg	O
/	O
ml	O
of	O
d	O
-pen	O
,	O
and	O
optimal	O
at	O
500	O
μg	O
/	O
ml	O
;	O
the	O
latter	O
is	O
very	O
similar	O
to	O
that	O
previously	O
used	O
in	O
vitro	O
for	O
d	O
-pen	O
-	O
specific	O
T	O
cells	O
isolated	O
from	O
experimental	O
animals	B
immunized	O
with	O
the	O
drug	O
(	O
O'Donnell	O
and	O
Coleman	O
,	O
1992	O
)	O
.	O

It	O
apparently	O
contrasts	O
with	O
the	O
peak	O
levels	O
of	O
about	O
5	O
μg	O
/	O
ml	O
measured	O
in	O
the	O
peripheral	O
blood	O
of	O
patients	B
taking	O
750	O
mg	O
/	O
day	O
(	O
Brooks	O
et	O
al.	O
,	O
1984	O
)	O
.	O

However	O
,	O
much	O
higher	O
doses	O
are	O
usually	O
required	O
in	O
culture	O
than	O
in	O
vivo	O
,	O
as	O
has	O
been	O
observed	O
previously	O
with	O
other	O
drugs	O
such	O
as	O
sulfonamides	O
,	O
carbamazepine	O
and	O
phenytoin	O
(	O
Mauri	O
-	O
Hellweg	O
et	O
al.	O
,	O
1995	O
)	O
,	O
as	O
well	O
as	O
with	O
d	O
-pen	O
itself	O
(	O
O'Donnell	O
and	O
Coleman	O
,	O
1992	O
)	O
.	O

It	O
therefore	O
seems	O
likely	O
that	O
,	O
in	O
vivo	O
,	O
the	O
drug	O
becomes	O
concentrated	O
in	O
specialized	O
microenvironments	O
or	O
reactive	O
under	O
conditions	O
that	O
are	O
not	O
reproduced	O
in	O
culture	O
,	O
and/or	O
that	O
prolonged	O
exposure	O
is	O
required	O
.	O

It	O
is	O
well	O
recognized	O
that	O
d	O
-pen	O
can	O
couple	O
directly	O
to	O
proteins	O
,	O
forming	O
disulfide	O
bonds	O
with	O
free	O
cysteine	O
residues	O
(	O
Coleman	O
et	O
al.	O
,	O
1988	O
):	O
it	O
can	O
also	O
break	O
pre	O
-	O
existing	O
disulfide	O
bonds	O
,	O
and	O
so	O
unfold	O
proteins	O
or	O
disaggregate	O
complexes	O
.	O

Several	O
published	O
reports	O
demonstrate	O
that	O
it	O
couples	O
directly	O
to	O
the	O
surface	O
of	O
presenting	O
cells	O
of	O
experimental	O
animals	B
in	O
vivo	O
,	O
though	O
the	O
identity	O
of	O
the	O
target	O
protein	O
(	O
s	O
)	O
has	O
not	O
been	O
determined	O
.	O

At	O
doses	O
of	O
125–1000	O
μg	O
/	O
ml	O
,	O
d	O
-pen	O
rapidly	O
couples	O
directly	O
to	O
the	O
surface	O
of	O
rat	B
macrophages	O
,	O
a	O
process	O
that	O
is	O
not	O
affected	O
by	O
cell	O
fixation	O
or	O
chloroquine	O
,	O
but	O
is	O
enhanced	O
by	O
oxidizing	O
agents	O
(	O
O'Donnell	O
et	O
al.	O
,	O
1991	O
)	O
.	O

These	O
cells	O
take	O
up	O
the	O
labeled	O
drug	O
in	O
a	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
and	O
retain	O
it	O
for	O
over	O
24	O
h.	O
In	O
contrast	O
,	O
although	O
lymphocytes	O
rapidly	O
acquire	O
labeled	O
d	O
-pen	O
,	O
they	O
also	O
lose	O
it	O
completely	O
within	O
2	O
h	O
(	O
Binderup	O
and	O
Arrigoni	O
-	O
Martelli	O
,	O
1979	O
)	O
.	O

Our	O
present	O
results	O
also	O
suggest	O
that	O
d	O
-pen	O
is	O
acting	O
by	O
coupling	O
directly	O
to	O
the	O
APC	O
,	O
and	O
it	O
seems	O
logical	O
to	O
suppose	O
that	O
its	O
target	O
is	O
the	O
class	O
II	O
/	O
peptide	O
complex	O
.	O

Since	O
there	O
is	O
a	O
well	O
-	O
known	O
association	O
with	O
HLA	O
-	O
DR1	O
in	O
d	O
-pen	O
-	O
induced	O
MG	O
(	O
Garlepp	O
et	O
al.	O
,	O
1983	O
)	O
,	O
the	O
uniform	O
restriction	O
of	O
our	O
clones	O
to	O
this	O
allele	O
argues	O
strongly	O
for	O
their	O
disease	O
-	O
relevance	O
.	O

This	O
would	O
be	O
further	O
supported	O
if	O
the	O
same	O
modification	O
were	O
already	O
present	O
in	O
vivo	O
on	O
the	O
APC	O
of	O
DR1	O
+	O
MG	O
patients	B
taking	O
d	O
-pen	O
,	O
and	O
recognizable	O
by	O
the	O
D	O
-	O
P1	O
T	O
cells	O
.	O

We	O
were	O
unable	O
to	O
test	O
this	O
possibility	O
because	O
our	O
patient	B
had	O
stopped	O
the	O
treatment	O
before	O
enrolment	O
in	O
the	O
study	O
.	O

Several	O
other	O
drugs	O
/	O
haptens	O
are	O
known	O
to	O
couple	O
either	O
to	O
peptides	O
resident	O
in	O
the	O
MHC	O
groove	O
or	O
directly	O
to	O
MHC	O
molecules	O
.	O

Examples	O
of	O
the	O
former	O
include	O
trinitrophenyl	O
(	O
TNP	O
)	O
and	O
penicillin	O
which	O
both	O
couple	O
to	O
lysine	O
residues	O
(	O
Martin	O
et	O
al.	O
,	O
1992	O
;	O
Padovan	O
et	O
al.	O
,	O
1997	O
)	O
,	O
and	O
nickel	O
which	O
couples	O
to	O
histidines	O
(	O
Romagnoli	O
et	O
al.	O
,	O
1992	O
)	O
,	O
while	O
gold	O
salts	O
are	O
thought	O
to	O
directly	O
modify	O
the	O
class	O
II	O
molecule	O
(	O
Sinigaglia	O
,	O
1994	O
)	O
.	O

Although	O
further	O
work	O
is	O
required	O
to	O
determine	O
which	O
of	O
these	O
two	O
possibilities	O
applies	O
to	O
d	O
-pen	O
,	O
it	O
is	O
worthy	O
of	O
note	O
that	O
HLA	O
-	O
DR1	O
is	O
the	O
only	O
human	B
DR	O
molecule	O
that	O
has	O
an	O
unpaired	O
cysteine	O
residue	O
.	O

It	O
is	O
at	O
position	O
30	O
in	O
the	O
floor	O
of	O
the	O
peptide	O
-	O
binding	O
groove	O
(	O
Stern	O
et	O
al.	O
,	O
1994	O
)	O
,	O
where	O
modification	O
of	O
analogous	O
amino	O
acids	O
in	O
other	O
HLA	O
alleles	O
can	O
dramatically	O
alter	O
T	O
cell	O
recognition	O
of	O
the	O
epitope	O
peptides	O
(	O
Krieger	O
et	O
al.	O
,	O
1991	O
;	O
Boehncke	O
et	O
al.	O
,	O
1993	O
)	O
.	O

Work	O
on	O
the	O
class	O
I	O
allele	O
HLA	O
-	O
B27	O
also	O
suggests	O
that	O
oxidative	O
modification	O
of	O
the	O
unusual	O
free	O
sulfhydryl	O
group	O
(	O
67	O
Cys	O
)	O
on	O
this	O
HLA	O
molecule	O
can	O
directly	O
influence	O
its	O
immunogenicity	O
(	O
Archer	O
et	O
al.	O
,	O
1990	O
)	O
.	O

The	O
failure	O
of	O
the	O
d	O
-pen	O
-	O
treated	O
B	O
cell	O
lines	O
to	O
stimulate	O
our	O
clones	O
is	O
intriguing	O
and	O
argues	O
that	O
the	O
drug	O
was	O
modifying	O
distinctive	O
resident	O
peptides	O
in	O
the	O
autologous	O
PBMC	O
that	O
are	O
not	O
identical	O
in	O
the	O
B	O
cell	O
lines	O
.	O

It	O
would	O
therefore	O
be	O
interesting	O
to	O
identify	O
the	O
key	O
cell	O
type	O
in	O
the	O
PBMC	O
(	O
e.g.	O
,	O
macrophage	O
or	O
dendritic	O
cell	O
)	O
.	O

One	O
might	O
then	O
,	O
in	O
principle	O
,	O
take	O
advantage	O
of	O
this	O
failure	O
by	O
comparing	O
the	O
peptides	O
that	O
react	O
with	O
labeled	O
d	O
-pen	O
in	O
these	O
cells	O
and	O
in	O
the	O
B	O
cell	O
lines	O
,	O
though	O
they	O
may	O
be	O
too	O
heterogeneous	O
to	O
allow	O
precise	O
identification	O
of	O
the	O
key	O
epitope	O
(	O
s	O
)	O
.	O

Remarkably	O
,	O
however	O
,	O
one	O
resident	O
AChR	O
peptide	O
has	O
already	O
been	O
identified	O
in	O
a	O
DR3	O
+	O
B	O
cell	O
line	O
(	O
Chicz	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
d	O
-pen	O
-	O
specific	O
clones	O
characterized	O
here	O
could	O
provide	O
important	O
clues	O
to	O
the	O
pathogenesis	O
of	O
both	O
drug	O
-	O
induced	O
and	O
idiopathic	O
MG	O
.	O

The	O
first	O
obvious	O
mechanism	O
is	O
that	O
d	O
-pen	O
-	O
modified	O
peptides	O
activate	O
T	O
cells	O
that	O
can	O
cross	O
-	O
react	O
with	O
epitopes	O
derived	O
from	O
the	O
AChR	O
,	O
though	O
it	O
is	O
hard	O
to	O
envisage	O
the	O
exact	O
nature	O
of	O
such	O
cross	O
-	O
reactions	O
,	O
and	O
,	O
as	O
yet	O
,	O
there	O
is	O
no	O
direct	O
evidence	O
for	O
them	O
.	O

In	O
fact	O
,	O
the	O
clone	O
we	O
tested	O
showed	O
no	O
detectable	O
recognition	O
of	O
either	O
AChR	O
or	O
its	O
α	O
,	O
γ	O
or	O
ε	O
subunits	O
after	O
these	O
were	O
pre	O
-	O
incubated	O
with	O
d	O
-pen	O
(	O
not	O
shown	O
)	O
,	O
though	O
some	O
of	O
the	O
69	O
other	O
clones	O
may	O
be	O
sufficiently	O
sensitive	O
to	O
do	O
so	O
.	O

We	O
also	O
tested	O
five	O
patients	B
with	O
d	O
-pen	O
-	O
induced	O
MG	O
for	O
recognition	O
of	O
the	O
untreated	O
AChR	O
α	O
-	O
subunit	O
(	O
present	O
in	O
all	O
isoforms	O
)	O
,	O
the	O
fetal	O
-	O
specific	O
γ	O
and	O
the	O
adult	O
-	O
specific	O
ε	O
.	O

Interestingly	O
,	O
in	O
four	O
of	O
these	O
five	O
cases	O
,	O
we	O
saw	O
responses	O
to	O
the	O
ε	O
rather	O
than	O
the	O
other	O
subunits	O
(	O
not	O
shown	O
)	O
.	O

Since	O
the	O
present	O
case	O
(	O
D	B
-	I
P1	I
)	O
again	O
appeared	O
to	O
be	O
representative	O
,	O
we	O
went	O
on	O
to	O
isolate	O
clones	O
that	O
proved	O
to	O
be	O
specific	O
for	O
the	O
ε:201–219	O
sequence	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

This	O
also	O
appears	O
to	O
be	O
a	O
dominant	O
epitope	O
for	O
EOMG	O
patients	B
and	O
is	O
presented	O
by	O
the	O
candidate	O
susceptibility	O
allele	O
,	O
DR52a	O
(	O
Hill	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Thus	O
,	O
one	O
might	O
hypothesize	O
that	O
AChR	O
-	O
cross	O
-	O
reactive	O
T	O
cells	O
initially	O
activated	O
by	O
d	O
-pen	O
lead	O
,	O
by	O
a	O
process	O
of	O
determinant	O
spreading	O
,	O
to	O
responsiveness	O
to	O
the	O
ε	O
subunit	O
that	O
then	O
induces	O
a	O
pathogenic	O
autoantibody	O
response	O
,	O
as	O
in	O
idiopathic	O
MG	O
.	O

These	O
T	O
cells	O
would	O
be	O
well	O
equipped	O
to	O
help	O
in	O
the	O
generation	O
of	O
complement	O
-	O
fixing	O
antibodies	O
by	O
virtue	O
of	O
their	O
Th1	O
cytokine	O
profile	O
.	O

However	O
,	O
whereas	O
this	O
response	O
appears	O
to	O
be	O
self	O
-	O
perpetuating	O
in	O
EOMG	O
,	O
the	O
antibody	O
titers	O
usually	O
fall	O
upon	O
withdrawal	O
of	O
d	O
-pen	O
,	O
with	O
concomitant	O
remission	O
of	O
symptoms	O
.	O

A	O
second	O
possibility	O
is	O
that	O
d	O
-pen	O
directly	O
`	O
haptenates	O
'	O
AChR	O
and/or	O
AChR	O
fragments	O
that	O
then	O
activate	O
pathogenic	O
T	O
cells	O
.	O

Hence	O
,	O
it	O
is	O
interesting	O
that	O
the	O
above	O
ε:201–219	O
sequence	O
includes	O
an	O
unpaired	O
210	O
Cys	O
at	O
p6	O
in	O
the	O
epitope	O
core	O
(	O
Beeson	O
et	O
al.	O
,	O
1993	O
)	O
.	O

This	O
residue	O
appears	O
to	O
be	O
important	O
for	O
T	O
cell	O
recognition	O
,	O
since	O
pre	O
-	O
exposure	O
to	O
d	O
-pen	O
prevented	O
this	O
peptide	O
from	O
stimulating	O
another	O
ε201–219-specific	O
clone	O
from	O
an	O
EOMG	O
patient	B
(	O
unpublished	O
observations	O
)	O
.	O

Hence	O
,	O
this	O
sequence	O
itself	O
may	O
be	O
an	O
alternative	O
target	O
for	O
d	O
-pen	O
modification	O
.	O

In	O
either	O
case	O
,	O
it	O
is	O
a	O
particularly	O
intriguing	O
possibility	O
that	O
d	O
-pen	O
is	O
mimicking	O
the	O
action	O
of	O
an	O
as	O
yet	O
unidentified	O
natural	O
`	O
counterpart	O
'	O
that	O
is	O
responsible	O
for	O
initiating	O
the	O
idiopathic	O
disease	O
.	O

An	O
analogous	O
process	O
has	O
been	O
implicated	O
in	O
other	O
conditions	O
presenting	O
with	O
autoimmune	O
features	O
such	O
as	O
the	O
plant	B
amino	O
acid	O
,	O
canavanine	O
,	O
in	O
SLE	O
,	O
and	O
an	O
analogue	O
of	O
l	O
-tryptophan	O
,	O
1,1′-ethylidenebis	O
[	O
l	O
-tryptophan	O
]	O
that	O
is	O
thought	O
to	O
induce	O
Eosinophilia	O
–	O
Myalgia	O
syndrome	O
(	O
Yoshida	O
and	O
Gershwin	O
,	O
1993	O
)	O
.	O

Although	O
definitive	O
proof	O
that	O
these	O
agents	O
are	O
responsible	O
for	O
causing	O
disease	O
is	O
awaited	O
,	O
the	O
latter	O
compound	O
has	O
been	O
shown	O
to	O
be	O
incorporated	O
into	O
self	O
-	O
proteins	O
,	O
apparently	O
creating	O
novel	O
epitopes	O
(	O
Buss	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Anti	O
-	O
hapten	O
responses	O
have	O
also	O
been	O
implicated	O
in	O
active	O
ankylosing	O
spondylitis	O
by	O
the	O
isolation	O
of	O
HLA	O
-	O
B27-restricted	O
cytotoxic	O
T	O
cells	O
that	O
recognize	O
both	O
APC	O
treated	O
with	O
the	O
compound	O
homocysteine	O
and	O
B	O
cells	O
infected	O
with	O
Salmonella	B
typhimurium	I
(	O
Gao	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
summary	O
,	O
the	O
isolation	O
and	O
characterization	O
of	O
these	O
d	O
-pen	O
-	O
specific	O
T	O
cell	O
clones	O
should	O
provide	O
a	O
useful	O
experimental	O
system	O
with	O
which	O
to	O
elucidate	O
the	O
basis	O
of	O
hapten	O
recognition	O
by	O
human	B
T	O
cells	O
,	O
and	O
perhaps	O
also	O
the	O
mechanisms	O
of	O
drug	O
-	O
induced	O
autoimmune	O
disease	O
.	O

Ultimately	O
it	O
may	O
also	O
provide	O
insights	O
into	O
the	O
factors	O
involved	O
in	O
the	O
initiation	O
of	O
idiopathic	O
MG	O
.	O

Acknowledgements	O

We	O
are	O
very	O
grateful	O
to	O
several	O
colleagues	O
for	O
referring	O
patients	B
or	O
providing	O
mAbs	O
,	O
to	O
donor	O
D	B
-	I
P1	I
and	O
to	O
Drs	O
.	O

E.	O
Sim	O
,	O
J.	O
Coleman	O
and	O
A.	O
Vincent	O
for	O
invaluable	O
suggestions	O
and	O
advice	O
.	O

MEH	O
was	O
supported	O
by	O
the	O
Medical	O
Research	O
Council	O
of	O
Great	O
Britain	O
.	O

Human	B
fascioliasis	O
,	O
caused	O
by	O
Fasciola	B
hepatica	I
,	I
is	O
a	O
great	O
worldwide	O
health	O
problem	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
;	O
ESTEBAN	O
et	O
al.	O
,	O
1998e	O
)	O
.	O

Several	O
areas	O
have	O
been	O
de-	O
scribed	O
as	O
presenting	O
true	O
human	B
endemics	O
,	O
ranging	O
from	O
low	O
to	O
very	O
high	O
prevalences	O
and	O
intensities	O
(	O
MAS	O
-	O
COMA	O
al.	O
,	O
1999a	O
)	O
.	O

Studies	O
carried	O
out	O
in	O
recent	O
years	O
have	O
demonstrated	O
that	O
the	O
most	O
important	O
human	B
fascioliasis	O
endemic	O
regions	O
are	O
located	O
in	O
South	O
America	O
(	O
MAS	O
-	O
COMAetfl	O
/	O
.	O
,	O
1995	O
,	O
1999a	O
;	O
WHO	O
,	O
1995;HlLLYER	O
&	O
APT	O
,	O
1997	O
;	O
ESTEBAN	O
et	O
al.	O
,	O
1998e	O
)	O
.	O

Coprological	O
(	O
MAS	O
-	O
COMA	O
al.	O
,	O
1995	O
;	O
ESTEBAN	O
al.	O
,	O
1997a	O
,	O
1997b	O
)	O
and	O
immunological	O
surveys	O
(	O
HILLYER	O
et	O
al.	O
,	O
1992	O
;	O
BJORLAND	O
et	O
al.	O
,	O
1995	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1995	O
;	O
O'NEILL	O
et	O
al.	O
,	O
1998	O
)	O
,	O
concerning	O
either	O
a	O
given	O
locality	O
or	O
only	O
a	O
very	O
few	O
,	O
have	O
shown	O
that	O
the	O
Northern	O
Bolivian	O
Altiplano	O
,	O
between	O
Lake	O
Titicaca	O
and	O
the	O
valley	O
of	O
the	O
city	O
of	O
La	O
Paz	O
,	O
presents	O
high	O
human	B
prevalences	O
and	O
intensities	O
.	O

Concerning	O
the	O
intermediate	O
snail	O
host	O
involved	O
,	O
despite	O
initial	O
reports	O
of	O
2	O
different	O
lymnaeid	O
transmit-	O
ting	O
species	O
(	O
Lymnaea	B
matrix	I
and	O
L.	B
cubensis	I
)	O
in	O
the	O
Bolivian	O
Altiplano	O
(	O
UENO	O
et	O
al.	O
,	O
1975	O
)	O
,	O
it	O
has	O
been	O
recently	O
demonstrated	O
that	O
only	O
1	O
transmitting	O
species	O
is	O
there	O
.	O

Shell	O
morphology	O
and	O
visceral	O
mass	O
anatomy	O
(	O
OVIEDO	O
et	O
al.	O
,	O
1995	O
)	O
,	O
and	O
molecular	O
(	O
BARGUES	O
&	O
MAS-	O
COMA	O
,	O
1997	O
;	O
BARGUES	O
et	O
al.	O
,	O
1997	O
)	O
and	O
isoenzyme	O
(	O
JABBOUR	O
-	O
ZAHAB	O
et	O
al.	O
,	O
1997	O
)	O
studies	O
have	O
proved	O
that	O
this	O
species	O
is	O
the	O
European	O
L.	B
truncatula	I
,	O
most	O
probably	O
introduced	O
by	O
Spanish	B
colonizers	I
long	O
ago	O
.	O

Investigations	O
carried	O
out	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
have	O
shown	O
that	O
there	O
are	O
different	O
animal	B
species	O
which	O
play	O
the	O
role	O
of	O
reservoirs	O
and	O
others	O
that	O
are	O
potential	O
definitive	O
hosts	O
(	O
UENO	O
&	O
MORALES	O
,	O
1973	O
;	O
UENO	O
et	O
al.	O
,	O
1975	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1995	O
,	O
1997	O
;	O
HILLYER	O
et	O
al.	O
,	O
1996	O
;	O
BUCHON	O
et	O
al.	O
,	O
1997	O
;	O
FUENTES	O
et	O
al.	O
,	O
1997	O
;	O
GROCK	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Sheep	B
may	O
be	O
consid-	O
ered	O
the	O
most	O
important	O
reservoir	O
(	O
GROCK	O
et	O
al.	O
,	O
1998	O
)	O
,	O
followed	O
by	O
cattle	B
(	O
BUCHON	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Pigs	B
and	O
donkeys	B
represent	O
effective	O
secondary	O
reservoir	O
hosts	O
of	O
the	O
parasite	B
in	O
this	O
area	O
and	O
must	O
also	O
be	O
taken	O
into	O
account	O
within	O
preventive	O
and	O
control	O
measures	O
(	O
MAS-	O
Address	O
for	O
correspondence	O
:	O
Professor	O
Dr	O
Jose	O
-	O
Guillermo	O
Esteban	O
,	O
Department	O
of	O
Parasitology	O
,	O
Faculty	O
of	O
Pharmacy	O
,	O
University	O
of	O
Valencia	O
,	O
Av	O
.	O

Vicente	O
Andres	O
Estelies	O
s	O
/	O
n	O
,	O
46100	O
Burjassot	O
-	O
Valencia	O
,	O
Spain	O
;	O
phone	O
+	O
34	O
96	O
3864298	O
,	O
fax	O
+	O
34	O
96	O
3864769	O
,	O
e	O
-	O
mail	O
jguillermo	O
.	O

esteban@uv.es	O
COMA	O
al.	O
,	O
1997	O
)	O
.	O

Horses	B
,	O
goats	B
,	O
llamas	B
and	O
alpacas	B
,	O
as	O
well	O
as	O
rabbits	B
,	O
hares	B
and	O
rodents	B
,	O
do	O
not	O
participate	O
in	O
the	O
transmission	O
(	O
FUENTES	O
et	O
al.	O
,	O
1997	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
present	O
and	O
analyse	O
the	O
results	O
obtained	O
in	O
31	O
coprological	O
surveys	O
including	O
different	O
Altiplanic	O
localities	O
.	O

The	O
purpose	O
is	O
to	O
obtain	O
a	O
general	O
overview	O
of	O
human	B
infection	O
prevalences	O
and	O
intensities	O
throughout	O
the	O
endemic	O
zone	O
.	O

This	O
is	O
the	O
first	O
time	O
that	O
such	O
a	O
large	O
epidemiological	O
study	O
of	O
a	O
human	B
fascioliasis	O
area	O
has	O
been	O
carried	O
out	O
.	O

Materials	O
and	O
Methods	O
This	O
study	O
was	O
conducted	O
in	O
the	O
Department	O
of	O
La	O
Paz	O
,	O
Bolivia	O
,	O
and	O
more	O
specifically	O
in	O
a	O
region	O
of	O
the	O
Northern	O
Bolivian	O
Altiplano	O
,	O
between	O
Lake	O
Titicaca	O
and	O
the	O
valley	O
of	O
the	O
city	O
of	O
La	O
Paz	O
,	O
at	O
a	O
very	O
high	O
altitude	O
(	O
3800	O
-	O
4200	O
m	O
)	O
(	O
Figure	O
)	O
.	O

The	O
surface	O
area	O
and	O
human	B
population	O
characteristics	O
of	O
this	O
zone	O
have	O
already	O
been	O
summarized	O
m	O
a	O
balantidiasis	O
study	O
concerning	O
the	O
same	O
area	O
(	O
ESTEBAN	O
etal	O
.	O
,	O
1998b	O
)	O
.	O

A	O
total	O
of	O
31	O
coprological	O
surveys	O
were	O
carried	O
out	O
in	O
24	O
localities	O
over	O
the	O
6-year	O
period	O
1992	O
-	O
97	O
(	O
Table	O
1	O
)	O
.	O

These	O
surveys	O
involved	O
2723	O
Aymara	O
subjects	B
(	O
1483	O
males	B
,	O
1240	O
females	B
)	O
aged	O
1	O
-	O
100	O
years	O
(	O
mean	O
SD	O
,	O
10	O
-	O
9	O
7	O
-	O
5	O
years	O
)	O
,	O
among	O
whom	O
were	O
2521	O
students	O
(	O
1350	O
boys	B
,	O
1171	O
girls	B
)	O
aged	O
5	O
to	O
19	O
years	O
(	O
9	O
-	O
6	O
-7	O
years	O
)	O
from	O
the	O
schools	O
of	O
these	O
24	O
localities	O
.	O

These	O
surveys	O
were	O
carried	O
out	O
so	O
that	O
the	O
sample	O
size	O
in	O
each	O
school	O
was	O
representative	O
of	O
both	O
the	O
student	O
enrolment	O
in	O
the	O
school	O
(	O
at	O
least	O
50	O
%	O
)	O
and	O
the	O
number	O
of	O
children	B
present	O
on	O
the	O
day	O
of	O
the	O
survey	O
(	O
at	O
least	O
75	O
%	O
)	O
.	O

In	O
Chijipata	O
Alto	O
and	O
Huacullani	O
,	O
where	O
high	O
prevalences	O
in	O
the	O
schools	O
were	O
detected	O
,	O
surveys	O
were	O
extended	O
to	O
total	O
inhabitants	O
and	O
involved	O
202	O
subjects	O
(	O
133	O
males	B
,	O
69	O
females	B
)	O
aged	O
1	O
to	O
100	O
years	O
(	O
26	O
-	O
7	O
0	O
-	O
1	O
years	O
)	O
.	O

Surveys	O
were	O
performed	O
so	O
that	O
the	O
sample	O
size	O
was	O
always	O
at	O
least	O
20	O
%	O
of	O
the	O
subject	O
number	O
of	O
each	O
locality	O
.	O

None	O
of	O
the	O
children	B
that	O
participated	O
in	O
these	O
community	O
surveys	O
was	O
included	O
in	O
the	O
school	O
surveys	O
of	O
the	O
same	O
localities	O
.	O

All	O
the	O
surveys	O
were	O
made	O
on	O
randomly	O
selected	O
persons	O
on	O
a	O
given	O
day	O
among	O
all	O
participating	O
subjects	O
.	O

One	O
stool	O
sample	O
per	O
subject	O
was	O
collected	O
from	O
all	O
participating	B
individuals	I
and	O
personal	O
data	O
(	O
name	O
,	O
sex	O
,	O
and	O
age	O
)	O
were	O
noted	O
.	O

The	O
relatively	O
low	O
receptivity	O
of	O
Aymara	O
adults	B
,	O
related	O
to	O
their	O
ethnic	O
and	O
religious	O
characteristics	O
(	O
ESTEBAN	O
et	O
al.	O
,	O
1998b	O
)	O
,	O
made	O
it	O
impos-	O
sible	O
to	O
obtain	O
multiple	O
stool	O
specimens	O
collected	O
at	O
2-	O
or	O
132	O
JOSE	O
-	O
GUILLERMO	O
ESTEBAN	O
ETAL	O
.	O

Figure	O
.	O

Map	O
showing	O
the	O
location	O
of	O
the	O
24	O
localities	O
surveyed	O
m	O
the	O
Northern	O
Bolivian	O
Altiplano	O
.	O

Closed	O
circles	O
,	O
localities	O
with	O
fascioliasis	O
;	O
open	O
circles	O
,	O
localities	O
in	O
which	O
fascioliasis	O
was	O
not	O
detected	O
.	O

3-day	O
intervals	O
.	O

Each	O
stool	O
sample	O
was	O
examined	O
using	O
the	O
Kato	O
-	O
Katz	O
technique	O
(	O
KATZ	O
et	O
al.	O
,	O
1972	O
)	O
for	O
hel-	O
minth	O
eggs	O
and	O
,	O
if	O
possible	O
,	O
direct	O
and	O
concentration	O
MIF	O
(	O
SAPERO	O
&	O
LAWLESS	O
,	O
1953	O
;	O
BLAGG	O
et	O
al.	O
,	O
1955	O
)	O
,	O
formol	O
-	O
ether	O
concentration	O
(	O
KNIGHT	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
modified	O
Ziehl	O
-	O
Neelsen	O
(	O
HENRIKSEN	O
&	O
POHLENZ	O
,	O
1981	O
)	O
techniques	O
were	O
applied	O
in	O
order	O
to	O
cover	O
all	O
the	O
protozoan	O
spectrum	O
.	O

Statistical	O
analyses	O
were	O
done	O
using	O
SPSS	O
6.1	O
(	O
SPSS	O
Institute	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
for	O
Windows	O
.	O

Statistical	O
comparison	O
of	O
categorical	O
variables	O
was	O
carried	O
out	O
with	O
X2	O
or	O
Fisher	O
's	O
exact	O
tests	O
.	O

Normally	O
distributed	O
data	O
were	O
analysed	O
using	O
Student	O
's	O
t	O
-	O
test	O
and	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
.	O

Mann	O
-	O
Whitney	O
utest	O
and	O
Kruskal	O
-	O
Wallis	O
test	O
(	O
Jf	O
)	O
were	O
used	O
for	O
non	O
-	O
normally	O
distributed	O
data	O
.	O

Prevalences	O
and	O
intensities	O
m	O
the	O
same	O
schoolchildren	B
studied	O
in	O
different	O
years	O
were	O
compared	O
with	O
McNemar	O
and	O
Wilcoxon	O
signed	O
-	O
rank	O
tests	O
,	O
respectively	O
.	O

Values	O
of	O
P	O
<	O
0	O
-	O
05	O
were	O
taken	O
as	O
significant	O
.	O

This	O
study	O
was	O
conducted	O
with	O
the	O
agreement	O
of	O
the	O
Secretaria	O
Nacional	O
de	O
Salud	O
del	O
Ministerio	O
de	O
Desar-	O
rollo	O
Humano	O
(	O
La	O
Paz	O
,	O
Bolivia	O
)	O
and	O
was	O
performed	O
in	O
collaboration	O
with	O
the	O
INLASA	O
Institute	O
in	O
La	O
Paz	O
.	O

All	O
investigations	O
were	O
made	O
with	O
the	O
consent	O
of	O
the	O
subjects	O
or	O
,	O
in	O
the	O
case	O
of	O
young	O
children	B
,	O
their	O
guardians	O
.	O

Results	O
Prevalences	O

The	O
total	O
prevalence	O
of	O
fascioliasis	O
in	O
the	O
2723	O
subjects	B
studied	O
was	O
15	O
-	O
4	O
%	O
.	O

The	O
maximum	O
prevalences	O
in	O
the	O
school	O
and	O
community	O
surveys	O
were	O
obtained	O
in	O
Chiji-	O
pata	O
Alto	O
(	O
68	O
-	O
2	O
%	O
and	O
65	O
-	O
4	O
%	O
,	O
respectively	O
in	O
1996	O
)	O
,	O
whereas	O
in	O
some	O
other	O
school	O
surveys	O
F.	O
hepatica	O
infec-	O
tion	O
was	O
not	O
even	O
detected	O
(	O
Table	O
1	O
)	O
.	O

Significant	O
differ-	O
ences	O
between	O
prevalence	O
rates	O
both	O
among	O
combined	O
school	O
surveys	O
and	O
among	O
combined	O
community	O
surveys	O
(	O
P	O
=	O
0	O
-	O
0001	O
by	O
Fisher	O
's	O
exact	O
test	O
,	O
and	O
x2=312	O
,	O
P	O
=	O
0	O
-	O
0001	O
,	O
respectively	O
)	O
were	O
detected	O
.	O

Comparison	O
analysis	O
of	O
prevalence	O
rates	O
detected	O
in	O
the	O
surveys	O
carried	O
out	O
in	O
the	O
same	O
school	O
(	O
i.e.	O
,	O
Acha-	O
cachi	O
,	O
Chijipata	O
Alto	O
and	O
Huacullani	O
)	O
or	O
in	O
the	O
same	O
community	O
(	O
i.e.	O
,	O
Huacullani	O
)	O
in	O
different	O
years	O
showed	O
no	O
statistical	O
differences	O
.	O

Moreover	O
,	O
no	O
statistical	O
differ-	O
ences	O
were	O
detected	O
between	O
prevalences	O
among	O
the	O
same	O
schoolchildren	B
analysed	O
in	O
different	O
years	O
.	O

Discrepancies	O
in	O
the	O
results	O
were	O
,	O
however	O
,	O
observed	O
when	O
comparing	O
the	O
total	O
prevalences	O
(	O
including	O
the	O
different	O
years	O
)	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
:	O
in	O
Chijipata	O
Alto	O

no	O
signifi-	O
ca	O
nt	O
difference	O
was	O
observed	O
(	O
60	O
-	O
5	O
%	O
in	O
the	O
2	O
combined	O
school	O
surveys	O
vs.	O
65	O
-	O
4	O
%	O
in	O
the	O
community	O
)	O
,	O
whereas	O
in	O
Huacullani	O
(	O
33	O
-	O
8	O
%	O
for	O
the	O
3	O
combined	O
school	O
surveys	O
vs.	O
16	O
-	O
5	O
%	O
for	O
the	O
2	O
combined	O
community	O
surveys	O
)	O
a	O
signifi-	O
ca	O
nt	O
difference	O
was	O
detected	O
(	O
%	O
2	O
=	O
19	O
-	O
06	O
,	O
P	O
=	O
0	O
-	O
0001	O
)	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
comparing	O
the	O
pre-	O
valences	O
obtained	O
in	O
the	O
school	O
survey	O
and	O
the	O
commu-	O
nity	O
survey	O
in	O
the	O
same	O
locality	O
carried	O
out	O
in	O
the	O
same	O
year	O
1996	O
:	O
in	O
Chijipata	O
Alto	O
there	O
was	O
no	O
significant	O
difference	O
(	O
68	O
-	O
2	O
%	O
in	O
the	O
school	O
vs.	O
65	O
-	O
4	O
%	O
in	O
the	O
com-	O
munity	O
)	O
,	O
whereas	O
in	O
Huacullani	O
(	O
34	O
-	O
8	O
%	O
in	O
the	O
school	O
vs.	O
18	O
-	O
4	O
%	O
in	O
the	O
community	O
)	O
a	O
significant	O
difference	O
was	O
detected	O
(	O
/2	O
=	O
8	O
-	O
89	O
,	O
P	O
=	O
0	O
-	O
0029	O
)	O
.	O

The	O
distribution	O
of	O
prevalences	O
according	O
to	O
sex	O
and	O
age	O
-	O
groups	O
in	O
the	O
school	O
surveys	O
and	O
also	O
in	O
the	O
com-	O
munity	O
surveys	O
is	O
shown	O
in	O
Table	O
2	O
.	O

In	O
relation	O
to	O
sex	O
,	O
a	O
significant	O
difference	O
was	O
detected	O
neither	O
among	O
schools	O
,	O
nor	O
among	O
communities	O
,	O
and	O
a	O
similar	O
result	O
was	O
obtained	O
when	O
considering	O
the	O
total	O
of	O
the	O
subjects	B
studied	O
in	O
all	O
the	O
surveys	O
.	O

In	O
the	O
school	O
surveys	O
,	O
the	O
distribution	O
of	O
prevalences	O
according	O
to	O
age	O
-	O
groups	O
did	O
show	O
significant	O
differences	O
Cy2	O
=	O
19	O
-	O
00	O
,	O
P	O
=	O
0	O
-	O
0001	O
)	O
when	O
comparing	O
age	O
-	O
groups	O
established	O
according	O
to	O
school	O
criteria	O
:	O
age	O
5	O
-	O
8	O
years	O
,	O
basic	O
level	O
,	O
9	O
-	O
12	O
years	O
,	O
intermediate	O
;	O
13	O
-	O
19	O
years	O
,	O
medium	O
level	O
and	O
students	O
still	O
in	O
school	O
but	O
eligible	O
for	O
military	O
service	O
.	O

The	O
highest	O
prevalences	O
were	O
de-	O
Table	O
1	O
.	O

The	O
study	O
populations	O
of	O
the	O
schools	O
and	O
communities	O
surveyed	O
in	O
Bolivia	O
and	O
the	O
prevalences	O
and	O
intensities	O
from	O
faecal	O
egg	O
counts	O
off	O
.	O

hepatica	O
Locality	O
Survey	O
year	O
;	O
Male	B
mple	O
studie	O
<	O
Female	B
i	O
Total	O
Age	O
Range	O
(	O
years	O
)	O
Meai	O
tt	O
(	O
SD	O
)	O
Prevalence%	O
(	O
CI	O
)	O
1	O
'	O
Inl	O
Range	O
:	O
ensity	O
(	O
epg	O
)	O
'	O
AM	O
GM	O
Schools	O
Achacachi	O
(	O
I	O
)	O
3	O
1996	O
48	O
44	O
92	O
5	O
-	O
13	O
8	O
-	O
7	O
(	O
2	O
-	O
1	O
)	O
6	O
-	O
5	O
(	O
5	O
-	O
0	O
)	O
48	O
-	O
336	O
139	O
106	O
Achacachi	O
(	O
1	O
)	O
1997	O
42	O
45	O
87	O
6	O
-	O
13	O
9	O
-	O
1	O
(	O
1	O
-	O
7	O
)	O
1	O
-	O
1	O
(	O
2	O
-	O
2	O
)	O
240	O
-	O
-	O
Acbocalla	O
(	O
ll	O
)	O
1996	O
92	O
96	O
188	O
5	O
-	O
16	O
8	O
-	O
8	O
(	O
2	O
-	O
6	O
)	O
5	O
-	O
3	O
(	O
3	O
-	O
2	O
)	O
48	O
-	O
744	O
304	O
226	O
Ancocagua	O
(	O
9	O
)	O
1997	O
85	O
83	O
168	O
5	O
-	O
19	O
10	O
-	O
6	O
(	O
3	O
-	O
4	O
)	O
5	O
-	O
9	O
(	O
3	O
-	O
6	O
)	O
24	O
-	O
4512	O
1229	O
332	O
Aygachi	O
(	O
16	O
)	O
1994	O
68	O
37	O
105	O
5	O
-	O
17	O
11	O
-	O
1	O
(	O
2	O
-	O
8	O
)	O
17	O
-	O
1	O
(	O
7	O
-	O
2	O
)	O
24	O
-	O
1200	O
320	O
179	O
BelYayes	O
(	O
17	O
)	O
1994	O
26	O
17	O
43	O
5	O
-	O
12	O
8	O
-	O
5	O
(	O
1	O
-	O
9	O
)	O
7	O
-	O
0	O
(	O
7	O
-	O
6	O
)	O
72	O
-	O
144	O
112	O
108	O
Caleria	O
(	O
15	O
)	O
1993	O
29	O
22	O
51	O
6	O
-	O
14	O
9	O
-	O
1	O
(	O
2	O
-	O
3	O
)	O
5	O
-	O
9	O
(	O
6	O
-	O
5	O
)	O
24	O
-	O
48	O
40	O
38	O
Causaya	O
(	O
24	O
)	O
1995	O
22	O
37	O
59	O
5	O
-	O
18	O
10	O
-	O
6	O
(	O
2	O
-	O
8	O
)	O
ND'1	O
-	O
-	O
-	O
Chambi	O
Grande	O
(	O
23	O
)	O
1995	O
9	O
16	O
25	O
5	O
-	O
12	O
7.4	O
(	O
1	O
-	O
6	O
)	O
12	O
-	O
0	O
(	O
12	O
-	O
7	O
)	O
240	O
-	O
840	O
496	O
435	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1996	O
11	O
11	O
22	O
5	O
-	O
10	O
7	O
-	O
5	O
(	O
1	O
-	O
3	O
)	O
68	O
-	O
2	O
(	O
19	O
-	O
5	O
)	O
24	O
-	O
3000	O
613	O
211	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1997	O
29	O
25	O
54	O
5	O
-	O
15	O
8	O
-	O
7	O
(	O
2	O
-	O
4	O
)	O
57	O
-	O
4	O
(	O
13	O
-	O
2	O
)	O
24	O
-	O
2424	O
477	O
240	O
Cohana	O
(	O
18	O
)	O
1994	O
97	O
70	O
167	O
5	O
-	O
16	O
10	O
-	O
4	O
(	O
2	O
-	O
6	O
)	O
3	O
-	O
6	O
(	O
2	O
-	O
8	O
)	O
24	O
-	O
120	O
72	O
60	O
Corapata	O
(	O
10	O
)	O
1993	O
43	O
42	O
85	O
5	O
-	O
16	O
10	O
-	O
2	O
(	O
2	O
-	O
7	O
)	O
17	O
-	O
6	O
(	O
8	O
-	O
1	O
)	O
48	O
-	O
480	O
198	O
157	O
Cuyahuani	O
(	O
3	O
)	O
1996	O
57	O
54	O
111	O
5	O
-	O
16	O
10	O
-	O
7	O
(	O
2	O
-	O
8	O
)	O
6	O
-	O
3	O
(	O
4	O
-	O
5	O
)	O
72	O
-	O
600	O
300	O
206	O
Huacullani	O
(	O
21	O
)	O
1992	O
70	O
53	O
123	O
5	O
-	O
15	O
10	O
-	O
0	O
(	O
1	O
-	O
9	O
)	O
38	O
-	O
2	O
(	O
8	O
-	O
6	O
)	O
24	O
-	O
2160	O
283	O
134	O
Huacullani	O
(	O
21	O
)	O
1993	O
141	O
115	O
256	O
5	O
-	O
19	O
10	O
-	O
8	O
(	O
3	O
-	O
4	O
)	O
31	O
-	O
2	O
(	O
5	O
-	O
7	O
)	O
24	O
-	O
5064	O
705	O
323	O
Huacullani	O
(	O
21	O
)	O
1996	O
65	O
70	O
135	O
8	O
-	O
15	O
11	O
-	O
5	O
(	O
1	O
-	O
5	O
)	O
34	O
-	O
8	O
(	O
8	O
-	O
0	O
)	O
24	O
-	O
4368	O
347	O
168	O
Huatajata	O
(	O
2	O
)	O
1996	O
102	O
91	O
193	O
5	O
-	O
12	O
7	O
-	O
8	O
(	O
1	O
-	O
7	O
)	O
ND'1	O
-	O
-	O
-	O
Iquiaca	O
(	O
8)	O
1995	O
71	O
62	O
133	O
5	O
-	O
14	O
9.4	O
(	O
2	O
-	O
3	O
)	O
9	O
-	O
0	O
(	O
4	O
-	O
9	O
)	O
48	O
-	O
2448	O
415	O
147	O
Kajchiri	O
(	O
13	O
)	O
1994	O
10	O
11	O
21	O
5	O
-	O
10	O
8	O
-	O
0	O
(	O
1	O
-	O
7	O
)	O
9	O
-	O
5	O
(	O
12	O
-	O
6	O
)	O
168	O
168	O
168	O
Kharapata	O
(	O
5	O
)	O
1996	O
48	O
49	O
97	O
5	O
-	O
15	O
9	O
-	O
5	O
(	O
2	O
-	O
2	O
)	O
11	O
-	O
3	O
(	O
6	O
-	O
3	O
)	O
24	O
-	O
216	O
85	O
59	O
Lacaya	O
Baja	O
(	O
20	O
)	O
1997	O
39	O
32	O
71	O
5	O
-	O
12	O
8	O
-	O
1	O
(	O
2	O
-	O
0	O
)	O
28	O
-	O
2	O
(	O
10	O
-	O
5	O
)	O
24	O
-	O
1224	O
302	O
208	O
Oketiti	O
(	O
7	O
)	O
1995	O
9	O
11	O
20	O
5	O
-	O
9	O
6	O
-	O
6	O
(	O
1	O
-	O
1	O
)	O
10	O
-	O
0	O
(	O
13	O
-	O
1	O
)	O
288	O
-	O
-	O
Pantini	O
(	O
6	O
)	O
1995	O
19	O
14	O
33	O
5	O
-	O
13	O
8	O
-	O
9	O
(	O
1	O
-	O
6	O
)	O
30	O
-	O
3	O
(	O
15	O
-	O
7	O
)	O
24	O
-	O
648	O
230	O
139	O
Quiripujo	O
(	O
19	O
)	O
1993	O
25	O
18	O
43	O
5	O
-	O
12	O
7	O
-	O
7	O
(	O
2	O
-	O
0	O
)	O
20	O
-	O
9	O
(	O
12	O
-	O
1	O
)	O
24	O
-	O
240	O
102	O
78	O
Ticuyo	O
(	O
14	O
)	O
1995	O
29	O
3	O
32	O
6	O
-	O
12	O
9	O
-	O
4	O
(	O
1	O
-	O
8	O
)	O
Niy1	O
-	O
-	O
-	O
Tuni	O
(	O
12	O
)	O
1994	O
13	O
12	O
25	O
5	O
-	O
10	O
7	O
-	O
5	O
(	O
1	O
-	O
5	O
)	O
ND'1	O
-	O
-	O
-	O
Yanarico	O
(	O
22	O
)	O
1995	O
51	O
31	O
82	O
5	O
-	O
16	O
9	O
-	O
7	O
(	O
2	O
-	O
5	O
)	O
7	O
-	O
3	O
(	O
5	O
-	O
6	O
)	O
72	O
-	O
120	O
96	O
93	O
Total	O
1992	O
-	O
97	O
1350	O
1171	O
2521	O
5	O
-	O
19	O
9	O
-	O
6	O
(	O
2	O
-	O
7	O
)	O
14	O
-	O
8	O
(	O
1	O
-	O
4	O
)	O
24	O
-	O
5064	O
419	O
185	O
Communities	O
Chijipata	O
Alto	O
(	O
4	O
)	O
1996	O
17	O
9	O
26	O
6	O
-	O
75	O
25	O
-	O
8	O
(	O
20	O
-	O
8	O
)	O
65	O
-	O
4	O
(	O
18	O
-	O
3	O
)	O
48	O
-	O
4440	O
1345	O
678	O
Huacullani	O
(	O
21	O
)	O
1996	O
80	O
45	O
125	O
1	O
-	O
70	O
22	O
-	O
9	O
(	O
17	O
-	O
9	O
)	O
18	O
-	O
4	O
(	O
6	O
-	O
8	O
)	O
24	O
-	O
1608	O
253	O
140	O
Huacullani	O
(	O
21	O
)	O
1997	O
36	O
15	O
51	O
2	O
-	O
100	O
35	O
-	O
4	O
(	O
22	O
-	O
6	O
)	O
11	O
-	O
8	O
(	O
8	O
-	O
8	O
)	O
24	O
-	O
264	O
144	O
113	O
Total	O
1996	O
-	O
97	O
133	O
69	O
202	O
1	O
-	O
100	O
26	O
-	O
7	O
(	O
20	O
-	O
1	O
)	O
22	O
-	O
8	O
(	O
5	O
-	O
8	O
)	O
24	O
-	O
4440	O
660	O
250	O
Total	O
surveys	O
1992	O
-	O
97	O
1483	O
1240	O
2723	O
1	O
-	O
100	O
10	O
-	O
9	O
(	O
7	O
-	O
5	O
)	O
15	O
-	O
4	O
(	O
1	O
-	O
4	O
)	O
24	O
-	O
5064	O

446	O
191	O
'	O
Number	O
m	O
map	O
(	O
see	O
Figure	O
)	O
.	O

'	O
'	O
Confidence	O
interval	O
(	O
95	O
%	O
)	O
.	O

'	O
Eggs	O
per	O
gram	O
of	O
faeces	O
(	O
AM	O
,	O
arithmetic	O
mean	O
;	O
GM	O
,	O
geometric	O
mean	O
)	O
.	O

'	O
'	O
Not	O
detected	O
.	O

154	O
JOSE	O
-	O
GUILLERMO	O
ESTEBAN	O
ETAL	O
.	O

Table	O
2	O
.	O

Prevalences	O
and	O
intensities	O
of	O
fasciolia-	O
sis	O
,	O
by	O
sex	O
and	O
age	O
-	O
group	O
,	O
in	O
the	O
school	O
and	O
com-	O
munity	O
surveys	O
in	O
Bolivia	O
Prevalence	O
Intensity	O
(	O
epg	O
)	O
b	O
)	O
%	O
(	O
CI	O
)	O
3	O
Range	O
AM	O
GM	O
Schools	O
Sex	O
Boys	B
14	O
-	O
5	O
(	O
1	O
-	O
9	O
)	O
24	O
-	O
3408	O
323	O
159	O
Girls	B
15	O
-	O
2	O
(	O
2	O
-	O
1	O
)	O
24	O
-	O
5064	O
528	O
219	O
Age	O
-	O
group	O
(	O
years	O
)	O
5	O
-	O
8	O
10	O
-	O
8	O
(	O
2	O
-	O
0	O
)	O
24	O
-	O
4512	O
377	O
202	O
9	O
-	O
12	O
17	O
-	O
0	O
(	O
2	O
-	O
1	O
)	O
24	O
-	O
5064	O
446	O
191	O
13	O
-	O
19	O
17	O
-	O
9	O
(	O
3	O
-	O
8	O
)	O
24	O
-	O
4488	O
401	O
147	O
Communities	O
Sex	O
Males	B
20	O
-	O
3	O
(	O
6	O
-	O
8	O
)	O
24	O
-	O
4440	O
753	O
280	O
Females	B
27	O
-	O
5	O
(	O
10	O
-	O
5	O
)	O
48	O
-	O
3758	O
525	O
212	O
Age	O
-	O
group	O
(	O
years	O
)	O
1	O
-	O
10	O
29	O
-	O
3	O
(	O
11	O
-	O
7	O
)	O
24	O
-	O
4440	O
796	O
198	O
11	O
-	O
20	O
43	O
-	O
8	O
(	O
17	O
-	O
2	O
)	O
48	O
-	O
3768	O
825	O
410	O
21	O
-	O
40	O
13	O
-	O
8	O
(	O
8	O
-	O
4	O
)	O
72	O
-	O
864	O
373	O
263	O
>	O
40	O
13	O
-	O
3	O
(	O
9	O
-	O
9	O
)	O
24	O
-	O
1608	O
368	O
147	O
""""	O
Confidence	O
interval	O
(	O
95	O
%	O
)	O
.	O

'	O
'	O
Eggs	O
per	O
gram	O
of	O
faeces	O
(	O
AM	O
,	O
arithmetic	O
mean	O
;	O
GM	O
,	O
geometric	O
mean	O
)	O
.	O

tected	O
in	O
the	O
age	O
-	O
groups	O
9	O
-	O
12	O
years	O
(	O
17	O
-	O
0	O
%	O
)	O
and	O
13	O
-	O
19	O
years	O
(	O
17	O
-	O
9	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
the	O
community	O
surveys	O
,	O
significant	O
differences	O
(	O
/2	O
=	O
14	O
-	O
5	O
,	O
P	O
=	O
0	O
-	O
0023	O
)	O
were	O
also	O
detected	O
,	O
with	O
highest	O
prevalences	O
in	O
the	O
age	O
-	O
groups	O
1	O
-	O
10	O
years	O
(	O
29	O
-	O
3	O
%	O
)	O
and	O
11	O
-	O
20	O
years	O
(	O
43	O
-	O
8	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

Intensities	O
Intensity	O
of	O
infection	O
,	O
measured	O
as	O
epg	O
by	O
the	O
Kato-	O
Katz	O
technique	O
,	O
in	O
school	O
and	O
community	O
surveys	O
is	O
shown	O
in	O
Table	O
1	O
.	O

Absolute	O
egg	O
counts	O
in	O
the	O
total	O
individuals	O
surveyed	O
with	O
detectable	O
infection	O
ranged	O
from	O
24	O
to	O
5064	O
epg	O
,	O
with	O
arithmetic	O
and	O
geometric	O
means	O
of	O
446	O
and	O
191	O
epg	O
,	O
respectively	O
.	O

Significant	O
differences	O
were	O
detected	O
among	O
the	O
different	O
school	O
surveys	O
(	O
.H	O
=	O
51	O
-	O
82	O
,	O
P	O
=	O
0	O
-	O
0005	O
)	O
as	O
well	O
as	O
among	O
the	O
different	O
community	O
surveys	O
=	O
12	O
-	O
66	O
,	O
P	O
=	O
0	O
-	O
0018	O
)	O
.	O

Comparison	O
analysis	O
of	O
intensities	O
detected	O
in	O
school	O
surveys	O
carried	O
out	O
in	O
different	O
years	O
in	O
the	O
same	O
locality	O
did	O
not	O
show	O
statistical	O
differences	O
in	O
the	O
case	O
of	O
Chiji-	O
pata	O
Alto	O
,	O
but	O
it	O
did	O
in	O
that	O
of	O
Huacullani	O
(	O
F	O
=	O
4	O
-	O
80	O
,	O
P	O
=	O
0	O
-	O
009	O
)	O
.	O

In	O
the	O
latter	O
,	O
however	O
,	O
no	O
significant	O
differ-	O
ence	O
was	O
detected	O
between	O
the	O
results	O
obtained	O
in	O
the	O
2	O
community	O
surveys	O
.	O

No	O
significant	O
differences	O
were	O
detected	O
between	O
intensities	O
among	O
the	O
same	O
school-	B
children	I
analysed	O
in	O
different	O
years	O
.	O

When	O
comparing	O
the	O
intensity	O
values	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
,	O
the	O
combined	O
results	O
showed	O
significant	O
differences	O
between	O
the	O
school	O
and	O
the	O
community	O
in	O
Chijipata	O
Alto	O
(=	O
229	O
-	O
5	O
,	O
P	O
=	O
0	O
-	O
0123	O
)	O
but	O
not	O
between	O
the	O
school	O
and	O
the	O
community	O
in	O
Huacullani	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
comparing	O
the	O
intensity	O
values	O
obtained	O
in	O
the	O
school	O
survey	O
and	O
community	O
survey	O
carried	O
out	O
in	O
a	O
given	O
locality	O
in	O
the	O
same	O
year	O
:	O
significant	O
differences	O
in	O
Chijipata	O
Alto	O
(	O
(	O
7=75	O
-	O
0	O
,	O
P	O
=	O
0	O
-	O
0472	O
)	O
,	O
but	O
not	O
in	O
Huacullani	O
.	O

Intensities	O
according	O
to	O
sex	O
and	O
age	O
-	O
groups	O
in	O
the	O
school	O
and	O
community	O
surveys	O
are	O
shown	O
in	O
Table	O
2	O
.	O

No	O
significant	O
differences	O
according	O
to	O
sex	O
were	O
detected	O
in	O
the	O
total	O
study	O
and	O
in	O
the	O
community	O
surveys	O
,	O
but	O
the	O
significantly	O
higher	O
F.	O
hepatica	O
egg	O
counts	O
for	O
the	O
girls	O
in	O
the	O
school	O
surveys	O
(	O
t	O
=	O
2	O
-	O
59	O
,	O
P	O
=	O
0	O
-	O
010	O
)	O
is	O
worth	O
men-	O
tioning	O
.	O

The	O
analyses	O
according	O
to	O
age	O
-	O
groups	O
did	O
not	O
show	O
any	O
significant	O
difference	O
.	O

Discussion	O
The	O
prevalences	O
and	O
intensities	O
obtained	O
by	O
coprolo-	O
gical	O
methods	O
in	O
this	O
study	O
are	O
the	O
highest	O
known	O
up	O
to	O
the	O
present	O
.	O

These	O
results	O
are	O
even	O
more	O
noteworthy	O
when	O
taking	O
into	O
consideration	O
the	O
fact	O
that	O
the	O
localities	O
surveyed	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
were	O
se-	O
lected	O
only	O
because	O
of	O
their	O
geographical	O
situation	O
,	O
in	O
order	O
to	O
cover	O
a	O
wide	O
geographical	O
area	O
.	O

The	O
probability	O
of	O
detecting	O
high	O
infection	O
rates	O
of	O
fascioliasis	O
was	O
not	O
taken	O
into	O
account	O
and	O
thus	O
survey	O
efforts	O
were	O
not	O
concentrated	O
on	O
the	O
subzones	O
presenting	O
the	O
highest	O
human	B
fascioliasis	O
rates	O
.	O

Owing	O
to	O
the	O
important	O
clinical	O
and	O
pathogenic	O
effects	O
of	O
fascioliasis	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
;	O
MAS	O
-	O
COMA	O
et	O
al.	O
,	O
1999a	O
,	O
m	O
press	O
)	O
,	O
the	O
analyses	O
of	O
prevalences	O
and	O
intensities	O
obtained	O
allow	O
us	O
to	O
conclude	O
that	O
the	O
Northern	O
Bolivian	O
Altiplano	O
must	O
be	O
catalogued	O
as	O
a	O
true	O
human	B
fascioliasis	O
endemic	O
area	O
.	O

The	O
term	O
outbreak	O
sometimes	O
used	O
for	O
this	O
area	O
(	O
BJORLAND	O
et	O
al.	O
,	O
1995	O
)	O
may	O
consequently	O
be	O
used	O
only	O
when	O
a	O
temporary	O
prevalence	O
increase	O
in	O
a	O
given	O
Altiplanic	O
locality	O
is	O
detected	O
.	O

Differences	O
detected	O
between	O
the	O
results	O
of	O
the	O
pre-	O
valences	O
obtained	O
in	O
different	O
localities	O
are	O
not	O
related	O
to	O
different	O
seasons	O
and	O
may	O
be	O
linked	O
to	O
the	O
patchy	O
distribution	O
of	O
the	O
transmission	O
foci	O
,	O
marked	O
by	O
the	O
presence	O
of	O
the	O
necessary	O
freshwater	O
lymnaeids	B
,	O
as	O
well	O
as	O
to	O
the	O
Aymara	O
children	O
's	O
tendency	O
not	O
to	O
travel	O
far	O
.	O

The	O
lack	O
of	O
seasonality	O
in	O
the	O
prevalences	O
detected	O
contrasts	O
with	O
the	O
well	O
-	O
known	O
seasonal	O
transmission	O
characteristics	O
of	O
fascioliasis	O
in	O
other	O
parts	O
of	O
the	O
world	O
.	O

This	O
may	O
be	O
explained	O
by	O
the	O
absence	O
of	O
marked	O
climatic	O
differences	O
between	O
the	O
different	O
seasons	O
in	O
the	O
Northern	O
Altiplano	O
.	O

The	O
non	O
-	O
significant	O
differences	O
in	O
prevalences	O
by	O
sex	O
and	O
the	O
fact	O
that	O
all	O
ages	O
are	O
susceptible	O
to	O
infection	O
(	O
positive	O
cases	O
from	O
2	O
to	O
70	O
years	O
)	O
,	O
despite	O
the	O
fact	O
that	O
the	O
subjects	B
aged	O
<	O
20	O
years	O
are	O
those	O
with	O
a	O
higher	O
infection	O
risk	O
,	O
could	O
be	O
explained	O
by	O
the	O
lack	O
of	O
gender	O
role	O
differences	O
and	O
by	O
the	O
ingestion	O
of	O
several	O
aquatic	O
vegetables	B
(	O
MAS	O
-	O
COMAeta	O
/	O
.	O
,	O
1995	O
)	O
as	O
a	O
risk	O
factor	O
for	O
F.	B
hepatica	I
infection	O
.	O

These	O
results	O
agree	O
with	O
a	O
few	O
studies	O
performed	O
in	O
areas	O
of	O
Egypt	O
(	O
FARAG	O
et	O
al.	O
,	O
1979	O
)	O
,	O
Peru	O
(	O
KNOBLOCH	O
et	O
al.	O
,	O
1985	O
;	O
SCHEZ	O
et	O
al.	O
,	O
1993	O
)	O
and	O
Chile	O
(	O
APT	O
et	O
al.	O
,	O
1993	O
)	O
.	O

The	O
very	O
high	O
egg	O
counts	O
are	O
worth	O
noting	O
when	O
compared	O
with	O
the	O
epg	O
normally	O
found	O
to	O
date	O
in	O
human	B
fascioliasis	O
diagnosis	O
:	O
1	O
-	O
4	O
epg	O
(	O
BENDEZet	O
al.	O
,	O
1982	O
;	O
KNOBLOCH	O
et	O
al.	O
,	O
1985	O
)	O
is	O
the	O
most	O
common	O
;	O
a	O
case	O
with	O
440	O
epg	O
(	O
AKAHANE	O
et	O
al.	O
,	O
1975	O
)	O
may	O
be	O
considered	O
as	O
rare	O
.	O

However	O
,	O
the	O
prospective	O
study	O
by	O
SAMPAIO	O
SILVA	O
(	O
1990	O
)	O
provided	O
a	O
geometric	O
mean	O
(	O
range	O
)	O
of	O
233	O
(	O
25-	O
2100	O
)	O
epg	O
,	O
which	O
was	O
the	O
highest	O
epg	O
count	O
known	O
up	O
to	O
our	O
study	O
.	O

With	O
the	O
exception	O
of	O
a	O
few	O
localities	O
,	O
the	O
distribution	O
of	O
intensities	O
corresponds	O
to	O
the	O
distribution	O
of	O
preva-	O
lences	O
,	O
and	O
the	O
scarce	O
disagreements	O
in	O
some	O
localities	O
may	O
be	O
explained	O
by	O
the	O
few	O
children	B
coming	O
from	O
the	O
very	O
few	O
surrounding	O
zones	O
including	O
transmission	O
foci	O
.	O

Intensity	O
results	O
obtained	O
in	O
schools	O
and	O
communities	O
surveyed	O
more	O
than	O
once	O
,	O
in	O
different	O
seasons	O
and	O
throughout	O
different	O
years	O
,	O
as	O
well	O
as	O
those	O
obtained	O
in	O
the	O
school	O
and	O
community	O
surveys	O
in	O
the	O
same	O
locality	O
are	O
difficult	O
to	O
interpret	O
.	O

Similarly	O
,	O
the	O
significantly	O
higher	O
F.	B
hepatica	I
egg	O
counts	O
for	O
the	O
girls	B
in	O
the	O
school	O
surveys	O
are	O
surprising	O
.	O

Concerning	O
intensity	O
in	O
humans	B
,	O
a	O
relationship	O
between	O
the	O
number	O
of	O
fluke	O
adults	B
and	O
eggs	O
in	O
faeces	O
has	O
never	O
been	O
studied	O
.	O

Data	O
from	O
animals	B
suggest	O
that	O
a	O
direct	O
relation	O
does	O
not	O
necessarily	O
exist	O
(	O
CHEN	O
&	O
MOTT	O
,	O
1990	O
)	O
.	O

It	O
is	O
evident	O
that	O
further	O
studies	O
on	O
this	O
aspect	O
are	O
needed	O
.	O

Intensity	O
data	O
according	O
to	O
age	O
-	O
groups	O
show	O
that	O
egg	O
output	O
counts	O
decrease	O
with	O
an	O
increase	O
of	O
age	O
.	O

In	O
3	O
persons	B
aged	O
>	O
60	O
years	O
,	O
egg	O
counts	O
of	O
24	O
-	O
168	O
epg	O
were	O
found	O
.	O

Consequently	O
,	O
adult	B
subjects	O
either	O
maintain	O
the	O
parasites	B
acquired	O
when	O
young	O
or	O
can	O
be	O
newly	O
infected	O
HUMAN	O
FASCIOLIASIS	O
IN	O
BOLIVIA	O
155	O
as	O
the	O
consequence	O
of	O
inhabiting	O
a	O
zone	O
of	O
high	O
infection	O
risk	O
.	O

A	O
case	O
of	O
a	O
2-year	O
-	O
old	O
child	B
shedding	O
48	O
epg	O
is	O
worth	O
mentioning	O
,	O
as	O
it	O
is	O
the	O
youngest	O
human	B
fascioliasis	O
case	O
reported	O
so	O
far	O
.	O

The	O
human	B
health	O
problem	O
of	O
this	O
distomatosis	O
in	O
the	O
Northern	O
Bolivian	O
Altiplano	O
is	O
related	O
to	O
the	O
hygienic-	O
sanitation	O
status	O
of	O
the	O
human	B
population	O
.	O

The	O
numer-	O
ous	O
different	O
protozoan	O
and	O
helminth	O
species	O
detected	O
in	O
the	O
area	O
surveyed	O
and	O
the	O
multiple	O
parasite	B
infections	O
detected	O
,	O
including	O
F.	B
hepatica	I
infection	O
,	O
in	O
the	O
same	O
subjects	O
(	O
ESTEBAN	O
et	O
al.	O
,	O
1996	O
,	O
1997a	O
;	O
1998a	O
,	O
1998b	O
)	O
are	O
illustrative	O
of	O
this	O
situation	O
.	O

Acknowledgements	O
Collaboration	O
by	O
Dr	O
J.	O
A.	O
Oviedo	O
(	O
Valencia	O
,	O
Spain	O
)	O
and	O
Miss	O
W.	O
Strauss	O
,	O
N.	O
lihoshi	O
,	O
M.	O
Magarinos	O
and	O
Dr	O
C.	O
Aguirre	O
(	O
La	O
Paz	O
,	O
Bolivia	O
)	O
is	O
acknowledged	O
.	O

Thanks	O
are	O
also	O
given	O
to	O
the	O
following	O
Bolivian	O
institutions	O
in	O
La	O
Paz	O
:	O
Direccion	O
Nacional	O
de	O
Epidemiologia	O
of	O
the	O
Ministerio	O
de	O
Prevision	O
Social	O
y	O
Salud	O
Plica	O
;	O
ComitRegional	O
de	O
Zoonosis	O
and	O
Centro	O
Piloto	O
of	O
the	O
Unidad	O
Sanitaria	O
La	O
Paz	O
;	O
and	O
Office	O
of	O
the	O
Pan	O
American	O
Health	O
Organization	O
.	O

This	O
work	O
was	O
supported	O
by	O
funding	O
from	O
the	O
STD	O
Program	O
of	O
the	O
Commission	O
of	O
the	O
European	O
Communities	O
(	O
DG	O
XII	O
:	O
Science	O
,	O
Research	O
and	O
Development	O
)	O
(	O
Contract	O
no.	O
TS3-	O
CT94	O
-	O
0294	O
)	O
,	O
Brussels	O
,	O
EU	O
,	O
by	O
the	O
Program	O
of	O
Scientific	O
Co-	O
operation	O
with	O
Latin	O
America	O
,	O
Institute	O
de	O
Cooperaci	O
Ibero-	O
americana	O
,	O
Agencia	O
Espanola	O
de	O
Cooperaci	O
Intemacional	O
(	O
ICI	O
-	O
AECI	O
)	O
and	O
by	O
Projects	O
no.	O
UE96	O
-	O
0001	O
and	O
no.	O
PM97-	O
0099	O
of	O
the	O
Direccion	O
General	O
de	O
Investigacion	O
Cientifica	O
y	O
Tnica	O
(	O
DGICYT	O
)	O
,	O
Spanish	O
Ministry	O
of	O
Education	O
and	O
Science	O
,	O
Madrid	O
.	O

Modular	O
polyketide	O
synthases	O
(	O
PKSs	O
)	O
are	O
responsible	O
for	O
producing	O
a	O
large	O
number	O
of	O
12	O
,	O
14-	O
and	O
16-membered	O
macrolide	O
antibiotics	O
including	O
methymycin	O
,	O
erythromycin	O
and	O
tylosin	O
.	O

These	O
large	O
,	O
multifunctional	O
enzymes	O
(	O
>	O
300,000	O
kDa	O
)	O
catalyze	O
the	O
biosynthesis	O
of	O
polyketide	O
macrolactones	O
through	O
multistep	O
pathways	O
involving	O
decarboxylative	O
condensations	O
between	O
acyl	O
thioesters	O
fol-	O
lowed	O
by	O
cycles	O
of	O
varying	O
B	O
-	O
carbon	O
processing	O
[	O
l	O
]	O
.	O

The	O
ability	O
to	O
control	O
aspects	O
of	O
polyketide	O
biosynthesis	O
,	O
such	O
as	O
monomer	O
selection	O
,	O
degree	O
of	O
B	O
-	O
carbon	O
processing	O
and	O
stereoselectivity	O
,	O
by	O
genetic	O
manipulation	O
of	O
PKSs	O
has	O
stimulated	O
great	O
interest	O
in	O
the	O
combinatorial	O
engineering	O
of	O
novel	O
antibiotics	O
[	O
2,3	O
]	O
.	O

Picromycin	O
(	O
1	O
;	O
Figure	O
1	O
)	O
is	O
of	O
par-	O
ticular	O
interest	O
for	O
such	O
use	O
because	O
of	O
its	O
close	O
structural	O
relationship	O
to	O
ketolide	O
compounds	O
(	O
e.g.	O
HMR	O
3004	O
)	O
,	O
a	O
new	O
class	O
of	O
semisynthetic	O
macrolides	O
with	O
activity	O
against	O
pathogens	B
resistant	O
to	O
erythromycin	O
[	O
4	O
]	O
.	O

Genetic	O
systems	O
that	O
allow	O
rapid	O
engineering	O
of	O
the	O
picromycin	O
PKS	O
would	O
therefore	O
be	O
valuable	O
for	O
creating	O
novel	O
ketolide	O
analogs	O
for	O
pharmaceutical	O
applications	O
.	O

A	O
pivotal	O
development	O
for	O
modular	O
PKS	O
engineering	O
was	O
the	O
heterologous	O
expression	O
of	O
the	O
erythromycin	O
PKS	O
(	O
6-deoxyerythronolide	O
B	O
synthase	O
,	O
DEBS	O
)	O
in	O
Streptomyces	B
coelicolor	I
[	O
5,6	O
]	O
.	O

The	O
advantages	O
to	O
this	O
plasmid	O
-	O
based	O
genetic	O
system	O
for	O
DEBS	O
were	O
that	O
it	O
overcame	O
the	O
tedious	O
and	O
limited	O
techniques	O
for	O
manipulating	O
the	O
natural	O
DEBS	O
host	O
organism	O
,	O
Saccharopolyspora	B
etythaea	I
,	O
it	O
allowed	O
more	O
facile	O
construction	O
of	O
mutant	O
PKSs	O
,	O
and	O
it	O
reduced	O
the	O
complexity	O
of	O
PKS	O
property	O
analysis	O
by	O
pro-	O
viding	O
a	O
leanhost	O
background	O
.	O

This	O
system	O
also	O
expe-	O
dited	O
the	O
construction	O
of	O
the	O
first	O
combinatorial	O
modular	O
polyketide	O
library	O
in	O
Streptomyces	B
[	O
7	O
]	O
.	O

Despite	O
the	O
success	O
of	O
this	O
system	O
,	O
as	O
well	O
as	O
the	O
increased	O
number	O
of	O
modular	O
PKS	O
gene	O
clusters	O
currently	O
available	O
,	O
DEBS	O
remained	O
the	O
only	O
modular	O
PKS	O
reported	O
to	O
be	O
expressed	O
in	O
a	O
het-	O
erologous	O
organism	O
.	O

The	O
picromycin	O
gene	O
cluster	O
from	O
Streptomyces	B
venezuelae	I
was	O
recently	O
cloned	O
and	O
sequenced	O
by	O
Sherman	O
and	O
coworkers	O
[	O
8	O
]	O
and	O
in	O
our	O
own	O
laboratories	O
(	O
[	O
9	O
]	O
;	O
M.C.B.	O
,	O
unpublished	O
observations	O
)	O
.	O

S.	B
venezuelae	I
is	O
unique	O
among	O
macrolide	O
-	O
producing	O
organisms	O
because	O
it	O
produces	O
primary	O
polyketides	O
with	O
two	O
different	O
ring	O
sizes	O
.	O

In	O
addi-	O
tion	O
to	O
the	O
14-membered	O
macrolide	O
picromycin	O
(	O
l	O
)	O
,	O
the	O
12-membered	O
macrolide	O
methymycin	O
(	O
2	O
;	O
Figure	O
1	O
)	O
is	O
also	O
produced	O
.	O

Based	O
on	O
the	O
structural	O
similarities	O
between	O
CHBIOL	O
80087	O
S1074	O
-	O
5521	O
(	O
99	O
)	O
80087	O
-	O
8	O
10.1016	O
/	O
S1074	O
-	O
5521	O
(	O
99	O
)	O
80087	O
-	O
8	O
Elucidating	O
the	O
mechanism	O
of	O
chain	O
termination	O
switching	O
in	O
the	O
picromycin	O
/	O
methymycin	O
polyketide	O
synthase	O
Li	O
Tang	O
Hong	O
Fu	O

Melanie	O
C	O
Betlach	O

Robert	O
McDaniel	O

*	O
mcdaniel@kosan.com	O

KOSAN	O
Biosciences	O
,	O
Inc.	O
,	O
3832	O
Bay	O
Center	O
Place	O
,	O
Hayward	O
,	O
CA	O
94545	O
,	O
USA	O

*	O
Correspondence	O
:	O
Robert	O
McDaniel	O
.	O

Background	O
A	O
single	O
modular	O
polyketide	O
synthase	O
(	O
PKS	O
)	O
gene	O
cluster	O
is	O
responsible	O
for	O
production	O
of	O
both	O
the	O
14-membered	O
macrolide	O
antibiotic	O
picromycin	O
and	O
the	O
12-membered	O
macrolide	O
antibiotic	O
methymycin	O
in	O
Streptomyces	B
Venezuelas	I
.	I

Building	O
on	O
the	O
success	O
of	O
the	O
heterologous	O
expression	O
system	O
engineered	O
using	O
the	O
erythromycin	O
PKS	O
,	O
we	O
have	O
constructed	O
an	O
analogous	O
system	O
for	O
the	O
picromycin	O
/	O
methymycin	O
PKS	O
.	O

Through	O
heterologous	O
expression	O
and	O
construction	O
of	O
a	O
hybrid	O
PKS	O
,	O
we	O
have	O
examined	O
the	O
contributions	O
that	O
the	O
PKS	O
,	O
its	O
internal	O
thioesterase	O
domain	O
(	O
pikTE	O
)	O
and	O
the	O
Pik	O
TEII	O
thioesterase	O
domain	O
make	O
in	O
termination	O
and	O
cyclization	O
of	O
the	O
two	O
polyketide	O
intermediates	O
.	O

Results	O
The	O
picromycin	O
/	O
methymycin	O
PKS	O
genes	O
were	O
functionally	O
expressed	O
in	O
the	O
heterologous	O
host	O
Streptomyces	B
lividans	I
,	O
resulting	O
in	O
production	O
of	O
both	O
narbonolide	O
and	O
10-deoxymethynolide	O
(	O
the	O
precursors	O
of	O
picromycin	O
and	O
methymycin	O
,	O
respectively	O
)	O
.	O

Co	O
-	O
expression	O
with	O
the	O
Pik	O
TEII	O
thioesterase	O
led	O
to	O
increased	O
production	O
levels	O
,	O
but	O
did	O
not	O
change	O
the	O
ratio	O
of	O
the	O
two	O
compounds	O
produced	O
,	O
leaving	O
the	O
function	O
of	O
this	O
protein	O
largely	O
unknown	O
.	O

Fusion	O
of	O
the	O
PKS	O
thioesterase	O
domain	O
(	O
pikTE	O
)	O
to	O
6-deoxyerythronolide	O
B	O
synthase	O
(	O
DEBS	O
)	O
resulted	O
in	O
formation	O
of	O
only	O
14-membered	O
macrolactones	O
.	O

Conclusions	O
These	O
experiments	O
demonstrate	O
that	O
the	O
PKS	O
alone	O
is	O
capable	O
of	O
catalyzing	O
the	O
synthesis	O
of	O
both	O
14-	O
and	O
12-membered	O
macrolactones	O
and	O
favor	O
a	O
model	O
by	O
which	O
different	O
macrolactone	O
rings	O
result	O
from	O
a	O
combination	O
of	O
the	O
arrangement	O
between	O
the	O
module	O
5	O
and	O
module	O
6	O
subunits	O
in	O
the	O
picromycin	O
PKS	O
complex	O
and	O
the	O
selectivity	O
of	O
the	O
pikTE	O
domain	O
.	O

Key	O
words	O
erythromycin	O
methymycin	O
picromycin	O
polyketide	O
thioesterase	O

Diltiazem	O
(	O
d	O
-cis	O
-diltiazem	O
)	O
,	O
a	O
benzothiazepine	O
Ca2	O
+	O
channel	O
blocker	O
,	O
has	O
been	O
used	O
for	O
the	O
treatment	O
of	O
ischemic	O
heart	O
disease	O
.	O

The	O
primary	O
mechanism	O
of	O
the	O
anti	O
-	O
ischemic	O
action	O
of	O
d	O
-cis	O
-diltiazem	O
is	O
considered	O
to	O
be	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
which	O
produces	O
improvement	O
of	O
the	O
myocardial	O
oxygen	O
balance	O
between	O
supply	O
and	O
demand	O
by	O
either	O
increasing	O
coronary	O
flow	O
or	O
decreasing	O
cardiac	O
mechanical	O
function	O
,	O
or	O
both	O
.	O

However	O
,	O
l	O
-cis	O
-diltiazem	O
,	O
which	O
is	O
an	O
optical	O
isomer	O
of	O
d	O
-cis	O
-diltiazem	O
with	O
about	O
1	O
/	O
20–1	O
/	O
100	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
Nasa	O
et	O
al.	O
,	O
1992	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
,	O
and	O
d	O
-cis	O
-diltiazem	O
attenuate	O
the	O
myocardial	O
derangements	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
to	O
a	O
similar	O
degree	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
)	O
.	O

This	O
fact	O
suggests	O
that	O
the	O
anti	O
-	O
ischemic	O
action	O
of	O
d	O
-cis	O
-diltiazem	O
does	O
not	O
entirely	O
depend	O
on	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
but	O
depends	O
on	O
other	O
unknown	O
actions	O
.	O

Recently	O
,	O
we	O
(	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
have	O
demonstrated	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuate	O
the	O
myocardial	O
derangements	O
induced	O
by	O
palmitoyl	O
-	O
l	O
-carnitine	O
,	O
which	O
accumulates	O
in	O
the	O
heart	O
during	O
ischemia	O
and	O
reperfusion	O
,	O
supporting	O
the	O
above	O
suggestion	O
.	O

During	O
ischemia	O
and	O
reperfusion	O
,	O
reactive	O
oxygen	O
species	O
,	O
such	O
as	O
superoxide	O
anion	O
,	O
hydroxyl	O
radical	O
and	O
hydrogen	O
peroxide	O
(	O
H2	O
O2	O
)	O
,	O
are	O
generated	O
intra-	O
and	O
extracellularly	O
in	O
the	O
myocardium	O
and	O
endothelium	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

These	O
reactive	O
oxygen	O
species	O
are	O
considered	O
important	O
in	O
producing	O
irreversible	O
damage	O
in	O
the	O
ischemia	O
-	O
reperfused	O
heart	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

In	O
fact	O
,	O
oxygen	O
radical	O
scavengers	O
and	O
anti	O
-	O
oxidants	O
protect	O
the	O
myocardium	O
against	O
ischemia	O
–	O
reperfusion	O
damage	O
(	O
Hess	O
and	O
Manson	O
,	O
1984	O
;	O
Lucchesi	O
,	O
1990	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

We	O
(	O
Hara	O
et	O
al.	O
,	O
1993	O
;	O
Hara	O
and	O
Abiko	O
,	O
1996	O
;	O
Kokita	O
and	O
Hara	O
,	O
1996	O
)	O
have	O
demonstrated	O
that	O
H2	O
O2	O
decreases	O
cardiac	O
mechanical	O
function	O
and	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
in	O
the	O
isolated	O
perfused	O
rat	B
heart	O
.	O

According	O
to	O
recent	O
physiological	O
studies	O
,	O
H2	O
O2	O
increases	O
the	O
intracellular	O
concentration	O
of	O
Na+	O
(	O
[	O
Na+	O
]	O
i	O
)	O
in	O
the	O
myocardium	O
(	O
Yanagida	O
et	O
al.	O
,	O
1995	O
)	O
,	O
probably	O
because	O
of	O
an	O
increase	O
in	O
Na+	O
current	O
in	O
cardiac	O
cells	O
(	O
Bhatnagar	O
et	O
al.	O
,	O
1990	O
;	O
Ward	O
and	O
Giles	O
,	O
1997	O
)	O
.	O

The	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
activates	O
the	O
Na+	O
/Ca2	O
+	O
exchanger	O
,	O
leading	O
to	O
intracellular	O
Ca2	O
+	O
overload	O
,	O
which	O
is	O
responsible	O
for	O
irreversible	O
myocardial	O
derangements	O
(	O
Goldhaber	O
,	O
1996	O
)	O
.	O

In	O
order	O
to	O
elucidate	O
the	O
mechanisms	O
of	O
action	O
of	O
l	O
-cis	O
-diltiazem	O
responsible	O
for	O
its	O
anti	O
-	O
ischemic	O
effect	O
and	O
to	O
relate	O
its	O
anti	O
-	O
ischemic	O
action	O
to	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
the	O
following	O
two	O
series	O
of	O
experiments	O
were	O
designed	O
.	O

The	O
first	O
series	O
of	O
experiments	O
was	O
performed	O
to	O
determine	O
the	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
dysfunction	O
,	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
and	O
damage	O
of	O
the	O
cell	O
membrane	O
,	O
and	O
the	O
second	O
series	O
of	O
experiments	O
was	O
carried	O
out	O
to	O
examine	O
the	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
.	O

2	O
Methods	O
The	O
protocol	O
of	O
animal	B
experiments	O
in	O
the	O
present	O
study	O
was	O
approved	O
by	O
the	O
`	O
Asahikawa	O
Medical	O
College	O
Committee	O
on	O
Animal	B
Research	O
'	O
.	O

2.1	O
Heart	O
perfusion	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

Male	O
Sprague	B
–	I
Dawley	I
rats	I
,	O
weighing	O
310–340	O
g	O
(	O
9–10	O
weeks	O
old	O
)	O
,	O
were	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

The	O
rats	B
were	O
anesthetized	O
with	O
sodium	O
pentobarbital	O
(	O
50	O
mg	O
kg−1	O
,	O
i.p	O
.	O
)	O
20	O
min	O
after	O
an	O
injection	O
with	O
heparin	O
(	O
1000	O
u	O
kg−1	O
,	O
i.p	O
.	O
)	O
.	O

After	O
thoracotomy	O
,	O
the	O
hearts	O
were	O
rapidly	O
removed	O
,	O
and	O
then	O
retrograde	O
perfusion	O
was	O
started	O
using	O
a	O
cannula	O
inserted	O
into	O
the	O
aorta	O
according	O
to	O
the	O
Langendorff	O
technique	O
.	O

The	O
perfusion	O
buffer	O
was	O
a	O
Krebs	O
–	O
Henseleit	O
bicarbonate	O
(	O
KHB	O
)	O
buffer	O
containing	O
(	O
in	O
mM	O
)	O
:	O
NaCl	O
,	O
118	O
;	O
KCl	O
,	O
4.7	O
;	O
KH2	O
PO4	O
,	O
1.2	O
;	O
MgSO4	O
,	O
1.2	O
;	O
CaCl2	O
,	O
2.5	O
;	O
NaHCO3	O
,	O
25	O
;	O
and	O
glucose	O
,	O
11	O
,	O
equilibrated	O
with	O
a	O
gas	O
mixture	O
of	O
95	O
%	O
O2	O
+	O
5	O
%	O
CO2	O
and	O
maintained	O
at	O
37	O
°	O
C	O
.	O

The	O
oxygen	O
tension	O
of	O
the	O
buffer	O
measured	O
by	O
a	O
blood	O
gas	O
analyzer	O
(	O
Model	O
813	O
,	O
Instrumentation	O
Laboratory	O
,	O
Lexington	O
,	O
USA	O
)	O
was	O
about	O
550	O
mm	O
Hg	O
.	O

The	O
hearts	O
,	O
mounted	O
in	O
a	O
water	O
-	O
jacketed	O
chamber	O
(	O
37	O
°	O
C	O
)	O
,	O
were	O
initially	O
perfused	O
at	O
a	O
constant	O
perfusion	O
pressure	O
of	O
80	O
cm	O
H2	O
O.	O
About	O
10	O
min	O
after	O
constant	O
pressure	O
perfusion	O
,	O
perfusion	O
was	O
switched	O
to	O
constant	O
flow	O
perfusion	O
(	O
10	O
ml	O
min−1	O
)	O
,	O
using	O
a	O
microtube	O
pump	O
(	O
Eyela	O
MP-3	O
,	O
Tokyo	O
-	O
Rikakikai	O
Instruments	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
which	O
was	O
maintained	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

The	O
heart	O
rate	O
was	O
kept	O
constant	O
by	O
pacing	O
the	O
heart	O
at	O
300	O
beats	O
min−1	O
with	O
an	O
electronic	O
stimulator	O
(	O
3F46	O
,	O
San	O
-	O
Ei	O
Instruments	O
,	O
Tokyo	O
,	O
Japan	O
)	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

Rectangular	O
pulses	O
of	O
2	O
ms	O
in	O
duration	O
with	O
a	O
voltage	O
of	O
6	O
V	O
(	O
about	O
3	O
×	O
the	O
threshold	O
voltage	O
)	O
were	O
applied	O
to	O
the	O
left	O
ventricle	O
for	O
pacing	O
of	O
the	O
heart	O
.	O

As	O
indices	O
of	O
mechanical	O
function	O
,	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
left	O
ventricular	O
developed	O
pressure	O
were	O
used	O
.	O

The	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
determined	O
from	O
the	O
left	O
ventricular	O
pressure	O
curves	O
recorded	O
continuously	O
during	O
the	O
course	O
of	O
the	O
study	O
,	O
and	O
the	O
left	O
ventricular	O
developed	O
pressure	O
value	O
was	O
calculated	O
as	O
left	O
ventricular	O
systolic	O
pressure	O
minus	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

For	O
measurement	O
of	O
left	O
ventricular	O
pressure	O
,	O
a	O
saline	O
-	O
filled	O
polyethylene	O
cannula	O
,	O
connected	O
to	O
a	O
pressure	O
transducer	O
,	O
was	O
inserted	O
into	O
the	O
left	O
ventricular	O
cavity	O
via	O
the	O
left	O
atrium	O
.	O

2.2	O
Experimental	O
protocol	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

The	O
hearts	O
were	O
divided	O
into	O
five	O
groups	O
:	O
vehicle	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
10	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
groups	O
.	O

In	O
these	O
groups	O
,	O
the	O
hearts	O
were	O
perfused	O
at	O
a	O
constant	O
flow	O
for	O
75	O
min	O
(	O
stabilization	O
period	O
for	O
20	O
min	O
and	O
observation	O
period	O
for	O
55	O
min	O
)	O
.	O

d	O
-cis	O
-Diltiazem	O
,	O
l	O
-cis	O
-diltiazem	O
or	O
vehicle	O
(	O
KHB	O
buffer	O
for	O
both	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
solutions	O
)	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
45	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
observation	O
period	O
.	O

The	O
final	O
concentration	O
of	O
d	O
-cis	O
-diltiazem	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
15	O
μM	O
and	O
that	O
of	O
l	O
-cis	O
-diltiazem	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
5	O
,	O
10	O
or	O
15	O
μM.	O
H2	O
O2	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
3.5	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
d	O
-cis	O
-diltiazem	O
,	O
l	O
-cis	O
-diltiazem	O
or	O
vehicle	O
.	O

The	O
final	O
concentration	O
of	O
H2	O
O2	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
600	O
μM.	O
During	O
the	O
observation	O
period	O
,	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
were	O
continuously	O
recorded	O
and	O
the	O
coronary	O
effluent	O
was	O
collected	O
for	O
determination	O
of	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
released	O
from	O
the	O
myocardium	O
.	O

To	O
measure	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
,	O
the	O
hearts	O
were	O
frozen	O
at	O
the	O
end	O
of	O
experiment	O
(	O
45	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
or	O
l	O
-cis	O
-diltiazem	O
)	O
with	O
freezing	O
clamps	O
previously	O
chilled	O
in	O
liquid	O
nitrogen	O
.	O

In	O
addition	O
,	O
some	O
hearts	O
in	O
the	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
groups	O
were	O
frozen	O
immediately	O
before	O
H2	O
O2	O
infusion	O
(	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
or	O
l	O
-cis	O
-diltiazem	O
)	O
.	O

The	O
frozen	O
myocardial	O
samples	O
were	O
stored	O
in	O
liquid	O
nitrogen	O
(	O
at	O
−196	O
°	O
C	O
)	O
until	O
the	O
biochemical	O
analysis	O
was	O
performed	O
.	O

2.3	O
Biochemical	O
analysis	O
(	O
the	O
first	O
series	O
of	O
experiments	O
)	O

The	O
frozen	O
myocardial	O
sample	O
was	O
pulverized	O
in	O
a	O
mortar	O
cooled	O
with	O
liquid	O
nitrogen	O
.	O

A	O
part	O
of	O
the	O
pulverized	O
tissue	O
powder	O
(	O
about	O
0.8–1.0	O
g	O
)	O
was	O
weighed	O
and	O
put	O
into	O
an	O
oven	O
overnight	O
,	O
in	O
order	O
to	O
measure	O
the	O
tissue	O
water	O
content	O
and	O
dry	O
weight	O
of	O
the	O
tissue	O
.	O

The	O
remainder	O
of	O
the	O
tissue	O
powder	O
was	O
used	O
for	O
determination	O
of	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
.	O

ATP	O
,	O
ADP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
were	O
measured	O
according	O
to	O
standard	O
enzymatic	O
procedures	O
(	O
Bergmeyer	O
,	O
1974a	O
)	O
,	O
using	O
a	O
spectrophotometer	O
(	O
Gilford	O
system	O
2600	O
,	O
Gilford	O
Instrument	O
Laboratories	O
,	O
Oberlin	O
,	O
USA	O
)	O
.	O

The	O
LDH	O
activity	O
in	O
the	O
coronary	O
effluent	O
was	O
measured	O
spectrophotometrically	O
according	O
to	O
an	O
enzymatic	O
method	O
(	O
Bergmeyer	O
,	O
1974b	O
)	O
,	O
using	O
an	O
LDH	O
assay	O
kit	O
(	O
Sigma	O
,	O
St.	O
Louis	O
,	O
USA	O
)	O
.	O

2.4	O
Heart	O
perfusion	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O

Male	O
Sprague	B
–	I
Dawley	I
rats	I
,	O
weighing	O
180–210	O
g	O
(	O
6–7	O
weeks	O
old	O
)	O
,	O
were	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
.	O

According	O
to	O
the	O
procedure	O
described	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
the	O
isolated	O
hearts	O
were	O
initially	O
perfused	O
by	O
the	O
Langendorff	O
technique	O
at	O
a	O
constant	O
perfusion	O
pressure	O
of	O
80	O
cm	O
H2	O
O.	O
About	O
10	O
min	O
after	O
constant	O
pressure	O
perfusion	O
,	O
perfusion	O
was	O
switched	O
to	O
constant	O
flow	O
perfusion	O
(	O
8.5	O
ml	O
min−1	O
)	O
,	O
using	O
a	O
microtube	O
pump	O
(	O
Eyela	O
MP-3	O
,	O
Tokyo	O
-	O
Rikakikai	O
Instruments	O
)	O
,	O
which	O
was	O
maintained	O
until	O
the	O
end	O
of	O
the	O
experiment	O
.	O

During	O
the	O
first	O
10	O
min	O
of	O
constant	O
flow	O
perfusion	O
,	O
the	O
hearts	O
were	O
perfused	O
with	O
normal	O
KHB	O
buffer	O
.	O

To	O
obtain	O
23	O
Na	O
-nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectra	O
,	O
perfusion	O
buffer	O
was	O
then	O
switched	O
to	O
a	O
KHB	O
buffer	O
containing	O
thulium	O
(	O
III	O
)	O
-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis-	O
(	O
methylenephosphonate	O
)	O
[	O
Tm	O
(	O
DOTP	O
)	O
5−	O
]	O
(	O
a	O
23	O
Na	O
-NMR	O
shift	O
reagent	O
)	O
,	O
equilibrated	O
with	O
a	O
gas	O
mixture	O
of	O
95	O
%	O
O2	O
+	O
5	O
%	O
CO2	O
and	O
maintained	O
at	O
37	O
°	O
C	O
.	O

The	O
buffer	O
for	O
the	O
study	O
with	O
23	O
Na	O
-NMR	O
spectra	O
was	O
the	O
same	O
as	O
the	O
normal	O
KHB	O
buffer	O
,	O
except	O
that	O
it	O
contained	O
104	O
mM	O
NaCl	O
,	O
3.5	O
mM	O
Na4	O
HTmDOTP	O
and	O
3.9	O
mM	O
CaCl2	O
.	O

The	O
reason	O
for	O
use	O
of	O
3.9	O
mM	O
CaCl2	O
was	O
that	O
addition	O
of	O
3.9	O
mM	O
CaCl2	O
would	O
produce	O
1	O
mM	O
free	O
Ca2	O
+	O
in	O
the	O
presence	O
of	O
the	O
shift	O
reagent	O
(	O
Buster	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Although	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
was	O
lower	O
than	O
that	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
(	O
2.5	O
mM	O
)	O
,	O
it	O
(	O
1	O
mM	O
)	O
was	O
chosen	O
to	O
avoid	O
precipitation	O
of	O
the	O
shift	O
reagent	O
(	O
Van	O
Emous	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
heart	O
rate	O
was	O
kept	O
constant	O
by	O
pacing	O
the	O
heart	O
at	O
300	O
beats	O
min−1	O
,	O
using	O
a	O
pair	O
of	O
copper	O
electrodes	O
and	O
an	O
electronic	O
stimulator	O
(	O
SEN-3301	O
,	O
Nihon	O
Kohden	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

For	O
measurement	O
of	O
left	O
ventricular	O
pressure	O
,	O
a	O
latex	O
balloon	O
connected	O
to	O
a	O
pressure	O
transducer	O
was	O
inserted	O
into	O
the	O
left	O
ventricular	O
cavity	O
via	O
the	O
left	O
atrium	O
.	O

Before	O
experiments	O
,	O
the	O
balloon	O
was	O
inflated	O
with	O
distilled	O
water	O
to	O
achieve	O
an	O
initial	O
end	O
-	O
diastolic	O
pressure	O
of	O
10	O
mm	O
Hg	O
;	O
thereafter	O
,	O
the	O
volume	O
was	O
kept	O
constant	O
during	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
hearts	O
perfused	O
with	O
the	O
buffer	O
were	O
placed	O
inside	O
a	O
glass	O
NMR	O
tube	O
(	O
13.4	O
mm	O
in	O
internal	O
diameter	O
)	O
that	O
was	O
introduced	O
into	O
the	O
NMR	O
probe	O
placed	O
in	O
a	O
superconducting	O
magnet	O
.	O

Because	O
the	O
internal	O
diameter	O
of	O
the	O
glass	O
NMR	O
tube	O
was	O
small	O
,	O
only	O
small	O
hearts	O
were	O
used	O
for	O
the	O
NMR	O
experiments	O
.	O

Therefore	O
,	O
relatively	O
small	O
rats	B
weighing	O
about	O
200	O
g	O
were	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
.	O

The	O
temperature	O
surrounding	O
the	O
glass	O
NMR	O
tube	O
was	O
maintained	O
at	O
about	O
20	O
°	O
C	O
by	O
air	O
conditioner	O
,	O
because	O
the	O
apparatus	O
used	O
in	O
the	O
present	O
study	O
is	O
not	O
equipped	O
to	O
provide	O
a	O
temperature	O
-	O
controlled	O
air	O
stream	O
around	O
the	O
NMR	O
tube	O
.	O

Coronary	O
effluent	O
was	O
removed	O
from	O
the	O
NMR	O
glass	O
tube	O
to	O
a	O
level	O
of	O
about	O
10	O
mm	O
above	O
the	O
heart	O
.	O

Perfusion	O
fluid	O
was	O
not	O
recirculated	O
.	O

2.5	O
23	O
Na	O
-NMR	O
measurements	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O
23	O
Na	O
-spectra	O
were	O
obtained	O
using	O
a	O
GX-270	O
spectrometer	O
(	O
JEOL	O
,	O
Tokyo	O
,	O
Japan	O
)	O
at	O
71.32	O
MHz	O
with	O
a	O
pulse	O
width	O
of	O
90	O
°	O
,	O
an	O
interpulse	O
delay	O
of	O
0.5	O
s	O
,	O
a	O
spectral	O
width	O
of	O
3000	O
Hz	O
and	O
data	O
size	O
of	O
2048	O
.	O

The	O
spectrometer	O
was	O
equipped	O
with	O
a	O
6.3-T	O
superconducting	O
magnet	O
and	O
an	O
NMR	O
probe	O
(	O
TU	O
(	O
15	O
)	O
,	O
JEOL	O
)	O
in	O
which	O
the	O
glass	O
NMR	O
tube	O
was	O
placed	O
.	O

Four	O
glass	O
capillaries	O
,	O
each	O
containing	O
1.67	O
μmol	O
NaCl	O
in	O
the	O
presence	O
of	O
50	O
mM	O
Tris	O
form	O
of	O
dysprosium	O
triethylenetetraminehexaacetic	O
acid	O
[	O
Tris3	O
Dy	O
(	O
TTHA	O
)	O
·3Tris	O
–	O
HCl	O
]	O
(	O
another	O
23	O
Na	O
-NMR	O
shift	O
reagent	O
)	O
,	O
were	O
placed	O
inside	O
of	O
the	O
NMR	O
tube	O
as	O
an	O
internal	O
standard	O
.	O

The	O
area	O
of	O
each	O
peak	O
in	O
the	O
23	O
Na	O
-NMR	O
spectra	O
was	O
analyzed	O
by	O
integration	O
after	O
Gaussian	O
and	O
Lorentzian	O
multiplication	O
and	O
baseline	O
correction	O
using	O
JEOL	O
ALICE2	O
software	O
(	O
JEOL	O
DATUM	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
[	O
Na+	O
]	O
i	O
of	O
the	O
cardiac	O
cells	O
was	O
calculated	O
by	O
a	O
comparison	O
between	O
the	O
peak	O
area	O
of	O
[	O
Na+	O
]	O
i	O
and	O
that	O
of	O
the	O
reference	O
solution	O
in	O
the	O
glass	O
capillaries	O
.	O

2.6	O
Experimental	O
protocol	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O

The	O
hearts	O
were	O
divided	O
into	O
four	O
groups	O
:	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
tetrodotoxin	O
(	O
3	O
μM	O
)	O
groups	O
.	O

In	O
these	O
groups	O
,	O
the	O
hearts	O
were	O
perfused	O
with	O
the	O
Tm	O
(	O
DOTP	O
)	O
5−	O
-containing	O
KHB	O
buffer	O
throughout	O
the	O
experiment	O
(	O
stabilization	O
period	O
for	O
10	O
min	O
and	O
observation	O
period	O
for	O
40	O
min	O
)	O
.	O

After	O
the	O
stabilization	O
period	O
,	O
d	O
-cis	O
-diltiazem	O
,	O
l	O
-cis	O
-diltiazem	O
or	O
vehicle	O
(	O
KHB	O
buffer	O
for	O
both	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
)	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
for	O
40	O
min	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
.	O

The	O
final	O
concentration	O
of	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
15	O
μM	O
and	O
the	O
final	O
concentration	O
of	O
tetrodotoxin	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
3	O
μM.	O
H2	O
O2	O
was	O
infused	O
into	O
the	O
aortic	O
cannula	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
for	O
4	O
min	O
from	O
10	O
min	O
after	O
the	O
start	O
of	O
infusion	O
of	O
l	O
-cis	O
-diltiazem	O
,	O
d	O
-cis	O
-diltiazem	O
or	O
tetrodotoxin	O
.	O

The	O
final	O
concentration	O
of	O
H2	O
O2	O
in	O
the	O
perfusate	O
was	O
set	O
to	O
1	O
mM.	O
Thus	O
,	O
the	O
concentration	O
of	O
H2	O
O2	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
higher	O
than	O
that	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
because	O
in	O
a	O
preliminary	O
experiment	O
,	O
a	O
high	O
concentration	O
of	O
H2	O
O2	O
was	O
needed	O
to	O
induce	O
mechanical	O
dysfunction	O
to	O
a	O
degree	O
similar	O
to	O
that	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

After	O
the	O
experiment	O
,	O
the	O
hearts	O
were	O
put	O
into	O
an	O
oven	O
(	O
80	O
°	O
C	O
)	O
for	O
48	O
h	O
,	O
in	O
order	O
to	O
measure	O
the	O
dry	O
weight	O
of	O
the	O
tissue	O
.	O

The	O
volume	O
of	O
intracellular	O
water	O
was	O
assumed	O
to	O
be	O
2.45	O
ml	O
g−1	O
dry	O
weight	O
(	O
Askenasy	O
et	O
al.	O
,	O
1995	O
)	O
.	O

2.7	O
Direct	O
effect	O
of	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
concentration	O
in	O
vitro	O
(	O
another	O
experiment	O
)	O
To	O
determine	O
whether	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
have	O
a	O
direct	O
scavenging	O
effect	O
on	O
H2	O
O2	O
,	O
the	O
effect	O
of	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
concentration	O
was	O
investigated	O
and	O
compared	O
with	O
that	O
of	O
dimethylthiourea	O
,	O
which	O
has	O
an	O
H2	O
O2	O
-scavenging	O
action	O
(	O
Jackson	O
et	O
al.	O
,	O
1985	O
)	O
.	O

A	O
mixture	O
of	O
H2	O
O2	O
(	O
600	O
μM	O
)	O
and	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
or	O
that	O
of	O
H2	O
O2	O
(	O
600	O
μM	O
)	O
and	O
dimethylthiourea	O
(	O
10	O
mM	O
)	O
in	O
0.1	O
M	O
phosphate	O
buffer	O
(	O
pH	O
7.0	O
)	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
.	O

The	O
H2	O
O2	O
concentration	O
in	O
the	O
buffer	O
was	O
measured	O
according	O
to	O
a	O
spectrophotometric	O
method	O
(	O
Hayashi	O
et	O
al.	O
,	O
1989	O
)	O
.	O

2.8	O
Drugs	O
d	O
-cis	O
-Diltiazem	O
(	O
Sigma	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
Tanabe	O
Seiyaku	O
,	O
Osaka	O
,	O
Japan	O
)	O
and	O
tetrodotoxin	O
(	O
Sankyo	O
,	O
Tokyo	O
,	O
Japan	O
)	O
were	O
dissolved	O
in	O
KHB	O
buffer	O
solution	O
.	O

These	O
agents	O
were	O
infused	O
at	O
a	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
,	O
using	O
an	O
infusion	O
pump	O
,	O
into	O
the	O
inflow	O
tube	O
connected	O
to	O
the	O
side	O
arm	O
of	O
the	O
aortic	O
cannula	O
.	O

H2	O
O2	O
(	O
Nacalai	O
Tesque	O
,	O
Kyoto	O
,	O
Japan	O
)	O
was	O
diluted	O
with	O
saline	O
solution	O
.	O

H2	O
O2	O
was	O
also	O
infused	O
into	O
the	O
inflow	O
tube	O
at	O
a	O
flow	O
rate	O
of	O
0.1	O
ml	O
min−1	O
using	O
another	O
infusion	O
pump	O
.	O

Dimethylthiourea	O
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
(	O
St.	O
Louis	O
,	O
USA	O
)	O
.	O

The	O
reagents	O
and	O
enzymes	O
used	O
for	O
biochemical	O
analysis	O
were	O
purchased	O
from	O
Sigma	O
.	O

Na4	O
HTmDOTP	O
was	O
purchased	O
from	O
Magnetic	O
Resonance	O
Solutions	O
(	O
Dallas	O
,	O
USA	O
)	O
.	O

Tris3	O
Dy	O
(	O
TTHA	O
)	O
·3Tris	O
–	O
HCl	O
(	O
50	O
mM	O
)	O
was	O
prepared	O
by	O
mixing	O
DyCl3	O
·	O
6H2	O
O	O
(	O
Sigma	O
)	O
(	O
50	O
mM	O
)	O
with	O
H6	O
TTHA	O
(	O
Sigma	O
)	O
(	O
50	O
mM	O
)	O
in	O
the	O
Tris	O
buffer	O
(	O
pH	O
7.4	O
)	O
.	O

2.9	O
Statistical	O
analysis	O
All	O
values	O
are	O
expressed	O
as	O
means±S.E.M.	O
When	O
changes	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
,	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
,	O
left	O
ventricular	O
developed	O
pressure	O
,	O
LDH	O
release	O
and	O
[	O
Na+	O
]	O
i	O
were	O
compared	O
between	O
vehicle	O
-	O
treated	O
and	O
drug	O
-	O
treated	O
groups	O
,	O
statistical	O
analysis	O
was	O
performed	O
with	O
a	O
two	O
-	O
way	O
repeated	O
measures	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
Dunnett	O
's	O
test	O
for	O
multiple	O
comparisons	O
.	O

If	O
a	O
significant	O
difference	O
was	O
obtained	O
between	O
these	O
groups	O
,	O
further	O
comparisons	O
at	O
each	O
time	O
point	O
were	O
performed	O
by	O
means	O
of	O
Dunnett	O
's	O
test	O
(	O
Fig.	O
1	O
Figs.	O
3	O
,	O
4	O
and	O
6	O
and	O
8	O
)	O
.	O

When	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	O
in	O
the	O
vehicle	O
group	O
were	O
compared	O
between	O
H2	O
O2	O
-untreated	O
and	O
H2	O
O2	O
-treated	O
hearts	O
,	O
unpaired	O
Student	O
's	O
t	O
-test	O
was	O
used	O
(	O
Fig.	O
2	O
Fig.	O
5	O
)	O
.	O

When	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	O
and	O
the	O
H2	O
O2	O
concentration	O
were	O
compared	O
between	O
vehicle	O
-	O
treated	O
and	O
drug	O
-	O
treated	O
groups	O
,	O
statistical	O
analysis	O
was	O
performed	O
with	O
a	O
one	O
-	O
way	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
for	O
multiple	O
comparisons	O
(	O
Figs.	O
2	O
and	O
5	O
,	O
Table	O
1	O
)	O
.	O

A	O
difference	O
was	O
considered	O
statistically	O
significant	O
at	O
P	O
<	O
0.05	O
.	O

3	O
Results	O
3.1	O
Effects	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
H2	O
O2	O
-induced	O
mechanical	O
derangements	O
in	O
the	O
heart	O
Fig.	O
1	O
shows	O
the	O
effect	O
of	O
various	O
concentrations	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
dysfunction	O
.	O

Before	O
the	O
start	O
of	O
the	O
infusion	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
1	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
between	O
the	O
vehicle	O
and	O
l	O
-cis	O
-diltiazem	O
groups	O
.	O

No	O
concentration	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
had	O
a	O
significant	O
action	O
on	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
before	O
H2	O
O2	O
infusion	O
(	O
20	O
min	O
in	O
Fig.	O
1	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
produced	O
a	O
temporary	O
,	O
but	O
marked	O
decrease	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
,	O
which	O
was	O
followed	O
by	O
incomplete	O
recovery	O
to	O
the	O
initial	O
level	O
.	O

H2	O
O2	O
also	O
produced	O
a	O
marked	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
,	O
which	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
.	O

The	O
decrease	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
induced	O
by	O
H2	O
O2	O
was	O
not	O
significantly	O
modified	O
by	O
any	O
concentration	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
P	O
=	O
0.616	O
by	O
ANOVA	O
)	O
.	O

In	O
contrast	O
,	O
a	O
high	O
concentration	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
significantly	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
although	O
lower	O
concentrations	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
or	O
10	O
μM	O
)	O
did	O
not	O
.	O

Fig.	O
2	O
shows	O
the	O
effects	O
of	O
various	O
concentrations	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
,	O
10	O
or	O
15	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
decreased	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
ADP	O
and	O
creatine	O
phosphate	O
and	O
increased	O
the	O
tissue	O
level	O
of	O
AMP	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
were	O
not	O
attenuated	O
by	O
lower	O
concentrations	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
5	O
or	O
10	O
μM	O
)	O
.	O

However	O
,	O
a	O
high	O
concentration	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
significantly	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
at	O
the	O
concentration	O
of	O
15	O
μM	O
,	O
l	O
-cis	O
-diltiazem	O
attenuates	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
and	O
metabolic	O
derangements	O
in	O
the	O
heart	O
.	O

Next	O
,	O
the	O
effect	O
of	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
was	O
compared	O
with	O
that	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
.	O

Fig.	O
3	O
shows	O
the	O
effects	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
changes	O
in	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Before	O
the	O
infusion	O
of	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
3	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
values	O
of	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
among	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
groups	O
.	O

Before	O
the	O
H2	O
O2	O
infusion	O
(	O
15	O
and	O
20	O
min	O
in	O
Fig.	O
3	O
)	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
left	O
ventricular	O
systolic	O
pressure	O
in	O
the	O
d	O
-cis	O
-diltiazem	O
group	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
while	O
there	O
was	O
no	O
decrease	O
in	O
the	O
l	O
-cis	O
-diltiazem	O
group	O
;	O
left	O
ventricular	O
systolic	O
pressure	O
decreased	O
only	O
in	O
the	O
d	O
-cis	O
-diltiazem	O
group	O
(	O
15–55	O
min	O
in	O
Fig.	O
3	O
)	O
.	O

As	O
seen	O
in	O
Fig.	O
1	O
,	O
in	O
the	O
vehicle	O
group	O
H2	O
O2	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
and	O
increased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
.	O

It	O
is	O
noteworthy	O
,	O
however	O
,	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuated	O
significantly	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

Fig.	O
4	O
shows	O
the	O
effects	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
,	O
which	O
is	O
expressed	O
as	O
left	O
ventricular	O
systolic	O
pressure	O
minus	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Before	O
the	O
infusion	O
of	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
(	O
0	O
,	O
5	O
and	O
10	O
min	O
in	O
Fig.	O
4	O
)	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
left	O
ventricular	O
developed	O
pressure	O
value	O
among	O
vehicle	O
,	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
groups	O
.	O

Before	O
the	O
H2	O
O2	O
infusion	O
(	O
15	O
and	O
20	O
min	O
in	O
Fig.	O
4	O
)	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
left	O
ventricular	O
developed	O
pressure	O
in	O
the	O
d	O
-cis	O
-diltiazem	O
group	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
while	O
there	O
was	O
no	O
decrease	O
in	O
the	O
l	O
-cis	O
-diltiazem	O
group	O
;	O
d	O
-cis	O
-diltiazem	O
alone	O
decreased	O
left	O
ventricular	O
developed	O
pressure	O
(	O
15–55	O
min	O
in	O
Fig.	O
4	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
decreased	O
left	O
ventricular	O
developed	O
pressure	O
markedly	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
.	O

l	O
-cis	O
-Diltiazem	O
attenuated	O
significantly	O
the	O
H2	O
O2	O
-induced	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
whereas	O
d	O
-cis	O
-diltiazem	O
did	O
not	O
attenuate	O
it	O
,	O
probably	O
because	O
of	O
its	O
cardiodepressive	O
action	O
.	O

Thus	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
changes	O
in	O
both	O
left	O
ventricular	O
developed	O
pressure	O
and	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
.	O

Fig.	O
5	O
shows	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
in	O
the	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
groups	O
before	O
H2	O
O2	O
infusion	O
(	O
20	O
min	O
in	O
Fig.	O
4	O
)	O
and	O
after	O
the	O
H2	O
O2	O
infusion	O
(	O
55	O
min	O
in	O
Fig.	O
4	O
)	O
.	O

The	O
tissue	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
before	O
H2	O
O2	O
infusion	O
were	O
similar	O
among	O
the	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
groups	O
(	O
P	O
>	O
0.05	O
by	O
ANOVA	O
)	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
decreased	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
ADP	O
and	O
creatine	O
phosphate	O
,	O
and	O
increased	O
the	O
tissue	O
level	O
of	O
AMP	O
(	O
P	O
<	O
0.05	O
)	O
.	O

These	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
energy	O
metabolites	O
induced	O
by	O
H2	O
O2	O
were	O
significantly	O
attenuated	O
by	O
d	O
-cis	O
-diltiazem	O
(	O
P	O
<	O
0.01	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

l	O
-cis	O
-Diltiazem	O
also	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
changes	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	O
,	O
AMP	O
and	O
creatine	O
phosphate	O
(	O
P	O
<	O
0.01	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
,	O
although	O
it	O
failed	O
to	O
attenuate	O
the	O
H2	O
O2	O
-induced	O
decrease	O
in	O
the	O
tissue	O
level	O
of	O
ADP	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuate	O
the	O
H2	O
O2	O
-induced	O
decrease	O
in	O
high	O
-	O
energy	O
phosphates	O
in	O
the	O
heart	O
.	O

Fig.	O
6	O
shows	O
the	O
effects	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
release	O
of	O
LDH	O
.	O

In	O
the	O
vehicle	O
,	O
d	O
-cis	O
-diltiazem	O
and	O
l	O
-cis	O
-diltiazem	O
groups	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
release	O
of	O
LDH	O
before	O
H2	O
O2	O
infusion	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
produced	O
a	O
marked	O
release	O
of	O
LDH	O
from	O
the	O
myocardium	O
into	O
the	O
effluent	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
;	O
the	O
LDH	O
release	O
reached	O
a	O
maximum	O
21.5	O
min	O
after	O
the	O
end	O
of	O
H2	O
O2	O
infusion	O
(	O
35	O
min	O
in	O
Fig.	O
6	O
)	O
.	O

The	O
LDH	O
release	O
induced	O
by	O
H2	O
O2	O
was	O
significantly	O
attenuated	O
by	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuate	O
the	O
H2	O
O2	O
-induced	O
damage	O
of	O
the	O
cardiac	O
cell	O
membrane	O
.	O

3.2	O
Effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
H2	O
O2	O
-induced	O
changes	O
in	O
[	O
Na+	O
]	O
i	O
Fig.	O
7	O
shows	O
typical	O
23	O
Na	O
spectra	O
for	O
the	O
rat	B
heart	O
in	O
the	O
presence	O
of	O
the	O
23	O
Na	O
shift	O
reagent	O
Tm	O
(	O
DOTP	O
)	O
5−	O
.	O

H2	O
O2	O
(	O
1	O
mM	O
)	O
was	O
added	O
to	O
the	O
heart	O
for	O
4	O
min	O
(	O
from	O
15	O
to	O
19	O
min	O
in	O
Fig.	O
7	O
)	O
.	O

It	O
is	O
evident	O
that	O
in	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
caused	O
an	O
increase	O
in	O
the	O
peak	O
of	O
[	O
Na+	O
]	O
i	O
,	O
which	O
was	O
markedly	O
attenuated	O
by	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
or	O
tetrodotoxin	O
(	O
3	O
μM	O
)	O
.	O

Fig.	O
8	O
shows	O
the	O
effects	O
of	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
tetrodotoxin	O
(	O
3	O
μM	O
)	O
on	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
in	O
myocardial	O
cells	O
.	O

In	O
the	O
vehicle	O
group	O
,	O
H2	O
O2	O
(	O
1	O
mM	O
)	O
increased	O
[	O
Na+	O
]	O
i	O
markedly	O
(	O
P	O
<	O
0.001	O
by	O
ANOVA	O
)	O
and	O
the	O
increase	O
reached	O
a	O
maximum	O
20	O
min	O
after	O
the	O
end	O
of	O
H2	O
O2	O
infusion	O
(	O
34	O
min	O
in	O
Fig.	O
8	O
)	O
.	O

The	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
induced	O
by	O
H2	O
O2	O
was	O
almost	O
completely	O
inhibited	O
by	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

Tetrodotoxin	O
also	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
(	O
P	O
<	O
0.05	O
by	O
ANOVA	O
followed	O
by	O
Dunnett	O
's	O
test	O
)	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuate	O
the	O
intracellular	O
accumulation	O
of	O
intracellular	O
Na+	O
induced	O
by	O
H2	O
O2	O
.	O

In	O
the	O
second	O
series	O
of	O
experiments	O
,	O
we	O
also	O
continuously	O
recorded	O
the	O
mechanical	O
function	O
(	O
left	O
ventricular	O
pressure	O
)	O
of	O
the	O
heart	O
,	O
and	O
similar	O
results	O
as	O
in	O
the	O
first	O
series	O
of	O
experiments	O
(	O
Fig.	O
3	O
)	O
were	O
obtained	O
:	O
H2	O
O2	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
increased	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
,	O
and	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
was	O
attenuated	O
by	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
,	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
or	O
tetrodotoxin	O
(	O
data	O
not	O
shown	O
)	O
.	O

If	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
have	O
a	O
Na+	O
channel	O
blocking	O
action	O
,	O
[	O
Na+	O
]	O
i	O
in	O
normal	O
cardiac	O
cells	O
(	O
without	O
H2	O
O2	O
)	O
should	O
decrease	O
after	O
treatment	O
of	O
the	O
heart	O
with	O
d	O
-cis	O
-	O
or	O
l	O
-cis	O
-diltiazem	O
.	O

However	O
,	O
neither	O
tetrodotoxin	O
,	O
nor	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
changed	O
[	O
Na+	O
]	O
i	O
in	O
the	O
normal	O
cardiac	O
cells	O
:	O
[	O
Na+	O
]	O
i	O
remained	O
unchanged	O
within	O
the	O
accuracy	O
of	O
the	O
assay	O
.	O

3.3	O
Effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
concentration	O
of	O
H2	O
O2	O
in	O
the	O
buffer	O
solution	O
in	O
vitro	O
We	O
examined	O
whether	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
have	O
a	O
direct	O
scavenging	O
effect	O
on	O
H2	O
O2	O
in	O
vitro	O
.	O

d	O
-cis	O
-	O
or	O
l	O
-cis	O
-Diltiazem	O
,	O
however	O
,	O
did	O
not	O
modify	O
the	O
H2	O
O2	O
concentration	O
in	O
the	O
buffer	O
solution	O
(	O
Table	O
1	O
)	O
.	O

In	O
contrast	O
,	O
dimethylthiourea	O
,	O
which	O
has	O
a	O
H2	O
O2	O
-scavenging	O
action	O
,	O
decreased	O
the	O
H2	O
O2	O
concentration	O
markedly	O
.	O

These	O
results	O
suggest	O
that	O
neither	O
d	O
-cis	O
-diltiazem	O
nor	O
l	O
-cis	O
-diltiazem	O
has	O
a	O
direct	O
scavenging	O
action	O
on	O
H2	O
O2	O
in	O
vitro	O
.	O

4	O
Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
myocardial	O
derangements	O
in	O
the	O
isolated	O
perfused	O
rat	B
heart	O
.	O

l	O
-cis	O
-Diltiazem	O
is	O
an	O
optical	O
isomer	O
of	O
d	O
-cis	O
-diltiazem	O
and	O
is	O
about	O
20–100	O
times	O
less	O
potent	O
than	O
d	O
-cis	O
-diltiazem	O
in	O
its	O
Ca2	O
+	O
channel	O
blocking	O
action	O
(	O
Nasa	O
et	O
al.	O
,	O
1992	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
.	O

We	O
used	O
H2	O
O2	O
as	O
a	O
substance	O
that	O
may	O
be	O
responsible	O
for	O
ischemic	O
derangements	O
for	O
the	O
following	O
reasons	O
:	O
(	O
1	O
)	O
H2	O
O2	O
and	O
its	O
metabolite	O
,	O
hydroxyl	O
radical	O
,	O
are	O
considered	O
important	O
in	O
the	O
pathogenesis	O
of	O
myocardial	O
damage	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
(	O
Brown	O
et	O
al.	O
,	O
1988	O
;	O
Loesser	O
et	O
al.	O
,	O
1991	O
)	O
;	O
(	O
2	O
)	O
H2	O
O2	O
penetrates	O
the	O
cell	O
membrane	O
and	O
reaches	O
the	O
intracellular	O
site	O
(	O
Fisher	O
,	O
1988	O
)	O
,	O
and	O
therefore	O
it	O
may	O
produce	O
severe	O
damage	O
to	O
the	O
cell	O
.	O

In	O
the	O
first	O
series	O
of	O
experiments	O
,	O
H2	O
O2	O
produced	O
an	O
increase	O
in	O
left	O
ventricular	O
end	O
-	O
diastolic	O
pressure	O
and	O
a	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
(	O
i.e.	O
,	O
mechanical	O
dysfunction	O
)	O
,	O
a	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
ATP	O
and	O
creatine	O
phosphate	O
and	O
an	O
increase	O
in	O
the	O
tissue	O
AMP	O
level	O
(	O
i.e.	O
,	O
energy	O
deficiency	O
)	O
,	O
and	O
an	O
increase	O
in	O
LDH	O
release	O
from	O
the	O
myocardium	O
(	O
i.e.	O
,	O
membrane	O
damage	O
)	O
.	O

These	O
alterations	O
induced	O
by	O
H2	O
O2	O
were	O
attenuated	O
by	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
.	O

In	O
contrast	O
to	O
l	O
-cis	O
-diltiazem	O
,	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
failed	O
to	O
attenuate	O
the	O
decrease	O
in	O
left	O
ventricular	O
developed	O
pressure	O
induced	O
by	O
H2	O
O2	O
,	O
because	O
d	O
-cis	O
-diltiazem	O
has	O
a	O
potent	O
Ca2	O
+	O
channel	O
blocking	O
action	O
,	O
leading	O
to	O
a	O
decrease	O
in	O
mechanical	O
function	O
.	O

In	O
fact	O
,	O
the	O
cardiodepressive	O
action	O
of	O
d	O
-cis	O
-diltiazem	O
was	O
observed	O
before	O
H2	O
O2	O
infusion	O
.	O

These	O
results	O
suggest	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
protect	O
the	O
myocardium	O
against	O
the	O
H2	O
O2	O
-induced	O
derangements	O
,	O
and	O
that	O
their	O
cardioprotective	O
action	O
is	O
not	O
only	O
due	O
to	O
the	O
Ca2	O
+	O
channel	O
blocking	O
action	O
.	O

Some	O
radical	O
scavengers	O
or	O
anti	O
-	O
oxidants	O
have	O
been	O
demonstrated	O
to	O
protect	O
the	O
myocardium	O
against	O
oxidative	O
stress	O
(	O
Nakaya	O
et	O
al.	O
,	O
1987	O
;	O
Weglicki	O
et	O
al.	O
,	O
1990	O
;	O
Nagy	O
et	O
al.	O
,	O
1996	O
)	O
.	O

In	O
fact	O
,	O
we	O
have	O
reported	O
that	O
,	O
in	O
the	O
isolated	O
perfused	O
rat	B
heart	O
,	O
catalase	O
(	O
a	O
H2	O
O2	O
scavenger	O
)	O
(	O
Hara	O
et	O
al.	O
,	O
1993	O
)	O
or	O
propofol	O
(	O
an	O
intravenous	O
anesthetic	O
drug	O
with	O
an	O
anti	O
-	O
oxidant	O
action	O
)	O
(	O
Kokita	O
and	O
Hara	O
,	O
1996	O
)	O
attenuates	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
dysfunction	O
and	O
the	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
.	O

There	O
is	O
evidence	O
to	O
show	O
that	O
d	O
-cis	O
-diltiazem	O
has	O
an	O
anti	O
-	O
oxidant	O
action	O
(	O
Janero	O
et	O
al.	O
,	O
1988	O
;	O
Mak	O
and	O
Weglicki	O
,	O
1990	O
;	O
Weglicki	O
et	O
al.	O
,	O
1990	O
)	O
,	O
whereas	O
there	O
is	O
no	O
information	O
about	O
the	O
anti	O
-	O
oxidant	O
action	O
of	O
l	O
-cis	O
-diltiazem	O
.	O

The	O
concentration	O
of	O
d	O
-cis	O
-diltiazem	O
required	O
for	O
its	O
anti	O
-	O
oxidant	O
action	O
is	O
much	O
higher	O
than	O
that	O
used	O
in	O
the	O
present	O
study	O
;	O
in	O
the	O
sarcolemmal	O
membrane	O
,	O
the	O
concentration	O
required	O
to	O
inhibit	O
50	O
%	O
of	O
lipid	O
peroxidation	O
(	O
IC50	O
)	O
induced	O
by	O
oxygen	O
radicals	O
is	O
510	O
μM	O
(	O
Janero	O
et	O
al.	O
,	O
1988	O
)	O
or	O
850	O
μM	O
(	O
Mak	O
and	O
Weglicki	O
,	O
1990	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
neither	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
nor	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
modified	O
the	O
H2	O
O2	O
concentration	O
in	O
the	O
buffer	O
solution	O
in	O
vitro	O
.	O

It	O
is	O
unlikely	O
,	O
therefore	O
,	O
that	O
the	O
protective	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
derangements	O
is	O
due	O
to	O
the	O
radical	O
scavenging	O
or	O
anti	O
-	O
oxidant	O
effect	O
.	O

According	O
to	O
recent	O
electrophysiological	O
studies	O
,	O
H2	O
O2	O
causes	O
an	O
increase	O
in	O
Na+	O
current	O
in	O
ventricular	O
myocytes	O
,	O
an	O
increase	O
which	O
is	O
blocked	O
by	O
tetrodotoxin	O
(	O
Bhatnagar	O
et	O
al.	O
,	O
1990	O
;	O
Ward	O
and	O
Giles	O
,	O
1997	O
)	O
.	O

Ver	O
Donck	O
and	O
Borgers	O
(	O
1991	O
)	O
have	O
suggested	O
that	O
the	O
reactive	O
oxygen	O
species	O
causes	O
excessive	O
Na+	O
entry	O
through	O
the	O
fast	O
Na+	O
channel	O
,	O
leading	O
to	O
intracellular	O
Ca2	O
+	O
overload	O
through	O
the	O
Na+	O
–Ca2	O
+	O
exchange	O
system	O
,	O
and	O
hence	O
myocardial	O
damage	O
.	O

In	O
fact	O
,	O
H2	O
O2	O
increases	O
intracellular	O
concentrations	O
of	O
both	O
Na+	O
and	O
Ca2	O
+	O
in	O
the	O
myocardium	O
(	O
Yanagida	O
et	O
al.	O
,	O
1995	O
)	O
.	O

Interestingly	O
,	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
have	O
been	O
demonstrated	O
to	O
block	O
the	O
Na+	O
channel	O
(	O
Nakajima	O
et	O
al.	O
,	O
1975	O
;	O
Itogawa	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
reported	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
inhibited	O
the	O
veratridine	O
(	O
a	O
Na+	O
channel	O
opener	O
)	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
and	O
hypercontracture	O
in	O
rat	B
myocytes	O
at	O
the	O
concentration	O
of	O
10	O
μM	O
or	O
higher	O
.	O

There	O
is	O
a	O
possibility	O
,	O
therefore	O
,	O
that	O
the	O
beneficial	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
derangements	O
is	O
due	O
to	O
their	O
blocking	O
effect	O
on	O
the	O
Na+	O
channel	O
.	O

To	O
determine	O
this	O
possibility	O
,	O
we	O
examined	O
the	O
effect	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
in	O
the	O
myocardium	O
using	O
an	O
NMR	O
technique	O
(	O
the	O
second	O
series	O
of	O
experiments	O
)	O
.	O

We	O
used	O
a	O
higher	O
concentration	O
of	O
H2	O
O2	O
in	O
the	O
second	O
series	O
of	O
experiments	O
than	O
in	O
the	O
first	O
series	O
of	O
experiments	O
:	O
in	O
the	O
second	O
series	O
of	O
experiments	O
,	O
1	O
mM	O
H2	O
O2	O
was	O
applied	O
for	O
4	O
min	O
,	O
whereas	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
600	O
μM	O
H2	O
O2	O
was	O
applied	O
for	O
3.5	O
min	O
.	O

This	O
is	O
because	O
in	O
the	O
second	O
series	O
of	O
experiments	O
,	O
a	O
large	O
amount	O
of	O
H2	O
O2	O
was	O
needed	O
to	O
induce	O
mechanical	O
dysfunction	O
to	O
a	O
degree	O
similar	O
to	O
that	O
seen	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

The	O
decreased	O
response	O
of	O
the	O
heart	O
to	O
H2	O
O2	O
in	O
the	O
second	O
series	O
of	O
experiments	O
may	O
be	O
due	O
to	O
the	O
difference	O
in	O
perfusion	O
conditions	O
,	O
such	O
as	O
lower	O
Ca2	O
+	O
concentration	O
and	O
lower	O
temperature	O
,	O
which	O
are	O
determinants	O
of	O
cardioprotection	O
;	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
(	O
1	O
mM	O
)	O
in	O
the	O
Tm	O
(	O
DOTP	O
)	O
5−	O
-containing	O
KHB	O
buffer	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
lower	O
than	O
that	O
(	O
2.5	O
mM	O
)	O
in	O
the	O
KHB	O
buffer	O
(	O
normal	O
KHB	O
buffer	O
)	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
,	O
and	O
the	O
temperature	O
around	O
the	O
NMR	O
tube	O
(	O
about	O
20	O
°	O
C	O
)	O
used	O
in	O
the	O
second	O
series	O
of	O
experiments	O
was	O
lower	O
that	O
in	O
the	O
water	O
-	O
jacketed	O
chamber	O
(	O
37	O
°	O
C	O
)	O
used	O
in	O
the	O
first	O
series	O
of	O
experiments	O
.	O

When	O
the	O
membrane	O
is	O
severely	O
damaged	O
,	O
intracellular	O
Na+	O
resonance	O
collapses	O
and	O
a	O
broad	O
Na+	O
resonance	O
appears	O
in	O
the	O
23	O
Na	O
-NMR	O
spectra	O
because	O
of	O
entry	O
of	O
the	O
shift	O
reagent	O
into	O
the	O
cell	O
,	O
and	O
therefore	O
measurement	O
of	O
[	O
Na+	O
]	O
i	O
is	O
impossible	O
(	O
Jansen	O
et	O
al.	O
,	O
1998	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
,	O
however	O
,	O
no	O
broad	O
Na+	O
resonance	O
was	O
observed	O
,	O
suggesting	O
that	O
the	O
measurement	O
of	O
[	O
Na+	O
]	O
i	O
was	O
appropriate	O
in	O
the	O
present	O
study	O
.	O

The	O
results	O
of	O
the	O
second	O
series	O
of	O
experiments	O
indicate	O
that	O
both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuate	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
in	O
the	O
heart	O
.	O

Tetrodotoxin	O
(	O
3	O
μM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
Na+	O
channels	O
(	O
Duff	O
et	O
al.	O
,	O
1988	O
)	O
,	O
also	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
in	O
the	O
heart	O
and	O
the	O
H2	O
O2	O
-induced	O
myocardial	O
derangements	O
.	O

Therefore	O
,	O
the	O
protective	O
action	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
may	O
be	O
due	O
to	O
their	O
ability	O
to	O
inhibit	O
the	O
Na+	O
channel	O
.	O

The	O
above	O
view	O
can	O
be	O
supported	O
by	O
our	O
previous	O
findings	O
that	O
tetrodotoxin	O
(	O
Hara	O
et	O
al.	O
,	O
1998	O
)	O
,	O
lidocaine	O
(	O
Hara	O
et	O
al.	O
,	O
1993	O
)	O
and	O
dilazep	O
(	O
Hara	O
and	O
Abiko	O
,	O
1996	O
)	O
,	O
all	O
of	O
which	O
have	O
a	O
Na+	O
channel	O
blocking	O
action	O
,	O
are	O
effective	O
in	O
attenuating	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
dysfunction	O
and	O
decrease	O
in	O
the	O
tissue	O
levels	O
of	O
high	O
-	O
energy	O
phosphates	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
mechanical	O
and	O
metabolic	O
derangements	O
incompletely	O
,	O
even	O
when	O
they	O
attenuated	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
completely	O
.	O

It	O
is	O
possible	O
therefore	O
that	O
the	O
harmful	O
action	O
of	O
H2	O
O2	O
on	O
the	O
heart	O
is	O
not	O
only	O
due	O
to	O
activation	O
of	O
the	O
fast	O
Na+	O
channel	O
,	O
but	O
also	O
due	O
to	O
other	O
mechanisms	O
,	O
such	O
as	O
activation	O
of	O
nonselective	O
cation	O
channels	O
(	O
Jabr	O
and	O
Cole	O
,	O
1995	O
)	O
and	O
inactivation	O
of	O
creatine	O
kinase	O
(	O
Banerjee	O
et	O
al.	O
,	O
1991	O
)	O
.	O

According	O
to	O
Nasa	O
et	O
al.	O
(	O
1990	O
)	O
,	O
d	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
and	O
l	O
-cis	O
-diltiazem	O
(	O
15	O
μM	O
)	O
are	O
capable	O
of	O
attenuating	O
the	O
myocardial	O
derangements	O
induced	O
by	O
ischemia	O
–	O
reperfusion	O
in	O
the	O
isolated	O
,	O
working	O
rat	O
heart	O
.	O

Therefore	O
,	O
the	O
beneficial	O
action	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
on	O
the	O
H2	O
O2	O
-induced	O
changes	O
may	O
contribute	O
to	O
their	O
protective	O
effect	O
on	O
the	O
myocardium	O
against	O
ischemia	O
–	O
reperfusion	O
damage	O
.	O

5	O
Conclusion	O
Both	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
protect	O
the	O
myocardium	O
against	O
the	O
H2	O
O2	O
-induced	O
derangements	O
in	O
the	O
isolated	O
perfused	O
rat	O
heart	O
.	O

The	O
protective	O
action	O
of	O
d	O
-cis	O
-	O
and	O
l	O
-cis	O
-diltiazem	O
may	O
be	O
due	O
to	O
inhibition	O
of	O
the	O
H2	O
O2	O
-induced	O
increase	O
in	O
[	O
Na+	O
]	O
i	O
,	O
at	O
least	O
in	O
part	O
.	O

Acknowledgements	O

We	O
thank	O
Mr.	O
Mitsutoshi	O
Kusakabe	O
for	O
his	O
help	O
in	O
experiments	O
with	O
NMR	O
technique	O
.	O

We	O
also	O
thank	O
Ms.	O
Min	O
Chen	O
for	O
her	O
valuable	O
help	O
during	O
experiments	O
,	O
Mr.	O
Tadahiko	O
Yokoyama	O
for	O
his	O
technical	O
assistance	O
,	O
and	O
Ms.	O
Miwa	O
Kashu	O
and	O
Ms.	O
Kaori	O
Inaba	O
for	O
their	O
secretarial	O
assistance	O
.	O

l	O
-cis	O
-Diltiazem	O
hydrochloride	O
was	O
kindly	O
supplied	O
by	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

Cordyceps	B
sinensis	I
(	I
Berk	I
.	I
)	I

Sacc	B
.	O

(	O
family	O
Clavicipitaceae	B
)	O
has	O
long	O
been	O
used	O
in	O
Chinese	O
medicine	O
to	O
treat	O
numerous	O
illnesses	O
,	O
promote	O
longevity	O
,	O
relieve	O
exhaustion	O
and	O
increase	O
athletic	O
prowess	O
(	O
Pegler	O
,	O
Yao	O
&	O
Li	O
,	O
1994	O
;	O
Steinkraus	O
&	O
Whitfield	O
,	O
1994	O
;	O
Jones	O
,	O
1993	O
;	O
Tsunoo	O
,	O
Taketomo	O
,	O
Tsuboi	O
,	O
Kamijio	O
,	O
Nemoto	O
,	O
Sasaki	O
,	O
Uchida	O
,	O
Yamashita	O
,	O
Kinjo	O
&	O
Haung	O
,	O
1995	O
)	O
.	O

The	O
medicinal	O
preparation	O
from	O
the	O
fruiting	O
bodies	O
of	O
C.	B
sinensis	I
is	O
named	O
dong	O
-	O
chong	O
-	O
xia	O
-	O
cao	O
which	O
translates	O
as	O
winter	O
worm	O
and	O
summer	O
grass	O
.	O

C.	B
sinensis	I
infects	O
the	O
larvae	O
of	O
the	O
sphinx	B
moth	I
,	O
Hepialus	B
armoricanus	I
,	O
found	O
only	O
in	O
the	O
highlands	O
of	O
the	O
Himalayan	O
region	O
,	O
and	O
the	O
larva	O
hibernates	O
underground	O
through	O
the	O
winter	O
.	O

The	O
fungus	B
kills	O
the	O
infected	O
host	B
and	O
grows	O
throughout	O
the	O
cadaver	O
,	O
and	O
in	O
the	O
summer	O
,	O
a	O
rod	O
-	O
like	O
stroma	O
of	O
the	O
fungus	B
grows	O
out	O
from	O
the	O
mummified	O
shell	O
of	O
the	O
dead	O
host	B
.	O

Cordyceps	B
species	O
are	O
generally	O
known	O
as	O
the	O
'	O
caterpillar	B
fungus	I
'	O
due	O
to	O
this	O
characteristic	O
parasitism	O
of	O
the	O
living	O
larvae	O
of	O
insects	B
(	O
Pegler	O
,	O
Yao	O
&	O
Li	O
,	O
1994	O
;	O
Steinkraus	O
&	O
Whitfield	O
,	O
1994	O
;	O
Jones	O
,	O
1993	O
)	O
.	O

A	O
number	O
of	O
bioactive	O
constituents	O
from	O
Cordyceps	B
species	O
have	O
been	O
reported	O
.	O

These	O
include	O
:	O
cordycepin	O
(	O
Cunningham	O
,	O
Herchinson	O
,	O
Manson	O
&	O
Spring	O
,	O
1951	O
;	O
Kredich	O
&	O
Guarino	O
,	O
1960	O
)	O
and	O
other	O
antibacterial	O
and	O
antitumor	O
adenosine	O
derivatives	O
(	O
Furuya	O
,	O
Hirotani	O
&	O
Matsuzawa	O
,	O
1983	O
)	O
,	O
ophicordin	O
,	O
an	O
antifungal	O
agent	O
(	O
Kneifel	O
,	O
Srinivasan	O
&	O
Maiti	O
,	O
1957	O
)	O
,	O
a	O
polysaccharide	O
shown	O
to	O
have	O
antitumor	O
activity	O
(	O
Miyazaki	O
,	O
Oikawa	O
&	O
Yamada	O
,	O
1977	O
;	O
Yamada	O
et	O
al.	O
,	O
1984	O
;	O
Ohmori	O
,	O
Tamura	O
,	O
Tsuru	O
&	O
Nomoto	O
,	O
1986	O
)	O
,	O
an	O
immunopotentiating	O
galactomannan	O
,	O
and	O
l	O
-tryptophan	O
(	O
Zhang	O
,	O
Zhang	O
,	O
Zhu	O
&	O
Chen	O
,	O
1991	O
)	O
.	O

A	O
recent	O
report	O
indicated	O
that	O
the	O
fruiting	O
body	O
of	O
C.	B
sinensis	I
contained	O
growth	O
inhibitors	O
against	O
tumor	O
cells	O
(	O
K562	O
,	O
Vero	O
,	O
Wish	O
,	O
Calu-1	O
and	O
Raji	O
)	O
other	O
than	O
cordycepin	O
and	O
polysaccharides	O
(	O
Kuo	O
,	O
Ching	O
-	O
Yuang	O
Lin	O
,	O
Wei	O
-	O
Jern	O
Tsai	O
,	O
Wu	O
,	O
Chen	O
&	O
Shiao	O
,	O
1994	O
)	O
.	O

We	O
report	O
herein	O
the	O
isolation	O
and	O
identification	O
of	O
two	O
antitumor	O
compounds	O
from	O
the	O
mycelia	O
of	O
C.	B
sinensis	I
.	O

Activity	O
guided	O
chemical	O
fractionations	O
of	O
the	O
methanol	O
extract	O
of	O
C.	B
sinensis	I
,	O
led	O
to	O
the	O
isolation	O
of	O
a	O
steroidal	O
glycoside	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
(	O
1a	O
)	O
and	O
5α	O
,	O
6α	O
-epoxy-24	O
(	O
R	O
)	O
-methylcholesta-7,22-dien-3β	O
-ol	O
(	O
2	O
)	O
.	O

Two	O
previously	O
identified	O
compounds	O
,	O
ergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
3	O
)	O
and	O
22,23-dihydroergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
4	O
)	O
were	O
also	O
isolated	O
during	O
the	O
fractionation	O
of	O
the	O
methanol	O
extract	O
(	O
Shiao	O
,	O
Lin	O
,	O
Lien	O
,	O
Tzean	O
&	O
Lee	O
,	O
1989	O
)	O
.	O

These	O
ergosterol	O
derivatives	O
were	O
not	O
active	O
against	O
the	O
tumor	O
cell	O
lines	O
used	O
in	O
this	O
study	O
.	O

2	O
Results	O
and	O
discussion	O
Compounds	O
3	O
and	O
4	O
were	O
identified	O
by	O
1	O
H	O
NMR	O
spectroscopy	O
as	O
ergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
3	O
)	O
and	O
22,23-dihydroergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
4	O
)	O
previously	O
isolated	O
from	O
the	O
fruiting	O
body	O
of	O
C.	O
sinensis	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Comparison	O
of	O
the	O
1	O
H	O
NMR	O
spectra	O
of	O
1a	O
with	O
3	O
and	O
4	O
suggests	O
that	O
1a	O
was	O
also	O
a	O
glycoside	O
derivative	O
of	O
a	O
sterol	O
.	O

Compound	O
1a	O
was	O
found	O
to	O
have	O
a	O
[	O
M+NH4	O
]	O
+	O
peak	O
from	O
CI	O
of	O
m	O
/z	O
=	O
608	O
[	O
C34	O
H54	O
O8	O
+	O
NH4	O
]	O
+	O
with	O
a	O
prominent	O
fragment	O
ion	O
peak	O
at	O
m	O
/z	O
412	O
in	O
agreement	O
with	O
the	O
proposed	O
presence	O
of	O
a	O
sugar	O
moiety	O
(	O
C6	O
H12	O
O6	O
)	O
.	O

The	O
observation	O
of	O
six	O
methyl	O
signals	O
in	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
1a	O
at	O
δ	O
0.69	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
7.0	O
Hz	O
)	O
,	O
0.70	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
Hz	O
)	O
,	O
0.76	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
)	O
indicates	O
that	O
the	O
sterol	O
fragment	O
of	O
1a	O
is	O
an	O
ergosterol	O
derivative	O
.	O

The	O
doublet	O
at	O
δ	O
4.2	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
)	O
indicates	O
that	O
the	O
attachment	O
of	O
the	O
sugar	O
moiety	O
at	O
C3	O
is	O
in	O
the	O
β	O
-configuration	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
;	O
Ahmed	O
,	O
Ahmed	O
&	O
Malik	O
,	O
1992	O
;	O
Wasylyk	O
,	O
Martin	O
,	O
Weinheimer	O
&	O
Alam	O
,	O
1989	O
)	O
,	O
similar	O
to	O
that	O
of	O
the	O
ergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
3	O
)	O
and	O
22,23-dihydroergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
4	O
)	O
(	O
Shiao	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
observation	O
of	O
the	O
two	O
doublets	O
at	O
δ	O
6.39	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
)	O
and	O
6.13	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
)	O
,	O
approximately	O
1	O
ppm	O
downfield	O
of	O
the	O
H6	O
and	O
H7	O
olefinic	O
protons	O
in	O
3	O
and	O
4	O
,	O
suggested	O
that	O
the	O
aglycone	O
of	O
1a	O
is	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-diene-3β	O
-ol	O
(	O
1b	O
)	O
.	O

The	O
close	O
comparison	O
of	O
the	O
13	O
C	O
data	O
of	O
1a	O
with	O
1b	O
listed	O
in	O
Table	O
1	O
agrees	O
with	O
this	O
proposal	O
.	O

The	O
identity	O
of	O
the	O
sugar	O
moiety	O
in	O
1a	O
was	O
not	O
conclusive	O
from	O
the	O
spectroscopic	O
data	O
.	O

However	O
comparison	O
of	O
the	O
1	O
H	O
and	O
13	O
C	O
NMR	O
spectra	O
of	O
1a	O
with	O
the	O
spectra	O
of	O
the	O
glucopyranosides	O
3	O
and	O
4	O
suggests	O
that	O
1a	O
is	O
also	O
a	O
glucopyranoside	O
.	O

The	O
synthesis	O
of	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
(	O
1a	O
)	O
from	O
ergosterol	O
(	O
6	O
)	O
was	O
carried	O
out	O
as	O
shown	O
in	O
Scheme	O
1	O
.	O

Deacetylation	O
of	O
5	O
(	O
Cerný	O
,	O
Pouzar	O
,	O
Drasar	O
,	O
Budesinsky	O
&	O
Havel	O
,	O
1984	O
)	O
followed	O
by	O
a	O
Diels	O
–	O
Alder	O
addition	O
of	O
singlet	O
O2	O
(	O
1	O
Δg	O
)	O
to	O
the	O
diene	O
in	O
ergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
3	O
)	O
(	O
Gunatilaka	O
,	O
Gopichand	O
,	O
Schmitz	O
&	O
Djerassi	O
,	O
1981	O
)	O
afforded	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
(	O
1a	O
)	O
.	O

Comparison	O
of	O
the	O
1	O
H	O
and	O
13	O
C	O
NMR	O
of	O
the	O
synthesized	O
molecule	O
both	O
confirmed	O
the	O
proposed	O
identity	O
of	O
the	O
sugar	O
moiety	O
and	O
the	O
stereochemistry	O
of	O
the	O
5α	O
,	O
8α	O
-epideoxy	O
functionality	O
in	O
the	O
isolated	O
compound	O
1a	O
.	O

5α	O
,	O
8α	O
-Epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
has	O
previously	O
been	O
isolated	O
from	O
a	O
variety	O
of	O
fungi	B
(	O
including	O
C.	B
sinensis	I
)	O
(	O
Xiao	O
,	O
Liu	O
&	O
Tu	O
,	O
1983	O
;	O
Takaishi	O
,	O
Adachi	O
,	O
Murakami	O
,	O
Ohashi	O
,	O
Nakano	O
&	O
Tomimatsu	O
,	O
1992	O
;	O
Tsantrizos	O
,	O
Folkins	O
,	O
Britten	O
,	O
Harpp	O
,	O
Ogilvie	O
,	O
1992	O
)	O
,	O
lichens	B
(	O
Hirayama	O
,	O
Fujikawa	O
,	O
Yosioka	O
&	O
Kitagawa	O
,	O
1975	O
;	O
Gonzalez	O
,	O
Barrera	O
,	O
Perez	O
&	O
Padron	O
,	O
1992	O
)	O
,	O
and	O
marine	B
organisms	I
(	O
Gunatilaka	O
et	O
al.	O
,	O
1981	O
;	O
Guyot	O
&	O
Durgeat	O
,	O
1981	O
)	O
and	O
has	O
been	O
shown	O
to	O
have	O
both	O
antitumor	O
(	O
Kahlos	O
,	O
Kangas	O
&	O
Hiltunen	O
,	O
1989	O
;	O
Kahlos	O
,	O
Hiltunen	O
&	O
Kangas	O
,	O
1989	O
;	O
Matsueda	O
,	O
Shimoyama	O
,	O
Imaizumi	O
&	O
Tsushima	O
,	O
1982	O
;	O
Cheng	O
,	O
Nagano	O
,	O
Bang	O
,	O
Ourrison	O
,	O
Beck	O
,	O
1977	O
)	O
and	O
anti	O
-	O
inflammatory	O
(	O
Yasukawa	O
et	O
al.	O
,	O
1994	O
,	O
1996	O
)	O
activity	O
.	O

Formation	O
of	O
1b	O
was	O
shown	O
to	O
be	O
endogenous	O
in	O
fungi	B
and	O
not	O
an	O
artifact	O
of	O
the	O
isolation	O
procedure	O
(	O
Nes	O
,	O
Xu	O
&	O
Haddon	O
,	O
1989	O
)	O
.	O

The	O
observation	O
of	O
six	O
methyl	O
signals	O
in	O
the	O
1	O
H	O
NMR	O
spectrum	O
of	O
compound	O
2	O
,	O
δ	O
0.49	O
(	O
3H	O
,	O
s	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
Hz	O
)	O
,	O
0.73	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
Hz	O
)	O
,	O
0.81	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
)	O
,	O
0.91	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
)	O
,	O
0.95	O
(	O
3H	O
,	O
s	O
)	O
indicates	O
that	O
compound	O
2	O
is	O
also	O
an	O
ergosterol	O
derivative	O
.	O

The	O
molecular	O
formula	O
for	O
compound	O
2	O
was	O
determined	O
to	O
be	O
C28	O
H44	O
O2	O
by	O
HRMS	O
(	O
M+	O
=	O
421.3347	O
)	O
.	O

The	O
additional	O
oxygen	O
in	O
the	O
molecular	O
formula	O
of	O
2	O
in	O
comparison	O
to	O
the	O
molecular	O
formula	O
of	O
ergosterol	O
(	O
6	O
)	O
(	O
C28	O
H44	O
O	O
)	O
and	O
the	O
observation	O
in	O
the	O
1	O
H	O
NMR	O
of	O
a	O
signal	O
at	O
3.50	O
ppm	O
combined	O
with	O
the	O
loss	O
of	O
an	O
olefinic	O
signal	O
indicates	O
that	O
one	O
of	O
the	O
5,7-diene	O
olefins	O
in	O
6	O
has	O
been	O
oxidized	O
to	O
the	O
epoxide	O
.	O

The	O
observation	O
of	O
a	O
correlation	O
in	O
the	O
COSY	O
between	O
the	O
trisubstituted	O
epoxy	O
methine	O
signal	O
at	O
3.50	O
ppm	O
and	O
the	O
olefin	O
methine	O
signal	O
at	O
5.20	O
ppm	O
is	O
in	O
agreement	O
with	O
this	O
proposal	O
.	O

The	O
observation	O
of	O
cross	O
-	O
peaks	O
in	O
the	O
HMBC	O
between	O
the	O
signal	O
at	O
5.20	O
ppm	O
with	O
the	O
13	O
C	O
signals	O
corresponding	O
to	O
C5	O
,	O
C9	O
and	O
C14	O
and	O
the	O
cross	O
peaks	O
for	O
the	O
signal	O
at	O
3.50	O
ppm	O
with	O
the	O
13	O
C	O
signals	O
corresponding	O
to	O
C5	O
,	O
C7	O
,	O
C8	O
and	O
C10	O
indicate	O
the	O
epoxide	O
is	O
in	O
the	O
5,6	O
position	O
.	O

The	O
downfield	O
chemical	O
shift	O
of	O
the	O
3β	O
-hydroxy	O
methine	O
at	O
3.90	O
ppm	O
is	O
consistent	O
with	O
the	O
α	O
stereochemistry	O
for	O
the	O
5	O
,	O
6-epoxy	O
group	O
(	O
Aiello	O
,	O
Fattorusso	O
,	O
Magno	O
,	O
Mayol	O
&	O
Menna	O
,	O
1990	O
;	O
Isaacs	O
,	O
Berman	O
&	O
Kashman	O
,	O
1991	O
;	O
Venkateswarlu	O
,	O
Reddy	O
&	O
Rao	O
,	O
1996	O
)	O
.	O

5α	O
,	O
6α	O
-Epoxy	O
sterols	O
similar	O
to	O
compound	O
2	O
are	O
unknown	O
.	O

A	O
small	O
number	O
of	O
5α	O
,	O
6α	O
-epoxy	O
sterols	O
have	O
been	O
isolated	O
from	O
marine	B
sponges	I
and	O
corals	B
(	O
Aiello	O
et	O
al.	O
,	O
1990	O
;	O
Isaacs	O
,	O
Berman	O
&	O
Kashman	O
,	O
1991	O
;	O
Venkateswarlu	O
,	O
Reddy	O
&	O
Rao	O
,	O
1996	O
;	O
Kobayashi	O
&	O
Kanda	O
,	O
1991	O
)	O
and	O
have	O
been	O
shown	O
to	O
have	O
cytotoxic	O
activities	O
.	O

Growth	O
inhibition	O
due	O
to	O
compounds	O
1a	O
,	O
1b	O
,	O
and	O
3	O
of	O
the	O
malignant	O
cell	O
lines	O
K562	O
(	O
erythroleukemia	O
)	O
,	O
Jurkat	O
(	O
T	O
-	O
lymphoblastic	O
)	O
,	O
HL-60	O
(	O
promyelocytic	O
leukemia	O
)	O
,	O
WM1341	O
(	O
malignant	O
melanoma	O
)	O
and	O
RPMI	O
8226	O
(	O
multiple	O
myeloma	O
)	O
from	O
the	O
American	O
Tissue	O
Type	O
Collection	O
(	O
ATCC	O
)	O
Rockville	O
,	O
MD	O
,	O
were	O
studied	O
to	O
compare	O
their	O
antitumor	O
activity	O
.	O

The	O
percent	O
inhibition	O
of	O
the	O
proliferation	O
of	O
these	O
five	O
malignant	O
cells	O
lines	O
determined	O
from	O
3	O
H	O
-	O
thymidine	O
incorporation	O
assays	O
are	O
shown	O
in	O
Fig.	O
1	O
(	O
a	O
–	O
d	O
)	O
for	O
200	O
,	O
100	O
and	O
10	O
μg	O
/	O
ml	O
concentrations	O
of	O
compounds	O
3	O
,	O
1b	O
,	O
and	O
1a	O
.	O

Compound	O
3	O
which	O
does	O
not	O
contain	O
the	O
5	O
,	O
8-epoxy	O
functionality	O
showed	O
little	O
to	O
no	O
significant	O
inhibition	O
of	O
proliferation	O
of	O
the	O
tumor	O
cells	O
.	O

Some	O
inhibition	O
of	O
Jurkat	O
and	O
RPMI	O
8226	O
was	O
detected	O
at	O
200	O
μg	O
/	O
ml	O
,	O
the	O
highest	O
concentration	O
in	O
this	O
study	O
.	O

As	O
clearly	O
shown	O
on	O
the	O
graphs	O
,	O
at	O
the	O
lower	O
concentration	O
,	O
the	O
glycoside	O
1a	O
was	O
found	O
to	O
inhibit	O
proliferation	O
of	O
all	O
five	O
malignant	O
cell	O
lines	O
to	O
a	O
greater	O
extent	O
(	O
10–40	O
%	O
)	O
than	O
the	O
aglycone	O
1b	O
as	O
a	O
control	O
.	O

3	O
Experimental	O
3.1	O
General	O
IR	O
spectra	O
were	O
acquired	O
with	O
a	O
Bomen	O
FT	O
-	O
IR	O
Michaelson-100	O
spectrophotometer	O
.	O

The	O
spectra	O
were	O
obtained	O
either	O
in	O
CHCl3	O
solution	O
using	O
a	O
0.2	O
mm	O
thick	O
NaCl	O
cell	O
,	O
or	O
as	O
a	O
solid	O
in	O
KBr	O
,	O
and	O
processed	O
using	O
the	O
Bomen	O
Spectra	O
Calc	O
program	O
.	O

LRMS	O
and	O
HRMS	O
were	O
obtained	O
on	O
a	O
Kratos	O
-	O
AEI	O
model	O
MS-50	O
spectrometer	O
.	O

All	O
spectra	O
were	O
obtained	O
at	O
an	O
ionization	O
energy	O
of	O
70	O
eV.	O
1	O
H	O
NMR	O
spectra	O
were	O
obtained	O
on	O
a	O
Bruker	O
WH-400	O
spectrometer	O
.	O

13	O
C	O
and	O
APT	O
were	O
obtained	O
on	O
a	O
Bruker	O
AC-200	O
spectrometer	O
.	O

HMBC	O
,	O
and	O
HMQC	O
spectra	O
were	O
obtained	O
on	O
a	O
Bruker	O
AMX-500	O
spectrometer	O
.	O

Silica	O
gel	O
(	O
Art	O
60	O
,	O
230–400	O
mesh	O
)	O
for	O
column	O
chromatography	O
(	O
CC	O
)	O
and	O
silica	O
gel	O
(	O
Kieselgel	O
60	O
F254	O
)	O
coated	O
on	O
aluminum	O
plates	O
for	O
thin	O
layer	O
chromatography	O
were	O
supplied	O
by	O
Merck	O
.	O

3.2	O
Fungal	B
material	O

The	O
mycelial	O
sample	O
of	O
C.	B
sinensis	I
was	O
obtained	O
from	O
North	O
American	O
Reishi	O
,	O
Box	O
1780	O
,	O
Gibsons	O
,	O
British	O
Columbia	O
,	O
Canada	O
,	O
V0N	O
1V0	O
.	O

3.3	O
Malignant	O
cell	O
inhibition	O
studies	O
3	O
H	O
-	O
Thymidine	O
incorporation	O
assays	O
were	O
carried	O
out	O
to	O
determine	O
inhibitory	O
effects	O
.	O

K562	O
(	O
erythroleukemia	O
)	O
,	O
Jurkat	O
(	O
T	O
-	O
lymphoblastic	O
)	O
,	O
HL-60	O
(	O
promyelocytic	O
leukemia	O
)	O
,	O
WM1341	O
(	O
malignant	O
melanoma	O
)	O
and	O
RPMI	O
8226	O
(	O
multiple	O
myeloma	O
)	O
malignant	O
cell	O
lines	O
were	O
obtained	O
from	O
the	O
American	O
Tissue	O
Type	O
Collection	O
(	O
ATCC	O
)	O
,	O
Rockville	O
,	O
MD	O
.	O

The	O
cell	O
lines	O
were	O
maintained	O
in	O
a	O
medium	O
consisting	O
of	O
RPMI	O
1640	O
/	O
FCS	O
10	O
%	O
at	O
37	O
°	O
C	O
in	O
an	O
atmosphere	O
of	O
5	O
%	O
CO2	O
.	O

Malignant	O
cell	O
lines,106	O
cells	O
/	O
ml	O
in	O
96-well	O
round	O
bottom	O
plates	O
(	O
Costar	O
)	O
,	O
were	O
cultured	O
with	O
various	O
concentrations	O
of	O
C.	B
sinensis	I
extracts	O
in	O
a	O
5	O
%	O
CO2	O
-air	O
humidified	O
atmosphere	O
at	O
37	O
°	O
C	O
.	O

After	O
16	O
h	O
of	O
co	O
-	O
culture	O
,	O
3	O
H	O
-	O
thymidine	O
(	O
1	O
MCi	O
/	O
well	O
,	O
Dupont	O
,	O
Montreal	O
)	O
was	O
added	O
to	O
each	O
well	O
.	O

3	O
H	O
-	O
Thymidine	O
uptake	O
was	O
measured	O
after	O
6	O
hours	O
of	O
incubation	O
using	O
a	O
scintillation	O
counter	O
.	O

The	O
inhibitory	O
effect	O
of	O
each	O
extract	O
on	O
tumor	O
cell	O
proliferation	O
was	O
calculated	O
using	O
Eq.	O
1	O
.	O
(	O
1	O
)	O

Inhibition	O
percent	O
(	O
%	O
)	O
=	O
Control	O
group	O
(	O
cpm	O
)	O
−Experimental	O
group	O
(	O
cpm	O
)	O
Control	O
group	O
(	O
cpm	O
)	O
×100	O
3.4	O
Activity	O
guided	O
fractionation	O
of	O
fungal	B
material	O
The	O
dry	O
mycelium	O
of	O
C.	B
sinensis	I
(	O
150	O
g	O
)	O
was	O
extracted	O
with	O
MeOH	O
three	O
times	O
(	O
500	O
ml	O
×	O
3	O
)	O
.	O

The	O
MeOH	O
extracts	O
were	O
combined	O
and	O
the	O
solvent	O
was	O
removed	O
under	O
reduced	O
pressure	O
.	O

The	O
crude	O
MeOH	O
extract	O
was	O
found	O
to	O
inhibit	O
K562	O
proliferation	O
by	O
36	O
%	O
at	O
500	O
μg	O
/	O
ml	O
,	O
in	O
the	O
3	O
H	O
-	O
thymidine	O
incorporation	O
assay	O
.	O

The	O
residue	O
was	O
then	O
redissolved	O
in	O
MeOH	O
/	O
H2	O
O	O
(	O
1:1	O
)	O
and	O
washed	O
with	O
hexanes	O
.	O

Methanol	O
was	O
distilled	O
from	O
the	O
aqueous	O
layer	O
under	O
reduced	O
pressure	O
.	O

The	O
remaining	O
aqueous	O
layer	O
was	O
extracted	O
with	O
EtOAc	O
.	O

Concentration	O
of	O
the	O
combined	O
EtOAc	O
extracts	O
under	O
reduced	O
pressure	O
provided	O
1.57	O
g	O
of	O
a	O
brown	O
oil	O
(	O
B1	O
)	O
.	O

This	O
residue	O
was	O
chromatographed	O
on	O
a	O
silica	O
gel	O
-	O
flash	O
column	O
(	O
230–400	O
mesh	O
,	O
50	O
×	O
8.0	O
cm	O
)	O
.	O

The	O
elution	O
was	O
started	O
with	O
CHCl3	O
and	O
the	O
polarity	O
of	O
solvents	O
was	O
increased	O
stepwise	O
in	O
the	O
following	O
sequence	O
:	O
CHCl3	O
,	O
CHCl3	O
/MeOH	O
(	O
8:2	O
)	O
,	O
CHCl3	O
/MeOH	O
(	O
5:5	O
)	O
,	O
CHCl3	O
/MeOH	O
(	O
2:8	O
)	O
and	O
MeOH	O
.	O

Fourteen	O
fractions	O
(	O
FA1–FA14	O
)	O
were	O
collected	O
and	O
dried	O
in	O
vacuo	O
.	O

Only	O
one	O
fraction	O
(	O
FA8	O
)	O
was	O
found	O
have	O
antitumor	O
activity	O
.	O

Fraction	O
FA8	O
was	O
further	O
chromatographed	O
on	O
a	O
silicagel	O
flash	O
-	O
column	O
eluted	O
with	O
CHCl3	O
/MeOH	O
(	O
8:2	O
)	O
to	O
afford	O
two	O
fractions	O
FB1	O
and	O
FB2	O
having	O
an	O
Rf	O
=	O
6.3	O
and	O
5.4	O
,	O
respectively	O
.	O

FB1	O
was	O
a	O
white	O
solid	O
(	O
38	O
mg	O
)	O
.	O

Recrystallization	O
of	O
FB1	O
in	O
CHCl3	O
afforded	O
10	O
mg	O
of	O
2	O
as	O
a	O
white	O
powder	O
.	O

Compound	O
2	O
was	O
found	O
to	O
have	O
61	O
%	O
antitumor	O
activity	O
against	O
Jurkat	O
cells	O
and	O
36.3	O
%	O
activity	O
against	O
K562	O
cells	O
at	O
100	O
μg	O
/	O
ml	O
.	O

Fraction	O
FB2	O
was	O
found	O
to	O
have	O
96	O
%	O
activity	O
against	O
Jurkat	O
cells	O
and	O
77	O
%	O
activity	O
against	O
K562	O
cancer	O
cells	O
at	O
100	O
μg	O
/	O
ml	O
.	O

FB2	O
was	O
further	O
separated	O
by	O
silica	O
gel	O
chromatography	O
eluted	O
with	O
Et2	O
O	O
:	O
hexanes	O
:	O
MeOH=5:5:1	O
to	O
afford	O
two	O
fractions	O
FC1	O
(	O
Rf	O
=	O
6.3	O
)	O
and	O
3	O
mg	O
of	O
compound	O
1a	O
(	O
Rf	O
=	O
5.4	O
)	O
as	O
a	O
white	O
solid	O
.	O

FC1	O
was	O
further	O
separated	O
by	O
HPLC	O
to	O
give	O
3	O
and	O
4	O
.	O

3.4.1	O
5α	O
,	O
6α	O
-Epoxy-24	O
(	O
R	O
)	O
-methylcholesta-7,22-dien-3β	O

-ol	O
(	O
2	O
)	O
.	O

IR	O
(	O
cm−1	O
,	O
CHCl3	O
):	O
4685	O
-	O
3110	O
(	O
hydroxyl	O
)	O
,	O
2950	O
,	O
2880	O
,	O
1673	O
,	O
1462	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	O
)	O
δ	O
:	O
0.49	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.72	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.73	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
1.2	O
(	O
2H	O
,	O
m	O
,	O
H17	O
,	O
H16	O
)	O
,	O
1.32	O
(	O
1H	O
,	O
m	O
,	O
H2	O
)	O
,	O
1.36	O
(	O
1H	O
,	O
m	O
,	O
H25	O
)	O
,	O
1.44–1.48	O
(	O
4H	O
,	O
m	O
,	O
H11	O
,	O
H11′	O
,	O
H15	O
,	O
H1	O
)	O
,	O
1.58	O
(	O
1H	O
,	O
m	O
,	O
H12	O
)	O
,	O
1.64	O
(	O
1H	O
,	O
m	O
,	O
H16′	O
)	O
,	O
1.72	O
(	O
1H	O
,	O
m	O
,	O
H2′	O
)	O
,	O
1.75	O
(	O
1H	O
,	O
m	O
,	O
H24	O
)	O
,	O
1.81	O
(	O
1H	O
,	O
m	O
,	O
H14	O
)	O
,	O
1.85	O
(	O
1H	O
,	O
m	O
,	O
H9	O
)	O
,	O
1.94	O
(	O
1H	O
,	O
m	O
,	O
H20	O
)	O
,	O
1.95	O
(	O
1H	O
,	O
m	O
,	O
H4	O
)	O
,	O
3.5	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
5.1	O
,	O
H-6	O
)	O
,	O
3.9	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
,	O
5.09	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.11	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
5.2	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	O
)	O
listed	O
in	O
Table	O
2	O
;	O
LRMS	O
(	O
EI	O
)	O
m	O
/z	O
(	O
rel	O
.	O

int	O
.	O

%	O
):	O
413	O
[	O
M+1	O
]	O
+	O
,	O
396	O
[	O
M−16	O
]	O
+	O
;	O
HRMS	O
(	O
EI	O
)	O
:	O
Calculated	O
for	O
C28	O
H44	O
O2	O
:	O
412.33414	O
;	O
found	O
:	O
412.33477	O
.	O

3.4.2	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
(	O
1a	O
)	O
IR	O
(	O
cm−1	O
,	O
CHCl3	O
):	O
3580–3055	O
(	O
hydroxyl	O
)	O
,	O
2950	O
,	O
2873	O
,	O
1681	O
,	O
1458	O
,	O
1371	O
;	O
[	O
α	O
]	O
D	O
(	O
25	O
°	O
C	O
)	O
:	O
−15.6	O
°	O
;	O
1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	O
)	O
δ	O
:	O
0.70	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
Me-27	O
)	O
,	O
0.71	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.72	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
Me-27	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.8	O
Hz	O
,	O
Me-28	O
)	O
,	O
0.76	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.6	O
Hz	O
,	O
Me-21	O
)	O
,	O
1.0–2.0	O
(	O
19H	O
,	O
m	O
)	O
,	O
2.1	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.1–3.2	O
(	O
2H	O
,	O
m	O
,	O
H-2′	O
,	O
H-3′	O
)	O
,	O
3.2–3.4	O
(	O
2H	O
,	O
m	O
,	O
H-4′	O
,	O
H-5′	O
)	O
,	O
3.5	O
(	O
1H	O
,	O
m	O
,	O
H-6a′	O
)	O
,	O
3.60	O
(	O
1H	O
,	O
m	O
,	O
H6b′	O
)	O
,	O
3.85	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
;	O
4.23	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.8	O
Hz	O
,	O
H-1′	O
)	O
,	O
5.05	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.09	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
6.13	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-7	O
)	O
,	O
6.39	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	O
):	O
Table	O
2	O
;	O
LRMS	O
(	O
CIMS	O
)	O
m	O
/z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
608	O
[	O
M+NH4	O
]	O
+	O
,	O
593	O
[	O
M+2	O
]	O
+	O
,	O
590	O
[	O
M	O
]	O
+	O
,	O
412	O
[	O
M−178	O
]	O
+	O
;	O
HRMS	O
(	O
DCIMS	O
)	O
:	O
Calculated	O
for	O
C34	O
H54	O
O8	O
+	O
NH+	O
4	O
:	O
608.41624	O
;	O
found	O
:	O
608.41572	O
.	O

3.5	O
Synthesis	O
of	O
1a	O
from	O
ergosterol	O
(	O
6	O
)	O
All	O
reactions	O
were	O
carried	O
out	O
under	O
nitrogen	O
atmosphere	O
in	O
flame	O
-	O
dried	O
glassware	O
unless	O
otherwise	O
stated	O
.	O

3.5.1	O
2,3,4,6-Tetra	O
-	O
O	O
-acetyl-3-O	O
-	O
β	O
-d	O
-glucopyranosyl	O
-	O
ergosta-6,22-dien-5α	O
,	O
8α	O
-epidioxy-3β	O
-ol	O
(	O
5	O
)	O
To	O
a	O
stirring	O
solution	O
of	O
2,3,4,6-tetra	O
-	O
O	O
-acetyl	O
-	O
α	O
-d	O
-glucosyl	O
trichloroacetimidate	O
(	O
0.172	O
g	O
,	O
0.4	O
mmol	O
)	O
in	O
10	O
ml	O
dry	O
CH2	O
Cl2	O
was	O
added	O
4	O
Å	O
molecular	O
sieves	O
(	O
1	O
g	O
)	O
followed	O
by	O
ergosterol	O
(	O
6	O
)	O
(	O
0.2	O
g	O
,	O
0.5	O
mmol	O
)	O
as	O
a	O
solid	O
powder	O
.	O

The	O
solution	O
was	O
cooled	O
to	O
0	O
°	O
C	O
prior	O
to	O
the	O
dropwise	O
addition	O
of	O
BF3	O
.Et2	O

O	O
(	O
0.4	O
ml	O
of	O
stock	O
30	O
μl	O
in	O
2.5	O
ml	O
CH2	O
Cl2	O
)	O
.	O

Upon	O
the	O
addition	O
of	O
BF3	O
.Et2	O

O	O
the	O
solution	O
turned	O
pink	O
,	O
then	O
quickly	O
returned	O
to	O
a	O
clear	O
colourless	O
solution	O
.	O

After	O
10	O
min	O
the	O
solution	O
was	O
allowed	O
to	O
warm	O
slowly	O
to	O
room	O
temperature	O
.	O

The	O
reaction	O
was	O
quenched	O
with	O
the	O
addition	O
of	O
Et3	O
N	O
(	O
60	O
μl	O
)	O
after	O
40	O
min	O
.	O

The	O
clear	O
solution	O
was	O
diluted	O
with	O
CH2	O
Cl2	O
,	O
filtered	O
to	O
remove	O
the	O
molecular	O
sieves	O
and	O
washed	O
twice	O
with	O
H2	O
O.	O
The	O
organic	O
layer	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
.	O

Column	O
chromatography	O
eluted	O
with	O
5	O
%	O
MeOH	O
in	O
CHCl3	O
afforded	O
5	O
(	O
0.0466	O
,	O
mmol	O
)	O
in	O
16	O
%	O
yield	O
(	O
Rf	O
=	O
0.78	O
,	O
15	O
%	O
MeOH	O
in	O
CHCl3	O
)	O
followed	O
by	O
unreacted	O
starting	O
material	O
(	O
0.1192	O
g	O
,	O
300	O
mmol	O
)	O
(	O
Rf	O
=	O
0.66	O
,	O
15	O
%	O
MeOH	O
in	O
CHCl3	O
)	O
.	O

1	O
H	O
NMR	O
(	O
400	O
MHz	O
,	O
CDCl3	O
)	O
δ	O
:	O
0.59	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.80	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.86	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
,	O
Me-28	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-21	O
)	O
,	O
1.7–2.0	O
(	O
18H	O
,	O
m	O
)	O
1.98	O
(	O
3H	O
,	O
s	O
)	O
,	O
1.99	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.01	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.03	O
(	O
3H	O
,	O
s	O
)	O
,	O
2.21	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.40	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.56	O
(	O
1H	O
,	O
m	O
,	O
H-3	O
)	O
,	O
3.66	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.10	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.24	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.60	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.7	O
,	O
H-1′	O
)	O
,	O
4.94	O
(	O
1H	O
,	O
m	O
)	O
,	O
5.04	O
(	O
1H	O
,	O
m	O
)	O
,	O
5.18	O
(	O
3H	O
,	O
m	O
,	O
H-22	O
,	O
H-23	O
)	O
,	O
5.36	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
5.55	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	O
)	O
12.0	O
,	O
16.1	O
,	O
17.6	O
,	O
19.2	O
,	O
19.6	O
,	O
19.6	O
,	O
19.9	O
,	O
20.5	O
,	O
20.6	O
,	O
20.7	O
,	O
21.0	O
,	O
22.9	O
,	O
28.2	O
,	O
29.7	O
,	O
33.0	O
,	O
33.0	O
,	O
37.1	O
,	O
37.4	O
,	O
38.2	O
,	O
39.0	O
,	O
40.3	O
,	O
42.8	O
,	O
46.1	O
,	O
54.5	O
,	O
55.7	O
,	O
62.0	O
,	O
68.5	O
,	O
71.4	O
,	O
71.7	O
,	O
72.8	O
,	O
78.6	O
,	O
99.5	O
,	O
116.1	O
,	O
119.9	O
,	O
131.9	O
,	O
135.4	O
,	O
139.0	O
,	O
141.6	O
,	O
169.2	O
,	O
169.3	O
,	O
170.3	O
,	O
170.6	O
.	O

3.5.2	O
Ergosteryl-3-O	O
-β	O
-d	O
-glucopyranoside	O
(	O
3	O
)	O
To	O
a	O
stirring	O
solution	O
of	O
5	O
(	O
0.0564	O
g	O
,	O
0.078	O
mmol	O
)	O
in	O
20	O
ml	O
MeOH	O
was	O
added	O
3	O
ml	O
Et3	O
N	O
and	O
0.5	O
ml	O
H2	O
O.	O
After	O
stirring	O
for	O
48	O
h	O
the	O
solvent	O
was	O
removed	O
under	O
reduced	O
pressure	O
.	O

The	O
residue	O
was	O
applied	O
to	O
a	O
silica	O
gel	O
column	O
,	O
and	O
eluted	O
with	O
15	O
%	O
MeOH	O
in	O
CHCl3	O
(	O
Rf	O
=	O
20.6	O
)	O
to	O
afford	O
a	O
white	O
solid	O
.	O

Recrystallization	O
from	O
MeOH	O
provided	O
3	O
(	O
0.0351	O
g	O
,	O
0.063	O
mmol	O
)	O
in	O
81	O
%	O
yield	O
as	O
small	O
white	O
needles	O
.	O

IR	O
(	O
cm−1	O
,	O
CHCl3	O
):	O
3400	O
,	O
2950	O
,	O
2875	O
,	O
1681	O
,	O
1458	O
,	O
1371	O
;	O
1	O
H	O
NMR	O
(	O
400	O
MHz	O
,	O
DMSO	O
)	O
δ	O
:	O
0.58	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.79	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.80	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.7	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.86	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.88	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.9	O
,	O
Me-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.5	O
,	O
Me-21	O
)	O
,	O
1.24	O
(	O
2H	O
,	O
m	O
)	O
1.45	O
(	O
1H	O
,	O
m	O
)	O
,	O
1.6	O
(	O
1H	O
,	O
m	O
)	O
1.68	O
(	O
1H	O
,	O
m	O
)	O
,	O
1.85	O
(	O
2H	O
,	O
m	O
)	O
,	O
2.0	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.18	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.54	O
(	O
1H	O
,	O
m	O
)	O
,	O
2.98	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.13	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.14	O
(	O
1H	O
,	O
m	O
)	O
,	O
3.3	O
(	O
1H	O
,	O
bs	O
)	O
,	O
3.46	O
(	O
2H	O
,	O
m	O
)	O
,	O
3.61	O
(	O
1H	O
,	O
m	O
)	O
,	O
4.24	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
7.7	O
Hz	O
,	O
H-1′	O
)	O
,	O
5.20	O
(	O
2H	O
,	O
m	O
,	O
H-22	O
,	O
H-23	O
)	O
,	O
5.34	O
(	O
1H	O
,	O
m	O
,	O
H-7	O
)	O
,	O
5.52	O
(	O
1H	O
,	O
m	O
,	O
H-6	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	O
,	O
):	O
Table	O
2	O
.	O

3.5.3	O
5α	O
,	O
8α	O
-Epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-d	O
-glucopyranoside	O
(	O
1a	O
)	O
To	O
a	O
solution	O
of	O
3	O
(	O
0.0211	O
g	O
,	O
0.038	O
mmol	O
)	O
in	O
20	O
ml	O
dry	O
EtOH	O
was	O
added	O
2	O
drops	O
of	O
a	O
10	O
%	O
solution	O
of	O
eosin	O
in	O
EtOH	O
.	O

Oxygen	O
was	O
bubbled	O
through	O
the	O
solution	O
.	O

The	O
reaction	O
vessel	O
was	O
then	O
placed	O
in	O
a	O
silver	O
dewa	O
and	O
irradiated	O
with	O
a	O
500	O
W	O
tungsten	O
lamp	O
.	O

Water	O
was	O
circulated	O
into	O
the	O
dewar	O
to	O
maintain	O
room	O
temperature	O
for	O
the	O
reaction	O
.	O

After	O
3	O
h	O
the	O
solution	O
was	O
concentrated	O
under	O
reduced	O
pressure	O
,	O
with	O
the	O
resulting	O
residue	O
applied	O
to	O
a	O
silica	O
gel	O
column	O
what	O
we	O
eluted	O
with	O
15	O
%	O
MeOH	O
in	O
CHCl3	O
to	O
afford	O
1a	O
(	O
0.0138	O
g	O
,	O
0.023	O
mmol	O
)	O
in	O
62	O
%	O
yield	O
as	O
a	O
white	O
solid	O
.	O

IR,1	O
H,13	O
C	O
and	O
LRMS	O
were	O
identical	O
to	O
spectra	O
of	O
1a	O
isolated	O
from	O
the	O
mycelia	O
of	O
C.	B
sinensis	I
.	O

3.5.4	O
Synthesis	O
of	O
5α	O
,	O
8α	O
-epidioxy-24	O
(	O
R	O
)	O
-methylcholesta-6,22-dien-3β	O
-ol	O
(	O
1b	O
)	O
(	O
ergosterol	O
peroxide	O
)	O
from	O
ergosterol	O
(	O
6	O
)	O
Following	O
the	O
same	O
procedure	O
as	O
used	O
for	O
the	O
preparation	O
of	O
1a	O
from	O
3	O
,	O
ergosterol	O
(	O
6	O
)	O
(	O
0.1040	O
g	O
,	O
0.26	O
mmol	O
)	O
was	O
oxidized	O
,	O
then	O
purified	O
by	O
silica	O
gel	O
column	O
eluted	O
with	O
15	O
%	O
EtOAc	O
in	O
CH2	O
Cl2	O
to	O
afford	O
1b	O
(	O
0.0932	O
g	O
,	O
0.22	O
mmol	O
)	O
in	O
85	O
%	O
yield	O
as	O
a	O
white	O
solid	O
.	O

1	O
H	O
NMR	O
(	O
500	O
MHz	O
,	O
CDCl3	O
)	O
0.61	O
(	O
3H	O
,	O
s	O
,	O
Me-18	O
)	O
,	O
0.67	O
(	O
3H	O
,	O
s	O
,	O
Me-19	O
)	O
,	O
0.907	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.67	O
Hz	O
,	O
Me-26	O
or	O
27	O
)	O
,	O
0.913	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.71	O
Hz	O
,	O
Me-26	O
or	O
-27	O
)	O
,	O
0.99	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.78	O
Hz	O
,	O
Me-28	O
)	O
,	O
1.00	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6.49	O
,	O
Me-21	O
)	O
,	O
1.1–2.0	O
(	O
20H	O
,	O
m	O
)	O
,	O
3.92	O
(	O
m	O
,	O
1H	O
,	O
H-3	O
)	O
,	O
5.14	O
(	O
1H	O
,	O
m	O
,	O
H-23	O
)	O
,	O
5.25	O
(	O
1H	O
,	O
m	O
,	O
H-22	O
)	O
,	O
5.95	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.37	O
Hz	O
,	O
H-6	O
)	O
,	O
6.29	O
(	O
1H	O
,	O
d	O
,	O
J	O
=	O
8.47	O
Hz	O
,	O
H-7	O
)	O
;	O
13	O
C	O
NMR	O
(	O
50	O
MHz	O
,	O
CDCl3	O
):	O
Table	O
2	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
North	O
American	O
Reishi	O
Inc.	O
,	O
British	O
Columbia	O
.	O

We	O
also	O
thank	O
Dr	O
S.	O
G.	O
Withers	O
for	O
providing	O
2,3,4,6-tetra	O
-	O
O	O
-acetyl	O
-	O
α	O
-d	O
-glucosyltrichloroacetimidate	O
.	O

The	O
biosynthesis	O
of	O
the	O
vitamin	O
biotin	O
,	O
a	O
cofactor	O
in	O
biological	O
carboxylation	O
reactions	O
,	O
occurs	O
in	O
micro	B
-	I
organisms	I
and	O
plants	B
and	O
involves	O
at	O
least	O
four	O
different	O
enzymes	O
(	O
Eisenberg	O
,	O
1973	O
;	O
Gloeckler	O
et	O
al	O
.	O
,	O
1990	O
;	O
Baldet	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Because	O
biotin	O
synthesis	O
is	O
unique	O
to	O
plants	B
and	O
microorganisms	B
,	O
enzymes	O
of	O
this	O
pathway	O
are	O
potential	O
targets	O
for	O
the	O
development	O
of	O
antimicrobial	O
drugs	O
and	O
herbicides	O
(	O
Rendina	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

One	O
of	O
these	O
enzymes	O
is	O
7,8-diaminopelargonic	O
acid	O
synthase	O
(	O
DAPA	O
synthase	O
)	O
,	O
an	O
aminotransferase	O
that	O
catalyses	O
the	O
antepenultimate	O
step	O
in	O
this	O
pathway	O
:	O
the	O
conversion	O
of	O
7-keto-8-aminopelargonic	O
acid	O
(	O
KAPA	O
)	O
to	O
7,8-diaminopelargonic	O
acid	O
(	O
DAPA	O
)	O
(	O
Figure	O
1	O
)	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

DAPA	O
synthase	O
from	O
Escherichia	B
coli	I
is	O
a	O
homodimer	O
with	O
a	O
molecular	O
mass	O
of	O
94	O
kDa	O
(	O
Stoner	O
&	O
Eisenberg	O
1975a	O
)	O
and	O
contains	O
429	O
residues	O
per	O
monomer	O
(	O
Otsuka	O
et	O
al	O
.	O
,	O
1988	O
)	O
.	O

It	O
is	O
unique	O
among	O
aminotransferases	O
in	O
that	O
it	O
uses	O
S	O
-adenosyl	O
-	O
l	O
-methionine	O
(	O
SAM	O
)	O
as	O
amino	O
group	O
donor	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

DAPA	O
synthase	O
uses	O
pyridoxal-5′-phosphate	O
(	O
PLP	O
)	O
as	O
cofactor	O
and	O
hence	O
belongs	O
to	O
the	O
family	O
of	O
vitamin	O
B6	O
-dependent	O
aminotransferases	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

In	O
general	O
terms	O
,	O
the	O
mechanism	O
of	O
vitamin	O
B6	O
-dependent	O
enzymes	O
is	O
rather	O
well	O
understood	O
(	O
John	O
,	O
1995	O
;	O
Hayashi	O
,	O
1995	O
)	O
and	O
it	O
is	O
expected	O
that	O
DAPA	O
synthase	O
follows	O
the	O
established	O
overall	O
scheme	O
of	O
PLP	O
catalysis	O
(	O
Figure	O
2	O
)	O
.	O

PLP	O
binds	O
covalently	O
to	O
the	O
active	O
site	O
lysine	O
residue	O
through	O
a	O
Schiff	O
base	O
linkage	O
(	O
the	O
internal	O
aldimine	O
)	O
.	O

Upon	O
binding	O
of	O
SAM	O
,	O
the	O
substrate	O
for	O
the	O
first	O
part	O
of	O
the	O
catalytic	O
cycle	O
,	O
an	O
external	O
aldimine	O
is	O
formed	O
between	O
the	O
substrate	O
and	O
the	O
cofactor	O
through	O
a	O
transaldimination	O
process	O
.	O

The	O
reaction	O
proceeds	O
through	O
deprotonation	O
of	O
the	O
former	O
Cα	O
carbon	O
of	O
the	O
substrate	O
,	O
leading	O
to	O
the	O
quinonoid	O
intermediate	O
followed	O
by	O
protonation	O
of	O
the	O
C-4′	O
carbon	O
.	O

It	O
has	O
been	O
shown	O
for	O
aspartate	O
aminotransferase	O
that	O
the	O
lysine	O
residue	O
previously	O
covalently	O
bound	O
to	O
the	O
cofactor	O
acts	O
as	O
proton	O
acceptor	O
and	O
donor	O
in	O
these	O
steps	O
(	O
Gehring	O
,	O
1984	O
;	O
Julin	O
et	O
al	O
.	O
,	O
1989	O
)	O
.	O

Hydrolysis	O
of	O
the	O
resulting	O
ketimine	O
intermediate	O
gives	O
the	O
keto	O
acid	O
of	O
the	O
first	O
substrate	O
SAM	O
and	O
pyridoxamine	O
phosphate	O
bound	O
to	O
the	O
enzyme	O
by	O
non	O
-	O
covalent	O
bonds	O
.	O

The	O
second	O
half	O
of	O
the	O
catalytic	O
cycle	O
is	O
in	O
principle	O
a	O
reversal	O
of	O
the	O
first	O
steps	O
.	O

KAPA	O
,	O
the	O
second	O
substrate	O
,	O
binds	O
and	O
receives	O
the	O
amino	O
group	O
from	O
pyridoxamine	O
phosphate	O
as	O
the	O
PLP	O
-	O
enzyme	O
complex	O
is	O
regenerated	O
.	O

Thus	O
,	O
both	O
substrates	O
have	O
to	O
be	O
accommodated	O
in	O
the	O
same	O
active	O
site	O
,	O
despite	O
differences	O
in	O
size	O
and	O
chemical	O
properties	O
.	O

Although	O
KAPA	O
bears	O
an	O
amino	O
group	O
,	O
DAPA	O
synthase	O
uses	O
KAPA	O
only	O
as	O
an	O
amino	O
group	O
acceptor	O
,	O
not	O
as	O
an	O
amino	O
group	O
donor	O
,	O
i.e.	O
KAPA	O
is	O
not	O
transaminated	O
by	O
DAPA	O
synthase	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975b	O
)	O
.	O

The	O
three	O
-	O
dimensional	O
structures	O
of	O
more	O
than	O
20	O
different	O
PLP	O
-	O
dependent	O
enzymes	O
have	O
been	O
determined	O
(	O
for	O
a	O
recent	O
review	O
,	O
see	O
Jansonius	O
1998	O
)	O
.	O

Christen	O
and	O
co	O
-	O
workers	O
organised	O
PLP	O
-	O
dependent	O
enzymes	O
into	O
three	O
different	O
families	O
,	O
α	O
,	O
β	O
and	O
γ	O
,	O
based	O
on	O
the	O
chemical	O
characteristics	O
of	O
the	O
catalysed	O
reaction	O
and	O
attempted	O
to	O
correlate	O
these	O
with	O
amino	O
acid	O
sequence	O
families	O
(	O
Alexander	O
et	O
al	O
.	O
,	O
1994	O
)	O
.	O

The	O
aminotransferases	O
belong	O
to	O
the	O
α	O
-	O
family	O
,	O
which	O
hosts	O
enzymes	O
acting	O
on	O
the	O
carbon	O
atom	O
adjacent	O
to	O
the	O
amino	O
group	O
of	O
the	O
substrate	O
.	O

Another	O
classification	O
based	O
on	O
fold	O
types	O
and	O
sequence	O
comparisons	O
was	O
introduced	O
by	O
Grishin	O
et	O
al.	O
(	O
1995	O
)	O
.	O

So	O
far	O
,	O
five	O
different	O
folds	O
that	O
can	O
bind	O
PLP	O
have	O
been	O
observed	O
and	O
it	O
has	O
been	O
proposed	O
on	O
the	O
basis	O
of	O
sequence	O
analysis	O
that	O
additional	O
hitherto	O
unknown	O
PLP	O
-	O
binding	O
folds	O
might	O
exist	O
(	O
Grishin	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Most	O
aminotransferases	O
of	O
known	O
structure	O
belong	O
to	O
fold	O
type	O
I	O
,	O
first	O
described	O
for	O
aspartate	O
aminotransferase	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
)	O
.	O

This	O
structural	O
family	O
is	O
characterised	O
by	O
a	O
large	O
domain	O
folded	O
into	O
a	O
central	O
β	O
-	O
sheet	O
,	O
with	O
surrounding	O
loops	O
and	O
helices	O
forming	O
most	O
of	O
the	O
PLP	O
binding	O
site	O
and	O
a	O
smaller	O
domain	O
partly	O
involved	O
in	O
substrate	O
binding	O
.	O

Exceptions	O
are	O
d	O
-amino	O
acid	O
aminotransferase	O
(	O
Sugio	O
et	O
al	O
.	O
,	O
1995	O
)	O
and	O
branched	O
chain	O
aminotransferase	O
(	O
Okada	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
which	O
fold	O
in	O
a	O
completely	O
different	O
manner	O
.	O

Sequence	O
analysis	O
suggested	O
that	O
DAPA	O
synthase	O
may	O
belong	O
to	O
the	O
aminotransferase	O
subclass	O
III	O
of	O
the	O
PLP	O
fold	O
type	O
I	O
family	O
(	O
Metha	O
et	O
al	O
.	O
,	O
1993	O
)	O
,	O
which	O
includes	O
a	O
number	O
of	O
enzymes	O
of	O
known	O
structure	O
:	O
ω	O
-	O
aminotransferase	O
(	O
Watanabe	O
et	O
al	O
.	O
,	O
1989	O
)	O
,	O
ornithine	O
aminotransferase	O
(	O
Shah	O
et	O
al	O
.	O
,	O
1997	O
,	O
Shen	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
2,2-dialkylglycine	O
decarboxylase	O
(	O
Toney	O
et	O
al	O
.	O
,	O
1993	O
,	O
1995	O
)	O
and	O
glutamate	O
semialdehyde	O
aminomutase	O
(	O
Hennig	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

Here	O
we	O
report	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
DAPA	O
synthase	O
from	O
E.	B
coli	I
at	O
1.8	O
Å	O
resolution	O
.	O

The	O
structure	O
analysis	O
reveals	O
that	O
this	O
enzyme	O
indeed	O
is	O
a	O
member	O
of	O
the	O
aspartate	O
aminotransferase	O
family	O
of	O
vitamin	O
B6	O
-dependent	O
enzymes	O
.	O

A	O
multiple	O
structure	O
alignment	O
suggests	O
that	O
at	O
least	O
six	O
subclasses	O
,	O
which	O
are	O
structurally	O
and	O
evolutionary	O
closely	O
related	O
,	O
exist	O
in	O
this	O
family	O
.	O

Furthermore	O
,	O
the	O
structure	O
of	O
a	O
ternary	O
complex	O
of	O
DAPA	O
synthase	O
with	O
the	O
substrate	O
KAPA	O
,	O
bound	O
to	O
the	O
PLP	O
form	O
of	O
the	O
enzyme	O
,	O
is	O
presented	O
.	O

This	O
structure	O
forms	O
the	O
basis	O
for	O
mechanistic	O
considerations	O
,	O
in	O
particular	O
with	O
respect	O
to	O
substrate	O
recognition	O
.	O

Results	O
Structure	O
determination	O
The	O
structure	O
of	O
DAPA	O
synthase	O
was	O
determined	O
to	O
1.8	O
Å	O
resolution	O
.	O

Despite	O
non	O
-	O
isomorphism	O
between	O
crystals	O
of	O
DAPA	O
synthase	O
,	O
two	O
heavy	O
-	O
atom	O
derivatives	O
containing	O
mercury	O
and	O
platinum	O
,	O
respectively	O
,	O
were	O
identified	O
after	O
extensive	O
screening	O
.	O

However	O
,	O
the	O
phases	O
derived	O
from	O
these	O
derivatives	O
were	O
not	O
of	O
sufficient	O
quality	O
to	O
allow	O
tracing	O
of	O
the	O
polypeptide	O
chain	O
.	O

Therefore	O
multiple	O
anomalous	O
dispersion	O
techniques	O
,	O
using	O
mercury	O
-	O
derivatised	O
crystals	O
were	O
employed	O
to	O
obtain	O
phase	O
information	O
(	O
for	O
data	O
collection	O
and	O
phasing	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
initial	O
map	O
at	O
2.0	O
Å	O
resolution	O
,	O
calculated	O
after	O
solvent	O
flattening	O
and	O
2-fold	O
non	O
-	O
crystallographic	O
averaging	O
,	O
was	O
of	O
excellent	O
quality	O
(	O
Figure	O
3	O
(	O
a	O
)	O
)	O
and	O
the	O
polypeptide	O
chain	O
could	O
be	O
readily	O
built	O
into	O
the	O
electron	O
density	O
.	O

After	O
a	O
few	O
refinement	O
cycles	O
,	O
most	O
of	O
the	O
side	O
-	O
chains	O
had	O
been	O
assigned	O
.	O

However	O
,	O
native	O
crystals	O
diffracted	O
to	O
higher	O
resolution	O
(	O
1.8	O
Å	O
)	O
and	O
it	O
was	O
desirable	O
to	O
use	O
these	O
data	O
for	O
the	O
refinement	O
.	O

Because	O
of	O
the	O
non	O
-	O
isomorphism	O
between	O
crystals	O
,	O
molecular	O
replacement	O
was	O
necessary	O
for	O
finding	O
the	O
correct	O
orientation	O
of	O
the	O
molecule	O
in	O
the	O
native	O
crystal	O
.	O

The	O
solution	O
was	O
verified	O
by	O
strong	O
and	O
well	O
defined	O
density	O
for	O
the	O
cofactor	O
,	O
PLP	O
,	O
which	O
had	O
been	O
excluded	O
from	O
the	O
search	O
model	O
.	O

Two	O
-	O
fold	O
non	O
-	O
crystallographic	O
symmetry	O
was	O
applied	O
in	O
the	O
subsequent	O
refinement	O
,	O
but	O
released	O
in	O
the	O
very	O
last	O
stages	O
causing	O
a	O
slight	O
drop	O
in	O
the	O
free	O
R	O
-value	O
.	O

Figure	O
3	O
(	O
b	O
)	O
shows	O
a	O
part	O
of	O
the	O
final	O
2F	O
o	O
−F	O
c	O
electron	O
density	O
map	O
,	O
with	O
the	O
refined	O
model	O
superimposed	O
.	O

The	O
final	O
model	O
contains	O
all	O
but	O
one	O
residue	O
,	O
556	O
water	O
molecules	O
,	O
two	O
PLP	O
molecules	O
covalently	O
linked	O
to	O
Lys274	O
in	O
each	O
chain	O
and	O
two	O
Na+	O
.	O

Only	O
the	O
backbone	O
is	O
modelled	O
for	O
the	O
C	O
-	O
terminal	O
residue	O
in	O
both	O
chains	O
(	O
Glu429	O
)	O
,	O
since	O
the	O
side	O
-	O
chains	O
were	O
disordered	O
.	O

The	O
side	O
-	O
chains	O
in	O
the	O
loop	O
region	O
between	O
residues	O
180	O
and	O
192	O
are	O
badly	O
ordered	O
,	O
and	O
in	O
one	O
of	O
the	O
monomers	O
residue	O
183	O
is	O
not	O
included	O
in	O
the	O
model	O
,	O
since	O
no	O
electron	O
density	O
corresponding	O
to	O
its	O
main	O
-	O
chain	O
atoms	O
was	O
observed	O
.	O

In	O
both	O
chains	O
residue	O
Trp14	O
,	O
which	O
is	O
positioned	O
in	O
the	O
interior	O
of	O
the	O
protein	O
,	O
was	O
built	O
as	O
a	O
leucine	O
residue	O
,	O
judged	O
by	O
the	O
electron	O
density	O
and	O
the	O
local	O
environment	O
of	O
the	O
side	O
-	O
chain	O
.	O

This	O
replacement	O
was	O
later	O
supported	O
by	O
N	O
-	O
terminal	O
amino	O
acid	O
sequencing	O
.	O

The	O
model	O
was	O
refined	O
to	O
a	O
final	O
R	O
-factor	O
of	O
17.5	O
%	O
and	O
a	O
free	O
R	O
-factor	O
of	O
22.6	O
%	O
.	O

A	O
summary	O
of	O
the	O
refinement	O
statistics	O
is	O
shown	O
in	O
Table	O
2	O
.	O

Two	O
residues	O
,	O
Trp53	O
and	O
Ile213	O
,	O
which	O
both	O
are	O
well	O
defined	O
in	O
the	O
electron	O
density	O
map	O
,	O
appear	O
in	O
the	O
disallowed	O
region	O
of	O
the	O
Ramachandran	O
plot	O
for	O
each	O
subunit	O
.	O

Trp53	O
is	O
involved	O
in	O
substrate	O
binding	O
and	O
Ile213	O
is	O
found	O
at	O
a	O
sharp	O
turn	O
in	O
the	O
beginning	O
of	O
a	O
β	O
-	O
strand	O
that	O
takes	O
the	O
chain	O
into	O
the	O
cofactor	O
binding	O
region	O
.	O

The	O
structure	O
of	O
the	O
monomer	O
The	O
monomer	O
of	O
DAPA	O
synthase	O
consists	O
of	O
two	O
domains	O
(	O
Figure	O
4	O
(	O
a	O
)	O
)	O
,	O
a	O
small	O
domain	O
comprising	O
the	O
N	O
-	O
and	O
C	O
-	O
terminal	O
parts	O
of	O
the	O
polypeptide	O
chain	O
(	O
residues	O
1–49	O
and	O
330–429	O
)	O
and	O
a	O
large	O
domain	O
formed	O
by	O
the	O
intervening	O
residues	O
containing	O
the	O
cofactor	O
binding	O
site	O
.	O

A	O
topological	O
description	O
of	O
the	O
structure	O
of	O
DAPA	O
synthase	O
is	O
presented	O
in	O
Figure	O
4	O
(	O
b	O
)	O
.	O

The	O
large	O
domain	O
starts	O
with	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
segment	O
formed	O
by	O
helices	O
α2	O
and	O
α3	O
,	O
which	O
takes	O
the	O
chain	O
over	O
the	O
surface	O
of	O
the	O
molecule	O
to	O
the	O
beginning	O
of	O
a	O
seven	O
-	O
stranded	O
β	O
-	O
sheet	O
,	O
the	O
central	O
feature	O
of	O
this	O
domain	O
,	O
which	O
is	O
typical	O
of	O
aminotransferases	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
)	O
.	O

The	O
order	O
of	O
the	O
strands	O
is	O
β4	O
,	O
β10	O
,	O
β9	O
,	O
β8	O
,	O
β7	O
,	O
β5	O
and	O
β6	O
,	O
where	O
all	O
except	O
β10	O
are	O
parallel	O
to	O
each	O
other	O
.	O

Towards	O
the	O
exterior	O
of	O
the	O
molecule	O
the	O
sheet	O
is	O
covered	O
by	O
two	O
helices	O
,	O
α5	O
and	O
α6	O
,	O
and	O
the	O
loop	O
between	O
strands	O
β8	O
and	O
β9	O
.	O

The	O
sheet	O
is	O
further	O
shielded	O
from	O
the	O
solvent	O
by	O
helices	O
α3	O
and	O
α8	O
,	O
which	O
pack	O
almost	O
perpendicular	O
to	O
the	O
strands	O
in	O
the	O
β	O
-	O
sheet	O
.	O

Helix	O
α4	O
and	O
the	O
extended	O
loop	O
between	O
β5	O
and	O
β6	O
pack	O
against	O
the	O
sheet	O
on	O
the	O
opposite	O
side	O
and	O
are	O
involved	O
in	O
subunit	O
-	O
subunit	O
interactions	O
.	O

Helices	O
α7-α8	O
form	O
a	O
helix	O
-	O
loop	O
-	O
helix	O
segment	O
,	O
which	O
follows	O
after	O
the	O
seven	O
-	O
stranded	O
β	O
-	O
sheet	O
and	O
completes	O
the	O
large	O
domain	O
.	O

The	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
folds	O
into	O
a	O
β	O
-	O
sheet	O
which	O
is	O
packed	O
against	O
three	O
helices	O
α9	O
,	O
α10	O
and	O
α11	O
,	O
on	O
one	O
side	O
.	O

The	O
other	O
side	O
of	O
the	O
sheet	O
is	O
turned	O
against	O
the	O
large	O
domain	O
,	O
so	O
that	O
a	O
crevice	O
is	O
formed	O
between	O
the	O
two	O
domains	O
,	O
which	O
accommodates	O
the	O
active	O
site	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
starts	O
with	O
an	O
α	O
-	O
helix	O
followed	O
by	O
three	O
short	O
β	O
-	O
strands	O
,	O
β1	O
,	O
β2	O
and	O
β3	O
,	O
folded	O
into	O
an	O
anti	O
-	O
parallel	O
β	O
-	O
sheet	O
,	O
and	O
then	O
proceeds	O
into	O
the	O
large	O
domain	O
via	O
a	O
connecting	O
peptide	O
segment	O
.	O

This	O
β	O
-	O
sheet	O
is	O
positioned	O
between	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
and	O
provides	O
one	O
wall	O
of	O
the	O
active	O
site	O
.	O

The	O
N	O
-	O
terminal	O
β	O
-	O
sheet	O
is	O
extended	O
by	O
a	O
very	O
short	O
strand	O
,	O
created	O
by	O
residues	O
located	O
between	O
strand	O
β13	O
and	O
helix	O
α10	O
in	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
domain	O
.	O

Following	O
this	O
interaction	O
the	O
polypeptide	O
chain	O
proceeds	O
back	O
into	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
,	O
extending	O
its	O
β	O
-	O
sheet	O
by	O
a	O
short	O
anti	O
-	O
parallel	O
β	O
-	O
strand	O
interaction	O
to	O
strand	O
β13	O
(	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

Most	O
of	O
the	O
interactions	O
between	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
involve	O
strand	O
β11	O
,	O
the	O
loop	O
following	O
that	O
strand	O
and	O
the	O
loop	O
between	O
β13	O
and	O
α11	O
.	O

Arg360	O
in	O
strand	O
β11	O
interacts	O
through	O
its	O
side	O
-	O
chain	O
with	O
the	O
main	O
-	O
chain	O
carbonyl	O
groups	O
of	O
residues	O
Gly219	O
and	O
Met220	O
,	O
situated	O
in	O
the	O
loop	O
region	O
between	O
β7	O
and	O
α6	O
in	O
the	O
large	O
domain	O
.	O

Arg253	O
in	O
the	O
large	O
domain	O
interacts	O
via	O
its	O
side	O
-	O
chain	O
with	O
the	O
main	O
-	O
chain	O
carbonyl	O
oxygen	O
atoms	O
of	O
Pro401	O
found	O
between	O
strand	O
β13	O
and	O
helix	O
α11	O
,	O
and	O
Ala364	O
between	O
strands	O
β11	O
and	O
β12	O
.	O

It	O
is	O
also	O
hydrogen	O
bonded	O
through	O
its	O
main	O
-	O
chain	O
carbonyl	O
oxygen	O
atom	O
to	O
the	O
phenolic	O
hydroxyl	O
group	O
of	O
Tyr403	O
.	O

Ile56	O
,	O
found	O
in	O
the	O
domain	O
interconnection	O
region	O
,	O
provides	O
a	O
main	O
-	O
chain	O
-	O
main	O
-	O
chain	O
interaction	O
with	O
Tyr403	O
in	O
the	O
small	O
domain	O
.	O

Finally	O
,	O
the	O
side	O
-	O
chain	O
hydroxyl	O
group	O
of	O
Tyr403	O
is	O
within	O
hydrogen	O
bonding	O
distance	O
of	O
the	O
main	O
-	O
chain	O
carbonyl	O
oxygen	O
atom	O
of	O
Phe251	O
in	O
the	O
loop	O
between	O
β8	O
and	O
β9	O
.	O

All	O
residues	O
involved	O
in	O
this	O
interface	O
except	O
Tyr403	O
and	O
Ala364	O
are	O
either	O
conserved	O
or	O
invariant	O
within	O
the	O
DAPA	O
synthases	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

The	O
domain	O
-	O
domain	O
interface	O
between	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
and	O
the	O
large	O
domain	O
involves	O
hydrogen	O
bond	O
interactions	O
between	O
the	O
main	O
-	O
chain	O
atoms	O
of	O
the	O
C	O
-	O
terminal	O
residues	O
of	O
strand	O
β1	O
,	O
Ala32	O
and	O
Gly34	O
,	O
and	O
main	O
-	O
chain	O
atoms	O
of	O
Tyr59	O
and	O
the	O
side	O
-	O
chain	O
of	O
Asn60	O
,	O
which	O
precede	O
helix	O
α2	O
in	O
the	O
large	O
domain	O
.	O

Tyr17	O
,	O
located	O
in	O
the	O
loop	O
between	O
α1	O
and	O
β1	O
,	O
is	O
hydrogen	O
-	O
bonded	O
through	O
its	O
phenolic	O
oxygen	O
to	O
the	O
side	O
-	O
chain	O
of	O
Asp147	O
,	O
which	O
is	O
part	O
of	O
the	O
extended	O
loop	O
between	O
strands	O
β5	O
and	O
β6	O
of	O
the	O
large	O
domain	O
.	O

Furthermore	O
,	O
two	O
of	O
the	O
residues	O
involved	O
in	O
the	O
domain	O
interconnection	O
,	O
Ser50	O
and	O
Trp53	O
,	O
interact	O
through	O
the	O
side	O
-	O
chain	O
hydroxyl	O
and	O
main	O
-	O
chain	O
carbonyl	O
oxygen	O
atom	O
,	O
respectively	O
,	O
with	O
the	O
guanidinium	O
group	O
of	O
Arg253	O
located	O
between	O
strands	O
β8	O
and	O
β9	O
.	O

These	O
three	O
residues	O
and	O
Gly34	O
are	O
invariant	O
throughout	O
the	O
sequenced	O
DAPA	O
synthases	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

The	O
DAPA	O
synthase	O
dimer	O
In	O
the	O
crystal	O
,	O
a	O
homodimer	O
of	O
DAPA	O
synthase	O
(	O
Figure	O
5	O
)	O
is	O
found	O
with	O
the	O
subunits	O
related	O
by	O
a	O
2-fold	O
non	O
-	O
crystallographic	O
axis	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
solution	O
studies	O
that	O
showed	O
that	O
DAPA	O
synthase	O
is	O
active	O
in	O
dimeric	O
form	O
(	O
Stoner	O
&	O
Eisenberg	O
,	O
1975a	O
)	O
.	O

Upon	O
dimerisation	O
,	O
an	O
area	O
of	O
5240	O
Å2	O
per	O
subunit	O
is	O
buried	O
,	O
which	O
corresponds	O
to	O
27	O
%	O
of	O
the	O
total	O
solvent	O
-	O
accessible	O
area	O
.	O

The	O
overall	O
dimension	O
of	O
the	O
dimer	O
is	O
85	O
Å	O
×	O
60	O
Å	O
×	O
60	O
Å.	O
Both	O
subunits	O
are	O
involved	O
in	O
building	O
up	O
the	O
two	O
identical	O
active	O
sites	O
of	O
the	O
DAPA	O
synthase	O
dimer	O
,	O
which	O
are	O
positioned	O
approximately	O
20	O
Å	O
apart	O
.	O

The	O
pattern	O
of	O
subunit	O
-	O
subunit	O
interactions	O
is	O
extensive	O
and	O
residues	O
from	O
both	O
domains	O
are	O
involved	O
in	O
these	O
interactions	O
.	O

In	O
the	O
large	O
domain	O
helix	O
α2	O
lines	O
up	O
with	O
and	O
packs	O
against	O
α2	O
from	O
the	O
other	O
monomer	O
,	O
and	O
both	O
form	O
the	O
top	O
of	O
the	O
molecule	O
,	O
as	O
shown	O
in	O
Figure	O
5	O
.	O

The	O
extended	O
loop	O
following	O
helix	O
α2	O
protrudes	O
into	O
the	O
neighbouring	O
subunit	O
,	O
forming	O
several	O
strong	O
interactions	O
with	O
loop	O
regions	O
from	O
both	O
domains	O
of	O
that	O
subunit	O
.	O

Helix	O
α3	O
,	O
which	O
covers	O
the	O
central	O
β	O
-	O
sheet	O
of	O
its	O
own	O
subunit	O
,	O
interacts	O
with	O
residues	O
from	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
from	O
the	O
other	O
subunit	O
.	O

Helix	O
α4	O
and	O
the	O
loop	O
between	O
β5	O
and	O
β6	O
,	O
which	O
protrude	O
from	O
the	O
central	O
β	O
-	O
sheet	O
region	O
,	O
pack	O
against	O
the	O
corresponding	O
residues	O
in	O
the	O
second	O
monomer	O
at	O
an	O
angle	O
of	O
approximately	O
90	O
°	O
,	O
mainly	O
through	O
hydrophobic	O
interactions	O
.	O

Furthermore	O
,	O
the	O
top	O
end	O
of	O
this	O
part	O
of	O
the	O
sheet	O
involving	O
strands	O
β4	O
,	O
β10	O
and	O
β11	O
,	O
including	O
PLP	O
binding	O
residue	O
Lys274	O
,	O
and	O
connecting	O
loops	O
form	O
interactions	O
with	O
the	O
other	O
subunit	O
of	O
DAPA	O
synthase	O
,	O
in	O
particular	O
with	O
helices	O
α7	O
and	O
α8	O
.	O

Dimer	O
interactions	O
formed	O
by	O
the	O
small	O
domain	O
are	O
almost	O
exclusively	O
made	O
up	O
of	O
the	O
N	O
-	O
terminal	O
part	O
in	O
which	O
the	O
N	O
-	O
terminal	O
helix	O
and	O
the	O
following	O
loop	O
folds	O
over	O
the	O
surface	O
of	O
the	O
second	O
monomer	O
.	O

The	O
loop	O
between	O
helix	O
α2	O
and	O
α3	O
is	O
of	O
central	O
importance	O
for	O
the	O
subunit	O
-	O
subunit	O
interactions	O
.	O

It	O
interacts	O
with	O
residues	O
located	O
in	O
helix	O
α1	O
,	O
in	O
the	O
loop	O
between	O
helix	O
α1	O
and	O
strand	O
β1	O
,	O
in	O
strand	O
β1	O
,	O
in	O
the	O
domain	O
interconnection	O
region	O
,	O
in	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
,	O
and	O
in	O
the	O
loop	O
between	O
helix	O
α10	O
and	O
strand	O
β13	O
of	O
the	O
second	O
subunit	O
.	O

The	O
pyridoxal-5′-phosphate	O
binding	O
site	O
The	O
electron	O
density	O
for	O
the	O
cofactor	O
is	O
very	O
well	O
defined	O
and	O
shows	O
clearly	O
that	O
PLP	O
is	O
covalently	O
bound	O
to	O
the	O
active	O
site	O
Lys274	O
(	O
Figure	O
3	O
(	O
b	O
)	O
)	O
.	O

The	O
PLP	O
binding	O
site	O
is	O
located	O
between	O
the	O
two	O
domains	O
of	O
the	O
monomer	O
at	O
the	O
interface	O
of	O
the	O
two	O
subunits	O
(	O
Figure	O
6	O
)	O
.	O

Residues	O
from	O
both	O
subunits	O
are	O
involved	O
in	O
cofactor	O
binding	O
,	O
although	O
each	O
active	O
site	O
cleft	O
is	O
mainly	O
made	O
up	O
of	O
one	O
monomer	O
.	O

The	O
lysine	O
residue	O
covalently	O
attached	O
to	O
PLP	O
is	O
located	O
on	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
,	O
and	O
points	O
towards	O
the	O
interior	O
of	O
the	O
protein	O
so	O
that	O
PLP	O
is	O
found	O
on	O
the	O
side	O
of	O
the	O
β	O
-	O
sheet	O
facing	O
the	O
second	O
subunit	O
in	O
the	O
dimer	O
.	O

The	O
cofactor	O
is	O
bound	O
at	O
the	O
bottom	O
of	O
the	O
active	O
site	O
,	O
with	O
its	O
re	O
side	O
facing	O
the	O
solvent	O
.	O

The	O
oxygen	O
atoms	O
of	O
the	O
phosphate	O
group	O
interact	O
with	O
the	O
main	O
-	O
chain	O
amides	O
of	O
Gly112	O
and	O
Ser113	O
,	O
and	O
the	O
side	O
-	O
chain	O
of	O
Ser113	O
,	O
located	O
at	O
the	O
N	O
terminus	O
of	O
helix	O
α4	O
,	O
thus	O
anchoring	O
PLP	O
firmly	O
to	O
the	O
enzyme	O
.	O

The	O
negative	O
charges	O
on	O
the	O
phosphate	O
oxygen	O
atoms	O
are	O
partly	O
neutralised	O
by	O
the	O
positive	O
dipole	O
charge	O
of	O
helix	O
α4	O
.	O

Further	O
,	O
Thr309	O
from	O
the	O
other	O
subunit	O
forms	O
a	O
hydrogen	O
bond	O
interaction	O
through	O
its	O
main	O
-	O
chain	O
amide	O
to	O
one	O
of	O
the	O
phosphate	O
oxygen	O
atoms	O
.	O

Several	O
well	O
ordered	O
water	O
molecules	O
within	O
hydrogen	O
bond	O
distance	O
of	O
the	O
phosphate	O
oxygen	O
atoms	O
are	O
also	O
found	O
in	O
the	O
active	O
site	O
of	O
the	O
holo	O
-	O
enzyme	O
.	O

The	O
carboxyl	O
group	O
of	O
Asp245	O
is	O
within	O
hydrogen	O
bonding	O
distance	O
of	O
the	O
pyridine	O
nitrogen	O
.	O

This	O
indicates	O
either	O
that	O
the	O
carboxyl	O
side	O
-	O
chain	O
is	O
protonated	O
and	O
can	O
form	O
a	O
hydrogen	O
bond	O
to	O
the	O
nitrogen	O
atom	O
or	O
that	O
this	O
nitrogen	O
is	O
protonated	O
.	O

The	O
aspartic	O
acid	O
side	O
-	O
chain	O
is	O
kept	O
in	O
place	O
by	O
interactions	O
with	O
the	O
main	O
-	O
chain	O
amide	O
of	O
residue	O
Ile247	O
and	O
with	O
the	O
side	O
-	O
chain	O
of	O
His145	O
.	O

No	O
direct	O
interactions	O
with	O
protein	O
atoms	O
are	O
found	O
for	O
the	O
phenolic	O
hydroxyl	O
group	O
,	O
O-3′	O
,	O
of	O
the	O
cofactor	O
.	O

There	O
are	O
,	O
however	O
,	O
water	O
-	O
mediated	O
contacts	O
to	O
the	O
side	O
-	O
chain	O
of	O
Glu211	O
and	O
the	O
main	O
-	O
chain	O
amide	O
of	O
Ala217	O
.	O

The	O
pyridine	O
ring	O
of	O
PLP	O
is	O
sandwiched	O
between	O
the	O
side	O
-	O
chain	O
of	O
Tyr144	O
protruding	O
from	O
the	O
active	O
site	O
,	O
which	O
stacks	O
perpendicular	O
to	O
the	O
ring	O
,	O
and	O
Ile247	O
,	O
which	O
provides	O
support	O
from	O
the	O
si	O
side	O
of	O
the	O
ring	O
facing	O
the	O
protein	O
.	O

Binding	O
of	O
the	O
substrate	O
KAPA	O
The	O
electron	O
density	O
map	O
for	O
the	O
ternary	O
complex	O
was	O
continuous	O
except	O
for	O
a	O
few	O
disordered	O
loop	O
regions	O
at	O
the	O
surface	O
of	O
the	O
molecule	O
.	O

These	O
regions	O
comprise	O
residues	O
160–168	O
and	O
300–301	O
in	O
each	O
subunit	O
with	O
no	O
electron	O
density	O
for	O
the	O
backbone	O
.	O

As	O
in	O
the	O
crystals	O
of	O
the	O
holoenzyme	O
,	O
the	O
loop	O
comprising	O
residues	O
180–192	O
has	O
weak	O
electron	O
density	O
,	O
with	O
disordered	O
side	O
-	O
chains	O
for	O
residues	O
180–192	O
and	O
no	O
electron	O
density	O
for	O
the	O
backbone	O
of	O
residues	O
183–184	O
.	O

The	O
C	O
-	O
terminal	O
residue	O
was	O
not	O
modelled	O
because	O
of	O
very	O
weak	O
electron	O
density	O
.	O

The	O
stereochemistry	O
of	O
the	O
refined	O
model	O
is	O
reasonable	O
(	O
Table	O
2	O
)	O
.	O

The	O
Ramachandran	O
plot	O
showed	O
one	O
outlier	O
,	O
residue	O
Ile213	O
,	O
with	O
well	O
defined	O
electron	O
density	O
.	O

This	O
residue	O
is	O
also	O
found	O
in	O
the	O
disallowed	O
region	O
of	O
the	O
Ramachandran	O
plot	O
for	O
the	O
model	O
of	O
the	O
holoenzyme	O
.	O

The	O
most	O
characteristic	O
feature	O
of	O
the	O
initial	O
electron	O
density	O
map	O
for	O
the	O
ternary	O
complex	O
was	O
the	O
clear	O
and	O
well	O
defined	O
difference	O
electron	O
density	O
in	O
the	O
active	O
site	O
close	O
to	O
the	O
PLP	O
molecule	O
.	O

A	O
KAPA	O
molecule	O
could	O
be	O
modelled	O
straightforwardly	O
into	O
this	O
difference	O
density	O
.	O

Refinement	O
gave	O
similar	O
B	O
-factors	O
for	O
the	O
atoms	O
of	O
the	O
substrate	O
to	O
those	O
for	O
surrounding	O
protein	O
atoms	O
,	O
indicating	O
high	O
occupancy	O
of	O
the	O
substrate	O
in	O
the	O
active	O
site	O
.	O

The	O
initial	O
difference	O
electron	O
density	O
for	O
bound	O
KAPA	O
is	O
shown	O
in	O
Figure	O
3	O
(	O
c	O
)	O
.	O

The	O
substrate	O
is	O
bound	O
in	O
a	O
rather	O
bent	O
fashion	O
in	O
the	O
active	O
site	O
cleft	O
,	O
with	O
the	O
carboxyl	O
tail	O
close	O
to	O
the	O
entrance	O
of	O
the	O
cleft	O
and	O
the	O
polar	O
head	O
group	O
close	O
to	O
the	O
re	O
face	O
of	O
the	O
cofactor	O
at	O
the	O
bottom	O
of	O
the	O
active	O
site	O
(	O
Figure	O
7	O
)	O
.	O

The	O
polar	O
head	O
/	O
tail	O
groups	O
anchor	O
the	O
substrate	O
to	O
the	O
protein	O
through	O
salt	O
bridges	O
and	O
hydrogen	O
bonds	O
,	O
while	O
the	O
hydrophobic	O
carbon	O
chain	O
packs	O
with	O
hydrophobic	O
amino	O
acid	O
side	O
-	O
chains	O
in	O
the	O
active	O
site	O
pocket	O
.	O

The	O
carboxyl	O
group	O
of	O
KAPA	O
forms	O
a	O
salt	O
bridge	O
with	O
the	O
side	O
-	O
chain	O
of	O
the	O
invariant	O
Arg391	O
.	O

One	O
of	O
the	O
oxygen	O
atoms	O
of	O
this	O
carboxyl	O
groups	O
is	O
also	O
within	O
hydrogen	O
bonding	O
distance	O
of	O
the	O
Nϵ	O
atom	O
of	O
the	O
side	O
-	O
chain	O
of	O
Trp52	O
.	O

The	O
aliphatic	O
carbon	O
atoms	O
of	O
the	O
KAPA	O
molecule	O
form	O
van	O
der	O
Waals	O
'	O
interactions	O
with	O
the	O
side	O
-	O
chains	O
of	O
residues	O
Tyr17	O
,	O
Trp53	O
,	O
Tyr144	O
and	O
Phe393	O
.	O

The	O
7-keto	O
oxygen	O
atom	O
of	O
KAPA	O
forms	O
a	O
hydrogen	O
bond	O
to	O
the	O
Nϵ	O
atom	O
of	O
Lys274	O
,	O
which	O
is	O
covalently	O
linked	O
to	O
the	O
PLP	O
in	O
this	O
ternary	O
complex	O
.	O

The	O
N8	O
nitrogen	O
atom	O
of	O
the	O
substrate	O
is	O
held	O
in	O
position	O
through	O
hydrogen	O
bonds	O
formed	O
to	O
the	O
hydroxyl	O
group	O
of	O
Tyr17	O
,	O
and	O
the	O
peptide	O
oxygen	O
of	O
Gly307	O
.	O

The	O
terminal	O
methyl	O
group	O
of	O
KAPA	O
forms	O
a	O
hydrophobic	O
contact	O
with	O
the	O
side	O
-	O
chain	O
of	O
Trp52	O
.	O

Very	O
few	O
significant	O
conformational	O
changes	O
occur	O
upon	O
binding	O
of	O
the	O
substrate	O
.	O

The	O
largest	O
changes	O
involve	O
only	O
side	O
-	O
chain	O
movements	O
.	O

They	O
include	O
the	O
side	O
-	O
chain	O
of	O
Tyr17	O
,	O
which	O
shifts	O
towards	O
the	O
KAPA	O
substrate	O
.	O

The	O
guanidinium	O
group	O
of	O
the	O
side	O
-	O
chain	O
of	O
Arg391	O
moves	O
about	O
3	O
Å	O
in	O
order	O
to	O
form	O
a	O
tight	O
salt	O
bridge	O
to	O
the	O
carboxyl	O
group	O
of	O
KAPA	O
.	O

The	O
most	O
pronounced	O
conformational	O
change	O
involves	O
the	O
side	O
-	O
chain	O
of	O
Trp53	O
,	O
which	O
adopts	O
a	O
position	O
perpendicular	O
to	O
its	O
location	O
in	O
the	O
unliganded	O
protein	O
.	O

This	O
conformational	O
change	O
has	O
as	O
a	O
consequence	O
that	O
this	O
residue	O
,	O
which	O
had	O
been	O
one	O
of	O
the	O
outliers	O
in	O
the	O
Ramachandran	O
plot	O
for	O
the	O
holoenzyme	O
,	O
is	O
now	O
located	O
in	O
a	O
favourable	O
region	O
of	O
the	O
Ramachandran	O
plot	O
.	O

The	O
metal	O
binding	O
site	O
A	O
strong	O
peak	O
in	O
electron	O
density	O
(	O
11	O
times	O
the	O
standard	O
deviation	O
of	O
a	O
F	O
o	O
−F	O
c	O
electron	O
density	O
map	O
)	O
was	O
found	O
located	O
close	O
to	O
a	O
tight	O
turn	O
between	O
helix	O
α3	O
and	O
strand	O
β4	O
,	O
formed	O
by	O
residues	O
96	O
to	O
100	O
.	O

Observed	O
distances	O
to	O
surrounding	O
protein	O
atoms	O
(	O
2.3	O
to	O
2.6	O
Å	O
)	O
were	O
not	O
consistent	O
with	O
a	O
water	O
molecule	O
in	O
this	O
position	O
.	O

On	O
the	O
basis	O
of	O
peak	O
height	O
,	O
ligand	O
distance	O
and	O
geometry	O
,	O
this	O
difference	O
density	O
was	O
modelled	O
as	O
a	O
sodium	O
ion	O
.	O

Binding	O
of	O
a	O
potassium	O
ion	O
at	O
this	O
site	O
was	O
excluded	O
,	O
since	O
it	O
is	O
not	O
present	O
in	O
the	O
crystallisation	O
solution	O
,	O
whereas	O
sodium	O
is	O
present	O
in	O
high	O
concentration	O
as	O
a	O
buffer	O
counterion	O
(	O
>	O
50	O
mM	O
)	O
.	O

The	O
ligands	O
to	O
the	O
Na+	O
form	O
a	O
close	O
to	O
octahedral	O
coordination	O
sphere	O
,	O
with	O
oxygen	O
atoms	O
provided	O
by	O
main	O
-	O
chain	O
carbonyl	O
groups	O
of	O
residues	O
Val96	O
,	O
Thr99	O
,	O
Pro100	O
and	O
Leu103	O
(	O
Figure	O
8)	O
.	O

Additional	O
ligands	O
are	O
the	O
side	O
-	O
chain	O
of	O
Thr99	O
and	O
a	O
water	O
molecule	O
.	O

Binding	O
sites	O
for	O
monovalent	O
metal	O
ions	O
have	O
been	O
observed	O
in	O
other	O
vitamin	O
B6	O
-dependent	O
enzymes	O
,	O
for	O
instance	O
2,2-dialkylglycine	O
decarboxylase	O
(	O
Toney	O
et	O
al	O
.	O
,	O
1993	O
,	O
1995	O
)	O
and	O
tryptophanase	O
(	O
Isupov	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

The	O
metal	O
binding	O
site	O
observed	O
in	O
DAPA	O
synthase	O
is	O
identical	O
to	O
site	O
II	O
in	O
the	O
decarboxylase	O
,	O
with	O
the	O
same	O
set	O
of	O
ligands	O
,	O
four	O
carbonyl	O
oxygen	O
atoms	O
,	O
a	O
threonine	O
side	O
-	O
chain	O
and	O
a	O
water	O
molecule	O
.	O

Because	O
this	O
metal	O
binding	O
site	O
is	O
remote	O
from	O
the	O
active	O
site	O
(	O
>	O
20	O
Å	O
)	O
,	O
its	O
role	O
is	O
likely	O
to	O
be	O
structural	O
rather	O
than	O
catalytic	O
.	O

Crystal	O
packing	O
DAPA	O
synthase	O
crystals	O
grown	O
under	O
the	O
same	O
conditions	O
occur	O
in	O
two	O
space	O
groups	O
,	O
C	O
2	O
and	O
P	O
21	O
,	O
with	O
cell	O
dimensions	O
a	O
=	O
130	O
Å	O
,	O
b	O
=	O
57.5	O
Å	O
,	O
c	O
=	O
117	O
Å	O
and	O
β=110	O
°	O
,	O
and	O
a	O
=	O
58.5	O
Å	O
,	O
b	O
=	O
55.6	O
Å	O
,	O
c	O
=	O
117	O
Å	O
and	O
β=96.9	O
°	O
,	O
respectively	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

It	O
was	O
evident	O
that	O
the	O
two	O
space	O
groups	O
were	O
closely	O
related	O
as	O
the	O
crystal	O
lattice	O
could	O
change	O
from	O
C	O
2	O
to	O
P	O
21	O
during	O
data	O
collection	O
.	O

This	O
transition	O
can	O
be	O
triggered	O
by	O
cooling	O
the	O
crystal	O
from	O
room	O
temperature	O
to	O
4	O
°	O
C	O
.	O

Further	O
,	O
the	O
native	O
Patterson	O
map	O
obtained	O
from	O
the	O
P	O
21	O
crystals	O
had	O
two	O
peaks	O
very	O
close	O
to	O
(	O
1	O
/	O
2,1	O
/	O
2,1	O
/	O
2	O
)	O
,	O
indicating	O
a	O
pseudo	O
symmetry	O
in	O
the	O
packing	O
pattern	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

A	O
slight	O
rearrangement	O
of	O
the	O
molecules	O
in	O
the	O
crystal	O
disrupts	O
the	O
perfect	O
alignment	O
between	O
the	O
2-fold	O
molecular	O
axes	O
relating	O
the	O
monomers	O
and	O
the	O
crystallographic	O
dyad	O
and	O
shifts	O
its	O
positions	O
from	O
exactly	O
(	O
1	O
/	O
4	O
,	O
y	O
,	O
0	O
)	O
and	O
(	O
3	O
/	O
4	O
,	O
y	O
,	O
0	O
)	O
,	O
resulting	O
in	O
a	O
change	O
from	O
space	O
group	O
C	O
2	O
to	O
P	O
21	O
(	O
Figure	O
9	O
)	O
.	O

The	O
relationship	O
between	O
the	O
two	O
space	O
groups	O
can	O
be	O
described	O
as	O
X	O
C	O
2=	O
−X	O
P	O
21	O
−Z	O
P	O
21	O
,	O
Y	O
C	O
2	O
=	O
Y	O
P	O
21	O
,	O
Z	O
C	O
2=2X	O
P	O
21	O
.	O

Discussion	O
Structural	O
relationships	O
between	O
vitamin	O
B6	O
enzymes	O
of	O
fold	O
type	O
I	O
In	O
order	O
to	O
analyse	O
structural	O
relationships	O
within	O
the	O
PLP	O
fold	O
type	O
I	O
family	O
,	O
a	O
general	O
search	O
of	O
the	O
Protein	O
Data	O
Bank	O
for	O
PLP	O
-	O
dependent	O
enzymes	O
topologically	O
similar	O
to	O
DAPA	O
synthase	O
was	O
performed	O
,	O
followed	O
by	O
a	O
multiple	O
structural	O
alignment	O
between	O
these	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
)	O
.	O

Ten	O
different	O
enzymes	O
aligned	O
with	O
DAPA	O
synthase	O
(	O
Table	O
3	O
)	O
.	O

The	O
pairwise	O
amino	O
acid	O
identities	O
of	O
structurally	O
aligned	O
elements	O
are	O
presented	O
in	O
Table	O
4	O
.	O

Furthermore	O
,	O
the	O
relationships	O
based	O
on	O
the	O
structural	O
similarities	O
between	O
these	O
enzymes	O
are	O
presented	O
in	O
Figure	O
10	O
(	O
a	O
)	O
(	O
see	O
Materials	O
and	O
Methods	O
for	O
details	O
)	O
.	O

Although	O
the	O
enzymes	O
in	O
the	O
fold	O
type	O
I	O
class	O
of	O
the	O
vitamin	O
B6	O
enzyme	O
superfamily	O
share	O
the	O
same	O
overall	O
fold	O
,	O
only	O
five	O
elements	O
of	O
secondary	O
structure	O
could	O
be	O
structurally	O
aligned	O
between	O
all	O
of	O
them	O
.	O

These	O
elements	O
correspond	O
to	O
strands	O
β4	O
,	O
β6	O
,	O
β7	O
,	O
β8	O
and	O
β9	O
,	O
as	O
defined	O
for	O
DAPA	O
synthase	O
Figure	O
10	O
(	O
b	O
)	O
.	O

A	O
slight	O
difference	O
in	O
the	O
twist	O
of	O
the	O
sheet	O
in	O
the	O
different	O
enzymes	O
prevents	O
alignment	O
of	O
the	O
two	O
outmost	O
strands	O
of	O
the	O
sheet	O
,	O
even	O
though	O
they	O
are	O
present	O
in	O
all	O
structures	O
.	O

Genuinely	O
different	O
areas	O
are	O
loops	O
involved	O
in	O
substrate	O
binding	O
and	O
subunit	O
-	O
subunit	O
interactions	O
.	O

According	O
to	O
the	O
multiple	O
structural	O
alignment	O
these	O
11	O
enzymes	O
can	O
be	O
divided	O
into	O
six	O
different	O
subclasses	O
(	O
Figure	O
10	O
(	O
a	O
)	O
and	O
Table	O
3	O
)	O
.	O

The	O
largest	O
subclass	O
includes	O
DAPA	O
synthase	O
,	O
2,2-dialkylglycine	O
decarboxylase	O
,	O
glutamate	O
semialdehyde	O
aminomutase	O
and	O
human	B
ornithine	O
aminotransferase	O
,	O
and	O
corresponds	O
to	O
aminotransferases	O
subclass	O
III	O
in	O
Grishin	O
's	O
classification	O
(	O
Grishin	O
et	O
al	O
.	O
,	O
1995	O
)	O
.	O

Aromatic	O
amino	O
acid	O
aminotransferase	O
and	O
aspartate	O
aminotransferase	O
make	O
up	O
the	O
members	O
of	O
aminotransferases	O
subclass	O
I	O
,	O
and	O
phosphoserine	O
aminotransferase	O
is	O
the	O
only	O
representative	O
of	O
the	O
aminotransferase	O
subclass	O
V.	O
There	O
are	O
no	O
coordinates	O
released	O
in	O
the	O
PDB	O
database	O
for	O
enzymes	O
that	O
might	O
belong	O
to	O
aminotransferase	O
subclass	O
II	O
as	O
defined	O
by	O
Grishin	O
et	O
al	O
.	O

(	O
1995	O
)	O
.	O

A	O
structure	O
-	O
based	O
classification	O
of	O
the	O
fold	O
type	O
I	O
enzymes	O
outside	O
the	O
aminotransferase	O
subclasses	O
had	O
not	O
been	O
addressed	O
earlier	O
.	O

In	O
our	O
comparison	O
,	O
tyrosine	O
phenol	O
-	O
lyase	O
and	O
tryptophan	O
indole	O
-	O
lyase	O
form	O
a	O
distinct	O
class	O
(	O
the	O
tyrosine	O
phenol	O
-	O
lyase	O
subclass	O
)	O
.	O

Cystathionine	O
β	O
-	O
lyase	O
shows	O
sequence	O
identities	O
in	O
the	O
range	O
of	O
26	O
%	O
to	O
32	O
%	O
to	O
metathione	O
γ	O
-	O
lyase	O
,	O
cystathionine	O
γ	O
-	O
lyase	O
,	O
O	O
-acetyl	O
-	O
l	O
-homoserine	O
sulfhydrylase	O
,	O
O	O
-succinylhomoserine	O
sulphfhydrylase	O
,	O
and	O
cystathionine	O
γ	O
-	O
synthase	O
,	O
indicating	O
that	O
they	O
belong	O
to	O
the	O
same	O
structural	O
subclass	O
(	O
the	O
cystathionine	O
β	O
-	O
lyase	O
subclass	O
)	O
.	O

The	O
larger	O
prokaryotic	B
ornithine	O
decarboxylase	O
is	O
the	O
sole	O
representative	O
of	O
its	O
subclass	O
so	O
far	O
.	O

There	O
is	O
a	O
striking	O
correlation	O
between	O
the	O
structure	O
of	O
the	O
N	O
-	O
terminal	O
part	O
of	O
the	O
polypeptide	O
chain	O
and	O
the	O
subclass	O
definition	O
obtained	O
from	O
the	O
multiple	O
structure	O
alignment	O
within	O
this	O
family	O
.	O

The	O
structure	O
of	O
this	O
chain	O
segment	O
is	O
rather	O
different	O
between	O
the	O
subclasses	O
,	O
but	O
similar	O
within	O
a	O
given	O
subclass	O
(	O
Figure	O
11	O
)	O
.	O

For	O
instance	O
,	O
the	O
N	O
-	O
terminal	O
β	O
-	O
meander	O
followed	O
by	O
a	O
helix	O
as	O
described	O
for	O
DAPA	O
synthase	O
holds	O
for	O
all	O
enzymes	O
in	O
subclass	O
III	O
(	O
Figure	O
11	O
(	O
a	O
)	O
)	O
.	O

In	O
the	O
tyrosine	O
phenol	O
-	O
lyase	O
subclass	O
a	O
helix	O
folds	O
over	O
the	O
hinge	O
region	O
and	O
covers	O
one	O
end	O
of	O
the	O
C	O
-	O
terminal	O
β	O
-	O
sheet	O
.	O

This	O
leaves	O
the	O
entrance	O
to	O
the	O
active	O
site	O
more	O
open	O
than	O
in	O
the	O
subclass	O
III	O
enzymes	O
.	O

An	O
N	O
-	O
terminal	O
arm	O
extends	O
outside	O
the	O
catalytic	O
dimer	O
and	O
is	O
involved	O
in	O
a	O
four	O
-	O
stranded	O
(	O
-sheet	O
built	O
up	O
by	O
two	O
strands	O
from	O
each	O
subunit	O
mediating	O
tetramer	O
formation	O
(	O
Antson	O
et	O
al	O
.	O
,	O
1993	O
)	O
(	O
Figure	O
11	O
(	O
b	O
)	O
)	O
.	O

In	O
cystathionine	O
-	O
β	O
-	O
lyase	O
(	O
Figure	O
11	O
(	O
c	O
)	O
)	O
the	O
N	O
-	O
terminus	O
protrudes	O
out	O
from	O
the	O
monomer	O
into	O
the	O
active	O
site	O
of	O
the	O
other	O
monomer	O
in	O
the	O
catalytic	O
dimer	O
and	O
then	O
turns	O
back	O
and	O
folds	O
into	O
an	O
α	O
-	O
helix	O
which	O
packs	O
against	O
the	O
outside	O
of	O
the	O
hinge	O
between	O
the	O
domains	O
in	O
its	O
original	O
subunit	O
.	O

Some	O
of	O
the	O
residues	O
in	O
the	O
N	O
-	O
terminal	O
segment	O
are	O
also	O
involved	O
in	O
tetramer	O
formation	O
.	O

In	O
the	O
aspartate	O
aminotransferase	O
and	O
aromatic	O
amino	O
acid	O
aminotransferase	O
the	O
N	O
terminus	O
starts	O
on	O
the	O
surface	O
of	O
the	O
second	O
subunit	O
and	O
then	O
crosses	O
over	O
the	O
active	O
site	O
cleft	O
before	O
joining	O
the	O
small	O
domain	O
.	O

The	O
N	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
forms	O
an	O
α	O
-	O
helix	O
which	O
lines	O
the	O
active	O
site	O
entrance	O
and	O
contributes	O
with	O
a	O
β	O
-	O
strand	O
interaction	O
to	O
the	O
C	O
-	O
terminal	O
β	O
-	O
sheet	O
(	O
Figure	O
11	O
(	O
d	O
)	O
)	O
.	O

Ornithine	O
decarboxylase	O
is	O
a	O
larger	O
PLP	O
-	O
dependent	O
enzyme	O
of	O
which	O
only	O
parts	O
,	O
domain	O
three	O
and	O
domain	O
four	O
,	O
correspond	O
to	O
the	O
fold	O
type	O
I	O
enzymes	O
.	O

The	O
small	O
domain	O
is	O
built	O
up	O
solely	O
by	O
domain	O
four	O
,	O
corresponding	O
to	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
small	O
domain	O
in	O
the	O
smaller	O
fold	O
type	O
I	O
enzymes	O
.	O

The	O
N	O
-	O
terminal	O
domains	O
consist	O
of	O
one	O
independently	O
folded	O
domain	O
followed	O
by	O
a	O
long	O
linker	O
connecting	O
it	O
to	O
the	O
PLP	O
binding	O
domain	O
three	O
(	O
Figure	O
11	O
(	O
f	O
)	O
)	O
.	O

Finally	O
,	O
the	O
subclass	O
V	O
enzymes	O
seem	O
to	O
lack	O
the	O
N	O
-	O
terminal	O
domain	O
completely	O
.	O

The	O
polypeptide	O
chain	O
starts	O
at	O
the	O
domain	O
linker	O
region	O
and	O
enters	O
the	O
large	O
domain	O
directly	O
(	O
Figure	O
11	O
(	O
e	O
)	O
)	O
.	O

The	O
active	O
site	O
:	O
similarities	O
and	O
differences	O
in	O
the	O
fold	O
type	O
I	O
enzymes	O
The	O
active	O
site	O
and	O
in	O
particular	O
the	O
pyridine	O
ring	O
of	O
the	O
PLP	O
cofactor	O
of	O
the	O
fold	O
type	O
I	O
enzymes	O
of	O
known	O
3-D	O
structure	O
superpose	O
very	O
well	O
(	O
Figure	O
12	O
)	O
.	O

The	O
maximum	O
distance	O
from	O
the	O
Schiff	O
-	O
base	O
nitrogen	O
atom	O
in	O
DAPA	O
synthase	O
to	O
the	O
corresponding	O
atom	O
of	O
related	O
enzymes	O
is	O
1.4	O
Å	O
(	O
ornithine	O
decarboxylase	O
and	O
phosphoserine	O
amino	O
transferase	O
)	O
,	O
and	O
that	O
for	O
the	O
pyridine	O
nitrogen	O
is	O
1.4	O
Å	O
(	O
phosphoserine	O
amino	O
transferase	O
)	O
.	O

The	O
residues	O
participating	O
in	O
binding	O
of	O
the	O
cofactor	O
are	O
presented	O
in	O
Table	O
5	O
.	O

It	O
is	O
notable	O
that	O
,	O
despite	O
the	O
similar	O
position	O
of	O
the	O
cofactor	O
in	O
the	O
active	O
site	O
(	O
Figure	O
12	O
)	O
,	O
the	O
loop	O
between	O
strands	O
β9	O
and	O
β10	O
carrying	O
the	O
active	O
site	O
lysine	O
residue	O
is	O
not	O
structurally	O
conserved	O
.	O

In	O
all	O
aminotransferase	O
subclass	O
III	O
enzymes	O
this	O
loop	O
is	O
shorter	O
,	O
with	O
the	O
consequence	O
that	O
the	O
lysine	O
residue	O
is	O
positioned	O
out	O
of	O
register	O
with	O
the	O
corresponding	O
lysine	O
in	O
the	O
enzymes	O
belonging	O
to	O
the	O
other	O
subclasses	O
(	O
Figure	O
12	O
)	O
.	O

This	O
suggests	O
a	O
deletion	O
of	O
one	O
amino	O
acid	O
in	O
the	O
ancestral	O
subclass	O
III	O
aminotransferase	O
.	O

The	O
Nϵ	O
atom	O
of	O
the	O
lysine	O
side	O
-	O
chain	O
,	O
however	O
,	O
is	O
found	O
at	O
approximately	O
the	O
same	O
position	O
.	O

The	O
aspartic	O
acid	O
residue	O
which	O
corresponds	O
to	O
Asp245	O
in	O
DAPA	O
synthase	O
is	O
the	O
only	O
structurally	O
conserved	O
residue	O
in	O
this	O
enzyme	O
family	O
.	O

This	O
amino	O
acid	O
forms	O
a	O
salt	O
bridge	O
/	O
hydrogen	O
bond	O
with	O
the	O
pyridine	O
nitrogen	O
and	O
was	O
proposed	O
to	O
provide	O
one	O
of	O
the	O
key	O
interactions	O
for	O
the	O
regulation	O
of	O
the	O
pK	O
a	O
of	O
the	O
aldimine	O
nitrogen	O
(	O
Hayashi	O
,	O
1995	O
;	O
John	O
,	O
1995	O
)	O
.	O

Stabilisation	O
of	O
this	O
interaction	O
is	O
provided	O
by	O
a	O
non	O
-	O
conserved	O
pattern	O
of	O
hydrogen	O
bonds	O
to	O
surrounding	O
residues	O
,	O
except	O
in	O
the	O
case	O
of	O
ornithine	O
decarboxylase	O
and	O
tryptophanase	O
in	O
which	O
the	O
aspartic	O
acid	O
only	O
interacts	O
with	O
the	O
pyridine	O
nitrogen	O
of	O
PLP	O
.	O

In	O
DAPA	O
synthase	O
,	O
glutamate	O
semialdehyde	O
aminomutase	O
and	O
dialkylglycine	O
decarboxylase	O
a	O
histidine	O
residue	O
forms	O
a	O
hydrogen	O
bond	O
to	O
one	O
of	O
the	O
carboxyl	O
oxygen	O
atoms	O
of	O
the	O
aspartic	O
acid	O
.	O

Similar	O
interactions	O
are	O
provided	O
by	O
a	O
histidine	O
from	O
a	O
different	O
loop	O
in	O
the	O
aspartate	O
and	O
aromatic	O
amino	O
acid	O
aminotransferases	O
.	O

In	O
the	O
subclass	O
III	O
and	O
V	O
enzymes	O
,	O
the	O
main	O
-	O
chain	O
amide	O
of	O
the	O
second	O
residue	O
following	O
the	O
aspartic	O
acid	O
is	O
within	O
hydrogen	O
bonding	O
distance	O
(	O
<	O
3.3	O
Å	O
)	O
to	O
the	O
carboxyl	O
group	O
of	O
this	O
aspartic	O
acid	O
whereas	O
in	O
cystathionine	O
β	O
-	O
lyase	O
,	O
phosphoserine	O
aminotransferase	O
and	O
tyrosine	O
phenol	O
-	O
lyase	O
the	O
side	O
-	O
chain	O
of	O
this	O
residue	O
(	O
Thr	O
/	O
Ser	O
)	O
provides	O
an	O
interaction	O
with	O
the	O
same	O
group	O
.	O

In	O
all	O
enzymes	O
except	O
DAPA	O
synthase	O
,	O
the	O
protein	O
provides	O
a	O
hydrogen	O
bond	O
partner	O
to	O
the	O
phenolic	O
oxygen	O
,	O
O-3′	O
,	O
of	O
the	O
pyridine	O
ring	O
.	O

The	O
nature	O
and	O
strength	O
of	O
this	O
interaction	O
might	O
influence	O
the	O
pK	O
a	O
of	O
the	O
resulting	O
Schiff	O
base	O
of	O
the	O
cofactor	O
with	O
the	O
catalytic	O
lysine	O
residue	O
(	O
Goldberg	O
et	O
al	O
.	O
,	O
1991	O
;	O
Inoue	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

As	O
described	O
,	O
a	O
water	O
-	O
mediated	O
interaction	O
with	O
a	O
glutamic	O
acid	O
residue	O
replaces	O
this	O
interaction	O
in	O
DAPA	O
synthase	O
.	O

A	O
structural	O
feature	O
distinguishing	O
the	O
subclass	O
III	O
aminotransferases	O
from	O
other	O
fold	O
type	O
I	O
PLP	O
enzymes	O
is	O
the	O
stacking	O
interactions	O
with	O
the	O
re	O
face	O
of	O
the	O
pyridine	O
ring	O
of	O
PLP	O
.	O

All	O
enzymes	O
of	O
known	O
structure	O
have	O
aromatic	O
residues	O
in	O
this	O
position	O
,	O
corresponding	O
to	O
Tyr144	O
in	O
DAPA	O
synthase	O
.	O

However	O
,	O
in	O
the	O
subclass	O
III	O
aminotransferases	O
the	O
aromatic	O
residue	O
packs	O
nearly	O
perpendicular	O
to	O
the	O
pyridine	O
ring	O
of	O
the	O
cofactor	O
,	O
while	O
in	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
the	O
stacking	O
is	O
close	O
to	O
parallel	O
.	O

It	O
has	O
been	O
proposed	O
for	O
aspartate	O
aminotransferase	O
that	O
the	O
parallel	O
stacking	O
,	O
which	O
is	O
optimised	O
from	O
nearly	O
parallel	O
to	O
parallel	O
in	O
the	O
external	O
aldimine	O
complex	O
,	O
increases	O
the	O
electron	O
withdrawing	O
effect	O
of	O
the	O
cofactor	O
and	O
favours	O
the	O
formation	O
of	O
the	O
quinonoid	O
intermediate	O
(	O
Ford	O
et	O
al	O
.	O
,	O
1980	O
;	O
Hayashi	O
et	O
al	O
.	O
,	O
1990	O
)	O
.	O

In	O
the	O
aminotransferase	O
subclass	O
III	O
enzymes	O
,	O
the	O
stacking	O
residue	O
is	O
part	O
of	O
the	O
loop	O
between	O
strands	O
β5	O
and	O
β6	O
,	O
which	O
narrows	O
the	O
active	O
site	O
entrance	O
.	O

With	O
this	O
conformation	O
of	O
the	O
polypeptide	O
backbone	O
,	O
the	O
aromatic	O
residue	O
would	O
clash	O
with	O
the	O
main	O
chain	O
if	O
it	O
packed	O
parallel	O
to	O
the	O
ring	O
.	O

In	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
the	O
loop	O
is	O
replaced	O
by	O
a	O
short	O
helix	O
beginning	O
immediately	O
after	O
the	O
aromatic	O
residue	O
.	O

This	O
difference	O
in	O
backbone	O
conformation	O
enables	O
a	O
parallel	O
stacking	O
to	O
the	O
pyridine	O
ring	O
of	O
the	O
cofactor	O
and	O
leaves	O
the	O
active	O
site	O
much	O
more	O
open	O
.	O

In	O
tryptophanase	O
,	O
cystathionine	O
β	O
-	O
lyase	O
and	O
tyrosine	O
phenol	O
-	O
lyase	O
the	O
active	O
site	O
entrance	O
is	O
instead	O
restricted	O
by	O
a	O
loop	O
protruding	O
from	O
the	O
β	O
-	O
sheet	O
in	O
the	O
small	O
domain	O
whereas	O
the	O
other	O
enzymes	O
simply	O
have	O
a	O
wider	O
active	O
site	O
entrance	O
.	O

Human	B
ornithine	O
decarboxylase	O
is	O
an	O
exception	O
,	O
having	O
an	O
extra	O
C	O
-	O
terminal	O
domain	O
packing	O
against	O
the	O
active	O
site	O
cleft	O
.	O

There	O
are	O
two	O
distinct	O
positions	O
of	O
the	O
phosphate	O
group	O
of	O
PLP	O
;	O
one	O
for	O
the	O
subclass	O
I	O
aminotransferases	O
and	O
one	O
for	O
all	O
the	O
others	O
fold	O
type	O
I	O
PLP	O
enzymes	O
(	O
Figure	O
12	O
)	O
.	O

This	O
is	O
caused	O
by	O
interactions	O
of	O
phosphate	O
oxygen	O
atoms	O
with	O
an	O
arginine	O
residue	O
(	O
Arg266	O
in	O
aspartate	O
aminotransferase	O
)	O
which	O
result	O
in	O
a	O
different	O
tilt	O
of	O
the	O
cofactor	O
in	O
aspartate	O
and	O
aromatic	O
amino	O
acid	O
aminotransferases	O
in	O
relation	O
to	O
the	O
other	O
fold	O
type	O
I	O
enzymes	O
.	O

Substrate	O
recognition	O
In	O
order	O
to	O
locate	O
the	O
active	O
site	O
in	O
DAPA	O
synthase	O
,	O
the	O
crystal	O
structure	O
of	O
a	O
ternary	O
complex	O
of	O
the	O
enzyme	O
with	O
PLP	O
and	O
KAPA	O
was	O
determined	O
(	O
Figure	O
7	O
)	O
.	O

This	O
complex	O
is	O
unproductive	O
,	O
since	O
it	O
combines	O
the	O
PLP	O
form	O
of	O
the	O
cofactor	O
with	O
the	O
amino	O
group	O
acceptor	O
KAPA	O
,	O
which	O
in	O
the	O
catalytic	O
reaction	O
reacts	O
with	O
the	O
pyridoxamine	O
form	O
of	O
the	O
enzyme	O
.	O

Since	O
KAPA	O
is	O
an	O
amino	O
acid	O
,	O
the	O
question	O
arises	O
as	O
to	O
why	O
it	O
does	O
not	O
act	O
as	O
amino	O
donor	O
in	O
the	O
reaction	O
,	O
i.e.	O
react	O
with	O
the	O
PLP	O
form	O
of	O
the	O
enzyme	O
.	O

The	O
structure	O
of	O
the	O
ternary	O
complex	O
provides	O
an	O
immediate	O
answer	O
.	O

In	O
order	O
to	O
react	O
with	O
the	O
C-4′	O
carbon	O
atom	O
of	O
the	O
cofactor	O
to	O
form	O
the	O
internal	O
aldimine	O
,	O
the	O
N8	O
amino	O
group	O
of	O
KAPA	O
must	O
bind	O
very	O
closely	O
to	O
this	O
part	O
of	O
the	O
cofactor	O
in	O
an	O
orientation	O
favourable	O
for	O
the	O
reaction	O
to	O
occur	O
.	O

In	O
the	O
complex	O
,	O
the	O
N8	O
amino	O
group	O
is	O
bound	O
tightly	O
to	O
protein	O
main	O
-	O
chain	O
and	O
side	O
-	O
chain	O
atoms	O
in	O
such	O
a	O
manner	O
that	O
it	O
points	O
away	O
from	O
the	O
internal	O
aldimine	O
group	O
,	O
thus	O
preventing	O
transamination	O
(	O
Figure	O
7	O
)	O
.	O

The	O
observed	O
binding	O
of	O
KAPA	O
does	O
however	O
position	O
the	O
seven	O
-	O
carbon	O
atom	O
of	O
KAPA	O
close	O
to	O
the	O
aldimine	O
and	O
thereby	O
facilitates	O
transfer	O
of	O
an	O
amino	O
group	O
to	O
this	O
carbon	O
atom	O
,	O
which	O
would	O
yield	O
the	O
product	O
,	O
7,8-diaminopelargonic	O
acid	O
.	O

An	O
important	O
conclusion	O
to	O
be	O
drawn	O
from	O
the	O
structure	O
of	O
the	O
ternary	O
complex	O
is	O
that	O
in	O
DAPA	O
synthase	O
,	O
as	O
opposed	O
to	O
other	O
enzymes	O
of	O
this	O
class	O
of	O
vitamin	O
B6	O
-dependent	O
enzymes	O
,	O
no	O
domain	O
-	O
domain	O
rotation	O
occurs	O
upon	O
substrate	O
binding	O
.	O

The	O
absence	O
of	O
such	O
large	O
-	O
scale	O
conformational	O
changes	O
is	O
not	O
unique	O
for	O
DAPA	O
synthase	O
but	O
has	O
also	O
been	O
shown	O
for	O
another	O
enzyme	O
in	O
this	O
family	O
,	O
human	B
ornithine	O
aminotransferase	O
(	O
Shah	O
et	O
al	O
.	O
,	O
1997	O
)	O
.	O

The	O
substrate	O
reacting	O
with	O
the	O
PLP	O
form	O
of	O
the	O
enzyme	O
is	O
SAM	O
and	O
the	O
active	O
site	O
,	O
as	O
seen	O
in	O
the	O
holoenzyme	O
should	O
therefore	O
be	O
poised	O
to	O
bind	O
SAM	O
.	O

The	O
outer	O
part	O
of	O
the	O
active	O
site	O
pocket	O
is	O
quite	O
open	O
and	O
there	O
are	O
several	O
areas	O
which	O
could	O
provide	O
hydrophobic	O
interactions	O
with	O
the	O
adenine	O
ring	O
and	O
still	O
leave	O
space	O
for	O
the	O
sugar	O
moiety	O
.	O

Therefore	O
,	O
modelling	O
the	O
binding	O
site	O
of	O
SAM	O
in	O
DAPA	O
synthase	O
is	O
highly	O
speculative	O
and	O
a	O
reliable	O
model	O
for	O
the	O
enzyme	O
-	O
PLP	O
-	O
SAM	O
complex	O
will	O
have	O
to	O
await	O
a	O
crystal	O
structure	O
determination	O
.	O

A	O
more	O
detailed	O
discussion	O
of	O
the	O
reaction	O
mechanism	O
of	O
DAPA	O
synthase	O
will	O
require	O
structural	O
information	O
from	O
this	O
and	O
other	O
complexes	O
along	O
the	O
reaction	O
pathway	O
,	O
in	O
combination	O
with	O
the	O
results	O
from	O
site	O
-	O
directed	O
mutagenesis	O
experiments	O
.	O

Materials	O
and	O
methods	O
Crystallisation	O
DAPA	O
synthase	O
was	O
expressed	O
,	O
purified	O
and	O
crystallised	O
as	O
described	O
(	O
Käck	O
et	O
al	O
.	O
,	O
1998	O
)	O
,	O
with	O
one	O
modification	O
in	O
the	O
crystallisation	O
protocol	O
.	O

After	O
one	O
week	O
of	O
equilibration	O
,	O
micro	O
-	O
seeding	O
was	O
employed	O
to	O
increase	O
the	O
reproducibility	O
of	O
crystal	O
formation	O
.	O

At	O
the	O
same	O
time	O
,	O
20–40	O
μl	O
of	O
4	O
M	O
sodium	O
chloride	O
was	O
added	O
to	O
the	O
well	O
solution	O
.	O

Crystals	O
of	O
the	O
ternary	O
complex	O
DAPA	O
synthase	O
-	O
PLP	O
-	O
KAPA	O
were	O
prepared	O
by	O
soaking	O
crystals	O
of	O
the	O
holoenzyme	O
overnight	O
in	O
5	O
mM	O
KAPA	O
,	O
25	O
%	O
PEG-4000	O
,	O
20	O
%	O
MPD	O
,	O
100	O
mM	O
Hepes	O
(	O
pH	O
7.5	O
)	O
.	O

The	O
substrate	O
KAPA	O
was	O
synthesised	O
as	O
described	O
(	O
Nudelman	O
et	O
al	O
.	O
,	O
1998	O
)	O
.	O

Data	O
collection	O
,	O
phasing	O
and	O
model	O
building	O
The	O
cell	O
dimensions	O
differed	O
slightly	O
between	O
crystals	O
,	O
reflecting	O
non	O
-	O
isomorphism	O
between	O
crystals	O
.	O

A	O
large	O
number	O
of	O
different	O
heavy	O
atoms	O
were	O
screened	O
in	O
order	O
to	O
find	O
a	O
useful	O
derivative	O
.	O

Finally	O
,	O
crystals	O
soaked	O
for	O
24	O
hours	O
at	O
4	O
°	O
C	O
in	O
25	O
%	O
polyethylene	O
glycol	O
4000	O
,	O
22	O
%	O
2-methyl-2,4	O
pentanediol	O
and	O
5	O
mM	O
ethyl	O
mercury	O
thiosalicylate	O
(	O
EMTS	O
)	O
or	O
K2	O
Pt	O
(	O
NO2	O
)	O
4	O
at	O
pH	O
7.5	O
were	O
isomorphous	O
enough	O
to	O
allow	O
identification	O
of	O
the	O
heavy	O
-	O
atom	O
sites	O
.	O

However	O
,	O
neither	O
the	O
multiple	O
isomorphous	O
replacement	O
electron	O
density	O
map	O
nor	O
the	O
2-fold	O
averaged	O
electron	O
density	O
map	O
was	O
interpretable	O
.	O

Multiple	O
anomalous	O
difference	O
data	O
were	O
therefore	O
collected	O
on	O
a	O
EMTS	O
-	O
soaked	O
crystal	O
with	O
cell	O
dimensions	O
a	O
=	O
58.50	O
Å	O
,	O
b	O
=	O
56.63	O
Å	O
,	O
c	O
=	O
121.7	O
Å	O
and	O
β=96.14	O
°	O
,	O
space	O
group	O
P	O
21	O
,	O
at	O
beamline	O
BM	O
14	O
at	O
the	O
ESRF	O
in	O
Grenoble	O
.	O

Data	O
were	O
collected	O
at	O
three	O
different	O
wavelengths	O
,	O
λ1	O
(	O
peak	O
)	O
=0.9918	O
Å	O
,	O
λ2	O
(	O
inflection	O
point	O
)	O
=1.007	O
Å	O
and	O
λ3	O
(	O
high	O
energy	O
remote	O
)	O
=0.8265	O
Å	O
at	O
100	O
K	O
to	O
2.0	O
Å	O
resolution	O
.	O

Data	O
processing	O
and	O
scaling	O
were	O
performed	O
with	O
the	O
programs	O
Denzo	O
and	O
Scalepack	O
(	O
Otwinowski	O
,	O
1993	O
)	O
.	O

Eight	O
mercury	O
sites	O
were	O
identified	O
by	O
visual	O
inspection	O
of	O
the	O
difference	O
Patterson	O
maps	O
and	O
using	O
difference	O
Fourier	O
methods	O
(	O
for	O
phasing	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
five	O
strongest	O
peaks	O
coincided	O
with	O
the	O
binding	O
sites	O
determined	O
earlier	O
,	O
while	O
three	O
minor	O
sites	O
differed	O
in	O
their	O
positions	O
,	O
compared	O
to	O
those	O
previously	O
derived	O
.	O

A	O
map	O
calculated	O
after	O
refinement	O
of	O
the	O
parameters	O
of	O
the	O
mercury	O
positions	O
using	O
mlphare	O
(	O
Otwinowski	O
,	O
1991	O
)	O
and	O
solvent	O
flattening	O
by	O
DM	O
(	O
Cowtan	O
&	O
Main	O
,	O
1996	O
)	O
was	O
of	O
excellent	O
quality	O
,	O
and	O
backbone	O
tracing	O
and	O
sequence	O
assignment	O
(	O
Otsuka	O
et	O
al	O
.	O
,	O
1988	O
)	O
were	O
straighforward	O
for	O
the	O
whole	O
protein	O
except	O
for	O
two	O
mobile	O
regions	O
containing	O
residues	O
160	O
to	O
183	O
and	O
298	O
to	O
304	O
,	O
respectively	O
;	O
2-fold	O
averaging	O
did	O
not	O
improve	O
the	O
map	O
significantly	O
.	O

The	O
model	O
was	O
refined	O
using	O
XPLOR	O
(	O
Brünger	O
et	O
al	O
.	O
,	O
1987	O
)	O
with	O
NCS	O
constraints	O
to	O
R	O
free	O
=	O
35.9	O
%	O
and	O
R	O
=	O
30.4	O
%	O
without	O
including	O
mercury	O
atoms	O
.	O

A	O
native	O
data	O
set	O
was	O
collected	O
using	O
a	O
300	O
mm	O
MAR	O
image	O
plate	O
detector	O
(	O
MAR	O
research	O
Hamburg	O
)	O
at	O
beam	O
line	O
X11	O
at	O
EMBL	O
in	O
Hamburg	O
to	O
1.8	O
Å	O
resolution	O
(	O
for	O
data	O
collection	O
statistics	O
see	O
Table	O
1	O
)	O
.	O

The	O
cell	O
-	O
dimensions	O
of	O
this	O
crystal	O
were	O
a	O
=	O
58.3	O
Å	O
,	O
b	O
=	O
55.6	O
Å	O
,	O
c	O
=	O
120.9	O
Å	O
and	O
β=97.0	O
°	O
,	O
space	O
group	O
P	O
21	O
.	O

Diffraction	O
data	O
for	O
the	O
ternary	O
complex	O
DAPA	O
synthase	O
-	O
PLP	O
-	O
KAPA	O
were	O
collected	O
at	O
100	O
K	O
to	O
2.7	O
Å	O
on	O
a	O
Mar	O
Research	O
image	O
plate	O
mounted	O
on	O
a	O
Rikagu	O
rotating	O
anode	O
operating	O
at	O
50	O
kV	O
and	O
90	O
mA.	O
Data	O
were	O
processed	O
and	O
scaled	O
using	O
Denzo	O
and	O
Scalepack	O
software	O
package	O
(	O
Otwinowski	O
,	O
1993	O
)	O
.	O

Data	O
collection	O
statistics	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
cell	O
-	O
dimensions	O
of	O
this	O
crystal	O
were	O
a	O
=	O
58.0	O
Å	O
,	O
b	O
=	O
55.9	O
Å	O
,	O
c	O
=	O
120.8	O
Å	O
and	O
β=95.7	O
°	O
.	O

Refinement	O
Because	O
of	O
non	O
-	O
isomorphism	O
between	O
the	O
crystals	O
,	O
molecular	O
replacement	O
had	O
to	O
be	O
used	O
in	O
order	O
to	O
find	O
the	O
position	O
of	O
the	O
native	O
enzyme	O
in	O
the	O
unit	O
cell	O
.	O

The	O
program	O
AMORE	O
(	O
Navaza	O
,	O
1994	O
)	O
was	O
used	O
for	O
this	O
task	O
with	O
the	O
dimer	O
as	O
the	O
search	O
molecule	O
.	O

Before	O
refinement	O
,	O
the	O
same	O
set	O
of	O
reflections	O
(	O
in	O
total	O
5	O
%	O
of	O
the	O
reflection	O
data	O
)	O
were	O
set	O
aside	O
to	O
monitor	O
R	O
free	O
.	O

The	O
top	O
solution	O
(	O
correlation	O
coefficient=76.7	O
%	O
)	O
gave	O
an	O
R	O
free	O
of	O
37.5	O
%	O
after	O
an	O
initial	O
rigid	O
body	O
refinement	O
to	O
2.5	O
Å	O
resolution	O
using	O
the	O
program	O
XPLOR	O
(	O
Brünger	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

A	O
clear	O
and	O
strong	O
difference	O
density	O
was	O
found	O
at	O
the	O
position	O
of	O
the	O
cofactor	O
,	O
PLP	O
,	O
which	O
had	O
not	O
been	O
included	O
in	O
the	O
model	O
,	O
confirming	O
that	O
this	O
was	O
the	O
correct	O
solution	O
.	O

After	O
rigid	O
body	O
refinement	O
the	O
structure	O
was	O
rebuilt	O
using	O
the	O
program	O
O	O
(	O
Jones	O
et	O
al	O
.	O
,	O
1991	O
)	O
and	O
refined	O
using	O
the	O
maximum	O
likelihood	O
method	O
as	O
implemented	O
in	O
Refmac	O
(	O
Murshudov	O
et	O
al	O
.	O
,	O
1997	O
)	O
with	O
strong	O
NCS	O
restraints	O
giving	O
R	O
=	O
35.4	O
%	O
and	O
R	O
free	O
=	O
36.4	O
%	O
after	O
the	O
first	O
round	O
of	O
refinement	O
.	O

On	O
the	O
basis	O
of	O
a	O
sigma	O
-	O
weighted	O
electron	O
density	O
map	O
calculated	O
subsequently	O
,	O
residues	O
162	O
-	O
180	O
and	O
residues	O
298	O
-	O
303	O
missing	O
from	O
the	O
previous	O
model	O
could	O
be	O
modelled	O
.	O

After	O
the	O
second	O
round	O
of	O
refinement	O
PLP	O
was	O
included	O
in	O
the	O
model	O
.	O

In	O
subsequent	O
refinement	O
runs	O
the	O
loop	O
region	O
between	O
residue	O
181	O
and	O
191	O
was	O
built	O
.	O

In	O
one	O
of	O
the	O
subunits	O
residue	O
183	O
is	O
still	O
not	O
included	O
in	O
the	O
final	O
model	O
.	O

Eighty	O
water	O
molecules	O
were	O
included	O
after	O
each	O
refinement	O
cycle	O
using	O
the	O
program	O
arp	O
(	O
Lamzin	O
&	O
Wilson	O
,	O
1993	O
)	O
,	O
resulting	O
in	O
a	O
final	O
number	O
of	O
556	O
water	O
molecules	O
of	O
which	O
about	O
two	O
thirds	O
follow	O
the	O
NCS	O
.	O

All	O
solvent	O
sites	O
were	O
inspected	O
manually	O
.	O

Non	O
-	O
crystallographic	O
restraints	O
were	O
used	O
until	O
the	O
last	O
stages	O
of	O
the	O
refinement	O
,	O
their	O
release	O
resulted	O
in	O
a	O
slight	O
drop	O
of	O
the	O
free	O
R	O
value	O
.	O

The	O
quality	O
of	O
the	O
final	O
model	O
was	O
assessed	O
with	O
PROCHECK	O
(	O
Laskowski	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

The	O
structure	O
of	O
the	O
ternary	O
complex	O
was	O
determined	O
to	O
2.7	O
Å	O
by	O
difference	O
Fourier	O
methods	O
.	O

Initial	O
phases	O
were	O
calculated	O
from	O
the	O
refined	O
model	O
of	O
the	O
holoenzyme	O
,	O
with	O
the	O
water	O
molecules	O
and	O
the	O
sodium	O
ions	O
excluded	O
.	O

A	O
KAPA	O
molecule	O
was	O
fitted	O
into	O
the	O
difference	O
electron	O
density	O
found	O
in	O
the	O
active	O
site	O
close	O
to	O
the	O
PLP	O
cofactor	O
;	O
5	O
%	O
of	O
the	O
reflection	O
data	O
were	O
excluded	O
from	O
the	O
refinement	O
and	O
used	O
to	O
calculate	O
the	O
free	O
R	O
value	O
.	O

The	O
model	O
of	O
the	O
ternary	O
complex	O
was	O
refined	O
using	O
Refmac	O
(	O
Murshudov	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
starting	O
in	O
the	O
first	O
cycle	O
as	O
a	O
rigid	O
body	O
refinement	O
.	O

Cycles	O
of	O
refinement	O
were	O
followed	O
by	O
manual	O
intervention	O
using	O
the	O
graphics	O
program	O
O	O
(	O
Jones	O
et	O
al	O
.	O
,	O
1991	O
)	O
.	O

The	O
final	O
model	O
contains	O
94	O
water	O
molecules	O
and	O
two	O
sodium	O
ions	O
,	O
refinement	O
statistics	O
are	O
given	O
in	O
Table	O
2	O
.	O

Structural	O
alignments	O
and	O
database	O
searches	O
The	O
program	O
TOP	O
(	O
Lu	O
,	O
1996	O
)	O
was	O
used	O
for	O
searching	O
the	O
Protein	O
Data	O
Bank	O
with	O
the	O
large	O
domain	O
of	O
the	O
refined	O
model	O
of	O
DAPA	O
synthase	O
as	O
probe	O
and	O
for	O
subsequent	O
superpositions	O
.	O

Exclusion	O
of	O
mutant	O
structures	O
and	O
complexes	O
resulted	O
in	O
15	O
different	O
PLP	O
enzymes	O
with	O
identical	O
topology	O
.	O

Five	O
of	O
these	O
were	O
structures	O
of	O
aspartate	O
aminotransferases	O
from	O
different	O
sources	O
.	O

As	O
these	O
enzymes	O
are	O
very	O
similar	O
,	O
only	O
one	O
of	O
these	O
,	O
the	O
E.	B
coli	I
enzyme	O
,	O
was	O
included	O
in	O
the	O
subsequent	O
multiple	O
structure	O
alignment	O
.	O

For	O
the	O
same	O
reason	O
,	O
only	O
one	O
of	O
the	O
two	O
structures	O
of	O
phosphoserine	O
aminotransferase	O
,	O
deposited	O
in	O
the	O
Protein	O
Data	O
Bank	O
was	O
used	O
in	O
the	O
following	O
multiple	O
structural	O
alignment	O
.	O

Generally	O
,	O
the	O
internal	O
aldimine	O
form	O
of	O
the	O
enzymes	O
was	O
used	O
in	O
this	O
comparison	O
.	O

The	O
domain	O
-	O
domain	O
orientation	O
as	O
compared	O
with	O
DAPA	O
synthase	O
varies	O
substantially	O
between	O
different	O
enzymes	O
,	O
from	O
27	O
°	O
rotation	O
for	O
aspartate	O
aminotransferase	O
to	O
6	O
°	O
rotation	O
for	O
ornithine	O
aminotransferase	O
.	O

In	O
order	O
to	O
extend	O
the	O
structural	O
alignment	O
and	O
comparison	O
to	O
the	O
whole	O
subunit	O
of	O
these	O
enzymes	O
,	O
a	O
second	O
topological	O
alignment	O
was	O
carried	O
out	O
using	O
the	O
small	O
domain	O
of	O
DAPA	O
synthase	O
as	O
search	O
model	O
.	O

The	O
superposed	O
large	O
and	O
small	O
domains	O
were	O
then	O
artificially	O
connected	O
with	O
the	O
same	O
rotation	O
as	O
in	O
DAPA	O
synthase	O
.	O

This	O
set	O
of	O
enzyme	O
models	O
formed	O
the	O
basis	O
for	O
the	O
multiple	O
structural	O
alignment	O
using	O
the	O
program	O
MAPS	O
(	O
G.	O
Lu	O
,	O
unpublished	O
)	O
.	O

In	O
this	O
program	O
,	O
an	O
initial	O
alignment	O
is	O
carried	O
out	O
using	O
the	O
same	O
algorithm	O
as	O
in	O
TOP	O
(	O
Lu	O
,	O
1996	O
)	O
.	O

The	O
program	O
then	O
proceeds	O
by	O
minimising	O
a	O
target	O
function	O
made	O
up	O
by	O
the	O
sum	O
of	O
pairwise	O
distances	O
between	O
equivalent	O
Cα	O
atoms	O
.	O

Segments	O
identified	O
as	O
structurally	O
equivalent	O
must	O
fulfil	O
certain	O
criteria	O
:	O
(	O
i	O
)	O
consist	O
of	O
at	O
least	O
three	O
consecutive	O
residues	O
;	O
(	O
ii	O
)	O
the	O
distance	O
between	O
aligned	O
Cα	O
—Cα	O
atoms	O
should	O
not	O
exceed	O
3.8	O
Å	O
;	O
and	O
(	O
iii	O
)	O
the	O
side	O
-	O
chain	O
should	O
point	O
in	O
a	O
similar	O
direction	O
(	O
the	O
angles	O
formed	O
by	O
the	O
Cα	O
—Cβ	O
bond	O
between	O
equivalent	O
residues	O
should	O
not	O
exceed	O
50	O
°	O
)	O
.	O

The	O
result	O
of	O
the	O
multiple	O
alignment	O
is	O
presented	O
in	O
terms	O
of	O
aligned	O
residues	O
between	O
all	O
proteins	O
and	O
an	O
alignment	O
score	O
of	O
r.m.s.	O
/	O
(	O
N	O
match	O
/N	O
average	O
)	O
a	O
(	O
structure	O
diversity	O
factor	O
)	O
,	O
where	O
a	O
is	O
chosen	O
empirically	O
as	O
1.5	O
.	O

The	O
structure	O
diversity	O
score	O
can	O
be	O
used	O
to	O
illustrate	O
the	O
structural	O
and	O
possibly	O
evolutionary	O
relationships	O
between	O
the	O
aligned	O
enzymes	O
.	O

Protein	O
data	O
bank	O
accession	O
Number	O

The	O
atomic	O
coordinates	O
and	O
observed	O
structure	O
factor	O
amplitudes	O
have	O
been	O
deposited	O
with	O
the	O
Protein	O
Data	O
Bank	O
,	O
Brookhaven	O
,	O
with	O
accession	O
codes	O
1qj5	O
,	O
1qj5sf	O
for	O
the	O
enzyme	O
-	O
PLP	O
and	O
1qj3	O
,	O
r1qj3sf	O
for	O
the	O
enzyme	O
-	O
PLP	O
-	O
KAPA	O
complex	O
,	O
respectively	O
.	O

Acknowledgements	O

We	O
thank	O
Ivan	O
M.	O
Turner	O
Sr	O
for	O
excellent	O
technical	O
assistance	O
and	O
Tom	O
Milller	O
for	O
carrying	O
out	O
the	O
N	O
-	O
terminal	O
sequencing	O
.	O

We	O
acknowledge	O
access	O
to	O
synchrotron	O
radiation	O
at	O
the	O
ESRF	O
,	O
Grenoble	O
,	O
France	O
,	O
and	O
thank	O
Dr	O
Andy	O
Thompson	O
at	O
beamline	O
BM14	O
for	O
assistance	O
and	O
advice	O
with	O
data	O
collection	O
.	O

We	O
also	O
acknowledge	O
access	O
to	O
beamline	O
X11	O
,	O
EMBL	O
outstation	O
,	O
c	O
/	O
o	O
DESY	O
,	O
Hamburg	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
Swedish	O
Agricultural	O
Research	O
Council	O
and	O
the	O
Swedish	O
Natural	O
Science	O
Research	O
Council	O
.	O

Stilbenes	O
occur	O
naturally	O
in	O
a	O
number	O
of	O
plant	B
families	O
[	O
1	O
]	O
but	O
grapes	B
and	O
related	O
products	O
are	O
considered	O
the	O
most	O
important	O
dietary	O
sources	O
of	O
these	O
substances	O
[	O
2,3	O
]	O
.	O

Trans	O
-resveratrol	O
and	O
the	O
3-O	O
-	O
β	O
-	O
glucoside	O
of	O
trans	O
-resveratrol	O
,	O
trans	O
-piceid	O
,	O
were	O
recently	O
identified	O
in	O
wine	O
[	O
4–6	O
]	O
.	O

Another	O
compound	O
3′-OH	O
-	O
trans	O
-piceid	O
(	O
trans	O
-astringin	O
)	O
has	O
recently	O
been	O
reported	O
to	O
be	O
a	O
constituent	O
of	O
Vitis	B
vinifera	I
cells	O
[	O
7	O
]	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
beneficial	O
role	O
that	O
moderate	O
wine	O
consumption	O
may	O
have	O
in	O
preventing	O
cardiovascular	O
disease	O
is	O
still	O
under	O
debate	O
[	O
8	O
]	O
,	O
and	O
great	O
interest	O
has	O
been	O
focused	O
on	O
stilbenes	O
.	O

Trans-	O
astringin	O
has	O
been	O
reported	O
to	O
have	O
antioxidant	O
properties	O
,	O
inhibiting	O
in	O
particular	O
the	O
oxidation	O
of	O
human	B
LDL	O
in	O
vitro	O
[	O
9	O
]	O
,	O
but	O
its	O
occurrence	O
in	O
wine	O
has	O
never	O
been	O
reported	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
a	O
simple	O
and	O
sensitive	O
method	O
to	O
determine	O
this	O
occurrence	O
.	O

A	O
HPLC	O
method	O
coupled	O
with	O
fluorimetric	O
detection	O
was	O
developed	O
for	O
this	O
.	O

2	O
Experimental	O
Methanol	O
and	O
acetic	O
acid	O
were	O
purchased	O
from	O
Carlo	O
Erba	O
(	O
Val	O
de	O
Reuil	O
,	O
France	O
)	O
and	O
Merck	O
(	O
Nogent	O
sur	O
Marne	O
,	O
France	O
)	O
.	O

Trans	O
-astringin	O
was	O
obtained	O
from	O
cell	O
suspension	O
cultures	O
[	O
10	O
]	O
and	O
identified	O
unambiguously	O
by	O
MS	O
and	O
NMR	O
as	O
previously	O
described	O
[	O
7	O
]	O
.	O

The	O
fluorescence	O
properties	O
of	O
trans	O
-astringin	O
were	O
determined	O
with	O
the	O
1064	O
Hewlett	O
-	O
Packard	O
spectrofluorimeter	O
.	O

Calibration	O
was	O
performed	O
with	O
solutions	O
of	O
different	O
concentrations	O
of	O
trans	O
-astringin	O
obtained	O
by	O
suitable	O
dilution	O
of	O
methanolic	O
solution	O
at	O
10	O
mg	O
/	O
l	O
.	O

Standard	O
solutions	O
were	O
stored	O
at	O
−20	O
°	O
C	O
and	O
protected	O
from	O
light	O
.	O

The	O
linear	O
regression	O
was	O
Y	O
=	O
499.9x	O
−0.8	O
(	O
r	O
=	O
0.999	O
;	O
CV<4.71	O
)	O
.	O

2.1	O
HPLC	O
analysis	O
A	O
Hewlett	O
-	O
Packard	O
Model	O
1100	O
with	O
two	O
low	O
pressure	O
pumps	O
and	O
a	O
1064	O
Hewlett	O
-	O
Packard	O
fluorimetric	O
detector	O
coupled	O
to	O
an	O
HP	O
Chem	O
Station	O
were	O
used	O
for	O
solvent	O
delivery	O
system	O
and	O
detection	O
.	O

A	O
Hewlett	O
-	O
Packard	O
column	O
,	O
packed	O
with	O
Nucleosil	O
100	O
C18	O
,	O
250	O
×	O
4	O
mm	O
,	O
5	O
μm	O
particle	O
size	O
was	O
used	O
for	O
the	O
stationary	O
phase	O
.	O

The	O
eluents	O
were	O
for	O
solvent	O
A	O
,	O
an	O
aqueous	O
solution	O
of	O
20	O
mM	O
acetic	O
acid	O
,	O
and	O
for	O
solvent	O
B	O
,	O
methanol	O
(	O
HPLC	O
grade	O
)	O
;	O
both	O
were	O
filtered	O
through	O
0.45	O
μm	O
Millipore	O
filters	O
.	O

Elution	O
was	O
performed	O
with	O
the	O
following	O
gradient	O
:	O
0–5	O
min	O
98	O
%	O
solvent	O
A	O
;	O
5–12	O
min	O
from	O
98	O
to	O
93	O
%	O
solvent	O
A	O
;	O
12–18	O
min	O
from	O
93	O
to	O
89	O
%	O
A	O
;	O
18–28	O
min	O
from	O
89	O
to	O
85	O
%	O
A	O
;	O
28–38	O
min	O
from	O
85	O
to	O
70	O
%	O
;	O
38–48	O
min	O
from	O
70	O
to	O
60	O
%	O
;	O
48–55	O
min	O
from	O
60	O
to	O
50	O
%	O
A	O
,	O
55–75	O
min	O
50	O
%	O
A.	O

The	O
flow	O
rate	O
was	O
0.5	O
ml	O
/	O
min	O
.	O

Ten	O
French	O
wines	O
(	O
5	O
red	O
,	O
5	O
white	O
)	O
from	O
the	O
South	O
of	O
France	O
were	O
analyzed	O
.	O

Wine	O
samples	O
were	O
directly	O
injected	O
into	O
the	O
HPLC	O
system	O
after	O
dilution	O
in	O
bi	O
-	O
distilled	O
water	O
and	O
filtration	O
(	O
Millex	O
-	O
FH13	O
;	O
Millipore	O
;	O
St.	O
Quentin	O
,	O
Yvelines	O
,	O
France	O
)	O
.	O

Dilution	O
of	O
1	O
/	O
3	O
was	O
used	O
,	O
and	O
20	O
μl	O
were	O
injected	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
maximum	O
excitation	O
and	O
emission	O
wavelength	O
in	O
a	O
methanolic	O
solution	O
as	O
well	O
as	O
in	O
a	O
mixture	O
of	O
20	O
mM	O
methanol	O
–	O
acetic	O
acid	O
(	O
v	O
/	O
v	O
,	O
50:50	O
)	O
(	O
the	O
composition	O
of	O
the	O
trans	O
-astringin	O
gradient	O
was	O
measured	O
when	O
in	O
the	O
spectrofluorimeter	O
cell	O
)	O
were	O
298	O
and	O
400	O
nm	O
respectively	O
.	O

The	O
threshold	O
of	O
detection	O
was	O
defined	O
as	O
the	O
amount	O
of	O
the	O
compound	O
resulting	O
in	O
a	O
peak	O
10-fold	O
higher	O
than	O
the	O
standard	O
deviation	O
of	O
the	O
baseline	O
noise	O
.	O

This	O
was	O
found	O
to	O
be	O
0.03	O
mg	O
/	O
l	O
.	O

Chromatograms	O
of	O
trans	O
-astringin	O
and	O
of	O
a	O
red	O
wine	O
sample	O
monitored	O
by	O
fluorescence	O
detection	O
are	O
reported	O
in	O
Fig.	O
2A	O
and	O
B	O
.	O

The	O
retention	O
time	O
was	O
53.7	O
min	O
.	O

The	O
HPLC	O
separation	O
and	O
the	O
good	O
resolution	O
of	O
the	O
peak	O
without	O
interference	O
allowed	O
the	O
identification	O
of	O
the	O
trans	O
-astringin	O
.	O

A	O
co	O
-	O
chromatographic	O
analysis	O
was	O
also	O
performed	O
;	O
it	O
confirmed	O
the	O
identification	O
of	O
trans	O
-astringin	O
by	O
HPLC	O
with	O
fluorimetric	O
detection	O
.	O

The	O
chromatogram	O
of	O
the	O
wine	O
in	O
which	O
trans	O
-astringin	O
was	O
added	O
is	O
reported	O
in	O
Fig.	O
2C	O
.	O

This	O
progressive	O
gradient	O
run	O
developed	O
here	O
has	O
allowed	O
the	O
analysis	O
of	O
other	O
stilbenes	O
:	O
trans	O
-resveratrol	O
,	O
trans	O
-piceid	O
[	O
11	O
]	O
,	O
and	O
other	O
phenolic	O
compounds	O
such	O
as	O
(	O
+	O
)	O
-catechin	O
,	O
tyrosol	O
,	O
gentisic	O
acid	O
[	O
12	O
]	O
.	O

The	O
standard	O
methanolic	O
solution	O
of	O
trans	O
-astringin	O
was	O
stable	O
for	O
at	O
least	O
30	O
days	O
at	O
−20	O
°	O
C	O
in	O
the	O
dark	O
.	O

When	O
this	O
solution	O
was	O
exposed	O
to	O
wide	O
-	O
spectrum	O
fluorescent	O
lighting	O
at	O
a	O
light	O
intensity	O
of	O
40	O
μmol	O
m−2	O
s−1	O
at	O
25	O
°	O
C	O
,	O
no	O
degradation	O
of	O
trans	O
-astringin	O
was	O
observed	O
during	O
the	O
first	O
two	O
h	O
,	O
corresponding	O
to	O
the	O
time	O
of	O
analysis	O
.	O

Therefore	O
,	O
trans	O
-astringin	O
can	O
be	O
handled	O
in	O
the	O
laboratory	O
without	O
very	O
stringent	O
precautions	O
.	O

We	O
found	O
low	O
levels	O
of	O
trans	O
-astringin	O
in	O
the	O
wine	O
analyzed	O
,	O
and	O
the	O
results	O
were	O
confirmed	O
by	O
mass	O
spectrometry	O
.	O

Trans	O
-astringin	O
was	O
extracted	O
from	O
red	O
wine	O
and	O
FAB	O
-	O
MS	O
spectra	O
showed	O
a	O
[	O
MH	O
]	O
+	O
peak	O
at	O
m	O
/	O
z	O
407	O
(	O
C20	O
H22	O
O9	O
requires	O
406	O
)	O
.	O

In	O
this	O
research	O
,	O
trans	O
-astringin	O
is	O
reported	O
for	O
the	O
first	O
time	O
to	O
be	O
present	O
in	O
both	O
red	O
and	O
white	O
wines	O
.	O

Concentrations	O
ranged	O
from	O
0.09	O
mg	O
/	O
l	O
to	O
0.29	O
mg	O
/	O
l	O
for	O
red	O
wines	O
and	O
from	O
0.10	O
mg	O
/	O
l	O
to	O
0.22	O
mg	O
/	O
l	O
for	O
white	O
wines	O
.	O

To	O
study	O
the	O
reproducibility	O
,	O
the	O
same	O
red	O
and	O
white	O
wine	O
samples	O
were	O
analyzed	O
on	O
five	O
different	O
days	O
.	O

The	O
CV	O
obtained	O
were	O
less	O
than	O
4.72	O
%	O
for	O
red	O
wines	O
and	O
less	O
than	O
4.23	O
%	O
for	O
white	O
wines	O
.	O

Fluorimetric	O
detection	O
evidenced	O
low	O
levels	O
of	O
trans	O
-astringin	O
in	O
wine	O
.	O

As	O
already	O
described	O
by	O
Pezet	O
et	O
al.	O
[	O
13	O
]	O
for	O
trans-	O
resveratrol	O
and	O
pterostilbene	O
,	O
the	O
use	O
of	O
a	O
fluorimetric	O
detector	O
is	O
well	O
adapted	O
to	O
the	O
low	O
concentrations	O
of	O
stilbenes	O
in	O
wines	O
.	O

In	O
particular	O
,	O
no	O
prior	O
treatment	O
of	O
the	O
wine	O
sample	O
is	O
required	O
.	O

For	O
the	O
ten	O
French	O
wines	O
analyzed	O
here	O
,	O
no	O
large	O
differences	O
were	O
observed	O
between	O
red	O
and	O
white	O
wines	O
,	O
but	O
analysis	O
of	O
more	O
samples	O
of	O
commercial	O
wine	O
is	O
needed	O
to	O
estimate	O
the	O
dietary	O
impact	O
and	O
bioavailability	O
of	O
the	O
trans	O
-astringin	O
in	O
the	O
wines	O
of	O
world	O
.	O

4	O
Conclusion	O
The	O
present	O
method	O
for	O
the	O
analysis	O
of	O
trans	O
-astringin	O
in	O
wine	O
combines	O
the	O
simplicity	O
of	O
direct	O
HPLC	O
injection	O
with	O
the	O
sensitivity	O
of	O
fluorescence	O
detection	O
.	O

Acknowledgements	O
The	O
authors	O
thank	O
Ray	O
Cooke	O
for	O
revising	O
the	O
English	O
manuscript	O
and	O
F.	O
Gasc	O
for	O
glassware	O
expertise	O
.	O

DNA	O
topoisomerases	O
are	O
the	O
enzymes	O
which	O
regulate	O
the	O
state	O
of	O
DNA	O
topology	O
.	O

The	O
enzymes	O
are	O
,	O
therefore	O
,	O
important	O
for	O
DNA	O
metabolism	O
,	O
such	O
as	O
replication	O
,	O
recombination	O
and	O
transcription	O
)	O

Nidulalin	O
A	O
(	O
1	O
)	O
2	O
and	O
its	O
derivatives	O
,	O
F390B	O
(	O
2	O
)	O
and	O
C	O
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
Penicillium	B
sp.	I
as	O
potent	O
cytotoxic	O
agents	O
(	O
Figure	O
1	O
)	O
.3	O
Nidulalin	O
A	O
,	O
a	O
major	O
metabolite	O
of	O
the	O
producing	O
strain	O
,	O
showed	O
potent	O
inhibitory	O
activity	O
against	O
DNA	O
topoisomerase	O
II	O
(	O
Topo	O
II	O
)	O
in	O
vitro.4	O
The	O
antitumor	O
activity	O
of	O
nidulalin	O
A	O
against	O
Colon	O
26	O
routine	O
adenocarcinoma	O
was	O
evaluated	O
in	O
vivo	O
,	O
however	O
,	O
no	O
antitumor	O
effect	O
was	O
observed	O
.	O

Further	O
investigation	O
revealed	O
that	O
rapid	O
hydrolysis	O
and	O
decarboxylation	O
of	O
the	O
methyl	O
ester	O
moiety	O
of	O
1	O
by	O
esterases	O
in	O
murine	B
plasma	O
gave	O
an	O
inactive	O
xanthone	O
derivative	O
4	O
,	O
which	O
was	O
identical	O
to	O
the	O
compound	O
derived	O
from	O
1	O
by	O
alkaline	O
hydrolysis	O
.	O

This	O
result	O
prompted	O
us	O
to	O
synthesize	O
stable	O
analogs	O
against	O
hydrolysis	O
.	O

In	O
this	O
communication	O
,	O
we	O
report	O
synthesis	O
and	O
antitumor	O
activity	O
of	O
derivatives	O
of	O
nidulalin	O
A	O
with	O
amide	O
moieties	O
in	O
place	O
of	O
the	O
methoxycarbonyl	O
group	O
.	O

Figure	O
1	O
MeO2C	O
ORe	O
Nidulalin	O
A	O
(	O
1	O
)	O
RI	O
=	O
R2	O
=	O
H	O
F390B	O
(	O
2	O
)	O
R~=H	O
,	O
R2	O
=	O
Ac	O
F390C	O
(	O
3	O
)	O
RI	O
=	O
OH	O
,	O
R2	O
=	O
H	O
4	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

PII	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00440	O
-	O
0	O
2654	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O
Synthesis	O
The	O
syntheses	O
of	O
amide	O
analogs	O
of	O
nidulalin	O
A	O
are	O
outlined	O
in	O
Scheme	O
1	O
.	O

Direct	O
amidation	O
by	O
methylamine	O
in	O
MeOH	O
afforded	O
approximately	O
4:3	O
mixture	O
of	O
lactams	O
10a	O
and	O
10b	O
via	O
Michael	O
addition	O
followed	O
by	O
intramolecular	O
aminolysis	O
(	O
Scheme	O
2	O
)	O
.	O

To	O
avoid	O
lactam	O
formation	O
,	O
nidulalin	O
A	O
was	O
reduced	O
by	O
NaBH4	O
in	O
MeOH	O
to	O
give	O
a	O
tetrahydroxanthone	O
derivative	O
5	O
in	O
87	O
%	O
yield,5	O
which	O
was	O
treated	O
with	O
1N	O
NaOH	O
followed	O
by	O
acetylation	O
with	O
acetic	O
anhydride	O
in	O
pyridine	O
to	O
give	O
carboxylic	O
acid	O
6	O
.	O

Condensation	O
of	O
6	O
with	O
various	O
amines	O
,	O
including	O
ammonia	O
,	O
methylamine	O
,	O
dimethylamine	O
,	O
2-aminoethanol	O
,	O
and	O
pyrrolidine	O
,	O
via	O
acid	O
chloride	O
followed	O
by	O
acetylation	O
of	O
a	O
hydroxyl	O
group	O
,	O
which	O
was	O
generated	O
during	O
amine	O
treatment	O
,	O
gave	O
corresponding	O
amides	O
7a	O
-	O
e	O
,	O
respectively	O
.	O

Oxidation	O
of	O
7a	O
with	O
SeOz	O
in	O
dioxane	O
at	O
65	O
gave	O
a	O
dihydroxanthone	O
derivative	O
8a	O
in	O
18	O
%	O
yield	O
.	O

In	O
the	O
same	O
manner	O
,	O
7h	O
-	O
e	O
were	O
converted	O
to	O
8h	O
-	O
e	O
,	O
respectively	O
.	O

The	O
acetyl	O
groups	O
of	O
8a	O
-	O
e	O
were	O
removed	O
by	O
alkaline	O
hydrolysis	O
to	O
give	O
amide	O
analogs	O
9a	O
-	O
e	O
,	O
respectively.6	O
Scheme	O
1	O
H	O
~	O
a	O
""""	O
"Me,""~"	O
b'c	O
""""	O
M~-O~.	O
Y	O
M	O
87	O
%	O
~	O
,	O
^,,-	O
,	O
7-	O
i	O
..	O
91	O
%	O
..	O

_	O
.=.	O
,	O
~w	O
~	O
v2'~	O
'	O
OH	O
I'-IU2U	O
OAc	O
Nidulalin	O
A	O
(	O
1	O
)	O

5	O
6	O
65	O
-	O
97	O
Yo	O
ROC	O
(	O
~Ac	O
17	O
-	O
35o	O
Me	O
""""	O
""""	O
~	O
-ROo~	O
OTAc	O
quan	O
.	O

7a	O
R	O
=	O
NH2	O
8a	O
R	O
=	O
NH2	O
9a	O
R	O
=	O
NH2	O
7b	O
R	O
=	O
NHMe	O
8b	O
R	O
=	O
NHMe	O
9b	O
R	O
=	O
NHMe	O
7R	O
=	O
NMe2	O
8c	O
R	O
=	O
NMe2	O
9c	O
R	O
=	O
NMe2	O
7d	O
R	O
=	O
NHCH2CH2OAc	O
8d	O
R	O
=	O
NHCH2CH2OAc	O
9d	O
R	O
=	O
NHCH2CH2OH	O
a	O
)	O
NaBH4	O
,	O
MeOH	O
,	O
5	O
b	O
)	O
1N	O
NaOH	O
,	O
5	O
c	O
)	O
Ac20	O
,	O
pyridine	O
,	O
rt	O
d	O
)	O
SOCI2	O
,	O
cat	O
.	O

DMF	O
,	O
CH2CI2	O
,	O
rt	O
e	O
)	O
aq	O
.	O

amines	O
,	O
5	O
f	O
)	O
Ac20	O
,	O
pyridine	O
,	O
rt	O
g	O
)	O
SeO2	O
,	O
dioxane	O
,	O
65	O
h	O
)	O

1N	O
NaOH	O
,	O
MeOH	O
,	O
5	O
Scheme	O
2	O
a	O
1	O
a	O
)	O
MeNH2	O
,	O
MeOH	O
,	O
rt	O
+	O
M	O
M	O
Me	O
O	O
/	O
j	O
OH	O
10a	O
10b	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O
2655	O
Result	O
and	O
Discussion	O
To	O
test	O
the	O
stability	O
,	O
the	O
amide	O
derivatives	O
were	O
treated	O
with	O
murine	B
plasma	O
.	O

The	O
inactive	O
compound	O
4	O
was	O
not	O
detected	O
by	O
HPLC	O
analyses	O
,	O
and	O
it	O
was	O
revealed	O
that	O
the	O
amide	O
analogs	O
were	O
stable	O
against	O
esterases	O
]	O
The	O
biological	O
activities	O
of	O
the	O
semisynthetic	O
compounds	O
of	O
nidulalin	O
A	O
are	O
shown	O
in	O
Table	O
1	O
.	O

The	O
amide	O
derivatives	O
9a	O
-	O
e	O
retained	O
cytotoxic	O
activity	O
against	O
both	O
human	B
and	O
murine	B
cancer	O
cell	O
lines	O
in	O
vitro	O
.	O

9a	O
inhibited	O
Topo	O
II	O
in	O
dose	O
dependent	O
manner	O
with	O
IC~0	O
value	O
of	O
29gM.	O
Furthermore	O
,	O
9a	O
possessed	O
weak	O
inhibitory	O
activity	O
against	O
topoisomerase	O
I	O
(	O
Topo	O
I	O
)	O
with	O
ICs0	O
value	O
of	O
631.tM.	O
In	O
spite	O
of	O
decreased	O
activity	O
against	O
Topo	O
II	O
,	O
cytotoxicity	O
of	O
9a	O
was	O
comparable	O
to	O
that	O
of	O
1	O
.	O

Lactam	O
10a	O
inhibited	O
neither	O
Topo	O
I	O
nor	O
Topo	O
II	O
since	O
a	O
conjugated	O
dienone	O
moiety	O
was	O
required	O
for	O
inhibitory	O
activity	O
against	O
Topo	O
II.4	O
The	O
reason	O
for	O
the	O
discrepancy	O
between	O
cytotoxicity	O
and	O
inhibitory	O
activity	O
against	O
Topo	O
I	O
and	O
Topo	O
II	O
of	O
these	O
compounds	O
is	O
not	O
clear	O
.	O

There	O
might	O
be	O
other	O
mechanisms	O
for	O
cytotoxicity	O
of	O
these	O
analogs	O
or	O
instability	O
of	O
1	O
in	O
cell	O
culture	O
might	O
decrease	O
its	O
cytotoxicity	O
.	O

Table	O
1	O
.	O

Biological	O
Activities	O
of	O
Nidulalin	O
A	O
Derivatives	O
in	O
vitro	O
Cytotoxicitya	O
Inhibitory	O
Activity	O
ICso	O
(	O
gM	O
)	O
IC,0	O
(	O
gM	O
)	O
Compound	O
HCT-116	O
K562	O
P388	O
Topo	O
Ib	O
Topo	O
IIc	O
9a	O
0.33	O
0.59	O
0.052	O
63	O
29	O
9b	O
1.13	O
2.26	O
0.24	O
>	O
300	O
132	O
9	O
e	O
0.79	O
0.98	O
0.15	O
ndd	O
nd	O
9d	O
7.88	O
10.61	O
2.67	O
102	O
23	O
9e	O
1.64	O
1.52	O
0.56	O
nd	O
nd	O
10a	O
19.6	O
6.31	O
nd	O
>	O
300	O
>	O
300	O
l	O
(	O
Nidulalin	O
A	O
)	O
0.14	O
0.32	O
0.024	O
172	O
2.2	O
a	O
)	O
Cells	O
were	O
treated	O
with	O
each	O
compound	O
for	O
72	O
hours	O
.	O

Cell	O
viability	O
was	O
evaluated	O
by	O
MTT	O
assay	O
,	O
b	O
)	O
Relaxation	O
assay	O
of	O
Topo	O
I	O
was	O
performed	O
as	O
shown	O
in	O
ref	O
.	O

8	O
.	O
c	O
)	O
Decatenation	O
assay	O
of	O
Topo	O
II	O
was	O
performed	O
as	O
shown	O
in	O
ref	O
.	O

9	O
.	O
d	O
)	O
not	O
determined	O
Table	O
2	O
.	O

Antitumor	O
Activity	O
of	O
9a	O
in	O
vivo	O
Compound	O
Route	O
IR	O
(	O
%	O
)	O
a	O
(	O
dose	O
)	O
9a	O
iv	O
42b	O
(	O
10mg	O
/	O
Kg	O
)	O
1	O
iv	O
24	O
(	O
20mg	O
/	O
Kg	O
)	O
a	O
)	O
Tumor	O
growth	O
suppression	O
was	O
determined	O
as	O
shown	O
in	O
note	O
10	O
.	O

b	O
)	O
P<0.01	O
by	O
T	O
-	O
test	O
Antitumor	O
activity	O
of	O
9a	O
was	O
evaluated	O
against	O
Colon	O
26	O
murine	B
tumor	O
model	O
in	O
vivo	O
(	O
Table	O
2	O
)	O
.	O

9a	O
,	O
at	O
a	O
dose	O
of	O
10mg	O
/	O
Kg	O
,	O
showed	O
moderate	O
antitumor	O
activity	O
in	O
this	O
model	O
,	O
while	O
1	O
showed	O
only	O
marginal	O
effect	O
even	O
at	O
a	O
higher	O
dose	O
(	O
20mg	O
/	O
Kg	O
)	O
.	O

From	O
above	O
results	O
,	O
it	O
is	O
demonstrated	O
that	O
the	O
methoxycarbonyl	O
group	O
modified	O
nidulalin	O
A	O
analogs	O
are	O
stable	O
against	O
esterases	O
and	O
effective	O
in	O
murine	B
tumor	O
model	O
in	O
vivo	O
.	O

Further	O
evaluation	O
of	O
antitumor	O
activity	O
and	O
synthesis	O
of	O
other	O
stable	O
analogs	O
are	O
underway	O
.	O

Acknowledgement	O

:	O
We	O
thank	O
Dr.	O
Yukio	O
Iino	O
,	O
Toshimi	O
Mizukoshi	O
,	O
Uno	O
Tagami	O
,	O
and	O
Reiko	O
Yuji	O
for	O
measurement	O
of	O
NMR	O
and	O
mass	O
spectra	O
.	O

We	O
are	O
also	O
grateful	O
to	O
Yumiko	O
Fukuda	O
for	O
skillful	O
technical	O
assistance	O
.	O

2656	O
S.	O
Sato	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
2653	O
-	O
2656	O

Phytosterol	O
supplements	O
decrease	O
serum	O
cholesterol	O
and	O
may	O
reduce	O
the	O
risk	O
of	O
cardiovascular	O
disease	O
[	O
1	O
]	O
.	O

In	O
a	O
feeding	O
trial	O
involving	O
a	O
stanol	O
-	O
supplemented	O
margarine	O
spread	O
[	O
2	O
]	O
,	O
a	O
method	O
was	O
needed	O
for	O
sensitive	O
and	O
precise	O
determination	O
of	O
sitosterol	O
,	O
campesterol	O
,	O
stigmasterol	O
,	O
sitostanol	O
,	O
campestanol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
in	O
human	B
serum	O
.	O

Quantitation	O
of	O
serum	O
sterols	O
and	O
stanols	O
(	O
5,6-dihydrosterols	O
)	O
is	O
complicated	O
by	O
the	O
presence	O
of	O
numerous	O
other	O
lipids	O
and	O
low	O
concentrations	O
(	O
0.2–13	O
μg	O
/	O
ml	O
)	O
of	O
the	O
analytes	O
relative	O
to	O
cholesterol	O
(	O
∼1500–3000	O
μg	O
/	O
ml	O
)	O
.	O

A	O
method	O
[	O
3,4	O
]	O
previously	O
reported	O
for	O
measurement	O
of	O
phytosterols	O
,	O
stanols	O
,	O
and	O
cholesterol	O
metabolites	O
[	O
5	O
]	O
lacked	O
sufficient	O
detail	O
about	O
preparation	O
of	O
serum	O
samples	O
,	O
chromatographic	O
conditions	O
,	O
and	O
analytical	O
sensitivity	O
,	O
and	O
was	O
not	O
readily	O
reproduced	O
.	O

Other	O
reports	O
[	O
6,7	O
]	O
do	O
not	O
include	O
validation	O
of	O
the	O
separation	O
and	O
quantification	O
of	O
phytosterols	O
and	O
stanols	O
as	O
well	O
as	O
cholesterol	O
metabolites	O
(	O
e.g.	O
desmosterol	O
,	O
lathosterol	O
)	O
.	O

Sample	O
clean	O
-	O
up	O
was	O
not	O
reported	O
in	O
some	O
of	O
the	O
published	O
methods	O
,	O
and	O
others	O
used	O
thin	O
-	O
layer	O
chromatography	O
.	O

Carryover	O
and	O
column	O
/	O
injector	O
contamination	O
are	O
problems	O
in	O
the	O
absence	O
of	O
serum	O
sample	O
clean	O
-	O
up	O
prior	O
to	O
chromatography	O
.	O

Very	O
polar	O
compounds	O
(	O
e.g.	O
phospholipids	O
)	O
are	O
an	O
important	O
consideration	O
in	O
sterol	O
analysis	O
when	O
semi	O
-	O
polar	O
or	O
polar	O
stationary	O
phases	O
are	O
employed	O
,	O
especially	O
when	O
analyzing	O
a	O
large	O
number	O
of	O
samples	O
.	O

A	O
60-m	O
capillary	O
column	O
with	O
a	O
moderately	O
polar	O
stationary	O
phase	O
(	O
14	O
%	O
cyanopropylphenyl–86	O
%	O
dimethylpolysiloxane	O
)	O
was	O
used	O
,	O
and	O
a	O
one	O
-	O
step	O
solid	O
-	O
phase	O
extraction	O
was	O
added	O
to	O
remove	O
highly	O
polar	O
compounds	O
from	O
the	O
saponified	O
total	O
lipid	O
extract	O
.	O

Epicholesterol	O
was	O
used	O
as	O
an	O
internal	O
standard	O
.	O

Since	O
the	O
primary	O
concern	O
was	O
to	O
detect	O
changes	O
in	O
low	O
levels	O
of	O
serum	O
sterols	O
and	O
stanols	O
as	O
a	O
result	O
of	O
dietary	O
supplementation	O
,	O
we	O
required	O
a	O
very	O
precise	O
assay	O
.	O

Consequently	O
,	O
numerous	O
quality	O
control	O
measures	O
were	O
implemented	O
.	O

In	O
this	O
paper	O
we	O
give	O
a	O
detailed	O
description	O
of	O
the	O
methodology	O
and	O
quality	O
control	O
employed	O
for	O
the	O
precise	O
quantitative	O
analysis	O
of	O
sitosterol	O
,	O
campesterol	O
,	O
stigmasterol	O
,	O
sitostanol	O
,	O
campestanol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
in	O
human	O
serum	O
.	O

2	O
Experimental	O
2.1	O
Materials	O
2.1.1	O
Chemicals	O
Epicholesterol	O
was	O
obtained	O
from	O
Steraloids	O
(	O
Wilton	O
,	O
NH	O
,	O
USA	O
)	O
.	O

Beta	O
-	O
sitosterol	O
,	O
campesterol	O
,	O
stigmasterol	O
,	O
sitostanol	O
,	O
fucosterol	O
,	O
lathosterol	O
,	O
lanosterol	O
,	O
and	O
desmosterol	O
,	O
cholestanol	O
,	O
squalene	O
,	O
pyrogallol	O
,	O
cyclohexane	O
,	O
and	O
pyridine	O
were	O
purchased	O
from	O
Sigma	O
Chemical	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

Campestanol	O
was	O
from	O
Research	O
Plus	O
(	O
Bayonne	O
,	O
NJ	O
,	O
USA	O
)	O
,	O
and	O
bis	O
(	O
trimethylsilyl	O
)	O
trifluoroacetamide	O
with	O
1	O
%	O
trimethylchlorosilane	O
(	O
BSTFA	O
w	O
/	O
1	O
%	O
TMCS	O
)	O
was	O
obtained	O
from	O
Alltech	O
Associates	O
(	O
Deerfield	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Hexane	O
,	O
chloroform	O
,	O
methanol	O
,	O
isopropanol	O
,	O
sodium	O
chloride	O
(	O
ACS	O
grade	O
)	O
,	O
and	O
potassium	O
hydroxide	O
(	O
NF	O
/	O
FCC	O
grade	O
)	O
were	O
from	O
Fisher	O
Scientific	O
(	O
Fairlawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

Absolute	O
ethanol	O
was	O
obtained	O
from	O
AAPER	O
Alcohol	O
and	O
Chemical	O
(	O
Shelbyville	O
,	O
KY	O
,	O
USA	O
)	O
.	O

All	O
solvents	O
were	O
HPLC	O
grade	O
and	O
used	O
without	O
further	O
purification	O
.	O

2.1.2	O
Serum	O
samples	O
Serum	O
samples	O
(	O
1–2	O
ml	O
)	O
frozen	O
in	O
2-ml	O
cryovials	O
were	O
obtained	O
from	O
a	O
human	B
feeding	O
trial	O
conducted	O
at	O
Pennsylvania	O
State	O
University	O
(	O
University	O
Park	O
,	O
PA	O
,	O
USA	O
)	O
and	O
Pennington	O
Biomedical	O
Research	O
Center	O
(	O
Baton	O
Rouge	O
,	O
LA	O
,	O
USA	O
)	O
.	O

Subjects	O
consumed	O
a	O
stanol	O
-	O
supplemented	O
margarine	O
that	O
provided	O
3	O
g	O
per	O
day	O
stanols	O
and	O
16	O
g	O
per	O
day	O
fat	O
in	O
a	O
controlled	O
feeding	O
trial	O
;	O
details	O
of	O
the	O
study	O
are	O
reported	O
elsewhere	O
[	O
2	O
]	O
.	O

Serum	O
samples	O
were	O
stored	O
at	O
−80	O
°	O
C	O
until	O
analyzed	O
.	O

2.2	O
Instrumentation	O
2.2.1	O
Gas	O
chromatography	O
Gas	O
chromatography	O
was	O
performed	O
with	O
a	O
Perkin	O
Elmer	O
GC	O
Autosystem	O
™	O
(	O
Perkin	O
Elmer	O
,	O
Norwalk	O
,	O
CT	O
,	O
USA	O
)	O
,	O
an	O
Rtx	O
®	O
-1701	O
(	O
14	O
%	O
cyanopropylphenyl–86	O
%	O
dimethylpolysiloxane	O
)	O
capillary	O
column	O
(	O
60-m	O
×	O
0.25-mm	O
I.D.	O
,	O
0.25-μm	O
film	O
thickness	O
;	O
Restek	O
,	O
Bellefonte	O
,	O
PA	O
,	O
USA	O
)	O
,	O
and	O
a	O
flame	O
ionization	O
detector	O
with	O
hydrogen	O
(	O
45	O
ml	O
/	O
min	O
)	O
and	O
air	O
(	O
450	O
ml	O
/	O
min	O
)	O
as	O
fuel	O
source	O
.	O

Hydrogen	O
at	O
1.18	O
ml	O
/	O
min	O
was	O
the	O
carrier	O
gas	O
.	O

Operating	O
conditions	O
were	O
:	O
injection	O
temperature	O
,	O
280	O
°	O
C	O
;	O
detector	O
temperature	O
,	O
280	O
°	O
C	O
;	O
oven	O
temperature	O
,	O
265	O
°	O
C	O
;	O
split	O
ratio	O
,	O
9:1	O
(	O
split	O
vent	O
flow	O
9.44	O
ml	O
/	O
min	O
)	O
;	O
injection	O
volume	O
,	O
1	O
μl	O
;	O
head	O
pressure	O
21	O
p.s.i	O
.	O

Detector	O
signal	O
output	O
was	O
monitored	O
by	O
computer	O
(	O
Dell	O
Dimension	O
XPS	O
D233	O
;	O
Dell	O
Computer	O
,	O
Round	O
Rock	O
,	O
TX	O
,	O
USA	O
)	O
and	O
all	O
chromatograms	O
and	O
data	O
were	O
generated	O
and	O
processed	O
using	O
Turbochrom	O
™	O
Workstation	O
version	O
6.0.2.1	O
software	O
(	O
Perkin	O
Elmer	O
)	O
.	O

2.3	O
Quality	O
control	O
measures	O
2.3.1	O
Preparation	O
of	O
glassware	O
All	O
glassware	O
(	O
and	O
other	O
labware	O
,	O
such	O
as	O
stir	O
bars	O
and	O
spatulas	O
)	O
was	O
scrupulously	O
cleaned	O
and	O
rinsed	O
with	O
distilled	O
deionized	O
water	O
and	O
acetone	O
,	O
then	O
immediately	O
before	O
use	O
,	O
rinsed	O
with	O
chloroform	O
,	O
then	O
ethanol	O
,	O
and	O
allowed	O
to	O
air	O
dry	O
.	O

All	O
glass	O
test	O
tubes	O
were	O
silanized	O
with	O
5	O
%	O
dimethyldicholorosilane	O
in	O
hexane	O
(	O
Sigma	O
)	O
.	O

2.3.2	O
Other	O
measures	O
to	O
prevent	O
contamination	O
Since	O
sterols	O
are	O
ubiquitous	O
in	O
the	O
lab	O
(	O
e.g.	O
in	O
skin	O
secretions	O
,	O
rubber	O
septa	O
,	O
vegetable	B
oils	O
and	O
fats	O
)	O
,	O
and	O
because	O
the	O
levels	O
of	O
these	O
compounds	O
in	O
serum	O
are	O
low	O
(	O
ng	O
to	O
μg	O
/	O
ml	O
)	O
,	O
it	O
is	O
essential	O
to	O
prevent	O
sample	O
contamination	O
to	O
preclude	O
falsely	O
elevated	O
values	O
of	O
the	O
analytes	O
.	O

Precautions	O
against	O
cross	O
-	O
contamination	O
are	O
especially	O
necessary	O
in	O
laboratories	O
where	O
vegetable	B
oils	O
or	O
other	O
materials	O
containing	O
significant	O
levels	O
of	O
phytosterols	O
are	O
analyzed	O
.	O

Tight	O
control	O
of	O
measuring	O
volumes	O
and	O
weights	O
is	O
essential	O
to	O
ensure	O
the	O
precision	O
and	O
accuracy	O
of	O
the	O
assay	O
in	O
the	O
ng	O
to	O
μg	O
range	O
.	O

2.3.3	O
Calibration	O
of	O
pipettes	O
and	O
balances	O
For	O
all	O
critical	O
volume	O
measurements	O
(	O
e.g.	O
standard	O
solutions	O
,	O
serum	O
aliquots	O
taken	O
for	O
analysis	O
)	O
,	O
automatic	O
pipettes	O
were	O
carefully	O
calibrated	O
for	O
accuracy	O
and	O
precision	O
immediately	O
before	O
use	O
,	O
using	O
the	O
solvent	O
of	O
the	O
solution	O
to	O
be	O
dispensed	O
(	O
e.g.	O
chloroform	O
or	O
ethanol	O
for	O
standards	O
,	O
water	O
for	O
serum	O
)	O
,	O
and	O
a	O
five	O
-	O
decimal	O
place	O
analytical	O
balance	O
,	O
calibrated	O
with	O
certified	O
standard	O
weights	O
.	O

The	O
pipetter	O
was	O
held	O
in	O
the	O
hand	O
5	O
min	O
to	O
warm	O
it	O
to	O
a	O
constant	O
temperature	O
before	O
calibration	O
.	O

To	O
determine	O
accuracy	O
,	O
the	O
weighed	O
volumes	O
were	O
compared	O
to	O
the	O
expected	O
mass	O
,	O
determined	O
from	O
the	O
density	O
of	O
the	O
liquid	O
at	O
the	O
measured	O
temperature	O
of	O
the	O
liquid	O
aliquoted	O
[	O
8	O
]	O
.	O

For	O
preparing	O
standard	O
mixtures	O
and	O
for	O
performing	O
standard	O
additions	O
to	O
serum	O
samples	O
,	O
volumetric	O
pipettes	O
were	O
used	O
.	O

2.3.4	O
Preparation	O
of	O
standard	O
solutions	O
2.3.4.1	O
Internal	O
standard	O
Test	O
tubes	O
containing	O
internal	O
standard	O
were	O
prepared	O
in	O
batches	O
.	O

Epicholesterol	O
(	O
3	O
mg	O
)	O
was	O
weighed	O
to	O
the	O
nearest	O
0.01	O
mg	O
into	O
a	O
1-l	O
volumetric	O
flask	O
,	O
brought	O
to	O
volume	O
with	O
absolute	O
ethanol	O
,	O
and	O
thoroughly	O
mixed	O
.	O

The	O
solution	O
was	O
dispensed	O
in	O
1.6-ml	O
aliquots	O
into	O
each	O
of	O
approximately	O
one	O
-	O
hundred	O
25	O
×	O
150	O
mm	O
glass	O
test	O
tubes	O
using	O
a	O
bottle	O
-	O
top	O
dispenser	O
that	O
had	O
been	O
calibrated	O
for	O
accuracy	O
and	O
precision	O
(	O
Section	O
2.3.3	O
)	O
,	O
yielding	O
5	O
μg	O
epicholesterol	O
per	O
tube	O
(	O
the	O
exact	O
amount	O
of	O
internal	O
standard	O
was	O
calculated	O
for	O
the	O
exact	O
weights	O
and	O
volumes	O
measured	O
)	O
.	O

The	O
tubes	O
were	O
capped	O
under	O
nitrogen	O
and	O
stored	O
at	O
<	O
10	O
°	O
C	O
for	O
up	O
to	O
2	O
months	O
.	O

Immediately	O
prior	O
to	O
use	O
,	O
the	O
solvent	O
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

2.3.4.2	O
Reference	O
and	O
calibration	O
standards	O
For	O
each	O
component	O
,	O
a	O
6	O
μg	O
/	O
ml	O
stock	O
standard	O
solution	O
was	O
made	O
.	O

Three	O
mg	O
of	O
component	O
was	O
weighed	O
to	O
the	O
nearest	O
0.01	O
mg	O
and	O
diluted	O
to	O
500	O
ml	O
in	O
a	O
volumetric	O
flask	O
,	O
using	O
absolute	O
ethanol	O
for	O
sterols	O
and	O
chloroform	O
for	O
stanols	O
.	O

Calibration	O
standard	O
solutions	O
containing	O
30	O
μg	O
/	O
ml	O
of	O
the	O
analyte	O
and	O
50	O
μg	O
/	O
ml	O
epicholesterol	O
were	O
prepared	O
in	O
batches	O
.	O

Solvent	O
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	O
,	O
then	O
the	O
mixture	O
was	O
derivatized	O
with	O
1	O
ml	O
pyridine	O
/	O
BSTFA	O
as	O
described	O
for	O
samples	O
(	O
Section	O
2.4.4	O
)	O
.	O

The	O
solution	O
was	O
distributed	O
among	O
ten	O
autosampler	O
vials	O
with	O
volume	O
reduction	O
inserts	O
(	O
∼100	O
μl	O
/	O
vial	O
)	O
and	O
stored	O
at	O
−60	O
°	O
C	O
.	O

These	O
standards	O
were	O
used	O
to	O
determine	O
calibration	O
factors	O
and	O
to	O
check	O
instrument	O
calibration	O
throughout	O
the	O
study	O
.	O

Two	O
reference	O
standard	O
mixtures	O
were	O
prepared	O
and	O
run	O
with	O
each	O
batch	O
of	O
samples	O
to	O
determine	O
run	O
-	O
specific	O
retention	O
times	O
for	O
the	O
analytes	O
.	O
'	O

Reference	O
A	O
'	O
contained	O
5	O
μg	O
/	O
ml	O
each	O
of	O
sitosterol	O
,	O
lathosterol	O
,	O
campestanol	O
,	O
stigmasterol	O
,	O
and	O
sitostanol	O
.	O
'	O

Reference	O
B	O
'	O
contained	O
5	O
μg	O
/	O
ml	O
each	O
of	O
desmosterol	O
,	O
campesterol	O
,	O
lanosterol	O
,	O
and	O
fucosterol	O
.	O

2.3.5	O
Preparation	O
of	O
quality	O
control	O
material	O
Accutrol	O
™	O
Human	B
Serum	O
(	O
normal	O
,	O
lyophilized	O
,	O
#	O
A2034	O
;	O
Sigma	O
)	O
was	O
used	O
as	O
a	O
control	O
material	O
.	O

No	O
standard	O
serum	O
with	O
certified	O
or	O
reference	O
values	O
for	O
phytosterols	O
could	O
be	O
found	O
,	O
and	O
homogeneous	O
fortification	O
of	O
the	O
serum	O
with	O
sitostanol	O
was	O
not	O
feasible	O
.	O

Because	O
of	O
the	O
potential	O
heterogeneity	O
of	O
reconstituted	O
aliquots	O
of	O
lyophilized	O
serum	O
(	O
due	O
to	O
variable	O
loss	O
of	O
dried	O
material	O
during	O
reconstitution	O
)	O
,	O
and	O
because	O
we	O
required	O
a	O
large	O
number	O
of	O
homogeneous	O
aliquots	O
to	O
adequately	O
monitor	O
assay	O
precision	O
,	O
we	O
prepared	O
a	O
composite	O
of	O
reconstituted	O
Accutrol	O
™	O
serum	O
and	O
dispensed	O
a	O
batch	O
of	O
380	O
1.25-ml	O
aliquots	O
.	O

One	O
-	O
hundred	O
vials	O
of	O
the	O
lyophilized	O
Accutrol	O
™	O
serum	O
(	O
from	O
the	O
same	O
lot	O
)	O
were	O
reconstituted	O
and	O
combined	O
.	O

In	O
batches	O
of	O
ten	O
at	O
a	O
time	O
,	O
vials	O
were	O
removed	O
from	O
the	O
refrigerator	O
and	O
each	O
was	O
reconstituted	O
with	O
5	O
ml	O
of	O
distilled	O
deionized	O
water	O
,	O
mixed	O
well	O
,	O
and	O
allowed	O
to	O
stand	O
for	O
10–20	O
min	O
at	O
room	O
temperature	O
(	O
20–23	O
°	O
C	O
)	O
,	O
then	O
placed	O
in	O
the	O
refrigerator	O
(	O
2–4	O
°	O
C	O
)	O
.	O

Within	O
3	O
days	O
,	O
a	O
composite	O
of	O
the	O
reconstituted	O
serum	O
was	O
made	O
in	O
a	O
walk	O
-	O
in	O
cold	O
room	O
(	O
7	O
°	O
C	O
)	O
.	O

As	O
much	O
as	O
possible	O
of	O
it	O
was	O
transferred	O
from	O
each	O
of	O
the	O
100	O
serum	O
vials	O
to	O
a	O
500-ml	O
glass	O
reagent	O
bottle	O
,	O
which	O
was	O
then	O
covered	O
and	O
stirred	O
at	O
medium	O
–	O
high	O
speed	O
for	O
1	O
h.	O
The	O
serum	O
was	O
then	O
dispensed	O
in	O
1.25-ml	O
aliquots	O
into	O
380	O
2-ml	O
microcentrifuge	O
tubes	O
in	O
batches	O
of	O
ten	O
at	O
a	O
time	O
,	O
using	O
a	O
new	O
pipette	O
tip	O
after	O
every	O
ten	O
samples	O
.	O

The	O
tubes	O
were	O
stored	O
at	O
−80	O
°	O
C	O
.	O

2.4	O
Sample	O
preparation	O
2.4.1	O
Total	O
lipid	O
extraction	O
Serum	O
samples	O
were	O
thawed	O
overnight	O
(	O
12–20	O
h	O
)	O
at	O
2–4	O
°	O
C	O
then	O
mixed	O
thoroughly	O
.	O

Using	O
a	O
calibrated	O
pipetter	O
,	O
0.90	O
ml	O
serum	O
was	O
dispensed	O
into	O
a	O
test	O
tube	O
containing	O
the	O
internal	O
standard	O
(	O
5	O
μg	O
epicholesterol	O
)	O
.	O

Total	O
lipid	O
was	O
extracted	O
by	O
a	O
modified	O
Folch	O
procedure	O
[	O
9	O
]	O
,	O
using	O
chloroform	O
–	O
methanol	O
(	O
2:1	O
,	O
v	O
/	O
v	O
)	O
followed	O
by	O
a	O
0.9	O
%	O
saline	O
wash	O
,	O
as	O
follows	O
.	O

After	O
mixing	O
the	O
sample	O
,	O
0.9	O
ml	O
of	O
methanol	O
was	O
added	O
,	O
then	O
tubes	O
were	O
capped	O
and	O
vortexed	O
at	O
high	O
speed	O
for	O
15	O
s.	O
Samples	O
were	O
then	O
shaken	O
for	O
10	O
min	O
on	O
an	O
orbital	O
shaker	O
at	O
300	O
rpm	O
.	O

If	O
phases	O
separated	O
before	O
orbital	O
shaking	O
,	O
the	O
tubes	O
were	O
first	O
shaken	O
briefly	O
by	O
hand	O
.	O

Chloroform	O
(	O
2	O
×	O
9.0	O
ml	O
)	O
and	O
6.75	O
ml	O
0.9	O
%	O
(	O
w	O
/	O
v	O
)	O
aqueous	O
sodium	O
chloride	O
were	O
added	O
,	O
tubes	O
were	O
capped	O
tightly	O
and	O
vortex	O
mixed	O
at	O
high	O
speed	O
for	O
15	O
s	O
,	O
then	O
shaken	O
at	O
300	O
rpm	O
on	O
the	O
orbital	O
shaker	O
for	O
10	O
min	O
(	O
if	O
phases	O
began	O
to	O
separate	O
before	O
orbital	O
shaking	O
,	O
tubes	O
were	O
first	O
shaken	O
by	O
hand	O
for	O
a	O
few	O
seconds	O
to	O
remix	O
)	O
.	O

Samples	O
were	O
then	O
centrifuged	O
at	O
200	O
g	O
at	O
20	O
°	O
C	O
for	O
10	O
min	O
to	O
facilitate	O
phase	O
separation	O
.	O

2.4.2	O
Saponification	O
The	O
chloroform	O
(	O
lower	O
)	O
layer	O
from	O
each	O
total	O
lipid	O
extraction	O
was	O
transferred	O
to	O
a	O
25	O
×	O
150	O
mm	O
test	O
tube	O
.	O

Care	O
was	O
taken	O
not	O
to	O
transfer	O
any	O
of	O
the	O
emulsion	O
or	O
solid	O
material	O
at	O
the	O
interface	O
between	O
the	O
upper	O
and	O
lower	O
phases	O
,	O
by	O
pushing	O
out	O
any	O
material	O
that	O
entered	O
the	O
pipette	O
tip	O
before	O
drawing	O
in	O
the	O
chloroform	O
solution	O
.	O

A	O
new	O
pipette	O
tip	O
was	O
used	O
for	O
each	O
sample	O
.	O

The	O
total	O
lipid	O
extract	O
was	O
saponified	O
by	O
a	O
modification	O
of	O
a	O
method	O
previously	O
described	O
by	O
Thompson	O
and	O
Merola	O
[	O
10	O
]	O
.	O

Solvent	O
was	O
evaporated	O
completely	O
from	O
the	O
total	O
lipid	O
extract	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

Ethanol	O
with	O
3	O
%	O
(	O
w	O
/	O
v	O
)	O
pyrogallol	O
(	O
8	O
ml	O
)	O
was	O
added	O
to	O
each	O
sample	O
.	O

Tubes	O
were	O
capped	O
and	O
vortexed	O
at	O
high	O
speed	O
for	O
10	O
s	O
,	O
then	O
0.5	O
ml	O
of	O
1.28	O
g	O
/	O
ml	O
aqueous	O
potassium	O
hydroxide	O
was	O
added	O
.	O

Tubes	O
were	O
capped	O
tightly	O
,	O
vortexed	O
for	O
10	O
s	O
at	O
high	O
speed	O
,	O
sonicated	O
for	O
30	O
s	O
,	O
then	O
heated	O
in	O
a	O
test	O
tube	O
rack	O
in	O
a	O
85–89	O
°	O
C	O
water	O
bath	O
for	O
30	O
min	O
,	O
ensuring	O
that	O
the	O
bottom	O
half	O
of	O
the	O
tubes	O
were	O
immersed	O
.	O

Tubes	O
(	O
in	O
rack	O
)	O
were	O
shaken	O
and	O
inverted	O
vigorously	O
after	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
and	O
30	O
min	O
of	O
heating	O
(	O
a	O
second	O
test	O
tube	O
rack	O
was	O
held	O
firmly	O
over	O
the	O
top	O
during	O
shaking	O
to	O
hold	O
the	O
tubes	O
)	O
.	O

The	O
capped	O
tubes	O
were	O
sonicated	O
again	O
for	O
30	O
s	O
,	O
cooled	O
under	O
running	O
tap	O
water	O
,	O
then	O
slowly	O
opened	O
.	O

Cyclohexane	O
(	O
20	O
ml	O
)	O
,	O
then	O
12	O
ml	O
distilled	O
deionized	O
water	O
were	O
added	O
to	O
each	O
sample	O
.	O

Tubes	O
were	O
recapped	O
,	O
shaken	O
vigorously	O
for	O
a	O
few	O
seconds	O
,	O
then	O
rocked	O
15	O
min	O
on	O
a	O
platform	O
mixer	O
at	O
maximum	O
speed	O
(	O
Thermolyne	O
Vari	O
-	O
Mix	O
platform	O
mixer	O
;	O
Barnstead	O
/	O
Thermolyne	O
No.	O
48725	O
)	O
.	O

No	O
residual	O
material	O
was	O
evident	O
in	O
the	O
bottom	O
or	O
on	O
the	O
sides	O
of	O
tubes	O
after	O
shaking	O
.	O

Samples	O
were	O
centrifuged	O
at	O
200	O
g	O
at	O
20	O
°	O
C	O
for	O
10	O
min	O
to	O
accelerate	O
phase	O
separation	O
.	O

For	O
each	O
sample	O
,	O
17.0	O
ml	O
(	O
2	O
×	O
8.5	O
ml	O
)	O
of	O
the	O
cyclohexane	O
(	O
upper	O
)	O
layer	O
was	O
transferred	O
to	O
a	O
25	O
×	O
150	O
mm	O
test	O
tube	O
,	O
with	O
care	O
taken	O
not	O
to	O
include	O
any	O
of	O
the	O
black	O
,	O
aqueous	O
phase	O
.	O

Cyclohexane	O
was	O
evaporated	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

Chloroform	O
(	O
0.5	O
ml	O
)	O
was	O
added	O
to	O
each	O
sample	O
,	O
then	O
samples	O
were	O
vortexed	O
for	O
10	O
s	O
at	O
high	O
speed	O
.	O

2.4.3	O
Solid	O
-	O
phase	O
extraction	O
A	O
modification	O
of	O
the	O
method	O
of	O
Kaluzny	O
et	O
al.	O
[	O
11	O
]	O
was	O
used	O
to	O
separate	O
the	O
neutral	O
lipid	O
fraction	O
(	O
containing	O
sterols	O
and	O
stanols	O
)	O
from	O
more	O
polar	O
lipids	O
.	O

Bond	O
Elute	O
LRC	O
®	O
aminopropyl	O
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
cartridges	O
10	O
ml	O
/	O
500	O
mg	O
(	O
Varian	O
Associates	O
,	O
Harbor	O
City	O
,	O
CA	O
,	O
USA	O
)	O
were	O
used	O
.	O

The	O
SPE	O
cartridges	O
were	O
attached	O
to	O
a	O
vacuum	O
manifold	O
(	O
Visaprep	O
DL	O
™	O
;	O
Supelco	O
,	O
Bellefonte	O
,	O
PA	O
,	O
USA	O
)	O
set	O
at	O
slightly	O
less	O
than	O
1″	O
Hg	O
with	O
valves	O
closed	O
.	O

Cartridges	O
were	O
conditioned	O
with	O
4	O
ml	O
hexane	O
,	O
which	O
was	O
discarded	O
.	O

A	O
16	O
×	O
125	O
mm	O
glass	O
test	O
tube	O
was	O
placed	O
under	O
each	O
outlet	O
.	O

With	O
vacuum	O
valves	O
closed	O
and	O
using	O
a	O
new	O
pipette	O
tip	O
for	O
each	O
sample	O
,	O
sample	O
was	O
transferred	O
into	O
the	O
SPE	O
cartridge	O
,	O
directly	O
onto	O
the	O
adsorbent	O
,	O
repeating	O
until	O
as	O
much	O
as	O
possible	O
had	O
been	O
transferred	O
.	O

With	O
vacuum	O
set	O
at	O
slightly	O
less	O
than	O
1″	O
Hg	O
,	O
valves	O
were	O
opened	O
one	O
by	O
one	O
until	O
the	O
sample	O
solution	O
had	O
just	O
completely	O
entered	O
the	O
adsorbent	O
,	O
then	O
turned	O
off	O
until	O
all	O
cartridges	O
had	O
been	O
set	O
.	O

Elution	O
solvent	O
(	O
chloroform	O
–	O
isopropanol	O
,	O
2:1	O
,	O
v	O
/	O
v	O
,	O
0.5	O
ml	O
)	O
was	O
added	O
to	O
each	O
cartridge	O
.	O

The	O
solvent	O
was	O
then	O
drawn	O
under	O
vacuum	O
through	O
the	O
cartridges	O
one	O
at	O
a	O
time	O
until	O
it	O
reached	O
just	O
above	O
the	O
column	O
bed	O
,	O
then	O
valve	O
was	O
closed	O
until	O
all	O
samples	O
had	O
been	O
taken	O
to	O
this	O
stage	O
.	O

An	O
additional	O
3.5	O
ml	O
of	O
the	O
elution	O
solvent	O
was	O
added	O
to	O
each	O
tube	O
,	O
then	O
all	O
valves	O
were	O
opened	O
and	O
the	O
solvent	O
was	O
allowed	O
to	O
pass	O
completely	O
(	O
dropwise	O
)	O
through	O
the	O
cartridges	O
.	O

The	O
vacuum	O
was	O
then	O
increased	O
to	O
draw	O
the	O
columns	O
dry	O
(	O
∼8″	O
Hg	O
for	O
at	O
least	O
2	O
min	O
)	O
.	O

2.4.4	O
Derivatization	O
Solvent	O
was	O
completely	O
evaporated	O
from	O
samples	O
at	O
60	O
°	O
C	O
with	O
a	O
stream	O
of	O
nitrogen	O
.	O

Freshly	O
prepared	O
derivatization	O
reagent	O
(	O
pyridine	O
–	O
BSTFA	O
with	O
1	O
%	O
TMCS	O
,	O
1:1	O
,	O
v	O
/	O
v	O
)	O
,	O
100	O
μl	O
,	O
was	O
pipetted	O
into	O
each	O
tube	O
and	O
vortex	O
mixed	O
for	O
10	O
s.	O

The	O
reagent	O
was	O
then	O
carefully	O
swirled	O
around	O
and	O
∼2″	O
up	O
the	O
sides	O
of	O
each	O
tube	O
.	O

Tubes	O
were	O
allowed	O
to	O
stand	O
at	O
least	O
1	O
min	O
,	O
vortex	O
mixed	O
for	O
3	O
s	O
,	O
then	O
allowed	O
to	O
stand	O
again	O
for	O
at	O
least	O
1	O
min	O
.	O

Each	O
sample	O
was	O
transferred	O
using	O
a	O
9″	O
glass	O
pasteur	O
pipette	O
into	O
a	O
100-μl	O
limited	O
volume	O
insert	O
in	O
an	O
autosampler	O
vial	O
,	O
sealed	O
with	O
a	O
PTFE	O
/	O
silicone	O
septum	O
cap	O
,	O
and	O
stored	O
at	O
<	O
10	O
°	O
C	O
until	O
assayed	O
by	O
GC	O
(	O
within	O
1	O
week	O
)	O
.	O

2.4.5	O
GC	O
analysis	O
and	O
quantitation	O
Analyte	O
retention	O
times	O
were	O
determined	O
using	O
commercially	O
available	O
standards	O
.	O

Analysis	O
of	O
selected	O
serum	O
samples	O
without	O
added	O
epicholesterol	O
internal	O
standard	O
confirmed	O
lack	O
of	O
sample	O
constituents	O
that	O
co	O
-	O
eluted	O
with	O
the	O
internal	O
standard	O
.	O

In	O
routine	O
assays	O
,	O
component	O
peaks	O
were	O
identified	O
by	O
the	O
adjusted	O
retention	O
time	O
,	O
which	O
compensated	O
for	O
any	O
shifts	O
in	O
expected	O
retention	O
times	O
based	O
on	O
that	O
of	O
the	O
internal	O
standard	O
[	O
12	O
]	O
.	O

A	O
relative	O
search	O
window	O
(	O
based	O
on	O
a	O
percent	O
of	O
the	O
absolute	O
retention	O
time	O
)	O
was	O
then	O
applied	O
to	O
the	O
adjusted	O
retention	O
time	O
as	O
the	O
criteria	O
for	O
identification	O
.	O

The	O
size	O
of	O
the	O
relative	O
search	O
window	O
was	O
determined	O
based	O
on	O
the	O
degree	O
of	O
absolute	O
retention	O
time	O
shift	O
that	O
was	O
expected	O
during	O
a	O
run	O
and	O
the	O
proximity	O
of	O
other	O
peaks	O
expected	O
in	O
the	O
samples	O
.	O

After	O
determining	O
the	O
method	O
was	O
linear	O
over	O
the	O
expected	O
concentration	O
ranges	O
(	O
below	O
)	O
,	O
analytes	O
were	O
quantified	O
based	O
on	O
a	O
single	O
point	O
response	O
factor	O
(	O
RF	O
)	O
:RF	O
=	O
RC	O
/RIS	O
MC	O
/MIS	O
where	O
R	O
C	O
is	O
the	O
peak	O
area	O
for	O
the	O
component	O
,	O
R	O
IS	O
is	O
the	O
peak	O
area	O
for	O
the	O
internal	O
standard	O
,	O
M	O
C	O
is	O
the	O
amount	O
of	O
component	O
and	O
M	O
IS	O
is	O
the	O
amount	O
of	O
internal	O
standard	O
added	O
to	O
the	O
sample	O
.	O

For	O
each	O
analyte	O
,	O
the	O
RF	O
was	O
determined	O
at	O
3	O
μg	O
as	O
the	O
average	O
of	O
triplicate	O
analysis	O
of	O
standards	O
.	O

In	O
samples	O
,	O
each	O
component	O
(	O
M	O
C	O
)	O
was	O
determined	O
using	O
the	O
response	O
factor	O
for	O
that	O
component	O
and	O
R	O
C	O
and	O
R	O
IS	O
determined	O
from	O
the	O
GC	O
analysis	O
.	O

Baseline	O
events	O
(	O
timed	O
events	O
in	O
the	O
instrument	O
method	O
which	O
effect	O
integration	O
of	O
peaks	O
)	O
were	O
set	O
up	O
in	O
the	O
standard	O
(	O
routine	O
)	O
Turbochrom	O
™	O
method	O
file	O
based	O
on	O
optimal	O
consistency	O
of	O
peak	O
integration	O
for	O
the	O
control	O
sample	O
.	O

In	O
sample	O
runs	O
,	O
individual	O
attention	O
was	O
paid	O
to	O
the	O
chromatograms	O
to	O
avoid	O
and	O
correct	O
any	O
obvious	O
integration	O
problems	O
(	O
usually	O
as	O
a	O
result	O
of	O
small	O
peak	O
size	O
and	O
interfering	O
peaks	O
)	O
,	O
by	O
modifying	O
baseline	O
events	O
as	O
necessary	O
.	O

2.5	O
Linearity	O
,	O
limit	O
of	O
detection	O
,	O
and	O
limit	O
of	O
quantitation	O
studies	O
The	O
expected	O
concentration	O
ranges	O
for	O
desmosterol	O
,	O
lathosterol	O
,	O
campesterol	O
,	O
sitosterol	O
,	O
stigmasterol	O
,	O
campestanol	O
,	O
sitostanol	O
,	O
lanosterol	O
,	O
and	O
fucosterol	O
were	O
tested	O
for	O
linearity	O
.	O

For	O
each	O
compound	O
,	O
standard	O
solutions	O
were	O
made	O
at	O
four	O
or	O
five	O
different	O
concentrations	O
between	O
0.05	O
μg	O
/	O
ml	O
and	O
25	O
μg	O
/	O
ml	O
.	O

Each	O
standard	O
solution	O
was	O
derivatized	O
and	O
assayed	O
in	O
duplicate	O
at	O
all	O
concentrations	O
,	O
except	O
in	O
quintuplicate	O
at	O
0.75	O
μg	O
/	O
ml	O
for	O
desmosterol	O
,	O
lanosterol	O
,	O
fucosterol	O
,	O
campestanol	O
,	O
and	O
sitostanol	O
and	O
at	O
5	O
μg	O
/	O
ml	O
for	O
campesterol	O
,	O
sitosterol	O
,	O
and	O
stigmasterol	O
.	O

For	O
each	O
compound	O
,	O
a	O
linear	O
regression	O
was	O
performed	O
on	O
the	O
data	O
(	O
component	O
/	O
internal	O
standard	O
area	O
ratio	O
vs.	O
component	O
/	O
internal	O
standard	O
mass	O
ratio	O
)	O
.	O

All	O
curves	O
were	O
linear	O
,	O
above	O
the	O
limit	O
of	O
detection	O
,	O
in	O
the	O
concentration	O
range	O
tested	O
(	O
r	O
2	O
=	O
0.99	O
or	O
greater	O
in	O
all	O
cases	O
)	O
.	O

The	O
method	O
limit	O
of	O
detection	O
(	O
MLOD	O
)	O
and	O
limit	O
of	O
quantitation	O
(	O
MLOQ	O
)	O
for	O
sitosterol	O
,	O
campesterol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
were	O
determined	O
from	O
results	O
of	O
the	O
repeated	O
analyses	O
(	O
n	O
=	O
55	O
)	O
of	O
0.9-ml	O
aliquots	O
of	O
the	O
Accutrol	O
™	O
control	O
serum	O
composite	O
.	O

For	O
each	O
component	O
,	O
the	O
MLOD	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
and	O
the	O
MLOQ	O
was	O
estimated	O
as	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
of	O
the	O
55	O
measurements	O
.	O

Since	O
sitostanol	O
and	O
campestanol	O
were	O
not	O
present	O
in	O
the	O
control	O
serum	O
and	O
lanosterol	O
and	O
stigmasterol	O
were	O
barely	O
detectable	O
,	O
the	O
MLODs	O
and	O
MLOQs	O
for	O
these	O
components	O
were	O
determined	O
by	O
analysis	O
of	O
the	O
Accutrol	O
™	O
serum	O
spiked	O
with	O
known	O
amounts	O
of	O
standards	O
,	O
as	O
follows	O
.	O

A	O
chloroform	O
solution	O
containing	O
0.5	O
μg	O
/	O
ml	O
of	O
stigmasterol	O
,	O
sitostanol	O
,	O
and	O
lanosterol	O
and	O
1	O
μg	O
/	O
ml	O
of	O
campestanol	O
was	O
prepared	O
.	O

One	O
ml	O
of	O
the	O
solution	O
was	O
added	O
to	O
each	O
of	O
seven	O
0.9-ml	O
Accutrol	O
™	O
composite	O
aliquots	O
,	O
which	O
were	O
then	O
assayed	O
as	O
described	O
above	O
,	O
except	O
for	O
the	O
volume	O
of	O
chloroform	O
added	O
during	O
the	O
total	O
lipid	O
extraction	O
which	O
was	O
reduced	O
by	O
the	O
volume	O
of	O
standard	O
added	O
.	O

MLOD	O
was	O
calculated	O
as	O
three	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
,	O
and	O
MLOQ	O
was	O
calculated	O
as	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
the	O
mean	O
of	O
the	O
seven	O
measurements	O
.	O

We	O
also	O
checked	O
the	O
method	O
performance	O
in	O
assaying	O
smaller	O
serum	O
aliquots	O
,	O
which	O
may	O
be	O
of	O
interest	O
when	O
the	O
sample	O
volume	O
is	O
limited	O
.	O

Seven	O
0.5-ml	O
and	O
seven	O
0.25-ml	O
aliquots	O
of	O
the	O
control	O
serum	O
composite	O
unspiked	O
and	O
spiked	O
with	O
sitostanol	O
,	O
campestanol	O
,	O
stigmasterol	O
,	O
and	O
lanosterol	O
in	O
amounts	O
near	O
the	O
MLOQ	O
determined	O
for	O
analysis	O
of	O
0.9	O
ml	O
serum	O
were	O
assayed	O
.	O

A	O
chloroform	O
solution	O
of	O
sitostanol	O
,	O
campestanol	O
,	O
stigmasterol	O
,	O
and	O
lanosterol	O
was	O
added	O
to	O
three	O
0.25	O
ml	O
and	O
three	O
0.5-ml	O
aliquots	O
of	O
the	O
Accutrol	O
™	O
control	O
composite	O
such	O
that	O
final	O
concentrations	O
were	O
1	O
μg	O
/	O
ml	O
campestanol	O
and	O
0.5	O
μg	O
/	O
ml	O
sitostanol	O
,	O
stigmasterol	O
,	O
and	O
lanosterol	O
.	O

Additionally	O
,	O
seven	O
serum	O
samples	O
from	O
a	O
clinical	O
feeding	O
trial	O
[	O
2	O
]	O
,	O
in	O
which	O
sitostanol	O
was	O
detected	O
,	O
were	O
re	O
-	O
assayed	O
in	O
0.25-ml	O
aliquots	O
and	O
compared	O
to	O
the	O
results	O
from	O
analysis	O
of	O
the	O
0.9-ml	O
aliquots	O
.	O

2.6	O
Recovery	O
studies	O
Recovery	O
analysis	O
was	O
based	O
on	O
fortification	O
of	O
samples	O
of	O
the	O
control	O
serum	O
composite	O
.	O

For	O
the	O
analytes	O
not	O
present	O
in	O
the	O
control	O
material	O
,	O
fortification	O
was	O
performed	O
at	O
four	O
different	O
concentrations	O
and	O
reported	O
for	O
all	O
concentrations	O
at	O
or	O
above	O
the	O
MLOQ	O
determined	O
for	O
the	O
individual	O
compounds	O
.	O

For	O
the	O
compounds	O
present	O
in	O
the	O
control	O
serum	O
,	O
samples	O
were	O
fortified	O
at	O
one	O
concentration	O
,	O
which	O
was	O
approximately	O
the	O
same	O
as	O
that	O
determined	O
from	O
analysis	O
of	O
the	O
control	O
serum	O
.	O

For	O
these	O
samples	O
,	O
the	O
values	O
calculated	O
for	O
the	O
unfortified	O
control	O
sample	O
analyzed	O
and	O
chromatographed	O
in	O
the	O
same	O
assay	O
were	O
subtracted	O
from	O
the	O
fortified	O
control	O
sample	O
values	O
to	O
determine	O
recovery:%R	O
=	O
Mfc	O
−Mc	O
Mf	O
×100	O
where	O
%	O
R	O
is	O
percent	O
recovery	O
,	O
M	O
fc	O
is	O
the	O
raw	O
amount	O
in	O
μg	O
of	O
component	O
determined	O
in	O
the	O
fortified	O
sample	O
,	O
M	O
c	O
is	O
the	O
raw	O
amount	O
in	O
μg	O
of	O
component	O
in	O
the	O
unfortified	O
material	O
,	O
and	O
M	O
f	O
is	O
the	O
fortification	O
amount	O
in	O
μg	O
.	O

2.6.1	O
Precision	O
studies	O
For	O
sitosterol	O
,	O
campesterol	O
,	O
lathosterol	O
,	O
desmosterol	O
,	O
and	O
lanosterol	O
,	O
precision	O
was	O
evaluated	O
from	O
the	O
results	O
of	O
repeated	O
analyses	O
of	O
the	O
control	O
sample	O
(	O
Accutrol	O
™	O
)	O
.	O

For	O
sitostanol	O
,	O
campestanol	O
,	O
and	O
stigmasterol	O
,	O
precision	O
was	O
estimated	O
from	O
repeated	O
analyses	O
of	O
the	O
control	O
composite	O
spiked	O
with	O
a	O
standard	O
mixture	O
of	O
these	O
components	O
.	O

2.7	O
Routine	O
quality	O
control	O
Prior	O
to	O
analysis	O
of	O
unknown	O
samples	O
,	O
three	O
assay	O
batches	O
of	O
5–13	O
aliquots	O
of	O
the	O
serum	O
control	O
material	O
(	O
Section	O
2.3.5	O
)	O
were	O
analyzed	O
over	O
a	O
period	O
of	O
2	O
weeks	O
.	O

A	O
control	O
chart	O
showing	O
the	O
mean	O
and	O
tolerance	O
limits	O
(	O
±3	O
times	O
the	O
standard	O
deviation	O
)	O
was	O
established	O
for	O
each	O
analyte	O
and	O
used	O
to	O
monitor	O
subsequent	O
assays	O
(	O
[	O
13	O
]	O
,	O
pp	O
.	O

130–132	O
)	O
.	O

An	O
aliquot	O
of	O
the	O
control	O
serum	O
composite	O
was	O
assayed	O
with	O
each	O
batch	O
of	O
samples	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Chromatograms	O
Representative	O
chromatograms	O
for	O
standards	O
,	O
the	O
control	O
serum	O
,	O
and	O
a	O
serum	O
sample	O
from	O
the	O
diet	O
intervention	O
(	O
which	O
contained	O
sitostanol	O
and	O
campestanol	O
)	O
are	O
shown	O
in	O
Fig.	O
1	O
.	O

3.2	O
Retention	O
times	O
and	O
response	O
factors	O
Table	O
1	O
summarizes	O
the	O
retention	O
times	O
,	O
relative	O
retention	O
times	O
,	O
and	O
response	O
factors	O
for	O
sitosterol	O
,	O
campesterol	O
,	O
stigmasterol	O
,	O
sitostanol	O
,	O
campestanol	O
,	O
desmosterol	O
,	O
lathosterol	O
,	O
and	O
also	O
lanosterol	O
,	O
fucosterol	O
,	O
and	O
squalene	O
using	O
the	O
present	O
method	O
.	O

Whereas	O
absolute	O
retention	O
times	O
sometimes	O
varied	O
up	O
to	O
0.2	O
min	O
.	O

(	O
e.g.	O
from	O
slight	O
changes	O
in	O
column	O
activity	O
and/or	O
head	O
pressure	O
)	O
,	O
relative	O
retention	O
times	O
were	O
consistent	O
within	O
0.02	O
min	O
across	O
runs	O
.	O

3.3	O
Linearity	O
,	O
limits	O
of	O
detection	O
,	O
limits	O
of	O
quantitation	O
,	O
and	O
analytical	O
ranges	O
Table	O
2	O
summarizes	O
the	O
method	O
linear	O
range	O
,	O
limit	O
of	O
detection	O
(	O
MLOD	O
)	O
,	O
and	O
limit	O
of	O
quantitation	O
(	O
MLOQ	O
)	O
for	O
each	O
component	O
(	O
sitosterol	O
,	O
campesterol	O
,	O
stigmasterol	O
,	O
sitostanol	O
,	O
campestanol	O
,	O
desmosterol	O
,	O
lathosterol	O
,	O
lanosterol	O
)	O
in	O
the	O
present	O
study	O
.	O

The	O
method	O
enabled	O
detection	O
of	O
all	O
components	O
at	O
concentrations	O
of	O
<	O
0.4	O
μg	O
/	O
ml	O
(	O
<	O
1	O
μmol	O
/	O
l	O
)	O
.	O

The	O
greatest	O
sensitivity	O
was	O
for	O
sitostanol	O
(	O
0.05	O
μg	O
/	O
ml	O
;	O
0.1	O
μmol	O
/	O
l	O
)	O
and	O
the	O
least	O
for	O
campesterol	O
and	O
campestanol	O
(	O
0.4	O
μg	O
/	O
ml	O
;	O
1	O
μmol	O
/	O
l	O
)	O
.	O

The	O
decreased	O
sensitivity	O
for	O
campesterol	O
and	O
campestanol	O
was	O
largely	O
due	O
to	O
interfering	O
peaks	O
in	O
the	O
region	O
which	O
limited	O
the	O
reliability	O
of	O
peak	O
area	O
estimates	O
at	O
low	O
analyte	O
levels	O
.	O

The	O
MLOQ	O
ranged	O
from	O
0.2	O
μg	O
/	O
ml	O
(	O
0.5	O
μmol	O
/	O
l	O
)	O
for	O
sitostanol	O
to	O
1.2	O
μg	O
/	O
ml	O
(	O
3	O
μmol	O
/	O
l	O
)	O
for	O
campesterol	O
and	O
campestanol	O
.	O

Response	O
was	O
linear	O
in	O
the	O
range	O
analyzed	O
for	O
each	O
component	O
(	O
MLOQ	O
to	O
10	O
or	O
25	O
μg	O
/	O
ml	O
)	O
.	O

The	O
statistically	O
determined	O
MLOD	O
and	O
MLOQ	O
(	O
defined	O
as	O
three	O
and	O
ten	O
times	O
the	O
standard	O
deviation	O
of	O
replicates	O
,	O
respectively	O
;	O
13	O
,	O
p.	O
80	O
)	O
included	O
effects	O
of	O
inconsistent	O
automated	O
peak	O
integration	O
due	O
to	O
background	O
interferences	O
.	O

The	O
statistically	O
determined	O
MLOQ	O
for	O
lanosterol	O
was	O
0.1	O
μg	O
/	O
ml	O
,	O
and	O
lanosterol	O
was	O
present	O
in	O
the	O
unfortified	O
control	O
serum	O
at	O
approximately	O
this	O
level	O
.	O

However	O
,	O
uncertainty	O
in	O
quantitation	O
of	O
lanosterol	O
occurred	O
due	O
to	O
occasional	O
incomplete	O
resolution	O
from	O
a	O
nearby	O
peak	O
,	O
and	O
the	O
results	O
for	O
55	O
analyses	O
of	O
the	O
control	O
material	O
and	O
control	O
material	O
spiked	O
with	O
various	O
levels	O
of	O
lanosterol	O
(	O
Table	O
4	O
)	O
suggested	O
that	O
the	O
practical	O
MLOQ	O
was	O
somewhat	O
higher	O
than	O
0.1	O
μg	O
/	O
ml	O
.	O

Therefore	O
,	O
the	O
MLOQ	O
and	O
MLOD	O
for	O
lanosterol	O
reported	O
in	O
Table	O
2	O
are	O
estimated	O
based	O
on	O
these	O
practical	O
findings	O
.	O

3.4	O
Recovery	O
Recovery	O
of	O
spiked	O
standards	O
is	O
shown	O
in	O
Table	O
3	O
and	O
appeared	O
quantitative	O
for	O
lathosterol	O
,	O
campesterol	O
,	O
sitosterol	O
,	O
sitostanol	O
,	O
campestanol	O
,	O
lanosterol	O
,	O
and	O
stigmasterol	O
.	O

Recovery	O
of	O
fortified	O
desmosterol	O
was	O
74	O
%	O
.	O

The	O
reason	O
for	O
this	O
result	O
is	O
unknown	O
;	O
we	O
did	O
not	O
attempt	O
to	O
repeat	O
the	O
experiment	O
.	O

3.5	O
Precision	O
Table	O
4	O
summarizes	O
the	O
mean	O
,	O
standard	O
deviation	O
,	O
and	O
relative	O
standard	O
deviation	O
for	O
sitosterol	O
,	O
campesterol	O
,	O
desmosterol	O
,	O
lathosterol	O
,	O
and	O
lanosterol	O
concentrations	O
assayed	O
in	O
the	O
control	O
material	O
over	O
the	O
course	O
of	O
23	O
assay	O
batches	O
by	O
two	O
analysts	O
over	O
a	O
2-month	O
period	O
.	O

Because	O
sitostanol	O
,	O
campestanol	O
,	O
and	O
stigmasterol	O
are	O
not	O
components	O
of	O
the	O
Accutrol	O
™	O
serum	O
and	O
could	O
not	O
be	O
readily	O
and	O
homogeneously	O
fortified	O
,	O
no	O
control	O
data	O
were	O
generated	O
for	O
these	O
compounds	O
.	O

For	O
sitosterol	O
,	O
campesterol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
,	O
the	O
standard	O
deviation	O
over	O
all	O
analyses	O
ranged	O
from	O
0.02	O
μg	O
/	O
ml	O
(	O
lanosterol	O
)	O
to	O
0.12	O
μg	O
/	O
ml	O
(	O
campesterol	O
)	O
.	O

The	O
within	O
-	O
assay	O
standard	O
deviations	O
were	O
similar	O
to	O
the	O
overall	O
RSD	O
for	O
all	O
components	O
.	O

The	O
relative	O
standard	O
deviation	O
for	O
lanosterol	O
was	O
much	O
higher	O
than	O
for	O
other	O
components	O
(	O
14	O
%	O
)	O
,	O
due	O
to	O
the	O
low	O
concentration	O
in	O
the	O
control	O
sample	O
(	O
0.1	O
μg	O
/	O
ml	O
)	O
.	O

Quality	O
control	O
charts	O
for	O
lathosterol	O
and	O
campesterol	O
in	O
the	O
control	O
serum	O
are	O
shown	O
in	O
Fig.	O
2	O
.	O

3.6	O
Method	O
performance	O
in	O
assay	O
of	O
smaller	O
volumes	O
of	O
serum	O
Table	O
5	O
shows	O
data	O
from	O
the	O
analyses	O
of	O
fortified	O
(	O
sitostanol	O
,	O
campestanol	O
,	O
lanosterol	O
,	O
stigmasterol	O
)	O
and	O
unfortified	O
0.25-	O
,	O
0.5-	O
,	O
and	O
0.9-ml	O
aliquots	O
of	O
the	O
control	O
serum	O
composite	O
.	O

All	O
compounds	O
were	O
fortified	O
at	O
concentrations	O
near	O
the	O
MLOQ	O
determined	O
for	O
analysis	O
of	O
0.9	O
ml	O
(	O
Table	O
2	O
)	O
.	O

Results	O
for	O
sitosterol	O
,	O
campesterol	O
,	O
lathosterol	O
,	O
desmosterol	O
,	O
sitostanol	O
,	O
and	O
campestanol	O
were	O
similar	O
for	O
all	O
volumes	O
analyzed	O
,	O
suggesting	O
that	O
for	O
these	O
components	O
,	O
sensitivity	O
and	O
precision	O
are	O
not	O
compromised	O
by	O
assaying	O
as	O
low	O
as	O
0.25	O
ml	O
.	O

In	O
the	O
fortified	O
serum	O
,	O
however	O
,	O
lanosterol	O
and	O
stigmasterol	O
that	O
were	O
measured	O
in	O
the	O
0.9-ml	O
aliquots	O
were	O
undetectable	O
in	O
the	O
smaller	O
aliquots	O
.	O

Table	O
6	O
summarizes	O
results	O
from	O
analyses	O
of	O
0.25-	O
and	O
0.9-ml	O
aliquots	O
of	O
seven	O
sitostanol	O
-	O
containing	O
serum	O
samples	O
(	O
from	O
the	O
feeding	O
trial	O
)	O
,	O
which	O
were	O
analyzed	O
to	O
compare	O
the	O
sensitivity	O
of	O
the	O
method	O
in	O
measuring	O
naturally	O
occurring	O
(	O
i.e.	O
unfortified	O
)	O
sitostanol	O
in	O
smaller	O
and	O
larger	O
sample	O
volumes	O
.	O

The	O
0.25-ml	O
assay	O
failed	O
to	O
detect	O
sitostanol	O
in	O
four	O
of	O
the	O
seven	O
samples	O
and	O
lanosterol	O
in	O
all	O
seven	O
samples	O
.	O

For	O
sitosterol	O
(	O
mean	O
2.24	O
μg	O
/	O
ml	O
)	O
,	O
stigmasterol	O
(	O
not	O
detected	O
)	O
and	O
campestanol	O
(	O
not	O
detected	O
)	O
results	O
were	O
similar	O
in	O
both	O
analyses	O
.	O

For	O
campesterol	O
,	O
lathosterol	O
,	O
and	O
desmosterol	O
,	O
results	O
were	O
somewhat	O
lower	O
(	O
3–25	O
%	O
on	O
average	O
)	O
for	O
the	O
0.25-ml	O
aliquots	O
.	O

These	O
results	O
suggest	O
that	O
in	O
a	O
range	O
of	O
actual	O
serum	O
samples	O
the	O
sensitivity	O
of	O
the	O
analysis	O
may	O
be	O
reduced	O
when	O
0.25-ml	O
vs.	O
0.9-ml	O
is	O
assayed	O
,	O
especially	O
for	O
lanosterol	O
and	O
sitostanol	O
.	O

4	O
Conclusions	O
A	O
sensitive	O
and	O
precise	O
method	O
was	O
developed	O
for	O
quantitation	O
of	O
phytosterols	O
,	O
stanols	O
,	O
and	O
selected	O
cholesterol	O
metabolites	O
in	O
human	B
serum	O
.	O

Analytes	O
were	O
detected	O
at	O
levels	O
of	O
120	O
ng	O
/	O
ml	O
to	O
6	O
μg	O
/	O
ml	O
with	O
standard	O
deviations	O
of	O
0.02	O
to	O
0.12	O
μg	O
/	O
ml	O
.	O

We	O
have	O
communicated	O
the	O
method	O
in	O
detail	O
to	O
facilitate	O
its	O
reproduction	O
in	O
other	O
laboratories	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
Fleischmann	O
's	O
Tablespread	O
Company	O
.	O

We	O
gratefully	O
acknowledge	O
technical	O
advice	O
from	O
Dr.	O
Robert	O
Whiton	O
in	O
evaluating	O
method	O
performance	O
parameters	O
and	O
chromatography	O
issues	O
.	O

The	O
majority	O
of	O
adult	O
cancers	O
are	O
carcinomas	O
of	O
epithelial	O
origin	O
with	O
lung	O
,	O
colon	O
,	O
and	O
uterus	O
as	O
the	O
primary	O
sites	O
,	O
which	O
reflects	O
a	O
selective	O
vulnerability	O
of	O
these	O
tissues	O
to	O
carcinogenic	O
insult	O
as	O
a	O
result	O
of	O
frequent	O
exposure	O
to	O
external	O
environment	O
.	O

Indeed	O
,	O
it	O
is	O
estimated	O
that	O
up	O
to	O
80	O
to	O
90	O
%	O
of	O
all	O
cancers	O
are	O
attributable	O
to	O
environmental	O
risk	O
factors	O
,	O
including	O
chemicals	O
,	O
radiations	O
,	O
and	O
viruses	O
.	O

The	O
notion	O
that	O
a	O
majority	O
of	O
human	B
cancers	O
have	O
an	O
environmental	O
origin	O
implies	O
an	O
optimistic	O
outlook	O
in	O
terms	O
of	O
cancer	O
prevention	O
since	O
most	O
cancer	O
-	O
causing	O
substances	O
are	O
introduced	O
into	O
the	O
environment	O
by	O
human	B
activities	O
and	O
are	O
hence	O
,	O
controllable	O
or	O
removable	O
.	O

The	O
elimination	O
of	O
environmental	O
carcinogens	O
or	O
at	O
least	O
avoiding	O
exposure	O
to	O
them	O
offers	O
the	O
opportunity	O
to	O
prevent	O
most	O
cancers	O
,	O
which	O
is	O
a	O
basis	O
of	O
primary	O
prevention	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
at	O
the	O
cellular	O
and	O
molecular	O
levels	O
of	O
carcinogenesis	O
have	O
led	O
to	O
the	O
development	O
of	O
a	O
new	O
promising	O
strategy	O
for	O
cancer	O
prevention	O
,	O
that	O
is	O
,	O
chemoprevention	O
[	O
1–3	O
]	O
.	O

Chemoprevention	O
is	O
defined	O
as	O
the	O
use	O
of	O
specific	O
chemical	O
substances	O
(	O
natural	O
or	O
synthetic	O
)	O
or	O
their	O
mixtures	O
to	O
suppress	O
,	O
retard	O
,	O
or	O
reverse	O
the	O
process	O
of	O
carcinogenesis	O
.	O

It	O
is	O
one	O
of	O
the	O
novel	O
approaches	O
of	O
controlling	O
cancer	O
alternative	O
to	O
therapy	O
that	O
has	O
some	O
limitations	O
and	O
drawbacks	O
in	O
the	O
treatment	O
of	O
patients	B
.	O

The	O
term	O
chemoprevention	O
was	O
initially	O
coined	O
by	O
Michael	O
Sporn	O
who	O
utilized	O
retinoids	O
to	O
halt	O
experimental	O
carcinogenesis	O
[	O
4	O
]	O
.	O

Since	O
we	O
are	O
all	O
exposed	O
in	O
greater	O
or	O
lesser	O
degree	O
to	O
environmental	O
carcinogens	O
from	O
diverse	O
sources	O
,	O
it	O
is	O
important	O
to	O
find	O
a	O
way	O
to	O
neutralize	O
these	O
carcinogens	O
or	O
protect	O
against	O
deleterious	O
effects	O
they	O
exert	O
.	O

In	O
this	O
respect	O
,	O
chemoprevention	O
offers	O
a	O
realistic	O
promise	O
of	O
reducing	O
the	O
incidence	O
of	O
human	B
cancer	O
.	O

The	O
primary	O
goal	O
of	O
chemoprevention	O
research	O
is	O
to	O
identify	O
effective	O
agents	O
and/or	O
develop	O
efficient	O
strategies	O
for	O
clinical	O
trials	O
and	O
ultimately	O
,	O
application	O
to	O
human	B
populations	O
.	O

In	O
order	O
to	O
better	O
practice	O
the	O
chemoprevention	O
,	O
one	O
must	O
precisely	O
understand	O
the	O
nature	O
and	O
mechanisms	O
of	O
carcinogenesis	O
.	O

2	O
Molecular	O
basis	O
of	O
chemoprevention	O
Carcinogenesis	O
is	O
characterized	O
by	O
a	O
complex	O
process	O
that	O
involves	O
a	O
series	O
of	O
individual	O
steps	O
.	O

From	O
the	O
stand	O
point	O
of	O
the	O
experimental	O
carcinogenesis	O
in	O
rodents	B
,	O
tumor	O
development	O
has	O
been	O
generally	O
considered	O
to	O
consist	O
of	O
three	O
distinct	O
steps	O
—	O
initiation	O
,	O
promotion	O
,	O
and	O
progression	O
as	O
depicted	O
in	O
Fig.	O
1	O
.	O

Initiation	O
is	O
an	O
irreversible	O
event	O
that	O
begins	O
when	O
the	O
cells	O
in	O
normal	O
tissues	O
are	O
exposed	O
to	O
a	O
carcinogen	O
and	O
their	O
genomic	O
DNA	O
undergoes	O
damage	O
that	O
remains	O
unrepaired	O
or	O
misrepaired	O
.	O

In	O
case	O
of	O
chemically	O
-	O
induced	O
carcinogenesis	O
,	O
initiation	O
involves	O
uptake	O
of	O
a	O
given	O
carcinogenic	O
agent	O
with	O
subsequent	O
distribution	O
and	O
transport	O
to	O
organs	O
and	O
tissues	O
where	O
metabolism	O
occurs	O
,	O
the	O
interaction	O
of	O
a	O
reactive	O
metabolite	O
with	O
cellular	O
DNA	O
with	O
subsequent	O
structural	O
alterations	O
in	O
the	O
DNA	O
molecule	O
,	O
and	O
final	O
fixation	O
of	O
the	O
genotoxic	O
damage	O
to	O
cause	O
mutation	O
.	O

The	O
resulting	O
somatic	O
mutation	O
in	O
a	O
damaged	O
cell	O
can	O
be	O
reproduced	O
during	O
mitosis	O
,	O
which	O
gives	O
rise	O
to	O
a	O
clone	O
of	O
mutated	O
cells	O
.	O

Promotion	O
is	O
expansion	O
of	O
the	O
damaged	O
cells	O
to	O
form	O
an	O
actively	O
proliferating	O
multi	O
-	O
cellular	O
premalignant	O
tumor	O
cell	O
population	O
.	O

Progression	O
is	O
the	O
irreversible	O
process	O
which	O
produces	O
a	O
new	O
clone	O
of	O
tumor	O
cells	O
with	O
increased	O
proliferative	O
capacity	O
,	O
invasiveness	O
,	O
and	O
metastatic	O
potential	O
.	O

Conventional	O
classification	O
of	O
chemopreventive	O
agents	O
,	O
first	O
proposed	O
by	O
Wattenberg	O
[	O
5	O
]	O
,	O
is	O
based	O
on	O
the	O
underlying	O
mechanisms	O
by	O
which	O
they	O
exert	O
protective	O
effects	O
in	O
a	O
specific	O
stage	O
of	O
multi	O
-	O
step	O
carcinogenesis	O
.	O

According	O
to	O
this	O
system	O
,	O
chemopreventers	O
are	O
subdivided	O
into	O
two	O
major	O
categories	O
,	O
i.e.	O
,	O
blocking	O
agents	O
and	O
suppressing	O
agents	O
(	O
Fig.	O
2	O
)	O
.	O

Blocking	O
agents	O
are	O
typically	O
those	O
compounds	O
that	O
can	O
inhibit	O
initiation	O
either	O
by	O
inhibiting	O
the	O
formation	O
of	O
carcinogens	O
from	O
precursor	O
molecules	O
or	O
reactive	O
metabolites	O
from	O
the	O
parent	O
carcinogens	O
,	O
or	O
by	O
preventing	O
the	O
ultimate	O
electrophilic	O
and	O
carcinogenic	O
species	O
from	O
interacting	O
with	O
critical	O
cellular	O
target	O
molecules	O
,	O
such	O
as	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
.	O

Suppressing	O
agents	O
are	O
considered	O
to	O
inhibit	O
malignant	O
expression	O
of	O
initiated	O
cells	O
,	O
in	O
either	O
the	O
promotion	O
or	O
the	O
progression	O
stage	O
.	O

Certain	O
chemopreventive	O
agents	O
(	O
e.g.	O
,	O
curcumin	O
and	O
resveratrol	O
)	O
have	O
more	O
than	O
one	O
defined	O
mechanism	O
of	O
action	O
,	O
and	O
hence	O
,	O
possess	O
both	O
blocking	O
and	O
suppressive	O
properties	O
[	O
6	O
]	O
.	O

A	O
vast	O
variety	O
of	O
chemical	O
compounds	O
have	O
been	O
identified	O
to	O
elicit	O
pronounced	O
chemopreventive	O
effects	O
and	O
many	O
of	O
them	O
are	O
of	O
plant	B
origin	O
that	O
are	O
present	O
naturally	O
in	O
our	O
daily	O
foods	O
or	O
have	O
been	O
used	O
for	O
traditional	O
herbal	B
medication	O
[	O
7–9	O
]	O
.	O

Some	O
spices	B
or	O
herbs	B
contain	O
bioactive	O
phenolic	O
substances	O
with	O
potent	O
antimutagenic	O
and	O
anticarcinogenic	O
properties	O
.	O

3	O
Some	O
novel	O
strategies	O
applicable	O
for	O
identifying	O
chemopreventive	O
phytochemicals	O
Numerous	O
phenolic	O
substances	O
present	O
in	O
fruits	B
and	O
vegetables	B
or	O
in	O
medicinal	O
plants	B
have	O
been	O
found	O
to	O
retain	O
potential	O
cancer	O
chemopreventive	O
activities	O
.	O

For	O
most	O
of	O
known	O
chemopreventive	O
phytochemicals	O
,	O
however	O
,	O
their	O
protective	O
effects	O
are	O
based	O
solely	O
on	O
the	O
results	O
from	O
animal	B
tests	O
.	O

Unfortunately	O
,	O
however	O
,	O
the	O
predictive	O
capability	O
of	O
the	O
majority	O
of	O
animal	B
model	O
studies	O
in	O
the	O
evaluation	O
of	O
cancer	O
chemopreventive	O
agents	O
for	O
use	O
in	O
humans	B
is	O
uncertain	O
and	O
often	O
limited	O
.	O

The	O
efficacy	O
,	O
as	O
well	O
as	O
the	O
safety	O
of	O
selected	O
phytochemicals	O
with	O
promising	O
chemopreventive	O
potential	O
should	O
be	O
validated	O
through	O
properly	O
-	O
designed	O
and	O
well	O
-	O
controlled	O
clinical	O
intervention	O
trials	O
.	O

The	O
use	O
of	O
a	O
reliable	O
biomarker	O
as	O
an	O
early	O
surrogate	O
endpoint	O
is	O
pivotal	O
in	O
conducting	O
prospective	O
chemopreventive	O
trials	O
.	O

There	O
have	O
been	O
extensive	O
studies	O
conducted	O
during	O
the	O
past	O
two	O
decades	O
to	O
search	O
for	O
potential	O
naturally	O
occurring	O
cancer	O
chemopreventive	O
agents	O
and	O
some	O
of	O
them	O
hold	O
promise	O
for	O
human	B
use	O
.	O

Antioxidant	O
vitamins	O
or	O
their	O
synthetic	O
derivatives	O
have	O
been	O
frequently	O
investigated	O
for	O
their	O
possible	O
chemopreventive	O
efficacy	O
among	O
normal	O
or	O
high	O
risk	O
(	O
e.g.	O
,	O
smokers	O
,	O
asbestos	O
workers	O
,	O
etc	O
.	O
)	O
populations	O
.	O

While	O
there	O
has	O
been	O
substantial	O
body	O
of	O
evidence	O
from	O
both	O
experimental	O
and	O
epidemiologic	O
studies	O
supporting	O
the	O
beneficial	O
effects	O
of	O
fruits	B
and	O
vegetables	B
,	O
which	O
are	O
good	O
sources	O
of	O
antioxidant	O
vitamins	O
,	O
the	O
chemopreventive	O
effects	O
of	O
dietary	O
supplementation	O
of	O
individual	O
vitamins	O
or	O
their	O
mixtures	O
remain	O
controversial	O
at	O
the	O
present	O
time	O
.	O

We	O
have	O
lessons	O
from	O
the	O
large	O
-	O
scale	O
randomized	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
Alpha	O
-	O
Tocopherol	O
,	O
Beta	O
-	O
Carotene	O
(	O
ATBC	O
)	O
Cancer	O
Prevention	O
Study	O
that	O
was	O
conducted	O
with	O
about	O
30,000	O
Finnish	O
male	B
smokers	I
under	O
the	O
joint	O
sponsorship	O
of	O
the	O
US	O
National	O
Cancer	O
Institute	O
and	O
the	O
National	O
Public	O
Health	O
Institute	O
in	O
Finland	O
.	O

In	O
this	O
particular	O
trial	O
,	O
a	O
daily	O
intake	O
of	O
20	O
mg	O
of	O
beta	O
-	O
carotene	O
was	O
not	O
protective	O
against	O
lung	O
cancer	O
.	O

On	O
the	O
contrary	O
,	O
the	O
cumulative	O
incidence	O
and	O
the	O
mortality	O
of	O
lung	O
cancer	O
increased	O
,	O
compared	O
with	O
those	O
observed	O
among	O
people	O
in	O
the	O
placebo	O
control	O
group	O
[	O
10	O
]	O
.	O

The	O
results	O
of	O
this	O
study	O
were	O
contradictory	O
to	O
the	O
beneficial	O
effects	O
of	O
beta	O
-	O
carotene	O
demonstrated	O
in	O
the	O
previous	O
intervention	O
trials	O
,	O
as	O
well	O
as	O
laboratory	O
studies	O
.	O

Nonetheless	O
,	O
the	O
unexpected	O
negative	O
finding	O
in	O
the	O
ATBC	O
study	O
is	O
not	O
surprising	O
and	O
may	O
not	O
be	O
fortuitous	O
.	O

Since	O
the	O
subjects	O
who	O
participated	O
in	O
this	O
study	O
were	O
relatively	O
old	O
(	O
50	O
to	O
69	O
years	O
of	O
age	O
)	O
with	O
a	O
smoking	O
habit	O
,	O
it	O
seems	O
likely	O
that	O
the	O
majority	O
of	O
them	O
already	O
had	O
mutated	O
genes	O
(	O
e.g.	O
,	O
p53	O
tumor	O
-	O
suppressor	O
or	O
ras	O
-oncogenes	O
)	O
or	O
premalignant	O
lesions	O
before	O
starting	O
beta	O
-	O
carotene	O
supplementation	O
,	O
as	O
a	O
result	O
of	O
cigarette	O
smoking	O
.	O

If	O
it	O
is	O
the	O
case	O
,	O
one	O
may	O
not	O
expect	O
the	O
beneficial	O
effects	O
of	O
beta	O
-	O
carotene	O
that	O
is	O
most	O
active	O
in	O
early	O
stages	O
of	O
carcinogenesis	O
.	O

Excess	O
amount	O
of	O
beta	O
-	O
carotene	O
might	O
have	O
met	O
the	O
substantial	O
growth	O
requirement	O
of	O
rapidly	O
proliferating	O
cancerous	O
cells	O
,	O
thereby	O
stimulating	O
their	O
growth	O
rather	O
than	O
suppressing	O
it	O
.	O

In	O
support	O
of	O
this	O
assumption	O
,	O
post	O
-	O
initiation	O
application	O
of	O
this	O
compound	O
stimulated	O
the	O
mammary	O
carcinogenesis	O
in	O
rodents	B
[	O
11	O
]	O
.	O

Similarly	O
,	O
dietary	O
supplementation	O
of	O
beta	O
-	O
carotene	O
enhanced	O
the	O
development	O
of	O
papillomas	O
in	O
mice	O
[	O
12	O
]	O
,	O
probably	O
via	O
stimulation	O
of	O
the	O
promotion	O
of	O
carcinogenesis	O
.	O

Besides	O
antioxidative	O
vitamins	O
,	O
fruits	B
and	O
vegetables	B
contain	O
countless	O
phytochemicals	O
of	O
less	O
nutritional	O
value	O
but	O
with	O
substantial	O
chemopreventive	O
potential	O
.	O

However	O
,	O
few	O
population	O
-	O
based	O
chemoprevention	O
trials	O
with	O
non	O
-	O
vitamin	O
phytochemicals	O
have	O
been	O
conducted	O
.	O

Rational	O
and	O
successful	O
implementation	O
of	O
chemopreventive	O
strategies	O
rely	O
on	O
the	O
precise	O
understanding	O
of	O
underlying	O
molecular	O
mechanisms	O
.	O

Alterations	O
of	O
carcinogen	O
metabolism	O
and	O
subsequent	O
DNA	O
adduction	O
may	O
represent	O
an	O
important	O
mechanism	O
by	O
which	O
a	O
given	O
phytochemical	O
modulates	O
chemically	O
-	O
induced	O
carcinogenesis	O
in	O
the	O
initiation	O
stage	O
.	O

Modulation	O
of	O
carcinogen	O
metabolism	O
is	O
often	O
considered	O
by	O
many	O
investigators	O
as	O
a	O
mechanistic	O
basis	O
for	O
protective	O
effects	O
of	O
many	O
types	O
of	O
chemopreventive	O
phytochemicals	O
.	O

However	O
,	O
carcinogen	O
-	O
metabolizing	O
enzymes	O
in	O
general	O
have	O
dual	O
roles	O
and	O
preventive	O
modulation	O
of	O
metabolism	O
,	O
i.e.	O
,	O
suppression	O
of	O
activation	O
or	O
acceleration	O
of	O
detoxification	O
of	O
one	O
carcinogen	O
,	O
may	O
alter	O
the	O
fate	O
of	O
other	O
xenobiotics	O
and	O
endogenous	O
compounds	O
[	O
13–15	O
]	O
,	O
which	O
may	O
limit	O
its	O
utilization	O
as	O
a	O
criterion	O
in	O
identifying	O
or	O
defining	O
new	O
chemopreventive	O
agents	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
initiation	O
is	O
unlikely	O
to	O
be	O
a	O
practical	O
approach	O
to	O
chemoprevention	O
,	O
since	O
there	O
are	O
diverse	O
types	O
of	O
initiators	O
present	O
in	O
our	O
environment	O
and	O
it	O
is	O
not	O
feasible	O
to	O
find	O
a	O
chemopreventive	O
agent	O
that	O
can	O
nullify	O
the	O
initiating	O
activities	O
of	O
all	O
the	O
carcinogens	O
to	O
which	O
we	O
are	O
exposed	O
.	O

Therefore	O
,	O
recent	O
chemopreventive	O
strategies	O
are	O
more	O
concerned	O
with	O
identifying	O
substances	O
with	O
antiproliferative	O
or	O
antiprogressive	O
activities	O
that	O
can	O
suppress	O
the	O
transformation	O
of	O
initiated	O
or	O
precancerous	O
cells	O
to	O
malignant	O
ones	O
,	O
rather	O
than	O
search	O
for	O
anti	O
-	O
initiators	O
.	O

Chemopreventive	O
agents	O
that	O
fall	O
into	O
this	O
category	O
include	O
modulators	O
of	O
signal	O
transduction	O
,	O
inhibitors	O
of	O
oncogene	O
activation	O
,	O
inhibitors	O
of	O
polyamine	O
metabolism	O
,	O
enhancers	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
,	O
inhibitors	O
of	O
angiogenesis	O
,	O
etc	O
.	O

[	O
16	O
]	O
.	O

Recently	O
,	O
considerable	O
attention	O
has	O
been	O
focused	O
on	O
dietary	O
and/or	O
pharmacological	O
manipulation	O
of	O
apoptosis	O
as	O
a	O
novel	O
and	O
promising	O
strategy	O
for	O
cancer	O
chemoprevention	O
,	O
as	O
well	O
as	O
therapy	O
[	O
17–19	O
]	O
.	O

The	O
maintenance	O
of	O
homeostasis	O
in	O
normal	O
mammalian	B
tissues	O
reflects	O
a	O
critical	O
balance	O
between	O
cell	O
proliferation	O
and	O
cell	O
death	O
via	O
apoptosis	O
.	O

In	O
contrast	O
,	O
apoptosis	O
may	O
be	O
inhibited	O
or	O
perturbed	O
in	O
tumors	O
in	O
which	O
the	O
rate	O
of	O
cell	O
proliferation	O
exceeds	O
that	O
of	O
cell	O
loss	O
.	O

If	O
misregulation	O
of	O
apoptosis	O
results	O
in	O
a	O
failure	O
of	O
tissue	O
size	O
regulation	O
,	O
which	O
eventually	O
leads	O
to	O
the	O
malignant	O
transformation	O
,	O
apoptotic	O
cell	O
death	O
could	O
be	O
induced	O
to	O
augment	O
interventions	O
designed	O
to	O
suppress	O
or	O
reverse	O
the	O
development	O
of	O
cancer	O
.	O

Indeed	O
,	O
various	O
chemopreventive	O
and	O
chemotherapeutic	O
agents	O
are	O
now	O
known	O
to	O
exert	O
their	O
antiproliferative	O
or	O
cytostatic	O
effects	O
by	O
inducing	O
apoptosis	O
in	O
(	O
pre	O
)	O
malignant	O
cells	O
[	O
17–23	O
]	O
.	O

Selected	O
chemopreventive	O
vitamins	O
or	O
phytochemicals	O
have	O
the	O
propensity	O
to	O
suppress	O
or	O
retard	O
the	O
growth	O
of	O
cancer	O
cells	O
in	O
this	O
way	O
[	O
[	O
17	O
,	O
24	O
,	O
25	O
]	O
,	O
and	O
more	O
examples	O
in	O
this	O
review	O
]	O
.	O

Suppression	O
of	O
prostaglandin	O
synthesis	O
through	O
selective	O
inhibition	O
of	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
is	O
another	O
promising	O
strategy	O
applicable	O
to	O
identification	O
and	O
development	O
of	O
chemopreventive	O
drugs	O
.	O

Prostaglandins	O
are	O
known	O
to	O
play	O
crucial	O
roles	O
in	O
pathogenesis	O
of	O
malignancy	O
,	O
particularly	O
in	O
colon	O
carcinogenesis	O
and	O
certain	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
such	O
as	O
aspirin	O
,	O
piroxicam	O
,	O
and	O
sulindac	O
,	O
have	O
protective	O
effects	O
on	O
experimental	O
carcinogenesis	O
[	O
26	O
,	O
27	O
]	O
.	O

Furthermore	O
,	O
epidemiologic	O
data	O
indicate	O
a	O
reduced	O
risk	O
of	O
colorectal	O
cancer	O
among	O
individuals	O
who	O
intake	O
aspirin	O
or	O
other	O
NSAIDs	O
on	O
a	O
regular	O
basis	O
[	O
28	O
]	O
.	O

Moreover	O
,	O
in	O
patients	B
with	O
familial	O
adenomatous	O
polyposis	O
,	O
the	O
NSAID	O
sulindac	O
caused	O
marked	O
regression	O
of	O
polyps	O
and	O
prevented	O
their	O
recurrence	O
[	O
29	O
]	O
.	O

Selected	O
NSAIDs	O
have	O
been	O
reported	O
to	O
suppress	O
growth	O
and	O
proliferation	O
of	O
cancer	O
cells	O
by	O
inducing	O
apoptosis	O
[	O
30–32	O
]	O
.	O

Some	O
phenolic	O
substances	O
derived	O
from	O
Zingiberaceae	B
(	O
ginger	B
family	O
)	O
plants	O
have	O
potent	O
anti	O
-	O
inflammatory	O
activity	O
and	O
induce	O
apoptosis	O
in	O
human	B
cancer	O
cell	O
lines	O
[	O
[	O
33–36	O
]	O
;	O
vide	O
infra	O
]	O
.	O

4	O
Selected	O
chemopreventive	O
dietary	O
and/or	O
medicinal	O
phenolic	O
substances	O
4.1	O
Capsaicin	O
Capsaicin	O
(	O
trans	O
-8-methyl	O
-	O
N	O
-vanillyl-6-nonenamide	O
;	O
structure	O
shown	O
in	O
Fig.	O
3	O
)	O
is	O
a	O
principal	O
pungent	O
ingredient	O
present	O
in	O
hot	O
red	B
and	O
chili	B
peppers	I
that	O
belong	O
to	O
the	O
plant	O
genus	O
Capsicum	B
(	O
Solanaceae	B
)	O
.	O

The	O
compound	O
has	O
been	O
tested	O
by	O
many	O
investigators	O
for	O
its	O
effects	O
on	O
experimental	O
carcinogenesis	O
and	O
mutagenesis	O
[	O
for	O
review	O
,	O
see	O
Refs	O
.	O

[	O
37	O
,	O
38	O
]	O
and	O
references	O
therein	O
]	O
.	O

Data	O
in	O
the	O
literature	O
indicate	O
that	O
capsaicin	O
has	O
a	O
dual	O
role	O
in	O
carcinogenic	O
and	O
mutagenic	O
processes	O
and	O
its	O
effects	O
in	O
some	O
degree	O
relies	O
on	O
the	O
doses	O
,	O
routes	O
of	O
administration	O
,	O
and	O
types	O
of	O
tissues	O
affected	O
.	O

Although	O
the	O
previous	O
studies	O
were	O
mainly	O
focused	O
on	O
evaluation	O
of	O
carcinogenic	O
or	O
co	O
-	O
carcinogenic	O
potential	O
of	O
capsaicin	O
in	O
hot	B
peppers	I
in	O
consideration	O
of	O
its	O
irritancy	O
,	O
the	O
compound	O
has	O
recently	O
been	O
reported	O
to	O
retain	O
protective	O
properties	O
against	O
experimental	O
carcinogenesis	O
and	O
mutagenesis	O
[	O
37	O
,	O
38	O
]	O
.	O

In	O
several	O
instances	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
capsaicin	O
modulates	O
microsomal	O
cytochrome	O
P	O
450-dependent	O
monooxygenase	O
activities	O
,	O
thereby	O
affecting	O
metabolism	O
of	O
carcinogens	O
and	O
other	O
xenobiotics	O
[	O
39–45	O
]	O
.	O

Capsaicin	O
was	O
found	O
to	O
interact	O
with	O
rat	B
hepatic	O
mixed	O
-	O
function	O
oxidases	O
as	O
revealed	O
by	O
prolongation	O
of	O
pentobarbital	O
or	O
hexobarbital	O
sleeping	O
time	O
[	O
39–41	O
]	O
and	O
inhibition	O
of	O
ethylmorphine	O
demethylase	O
activity	O
,	O
as	O
well	O
as	O
production	O
of	O
a	O
type	O
I	O
spectral	O
change	O
[	O
39	O
]	O
.	O

The	O
compound	O
also	O
suppresses	O
the	O
activity	O
of	O
rat	B
epidermal	O
aryl	O
hydrocarbon	O
hydroxylase	O
[	O
42	O
]	O
that	O
is	O
responsible	O
for	O
the	O
biotransformation	O
of	O
benzo	O
[	O
a	O
]	O
pyrene	O
and	O
other	O
polyaromatic	O
hydrocarbons	O
.	O

Metabolism	O
and	O
subsequent	O
covalent	O
DNA	O
binding	O
of	O
benzo	O
[	O
a	O
]	O
pyrene	O
in	O
human	B
and	O
murine	B
keratinocytes	O
were	O
attenuated	O
by	O
capsaicin	O
[	O
42	O
]	O
.	O

Taken	O
together	O
,	O
the	O
above	O
findings	O
suggest	O
that	O
capsaicin	O
can	O
influence	O
the	O
initiating	O
activities	O
of	O
certain	O
chemical	O
carcinogens	O
through	O
modulation	O
of	O
their	O
metabolic	O
activation	O
and/or	O
detoxification	O
.	O

Benzo	O
[	O
a	O
]	O
pyrene	O
-	O
induced	O
pulmonary	O
tumor	O
in	O
mice	B
was	O
inhibited	O
by	O
capsaicin	O
treatment	O
[	O
43	O
]	O
.	O

Capsaicin	O
displayed	O
inhibitory	O
effects	O
on	O
metabolism	O
,	O
mutagenicity	O
and/or	O
covalent	O
DNA	O
binding	O
of	O
aflatoxin	O
B1	O
[	O
44	O
]	O
and	O
the	O
tobacco	B
-	O
specific	O
nitrosamine	O
,	O
4-	O
(	O
methylnitrosamino	O
)	O
-1-	O
(	O
3-pyridyl	O
)	O
-1-butanone	O
(	O
NNK	O
)	O
[	O
45–47	O
]	O
.	O

Capsaicin	O
and	O
its	O
saturated	O
analog	O
dihydrocapsaicin	O
(	O
Fig.	O
3	O
for	O
chemical	O
structures	O
)	O
have	O
been	O
shown	O
to	O
inhibit	O
cytochrome	O
P	O
450	O
2E1	O
[	O
48	O
,	O
49	O
]	O
,	O
an	O
isoform	O
that	O
catalyzes	O
metabolic	O
activation	O
,	O
as	O
well	O
as	O
detoxification	O
of	O
many	O
low	O
molecular	O
weight	O
carcinogens	O
.	O

In	O
agreement	O
with	O
these	O
findings	O
,	O
both	O
compounds	O
inhibited	O
the	O
mutagenicity	O
and/or	O
tumorigenicity	O
of	O
vinyl	O
carbamate	O
and	O
dimethylnitrosamine	O
[	O
49	O
]	O
,	O
which	O
are	O
preferentially	O
activated	O
by	O
cytochrome	O
P	O
450	O
2E1	O
.	O

In	O
another	O
study	O
,	O
capsaicin	O
ameliorated	O
the	O
peroxidative	O
changes	O
in	O
rat	B
hepatic	O
and	O
pulmonary	O
tissues	O
induced	O
by	O
chloroform	O
,	O
carbon	O
tetrachloride	O
,	O
or	O
dichloromethane	O
[	O
50	O
]	O
.	O

Cytochrome	O
P	O
450	O
2E1	O
again	O
plays	O
a	O
role	O
in	O
activation	O
of	O
these	O
halogenated	O
hydrocarbons	O
.	O

Capsaicin	O
pretreatment	O
also	O
protects	O
against	O
the	O
free	O
radical	O
-	O
induced	O
pulmonary	O
damage	O
in	O
rats	B
exposed	O
to	O
such	O
gaseous	O
chemical	O
irritants	O
as	O
sulfur	O
dioxide	O
and	O
nitrogen	O
dioxide	O
[	O
51	O
]	O
.	O

It	O
has	O
been	O
reported	O
that	O
intraperitoneal	O
administration	O
of	O
capsaicin	O
attenuates	O
cyclophosphamide	O
-	O
induced	O
chromosomal	O
aberrations	O
and	O
DNA	O
breaks	O
in	O
mice	B
[	O
52	O
]	O
.	O

Although	O
topical	O
application	O
of	O
capsaicin	O
can	O
initially	O
induce	O
ear	O
edema	O
in	O
mice	B
[	O
53	O
]	O
,	O
subsequent	O
reapplications	O
of	O
the	O
compound	O
suppressed	O
the	O
inflammatory	O
response	O
[	O
54	O
]	O
.	O

Carrageenan	O
-	O
induced	O
inflammation	O
in	O
rats	B
was	O
also	O
ameliorated	O
by	O
capsaicin	O
treatment	O
[	O
55	O
]	O
.	O

Furthermore	O
,	O
capsaicin	O
was	O
found	O
to	O
inhibit	O
platelet	O
aggregation	O
[	O
56–58	O
]	O
.	O

Another	O
study	O
,	O
however	O
,	O
has	O
demonstrated	O
the	O
stimulation	O
of	O
prostaglandin	O
biosynthesis	O
by	O
capsaicin	O
[	O
59	O
]	O
.	O

The	O
observed	O
antiplatelet	O
or	O
anti	O
-	O
inflammatory	O
effects	O
of	O
capsaicin	O
appears	O
to	O
be	O
associated	O
with	O
its	O
interference	O
with	O
phospholipase	O
A2	O
[	O
60	O
]	O
,	O
a	O
key	O
enzyme	O
mediating	O
the	O
inflammatory	O
process	O
.	O

Since	O
tumor	O
promotion	O
is	O
related	O
to	O
inflammation	O
which	O
can	O
stimulate	O
the	O
proliferation	O
of	O
initiated	O
cells	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
determine	O
if	O
capsaicin	O
could	O
act	O
as	O
an	O
anti	O
-	O
tumor	O
promoting	O
agent	O
.	O

Capsaicin	O
was	O
found	O
to	O
antagonize	O
the	O
mouse	O
ear	O
edema	O
induced	O
by	O
croton	O
oil	O
[	O
61	O
]	O
,	O
lending	O
further	O
support	O
to	O
the	O
above	O
idea	O
.	O

Our	O
preliminary	O
study	O
indicates	O
that	O
topical	O
application	O
of	O
capsaicin	O
along	O
with	O
phorbol	O
ester	O
onto	O
shaven	O
backs	O
of	O
ICR	B
mice	I
,	O
after	O
initiation	O
with	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
,	O
transiently	O
increased	O
the	O
skin	O
tumor	O
formation	O
,	O
but	O
the	O
overall	O
papillomagenesis	O
did	O
not	O
increase	O
[	O
62	O
]	O
.	O

Apparently	O
,	O
some	O
of	O
the	O
tumors	O
became	O
slightly	O
regressed	O
after	O
12	O
weeks	O
of	O
post	O
-	O
initiation	O
.	O

Epithelial	O
thickening	O
and	O
appearance	O
of	O
atypical	O
cells	O
caused	O
by	O
combination	O
of	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
and	O
phorbol	O
ester	O
were	O
also	O
reduced	O
by	O
capsaicin	O
treatment	O
.	O

According	O
to	O
a	O
recent	O
study	O
by	O
Morre	O
et	O
al.	O
[	O
63	O
]	O
,	O
capsaicin	O
preferentially	O
repressed	O
the	O
growth	O
of	O
some	O
transformed	O
cells	O
of	O
human	B
origin	O
,	O
including	O
HeLa	O
,	O
ovarian	O
carcinoma	O
,	O
mammary	O
adenocarcinoma	O
,	O
and	O
promyelocytic	O
leukemia	O
(	O
HL-60	O
)	O
cells	O
in	O
culture	O
.	O

The	O
inhibition	O
of	O
cell	O
survival	O
was	O
associated	O
with	O
induction	O
of	O
apoptosis	O
as	O
revealed	O
by	O
characteristic	O
morphological	O
changes	O
and	O
appearance	O
of	O
fragmented	O
nuclear	O
DNA	O
[	O
63	O
]	O
.	O

The	O
capsaicin	O
-	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
the	O
aforementioned	O
cells	O
were	O
correlated	O
with	O
inhibition	O
of	O
plasma	O
membrane	O
NADH	O
oxidase	O
activity	O
[	O
63	O
]	O
.	O

The	O
same	O
investigators	O
have	O
subsequently	O
observed	O
the	O
similar	O
findings	O
with	O
human	B
and	O
mouse	B
melanoma	O
cell	O
lines	O
in	O
terms	O
of	O
growth	O
inhibition	O
,	O
apoptosis	O
induction	O
,	O
and	O
inhibition	O
of	O
plasma	O
membrane	O
NADH	O
oxidase	O
[	O
64	O
]	O
.	O

Interestingly	O
,	O
direct	O
injection	O
of	O
capsaicin	O
into	O
the	O
B16	B
mouse	I
melanoma	O
transplanted	O
in	O
C57BL	B
/	I
6	I
mice	I
significantly	O
blunted	O
the	O
growth	O
of	O
tumors	O
[	O
64	O
]	O
.	O

Capsaicin	O
-	O
induced	O
apoptosis	O
has	O
been	O
suggested	O
to	O
be	O
regulated	O
by	O
Bcl-2	O
and	O
the	O
protein	O
phosphatase	O
,	O
calcineurin	O
[	O
65	O
]	O
.	O

In	O
another	O
study	O
,	O
capsaicin	O
-	O
induced	O
apoptotic	O
death	O
of	O
cultured	O
human	B
gastric	O
cancer	O
cells	O
,	O
which	O
appeared	O
to	O
be	O
mediated	O
via	O
overexpression	O
of	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
and/or	O
c	O
-	O
myc	O
proto	O
-	O
oncogene	O
[	O
66	O
]	O
.	O

One	O
of	O
the	O
important	O
cellular	O
mediators	O
of	O
cellular	O
processes	O
in	O
response	O
to	O
diversified	O
extracellular	O
stimuli	O
including	O
oxidants	O
,	O
UV	O
,	O
mitogens	O
,	O
cytokines	O
,	O
viruses	O
,	O
tumor	O
necrosis	O
factor	O
-	O
α	O
(	O
TNF	O
-	O
α	O
)	O
,	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
etc	O
.	O
is	O
a	O
nuclear	O
transcription	O
factor	O
NF	O
-	O
κB	O
[	O
67–71	O
]	O
.	O

Upon	O
activation	O
by	O
external	O
signals	O
,	O
NF	O
-	O
κB	O
is	O
migrated	O
to	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
a	O
specific	O
segment	O
of	O
DNA	O
,	O
thereby	O
triggering	O
expression	O
of	O
a	O
variety	O
of	O
rapid	O
-	O
response	O
genes	O
involved	O
in	O
some	O
important	O
physiological	O
reactions	O
,	O
such	O
as	O
inflammation	O
,	O
cell	O
adhesion	O
,	O
viral	O
replication	O
,	O
immune	O
response	O
,	O
and	O
proliferation	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
has	O
been	O
suggested	O
as	O
a	O
second	O
messenger	O
in	O
a	O
signal	O
transduction	O
pathway	O
for	O
activation	O
of	O
NF	O
-	O
κB	O
[	O
72	O
,	O
73	O
]	O
.	O

According	O
to	O
the	O
study	O
of	O
Singh	O
et	O
al.	O
[	O
74	O
]	O
,	O
capsaicin	O
abrogates	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
by	O
TPA	O
,	O
as	O
well	O
as	O
by	O
TNF	O
-	O
α	O
,	O
which	O
may	O
provide	O
a	O
mechanistic	O
basis	O
for	O
the	O
possible	O
anti	O
-	O
tumor	O
promoting	O
activity	O
of	O
capsaicin	O
.	O

Another	O
eukaryotic	O
transcription	O
factor	O
that	O
is	O
responsive	O
to	O
ROS	O
and	O
is	O
hence	O
,	O
regulated	O
by	O
cellular	O
redox	O
status	O
is	O
activator	O
protein	O
1	O
(	O
AP-1	O
)	O
[	O
67	O
]	O
.	O

The	O
regulation	O
of	O
AP-1	O
in	O
response	O
to	O
external	O
stimuli	O
is	O
considered	O
to	O
be	O
mediated	O
by	O
members	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
family	O
,	O
among	O
which	O
c	O
-	O
jun	O
-N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
;	O
also	O
known	O
as	O
stress	O
-	O
activated	O
protein	O
kinase	O
abbreviated	O
as	O
SAPK	O
)	O
and	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
isoforms	O
are	O
best	O
characterized	O
.	O

There	O
is	O
some	O
evidence	O
that	O
JNK	O
and	O
ERK	O
exert	O
opposite	O
effects	O
on	O
apoptosis	O
[	O
75	O
]	O
.	O

Capsaicin	O
induced	O
apoptosis	O
in	O
cultured	O
Jurkat	O
cells	O
through	O
generation	O
of	O
ROS	O
[	O
76	O
]	O
.	O

When	O
treated	O
to	O
these	O
cells	O
at	O
a	O
concentration	O
of	O
300	O
μM	O
,	O
capsaicin	O
rapidly	O
activated	O
JNK	O
:	O
the	O
activity	O
was	O
detectable	O
as	O
early	O
as	O
5	O
min	O
after	O
the	O
treatment	O
,	O
while	O
ERK	O
activity	O
was	O
not	O
affected	O
under	O
the	O
same	O
experimental	O
conditions	O
[	O
76	O
]	O
.	O

Despite	O
the	O
activation	O
of	O
JNK	O
by	O
capsaicin	O
,	O
there	O
was	O
no	O
induction	O
of	O
AP-1	O
activity	O
.	O

On	O
the	O
contrary	O
,	O
capsaicin	O
blocked	O
the	O
TPA	O
-	O
induced	O
AP-1	O
activation	O
[	O
76	O
]	O
.	O

The	O
latter	O
finding	O
,	O
together	O
with	O
the	O
previous	O
observation	O
by	O
Singh	O
et	O
al.	O
[	O
74	O
]	O
on	O
suppression	O
of	O
TPA	O
-	O
induced	O
NF	O
-	O
κB	O
activation	O
by	O
capsaicin	O
,	O
may	O
provide	O
important	O
molecular	O
basis	O
for	O
anti	O
-	O
tumor	O
promoting	O
potential	O
of	O
this	O
vanilloid	O
.	O

4.2	O
Gingerol	O
and	O
paradol	O
Ginger	B
(	O
Zingiber	B
officinale	I
Roscoe	I
,	O
Zingiberaceae	B
)	O
is	O
among	O
the	O
most	O
frequently	O
and	O
heavily	O
consumed	O
dietary	O
condiments	O
throughout	O
the	O
world	O
.	O

Besides	O
its	O
extensive	O
use	O
as	O
a	O
spice	O
,	O
the	O
rhizome	O
of	O
ginger	B
has	O
also	O
been	O
used	O
in	O
traditional	O
oriental	O
herbal	O
medicine	O
for	O
the	O
management	O
of	O
such	O
symptoms	O
as	O
common	O
cold	O
,	O
digestive	O
disorders	O
,	O
rheumatism	O
,	O
neurologia	O
,	O
colic	O
and	O
motion	O
-	O
sickness	O
.	O

The	O
oleoresin	O
from	O
rhizomes	O
of	O
ginger	B
contains	O
[	O
6	O
]	O
-gingerol	O
(	O
1-	O
[	O
4′-hydroxy-3′-methoxyphenyl	O
]	O
-5-hydroxy-3-decanone	O
)	O
and	O
its	O
homologs	O
as	O
pungent	O
ingredients	O
that	O
have	O
been	O
found	O
to	O
possess	O
many	O
interesting	O
pharmacological	O
and	O
physiological	O
activities	O
,	O
such	O
as	O
anti	O
-	O
inflammatory	O
,	O
analgesic	O
,	O
antipyretic	O
,	O
antihepatotoxic	O
,	O
and	O
cardiotonic	O
effects	O
[	O
77	O
,	O
78	O
]	O
.	O

The	O
chemical	O
structure	O
of	O
[	O
6	O
]	O
-gingerol	O
that	O
is	O
known	O
as	O
a	O
major	O
pungent	O
and	O
pharmacologically	O
active	O
principle	O
of	O
ginger	B
is	O
shown	O
in	O
Fig.	O
3	O
.	O

Gingerol	O
has	O
been	O
found	O
to	O
possess	O
substantial	O
antioxidant	O
activity	O
as	O
determined	O
by	O
inhibition	O
of	O
phospholipid	O
peroxidation	O
induced	O
by	O
the	O
FeCl3	O
–ascorbate	O
system	O
[	O
79	O
]	O
.	O

The	O
antioxidative	O
properties	O
of	O
gingerol	O
and	O
other	O
constituents	O
of	O
ginger	B
have	O
been	O
confirmed	O
in	O
various	O
in	O
vitro	O
and	O
in	O
vivo	O
test	O
systems	O
[	O
80	O
,	O
81	O
]	O
.	O

Gingerol	O
also	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
xanthine	O
oxidase	O
[	O
82	O
]	O
responsible	O
for	O
generation	O
of	O
superoxide	O
anion	O
.	O

Guh	O
et	O
al.	O
[	O
83	O
]	O
reported	O
concentration	O
-	O
dependent	O
inhibition	O
by	O
gingerol	O
of	O
arachidonic	O
acid	O
-	O
induced	O
platelet	O
aggregation	O
and	O
formation	O
of	O
thromboxane	O
B2	O
and	O
prostaglandin	O
D2	O
.	O

The	O
compound	O
also	O
completely	O
abolished	O
phosphoinositide	O
breakdown	O
induced	O
by	O
arachidonic	O
acid	O
.	O

Gingerol	O
,	O
shogaol	O
and	O
other	O
structurally	O
-	O
related	O
substances	O
in	O
ginger	B
inhibit	O
prostaglandin	O
and	O
leukotriene	O
biosynthesis	O
through	O
suppression	O
of	O
5-lipoxygenase	O
or	O
prostaglandin	O
synthetase	O
[	O
84–87	O
]	O
.	O

Since	O
tumor	O
promotion	O
is	O
closely	O
associated	O
with	O
inflammation	O
and	O
oxidative	O
stress	O
,	O
it	O
is	O
likely	O
that	O
a	O
compound	O
with	O
a	O
strong	O
inhibitory	O
effect	O
on	O
the	O
arachidonic	O
acid	O
metabolism	O
would	O
have	O
anti	O
-	O
tumor	O
promoting	O
potential	O
.	O

In	O
line	O
with	O
this	O
notion	O
,	O
our	O
recent	O
study	O
has	O
demonstrated	O
that	O
gingerol	O
protects	O
TPA	O
-	O
induced	O
ear	O
edema	O
,	O
epidermal	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
activity	O
,	O
and	O
skin	O
tumor	O
promotion	O
in	O
female	O
ICR	B
mice	I
[	O
88	O
]	O
.	O

Furthermore	O
,	O
topical	O
application	O
of	O
the	O
ginger	B
extract	O
30	O
min	O
prior	O
to	O
TPA	O
led	O
to	O
dramatic	O
protection	O
against	O
DMBA	O
-	O
initiated	O
skin	O
carcinogenesis	O
in	O
SENCAR	B
mice	I
[	O
89	O
]	O
and	O
suppressed	O
TPA	O
-	O
caused	O
induction	O
of	O
epidermal	O
ODC	O
and	O
its	O
mRNA	O
expression	O
,	O
as	O
well	O
as	O
cyclooxygenase	O
(	O
COX	O
)	O
and	O
lipoxygenase	O
activities	O
[	O
89	O
]	O
.	O

Azoxymethane	O
-	O
induced	O
intestinal	O
carcinogenesis	O
in	O
rats	B
was	O
significantly	O
suppressed	O
by	O
dietary	O
administration	O
of	O
gingerol	O
[	O
90	O
]	O
.	O

Gingerol	O
was	O
reported	O
as	O
one	O
of	O
the	O
most	O
active	O
constituents	O
contained	O
in	O
traditional	O
oriental	O
herbal	O
medication	O
,	O
`	O
Keishi	O
-	O
ka	O
-	O
kei	O
-	O
to	O
'	O
that	O
exhibited	O
substantial	O
inhibitory	O
effects	O
on	O
pulmonary	O
metastasis	O
in	O
mice	B
transplanted	O
with	O
B16F10	O
melanoma	O
cells	O
[	O
91	O
]	O
.	O

[	O
6	O
]	O
-Paradol	O
(	O
1-	O
[	O
4′-hydroxy-3′-methoxyphenyl	O
]	O
-3-decanone	O
;	O
Fig.	O
3	O
)	O
,	O
a	O
pungent	O
compound	O
isolated	O
from	O
the	O
seeds	O
of	O
Grains	B
of	I
Paradise	I
(	O
Aframomum	B
melegueta	I
Roscoe	I
,	O
Zingiberaceae	B
)	O
,	O
as	O
well	O
as	O
from	O
the	O
rhizome	O
of	O
ginger	B
,	O
also	O
attenuated	O
promotion	O
of	O
skin	O
carcinogenesis	O
and	O
TPA	O
-	O
induced	O
ear	O
edema	O
in	O
female	O
ICR	B
mice	I
[	O
92	O
]	O
.	O

Both	O
[	O
6	O
]	O
-gingerol	O
and	O
[	O
6	O
]	O
-paradol	O
induce	O
apoptosis	O
in	O
HL-60	O
cells	O
[	O
36	O
]	O
.	O

4.3	O
Curcumin	O
Curcumin	O
(	O
diferuloylmethane	O
;	O
Fig.	O
4	O
)	O
is	O
a	O
yellow	O
odorless	O
pigment	O
isolated	O
from	O
the	O
rhizome	O
of	O
turmeric	B
(	O
Curcuma	B
longa	I
L.	I
,	O
Zingiberaceae	B
)	O
.	O

Curcumin	O
possesses	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
[	O
93–102	O
]	O
.	O

This	O
yellow	O
-	O
coloured	O
compound	O
inhibits	O
mutagenicity	O
of	O
certain	O
chemical	O
carcinogens	O
[	O
103–105	O
]	O
and	O
also	O
hampers	O
their	O
covalent	O
DNA	O
binding	O
in	O
vivo	O
[	O
106	O
]	O
,	O
as	O
well	O
as	O
,	O
in	O
vitro	O
[	O
107	O
,	O
108	O
]	O
.	O

Curcumin	O
also	O
protected	O
against	O
chemically	O
-	O
induced	O
liver	O
damage	O
in	O
experimental	O
animals	B
[	O
109	O
,	O
110	O
]	O
.	O

Its	O
anticarcinogenic	O
activity	O
was	O
evaluated	O
in	O
many	O
animal	B
tumor	O
models	O
[	O
reviewed	O
in	O
Refs	O
.	O

[	O
111–113	O
]	O
]	O
.	O

One	O
of	O
the	O
most	O
prominent	O
effects	O
curcumin	O
exerts	O
on	O
experimental	O
carcinogenesis	O
is	O
its	O
capability	O
to	O
inhibit	O
tumor	O
promotion	O
[	O
113–116	O
]	O
.	O

Thus	O
,	O
curcumin	O
was	O
reported	O
to	O
alleviate	O
TPA	O
-	O
induced	O
skin	O
tumor	O
promotion	O
and	O
epidermal	O
ODC	O
mRNA	O
expression	O
[	O
115	O
]	O
,	O
as	O
well	O
as	O
,	O
ODC	O
activity	O
[	O
114	O
]	O
.	O

Topical	O
application	O
of	O
curcumin	O
onto	O
dorsal	O
skins	O
of	O
mice	O
significantly	O
inhibited	O
epidermal	O
COX	O
and	O
lipoxygenase	O
[	O
117	O
]	O
.	O

Colonic	O
mucosal	O
COX	O
and	O
lipoxygenase	O
activities	O
were	O
suppressed	O
by	O
dietary	O
curcumin	O
,	O
which	O
appears	O
to	O
account	O
for	O
its	O
chemopreventive	O
effects	O
on	O
colon	O
carcinogenesis	O
.	O

Likewise	O
,	O
F344	B
rats	I
fed	O
curcumin	O
in	O
the	O
diet	O
exhibited	O
reduced	O
catalytic	O
activities	O
of	O
phospholipase	O
A2	O
and	O
phospholipase	O
Cγ1	O
that	O
are	O
involved	O
in	O
arachidonic	O
acid	O
release	O
from	O
cellular	O
phospholipid	O
[	O
118	O
]	O
.	O

It	O
also	O
attenuates	O
oxidative	O
DNA	O
damage	O
in	O
mouse	B
epidermis	O
[	O
116	O
]	O
and	O
in	O
cultured	O
mouse	B
fibroblast	O
cells	O
[	O
119	O
]	O
.	O

The	O
compound	O
was	O
found	O
to	O
suppress	O
the	O
generation	O
of	O
ROS	O
including	O
superoxide	O
and	O
hydrogen	O
peroxide	O
in	O
peritoneal	O
macrophages	O
[	O
120	O
,	O
121	O
]	O
.	O

Its	O
antioxidant	O
effects	O
were	O
confirmed	O
in	O
various	O
systems	O
.	O

It	O
is	O
of	O
interest	O
to	O
note	O
that	O
tetrahydrocurcumin	O
,	O
that	O
is	O
one	O
of	O
the	O
plausible	O
metabolites	O
of	O
curcumin	O
,	O
exhibits	O
stronger	O
antioxidative	O
[	O
102	O
]	O
and	O
anti	O
-	O
inflammatory	O
[	O
97	O
]	O
activities	O
than	O
does	O
curcumin	O
.	O

Curcumin	O
inhibits	O
lipopolysaccharide-	O
and	O
interferon	O
-	O
γ	O
-	O
induced	O
production	O
of	O
nitric	O
oxide	O
in	O
macrophages	O
[	O
122	O
]	O
or	O
nitrite	O
in	O
mouse	B
peritoneal	O
cells	O
[	O
123	O
]	O
,	O
possibly	O
by	O
suppression	O
of	O
nitric	O
oxide	O
synthase	O
.	O

More	O
recently	O
,	O
Chan	O
et	O
al.	O
[	O
124	O
]	O
have	O
reported	O
the	O
inhibition	O
by	O
curcumin	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
expression	O
in	O
isolated	O
BALB	B
/	I
c	I
mouse	I
peritoneal	O
macrophages	O
and	O
also	O
in	O
the	O
livers	O
of	O
lipopolysaccharide	O
-	O
injected	O
mice	B
.	O

TPA	O
-	O
induced	O
protein	O
kinase	O
C	O
activation	O
and	O
c	O
-	O
jun	O
expression	O
were	O
markedly	O
suppressed	O
by	O
curcumin	O
in	O
mouse	B
fibroblast	O
cells	O
[	O
125	O
]	O
.	O

When	O
applied	O
topically	O
on	O
the	O
dorsal	O
side	O
of	O
mouse	B
skin	O
,	O
curcumin	O
significantly	O
inhibited	O
expression	O
of	O
such	O
proto	O
-	O
oncogenes	O
as	O
c	O
-	O
fos	O
,	O
c	O
-	O
jun	O
,	O
and	O
c	O
-	O
myc	O
[	O
126	O
]	O
.	O

Curcumin	O
also	O
exhibited	O
inhibitory	O
effects	O
on	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
receptor	O
kinase	O
activity	O
in	O
cultured	O
human	B
epidermoid	O
carcinoma	O
A431	O
[	O
127	O
]	O
or	O
NIH3T3	O
cells	O
[	O
128	O
]	O
.	O

Other	O
types	O
of	O
protein	O
kinases	O
were	O
also	O
found	O
to	O
be	O
inhibited	O
by	O
this	O
compound	O
in	O
a	O
non	O
-	O
competitive	O
manner	O
[	O
129	O
]	O
.	O

The	O
pleiotropic	O
effects	O
of	O
curcumin	O
appear	O
to	O
be	O
mediated	O
at	O
least	O
in	O
part	O
through	O
inhibition	O
of	O
transcription	O
factors	O
[	O
130	O
]	O
.	O

According	O
to	O
a	O
recent	O
study	O
by	O
Huang	O
et	O
al.	O
[	O
131	O
]	O
,	O
curcumin	O
suppresses	O
TPA	O
-	O
responsive	O
element	O
-	O
binding	O
activity	O
of	O
c	O
-	O
Jun	O
/	O
AP-1	O
,	O
which	O
may	O
account	O
for	O
the	O
anti	O
-	O
tumor	O
promoting	O
effect	O
of	O
this	O
chemopreventive	O
agent	O
.	O

More	O
recently	O
,	O
curcumin	O
has	O
been	O
reported	O
to	O
inhibit	O
TNF	O
-	O
α	O
-	O
induced	O
binding	O
of	O
AP-1	O
to	O
DNA	O
in	O
bovine	B
aortic	O
endothelial	O
cells	O
[	O
132	O
]	O
.	O

Besides	O
interfering	O
with	O
AP-1	O
activation	O
,	O
curcumin	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
activation	O
of	O
NF	O
-	O
κB	O
[	O
133	O
]	O
that	O
is	O
another	O
important	O
eukaryotic	O
transcription	O
factor	O
.	O

The	O
suppression	O
of	O
protein	O
kinases	O
,	O
ODC	O
,	O
and	O
nuclear	O
transcription	O
factors	O
by	O
curcumin	O
suggests	O
that	O
this	O
phenolic	O
compound	O
can	O
act	O
as	O
a	O
cytostatic	O
agent	O
by	O
interfering	O
with	O
certain	O
signal	O
transduction	O
pathways	O
that	O
are	O
critical	O
for	O
cell	O
growth	O
and	O
proliferation	O
.	O

Indeed	O
,	O
curcumin	O
possesses	O
antiproliferative	O
activity	O
[	O
134	O
,	O
135	O
]	O
and	O
the	O
capability	O
of	O
inducing	O
programmed	O
death	O
or	O
apoptosis	O
in	O
cancer	O
cells	O
[	O
34	O
,	O
35	O
]	O
.	O

Furthermore	O
,	O
curcumin	O
exhibited	O
synergistic	O
effects	O
on	O
induction	O
of	O
differentiation	O
in	O
HL-60	O
cells	O
when	O
combined	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
or	O
1α,25-dihydroxyvitamin	O
D3	O
[	O
113	O
]	O
.	O

It	O
also	O
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
farnesyl	O
protein	O
transferase	O
[	O
136	O
]	O
that	O
plays	O
a	O
crucial	O
role	O
in	O
functional	O
activation	O
of	O
Ras	O
protein	O
.	O

A	O
recent	O
study	O
by	O
Ciolino	O
et	O
al.	O
[	O
137	O
]	O
has	O
revealed	O
inhibition	O
of	O
cytochrome	O
P	O
450	O
1A1	O
activity	O
and	O
formation	O
of	O
carcinogen	O
-	O
DNA	O
adducts	O
in	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
-	O
treated	O
human	B
mammary	O
epithelial	O
carcinoma	O
(	O
MCF-7	O
)	O
cells	O
by	O
competitively	O
binding	O
to	O
the	O
aryl	O
hydrocarbon	O
receptor	O
.	O

Besides	O
preventing	O
malignant	O
transformation	O
,	O
the	O
compound	O
has	O
antimetastatic	O
potential	O
as	O
demonstrated	O
by	O
suppression	O
of	O
matrix	O
metalloproteinase-9	O
in	O
the	O
human	B
hepatocellular	O
carcinoma	O
cell	O
line	O
[	O
138	O
]	O
.	O

4.4	O
Diarylheptanoids	O
structurally	O
-	O
related	O
to	O
curcuminoids	O
Diarylheptanoids	O
structurally	O
-	O
related	O
to	O
curcumin	O
are	O
present	O
in	O
certain	O
plants	B
of	O
ginger	B
family	O
(	O
Zingiberaceae	B
)	O
and	O
have	O
been	O
reported	O
to	O
possess	O
a	O
strong	O
anti	O
-	O
inflammatory	O
activity	O
.	O

For	O
instance	O
,	O
yakuchinone	O
A	O
(	O
1-	O
[	O
4′-hydroxy-3′-methoxyphenyl	O
]	O
-7-phenyl-3-heptanone	O
)	O
and	O
yakuchinone	O
B	O
(	O
1-	O
[	O
4′-hydroxy-3′-methoxyphenyl	O
]	O
-7-phenylhept-1-en-3-one	O
)	O
which	O
are	O
present	O
in	O
Alpinia	B
oxyphylla	I
Miquel	I
have	O
been	O
reported	O
to	O
be	O
strong	O
inhibitors	O
of	O
prostaglandin	O
biosynthesis	O
in	O
vitro	O
[	O
85	O
,	O
87	O
]	O
.	O

Like	O
curcumin	O
,	O
these	O
substances	O
have	O
a	O
diarylheptanoid	O
moiety	O
with	O
a	O
carbonyl	O
functional	O
group	O
(	O
refer	O
to	O
the	O
structures	O
in	O
Fig.	O
4	O
)	O
and	O
are	O
hence	O
,	O
anticipated	O
to	O
exhibit	O
potential	O
cancer	O
chemopreventive	O
activities	O
.	O

Results	O
of	O
our	O
recent	O
study	O
showed	O
that	O
topical	O
application	O
of	O
the	O
methanol	O
extract	O
of	O
A.	B
oxyphylla	I
to	O
the	O
dorsal	O
epidermis	O
of	O
mice	B
during	O
the	O
process	O
of	O
tumor	O
promotion	O
markedly	O
suppressed	O
the	O
papilloma	O
formation	O
[	O
33	O
]	O
.	O

The	O
extract	O
also	O
attenuated	O
the	O
mouse	B
ear	O
edema	O
induced	O
by	O
the	O
tumor	O
promoter	O
,	O
TPA	O
[	O
33	O
]	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
yakuchinone	O
A	O
and	O
yakuchinone	O
B	O
,	O
major	O
pungent	O
ingredients	O
derived	O
from	O
A.	B
oxyphylla	I
,	O
can	O
act	O
as	O
anti	O
-	O
tumor	O
promoters	O
as	O
determined	O
by	O
their	O
ability	O
to	O
suppress	O
phorbol	O
ester	O
-	O
induced	O
ODC	O
activation	O
and	O
papilloma	O
formation	O
in	O
mouse	B
skin	O
[	O
139	O
,	O
140	O
]	O
.	O

TPA	O
-	O
stimulated	O
superoxide	O
generation	O
and	O
TNF	O
-	O
α	O
production	O
in	O
HL-60	O
cells	O
and	O
on	O
DNA	O
binding	O
of	O
AP-1	O
in	O
NIH3T3	O
cells	O
were	O
also	O
suppressed	O
by	O
the	O
above	O
compounds	O
[	O
139	O
,	O
140	O
]	O
.	O

Furthermore	O
,	O
both	O
yakuchinone	O
A	O
and	O
yakuchinone	O
B	O
induce	O
apoptotic	O
death	O
in	O
HL-60	O
cells	O
,	O
which	O
accounts	O
for	O
their	O
antiproliferative	O
activity	O
[	O
139	O
]	O
.	O

Phenolic	O
diarylheptanoids	O
from	O
Alpinia	B
officinarum	I
Hance	I
(	O
Zingiberaceae	B
)	O
,	O
structurally	O
analogous	O
to	O
yakuchinone	O
A	O
and	O
yakuchinone	O
B	O
,	O
and	O
non	O
-	O
phenolic	O
diarylheptanoids	O
present	O
in	O
a	O
Thai	O
medicinal	O
plant	O
,	O
Curcuma	B
xanthorrhiza	I
(	O
Zingiberaceae	B
)	O
,	O
also	O
exhibit	O
strong	O
anti	O
-	O
inflammatory	O
effects	O
[	O
86	O
,	O
141	O
]	O
.	O

Certain	O
diarylheptanoids	O
isolated	O
from	O
the	O
seeds	O
of	O
Alpinia	B
blepharocalyx	I
K.	I
Schum	I
mitigated	O
collagen-	O
,	O
arachidonic	O
acid-	O
and	O
adenosine	O
diphosphate	O
-	O
induced	O
platelet	O
aggregation	O
of	O
human	B
blood	O
[	O
142	O
]	O
and	O
suppressed	O
nitric	O
oxide	O
production	O
in	O
lipopolysaccharide	O
-	O
activated	O
murine	B
macrophages	O
in	O
vitro	O
[	O
143	O
]	O
.	O

Bioassay	O
-	O
directed	O
fractionation	O
of	O
the	O
ethanol	O
extract	O
of	O
Curcuma	B
zedoaria	I
(	O
Zingiberaceae	B
)	O
afforded	O
demethoxy-	O
and	O
bisdemethoxycurcumin	O
,	O
as	O
well	O
as	O
curcumin	O
,	O
which	O
were	O
cytotoxic	O
against	O
human	B
ovarian	O
cancer	O
cells	O
[	O
144	O
]	O
.	O

The	O
same	O
diarylheptanoids	O
were	O
also	O
found	O
in	O
C.	B
longa	I
L.	I
and	O
displayed	O
topoisomerase	O
I	O
and	O
II	O
inhibitory	O
activity	O
[	O
145	O
]	O
.	O

It	O
will	O
be	O
worthwhile	O
investigating	O
chemopreventive	O
effects	O
of	O
these	O
novel	O
diarylheptanoids	O
,	O
particularly	O
with	O
regard	O
to	O
their	O
anti	O
-	O
tumor	O
promotional	O
potential	O
.	O

4.5	O
Resveratrol	O
Resveratrol	O
(	O
3,5,4′-trihydroxy	O
-	O
trans	O
-stilbene	O
;	O
Fig.	O
5	O
)	O
,	O
a	O
phytoalexin	O
present	O
in	O
grapes	B
and	O
other	O
plants	B
,	O
has	O
potent	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
which	O
have	O
been	O
considered	O
to	O
be	O
responsible	O
for	O
beneficial	O
effects	O
of	O
red	O
wine	O
consumption	O
on	O
coronary	O
heart	O
disease	O
[	O
146–148	O
]	O
.	O

This	O
triphenolic	O
stilbene	O
has	O
been	O
suggested	O
as	O
a	O
potential	O
cancer	O
chemopreventive	O
agent	O
based	O
on	O
its	O
striking	O
inhibitory	O
effects	O
on	O
diverse	O
cellular	O
events	O
associated	O
with	O
tumor	O
initiation	O
,	O
promotion	O
,	O
and	O
progression	O
[	O
149	O
]	O
.	O

Resveratrol	O
has	O
been	O
reported	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
hepatic	O
cytochrome	O
P	O
450-linked	O
alkoxyresorufin	O
O	O
-dealkylase	O
activities	O
[	O
150	O
]	O
responsible	O
for	O
oxidative	O
metabolism	O
of	O
many	O
carcinogenic	O
polynuclear	O
aromatic	O
carcinogens	O
.	O

It	O
also	O
induces	O
phase-2	O
detoxification	O
enzymes	O
,	O
such	O
as	O
NAD	O
(	O
P	O
)	O
H	O
:	O
quinone	O
oxidoreductase	O
[	O
149	O
]	O
.	O

Recent	O
work	O
by	O
Uenobe	O
et	O
al.	O
[	O
151	O
]	O
demonstrated	O
an	O
antimutagenic	O
activity	O
of	O
resveratrol	O
against	O
the	O
foodborne	O
heterocyclic	O
amine	O
,	O
3-amino-1,4-dimethyl-5H	O
-	O
pyrido	O
[	O
4,3-b	O
]	O
indole	O
(	O
Trp	O
-	O
P-1	O
)	O
in	O
bacteria	B
.	O

Resveratrol	O
attenuated	O
PC12	O
cell	O
death	O
induced	O
by	O
ter	O
-butyl	O
hydroperoxide	O
in	O
the	O
presence	O
of	O
ferric	O
ion	O
[	O
152	O
]	O
or	O
by	O
ethanol	O
[	O
153	O
]	O
,	O
and	O
was	O
found	O
to	O
be	O
protective	O
against	O
cytotoxicity	O
and	O
NF	O
-	O
κB	O
activation	O
induced	O
by	O
oxidized	O
lipoproteins	O
in	O
PC12	O
cells	O
[	O
154	O
,	O
155	O
]	O
.	O

In	O
addition	O
,	O
the	O
compound	O
inhibited	O
growth	O
of	O
human	B
breast	O
epithelial	O
cells	O
in	O
culture	O
[	O
156	O
]	O
.	O

Proliferation	O
of	O
K-562	O
human	B
erythroleukemia	O
cells	O
and	O
P-815	O
murine	B
mastocytoma	O
cells	O
was	O
also	O
suppressed	O
by	O
resveratrol	O
treatment	O
,	O
which	O
might	O
be	O
associated	O
with	O
inhibition	O
of	O
ribonucleotide	O
reductase	O
[	O
157	O
]	O
.	O

One	O
of	O
the	O
plausible	O
mechanisms	O
that	O
could	O
account	O
for	O
the	O
chemopreventive	O
activity	O
of	O
resveratrol	O
is	O
suppression	O
of	O
prostaglandin	O
biosynthesis	O
catalyzed	O
COX	O
.	O

Prostaglandins	O
are	O
known	O
to	O
play	O
pivotal	O
roles	O
in	O
pathogenesis	O
of	O
malignancy	O
,	O
particularly	O
in	O
colon	O
and	O
mammary	O
carcinogenesis	O
and	O
suppression	O
of	O
prostaglandin	O
biosynthesis	O
through	O
selective	O
inhibition	O
of	O
COX	O
is	O
hence	O
,	O
now	O
regarded	O
as	O
an	O
important	O
cancer	O
chemopreventive	O
strategy	O
.	O

Resveratrol	O
was	O
shown	O
to	O
inhibit	O
COX-1	O
activity	O
in	O
microsomes	O
derived	O
from	O
sheep	B
seminal	O
vesicles	O
[	O
149	O
]	O
.	O

More	O
recently	O
,	O
Subbaramaiah	O
et	O
al.	O
[	O
158	O
]	O
have	O
reported	O
that	O
resveratrol	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
the	O
inducible	O
isozyme	O
COX-2	O
in	O
cultured	O
human	B
mammary	O
epithelial	O
cells	O
with	O
and	O
without	O
TPA	O
treatment	O
.	O

Likewise	O
,	O
human	B
recombinant	O
COX-2	O
expressed	O
in	O
baculovirus	O
was	O
inhibited	O
by	O
resveratrol	O
[	O
158	O
]	O
.	O

Besides	O
inhibiting	O
the	O
catalytic	O
activity	O
of	O
COX-2	O
,	O
the	O
compound	O
also	O
blocked	O
TPA	O
-	O
mediated	O
induction	O
of	O
cox	O
-2	O
mRNA	O
in	O
cultured	O
human	B
mammary	O
epithelial	O
cells	O
through	O
repression	O
of	O
AP-1-dependent	O
transactivation	O
[	O
158	O
]	O
.	O

More	O
recently	O
,	O
topical	O
application	O
of	O
resveratrol	O
onto	O
dorsal	O
skin	O
of	O
CD-1	B
mice	I
led	O
to	O
profound	O
attenuation	O
of	O
oxidative	O
stress	O
and	O
expression	O
of	O
epidermal	O
TGF	O
-	O
β1	O
and	O
c	O
-	O
fos	O
induced	O
by	O
TPA	O
,	O
but	O
the	O
induction	O
of	O
cox	O
-1	O
,	O
cox	O
-2	O
,	O
c	O
-	O
myc	O
,	O
c	O
-	O
jun	O
and	O
TNF	O
-	O
α	O
mRNAs	O
was	O
not	O
affected	O
[	O
159	O
]	O
.	O

As	O
mentioned	O
earlier	O
,	O
some	O
anti	O
-	O
inflammatory	O
chemopreventive	O
agents	O
have	O
been	O
found	O
to	O
suppress	O
growth	O
and	O
proliferation	O
of	O
transformed	O
cells	O
through	O
induction	O
of	O
programmed	O
death	O
or	O
apoptosis	O
[	O
30–32	O
]	O
.	O

Although	O
resveratrol	O
exerts	O
anti	O
-	O
inflammatory	O
effects	O
through	O
selective	O
suppression	O
of	O
COX-2	O
,	O
little	O
information	O
is	O
available	O
in	O
the	O
literature	O
in	O
regards	O
to	O
its	O
apoptosis	O
-	O
inducing	O
capability	O
in	O
tumor	O
cells	O
.	O

Mgbonyebi	O
et	O
al.	O
[	O
156	O
]	O
reported	O
the	O
growth	O
inhibition	O
by	O
resveratrol	O
of	O
several	O
types	O
of	O
human	B
breast	O
epithelial	O
cells	O
,	O
which	O
was	O
independent	O
of	O
estrogen	O
receptor	O
status	O
of	O
the	O
cells	O
.	O

Although	O
the	O
antiproliferative	O
activity	O
of	O
resveratrol	O
was	O
demonstrated	O
[	O
156	O
]	O
,	O
the	O
mode	O
of	O
cell	O
death	O
induced	O
by	O
this	O
phytochemical	O
was	O
not	O
clarified	O
in	O
the	O
above	O
investigation	O
.	O

Suppression	O
of	O
HL-60	O
cells	O
by	O
resveratrol	O
was	O
shown	O
to	O
be	O
mediated	O
via	O
induction	O
of	O
apoptosis	O
as	O
determined	O
by	O
nuclear	O
fragmentation	O
,	O
chromatin	O
condensation	O
,	O
a	O
time	O
-	O
related	O
increase	O
in	O
the	O
frequency	O
of	O
subdiploid	O
(	O
apoptotic	O
)	O
cells	O
,	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
[	O
160	O
]	O
.	O

Besides	O
suppression	O
of	O
proliferation	O
,	O
the	O
compound	O
induced	O
differentiation	O
of	O
HL-60	O
cells	O
at	O
concentrations	O
as	O
low	O
as	O
30	O
μM	O
,	O
which	O
appears	O
to	O
be	O
associated	O
with	O
reversible	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
-	O
phase	O
check	O
point	O
[	O
161	O
]	O
.	O

Moreover	O
,	O
resveratrol	O
was	O
found	O
to	O
induce	O
apoptosis	O
in	O
HL-60	O
cells	O
by	O
triggering	O
the	O
CD95	O
signaling	O
system	O
[	O
162	O
]	O
.	O

The	O
growth	O
of	O
estrogen	O
-	O
dependent	O
T47D	O
breast	O
carcinoma	O
cells	O
was	O
also	O
suppressed	O
by	O
resveratrol	O
treatment	O
[	O
162	O
]	O
.	O

The	O
latter	O
finding	O
is	O
contradictory	O
to	O
the	O
result	O
of	O
a	O
previous	O
work	O
by	O
Gehm	O
et	O
al.	O
[	O
163	O
]	O
,	O
who	O
demonstrated	O
stimulation	O
of	O
T47D	O
cell	O
proliferation	O
by	O
resveratrol	O
through	O
interaction	O
with	O
the	O
estrogen	O
receptor	O
.	O

The	O
exact	O
reason	O
for	O
this	O
discrepancy	O
remains	O
unknown	O
.	O

In	O
another	O
study	O
,	O
resveratrol	O
caused	O
estrogen	O
mimic	O
induction	O
of	O
prolactin	O
secretion	O
in	O
the	O
immortalized	O
pituitary	O
cell	O
line	O
PR1	O
,	O
but	O
it	O
exhibited	O
neither	O
estrogen	O
receptor	O
binding	O
nor	O
growth	O
stimulatory	O
activity	O
in	O
these	O
cells	O
[	O
164	O
]	O
.	O

4.6	O
Epigallocatechin	O
gallate	O
Epidemiologic	O
,	O
as	O
well	O
as	O
laboratory	O
studies	O
,	O
have	O
revealed	O
that	O
increased	O
consumption	O
of	O
green	B
tea	I
has	O
been	O
associated	O
with	O
reduced	O
frequencies	O
of	O
several	O
types	O
of	O
malignant	O
tumors	O
[	O
165–169	O
]	O
.	O

Among	O
many	O
polyphenolic	O
compounds	O
isolated	O
from	O
green	B
tea	I
,	O
(	O
−	O
)	O
-epigallocatechin	O
gallate	O
(	O
EGCG	O
;	O
Fig.	O
5	O
)	O
is	O
believed	O
to	O
be	O
a	O
key	O
active	O
constituent	O
in	O
terms	O
of	O
cancer	O
chemopreventive	O
potential	O
[	O
113	O
,	O
165	O
,	O
170–172	O
]	O
.	O

The	O
strong	O
antioxidative	O
activity	O
retained	O
in	O
this	O
polyphenol	O
has	O
been	O
confirmed	O
in	O
numerous	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
[	O
173–186	O
]	O
,	O
which	O
appears	O
to	O
contribute	O
in	O
part	O
to	O
the	O
antimutagenic	O
and	O
anticarcinogenic	O
effects	O
of	O
green	B
tea	I
.	O

Thus	O
,	O
pretreatment	O
of	O
SENCAR	B
mice	I
with	O
EGCG	O
significantly	O
ameliorated	O
TPA	O
-	O
induced	O
infiltration	O
and	O
diminished	O
the	O
formation	O
of	O
hydrogen	O
peroxide	O
and	O
oxidized	O
DNA	O
bases	O
including	O
8-hydroxy-2′-deoxyguanosine	O
(	O
8-OH	O
-	O
dG	O
)	O
and	O
5-hydroxymethyl-2′-deoxyuridine	O
in	O
the	O
skin	O
[	O
174	O
]	O
.	O

Likewise	O
,	O
TPA	O
-	O
induced	O
oxidative	O
DNA	O
base	O
modification	O
was	O
inhibited	O
dose	O
-	O
dependently	O
by	O
EGCG	O
in	O
cultured	O
HeLa	O
cells	O
[	O
175	O
]	O
.	O

EGCG	O
and	O
structurally	O
-	O
related	O
green	B
tea	I
catechins	O
were	O
found	O
to	O
be	O
stronger	O
inhibitors	O
of	O
lipid	O
peroxidation	O
in	O
rat	O
liver	O
homogenates	O
than	O
such	O
antioxidants	O
as	O
glutathione	O
,	O
ascorbic	O
acid	O
,	O
tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
butylated	O
hydroxyanisole	O
[	O
176	O
]	O
.	O

The	O
antioxidant	O
activities	O
of	O
theaflavins	O
and	O
thearubigin	O
purified	O
from	O
the	O
infusion	O
of	O
black	B
tea	I
leaves	O
were	O
lower	O
than	O
those	O
of	O
green	B
tea	I
polyphenols	O
[	O
176	O
]	O
,	O
although	O
the	O
total	O
lyophilized	O
infusion	O
products	O
of	O
green	B
tea	I
and	O
black	B
tea	I
leaves	O
were	O
equally	O
active	O
.	O

EGCG	O
exhibited	O
a	O
strong	O
inhibitory	O
effect	O
on	O
Cu2	O
+	O
-mediated	O
oxidation	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
vitro	O
and	O
was	O
again	O
more	O
potent	O
than	O
theaflavin	O
,	O
α	O
-	O
tocopherol	O
,	O
and	O
butylated	O
hydroxytoluene	O
in	O
this	O
regard	O
[	O
177	O
]	O
.	O

Kidney	O
slices	O
from	O
rats	B
subjected	O
to	O
oral	O
administration	O
of	O
EGCG	O
(	O
50	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
for	O
7	O
days	O
or	O
fed	O
3	O
%	O
green	B
tea	I
leaf	O
powder	O
for	O
50	O
days	O
exhibited	O
lesser	O
extent	O
of	O
ter	O
-butyl	O
hydroperoxide	O
-	O
induced	O
lipid	O
peroxidation	O
,	O
compared	O
with	O
the	O
control	O
animals	B
[	O
178	O
]	O
.	O

EGCG	O
,	O
as	O
well	O
as	O
green	B
tea	I
given	O
to	O
rats	B
in	O
drinking	O
water	O
was	O
protective	O
against	O
hepatotoxicity	O
and	O
liver	O
nuclear	O
8-OH	O
-	O
dG	O
formation	O
induced	O
by	O
the	O
carcinogen	O
2-nitropropane	O
[	O
179	O
]	O
.	O

Pentachlorophenol	O
-	O
induced	O
hepatic	O
8-OH	O
-	O
dG	O
formation	O
in	O
male	O
B6C3F1	B
mice	I
was	O
reduced	O
by	O
oral	O
administration	O
of	O
EGCG	O
[	O
180	O
]	O
.	O

Peroxynitrite	O
-	O
mediated	O
formation	O
of	O
8-OH	O
-	O
dG	O
in	O
calf	B
thymus	O
DNA	O
and	O
nitration	O
of	O
tyrosine	O
to	O
3-nitrotyrosine	O
were	O
suppressed	O
by	O
EGCG	O
[	O
181	O
]	O
.	O

Strand	O
scission	O
in	O
Escherichia	B
coli	I
pUC18	I
plasmid	O
DNA	O
by	O
gamma	O
-	O
ray	O
or	O
beta	O
-	O
ray	O
was	O
inhibited	O
in	O
the	O
presence	O
of	O
EGCG	O
,	O
which	O
might	O
be	O
attributable	O
to	O
its	O
hydroxyl	O
radical	O
scavenging	O
effect	O
[	O
182	O
,	O
183	O
]	O
.	O

Among	O
the	O
tea	B
flavonoids	O
tested	O
,	O
EGCG	O
exerted	O
the	O
most	O
pronounced	O
protection	O
against	O
oxidation	O
of	O
LDL	O
as	O
revealed	O
by	O
prolongation	O
of	O
the	O
oxidation	O
time	O
[	O
184	O
]	O
.	O

The	O
EGCG	O
was	O
found	O
to	O
block	O
the	O
production	O
of	O
ROS	O
derived	O
from	O
NADPH	O
-	O
cytochrome	O
P	O
450-mediated	O
oxidation	O
of	O
the	O
cooked	O
meat	O
carcinogen	O
,	O
2-amino-3-methylimidazo	O
[	O
4,5-f	O
]	O
quinoline	O
(	O
IQ	O
)	O
[	O
185	O
]	O
.	O

The	O
EGCG	O
and	O
epigallocatechin	O
were	O
found	O
to	O
inhibit	O
xanthine	O
oxidase	O
[	O
186	O
]	O
.	O

The	O
EGCG	O
has	O
also	O
been	O
reported	O
to	O
attenuate	O
the	O
nitric	O
oxide	O
production	O
[	O
187	O
,	O
188	O
]	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
suppression	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
(	O
iNOS	O
)	O
or	O
its	O
mRNA	O
expression	O
[	O
187	O
,	O
189	O
]	O
.	O

The	O
electrophorectic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
EGCG	O
blunted	O
activation	O
of	O
NF	O
-	O
κB	O
responsible	O
for	O
iNOS	O
induction	O
[	O
187	O
]	O
.	O

These	O
results	O
indicate	O
that	O
EGCG	O
inhibits	O
the	O
binding	O
of	O
NF	O
-	O
κB	O
to	O
iNOS	O
promoter	O
,	O
thereby	O
hampering	O
the	O
transcription	O
of	O
iNOS	O
gene	O
.	O

Interferon	O
-	O
gamma	O
and	O
lipopolysaccharide	O
-	O
induced	O
nitrite	O
production	O
in	O
mouse	B
peritoneal	O
cells	O
was	O
also	O
inhibited	O
by	O
EGCG	O
[	O
190	O
]	O
.	O

The	O
chemopreventive	O
effects	O
of	O
EGCG	O
and	O
other	O
structurally	O
-	O
related	O
green	B
tea	I
polyphenols	O
have	O
been	O
investigated	O
using	O
diverse	O
rodent	B
tumor	O
models	O
(	O
recently	O
reviewed	O
in	O
Ref	O
.	O

[	O
191	O
]	O
)	O
.	O

Thus	O
,	O
EGCG	O
exhibited	O
protective	O
effects	O
against	O
N	O
-ethyl	O
-	O
N	O
′-nitrosoguanidine	O
-	O
induced	O
murine	B
duodenum	O
carcinogenesis	O
[	O
165	O
,	O
192	O
,	O
193	O
]	O
,	O
N	O
-methyl	O
-	O
N	O
′-nitrosoguanidine	O
-	O
induced	O
rat	B
gastric	O
carcinogenesis	O
[	O
193	O
,	O
194	O
]	O
,	O
diethylnitrosamine	O
-	O
initiated	O
and	O
phenobarbital	O
-	O
promoted	O
formation	O
of	O
hepatic	O
preneoplastic	O
foci	O
in	O
male	O
F344	B
rats	I
[	O
195	O
]	O
,	O
mouse	B
skin	O
carcinogenesis	O
[	O
170	O
,	O
196–200	O
]	O
,	O
tobacco	B
-	O
specific	O
nitrosamine	O
-	O
induced	O
mouse	B
pulmonary	O
tumorigenesis	O
[	O
[	O
201	O
]	O
,	O
reviewed	O
in	O
Ref	O
.	O

[	O
202	O
]	O
]	O
,	O
rat	B
sarcoma	O
induction	O
following	O
subcutaneous	O
injection	O
of	O
benzo	O
[	O
a	O
]	O
pyrene	O
[	O
203	O
]	O
,	O
and	O
spontaneous	O
hepatoma	O
formation	O
in	O
C3H	B
/	I
HeNCrj	I
mice	I
[	O
204	O
]	O
.	O

One	O
of	O
the	O
most	O
plausible	O
mechanisms	O
underlying	O
the	O
chemopreventive	O
activity	O
of	O
EGCG	O
is	O
suppression	O
of	O
promotion	O
of	O
carcinogenesis	O
[	O
170	O
,	O
193	O
,	O
196	O
,	O
197	O
]	O
examined	O
in	O
animals	B
and	O
also	O
in	O
cultured	O
cells	O
[	O
205	O
]	O
.	O

Thus	O
,	O
EGCG	O
has	O
been	O
reported	O
to	O
influence	O
some	O
biochemical	O
events	O
related	O
to	O
tumor	O
promotion	O
,	O
such	O
as	O
suppression	O
of	O
mouse	B
epidermal	O
ODC	O
activity	O
induced	O
by	O
TPA	O
[	O
197	O
]	O
or	O
okadaic	O
acid	O
[	O
170	O
]	O
,	O
inhibition	O
of	O
protein	O
kinase	O
C	O
activation	O
induced	O
by	O
teleocidin	O
[	O
171	O
]	O
or	O
TPA	O
[	O
206	O
]	O
,	O
attenuation	O
of	O
okadaic	O
acid	O
-	O
stimulated	O
production	O
of	O
TNF	O
-	O
α	O
and	O
its	O
mRNA	O
expression	O
in	O
cultured	O
BALB	O
/	O
3T3	O
cells	O
[	O
172	O
,	O
207	O
]	O
,	O
inhibition	O
of	O
binding	O
of	O
tumor	O
promoters	O
to	O
the	O
particulate	O
fraction	O
of	O
mouse	B
skin	O
[	O
170	O
]	O
or	O
to	O
its	O
receptor	O
protein	O
kinase	O
C	O
[	O
206	O
]	O
,	O
mitigation	O
of	O
TPA	O
-	O
induced	O
oxidative	O
damage	O
in	O
mouse	B
skin	O
[	O
174	O
]	O
and	O
cultured	O
cells	O
[	O
175	O
]	O
,	O
enhancement	O
of	O
gap	O
junctional	O
intercellular	O
communication	O
[	O
208	O
]	O
.	O

The	O
ODC	O
activity	O
in	O
gastric	O
mucosal	O
cells	O
of	O
N	O
-methyl	O
-	O
N	O
′-nitrosoguanidine	O
-	O
treated	O
rats	B
was	O
also	O
reduced	O
by	O
oral	O
administration	O
of	O
EGCG	O
[	O
194	O
]	O
.	O

TPA	O
-	O
induced	O
expression	O
of	O
ODC	O
gene	O
,	O
protein	O
kinase	O
C	O
gene	O
,	O
and	O
c	O
-	O
myc	O
proto	O
-	O
oncogene	O
in	O
mouse	B
skin	O
was	O
all	O
repressed	O
by	O
topical	O
application	O
of	O
EGCG	O
[	O
209	O
]	O
.	O

Likewise	O
,	O
increases	O
in	O
the	O
transcript	O
level	O
of	O
epidermal	O
IL-1α	O
gene	O
in	O
SENCAR	B
mice	I
treated	O
with	O
different	O
types	O
of	O
tumor	O
promoters	O
were	O
suppressed	O
by	O
topical	O
pretreatment	O
with	O
EGCG	O
[	O
210	O
]	O
.	O

In	O
contrast	O
,	O
EGCG	O
alone	O
stimulated	O
the	O
production	O
of	O
IL-1α	O
and	O
its	O
mRNA	O
expression	O
in	O
human	B
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
culture	O
[	O
211	O
]	O
.	O

EGCG	O
abrogated	O
TPA	O
-	O
induced	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
c	O
-	O
jun	O
expression	O
,	O
and	O
transformation	O
in	O
cultured	O
mouse	B
fibroblasts	O
in	O
culture	O
[	O
212	O
]	O
.	O

Very	O
recently	O
,	O
Dong	O
et	O
al.	O
[	O
213	O
]	O
reported	O
that	O
EGCG	O
and	O
theaflavins	O
inhibited	O
EGF-	O
or	O
TPA	O
-	O
induced	O
transformation	O
of	O
JB6	B
mouse	I
epidermal	O
cell	O
line	O
which	O
was	O
associated	O
with	O
their	O
repression	O
of	O
AP-1-dependent	O
transcriptional	O
activity	O
and	O
its	O
DNA	O
binding	O
activity	O
.	O

The	O
inhibition	O
of	O
AP-1	O
activation	O
by	O
these	O
substances	O
appears	O
to	O
be	O
mediated	O
via	O
down	O
-	O
regulation	O
of	O
JNK	O
,	O
but	O
not	O
the	O
ERK	O
pathway	O
[	O
213	O
]	O
.	O

The	O
anticarcinogenic	O
,	O
as	O
well	O
as	O
antigenotoxic	O
activities	O
of	O
EGCG	O
have	O
been	O
confirmed	O
in	O
many	O
other	O
in	O
vivo	O
and	O
in	O
vitro	O
bioassays	O
(	O
extensively	O
reviewed	O
in	O
Ref	O
.	O

[	O
192	O
]	O
and	O
see	O
references	O
therein	O
)	O
although	O
some	O
studies	O
revealed	O
no	O
protective	O
effects	O
[	O
214	O
]	O
.	O

Besides	O
inhibiting	O
the	O
tumor	O
promotion	O
,	O
EGCG	O
administered	O
intraperitoneally	O
and	O
the	O
green	B
tea	I
polyphenol	O
fraction	O
given	O
orally	O
or	O
intraperitoneally	O
caused	O
growth	O
inhibition	O
and/or	O
regression	O
of	O
experimentally	O
induced	O
skin	O
papillomas	O
in	O
mice	B
[	O
198	O
]	O
.	O

Topically	O
applied	O
green	B
tea	I
polyphenol	O
fraction	O
also	O
inhibited	O
the	O
progression	O
of	O
papillomas	O
to	O
squamous	O
cell	O
carcinoma	O
[	O
199	O
]	O
.	O

Similarly	O
,	O
i.p	O
.	O

injection	O
of	O
this	O
polyphenol	O
caused	O
growth	O
inhibition	O
and	O
regression	O
of	O
tumors	O
arising	O
from	O
human	B
prostate	O
cancer	O
cells	O
,	O
PC-3	O
and	O
LNCaP	O
104-R	O
,	O
subcutaneously	O
inoculated	O
into	O
nude	O
mice	B
[	O
215	O
]	O
.	O

Other	O
structurally	O
-	O
related	O
catechins	O
,	O
such	O
as	O
(	O
−	O
)	O
-epicatechin	O
gallate	O
,	O
were	O
not	O
active	O
in	O
this	O
respect	O
.	O

EGCG	O
also	O
effectively	O
suppressed	O
the	O
growth	O
of	O
human	B
mammary	O
cancer	O
cells	O
(	O
MCF-7	O
)	O
in	O
athymic	O
mice	B
[	O
215	O
]	O
.	O

In	O
line	O
with	O
these	O
in	O
vivo	O
findings	O
,	O
EGCG	O
downregulated	O
the	O
aberrant	O
hyperproliferation	O
of	O
c	O
-	O
myc	O
oncogene	O
-	O
transfected	O
mouse	B
mammary	O
epithelial	O
cells	O
as	O
demonstrated	O
by	O
its	O
ability	O
to	O
suppress	O
the	O
anchorage	O
-	O
independent	O
growth	O
of	O
these	O
cells	O
in	O
soft	O
agar	O
[	O
216	O
]	O
.	O

Aberrant	O
hyperproliferation	O
of	O
spontaneously	O
immortalized	O
murine	B
mammary	O
epithelial	O
cells	O
subjected	O
to	O
initiation	O
with	O
a	O
chemical	O
carcinogen	O
or	O
by	O
oncogene	O
transfection	O
and	O
their	O
subsequent	O
growth	O
in	O
syngenic	O
mice	B
were	O
also	O
blocked	O
by	O
EGCG	O
treatment	O
[	O
217	O
]	O
.	O

In	O
contrast	O
to	O
the	O
above	O
positive	O
findings	O
,	O
EGCG	O
given	O
as	O
a	O
diet	O
to	O
female	O
Sprague	B
–	I
Dawley	I
rats	I
during	O
the	O
late	O
promotion	O
or	O
progression	O
stages	O
of	O
7,12-dimethylbenz	O
[	O
a	O
]	O
anthracene	O
-	O
initiated	O
mammary	O
carcinogenesis	O
exhibited	O
no	O
significant	O
protective	O
effects	O
[	O
218	O
]	O
.	O

There	O
have	O
been	O
a	O
series	O
of	O
papers	O
published	O
,	O
which	O
deal	O
with	O
the	O
growth	O
inhibitory	O
or	O
antiproliferative	O
activities	O
of	O
green	B
tea	I
polyphenols	O
in	O
numerous	O
types	O
of	O
tumor	O
cells	O
[	O
[	O
219	O
,	O
220	O
]	O
,	O
and	O
vide	O
infra	O
]	O
.	O

Like	O
other	O
chemopreventive	O
phytochemicals	O
listed	O
above	O
,	O
the	O
growth	O
inhibitory	O
effects	O
of	O
EGCG	O
in	O
cancer	O
cells	O
appears	O
in	O
part	O
to	O
be	O
mediated	O
via	O
apoptosis	O
.	O

Hibasami	O
et	O
al.	O
[	O
221	O
]	O
reported	O
that	O
human	B
lymphoid	O
leukemia	O
Molt	O
4B	O
cells	O
exposed	O
to	O
EGCG	O
underwent	O
programmed	O
death	O
as	O
determined	O
by	O
appearance	O
of	O
DNA	O
ladder	O
on	O
agarose	O
gel	O
electrophoresis	O
.	O

Other	O
green	B
tea	I
polyphenols	O
,	O
such	O
as	O
epigallocatechin	O
and	O
epicatechin	O
gallate	O
,	O
also	O
inhibited	O
growth	O
of	O
Molt	O
4B	O
cells	O
via	O
induction	O
of	O
apoptotic	O
death	O
[	O
221	O
,	O
222	O
]	O
.	O

Each	O
of	O
these	O
polyphenols	O
exhibited	O
an	O
inhibitory	O
effect	O
on	O
the	O
growth	O
of	O
human	B
lung	O
cancer	O
cell	O
line	O
PC-9	O
,	O
possibly	O
through	O
arrest	O
of	O
the	O
cell	O
cycle	O
in	O
the	O
G2	O
/M	O
phase	O
[	O
166	O
,	O
223	O
]	O
.	O

In	O
a	O
subsequent	O
study	O
,	O
the	O
apoptosis	O
-	O
inducing	O
activity	O
of	O
EGCG	O
in	O
PC-9	O
cells	O
has	O
been	O
found	O
to	O
be	O
synergistically	O
enhanced	O
by	O
combined	O
treatment	O
with	O
other	O
chemopreventive	O
agents	O
,	O
including	O
sulindac	O
and	O
tamoxifen	O
[	O
224	O
]	O
.	O

In	O
another	O
study	O
,	O
EGCG	O
induced	O
apoptosis	O
of	O
human	B
epidermoid	O
carcinoma	O
cell	O
line	O
(	O
A431	O
)	O
,	O
human	B
carcinoma	O
keratinocyte	O
cell	O
line	O
(	O
HaCaT	O
)	O
,	O
human	B
prostate	O
carcinoma	O
cell	O
line	O
(	O
DU145	O
)	O
,	O
and	O
mouse	B
lymphoma	O
cell	O
line	O
(	O
L5178Y	O
)	O
and	O
its	O
apoptosis	O
inducing	O
activity	O
was	O
related	O
to	O
the	O
cell	O
cycle	O
arrest	O
in	O
the	O
G0	O
–G1	O
phase	O
[	O
225	O
]	O
.	O

Antiproliferative	O
activity	O
of	O
EGCG	O
against	O
A431	O
cells	O
has	O
been	O
attributed	O
to	O
its	O
suppression	O
of	O
EGF	O
binding	O
to	O
its	O
receptor	O
and	O
subsequent	O
autophosphorylation	O
of	O
the	O
EGF	O
receptor	O
required	O
for	O
EGF	O
signaling	O
[	O
226	O
]	O
.	O

The	O
EGCG	O
and	O
epigallocatechin	O
treated	O
to	O
Ehrlich	O
ascites	O
tumor	O
cells	O
caused	O
significant	O
reduction	O
in	O
cell	O
viability	O
[	O
227	O
]	O
.	O

While	O
epigallocatechin	O
suppressed	O
the	O
tyrosine	O
phosphorylation	O
of	O
42	O
kDa	O
and	O
45	O
kDa	O
proteins	O
in	O
treated	O
cells	O
,	O
EGCG	O
was	O
not	O
inhibitory	O
on	O
the	O
protein	O
tyrosine	O
kinase	O
activity	O
[	O
227	O
]	O
.	O

The	O
growth	O
of	O
premalignant	O
and	O
malignant	O
cells	O
derived	O
respectively	O
from	O
dysplastic	O
leukoplakia	O
and	O
squamous	O
carcinoma	O
of	O
oral	O
epithelial	O
origin	O
was	O
also	O
inhibited	O
by	O
EGCG	O
,	O
which	O
was	O
considered	O
to	O
be	O
associated	O
with	O
cell	O
cycle	O
arrest	O
in	O
the	O
G1	O
phase	O
[	O
228	O
,	O
229	O
]	O
.	O

The	O
malignant	O
oral	O
epithelium	O
was	O
less	O
responsive	O
to	O
EGCG	O
than	O
normal	O
and	O
dysplastic	O
cells	O
[	O
229	O
]	O
.	O

Treatment	O
of	O
benzo	O
[	O
a	O
]	O
pyrene	O
-	O
initiated	O
human	B
mammary	O
epithelial	O
184-B5	O
cells	O
with	O
EGCG	O
led	O
to	O
increases	O
in	O
sub	O
G0	O
population	O
and	O
apoptotic	O
cell	O
death	O
,	O
which	O
might	O
account	O
for	O
suppression	O
of	O
aberrant	O
proliferation	O
in	O
these	O
cells	O
[	O
230	O
]	O
.	O

Human	B
stomach	O
KATO	O
III	O
cells	O
also	O
underwent	O
apoptotic	O
death	O
when	O
exposed	O
to	O
EGCG	O
[	O
231	O
]	O
.	O

When	O
different	O
types	O
of	O
polyphenols	O
derived	O
from	O
green	B
tea	I
extracts	O
were	O
treated	O
to	O
human	O
lung	O
and	O
colon	O
cancer	O
cell	O
lines	O
,	O
EGCG	O
and	O
epigallocatechin	O
exhibited	O
strong	O
growth	O
inhibitory	O
effects	O
followed	O
by	O
epicatechin	O
gallate	O
and	O
epicatechin	O
[	O
232	O
]	O
.	O

The	O
incubation	O
of	O
the	O
human	O
lung	O
tumor	O
cell	O
line	O
H661	O
with	O
EGCG	O
resulted	O
in	O
apoptosis	O
,	O
which	O
was	O
considered	O
to	O
be	O
mediated	O
by	O
hydrogen	O
peroxide	O
produced	O
by	O
this	O
polyphenol	O
[	O
232	O
]	O
.	O

EGCG	O
was	O
proven	O
to	O
be	O
the	O
most	O
potent	O
green	B
tea	I
catechin	O
in	O
terms	O
of	O
suppressing	O
the	O
growth	O
of	O
several	O
human	B
prostate	O
cancer	O
cell	O
lines	O
,	O
including	O
LNCaP	O
,	O
PC-3	O
,	O
and	O
DU145	O
[	O
233	O
]	O
.	O

The	O
selective	O
inhibition	O
of	O
5α	O
-	O
reductase	O
by	O
EGCG	O
suggests	O
that	O
its	O
antiproliferative	O
activity	O
against	O
prostate	O
cancer	O
cells	O
is	O
mediated	O
via	O
modulation	O
of	O
androgen	O
action	O
[	O
234	O
]	O
.	O

The	O
antiproliferative	O
and	O
apoptosis	O
-	O
inducing	O
effects	O
of	O
EGCG	O
were	O
shown	O
to	O
be	O
specific	O
for	O
tumor	O
cells	O
[	O
225	O
,	O
235	O
]	O
,	O
which	O
was	O
partly	O
associated	O
with	O
its	O
differential	O
modulation	O
of	O
c	O
-	O
myc	O
and	O
c	O
-	O
fos	O
expression	O
[	O
235	O
]	O
.	O

EGCG	O
also	O
possesses	O
a	O
potential	O
antimetastatic	O
activity	O
as	O
revealed	O
by	O
inhibition	O
of	O
matrix	O
metalloproteinase	O
activity	O
in	O
mouse	B
Lewis	O
lung	O
carcinoma	O
cells	O
[	O
236	O
]	O
.	O

Furthermore	O
,	O
administration	O
of	O
EGCG	O
inhibited	O
metastasis	O
of	O
mouse	B
B16	O
melanoma	O
cells	O
[	O
237	O
]	O
.	O

Adhesion	O
of	O
mouse	O
lung	O
carcinoma	O
cells	O
to	O
endothelial	O
cells	O
was	O
also	O
inhibited	O
by	O
EGCG	O
[	O
238	O
]	O
.	O

It	O
also	O
reduced	O
the	O
lifespan	O
of	O
cultured	O
monoblastoid	O
leukemia	O
and	O
HT29	O
colon	O
adenocarcinoma	O
cells	O
through	O
direct	O
inactivation	O
of	O
telomerase	O
[	O
239	O
]	O
,	O
an	O
enzyme	O
essential	O
for	O
unlocking	O
the	O
proliferation	O
of	O
cancer	O
cells	O
.	O

5	O
Concluding	O
remarks	O
A	O
wide	O
variety	O
of	O
phenolic	O
substances	O
present	O
in	O
dietary	O
and	O
medicinal	O
plants	B
possess	O
striking	O
antioxidative	O
and	O
anti	O
-	O
inflammatory	O
properties	O
,	O
which	O
to	O
some	O
extent	O
,	O
contribute	O
to	O
their	O
cancer	O
chemopreventive	O
potential	O
.	O

Examples	O
are	O
pungent	O
vanilloids	O
in	O
red	B
pepper	I
and	O
ginger	B
,	O
and	O
diarylheptanoids	O
isolated	O
from	O
certain	O
medicinal	O
plants	B
of	O
ginger	B
family	O
.	O

These	O
phenolic	O
substances	O
have	O
the	O
ability	O
to	O
inhibit	O
mouse	B
skin	O
tumor	O
promotion	O
and	O
to	O
abrogate	O
various	O
biochemical	O
processes	O
induced	O
or	O
mediated	O
by	O
the	O
tumor	O
promoters	O
including	O
TPA	O
and	O
okadaic	O
acid	O
.	O

They	O
also	O
induce	O
apoptosis	O
in	O
premalignant	O
or	O
cancerous	O
cells	O
.	O

Resveratrol	O
,	O
a	O
phytoalexin	O
present	O
in	O
grapes	B
and	O
red	O
wine	O
and	O
EGCG	O
,	O
one	O
of	O
the	O
major	O
antioxidative	O
polyphenols	O
contained	O
in	O
green	B
tea	I
,	O
have	O
been	O
shown	O
to	O
possess	O
a	O
broad	O
spectrum	O
of	O
anticarcinogenic	O
effects	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
resveratrol	O
and	O
EGCG	O
suppress	O
growth	O
and	O
proliferation	O
of	O
various	O
types	O
of	O
tumor	O
cells	O
via	O
induction	O
of	O
apoptosis	O
or	O
arrest	O
of	O
a	O
specific	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Most	O
of	O
the	O
naturally	O
occurring	O
chemopreventive	O
phenolics	O
exert	O
multifacet	O
action	O
,	O
and	O
any	O
clinical	O
applications	O
using	O
these	O
substances	O
should	O
be	O
based	O
on	O
the	O
precise	O
understanding	O
of	O
the	O
physiologically	O
relevant	O
action	O
mechanism	O
(	O
s	O
)	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
grant	O
from	O
Korea	O
Science	O
Engineering	O
Foundation	O
through	O
the	O
Research	O
Center	O
for	O
New	O
Drug	O
Development	O
of	O
Seoul	O
National	O
University	O
and	O
also	O
by	O
a	O
grant	O
for	O
'	O
98	O
Good	O
Health	O
R&D	O
project	O
(	O
HMP-96-D-2	O
-	O
1034	O
)	O
sponsored	O
by	O
the	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
,	O
Republic	O
of	O
Korea	O
.	O

Guillain	O
-	O
Barré	O
syndrome	O
(	O
GBS	O
)	O
is	O
an	O
acute	O
immune	O
-	O
mediated	O
polyradiculoneuropathy	O
.	O

An	O
infection	O
often	O
precedes	O
the	O
onset	O
of	O
GBS	O
.	O

Although	O
a	O
subtype	O
with	O
primary	O
axonal	O
degeneration	O
has	O
recently	O
been	O
reported	O
[	O
1	O
]	O
,	O
the	O
predominant	O
pathogenetic	O
process	O
is	O
considered	O
to	O
be	O
demyelination	O
.	O

Gangliosides	O
are	O
surface	O
membrane	O
antigens	O
distributed	O
predominantly	O
in	O
the	O
nervous	O
system	O
.	O

Antiganglioside	O
antibodies	O
are	O
frequently	O
elevated	O
in	O
the	O
acute	O
phase	O
sera	O
of	O
GBS	O
[	O
2–4	O
]	O
.	O

Among	O
the	O
gangliosides	O
,	O
LM1	O
(	O
sialosylneolactotetraosylceramide	O
)	O
is	O
the	O
predominant	O
one	O
in	O
the	O
peripheral	O
nerve	O
myelin	O
[	O
5	O
]	O
.	O

Anti	O
-	O
LM1	O
antibody	O
may	O
therefore	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
GBS	O
.	O

In	O
this	O
paper	O
,	O
we	O
investigate	O
the	O
presence	O
of	O
the	O
anti	O
-	O
LM1	O
antibody	O
in	O
the	O
serum	O
of	O
patients	B
with	O
GBS	O
and	O
the	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Patients	B
'	O
sera	O
Serum	O
samples	O
were	O
obtained	O
from	O
140	O
consecutive	O
patients	B
with	O
acute	O
GBS	O
within	O
two	O
weeks	O
of	O
the	O
onset	O
of	O
neurologic	O
symptoms	O
,	O
24	O
normal	O
controls	O
and	O
147	O
disease	O
controls	O
,	O
which	O
included	O
patients	B
with	O
chronic	O
inflammatory	O
demyelinating	O
polyneuropathy	O
(	O
CIDP	O
)	O
,	O
33	O
;	O
Miller	O
Fisher	O
syndrome	O
(	O
MFS	O
)	O
,	O
47	O
;	O
other	O
neuropathies	O
,	O
7	O
;	O
multiple	O
sclerosis	O
,	O
13	O
;	O
collagen	O
disease	O
,	O
13	O
;	O
myasthenia	O
gravis	O
,	O
6	O
and	O
other	O
neurodegenerative	O
disease	O
,	O
28	O
.	O

All	O
the	O
patients	B
with	O
GBS	O
met	O
the	O
clinical	O
criteria	O
defined	O
by	O
Asbury	O
and	O
Cornblath	O
[	O
6	O
]	O
.	O

Except	O
for	O
the	O
subjects	B
with	O
degenerative	O
disorders	O
and	O
normal	O
controls	O
,	O
the	O
serum	O
samples	O
were	O
collected	O
during	O
the	O
acute	O
phase	O
or	O
relapse	O
.	O

2.2	O
Enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
An	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
as	O
described	O
elsewhere	O
[	O
2	O
]	O
to	O
investigate	O
the	O
serum	O
anti	O
-	O
LM1	O
antibodies	O
.	O

Ninety	O
-	O
six	O
-	O
well	O
Linbro	O
microtiter	O
plates	O
(	O
Flow	O
Laboratories	O
,	O
McLean	O
,	O
VA	O
,	O
USA	O
)	O
were	O
used	O
.	O

Each	O
well	O
was	O
coated	O
with	O
0.2	O
μg	O
of	O
antigen	O
,	O
with	O
an	O
uncoated	O
well	O
being	O
used	O
as	O
the	O
control	O
.	O

After	O
incubation	O
with	O
1	O
%	O
bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
,	O
serum	O
diluted	O
1:40	O
with	O
1	O
%	O
BSA	O
in	O
PBS	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
After	O
each	O
well	O
had	O
been	O
washed	O
with	O
0.1	O
%	O
BSA	O
in	O
PBS	O
,	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
human	O
IgM	O
or	O
IgG	O
antibody	O
(	O
Cappel	O
,	O
West	O
Chester	O
,	O
PA	O
,	O
USA	O
)	O
,	O
diluted	O
1:200	O
and	O
1:500	O
,	O
respectively	O
,	O
with	O
1	O
%	O
BSA	O
in	O
PBS	O
,	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O

The	O
wells	O
then	O
were	O
washed	O
with	O
0.1	O
%	O
BSA	O
in	O
PBS	O
and	O
a	O
color	O
reaction	O
was	O
obtained	O
by	O
incubation	O
with	O
200	O
μl	O
of	O
orthophenylenediamine	O
dihydrochloride	O
(	O
40	O
mg	O
/	O
dl	O
of	O
phosphate	O
–	O
citrate	O
buffer	O
,	O
pH	O
5.0	O
)	O
at	O
room	O
temperature	O
for	O
2	O
min	O
.	O

The	O
reaction	O
was	O
stopped	O
by	O
the	O
addition	O
of	O
8	O
N	O
H2	O
SO4	O
,	O
after	O
which	O
the	O
optical	O
density	O
(	O
OD	O
,	O
492	O
nm	O
)	O
was	O
read	O
with	O
an	O
ELISA	O
reader	O
(	O
Bio	O
-	O
Rad	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Each	O
OD	O
value	O
was	O
corrected	O
by	O
subtracting	O
the	O
OD	O
of	O
a	O
control	O
well	O
that	O
had	O
been	O
processed	O
the	O
same	O
way	O
.	O

Serum	O
with	O
an	O
OD	O
of	O
more	O
than	O
the	O
mean+3	O
SD	O
of	O
the	O
ODs	O
of	O
the	O
24	O
normal	O
controls	O
was	O
considered	O
positive	O
.	O

Each	O
serum	O
sample	O
positive	O
for	O
the	O
anti	O
-	O
LM1	O
antibody	O
was	O
diluted	O
serially	O
from	O
1:40	O
to	O
1:5120	O
and	O
ELISA	O
was	O
preformed	O
as	O
described	O
.	O

Anti	O
-	O
LM1	O
antibody	O
titer	O
was	O
expressed	O
as	O
the	O
maximal	O
dilution	O
factor	O
that	O
gave	O
a	O
corrected	O
OD	O
of	O
more	O
than	O
0.1	O
.	O

Serum	O
samples	O
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
assayed	O
for	O
antibodies	O
to	O
several	O
other	O
gangliosides	O
such	O
as	O
GM1	O
,	O
GM2	O
,	O
GM3	O
,	O
GM1b	O
,	O
GD1a	O
,	O
GD1b	O
,	O
GD3	O
,	O
GalNAc	O
-	O
GD1a	O
,	O
GT1b	O
and	O
GQ1b	O
,	O
and	O
serum	O
samples	O
of	O
all	O
patients	B
with	O
GBS	O
were	O
assayed	O
for	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
.	O

Antibodies	O
against	O
those	O
gangliosides	O
were	O
investigated	O
by	O
the	O
use	O
of	O
ELISA	O
as	O
described	O
previously	O
[	O
2	O
]	O
.	O

2.3	O
Thin	O
-	O
layer	O
chromatogram	O
immunostaining	O
Thin	O
-	O
layer	O
chromatogram	O
(	O
TLC	O
)	O
immunostaining	O
was	O
performed	O
as	O
described	O
elsewhere	O
[	O
2	O
]	O
to	O
confirm	O
the	O
serum	O
antibody	O
reactivities	O
with	O
gangliosides	O
.	O

2.4	O
Clinical	O
features	O
The	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
investigated	O
.	O

The	O
clinical	O
grade	O
was	O
determined	O
as	O
described	O
by	O
Hughes	O
et	O
al.	O
[	O
7	O
]	O
.	O

Patients	B
were	O
classified	O
electrophysiologically	O
as	O
having	O
either	O
acute	O
inflammatory	O
demyelinating	O
polyradiculoneuropathy	O
(	O
AIDP	O
)	O
,	O
with	O
or	O
without	O
axonal	O
degeneration	O
(	O
AD	O
)	O
,	O
acute	O
motor	O
axonal	O
neuropathy	O
,	O
or	O
acute	O
motor	O
and	O
sensory	O
axonal	O
neuropathy	O
according	O
to	O
the	O
criteria	O
described	O
by	O
Rees	O
et	O
al.	O
[	O
8	O
]	O
.	O

Patients	B
who	O
had	O
insufficient	O
evidence	O
of	O
demyelination	O
or	O
axonal	O
degeneration	O
were	O
labeled	O
as	O
unclassifiable	O
.	O

2.5	O
Statistical	O
analysis	O
The	O
difference	O
in	O
the	O
percentages	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
-	O
positive	O
cases	O
among	O
GBS	O
patients	B
with	O
or	O
without	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
was	O
analyzed	O
using	O
the	O
Fisher	O
's	O
exact	O
test	O
.	O

3	O
Results	O
3.1	O
Investigation	O
of	O
serum	O
antiganglioside	O
antibodies	O
Seven	O
patients	B
with	O
GBS	O
,	O
one	O
with	O
CIDP	O
and	O
two	O
with	O
MFS	O
had	O
the	O
IgG	O
anti	O
-	O
LM1	O
antibody	O
in	O
the	O
serum	O
(	O
Fig.	O
1	O
)	O
.	O

All	O
the	O
patients	B
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
titers	O
of	O
1:160	O
or	O
more	O
were	O
GBS	O
patients	B
.	O

The	O
IgM	O
anti	O
-	O
LM1	O
antibody	O
was	O
detected	O
in	O
only	O
two	O
patients	B
,	O
one	O
with	O
GBS	O
and	O
the	O
other	O
with	O
MFS	O
.	O

The	O
binding	O
of	O
the	O
patients	B
'	O
antibody	O
to	O
LM1	O
was	O
confirmed	O
by	O
TLC	O
-	O
immunostaining	O
(	O
Fig.	O
2	O
)	O
.	O

Follow	O
-	O
up	O
serum	O
samples	O
were	O
available	O
from	O
three	O
patients	B
(	O
patients	B
3	B
,	O
4	B
and	O
5	B
)	O
.	O

Anti	O
-	O
LM1	O
IgG	O
antibody	O
titer	O
decreased	O
over	O
the	O
course	O
of	O
the	O
disease	O
in	O
each	O
patient	B
;	O
1:80	O
on	O
day	O
2	O
of	O
neurological	O
onset	O
and	O
1:40	O
on	O
day	O
7	O
in	O
patient	B
3	I
;	O
1:160	O
on	O
day	O
3	O
,	O
1:80	O
on	O
day	O
12	O
and	O
<	O
1:40	O
on	O
day	O
25	O
in	O
patient	B
4	I
;	O
1:640	O
on	O
day	O
2	O
and	O
<	O
1:40	O
on	O
day	O
22	O
in	O
patient	B
5	I
.	O

No	O
anti	O
-	O
LM1	O
antibody	O
was	O
detected	O
either	O
in	O
the	O
normal	O
or	O
in	O
the	O
disease	O
controls	O
other	O
than	O
CIDP	O
and	O
MFS	O
.	O

Six	O
of	O
seven	O
GBS	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
also	O
had	O
antibodies	O
against	O
other	O
gangliosides	O
.	O

In	O
particular	O
,	O
five	O
patients	B
had	O
the	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
(	O
Table	O
1	O
)	O
.	O

The	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
was	O
detected	O
in	O
14	O
of	O
the	O
140	O
serum	O
samples	O
of	O
patients	B
with	O
GBS	O
.	O

The	O
percentage	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
-	O
positive	O
cases	O
was	O
significantly	O
higher	O
in	O
GBS	O
cases	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
than	O
in	O
those	O
without	O
it	O
(	O
P	O
<	O
0.001	O
)	O
.	O

3.2	O
Clinical	O
features	O
of	O
GBS	O
patients	B
with	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
Of	O
the	O
seven	O
cases	O
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
respiratory	O
tract	O
infection	O
preceded	O
the	O
onset	O
of	O
GBS	O
in	O
five	O
patients	B
and	O
gastrointestinal	O
tract	O
infection	O
in	O
two	O
patients	B
.	O

All	O
the	O
five	O
patients	B
in	O
whom	O
the	O
onset	O
of	O
GBS	O
was	O
preceded	O
by	O
respiratory	O
tract	O
infection	O
had	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
.	O

Four	O
of	O
those	O
five	O
patients	B
had	O
ophthalmoplegia	O
.	O

One	O
of	O
the	O
two	O
patients	B
(	O
patient	B
7	I
)	O
with	O
preceding	O
gastrointestinal	O
infection	O
had	O
an	O
antibody	O
to	O
Campylobacter	B
jejuni	I
(	O
C.	B
jejuni	I
)	O
.	O

Electrophysiological	O
examinations	O
showed	O
that	O
four	O
of	O
the	O
seven	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
were	O
of	O
the	O
AIDP	O
type	O
and	O
one	O
patient	B
(	O
patient	B
7	I
)	O
was	O
of	O
the	O
AIDP	O
type	O
with	O
axonal	O
damage	O
.	O

In	O
the	O
remaining	O
two	O
patients	B
,	O
no	O
abnormal	O
findings	O
were	O
seen	O
electrophysiologically	O
.	O

Plasmapheresis	O
was	O
performed	O
for	O
all	O
those	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

One	O
month	O
after	O
the	O
onset	O
of	O
neuropathy	O
,	O
six	O
patients	B
had	O
recovered	O
to	O
clinical	O
Grade	O
1	O
,	O
whereas	O
only	O
patient	B
7	I
still	O
had	O
Grade	O
4	O
.	O

4	O
Discussion	O
We	O
detected	O
the	O
IgG	O
antibody	O
to	O
LM1	O
in	O
the	O
sera	O
of	O
7	O
out	O
of	O
140	O
(	O
5	O
%	O
)	O
GBS	O
patients	B
,	O
1	O
out	O
of	O
33	O
(	O
3.0	O
%	O
)	O
CIDP	O
patients	B
,	O
and	O
2	O
out	O
of	O
47	O
(	O
4.3	O
%	O
)	O
MFS	O
patients	B
.	O

The	O
IgM	O
antibody	O
to	O
LM1	O
was	O
found	O
only	O
in	O
two	O
patients	B
,	O
each	O
with	O
GBS	O
and	O
MFS	O
.	O

The	O
sera	O
of	O
patients	B
with	O
other	O
diseases	O
and	O
of	O
the	O
normal	O
controls	O
did	O
not	O
contain	O
anti	O
-	O
LM1	O
antibodies	O
.	O

Several	O
research	O
groups	O
have	O
found	O
serum	O
anti	O
-	O
LM1	O
antibodies	O
in	O
patients	B
with	O
demyelinating	O
neuropathies	O
[	O
9–11	O
]	O
,	O
however	O
,	O
the	O
results	O
are	O
conflicting	O
.	O

Fredman	O
et	O
al.	O
[	O
9	O
]	O
reported	O
that	O
43	O
%	O
of	O
GBS	O
patients	B
,	O
67	O
%	O
of	O
CIDP	O
patients	B
and	O
20	O
%	O
of	O
the	O
normal	O
controls	O
had	O
anti	O
-	O
LM1	O
antibodies	O
,	O
mostly	O
of	O
the	O
IgG	O
type	O
.	O

Ilyas	O
et	O
al.	O
[	O
10	O
]	O
reported	O
that	O
23	O
%	O
of	O
GBS	O
patients	B
and	O
2.3	O
%	O
of	O
the	O
disease	O
and	O
normal	O
controls	O
had	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
but	O
no	O
significant	O
elevation	O
of	O
anti	O
-	O
LM1	O
IgM	O
antibody	O
titers	O
was	O
detected	O
.	O

Yuki	O
et	O
al.	O
[	O
11	O
]	O
found	O
the	O
IgG	O
antibody	O
to	O
LM1	O
in	O
8	O
%	O
of	O
GBS	O
patients	B
,	O
3	O
%	O
of	O
CIDP	O
patients	B
and	O
5	O
%	O
of	O
MFS	O
patients	B
,	O
and	O
the	O
IgM	O
antibody	O
to	O
LM1	O
in	O
13	O
%	O
of	O
GBS	O
patients	B
,	O
7	O
%	O
of	O
CIDP	O
patients	B
and	O
7	O
%	O
of	O
MFS	O
patients	B
.	O

These	O
differences	O
in	O
results	O
could	O
have	O
been	O
caused	O
by	O
differences	O
in	O
the	O
cut	O
-	O
off	O
levels	O
of	O
the	O
methods	O
used	O
and	O
in	O
the	O
immunogenetic	O
background	O
.	O

We	O
then	O
investigated	O
the	O
clinical	O
and	O
electrophysiological	O
features	O
of	O
GBS	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
,	O
which	O
have	O
never	O
been	O
reported	O
so	O
far	O
.	O

Considering	O
that	O
LM1	O
is	O
the	O
predominant	O
ganglioside	O
in	O
the	O
peripheral	O
nerve	O
myelin	O
,	O
the	O
anti	O
-	O
LM1	O
antibody	O
can	O
possibly	O
play	O
a	O
role	O
as	O
a	O
demyelinating	O
factor	O
in	O
the	O
pathogenesis	O
of	O
GBS	O
.	O

Of	O
the	O
seven	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
in	O
this	O
study	O
,	O
demyelination	O
was	O
confirmed	O
in	O
five	O
,	O
and	O
two	O
patients	B
were	O
labeled	O
as	O
unclassifiable	O
.	O

Only	O
patient	B
7	I
,	O
subsequent	O
to	O
C.	B
jejuni	I
infection	O
,	O
had	O
electrophysiological	O
findings	O
suggestive	O
of	O
axonal	O
damage	O
in	O
addition	O
to	O
demyelination	O
.	O

GBS	O
patients	B
subsequent	O
to	O
C.	B
jejuni	I
infection	O
have	O
been	O
reported	O
to	O
frequently	O
have	O
axonal	O
degeneration	O
[	O
8	O
]	O
.	O

In	O
patient	B
7	I
,	O
some	O
other	O
factor	O
induced	O
by	O
the	O
preceding	O
C.	B
jejuni	I
infection	O
might	O
also	O
be	O
elevated	O
to	O
cause	O
axonal	O
damage	O
.	O

Except	O
for	O
patient	B
7	I
,	I
all	O
patients	B
with	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
exhibited	O
good	O
recovery	O
,	O
being	O
classified	O
Grade	O
1	O
within	O
one	O
month	O
of	O
the	O
onset	O
of	O
neuropathy	O
.	O

The	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
might	O
be	O
a	O
demyelinating	O
factor	O
,	O
not	O
being	O
associated	O
with	O
axonal	O
degeneration	O
.	O

Five	O
of	O
the	O
seven	O
GBS	O
patients	B
with	O
an	O
elevated	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
titer	O
also	O
had	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
elevation	O
.	O

This	O
percentage	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
GBS	O
patient	B
group	O
without	O
the	O
anti	O
-	O
LM1	O
IgG	O
antibody	O
.	O

The	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
is	O
specifically	O
and	O
very	O
frequently	O
found	O
in	O
patients	B
with	O
MFS	O
and	O
GBS	O
with	O
ophthalmoplegia	O
[	O
12,13	O
]	O
.	O

As	O
ganglioside	O
GQ1b	O
is	O
localized	O
in	O
the	O
paranodal	O
regions	O
of	O
the	O
human	B
cranial	O
nerves	O
innervating	O
the	O
extraocular	O
muscles	O
,	O
it	O
could	O
be	O
a	O
causative	O
factor	O
of	O
ophthalmoplegia	O
in	O
MFS	O
and	O
GBS	O
[	O
13	O
]	O
.	O

Because	O
the	O
carbohydrate	O
structure	O
of	O
LM1	O
is	O
quite	O
different	O
from	O
that	O
of	O
GQ1b	O
(	O
Table	O
2	O
)	O
,	O
coexistence	O
of	O
antibody	O
activities	O
against	O
LM1	O
and	O
GQ1b	O
can	O
not	O
be	O
explained	O
by	O
cross	O
-	O
reactivity	O
.	O

Most	O
of	O
the	O
patients	B
with	O
elevated	O
titers	O
of	O
anti	O
-	O
GQ1b	O
IgG	O
antibody	O
have	O
the	O
antecedent	O
respiratory	O
tract	O
infections	O
(	O
Kusunoki	O
et	O
al.	O
,	O
unpublished	O
observation	O
)	O
.	O

The	O
data	O
in	O
this	O
study	O
show	O
that	O
all	O
five	O
patients	B
with	O
both	O
the	O
anti	O
-	O
LM1	O
and	O
anti	O
-	O
GQ1b	O
IgG	O
antibodies	O
in	O
the	O
serum	O
had	O
a	O
respiratory	O
tract	O
infection	O
before	O
the	O
onset	O
of	O
neuropathy	O
.	O

This	O
is	O
in	O
striking	O
contrast	O
to	O
antibodies	O
to	O
GM1	O
and	O
GalNAc	O
-	O
GD1a	O
,	O
which	O
are	O
elevated	O
mainly	O
subsequent	O
to	O
gastrointestinal	O
tract	O
infections	O
[	O
2,14	O
]	O
.	O

Elevated	O
titers	O
of	O
both	O
anti	O
-	O
GQ1b	O
and	O
anti	O
-	O
LM1	O
antibodies	O
may	O
be	O
associated	O
with	O
some	O
unknown	O
infectious	O
agent	O
(	O
s	O
)	O
affecting	O
the	O
respiratory	O
tract	O
.	O

Direct	O
evidence	O
that	O
anti	O
-	O
LM1	O
antibodies	O
cause	O
demyelination	O
has	O
not	O
yet	O
been	O
shown	O
.	O

Although	O
the	O
anti	O
-	O
LM1	O
antibody	O
is	O
present	O
in	O
only	O
about	O
5	O
%	O
of	O
GBS	O
patients	B
,	O
it	O
is	O
still	O
an	O
important	O
clue	O
to	O
understanding	O
the	O
pathogenetic	O
mechanisms	O
of	O
demyelination	O
in	O
a	O
subset	O
of	O
GBS	O
cases	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
see	O
whether	O
it	O
is	O
actually	O
a	O
demyelinating	O
factor	O
or	O
not	O
.	O

Acknowledgments	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
of	O
Japan	O
(	O
10670576	O
)	O
,	O
and	O
by	O
a	O
Research	O
Grant	O
for	O
Neuroimmunological	O
Diseases	O
from	O
the	O
Ministry	O
of	O
Health	O
and	O
Welfare	O
of	O
Japan	O
.	O

We	O
thank	O
Ms	O
R.	O
Mashiko	O
and	O
Ms	O
H.	O
Mashiko	O
for	O
their	O
technical	O
assistance	O
.	O

We	O
also	O
thank	O
Drs	O
K.	O
Ikeguchi	O
,	O
K.	O
Fujiwara	O
,	O
Y.	O
Yasukawa	O
,	O
K.	O
Ohta	O
,	O
N.	O
Shima	O
and	O
K.	O
Arimura	O
for	O
providing	O
us	O
with	O
the	O
clinical	O
information	O
of	O
the	O
patients	B
.	O

Chalcone	O
synthase	O
(	O
CHS	O
,	O
E.C.	O
2.3.1.74	O
)	O
catalyzes	O
the	O
first	O
reaction	O
of	O
flavonoid	O
biosynthesis	O
and	O
stilbene	O
synthase	O
(	O
STS	O
,	O
E.C.	O
2.3.1.95	O
)	O
catalyzes	O
biosynthesis	O
of	O
stilbene	O
backbone	O
of	O
stilbene	O
-	O
type	O
phytoalexins	O
.	O

CHS	O
and	O
STS	O
are	O
similar	O
both	O
in	O
mechanistic	O
and	O
structural	O
aspects	O
and	O
are	O
representative	O
members	O
of	O
the	O
CHS	O
superfamily	O
[	O
1	O
]	O
.	O

CHS	O
and	O
STS	O
are	O
homodimers	O
of	O
identical	O
subunits	O
of	O
43	O
kDa	O
and	O
catalyze	O
repetitive	O
decarboxylative	O
condensation	O
of	O
a	O
p	O
-coumaroyl	O
residue	O
with	O
three	O
C2	O
-units	O
from	O
malonyl	O
-	O
CoA.	O
Although	O
both	O
enzymes	O
share	O
common	O
starting	O
materials	O
with	O
identical	O
stoichiometry	O
and	O
apparently	O
use	O
the	O
same	O
condensation	O
mechanism	O
up	O
to	O
the	O
common	O
tetraketide	O
intermediate	O
,	O
CHS	O
and	O
STS	O
catalyze	O
different	O
ring	O
closure	O
reactions	O
involving	O
different	O
atoms	O
to	O
give	O
rise	O
to	O
different	O
products	O
,	O
naringenin	O
chalcone	O
and	O
resveratrol	O
,	O
respectively	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
amino	O
acid	O
homology	O
between	O
these	O
two	O
enzymes	O
is	O
more	O
than	O
65	O
%	O
,	O
and	O
a	O
phylogenetic	O
analysis	O
showed	O
a	O
higher	O
homology	O
between	O
CHS	O
and	O
STS	O
from	O
related	O
plants	B
than	O
among	O
CHSs	O
and	O
STSs	O
,	O
suggesting	O
that	O
STSs	O
have	O
evolved	O
from	O
CHSs	O
several	O
times	O
independently	O
[	O
2	O
]	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
,	O
under	O
certain	O
in	O
vitro	O
conditions	O
,	O
CHS	O
produces	O
not	O
only	O
naringenin	O
chalcone	O
but	O
also	O
triacetic	O
acid	O
lactone	O
(	O
TAL	O
)	O
and	O
styrylpyrone	O
as	O
early	O
release	O
(	O
derailment	O
)	O
byproducts	O
[	O
3,4	O
]	O
.	O

TAL	O
was	O
also	O
detected	O
from	O
the	O
reaction	O
products	O
by	O
fatty	O
acid	O
synthase	O
[	O
5	O
]	O
and	O
certain	O
polyketide	O
synthases	O
[	O
6,7	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
such	O
derailment	O
products	O
have	O
not	O
been	O
observed	O
in	O
the	O
reaction	O
catalyzed	O
by	O
STS	O
[	O
8	O
]	O
.	O

Using	O
purified	O
Pueraria	B
lobata	I
(	O
kudzu	B
)	O
CHS	O
and	O
Arachis	B
hypogaea	I
(	O
peanut	B
)	O
STS	O
that	O
was	O
overexpressed	O
in	O
Escherichia	B
coli	I
,	O
we	O
have	O
detected	O
bisnoryangonin	O
(	O
BNY	O
,	O
the	O
derailed	O
lactone	O
after	O
two	O
condensations	O
)	O
and	O
p	O
-coumaroyltriacetic	O
acid	O
lactone	O
(	O
CTAL	O
,	O
the	O
derailed	O
lactone	O
after	O
three	O
condensations	O
)	O
from	O
the	O
reaction	O
products	O
produced	O
by	O
either	O
CHS	O
or	O
STS	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
cross	O
-	O
reaction	O
between	O
CHS	O
and	O
STS	O
,	O
i.e.	O
resveratrol	O
production	O
by	O
CHS	O
and	O
naringenin	O
production	O
by	O
STS	O
in	O
small	O
but	O
detectable	O
amounts	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Cloning	O
Transcription	O
of	O
STS	O
was	O
induced	O
by	O
cutting	O
peanut	B
seedlings	O
(	O
Sakata	O
,	O
Japan	O
)	O
into	O
slices	O
(	O
1	O
mm	O
thick	O
)	O
that	O
had	O
been	O
immersed	O
in	O
water	O
for	O
3	O
days	O
[	O
9	O
]	O
.	O

The	O
slices	O
were	O
then	O
left	O
overnight	O
in	O
water	O
at	O
25	O
°	O
C	O
in	O
darkness	O
.	O

Total	O
RNA	O
was	O
prepared	O
by	O
the	O
phenol	O
method	O
.	O

cDNA	O
was	O
synthesized	O
using	O
an	O
oligo	O
dT	O
-	O
Xba	O
I	O
primer	O
(	O
5′-GTC	O
GAC	O
TCT	O
AGA	O
(	O
T	O
)	O
15	O
-3′	O
)	O
and	O
PCR	O
-	O
amplified	O
with	O
primers	O
designed	O
from	O
the	O
published	O
A.	B
hypogaea	I
STS	O
sequence	O
[	O
10	O
]	O
;	O
the	O
forward	O
primer	O
(	O
5′-CAT	O
CCA	O
TG	O
G	O
TGT	O
CTG	O
TGA	O
GTG	O
AAT	O
TC-3′	O
)	O
and	O
the	O
reverse	O
primer	O
(	O
5′-GTA	O
TTA	O
TAT	O
GGC	O
CAT	O
GCT	O
GCG	O
GAG-3′	O
)	O
.	O

The	O
forward	O
primer	O
carries	O
an	O
Nco	O
I	O
site	O
suitable	O
for	O
cloning	O
into	O
the	O
expression	O
vector	O
,	O
pET-3d	O
.	O

The	O
resulting	O
PCR	O
product	O
was	O
first	O
blunt	O
-	O
ligated	O
into	O
the	O
Sma	O
I	O
site	O
of	O
pBluescriptIISK	O
(	O
+	O
)	O
(	O
MBI	O
Fermentas	O
)	O
,	O
rescued	O
by	O
Nco	O
I	O
/	O
Bam	O
HI	O
digestion	O
,	O
and	O
ligated	O
into	O
the	O
Nco	O
I	O
/	O
Bam	O
HI	O
restricted	O
vector	O
pET-3d	O
to	O
give	O
pET-3d	O
/	O
STS	O
.	O

The	O
Nco	O
I	O
digestion	O
was	O
carried	O
out	O
in	O
the	O
presence	O
of	O
EtBr	O
(	O
40	O
μg	O
/	O
ml	O
)	O
to	O
obtain	O
the	O
1.2-kb	O
full	O
-	O
length	O
cDNA	O
because	O
of	O
the	O
presence	O
of	O
another	O
Nco	O
I	O
site	O
in	O
the	O
coding	O
region	O
.	O

DNA	O
sequencing	O
was	O
carried	O
out	O
on	O
both	O
strands	O
with	O
several	O
forward	O
and	O
reverse	O
primers	O
using	O
the	O
Dye	O
Terminator	O
Cycle	O
Sequencing	O
kit	O
from	O
Applied	O
Biosystems	O
(	O
CA	O
,	O
USA	O
)	O
.	O

Construction	O
of	O
pET-3d	O
/	O
CHS	O
using	O
similar	O
methods	O
has	O
been	O
described	O
[	O
11	O
]	O
.	O

2.2	O
Protein	O
expression	O
and	O
purification	O
E.	B
coli	I
BL21	I
(	I
DE3	I
)	I
pLysE	I
cells	O
transformed	O
with	O
either	O
pET-3d	O
/	O
CHS	O
or	O
pET-3d	O
/	O
STS	O
were	O
grown	O
at	O
37	O
°	O
C	O
in	O
LB	O
medium	O
containing	O
50	O
μg	O
/	O
ml	O
ampicillin	O
and	O
25	O
μg	O
/	O
ml	O
chloramphenicol	O
and	O
induced	O
with	O
0.4	O
mM	O
IPTG	O
.	O

After	O
an	O
induction	O
period	O
of	O
4	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
cells	O
were	O
harvested	O
,	O
washed	O
and	O
suspended	O
in	O
buffer	O
A	O
(	O
10	O
mM	O
potassium	O
phosphate	O
(	O
KPi	O
)	O
buffer	O
(	O
pH	O
7.5	O
)	O
,	O
2	O
mM	O
DTT	O
)	O
.	O

Following	O
sonication	O
(	O
10	O
s	O
×10	O
)	O
on	O
ice	O
and	O
centrifugation	O
(	O
12	O
000	O
×	O
g	O
,	O
4	O
°	O
C	O
,	O
15	O
min	O
)	O
,	O
soluble	O
fractions	O
were	O
obtained	O
.	O

After	O
(	O
NH4	O
)	O
2	O
SO4	O
precipitation	O
(	O
30–80	O
%	O
saturation	O
)	O
,	O
CHS	O
was	O
purified	O
to	O
apparent	O
homogeneity	O
by	O
successive	O
chromatography	O
procedures	O
:	O
(	O
1	O
)	O
DEAE	O
-	O
Toyopearl	O
(	O
TOSOH	O
,	O
Tokyo	O
,	O
Japan	O
)	O
anion	O
exchange	O
chromatography	O
using	O
a	O
linear	O
gradient	O
of	O
NaCl	O
(	O
0–500	O
mM	O
)	O
in	O
buffer	O
A	O
,	O
(	O
2	O
)	O
Bio	O
-	O
Gel	O
hydroxyapatite	O
(	O
Bio	O
-	O
Rad	O
)	O
using	O
a	O
linear	O
gradient	O
of	O
10–300	O
mM	O
KPi	O
(	O
pH	O
7.5	O
)	O
containing	O
2	O
mM	O
DTT	O
and	O
(	O
3	O
)	O
chromatofocusing	O
on	O
polybuffer	O
exchanger	O
(	O
PBE94	O
,	O
Pharmacia	O
)	O
pre	O
-	O
equilibrated	O
with	O
25	O
mM	O
imidazole	O
-	O
HCl	O
(	O
pH	O
7.4	O
)	O
,	O
2	O
mM	O
DTT	O
and	O
eluted	O
with	O
Polybuffer74-HCl	O
(	O
pH	O
5.0	O
)	O
,	O
2	O
mM	O
DTT	O
.	O

STS	O
was	O
similarly	O
purified	O
after	O
successive	O
DEAE	O
ion	O
exchange	O
and	O
hydroapatite	O
chromatography	O
steps	O
.	O

Protein	O
contents	O
were	O
determined	O
with	O
Bradford	O
's	O
dye	O
method	O
(	O
Bio	O
-	O
Rad	O
)	O
[	O
12	O
]	O
,	O
using	O
bovine	B
serum	O
albumin	O
as	O
standard	O
.	O

Expression	O
and	O
purification	O
of	O
P.	B
lobata	I
CHS	O
and	O
A.	B
hypogaea	I
STS	O
as	O
thioredoxin	O
-	O
HisTag	O
fusion	O
proteins	O
(	O
Trx	O
-	O
CHS	O
and	O
Trx	O
-	O
STS	O
)	O
used	O
in	O
the	O
LC	O
-	O
MS	O
analysis	O
of	O
cross	O
-	O
reaction	O
will	O
be	O
described	O
elsewhere	O
.	O

2.3	O
Enzyme	O
assay	O
For	O
both	O
CHS	O
and	O
STS	O
,	O
the	O
reaction	O
mixture	O
(	O
0.1	O
ml	O
)	O
contained	O
appropriate	O
amounts	O
of	O
protein	O
(	O
2–5	O
μg	O
of	O
purified	O
enzyme	O
)	O
,	O
0.1	O
mM	O
p	O
-coumaroyl	O
-	O
CoA	O
and	O
16.8	O
μM	O
[	O
2	O
-	O
14	O
C	O
]	O
malonyl	O
-	O
CoA	O
(	O
2.2	O
GBq	O
/	O
mmol	O
,	O
NEN	O
)	O
in	O
0.1	O
M	O
KPi	O
buffer	O
(	O
pH	O
7.5	O
)	O
(	O
K2	O
HPO4	O
/KH2	O
PO4	O
)	O
containing	O
2	O
mM	O
DTT	O
.	O

After	O
incubation	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
,	O
50	O
μl	O
of	O
50	O
%	O
acetic	O
acid	O
was	O
added	O
and	O
the	O
reaction	O
products	O
were	O
extracted	O
with	O
200	O
μl	O
of	O
ethyl	O
acetate	O
.	O

A	O
portion	O
(	O
50	O
μl	O
)	O
of	O
the	O
extract	O
was	O
analyzed	O
by	O
TLC	O
on	O
RP18	O
plate	O
(	O
Merck	O
)	O
with	O
methanol	O
:	O
H2	O
O	O
:	O
acetic	O
acid	O
(	O
60:40:1	O
)	O
as	O
solvent	O
and	O
the	O
radioactive	O
products	O
were	O
quantified	O
with	O
an	O
Imaging	O
Plate	O
analyzer	O
(	O
BAS2000	O
,	O
Fuji	O
)	O
.	O

Authentic	O
compounds	O
,	O
TAL	O
(	O
R	O
f	O
=	O
0.65	O
,	O
Tokyo	O
Kasei	O
)	O
,	O
resveratrol	O
(	O
R	O
f	O
=	O
0.50	O
,	O
Sigma	O
)	O
and	O
naringenin	O
(	O
R	O
f	O
=	O
0.32	O
,	O
Nacalai	O
tesque	O
)	O
were	O
used	O
as	O
internal	O
standards	O
to	O
identify	O
the	O
products	O
.	O

The	O
specific	O
enzyme	O
activity	O
was	O
expressed	O
in	O
pmol	O
of	O
the	O
product	O
produced	O
/	O
s	O
/	O
mg	O
(	O
pkat	O
/	O
mg	O
)	O
.	O

2.4	O
Identification	O
of	O
bisnoryangonin	O
and	O
p	O
-coumaroyltriacetic	O
acid	O
lactone	O
For	O
identification	O
of	O
BNY	O
,	O
the	O
ethyl	O
acetate	O
-	O
extracted	O
products	O
produced	O
by	O
STS	O
and	O
CHS	O
were	O
first	O
separated	O
by	O
HPLC	O
.	O

The	O
column	O
(	O
5	O
μm	O
,	O
4.6	O
mm	O
I.D.	O
×150	O
mm	O
,	O
ODS80Ts	O
,	O
TOSOH	O
)	O
was	O
washed	O
at	O
a	O
flow	O
rate	O
of	O
0.6	O
ml	O
/	O
min	O
at	O
40	O
°	O
C	O
with	O
45	O
%	O
methanol	O
in	O
H2	O
O	O
containing	O
1	O
%	O
acetic	O
acid	O
for	O
10	O
min	O
and	O
then	O
the	O
concentration	O
of	O
methanol	O
was	O
increased	O
to	O
55	O
%	O
during	O
the	O
next	O
30	O
min	O
.	O

Detection	O
was	O
with	O
an	O
UV	O
monitor	O
at	O
254	O
nm	O
.	O

The	O
peak	O
at	O
R	O
t	O
=	O
16.3	O
min	O
was	O
collected	O
and	O
,	O
after	O
evaporation	O
of	O
the	O
solvent	O
,	O
the	O
residues	O
were	O
dissolved	O
in	O
methanol	O
and	O
reacted	O
with	O
trimethylsilyldiazomethane	O
in	O
the	O
dark	O
for	O
30	O
min	O
at	O
22	O
°	O
C	O
.	O

The	O
resulting	O
sample	O
was	O
subjected	O
to	O
GC	O
-	O
MS	O
(	O
Hewlett	O
Packard	O
5890	O
coupled	O
with	O
JEOL	O
JMS	O
-	O
SX102A	O
)	O
analysis	O
using	O
a	O
DB5	O
column	O
(	O
0.25	O
mm	O
I.D.	O
×30	O
m	O
,	O
film	O
thickness	O
0.25	O
μm	O
,	O
J	O
and	O
W	O
)	O
at	O
200	O
°	O
C	O
to	O
250	O
°	O
C	O
(	O
10	O
°	O
C	O
/	O
min	O
)	O
.	O

The	O
retention	O
time	O
and	O
mass	O
spectrum	O
were	O
found	O
to	O
be	O
identical	O
to	O
those	O
of	O
authentic	O
yangonin	O
:	O
GC	O
,	O
R	O
t	O
=	O
22	O
min	O
;	O
EIMS	O
(	O
70	O
eV	O
,	O
m	O
/z	O
)	O
,	O
258	O
(	O
M+	O
)	O
,	O
230	O
,	O
187	O
.	O

Production	O
of	O
CTAL	O
by	O
CHS	O
and	O
STS	O
was	O
confirmed	O
by	O
LC	O
-	O
MS	O
(	O
see	O
below	O
)	O
.	O

CTAL	O
:	O
Multi	O
-	O
stage	O
LC	O
-	O
APCIMS	O
,	O
MS	O
m	O
/z	O
273.1	O
[	O
M+H	O
]	O
+	O
,	O
271.1	O
[	O
M−H	O
]	O
−	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
of	O
m	O
/z	O
271.1	O
)	O
227.2	O
[	O
M−H−CO2	O
]	O
−	O
,	O
MS	O
/	O
MS	O
/	O
MS	O
(	O
transitions	O
m	O
/z	O
271.1>227.2	O
)	O
185.2	O
[	O
M−H−CO2	O
−CH2	O
CO	O
]	O
−	O
.	O

2.5	O
Cross	O
-	O
reaction	O
The	O
enzyme	O
reaction	O
was	O
carried	O
out	O
under	O
the	O
same	O
conditions	O
as	O
described	O
above	O
except	O
that	O
the	O
reaction	O
volume	O
was	O
1	O
ml	O
and	O
about	O
50	O
μg	O
of	O
enzyme	O
(	O
10–40	O
pkat	O
/	O
mg	O
)	O
was	O
used	O
.	O

Radioactive	O
products	O
thus	O
obtained	O
were	O
redissolved	O
in	O
500	O
μl	O
of	O
50	O
%	O
aqueous	O
methanol	O
containing	O
1	O
%	O
acetic	O
acid	O
in	O
which	O
authentic	O
resveratrol	O
(	O
1.5	O
μg	O
)	O
and	O
naringenin	O
(	O
2	O
μg	O
)	O
were	O
added	O
.	O

Using	O
a	O
Hitachi	O
655	O
HPLC	O
system	O
and	O
ODS-80Ts	O
column	O
(	O
TOSOH	O
)	O
,	O
the	O
radioactive	O
products	O
were	O
separated	O
with	O
isocratic	O
elution	O
with	O
50	O
%	O
aqueous	O
methanol	O
containing	O
1	O
%	O
acetic	O
acid	O
for	O
30	O
min	O
.	O

Radioactivity	O
of	O
each	O
0.5	O
ml	O
fraction	O
was	O
measured	O
with	O
a	O
β	O
-	O
scintillation	O
counter	O
and	O
the	O
fractions	O
corresponding	O
to	O
main	O
product	O
(	O
naringenin	O
for	O
CHS	O
and	O
resveratrol	O
for	O
STS	O
)	O
and	O
cross	O
-	O
reaction	O
product	O
(	O
resveratrol	O
for	O
CHS	O
and	O
naringenin	O
for	O
STS	O
)	O
were	O
collected	O
.	O

For	O
carrier	O
dilution	O
analysis	O
,	O
recrystallization	O
of	O
the	O
radioactive	O
products	O
with	O
carrier	O
compounds	O
was	O
performed	O
at	O
least	O
four	O
times	O
in	O
two	O
different	O
solvent	O
systems	O
(	O
methanol	O
and	O
ethyl	O
acetate	O
/	O
hexane	O
)	O
and	O
specific	O
radioactivity	O
was	O
measured	O
after	O
each	O
recrystallization	O
step	O
.	O

The	O
identity	O
of	O
the	O
cross	O
-	O
reaction	O
products	O
was	O
further	O
confirmed	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
.	O

First	O
,	O
the	O
CHS	O
and	O
STS	O
reaction	O
products	O
were	O
methylated	O
with	O
trimethylsilyldiazomethane	O
and	O
analyzed	O
by	O
GC	O
-	O
MS	O
as	O
described	O
above	O
.	O

From	O
the	O
methylated	O
CHS	O
reaction	O
products	O
,	O
a	O
peak	O
of	O
m	O
/z	O
=	O
256	O
(	O
R	O
t	O
=	O
12.99	O
min	O
)	O
corresponding	O
to	O
dimethylresveratrol	O
was	O
detected	O
with	O
mono-	O
(	O
m	O
/z	O
286	O
)	O
,	O
di-	O
(	O
m	O
/z	O
300	O
)	O
and	O
trimethylnaringenin	O
(	O
m	O
/z	O
314	O
)	O
.	O

Likewise	O
,	O
a	O
peak	O
of	O
m	O
/z	O
=	O
300	O
(	O
R	O
t	O
=	O
15.35	O
min	O
)	O
corresponding	O
to	O
dimethylnaringenin	O
was	O
detected	O
from	O
the	O
methylated	O
STS	O
reaction	O
mixture	O
together	O
with	O
di-	O
(	O
m	O
/z	O
256	O
)	O
and	O
trimethylresveratrol	O
(	O
m	O
/z	O
270	O
)	O
.	O

For	O
LC	O
-	O
MS	O
analysis	O
,	O
Trx	O
-	O
CHS	O
(	O
11	O
mg	O
,	O
250	O
pkat	O
)	O
or	O
Trx	O
-	O
STS	O
(	O
9.5	O
mg	O
,	O
160	O
pkat	O
)	O
was	O
incubated	O
with	O
0.1	O
mM	O
p	O
-coumaroyl	O
-	O
CoA	O
and	O
0.3	O
mM	O
malonyl	O
-	O
CoA	O
in	O
50	O
ml	O
of	O
0.1	O
M	O
KPi	O
buffer	O
(	O
pH	O
7.4	O
)	O
containing	O
1	O
mM	O
DTT	O
for	O
40	O
min	O
at	O
37	O
°	O
C	O
.	O

At	O
the	O
end	O
of	O
incubation	O
,	O
the	O
pH	O
was	O
raised	O
to	O
9	O
with	O
1	O
N	O
NaOH	O
,	O
and	O
the	O
reaction	O
mixture	O
was	O
further	O
incubated	O
at	O
37	O
°	O
C	O
for	O
another	O
10	O
min	O
to	O
complete	O
chemical	O
transformation	O
of	O
naringenin	O
chalcone	O
to	O
naringenin	O
[	O
13	O
]	O
.	O

The	O
ethyl	O
acetate	O
extract	O
was	O
dried	O
over	O
Na2	O
SO4	O
and	O
the	O
solvent	O
was	O
removed	O
under	O
vacuum	O
at	O
30	O
°	O
C	O
.	O

The	O
remaining	O
products	O
were	O
analyzed	O
by	O
LC	O
-	O
MS	O
(	O
Thermoquest	O
LCQ	O
)	O
as	O
previously	O
described	O
[	O
14	O
]	O
.	O

Resveratrol	O
:	O
LC	O
-	O
APCIMS	O
(	O
positive	O
)	O
,	O
229.1	O
[	O
M+H	O
]	O
+	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
at	O
229	O
)	O
m	O
/z	O
(	O
rel	O
.	O

%	O
)	O
211	O
(	O
65	O
)	O
,	O
135	O
(	O
100	O
)	O
,	O
119	O
(	O
12	O
)	O
,	O
107	O
(	O
11	O
)	O
.	O

Naringenin	O
:	O
LC	O
-	O
APCIMS	O
(	O
positive	O
)	O
,	O
273.2	O
[	O
M+H	O
]	O
+	O
,	O
MS	O
/	O
MS	O
(	O
precursor	O
ion	O
at	O
273	O
)	O
m	O
/z	O
(	O
rel	O
.	O

%	O
)	O
171	O
(	O
18	O
)	O
,	O
153	O
(	O
80	O
)	O
,	O
147	O
(	O
100	O
)	O
.	O

3	O
Results	O
3.1	O
Sequence	O
of	O
A.	B
hypogaea	I
STS	O
When	O
the	O
deduced	O
amino	O
acid	O
sequence	O
of	O
Japanese	B
peanut	I
STS	O
cloned	O
in	O
this	O
study	O
(	O
Accession	O
number	O
:	O
AB027606	O
)	O
was	O
compared	O
to	O
the	O
published	O
peanut	B
STS	O
sequence	O
(	O
Swiss	O
-	O
Prot	O
P20178	O
)	O
[	O
10	O
]	O
,	O
8	O
out	O
of	O
389	O
amino	O
acids	O
were	O
found	O
to	O
be	O
different	O
.	O

Those	O
are	O
Ser-46	O
corresponding	O
to	O
Gly-46	O
in	O
Ref	O
.	O

[	O
10	O
]	O
,	O
Ser-195	O
to	O
Ala-195	O
,	O
Ser-202	O
to	O
Asn-202	O
,	O
Leu-236	O
to	O
Ile-236	O
,	O
Asp-281	O
to	O
Gly-281	O
,	O
Pro-304	O
to	O
Leu-304	O
,	O
Glu-315	O
to	O
Gln-315	O
and	O
Ala-356	O
to	O
Thr-356	O
.	O

This	O
difference	O
in	O
amino	O
acid	O
sequence	O
probably	O
reflects	O
different	O
origins	O
of	O
the	O
plant	B
materials	O
used	O
.	O

3.2	O
Purification	O
of	O
CHS	O
and	O
STS	O
Purification	O
of	O
CHS	O
and	O
STS	O
overexpressed	O
in	O
E.	B
coli	I
is	O
summarized	O
in	O
Table	O
1	O
.	O

Typical	O
experiments	O
yielded	O
0.3–0.4	O
mg	O
of	O
apparently	O
homogeneous	O
enzymes	O
from	O
300	O
ml	O
bacteria	B
culture	O
(	O
Fig.	O
2A	O
)	O
.	O

Recovery	O
was	O
10–30	O
%	O
with	O
about	O
10-fold	O
enrichment	O
.	O

3.3	O
Identification	O
of	O
BNY	O
and	O
p	O
-coumaroyltriacetic	O
acid	O
lactone	O
Production	O
of	O
BNY	O
and	O
CTAL	O
by	O
STS	O
as	O
well	O
as	O
by	O
CHS	O
was	O
clearly	O
visualized	O
by	O
TLC	O
(	O
Fig.	O
2B	O
)	O
.	O

The	O
TLC	O
spots	O
were	O
identified	O
with	O
non	O
-	O
labeled	O
carrier	O
compounds	O
(	O
resveratrol	O
and	O
naringenin	O
)	O
and	O
with	O
parallel	O
experiment	O
using	O
p	O
-coumaroyltriacetic	O
acid	O
synthase	O
which	O
has	O
been	O
recently	O
cloned	O
from	O
Hydrangea	B
macrophylla	I
and	O
shown	O
to	O
produce	O
CTAL	O
and	O
BNY	O
as	O
the	O
main	O
product	O
and	O
a	O
major	O
byproduct	O
,	O
respectively	O
[	O
14	O
]	O
.	O

Further	O
,	O
the	O
identity	O
of	O
BNY	O
and	O
CTAL	O
was	O
unambiguously	O
determined	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
.	O

The	O
production	O
of	O
these	O
derailment	O
products	O
by	O
CHS	O
and	O
STS	O
were	O
dependent	O
on	O
the	O
presence	O
of	O
sulfhydryl	O
reagents	O
such	O
as	O
DTT	O
in	O
the	O
reaction	O
mixture	O
,	O
consistent	O
with	O
the	O
earlier	O
report	O
with	O
CHS	O
[	O
3	O
]	O
.	O

It	O
was	O
thought	O
that	O
sulfhydryl	O
reagent	O
would	O
act	O
as	O
an	O
acceptor	O
to	O
the	O
enzyme	O
-	O
bound	O
triketide	O
(	O
or	O
tetraketide	O
)	O
intermediate	O
in	O
a	O
non	O
-	O
enzymatic	O
trans	O
-esterification	O
to	O
form	O
unstable	O
thiol	O
adduct	O
,	O
which	O
should	O
be	O
immediately	O
converted	O
to	O
the	O
corresponding	O
pyrone	O
[	O
3	O
]	O
.	O

In	O
agreement	O
with	O
this	O
notion	O
,	O
DTT	O
showed	O
apparently	O
parallel	O
effects	O
on	O
formation	O
of	O
BNY	O
and	O
CTAL	O
.	O

However	O
,	O
the	O
requirement	O
of	O
the	O
sulfhydryl	O
reagent	O
was	O
not	O
absolute	O
,	O
as	O
these	O
byproducts	O
were	O
still	O
detectable	O
when	O
the	O
enzyme	O
reaction	O
was	O
carried	O
out	O
in	O
the	O
absence	O
of	O
DTT	O
(	O
data	O
not	O
shown	O
)	O
.	O

Acidification	O
of	O
the	O
reaction	O
mixture	O
to	O
pH<5	O
greatly	O
enhanced	O
the	O
amounts	O
of	O
BNY	O
and	O
CTAL	O
detected	O
on	O
TLC	O
.	O

These	O
results	O
suggest	O
that	O
the	O
majority	O
of	O
these	O
compounds	O
,	O
both	O
being	O
pyrone	O
derivatives	O
,	O
are	O
present	O
in	O
the	O
reaction	O
mixture	O
as	O
free	O
acids	O
at	O
neutral	O
pH	O
,	O
thus	O
poorly	O
extractable	O
by	O
ethyl	O
acetate	O
,	O
and	O
that	O
lactonization	O
to	O
form	O
pyrone	O
ring	O
is	O
non	O
-	O
enzymatic	O
.	O

Similar	O
pH	O
-	O
dependence	O
of	O
extraction	O
of	O
pyrone	O
derivatives	O
was	O
also	O
reported	O
recently	O
by	O
others	O
[	O
15	O
]	O
.	O

Whereas	O
CTAL	O
was	O
a	O
major	O
byproduct	O
of	O
the	O
CHS	O
reaction	O
,	O
BNY	O
was	O
a	O
major	O
byproduct	O
of	O
the	O
STS	O
reaction	O
(	O
Fig.	O
2B	O
)	O
.	O

3.4	O
Cross	O
-	O
reaction	O
When	O
the	O
reaction	O
products	O
produced	O
by	O
purified	O
recombinant	O
enzyme	O
were	O
analyzed	O
by	O
HPLC	O
,	O
a	O
small	O
radioactive	O
peak	O
corresponding	O
to	O
resveratrol	O
(	O
R	O
t	O
=	O
10	O
min	O
)	O
was	O
detected	O
in	O
the	O
CHS	O
products	O
and	O
a	O
peak	O
corresponding	O
to	O
naringenin	O
(	O
R	O
t	O
=	O
20	O
min	O
)	O
was	O
detected	O
in	O
the	O
STS	O
products	O
(	O
Fig.	O
3	O
)	O
.	O

Cross	O
-	O
reaction	O
was	O
verified	O
by	O
carrier	O
dilution	O
analysis	O
.	O

Successive	O
rounds	O
of	O
recrystallization	O
of	O
radioactive	O
products	O
in	O
the	O
presence	O
of	O
non	O
-	O
labeled	O
compounds	O
gave	O
crystals	O
of	O
constant	O
specific	O
radioactivity	O
.	O

For	O
resveratrol	O
produced	O
by	O
CHS	O
,	O
the	O
specific	O
radioactivity	O
was	O
8200	O
dpm	O
/	O
mmol	O
(	O
methanol	O
)	O
,	O
7300	O
(	O
methanol	O
)	O
,	O
7000	O
(	O
ethyl	O
acetate	O
/	O
hexane	O
)	O
and	O
6700	O
(	O
ethyl	O
acetate	O
/	O
hexane	O
)	O
,	O
and	O
for	O
naringenin	O
produced	O
by	O
STS	O
,	O
it	O
was	O
8900	O
dpm	O
/	O
mmol	O
(	O
methanol	O
)	O
,	O
7900	O
(	O
methanol	O
)	O
,	O
7500	O
(	O
ethyl	O
acetate	O
/	O
hexane	O
)	O
and	O
8300	O
(	O
ethyl	O
acetate	O
/	O
hexane	O
)	O
.	O

The	O
cross	O
-	O
reaction	O
was	O
determined	O
to	O
be	O
2.7–4.2	O
%	O
(	O
resveratrol	O
/	O
naringenin	O
)	O
for	O
CHS	O
and	O
1.4–2.3	O
%	O
(	O
naringenin	O
/	O
resveratrol	O
)	O
for	O
STS	O
.	O

The	O
cross	O
-	O
reaction	O
was	O
further	O
confirmed	O
by	O
GC	O
-	O
MS	O
and	O
LC	O
-	O
MS	O
analyses	O
.	O

The	O
retention	O
time	O
,	O
molecular	O
mass	O
and	O
major	O
daughter	O
ions	O
in	O
MS	O
/	O
MS	O
were	O
indistinguishable	O
to	O
those	O
of	O
authentic	O
compounds	O
and	O
those	O
found	O
in	O
the	O
literature	O
[	O
16	O
]	O
.	O

Trx	O
fusion	O
enzymes	O
were	O
indistinguishable	O
from	O
the	O
native	O
enzymes	O
with	O
regard	O
to	O
the	O
pattern	O
of	O
byproduct	O
production	O
and	O
kinetic	O
parameters	O
(	O
data	O
not	O
shown	O
)	O
.	O

4	O
Discussion	O
CHS	O
purified	O
from	O
plants	B
was	O
shown	O
to	O
produce	O
styrylpyrones	O
and	O
other	O
minor	O
byproducts	O
in	O
certain	O
in	O
vitro	O
conditions	O
[	O
3,4	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
,	O
like	O
CHS	O
,	O
purified	O
recombinant	O
peanut	B
STS	O
produced	O
not	O
only	O
BNY	O
,	O
a	O
styrylpyrone	O
,	O
but	O
also	O
CTAL	O
,	O
the	O
recently	O
found	O
derailment	O
product	O
at	O
the	O
stage	O
of	O
tetraketide	O
intermediate	O
[	O
14	O
]	O
.	O

This	O
was	O
not	O
unexpected	O
since	O
it	O
has	O
been	O
thought	O
that	O
CHS	O
and	O
STS	O
catalyze	O
identical	O
condensation	O
steps	O
leading	O
to	O
the	O
linear	O
tetraketide	O
intermediate	O
prior	O
to	O
different	O
cyclization	O
steps	O
[	O
1	O
]	O
.	O

Detection	O
of	O
BNY	O
and	O
CTAL	O
from	O
the	O
STS	O
reaction	O
products	O
provides	O
an	O
unequivocal	O
evidence	O
for	O
this	O
notion	O
.	O

Under	O
the	O
conditions	O
employed	O
,	O
CHS	O
produces	O
more	O
byproducts	O
than	O
STS	O
(	O
Figs.	O
2B	O
and	O
3	O
)	O
.	O

This	O
may	O
reflect	O
the	O
more	O
loosely	O
structured	O
active	O
site	O
of	O
CHS	O
compared	O
with	O
that	O
of	O
STS	O
,	O
in	O
vitro	O
,	O
which	O
allows	O
to	O
a	O
greater	O
extent	O
premature	O
thioester	O
exchange	O
with	O
sulfhydryl	O
reagent	O
present	O
in	O
the	O
reaction	O
mixture	O
or	O
thioester	O
hydrolysis	O
by	O
water	O
to	O
give	O
derailment	O
products	O
.	O

CHS	O
is	O
believed	O
to	O
be	O
present	O
in	O
the	O
cell	O
as	O
a	O
part	O
of	O
multi	O
-	O
enzyme	O
complex	O
of	O
flavonoid	O
biosynthesis	O
including	O
polyketide	O
reductase	O
,	O
chalcone	O
isomerase	O
and	O
other	O
modifying	O
enzymes	O
to	O
achieve	O
'	O
metabolite	O
channeling	O
'	O
[	O
1,17	O
]	O
.	O

Cyclization	O
steps	O
in	O
CHS	O
and	O
STS	O
are	O
different	O
;	O
Dieckmann	O
condensation	O
leading	O
to	O
naringenin	O
chalcone	O
in	O
CHS	O
and	O
aldol	O
condensation	O
to	O
stilbene	O
in	O
STS	O
.	O

Nonetheless	O
,	O
CHS	O
and	O
STS	O
produce	O
counterpart	O
products	O
in	O
low	O
amounts	O
(	O
2–4	O
%	O
of	O
main	O
products	O
)	O
which	O
could	O
not	O
be	O
detected	O
by	O
routine	O
assays	O
.	O

The	O
possibility	O
that	O
the	O
cross	O
-	O
reaction	O
products	O
were	O
formed	O
during	O
work	O
-	O
up	O
by	O
chemical	O
transformation	O
was	O
thought	O
to	O
be	O
unlikely	O
based	O
on	O
the	O
following	O
.	O

First	O
,	O
although	O
the	O
corresponding	O
chemical	O
transformations	O
are	O
known	O
,	O
they	O
are	O
normally	O
carried	O
out	O
under	O
harsh	O
conditions	O
unlike	O
the	O
work	O
-	O
up	O
procedures	O
used	O
in	O
this	O
study	O
.	O

For	O
example	O
,	O
the	O
Dieckmann	O
condensation	O
of	O
methyl	O
ester	O
of	O
7-phenyl-3,5,7-trioxoheptanoic	O
acid	O
to	O
corresponding	O
acylphloroglucinol	O
required	O
a	O
prolonged	O
incubation	O
under	O
strongly	O
basic	O
conditions	O
,	O
such	O
as	O
2	O
M	O
KOH	O
[	O
18	O
]	O
.	O

Even	O
though	O
aldol	O
condensation	O
of	O
triketo	O
acids	O
can	O
proceed	O
in	O
weakly	O
acidic	O
(	O
pH	O
5	O
)	O
aqueous	O
buffer	O
,	O
the	O
products	O
are	O
fairly	O
stable	O
β	O
-	O
resorcylic	O
acids	O
[	O
18	O
]	O
.	O

Decarboxylation	O
of	O
aromatic	O
carboxylic	O
acids	O
such	O
as	O
conversion	O
of	O
6-styryl	O
-	O
β	O
-	O
resorcylic	O
acid	O
to	O
pinosylvin	O
and	O
of	O
orsellinic	O
acid	O
to	O
orcinol	O
have	O
been	O
achieved	O
either	O
by	O
heat	O
(	O
180	O
°	O
C	O
)	O
[	O
18,19	O
]	O
,	O
by	O
alcoholic	O
KOH	O
[	O
20	O
]	O
or	O
by	O
a	O
decarboxylase	O
[	O
21	O
]	O
.	O

It	O
should	O
be	O
noted	O
that	O
stilbene	O
carboxylic	O
acids	O
,	O
though	O
found	O
in	O
nature	O
[	O
22	O
]	O
,	O
have	O
not	O
been	O
detected	O
from	O
the	O
STS	O
reaction	O
mixture	O
.	O

Secondly	O
,	O
neither	O
naringenin	O
nor	O
resveratrol	O
was	O
detected	O
after	O
using	O
an	O
identical	O
work	O
-	O
up	O
procedure	O
in	O
the	O
reaction	O
mixture	O
produced	O
by	O
p	O
-coumaroyltriacetic	O
acid	O
synthase	O
(	O
CTAS	O
)	O
,	O
which	O
catalyzes	O
,	O
like	O
CHS	O
and	O
STS	O
,	O
three	O
condensation	O
reactions	O
between	O
p	O
-coumaroyl	O
-	O
CoA	O
and	O
malonyl	O
-	O
CoA	O
to	O
triketo	O
acid	O
but	O
does	O
not	O
catalyze	O
any	O
cyclization	O
reaction	O
[	O
14	O
]	O
.	O

This	O
suggested	O
that	O
lactonization	O
of	O
the	O
free	O
triketo	O
acid	O
predominates	O
during	O
work	O
-	O
up	O
to	O
give	O
CTAL	O
as	O
a	O
major	O
byproduct	O
(	O
Fig.	O
1	O
)	O
and	O
,	O
therefore	O
,	O
we	O
concluded	O
that	O
the	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
was	O
most	O
likely	O
enzymatic	O
of	O
nature	O
.	O

One	O
reasonable	O
interpretation	O
for	O
this	O
seemingly	O
unnatural	O
cross	O
-	O
reaction	O
is	O
that	O
parts	O
of	O
heterologously	O
overexpressed	O
enzymes	O
are	O
in	O
unnatural	O
conformational	O
states	O
and	O
these	O
misfolded	O
,	O
yet	O
soluble	O
enzymes	O
are	O
responsible	O
for	O
the	O
observed	O
cross	O
-	O
reaction	O
.	O

Overexpression	O
in	O
E.	B
coli	I
often	O
leads	O
to	O
misfolding	O
especially	O
for	O
membrane	O
-	O
associated	O
eukaryotic	B
proteins	O
,	O
as	O
bacteria	B
lack	O
an	O
intracellular	O
membrane	O
environment	O
that	O
may	O
be	O
necessary	O
for	O
efficient	O
and	O
accurate	O
folding	O
[	O
23	O
]	O
.	O

Both	O
CHS	O
and	O
STS	O
are	O
shown	O
to	O
be	O
weakly	O
membrane	O
-	O
associated	O
in	O
the	O
plant	B
cells	O
[	O
24,25	O
]	O
and	O
CHS	O
is	O
associated	O
with	O
other	O
enzymes	O
involved	O
in	O
the	O
flavonoid	O
biosynthesis	O
pathway	O
[	O
17	O
]	O
.	O

However	O
,	O
an	O
attempt	O
to	O
resolve	O
conformational	O
heterogeneity	O
using	O
hydroxyapatite	O
chromatography	O
was	O
unsuccessful	O
,	O
as	O
cross	O
-	O
reaction	O
activities	O
were	O
co	O
-	O
purified	O
with	O
the	O
natural	O
activities	O
(	O
data	O
not	O
shown	O
)	O
.	O

Another	O
intriguing	O
and	O
probably	O
more	O
conceivable	O
possibility	O
is	O
that	O
CHS	O
and	O
STS	O
possess	O
intrinsic	O
potential	O
to	O
catalyze	O
cross	O
-	O
reaction	O
possibly	O
due	O
to	O
conformational	O
flexibility	O
of	O
their	O
active	O
sites	O
,	O
and	O
that	O
this	O
intrinsic	O
,	O
yet	O
'	O
cryptic	O
'	O
capability	O
of	O
these	O
enzymes	O
to	O
perform	O
the	O
cross	O
-	O
reaction	O
was	O
manifested	O
under	O
non	O
-	O
optimal	O
folding	O
conditions	O
during	O
bacterial	B
overexpression	O
.	O

Our	O
recent	O
finding	O
that	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
expressed	O
in	O
eukaryotic	B
systems	O
(	O
yeasts	B
and	O
insect	B
cells	O
)	O
apparently	O
decreased	O
as	O
compared	O
to	O
the	O
cross	O
-	O
reaction	O
found	O
in	O
this	O
study	O
with	O
bacterial	B
expression	O
system	O
seems	O
to	O
support	O
this	O
idea	O
(	O
Sankawa	O
,	O
unpublished	O
data	O
)	O
.	O

In	O
line	O
with	O
this	O
idea	O
,	O
it	O
should	O
be	O
noted	O
that	O
cyclization	O
steps	O
in	O
CHS	O
and	O
STS	O
are	O
proposed	O
to	O
be	O
under	O
pure	O
topological	O
control	O
[	O
8	O
]	O
.	O

Indeed	O
,	O
the	O
recently	O
solved	O
crystal	O
structure	O
of	O
alfalfa	B
(	O
Medicago	B
sativa	I
)	O
CHS	O
by	O
Ferrer	O
et	O
al.	O
did	O
not	O
reveal	O
apparent	O
functional	O
amino	O
acids	O
in	O
the	O
cyclization	O
pocket	O
that	O
might	O
participate	O
in	O
a	O
specific	O
CHS	O
-	O
type	O
cyclization	O
reaction	O
[	O
26	O
]	O
.	O

The	O
authors	O
,	O
therefore	O
,	O
proposed	O
that	O
alterations	O
in	O
the	O
surface	O
topology	O
of	O
the	O
cyclization	O
pockets	O
of	O
CHS	O
and	O
STS	O
may	O
affect	O
the	O
stereochemistry	O
of	O
the	O
cyclization	O
reactions	O
.	O

Based	O
on	O
phylogenetic	O
analysis	O
,	O
Schröder	O
et	O
al.	O
[	O
2	O
]	O
proposed	O
different	O
STSs	O
evolved	O
from	O
CHSs	O
independently	O
several	O
times	O
by	O
a	O
limited	O
number	O
of	O
amino	O
acid	O
exchanges	O
.	O

However	O
,	O
consensus	O
(	O
signature	O
)	O
amino	O
acid	O
sequences	O
characteristic	O
to	O
CHS	O
or	O
to	O
STS	O
have	O
yet	O
to	O
be	O
recognized	O
.	O

It	O
may	O
result	O
from	O
the	O
insufficient	O
number	O
of	O
STS	O
sequences	O
available	O
(	O
6	O
entries	O
in	O
Swiss	O
-	O
Prot	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
STS	O
conceivably	O
gained	O
its	O
new	O
activity	O
by	O
changing	O
active	O
site	O
geometry	O
rather	O
than	O
by	O
introducing	O
a	O
few	O
new	O
functional	O
amino	O
acids	O
in	O
the	O
active	O
site	O
of	O
STS	O
.	O

A	O
closely	O
related	O
case	O
can	O
be	O
found	O
in	O
chemical	O
diversity	O
of	O
higher	O
plant	B
fatty	O
acids	O
,	O
where	O
independent	O
,	O
multiple	O
evolution	O
of	O
oleate	O
12-hydroxylase	O
from	O
oleate	O
12-desaturase	O
was	O
proposed	O
.	O

Site	O
-	O
directed	O
mutagenesis	O
studies	O
involving	O
as	O
few	O
as	O
seven	O
amino	O
acids	O
suggested	O
that	O
catalytic	O
plasticity	O
in	O
these	O
two	O
enzymes	O
is	O
achieved	O
by	O
changing	O
active	O
site	O
geometry	O
leading	O
to	O
different	O
partitioning	O
of	O
a	O
common	O
intermediate	O
into	O
different	O
reaction	O
products	O
[	O
27	O
]	O
.	O

Clearly	O
,	O
further	O
studies	O
with	O
regard	O
to	O
the	O
origin	O
of	O
the	O
cross	O
-	O
reaction	O
of	O
CHS	O
and	O
STS	O
overexpressed	O
in	O
E.	B
coli	I
are	O
warranted	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
grateful	O
to	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
of	O
Japan	O
for	O
Grants	O
-	O
in	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
(	O
No.	O
09044212	O
)	O
and	O
(	O
C	O
)	O
(	O
No.	O
10680564	O
)	O
.	O

D	O
.-	O
Y.	O
Suh	O
thanks	O
the	O
Tokyo	O
Biochemistry	O
Research	O
Foundation	O
for	O
a	O
fellowship	O
(	O
TBRF-98	O
-	O
10	O
)	O
.	O

There	O
are	O
currently	O
several	O
potent	O
fungal	B
inhibitors	O
of	O
serine	O
palmitoyl-	O
transferase	O
(	O
3-ketosphinganine	O
synthase	O
)	O
[	O
palmitoyl	O
-	O
CoA	O
:	O
L	O
-	O
serine	O
C	O
-	O
pal-	O
mitoyltransferase	O
(	O
decarboxylating	O
)	O
;	O
EC	O
2.31.50	O
]	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
de	O
novo	O
biosynthesis	O
of	O
ceramides	O
and	O
more	O
complex	O
sphingolipids	O
.	O

1'2	O
In	O
t	O
A.	O
H.	O
Merrill	O
,	O
Jr.	O
and	O
E.	O
Wang	O
,	O
Methods	O
Enzymol	O
.	O
51	O
,	O
427	O
(	O
1992	O
)	O
.	O

2	O
R.	O
C.	O
Dickson	O
,	O
R.	O
L.	O
Lester	O
,	O
and	O
M.	O
Marek	O
,	O
Methods	O
Enzymol	O
.	O

311	O
[	O
1	O
]	O
1999	O
(	O
this	O
volume	O
)	O
.	O

Copyright	O
©	O
1999	O
by	O
Academic	O
Press	O
All	O
rights	O
of	O
reproduction	O
in	O
any	O
form	O
reserved	O
.	O

0076	O
-	O
6879	O
/	O
99	O
$	O
30.00	O
METHODS	O
IN	O
ENZYMOLOGY	O
,	O
VOL	O
.	O

311	O
is	O
measured	O
when	O
casamino	O
acids	O
are	O
omitted	O
from	O
the	O
sphingolipid	O
inhibition	O
assay	O
and	O
the	O
comparatively	O
poor	O
activity	O
that	O
australifungin	O
demonstrates	O
in	O
medium	O
that	O
contains	O
serum	O
or	O
peptone	O
.	O

In	O
addition	O
to	O
the	O
loss	O
in	O
potency	O
,	O
caution	O
is	O
also	O
advised	O
when	O
using	O
australifungin	O
in	O
assays	O
that	O
employ	O
trace	O
amounts	O
of	O
sphingoid	O
bases	O
;	O
high	O
concentrations	O
of	O
australifungin	O
can	O
result	O
in	O
nonspecific	O
inhibition	O
due	O
to	O
sequestration	O
of	O
the	O
sphingoid	O
base	O
.	O

Serine	O
Palmitolytransferase	O
Inhibitors	O
Viridiofungins	O
are	O
at	O
least	O
five	O
-	O
fold	O
less	O
potent	O
and	O
are	O
not	O
as	O
specific	O
for	O
serine	O
palmitoyltransferase	O
inhibition	O
as	O
the	O
sphingofungin	O
/	O
myriocin	O
class	O
of	O
compounds	O
.	O

Viridiofungins	O
are	O
known	O
to	O
inhibit	O
squalene	O
synthase	O
,	O
geranyl	O
geranyltransferase	O
,	O
and	O
other	O
enzymes	O
that	O
are	O
sensitive	O
to	O
di-	O
and	O
tricarboxylic	O
acids	O
,	O
albeit	O
at	O
higher	O
concentrations	O
than	O
required	O
for	O
serine	O
palmitoyltransferase	O
inhibition	O
.	O

Because	O
of	O
this	O
difference	O
in	O
enzyme	O
sensi-	O
tivity	O
,	O
viridiofungin	O
A	O
showed	O
selective	O
inhibition	O
of	O
sphingolipid	O
synthesis	O
in	O
labeling	O
studies	O
in	O
C.	B
albicans	I
,	O
with	O
no	O
evidence	O
for	O
inhibition	B
of	O
sterol	O
synthesis	O
at	O
growth	O
inhibitory	O
concentrations	O
of	O
drug	O
.	O

7'22	O
For	O
unknown	O
reasons	O
,	O
viridiofungins	O
lack	O
in	O
vitro	O
activity	O
against	O
Saccharomyces	B
serine	O
palmitoyltransferase	O
and	O
do	O
not	O
inhibit	O
sphingolipid	O
synthesis	O
in	O
this	O
yeast	B
,	O
although	O
they	O
do	O
inhibit	O
the	O
mammalian	B
enzyme	O
and	O
appear	O
to	O
be	O
selective	O
for	O
sphingolipid	O
inhibition	O
in	O
HepG2	O
cells	O
.	O

2t~	O
A.	O
H.	O
Merrill	O
,	O
Jr.	O
,	O
D.	O
C.	O
Liotta	O
,	O
and	O
R.	O
T.	O
Riley	O
,	O
Trends	O
Cell	O
Biol	O
.	O

6	O
,	O
218	O
(	O
1996	O
)	O
.	O

3o	O
R.	O
T.	O
Riley	O
et	O
al.	O
,	O
J.	O
Food	O
Protect	O
.	O

57	O
,	O
638	O
(	O
1994	O
)	O
.	O

INHIBITORS	O
OF	O
SPHINGOLIPID	O
BIOSYNTHESIS	O
348	O
[	O
36	O
]	O
Inositol	O
Phosphoceramide	O
Synthase	O
Inhibitors	O
Unlike	O
inhibitors	O
to	O
earlier	O
steps	O
in	O
sphingolipid	O
synthesis	O
,	O
khafrefungin	O
and	O
rustmicin	O
do	O
not	O
have	O
any	O
detectable	O
effect	O
on	O
lipid	O
synthesis	O
in	O
mam-	B
malian	I
cells	O
(	O
unpublished	O
data	O
and	O
Ref	O
.	O
13	O
)	O
,	O
and	O
rustmicin	O
and	O
aureobasidin	O
A	O
have	O
been	O
nontoxic	O
in	O
animal	B
studies	O
,	O
a4'31	O
supporting	O
the	O
idea	O
that	O
inositol	O
phosphoceramide	O
synthase	O
is	O
a	O
fungal	B
selective	O
target	O
.	O

Khafrefungin	O
was	O
lytic	O
to	O
washed	O
red	O
blood	O
cells	O
at	O
12.5	O
to	O
25	O
/	O
xg	O
/	O
ml	O
.	O

However	O
,	O
this	O
toxicity	O
may	O
be	O
due	O
to	O
the	O
detergent	O
-	O
like	O
properties	O
of	O
the	O
compound	O
.	O

Although	O
all	O
three	O
inositol	O
phosphoceramide	O
synthase	O
inhibitors	O
are	O
very	O
potent	O
in	O
vitro	O
(	O
picomolar	O
to	O
low	O
nanomolar	O
)	O
,	O
substantially	O
higher	O
concentrations	O
are	O
required	O
to	O
kill	O
fungi	B
.	O

In	O
the	O
case	O
of	O
rustmicin	O
,	O
two	O
factors	O
that	O
limit	O
whole	O
cell	O
activity	O
were	O
identified	O
:	O
efflux	O
via	O
multidrug	O
transporters	O
and	O
chemical	O
instability	O
.	O

TM	O
Even	O
at	O
its	O
optimal	O
pH	O
of	O
5.5	O
,	O
rustmicin	O
degrades	O
relatively	O
rapidly	O
in	O
aqueous	O
media	O
.	O

Despite	O
these	O
limitations	O
,	O
concentrations	O
of	O
rust-	O
micin	O
that	O
are	O
required	O
to	O
completely	O
inhibit	O
phosphosphingolipid	O
synthesis	O
and	O
accumulate	O
ceramide	O
in	O
fungi	B
are	O
achieved	O
easily	O
.	O

Acknowledgments	O

We	O
thank	O
M.	O
Zweerink	O
and	O
BS	O
:	O
MIE	O
00110948	O
S0076	O
-	O
6879	O
(	O
00	O
)	O
11094	O
-	O
8	O
10.1016	O
/	O
S0076	O
-	O
6879	O
(	O
00	O
)	O
11094	O
-	O
8	O
Section	O
II	O
.	O

inhibitors	O
of	O
sphingolipid	O
biosynthesis	O
[	O
35	O
]	O
Isolation	O
and	O
characterization	O
of	O
novel	O
inhibitors	O
of	O
sphingolipid	O
synthesis	O
:	O
Australifungin	O
,	O
viridiofungins	O
,	O
rustmicin	O
,	O
and	O
khafrefungin	O
Suzanne	O
M.	O
Mandala	O
Guy	O
H.	O
Harris	O
Publisher	O
Summary	O
Sphingolipid	O
synthesis	O
is	O
an	O
essential	O
process	O
in	O
yeast	B
and	O
the	O
pathogenic	O
fungi	B
that	O
cause	O
life	O
-	O
threatening	O
human	B
infections	O
such	O
as	O
candidiasis	O
,	O
aspergillosis	O
,	O
and	O
cryptococcosis	O
.	O

Although	O
many	O
steps	O
in	O
the	O
human	B
and	O
fungal	B
sphingolipid	O
biosynthetic	O
pathway	O
are	O
similar	O
,	O
there	O
are	O
several	O
enzymes	O
found	O
uniquely	O
in	O
fungi	B
that	O
are	O
potential	O
targets	O
for	O
the	O
development	O
of	O
nontoxic	O
therapeutic	O
antifungals	O
.	O

In	O
the	O
screening	O
program	O
,	O
it	O
has	O
been	O
found	O
that	O
natural	O
products	O
are	O
a	O
rich	O
source	O
of	O
structurally	O
diverse	O
inhibitors	O
of	O
sphingolipid	O
synthesis	O
.	O

Natural	O
product	O
inhibitors	O
to	O
four	O
different	O
enzymes	O
that	O
affect	O
sphingolipid	O
synthesis	O
have	O
been	O
discovered	O
:	O
sphingofungins	O
,	O
lipoxamycin	O
,	O
myriocin	O
/	O
ISP1	O
,	O
and	O
viridiofungins	O
inhibit	O
serine	O
palmitoyltransferase	O
;	O
fumonisin	O
B1	O
and	O
australifungin	O
,	O
inhibit	O
ceramide	O
synthase	O
;	O
aureobasidins	O
,	O
khafrefungin	O
,	O
and	O
rustmicin	O
inhibit	O
inositol	O
phosphoceramide	O
synthase	O
;	O
and	O
minimoidin	O
inhibits	O
the	O
fatty	O
acid	O
elongation	O
pathway	O
.	O

Most	O
of	O
these	O
compounds	O
have	O
fungicidal	O
activity	O
against	O
a	O
broad	O
spectrum	O
of	O
pathogenic	O
fungi	B
,	O
but	O
only	O
the	O
inhibitors	O
of	O
inositol	O
phosphoceramide	O
are	O
fungal	B
selective	O
;	O
compounds	O
that	O
inhibit	O
early	O
biosynthetic	O
steps	O
show	O
comparable	O
activity	O
against	O
orthologous	O
mammalian	B
enzymes	O
.	O

This	O
chapter	O
describes	O
a	O
method	O
to	O
identify	O
sphingolipid	O
inhibitors	O
and	O
detailed	O
protocol	O
for	O
the	O
isolation	O
of	O
australifungin	O
.	O

More	O
abbreviated	O
descriptions	O
of	O
the	O
isolation	O
of	O
viridiofungins	O
,	O
khafrefungin	O
,	O
and	O
rustmicin	O
are	O
also	O
included	O
.	O

The	O
protein	O
mediator	O
known	O
as	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
has	O
emerged	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
the	O
host	O
inflammatory	O
and	O
immune	O
response	O
.	O

Described	O
originally	O
as	O
a	O
lymphocyte	O
""""	O
activity	O
""""	O
responsible	O
for	O
inhibiting	O
the	O
random	O
migration	O
of	O
macrophages	O
in	O
vitro	O
,	O
l'z	O
MIF	O
has	O
been	O
shown	O
to	O
be	O
released	O
from	O
the	O
anterior	O
pituitary	O
gland	O
during	O
stress	O
and	O
to	O
be	O
critically	O
involved	O
in	O
the	O
toxic	O
response	O
to	O
septic	O
shock.3	O
Macrophages	O
,	O
T	O
cells	O
,	O
and	O
eosinophils	O
release	O
MIF	O
in	O
response	O
to	O
pro	O
-	O
inflammatory	O
stimuli	O
,	O
and	O
the	O
expression	O
of	O
MIF	O
is	O
required	O
for	O
T	O
-	O
cell	O
activation	O
and	O
antibody	O
production	O
by	O
B	O
cells.4'5	O
More	O
recent	O
studies	O
have	O
shown	O
that	O
macrophages	O
and	O
T	O
cells	O
can	O
secrete	O
MIF	O
in	O
response	O
to	O
glucocorticoid	O
stimulation	O
,	O
and	O
that	O
once	O
released	O
,	O
MIF	O
can	O
""""	O
override	O
""""	O
the	O
immuno	O
-	O
suppressive	O
effects	O
of	O
steroids	O
on	O
cytokine	O
production	O
and	O
cellular	O
activation.4'5	O
Studies	O
performed	O
in	O
models	O
of	O
the	O
inflammatory	O
and	O
immune	O
response	O
indicate	O
that	O
MIF	O
acts	O
extracellularly	O
by	O
stimulating	O
the	O
specific	O
response	O
of	O
target	O
cells	O
.	O

In	O
1996	O
however	O
,	O
Rorsman	O
et	O
al.	O
reported	O
that	O
recombinant	O
MIF	O
(	O
rMIF	O
)	O
catalyzes	O
a	O
tautomerization	O
reaction	O
,	O
converting	O
the	O
non	O
-	O
naturally	O
occurring	O
D	O
-	O
isomer	O
of	O
dopachrome	O
(	O
2-carboxy-2,3-dihydroindole-5,6-quinone	O
)	O
to	O
dihydroxyindole	O
carboxylic	O
acid	O
(	O
DHICA	O
)	O
.6	O
Intriguingly	O
,	O
subsequent	O
elucidation	O
of	O
the	O
three	O
-	O
dimensional	O
crystal	O
structure	O
of	O
MIF	O
revealed	O
it	O
to	O
exhibit	O
significant	O
three	O
-	O
dimensional	O
(	O
but	O
not	O
primary	O
sequence	O
)	O
homology	O
with	O
two	O
bacterial	O
isomerases	O
,	O
4-	O
oxalocrotonate	O
tautomerase	O
and	O
5-carboxymethyl-2-hydroxymuconate	O
isomerase.7	O
-	O
9	O
These	O
proteins	O
share	O
with	O
MIF	O
an	O
apparently	O
conserved	O
active	O
site	O
structure	O
that	O
consists	O
of	O
a	O
hydrophobic	O
cleft	O
bearing	O
an	O
active	O
site	O
proline	O
.	O

More	O
recently	O
,	O
Rorsman	O
and	O
colleagues	O
have	O
proposed	O
that	O
MIF	O
acts	O
physiologically	O
to	O
catalyze	O
the	O
keto	O
-	O
enol	O
tautomerization	O
of	O
p	O
-	O
hydroxyphenylpyruvate	O
and	O
phenylpyruvate.lFinally	O
,	O
the	O
presence	O
of	O
the	O
CXXC	O
*	O
Present	O
Address	O
:	O
Chemical	O
Development	O
,	O
New	O
Product	O
Research	O
,	O
R.	O
W.	O
Johnson	O
pharmaceutical	O
Research	O
Institute	O
,	O
Route	O
202	O
,	O
Raritan	O
,	O
NJ	O
08869	O
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

PII	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00561	O
-	O
2	O
3194	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
motif	O
in	O
MIF	O
has	O
prompted	O
yet	O
additional	O
studies	O
which	O
suggest	O
that	O
MIF	O
may	O
function	O
as	O
a	O
physiologically-	O
relevant	O
protein	O
-	O
thiol	O
oxidoreductase.~	O
These	O
observations	O
notwithstanding	O
,	O
the	O
precise	O
relationship	O
between	O
MIF	O
's	O
enzymatic	O
and	O
immunological	O
activities	O
remain	O
unclear	O
.	O

In	O
two	O
separate	O
studies	O
,	O
the	O
creation	O
of	O
an	O
enzymatically	O
-	O
inactive	O
form	O
of	O
MIF	O
by	O
site	O
-	O
directed	O
mutagenesis	O
shows	O
the	O
protein	O
retains	O
full	O
glucocorticoid	O
-	O
regulatory	O
activity,12	O
but	O
loses	O
neutrophil	O
priming	O
activity	O
)	O
3	O
In	O
an	O
effort	O
to	O
further	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
MIF	O
in	O
biological	O
systems	O
,	O
we	O
have	O
endeavored	O
to	O
identify	O
potential	O
small	O
molecule	O
inhibitors	O
of	O
MIF	O
's	O
isomerization	O
activity	O
.	O

We	O
report	O
herein	O
a	O
study	O
of	O
MIF	O
substrate	O
analogs	O
which	O
inhibit	O
dopachrome	O
tautomerization	O
at	O
concentrations	O
tenfold	O
less	O
than	O
substrate	O
.	O

Such	O
inhibitors	O
may	O
prove	O
useful	O
in	O
the	O
study	O
of	O
MIF	O
structure	O
function	O
relationships	O
and	O
also	O
assist	O
in	O
the	O
development	O
of	O
small	O
molecules	O
that	O
can	O
be	O
specifically	O
targeted	O
to	O
MIF	O
for	O
pharmacological	O
purposes	O
.	O

Materials	O
and	O
Methods	O
Reagents	O
.	O

All	O
chemicals	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MA	O
)	O
or	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
)	O
.	O

Pure	O
,	O
bioactive	O
recombinant	O
human	B
MIF	O
was	O
prepared	O
by	O
expression	O
in	O
E.	B
coli	I
following	O
methods	O
described	O
previously	O
)	O
4	O
Preparation	O
of	O
MIF	O
Substrates	O
and	O
Analogs	O
.	O

The	O
MIF	O
-	O
substrates	O
lb-4b	O
(	O
Table	O
1	O
)	O
and	O
the	O
test	O
inhibitors	O
5b	O
-	O
llb	O
were	O
prepared	O
by	O
oxidizing	O
their	O
precursors	O
la-4a	O
and	O
5a-10a	O
with	O
soCum	O
periodate,7'8	O
as	O
shown	O
in	O
Scheme	O
1	O
.	O

Compounds	O
7a	O
and	O
8a	O
were	O
prepared	O
from	O
5a	O
and	O
6a	O
by	O
an	O
esterification	O
procedure.8	O

The	O
oxidation	O
was	O
performed	O
10	O
min	O
prior	O
to	O
the	O
tautomerization	O
assay	O
and	O
the	O
dopachrome	O
compounds	O
were	O
tested	O
without	O
further	O
purification	O
.	O

The	O
test	O
compounds	O
11	O
-	O
13	O
(	O
Table	O
1	O
)	O
were	O
obtained	O
from	O
Aldrich	O
.	O

Compd	O
D	O
/	O
L	O
RI	O
R2	O
R3	O
R1	O
,	O
.	O

O	O
~	O
R2	O
HO	O
~	O
R2	O
NalO4	O
HO	O
I.,~	O
/	O
Iql~23	O
HO	O
/	O
~-~.	O
/	O
-N	O
R3	O
a	O
b	O
1	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
l0	O
D	O
L	O
L	O
DL	O
L	O
DL	O
L	O
DL	O
DL	O
DL	O
H	O
H	O
H	O
H	O
H	O
H	O
H	O
H	O
OH	O
OH	O
H	O
H	O
H	O
H	O
Me	O
Me	O
Me	O
Me	O
H	O
H	O
CO2H	O
CO2H	O
CO2Me	O
CO2Me	O
CO2H	O
CO2H	O
CO2Me	O
CO2Me	O
CO2H	O
CH3	O
Scheme	O
1	O
Dopachrome	O
Tautomerization	O
Assay	O
.	O

The	O
DOPA	O
-	O
related	O
precursors	O
(	O
la-10a	O
)	O
were	O
prepared	O
as	O
10	O
mM	O
stock	O
solutions	O
in	O
MIF	O
assay	O
buffer	O
(	O
10	O
mM	O
sodium	O
phosphate	O
,	O
pH	O
6.0	O
)	O
.	O

Thirty	O
minutes	O
before	O
the	O
tautomerization	O
assay	O
,	O
1.0	O
mL	O
of	O
each	O
stock	O
solution	O
was	O
diluted	O
with	O
7	O
mL	O
of	O
assay	O
buffer	O
,	O
and	O
1.0	O
mL	O
of	O
sodium	O
periodate	O
stock	O
solution	O
(	O
20	O
mM	O
in	O
water	O
)	O
was	O
added	O
to	O
initiate	O
the	O
oxidation	O
of	O
the	O
precursors	O
,	O
thus	O
generating	O
each	O
respective	O
dopachrome	O
derivative	O
(	O
lb-10b	O
)	O
)	O
5	O
After	O
10	O
min	O
,	O
1	O
mL	O
of	O
methionine	O
(	O
20	O
mM	O
in	O
X	O
,	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
3195	O
water	O
)	O
was	O
added	O
to	O
react	O
with	O
the	O
excess	O
periodate	O
.	O

The	O
dopachrome	O
compounds	O
were	O
generated	O
as	O
orange	O
solutions	O
at	O
a	O
final	O
concentration	O
of	O
1	O
mM.	O
Test	O
inhibitors	O
11	O
-	O
13	O
were	O
prepared	O
as	O
10	O
~M	O
stock	O
solution	O
and	O
diluted	O
to	O
1	O
mM	O
solution	O
with	O
assay	O
buffer	O
before	O
the	O
assay	O
.	O

To	O
perform	O
the	O
tautomerization	O
assay	O
,	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
the	O
MIF	O
-	O
substrate	O
(	O
lb	O
,	O
2b	O
,	O
3b	O
,	O
or	O
4b	O
)	O
was	O
mixed	O
with	O
0.5	O
mL	O
of	O
assay	O
buffer	O
.	O

After	O
the	O
Table	O
1	O
.	O

Inhibition	O
of	O
MIF	O
tautomerase	O
activity	O
by	O
test	O
compounds	O
No.	O
Structure	O
5b	O
L-	O
HO	O
~	O
/	O
~N	O
""""	O
""""	O
CO2H	O
6b	O
7b	O
8b	O
9b	O
10b	O
11	O
12	O
13	O
DL-	O
DL-	O
HOAL'~'	O
/	O
L	O
~	O
N	O
""""	O
""""	O
CO2H	O
O	O

~e	O
L-	O
HO	O
"~'~""~"""	O
/	O
~N~	O
""""	O
CO2Me	O
DL-	O
HO	O
~	O
/	O
"t""~"	O
/	O
X~'N	O
""""	O
""""	O
CO2Me	O
OH	O
OH	O
OH	O
OH3	O
O	O
Conc	O
.	O

of	O
test	O
compounds	O
(	O
mM	O
)	O
0.5	O
0.5	O
0.5	O
0.5	O
0.5	O
0.25	O
0.125	O
0.06	O
0.5	O
0.25	O
0.125	O
0.06	O
0.5	O
0.25	O
0.125	O
0.02	O
0.5	O
0.5	O
%	O
inhibition	O
'	O
29	O
35	O
45	O
34	O
100	O
98	O
41	O
9	O
92	O
88	O
54	O
22	O
98	O
79	O
54	O
21	O
a0.5	O
mM	O
of	O
3b	O
was	O
used	O
as	O
MIF	O
-	O
substrate	O
in	O
this	O
assay	O
.	O

3196	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
background	O
rate	O
was	O
monitored	O
,	O
10	O
I.tL	O
of	O
recombinant	O
MIF	O
solution	O
from	O
a	O
20	O
mg	O
/	O
mL	O
stock	O
was	O
added	O
.	O

The	O
decrease	O
in	O
absorbance	O
(	O
~	O
,	O
=	O
475	O
nm	O
)	O
at	O
1	O
min	O
following	O
addition	O
of	O
MIF	O
was	O
measured	O
as	O
an	O
index	O
of	O
tautomerase	O
activity	O
,	O
For	O
the	O
inhibitory	O
assay	O
,	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
the	O
MIF	O
-	O
substrate	O
(	O
3b	O
)	O
was	O
mixed	O
with	O
0.5	O
mL	O
of	O
the	O
1	O
mM	O
solution	O
of	O
one	O
of	O
the	O
test	O
inhibitors	O
(	O
5b-10b	O
and	O
11	O
-	O
13	O
)	O
,	O
followed	O
by	O
addition	O
of	O
10	O
mL	O
of	O
recombinant	O
MIF	O
stock	O
solution	O
(	O
20	O
mg	O
/	O
mL	O
)	O
.	O

Compounds	O
9b	O
,	O
10b	O
,	O
and	O
12	O
were	O
tested	O
at	O
final	O
concentrations	O
of	O
0.25	O
mM	O
,	O
0.125	O
mM	O
,	O
and	O
0.06	O
mM	O
in	O
addition	O
to	O
the	O
standard	O
0.5	O
mM	O
assay	O
.	O

The	O
percent	O
inhibition	O
of	O
the	O
decrease	O
in	O
absorbance	O
(	O
~	O
,	O
=	O
475	O
nm	O
)	O
at	O
1	O
min	O
in	O
the	O
presence	O
of	O
inhibitors	O
was	O
calculated	O
from	O
the	O
spectrophotometric	O
data	O
by	O
standard	O
methods.6	O
Results	O
and	O
Discussion	O
Tautomerization	O
of	O
an	O
orange	O
colored	O
solution	O
of	O
D	O
-	O
dopachrome	O
(	O
lb	O
)	O
by	O
MIF	O
produces	O
the	O
non	O
-	O
colored	O
DHICA.6	O
This	O
conversion	O
can	O
be	O
quantitated	O
spectrophotometrically	O
by	O
measuring	O
the	O
rate	O
of	O
decrease	O
of	O
the	O
iminochrome	O
absorbance	O
at	O
a	O
wavelength	O
of	O
475	O
nm	O
.	O

The	O
methyl	O
ester	O
derivatives	O
of	O
D-	O
(	O
or	O
L-	O
)	O
dopachrome	O
were	O
found	O
to	O
be	O
better	O
substrates	O
for	O
this	O
reaction	O
than	O
dopachromes	O
(	O
lb	O
and	O
2b	O
)	O
.	O

In	O
our	O
study	O
L	O
-	O
dopachrome	O
methyl	O
ester	O
3b	O
was	O
used	O
as	O
a	O
test	O
substrate	O
for	O
the	O
identification	O
of	O
compounds	O
with	O
the	O
ability	O
to	O
inhibit	O
the	O
tautomerization	O
reaction	O
.	O

The	O
dopachrome	O
tautomerization	O
by	O
MIF	O
may	O
occur	O
by	O
two	O
different	O
pathways	O
as	O
shown	O
in	O
Scheme	O
2	O
.	O

The	O
first	O
proceeds	O
via	O
the	O
initial	O
conversion	O
of	O
dopachrome	O
to	O
indolidine	O
14	O
and	O
subsequent	O
rearrangement	O
to	O
an	O
indole	O
.	O

A	O
possible	O
alternative	O
pathway	O
involves	O
the	O
formation	O
of	O
quinone	O
methide	O
intermediate	O
15	O
which	O
is	O
then	O
transformed	O
further	O
into	O
an	O
indole	O
.	O

H	O
H	O
O	O
H	O
H	O
H	O
O	O
H	O
H	O
H	O
.	O

HO~	O
""""	O
11	O
...	O
L	O

/	O
/	O
'--CO2R	O
HO	O
/	O
~	O
~N	O
14	O
HO	O
~	O
H	O
f	O
O	O
/	O
'~-.,J--~	O
N~	O
""""	O
CO2R	O
H	O
15	O
Scheme	O
2	O
HO	O
~	O
co2R	O
HO	O
/	O
~	O
~N	O
iH	O
Understanding	O
the	O
mechanism	O
of	O
MIF	O
catalyzed	O
substrate	O
tautomerization	O
is	O
helpful	O
in	O
the	O
design	O
and	O
search	O
of	O
MIF	O
inhibitors	O
.	O

Initial	O
molecular	O
modeling	O
studies	O
have	O
suggested	O
that	O
the	O
pathway	O
through	O
indolidine	O
14	O
might	O
be	O
favored	O
,	O
while	O
comparison	O
to	O
structurally	O
related	O
tautomerases	O
and	O
more	O
recent	O
mechanistic	O
data	O
have	O
favored	O
the	O
quinone	O
methide	O
pathway	O
.	O

16,17	O
It	O
is	O
known	O
that	O
s	O
-	O
methyl	O
quinone	O
methide	O
have	O
UV	O
and	O
visible	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O
3197	O
spectra	O
which	O
are	O
easily	O
distinguished	O
from	O
the	O
corresponding	O
dopachrome	O
spectra.~	O

When	O
5b-41b	O
were	O
exposed	O
to	O
MIF	O
,	O
no	O
change	O
of	O
their	O
spectra	O
was	O
observed	O
.	O

This	O
observation	O
supports	O
the	O
indolidine	O
pathway	O
described	O
above	O
and	O
suggests	O
that	O
R	O
-	O
proton	O
extraction	O
is	O
the	O
initial	O
step	O
in	O
dopachrome	O
tautomerization	O
by	O
MIF	O
.	O

L-	O
and	O
DL-~-methyl	O
dopachrome	O
(	O
Sb	O
and	O
6b	O
)	O
and	O
their	O
methyl	O
esters	O
(	O
7b	O
and	O
8b	O
)	O
,	O
when	O
present	O
at	O
the	O
same	O
concentration	O
(	O
0.5	O
mM	O
)	O
as	O
the	O
MIF	O
-	O
substrate	O
3b	O
,	O
each	O
displayed	O
a	O
moderate	O
inhibitory	O
effect	O
on	O
MIF	O
tautomerase	O
activity	O
,	O
with	O
the	O
esters	O
showing	O
slightly	O
higher	O
activity	O
than	O
the	O
free	O
acids	O
as	O
shown	O
in	O
Table	O
1	O
.	O

The	O
moderate	O
inhibitory	O
activity	O
of	O
or	O
-	O
substituted	O
dopachromes	O
may	O
result	O
from	O
the	O
competition	O
with	O
MIF	O
-	O
substrate	O
3b	O
for	O
the	O
active	O
site	O
of	O
MIF	O
protein	O
.	O

To	O
identify	O
inhibitors	O
with	O
higher	O
activity	O
,	O
we	O
needed	O
to	O
design	O
compounds	O
with	O
stronger	O
binding	O
affinity	O
or	O
even	O
ones	O
capable	O
of	O
binding	O
covalently	O
to	O
the	O
MIF	O
protein	O
thereby	O
blocking	O
the	O
active	O
site	O
and	O
possibly	O
changing	O
the	O
secondary	O
structure	O
of	O
MIF	O
.	O

As	O
proposed	O
in	O
Scheme	O
3	O
,	O
dopachromes	O
with	O
a	O
leaving	O
group	O
at	O
~l	O
-	O
position	O
may	O
form	O
a	O
very	O
reactive	O
intermediate	O
16	O
following	O
et	O
-	O
deprotonation	O
by	O
MIF	O
.	O

Compound	O
16	O
may	O
react	O
with	O
nucleophilic	O
residues	O
of	O
the	O
MIF	O
protein	O
to	O
form	O
a	O
covalent	O
bond	O
with	O
the	O
protein	O
.	O

Our	O
data	O
have	O
indeed	O
shown	O
that	O
9b	O
,	O
10b	O
,	O
and	O
11	O
all	O
displayed	O
strong	O
inhibition	O
on	O
MIF	O
tautomerase	O
activity	O
(	O
Table	O
1	O
)	O
.	O

Particularly	O
,	O
compounds	O
9b	O
,	O
lOb	O
,	O
and	O
11	O
all	O
showed	O
about	O
50	O
%	O
inhibition	O
even	O
at	O
a	O
concentration	O
four	O
times	O
less	O
than	O
that	O
of	O
MIF	O
-	O
substrate	O
.	O

Further	O
,	O
10b	O
and	O
11	O
showed	O
activity	O
at	O
a	O
concentration	O
ten	O
times	O
less	O
than	O
that	O
of	O
MIF	O
-	O
substrate	O
.	O

Studies	O
of	O
the	O
proposed	O
MIF	O
-	O
covalent	O
complexes	O
(	O
MIF-10b	O
or	O
11	O
)	O
by	O
mass	O
spectrometry	O
were	O
,	O
however	O
,	O
inconclusive	O
.	O

Detailed	O
elucidation	O
of	O
the	O
nature	O
of	O
enhanced	O
binding	O
of	O
these	O
inhibitors	O
to	O
MIF	O
requires	O
further	O
study	O
.	O

H	O
H	O
MIF	O
O~~X-	O
HO~~N	O
H	O
R	O
HOI~	O
-N	O
R	O
HOI~	O
-N	O
HO	O
16	O
Scheme	O
3	O
Finally	O
,	O
we	O
examined	O
acyclic	O
compounds	O
containing	O
some	O
structural	O
features	O
similar	O
to	O
the	O
active	O
MIF	O
substrates	O
/	O
inhibitors	O
.	O

Thus	O
,	O
compounds	O
12	O
and	O
13	O
were	O
tested	O
and	O
found	O
to	O
be	O
inactive	O
in	O
the	O
MIF	O
tautomerization	O
assay	O
.	O

We	O
have	O
identified	O
several	O
inhibitors	O
of	O
MIF	O
tautomerase	O
activity	O
.	O

This	O
discovery	O
should	O
lead	O
to	O
the	O
development	O
of	O
inhibitors	O
of	O
MIF	O
biological	O
activities	O
and	O
the	O
development	O
of	O
agents	O
for	O
the	O
treatment	O
of	O
MIF	O
related	O
diseases	O
.	O

Acknowledgments	O
:	O
These	O
studies	O
were	O
supported	O
by	O
NIH	O
grant	O
AI35931	O
.	O

3198	O
X.	O
Zhang	O
,	O
R.	O
Bucala	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
3193	O
-	O
3198	O

Parasitic	B
diseases	O
caused	O
by	O
helminths	B
afflict	O
billions	O
of	O
people	B
worldwide	O
and	O
are	O
among	O
the	O
main	O
causes	O
of	O
morbidity	O
and	O
mortality	O
resulting	O
from	O
infectious	O
disease	O
.	O

Such	O
diseases	O
in	O
animals	B
also	O
have	O
major	O
economic	O
consequences	O
.	O

Recent	O
information	O
about	O
the	O
basic	O
biochemistry	O
and	O
the	O
immunological	O
responses	O
of	O
infected	O
hosts	O
to	O
parasitic	B
helminths	B
and	O
their	O
eggs	O
has	O
led	O
to	O
increased	O
interest	O
in	O
parasite	O
glycoconjugates	O
,	O
since	O
they	O
are	O
the	O
major	O
focus	O
of	O
the	O
immune	O
response	O
(	O
for	O
reviews	O
,	O
see	O
[	O
1–4	O
]	O
)	O
.	O

However	O
,	O
only	O
a	O
few	O
helminth	B
carbohydrate	O
structures	O
have	O
sofar	O
been	O
structurally	O
characterized	O
.	O

A	O
typical	O
feature	O
of	O
helminth	B
infections	O
is	O
the	O
induction	O
of	O
specific	O
IgE	O
[	O
5,6	O
]	O
and	O
this	O
is	O
the	O
result	O
of	O
a	O
T	O
-	O
helper-2	O
(	O
Th2	O
)	O
response	O
.	O

In	O
the	O
presence	O
of	O
antigen	O
this	O
IgE	O
triggers	O
the	O
activation	O
and	O
proliferation	O
of	O
mast	O
cells	O
and	O
eosinophils	O
(	O
i.e.	O
type	O
I	O
hypersensitivity	O
reactions	O
)	O
.	O

The	O
exact	O
implications	O
of	O
these	O
IgE	O
responses	O
,	O
however	O
,	O
are	O
still	O
unclear	O
.	O

Several	O
studies	O
have	O
shown	O
that	O
high	O
parasite	B
specific	O
IgE	O
levels	O
are	O
associated	O
with	O
resistance	O
to	O
reinfection	O
,	O
suggesting	O
a	O
protective	O
role	O
for	O
IgE	O
[	O
6–9	O
]	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
structures	O
of	O
the	O
parasite	B
antigens	O
that	O
induce	O
these	O
IgE	O
responses	O
.	O

N	O
-	O
glycans	O
carrying	O
a	O
'	O
core	O
α1→3-Fuc	O
'	O
(	O
R	O
-	O
GlcNAcβ1→4	O
(	O
Fucα1→3	O
)	O
GlcNAcβ1-Asn	O
)	O
or	O
a	O
'	O
core	O
β1→2-Xyl	O
'	O
(	O
Xylβ1→2Manβ1→4GlcNAcβ1-R	O
)	O
are	O
found	O
on	O
many	O
plant	B
,	O
insect	B
and	O
mollusc	B
,	O
but	O
not	O
mammalian	B
,	O
glycoproteins	O
[	O
10–14	O
]	O
,	O
and	O
can	O
contribute	O
to	O
the	O
allergenicity	O
and	O
IgE	O
cross	O
-	O
reactivity	O
between	O
extracts	O
of	O
these	O
organisms	O
[	O
15–17	O
]	O
.	O

Recently	O
it	O
has	O
been	O
reported	O
that	O
the	O
ruminant	O
nematode	B
Haemonchus	B
contortus	I
expresses	O
glycoproteins	O
carrying	O
core	O
α1→3-Fuc	O
residues	O
[	O
18	O
]	O
,	O
and	O
that	O
both	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
epitopes	O
have	O
been	O
observed	O
on	O
egg	O
glycoproteins	B
of	O
the	O
human	B
schistosomes	B
,	O
Schistosoma	B
mansoni	I
and	O
Schistosoma	B
japonicum	I
[	O
19	O
]	O
.	O

Thus	O
,	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
epitopes	O
might	O
contribute	O
to	O
the	O
IgE	O
response	O
observed	O
in	O
helminth	B
infections	O
.	O

To	O
identify	O
the	O
possible	O
presence	O
of	O
such	O
epitopes	O
in	O
other	O
helminths	B
,	O
we	O
have	O
analyzed	O
the	O
glycoproteins	O
of	O
different	O
parasitic	B
helminths	B
,	O
and	O
also	O
of	O
the	O
free	O
living	O
nematode	B
Caenorhabditis	B
elegans	I
in	O
Western	O
blots	O
using	O
immunopurified	O
core	O
α1→3-Fuc	O
specific	O
and	O
β1→2-Xyl	O
specific	O
antibodies	O
[	O
20	O
]	O
.	O

The	O
results	O
show	O
that	O
core	O
α1→3-fucosylation	O
and	O
β1→2-xylosylation	O
are	O
common	O
glycan	O
modifications	O
occurring	O
in	O
many	O
different	O
helminths	B
.	O

In	O
addition	O
,	O
we	O
report	O
that	O
glycans	O
carrying	O
core	O
α1→3-Fuc	O
are	O
recognized	O
by	O
IgE	O
antibodies	O
from	O
sheep	B
infected	O
with	O
H.	B
contortus	I
and	O
mice	B
infected	O
with	O
S.	B
mansoni	I
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Antigen	O
preparations	O
and	O
sera	O
Honeybee	B
venom	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
and	O
cucurbita	B
ascorbate	O
oxidase	O
were	O
purchased	O
from	O
Sigma	O
.	O

Adult	O
H.	B
contortus	I
were	O
obtained	O
post	O
mortem	O
from	O
the	O
abomasum	O
of	O
sheep	B
experimentally	O
infected	O
with	O
20	O
000	O
L3	O
larvae	O
.	O

H.	B
contortus	I
excretory	O
secretory	O
(	O
ES	O
)	O
products	O
were	O
obtained	O
as	O
described	O
before	O
[	O
21	O
]	O
.	O

Sheep	B
antisera	O
were	O
collected	O
28	O
days	O
after	O
infection	O
from	O
two	O
sheep	B
,	O
experimentally	O
infected	O
with	O
the	O
H.	B
contortus	I
larvae	O
.	O

The	O
preparation	O
of	O
extracts	O
of	O
adult	O
Dirofilaria	B
immitis	I
,	O
Hymenolepis	B
diminuta	I
,	O
Fasciola	B
hepatica	I
,	O
S.	B
mansoni	I
,	O
S.	B
japonicum	I
and	O
Schistosoma	B
haematobium	I
was	O
described	O
previously	O
[	O
22	O
]	O
.	O

Extracts	O
of	O
C.	B
elegans	I
were	O
generated	O
by	O
resuspending	O
the	O
worm	B
pellets	O
in	O
SDS	O
-	O
PAGE	O
buffer	O
,	O
followed	O
by	O
incubation	O
for	O
10	O
min	O
at	O
100	O
°	O
C	O
.	O

Insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

Trichinella	B
spiralis	I
,	O
Toxocara	B
canis	I
and	O
cercariae	B
of	O
Trichobilharzia	B
ocellata	I
were	O
resuspended	O
in	O
100	O
μl	O
PBS	O
including	O
the	O
protease	O
inhibitors	O
Pefabloc	O
(	O
1	O
mg	O
/	O
ml	O
)	O
,	O
EDTA	O
(	O
0,5	O
mg	O
/	O
ml	O
)	O
,	O
leupeptin	O
(	O
10	O
μg	O
/	O
ml	O
)	O
,	O
pepstatin	O
(	O
10	O
μg	O
/	O
ml	O
)	O
,	O
aprotinin	O
(	O
1	O
μg	O
/	O
ml	O
)	O
(	O
Boehringer	O
Mannheim	O
)	O
,	O
and	O
homogenized	O
with	O
a	O
polytron	O
.	O

Triton	O
X-100	O
(	O
1	O
%	O
)	O
was	O
added	O
,	O
and	O
the	O
mixture	O
incubated	O
on	O
ice	O
for	O
20	O
min	O
.	O

After	O
addition	O
of	O
SDS	O
-	O
PAGE	O
buffer	O
and	O
incubation	O
for	O
10	O
min	O
at	O
100	O
°	O
C	O
,	O
insoluble	O
material	O
was	O
removed	O
by	O
centrifugation	O
.	O

2.2	O
Preparation	O
of	O
antisera	O
The	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
were	O
prepared	O
as	O
described	O
previously	O
[	O
20	O
]	O
.	O

Briefly	O
,	O
antiserum	O
raised	O
against	O
horseradish	B
peroxidase	O
was	O
fractionated	O
on	O
an	O
affinity	O
column	O
of	O
honeybee	B
PLA2	O
,	O
resulting	O
in	O
serum	O
fractions	O
specific	O
for	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
,	O
respectively	O
.	O

Antisera	O
were	O
tested	O
for	O
their	O
specificity	O
as	O
described	O
.	O

2.3	O
SDS	O
-	O
PAGE	O
and	O
Western	O
blotting	O
Helminth	B
extracts	O
(	O
approximately	O
20–40	O
μg	O
of	O
protein	O
)	O
and	O
controls	O
were	O
separated	O
by	O
SDS	O
/	O
PAGE	O
on	O
15	O
%	O
gels	O
using	O
the	O
Mini	O
-	O
Protean	O
II	O
system	O
(	O
BioRad	O
)	O
.	O

Western	O
blotting	O
and	O
antibody	O
reactions	O
were	O
performed	O
essentially	O
as	O
described	O
previously	O
[	O
23	O
]	O
.	O

For	O
detection	O
of	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
containing	O
glycoproteins	O
,	O
rabbit	B
polyclonal	O
anti	O
-	O
core	O
α1→3-Fuc	O
or	O
anti	O
-	O
β1→2-Xyl	O
specific	O
antibodies	O
were	O
used	O
as	O
the	O
first	O
antibody	O
and	O
goat	B
anti	O
-	O
rabbit	B
(	O
IgG	O
/	O
IgM	O
)	O
peroxidase	O
conjugate	O
(	O
TAGO	O
,	O
Inc.	O
Immunodiagnostic	O
reagents	O
)	O
as	O
the	O
second	O
antibody	O
.	O

For	O
detection	O
of	O
mouse	B
IgE	O
(	O
Fig.	O
4	O
)	O
the	O
blots	O
were	O
incubated	O
overnight	O
with	O
1:2	O
diluted	O
mouse	B
serum	O
followed	O
by	O
incubation	O
with	O
rabbit	B
anti	O
-	O
mouse	B
IgE	O
peroxidase	O
conjugate	O
(	O
Nordic	O
,	O
the	O
Netherlands	O
)	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Bound	O
antibodies	O
were	O
visualized	O
using	O
0.6	O
mg	O
/	O
ml	O
chloronaphtol	O
in	O
TBS	O
containing	O
0.03	O
%	O
H2	O
O2	O
.	O

2.4	O
ELISA	O
ELISA	O
was	O
performed	O
as	O
the	O
ES	O
specific	O
ELISA	O
described	O
previously	O
[	O
24	O
]	O
.	O

Plates	O
were	O
coated	O
with	O
H.	B
contortus	I
ES	O
,	O
PLA2	O
,	O
Arabidopsis	B
thaliana	I
,	O
A.	B
thaliana	I
cgl	O
,	O
and	O
human	B
transferrin	O
.	O

Competitive	O
glycoproteins	O
were	O
added	O
to	O
the	O
sheep	B
serum	O
in	O
a	O
final	O
concentration	O
range	O
of	O
80	O
to	O
0.026	O
μg	O
/	O
ml	O
.	O

Zero	O
%	O
inhibition	O
was	O
defined	O
as	O
the	O
OD	O
value	O
of	O
serum	O
without	O
competitive	O
glycoproteins	O
,	O
and	O
100	O
%	O
inhibition	O
as	O
the	O
OD	O
value	O
measured	O
with	O
80	O
μg	O
/	O
ml	O
autologous	O
glycoproteins	O
.	O

The	O
monosaccharides	O
D	O
-	O
Glc	O
,	O
L	O
-	O
Fuc	O
,	O
D	O
-	O
Xyl	O
or	O
L	O
-	O
Xyl	O
were	O
added	O
to	O
the	O
sheep	B
serum	O
in	O
a	O
final	O
concentration	O
range	O
of	O
0.01	O
to	O
1.4	O
M.	O
3	O
Results	O
3.1	O
Specificity	O
of	O
the	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
The	O
antisera	O
used	O
in	O
this	O
study	O
were	O
raised	O
against	O
the	O
plant	B
glycoprotein	O
horseradish	B
peroxidase	O
,	O
which	O
carries	O
glycans	O
shown	O
in	O
Fig.	O
1	O
.	O

Fractionation	O
of	O
this	O
antiserum	O
on	O
an	O
affinity	O
column	O
of	O
honeybee	B
venom	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
resulted	O
in	O
serum	O
fractions	O
highly	O
specific	O
for	O
either	O
the	O
core	O
α1→3-Fuc	O
,	O
or	O
β1→2-Xyl	O
,	O
respectively	O
.	O

To	O
confirm	O
their	O
specificity	O
purified	O
antibodies	O
were	O
tested	O
with	O
many	O
different	O
plant	O
and	O
mammalian	B
glycoproteins	O
,	O
containing	O
either	O
a	O
core	O
α1→3-Fuc	O
or	O
a	O
β1→2-Xyl	O
,	O
or	O
no	O
core	O
modification	O
[	O
20	O
]	O
.	O

Furthermore	O
,	O
both	O
antisera	O
reacted	O
strongly	O
with	O
glycoproteins	O
isolated	O
from	O
the	O
leaves	O
of	O
A.	B
thaliana	I
(	O
Figs.	O
2	O
,	O
4C	O
and	O
D	O
)	O
,	O
the	O
N	O
-	O
glycans	O
of	O
which	O
have	O
been	O
fully	O
identified	O
recently	O
and	O
shown	O
to	O
consist	O
of	O
high	O
mannose	O
-	O
type	O
N	O
-	O
glycans	O
and	O
complex	O
-	O
type	O
core	O
α1→3-fucosylated	O
and	O
β1→2-xylosylated	O
N	O
-	O
glycans	O
[	O
25	O
]	O
.	O

No	O
other	O
complex	O
-	O
type	O
modifications	O
have	O
been	O
demonstrated	O
in	O
A.	B
thaliana	I
[	O
25	O
]	O
.	O

The	O
antisera	O
did	O
not	O
bind	O
to	O
glycoproteins	O
of	O
the	O
cgl	O
mutant	O
of	O
A.	B
thaliana	I
,	O
lacking	O
N	O
-acetylglucosaminyltransferase	O
I	O
,	O
and	O
thus	O
lacking	O
the	O
expression	O
of	O
the	O
core	O
α3-fucosylated	O
and	O
β2-xylosylated	O
N	O
-	O
glycans	O
[	O
26	O
]	O
(	O
Figs.	O
2	O
,	O
4C	O
and	O
D	O
)	O
.	O

Importantly	O
,	O
the	O
results	O
in	O
Fig.	O
2	O
show	O
that	O
no	O
cross	O
-	O
reactivity	O
was	O
observed	O
of	O
the	O
core	O
α1→3-Fuc	O
antiserum	O
with	O
LPS	O
from	O
Helicobacter	B
pylori	I
strain	I
O3	I
,	O
containing	O
Galβ1→4	O
(	O
Fucα1→3	O
)	O
GlcNAc	O
(	O
Lex	O
,	O
[	O
27	O
]	O
)	O
,	O
sialyl	O
-	O
Lex	O
containing	O
α1	O
-acid	O
glycoprotein	O
(	O
AGP	O
)	O
derived	O
from	O
patients	B
suffering	O
from	O
rheumatoid	O
arthritis	O
[	O
28	O
]	O
,	O
core	O
α1→6-fucosylated	O
human	B
IgG	O
,	O
or	O
neoglycoprotein	O
containing	O
GalNAcβ1→4	O
(	O
Fucα1→3	O
)	O
GlcNAc	O
(	O
LDNF	O
)	O
units	O
,	O
indicating	O
that	O
the	O
core	O
α1→3-Fuc	O
specific	O
antiserum	O
does	O
not	O
recognize	O
other	O
Fucα1→3GlcNAc	O
moieties	O
found	O
in	O
the	O
core	O
or	O
outer	O
antennae	O
of	O
N-	O
or	O
O	O
-	O
linked	O
glycans	O
.	O

3.2	O
Core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
residues	O
on	O
protein	O
-	O
linked	O
glycans	O
of	O
different	O
helminths	B
The	O
presence	O
of	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
residues	O
on	O
protein	O
-	O
linked	O
glycans	O
of	O
different	O
helminths	B
was	O
determined	O
by	O
Western	O
blotting	O
,	O
using	O
the	O
affinity	O
purified	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antisera	O
[	O
20	O
]	O
.	O

The	O
extracts	O
were	O
derived	O
from	O
adult	O
helminths	B
,	O
except	O
the	O
extract	O
of	O
T.	B
ocellata	I
,	O
which	O
was	O
derived	O
from	O
cercariae	B
.	O

In	O
addition	O
to	O
the	O
adult	O
stages	O
,	O
soluble	O
antigens	O
were	O
tested	O
from	O
H.	B
contortus	I
(	O
i.e.	O
excretory	O
/	O
secretory	O
(	O
ES	O
)	O
antigens	O
)	O
and	O
S.	B
mansoni	I
(	O
soluble	O
egg	O
antigens	O
(	O
SE	O
)	O
)	O
.	O

The	O
extracts	O
from	O
most	O
helminths	B
tested	O
contained	O
many	O
glycoproteins	O
that	O
reacted	O
moderate	O
to	O
strongly	O
with	O
the	O
core	O
α1→3-Fuc	O
specific	O
antibodies	O
,	O
whereas	O
reaction	O
of	O
H.	B
diminuta	I
,	O
F.	B
hepatica	I
and	O
T.	B
canis	I
glycoproteins	O
was	O
less	O
abundant	O
(	O
Fig.	O
3	O
,	O
upper	O
panel	O
)	O
.	O

The	O
β1→2-Xyl	O
specific	O
antiserum	O
showed	O
binding	O
to	O
glycoproteins	O
of	O
some	O
of	O
the	O
extracts	O
,	O
i.e.	O
of	O
C.	B
elegans	I
,	O
S.	B
mansoni	I
,	O
S.	B
haematobium	I
,	O
S.	B
mansoni	I
SE	O
antigens	O
,	O
D.	B
immitis	I
,	O
T.	B
canis	I
,	O
and	O
of	O
cercariae	B
of	O
T.	B
ocellata	I
,	O
whereas	O
no	O
binding	O
was	O
observed	O
with	O
the	O
other	O
parasite	B
derived	O
samples	O
(	O
Fig.	O
3	O
,	O
lower	O
panel	O
)	O
.	O

3.3	O
IgE	O
in	O
sera	O
of	O
S.	O
mansoni	O
infected	O
mice	B
cross	O
-	O
reacts	O
with	O
A.	B
thaliana	I
glycoproteins	O
We	O
next	O
sought	O
to	O
determine	O
whether	O
infection	O
of	O
mice	B
with	O
S.	B
mansoni	I
results	O
in	O
IgE	O
to	O
core	O
α1→3-fucosylated	O
and/or	O
β1→2-xylosylated	O
N	O
-	O
glycans	O
.	O

Western	O
blots	O
containing	O
proteins	O
of	O
S.	B
mansoni	I
,	O
A.	B
thaliana	I
[	O
25	O
]	O
and	O
the	O
cgl	O
mutant	O
of	O
A.	B
thaliana	I
lacking	O
the	O
core	O
antigens	O
[	O
26	O
]	O
,	O
were	O
analyzed	O
using	O
different	O
antibodies	O
.	O

IgE	O
from	O
pooled	O
sera	O
of	O
mice	B
experimentally	O
infected	O
with	O
S.	B
mansoni	I
binds	O
to	O
several	O
S.	B
mansoni	I
proteins	O
,	O
in	O
contrast	O
to	O
IgE	O
from	O
normal	O
mouse	B
serum	O
that	O
showed	O
no	O
reactivity	O
.	O

IgE	O
from	O
the	O
infected	O
mice	B
serum	O
cross	O
-	O
reacted	O
with	O
many	O
proteins	O
of	O
A.	B
thaliana	I
,	O
but	O
not	O
with	O
the	O
cgl	O
mutant	O
,	O
indicating	O
that	O
the	O
antibodies	O
specifically	O
recognize	O
complex	O
-	O
type	O
glycans	O
carrying	O
a	O
core	O
α1→3-Fuc	O
or	O
β1→2-Xyl	O
residue	O
(	O
Fig.	O
4	O
)	O
.	O

We	O
also	O
could	O
detect	O
a	O
weak	O
binding	O
of	O
the	O
IgE	O
antibodies	O
from	O
infected	O
mice	B
with	O
honeybee	B
PLA2	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
the	O
core	O
-	O
linked	O
α1→3-Fuc	O
is	O
an	O
epitope	O
for	O
IgE	O
of	O
S.	B
mansoni	I
infected	O
mice	B
.	O

3.4	O
IgE	O
in	O
sera	O
from	O
H.	B
contortus	I
infected	O
sheep	B
recognizes	O
core	O
α1→3-fucosylated	O
N	O
-	O
glycans	O
Sera	O
from	O
sheep	B
infected	O
with	O
H.	B
contortus	I
were	O
analyzed	O
by	O
ELISA	O
.	O

The	O
results	O
in	O
Fig.	O
5A	O
show	O
that	O
IgE	O
in	O
serum	O
of	O
infected	O
sheep	B
recognizes	O
H.	B
contortus	I
ES	O
glycoproteins	O
,	O
honeybee	B
PLA2	O
and	O
A.	B
thaliana	I
glycoproteins	O
,	O
and	O
did	O
not	O
recognize	O
human	B
transferrin	O
or	O
glycoproteins	O
from	O
the	O
cgl	O
mutant	O
of	O
A.	B
thaliana	I
lacking	O
the	O
core	O
antigens	O
.	O

In	O
contrast	O
,	O
binding	O
of	O
IgG	O
antibodies	O
from	O
the	O
infected	O
sheep	B
sera	O
to	O
A.	B
thaliana	I
and	O
PLA2	O
proteins	O
was	O
hardly	O
detectable	O
,	O
whereas	O
IgG	O
binding	O
was	O
observed	O
to	O
many	O
H.	B
contortus	I
ES	O
proteins	O
(	O
Fig.	O
5A	O
,	O
[	O
29	O
]	O
)	O
.	O

These	O
results	O
suggest	O
that	O
IgE	O
from	O
the	O
sera	O
of	O
H.	B
contortus	I
infected	O
sheep	B
recognizes	O
the	O
core	O
α1→3-Fuc	O
epitope	O
that	O
occurs	O
on	O
both	O
plant	B
glycoproteins	O
and	O
honeybee	B
PLA2	O
.	O

To	O
further	O
validate	O
this	O
possibility	O
,	O
inhibition	O
experiments	O
were	O
performed	O
(	O
Fig.	O
5B	O
,	O
C	O
)	O
.	O

It	O
was	O
shown	O
that	O
PLA2	O
could	O
block	O
the	O
binding	O
of	O
IgE	O
from	O
infected	O
sheep	B
to	O
ES	O
.	O

Similarly	O
,	O
ES	O
could	O
block	O
the	O
binding	O
of	O
this	O
IgE	O
to	O
PLA2	O
,	O
whereas	O
human	B
transferrin	O
lacking	O
the	O
core	O
fucose	O
did	O
not	O
block	O
the	O
IgE	O
binding	O
.	O

Binding	O
of	O
sheep	B
IgE	O
to	O
H.	B
contortus	I
ES	O
was	O
inhibited	O
to	O
80	O
%	O
by	O
L	O
-	O
Fuc	O
at	O
a	O
concentration	O
of	O
1	O
M	O
,	O
whereas	O
the	O
same	O
concentrations	O
of	O
D	O
-	O
Xyl	O
,	O
L	O
-	O
Xyl	O
or	O
D	O
-	O
Glc	O
showed	O
only	O
25	O
%	O
inhibition	O
in	O
the	O
same	O
experiment	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
an	O
important	O
part	O
of	O
the	O
ES	O
specific	O
IgE	O
in	O
the	O
sera	O
of	O
H.	B
contortus	I
infected	O
sheep	B
recognizes	O
core	O
α1→3-fucosylated	O
N	O
-	O
glycans	O
.	O

4	O
Discussion	O
We	O
report	O
in	O
this	O
study	O
that	O
IgE	O
from	O
serum	O
of	O
S.	B
mansoni	I
infected	O
mice	B
and	O
H.	B
contortus	I
infected	O
sheep	B
cross	O
-	O
reacts	O
with	O
A.	B
thaliana	I
glycoproteins	O
that	O
carry	O
core	O
α1→3-fucosylated	O
and	O
β1→2-xylosylated	O
N	O
-	O
glycans	O
.	O

In	O
contrast	O
,	O
IgE	O
from	O
these	O
sera	O
did	O
not	O
bind	O
to	O
glycoproteins	O
of	O
the	O
cgl	O
mutant	O
of	O
A.	B
thaliana	I
,	O
that	O
lack	O
the	O
core	O
antigens	O
and	O
other	O
complex	O
-	O
type	O
glycan	O
modifications	O
[	O
14,25,26	O
]	O
.	O

These	O
results	O
indicate	O
that	O
the	O
core	O
α1→3-Fuc	O
and/or	O
the	O
β1→2-Xyl	O
residues	O
are	O
epitopes	O
for	O
both	O
IgE	O
from	O
S.	B
mansoni	I
infected	O
mice	B
and	O
H.	B
contortus	I
infected	O
sheep	B
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
human	B
schistosome	B
S.	B
mansoni	I
synthesizes	O
glycoproteins	O
carrying	O
both	O
core	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
residues	O
[	O
19	O
]	O
,	O
which	O
was	O
confirmed	O
by	O
our	O
studies	O
using	O
the	O
affinity	O
purified	O
α1→3-Fuc	O
and	O
β1→2-Xyl	O
specific	O
antibodies	O
.	O

Since	O
these	O
core	O
antigens	O
do	O
not	O
occur	O
in	O
mammals	B
they	O
may	O
induce	O
the	O
generation	O
of	O
anti	O
-	O
glycan	O
antibodies	O
during	O
schistosome	B
infection	O
.	O

We	O
can	O
not	O
deduce	O
from	O
our	O
data	O
whether	O
one	O
or	O
both	O
of	O
the	O
core	O
antigens	O
in	O
A.	B
thaliana	I
are	O
involved	O
in	O
binding	O
of	O
IgE	O
from	O
S.	B
mansoni	I
infected	O
mice	B
.	O

In	O
contrast	O
,	O
the	O
ruminant	O
nematode	B
H.	B
contortus	I
contains	O
glycoproteins	O
carrying	O
core	O
α1→3-fucosylated	O
N	O
-	O
glycans	O
but	O
no	O
evidence	O
was	O
presented	O
for	O
the	O
presence	O
of	O
a	O
β1→2-Xyl	O
(	O
[	O
18	O
]	O
,	O
this	O
study	O
)	O
.	O

This	O
suggests	O
that	O
the	O
core	O
α1→3-Fuc	O
is	O
likely	O
to	O
be	O
the	O
A.	B
thaliana	I
epitope	O
that	O
reacted	O
with	O
IgE	O
from	O
H.	B
contortus	I
infected	O
sheep	B
.	O

Evidence	O
is	O
presented	O
using	O
both	O
ELISA	O
and	O
competitive	O
ELISA	O
that	O
the	O
core	O
α1→3-Fuc	O
residue	O
indeed	O
is	O
a	O
major	O
epitope	O
recognized	O
by	O
parasite	B
specific	O
IgE	O
from	O
serum	O
of	O
H.	B
contortus	I
infected	O
sheep	B
.	O

Importantly	O
,	O
hardly	O
any	O
IgG	O
reactivity	O
to	O
this	O
core	O
antigen	O
was	O
demonstrable	O
in	O
these	O
sera	O
.	O

In	O
contrast	O
,	O
IgM	O
or	O
IgG	O
antibodies	O
have	O
been	O
demonstrated	O
in	O
sera	O
of	O
parasite	B
infected	O
hosts	O
to	O
other	O
parasite	B
derived	O
carbohydrate	O
components	O
(	O
[	O
30	O
]	O
;	O
Van	O
Remoortere	O
et	O
al.	O
,	O
manuscript	O
in	O
preparation	O
)	O
.	O

This	O
suggests	O
that	O
the	O
core	O
α1→3-Fuc	O
epitope	O
preferentially	O
triggers	O
a	O
Th2	O
response	O
leading	O
to	O
the	O
production	O
of	O
IgE	O
,	O
although	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
core	O
fucose	O
specific	O
IgE	O
is	O
a	O
product	O
rather	O
than	O
an	O
inducer	O
of	O
a	O
Th2	O
response	O
.	O

Interestingly	O
,	O
several	O
T	O
cell	O
clones	O
have	O
been	O
identified	O
from	O
bee	B
venom	O
sensitized	O
subjects	B
which	O
proliferate	O
in	O
response	O
to	O
honeybee	B
PLA2	O
but	O
not	O
to	O
its	O
non	O
-	O
glycosylated	O
variants	O
,	O
providing	O
evidence	O
for	O
the	O
involvement	O
of	O
an	O
N	O
-	O
glycan	O
in	O
T	O
cell	O
recognition	O
[	O
31	O
]	O
.	O

It	O
will	O
be	O
important	O
to	O
establish	O
whether	O
the	O
core	O
α-1→3-Fuc	O
antigen	O
is	O
involved	O
in	O
these	O
immunological	O
processes	O
.	O

Recently	O
it	O
has	O
been	O
demonstrated	O
that	O
vaccination	O
of	O
sheep	B
with	O
ES	O
antigens	O
of	O
H.	B
contortus	I
induces	O
protection	O
against	O
challenge	O
infection	O
and	O
that	O
this	O
protection	O
is	O
correlated	O
with	O
IgE	O
rather	O
than	O
with	O
IgG	O
[	O
32	O
]	O
.	O

It	O
thus	O
appears	O
that	O
the	O
core	O
α1→3-Fuc	O
antigen	O
may	O
be	O
an	O
important	O
protective	O
antigen	O
in	O
H.	B
contortus	I
infections	O
,	O
and	O
perhaps	O
other	O
helminth	B
infections	O
.	O

To	O
identify	O
the	O
possible	O
presence	O
of	O
core	O
-	O
fucosylated	O
and	O
core	O
-	O
xylosylated	O
epitopes	O
in	O
other	O
helminths	B
we	O
analyzed	O
different	O
species	O
.	O

Our	O
results	O
show	O
that	O
many	O
helminths	B
from	O
different	O
orders	O
of	O
the	O
phyla	B
Platyhelminthes	B
and	O
Nematodes	B
synthesize	O
glycoproteins	O
containing	O
core	O
α1→3-fucosylated	O
N	O
-	O
glycans	O
.	O

In	O
addition	O
several	O
of	O
these	O
organisms	O
also	O
synthesize	O
N	O
-	O
glycans	O
containing	O
β1→2-Xyl	O
.	O

Remarkably	O
,	O
only	O
small	O
amounts	O
of	O
β1→2-Xyl	O
were	O
found	O
on	O
glycoproteins	O
of	O
adult	O
S.	B
japonicum	I
,	O
whereas	O
the	O
related	O
S.	B
mansoni	I
and	O
S.	B
haematobium	I
showed	O
many	O
β1→2-xylosylated	O
glycoproteins	O
.	O

Recent	O
data	O
from	O
Khoo	O
et	O
al.	O
[	O
19	O
]	O
described	O
the	O
presence	O
of	O
β1→2-xylosylated	O
N	O
-	O
glycans	O
in	O
egg	O
glycoproteins	O
of	O
S.	B
japonicum	I
.	O

It	O
may	O
be	O
possible	O
that	O
in	O
S.	B
japonicum	I
β1→2-xylosylation	O
is	O
stage	O
specific	O
.	O

Alternatively	O
,	O
the	O
plant	B
specific	O
antiserum	O
may	O
be	O
unable	O
to	O
bind	O
some	O
core	O
β1→2-Xyl	O
residues	O
,	O
due	O
to	O
masking	O
of	O
the	O
epitope	O
,	O
e.g.	O
by	O
the	O
presence	O
of	O
multiple	O
core	O
fucose	O
residues	O
[	O
19	O
]	O
or	O
other	O
modifications	O
.	O

Cross	O
-	O
reactivity	O
has	O
been	O
observed	O
for	O
many	O
years	O
in	O
immunoassays	O
of	O
plant	B
,	O
arthropod	B
and	O
mollusc	B
extracts	O
[	O
33–35	O
]	O
.	O

Part	O
of	O
this	O
cross	O
-	O
reactivity	O
is	O
caused	O
by	O
conserved	O
proteins	O
,	O
as	O
profilins	O
in	O
plants	B
[	O
36	O
]	O
,	O
and	O
tropomyosins	O
in	O
crustacea	B
and	O
mollusca	B
[	O
37	O
]	O
.	O

In	O
addition	O
,	O
cross	O
-	O
reactivity	O
between	O
several	O
parasitic	B
helminths	B
,	O
and	O
between	O
helminths	B
and	O
molluscs	B
has	O
been	O
reported	O
[	O
38–40	O
]	O
.	O

The	O
highly	O
antigenic	O
core	O
α1→3-Fuc	O
and/or	O
β1→2-Xyl	O
in	O
N	O
-	O
glycans	O
,	O
that	O
are	O
conserved	O
among	O
many	O
invertebrates	B
and	O
plants	B
,	O
have	O
been	O
shown	O
to	O
contribute	O
to	O
such	O
cross	O
-	O
reactions	O
[	O
35,41	O
]	O
.	O

In	O
some	O
cases	O
it	O
has	O
been	O
established	O
that	O
IgE	O
antibodies	O
from	O
patients	B
allergic	O
for	O
honeybee	B
venom	O
or	O
plant	B
substances	O
such	O
as	O
cereal	B
flour	O
proteins	O
bind	O
to	O
core	O
α1→3-Fuc	O
and/or	O
β1→2-Xyl	O
containing	O
N	O
-	O
glycans	O
[	O
15–17	O
]	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
core	O
α1→3-Fuc	O
structure	O
is	O
commonly	O
found	O
on	O
helminth	B
glycoproteins	O
and	O
that	O
IgE	O
antibodies	O
from	O
helminth	B
infected	O
hosts	O
bind	O
to	O
this	O
glycan	O
epitope	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
an	O
antigen	O
that	O
may	O
be	O
important	O
in	O
the	O
induction	O
of	O
both	O
helminth	B
-	O
mediated	O
Th2-type	O
immunity	O
and	O
in	O
allergic	O
reactions	O
.	O

Recognition	O
of	O
putative	O
features	O
common	O
to	O
helminths	B
presumably	O
informs	O
the	O
host	O
immune	O
system	O
that	O
a	O
stereotypic	O
type	O
2	O
cytokine	O
response	O
will	O
be	O
more	O
protective	O
than	O
a	O
type	O
1	O
or	O
type	O
0	O
.	O

It	O
has	O
been	O
hypothesized	O
previously	O
that	O
some	O
of	O
these	O
helminth	B
features	O
are	O
shared	O
with	O
allergens	O
and	O
may	O
be	O
responsible	O
for	O
the	O
obviously	O
maladaptive	O
responses	O
made	O
to	O
non	O
-	O
threatening	O
molecules	O
as	O
pollen	O
antigens	O
and	O
bee	B
venom	O
phospholipase	O
[	O
42	O
]	O
.	O

This	O
stresses	O
the	O
importance	O
of	O
the	O
conserved	O
core	O
α1→3-Fuc	O
epitope	O
as	O
a	O
potential	O
'	O
pan	O
allergen	O
'	O
[	O
41	O
]	O
.	O

Interestingly	O
,	O
several	O
studies	O
have	O
shown	O
an	O
inverse	O
relationship	O
between	O
exposure	O
to	O
helminth	B
infections	O
and	O
the	O
incidence	O
of	O
allergies	O
[	O
43–45	O
]	O
.	O

It	O
is	O
exciting	O
to	O
consider	O
the	O
possibility	O
that	O
detailed	O
knowledge	O
of	O
the	O
parasite	B
structures	O
involved	O
in	O
Th2	O
activation	O
and	O
IgE	O
induction	O
and	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
by	O
which	O
they	O
evoke	O
these	O
immune	O
responses	O
may	O
lead	O
to	O
novel	O
therapies	O
against	O
both	O
parasitic	B
diseases	O
and	O
atopic	O
disorders	O
.	O

Acknowledgments	O
We	O
gratefully	O
acknowledge	O
Ms.	O
A.	O
van	O
Tetering	O
for	O
technical	O
assistance	O
in	O
part	O
of	O
the	O
work	O
.	O

We	O
thank	O
Dr.	O
A.M.	O
Deelder	O
(	O
Dept	O
.	O

of	O
Parasitology	O
,	O
Leiden	O
,	O
The	O
Netherlands	O
)	O
for	O
serum	O
from	O
schistosome	B
infected	O
mice	B
,	O
Dr.	O
H.	O
Bakker	O
(	O
CPRO	O
-	O
DLO	O
,	O
Wageningen	O
,	O
The	O
Netherlands	O
)	O
for	O
extracts	O
of	O
A.	B
thaliana	I
,	O
Dr.	O
H.	O
van	O
Luenen	O
(	O
NKI	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
C.	B
elegans	I
,	O
Drs	O
.	O

A.K.	O
Nyame	O
(	O
University	O
of	O
Oklahoma	O
,	O
USA	O
)	O
,	O
Y.	O
Rombouts	O
(	O
RIVM	O
,	O
Bilthoven	O
,	O
The	O
Netherlands	O
)	O
,	O
and	O
M.	O
de	O
Jong	O
-	O
Brink	O
(	O
Dept	O
.	O

of	O
Neurobiology	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
parasites	B
and	O
parasite	B
extracts	O
,	O
Drs	O
A.	O
van	O
Remoortere	O
(	O
Dept	O
.	O
of	O
Medical	O
Chemistry	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
gift	O
of	O
neoglycoprotein	O
,	O
Dr.	O
B.	O
Appelmelk	O
(	O
Dept	O
.	O
of	O
Medical	O
Microbiology	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
H.	O
pylori	O
LPS	O
,	O
and	O
Dr.	O
W.	O
van	O
Dijk	O
(	O
Dept	O
.	O
of	O
Medical	O
Chemistry	O
,	O
VU	O
,	O
Amsterdam	O
,	O
The	O
Netherlands	O
)	O
for	O
AGP	O
.	O

We	O
thank	O
Dr.	O
P.	O
Lerouge	O
(	O
CNRS	O
,	O
Rouen	O
,	O
France	O
)	O
for	O
stimulating	O
discussions	O
and	O
Dr.	O
A.W.	O
Cornelissen	O
(	O
Dept	O
.	O

of	O
Parasitology	O
,	O
Utrecht	O
,	O
The	O
Netherlands	O
)	O
for	O
critical	O
reading	O
of	O
the	O
manuscript	O
.	O

L.V.	O
was	O
supported	O
by	O
a	O
grant	O
from	O
The	O
Technology	O
Foundation	O
(	O
STW	O
,	O
The	O
Netherlands	O
;	O
project	O
:	O
UDG55.3762	O
)	O
.	O

Collaboration	O
between	O
Drs	O
.	O

I.	O
van	O
Die	O
and	O
R.	O
Cummings	O
was	O
facilitated	O
by	O
a	O
NATO	O
Collaborative	O
Research	O
Grant	O
(	O
CRG972098	O
)	O
.	O

It	O
is	O
now	O
well	O
established	O
that	O
there	O
are	O
two	O
isozymes	O
of	O
prostaglandin	O
(	O
PG	O
)	O
-forming	O
cyclooxygenase	O
;	O
constitutive	O
cyclooxygenase-1	O
and	O
inducible	O
cyclooxygenase-2	O
[	O
1,2	O
]	O
.	O

MC3T3-E1	B
cell	O
cloned	O
from	O
newborn	O
mouse	B
calvaria	O
is	O
an	O
osteogenic	O
cell	O
line	O
which	O
differentiates	O
into	O
an	O
osteoblast	O
[	O
3,4	O
]	O
.	O

Much	O
earlier	O
our	O
extensive	O
studies	O
demonstrated	O
the	O
production	O
of	O
E2	O
as	O
a	O
major	O
arachidonate	O
metabolite	O
in	O
this	O
cell	O
line	O
[	O
5	O
]	O
and	O
the	O
induction	O
of	O
cyclooxygenase	O
by	O
various	O
bioregulators	O
[	O
5–9	O
]	O
.	O

Later	O
the	O
induced	O
enzyme	O
in	O
MC3T3-E1	B
cells	O
was	O
identified	O
as	O
cyclooxygenase-2	O
[	O
8–10	O
]	O
.	O

Previously	O
humulon	O
(	O
(	O
R	O
)	O
-3,5,6-trihydroxy-4,6-bis	O
(	O
3-methyl-2-butenyl	O
)	O
-2-	O
(	O
3-methyl-1-oxobutyl	O
)	O
-2,4-cyclohexadien-1-one	O
)	O
(	O
Fig.	O
1	O
)	O
isolated	O
from	O
hop	B
(	O
Humulus	B
lupulus	I
L.	O
)	O
extract	O
was	O
found	O
as	O
an	O
inhibitor	O
of	O
bone	O
resorption	O
(	O
IC50	O
:	O
5.9	O
nM	O
)	O
[	O
11	O
]	O
.	O

We	O
noted	O
this	O
activity	O
of	O
humulon	O
,	O
and	O
were	O
interested	O
in	O
a	O
possible	O
inhibitory	O
or	O
suppressive	O
effect	O
of	O
humulon	O
on	O
cyclooxygenase-2	O
leading	O
to	O
a	O
decreased	O
production	O
of	O
PGE2	O
as	O
a	O
bone	O
resorption	O
factor	O
[	O
12	O
]	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Humulon	O
was	O
purified	O
from	O
hop	B
paste	O
as	O
described	O
previously	O
[	O
11	O
]	O
,	O
and	O
the	O
purified	O
material	O
was	O
dissolved	O
in	O
dimethyl	O
sulfoxide	O
at	O
a	O
concentration	O
of	O
10	O
mM.	O
MC3T3-E1	B
cells	O
were	O
cultured	O
as	O
described	O
previously	O
[	O
5	O
]	O
.	O

Confluent	O
cultures	O
were	O
usually	O
obtained	O
on	O
the	O
4th	O
day	O
.	O

Then	O
,	O
the	O
medium	O
was	O
changed	O
to	O
α	O
-	O
MEM	O
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
supplemented	O
with	O
2	O
%	O
newborn	O
bovine	B
serum	O
(	O
Irvine	O
Scientific	O
,	O
Santa	O
Ana	O
,	O
CA	O
,	O
USA	O
)	O
and	O
a	O
compound	O
to	O
be	O
tested	O
.	O

At	O
indicated	O
time	O
intervals	O
,	O
the	O
cells	O
were	O
scraped	O
from	O
dishes	O
and	O
subjected	O
to	O
various	O
assays	O
described	O
below	O
.	O

2.2	O
Assays	O
of	O
cyclooxygenase-1	O
and	O
-2	O
activities	O
For	O
cyclooxygenase-1	O
preparation	O
,	O
lyophilized	O
powder	O
of	O
sheep	B
seminal	O
vesicle	O
microsomes	O
(	O
Eldan	O
Technologies	O
,	O
Jerusalem	O
,	O
Israel	O
)	O
was	O
suspended	O
in	O
20	O
mM	O
phosphate	O
buffer	O
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	O
.	O

For	O
cyclooxygenase-2	O
preparation	O
,	O
5	O
×	O
107	O
MC3T3-E1	I
cells	O
were	O
incubated	O
with	O
100	O
nM	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
100	O
nM	O
A23187	O
for	O
9	O
h.	O
The	O
cells	O
were	O
subjected	O
to	O
sonic	O
disruption	O
,	O
and	O
centrifuged	O
at	O
180	O
000	O
×	O
g	O
for	O
50	O
min	O
.	O

The	O
resultant	O
pellet	O
was	O
collected	O
as	O
the	O
microsomal	O
fraction	O
,	O
and	O
suspended	O
in	O
1	O
ml	O
of	O
20	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	O
.	O

The	O
enzyme	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

2.3	O
Cyclooxygenase-2	O
induction	O
MC3T3-E1	B
cells	O
(	O
2.2	O
×	O
106	O
cells	O
)	O
were	O
incubated	O
with	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
(	O
10–20	O
ng	O
/	O
ml	O
)	O
.	O

For	O
determination	O
of	O
PGE2	O
synthesis	O
,	O
aliquots	O
were	O
removed	O
from	O
the	O
culture	O
medium	O
(	O
1	O
ml	O
)	O
of	O
3	O
×	O
105	O
MC3T3-E1	B
cells	O
,	O
and	O
subjected	O
to	O
radioimmunoassay	O
for	O
PGE2	O
as	O
described	O
previously	O
[	O
5	O
]	O
.	O

For	O
catalytic	O
activity	O
assay	O
,	O
the	O
cells	O
were	O
scraped	O
from	O
the	O
dishes	O
,	O
suspended	O
in	O
200	O
μl	O
of	O
20	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
7.4	O
)	O
containing	O
5	O
mM	O
tryptophan	O
,	O
and	O
subjected	O
to	O
sonication	O
.	O

Aliquots	O
(	O
1–30	O
μl	O
)	O
of	O
the	O
sonicate	O
were	O
incubated	O
with	O
10	O
μM	O
[	O
1	O
-	O
14	O
C	O
]	O
arachidonic	O
acid	O
(	O
2.1	O
GBq	O
/	O
mmol	O
,	O
Amersham	O
Pharmacia	O
Biotech	O
,	O
Bucks	O
,	O
UK	O
)	O
for	O
2	O
min	O
at	O
24	O
°	O
C	O
in	O
a	O
100-μl	O
mixture	O
containing	O
100	O
mM	O
Tris	O
–	O
HCl	O
(	O
pH	O
8.0	O
)	O
,	O
2	O
μM	O
hematin	O
,	O
and	O
5	O
mM	O
tryptophan	O
.	O

The	O
reaction	O
products	O
were	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
MC3T3-E1	B
cells	O
using	O
ISOGEN	O
(	O
Nippon	O
Gene	O
,	O
Tokyo	O
,	O
Japan	O
)	O
and	O
subjected	O
to	O
Northern	O
blot	O
analysis	O
for	O
cyclooxygenase-2	O
and	O
β	O
-	O
actin	O
mRNA	O
as	O
described	O
previously	O
[	O
8	O
]	O
.	O

2.4	O
Reporter	O
gene	O
assay	O
A	O
DNA	O
fragment	O
(	O
nucleotides	O
−815	O
to	O
+	O
123	O
)	O
was	O
prepared	O
from	O
the	O
5′-flanking	O
region	O
of	O
the	O
mouse	B
cyclooxygenase-2	O
gene	O
as	O
described	O
previously	O
[	O
9	O
]	O
,	O
and	O
was	O
inserted	O
into	O
the	O
luciferase	O
plasmid	O
pGL3	O
Basic	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

The	O
complementary	O
oligonucleotide	O
with	O
a	O
specific	O
sequence	O
of	O
glucocorticoid	O
response	O
element	O
(	O
5′-AGAGGATCTGTACA	O
GGATGTTCT	O
AGAT-3′	O
;	O
consensus	O
sequence	O
of	O
the	O
glucocorticoid	O
response	O
element	O
is	O
underlined	O
)	O
was	O
synthesized	O
essentially	O
by	O
the	O
same	O
method	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

The	O
oligonucleotide	O
of	O
the	O
glucocorticoid	O
response	O
element	O
,	O
NFκB	O
response	O
element	O
[	O
9	O
]	O
or	O
NF	O
-	O
IL6	O
response	O
element	O
[	O
9	O
]	O
was	O
inserted	O
in	O
front	O
of	O
the	O
herpes	B
simplex	I
virus	I
thymidine	O
kinase	O
gene	O
[	O
13	O
]	O
of	O
the	O
tk	O
-	O
pGL3	O
vector	O
[	O
14	O
]	O
.	O

For	O
the	O
transfection	O
of	O
luciferase	O
plasmid	O
,	O
7.8	O
×	O
105	O
confluent	O
cells	O
were	O
treated	O
with	O
pGL3	O
plasmid	O
DNA	O
(	O
3	O
μg	O
)	O
,	O
standard	O
β	O
-	O
galactosidase	O
DNA	O
(	O
1.5	O
μg	O
)	O
,	O
and	O
13.5	O
μl	O
of	O
Trans	O
IT	O
™	O
-LT1	O
(	O
Takara	O
,	O
Tokyo	O
,	O
Japan	O
)	O
in	O
2.3	O
ml	O
of	O
serum	O
-	O
free	O
α	O
-	O
MEM	O
for	O
4	O
h	O
at	O
37	O
°	O
C	O
.	O

After	O
transfection	O
the	O
medium	O
was	O
changed	O
to	O
5	O
ml	O
of	O
α	O
-	O
MEM	O
with	O
10	O
%	O
fetal	O
bovine	B
serum	O
(	O
Life	O
Technologies	O
,	O
Gaithersburg	O
,	O
MD	O
,	O
USA	O
)	O
,	O
and	O
the	O
transfected	O
cells	O
were	O
further	O
incubated	O
for	O
3	O
days	O
.	O

The	O
medium	O
was	O
changed	O
to	O
α	O
-	O
MEM	O
described	O
above	O
.	O

After	O
12	O
h	O
the	O
cells	O
were	O
scraped	O
from	O
the	O
dishes	O
,	O
and	O
the	O
luciferase	O
assay	O
was	O
performed	O
as	O
described	O
previously	O
[	O
9	O
]	O
.	O

The	O
results	O
were	O
normalized	O
with	O
β	O
-	O
galactosidase	O
activity	O
.	O

3	O
Results	O
We	O
investigated	O
the	O
possibility	O
that	O
humulon	O
suppressed	O
the	O
TNFα	O
-	O
mediated	O
induction	O
of	O
cyclooxygenase-2	O
.	O

When	O
MC3T3-E1	B
cells	O
were	O
incubated	O
with	O
10	O
ng	O
/	O
ml	O
TNFα	O
in	O
the	O
presence	O
of	O
humulon	O
for	O
12	O
h	O
,	O
the	O
amount	O
of	O
released	O
PGE2	O
decreased	O
depending	O
on	O
the	O
concentration	O
of	O
humulon	O
with	O
an	O
IC50	O
of	O
about	O
30	O
nM	O
(	O
Fig.	O
2A	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
2C	O
,	O
the	O
cyclooxygenase	O
activity	O
of	O
the	O
TNFα	O
-	O
treated	O
cells	O
was	O
reduced	O
by	O
humulon	O
dose	O
-	O
dependently	O
.	O

Furthermore	O
,	O
Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
addition	O
of	O
humulon	O
suppressed	O
the	O
TNFα	O
-	O
induced	O
increase	O
of	O
cyclooxygenase-2	O
mRNA	O
(	O
Fig.	O
2E	O
)	O
.	O

For	O
analysis	O
of	O
the	O
promoter	O
activity	O
,	O
a	O
luciferase	O
vector	O
of	O
cyclooxygenase-2	O
gene	O
was	O
constructed	O
,	O
and	O
transfected	O
to	O
MC3T3-E1	B
cells	O
by	O
the	O
lipofection	O
method	O
.	O

The	O
luciferase	O
activity	O
of	O
the	O
cell	O
lysate	O
was	O
measured	O
12	O
h	O
after	O
the	O
addition	O
of	O
10	O
ng	O
/	O
ml	O
TNFα	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
humulon	O
(	O
Fig.	O
2	O
G	O
)	O
.	O

Since	O
the	O
same	O
range	O
of	O
humulon	O
concentration	O
was	O
required	O
for	O
the	O
decrease	O
in	O
the	O
PGE2	O
release	O
,	O
enzyme	O
activity	O
,	O
mRNA	O
level	O
and	O
promoter	O
activity	O
,	O
we	O
presumed	O
that	O
the	O
induction	O
of	O
cyclooxygenase-2	O
by	O
TNFα	O
was	O
inhibited	O
at	O
the	O
step	O
of	O
transcription	O
.	O

Then	O
,	O
we	O
examined	O
whether	O
or	O
not	O
humulon	O
inhibited	O
the	O
catalytic	O
activities	O
of	O
cyclooxygenases-1	O
and	O
-2	O
.	O

As	O
shown	O
in	O
Fig.	O
3	O
,	O
the	O
cyclooxygenase-1	O
activity	O
was	O
hardly	O
affected	O
by	O
humulon	O
below	O
10	O
μM	O
,	O
whereas	O
the	O
cyclooxygenase-2	O
activity	O
was	O
inhibited	O
with	O
an	O
IC50	O
value	O
of	O
about	O
1.6	O
μM.	O
Thus	O
,	O
the	O
catalytic	O
activity	O
of	O
cyclooxygenase-2	O
was	O
inhibited	O
by	O
humulon	O
,	O
but	O
its	O
IC50	O
was	O
higher	O
by	O
about	O
two	O
orders	O
of	O
magnitude	O
than	O
the	O
IC50	O
of	O
the	O
cyclooxygenase-2	O
suppression	O
.	O

As	O
reported	O
preliminarily	O
earlier	O
[	O
15	O
]	O
,	O
the	O
TNFα	O
-	O
dependent	O
cyclooxygenase-2	O
induction	O
in	O
MC3T3-E1	B
cells	O
was	O
suppressed	O
by	O
dexamethasone	O
which	O
is	O
well	O
known	O
as	O
a	O
potent	O
anti	O
-	O
inflammatory	O
drug	O
and	O
a	O
suppressor	O
of	O
cyclooxygenase-2	O
induction	O
in	O
most	O
cells	O
[	O
1,2	O
]	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
dexamethasone	O
in	O
MC3T3-E1	B
cells	O
.	O

When	O
the	O
cells	O
were	O
incubated	O
with	O
20	O
ng	O
/	O
ml	O
TNFα	O
for	O
12	O
h	O
,	O
the	O
amount	O
of	O
released	O
PGE2	O
(	O
Fig.	O
2B	O
)	O
and	O
the	O
cyclooxygenase-2	O
activity	O
(	O
Fig.	O
2D	O
)	O
decreased	O
depending	O
on	O
the	O
concentration	O
of	O
added	O
dexamethasone	O
(	O
IC50	O
:	O
1	O
nM	O
)	O
.	O

As	O
shown	O
in	O
Fig.	O
2F	O
,	O
the	O
cyclooxygenase-2	O
mRNA	O
level	O
was	O
also	O
decreased	O
in	O
the	O
presence	O
of	O
dexamethasone	O
.	O

The	O
TNFα	O
-	O
dependent	O
luciferase	O
activity	O
was	O
also	O
decreased	O
by	O
dexamethasone	O
with	O
an	O
IC50	O
of	O
about	O
1	O
nM	O
(	O
Fig.	O
2H	O
)	O
.	O

These	O
data	O
indicated	O
that	O
dexamethasone	O
suppressed	O
the	O
cyclooxygenase-2	O
induction	O
by	O
reducing	O
its	O
mRNA	O
level	O
in	O
MC3T3-E1	B
cells	O
.	O

Our	O
previous	O
work	O
with	O
MC3T3-E1	B
cells	O
demonstrated	O
the	O
involvement	O
of	O
NFκB	O
and	O
NF	O
-	O
IL6	O
as	O
transcription	O
factors	O
in	O
the	O
cyclooxygenase-2	O
induction	O
by	O
TNFα	O
[	O
9	O
]	O
.	O

We	O
investigated	O
whether	O
or	O
not	O
humulon	O
and	O
dexamethasone	O
functioned	O
with	O
the	O
aid	O
of	O
NFκB	O
(	O
nucleotides	O
−401	O
to	O
−393	O
)	O
and	O
NF	O
-	O
IL6	O
(	O
nucleotides	O
−138	O
to	O
−130	O
)	O
response	O
elements	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
we	O
constructed	O
a	O
luciferase	O
vector	O
containing	O
thymidine	O
kinase	O
gene	O
and	O
NFκB	O
or	O
NF	O
-	O
IL6	O
response	O
element	O
.	O

Each	O
vector	O
was	O
transfected	O
to	O
MC3T3-E1	B
cells	O
,	O
and	O
the	O
luciferase	O
activity	O
was	O
measured	O
.	O

Both	O
humulon	O
and	O
dexamethasone	O
decreased	O
the	O
luciferase	O
activity	O
induced	O
by	O
TNFα	O
.	O

Thus	O
,	O
the	O
suppressive	O
effect	O
of	O
humulon	O
and	O
dexamethasone	O
on	O
the	O
cyclooxygenase-2	O
induction	O
was	O
attributable	O
presumably	O
to	O
NFκB	O
or	O
NF	O
-	O
IL6	O
or	O
both	O
.	O

To	O
investigate	O
whether	O
or	O
not	O
humulon	O
bound	O
to	O
glucocorticoid	O
receptor	O
,	O
we	O
used	O
RU486	O
as	O
a	O
glucocorticoid	O
receptor	O
antagonist	O
[	O
16	O
]	O
.	O

The	O
TNFα	O
-	O
dependent	O
PGE2	O
production	O
decreased	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU486	O
dose	O
-	O
dependently	O
(	O
Fig.	O
5A	O
)	O
.	O

However	O
,	O
the	O
decreased	O
PGE2	O
production	O
by	O
humulon	O
was	O
not	O
affected	O
by	O
RU486	O
(	O
Fig.	O
5A	O
)	O
.	O

Then	O
,	O
we	O
constructed	O
a	O
luciferase	O
vector	O
containing	O
thymidine	O
kinase	O
gene	O
and	O
glucocorticoid	O
response	O
element	O
(	O
Fig.	O
5B	O
)	O
.	O

The	O
vector	O
was	O
transfected	O
to	O
MC3T3-E1	B
cells	O
,	O
and	O
the	O
luciferase	O
activity	O
of	O
the	O
cell	O
lysate	O
was	O
measured	O
12	O
h	O
after	O
the	O
addition	O
of	O
TNFα	O
plus	O
dexamethasone	O
or	O
humulon	O
.	O

As	O
shown	O
in	O
Fig.	O
5B	O
,	O
the	O
addition	O
of	O
dexamethasone	O
increased	O
luciferase	O
activity	O
of	O
MC3T3-E1	B
cells	O
by	O
16–18	O
fold	O
.	O

Therefore	O
,	O
dexamethasone	O
bound	O
to	O
the	O
glucocorticoid	O
receptor	O
and	O
then	O
to	O
the	O
glucocorticoid	O
response	O
element	O
.	O

In	O
contrast	O
,	O
when	O
the	O
transfected	O
cells	O
were	O
incubated	O
with	O
humulon	O
,	O
the	O
luciferase	O
activity	O
was	O
not	O
increased	O
.	O

These	O
data	O
suggested	O
that	O
the	O
humulon	O
-	O
dependent	O
suppression	O
of	O
cyclooxygenase-2	O
induction	O
was	O
not	O
mediated	O
by	O
glucocorticoid	O
receptor	O
.	O

4	O
Discussion	O
As	O
for	O
the	O
inhibitors	O
of	O
cyclooxygenase	O
induction	O
other	O
than	O
glucocorticoid	O
,	O
a	O
recent	O
paper	O
reported	O
a	O
cyclooxygenase-2	O
transcription	O
in	O
phorbol	O
ester	O
-	O
treated	O
human	B
epithelial	O
cells	O
inhibited	O
by	O
resveratrol	O
,	O
which	O
is	O
a	O
phytoalexin	O
found	O
in	O
grapes	B
and	O
other	O
foods	O
[	O
17	O
]	O
.	O

The	O
compound	O
reduced	O
both	O
the	O
enzyme	O
activity	O
and	O
the	O
gene	O
transcription	O
at	O
a	O
concentration	O
in	O
the	O
order	O
of	O
10	O
μM.	O
Resveratrol	O
also	O
blocked	O
cyclooxygenase-2	O
activation	O
by	O
protein	O
kinase	O
C	O
-	O
α	O
,	O
ERK1	O
,	O
and	O
c	O
-	O
Jun	O
[	O
17	O
]	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
aspirin	O
at	O
pharmacological	O
concentrations	O
(	O
0.1–100	O
μM	O
)	O
inhibited	O
cyclooxygenase-2	O
transcription	O
induced	O
by	O
phorbol	O
ester	O
,	O
interleukin-1β	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
[	O
18	O
]	O
.	O

It	O
is	O
established	O
that	O
glucocorticoid	O
binds	O
to	O
its	O
intracellular	O
receptor	O
migrating	O
into	O
nucleus	O
and	O
the	O
steroid	O
-	O
receptor	O
complex	O
binds	O
to	O
a	O
glucocorticoid	O
response	O
element	O
of	O
the	O
promoter	O
region	O
of	O
target	O
gene	O
[	O
19	O
]	O
.	O

Inoue	O
and	O
others	O
reported	O
that	O
the	O
activation	O
of	O
the	O
cyclooxygenase-2	O
gene	O
promoter	O
by	O
LPS	O
was	O
suppressed	O
by	O
glucocorticoid	O
,	O
and	O
the	O
suppression	O
was	O
enhanced	O
by	O
transfection	O
of	O
the	O
glucocorticoid	O
receptor	O
cDNA	O
to	O
vascular	O
endothelial	O
cells	O
[	O
20	O
]	O
.	O

However	O
,	O
there	O
is	O
no	O
typical	O
sequence	O
for	O
glucocorticoid	O
response	O
element	O
within	O
1.2	O
kb	O
upstream	O
in	O
cyclooxygenase-2	O
gene	O
promoter	O
[	O
1,2	O
]	O
.	O

One	O
of	O
the	O
two	O
NFκB	O
sites	O
(	O
nucleotides	O
–223	O
to	O
–214	O
)	O
was	O
involved	O
in	O
both	O
the	O
LPS	O
-	O
induced	O
human	B
cyclooxygenase-2	O
gene	O
expression	O
in	O
U937	B
cells	I
and	O
its	O
suppression	O
by	O
dexamethasone	O
and	O
herbimycin	O
A	O
[	O
21	O
]	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
demonstrated	O
that	O
humulon	O
has	O
a	O
glucocorticoid	O
-	O
like	O
suppression	O
activity	O
in	O
TNFα	O
-	O
induced	O
cyclooxygenase-2	O
transcription	O
and	O
its	O
signal	O
transduction	O
may	O
be	O
independent	O
from	O
glucocorticoid	O
receptor	O
.	O

However	O
,	O
these	O
results	O
required	O
further	O
investigations	O
of	O
a	O
detailed	O
molecular	O
mechanism	O
and	O
of	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
action	O
of	O
humulon	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
H.	O
Kondoh	O
of	O
Osaka	O
University	O
for	O
providing	O
the	O
herpes	B
simplex	I
virus	I
thymidine	O
kinase	O
gene	O
;	O
Dr.	O
Y.	O
Taketani	O
of	O
the	O
University	O
of	O
Tokushima	O
for	O
providing	O
tk	O
-	O
pGL3	O
vector	O
;	O
and	O
Mr.	O
H.	O
Kurobe	O
for	O
technical	O
assistance	O
.	O

This	O
work	O
was	O
supported	O
by	O
grants	O
-	O
in	O
-	O
aid	O
for	O
scientific	O
research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
of	O
Japan	O
,	O
the	O
Japanese	O
Foundation	O
of	O
Metabolism	O
and	O
Disease	O
,	O
and	O
the	O
Japan	O
Foundation	O
for	O
Applied	O
Enzymology	O
.	O

Butea	B
monosperma	I
(	O
Fabaceae	O
)	O
is	O
a	O
medium	O
sized	O
tree	O
native	O
of	O
the	O
mountainous	O
regions	O
of	O
India	O
and	O
Burma	O
and	O
now	O
grows	O
wild	O
throughout	O
India	O
(	O
Anonymous	O
,	O
1988	O
)	O
.	O

The	O
bark	O
is	O
reported	O
to	O
possess	O
antitumour	O
and	O
antiulcer	O
properties	O
(	O
Anonymous	O
,	O
1988	O
)	O
,	O
while	O
stem	O
bark	O
possess	O
antifungal	O
activity	O
(	O
Bandara	O
et	O
al.	O
,	O
1989	O
;	O
1990	O
)	O
.	O

The	O
root	O
bark	O
is	O
used	O
as	O
an	O
aphrodisiac	O
,	O
analgesic	O
and	O
anthelmintic	O
(	O
Anonymous	O
,	O
1988	O
)	O
,	O
whereas	O
the	O
leaves	O
possess	O
antimicrobial	O
property	O
(	O
Zaffar	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
flowers	O
are	O
used	O
for	O
the	O
treatment	O
of	O
liver	O
disorders	O
(	O
Wagner	O
et	O
al.	O
,	O
1986	O
)	O
and	O
the	O
seeds	O
as	O
anthelmintic	O
(	O
Lal	O
et	O
al.	O
,	O
1978	O
)	O
.	O

Flavonoids	O
from	O
flowers	O
(	O
Gupta	O
et	O
al.	O
,	O
1970	O
)	O
,	O
stem	O
bark	O
(	O
Bandara	O
et	O
al.	O
,	O
1990	O
)	O
and	O
nitrogenous	O
compounds	O
from	O
the	O
seeds	O
(	O
Guha	O
et	O
al.	O
,	O
1990	O
;	O
Mehta	O
and	O
Bokadia	O
,	O
1981	O
)	O
have	O
been	O
reported	O
earlier	O
.	O

During	O
the	O
course	O
of	O
investigation	O
on	O
the	O
yellow	O
dye	O
from	O
the	O
flowers	O
,	O
it	O
was	O
of	O
interest	O
to	O
work	O
on	O
the	O
stems	O
as	O
relatively	O
few	O
compounds	O
have	O
been	O
reported	O
from	O
it	O
.	O

This	O
report	O
describes	O
the	O
characterisation	O
of	O
a	O
new	O
euphane	O
and	O
a	O
new	O
lipid	O
derivative	O
.	O

2	O
Results	O
and	O
discussion	O
Compounds	O
1–5	O
were	O
isolated	O
from	O
the	O
stems	O
of	O
B.	B
monosperma	I
.	O

Compound	O
1	O
was	O
obtained	O
as	O
colourless	O
needles	O
.	O

Its	O
IR	O
spectrum	O
bands	O
corresponded	O
to	O
OH	O
(	O
3480	O
cm−1	O
)	O
,	O
terminal	O
unsaturated	O
CH2	O
(	O
1610	O
,	O
880	O
cm−1	O
)	O
and	O
gem	O
dimethyl	O
(	O
1380	O
,	O
1360	O
cm−1	O
)	O
functions	O
.	O

An	O
[	O
M	O
]	O
+	O
at	O
m	O
/	O
z	O
428	O
suggested	O
the	O
molecular	O
formula	O
as	O
C30	O
H52	O
O.	O
Its	O
1	O
H	O
NMR	O
spectrum	O
exhibited	O
signals	O
due	O
to	O
five	O
quaternary	O
methyls	O
(	O
δ	O
0.79	O
,	O
0.83	O
,	O
0.94	O
,	O
0.96	O
,	O
1.04	O
)	O
,	O
a	O
vinylic	O
methyl	O
(	O
δ	O
1.62	O
)	O
,	O
and	O
a	O
secondary	O
methyl	O
(	O
δ	O
1.08	O
)	O
indicative	O
of	O
a	O
tetracyclic	O
triterpene	O
skeleton	O
(	O
Hemmert	O
et	O
al.	O
,	O
1966	O
)	O
.	O

Two	O
broad	O
singlets	O
at	O
δ	O
4.56	O
and	O
4.68	O
,	O
each	O
integrating	O
for	O
one	O
proton	O
,	O
corresponded	O
to	O
the	O
methine	O
protons	O
of	O
an	O
olefinic	O
methylene	O
group	O
(	O
Jagodzinska	O
et	O
al.	O
,	O
1985	O
)	O
which	O
in	O
conjunction	O
with	O
a	O
broad	O
singlet	O
at	O
δ	O
1.62	O
suggested	O
the	O
existence	O
of	O
a	O
isopropylidene	O
group	O
.	O

This	O
was	O
also	O
substantiated	O
by	O
the	O
appearance	O
of	O
signals	O
at	O
δ	O
151.0	O
and	O
109.30	O
in	O
the	O
13	O
C	O
NMR	O
spectrum	O
for	O
>	O
CCH2	O
grouping	O
(	O
Schneider	O
and	O
Agrawal	O
,	O
1984	O
)	O
.	O

A	O
multiplet	O
at	O
δ	O
3.34	O
(	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
)	O
was	O
assigned	O
to	O
a	O
methine	O
proton	O
with	O
an	O
axially	O
oriented	O
C-3	O
OH	O
group	O
(	O
Jolad	O
et	O
al.	O
,	O
1981	O
;	O
Nakanishi	O
et	O
al.	O
,	O
1986	O
)	O
.	O

There	O
is	O
a	O
remarkable	O
similarity	O
in	O
the	O
13	O
C	O
NMR	O
chemical	O
shifts	O
of	O
euphenol	O
and	O
lanosterol	O
except	O
for	O
those	O
of	O
C-12	O
,	O
C-15	O
,	O
C-16	O
and	O
C-19	O
(	O
Knight	O
,	O
1974	O
)	O
.	O

This	O
excludes	O
1	O
to	O
be	O
included	O
under	O
lanosterol	O
series	O
.	O

Such	O
difference	O
is	O
also	O
seen	O
in	O
euphane	O
and	O
tirucallane	O
triterpenoids	O
(	O
Jolad	O
et	O
al.	O
,	O
1981	O
;	O
Bhakuni	O
et	O
al.	O
,	O
1987	O
;	O
Singh	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
chemical	O
shift	O
range	O
of	O
the	O
methyl	O
protons	O
except	O
for	O
vinylic	O
CH3	O
suggested	O
a	O
euphane	O
or	O
tirucallane	O
skeleton	O
(	O
differing	O
C-20	O
stereochemistry	O
)	O
in	O
1	O
,	O
and	O
a	O
(	O
+	O
)	O
optical	O
rotation	O
37.8	O
°	O
of	O
1	O
indicated	O
that	O
it	O
belonged	O
to	O
euphane	O
rather	O
than	O
tirucallane	O
series	O
(	O
Itoh	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
MS	O
of	O
1	O
,	O
the	O
loss	O
of	O
CH3	O
and	O
H2	O
O	O
from	O
[	O
M	O
]	O
+	O
was	O
seen	O
at	O
m	O
/	O
z	O
413	O
and	O
410	O
.	O

The	O
formation	O
of	O
a	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
316	O
[	O
M	O
-	O
side	O
chain	O
(	O
C8	O
H15	O
)	O
–H	O
]	O
+	O
suggested	O
the	O
presence	O
of	O
a	O
monounsaturated	O
side	O
chain	O
(	O
Wyllie	O
and	O
Djerassi	O
,	O
1968	O
)	O
and	O
the	O
existence	O
of	O
OH	O
group	O
in	O
the	O
tetracyclic	O
system	O
.	O

Compound	O
1	O
on	O
treatment	O
with	O
Ac2	O
O	O
/	O
pyridine	O
afforded	O
an	O
acetate	O
(	O
1a	O
)	O
,	O
C32	O
H54	O
O2	O
,	O
whose	O
1	O
H	O
NMR	O
spectrum	O
was	O
similar	O
to	O
1	O
except	O
for	O
the	O
appearance	O
of	O
a	O
new	O
signal	O
at	O
δ	O
2.04	O
and	O
downfield	O
shifted	O
C-3	O
methine	O
by	O
1.11	O
ppm	O
.	O

In	O
the	O
13	O
C	O
NMR	O
spectrum	O
of	O
1	O
,	O
the	O
appearance	O
of	O
C-18	O
,	O
C-20	O
and	O
C-21	O
at	O
15.4	O
,	O
35.6	O
and	O
19.3	O
also	O
established	O
the	O
euphane	O
skeleton	O
(	O
Wehrli	O
and	O
Nishida	O
,	O
1979	O
;	O
Knight	O
,	O
1974	O
)	O
.	O

The	O
13	O
C	O
NMR	O
spectral	O
data	O
of	O
1	O
(	O
Table	O
1	O
)	O
were	O
analysed	O
by	O
analogy	O
with	O
the	O
reported	O
values	O
for	O
euphane	O
and	O
other	O
related	O
triterpenoids	O
(	O
Wehrli	O
et	O
al.	O
,	O
1979	O
;	O
Knight	O
,	O
1974	O
;	O
Singh	O
et	O
al.	O
,	O
1989	O
)	O
.	O

These	O
data	O
led	O
to	O
characterise	O
1	O
as	O
3α	O
-	O
hydroxyeuph-25-ene	O
.	O

Compound	O
4	O
showed	O
IR	O
bands	O
at	O
3438	O
(	O
OH	O
)	O
,	O
1730	O
(	O
CO	O
)	O
,	O
1670	O
(	O
tetrasubstituted	O
)	O
(	O
Nakanishi	O
and	O
Solomon	O
,	O
1977	O
)	O
,	O
1386	O
(	O
Me	O
)	O
and	O
720	O
cm−1	O
(	O
straight	O
chain	O
)	O
.	O

It	O
was	O
assigned	O
the	O
molecular	O
formula	O
C26	O
H48	O
O3	O
(	O
[	O
M	O
]	O
+	O
=	O
408	O
and	O
elemental	O
analysis	O
)	O
.	O

Successive	O
loss	O
of	O
two	O
H2	O
O	O
molecules	O
was	O
seen	O
at	O
m	O
/	O
z	O
390	O
and	O
372	O
,	O
whereas	O
the	O
location	O
of	O
these	O
OH	O
groups	O
was	O
assigned	O
at	O
C-2	O
and	O
C-14	O
since	O
significant	O
α	O
-	O
fission	O
ions	O
were	O
appeared	O
at	O
m	O
/	O
z	O
311	O
,	O
281	O
,	O
127	O
,	O
97	O
and	O
351	O
,	O
321	O
,	O
87	O
,	O
57	O
,	O
respectively	O
.	O

The	O
other	O
diagnostic	O
α	O
-	O
fission	O
ions	O
at	O
m	O
/	O
z	O
225	O
,	O
211	O
,	O
197	O
,	O
183	O
together	O
with	O
ß	O
-	O
fission	O
ions	O
involving	O
McLafferty	O
rearrangement	O
(	O
Budzikiewicz	O
et	O
al.	O
,	O
1964	O
)	O
at	O
m	O
/	O
z	O
226	O
and	O
182	O
located	O
the	O
keto	O
group	O
at	O
C-8	O
.	O

The	O
abundant	O
ions	O
at	O
m	O
/	O
z	O
83	O
and	O
325	O
indicated	O
the	O
presence	O
of	O
a	O
cyclohexyl	O
moiety	O
at	O
the	O
end	O
carbon	O
atom	O
(	O
Bhakuni	O
and	O
Shukla	O
,	O
1992	O
)	O
.	O

The	O
tetrasubstituted	O
double	O
bond	O
along	O
with	O
the	O
two	O
methyl	O
groups	O
were	O
assigned	O
at	O
C-11,12	O
since	O
significant	O
ions	O
were	O
seen	O
at	O
m	O
/	O
z	O
307	O
,	O
253	O
,	O
155	O
and	O
101	O
.	O

These	O
data	O
suggested	O
the	O
structure	O
of	O
4	O
as	O
2,14-dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane	O
which	O
was	O
also	O
in	O
full	O
accord	O
with	O
its	O
1	O
H	O
NMR	O
(	O
see	O
Section	O
3	O
)	O
.	O

Compounds	O
2	O
,	O
3	O
and	O
5	O
were	O
identified	O
as	O
nonacosanoic	O
acid	O
,	O
stigmasterol	O
and	O
stigmasterol	O
-	O
ßD	O
-glucopyranoside	O
,	O
respectively	O
,	O
by	O
comparison	O
with	O
authentic	O
samples	O
.	O

The	O
straight	O
chain	O
alcohols	O
having	O
a	O
cyclohexane	O
moiety	O
are	O
not	O
commonly	O
found	O
in	O
nature	O
.	O

3	O
Experimental	O
3.1	O
General	O
Mps	O
:	O
uncorrected	O
;	O
IR	O
:	O
KBr	O
;	O
1	O
H	O
NMR	O
:	O
Bruker	O
(	O
200	O
MHz	O
)	O
in	O
CDCl3	O
,	O
chemical	O
shifts	O
in	O
δ	O
(	O
ppm	O
)	O
with	O
TMS	O
as	O
internal	O
standard	O
;	O
13	O
C	O
NMR	O
:	O
75	O
MHz	O
,	O
CDCl3	O
;	O
EIMS	O
:	O
70	O
ev	O
;	O
TLC	O
:	O
silica	O
gel	O
G	O
;	O
CC	O
:	O
silica	O
gel	O
(	O
Merk	O
,	O
60–120	O
mesh	O
)	O
.	O

Spots	O
were	O
detected	O
by	O
exposure	O
to	O
I2	O
vapour	O
.	O

The	O
homogeneity	O
of	O
the	O
isolates	O
was	O
checked	O
on	O
TLC	O
in	O
at	O
least	O
two	O
solvent	O
systems	O
.	O

3.2	O
Plant	O
material	O
The	O
stems	O
of	O
B.	B
monosperma	I
were	O
collected	O
from	O
the	O
local	O
area	O
and	O
identified	O
in	O
our	O
Botany	O
Department	O
where	O
a	O
voucher	O
specimen	O
has	O
been	O
maintained	O
.	O

3.3	O
Extraction	O
and	O
isolation	O
Dried	O
and	O
powdered	O
stems	O
(	O
2.8	O
kg	O
)	O
were	O
extracted	O
with	O
MeOH	O
(	O
5	O
×	O
11	O
l	O
)	O
and	O
the	O
combined	O
extract	O
concentrated	O
to	O
500	O
ml	O
.	O

After	O
the	O
addition	O
of	O
water	O
(	O
500	O
ml	O
)	O
,	O
the	O
extract	O
was	O
fractionated	O
with	O
n	O
-hexane	O
(	O
5	O
×	O
200	O
ml	O
,	O
7.33	O
g	O
)	O
,	O
EtOAc	O
(	O
5	O
×	O
200	O
ml	O
,	O
13.34	O
g	O
)	O
and	O
n	O
-BuOH	O
(	O
5	O
×	O
200	O
ml	O
,	O
33.2	O
g	O
)	O
.	O

A	O
portion	O
(	O
6.1	O
g	O
)	O
of	O
the	O
hexane	O
fraction	O
was	O
chromatographed	O
over	O
silica	O
gel	O
(	O
300	O
g	O
)	O
,	O
eluting	O
with	O
varying	O
proportions	O
of	O
hexane	O
,	O
EtOAc	O
and	O
MeOH	O
to	O
provide	O
compounds	O
1	O
(	O
50	O
mg	O
)	O
,	O
2	O
(	O
61	O
mg	O
)	O
,	O
3	O
(	O
68	O
mg	O
)	O
,	O
4	O
(	O
25	O
mg	O
)	O
and	O
5	O
(	O
46	O
mg	O
)	O
.	O

The	O
fractions	O
collected	O
were	O
100	O
ml	O
each	O
and	O
monitored	O
by	O
TLC	O
.	O

3.4	O
3α	O
-	O
Hydroxyeuph-25-ene	O
(	O
1	O
)	O
Removal	O
of	O
solvent	O
from	O
the	O
fractions	O
65–68	O
of	O
hexane	O
–	O
EtOAc	O
(	O
95:5	O
)	O
gave	O
a	O
residue	O
,	O
mp	O
180–82	O
°	O
C	O
,	O
α	O
D	O
+	O
37.8	O
°	O
(	O
CHCl3	O
)	O
.	O

IR	O
:	O
γ	O
max	O
cm−1	O
:	O
3480	O
,	O
2930	O
,	O
1610	O
,	O
1450	O
,	O
1360	O
,	O
1244	O
,	O
1110	O
,	O
1014	O
,	O
880	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.79	O
(	O
3H	O
,	O
s	O
,	O
19-H3	O
)	O
,	O
0.83	O
(	O
3H	O
,	O
s	O
,	O
18-H3	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
29-H3	O
)	O
,	O
0.96	O
(	O
3H	O
,	O
s	O
,	O
28-H3	O
)	O
,	O
1.04	O
(	O
3H	O
,	O
s	O
,	O
30-H3	O
)	O
,	O
1.08	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6	O
Hz	O
,	O
21-H3	O
)	O
,	O
1.62	O
(	O
3H	O
,	O
s	O
,	O
27-H3	O
)	O
,	O
1.90	O
(	O
1H	O
,	O
m	O
,	O
20-H	O
)	O
,	O
2.36	O
(	O
2H	O
,	O
m	O
,	O
24-H2	O
)	O
,	O
3.34	O
(	O
1H	O
,	O
m	O
,	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
,	O
3ß	O
-	O
H	O
)	O
,	O
4.56	O
,	O
4.68	O
,	O
(	O
2H	O
,	O
each	O
br	O
s	O
,	O
26-H2	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
428	O
[	O
M	O
]	O
+	O
(	O
C30	O
H52	O
O	O
,	O
67	O
)	O
,	O
413	O
[	O
M	O
−	O
Me	O
]	O
+	O
(	O
19	O
)	O
,	O
410	O
[	O
M	O
−	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
395	O
[	O
M	O
−	O
Me	O
–	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
387	O
[	O
M	O
−	O
41	O
]	O
+	O
(	O
6	O
)	O
,	O
317	O
[	O
M	O
−	O
sc	O
]	O
+	O
(	O
15	O
)	O
,	O
316	O
[	O
M	O
−	O
sc	O
–	O
H	O
]	O
+	O
(	O
18	O
)	O
,	O
301	O
[	O
316	O
−	O
Me	O
]	O
+	O
(	O
5	O
)	O
,	O
298	O
[	O
316	O
−	O
H2	O
O	O
]	O
+	O
(	O
5	O
)	O
,	O
286	O
[	O
301	O
−	O
Me	O
]	O
+	O
(	O
5	O
)	O
,	O
196	O
(	O
5	O
)	O
,	O
194	O
(	O
8)	O
,	O
178	O
[	O
196	O
−	O
H2	O
O	O
]	O
+	O
(	O
18	O
)	O
,	O
179	O
[	O
194	O
−	O
Me	O
]	O
+	O
(	O
10	O
)	O
,	O
161	O
(	O
12	O
)	O
,	O
128	O
(	O
5	O
)	O
,	O
111	O
(	O
20	O
)	O
,	O
110	O
(	O
15	O
)	O
,	O
95	O
(	O
100	O
)	O
,	O
81	O
(	O
80	O
)	O
,	O
69	O
(	O
75	O
)	O
.	O

3.5	O
Monoacetate	O
(	O
1a	O
)	O
of	O
1	O
Compound	O
1	O
(	O
25	O
mg	O
)	O
was	O
acetylated	O
with	O
C5	O
H5	O
N	O
–	O
Ac2	O
O	O
(	O
1	O
ml	O
each	O
)	O
,	O
overnight	O
at	O
room	O
temperature	O
.	O

The	O
usual	O
work	O
-	O
up	O
yielded	O
1a	O
,	O
mp	O
205	O
°	O
C	O
,	O
20	O
mg	O
.	O

IR	O
γ	O
max	O
cm−1	O
:	O
2940	O
,	O
2856	O
,	O
1738	O
,	O
1640	O
,	O
1460	O
,	O
1374	O
,	O
1245	O
,	O
1020	O
,	O
978	O
,	O
880	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.79	O
(	O
3H	O
,	O
s	O
,	O
19-H3	O
)	O
,	O
0.84	O
(	O
3H	O
,	O
s	O
,	O
18-H3	O
)	O
,	O
0.94	O
(	O
3H	O
,	O
s	O
,	O
29-H3	O
)	O
,	O
0.97	O
(	O
3H	O
,	O
s	O
,	O
28-H3	O
)	O
,	O
1.03	O
(	O
3H	O
,	O
s	O
,	O
30-H3	O
)	O
,	O
1.08	O
(	O
3H	O
,	O
d	O
,	O
J	O
=	O
6	O
Hz	O
,	O
21-H3	O
)	O
,	O
1.68	O
(	O
3H	O
,	O
s	O
,	O
27-H3	O
)	O
,	O
1.90	O
(	O
1H	O
,	O
m	O
,	O
20-H	O
)	O
,	O
2.04	O
(	O
3H	O
,	O
s	O
,	O
OAc	O
)	O
,	O
2.36	O
(	O
2H	O
,	O
m	O
,	O
24-H2	O
)	O
,	O
4.45	O
(	O
1H	O
,	O
m	O
,	O
W	O
1	O
/	O
2	O
=	O
7	O
Hz	O
,	O
3ßH	O
)	O
,	O
4.56	O
,	O
4.68	O
(	O
2H	O
,	O
each	O
br	O
s	O
,	O
26-H2	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
470	O
[	O
M	O
]	O
+	O
(	O
C32	O
H54	O
O2	O
,	O
11	O
)	O
,	O
455	O
(	O
4	O
)	O
,	O
429	O
(	O
5	O
)	O
,	O
410	O
(	O
2	O
)	O
,	O
359	O
(	O
5	O
)	O
,	O
257	O
(	O
5	O
)	O
,	O
238	O
(	O
5	O
)	O
,	O
236	O
(	O
4	O
)	O
,	O
188	O
(	O
100	O
)	O
,	O
176	O
(	O
15	O
)	O
,	O
161	O
(	O
17	O
)	O
,	O
160	O
(	O
21	O
)	O
,	O
111	O
(	O
20	O
)	O
,	O
110	O
(	O
15	O
)	O
,	O
95	O
(	O
60	O
)	O
,	O
81	O
(	O
80	O
)	O
,	O
69	O
(	O
40	O
)	O
,	O
55	O
(	O
50	O
)	O
,	O
43	O
(	O
98	O
)	O
.	O

3.6	O
Nonacosanoic	O
acid	O
(	O
2	O
)	O
Fractions	O
71–75	O
of	O
hexane	O
–	O
EtOAc	O
(	O
95:5	O
)	O
eluates	O
yielded	O
a	O
residue	O
,	O
mp	O
68–70	O
°	O
C	O
,	O
identified	O
by	O
co	O
-	O
TLC	O
,	O
MS	O
,	O
1	O
H	O
NMR	O
.	O

3.7	O
Stigmasterol	O
(	O
3	O
)	O
Fractions	O
90–95	O
of	O
hexane	O
–	O
EtOAc	O
(	O
95:5	O
)	O
eluates	O
when	O
freed	O
of	O
the	O
solvent	O
provided	O
3	O
,	O
mp	O
160	O
°	O
C	O
,	O
identified	O
by	O
co	O
-	O
TLC	O
,	O
MS	O
,	O
IR	O
,	O
1	O
H	O
NMR	O
.	O

3.8	O
2,14-Dihydroxy-11,12-dimethyl-8-oxooctadec-11-enylcyclohexane	O
(	O
4	O
)	O
Elimination	O
of	O
solvent	O
from	O
the	O
fractions	O
221–226	O
of	O
hexane	O
–	O
EtOAc	O
(	O
1:1	O
)	O
eluates	O
furnished	O
4	O
,	O
mp	O
83–84	O
°	O
C	O
.	O

IR	O
γ	O
max	O
cm−1	O
:	O
3438	O
,	O
2920	O
,	O
2850	O
,	O
1730	O
,	O
1670	O
,	O
1450	O
,	O
1386	O
,	O
1180	O
,	O
1110	O
,	O
1052	O
,	O
720	O
;	O
1	O
H	O
NMR	O
:	O
δ	O
0.88	O
(	O
3H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
18-H3	O
)	O
,	O
1.25	O
(	O
10H	O
,	O
br	O
s	O
,	O
5	O
×	O
CH2	O
)	O
,	O
1.50	O
(	O
10H	O
,	O
br	O
s	O
,	O
cyclohexyl	O
(	O
CH2	O
)	O
5	O
)	O
,	O
1.64	O
(	O
1H	O
,	O
m	O
,	O
1′	O
-H	O
)	O
,	O
1.60	O
(	O
6H	O
,	O
s	O
,	O
11-H3	O
,	O
12-H3	O
)	O
,	O
1.90	O
(	O
4H	O
,	O
m	O
,	O
3-H2	O
,	O
15-H2	O
)	O
,	O
2.02	O
(	O
2H	O
,	O
m	O
,	O
1-H2	O
)	O
,	O
2.35	O
(	O
4H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
7-H2	O
,	O
9-H2	O
)	O
,	O
2.45	O
(	O
2H	O
,	O
t	O
,	O
J	O
=	O
6	O
Hz	O
,	O
10-H2	O
)	O
,	O
2.48	O
(	O
2H	O
,	O
d	O
,	O
J	O
=	O
5	O
Hz	O
,	O
13-H2	O
)	O
,	O
3.64	O
(	O
1H	O
,	O
m	O
,	O
2-H	O
)	O
,	O
3.94	O
(	O
1H	O
,	O
m	O
,	O
14-H	O
)	O
;	O
MS	O
m	O
/	O
z	O
(	O
rel	O
.	O

int	O
.	O
)	O
:	O
408	O
[	O
M	O
]	O
+	O
(	O
C26	O
H48	O
O3	O
,	O
2	O
)	O
,	O
390	O
[	O
M	O
−	O
H2	O
O	O
]	O
+	O
(	O
7	O
)	O
,	O
372	O
[	O
M	O
−	O
2H2	O
O	O
]	O
+	O
(	O
7	O
)	O
,	O
393	O
[	O
M	O
−	O
Me	O
]	O
+	O
(	O
3	O
)	O
,	O
378	O
[	O
M	O
−2	O
×	O
Me	O
]	O
+	O
(	O
3	O
)	O
,	O
351	O
(	O
4	O
)	O
,	O
325	O
(	O
5	O
)	O
,	O
321	O
(	O
3	O
)	O
,	O
311	O
(	O
4	O
)	O
,	O
307	O
(	O
5	O
)	O
,	O
281	O
(	O
4	O
)	O
,	O
253	O
(	O
5	O
)	O
,	O
226	O
(	O
6	O
)	O
,	O
225	O
(	O
5	O
)	O
,	O
211	O
(	O
7	O
)	O
,	O
197	O
(	O
6	O
)	O
,	O
183	O
(	O
10	O
)	O
,	O
182	O
(	O
7	O
)	O
,	O
155	O
(	O
4	O
)	O
,	O
127	O
(	O
19	O
)	O
,	O
101	O
(	O
6	O
)	O
,	O
97	O
(	O
90	O
)	O
,	O
87	O
(	O
12	O
)	O
,	O
83	O
(	O
65	O
)	O
,	O
57	O
(	O
100	O
)	O
(	O
Found	O
:	O
C	O
,	O
76.40	O
;	O
H	O
,	O
11.82	O
.	O

C26	O
H48	O
O3	O
requires	O
:	O
C	O
,	O
76.47	O
;	O
H	O
,	O
11.76	O
%	O
)	O
.	O

3.9	O
Stigmasterol	O
-	O
ßD	O
-glucopyranoside	O
(	O
5	O
)	O
Removal	O
of	O
solvent	O
from	O
290–301	O
fractions	O
of	O
MeOH	O
–	O
EtOAc	O
(	O
2:98	O
)	O
eluates	O
gave	O
5	O
,	O
mp	O
263–65	O
°	O
C	O
,	O
identified	O
by	O
MS	O
,	O
1	O
H	O
NMR	O
and	O
hydrolysis	O
products	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
M.	O
Mishra	O
)	O
is	O
grateful	O
to	O
the	O
Director	O
,	O
CIMAP	O
for	O
the	O
award	O
of	O
a	O
Junior	O
Research	O
Fellowship	O
.	O

Arachidonic	O
acid	O
(	O
AA	O
)	O
is	O
metabolized	O
to	O
form	O
four	O
different	O
epoxides	O
(	O
namely	O
5,6-	O
,	O
8,9-	O
,	O
11,12-	O
,	O
14,15-EET	O
)	O
via	O
the	O
cytochrome	O
P-450	O
monooxygenase	O
(	O
epoxygenase	O
)	O
pathway	O
[	O
1	O
]	O
.	O

14,15-EET	O
is	O
found	O
in	O
the	O
urine	O
[	O
2	O
]	O
and	O
produced	O
by	O
platelets	O
and	O
endothelial	O
cells	O
[	O
3,4	O
]	O
.	O

The	O
occurrence	O
of	O
14,15-EET	O
and	O
other	O
EETs	O
in	O
tissues	O
and	O
various	O
cell	O
types	O
leads	O
to	O
the	O
hypothesis	O
that	O
these	O
substances	O
may	O
be	O
stored	O
in	O
cells	O
by	O
conjugative	O
protein	O
binding	O
or	O
by	O
incorporation	O
into	O
membrane	O
phospholipids	O
(	O
PL	O
)	O
[	O
5	O
]	O
.	O

The	O
stored	O
form	O
of	O
EETs	O
can	O
be	O
released	O
upon	O
activation	O
of	O
specific	O
phospholipase	O
,	O
for	O
example	O
,	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
or	O
phospholipase	O
C	O
(	O
PLC	O
)	O
,	O
by	O
neuronal	O
,	O
hormonal	O
or	O
chemical	O
stimulation	O
[	O
6,7	O
]	O
.	O

Of	O
the	O
various	O
systems	O
in	O
which	O
,	O
epoxygenase	O
and	O
its	O
epoxides	O
(	O
EETs	O
)	O
have	O
studied	O
,	O
the	O
kidney	O
seems	O
to	O
be	O
a	O
major	O
organ	O
for	O
production	O
and	O
action	O
of	O
the	O
EETs	O
.	O

The	O
main	O
forms	O
of	O
EETs	O
found	O
in	O
the	O
kidney	O
and	O
in	O
urine	O
are	O
8,9-	O
and	O
14,15-EET	O
[	O
2	O
]	O
.	O

The	O
levels	O
of	O
EETs	O
in	O
the	O
kidney	O
seemed	O
to	O
vary	O
as	O
a	O
function	O
of	O
renal	O
pathology	O
[	O
8–10	O
]	O
.	O

In	O
the	O
kidney	O
,	O
certain	O
EETs	O
and	O
their	O
dihydroxyeicosatrienoic	O
acid	O
metabolites	O
(	O
diols	O
or	O
DHETs	O
)	O
have	O
prominent	O
biological	O
functions	O
,	O
such	O
as	O
:	O
inhibition	O
of	O
Na+	O
/K+	O
ATPase	O
[	O
11	O
]	O
and	O
suppression	O
of	O
vasopressin	O
(	O
AVP	O
)	O
action	O
on	O
rabbit	B
kidney	O
cortical	O
collecting	O
duct	O
(	O
CCD	O
)	O
[	O
9	O
]	O
.	O

With	O
our	O
previous	O
reports	O
[	O
12,13	O
]	O
,	O
it	O
is	O
conceivable	O
that	O
14,15-EET	O
and	O
its	O
metabolite	O
(	O
14,15-DHET	O
)	O
may	O
play	O
an	O
important	O
role	O
in	O
maintaining	O
blood	O
pressure	O
,	O
modulating	O
renal	O
function	O
,	O
and	O
regulating	O
monocyte	O
adhesion	O
.	O

In	O
other	O
systems	O
,	O
Malcolm	O
and	O
Fitzpatrick	O
reported	O
that	O
14,15-EET	O
inhibited	O
Ca+2	O
entry	O
into	O
cells	O
[	O
14	O
]	O
.	O

We	O
had	O
shown	O
that	O
14,15-EET	O
can	O
enhance	O
monocyte	O
attachment	O
to	O
endothelium	O
and	O
decrease	O
the	O
mean	O
arterial	O
blood	O
pressure	O
in	O
normal	O
and	O
spontaneously	O
hypertensive	O
rats	B
[	O
12,13	O
]	O
.	O

Catella	O
et	O
al.	O
[	O
15	O
]	O
reported	O
high	O
amounts	O
of	O
14,15-EET	O
in	O
the	O
urine	O
of	O
patients	B
with	O
pregnancy	O
-	O
induced	O
hypertension	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
14,15-EET	O
in	O
blood	O
pressure	O
regulation	O
.	O

These	O
wide	O
varieties	O
of	O
biological	O
function	O
suggest	O
that	O
14,15-EET	O
may	O
act	O
through	O
specific	O
receptors	O
and	O
signal	O
transduction	O
pathways	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
population	O
of	O
specific	O
high	O
affinity	O
binding	O
sites	O
for	O
14,15-EET	O
in	O
GPM	B
cells	O
that	O
may	O
be	O
associated	O
with	O
receptors	O
.	O

This	O
population	O
of	O
14,15-EET	O
binding	O
sites	O
in	O
GPM	B
cells	O
was	O
down	O
regulated	O
by	O
cholera	O
toxin	O
or	O
dibutyryl	O
-	O
cAMP	O
that	O
suggested	O
a	O
postreceptor	O
mechanism	O
coupled	O
to	O
PKA	O
-	O
dependent	O
signal	O
transduction	O
pathway	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
White	B
Hartley	I
guinea	I
pigs	I
weighing	O
250	O
to	O
350	O
g	O
were	O
obtained	O
from	O
Taconic	O
Farms	O
(	O
Germantown	O
,	O
NY	O
,	O
USA	O
)	O
.	O

Percoll	O
,	O
HEPES	O
,	O
deoxyribonuclease	O
,	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
sodium	O
bicarbonate	O
(	O
a	O
cell	O
culture	O
grade	O
)	O
,	O
Tris	O
-	O
base	O
,	O
chymotrypsin	O
(	O
type	O
IS	O
and	O
type	O
II	O
)	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
proteinase	O
K	O
,	O
and	O
dibutyryl	O
cAMP	O
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

The	O
gelatin	O
was	O
obtained	O
from	O
Fisher	O
Scientific	O
(	O
Fairlawn	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

H-89	O
and	O
K252a	O
were	O
from	O
LC	O
Laboratories	O
(	O
Woburn	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Hank	O
's	O
Balanced	O
Salt	O
Solution	O
(	O
HBSS	O
)	O
and	O
horse	B
serums	O
were	O
obtained	O
from	O
GIBCO	O
(	O
Grand	O
Island	O
,	O
NY	O
,	O
USA	O
)	O
,	O
[	O
3	O
H	O
]	O
-14,15-EET	O
(	O
100	O
Ci	O
/	O
mmole	O
)	O
and	O
14,15-EET	O
was	O
synthesized	O
and	O
purified	O
by	O
RP	O
,	O
reversed	O
phase	O
-	O
HPLC	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O

2.2	O
Harvest	O
and	O
purification	O
of	O
guinea	B
pig	I
monocytes	O
Female	O
white	B
Hartley	I
guinea	I
pigs	I
(	O
250–350	O
g	O
)	O
were	O
injected	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
with	O
0.5	O
ml	O
horse	B
serum	O
twice	O
a	O
week	O
for	O
2	O
weeks	O
,	O
and	O
afterwards	O
,	O
once	O
weekly	O
.	O

After	O
a	O
minimum	O
of	O
48	O
h	O
from	O
the	O
last	O
injection	O
,	O
the	O
cells	O
were	O
harvested	O
by	O
peritoneal	O
lavage	O
.	O

The	O
animals	O
were	O
anesthetized	O
with	O
metofane	O
and	O
a	O
20	O
g	O
×	O
2″	O
(	O
Surflo	O
)	O
Teflon	O
intercath	O
was	O
inserted	O
into	O
the	O
peritoneal	O
cavity	O
.	O

The	O
cavity	O
was	O
washed	O
with	O
20	O
ml	O
of	O
Hank	O
's	O
buffered	O
saline	O
solution	O
without	O
calcium	O
or	O
magnesium	O
(	O
HBSS	O
)	O
,	O
containing	O
5	O
mM	O
HEPES	O
,	O
pH	O
7.3	O
and	O
10	O
Units	O
/	O
ml	O
of	O
heparin	O
.	O

The	O
collected	O
cells	O
were	O
centrifuged	O
at	O
275	O
×	O
g	O
for	O
5	O
min	O
,	O
washed	O
and	O
resuspended	O
in	O
4	O
ml	O
of	O
HBSS	O
containing	O
10	O
%	O
gelatin	O
and	O
5	O
mg	O
deoxyribonuclease	O
(	O
HBSS	O
-	O
GD	O
)	O
.	O

Hypotonic	O
lysis	O
removed	O
contaminating	O
red	O
blood	O
cells	O
.	O

Four	O
milliliters	O
of	O
aliquots	O
of	O
the	O
cell	O
suspension	O
were	O
layered	O
on	O
top	O
of	O
a	O
Percoll	O
density	O
gradient	O
and	O
centrifuged	O
at	O
1600	O
×	O
g	O
for	O
30	O
min	O
.	O

The	O
discontinuous	O
density	O
gradient	O
was	O
prepared	O
by	O
overlaying	O
successive	O
layers	O
of	O
86	O
%	O
,	O
76	O
%	O
,	O
64	O
%	O
,	O
and	O
45	O
%	O
isotonic	O
Percoll	O
containing	O
0.03	O
mg	O
/	O
ml	O
deoxyribonuclease	O
to	O
give	O
the	O
following	O
densities	O
:	O
A	O
:	O
1.06	O
,	O
B	O
:	O
1.08	O
,	O
C	O
:	O
1.09	O
,	O
D	O
:	O
1.10	O
g	O
/	O
ml	O
[	O
17,18	O
]	O
.	O

The	O
four	O
bands	O
of	O
cells	O
were	O
collected	O
at	O
the	O
interface	O
of	O
the	O
different	O
density	O
layers	O
,	O
and	O
to	O
remove	O
any	O
remaining	O
Percoll	O
,	O
each	O
was	O
diluted	O
1:4	O
with	O
HBSS	O
-	O
GD	O
,	O
centrifuged	O
,	O
washed	O
once	O
,	O
and	O
resuspended	O
in	O
HBSS	O
-	O
GD	O
.	O

Differential	O
counts	O
were	O
obtained	O
using	O
slide	O
preparation	O
stained	O
with	O
Diff	O
Quick	O
(	O
American	O
Scientific	O
)	O
.	O

From	O
this	O
procedure	O
we	O
could	O
collect	O
the	O
lymphocytes	O
and	O
monocytes	O
,	O
A	O
and	O
B	O
bands	O
,	O
respectively	O
.	O

Eosinophils	O
were	O
collected	O
mainly	O
from	O
the	O
C	O
and	O
D	O
bands	O
[	O
17,18	O
]	O
.	O

Cell	O
viability	O
was	O
determined	O
by	O
trypan	O
blue	O
exclusion	O
and	O
found	O
to	O
be	O
>	O
99	O
%	O
.	O

2.3	O
Radioligand	O
binding	O
assays	O
All	O
assays	O
were	O
performed	O
in	O
duplicate	O
with	O
intact	O
GPM	B
cells	O
suspended	O
in	O
HBSS	O
buffer	O
,	O
pH	O
7.4	O
containing	O
10	O
mM	O
CaCl2	O
and	O
10	O
mM	O
MgCl2	O
at	O
a	O
final	O
volume	O
of	O
250	O
μl	O
.	O

In	O
the	O
saturation	O
binding	O
experiment	O
,	O
GPM	B
cells	O
(	O
106	O
cells	O
)	O
were	O
added	O
to	O
polypropylene	O
tubes	O
(	O
12	O
×	O
75	O
mm	O
)	O
and	O
incubated	O
at	O
4	O
°	O
C	O
for	O
4	O
min	O
with	O
increasing	O
concentrations	O
of	O
[	O
3	O
H	O
]	O
-14,15-EET	O
(	O
0.4	O
nM–30	O
nM	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
μM	O
unlabeled	O
14,15-EET	O
.	O

For	O
nonsaturation	O
experiments	O
,	O
1000-fold	O
excess	O
of	O
unlabeled	O
14,15-EET	O
was	O
used	O
.	O

Bound	O
and	O
free	O
[	O
3	O
H	O
]	O
-14,15-EET	O
were	O
separated	O
by	O
centrifugation	O
at	O
2000	O
rev.	O
/	O
min	O
,	O
4	O
°	O
C	O
for	O
2	O
min	O
.	O

Pellets	O
were	O
washed	O
with	O
250	O
μl	O
of	O
HBSS	O
twice	O
and	O
centrifuged	O
at	O
2000	O
rev.	O
/	O
min	O
,	O
4	O
°	O
C	O
for	O
2	O
min	O
.	O

Pellets	O
were	O
taken	O
up	O
in	O
200	O
μl	O
20	O
%	O
NaOH	O
,	O
heated	O
on	O
40	O
°	O
C	O
water	O
bath	O
with	O
constant	O
shaking	O
,	O
and	O
then	O
taken	O
up	O
in	O
4.8	O
ml	O
of	O
scintillation	O
liquid	O
.	O

The	O
radioactivity	O
was	O
measured	O
by	O
a	O
Beckman	O
7500	O
Scintillation	O
Counter	O
after	O
equilibration	O
for	O
13	O
to	O
18	O
h	O
in	O
5	O
ml	O
of	O
scintillation	O
fluid	O
.	O

The	O
competition	O
studies	O
of	O
[	O
3	O
H	O
]	O
14,15-EET	O
specific	O
binding	O
to	O
guinea	O
pig	O
mononuclear	O
cells	O
was	O
conducted	O
by	O
incubating	O
GPM	B
cells	O
(	O
106	O
cells	O
)	O
with	O
2	O
nM	O
of	O
[	O
3	O
H	O
]	O
14,15-EET	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
(	O
10−11	O
to	O
10−4	O
M	O
)	O
of	O
stereo	O
isomers	O
and	O
analogs	O
of	O
14,15-EET	O
.	O

For	O
the	O
experiments	O
on	O
the	O
effects	O
of	O
proteases	O
(	O
chymotrypsin	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
and	O
Proteinase	O
K	O
)	O
,	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
H-89	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
to	O
GPM	B
cells	O
,	O
the	O
cells	O
were	O
pretreated	O
with	O
one	O
of	O
the	O
following	O
group	O
of	O
agents	O
:	O
1	O
)	O
proteases	O
(	O
chymotrypsin	O
-	O
type	O
IS	O
and	O
type	O
II	O
,	O
papain	O
,	O
pronase	O
E	O
and	O
proteinase	O
K	O
,	O
100	O
μg	O
/	O
ml	O
)	O
at	O
37	O
°	O
C	O
for	O
20	O
min	O
;	O
2	O
)	O
cholera	O
toxin	O
(	O
25–200	O
μg	O
/	O
ml	O
)	O
and	O
pertussis	O
toxin	O
(	O
20–200	O
ng	O
/	O
ml	O
)	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
;	O
3	O
)	O
dibutyryl	O
cAMP	O
(	O
DBcAMP	O
)	O
(	O
10–100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
;	O
4	O
)	O
H-89	O
(	O
0.01–1	O
μm	O
)	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
,	O
then	O
in	O
the	O
presence	O
of	O
DBcAMP	O
(	O
100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
another	O
30	O
min	O
,	O
separately	O
before	O
the	O
binding	O
assay	O
.	O

The	O
pretreated	O
GPM	B
cells	O
were	O
centrifuged	O
at	O
1000	O
rev.	O
/	O
min	O
,	O
at	O
4	O
°	O
C	O
for	O
5	O
min	O
,	O
washed	O
with	O
HBSS	O
buffer	O
,	O
centrifuged	O
,	O
and	O
resuspended	O
in	O
HBSS	O
before	O
the	O
binding	O
assay	O
.	O

2.4	O
cAMP	O
and	O
cGMP	O
determination	O
GPM	B
cells	O
(	O
4	O
×	O
106	O
)	O
were	O
preincubated	O
with	O
or	O
without	O
400	O
μM	O
of	O
IBMX	O
for	O
5	O
min	O
before	O
the	O
addition	O
of	O
14,15-EET	O
(	O
0.1–100	O
μM	O
)	O
.	O

The	O
assays	O
were	O
incubated	O
for	O
another	O
10	O
min	O
at	O
37	O
°	O
C	O
and	O
terminated	O
by	O
addition	O
of	O
ethanol	O
(	O
its	O
final	O
concentration	O
was	O
65	O
%	O
)	O
.	O

The	O
cell	O
debris	O
was	O
removed	O
by	O
centrifugation	O
and	O
the	O
supernatant	O
was	O
dried	O
under	O
vacuum	O
and	O
redissolved	O
in	O
0.05	O
M	O
acetate	O
buffer	O
for	O
further	O
determination	O
of	O
cAMP	O
and	O
cGMP	O
by	O
RIA	O
kit	O
(	O
Amersham	O
Corp.	O
,	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

2.5	O
Statistical	O
analysis	O
Experimental	O
results	O
were	O
summarized	O
as	O
mean	O
values	O
±	O
SEM	O
.	O

Data	O
were	O
analyzed	O
using	O
one	O
-	O
way	O
ANOVA	O
through	O
the	O
Sigma	O
stat	O
program	O
(	O
Jandel	O
Scientific	O
)	O
.	O

Difference	O
between	O
groups	O
was	O
then	O
determined	O
using	O
the	O
Bonferroni	O
's	O
t	O
-test	O
.	O

When	O
the	O
test	O
of	O
the	O
normality	O
failed	O
,	O
Dunn	O
's	O
test	O
of	O
ANOVA	O
by	O
ranks	O
was	O
used	O
.	O

Groups	O
were	O
deemed	O
to	O
be	O
significantly	O
different	O
from	O
one	O
another	O
when	O
P	O
<	O
0.05	O
.	O

3	O
Results	O
3.1	O
Binding	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
to	O
GPM	B
cells	O
The	O
binding	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
to	O
GPM	B
cells	O
was	O
time	O
dependent	O
and	O
cell	O
concentration	O
dependent	O
(	O
Fig.	O
1A	O
and	O
B	O
)	O
.	O

Maximum	O
binding	O
at	O
4	O
°	O
C	O
was	O
reached	O
at	O
4	O
min	O
with	O
the	O
cell	O
density	O
of	O
2	O
×	O
106	O
cells	O
/	O
ml	O
.	O

Cell	O
bound	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
was	O
readily	O
dissociated	O
in	O
a	O
time	O
-	O
dependent	O
fashion	O
when	O
1000-fold	O
higher	O
concentration	O
of	O
unlabeled	O
of	O
14	O
(	O
R	O
)	O
,	O
15	O
(	O
S	O
)	O
-EET	O
,	O
or	O
14	O
(	O
S	O
)	O
,	O
15	O
(	O
R	O
)	O
-EET	O
was	O
added	O
to	O
the	O
reaction	O
mixture	O
with	O
14	O
(	O
R	O
)	O
,	O
15	O
(	O
S	O
)	O
-EET	O
more	O
effective	O
than	O
the	O
14	O
(	O
S	O
)	O
,	O
15	O
(	O
R	O
)	O
-EET	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
displacement	O
of	O
bound	O
radioligand	O
reached	O
maximum	O
(	O
66	O
%	O
)	O
in	O
5	O
min	O
after	O
the	O
addition	O
of	O
unlabeled	O
14	O
(	O
R	O
)	O
,	O
15	O
(	O
S	O
)	O
-EET	O
.	O

The	O
saturability	O
of	O
the	O
specific	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
was	O
shown	O
by	O
incubating	O
the	O
GPM	B
cells	O
with	O
increasing	O
concentrations	O
of	O
radioligand	O
in	O
the	O
presence	O
or	O
absence	O
of	O
20	O
μM	O
unlabeled	O
14,15-EET	O
.	O

As	O
shown	O
in	O
Fig.	O
3A	O
,	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
to	O
GPM	B
cells	O
was	O
saturable	O
and	O
of	O
high	O
affinity	O
.	O

Nonspecific	O
binding	O
increased	O
linearly	O
with	O
increasing	O
concentration	O
of	O
ligand	O
.	O

Total	O
binding	O
also	O
increased	O
with	O
increasing	O
concentration	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
.	O

This	O
showed	O
that	O
nonspecific	O
binding	O
was	O
of	O
high	O
capacity	O
,	O
nonsaturable	O
and	O
low	O
affinity	O
whereas	O
specific	O
binding	O
was	O
of	O
low	O
capacity	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
.	O

Scatchard	O
analysis	O
of	O
specific	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
to	O
GPM	B
cells	O
(	O
Fig.	O
3B	O
)	O
shows	O
that	O
the	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
binding	O
sites	O
in	O
GPM	B
cells	O
belong	O
to	O
a	O
high	O
affinity	O
population	O
.	O

The	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
is	O
35.06	O
±	O
1.73	O
nM	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
the	O
maximum	O
number	O
of	O
binding	O
sites	O
(	O
B	O
max	O
)	O
was	O
estimated	O
to	O
be	O
2.36	O
±	O
0.31	O
pmol	O
/	O
106	O
cells	O
and	O
the	O
number	O
of	O
binding	O
sites	O
per	O
cell	O
calculated	O
to	O
be	O
1.42	O
±	O
0.19	O
×	O
106	O
sites	O
/	O
cell	O
(	O
n	O
=	O
4	O
)	O
.	O

3.2	O
Competition	O
studies	O
of	O
[	O
3	O
H	O
]	O
14,15-EET	O
specific	O
binding	O
to	O
guinea	B
pig	I
mononuclear	O
cells	O
by	O
14,15-EET	O
stereoisomers	O
and	O
other	O
EETs	O
To	O
examine	O
the	O
specificity	O
of	O
the	O
binding	O
sites	O
for	O
[	O
3	O
H	O
]	O
14,15-EET	O
,	O
we	O
conducted	O
competition	O
binding	O
studies	O
with	O
stereoisomers	O
and	O
analogs	O
of	O
14,15-EET	O
and	O
other	O
EETs	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
,	O
14	O
(	O
R	O
)	O
,	O
15	O
(	O
S	O
)	O
-EET	O
was	O
an	O
effective	O
competing	O
ligand	O
with	O
a	O
K	O
i	O
of	O
226.3	O
nM	O
followed	O
by	O
11	O
(	O
R	O
)	O
,	O
12	O
(	O
S	O
)	O
-EET	O
,	O
14	O
(	O
S	O
)	O
,	O
15	O
(	O
R	O
)	O
-EET	O
,	O
14,15	O
thia	O
(	O
S	O
)	O
-ET	O
,	O
and	O
14,15-aza	O
(	O
N	O
)	O
-ET	O
with	O
K	O
i	O
of	O
595.1	O
nM	O
,	O
612.5	O
nM	O
,	O
3.54	O
μM	O
,	O
and	O
5	O
μM	O
,	O
respectively	O
.	O

3.3	O
Effects	O
of	O
protease	O
enzymes	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
on	O
GPM	B
cells	O
Preincubation	O
of	O
the	O
intact	O
GPM	B
cells	O
with	O
100	O
μg	O
/	O
ml	O
of	O
various	O
protease	O
enzymes	O
such	O
as	O
:	O
chymotrypsin	O
-	O
type	O
IS	O
and	O
type	O
II	O
,	O
papain	O
,	O
pronase	O
E	O
,	O
and	O
proteinase	O
K	O
at	O
37	O
°	O
C	O
for	O
20	O
min	O
led	O
to	O
significant	O
reduction	O
of	O
binding	O
(	O
n	O
=	O
3	O
)	O
(	O
Fig.	O
5	O
)	O
.	O

Papain	O
produced	O
the	O
most	O
reduction	O
(	O
51.60	O
%	O
)	O
on	O
the	O
binding	O
of	O
[	O
3	O
H	O
]	O
-14,15-EET	O
to	O
its	O
receptor	O
followed	O
by	O
proteinase	O
K	O
(	O
47.14	O
%	O
)	O
,	O
chymotrypsin	O
-	O
type	O
II	O
(	O
42.04	O
%	O
)	O
,	O
chymotrypsin	O
-	O
type	O
IS	O
(	O
27.33	O
%	O
)	O
,	O
and	O
pronase	O
E	O
(	O
15.98	O
%	O
)	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
14,15-EET	O
binding	O
sites	O
of	O
the	O
intact	O
GPM	B
cells	O
are	O
protein	O
in	O
nature	O
.	O

3.4	O
Effects	O
of	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
on	O
GPM	B
cells	O
The	O
effects	O
of	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
,	O
agents	O
known	O
to	O
enhance	O
cAMP	O
levels	O
,	O
were	O
tested	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
in	O
GPM	B
cells	O
.	O

GPM	B
cells	O
were	O
pretreated	O
with	O
cholera	O
toxin	O
(	O
25–200	O
μg	O
/	O
ml	O
)	O
and	O
pertussis	O
toxin	O
(	O
20–200	O
ng	O
/	O
ml	O
)	O
separately	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
,	O
followed	O
by	O
radioligand	O
binding	O
assay	O
.	O

14,15-EET	O
receptor	O
binding	O
was	O
decreased	O
58.99	O
±	O
6.37	O
%	O
by	O
cholera	O
toxin	O
(	O
200	O
μg	O
/	O
ml	O
)	O
(	O
Fig.	O
6A	O
)	O
and	O
40.50	O
±	O
3.78	O
%	O
by	O
pertussis	O
toxin	O
(	O
200	O
ng	O
/	O
ml	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
agents	O
that	O
increase	O
intracellular	O
cAMP	O
level	O
can	O
effectively	O
down	O
regulate	O
14,15-EET	O
receptor	O
binding	O
.	O

The	O
down	O
regulation	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
binding	O
in	O
GPM	B
cells	O
by	O
cholera	O
toxin	O
(	O
200	O
μg	O
/	O
ml	O
)	O
is	O
shown	O
by	O
the	O
decrease	O
of	O
number	O
of	O
binding	O
sites	O
(	O
B	O
max	O
,	O
32.0	O
%	O
decrease	O
)	O
on	O
the	O
cell	O
surface	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
(	O
Fig.	O
6B	O
)	O
.	O

3.5	O
Effects	O
of	O
dibutyryl	O
cAMP	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
on	O
GPM	B
cells	O
We	O
pretreated	O
GPM	B
cells	O
with	O
various	O
concentrations	O
of	O
dibutyryl	O
cAMP	O
(	O
DBcAMP	O
)	O
at	O
37	O
°	O
C	O
for	O
30	O
min	O
followed	O
by	O
the	O
radioligand	O
binding	O
assays	O
as	O
described	O
.	O

Similar	O
to	O
the	O
effect	O
of	O
cholera	O
toxin	O
,	O
a	O
significant	O
reduction	O
of	O
specific	O
binding	O
(	O
>	O
35	O
%	O
reduction	O
)	O
for	O
[	O
3	O
H	O
]	O
14,15-EET	O
was	O
observed	O
after	O
the	O
cells	O
were	O
treated	O
with	O
DBcAMP	O
.	O

The	O
reduction	O
of	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
to	O
GPM	B
cells	O
was	O
dose	O
-	O
dependent	O
with	O
respect	O
to	O
DBcAMP	O
(	O
Fig.	O
7A	O
)	O
and	O
maximum	O
response	O
was	O
reached	O
at	O
100	O
nM.	O
Scatchard	O
analysis	O
revealed	O
that	O
the	O
number	O
of	O
the	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
sites	O
(	O
B	O
max	O
)	O
in	O
GPM	B
cell	O
surface	O
was	O
decreased	O
by	O
19.1	O
%	O
after	O
incubation	O
with	O
100	O
nM	O
of	O
DBcAMP	O
without	O
changing	O
the	O
K	O
d	O
(	O
Fig.	O
7B	O
)	O
in	O
the	O
same	O
fashion	O
as	O
the	O
treatment	O
with	O
cholera	O
toxin	O
.	O

3.6	O
Effect	O
of	O
protein	O
kinase	O
inhibitors	O
on	O
the	O
reduction	O
of	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
in	O
GPM	B
cells	O
by	O
DBcAMP	O
Because	O
pretreatment	O
of	O
GPM	B
cells	O
with	O
DBcAMP	O
or	O
cholera	O
toxin	O
resulted	O
in	O
the	O
down	O
regulation	O
of	O
14,15-EET	O
binding	O
site	O
density	O
,	O
we	O
further	O
examined	O
whether	O
this	O
effect	O
was	O
due	O
to	O
activation	O
of	O
PKA	O
.	O

GPM	B
cells	O
were	O
incubated	O
with	O
various	O
concentrations	O
of	O
PKA	O
inhibitor	O
,	O
H-89	O
[	O
19	O
]	O
,	O
at	O
37	O
°	O
C	O
for	O
10	O
min	O
before	O
the	O
pretreatment	O
of	O
DBcAMP	O
(	O
100	O
nM	O
)	O
at	O
37	O
°	O
C	O
for	O
an	O
30	O
min	O
.	O

The	O
cells	O
were	O
washed	O
with	O
HBSS	O
once	O
and	O
resuspended	O
in	O
HBSS	O
.	O

Low	O
doses	O
of	O
H-89	O
(	O
0.01	O
μM	O
)	O
alone	O
showed	O
a	O
slightly	O
decrease	O
in	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
but	O
a	O
higher	O
dose	O
(	O
0.1–1.0	O
μM	O
)	O
showed	O
significant	O
increases	O
as	O
compared	O
with	O
controls	O
(	O
untreated	O
GPM	B
cells	O
)	O
.	O

However	O
,	O
when	O
GPM	B
cells	O
were	O
pretreated	O
with	O
H-89	O
from	O
0.1	O
to	O
1.0	O
μM	O
before	O
treatment	O
with	O
DBcAMP	O
,	O
H-89	O
readily	O
reversed	O
the	O
down	O
regulatory	O
response	O
of	O
DBcAMP	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
in	O
GPM	B
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Fig.	O
8)	O
.	O

Under	O
similar	O
conditions	O
,	O
K252a	O
(	O
a	O
protein	O
kinase	O
C	O
inhibitor	O
)	O
could	O
not	O
reverse	O
the	O
downward	O
regulatory	O
effect	O
of	O
DBcAMP	O
on	O
[	O
3	O
H	O
]	O
-14,15-EET	O
binding	O
in	O
GPM	B
cells	O
.	O

3.7	O
Effects	O
of	O
14,15-EET	O
on	O
the	O
level	O
of	O
cAMP	O
and	O
cGMP	O
in	O
intact	O
GPM	B
cells	O
Because	O
cholera	O
toxin	O
and	O
cAMP	O
both	O
are	O
able	O
to	O
down	O
regulate	O
the	O
14,15-EET	O
receptor	O
binding	O
,	O
the	O
effects	O
of	O
14,15-EET	O
on	O
the	O
intracellular	O
levels	O
of	O
cAMP	O
or	O
cGMP	O
were	O
examined	O
.	O

GPM	B
cells	O
were	O
preincubated	O
with	O
or	O
without	O
400	O
μM	O
of	O
IBMX	O
for	O
5	O
min	O
at	O
37	O
°	O
C	O
and	O
incubated	O
with	O
various	O
concentrations	O
of	O
14,15-EET	O
(	O
0.01–100	O
μM	O
)	O
for	O
additional	O
10	O
min	O
.	O

We	O
found	O
that	O
14,15-EET	O
can	O
indeed	O
induce	O
an	O
increase	O
of	O
intracellular	O
level	O
of	O
cAMP	O
in	O
GPM	B
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
0.1	O
to	O
100	O
μM	O
)	O
(	O
Fig.	O
9	O
)	O
.	O

Maximal	O
effect	O
on	O
the	O
increase	O
of	O
cAMP	O
in	O
GPM	B
cells	O
required	O
the	O
presence	O
of	O
IBMX	O
,	O
a	O
phospodiesterase	O
inhibitor	O
.	O

When	O
the	O
cells	O
were	O
pretreated	O
with	O
100	O
μM	O
of	O
14,15-EET	O
,	O
there	O
was	O
a	O
nearly	O
12-fold	O
increase	O
in	O
intracellular	O
level	O
of	O
cAMP	O
,	O
from	O
2.67	O
pmol	O
/	O
106	O
cells	O
(	O
without	O
14,15-EET	O
)	O
to	O
32.42	O
pmol	O
/	O
106	O
cells	O
(	O
pretreated	O
with	O
100	O
μM	O
of	O
14,15-EET	O
)	O
.	O

However	O
,	O
under	O
similar	O
conditions	O
,	O
14,15-EET	O
had	O
no	O
effect	O
on	O
the	O
levels	O
of	O
cGMP	O
in	O
GPM	B
cells	O
in	O
the	O
presence	O
of	O
IBMX	O
.	O

4	O
Discussion	O
14,15-epoxyeicosatrienoic	O
acid	O
(	O
14,15-EET	O
)	O
was	O
originally	O
found	O
to	O
produce	O
by	O
platelets	O
and	O
subsequently	O
by	O
endothelial	O
cells	O
[	O
3,4	O
]	O
.	O

Our	O
earlier	O
data	O
showed	O
that	O
a	O
profound	O
increase	O
in	O
EET	O
(	O
especially	O
14,15-EET	O
)	O
generation	O
in	O
endothelial	O
cells	O
(	O
EC	O
)	O
after	O
exposure	O
to	O
240	O
mg	O
/	O
dl	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-cholesterol	O
.	O

Subsequent	O
data	O
showed	O
that	O
14,15-EET	O
induced	O
an	O
8-fold	O
increase	O
of	O
U-937	B
cell	O
adhesion	O
to	O
cultured	O
human	B
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	B
)	O
as	O
compared	O
with	O
non	O
-	O
treated	O
control	O
[	O
13	O
]	O
.	O

These	O
results	O
support	O
the	O
notion	O
that	O
14,15-EET	O
may	O
mediate	O
the	O
atherogenic	O
LDL	O
induced	O
enhancement	O
of	O
U-937	B
cells	O
'	O
adhesion	O
on	O
HUVEC	B
[	O
20	O
]	O
.	O

Because	O
endothelial	O
cells	O
derived	O
from	O
human	B
umbilical	O
veins	O
(	O
HUVE	B
)	O
do	O
not	O
possess	O
any	O
specific	O
binding	O
for	O
[	O
3	O
H	O
]	O
-14,15-EET	O
that	O
suggested	O
a	O
lack	O
of	O
14,15-EET	O
receptors	O
in	O
endothelium	O
[	O
21,22	O
]	O
,	O
the	O
enhancement	O
of	O
monocyte	O
adhesion	O
by	O
14,15-EET	O
may	O
act	O
through	O
a	O
receptor	O
and	O
the	O
activation	O
of	O
a	O
signal	O
transduction	O
mechanism	O
in	O
monocytes	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
identified	O
and	O
characterized	O
a	O
population	O
of	O
specific	O
high	O
affinity	O
binding	O
sites	O
for	O
[	O
3	O
H	O
]	O
-14,15-EET	O
in	O
GPM	B
cells	O
and	O
found	O
the	O
ligand	O
binding	O
is	O
high	O
affinity	O
with	O
a	O
K	O
d	O
of	O
35.06	O
±	O
1.73	O
nM	O
and	O
B	O
max	O
of	O
2.36	O
±	O
0.32	O
pmol	O
/	O
106	O
cells	O
.	O

The	O
calculated	O
number	O
of	O
binding	O
sites	O
per	O
cell	O
was	O
1.42	O
±	O
0.19	O
×	O
106	O
sites	O
/	O
cell	O
.	O

This	O
binding	O
site	O
is	O
stereospecific	O
for	O
14	O
(	O
R	O
)	O
,	O
15	O
(	O
S	O
)	O
-EET	O
and	O
has	O
less	O
affinity	O
toward	O
other	O
EETs	O
and	O
11	O
(	O
R	O
)	O
,	O
12	O
(	O
S	O
)	O
-EET	O
(	O
Fig.	O
4	O
)	O
.	O

The	O
binding	O
of	O
[	O
3	O
H	O
]	O
-14,15-EET	O
to	O
GPM	B
cells	O
is	O
reversible	O
(	O
Fig.	O
2	O
)	O
and	O
protease	O
sensitive	O
which	O
showed	O
that	O
this	O
binding	O
site	O
is	O
associated	O
with	O
a	O
protein	O
species	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
rapid	O
time	O
course	O
of	O
radioligand	O
binding	O
in	O
the	O
cold	O
temperature	O
and	O
the	O
reversibility	O
suggested	O
that	O
the	O
binding	O
be	O
not	O
likely	O
due	O
to	O
the	O
esterification	O
of	O
14,15-EET	O
into	O
the	O
membrane	O
phospholipids	O
.	O

14,15-EET	O
binding	O
in	O
GPM	B
cells	O
is	O
attenuated	O
by	O
cholera	O
toxin	O
or	O
pertussis	O
toxin	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
.	O

Because	O
both	O
cholera	O
toxin	O
and	O
pertussis	O
toxin	O
activate	O
adenyl	O
cyclase	O
and	O
report	O
to	O
increase	O
intracellular	O
cAMP	O
[	O
23	O
]	O
,	O
we	O
found	O
that	O
addition	O
of	O
dibutyryl	O
cAMP	O
(	O
DBcAMP	O
)	O
can	O
reduce	O
the	O
binding	O
of	O
[	O
3	O
H	O
]	O
-	O
14,15-EET	O
on	O
GPM	B
cells	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
by	O
reducing	O
the	O
cell	O
surface	O
receptor	O
density	O
(	O
B	O
max	O
)	O
without	O
changing	O
the	O
dissociation	O
constant	O
(	O
K	O
d	O
)	O
(	O
Fig.	O
7A	O
and	O
B	O
)	O
.	O

However	O
pertussis	O
toxin	O
was	O
less	O
effective	O
as	O
compared	O
with	O
cholera	O
toxin	O
probably	O
due	O
to	O
the	O
fact	O
it	O
is	O
less	O
effective	O
in	O
increasing	O
intracellular	O
cAMP	O
level	O
in	O
GPM	B
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
reagents	O
that	O
elevated	O
intracellular	O
cAMP	O
levels	O
in	O
GPM	B
cells	O
down	O
regulate	O
14,15-EET	O
binding	O
and	O
the	O
binding	O
sites	O
are	O
likely	O
associated	O
with	O
a	O
functional	O
receptor	O
.	O

The	O
fact	O
that	O
the	O
down	O
regulation	O
of	O
14,15-EET	O
receptor	O
binding	O
induced	O
by	O
cAMP	O
can	O
be	O
reversed	O
by	O
a	O
PKA	O
inhibitor	O
,	O
H-89	O
,	O
further	O
suggest	O
these	O
processes	O
may	O
be	O
mediated	O
through	O
the	O
activation	O
of	O
PKA	O
linked	O
signal	O
transduction	O
pathway	O
.	O

The	O
high	O
concentration	O
(	O
μM	O
range	O
)	O
of	O
14,15-EET	O
required	O
to	O
increase	O
the	O
level	O
of	O
cAMP	O
possibly	O
due	O
to	O
phosphodiesterase	O
in	O
GPM	B
cells	O
being	O
active	O
that	O
cAMP	O
could	O
not	O
accumulate	O
even	O
in	O
the	O
presence	O
of	O
IBMX	O
.	O

Another	O
possibility	O
is	O
due	O
to	O
GPM	B
cells	O
that	O
might	O
have	O
different	O
types	O
of	O
phosphodiesterase	O
that	O
IBMX	O
can	O
not	O
effectively	O
inhibit	O
.	O

Although	O
it	O
seems	O
clear	O
that	O
14,15-EET	O
transduction	O
system	O
involves	O
cAMP	O
mediation	O
and	O
a	O
PKA	O
-	O
dependent	O
mechanism	O
,	O
the	O
precise	O
details	O
of	O
the	O
process	O
,	O
i.e.	O
whether	O
down	O
regulation	O
is	O
secondary	O
to	O
phosphorylation	O
of	O
receptor	O
protein	O
or	O
by	O
internalization	O
require	O
further	O
investigation	O
.	O

Salvia	B
is	O
an	O
important	O
genus	O
consisting	O
of	O
ca	O
900	O
species	O
in	O
the	O
family	O
Lamiaceae	O
(	O
formerly	O
Labiatae	O
)	O
and	O
some	O
species	O
of	O
Salvia	B
have	O
been	O
cultivated	O
worldwide	O
for	O
use	O
in	O
folk	O
medicines	O
and	O
for	O
culinary	O
purposes	O
.	O

The	O
dried	O
root	O
of	O
Salvia	B
miltiorrhiza	I
(	O
Chinese	O
Danshen	O
)	O
,	O
for	O
example	O
,	O
has	O
been	O
used	O
extensively	O
for	O
the	O
treatment	O
of	O
coronary	O
heart	O
disease	O
,	O
cerebrovascular	O
disease	O
,	O
hepatitis	O
,	O
hepatocirrhosis	O
,	O
chronic	O
renal	O
failure	O
,	O
dysmenorrhea	O
and	O
neuroasthenic	O
insomnia	O
(	O
Li	O
,	O
1998	O
)	O
.	O

Studies	O
on	O
the	O
chemical	O
constituents	O
of	O
Salvia	B
have	O
been	O
mainly	O
confined	O
to	O
the	O
diterpenoids	O
and	O
the	O
tanshinones	O
(	O
Chang	O
et	O
al.	O
,	O
1990	O
;	O
Zhang	O
et	O
al.	O
,	O
1990	O
)	O
and	O
several	O
reviews	O
on	O
these	O
components	O
have	O
now	O
been	O
published	O
(	O
Prokopenko	O
and	O
Litvinenko	O
,	O
1980	O
;	O
Kong	O
,	O
1989	O
;	O
Tang	O
and	O
Eisenbrand	O
,	O
1992	O
;	O
Al	O
-	O
Hazimi	O
and	O
Miana	O
,	O
1994	O
;	O
Rodriguez	O
-	O
Hahn	O
et	O
al.	O
,	O
1995	O
;	O
Ulubelen	O
and	O
Topcu	O
,	O
1998	O
)	O
.	O

However	O
,	O
in	O
recent	O
years	O
much	O
attention	O
has	O
been	O
directed	O
to	O
the	O
biologically	O
active	O
,	O
water	O
-	O
soluble	O
components	O
in	O
the	O
dried	O
root	O
decoction	O
used	O
in	O
traditional	O
medicine	O
(	O
Zhang	O
and	O
Liu	O
,	O
1996	O
)	O
.	O

These	O
studies	O
,	O
particularly	O
in	O
China	O
,	O
have	O
led	O
to	O
the	O
isolation	O
and	O
identification	O
of	O
a	O
host	O
of	O
caffeic	O
acid	O
derived	O
metabolites	O
(	O
Li	O
,	O
1998	O
)	O
,	O
many	O
of	O
which	O
possess	O
a	O
variety	O
of	O
biological	O
activities	O
including	O
antioxidant	O
,	O
antiplatelet	O
,	O
antitumor	O
and	O
antiviral	O
activity	O
(	O
see	O
Table	O
1	O
)	O
.	O

This	O
review	O
is	O
written	O
to	O
take	O
into	O
account	O
of	O
the	O
rapid	O
development	O
in	O
the	O
phytochemistry	O
and	O
therapeutical	O
applications	O
of	O
species	O
of	O
Salvia	B
.	O

2	O
Phenolic	O
acids	O
The	O
polar	O
phenolic	O
acids	O
constitute	O
the	O
major	O
part	O
of	O
the	O
water	O
-	O
soluble	O
components	O
of	O
the	O
Salvia	B
decoction	O
.	O

Most	O
of	O
the	O
phenolic	O
acids	O
identified	O
so	O
far	O
are	O
those	O
from	O
the	O
Chinese	O
Danshen	O
,	O
S.	B
miltiorrhiza	I
,	O
S.	B
chinensis	I
and	O
S.	B
yunnanensis	I
and	O
the	O
compounds	O
unique	O
to	O
Salvia	B
are	O
consequently	O
designated	O
salvianolic	O
acids	O
A	O
–	O
K	O
or	O
yunnaneic	O
acids	O
A	O
–	O
H	O
to	O
reflect	O
their	O
origin	O
(	O
see	O
Table	O
2	O
)	O
.	O

Apart	O
from	O
a	O
few	O
simple	O
benzoic	O
acids	O
such	O
as	O
4-hydroxybenzoic	O
acid	O
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
,	O
3,4-dihydroxybenzoic	O
acid	O
or	O
protocatechuic	O
acid	O
(	O
Wu	O
et	O
al.	O
,	O
1999a	O
)	O
,	O
3-methoxy-4-hydroxybenzoic	O
acid	O
or	O
vanillic	O
acid	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
2,4-dimethoxybenzoic	O
acid	O
(	O
Topcu	O
et	O
al.	O
,	O
1995	O
)	O
,	O
an	O
ether	O
linked	O
dimer	O
of	O
hexyl	O
4-hydroxybenzoate	O
or	O
di	O
(	O
4-hexyloxycarbonylphenyl	O
)	O
ether	O
(	O
Ulubelen	O
et	O
al.	O
,	O
1995	O
)	O
and	O
two	O
coumarins	O
6,7-dihydroxycoumarin	O
(	O
esculetin	O
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
and	O
7-methoxycoumarin	O
(	O
herniarin	O
)	O
(	O
El	O
-	O
Missiry	O
et	O
al.	O
,	O
1994	O
)	O
,	O
the	O
majority	O
of	O
the	O
phenolic	O
acids	O
in	O
Salvia	B
species	I
are	O
exclusively	O
those	O
of	O
caffeic	O
acid	O
(	O
1	O
)	O
derivatives	O
,	O
which	O
are	O
unique	O
to	O
Salvia	B
except	O
for	O
rosmarinic	O
acid	O
(	O
2	O
)	O
and	O
lithospermic	O
acid	O
(	O
9	O
)	O
(	O
see	O
Fig.	O
1	O
for	O
chemical	O
structures	O
)	O
.	O

2.1	O
Caffeic	O
acid	O
metabolites	O
Caffeic	O
acid	O
plays	O
a	O
central	O
role	O
in	O
the	O
biochemistry	O
of	O
Lamiaceae	B
and	O
occurs	O
predominantly	O
in	O
the	O
dimer	O
form	O
as	O
rosmarinic	O
acid	O
(	O
Gerhardt	O
and	O
Schroeter	O
,	O
1983	O
)	O
.	O

In	O
the	O
Salvia	B
species	I
the	O
caffeic	O
acid	O
is	O
the	O
building	O
block	O
of	O
a	O
variety	O
of	O
the	O
plant	O
metabolites	O
from	O
the	O
more	O
simple	O
monomers	O
to	O
multiple	O
condensation	O
products	O
to	O
give	O
rise	O
to	O
a	O
variety	O
of	O
oligomers	O
.	O

The	O
trimers	O
and	O
tetramers	O
are	O
more	O
interesting	O
from	O
the	O
therapeutic	O
point	O
of	O
view	O
as	O
they	O
have	O
been	O
shown	O
to	O
possess	O
significant	O
biological	O
activities	O
.	O

2.1.1	O
Caffeic	O
acid	O
monomers	O
The	O
monomers	O
that	O
are	O
frequently	O
present	O
in	O
Salvia	B
are	O
represented	O
by	O
caffeic	O
acid	O
itself	O
and	O
3-	O
(	O
3,4-dihydroxyphenyl	O
)	O
lactic	O
acid	O
(	O
3	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
.	O

The	O
latter	O
compound	O
,	O
also	O
known	O
as	O
danshensu	O
(	O
Chinese	O
word	O
to	O
mean	O
literally	O
the	O
element	O
of	O
Danshen	O
)	O
was	O
first	O
isolated	O
from	O
S.	B
miltiorrhiza	I
(	O
Yang	O
and	O
Zhang	O
,	O
1981	O
)	O
and	O
found	O
to	O
be	O
a	O
coronary	O
vasodilator	O
and	O
to	O
scavenge	O
the	O
free	O
oxygen	O
radicals	O
generated	O
during	O
ischemia	O
-	O
reperfusion	O
injury	O
in	O
the	O
myocardium	O
as	O
effectively	O
as	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
(	O
Zhao	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
amide	O
of	O
3	O
,	O
3-	O
(	O
3,4-dihydroxyphenyl	O
)	O
lactamide	O
(	O
4	O
)	O
,	O
also	O
found	O
in	O
S.	B
miltiorrhiza	I
,	O
had	O
been	O
reported	O
to	O
possess	O
radical	O
scavenging	O
activity	O
greater	O
than	O
ascorbic	O
acid	O
(	O
Kang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Other	O
monomeric	O
derivatives	O
including	O
ferulic	O
acid	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
,	O
isoferulic	O
acid	O
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
and	O
two	O
caffeic	O
acid	O
esters	O
mono	O
-	O
feruloyl	O
-	O
R	O
,	O
R	O
-	O
(	O
+	O
)	O
-tartaric	O
acid	O
(	O
6	O
)	O
(	O
Qian	O
et	O
al.	O
,	O
1993	O
)	O
and	O
chlorogenic	O
acid	O
(	O
5-caffeoylquinic	O
acid	O
)	O
(	O
7	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
)	O
have	O
also	O
been	O
described	O
as	O
Salvia	B
constituents	O
.	O

The	O
identification	O
of	O
mono	O
-	O
feruloyl	O
-	O
R	O
,	O
R	O
-	O
(	O
+	O
)	O
-tartaric	O
acid	O
has	O
been	O
corroborated	O
by	O
chemical	O
synthesis	O
,	O
along	O
with	O
its	O
two	O
S	O
,	O
S	O
-	O
(	O
-	O
)	O
-	O
and	O
R	O
,	O
S	O
-	O
(	O
meso	O
)	O
-isomers	O
.	O

Chlorogenic	O
acid	O
,	O
despite	O
being	O
common	O
and	O
widespread	O
in	O
fruits	O
,	O
is	O
surprisingly	O
uncommon	O
in	O
Lamiaceae	B
,	O
which	O
is	O
generally	O
dominated	O
by	O
rosmarinic	O
acid	O
(	O
Gerhardt	O
and	O
Schroeter	O
,	O
1983	O
)	O
.	O

Caffeic	O
acids	O
esterified	O
with	O
sugars	O
are	O
quite	O
common	O
in	O
nature	O
and	O
those	O
identified	O
in	O
Salvia	B
are	O
discussed	O
under	O
Phenolic	O
Glycosides	O
(	O
see	O
below	O
)	O
.	O

2.1.2	O
Caffeic	O
acid	O
dimers	O
Rosmarinic	O
acid	O
(	O
2	O
)	O
is	O
the	O
most	O
abundant	O
caffeic	O
acid	O
dimer	O
in	O
Salvia	B
species	I
(	O
Ai	O
and	O
Li	O
,	O
1988	O
;	O
Cuvelier	O
et	O
al.	O
,	O
1994	O
;	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
and	O
has	O
been	O
reported	O
to	O
be	O
the	O
major	O
phenolic	O
compound	O
responsible	O
for	O
the	O
high	O
antioxidant	O
activity	O
of	O
Salvia	B
samples	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
.	O

There	O
have	O
been	O
many	O
publications	O
on	O
rosmarinic	O
acid	O
dealing	O
with	O
its	O
detection	O
and	O
quantitative	O
estimation	O
in	O
various	O
Salvia	B
preparations	O
(	O
Janicsak	O
and	O
Mathe	O
,	O
1997	O
;	O
Yuan	O
et	O
al.	O
,	O
1998	O
;	O
Areias	O
et	O
al.	O
,	O
2000	O
)	O
,	O
its	O
biochemical	O
production	O
in	O
cell	O
cultures	O
(	O
Morimoto	O
et	O
al.	O
,	O
1994	O
)	O
or	O
chemical	O
synthesis	O
(	O
Eicher	O
et	O
al.	O
,	O
1996	O
)	O
and	O
its	O
metabolism	O
in	O
rats	B
(	O
Nakazawa	O
and	O
Ohsawa	O
,	O
1998	O
)	O
.	O

Other	O
types	O
of	O
dimers	O
identified	O
in	O
Salvia	B
include	O
przewalskinic	O
acid	O
A	O
(	O
8	O
)	O
from	O
the	O
Tibetan	O
sage	O
S.	B
przewalskii	I
(	O
Lu	O
et	O
al.	O
,	O
1991	O
)	O
,	O
salvianolic	O
acid	O
G	O
(	O
11	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1991	O
)	O
and	O
the	O
stilbenoid	O
salvianolic	O
acid	O
F	O
or	O
2-	O
(	O
3,4-dihydroxystyryl	O
)	O
caffeic	O
acid	O
(	O
12	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1996	O
)	O
both	O
from	O
S.	B
miltiorrhiza	I
.	O

The	O
dihydrobenzofuran	O
compound	O
przewalskinic	O
acid	O
A	O
is	O
apparently	O
related	O
to	O
lithospermic	O
acid	O
(	O
9	O
)	O
and	O
salvianolic	O
acid	O
B	O
or	O
lithospermic	O
acid	O
B	O
(	O
10	O
)	O
,	O
whereas	O
salvianolic	O
acid	O
G	O
,	O
with	O
a	O
dibenzooxepin	O
skeleton	O
,	O
is	O
the	O
first	O
of	O
its	O
kind	O
found	O
in	O
Salvia	B
.	O

Salvianolic	O
acid	O
F	O
,	O
which	O
has	O
been	O
synthesised	O
by	O
Dalla	O
and	O
Cotelle	O
(	O
1999	O
)	O
,	O
is	O
a	O
decarboxylated	O
caffeic	O
acid	O
dimer	O
.	O

In	O
addition	O
,	O
Ulubelen	O
and	O
co	O
-	O
workers	O
(	O
1996	O
)	O
have	O
reported	O
the	O
existence	O
of	O
two	O
isomeric	O
caffeic	O
acid	O
ester	O
dimers	O
linked	O
by	O
ether	O
bond	O
,	O
namely	O
the	O
dioctyl	O
3-O	O
-3′-di	O
-	O
cis	O
-	O
and	O
di	O
-	O
trans	O
-isoferulate	O
(	O
14	O
,	O
15	O
)	O
in	O
S.	B
forskahlei	I
.	O

2.1.3	O
Caffeic	O
acid	O
trimers	O
Trimers	O
derived	O
from	O
caffeic	O
acid	O
constitute	O
the	O
largest	O
group	O
of	O
metabolites	O
in	O
Salvia	B
.	O

They	O
include	O
compounds	O
such	O
as	O
lithospermic	O
acid	O
(	O
9	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
,	O
salvianolic	O
acids	O
H	O
(	O
16	O
)	O
(	O
Zhang	O
and	O
Li	O
,	O
1993	O
)	O
,	O
I	O
(	O
17	O
)	O
(	O
Zhang	O
and	O
Li	O
,	O
1994	O
)	O
,	O
J	O
(	O
18	O
)	O
(	O
Ai	O
et	O
al.	O
,	O
1994	O
)	O
and	O
K	O
(	O
19	O
)	O
(	O
Tezuka	O
et	O
al.	O
,	O
1998	O
;	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
,	O
sagecoumarin	O
(	O
20	O
)	O
(	O
Lu	O
et	O
al.	O
,	O
1999	O
)	O
,	O
three	O
decarboxylated	O
forms	O
of	O
salvianolic	O
acids	O
A	O
(	O
13	O
)	O
(	O
Li	O
et	O
al.	O
,	O
1984	O
)	O
,	O
C	O
(	O
21	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
and	O
isosalvianolic	O
acid	O
C	O
(	O
22	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
as	O
well	O
as	O
yunnaneic	O
acids	O
C	O
(	O
24	O
)	O
,	O
D	O
(	O
25	O
)	O
,	O
E	O
(	O
26	O
)	O
and	O
F	O
(	O
27	O
)	O
(	O
Tanaka	O
et	O
al.	O
,	O
1996	O
;	O
1997	O
)	O
.	O

These	O
last	O
mentioned	O
are	O
apparent	O
Diels	O
–	O
Alder	O
adducts	O
of	O
caffeic	O
acids	O
.	O

Lithospermic	O
acid	O
and	O
both	O
its	O
mono	O
-	O
and	O
dimethyl	O
esters	O
were	O
the	O
active	O
components	O
that	O
inhibited	O
adenylate	O
cyclase	O
(	O
Kohda	O
et	O
al.	O
,	O
1989	O
)	O
.	O

In	O
addition	O
,	O
dimethyl	O
lithospermate	O
was	O
also	O
shown	O
to	O
be	O
a	O
stronger	O
radical	O
scavenger	O
than	O
ascorbic	O
acid	O
(	O
Kang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
new	O
member	O
of	O
the	O
salvianolic	O
acid	O
series	O
is	O
salvianolic	O
acid	O
K	O
and	O
its	O
presence	O
has	O
been	O
detected	O
by	O
LC	O
–	O
MS	O
in	O
10	O
Salvia	B
species	I
(	O
Kasimu	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Salvianolic	O
acid	O
A	O
,	O
the	O
stilbenoid	O
caffeic	O
acid	O
trimer	O
has	O
been	O
shown	O
to	O
possess	O
a	O
strong	O
oxygen	O
free	O
radical	O
scavenging	O
activity	O
(	O
Huang	O
and	O
Zhang	O
,	O
1992	O
;	O
Li	O
et	O
al.	O
,	O
1995	O
)	O
which	O
may	O
be	O
the	O
basis	O
for	O
some	O
of	O
its	O
biological	O
activities	O
(	O
see	O
Table	O
1	O
)	O
.	O

Salvianolic	O
acid	O
A	O
is	O
apparently	O
not	O
very	O
stable	O
and	O
its	O
reactivity	O
has	O
been	O
demonstrated	O
by	O
its	O
conversion	O
to	O
salvianolic	O
acid	O
C	O
on	O
a	O
TLC	O
plate	O
that	O
was	O
impregnated	O
with	O
2	O
%	O
of	O
formic	O
acid	O
solution	O
.	O

This	O
suggested	O
that	O
salvianolic	O
acid	O
C	O
,	O
a	O
benzofuran	O
compound	O
,	O
was	O
likely	O
a	O
cyclization	O
product	O
of	O
salvianolic	O
acid	O
A	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
.	O

Isosalvianolic	O
acid	O
C	O
,	O
a	O
second	O
depside	O
to	O
salvianolic	O
acid	O
G	O
with	O
a	O
dibenzooxepin	O
skeleton	O
,	O
has	O
been	O
identified	O
only	O
in	O
S.	B
chinensis	I
along	O
with	O
salvianolic	O
acid	O
D	O
(	O
23	O
)	O
(	O
Qian	O
and	O
Li	O
,	O
1992	O
)	O
,	O
the	O
latter	O
could	O
be	O
considered	O
as	O
an	O
abridged	O
caffeic	O
acid	O
trimer	O
that	O
was	O
first	O
found	O
in	O
S.	B
miltiorrhiza	I
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
.	O

Yunnaneic	O
acids	O
C	O
and	O
D	O
both	O
of	O
which	O
contain	O
the	O
bicyclo	O
[	O
2.2.2	O
]	O
octane	O
core	O
structure	O
appear	O
to	O
be	O
the	O
Diels	O
–	O
Alder	O
adducts	O
involving	O
the	O
double	O
bond	O
of	O
the	O
caffeic	O
acid	O
and	O
the	O
phenol	O
ring	O
or	O
its	O
quinone	O
form	O
in	O
a	O
rosmarinic	O
acid	O
moiety	O
.	O

Further	O
oxidation	O
of	O
yunnaneic	O
acid	O
C	O
resulted	O
in	O
the	O
formation	O
of	O
yunnaneic	O
acid	O
E	O
while	O
the	O
addition	O
of	O
an	O
acetyl	O
group	O
to	O
the	O
bicyclo	O
[	O
2.2.2	O
]	O
octa-1,2-dione	O
skeleton	O
in	O
yunnaneic	O
acid	O
C	O
led	O
to	O
yunnaneic	O
acid	O
F.	O
2.1.4	O
Caffeic	O
acid	O
tetramers	O
Caffeic	O
acid	O
tetramers	O
are	O
in	O
effect	O
dimerised	O
rosmarinic	O
acids	O
as	O
in	O
salvianolic	O
acids	O
B	O
(	O
10	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1988	O
)	O
,	O
E	O
(	O
28	O
)	O
(	O
Ai	O
and	O
Li	O
,	O
1992	O
)	O
and	O
L	O
(	O
32	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2001b	O
)	O
,	O
rabdosiin	O
(	O
29	O
)	O
,	O
yunnaneic	O
acids	O
G	O
(	O
30	O
)	O
and	O
H	O
(	O
31	O
)	O
(	O
Tanaka	O
et	O
al.	O
,	O
1997	O
)	O
,	O
and	O
sagerinic	O
acid	O
(	O
33	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
1999	O
)	O
.	O

Distribution	O
of	O
salvianolic	O
acid	O
E	O
is	O
more	O
restricted	O
and	O
has	O
been	O
reported	O
only	O
in	O
S.	B
miltiorrhiza	I
while	O
salvianolic	O
acid	O
B	O
,	O
which	O
is	O
also	O
known	O
as	O
lithospermic	O
acid	O
B	O
,	O
is	O
more	O
common	O
in	O
Salvia	B
species	I
and	O
occurs	O
mainly	O
as	O
potassium	O
,	O
ammonium	O
or	O
magnesium	O
salts	O
.	O

These	O
salts	O
constitute	O
largely	O
the	O
most	O
important	O
bioactive	O
Salvia	B
components	O
in	O
sage	B
(	O
see	O
Table	O
1	O
)	O
.	O

Three	O
methyl	O
esters	O
of	O
lithospermic	O
acid	O
B	O
,	O
namely	O
the	O
9′-	O
and	O
9‴-monomethyl	O
lithospermate	O
B	O
and	O
dimethyl	O
lithospermate	O
B	O
,	O
have	O
been	O
found	O
recently	O
in	O
Tibetan	B
sage	I
together	O
with	O
other	O
known	O
polyphenolic	O
compounds	O
(	O
Wu	O
et	O
al.	O
,	O
1999b	O
)	O
.	O

In	O
addition	O
to	O
the	O
yunnaneic	O
acids	O
C	O
to	O
F	O
mentioned	O
above	O
,	O
Tanaka	O
et	O
al.	O
(	O
1997	O
)	O
have	O
also	O
identified	O
three	O
oxidatively	O
cyclized	O
rosmarinic	O
acid	O
dimers	O
with	O
a	O
1,2-dihydronaphthalene	O
core	O
comprising	O
of	O
rabdosiin	O
,	O
yunnaneic	O
acids	O
G	O
and	O
H	O
in	O
S.	B
yunnanesis	I
.	O

Most	O
recently	O
,	O
salvianolic	O
acid	O
L	O
,	O
an	O
isomer	O
of	O
rabdosiin	O
or	O
yunnaneic	O
acid	O
G	O
,	O
has	O
been	O
found	O
in	O
S.	B
officinalis	I
.	O

In	O
addition	O
,	O
a	O
more	O
structurally	O
interesting	O
new	O
type	O
of	O
[	O
2	O
+	O
2	O
]	O
-rosmarinic	O
acid	O
dimer	O
is	O
sagerinic	O
acid	O
reported	O
in	O
S.	B
officinalis	I
,	O
which	O
contained	O
a	O
cyclobutane	O
ring	O
in	O
the	O
μ	O
-	O
truxinate	O
form	O
.	O

Sagerinic	O
acid	O
is	O
the	O
first	O
example	O
of	O
a	O
natural	O
[	O
2	O
+	O
2	O
]	O
-dimers	O
of	O
caffeic	O
acid	O
esters	O
.	O

2.1.5	O
Higher	O
caffeic	O
acid	O
oligomers	O
Yunnaneic	O
acids	O
A	O
(	O
34	O
)	O
and	O
B	O
(	O
35	O
)	O
found	O
in	O
S.	B
yunnanesis	I
(	O
Tanaka	O
et	O
al.	O
,	O
1996	O
)	O
are	O
the	O
only	O
known	O
hexamers	O
of	O
caffeic	O
acid	O
.	O

These	O
two	O
compounds	O
could	O
be	O
formed	O
by	O
spiroacetal	O
bonding	O
between	O
yunnaneic	O
acid	O
C	O
(	O
24	O
)	O
and	O
yunnaneic	O
acid	O
D	O
(	O
25	O
)	O
or	O
between	O
two	O
molecules	O
of	O
24	O
.	O

The	O
presence	O
of	O
these	O
Diels	O
–	O
Alder	O
type	O
adducts	O
in	O
S.	B
yunnanesis	I
indicates	O
the	O
complexity	O
in	O
the	O
biochemistry	O
of	O
plant	O
metabolism	O
.	O

2.2	O
Phenolic	O
glycosides	O
The	O
phenolic	O
glycosides	O
are	O
apparently	O
not	O
very	O
common	O
in	O
Salvia	B
and	O
rosmarinic	O
acid	O
3′-glucoside1	O
1	O
Unless	O
otherwise	O
mentioned	O
,	O
common	O
sugars	O
glucose	O
,	O
galactose	O
,	O
xylose	O
,	O
arabinose	O
,	O
rhamnose	O
,	O
fructose	O
and	O
apiose	O
denote	O
β	O
-	O
d	O
-glucopyranose	O
,	O
β	O
-	O
d	O
-galactopyranose	O
,	O
β	O
-	O
d	O
-xylopyranose	O
,	O
α	O
-	O
l	O
-arabiopyranose	O
,	O
α	O
-	O
l	O
-rhamnopyranose	O
,	O
β	O
-	O
d	O
-fructofuranose	O
and	O
β	O
-	O
d	O
-apiofuranose	O
,	O
respectively	O
.	O

(	O
salviaflaside	O
)	O
(	O
36	O
)	O
and	O
its	O
methyl	O
ester	O
(	O
Zhao	O
et	O
al.	O
,	O
1996a	O
)	O
as	O
well	O
as	O
the	O
cis	O
and	O
trans	O
-p	O
-coumaric	O
acid	O
4-O	O
-	O
(	O
2-O	O
-apiosyl	O
)	O
glucosides	O
(	O
37	O
,	O
38	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
are	O
the	O
only	O
examples	O
of	O
the	O
glycosylated	O
phenolic	O
acids	O
.	O

In	O
contrast	O
the	O
phenolic	O
acids	O
esterified	O
with	O
sugars	O
,	O
in	O
which	O
the	O
phenolic	O
acids	O
serve	O
as	O
acylating	O
agents	O
to	O
give	O
rise	O
to	O
acylated	O
sugars	O
,	O
are	O
more	O
common	O
.	O

These	O
acylated	O
sugars	O
include	O
6-O	O
-feruloyl	O
-	O
α-	O
and	O
β	O
-	O
glucose	O
(	O
39	O
,	O
40	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
1998	O
)	O
,	O
1-O	O
-	O
(	O
2,3,4-trihydroxy-3-methyl	O
)	O
butyl-6-O	O
-feruloylglucoside	O
(	O
41	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
,	O
6-O	O
-caffeoyl-1-O	O
-fructosyl	O
-	O
α	O
-	O
glucoside	O
(	O
42	O
)	O
,	O
1-O	O
-caffeoyl-6-O	O
-apiosylglucoside	O
(	O
43	O
)	O
,	O
1-O	O
-p	O
-hydroxybenzoyl-6-O	O
-apiosylglucoside	O
(	O
44	O
)	O
,	O
all	O
from	O
S.	B
officinalis	I
(	O
Wang	O
et	O
al.	O
,	O
1999	O
)	O
,	O
and	O
prionitisides	O
A	O
(	O
45	O
)	O
and	O
B	O
(	O
46	O
)	O
from	O
S.	B
prionitis	I
.	O

The	O
structures	O
of	O
prionitisides	O
A	O
and	O
B	O
were	O
elucidated	O
as	O
2-	O
(	O
3,4-dihydroxyphenyl	O
)	O
-3-glucosyloxycarbonyl-4,6-dihydroxybenzofuran	O
and	O
2-	O
(	O
3,4-dihydroxyphenyl	O
)	O
-3-rutinosyloxy	O
carbonyl-4,6-dihydroxybenzofuran	O
,	O
respectively	O
(	O
Zhao	O
et	O
al.	O
,	O
1996b	O
)	O
.	O

Several	O
phenolic	O
acetophenone	O
glycosides	O
have	O
been	O
also	O
identified	O
in	O
S.	B
officinalis	I
and	O
these	O
include	O
4-hydroxyacetophenone	O
4-O	O
-glucoside	O
(	O
picein	O
)	O
(	O
47	O
)	O
,	O
4-hydroxyacetophenone	O
4-O	O
-	O
(	O
6-O	O
-apiosyl	O
)	O
glucoside	O
(	O
48	O
)	O
,	O
4-hydroxyacetophenone	O
4-O	O
-	O
(	O
2-O	O
-	O
(	O
5-O	O
-syringoylapiosyl	O
)	O
glucoside	O
)	O
(	O
49	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
2000	O
)	O
.	O

Also	O
present	O
in	O
S.	B
officinalis	I
are	O
glycosides	O
of	O
neolignans	O
namely	O
1-hydroxypinoresinol	O
1-O	O
-glucoside	O
(	O
50	O
)	O
,	O
isolariciresinol	O
3α	O
-	O
O	O
-glucoside	O
(	O
51	O
)	O
and	O
2-	O
(	O
3-methoxy-4-glucosyloxyphenyl	O
)	O
-3-hydroxymethyl-5-	O
(	O
3-hydroxypropyl	O
)	O
-7-methoxy-2,3-dihydrobenzofuran	O
(	O
52	O
)	O
(	O
Wang	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
addition	O
,	O
two	O
related	O
isolariciresinol	O
compounds	O
feruloyl	O
-	O
secoisolariciresinol	O
12-methylmyristate	O
(	O
53	O
)	O
(	O
Powell	O
and	O
Plattner	O
,	O
1976	O
)	O
and	O
secoisolariciresinol	O
di	O
(	O
12-methylmyristate	O
)	O
(	O
54	O
)	O
(	O
Plattner	O
and	O
Powell	O
,	O
1978	O
)	O
and	O
a	O
structurally	O
related	O
compound	O
to	O
52	O
2-	O
(	O
3-methoxy-4-hydroxyphenyl	O
)	O
-5-	O
(	O
3-hydroxypropyl	O
)	O
-7-methoxybenzofuran-3-carbaldehyde	O
(	O
55	O
)	O
(	O
Yang	O
et	O
al.	O
,	O
1991	O
)	O
have	O
been	O
reported	O
in	O
the	O
seed	O
of	O
S.	B
plebeia	I
and	O
in	O
the	O
root	O
of	O
S.	B
miltiorrhiza	I
,	O
respectively	O
.	O

Compound	O
55	O
has	O
also	O
been	O
produced	O
synthetically	O
(	O
Kuo	O
and	O
Wu	O
,	O
1996	O
)	O
and	O
shown	O
to	O
be	O
a	O
novel	O
adenosine	O
A1	O
receptor	O
ligand	O
.	O

3	O
Flavonoids	O
Flavonoids	O
are	O
widely	O
distributed	O
in	O
species	O
of	O
Salvia	B
(	O
Sagdullaeva	O
and	O
Khazanovich	O
,	O
1972	O
;	O
Smirnova	O
et	O
al.	O
,	O
1974b	O
;	O
Adzet	O
et	O
al.	O
,	O
1987	O
;	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
,	O
being	O
mostly	O
present	O
as	O
flavones	O
,	O
flavonols	O
and	O
their	O
glycosides	O
(	O
see	O
Tables	O
3	O
and	O
4	O
)	O
.	O

The	O
6-hydroxylated	O
flavones	O
have	O
been	O
reported	O
to	O
be	O
of	O
particularly	O
taxonomic	O
significance	O
to	O
this	O
genus	O
(	O
Tomas	O
-	O
Barberan	O
and	O
Wollenweber	O
,	O
1990	O
)	O
.	O

3.1	O
Flavone	O
and	O
flavonol	O
aglycones	O
The	O
majority	O
of	O
flavonoids	O
are	O
flavones	O
of	O
apigenin	O
(	O
5,7,4′-trihydroxyflavone	O
)	O
(	O
56	O
)	O
and	O
luteolin	O
(	O
5,7,3′,4′-tetrahydroxyflavone	O
)	O
(	O
60	O
)	O
and	O
their	O
corresponding	O
6-hydroxylated	O
derivatives	O
.	O

The	O
methyl	O
ethers	O
of	O
flavones	O
are	O
widely	O
distributed	O
in	O
the	O
leaves	O
of	O
Salvia	B
or	O
in	O
the	O
exudate	O
from	O
aerial	O
parts	O
(	O
Wollenweber	O
,	O
1974	O
;	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

The	O
etherification	O
of	O
apigenin	O
seemed	O
to	O
occur	O
preferably	O
on	O
the	O
phenolic	O
7-OH	O
while	O
the	O
catechol	O
B	O
-	O
ring	O
of	O
luteolin	O
is	O
etherified	O
before	O
the	O
A	O
-	O
ring	O
.	O

Thus	O
apigenin	O
7-methyl	O
ether	O
(	O
genkwanin	O
)	O
(	O
57	O
)	O
and	O
7,4′-dimethyl	O
ether	O
(	O
59	O
)	O
are	O
common	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
while	O
the	O
4′-methyl	O
ether	O
(	O
acacetin	O
)	O
(	O
58	O
)	O
has	O
been	O
found	O
only	O
in	O
S.	B
nicolsoniana	I
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
and	O
S.	B
yosgadensis	I
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Likewise	O
,	O
luteolin	O
3′-methyl	O
ether	O
(	O
chrysoeriol	O
)	O
(	O
62	O
)	O
and	O
4′-methyl	O
ether	O
(	O
diosmetin	O
)	O
(	O
63	O
)	O
are	O
more	O
frequently	O
encountered	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
;	O
Topcu	O
et	O
al.	O
,	O
1995	O
)	O
,	O
followed	O
by	O
7-methyl	O
ether	O
(	O
61	O
)	O
and	O
7,3′,4′-trimethyl	O
ether	O
(	O
66	O
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
.	O

Luteolin	O
7,4′-dimethyl	O
ether	O
(	O
64	O
)	O
(	O
Miski	O
et	O
al.	O
,	O
1983	O
)	O
and	O
3′,4′-dimethyl	O
ether	O
(	O
65	O
)	O
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
have	O
only	O
been	O
reported	O
once	O
before	O
in	O
S.	B
palaestina	I
and	O
S.	B
nicolsoniana	I
,	O
respectively	O
.	O

The	O
6-hydroxyflavones	O
are	O
the	O
flavonoids	O
that	O
characterise	O
species	O
of	O
Salvia	B
.	O

They	O
include	O
a	O
variety	O
of	O
6-hydroxylated	O
apigenin	O
and	O
luteolin	O
derivatives	O
,	O
with	O
6-hydroxyapigenin-6,7-dimethyl	O
ether	O
(	O
cirsimaritin	O
)	O
(	O
69	O
)	O
,	O
6,7,4′-trimethyl	O
ether	O
(	O
salvigenin	O
)	O
(	O
72	O
)	O
,	O
and	O
6-hydroxyluteolin	O
6-methyl	O
ether	O
(	O
nepetin	O
or	O
eupafolin	O
)	O
(	O
75	O
)	O
,	O
6,7-dimethyl	O
ether	O
(	O
cirsiliol	O
)	O
(	O
77	O
)	O
,	O
6,7,4′-trimethyl	O
ether	O
(	O
eupatorin	O
)	O
(	O
81	O
)	O
and	O
6,7,3′,4′-tetramethyl	O
ether	O
(	O
83	O
)	O
being	O
the	O
most	O
common	O
(	O
Tomas	O
-	O
Lorente	O
et	O
al.	O
,	O
1988	O
;	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

6-Hydroxyapigenin	O
(	O
scutellarein	O
)	O
itself	O
(	O
67	O
)	O
was	O
only	O
detected	O
in	O
sage	B
extracts	O
by	O
HPLC	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
other	O
6-hydroxyapigenin	O
methyl	O
ethers	O
including	O
6-methyl	O
ether	O
(	O
hispidulin	O
)	O
(	O
68	O
)	O
,	O
6,4′-dimethyl	O
ether	O
(	O
pectolinarigenin	O
)	O
(	O
70	O
)	O
,	O
7,4′-dimethyl	O
ether	O
(	O
71	O
)	O
and	O
5,6,7,4′-tetramethyl	O
ether	O
(	O
5-methoxysalvigenin	O
)	O
(	O
73	O
)	O
were	O
reported	O
only	O
occasionally	O
,	O
as	O
were	O
the	O
6-hydroxyluteolin	O
7-methyl	O
ether	O
(	O
pedalitin	O
)	O
(	O
76	O
)	O
,	O
6,3′-dimethyl	O
ether	O
(	O
jaceosidin	O
)	O
(	O
78	O
)	O
,	O
7,4′-dimethyl	O
ether	O
(	O
nuchensin	O
)	O
(	O
79	O
)	O
,	O
6,7,3′-trimethyl	O
ether	O
(	O
cirsilineol	O
)	O
(	O
80	O
)	O
and	O
6,3′,4′-trimethyl	O
ether	O
(	O
eupatilin	O
)	O
(	O
82	O
)	O
.	O

Cirsimaritin	O
was	O
reported	O
to	O
have	O
a	O
high	O
anti	O
-	O
microbial	O
activity	O
against	O
several	O
bacteria	O
strains	O
(	O
Miski	O
et	O
al.	O
,	O
1983	O
)	O
while	O
hispidulin	O
possessed	O
antihepatotoxic	O
activity	O
(	O
Oshima	O
et	O
al.	O
,	O
1984	O
)	O
.	O

In	O
a	O
more	O
recent	O
report	O
(	O
Viola	O
et	O
al.	O
,	O
1998	O
)	O
,	O
the	O
sedative	O
-	O
depressant	O
property	O
for	O
cirsiliol	O
was	O
described	O
.	O

An	O
unusual	O
flavone	O
which	O
lacks	O
the	O
5-OH	O
group	O
,	O
namely	O
6,7,3′,4′-tetramethoxyflavone	O
(	O
74	O
)	O
,	O
was	O
described	O
by	O
Miski	O
et	O
al.	O
(	O
1983	O
)	O
.	O

The	O
8-hydroxylated	O
flavones	O
are	O
rare	O
in	O
Salvia	B
,	O
with	O
8-hydroxyapigenin	O
7-methyl	O
ether	O
(	O
salvitin	O
)	O
(	O
85	O
)	O
being	O
the	O
only	O
representative	O
found	O
in	O
S.	B
plebeia	I
(	O
Gupta	O
et	O
al.	O
,	O
1975	O
)	O
while	O
8-hydroxyapigenin	O
(	O
isoscutellarein	O
)	O
(	O
84	O
)	O
itself	O
was	O
detected	O
by	O
HPLC	O
in	O
sage	B
samples	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
.	O

The	O
four	O
dihydroflavones	O
that	O
have	O
been	O
described	O
to	O
date	O
in	O
Salvia	B
include	O
5-hydroxy-7-methoxyflavanone	O
(	O
86	O
)	O
(	O
Gonzalez	O
et	O
al.	O
,	O
1989	O
)	O
,	O
5,7-dihydroxy-4′-methoxyflavanone	O
(	O
isosakuranetin	O
or	O
narigenin-4′-methyl	O
ether	O
)	O
(	O
87	O
)	O
(	O
Pereda	O
-	O
Miranda	O
and	O
Delgado	O
,	O
1986	O
)	O
,	O
5,7,3′-trihydroxy-4′-methoxyflavanone	O
(	O
hesperetin	O
)	O
(	O
88	O
)	O
(	O
Cuvelier	O
et	O
al.	O
,	O
1996	O
)	O
and	O
5,3′-dihydroxy-7,4′-dimethoxyflavanone	O
(	O
89	O
)	O
.	O

The	O
last	O
mentioned	O
compound	O
was	O
also	O
found	O
to	O
possess	O
coronary	O
dilator	O
activity	O
(	O
Chen	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Flavonols	O
are	O
mostly	O
those	O
of	O
kaempferol	O
(	O
5,7,4′-trihydroxyflavonol	O
)	O
and	O
quercetin	O
(	O
5,7,3′,4′-tetrahydroxyflavonol	O
)	O
methyl	O
ethers	O
.	O

Kaempferol	O
(	O
90	O
)	O
itself	O
was	O
present	O
in	O
S.	B
farinacea	I
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
and	O
S.	B
folium	I
(	O
Tamas	O
et	O
al.	O
,	O
1986	O
)	O
while	O
quercetin	O
was	O
only	O
reported	O
in	O
S.	B
dorrii	I
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Kaempferol	O
3-methyl	O
ether	O
(	O
isokaempferide	O
)	O
(	O
91	O
)	O
,	O
3,7-dimethyl	O
ether	O
(	O
kumatakenin	O
)	O
(	O
92	O
)	O
and	O
quercetin	O
3-methyl	O
ether	O
(	O
94	O
)	O
,	O
3′-methyl	O
ether	O
(	O
isorhamnetin	O
)	O
(	O
95	O
)	O
,	O
3,3′-dimethyl	O
ether	O
(	O
96	O
)	O
and	O
3,7,4′-trimethyl	O
ether	O
(	O
ayanin	O
)	O
(	O
97	O
)	O
are	O
also	O
known	O
Salvia	B
constituents	O
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
;	O
Gökdil	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Kaempferol-3-methyl	O
ether	O
,	O
together	O
with	O
seven	O
other	O
flavones	O
were	O
identified	O
in	O
S.	B
yosgadensis	I
(	O
Topcu	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Quercetin	O
3,7,3′,4′-tetramethyl	O
ether	O
,	O
or	O
retusin	O
(	O
98	O
)	O
was	O
identified	O
by	O
TLC	O
in	O
S.	B
glutinosa	I
(	O
Wollenweber	O
,	O
1974	O
)	O
.	O

6-Hydroxylated	O
flavonols	O
are	O
mostly	O
confined	O
to	O
6-hydroxykaempferol	O
derivatives	O
and	O
include	O
6-hydroxykaempferol	O
3,6-dimethyl	O
ether	O
(	O
99	O
)	O
(	O
Gökdil	O
et	O
al.	O
,	O
1997	O
)	O
,	O
3,6,4′-trimethyl	O
ether	O
(	O
santin	O
)	O
(	O
100	O
)	O
(	O
Ulubelen	O
and	O
Tuzlaci	O
,	O
1990	O
)	O
and	O
interestingly	O
the	O
5,6-dimethyl	O
ether	O
(	O
101	O
)	O
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Compound	O
101	O
is	O
one	O
of	O
the	O
only	O
two	O
flavone	O
5-methyl	O
ethers	O
known	O
to	O
Salvia	B
species	I
,	O
the	O
other	O
being	O
6-hydroxygalangin	O
5,6-dimethyl	O
ether	O
(	O
102	O
)	O
found	O
in	O
S.	B
columbariae	I
(	O
Wollenweber	O
et	O
al.	O
,	O
1992	O
)	O
which	O
is	O
also	O
the	O
only	O
one	O
galangin	O
(	O
5,7-dihydroxyflavonol	O
)	O
compound	O
reported	O
in	O
Salvia	B
.	O

No	O
corresponding	O
6-hydroxyquercetin	O
derivatives	O
have	O
been	O
described	O
so	O
far	O
in	O
Salvia	B
.	O

3.2	O
Flavone	O
and	O
flavonol	O
glycosides	O
Flavone	O
O	O
-glycosides	O
are	O
apparently	O
common	O
in	O
Salvia	B
and	O
most	O
of	O
them	O
are	O
flavone	O
7-glycosides	O
represented	O
by	O
apigenin	O
7-glucoside	O
(	O
cosmosiin	O
)	O
(	O
103	O
)	O
,	O
luteolin	O
7-glucoside	O
(	O
cinaroside	O
)	O
(	O
110	O
)	O
and	O
their	O
corresponding	O
7-glucuronides	O
(	O
104	O
,	O
111	O
)	O
.	O

There	O
are	O
several	O
apigenins	O
glycosylated	O
with	O
two	O
or	O
more	O
sugars	O
and	O
among	O
these	O
are	O
apigenin	O
7,4′-diglucoside	O
(	O
105	O
)	O
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
,	O
apigenin	O
7-cellobioside	O
(	O
107	O
)	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
,	O
apigenin	O
7-rutinoside	O
(	O
108	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
)	O
and	O
apigenin	O
7-cellobioside-4′-glucoside	O
(	O
109	O
)	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
.	O

The	O
latter	O
compound	O
is	O
the	O
only	O
trisaccharide	O
of	O
flavones	O
and	O
together	O
with	O
apigenin	O
7,4′-diglucoside	O
are	O
the	O
only	O
two	O
apigenin	O
derivatives	O
in	O
which	O
two	O
phenolic	O
hydroxyl	O
groups	O
are	O
glycosylated	O
.	O

Apigenin	O
7,4′-diglucoside	O
occurred	O
as	O
a	O
co	O
-	O
pigment	O
in	O
the	O
blue	O
flower	O
of	O
S.	B
patens	I
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
.	O

Other	O
flavone	O
disaccharides	O
like	O
apigenin	O
7-cellobioside	O
and	O
apigenin	O
7-cellobioside-4′-glucoside	O
present	O
in	O
Salvia	B
flowers	O
could	O
very	O
well	O
serve	O
as	O
co	O
-	O
pigments	O
(	O
Veitch	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Compared	O
to	O
apigenin	O
,	O
luteolin	O
glycosides	O
appeared	O
to	O
be	O
more	O
common	O
.	O

Luteolin	O
3′-glucuronide	O
(	O
112	O
)	O
was	O
present	O
in	O
S.	B
officinalis	I
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
while	O
luteolin	O
4′-glucuronide	O
(	O
113	O
)	O
was	O
found	O
in	O
S.	B
lavandulifolia	I
along	O
with	O
other	O
flavonoids	O
(	O
Canigueral	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
3′-OH	O
of	O
luteolin	O
is	O
often	O
methylated	O
and	O
thus	O
chrysoeriol	O
glycosides	O
such	O
as	O
7-glucoside	O
(	O
114	O
)	O
,	O
7-glucuronide	O
(	O
115	O
)	O
and	O
7-xyloside	O
(	O
116	O
)	O
have	O
been	O
frequently	O
reported	O
in	O
Salvia	B
(	O
Smirnova	O
et	O
al.	O
,	O
1974b	O
;	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
.	O

Several	O
luteolin	O
disaccharides	O
have	O
been	O
identified	O
in	O
Salvia	B
and	O
these	O
include	O
luteolin	O
3′-glucoside-7-glucuronide	O
(	O
117	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
,	O
7-rutinoside	O
(	O
118	O
)	O
(	O
Kokkalou	O
and	O
Kapetanidis	O
,	O
1988	O
;	O
Tomas	O
-	O
Lorente	O
et	O
al.	O
,	O
1988	O
)	O
,	O
7-cellobioside	O
(	O
119	O
)	O
(	O
Abdalla	O
,	O
1984	O
)	O
and	O
5-rutinoside	O
(	O
127	O
)	O
(	O
Zarzuelo	O
et	O
al.	O
,	O
1995	O
)	O
.	O

The	O
6-hydroxyflavone	O
glycosides	O
,	O
like	O
their	O
aglycones	O
,	O
are	O
also	O
important	O
constituents	O
of	O
Salvia	B
.	O

While	O
6-hydroxyapigenin	O
glycosides	O
are	O
exclusively	O
those	O
of	O
6-methylated	O
derivatives	O
such	O
as	O
6-methoxyapigenin	O
7-glucoside	O
(	O
homoplantagenin	O
)	O
(	O
120	O
)	O
and	O
7-glucuronide	O
(	O
121	O
)	O
,	O
salvigenin	O
5-glucoside	O
(	O
122	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
;	O
Ulubelen	O
and	O
Topcu	O
,	O
1984	O
)	O
,	O
the	O
corresponding	O
6-hydroxyluteolin	O
glycosides	O
are	O
evenly	O
distributed	O
between	O
those	O
that	O
are	O
methylated	O
and	O
unmethylated	O
,	O
thus	O
6-hydroxyluteolin	O
7-glucoside	O
(	O
123	O
)	O
and	O
7-glucuronide	O
(	O
124	O
)	O
(	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
,	O
6-methoxyluteolin	O
7-glucoside	O
(	O
nepitrin	O
)	O
(	O
125	O
)	O
,	O
7-glucuronide	O
(	O
126	O
)	O
(	O
Abdalla	O
et	O
al.	O
,	O
1983	O
)	O
,	O
6-hydroxyluteolin	O
5-glucoside	O
(	O
128	O
)	O
(	O
Ulubelen	O
et	O
al.	O
,	O
1981	O
)	O
and	O
6-methoxyluteolin	O
7-methyl	O
ether-5-glucoside	O
(	O
129	O
)	O
(	O
Saleh	O
and	O
Sabri	O
,	O
1980	O
)	O
have	O
all	O
been	O
found	O
in	O
Salvia	B
.	O

Another	O
compound	O
,	O
identified	O
as	O
acetylpectolinarin	O
by	O
Smirnova	O
et	O
al.	O
(	O
1974a	O
)	O
,	O
could	O
likely	O
be	O
6-methoxyapigenin	O
4′-methyl	O
ether-7-rutinoside	O
,	O
as	O
its	O
acidic	O
hydrolysis	O
gave	O
pectolinarigenin	O
(	O
6-hydroxyapigenin	O
6,4′-dimethyl	O
ether	O
)	O
together	O
with	O
glucose	O
and	O
rhamnose	O
.	O

Flavone	O
C	O
-glycosides	O
are	O
widespread	O
in	O
nature	O
and	O
those	O
present	O
in	O
Salvia	B
are	O
mostly	O
those	O
of	O
apigenin	O
including	O
apigenin	O
8-C	O
-glucoside	O
(	O
vitexin	O
)	O
(	O
130	O
)	O
and	O
apigenin	O
8-C	O
-arabinoside	O
(	O
schaftoside	O
)	O
(	O
131	O
)	O
from	O
S.	B
blepharophylla	I
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
and	O
the	O
more	O
common	O
apigenin	O
6,8-di	O
-	O
C	O
-glucoside	O
(	O
vicenin-2	O
)	O
(	O
132	O
)	O
(	O
Abdalla	O
,	O
1984	O
;	O
Lu	O
and	O
Foo	O
,	O
2000	O
)	O
.	O

Luteolin	O
6,8-di	O
-	O
C	O
-glucoside	O
(	O
133	O
)	O
from	O
S.	B
aegypteacae	I
(	O
Abdalla	O
,	O
1984	O
)	O
is	O
the	O
only	O
example	O
of	O
luteolin	O
C	O
-glycosides	O
reported	O
.	O

The	O
flavonol	O
glycosides	O
found	O
in	O
Salvia	B
are	O
exclusively	O
those	O
of	O
the	O
3-glycosides	O
.	O

There	O
are	O
three	O
kaempferol	O
glycosides	O
known	O
but	O
they	O
cover	O
a	O
range	O
of	O
compounds	O
from	O
mono-	O
to	O
triglycoside	O
which	O
are	O
exemplified	O
by	O
kaempferol	O
3-glucoside	O
(	O
astragalin	O
)	O
(	O
134	O
)	O
in	O
S.	B
cavaleriei	I
(	O
Zhao	O
et	O
al.	O
,	O
1997	O
)	O
,	O
3-robinoside	O
(	O
141	O
)	O
and	O
3-	O
(	O
2,6-dirhamnosylglucoside	O
)	O
or	O
3-	O
(	O
2	O
G	O
-rhamnosylrutinoside	O
)	O
(	O
135	O
)	O
in	O
S.	B
farnacea	I
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
.	O

The	O
quercetin	O
glycosides	O
also	O
include	O
their	O
methyl	O
ethers	O
,	O
thus	O
in	O
addition	O
to	O
the	O
more	O
common	O
3-glucoside	O
(	O
isoquercitrin	O
)	O
(	O
137	O
)	O
,	O
3-glucuronide	O
(	O
miquelianin	O
)	O
(	O
138	O
)	O
and	O
3-robinoside	O
(	O
142	O
)	O
,	O
all	O
of	O
which	O
occur	O
in	O
S.	B
blepharophylla	I
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
,	O
rhamnetin	O
(	O
quercetin	O
7-methyl	O
ether	O
)	O
3-glucoside	O
(	O
139	O
)	O
from	O
S.	B
blepharophylla	I
(	O
Bisio	O
et	O
al.	O
,	O
1997	O
)	O
,	O
isorhamnetin	O
(	O
quercetin	O
3′-methyl	O
ether	O
)	O
3-galactoside	O
(	O
140	O
)	O
and	O
3-	O
(	O
2	O
G	O
-rhamnosylrutinoside	O
)	O
(	O
136	O
)	O
both	O
from	O
S.	B
farinacea	I
(	O
Kamel	O
et	O
al.	O
,	O
1992	O
)	O
have	O
also	O
been	O
reported	O
.	O

3.3	O
Anthocyanins	O
The	O
anthocyanins	O
are	O
particularly	O
abundant	O
in	O
the	O
red	O
or	O
purple	O
flowers	O
of	O
Salvia	B
(	O
Asen	O
,	O
1961	O
;	O
Shibata	O
et	O
al.	O
,	O
1966	O
;	O
Cornu	O
and	O
Paynot	O
,	O
1969	O
;	O
Albulescu	O
and	O
Gavrila	O
-	O
Dinu	O
,	O
1981	O
;	O
Zhang	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Salvia	B
anthocyanins	O
(	O
see	O
Table	O
5	O
)	O
were	O
first	O
studied	O
by	O
Willstätter	O
and	O
Bolton	O
(	O
1916	O
)	O
and	O
the	O
pigment	O
known	O
as	O
salvianin	O
was	O
identified	O
as	O
pelargonidin	O
diglucoside	O
with	O
caffeic	O
acid	O
and	O
malonic	O
acid	O
substituents	O
.	O

Subsequent	O
investigations	O
led	O
to	O
the	O
first	O
structural	O
assignment	O
of	O
salvianin	O
as	O
pelargonidin	O
3-	O
(	O
6-caffeoylglucoside	O
)	O
-5-glucoside	O
(	O
145	O
)	O
(	O
Birkofer	O
et	O
al.	O
,	O
1965	O
)	O
,	O
but	O
this	O
structure	O
was	O
later	O
revised	O
to	O
pelargonidin	O
3-	O
(	O
6-caffeoylglucoside	O
)	O
-5-	O
(	O
4,6-dimalonylglucoside	O
)	O
(	O
143	O
)	O
(	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
earlier	O
structure	O
was	O
revised	O
because	O
plant	O
pigments	O
were	O
extracted	O
with	O
alcohols	O
which	O
were	O
acidified	O
with	O
mineral	O
acids	O
causing	O
hydrolysis	O
of	O
the	O
labile	O
malonyl	O
moiety	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
)	O
.	O

The	O
mono-	O
and	O
bis	O
-	O
demalonyl	O
derivatives	O
of	O
salvianin	O
(	O
144	O
,	O
145	O
)	O
have	O
also	O
been	O
identified	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
;	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Furthermore	O
,	O
the	O
caffeoyl	O
group	O
in	O
salvianin	O
can	O
be	O
replaced	O
by	O
a	O
p	O
-coumaroyl	O
group	O
,	O
leading	O
to	O
the	O
corresponding	O
pelargonidin	O
3-	O
(	O
6-p	O
-coumaroylglucoside	O
)	O
-5-	O
(	O
4,6-dimalonylglucoside	O
)	O
or	O
monardaein	O
(	O
146	O
)	O
and	O
its	O
demalonated	O
derivatives	O
(	O
147	O
,	O
148	O
)	O
(	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
)	O
.	O

Likewise	O
,	O
the	O
pelargonidin	O
aglycone	O
can	O
be	O
replaced	O
by	O
cyanidin	O
,	O
delphinidin	O
and	O
even	O
malvidin	O
,	O
so	O
the	O
respective	O
cyanidin	O
and	O
delphinidin	O
3-	O
(	O
caffeoylglucoside	O
)	O
-5-	O
(	O
dimalonylglucosides	O
)	O
(	O
149	O
,	O
155	O
)	O
or	O
3-	O
(	O
p	O
-coumaroylglucoside	O
)	O
-5-	O
(	O
dimalonylglucosides	O
)	O
(	O
152	O
,	O
158	O
)	O
and	O
their	O
demalonated	O
derivatives	O
(	O
150	O
,	O
151	O
,	O
153	O
,	O
154	O
,	O
156	O
,	O
157	O
,	O
159	O
,	O
160	O
)	O
have	O
all	O
been	O
identified	O
in	O
scarlet	O
,	O
purple	O
and	O
blue	O
flowers	O
of	O
Salvia	B
(	O
Takeda	O
et	O
al.	O
,	O
1986	O
;	O
Tomas	O
-	O
Barberan	O
et	O
al.	O
,	O
1987	O
;	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Malvidin	O
3-	O
(	O
6-p	O
-coumaroylglucoside	O
)	O
-5-	O
(	O
6-malonylglucoside	O
)	O
(	O
salviamalvin	O
)	O
(	O
162	O
)	O
,	O
along	O
with	O
malonylawobanin	O
(	O
159	O
)	O
,	O
have	O
been	O
isolated	O
from	O
the	O
blue	O
flowers	O
of	O
S.	B
farinacea	I
(	O
Kondo	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Studies	O
on	O
the	O
distribution	O
pattern	O
of	O
anthocyanins	O
in	O
10	O
species	O
of	O
Salvia	B
showed	O
that	O
the	O
red	O
,	O
scarlet	O
and	O
pink	O
-	O
coloured	O
flower	O
varieties	O
contained	O
pelargonidin	O
,	O
the	O
blue	O
ones	O
the	O
delphinidin	O
and	O
the	O
amethyst-	O
and	O
grape	O
-	O
violet	O
-	O
colored	O
ones	O
were	O
the	O
cyanidin	O
derivatives	O
(	O
Haque	O
et	O
al.	O
,	O
1981	O
)	O
.	O

An	O
acetylated	O
anthocyanin	O
,	O
delphinidin	O
3-	O
(	O
6-p	O
-coumaroylglucoside	O
)	O
-5-	O
(	O
4-acetyl-6-malonylglucoside	O
)	O
(	O
161	O
)	O
together	O
with	O
its	O
parent	O
compound	O
have	O
been	O
reported	O
in	O
the	O
blue	O
petals	O
of	O
S.	B
uliginosa	I
(	O
Ishikawa	O
et	O
al.	O
,	O
1999	O
)	O
.	O

An	O
example	O
of	O
a	O
stable	O
complex	O
of	O
anthocyanins	O
with	O
flavonoids	O
as	O
co	O
-	O
pigments	O
is	O
a	O
blue	O
pigment	O
found	O
in	O
the	O
blue	O
flowers	O
of	O
S.	B
patens	I
.	O

The	O
pigment	O
is	O
composed	O
of	O
delphinidin	O
3-	O
(	O
6-p	O
-coumaroylglucoside	O
)	O
-5-	O
(	O
6-malonylglucoside	O
)	O
(	O
malonylawobanin	O
)	O
(	O
159	O
)	O
,	O
apigenin	O
7,4′-diglucoside	O
(	O
105	O
)	O
and	O
magnesium	O
cation	O
(	O
Takeda	O
et	O
al.	O
,	O
1994	O
)	O
.	O

3.4	O
Proanthocyanidins	O
Proanthocyanidins	O
,	O
or	O
condensed	O
tannins	O
,	O
have	O
been	O
reported	O
in	O
Salvia	B
species	I
(	O
Brieskorn	O
,	O
1949	O
;	O
Savin	O
and	O
Ivanic	O
,	O
1973	O
;	O
Murko	O
and	O
Baldasar	O
,	O
1977	O
)	O
.	O

The	O
so	O
-	O
called	O
salviatannin	O
(	O
164	O
)	O
has	O
only	O
been	O
investigated	O
with	O
UV	O
and	O
IR	O
and	O
deduced	O
to	O
be	O
based	O
on	O
catechin	O
(	O
163	O
)	O
which	O
gave	O
catechol	O
and	O
catechuic	O
acid	O
after	O
alkali	O
pyrolysis	O
(	O
Murko	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Later	O
,	O
salviatannin	O
was	O
also	O
detected	O
by	O
paper	O
chromatography	O
followed	O
by	O
spraying	O
color	O
reagent	O
(	O
Hu	O
,	O
1982	O
)	O
or	O
analysed	O
by	O
absorption	O
onto	O
hide	O
powder	O
followed	O
by	O
gravimetry	O
(	O
Karuza	O
-	O
Stojakovic	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
tannins	O
present	O
in	O
Salvia	B
intravenous	O
preparations	O
could	O
be	O
removed	O
by	O
passing	O
through	O
a	O
polyamide	O
column	O
(	O
Hu	O
,	O
1982	O
)	O
or	O
by	O
precipitation	O
with	O
5	O
%	O
gelatin	O
solutions	O
followed	O
by	O
filtration	O
(	O
Ren	O
et	O
al.	O
,	O
1986	O
)	O
.	O

4	O
Conclusion	O
Salvia	B
species	I
commonly	O
called	O
sages	B
are	O
widely	O
used	O
in	O
traditional	O
medicine	O
and	O
are	O
a	O
rich	O
source	O
of	O
polyphenolic	O
flavonoids	O
and	O
phenolic	O
acids	O
.	O

Flavones	O
,	O
flavonols	O
and	O
their	O
glycosides	O
constitute	O
the	O
majority	O
of	O
flavonoids	O
present	O
.	O

Malonylated	O
anthocyanins	O
are	O
abundant	O
in	O
red	O
to	O
blue	O
Salvia	B
flowers	O
while	O
the	O
presence	O
of	O
proanthocyanidins	O
(	O
condensed	O
tannins	O
)	O
in	O
Salvia	B
have	O
not	O
been	O
demonstrated	O
conclusively	O
.	O

The	O
phenolic	O
acids	O
are	O
exclusively	O
those	O
based	O
on	O
caffeic	O
acid	O
building	O
block	O
with	O
compounds	O
formed	O
from	O
two	O
to	O
four	O
or	O
more	O
caffeic	O
acid	O
units	O
.	O

The	O
depsides	O
formed	O
from	O
these	O
are	O
believed	O
to	O
be	O
responsible	O
for	O
the	O
many	O
biological	O
activities	O
in	O
the	O
sage	B
decoction	O
used	O
in	O
traditional	O
medicine	O
.	O

In	O
addition	O
to	O
the	O
dried	O
root	O
,	O
the	O
aerial	O
part	O
of	O
sage	B
has	O
been	O
shown	O
to	O
also	O
contain	O
a	O
rich	O
source	O
of	O
polar	O
polyphenols	O
including	O
flavonoids	O
and	O
phenolic	O
acids	O
which	O
could	O
potentially	O
be	O
used	O
also	O
as	O
herbal	O
materials	O
.	O

Daphnia	B
are	O
an	O
important	O
and	O
widely	O
studied	O
model	O
species	O
in	O
ecological	O
and	O
toxicological	O
studies	O
throughout	O
the	O
world	O
and	O
an	O
official	O
(	O
OECD	O
)	O
recommended	O
test	O
organism	O
.	O

Their	O
small	O
size	O
,	O
wide	O
distribution	O
and	O
easy	O
growth	O
conditions	O
make	O
this	O
organism	O
ideal	O
for	O
functional	O
genomics	O
based	O
studies	O
,	O
including	O
metabolic	O
profiling	O
and	O
transcriptomics	O
.	O

In	O
this	O
study	O
we	O
used	O
an	O
integrated	O
systems	O
approach	O
in	O
which	O
transcriptomic	O
,	O
metabolomic	O
and	O
energetic	O
responses	O
of	O
juvenile	O
(	O
4days	O
old	O
)	O
daphnids	B
were	O
evaluated	O
in	O
response	O
to	O
exposure	O
to	O
two	O
poly	O
aromatic	O
hydrocarbons	O
(	O
pyrene	O
and	O
fluoranthene	O
)	O
and	O
binary	O
mixtures	O
thereof	O
.	O

In	O
addition	O
,	O
these	O
responses	O
were	O
linked	O
to	O
responses	O
measured	O
during	O
chronic	O
experiments	O
(	O
21days	O
)	O
assessing	O
survival	O
,	O
growth	O
and	O
reproductive	O
traits	O
.	O

Custom	O
Daphnia	B
magna	I
microarrays	O
were	O
used	O
to	O
assess	O
transcriptomic	O
changes	O
.	O

Hierarchical	O
cluster	O
analysis	O
did	O
not	O
result	O
in	O
a	O
clear	O
distinction	O
between	O
the	O
single	O
compounds	O
suggesting	O
similar	O
molecular	O
modes	O
of	O
action	O
.	O

Cluster	O
analysis	O
with	O
both	O
the	O
single	O
compounds	O
and	O
the	O
binary	O
mixture	O
treatments	O
resulted	O
in	O
a	O
separation	O
of	O
treatments	O
based	O
on	O
differences	O
in	O
toxic	O
ratios	O
rather	O
than	O
component	O
differences	O
.	O

Changes	O
in	O
the	O
metabolic	O
profiles	O
of	O
the	O
organisms	O
were	O
investigated	O
using	O
Nuclear	O
Magnetic	O
Resonance	O
Spectroscopy	O
and	O
Gas	O
and	O
Liquid	O
Chromatography	O
Mass	O
Spectrometry	O
.	O

These	O
multivariate	O
metabolomic	O
datasets	O
were	O
analyzed	O
with	O
Principal	O
Components	O
Analysis	O
and	O
Partial	O
Least	O
Squares	O
Discriminant	O
Analysis	O
.	O

The	O
major	O
metabolite	O
changes	O
responsible	O
for	O
the	O
differences	O
observed	O
indicated	O
a	O
disturbance	O
in	O
aminosugar	O
metabolism	O
in	O
all	O
cases	O
.	O

The	O
study	O
demonstrates	O
the	O
potential	O
of	O
'	O
omics	O
'	O
to	O
provide	O
screening	O
tools	O
for	O
monitoring	O
of	O
the	O
freshwater	O
environment	O
--	O
in	O
invertebrate	B
species	O
--	O
which	O
is	O
reasonably	O
rapid	O
,	O
cost	O
-	O
effective	O
and	O
has	O
the	O
potential	O
to	O
greatly	O
increase	O
the	O
amount	O
of	O
information	O
obtained	O
from	O
aquatic	O
toxicology	O
testing	O
.	O

Scp160p	O
,	O
a	O
multiple	O
KH	O
-	O
domain	O
protein	O
,	O
is	O
a	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	B
Abstract	O
Scp160p	O
is	O
a	O
160	O
kDa	O
protein	O
in	O
the	O
yeast	B
Saccharomyces	B
cerevisiae	I
that	O
contains	O
14	O
repeats	O
of	O
the	O
hnRNP	O
K	O
-	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
and	O
demonstrates	O
significant	O
sequence	O
homology	O
to	O
a	O
family	O
of	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

As	O
a	O
first	O
step	O
towards	O
defining	O
the	O
function	O
of	O
Scp160p	O
,	O
we	O
have	O
characterized	O
the	O
subcellular	O
distribution	O
and	O
in	O
vivo	O
interactions	O
of	O
this	O
protein	O
.	O

Using	O
sucrose	O
gradient	O
fractionation	O
studies	O
we	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
predominantly	O
associated	O
with	O
polyribosomes	O
.	O

Furthermore	O
,	O
we	O
have	O
found	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
by	O
EDTA	O
in	O
the	O
form	O
of	O
a	O
large	O
complex	O
of	O
≥1300	O
kDa	O
that	O
is	O
sensitive	O
both	O
to	O
RNase	O
and	O
NaCl	O
.	O

Using	O
affinity	O
-	O
chromatography	O
to	O
isolate	O
these	O
complexes	O
,	O
we	O
have	O
identified	O
two	O
protein	O
components	O
other	O
than	O
Scp160p	O
:	O
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
confirms	O
these	O
complexes	O
to	O
be	O
mRNPs	O
.	O

The	O
presence	O
of	O
Bfr1p	O
is	O
intriguing	O
because	O
the	O
null	O
phenotype	O
for	O
this	O
gene	O
is	O
essentially	O
the	O
same	O
as	O
that	O
reported	O
for	O
scp160-null	O
cells	O
:	O
increased	O
cell	O
size	O
and	O
aberrant	O
DNA	O
content	O
.	O

These	O
results	O
demonstrate	O
that	O
Scp160p	O
associates	O
with	O
polyribosome	O
-	O
bound	O
mRNP	O
complexes	O
in	O
vivo	O
,	O
implicating	O
a	O
role	O
for	O
this	O
protein	O
in	O
one	O
or	O
more	O
levels	O
of	O
mRNA	O
metabolism	O
in	O
yeast	B
.	O

INTRODUCTION	O
Scp160p	O
is	O
a	O
1222	O
amino	O
acid	O
Saccharomyces	B
cerevisiae	I
protein	O
that	O
contains	O
14	O
copies	O
of	O
the	O
hnRNP	O
K	O
homology	O
(	O
KH	O
)	O
domain	O
,	O
a	O
highly	O
conserved	O
motif	O
found	O
in	O
many	O
proteins	O
involved	O
in	O
RNA	O
metabolism	O
(	O
1	O
)	O
.	O

KH	O
domain	O
-	O
containing	O
proteins	O
appear	O
to	O
have	O
diverse	O
functions	O
and	O
have	O
been	O
identified	O
in	O
all	O
kingdoms	O
of	O
life	O
,	O
including	O
the	O
ribosomal	O
protein	O
S3	O
from	O
Escherichia	B
coli	I
(	O
1	O
)	O
,	O
Mer1p	O
from	O
S.cerevisiae	B
,	O
a	O
meiosis	O
-	O
specific	O
splicing	O
factor	O
(	O
1	O
)	O
,	O
MEX-3	O
from	O
Caenorhabditis	B
elegans	I
,	O
presumably	O
involved	O
in	O
mRNA	O
localization	O
during	O
development	O
(	O
2	O
)	O
,	O
and	O
FMRP	O
,	O
the	O
fragile	O
-	O
X	O
mental	O
retardation	O
protein	O
in	O
humans	B
(	O
3	O
)	O
.	O

A	O
partial	O
clone	O
of	O
Scp160p	O
,	O
known	O
as	O
HX	O
,	O
was	O
one	O
of	O
the	O
first	O
multiple	O
-	O
KH	O
proteins	O
identified	O
(	O
1	O
)	O
.	O

Whole	O
cell	O
immunofluorescence	O
studies	O
have	O
demonstrated	O
that	O
Scp160p	O
localizes	O
to	O
the	O
cytoplasm	O
,	O
with	O
enrichment	O
around	O
the	O
nuclear	O
envelope	O
,	O
and	O
what	O
appears	O
to	O
be	O
the	O
endoplasmic	O
reticulum	O
(	O
3	O
)	O
.	O

Deletion	O
of	O
the	O
SCP160	O
locus	O
in	O
yeast	B
is	O
not	O
lethal	O
,	O
but	O
results	O
in	O
a	O
complex	O
phenotype	O
,	O
including	O
increased	O
DNA	O
content	O
per	O
cell	O
,	O
missegregation	O
of	O
genetic	O
markers	O
during	O
sporulation	O
,	O
and	O
abnormal	O
cell	O
morphology	O
,	O
including	O
increased	O
size	O
and	O
irregular	O
shape	O
(	O
4	O
)	O
.	O

Observation	O
of	O
this	O
phenotype	O
led	O
to	O
the	O
hypothesis	O
that	O
Scp160p	O
may	O
function	O
in	O
regulating	O
ploidy	O
during	O
cell	O
division	O
.	O

More	O
recently	O
,	O
Weber	O
and	O
colleagues	O
demonstrated	O
in	O
vitro	O
RNA	O
binding	O
activity	O
of	O
Scp160p	O
using	O
northwestern	O
blot	O
analyses	O
;	O
the	O
protein	O
was	O
found	O
to	O
bind	O
efficiently	O
to	O
ribohomopolymers	O
and	O
rRNA	O
,	O
but	O
not	O
to	O
tRNA	O
(	O
5	O
)	O
.	O

Cell	O
fractionation	O
studies	O
revealed	O
that	O
a	O
large	O
percentage	O
of	O
Scp160p	O
associates	O
with	O
membrane	O
-	O
pellets	O
,	O
and	O
is	O
released	O
by	O
treatment	O
with	O
either	O
10	O
mM	O
EDTA	O
or	O
500	O
mM	O
NaCl	O
(	O
5	O
)	O
.	O

While	O
these	O
authors	O
interpreted	O
these	O
results	O
to	O
suggest	O
that	O
the	O
nuclear	O
envelope	O
/	O
ER	O
localization	O
of	O
Scp160p	O
was	O
due	O
primarily	O
to	O
interactions	O
of	O
the	O
protein	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
clear	O
evidence	O
of	O
this	O
association	O
has	O
not	O
been	O
reported	O
(	O
5	O
)	O
.	O

Currently	O
,	O
the	O
relationship	O
between	O
the	O
phenotype	O
of	O
scp160	O
null	O
mutants	O
and	O
the	O
RNA	O
-	O
binding	O
activity	O
of	O
Scp160p	O
remains	O
unclear	O
.	O

Scp160p	O
demonstrates	O
significant	O
sequence	O
homology	O
(	O
~23	O
%	O
identity	O
and	O
~40	O
%	O
similarity	O
at	O
the	O
amino	O
acid	O
level	O
)	O
to	O
a	O
class	O
of	O
vertebrate	O
KH	O
-	O
domain	O
proteins	O
collectively	O
known	O
as	O
vigilins	O
.	O

First	O
identified	O
in	O
chicken	B
,	O
vigilin	O
homologues	O
have	O
now	O
been	O
found	O
in	O
human	B
(	O
6	O
)	O
,	O
Xenopus	B
laevis	I
(	O
7	O
)	O
,	O
Drosophila	B
melanogaster	I
(	O
8)	O
,	O
C.elegans	B
(	O
5	O
)	O
and	O
Schizosaccharomyces	B
pombe	I
.	O

While	O
all	O
of	O
the	O
vigilin	O
proteins	O
studied	O
to	O
date	O
are	O
reported	O
to	O
bind	O
nucleic	O
acid	O
,	O
both	O
the	O
type	O
of	O
nucleic	O
acid	O
bound	O
and	O
the	O
functional	O
significance	O
of	O
these	O
interactions	O
remain	O
unclear	O
.	O

For	O
example	O
,	O
Kruse	O
and	O
colleagues	O
reported	O
from	O
their	O
work	O
with	O
human	B
cells	O
in	O
culture	O
that	O
vigilin	O
may	O
be	O
involved	O
in	O
the	O
binding	O
and	O
transport	O
of	O
tRNA	O
(	O
9–11	O
)	O
.	O

In	O
contrast	O
,	O
Dodson	O
and	O
Shapiro	O
concluded	O
from	O
their	O
work	O
with	O
Xenopus	O
vigilin	O
that	O
,	O
in	O
response	O
to	O
estrogen	O
,	O
the	O
protein	O
bound	O
specifically	O
to	O
the	O
3′	O
UTR	O
of	O
vitellogenin	O
mRNA	O
(	O
7,12	O
)	O
,	O
potentially	O
stabilizing	O
the	O
message	O
(	O
13	O
)	O
.	O

Lastly	O
,	O
DDP1	O
,	O
the	O
Drosophila	O
homolog	O
of	O
vigilin	O
,	O
was	O
reported	O
recently	O
to	O
interact	O
with	O
the	O
dodeca	O
-	O
satellite	O
repeat	O
regions	O
of	O
centromeric	O
heterochromatin	O
in	O
embryonic	O
and	O
larval	O
cell	O
nuclei	O
,	O
suggesting	O
a	O
possible	O
role	O
for	O
this	O
protein	O
in	O
heterochromatin	O
structure	O
(	O
8)	O
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
begin	O
elucidating	O
the	O
function	O
of	O
Scp160p	O
in	O
yeast	B
by	O
characterizing	O
the	O
subcellular	O
distribution	O
and	O
macromolecular	O
interactions	O
of	O
this	O
protein	O
.	O

We	O
have	O
demonstrated	O
that	O
Scp160p	O
in	O
cytoplasmic	O
lysates	O
is	O
associated	O
predominantly	O
with	O
polyribosomes	O
,	O
and	O
that	O
following	O
treatment	O
with	O
EDTA	O
,	O
Scp160p	O
remains	O
in	O
an	O
RNase	O
/	O
NaCl	O
-	O
sensitive	O
complex	O
of	O
apparent	O
molecular	O
weight	O
approximately	O
≥1300	O
kDa	O
.	O

Affinity	O
purification	O
of	O
this	O
complex	O
revealed	O
the	O
presence	O
of	O
poly	O
(	O
A	O
)	O
-binding	O
protein	O
(	O
Pab1p	O
)	O
,	O
a	O
well	O
-	O
characterized	O
component	O
of	O
eukaryotic	O
mRNPs	O
(	O
14,15	O
)	O
.	O

Finally	O
,	O
a	O
third	O
abundant	O
protein	O
component	O
of	O
this	O
complex	O
was	O
identified	O
as	O
Bfr1p	O
,	O
a	O
protein	O
not	O
previously	O
reported	O
to	O
associate	O
with	O
mRNPs	O
.	O

While	O
the	O
function	O
of	O
Bfr1p	O
remains	O
unknown	O
,	O
gene	O
deletion	O
reportedly	O
leads	O
to	O
a	O
phenotype	O
remarkably	O
similar	O
to	O
that	O
of	O
scp160	O
deletion	O
(	O
16	O
)	O
.	O

These	O
results	O
indicate	O
a	O
role	O
for	O
Scp160p	O
in	O
mRNA	O
metabolism	O
in	O
yeast	B
,	O
and	O
by	O
extension	O
,	O
support	O
results	O
seen	O
with	O
Xenopus	O
vigilin	O
in	O
its	O
interactions	O
with	O
mRNA	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
data	O
reported	O
here	O
demonstrate	O
Scp160p	O
to	O
be	O
the	O
first	O
example	O
of	O
a	O
KH	O
-	O
domain	O
protein	O
that	O
functions	O
as	O
a	O
component	O
of	O
polyribosome	O
-	O
associated	O
mRNP	O
complexes	O
in	O
the	O
yeast	B
,	O
S.cerevisiae	B
.	O

MATERIALS	O
AND	O
METHODS	O
Plasmids	O
,	O
yeast	B
strains	O
and	O
culture	O
conditions	O
All	O
recombinant	O
DNA	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
techniques	O
and	O
utilized	O
E.coli	B
strain	O
XL1-Blue	O
(	O
Stratagene	O
)	O
.	O

The	O
yeast	B
strain	O
JFy1511	O
,	O
expressing	O
FLAG	O
–	O
Scp160p	O
,	O
was	O
derived	O
by	O
two	O
-	O
step	O
gene	O
replacement	O
from	O
strain	O
yJJ52	O
(	O
MATα	O
gal7Δ102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
;	O
generously	O
donated	O
by	O
Drs	O
Mark	O
Parthun	O
and	O
Judith	O
Jaehning	O
,	O
University	O
of	O
Colorado	O
Health	O
Sciences	O
Center	O
)	O
,	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
wild	O
-	O
type	O
SCP160	O
coding	O
sequence	O
was	O
obtained	O
by	O
PCR	O
amplification	O
from	O
a	O
genomic	O
DNA	O
preparation	O
from	O
yJFK1	O
(	O
MATα	O
gal7Δ102	O
ura3	O
-	O
52	O
trp1	O
-	O
289	O
ade1	O
lys1	O
leu2	O
-	O
3	O
,	O
112	O
ΔGAL80::URA3	O
)	O
,	O
using	O
a	O
16:1	O
mixture	O
of	O
Taq	O
(	O
Fisher	O
Biotech	O
)	O
and	O
Pfu	O
(	O
Stratagene	O
)	O
DNA	O
polymerases	O
and	O
the	O
following	O
primers	O
:	O
Scp160F1	O
(	O
5′-GCCGGTCGA	O
-	O
CTAACTGCAATGTCTGAAGAACAAACCGCTATTG-3′	O
)	O
and	O
Scp160R1	O
(	O
5′-GCGCGTCGACGAGCTTGTCTATCTT	O
-	O
CTTAAGG-3′	O
)	O
.	O

A	O
wild	O
-	O
type	O
SCP160	O
genomic	O
clone	O
,	O
containing	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
was	O
PCR	O
amplified	O
from	O
yJFK1	O
genomic	O
DNA	O
using	O
the	O
primers	O
Scp160F0	O
(	O
5′-GCCGAGCTCACACCAGCTTTGTCCTGG-3′	O
)	O
and	O
Scp160R2	O
(	O
5′-GCGCAAGCTTGTGCGGTA	O
-	O
TCCCAGTCTATG-3′	O
)	O
.	O

The	O
resultant	O
clone	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

The	O
N	O
-	O
terminal	O
FLAG	O
and	O
HA	O
tags	O
were	O
added	O
using	O
PCR	O
with	O
the	O
primers	O
ScpFLAGF1	O
(	O
5′-CCAT	O
-	O
TATAACTGCAATGGACTACAAGGACGACGACGACGAC	O
-	O
AAGATGTCTGAAGAACAAACCGCTATTG-3′	O
)	O
and	O
ScpHAF1	O
(	O
5′-CCCCCTCCTGTCGACATTATAACTGCAATGCACCA	O
-	O
TCACCATCACCATTCTGAAGAACAAACCGCTATTG-3′	O
)	O
respectively	O
.	O

For	O
integration	O
,	O
constructs	O
containing	O
the	O
1	O
kb	O
upstream	O
and	O
300	O
bp	O
downstream	O
sequence	O
were	O
subcloned	O
into	O
the	O
plasmid	O
YIplac211	O
(	O
17	O
)	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
HA	O
-	O
tagged	O
construct	O
was	O
subcloned	O
into	O
the	O
low	O
copy	O
number	O
plasmid	O
,	O
YCplac22	O
using	O
SacI	O
and	O
HindIII	O
restriction	O
sites	O
.	O

The	O
SCP160	O
deletion	O
construct	O
was	O
made	O
by	O
removal	O
of	O
a	O
3.4	O
kb	O
ApaI	O
–	O
KpnI	O
fragment	O
from	O
the	O
coding	O
region	O
of	O
this	O
construct	O
,	O
followed	O
by	O
treatment	O
with	O
Klenow	O
fragment	O
and	O
re	O
-	O
ligation	O
following	O
attachment	O
of	O
BamHI	O
linker	O
oligonucleotides	O
.	O

Genomic	O
integration	O
of	O
the	O
plasmid	O
sequences	O
and	O
subsequent	O
removal	O
of	O
the	O
endogenous	O
SCP160	O
allele	O
were	O
achieved	O
by	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
(	O
18	O
)	O
and	O
confirmed	O
by	O
PCR	O
.	O

The	O
N	O
-	O
terminally	O
HA	O
-	O
tagged	O
allele	O
of	O
BFR1	O
was	O
generated	O
by	O
PCR	O
-	O
amplifiction	O
of	O
the	O
BFR1	O
locus	O
from	O
wild	O
-	O
type	O
(	O
W303	O
)	O
yeast	B
genomic	O
DNA	O
using	O
the	O
primers	O
BFR1HAF1	O
(	O
5′-CCGCGGATCCATGTACC	O
-	O
CATACGACGTCCCAGACTACGCTATGTCCTCCCAAC	O
-	O
AACACAA-3′	O
)	O
and	O
BFR1HINDR1	O
(	O
5′-CCGCAAGCTTGTCG	O
-	O
ACTATTTCATATGCCACAGGAAACAG-3′	O
)	O
,	O
and	O
subcloned	O
into	O
YIPlac211	O
.	O

The	O
BFR1	O
promoter	O
region	O
was	O
PCR	O
-	O
amplified	O
in	O
a	O
similar	O
manner	O
using	O
the	O
primers	O
BFR1SACF1	O
(	O
5′-CCGCGAG	O
-	O
CTCAGCATTAAGCATTCACGAGC-3′	O
)	O
and	O
BFR1BAMR1	O
(	O
5′-CCGCGGATCCGGCAATGGCTGTGTTGTTAGA-3′	O
)	O
and	O
subcloned	O
into	O
the	O
appropriate	O
position	O
upstream	O
of	O
the	O
HA	O
–	O
Bfr1p	O
open	O
reading	O
frame	O
in	O
the	O
plasmid	O
backbone	O
.	O

The	O
entire	O
open	O
reading	O
frame	O
was	O
confirmed	O
by	O
dideoxy	O
sequencing	O
.	O

Finally	O
,	O
the	O
HA	O
–	O
BFR1	O
allele	O
was	O
substituted	O
into	O
the	O
yeast	B
genome	O
in	O
place	O
of	O
the	O
native	O
allele	O
using	O
linearization	O
with	O
SphI	O
and	O
standard	O
two	O
-	O
step	O
gene	O
replacement	O
techniques	O
.	O

All	O
yeast	B
transformations	O
and	O
culture	O
manipulations	O
were	O
performed	O
according	O
to	O
standard	O
protocols	O
as	O
described	O
elsewhere	O
(	O
19	O
)	O
.	O

Confirmation	O
of	O
genomic	O
integrations	O
All	O
genomic	O
integrations	O
were	O
confirmed	O
by	O
PCR	O
amplifications	O
from	O
purified	O
yeast	B
genomic	O
DNA	O
.	O

For	O
scp160	O
deletion	O
mutants	O
,	O
the	O
primers	O
Scp160PF	O
(	O
5′-GATTTCCTAACTTTCC	O
-	O
GTCTA-3′	O
)	O
and	O
Scp160R5	O
(	O
5′-GCGCAAGCTTCACCGCCTTATAACGAAGAC-3′	O
)	O
that	O
flanked	O
the	O
deleted	O
region	O
were	O
used	O
.	O

Similarly	O
,	O
epitope	O
tags	O
on	O
Scp160p	O
were	O
confirmed	O
by	O
PCR	O
using	O
primers	O
that	O
flanked	O
the	O
tag	O
sequence	O
.	O

Positive	O
clones	O
were	O
further	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
crude	O
cell	O
lysates	O
using	O
the	O
appropriate	O
anti	O
-	O
tag	O
antibodies	O
.	O

The	O
presence	O
of	O
HA	O
–	O
Bfr1p	O
in	O
cells	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
of	O
soluble	O
cell	O
lysates	O
using	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
.	O

Polyribosome	O
isolation	O
Polyribosomes	O
were	O
isolated	O
using	O
a	O
combination	O
of	O
protocols	O
described	O
by	O
Stansfield	O
and	O
colleagues	O
(	O
20	O
)	O
and	O
by	O
Dr	O
Maurice	O
Swanson	O
(	O
personal	O
communication	O
)	O
.	O

In	O
brief	O
,	O
a	O
100	O
ml	O
culture	O
of	O
yeast	B
was	O
grown	O
in	O
either	O
YEPD	O
or	O
Hartwell	O
synthetic	O
medium	O
,	O
to	O
early	O
-	O
log	O
phase	O
(	O
OD600	O
=	O
1.0	O
)	O
,	O
at	O
which	O
time	O
cyclohexamide	O
(	O
Sigma	O
)	O
was	O
added	O
directly	O
to	O
the	O
culture	O
to	O
a	O
final	O
concentration	O
of	O
100	O
µg	O
/	O
ml	O
.	O

The	O
culture	O
was	O
incubated	O
on	O
ice	O
for	O
15	O
min	O
,	O
and	O
cells	O
were	O
harvested	O
by	O
centrifugation	O
(	O
4000	O
r.p.m.	O
/	O
10	O
min	O
)	O
.	O

Following	O
two	O
washes	O
in	O
10	O
ml	O
of	O
water	O
containing	O
100	O
µg	O
/	O
ml	O
cyclohexamide	O
,	O
cells	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
1	O
ml	O
lysis	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7.2	O
,	O
50	O
mM	O
KCl	O
,	O
30	O
mM	O
MgCl2	O
,	O
5	O
mM	O
β	O
-	O
mercaptoethanol	O
,	O
200	O
µg	O
/	O
ml	O
cyclohexamide	O
,	O
2	O
µg	O
/	O
ml	O
aprotonin	O
,	O
1	O
mM	O
PMSF	O
,	O
0.5	O
µg	O
/	O
ml	O
leupeptin	O
,	O
2.9	O
µg	O
/	O
ml	O
E64	O
,	O
1	O
µg	O
/	O
ml	O
antipain	O
,	O
0.2	O
µg	O
/	O
ml	O
chymostatin	O
)	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
,	O
and	O
then	O
assayed	O
for	O
absorbance	O
at	O
260	O
nm	O
.	O

Approximately	O
12	O
OD260	O
units	O
were	O
loaded	O
onto	O
a	O
11	O
ml	O
15–45	O
%	O
sucrose	O
gradient	O
made	O
in	O
10	O
mM	O
Tris	O
,	O
pH	O
7.4	O
,	O
70	O
mM	O
NH4Cl	O
,	O
4	O
mM	O
MgOAc	O
,	O
using	O
a	O
Gradient	O
Master	O
automatic	O
system	O
,	O
and	O
the	O
gradient	O
was	O
centrifuged	O
in	O
a	O
SW41ti	O
rotor	O
(	O
Beckman	O
)	O
at	O
39	O
000	O
r.p.m	O
.	O

for	O
2.5	O
h.	O
0.5	O
ml	O
fractions	O
were	O
collected	O
using	O
an	O
Isco	O
gradient	O
fractionator	O
,	O
and	O
gradient	O
profiles	O
were	O
determined	O
by	O
monitoring	O
absorbance	O
at	O
254	O
nm	O
.	O

For	O
EDTA	O
controls	O
,	O
lysis	O
buffer	O
containing	O
5	O
mM	O
MgCl2	O
was	O
used	O
,	O
and	O
30	O
mM	O
EDTA	O
was	O
added	O
to	O
the	O
sample	O
before	O
loading	O
onto	O
the	O
gradient	O
.	O

Where	O
indicated	O
,	O
addition	O
of	O
50	O
U	O
/	O
ml	O
of	O
RNase	O
One	O
(	O
Promega	O
)	O
was	O
performed	O
prior	O
to	O
loading	O
the	O
sample	O
onto	O
the	O
gradient	O
.	O

Gel	O
filtration	O
chromatography	O
Gel	O
filtration	O
chromatography	O
was	O
performed	O
using	O
a	O
120	O
ml	O
Hi	O
-	O
Prep	O
S-300	O
Sephacryl	O
column	O
(	O
Pharmacia	O
)	O
with	O
a	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
,	O
attached	O
to	O
an	O
FPLC	O
system	O
(	O
Pharmacia	O
)	O
.	O

The	O
column	O
had	O
been	O
calibrated	O
previously	O
using	O
the	O
following	O
molecular	O
weight	O
standards	O
(	O
Sigma	O
)	O
:	O
blue	O
dextran	O
(	O
2000	O
kDa	O
)	O
,	O
thyroglobulin	O
(	O
669	O
kDa	O
)	O
,	O
apoferritin	O
(	O
443	O
kDa	O
)	O
,	O
alcohol	O
dehydrogenase	O
(	O
150	O
kDa	O
)	O
,	O
and	O
bovine	B
serum	O
albumin	O
(	O
66	O
kDa	O
)	O
.	O

Yeast	B
were	O
lysed	O
as	O
described	O
for	O
polyribosome	O
analysis	O
,	O
with	O
an	O
additional	O
clarification	O
by	O
passage	O
through	O
a	O
0.2	O
µm	O
syringe	O
-	O
tip	O
filter	O
(	O
Acrodisc	O
)	O
and	O
run	O
over	O
the	O
column	O
at	O
a	O
rate	O
of	O
0.5	O
ml	O
/	O
min	O
in	O
polyribosome	O
lysis	O
buffer	O
following	O
treatment	O
with	O
the	O
indicated	O
reagents	O
.	O

Fractions	O
(	O
2.0	O
ml	O
)	O
were	O
collected	O
,	O
from	O
which	O
12	O
µl	O
were	O
combined	O
with	O
sample	O
buffer	O
(	O
2	O
%	O
SDS	O
,	O
10	O
%	O
glycerol	O
,	O
100	O
mM	O
dithiothreitol	O
,	O
60	O
mM	O
Tris	O
pH	O
6.8	O
,	O
0.001	O
%	O
bromophenol	O
blue	O
)	O
and	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

α	O
-	O
FLAG	O
affinity	O
chromatography	O
For	O
most	O
experiments	O
,	O
one	O
liter	O
yeast	B
cultures	O
were	O
grown	O
to	O
early	O
log	O
-	O
phase	O
and	O
harvested	O
by	O
centrifugation	O
.	O

Cells	O
were	O
washed	O
twice	O
in	O
T75	O
buffer	O
(	O
25	O
mM	O
Tris	O
pH	O
7.5	O
,	O
75	O
mM	O
NaCl	O
)	O
and	O
then	O
were	O
lysed	O
by	O
vortex	O
agitation	O
with	O
an	O
equal	O
volume	O
of	O
glass	O
beads	O
in	O
4	O
ml	O
T75	O
buffer	O
containing	O
30	O
mM	O
EDTA	O
.	O

Lysate	O
was	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
,	O
and	O
centrifuged	O
for	O
10	O
min	O
at	O
3000	O
g	O
at	O
4	O
°	O
C	O
.	O

The	O
supernatant	O
was	O
again	O
transferred	O
to	O
a	O
clean	O
microfuge	O
tube	O
and	O
centrifuged	O
at	O
12	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
°	O
C	O
,	O
and	O
finally	O
passed	O
through	O
a	O
0.2	O
µm	O
syringe	O
filter	O
.	O

Lysate	O
was	O
then	O
pre	O
-	O
purified	O
by	O
running	O
over	O
the	O
S-300	O
gel	O
-	O
filtration	O
column	O
in	O
T75	O
buffer	O
,	O
with	O
pooling	O
of	O
the	O
void	O
volume	O
fractions	O
(	O
~10	O
ml	O
total	O
)	O
.	O

For	O
several	O
experiments	O
(	O
Fig.	O
5A	O
,	O
B	O
,	O
E	O
and	O
F	O
)	O
,	O
a	O
low	O
concentration	O
(	O
<	O
10	O
µg	O
/	O
ml	O
)	O
of	O
FLAG	O
peptide	O
(	O
N	O
-	O
DYKDDDDK	O
-	O
C	O
)	O
was	O
added	O
to	O
this	O
sample	O
.	O

This	O
void	O
material	O
was	O
then	O
loaded	O
onto	O
a	O
1	O
ml	O
M2	O
α	O
-	O
FLAG	O
column	O
(	O
Sigma	O
)	O
;	O
column	O
flow	O
-	O
through	O
was	O
passed	O
over	O
the	O
column	O
a	O
second	O
time	O
.	O

The	O
column	O
was	O
then	O
washed	O
extensively	O
with	O
75	O
ml	O
T75	O
buffer	O
;	O
material	O
bound	O
to	O
the	O
column	O
was	O
eluted	O
with	O
5	O
ml	O
T75	O
containing	O
184	O
mg	O
/	O
ml	O
FLAG	O
peptide	O
.	O

The	O
peptide	O
solution	O
was	O
allowed	O
to	O
incubate	O
on	O
the	O
column	O
for	O
20	O
min	O
prior	O
to	O
collection	O
of	O
the	O
first	O
1	O
ml	O
fraction	O
;	O
subsequent	O
fractions	O
were	O
collected	O
every	O
10	O
min	O
.	O

Samples	O
of	O
crude	O
material	O
,	O
S-300	O
void	O
,	O
α	O
-	O
FLAG	O
flow	O
-	O
through	O
,	O
first	O
and	O
last	O
wash	O
,	O
and	O
eluate	O
fractions	O
were	O
analyzed	O
by	O
western	O
blot	O
using	O
the	O
indicated	O
antibodies	O
.	O

For	O
Figure	O
5A	O
and	O
E	O
,	O
samples	O
of	O
first	O
and	O
last	O
wash	O
and	O
eluate	O
fractions	O
were	O
concentrated	O
,	O
run	O
on	O
SDS	O
–	O
PAGE	O
and	O
stained	O
with	O
colloidal	O
G250	O
Coomassie	O
.	O

Concentration	O
of	O
samples	O
Where	O
indicated	O
,	O
samples	O
were	O
concentrated	O
using	O
the	O
method	O
of	O
Traub	O
et	O
al.	O
(	O
21	O
)	O
.	O

400	O
µl	O
of	O
sample	O
were	O
transferred	O
to	O
a	O
microfuge	O
tube	O
,	O
and	O
combined	O
with	O
400	O
µl	O
of	O
methanol	O
,	O
and	O
100	O
µl	O
of	O
chloroform	O
.	O

Samples	O
were	O
then	O
vortexed	O
vigorously	O
,	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
12	O
000	O
g.	O

The	O
supernatant	O
was	O
discarded	O
,	O
leaving	O
the	O
interface	O
intact	O
,	O
and	O
an	O
additional	O
400	O
µl	O
of	O
methanol	O
was	O
added	O
to	O
each	O
tube	O
.	O

Samples	O
were	O
then	O
inverted	O
several	O
times	O
,	O
and	O
centrifuged	O
again	O
for	O
5	O
min	O
.	O

The	O
supernatant	O
was	O
discarded	O
,	O
and	O
the	O
protein	O
pellet	O
was	O
air	O
-	O
dried	O
and	O
resuspended	O
in	O
1	O
×	O
sample	O
buffer	O
.	O

Western	O
blot	O
analysis	O
Western	O
blot	O
analysis	O
was	O
performed	O
essentially	O
as	O
described	O
previously	O
(	O
19	O
)	O
.	O

Briefly	O
,	O
samples	O
to	O
be	O
analyzed	O
were	O
mixed	O
with	O
sample	O
buffer	O
,	O
boiled	O
,	O
electrophoresed	O
through	O
a	O
10	O
%	O
SDS	O
–	O
polyacrylamide	O
gel	O
,	O
and	O
electro	O
-	O
blotted	O
onto	O
nitrocellulose	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

FLAG	O
–	O
Scp160p	O
fusion	O
protein	O
was	O
detected	O
by	O
incubation	O
of	O
the	O
filter	O
with	O
mouse	B
M2	O
anti	O
-	O
FLAG	O
monoclonal	O
antibody	O
(	O
10	O
µg	O
/	O
ml	O
final	O
concentration	O
)	O
,	O
followed	O
by	O
HRP	O
-	O
conjugated	O
sheep	B
anti	O
-	O
mouse	B
secondary	O
antibody	O
(	O
Amersham	O
)	O
,	O
diluted	O
1:5000	O
as	O
per	O
the	O
manufacturer	O
's	O
instructions	O
,	O
and	O
ECL	O
reagent	O
(	O
Amersham	O
)	O
,	O
followed	O
by	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
.	O

HA	O
-	O
tagged	O
Scp160p	O
and	O
HA	O
-	O
tagged	O
Bfr1p	O
were	O
detected	O
using	O
the	O
12CA5	O
mAb	O
(	O
Boehringer	O
Mannheim	O
)	O
at	O
a	O
final	O
concentration	O
of	O
0.8	O
µg	O
/	O
ml	O
;	O
Pab1p	O
and	O
Pub1p	O
were	O
detected	O
using	O
1G1	O
mAb	O
at	O
1:5000	O
,	O
and	O
4C3	O
mAb	O
at	O
1:1000	O
,	O
respectively	O
,	O
both	O
generous	O
gifts	O
from	O
Dr	O
Maurice	O
Swanson	O
(	O
22,23	O
)	O
.	O

Where	O
appropriate	O
,	O
films	O
were	O
analyzed	O
by	O
scanning	O
densitometry	O
(	O
Molecular	O
Dynamics	O
)	O
,	O
and	O
quantitated	O
using	O
ImageQuant	O
software	O
(	O
Molecular	O
Dynamics	O
)	O
.	O

Colloidal	O
G250	O
coomassie	O
staining	O
Procedure	O
used	O
was	O
that	O
of	O
Neuhoff	O
(	O
24	O
)	O
.	O

Briefly	O
,	O
a	O
one	O
liter	O
stock	O
of	O
staining	O
solution	O
was	O
prepared	O
containing	O
1	O
g	O
Coomassie	O
brilliant	O
blue	O
G-250	O
(	O
Sigma	O
)	O
,	O
100	O
g	O
ammonium	O
sulfate	O
(	O
Sigma	O
)	O
,	O
and	O
11.76	O
ml	O
85	O
%	O
phosphoric	O
acid	O
(	O
Fisher	O
)	O
.	O

Following	O
SDS	O
–	O
PAGE	O
,	O
gels	O
were	O
fixed	O
in	O
40	O
%	O
methanol	O
,	O
10	O
%	O
acetic	O
acid	O
for	O
10	O
min	O
.	O

Gels	O
were	O
then	O
rinsed	O
several	O
times	O
in	O
water	O
,	O
then	O
stained	O
using	O
40	O
ml	O
of	O
the	O
stock	O
staining	O
solution	O
mixed	O
with	O
10	O
ml	O
methanol	O
,	O
for	O
2	O
h	O
at	O
room	O
temperature	O
.	O

Stain	O
was	O
then	O
poured	O
off	O
,	O
and	O
residual	O
stain	O
was	O
removed	O
by	O
rinsing	O
in	O
water	O
.	O

By	O
performing	O
a	O
standard	O
analysis	O
using	O
bovine	B
serum	O
albumin	O
,	O
the	O
stain	O
was	O
able	O
to	O
detect	O
~15	O
ng	O
total	O
protein	O
per	O
lane	O
.	O

Pichia	O
expression	O
system	O
An	O
N	O
-	O
terminally	O
HIS6	O
/	O
FLAG	O
-	O
tagged	O
allele	O
of	O
the	O
SCP160	O
coding	O
sequence	O
was	O
blunt	O
-	O
end	O
sub	O
-	O
cloned	O
into	O
the	O
BamHI	O
/	O
SnaBI	O
sites	O
of	O
the	O
Pichia	O
expression	O
vector	O
pPIC3.5	O
K	O
(	O
Invitrogen	O
)	O
.	O

The	O
construct	O
was	O
then	O
linearized	O
using	O
SalI	O
and	O
integrated	O
into	O
the	O
genome	O
of	O
the	O
Pichia	O
strain	O
GS115	O
(	O
Invitrogen	O
)	O
.	O

High	O
expression	O
transformants	O
were	O
selected	O
initially	O
on	O
histidine	O
-	O
deficient	O
medium	O
followed	O
by	O
selection	O
on	O
increasing	O
concentrations	O
of	O
G418	O
(	O
US	O
Biological	O
)	O
.	O

Crude	O
lysates	O
of	O
the	O
resultant	O
transformants	O
were	O
then	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
anti	O
-	O
FLAG	O
antibody	O
M2	O
,	O
and	O
the	O
best	O
expressing	O
strain	O
was	O
cultured	O
in	O
a	O
fermenter	O
,	O
harvested	O
,	O
and	O
lysed	O
by	O
agitation	O
with	O
glass	O
beads	O
.	O

To	O
purify	O
Scp160p	O
,	O
2	O
ml	O
of	O
crude	O
lysate	O
was	O
first	O
diluted	O
to	O
10	O
ml	O
with	O
25	O
mM	O
Tris	O
,	O
pH	O
7.5	O
,	O
1	O
M	O
NaCl	O
,	O
then	O
twice	O
passed	O
over	O
a	O
1	O
ml	O
α	O
-	O
FLAG	O
affinity	O
column	O
.	O

The	O
column	O
was	O
then	O
washed	O
with	O
75	O
ml	O
of	O
25	O
mM	O
Tris	O
,	O
pH	O
7.5	O
,	O
1	O
M	O
NaCl	O
,	O
and	O
then	O
eluted	O
with	O
184	O
µg	O
/	O
ml	O
FLAG	O
peptide	O
prepared	O
in	O
the	O
same	O
buffer	O
.	O

RESULTS	O
Expression	O
of	O
tagged	O
Scp160p	O
in	O
yeast	B
An	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
form	O
of	O
Scp160p	O
was	O
created	O
to	O
facilitate	O
detection	O
of	O
the	O
protein	O
in	O
cells	O
and	O
extracts	O
(	O
Fig.	O
1A	O
)	O
.	O

To	O
probe	O
functionality	O
of	O
this	O
fusion	O
protein	O
,	O
we	O
used	O
two	O
-	O
step	O
gene	O
replacement	O
(	O
18	O
)	O
to	O
substitute	O
the	O
modified	O
allele	O
into	O
the	O
SCP160	O
locus	O
of	O
haploid	O
yeast	B
,	O
and	O
then	O
tested	O
the	O
morphological	O
phenotype	O
of	O
the	O
resultant	O
cells	O
.	O

All	O
strains	O
were	O
confirmed	O
by	O
PCR	O
analysis	O
of	O
the	O
SCP160	O
locus	O
with	O
appropriate	O
primers	O
(	O
Materials	O
and	O
Methods	O
)	O
,	O
and	O
expression	O
of	O
the	O
tagged	O
protein	O
was	O
confirmed	O
by	O
western	O
blot	O
analysis	O
with	O
the	O
appropriate	O
antibody	O
(	O
M2αFLAG	O
)	O
(	O
Fig.	O
1B	O
)	O
.	O

In	O
all	O
cases	O
,	O
yeast	B
expressing	O
tagged	O
Scp160p	O
in	O
place	O
of	O
the	O
native	O
protein	O
appeared	O
indistinguishable	O
from	O
the	O
corresponding	O
wild	O
-	O
type	O
strains	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
also	O
deleted	O
almost	O
the	O
entire	O
SCP160	O
coding	O
region	O
from	O
the	O
genomes	O
of	O
these	O
yeast	B
strains	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
confirmed	O
the	O
expected	O
mutant	O
phenotype	O
(	O
data	O
not	O
shown	O
)	O
.	O

Scp160p	O
associates	O
with	O
polyribosomes	O
To	O
test	O
the	O
hypothesis	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
we	O
used	O
sucrose	O
gradient	O
ultracentrifugation	O
to	O
size	O
-	O
fractionate	O
subcellular	O
components	O
of	O
lysates	O
prepared	O
from	O
yeast	B
expressing	O
the	O
N	O
-	O
terminal	O
FLAG	O
-	O
tagged	O
Scp160p	O
protein	O
.	O

Western	O
blot	O
analyses	O
of	O
gradient	O
fractions	O
with	O
an	O
α	O
-	O
FLAG	O
antibody	O
(	O
M2	O
,	O
Boehringer	O
Mannheim	O
)	O
,	O
revealed	O
a	O
160	O
kDa	O
band	O
that	O
was	O
most	O
abundant	O
in	O
the	O
denser	O
fractions	O
,	O
consistent	O
with	O
the	O
location	O
of	O
polyribosomes	O
(	O
>	O
80S	O
)	O
(	O
Fig.	O
2A	O
,	O
solid	O
arrow	O
)	O
.	O

A	O
convenient	O
internal	O
control	O
for	O
these	O
gradients	O
was	O
provided	O
by	O
an	O
unknown	O
endogenous	O
yeast	B
cross	O
-	O
reacting	O
protein	O
at	O
~100	O
kDa	O
,	O
that	O
exemplified	O
the	O
migration	O
pattern	O
of	O
a	O
free	O
protein	O
,	O
appearing	O
only	O
in	O
the	O
upper	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig.	O
2A	O
,	O
open	O
arrow	O
)	O
.	O

To	O
determine	O
whether	O
the	O
migration	O
pattern	O
of	O
Scp160p	O
in	O
these	O
sucrose	O
gradients	O
truly	O
reflected	O
association	O
with	O
yeast	B
polyribosomes	O
,	O
lysates	O
were	O
pre	O
-	O
treated	O
with	O
either	O
30	O
mM	O
EDTA	O
or	O
50	O
U	O
/	O
ml	O
RNase	O
One	O
(	O
Promega	O
)	O
immediately	O
prior	O
to	O
sucrose	O
gradient	O
fractionation	O
.	O

EDTA	O
chelates	O
Mg2	O
+	O
cations	O
,	O
resulting	O
in	O
the	O
dissociation	O
of	O
the	O
small	O
and	O
large	O
ribosomal	O
subunits	O
,	O
reflected	O
in	O
gradient	O
profiles	O
(	O
OD254	O
)	O
by	O
the	O
disappearance	O
of	O
80S	O
monosomes	O
and	O
polyribosomes	O
along	O
with	O
a	O
marked	O
increase	O
in	O
the	O
abundance	O
of	O
free	O
ribosomal	O
subunits	O
(	O
Fig.	O
2B	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
the	O
greatest	O
intensity	O
of	O
FLAG	O
–	O
Scp160p	O
signal	O
was	O
seen	O
only	O
in	O
the	O
upper	O
-	O
most	O
fractions	O
of	O
the	O
gradient	O
(	O
Fig.	O
2B	O
)	O
.	O

Alternatively	O
,	O
pre	O
-	O
treatment	O
of	O
lysates	O
with	O
RNase	O
,	O
which	O
results	O
in	O
inter	O
-	O
ribosomal	O
severing	O
of	O
translating	O
messages	O
,	O
gave	O
rise	O
to	O
a	O
large	O
pool	O
of	O
single	O
80S	O
ribosomes	O
(	O
Fig.	O
2C	O
)	O
.	O

Again	O
,	O
FLAG	O
–	O
Scp160p	O
was	O
shifted	O
to	O
the	O
uppermost	O
fractions	O
of	O
these	O
gradients	O
.	O

Although	O
some	O
of	O
the	O
Scp160p	O
signal	O
was	O
detected	O
in	O
fractions	O
larger	O
than	O
40S	O
,	O
the	O
migration	O
pattern	O
of	O
the	O
100	O
kDa	O
cross	O
-	O
reacting	O
protein	O
in	O
these	O
experiments	O
indicated	O
that	O
RNase	O
treatment	O
caused	O
an	O
apparent	O
diffusion	O
of	O
material	O
in	O
the	O
upper	O
portion	O
of	O
the	O
gradient	O
.	O

Characterization	O
of	O
Scp160p	O
-	O
containing	O
complexes	O
following	O
EDTA	O
and	O
RNase	O
treatment	O
Gel	O
-	O
filtration	O
chromatography	O
was	O
used	O
to	O
determine	O
the	O
apparent	O
molecular	O
weight	O
of	O
Scp160p	O
following	O
its	O
release	O
from	O
polyribosomes	O
by	O
both	O
EDTA	O
and	O
RNase	O
treatment	O
.	O

Lysates	O
were	O
prepared	O
as	O
described	O
above	O
for	O
sucrose	O
gradient	O
analysis	O
,	O
but	O
were	O
instead	O
size	O
fractionated	O
over	O
a	O
Sephacryl	O
S-300	O
Hi	O
-	O
Prep	O
column	O
,	O
with	O
an	O
inclusion	O
cut	O
-	O
off	O
of	O
1300	O
kDa	O
.	O

As	O
expected	O
,	O
Scp160p	O
from	O
untreated	O
lysates	O
eluted	O
in	O
the	O
void	O
volume	O
,	O
confirming	O
its	O
association	O
with	O
large	O
complexes	O
,	O
ostensibly	O
polyribosomes	O
(	O
Fig.	O
3A	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
EDTA	O
treated	O
lysates	O
,	O
all	O
Scp160p	O
signal	O
was	O
still	O
detected	O
in	O
the	O
void	O
volume	O
,	O
indicating	O
it	O
remained	O
in	O
a	O
complex	O
of	O
>	O
1300	O
kDa	O
(	O
Fig.	O
3B	O
,	O
solid	O
arrow	O
)	O
.	O

In	O
contrast	O
,	O
limited	O
RNase	O
treatment	O
(	O
10	O
min	O
)	O
resulted	O
in	O
the	O
appearance	O
of	O
an	O
Scp160p	O
-	O
containing	O
species	O
of	O
~450	O
kDa	O
,	O
in	O
addition	O
to	O
a	O
fraction	O
still	O
visible	O
in	O
the	O
void	O
(	O
Fig.	O
3C	O
,	O
solid	O
arrow	O
)	O
.	O

More	O
extensive	O
RNase	O
treatment	O
(	O
30	O
min	O
)	O
led	O
to	O
complete	O
conversion	O
to	O
the	O
450	O
kDa	O
species	O
(	O
Fig.	O
3D	O
,	O
solid	O
arrow	O
)	O
.	O

Sequential	O
treatment	O
,	O
first	O
with	O
RNase	O
,	O
then	O
with	O
EDTA	O
,	O
also	O
resulted	O
in	O
a	O
450	O
kDa	O
species	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
all	O
components	O
of	O
this	O
apparent	O
450	O
kDa	O
complex	O
were	O
also	O
present	O
following	O
EDTA	O
treatment	O
alone	O
.	O

As	O
before	O
,	O
the	O
100	O
kDa	O
,	O
endogenous	O
α	O
-	O
FLAG	O
cross	O
-	O
reacting	O
protein	O
(	O
Fig.	O
3	O
,	O
open	O
arrows	O
)	O
served	O
as	O
a	O
convenient	O
internal	O
control	O
,	O
eluting	O
from	O
the	O
column	O
at	O
a	O
volume	O
consistent	O
with	O
its	O
expected	O
monomeric	O
size	O
.	O

To	O
characterize	O
further	O
the	O
stability	O
of	O
the	O
large	O
(	O
apparent	O
molecular	O
weight	O
>	O
1300	O
kDa	O
)	O
,	O
EDTA	O
-	O
resistant	O
complex	O
,	O
lysates	O
were	O
treated	O
with	O
increasing	O
concentrations	O
of	O
NaCl	O
prior	O
to	O
size	O
fractionation	O
(	O
Fig.	O
3	O
,	O
panels	O
E	O
,	O
F	O
and	O
G	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3E	O
,	O
at	O
75	O
mM	O
NaCl	O
,	O
the	O
large	O
complex	O
remained	O
intact	O
.	O

However	O
,	O
at	O
a	O
NaCl	O
concentration	O
of	O
150	O
mM	O
,	O
the	O
Scp160p	O
complex	O
was	O
partially	O
reduced	O
to	O
450	O
kDa	O
,	O
with	O
some	O
signal	O
still	O
remaining	O
in	O
the	O
void	O
(	O
Fig.	O
3F	O
,	O
solid	O
arrow	O
)	O
.	O

Following	O
treatment	O
with	O
1	O
M	O
NaCl	O
,	O
Scp160p	O
was	O
only	O
visible	O
as	O
the	O
450	O
kDa	O
species	O
(	O
Fig.	O
3	O
G	O
,	O
solid	O
arrow	O
)	O
.	O

The	O
fact	O
that	O
RNase	O
treatment	O
and	O
high	O
salt	O
both	O
generated	O
Scp160p	O
species	O
of	O
similar	O
apparent	O
molecular	O
weight	O
suggests	O
that	O
these	O
high	O
salt	O
concentrations	O
resulted	O
in	O
the	O
disassociation	O
of	O
RNA	O
,	O
and	O
perhaps	O
other	O
components	O
,	O
from	O
Scp160p	O
.	O

Pab1p	O
and	O
Bfr1p	O
are	O
present	O
in	O
EDTA	O
-	O
resistant	O
Scp160p	O
-	O
containing	O
complexes	O
To	O
determine	O
if	O
the	O
>	O
1300	O
kDa	O
Scp160p	O
-	O
containing	O
complexes	O
remaining	O
after	O
EDTA	O
treatment	O
were	O
mRNPs	O
,	O
we	O
assayed	O
for	O
the	O
presence	O
of	O
the	O
yeast	B
poly	O
(	O
A	O
)	O
binding	O
protein	O
,	O
Pab1p	O
,	O
following	O
α	O
-	O
FLAG	O
affinity	O
purification	O
as	O
illustrated	O
in	O
Figure	O
4	O
.	O

Pab1p	O
is	O
an	O
abundant	O
and	O
well	O
-	O
characterized	O
component	O
of	O
mRNP	O
complexes	O
in	O
yeast	B
,	O
as	O
well	O
as	O
higher	O
eukaryotes	O
(	O
14,15,25	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
5A	O
and	O
B	O
,	O
Pab1p	O
did	O
co	O
-	O
purify	O
with	O
FLAG	O
–	O
Scp160p	O
;	O
moreover	O
,	O
treatment	O
with	O
RNase	O
immediately	O
prior	O
to	O
FLAG	O
-	O
purification	O
completely	O
abolished	O
this	O
interaction	O
(	O
Fig.	O
5C	O
)	O
,	O
indicating	O
an	O
RNA	O
-	O
dependant	O
association	O
between	O
these	O
two	O
proteins	O
.	O

We	O
also	O
probed	O
the	O
isolated	O
complexes	O
for	O
the	O
presence	O
of	O
another	O
abundant	O
mRNP	O
-	O
component	O
protein	O
,	O
Pub1p	O
(	O
23,26	O
)	O
.	O

Pub1p	O
,	O
as	O
opposed	O
to	O
Pab1p	O
,	O
is	O
not	O
reported	O
to	O
associate	O
with	O
polyribosomes	O
,	O
and	O
is	O
hypothesized	O
to	O
bind	O
a	O
pool	O
of	O
non	O
-	O
translatable	O
mRNAs	O
(	O
23	O
)	O
.	O

As	O
predicted	O
,	O
Pub1p	O
did	O
not	O
co	O
-	O
purify	O
with	O
Scp160p	O
(	O
Fig.	O
5D	O
)	O
.	O

The	O
absence	O
of	O
Pub1p	O
in	O
Scp160p	O
-	O
containing	O
complexes	O
served	O
as	O
a	O
negative	O
control	O
,	O
demonstrating	O
that	O
abundant	O
RNA	O
-	O
binding	O
proteins	O
did	O
not	O
co	O
-	O
purify	O
non	O
-	O
specifically	O
by	O
this	O
protocol	O
.	O

In	O
addition	O
,	O
we	O
performed	O
mock	O
purifications	O
using	O
lysates	O
from	O
yeast	B
expressing	O
the	O
wild	O
-	O
type	O
allele	O
of	O
SCP160	O
without	O
the	O
FLAG	O
epitope	O
(	O
Fig.	O
5F	O
)	O
,	O
or	O
with	O
an	O
unrelated	O
FLAG	O
-	O
tagged	O
protein	O
,	O
human	B
galactose	O
1-phosphate	O
uridylyltransferase	O
(	O
GALT	O
)	O
(	O
Fig.	O
5	O
G	O
,	O
lower	O
panel	O
)	O
.	O

In	O
neither	O
case	O
did	O
Pab1p	O
bind	O
and	O
elute	O
from	O
the	O
FLAG	O
affinity	O
column	O
.	O

Finally	O
,	O
no	O
bands	O
were	O
visible	O
by	O
colloidal	O
G250	O
Coomassie	O
staining	O
of	O
samples	O
from	O
the	O
mock	O
(	O
wild	O
-	O
type	O
)	O
preparations	O
(	O
Fig.	O
5E	O
)	O
,	O
further	O
demonstrating	O
the	O
specificity	O
of	O
this	O
procedure	O
.	O

By	O
colloidal	O
G250	O
Coomassie	O
staining	O
(	O
Materials	O
and	O
Methods	O
)	O
of	O
the	O
FLAG	O
-	O
purified	O
complex	O
,	O
we	O
observed	O
in	O
addition	O
to	O
Scp160p	O
,	O
two	O
major	O
bands	O
,	O
at	O
~70	O
kDa	O
and	O
~55	O
kDa	O
,	O
which	O
ostensibly	O
represent	O
co	O
-	O
purifying	O
proteins	O
(	O
Fig.	O
5A	O
,	O
bottom	O
panel	O
)	O
.	O

Western	O
blot	O
analysis	O
suggested	O
that	O
the	O
~70	O
kDa	O
species	O
is	O
Pab1p	O
.	O

To	O
identify	O
the	O
55	O
kDa	O
protein	O
,	O
that	O
band	O
was	O
excised	O
from	O
the	O
gel	O
,	O
and	O
sent	O
to	O
the	O
Keck	O
microchemical	O
facility	O
at	O
Yale	O
University	O
for	O
analysis	O
by	O
in	O
gel	O
tryptic	O
digestion	O
,	O
followed	O
by	O
MALDI	O
-	O
mass	O
spectrometry	O
.	O

The	O
results	O
of	O
these	O
analyses	O
clearly	O
identified	O
the	O
unknown	O
protein	O
as	O
Bfr1p	O
.	O

To	O
confirm	O
this	O
result	O
,	O
an	O
N	O
-	O
terminal	O
HA	O
tag	O
was	O
engineered	O
onto	O
the	O
genomic	O
BFR1	O
locus	O
in	O
strains	O
expressing	O
FLAG	O
-	O
tagged	O
or	O
wild	O
-	O
type	O
Scp160p	O
.	O

Scp160p	O
complexes	O
were	O
then	O
isolated	O
from	O
both	O
of	O
these	O
strains	O
using	O
the	O
protocol	O
described	O
above	O
.	O

As	O
seen	O
in	O
Figure	O
6	O
,	O
an	O
HA	O
-	O
tagged	O
protein	O
of	O
~55	O
kDa	O
(	O
center	O
panel	O
)	O
appears	O
in	O
α	O
-	O
FLAG	O
column	O
elutions	O
only	O
when	O
FLAG	O
–	O
Scp160p	O
is	O
also	O
present	O
(	O
top	O
panel	O
)	O
.	O

No	O
signal	O
is	O
visible	O
in	O
mock	O
purifications	O
of	O
extracts	O
where	O
Scp160p	O
is	O
not	O
FLAG	O
-	O
tagged	O
(	O
bottom	O
panel	O
)	O
.	O

Monomeric	O
Scp160p	O
migrates	O
as	O
a	O
~450	O
kDa	O
protein	O
under	O
native	O
conditions	O
As	O
a	O
first	O
step	O
to	O
characterize	O
the	O
post	O
RNase	O
/	O
NaCl	O
450	O
kDa	O
Scp160p	O
species	O
we	O
compared	O
it	O
with	O
Scp160p	O
over	O
-	O
expressed	O
and	O
purified	O
from	O
an	O
exogenous	O
host	O
,	O
the	O
yeast	B
Pichia	B
pastoris	I
.	O

The	O
purified	O
N	O
-	O
terminal	O
FLAG	O
/	O
hexahistidine	O
-	O
tagged	O
Scp160p	O
was	O
run	O
over	O
an	O
S300	O
gel	O
filtration	O
column	O
;	O
2	O
ml	O
fractions	O
were	O
collected	O
and	O
analyzed	O
by	O
α	O
-	O
FLAG	O
western	O
blot	O
.	O

As	O
seen	O
in	O
Figure	O
7A	O
,	O
purified	O
Scp160p	O
eluted	O
at	O
a	O
volume	O
consistent	O
with	O
a	O
>	O
443	O
kDa	O
protein	O
.	O

To	O
confirm	O
that	O
no	O
other	O
proteins	O
were	O
associated	O
with	O
the	O
purified	O
Scp160p	O
,	O
12	O
µl	O
of	O
the	O
protein	O
was	O
run	O
on	O
SDS	O
–	O
PAGE	O
and	O
subjected	O
to	O
colloidal	O
G250	O
Coomassie	O
staining	O
before	O
loading	O
on	O
the	O
S-300	O
column	O
(	O
Fig.	O
7B	O
)	O
.	O

As	O
shown	O
,	O
no	O
bands	O
other	O
than	O
Scp160p	O
were	O
visible	O
.	O

Several	O
KH	O
-	O
domain	O
proteins	O
,	O
including	O
Sam68	O
and	O
FMRP	O
,	O
have	O
been	O
reported	O
to	O
form	O
homodimers	O
in	O
vivo	O
(	O
27	O
)	O
.	O

Therefore	O
,	O
we	O
explored	O
the	O
possibility	O
that	O
the	O
~450	O
kDa	O
Scp160p	O
species	O
might	O
contain	O
two	O
or	O
more	O
copies	O
of	O
Scp160p	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
yeast	B
expressing	O
FLAG	O
–	O
Scp160p	O
were	O
transfected	O
with	O
a	O
centromeric	O
plasmid	O
,	O
YCplac22–HA	O
–	O
Scp160p	O
,	O
encoding	O
a	O
distinct	O
,	O
HA	O
-	O
tagged	O
allele	O
of	O
the	O
protein	O
.	O

The	O
functionality	O
of	O
this	O
tagged	O
protein	O
had	O
previously	O
been	O
demonstrated	O
by	O
polyribosome	O
association	O
as	O
well	O
as	O
complementation	O
of	O
the	O
null	O
morphological	O
phenotype	O
in	O
cells	O
expressing	O
only	O
HA	O
–	O
Scp160p	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
seen	O
in	O
Figure	O
7C	O
,	O
when	O
yeast	B
co	O
-	O
expressing	O
the	O
two	O
alleles	O
were	O
lysed	O
and	O
the	O
FLAG	O
-	O
tagged	O
protein	O
was	O
isolated	O
as	O
described	O
above	O
,	O
no	O
HA	O
–	O
Scp160p	O
co	O
-	O
purified	O
with	O
the	O
FLAG	O
–	O
Scp160p	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
Scp160p	O
does	O
not	O
form	O
homo	O
-	O
dimers	O
or	O
higher	O
-	O
order	O
multimers	O
in	O
vivo	O
,	O
and	O
that	O
the	O
~450	O
kDa	O
species	O
of	O
Scp160p	O
observed	O
is	O
simply	O
the	O
monomeric	O
protein	O
.	O

DISCUSSION	O
The	O
data	O
presented	O
here	O
demonstrate	O
two	O
main	O
points	O
regarding	O
the	O
biochemical	O
associations	O
and	O
function	O
of	O
Scp160p	O
in	O
yeast	B
.	O

First	O
,	O
the	O
sucrose	O
gradient	O
fractionation	O
data	O
clearly	O
demonstrate	O
that	O
Scp160p	O
exists	O
primarily	O
associated	O
with	O
large	O
complexes	O
,	O
likely	O
to	O
be	O
polyribosomes	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
time	O
a	O
vigilin	O
family	O
member	O
has	O
been	O
shown	O
to	O
associate	O
with	O
polyribosomes	O
in	O
this	O
manner	O
.	O

Interestingly	O
,	O
Weber	O
and	O
colleagues	O
did	O
not	O
observe	O
sucrose	O
gradient	O
fractionation	O
data	O
consistent	O
with	O
polyribosome	O
association	O
of	O
Scp160p	O
(	O
5	O
)	O
.	O

These	O
authors	O
hypothesized	O
that	O
Scp160p	O
associates	O
only	O
with	O
membrane	O
-	O
bound	O
polyribosomes	O
,	O
and	O
that	O
Scp160p	O
is	O
not	O
found	O
complexed	O
with	O
cytosolic	O
polyribosomes	O
(	O
5	O
)	O
.	O

Our	O
data	O
do	O
not	O
support	O
this	O
hypothesis	O
,	O
since	O
unlike	O
Weber	O
and	O
colleagues	O
,	O
we	O
were	O
able	O
to	O
detect	O
significant	O
amounts	O
of	O
Scp160p	O
associated	O
with	O
polyribosomes	O
without	O
using	O
detergents	O
during	O
preparation	O
.	O

There	O
are	O
several	O
possible	O
explanations	O
for	O
this	O
discrepancy	O
.	O

First	O
,	O
the	O
lysate	O
buffer	O
utilized	O
by	O
that	O
group	O
contained	O
100	O
mM	O
NaCl	O
,	O
whereas	O
our	O
buffer	O
contained	O
50	O
mM	O
KCl	O
.	O

Our	O
data	O
shown	O
in	O
Figure	O
3	O
suggest	O
that	O
100	O
mM	O
NaCl	O
may	O
have	O
caused	O
an	O
instability	O
in	O
the	O
Scp160p	O
–	O
RNA	O
interaction	O
,	O
leading	O
to	O
release	O
from	O
polyribosomes	O
during	O
their	O
procedure	O
.	O

Secondly	O
,	O
Weber	O
's	O
lysate	O
buffer	O
reportedly	O
contained	O
heparin	O
to	O
inhibit	O
ribonucleases	O
;	O
a	O
number	O
of	O
reports	O
(	O
28,29	O
)	O
suggest	O
that	O
heparin	O
can	O
disrupt	O
RNA	O
–	O
protein	O
interactions	O
.	O

Although	O
we	O
have	O
not	O
in	O
the	O
past	O
included	O
heparin	O
in	O
any	O
of	O
our	O
experiments	O
,	O
we	O
have	O
observed	O
disruption	O
of	O
the	O
polyribosome	O
association	O
in	O
buffer	O
containing	O
residual	O
diethylpyrocarbonate	O
,	O
another	O
inhibitor	O
of	O
ribonucleases	O
(	O
data	O
not	O
shown	O
)	O
.	O

Second	O
,	O
our	O
data	O
provide	O
compelling	O
evidence	O
that	O
Scp160p	O
is	O
released	O
from	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
complex	O
.	O

Since	O
Scp160p	O
does	O
not	O
remain	O
associated	O
with	O
either	O
single	O
ribosomes	O
or	O
ribosomal	O
subunits	O
following	O
treatment	O
with	O
EDTA	O
or	O
RNase	O
,	O
it	O
seems	O
unlikely	O
that	O
Scp160p	O
is	O
a	O
constitutive	O
component	O
of	O
the	O
translational	O
machinery	O
.	O

Partial	O
purification	O
of	O
the	O
EDTA	O
-	O
resistant	O
Scp160p	O
complexes	O
allowed	O
us	O
to	O
demonstrate	O
the	O
presence	O
of	O
Pab1p	O
but	O
not	O
Pub1p	O
in	O
these	O
preparations	O
,	O
which	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
mRNP	O
complexes	O
.	O

Previously	O
,	O
Scp160p	O
had	O
been	O
shown	O
to	O
bind	O
ribohomopolymers	O
and	O
rRNA	O
in	O
vitro	O
,	O
although	O
the	O
in	O
vivo	O
nucleic	O
acid	O
targets	O
of	O
Scp160p	O
were	O
unknown	O
(	O
5	O
)	O
.	O

The	O
presence	O
of	O
Pab1p	O
in	O
RNase	O
-	O
sensitive	O
Scp160p	O
complexes	O
indicates	O
that	O
Scp160p	O
is	O
primarily	O
bound	O
to	O
polyadenylated	O
RNAs	O
.	O

Whether	O
or	O
not	O
Scp160p	O
binds	O
only	O
specific	O
sets	O
of	O
mRNAs	O
will	O
be	O
the	O
subject	O
of	O
future	O
studies	O
.	O

In	O
addition	O
to	O
Scp160p	O
and	O
Pab1p	O
,	O
we	O
have	O
identified	O
a	O
third	O
component	O
of	O
the	O
complex	O
,	O
the	O
protein	O
Bfr1p	O
.	O

The	O
gene	O
,	O
BFR1	O
,	O
was	O
originally	O
identified	O
in	O
a	O
screen	O
for	O
high	O
-	O
copy	O
suppressors	O
of	O
Brefeldin	O
-	O
A	O
induced	O
lethality	O
,	O
suggesting	O
a	O
role	O
in	O
the	O
secretory	O
pathway	O
(	O
16	O
)	O
.	O

Interestingly	O
,	O
however	O
,	O
bfr1	O
null	O
mutants	O
do	O
not	O
demonstrate	O
any	O
defects	O
in	O
the	O
secretory	O
pathway	O
,	O
but	O
rather	O
display	O
similar	O
phenotypes	O
to	O
scp160	O
null	O
mutants	O
,	O
most	O
notably	O
increased	O
ploidy	O
and	O
increased	O
cell	O
size	O
(	O
16	O
)	O
.	O

It	O
is	O
therefore	O
unclear	O
whether	O
Bfr1p	O
is	O
capable	O
of	O
functioning	O
in	O
both	O
RNA	O
metabolism	O
and	O
secretion	O
directly	O
,	O
or	O
if	O
the	O
Scp160p	O
–	O
Bfr1p	O
complex	O
regulates	O
the	O
expression	O
of	O
one	O
or	O
more	O
secretory	O
genes	O
at	O
the	O
post	O
-	O
transcriptional	O
level	O
.	O

Additionally	O
,	O
two	O
-	O
hybrid	O
analysis	O
indicated	O
an	O
interaction	O
of	O
Bfr1p	O
with	O
the	O
protein	O
Bbp1p	O
,	O
a	O
component	O
of	O
the	O
mitotic	O
spindle	O
apparatus	O
(	O
30	O
)	O
.	O

While	O
Bbp1p	O
is	O
an	O
essential	O
gene	O
,	O
overexpression	O
leads	O
to	O
a	O
phenotype	O
similar	O
to	O
both	O
bfr1	O
and	O
scp160	O
null	O
strains	O
(	O
30	O
)	O
.	O

Future	O
work	O
will	O
address	O
the	O
functional	O
relationship	O
between	O
Scp160p	O
and	O
Bfr1p	O
including	O
the	O
possibility	O
that	O
these	O
proteins	O
represent	O
a	O
regulatory	O
mechanism	O
connecting	O
the	O
translational	O
machinery	O
with	O
cell	O
division	O
and/or	O
the	O
secretory	O
pathway	O
.	O

Following	O
treatment	O
with	O
either	O
RNase	O
or	O
>	O
150	O
mM	O
NaCl	O
,	O
Scp160p	O
remained	O
as	O
an	O
apparent	O
~450	O
kDa	O
species	O
.	O

Considering	O
that	O
purified	O
Scp160p	O
alone	O
also	O
migrates	O
at	O
this	O
size	O
,	O
we	O
conclude	O
that	O
this	O
apparent	O
complex	O
may	O
consist	O
only	O
of	O
Scp160p	O
,	O
although	O
the	O
presence	O
of	O
other	O
small	O
components	O
can	O
not	O
be	O
ruled	O
out	O
at	O
this	O
time	O
.	O

Furthermore	O
,	O
by	O
utilizing	O
yeast	B
co	O
-	O
expressing	O
two	O
distinct	O
epitope	O
-	O
tagged	O
versions	O
of	O
Scp160p	O
,	O
we	O
have	O
ruled	O
out	O
the	O
possibility	O
of	O
self	O
-	O
association	O
of	O
Scp160p	O
.	O

Although	O
both	O
tagged	O
proteins	O
appear	O
functional	O
,	O
it	O
remains	O
a	O
formal	O
possibility	O
that	O
the	O
tags	O
somehow	O
prevented	O
formation	O
of	O
FLAG	O
–	O
HA	O
hetero	O
-	O
complexes	O
.	O

Nonetheless	O
,	O
it	O
seems	O
most	O
likely	O
that	O
native	O
Scp160p	O
monomers	O
may	O
simply	O
migrate	O
aberrantly	O
under	O
native	O
conditions	O
due	O
to	O
an	O
unusual	O
shape	O
or	O
some	O
other	O
physical	O
property	O
.	O

In	O
conclusion	O
we	O
have	O
shown	O
convincing	O
evidence	O
that	O
Scp160p	O
exists	O
in	O
yeast	B
cytoplasmic	O
extracts	O
primarily	O
associated	O
with	O
polyribosomes	O
.	O

We	O
have	O
purified	O
Scp160p	O
following	O
disruption	O
of	O
polyribosomes	O
with	O
EDTA	O
,	O
and	O
identified	O
two	O
associated	O
proteins	O
:	O
Pab1p	O
and	O
Bfr1p	O
.	O

The	O
presence	O
of	O
Pab1p	O
suggests	O
that	O
Scp160p	O
associates	O
with	O
polyribosomes	O
as	O
a	O
component	O
of	O
an	O
mRNP	O
,	O
demonstrating	O
Scp160p	O
to	O
be	O
the	O
first	O
S.cerevisiae	B
multiple	O
-	O
KH	O
domain	O
protein	O
characterized	O
to	O
function	O
in	O
this	O
way	O
.	O

Mutations	O
of	O
PIK3CA	O
in	O
gastric	O
adenocarcinoma	O
Abstract	O
Background	O
Activation	O
of	O
the	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
through	O
mutational	O
inactivation	O
of	O
PTEN	O
tumour	O
suppressor	O
gene	O
is	O
common	O
in	O
diverse	O
cancer	O
types	O
,	O
but	O
rarely	O
reported	O
in	O
gastric	O
cancer	O
.	O

Recently	O
,	O
mutations	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110α	O
catalytic	O
subunit	O
of	O
PI3	O
K	O
,	O
have	O
been	O
identified	O
in	O
various	O
human	B
cancers	O
,	O
including	O
3	O
of	O
12	O
gastric	O
cancers	O
.	O

Eighty	O
percent	O
of	O
these	O
reported	O
mutations	O
clustered	O
within	O
2	O
regions	O
involving	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

In	O
vitro	O
study	O
on	O
one	O
of	O
the	O
""""	O
hot	O
-	O
spot	O
""""	O
mutants	O
has	O
demonstrated	O
it	O
as	O
an	O
activating	O
mutation	O
.	O

Methods	O
Based	O
on	O
these	O
data	O
,	O
we	O
initiated	O
PIK3CA	O
mutation	O
screening	O
in	O
94	O
human	B
gastric	O
cancers	O
by	O
direct	O
sequencing	O
of	O
the	O
gene	O
regions	O
in	O
which	O
80	O
%	O
of	O
all	O
the	O
known	O
PIK3CA	O
mutations	O
were	O
found	O
.	O

We	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
the	O
previous	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
.	O

Using	O
Significance	O
Analysis	O
of	O
Microarrays	O
(	O
SAM	O
)	O
,	O
we	O
further	O
searched	O
for	O
genes	O
that	O
show	O
correlating	O
expression	O
with	O
PIK3CA	O
.	O

Results	O
We	O
have	O
identified	O
PIK3CA	O
mutations	O
in	O
4	O
cases	O
(	O
4.3	O
%	O
)	O
,	O
all	O
involving	O
the	O
previously	O
reported	O
hotspots	O
.	O

Among	O
these	O
4	O
cases	O
,	O
3	O
tumours	O
demonstrated	O
microsatellite	O
instability	O
and	O
2	O
tumours	O
harboured	O
concurrent	O
KRAS	O
mutation	O
.	O

Data	O
extracted	O
from	O
microarray	O
studies	O
showed	O
an	O
increased	O
expression	O
of	O
PIK3CA	O
in	O
gastric	O
cancers	O
when	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
p	O
<	O
0.001	O
)	O
.	O

SAM	O
further	O
identified	O
2910	O
genes	O
whose	O
expression	O
levels	O
were	O
positively	O
associated	O
with	O
that	O
of	O
PIK3CA	O
.	O

Conclusion	O
Our	O
data	O
suggested	O
that	O
activation	O
of	O
the	O
PI3	O
K	O
signalling	O
pathway	O
in	O
gastric	O
cancer	O
may	O
be	O
achieved	O
through	O
up	O
-	O
regulation	O
or	O
mutation	O
of	O
PIK3CA	O
,	O
in	O
which	O
the	O
latter	O
may	O
be	O
a	O
consequence	O
of	O
mismatch	O
repair	O
deficiency	O
.	O

Background	O
The	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3K	O
)	O
-AKT	O
signalling	O
pathway	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
diverse	O
cellular	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
survival	O
and	O
motility	O
.	O

Abnormal	O
activation	O
of	O
this	O
pathway	O
is	O
frequently	O
observed	O
in	O
various	O
cancer	O
types	O
,	O
leading	O
to	O
aberrant	O
cell	O
cycle	O
progression	O
,	O
altered	O
adhesion	O
and	O
motility	O
,	O
inhibition	O
of	O
apoptosis	O
and	O
induction	O
of	O
angiogenesis	O
[	O
1	O
]	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
genetic	O
alterations	O
involving	O
various	O
members	O
along	O
this	O
signalling	O
pathway	O
could	O
lead	O
to	O
its	O
activation	O
in	O
cancer	O
.	O

These	O
include	O
mutation	O
,	O
allelic	O
loss	O
or	O
promoter	O
methylation	O
of	O
the	O
negative	O
regulator	O
PTEN	O
[	O
2	O
]	O
;	O
or	O
alternatively	O
,	O
chromosomal	O
amplification	O
or	O
over	O
-	O
expression	O
of	O
the	O
positive	O
regulators	O
PIK3CA	O
[	O
3	O
-	O
5	O
]	O
and	O
the	O
various	O
AKT	O
kinases	O
[	O
6,7	O
]	O
.	O

Furthermore	O
,	O
changes	O
in	O
other	O
related	O
pathways	O
that	O
are	O
commonly	O
altered	O
in	O
cancer	O
,	O
such	O
as	O
those	O
involved	O
in	O
growth	O
factor	O
stimulation	O
via	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
or	O
through	O
direct	O
interaction	O
with	O
the	O
activated	O
form	O
of	O
small	O
GTPase	O
RAS	O
,	O
can	O
also	O
lead	O
to	O
PI3K	O
-	O
AKT	O
pathway	O
activation	O
[	O
8	O
]	O
.	O

Activation	O
of	O
this	O
pathway	O
results	O
in	O
the	O
phosphorylation	O
of	O
AKT	O
at	O
Thr-308	O
/	O
309	O
and	O
Ser-473	O
/	O
474	O
.	O

These	O
phosphorylated	O
forms	O
of	O
AKT	O
proteins	O
have	O
been	O
detected	O
by	O
Western	O
blot	O
or	O
immunohistochemistry	O
in	O
various	O
cancer	O
types	O
,	O
suggesting	O
the	O
frequent	O
activation	O
of	O
PI3K	O
-	O
AKT	O
pathway	O
in	O
the	O
carcinogenic	O
process	O
[	O
7,9	O
]	O
.	O

Although	O
genetic	O
changes	O
along	O
the	O
PI3K	O
-	O
AKT	O
pathway	O
have	O
been	O
repeatedly	O
documented	O
in	O
brain	O
,	O
ovarian	O
,	O
endometrial	O
,	O
breast	O
,	O
prostate	O
and	O
thyroid	O
cancers	O
[	O
1,2	O
]	O
,	O
reports	O
on	O
its	O
mechanism	O
of	O
activation	O
in	O
gastric	O
cancer	O
are	O
limited	O
.	O

Gastric	O
cancer	O
is	O
the	O
second	O
most	O
common	O
cancer	O
worldwide	O
but	O
its	O
molecular	O
basis	O
of	O
tumourigenesis	O
is	O
still	O
poorly	O
understood	O
.	O

Previous	O
immunohistochemical	O
study	O
has	O
demonstrated	O
the	O
presence	O
of	O
the	O
phosphorylated	O
form	O
of	O
AKT	O
in	O
78	O
%	O
of	O
gastric	O
cancer	O
[	O
10	O
]	O
,	O
suggesting	O
that	O
activation	O
of	O
this	O
pathway	O
may	O
also	O
be	O
common	O
in	O
gastric	O
cancer	O
.	O

Though	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
involving	O
the	O
PTEN	O
locus	O
has	O
been	O
demonstrated	O
in	O
47	O
%	O
of	O
gastric	O
cancer	O
in	O
a	O
recent	O
study	O
,	O
mutation	O
or	O
promoter	O
methylation	O
was	O
absent	O
even	O
in	O
cases	O
with	O
LOH	O
[	O
11	O
]	O
.	O

Thus	O
data	O
from	O
this	O
study	O
could	O
not	O
support	O
the	O
two	O
-	O
hit	O
inactivation	O
of	O
PTEN	O
in	O
gastric	O
cancer	O
,	O
while	O
the	O
biological	O
significance	O
of	O
PTEN	O
haploinsufficiency	O
remains	O
controversial	O
.	O

Alternatively	O
,	O
amplification	O
of	O
AKT1	O
has	O
been	O
reported	O
in	O
a	O
single	O
case	O
of	O
gastric	O
cancer	O
[	O
12	O
]	O
,	O
and	O
amplification	O
of	O
PIK3CA	O
associated	O
with	O
elevated	O
mRNA	O
levels	O
has	O
been	O
found	O
in	O
36	O
%	O
of	O
gastric	O
cancer	O
[	O
11	O
]	O
.	O

More	O
recently	O
,	O
Samuels	O
et	O
al.	O
screened	O
a	O
diverse	O
spectrum	O
of	O
human	B
cancers	O
for	O
mutation	O
in	O
16	O
PI3	O
K	O
or	O
PI3K	O
-	O
like	O
genes	O
and	O
found	O
a	O
high	O
frequency	O
of	O
somatic	O
mutation	O
in	O
PIK3CA	O
,	O
which	O
encodes	O
the	O
p110α	O
catalytic	O
subunit	O
.	O

Major	O
screening	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
identified	O
PIK3CA	O
mutations	O
in	O
74	O
out	O
of	O
234	O
(	O
32	O
%	O
)	O
cases	O
,	O
while	O
mutations	O
were	O
also	O
noted	O
in	O
3	O
out	O
of	O
12	O
(	O
25	O
%	O
)	O
gastric	O
cancers	O
.	O

Reported	O
mutations	O
were	O
mostly	O
of	O
missense	O
type	O
,	O
and	O
clustered	O
within	O
2	O
regions	O
in	O
the	O
helical	O
and	O
kinase	O
domains	O
.	O

Expression	O
of	O
a	O
""""	O
hot	O
-	O
spot	O
""""	O
mutant	O
,	O
H1047R	O
,	O
conferred	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
lipid	O
kinase	O
activity	O
of	O
PIK3CA	O
,	O
suggesting	O
it	O
as	O
an	O
activating	O
mutation	O
[	O
13	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
examined	O
a	O
series	O
of	O
94	O
human	B
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutation	O
.	O

We	O
have	O
also	O
examined	O
PIK3CA	O
expression	O
level	O
by	O
extracting	O
data	O
from	O
a	O
large	O
-	O
scale	O
gene	O
expression	O
profiling	O
study	O
previously	O
performed	O
for	O
these	O
cases	O
[	O
14,15	O
]	O
.	O

Using	O
SAM	O
,	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
have	O
also	O
been	O
identified	O
.	O

Methods	O
Patient	O
samples	O
preparation	O
DNA	O
samples	O
used	O
for	O
sequencing	O
were	O
prepared	O
from	O
frozen	O
tumour	O
and	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
from	O
94	O
gastric	O
cancer	O
patients	O
who	O
underwent	O
gastrectomy	O
in	O
the	O
Department	O
of	O
Surgery	O
,	O
Queen	O
Mary	O
Hospital	O
,	O
The	O
University	O
of	O
Hong	O
Kong	O
,	O
as	O
previously	O
described	O
[	O
16	O
]	O
.	O

Majority	O
of	O
the	O
frozen	O
samples	O
(	O
n	O
=	O
81	O
)	O
showed	O
tumour	O
component	O
of	O
over	O
70	O
%	O
,	O
whereas	O
in	O
13	O
cases	O
a	O
lower	O
proportion	O
between	O
50	O
to	O
70	O
%	O
was	O
accepted	O
due	O
to	O
the	O
tumours	O
'	O
inherent	O
diffuse	O
infiltrative	O
nature	O
with	O
entrapment	O
of	O
non	O
-	O
neoplastic	O
components	O
.	O

Analysis	O
for	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
BRAF	O
and	O
KRAS	O
mutation	O
have	O
been	O
performed	O
and	O
reported	O
previously	O
[	O
16	O
]	O
.	O

RNA	O
preparation	O
and	O
gene	O
expression	O
profiling	O
using	O
a	O
cDNA	O
microarray	O
containing	O
44,500	O
cDNA	O
clones	O
,	O
representing	O
around	O
30,300	O
unique	O
genes	O
,	O
has	O
been	O
performed	O
and	O
reported	O
in	O
90	O
of	O
these	O
tumours	O
in	O
comparison	O
to	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
[	O
14,15	O
]	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
University	O
of	O
Hong	O
Kong	O
.	O

Mutational	O
screening	O
Mutation	O
screening	O
of	O
PIK3CA	O
was	O
performed	O
for	O
exons	O
9	O
and	O
20	O
,	O
covering	O
the	O
mutational	O
hotspots	O
;	O
and	O
for	O
exon	O
18	O
,	O
from	O
which	O
a	O
mutation	O
was	O
found	O
in	O
a	O
gastric	O
cancer	O
.	O

Mutations	O
in	O
these	O
3	O
exons	O
constituted	O
80	O
%	O
of	O
all	O
PIK3CA	O
mutations	O
detected	O
in	O
the	O
previous	O
study	O
[	O
13	O
]	O
.	O

PIK3CA	O
intron	O
-	O
specific	O
external	O
amplification	O
primers	O
and	O
internal	O
sequencing	O
primers	O
were	O
designed	O
according	O
to	O
the	O
previous	O
study	O
[	O
13	O
]	O
with	O
some	O
modifications	O
[	O
see	O
Additional	O
file	O
1	O
]	O
.	O

In	O
particular	O
,	O
primers	O
for	O
exon	O
9	O
have	O
been	O
modified	O
to	O
avoid	O
amplification	O
of	O
homologous	O
sequences	O
located	O
in	O
other	O
chromosomes	O
.	O

PCR	O
products	O
were	O
generated	O
using	O
the	O
external	O
primers	O
and	O
directly	O
sequenced	O
using	O
the	O
internal	O
primers	O
with	O
the	O
DYEnamic	O
™	O
ET	O
Terminator	O
Cycle	O
Sequencing	O
Kit	O
(	O
Amersham	O
Biosciences	O
,	O
Freiburg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instruction	O
.	O

Electrophoresis	O
was	O
performed	O
in	O
the	O
ABI	O
Prism	O
®	O
3700	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
each	O
exon	O
,	O
PCR	O
products	O
were	O
generated	O
from	O
2	O
independent	O
PCR	O
reactions	O
for	O
sequencing	O
of	O
the	O
forward	O
and	O
reverse	O
strands	O
.	O

For	O
exon	O
9	O
,	O
2	O
independent	O
PCR	O
followed	O
by	O
sequencing	O
of	O
the	O
forward	O
strand	O
were	O
performed	O
.	O

Analysis	O
of	O
the	O
chromatograms	O
was	O
performed	O
using	O
the	O
mutation	O
analysis	O
software	O
Mutation	O
Explorer	O
™	O
(	O
SoftGenetics	O
,	O
State	O
College	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Extraction	O
of	O
expression	O
data	O
and	O
statistical	O
analysis	O
Gene	O
expression	O
data	O
were	O
extracted	O
from	O
the	O
microarray	O
database	O
containing	O
126	O
samples	O
(	O
90	O
gastric	O
cancers	O
,	O
14	O
lymph	O
node	O
metastasis	O
and	O
22	O
non	O
-	O
tumour	O
gastric	O
mucosae	O
)	O
based	O
on	O
a	O
3-fold	O
signal	O
above	O
background	O
ratio	O
for	O
either	O
channel	O
and	O
with	O
80	O
%	O
good	O
data	O
[	O
14	O
]	O
.	O

Gene	O
expression	O
data	O
from	O
20,336	O
cDNA	O
clones	O
satisfied	O
this	O
selection	O
criteria	O
and	O
were	O
extracted	O
,	O
which	O
included	O
a	O
cDNA	O
clone	O
corresponding	O
to	O
PIK3CA	O
(	O
IMAGE	O
clone	O
number	O
345430	O
,	O
GenBank	O
accession	O
no.	O
W72473	O
)	O
.	O

Expression	O
data	O
for	O
PIK3CA	O
was	O
extracted	O
and	O
the	O
differences	O
in	O
expression	O
levels	O
between	O
tumour	O
and	O
non	O
-	O
tumour	O
tissues	O
were	O
examined	O
using	O
the	O
Student	O
's	O
t	O
-	O
Test	O
.	O

SAM	O
was	O
performed	O
to	O
identify	O
genes	O
with	O
significant	O
correlating	O
expression	O
with	O
PIK3CA	O
[	O
17	O
]	O
.	O

The	O
missing	O
values	O
in	O
the	O
dataset	O
were	O
estimated	O
by	O
a	O
K	O
-	O
nearest	O
neighbours	O
impute	O
algorithm	O
using	O
10	O
nearest	O
neighbour	O
[	O
18	O
]	O
followed	O
by	O
5000	O
permutations	O
in	O
the	O
SAM	O
analysis	O
.	O

Results	O
Among	O
the	O
94	O
gastric	O
adenocarcinoma	O
analysed	O
,	O
we	O
have	O
detected	O
PIK3CA	O
mutation	O
in	O
4	O
cases	O
.	O

Two	O
cases	O
harboured	O
the	O
mutation	O
A3140	O
G	O
(	O
H1047R	O
)	O
in	O
exon	O
20	O
,	O
and	O
the	O
other	O
2	O
cases	O
with	O
mutations	O
G1624A	O
(	O
E542	O
K	O
)	O
and	O
G1633A	O
(	O
E545	O
K	O
)	O
in	O
exon	O
9	O
.	O

Representative	O
sequence	O
chromatograms	O
are	O
shown	O
in	O
figure	O
1	O
.	O

All	O
four	O
mutations	O
were	O
absent	O
in	O
the	O
corresponding	O
non	O
-	O
neoplastic	O
mucosae	O
and	O
thus	O
were	O
confirmed	O
as	O
somatic	O
mutations	O
.	O

Though	O
the	O
overall	O
mutation	O
frequency	O
(	O
4.3	O
%	O
)	O
was	O
lower	O
than	O
that	O
of	O
the	O
previous	O
study	O
,	O
the	O
nature	O
of	O
the	O
4	O
mutations	O
found	O
were	O
consistent	O
with	O
those	O
identified	O
at	O
the	O
reported	O
hotspots	O
.	O

In	O
particular	O
,	O
the	O
H1047R	O
mutation	O
has	O
been	O
reported	O
in	O
2	O
gastric	O
cancers	O
and	O
15	O
colorectal	O
cancers	O
[	O
13	O
]	O
.	O

While	O
the	O
E542	O
K	O
and	O
the	O
E545	O
K	O
mutations	O
were	O
not	O
found	O
in	O
gastric	O
cancer	O
in	O
the	O
previous	O
series	O
,	O
a	O
large	O
number	O
of	O
colorectal	O
tumours	O
did	O
harbour	O
these	O
2	O
mutations	O
.	O

PIK3CA	O
mutation	O
spectrum	O
and	O
their	O
corresponding	O
clinico	O
-	O
pathological	O
features	O
were	O
listed	O
in	O
Table	O
1	O
.	O

We	O
noted	O
a	O
higher	O
tendency	O
of	O
high	O
-	O
level	O
MSI	O
in	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutations	O
(	O
3	O
in	O
4	O
,	O
75	O
%	O
)	O
than	O
in	O
those	O
without	O
(	O
18	O
in	O
90	O
,	O
20	O
%	O
)	O
.	O

Moreover	O
,	O
though	O
the	O
overall	O
incidence	O
of	O
KRAS	O
mutation	O
in	O
the	O
studied	O
population	O
was	O
low	O
(	O
8	O
in	O
94	O
)	O
,	O
2	O
of	O
the	O
4	O
gastric	O
cancers	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
a	O
KRAS	O
mutation	O
.	O

Since	O
over	O
-	O
expression	O
of	O
PIK3CA	O
has	O
been	O
reported	O
in	O
gastric	O
cancer	O
[	O
11	O
]	O
,	O
we	O
have	O
also	O
extracted	O
PIK3CA	O
expression	O
data	O
from	O
our	O
previous	O
cDNA	O
microarray	O
study	O
of	O
these	O
cases	O
[	O
14,15	O
]	O
.	O

We	O
have	O
confirmed	O
that	O
expression	O
level	O
of	O
PIK3CA	O
was	O
significantly	O
higher	O
in	O
gastric	O
cancers	O
(	O
n	O
=	O
87	O
,	O
mean	O
=	O
0.099	O
,	O
SD	O
=	O
0.428	O
)	O
when	O
compared	O
with	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
(	O
n	O
=	O
22	O
,	O
mean	O
=	O
-0.418	O
,	O
SD	O
=	O
0.426	O
;	O
Student	O
's	O
t	O
-	O
Test	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Using	O
PIK3CA	O
expression	O
level	O
as	O
a	O
continuous	O
variable	O
for	O
SAM	O
analysis	O
[	O
17	O
]	O
,	O
we	O
found	O
2910	O
cDNA	O
clones	O
(	O
corresponding	O
to	O
about	O
2546	O
unique	O
genes	O
)	O
whose	O
expression	O
associated	O
positively	O
with	O
PIK3CA	O
expression	O
(	O
median	O
number	O
of	O
false	O
significant	O
=	O
0.372	O
,	O
Delta	O
=	O
1.107	O
)	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

Interestingly	O
,	O
no	O
gene	O
was	O
found	O
to	O
be	O
negatively	O
associated	O
with	O
PIK3CA	O
expression	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
have	O
reported	O
the	O
presence	O
of	O
PIK3CA	O
gene	O
mutation	O
in	O
4.3	O
%	O
of	O
gastric	O
cancer	O
.	O

A	O
high	O
tendency	O
(	O
3	O
in	O
4	O
)	O
of	O
mismatch	O
repair	O
deficiency	O
was	O
noted	O
in	O
cases	O
harbouring	O
PIK3CA	O
mutation	O
.	O

Though	O
the	O
small	O
number	O
of	O
PIK3CA	O
mutations	O
in	O
our	O
study	O
may	O
not	O
justify	O
statistical	O
claim	O
of	O
significance	O
;	O
suggestion	O
of	O
such	O
,	O
despite	O
of	O
its	O
not	O
being	O
mentioned	O
by	O
the	O
authors	O
,	O
can	O
be	O
found	O
from	O
a	O
previous	O
study	O
in	O
CRC	O
by	O
Samuels	O
et	O
al	O
..	O
From	O
their	O
study	O
of	O
33	O
MSI	O
and	O
201	O
microsatellite	O
stable	O
(	O
MSS	O
)	O
CRC	O
cases	O
,	O
PIK3CA	O
mutation	O
was	O
present	O
in	O
48	O
%	O
of	O
the	O
MSI	O
tumours	O
,	O
but	O
only	O
in	O
29	O
%	O
of	O
the	O
MSS	O
tumours	O
.	O

A	O
significant	O
association	O
would	O
have	O
been	O
revealed	O
if	O
statistical	O
analysis	O
had	O
been	O
applied	O
(	O
Fisher	O
's	O
exact	O
test	O
,	O
p	O
=	O
0.014	O
)	O
[	O
13	O
]	O
.	O

Gastrointestinal	O
tract	O
cancers	O
with	O
MSI	O
are	O
known	O
to	O
have	O
a	O
different	O
molecular	O
pathway	O
of	O
tumour	O
evolution	O
compared	O
with	O
their	O
MSS	O
counterparts	O
[	O
19,20	O
]	O
.	O

This	O
can	O
be	O
attributed	O
to	O
their	O
propensity	O
for	O
frameshift	O
mutations	O
in	O
repeat	O
sequences	O
,	O
resulting	O
in	O
selective	O
disruption	O
of	O
genes	O
with	O
such	O
sequences	O
within	O
their	O
coding	O
regions	O
.	O

With	O
2	O
poly	O
-	O
adenine	O
tracts	O
within	O
its	O
coding	O
region	O
,	O
PTEN	O
can	O
be	O
inactivated	O
through	O
frameshift	O
mutations	O
in	O
MSI	O
CRC	O
,	O
resulting	O
in	O
the	O
selective	O
targeting	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
[	O
21,22	O
]	O
.	O

It	O
is	O
also	O
known	O
that	O
mismatch	O
repair	O
deficiency	O
would	O
lead	O
to	O
an	O
elevated	O
rate	O
of	O
missense	O
mutation	O
due	O
to	O
impaired	O
single	O
nucleotide	O
mismatch	O
repair	O
[	O
23	O
]	O
.	O

Thus	O
,	O
the	O
observed	O
higher	O
incidence	O
of	O
PIK3CA	O
missense	O
mutation	O
in	O
MSI	O
colorectal	O
and	O
gastric	O
cancers	O
suggests	O
yet	O
another	O
mechanism	O
for	O
the	O
activation	O
of	O
the	O
PI3K	O
-	O
AKT	O
signalling	O
pathway	O
through	O
mismatch	O
repair	O
deficiency	O
.	O

Our	O
data	O
also	O
showed	O
a	O
higher	O
tendency	O
of	O
KRAS	O
mutation	O
in	O
cases	O
with	O
PIK3CA	O
mutations	O
(	O
2	O
in	O
4	O
)	O
than	O
in	O
those	O
without	O
(	O
6	O
in	O
90	O
)	O
.	O

Yet	O
again	O
due	O
to	O
the	O
low	O
incidence	O
of	O
both	O
mutations	O
in	O
our	O
samples	O
,	O
statistical	O
significance	O
may	O
not	O
be	O
claimed	O
.	O

In	O
the	O
study	O
by	O
Samuels	O
et	O
al.	O
,	O
some	O
of	O
the	O
colorectal	O
tumours	O
with	O
PIK3CA	O
mutation	O
also	O
harboured	O
KRAS	O
or	O
BRAF	O
mutation	O
[	O
13	O
]	O
.	O

The	O
PI3K	O
-	O
AKT	O
pathway	O
is	O
known	O
to	O
have	O
a	O
close	O
association	O
with	O
the	O
RAS	O
-	O
MEKK	O
signalling	O
pathway	O
[	O
8	O
]	O
.	O

Constitutively	O
active	O
RAS	O
can	O
interact	O
with	O
the	O
catalytic	O
subunit	O
of	O
PI3	O
K	O
and	O
lead	O
to	O
its	O
activation	O
.	O

Ras	O
-	O
dependent	O
PI3	O
K	O
activation	O
contributes	O
to	O
the	O
transforming	O
phenotype	O
by	O
mediating	O
anchorage	O
-	O
independent	O
growth	O
,	O
cytoskeletal	O
reorganisation	O
and	O
apoptosis	O
evasion	O
.	O

It	O
has	O
been	O
observed	O
that	O
genes	O
involved	O
in	O
the	O
same	O
signalling	O
pathway	O
may	O
manifest	O
mutations	O
in	O
cancer	O
cells	O
in	O
a	O
mutually	O
exclusive	O
manner	O
,	O
presumably	O
due	O
to	O
the	O
lack	O
of	O
selective	O
growth	O
advantage	O
in	O
having	O
a	O
second	O
hit	O
in	O
the	O
already	O
altered	O
pathway	O
.	O

A	O
prominent	O
example	O
is	O
the	O
mutually	O
exclusive	O
occurrence	O
of	O
the	O
BRAF	O
hotspot	O
mutation	O
(	O
V600E	O
)	O
and	O
KRAS	O
mutations	O
in	O
colorectal	O
cancer	O
[	O
24,25	O
]	O
.	O

However	O
,	O
there	O
exist	O
other	O
examples	O
of	O
alterations	O
in	O
multiple	O
components	O
of	O
the	O
same	O
signalling	O
pathway	O
that	O
may	O
lead	O
to	O
a	O
multi	O
-	O
level	O
modulation	O
of	O
its	O
activity	O
.	O

For	O
example	O
,	O
non	O
-	O
V600E	O
BRAF	O
mutations	O
tend	O
to	O
occur	O
together	O
with	O
KRAS	O
mutations	O
[	O
26	O
]	O
,	O
and	O
inactivation	O
of	O
the	O
secreted	O
frizzled	O
-	O
related	O
proteins	O
(	O
antagonists	O
of	O
WNT	O
)	O
by	O
promoter	O
methylation	O
frequently	O
coincides	O
with	O
mutations	O
in	O
the	O
Adenomatous	O
Polyposis	O
Coli	O
gene	O
to	O
achieve	O
multi	O
-	O
level	O
activation	O
of	O
the	O
WNT	O
signalling	O
pathway	O
in	O
colorectal	O
cancers	O
[	O
27	O
]	O
.	O

Whether	O
PIK3CA	O
functions	O
independently	O
from	O
RAS	O
,	O
or	O
acts	O
synergistically	O
with	O
RAS	O
to	O
produce	O
additive	O
effects	O
on	O
the	O
activation	O
of	O
the	O
same	O
pathway	O
awaits	O
further	O
clarification	O
.	O

By	O
extracting	O
data	O
from	O
microarray	O
,	O
we	O
have	O
confirmed	O
the	O
up	O
-	O
regulation	O
of	O
PIK3CA	O
expression	O
in	O
gastric	O
cancer	O
tissues	O
compared	O
with	O
the	O
non	O
-	O
neoplastic	O
gastric	O
mucosae	O
and	O
identified	O
a	O
large	O
number	O
of	O
genes	O
that	O
showed	O
a	O
significant	O
positive	O
correlation	O
in	O
expression	O
level	O
with	O
PIK3CA	O
.	O

These	O
genes	O
participate	O
in	O
diverse	O
cellular	O
processes	O
with	O
177	O
as	O
putative	O
cell	O
cycle	O
-	O
regulated	O
genes	O
[	O
28	O
]	O
and	O
126	O
mapped	O
to	O
genes	O
with	O
known	O
functions	O
in	O
cell	O
cycle	O
regulation	O
,	O
cell	O
proliferation	O
or	O
DNA	O
replication	O
[	O
see	O
Additional	O
file	O
2	O
]	O
.	O

While	O
some	O
of	O
these	O
genes	O
maybe	O
induced	O
by	O
PIK3CA	O
,	O
others	O
maybe	O
co	O
-	O
ordinately	O
regulated	O
by	O
common	O
upstream	O
signals	O
.	O

Expression	O
data	O
set	O
at	O
one	O
point	O
was	O
limited	O
in	O
differentiating	O
the	O
above	O
cause	O
and	O
consequence	O
,	O
yet	O
it	O
certainly	O
revealed	O
the	O
complexity	O
of	O
the	O
carcinogenic	O
process	O
and	O
the	O
intricate	O
relationship	O
of	O
PIK3CA	O
signalling	O
with	O
other	O
cellular	O
processes	O
.	O

Contrary	O
to	O
our	O
expectation	O
,	O
the	O
incidence	O
of	O
PIK3CA	O
mutation	O
found	O
in	O
the	O
current	O
study	O
(	O
4	O
%	O
)	O
is	O
much	O
lower	O
compared	O
with	O
that	O
observed	O
by	O
Samuel	O
et	O
al.	O
(	O
25	O
%	O
)	O
[	O
13	O
]	O
.	O

The	O
reason	O
for	O
discrepancy	O
may	O
simply	O
be	O
a	O
result	O
of	O
sample	O
bias	O
as	O
the	O
previous	O
study	O
involved	O
only	O
a	O
small	O
number	O
of	O
gastric	O
cancers	O
(	O
n	O
=	O
12	O
)	O
.	O

However	O
,	O
ethnic	O
differences	O
can	O
also	O
be	O
another	O
possibility	O
.	O

The	O
diverse	O
pathological	O
spectrum	O
and	O
aetiological	O
factors	O
of	O
gastric	O
cancers	O
in	O
different	O
geographical	O
locations	O
may	O
be	O
paralleled	O
by	O
differences	O
in	O
molecular	O
pathway	O
of	O
tumour	O
development	O
.	O

Since	O
our	O
current	O
study	O
is	O
only	O
based	O
on	O
a	O
Chinese	O
population	O
with	O
an	O
intermediate	O
gastric	O
cancer	O
incidence	O
,	O
further	O
studies	O
involving	O
patients	O
from	O
different	O
ethnic	O
groups	O
will	O
be	O
able	O
to	O
address	O
this	O
possibility	O
.	O

Conclusion	O
Large	O
-	O
scale	O
screening	O
of	O
gastric	O
adenocarcinomas	O
for	O
PIK3CA	O
mutations	O
revealed	O
a	O
mutation	O
incidence	O
of	O
4.3	O
%	O
.	O

Increased	O
PIK3CA	O
expression	O
level	O
was	O
observed	O
in	O
gastric	O
tumours	O
compared	O
with	O
non	O
-	O
neoplastic	O
mucosae	O
.	O

This	O
increase	O
in	O
PIK3CA	O
level	O
was	O
associated	O
with	O
the	O
elevated	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
,	O
which	O
may	O
constitute	O
the	O
upstream	O
regulators	O
or	O
downstream	O
targets	O
of	O
PIK3CA	O
along	O
the	O
PI3	O
K	O
signalling	O
pathway	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
VSWL	O
carried	O
out	O
the	O
molecular	O
analysis	O
,	O
performed	O
data	O
analysis	O
and	O
drafted	O
the	O
manuscript	O
.	O

CWW	O
,	O
TLC	O
,	O
WZ	O
assisted	O
in	O
the	O
molecular	O
analysis	O
.	O

KMC	O
provided	O
the	O
clinical	O
data	O
.	O

ASWC	O
assisted	O
in	O
data	O
analysis	O
and	O
edited	O
the	O
manuscript	O
.	O

SS	O
and	O
XC	O
participated	O
in	O
the	O
microarray	O
study	O
and	O
data	O
analysis	O
.	O

STY	O
and	O
SYL	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
,	O
coordination	O
and	O
data	O
analysis	O
,	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O
Supplementary	O
Material	O

Structural	O
organization	O
and	O
interactions	O
of	O
transmembrane	O
domains	O
in	O
tetraspanin	O
proteins	O
Abstract	O
Background	O
Proteins	O
of	O
the	O
tetraspanin	O
family	O
contain	O
four	O
transmembrane	O
domains	O
(	O
TM1	O
-	O
4	O
)	O
linked	O
by	O
two	O
extracellular	O
loops	O
and	O
a	O
short	O
intracellular	O
loop	O
,	O
and	O
have	O
short	O
intracellular	O
N-	O
and	O
C	O
-	O
termini	O
.	O

While	O
structure	O
and	O
function	O
analysis	O
of	O
the	O
larger	O
extracellular	O
loop	O
has	O
been	O
performed	O
,	O
the	O
organization	O
and	O
role	O
of	O
transmembrane	O
domains	O
have	O
not	O
been	O
systematically	O
assessed	O
.	O

Results	O
Among	O
28	O
human	B
tetraspanin	O
proteins	O
,	O
the	O
TM1	O
-	O
3	O
sequences	O
display	O
a	O
distinct	O
heptad	O
repeat	O
motif	O
(	O
abcdefg	O
)	O
n	O
.	O

In	O
TM1	O
,	O
position	O
a	O
is	O
occupied	O
by	O
structurally	O
conserved	O
bulky	O
residues	O
and	O
position	O
d	O
contains	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
.	O

In	O
TM2	O
,	O
position	O
a	O
is	O
occupied	O
by	O
conserved	O
small	O
residues	O
(	O
Gly	O
/	O
Ala	O
/	O
Thr	O
)	O
,	O
and	O
position	O
d	O
has	O
a	O
conserved	O
Gly	O
and	O
two	O
bulky	O
aliphatic	O
residues	O
.	O

In	O
TM3	O
,	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
repeat	O
are	O
filled	O
by	O
two	O
leucines	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
,	O
and	O
two	O
d	O
positions	O
are	O
occupied	O
by	O
either	O
Phe	O
/	O
Tyr	O
or	O
Val	O
/	O
Ile	O
/	O
Leu	O
residues	O
.	O

No	O
heptad	O
motif	O
is	O
apparent	O
in	O
TM4	O
sequences	O
.	O

Mutations	O
of	O
conserved	O
glycines	O
in	O
human	B
CD9	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
;	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
caused	O
aggregation	O
of	O
mutant	O
proteins	O
inside	O
the	O
cell	O
.	O

Modeling	O
of	O
the	O
TM1-TM2	O
interface	O
in	O
CD9	O
,	O
using	O
a	O
novel	O
algorithm	O
,	O
predicts	O
tight	O
packing	O
of	O
conserved	O
bulky	O
residues	O
against	O
conserved	O
Gly	O
residues	O
along	O
the	O
two	O
helices	O
.	O

The	O
homodimeric	O
interface	O
of	O
CD9	O
was	O
mapped	O
,	O
by	O
disulfide	O
cross	O
-	O
linking	O
of	O
single	O
-	O
cysteine	O
mutants	O
,	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
(	O
positions	O
g	O
and	O
c	O
)	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
(	O
positions	O
d	O
,	O
g	O
and	O
a	O
,	O
respectively	O
)	O
.	O

Mutations	O
of	O
a	O
and	O
d	O
residues	O
in	O
both	O
TM1	O
and	O
TM2	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
)	O
,	O
involved	O
in	O
intramolecular	O
TM1-TM2	O
interaction	O
,	O
also	O
strongly	O
diminished	O
intermolecular	O
interaction	O
,	O
as	O
assessed	O
by	O
cross	O
-	O
linking	O
of	O
Cys80	O
.	O

Conclusion	O
Our	O
results	O
suggest	O
that	O
tetraspanin	O
intra-	O
and	O
intermolecular	O
interactions	O
are	O
mediated	O
by	O
conserved	O
residues	O
in	O
adjacent	O
,	O
but	O
distinct	O
regions	O
of	O
TM1	O
and	O
TM2	O
.	O

A	O
key	O
structural	O
element	O
that	O
defines	O
TM1-TM2	O
interaction	O
in	O
tetraspanins	O
is	O
the	O
specific	O
packing	O
of	O
bulky	O
residues	O
against	O
small	O
residues	O
.	O

Background	O
Tetraspanins	O
constitute	O
a	O
large	O
family	O
of	O
integral	O
membrane	O
proteins	O
,	O
characteristically	O
containing	O
4	O
,	O
6	O
or	O
8	O
conserved	O
cysteine	O
residues	O
in	O
the	O
large	O
extracellular	O
loop	O
(	O
including	O
the	O
CCG	O
and	O
PxxCC	O
motifs	O
)	O
,	O
which	O
form	O
disulfide	O
bonds	O
,	O
and	O
several	O
conserved	O
polar	O
residues	O
in	O
the	O
intracellular	O
loop	O
and	O
transmembrane	O
regions	O
[	O
1,2	O
]	O
.	O

There	O
are	O
32	O
putative	O
tetraspanin	O
family	O
members	O
in	O
mammals	O
,	O
37	O
in	O
Drosophila	B
melanogaster	I
and	O
20	O
in	O
Caenorhabditis	B
elegans	I
.	O

Tetraspanins	O
play	O
diverse	O
roles	O
in	O
cell	O
adhesion	O
,	O
migration	O
and	O
fusion	O
processes	O
,	O
cellular	O
activation	O
and	O
signaling	O
(	O
reviewed	O
in	O
refs	O
.	O

[	O
2	O
-	O
4	O
]	O
)	O
.	O

Mammalian	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
CD63	O
,	O
CD81	O
,	O
CD82	O
,	O
CD151	O
,	O
rds	O
/	O
peripherin	O
,	O
and	O
uroplakins	O
Ia	O
and	O
Ib	O
have	O
been	O
most	O
extensively	O
studied	O
,	O
with	O
mouse	B
knock	O
-	O
out	O
models	O
available	O
for	O
CD9	O
[	O
5	O
-	O
7	O
]	O
,	O
CD81	O
[	O
8,9	O
]	O
,	O
CD151	O
[	O
10	O
]	O
and	O
a	O
few	O
others	O
.	O

However	O
,	O
the	O
majority	O
of	O
tetraspanins	O
are	O
characterized	O
very	O
little	O
,	O
if	O
at	O
all	O
,	O
at	O
genetic	O
,	O
biochemical	O
or	O
structural	O
levels	O
.	O

The	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
tetraspanins	O
has	O
received	O
most	O
attention	O
,	O
since	O
it	O
contains	O
functionally	O
important	O
sites	O
.	O

Sequence	O
QRD	O
(	O
194–196	O
)	O
in	O
CD151	O
is	O
important	O
for	O
association	O
with	O
integrins	O
,	O
which	O
has	O
functional	O
consequences	O
for	O
integrin	O
-	O
dependent	O
cell	O
spreading	O
and	O
multicellular	O
cable	O
formation	O
[	O
11	O
]	O
.	O

A	O
site	O
in	O
the	O
LEL	O
of	O
CD9	O
,	O
SFQ	O
(	O
residues	O
173–175	O
)	O
,	O
is	O
essential	O
for	O
CD9	O
function	O
in	O
sperm	O
-	O
egg	O
fusion	O
[	O
12	O
]	O
.	O

The	O
crystal	O
structure	O
of	O
tetraspanin	O
CD81	O
LEL	O
revealed	O
five	O
α	O
-	O
helixes	O
,	O
A	O
-	O
E	O
[	O
13	O
]	O
.	O

Helices	O
A	O
,	O
B	O
and	O
E	O
form	O
a	O
relatively	O
conserved	O
region	O
in	O
tetraspanins	O
,	O
whereas	O
the	O
region	O
between	O
helices	O
B	O
and	O
E	O
is	O
the	O
most	O
variable	O
[	O
14	O
]	O
.	O

Interestingly	O
,	O
the	O
variable	O
region	O
contains	O
most	O
of	O
the	O
functionally	O
important	O
sites	O
involved	O
in	O
tetraspanin	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
remarkable	O
biochemical	O
property	O
of	O
tetraspanin	O
molecules	O
is	O
their	O
ability	O
to	O
associate	O
with	O
a	O
large	O
number	O
of	O
other	O
transmembrane	O
proteins	O
,	O
including	O
integrins	O
,	O
membrane	O
-	O
associated	O
growth	O
factors	O
and	O
receptors	O
,	O
MHC	O
class	O
II	O
molecules	O
,	O
Ig	O
superfamily	O
proteins	O
,	O
and	O
each	O
other	O
[	O
2,3,15	O
]	O
.	O

Several	O
of	O
these	O
lateral	O
associations	O
of	O
tetraspanins	O
are	O
detected	O
in	O
""""	O
mild	O
""""	O
detergents	O
(	O
Brij	O
series	O
,	O
CHAPS	O
)	O
,	O
but	O
are	O
disrupted	O
by	O
""""	O
strong	O
""""	O
detergents	O
such	O
as	O
Triton	O
X-100	O
or	O
SDS	O
.	O

Multiprotein	O
complexes	O
of	O
tetraspanins	O
and	O
associated	O
molecules	O
,	O
also	O
called	O
the	O
""""	O
tetraspanin	O
web	O
""""	O
[	O
16	O
]	O
,	O
may	O
represent	O
a	O
distinct	O
tetraspanin	O
-	O
enriched	O
membrane	O
microdomain	O
[	O
17,18	O
]	O
.	O

The	O
formation	O
of	O
this	O
microdomain	O
is	O
influenced	O
by	O
palmitoylation	O
of	O
several	O
conserved	O
juxtamembrane	O
cysteine	O
residues	O
in	O
tetraspanins	O
[	O
19	O
-	O
21	O
]	O
.	O

The	O
transmembrane	O
domains	O
,	O
encompassing	O
nearly	O
half	O
of	O
a	O
tetraspanin	O
protein	O
,	O
are	O
the	O
most	O
conserved	O
part	O
of	O
the	O
molecule	O
(	O
Stipp	O
et	O
al.	O
[	O
1	O
]	O
and	O
this	O
study	O
)	O
.	O

However	O
,	O
very	O
little	O
functional	O
information	O
is	O
available	O
on	O
these	O
domains	O
.	O

The	O
differential	O
detergent	O
sensitivity	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
suggests	O
that	O
hydrophobic	O
interactions	O
between	O
TM	O
helices	O
may	O
play	O
a	O
role	O
.	O

Indeed	O
,	O
when	O
the	O
large	O
extracellular	O
loop	O
(	O
LEL	O
)	O
of	O
CD151	O
is	O
deleted	O
,	O
the	O
molecule	O
is	O
still	O
able	O
to	O
associate	O
with	O
other	O
tetraspanins	O
[	O
22	O
]	O
.	O

Thus	O
,	O
TM	O
domains	O
are	O
strong	O
candidates	O
for	O
mediating	O
tetraspanin	O
-	O
tetraspanin	O
interactions	O
.	O

The	O
importance	O
of	O
TM	O
domain	O
interactions	O
in	O
intramolecular	O
organization	O
was	O
demonstrated	O
in	O
a	O
study	O
showing	O
that	O
CD82	O
fragment	O
TM2	O
-	O
4	O
,	O
lacking	O
TM1	O
,	O
was	O
retained	O
in	O
the	O
endoplasmic	O
reticulum	O
,	O
but	O
was	O
transported	O
to	O
the	O
cell	O
surface	O
upon	O
co	O
-	O
expression	O
of	O
TM1	O
[	O
23	O
]	O
.	O

This	O
in	O
vivo	O
reconstitution	O
experiment	O
demonstrated	O
a	O
strong	O
interaction	O
between	O
TM1	O
and	O
the	O
rest	O
of	O
the	O
molecule	O
.	O

Expression	O
of	O
a	O
truncated	O
CD9	O
molecule	O
(	O
TM3-LEL	O
-	O
TM4	O
)	O
results	O
in	O
intracellular	O
accumulation	O
of	O
the	O
protein	O
and	O
significant	O
misfolding	O
of	O
the	O
LEL	O
,	O
as	O
judged	O
by	O
inappropriate	O
disulfide	O
formation	O
and	O
diminished	O
antibody	O
reactivity	O
(	O
our	O
unpublished	O
data	O
)	O
.	O

Similarly	O
,	O
a	O
CD9	O
epitope	O
in	O
the	O
LEL	O
is	O
lost	O
in	O
molecules	O
lacking	O
either	O
TM2+TM3	O
or	O
just	O
TM4	O
[	O
24	O
]	O
.	O

Thus	O
,	O
TM	O
domain	O
interactions	O
and	O
packing	O
are	O
crucial	O
for	O
proper	O
folding	O
,	O
stability	O
and	O
transport	O
of	O
tetraspanin	O
molecules	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
showed	O
that	O
covalent	O
cross	O
-	O
linking	O
of	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
can	O
be	O
used	O
as	O
a	O
tool	O
for	O
detection	O
of	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
[	O
25	O
]	O
.	O

Inhibition	O
of	O
cysteine	O
palmitoylation	O
by	O
2-bromopalmitate	O
(	O
2-BP	O
)	O
made	O
cysteines	O
available	O
for	O
cross	O
-	O
linking	O
and	O
enabled	O
demonstration	O
of	O
specific	O
tetraspanin	O
homodimerization	O
and	O
low	O
levels	O
of	O
heterodimerization	O
.	O

We	O
concluded	O
that	O
tetraspanin	O
homodimers	O
,	O
formed	O
in	O
the	O
Golgi	O
,	O
may	O
be	O
a	O
fundamental	O
structural	O
unit	O
within	O
tetraspanin	O
microdomains	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
detailed	O
sequence	O
analysis	O
of	O
human	B
tetraspanin	O
TM	O
domains	O
.	O

We	O
show	O
that	O
a	O
heptad	O
repeat	O
containing	O
conserved	O
glycine	O
,	O
asparagine	O
and	O
large	O
hydrophobic	O
residues	O
occurs	O
in	O
TM1	O
and	O
TM2	O
domains	O
,	O
and	O
predict	O
tight	O
intramolecular	O
association	O
of	O
these	O
two	O
domains	O
by	O
packing	O
of	O
the	O
large	O
residues	O
against	O
the	O
small	O
residues	O
.	O

Moreover	O
,	O
by	O
using	O
cysteine	O
cross	O
-	O
linking	O
we	O
map	O
a	O
dimerization	O
interface	O
in	O
the	O
human	B
CD9	O
protein	O
,	O
and	O
show	O
that	O
conserved	O
heptad	O
motif	O
glycine	O
residues	O
are	O
also	O
important	O
for	O
intermolecular	O
CD9	O
associations	O
.	O

Results	O
Sequence	O
analysis	O
of	O
tetraspanin	O
transmembrane	O
domains	O
:	O
presence	O
of	O
the	O
heptad	O
repeat	O
motif	O
We	O
focused	O
our	O
attention	O
on	O
28	O
human	B
tetraspanins	O
identified	O
from	O
the	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

All	O
tetraspanins	O
have	O
in	O
common	O
four	O
hydrophobic	O
stretches	O
(	O
TM	O
domains	O
)	O
of	O
20–25	O
residues	O
,	O
and	O
contain	O
highly	O
conserved	O
residues	O
in	O
the	O
second	O
extracellular	O
loop	O
,	O
in	O
particular	O
the	O
Cys	O
-	O
Cys	O
-	O
Gly	O
(	O
CCG	O
)	O
motif	O
.	O

Detailed	O
analysis	O
of	O
the	O
large	O
extracellular	O
loop	O
sequences	O
[	O
14	O
]	O
,	O
and	O
dendrograms	O
based	O
on	O
full	O
-	O
length	O
alignment	O
can	O
be	O
found	O
in	O
earlier	O
studies	O
[	O
26,27	O
]	O
.	O

The	O
length	O
of	O
each	O
transmembrane	O
domain	O
was	O
established	O
based	O
on	O
previous	O
sequence	O
analysis	O
of	O
tetraspanin	O
sequences	O
[	O
27,28	O
]	O
,	O
and	O
on	O
annotations	O
to	O
the	O
database	O
entries	O
.	O

Manual	O
adjustments	O
based	O
on	O
sequence	O
homology	O
and	O
hydrophobicity	O
profiles	O
were	O
done	O
to	O
fully	O
delineate	O
the	O
TM	O
domains	O
.	O

The	O
resulting	O
lengths	O
of	O
TM	O
domains	O
were	O
:	O
TM1	O
–	O
23	O
residues	O
;	O
TM2	O
–	O
21	O
residues	O
;	O
TM3	O
–	O
25	O
residues	O
;	O
TM4	O
–	O
25	O
residues	O
.	O

Two	O
more	O
residues	O
could	O
be	O
added	O
onto	O
the	O
N	O
-	O
terminal	O
part	O
of	O
TM2	O
;	O
however	O
,	O
relatively	O
small	O
sequence	O
conservation	O
of	O
these	O
residues	O
among	O
tetraspanins	O
and	O
occurrence	O
of	O
polar	O
/	O
charged	O
side	O
chains	O
in	O
some	O
tetraspanins	O
precluded	O
us	O
from	O
doing	O
so	O
for	O
the	O
global	O
alignment	O
.	O

Figures	O
1	O
and	O
2	O
show	O
a	O
multiple	O
sequence	O
alignment	O
of	O
four	O
TM	O
domains	O
of	O
28	O
human	B
tetraspanins	O
.	O

For	O
each	O
position	O
within	O
the	O
domains	O
,	O
consensus	O
residues	O
were	O
determined	O
and	O
classified	O
(	O
with	O
individual	O
color	O
code	O
)	O
in	O
4	O
categories	O
:	O
1	O
)	O
large	O
hydrophobic	O
residues	O
(	O
including	O
Val	O
,	O
Met	O
,	O
Leu	O
,	O
Ile	O
,	O
Phe	O
,	O
Tyr	O
,	O
Trp	O
)	O
,	O
2	O
)	O
small	O
residues	O
(	O
Gly	O
,	O
Ala	O
,	O
Ser	O
and	O
Thr	O
)	O
,	O
3	O
)	O
Cys	O
,	O
and	O
4	O
)	O
Asn	O
.	O

When	O
more	O
than	O
two	O
types	O
of	O
residues	O
occupied	O
a	O
given	O
position	O
in	O
a	O
TM	O
,	O
a	O
dual	O
-	O
color	O
pattern	O
that	O
reflected	O
the	O
prevalence	O
of	O
the	O
particular	O
residue	O
type	O
was	O
used	O
(	O
Figure	O
1	O
)	O
.	O

Cysteine	O
residues	O
were	O
shown	O
separately	O
due	O
to	O
their	O
importance	O
as	O
palmitoylation	O
target	O
sites	O
.	O

The	O
highly	O
conserved	O
asparagine	O
residue	O
in	O
TM1	O
was	O
considered	O
separately	O
.	O

No	O
proline	O
residues	O
are	O
found	O
in	O
TM	O
domains	O
1–3	O
of	O
human	B
tetraspanins	O
.	O

An	O
inspection	O
of	O
the	O
multiple	O
sequence	O
alignment	O
reveals	O
a	O
repeating	O
heptad	O
amino	O
acid	O
pattern	O
,	O
(	O
abcdefg	O
)	O
n	O
,	O
in	O
TM1	O
,	O
2	O
and	O
3	O
(	O
Figure	O
1	O
,	O
2	O
)	O
.	O

Heptad	O
repeats	O
promote	O
helical	O
coiled	O
coil	O
interactions	O
in	O
multiple	O
soluble	O
and	O
membrane	O
-	O
spanning	O
proteins	O
[	O
29	O
-	O
31	O
]	O
.	O

In	O
the	O
heptad	O
repeat	O
,	O
hydrophobic	O
residues	O
in	O
positions	O
a	O
and	O
d	O
are	O
of	O
special	O
importance	O
,	O
as	O
they	O
directly	O
mediate	O
interhelical	O
contacts	O
by	O
creating	O
a	O
tight	O
knobs	O
-	O
into	O
-	O
holes	O
packing	O
in	O
the	O
coiled	O
coil	O
structure	O
[	O
32	O
]	O
.	O

For	O
instance	O
,	O
in	O
the	O
leucine	O
zipper	O
of	O
the	O
yeast	B
transcription	O
factor	O
GCN4	O
,	O
positions	O
a	O
and	O
d	O
contain	O
Val	O
and	O
Leu	O
residues	O
,	O
respectively	O
,	O
with	O
an	O
Asn	O
residue	O
in	O
a	O
single	O
a	O
position	O
forming	O
a	O
hydrogen	O
bond	O
across	O
the	O
GCN4	O
dimer	O
interface	O
[	O
33	O
]	O
.	O

In	O
TM1	O
of	O
tetraspanins	O
,	O
highly	O
conserved	O
Asn	O
,	O
Gly	O
and	O
Gly	O
residues	O
(	O
numbers	O
18	O
,	O
25	O
and	O
32	O
in	O
the	O
CD9	O
sequence	O
)	O
appear	O
at	O
d	O
positions	O
of	O
the	O
heptad	O
repeats	O
,	O
and	O
residues	O
14	O
,	O
21	O
and	O
28	O
are	O
at	O
a	O
positions	O
(	O
Figure	O
1	O
)	O
.	O

In	O
TM2	O
,	O
residues	O
67	O
,	O
74	O
and	O
81	O
(	O
consensus	O
Gly	O
,	O
Gly	O
and	O
Ala	O
,	O
respectively	O
)	O
occupy	O
a	O
positions	O
,	O
whereas	O
residues	O
63	O
,	O
70	O
and	O
77	O
are	O
at	O
d	O
positions	O
.	O

Another	O
highly	O
conserved	O
glycine	O
,	O
Gly80	O
,	O
occupies	O
the	O
3rd	O
g	O
position	O
in	O
TM2	O
.	O

In	O
TM3	O
,	O
the	O
conserved	O
pattern	O
consists	O
of	O
two	O
leucine	O
residues	O
(	O
Leu89	O
and	O
Leu96	O
)	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Glu	O
/	O
Gln103	O
)	O
in	O
a	O
positions	O
(	O
Figure	O
2	O
)	O
.	O

Two	O
d	O
positions	O
are	O
also	O
conserved	O
–	O
Phe	O
/	O
Tyr92	O
and	O
Ile	O
/	O
Val	O
/	O
Leu99	O
.	O

TM4	O
lacks	O
a	O
conserved	O
heptad	O
pattern	O
and	O
has	O
only	O
a	O
single	O
conserved	O
position	O
,	O
Glu	O
/	O
Gln209	O
(	O
with	O
four	O
exceptions	O
)	O
.	O

These	O
features	O
of	O
TM1	O
-	O
4	O
of	O
tetraspanins	O
are	O
displayed	O
on	O
helical	O
wheel	O
diagrams	O
(	O
Figure	O
3	O
)	O
.	O

Analysis	O
of	O
TM1	O
sequences	O
The	O
conserved	O
Asn	O
-	O
Gly	O
-	O
Gly	O
motif	O
,	O
occupying	O
designated	O
d	O
positions	O
of	O
the	O
heptad	O
repeat	O
,	O
is	O
the	O
most	O
prominent	O
structural	O
feature	O
of	O
TM1	O
.	O

We	O
also	O
compared	O
sequences	O
of	O
CD9	O
orthologs	O
from	O
10	O
different	O
organisms	O
(	O
the	O
most	O
available	O
for	O
any	O
tetraspanin	O
)	O
to	O
gain	O
further	O
insight	O
into	O
conservation	O
and	O
variability	O
of	O
the	O
TM1	O
sequence	O
.	O

As	O
shown	O
in	O
Figure	O
4	O
,	O
positions	O
a	O
,	O
d	O
and	O
g	O
in	O
TM1	O
are	O
among	O
the	O
most	O
conserved	O
(	O
0	O
,	O
1	O
and	O
1	O
substitution	O
,	O
respectively	O
)	O
,	O
while	O
interspecies	O
variability	O
tends	O
to	O
occur	O
in	O
other	O
positions	O
:	O
b	O
(	O
5	O
substitutions	O
)	O
,	O
c	O
(	O
4	O
substitutions	O
)	O
,	O
e	O
(	O
4	O
substitutions	O
)	O
and	O
f	O
(	O
4	O
substitutions	O
)	O
.	O

Thus	O
,	O
the	O
positions	O
typically	O
involved	O
in	O
coiled	O
coil	O
interactions	O
(	O
a	O
and	O
d	O
)	O
are	O
the	O
most	O
conserved	O
.	O

When	O
residues	O
of	O
TM1	O
are	O
plotted	O
as	O
a	O
helical	O
wheel	O
,	O
additional	O
structural	O
features	O
are	O
revealed	O
(	O
Figure	O
3	O
)	O
.	O

There	O
are	O
highly	O
conserved	O
aliphatic	O
and	O
aromatic	O
residues	O
in	O
the	O
first	O
three	O
a	O
positions	O
of	O
the	O
heptad	O
motif	O
(	O
Phe15	O
,	O
Trp22	O
and	O
Leu29	O
in	O
CD9	O
)	O
,	O
as	O
well	O
as	O
in	O
g	O
positions	O
(	O
Leu14	O
,	O
Phe21	O
,	O
Val28	O
in	O
CD9	O
)	O
.	O

The	O
""""	O
ridges	O
""""	O
formed	O
by	O
these	O
bulky	O
residues	O
are	O
flanking	O
the	O
""""	O
groove	O
"""-"	O
forming	O
Gly	O
residues	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
position	O
d	O
motif	O
.	O

In	O
contrast	O
,	O
b	O
,	O
c	O
,	O
e	O
and	O
f	O
positions	O
show	O
an	O
overall	O
higher	O
variability	O
among	O
tetraspanins	O
,	O
as	O
also	O
seen	O
in	O
the	O
comparison	O
of	O
CD9	O
orthologs	O
described	O
above	O
.	O

Analysis	O
of	O
TM2	O
sequences	O
A	O
landmark	O
feature	O
of	O
TM2	O
in	O
tetraspanins	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
glycine	O
residues	O
(	O
Gly67	O
,	O
74	O
,	O
77	O
and	O
80	O
in	O
CD9	O
,	O
Figure	O
1	O
)	O
.	O

Other	O
substitutions	O
at	O
these	O
positions	O
are	O
almost	O
exclusively	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
or	O
Ser	O
.	O

In	O
addition	O
,	O
Ala	O
,	O
Ser	O
or	O
Thr	O
occupy	O
position	O
81	O
.	O

This	O
residue	O
,	O
together	O
with	O
Gly67	O
and	O
Gly74	O
,	O
forms	O
face	O
a	O
of	O
the	O
helix	O
.	O

Residue	O
Gly77	O
(	O
position	O
d	O
)	O
is	O
preceded	O
by	O
conserved	O
,	O
chiefly	O
large	O
hydrophobic	O
residues	O
on	O
the	O
same	O
helical	O
face	O
(	O
Leu63	O
and	O
Met70	O
in	O
CD9	O
)	O
.	O

Extremely	O
conserved	O
Gly80	O
falls	O
into	O
heptad	O
position	O
g	O
(	O
Figure	O
3	O
)	O
.	O

Among	O
CD9	O
orthologs	O
,	O
heptad	O
positions	O
a	O
and	O
d	O
are	O
absolutely	O
conserved	O
,	O
whereas	O
other	O
positions	O
have	O
the	O
following	O
number	O
of	O
substitutions	O
:	O
b	O
–	O
3	O
;	O
c	O
–	O
2	O
;	O
e	O
–	O
1	O
;	O
f	O
–	O
3	O
;	O
g	O
–	O
1	O
(	O
Figure	O
4	O
)	O
.	O

Two	O
of	O
the	O
f	O
position	O
residues	O
in	O
TM2	O
(	O
65	O
and	O
79	O
)	O
also	O
show	O
higher	O
variability	O
among	O
different	O
tetraspanins	O
(	O
Figures	O
1	O
,	O
3	O
)	O
.	O

Cysteine	O
residues	O
are	O
frequently	O
found	O
near	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
helix	O
at	O
positions	O
78	O
and	O
79	O
;	O
these	O
cysteines	O
are	O
likely	O
to	O
be	O
palmitoylated	O
.	O

Analysis	O
of	O
TM3	O
and	O
TM4	O
sequences	O
The	O
TM3	O
domain	O
provides	O
another	O
example	O
of	O
the	O
heptad	O
repeat	O
pattern	O
.	O

Position	O
a	O
is	O
occupied	O
by	O
two	O
highly	O
conserved	O
leucine	O
and	O
a	O
glutamate	O
/	O
glutamine	O
residue	O
(	O
Leu89	O
,	O
Leu96	O
and	O
Glu	O
/	O
Gln103	O
in	O
CD9	O
)	O
.	O

Furthermore	O
,	O
two	O
d	O
positions	O
are	O
conserved	O
–	O
Phe	O
/	O
Tyr92	O
(	O
aromatic	O
residue	O
)	O
and	O
Ile	O
/	O
Val99	O
(	O
β	O
-	O
branched	O
aliphatic	O
residue	O
;	O
Figures	O
2	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
residue	O
100	O
in	O
position	O
e	O
is	O
generally	O
Phe	O
or	O
Leu	O
.	O

Among	O
CD9	O
orthologs	O
,	O
position	O
a	O
has	O
1	O
substitution	O
,	O
positions	O
b	O
,	O
c	O
and	O
f	O
each	O
have	O
6	O
,	O
positions	O
d	O
and	O
e	O
each	O
have	O
2	O
,	O
and	O
g	O
has	O
4	O
.	O

Thus	O
,	O
as	O
for	O
TM1	O
and	O
TM2	O
,	O
positions	O
a	O
and	O
d	O
are	O
among	O
the	O
most	O
conserved	O
,	O
but	O
overall	O
TM3	O
has	O
more	O
variable	O
positions	O
than	O
TM1	O
or	O
TM2	O
(	O
Figure	O
3	O
)	O
.	O

Less	O
than	O
half	O
of	O
TM3	O
sequences	O
contain	O
cysteine	O
residues	O
,	O
and	O
those	O
tend	O
to	O
occur	O
at	O
the	O
internal	O
positions	O
of	O
the	O
helix	O
(	O
Figure	O
2	O
)	O
.	O

TM4	O
shows	O
less	O
conservation	O
among	O
various	O
tetraspanin	O
family	O
members	O
than	O
the	O
other	O
TM	O
domains	O
(	O
Figures	O
2	O
,	O
3	O
)	O
.	O

The	O
only	O
highly	O
conserved	O
feature	O
is	O
the	O
glutamate	O
/	O
glutamine	O
residue	O
in	O
position	O
209	O
.	O

In	O
addition	O
,	O
one	O
or	O
two	O
cysteine	O
residues	O
can	O
be	O
found	O
at	O
the	O
C	O
-	O
terminal	O
end	O
of	O
TM4	O
in	O
some	O
tetraspanins	O
(	O
e.g.	O
CD9	O
,	O
CD81	O
,	O
CD151	O
)	O
,	O
and	O
many	O
sequences	O
contain	O
additional	O
polar	O
residues	O
(	O
Arg	O
,	O
Lys	O
,	O
His	O
,	O
Asn	O
,	O
Gln	O
)	O
.	O

No	O
conserved	O
heptad	O
motif	O
was	O
identified	O
in	O
TM4	O
,	O
as	O
also	O
confirmed	O
by	O
analysis	O
of	O
substitutions	O
in	O
CD9	O
orthologs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutational	O
analysis	O
of	O
conserved	O
glycine	O
residues	O
in	O
TM1	O
and	O
TM2	O
The	O
conserved	O
nature	O
of	O
the	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
prompted	O
an	O
analysis	O
of	O
their	O
functional	O
role	O
.	O

To	O
this	O
end	O
,	O
we	O
have	O
probed	O
whether	O
mutations	O
of	O
these	O
residues	O
destabilize	O
the	O
protein	O
molecule	O
.	O

We	O
expressed	O
a	O
construct	O
of	O
the	O
first	O
and	O
second	O
TMs	O
of	O
CD9	O
,	O
connected	O
by	O
the	O
small	O
extracellular	O
loop	O
,	O
and	O
tagged	O
with	O
a	O
C	O
-	O
terminal	O
green	O
fluorescent	O
protein	O
(	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
molecule	O
)	O
.	O

In	O
human	B
rhabdomyosarcoma	O
RD	O
cells	O
,	O
the	O
wild	O
-	O
type	O
fusion	O
protein	O
localized	O
mostly	O
in	O
a	O
reticular	O
,	O
intracellular	O
pattern	O
,	O
without	O
forming	O
any	O
large	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
A	O
)	O
.	O

Remarkably	O
,	O
when	O
double	O
mutants	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
were	O
expressed	O
,	O
the	O
protein	O
formed	O
distinct	O
large	O
aggregates	O
in	O
a	O
high	O
proportion	O
of	O
cells	O
(	O
Figure	O
5	O
,	O
panels	O
C	O
and	O
E	O
)	O
.	O

In	O
contrast	O
,	O
double	O
mutant	O
Gly77Leu	O
+	O
Gly80Leu	O
did	O
not	O
form	O
such	O
aggregates	O
(	O
Figure	O
5	O
,	O
panel	O
G	O
)	O
.	O

Results	O
with	O
respective	O
single	O
mutants	O
were	O
similar	O
to	O
that	O
with	O
double	O
mutants	O
,	O
with	O
the	O
aggregation	O
being	O
somewhat	O
more	O
pronounced	O
for	O
Leu	O
substitutions	O
of	O
Gly67	O
and	O
Gly74	O
compared	O
to	O
Gly25	O
and	O
Gly32	O
mutations	O
.	O

No	O
aggregation	O
was	O
observed	O
for	O
Asn18Ser	O
and	O
Asn18Tyr	O
mutants	O
(	O
data	O
not	O
shown	O
)	O
.	O

Also	O
,	O
nearly	O
identical	O
results	O
were	O
obtained	O
with	O
human	B
HT1080	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
interpret	O
these	O
results	O
as	O
an	O
indication	O
that	O
aggregating	O
mutants	O
are	O
destabilized	O
or	O
misfolded	O
while	O
non	O
-	O
aggregating	O
mutants	O
retain	O
the	O
wild	O
-	O
type	O
conformation	O
.	O

Intriguingly	O
,	O
mutations	O
to	O
the	O
conserved	O
GG7	O
motifs	O
caused	O
protein	O
aggregation	O
while	O
the	O
mutation	O
of	O
other	O
glycines	O
had	O
no	O
detectable	O
effect	O
.	O

These	O
results	O
also	O
suggest	O
that	O
wild	O
-	O
type	O
GFP	O
,	O
which	O
has	O
weak	O
tendency	O
to	O
self	O
-	O
associate	O
,	O
could	O
enhance	O
non	O
-	O
specific	O
interactions	O
of	O
destabilized	O
mutant	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
moieties	O
,	O
leading	O
to	O
their	O
aggregation	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
aggregation	O
of	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
Gly67Leu	O
+	O
Gly74Leu	O
double	O
mutants	O
was	O
suppressed	O
when	O
monomeric	O
GFP	O
molecule	O
,	O
Leu221Lys	O
[	O
34	O
]	O
was	O
used	O
(	O
Figure	O
5	O
,	O
panels	O
D	O
and	O
F	O
)	O
.	O

The	O
use	O
of	O
monomeric	O
GFP	O
did	O
not	O
affect	O
intercellular	O
localization	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
(	O
Figure	O
5	O
,	O
panel	O
B	O
)	O
,	O
or	O
a	O
Gly77Leu	O
+	O
Gly80Leu	O
double	O
mutant	O
(	O
Figure	O
5	O
,	O
panel	O
H	O
)	O
.	O

In	O
summary	O
,	O
Leu	O
substitutions	O
of	O
Gly	O
residues	O
that	O
are	O
part	O
of	O
the	O
Asn	O
-	O
Gly	O
-	O
Gly	O
(	O
NGG7	O
)	O
motif	O
in	O
TM1	O
,	O
or	O
Gly	O
-	O
Gly	O
-	O
Ala	O
(	O
GGA7	O
)	O
motif	O
in	O
TM2	O
,	O
resulted	O
in	O
destabilization	O
and	O
aggregation	O
of	O
GFP	O
-	O
fused	O
TM	O
(	O
1	O
+	O
2	O
)	O
proteins	O
,	O
whereas	O
substitutions	O
of	O
Gly77	O
or	O
Gly80	O
,	O
which	O
are	O
not	O
part	O
of	O
these	O
motifs	O
(	O
Figure	O
3	O
)	O
,	O
failed	O
to	O
show	O
such	O
aggregation	O
.	O

Prediction	O
and	O
modelling	O
of	O
interaction	O
between	O
TM1	O
and	O
TM2	O
Consecutive	O
helices	O
in	O
polytopic	O
membrane	O
proteins	O
frequently	O
interact	O
[	O
35	O
]	O
.	O

Sequence	O
analysis	O
of	O
TM1	O
and	O
TM2	O
helices	O
of	O
tetraspanins	O
reveals	O
a	O
remarkable	O
complementarity	O
in	O
the	O
distribution	O
of	O
large	O
and	O
small	O
residues	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
along	O
the	O
helical	O
axis	O
(	O
Figure	O
3	O
)	O
,	O
suggesting	O
that	O
these	O
residues	O
may	O
interact	O
.	O

To	O
further	O
elucidate	O
the	O
potential	O
for	O
TM1-TM2	O
interaction	O
,	O
the	O
putative	O
interface	O
was	O
modeled	O
using	O
a	O
novel	O
algorithm	O
that	O
considers	O
mutational	O
data	O
during	O
each	O
step	O
of	O
a	O
Monte	O
Carlo	O
simulated	O
annealing	O
cycle	O
(	O
see	O
Methods	O
for	O
details	O
)	O
.	O

Specifically	O
,	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
and	O
Gly74Leu	O
were	O
scored	O
as	O
disruptive	O
mutations	O
,	O
while	O
Asn18Ser	O
,	O
Gly77Leu	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
,	O
based	O
on	O
their	O
effects	O
on	O
protein	O
stability	O
(	O
Figure	O
5	O
and	O
data	O
not	O
shown	O
)	O
.	O

The	O
resulting	O
model	O
predicts	O
left	O
-	O
handed	O
crossing	O
of	O
TM1	O
and	O
TM2	O
helices	O
at	O
an	O
angle	O
of	O
+	O
28	O
°	O
.	O

The	O
key	O
element	O
of	O
the	O
structure	O
is	O
the	O
apposition	O
of	O
bulky	O
and	O
small	O
heptad	O
position	O
a	O
and	O
d	O
residues	O
,	O
as	O
follows	O
:	O
Gly32-Leu63	O
;	O
Gly67-Leu29	O
;	O
Gly25-Met70	O
;	O
Gly74-Trp22	O
;	O
Asn18-Gly77	O
;	O
Ala81-Phe15	O
(	O
Figure	O
6	O
)	O
.	O

Our	O
model	O
predicts	O
that	O
each	O
of	O
these	O
residue	O
pairs	O
are	O
in	O
van	O
der	O
Waals	O
contact	O
.	O

Additionally	O
,	O
two	O
potential	O
H	O
-	O
bonds	O
are	O
predicted	O
in	O
this	O
model	O
,	O
indicating	O
close	O
packing	O
:	O
Gly67	O
Cα	O
to	O
Gly25	O
carbonyl	O
oxygen	O
,	O
and	O
Trp22	O
Cα	O
to	O
Met70	O
carbonyl	O
oxygen	O
.	O

The	O
packing	O
is	O
tighter	O
in	O
the	O
ectodomain	O
-	O
proximal	O
portion	O
of	O
the	O
helices	O
(	O
Figure	O
6	O
,	O
panel	O
B	O
)	O
,	O
as	O
determined	O
by	O
Cα	O
-	O
Cα	O
distances	O
between	O
interacting	O
residue	O
pairs	O
.	O

The	O
key	O
elements	O
of	O
the	O
model	O
are	O
corroborated	O
by	O
the	O
presence	O
of	O
apparently	O
complementary	O
substitutions	O
in	O
TM1	O
and	O
TM2	O
sequences	O
of	O
different	O
tetraspanins	O
(	O
Figure	O
1	O
,	O
boxed	O
residues	O
)	O
.	O

For	O
example	O
,	O
Gly74	O
is	O
predicted	O
to	O
interact	O
with	O
Trp22	O
.	O

In	O
8	O
of	O
the	O
10	O
tetraspanins	O
that	O
contain	O
a	O
substitution	O
for	O
Gly74	O
,	O
a	O
compensatory	O
substitution	O
occurs	O
at	O
the	O
Trp22	O
position	O
(	O
Figure	O
1	O
)	O
.	O

Thus	O
,	O
a	O
larger	O
non	O
-	O
glycine	O
side	O
chain	O
at	O
position	O
74	O
may	O
necessitate	O
a	O
less	O
bulky	O
non	O
-	O
Trp	O
side	O
chain	O
in	O
position	O
22	O
.	O

Likewise	O
,	O
the	O
presence	O
of	O
a	O
Cβ	O
at	O
position	O
25	O
,	O
typically	O
occupied	O
by	O
glycine	O
,	O
necessitates	O
a	O
non	O
-	O
β	O
-	O
branched	O
amino	O
acid	O
at	O
position	O
70	O
,	O
which	O
is	O
occupied	O
by	O
a	O
β	O
-	O
branched	O
residue	O
in	O
nearly	O
half	O
of	O
all	O
cases	O
.	O

Indeed	O
,	O
we	O
find	O
that	O
in	O
each	O
of	O
5	O
cases	O
in	O
which	O
position	O
25	O
contains	O
a	O
Cβ	O
,	O
a	O
leucine	O
residue	O
occurs	O
in	O
position	O
70	O
.	O

This	O
analysis	O
is	O
consistent	O
with	O
our	O
molecular	O
model	O
that	O
suggests	O
Leu70	O
will	O
pack	O
most	O
favorably	O
against	O
a	O
Cβ	O
at	O
position	O
25	O
than	O
a	O
β	O
-	O
branched	O
residue	O
or	O
a	O
methionine	O
.	O

Role	O
of	O
TM1	O
and	O
TM2	O
heptad	O
motif	O
residues	O
in	O
CD9	O
dimerization	O
To	O
probe	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
approach	O
.	O

We	O
established	O
previously	O
a	O
simple	O
and	O
efficient	O
method	O
for	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

After	O
cells	O
are	O
pre	O
-	O
treated	O
with	O
2-BP	O
for	O
16–24	O
hours	O
to	O
expose	O
normally	O
palmitoylated	O
cysteines	O
,	O
the	O
cysteines	O
can	O
be	O
cross	O
-	O
linked	O
using	O
any	O
of	O
the	O
following	O
methods	O
:	O
a	O
)	O
Spontaneous	O
oxidation	O
in	O
Brij97	O
lysates	O
(	O
a	O
condition	O
that	O
preserves	O
tetraspanin	O
-	O
tetraspanin	O
associations	O
)	O
,	O
b	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
,	O
by	O
pre	O
-	O
lysis	O
oxidation	O
of	O
cells	O
with	O
Cu2	O
+	O
-phenanthroline	O
(	O
CuP	O
)	O
to	O
promote	O
disulfide	O
bond	O
formation	O
.	O

c	O
)	O
In	O
situ	O
cross	O
-	O
linking	O
with	O
thiol	O
-	O
reactive	O
cross	O
-	O
linking	O
agents	O
of	O
defined	O
length	O
(	O
e.g.	O
DTME	O
,	O
BMB	O
)	O
.	O

The	O
first	O
two	O
approaches	O
produce	O
in	O
essence	O
""""	O
zero	O
-	O
length	O
""""	O
disulfides	O
,	O
indicative	O
of	O
close	O
proximity	O
of	O
target	O
cysteines	O
and	O
presumably	O
high	O
specificity	O
of	O
interaction	O
.	O

In	O
contrast	O
,	O
chemical	O
cross	O
-	O
linkers	O
with	O
6–20	O
Å	O
spacer	O
arm	O
may	O
cross	O
-	O
link	O
with	O
higher	O
efficiency	O
,	O
but	O
not	O
necessarily	O
higher	O
specificity	O
.	O

However	O
,	O
they	O
provide	O
advantages	O
such	O
as	O
variable	O
membrane	O
permeability	O
,	O
and	O
potential	O
linkage	O
cleavability	O
.	O

For	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
permeable	O
cross	O
-	O
linker	O
DTME	O
(	O
13.3	O
Å	O
-	O
long	O
,	O
reducible	O
)	O
provides	O
highly	O
specific	O
and	O
efficient	O
cross	O
-	O
linking	O
[	O
25	O
]	O
.	O

Here	O
we	O
have	O
used	O
a	O
cysteine	O
cross	O
-	O
linking	O
strategy	O
,	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
to	O
map	O
the	O
residues	O
from	O
TM1	O
and	O
TM2	O
contributing	O
to	O
the	O
CD9	O
dimerization	O
interface	O
.	O

For	O
subsequent	O
cross	O
-	O
linking	O
experiments	O
using	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
,	O
the	O
non	O
-	O
dimerizing	O
form	O
of	O
GFP	O
was	O
used	O
.	O

This	O
avoids	O
potential	O
GFP	O
-	O
dependent	O
dimerization	O
and	O
aggregation	O
that	O
can	O
be	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
,	O
especially	O
when	O
fusions	O
with	O
transmembrane	O
proteins	O
are	O
studied	O
[	O
36	O
]	O
.	O

Importantly	O
,	O
the	O
Leu221Lys	O
mutation	O
in	O
GFP	O
prevented	O
aggregation	O
of	O
mutant	O
forms	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
,	O
which	O
was	O
observed	O
with	O
wild	O
-	O
type	O
GFP	O
fusion	O
(	O
Figure	O
5	O
)	O
.	O

The	O
TM	O
(	O
1	O
+	O
2	O
)	O
fragment	O
of	O
CD9	O
contains	O
three	O
native	O
cysteines	O
–	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
.	O

Single	O
-	O
cysteine	O
mutants	O
of	O
TM	O
(	O
1	O
+	O
2	O
)	O
were	O
constructed	O
,	O
in	O
which	O
a	O
cysteine	O
was	O
placed	O
at	O
various	O
faces	O
of	O
TM1	O
or	O
TM2	O
while	O
all	O
of	O
the	O
wild	O
-	O
type	O
cysteines	O
were	O
simultaneously	O
replaced	O
by	O
serines	O
.	O

The	O
mutant	O
proteins	O
were	O
transiently	O
expressed	O
in	O
RD	O
cells	O
(	O
having	O
little	O
endogenous	O
CD9	O
)	O
,	O
which	O
were	O
then	O
treated	O
for	O
16–18	O
hours	O
with	O
2-BP	O
.	O

To	O
achieve	O
maximal	O
specificity	O
in	O
cross	O
-	O
linking	O
we	O
used	O
a	O
""""	O
zero	O
-	O
length	O
""""	O
agent	O
,	O
CuP.	O
First	O
,	O
single	O
-	O
cysteine	O
replacements	O
were	O
constructed	O
for	O
residues	O
Leu14	O
,	O
Phe15	O
,	O
Gly16	O
,	O
Phe17	O
and	O
Asn18	O
,	O
covering	O
just	O
over	O
one	O
complete	O
helical	O
turn	O
at	O
the	O
beginning	O
of	O
TM1	O
.	O

While	O
residue	O
Asn18	O
is	O
highly	O
conserved	O
,	O
positions	O
14	O
,	O
15	O
and	O
17	O
are	O
occupied	O
by	O
bulky	O
hydrophobic	O
residues	O
in	O
most	O
tetraspanins	O
,	O
whereas	O
position	O
16	O
shows	O
less	O
conservation	O
(	O
Figures	O
1	O
,	O
4	O
)	O
.	O

All	O
of	O
the	O
single	O
-	O
cysteine	O
mutants	O
showed	O
diffused	O
pattern	O
of	O
protein	O
localization	O
,	O
without	O
any	O
signs	O
of	O
aggregation	O
.	O

As	O
shown	O
in	O
Figure	O
7A	O
,	O
the	O
highest	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
was	O
observed	O
for	O
Leu14Cys	O
and	O
Phe17Cys	O
mutants	O
,	O
a	O
lower	O
level	O
for	O
Phe15Cys	O
and	O
Gly16Cys	O
mutants	O
,	O
and	O
very	O
little	O
cross	O
-	O
linking	O
for	O
Asn18Cys	O
substitution	O
.	O

These	O
results	O
indicate	O
that	O
:	O
a	O
)	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
CD9	O
alone	O
can	O
mediate	O
its	O
dimerization	O
,	O
and	O
b	O
)	O
the	O
g	O
and	O
c	O
residues	O
of	O
TM1	O
(	O
e.g.	O
Leu14	O
and	O
Phe17	O
,	O
Figure	O
3	O
)	O
are	O
likely	O
to	O
be	O
part	O
of	O
the	O
intermolecular	O
interface	O
.	O

Similarly	O
,	O
single	O
-	O
cysteine	O
substitutions	O
were	O
made	O
for	O
residues	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
;	O
in	O
addition	O
,	O
proteins	O
carrying	O
a	O
single	O
wild	O
-	O
type	O
cysteine	O
,	O
Cys9	O
,	O
Cys78	O
or	O
Cys79	O
,	O
were	O
tested	O
.	O

No	O
protein	O
aggregation	O
was	O
observed	O
for	O
any	O
of	O
these	O
single	O
-	O
cysteine	O
mutants	O
.	O

As	O
shown	O
in	O
Figure	O
7B	O
,	O
the	O
relatively	O
low	O
level	O
of	O
intermolecular	O
cross	O
-	O
linking	O
of	O
wild	O
-	O
type	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
was	O
enhanced	O
dramatically	O
in	O
single	O
-	O
cysteine	O
TM2	O
mutants	O
Gly80Cys	O
and	O
Ala81Cys	O
.	O

The	O
Gly77Cys	O
mutant	O
also	O
had	O
an	O
elevated	O
level	O
of	O
cross	O
-	O
linking	O
.	O

In	O
contrast	O
,	O
any	O
of	O
the	O
three	O
native	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
produced	O
level	O
of	O
cross	O
-	O
linking	O
not	O
much	O
greater	O
than	O
the	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
BMB	O
(	O
data	O
not	O
shown	O
)	O
.	O

Likewise	O
,	O
comparable	O
results	O
were	O
obtained	O
with	O
single	O
-	O
cysteine	O
mutants	O
of	O
untagged	O
,	O
full	O
-	O
length	O
CD9	O
,	O
using	O
CuP	O
(	O
Figure	O
7C	O
)	O
as	O
well	O
as	O
DTME	O
cross	O
-	O
linker	O
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
cross	O
-	O
linking	O
results	O
for	O
TM1	O
and	O
TM2	O
are	O
consistent	O
with	O
our	O
model	O
that	O
places	O
residues	O
Leu14	O
,	O
Phe17	O
and	O
Gly80	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1-TM2	O
pair	O
(	O
Figure	O
6	O
,	O
panel	O
C	O
)	O
.	O

The	O
strong	O
cross	O
-	O
linking	O
with	O
Leu14Cys	O
,	O
Phe17Cys	O
and	O
Gly80Cys	O
places	O
the	O
intermolecular	O
interface	O
toward	O
the	O
c	O
and	O
g	O
phases	O
of	O
the	O
TM1	O
helix	O
,	O
and	O
the	O
g	O
phase	O
of	O
the	O
TM2	O
helix	O
,	O
away	O
from	O
its	O
e	O
and	O
f	O
faces	O
containing	O
wild	O
-	O
type	O
cysteines	O
78	O
and	O
79	O
.	O

Critical	O
residues	O
at	O
the	O
TM1-TM2	O
interface	O
also	O
affect	O
dimerization	O
indirectly	O
.	O

To	O
assess	O
specific	O
CD9	O
dimerization	O
,	O
we	O
used	O
a	O
Gly80Cys	O
substitution	O
at	O
the	O
intermolecular	O
interface	O
for	O
cross	O
-	O
linking	O
.	O

As	O
shown	O
in	O
Figure	O
8A	O
,	O
single	O
replacements	O
of	O
conserved	O
heptad	O
residues	O
in	O
positions	O
18	O
,	O
25	O
,	O
32	O
,	O
67	O
and	O
74	O
(	O
Asn18Ser	O
,	O
Gly25	O
/	O
32	O
/	O
67	O
/	O
74→Leu	O
)	O
strongly	O
decreased	O
the	O
cross	O
-	O
linking	O
mediated	O
by	O
Cys80	O
.	O

The	O
effect	O
was	O
most	O
pronounced	O
for	O
mutations	O
of	O
residues	O
,	O
Gly32	O
and	O
Gly67	O
,	O
located	O
in	O
the	O
tightly	O
packed	O
extracellular	O
end	O
of	O
TM	O
helices	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
mutations	O
of	O
residues	O
closer	O
to	O
the	O
cytoplasmic	O
end	O
of	O
TM2	O
(	O
Gly74	O
and	O
especially	O
Ala81	O
)	O
had	O
only	O
modest	O
to	O
very	O
little	O
effect	O
on	O
cross	O
-	O
linking	O
.	O

Relatively	O
low	O
efficiency	O
of	O
intermolecular	O
cross	O
-	O
linking	O
via	O
native	O
residues	O
Cys9	O
,	O
78	O
,	O
and	O
79	O
(	O
Figures	O
7B	O
,	O
C	O
)	O
correlates	O
well	O
with	O
the	O
predicted	O
location	O
of	O
Cys78	O
and	O
79	O
away	O
from	O
the	O
dimeric	O
interface	O
(	O
Figure	O
3	O
)	O
,	O
and	O
suggests	O
that	O
the	O
extramembrane	O
N	O
-	O
terminal	O
part	O
of	O
CD9	O
(	O
residues	O
1–13	O
)	O
does	O
not	O
self	O
-	O
associate	O
.	O

We	O
next	O
examined	O
whether	O
mutations	O
of	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
decreased	O
low	O
-	O
level	O
background	O
cross	O
-	O
linking	O
via	O
native	O
cysteines	O
.	O

As	O
expected	O
,	O
these	O
mutations	O
had	O
virtually	O
no	O
effect	O
on	O
dimer	O
formation	O
of	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
(	O
Figure	O
8B	O
)	O
.	O

The	O
level	O
of	O
covalent	O
dimer	O
formed	O
was	O
not	O
diminished	O
for	O
triple	O
Asn18Ser	O
+	O
Gly25Leu	O
+	O
Gly32Leu	O
and	O
double	O
Gly67Leu	O
+	O
Gly74Leu	O
mutants	O
,	O
compared	O
to	O
wild	O
-	O
type	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
molecule	O
.	O

Similarly	O
,	O
the	O
same	O
triple	O
and	O
double	O
mutations	O
in	O
the	O
context	O
of	O
full	O
-	O
length	O
CD9-GFP	O
protein	O
(	O
with	O
six	O
cysteines	O
)	O
produced	O
wild	O
-	O
type	O
levels	O
of	O
cross	O
-	O
linking	O
(	O
Figure	O
8C	O
)	O
.	O

We	O
interpret	O
these	O
findings	O
as	O
evidence	O
for	O
at	O
least	O
two	O
types	O
of	O
associations	O
between	O
CD9	O
molecules	O
:	O
primary	O
,	O
involving	O
residues	O
14	O
,	O
17	O
and	O
80	O
,	O
and	O
dependent	O
on	O
integrity	O
of	O
conserved	O
heptad	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
and	O
less	O
efficient	O
secondary	O
interactions	O
,	O
probably	O
representing	O
random	O
collision	O
events	O
,	O
and	O
independent	O
of	O
the	O
heptad	O
residues	O
(	O
see	O
Discussion	O
for	O
more	O
details	O
)	O
.	O

TM3	O
and	O
TM4	O
cysteine	O
residues	O
in	O
CD9	O
dimerization	O
After	O
identifying	O
the	O
roles	O
of	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
CD9	O
dimerization	O
,	O
we	O
next	O
probed	O
whether	O
residues	O
proximal	O
to	O
TM	O
domains	O
3	O
and	O
4	O
are	O
also	O
involved	O
.	O

To	O
this	O
end	O
,	O
disulfide	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
CD9	O
molecules	O
containing	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
87	O
,	O
just	O
before	O
TM3	O
;	O
218	O
and	O
219	O
in	O
TM4	O
)	O
or	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
9	O
,	O
78	O
and	O
79	O
)	O
was	O
compared	O
(	O
Figure	O
9	O
)	O
.	O

We	O
found	O
that	O
the	O
C	O
-	O
terminal	O
cysteines	O
were	O
only	O
slightly	O
better	O
than	O
N	O
-	O
terminal	O
cysteines	O
with	O
respect	O
to	O
detection	O
of	O
CD9	O
dimers	O
.	O

However	O
,	O
markedly	O
more	O
trimers	O
and	O
tetramers	O
were	O
detected	O
using	O
C	O
-	O
terminal	O
cysteines	O
.	O

Thus	O
,	O
residues	O
87	O
,	O
218	O
and	O
219	O
at	O
TM3	O
and	O
TM4	O
in	O
CD9	O
can	O
together	O
form	O
contacts	O
across	O
the	O
dimeric	O
interface	O
and	O
also	O
additional	O
contacts	O
with	O
other	O
neighboring	O
CD9	O
molecules	O
.	O

Discussion	O
Here	O
we	O
provide	O
the	O
first	O
detailed	O
analysis	O
of	O
tetraspanin	O
protein	O
transmembrane	O
domains	O
.	O

First	O
,	O
we	O
show	O
1	O
)	O
the	O
presence	O
of	O
a	O
heptad	O
repeat	O
motif	O
in	O
TM1	O
and	O
TM2	O
,	O
containing	O
highly	O
conserved	O
Asn	O
and	O
Gly	O
residues	O
,	O
2	O
)	O
a	O
leucine	O
and	O
glutamate	O
/	O
glutamine	O
-	O
containing	O
heptad	O
motif	O
in	O
TM3	O
,	O
and	O
3	O
)	O
high	O
variability	O
and	O
absence	O
of	O
heptad	O
repeats	O
in	O
TM4	O
sequences	O
.	O

Second	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
specific	O
,	O
intramolecular	O
interaction	O
between	O
TM1	O
and	O
TM2	O
domains	O
,	O
in	O
which	O
bulky	O
hydrophobic	O
residues	O
pack	O
against	O
GG7	O
motif	O
,	O
and	O
present	O
a	O
molecular	O
model	O
for	O
this	O
interaction	O
.	O

Third	O
,	O
experimental	O
mapping	O
of	O
the	O
CD9	O
dimerization	O
interface	O
firmly	O
establishes	O
an	O
additional	O
role	O
for	O
conserved	O
TM1	O
and	O
TM2	O
residues	O
in	O
dimeric	O
intermolecular	O
interactions	O
.	O

Fourth	O
,	O
preliminary	O
evidence	O
is	O
provided	O
to	O
suggest	O
that	O
TM3	O
and	O
TM4	O
domains	O
contribute	O
to	O
expansion	O
of	O
CD9	O
dimers	O
into	O
higher	O
order	O
multimers	O
.	O

Conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
:	O
role	O
in	O
intramolecular	O
packing	O
We	O
hypothesized	O
that	O
the	O
first	O
two	O
transmembrane	O
domains	O
of	O
tetraspanins	O
might	O
interact	O
with	O
each	O
other	O
because	O
:	O
a	O
)	O
consecutive	O
TM	O
domains	O
frequently	O
associate	O
in	O
known	O
protein	O
3D	O
structures	O
[	O
35	O
]	O
,	O
and	O
b	O
)	O

they	O
both	O
contain	O
a	O
series	O
of	O
highly	O
conserved	O
amino	O
acids	O
–	O
several	O
Gly	O
residues	O
and	O
an	O
Asn	O
residue	O
(	O
Figure	O
1	O
)	O
.	O

Conserved	O
Gly	O
residues	O
are	O
a	O
frequent	O
theme	O
in	O
the	O
organization	O
of	O
interacting	O
transmembrane	O
domains	O
.	O

Analysis	O
of	O
3D	O
helix	O
packing	O
in	O
polytopic	O
membrane	O
proteins	O
reveals	O
that	O
Gly	O
residues	O
tend	O
to	O
localize	O
in	O
buried	O
positions	O
,	O
especially	O
at	O
the	O
helix	O
-	O
helix	O
interfaces	O
and	O
helix	O
crossing	O
points	O
[	O
37,38	O
]	O
.	O

Due	O
to	O
the	O
absence	O
of	O
a	O
side	O
chain	O
,	O
Gly	O
provides	O
a	O
flat	O
surface	O
for	O
packing	O
of	O
a	O
side	O
chain	O
from	O
another	O
residue	O
,	O
without	O
loss	O
of	O
side	O
-	O
chain	O
entropy	O
upon	O
interaction	O
.	O

The	O
most	O
common	O
Gly	O
-	O
containing	O
motif	O
is	O
GxxxG	O
[	O
39,40	O
]	O
.	O

In	O
glycophorin	O
A	O
(	O
GpA	O
)	O
,	O
the	O
major	O
glycoprotein	O
in	O
erythrocyte	O
cell	O
membranes	O
,	O
Gly79	O
and	O
Gly83	O
are	O
part	O
of	O
the	O
LIxxGVxxGVxxT	O
sequence	O
that	O
promotes	O
homodimerization	O
of	O
parallel	O
transmembrane	O
α	O
-	O
helixes	O
[	O
41,42	O
]	O
.	O

In	O
the	O
GpA	O
dimerization	O
motif	O
,	O
Gly	O
residues	O
allow	O
for	O
tight	O
packing	O
in	O
the	O
right	O
-	O
handed	O
helical	O
crossing	O
[	O
43	O
]	O
.	O

There	O
are	O
also	O
examples	O
of	O
left	O
-	O
handed	O
helical	O
crossing	O
in	O
the	O
context	O
of	O
a	O
GxxxG	O
motif	O
[	O
44	O
]	O
.	O

Other	O
membrane	O
proteins	O
that	O
use	O
the	O
GxxxG	O
motif	O
for	O
homo-	O
or	O
heterodimerization	O
include	O
bacteriophage	B
M13	I
coat	O
proteins	O
[	O
45	O
]	O
,	O
yeast	B
alpha	O
factor	O
receptor	O
[	O
46	O
]	O
,	O
integrin	O
α	O
IIb	O
subunit	O
[	O
47	O
]	O
,	O
and	O
ErbB1	O
receptor	O
tyrosine	O
kinase	O
[	O
48	O
]	O
.	O

Other	O
small	O
residues	O
,	O
such	O
as	O
Ala	O
and	O
Ser	O
,	O
can	O
substitute	O
for	O
Gly	O
in	O
this	O
motif	O
[	O
49	O
]	O
.	O

A	O
protein	O
motif	O
in	O
which	O
Gly	O
residues	O
are	O
separated	O
by	O
6	O
other	O
residues	O
(	O
GG7	O
)	O
is	O
also	O
common	O
in	O
transmembrane	O
helices	O
,	O
especially	O
in	O
transporter	O
/	O
channel	O
-	O
like	O
membrane	O
proteins	O
[	O
50	O
]	O
.	O

However	O
,	O
the	O
structural	O
features	O
associated	O
with	O
this	O
motif	O
are	O
not	O
well	O
known	O
.	O

In	O
particular	O
,	O
it	O
is	O
unclear	O
whether	O
left	O
-	O
handed	O
GG7	O
heptad	O
repeat	O
motif	O
(	O
as	O
opposed	O
to	O
the	O
""""	O
classic	O
""""	O
right	O
-	O
handed	O
GxxxG	O
motif	O
)	O
can	O
drive	O
membrane	O
helix	O
association	O
.	O

In	O
a	O
recent	O
work	O
addressing	O
this	O
issue	O
,	O
Lear	O
et	O
al.	O
[	O
51	O
]	O
showed	O
that	O
a	O
synthetic	O
peptide	O
containing	O
Gly	O
at	O
heptad	O
positions	O
a	O
and	O
d	O
could	O
self	O
-	O
associate	O
in	O
vitro	O
,	O
likely	O
in	O
an	O
antiparallel	O
orientation	O
.	O

Heptad	O
repeats	O
containing	O
conserved	O
Gly	O
residues	O
occur	O
in	O
TM	O
domains	O
of	O
α	O
and	O
β	O
chains	O
of	O
MHC	O
class	O
II	O
proteins	O
,	O
and	O
mutations	O
of	O
the	O
Gly	O
residues	O
disrupt	O
the	O
αβ	O
heterodimer	O
[	O
52	O
]	O
.	O

These	O
examples	O
demonstrate	O
that	O
Gly	O
-	O
based	O
heptad	O
motifs	O
may	O
be	O
used	O
for	O
both	O
intra-	O
and	O
intermolecular	O
associations	O
.	O

In	O
this	O
work	O
,	O
we	O
identified	O
a	O
highly	O
conserved	O
GG7	O
motif	O
in	O
the	O
first	O
two	O
tetraspanin	O
TM	O
domains	O
.	O

The	O
GG7	O
sequence	O
in	O
tetraspanins	O
is	O
a	O
part	O
of	O
a	O
larger	O
motif	O
that	O
also	O
includes	O
a	O
conserved	O
Asn	O
residue	O
in	O
TM1	O
(	O
NGG7	O
)	O
and	O
an	O
Ala	O
/	O
Ser	O
/	O
Thr	O
residue	O
in	O
TM2	O
(	O
GGA7	O
)	O
.	O

The	O
seven	O
-	O
residue	O
periodicity	O
of	O
these	O
motifs	O
strongly	O
suggests	O
their	O
involvement	O
in	O
left	O
-	O
handed	O
coiled	O
coil	O
packing	O
reminiscent	O
of	O
the	O
leucine	O
zipper	O
,	O
rather	O
than	O
right	O
-	O
handed	O
packing	O
of	O
the	O
GpA	O
-	O
like	O
GxxxG	O
motif	O
.	O

For	O
antiparallel	O
helices	O
,	O
the	O
left	O
-	O
handed	O
crossing	O
is	O
in	O
fact	O
predominant	O
over	O
the	O
right	O
-	O
handed	O
in	O
known	O
TM	O
domain	O
structures	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
heptad	O
Gly	O
residues	O
in	O
NGG7	O
and	O
GGA7	O
sequences	O
provide	O
specific	O
packing	O
between	O
antiparallel	O
tetraspanin	O
TM1	O
and	O
TM2	O
helices	O
by	O
allowing	O
tight	O
van	O
der	O
Waals	O
interactions	O
with	O
large	O
hydrophobic	O
residues	O
(	O
Figure	O
6	O
)	O
.	O

Highly	O
efficient	O
packing	O
of	O
bulky	O
side	O
chains	O
against	O
glycine	O
residues	O
is	O
observed	O
in	O
known	O
transmembrane	O
protein	O
3D	O
structures	O
[	O
38,53,54	O
]	O
.	O

An	O
example	O
includes	O
packing	O
of	O
helices	O
M1	O
and	O
M2	O
in	O
potassium	O
channel	O
KcsA	O
,	O
where	O
Val91	O
in	O
M2	O
is	O
paired	O
with	O
Gly43	O
in	O
M1	O
,	O
and	O
Leu36	O
in	O
M1	O
contacts	O
Ala98	O
and	O
Gly99	O
in	O
helix	O
M2	O
[	O
54,55	O
]	O
.	O

In	O
addition	O
to	O
facilitating	O
helix	O
-	O
helix	O
packing	O
,	O
Gly	O
residues	O
frequently	O
provide	O
additional	O
CαH	O
...	O

O	O
hydrogen	O
bonds	O
between	O
two	O
helices	O
[	O
44	O
]	O
.	O

In	O
our	O
model	O
,	O
two	O
Cα	O
-	O
backbone	O
carbonyl	O
H	O
-	O
bonds	O
are	O
predicted	O
–	O
between	O
residues	O
Gly27-Gly67	O
,	O
and	O
Trp22-Met70	O
.	O

Although	O
polar	O
and	O
charged	O
amino	O
acid	O
residues	O
(	O
such	O
as	O
Asn	O
in	O
the	O
TM1	O
heptad	O
motif	O
)	O
are	O
infrequent	O
in	O
transmembrane	O
domains	O
,	O
they	O
are	O
functionally	O
important	O
.	O

Polar	O
residues	O
such	O
as	O
glutamine	O
,	O
glutamic	O
acid	O
,	O
aspartic	O
acid	O
and	O
asparagine	O
can	O
promote	O
strong	O
oligomerization	O
of	O
model	O
membrane	O
-	O
associated	O
helices	O
[	O
56	O
-	O
58	O
]	O
.	O

Ruan	O
et	O
al.	O
[	O
59	O
]	O
used	O
asparagine	O
scanning	O
mutagenesis	O
to	O
probe	O
the	O
interface	O
of	O
self	O
-	O
associating	O
polyleucine	O
helices	O
by	O
detecting	O
their	O
enhanced	O
self	O
-	O
interaction	O
in	O
vitro	O
and	O
in	O
the	O
E.	B
coli	I
-	O
based	O
ToxR	O
assay	O
.	O

Thus	O
,	O
a	O
hydrogen	O
bond	O
in	O
an	O
apolar	O
environment	O
can	O
result	O
in	O
strong	O
,	O
though	O
not	O
necessarily	O
specific	O
,	O
association	O
of	O
transmembrane	O
helices	O
.	O

In	O
fact	O
,	O
mutations	O
to	O
polar	O
residues	O
in	O
transmembrane	O
proteins	O
are	O
commonly	O
associated	O
with	O
disease	O
[	O
60	O
]	O
.	O

Because	O
of	O
this	O
potential	O
for	O
non	O
-	O
specific	O
interactions	O
,	O
polar	O
residues	O
tend	O
to	O
localize	O
at	O
buried	O
positions	O
in	O
TM	O
domains	O
.	O

In	O
our	O
case	O
,	O
the	O
conserved	O
Asn18	O
residue	O
in	O
CD9	O
is	O
predicted	O
to	O
be	O
a	O
part	O
of	O
the	O
TM1-TM2	O
interface	O
,	O
though	O
our	O
model	O
does	O
not	O
predict	O
any	O
electrostatic	O
interaction	O
between	O
Asn18	O
and	O
TM2	O
(	O
Figure	O
6	O
)	O
.	O

Consistently	O
,	O
substitution	O
such	O
as	O
Asn18Tyr	O
(	O
and	O
Gly77Leu	O
)	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
protein	O
was	O
not	O
destabilizing	O
as	O
analyzed	O
by	O
protein	O
aggregation	O
.	O

Curiously	O
,	O
the	O
full	O
-	O
length	O
Asn18Ser	O
CD9	O
migrated	O
slightly	O
slower	O
on	O
SDS	O
-	O
PAGE	O
gel	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
Asn18	O
does	O
play	O
a	O
role	O
in	O
maintaining	O
conformation	O
of	O
the	O
molecule	O
.	O

The	O
Asn18Cys	O
single	O
-	O
cysteine	O
mutant	O
shows	O
very	O
little	O
intermolecular	O
cross	O
-	O
linking	O
(	O
Figure	O
7A	O
)	O
,	O
supporting	O
the	O
proposed	O
location	O
of	O
this	O
residue	O
at	O
the	O
intramolecular	O
interface	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
the	O
""""	O
pocket	O
""""	O
between	O
TM1	O
and	O
TM2	O
lined	O
by	O
Asn18	O
and	O
Gly77	O
might	O
be	O
important	O
for	O
accommodating	O
palmitate	O
moieties	O
that	O
target	O
Cys78	O
and	O
Cys79	O
residues	O
,	O
and/or	O
important	O
for	O
access	O
by	O
the	O
putative	O
palmitoyl	O
transferase	O
to	O
those	O
residues	O
.	O

Understanding	O
the	O
exact	O
role	O
of	O
these	O
highly	O
conserved	O
Asn18	O
and	O
Gly77	O
residues	O
in	O
tetraspanins	O
awaits	O
further	O
investigation	O
.	O

In	O
summary	O
,	O
we	O
identified	O
conserved	O
glycine	O
residues	O
of	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
key	O
elements	O
required	O
for	O
intramolecular	O
packing	O
.	O

Mutations	O
of	O
these	O
key	O
residues	O
(	O
Gly25	O
,	O
Gly32	O
,	O
Gly67	O
and	O
Gly74	O
in	O
CD9	O
)	O
resulted	O
in	O
protein	O
destabilization	O
and	O
aggregation	O
.	O

There	O
is	O
ample	O
evidence	O
in	O
the	O
literature	O
for	O
mutations	O
in	O
transmembrane	O
proteins	O
that	O
lead	O
to	O
protein	O
destabilization	O
,	O
misassembly	O
and	O
pathologic	O
conditions	O
[	O
61	O
]	O
.	O

Thus	O
,	O
we	O
have	O
identified	O
conserved	O
heptad	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
of	O
tetraspanins	O
as	O
plausible	O
targets	O
of	O
destabilizing	O
mutations	O
with	O
potential	O
functional	O
consequences	O
.	O

Intermolecular	O
interactions	O
in	O
tetraspanins	O
Tetraspanin	O
CD9	O
forms	O
mostly	O
homodimers	O
,	O
but	O
also	O
a	O
low	O
level	O
of	O
heterodimers	O
with	O
CD81	O
and	O
CD151	O
[	O
25	O
]	O
.	O

Thus	O
,	O
mapping	O
the	O
dimerization	O
interface	O
is	O
an	O
important	O
next	O
step	O
in	O
structure	O
-	O
function	O
analysis	O
of	O
tetraspanins	O
.	O

Disulfide	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
often	O
in	O
combination	O
with	O
cysteine	O
-	O
scanning	O
mutagenesis	O
,	O
is	O
a	O
common	O
strategy	O
to	O
probe	O
oligomerization	O
or	O
intersubunit	O
interactions	O
of	O
transmembrane	O
proteins	O
such	O
as	O
histidine	O
kinase	O
EnvZ	O
[	O
62	O
]	O
,	O
M	O
(	O
3	O
)	O
muscarinic	O
acetylcholine	O
receptor	O
[	O
63	O
]	O
,	O
E.	B
coli	I
lactose	O
permease	O
[	O
64	O
]	O
,	O
synaptobrevin	O
[	O
65	O
]	O
,	O
integrins	O
[	O
66	O
]	O
and	O
many	O
others	O
.	O

In	O
tetraspanins	O
such	O
as	O
CD9	O
,	O
membrane	O
-	O
proximal	O
cysteine	O
residues	O
are	O
especially	O
useful	O
targets	O
for	O
disulfide	O
trapping	O
,	O
as	O
their	O
linkage	O
can	O
be	O
enhanced	O
by	O
pre	O
-	O
treating	O
cells	O
with	O
2-BP	O
.	O

While	O
the	O
ability	O
of	O
wild	O
-	O
type	O
cysteines	O
in	O
CD9	O
to	O
be	O
cross	O
-	O
linked	O
may	O
indicate	O
that	O
they	O
are	O
close	O
to	O
the	O
dimerization	O
interface	O
,	O
more	O
precise	O
mapping	O
was	O
achieved	O
here	O
using	O
cysteine	O
-	O
scanning	O
mutagenesis	O
.	O

Our	O
data	O
clearly	O
identify	O
regions	O
,	O
near	O
the	O
cytoplasmic	O
face	O
of	O
TM1	O
and	O
TM2	O
,	O
important	O
for	O
dimerization	O
.	O

Intermolecular	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
was	O
highest	O
when	O
single	O
cysteines	O
were	O
placed	O
in	O
positions	O
14	O
,	O
17	O
,	O
77	O
,	O
80	O
and	O
81	O
in	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
molecule	O
,	O
or	O
at	O
positions	O
77	O
,	O
80	O
or	O
81	O
in	O
the	O
full	O
-	O
length	O
CD9	O
protein	O
.	O

Positions	O
14	O
,	O
17	O
and	O
80	O
are	O
distinct	O
from	O
the	O
intramolecular	O
interface	O
and	O
are	O
on	O
the	O
same	O
side	O
of	O
the	O
TM1-TM2	O
pair	O
(	O
Figure	O
6	O
)	O
.	O

Thus	O
,	O
they	O
are	O
well	O
-	O
positioned	O
to	O
participate	O
in	O
an	O
interaction	O
with	O
another	O
molecule	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
model	O
predicts	O
that	O
wild	O
-	O
type	O
cysteines	O
(	O
Cys78	O
,	O
79	O
)	O
,	O
which	O
do	O
not	O
yield	O
very	O
efficient	O
zero	O
-	O
length	O
cross	O
-	O
linking	O
,	O
are	O
on	O
the	O
other	O
side	O
of	O
TM1-TM2	O
pair	O
.	O

While	O
using	O
the	O
cysteine	O
at	O
position	O
80	O
as	O
the	O
dimeric	O
interface	O
probe	O
,	O
mutations	O
of	O
conserved	O
residues	O
in	O
TM1	O
and	O
TM2	O
(	O
especially	O
Gly32	O
and	O
Gly67	O
to	O
Leu	O
)	O
clearly	O
reduced	O
intermolecular	O
cross	O
-	O
linking	O
.	O

We	O
do	O
not	O
suggest	O
that	O
those	O
residues	O
are	O
directly	O
involved	O
in	O
intermolecular	O
interaction	O
.	O

Rather	O
,	O
we	O
propose	O
that	O
destabilization	O
of	O
the	O
intramolecular	O
TM1-TM2	O
interaction	O
by	O
Gly	O
to	O
Leu	O
substitutions	O
(	O
discussed	O
above	O
)	O
causes	O
an	O
overall	O
conformational	O
change	O
that	O
reduces	O
dimer	O
formation	O
.	O

An	O
Ala81Leu	O
mutation	O
did	O
not	O
reduce	O
cross	O
-	O
linking	O
via	O
Cys80	O
,	O
even	O
though	O
single	O
-	O
cysteine	O
Ala81Cys	O
molecules	O
themselves	O
produced	O
a	O
high	O
level	O
of	O
cross	O
-	O
linking	O
.	O

These	O
results	O
,	O
together	O
with	O
data	O
on	O
Gly32Leu	O
and	O
Gly67Leu	O
mutations	O
,	O
are	O
consistent	O
with	O
our	O
model	O
predicting	O
that	O
helices	O
1	O
and	O
2	O
interact	O
more	O
tightly	O
near	O
the	O
extracellular	O
end	O
and	O
less	O
at	O
the	O
cytoplasmic	O
end	O
.	O

This	O
would	O
give	O
more	O
flexibility	O
to	O
a	O
cysteine	O
at	O
position	O
81	O
and	O
also	O
limit	O
the	O
effect	O
of	O
an	O
Ala81Leu	O
mutation	O
.	O

Location	O
of	O
this	O
residue	O
at	O
the	O
membrane	O
/	O
cytoplasmic	O
border	O
could	O
also	O
make	O
it	O
more	O
accessible	O
to	O
CuP	O
reagent	O
as	O
compared	O
to	O
residues	O
buried	O
in	O
TM	O
domain	O
,	O
thus	O
elevating	O
the	O
efficiency	O
of	O
disulfide	O
formation	O
of	O
the	O
Ala81Cys	O
mutant	O
.	O

Multiple	O
interfaces	O
in	O
tetraspanin	O
molecules	O
In	O
the	O
full	O
-	O
length	O
CD9	O
molecules	O
,	O
the	O
3	O
C	O
-	O
terminal	O
cysteines	O
(	O
Cys87	O
,	O
218	O
and	O
219	O
)	O
located	O
at	O
or	O
in	O
TM3	O
and	O
TM4	O
promoted	O
efficient	O
dimer	O
and	O
even	O
more	O
efficient	O
oligomer	O
formation	O
compared	O
to	O
the	O
3	O
N	O
-	O
terminal	O
cysteines	O
(	O
Figure	O
9	O
)	O
.	O

Cys87	O
alone	O
can	O
be	O
used	O
to	O
capture	O
CD9	O
dimers	O
[	O
25	O
]	O
.	O

These	O
results	O
suggest	O
the	O
existence	O
of	O
two	O
dimeric	O
interfaces	O
in	O
CD9	O
molecule	O
–	O
the	O
TM	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
and	O
the	O
TM	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
(	O
Figure	O
10	O
)	O
.	O

In	O
a	O
TM	O
(	O
1	O
+	O
2	O
)	O
molecule	O
,	O
the	O
destabilization	O
of	O
1–2	O
interaction	O
,	O
e.g.	O
by	O
Gly→Leu	O
mutations	O
,	O
would	O
affect	O
the	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
,	O
as	O
discussed	O
above	O
.	O

However	O
,	O
these	O
mutations	O
would	O
not	O
interfere	O
with	O
the	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
interface	O
in	O
a	O
full	O
-	O
length	O
molecule	O
,	O
which	O
includes	O
Cys87	O
,	O
218	O
and	O
219	O
.	O

Thus	O
,	O
cross	O
-	O
linking	O
of	O
full	O
-	O
length	O
molecules	O
,	O
containing	O
all	O
6	O
cysteine	O
residues	O
,	O
would	O
be	O
unaffected	O
,	O
as	O
seen	O
in	O
Figure	O
8C	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
Cys9	O
,	O
Cys78	O
and	O
Cys79	O
are	O
apparently	O
not	O
at	O
the	O
primary	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
interface	O
.	O

Their	O
relative	O
inefficiency	O
in	O
cross	O
-	O
linking	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
protein	O
likely	O
reflects	O
weak	O
secondary	O
contacts	O
between	O
the	O
molecules	O
,	O
or	O
possibly	O
random	O
collision	O
events	O
.	O

Such	O
events	O
should	O
be	O
independent	O
of	O
mutations	O
in	O
the	O
conserved	O
Gly	O
residues	O
in	O
TM1	O
and	O
TM2	O
,	O
as	O
was	O
demonstrated	O
in	O
Figure	O
8B	O
.	O

The	O
potential	O
existence	O
of	O
two	O
interfaces	O
in	O
tetraspanin	O
molecules	O
,	O
1	O
-	O
2	O
/	O
1	O
-	O
2	O
and	O
3	O
-	O
4	O
/	O
3	O
-	O
4	O
,	O
should	O
provide	O
enhanced	O
flexibility	O
for	O
forming	O
additional	O
intermolecular	O
contacts	O
.	O

Current	O
understanding	O
of	O
tetraspanin	O
microdomains	O
assumes	O
a	O
few	O
strong	O
,	O
primary	O
homotypic	O
and	O
heterotypic	O
tetraspanin	O
complexes	O
(	O
e.g.	O
CD9-CD9	O
,	O
CD9-CD81	O
,	O
CD151-α3	O
integrin	O
,	O
CD81-EWI2	O
)	O
that	O
help	O
bring	O
together	O
various	O
other	O
proteins	O
,	O
forming	O
secondary	O
-	O
type	O
associations	O
.	O

Such	O
properties	O
of	O
tetraspanins	O
may	O
bring	O
signaling	O
molecules	O
such	O
as	O
protein	O
kinase	O
C	O
or	O
phosphatidylinositol	O
4-kinase	O
to	O
the	O
vicinity	O
of	O
integrins	O
[	O
67,68	O
]	O
.	O

The	O
organization	O
of	O
the	O
TM3	O
domain	O
points	O
to	O
a	O
potential	O
role	O
in	O
protein	O
-	O
protein	O
interactions	O
.	O

A	O
motif	O
of	O
Leu	O
-	O
Leu	O
-	O
Glu	O
(	O
Gln	O
)	O
spaced	O
7	O
residues	O
apart	O
(	O
heptad	O
positions	O
a	O
)	O
,	O
with	O
highly	O
conserved	O
residues	O
in	O
two	O
consecutive	O
positions	O
d	O
,	O
poses	O
as	O
a	O
likely	O
interaction	O
module	O
.	O

If	O
responsible	O
for	O
heterologous	O
protein	O
-	O
protein	O
interactions	O
,	O
it	O
would	O
form	O
another	O
distinct	O
interface	O
of	O
tetraspanin	O
molecule	O
.	O

Our	O
preliminary	O
data	O
indicate	O
that	O
replacing	O
the	O
Leu	O
and	O
Glu	O
residues	O
in	O
TM3	O
of	O
CD9	O
with	O
Ala	O
has	O
no	O
effect	O
on	O
cell	O
surface	O
expression	O
of	O
the	O
protein	O
and	O
its	O
dimerization	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
remains	O
to	O
be	O
tested	O
if	O
interactions	O
with	O
other	O
proteins	O
will	O
be	O
affected	O
.	O

Similarly	O
,	O
the	O
TM4	O
domain	O
may	O
provide	O
additional	O
contributions	O
to	O
lateral	O
tetraspanin	O
associations	O
.	O

Much	O
higher	O
sequence	O
variability	O
,	O
and	O
the	O
lack	O
of	O
a	O
distinct	O
heptad	O
pattern	O
suggests	O
that	O
TM4	O
is	O
a	O
major	O
contributor	O
to	O
diversity	O
among	O
tetraspanin	O
complexes	O
.	O

Structure	O
-	O
function	O
analysis	O
of	O
TM3	O
and	O
TM4	O
domains	O
in	O
tetraspanins	O
is	O
the	O
subject	O
of	O
ongoing	O
investigation	O
.	O

Conclusion	O
We	O
have	O
defined	O
the	O
TM1-TM2	O
intramolecular	O
interface	O
in	O
tetraspanin	O
CD9	O
,	O
providing	O
evidence	O
for	O
glycines	O
(	O
Gly25	O
and	O
Gly32	O
in	O
TM1	O
,	O
Gly67	O
and	O
Gly74	O
in	O
TM2	O
)	O
packing	O
against	O
apposing	O
bulky	O
aliphatic	O
residues	O
.	O

Second	O
,	O
we	O
mapped	O
an	O
intermolecular	O
CD9	O
interface	O
(	O
involved	O
in	O
CD9	O
homodimer	O
formation	O
)	O
to	O
the	O
vicinity	O
of	O
residues	O
Leu14	O
and	O
Phe17	O
in	O
TM1	O
and	O
Gly77	O
,	O
Gly80	O
and	O
Ala81	O
in	O
TM2	O
.	O

Finally	O
,	O
we	O
provide	O
preliminary	O
evidence	O
that	O
TM3	O
and	O
TM4	O
in	O
CD9	O
may	O
contribute	O
to	O
a	O
second	O
intermolecular	O
interface	O
.	O

Key	O
CD9	O
residues	O
involved	O
in	O
intra-	O
and	O
intermolecular	O
interactions	O
are	O
highly	O
conserved	O
throughout	O
the	O
tetraspanin	O
family	O
,	O
thus	O
suggesting	O
that	O
our	O
findings	O
will	O
apply	O
to	O
most	O
tetraspanins	O
.	O

Methods	O
Materials	O
Cell	O
culture	O
reagents	O
were	O
from	O
Invitrogen	O
(	O
Carlsbad	O
,	O
CA	O
)	O
.	O

2-bromopalmitate	O
was	O
from	O
Fluka	O
(	O
Milwaukee	O
,	O
WI	O
)	O
,	O
N	O
-	O
ethylmaleimide	O
(	O
NEM	O
)	O
and	O
1,10-phenanthroline	O
were	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
,	O
and	O
chemical	O
cross	O
-	O
linkers	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
(	O
DTME	O
)	O
and	O
1,4-Bis	O
-	O
maleimidobutane	O
(	O
BMB	O
)	O
were	O
purchased	O
from	O
Pierce	O
Endogen	O
(	O
Rockford	O
,	O
IL	O
)	O
.	O

Triton	O
X-100	O
,	O
protease	O
inhibitor	O
cocktail	O
and	O
FuGENE	O
6	O
transfection	O
reagent	O
were	O
obtained	O
from	O
Roche	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

Restriction	O
endonucleases	O
and	O
Pfu	O
DNA	O
polymerase	O
were	O
obtained	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
and	O
Stratagene	O
(	O
Carlsbad	O
,	O
CA	O
)	O
,	O
respectively	O
.	O

All	O
other	O
chemicals	O
were	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
or	O
Fisher	O
Scientific	O
(	O
Pittsburg	O
,	O
PA	O
)	O
.	O

Sequence	O
analysis	O
Tetraspanin	O
sequences	O
were	O
obtained	O
from	O
SWISS	O
-	O
PROT	O
and	O
GenBank	O
databases	O
.	O

Locus	O
designations	O
,	O
accession	O
numbers	O
and	O
the	O
most	O
commonly	O
used	O
protein	O
names	O
are	O
summarized	O
in	O
Tables	O
1	O
and	O
2	O
.	O

TM	O
segments	O
were	O
delineated	O
by	O
inspection	O
of	O
hydrophobicity	O
profiles	O
,	O
using	O
database	O
annotations	O
and	O
previous	O
analyses	O
of	O
TM	O
sequences	O
as	O
a	O
guide	O
(	O
[	O
28	O
]	O
,	O
M.	O
Hemler	O
,	O
unpublished	O
)	O
,	O
and	O
aligned	O
manually	O
.	O

Residue	O
numbers	O
in	O
human	B
CD9	O
sequence	O
are	O
used	O
a	O
reference	O
point	O
throughout	O
the	O
study	O
.	O

DNA	O
cloning	O
and	O
mutagenesis	O
Sequence	O
encoding	O
CD9	O
protein	O
was	O
cloned	O
into	O
vector	O
pcDNA3	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
)	O
and	O
pEGFP	O
-	O
N1	O
(	O
Clontech	O
,	O
Palo	O
Alto	O
,	O
CA	O
)	O
,	O
for	O
expression	O
of	O
untagged	O
and	O
C	O
-	O
terminally	O
GFP	O
-	O
tagged	O
CD9	O
,	O
respectively	O
.	O

pEGFP	O
-	O
N1	O
encoding	O
CD9	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
fusion	O
protein	O
was	O
constructed	O
by	O
subcloning	O
DNA	O
for	O
residues	O
1–83	O
of	O
CD9	O
into	O
HindIII	O
and	O
PstI	O
sites	O
of	O
the	O
vector	O
;	O
to	O
introduce	O
the	O
PstI	O
site	O
,	O
codon	O
GTG	O
for	O
Val82	O
was	O
changed	O
to	O
CTG	O
(	O
coding	O
for	O
Ala	O
)	O
.	O

In	O
the	O
resulting	O
fusion	O
protein	O
,	O
there	O
is	O
a	O
13-amino	O
acid	O
linker	O
(	O
with	O
no	O
cysteines	O
)	O
between	O
CD9	O
and	O
GFP	O
.	O

To	O
minimize	O
the	O
low	O
inherent	O
ability	O
of	O
GFP	O
to	O
homodimerize	O
,	O
which	O
could	O
potentially	O
influence	O
the	O
results	O
of	O
CD9	O
cross	O
-	O
linking	O
,	O
we	O
used	O
a	O
monomeric	O
GFP	O
mutant	O
,	O
Leu221→Lys	O
[	O
34	O
]	O
,	O
for	O
cross	O
-	O
linking	O
experiments	O
.	O

Mutations	O
were	O
introduced	O
in	O
full	O
-	O
length	O
and	O
TM	O
(	O
1	O
+	O
2	O
)	O
CD9	O
proteins	O
by	O
a	O
PCR	O
-	O
based	O
strategy	O
using	O
mutagenic	O
primers	O
and	O
Pfu	O
DNA	O
polymerase	O
.	O

All	O
mutations	O
were	O
confirmed	O
by	O
DNA	O
sequencing	O
.	O

Protein	O
expression	O
,	O
microscopy	O
,	O
cysteine	O
disulfide	O
cross	O
-	O
linking	O
and	O
Western	O
blotting	O
DNA	O
constructs	O
encoding	O
TM	O
(	O
1	O
+	O
2	O
)	O
-GFP	O
or	O
full	O
-	O
length	O
CD9	O
proteins	O
were	O
transfected	O
into	O
human	B
rhabdomyosarcoma	O
RD	O
cells	O
using	O
the	O
FuGENE	O
6	O
reagent	O
.	O

Cells	O
expressing	O
GFP	O
fusion	O
proteins	O
were	O
analysed	O
by	O
fluorescence	O
microscopy	O
18–28	O
hours	O
post	O
-	O
transfection	O
.	O

Images	O
were	O
captured	O
using	O
Spot	O
1.4.0	O
camera	O
(	O
Diagnostic	O
Instruments	O
,	O
Sterling	O
Heights	O
,	O
MI	O
)	O
attached	O
to	O
Nikon	O
Eclipse	O
TE300	O
microscope	O
.	O

For	O
experiments	O
involving	O
cysteine	O
-	O
mediated	O
cross	O
-	O
linking	O
,	O
cells	O
were	O
treated	O
with	O
50	O
μM	O
2-BP	O
starting	O
24–26	O
hours	O
post	O
-	O
transfection	O
and	O
continuing	O
for	O
16–18	O
hours	O
.	O

Cross	O
-	O
linking	O
was	O
carried	O
out	O
by	O
incubating	O
cells	O
in	O
HBSM	O
buffer	O
(	O
25	O
mM	O
Hepes	O
-	O
NaOH	O
,	O
pH	O
7.2	O
,	O
150	O
mM	O
NaCl	O
,	O
2	O
mM	O
MgCl2	O
)	O
containing	O
either	O
a	O
)	O
0.6	O
mM	O
CuSO4	O
and	O
1.8	O
mM	O
1,10-phenanthroline	O
(	O
CuP	O
complex	O
)	O
or	O
b	O
)	O
0.2	O
mg	O
/	O
ml	O
homobifunctional	O
cysteine	O
-	O
reactive	O
cross	O
-	O
linker	O
(	O
e.g.	O
DTME	O
)	O
,	O
diluted	O
from	O
fresh	O
10	O
mg	O
/	O
ml	O
solution	O
in	O
DMSO	O
.	O

After	O
incubation	O
for	O
10–15	O
minutes	O
(	O
with	O
CuP	O
)	O
or	O
30–45	O
minutes	O
(	O
with	O
cross	O
-	O
linker	O
)	O
,	O
cells	O
were	O
washed	O
twice	O
for	O
10	O
minutes	O
with	O
HBSM	O
containing	O
10	O
mM	O
NEM	O
to	O
block	O
residual	O
free	O
cysteines	O
.	O

Cells	O
were	O
lysed	O
in	O
HBSM	O
containing	O
1	O
%	O
Triton	O
X-100	O
,	O
0.1	O
%	O
SDS	O
and	O
a	O
cocktail	O
of	O
protease	O
inhibitors	O
with	O
1	O
mM	O
EDTA	O
at	O
4	O
°	O
C	O
for	O
45–60	O
minutes	O
.	O

Cell	O
lysate	O
was	O
clarified	O
by	O
centrifugation	O
at	O
14,000	O
×	O
g	O
for	O
15	O
minutes	O
,	O
an	O
aliquot	O
was	O
removed	O
,	O
and	O
proteins	O
from	O
it	O
were	O
precipitated	O
by	O
addition	O
of	O
trichloroacetic	O
acid	O
to	O
10	O
%	O
on	O
ice	O
followed	O
by	O
centrifugation	O
at	O
14,000	O
×	O
g	O
for	O
10	O
minutes	O
.	O

After	O
two	O
washes	O
with	O
ice	O
-	O
cold	O
acetone	O
,	O
protein	O
pellet	O
was	O
solubilized	O
in	O
SDS	O
-	O
PAGE	O
sample	O
buffer	O
without	O
a	O
reducing	O
agent	O
(	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
6.8	O
,	O
1	O
%	O
SDS	O
,	O
8	O
%	O
glycerol	O
)	O
.	O

In	O
some	O
experiments	O
,	O
CD9	O
protein	O
was	O
immunoprecipitated	O
using	O
monoclonal	O
antibody	O
Alb6	O
(	O
Immunotech	O
,	O
Marseille	O
,	O
France	O
)	O
.	O

Proteins	O
were	O
separated	O
by	O
SDS	O
-	O
PAGE	O
and	O
analyzed	O
by	O
Western	O
blotting	O
using	O
monoclonal	O
antibody	O
JL-8	O
(	O
Clontech	O
)	O
for	O
GFP	O
or	O
Alb6	O
for	O
CD9	O
.	O

Bands	O
from	O
X	O
-	O
ray	O
films	O
were	O
quantitated	O
using	O
GeneTools	O
™	O
software	O
from	O
Syngene	O
(	O
Frederick	O
,	O
MD	O
)	O
.	O

Modeling	O
of	O
TM1-TM2	O
interaction	O
An	O
atomic	O
model	O
of	O
the	O
CD9	O
TM1-TM2	O
dimer	O
was	O
constructed	O
with	O
a	O
Monte	O
Carlo	O
-	O
simulated	O
annealing	O
(	O
MCSA	O
)	O
algorithm	O
[	O
69	O
]	O
.	O

Two	O
idealized	O
α	O
-	O
helices	O
corresponding	O
to	O
TM1	O
residues	O
Tyr12	O
through	O
Leu35	O
and	O
TM2	O
residues	O
Gly59	O
through	O
Val82	O
were	O
docked	O
with	O
six	O
orthogonal	O
parameters	O
:	O
three	O
rigid	O
body	O
translations	O
and	O
three	O
rotations	O
.	O

During	O
each	O
step	O
of	O
a	O
MCSA	O
cycle	O
,	O
there	O
was	O
an	O
equal	O
probability	O
of	O
changing	O
either	O
one	O
parameter	O
or	O
all	O
six	O
parameters	O
to	O
random	O
values	O
.	O

A	O
conformation	O
's	O
energy	O
was	O
calculated	O
in	O
vacuo	O
with	O
the	O
AMBER	O
united	O
-	O
atom	O
force	O
field	O
for	O
van	O
der	O
Waals	O
interactions	O
[	O
70	O
]	O
.	O

The	O
van	O
der	O
Waals	O
term	O
was	O
modified	O
as	O
described	O
by	O
Kuhlman	O
and	O
Baker	O
[	O
71	O
]	O
.	O

If	O
a	O
structure	O
had	O
favorable	O
dimerization	O
energy	O
,	O
the	O
energies	O
of	O
select	O
mutants	O
were	O
calculated	O
.	O

Structures	O
were	O
selected	O
with	O
a	O
novel	O
scoring	O
function	O
that	O
maximizes	O
the	O
Boltzmann	O
probability	O
of	O
dimerization	O
for	O
silent	O
mutations	O
while	O
minimizing	O
the	O
probability	O
for	O
disruptive	O
mutations	O
.	O

Asn18Ser	O
,	O
Gly77Leu	O
,	O
and	O
Gly80Leu	O
were	O
scored	O
as	O
silent	O
mutations	O
while	O
Gly25Leu	O
,	O
Gly32Leu	O
,	O
Gly67Leu	O
,	O
and	O
Gly74Leu	O
were	O
considered	O
to	O
be	O
disruptive	O
.	O

Each	O
MCSA	O
cycle	O
consisted	O
of	O
50,000	O
steps	O
with	O
an	O
exponential	O
temperature	O
decay	O
from	O
10,000	O
to	O
10	O
K.	O
Ten	O
MCSA	O
cycles	O
through	O
global	O
sample	O
space	O
were	O
used	O
to	O
restrict	O
the	O
search	O
area	O
.	O

Parameters	O
were	O
restricted	O
to	O
±	O
2	O
standard	O
deviations	O
from	O
their	O
mean	O
value	O
for	O
structures	O
within	O
10	O
kcal	O
of	O
the	O
best	O
structure	O
.	O

MCSA	O
cycles	O
were	O
repeated	O
as	O
described	O
above	O
with	O
additional	O
optimization	O
of	O
χ	O
values	O
:	O
rotamers	O
at	O
the	O
protein	O
-	O
protein	O
interface	O
were	O
optimized	O
with	O
Dead	O
End	O
Elimination	O
[	O
72	O
]	O
,	O
and	O
χ	O
values	O
were	O
further	O
optimized	O
with	O
Monte	O
Carlo	O
.	O

All	O
MCSA	O
cycles	O
converged	O
upon	O
structures	O
that	O
were	O
within	O
a	O
root	O
mean	O
squared	O
deviation	O
(	O
RMSD	O
)	O
of	O
1.5	O
Å	O
with	O
the	O
best	O
structure	O
,	O
and	O
structures	O
that	O
scored	O
within	O
5	O
kcal	O
of	O
the	O
best	O
score	O
had	O
an	O
RMSD	O
of	O
less	O
than	O
0.5	O
Å	O
with	O
the	O
best	O
structure	O
.	O

List	O
of	O
abbreviations	O
2-BP	O
,	O
2-bromopalmitate	O
;	O
CuP	O
,	O
Cu2	O
+	O
-phenanthroline	O
;	O
DTME	O
,	O
dithio	O
-	O
bis	O
-	O
maleimidoethane	O
;	O
LEL	O
,	O
large	O
extracellular	O
loop	O
;	O
NEM	O
,	O
N	O
-	O
ethylmaleimide	O
;	O
TM	O
,	O
transmembrane	O
(	O
domain	O
)	O
.	O

Authors	O
'	O
contributions	O
OVK	O
carried	O
out	O
sequence	O
comparisons	O
,	O
mutational	O
analysis	O
and	O
cross	O
-	O
linking	O
experiments	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

DGM	O
built	O
the	O
TM1-TM2	O
interaction	O
model	O
and	O
contributed	O
to	O
the	O
manuscript	O
.	O

WFD	O
supervised	O
DGM	O
's	O
work	O
.	O

MEH	O
coordinated	O
the	O
whole	O
study	O
and	O
prepared	O
the	O
final	O
manuscript	O
.	O

Gender	O
differences	O
in	O
factors	O
influencing	O
insulin	O
resistance	O
in	O
elderly	O
hyperlipemic	O
non	O
-	O
diabetic	O
subjects	O
Abstract	O
Background	O
The	O
increase	O
in	O
the	O
prevalence	O
of	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
,	O
a	O
disorder	O
that	O
greatly	O
increases	O
the	O
risk	O
of	O
diabetes	O
,	O
heart	O
attack	O
and	O
stroke	O
,	O
is	O
alarming	O
.	O

One	O
of	O
the	O
most	O
frequent	O
and	O
early	O
symptoms	O
of	O
metabolic	O
syndrome	O
is	O
hypertriglyceridemia	O
.	O

We	O
examined	O
the	O
gender	O
differences	O
between	O
various	O
metabolic	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
elderly	O
non	O
-	O
diabetic	O
men	O
and	O
postmenopausal	O
women	O
of	O
comparable	O
age	O
suffering	O
from	O
hypertriglyceridemia	O
,	O
and	O
compared	O
them	O
with	O
healthy	O
subjects	O
of	O
equal	O
age	O
.	O

Results	O
The	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	O
and	O
women	O
than	O
in	O
controls	O
;	O
95	O
%	O
confidence	O
limits	O
of	O
hyperlipemic	O
subjects	O
did	O
not	O
overlap	O
with	O
controls	O
.	O

In	O
both	O
normolipemic	O
and	O
hyperlipemic	O
men	O
and	O
women	O
serum	O
leptin	O
correlated	O
significantly	O
with	O
insulin	O
resistance	O
,	O
while	O
HDL	O
-	O
cholesterol	O
correlated	O
inversely	O
with	O
HOMA	O
-	O
IR	O
only	O
in	O
women	O
(	O
both	O
normo-	O
and	O
hyperlipemic	O
)	O
,	O
and	O
serum	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
only	O
in	O
hyperlipemic	O
women	O
.	O

According	O
to	O
results	O
of	O
multiple	O
regression	O
analysis	O
with	O
HOMA	O
-	O
IR	O
as	O
a	O
dependent	O
variable	O
,	O
leptin	O
played	O
a	O
significant	O
role	O
in	O
determining	O
insulin	O
resistance	O
in	O
both	O
genders	O
,	O
but	O
–	O
aside	O
from	O
leptin	O
–	O
triglycerides	O
,	O
TNFα	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
women	O
,	O
while	O
body	O
mass	O
index	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
were	O
significant	O
determinants	O
in	O
men	O
.	O

The	O
coefficient	O
of	O
determination	O
(	O
R2	O
)	O
of	O
HOMA	O
IR	O
by	O
above	O
mentioned	O
metabolic	O
variables	O
was	O
in	O
women	O
above	O
60	O
%	O
,	O
in	O
men	O
only	O
about	O
40	O
%	O
.	O

Conclusion	O
The	O
significant	O
role	O
of	O
serum	O
leptin	O
in	O
determination	O
of	O
insulin	O
resistance	O
in	O
both	O
elderly	O
men	O
and	O
postmenopausal	O
women	O
of	O
equal	O
age	O
was	O
confirmed	O
.	O

However	O
,	O
the	O
study	O
also	O
revealed	O
significant	O
gender	O
differences	O
:	O
in	O
women	O
a	O
strong	O
influence	O
of	O
triglycerides	O
,	O
TNFα	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
,	O
in	O
men	O
only	O
a	O
mild	O
role	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

Background	O
In	O
association	O
with	O
pandemic	O
obesity	O
the	O
prevalence	O
of	O
the	O
insulin	O
resistance	O
-	O
related	O
metabolic	O
syndrome	O
is	O
constantly	O
growing	O
[	O
1	O
]	O
.	O

As	O
a	O
consequence	O
of	O
this	O
fact	O
,	O
type	O
2	O
diabetes	O
mellitus	O
and	O
cardiovascular	O
mortality	O
occurs	O
in	O
much	O
younger	O
age	O
groups	O
[	O
2	O
]	O
.	O

A	O
typical	O
hyperlipemia	O
,	O
consisting	O
of	O
an	O
increase	O
of	O
serum	O
triglycerides	O
and	O
a	O
decrease	O
of	O
serum	O
HDL	O
-	O
cholesterol	O
,	O
is	O
a	O
characteristic	O
and	O
an	O
early	O
symptom	O
of	O
this	O
syndrome	O
[	O
3	O
]	O
.	O

With	O
increasing	O
age	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
and	O
adiposity	O
,	O
insulin	O
sensitivity	O
declines	O
and	O
the	O
number	O
of	O
cardiovascular	O
risk	O
factors	O
increases	O
in	O
both	O
genders	O
[	O
4	O
-	O
6	O
]	O
.	O

It	O
was	O
repeatedly	O
demonstrated	O
that	O
plasma	O
concentration	O
of	O
leptin	O
–	O
a	O
hormone	O
produced	O
mainly	O
by	O
adipose	O
tissue	O
–	O
is	O
substantially	O
higher	O
in	O
all	O
age	O
groups	O
of	O
women	O
than	O
in	O
men	O
[	O
7	O
-	O
10	O
]	O
.	O

This	O
may	O
be	O
caused	O
by	O
different	O
size	O
and/or	O
distribution	O
of	O
fat	O
tissue	O
compartments	O
influenced	O
by	O
hormones	O
:	O
estrogens	O
stimulate	O
,	O
whereas	O
testosterone	O
inhibits	O
leptin	O
secretion	O
.	O

In	O
women	O
subcutaneous	O
fat	O
mass	O
prevails	O
–	O
and	O
during	O
augmentation	O
of	O
overweight	O
it	O
increases	O
–	O
while	O
in	O
men	O
intra	O
-	O
abdominal	O
fat	O
mass	O
prevails	O
[	O
11	O
-	O
13	O
]	O
.	O

Subcutaneous	O
fat	O
in	O
particular	O
serves	O
as	O
a	O
substantial	O
source	O
of	O
tumor	O
necrosis	O
factor	O
α	O
(	O
TNFα	O
)	O
,	O
which	O
represents	O
one	O
of	O
the	O
factors	O
that	O
interfere	O
with	O
insulin	O
signal	O
transduction	O
into	O
the	O
cells	O
[	O
14	O
-	O
16	O
]	O
.	O

Leptin	O
,	O
TNFα	O
and	O
some	O
other	O
factors	O
are	O
abundantly	O
expressed	O
in	O
adipose	O
tissue	O
and	O
contribute	O
to	O
the	O
insulin	O
resistance	O
that	O
accompanies	O
overweight	O
and	O
obesity	O
.	O

Leptin	O
correlates	O
positively	O
with	O
hyperinsulinemia	O
,	O
BMI	O
,	O
fat	O
mass	O
and	O
hypertriglyceridemia	O
,	O
respectively	O
,	O
and	O
correlates	O
inversely	O
with	O
HDL	O
-	O
cholesterol	O
and	O
lean	O
body	O
mass	O
[	O
17	O
-	O
25	O
]	O
.	O

The	O
incidence	O
and	O
mortality	O
of	O
ischemic	O
heart	O
disease	O
and	O
of	O
other	O
consequences	O
of	O
atherosclerosis	O
increases	O
with	O
age	O
in	O
both	O
genders	O
,	O
especially	O
after	O
the	O
age	O
of	O
sixty	O
.	O

In	O
premenopausal	O
women	O
,	O
however	O
,	O
the	O
incidence	O
of	O
these	O
disorders	O
is	O
considerably	O
less	O
frequent	O
than	O
in	O
men	O
of	O
appropriate	O
age	O
.	O

After	O
the	O
menopause	O
the	O
prevalence	O
of	O
metabolic	O
syndrome	O
and	O
cardiovascular	O
mortality	O
in	O
women	O
gradually	O
increases	O
,	O
attaining	O
values	O
comparable	O
to	O
men	O
at	O
about	O
the	O
age	O
of	O
70	O
[	O
2,26	O
]	O
.	O

Paradoxically	O
,	O
it	O
takes	O
place	O
at	O
the	O
time	O
when	O
serum	O
leptin	O
concentration	O
in	O
women	O
has	O
relatively	O
decreased	O
[	O
27,28	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
interrelations	O
between	O
several	O
metabolic	O
variables	O
and	O
factors	O
related	O
to	O
insulin	O
resistance	O
in	O
groups	O
of	O
both	O
normal	O
and	O
hyperlipemic	O
postmenopausal	O
women	O
and	O
men	O
of	O
appropriate	O
age	O
,	O
and	O
to	O
attempt	O
to	O
elucidate	O
the	O
gender	O
differences	O
and	O
some	O
pathophysiologic	O
mechanisms	O
of	O
these	O
differences	O
.	O

We	O
compared	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
serum	O
lipid	O
and	O
insulin	O
parameters	O
,	O
uric	O
acid	O
,	O
leptin	O
and	O
TNFα	O
between	O
groups	O
of	O
subjects	O
without	O
apparent	O
symptoms	O
of	O
metabolic	O
syndrome	O
,	O
and	O
groups	O
showing	O
mild	O
hypertriglyceridemia	O
with	O
decreased	O
HDL	O
-	O
cholesterol	O
.	O

In	O
addition	O
,	O
serum	O
concentration	O
of	O
the	O
heart	O
fraction	O
of	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFATP	O
)	O
was	O
explored	O
as	O
a	O
factor	O
that	O
might	O
reflect	O
the	O
regulative	O
role	O
of	O
PPAR	O
gamma	O
in	O
lipid	O
homeostasis	O
[	O
29,30	O
]	O
,	O
and	O
serum	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
)	O
was	O
investigated	O
as	O
an	O
indirect	O
indicator	O
of	O
oxidized	O
lipid	O
fractions	O
related	O
to	O
atherosclerotic	O
complications	O
[	O
31,32	O
]	O
.	O

Methods	O
Subjects	O
The	O
study	O
was	O
carried	O
out	O
on	O
70	O
out	O
-	O
patients	O
of	O
the	O
Metabolic	O
Center	O
at	O
the	O
hospital	O
in	O
Sternberk	O
,	O
Czech	O
Republic	O
.	O

From	O
these	O
,	O
40	O
patients	O
(	O
20	O
men	O
and	O
20	O
women	O
)	O
were	O
selected	O
with	O
mild	O
hyperlipidemia	O
,	O
i.e.	O
with	O
plasma	O
triglyceride	O
concentration	O
exceeding	O
2.0	O
mmol	O
/	O
l	O
,	O
total	O
cholesterol	O
exceeding	O
6.0	O
mmol	O
/	O
l	O
,	O
LDL	O
cholesterol	O
exceeding	O
4.0	O
mmol	O
/	O
l	O
,	O
and	O
with	O
HDL	O
cholesterol	O
concentration	O
in	O
men	O
under	O
1.0	O
mmol	O
/	O
l	O
,	O
and	O
in	O
women	O
under	O
1.2	O
mmol	O
/	O
l	O
.	O

These	O
groups	O
were	O
denominated	O
as	O
""""	O
hyperlipemic	O
""""	O
.	O

Two	O
other	O
groups	O
(	O
10	O
men	O
and	O
20	O
women	O
)	O
with	O
approximately	O
normal	O
serum	O
values	O
of	O
these	O
variables	O
were	O
taken	O
as	O
""""	O
controls	O
""""	O
.	O

The	O
average	O
age	O
in	O
men	O
was	O
59.1	O
±	O
10.6	O
y	O
,	O
and	O
in	O
women	O
59.4	O
±	O
10.1	O
y	O
,	O
respectively	O
.	O

The	O
differences	O
between	O
lipid	O
parameters	O
of	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
highly	O
statistically	O
significant	O
,	O
while	O
the	O
age	O
differences	O
were	O
insignificant	O
(	O
see	O
Table	O
1	O
)	O
.	O

None	O
of	O
the	O
patients	O
had	O
clinically	O
apparent	O
diabetes	O
mellitus	O
,	O
but	O
some	O
of	O
the	O
hyperlipemic	O
patients	O
exerted	O
impaired	O
glucose	O
tolerance	O
or	O
impaired	O
fasting	O
glucose	O
(	O
values	O
between	O
6.1	O
and	O
7.0	O
mmol	O
/	O
l	O
,	O
or	O
between	O
6.1	O
and	O
7.8	O
mmol	O
/	O
l	O
,	O
respectively	O
)	O
.	O

None	O
of	O
the	O
patients	O
was	O
treated	O
with	O
insulin	O
,	O
peroral	O
antidiabetics	O
or	O
antihyperlipemic	O
drugs	O
;	O
some	O
of	O
them	O
were	O
treated	O
with	O
antihypertensive	O
therapy	O
.	O

No	O
signs	O
of	O
major	O
clinical	O
or	O
laboratory	O
symptoms	O
of	O
other	O
diseases	O
were	O
present	O
in	O
any	O
group	O
of	O
the	O
explored	O
patients	O
.	O

Blood	O
samples	O
were	O
obtained	O
in	O
the	O
morning	O
via	O
a	O
venipuncture	O
after	O
overnight	O
fasting	O
.	O

After	O
clotting	O
the	O
serum	O
was	O
separated	O
and	O
stored	O
at	O
-20	O
°	O
until	O
used	O
.	O

An	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
probands	O
.	O

Body	O
mass	O
indexes	O
(	O
BMI	O
)	O
,	O
defined	O
as	O
weight	O
in	O
kilograms	O
divided	O
by	O
the	O
square	O
of	O
height	O
in	O
meters	O
,	O
were	O
calculated	O
.	O

Biochemical	O
methods	O
Serum	O
leptin	O
concentrations	O
were	O
measured	O
by	O
a	O
sandwich	O
ELISA	O
test	O
kit	O
(	O
Human	B
Leptin	O
ELISA	O
,	O
BioVendor	O
Laboratory	O
Medicine	O
,	O
Inc	O
,	O
Czech	O
Republic	O
)	O
.	O

Its	O
sensitivity	O
limit	O
was	O
0.2	O
ng	O
/	O
ml	O
,	O
intraassay	O
CV	O
6.1	O
%	O
at	O
the	O
level	O
of	O
7.5	O
ng	O
/	O
m	O
,	O
inter	O
-	O
assay	O
CV	O
8.5	O
%	O
at	O
the	O
level	O
of	O
4.8	O
ng	O
/	O
ml	O
.	O

Tetramethylbenzidine	O
was	O
used	O
as	O
a	O
substrate	O
;	O
quality	O
controls	O
were	O
human	B
based	O
.	O

Several	O
other	O
hormones	O
and	O
peptides	O
were	O
estimated	O
by	O
routine	O
immunochemical	O
tests	O
:	O
insulin	O
,	O
C	O
-	O
peptide	O
,	O
TNFα	O
(	O
IMMULITE	O
,	O
Diagnostic	O
Products	O
Corporation	O
,	O
Los	O
Angeles	O
,	O
CA	O
,	O
U.S.A.	O
)	O
,	O
proinsulin	O
intact	O
(	O
DAKO	O
,	O
Denmark	O
)	O
,	O
IgG	O
anticardiolipin	O
(	O
ACL	O
-	O
IgG	O
,	O
IMMCO	O
Diagnostics	O
,	O
Buffalo	O
,	O
NY	O
,	O
U.S.A.	O
)	O
and	O
heart	O
fatty	O
acid	O
binding	O
protein	O
(	O
hFABP	O
,	O
Hbt	O
HUMAN	O
H	O
-	O
FABP	O
,	O
HyCult	O
Biotechnology	O
,	O
Uden	O
,	O
the	O
Netherlands	O
)	O
.	O

Serum	O
concentration	O
of	O
glucose	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
,	O
LDL	O
-	O
cholesterol	O
,	O
Apoprotein	O
B	O
and	O
uric	O
acid	O
were	O
measured	O
on	O
a	O
ILAB-600	O
biochemical	O
analyzer	O
(	O
Instrumentation	O
Laboratory	O
,	O
Lexington	O
,	O
Ma	O
,	O
U.S.A.	O
)	O
using	O
BioVendor	O
sets	O
.	O

All	O
samples	O
were	O
processed	O
and	O
examined	O
according	O
to	O
principles	O
of	O
good	O
laboratory	O
practice	O
and	O
under	O
constant	O
intralaboratory	O
and	O
external	O
quality	O
control	O
.	O

The	O
homeostatic	O
indexes	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
IR	O
and	O
QUICKI	O
)	O
were	O
calculated	O
according	O
to	O
the	O
homeostasis	O
model	O
of	O
assessment	O
[	O
33	O
-	O
35	O
]	O
as	O
follows	O
:	O
HOMA	O
IR	O
=	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22.5	O
;	O
QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O
.	O

Statistics	O
Statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Version	O
6	O
SAS	O
/	O
STAT	O
software	O
(	O
SAS	O
Institute	O
,	O
Inc.	O
,	O
Cary	O
,	O
NC	O
,	O
U.S.A.	O
)	O
.	O

The	O
Shapiro	O
-	O
Wilks	O
tests	O
were	O
used	O
in	O
testing	O
the	O
normality	O
of	O
distribution	O
.	O

Some	O
of	O
the	O
data	O
obtained	O
were	O
not	O
normally	O
distributed	O
.	O

The	O
statistical	O
significance	O
of	O
differences	O
between	O
the	O
means	O
in	O
the	O
hyperlipemic	O
and	O
control	O
groups	O
were	O
evaluated	O
using	O
the	O
unpaired	O
Student	O
's	O
T	O
-	O
test	O
in	O
the	O
case	O
of	O
normal	O
distribution	O
of	O
data	O
sets	O
,	O
and	O
using	O
the	O
Kolmogorov	O
-	O
Smirnov	O
test	O
when	O
at	O
least	O
in	O
one	O
of	O
the	O
data	O
sets	O
the	O
normal	O
distribution	O
was	O
excluded	O
.	O

Spearman	O
's	O
rank	O
-	O
order	O
correlation	O
was	O
used	O
for	O
correlation	O
analysis	O
.	O

Multiple	O
regression	O
analysis	O
was	O
performed	O
using	O
HOMA	O
IR	O
indexes	O
of	O
insulin	O
resistance	O
as	O
dependent	O
variables	O
,	O
and	O
other	O
metabolic	O
and	O
hormonal	O
factors	O
(	O
lipid	O
parameters	O
,	O
BMI	O
,	O
leptin	O
,	O
TNFα	O
,	O
hFABP	O
,	O
ACL	O
-	O
IgG	O
)	O
as	O
independent	O
variables	O
.	O

The	O
so	O
-	O
called	O
step	O
-	O
down	O
regression	O
model	O
was	O
used	O
to	O
select	O
dominant	O
independent	O
variables	O
.	O

Various	O
four	O
-	O
member	O
groups	O
of	O
independent	O
(	O
explanatory	O
)	O
variables	O
were	O
used	O
for	O
the	O
analysis	O
and	O
the	O
non	O
-	O
zero	O
intercept	O
was	O
taken	O
into	O
account	O
.	O

The	O
independent	O
variables	O
were	O
then	O
dropped	O
,	O
one	O
at	O
a	O
time	O
;	O
at	O
each	O
stage	O
one	O
variable	O
making	O
the	O
least	O
contribution	O
to	O
the	O
dependent	O
variable	O
(	O
i.e.	O
that	O
showed	O
the	O
least	O
p	O
-	O
value	O
in	O
the	O
test	O
of	O
the	O
regression	O
coefficient	O
being	O
zero	O
)	O
was	O
excluded	O
.	O

The	O
coefficient	O
of	O
determination	O
R2	O
,	O
which	O
can	O
be	O
viewed	O
as	O
a	O
percentage	O
explaining	O
the	O
total	O
variance	O
,	O
was	O
simultaneously	O
monitored	O
.	O

A	O
great	O
drop	O
in	O
R2	O
after	O
excluding	O
some	O
independent	O
variable	O
enabled	O
selection	O
of	O
those	O
independent	O
variables	O
that	O
could	O
be	O
thought	O
to	O
be	O
the	O
most	O
important	O
determinants	O
of	O
the	O
dependent	O
variable	O
.	O

Results	O
Table	O
1	O
demonstrates	O
mean	O
parameters	O
in	O
individual	O
groups	O
of	O
subjects	O
matched	O
according	O
to	O
sex	O
,	O
lipid	O
parameters	O
and	O
age	O
.	O

While	O
the	O
age	O
of	O
all	O
four	O
groups	O
did	O
not	O
differ	O
substantially	O
,	O
the	O
concentrations	O
of	O
total	O
serum	O
cholesterol	O
,	O
triglycerides	O
,	O
HDL	O
-	O
cholesterol	O
and	O
LDL	O
-	O
cholesterol	O
differ	O
very	O
significantly	O
in	O
both	O
male	O
and	O
female	O
hyperlipemic	O
groups	O
as	O
compared	O
with	O
controls	O
.	O

In	O
addition	O
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
control	O
women	O
was	O
significantly	O
higher	O
than	O
in	O
control	O
men	O
,	O
the	O
concentration	O
of	O
triglycerides	O
in	O
hyperlipemic	O
women	O
was	O
lower	O
than	O
in	O
hyperlipemic	O
men	O
,	O
and	O
the	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
in	O
hyperlipemic	O
women	O
was	O
very	O
significantly	O
higher	O
when	O
compared	O
with	O
hyperlipemic	O
men	O
.	O

Table	O
2	O
shows	O
the	O
values	O
of	O
other	O
metabolic	O
and	O
insulin	O
parameters	O
,	O
factors	O
related	O
to	O
insulin	O
resistance	O
and	O
indexes	O
of	O
insulin	O
resistance	O
,	O
respectively	O
.	O

Body	O
mass	O
indexes	O
and	O
uric	O
acid	O
concentration	O
were	O
significantly	O
higher	O
in	O
hyperlipemic	O
men	O
as	O
compared	O
to	O
controls	O
,	O
but	O
not	O
in	O
hyperlipemic	O
women	O
.	O

Uric	O
acid	O
concentration	O
was	O
substantially	O
lower	O
in	O
hyperlipemic	O
women	O
than	O
in	O
hyperlipemic	O
men	O
.	O

Plasma	O
concentrations	O
of	O
glycemia	O
,	O
insulin	O
and	O
intact	O
proinsulin	O
were	O
significantly	O
higher	O
in	O
both	O
hyperlipemic	O
men	O
and	O
women	O
as	O
compared	O
with	O
controls	O
of	O
identical	O
gender	O
,	O
while	O
the	O
concentration	O
of	O
leptin	O
increased	O
only	O
in	O
hyperlipemic	O
men	O
.	O

However	O
,	O
serum	O
leptin	O
concentrations	O
of	O
both	O
control	O
and	O
hyperlipemic	O
women	O
were	O
significantly	O
higher	O
than	O
in	O
corresponding	O
groups	O
of	O
men	O
.	O

Serum	O
concentrations	O
of	O
TNFα	O
,	O
hFABP	O
and	O
ACL	O
-	O
IgG	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	O
and	O
women	O
were	O
not	O
significantly	O
different	O
from	O
control	O
groups	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
indexes	O
of	O
insulin	O
resistance	O
HOMA	O
IR	O
and	O
QUICKI	O
differed	O
very	O
significantly	O
in	O
hyperlipemic	O
groups	O
of	O
both	O
men	O
and	O
women	O
as	O
compared	O
with	O
corresponding	O
control	O
groups	O
,	O
more	O
distinctly	O
in	O
women	O
.	O

From	O
Fig.	O
1	O
,	O
presenting	O
95	O
%	O
confidence	O
limits	O
of	O
insulin	O
resistance	O
indexes	O
HOMA	O
IR	O
and	O
QUICKI	O
,	O
we	O
concluded	O
that	O
in	O
groups	O
of	O
hyperlipemic	O
patients	O
of	O
both	O
genders	O
the	O
insulin	O
resistance	O
was	O
substantially	O
higher	O
than	O
in	O
control	O
groups	O
;	O
the	O
groups	O
did	O
not	O
overlap	O
each	O
other	O
.	O

In	O
Table	O
3	O
the	O
results	O
of	O
Spearman	O
's	O
correlations	O
between	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
and	O
various	O
metabolic	O
parameters	O
are	O
presented	O
.	O

In	O
the	O
control	O
group	O
of	O
men	O
,	O
positive	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
,	O
and	O
inverse	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
,	O
respectively	O
,	O
were	O
found	O
.	O

In	O
the	O
control	O
group	O
of	O
women	O
,	O
the	O
significance	O
of	O
Spearman	O
's	O
correlation	O
between	O
HOMA	O
IR	O
and	O
leptin	O
was	O
more	O
expressive	O
;	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
was	O
also	O
present	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
men	O
,	O
the	O
significance	O
of	O
the	O
correlation	O
between	O
HOMA	O
IR	O
was	O
more	O
expressive	O
in	O
relation	O
to	O
the	O
control	O
group	O
,	O
and	O
no	O
significant	O
correlation	O
between	O
HOMA	O
IR	O
and	O
ACL	O
IgG	O
was	O
found	O
.	O

In	O
the	O
hyperlipemic	O
group	O
of	O
women	O
,	O
however	O
,	O
the	O
significance	O
of	O
Spearman	O
's	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
leptin	O
concentration	O
weakened	O
,	O
the	O
inverse	O
correlation	O
between	O
HOMA	O
IR	O
and	O
HDL	O
-	O
cholesterol	O
remained	O
approximately	O
unchanged	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
HOMA	O
IR	O
and	O
serum	O
concentration	O
of	O
TNFα	O
appeared	O
.	O

Table	O
4	O
shows	O
results	O
of	O
multiple	O
regression	O
analysis	O
,	O
when	O
data	O
from	O
both	O
control	O
and	O
hyperlipemic	O
groups	O
of	O
each	O
gender	O
were	O
judged	O
together	O
.	O

HOMA	O
IR	O
was	O
considered	O
as	O
a	O
dependent	O
variable	O
and	O
differently	O
changed	O
constellations	O
of	O
metabolic	O
and	O
other	O
factors	O
were	O
taken	O
as	O
independent	O
variables	O
.	O

In	O
men	O
,	O
BMI	O
and	O
leptin	O
seemed	O
to	O
play	O
a	O
main	O
role	O
in	O
influencing	O
the	O
insulin	O
resistance	O
index	O
HOMA	O
IR	O
,	O
while	O
TGL	O
,	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
did	O
n't	O
play	O
any	O
significant	O
role	O
(	O
see	O
left	O
columns	O
of	O
Table	O
4	O
)	O
.	O

The	O
decreasing	O
of	O
HDL	O
-	O
cholesterol	O
concentration	O
may	O
also	O
have	O
some	O
influence	O
(	O
see	O
a	O
significant	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
this	O
factor	O
in	O
Table	O
4A	O
,	O
4B	O
)	O
.	O

But	O
in	O
the	O
presence	O
of	O
leptin	O
in	O
the	O
group	O
of	O
independent	O
factors	O
,	O
the	O
drop	O
of	O
R2	O
after	O
exclusion	O
of	O
HDL	O
-	O
cholesterol	O
from	O
these	O
factors	O
was	O
minimal	O
(	O
see	O
Table	O
4C	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
after	O
the	O
exclusion	O
of	O
TNFα	O
from	O
the	O
group	O
of	O
independent	O
variables	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
the	O
value	O
of	O
R2	O
has	O
unexpectedly	O
risen	O
,	O
which	O
could	O
reflect	O
the	O
interference	O
of	O
TNFα	O
with	O
factors	O
increasing	O
the	O
insulin	O
resistance	O
.	O

In	O
women	O
(	O
see	O
right	O
columns	O
of	O
Table	O
4	O
)	O
,	O
the	O
maximal	O
values	O
of	O
R2	O
were	O
achieved	O
with	O
combination	O
of	O
independent	O
variables	O
containing	O
TGL	O
,	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
(	O
about	O
60	O
%	O
influence	O
on	O
HOMA	O
IR	O
!	O

–	O
see	O
Table	O
4A	O
,	O
4B	O
,	O
4C	O
)	O
.	O

TNFα	O
seemed	O
to	O
play	O
quite	O
a	O
different	O
role	O
than	O
in	O
men	O
:	O
after	O
exclusion	O
of	O
this	O
factor	O
from	O
the	O
group	O
of	O
independent	O
factors	O
R2significantly	O
decreased	O
(	O
see	O
Table	O
4B	O
,	O
4D	O
)	O
.	O

In	O
contrast	O
to	O
men	O
,	O
the	O
role	O
of	O
BMI	O
seemed	O
to	O
be	O
minimal	O
.	O

As	O
in	O
men	O
,	O
the	O
role	O
of	O
ACL	O
IgG	O
and	O
LDL	O
-	O
cholesterol	O
in	O
influencing	O
HOMA	O
IR	O
was	O
negligible	O
,	O
but	O
in	O
contrast	O
to	O
men	O
,	O
hFABP	O
might	O
play	O
a	O
certain	O
role	O
in	O
this	O
process	O
(	O
see	O
Table	O
4D	O
)	O
.	O

Generally	O
,	O
the	O
insulin	O
resistance	O
(	O
represented	O
by	O
HOMA	O
IR	O
)	O
was	O
in	O
men	O
much	O
less	O
influenced	O
by	O
metabolic	O
variables	O
than	O
in	O
women	O
;	O
while	O
in	O
women	O
in	O
some	O
combinations	O
of	O
dependent	O
variables	O
R2	O
reached	O
64	O
%	O
,	O
in	O
men	O
the	O
maximal	O
value	O
of	O
R2	O
was	O
only	O
39	O
%	O
.	O

Discussion	O
In	O
our	O
previous	O
paper	O
[	O
36	O
]	O
,	O
the	O
mean	O
value	O
of	O
HOMA	O
IR	O
in	O
healthy	O
subjects	O
of	O
both	O
genders	O
and	O
of	O
age	O
comparable	O
with	O
our	O
controls	O
was	O
1.57	O
±	O
0.87	O
,	O
and	O
the	O
mean	O
value	O
of	O
index	O
QUICKI	O
0.366	O
±	O
0.029	O
,	O
respectively	O
.	O

These	O
values	O
,	O
as	O
well	O
as	O
the	O
95	O
%	O
confidence	O
limits	O
,	O
correspond	O
to	O
values	O
found	O
in	O
controls	O
in	O
this	O
study	O
.	O

In	O
accordance	O
with	O
many	O
previous	O
papers	O
,	O
serum	O
concentrations	O
of	O
leptin	O
in	O
women	O
(	O
both	O
control	O
and	O
hyperlipemic	O
)	O
were	O
substantially	O
higher	O
than	O
in	O
men	O
.	O

In	O
the	O
control	O
group	O
of	O
women	O
the	O
correlation	O
between	O
leptin	O
and	O
HOMA	O
IR	O
was	O
highly	O
significant	O
.	O

However	O
,	O
in	O
hyperlipemic	O
women	O
the	O
significance	O
of	O
this	O
correlation	O
lessened	O
,	O
because	O
HOMA	O
IR	O
increased	O
considerably	O
(	O
and	O
significantly	O
)	O
but	O
serum	O
concentration	O
of	O
leptin	O
only	O
slightly	O
(	O
insignificantly	O
)	O
.	O

In	O
men	O
the	O
significance	O
of	O
correlations	O
between	O
serum	O
leptin	O
and	O
HOMA	O
IR	O
was	O
high	O
and	O
approximately	O
the	O
same	O
in	O
both	O
the	O
control	O
and	O
hyperlipemic	O
groups	O
,	O
because	O
the	O
values	O
of	O
HOMA	O
IR	O
as	O
well	O
as	O
serum	O
leptin	O
have	O
nearly	O
doubled	O
in	O
hyperlipemic	O
in	O
relation	O
to	O
control	O
groups	O
.	O

In	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	O
the	O
high	O
concentration	O
of	O
serum	O
leptin	O
was	O
not	O
associated	O
with	O
higher	O
insulin	O
resistance	O
:	O
HOMA	O
IR	O
did	O
not	O
differ	O
substantially	O
from	O
men	O
.	O

A	O
significant	O
increase	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	O
was	O
associated	O
by	O
only	O
slight	O
and	O
insignificant	O
increase	O
of	O
leptin	O
concentration	O
.	O

According	O
to	O
Spearman	O
's	O
correlations	O
,	O
an	O
increase	O
of	O
serum	O
TNFα	O
and/or	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
might	O
also	O
play	O
a	O
distinct	O
role	O
in	O
this	O
respect	O
.	O

(	O
see	O
Table	O
3	O
)	O
.	O

In	O
contrast	O
to	O
women	O
,	O
in	O
hyperlipemic	O
men	O
the	O
increase	O
of	O
insulin	O
resistance	O
index	O
was	O
approximately	O
proportional	O
with	O
the	O
increase	O
of	O
leptin	O
concentration	O
.	O

Multiple	O
regression	O
analysis	O
affirmed	O
the	O
importance	O
of	O
leptin	O
serum	O
in	O
increasing	O
of	O
insulin	O
resistance	O
in	O
both	O
genders	O
.	O

In	O
men	O
,	O
only	O
BMI	O
and	O
HDL	O
-	O
cholesterol	O
from	O
other	O
factors	O
studied	O
seemed	O
to	O
play	O
a	O
certain	O
role	O
,	O
but	O
the	O
maximal	O
values	O
of	O
influencing	O
HOMA	O
IR	O
reached	O
only	O
39	O
%	O
,	O
with	O
leptin	O
and	O
BMI	O
being	O
the	O
more	O
important	O
factors	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
women	O
the	O
maximal	O
determination	O
of	O
HOMA	O
IR	O
as	O
high	O
as	O
60	O
%	O
was	O
registered	O
in	O
combination	O
of	O
serum	O
leptin	O
,	O
TGL	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
as	O
independent	O
factors	O
;	O
the	O
role	O
of	O
BMI	O
was	O
insignificant	O
.	O

It	O
is	O
not	O
known	O
how	O
leptin	O
is	O
regulated	O
.	O

A	O
strong	O
correlation	O
between	O
plasma	O
leptin	O
and	O
fasting	O
insulin	O
undoubtedly	O
exists	O
,	O
but	O
hyperleptinemia	O
in	O
both	O
obese	O
and	O
lean	O
humans	B
is	O
not	O
likely	O
the	O
result	O
of	O
hyperinsulinemia	O
[	O
37	O
]	O
.	O

A	O
relationship	O
between	O
leptin	O
and	O
insulin	O
dependent	O
on	O
sex	O
or	O
BMI	O
was	O
reported	O
,	O
but	O
relationship	O
between	O
triglyceride	O
concentrations	O
and	O
leptin	O
was	O
independent	O
of	O
sex	O
,	O
BMI	O
,	O
and	O
insulin	O
[	O
18,24	O
]	O
.	O

Hyperleptinemia	O
,	O
as	O
an	O
early	O
sign	O
of	O
obesity	O
,	O
was	O
closely	O
linked	O
to	O
subcutaneous	O
fat	O
mass	O
[	O
39,40	O
]	O
.	O

Percentage	O
of	O
body	O
fat	O
has	O
been	O
shown	O
to	O
be	O
the	O
strongest	O
predictor	O
of	O
leptin	O
levels	O
even	O
in	O
lean	O
women	O
[	O
41	O
]	O
.	O

Leptin	O
was	O
highly	O
correlated	O
with	O
percentage	O
of	O
body	O
fat	O
and	O
with	O
fat	O
mass	O
in	O
adults	O
irrespective	O
of	O
gender	O
and	O
age	O
;	O
however	O
,	O
the	O
mean	O
determinant	O
of	O
leptin	O
plasma	O
concentration	O
in	O
men	O
and	O
postmenopausal	O
women	O
was	O
BMI	O
,	O
while	O
in	O
premenopausal	O
women	O
it	O
was	O
only	O
the	O
fat	O
mass	O
[	O
42	O
]	O
.	O

These	O
findings	O
contrast	O
with	O
our	O
results	O
showing	O
minimal	O
influence	O
of	O
BMI	O
on	O
HOMA	O
IR	O
in	O
postmenopausal	O
women	O
.	O

All	O
factors	O
mentioned	O
are	O
connected	O
with	O
fat	O
tissue	O
:	O
leptin	O
and	O
TNFα	O
are	O
directly	O
produced	O
chiefly	O
by	O
adipocytes	O
,	O
BMI	O
growth	O
is	O
obviously	O
accompanied	O
by	O
fat	O
mass	O
increase	O
,	O
and	O
the	O
typical	O
hypertriglyceridemia	O
associated	O
with	O
a	O
decrease	O
of	O
HDL	O
-	O
cholesterol	O
goes	O
along	O
with	O
obesity	O
and	O
fat	O
mass	O
growth	O
.	O

The	O
gender	O
differences	O
in	O
circulating	O
leptin	O
were	O
best	O
explained	O
by	O
percentage	O
of	O
body	O
fat	O
and	O
–	O
inversely	O
–	O
by	O
lean	O
body	O
mass	O
[	O
25	O
]	O
.	O

In	O
both	O
genders	O
the	O
intra	O
-	O
abdominal	O
fat	O
correlated	O
with	O
insulin	O
resistance	O
,	O
while	O
the	O
subcutaneous	O
fat	O
correlated	O
with	O
circulating	O
leptin	O
[	O
11,12	O
]	O
.	O

In	O
men	O
obesity	O
led	O
to	O
a	O
prevalent	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
while	O
in	O
women	O
of	O
subcutaneous	O
fat	O
[	O
13	O
]	O
.	O

Influences	O
of	O
different	O
compartments	O
of	O
adipose	O
tissues	O
could	O
elucidate	O
the	O
variability	O
of	O
correlations	O
between	O
insulin	O
resistance	O
and	O
high	O
leptin	O
concentrations	O
in	O
lean	O
and	O
obese	O
subjects	O
of	O
both	O
genders	O
[	O
43	O
]	O
.	O

In	O
our	O
non	O
-	O
hyperlipemic	O
postmenopausal	O
women	O
the	O
content	O
of	O
subcutaneous	O
fat	O
mass	O
might	O
be	O
higher	O
than	O
in	O
non	O
-	O
hyperlipemic	O
men	O
of	O
appropriate	O
age	O
,	O
which	O
indicated	O
a	O
higher	O
serum	O
concentration	O
of	O
leptin	O
.	O

However	O
,	O
the	O
insulin	O
resistance	O
–	O
related	O
to	O
intra	O
-	O
abdominal	O
fat	O
mass	O
–	O
did	O
not	O
differ	O
from	O
men	O
.	O

The	O
significant	O
increase	O
of	O
insulin	O
resistance	O
and	O
leptin	O
concentration	O
in	O
hyperlipemic	O
men	O
might	O
reflect	O
the	O
growing	O
content	O
of	O
both	O
subcutaneous	O
and	O
intra	O
-	O
abdominal	O
fat	O
mass	O
(	O
see	O
the	O
significant	O
increase	O
of	O
BMI	O
)	O
.	O

In	O
hyperlipemic	O
women	O
the	O
significant	O
increase	O
of	O
insulin	O
resistance	O
accompanying	O
only	O
minimal	O
insignificant	O
increase	O
of	O
leptin	O
could	O
be	O
caused	O
by	O
prevalent	O
growing	O
of	O
intra	O
-	O
abdominal	O
fat	O
mass	O
.	O

In	O
elderly	O
postmenopausal	O
women	O
,	O
an	O
association	O
between	O
leptin	O
and	O
plasma	O
lipoprotein	O
concentration	O
was	O
found	O
which	O
depended	O
on	O
adiposity	O
[	O
17	O
]	O
,	O
and	O
inverse	O
correlations	O
between	O
serum	O
leptin	O
and	O
HDL	O
-	O
cholesterol	O
were	O
described	O
[	O
44	O
]	O
.	O

In	O
our	O
study	O
,	O
insulin	O
resistance	O
in	O
women	O
seemed	O
to	O
be	O
more	O
notably	O
than	O
in	O
men	O
influenced	O
by	O
lipid	O
disorders	O
,	O
i.e.	O
positively	O
by	O
serum	O
triglycerides	O
and	O
inversely	O
by	O
HDL	O
-	O
cholesterol	O
.	O

These	O
findings	O
might	O
be	O
important	O
in	O
considering	O
the	O
concept	O
of	O
treatment	O
of	O
insulin	O
resistance	O
-	O
related	O
disorders	O
in	O
postmenopausal	O
women	O
.	O

The	O
significant	O
role	O
of	O
TNFα	O
in	O
insulin	O
resistance	O
,	O
caused	O
by	O
inhibiting	O
the	O
transduction	O
of	O
insulin	O
signaling	O
and	O
by	O
down	O
-	O
regulation	O
of	O
glucose	O
transporter	O
GLUT-4	O
and	O
insulin	O
receptor	O
substrate-1	O
,	O
has	O
been	O
repeatedly	O
confirmed	O
[	O
45	O
-	O
48	O
]	O
.	O

Our	O
results	O
supported	O
these	O
findings	O
unambiguously	O
only	O
in	O
women	O
,	O
while	O
in	O
men	O
TNFα	O
seemed	O
paradoxically	O
to	O
interfere	O
with	O
other	O
factors	O
–	O
mainly	O
BMI	O
and	O
leptin	O
–	O
in	O
influencing	O
insulin	O
resistance	O
,	O
thus	O
playing	O
a	O
quite	O
different	O
role	O
.	O

Previously	O
it	O
was	O
found	O
[	O
46	O
]	O
that	O
correlation	O
between	O
serum	O
TNFα	O
on	O
the	O
one	O
side	O
,	O
and	O
insulin	O
,	O
HOMA	O
IR	O
,	O
serum	O
triglycerids	O
,	O
respectively	O
,	O
on	O
the	O
other	O
side	O
,	O
was	O
substantially	O
more	O
significant	O
in	O
women	O
than	O
in	O
men	O
.	O

Serum	O
concentration	O
of	O
TNFα	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
of	O
both	O
genders	O
correlated	O
only	O
with	O
the	O
quantity	O
of	O
intra	O
-	O
abdominal	O
fat	O
compartment	O
[	O
50	O
]	O
.	O

Visceral	O
obesity	O
correlated	O
with	O
plasmatic	O
aldosterone	O
and	O
with	O
insulin	O
resistance	O
only	O
in	O
premenopausal	O
women	O
,	O
but	O
not	O
in	O
men	O
[	O
51	O
]	O
.	O

From	O
all	O
these	O
data	O
we	O
might	O
support	O
our	O
above	O
mentioned	O
conclusion	O
–	O
that	O
rising	O
of	O
insulin	O
resistance	O
in	O
hyperlipemic	O
women	O
was	O
associated	O
with	O
an	O
increase	O
of	O
intra	O
-	O
abdominal	O
fat	O
,	O
because	O
this	O
fat	O
mass	O
in	O
particular	O
is	O
a	O
source	O
of	O
TNFα	O
,	O
which	O
interfered	O
with	O
insulin	O
sensitivity	O
only	O
in	O
women	O
.	O

We	O
came	O
to	O
this	O
conclusion	O
irrespective	O
of	O
the	O
finding	O
that	O
the	O
increase	O
of	O
serum	O
TNFα	O
in	O
hyperlipemic	O
women	O
was	O
statistically	O
insignificant	O
;	O
results	O
of	O
Spearman	O
's	O
correlation	O
(	O
Table	O
3	O
)	O
and	O
multiple	O
regression	O
analysis	O
confirm	O
a	O
distinct	O
role	O
of	O
this	O
factor	O
.	O

In	O
hyperlipemic	O
men	O
not	O
only	O
the	O
serum	O
concentration	O
of	O
TNFα	O
has	O
decreased	O
instead	O
of	O
increasing	O
,	O
but	O
according	O
to	O
multiple	O
regression	O
analysis	O
it	O
played	O
a	O
quite	O
different	O
role	O
in	O
influencing	O
insulin	O
sensitivity	O
,	O
interfering	O
with	O
factors	O
that	O
determined	O
insulin	O
resistance	O
(	O
leptin	O
and	O
BMI	O
)	O
.	O

In	O
the	O
control	O
group	O
of	O
men	O
IgG	O
anticardiolipin	O
was	O
inversely	O
correlated	O
to	O
HOMA	O
IR	O
.	O

The	O
significance	O
of	O
this	O
finding	O
is	O
not	O
clear	O
.	O

These	O
antibodies	O
indicate	O
vascular	O
and	O
thrombotic	O
complications	O
and	O
oxidative	O
modification	O
of	O
lipoproteins	O
[	O
52,53	O
]	O
and	O
may	O
represent	O
an	O
increased	O
risk	O
of	O
atherogenic	O
and	O
inflammatory	O
complications	O
.	O

In	O
this	O
case	O
,	O
however	O
,	O
their	O
growing	O
might	O
be	O
connected	O
with	O
an	O
increase	O
in	O
insulin	O
sensitivity	O
.	O

Anyway	O
,	O
ACL	O
IgG	O
evidently	O
did	O
not	O
participate	O
significantly	O
in	O
influencing	O
the	O
increase	O
of	O
insulin	O
resistance	O
associated	O
with	O
hyperlipidemia	O
,	O
although	O
other	O
anti	O
-	O
cardiolipin	O
correlations	O
could	O
be	O
masked	O
by	O
the	O
relatively	O
large	O
inter	O
-	O
individual	O
variations	O
in	O
this	O
parameter	O
.	O

Neither	O
serum	O
concentration	O
of	O
hFABP	O
,	O
a	O
factor	O
ensuring	O
transmembrane	O
transport	O
and	O
oxidative	O
metabolisation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
[	O
54,55	O
]	O
,	O
was	O
significantly	O
changed	O
in	O
hyperlipemic	O
and	O
insulin	O
resistant	O
subjects	O
of	O
both	O
genders	O
.	O

This	O
factor	O
was	O
very	O
weakly	O
associated	O
only	O
with	O
HOMA	O
IR	O
in	O
women	O
(	O
see	O
Table	O
4D	O
)	O
,	O
indicating	O
that	O
enhanced	O
metabolisation	O
of	O
fatty	O
acids	O
in	O
cells	O
might	O
to	O
some	O
degree	O
contribute	O
to	O
insulin	O
resistance	O
.	O

Conclusions	O
In	O
postmenopausal	O
women	O
as	O
well	O
as	O
in	O
men	O
of	O
approximately	O
equal	O
age	O
serum	O
leptin	O
plays	O
a	O
significant	O
role	O
as	O
an	O
important	O
determinant	O
of	O
insulin	O
resistance	O
.	O

In	O
addition	O
to	O
this	O
factor	O
,	O
in	O
women	O
the	O
grade	O
of	O
insulin	O
resistance	O
is	O
very	O
considerably	O
influenced	O
by	O
serum	O
triglycerides	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
by	O
decreased	O
concentration	O
of	O
HDL	O
-	O
cholesterol	O
,	O
while	O
in	O
men	O
only	O
a	O
mild	O
influence	O
of	O
BMI	O
and	O
decreased	O
HDL	O
-	O
cholesterol	O
is	O
observed	O
.	O

These	O
findings	O
are	O
explained	O
as	O
a	O
consequence	O
of	O
gender	O
-	O
related	O
differences	O
in	O
adipose	O
tissue	O
composition	O
and/or	O
distribution	O
in	O
both	O
normal	O
-	O
weight	O
and	O
over	O
-	O
weight	O
subjects	O
and	O
should	O
be	O
taken	O
into	O
account	O
in	O
treatment	O
of	O
patients	O
with	O
metabolic	O
risk	O
factors	O
of	O
cardiovascular	O
diseases	O
.	O

List	O
of	O
abbreviations	O
HDL	O
-	O
Cholesterol	O
=	O
high	O
-	O
density	O
cholesterol	O
LDL	O
-	O
cholesterol	O
=	O
low	O
-	O
density	O
cholesterol	O
HOMA	O
IR	O
=	O
Homeostasis	O
Assessment	O
of	O
Insulin	O
Resistance	O
=	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
*	O
fasting	O
glucose	O
(	O
mmol	O
/	O
l	O
)	O
/	O
22,5	O
QUICKI	O
=	O
1	O
/	O
[	O
log	O
fasting	O
insulin	O
(	O
μU	O
/	O
ml	O
)	O
+	O
log	O
fasting	O
glucose	O
(	O
mg	O
/	O
100	O
ml	O
)	O
]	O
TNFα	O
=	O
tumor	O
necrosis	O
factor	O
alpha	O
BMI	O
=	O
body	O
mass	O
index	O
R2	O
=	O
coefficient	O
of	O
determination	O
hFABP	O
=	O
heart	O
fatty	O
acid	O
binding	O
protein	O
ACL	O
-	O
IgG	O
=	O
IgG	O
fraction	O
of	O
anticardiolipin	O
TGL	O
=	O
triglycerides	O
GLUT-4	O
=	O
glucose	O
transporter-4	O
PPARγ	O
=	O
Peroxisome	O
Proliferator	O
-	O
Associated	O
Receptor	O
gamma	O
CV	O
=	O
coefficient	O
of	O
variation	O
Authors	O
'	O
contributions	O
Dr.	O
Radka	O
Lichnovská	O
collected	O
the	O
clinical	O
material	O
,	O
performed	O
analysis	O
of	O
biochemical	O
values	O
and	O
edited	O
the	O
manuscript	O
.	O

Dr.	O
Simona	O
Gwozdziewiczová	O
performed	O
analysis	O
of	O
clinical	O
and	O
biochemical	O
data	O
and	O
edited	O
the	O
manuscript	O
.	O

Prof.	O
Jirí	O
Hrebícek	O
initiated	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
wrote	O
and	O
edited	O
the	O
manuscript	O
.	O

Enp1	O
,	O
a	O
yeast	B
protein	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
and	O
40S	O
subunit	O
synthesis	O
Abstract	O
ENP1	O
is	O
an	O
essential	O
Saccharomyces	B
cerevisiae	I
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

Enp1	O
protein	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
concentrated	O
in	O
the	O
nucleolus	O
.	O

An	O
enp1	O
-	O
1	O
temperature	O
-	O
sensitive	O
mutant	O
inhibited	O
35S	O
pre	O
-	O
rRNA	O
early	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
as	O
shown	O
by	O
northern	O
analysis	O
of	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
.	O

Pulse	O
-	O
chase	O
analysis	O
further	O
revealed	O
that	O
the	O
enp1	O
-	O
1	O
strain	O
was	O
defective	O
in	O
the	O
synthesis	O
of	O
20S	O
pre	O
-	O
rRNA	O
and	O
hence	O
18S	O
rRNA	O
,	O
which	O
led	O
to	O
reduced	O
formation	O
of	O
40S	O
ribosomal	O
subunits	O
.	O

Co	O
-	O
precipitation	O
analysis	O
revealed	O
that	O
Enp1	O
was	O
associated	O
with	O
Nop1	O
protein	O
,	O
as	O
well	O
as	O
with	O
U3	O
and	O
U14	O
RNAs	O
,	O
two	O
snoRNAs	O
implicated	O
in	O
early	O
pre	O
-	O
rRNA	O
processing	O
steps	O
.	O

These	O
results	O
suggest	O
a	O
direct	O
role	O
for	O
Enp1	O
in	O
the	O
early	O
steps	O
of	O
rRNA	O
processing	O
.	O

INTRODUCTION	O
Ribosome	O
biogenesis	O
is	O
one	O
of	O
the	O
major	O
cellular	O
activities	O
in	O
eukaryotic	O
cells	O
.	O

It	O
takes	O
place	O
primarily	O
in	O
a	O
specialized	O
subnuclear	O
compartment	O
,	O
the	O
nucleolus	O
(	O
1,2	O
)	O
.	O

In	O
the	O
yeast	B
Saccharomyces	B
cerevisiae	I
,	O
each	O
rRNA	O
gene	O
is	O
transcribed	O
by	O
RNA	O
polymerase	O
I	O
into	O
a	O
35S	O
rRNA	O
precursor	O
,	O
consisting	O
of	O
18S	O
,	O
5.8S	O
and	O
25S	O
rRNA	O
sequences	O
flanked	O
by	O
two	O
external	O
transcribed	O
spacers	O
(	O
ETS	O
)	O
and	O
separated	O
by	O
two	O
internal	O
transcribed	O
spacers	O
(	O
ITS	O
)	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
35S	O
precursor	O
goes	O
through	O
a	O
series	O
of	O
modifications	O
and	O
processing	O
steps	O
to	O
generate	O
the	O
mature	O
18S	O
,	O
5.8S	O
and	O
25S	O
rRNAs	O
.	O

The	O
processing	O
occurs	O
first	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
resulting	O
in	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
27SA2	O
pre	O
-	O
rRNA	O
.	O

The	O
20S	O
pre	O
-	O
rRNA	O
is	O
then	O
cleaved	O
,	O
leading	O
to	O
the	O
mature	O
18S	O
rRNA	O
found	O
in	O
the	O
40S	O
ribosomal	O
subunit	O
.	O

The	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
processed	O
through	O
two	O
alternative	O
pathways	O
.	O

The	O
majority	O
of	O
27SA2	O
pre	O
-	O
rRNA	O
is	O
cleaved	O
at	O
sites	O
A3	O
and	O
B2	O
to	O
form	O
the	O
27SA3	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
subsequently	O
processed	O
to	O
produce	O
27SBS	O
.	O

Alternatively	O
,	O
27SA2	O
pre	O
-	O
rRNA	O
can	O
be	O
processed	O
at	O
sites	O
B1L	O
and	O
B2	O
to	O
generate	O
27SBL	O
pre	O
-	O
rRNA	O
.	O

Both	O
27SBS	O
and	O
27SBL	O
pre	O
-	O
rRNAs	O
are	O
then	O
cleaved	O
at	O
sites	O
C1	O
and	O
C2	O
to	O
generate	O
the	O
mature	O
25S	O
rRNA	O
,	O
and	O
7SS	O
or	O
7SL	O
intermediates	O
,	O
which	O
are	O
then	O
processed	O
to	O
mature	O
5.8SS	O
or	O
5.8SL	O
rRNAs	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
25S	O
rRNA	O
and	O
5.8S	O
rRNA	O
are	O
the	O
RNA	O
components	O
of	O
the	O
60S	O
ribosomal	O
subunit	O
(	O
3	O
)	O
.	O

During	O
the	O
course	O
of	O
rRNA	O
modification	O
and	O
processing	O
,	O
many	O
of	O
the	O
ribosomal	O
proteins	O
are	O
assembled	O
onto	O
the	O
rRNA	O
molecules	O
to	O
form	O
the	O
ribosome	O
complex	O
.	O

Ribosome	O
biogenesis	O
needs	O
a	O
large	O
number	O
of	O
trans	O
-	O
acting	O
factors	O
,	O
including	O
small	O
nucleolar	O
RNAs	O
(	O
snoRNAs	O
)	O
,	O
protein	O
components	O
of	O
the	O
snoRNP	O
complexes	O
,	O
rRNA	O
modifying	O
enzymes	O
,	O
endo-	O
and	O
exonucleases	O
,	O
putative	O
RNA	O
helicases	O
and	O
other	O
protein	O
factors	O
(	O
3,4	O
)	O
.	O

In	O
yeast	B
cells	O
there	O
are	O
more	O
than	O
100	O
different	O
snoRNAs	O
playing	O
important	O
roles	O
in	O
rRNA	O
modification	O
and	O
processing	O
.	O

On	O
the	O
basis	O
of	O
their	O
structure	O
,	O
the	O
snoRNAs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
:	O
the	O
box	O
C	O
/	O
D	O
family	O
and	O
box	O
H	O
/	O
ACA	O
family	O
.	O

Only	O
one	O
snoRNA	O
,	O
MRP	O
RNA	O
,	O
belongs	O
to	O
neither	O
family	O
(	O
5–7	O
)	O
.	O

While	O
the	O
majority	O
of	O
the	O
snoRNAs	O
participate	O
in	O
RNA	O
pseudouridylation	O
and	O
2′-O	O
-	O
ribose	O
methylation	O
,	O
a	O
few	O
of	O
them	O
,	O
including	O
MRP	O
snoRNA	O
,	O
box	O
C	O
/	O
D	O
snoRNAs	O
U3	O
and	O
U14	O
,	O
and	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
snR10	O
and	O
snR30	O
,	O
are	O
required	O
for	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
(	O
8–12	O
)	O
.	O

Not	O
only	O
are	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
essential	O
for	O
early	O
cleavages	O
of	O
35S	O
pre	O
-	O
rRNA	O
to	O
18S	O
rRNA	O
,	O
the	O
proteins	O
associated	O
with	O
them	O
,	O
including	O
Nop1	O
,	O
Nop5	O
,	O
Gar1	O
and	O
Nop10	O
,	O
have	O
also	O
been	O
shown	O
to	O
be	O
required	O
for	O
18S	O
rRNA	O
synthesis	O
(	O
13–16	O
)	O
.	O

The	O
ENP1	O
(	O
Essential	O
Nuclear	O
Protein	O
1	O
)	O
gene	O
was	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
suppressors	O
of	O
an	O
ost4	O
mutation	O
(	O
oligosaccharide	O
transferase	O
4	O
)	O
(	O
17	O
)	O
.	O

However	O
,	O
in	O
subsequent	O
studies	O
it	O
was	O
found	O
not	O
to	O
be	O
involved	O
in	O
OST4	O
function	O
(	O
18	O
)	O
.	O

ENP1	O
is	O
an	O
essential	O
gene	O
encoding	O
a	O
483	O
amino	O
acid	O
polypeptide	O
.	O

The	O
Enp1	O
protein	O
is	O
highly	O
conserved	O
and	O
homologs	O
are	O
found	O
in	O
all	O
eukaryotes	O
.	O

The	O
yeast	B
protein	O
was	O
localized	O
to	O
the	O
nucleus	O
in	O
a	O
previous	O
study	O
(	O
18	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
an	O
Enp1	O
human	B
homolog	O
,	O
called	O
bystin	O
,	O
was	O
reported	O
to	O
localize	O
to	O
the	O
cytoplasm	O
and	O
was	O
proposed	O
to	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
the	O
Enp1	O
protein	O
not	O
only	O
is	O
nuclear	O
but	O
is	O
enriched	O
in	O
the	O
nucleolus	O
.	O

We	O
also	O
found	O
that	O
Enp1	O
is	O
required	O
for	O
the	O
synthesis	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
and	O
its	O
presence	O
is	O
necessary	O
for	O
the	O
pre	O
-	O
rRNA	O
processing	O
to	O
form	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
.	O

An	O
association	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNAs	O
,	O
and	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
,	O
was	O
established	O
.	O

We	O
also	O
found	O
that	O
human	B
Enp1	O
,	O
expressed	O
in	O
yeast	B
,	O
was	O
located	O
in	O
the	O
nucleus	O
and	O
the	O
nucleolus	O
,	O
suggesting	O
that	O
the	O
function	O
of	O
this	O
protein	O
is	O
conserved	O
.	O

MATERIALS	O
AND	O
METHODS	O
Yeast	B
strains	O
and	O
media	O
The	O
S.cerevisiae	B
strains	O
used	O
in	O
this	O
study	O
are	O
all	O
derivatives	O
of	O
a	O
wild	O
-	O
type	O
diploid	O
strain	O
W303	O
(	O
MATa	O
/	O
MATα	O
ura3	O
-	O
1	O
/	O
ura3	O
-	O
1	O
leu2	O
-	O
3,112	O
/	O
leu2	O
-	O
3,112	O
trp1	O
-	O
1	O
/	O
trp1	O
-	O
1	O
his3	O
-	O
11,15	O
/	O
his3	O
-	O
11,15	O
ade2	O
-	O
1	O
/	O
ade2	O
-	O
1	O
can1	O
-	O
100	O
/	O
can1	O
-	O
100	O
)	O
except	O
for	O
strain	O
RS1938	O
.	O

Strain	O
JBY45	O
(	O
MATa	O
/	O
MATα	O
ENP1	O
/	O
Δenp1::his5	O
+	O
)	O
was	O
constructed	O
by	O
replacing	O
one	O
copy	O
of	O
the	O
ENP1	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
with	O
the	O
Schizosaccharomyces	B
pombe	I
his5	O
+	O
gene	O
(	O
18	O
)	O
.	O

Strain	O
JBY46	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB23	O
(	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
is	O
a	O
haploid	O
strain	O
derived	O
from	O
JBY45	O
with	O
wild	O
-	O
type	O
ENP1	O
on	O
a	O
low	O
copy	O
number	O
plasmid	O
.	O

Strain	O
JBY48	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
and	O
strain	O
JBY49	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB39	O
(	O
enp1	O
-	O
2	O
,	O
TRP1	O
,	O
CEN6	O
)	O
]	O
have	O
plasmids	O
with	O
enp1	O
temperature	O
-	O
sensitive	O
(	O
ts	O
)	O
mutations	O
.	O

Strain	O
JBY51	O
(	O
MATa	O
Δenp1::his5	O
+	O
TRP1::enp1	O
-	O
1	O
)	O
is	O
an	O
enp1	O
ts	O
strain	O
generated	O
by	O
integrating	O
the	O
enp1	O
-	O
1	O
gene	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
.	O

Strain	O
CWY13	O
[	O
MATa	O
Δenp1::his5+	O
/	O
pJB24	O
(	O
pMET25-GFP	O
-	O
ENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
GFP	O
-	O
ENP1	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
.	O

Strain	O
CWY14	O
(	O
MATa	O
ENP1-TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
Tandem	O
Affinity	O
Purification	O
(	O
TAP	O
)	O
tag	O
(	O
20,21	O
)	O
to	O
the	O
3′	O
end	O
of	O
ENP1	O
.	O

Strain	O
YRH39	O
(	O
MATα	O
HST2-TAP	O
)	O
was	O
created	O
by	O
fusing	O
sequences	O
encoding	O
a	O
TAP	O
tag	O
to	O
the	O
3′end	O
of	O
HST2	O
.	O

Strain	O
RS1938	O
(	O
Δnop1::URA3	O
pUN100-ProtA	O
-	O
NOP1	O
)	O
was	O
created	O
by	O
transforming	O
RS1935	O
(	O
MATa	O
/	O
α	O
leu2	O
/	O
leu2	O
ura3	O
/	O
ura3	O
lys2	O
/	O
lys2	O
ade2	O
/	O
ade2	O
Δnop1::URA3	O
/	O
NOP1	O
)	O
with	O
pUN100-ProtA	O
-	O
NOP1	O
(	O
strain	O
and	O
plasmid	O
supplied	O
by	O
T.	O
Schafer	O
)	O
,	O
followed	O
by	O
tetrad	O
dissection	O
.	O

Strain	O
CWY15	O
[	O
MATa	O
/	O
pCW109	O
(	O
pMET25-GFP	O
-	O
hENP1	O
,	O
URA3	O
,	O
CEN6	O
)	O
]	O
has	O
a	O
human	B
homolog	O
of	O
Enp1	O
expressed	O
in	O
W303	O
-	O
1a	O
.	O

The	O
media	O
used	O
were	O
prepared	O
as	O
described	O
(	O
22	O
)	O
.	O

Cloning	O
of	O
ENP1	O
pRS426-MEG1	O
(	O
The	O
original	O
name	O
of	O
ENP1	O
)	O
was	O
a	O
gift	O
from	O
Dr	O
William	O
J.	O
Lennarz	O
.	O

It	O
contains	O
the	O
ENP1	O
gene	O
within	O
a	O
2.6	O
kb	O
EcoRI	O
genomic	O
fragment	O
cloned	O
into	O
pRS426	O
(	O
18	O
)	O
.	O

The	O
EcoRI	O
fragment	O
was	O
subsequently	O
cloned	O
into	O
pRS314	O
(	O
TRP1	O
,	O
CEN6	O
)	O
,	O
pRS316	O
(	O
URA3	O
,	O
CEN6	O
)	O
and	O
pRS424	O
(	O
TRP1	O
,	O
2µ	O
)	O
to	O
create	O
pJB20	O
,	O
pJB23	O
and	O
pJB21	O
,	O
respectively	O
.	O

pGFP	O
-	O
N	O
-	O
FUS	O
is	O
a	O
centromeric	O
plasmid	O
for	O
fusing	O
green	O
fluorescence	O
protein	O
(	O
GFP	O
)	O
to	O
a	O
polypeptide	O
's	O
N	O
-	O
terminus	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
(	O
23	O
)	O
.	O

Cloning	O
the	O
ENP1	O
ORF	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
via	O
XbaI	O
and	O
SalI	O
sites	O
generated	O
plasmid	O
pJB24	O
.	O

pJB19	O
(	O
enp1	O
-	O
1	O
,	O
TRP1	O
,	O
CEN6	O
)	O
contains	O
the	O
enp1	O
-	O
1	O
mutant	O
gene	O
.	O

The	O
human	B
homolog	O
of	O
yeast	B
Enp1	O
was	O
PCR	O
amplified	O
from	O
a	O
human	B
cDNA	O
clone	O
BC007340	O
(	O
Research	O
Genetics	O
)	O
,	O
then	O
cloned	O
into	O
pGFP	O
-	O
N	O
-	O
FUS	O
,	O
p415-ADH	O
,	O
p415-GPD	O
and	O
p415-TEF	O
(	O
24	O
)	O
via	O
XbaI	O
and	O
SalI	O
sites	O
to	O
generate	O
pCW109	O
,	O
pCW113	O
,	O
pCW115	O
and	O
pCW117	O
,	O
respectively	O
.	O

The	O
fragment	O
of	O
the	O
human	B
Enp1	O
homolog	O
(	O
amino	O
acids	O
152–437	O
)	O
was	O
also	O
cloned	O
into	O
these	O
vectors	O
to	O
generate	O
pCW110	O
,	O
pCW114	O
,	O
pCW116	O
and	O
pCW118	O
.	O

Random	O
mutagenesis	O
of	O
ENP1	O
to	O
generate	O
enp1	O
ts	O
mutants	O
The	O
enp1	O
ts	O
mutants	O
were	O
generated	O
with	O
a	O
protocol	O
introducing	O
random	O
mutations	O
by	O
PCR	O
(	O
25	O
)	O
.	O

The	O
PCR	O
was	O
performed	O
with	O
oligonucleotides	O
ENP1-MUT5′	O
(	O
5′-GGTGGTGTCAGT	O
AGGGGA-3′	O
)	O
,	O
ENP1-MUT3′	O
(	O
5′-CAGTCTGCAATATA	O
TGGAC-3′	O
)	O
and	O
plasmid	O
template	O
pJB20	O
(	O
see	O
above	O
)	O
.	O

The	O
nucleotide	O
concentrations	O
in	O
the	O
reaction	O
were	O
1	O
mM	O
each	O
for	O
dATP	O
,	O
dGTP	O
,	O
dCTP	O
and	O
dTTP	O
.	O

After	O
strain	O
JBY46	O
was	O
transformed	O
with	O
the	O
PCR	O
product	O
and	O
with	O
pJB20	O
gapped	O
by	O
NheI	O
and	O
NsiI	O
,	O
the	O
transformants	O
were	O
replica	O
-	O
plated	O
onto	O
two	O
plates	O
containing	O
5-FOA	O
synthetic	O
medium	O
without	O
tryptophan	O
;	O
one	O
replica	O
was	O
incubated	O
at	O
23	O
°	O
C	O
and	O
the	O
other	O
at	O
37	O
°	O
C	O
.	O

Colonies	O
growing	O
at	O
23	O
°	O
C	O
but	O
not	O
at	O
37	O
°	O
C	O
were	O
picked	O
as	O
candidates	O
.	O

Since	O
approximately	O
10	O
%	O
of	O
the	O
colonies	O
were	O
inviable	O
at	O
both	O
temperatures	O
,	O
we	O
knew	O
that	O
10	O
%	O
of	O
the	O
ENP1	O
PCR	O
products	O
lost	O
their	O
function	O
after	O
the	O
PCR	O
mutagenesis	O
.	O

This	O
confirmed	O
the	O
effectiveness	O
of	O
the	O
mutagenesis	O
procedure	O
.	O

Two	O
candidates	O
showed	O
good	O
growth	O
at	O
23	O
°	O
C	O
but	O
no	O
growth	O
at	O
37	O
°	O
C	O
.	O

They	O
were	O
named	O
strains	O
JBY48	O
and	O
JBY49	O
and	O
contained	O
plasmids	O
with	O
the	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
mutations	O
,	O
respectively	O
.	O

The	O
mutated	O
enp1	O
-	O
1	O
gene	O
on	O
pJB19	O
was	O
cloned	O
into	O
an	O
integration	O
vector	O
,	O
pRS304	O
,	O
as	O
an	O
EcoRI	O
fragment	O
.	O

The	O
plasmid	O
was	O
subsequently	O
linearized	O
with	O
SnaBI	O
within	O
the	O
TRP1	O
marker	O
and	O
was	O
integrated	O
at	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
of	O
strain	O
JBY46	O
.	O

Selection	O
on	O
5-FOA	O
was	O
used	O
to	O
remove	O
plasmid	O
pJB23	O
,	O
creating	O
strain	O
JBY51	O
.	O

Sucrose	O
gradient	O
analysis	O
Polyribosome	O
preparation	O
and	O
analysis	O
were	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
26	O
)	O
.	O

Cells	O
grown	O
in	O
YPD	O
were	O
collected	O
at	O
mid	O
-	O
log	O
phase	O
(	O
OD600	O
0.8–1.0	O
)	O
and	O
were	O
broken	O
with	O
glass	O
beads	O
.	O

The	O
lysate	O
was	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
was	O
stored	O
at	O
–80	O
°	O
C	O
.	O

Lysate	O
(	O
30	O
U	O
of	O
absorbance	O
at	O
OD260	O
)	O
was	O
layered	O
over	O
a	O
7–47	O
%	O
(	O
w	O
/	O
v	O
)	O
sucrose	O
gradient	O
,	O
which	O
was	O
centrifuged	O
at	O
28	O
000	O
r.p.m	O
.	O

for	O
5	O
h	O
at	O
4	O
°	O
C	O
in	O
a	O
SW28	O
rotor	O
and	O
was	O
analyzed	O
with	O
an	O
ISCO	O
UA-5	O
gradient	O
UV	O
detection	O
system	O
on	O
absorbency	O
at	O
254	O
nm	O
.	O

Immunofluorescence	O
Immunofluorescence	O
analysis	O
was	O
carried	O
out	O
essentially	O
as	O
described	O
(	O
27	O
)	O
.	O

Cells	O
were	O
fixed	O
with	O
3.7	O
%	O
formaldehyde	O
at	O
room	O
temperature	O
for	O
1.5	O
h.	O
Antibodies	O
included	O
a	O
mouse	B
monoclonal	O
anti	O
-	O
Nop1	O
(	O
a	O
gift	O
from	O
John	O
P.	O
Aris	O
,	O
University	O
of	O
Florida	O
,	O
Gainesville	O
,	O
Florida	O
)	O
and	O
a	O
Texas	O
-	O
red	O
-	O
conjugated	O
donkey	B
-	O
anti	O
-	O
mouse	B
antibody	O
(	O
Jackson	O
Lab	O
)	O
,	O
both	O
used	O
at	O
1:500	O
dilution	O
.	O

Images	O
were	O
taken	O
on	O
a	O
Zeiss	O
Axioplan2	O
microscope	O
equipped	O
with	O
a	O
Zeiss	O
AxioCam	O
camera	O
.	O

Pulse	O
-	O
chase	O
labeling	O
analysis	O
of	O
rRNA	O
For	O
[	O
methyl-3H	O
]	O
methionine	O
pulse	O
-	O
chase	O
analysis	O
,	O
cells	O
were	O
grown	O
in	O
synthetic	O
medium	O
without	O
methionine	O
at	O
room	O
temperature	O
or	O
37	O
°	O
C	O
for	O
2	O
h.	O
When	O
the	O
OD600	O
reached	O
1.0	O
,	O
6	O
ml	O
of	O
the	O
culture	O
were	O
pulse	O
-	O
labeled	O
with	O
250	O
µCi	O
[	O
methyl-3H	O
]	O
methionine	O
(	O
Amersham	O
Pharmacia	O
)	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
(	O
500	O
µg	O
/	O
ml	O
)	O
for	O
2	O
,	O
4	O
or	O
12	O
min	O
.	O

For	O
each	O
time	O
point	O
of	O
the	O
chase	O
1.25	O
ml	O
of	O
culture	O
was	O
mixed	O
with	O
ice	O
and	O
collected	O
.	O

The	O
pellets	O
were	O
frozen	O
immediately	O
in	O
liquid	O
N2	O
and	O
stored	O
at	O
–80	O
°	O
C	O
before	O
total	O
RNA	O
was	O
purified	O
using	O
a	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
a	O
1.2	O
%	O
agarose	O
formaldehyde	O
gel	O
and	O
transferred	O
onto	O
Hybond	O
-	O
N+	O
nylon	O
membranes	O
(	O
Amersham	O
Pharmacia	O
)	O
.	O

After	O
being	O
sprayed	O
with	O
EN3HANCE	O
(	O
Du	O
Pont	O
)	O
,	O
the	O
membranes	O
were	O
exposed	O
to	O
film	O
at	O
–80	O
°	O
C	O
(	O
29	O
)	O
.	O

Northern	O
analysis	O
Cells	O
were	O
grown	O
inYPD	O
at	O
room	O
temperature	O
or	O
37	O
°	O
C	O
for	O
2–4	O
h.	O
When	O
the	O
OD600	O
reached	O
1.0	O
,	O
10	O
ml	O
of	O
cells	O
were	O
collected	O
and	O
frozen	O
immediately	O
.	O

Total	O
RNA	O
was	O
extracted	O
as	O
described	O
(	O
28	O
)	O
.	O

Five	O
micrograms	O
of	O
RNA	O
were	O
separated	O
on	O
1.2	O
%	O
agarose	O
formaldehyde	O
gels	O
(	O
for	O
high	O
molecular	O
weight	O
RNA	O
)	O
or	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
(	O
for	O
low	O
molecular	O
weight	O
RNA	O
)	O
for	O
each	O
sample	O
.	O

The	O
RNA	O
was	O
then	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
(	O
Bio	O
-	O
Rad	O
)	O
.	O

Probes	O
for	O
hybridyzation	O
were	O
specific	O
oligonucleotides	O
end	O
-	O
labeled	O
using	O
[	O
γ-32P	O
]	O
ATP	O
.	O

After	O
hybridization	O
and	O
washes	O
,	O
membranes	O
were	O
exposed	O
to	O
phosphorimager	O
screens	O
or	O
X	O
-	O
ray	O
films	O
(	O
29	O
)	O
.	O

Oligonucleotides	O
specific	O
for	O
various	O
regions	O
of	O
35S	O
pre	O
-	O
rRNA	O
are	O
:	O
1	O
,	O
GGTCTCTCTGCTGCCG	O
GAAATG	O
;	O
3	O
,	O
AATGAGCCATTCGCAGTTTCACTG	O
;	O
4	O
,	O
GCTCTCATGCTCTTGCCAAAAC	O
;	O
5	O
,	O
TGTTTGTTACCT	O
CTGGGCCCCG	O
;	O
6	O
,	O
TCCAGTTACGAAAATTCTTG	O
;	O
7	O
,	O
CGTATCGCATTTCGCTGCGTTC	O
;	O
8	O
,	O
GTTCGCCTAGAC	O
GCTCTCTCTTC	O
;	O
9	O
,	O
GCGAGATTCCCCTACCCAC	O
.	O

The	O
regions	O
complementary	O
to	O
these	O
oligonucleotides	O
are	O
shown	O
in	O
Figure	O
6A	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
C	O
/	O
D	O
snoRNAs	O
are	O
:	O
U3	O
,	O
TTCGGTTTCTCACTCACTCTGGGGTAC	O
;	O
U14	O
,	O
GGAACCAGTCTTTCATCACCGTG	O
.	O

The	O
oligonucleotides	O
probing	O
box	O
H	O
/	O
ACA	O
snoRNAs	O
are	O
:	O
snoRNA10	O
,	O
CCTTG	O
CAACGGTCCTCATCCGGG	O
;	O
snoRNA30	O
,	O
GTCCGAAGC	O
GCCATCTAGATGA	O
.	O

RNA	O
and	O
protein	O
precipitation	O
analysis	O
Cells	O
were	O
grown	O
in	O
YPD	O
(	O
1	O
l	O
)	O
to	O
OD600	O
1.0	O
,	O
then	O
collected	O
,	O
washed	O
once	O
in	O
ice	O
-	O
cold	O
PBS	O
and	O
broken	O
using	O
glass	O
beads	O
in	O
10	O
ml	O
IPP150	O
buffer	O
(	O
10	O
mM	O
Tris	O
pH	O
8.0	O
,	O
150	O
mM	O
NaCl	O
and	O
0.1	O
%	O
NP-40	O
)	O
with	O
protease	O
inhibitors	O
.	O

The	O
lysates	O
were	O
mixed	O
with	O
200	O
µl	O
IgG	O
agarose	O
beads	O
for	O
2	O
h	O
at	O
4	O
°	O
C	O
.	O

After	O
several	O
washes	O
with	O
50	O
ml	O
IPP150	O
buffer	O
,	O
the	O
IgG	O
beads	O
were	O
collected	O
and	O
the	O
RNA	O
associated	O
with	O
the	O
beads	O
extracted	O
by	O
the	O
hot	O
phenol	O
method	O
(	O
28	O
)	O
.	O

One	O
-	O
tenth	O
of	O
the	O
precipitated	O
RNA	O
was	O
then	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
7	O
M	O
urea	O
denaturing	O
gels	O
and	O
electro	O
-	O
transferred	O
to	O
Zeta	O
-	O
Probe	O
GT	O
nylon	O
membranes	O
.	O

They	O
were	O
probed	O
with	O
[	O
γ-32P	O
]	O
ATP	O
labeled	O
oligonucleotides	O
.	O

For	O
the	O
lanes	O
showing	O
total	O
RNA	O
,	O
2	O
µg	O
RNA	O
prepared	O
from	O
exponentially	O
growing	O
cultures	O
were	O
loaded	O
.	O

For	O
co	O
-	O
precipitation	O
analysis	O
of	O
proteins	O
,	O
the	O
IgG	O
beads	O
were	O
resuspended	O
in	O
2	O
×	O
Laemmli	O
sample	O
buffer	O
,	O
boiled	O
for	O
5	O
min	O
and	O
separated	O
by	O
SDS	O
–	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O

Approximately	O
1	O
%	O
of	O
the	O
precipitate	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

For	O
the	O
total	O
protein	O
,	O
0.1	O
%	O
of	O
the	O
extract	O
prior	O
to	O
precipitation	O
was	O
loaded	O
onto	O
each	O
lane	O
.	O

Following	O
electrophoresis	O
,	O
the	O
proteins	O
were	O
transferred	O
to	O
nitrocellulose	O
membranes	O
and	O
detected	O
using	O
anti	O
-	O
Nop1	O
antibody	O
at	O
1:3000	O
dilution	O
(	O
provided	O
by	O
J.	O
Aris	O
)	O
and	O
anti	O
-	O
L3	O
antibody	O
(	O
provided	O
by	O
J.	O
Warner	O
)	O
at	O
1:3000	O
dilution	O
followed	O
by	O
peroxidase	O
-	O
conjugated	O
anti	O
-	O
mouse	B
secondary	O
antibody	O
at	O
1:5000	O
dilution	O
.	O

The	O
antibody	O
complexes	O
were	O
detected	O
using	O
ECL	O
-	O
Plus	O
reagents	O
(	O
Amersham	O
Pharmacia	O
)	O
as	O
specified	O
by	O
the	O
manufacturer	O
.	O

RESULTS	O
Construction	O
and	O
analysis	O
of	O
ENP1	O
temperature	O
-	O
sensitive	O
alleles	O
ENP1	O
is	O
an	O
essential	O
yeast	B
gene	O
conserved	O
among	O
eukaryotes	O
(	O
18	O
)	O
.	O

To	O
study	O
its	O
functions	O
,	O
we	O
first	O
created	O
a	O
diploid	O
strain	O
,	O
JBY45	O
,	O
heterozygous	O
for	O
the	O
Δenp1	O
mutation	O
.	O

Then	O
two	O
enp1	O
ts	O
mutant	O
alleles	O
(	O
enp1	O
-	O
1	O
and	O
enp1	O
-	O
2	O
)	O
were	O
generated	O
by	O
random	O
PCR	O
mutagenesis	O
,	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Both	O
mutant	O
alleles	O
were	O
recessive	O
to	O
the	O
wild	O
-	O
type	O
ENP1	O
gene	O
.	O

The	O
enp1	O
-	O
1	O
gene	O
was	O
integrated	O
into	O
the	O
chromosomal	O
trp1	O
-	O
1	O
locus	O
to	O
create	O
strain	O
JBY51	O
and	O
all	O
subsequent	O
experiments	O
were	O
done	O
with	O
this	O
enp1	O
allele	O
.	O

At	O
23	O
°	O
C	O
the	O
growth	O
of	O
JBY51	O
was	O
comparable	O
to	O
that	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
but	O
at	O
37	O
°	O
C	O
it	O
did	O
not	O
grow	O
(	O
Fig.	O
2	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
enp1	O
-	O
1	O
contains	O
two	O
point	O
mutations	O
,	O
resulting	O
in	O
substitutions	O
of	O
two	O
amino	O
acids	O
:	O
W242→G	O
and	O
V415→A.	O
No	O
attempt	O
was	O
made	O
to	O
determine	O
whether	O
both	O
mutations	O
were	O
required	O
for	O
the	O
ts	O
phenotype	O
.	O

Flow	O
cytometry	O
of	O
strain	O
JBY51	O
showed	O
DNA	O
content	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
strain	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
ENP1	O
is	O
not	O
involved	O
in	O
cell	O
cycle	O
regulation	O
.	O

Enp1	O
is	O
enriched	O
in	O
the	O
nucleolus	O
Enp1	O
tagged	O
at	O
the	O
C	O
-	O
terminus	O
with	O
the	O
myc	O
epitope	O
was	O
previously	O
found	O
to	O
localize	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

To	O
expand	O
this	O
analysis	O
,	O
we	O
fused	O
GFP	O
to	O
the	O
N	O
-	O
terminus	O
of	O
Enp1	O
,	O
and	O
expressed	O
the	O
tagged	O
Enp1	O
protein	O
under	O
control	O
of	O
the	O
MET25	O
promoter	O
as	O
the	O
sole	O
source	O
of	O
Enp1	O
protein	O
in	O
the	O
cells	O
.	O

Cells	O
of	O
strain	O
CWY13	O
(	O
pMET25-GFP	O
-	O
ENP1	O
)	O
were	O
grown	O
in	O
media	O
with	O
methionine	O
(	O
transcription	O
partially	O
repressed	O
)	O
or	O
without	O
methionine	O
(	O
transcription	O
not	O
repressed	O
)	O
.	O

Growth	O
of	O
CWY13	O
was	O
comparable	O
to	O
that	O
of	O
wild	O
-	O
type	O
cells	O
in	O
both	O
media	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
the	O
GFP	O
tagged	O
Enp1	O
protein	O
was	O
functional	O
.	O

In	O
cells	O
cultured	O
in	O
medium	O
without	O
methionine	O
,	O
in	O
which	O
the	O
ENP	O
transcription	O
was	O
not	O
repressed	O
,	O
the	O
GFP	O
-	O
Enp1	O
protein	O
was	O
expressed	O
at	O
a	O
high	O
level	O
and	O
showed	O
strong	O
green	O
fluorescence	O
distributed	O
throughout	O
the	O
nucleus	O
(	O
data	O
not	O
shown	O
)	O
,	O
consistent	O
with	O
the	O
original	O
observation	O
(	O
18	O
)	O
.	O

With	O
methionine	O
added	O
to	O
the	O
medium	O
,	O
however	O
,	O
the	O
fluorescent	O
signal	O
of	O
GFP	O
-	O
Enp1	O
was	O
weaker	O
and	O
surprisingly	O
showed	O
crescent	O
or	O
cap	O
-	O
like	O
patterns	O
typical	O
of	O
nucleolar	O
proteins	O
(	O
Fig.	O
3A	O
)	O
.	O

This	O
nucleolar	O
enrichment	O
was	O
confirmed	O
by	O
its	O
co	O
-	O
localization	O
with	O
the	O
nucleolar	O
protein	O
Nop1	O
(	O
Fig.	O
3B	O
)	O
.	O

ENP1	O
mutation	O
leads	O
to	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O
The	O
nucleolar	O
enrichment	O
suggested	O
that	O
Enp1	O
might	O
play	O
some	O
role	O
in	O
ribosome	O
synthesis	O
.	O

To	O
test	O
this	O
possibility	O
,	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
,	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
and	O
a	O
top2	O
ts	O
strain	O
RS191	O
(	O
30	O
)	O
were	O
grown	O
in	O
YPD	O
at	O
23	O
or	O
37	O
°	O
C	O
and	O
their	O
ribosome	O
profiles	O
analyzed	O
after	O
separation	O
on	O
sucrose	O
gradients	O
.	O

At	O
23	O
°	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
polysome	O
profiles	O
similar	O
to	O
those	O
of	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
strains	O
(	O
Fig.	O
4A	O
–	O
C	O
)	O
.	O

In	O
contrast	O
,	O
after	O
incubation	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
(	O
37	O
°	O
C	O
)	O
for	O
40	O
min	O
(	O
data	O
not	O
shown	O
)	O
and	O
2	O
h	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
reduced	O
levels	O
of	O
40S	O
ribosomal	O
subunits	O
,	O
80S	O
monosomes	O
and	O
polysomes	O
,	O
along	O
with	O
a	O
dramatic	O
increase	O
in	O
the	O
free	O
60S	O
subunit	O
peak	O
(	O
Fig.	O
4F	O
)	O
,	O
while	O
the	O
wild	O
-	O
type	O
and	O
top2	O
-	O
1	O
cells	O
showed	O
little	O
change	O
in	O
polysome	O
profile	O
at	O
37	O
°	O
C	O
(	O
Fig.	O
4D	O
and	O
E	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
changes	O
of	O
the	O
enp1	O
-	O
1	O
polysome	O
profile	O
were	O
due	O
to	O
specific	O
defects	O
caused	O
by	O
the	O
enp1	O
-	O
1	O
mutation	O
,	O
and	O
not	O
due	O
simply	O
to	O
the	O
shift	O
to	O
37	O
°	O
C	O
for	O
a	O
wild	O
-	O
type	O
or	O
ts	O
strain	O
.	O

The	O
processing	O
of	O
pre	O
-	O
rRNA	O
for	O
18S	O
rRNA	O
is	O
impaired	O
in	O
enp1	O
mutants	O
In	O
most	O
cases	O
reductions	O
in	O
ribosomal	O
subunit	O
levels	O
are	O
the	O
results	O
of	O
defects	O
in	O
pre	O
-	O
rRNA	O
processing	O
or	O
ribosome	O
assembly	O
or	O
both	O
(	O
3	O
)	O
.	O

To	O
study	O
the	O
mechanism	O
by	O
which	O
Enp1	O
affects	O
the	O
40S	O
subunit	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
enp1	O
mutations	O
on	O
processing	O
of	O
the	O
pre	O
-	O
rRNA	O
using	O
pulse	O
-	O
chase	O
labeling	O
.	O

[	O
methyl-3H	O
]	O
methionine	O
is	O
preferred	O
for	O
labeling	O
rRNAs	O
in	O
pulse	O
-	O
chase	O
analysis	O
because	O
rRNAs	O
are	O
specifically	O
methylated	O
during	O
the	O
early	O
steps	O
of	O
the	O
processing	O
.	O

Cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
were	O
grown	O
at	O
23	O
or	O
37	O
°	O
C	O
for	O
2	O
h	O
before	O
they	O
were	O
labeled	O
with	O
[	O
methyl-3H	O
]	O
methionine	O
for	O
3	O
min	O
and	O
chased	O
with	O
cold	O
methionine	O
for	O
2	O
,	O
4	O
and	O
12	O
min	O
.	O

In	O
wild	O
-	O
type	O
cells	O
,	O
the	O
labeled	O
35S	O
rRNA	O
precursor	O
,	O
27S	O
and	O
20S	O
rRNA	O
intermediates	O
were	O
rapidly	O
chased	O
into	O
mature	O
25S	O
and	O
18S	O
rRNAs	O
(	O
Fig.	O
5	O
)	O
,	O
at	O
23	O
or	O
37	O
°	O
C	O
.	O

In	O
contrast	O
,	O
enp1	O
-	O
1	O
cells	O
showed	O
dramatic	O
changes	O
after	O
incubation	O
at	O
37	O
°	O
C	O
.	O

Although	O
at	O
23	O
°	O
C	O
the	O
synthesis	O
and	O
processing	O
were	O
comparable	O
to	O
those	O
of	O
wild	O
-	O
type	O
cells	O
,	O
cells	O
cultured	O
at	O
37	O
°	O
C	O
for	O
2	O
h	O
had	O
neither	O
20S	O
pre	O
-	O
rRNA	O
nor	O
18S	O
rRNA	O
,	O
while	O
25S	O
rRNA	O
was	O
generated	O
at	O
normal	O
levels	O
.	O

The	O
37	O
°	O
C	O
grown	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
low	O
levels	O
of	O
aberrant	O
23S	O
and	O
possibly	O
21S	O
intermediates	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
defect	O
in	O
18S	O
rRNA	O
synthesis	O
was	O
further	O
supported	O
by	O
pulse	O
-	O
chase	O
experiments	O
carried	O
out	O
using	O
[	O
5,6	O
-	O
3H	O
]	O
uracil	O
.	O

The	O
results	O
obtained	O
were	O
essentially	O
the	O
same	O
;	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
produced	O
,	O
while	O
processing	O
to	O
25S	O
rRNA	O
was	O
not	O
affected	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggested	O
that	O
the	O
enp1	O
mutation	O
leads	O
to	O
specific	O
defects	O
in	O
the	O
processing	O
pathway	O
for	O
20S	O
pre	O
-	O
rRNA	O
and	O
18S	O
rRNA	O
,	O
resulting	O
in	O
reduced	O
40S	O
subunit	O
synthesis	O
and	O
a	O
lowered	O
level	O
of	O
the	O
40S	O
subunit	O
.	O

Enp1	O
is	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
sites	O
To	O
define	O
the	O
processing	O
steps	O
affected	O
by	O
the	O
enp1	O
mutation	O
,	O
the	O
steady	O
state	O
levels	O
of	O
rRNA	O
precursors	O
and	O
mature	O
RNAs	O
were	O
analyzed	O
by	O
northern	O
blotting	O
.	O

Total	O
RNAs	O
were	O
isolated	O
from	O
cells	O
of	O
W303	O
-	O
1a	O
(	O
ENP1	O
)	O
and	O
JBY51	O
(	O
enp1	O
-	O
1	O
)	O
grown	O
at	O
37	O
°	O
C	O
for	O
2	O
or	O
4	O
h.	O
After	O
separation	O
on	O
formaldehyde	O
agarose	O
,	O
RNAs	O
were	O
transferred	O
onto	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
specific	O
to	O
various	O
regions	O
of	O
the	O
35S	O
pre	O
-	O
rRNA	O
(	O
Fig.	O
6A	O
)	O
.	O

After	O
incubation	O
at	O
37	O
°	O
C	O
,	O
enp1	O
-	O
1	O
cells	O
had	O
wild	O
-	O
type	O
levels	O
of	O
25S	O
rRNA	O
,	O
but	O
reduced	O
levels	O
of	O
18S	O
rRNA	O
(	O
Fig.	O
6B	O
)	O
.	O

A	O
probe	O
specific	O
to	O
ITS1	O
(	O
P5	O
)	O
further	O
revealed	O
that	O
enp1	O
-	O
1	O
cells	O
incubated	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
accumulated	O
two	O
aberrant	O
rRNAs	O
,	O
23S	O
and	O
21S	O
(	O
Fig.	O
6C	O
)	O
.	O

Aberrant	O
rRNA	O
processing	O
products	O
of	O
similar	O
sizes	O
have	O
been	O
described	O
in	O
numerous	O
studies	O
(	O
14,31–34	O
)	O
and	O
result	O
from	O
defects	O
in	O
processing	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Additional	O
probes	O
were	O
used	O
to	O
verify	O
the	O
origins	O
of	O
the	O
23S	O
and	O
21S	O
RNAs	O
in	O
the	O
enp1	O
-	O
1	O
strain	O
.	O

The	O
23S	O
product	O
was	O
detected	O
by	O
oligos	O
1	O
,	O
2	O
,	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
6	O
,	O
7	O
or	O
8	O
(	O
Fig.	O
6D	O
,	O
E	O
,	O
C	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
this	O
RNA	O
extends	O
from	O
the	O
5′	O
end	O
of	O
the	O
35S	O
rRNA	O
to	O
the	O
A3	O
site	O
.	O

The	O
21S	O
product	O
was	O
detected	O
by	O
oligos	O
4	O
and	O
5	O
,	O
but	O
not	O
by	O
oligos	O
1	O
,	O
2	O
,	O
6	O
,	O
7	O
and	O
8	O
(	O
Fig.	O
6E	O
,	O
C	O
,	O
D	O
,	O
F	O
,	O
G	O
and	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
it	O
extends	O
from	O
the	O
A1	O
to	O
the	O
A3	O
site	O
.	O

At	O
37	O
°	O
C	O
the	O
enp1	O
-	O
1	O
cells	O
also	O
had	O
less	O
32S	O
and	O
20S	O
rRNA	O
intermediates	O
(	O
Fig.	O
6B	O
and	O
E	O
)	O
.	O

These	O
results	O
suggest	O
that	O
the	O
enp1	O
mutation	O
led	O
to	O
complete	O
or	O
nearly	O
complete	O
inhibition	O
of	O
processing	O
at	O
site	O
A0	O
and	O
A2	O
,	O
and	O
partial	O
inhibition	O
of	O
processing	O
at	O
site	O
A1	O
.	O

As	O
a	O
consequence	O
,	O
the	O
35S	O
pre	O
-	O
rRNA	O
was	O
cleaved	O
at	O
site	O
A3	O
instead	O
,	O
producing	O
23S	O
and	O
21S	O
rRNA	O
products	O
.	O

Consistent	O
with	O
this	O
theory	O
,	O
the	O
27SA2	O
rRNA	O
intermediate	O
level	O
was	O
greatly	O
reduced	O
in	O
enp1	O
cells	O
at	O
37	O
°	O
C	O
(	O
Fig.	O
6C	O
)	O
due	O
to	O
the	O
inhibition	O
of	O
processing	O
at	O
A2	O
,	O
while	O
the	O
27SB	O
pre	O
-	O
rRNA	O
level	O
was	O
similar	O
to	O
wild	O
-	O
type	O
cells	O
(	O
Fig.	O
6	O
G	O
)	O
.	O

Moreover	O
,	O
no	O
difference	O
in	O
the	O
5.8	O
rRNA	O
level	O
was	O
observed	O
between	O
the	O
wild	O
-	O
type	O
cells	O
and	O
enp1	O
cells	O
(	O
Fig.	O
6H	O
)	O
.	O

Enp1	O
is	O
associated	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
and	O
with	O
Nop1	O
It	O
has	O
previously	O
been	O
shown	O
that	O
mutations	O
in	O
the	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
in	O
their	O
associated	O
proteins	O
affect	O
processing	O
of	O
35S	O
pre	O
-	O
rRNA	O
at	O
A0	O
,	O
A1	O
and	O
A2	O
.	O

Because	O
of	O
the	O
similarity	O
with	O
the	O
processing	O
defects	O
of	O
enp1	O
-	O
1	O
strains	O
,	O
we	O
tested	O
the	O
association	O
between	O
Enp1	O
and	O
snoRNAs	O
.	O

To	O
do	O
this	O
,	O
we	O
created	O
a	O
strain	O
in	O
which	O
a	O
TAP	O
tag	O
was	O
fused	O
to	O
the	O
C	O
-	O
terminus	O
of	O
Enp1	O
.	O

The	O
TAP	O
tag	O
contains	O
Staphylococcus	B
aureus	I
Protein	O
A	O
as	O
well	O
as	O
calmodulin	O
-	O
binding	O
peptide	O
sequences	O
,	O
so	O
the	O
tagged	O
Enp1	O
binds	O
IgG	O
beads	O
with	O
high	O
specificity	O
.	O

Cells	O
grew	O
well	O
with	O
the	O
TAP	O
-	O
tagged	O
Enp1	O
as	O
the	O
only	O
source	O
of	O
Enp1	O
protein	O
,	O
showing	O
that	O
it	O
was	O
functional	O
.	O

As	O
a	O
control	O
,	O
we	O
used	O
a	O
TAP	O
tag	O
on	O
an	O
unrelated	O
cytoplasmic	O
protein	O
,	O
Hst2	O
.	O

Strain	O
CWY14	O
(	O
ENP1-TAP	O
)	O
and	O
the	O
Hst2-TAP	O
tagged	O
strain	O
were	O
grown	O
in	O
YPD	O
to	O
mid	O
-	O
exponential	O
phase	O
before	O
being	O
harvested	O
.	O

Extracts	O
were	O
prepared	O
and	O
mixed	O
with	O
IgG	O
agarose	O
beads	O
to	O
precipitate	O
Enp1-TAP	O
and	O
associated	O
RNAs	O
.	O

Total	O
RNAs	O
were	O
extracted	O
from	O
washed	O
IgG	O
beads	O
,	O
separated	O
on	O
6	O
%	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
.	O

Northern	O
analysis	O
revealed	O
that	O
Enp1-TAP	O
precipitates	O
were	O
enriched	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
relative	O
to	O
precipitates	O
from	O
the	O
Hst2-tagged	O
strain	O
(	O
Fig.	O
7A	O
)	O
.	O

The	O
Enp1-TAP	O
samples	O
were	O
not	O
enriched	O
with	O
snR30	O
snoRNA	O
(	O
Fig.	O
7A	O
)	O
,	O
nor	O
with	O
U24	O
or	O
U18	O
snoRNAs	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
found	O
no	O
change	O
in	O
the	O
levels	O
of	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
in	O
the	O
enp1	O
mutant	O
,	O
indicating	O
that	O
the	O
mutation	O
did	O
not	O
affect	O
snoRNAs	O
levels	O
(	O
Fig.	O
6I	O
)	O
.	O

The	O
results	O
indicate	O
that	O
Enp1	O
associates	O
in	O
vivo	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

Much	O
less	O
U3	O
RNA	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1-TAP	O
than	O
with	O
Protein	O
A	O
-	O
tagged	O
Nop1	O
,	O
which	O
is	O
known	O
to	O
associate	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
(	O
Fig.	O
7A	O
)	O
.	O

However	O
,	O
Protein	O
A	O
-	O
Nop1	O
was	O
much	O
more	O
efficiently	O
precipitated	O
than	O
was	O
the	O
Enp1-TAP	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
similar	O
amounts	O
of	O
RNAs	O
are	O
associated	O
with	O
the	O
two	O
proteins	O
and	O
that	O
the	O
proteins	O
are	O
part	O
of	O
the	O
same	O
complex	O
.	O

To	O
address	O
this	O
further	O
,	O
we	O
checked	O
for	O
the	O
presence	O
of	O
Nop1	O
in	O
the	O
Enp1-TAP	O
immunoprecipitates	O
.	O

Figure	O
7B	O
shows	O
that	O
Nop1	O
indeed	O
is	O
in	O
the	O
Enp1	O
precipitate	O
but	O
not	O
in	O
the	O
Hst2	O
control	O
,	O
whereas	O
an	O
abundant	O
ribosomal	O
protein	O
,	O
L3	O
,	O
is	O
in	O
neither	O
precipitate	O
.	O

U3	O
and	O
U14	O
snoRNAs	O
have	O
been	O
shown	O
to	O
interact	O
with	O
rRNA	O
precursors	O
and	O
these	O
interactions	O
are	O
required	O
for	O
pre	O
-	O
rRNA	O
processing	O
(	O
35–37	O
)	O
.	O

Using	O
an	O
in	O
vitro	O
system	O
,	O
U3	O
was	O
also	O
shown	O
to	O
be	O
associated	O
with	O
its	O
rRNA	O
substrate	O
and	O
processing	O
product	O
(	O
38	O
)	O
.	O

This	O
raised	O
the	O
possibility	O
that	O
Enp1	O
might	O
also	O
be	O
associated	O
with	O
rRNAs	O
since	O
its	O
function	O
in	O
rRNA	O
processing	O
appeared	O
linked	O
to	O
those	O
of	O
U3	O
and	O
U14	O
snoRNAs	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
further	O
analyzed	O
the	O
RNAs	O
that	O
co	O
-	O
precipiate	O
with	O
TAP	O
-	O
tagged	O
Enp1	O
.	O

The	O
RNAs	O
were	O
separated	O
on	O
1.2	O
%	O
agarose	O
formaldehyde	O
gels	O
or	O
on	O
polyacrylamide	O
denaturing	O
gels	O
,	O
transferred	O
to	O
nylon	O
membranes	O
and	O
probed	O
with	O
radiolabeled	O
oligonucleotides	O
for	O
pre	O
-	O
rRNAs	O
.	O

A	O
probe	O
(	O
P4	O
;	O
see	O
Fig.	O
6	O
)	O
specific	O
to	O
20s	O
and	O
its	O
precursors	O
revealed	O
that	O
pre	O
-	O
rRNAs	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
specifically	O
co	O
-	O
precipitated	O
with	O
Enp1-TAP	O
(	O
Fig.	O
7C	O
)	O
.	O

No	O
such	O
enrichment	O
was	O
found	O
using	O
a	O
probe	O
(	O
P8	O
;	O
see	O
Fig.	O
6	O
)	O
specific	O
for	O
27S	O
RNAs	O
or	O
a	O
probe	O
for	O
5.8S	O
RNA	O
(	O
Fig.	O
7C	O
)	O
.	O

These	O
results	O
clearly	O
demonstrated	O
that	O
Enp1	O
is	O
associated	O
with	O
substrates	O
and	O
products	O
of	O
the	O
early	O
steps	O
of	O
18S	O
rRNA	O
processing	O
.	O

Comparison	O
of	O
Enp1	O
with	O
homologs	O
in	O
other	O
organisms	O
Homologs	O
of	O
Enp1	O
protein	O
in	O
human	B
,	O
Drosophila	B
and	O
Caenorhabditis	B
elegans	I
have	O
been	O
reported	O
(	O
18	O
)	O
.	O

A	O
previously	O
described	O
human	B
homolog	O
,	O
bystin	O
,	O
was	O
only	O
306	O
amino	O
acids	O
in	O
length	O
,	O
and	O
lacked	O
sequences	O
corresponding	O
to	O
the	O
N	O
-	O
terminal	O
163	O
amino	O
acids	O
of	O
yeast	B
Enp1	O
(	O
19	O
)	O
.	O

In	O
contrast	O
,	O
we	O
identified	O
a	O
human	B
expressed	O
sequence	O
tag	O
(	O
EST	O
)	O
,	O
BC007340	O
in	O
a	O
Blast	O
search	O
that	O
revealed	O
an	O
ORF	O
of	O
1311	O
nucleotides	O
encoding	O
a	O
437	O
amino	O
acid	O
polypeptide	O
(	O
39	O
)	O
.	O

Comparison	O
of	O
this	O
437	O
amino	O
acid	O
polypeptide	O
with	O
human	B
bystin	O
(	O
19	O
)	O
showed	O
that	O
they	O
were	O
encoded	O
by	O
the	O
same	O
gene	O
on	O
human	B
chromosome	O
6	O
.	O

The	O
reported	O
sequence	O
for	O
human	B
bystin	O
is	O
a	O
fragment	O
of	O
the	O
437	O
amino	O
acid	O
human	B
Enp1	O
protein	O
,	O
due	O
to	O
a	O
truncated	O
cDNA	O
sequence	O
.	O

Also	O
,	O
a	O
sequence	O
discrepancy	O
at	O
the	O
C	O
-	O
terminus	O
is	O
due	O
to	O
inaccurate	O
DNA	O
sequence	O
of	O
the	O
human	B
bystin	O
,	O
as	O
confirmed	O
by	O
available	O
human	B
genome	O
and	O
EST	O
sequences	O
.	O

Searches	O
of	O
the	O
database	O
of	O
other	O
organisms	O
identified	O
Enp1	O
homologs	O
in	O
S.pombe	B
,	O
Arabidopsis	B
thaliana	I
,	O
C.elegans	B
,	O
Drosophila	B
melanogaster	I
and	O
mouse	B
.	O

The	O
alignment	O
of	O
the	O
homologs	O
showed	O
that	O
they	O
shared	O
homology	O
from	O
the	O
N	O
-	O
terminus	O
to	O
the	O
C	O
-	O
terminus	O
,	O
with	O
the	O
C	O
-	O
terminal	O
half	O
extremely	O
well	O
conserved	O
,	O
with	O
close	O
to	O
90	O
%	O
similarity	O
(	O
Fig.	O
8)	O
.	O

One	O
interesting	O
observation	O
is	O
that	O
the	O
two	O
amino	O
acids	O
changed	O
in	O
the	O
enp1	O
-	O
1	O
mutant	O
,	O
W242	O
and	O
V415	O
,	O
are	O
conserved	O
among	O
all	O
homologs	O
.	O

The	O
human	B
Enp1	O
homolog	O
was	O
cloned	O
and	O
expressed	O
in	O
yeast	B
and	O
tested	O
for	O
function	O
.	O

Expressed	O
under	O
the	O
control	O
of	O
ADH	O
,	O
TEF	O
or	O
GPD	O
promoter	O
,	O
the	O
human	B
Enp1	O
homolog	O
did	O
not	O
complement	O
a	O
yeast	B
enp1	O
null	O
mutant	O
.	O

However	O
,	O
a	O
GFP	O
fusion	O
to	O
the	O
N	O
-	O
terminus	O
of	O
human	B
Enp1	O
homolog	O
localized	O
to	O
the	O
nucleus	O
and	O
was	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

DISCUSSION	O
ENP1	O
is	O
a	O
yeast	B
gene	O
first	O
identified	O
in	O
a	O
genetic	O
screen	O
for	O
complementation	O
of	O
mutations	O
in	O
ost4	O
,	O
which	O
encodes	O
a	O
subunit	O
of	O
oligosaccharide	O
transferase	O
(	O
17	O
)	O
,	O
although	O
subsequent	O
work	O
showed	O
that	O
it	O
is	O
unlikely	O
that	O
Enp1	O
has	O
any	O
connection	O
to	O
oligosaccharide	O
transferase	O
(	O
18	O
)	O
.	O

ENP1	O
was	O
shown	O
to	O
be	O
essential	O
for	O
viability	O
and	O
the	O
Enp1	O
protein	O
localized	O
to	O
the	O
nucleus	O
(	O
18	O
)	O
.	O

When	O
we	O
re	O
-	O
examined	O
the	O
localization	O
of	O
Enp1	O
,	O
we	O
observed	O
that	O
the	O
protein	O
was	O
enriched	O
in	O
the	O
nucleolus	O
.	O

This	O
finding	O
led	O
us	O
to	O
test	O
for	O
a	O
role	O
of	O
Enp1	O
in	O
ribosome	O
synthesis	O
.	O

Using	O
an	O
enp1	O
ts	O
mutant	O
,	O
we	O
found	O
that	O
depletion	O
of	O
Enp1	O
caused	O
a	O
40S	O
ribosomal	O
subunit	O
deficiency	O
.	O

Further	O
analysis	O
revealed	O
that	O
this	O
deficiency	O
was	O
not	O
due	O
to	O
a	O
change	O
of	O
the	O
subunit	O
's	O
stability	O
,	O
but	O
to	O
a	O
defect	O
in	O
the	O
synthesis	O
of	O
the	O
subunit	O
's	O
18S	O
rRNA	O
component	O
.	O

Pulse	O
-	O
chase	O
analysis	O
of	O
RNA	O
synthesis	O
in	O
an	O
enp1	O
-	O
1	O
strain	O
revealed	O
that	O
no	O
20S	O
pre	O
-	O
rRNA	O
or	O
18S	O
rRNA	O
was	O
made	O
at	O
the	O
non	O
-	O
permissive	O
temperature	O
,	O
while	O
levels	O
of	O
25S	O
rRNA	O
appeared	O
normal	O
.	O

Low	O
levels	O
of	O
precursors	O
to	O
18S	O
rRNA	O
were	O
detected	O
in	O
the	O
mutants	O
,	O
and	O
they	O
were	O
extremely	O
unstable	O
.	O

Northern	O
analysis	O
of	O
steady	O
state	O
RNA	O
levels	O
demonstrated	O
that	O
the	O
enp1	O
mutation	O
specifically	O
inhibited	O
the	O
pre	O
-	O
rRNA	O
early	O
cleavages	O
at	O
sites	O
A0	O
,	O
A1	O
and	O
A2	O
,	O
which	O
are	O
required	O
for	O
the	O
production	O
of	O
the	O
20S	O
pre	O
-	O
rRNA	O
and	O
the	O
18S	O
rRNA	O
.	O

These	O
defects	O
of	O
the	O
enp1	O
mutation	O
on	O
rRNA	O
processing	O
are	O
very	O
similar	O
to	O
those	O
caused	O
by	O
mutation	O
of	O
KRR1	O
,	O
another	O
essential	O
nucleolar	O
gene	O
required	O
for	O
synthesis	O
of	O
the	O
40S	O
,	O
but	O
not	O
the	O
60S	O
subunit	O
(	O
40	O
)	O
.	O

Co	O
-	O
precipitation	O
analyses	O
provided	O
strong	O
evidence	O
that	O
Enp1	O
is	O
directly	O
involved	O
in	O
pre	O
-	O
rRNA	O
processing	O
.	O

In	O
these	O
experiments	O
,	O
TAP	O
-	O
tagged	O
Enp1	O
bound	O
to	O
IgG	O
beads	O
specifically	O
co	O
-	O
precipitated	O
with	O
two	O
snoRNAs	O
,	O
U3	O
and	O
U14	O
,	O
and	O
with	O
the	O
35S	O
,	O
33S	O
,	O
32S	O
and	O
20S	O
pre	O
-	O
rRNAs	O
.	O

Among	O
the	O
more	O
than	O
100	O
snoRNAs	O
in	O
yeast	B
cells	O
,	O
U3	O
,	O
U14	O
,	O
snR10	O
,	O
snR30	O
and	O
MRP	O
RNA	O
are	O
the	O
only	O
ones	O
required	O
for	O
rRNA	O
processing	O
.	O

It	O
has	O
been	O
shown	O
that	O
mutations	O
in	O
U3	O
,	O
U14	O
,	O
snR10	O
and	O
snR30	O
snoRNAs	O
and	O
protein	O
components	O
of	O
the	O
snoRNPs	O
affect	O
processing	O
at	O
sites	O
A0	O
,	O
A1	O
or	O
A2	O
(	O
15,16,41,42	O
)	O
.	O

Enp1	O
's	O
interaction	O
with	O
U3	O
and	O
U14	O
snoRNAs	O
suggests	O
that	O
Enp1	O
's	O
function	O
in	O
rRNA	O
processing	O
involves	O
these	O
two	O
snoRNAs	O
.	O

The	O
fact	O
that	O
the	O
nucleolar	O
protein	O
,	O
Nop1	O
,	O
known	O
to	O
bind	O
to	O
U3	O
and	O
U14	O
RNAs	O
,	O
also	O
was	O
found	O
in	O
the	O
Enp1	O
precipitate	O
,	O
provides	O
additional	O
evidence	O
that	O
Enp1	O
is	O
part	O
of	O
a	O
complex	O
involved	O
in	O
processing	O
of	O
rRNA	O
.	O

Recently	O
,	O
a	O
genome	O
-	O
wide	O
study	O
of	O
yeast	B
protein	O
complexes	O
,	O
using	O
a	O
TAP	O
tag	O
method	O
similar	O
to	O
ours	O
,	O
reported	O
a	O
number	O
of	O
proteins	O
that	O
co	O
-	O
immunoprecipitated	O
with	O
Enp1	O
(	O
43	O
)	O
.	O

These	O
proteins	O
included	O
Imp4	O
,	O
Kre31	O
,	O
Kre33	O
,	O
Mpp10	O
,	O
Nop1	O
,	O
Nop14	O
and	O
Sof1	O
,	O
all	O
of	O
which	O
have	O
been	O
implicated	O
in	O
18S	O
RNA	O
processing	O
or	O
40S	O
biogenesis	O
.	O

Very	O
recently	O
(	O
after	O
the	O
studies	O
in	O
this	O
manuscript	O
were	O
concluded	O
)	O
Grandi	O
et	O
al.	O
published	O
an	O
analysis	O
of	O
components	O
of	O
the	O
90s	O
preribosomal	O
particle	O
,	O
which	O
include	O
the	O
35S	O
pre	O
-	O
rRNA	O
,	O
U3	O
snoRNP	O
and	O
rRNA	O
processing	O
factors	O
for	O
the	O
40S	O
subunit	O
(	O
44	O
)	O
.	O

In	O
agreement	O
with	O
our	O
findings	O
,	O
they	O
found	O
that	O
Enp1	O
is	O
a	O
component	O
of	O
this	O
90s	O
complex	O
and	O
also	O
of	O
a	O
smaller	O
complex	O
containing	O
the	O
20S	O
pre	O
-	O
rRNA	O
.	O

Surprisingly	O
,	O
none	O
of	O
the	O
other	O
proteins	O
involved	O
in	O
processing	O
of	O
pre	O
-	O
rRNAs	O
that	O
were	O
tested	O
associated	O
with	O
the	O
20S	O
rRNA	O
,	O
suggesting	O
that	O
those	O
proteins	O
,	O
but	O
not	O
Enp1	O
,	O
are	O
released	O
prior	O
to	O
20S	O
pre	O
-	O
rRNA	O
formation	O
(	O
44	O
)	O
.	O

The	O
authors	O
also	O
showed	O
co	O
-	O
precipitation	O
of	O
Enp1	O
with	O
dimethylated	O
20S	O
pre	O
-	O
rRNA	O
,	O
which	O
is	O
formed	O
after	O
export	O
of	O
20S	O
to	O
the	O
cytoplasm	O
.	O

These	O
results	O
of	O
Grandi	O
et	O
al.	O
suggest	O
that	O
Enp1	O
may	O
also	O
be	O
involved	O
in	O
later	O
steps	O
of	O
processing	O
or	O
nuclear	O
export	O
.	O

A	O
previous	O
study	O
on	O
the	O
Enp1	O
human	B
homolog	O
,	O
bystin	O
,	O
reported	O
that	O
the	O
protein	O
was	O
localized	O
in	O
the	O
cytoplasm	O
of	O
mammalian	O
cells	O
and	O
might	O
be	O
involved	O
in	O
cell	O
adhesion	O
(	O
19	O
)	O
.	O

Our	O
discovery	O
of	O
the	O
437	O
amino	O
acid	O
human	B
Enp1	O
homolog	O
revealed	O
that	O
the	O
bystin	O
studied	O
previously	O
was	O
from	O
a	O
truncated	O
library	O
cDNA	O
encoding	O
only	O
the	O
C	O
-	O
terminal	O
306	O
amino	O
acids	O
.	O

Although	O
the	O
human	B
homolog	O
of	O
Enp1	O
did	O
not	O
complement	O
a	O
yeast	B
Δenp1	O
mutant	O
,	O
we	O
did	O
show	O
that	O
it	O
was	O
localized	O
to	O
the	O
nucleus	O
and	O
enriched	O
in	O
the	O
nucleolus	O
(	O
data	O
not	O
shown	O
)	O
.	O

This	O
strongly	O
suggests	O
that	O
the	O
conserved	O
function	O
of	O
Enp1	O
is	O
in	O
rRNA	O
processing	O
.	O

The	O
cytoplasmic	O
localization	O
of	O
bystin	O
and	O
its	O
proposed	O
function	O
in	O
cell	O
adhesion	O
are	O
unlikely	O
to	O
reflect	O
the	O
actual	O
function	O
of	O
the	O
human	B
Enp1	O
homolog	O
.	O

It	O
will	O
be	O
important	O
to	O
study	O
the	O
nature	O
of	O
the	O
associations	O
between	O
Enp1	O
and	O
U3	O
and	O
U14	O
snoRNPs	O
,	O
and	O
to	O
learn	O
more	O
about	O
the	O
exact	O
role	O
of	O
Enp1	O
in	O
ribosomal	O
RNA	O
processing	O
.	O

Piezoelectric	O
osteotomy	O
in	O
hand	O
surgery	O
:	O
first	O
experiences	O
with	O
a	O
new	O
technique	O
Abstract	O
Background	O
In	O
hand	O
and	O
spinal	O
surgery	O
nerve	O
lesions	O
are	O
feared	O
complications	O
with	O
the	O
use	O
of	O
standard	O
oscillating	O
saws	O
.	O

Oral	O
surgeons	O
have	O
started	O
using	O
a	O
newly	O
developed	O
ultrasound	O
bone	O
scalpel	O
when	O
performing	O
precise	O
osteotomies	O
.	O

By	O
using	O
a	O
frequency	O
of	O
25–29	O
kHz	O
only	O
mineralized	O
tissue	O
is	O
cut	O
,	O
sparing	O
the	O
soft	O
tissue	O
.	O

This	O
reduces	O
the	O
risk	O
of	O
nerve	O
lesions	O
.	O

As	O
there	O
is	O
a	O
lack	O
of	O
experience	O
with	O
this	O
technique	O
in	O
the	O
field	O
of	O
orthopaedic	O
bone	O
surgery	O
,	O
we	O
performed	O
the	O
first	O
ultrasound	O
osteotomy	O
in	O
hand	O
surgery	O
.	O

Method	O
While	O
performing	O
a	O
correctional	O
osteotomy	O
of	O
the	O
5th	O
metacarpal	O
bone	O
we	O
used	O
the	O
Piezosurgery	O
®	O
Device	O
from	O
Mectron	O
[	O
Italy	O
]	O
instead	O
of	O
the	O
usual	O
oscillating	O
saw	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Results	O

The	O
cut	O
was	O
highly	O
precise	O
and	O
there	O
were	O
no	O
vibrations	O
of	O
the	O
bone	O
.	O

The	O
time	O
needed	O
for	O
the	O
operation	O
was	O
slightly	O
longer	O
than	O
the	O
time	O
needed	O
while	O
using	O
the	O
usual	O
saw	O
.	O

Bone	O
healing	O
was	O
good	O
and	O
at	O
no	O
point	O
were	O
there	O
any	O
neurovascular	O
disturbances	O
.	O

Conclusion	O

The	O
Piezosurgery	O
®	O
Device	O
is	O
useful	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
we	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand-	O
and	O
spinal	O
surgery	O
.	O

Background	O
For	O
osteotomies	O
of	O
the	O
hand	O
oscillating	O
saws	O
are	O
usually	O
used	O
[	O
1	O
]	O
.	O

Even	O
though	O
they	O
are	O
varied	O
in	O
size	O
,	O
they	O
are	O
not	O
very	O
precise	O
for	O
use	O
in	O
the	O
vicinity	O
of	O
nerves	O
and	O
arteries	O
.	O

They	O
also	O
pose	O
problems	O
while	O
being	O
used	O
in	O
conjunction	O
with	O
magnification	O
,	O
as	O
one	O
's	O
range	O
of	O
sight	O
and	O
focus	O
is	O
restricted	O
when	O
wearing	O
magnifying	O
glasses	O
.	O

For	O
that	O
reason	O
oral	O
surgeons	O
have	O
moved	O
to	O
using	O
the	O
newly	O
developed	O
piezoelectrical	O
bone	O
scalpel	O
when	O
operating	O
in	O
the	O
near	O
vicinity	O
of	O
nerves	O
or	O
arteries	O
.	O

The	O
tip	O
of	O
this	O
instrument	O
oscillates	O
in	O
the	O
frequency	O
of	O
ultrasound	O
[	O
2	O
]	O
.	O

The	O
mechanism	O
of	O
this	O
device	O
is	O
based	O
on	O
the	O
so	O
called	O
Piezo	O
–	O
Effect	O
.	O

French	O
Physicists	O
Jean	O
and	O
Marie	O
Curie	O
first	O
mentioned	O
the	O
direct	O
Piezo	O
-	O
Effect	O
1880	O
,	O
whereby	O
certain	O
crystals	O
produce	O
electrical	O
current	O
while	O
under	O
mechanical	O
pressure	O
.	O

The	O
reciprocal	O
effect	O
,	O
by	O
which	O
the	O
crystals	O
are	O
deformed	O
when	O
under	O
electrical	O
current	O
,	O
was	O
then	O
discovered	O
a	O
while	O
later	O
.	O

This	O
is	O
the	O
effect	O
being	O
used	O
by	O
the	O
Piezosurgery	O
Device	O
®	O
.	O

In	O
this	O
device	O
,	O
the	O
electrical	O
field	O
is	O
located	O
in	O
the	O
handle	O
of	O
the	O
saw	O
[	O
3	O
]	O
.	O

Due	O
to	O
the	O
deformation	O
caused	O
by	O
the	O
electrical	O
current	O
,	O
a	O
cutting	O
–	O
hammering	O
movement	O
is	O
produced	O
at	O
the	O
tip	O
of	O
the	O
instrument	O
.	O

These	O
micro	O
movements	O
are	O
in	O
the	O
frequency	O
range	O
of	O
25	O
to	O
29	O
kHz	O
and	O
,	O
depending	O
on	O
the	O
insert	O
,	O
with	O
an	O
amplitude	O
of	O
60	O
to	O
210	O
μm	O
.	O

This	O
way	O
only	O
mineralized	O
tissue	O
is	O
selectively	O
cut	O
.	O

Neurovascular	O
tissue	O
and	O
other	O
soft	O
tissue	O
would	O
only	O
be	O
cut	O
by	O
a	O
frequency	O
of	O
above	O
50	O
kHz	O
[	O
3	O
-	O
5	O
]	O
.	O

Depending	O
on	O
the	O
strength	O
of	O
the	O
bone	O
and	O
the	O
blade	O
geometry	O
,	O
the	O
efficiency	O
of	O
the	O
cutting	O
can	O
be	O
regulated	O
by	O
the	O
frequency	O
modulator	O
and	O
the	O
power	O
level	O
.	O

For	O
cooling	O
there	O
is	O
an	O
integrated	O
pump	O
with	O
five	O
different	O
working	O
levels	O
.	O

This	O
pump	O
automatically	O
washes	O
physiological	O
solution	O
to	O
the	O
area	O
being	O
cut	O
.	O

The	O
cost	O
of	O
the	O
device	O
is	O
about	O
7.000	O
USD	O
.	O

Additional	O
costs	O
per	O
operation	O
are	O
for	O
the	O
cooling	O
liquid	O
and	O
are	O
in	O
the	O
range	O
of	O
a	O
few	O
dollars	O
.	O

We	O
have	O
used	O
the	O
Piezosurgery	O
Device	O
®	O
by	O
Mectron	O
[	O
Italy	O
]	O
[	O
3	O
]	O
for	O
the	O
first	O
time	O
in	O
osteotomies	O
of	O
the	O
long	O
bone	O
in	O
the	O
field	O
of	O
hand	O
surgery	O
.	O

We	O
will	O
report	O
on	O
our	O
experience	O
with	O
one	O
case	O
,	O
with	O
a	O
follow	O
up	O
time	O
of	O
one	O
year	O
.	O

Method	O
The	O
correctional	O
osteotomy	O
was	O
performed	O
on	O
a	O
23	O
year	O
old	O
worker	O
who	O
suffered	O
a	O
malunited	O
metacarpal	O
bone	O
fracture	O
of	O
the	O
fifth	O
finger	O
on	O
his	O
dominant	O
hand	O
.	O

The	O
X	O
-	O
ray	O
revealed	O
a	O
45	O
degree	O
angular	O
deformity	O
of	O
the	O
fifth	O
metacarpal	O
neck	O
with	O
internal	O
rotation	O
.	O

(	O
Figure	O
1	O
)	O
.	O

The	O
operation	O
was	O
performed	O
under	O
regional	O
anesthesia	O
.	O

A	O
longitudinal	O
incision	O
was	O
made	O
over	O
the	O
fifth	O
metacarpal	O
.	O

The	O
tendon	O
of	O
the	O
extensor	O
digiti	O
minimi	O
was	O
found	O
and	O
on	O
its	O
radial	O
side	O
the	O
periosteum	O
of	O
metacarpal	O
five	O
was	O
reached	O
.	O

The	O
periosteum	O
was	O
opened	O
longitudinally	O
over	O
the	O
defect	O
as	O
usual	O
.	O

For	O
the	O
correction	O
of	O
the	O
defect	O
of	O
45	O
degrees	O
,	O
a	O
bone	O
wedge	O
was	O
excised	O
.	O

Instead	O
of	O
using	O
the	O
traditional	O
oscillating	O
saw	O
,	O
the	O
Piezosurgery	O
Device	O
®	O
[	O
3	O
]	O
was	O
used	O
(	O
Figure	O
2	O
)	O
.	O

We	O
used	O
a	O
sharp	O
hardened	O
saw	O
coated	O
with	O
titannitrid	O
(	O
Figure	O
3	O
)	O
.	O

For	O
most	O
of	O
the	O
surgery	O
the	O
highest	O
power	O
level	O
,	O
the	O
boosted	O
burst	O
c	O
,	O
was	O
used	O
.	O

We	O
set	O
the	O
automatic	O
cooling	O
of	O
the	O
area	O
with	O
water	O
to	O
its	O
highest	O
level	O
.	O

The	O
angulation	O
and	O
rotation	O
was	O
corrected	O
and	O
fixed	O
with	O
a	O
1.5	O
mm	O
titanium	O
five	O
-	O
hole	O
plate	O
and	O
four	O
screws	O
.	O

Closure	O
of	O
the	O
wound	O
was	O
done	O
in	O
layers	O
.	O

Mobilization	O
was	O
started	O
on	O
the	O
10th	O
postoperative	O
day	O
.	O

The	O
overall	O
time	O
of	O
observation	O
was	O
one	O
year	O
.	O

Results	O
and	O
discussion	O
The	O
Piezosurgery	O
®	O
Device	O
is	O
ideally	O
sized	O
for	O
hand	O
surgery	O
.	O

The	O
cutting	O
was	O
very	O
precise	O
.	O

The	O
edges	O
of	O
the	O
osteotomy	O
were	O
all	O
sharp	O
to	O
the	O
edge	O
,	O
there	O
was	O
no	O
need	O
to	O
split	O
the	O
bone	O
with	O
a	O
chisel	O
,	O
nor	O
was	O
there	O
the	O
danger	O
of	O
a	O
break	O
out	O
.	O

During	O
the	O
osteotomy	O
there	O
were	O
no	O
disturbing	O
vibrations	O
in	O
the	O
area	O
of	O
operation	O
.	O

This	O
absence	O
of	O
vibration	O
is	O
very	O
practical	O
for	O
operations	O
using	O
a	O
magnifier	O
.	O

Vercellotti	O
mentions	O
that	O
to	O
overcome	O
any	O
problems	O
during	O
surgery	O
,	O
instead	O
of	O
increasing	O
pressure	O
on	O
the	O
hand	O
piece	O
,	O
as	O
in	O
traditional	O
techniques	O
,	O
it	O
is	O
necessary	O
to	O
find	O
the	O
correct	O
pressure	O
to	O
achieve	O
the	O
desired	O
result	O
.	O

With	O
piezoelectric	O
surgery	O
,	O
increasing	O
the	O
working	O
pressure	O
above	O
a	O
certain	O
limit	O
impedes	O
the	O
vibrations	O
of	O
the	O
insert	O
[	O
4	O
]	O
.	O

We	O
have	O
also	O
experienced	O
this	O
in	O
our	O
study	O
.	O

The	O
instrument	O
can	O
be	O
moved	O
in	O
all	O
directions	O
comparable	O
to	O
a	O
pen	O
.	O

The	O
tip	O
of	O
the	O
instrument	O
is	O
exchangeable	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
multiplanar	O
as	O
well	O
as	O
curved	O
cutting	O
.	O

Because	O
of	O
the	O
automatic	O
water	O
cooling	O
during	O
the	O
whole	O
procedure	O
,	O
there	O
is	O
always	O
a	O
clear	O
view	O
onto	O
the	O
object	O
.	O

This	O
is	O
something	O
oral	O
surgeons	O
found	O
especially	O
useful	O
[	O
6	O
]	O
.	O

The	O
authors	O
mention	O
that	O
the	O
downside	O
of	O
the	O
device	O
is	O
the	O
relative	O
slow	O
sawing	O
process	O
.	O

We	O
needed	O
about	O
30	O
seconds	O
for	O
one	O
cut	O
of	O
the	O
relatively	O
small	O
bone	O
.	O

This	O
is	O
about	O
20	O
seconds	O
longer	O
than	O
the	O
time	O
needed	O
for	O
cutting	O
with	O
the	O
usual	O
saw	O
.	O

Although	O
the	O
power	O
can	O
be	O
regulated	O
with	O
the	O
power	O
box	O
and	O
the	O
use	O
of	O
different	O
scalpels	O
,	O
we	O
agree	O
with	O
other	O
authors	O
that	O
the	O
optimal	O
use	O
of	O
this	O
device	O
is	O
in	O
surgeries	O
of	O
small	O
bones	O
where	O
precise	O
and	O
soft	O
tissue	O
friendly	O
cutting	O
is	O
required	O
[	O
7	O
]	O
.	O

As	O
other	O
literature	O
has	O
shown	O
,	O
the	O
device	O
selectively	O
cuts	O
bone	O
while	O
sparing	O
nerves	O
and	O
other	O
soft	O
tissue	O
[	O
2,3	O
]	O
.	O

This	O
allows	O
for	O
minimal	O
invasive	O
surgeries	O
with	O
limited	O
retraction	O
of	O
soft	O
tissue	O
and	O
minimal	O
stripping	O
of	O
the	O
periosteum	O
,	O
saves	O
time	O
and	O
might	O
have	O
a	O
positive	O
effect	O
on	O
the	O
healing	O
process	O
.	O

Our	O
aim	O
of	O
the	O
first	O
time	O
use	O
of	O
the	O
Piezosurgery	O
®	O
Device	O
in	O
hand	O
surgery	O
was	O
to	O
check	O
its	O
usability	O
in	O
osteotomies	O
of	O
tubular	O
bones	O
.	O

The	O
preparation	O
of	O
the	O
bone	O
was	O
done	O
in	O
the	O
usual	O
manner	O
as	O
is	O
done	O
when	O
cutting	O
with	O
an	O
oscillating	O
saw	O
.	O

The	O
reason	O
for	O
this	O
was	O
to	O
fully	O
visualize	O
the	O
cutting	O
process	O
using	O
this	O
new	O
device	O
,	O
although	O
in	O
the	O
future	O
,	O
it	O
should	O
be	O
possible	O
to	O
minimize	O
the	O
bony	O
exposure	O
.	O

In	O
our	O
patient	O
the	O
postoperative	O
healing	O
of	O
the	O
wound	O
and	O
the	O
bone	O
consolidation	O
(	O
Figure	O
4	O
)	O
were	O
smooth	O
.	O

The	O
duration	O
of	O
postoperative	O
sick	O
leave	O
was	O
four	O
weeks	O
which	O
is	O
more	O
rapid	O
than	O
the	O
usual	O
recovery	O
period	O
.	O

The	O
patient	O
regained	O
full	O
use	O
of	O
his	O
finger	O
according	O
to	O
the	O
state	O
before	O
the	O
fracture	O
.	O

At	O
no	O
point	O
was	O
there	O
any	O
loss	O
of	O
sensitivity	O
.	O

The	O
patient	O
as	O
well	O
as	O
the	O
surgeons	O
were	O
fully	O
satisfied	O
with	O
the	O
result	O
.	O

Conclusion	O

The	O
Piezosurgery	O
®	O
Device	O
is	O
a	O
useful	O
device	O
for	O
small	O
long	O
bone	O
osteotomies	O
.	O

We	O
feel	O
that	O
this	O
device	O
has	O
great	O
potential	O
in	O
the	O
field	O
of	O
hand-	O
and	O
spinal	O
surgery	O
.	O

As	O
the	O
device	O
selectively	O
cuts	O
bone	O
,	O
considerable	O
nerve	O
lesions	O
can	O
be	O
avoided	O
and	O
minimal	O
invasive	O
surgeries	O
are	O
possible	O
.	O

Using	O
the	O
fine	O
tip	O
enables	O
curved	O
cutting	O
and	O
provides	O
an	O
opportunity	O
for	O
new	O
osteotomy	O
techniques	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
DJH	O
initiated	O
and	O
coordinated	O
the	O
new	O
application	O
of	O
Piezosurgery	O
®	O
device	O
and	O
wrote	O
the	O
publication	O
.	O

StSt	O
lead	O
the	O
osteotomy	O
as	O
he	O
was	O
experienced	O
with	O
this	O
tool	O
from	O
oral	O
surgery	O
.	O

He	O
played	O
a	O
major	O
part	O
in	O
writing	O
the	O
technical	O
aspects	O
.	O

OVK	O
was	O
the	O
treating	O
surgeon	O
,	O
performed	O
the	O
operation	O
and	O
evaluated	O
the	O
new	O
tool	O
.	O

SS	O
performed	O
a	O
literature	O
review	O
and	O
wrote	O
part	O
of	O
the	O
publication	O
.	O

PH	O
was	O
the	O
treating	O
chief	O
surgeon	O
,	O
evaluated	O
the	O
new	O
tool	O
and	O
lead	O
the	O
treatment	O
in	O
all	O
aspects	O
.	O

Consent	O
We	O
obtained	O
oral	O
consent	O
from	O
the	O
patient	O
but	O
could	O
not	O
obtain	O
written	O
consent	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Alexithymia	O
and	O
anxiety	O
in	O
female	O
chronic	O
pain	O
patients	O
Abstract	O
Objectives	O
Alexithymia	O
is	O
highly	O
prevalent	O
among	O
chronic	O
pain	O
patients	O
.	O

Pain	O
is	O
a	O
remarkable	O
cause	O
for	O
high	O
levels	O
of	O
chronic	O
anxiety	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
and	O
to	O
determine	O
anxiety	O
levels	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
.	O

Methods	O
Thirty	O
adult	O
females	O
(	O
mean	O
age	O
:	O
34,63	O
±	O
10,62	O
years	O
)	O
,	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
with	O
the	O
diagnosis	O
of	O
chronic	O
pain	O
disorder	O
(	O
DSM	O
-	O
IV	O
)	O
,	O
were	O
included	O
in	O
the	O
study	O
.	O

Thirty	O
seven	O
healthy	O
females	O
(	O
mean	O
age	O
:	O
34,46	O
±	O
7,43	O
years	O
)	O
,	O
who	O
matched	O
for	O
sociodemographic	O
features	O
with	O
the	O
patient	O
group	O
,	O
consisted	O
the	O
control	O
group	O
.	O

A	O
sociodemographic	O
data	O
form	O
,	O
26-item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS-26	O
)	O
,	O
Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
were	O
administered	O
to	O
each	O
subject	O
and	O
information	O
was	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	O
'	O
pain	O
,	O
including	O
intensity	O
(	O
measured	O
by	O
VAS	O
)	O
,	O
and	O
duration	O
.	O

Results	O
Chronic	O
pain	O
patients	O
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
TAS-26	O
scores	O
and	O
the	O
duration	O
of	O
pain	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
group	O
did	O
not	O
differ	O
in	O
their	O
perception	O
of	O
pain	O
.	O

Neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	O
.	O

Discussion	O
Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
.	O

The	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

Background	O
The	O
original	O
definition	O
of	O
alexithymia	O
is	O
the	O
inability	O
to	O
identify	O
and	O
use	O
verbal	O
language	O
to	O
describe	O
feelings	O
[	O
1,2	O
]	O
.	O

Alexithymia	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
psychiatric	O
disorders	O
as	O
well	O
as	O
physical	O
illness	O
[	O
3	O
-	O
10	O
]	O
.	O

As	O
a	O
measure	O
,	O
Toronto	O
Alexithymia	O
Scale	O
was	O
significantly	O
correlated	O
with	O
the	O
measures	O
of	O
the	O
tendency	O
to	O
experience	O
and	O
report	O
physical	O
signs	O
and	O
symptoms	O
[	O
11	O
]	O
.	O

Several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	O
.	O

Chronic	O
pain	O
patients	O
frequently	O
exhibit	O
many	O
of	O
the	O
core	O
features	O
of	O
alexithymia	O
,	O
such	O
as	O
problems	O
in	O
identifying	O
and	O
describing	O
subjective	O
feelings	O
,	O
impoverished	O
imaginative	O
abilities	O
,	O
and	O
excessive	O
preoccupation	O
with	O
physical	O
symptoms	O
and	O
external	O
events	O
.	O

Although	O
several	O
studies	O
have	O
found	O
a	O
high	O
prevalence	O
of	O
alexithymia	O
in	O
pain	O
patients	O
,	O
the	O
way	O
alexithymia	O
may	O
possibly	O
influence	O
pain	O
experience	O
is	O
still	O
unclear	O
[	O
12,13	O
]	O
.	O

DSM	O
-	O
IV	O
-	O
TR	O
defines	O
pain	O
disorder	O
as	O
the	O
presence	O
of	O
pain	O
that	O
is	O
""""	O
the	O
predominant	O
focus	O
of	O
clinical	O
attention	O
""""	O
[	O
14	O
]	O
.	O

In	O
chronic	O
pain	O
disorder	O
,	O
patients	O
complain	O
of	O
chronic	O
pain	O
,	O
for	O
which	O
no	O
physical	O
etiology	O
could	O
be	O
found	O
or	O
the	O
underlying	O
disorder	O
is	O
insufficient	O
in	O
explaining	O
the	O
symptoms	O
.	O

The	O
pain	O
causes	O
clinically	O
significant	O
distress	O
or	O
impairment	O
in	O
social	O
,	O
occupational	O
,	O
or	O
other	O
important	O
areas	O
of	O
functioning	O
.	O

Psychological	O
factors	O
are	O
judged	O
to	O
have	O
an	O
important	O
role	O
in	O
the	O
onset	O
,	O
severity	O
,	O
exacerbation	O
,	O
or	O
maintenance	O
of	O
the	O
pain	O
[	O
15	O
]	O
.	O

The	O
alexithymic	O
person	O
's	O
difficulty	O
in	O
identifying	O
and	O
describing	O
feelings	O
may	O
increase	O
symptom	O
reporting	O
by	O
several	O
mechanisms	O
.	O

Consequently	O
,	O
due	O
to	O
the	O
difficulty	O
to	O
experience	O
and	O
express	O
emotions	O
,	O
alexithymia	O
has	O
been	O
linked	O
with	O
somatosensory	O
amplification	O
,	O
which	O
is	O
the	O
tendency	O
to	O
focus	O
on	O
benign	O
somatic	O
sensations	O
.	O

Alexithymic	O
subjects	O
are	O
considered	O
to	O
focus	O
on	O
somatic	O
manifestations	O
of	O
emotional	O
arousal	O
,	O
resulting	O
in	O
misinterpretation	O
of	O
somatic	O
sensations	O
as	O
signs	O
of	O
physical	O
illness	O
[	O
12,13,16	O
]	O
.	O

Accordingly	O
,	O
previous	O
studies	O
have	O
found	O
evidence	O
of	O
an	O
association	O
between	O
alexithymia	O
and	O
the	O
development	O
of	O
functional	O
somatic	O
symptoms	O
,	O
as	O
seen	O
in	O
patients	O
with	O
somatoform	O
disorders	O
.	O

On	O
the	O
other	O
hand	O
,	O
alexithymia	O
may	O
also	O
occur	O
as	O
a	O
secondary	O
state	O
reaction	O
in	O
response	O
to	O
severe	O
and	O
chronic	O
medical	O
illness	O
[	O
17	O
-	O
21	O
]	O
.	O

Based	O
on	O
previous	O
findings	O
,	O
these	O
factors	O
are	O
worth	O
receiving	O
more	O
attention	O
in	O
terms	O
of	O
clinical	O
research	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
prevalence	O
of	O
alexithymia	O
among	O
DSM	O
-	O
IV	O
somatoform	O
pain	O
disorder	O
(	O
chronic	O
pain	O
)	O
female	O
patients	O
and	O
to	O
examine	O
the	O
relationship	O
between	O
alexithymia	O
and	O
the	O
self	O
-	O
reporting	O
of	O
pain	O
in	O
this	O
group	O
of	O
patients	O
.	O

Besides	O
,	O
the	O
study	O
searched	O
for	O
the	O
anxiety	O
levels	O
of	O
chronic	O
pain	O
patients	O
with	O
or	O
without	O
alexithymia	O
.	O

Materials	O
and	O
methods	O
Sample	O
The	O
sample	O
consisted	O
of	O
30	O
females	O
who	O
applied	O
to	O
the	O
outpatient	O
psychiatry	O
clinic	O
at	O
a	O
public	O
hospital	O
and	O
who	O
met	O
DSM	O
-	O
IV	O
diagnostic	O
criteria	O
for	O
chronic	O
pain	O
disorder	O
.	O

Patients	O
with	O
concomitant	O
psychiatric	O
disorders	O
,	O
such	O
as	O
major	O
depression	O
,	O
anxiety	O
disorders	O
and	O
somatoform	O
disorders	O
other	O
than	O
pain	O
disorder	O
were	O
excluded	O
.	O

Patients	O
either	O
directly	O
applied	O
to	O
the	O
psychiatry	O
clinic	O
themselves	O
or	O
were	O
referred	O
for	O
psychiatric	O
assessment	O
from	O
another	O
outpatient	O
clinic	O
,	O
mainly	O
physical	O
medicine	O
and	O
rehabilitation	O
.	O

After	O
complete	O
description	O
of	O
the	O
study	O
,	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
.	O

The	O
control	O
group	O
was	O
37	O
healthy	O
females	O
,	O
who	O
matched	O
for	O
age	O
,	O
and	O
education	O
with	O
the	O
subjects	O
.	O

All	O
subjects	O
participated	O
voluntarily	O
in	O
the	O
study	O
and	O
gave	O
consent	O
after	O
the	O
procedure	O
had	O
been	O
fully	O
explained	O
to	O
them	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
and	O
the	O
healthy	O
controls	O
was	O
34,63	O
±	O
10,62	O
(	O
range	O
:	O
16–62	O
)	O
and	O
34,46	O
±	O
7,43	O
(	O
range	O
:	O
22–57	O
)	O
years	O
and	O
the	O
educational	O
level	O
was	O
6,13	O
±	O
3,03	O
(	O
range	O
:	O
5–11	O
)	O
and	O
6,59	O
±	O
2,9	O
(	O
range	O
:	O
5–14	O
)	O
years	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
with	O
respect	O
to	O
age	O
(	O
t	O
=	O
0,79	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0,05	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1,02	O
,	O
df	O
=	O
65	O
,	O
P	O
>	O
0,05	O
)	O
,	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0,51	O
,	O
df	O
=	O
1	O
,	O
P	O
>	O
0,05	O
)	O
.	O

Measures	O
A	O
detailed	O
sociodemographic	O
data	O
form	O
was	O
used	O
for	O
all	O
subjects	O
.	O

All	O
participants	O
were	O
applied	O
Structured	O
Clinical	O
Interview	O
for	O
DSM	O
-	O
IV	O
(	O
SCID	O
-	O
I	O
)	O
[	O
22	O
]	O
,	O
Turkish	O
version	O
[	O
23	O
]	O
.	O

Regarding	O
the	O
pain	O
assessment	O
,	O
information	O
was	O
first	O
obtained	O
on	O
several	O
aspects	O
of	O
the	O
patients	O
'	O
pain	O
,	O
such	O
as	O
intensity	O
,	O
and	O
duration	O
.	O

Pain	O
intensity	O
was	O
measured	O
by	O
Visual	O
Analogue	O
Scale	O
(	O
VAS	O
)	O
,	O
using	O
a	O
horizontal	O
10-cm	O
line	O
with	O
the	O
statement	O
'	O
no	O
pain	O
at	O
all	O
'	O
at	O
the	O
extreme	O
left	O
-	O
hand	O
end	O
and	O
'	O
the	O
worst	O
possible	O
pain	O
'	O
or	O
'	O
unbearable	O
'	O
at	O
the	O
right	O
-	O
hand	O
extreme	O
.	O

VAS	O
is	O
scored	O
by	O
measuring	O
the	O
distance	O
from	O
the	O
end	O
of	O
the	O
scale	O
indicating	O
absence	O
of	O
pain	O
(	O
or	O
no	O
distress	O
or	O
no	O
pain	O
relief	O
)	O
to	O
the	O
place	O
marked	O
by	O
the	O
patient	O
[	O
24	O
]	O
.	O

The	O
psychometric	O
scales	O
used	O
in	O
the	O
study	O
were	O
the	O
26-item	O
Toronto	O
Alexithymia	O
Scale	O
(	O
TAS-26	O
]	O
and	O
the	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
,	O
which	O
were	O
both	O
validated	O
in	O
Turkish	O
population	O
studies	O
[	O
25	O
-	O
28	O
]	O
.	O

TAS	O
is	O
a	O
psychometrically	O
well	O
validated	O
and	O
reliable	O
instrument	O
in	O
the	O
assessment	O
of	O
alexithymia	O
.	O

TAS	O
has	O
been	O
validated	O
in	O
Turkish	O
studies	O
as	O
a	O
true	O
or	O
false	O
scale	O
.	O

Twenty	O
-	O
six	O
items	O
are	O
scored	O
either	O
as	O
1	O
or	O
0	O
and	O
the	O
higher	O
scores	O
indicate	O
higher	O
degrees	O
of	O
alexithymia	O
.	O

TAS	O
has	O
an	O
interval	O
consistency	O
of	O
0.65	O
[	O
Kuder	O
-	O
Richardson	O
)	O
and	O
test	O
-	O
retest	O
reliability	O
is	O
r	O
=	O
0.71	O
,	O
p	O
<	O
0.01	O
in	O
Turkish	O
reliability	O
and	O
validity	O
study	O
.	O

The	O
sample	O
was	O
divided	O
into	O
nonalexithymic	O
and	O
alexityhmic	O
groups	O
,	O
with	O
the	O
recommended	O
cut	O
-	O
off	O
score	O
of	O
11	O
[	O
27	O
]	O
.	O

Spielberger	O
Trait	O
Anxiety	O
Inventory	O
(	O
STAI	O
)	O
is	O
one	O
of	O
the	O
two	O
sections	O
of	O
the	O
Spielberger	O
Anxiety	O
Inventory	O
(	O
the	O
other	O
,	O
measuring	O
state	O
anxiety	O
)	O
.	O
'	O

Trait	O
anxiety	O
'	O
has	O
been	O
defined	O
as	O
anxiety	O
proneness	O
,	O
that	O
is	O
,	O
the	O
tendency	O
to	O
respond	O
to	O
situations	O
perceived	O
as	O
threatening	O
with	O
elevations	O
in	O
the	O
intensity	O
of	O
state	O
anxiety	O
[	O
26	O
]	O
.	O

Statistical	O
analysis	O
In	O
order	O
to	O
determine	O
the	O
relative	O
importance	O
of	O
a	O
number	O
of	O
factors	O
in	O
pain	O
disorders	O
,	O
we	O
used	O
both	O
correlation	O
analyses	O
.	O

The	O
alexithymic	O
and	O
nonalexithymic	O
groups	O
were	O
compared	O
using	O
the	O
independent	O
sample	O
t	O
-	O
tests	O
on	O
scores	O
of	O
psychological	O
tests	O
.	O

The	O
statistical	O
procedure	O
,	O
which	O
was	O
carried	O
out	O
by	O
a	O
SPSS	O
package	O
program	O
for	O
Windows	O
using	O
Chi	O
-	O
square	O
,	O
Fisher	O
's	O
exact	O
test	O
,	O
two	O
tailed	O
t	O
test	O
and	O
Pearson	O
correlation	O
coefficients	O
,	O
was	O
also	O
used	O
to	O
determine	O
group	O
differences	O
(	O
alexithymics	O
versus	O
nonalexithymics	O
)	O
in	O
sociodemographic	O
variables	O
and	O
various	O
aspects	O
of	O
pain	O
.	O

Results	O
In	O
the	O
chronic	O
pain	O
group	O
,	O
56.7	O
%	O
of	O
patients	O
(	O
n	O
=	O
17	O
)	O
had	O
a	O
score	O
greater	O
than	O
11	O
on	O
the	O
TAS-26	O
,	O
and	O
were	O
considered	O
alexithymic	O
.	O

The	O
mean	O
TAS-26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
17	O
)	O
was	O
17.88	O
±	O
3.43	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
13	O
)	O
was	O
8.39	O
±	O
2.02	O
.	O

Age	O
(	O
t	O
=	O
1,38	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,18	O
)	O
,	O
education	O
(	O
t	O
=	O
-0,21	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,16	O
)	O
and	O
marital	O
status	O
(	O
x2	O
=	O
0,27	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0,87	O
)	O
were	O
not	O
associated	O
with	O
alexithymia	O
(	O
Table	O
1	O
)	O
.	O

In	O
the	O
control	O
group	O
,	O
24,3	O
%	O
of	O
patients	O
(	O
n	O
=	O
9	O
)	O
were	O
alexithymic	O
according	O
to	O
TAS-26	O
.	O

The	O
mean	O
TAS-26	O
score	O
of	O
the	O
alexithymic	O
group	O
(	O
n	O
=	O
9	O
)	O
was	O
13,82	O
±	O
1,93	O
and	O
the	O
nonalexithymic	O
group	O
(	O
n	O
=	O
28	O
)	O
was	O
10,33	O
±	O
0,86	O
.	O

Alexithymia	O
was	O
not	O
associated	O
with	O
age	O
(	O
t	O
=	O
-1,08	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0,29	O
)	O
,	O
educational	O
level	O
(	O
t	O
=	O
1,1	O
,	O
df	O
=	O
35	O
,	O
p	O
>	O
0,28	O
)	O
,	O
or	O
marital	O
status	O
(	O
x2	O
=	O
0,74	O
,	O
df	O
=	O
1	O
,	O
p	O
>	O
0,79	O
)	O
or	O
anxiety	O
levels	O
in	O
the	O
control	O
subjects	O
(	O
Table	O
1	O
)	O
.	O

The	O
duration	O
and	O
severity	O
of	O
pain	O
,	O
TAS-26	O
scores	O
,	O
and	O
STAI	O
scores	O
of	O
the	O
female	O
pain	O
patients	O
are	O
shown	O
in	O
Table	O
2	O
.	O

Comparison	O
of	O
the	O
alexithymics	O
with	O
nonalexithymics	O
on	O
either	O
the	O
severity	O
of	O
pain	O
or	O
pain	O
duration	O
showed	O
no	O
statistical	O
significance	O
(	O
t	O
=	O
0,64	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,52	O
,	O
t	O
=	O
2,05	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,05	O
,	O
respectively	O
)	O
.	O

TAS-26	O
score	O
and	O
duration	O
of	O
pain	O
were	O
found	O
positively	O
correlated	O
(	O
r	O
=	O
0,50	O
,	O
n	O
=	O
30	O
,	O
p	O
>	O
0,005	O
)	O
.	O

STAI	O
(	O
trait	O
)	O
scores	O
of	O
the	O
alexithymics	O
in	O
the	O
pain	O
group	O
did	O
not	O
significantly	O
differ	O
from	O
the	O
nonlalexithymics	O
(	O
t	O
=	O
0,06	O
,	O
df	O
=	O
28	O
,	O
p	O
>	O
0,95	O
)	O
and	O
besides	O
,	O
TAS-26	O
and	O
STAI	O
scores	O
were	O
not	O
correlated	O
(	O
r	O
=	O
0,06	O
,	O
p	O
>	O
0,72	O
)	O
.	O

In	O
summary	O
,	O
there	O
are	O
three	O
points	O
to	O
be	O
emphasized	O
.	O

First	O
,	O
chronic	O
pain	O
patients	O
were	O
found	O
significantly	O
more	O
alexithymic	O
than	O
controls	O
(	O
56,7	O
%	O
to	O
24,3	O
%	O
)	O
.	O

Second	O
,	O
a	O
positive	O
correlation	O
was	O
observed	O
between	O
TAS-26	O
scores	O
and	O
duration	O
of	O
pain	O
.	O

Third	O
,	O
neither	O
positive	O
correlation	O
nor	O
significant	O
difference	O
was	O
found	O
between	O
alexithymia	O
and	O
trait	O
anxiety	O
in	O
pain	O
patients	O
.	O

Discussion	O
The	O
results	O
of	O
the	O
present	O
study	O
suggest	O
that	O
patients	O
with	O
chronic	O
pain	O
disorder	O
are	O
more	O
alexithymic	O
than	O
individuals	O
with	O
no	O
pain	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
results	O
obtained	O
with	O
earlier	O
measures	O
of	O
alexithymia	O
[	O
11	O
-	O
13	O
]	O
.	O

Although	O
they	O
may	O
share	O
common	O
clinical	O
features	O
,	O
alexithymia	O
and	O
somatoform	O
pain	O
are	O
independent	O
constructs	O
.	O

Alexithymia	O
may	O
be	O
a	O
consequence	O
to	O
the	O
effects	O
of	O
severe	O
physical	O
symptoms	O
,	O
such	O
as	O
a	O
reduced	O
quality	O
of	O
life	O
and	O
limitations	O
in	O
daily	O
activities	O
.	O

Besides	O
,	O
alexithymia	O
may	O
be	O
conceptualized	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
[	O
2,3,15	O
-	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
question	O
investigated	O
was	O
whether	O
alexithymia	O
has	O
any	O
correlation	O
with	O
the	O
duration	O
or	O
severity	O
of	O
the	O
pain	O
itself	O
.	O

There	O
were	O
no	O
significant	O
differences	O
between	O
alexithymic	O
and	O
nonalexitymic	O
patients	O
on	O
self	O
reports	O
of	O
current	O
pain	O
severity	O
.	O

This	O
is	O
in	O
accordance	O
with	O
Cox	O
's	O
study	O
[	O
1994	O
]	O
in	O
which	O
it	O
was	O
further	O
pointed	O
out	O
that	O
alexithymic	O
patients	O
were	O
found	O
to	O
use	O
significantly	O
more	O
verbal	O
descriptors	O
of	O
pain	O
compared	O
to	O
nonalexithymic	O
patients	O
[	O
13	O
]	O
.	O

In	O
our	O
study	O
,	O
pain	O
intensity	O
was	O
only	O
evaluated	O
by	O
using	O
VAS	O
.	O

One	O
problem	O
in	O
trying	O
to	O
measure	O
the	O
intensity	O
of	O
pain	O
is	O
the	O
lack	O
of	O
an	O
objective	O
way	O
.	O

Pain	O
is	O
a	O
subjective	O
experience	O
and	O
each	O
patient	O
may	O
communicate	O
in	O
a	O
different	O
way	O
,	O
verbally	O
or	O
nonverbally	O
[	O
29	O
]	O
.	O

Patients	O
in	O
this	O
sample	O
were	O
sufferers	O
of	O
chronic	O
pain	O
,	O
who	O
had	O
already	O
chosen	O
an	O
approved	O
way	O
of	O
expressing	O
their	O
distress	O
.	O

Since	O
this	O
is	O
true	O
regardless	O
of	O
alexithymia	O
,	O
alexithymic	O
groups	O
and	O
nonalexithymic	O
groups	O
in	O
this	O
sample	O
showed	O
no	O
difference	O
on	O
pain	O
severity	O
.	O

The	O
positive	O
correlation	O
between	O
alexithymia	O
and	O
the	O
duration	O
of	O
pain	O
in	O
this	O
sample	O
supports	O
the	O
assumption	O
of	O
a	O
two	O
-	O
way	O
hypothesis	O
.	O

It	O
is	O
often	O
assumed	O
that	O
pain	O
can	O
be	O
caused	O
by	O
alexithymic	O
personality	O
traits	O
and	O
also	O
that	O
severe	O
and	O
chronic	O
pain	O
may	O
cause	O
emotional	O
change	O
.	O

One	O
of	O
the	O
limitations	O
of	O
this	O
study	O
is	O
that	O
because	O
of	O
the	O
cross	O
-	O
sectional	O
design	O
,	O
we	O
are	O
unable	O
to	O
draw	O
conclusions	O
about	O
the	O
direction	O
of	O
causality	O
between	O
alexithymia	O
and	O
pain	O
.	O

The	O
duration	O
of	O
the	O
patients	O
'	O
pain	O
could	O
approximately	O
be	O
determined	O
,	O
yet	O
the	O
preexisting	O
level	O
of	O
alexithymia	O
was	O
not	O
known	O
.	O

In	O
the	O
usual	O
absence	O
of	O
internal	O
stimuli	O
,	O
alexithymic	O
person	O
may	O
be	O
expected	O
to	O
maintain	O
an	O
external	O
focus	O
of	O
attention	O
,	O
such	O
as	O
pain	O
.	O

Symptom	O
chronicity	O
may	O
force	O
the	O
alexithymic	O
person	O
to	O
attent	O
to	O
and	O
amplify	O
this	O
somatic	O
sensation	O
.	O

Difficulties	O
in	O
the	O
ability	O
to	O
identify	O
and	O
differentiate	O
emotions	O
and	O
somatic	O
experiences	O
are	O
core	O
features	O
of	O
the	O
alexithymic	O
construct	O
.	O

Therefore	O
,	O
alexithymic	O
patients	O
might	O
be	O
expected	O
to	O
differ	O
from	O
nonalexithymic	O
ones	O
in	O
their	O
anxiety	O
levels	O
.	O

Yet	O
,	O
in	O
our	O
pain	O
group	O
alexithymic	O
patients	O
showed	O
no	O
significant	O
difference	O
from	O
the	O
nonalexithymics	O
on	O
trait	O
anxiety	O
.	O

Besides	O
,	O
alexithymia	O
and	O
anxiety	O
were	O
not	O
correlated	O
at	O
all	O
.	O

The	O
reasons	O
may	O
be	O
lying	O
in	O
the	O
specific	O
characteristics	O
of	O
this	O
patient	O
group	O
itself	O
.	O

The	O
study	O
included	O
patients	O
suffering	O
from	O
chronic	O
symptoms	O
;	O
with	O
an	O
average	O
of	O
7,44	O
±	O
6,82	O
years	O
of	O
pain	O
in	O
the	O
alexithymic	O
and	O
3,31	O
±	O
2,79	O
years	O
in	O
the	O
nonalexithymic	O
groups	O
.	O

Persistency	O
of	O
any	O
physical	O
symptom	O
may	O
bring	O
along	O
alexithymia	O
as	O
a	O
coping	O
strategy	O
.	O

In	O
their	O
paper	O
,	O
Crook	O
and	O
Tunks	O
(	O
1988	O
)	O
examined	O
the	O
types	O
of	O
coping	O
strategies	O
used	O
by	O
persistent	O
pain	O
sufferers	O
and	O
addressed	O
to	O
the	O
importance	O
to	O
alter	O
their	O
attitudes	O
and	O
behavior	O
that	O
tend	O
toward	O
catastrophizing	O
,	O
avoidance	O
and	O
withdrawal	O
,	O
rather	O
than	O
simply	O
concentrate	O
on	O
trying	O
to	O
teach	O
them	O
techniques	O
for	O
'	O
coping	O
with	O
stress	O
'	O
to	O
help	O
persistent	O
pain	O
sufferers	O
[	O
30	O
]	O
.	O

Sufferers	O
of	O
chronic	O
symptoms	O
in	O
this	O
sample	O
were	O
members	O
of	O
a	O
subgroup	O
who	O
have	O
been	O
seeking	O
medical	O
care	O
for	O
a	O
long	O
time	O
and	O
besides	O
given	O
the	O
chance	O
of	O
being	O
referred	O
to	O
a	O
psychiatrist	O
.	O

Therefore	O
,	O
alexithymic	O
or	O
not	O
,	O
their	O
anxiety	O
might	O
have	O
induced	O
unique	O
coping	O
strategies	O
and	O
illness	O
behavior	O
.	O

Alexithymia	O
may	O
be	O
important	O
in	O
addressing	O
the	O
diversity	O
of	O
subjective	O
factors	O
involved	O
in	O
pain	O
[	O
31	O
]	O
.	O

It	O
is	O
not	O
known	O
whether	O
it	O
should	O
be	O
addressed	O
in	O
the	O
treatment	O
of	O
pain	O
patients	O
,	O
but	O
a	O
high	O
level	O
of	O
alexithymia	O
may	O
effect	O
the	O
nature	O
of	O
assessment	O
.	O

In	O
summary	O
,	O
the	O
conceptualization	O
of	O
alexithymia	O
as	O
a	O
personality	O
trait	O
as	O
well	O
as	O
a	O
secondary	O
state	O
reaction	O
is	O
underlined	O
by	O
our	O
data	O
.	O

However	O
,	O
regarding	O
the	O
cross	O
-	O
sectional	O
design	O
of	O
this	O
study	O
,	O
only	O
limited	O
conclusions	O
can	O
be	O
drawn	O
about	O
the	O
nature	O
of	O
the	O
causal	O
relationship	O
between	O
alexithymia	O
and	O
chronic	O
pain	O
.	O

Therefore	O
,	O
future	O
longitudinal	O
studies	O
assessing	O
the	O
cause	O
of	O
alexithymic	O
characteristics	O
are	O
required	O
to	O
fully	O
elucidate	O
the	O
concepts	O
of	O
primary	O
and	O
secondary	O
alexithymia	O
.	O

The	O
role	O
of	O
the	O
muscarinic	O
system	O
in	O
regulating	O
estradiol	O
secretion	O
varies	O
during	O
the	O
estrous	O
cycle	O
:	O
the	O
hemiovariectomized	O
rat	B
model	O
Abstract	O
There	O
is	O
evidence	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
.	O

The	O
present	O
study	O
analyzed	O
the	O
acute	O
effects	O
of	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
and	O
blocking	O
the	O
cholinergic	O
system	O
,	O
by	O
injecting	O
atropine	O
sulfate	O
(	O
ATR	O
)	O
,	O
on	O
estradiol	O
(	O
E2	O
)	O
serum	O
concentrations	O
during	O
the	O
estrous	O
cycle	O
.	O

The	O
results	O
indicate	O
that	O
ULO	O
effects	O
on	O
E2	O
concentrations	O
are	O
asymmetric	O
,	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
and	O
partially	O
depend	O
on	O
the	O
cholinergic	O
innervation	O
.	O

Background	O
Estradiol	O
secretion	O
is	O
regulated	O
by	O
pituitary	O
[	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
luteinizing	O
hormones	O
(	O
LH	O
)	O
,	O
prolactin	O
,	O
and	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
]	O
.	O

The	O
effects	O
of	O
these	O
hormones	O
are	O
modulated	O
by	O
neurotransmitters	O
released	O
by	O
the	O
intrinsic	O
ovarian	O
innervation	O
near	O
the	O
follicular	O
wall	O
.	O

Acetylcholine	O
produced	O
by	O
the	O
follicle	O
may	O
be	O
one	O
of	O
the	O
neurotransmitters	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
pituitary	O
hormones	O
on	O
the	O
follicle	O
[	O
1	O
-	O
3	O
]	O
.	O

Evidence	O
suggesting	O
that	O
one	O
gonad	O
has	O
functional	O
predominance	O
in	O
mammals	O
and	O
birds	O
have	O
been	O
published	O
[	O
1,4	O
-	O
8	O
]	O
.	O

In	O
previous	O
studies	O
we	O
have	O
shown	O
that	O
unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
modifies	O
progesterone	O
and/or	O
testosterone	O
serum	O
concentrations	O
,	O
and	O
that	O
the	O
effects	O
of	O
ULO	O
depend	O
on	O
both	O
,	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
ULO	O
was	O
performed	O
and	O
the	O
ovary	O
(	O
left	O
or	O
right	O
)	O
remaining	O
in	O
situ	O
[	O
9	O
-	O
11	O
]	O
.	O

Asymmetry	O
in	O
ovarian	O
functions	O
has	O
been	O
explained	O
by	O
differences	O
in	O
the	O
ovarian	O
innervation	O
participating	O
in	O
modulating	O
the	O
effects	O
of	O
gonadotropin	O
on	O
the	O
ovarian	O
follicles	O
[	O
1,6	O
]	O
.	O

Kawakami	O
et	O
al	O
[	O
12	O
]	O
showed	O
that	O
electrical	O
stimulation	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
,	O
the	O
ventro	O
-	O
medial	O
hypothalamus	O
,	O
and	O
the	O
areas	O
in	O
the	O
mesencephalon	O
of	O
hypophysectomized	O
and	O
adrenalectomized	O
female	O
rats	B
resulted	O
in	O
a	O
significant	O
increase	O
of	O
estradiol	O
(	O
E2	O
)	O
and	O
progesterone	O
(	O
P4	O
)	O
plasma	O
concentrations	O
in	O
the	O
contra	O
-	O
lateral	O
ovarian	O
venous	O
blood	O
.	O

In	O
turn	O
,	O
stimulating	O
the	O
dorsal	O
hippocampus	O
,	O
the	O
lateral	O
amygdala	O
,	O
and	O
the	O
mesencephalic	O
areas	O
resulted	O
in	O
lower	O
E2	O
and	O
P4	O
concentrations	O
.	O

Ovarian	O
denervation	O
of	O
rats	B
in	O
proestrus	O
stage	O
blocks	O
E2	O
secretion	O
induced	O
by	O
stimulating	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
.	O

In	O
addition	O
,	O
the	O
electrochemical	O
stimulation	O
in	O
proestrus	O
day	O
of	O
the	O
medial	O
basal	O
pre	O
-	O
chiasmatic	O
area	O
of	O
untreated	O
rats	B
increased	O
E2	O
and	O
P4	O
concentrations	O
in	O
serum	O
.	O

This	O
effect	O
was	O
not	O
observed	O
when	O
stimulation	O
was	O
applied	O
to	O
the	O
pre	O
-	O
optic	O
supra	O
-	O
chiasmatic	O
area	O
.	O

According	O
to	O
the	O
authors	O
'	O
interpretation	O
of	O
the	O
results	O
,	O
the	O
efferent	O
neural	O
system	O
connecting	O
the	O
brain	O
and	O
the	O
ovaries	O
is	O
supplementary	O
to	O
the	O
brain	O
-	O
pituitary	O
-	O
ovarian	O
hormonal	O
mechanisms	O
regulating	O
ovarian	O
steroid	O
secretion	O
,	O
and	O
the	O
system	O
may	O
be	O
required	O
for	O
adjusting	O
ovarian	O
responsiveness	O
and	O
sensitivity	O
to	O
gonadotropins	O
[	O
12,13	O
]	O
.	O

Gerendai	O
et	O
al.	O
[	O
14	O
]	O
described	O
a	O
multi	O
-	O
synaptic	O
neural	O
pathway	O
between	O
the	O
central	O
nervous	O
system	O
and	O
the	O
ovaries	O
,	O
with	O
the	O
vagus	O
nerve	O
being	O
one	O
of	O
the	O
main	O
neural	O
pathways	O
.	O

In	O
ULO	O
treated	O
rats	B
,	O
bi	O
-	O
lateral	O
sectioning	O
the	O
vagus	O
nerve	O
(	O
ventral	O
or	O
dorsal	O
)	O
results	O
in	O
lower	O
compensatory	O
ovarian	O
hypertrophy	O
.	O

The	O
effects	O
of	O
sectioning	O
the	O
left	O
vagus	O
nerve	O
depend	O
on	O
the	O
remaining	O
ovary	O
in	O
situ	O
:	O
rats	B
with	O
the	O
left	O
ovary	O
in	O
situ	O
had	O
a	O
larger	O
proportion	O
of	O
ovulating	O
animals	O
,	O
compensatory	O
ovarian	O
hypertrophy	O
and	O
number	O
of	O
ova	O
shed	O
.	O

In	O
turn	O
,	O
rats	B
with	O
the	O
right	O
ovary	O
in	O
situ	O
showed	O
a	O
decrease	O
in	O
all	O
parameters	O
studied	O
[	O
15	O
]	O
.	O

Based	O
on	O
available	O
information	O
,	O
the	O
present	O
study	O
aims	O
to	O
analyze	O
if	O
changes	O
in	O
E2	O
secretion	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
vary	O
during	O
the	O
estrous	O
cycle	O
,	O
using	O
the	O
unilateral	O
ovariectomized	O
animal	O
as	O
a	O
model	O
of	O
study	O
.	O

We	O
also	O
investigated	O
if	O
,	O
throughout	O
estrous	O
cycle	O
diestrus	O
1	O
(	O
D1	O
)	O
,	O
diestrus	O
2	O
(	O
D2	O
)	O
and	O
proestrus	O
(	O
P	O
)	O
,	O
the	O
cholinergic	O
system	O
modulates	O
E2	O
secretion	O
in	O
an	O
asymmetric	O
way	O
.	O

For	O
this	O
purpose	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
injecting	O
ATR	O
at	O
13.00	O
h	O
to	O
rats	B
on	O
D1	O
,	O
D2	O
or	O
P	O
with	O
or	O
without	O
unilateral	O
or	O
bilateral	O
ovariectomy	O
.	O

Materials	O
and	O
methods	O
The	O
study	O
was	O
performed	O
with	O
virgin	O
adult	O
female	O
rats	B
(	O
195–225-g	O
body	O
weight	O
)	O
of	O
the	O
CIIZ	O
-	O
V	O
strain	O
from	O
our	O
own	O
stock	O
.	O

Animals	O
were	O
kept	O
under	O
controlled	O
lighting	O
conditions	O
(	O
lights	O
on	O
from	O
05:00	O
to	O
19:00	O
h	O
)	O
,	O
with	O
free	O
access	O
to	O
food	O
(	O
Purina	O
S.A.	O
,	O
Mexico	O
)	O
and	O
tap	O
water	O
;	O
following	O
NIH	O
Guide	O
parameters	O
for	O
the	O
care	O
of	O
laboratory	O
animals	O
.	O

The	O
Committee	O
of	O
the	O
Facultad	O
de	O
Estudios	O
Superiores	O
Zaragoza	O
approved	O
the	O
experimental	O
protocols	O
.	O

Estrous	O
cycles	O
were	O
monitored	O
by	O
daily	O
vaginal	O
smears	O
.	O

Only	O
rats	B
showing	O
at	O
least	O
two	O
consecutive	O
4-day	O
cycles	O
were	O
used	O
in	O
the	O
experiment	O
.	O

All	O
surgeries	O
were	O
performed	O
under	O
ether	O
anesthesia	O
,	O
between	O
13:00–13:15	O
hours	O
.	O

Rats	B
were	O
sacrificed	O
by	O
decapitation	O
one	O
hour	O
after	O
treatment	O
.	O

Experimental	O
groups	O
Rats	B
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
experimental	O
groups	O
described	O
below	O
.	O

Animals	O
from	O
different	O
experimental	O
groups	O
were	O
treated	O
simultaneously	O
and	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

The	O
number	O
of	O
animals	O
used	O
in	O
each	O
experimental	O
group	O
is	O
presented	O
in	O
Tables	O
1	O
,	O
2	O
and	O
3	O
.	O

Control	O
group	O
(	O
N	O
=	O
48	O
)	O
.	O

Non	O
-	O
treated	O
cyclic	O
rats	B
sacrificed	O
at	O
14:00	O
h	O
on	O
D1	O
(	O
17	O
rats	B
)	O
,	O
D2	O
(	O
19	O
rats	B
)	O
and	O
P	O
(	O
12	O
rats	B
)	O
.	O

Ether	O
anesthesia	O
(	O
N	O
=	O
24	O
)	O
:	O
Groups	O
of	O
rats	B
,	O
on	O
specific	O
stages	O
(	O
D1	O
,	O
D2	O
or	O
P	O
)	O
of	O
the	O
estrous	O
cycle	O
,	O
were	O
anesthetized	O
for	O
10	O
min	O
and	O
sacrificed	O
one	O
hour	O
later	O
.	O

Unilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
)	O
(	O
N	O
=	O
53	O
)	O
:	O
A	O
unilateral	O
incision	O
was	O
performed	O
2-cm	O
below	O
the	O
last	O
rib	O
;	O
affecting	O
skin	O
,	O
muscle	O
,	O
and	O
peritoneum	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Bilateral	O
peritoneal	O
perforation	O
(	O
sham	O
operation	O
2	O
)	O
(	O
N	O
=	O
27	O
)	O
.	O

A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
,	O
was	O
performed	O
.	O

The	O
ovaries	O
were	O
not	O
injured	O
or	O
manipulated	O
.	O

After	O
surgical	O
procedures	O
the	O
wound	O
was	O
sealed	O
.	O

Unilateral	O
ovariectomy	O
(	O
ULO	O
)	O
(	O
N	O
=	O
50	O
)	O
:	O
A	O
unilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
right	O
or	O
left	O
ovary	O
was	O
extirpated	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Bilateral	O
ovariectomy	O
(	O
N	O
=	O
23	O
)	O
:	O
A	O
bilateral	O
incision	O
below	O
the	O
last	O
rib	O
,	O
including	O
skin	O
and	O
muscle	O
was	O
performed	O
,	O
and	O
the	O
ovaries	O
removed	O
.	O

The	O
wound	O
was	O
subsequently	O
sealed	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
To	O
analyze	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
,	O
groups	O
of	O
animals	O
were	O
injected	O
with	O
atropine	O
sulfate	O
(	O
ATR	O
,	O
Sigma	O
Chem	O
.	O

Co.	O
St.	O
Louis	O
,	O
Mo.	O
)	O
.	O

ATR	O
was	O
injected	O
one	O
hour	O
before	O
surgery	O
at	O
doses	O
known	O
to	O
block	O
ovulation	O
:	O
in	O
D1	O
,	O
100	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b.w	O
.	O
)	O
;	O
in	O
D2	O
,	O
300	O
mg	O
/	O
kg	O
b.w	O
.	O
;	O
and	O
in	O
P	O
,	O
700	O
mg	O
/	O
kg	O
b.w	O
.	O

[	O
16	O
]	O
.	O

One	O
hour	O
after	O
ATR	O
treatment	O
,	O
rats	B
were	O
randomly	O
allotted	O
to	O
one	O
of	O
the	O
following	O
treatments	O
:	O
unilateral	O
peritoneal	O
perforation	O
,	O
bilateral	O
peritoneal	O
perforation	O
,	O
ULO	O
,	O
or	O
bilateral	O
ovariectomy	O
.	O

All	O
animals	O
were	O
sacrificed	O
one	O
hour	O
after	O
surgery	O
.	O

For	O
control	O
purposes	O
,	O
untreated	O
rats	B
,	O
on	O
D1	O
,	O
D2	O
or	O
P	O
,	O
were	O
injected	O
with	O
ATR	O
in	O
the	O
same	O
dose	O
as	O
in	O
their	O
corresponding	O
treatment	O
group	O
.	O

The	O
animals	O
were	O
sacrificed	O
two	O
hours	O
after	O
treatment	O
.	O

Autopsy	O
procedures	O
Animals	O
were	O
sacrificed	O
by	O
decapitation	O
.	O

The	O
blood	O
of	O
the	O
trunk	O
was	O
collected	O
in	O
a	O
test	O
tube	O
,	O
allowed	O
to	O
clot	O
at	O
room	O
temperature	O
for	O
30	O
minutes	O
and	O
centrifuged	O
at	O
3,000	O
rpm	O
for	O
15	O
minutes	O
.	O

Serum	O
was	O
stored	O
at	O
-20	O
°	O
C	O
,	O
until	O
E2	O
concentrations	O
were	O
measured	O
.	O

Hormone	O
assay	O
Concentrations	O
of	O
E2	O
in	O
serum	O
were	O
measured	O
by	O
Radio	O
-	O
Immuno	O
-	O
Assay	O
(	O
RIA	O
)	O
;	O
using	O
kits	O
purchased	O
from	O
Diagnostic	O
Products	O
(	O
Los	O
Angeles	O
,	O
CA	O
)	O
.	O

Results	O
are	O
expressed	O
in	O
pg	O
/	O
ml	O
.	O

The	O
Intra-	O
and	O
inter	O
-	O
assay	O
variation	O
coefficients	O
were	O
6.9	O
%	O
and	O
10.8	O
%	O
,	O
respectively	O
.	O

Statistics	O
Data	O
on	O
hormonal	O
concentrations	O
in	O
serum	O
were	O
analyzed	O
using	O
multivariate	O
analysis	O
of	O
variance	O
(	O
MANOVA	O
)	O
followed	O
by	O
Tukey	O
's	O
test	O
.	O

Differences	O
in	O
serum	O
hormone	O
concentrations	O
between	O
two	O
groups	O
were	O
analyzed	O
by	O
Student	O
's	O
t	O
-	O
test	O
.	O

A	O
probability	O
value	O
of	O
less	O
than	O
5	O
%	O
was	O
considered	O
significant	O
.	O

Results	O
Effects	O
of	O
ether	O
anesthesia	O
and	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
In	O
the	O
control	O
group	O
,	O
animals	O
sacrificed	O
on	O
P	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentration	O
than	O
animals	O
sacrificed	O
on	O
D1	O
or	O
D2	O
(	O
D1	O
:	O
55.3	O
±	O
8.0	O
;	O
D2	O
:	O
59.1	O
±	O
7.9	O
;	O
P	O
:	O
158.4	O
±	O
1.8	O
)	O
.	O

Compared	O
to	O
the	O
control	O
group	O
,	O
ether	O
anesthesia	O
treatment	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
(	O
D1	O
:	O
62.9	O
±	O
8.4	O
;	O
D2	O
:	O
69.5	O
±	O
12.0	O
;	O
P	O
:	O
164.1	O
±	O
17.6	O
)	O
.	O

Since	O
ether	O
anesthesia	O
did	O
not	O
modify	O
E2	O
serum	O
concentrations	O
,	O
treatment	O
results	O
are	O
compared	O
to	O
their	O
respective	O
control	O
group	O
.	O

The	O
effects	O
on	O
E2	O
serum	O
concentrations	O
of	O
unilaterally	O
or	O
bilaterally	O
perforating	O
the	O
peritoneum	O
depended	O
on	O
the	O
side	O
of	O
the	O
peritoneum	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
perforation	O
surgery	O
was	O
performed	O
.	O

Perforating	O
the	O
left	O
peritoneum	O
on	O
D1	O
resulted	O
in	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
,	O
while	O
bilateral	O
perforation	O
,	O
or	O
perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
,	O
had	O
no	O
apparent	O
effects	O
(	O
Table	O
1	O
)	O
.	O

Perforating	O
the	O
right	O
side	O
of	O
the	O
peritoneum	O
on	O
D2	O
day	O
resulted	O
in	O
E2	O
concentration	O
increases	O
(	O
184	O
%	O
)	O
,	O
while	O
perforating	O
the	O
left	O
side	O
resulted	O
in	O
a	O
decrease	O
(	O
51	O
%	O
)	O
of	O
E2	O
serum	O
concentrations	O
.	O

Bilateral	O
perforation	O
had	O
no	O
apparent	O
effects	O
on	O
hormone	O
concentrations	O
.	O

Perforating	O
the	O
peritoneum	O
on	O
P	O
phase	O
(	O
left	O
,	O
right	O
or	O
bilateral	O
)	O
resulted	O
in	O
hormone	O
serum	O
concentration	O
decreases	O
(	O
Left	O
30	O
%	O
;	O
Right	O
50	O
%	O
;	O
Bilateral	O
41	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Effects	O
of	O
unilateral	O
or	O
bilateral	O
ovariectomy	O
When	O
surgery	O
was	O
performed	O
on	O
D1	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
between	O
rats	B
with	O
ULO	O
(	O
animals	O
with	O
intact	O
left	O
or	O
right	O
ovary	O
in	O
situ	O
)	O
or	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

Animals	O
with	O
the	O
left	O
intact	O
ovary	O
in	O
situ	O
showed	O
significantly	O
higher	O
E2	O
serum	O
concentrations	O
than	O
animals	O
with	O
the	O
right	O
intact	O
ovary	O
in	O
situ	O
(	O
61.5	O
±	O
9.4	O
vs.	O
17.3	O
±	O
4.3	O
,	O
p	O
<	O
0.05	O
Student	O
's	O
t	O
test	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
animals	O
with	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
performed	O
on	O
D2	O
had	O
lower	O
E2	O
serum	O
concentrations	O
(	O
55	O
%	O
)	O
.	O

Such	O
differences	O
were	O
not	O
observed	O
in	O
rats	B
with	O
left	O
ULO	O
(	O
Figure	O
1	O
)	O
.	O

As	O
in	O
rats	B
treated	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
in	O
animals	O
treated	O
on	O
D2	O
with	O
the	O
left	O
ovary	O
in	O
situ	O
(	O
right	O
ULO	O
)	O
than	O
in	O
animals	O
with	O
the	O
right	O
ovary	O
in	O
situ	O
(	O
49.5	O
±	O
10.8	O
vs.	O
26.0	O
±	O
6.9	O
)	O
.	O

In	O
animals	O
treated	O
on	O
P	O
,	O
right	O
ULO	O
(	O
left	O
ovary	O
in	O
situ	O
)	O
resulted	O
in	O
higher	O
E2	O
(	O
180	O
%	O
)	O
serum	O
concentrations	O
than	O
in	O
animals	O
with	O
unilateral	O
peritoneum	O
perforation	O
.	O

ULO	O
performed	O
on	O
the	O
left	O
side	O
(	O
right	O
ovary	O
in	O
situ	O
)	O
,	O
resulted	O
in	O
significantly	O
lower	O
(	O
45	O
%	O
)	O
E2	O
serum	O
concentrations	O
compared	O
to	O
rats	B
with	O
a	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
(	O
Figure	O
1	O
)	O
.	O

As	O
observed	O
in	O
rats	B
treated	O
on	O
D1	O
or	O
D2	O
,	O
when	O
the	O
intact	O
left	O
ovary	O
remains	O
in	O
situ	O
,	O
estradiol	O
serum	O
concentrations	O
were	O
significantly	O
higher	O
than	O
in	O
animals	O
with	O
the	O
intact	O
right	O
ovary	O
in	O
situ	O
(	O
142.0	O
±	O
14.1	O
vs.	O
61.5	O
±	O
6.0	O
)	O
.	O

Compared	O
to	O
animals	O
with	O
a	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
bilateral	O
ovariectomy	O
resulted	O
in	O
significantly	O
lower	O
E2	O
serum	O
concentrations	O
,	O
regardless	O
of	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
surgery	O
performed	O
(	O
D1	O
74	O
%	O
;	O
D2	O
73	O
%	O
;	O
P	O
84	O
%	O
)	O
.	O

Results	O
are	O
summarized	O
in	O
Table	O
2	O
.	O

Effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
Injecting	O
ATR	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
decreases	O
(	O
84	O
%	O
and	O
67	O
%	O
,	O
respectively	O
)	O
,	O
and	O
had	O
no	O
apparent	O
effects	O
on	O
E2	O
serum	O
concentrations	O
when	O
injected	O
on	O
D2	O
(	O
Table	O
3	O
)	O
.	O

Figure	O
2	O
shows	O
that	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
depended	O
on	O
both	O
,	O
the	O
side	O
(	O
left	O
or	O
right	O
)	O
and	O
the	O
phase	O
of	O
the	O
estrous	O
when	O
surgery	O
was	O
performed	O
.	O

Injecting	O
ATR	O
on	O
D1	O
or	O
D2	O
resulted	O
in	O
a	O
significant	O
drop	O
in	O
E2	O
serum	O
concentrations	O
in	O
animals	O
with	O
sham	O
treatment	O
on	O
the	O
right	O
side	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
left	O
side	O
peritoneum	O
perforation	O
on	O
D1	O
or	O
P	O
resulted	O
in	O
a	O
drop	O
in	O
E2	O
serum	O
concentrations	O
(	O
52	O
%	O
;	O
47	O
%	O
,	O
respectively	O
)	O
,	O
while	O
the	O
same	O
treatment	O
performed	O
on	O
D2	O
resulted	O
in	O
a	O
significant	O
E2	O
concentrations	O
increase	O
(	O
157	O
%	O
)	O
.	O

Figure	O
3	O
shows	O
the	O
effects	O
of	O
blocking	O
the	O
cholinergic	O
system	O
of	O
rats	B
with	O
ULO	O
.	O

ATR	O
treatment	O
on	O
D1	O
or	O
P	O
stages	O
performed	O
on	O
rats	B
with	O
the	O
left	O
ovary	O
in	O
situ	O
resulted	O
in	O
a	O
significant	O
drop	O
of	O
E2	O
serum	O
concentrations	O
(	O
65	O
%	O
;	O
62	O
%	O
respectively	O
)	O
.	O

Such	O
effects	O
were	O
not	O
observed	O
in	O
rats	B
treated	O
on	O
D2	O
.	O

When	O
ATR	O
treatment	O
was	O
performed	O
on	O
rats	B
with	O
the	O
right	O
ovary	O
in	O
situ	O
on	O
D1	O
,	O
E2	O
serum	O
concentrations	O
were	O
lower	O
(	O
48	O
%	O
)	O
than	O
in	O
ULO	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increase	O
(	O
159	O
%	O
)	O
.	O

When	O
the	O
treatment	O
was	O
performed	O
on	O
P	O
,	O
no	O
significant	O
differences	O
in	O
E2	O
serum	O
concentrations	O
were	O
observed	O
.	O

Compared	O
to	O
bilateral	O
treatment	O
,	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
,	O
ATR	O
treatment	O
on	O
D1	O
resulted	O
in	O
significant	O
E2	O
serum	O
concentrations	O
decreases	O
,	O
90	O
%	O
in	O
bilateral	O
peritoneal	O
perforation	O
and	O
60	O
%	O
in	O
bilateral	O
ovariectomized	O
animals	O
.	O

Blocking	O
the	O
cholinergic	O
system	O
on	O
D2	O
,	O
to	O
rats	B
with	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
or	O
bilateral	O
ovariectomy	O
resulted	O
in	O
E2	O
serum	O
concentrations	O
increases	O
(	O
159	O
%	O
and	O
253	O
%	O
respectively	O
)	O
,	O
while	O
injecting	O
ATR	O
to	O
animals	O
treated	O
on	O
P	O
had	O
no	O
apparent	O
effects	O
(	O
Figure	O
4	O
)	O
.	O

Discussion	O
The	O
results	O
obtained	O
in	O
the	O
present	O
study	O
suggest	O
that	O
the	O
ability	O
to	O
compensate	O
the	O
secretion	O
of	O
E2	O
by	O
the	O
missing	O
ovary	O
is	O
different	O
between	O
the	O
right	O
and	O
left	O
ovaries	O
and	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

Similarly	O
,	O
our	O
results	O
suggest	O
that	O
the	O
cholinergic	O
system	O
participates	O
in	O
regulating	O
E2	O
secretion	O
by	O
the	O
ovary	O
,	O
and	O
that	O
such	O
participation	O
varies	O
depending	O
on	O
the	O
ovary	O
remaining	O
in	O
situ	O
and	O
the	O
stage	O
of	O
the	O
estrous	O
cycle	O
when	O
the	O
surgical	O
procedure	O
was	O
performed	O
.	O

Previously	O
,	O
we	O
suggested	O
the	O
existence	O
of	O
a	O
neural	O
pathway	O
arising	O
from	O
the	O
peritoneum	O
that	O
participates	O
in	O
regulating	O
E2	O
[	O
9	O
]	O
,	O
P4	O
[	O
10	O
]	O
and	O
testosterone	O
secretion	O
[	O
11	O
]	O
.	O

In	O
the	O
rat	B
,	O
the	O
sensory	O
information	O
arising	O
from	O
the	O
peritoneum	O
is	O
sent	O
to	O
the	O
nucleus	O
tractus	O
solitarius	O
and	O
stimulates	O
neurokinine	O
-	O
B	O
receptors	O
[	O
17	O
]	O
.	O

Since	O
perforating	O
the	O
peritoneum	O
unilaterally	O
on	O
each	O
day	O
of	O
the	O
estrous	O
cycle	O
changed	O
E2	O
serum	O
concentrations	O
,	O
we	O
think	O
that	O
each	O
side	O
of	O
the	O
peritoneum	O
sends	O
different	O
neural	O
information	O
through	O
the	O
superior	O
ovarian	O
nerve	O
(	O
SON	O
)	O
to	O
the	O
ovary	O
and	O
the	O
central	O
nervous	O
system	O
,	O
perhaps	O
reaching	O
nuclei	O
related	O
to	O
the	O
vagus	O
nerve	O
.	O

A	O
study	O
analyzing	O
the	O
distribution	O
of	O
sensory	O
neurons	O
innervating	O
the	O
peritoneum	O
showed	O
that	O
when	O
tracer	O
was	O
placed	O
on	O
the	O
area	O
where	O
the	O
peritoneum	O
covers	O
the	O
abdominal	O
wall	O
,	O
labeled	O
neurons	O
were	O
observed	O
only	O
in	O
the	O
ipsilateral	O
dorsal	O
root	O
ganglia	O
[	O
18	O
]	O
.	O

The	O
authors	O
suggest	O
that	O
most	O
of	O
the	O
parietal	O
peritoneum	O
receives	O
sensory	O
nerves	O
from	O
dorsal	O
root	O
ganglia	O
,	O
and	O
visceral	O
peritoneum	O
from	O
both	O
,	O
the	O
spinal	O
and	O
vagus	O
nerves	O
.	O

According	O
to	O
Stener	O
-	O
Victorin	O
et	O
al.	O
(	O
19	O
)	O
repeated	O
electro	O
-	O
acupunture	O
treatments	O
in	O
rats	B
with	O
polycystic	O
ovary	O
syndrome	O
(	O
PCO	O
)	O
,	O
induced	O
by	O
a	O
single	O
injection	O
of	O
estradiol	O
valerate	O
,	O
resulted	O
in	O
lower	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
concentrations	O
at	O
the	O
ovarian	O
level	O
than	O
in	O
non	O
-	O
electro	O
-	O
acupunture	O
treated	O
PCO	O
rats	B
.	O

In	O
our	O
experiments	O
,	O
perforating	O
the	O
peritoneum	O
affected	O
the	O
same	O
somatic	O
segments	O
employed	O
by	O
Stener	O
-	O
Victorin	O
et	O
.	O

al.	O
[	O
19	O
]	O
.	O

We	O
presume	O
that	O
peritoneum	O
surgery	O
resulted	O
in	O
an	O
increase	O
of	O
NGF	O
concentrations	O
at	O
the	O
ovarian	O
level	O
,	O
which	O
in	O
turn	O
induced	O
hyper	O
-	O
androgenism	O
,	O
as	O
observed	O
in	O
women	O
with	O
PCO	O
[	O
20	O
]	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
the	O
unilateral	O
perforation	O
of	O
the	O
peritoneum	O
results	O
in	O
a	O
significant	O
increase	O
in	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Because	O
E2	O
serum	O
concentrations	O
did	O
not	O
increase	O
after	O
left	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
we	O
suppose	O
that	O
the	O
neural	O
information	O
originating	O
from	O
the	O
peritoneum	O
inhibits	O
the	O
mechanisms	O
regulating	O
aromatase	O
activity	O
within	O
the	O
follicle	O
.	O

One	O
of	O
the	O
ovaries	O
'	O
sources	O
of	O
catecholamines	O
arrives	O
through	O
the	O
SON	O
.	O

In	O
the	O
ovary	O
,	O
the	O
SON	O
fibers	O
are	O
mainly	O
distributed	O
in	O
the	O
peri	O
-	O
follicular	O
theca	O
layer	O
,	O
and	O
in	O
close	O
relation	O
with	O
the	O
cells	O
of	O
the	O
theca	O
interna	O
[	O
21,22	O
]	O
.	O

Sectioning	O
the	O
SON	O
of	O
rats	B
in	O
P	O
results	O
in	O
a	O
sudden	O
drop	O
of	O
P4	O
and	O
E2	O
concentrations	O
in	O
the	O
ovarian	O
vein	O
effluent	O
[	O
23	O
]	O
,	O
while	O
the	O
same	O
procedure	O
on	O
estrus	O
did	O
not	O
modify	O
E2	O
concentrations	O
[	O
24	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
perforating	O
the	O
peritoneum	O
modifies	O
the	O
type	O
and/or	O
rate	O
of	O
information	O
arriving	O
to	O
the	O
ovary	O
via	O
the	O
SON	O
.	O

Another	O
possibility	O
is	O
that	O
perforating	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
results	O
in	O
an	O
increase	O
release	O
of	O
ovarian	O
gamma	O
amino	O
butyric	O
acid	O
(	O
GABA	O
)	O
,	O
and	O
a	O
subsequent	O
increase	O
of	O
E2	O
concentrations	O
.	O

According	O
to	O
Erdö	O
,	O
et	O
.	O

al.	O
[	O
25	O
]	O
and	O
Laszlo	O
,	O
et	O
.	O

al.	O
[	O
26	O
]	O
,	O
injecting	O
GABA	O
into	O
pseudo	O
-	O
pregnant	O
rats	B
increases	O
E2	O
concentration	O
in	O
the	O
blood	O
.	O

Present	O
results	O
indicate	O
that	O
injecting	O
ATR	O
,	O
before	O
unilateral	O
or	O
bilateral	O
perforation	O
of	O
the	O
peritoneum	O
,	O
to	O
rats	B
in	O
D1	O
or	O
P	O
,	O
results	O
in	O
lower	O
E2serum	O
concentrations	O
;	O
leading	O
us	O
to	O
think	O
that	O
some	O
of	O
the	O
neural	O
fibers	O
present	O
in	O
the	O
peritoneum	O
are	O
muscarinic	O
.	O

It	O
is	O
also	O
possible	O
that	O
blocking	O
the	O
cholinergic	O
innervation	O
,	O
by	O
ATR	O
treatment	O
,	O
results	O
in	O
lower	O
adrenaline	O
and	O
norepinephrine	O
release	O
by	O
the	O
adrenal	O
medulla	O
.	O

Our	O
results	O
,	O
and	O
those	O
of	O
others	O
,	O
suggest	O
that	O
stimulating	O
on	O
D2	O
the	O
sensory	O
receptors	O
located	O
on	O
the	O
left	O
side	O
of	O
the	O
peritoneum	O
triggers	O
an	O
E2	O
secretion	O
inhibitory	O
mechanism	O
,	O
that	O
the	O
sensory	O
pathway	O
arising	O
from	O
the	O
right	O
side	O
has	O
a	O
stimulatory	O
effect	O
,	O
and	O
that	O
both	O
are	O
mediated	O
by	O
the	O
cholinergic	O
muscarinic	O
system	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
injecting	O
ATR	O
to	O
rats	B
in	O
D2	O
results	O
in	O
increases	O
of	O
P4	O
serum	O
concentrations	O
originating	O
from	O
the	O
adrenals	O
[	O
8	O
]	O
,	O
without	O
having	O
apparent	O
effects	O
on	O
testosterone	O
serum	O
concentrations	O
[	O
11	O
]	O
.	O

Since	O
P4	O
and	O
androgens	O
are	O
precursors	O
in	O
the	O
synthesis	O
of	O
E2	O
,	O
we	O
presume	O
that	O
this	O
mechanism	O
may	O
explain	O
the	O
increase	O
in	O
E2	O
serum	O
concentrations	O
observed	O
in	O
rats	B
with	O
peritoneum	O
perforation	O
previously	O
injected	O
with	O
ATR	O
.	O

Another	O
possibility	O
explaining	O
the	O
differences	O
on	O
E2	O
secretion	O
regulation	O
during	O
the	O
estrous	O
cycle	O
is	O
that	O
the	O
effects	O
of	O
the	O
cholinergic	O
system	O
take	O
place	O
through	O
changes	O
at	O
the	O
celiac	O
ganglion	O
level	O
.	O

According	O
to	O
Aguado	O
and	O
Ojeda	O
[	O
23	O
]	O
,	O
acetylcholine	O
inhibits	O
P4	O
secretion	O
in	O
the	O
celiac	O
ganglion	O
-	O
SON	O
-	O
ovary	O
preparation	O
obtained	O
from	O
rats	B
in	O
D1	O
or	O
D2	O
,	O
while	O
the	O
preparation	O
obtained	O
from	O
rats	B
in	O
P	O
resulted	O
in	O
only	O
a	O
moderate	O
stimulation	O
.	O

Since	O
there	O
is	O
evidence	O
that	O
fibers	O
from	O
the	O
vagus	O
nerve	O
innervate	O
neurons	O
in	O
the	O
celiac	O
ganglion	O
[	O
27	O
]	O
,	O
we	O
presume	O
that	O
the	O
cholinergic	O
system	O
modulates	O
the	O
sympathetic	O
post	O
-	O
ganglionar	O
activity	O
and	O
the	O
secretory	O
ability	O
of	O
the	O
ovaries	O
through	O
the	O
SON	O
.	O

Conclusion	O
Based	O
on	O
the	O
differences	O
in	O
E2	O
serum	O
concentrations	O
in	O
rats	B
with	O
ULO	O
,	O
present	O
results	O
suggest	O
that	O
the	O
capacity	O
to	O
release	O
E2	O
by	O
the	O
left	O
and	O
right	O
ovaries	O
varies	O
during	O
the	O
estrous	O
cycle	O
.	O

We	O
presume	O
that	O
the	O
left	O
ovary	O
releases	O
more	O
E2	O
than	O
the	O
right	O
one	O
.	O

As	O
previously	O
proposed	O
,	O
another	O
possibility	O
is	O
that	O
neural	O
communication	O
between	O
the	O
ovaries	O
modulates	O
E2	O
secretion	O
.	O

Molecular	O
polymorphism	O
,	O
differentiation	O
and	O
introgression	O
in	O
the	O
period	O
gene	O
between	O
Lutzomyia	B
intermedia	I
and	O
Lutzomyia	B
whitmani	I
Abstract	O
Background	O
Lutzomyia	B
intermedia	I
and	O
Lutzomyia	B
whitmani	I
(	O
Diptera	O
:	O
Psychodidae	O
)	O
are	O
important	O
and	O
very	O
closely	O
related	O
vector	O
species	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
,	O
which	O
are	O
distinguishable	O
by	O
a	O
few	O
morphological	O
differences	O
.	O

There	O
is	O
evidence	O
of	O
mitochondrial	O
introgression	O
between	O
the	O
two	O
species	O
but	O
it	O
is	O
not	O
clear	O
whether	O
gene	O
flow	O
also	O
occurs	O
in	O
nuclear	O
genes	O
.	O

Results	O
We	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
clock	O
gene	O
period	O
(	O
per	O
)	O
of	O
these	O
two	O
species	O
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

AMOVA	O
and	O
Fst	O
estimates	O
showed	O
no	O
evidence	O
for	O
geographical	O
differentiation	O
within	O
species	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
values	O
were	O
highly	O
significant	O
for	O
both	O
analyses	O
between	O
species	O
.	O

The	O
two	O
species	O
show	O
no	O
fixed	O
differences	O
and	O
a	O
higher	O
number	O
of	O
shared	O
polymorphisms	O
compared	O
to	O
exclusive	O
mutations	O
.	O

In	O
addition	O
,	O
some	O
haplotypes	O
that	O
are	O
""""	O
typical	O
""""	O
of	O
one	O
species	O
were	O
found	O
in	O
some	O
individuals	O
of	O
the	O
other	O
species	O
suggesting	O
either	O
the	O
persistence	O
of	O
old	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

Two	O
tests	O
of	O
gene	O
flow	O
,	O
one	O
based	O
on	O
linkage	O
disequilibrium	O
and	O
a	O
MCMC	O
analysis	O
based	O
on	O
coalescence	O
,	O
suggest	O
that	O
the	O
two	O
species	O
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

Conclusion	O
Introgression	O
might	O
be	O
occurring	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
period	O
,	O
a	O
gene	O
controlling	O
behavioral	O
rhythms	O
in	O
Drosophila	O
.	O

This	O
result	O
raises	O
the	O
question	O
of	O
whether	O
similar	O
phenomena	O
are	O
occurring	O
at	O
other	O
loci	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

Background	O

The	O
Phlebotominae	O
sand	O
flies	O
Lutzomyia	B
intermedia	I
Lutz	O
&	O
Neiva	O
1912	O
and	O
Lutzomyia	B
whitmani	I
Antunes	O
&	O
Coutinho	O
1912	O
are	O
vectors	O
of	O
cutaneous	O
leishmaniasis	O
in	O
Brazil	O
.	O

These	O
are	O
closely	O
related	O
species	O
that	O
can	O
be	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
[	O
1	O
]	O
and	O
both	O
show	O
high	O
anthropophily	O
and	O
reported	O
natural	O
infections	O
with	O
Leishmania	O
in	O
different	O
regions	O
of	O
Brazil	O
[	O
2	O
]	O
.	O

Despite	O
their	O
importance	O
as	O
vectors	O
,	O
only	O
a	O
handful	O
of	O
studies	O
have	O
been	O
carried	O
out	O
in	O
these	O
two	O
species	O
using	O
molecular	O
techniques	O
[	O
3	O
-	O
6	O
]	O
.	O

One	O
of	O
the	O
most	O
important	O
findings	O
from	O
an	O
epidemiological	O
perspective	O
is	O
the	O
evidence	O
obtained	O
for	O
introgression	O
between	O
the	O
two	O
species	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
.	O

This	O
was	O
particularly	O
interesting	O
because	O
apparently	O
,	O
only	O
lineages	O
of	O
L.	B
whitmani	I
sympatric	O
with	O
L.	B
intermedia	I
have	O
been	O
involved	O
in	O
cutaneous	O
leishmaniasis	O
transmission	O
in	O
the	O
peridomestic	O
environment	O
[	O
4	O
]	O
,	O
which	O
suggests	O
that	O
genes	O
controlling	O
aspects	O
of	O
vectorial	O
capacity	O
could	O
be	O
passing	O
from	O
one	O
species	O
to	O
the	O
other	O
.	O

In	O
fact	O
,	O
mitochondrial	O
introgression	O
has	O
been	O
reported	O
in	O
other	O
sand	O
fly	O
species	O
[	O
7,8	O
]	O
suggesting	O
that	O
might	O
be	O
a	O
common	O
phenomenon	O
in	O
these	O
insect	O
vectors	O
.	O

However	O
,	O
because	O
mitochondrial	O
genes	O
can	O
introgress	O
relatively	O
easily	O
between	O
closely	O
related	O
species	O
[	O
9	O
]	O
,	O
it	O
becomes	O
important	O
to	O
examine	O
whether	O
introgression	O
can	O
occur	O
with	O
nuclear	O
genes	O
.	O

The	O
Drosophila	O
period	O
(	O
per	O
)	O
gene	O
homologue	O
was	O
isolated	O
in	O
sand	O
flies	O
by	O
Peixoto	O
et	O
al.	O
[	O
10	O
]	O
.	O

This	O
circadian	O
clock	O
gene	O
was	O
originally	O
identified	O
using	O
mutagenesis	O
by	O
Konopka	O
and	O
Benzer	O
[	O
11	O
]	O
,	O
but	O
is	O
also	O
known	O
to	O
control	O
the	O
differences	O
in	O
the	O
""""	O
lovesong	O
""""	O
rhythms	O
between	O
D.	B
melanogaster	I
and	O
D.	B
simulans	I
[	O
12	O
]	O
,	O
that	O
are	O
important	O
to	O
the	O
sexual	O
isolation	O
between	O
these	O
two	O
species	O
[	O
13	O
-	O
15	O
]	O
.	O

In	O
addition	O
,	O
per	O
was	O
implicated	O
in	O
the	O
control	O
of	O
species	O
-	O
specific	O
circadian	O
mating	O
rhythms	O
in	O
Drosophila	O
and	O
Bractocera	O
,	O
which	O
might	O
also	O
constitute	O
a	O
reproductive	O
isolation	O
mechanism	O
[	O
16	O
-	O
18	O
]	O
.	O

Thus	O
per	O
may	O
possibly	O
represent	O
an	O
example	O
of	O
a	O
Drosophila	O
speciation	O
gene	O
[	O
19	O
]	O
,	O
and	O
in	O
fact	O
it	O
has	O
been	O
used	O
as	O
a	O
molecular	O
marker	O
in	O
a	O
number	O
of	O
speciation	O
and	O
evolutionary	O
studies	O
,	O
not	O
only	O
in	O
Drosophila	O
(	O
reviewed	O
in	O
[	O
20	O
]	O
)	O
but	O
also	O
in	O
other	O
insects	O
(	O
e.g.	O
[	O
21	O
]	O
)	O
including	O
sand	O
flies	O
[	O
22	O
-	O
24	O
]	O
.	O

Because	O
per	O
controls	O
the	O
circadian	O
clock	O
in	O
different	O
insects	O
[	O
25	O
]	O
,	O
it	O
is	O
almost	O
certainly	O
involved	O
in	O
the	O
rhythms	O
of	O
activity	O
and	O
biting	O
of	O
sand	O
flies	O
[	O
26	O
]	O
,	O
which	O
are	O
very	O
important	O
to	O
leishmaniasis	O
transmission	O
.	O

In	O
addition	O
,	O
per	O
might	O
be	O
involved	O
in	O
reproductive	O
isolation	O
in	O
sand	O
flies	O
,	O
via	O
mating	O
rhythms	O
,	O
or	O
via	O
their	O
""""	O
lovesongs	O
""""	O
[	O
2,27	O
]	O
.	O

per	O
is	O
thus	O
a	O
particularly	O
interesting	O
marker	O
,	O
among	O
the	O
few	O
available	O
,	O
for	O
an	O
introgression	O
analysis	O
in	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

Evidence	O
for	O
introgression	O
in	O
per	O
might	O
suggest	O
that	O
gene	O
flow	O
between	O
these	O
two	O
vector	O
species	O
is	O
occurring	O
at	O
other	O
genes	O
controlling	O
important	O
aspects	O
of	O
behavior	O
and	O
vectorial	O
capacity	O
.	O

It	O
might	O
also	O
suggest	O
that	O
per	O
does	O
not	O
have	O
a	O
strong	O
role	O
in	O
their	O
reproductive	O
isolation	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
analyzed	O
the	O
molecular	O
variation	O
within	O
the	O
per	O
gene	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
five	O
different	O
localities	O
in	O
Eastern	O
Brazil	O
.	O

Results	O
Polymorphism	O
and	O
divergence	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
A	O
total	O
of	O
68	O
sequences	O
from	O
L.	B
intermedia	I
and	O
53	O
from	O
L.	B
whitmani	I
homologue	O
to	O
a	O
fragment	O
of	O
the	O
period	O
gene	O
were	O
analyzed	O
from	O
populations	O
of	O
five	O
localities	O
in	O
Eastern	O
Brazil	O
(	O
Fig	O
1	O
)	O
.	O

The	O
alignment	O
of	O
72	O
variable	O
sites	O
is	O
shown	O
in	O
Fig	O
2	O
.	O

Although	O
most	O
of	O
the	O
changes	O
are	O
either	O
synonymous	O
or	O
occur	O
within	O
the	O
58	O
bp	O
intron	O
,	O
non	O
-	O
synonymous	O
substitutions	O
are	O
observed	O
causing	O
9	O
amino	O
acid	O
differences	O
among	O
the	O
sequences	O
(	O
Fig	O
2	O
)	O
.	O

Table	O
1	O
shows	O
the	O
number	O
of	O
sequences	O
of	O
each	O
population	O
of	O
the	O
two	O
species	O
,	O
the	O
number	O
of	O
polymorphic	O
sites	O
(	O
S	O
)	O
and	O
the	O
estimates	O
of	O
molecular	O
polymorphism	O
θ	O
(	O
based	O
on	O
the	O
total	O
number	O
of	O
mutations	O
)	O
and	O
π	O
.	O

Table	O
1	O
also	O
shows	O
the	O
Tajima	O
's	O
[	O
28	O
]	O
and	O
Fu	O
&	O
Li	O
's	O
[	O
29	O
]	O
statistics	O
.	O

Within	O
each	O
species	O
,	O
all	O
populations	O
present	O
similar	O
levels	O
of	O
polymorphism	O
with	O
the	O
exception	O
of	O
L.	B
whitmani	I
from	O
Ilhéus	O
,	O
which	O
seems	O
to	O
be	O
less	O
polymorphic	O
than	O
the	O
others	O
.	O

This	O
population	O
was	O
also	O
the	O
only	O
one	O
presenting	O
a	O
significant	O
value	O
in	O
the	O
Fu	O
&	O
Li	O
test	O
but	O
only	O
at	O
the	O
5	O
%	O
level	O
.	O

Finally	O
,	O
the	O
last	O
column	O
of	O
Table	O
1	O
presents	O
the	O
recombination	O
estimator	O
γ	O
[	O
30	O
]	O
indicating	O
that	O
both	O
species	O
show	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
.	O

To	O
investigate	O
the	O
level	O
of	O
intra	O
and	O
interspecific	O
differences	O
,	O
initially	O
an	O
AMOVA	O
was	O
carried	O
out	O
as	O
shown	O
in	O
Table	O
2	O
.	O

The	O
results	O
show	O
a	O
non	O
-	O
significant	O
within	O
species	O
and	O
a	O
significant	O
between	O
species	O
molecular	O
variation	O
at	O
the	O
per	O
locus	O
.	O

Table	O
3	O
shows	O
a	O
more	O
detailed	O
analysis	O
of	O
the	O
intraspecific	O
differentiation	O
among	O
populations	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

None	O
of	O
the	O
pairwise	O
and	O
overall	O
fixation	O
indexes	O
(	O
Fst	O
)	O
are	O
significant	O
in	O
the	O
case	O
of	O
L.	B
intermedia	I
and	O
only	O
one	O
(	O
Posse	O
×	O
Ilhéus	O
)	O
has	O
a	O
borderline	O
significant	O
value	O
in	O
L.	B
whitmani	I
.	O

The	O
results	O
therefore	O
show	O
that	O
no	O
significant	O
geographical	O
heterogeneity	O
was	O
detected	O
among	O
the	O
populations	O
of	O
the	O
two	O
species	O
.	O

The	O
estimated	O
number	O
of	O
migrants	O
per	O
generation	O
,	O
based	O
on	O
the	O
overall	O
Fst	O
values	O
,	O
is	O
20.683	O
for	O
L.	B
intermedia	I
and	O
23.125	O
for	O
L.	B
whitmani	I
.	O

Table	O
4	O
shows	O
measures	O
for	O
DNA	O
divergence	O
between	O
species	O
(	O
Dxy	O
and	O
Da	O
)	O
,	O
as	O
well	O
as	O
the	O
Fst	O
and	O
Nm	O
values	O
considering	O
each	O
species	O
as	O
a	O
unique	O
population	O
.	O

Dxy	O
is	O
the	O
average	O
number	O
of	O
nucleotide	O
substitutions	O
per	O
site	O
between	O
alleles	O
from	O
two	O
different	O
populations	O
and	O
Da	O
is	O
the	O
number	O
of	O
net	O
nucleotide	O
substitutions	O
between	O
two	O
populations	O
.	O

Table	O
4	O
also	O
shows	O
the	O
number	O
of	O
polymorphisms	O
exclusive	O
for	O
each	O
species	O
(	O
Sint	O
and	O
Swhit	O
)	O
,	O
the	O
number	O
of	O
shared	O
polymorphisms	O
(	O
Ss	O
)	O
and	O
the	O
number	O
of	O
fixed	O
differences	O
(	O
Sf	O
)	O
between	O
species	O
.	O

As	O
one	O
can	O
note	O
,	O
there	O
is	O
a	O
high	O
number	O
of	O
shared	O
polymorphisms	O
between	O
species	O
,	O
and	O
no	O
fixed	O
differences	O
between	O
them	O
suggesting	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
.	O

In	O
fact	O
,	O
there	O
is	O
one	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
(	O
IPO13	O
,	O
WPO10	O
and	O
WPO19	O
)	O
and	O
three	O
L.	B
whitmani	I
sequences	O
(	O
WAC02	O
,	O
WPO13	O
and	O
WPO14	O
)	O
which	O
show	O
only	O
one	O
nucleotide	O
difference	O
to	O
""""	O
typical	O
""""	O
L.	B
intermedia	I
haplotypes	O
(	O
see	O
also	O
below	O
)	O
.	O

Genealogy	O
of	O
period	O
sequences	O
A	O
phylogenetic	O
analysis	O
of	O
the	O
period	O
gene	O
sequences	O
from	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
was	O
carried	O
out	O
with	O
the	O
Minimum	O
Evolution	O
method	O
using	O
the	O
Kimura	O
2-parameter	O
distance	O
(	O
Fig	O
3	O
)	O
.	O

A	O
sequence	O
from	O
L.	B
umbratilis	I
,	O
a	O
related	O
species	O
from	O
the	O
same	O
subgenus	O
Nyssomyia	O
,	O
was	O
used	O
as	O
outgroup	O
[	O
24	O
]	O
.	O

The	O
tree	O
shows	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
as	O
non	O
-	O
monophyletic	O
.	O

However	O
,	O
despite	O
the	O
low	O
bootstrap	O
values	O
,	O
which	O
are	O
below	O
50	O
%	O
in	O
most	O
cases	O
,	O
there	O
is	O
a	O
large	O
group	O
that	O
contains	O
most	O
L.	B
intermedia	I
sequences	O
and	O
a	O
second	O
large	O
group	O
with	O
most	O
L.	B
whitmani	I
sequences	O
.	O

A	O
few	O
other	O
sequences	O
are	O
clustered	O
outside	O
these	O
two	O
main	O
groups	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
there	O
are	O
three	O
L.	B
whitmani	I
alleles	O
(	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
inside	O
L.	B
intermedia	I
main	O
group	O
,	O
as	O
well	O
as	O
one	O
L.	B
intermedia	I
allele	O
(	O
ICP16	O
)	O
inside	O
the	O
L.	B
whitmani	I
main	O
group	O
.	O

In	O
addition	O
,	O
a	O
second	O
L.	B
intermedia	I
allele	O
(	O
IPO13	O
)	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
as	O
mentioned	O
above	O
.	O

Again	O
,	O
the	O
results	O
suggest	O
either	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
or	O
the	O
occurrence	O
of	O
introgression	O
between	O
the	O
two	O
species	O
.	O

Very	O
similar	O
results	O
were	O
obtained	O
using	O
the	O
maximum	O
likelihood	O
algorithm	O
as	O
implemented	O
in	O
PAUP	O
4.0b10	O
software	O
[	O
31	O
]	O
(	O
data	O
not	O
shown	O
)	O
.	O

As	O
mentioned	O
before	O
,	O
there	O
is	O
evidence	O
of	O
intragenic	O
recombination	O
in	O
the	O
per	O
gene	O
fragment	O
of	O
both	O
species	O
(	O
see	O
Table	O
1	O
)	O
and	O
for	O
that	O
reason	O
the	O
bifurcating	O
tree	O
shown	O
in	O
Fig	O
3	O
has	O
to	O
be	O
viewed	O
with	O
caution	O
,	O
as	O
different	O
regions	O
of	O
the	O
gene	O
might	O
have	O
different	O
phylogenetic	O
histories	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
constructed	O
Minimum	O
Evolution	O
trees	O
with	O
the	O
two	O
most	O
polymorphic	O
non	O
-	O
recombining	O
blocks	O
of	O
the	O
per	O
gene	O
fragment	O
identified	O
using	O
the	O
Hudson	O
and	O
Kaplan	O
[	O
33	O
]	O
method	O
available	O
in	O
the	O
DNAsp	O
4.1	O
program	O
[	O
34	O
]	O
.	O

We	O
did	O
not	O
observed	O
major	O
changes	O
in	O
the	O
genealogy	O
of	O
the	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
per	O
sequences	O
,	O
especially	O
regarding	O
the	O
five	O
haplotypes	O
(	O
ICP16	O
,	O
IPO13	O
,	O
WAC2	O
,	O
WPO13	O
and	O
WPO14	O
)	O
that	O
clearly	O
cluster	O
with	O
sequences	O
of	O
the	O
other	O
species	O
(	O
data	O
not	O
shown	O
)	O
.	O

Finally	O
,	O
a	O
haplotype	O
network	O
was	O
estimated	O
from	O
per	O
sequences	O
using	O
statistical	O
parsimony	O
,	O
as	O
described	O
by	O
Templeton	O
et	O
al.	O
[	O
35	O
]	O
and	O
implemented	O
in	O
the	O
TCS1.21	O
software	O
[	O
36	O
]	O
(	O
Fig	O
4	O
)	O
.	O

A	O
small	O
number	O
of	O
ambiguities	O
were	O
resolved	O
as	O
suggested	O
by	O
Crandall	O
and	O
Templeton	O
[	O
37	O
]	O
.	O

The	O
haplotype	O
network	O
shows	O
connections	O
between	O
sequences	O
from	O
each	O
species	O
,	O
separating	O
most	O
of	O
the	O
sequences	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
in	O
two	O
groups	O
.	O

No	O
intraspecific	O
geographical	O
structuring	O
was	O
found	O
.	O

Once	O
again	O
,	O
some	O
of	O
the	O
L.	B
whitmani	I
sequences	O
(	O
WAC2	O
,	O
WAC10	O
,	O
WPO13	O
and	O
WPO14	O
)	O
appear	O
more	O
closely	O
related	O
to	O
L.	B
intermedia	I
haplotypes	O
.	O

In	O
addition	O
,	O
one	O
L.	B
intermedia	I
allele	O
(	O
ICP16	O
)	O
is	O
connected	O
by	O
a	O
small	O
number	O
of	O
mutations	O
to	O
some	O
of	O
the	O
main	O
L.	B
whitmani	I
haplotypes	O
and	O
IPO13	O
is	O
a	O
shared	O
haplotype	O
between	O
the	O
two	O
species	O
.	O

These	O
results	O
confirm	O
the	O
same	O
putative	O
introgressed	O
sequences	O
indicated	O
by	O
the	O
phylogenetic	O
reconstructions	O
.	O

LD	O
test	O
of	O
introgression	O
We	O
tested	O
the	O
hypothesis	O
of	O
gene	O
flow	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
using	O
a	O
method	O
based	O
on	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
developed	O
by	O
Machado	O
et	O
al.	O
[	O
38	O
]	O
.	O

In	O
this	O
test	O
,	O
x	O
is	O
the	O
difference	O
between	O
the	O
average	O
LD	O
found	O
among	O
all	O
pairs	O
of	O
shared	O
polymorphisms	O
(	O
DSS	O
)	O
between	O
the	O
two	O
species	O
and	O
the	O
average	O
LD	O
among	O
all	O
pairs	O
of	O
sites	O
for	O
which	O
one	O
member	O
is	O
a	O
shared	O
polymorphism	O
and	O
the	O
other	O
is	O
an	O
exclusive	O
polymorphism	O
(	O
DSX	O
)	O
.	O

In	O
case	O
of	O
gene	O
flow	O
x	O
should	O
tend	O
to	O
be	O
positive	O
[	O
see	O
[	O
38	O
]	O
for	O
more	O
details	O
]	O
.	O

Because	O
of	O
limitations	O
on	O
the	O
total	O
number	O
of	O
sequences	O
that	O
could	O
be	O
handled	O
by	O
the	O
WH	O
program	O
we	O
could	O
not	O
perform	O
the	O
simulations	O
with	O
all	O
sequences	O
.	O

Therefore	O
,	O
we	O
carried	O
out	O
the	O
LD	O
test	O
of	O
introgression	O
between	O
each	O
pair	O
of	O
sympatric	O
populations	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
from	O
the	O
localities	O
of	O
Posse	O
,	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
.	O

The	O
input	O
files	O
were	O
prepared	O
using	O
the	O
values	O
of	O
recombination	O
and	O
linkage	O
disequilibrium	O
calculated	O
by	O
the	O
SITES	O
program	O
[	O
30	O
]	O
for	O
each	O
population	O
(	O
data	O
not	O
shown	O
)	O
.	O

Although	O
no	O
significant	O
values	O
were	O
found	O
for	O
the	O
smaller	O
samples	O
of	O
Afonso	O
Claudio	O
and	O
Corte	O
de	O
Pedra	O
,	O
the	O
results	O
(	O
Table	O
5	O
)	O
present	O
evidence	O
for	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
both	O
directions	O
(	O
from	O
L.	B
intermedia	I
to	O
L.	B
whitmani	I
and	O
vice	O
-	O
versa	O
)	O
in	O
the	O
locality	O
of	O
Posse	O
.	O

Isolation	O
with	O
Migration	O
model	O
To	O
further	O
examine	O
the	O
gene	O
flow	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
we	O
used	O
the	O
IM	O
software	O
[	O
39	O
]	O
.	O

The	O
Isolation	O
with	O
Migration	O
model	O
has	O
six	O
demographic	O
parameters	O
that	O
include	O
two	O
migration	O
rates	O
,	O
one	O
for	O
each	O
population	O
.	O

The	O
IM	O
software	O
estimates	O
the	O
posterior	O
probability	O
for	O
each	O
of	O
the	O
model	O
parameters	O
,	O
fitting	O
the	O
Isolation	O
with	O
Migration	O
model	O
to	O
the	O
data	O
.	O

One	O
of	O
the	O
assumptions	O
of	O
this	O
model	O
is	O
that	O
the	O
loci	O
studied	O
do	O
not	O
have	O
internal	O
recombination	O
.	O

Therefore	O
,	O
we	O
identified	O
four	O
different	O
non	O
-	O
recombining	O
blocks	O
of	O
our	O
fragment	O
of	O
per	O
,	O
which	O
were	O
then	O
treated	O
as	O
different	O
loci	O
in	O
the	O
analysis	O
.	O

The	O
four	O
-	O
gametes	O
test	O
[	O
33	O
]	O
implemented	O
in	O
DnaSP4.1	O
was	O
used	O
for	O
the	O
identification	O
of	O
possible	O
recombination	O
events	O
.	O

Since	O
the	O
program	O
estimates	O
parameters	O
for	O
a	O
pair	O
of	O
closely	O
related	O
populations	O
or	O
species	O
,	O
all	O
sequences	O
of	O
each	O
species	O
were	O
used	O
in	O
the	O
analysis	O
as	O
a	O
single	O
population	O
.	O

We	O
performed	O
MCMC	O
runs	O
using	O
the	O
IM	O
software	O
with	O
different	O
seed	O
numbers	O
,	O
in	O
order	O
to	O
guarantee	O
convergence	O
of	O
the	O
sample	O
.	O

Maximum	O
likelihood	O
estimates	O
of	O
migration	O
parameters	O
revealed	O
a	O
non	O
-	O
zero	O
value	O
for	O
both	O
species	O
,	O
m1	O
=	O
1.398	O
and	O
m2	O
=	O
1.014	O
(	O
m1	O
–	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
;	O
m2	O
–	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
)	O
.	O

Fig	O
5	O
shows	O
the	O
posterior	O
distributions	O
for	O
migration	O
rates	O
and	O
reveals	O
a	O
null	O
probability	O
for	O
the	O
absence	O
of	O
migration	O
from	O
L.	B
whitmani	I
towards	O
L.	B
intermedia	I
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
migration	O
in	O
the	O
opposite	O
direction	O
is	O
not	O
included	O
in	O
the	O
95	O
%	O
confidence	O
interval	O
(	O
values	O
range	O
from	O
0.222	O
to	O
8.898	O
)	O
,	O
thus	O
supporting	O
the	O
presence	O
of	O
migration	O
in	O
both	O
directions	O
.	O

The	O
conversion	O
of	O
the	O
migration	O
rate	O
estimate	O
to	O
population	O
migration	O
rate	O
per	O
generation	O
(	O
m1	O
and	O
m2	O
)	O
is	O
not	O
accurate	O
when	O
the	O
population	O
size	O
is	O
based	O
on	O
a	O
single	O
locus	O
.	O

However	O
,	O
the	O
average	O
of	O
the	O
migrant	O
number	O
per	O
generation	O
for	O
both	O
species	O
was	O
very	O
close	O
to	O
the	O
Nm	O
estimate	O
based	O
on	O
Fst	O
values	O
(	O
Nm	O
~0.49	O
in	O
Table	O
4	O
,	O
m1	O
~0.52	O
and	O
m2	O
~0.34	O
)	O
.	O

Discussion	O
There	O
is	O
some	O
evidence	O
that	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
might	O
represent	O
sibling	O
-	O
species	O
complexes	O
in	O
Brazil	O
.	O

Lutzomyia	B
neivai	I
Pinto	O
1926	O
,	O
a	O
sibling	O
of	O
L.	B
intermedia	I
is	O
found	O
in	O
parts	O
of	O
Southern	O
and	O
Western	O
Brazil	O
and	O
some	O
other	O
countries	O
of	O
South	O
America	O
[	O
40	O
]	O
.	O

The	O
present	O
study	O
did	O
not	O
include	O
populations	O
of	O
this	O
species	O
.	O

In	O
the	O
case	O
of	O
L.	B
whitmani	I
,	O
mitochondrial	O
data	O
[	O
3,6	O
]	O
indicates	O
three	O
main	O
lineages	O
in	O
Brazil	O
:	O
an	O
Amazonian	O
group	O
,	O
a	O
North	O
-	O
South	O
group	O
and	O
a	O
Northeast	O
group	O
.	O

We	O
did	O
not	O
find	O
strong	O
evidence	O
of	O
a	O
geographical	O
differentiation	O
in	O
the	O
period	O
gene	O
among	O
populations	O
of	O
L.	B
whitmani	I
although	O
one	O
of	O
the	O
pairwise	O
Fst	O
comparisons	O
(	O
Posse	O
×	O
Ilhéus	O
)	O
was	O
significant	O
at	O
the	O
5	O
%	O
level	O
.	O

When	O
we	O
compare	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
,	O
we	O
find	O
a	O
highly	O
significant	O
Fst	O
value	O
(	O
0.3373	O
)	O
,	O
which	O
is	O
however	O
smaller	O
than	O
that	O
observed	O
for	O
the	O
period	O
gene	O
between	O
sympatric	O
siblings	O
of	O
Lutzomyia	B
longipalpis	I
(	O
Fst	O
=	O
0.3952	O
)	O
[	O
23	O
]	O
,	O
a	O
complex	O
of	O
cryptic	O
species	O
that	O
are	O
vectors	O
of	O
American	O
visceral	O
leishmaniasis	O
.	O

Therefore	O
,	O
despite	O
the	O
presence	O
of	O
diagnostic	O
morphological	O
characters	O
to	O
identify	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
[	O
1	O
]	O
the	O
level	O
of	O
molecular	O
divergence	O
in	O
period	O
is	O
not	O
as	O
high	O
as	O
the	O
cryptic	O
L.	B
longipalpis	I
siblings	O
.	O

Even	O
though	O
it	O
is	O
hard	O
to	O
distinguish	O
introgression	O
from	O
the	O
persistence	O
of	O
ancestral	O
polymorphisms	O
,	O
a	O
test	O
of	O
gene	O
flow	O
based	O
on	O
the	O
signature	O
introgression	O
leaves	O
on	O
the	O
patterns	O
of	O
linkage	O
disequilibrium	O
[	O
38	O
]	O
as	O
well	O
as	O
simulations	O
that	O
fit	O
the	O
""""	O
Isolation	O
with	O
Migration	O
""""	O
model	O
to	O
the	O
data	O
suggest	O
that	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
might	O
be	O
exchanging	O
alleles	O
at	O
the	O
per	O
locus	O
.	O

This	O
is	O
further	O
supported	O
by	O
the	O
presence	O
of	O
shared	O
haplotypes	O
between	O
the	O
two	O
species	O
in	O
Posse	O
and	O
very	O
similar	O
sequences	O
in	O
all	O
sympatric	O
populations	O
.	O

There	O
is	O
mounting	O
evidence	O
that	O
introgression	O
plays	O
a	O
major	O
role	O
in	O
the	O
evolution	O
of	O
closely	O
related	O
insect	O
vector	O
species	O
.	O

Introgression	O
among	O
vectors	O
may	O
have	O
important	O
epidemiological	O
consequences	O
.	O

Gene	O
flow	O
in	O
loci	O
that	O
affect	O
vectorial	O
capacity	O
,	O
such	O
as	O
those	O
controlling	O
host	O
preference	O
and	O
susceptibility	O
to	O
parasite	O
infection	O
,	O
can	O
change	O
the	O
transmission	O
patterns	O
and	O
consequently	O
make	O
the	O
disease	O
control	O
a	O
harder	O
task	O
.	O

Introgression	O
of	O
genes	O
that	O
control	O
adaptation	O
to	O
particular	O
types	O
of	O
environment	O
can	O
also	O
have	O
a	O
major	O
impact	O
on	O
the	O
spread	O
of	O
vector	O
-	O
borne	O
diseases	O
as	O
was	O
proposed	O
for	O
the	O
major	O
African	O
malaria	O
vector	O
Anopheles	B
gambiae	I
[	O
41	O
]	O
.	O

The	O
same	O
can	O
be	O
said	O
about	O
genes	O
controlling	O
insecticide	O
resistance	O
.	O

For	O
example	O
,	O
Weill	O
et	O
al.	O
[	O
42	O
]	O
found	O
a	O
kdr	O
mutation	O
responsible	O
for	O
pyrethroid	O
resistance	O
in	O
the	O
Mopti	O
form	O
of	O
Anopheles	B
gambiae	I
,	O
a	O
normally	O
susceptible	O
taxon	O
of	O
this	O
species	O
complex	O
.	O

Sequence	O
analysis	O
reveals	O
that	O
this	O
resistant	O
allele	O
probably	O
originates	O
through	O
introgression	O
from	O
the	O
Savanna	O
form	O
.	O

Although	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
are	O
closely	O
related	O
and	O
only	O
distinguished	O
by	O
a	O
few	O
morphological	O
differences	O
,	O
they	O
do	O
show	O
differentiation	O
in	O
some	O
other	O
important	O
traits	O
.	O

For	O
example	O
,	O
in	O
Posse	O
,	O
one	O
of	O
the	O
localities	O
we	O
studied	O
,	O
the	O
two	O
species	O
show	O
differences	O
in	O
abundance	O
during	O
the	O
year	O
.	O

L.	B
intermedia	I
is	O
more	O
abundant	O
in	O
the	O
summer	O
while	O
L.	B
whitmani	I
is	O
more	O
frequent	O
in	O
the	O
winter	O
months	O
[	O
2	O
]	O
.	O

They	O
also	O
show	O
differences	O
in	O
microhabitat	O
preferences	O
,	O
L.	B
intermedia	I
being	O
more	O
common	O
in	O
the	O
peridomestic	O
area	O
while	O
L.	B
whitmani	I
is	O
found	O
mainly	O
in	O
the	O
surrounding	O
forest	O
[	O
2	O
]	O
.	O

In	O
addition	O
,	O
the	O
two	O
species	O
show	O
marked	O
differences	O
in	O
their	O
tendencies	O
to	O
bite	O
humans	B
in	O
the	O
early	O
morning	O
,	O
with	O
L.	B
whitmani	I
showing	O
higher	O
feeding	O
rates	O
than	O
L.	B
intermedia	I
[	O
26	O
]	O
.	O

Therefore	O
,	O
despite	O
the	O
evidence	O
of	O
introgression	O
in	O
the	O
period	O
gene	O
in	O
this	O
locality	O
,	O
there	O
are	O
important	O
ecological	O
and	O
behavioral	O
differences	O
between	O
the	O
two	O
species	O
in	O
Posse	O
suggesting	O
that	O
gene	O
flow	O
is	O
probably	O
rather	O
limited	O
in	O
loci	O
controlling	O
these	O
traits	O
.	O

Hence	O
,	O
it	O
is	O
yet	O
not	O
clear	O
whether	O
introgression	O
has	O
played	O
an	O
important	O
role	O
in	O
the	O
evolution	O
of	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

Further	O
work	O
with	O
other	O
genes	O
might	O
help	O
clarify	O
the	O
issue	O
.	O

Conclusion	O
Evidence	O
for	O
introgression	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
obtained	O
using	O
mitochondrial	O
DNA	O
[	O
4	O
]	O
seems	O
to	O
be	O
corroborated	O
by	O
our	O
data	O
on	O
the	O
period	O
gene	O
,	O
a	O
nuclear	O
marker	O
.	O

Nevertheless	O
,	O
considering	O
that	O
period	O
is	O
potentially	O
involved	O
in	O
reproductive	O
isolation	O
and	O
might	O
be	O
,	O
therefore	O
,	O
less	O
prone	O
to	O
introgression	O
than	O
the	O
""""	O
average	O
""""	O
gene	O
[	O
43	O
]	O
,	O
it	O
is	O
possible	O
that	O
much	O
higher	O
levels	O
of	O
gene	O
flow	O
between	O
the	O
two	O
species	O
occur	O
at	O
other	O
genes	O
.	O

It	O
might	O
,	O
on	O
the	O
other	O
hand	O
,	O
suggest	O
that	O
this	O
behavioral	O
gene	O
,	O
or	O
at	O
least	O
the	O
fragment	O
we	O
analyzed	O
,	O
did	O
not	O
play	O
a	O
role	O
in	O
speciation	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
.	O

In	O
fact	O
the	O
same	O
has	O
been	O
suggested	O
for	O
some	O
Drosophila	O
species	O
[	O
44	O
]	O
despite	O
per	O
's	O
role	O
controlling	O
lovesong	O
and	O
mating	O
rhythm	O
differences	O
between	O
D.	B
melanogaster	I
and	O
D.	B
simulans	I
[	O
13	O
-	O
16	O
]	O
.	O

Although	O
the	O
evidence	O
for	O
introgression	O
in	O
the	O
per	O
gene	O
between	O
L.	B
intermedia	I
and	O
L.	B
whitmani	I
is	O
not	O
overwhelming	O
,	O
it	O
does	O
indicate	O
the	O
need	O
to	O
extend	O
this	O
analysis	O
to	O
other	O
loci	O
in	O
the	O
future	O
.	O

We	O
are	O
currently	O
isolating	O
new	O
molecular	O
markers	O
in	O
the	O
two	O
species	O
to	O
carry	O
out	O
a	O
multi	O
-	O
locus	O
approach	O
[	O
39	O
]	O
that	O
might	O
help	O
determining	O
how	O
much	O
variation	O
in	O
gene	O
flow	O
and	O
differentiation	O
there	O
is	O
across	O
the	O
genome	O
of	O
these	O
two	O
very	O
important	O
leishmaniasis	O
vectors	O
.	O

Methods	O
Sand	O
fly	O
samples	O
Sand	O
fly	O
samples	O
used	O
in	O
this	O
work	O
were	O
all	O
the	O
F1	O
generation	O
from	O
wild	O
collected	O
females	O
from	O
the	O
Brazilian	O
localities	O
of	O
Posse	O
(	O
Petrópolis	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
°	O
30	O
'S	O
43	O
°	O
10'W	O
)	O
,	O
Jacarepaguá	O
(	O
Rio	O
de	O
Janeiro	O
,	O
Rio	O
de	O
Janeiro	O
State	O
,	O
22	O
°	O
55	O
'S	O
43	O
°	O
21'W	O
)	O
,	O
Afonso	O
Claudio	O
(	O
Espírito	O
Santo	O
State	O
,	O
20	O
°	O
04	O
'S	O
41	O
°	O
07'W	O
)	O
,	O
Corte	O
de	O
Pedra	O
(	O
Presidente	O
Tancredo	O
Neves	O
,	O
Bahia	O
State	O
,	O
13	O
°	O
27	O
'S	O
39	O
°	O
25'W	O
)	O
and	O
Ilhéus	O
(	O
Bahia	O
State	O
,	O
14	O
°	O
50	O
'S	O
39	O
°	O
06'W	O
)	O
.	O

L.	B
intermedia	I
and	O
L.	B
whitmani	I
were	O
identified	O
according	O
to	O
Young	O
and	O
Duncan	O
[	O
1	O
]	O
.	O

The	O
progeny	O
of	O
each	O
wild	O
caught	O
female	O
was	O
raised	O
separately	O
according	O
to	O
Souza	O
et	O
al.	O
[	O
45	O
]	O
and	O
only	O
one	O
F1	O
male	O
of	O
each	O
female	O
was	O
used	O
for	O
the	O
molecular	O
analysis	O
,	O
which	O
included	O
68	O
individuals	O
of	O
L.	B
intermedia	I
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
18	O
from	O
Posse	O
,	O
20	O
from	O
Corte	O
de	O
Pedra	O
and	O
18	O
from	O
Jacarepaguá	O
)	O
and	O
51	O
individuals	O
of	O
L.	B
whitmani	I
(	O
12	O
from	O
Afonso	O
Claudio	O
,	O
17	O
from	O
Posse	O
,	O
3	O
from	O
Corte	O
de	O
Pedra	O
and	O
19	O
from	O
Ilhéus	O
)	O
.	O

Note	O
that	O
,	O
although	O
the	O
distribution	O
of	O
the	O
two	O
species	O
shows	O
considerable	O
overlap	O
in	O
Eastern	O
Brazil	O
,	O
in	O
many	O
localities	O
only	O
one	O
species	O
is	O
found	O
or	O
is	O
far	O
more	O
abundant	O
than	O
the	O
other	O
.	O

There	O
are	O
also	O
seasonal	O
and	O
microhabitat	O
differences	O
in	O
abundance	O
between	O
them	O
in	O
areas	O
of	O
sympatry	O
[	O
2	O
]	O
.	O

DNA	O
methods	O
Genomic	O
DNA	O
was	O
prepared	O
according	O
to	O
Jowett	O
[	O
46	O
]	O
with	O
slight	O
modifications	O
and	O
the	O
PCR	O
was	O
carried	O
out	O
for	O
30	O
cycles	O
at	O
95	O
°	O
C	O
for	O
30	O
sec	O
,	O
60	O
°	O
C	O
for	O
30	O
sec	O
and	O
72	O
°	O
C	O
for	O
30	O
sec	O
,	O
using	O
Abgene	O
,	O
Amersham	O
Biosciences	O
or	O
Biotools	O
reagents	O
according	O
to	O
manufacturers	O
directions	O
.	O

The	O
per	O
primer	O
sequences	O
are	O
:	O
5llper2	O
:	O
5'-AGCATCCTTTTGTAGCAAAC-3	O
'	O
(	O
forward	O
)	O
and	O
3llper2	O
:	O
5'-TCAGATGAACTCTTGCTGTC-3	O
'	O
(	O
reverse	O
)	O
.	O

These	O
primers	O
amplify	O
a	O
486	O
bp	O
fragment	O
of	O
the	O
sand	O
fly	O
per	O
gene	O
homologue	O
that	O
includes	O
part	O
of	O
the	O
PAS	O
/	O
CLD	O
domain	O
,	O
an	O
intron	O
(	O
58	O
bp	O
)	O
and	O
the	O
beginning	O
of	O
the	O
perS	O
domain	O
[	O
24	O
]	O
.	O

The	O
amplified	O
fragments	O
were	O
cloned	O
using	O
the	O
pMOSBlue	O
blunt	O
ended	O
cloning	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
and	O
plasmid	O
DNA	O
preparation	O
was	O
carried	O
out	O
using	O
the	O
""""	O
Flexiprep	O
""""	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Cloned	O
PCR	O
fragments	O
were	O
sequenced	O
at	O
Fundação	O
Oswaldo	O
Cruz	O
and	O
at	O
University	O
of	O
Leicester	O
using	O
ABI	O
377	O
sequencers	O
.	O

With	O
the	O
exception	O
of	O
two	O
L.	B
whitmani	I
individuals	O
from	O
Corte	O
de	O
Pedra	O
(	O
see	O
below	O
)	O
,	O
only	O
one	O
sequence	O
of	O
each	O
sand	O
fly	O
(	O
representing	O
one	O
of	O
the	O
two	O
possible	O
alleles	O
)	O
was	O
used	O
in	O
the	O
analysis	O
but	O
an	O
average	O
of	O
three	O
sequences	O
per	O
individual	O
were	O
obtained	O
in	O
order	O
to	O
check	O
possible	O
PCR	O
induced	O
mutations	O
.	O

In	O
addition	O
,	O
PCR	O
fragments	O
were	O
also	O
sequenced	O
directly	O
in	O
some	O
cases	O
for	O
the	O
same	O
reason	O
.	O

In	O
the	O
case	O
of	O
the	O
two	O
L.	B
whitmani	I
mentioned	O
above	O
6	O
and	O
9	O
clones	O
were	O
sequenced	O
respectively	O
from	O
specimens	O
WCP01	O
and	O
WCP03	O
to	O
determine	O
both	O
alleles	O
simply	O
to	O
increase	O
the	O
size	O
of	O
this	O
small	O
sample	O
.	O

Negative	O
controls	O
were	O
performed	O
for	O
all	O
amplification	O
reactions	O
.	O

In	O
addition	O
,	O
PCR	O
,	O
cloning	O
and	O
sequencing	O
were	O
repeated	O
for	O
two	O
individuals	O
to	O
confirm	O
putative	O
introgressed	O
sequences	O
and	O
to	O
exclude	O
the	O
possibility	O
that	O
they	O
were	O
the	O
result	O
of	O
PCR	O
contamination	O
.	O

Finally	O
,	O
for	O
at	O
least	O
two	O
individuals	O
with	O
putative	O
introgressed	O
sequences	O
,	O
we	O
could	O
define	O
the	O
other	O
allele	O
from	O
additional	O
clones	O
(	O
not	O
included	O
in	O
the	O
analysis	O
)	O
,	O
which	O
showed	O
to	O
be	O
typical	O
of	O
the	O
species	O
,	O
indicating	O
no	O
identification	O
problems	O
.	O

The	O
sequences	O
were	O
submitted	O
to	O
GenBank	O
(	O
accession	O
numbers	O
AY927062	O
to	O
AY927182	O
)	O
.	O

Sequence	O
analyses	O
The	O
preliminary	O
sequence	O
editing	O
was	O
carried	O
out	O
using	O
the	O
Wisconsin	O
Package	O
Version	O
9.1	O
,	O
Genetics	O
Computer	O
Group	O
(	O
GCG	O
)	O
,	O
Madison	O
,	O
and	O
ClustalX	O
[	O
47	O
]	O
was	O
used	O
to	O
perform	O
the	O
multiple	O
alignment	O
.	O

Analyses	O
of	O
population	O
polymorphisms	O
and	O
differentiation	O
between	O
populations	O
were	O
carried	O
out	O
using	O
DNAsp4.1	O
[	O
34	O
]	O
and	O
ProSeq	O
[	O
48	O
]	O
softwares	O
,	O
while	O
Arlequin	O
v.	O
2.0	O
[	O
49	O
]	O
was	O
used	O
for	O
an	O
analysis	O
of	O
molecular	O
variance	O
(	O
AMOVA	O
)	O
between	O
populations	O
.	O

The	O
Minimum	O
Evolution	O
phylogenetic	O
tree	O
was	O
constructed	O
using	O
MEGA	O
3.1	O
software	O
[	O
50	O
]	O
.	O

The	O
haplotype	O
network	O
was	O
estimated	O
using	O
TCS1.21	O
[	O
36	O
]	O
.	O

Recombination	O
and	O
linkage	O
disequilibrium	O
analyses	O
were	O
performed	O
using	O
the	O
DNAsp4.1	O
and	O
SITES	O
program	O
[	O
30	O
]	O
.	O

Linkage	O
disequilibrium	O
simulations	O
were	O
carried	O
out	O
by	O
the	O
WH	O
program	O
[	O
51,52	O
]	O
and	O
Markov	O
Chain	O
Monte	O
Carlo	O
(	O
MCMC	O
)	O
simulations	O
of	O
the	O
isolation	O
with	O
migration	O
model	O
were	O
performed	O
using	O
the	O
algorithm	O
implemented	O
in	O
the	O
IM	O
program	O
[	O
39	O
]	O
.	O

Authors	O
'	O
contributions	O
CJM	O
generate	O
and	O
analyzed	O
all	O
the	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

NAS	O
and	O
CAC	O
collected	O
and	O
maintained	O
sand	O
fly	O
samples	O
.	O

CPK	O
helped	O
to	O
write	O
the	O
manuscript	O
and	O
supervised	O
CJM	O
during	O
her	O
stay	O
in	O
Leicester	O
.	O

AAP	O
is	O
the	O
principal	O
investigator	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
helped	O
to	O
write	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

A	O
disease	O
-	O
specific	O
measure	O
of	O
health	O
-	O
related	O
quality	O
of	O
life	O
for	O
use	O
in	O
adults	O
with	O
immune	O
thrombocytopenic	O
purpura	O
:	O
Its	O
development	O
and	O
validation	O
Abstract	O
Background	O
No	O
validated	O
disease	O
-	O
specific	O
measures	O
are	O
available	O
to	O
assess	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
in	O
adult	O
subjects	O
with	O
immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
develop	O
and	O
validate	O
the	O
ITP	O
-	O
Patient	O
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
for	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O
Information	O
from	O
literature	O
reviews	O
,	O
focus	O
groups	O
with	O
subjects	O
,	O
and	O
clinicians	O
were	O
used	O
to	O
develop	O
50	O
ITP	O
-	O
PAQ	O
items	O
.	O

Factor	O
analyses	O
were	O
conducted	O
to	O
develop	O
the	O
scale	O
structure	O
and	O
reduce	O
the	O
number	O
of	O
items	O
.	O

The	O
final	O
44-item	O
ITP	O
-	O
PAQ	O
,	O
which	O
includes	O
ten	O
scales	O
[	O
Symptoms	O
(	O
S	O
)	O
,	O
Bother	O
-	O
Physical	O
Health	O
(	O
B	O
)	O
,	O
Fatigue	O
/	O
Sleep	O
(	O
FT	O
)	O
,	O
Activity	O
(	O
A	O
)	O
,	O
Fear	O
(	O
FR	O
)	O
,	O
Psychological	O
Health	O
(	O
PH	O
)	O
,	O
Work	O
(	O
W	O
)	O
,	O
Social	O
Activity	O
(	O
SA	O
)	O
,	O
Women	O
's	O
Reproductive	O
Health	O
(	O
RH	O
)	O
,	O
and	O
Overall	O
(	O
QoL	O
)	O
]	O
,	O
was	O
self	O
-	O
administered	O
to	O
adult	O
ITP	O
subjects	O
at	O
baseline	O
and	O
7–10	O
days	O
later	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
internal	O
consistency	O
reliability	O
,	O
construct	O
and	O
known	O
groups	O
validity	O
of	O
the	O
final	O
ITP	O
-	O
PAQ	O
were	O
evaluated	O
.	O

Results	O
Seventy	O
-	O
three	O
subjects	O
with	O
ITP	O
completed	O
the	O
questionnaire	O
twice	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
as	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
,	O
ranged	O
from	O
0.52–0.90	O
.	O

Internal	O
consistency	O
reliability	O
was	O
demonstrated	O
with	O
Cronbach	O
's	O
alpha	O
for	O
all	O
scales	O
above	O
the	O
acceptable	O
level	O
of	O
0.70	O
(	O
range	O
:	O
0.71–0.92	O
)	O
,	O
except	O
for	O
RH	O
(	O
0.66	O
)	O
.	O

Construct	O
validity	O
,	O
assessed	O
by	O
correlating	O
ITP	O
-	O
PAQ	O
scales	O
with	O
established	O
measures	O
(	O
Short	O
Form-36	O
v.1	O
,	O
SF-36	O
and	O
Center	O
for	O
Epidemiologic	O
Studies	O
Depression	O
Scale	O
,	O
CES	O
-	O
D	O
)	O
,	O
was	O
demonstrated	O
through	O
moderate	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
SA	O
and	O
SF-36	O
Social	O
Function	O
scales	O
(	O
r	O
=	O
0.67	O
)	O
,	O
and	O
between	O
ITP	O
-	O
PAQ	O
PH	O
and	O
SF-36	O
Mental	O
Health	O
Scales	O
(	O
r	O
=	O
0.63	O
)	O
.	O

Moderate	O
to	O
strong	O
inter	O
-	O
scale	O
correlations	O
were	O
reported	O
between	O
ITP	O
-	O
PAQ	O
scales	O
and	O
the	O
CES	O
-	O
D	O
,	O
except	O
for	O
the	O
RH	O
scale	O
.	O

Known	O
groups	O
validity	O
was	O
evaluated	O
by	O
comparing	O
mean	O
scores	O
for	O
groups	O
that	O
differed	O
clinically	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.01	O
)	O
were	O
observed	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
[	O
S	O
,	O
FT	O
,	O
B	O
,	O
A	O
,	O
PH	O
,	O
and	O
QoL	O
,	O
perceived	O
effectiveness	O
of	O
ITP	O
treatment	O
[	O
S	O
]	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
[	O
PH	O
]	O
.	O

Conclusion	O
Results	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Further	O
work	O
should	O
be	O
conducted	O
to	O
assess	O
the	O
responsiveness	O
and	O
to	O
estimate	O
the	O
minimal	O
clinical	O
important	O
difference	O
of	O
the	O
ITP	O
-	O
PAQ	O
to	O
more	O
fully	O
understand	O
the	O
impact	O
of	O
ITP	O
and	O
its	O
treatments	O
on	O
HRQoL.	O
Background	O
Immune	O
thrombocytopenic	O
purpura	O
(	O
ITP	O
)	O
is	O
a	O
disorder	O
characterized	O
by	O
autoimmune	O
-	O
mediated	O
platelet	O
destruction	O
and	O
suboptimal	O
platelet	O
production	O
[	O
1	O
-	O
3	O
]	O
that	O
results	O
in	O
a	O
decrease	O
in	O
the	O
number	O
of	O
circulating	O
platelets	O
and	O
increases	O
the	O
risk	O
of	O
bleeding	O
events	O
.	O

The	O
estimated	O
prevalence	O
rate	O
for	O
ITP	O
in	O
the	O
United	O
States	O
is	O
9.5	O
/	O
100,000	O
[	O
4	O
]	O
.	O

Adult	O
women	O
are	O
disproportionately	O
affected	O
by	O
the	O
disorder	O
,	O
with	O
a	O
female	O
to	O
male	O
ratio	O
of	O
nearly	O
two	O
to	O
one	O
[	O
5	O
]	O
.	O

The	O
disorder	O
rarely	O
remits	O
spontaneously	O
in	O
adult	O
subjects	O
[	O
1	O
]	O
.	O

The	O
mortality	O
rate	O
is	O
relatively	O
low	O
(	O
<	O
1	O
%	O
)	O
[	O
6	O
]	O
in	O
adults	O
less	O
than	O
65	O
years	O
of	O
age	O
.	O

Morbidity	O
increases	O
above	O
age	O
65	O
,	O
primarily	O
as	O
a	O
result	O
of	O
an	O
increase	O
in	O
age	O
-	O
related	O
major	O
bleeding	O
events	O
[	O
7	O
]	O
.	O

Initial	O
therapy	O
for	O
ITP	O
consists	O
of	O
some	O
combination	O
of	O
glucocorticoids	O
,	O
intravenous	O
immune	O
globulin	O
(	O
IVIg	O
)	O
or	O
anti	O
-	O
D	O
[	O
8	O
]	O
.	O

Splenectomy	O
is	O
often	O
considered	O
if	O
these	O
therapies	O
fail	O
.	O

Approximately	O
two	O
-	O
thirds	O
of	O
patients	O
treated	O
with	O
splenectomy	O
achieve	O
a	O
sustained	O
remission	O
[	O
1,5,9	O
]	O
.	O

Patients	O
who	O
fail	O
splenectomy	O
are	O
treated	O
with	O
a	O
wide	O
variety	O
of	O
agents	O
including	O
corticosteroids	O
,	O
danazol	O
,	O
and	O
chemotherapeutic	O
agents	O
.	O

Morbidity	O
and	O
mortality	O
in	O
these	O
refractory	O
patients	O
are	O
substantial	O
[	O
1,6,8	O
]	O
.	O

Patient	O
-	O
reported	O
outcomes	O
(	O
PRO	O
)	O
,	O
including	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
measures	O
,	O
are	O
critical	O
components	O
for	O
evaluating	O
and	O
understanding	O
treatment	O
effects	O
from	O
the	O
subject	O
's	O
perspective	O
.	O

The	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
indicates	O
that	O
PRO	O
measures	O
are	O
important	O
to	O
assess	O
because	O
they	O
may	O
:	O
1	O
)	O
detect	O
treatment	O
effects	O
known	O
only	O
to	O
the	O
subject	O
;	O
2	O
)	O
understand	O
the	O
subject	O
's	O
perspective	O
regarding	O
treatment	O
effect	O
;	O
or	O
3	O
)	O
provide	O
information	O
not	O
included	O
in	O
a	O
clinician	O
's	O
subject	O
notes	O
[	O
10	O
]	O
.	O

Furthermore	O
,	O
the	O
Committee	O
for	O
Medicinal	O
Products	O
for	O
Human	B
Use	O
of	O
the	O
European	O
Medicines	O
Agency	O
defines	O
HRQoL	O
as	O
""""	O
the	O
subject	O
's	O
subjective	O
perception	O
of	O
the	O
impact	O
of	O
his	O
disease	O
and	O
its	O
treatment	O
(	O
s	O
)	O
on	O
his	O
daily	O
life	O
,	O
physical	O
,	O
psychological	O
and	O
social	O
functioning	O
and	O
well	O
-	O
being	O
""""	O
[	O
11	O
]	O
.	O

Currently	O
,	O
limited	O
data	O
are	O
available	O
on	O
the	O
assessment	O
of	O
the	O
impact	O
of	O
symptoms	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Symptoms	O
of	O
ITP	O
,	O
such	O
as	O
spontaneous	O
bruising	O
,	O
menorrhagia	O
,	O
mucosal	O
bleeding	O
and	O
prolonged	O
bleeding	O
with	O
injury	O
,	O
may	O
significantly	O
affect	O
HRQoL	O
in	O
ITP	O
subjects	O
[	O
12	O
]	O
.	O

Treatments	O
for	O
chronic	O
ITP	O
can	O
also	O
be	O
associated	O
with	O
substantial	O
side	O
effects	O
[	O
5,8	O
]	O
.	O

In	O
addition	O
,	O
subjects	O
who	O
are	O
resistant	O
to	O
current	O
therapies	O
are	O
likely	O
to	O
experience	O
an	O
even	O
greater	O
decrement	O
to	O
their	O
HRQoL	O
than	O
responders	O
to	O
treatment	O
.	O

Thus	O
,	O
restoring	O
and/or	O
maintaining	O
quality	O
of	O
life	O
should	O
be	O
an	O
important	O
goal	O
of	O
treatment	O
.	O

While	O
the	O
primary	O
markers	O
for	O
ITP	O
include	O
hematologic	O
measures	O
such	O
as	O
platelet	O
counts	O
,	O
clinical	O
measures	O
typically	O
do	O
not	O
assess	O
a	O
subject	O
's	O
functioning	O
and	O
well	O
-	O
being	O
.	O

Therefore	O
,	O
subjects	O
and	O
physicians	O
may	O
want	O
to	O
weigh	O
the	O
impact	O
of	O
ITP	O
therapies	O
on	O
HRQoL	O
endpoints	O
when	O
making	O
treatment	O
decisions	O
.	O

Previously	O
,	O
no	O
validated	O
disease	O
-	O
specific	O
measures	O
were	O
available	O
to	O
evaluate	O
quality	O
of	O
life	O
in	O
adult	O
ITP	O
subjects	O
;	O
however	O
,	O
two	O
disease	O
-	O
specific	O
HRQoL	O
questionnaires	O
have	O
been	O
developed	O
for	O
use	O
in	O
children	O
with	O
ITP	O
[	O
13,14	O
]	O
.	O

Thus	O
,	O
we	O
sought	O
to	O
develop	O
a	O
questionnaire	O
that	O
would	O
be	O
appropriate	O
to	O
assess	O
the	O
impact	O
of	O
ITP	O
symptoms	O
and	O
its	O
treatments	O
on	O
HRQoL	O
in	O
adult	O
subjects	O
.	O

The	O
objective	O
of	O
this	O
current	O
manuscript	O
is	O
to	O
describe	O
the	O
development	O
and	O
initial	O
validation	O
of	O
a	O
newly	O
developed	O
HRQoL	O
questionnaire	O
for	O
use	O
in	O
adult	O
subjects	O
with	O
ITP	O
.	O

Methods	O
Overview	O
A	O
newly	O
developed	O
questionnaire	O
,	O
which	O
assesses	O
issues	O
of	O
importance	O
to	O
ITP	O
subjects	O
,	O
was	O
developed	O
based	O
on	O
available	O
published	O
literature	O
,	O
existing	O
questionnaires	O
,	O
expert	O
clinical	O
opinion	O
,	O
and	O
input	O
from	O
subjects	O
with	O
ITP	O
.	O

Subjects	O
and	O
Procedures	O
To	O
develop	O
the	O
questionnaire	O
,	O
three	O
focus	O
groups	O
with	O
ITP	O
subjects	O
were	O
conducted	O
in	O
geographically	O
diverse	O
locations	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
New	O
York	O
,	O
NY	O
,	O
and	O
Oklahoma	O
City	O
,	O
OK	O
)	O
.	O

Each	O
of	O
the	O
three	O
sites	O
recruited	O
a	O
convenience	O
sample	O
of	O
five	O
to	O
eight	O
ITP	O
subjects	O
who	O
were	O
being	O
treated	O
on	O
an	O
outpatient	O
basis	O
.	O

To	O
be	O
eligible	O
,	O
subjects	O
were	O
required	O
to	O
have	O
active	O
disease	O
and	O
be	O
≥	O
18	O
years	O
of	O
age	O
.	O

Although	O
platelet	O
count	O
data	O
were	O
not	O
required	O
for	O
participation	O
in	O
the	O
focus	O
groups	O
,	O
clinicians	O
at	O
each	O
site	O
considered	O
the	O
subjects	O
to	O
have	O
active	O
disease	O
,	O
usually	O
an	O
indication	O
that	O
platelet	O
levels	O
have	O
dropped	O
below	O
120	O
×	O
109L	O
and	O
the	O
subject	O
requires	O
treatment	O
and/or	O
more	O
frequent	O
monitoring	O
.	O

In	O
total	O
,	O
23	O
ITP	O
subjects	O
participated	O
in	O
the	O
focus	O
groups	O
after	O
providing	O
their	O
informed	O
consent	O
.	O

To	O
validate	O
the	O
questionnaire	O
,	O
a	O
convenience	O
sample	O
of	O
subjects	O
was	O
recruited	O
from	O
the	O
same	O
three	O
clinical	O
sites	O
in	O
New	O
York	O
,	O
NY	O
,	O
Oklahoma	O
City	O
,	O
OK	O
,	O
and	O
La	O
Jolla	O
,	O
CA	O
.	O

Subjects	O
were	O
eligible	O
if	O
they	O
were	O
≥	O
18	O
years	O
of	O
age	O
,	O
had	O
active	O
disease	O
,	O
and	O
were	O
willing	O
to	O
complete	O
a	O
self	O
-	O
administered	O
questionnaire	O
at	O
two	O
time	O
points	O
.	O

Target	O
enrollment	O
was	O
roughly	O
72	O
subjects	O
(	O
24	O
subjects	O
from	O
each	O
site	O
)	O
.	O

The	O
study	O
protocol	O
was	O
approved	O
by	O
a	O
local	O
institutional	O
review	O
board	O
at	O
each	O
site	O
and	O
was	O
carried	O
out	O
in	O
accordance	O
with	O
Good	O
Clinical	O
Practice	O
and	O
International	O
Conference	O
on	O
Harmonization	O
guidelines	O
and	O
the	O
Declaration	O
of	O
Helsinki	O
.	O

Written	O
informed	O
consent	O
was	O
obtained	O
from	O
each	O
subject	O
prior	O
to	O
enrollment	O
.	O

Creation	O
of	O
Questionnaire	O
/	O
Item	O
Selection	O
A	O
trained	O
moderator	O
led	O
all	O
focus	O
groups	O
using	O
a	O
detailed	O
discussion	O
guide	O
.	O

Subjects	O
discussed	O
their	O
ITP	O
history	O
,	O
treatment	O
,	O
ITP	O
symptoms	O
,	O
and	O
the	O
impact	O
of	O
ITP	O
on	O
daily	O
activities	O
.	O

Each	O
focus	O
group	O
lasted	O
approximately	O
three	O
hours	O
,	O
and	O
subjects	O
were	O
provided	O
with	O
an	O
honorarium	O
for	O
their	O
time	O
.	O

Following	O
the	O
focus	O
group	O
session	O
,	O
all	O
subjects	O
completed	O
a	O
questionnaire	O
which	O
included	O
the	O
SF-36	O
v1	O
[	O
15	O
]	O
and	O
ITP	O
-	O
specific	O
questions	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
were	O
developed	O
based	O
on	O
clinical	O
input	O
[	O
12,16	O
-	O
18	O
]	O
.	O

The	O
ITP	O
-	O
specific	O
items	O
assessed	O
the	O
impact	O
of	O
ITP	O
on	O
the	O
subject	O
's	O
overall	O
quality	O
of	O
life	O
,	O
relationships	O
,	O
ability	O
to	O
sleep	O
,	O
menstruation	O
/	O
gynecological	O
history	O
,	O
and	O
sexual	O
activity	O
.	O

The	O
ITP	O
-	O
specific	O
questions	O
also	O
assessed	O
the	O
subject	O
's	O
response	O
to	O
ITP	O
treatments	O
and	O
any	O
side	O
effects	O
.	O

Transcripts	O
of	O
the	O
focus	O
groups	O
were	O
summarized	O
and	O
reviewed	O
by	O
the	O
study	O
team	O
.	O

The	O
initial	O
draft	O
of	O
the	O
ITP	O
Subject	O
Assessment	O
Questionnaire	O
(	O
ITP	O
-	O
PAQ	O
)	O
was	O
developed	O
after	O
reviewing	O
information	O
from	O
the	O
literature	O
searches	O
,	O
existing	O
questionnaires	O
,	O
expert	O
opinion	O
,	O
focus	O
group	O
transcripts	O
,	O
and	O
the	O
questionnaire	O
responses	O
from	O
the	O
focus	O
group	O
subjects	O
.	O

The	O
initial	O
ITP	O
-	O
PAQ	O
consisted	O
of	O
50	O
items	O
that	O
assesses	O
the	O
impact	O
of	O
ITP	O
in	O
the	O
areas	O
of	O
physical	O
health	O
,	O
mental	O
health	O
,	O
work	O
,	O
social	O
activity	O
,	O
reproductive	O
health	O
(	O
relevant	O
for	O
women	O
only	O
)	O
,	O
and	O
overall	O
quality	O
of	O
life	O
.	O

Factor	O
analyses	O
were	O
conducted	O
which	O
yielded	O
six	O
unique	O
domains	O
.	O

The	O
impact	O
of	O
ITP	O
on	O
physical	O
health	O
was	O
measured	O
by	O
four	O
scales	O
that	O
evaluated	O
ITP	O
-	O
related	O
symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
and	O
Activity	O
.	O

Its	O
impact	O
on	O
mental	O
health	O
was	O
measured	O
by	O
two	O
scales	O
that	O
evaluated	O
psychological	O
distress	O
and	O
fear	O
.	O

A	O
copy	O
of	O
the	O
questionnaire	O
can	O
be	O
obtained	O
by	O
contacting	O
Janet	O
L.	O
Nichol	O
and	O
sample	O
items	O
are	O
included	O
Table	O
2	O
.	O

Statistical	O
Analyses	O
A	O
validation	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
psychometric	O
properties	O
of	O
the	O
newly	O
developed	O
ITP	O
-	O
PAQ	O
questionnaire	O
so	O
that	O
it	O
could	O
be	O
used	O
to	O
measure	O
the	O
impact	O
of	O
ITP	O
in	O
adult	O
subjects	O
in	O
future	O
studies	O
.	O

Standard	O
psychometric	O
methods	O
were	O
used	O
to	O
evaluate	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
questionnaire	O
[	O
19,20	O
]	O
.	O

Eligible	O
subjects	O
completed	O
the	O
baseline	O
questionnaire	O
at	O
the	O
site	O
or	O
by	O
mail	O
after	O
providing	O
telephone	O
consent	O
.	O

An	O
informed	O
consent	O
form	O
and	O
baseline	O
questionnaire	O
was	O
mailed	O
to	O
those	O
subjects	O
who	O
gave	O
their	O
initial	O
consent	O
via	O
telephone	O
.	O

These	O
completed	O
documents	O
were	O
returned	O
by	O
mail	O
to	O
the	O
investigators	O
.	O

At	O
follow	O
up	O
,	O
each	O
subject	O
was	O
mailed	O
the	O
same	O
questionnaire	O
and	O
asked	O
to	O
complete	O
it	O
a	O
second	O
time	O
(	O
for	O
evaluating	O
test	O
-	O
retest	O
reliability	O
)	O
approximately	O
two	O
weeks	O
later	O
.	O

Additionally	O
,	O
subjects	O
completed	O
the	O
SF-36	O
and	O
the	O
CES	O
-	O
D	O
[	O
21	O
]	O
for	O
validation	O
purposes	O
at	O
both	O
assessments	O
.	O

Demographic	O
and	O
clinical	O
characteristics	O
were	O
also	O
solicited	O
in	O
order	O
to	O
more	O
fully	O
describe	O
the	O
study	O
population	O
.	O

Each	O
study	O
subject	O
received	O
an	O
honorarium	O
for	O
completing	O
the	O
questionnaires	O
.	O

Scale	O
creation	O
and	O
confirmatory	O
factor	O
analysis	O
Confirmatory	O
factor	O
analyses	O
were	O
conducted	O
to	O
test	O
the	O
hypothesized	O
structure	O
of	O
the	O
scales	O
.	O

Two	O
models	O
using	O
LISREL	O
version	O
8	O
were	O
tested	O
[	O
22	O
]	O
.	O

The	O
first	O
model	O
consisted	O
of	O
all	O
50	O
HRQoL	O
items	O
and	O
10	O
factors	O
,	O
whereas	O
the	O
second	O
model	O
consisted	O
of	O
a	O
subset	O
of	O
the	O
50-item	O
correlation	O
matrix	O
.	O

Only	O
women	O
respond	O
to	O
the	O
six	O
items	O
comprising	O
the	O
Reproductive	O
Health	O
scale	O
,	O
so	O
the	O
items	O
were	O
not	O
included	O
in	O
the	O
second	O
LISREL	O
model	O
to	O
avoid	O
estimation	O
biases	O
.	O

The	O
remaining	O
44	O
items	O
were	O
analyzed	O
.	O

Model	O
fit	O
was	O
evaluated	O
using	O
the	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
GFI	O
)	O
,	O
the	O
normed	O
fit	O
index	O
(	O
NFI	O
)	O
,	O
the	O
non	O
-	O
normed	O
fit	O
index	O
(	O
NNFI	O
)	O
,	O
the	O
comparative	O
fit	O
index	O
(	O
CIF	O
)	O
,	O
and	O
the	O
root	O
mean	O
square	O
error	O
of	O
approximation	O
(	O
RMSEA	O
)	O
.	O

For	O
the	O
confirmatory	O
models	O
,	O
index	O
values	O
greater	O
than	O
0.95	O
indicate	O
better	O
fit	O
,	O
and	O
RMSEA	O
values	O
less	O
than	O
0.05	O
are	O
considered	O
evidence	O
of	O
adequate	O
fit	O
[	O
23	O
]	O
.	O

Reliability	O
and	O
stability	O
Two	O
forms	O
of	O
reliability	O
were	O
assessed	O
:	O
test	O
-	O
retest	O
reliability	O
and	O
internal	O
consistency	O
reliability	O
.	O

Test	O
-	O
retest	O
reliability	O
,	O
a	O
measure	O
of	O
the	O
degree	O
to	O
which	O
the	O
questionnaire	O
yields	O
stable	O
scores	O
over	O
a	O
short	O
period	O
of	O
time	O
(	O
assuming	O
there	O
is	O
no	O
underlying	O
change	O
)	O
,	O
was	O
measured	O
by	O
the	O
intra	O
-	O
class	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
[	O
24,25	O
]	O
.	O

An	O
ICC	O
of	O
≥	O
0.70	O
was	O
considered	O
acceptable	O
[	O
26	O
]	O
.	O

Internal	O
consistency	O
reliability	O
,	O
the	O
extent	O
to	O
which	O
items	O
within	O
each	O
scale	O
correlate	O
with	O
each	O
other	O
to	O
form	O
a	O
multi	O
-	O
item	O
scale	O
,	O
was	O
assessed	O
using	O
Cronbach	O
's	O
alpha	O
[	O
25,27	O
]	O
.	O

Data	O
from	O
both	O
assessments	O
were	O
used	O
to	O
evaluate	O
internal	O
consistency	O
reliability	O
.	O

An	O
alpha	O
coefficient	O
of	O
≥	O
0.70	O
was	O
considered	O
acceptable	O
,	O
which	O
is	O
the	O
commonly	O
accepted	O
minimal	O
standard	O
for	O
reliability	O
coefficients	O
endorsed	O
by	O
the	O
Scientific	O
Advisory	O
Committee	O
of	O
the	O
Medical	O
Outcomes	O
Trust	O
[	O
26	O
]	O
.	O

Construct	O
Validity	O
Construct	O
validity	O
was	O
assessed	O
by	O
examining	O
the	O
inter	O
-	O
scale	O
correlations	O
between	O
the	O
ITP	O
-	O
PAQ	O
and	O
the	O
CES	O
-	O
D	O
and	O
the	O
ITP	O
-	O
PAQ	O
with	O
the	O
SF-36	O
and	O
by	O
examining	O
the	O
strength	O
of	O
the	O
within	O
ITP	O
-	O
PAQ	O
scale	O
correlations	O
[	O
25,28	O
]	O
.	O

For	O
both	O
inter	O
-	O
scale	O
and	O
intra	O
-	O
scale	O
correlations	O
,	O
we	O
made	O
a	O
priori	O
hypotheses	O
about	O
the	O
directionality	O
and	O
magnitude	O
of	O
the	O
correlation	O
and	O
observed	O
the	O
extent	O
to	O
which	O
hypothesized	O
relationships	O
held	O
.	O

For	O
example	O
,	O
we	O
hypothesized	O
that	O
the	O
scales	O
of	O
the	O
ITP	O
-	O
PAQ	O
would	O
be	O
negatively	O
correlated	O
with	O
the	O
CES	O
-	O
D	O
and	O
positively	O
correlated	O
with	O
those	O
of	O
the	O
SF-36	O
.	O

We	O
expected	O
the	O
Pearson	O
correlations	O
to	O
be	O
moderate	O
in	O
size	O
.	O

Known	O
Groups	O
Known	O
groups	O
validity	O
evaluates	O
the	O
ability	O
of	O
the	O
measure	O
to	O
discriminate	O
between	O
groups	O
known	O
to	O
be	O
clinically	O
different	O
[	O
28	O
]	O
.	O

We	O
only	O
collected	O
patient	O
-	O
reported	O
information	O
using	O
the	O
questionnaire	O
and	O
did	O
not	O
collect	O
clinical	O
information	O
such	O
as	O
platelet	O
counts	O
.	O

Therefore	O
,	O
the	O
following	O
four	O
criteria	O
were	O
identified	O
as	O
proxies	O
for	O
severity	O
:	O
•	O
Currently	O
on	O
treatment	O
•	O
Splenectomy	O
status	O
•	O
Subjects	O
'	O
self	O
-	O
perception	O
of	O
the	O
effectiveness	O
of	O
current	O
medication	O
•	O
Length	O
of	O
time	O
since	O
diagnosis	O

It	O
was	O
hypothesized	O
that	O
subjects	O
not	O
being	O
treated	O
,	O
who	O
did	O
not	O
have	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
more	O
effective	O
,	O
and	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
a	O
longer	O
time	O
would	O
be	O
healthier	O
and	O
therefore	O
report	O
higher	O
HRQoL	O
scores	O
.	O

In	O
contrast	O
,	O
subjects	O
on	O
any	O
treatment	O
,	O
who	O
had	O
received	O
a	O
splenectomy	O
,	O
who	O
perceived	O
their	O
medication	O
to	O
be	O
less	O
effective	O
,	O
and	O
who	O
were	O
diagnosed	O
more	O
recently	O
would	O
report	O
worse	O
HRQoL.	O
In	O
addition	O
,	O
subjects	O
were	O
also	O
categorized	O
by	O
gender	O
.	O

Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
for	O
each	O
of	O
the	O
analyses	O
:	O
female	O
vs.	O
male	O
,	O
intact	O
spleen	O
vs.	O
removed	O
spleen	O
,	O
currently	O
on	O
ITP	O
treatment	O
vs.	O
not	O
currently	O
on	O
ITP	O
treatment	O
,	O
subject	O
's	O
perception	O
of	O
the	O
effectiveness	O
of	O
their	O
current	O
ITP	O
medication	O
(	O
extremely	O
/	O
moderately	O
effective	O
vs.	O
not	O
at	O
all	O
effective	O
)	O
,	O
and	O
ITP	O
diagnosis	O
less	O
than	O
one	O
year	O
ago	O
vs.	O
ITP	O
diagnosis	O
more	O
than	O
one	O
year	O
ago	O
.	O

Results	O
Demographics	O
and	O
clinical	O
characteristics	O
Table	O
1	O
describes	O
the	O
demographic	O
and	O
clinical	O
characteristics	O
of	O
the	O
73	O
subjects	O
included	O
in	O
the	O
validation	O
analyses	O
.	O

The	O
majority	O
were	O
female	O
(	O
77	O
%	O
)	O
and	O
Caucasian	O
(	O
84	O
%	O
)	O
.	O

The	O
mean	O
age	O
was	O
45	O
years	O
(	O
SD	O
=	O
15.7	O
)	O
,	O
and	O
most	O
of	O
the	O
subjects	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
five	O
years	O
(	O
57	O
%	O
)	O
.	O

Fifty	O
-	O
two	O
percent	O
of	O
the	O
subjects	O
reported	O
that	O
they	O
were	O
currently	O
taking	O
medications	O
for	O
their	O
ITP	O
.	O

Furthermore	O
,	O
58	O
%	O
indicated	O
that	O
they	O
had	O
a	O
splenectomy	O
.	O

Among	O
the	O
42	O
subjects	O
who	O
had	O
a	O
splenectomy	O
,	O
55	O
%	O
reported	O
that	O
the	O
removal	O
of	O
their	O
spleen	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

With	O
one	O
exception	O
,	O
the	O
remaining	O
subjects	O
did	O
not	O
provide	O
a	O
response	O
.	O

Confirmatory	O
factor	O
analysis	O
The	O
first	O
confirmatory	O
factor	O
analysis	O
of	O
the	O
50-item	O
and	O
ten	O
factors	O
model	O
converged	O
in	O
28	O
iterations	O
.	O

However	O
,	O
neither	O
the	O
inter	O
-	O
item	O
correlation	O
matrix	O
nor	O
the	O
inter	O
-	O
factor	O
correlation	O
matrix	O
was	O
positive	O
-	O
definite	O
,	O
which	O
suggests	O
that	O
the	O
proposed	O
model	O
is	O
wrong	O
for	O
the	O
data	O
or	O
the	O
data	O
are	O
inadequate	O
for	O
the	O
model	O
[	O
22	O
]	O
.	O

The	O
chi	O
-	O
square	O
value	O
of	O
the	O
model	O
was	O
316.64	O
with	O
1129	O
degrees	O
of	O
freedom	O
(	O
p	O
=	O
1.0	O
)	O
,	O
which	O
does	O
not	O
support	O
the	O
hypothesized	O
scale	O
structure	O
of	O
the	O
initial	O
ITP	O
-	O
PAQ	O
.	O

The	O
confirmatory	O
analysis	O
of	O
this	O
LISREL	O
model	O
indicate	O
that	O
computing	O
domain	O
scores	O
for	O
the	O
Physical	O
Health	O
and	O
Mental	O
Health	O
domains	O
is	O
not	O
appropriate	O
for	O
the	O
ITP	O
-	O
PAQ	O
.	O

The	O
second	O
LISREL	O
model	O
was	O
analyzed	O
to	O
confirm	O
the	O
scale	O
structure	O
,	O
excluding	O
the	O
Reproductive	O
Health	O
scale	O
.	O

For	O
this	O
model	O
,	O
126	O
parameters	O
were	O
estimated	O
:	O
46	O
factor	O
loadings	O
,	O
44	O
error	O
terms	O
,	O
and	O
36	O
inter	O
-	O
factor	O
correlations	O
.	O

The	O
model	O
converged	O
in	O
39	O
iterations	O
,	O
with	O
a	O
chi	O
-	O
square	O
value	O
of	O
1043.10	O
with	O
864	O
degrees	O
of	O
freedom	O
(	O
p	O
<	O
0.01	O
)	O
.	O

The	O
Goodness	O
of	O
Fit	O
Index	O
(	O
GFI	O
)	O
,	O
Normed	O
Fit	O
Index	O
(	O
NFI	O
)	O
,	O
Non	O
-	O
normed	O
Fit	O
Index	O
(	O
NNFI	O
)	O
,	O
and	O
Comparative	O
Fit	O
Index	O
(	O
CFI	O
)	O
was	O
0.60	O
,	O
0.63	O
,	O
0.91	O
,	O
and	O
0.92	O
,	O
respectively	O
,	O
and	O
the	O
RMSEA	O
was	O
0.05	O
[	O
90	O
%	O
CI	O
,	O
0.04–0.065	O
]	O
.	O

Furthermore	O
,	O
the	O
inter	O
-	O
factor	O
correlations	O
ranged	O
form	O
0.33	O
between	O
the	O
Symptoms	O
and	O
Work	O
scales	O
to	O
0.96	O
between	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Overall	O
QoL	O
scales	O
.	O

In	O
addition	O
to	O
the	O
confirmatory	O
factor	O
analyses	O
,	O
Cronbach	O
's	O
alphas	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
were	O
used	O
for	O
item	O
reduction	O
.	O

Items	O
with	O
low	O
factor	O
loadings	O
and	O
item	O
-	O
to	O
-	O
total	O
correlations	O
that	O
reduced	O
the	O
internal	O
consistency	O
were	O
eliminated	O
.	O

Although	O
initial	O
factor	O
analyses	O
identified	O
six	O
domains	O
for	O
future	O
use	O
,	O
the	O
final	O
version	O
of	O
the	O
ITP	O
-	O
PAQ	O
contained	O
44	O
items	O
that	O
included	O
the	O
following	O
ten	O
scales	O
:	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Activity	O
,	O
Fear	O
,	O
Psychological	O
Health	O
,	O
Work	O
,	O
Social	O
Activity	O
,	O
Women	O
's	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL.	O
Table	O
2	O
provides	O
information	O
on	O
the	O
number	O
of	O
items	O
,	O
item	O
variability	O
and	O
sample	O
items	O
from	O
each	O
scale	O
of	O
the	O
questionnaire	O
.	O

Each	O
scale	O
is	O
scored	O
from	O
0	O
to	O
100	O
,	O
with	O
higher	O
scores	O
representing	O
better	O
quality	O
of	O
life	O
.	O

Test	O
-	O
retest	O
reliability	O
Of	O
the	O
73	O
subjects	O
who	O
completed	O
the	O
first	O
administration	O
of	O
the	O
questionnaire	O
,	O
most	O
of	O
the	O
subjects	O
completed	O
the	O
second	O
questionnaire	O
within	O
a	O
15-day	O
period	O
(	O
75	O
%	O
)	O
,	O
during	O
which	O
subjects	O
were	O
expected	O
to	O
remain	O
clinically	O
stable	O
.	O

However	O
,	O
20	O
%	O
of	O
the	O
73	O
subjects	O
completed	O
the	O
questionnaire	O
within	O
three	O
weeks	O
following	O
the	O
first	O
administration	O
.	O

The	O
remaining	O
5	O
%	O
of	O
subjects	O
completed	O
it	O
between	O
four	O
and	O
nine	O
weeks	O
after	O
the	O
first	O
""""	O
test	O
.	O

""""	O
ICC	O
's	O
were	O
computed	O
for	O
the	O
entire	O
sample	O
(	O
n	O
=	O
73	O
)	O
and	O
for	O
a	O
sub	O
-	O
sample	O
of	O
respondents	O
who	O
completed	O
the	O
second	O
questionnaire	O
within	O
three	O
weeks	O
(	O
n	O
=	O
69	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
all	O
scales	O
had	O
acceptable	O
test	O
-	O
retest	O
reliability	O
(	O
ICC	O
≥	O
0.70	O
)	O
as	O
measured	O
by	O
the	O
ICC	O
(	O
Table	O
3	O
)	O
.	O

For	O
the	O
entire	O
sample	O
,	O
ICC	O
values	O
ranged	O
from	O
0.52–0.90	O
,	O
while	O
ICC	O
values	O
for	O
the	O
sub	O
-	O
sample	O
ranged	O
from	O
0.56–0.89	O
.	O

Internal	O
consistency	O
reliability	O
Internal	O
consistency	O
reliability	O
,	O
measured	O
by	O
Cronbach	O
's	O
alpha	O
,	O
ranged	O
from	O
0.66	O
to	O
0.92	O
(	O
Table	O
3	O
)	O
.	O

With	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Cronbach	O
's	O
alpha	O
coefficients	O
exceeded	O
the	O
acceptable	O
level	O
of	O
0.70	O
.	O

Cronbach	O
's	O
alpha	O
for	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
ranged	O
from	O
0.71–0.89	O
,	O
while	O
Cronbach	O
's	O
alpha	O
for	O
the	O
Psychological	O
Health	O
and	O
Fear	O
scales	O
ranged	O
from	O
0.87–0.92	O
.	O

Additionally	O
,	O
Cronbach	O
's	O
alphas	O
for	O
the	O
Social	O
Activity	O
,	O
Work	O
,	O
Reproductive	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
were	O
0.72	O
,	O
0.86	O
,	O
0.66	O
,	O
and	O
0.89	O
,	O
respectively	O
.	O

Construct	O
validity	O
Table	O
4	O
displays	O
the	O
results	O
of	O
inter	O
-	O
scale	O
Pearson	O
correlation	O
coefficients	O
for	O
the	O
initial	O
test	O
administration	O
of	O
the	O
ITP	O
-	O
PAQ	O
.	O

As	O
expected	O
,	O
the	O
Symptoms	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
moderately	O
to	O
strongly	O
inter	O
-	O
correlated	O
based	O
on	O
the	O
data	O
from	O
the	O
initial	O
administration	O
(	O
correlation	O
coefficients	O
ranged	O
from	O
0.56–0.75	O
;	O
p	O
<	O
0.05	O
)	O
.	O

The	O
Overall	O
QoL	O
scale	O
was	O
moderately	O
to	O
strongly	O
correlated	O
with	O
the	O
other	O
ITP	O
-	O
PAQ	O
scales	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
.	O

In	O
addition	O
to	O
examining	O
the	O
correlations	O
within	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
construct	O
validity	O
was	O
also	O
assessed	O
by	O
comparing	O
the	O
ITP	O
-	O
PAQ	O
scale	O
scores	O
with	O
those	O
of	O
the	O
CES	O
-	O
D	O
and	O
the	O
SF-36	O
.	O

The	O
CES	O
-	O
D	O
was	O
negatively	O
correlated	O
with	O
all	O
ITP	O
-	O
PAQ	O
scales	O
,	O
except	O
for	O
the	O
Reproductive	O
Health	O
scale	O
.	O

Other	O
than	O
the	O
Reproductive	O
Health	O
scale	O
,	O
Pearson	O
correlations	O
ranged	O
from	O
-0.37	O
to	O
-0.70	O
(	O
p	O
<	O
0.05	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF-36	O
scales	O
;	O
however	O
,	O
the	O
Reproductive	O
Health	O
scale	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
SF-36	O
scales	O
.	O

The	O
mean	O
SF-36	O
scores	O
of	O
the	O
subjects	O
with	O
ITP	O
were	O
compared	O
to	O
those	O
of	O
the	O
general	O
U.S.	O
population	O
norms	O
[	O
15	O
]	O
.	O

Results	O
from	O
t	O
-	O
tests	O
indicate	O
that	O
there	O
were	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.05	O
)	O
in	O
SF-36	O
mean	O
scores	O
between	O
subjects	O
with	O
ITP	O
(	O
range	O
,	O
43.04–72.86	O
)	O
and	O
the	O
general	O
U.S.	O
population	O
(	O
range	O
,	O
60.86–84.15	O
)	O
.	O

Subjects	O
with	O
ITP	O
reported	O
lower	O
scores	O
on	O
each	O
SF-36	O
scale	O
compared	O
to	O
the	O
US	O
norm	O
(	O
data	O
not	O
shown	O
)	O
.	O

Known	O
groups	O
validity	O
Subjects	O
were	O
categorized	O
into	O
two	O
groups	O
according	O
to	O
gender	O
,	O
splenectomy	O
status	O
,	O
current	O
ITP	O
treatment	O
status	O
,	O
subject	O
's	O
perception	O
of	O
the	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
and	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
.	O

When	O
subjects	O
were	O
grouped	O
according	O
to	O
gender	O
or	O
splenectomy	O
status	O
,	O
no	O
statistically	O
significant	O
differences	O
were	O
observed	O
for	O
any	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
were	O
currently	O
receiving	O
treatment	O
for	O
ITP	O
reported	O
lower	O
scores	O
on	O
all	O
ITP	O
-	O
PAQ	O
scales	O
compared	O
to	O
subjects	O
who	O
were	O
not	O
currently	O
receiving	O
treatment	O
.	O

Statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.01	O
)	O
were	O
reported	O
for	O
the	O
following	O
ITP	O
-	O
PAQ	O
scales	O
when	O
subjects	O
were	O
categorized	O
by	O
treatment	O
status	O
:	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
(	O
Figure	O
1	O
)	O
.	O

When	O
subjects	O
were	O
categorized	O
by	O
effectiveness	O
of	O
ITP	O
treatment	O
,	O
statistically	O
significant	O
differences	O
(	O
p	O
<	O
0.05	O
)	O
were	O
observed	O
for	O
the	O
Symptoms	O
and	O
Activity	O
scales	O
(	O
Figure	O
1	O
)	O
,	O
while	O
statistically	O
significant	O
differences	O
were	O
only	O
found	O
for	O
the	O
Psychological	O
Health	O
scale	O
when	O
subjects	O
were	O
categorized	O
according	O
to	O
time	O
elapsed	O
since	O
ITP	O
diagnosis	O
(	O
data	O
not	O
shown	O
)	O
.	O

Subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
<	O
1	O
year	O
had	O
a	O
lower	O
mean	O
score	O
on	O
the	O
Psychological	O
Health	O
scale	O
compared	O
to	O
subjects	O
who	O
had	O
been	O
diagnosed	O
with	O
ITP	O
for	O
at	O
least	O
one	O
year	O
(	O
50.38	O
vs.	O
66.46	O
,	O
respectively	O
;	O
p	O
=	O
0.02	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Discussion	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
develop	O
and	O
undertake	O
initial	O
validation	O
analyses	O
of	O
the	O
ITP	O
-	O
PAQ	O
as	O
a	O
tool	O
for	O
measuring	O
HRQoL	O
specifically	O
related	O
to	O
adult	O
subjects	O
with	O
ITP	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
preliminary	O
evidence	O
of	O
the	O
reliability	O
and	O
validity	O
of	O
the	O
ITP	O
-	O
PAQ	O
in	O
this	O
population	O
.	O

The	O
results	O
indicate	O
that	O
,	O
with	O
the	O
exception	O
of	O
the	O
Reproductive	O
Health	O
scale	O
,	O
the	O
questionnaire	O
has	O
good	O
internal	O
consistency	O
.	O

The	O
Reproductive	O
Health	O
scale	O
may	O
not	O
have	O
reached	O
an	O
acceptable	O
level	O
because	O
the	O
items	O
could	O
in	O
fact	O
be	O
measuring	O
slightly	O
different	O
concepts	O
.	O

For	O
example	O
,	O
the	O
Reproductive	O
Health	O
scale	O
includes	O
items	O
that	O
assess	O
symptom	O
bother	O
related	O
to	O
menstruation	O
in	O
addition	O
to	O
items	O
that	O
ask	O
how	O
ITP	O
impacts	O
reproductive	O
choices	O
,	O
such	O
as	O
becoming	O
pregnant	O
,	O
giving	O
birth	O
,	O
and	O
adopting	O
children	O
.	O

Perhaps	O
,	O
the	O
symptom	O
bother	O
items	O
in	O
this	O
scale	O
may	O
fit	O
more	O
appropriately	O
with	O
the	O
Bother	O
-	O
Physical	O
Health	O
scale	O
,	O
and	O
the	O
reproductive	O
choice	O
items	O
could	O
comprise	O
a	O
separate	O
scale	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
also	O
demonstrated	O
acceptable	O
test	O
-	O
retest	O
reliability	O
,	O
even	O
though	O
the	O
time	O
interval	O
between	O
test	O
and	O
retest	O
administrations	O
of	O
the	O
questionnaire	O
exceeded	O
the	O
targeted	O
time	O
interval	O
of	O
seven	O
to	O
ten	O
days	O
.	O

However	O
,	O
two	O
scales	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
,	O
reported	O
ICC	O
values	O
below	O
the	O
acceptable	O
value	O
of	O
0.70	O
.	O

In	O
addition	O
to	O
the	O
lag	O
between	O
the	O
two	O
administrations	O
of	O
the	O
questionnaire	O
,	O
subjects	O
may	O
have	O
experienced	O
an	O
increase	O
in	O
bother	O
and/or	O
a	O
decrease	O
in	O
activity	O
due	O
to	O
ITP	O
during	O
the	O
extended	O
time	O
interval	O
.	O

Additionally	O
,	O
the	O
comparatively	O
low	O
ICC	O
values	O
of	O
the	O
Bother	O
-	O
Physical	O
Health	O
and	O
Activity	O
scales	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
relatively	O
low	O
number	O
of	O
items	O
contained	O
in	O
each	O
of	O
these	O
scales	O
(	O
four	O
and	O
two	O
items	O
,	O
respectively	O
)	O
compared	O
to	O
the	O
Symptoms	O
scale	O
which	O
contains	O
six	O
items	O
.	O

In	O
general	O
,	O
the	O
construct	O
validity	O
of	O
the	O
questionnaire	O
was	O
supported	O
by	O
inter	O
-	O
scale	O
correlations	O
.	O

As	O
expected	O
,	O
the	O
Bother	O
-	O
Physical	O
Health	O
,	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
and	O
Activity	O
scales	O
were	O
more	O
strongly	O
correlated	O
to	O
one	O
another	O
than	O
with	O
other	O
scales	O
.	O

However	O
,	O
the	O
Reproductive	O
Health	O
scale	O
had	O
a	O
lower	O
internal	O
consistency	O
reliability	O
and	O
it	O
was	O
weakly	O
correlated	O
with	O
the	O
ITP	O
-	O
PAQ	O
scales	O
,	O
the	O
SF-36	O
,	O
and	O
the	O
CES	O
-	O
D	O
,	O
possibly	O
due	O
to	O
the	O
differing	O
concepts	O
measured	O
by	O
the	O
items	O
within	O
this	O
scale	O
or	O
the	O
all	O
-	O
female	O
sample	O
.	O

Most	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
moderately	O
correlated	O
with	O
the	O
SF-36	O
scales	O
and	O
the	O
CES	O
-	O
D	O
;	O
however	O
,	O
correlations	O
between	O
some	O
of	O
the	O
scales	O
were	O
<	O
0.40	O
(	O
e.g.	O
,	O
Fear	O
and	O
SF-36	O
Mental	O
Health	O
,	O
0.30	O
;	O
p	O
<	O
0.05	O
)	O
.	O

This	O
low	O
correlation	O
could	O
be	O
due	O
to	O
the	O
ITP	O
-	O
PAQ	O
assessing	O
fear	O
associated	O
with	O
ITP	O
(	O
e.g.	O
,	O
fear	O
of	O
having	O
a	O
bleeding	O
episode	O
)	O
,	O
while	O
the	O
SF-36	O
provides	O
a	O
more	O
general	O
assessment	O
of	O
mental	O
health	O
issues	O
(	O
e.g.	O
,	O
felt	O
downhearted	O
and	O
blue	O
)	O
.	O

The	O
known	O
-	O
groups	O
validity	O
results	O
indicate	O
that	O
some	O
of	O
the	O
ITP	O
-	O
PAQ	O
scales	O
(	O
Symptoms	O
,	O
Fatigue	O
/	O
Sleep	O
,	O
Bother	O
-	O
Physical	O
Health	O
,	O
Activity	O
,	O
Psychological	O
Health	O
,	O
and	O
Overall	O
QoL	O
scales	O
)	O
were	O
able	O
to	O
differentiate	O
ITP	O
subjects	O
who	O
were	O
currently	O
receiving	O
ITP	O
treatment	O
from	O
those	O
who	O
were	O
not	O
receiving	O
treatment	O
for	O
ITP	O
,	O
providing	O
preliminary	O
evidence	O
of	O
the	O
ITP	O
-	O
PAQ	O
's	O
ability	O
to	O
distinguish	O
between	O
groups	O
known	O
to	O
be	O
different	O
.	O

However	O
,	O
the	O
ITP	O
-	O
PAQ	O
scales	O
were	O
generally	O
unable	O
to	O
distinguish	O
between	O
subjects	O
when	O
they	O
were	O
grouped	O
by	O
gender	O
,	O
splenectomy	O
status	O
,	O
perceived	O
effectiveness	O
of	O
treatment	O
and	O
length	O
of	O
time	O
since	O
ITP	O
diagnosis	O
.	O

The	O
ITP	O
-	O
PAQ	O
may	O
not	O
be	O
able	O
to	O
differentiate	O
between	O
female	O
and	O
male	O
subjects	O
because	O
the	O
disorder	O
may	O
affect	O
females	O
and	O
males	O
similarly	O
.	O

Additionally	O
,	O
significant	O
differences	O
may	O
not	O
have	O
been	O
observed	O
between	O
subjects	O
who	O
have	O
undergone	O
splenectomy	O
and	O
subjects	O
who	O
have	O
not	O
because	O
55	O
%	O
of	O
subjects	O
who	O
had	O
a	O
splenectomy	O
indicated	O
that	O
it	O
did	O
not	O
cure	O
their	O
ITP	O
.	O

Specifically	O
,	O
the	O
known	O
-	O
groups	O
could	O
be	O
defined	O
as	O
'	O
subjects	O
without	O
a	O
splenectomy	O
'	O
versus	O
'	O
subjects	O
with	O
a	O
failed	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
likely	O
worsened	O
)	O
versus	O
'	O
subjects	O
with	O
a	O
successful	O
splenectomy	O
'	O
(	O
for	O
whom	O
QoL	O
may	O
have	O
improved	O
)	O
.	O

In	O
the	O
future	O
,	O
to	O
assess	O
whether	O
the	O
ITP	O
-	O
PAQ	O
scales	O
can	O
differentiate	O
between	O
groups	O
of	O
subjects	O
,	O
it	O
may	O
be	O
worthwhile	O
to	O
categorize	O
subjects	O
by	O
a	O
more	O
clinically	O
relevant	O
measure	O
,	O
such	O
as	O
platelet	O
count	O
.	O

Several	O
limitations	O
should	O
be	O
considered	O
when	O
interpreting	O
our	O
findings	O
.	O

Subjects	O
were	O
drawn	O
from	O
a	O
convenience	O
sample	O
.	O

The	O
study	O
population	O
was	O
fairly	O
homogeneous	O
,	O
comprised	O
primarily	O
of	O
Caucasian	O
female	O
subjects	O
.	O

The	O
data	O
was	O
validated	O
using	O
only	O
patient	O
-	O
reported	O
data	O
collected	O
via	O
questionnaire	O
.	O

The	O
lack	O
of	O
clinical	O
data	O
in	O
this	O
initial	O
validation	O
study	O
will	O
be	O
addressed	O
in	O
on	O
-	O
going	O
pivotal	O
trials	O
that	O
will	O
collect	O
clinical	O
data	O
such	O
as	O
platelet	O
counts	O
and	O
platelet	O
response	O
.	O

In	O
addition	O
,	O
the	O
time	O
interval	O
between	O
the	O
initial	O
and	O
retest	O
administration	O
of	O
the	O
questionnaire	O
may	O
have	O
been	O
too	O
lengthy	O
to	O
properly	O
evaluate	O
the	O
test	O
-	O
retest	O
reliability	O
.	O

Because	O
25	O
%	O
of	O
subjects	O
did	O
not	O
complete	O
the	O
questionnaire	O
within	O
the	O
targeted	O
fifteen	O
day	O
interval	O
,	O
those	O
subjects	O
may	O
have	O
undergone	O
clinical	O
changes	O
that	O
may	O
have	O
affected	O
their	O
responses	O
.	O

In	O
future	O
validation	O
studies	O
platelet	O
counts	O
or	O
type	O
of	O
platelet	O
response	O
should	O
be	O
used	O
to	O
identify	O
a	O
stable	O
cohort	O
for	O
the	O
test	O
-	O
retest	O
analyses	O
.	O

Furthermore	O
,	O
the	O
criteria	O
used	O
to	O
categorize	O
the	O
subjects	O
for	O
the	O
known	O
groups	O
validity	O
evaluation	O
may	O
not	O
have	O
been	O
sufficient	O
to	O
allow	O
for	O
the	O
ITP	O
-	O
PAQ	O
scales	O
to	O
detect	O
differences	O
between	O
groups	O
.	O

Grouping	O
the	O
subjects	O
by	O
a	O
different	O
criterion	O
,	O
such	O
as	O
a	O
relevant	O
clinical	O
measure	O
,	O
may	O
bolster	O
the	O
findings	O
for	O
its	O
known	O
groups	O
validity	O
.	O

Conclusion	O
The	O
primary	O
goal	O
of	O
this	O
manuscript	O
was	O
to	O
describe	O
the	O
development	O
of	O
a	O
new	O
ITP	O
-	O
specific	O
HRQoL	O
questionnaire	O
for	O
adults	O
with	O
ITP	O
and	O
to	O
present	O
our	O
initial	O
findings	O
on	O
the	O
psychometric	O
properties	O
of	O
this	O
questionnaire	O
.	O

The	O
results	O
of	O
this	O
initial	O
validation	O
study	O
indicate	O
that	O
the	O
questionnaire	O
generally	O
has	O
acceptable	O
reliability	O
and	O
validity	O
.	O

We	O
plan	O
to	O
conduct	O
additional	O
analyses	O
using	O
more	O
objective	O
clinical	O
measures	O
such	O
as	O
platelet	O
counts	O
as	O
a	O
criterion	O
for	O
known	O
groups	O
validity	O
.	O

Further	O
validation	O
work	O
should	O
also	O
be	O
conducted	O
to	O
assess	O
its	O
responsiveness	O
and	O
to	O
estimate	O
its	O
minimal	O
clinical	O
important	O
difference	O
value	O
so	O
that	O
it	O
can	O
become	O
a	O
more	O
widely	O
used	O
HRQoL	O
measure	O
in	O
the	O
ITP	O
population	O
.	O

Competing	O
interests	O
The	O
validation	O
study	O
design	O
,	O
analysis	O
,	O
interpretation	O
of	O
results	O
,	O
and	O
the	O
writing	O
of	O
the	O
manuscript	O
represent	O
the	O
joint	O
collaboration	O
of	O
all	O
authors	O
of	O
this	O
study	O
,	O
which	O
was	O
funded	O
solely	O
by	O
Amgen	O
,	O
Inc	O
,	O
Thousand	O
Oaks	O
,	O
California	O
,	O
USA	O
.	O

Ovation	O
Research	O
Group	O
provided	O
no	O
additional	O
funding	O
for	O
this	O
study	O
.	O

The	O
decision	O
to	O
submit	O
this	O
manuscript	O
for	O
publication	O
was	O
subject	O
to	O
the	O
approval	O
of	O
Amgen	O
,	O
Inc.	O
and	O
all	O
authors	O
.	O

Gary	O
Okano	O
and	O
Janet	O
Nichol	O
are	O
employees	O
of	O
Amgen	O
,	O
Inc.	O
James	O
Bussel	O
is	O
an	O
employee	O
of	O
Weill	O
Cornell	O
Medical	O
Center	O
.	O

James	O
George	O
is	O
employed	O
by	O
the	O
University	O
of	O
Oklahoma	O
Health	O
Sciences	O
Center	O
.	O

Robert	O
McMillan	O
is	O
a	O
Professor	O
Emeritus	O
of	O
the	O
Scripps	O
Research	O
Institute	O
.	O

Susan	O
Mathias	O
is	O
an	O
employee	O
of	O
Ovation	O
Research	O
Group	O
.	O

Authors	O
'	O
contributions	O
SDM	O
supervised	O
the	O
interpretation	O
of	O
the	O
results	O
from	O
the	O
validation	O
study	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

JBB	O
,	O
JNG	O
,	O
RM	O
,	O
and	O
JLN	O
provided	O
clinical	O
expertise	O
in	O
the	O
development	O
of	O
the	O
questionnaire	O
,	O
and	O
participated	O
in	O
the	O
design	O
and	O
execution	O
of	O
the	O
study	O
.	O

GJO	O
assisted	O
in	O
interpreting	O
the	O
results	O
and	O
drafting	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Integration	O
in	O
primary	O
community	O
care	O
networks	O
(	O
PCCNs	O
)	O
:	O
examination	O
of	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
in	O
a	O
national	O
demonstration	O
project	O
in	O
Taiwan	O
Abstract	O
Background	O
Taiwan	O
's	O
primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
,	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
on	O
March	O
2003	O
,	O
was	O
established	O
to	O
discourage	O
hospital	O
shopping	O
behavior	O
of	O
people	O
and	O
drive	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
into	O
cooperate	O
care	O
models	O
.	O

Between	O
2003	O
and	O
2005	O
,	O
268	O
PCCNs	O
were	O
established	O
.	O

This	O
study	O
profiled	O
the	O
individual	O
members	O
in	O
the	O
PCCNs	O
to	O
study	O
the	O
nature	O
and	O
extent	O
to	O
which	O
their	O
network	O
infrastructures	O
have	O
been	O
integrated	O
among	O
the	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
within	O
individual	O
PCCNs	O
.	O

Methods	O
The	O
thorough	O
questionnaire	O
items	O
,	O
covering	O
the	O
network	O
working	O
infrastructures	O
–	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
integration	O
in	O
PCCNs	O
,	O
were	O
developed	O
with	O
validity	O
and	O
reliability	O
confirmed	O
.	O

One	O
thousand	O
five	O
hundred	O
and	O
fifty	O
-	O
seven	O
clinics	O
that	O
had	O
belonged	O
to	O
PCCNs	O
for	O
more	O
than	O
one	O
year	O
,	O
based	O
on	O
the	O
2003–2005	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
,	O
were	O
surveyed	O
by	O
mail	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinic	O
members	O
responded	O
to	O
the	O
surveys	O
giving	O
a	O
59.6	O
%	O
response	O
rate	O
.	O

Results	O

Overall	O
,	O
the	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
at	O
the	O
early	O
integration	O
stage	O
.	O

In	O
addition	O
,	O
it	O
found	O
that	O
there	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Conclusion	O

There	O
was	O
still	O
room	O
for	O
better	O
integrated	O
partnerships	O
,	O
as	O
evidenced	O
by	O
the	O
great	O
variety	O
of	O
relationships	O
and	O
differences	O
in	O
extent	O
of	O
integration	O
in	O
this	O
study	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
for	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
willingness	O
to	O
turn	O
their	O
business	O
into	O
multi	O
-	O
organizations	O
.	O

Background	O
Taiwan	O
's	O
National	O
Health	O
Insurance	O
(	O
NHI	O
)	O
under	O
the	O
control	O
of	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
,	O
was	O
launched	O
in	O
March	O
1995	O
to	O
replace	O
its	O
social	O
insurance	O
system	O
that	O
was	O
covering	O
59	O
%	O
of	O
its	O
population	O
:	O
government	O
employees	O
,	O
labourers	O
,	O
farmers	O
and	O
servicemen	O
[	O
1	O
]	O
.	O

By	O
June	O
2003	O
the	O
number	O
of	O
people	O
insured	O
had	O
reached	O
21,956,729	O
(	O
99	O
%	O
)	O
.	O

There	O
were	O
17,259	O
medical	O
providers	O
(	O
92	O
%	O
)	O
,	O
including	O
575	O
hospitals	O
and	O
16,684	O
clinics	O
contracted	O
with	O
the	O
BNHI	O
for	O
serving	O
the	O
enrolled	O
population	O
.	O

The	O
unique	O
phenomenon	O
characterized	O
in	O
Taiwan	O
health	O
care	O
industry	O
different	O
from	O
those	O
in	O
the	O
western	O
countries	O
is	O
the	O
freedom	O
of	O
patients	O
to	O
choose	O
the	O
health	O
care	O
providers	O
they	O
want	O
,	O
no	O
matter	O
what	O
their	O
disease	O
severity	O
is	O
.	O

Furthermore	O
,	O
Taiwan	O
people	O
favor	O
the	O
larger	O
scales	O
of	O
facilities	O
and	O
this	O
fallacy	O
leads	O
to	O
the	O
phenomenon	O
of	O
big	O
-	O
hospital	O
shopping	O
.	O

For	O
example	O
,	O
people	O
choose	O
the	O
medical	O
centers	O
which	O
are	O
accredited	O
as	O
the	O
highest	O
level	O
of	O
medical	O
science	O
in	O
Taiwan	O
when	O
they	O
only	O
suffer	O
from	O
a	O
common	O
cold	O
.	O

In	O
the	O
spring	O
of	O
2003	O
,	O
the	O
SARS	O
epidemic	O
viciously	O
attacked	O
the	O
health	O
of	O
Taiwan	O
's	O
people	O
.	O

The	O
people	O
's	O
freedom	O
to	O
choose	O
medical	O
providers	O
caused	O
the	O
national	O
health	O
authority	O
to	O
barely	O
control	O
and	O
traced	O
the	O
flow	O
of	O
epidemic	O
.	O

This	O
event	O
made	O
Taiwan	O
national	O
health	O
authorities	O
rethink	O
what	O
happened	O
and	O
how	O
it	O
damaged	O
under	O
the	O
traditional	O
fragmented	O
health	O
care	O
providers	O
in	O
Taiwan	O
.	O

One	O
health	O
reform	O
launched	O
was	O
named	O
the	O
""""	O
Primary	O
Community	O
Care	O
Network	O
(	O
PCCN	O
)	O
demonstration	O
project	O
""""	O
,	O
a	O
nationwide	O
health	O
care	O
financing	O
program	O
funded	O
by	O
the	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
in	O
March	O
2003	O
and	O
it	O
was	O
a	O
new	O
model	O
for	O
the	O
Taiwan	O
government	O
to	O
redefine	O
the	O
role	O
of	O
family	O
physicians	O
in	O
the	O
health	O
care	O
delivery	O
system	O
.	O

A	O
PCCN	O
in	O
Taiwan	O
consists	O
of	O
a	O
group	O
of	O
clinic	O
physicians	O
whose	O
medical	O
jobs	O
are	O
viewed	O
as	O
family	O
care	O
and	O
at	O
least	O
one	O
hospital	O
for	O
secondary	O
or	O
tertiary	O
care	O
.	O

The	O
idea	O
of	O
member	O
component	O
design	O
in	O
PCCNs	O
was	O
aimed	O
to	O
lead	O
the	O
Taiwan	O
citizens	O
to	O
choose	O
one	O
clinic	O
physician	O
as	O
their	O
personal	O
family	O
physician	O
for	O
health	O
maintenance	O
and	O
this	O
family	O
physician	O
also	O
would	O
have	O
the	O
responsibility	O
of	O
referring	O
the	O
patients	O
to	O
specialty	O
care	O
if	O
necessary	O
.	O

From	O
a	O
national	O
health	O
authority	O
perspective	O
,	O
they	O
expected	O
the	O
Taiwan	O
people	O
to	O
put	O
an	O
end	O
to	O
their	O
fallacy	O
that	O
""""	O
bigger	O
is	O
better	O
""""	O
for	O
health	O
care	O
organizations	O
and	O
establish	O
the	O
idea	O
of	O
""""	O
human	B
health	O
""""	O
,	O
starting	O
with	O
prevention	O
and	O
primary	O
care	O
,	O
followed	O
by	O
secondary	O
or	O
tertiary	O
care	O
,	O
emphasizing	O
health	O
promotion	O
and	O
maintenance	O
instead	O
of	O
disease	O
curing	O
.	O

Furthermore	O
,	O
it	O
could	O
decrease	O
the	O
inappropriateness	O
of	O
medical	O
usage	O
,	O
i.e.	O
,	O
over	O
-	O
uses	O
of	O
secondary	O
and	O
tertiary	O
medical	O
services	O
in	O
the	O
high	O
-	O
tech	O
hospitals	O
.	O

In	O
addition	O
,	O
the	O
national	O
health	O
authority	O
was	O
expected	O
to	O
drive	O
the	O
traditional	O
fragmented	O
heath	O
care	O
providers	O
into	O
coordinated	O
medical	O
multidisciplinary	O
teams	O
and	O
share	O
the	O
limited	O
medical	O
resources	O
through	O
the	O
PCCN	O
demonstration	O
project	O
.	O

In	O
summary	O
,	O
the	O
PCCN	O
demonstration	O
project	O
was	O
aimed	O
to	O
:	O
1	O
)	O
change	O
the	O
traditional	O
patients	O
'	O
customs	O
of	O
freely	O
choosing	O
health	O
care	O
organizations	O
and	O
establish	O
referral	O
channels	O
along	O
the	O
continuum	O
of	O
care	O
,	O
and	O
2	O
)	O
establish	O
partnerships	O
among	O
the	O
primary	O
care	O
clinics	O
and	O
hospitals	O
to	O
provide	O
a	O
continuum	O
of	O
health	O
care	O
services	O
.	O

It	O
was	O
also	O
expected	O
to	O
establish	O
the	O
primary	O
care	O
system	O
of	O
family	O
physicians	O
to	O
provide	O
whole	O
-	O
people	O
health	O
care	O
and	O
improve	O
care	O
quality	O
[	O
1	O
]	O
.	O

Partnership	O
structures	O
in	O
the	O
PCCNs	O
represent	O
the	O
virtual	O
vertical	O
(	O
i.e.	O
,	O
between	O
the	O
member	O
clinics	O
and	O
hospitals	O
)	O
and	O
virtual	O
horizontal	O
(	O
i.e.	O
,	O
among	O
the	O
member	O
clinics	O
)	O
aspects	O
of	O
organizing	O
,	O
which	O
designate	O
the	O
formal	O
relationships	O
between	O
individuals	O
and	O
the	O
total	O
network	O
and	O
include	O
organizational	O
design	O
to	O
ensure	O
effective	O
communication	O
,	O
coordination	O
,	O
and	O
integration	O
across	O
the	O
total	O
network	O
.	O

Each	O
PCCN	O
consists	O
of	O
five	O
to	O
ten	O
clinics	O
:	O
half	O
of	O
them	O
should	O
offer	O
the	O
services	O
of	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgery	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatric	O
,	O
or	O
family	O
medicine	O
.	O

And	O
each	O
PCCN	O
has	O
a	O
central	O
headquarters	O
,	O
usually	O
in	O
one	O
of	O
the	O
clinic	O
facilities	O
,	O
to	O
coordinate	O
and	O
integrate	O
the	O
network	O
.	O

All	O
the	O
clinic	O
physicians	O
in	O
a	O
PCCN	O
are	O
assigned	O
the	O
roles	O
of	O
""""	O
family	O
physicians	O
""""	O
or	O
""""	O
gatekeepers	O
""""	O
who	O
recruit	O
people	O
from	O
the	O
local	O
community	O
,	O
keep	O
background	O
and	O
medical	O
files	O
on	O
them	O
,	O
certify	O
family	O
physician	O
education	O
training	O
programs	O
,	O
and	O
hold	O
office	O
hours	O
in	O
the	O
member	O
hospital	O
,	O
where	O
they	O
serve	O
as	O
joint	O
faculty	O
members	O
for	O
further	O
medical	O
consultations	O
or	O
medical	O
utilizations	O
of	O
labs	O
and	O
tests	O
,	O
if	O
necessary	O
.	O

In	O
addition	O
,	O
the	O
hospital	O
member	O
is	O
asked	O
to	O
help	O
clinic	O
physicians	O
in	O
their	O
network	O
to	O
set	O
up	O
a	O
medical	O
information	O
system	O
,	O
share	O
hospital	O
resources	O
(	O
medical	O
equipment	O
and	O
library	O
literature	O
)	O
with	O
the	O
clinic	O
physicians	O
in	O
their	O
network	O
and	O
establish	O
referral	O
channels	O
among	O
the	O
network	O
members	O
.	O

Furthermore	O
,	O
this	O
new	O
demonstration	O
model	O
tries	O
to	O
minimize	O
the	O
barriers	O
to	O
patient	O
access	O
by	O
setting	O
up	O
24-hour	O
a	O
day	O
,	O
7-day	O
a	O
week	O
medical	O
consultation	O
telephone	O
lines	O
for	O
providing	O
urgent	O
services	O
onsite	O
and	O
for	O
taking	O
care	O
of	O
the	O
patients	O
whose	O
family	O
physicians	O
'	O
practices	O
are	O
closed	O
to	O
assure	O
seamless	O
care	O
channels	O
.	O

The	O
BNHI	O
funded	O
these	O
extra	O
demonstration	O
actions	O
,	O
at	O
around	O
one	O
hundred	O
thousand	O
US	O
dollars	O
(	O
i.e.	O
,	O
NT$3,500,000	O
)	O
for	O
each	O
PCCN	O
under	O
the	O
current	O
fee	O
-	O
for	O
-	O
service	O
payment	O
system	O
[	O
1	O
]	O
.	O

Figure	O
1	O
describes	O
the	O
organizational	O
structure	O
of	O
individual	O
PCCNs	O
introduced	O
in	O
the	O
demonstration	O
project	O
in	O
Taiwan	O
.	O

To	O
date	O
,	O
the	O
PCCN	O
demonstration	O
project	O
has	O
been	O
in	O
operation	O
for	O
more	O
than	O
three	O
years	O
.	O

There	O
have	O
been	O
268	O
PCCNs	O
formed	O
in	O
the	O
period	O
of	O
2003	O
to	O
2005	O
around	O
Taiwan	O
.	O

The	O
geographical	O
distributions	O
of	O
PCCNs	O
and	O
their	O
members	O
were	O
described	O
in	O
Table	O
1	O
.	O

Analyzing	O
all	O
1,557	O
participating	O
clinic	O
members	O
in	O
the	O
demonstration	O
project	O
in	O
terms	O
of	O
medical	O
specialties	O
,	O
they	O
cover	O
general	O
medicine	O
,	O
internal	O
medicine	O
,	O
surgeries	O
,	O
obstetrics	O
and	O
gynecology	O
,	O
pediatrics	O
,	O
family	O
medicines	O
,	O
otolaryngology	O
,	O
ophthalmology	O
,	O
rehabilitation	O
medicine	O
,	O
dermatology	O
,	O
and	O
psychiatry	O
,	O
with	O
237	O
clinics	O
providing	O
more	O
than	O
two	O
specialties	O
.	O

On	O
the	O
other	O
hand	O
,	O
each	O
PCCN	O
recruits	O
at	O
least	O
one	O
district	O
or	O
regional	O
accredited	O
hospital	O
for	O
acute	O
care	O
demands	O
(	O
required	O
for	O
network	O
members	O
)	O
and	O
a	O
medical	O
center	O
for	O
tertiary	O
care	O
support	O
(	O
not	O
required	O
for	O
network	O
members	O
)	O
.	O

There	O
are	O
6	O
medical	O
centers	O
,	O
52	O
regional	O
hospitals	O
,	O
and	O
71	O
district	O
hospitals	O
joining	O
in	O
the	O
demonstration	O
project	O
.	O

See	O
Table	O
1	O
for	O
more	O
detailed	O
information	O
about	O
the	O
PCCN	O
members	O
.	O

To	O
date	O
,	O
there	O
have	O
been	O
few	O
empirical	O
studies	O
of	O
the	O
working	O
relationships	O
that	O
have	O
developed	O
between	O
members	O
of	O
the	O
PCCN	O
program	O
.	O

Partnership	O
needs	O
a	O
method	O
to	O
determine	O
at	O
an	O
early	O
stage	O
,	O
to	O
make	O
sure	O
whether	O
they	O
are	O
making	O
the	O
most	O
of	O
collaboration	O
[	O
2	O
]	O
and	O
the	O
acceptance	O
of	O
the	O
contracting	O
networks	O
in	O
Taiwan	O
as	O
an	O
organizational	O
innovation	O
worthy	O
of	O
greater	O
diffusion	O
deserves	O
to	O
be	O
explored	O
.	O

Therefore	O
,	O
this	O
study	O
used	O
a	O
structured	O
questionnaire	O
to	O
characterize	O
the	O
relationship	O
among	O
the	O
members	O
in	O
the	O
individual	O
PCCNs	O
,	O
with	O
regard	O
to	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financing	O
,	O
as	O
well	O
as	O
information	O
integration	O
infrastructures	O
.	O

The	O
results	O
of	O
this	O
study	O
provide	O
descriptive	O
analyses	O
in	O
detail	O
to	O
map	O
the	O
partnership	O
developments	O
,	O
to	O
enrich	O
the	O
body	O
of	O
knowledge	O
of	O
the	O
partner	O
relationships	O
and	O
to	O
help	O
policy	O
makers	O
understand	O
the	O
coordinated	O
efforts	O
of	O
these	O
health	O
care	O
providers	O
which	O
have	O
developed	O
under	O
this	O
system	O
.	O

It	O
also	O
provides	O
the	O
recommendations	O
for	O
heath	O
policy	O
decision	O
-	O
making	O
and	O
management	O
of	O
networks	O
of	O
health	O
care	O
providers	O
for	O
the	O
future	O
involvement	O
.	O

Methods	O
This	O
study	O
was	O
aimed	O
at	O
providing	O
descriptive	O
analyses	O
to	O
map	O
the	O
partnership	O
development	O
.	O

To	O
understand	O
the	O
actual	O
integration	O
actions	O
done	O
by	O
network	O
members	O
,	O
the	O
theoretical	O
concept	O
employed	O
by	O
network	O
partnerships	O
were	O
described	O
and	O
then	O
the	O
derived	O
survey	O
instrument	O
was	O
developed	O
.	O

Theoretical	O
framework	O
for	O
organization	O
design	O
of	O
network	O
integration	O
The	O
rapid	O
organizational	O
changes	O
in	O
the	O
health	O
care	O
industry	O
have	O
driven	O
theorists	O
from	O
every	O
discipline	O
and	O
across	O
the	O
world	O
to	O
seek	O
an	O
approach	O
that	O
allows	O
organizations	O
to	O
flourish	O
.	O

Organization	O
theory	O
allows	O
investigators	O
to	O
profile	O
an	O
organization	O
from	O
the	O
aspect	O
of	O
patterns	O
and	O
regularities	O
in	O
organizational	O
design	O
and	O
behavior	O
.	O

In	O
the	O
early	O
20th	O
century	O
,	O
classical	O
management	O
theorists	O
claimed	O
that	O
an	O
organization	O
has	O
""""	O
a	O
best	O
way	O
""""	O
to	O
be	O
organized	O
and	O
managed	O
[	O
3	O
]	O
.	O

That	O
implied	O
that	O
all	O
organizations	O
would	O
own	O
the	O
""""	O
same	O
""""	O
organizational	O
styles	O
or	O
structures	O
.	O

In	O
the	O
1960s	O
,	O
several	O
theorists	O
[	O
4	O
-	O
8	O
]	O
challenged	O
this	O
assumption	O
by	O
applying	O
a	O
""""	O
contingency	O
approach	O
""""	O
to	O
propose	O
that	O
there	O
is	O
no	O
best	O
way	O
to	O
organize	O
an	O
organization	O
,	O
and	O
that	O
the	O
effectiveness	O
of	O
an	O
organizational	O
structure	O
varies	O
with	O
the	O
situation	O
of	O
an	O
organization	O
.	O

Furthermore	O
,	O
it	O
is	O
proposed	O
that	O
the	O
best	O
way	O
to	O
organize	O
an	O
organization	O
depends	O
on	O
the	O
nature	O
of	O
the	O
environment	O
to	O
which	O
the	O
organization	O
relates	O
.	O

Contingency	O
theory	O
delineates	O
the	O
concepts	O
""""	O
organization	O
's	O
internal	O
features	O
,	O
""""	O
""""	O
the	O
demands	O
of	O
organizational	O
environments	O
,	O
""""	O
""""	O
best	O
adaptation	O
,	O
""""	O
and	O
,	O
the	O
most	O
important	O
and	O
difficult	O
of	O
all	O
,	O
""""	O
best	O
match	O
""""	O
[	O
9	O
]	O
.	O

Lawrence	O
&	O
Lorsch	O
[	O
7	O
]	O
argued	O
that	O
environments	O
characterized	O
by	O
uncertainty	O
and	O
rapid	O
rates	O
of	O
change	O
in	O
market	O
conditions	O
or	O
technology	O
impose	O
different	O
demands	O
,	O
including	O
constraints	O
and	O
opportunities	O
,	O
on	O
organizations	O
than	O
do	O
placid	O
and	O
stable	O
environments	O
.	O

Similarly	O
to	O
Lawrence	O
and	O
Lorsch	O
's	O
views	O
mentioned	O
above	O
,	O
Galbraith	O
[	O
10,11	O
]	O
stressed	O
the	O
contingency	O
perspective	O
on	O
information	O
processing	O
.	O

The	O
information	O
-	O
processing	O
approach	O
emphasizes	O
that	O
environment	O
,	O
size	O
,	O
and	O
technology	O
impose	O
different	O
information	O
-	O
processing	O
requirements	O
on	O
organizations	O
,	O
and	O
thus	O
an	O
organization	O
must	O
be	O
designed	O
to	O
encourage	O
information	O
flow	O
in	O
both	O
vertical	O
and	O
horizontal	O
directions	O
to	O
achieve	O
the	O
overall	O
tasks	O
of	O
the	O
organization	O
and	O
,	O
finally	O
,	O
organizational	O
effectiveness	O
[	O
11	O
-	O
14	O
]	O
.	O

Some	O
theorists	O
have	O
criticized	O
conventional	O
contingency	O
theorists	O
who	O
presume	O
that	O
organizational	O
structure	O
is	O
driven	O
by	O
the	O
environment	O
.	O

Child	O
[	O
15	O
]	O
,	O
Miller	O
[	O
16	O
]	O
,	O
Van	O
de	O
Ven	O
and	O
Drazin	O
[	O
17	O
]	O
,	O
and	O
Tushman	O
and	O
Romanelli	O
[	O
18	O
]	O
raised	O
such	O
criticisms	O
;	O
they	O
argued	O
that	O
organizations	O
become	O
what	O
they	O
are	O
not	O
only	O
because	O
of	O
the	O
environment	O
,	O
but	O
also	O
because	O
of	O
choices	O
made	O
by	O
members	O
,	O
especially	O
choices	O
about	O
strategy	O
and	O
organizational	O
design	O
.	O

As	O
Thompson	O
's	O
words	O
in	O
the	O
book	O
Organizations	O
in	O
Action	O
[	O
8	O
]	O
put	O
it	O
,	O
""""	O
organizations	O
are	O
not	O
determined	O
simply	O
by	O
their	O
environments	O
(	O
p.27	O
)	O
.	O

""""	O
He	O
also	O
pointed	O
out	O
that	O
""""	O
administration	O
may	O
innovate	O
on	O
any	O
or	O
all	O
of	O
the	O
necessary	O
dimensions	O
,	O
but	O
only	O
to	O
the	O
extent	O
that	O
innovations	O
are	O
acceptable	O
to	O
those	O
on	O
whom	O
the	O
organization	O
can	O
and	O
must	O
depend	O
.	O
""""	O

Instead	O
of	O
assuming	O
that	O
administrators	O
are	O
highly	O
constrained	O
in	O
their	O
decisions	O
,	O
strategic	O
contingency	O
theorists	O
emphasized	O
""""	O
the	O
importance	O
of	O
choice	O
,	O
""""	O
that	O
is	O
,	O
""""	O
the	O
freedom	O
of	O
agency	O
""""	O
[	O
15	O
]	O
.	O

Furthermore	O
,	O
Pfeffer	O
[	O
19	O
]	O
explicitly	O
pointed	O
out	O
that	O
""""	O
organizational	O
structures	O
are	O
the	O
outcomes	O
of	O
political	O
contests	O
within	O
organizations	O
(	O
p.38	O
)	O
.	O

""""	O
Daft	O
[	O
14	O
]	O
proposed	O
a	O
top	O
management	O
model	O
to	O
delineate	O
how	O
""""	O
a	O
strategy	O
is	O
a	O
plan	O
for	O
interacting	O
with	O
the	O
competitive	O
environment	O
to	O
achieve	O
organizational	O
goals	O
.	O
""""	O

He	O
stated	O
that	O
the	O
major	O
responsibility	O
of	O
top	O
management	O
is	O
to	O
determine	O
the	O
goals	O
,	O
strategy	O
,	O
and	O
design	O
of	O
an	O
organization	O
to	O
adapt	O
to	O
a	O
changing	O
environment	O
.	O

To	O
assess	O
the	O
external	O
and	O
internal	O
environments	O
of	O
an	O
organization	O
seems	O
to	O
be	O
the	O
first	O
task	O
for	O
top	O
managers	O
in	O
defining	O
an	O
organization	O
's	O
goals	O
and	O
missions	O
.	O

Then	O
,	O
guided	O
by	O
the	O
goals	O
and	O
missions	O
of	O
the	O
organization	O
,	O
top	O
managers	O
shape	O
the	O
design	O
of	O
the	O
organization	O
,	O
including	O
structural	O
forms	O
,	O
information	O
system	O
,	O
technology	O
,	O
human	B
resources	O
,	O
organizational	O
culture	O
,	O
and	O
inter	O
-	O
organizational	O
linkages	O
,	O
to	O
achieve	O
the	O
final	O
organizational	O
performance	O
.	O

Integration	O
refers	O
to	O
the	O
mechanisms	O
of	O
coordination	O
,	O
the	O
ways	O
guided	O
to	O
partnership	O
goals	O
to	O
fit	O
internal	O
and	O
external	O
conditions	O
[	O
7,20,21	O
]	O
.	O

In	O
the	O
early	O
1990s	O
,	O
proposals	O
for	O
US	O
national	O
health	O
care	O
reform	O
recognized	O
the	O
need	O
for	O
integrating	O
mechanisms	O
to	O
achieve	O
both	O
financial	O
success	O
and	O
quality	O
of	O
care	O
of	O
a	O
well	O
-	O
organized	O
system	O
of	O
care	O
[	O
22,23	O
]	O
.	O

Several	O
researchers	O
also	O
viewed	O
inter	O
-	O
organizational	O
cooperation	O
as	O
resource	O
exchanges	O
,	O
including	O
client	O
referrals	O
,	O
money	O
,	O
and	O
staff	O
[	O
24	O
-	O
27	O
]	O
.	O

From	O
practical	O
ways	O
of	O
viewing	O
integration	O
,	O
the	O
success	O
of	O
integration	O
lies	O
in	O
the	O
coordinative	O
mechanisms	O
and	O
partnership	O
working	O
that	O
support	O
it	O
[	O
28	O
]	O
,	O
including	O
an	O
administrative	O
organization	O
that	O
coordinates	O
the	O
operations	O
of	O
various	O
health	O
care	O
services	O
;	O
a	O
management	O
information	O
system	O
that	O
integrates	O
clinical	O
,	O
utilization	O
,	O
and	O
financial	O
data	O
and	O
follows	O
clients	O
across	O
different	O
settings	O
;	O
a	O
care	O
coordination	O
program	O
such	O
as	O
case	O
management	O
or	O
disease	O
management	O
that	O
works	O
with	O
clients	O
to	O
arrange	O
health	O
care	O
services	O
;	O
and	O
a	O
financial	O
mechanism	O
that	O
enables	O
pooling	O
of	O
funds	O
across	O
services	O
[	O
29	O
-	O
35	O
]	O
.	O

Fox	O
[	O
36	O
]	O
suggested	O
the	O
success	O
of	O
integrated	O
health	O
networks	O
should	O
ensure	O
that	O
the	O
new	O
business	O
link	O
such	O
aspects	O
as	O
technology	O
,	O
functional	O
skills	O
,	O
customer	O
access	O
,	O
management	O
,	O
or	O
products	O
that	O
can	O
be	O
shared	O
across	O
both	O
the	O
core	O
and	O
the	O
new	O
business	O
;	O
to	O
conduct	O
market	O
financial	O
evaluation	O
;	O
to	O
share	O
the	O
risk	O
of	O
vertical	O
integration	O
with	O
outside	O
entities	O
,	O
to	O
develop	O
the	O
management	O
structure	O
that	O
can	O
reflect	O
the	O
degree	O
of	O
coordination	O
necessary	O
to	O
support	O
the	O
core	O
business	O
activities	O
;	O
to	O
ensure	O
that	O
the	O
integration	O
strategy	O
meets	O
the	O
needs	O
of	O
customers	O
,	O
including	O
medical	O
treatment	O
,	O
the	O
use	O
of	O
medical	O
technology	O
,	O
and	O
the	O
preferred	O
methods	O
of	O
purchase	O
;	O
and	O
to	O
measure	O
the	O
new	O
business	O
by	O
its	O
value	O
to	O
the	O
enterprise	O
as	O
a	O
whole	O
,	O
rather	O
than	O
by	O
its	O
profitability	O
as	O
a	O
stand	O
-	O
alone	O
entity	O
.	O

In	O
summary	O
,	O
the	O
effects	O
that	O
integration	O
in	O
inter	O
-	O
organizational	O
designs	O
has	O
on	O
network	O
management	O
were	O
substantial	O
from	O
a	O
managerial	O
perspective	O
.	O

Borrowing	O
the	O
ideas	O
of	O
strategic	O
contingency	O
perspective	O
[	O
8,15,19	O
]	O
and	O
top	O
management	O
model	O
[	O
14	O
]	O
,	O
it	O
could	O
be	O
imply	O
that	O
success	O
(	O
organization	O
performance	O
)	O
in	O
reengineering	O
a	O
network	O
lies	O
in	O
the	O
integration	O
of	O
process	O
and	O
services	O
(	O
see	O
Figure	O
1	O
)	O
,	O
including	O
leadership	O
/	O
governing	O
structure	O
,	O
teamwork	O
between	O
disciplines	O
and	O
patient	O
care	O
,	O
financial	O
planning	O
,	O
and	O
information	O
systems	O
,	O
characterized	O
as	O
the	O
constructs	O
of	O
governance	O
,	O
clinical	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
,	O
respectively	O
,	O
in	O
this	O
study	O
.	O

In	O
addition	O
,	O
another	O
construct	O
,	O
marketing	O
infrastructure	O
,	O
was	O
especially	O
important	O
and	O
designed	O
to	O
explore	O
for	O
PCCNs	O
in	O
this	O
study	O
because	O
of	O
patients	O
'	O
freedom	O
of	O
making	O
healthcare	O
choice	O
and	O
the	O
traditional	O
fragmented	O
health	O
care	O
systems	O
by	O
individual	O
health	O
care	O
organizations	O
in	O
Taiwan	O
.	O

One	O
major	O
reason	O
for	O
Taiwan	O
people	O
's	O
hospital	O
shopping	O
preferences	O
was	O
that	O
Taiwan	O
people	O
usually	O
believe	O
the	O
bigger	O
the	O
facility	O
,	O
the	O
better	O
capacities	O
a	O
facility	O
has	O
no	O
matter	O
on	O
any	O
aspect	O
from	O
medical	O
professionals	O
to	O
tangible	O
medical	O
equipment	O
and	O
plants	O
.	O

And	O
this	O
fallacy	O
made	O
the	O
public	O
want	O
to	O
overuse	O
the	O
facility	O
with	O
high	O
-	O
tech	O
medical	O
services	O
no	O
matter	O
if	O
it	O
fits	O
their	O
needs	O
.	O

From	O
the	O
health	O
policy	O
and	O
management	O
perspectives	O
,	O
therefore	O
,	O
the	O
health	O
care	O
providers	O
were	O
encouraged	O
to	O
market	O
their	O
services	O
as	O
a	O
new	O
corporate	O
identity	O
and	O
brand	O
strategy	O
[	O
37	O
]	O
,	O
including	O
offering	O
tangible	O
resources	O
such	O
as	O
books	O
,	O
libraries	O
,	O
medical	O
equipment	O
,	O
and	O
intangible	O
resources	O
such	O
as	O
knowledge	O
and	O
information	O
exchanges	O
(	O
education	O
)	O
and	O
reputation	O
sharing	O
one	O
another	O
among	O
PCCN	O
members	O
.	O

Furthermore	O
,	O
through	O
the	O
process	O
of	O
marketing	O
resource	O
exchanges	O
,	O
therefore	O
,	O
each	O
PCCN	O
could	O
establish	O
the	O
images	O
of	O
""""	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
""""	O
for	O
the	O
public	O
and	O
for	O
the	O
health	O
care	O
providers	O
.	O

It	O
also	O
makes	O
it	O
be	O
more	O
visible	O
to	O
the	O
public	O
.	O

The	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
were	O
constructed	O
as	O
a	O
conceptual	O
framework	O
in	O
this	O
study	O
to	O
help	O
to	O
portray	O
how	O
the	O
PCCN	O
members	O
have	O
done	O
.	O

The	O
survey	O
instrument	O
development	O
was	O
described	O
in	O
the	O
following	O
.	O

Survey	O
instrument	O
development	O
:	O
integration	O
infrastructures	O
and	O
measurements	O
of	O
partnerships	O
Based	O
on	O
the	O
five	O
integration	O
infrastructures	O
of	O
network	O
management	O
,	O
the	O
structured	O
questionnaire	O
were	O
derived	O
from	O
extensive	O
literature	O
reviews	O
.	O

Governance	O
infrastructure	O
Governance	O
assumes	O
the	O
broad	O
responsibility	O
for	O
organizational	O
goals	O
and	O
survival	O
and	O
involves	O
the	O
series	O
process	O
of	O
setting	O
and	O
monitoring	O
organizational	O
goals	O
and	O
strategy	O
development	O
through	O
a	O
board	O
of	O
representatives	O
[	O
38	O
]	O
.	O

Governance	O
or	O
administrative	O
integration	O
infrastructure	O
in	O
establishing	O
network	O
partnerships	O
refers	O
to	O
administrative	O
structures	O
(	O
or	O
responsibilities	O
)	O
created	O
to	O
facilitate	O
communication	O
,	O
clear	O
lines	O
of	O
authority	O
,	O
accountability	O
,	O
and	O
responsibility	O
for	O
patient	O
care	O
services	O
;	O
to	O
negotiate	O
budgets	O
and	O
financial	O
trade	O
-	O
offs	O
;	O
and	O
to	O
present	O
a	O
cohesive	O
,	O
consistent	O
message	O
in	O
interactions	O
with	O
external	O
agencies	O
and	O
the	O
community	O
[	O
29,39	O
-	O
41	O
]	O
and	O
most	O
important	O
for	O
members	O
in	O
contract	O
agreements	O
,	O
to	O
manage	O
participation	O
[	O
33	O
]	O
.	O

From	O
a	O
multidisciplinary	O
perspective	O
,	O
Mitchell	O
and	O
Shortell	O
[	O
42	O
]	O
applied	O
the	O
concepts	O
of	O
governance	O
and	O
management	O
characteristics	O
in	O
effective	O
community	O
health	O
partnerships	O
.	O

The	O
construct	O
of	O
governance	O
involved	O
several	O
tasks	O
,	O
including	O
setting	O
priorities	O
for	O
strategic	O
goals	O
,	O
choosing	O
the	O
membership	O
composition	O
,	O
obtaining	O
the	O
necessary	O
financial	O
resources	O
,	O
and	O
setting	O
up	O
the	O
accountability	O
systems	O
,	O
and	O
so	O
on	O
.	O

The	O
construct	O
of	O
the	O
management	O
refers	O
to	O
the	O
tasks	O
of	O
engaging	O
and	O
maintaining	O
organizational	O
members	O
'	O
interest	O
in	O
a	O
shared	O
vision	O
and	O
mission	O
,	O
providing	O
appropriate	O
structures	O
and	O
coordination	O
mechanisms	O
for	O
the	O
specified	O
strategies	O
,	O
promoting	O
constructive	O
conflicts	O
and	O
managing	O
destructive	O
conflicts	O
,	O
implementing	O
information	O
systems	O
to	O
monitor	O
the	O
dynamics	O
,	O
adjusting	O
the	O
leadership	O
in	O
the	O
overall	O
membership	O
,	O
and	O
so	O
on	O
.	O

The	O
issues	O
of	O
governance	O
and	O
administrative	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
2,38,40,41,43	O
-	O
47	O
]	O
:	O
•	O
planning	O
the	O
shared	O
visions	O
and	O
missions	O
•	O
determining	O
the	O
shared	O
service	O
strategies	O
,	O
cooperation	O
priorities	O
,	O
policies	O
and	O
principles	O
•	O
identifying	O
the	O
information	O
needed	O
and	O
how	O
to	O
get	O
it	O
•	O
organizing	O
the	O
network	O
dynamics	O
and	O
member	O
roles	O
•	O
leading	O
and	O
managing	O
the	O
conflicts	O
and	O
communication	O
•	O
designing	O
and	O
controlling	O
the	O
shared	O
network	O
performance	O
systems	O
,	O
including	O
indicator	O
settings	O
,	O
feedbacks	O
,	O
and	O
accountability	O
.	O

Clinical	O
infrastructure	O
The	O
idea	O
of	O
care	O
integration	O
begins	O
through	O
such	O
public	O
programs	O
that	O
include	O
social	O
workers	O
in	O
public	O
welfare	O
departments	O
,	O
caseworkers	O
in	O
mental	O
health	O
,	O
or	O
nurses	O
in	O
public	O
health	O
departments	O
.	O

In	O
the	O
late	O
1980s	O
,	O
care	O
integration	O
was	O
deemed	O
necessary	O
for	O
the	O
streamlining	O
of	O
care	O
and	O
negotiating	O
the	O
maze	O
of	O
long	O
-	O
term	O
care	O
services	O
.	O

At	O
that	O
time	O
,	O
it	O
was	O
referred	O
to	O
as	O
service	O
coordination	O
or	O
case	O
management	O
,	O
or	O
in	O
other	O
related	O
terms	O
[	O
29	O
]	O
.	O

The	O
purpose	O
of	O
care	O
integration	O
is	O
to	O
work	O
directly	O
with	O
patients	O
and	O
their	O
families	O
over	O
time	O
to	O
help	O
them	O
arrange	O
and	O
manage	O
the	O
complex	O
resources	O
that	O
patients	O
may	O
need	O
to	O
maintain	O
health	O
and	O
independent	O
functioning	O
.	O

At	O
the	O
same	O
time	O
,	O
care	O
integration	O
is	O
used	O
to	O
achieve	O
the	O
most	O
cost	O
-	O
effective	O
use	O
possible	O
of	O
scarce	O
resources	O
,	O
by	O
steering	O
patients	O
to	O
the	O
health	O
,	O
social	O
,	O
and	O
support	O
services	O
most	O
appropriate	O
for	O
them	O
at	O
a	O
given	O
time	O
[	O
29	O
]	O
.	O

Conrad	O
and	O
Dowling	O
[	O
33	O
]	O
pointed	O
out	O
that	O
to	O
coordinate	O
and	O
integrate	O
patient	O
care	O
relies	O
on	O
connecting	O
patient	O
services	O
at	O
the	O
different	O
stages	O
of	O
the	O
patient	O
care	O
processes	O
.	O

Care	O
coordination	O
in	O
integrated	O
networks	O
can	O
be	O
achieved	O
through	O
integration	O
of	O
training	O
programs	O
and	O
some	O
clinical	O
services	O
,	O
provision	O
of	O
complementary	O
clinical	O
capabilities	O
,	O
clinical	O
geographic	O
proximity	O
design	O
,	O
clear	O
role	O
definition	O
of	O
each	O
institution	O
,	O
commitment	O
and	O
flexibility	O
of	O
leaderships	O
and	O
medical	O
staffs	O
,	O
and	O
the	O
support	O
of	O
a	O
large	O
referring	O
physician	O
groups	O
embracing	O
the	O
affiliation	O
concepts	O
[	O
48	O
]	O
.	O

The	O
issues	O
of	O
clinical	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
48	O
-	O
50	O
]	O
:	O
•	O
planning	O
and	O
differentiating	O
target	O
markets	O
based	O
on	O
the	O
clinical	O
services	O
of	O
the	O
network	O
members	O
•	O
uniting	O
individual	O
clinical	O
professionals	O
for	O
clinical	O
project	O
planning	O
•	O
designing	O
patient	O
-	O
centered	O
care	O
or	O
case	O
management	O
teams	O
•	O
establishing	O
committees	O
responsible	O
for	O
patient	O
-	O
centered	O
case	O
report	O
meetings	O
,	O
case	O
referral	O
,	O
transfer	O
,	O
and	O
tracing	O
,	O
file	O
management	O
(	O
record	O
and	O
information	O
exchanges	O
)	O
,	O
clinical	O
quality	O
management	O
(	O
quality	O
assurance	O
,	O
improvement	O
,	O
risk	O
and	O
malpractice	O
management	O
,	O
and	O
utilization	O
review	O
)	O
,	O
and	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
.	O

Marketing	O
infrastructure	O
Marketing	O
integration	O
refers	O
to	O
how	O
to	O
work	O
together	O
as	O
a	O
whole	O
both	O
from	O
the	O
provider	O
and	O
patient	O
perspectives	O
.	O

One	O
of	O
the	O
case	O
reports	O
interviewing	O
developing	O
integrated	O
delivery	O
system	O
or	O
networks	O
realized	O
that	O
the	O
most	O
important	O
thing	O
is	O
how	O
an	O
integrated	O
system	O
or	O
network	O
is	O
promoted	O
and	O
what	O
is	O
promoted	O
for	O
the	O
consumers	O
[	O
51	O
]	O
,	O
including	O
focusing	O
on	O
product	O
development	O
,	O
making	O
sure	O
the	O
branding	O
holds	O
together	O
,	O
marketing	O
directly	O
to	O
consumers	O
,	O
demonstrating	O
values	O
to	O
consumers	O
,	O
and	O
even	O
conducting	O
marketing	O
research	O
to	O
make	O
efforts	O
for	O
the	O
long	O
term	O
.	O

In	O
a	O
health	O
care	O
network	O
with	O
several	O
organizational	O
members	O
and	O
target	O
patients	O
,	O
the	O
marketing	O
infrastructure	O
in	O
PCCNs	O
here	O
refers	O
to	O
provider	O
members	O
'	O
marketing	O
,	O
meaning	O
the	O
resource	O
sharing	O
and	O
market	O
development	O
in	O
a	O
PCCN	O
as	O
a	O
whole	O
.	O

The	O
issues	O
of	O
the	O
marketing	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
[	O
37,52	O
-	O
54	O
]	O
:	O
•	O
sharing	O
the	O
literature	O
and	O
facility	O
publications	O
among	O
the	O
network	O
members	O
•uniting	O
public	O
promotions	O
such	O
as	O
united	O
activities	O
,	O
electronic	O
and	O
paper	O
media	O
for	O
enhancing	O
the	O
network	O
reputation	O
as	O
""""	O
one	O
system	O
,	O
one	O
brand	O
and	O
quality	O
""""	O
•	O
differentiating	O
target	O
markets	O
of	O
the	O
network	O
for	O
competing	O
in	O
the	O
medical	O
industry	O
.	O

Financial	O
infrastructure	O
Comprehensive	O
,	O
flexible	O
,	O
and	O
adequate	O
financing	O
is	O
a	O
goal	O
of	O
the	O
ideal	O
continuum	O
of	O
care	O
.	O

That	O
component	O
is	O
the	O
most	O
critical	O
and	O
challenging	O
to	O
manage	O
under	O
the	O
changes	O
in	O
the	O
health	O
care	O
delivery	O
environment	O
.	O

Gillies	O
et	O
al.	O
[	O
30	O
]	O
suggested	O
that	O
integrating	O
financial	O
management	O
across	O
operating	O
units	O
adds	O
the	O
greatest	O
value	O
to	O
systems	O
or	O
organizations	O
.	O

In	O
one	O
case	O
study	O
,	O
Bramson	O
et	O
al.	O
[	O
55	O
]	O
also	O
showed	O
that	O
reducing	O
costs	O
through	O
joint	O
purchasing	O
by	O
the	O
radiology	O
departments	O
of	O
a	O
vertically	O
integrated	O
health	O
system	O
could	O
yield	O
substantial	O
savings	O
.	O

The	O
issues	O
of	O
the	O
financial	O
integration	O
in	O
the	O
PCCNs	O
could	O
include	O
:	O
•	O
budgeting	O
•	O
uniting	O
equipment	O
,	O
medical	O
materials	O
,	O
and	O
drug	O
purchasing	O
and	O
routine	O
administrative	O
stuff	O
management	O
•	O
pooling	O
recruitment	O
funds	O
•	O
designing	O
a	O
financial	O
risk	O
and	O
sharing	O
mechanism	O
.	O

Information	O
infrastructure	O
Information	O
is	O
an	O
essential	O
component	O
of	O
an	O
organization	O
.	O

A	O
complete	O
information	O
system	O
can	O
help	O
an	O
organization	O
to	O
integrate	O
its	O
individual	O
units	O
and	O
efficiently	O
manage	O
the	O
continuum	O
.	O

The	O
ideal	O
information	O
system	O
for	O
a	O
continuum	O
of	O
care	O
was	O
conceived	O
of	O
and	O
formed	O
in	O
the	O
mid-1980s	O
[	O
56	O
]	O
.	O

During	O
the	O
late	O
1980s	O
,	O
computer	O
technology	O
began	O
to	O
make	O
an	O
information	O
system	O
feasible	O
and	O
affordable	O
through	O
new	O
computer	O
chips	O
with	O
expanded	O
capability	O
and	O
networking	O
technology	O
.	O

In	O
the	O
1990s	O
,	O
the	O
individual	O
services	O
of	O
the	O
continuum	O
upgraded	O
their	O
information	O
systems	O
to	O
combine	O
clinical	O
,	O
financial	O
,	O
and	O
utilization	O
data	O
[	O
29	O
]	O
.	O

Some	O
studies	O
have	O
argued	O
that	O
the	O
quality	O
of	O
information	O
systems	O
can	O
drive	O
costs	O
down	O
,	O
because	O
a	O
good	O
information	O
system	O
can	O
give	O
physicians	O
easy	O
electronic	O
access	O
to	O
complete	O
the	O
documentation	O
of	O
the	O
patients	O
'	O
clinical	O
records	O
,	O
better	O
inform	O
them	O
about	O
reimbursement	O
and	O
capitation	O
issues	O
,	O
help	O
them	O
easily	O
associate	O
and	O
manage	O
cases	O
together	O
,	O
and	O
achieve	O
a	O
higher	O
level	O
of	O
professional	O
satisfaction	O
[	O
57,58	O
]	O
.	O

Using	O
Inova	O
Health	O
System	O
,	O
an	O
integrated	O
delivery	O
system	O
in	O
northern	O
Virginia	O
,	O
as	O
an	O
example	O
,	O
Wager	O
,	O
Heda	O
,	O
and	O
Austin	O
[	O
59	O
]	O
showed	O
that	O
by	O
developing	O
a	O
health	O
information	O
network	O
within	O
an	O
integrated	O
delivery	O
system	O
,	O
Inova	O
can	O
have	O
a	O
clinical	O
transaction	O
system	O
for	O
hospitals	O
and	O
other	O
entities	O
,	O
a	O
data	O
repository	O
for	O
decision	O
support	O
and	O
outcome	O
management	O
,	O
a	O
managed	O
care	O
information	O
system	O
to	O
support	O
managed	O
care	O
and	O
capitation	O
contracts	O
,	O
and	O
greater	O
capability	O
to	O
acquire	O
physicians	O
.	O

The	O
issues	O
of	O
information	O
coordination	O
include	O
[	O
60	O
-	O
68	O
]	O
:	O
•	O
establishing	O
an	O
electronic	O
medical	O
record	O
system	O
,	O
regional	O
information	O
network	O
for	O
patient	O
clinical	O
and	O
administrative	O
data	O
,	O
clinical	O
service	O
arrangements	O
and	O
administrative	O
work	O
•	O
uniting	O
the	O
system	O
information	O
management	O
and	O
web	O
pages	O
.	O

The	O
structured	O
questionnaire	O
was	O
developed	O
with	O
the	O
wording	O
of	O
practical	O
managerial	O
actions	O
based	O
on	O
the	O
five	O
concepts	O
just	O
mentioned	O
.	O

There	O
were	O
19	O
survey	O
items	O
on	O
governance	O
infrastructure	O
,	O
25	O
on	O
clinical	O
infrastructure	O
,	O
13	O
on	O
marketing	O
infrastructure	O
,	O
20	O
on	O
financial	O
infrastructure	O
,	O
and	O
7	O
on	O
information	O
infrastructure	O
.	O

All	O
84	O
items	O
were	O
,	O
simultaneously	O
,	O
applied	O
to	O
examine	O
the	O
relationships	O
of	O
the	O
clinic	O
's	O
peer	O
members	O
and	O
the	O
relationship	O
of	O
clinic	O
and	O
hospital	O
members	O
in	O
a	O
PCCN	O
,	O
and	O
it	O
resulted	O
in	O
a	O
total	O
of	O
168	O
survey	O
questions	O
.	O

The	O
detailed	O
information	O
of	O
the	O
item	O
questions	O
was	O
listed	O
in	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
.	O

The	O
structured	O
questionnaires	O
were	O
drafted	O
from	O
previous	O
literatures	O
and	O
then	O
examined	O
by	O
two	O
academic	O
professors	O
for	O
theoretical	O
accuracy	O
.	O

Then	O
one	O
pilot	O
study	O
was	O
pre	O
-	O
tested	O
for	O
the	O
PCCN	O
pioneers	O
(	O
i.e.	O
,	O
92	O
network	O
clinic	O
members	O
)	O
and	O
116	O
hospital	O
providers	O
which	O
have	O
partner	O
relationships	O
with	O
other	O
health	O
care	O
organizations	O
(	O
i.e.	O
,	O
hospitals	O
,	O
clinics	O
,	O
long	O
-	O
term	O
care	O
facilities	O
)	O
.	O

The	O
wordings	O
and	O
meanings	O
of	O
each	O
question	O
item	O
were	O
revised	O
to	O
assure	O
content	O
validity	O
.	O

The	O
Cronbach	O
α	O
values	O
for	O
the	O
five	O
integration	O
constructs	O
–	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
finance	O
,	O
and	O
information	O
infrastructure	O
were	O
0.946	O
,	O
0.958	O
,	O
0.932	O
,	O
0.944	O
,	O
and	O
0.898	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
clinic	O
member	O
relationships	O
;	O
and	O
0.945	O
,	O
0.949	O
,	O
0.916	O
,	O
0.948	O
,	O
and	O
0.896	O
for	O
the	O
measures	O
of	O
clinic	O
-	O
hospital	O
member	O
relationships	O
.	O

Study	O
subjects	O
To	O
find	O
the	O
member	O
partnership	O
,	O
we	O
sent	O
questionnaires	O
to	O
1,557	O
individual	O
clinics	O
which	O
had	O
belonged	O
to	O
PCCNs	O
for	O
at	O
least	O
one	O
year	O
,	O
based	O
on	O
information	O
contained	O
in	O
the	O
Taiwan	O
Primary	O
Community	O
Care	O
Network	O
List	O
(	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
2003	O
,	O
2004	O
and	O
2005	O
)	O
.	O

We	O
let	O
clinic	O
members	O
in	O
all	O
PCCNs	O
point	O
out	O
how	O
they	O
coordinate	O
with	O
their	O
peer	O
clinic	O
members	O
and	O
hospital	O
members	O
within	O
a	O
PCCN	O
because	O
individual	O
clinic	O
members	O
could	O
be	O
better	O
informants	O
than	O
hospital	O
members	O
,	O
which	O
need	O
to	O
deal	O
with	O
multiple	O
clinic	O
relationships	O
and	O
therefore	O
might	O
find	O
it	O
hard	O
to	O
describe	O
the	O
coordination	O
involvement	O
one	O
by	O
one	O
with	O
clinic	O
members	O
.	O

Moreover	O
,	O
networks	O
form	O
for	O
various	O
reasons	O
and	O
it	O
might	O
lead	O
to	O
the	O
various	O
involvements	O
by	O
individual	O
network	O
members	O
(	O
i.e.	O
,	O
hospital	O
and	O
clinic	O
members	O
)	O
.	O

Therefore	O
,	O
using	O
the	O
participating	O
clinics	O
as	O
individual	O
survey	O
units	O
,	O
the	O
results	O
could	O
portray	O
the	O
overall	O
dynamics	O
and	O
processes	O
more	O
authentically	O
and	O
detailed	O
throughout	O
all	O
PCCNs	O
in	O
the	O
demonstration	O
project	O
.	O

Nine	O
hundred	O
and	O
twenty	O
-	O
eight	O
clinics	O
responded	O
(	O
59.6	O
%	O
)	O
,	O
with	O
239	O
clinics	O
in	O
the	O
Taipei	O
region	O
,	O
165	O
in	O
the	O
northern	O
region	O
,	O
241	O
in	O
the	O
central	O
region	O
,	O
108	O
in	O
the	O
southern	O
region	O
,	O
150	O
in	O
the	O
Kao	O
-	O
Ping	O
region	O
,	O
and	O
15	O
in	O
the	O
eastern	O
region	O
of	O
Taiwan	O
.	O

Ten	O
clinics	O
had	O
not	O
mentioned	O
their	O
practicing	O
locations	O
.	O

There	O
is	O
no	O
statistically	O
significant	O
difference	O
in	O
geographical	O
distribution	O
between	O
the	O
respondents	O
and	O
the	O
study	O
population	O
(	O
χ2	O
=	O
4.208	O
,	O
p	O
>	O
0.05	O
)	O
.	O

Analytical	O
techniques	O
The	O
data	O
was	O
first	O
analyzed	O
descriptively	O
with	O
frequency	O
counts	O
(	O
percentage	O
)	O
for	O
each	O
survey	O
item	O
,	O
instead	O
of	O
using	O
mean	O
as	O
a	O
statistical	O
method	O
,	O
because	O
the	O
variation	O
among	O
the	O
respondents	O
may	O
not	O
represent	O
the	O
normal	O
distribution	O
and	O
it	O
might	O
ignore	O
the	O
extreme	O
values	O
for	O
the	O
respondents	O
'	O
answers	O
.	O

To	O
compare	O
how	O
the	O
respondents	O
perceived	O
the	O
strength	O
of	O
integration	O
existing	O
in	O
clinic	O
-	O
clinic	O
and	O
clinic	O
-	O
hospital	O
relationships	O
,	O
paired	O
t	O
-	O
tests	O
were	O
performed	O
for	O
individual	O
survey	O
items	O
,	O
using	O
the	O
original	O
numerical	O
scores	O
.	O

Results	O
Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
governance	O
infrastructure	O
With	O
regard	O
to	O
the	O
governance	O
infrastructures	O
,	O
the	O
frequency	O
was	O
counted	O
for	O
each	O
survey	O
item	O
with	O
recalculated	O
scales	O
:	O
disagree	O
(	O
Likert	O
scale	O
1	O
and	O
2	O
)	O
,	O
fair	O
(	O
Likert	O
scale	O
3	O
)	O
,	O
and	O
agree	O
(	O
Likert	O
scale	O
4	O
and	O
5	O
)	O
with	O
individual	O
items	O
.	O

In	O
clinic	O
-	O
clinic	O
relationship	O
(	O
Table	O
2	O
)	O
,	O
the	O
majority	O
of	O
clinic	O
members	O
agree	O
that	O
the	O
determined	O
deals	O
were	O
obeyed	O
(	O
Table	O
2	O
,	O
item	O
1	O
:	O
88.69	O
%	O
)	O
,	O
the	O
goals	O
and	O
strategies	O
of	O
members	O
were	O
well	O
-	O
understood	O
(	O
Table	O
2	O
,	O
item	O
16	O
:	O
79.74	O
%	O
)	O
,	O
and	O
the	O
united	O
principals	O
for	O
individual	O
members	O
were	O
developed	O
(	O
Table	O
2	O
,	O
item	O
15	O
:	O
79.42	O
%	O
)	O
.	O

The	O
higher	O
percentages	O
were	O
also	O
found	O
in	O
clinic	O
-	O
hospital	O
relationship	O
in	O
the	O
same	O
items	O
(	O
Table	O
2	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
establishing	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
:	O
27.91	O
%	O
)	O
,	O
designing	O
and	O
employing	O
the	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
:	O
21.23	O
%	O
)	O
,	O
and	O
establishing	O
communication	O
models	O
and	O
channels	O
(	O
Table	O
2	O
,	O
item	O
12	O
:	O
19.94	O
%	O
)	O
still	O
occupied	O
higher	O
percentages	O
not	O
developed	O
and	O
deserved	O
to	O
been	O
made	O
the	O
focus	O
of	O
more	O
efforts	O
in	O
the	O
future	O
.	O

Paired	O
t	O
-	O
test	O
analyses	O
for	O
all	O
individual	O
survey	O
items	O
of	O
governance	O
infrastructure	O
showed	O
that	O
the	O
deals	O
obeyed	O
(	O
Table	O
2	O
,	O
item1	O
)	O
and	O
plans	O
and	O
goals	O
controlled	O
(	O
Table	O
2	O
,	O
item	O
2	O
)	O
were	O
achieved	O
more	O
in	O
clinic	O
-	O
clinic	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
hospital	O
relationships	O
;	O
however	O
,	O
the	O
design	O
of	O
network	O
performance	O
indicators	O
(	O
Table	O
2	O
,	O
item	O
3	O
)	O
,	O
development	O
of	O
disintegration	O
policy	O
and	O
principals	O
(	O
Table	O
2	O
,	O
item	O
8)	O
,	O
and	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
,	O
item	O
11	O
)	O
were	O
reached	O
more	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
clinical	O
infrastructure	O
Examining	O
the	O
extent	O
of	O
clinical	O
infrastructure	O
for	O
network	O
members	O
,	O
establishing	O
two	O
-	O
directed	O
patient	O
referral	O
systems	O
and	O
patient	O
referral	O
information	O
files	O
(	O
Table	O
3	O
,	O
items	O
35	O
&	O
37	O
)	O
and	O
uniting	O
medical	O
continuing	O
education	O
and	O
on	O
-	O
job	O
education	O
(	O
Table	O
3	O
,	O
item	O
34	O
)	O
were	O
shown	O
at	O
a	O
highly	O
implemented	O
rate	O
in	O
clinic	O
-	O
clinic	O
(	O
more	O
than	O
70	O
%	O
)	O
and	O
clinic	O
-	O
hospital	O
(	O
more	O
than	O
80	O
%	O
)	O
relationships	O
.	O

On	O
the	O
other	O
hand	O
,	O
network	O
members	O
had	O
higher	O
percentages	O
(	O
more	O
than	O
40	O
%	O
)	O
not	O
to	O
think	O
about	O
the	O
possible	O
integration	O
mechanisms	O
including	O
establishing	O
committees	O
to	O
deal	O
with	O
medical	O
malpractice	O
(	O
Table	O
3	O
,	O
item	O
44	O
)	O
,	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
,	O
and	O
designing	O
patient	O
-	O
centered	O
case	O
management	O
teams	O
(	O
Table	O
3	O
,	O
item	O
22	O
)	O
.	O

Overall	O
,	O
there	O
was	O
better	O
clinical	O
integration	O
involvement	O
for	O
all	O
the	O
described	O
items	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
those	O
in	O
clinic	O
-	O
clinic	O
relationships	O
within	O
a	O
network	O
in	O
this	O
study	O
(	O
see	O
Table	O
3	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
marketing	O
infrastructure	O
For	O
marketing	O
planning	O
,	O
the	O
clinics	O
had	O
better	O
integrated	O
marketing	O
activities	O
with	O
their	O
respective	O
hospitals	O
than	O
with	O
peer	O
clinic	O
members	O
within	O
PCCNs	O
for	O
all	O
studied	O
items	O
(	O
Table	O
4	O
,	O
paired	O
t	O
-	O
test	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Examining	O
the	O
clinic	O
-	O
clinic	O
relationships	O
,	O
uniting	O
social	O
activities	O
(	O
Table	O
4	O
,	O
item	O
53	O
)	O
,	O
sharing	O
the	O
individual	O
facility	O
reports	O
for	O
updated	O
services	O
(	O
Table	O
4	O
,	O
item	O
46	O
)	O
,	O
public	O
promotion	O
(	O
Table	O
4	O
,	O
item	O
54	O
)	O
,	O
and	O
uniting	O
and	O
joining	O
the	O
facility	O
activities	O
(	O
Table	O
4	O
,	O
item	O
51	O
)	O
were	O
the	O
top	O
four	O
marketing	O
works	O
done	O
among	O
clinic	O
members	O
(	O
more	O
than	O
60	O
%	O
implemented	O
rate	O
)	O
;	O
and	O
those	O
items	O
also	O
showed	O
a	O
higher	O
implemented	O
rate	O
(	O
more	O
than	O
70	O
%	O
)	O
between	O
clinic	O
and	O
hospital	O
members	O
.	O

On	O
the	O
other	O
hand	O
,	O
facility	O
assets	O
such	O
as	O
reports	O
(	O
Table	O
4	O
,	O
item	O
49	O
)	O
,	O
and	O
professional	O
literatures	O
and	O
books	O
(	O
Table	O
4	O
,	O
item	O
45	O
)	O
were	O
not	O
well	O
-	O
shared	O
among	O
clinic	O
members	O
(	O
""""	O
never	O
-	O
thinking	O
""""	O
rate	O
:	O
42.13	O
%	O
)	O
.	O

In	O
addition	O
,	O
uniting	O
the	O
network	O
publication	O
could	O
make	O
more	O
efforts	O
in	O
the	O
future	O
(	O
""""	O
never	O
-	O
thinking	O
""""	O
rate	O
in	O
item	O
50	O
:	O
39.98	O
%	O
)	O
.	O

The	O
room	O
for	O
clinic	O
-	O
hospital	O
partnership	O
to	O
think	O
about	O
acting	O
was	O
kind	O
of	O
different	O
from	O
those	O
in	O
the	O
clinic	O
-	O
clinic	O
relationship	O
.	O

In	O
addition	O
to	O
the	O
uniting	O
publication	O
that	O
can	O
be	O
encouraged	O
to	O
improve	O
the	O
clinic	O
-	O
hospital	O
relationship	O
(	O
Table	O
4	O
,	O
item	O
50	O
:	O
27.48	O
%	O
)	O
,	O
cooperating	O
in	O
research	O
projects	O
(	O
Table	O
4	O
,	O
item	O
52	O
:	O
25.00	O
%	O
)	O
and	O
identifying	O
and	O
differentiating	O
target	O
markets	O
(	O
Table	O
4	O
,	O
item	O
57	O
:	O
24.57	O
%	O
)	O
had	O
still	O
more	O
opportunities	O
to	O
be	O
focused	O
on	O
in	O
the	O
future	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
financial	O
infrastructure	O
The	O
PCCN	O
members	O
were	O
found	O
to	O
have	O
a	O
lower	O
extent	O
of	O
financial	O
integration	O
as	O
evidenced	O
by	O
higher	O
percentage	O
of	O
'	O
'	O
never	O
thinking	O
'	O
'	O
scale	O
about	O
the	O
survey	O
items	O
on	O
almost	O
all	O
items	O
(	O
see	O
Table	O
5	O
)	O
.	O

Slightly	O
more	O
integration	O
(	O
that	O
is	O
,	O
'	O
'	O
acting	O
'	O
'	O
rate	O
)	O
was	O
found	O
in	O
only	O
four	O
items	O
both	O
in	O
clinic	O
-	O
clinic	O
relationships	O
and	O
in	O
clinic	O
-	O
hospital	O
relationships	O
,	O
including	O
uniting	O
budget	O
planning	O
(	O
Table	O
5	O
:	O
item	O
58	O
)	O
,	O
sharing	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
(	O
Table	O
5	O
:	O
item	O
68	O
)	O
,	O
uniting	O
budgeting	O
for	O
certain	O
services	O
(	O
Table	O
5	O
:	O
items	O
72	O
)	O
,	O
and	O
designing	O
the	O
resource	O
distribution	O
principals	O
based	O
on	O
the	O
whole	O
network	O
goals	O
(	O
Table	O
5	O
:	O
item	O
77	O
)	O
.	O

Further	O
examining	O
the	O
financial	O
infrastructure	O
in	O
clinic	O
-	O
clinic	O
relationship	O
and	O
clinic	O
-	O
hospital	O
relationship	O
,	O
paired	O
-	O
t	O
tests	O
revealed	O
that	O
clinic	O
-	O
hospital	O
partnerships	O
were	O
involved	O
more	O
in	O
places	O
,	O
materials	O
,	O
and	O
equipment	O
sharing	O
and	O
maintenance	O
(	O
Table	O
5	O
,	O
items	O
62	O
and	O
68	O
)	O
(	O
p	O
<	O
0.05	O
)	O
and	O
higher	O
financial	O
infrastructure	O
coordination	O
exists	O
in	O
clinic	O
-	O
clinic	O
relationships	O
(	O
Table	O
5	O
,	O
items	O
58	O
,	O
59	O
,	O
63–65	O
,	O
72	O
,	O
74	O
,	O
75	O
,	O
and	O
77	O
)	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Profiling	O
the	O
partnerships	O
in	O
Taiwan	O
PCCNs	O
:	O
information	O
infrastructure	O
There	O
was	O
significantly	O
greater	O
integration	O
of	O
information	O
in	O
clinic	O
-	O
hospital	O
than	O
clinic	O
-	O
clinic	O
relationships	O
in	O
all	O
items	O
in	O
this	O
category	O
(	O
Table	O
6	O
,	O
paired	O
t	O
-	O
tests	O
,	O
p	O
<	O
0.001	O
)	O
.	O

The	O
greatest	O
integration	O
was	O
found	O
in	O
electronic	O
patient	O
records	O
(	O
Table	O
6	O
:	O
item	O
78	O
)	O
,	O
followed	O
by	O
information	O
integration	O
for	O
patient	O
data	O
(	O
Table	O
6	O
:	O
item	O
79	O
)	O
and	O
clinical	O
service	O
arrangements	O
(	O
Table	O
6	O
:	O
item	O
81	O
)	O
.	O

The	O
lowest	O
level	O
of	O
integration	O
in	O
information	O
infrastructure	O
was	O
found	O
in	O
administrative	O
works	O
such	O
as	O
registration	O
,	O
billing	O
and	O
so	O
on	O
(	O
Table	O
6	O
:	O
item	O
82	O
,	O
'	O
'	O
never	O
-	O
thinking	O
'	O
'	O
rate	O
more	O
than	O
50	O
%	O
)	O
within	O
network	O
members	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
we	O
surveyed	O
943	O
clinics	O
that	O
had	O
belonged	O
to	O
Taiwan	O
PCCNs	O
for	O
more	O
than	O
a	O
year	O
to	O
understand	O
the	O
nature	O
and	O
extent	O
of	O
integration	O
to	O
which	O
they	O
and	O
their	O
associated	O
PCCN	O
members	O
(	O
clinics	O
and	O
hospitals	O
)	O
had	O
in	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
.	O

It	O
was	O
found	O
a	O
wide	O
variance	O
in	O
the	O
kind	O
and	O
degree	O
of	O
integration	O
among	O
them	O
and	O
a	O
lot	O
of	O
room	O
for	O
better	O
integration	O
(	O
Table	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
)	O
.	O

From	O
the	O
governance	O
perspective	O
,	O
we	O
found	O
lower	O
integration	O
was	O
found	O
in	O
the	O
establishment	O
of	O
fair	O
coordination	O
mechanism	O
(	O
Table	O
2	O
:	O
item	O
11	O
)	O
among	O
member	O
clinics	O
and	O
member	O
hospitals	O
.	O

Coordination	O
could	O
be	O
viewed	O
from	O
different	O
perspectives	O
,	O
including	O
the	O
use	O
of	O
standardized	O
languages	O
and	O
forms	O
,	O
organizational	O
rules	O
and	O
procedures	O
,	O
the	O
establishment	O
of	O
common	O
rules	O
,	O
policies	O
,	O
and	O
procedures	O
,	O
and	O
the	O
monitoring	O
through	O
memos	O
,	O
reports	O
,	O
and	O
a	O
computerized	O
information	O
system	O
[	O
69,70	O
]	O
.	O

Facing	O
the	O
cumbersome	O
integration	O
processes	O
,	O
it	O
suggests	O
that	O
each	O
PCCN	O
's	O
headquarters	O
should	O
become	O
actively	O
involved	O
and	O
clarify	O
the	O
authority	O
,	O
responsibility	O
and	O
accountability	O
of	O
individual	O
members	O
,	O
identify	O
the	O
potential	O
conflict	O
sources	O
,	O
and	O
publicize	O
the	O
rules	O
and	O
regulation	O
of	O
network	O
integration	O
dynamics	O
covering	O
decision	O
making	O
processes	O
,	O
market	O
planning	O
,	O
clinical	O
teamwork	O
designs	O
,	O
and	O
financial	O
reports	O
of	O
individual	O
network	O
members	O
.	O

These	O
actions	O
could	O
enhance	O
the	O
trust	O
and	O
respect	O
of	O
network	O
members	O
one	O
another	O
and	O
could	O
improve	O
the	O
small	O
extent	O
of	O
integration	O
found	O
in	O
this	O
study	O
about	O
the	O
mechanisms	O
for	O
communication	O
models	O
and	O
channels	O
in	O
the	O
PCCNs	O
(	O
Table	O
2	O
:	O
item	O
12	O
)	O
.	O

From	O
the	O
network	O
management	O
perspective	O
,	O
communication	O
could	O
occur	O
between	O
the	O
various	O
entities	O
such	O
as	O
between	O
hospital	O
and	O
clinics	O
,	O
primary	O
care	O
physicians	O
and	O
specialists	O
,	O
managers	O
and	O
clinical	O
professionals	O
,	O
and	O
even	O
among	O
the	O
clinical	O
professionals	O
in	O
the	O
network	O
.	O

To	O
develop	O
effective	O
and	O
timely	O
communication	O
channels	O
was	O
the	O
key	O
for	O
the	O
management	O
of	O
integrated	O
organizations	O
[	O
30	O
-	O
32	O
]	O
and	O
could	O
alleviate	O
the	O
tensions	O
that	O
sometimes	O
occur	O
in	O
the	O
dynamics	O
of	O
the	O
multi	O
-	O
organizations	O
.	O

In	O
this	O
study	O
,	O
it	O
was	O
found	O
a	O
low	O
level	O
of	O
involvement	O
of	O
medical	O
teams	O
in	O
medical	O
projects	O
,	O
patient	O
-	O
centered	O
case	O
management	O
,	O
and	O
case	O
report	O
meetings	O
among	O
the	O
network	O
members	O
(	O
Table	O
3	O
:	O
item	O
21	O
,	O
22	O
,	O
and	O
23	O
)	O
from	O
a	O
clinical	O
integration	O
perspective	O
.	O

Several	O
researchers	O
have	O
addressed	O
that	O
clinical	O
integration	O
providing	O
a	O
process	O
of	O
medical	O
management	O
,	O
care	O
management	O
,	O
case	O
management	O
,	O
and	O
patient	O
management	O
designed	O
to	O
transform	O
the	O
traditionally	O
fragmented	O
delivery	O
system	O
into	O
a	O
more	O
cohesive	O
system	O
[	O
71	O
]	O
,	O
and	O
lead	O
to	O
higher	O
service	O
quality	O
and	O
assure	O
financial	O
objectives	O
[	O
72,73	O
]	O
.	O

More	O
attention	O
could	O
be	O
paid	O
to	O
these	O
activities	O
in	O
the	O
future	O
.	O

In	O
addition	O
,	O
it	O
was	O
also	O
found	O
less	O
integration	O
in	O
planning	O
and	O
differentiating	O
clinical	O
market	O
areas	O
(	O
Table	O
3	O
,	O
item	O
20	O
)	O
among	O
the	O
network	O
members	O
in	O
the	O
category	O
of	O
clinical	O
infrastructure	O
.	O

This	O
may	O
result	O
from	O
the	O
existing	O
specialty	O
diversities	O
in	O
individual	O
PCCNs	O
,	O
which	O
might	O
not	O
need	O
to	O
involve	O
planning	O
and	O
differentiating	O
market	O
area	O
based	O
on	O
the	O
members	O
'	O
clinical	O
services	O
at	O
the	O
early	O
stage	O
of	O
network	O
development	O
.	O

There	O
was	O
more	O
involvement	O
in	O
marketing	O
efforts	O
in	O
clinic	O
-	O
hospital	O
relationships	O
than	O
in	O
clinic	O
-	O
clinic	O
relationships	O
.	O

Generally	O
speaking	O
,	O
hospitals	O
have	O
more	O
resources	O
(	O
i.e.	O
,	O
money	O
,	O
human	B
resources	O
,	O
materials	O
,	O
and	O
physical	O
assets	O
)	O
than	O
clinics	O
,	O
which	O
might	O
explain	O
the	O
stronger	O
marketing	O
involvements	O
between	O
the	O
clinic	O
and	O
hospital	O
members	O
,	O
including	O
the	O
library	O
sharing	O
(	O
books	O
and	O
literatures	O
)	O
,	O
facility	O
brochure	O
dissemination	O
,	O
public	O
promoting	O
,	O
and	O
medical	O
research	O
cooperation	O
.	O

These	O
integration	O
efforts	O
also	O
meet	O
the	O
expectation	O
of	O
the	O
national	O
health	O
authority	O
for	O
resource	O
sharing	O
and	O
medical	O
quality	O
image	O
enhancement	O
among	O
the	O
health	O
care	O
providers	O
.	O

Financial	O
infrastructure	O
was	O
found	O
to	O
be	O
the	O
least	O
integrated	O
,	O
with	O
most	O
items	O
never	O
considered	O
.	O

Perhaps	O
the	O
only	O
reason	O
for	O
the	O
higher	O
score	O
of	O
budget	O
planning	O
activities	O
(	O
Table	O
5	O
:	O
items	O
58	O
and	O
77	O
)	O
was	O
that	O
BHNI	O
required	O
each	O
PCCN	O
to	O
design	O
and	O
determine	O
its	O
budgeting	O
arrangement	O
in	O
advance	O
before	O
joining	O
the	O
demonstration	O
project	O
.	O

While	O
slightly	O
more	O
financial	O
involvement	O
was	O
made	O
among	O
network	O
members	O
(	O
Table	O
5	O
:	O
items	O
68	O
,	O
72	O
&	O
73	O
)	O
,	O
possibly	O
due	O
to	O
similar	O
needs	O
,	O
there	O
remains	O
a	O
lot	O
of	O
room	O
for	O
financial	O
integration	O
in	O
the	O
future	O
.	O

There	O
was	O
a	O
need	O
for	O
networks	O
to	O
develop	O
electronic	O
information	O
systems	O
,	O
though	O
creating	O
and	O
managing	O
an	O
integrated	O
information	O
system	O
involves	O
very	O
detailed	O
work	O
.	O

Most	O
of	O
the	O
clinics	O
surveyed	O
have	O
focused	O
more	O
on	O
the	O
individual	O
public	O
members	O
'	O
administrative	O
works	O
such	O
as	O
filing	O
patient	O
medical	O
records	O
,	O
collecting	O
and	O
managing	O
network	O
patient	O
clinical	O
data	O
,	O
and	O
scheduling	O
clinical	O
services	O
,	O
which	O
were	O
required	O
by	O
the	O
BNHI	O
.	O

The	O
factors	O
for	O
the	O
health	O
care	O
managers	O
to	O
adopt	O
the	O
integrated	O
clinical	O
information	O
systems	O
include	O
the	O
decision	O
of	O
make	O
or	O
buy	O
,	O
adoption	O
leadership	O
,	O
adoption	O
objectives	O
,	O
implementation	O
leadership	O
,	O
phased	O
versus	O
simultaneous	O
implementation	O
,	O
parallel	O
systems	O
,	O
information	O
technology	O
implementation	O
policies	O
and	O
practices	O
,	O
use	O
levels	O
and	O
resistance	O
,	O
and	O
realized	O
benefits	O
and	O
return	O
on	O
investment	O
calculation	O
[	O
66	O
]	O
,	O
which	O
might	O
be	O
very	O
cumbersome	O
and	O
time	O
-	O
consuming	O
.	O

It	O
suggests	O
that	O
the	O
network	O
partners	O
might	O
be	O
engaged	O
,	O
firstly	O
,	O
more	O
in	O
simpler	O
network	O
cooperation	O
such	O
as	O
the	O
administrative	O
systems	O
for	O
patient	O
admission	O
to	O
the	O
network	O
members	O
and	O
establishing	O
united	O
web	O
pages	O
for	O
patients	O
to	O
access	O
their	O
family	O
physicians	O
and	O
network	O
members	O
for	O
medical	O
and	O
public	O
promotion	O
purposes	O
.	O

And	O
for	O
further	O
integrated	O
information	O
investments	O
,	O
efforts	O
must	O
be	O
redirected	O
for	O
network	O
members	O
to	O
work	O
together	O
to	O
define	O
the	O
approach	O
to	O
specific	O
classes	O
of	O
integration	O
for	O
the	O
long	O
term	O
[	O
74	O
]	O
.	O

Conclusion	O
This	O
study	O
tried	O
to	O
portray	O
and	O
trace	O
how	O
the	O
facility	O
participants	O
were	O
involved	O
in	O
the	O
Taiwan	O
PCCNs	O
.	O

It	O
was	O
found	O
that	O
Taiwan	O
PCCNs	O
'	O
members	O
had	O
higher	O
involvement	O
in	O
the	O
governance	O
infrastructure	O
,	O
which	O
was	O
usually	O
viewed	O
as	O
the	O
most	O
important	O
for	O
establishment	O
of	O
core	O
values	O
in	O
PCCNs	O
'	O
organization	O
design	O
and	O
management	O
.	O

There	O
existed	O
a	O
higher	O
extent	O
of	O
integration	O
of	O
clinical	O
,	O
marketing	O
,	O
and	O
information	O
infrastructures	O
among	O
the	O
hospital	O
-	O
clinic	O
member	O
relationship	O
than	O
those	O
among	O
clinic	O
members	O
within	O
individual	O
PCCNs	O
.	O

The	O
financial	O
infrastructure	O
was	O
shown	O
the	O
least	O
integrated	O
relative	O
to	O
other	O
functional	O
infrastructures	O
at	O
the	O
early	O
stage	O
of	O
PCCN	O
formation	O
.	O

Page	O
[	O
43	O
]	O
argued	O
that	O
networks	O
form	O
and	O
grow	O
for	O
various	O
reasons	O
,	O
however	O
,	O
only	O
some	O
of	O
them	O
could	O
be	O
compatible	O
with	O
the	O
iterative	O
processes	O
of	O
collaboration	O
.	O

Some	O
participants	O
in	O
the	O
PCCNs	O
may	O
simply	O
seek	O
short	O
-	O
term	O
economic	O
gains	O
and	O
have	O
little	O
interest	O
in	O
joint	O
learning	O
and	O
continuous	O
improvement	O
.	O

From	O
an	O
organizational	O
design	O
perspective	O
,	O
the	O
old	O
phrase	O
proposed	O
by	O
the	O
wisdom	O
of	O
the	O
saying	O
about	O
developing	O
the	O
integrated	O
organizations	O
(	O
networks	O
)	O
should	O
be	O
–	O
""""	O
coming	O
together	O
is	O
the	O
beginning	O
,	O
and	O
working	O
together	O
is	O
the	O
success	O
.	O
""""	O

Page	O
[	O
43	O
]	O
examined	O
the	O
virtual	O
provider	O
organizations	O
such	O
as	O
physician	O
-	O
hospital	O
organizations	O
and	O
pointed	O
out	O
the	O
issue	O
of	O
the	O
provider	O
attitudes	O
and	O
behaviors	O
as	O
the	O
critically	O
successful	O
continuous	O
improvements	O
in	O
the	O
health	O
care	O
environments	O
.	O

A	O
wide	O
variance	O
of	O
degree	O
of	O
network	O
integration	O
in	O
Taiwan	O
PCCNs	O
still	O
leaves	O
room	O
to	O
improve	O
.	O

In	O
this	O
study	O
,	O
the	O
thoroughly	O
surveyed	O
items	O
,	O
that	O
is	O
,	O
the	O
potential	O
network	O
design	O
content	O
,	O
were	O
employed	O
.	O

In	O
addition	O
to	O
provide	O
how	O
the	O
network	O
members	O
have	O
done	O
their	O
initial	O
work	O
at	O
the	O
early	O
stage	O
of	O
network	O
forming	O
in	O
this	O
study	O
,	O
the	O
detailed	O
surveyed	O
items	O
,	O
the	O
concepts	O
proposed	O
by	O
the	O
managerial	O
and	O
theoretical	O
professionals	O
,	O
could	O
be	O
also	O
a	O
guide	O
for	O
those	O
health	O
care	O
providers	O
who	O
have	O
a	O
willingness	O
to	O
join	O
multi	O
-	O
organizations	O
.	O

It	O
suggests	O
that	O
health	O
care	O
providers	O
could	O
take	O
more	O
detailed	O
looks	O
about	O
those	O
surveyed	O
items	O
and	O
give	O
some	O
possible	O
opportunities	O
to	O
create	O
the	O
potential	O
actions	O
.	O

Further	O
research	O
could	O
be	O
empirically	O
done	O
to	O
explore	O
the	O
relative	O
influence	O
of	O
these	O
integration	O
mechanisms	O
on	O
the	O
effectiveness	O
of	O
organizational	O
partnerships	O
.	O

The	O
partnerships	O
within	O
each	O
PCCN	O
represent	O
various	O
relationships	O
that	O
depend	O
on	O
how	O
much	O
the	O
members	O
are	O
engaged	O
in	O
the	O
projects	O
.	O

In	O
addition	O
to	O
the	O
macro	O
concepts	O
including	O
governance	O
,	O
clinical	O
,	O
marketing	O
,	O
financial	O
,	O
and	O
information	O
infrastructures	O
explored	O
in	O
this	O
study	O
,	O
other	O
managerial	O
issues	O
for	O
integrated	O
organizations	O
were	O
also	O
suggested	O
such	O
as	O
formation	O
of	O
an	O
integrated	O
cultural	O
atmosphere	O
,	O
human	B
resources	O
management	O
,	O
physician	O
involvement	O
,	O
mission	O
and	O
commitment	O
establishment	O
,	O
from	O
micro	O
organizational	O
behavior	O
perspective	O
[	O
30	O
-	O
32,34,36,75,76	O
]	O
.	O

Micro	O
managerial	O
and	O
longitudinal	O
research	O
designs	O
could	O
be	O
employed	O
to	O
more	O
precisely	O
catch	O
the	O
never	O
completing	O
integration	O
efforts	O
in	O
the	O
future	O
.	O

Abbreviations	O
primary	O
community	O
care	O
network	O
(	O
PCCN	O
)	O
;	O
Bureau	O
of	O
National	O
Health	O
Insurance	O
(	O
BNHI	O
)	O
Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
BYJL	O
independently	O
designed	O
and	O
conducted	O
this	O
study	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Recombinant	O
activated	O
protein	O
C	O
in	O
sepsis	O
:	O
endothelium	O
protection	O
or	O
endothelium	O
therapy	O
?	O

Abstract	O
Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
.	O

Looney	O
and	O
Mattay	O
,	O
in	O
the	O
previous	O
issue	O
of	O
Critical	O
Care	O
,	O
highlight	O
the	O
role	O
of	O
activated	O
protein	O
C	O
(	O
APC	O
)	O
as	O
a	O
protective	O
endothelial	O
drug	O
in	O
septic	O
situations	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
and	O
it	O
remains	O
uncertain	O
whether	O
these	O
properties	O
are	O
relevant	O
in	O
human	B
septic	O
shock	O
.	O

Before	O
considering	O
recombinant	O
APC	O
(	O
rAPC	O
)	O
as	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
,	O
we	O
have	O
to	O
demonstrate	O
its	O
efficiency	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
when	O
infused	O
a	O
long	O
time	O
after	O
the	O
septic	O
challenge	O
.	O

Nevertheless	O
,	O
if	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	O
earlier	O
.	O

At	O
the	O
least	O
,	O
genetically	O
engineered	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
demonstrate	O
the	O
usefulness	O
of	O
these	O
variants	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
use	O
of	O
recombinant	O
activated	O
protein	O
C	O
(	O
rAPC	O
)	O
is	O
one	O
of	O
the	O
hottest	O
topics	O
in	O
septic	O
shock	O
therapy	O
.	O

The	O
pivotal	O
phase	O
3	O
placebo	O
-	O
controlled	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
(	O
PROWESS	O
)	O
clinical	O
trial	O
demonstrated	O
a	O
19.4	O
%	O
relative	O
risk	O
reduction	O
in	O
28-day	O
mortality	O
(	O
6.1	O
%	O
absolute	O
risk	O
reduction	O
)	O
with	O
an	O
increased	O
risk	O
(	O
3.5	O
%	O
versus	O
2.0	O
%	O
)	O
of	O
serious	O
bleeding	O
events	O
compared	O
with	O
placebo	O
.	O

Two	O
recent	O
and	O
important	O
articles	O
have	O
highlighted	O
the	O
role	O
of	O
APC	O
as	O
a	O
protective	O
endothelial	O
drug	O
[	O
1	O
]	O
and	O
as	O
a	O
cyto	O
-	O
protective	O
drug	O
[	O
2	O
]	O
.	O

Beneficial	O
effects	O
of	O
rAPC	O
in	O
the	O
PROWESS	O
study	O
were	O
thought	O
to	O
be	O
related	O
to	O
a	O
reduction	O
in	O
coagulation	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
to	O
a	O
reduction	O
in	O
inflammatory	O
response	O
to	O
sepsis	O
[	O
3	O
]	O
.	O

Post	O
-	O
PROWESS	O
investigations	O
have	O
been	O
associated	O
with	O
a	O
myriad	O
of	O
cellular	O
or	O
animal	O
studies	O
demonstrating	O
that	O
rAPC	O
,	O
through	O
reactions	O
mediated	O
by	O
endothelial	O
protein	O
C	O
receptor	O
and	O
the	O
effector	O
receptor	O
,	O
protease	O
activated	O
receptor-1	O
,	O
acts	O
directly	O
on	O
cells	O
to	O
exert	O
multiple	O
cytoprotective	O
effects	O
including	O
:	O
down	O
regulation	O
of	O
pro	O
-	O
inflammatory	O
gene	O
expression	O
[	O
4	O
]	O
;	O
anti	O
-	O
inflammatory	O
activities	O
[	O
5	O
]	O
;	O
anti	O
-	O
apoptotic	O
activity	O
[	O
6	O
]	O
;	O
and	O
protection	O
of	O
endothelial	O
barrier	O
function	O
[	O
1,2	O
]	O
.	O

Endothelium	O
dysfunction	O
is	O
one	O
of	O
the	O
hallmarks	O
of	O
sepsis	O
[	O
7	O
]	O
.	O

Sepsis	O
,	O
per	O
se	O
,	O
may	O
induce	O
phenotypic	O
modulations	O
of	O
the	O
endothelium	O
through	O
direct	O
or	O
indirect	O
interaction	O
of	O
the	O
endothelial	O
layer	O
with	O
components	O
of	O
the	O
bacterial	O
wall	O
,	O
inducing	O
a	O
myriad	O
of	O
host	O
-	O
derived	O
factors	O
from	O
endothelial	O
cells	O
.	O

Phenotypic	O
modifications	O
include	O
changes	O
in	O
pro	O
-	O
coagulant	O
and	O
proadhesive	O
properties	O
,	O
increased	O
endothelial	O
permeability	O
,	O
endothelial	O
cell	O
apoptosis	O
and	O
changes	O
in	O
vasomotor	O
properties	O
;	O
the	O
last	O
of	O
these	O
is	O
crucial	O
since	O
vasoplegia	O
is	O
directly	O
related	O
to	O
septic	O
shock	O
mortality	O
.	O

Recent	O
animal	O
and	O
human	B
data	O
have	O
suggested	O
that	O
rAPC	O
may	O
improve	O
both	O
vascular	O
and	O
myocardial	O
dysfunction	O
and	O
vascular	O
reactivity	O
to	O
catecholamine	O
during	O
endotoxin	O
and/or	O
septic	O
challenge	O
[	O
8,9	O
]	O
.	O

From	O
bench	O
to	O
bedside	O
Experimental	O
evidence	O
supports	O
a	O
role	O
of	O
APC	O
in	O
maintaining	O
the	O
integrity	O
of	O
the	O
endothelium	O
through	O
both	O
direct	O
and	O
indirect	O
mechanisms	O
.	O

Nevertheless	O
,	O
the	O
results	O
of	O
in	O
vivo	O
studies	O
are	O
less	O
explicit	O
.	O

In	O
a	O
retrospective	O
study	O
of	O
septic	O
shock	O
in	O
humans	B
,	O
Monnet	O
and	O
colleagues	O
[	O
9	O
]	O
demonstrated	O
that	O
APC	O
infusion	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
delivered	O
norepinephrine	O
.	O

Wiel	O
and	O
colleagues	O
[	O
10	O
]	O
demonstrated	O
in	O
a	O
rabbit	B
model	O
of	O
endotoxin	O
induced	O
shock	O
that	O
APC	O
decreased	O
aorta	O
endothelial	O
injury	O
.	O

By	O
contrast	O
,	O
in	O
a	O
lung	O
model	O
of	O
endotoxin	O
induced	O
inflammation	O
,	O
Robriquet	O
and	O
colleagues	O
[	O
11	O
]	O
demonstrated	O
a	O
trend	O
to	O
an	O
increased	O
vascular	O
permeability	O
using	O
high	O
doses	O
of	O
human	B
APC	O
.	O

This	O
last	O
result	O
was	O
in	O
sharp	O
contrast	O
with	O
the	O
results	O
obtained	O
by	O
Nick	O
and	O
colleagues	O
[	O
12	O
]	O
in	O
a	O
human	B
model	O
of	O
pulmonary	O
endotoxin	O
administration	O
.	O

APC	O
appears	O
to	O
improve	O
mortality	O
in	O
septic	O
shock	O
with	O
a	O
high	O
APACHE	O
2	O
score	O
and	O
is	O
potentially	O
detrimental	O
in	O
severe	O
sepsis	O
.	O

In	O
rats	O
,	O
APC	O
markedly	O
decreased	O
tumour	O
necrosis	O
factor	O
concentrations	O
whereas	O
they	O
remained	O
unchanged	O
in	O
either	O
human	B
septic	O
shock	O
or	O
endotoxemia	O
.	O

The	O
question	O
arises	O
,	O
therefore	O
,	O
as	O
to	O
whether	O
it	O
is	O
truly	O
possible	O
to	O
reconcile	O
all	O
these	O
discrepancies	O
?	O

Moreover	O
,	O
can	O
these	O
stirring	O
laboratory	O
data	O
be	O
translated	O
into	O
clinical	O
practice	O
?	O

Limitations	O
of	O
experimental	O
studies	O
:	O
endothelium	O
protection	O
versus	O
endothelium	O
therapy	O
Clearly	O
,	O
in	O
cellular	O
and	O
animal	O
models	O
,	O
rAPC	O
has	O
been	O
given	O
either	O
as	O
a	O
pre	O
-	O
treatment	O
or	O
concurrent	O
with	O
septic	O
challenge	O
.	O

This	O
mode	O
of	O
administration	O
favours	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
rAPC	O
,	O
which	O
are	O
particularly	O
efficient	O
in	O
murine	O
models	O
in	O
protecting	O
the	O
endothelium	O
from	O
cytokine	O
-	O
mediated	O
apoptosis	O
or	O
upregulation	O
of	O
endothelial	O
adhesion	O
molecules	O
.	O

Thus	O
,	O
studies	O
using	O
post	O
-	O
injury	O
treatment	O
are	O
needed	O
in	O
models	O
that	O
mimic	O
septic	O
shock	O
,	O
such	O
as	O
experimental	O
pneumonia	O
or	O
peritonitis	O
treated	O
by	O
antibiotics	O
and	O
volume	O
resuscitation	O
,	O
and	O
where	O
the	O
effects	O
of	O
rAPC	O
would	O
be	O
investigated	O
16	O
to	O
24	O
hours	O
after	O
septic	O
challenge	O
.	O

If	O
we	O
can	O
demonstrate	O
the	O
efficiency	O
of	O
rAPC	O
to	O
protect	O
or	O
to	O
reduce	O
endothelium	O
injury	O
in	O
these	O
conditions	O
,	O
we	O
can	O
ultimately	O
postulate	O
that	O
rAPC	O
is	O
also	O
a	O
therapeutic	O
drug	O
for	O
the	O
endothelium	O
.	O

The	O
earlier	O
the	O
better	O
If	O
rAPC	O
is	O
efficient	O
when	O
infused	O
in	O
the	O
early	O
phase	O
of	O
septic	O
challenge	O
,	O
we	O
thus	O
need	O
to	O
treat	O
our	O
patients	O
earlier	O
.	O

At	O
least	O
two	O
studies	O
suggest	O
that	O
treatment	O
with	O
rAPC	O
within	O
24	O
hours	O
may	O
carry	O
a	O
larger	O
survival	O
advantage	O
for	O
patients	O
with	O
severe	O
sepsis	O
,	O
compared	O
with	O
those	O
treated	O
more	O
than	O
24	O
hours	O
after	O
organ	O
dysfunction	O
[	O
13	O
]	O
.	O

Interventions	O
directed	O
at	O
specific	O
endpoints	O
,	O
when	O
initiated	O
early	O
in	O
the	O
'	O
golden	O
hours	O
'	O
of	O
a	O
patient	O
's	O
condition	O
,	O
seem	O
to	O
be	O
promising	O
[	O
14	O
]	O
.	O

The	O
beneficial	O
effects	O
of	O
earlier	O
administration	O
of	O
rAPC	O
to	O
appropriate	O
patients	O
may	O
fit	O
into	O
this	O
paradigm	O
.	O

The	O
future	O
Extensive	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
have	O
focused	O
on	O
the	O
cytoprotective	O
effects	O
of	O
APC	O
and	O
most	O
authors	O
agree	O
that	O
its	O
anticoagulant	O
and	O
cytoprotective	O
effects	O
are	O
mediated	O
by	O
distinct	O
APC	O
structural	O
features	O
.	O

Positively	O
charged	O
residues	O
in	O
surface	O
loops	O
in	O
the	O
APC	O
protease	O
domain	O
have	O
been	O
identified	O
as	O
participating	O
in	O
the	O
anticoagulant	O
activity	O
but	O
not	O
in	O
cellular	O
effects	O
.	O

Hence	O
,	O
variants	O
have	O
been	O
designed	O
with	O
greater	O
anti	O
-	O
apoptotic	O
activity	O
and	O
reduced	O
anticoagulant	O
activity	O
relative	O
to	O
wild	O
-	O
type	O
APC	O
[	O
2	O
]	O
.	O

Whether	O
these	O
genetically	O
engineered	O
variants	O
actually	O
provide	O
superior	O
pharmacological	O
properties	O
remains	O
to	O
be	O
elucidated	O
in	O
vivo	O
.	O

Such	O
investigations	O
may	O
allow	O
the	O
design	O
of	O
therapeutic	O
APC	O
variants	O
with	O
decreased	O
anticoagulant	O
activity	O
to	O
reduce	O
the	O
risk	O
of	O
bleeding	O
on	O
the	O
one	O
hand	O
,	O
but	O
also	O
with	O
normal	O
cytoprotective	O
properties	O
in	O
order	O
to	O
retain	O
full	O
beneficial	O
effects	O
on	O
sepsis	O
outcome	O
.	O

Abbreviations	O
PROWESS	O
=	O
Protein	O
C	O
Worldwide	O
Evaluation	O
in	O
Severe	O
Sepsis	O
;	O
rAPC	O
=	O
recombinant	O
activated	O
protein	O
C.	O
Competing	O
interests	O
BL	O
has	O
received	O
reimbursements	O
and	O
funding	O
from	O
Eli	O
Lilly	O
,	O
France	O
.	O

The	O
comparative	O
analysis	O
of	O
statistics	O
,	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
in	O
the	O
automated	O
annotation	O
problem	O
Abstract	O
Background	O
This	O
paper	O
discusses	O
the	O
problem	O
of	O
automated	O
annotation	O
.	O

It	O
is	O
a	O
continuation	O
of	O
the	O
previous	O
work	O
on	O
the	O
A4-algorithm	O
(	O
Adaptive	O
algorithm	O
of	O
automated	O
annotation	O
)	O
developed	O
by	O
Leontovich	O
and	O
others	O
.	O

Results	O
A	O
number	O
of	O
new	O
statistics	O
for	O
the	O
automated	O
annotation	O
of	O
biological	O
sequences	O
is	O
introduced	O
.	O

All	O
these	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
.	O

Conclusion	O
Some	O
of	O
the	O
statistics	O
yield	O
a	O
prediction	O
quality	O
that	O
is	O
significantly	O
higher	O
(	O
up	O
to	O
1.5	O
times	O
higher	O
)	O
in	O
comparison	O
with	O
the	O
results	O
obtained	O
with	O
the	O
A4-procedure	O
.	O

Background	O
Many	O
biological	O
databanks	O
,	O
both	O
dealing	O
with	O
protein	O
sequences	O
(	O
e.g.	O
,	O
SWISS	O
-	O
PROT	O
)	O
and	O
nucleotide	O
sequences	O
(	O
e.g.	O
,	O
GeneBank	O
)	O
,	O
contain	O
not	O
only	O
primary	O
structures	O
of	O
sequences	O
(	O
i.e.	O
,	O
sequences	O
of	O
letters	O
–	O
amino	O
acids	O
or	O
nucleotides	O
)	O
,	O
but	O
also	O
information	O
about	O
functions	O
and	O
properties	O
of	O
these	O
sequences	O
.	O

This	O
information	O
is	O
stored	O
in	O
so	O
called	O
description	O
fields	O
of	O
the	O
sequences	O
.	O

There	O
exist	O
different	O
types	O
of	O
description	O
fields	O
–	O
KW	O
(	O
KeyWords	O
)	O
,	O
DE	O
(	O
Descriptions	O
)	O
,	O
...	O
,	O
FT	O
(	O
Feature	O
Table	O
)	O
,	O
...	O
;	O
elements	O
of	O
description	O
fields	O
are	O
referred	O
to	O
as	O
words	O
.	O

Words	O
from	O
KW	O
,	O
DE	O
,	O
...	O
fields	O
describe	O
a	O
sequence	O
as	O
a	O
whole	O
,	O
while	O
words	O
from	O
FT	O
fields	O
correspond	O
to	O
certain	O
positions	O
(	O
letters	O
)	O
of	O
a	O
sequence	O
.	O

The	O
automated	O
annotation	O
problem	O
can	O
be	O
described	O
as	O
follows	O
.	O

Consider	O
a	O
biological	O
sequence	O
(	O
referred	O
to	O
as	O
a	O
query	O
sequence	O
)	O
with	O
known	O
primary	O
structure	O
(	O
i.e.	O
letter	O
sequence	O
)	O
but	O
unknown	O
properties	O
and	O
functions	O
(	O
i.e.	O
,	O
description	O
fields	O
)	O
.	O

The	O
task	O
is	O
to	O
determine	O
functions	O
and	O
properties	O
of	O
this	O
sequence	O
(	O
in	O
other	O
words	O
,	O
to	O
restore	O
its	O
description	O
fields	O
)	O
on	O
the	O
basis	O
of	O
the	O
primary	O
structure	O
.	O

The	O
annotation	O
should	O
be	O
fully	O
automated	O
.	O

This	O
is	O
the	O
subject	O
of	O
the	O
current	O
paper	O
.	O

There	O
are	O
two	O
main	O
approaches	O
to	O
the	O
solution	O
of	O
this	O
problem	O
.	O

In	O
the	O
first	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
static	O
one	O
)	O
a	O
certain	O
fixed	O
protein	O
classification	O
(	O
grouping	O
proteins	O
according	O
to	O
similarity	O
in	O
structure	O
and/or	O
functions	O
)	O
,	O
specified	O
beforehand	O
,	O
is	O
used	O
:	O
for	O
a	O
query	O
protein	O
the	O
search	O
of	O
a	O
relative	O
group	O
(	O
super	O
family	O
)	O
is	O
performed	O
on	O
the	O
basis	O
of	O
primary	O
structures	O
,	O
and	O
properties	O
/	O
functions	O
of	O
this	O
group	O
are	O
extended	O
to	O
the	O
query	O
protein	O
.	O

An	O
example	O
of	O
this	O
approach	O
is	O
described	O
in	O
the	O
paper	O
by	O
W.	O
Fleischmann	O
et	O
al.	O
[	O
1	O
]	O
,	O
it	O
uses	O
the	O
protein	O
classification	O
(	O
more	O
than	O
1000	O
families	O
)	O
,	O
stored	O
in	O
the	O
Prosite	O
databank	O
.	O

The	O
second	O
approach	O
(	O
it	O
can	O
be	O
called	O
a	O
dynamic	O
or	O
an	O
adaptive	O
one	O
)	O
does	O
not	O
use	O
protein	O
classification	O
.	O

Instead	O
,	O
a	O
""""	O
dynamic	O
""""	O
collection	O
of	O
bank	O
sequences	O
that	O
are	O
similar	O
to	O
a	O
query	O
sequence	O
is	O
generated	O
,	O
and	O
then	O
common	O
properties	O
/	O
functions	O
of	O
these	O
bank	O
sequences	O
are	O
extended	O
to	O
the	O
query	O
sequence	O
.	O

One	O
of	O
the	O
first	O
examples	O
of	O
this	O
approach	O
was	O
described	O
by	O
M.A.	O
Andrade	O
et	O
al.	O
[	O
2	O
]	O
.	O

In	O
this	O
paper	O
the	O
prediction	O
was	O
based	O
on	O
so	O
called	O
word	O
reliability	O
function	O
–	O
a	O
function	O
depending	O
on	O
the	O
degree	O
of	O
similarity	O
between	O
a	O
query	O
sequence	O
and	O
corresponding	O
bank	O
sequences	O
.	O

In	O
other	O
examples	O
of	O
annotation	O
procedures	O
based	O
on	O
the	O
dynamic	O
approach	O
prediction	O
was	O
performed	O
in	O
a	O
""""	O
naive	O
""""	O
way	O
–	O
all	O
properties	O
/	O
functions	O
of	O
similar	O
proteins	O
were	O
extended	O
to	O
a	O
query	O
protein	O
,	O
or	O
using	O
stochastic	O
methods	O
–	O
only	O
properties	O
/	O
functions	O
that	O
are	O
most	O
frequent	O
for	O
the	O
collection	O
of	O
similar	O
proteins	O
were	O
extended	O
(	O
see	O
[	O
3,4	O
]	O
)	O
.	O

The	O
current	O
paper	O
uses	O
the	O
dynamic	O
approach	O
.	O

This	O
paper	O
is	O
a	O
sequel	O
to	O
paper	O
[	O
5	O
]	O
that	O
describes	O
the	O
A4	O
algorithm	O
(	O
the	O
Adaptive	O
Algorithm	O
of	O
Automated	O
Annotation	O
)	O
,	O
so	O
results	O
of	O
the	O
paper	O
[	O
5	O
]	O
are	O
constantly	O
used	O
here	O
.	O

The	O
A4	O
algorithm	O
is	O
based	O
on	O
a	O
stochastic	O
approach	O
.	O

More	O
precisely	O
,	O
it	O
is	O
based	O
on	O
the	O
notion	O
of	O
transfer	O
probabilities	O
.	O

Transfer	O
probabilities	O
are	O
the	O
probabilities	O
of	O
word	O
transfer	O
(	O
extension	O
)	O
from	O
description	O
fields	O
of	O
one	O
sequence	O
to	O
description	O
fields	O
of	O
another	O
sequence	O
;	O
they	O
depend	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
word	O
transfer	O
frequencies	O
in	O
the	O
found	O
collection	O
of	O
sequences	O
similar	O
to	O
a	O
query	O
sequence	O
.	O

For	O
each	O
word	O
from	O
description	O
fields	O
of	O
sequences	O
included	O
in	O
the	O
collection	O
the	O
prediction	O
of	O
the	O
fact	O
that	O
this	O
word	O
belongs	O
(	O
or	O
does	O
not	O
belong	O
)	O
to	O
the	O
description	O
field	O
of	O
a	O
query	O
sequence	O
is	O
performed	O
;	O
this	O
prediction	O
is	O
based	O
on	O
transfer	O
probabilities	O
.	O

In	O
the	O
current	O
paper	O
we	O
introduce	O
and	O
analyze	O
a	O
number	O
of	O
new	O
statistics	O
for	O
the	O
prediction	O
.	O

All	O
of	O
them	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
[	O
6	O
]	O
(	O
which	O
is	O
the	O
most	O
powerful	O
criterion	O
)	O
.	O

As	O
in	O
[	O
5	O
]	O
,	O
all	O
these	O
statistics	O
are	O
evaluated	O
using	O
transfer	O
probabilities	O
.	O

Two	O
approaches	O
to	O
statistics	O
definition	O
are	O
introduced	O
:	O
a	O
""""	O
discrete	O
""""	O
approach	O
and	O
a	O
""""	O
continuous	O
""""	O
approach	O
.	O

A	O
detailed	O
analysis	O
and	O
comparison	O
of	O
introduced	O
statistics	O
are	O
performed	O
and	O
the	O
best	O
statistics	O
are	O
selected	O
.	O

The	O
emphasis	O
is	O
on	O
a	O
precise	O
description	O
of	O
the	O
way	O
these	O
statistics	O
can	O
be	O
constructed	O
using	O
well	O
-	O
known	O
concepts	O
from	O
statistical	O
decision	O
theory	O
.	O

The	O
current	O
A4	O
algorithm	O
uses	O
SPKW	O
as	O
a	O
language	O
of	O
annotation	O
.	O

Of	O
course	O
,	O
it	O
is	O
possible	O
to	O
use	O
GO	O
terms	O
in	O
A4	O
as	O
well	O
.	O

That	O
would	O
facilitate	O
comparison	O
with	O
other	O
approaches	O
.	O

However	O
,	O
at	O
the	O
current	O
stage	O
of	O
our	O
research	O
we	O
test	O
and	O
choose	O
""""	O
the	O
best	O
decision	O
making	O
algorithm	O
""""	O
,	O
not	O
""""	O
the	O
best	O
annotation	O
terminology	O
""""	O
.	O

Obviously	O
,	O
which	O
annotation	O
is	O
used	O
hardly	O
matters	O
for	O
the	O
problem	O
of	O
finding	O
the	O
optimal	O
""""	O
decision	O
making	O
algorithm	O
""""	O
Results	O
Algorithm	O
description	O
Generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
First	O
,	O
we	O
introduce	O
some	O
notation	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
""""	O
a	O
word	O
ω	O
belongs	O
to	O
a	O
sequence	O
π	O
""""	O
instead	O
of	O
""""	O
a	O
word	O
ω	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
sequence	O
π	O
""""	O
.	O

If	O
ω	O
is	O
a	O
KW	O
-	O
type	O
word	O
(	O
to	O
be	O
definite	O
,	O
further	O
in	O
the	O
paper	O
we	O
consider	O
only	O
amino	O
-	O
acid	O
sequences	O
and	O
KW	O
-	O
type	O
words	O
)	O
,	O
we	O
write	O
ω	O
∈	O
KW	O
[	O
π	O
]	O
.	O

The	O
application	O
of	O
an	O
annotation	O
procedure	O
to	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
(	O
i.e.	O
,	O
the	O
prediction	O
of	O
description	O
fields	O
)	O
starts	O
with	O
generating	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
this	O
query	O
sequence	O
with	O
known	O
description	O
fields	O
.	O

These	O
similar	O
sequences	O
are	O
selected	O
from	O
a	O
certain	O
databank	O
that	O
contains	O
annotated	O
amino	O
-	O
acid	O
sequences	O
,	O
e.g.	O
,	O
SWISS	O
-	O
PROT	O
.	O

There	O
exist	O
different	O
approaches	O
to	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
(	O
see	O
[	O
7	O
]	O
)	O
.	O

This	O
collections	O
can	O
be	O
generated	O
on	O
the	O
basis	O
of	O
global	O
alignments	O
between	O
a	O
query	O
sequence	O
and	O
bank	O
sequences	O
(	O
global	O
alignments	O
can	O
be	O
constructed	O
,	O
e.g.	O
,	O
by	O
CLUSTAL	O
procedure	O
)	O
using	O
an	O
identity	O
percentage	O
or	O
,	O
more	O
generally	O
,	O
a	O
similarity	O
percentage	O
as	O
a	O
similarity	O
measure	O
.	O

Another	O
variant	O
is	O
to	O
use	O
local	O
alignments	O
(	O
i.e.	O
,	O
alignments	O
of	O
most	O
similar	O
fragments	O
of	O
compared	O
sequences	O
,	O
see	O
[	O
7	O
]	O
)	O
instead	O
of	O
global	O
alignments	O
.	O

Local	O
alignments	O
can	O
be	O
constructed	O
,	O
for	O
example	O
,	O
by	O
a	O
well	O
-	O
known	O
BLAST	O
procedure	O
[	O
7,8	O
]	O
,	O
in	O
which	O
sum	O
of	O
weights	O
or	O
a	O
corresponding	O
e	O
-	O
value	O
serves	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
fragments	O
(	O
and	O
thus	O
between	O
compared	O
sequences	O
)	O
.	O

Other	O
alignment	O
procedures	O
are	O
also	O
acceptable	O
;	O
alignment	O
procedure	O
selection	O
does	O
not	O
play	O
a	O
critical	O
role	O
.	O

Since	O
we	O
build	O
on	O
the	O
A4	O
procedure	O
,	O
we	O
briefly	O
summarize	O
that	O
approach	O
.	O

In	O
the	O
A4	O
procedure	O
a	O
collection	O
of	O
similar	O
sequences	O
is	O
generated	O
on	O
the	O
basis	O
of	O
local	O
alignments	O
of	O
a	O
special	O
type	O
.	O

These	O
alignments	O
are	O
constructed	O
by	O
the	O
DotHelix	O
procedure	O
(	O
[	O
9	O
]	O
)	O
,	O
in	O
which	O
the	O
""""	O
power	O
""""	O
(	O
sum	O
of	O
weights	O
divided	O
by	O
the	O
root	O
of	O
the	O
length	O
of	O
the	O
local	O
alignment	O
,	O
see	O
[	O
9,10	O
]	O
for	O
details	O
)	O
serves	O
as	O
a	O
similarity	O
measure	O
.	O

Each	O
local	O
alignment	O
constructed	O
by	O
DotHelix	O
procedure	O
is	O
a	O
chain	O
of	O
closely	O
located	O
gapless	O
local	O
alignments	O
.	O

Local	O
alignments	O
that	O
are	O
generated	O
during	O
the	O
construction	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
are	O
referred	O
to	O
as	O
primary	O
local	O
alignments	O
.	O

Each	O
sequence	O
from	O
a	O
collection	O
of	O
similar	O
sequences	O
π1,	O
...	O
,πn	O
can	O
have	O
several	O
corresponding	O
primary	O
local	O
alignments	O
,	O
but	O
for	O
the	O
sake	O
of	O
simplicity	O
we	O
assume	O
that	O
each	O
similar	O
sequence	O
πi	O
has	O
exactly	O
one	O
corresponding	O
primary	O
local	O
alignment	O
,	O
the	O
one	O
with	O
the	O
maximum	O
similarity	O
measure	O
.	O

Let	O
μi	O
denote	O
the	O
similarity	O
measure	O
(	O
power	O
)	O
of	O
a	O
primary	O
alignment	O
that	O
corresponds	O
to	O
πi	O
.	O

The	O
value	O
of	O
μi	O
characterizes	O
the	O
measure	O
of	O
similarity	O
between	O
fragments	O
that	O
constitute	O
this	O
alignment	O
;	O
at	O
the	O
same	O
time	O
μi	O
can	O
be	O
treated	O
as	O
a	O
measure	O
of	O
similarity	O
between	O
the	O
whole	O
query	O
sequence	O
π0	O
and	O
the	O
whole	O
similar	O
sequence	O
πi	O
.	O

We	O
assume	O
that	O
similar	O
sequences	O
are	O
ordered	O
in	O
such	O
a	O
way	O
that	O
μ1	O
≥	O
μ2	O
≥	O
...	O

≥	O
μn	O
.	O

The	O
exact	O
stochastic	O
formulation	O
of	O
the	O
problem	O
Let	O
π0	O
be	O
an	O
unannotated	O
amino	O
-	O
acid	O
query	O
sequence	O
,	O
π1,	O
...	O
,πn	O
be	O
a	O
collection	O
of	O
sequences	O
similar	O
to	O
π0	O
,	O
and	O
ω	O
be	O
a	O
word	O
that	O
belongs	O
to	O
some	O
similar	O
sequences	O
(	O
i.e.	O
,	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
.	O

for	O
at	O
least	O
one	O
similar	O
sequence	O
πi	O
)	O
.	O

The	O
task	O
is	O
to	O
predict	O
whether	O
this	O
word	O
ω	O
belongs	O
to	O
the	O
query	O
sequence	O
π0	O
or	O
not	O
.	O

Let	O
us	O
put	O
ξi	O
=	O
1	O
,	O
if	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
,	O
and	O
ξi	O
=	O
0	O
,	O
if	O
ω	O
∉	O
KW	O
[	O
πi	O
]	O
(	O
i	O
=	O
1,	O
...	O
,n	O
)	O
.	O

we	O
also	O
put	O
ξ0	O
=	O
1	O
,	O
if	O
ω	O
∈	O
KW	O
[	O
π0	O
]	O
,	O
and	O
ξ0	O
=	O
0	O
,	O
if	O
ω	O
∉	O
KW	O
[	O
π0	O
]	O
.	O

Variables	O
ξi	O
can	O
be	O
treated	O
as	O
random	O
variates	O
Actually	O
,	O
they	O
depend	O
on	O
ω	O
.	O

For	O
the	O
sake	O
of	O
brevity	O
we	O
write	O
ξi	O
instead	O
of	O
ξi	O
(	O
ω	O
)	O
.	O

In	O
this	O
notation	O
the	O
problem	O
can	O
be	O
stated	O
as	O
follows	O
.	O

Measures	O
of	O
similarity	O
μi	O
between	O
the	O
query	O
sequence	O
π0	O
and	O
similar	O
sequences	O
πi	O
and	O
values	O
of	O
random	O
variates	O
ξi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
are	O
given	O
.	O

The	O
task	O
is	O
to	O
determine	O
whether	O
the	O
word	O
ω	O
belongs	O
to	O
the	O
query	O
sequence	O
π0	O
or	O
not	O
.	O

In	O
other	O
words	O
,	O
two	O
hypotheses	O
are	O
considered	O
,	O
H1	O
:	O
ξ0	O
=	O
1	O
(	O
i.e.	O
,	O
ω	O
∈	O
KW	O
[	O
π0	O
]	O
)	O
,	O
and	O
H0	O
:	O
ξ0	O
=	O
0	O
(	O
i.e.	O
,	O
ω	O
∉	O
KW	O
[	O
π0	O
]	O
)	O
,	O
and	O
the	O
task	O
is	O
to	O
construct	O
a	O
procedure	O
that	O
allows	O
to	O
decide	O
which	O
hypothesis	O
is	O
true	O
on	O
the	O
basis	O
of	O
ξ	O
=	O
(	O
ξ1,	O
...	O
,ξn	O
)	O
.	O

As	O
announced	O
in	O
the	O
introduction	O
,	O
we	O
base	O
our	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
.	O

Let	O
us	O
recall	O
the	O
famous	O
Bayes	O
'	O
Theorem	O
that	O
can	O
be	O
written	O
as	O
P	O
{	O
H1|ξ	O
}	O
P	O
{	O
H0|ξ	O
}	O
=P	O
{	O
ξ0=1|ξ	O
}	O
P	O
{	O
ξ0=0|ξ	O
}	O
=P	O
{	O
ξ0=1,ξ	O
}	O
/	O
P	O
{	O
ξ	O
}	O
P	O
{	O
ξ0=0,ξ	O
}	O
/	O
P	O
{	O
ξ	O
}	O
=P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
⋅P	O
{	O
ξ0=1	O
}	O
P	O
{	O
ξ0=0	O
}	O
.	O
Here	O
the	O
left	O
part	O
is	O
the	O
posterior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
posteriori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
(	O
a	O
posteriori	O
means	O
that	O
values	O
ξ1,	O
...	O
,ξn	O
are	O
known	O
)	O
.	O

It	O
is	O
equal	O
to	O
the	O
product	O
of	O
the	O
likelihood	O
ratio	O
P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
(	O
i.e.	O
,	O
the	O
ratio	O
of	O
probabilities	O
that	O
the	O
set	O
of	O
values	O
ξ	O
=	O
ξ	O
(	O
ω	O
)	O
is	O
realized	O
for	O
the	O
word	O
ω	O
given	O
the	O
conditions	O
ξ0	O
=	O
1	O
and	O
ξ0	O
=	O
0	O
respectively	O
)	O
and	O
the	O
prior	O
odds	O
,	O
that	O
is	O
the	O
ratio	O
of	O
a	O
priori	O
probabilities	O
of	O
hypotheses	O
H1	O
and	O
H0	O
.	O

Statistical	O
decision	O
theory	O
tells	O
us	O
that	O
the	O
optimal	O
prediction	O
procedure	O
should	O
be	O
based	O
on	O
the	O
statistic	O
P	O
{	O
H1|ξ	O
}	O
P	O
{	O
H0|ξ	O
}	O
or	O
equivalently	O
on	O
the	O
likelihood	O
ratio	O
.	O

For	O
any	O
statistic	O
a	O
threshold	O
value	O
should	O
be	O
specified	O
for	O
the	O
procedure	O
:	O
if	O
the	O
value	O
of	O
the	O
statistic	O
is	O
greater	O
than	O
the	O
threshold	O
,	O
hypothesis	O
H1	O
is	O
accepted	O
,	O
otherwise	O
hypothesis	O
H0	O
is	O
accepted	O
.	O

The	O
threshold	O
value	O
should	O
be	O
selected	O
in	O
such	O
a	O
way	O
that	O
the	O
total	O
number	O
of	O
incorrect	O
predictions	O
(	O
i.e.	O
,	O
the	O
sum	O
of	O
the	O
number	O
of	O
type	O
1	O
errors	O
and	O
the	O
number	O
of	O
type	O
2	O
errors	O
)	O
would	O
be	O
minimal	O
.	O

It	O
is	O
clear	O
that	O
if	O
the	O
prior	O
odds	O
are	O
equal	O
to	O
1	O
,	O
then	O
a	O
threshold	O
value	O
of	O
one	O
should	O
be	O
selected	O
for	O
the	O
likelihood	O
ratio	O
;	O
total	O
number	O
of	O
errors	O
would	O
(	O
theoretically	O
)	O
be	O
minimal	O
for	O
this	O
threshold	O
.	O

Surely	O
,	O
the	O
assumption	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
does	O
not	O
seem	O
to	O
be	O
natural	O
.	O

Indeed	O
,	O
the	O
number	O
of	O
considered	O
words	O
that	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
is	O
much	O
greater	O
(	O
approximately	O
8	O
times	O
greater	O
)	O
than	O
the	O
number	O
of	O
considered	O
words	O
that	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

But	O
statistics	O
that	O
are	O
obtained	O
from	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
equals	O
1	O
,	O
and	O
the	O
assumption	O
that	O
this	O
a	O
priori	O
ratio	O
does	O
not	O
equal	O
1	O
,	O
but	O
is	O
constant	O
(	O
i.e.	O
,	O
it	O
does	O
not	O
depend	O
on	O
a	O
word	O
ω	O
)	O
are	O
equivalent	O
.	O

Essentially	O
these	O
are	O
the	O
same	O
statistics	O
(	O
only	O
the	O
threshold	O
value	O
should	O
be	O
changed	O
:	O
a	O
value	O
P	O
{	O
ξ0=0	O
}	O
P	O
{	O
ξ0=1	O
}	O
should	O
be	O
taken	O
instead	O
of	O
1	O
;	O
as	O
it	O
was	O
noted	O
,	O
this	O
value	O
approximately	O
equals	O
8	O
in	O
our	O
data	O
)	O
.	O

Therefore	O
,	O
we	O
assume	O
from	O
now	O
on	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
equals	O
1	O
.	O

Thus	O
all	O
considered	O
statistics	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
(	O
1	O
)	O
P	O
{	O
ξ|ξ0=1	O
}	O
P	O
{	O
ξ|ξ0=0	O
}	O
Assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
.	O

Transfer	O
probabilities	O
By	O
virtue	O
of	O
equation	O
(	O
1	O
)	O
we	O
need	O
to	O
estimate	O
conditional	O
probabilities	O
P	O
{	O
ξ|ξ0	O
=	O
ε	O
}	O
,	O
where	O
ε	O
=	O
1	O
or	O
0	O
in	O
order	O
to	O
calculate	O
the	O
likelihood	O
ratio	O
.	O

Our	O
derivation	O
of	O
these	O
estimates	O
uses	O
the	O
assumption	O
that	O
variables	O
ξi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
are	O
independent	O
in	O
the	O
aggregate	O
.	O

Surely	O
,	O
this	O
assumption	O
is	O
false	O
.	O

In	O
reality	O
variables	O
ξi	O
are	O
dependent	O
,	O
and	O
the	O
dependence	O
is	O
considerably	O
strong	O
.	O

Nevertheless	O
,	O
in	O
our	O
definition	O
of	O
the	O
likelihood	O
ratio	O
statistic	O
(	O
and	O
the	O
statistic	O
that	O
is	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
)	O
we	O
use	O
the	O
independence	O
assumption	O
.	O

Since	O
variables	O
ξi	O
are	O
not	O
independent	O
,	O
one	O
can	O
not	O
assert	O
that	O
the	O
obtained	O
statistics	O
are	O
the	O
most	O
powerful	O
,	O
but	O
these	O
statistics	O
can	O
be	O
still	O
quite	O
good	O
.	O

In	O
decision	O
theory	O
,	O
this	O
approach	O
is	O
known	O
as	O
the	O
naive	O
Bayes	O
procedure	O
.	O

The	O
independence	O
of	O
variables	O
ξi	O
implies	O
the	O
equality	O
(	O
2	O
)	O
P	O
{	O
ξ|ξ0	O
=	O
ε	O
}	O
=∏i=1nP	O
{	O
ξi|ξ0	O
=	O
ε	O
}	O
,ε=1,0	O
Each	O
variable	O
ξi	O
has	O
exactly	O
two	O
possible	O
values	O
:	O
1	O
and	O
0	O
.	O

Thus	O
,	O
everything	O
is	O
reduced	O
to	O
the	O
following	O
four	O
conditional	O
probabilities	O
:	O
(	O
3	O
)	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
0|ξ0=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
0	O
}	O
,	O
P	O
{	O
ξi	O
=	O
0|ξ0	O
=	O
0	O
}	O
.	O
In	O
addition	O
,	O
it	O
is	O
clear	O
that	O
(	O
4	O
)	O
P	O
{	O
ξi=1|ξ0=1	O
}	O
+P	O
{	O
ξi=0|ξ0=1	O
}	O
=1,P	O
{	O
ξi=1|ξ0=0	O
}	O
+P	O
{	O
ξi=0|ξ0=0	O
}	O
=1	O
,	O
so	O
actually	O
everything	O
is	O
reduced	O
to	O
two	O
conditional	O
probabilities	O
P	O
{	O
ξi	O
=	O
1|ξ0	O
=	O
1	O
}	O
,	O
P	O
{	O
ξi	O
=	O
1|ξ0=	O
0	O
}	O
.	O
Conditional	O
probabilities	O
(	O
3	O
)	O
are	O
a	O
special	O
case	O
of	O
conditional	O
probabilities	O
of	O
the	O
type	O
P	O
{	O
ξi	O
=	O
ε1|ξj	O
=	O
ε2	O
}	O
,	O
where	O
ε1	O
,	O
ε2	O
=	O
1	O
or	O
0	O
,	O
i	O
,	O
j	O
=	O
0,1,	O
...	O
,n	O
(	O
above	O
special	O
case	O
corresponds	O
to	O
j	O
=	O
0	O
)	O
.	O

We	O
call	O
all	O
this	O
conditional	O
probabilities	O
transfer	O
probabilities	O
and	O
denote	O
them	O
by	O
P	O
{	O
ξi	O
=	O
ε1|ξj	O
=	O
ε2	O
}	O
=pε1|ε2	O
.	O

Transfer	O
probabilities	O
depend	O
on	O
i	O
,	O
j	O
(	O
and	O
certainly	O
on	O
the	O
word	O
ω	O
)	O
:	O
pε1|ε2	O
=	O
pε1|ε2	O
(	O
i	O
,	O
j;ω	O
)	O
.	O

Conditional	O
probabilities	O
play	O
a	O
central	O
role	O
in	O
our	O
procedure	O
.	O

According	O
to	O
equation	O
(	O
4	O
)	O
,	O
it	O
suffices	O
to	O
explain	O
how	O
transfer	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
evaluated	O
.	O

We	O
suppose	O
that	O
transfer	O
probabilities	O
satisfy	O
the	O
following	O
assumptions	O
(	O
""""	O
axioms	O
""""	O
)	O
(	O
the	O
sense	O
of	O
these	O
assumptions	O
is	O
obvious	O
)	O
.	O

Assumption	O
1	O
)	O

For	O
a	O
fixed	O
word	O
ω	O
and	O
for	O
sequences	O
π0	O
,	O
π1,	O
...	O
,πn	O
(	O
i.e.	O
,	O
for	O
the	O
sequence	O
π0	O
and	O
sequences	O
similar	O
to	O
π0	O
)	O
transfer	O
probabilities	O
depend	O
only	O
on	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
.	O

Thus	O
,	O
we	O
have	O
:	O
p1|1	O
=	O
p1|1	O
(	O
i	O
,	O
j;ω	O
)	O
=	O
p1|1	O
(	O
μij;ω	O
)	O
=	O
p1|1	O
(	O
μij	O
)	O
=	O
1	O
-	O
p0|1	O
(	O
μij	O
)	O
,	O
p1|0	O
=	O
p1|0	O
(	O
i	O
,	O
j;ω	O
)	O
=	O
p1|0	O
(	O
μij;ω	O
)	O
=	O
p1|0	O
(	O
μij	O
)	O
=	O
1	O
-	O
p0|0	O
(	O
μij	O
)	O
,	O
where	O
μij	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
πi	O
,	O
πj	O
(	O
i	O
,	O
j	O
=	O
0,1,	O
...	O
,n	O
)	O
.	O

Particularly	O
,	O
if	O
one	O
of	O
these	O
sequences	O
is	O
the	O
query	O
sequence	O
π0	O
and	O
μj	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
πj	O
,	O
π0	O
,	O
we	O
have	O
(	O
5	O
)	O
P	O
{	O
ξj	O
=	O
1|ξ0	O
=	O
1	O
}	O
=	O
p1|1	O
(	O
μj	O
)	O
,	O
P	O
{	O
ξj	O
=	O
1|ξ0	O
=	O
0	O
}	O
=	O
p1|0	O
(	O
μj	O
)	O
.	O

Assumption	O
2	O
)	O
Transfer	O
probabilities	O
(	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
)	O
depend	O
on	O
similarity	O
measure	O
μ	O
monotonically	O
:	O
the	O
probability	O
p1|1	O
(	O
μ	O
)	O
increases	O
(	O
does	O
not	O
decrease	O
)	O
and	O
the	O
probability	O
p1|0	O
(	O
μ	O
)	O
decreases	O
(	O
does	O
not	O
increase	O
)	O
as	O
μ	O
increases	O
.	O

Assumption	O
3	O
)	O
The	O
inequality	O
(	O
6	O
)	O
p1|1	O
(	O
μ	O
)	O
>	O
p1|0	O
(	O
μ	O
)	O
always	O
holds	O
(	O
if	O
μ	O
>	O
0	O
)	O
.	O

Transfer	O
probabilities	O
are	O
evaluated	O
on	O
the	O
basis	O
of	O
the	O
measure	O
of	O
similarity	O
between	O
similar	O
sequences	O
for	O
which	O
it	O
is	O
known	O
whether	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
using	O
the	O
so	O
called	O
isotonic	O
regression	O
procedure	O
(	O
see	O
[	O
11	O
]	O
)	O
.	O

(	O
In	O
[	O
5	O
]	O
this	O
procedure	O
was	O
referred	O
to	O
as	O
monotonization	O
procedure	O
)	O
.	O

Results	O
of	O
this	O
procedure	O
are	O
piecewise	O
-	O
constant	O
monotonous	O
functions	O
of	O
the	O
similarity	O
measure	O
μ	O
that	O
increase	O
(	O
do	O
not	O
decrease	O
)	O
for	O
probabilities	O
p1|1	O
(	O
μ	O
)	O
and	O
decrease	O
(	O
do	O
not	O
increase	O
)	O
for	O
probabilities	O
p1|0	O
(	O
μ	O
)	O
.	O

We	O
briefly	O
recall	O
the	O
isotonic	O
regression	O
problem	O
.	O

Let	O
one	O
have	O
two	O
number	O
sets	O
(	O
i.e.	O
,	O
a	O
set	O
of	O
points	O
in	O
the	O
plain	O
)	O
xi	O
,	O
yi	O
,	O
i	O
=	O
1,	O
...	O
,n	O
,	O
for	O
which	O
x1	O
≤	O
x2	O
≤	O
...	O
≤	O
xn	O
.	O

The	O
task	O
is	O
to	O
find	O
values	O
z1	O
,	O
z2,	O
...	O
,zn	O
,	O
z1	O
≤	O
z2	O
≤	O
...	O

≤	O
zn	O
,	O
that	O
minimize	O
the	O
deviation	O
∑i=1n	O
(	O
zi−yi	O
)	O
2	O
.	O

This	O
is	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
problem	O
.	O

The	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
problem	O
is	O
similar	O
;	O
the	O
only	O
difference	O
is	O
that	O
here	O
z1	O
≥	O
z2	O
≥	O
...	O

≥	O
zn	O
.	O

The	O
isotonic	O
regression	O
procedure	O
constructs	O
a	O
monotonic	O
number	O
sequence	O
z1,	O
...	O
,zn	O
(	O
while	O
in	O
linear	O
regression	O
values	O
of	O
zi	O
are	O
linearly	O
expressed	O
in	O
terms	O
of	O
xi	O
:	O
zi	O
=	O
αxi	O
+	O
β	O
)	O
.	O

An	O
algorithm	O
for	O
the	O
solution	O
of	O
isotonic	O
regression	O
problem	O
can	O
be	O
easily	O
constructed	O
.	O

We	O
do	O
not	O
describe	O
it	O
here	O
.	O

We	O
only	O
note	O
that	O
each	O
zi	O
is	O
the	O
mean	O
value	O
of	O
{	O
yj	O
}	O
over	O
a	O
window	O
of	O
variable	O
length	O
:	O

Li	O
:	O
zi=	O
(	O
∑j	O
=	O
t	O
(	O
i	O
)	O
t	O
(	O
i	O
)	O
+L	O
(	O
i	O
)	O
−1yi	O
)	O
/	O
Li	O
.	O

For	O
different	O
indices	O
these	O
windows	O
either	O
coincide	O
or	O
do	O
not	O
overlap	O
,	O
and	O
the	O
i	O
-	O
th	O
window	O
contains	O
i.	O
We	O
also	O
note	O
that	O
the	O
values	O
of	O
xi	O
are	O
not	O
essential	O
in	O
the	O
isotonic	O
regression	O
problem	O
,	O
only	O
the	O
order	O
of	O
values	O
of	O
yi	O
is	O
essential	O
.	O

To	O
obtain	O
the	O
transfer	O
probabilities	O
using	O
isotonic	O
regression	O
we	O
proceed	O
as	O
follows	O
.	O

For	O
the	O
evaluation	O
of	O
p1|1	O
we	O
consider	O
pairs	O
of	O
similar	O
sequences	O
πi	O
,	O
πj	O
that	O
satisfy	O
the	O
condition	O
ω	O
∈	O
KW	O
[	O
πi	O
]	O
.	O

Let	O
μij	O
denote	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
πi	O
,	O
πj	O
.	O

We	O
put	O
ξij	O
=	O
1	O
if	O
the	O
word	O
ω	O
belongs	O
to	O
the	O
sequence	O
πj	O
,	O
and	O
put	O
ξij	O
=	O
0	O
if	O
ω	O
does	O
not	O
belong	O
to	O
πj	O
(	O
recall	O
that	O
the	O
word	O
ω	O
belongs	O
to	O
πi	O
)	O
.	O

Then	O
we	O
apply	O
the	O
monotone	O
-	O
increasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
μij	O
,	O
ξij	O
)	O
,	O
where	O
μij	O
are	O
in	O
ascending	O
order	O
.	O

The	O
resulting	O
values	O
are	O
the	O
estimates	O
of	O
the	O
transfer	O
probabilities	O
p1|1	O
(	O
μij	O
)	O
.	O

Similarly	O
,	O
applying	O
the	O
monotone	O
-	O
decreasing	O
isotonic	O
regression	O
procedure	O
to	O
the	O
collection	O
of	O
points	O
(	O
μij	O
,	O
ξij	O
)	O
that	O
correspond	O
to	O
pairs	O
of	O
similar	O
sequences	O
πi	O
,	O
πj	O
for	O
which	O
ω	O
does	O
not	O
belong	O
to	O
πi	O
,	O
we	O
obtain	O
values	O
of	O
the	O
transfer	O
probabilities	O
p1|0	O
(	O
μij	O
)	O
.	O

As	O
we	O
noted	O
,	O
the	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
supposed	O
to	O
satisfy	O
condition	O
(	O
6	O
)	O
.	O

Therefore	O
,	O
if	O
it	O
turns	O
out	O
that	O
functions	O
p1|1	O
(	O
μ	O
)	O
,	O
p1|0	O
(	O
μ	O
)	O
obtained	O
after	O
the	O
application	O
of	O
isotonic	O
regression	O
procedure	O
do	O
not	O
satisfy	O
this	O
condition	O
for	O
some	O
values	O
of	O
μ	O
,	O
then	O
we	O
consider	O
that	O
probabilities	O
p1|1	O
,	O
p1|0	O
are	O
not	O
defined	O
for	O
these	O
values	O
of	O
μ	O
.	O

Hence	O
,	O
it	O
is	O
possible	O
that	O
transfer	O
probabilities	O
are	O
defined	O
only	O
for	O
sufficiently	O
large	O
values	O
of	O
μ	O
,	O
but	O
not	O
for	O
all	O
μ	O
.	O

In	O
particular	O
,	O
it	O
is	O
possible	O
that	O
for	O
some	O
words	O
there	O
are	O
no	O
values	O
of	O
μ	O
such	O
that	O
inequality	O
(	O
6	O
)	O
holds	O
.	O

These	O
words	O
are	O
referred	O
to	O
as	O
degenerate	O
words	O
.	O

Statistics	O
description	O
All	O
statistics	O
considered	O
in	O
this	O
paper	O
are	O
based	O
on	O
the	O
likelihood	O
ratio	O
criterion	O
,	O
that	O
is	O
on	O
formula	O
(	O
1	O
)	O
under	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
(	O
formula	O
(	O
2	O
)	O
)	O
.	O

Two	O
approaches	O
are	O
used	O
in	O
the	O
definitions	O
of	O
these	O
statistics	O
.	O

One	O
of	O
them	O
can	O
be	O
called	O
a	O
""""	O
discrete	O
""""	O
approach	O
;	O
the	O
other	O
can	O
be	O
called	O
a	O
""""	O
continuous	O
""""	O
approach	O
.	O

The	O
discrete	O
approach	O
is	O
based	O
directly	O
on	O
formulae	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
and	O
the	O
definition	O
of	O
transfer	O
probabilities	O
.	O

It	O
follows	O
from	O
(	O
5	O
)	O
that	O
the	O
following	O
formulae	O
for	O
conditional	O
probabilities	O
hold	O
:	O
P	O
{	O
ξi|ξ0	O
=	O
1	O
}	O
=	O
p1|1	O
(	O
μi	O
)	O
,	O
if	O
ξi	O
=	O
1	O
,	O
P	O
{	O
ξi|ξ0	O
=	O
1	O
}	O
=	O
p0|1	O
(	O
μi	O
)	O
=	O
1	O
-	O
p1|1	O
(	O
μi	O
)	O
,	O
if	O
ξi	O
=	O
0	O
,	O
and	O
hence	O
(	O
7	O
)	O
P	O
{	O
ξi|ξ0=1	O
}	O
=	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
⋅	O
(	O
p1|1	O
(	O
μi	O
)	O
1−p1|1	O
(	O
μi	O
)	O
)	O
)	O
ξi	O
.	O

Similarly	O
,	O
(	O
8	O
)	O
P	O
{	O
ξi|ξ0=0	O
}	O
=	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
⋅	O
(	O
p1|0	O
(	O
μi	O
)	O
1−p1|0	O
(	O
μi	O
)	O
)	O
ξi	O
.	O

Relations	O
(	O
7	O
)	O
,	O
(	O
8)	O
together	O
with	O
(	O
1	O
)	O
,	O
(	O
2	O
)	O
imply	O
the	O
following	O
formula	O
for	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
:	O
(	O
9	O
)	O
T	O
(	O
1	O
)	O
(	O
ξ;ω	O
)	O
=T	O
(	O
1	O
)	O
(	O
ξ	O
)	O
=ln⁡	O
(	O
∏i=1nP	O
{	O
ξi|ξ0=1	O
}	O
P	O
{	O
ξi|ξ0=0	O
}	O
)	O
=α0+∑i=1nαi⋅ξi	O
,	O
where	O
(	O
10	O
)	O
α0=∑i=1nα0i	O
,	O
α0i	O
=	O
ln⁡1−p1|1	O
(	O
μi	O
)	O
1−p1|0	O
(	O
μi	O
)	O
<0	O
(	O
11	O
)	O
αi	O
=	O
ln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
>0	O
.	O

One	O
can	O
see	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
can	O
be	O
expressed	O
as	O
a	O
linear	O
combination	O
of	O
the	O
ξi	O
.	O

As	O
we	O
noted	O
,	O
theoretically	O
the	O
best	O
threshold	O
value	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
equal	O
to	O
1n1	O
=	O
0	O
.	O

However	O
,	O
that	O
is	O
only	O
theoretical	O
.	O

As	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
is	O
incorrect	O
and	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
only	O
a	O
rough	O
estimate	O
of	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
,	O
the	O
best	O
threshold	O
value	O
is	O
not	O
necessarily	O
equal	O
to	O
zero	O
(	O
and	O
this	O
threshold	O
does	O
not	O
really	O
equal	O
zero	O
in	O
practice	O
)	O
.	O

Let	O
us	O
put	O
η	O
=	O
η	O
(	O
ω	O
)	O
=T	O
(	O
1	O
)	O
−α0∑i=1nαi	O
.	O

From	O
the	O
definition	O
of	O
η	O
and	O
relations	O
(	O
9	O
)	O
–	O
(	O
11	O
)	O
it	O
follows	O
that	O
(	O
12	O
)	O
η=∑i=1na^iξi	O
,	O
where	O
(	O
13	O
)	O
a^i	O
=	O
ln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
∑i=1nln⁡p1|1	O
(	O
μi	O
)	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
p1|0	O
(	O
μi	O
)	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
>0	O
.	O

We	O
note	O
that	O
(	O
14	O
)	O
∑i=1na^i=1	O
.	O

The	O
variable	O
η	O
(	O
ω	O
)	O
can	O
be	O
treated	O
as	O
a	O
second	O
statistic	O
.	O

Its	O
values	O
lie	O
between	O
0	O
and	O
1	O
.	O

Statistics	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
linearly	O
dependent	O
,	O
and	O
hence	O
for	O
a	O
fixed	O
word	O
ω	O
these	O
statistics	O
are	O
equivalent	O
.	O

However	O
,	O
the	O
coefficients	O
α0	O
and	O
αi	O
(	O
i	O
=	O
1,	O
...	O
,n	O
)	O
are	O
different	O
for	O
different	O
words	O
ω	O
,	O
so	O
the	O
relation	O
between	O
thresholds	O
,	O
used	O
in	O
the	O
prediction	O
,	O
is	O
different	O
for	O
different	O
words	O
;	O
consequently	O
,	O
the	O
statistics	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
(	O
We	O
will	O
see	O
later	O
that	O
if	O
thresholds	O
are	O
well	O
-	O
chosen	O
,	O
then	O
η	O
leads	O
to	O
better	O
results	O
than	O
T	O
(	O
1	O
)	O
)	O
.	O

The	O
other	O
approach	O
to	O
the	O
definition	O
of	O
statistics	O
,	O
used	O
in	O
the	O
annotation	O
procedure	O
,	O
starts	O
from	O
a	O
linear	O
combination	O
η=∑i=1naiξi	O
of	O
the	O
ξi	O
as	O
in	O
formula	O
(	O
12	O
)	O
.	O

Here	O
coefficients	O
αi	O
are	O
not	O
necessarily	O
given	O
by	O
(	O
13	O
)	O
,	O
but	O
should	O
be	O
positive	O
and	O
satisfy	O
the	O
relation	O
(	O
14	O
)	O
.	O

This	O
approach	O
uses	O
the	O
assumption	O
that	O
η	O
has	O
the	O
normal	O
distribution	O
.	O

Certainly	O
this	O
assumption	O
is	O
not	O
correct	O
(	O
at	O
least	O
because	O
the	O
inequality	O
0	O
≤	O
η	O
≤	O
1	O
always	O
holds	O
)	O
.	O

Nevertheless	O
,	O
we	O
use	O
this	O
assumption	O
(	O
and	O
,	O
similarly	O
to	O
the	O
discrete	O
approach	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
variables	O
ξi	O
(	O
ω	O
)	O
)	O
.	O

(	O
As	O
the	O
normal	O
distribution	O
is	O
continuous	O
,	O
this	O
approach	O
can	O
be	O
called	O
""""	O
continuous	O
""""	O
)	O
.	O

Thus	O
,	O
we	O
consider	O
a	O
random	O
variable	O
(	O
15	O
)	O
η=∑i=1naiξi	O
and	O
assume	O
that	O
it	O
has	O
a	O
normal	O
distribution	O
.	O

Denote	O
by	O
M1η	O
=	O
M	O
(	O
η|ξ0=1	O
)	O
,D1η	O
=	O
D	O
(	O
η|ξ0=1	O
)	O
=σ12,M0η	O
=	O
M	O
(	O
η|ξ0=0	O
)	O
,D0η	O
=	O
D	O
(	O
η|ξ0=0	O
)	O
=σ02	O
the	O
conditional	O
expectations	O
and	O
dispersions	O
of	O
η	O
given	O
that	O
ξ0	O
=	O
1	O
or	O
0	O
respectively	O
.	O

We	O
have	O
M1η	O
=	O
∑aiM	O
(	O
ξi|ξ0	O
=	O
1	O
)	O
=	O
∑aip1|1	O
(	O
μi	O
)	O
,	O
M0η	O
=	O
∑aip1|0	O
(	O
μi	O
)	O
.	O

Further	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
ξi	O
(	O
ω	O
)	O
implies	O
that	O
D1η	O
=	O
σ12=∑iai2⋅p1|1	O
(	O
μi	O
)	O
⋅	O
(	O
1−p1|1	O
(	O
μi	O
)	O
)	O
,D0η	O
=	O
σ02=∑iai2⋅p1|0	O
(	O
μi	O
)	O
⋅	O
(	O
1−p1|0	O
(	O
μi	O
)	O
)	O
.	O

(	O
We	O
note	O
that	O
it	O
is	O
the	O
only	O
place	O
where	O
the	O
independence	O
of	O
ξi	O
is	O
used	O
;	O
therefore	O
,	O
the	O
assumption	O
of	O
independence	O
of	O
ξi	O
is	O
not	O
as	O
essential	O
in	O
this	O
approach	O
as	O
it	O
was	O
in	O
the	O
definition	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
)	O
.	O

It	O
follows	O
from	O
the	O
assumption	O
of	O
a	O
normal	O
distribution	O
that	O
in	O
cases	O
ξ0	O
=	O
1	O
and	O
0	O
the	O
variables	O
(	O
16	O
)	O
η−M1ησ1	O
and	O
η−M0ησ0	O
have	O
standard	O
normal	O
distribution	O
N	O
(	O
0,1	O
)	O
As	O
above	O
,	O
we	O
use	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
as	O
a	O
statistic	O
and	O
in	O
addition	O
assume	O
that	O
the	O
ratio	O
of	O
a	O
priori	O
hypothesis	O
probabilities	O
is	O
equal	O
to	O
1	O
.	O

Let	O
us	O
denote	O
this	O
statistic	O
by	O
T	O
(	O
2	O
)	O
.	O

Relation	O
(	O
16	O
)	O
implies	O
that	O
T	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡P	O
{	O
λ≤η≤λ+dλ|ξ0=1	O
}	O
P	O
{	O
λ≤η≤λ+dλ|ξ0=0	O
}	O
=ln⁡	O
(	O
1	O
/	O
2π⋅σ1	O
)	O
⋅exp⁡	O
{	O
−12⋅	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
2	O
}	O
(	O
1	O
/	O
2π⋅σ0	O
)	O
⋅exp⁡	O
{	O
12⋅	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
2	O
}	O
=12⋅	O
{	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
2−	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
2	O
}	O
+ln⁡	O
(	O
σ0	O
/	O
σ1	O
)	O
.	O

Another	O
variant	O
of	O
this	O
statistic	O
–	O
statistic	O
T^	O
(	O
2	O
)	O
–	O
was	O
used	O
in	O
the	O
paper	O
[	O
5	O
]	O
.	O

The	O
statistic	O
T^	O
(	O
2	O
)	O
is	O
the	O
ratio	O
of	O
type	O
1	O
error	O
to	O
type	O
2	O
error	O
:	O
(	O
17	O
)	O
T^	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡P	O
(	O
1	O
)	O
(	O
λ	O
)	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
=ln⁡Φ	O
(	O
(	O
λ−M1η	O
)	O
/	O
σ1	O
)	O
1−Φ	O
(	O
(	O
λ−M0η	O
)	O
/	O
σ0	O
)	O
,	O
where	O
Φ	O
(	O
x	O
)	O
is	O
the	O
cumulative	O
normal	O
distribution	O
function	O
:	O
Φ	O
(	O
x	O
)	O
=12π∫−∞xe−z22dz	O
.	O

The	O
statistics	O
η	O
and	O
T^	O
(	O
2	O
)	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
(	O
although	O
not	O
equivalent	O
for	O
the	O
whole	O
totality	O
of	O
words	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
statistics	O
η	O
and	O
T	O
(	O
2	O
)	O
are	O
not	O
necessarily	O
equivalent	O
,	O
as	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
η	O
may	O
turn	O
out	O
to	O
be	O
not	O
monotonic	O
.	O

Moreover	O
,	O
it	O
is	O
never	O
monotonic	O
for	O
all	O
values	O
of	O
η	O
.	O

However	O
,	O
we	O
are	O
interested	O
only	O
in	O
values	O
0	O
≤	O
η	O
≤	O
1	O
,	O
and	O
usually	O
(	O
though	O
not	O
always	O
)	O
the	O
dependence	O
of	O
T	O
(	O
2	O
)	O
on	O
η	O
is	O
monotonous	O
for	O
these	O
values	O
of	O
η	O
,	O
and	O
in	O
this	O
case	O
the	O
statistics	O
η	O
and	O
T	O
(	O
2	O
)	O
are	O
equivalent	O
(	O
for	O
a	O
fixed	O
word	O
ω	O
)	O
.	O

Furthermore	O
,	O
even	O
in	O
the	O
case	O
where	O
the	O
dependence	O
is	O
not	O
monotonic	O
,	O
the	O
monotonicity	O
is	O
violated	O
only	O
for	O
the	O
values	O
of	O
η	O
close	O
either	O
to	O
0	O
or	O
to	O
1	O
,	O
and	O
the	O
lack	O
of	O
monotonicity	O
can	O
be	O
disregarded	O
.	O

We	O
still	O
have	O
to	O
discuss	O
the	O
question	O
of	O
the	O
choice	O
of	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
.	O

One	O
of	O
the	O
variants	O
was	O
described	O
above	O
:	O
formula	O
(	O
13	O
)	O
can	O
be	O
applied	O
.	O

Another	O
variant	O
was	O
introduced	O
in	O
[	O
5	O
]	O
.	O

This	O
variant	O
can	O
be	O
described	O
as	O
follows	O
.	O

As	O
above	O
,	O
we	O
assume	O
that	O
the	O
variate	O
η	O
=	O
∑aiξi	O
has	O
a	O
normal	O
distribution	O
.	O

Each	O
set	O
of	O
coefficients	O
ai	O
and	O
each	O
threshold	O
value	O
λ	O
have	O
corresponding	O
theoretical	O
frequencies	O
of	O
type	O
1	O
and	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
,	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

The	O
idea	O
is	O
to	O
take	O
the	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
that	O
gives	O
the	O
minimum	O
sum	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
+	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
,	O
where	O
λ	O
is	O
the	O
best	O
threshold	O
value	O
for	O
this	O
coefficient	O
set	O
.	O

However	O
,	O
analytically	O
it	O
is	O
very	O
cumbersome	O
,	O
so	O
the	O
following	O
simplification	O
was	O
implemented	O
.	O

For	O
a	O
fixed	O
set	O
of	O
coefficients	O
{	O
ai	O
}	O
we	O
select	O
the	O
threshold	O
value	O
λ	O
such	O
that	O
the	O
frequency	O
of	O
type	O
1	O
errors	O
is	O
equal	O
to	O
the	O
frequency	O
of	O
type	O
2	O
errors	O
:	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

Then	O
we	O
find	O
the	O
set	O
of	O
coefficients	O
that	O
minimizes	O
these	O
frequencies	O
P	O
(	O
1	O
)	O
(	O
λ	O
)	O
=	O
P	O
(	O
2	O
)	O
(	O
λ	O
)	O
.	O

Here	O
the	O
search	O
of	O
the	O
coefficient	O
set	O
can	O
be	O
reduced	O
to	O
a	O
conditional	O
extremum	O
problem	O
.	O

The	O
A4	O
algorithm	O
uses	O
an	O
iterated	O
procedure	O
for	O
the	O
solution	O
of	O
this	O
problem	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

In	O
order	O
to	O
optimize	O
the	O
automated	O
annotation	O
procedure	O
,	O
that	O
is	O
to	O
increase	O
the	O
prediction	O
quality	O
,	O
certain	O
modifications	O
of	O
the	O
procedure	O
were	O
introduced	O
.	O

For	O
each	O
statistic	O
(	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
)	O
many	O
variants	O
(	O
up	O
to	O
36	O
)	O
,	O
including	O
the	O
variant	O
that	O
was	O
described	O
above	O
,	O
were	O
considered	O
–	O
each	O
variant	O
corresponds	O
to	O
a	O
certain	O
combination	O
of	O
these	O
modifications	O
.	O

Some	O
variants	O
really	O
turned	O
out	O
to	O
be	O
better	O
than	O
the	O
variants	O
described	O
above	O
.	O

A	O
simplified	O
scheme	O
of	O
modifications	O
(	O
and	O
thereby	O
of	O
statistic	O
variants	O
)	O
can	O
be	O
described	O
as	O
follows	O
.	O

1	O
)	O
What	O
primary	O
local	O
alignments	O
are	O
considered	O
?	O

In	O
the	O
described	O
variant	O
of	O
statistics	O
only	O
one	O
primary	O
local	O
alignment	O
(	O
the	O
one	O
with	O
the	O
maximum	O
power	O
)	O
was	O
considered	O
.	O

Meanwhile	O
,	O
all	O
constructed	O
local	O
alignments	O
with	O
sufficiently	O
high	O
power	O
can	O
be	O
considered	O
,	O
as	O
it	O
was	O
done	O
in	O
[	O
5	O
]	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
individual	O
similar	O
sequences	O
,	O
but	O
to	O
primary	O
local	O
alignments	O
of	O
this	O
sequences	O
.	O

2	O
)	O
Are	O
the	O
lengths	O
of	O
primary	O
local	O
alignments	O
taken	O
into	O
consideration	O
?	O

In	O
the	O
described	O
variant	O
lengths	O
of	O
primary	O
local	O
alignments	O
were	O
not	O
taken	O
into	O
consideration	O
,	O
but	O
these	O
lengths	O
can	O
be	O
considered	O
as	O
well	O
.	O

In	O
this	O
case	O
indices	O
i	O
in	O
(	O
9	O
)	O
,	O
(	O
12	O
)	O
,	O
(	O
15	O
)	O
correspond	O
not	O
to	O
similar	O
sequences	O
or	O
primary	O
local	O
alignments	O
,	O
but	O
to	O
individual	O
positions	O
of	O
these	O
primary	O
local	O
alignments	O
(	O
as	O
in	O
case	O
of	O
FT	O
-	O
type	O
words	O
)	O
.	O

In	O
this	O
case	O
the	O
total	O
number	O
of	O
variates	O
ξi	O
is	O
equal	O
to	O
the	O
overall	O
length	O
of	O
all	O
primary	O
local	O
alignments	O
.	O

For	O
these	O
variants	O
of	O
statistics	O
long	O
local	O
alignments	O
turn	O
out	O
to	O
be	O
more	O
significant	O
than	O
short	O
local	O
alignments	O
with	O
the	O
same	O
power	O
.	O

3	O
)	O
How	O
are	O
the	O
coefficients	O
ai	O
calculated	O
?	O

The	O
coefficients	O
ai	O
in	O
(	O
15	O
)	O
can	O
be	O
calculated	O
using	O
different	O
methods	O
–	O
either	O
formula	O
(	O
13	O
)	O
can	O
be	O
used	O
,	O
or	O
an	O
iterative	O
method	O
(	O
described	O
in	O
[	O
5	O
]	O
)	O
can	O
be	O
applied	O
.	O

(	O
For	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
coefficients	O
ai	O
are	O
always	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
)	O
.	O

As	O
there	O
are	O
3	O
modifications	O
,	O
the	O
total	O
number	O
of	O
basic	O
variants	O
(	O
in	O
the	O
described	O
simplified	O
scheme	O
)	O
equals	O
23	O
=	O
8	O
(	O
and	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
it	O
equals	O
4	O
)	O
.	O

So	O
,	O
variants	O
of	O
the	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
are	O
considered	O
in	O
this	O
paper	O
.	O

Moreover	O
,	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
as	O
in	O
the	O
paper	O
[	O
5	O
]	O
)	O
the	O
simple	O
statistic	O
(	O
18	O
)	O
q	O
=	O
q	O
(	O
ω	O
)	O
=∑inξin	O
(	O
the	O
frequency	O
of	O
occurrence	O
of	O
a	O
word	O
ω	O
in	O
the	O
collection	O
of	O
similar	O
sequences	O
)	O
is	O
also	O
considered	O
.	O

Finally	O
we	O
quote	O
a	O
scheme	O
of	O
the	O
A4	O
algorithm	O
in	O
Figure	O
1	O
(	O
this	O
scheme	O
is	O
essentially	O
taken	O
from	O
[	O
5	O
]	O
)	O
.	O

A	O
short	O
description	O
of	O
each	O
stage	O
can	O
be	O
found	O
in	O
[	O
5	O
]	O
.	O

Here	O
we	O
only	O
note	O
that	O
the	O
most	O
time	O
-	O
consuming	O
stage	O
is	O
the	O
first	O
one	O
–	O
the	O
generation	O
of	O
a	O
collection	O
of	O
similar	O
sequences	O
.	O

We	O
also	O
note	O
that	O
in	O
the	O
current	O
investigation	O
regions	O
were	O
not	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
for	O
the	O
whole	O
query	O
sequence	O
.	O

Testing	O
results	O
Testing	O
scheme	O
A	O
collection	O
of	O
518	O
sequences	O
,	O
randomly	O
selected	O
from	O
SWISS	O
-	O
PROT	O
databank	O
,	O
was	O
generated	O
.	O

Note	O
that	O
only	O
initially	O
annotated	O
sequences	O
(	O
i.e.	O
,	O
sequences	O
whose	O
description	O
fields	O
were	O
not	O
obtained	O
by	O
the	O
extension	O
from	O
similar	O
sequences	O
)	O
were	O
selected	O
.	O

The	O
prediction	O
was	O
performed	O
for	O
KW	O
-	O
type	O
words	O
.	O

All	O
selected	O
sequences	O
were	O
divided	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
contained	O
210	O
sequences	O
.	O

This	O
group	O
was	O
used	O
during	O
the	O
""""	O
learning	O
stage	O
""""	O
:	O
the	O
procedure	O
was	O
applied	O
to	O
all	O
sequences	O
from	O
the	O
group	O
,	O
and	O
values	O
of	O
procedure	O
parameters	O
(	O
including	O
optimal	O
threshold	O
values	O
)	O
that	O
minimize	O
the	O
total	O
number	O
of	O
errors	O
for	O
the	O
first	O
group	O
were	O
selected	O
.	O

The	O
remaining	O
308	O
sequences	O
were	O
used	O
for	O
the	O
""""	O
main	O
testing	O
""""	O
that	O
was	O
performed	O
using	O
parameter	O
values	O
obtained	O
on	O
the	O
basis	O
of	O
""""	O
learning	O
""""	O
results	O
.	O

A	O
list	O
of	O
all	O
these	O
308	O
sequences	O
is	O
given	O
in	O
Additional	O
file	O
1	O
.	O

The	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
the	O
description	O
fields	O
of	O
308	O
selected	O
sequences	O
,	O
used	O
as	O
query	O
sequences	O
,	O
was	O
equal	O
to	O
1176	O
(	O
the	O
positive	O
prediction	O
was	O
preferable	O
for	O
these	O
words	O
)	O
.	O

As	O
it	O
was	O
noted	O
,	O
a	O
collection	O
of	O
similar	O
sequences	O
was	O
generated	O
for	O
each	O
query	O
sequence	O
;	O
the	O
number	O
of	O
sequences	O
in	O
these	O
collections	O
equaled	O
100	O
.	O

Then	O
the	O
list	O
of	O
all	O
KW	O
-	O
type	O
words	O
from	O
description	O
fields	O
of	O
similar	O
sequences	O
was	O
formed	O
.	O

The	O
majority	O
of	O
these	O
words	O
belonged	O
only	O
to	O
one	O
similar	O
sequence	O
.	O

All	O
such	O
words	O
are	O
degenerate	O
,	O
transfer	O
probabilities	O
are	O
not	O
defined	O
for	O
them	O
.	O

At	O
the	O
same	O
time	O
nearly	O
all	O
these	O
words	O
did	O
not	O
belong	O
to	O
the	O
query	O
sequence	O
.	O

Hence	O
it	O
was	O
sensible	O
to	O
perform	O
prediction	O
only	O
for	O
words	O
that	O
belonged	O
to	O
at	O
least	O
two	O
similar	O
sequences	O
.	O

For	O
all	O
these	O
words	O
transfer	O
probabilities	O
were	O
evaluated	O
,	O
non	O
-	O
degenerate	O
words	O
(	O
i.e.	O
,	O
words	O
with	O
defined	O
transfer	O
probabilities	O
)	O
were	O
determined	O
,	O
and	O
the	O
prediction	O
was	O
performed	O
(	O
for	O
both	O
degenerate	O
and	O
non	O
-	O
degenerate	O
words	O
)	O
.	O

Table	O
1	O
shows	O
certain	O
characteristics	O
of	O
sequences	O
used	O
for	O
the	O
testing	O
.	O

The	O
average	O
number	O
of	O
words	O
considered	O
per	O
query	O
sequence	O
equals	O
30	O
and	O
the	O
entire	O
range	O
was	O
from	O
3	O
to	O
67	O
.	O

Final	O
results	O
Testing	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O

The	O
table	O
contains	O
testing	O
results	O
for	O
the	O
basic	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
as	O
well	O
as	O
for	O
the	O
statistics	O
q	O
and	O
SAnd	O
,	O
included	O
into	O
the	O
table	O
for	O
the	O
purpose	O
of	O
comparison	O
(	O
See	O
the	O
Discussion	O
section	O
)	O
.	O

Each	O
line	O
of	O
the	O
table	O
corresponds	O
to	O
a	O
certain	O
variant	O
of	O
studied	O
statistics	O
.	O

The	O
first	O
column	O
shows	O
which	O
statistic	O
and	O
which	O
variant	O
of	O
this	O
statistic	O
corresponds	O
to	O
a	O
line	O
.	O

Variants	O
are	O
given	O
in	O
square	O
brackets	O
:	O
the	O
first	O
number	O
equals	O
0	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
,	O
and	O
1	O
otherwise	O
;	O
the	O
second	O
number	O
equals	O
0	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
formula	O
(	O
13	O
)	O
,	O
and	O
1	O
if	O
the	O
coefficients	O
ai	O
are	O
calculated	O
using	O
the	O
iterative	O
procedure	O
(	O
for	O
the	O
statistic	O
T	O
(	O
1	O
)	O
the	O
second	O
number	O
is	O
always	O
0	O
)	O
.	O

The	O
second	O
column	O
contains	O
the	O
number	O
N1	O
of	O
type	O
1	O
errors	O
(	O
i.e.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
belongs	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
negative	O
)	O
.	O

The	O
third	O
column	O
contains	O
the	O
number	O
N2	O
of	O
type	O
2	O
errors	O
(	O
i.e.	O
,	O
number	O
of	O
cases	O
when	O
the	O
prediction	O
for	O
a	O
word	O
that	O
does	O
not	O
belong	O
to	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
is	O
positive	O
)	O
.	O

The	O
forth	O
column	O
contains	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
=	O
N1	O
+	O
N2	O
.	O

The	O
next	O
columns	O
contain	O
sums	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
and	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
,	O
where	O
P	O
(	O
1	O
)	O
is	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
,	O
P	O
(	O
2	O
)	O
is	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
,	O
and	O
P	O
(	O
+	O
)	O
is	O
the	O
ratio	O
of	O
false	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
predictions	O
:	O
P	O
(	O
1	O
)	O
=N1nq	O
,	O
P	O
(	O
2	O
)	O
=N2nall−nq	O
,	O
P	O
(	O
+	O
)	O
=N2n+	O
(	O
nall	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
performed	O
,	O
i.e.	O
,	O
total	O
number	O
of	O
KW	O
-	O
type	O
words	O
in	O
description	O
fields	O
of	O
all	O
sequences	O
,	O
similar	O
to	O
at	O
least	O
one	O
query	O
sequence	O
,	O
nq	O
is	O
the	O
number	O
of	O
words	O
(	O
from	O
the	O
list	O
of	O
these	O
nall	O
words	O
)	O
that	O
belong	O
to	O
query	O
sequences	O
,	O
n+	O
is	O
the	O
total	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
is	O
positive	O
;	O
here	O
nall	O
=	O
9236	O
,	O
nq	O
=	O
1176	O
,	O
nall	O
-	O
nq	O
=	O
8060	O
;	O
the	O
value	O
of	O
n+	O
of	O
depends	O
on	O
the	O
threshold	O
evaluated	O
for	O
the	O
given	O
version	O
of	O
statistic	O
at	O
the	O
""""	O
learning	O
stage	O
""""	O
)	O
.	O

Lines	O
are	O
ordered	O
according	O
to	O
the	O
prediction	O
quality	O
:	O
higher	O
lines	O
correspond	O
to	O
statistic	O
variants	O
with	O
lower	O
total	O
number	O
of	O
errors	O
.	O

For	O
a	O
fixed	O
statistic	O
,	O
lines	O
that	O
correspond	O
to	O
the	O
best	O
variant	O
of	O
this	O
statistic	O
(	O
i.e.	O
,	O
for	O
the	O
variant	O
that	O
leads	O
to	O
the	O
lowest	O
total	O
number	O
of	O
errors	O
)	O
are	O
marked	O
.	O

Recall	O
that	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
[	O
1,0	O
]	O
is	O
exactly	O
the	O
statistic	O
that	O
was	O
considered	O
in	O
[	O
5	O
]	O
(	O
note	O
that	O
it	O
is	O
the	O
best	O
variant	O
for	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
)	O
.	O

The	O
results	O
could	O
also	O
have	O
been	O
presented	O
as	O
a	O
confusion	O
table	O
as	O
laid	O
out	O
in	O
Table	O
3	O
,	O
but	O
doing	O
so	O
for	O
all	O
variants	O
would	O
take	O
a	O
lot	O
of	O
space	O
.	O

The	O
testing	O
results	O
showed	O
that	O
the	O
first	O
modification	O
(	O
consideration	O
of	O
all	O
primary	O
local	O
alignments	O
or	O
only	O
one	O
primary	O
local	O
alignment	O
with	O
the	O
maximum	O
power	O
)	O
did	O
not	O
significantly	O
affect	O
the	O
prediction	O
quality	O
,	O
so	O
results	O
are	O
only	O
presented	O
for	O
one	O
case	O
(	O
all	O
local	O
alignments	O
are	O
considered	O
,	O
similarly	O
to	O
[	O
5	O
]	O
)	O
.	O

Note	O
that	O
the	O
results	O
presented	O
in	O
the	O
Table	O
correspond	O
to	O
the	O
whole	O
totality	O
of	O
words	O
including	O
degenerate	O
words	O
(	O
though	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
,	O
T	O
(	O
nik	O
)	O
were	O
evaluated	O
only	O
for	O
non	O
-	O
degenerate	O
words	O
,	O
for	O
degenerate	O
words	O
the	O
prediction	O
was	O
performed	O
on	O
the	O
basis	O
of	O
the	O
statistic	O
q	O
,	O
i.e.	O
,	O
on	O
the	O
basis	O
of	O
word	O
frequency	O
)	O
.	O

In	O
particular	O
,	O
the	O
total	O
number	O
of	O
errors	O
includes	O
errors	O
for	O
degenerate	O
words	O
.	O

It	O
is	O
worth	O
noticing	O
that	O
the	O
total	O
number	O
of	O
errors	O
for	O
degenerate	O
words	O
in	O
case	O
of	O
the	O
best	O
choice	O
of	O
threshold	O
q0	O
for	O
the	O
frequency	O
q	O
(	O
ω	O
)	O
turned	O
out	O
to	O
be	O
surprisingly	O
small	O
:	O
only	O
13	O
(	O
whereas	O
the	O
number	O
of	O
errors	O
for	O
the	O
whole	O
totality	O
of	O
words	O
was	O
220	O
)	O
;	O
these	O
errors	O
included	O
twelve	O
type	O
1	O
errors	O
and	O
one	O
type	O
2	O
error	O
(	O
recall	O
that	O
the	O
prediction	O
was	O
performed	O
for	O
2029	O
degenerate	O
words	O
,	O
and	O
the	O
prediction	O
was	O
incorrect	O
only	O
in	O
13	O
cases	O
)	O
.	O

Such	O
a	O
small	O
number	O
of	O
errors	O
can	O
seemingly	O
be	O
explained	O
by	O
the	O
fact	O
that	O
for	O
degenerate	O
words	O
the	O
frequency	O
q	O
(	O
ω	O
)	O
is	O
nearly	O
always	O
close	O
either	O
to	O
1	O
or	O
to	O
0	O
,	O
otherwise	O
in	O
almost	O
all	O
cases	O
transfer	O
probabilities	O
p1|1	O
,	O
p1|0	O
can	O
be	O
defined	O
for	O
at	O
least	O
some	O
values	O
of	O
similarity	O
measure	O
μ	O
and	O
hence	O
a	O
word	O
ω	O
turns	O
out	O
to	O
be	O
non	O
-	O
degenerate	O
.	O

We	O
also	O
note	O
that	O
along	O
with	O
type	O
1	O
and	O
type	O
2	O
errors	O
other	O
errors	O
can	O
occur	O
,	O
as	O
it	O
is	O
possible	O
that	O
some	O
words	O
from	O
description	O
fields	O
of	O
a	O
query	O
sequence	O
do	O
not	O
belong	O
to	O
description	O
fields	O
of	O
similar	O
sequences	O
and	O
hence	O
the	O
prediction	O
is	O
not	O
performed	O
for	O
these	O
words	O
at	O
all	O
.	O

However	O
,	O
we	O
used	O
a	O
large	O
number	O
of	O
similar	O
sequences	O
(	O
100	O
)	O
for	O
the	O
prediction	O
,	O
so	O
such	O
errors	O
were	O
extremely	O
rare	O
(	O
only	O
two	O
words	O
for	O
the	O
whole	O
test	O
set	O
of	O
518	O
sequences	O
,	O
whereas	O
the	O
number	O
of	O
words	O
for	O
which	O
the	O
prediction	O
was	O
performed	O
equaled	O
9236	O
)	O
.	O

Hence	O
,	O
in	O
our	O
case	O
these	O
errors	O
can	O
be	O
disregarded	O
.	O

Statistical	O
analysis	O
showed	O
that	O
the	O
precision	O
of	O
the	O
evaluation	O
of	O
N1	O
,	O
N2	O
,	O
Nall	O
is	O
reasonable	O
:	O
it	O
can	O
be	O
checked	O
that	O
the	O
relative	O
precision	O
of	O
Nall	O
(	O
the	O
standard	O
error	O
of	O
ln	O
(	O
Nall	O
)	O
)	O
is	O
in	O
the	O
order	O
of	O
7–10	O
%	O
which	O
is	O
in	O
line	O
with	O
the	O
relative	O
precision	O
of	O
a	O
Poisson	O
random	O
variable	O
that	O
is	O
given	O
by	O
1	O
/	O
Nall	O
.	O

However	O
,	O
since	O
the	O
""""	O
methods	O
""""	O
(	O
the	O
statistics	O
and	O
their	O
variants	O
)	O
are	O
compared	O
on	O
the	O
same	O
sequences	O
,	O
the	O
standard	O
error	O
for	O
the	O
comparison	O
between	O
methods	O
is	O
much	O
smaller	O
due	O
to	O
the	O
high	O
correlation	O
of	O
results	O
for	O
the	O
same	O
sequence	O
and	O
is	O
in	O
the	O
order	O
of	O
2–4	O
%	O
.	O

This	O
implies	O
that	O
""""	O
methods	O
""""	O
for	O
which	O
Nall	O
differ	O
by	O
more	O
than	O
10	O
%	O
can	O
considered	O
to	O
be	O
significantly	O
different	O
.	O

This	O
shows	O
that	O
size	O
of	O
the	O
experiment	O
with	O
210	O
randomly	O
selected	O
sequences	O
in	O
the	O
learning	O
stage	O
and	O
308	O
sequences	O
in	O
the	O
testing	O
stage	O
is	O
large	O
enough	O
to	O
obtain	O
valid	O
statements	O
about	O
the	O
accuracy	O
of	O
the	O
proposed	O
methodology	O
and	O
allows	O
statistical	O
comparisons	O
of	O
different	O
statistics	O
and	O
variants	O
.	O

When	O
the	O
set	O
of	O
tested	O
sequences	O
is	O
fixed	O
,	O
the	O
total	O
number	O
of	O
errors	O
Nall	O
is	O
an	O
objective	O
characteristic	O
of	O
prediction	O
quality	O
,	O
and	O
the	O
optimal	O
threshold	O
values	O
(	O
selected	O
during	O
the	O
""""	O
learning	O
stage	O
""""	O
)	O
provide	O
exactly	O
the	O
minimum	O
of	O
the	O
total	O
number	O
of	O
errors	O
.	O

However	O
,	O
if	O
different	O
testing	O
results	O
(	O
based	O
on	O
different	O
sets	O
of	O
query	O
sequences	O
)	O
are	O
compared	O
,	O
then	O
absolute	O
numbers	O
of	O
errors	O
can	O
not	O
be	O
treated	O
as	O
a	O
procedure	O
quality	O
measure	O
,	O
and	O
relative	O
quantities	O
(	O
proportions	O
)	O
should	O
be	O
considered	O
instead	O
of	O
absolute	O
quantities	O
.	O

Usually	O
a	O
sum	O
of	O
the	O
proportion	O
of	O
type	O
1	O
errors	O
and	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
used	O
as	O
a	O
quality	O
measure	O
;	O
values	O
of	O
this	O
sum	O
are	O
presented	O
in	O
the	O
fifth	O
column	O
of	O
Table	O
2	O
.	O

However	O
,	O
in	O
our	O
situation	O
the	O
number	O
of	O
words	O
nall	O
-	O
nq	O
that	O
do	O
not	O
belong	O
to	O
query	O
sequences	O
is	O
much	O
larger	O
than	O
nq	O
,	O
and	O
for	O
the	O
majority	O
of	O
these	O
words	O
it	O
is	O
obvious	O
that	O
they	O
do	O
not	O
belong	O
to	O
a	O
query	O
sequence	O
.	O

Consequently	O
,	O
in	O
case	O
of	O
optimal	O
parameter	O
values	O
the	O
proportion	O
of	O
type	O
2	O
errors	O
P	O
(	O
2	O
)	O
is	O
small	O
,	O
it	O
is	O
considerably	O
smaller	O
than	O
P	O
(	O
1	O
)	O
.	O

Thus	O
the	O
quantity	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
2	O
)	O
is	O
not	O
representative	O
in	O
our	O
case	O
(	O
see	O
[	O
5	O
]	O
)	O
.	O

The	O
ratio	O
P	O
(	O
+	O
)	O
of	O
the	O
number	O
of	O
wrong	O
positive	O
predictions	O
to	O
the	O
total	O
number	O
of	O
positive	O
predictions	O
is	O
more	O
representative	O
than	O
P	O
(	O
2	O
)	O
.	O

Hence	O
,	O
it	O
is	O
natural	O
to	O
measure	O
procedure	O
quality	O
by	O
the	O
sum	O
P	O
(	O
1	O
)	O
+	O
P	O
(	O
+	O
)	O
.	O

Exactly	O
this	O
procedure	O
quality	O
measure	O
was	O
used	O
in	O
[	O
5	O
]	O
.	O

In	O
medical	O
decision	O
making	O
(	O
diagnostic	O
testing	O
)	O
the	O
terms	O
sensitivity	O
(	O
sens	O
=	O
1	O
-	O
P	O
(	O
1	O
)	O
)	O
and	O
specificity	O
(	O
spec	O
=	O
1	O
-	O
P	O
(	O
2	O
)	O
)	O
are	O
frequently	O
used	O
to	O
quantify	O
the	O
accuracy	O
of	O
a	O
procedure	O
,	O
while	O
the	O
quantity	O
1	O
-	O
P	O
(	O
+	O
)	O
is	O
known	O
as	O
the	O
positive	O
predictive	O
value	O
.	O

Alternative	O
terminology	O
is	O
discussed	O
in	O
[	O
12	O
]	O
.	O

The	O
ROC	O
curve	O
plotting	O
sens	O
against	O
1	O
-	O
spec	O
is	O
a	O
popular	O
way	O
of	O
showing	O
the	O
overall	O
performance	O
of	O
a	O
diagnostic	O
test	O
without	O
specification	O
of	O
a	O
cut	O
off	O
value	O
.	O

It	O
is	O
also	O
used	O
and	O
discussed	O
in	O
[	O
12	O
]	O
,	O
but	O
with	O
different	O
labels	O
for	O
the	O
axes	O
.	O

Figure	O
2	O
contains	O
ROC	O
curves	O
for	O
the	O
best	O
variants	O
of	O
the	O
statistics	O
(	O
i.e.	O
,	O
for	O
variants	O
that	O
were	O
marked	O
in	O
Table	O
2	O
)	O
applied	O
to	O
the	O
non	O
-	O
degenerate	O
words	O
.	O

Discussion	O
Overall	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
η	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
Mean	O
values	O
of	O
Nall	O
(	O
where	O
averaging	O
is	O
performed	O
over	O
all	O
variants	O
presented	O
in	O
Table	O
2	O
)	O
for	O
different	O
statistics	O
are	O
the	O
following	O
:	O
241	O
for	O
η	O
,	O
310	O
for	O
T	O
(	O
1	O
)	O
,	O
320	O
for	O
T	O
(	O
2	O
)	O
,	O
and	O
356	O
for	O
T^	O
(	O
2	O
)	O
(	O
recall	O
that	O
differences	O
in	O
the	O
order	O
of	O
10	O
%	O
can	O
be	O
considered	O
to	O
be	O
significant	O
)	O
.	O

These	O
numbers	O
show	O
that	O
the	O
statistics	O
can	O
clearly	O
be	O
ordered	O
with	O
respect	O
to	O
the	O
prediction	O
quality	O
:	O
the	O
best	O
statistic	O
is	O
η	O
,	O
then	O
comes	O
T	O
(	O
1	O
)	O
,	O
then	O
T	O
(	O
2	O
)	O
,	O
and	O
finally	O
T^	O
(	O
2	O
)	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
η	O
,	O
T	O
(	O
1	O
)	O
,	O
as	O
well	O
as	O
for	O
the	O
comparison	O
of	O
statistics	O
the	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
this	O
conclusion	O
is	O
obvious	O
.	O

For	O
the	O
comparison	O
of	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
it	O
seems	O
to	O
be	O
less	O
obvious	O
,	O
but	O
the	O
consideration	O
of	O
variants	O
in	O
which	O
the	O
calculation	O
of	O
coefficients	O
ai	O
is	O
performed	O
using	O
formula	O
(	O
13	O
)	O
(	O
i.e.	O
,	O
variants	O
[	O
0,0	O
]	O
and	O
[	O
1,0	O
]	O
;	O
recall	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
has	O
only	O
such	O
variants	O
)	O
clearly	O
shows	O
that	O
the	O
statistic	O
T	O
(	O
1	O
)	O
is	O
considerably	O
better	O
than	O
T	O
(	O
2	O
)	O
.	O

The	O
same	O
conclusion	O
can	O
be	O
drawn	O
from	O
the	O
comparison	O
of	O
ROC	O
curves	O
presented	O
in	O
Fig.	O
2	O
.	O

Testing	O
results	O
show	O
that	O
the	O
prediction	O
quality	O
for	O
the	O
best	O
variant	O
of	O
the	O
statistic	O
η	O
(	O
see	O
the	O
first	O
line	O
of	O
Table	O
2	O
)	O
is	O
much	O
higher	O
(	O
higher	O
by	O
50	O
%	O
)	O
in	O
comparison	O
with	O
results	O
of	O
[	O
5	O
]	O
(	O
see	O
the	O
line	O
of	O
Table	O
2	O
that	O
corresponds	O
to	O
T^	O
(	O
2	O
)	O
[	O
0,1	O
]	O
)	O
.	O

That	O
is	O
the	O
most	O
striking	O
finding	O
of	O
the	O
current	O
paper	O
.	O

It	O
is	O
interesting	O
to	O
see	O
that	O
the	O
statistic	O
η	O
turned	O
out	O
to	O
be	O
better	O
than	O
T	O
(	O
1	O
)	O
:	O
the	O
latter	O
would	O
be	O
expected	O
to	O
be	O
better	O
as	O
it	O
equals	O
the	O
logarithm	O
of	O
the	O
likelihood	O
ratio	O
(	O
in	O
reality	O
,	O
it	O
does	O
not	O
equal	O
this	O
logarithm	O
because	O
the	O
ξi	O
are	O
not	O
independent	O
)	O
.	O

We	O
suppose	O
that	O
this	O
fact	O
can	O
be	O
explained	O
as	O
follows	O
.	O

Recall	O
that	O
T	O
(	O
1	O
)	O
and	O
η	O
are	O
equivalent	O
for	O
an	O
arbitrary	O
fixed	O
word	O
ω	O
.	O

These	O
statistics	O
turn	O
out	O
to	O
be	O
not	O
equivalent	O
only	O
if	O
they	O
are	O
compared	O
on	O
the	O
whole	O
totality	O
of	O
words	O
.	O

It	O
is	O
worth	O
noting	O
that	O
the	O
variation	O
of	O
the	O
values	O
of	O
the	O
statistic	O
T	O
(	O
1	O
)	O
(	O
i.e.	O
,	O
the	O
difference	O
between	O
values	O
of	O
T	O
(	O
1	O
)	O
in	O
cases	O
ξ1	O
=	O
....	O
=	O
ξn	O
=	O
0	O
and	O
ξ1	O
=	O
....	O
=	O
ξn	O
=	O
1	O
)	O
significantly	O
depends	O
on	O
a	O
word	O
ω	O
:	O
for	O
some	O
words	O
these	O
values	O
vary	O
from	O
-700	O
to	O
700	O
,	O
for	O
some	O
other	O
from	O
-0.01	O
to	O
0.01	O
.	O

In	O
principle	O
,	O
the	O
optimal	O
threshold	O
value	O
is	O
different	O
for	O
different	O
words	O
.	O

As	O
the	O
ranges	O
of	O
T	O
(	O
1	O
)	O
values	O
essentially	O
vary	O
,	O
then	O
it	O
is	O
probable	O
that	O
optimal	O
thresholds	O
also	O
essentially	O
vary	O
.	O

The	O
optimal	O
threshold	O
for	O
the	O
whole	O
totality	O
of	O
words	O
is	O
a	O
certain	O
mean	O
value	O
of	O
thresholds	O
over	O
individual	O
words	O
ω	O
.	O

Since	O
the	O
optimal	O
thresholds	O
are	O
significantly	O
different	O
for	O
different	O
words	O
,	O
the	O
quality	O
of	O
the	O
mean	O
is	O
low	O
:	O
for	O
certain	O
words	O
(	O
e.g.	O
,	O
words	O
with	O
small	O
variation	O
of	O
T	O
(	O
1	O
)	O
)	O

this	O
mean	O
is	O
completely	O
unrepresentative	O
.	O

In	O
the	O
same	O
time	O
,	O
the	O
range	O
of	O
values	O
of	O
η	O
is	O
the	O
same	O
for	O
all	O
words	O
(	O
these	O
values	O
lie	O
between	O
0	O
and	O
1	O
)	O
.	O

Consequently	O
,	O
the	O
difference	O
between	O
optimal	O
thresholds	O
for	O
individual	O
words	O
is	O
probably	O
not	O
so	O
significant	O
,	O
and	O
the	O
mean	O
gives	O
better	O
quality	O
for	O
individual	O
words	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
.	O

From	O
the	O
point	O
of	O
view	O
of	O
prediction	O
quality	O
the	O
statistic	O
T	O
(	O
2	O
)	O
turned	O
out	O
to	O
be	O
worse	O
than	O
T	O
(	O
1	O
)	O
.	O

It	O
is	O
not	O
surprising	O
,	O
because	O
during	O
the	O
derivation	O
of	O
the	O
formula	O
for	O
T	O
(	O
2	O
)	O
along	O
with	O
the	O
incorrect	O
assumption	O
of	O
independence	O
of	O
ξi	O
we	O
also	O
made	O
the	O
incorrect	O
assumption	O
of	O
the	O
normal	O
distribution	O
of	O
η	O
.	O

This	O
consideration	O
is	O
applicable	O
to	O
T^	O
(	O
2	O
)	O
as	O
well	O
.	O

Since	O
the	O
cut	O
-	O
off	O
points	O
for	O
these	O
statistics	O
are	O
determined	O
empirically	O
in	O
the	O
test	O
set	O
and	O
validated	O
in	O
the	O
training	O
set	O
,	O
the	O
violation	O
of	O
the	O
normality	O
assumption	O
does	O
not	O
invalidate	O
the	O
procedures	O
as	O
such	O
,	O
but	O
might	O
affect	O
their	O
performance	O
.	O

Effect	O
of	O
procedure	O
modifications	O
The	O
next	O
issue	O
is	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
procedure	O
modifications	O
.	O

One	O
can	O
see	O
that	O
for	O
a	O
fixed	O
statistic	O
the	O
prediction	O
quality	O
significantly	O
depends	O
on	O
the	O
choice	O
of	O
the	O
variant	O
.	O

Thus	O
,	O
the	O
introduction	O
of	O
modifications	O
turned	O
out	O
to	O
be	O
effective	O
.	O

It	O
is	O
interesting	O
that	O
all	O
statistics	O
for	O
which	O
coefficients	O
aj	O
can	O
be	O
calculated	O
in	O
different	O
ways	O
(	O
these	O
are	O
the	O
statistics	O
η	O
,	O
T	O
(	O
2	O
)	O
T^	O
(	O
2	O
)	O
)	O
prediction	O
quality	O
was	O
better	O
in	O
case	O
when	O
these	O
coefficients	O
were	O
calculated	O
using	O
the	O
iterative	O
procedure	O
.	O

At	O
the	O
same	O
time	O
the	O
dependence	O
of	O
prediction	O
quality	O
on	O
the	O
modification	O
related	O
to	O
the	O
consideration	O
of	O
lengths	O
of	O
primary	O
local	O
alignments	O
is	O
more	O
intricate	O
:	O
for	O
the	O
statistic	O
η	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
for	O
the	O
statistics	O
T	O
(	O
1	O
)	O
,	O
T	O
(	O
2	O
)	O
,	O
the	O
results	O
are	O
better	O
if	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
considered	O
,	O
but	O
for	O
the	O
statistic	O
T^	O
(	O
2	O
)	O
results	O
are	O
better	O
when	O
lengths	O
of	O
primary	O
local	O
alignments	O
are	O
not	O
considered	O
.	O

Currently	O
reasons	O
of	O
this	O
fact	O
are	O
not	O
clear	O
for	O
us	O
.	O

As	O
it	O
was	O
noted	O
,	O
the	O
dependence	O
of	O
results	O
on	O
modifications	O
dealing	O
with	O
the	O
number	O
of	O
considered	O
primary	O
local	O
alignments	O
for	O
similar	O
sequences	O
is	O
not	O
essential	O
.	O

(	O
However	O
,	O
we	O
note	O
that	O
for	O
nearly	O
all	O
variants	O
that	O
were	O
described	O
above	O
as	O
well	O
as	O
variants	O
that	O
were	O
not	O
described	O
,	O
prediction	O
quality	O
is	O
better	O
in	O
case	O
when	O
all	O
primary	O
local	O
alignments	O
are	O
considered	O
)	O
.	O

Comparison	O
with	O
other	O
procedures	O
For	O
the	O
purpose	O
of	O
comparison	O
we	O
compared	O
our	O
findings	O
with	O
the	O
simple	O
statistic	O
q	O
(	O
ω	O
)	O
(	O
the	O
frequency	O
of	O
word	O
occurrence	O
in	O
the	O
list	O
of	O
similar	O
sequences	O
,	O
see	O
(	O
18	O
)	O
)	O
was	O
also	O
considered	O
,	O
using	O
a	O
threshold	O
of	O
q	O
=	O
0.422	O
.	O

As	O
expected	O
,	O
q	O
(	O
ω	O
)	O
gave	O
essentially	O
worse	O
results	O
in	O
comparison	O
with	O
T	O
(	O
1	O
)	O
,	O
η	O
,	O
T	O
(	O
2	O
)	O
,	O
T^	O
(	O
2	O
)	O
(	O
see	O
Table	O
2	O
)	O
.	O

Furthermore	O
,	O
we	O
compared	O
our	O
results	O
with	O
the	O
results	O
,	O
which	O
predicts	O
all	O
of	O
the	O
words	O
for	O
which	O
there	O
is	O
among	O
similar	O
sequences	O
at	O
least	O
one	O
sequence	O
with	O
a	O
power	O
above	O
a	O
certain	O
threshold	O
.	O

Such	O
an	O
approach	O
was	O
used	O
by	O
Andrade	O
M.	O
et	O
al.	O
[	O
2	O
]	O
.	O

This	O
is	O
the	O
statistics	O
SAnd	O
as	O
already	O
mentioned	O
in	O
Table	O
2	O
.	O

It	O
is	O
defined	O
as	O
SAnd	O
(	O
ω	O
)	O
=	O
max	O
μj	O
,	O
where	O
μj	O
is	O
the	O
measure	O
of	O
similarity	O
between	O
sequences	O
π0	O
,	O
πj	O
,	O
and	O
the	O
maximum	O
is	O
taken	O
on	O
the	O
j	O
for	O
which	O
ξj	O
(	O
ω	O
)	O
=	O
1	O
(	O
i.e.	O
the	O
word	O
belongs	O
to	O
these	O
sequences	O
)	O
.	O

In	O
our	O
application	O
similarity	O
is	O
measured	O
by	O
the	O
power	O
value	O
(	O
see	O
[	O
9,10	O
]	O
)	O
as	O
used	O
in	O
the	O
other	O
statistics	O
in	O
this	O
paper	O
and	O
mentioned	O
before	O
,	O
while	O
[	O
2	O
]	O
used	O
the	O
E	O
-	O
value	O
.	O

That	O
makse	O
the	O
cut	O
-	O
offs	O
hard	O
to	O
compare	O
.	O

The	O
results	O
for	O
these	O
statistics	O
are	O
given	O
in	O
the	O
same	O
Table	O
2	O
.	O

The	O
results	O
were	O
better	O
than	O
in	O
the	O
statistics	O
q	O
(	O
ω	O
)	O
,	O
but	O
worse	O
than	O
in	O
any	O
of	O
our	O
statistics	O
.	O

Surprisingly	O
,	O
it	O
turned	O
out	O
that	O
the	O
prediction	O
quality	O
is	O
better	O
when	O
only	O
some	O
similar	O
sequences	O
(	O
e.g.	O
,	O
10	O
from	O
100	O
)	O
are	O
used	O
for	O
the	O
evaluation	O
of	O
a	O
statistic	O
(	O
but	O
not	O
for	O
the	O
evaluation	O
of	O
transfer	O
probabilities	O
!	O
)	O
.	O

It	O
means	O
that	O
a	O
large	O
part	O
of	O
similar	O
sequences	O
only	O
leads	O
to	O
an	O
increase	O
of	O
""""	O
noise	O
""""	O
.	O

(	O
See	O
[	O
13	O
]	O
for	O
details	O
.	O
)	O

We	O
would	O
also	O
like	O
to	O
mention	O
the	O
work	O
[	O
14	O
]	O
on	O
FunCat	O
categories	O
containing	O
a	O
set	O
of	O
about	O
7,500	O
well	O
annotated	O
proteins	O
and	O
providing	O
a	O
benchmarking	O
for	O
different	O
methods	O
of	O
automated	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
to	O
apply	O
our	O
procedure	O
to	O
this	O
database	O
,	O
but	O
that	O
has	O
not	O
been	O
realized	O
yet	O
.	O

We	O
did	O
not	O
attempt	O
at	O
this	O
stage	O
to	O
apply	O
our	O
approach	O
to	O
the	O
GO	O
annotation	O
.	O

It	O
would	O
be	O
interesting	O
further	O
research	O
to	O
switch	O
to	O
GO	O
data	O
and	O
to	O
compare	O
our	O
approach	O
with	O
other	O
approaches	O
in	O
the	O
literature	O
.	O

There	O
is	O
a	O
similarity	O
with	O
the	O
approach	O
of	O
Kajan	O
et	O
al.	O
[	O
15	O
]	O
.	O

They	O
also	O
base	O
their	O
procedures	O
on	O
the	O
likelihood	O
ratio	O
,	O
but	O
use	O
approximations	O
based	O
on	O
maximal	O
similarity	O
(	O
or	O
minimal	O
distance	O
)	O
,	O
while	O
we	O
attempt	O
to	O
estimate	O
the	O
likelihood	O
ratio	O
from	O
pairwise	O
comparisons	O
within	O
the	O
set	O
of	O
similar	O
sequences	O
.	O

There	O
is	O
also	O
an	O
interesting	O
relation	O
with	O
the	O
GOPET	O
tool	O
presented	O
in	O
[	O
16	O
]	O
based	O
on	O
earlier	O
work	O
by	O
the	O
same	O
authors	O
[	O
17	O
]	O
.	O

These	O
authors	O
use	O
a	O
number	O
of	O
characteristics	O
of	O
the	O
set	O
of	O
found	O
similar	O
sequences	O
for	O
term	O
(	O
word	O
)	O
,	O
such	O
as	O
maximal	O
e	O
-	O
value	O
,	O
frequency	O
of	O
the	O
term	O
etc	O
.	O
,	O
as	O
a	O
coordinates	O
of	O
decision	O
making	O
space	O
.	O

They	O
use	O
more	O
features	O
while	O
we	O
concentrate	O
on	O
the	O
similarity	O
.	O

That	O
might	O
be	O
an	O
advantage	O
for	O
their	O
method	O
.	O

On	O
the	O
other	O
hand	O
we	O
try	O
to	O
use	O
the	O
information	O
from	O
all	O
similar	O
sequences	O
in	O
an	O
optimal	O
way	O
relying	O
on	O
statistical	O
decision	O
theory	O
by	O
means	O
of	O
the	O
use	O
of	O
transfer	O
probabilities	O
and	O
the	O
concept	O
of	O
likelihood	O
ratio	O
.	O

It	O
is	O
an	O
interesting	O
topic	O
of	O
further	O
research	O
to	O
compare	O
the	O
two	O
methods	O
.	O

So	O
far	O
we	O
only	O
predicted	O
the	O
presence	O
of	O
a	O
key	O
word	O
.	O

It	O
is	O
quite	O
a	O
challenge	O
to	O
obtain	O
a	O
true	O
prediction	O
of	O
function	O
.	O

Conclusion	O
The	O
main	O
conclusion	O
of	O
the	O
paper	O
is	O
that	O
the	O
introduction	O
of	O
the	O
concept	O
of	O
likelihood	O
ratio	O
coming	O
from	O
statistical	O
decision	O
theory	O
is	O
very	O
helpful	O
in	O
the	O
development	O
of	O
automated	O
annotation	O
procedures	O
.	O

We	O
obtained	O
a	O
substantial	O
improvement	O
when	O
compared	O
with	O
our	O
previous	O
results	O
.	O

We	O
are	O
sure	O
that	O
there	O
is	O
room	O
for	O
further	O
improvement	O
.	O

Issues	O
for	O
further	O
research	O
are	O
the	O
size	O
of	O
the	O
set	O
of	O
similar	O
sequences	O
and	O
the	O
combination	O
of	O
different	O
statistics	O
into	O
a	O
""""	O
super	O
-	O
predictor	O
""""	O
.	O

Authors	O
'	O
contributions	O
A.M.	O
Leontovich	O
and	O
H.C.	O
van	O
Houwelingen	O
developed	O
the	O
approach	O
.	O

A.M.	O
Leontovich	O
developed	O
the	O
methodology	O
and	O
the	O
algorithms	O
in	O
cooperation	O
with	O
K.Y.	O
Tokmachev	O
and	O
H.C.	O
van	O
Houwelingen	O
.	O

K.Y.	O
Tokmachev	O
carried	O
out	O
all	O
computations	O
.	O

Supplementary	O
Material	O

Carbonic	O
Anhydrase	O
Inhibitors	O
.	O

Part	O
541	O
:	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
of	O
Antiglaucoma	O
Agents	O
Abstract	O
Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	B
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

CARBONIC	O
ANHYDRASE	O
INHIBITORS	O
.	O

Part	O
54	O
METAL	O
COMPLEXES	O
OF	O
HETEROCYCLIC	O
SULFONAMIDES	O
:	O
A	O
NEW	O
CLASS	O
OF	O
ANTIGLAUCOMA	O
AGENTS	O
Claudiu	O
T.	O
Supuran	O

*	O
,	O
Andrea	O
Scozzafava	O
and	O
Andrei	O
Jitianu	O
2	O
Universit	O
&	O
degli	O
Studi	O
,	O
Dipartimento	O
di	O
Chimica	O
,	O
Laboratorio	O
di	O
Chimica	O
Inorganica	O

e	O
Bioinorganica	O
,	O
Via	O
Gino	O
Capponi	O
7	O
,	O
1	O
-	O
50121	O
,	O
Florence	O
,	O
Italy	O
2	O

""""	O
I.G.	O
Murgulescu	O
""""	O
Institute	O
of	O
Physical	O
Chemistry	O
,	O
Academia	O
Romana	O
,	O
Spl	O
.	O

Independentei	O
202	O
,	O
R-77208	O
Bucharest	O
,	O
Roumania	O
Abstract	O
:	O
Metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
inhibitory	O
properties	O
were	O
recently	O
shown	O
to	O
be	O
useful	O
as	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
lowering	O
agents	O
in	O
experimental	O
animals	O
,	O
and	O
might	O
be	O
developed	O
as	O
a	O
novel	O
class	O
of	O
antiglaucoma	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
CA	O
inhibitor	O
and	O
of	O
the	O
metal	O
complexes	O
containing	O
main	O
group	O
metal	O
ions	O
,	O
such	O
as	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
and	O
the	O
new	O
sulfonamide	O
as	O
well	O
as	O
5-amino	O
-	O
l,3,4thiadiazole-2-sulfonamide	O
as	O
ligands	O
.	O

The	O
new	O
complexes	O
were	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
CA	O
I	O
,	O
II	O
and	O
IV	O
.	O

Some	O
of	O
them	O
(	O
but	O
not	O
the	O
parent	O
sulfonamides	O
)	O
strongly	O
lowered	O
IOP	O
in	O
rabbits	B
when	O
administered	O
as	O
a	O
2	O
%	O
solution	O
into	O
the	O
eye	O
.	O

Introduction	O
Sulfonamides	O
possessing	O
carbonic	O
anhydrase	O
(	O
CA	O
,	O
EC	O
4.2.1.1	O
)	O
inhibitory	O
properties	O
[	O
2	O
]	O
such	O
as	O
acetazolamide	O
1	O
,	O
methazolamide	O
2	O
,	O
ethoxzolamide	O
3	O
and	O
dichlorophenamide	O
4	O
have	O
been	O
used	O
for	O
more	O
than	O
40	O
years	O
as	O
pressure	O
lowering	O
systemic	O
drugs	O
in	O
the	O
treatment	O
of	O
open	O
-	O
angle	O
glaucoma	O
[	O
3,4	O
]	O
.	O

Their	O
effect	O
is	O
due	O
to	O
inhibition	O
of	O
at	O
least	O
two	O
CA	O
isozymes	O
present	O
within	O
cilliary	O
processes	O
of	O
the	O
eye	O
,	O
ie	O
,	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
which	O
is	O
followed	O
by	O
lowered	O
bicarbonate	O
formation	O
and	O
reduction	O
of	O
aqueous	O
humor	O
secretion	O
[	O
5	O
-	O
7	O
]	O
.	O

Their	O
main	O
drawback	O
is	O
constituted	O
by	O
side	O
effects	O
such	O
as	O
fatigue	O
,	O
augmented	O
diuresis	O
,	O
or	O
paresthesias	O
,	O
due	O
to	O
CA	O
inhibition	O
in	O
other	O
tissues	O
/	O
organs	O
than	O
the	O
target	O
one	O
,	O
ie	O
,	O
the	O
eye	O
[	O
8	O
]	O
.	O

N	O
--	O
N	O
XN	O
--	O
N	O
EtO	O
S	O
NH	O
2	O
O	O
NH	O
O	O
:	O
S----O	O
NHEt	O
The	O
above	O
-	O
mentioned	O
side	O
effects	O
are	O
absent	O
in	O
the	O
case	O
in	O
which	O
the	O
inhibitor	O
has	O
topical	O
activity	O
,	O
and	O
is	O
applied	O
directly	O
into	O
the	O
eye	O
.	O

This	O
route	O
has	O
been	O
demonstrated	O
only	O
in	O
1983	O
by	O
Maren	O
's	O
group	O
[	O
9	O
]	O
and	O
was	O
followed	O
by	O
the	O
development	O
of	O
the	O
first	O
clinical	O
agent	O
of	O
this	O
type	O
,	O
dorzolamide	O
5	O
[	O
10,11	O
]	O
.	O

Dorzolamide	O
(	O
Trusopt	O
)	O
has	O
been	O
introduced	O
in	O
clinical	O
use	O
in	O
1995	O
in	O
USA	O
and	O
Europe	O
and	O
it	O
constituted	O
the	O
beginning	O
of	O
a	O
radically	O
new	O
treatment	O
of	O
glaucoma	O
,	O
devoid	O
of	O
the	O
severe	O
side	O
effects	O
observed	O
with	O
the	O
systemic	O
inhibitors	O
[	O
4	O
-	O
6	O
]	O
.	O

The	O
success	O
of	O
topical	O
antiglaucoma	O
CA	O
inhibitors	O
fostered	O
much	O
research	O
in	O
the	O
synthesis	O
and	O
clinical	O
evaluation	O
of	O
other	O
types	O
of	O
such	O
compounds	O
[	O
12	O
-	O
15	O
]	O
.	O

307	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O
A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
On	O
the	O
other	O
hand	O
,	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
of	O
type	O
1	O
-	O
5	O
have	O
been	O
recently	O
prepared	O
by	O
two	O
groups	O
16	O
-	O
20	O
]	O
,	O
and	O
it	O
was	O
proved	O
that	O
they	O
possess	O
much	O
stronger	O
CA	O
inhibitory	O
properties	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
were	O
prepared	O
18	O
-	O
22	O
]	O
.	O

Although	O
the	O
mechanism	O
of	O
CA	O
inhibition	O
of	O
the	O
metal	O
complexes	O
is	O
presently	O
unknown	O
,	O
it	O
was	O
hypothesized	O
that	O
their	O
increased	O
inhibitory	O
power	O
might	O
be	O
due	O
to	O
two	O
processes	O
,	O
occurring	O
separately	O
or	O
in	O
concert	O
,	O
ie	O
,	O
(	O
i	O
)	O
dissociation	O
of	O
the	O
complex	O
inhibitor	O
in	O
sulfonamide	O
anions	O
and	O
metal	O
ions	O
(	O
in	O
diluted	O
solution	O
)	O
,	O
which	O
in	O
turn	O
both	O
interact	O
thereafter	O
with	O
the	O
enzyme	O
,	O
at	O
different	O
binding	O
sites	O
,	O
and	O
(	O
ii	O
)	O
direct	O
interaction	O
of	O
the	O
undissociated	O
complex	O
with	O
the	O
enzyme	O
,	O
and	O
more	O
specifically	O
with	O
the	O
hydrophilic	O
patch	O
at	O
the	O
entrance	O
of	O
CA	O
II	O
active	O
site	O
[	O
23	O
]	O
,	O
this	O
being	O
the	O
isozyme	O
most	O
susceptible	O
to	O
inhibition	O
with	O
this	O
class	O
of	O
compounds	O
[	O
2,22	O
]	O
.	O

Whether	O
initially	O
the	O
first	O
mechanism	O
of	O
action	O
mentioned	O
above	O
was	O
favored	O
by	O
us	O
[	O
22	O
]	O
,	O
recent	O
evidences	O
suggested	O
that	O
the	O
undissociated	O
complex	O
might	O
be	O
the	O
inhibitory	O
species	O
,	O
at	O
least	O
for	O
some	O
isozymes	O
[	O
24	O
]	O
.	O

Since	O
metal	O
complexes	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
they	O
were	O
prepared	O
,	O
it	O
appeared	O
of	O
interest	O
to	O
test	O
whether	O
this	O
property	O
might	O
be	O
useful	O
for	O
their	O
use	O
in	O
lowering	O
IOP	O
in	O
experimental	O
animals	O
and	O
whence	O
as	O
a	O
possible	O
glaucoma	O
therapy	O
.	O

Recently	O
we	O
proved	O
[	O
25	O
,	O
26	O
]	O
that	O
some	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
(	O
which	O
themselves	O
do	O
not	O
possess	O
IOP	O
lowering	O
properties	O
)	O
act	O
as	O
very	O
powerful	O
such	O
agents	O
when	O
administered	O
as	O
diluted	O
solutions	O
directly	O
into	O
the	O
eye	O
of	O
experimental	O
animals	O
,	O
and	O
would	O
thus	O
offer	O
the	O
possibility	O
of	O
developing	O
such	O
totally	O
novel	O
drugs	O
.	O

Here	O
we	O
report	O
the	O
synthesis	O
of	O
a	O
heterocyclic	O
sulfonamide	O
possessing	O
strong	O
CA	O
inhibitory	O
properties	O
,	O
ie	O
,	O
5-	O
(	O
chloroacetamido	O
)	O
-l,3,4-thiadiazole-2-sulfonamide	O
,	O
and	O
of	O
the	O
metal	O
complexes	O
of	O
this	O
sulfonamide	O
and	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
,	O
containing	O
some	O
main	O
group	O
metal	O
ions	O
.	O

The	O
new	O
compounds	O
have	O
been	O
characterized	O
by	O
standard	O
physico	O
-	O
chemical	O
procedures	O
,	O
and	O
were	O
assayed	O
as	O
inhibitors	O
of	O
three	O
CA	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
h	O
human	B
;	O
b	O
bovine	B
;	O
these	O
are	O
the	O
isozymes	O
considered	O
to	O
play	O
a	O
critical	O
role	O
in	O
aqueous	O
humour	O
secretion	O
within	O
the	O
eye	O
of	O
higher	O
vertebrates	O
[	O
2	O
-	O
5	O
]	O
)	O
.	O

Materials	O
and	O
Methods	O
Melting	O
points	O
were	O
recorded	O
with	O
a	O
heating	O
plate	O
microscope	O
and	O
are	O
not	O
corrected	O
.	O

IR	O
spectra	O
were	O
recorded	O
in	O
KBr	O
pellets	O
with	O
a	O
Carl	O
Zeiss	O
IR-80	O
instrument	O
.	O

1H	O
-	O
NMR	O
spectra	O
were	O
recorded	O
in	O
DMSO	O
-	O
d6	O
as	O
solvent	O
,	O
with	O
a	O
Bruker	O
CPX200	O
instrument	O
.	O

Chemical	O
shifts	O
are	O
reported	O
as	O
values	O
,	O
relative	O
to	O
Me4Si	O
as	O
internal	O
standard	O
.	O

Conductimetric	O
measurements	O
were	O
done	O
at	O
room	O
temperature	O
(	O
1	O
mM	O
concentration	O
of	O
complex	O
)	O
in	O
DMSO	O
solution	O
with	O
a	O
Fisher	O
conductimeter	O
.	O

Elemental	O
analyses	O
were	O
done	O
by	O
combustion	O
for	O
C	O
,	O
H	O
,	O
N	O
with	O
an	O
automated	O
Carlo	O
Erba	O
analyzer	O
,	O
and	O
gravimetrically	O
for	O
the	O
metal	O
ions	O
,	O
and	O
were	O
0.4	O
%	O
of	O
the	O
theoretical	O
values	O
.	O

Thermogravimetric	O
measurements	O
were	O
done	O
in	O
air	O
,	O
at	O
a	O
heating	O
rate	O
of	O
10C	O
/	O
min	O
.	O
,	O
with	O
a	O
Perkin	O
Elmer	O
3600	O
thermobalance	O
.	O

Sulfonamides	O
used	O
as	O
standards	O
in	O
the	O
enzymatic	O
assay	O
(	O
except	O
for	O
5	O
)	O
,	O
acetazolamide	O
,	O
pyridine	O
,	O
and	O
chloroacetyl	O
chloride	O
used	O
for	O
the	O
preparation	O
of	O
compound	O
7	O
,	O
solvents	O
as	O
well	O
as	O
inorganic	O
reagents	O
were	O
from	O
Sigma	O
,	O
Merck	O
and	O
Carlo	O
Erba	O
.	O

5-Amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
was	O
prepared	O
from	O
acetazolamide	O
by	O
literature	O
procedures	O
[	O
27	O
]	O
,	O
by	O
desacetylation	O
with	O
concentrated	O
hydrochloric	O
acid	O
,	O
followed	O
by	O
neutralization	O
with	O
sodium	O
bicarbonate	O
of	O
the	O
corresponding	O
hydrochloride	O
(	O
Scheme	O
1	O
)	O
.	O

Dorzolamide	O
hydrochloride	O
5	O
was	O
from	O
Merck	O
,	O
Sharp	O
and	O
Dohme	O
or	O
was	O
prepared	O
as	O
described	O
by	O
Ponticello	O
et	O
al	O
10,11	O
]	O
.	O

Human	B
CA	O
and	O
CA	O
II	O
cDNAs	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
strain	O
BL21	O
(	O
DE3	O
)	O
from	O
the	O
plasmids	O
pACA	O
/	O
hCA	O
I	O
and	O
pACAdaCA	O
II	O
described	O
by	O
Forsman	O
et	O
al.	O
[	O
28	O
]	O
(	O
the	O
two	O
plasmids	O
were	O
a	O
gift	O
from	O
Prof.	O
Sven	O
Lindskog	O
,	O
Umea	O
University	O
,	O
Sweden	O
)	O
.	O

Cell	O
growth	O
conditions	O
were	O
those	O
described	O
by	O
Lindskog	O
's	O
group	O
[	O
29	O
]	O
,	O
and	O
enzymes	O
were	O
purified	O
by	O
affinity	O
chromatography	O
according	O
to	O
the	O
method	O
of	O
Khalifah	O
et	O
al	O
[	O
30	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
determined	O
spectrophotometrically	O
at	O
280	O
nm	O
,	O
utilizing	O
a	O
molar	O
absorptivity	O
of	O
49	O
mM	O
-	O
l.cm-1	O
for	O
hCA	O
and	O
54	O
mM	O
-	O
l.cm-1	O
for	O
hCA	O
II	O
,	O
respectively	O
,	O
based	O
on	O
M	O
28.85	O
kDa	O
for	O
hCA	O
I	O
,	O
and	O
29.3	O
kDa	O
for	O
hCA	O
II	O
,	O
respectively	O
[	O
31,32	O
]	O
.	O

bCA	O
IV	O
was	O
isolated	O
from	O
bovine	B
lung	O
microsomes	O
as	O
described	O
by	O
Maren	O
et	O
al	O
,	O
and	O
its	O
concentration	O
has	O
been	O
determined	O
by	O
titration	O
with	O
ethoxzolamide	O
[	O
33	O
]	O
.	O

Synthesis	O
of	O
5-	O
(	O
chloroacetamido	O
)	O
-	O
l	O
,	O
3	O
,	O
4-thiadiazole-2-sulfonamide	O
7	O
An	O
amount	O
of	O
1.80	O
g	O
(	O
10	O
mmol	O
)	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
6	O
was	O
suspended	O
in	O
20	O
mL	O
of	O
anhydrous	O
acetonitrile	O
and	O
0.9	O
mL	O
(	O
0.87	O
g	O
,	O
11	O
mmol	O
)	O
of	O
pyridine	O
added	O
.	O

The	O
mixture	O
was	O
magnetically	O
stirred	O
at	O
4	O
C	O
for	O
10	O
minutes	O
,	O
then	O
10.5	O
mmol	O
of	O
monochloroacetyl	O
chloride	O
,	O
dissolved	O
in	O
3	O
mL	O
acetonitrile	O
,	O
were	O
added	O
dropwise	O
for	O
5	O
min	O
,	O
and	O
stirring	O
was	O
continued	O
for	O
other	O
2	O
hours	O
at	O
room	O
temperature	O
.	O

After	O
an	O
additional	O
30	O
min	O
of	O
refluxation	O
,	O
followed	O
by	O
cooling	O
,	O
the	O
precipitated	O
crystals	O
were	O
filtered	O
and	O
recrystallized	O
from	O
ethanol	O
.	O

Yield	O
of	O
62	O
%	O
white	O
crystals	O
,	O
mp	O
246	O
-	O
248	O
o	O
lit	O
[	O
34	O
]	O
mp	O
IR	O
(	O
KBr	O
)	O
,	O
cm	O
-	O
l	O
:	O
590	O
,	O
610	O
,	O
660	O
,	O
790	O
,	O
935	O
,	O
1090	O
,	O
1115	O
,	O
1170	O
,	O
1350	O
,	O
1400	O
,	O
1550	O
,	O
1650	O
,	O
1720	O
,	O
2870	O
,	O
3280	O
3370	O
(	O
broad	O
)	O
;	O
UV	O
spectrum	O
,	O
,	O
max	O
,	O
nm	O
(	O
lg	O
)	O
:	O
255	O
(	O
3.50	O
)	O
;	O
288	O
(	O
4.37	O
)	O
H	O
-	O
NMR	O
(	O
DMSO	O
-	O
d6	O
)	O
,	O
i	O
,	O
ppm	O
:	O
2.96	O
(	O
s	O
,	O
2H	O
,	O
CH2	O
)	O
;	O
8.20	O
(	O
s	O
,	O
2H	O
,	O
SOzNH2	O
)	O
;	O
12.22	O
(	O
s	O
,	O
1H	O
,	O
CONH	O
)	O
.	O

Analysis	O
,	O
found	O
:	O
C	O
,	O
18.56	O
;	O
H	O
,	O
1.88	O
;	O
N	O
,	O
21.76	O
;	O
S	O
,	O
24.62	O
%	O
;	O
C4HsC1N403S2	O
requires	O
""""	O
C	O
,	O
18.72	O
;	O
H	O
,	O
1.96	O
;	O
N	O
,	O
21.83	O
;	O
S	O
,	O
24.98	O
%	O
.	O

General	O
procedure	O
for	O
the	O
preparation	O
of	O
compounds	O
8	O
-	O
20	O
An	O
amount	O
of	O
6	O
mmol	O
of	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
or	O
7	O
was	O
prepared	O
by	O
reacting	O
the	O
corresponding	O
sulfonamide	O
with	O
the	O
required	O
amount	O
of	O
an	O
alcoholic	O
1N	O
NaOH	O
solution	O
,	O
in	O
ethanol	O
as	O
solvent	O
.	O

To	O
this	O
308	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
solution	O
was	O
added	O
the	O
aqueous	O
metal	O
salt	O
(	O
Zn	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
AI	O
(	O
III	O
)	O
,	O
Cd	O
(	O
II	O
)	O
chlorides	O
,	O
and	O
Be	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
nitrate	O
)	O
solution	O
,	O
working	O
in	O
molar	O
ratios	O
RSOzNH-	O
Mn+	O
of	O
2:1	O
for	O
the	O
divalent	O
cations	O
and	O
3:1	O
for	O
the	O
trivalent	O
cation	O
,	O
respectively	O
.	O

The	O
aqueous	O
-	O
alcoholic	O
reaction	O
mixture	O
was	O
heated	O
on	O
a	O
steam	O
bath	O
for	O
one	O
hour	O
,	O
adjusting	O
the	O
pH	O
at	O
7	O
if	O
necessary	O
,	O
and	O
after	O
being	O
cooled	O
at	O
0	O
C	O
the	O
precipitated	O
complexes	O
were	O
filtered	O
and	O
thoroughly	O
washed	O
with	O
alcohol	O
-	O
water	O
1:1	O
(	O
v	O
/	O
v	O
)	O
and	O
air	O
dried	O
.	O

Yields	O
were	O
in	O
the	O
range	O
of	O
85	O
-	O
90	O
%	O
.	O

The	O
obtained	O
white	O
powders	O
of	O
compounds	O
8	O
-	O
20	O
melted	O
with	O
decomposition	O
at	O
temperatures	O
higher	O
than	O
350	O
C	O
,	O
and	O
were	O
poorly	O
soluble	O
in	O
water	O
and	O
alcohol	O
,	O
but	O
had	O
good	O
solubilities	O
in	O
DMSO	O
,	O
DMF	O
as	O
well	O
as	O
mixtures	O
of	O
DMSO	O
-	O
water	O
,	O
DMF	O
-	O
water	O
.	O

Pharmacology	O
Carbonic	O
anhydrase	O
inhibition	O
Initial	O
rates	O
of	O
4-nitrophenyl	O
acetate	O
hydrolysis	O
catalysed	O
by	O
different	O
CA	O
isozymes	O
were	O
monitored	O
spectrophotometrically	O
,	O
at	O
400	O
rim	O
,	O
with	O
a	O
Cary	O
3	O
instrument	O
interfaced	O
with	O
an	O
IBM	O
compatible	O
PC	O
[	O
35	O
]	O
.	O

Solutions	O
of	O
substrate	O
were	O
prepared	O
in	O
anhydrous	O
acetonitrile	O
;	O
the	O
substrate	O
concentrations	O
varied	O
between	O
2.10	O
-	O
2	O
and	O
1.10	O
-	O
6	O
M	O
,	O
working	O
at	O
25C	O
.	O

A	O
molar	O
absorption	O
coefficient	O
of	O
18,400	O
M	O
-	O
l.cm-1	O
was	O
used	O
for	O
the	O
4-nitrophenolate	O
formed	O
by	O
hydrolysis	O
,	O
in	O
the	O
conditions	O
of	O
the	O
experiments	O
(	O
pH	O
7.40	O
)	O
,	O
as	O
reported	O
in	O
the	O
literature	O
[	O
35	O
]	O
.	O

Non	O
-	O
enzymatic	O
hydrolysis	O
rates	O
were	O
always	O
subtracted	O
from	O
the	O
observed	O
rates	O
.	O

Duplicate	O
experiments	O
were	O
done	O
for	O
each	O
inhibitor	O
concentration	O
,	O
and	O
the	O
values	O
reported	O
throughout	O
the	O
paper	O
are	O
the	O
mean	O
of	O
such	O
results	O
.	O

Stock	O
solutions	O
of	O
inhibitor	O
(	O
1	O
mM	O
)	O
were	O
prepared	O
in	O
distilled	O
-	O
deionized	O
water	O
with	O
1020	O
%	O
(	O
v	O
/	O
v	O
)	O
DMSO	O
(	O
which	O
is	O
not	O
inhibitory	O
at	O
these	O
concentrations	O
[	O
2	O
]	O
)	O
and	O
dilutions	O
up	O
to	O
0.01	O
nM	O
were	O
done	O
thereafter	O
with	O
distilled	O
-	O
deionized	O
water	O
.	O

Inhibitor	O
and	O
enzyme	O
solutions	O
were	O
preincubated	O
together	O
for	O
10	O
min	O
at	O
room	O
temperature	O
prior	O
to	O
assay	O
,	O
in	O
order	O
to	O
allow	O
for	O
the	O
formation	O
of	O
the	O
E	O
-	O
I	O
complex	O
.	O

The	O
inhibition	O
constant	O
KI	O
was	O
determined	O
as	O
described	O
by	O
Pocket	O
and	O
Stone	O
[	O
35	O
]	O
.	O

Enzyme	O
concentrations	O
were	O
3.3	O
nM	O
for	O
hCA	O
II	O
,	O
l0	O
nM	O
for	O
hCA	O
and	O
34	O
nM	O
for	O
bCA	O
IV	O
(	O
this	O
isozyme	O
has	O
a	O
decreased	O
esterase	O
activity	O
[	O
36	O
]	O
and	O
higher	O
concentrations	O
had	O
to	O
be	O
used	O
for	O
the	O
-	O
measurements	O
)	O
.	O

Measurement	O
of	O
tonometric	O
lOP	O
Adult	O
male	O
New	O
Zealand	O
albino	O
rabbits	B
weighing	O
2	O
-	O
3	O
kg	O
were	O
used	O
in	O
the	O
experiments	O
(	O
three	O
animals	O
were	O
used	O
for	O
each	O
inhibitor	O
studied	O
)	O
.	O

The	O
experimental	O
procedures	O
conform	O
to	O
the	O
Association	O
for	O
Research	O
in	O
Vision	O
and	O
Ophthalmology	O
Resolution	O
on	O
the	O
use	O
of	O
animals	O
.	O

The	O
rabbits	B
were	O
kept	O
in	O
individual	O
cages	O
with	O
food	O
and	O
water	O
provided	O
ad	O
libitum	O
.	O

The	O
animals	O
were	O
maintained	O
on	O
a	O
12	O
h	O
:	O
12	O
h	O
light	O
/	O
dark	O
cycle	O
in	O
a	O
temperature	O
controlled	O
room	O
,	O
at	O
22	O
-	O
26	O
C.	O
Solutions	O
of	O
inhibitors	O
(	O
2	O
%	O
,	O
by	O
weight	O
)	O
were	O
obtained	O
in	O
DMSOwater	O
(	O
2:3	O
,	O
v	O
/	O
v	O
)	O
due	O
to	O
the	O
low	O
water	O
solubility	O
of	O
some	O
of	O
these	O
derivatives	O
.	O

Control	O
experiments	O
with	O
DMSO	O
(	O
at	O
the	O
same	O
concentration	O
as	O
that	O
used	O
for	O
obtaining	O
the	O
inhibitors	O
solutions	O
showed	O
that	O
it	O
does	O
not	O
possess	O
IOP	O
lowering	O
or	O
increasing	O
effects	O
.	O

IOP	O
was	O
measured	O
using	O
a	O
Digilab	O
30R	O
pneumatonometer	O
(	O
BioRad	O
,	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
as	O
described	O
by	O
Maren	O
's	O
group	O
[	O
37	O
-	O
39	O
]	O
.	O

The	O
pressure	O
readings	O
were	O
matched	O
with	O
two	O
-	O
point	O
standard	O
pressure	O
measurements	O
at	O
least	O
twice	O
each	O
day	O
using	O
a	O
Digilab	O
Calibration	O
verifier	O
.	O

All	O
IOP	O
measurements	O
were	O
done	O
by	O
the	O
same	O
investigator	O
with	O
the	O
same	O
tonometer	O
.	O

One	O
drop	O
of	O
0.2	O
%	O
oxybuprocaine	O
hydrochloride	O
(	O
novesine	O
,	O
Sandoz	O
)	O
diluted	O
"1""1"	O
with	O
saline	O
was	O
instilled	O
in	O
each	O
eye	O
immediately	O
before	O
each	O
set	O
of	O
pressure	O
measurements	O
.	O

IOP	O
was	O
measured	O
three	O
times	O
at	O
each	O
time	O
interval	O
,	O
and	O
the	O
means	O
reported	O
.	O

IOP	O
was	O
measured	O
first	O
immediately	O
before	O
drug	O
administration	O
,	O
then	O
at	O
30	O
min	O
after	O
the	O
instillation	O
of	O
the	O
pharmacological	O
agent	O
,	O
and	O
then	O
each	O
30	O
minutes	O
for	O
a	O
period	O
of	O
several	O
hours	O
.	O

For	O
all	O
IOP	O
experiments	O
drug	O
was	O
administered	O
to	O
only	O
one	O
eye	O
,	O
leaving	O
the	O
contralateral	O
eye	O
as	O
an	O
untreated	O
control	O
.	O

The	O
ocular	O
hypotensive	O
activity	O
is	O
expressed	O
as	O
the	O
average	O
difference	O
in	O
IOP	O
between	O
the	O
treated	O
and	O
control	O
eye	O
,	O
in	O
this	O
way	O
minimizing	O
the	O
diurnal	O
,	O
seasonal	O
and	O
interindividual	O
variations	O
commonly	O
observed	O
in	O
the	O
rabbit	B
[	O
37	O
-	O
39	O
]	O
.	O

All	O
data	O
are	O
expressed	O
as	O
mean	O
SE	O
,	O
using	O
a	O
one	O
-	O
tailed	O
test	O
.	O

Results	O
and	O
Discussion	O
Reaction	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
[	O
19b	O
]	O
with	O
chloroacteyl	O
chloride	O
in	O
the	O
presence	O
of	O
pyridine	O
afforded	O
5-	O
(	O
chloroacetamido	O
)	O
-l,3,4-thiadiazole-2-sulfonamide	O
7	O
,	O
by	O
the	O
procedure	O
already	O
reported	O
by	O
Young	O
et	O
al.	O
[	O
34	O
]	O
(	O
Scheme	O
1	O
)	O
.	O

The	O
sulfonamide	O
7	O
has	O
been	O
characterized	O
by	O
elemental	O
analysis	O
and	O
spectroscopic	O
methods	O
which	O
confirmed	O
its	O
structure	O
(	O
only	O
its	O
m.p	O
.	O
has	O
been	O
reported	O
in	O
ref	O
.	O

[	O
34	O
]	O
)	O
.	O

The	O
sodium	O
salt	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
obtained	O
in	O
situ	O
from	O
the	O
corresponding	O
sulfonamide	O
and	O
sodium	O
hydroxide	O
,	O
were	O
then	O
used	O
for	O
the	O
preparation	O
of	O
coordination	O
compounds	O
,	O
containing	O
the	O
following	O
metal	O
ions	O
:	O
Be	O
(	O
II	O
)	O
,	O
Mg	O
(	O
II	O
)	O
,	O
Al	O
(	O
III	O
)	O
,	O
Zn	O
(	O
II	O
)	O
,	O
Cd	O
(	O
II	O
)	O
and	O
Hg	O
(	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
although	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
is	O
the	O
parent	O
compound	O
of	O
important	O
sulfonamide	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
benzolamide	O
,	O
methazolamide	O
,	O
etc	O
.	O
,	O
its	O
coordination	O
chemistry	O
has	O
been	O
scarcely	O
investigated	O
up	O
to	O
now	O
[	O
22	O
,	O
40	O
]	O
.	O

The	O
new	O
complexes	O
prepared	O
in	O
this	O
work	O
are	O
shown	O
in	O
Table	O
I.	O
Both	O
compounds	O
containing	O
the	O
sulfonamide	O
-	O
deprotonated	O
species	O
of	O
sulfonamide	O
7	O
(	O
LH	O
)	O
,	O
as	O
well	O
as	O
complexes	O
in	O
which	O
the	O
anion	O
of	O
5amino-1,3,4-thiadiazole-2-sulfonamide	O
(	O
tda	O
)	O
act	O
as	O
ligands	O
,	O
have	O
been	O
prepared	O
.	O

In	O
fact	O
in	O
another	O
work	O
[	O
40	O
]	O
it	O
was	O
documented	O
that	O
in	O
some	O
cases	O
,	O
sulfonamides	O
derived	O
from	O
this	O
ring	O
system	O
may	O
undergo	O
hydrolysis	O
to	O
309	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
""""	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
the	O
moiety	O
substituting	O
the	O
5	O
position	O
,	O
with	O
the	O
formation	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole-2-sulfonamide	O
6	O
,	O
which	O
thereafter	O
coordinates	O
metal	O
ions	O
present	O
in	O
solution	O
.	O

N	O
CIH	O
N	O
I	O
N	O
+	O
NaHCO	O
2	O
N	O
2	O
S	O
'	O
-NaCl	O
I	O
S	O
N	O
II	O
SO2NH	O
1_12	O
O	O
Py	O
/	O
MeCN	O
6Htda	O
+	O
CIOCCH2CI	O
0	O
Cl	O
CH	O
2	O
Scheme	O
1	O
HN	O
.I	O

N	O
N	O
S	O
7	O
:	O
LH	O
II	O
SqNH	O
Thus	O
,	O
the	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
(	O
NH3	O
)	O
]	O
.H20	O
prepared	O
in	O
this	O
way	O
has	O
recently	O
been	O
reported	O
by	O
this	O
group	O
[	O
40	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
when	O
the	O
ligand	O
7	O
has	O
not	O
been	O
hydrolyzed	O
(	O
during	O
the	O
preparation	O
of	O
the	O
coordination	O
compounds	O
)	O
in	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
to	O
5-amino	O
-	O
l,3,4-thiadiazole-2sulfonamide	O
and	O
chloroacetate	O
,	O
the	O
metal	O
complexes	O
contining	O
6	O
as	O
ligand	O
have	O
been	O
prepared	O
from	O
the	O
last	O
(	O
pure	O
)	O
compound	O
(	O
as	O
sodium	O
salt	O
)	O
and	O
the	O
corresponding	O
metal	O
salt	O
,	O
by	O
the	O
general	O
procedure	O
described	O
in	O
the	O
Experimental	O
part	O
.	O

Table	O

I	O
:	O
Prepared	O
complexes	O
8	O
-	O
20	O
,	O
containing	O
the	O
conjugate	O
bases	O
of	O
sulfonamides	O
6	O
and	O
7	O
as	O
ligands	O
and	O
their	O
elemental	O
analysis	O
data	O
.	O

L	O
stands	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
7	O
,	O
whereas	O
tda	O
for	O
the	O
sulfonamide	O
deprotonated	O
species	O
of	O
5-amino-1,3,4-thiadiazole-2-sulfonamide	O
6	O
.	O

No.	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
Complex	O
Yield	O
(	O
%	O
)	O
%	O
Ma	O
Analysis	O
(	O
calculated	O
/	O
found	O
)	O
%	O
H	O
b	O
%	O
C	O
b	O
13.0	O
/	O
13.1	O
11.0	O
/	O
10.8	O
11.3	O
/	O
11.4	O
10.2	O
/	O
10.1	O
8.5	O
/	O
8.1	O
7.9	O
/	O
7.9	O
12.7	O
/	O
12.8	O
18.4	O
/	O
18.1	O
18.1	O
/	O
17.9	O
16.6	O
/	O
16.2	O
15.3	O
/	O
14.9	O
13.4	O
/	O
13.3	O
12.7	O
/	O
12.5	O
1.6	O
/	O
1.3	O
2.7	O
/	O
2.3	O
1.4	O
/	O
1.1	O
1.2	O
/	O
1.2	O
1.0	O
/	O
1.2	O
1.6	O
/	O
1.3	O
1.6	O
/	O
1.6	O
1.5	O
/	O
1.5	O
1.5	O
/	O
1.3	O
1.3	O
/	O
1.4	O
1.2	O
/	O
1.1	O
1.1	O
/	O
1.2	O
1.0	O
/	O
1.0	O
%	O
N	O
b	O
30.4	O
/	O
30.2	O
25.6	O
/	O
25.5	O
26.4	O
/	O
26.4	O

13.7	O
/	O
23.3	O
20.0	O
/	O
19.8	O

18.6	O
/	O
18.5	O
29.7	O
/	O
29.6	O

21.5	O
/	O
21.3	O
21.1	O
/	O
20.8	O

19.4	O
/	O
19.3	O
17.9	O
/	O
17.8	O
15.7	O
/	O
15.6	O
14.8	O
/	O
14.6	O
[	O
Be	O
(	O
tda	O
)	O
2	O
]	O
[	O
Mg	O
(	O
tda	O
)	O
2	O
]	O
.3	O
H20	O
[	O
Zn	O
(	O
tda	O
)	O
2	O
]	O
[	O
Cd	O
(	O
tda	O
)	O
2	O
]	O
[	O
Hg	O
(	O
tda	O
)	O
2	O
]	O
[	O
Pb	O
(	O
tda	O
)	O
z	O
(	O
OH2	O
)	O
2	O
]	O
[	O
Al	O
(	O
tda	O
)	O
3	O
]	O
[	O
BeL2	O
]	O
[	O
ALL3	O
]	O
[	O
ZnL2	O
]	O
[	O
CdL2	O
]	O
[	O
HgL2	O
]	O
[	O
PbLz	O
(	O
OH2	O
)	O
2	O
]	O
78	O
76	O
83	O
90	O
95	O
84	O
72	O
75	O
59	O
87	O
88	O
92	O
95	O
2.4	O
/	O
2.5	O
5.5	O
/	O
5.1	O
15.4	O
/	O
15.0	O
23.8	O
/	O
24.1	O
35.8	O
/	O
35.7	O
34.4	O
/	O
34.7	O
4.7	O
/	O
4.4	O
1.7	O
/	O
1.6	O
3.4	O
/	O
3.5	O
11.3	O
/	O
11.5	O
18.0	O
/	O
18.1	O
28.1	O
/	O
28.3	O
27.4	O
/	O
27.2	O
aBy	O
gravimetry	O
;	O
bBy	O
combustion	O
.	O

The	O
new	O
complexes	O
have	O
also	O
been	O
characterized	O
by	O
spectroscopic	O
,	O
conductimetric	O
and	O
thermogravimetric	O
measurements	O
(	O
Table	O
II	O
)	O
.	O

By	O
comparing	O
the	O
IR	O
spectra	O
of	O
the	O
complexes	O
and	O
the	O
corresponding	O
ligands	O
,	O
the	O
following	O
observations	O
should	O
be	O
made	O
:	O
(	O
i	O
)	O
the	O
shift	O
of	O
the	O
two	O
sulfonamido	O
vibrations	O
(	O
both	O
the	O
symmetric	O
as	O
well	O
as	O
the	O
the	O
assymetric	O
one	O
)	O
,	O
towards	O
lower	O
wavenumbers	O
in	O
the	O
spectra	O
of	O
the	O
complexes	O
,	O
as	O
compared	O
to	O
the	O
spectra	O
of	O
the	O
corresponding	O
ligand	O
(	O
Table	O
II	O
)	O
,	O
as	O
already	O
documented	O
previously	O
for	O
similar	O
complexes	O
[	O
13	O
-	O
22	O
]	O
.	O

This	O
is	O
a	O
direct	O
indication	O
that	O
the	O
deprotonated	O
sulfonamido	O
310	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
moieties	O
of	O
the	O
ligands	O
interacts	O
with	O
the	O
metal	O
ions	O
in	O
the	O
newly	O
prepared	O
coordination	O
compounds	O
;	O
(	O
ii	O
)	O
the	O
amide	O
vibrations	O
(	O
the	O
most	O
intense	O
such	O
bands	O
at	O
1670	O
-	O
1680	O
cm-1	O
)	O
of	O
ligand	O
7	O
appear	O
unchanged	O
in	O
the	O
IR	O
spectra	O
of	O
complexes	O
15	O
-	O
20	O
(	O
data	O
not	O
shown	O
)	O
,	O
suggesting	O
that	O
these	O
moieties	O
do	O
not	O
participate	O
in	O
coordination	O
of	O
the	O
metal	O
ions	O
;	O
(	O
iii	O
)	O
the	O
C	O
-	O
N	O
stretching	O
vibration	O
in	O
the	O
spectra	O
of	O
the	O
prepared	O
complexes	O
is	O
shifted	O
with	O
5	O
-	O
20	O
cm-1	O
towards	O
lower	O
wavenumbers	O
,	O
as	O
compared	O
to	O
the	O
same	O
vibration	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
and	O
7	O
,	O
indicating	O
that	O
one	O
of	O
the	O
endocyclic	O
nitrogens	O
of	O
the	O
thiadiazolic	O
ring	O
(	O
presumably	O
N3	O
)	O
acts	O
as	O
donor	O
atom	O
,	O
as	O
already	O
documented	O
by	O
X	O
-	O
ray	O
crystallographic	O
and	O
spectroscopic	O
determinations	O
on	O
complexes	O
of	O
other	O
sulfonamides	O
(	O
such	O
as	O
1	O
-	O
3	O
)	O
with	O
divalent	O
metal	O
ions	O
[	O
13	O
-	O
22	O
]	O
(	O
Table	O
II	O
)	O
;	O
(	O
iv	O
)	O
changes	O
in	O
the	O
region	O
3100	O
-	O
3160	O
cm-	O
,	O
as	O
the	O
bands	O
present	O
in	O
the	O
spectra	O
of	O
sulfonamides	O
6	O
,	O
7	O
are	O
present	O
in	O
the	O
spectra	O
of	O
complexes	O
8	O
-	O
20	O
too	O
,	O
but	O
they	O
are	O
not	O
well	O
resolved	O
,	O
and	O
have	O
a	O
smaller	O
intensity	O
.	O

This	O
is	O
probably	O
due	O
to	O
deprotonation	O
of	O
the	O
SO2NH2	O
moiety	O
and	O
participation	O
in	O
the	O
binding	O
of	O
cations	O
;	O
(	O
v	O
)	O
the	O
amino	O
vibrations	O
from	O
3320	O
cm-	O
in	O
the	O
spectra	O
of	O
6	O
appear	O
unchanged	O
in	O
the	O
spectra	O
of	O
its	O
complexes	O
8	O
-	O
14	O
(	O
data	O
not	O
s.hown	O
)	O
.	O

In	O
the	O
1H	O
-	O
NMR	O
spectra	O
of	O
compound	O
6	O
and	O
its	O
metal	O
complexes	O
,	O
the	O
signal	O
of	O
the	O
amino	O
group	O
has	O
been	O
evidenced	O
as	O
a	O
broad	O
singlet	O
centered	O
at	O
4.54	O
ppm	O
(	O
Table	O
II	O
)	O
,	O
which	O
is	O
not	O
exchangeable	O
by	O
addition	O
of	O
D20	O
into	O
the	O
NMR	O
tube	O
,	O
in	O
contrast	O
to	O
the	O
sulfonamido	O
NH2	O
protons	O
(	O
which	O
readily	O
exchange	O
)	O
.	O

This	O
proves	O
that	O
the	O
5-amino	O
moiety	O
is	O
not	O
involved	O
in	O
binding	O
the	O
metal	O
ions	O
,	O
as	O
already	O
shown	O
in	O
the	O
X	O
-	O
ray	O
crystallographic	O
work	O
of	O
the	O
complex	O
[	O
Zn	O
(	O
tda	O
)	O
z	O
(	O
NH3	O
)	O
]	O
.H20	O
previously	O
reported	O
[	O
40	O
]	O
.	O

For	O
sulfonamide	O
7	O
the	O
CONH	O
proton	O
resonates	O
as	O
a	O
singlet	O
at	O
12.22	O
ppm	O
.	O

In	O
complexes	O
15	O
-	O
20	O
only	O
very	O
minor	O
shifts	O
of	O
this	O
signal	O
were	O
evidenced	O
(	O
Table	O
II	O
)	O
,	O
proving	O
basically	O
that	O
the	O
CONH	O
moiety	O
does	O
not	O
interact	O
with	O
the	O
metal	O
ions	O
in	O
these	O
complexes	O
.	O

Table	O
II	O
:	O
Spectroscopic	O
,	O
thermogravimetric	O
and	O
conductimetric	O
data	O
for	O
compounds	O
6	O
-	O
20	O
.	O

1H	O
-	O
NMR	O
Spectrab	O
Comp	O
.	O

IR	O
Spectraa	O
,	O
cm-1	O
as	O
v	O
(	O
C	O
=	O
N	O
)	O
CONH	O
,	O
i	O
(	O
ppm	O
)	O
v	O
(	O
SO2	O
)	O
S	O
;	O
v	O
(	O
SO2	O
)	O
6	O
8	O
9	O
10	O
11	O
TG	O
analysisc	O
calc.	O
/	O
found	O
Conductimetryd	O
AM	O
(	O
-1	O
x	O
cm2x	O
mol-	O
)	O
2	O
7	O
4	O
5	O
3	O
2	O
2	O
6	O
3	O
4	O
2	O
9	O
3	O
2	O
8	O
12	O
13	O
14	O
7	O
15	O
16	O
17	O
18	O
19	O
20	O
1170	O
;	O
1150	O
;	O
1150	O
;	O
1145	O
;	O
1145	O
;	O
1140	O
;	O
1145	O
;	O
1150	O
;	O
1170	O
;	O
1130	O
;	O
1140	O
;	O
1140	O
;	O
1150	O
;	O
1140	O
;	O
1145	O
;	O
1350	O
1300	O
1305	O
1300	O
1305	O
1300	O
1300	O
1300	O
1350	O
1335	O
1330	O
1330	O
1330	O
1335	O
1330	O
1610	O
1600	O
1600	O
1600	O
1600	O
1590	O
1605	O
1605	O
1610	O
1605	O
1610	O
1610	O
1605	O

1600	O
1600	O
A	O
A	O
A	O
A	O
A	O
A	O
A	O
e	O
e	O
12.3	O
/	O
12.1f	O
e	O
e	O
e	O
5.9	O
/	O
5.7	O
g	O
A	O
12.22	O
(	O
1H	O
)	O
12.19	O
(	O
2H	O
)	O
12.18	O
(	O
3H	O
)	O
12.20	O
(	O
2H	O
)	O
12.18	O
(	O
2H	O
)	O
12.19	O
(	O
2H	O
)	O
12.21	O
(	O
2H	O
)	O
e	O
e	O
e	O
e	O
e	O
e	O
e	O
4.7	O
/	O
4.8	O
g	O
a	O
In	O
KBr	O
;	O
bin	O
DMSO	O
-	O
d6	O
;	O
A	O
the	O
signal	O
of	O
the	O
5-amino	O
group	O
of	O
6	O
(	O
appearing	O
in	O
the	O
ligand	O
at	O
4.54	O
ppm	O
as	O
a	O
broad	O
singlet	O
)	O
appears	O
at	O
the	O
same	O
chemical	O
shift	O
(	O
4.50	O
4.55	O
ppm	O
)	O
in	O
complexes	O
8	O
-	O
14	O
;	O
cWeight	O
loss	O
between	O
70	O
-	O
250	O
C	O
;	O
d	O
mM	O
solution	O
,	O
in	O
DMF	O
,	O
at	O
25C	O
;	O
e	O
No	O
weight	O
loss	O
seen	O
under	O
250	O
C	O
;	O
fCorresponding	O
to	O
three	O
lattice	O
water	O
molecules	O
lost	O
at	O
70	O
-	O
110C	O
,	O
and	O
gCorresponding	O
to	O
two	O
coordinated	O
water	O
molecules	O
,	O
lost	O
at	O
160	O
-	O
180	O
C.	O
Thermogravimetric	O
analysis	O
showed	O
the	O
presence	O
of	O
uncoordinated	O
water	O
molecules	O
in	O
the	O
molecule	O
of	O
complex	O
9	O
(	O
the	O
three	O
waters	O
were	O
lost	O
in	O
a	O
single	O
step	O
,	O
between	O
70	O
-	O
110	O
C	O
)	O
and	O
of	O
coordinated	O
water	O
in	O
the	O
molecules	O
of	O
the	O
lead	O
(	O
II	O
)	O
derivatives	O
13	O
and	O
20	O
.	O

All	O
these	O
compounds	O
behaved	O
as	O
non	O
-	O
electrolytes	O
in	O
DMF	O
as	O
solvent	O
(	O
Table	O
II	O
)	O
.	O

Mention	O
should	O
be	O
made	O
that	O
the	O
Mg	O
(	O
II	O
)	O
complex	O
of	O
sulfonamide	O
7	O
could	O
not	O
be	O
isolated	O
.	O

Instead	O
,	O
only	O
the	O
correponding	O
complex	O
of	O
5-amino	O
-	O
l,3,4-thiadiazole	O
has	O
been	O
obtained	O
from	O
reaction	O
mixtures	O
containing	O
magnesium	O
salts	O
and	O
the	O
sodium	O
salt	O
of	O
7	O
,	O
probably	O
due	O
to	O
a	O
metal	O
ion	O
assisted	O
hydrolysis	O
of	O
7	O
to	O
6	O
and	O
chloroacetate	O
.	O

Generally	O
such	O
hydrolytic	O
processes	O
involve	O
highly	O
acidic	O
conditions	O
and	O
prolonged	O
heating	O
of	O
the	O
5-alkylamido-1,3,4-thiadiazole-2-sulfonamide	O
derivatives	O
[	O
41	O
]	O
,	O
but	O
they	O
might	O
become	O
milder	O
by	O
taking	O
into	O
account	O
the	O
putative	O
catalytic	O
effect	O
of	O
Mg2	O
+	O
ions	O
reported	O
here	O
.	O

The	O
data	O
shown	O
above	O
lead	O
to	O
the	O
conclusion	O
that	O
ligand	O
7	O
shares	O
a	O
common	O
coordination	O
chemistry	O
with	O
acetazolamide	O
1	O
with	O
which	O
it	O
is	O
structurally	O
related	O
,	O
whereas	O
6	O
probably	O
also	O
behaves	O
similarly	O
to	O
acetazolamide	O
in	O
the	O
sense	O
that	O
the	O
5-amino	O
group	O
seems	O
not	O
to	O
be	O
involved	O
in	O
coordinating	O
metal	O
ions	O
,	O
at	O
311	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
:	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
least	O
in	O
the	O
complexes	O
reported	O
by	O
us	O
here	O
(	O
and	O
also	O
in	O
the	O
compound	O
characterized	O
by	O
X	O
-	O
ray	O
crystallography	O
mentioned	O
above	O
[	O
40	O
]	O
)	O
.	O

Thus	O
,	O
in	O
all	O
complexes	O
reported	O
here	O
these	O
sulfonamides	O
(	O
as	O
monodeprotonated	O
species	O
at	O
the	O
SO2NH	O
2	O
moieties	O
)	O
act	O
as	O
bidentate	O
ligands	O
,	O
through	O
the	O
endocyclic	O
N-3	O
and	O
the	O
NH-	O
groups	O
.	O

The	O
proposed	O
formulae	O
of	O
the	O
new	O
complxes	O
are	O
shown	O
below	O
.	O

Except	O
for	O
the	O
two	O
Pb	O
(	O
II	O
)	O
complexes	O
13	O
and	O
20	O
,	O
as	O
well	O
as	O
the	O
AI	O
(	O
III	O
)	O
derivatives	O
14	O
and	O
16	O
,	O
which	O
presumably	O
are	O
pseudo	O
-	O
octahedral	O
,	O
the	O
other	O
derivatives	O
are	O
supposed	O
to	O
contain	O
tetrahedral	O
M	O
(	O
II	O
)	O
ions	O
.	O

R	O
R	O
"13""R"	O
=	O
20	O
""""	O
R=	O
H2N	O
CICH2CONH	O
14	O
:	O
R	O
=	O
16	O
:	O
R	O
=	O
H2N	O
CICH2CONH	O
The	O
compounds	O
6	O
-	O
20	O
together	O
with	O
the	O
standard	O
CA	O
inhibitors	O
1	O
-	O
5	O
were	O
assayed	O
for	O
inhibition	O
against	O
three	O
isozymes	O
,	O
hCA	O
I	O
,	O
hCA	O
II	O
and	O
bCA	O
IV	O
(	O
Table	O
III	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
chloracetamido	O
derivative	O
is	O
more	O
inhibitory	O
than	O
acetazolamide	O
,	O
methazolamide	O
and	O
dichlorophenamide	O
,	O
whereas	O
the	O
unacylated	O
compound	O
6	O
is	O
less	O
inhibitory	O
than	O
the	O
above	O
sulfonamides	O
.	O

The	O
metal	O
complexes	O
820	O
are	O
much	O
more	O
inhibitory	O
than	O
the	O
sulfonamides	O
from	O
which	O
they	O
derive	O
6	O
,	O
7	O
and	O
than	O
all	O
other	O
simple	O
sulfonamides	O
assayed	O
.	O

They	O
behave	O
similarly	O
to	O
the	O
metal	O
complexes	O
of	O
acetazolamide	O
,	O
methazolamide	O
or	O
dorzolamide	O
previously	O
reported	O
by	O
this	O
group	O
,	O
which	O
were	O
all	O
more	O
inhibitory	O
than	O
the	O
parent	O
sulfonamide	O
from	O
which	O
were	O
prepared	O
[	O
16	O
-	O
22	O
,	O
40	O
]	O
.	O

Particularly	O
strong	O
inhibition	O
was	O
observed	O
for	O
the	O
Zn	O
(	O
II	O
)	O
,	O
Hg	O
(	O
II	O
)	O
,	O
Pb	O
(	O
II	O
)	O
and	O
Cd	O
(	O
II	O
)	O
complexes	O
,	O
especially	O
against	O
CA	O
II	O
and	O
CA	O
IV	O
,	O
the	O
isozymes	O
critical	O
for	O
aqueous	O
humor	O
formation	O
.	O

In	O
vivo	O
IOP	O
lowering	O
experiments	O
were	O
done	O
in	O
rabbits	B
with	O
some	O
of	O
the	O
new	O
compounds	O
prepared	O
in	O
the	O
present	O
work	O
,	O
such	O
as	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
Zn	O
(	O
II	O
)	O
complexes	O
,	O
which	O
were	O
among	O
the	O
strong	O
CA	O
II	O
and	O
CA	O
IV	O
inhibitors	O
in	O
the	O
obtained	O
series	O
.	O

Some	O
of	O
the	O
IOP	O
lowering	O
data	O
at	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
the	O
instillation	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
within	O
the	O
rabbit	B
eye	O
are	O
shown	O
in	O
312	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
Table	O
IV	O
,	O
with	O
dorzolamide	O
(	O
at	O
the	O
same	O
concentration	O
)	O
as	O
standard	O
.	O

In	O
Fig.	O
the	O
time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
5	O
and	O
the	O
two	O
Zn	O
(	O
II	O
)	O
complexes	O
10	O
and	O
17	O
is	O
presented	O
.	O

Table	O
III	O
.	O

CA	O
inhibition	O
data	O
with	O
the	O
standard	O
inhibitors	O
1	O
-	O
5	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
,	O
and	O
their	O
metal	O
complexes	O
8	O
-	O
20	O
.	O

No	O
1	O
2	O
3	O
4	O
5	O
6	O
7	O
8	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
16	O
17	O
18	O
19	O
20	O
a	O
Inhibitor	O
KI	O
hCA	O
Ia	O
900	O
780	O
25	O
1200	O
>	O
50,000	O
1550	O
640	O
1050	O

350	O
50	O
40	O
12	O
80	O
240	O
120	O
80	O
40	O
40	O
9	O
15	O
(	O
nM	O
)	O
bCA	O
IVb	O
220	O
240	O
13	O
380	O
43	O
780	O
24	O
540	O
220	O
25	O
19	O
10	O
26	O
110	O
12	O
16	O
9	O
10	O
5	O
10	O
hCA	O
IIa	O
12	O
14	O
8	O
38	O
9	O
230	O
5	O
190	O
110	O
15	O
14	O
7	O
10	O
76	O
5	O
4	O
3	O
3	O
2	O
5	O
Acetazolamide	O
Methazolamide	O
Ethoxzolamide	O
Dichlorophenamide	O
Dorzolamide	O
Human	B
(	O
cloned	O
)	O
isozymes	O
;	O
b	O
From	O
bovine	B
lung	O
microsomes	O
.	O

Table	O
IV	O
:	O
IOP	O
lowering	O
following	O
topical	O
application	O
of	O
CA	O
inhibitors	O
,	O
half	O
an	O
hour	O
and	O
one	O
hour	O
after	O
instillation	O
into	O
the	O
eye	O
of	O
a	O
drop	O
(	O
50	O
L	O
)	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
.	O

Inhibitor	O
lOP	O
SE	O
1	O
/	O
2	O
h	O
a	O
(	O
mm	O
Hg	O
)	O
lh	O
4.1	O
0.15	O
0	O
0.09	O
0	O
0.09	O
5.0	O
0.12	O
8.1	O
0.21	O
Dorzolamide	O
5	O
6	O
7	O
10	O
17	O
a	O
2.2	O
0.10	O
0	O
0.10	O
0	O
0.10	O
2.00.09	O
8.0	O
0.14	O
IOP	O
IOP	O
control	O
eye	O
""""	O
IOP	O
treated	O
eye	O
(	O
N	O
3	O
)	O
.	O

As	O
seen	O
from	O
the	O
above	O
data	O
,	O
the	O
sulfonamides	O
6	O
and	O
7	O
are	O
totally	O
ineffective	O
as	O
lOP	O
lowering	O
agents	O
,	O
similarly	O
to	O
the	O
classical	O
clinically	O
used	O
inhibitors	O
of	O
type	O
1	O
-	O
5	O
[	O
2,3	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
dorzolamide	O
,	O
the	O
first	O
topical	O
sulfonamide	O
used	O
clinically	O
in	O
the	O
treatment	O
of	O
glaucoma	O
is	O
an	O
effective	O
such	O
agent	O
,	O
with	O
a	O
decrease	O
of	O
lOP	O
of	O
around	O
4	O
mm	O
Hg	O
,	O
one	O
hour	O
after	O
administration	O
directly	O
into	O
the	O
eye	O
(	O
Table	O
IV	O
)	O
.	O

From	O
the	O
data	O
of	O
this	O
table	O
,	O
it	O
is	O
obvious	O
that	O
the	O
metal	O
complexes	O
of	O
heterocyclic	O
sulfonamides	O
investigated	O
by	O
us	O
behave	O
as	O
much	O
more	O
effective	O
IOP	O
lowering	O
agents	O
than	O
dorzolamide	O
,	O
and	O
their	O
effect	O
is	O
generally	O
longerlasting	O
(	O
Fig.	O
1	O
)	O
.	O

A	O
last	O
remark	O
should	O
be	O
made	O
about	O
the	O
possible	O
mechanism	O
of	O
action	O
of	O
the	O
new	O
class	O
of	O
IOP	O
lowering	O
agents	O
.	O

Obviously	O
,	O
their	O
activity	O
is	O
due	O
to	O
inhibition	O
of	O
CA	O
isozymes	O
present	O
in	O
the	O
cilliary	O
processes	O
within	O
the	O
eye	O
,	O
similarly	O
to	O
other	O
topically	O
active	O
sulfonamides	O
[	O
2	O
-	O
6	O
]	O
.	O

The	O
fact	O
that	O
the	O
sulfonamide	O
per	O
se	O
is	O
inactive	O
via	O
the	O
topical	O
route	O
,	O
whereas	O
the	O
metal	O
complexes	O
result	O
much	O
better	O
than	O
the	O
drug	O
313	O
Vol	O
.	O

4	O
,	O
No.	O
6	O
,	O
1997	O
Metal	O
Complexes	O
of	O
Heterocyclic	O
Sulfonamides	O
.	O
""""	O

A	O
New	O
Class	O
ofAntiglaucoma	O
Agents	O
dorzolamide	O
,	O
indicates	O
that	O
the	O
presence	O
of	O
metal	O
ions	O
in	O
the	O
molecules	O
of	O
these	O
CA	O
inhibitors	O
is	O
essential	O
and	O
confers	O
them	O
completely	O
new	O
properties	O
.	O

Lowering	O
of	O
IOP	O
(	O
ram	O
Hg	O
)	O
""""	O
||	O
,	O
/	O
""""	O
,	O
,	O
'	O
""""	O
,	O
.	O
,	O
,	O
<	O
.7	O
,	O
/	O
/	O
.6	O
-0	O
-10	O
0	O
2	O
Time	O
(	O
hours	O
)	O
Fig	O
l	O
""""	O
Time	O
dependence	O
of	O
IOP	O
lowering	O
with	O
dorzolamide	O
(	O
curve	O
1	O
)	O
;	O
the	O
zinc	O
complex	O
10	O
(	O
curve	O
3	O
)	O
and	O
the	O
zinc	O
complex	O
17	O
(	O
curve	O
3	O
)	O
,	O
after	O
topical	O
administration	O
of	O
one	O
drop	O
of	O
2	O
%	O
solution	O
of	O
inhibitor	O
in	O
rabbit	B
.	O

Preliminary	O
results	O
from	O
this	O
laboratory	O
indicate	O
that	O
the	O
metal	O
complexes	O
of	O
topically	O
active	O
sulfonamides	O
show	O
also	O
increased	O
lOP	O
lowering	O
effects	O
with	O
respect	O
to	O
the	O
complexes	O
prepared	O
in	O
the	O
present	O
study	O
[	O
42	O
]	O
.	O

Our	O
hypothesis	O
is	O
that	O
the	O
presence	O
of	O
the	O
metal	O
ion	O
in	O
the	O
molecules	O
of	O
these	O
complex	O
inhibitors	O
induces	O
a	O
dramatic	O
change	O
in	O
their	O
physico	O
-	O
chemical	O
properties	O
as	O
compared	O
to	O
those	O
of	O
the	O
parent	O
sulfonamide	O
.	O

This	O
phenomenon	O
is	O
certainly	O
governed	O
by	O
the	O
strong	O
polarization	O
induced	O
by	O
the	O
metal	O
ions	O
.	O

In	O
this	O
way	O
,	O
it	O
is	O
quite	O
probable	O
that	O
the	O
right	O
balance	O
between	O
the	O
lipo-	O
and	O
hydrosolubility	O
of	O
these	O
compounds	O
is	O
achieved	O
,	O
which	O
has	O
been	O
considered	O
to	O
be	O
the	O
critical	O
factor	O
for	O
not	O
observing	O
topical	O
activity	O
in	O
the	O
classical	O
CA	O
inhibitors	O
,	O
such	O
as	O
acetazolamide	O
,	O
methazolamide	O
and	O
ethoxzolamide	O
,	O
which	O
were	O
either	O
too	O
lipophilic	O
or	O
too	O
hy.drosoluble	O
[	O
2,3	O
]	O
.	O

So	O
,	O
by	O
choosing	O
different	O
metal	O
ions	O
and	O
diverse	O
sulfonamides	O
,	O
much	O
larger	O
possibilities	O
arise	O
to	O
finely	O
tune	O
the	O
pharmacological	O
properties	O
which	O
strongly	O
influence	O
the	O
value	O
of	O
a	O
drug	O
.	O

In	O
conclusion	O
we	O
describe	O
here	O
a	O
novel	O
class	O
of	O
lOP	O
lowering	O
agents	O
,	O
ie	O
,	O
the	O
metal	O
complexes	O
of	O
sulfonamide	O
CA	O
inhibitors	O
.	O

These	O
derivatives	O
appear	O
to	O
be	O
very	O
active	O
and	O
longer	O
lasting	O
than	O
the	O
drug	O
dorzolamide	O
,	O
and	O
might	O
constitute	O
the	O
premises	O
for	O
a	O
new	O
generation	O
of	O
antiglaucoma	O
drugs	O
.	O

Acknowledgments	O
.	O

We	O
are	O
grateful	O
to	O
Prof.	O
S.	O
Lindskog	O
(	O
Umea	O
Univ	O
.	O
,	O
Sweden	O
)	O
for	O
the	O
gift	O
of	O
the	O
hCA	O
and	O
II	O
plasmids	O
.	O

References	O
Preceding	O
part	O
of	O
this	O
series	O
""""	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Ilies	O
MA	O
,	O
Iorga	O
B	O
,	O
Cristea	O
T	O
,	O
Chiraleu	O
F	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O

Eur	O
J	O
Med	O
Chem	O
,	O
submitted	O
.	O

2	O
Supuran	O
CT	O
(	O
1994	O
)	O
""""	O
Carbonic	O
anhydrase	O
inhibitors	O
""""	O
In	O
Carbonic	O
Anhydrase	O
and	O
Modulation	O
of	O
Physiologic	O
and	O
Pathologic	O
Processes	O
in	O
the	O
Organism	O
,	O
(	O

Puscas	O
I	O
,	O
Ed	O
)	O
Helicon	O
,	O
Timisoara	O
,	O
pp	O
.	O

29	O
-	O
111	O
.	O

3	O
Maren	O
TH	O
(	O
1991	O
)	O
""""	O
The	O
links	O
among	O
biochemistry	O
,	O
physiology	O
and	O
pharmacology	O
in	O
carbonic	O
anhydrase	O
mediated	O
systems	O
""""	O
.	O

In	O
Carbonic	O
Anhydrase	O
From	O
Biochemistry	O
and	O
Genetics	O
to	O
Physiology	O
and	O
Clinical	O
Medicine	O
,	O
(	O
Botr6	O
F	O
,	O
Gros	O
G	O
,	O
Storey	O
BT	O
Eds	O
)	O
VCH	O
,	O
Weinheim	O
,	O
pp	O
.	O

186	O
-	O
207	O
.	O
4	O
Bayer	O
A	O
,	O
Ferrari	O
F	O
,	O
Maren	O
TH	O
,	O
Erb	O
C	O
(	O
1996	O
)	O
dFr	O
Ophtalrnol	O
19	O
,	O
3:57	O
-	O
362	O
.	O
:	O
5	O
Maren	O
TH	O
,	O
Conroy	O
CW	O
,	O
Wynns	O
GC	O
,	O
Levy	O
NS	O
(	O
1997	O
)	O
d	O
Ocul	O
Pharrnacol	O
Therapeut	O
13	O
,	O
23	O
-	O
30	O
.	O
6	O
Sugrue	O
MF	O
(	O
1996	O
)	O
d	O
Ocul	O
Pharmacol	O
Ther	O
12,363	O
-	O
376	O
.	O

7	O
Bartlett	O
JD	O
,	O
Jaanus	O
SD	O
(	O
1989	O
)	O
""""	O
Carbonic	O
anhydrase	O
inhibitors	O
""""	O
.	O

In	O
Clinical	O
Ocular	O
Pharmacology	O
,	O
Second	O
Edition	O
,	O
Butterworths	O
Publishers	O
,	O
Boston	O
,	O
pp	O
.	O

2:54	O
-	O
263	O
.	O
8	O
Alward	O
PD	O
,	O
Wilensky	O
JT	O
(	O
1981	O
)	O
Arch	O
Ophthalmo199	O
,	O
1973	O
-	O
1976	O
.	O

314	O
Claudiu	O
T.	O
Supuran	O
et	O
al.	O
Metal	O
-	O
Based	O
Drugs	O
9	O
Maren	O
TH	O
,	O
Jankowska	O
L	O
,	O
Sanyal	O
G	O
,	O
Edelhauser	O
HF	O
(	O
1983	O
)	O
Exp	O
Eye	O
Res	O
36	O
,	O
457	O
-	O
480	O
.	O
10	O
a	O
)	O

Ponticello	O
GS	O
,	O
Freedman	O
MB	O
,	O
Habecker	O
CN	O
,	O
Lyle	O
PA	O
,	O
Schwam	O
H	O
,	O
Varga	O
SL	O
,	O
Christy	O
ME	O
,	O
Randall	O
WC	O
,	O
Baldwin	O
JJ	O
(	O
1987	O
)	O

J	O
Med	O
Chem	O
30	O
,	O
591	O
-	O
597	O
;	O
b	O
)	O
Greer	O
J	O
,	O
Erickson	O
JW	O
,	O
Baldwin	O
JJ	O
,	O
Varney	O
MD	O
(	O
1994	O
)	O

J	O
Med	O
Chem	O
37	O
,	O
1035	O
-	O
1054	O
.	O
11	O
Baldwin	O
JJ	O
,	O
Ponticello	O
GS	O
,	O
Anderson	O
GS	O
,	O
Christy	O
ME	O
,	O
Murcko	O
MA	O
,	O
Randall	O
WC	O
,	O
Schwam	O
H	O
,	O
Sugrue	O
MF	O
,	O
Springer	O
JP	O
,	O
Gautheron	O
P	O
,	O
Grove	O
J	O
,	O
Mallorga	O
P	O
,	O
Viader	O
MP	O
,	O
McKeever	O
BM	O
,	O
Navia	O
MA	O
(	O
1989	O
)	O

J	O
Med	O
Chem	O
32	O
,	O
2510	O
-	O
2513	O
.	O

12	O
Chow	O
K	O
,	O
Lai	O
R	O
,	O
Holmes	O
JM	O
,	O
Wijono	O
M	O
,	O
Wheeler	O
LA	O
,	O
Garst	O
ME	O
(	O
1996	O
)	O
EurJMed	O
Chem	O
31	O
,	O
175	O
-	O
186	O
.	O

13	O
Supuran	O
CT	O
,	O
Nicolae	O
A	O
,	O
Popescu	O
A	O
(	O
1996	O
)	O
Eur	O
JMed	O
Chem	O
31	O
,	O
431	O
-	O
438	O
.	O

14	O
Supuran	O
CT	O
,	O
Popescu	O
A	O
,	O
Ilisiu	O
M	O
,	O
Costandache	O
A	O
,	O
Banciu	O
MD	O
(	O
1996	O
)	O

Eur	O
JMed	O
Chem	O
31	O
,	O
439	O
-	O
448	O
.	O

15	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Popescu	O
A	O
,	O
Bobes	O
-	O
Tureac	O
R	O
,	O
Banciu	O
A	O
,	O
Creanga	O
A	O
,	O
Bobes	O
-	O
Tureac	O
G	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O

Eur	O
JMed	O
Chem	O
32	O
,	O
445	O
-	O
452	O
.	O

16	O
Alzuet	O
G	O
,	O
Casanova	O
J	O
,	O
Ramirez	O
JA	O
,	O
Borras	O
J	O
,	O
Carugo	O
O	O
(	O
1995	O
)	O
J	O
Inorg	O
Bioehem	O
57	O
,	O
219	O
-	O
234	O
.	O

17	O
Sumalan	O
SL	O
,	O
Casanova	O
J	O
,	O
Alzuet	O
G	O
,	O
Borras	O
J	O
,	O
Castifieiras	O
A	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O

J	O
Inorg	O
Biochem	O
62	O
,	O
3139	O
.	O

18	O
a	O
)	O
Supuran	O
CT	O
(	O
1995	O
)	O
Metal	O
Based	O
Drugs	O
2	O
,	O
327	O
-	O
330	O
;	O
b	O
)	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
19	O
-	O
26	O
.	O

19	O
a	O
)	O
Borras	O
J	O
,	O
Cristea	O
T	O
,	O
Supuran	O
CT	O
(	O
1996	O
)	O
,	O
Main	O
Group	O
Met	O
Chem	O
19	O
,	O
339	O
-	O
346	O
;	O
b	O
)	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
1	O
-	O
7	O
.	O
20	O
a	O
)	O

Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
37	O
-	O
51	O
;	O
b	O
)	O
Supuran	O
CT	O
,	O
Briganti	O
F	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
12	O
,	O
175	O
-	O
190	O
.	O

21	O
Mincione	O
G	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Metal	O
Based	O
Drugs	O
4	O
,	O
27	O
-	O
34	O
.	O
22	O
Alzuet	O
G	O
,	O
Ferrer	O
S	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1994	O
)	O
Roum	O
Chem	O
Quart	O
Rev	O
2	O
,	O
283	O
-	O
300	O
.	O

23	O
Briganti	O
F	O
,	O
Mangani	O
S	O
,	O
Orioli	O
P	O
,	O
Scozzafava	O
A	O
,	O
Vernaglione	O
G	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
10384	O
-	O
10392	O
.	O

24	O
Borras	O
J	O
,	O
Casanova	O
J	O
,	O
Cristea	O
T	O
,	O
Gheorghe	O
A	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
,	O
Tudor	O
V	O
(	O
1996	O
)	O
Metal	O
Based	O
Drugs	O
3	O
,	O
143	O
-	O
148	O
.	O

25	O
Supuran	O
CT	O
,	O
Mincione	O
F	O
,	O
Scozzafava	O
A	O
,	O
Briganti	O
F	O
,	O
Mincione	O
G	O
,	O
Ilies	O
MA	O
(	O
1997	O
)	O
Eur	O
J	O
Med	O
Chem	O
,	O
in	O
press	O
.	O

26	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
,	O
Saramet	O
I	O
,	O
Banciu	O
MD	O
(	O
1997	O
)	O
J	O
Enzyme	O
Inhibition	O
,	O
in	O
press	O
.	O

27	O
Jitianu	O
A	O
,	O
Ilies	O
MA	O
,	O
Scozzafava	O
A	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O

Main	O
Group	O
Met	O
Chem	O
20	O
,	O
151	O
-	O
156	O
.	O

28	O
Forsman	O
C	O
,	O
Behravan	O
G	O
,	O
Osterman	O
A	O
,	O
Jonsson	O
BH	O
(	O
1988	O
)	O
Acta	O
Chem	O
Scand	O
B42	O
,	O
314	O
-	O
318	O
.	O

29	O
Behravan	O
G	O
,	O
Jonasson	O
P	O
,	O
Jonsson	O
BH	O
,	O
Lindskog	O
S	O
(	O
1991	O
)	O
Eur	O
JBiochem	O
198	O
,	O
589	O
-	O
592	O
.	O
30	O
Khalifah	O
RG	O
,	O
Strader	O
DJ	O
,	O
Bryant	O
SH	O
,	O
Gibson	O
SM	O
(	O
1977	O
)	O
Biochemistry	O
16	O
,	O
2241	O
-	O
2247	O
.	O

31	O
Nyman	O
PO	O
,	O
Lindskog	O
S	O
(	O
1964	O
)	O
Biochim	O
Biophys	O
Acta	O
85	O
,	O
141	O
-	O
151	O
.	O

32	O
Henderson	O
LE	O
,	O
Henriksson	O
D	O
,	O
Nyman	O
PO	O
(	O
1976	O
)	O
JBiol	O
Chem	O
251	O
,	O
5457	O
-	O
5463	O
.	O

33	O
Maren	O
TH	O
,	O
Wynns	O
GC	O
,	O
Wistrand	O
PJ	O
(	O
1993	O
)	O
Mol	O
Pharmaco144	O
,	O
901	O
-	O
906	O
.	O

34	O
Young	O
RW	O
,	O
Wood	O
KH	O
,	O
Vaughan	O
JR	O
,	O
Anderson	O
GW	O
(	O
1956	O
)	O
J	O
Am	O
Chem	O
Soc	O
78	O
,	O
4649	O
-	O
4654	O
.	O

35	O
Pocker	O
Y	O
,	O
Stone	O
JT	O
(	O
1967	O
)	O
Biochemistry	O
6	O
,	O
668	O
-	O
678	O
.	O
36	O
Baird	O
TT	O
,	O
Waheed	O
A	O
,	O
Okuyama	O
T	O
,	O
Sly	O
WS	O
,	O
Fierke	O
CA	O
(	O
1997	O
)	O
Biochemistry	O
36	O
,	O
2669	O
-	O
2678	O
.	O

37	O
Maren	O
TH	O
,	O
Bar	O
-	O
Ilan	O
A	O
,	O
Conroy	O
CW	O
,	O
Brechue	O
WF	O
(	O
1990	O
)	O
Exp	O
Eye	O
Res	O
50	O
,	O
27	O
-	O
36	O
.	O

38	O
Maren	O
TH	O
,	O
Brechue	O
WF	O
,	O
Bar	O
-	O
Ilan	O
A	O
(	O
1992	O
)	O

Exp	O
Eye	O
Res	O
55	O
,	O
73	O
-	O
79	O
.	O

39	O
Brechue	O
WF	O
,	O
Maren	O
TH	O
(	O
1993	O
)	O

Invest	O
Ophthalmol	O
Vis	O
Sci	O
34	O
,	O
2581	O
-	O
2587	O
.	O

40	O
Borja	O
P	O
,	O
Alzuet	O
G	O
,	O
Server	O
-	O
Carri6	O
J	O
,	O
Borras	O
J	O
,	O
Supuran	O
CT	O
(	O
1997	O
)	O
J	O
Biol	O
Inorg	O
Chem	O
(	O
JBIC	O
)	O
,	O
in	O
press	O
.	O

41	O
Supuran	O
CT	O
,	O
Balaban	O
AT	O
,	O
Gheorghiu	O
MD	O
,	O
Schiketanz	O
A	O
,	O
Dinculescu	O
A	O
,	O
Puscas	O
I	O
(	O
1990	O
)	O
Rev	O
Roum	O
Chim	O
35	O
,	O
399	O
-	O
405	O
.	O

42	O
Supuran	O
CT	O
,	O
Scozzafava	O
A	O
(	O
1997	O
)	O
unpublished	O
results	O
.	O

Received	O
:	O
September	O
24	O
,	O
1997	O
Accepted	O
:	O
October	O
17	O
,	O
1997	O
Received	O
in	O
revised	O
camera	O
-	O
ready	O
format	O
""""	O
October	O
23	O
,	O
1997	O
315	O

Purinergic	O
signalling	O
in	O
the	O
subretinal	O
space	O
:	O
a	O
role	O
in	O
the	O
communication	O
between	O
the	O
retina	O
and	O
the	O
RPE	O
Abstract	O
The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
is	O
separated	O
from	O
the	O
photoreceptor	O
outer	O
segments	O
by	O
the	O
subretinal	O
space	O
.	O

While	O
the	O
actual	O
volume	O
of	O
this	O
space	O
is	O
minimal	O
,	O
the	O
communication	O
that	O
occurs	O
across	O
this	O
microenvironment	O
is	O
important	O
to	O
the	O
visual	O
process	O
,	O
and	O
accumulating	O
evidence	O
suggests	O
the	O
purines	O
ATP	O
and	O
adenosine	O
contribute	O
to	O
this	O
communication	O
.	O

P1	O
and	O
P2	O
receptors	O
are	O
localized	O
to	O
membranes	O
on	O
both	O
the	O
photoreceptor	O
outer	O
segments	O
and	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
which	O
border	O
subretinal	O
space	O
.	O

ATP	O
is	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
into	O
this	O
space	O
in	O
response	O
to	O
various	O
triggers	O
including	O
glutamate	O
and	O
chemical	O
ischemia	O
.	O

This	O
ATP	O
is	O
dephosphorylated	O
into	O
adenosine	O
by	O
a	O
series	O
of	O
ectoenzymes	O
on	O
the	O
RPE	O
apical	O
membrane	O
.	O

Regulation	O
of	O
release	O
and	O
ectoenzyme	O
activity	O
in	O
response	O
to	O
light	O
-	O
sensitive	O
signals	O
can	O
alter	O
the	O
balance	O
of	O
purines	O
in	O
subretinal	O
space	O
,	O
and	O
thus	O
coordinate	O
communication	O
across	O
subretinal	O
space	O
with	O
the	O
visual	O
process	O
.	O

Introduction	O
The	O
retinal	O
pigment	O
epithelium	O
(	O
RPE	O
)	O
lies	O
between	O
the	O
outer	O
segments	O
of	O
the	O
photoreceptors	O
and	O
the	O
choroidal	O
blood	O
supply	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
RPE	O
combines	O
the	O
functions	O
of	O
epithelial	O
and	O
glial	O
cells	O
,	O
providing	O
a	O
barrier	O
while	O
also	O
supporting	O
the	O
neural	O
photoreceptors	O
and	O
modulating	O
their	O
function	O
.	O

Tight	O
communication	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
is	O
critical	O
to	O
coordinate	O
the	O
multiple	O
levels	O
of	O
interaction	O
,	O
and	O
the	O
purinergic	O
contribution	O
to	O
this	O
communication	O
is	O
becoming	O
apparent	O
.	O

The	O
relevance	O
of	O
this	O
purinergic	O
input	O
is	O
emphasized	O
by	O
the	O
many	O
functional	O
effects	O
of	O
P1	O
and	O
P2	O
receptor	O
stimulation	O
and	O
by	O
the	O
multiple	O
mechanisms	O
in	O
place	O
to	O
regulate	O
subretinal	O
levels	O
of	O
purine	O
agonists	O
.	O

As	O
the	O
dynamics	O
of	O
ATP	O
release	O
and	O
extracellular	O
conversion	O
into	O
adenosine	O
will	O
modify	O
agonist	O
availability	O
,	O
the	O
modulation	O
of	O
these	O
processes	O
can	O
exert	O
a	O
temporal	O
control	O
on	O
purinergic	O
signaling	O
.	O

The	O
following	O
review	O
will	O
outline	O
the	O
main	O
interactions	O
between	O
the	O
RPE	O
and	O
photoreceptors	O
,	O
describe	O
the	O
effects	O
of	O
stimulating	O
purinergic	O
receptors	O
on	O
both	O
sides	O
of	O
subretinal	O
space	O
,	O
and	O
summarize	O
how	O
levels	O
of	O
ATP	O
,	O
ADP	O
,	O
and	O
adenosine	O
are	O
manipulated	O
in	O
this	O
microenvironment	O
.	O

Fig.	O
1Schematic	O
illustration	O
of	O
the	O
key	O
components	O
of	O
purinergic	O
signaling	O
in	O
the	O
subretinal	O
microenvironment	O
.	O

Stimulation	O
of	O
P2	O
receptors	O
on	O
the	O
RPE	O
can	O
enhance	O
transepithelial	O
fluid	O
absorption	O
while	O
P1	O
receptors	O
can	O
modulate	O
phagocytosis	O
.	O

ATP	O
released	O
through	O
CFTR	O
and	O
other	O
Cl−	O
channels	O
can	O
stimulate	O
P2	O
receptors	O
or	O
be	O
converted	O
to	O
ADP	O
,	O
AMP	O
,	O
and	O
adenosine	O
(	O
Ado	O
)	O
by	O
a	O
series	O
of	O
ectonucleotidases	O
present	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
.	O

By	O
controlling	O
the	O
balance	O
of	O
extracellular	O
purines	O
available	O
to	O
stimulate	O
these	O
receptors	O
these	O
mechanisms	O
can	O
control	O
levels	O
of	O
endogenous	O
purines	O
available	O
to	O
activate	O
the	O
receptors	O
.	O

While	O
theoretically	O
possible	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
these	O
subretinal	O
purines	O
can	O
actually	O
stimulate	O
photoreceptors	O
Purines	O
and	O
subretinal	O
space	O
RPE	O
-	O
photoreceptor	O
interactions	O
across	O
the	O
subretinal	O
space	O
The	O
outer	O
segments	O
of	O
the	O
rods	O
and	O
cones	O
are	O
responsible	O
for	O
the	O
initial	O
stages	O
of	O
vision	O
,	O
converting	O
photon	O
energy	O
into	O
a	O
series	O
of	O
enzymatic	O
reactions	O
that	O
close	O
the	O
light	O
-	O
sensitive	O
channels	O
on	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
hyperpolarize	O
the	O
cells	O
,	O
and	O
reduce	O
the	O
release	O
of	O
glutamate	O
from	O
the	O
synaptic	O
terminals	O
[	O
1	O
,	O
2	O
]	O
.	O

Efficient	O
photoreceptor	O
function	O
depends	O
upon	O
both	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
support	O
from	O
the	O
RPE	O
.	O

The	O
critical	O
nature	O
of	O
these	O
interactions	O
is	O
evident	O
from	O
the	O
rapid	O
degeneration	O
of	O
photoreceptors	O
in	O
the	O
absence	O
of	O
a	O
healthy	O
RPE	O
layer	O
and	O
by	O
the	O
RPE	O
localization	O
of	O
defective	O
gene	O
product	O
in	O
some	O
forms	O
of	O
hereditary	O
photoreceptor	O
degeneration	O
[	O
3	O
]	O
.	O

The	O
apical	O
membrane	O
of	O
the	O
RPE	O
is	O
separated	O
from	O
the	O
plasma	O
membrane	O
of	O
the	O
outer	O
segments	O
by	O
an	O
extracellular	O
space	O
of	O
only	O
10–20	O
nm	O
[	O
4	O
]	O
.	O

Although	O
small	O
,	O
this	O
subretinal	O
space	O
contains	O
a	O
highly	O
structured	O
matrix	O
which	O
ensheathes	O
the	O
outer	O
segments	O
and	O
extends	O
to	O
the	O
RPE	O
[	O
5	O
,	O
6	O
]	O
.	O

The	O
presence	O
of	O
enzymes	O
within	O
this	O
interphotoreceptor	O
matrix	O
emphasizes	O
that	O
this	O
extracellular	O
space	O
itself	O
is	O
functionally	O
active	O
[	O
7	O
,	O
8	O
]	O
.	O

This	O
intimate	O
anatomical	O
relationship	O
between	O
photoreceptors	O
and	O
the	O
RPE	O
reflects	O
multiple	O
functional	O
interactions	O
.	O

For	O
example	O
,	O
the	O
RPE	O
accepts	O
,	O
recycles	O
,	O
and	O
exports	O
central	O
components	O
of	O
the	O
phototransduction	O
process	O
[	O
9	O
]	O
.	O

The	O
outer	O
segments	O
are	O
continuously	O
resynthesized	O
,	O
and	O
the	O
phagocytosis	O
,	O
degradation	O
,	O
and	O
processing	O
of	O
shed	O
outer	O
segment	O
tips	O
by	O
the	O
RPE	O
cells	O
is	O
central	O
to	O
this	O
renewal	O
[	O
10	O
]	O
.	O

The	O
ion	O
channels	O
and	O
transporters	O
on	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
help	O
regulate	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
[	O
11	O
]	O
.	O

As	O
extracellular	O
levels	O
of	O
ions	O
can	O
modify	O
the	O
ionic	O
driving	O
forces	O
across	O
the	O
photoreceptor	O
plasma	O
membrane	O
,	O
these	O
RPE	O
transporters	O
can	O
influence	O
the	O
state	O
of	O
neural	O
activity	O
.	O

The	O
transport	O
of	O
fluid	O
and	O
ions	O
from	O
the	O
apical	O
membrane	O
to	O
basolateral	O
membrane	O
of	O
the	O
RPE	O
is	O
also	O
one	O
of	O
the	O
main	O
forces	O
keeping	O
the	O
retina	O
attached	O
[	O
12	O
]	O
.	O

The	O
control	O
of	O
photoreceptor	O
activity	O
by	O
light	O
gives	O
a	O
rapid	O
temporal	O
dependence	O
to	O
some	O
interactions	O
between	O
the	O
photoreceptors	O
and	O
the	O
RPE	O
.	O

The	O
volume	O
of	O
subretinal	O
space	O
increases	O
in	O
response	O
to	O
light	O
[	O
13	O
]	O
,	O
linking	O
small	O
changes	O
in	O
the	O
ionic	O
composition	O
of	O
the	O
subretinal	O
space	O
with	O
activity	O
of	O
the	O
RPE	O
transport	O
mechanisms	O
which	O
maintain	O
this	O
volume	O
[	O
14	O
,	O
15	O
]	O
.	O

Other	O
processes	O
are	O
controlled	O
on	O
a	O
diurnal	O
cycle	O
.	O

The	O
shed	O
tips	O
of	O
the	O
outer	O
segments	O
are	O
phagocytosed	O
by	O
the	O
RPE	O
soon	O
after	O
the	O
onset	O
of	O
light	O
[	O
16	O
,	O
17	O
]	O
.	O

These	O
processes	O
can	O
both	O
be	O
modulated	O
by	O
purine	O
levels	O
in	O
subretinal	O
space	O
,	O
indicating	O
purinergic	O
regulation	O
is	O
important	O
over	O
multiple	O
time	O
scales	O
.	O

Purinergic	O
receptors	O
on	O
photoreceptors	O
A2	O
adenosine	O
receptors	O
were	O
localized	O
to	O
both	O
the	O
inner	O
and	O
outer	O
segments	O
of	O
photoreceptor	O
outer	O
segments	O
over	O
a	O
decade	O
ago	O
by	O
Blazynski	O
and	O
colleagues	O
[	O
18	O
]	O
,	O
with	O
more	O
recent	O
reports	O
emphasizing	O
their	O
functional	O
role	O
.	O

A2	O
agonists	O
inhibit	O
the	O
L	O
-	O
type	O
Ca2	O
+	O
channel	O
on	O
rod	O
outer	O
segments	O
[	O
19	O
]	O
and	O
can	O
inhibit	O
the	O
synaptic	O
release	O
of	O
glutamate	O
from	O
rods	O
,	O
suggesting	O
changes	O
in	O
adenosine	O
levels	O
in	O
subretinal	O
space	O
could	O
modulate	O
light	O
sensitivity	O
[	O
20	O
]	O
.	O

The	O
A2	O
agonist	O
DPMA	O
and	O
the	O
adenosine	O
deaminase	O
inhibitor	O
EHNA	O
reduce	O
mRNA	O
for	O
opsin	O
in	O
rods	O
,	O
suggesting	O
that	O
endogenous	O
levels	O
of	O
adenosine	O
can	O
downregulate	O
opsin	O
message	O
at	O
night	O
[	O
21	O
]	O
.	O

EHNA	O
and	O
the	O
A2A	O
receptor	O
agonist	O
CGS21680	O
also	O
increase	O
the	O
survival	O
of	O
chick	O
embryonic	O
photoreceptors	O
in	O
culture	O
[	O
22	O
]	O
,	O
indicating	O
a	O
long	O
-	O
term	O
neuroprotective	O
role	O
for	O
adenosine	O
.	O

P2	O
receptors	O
are	O
also	O
present	O
in	O
the	O
photoreceptors	O
.	O

mRNA	O
for	O
the	O
P2X2	O
receptor	O
is	O
expressed	O
in	O
the	O
photoreceptor	O
cell	O
bodies	O
,	O
with	O
immunohistochemical	O
localization	O
of	O
the	O
protein	O
to	O
outer	O
segments	O
[	O
23	O
]	O
.	O

In	O
situ	O
hybridization	O
indicates	O
the	O
photoreceptor	O
layer	O
has	O
the	O
highest	O
level	O
of	O
P2Y2	O
receptor	O
of	O
any	O
region	O
in	O
the	O
rabbit	B
retina	O
,	O
although	O
staining	O
was	O
not	O
pronounced	O
in	O
monkey	O
[	O
24	O
]	O
.	O

P2X7	O
receptors	O
have	O
recently	O
been	O
localized	O
to	O
photoreceptor	O
synaptic	O
terminals	O
,	O
with	O
evidence	O
for	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synapse	O
,	O
and	O
functional	O
evidence	O
suggesting	O
ATP	O
augments	O
transmission	O
of	O
the	O
light	O
response	O
by	O
rods	O
[	O
25	O
]	O
.	O

It	O
was	O
suggested	O
that	O
ATP	O
might	O
be	O
co	O
-	O
released	O
from	O
photoreceptors	O
with	O
glutamate	O
,	O
although	O
this	O
remains	O
to	O
be	O
tested	O
directly	O
.	O

Purinergic	O
receptors	O
on	O
the	O
RPE	O
Stimulation	O
of	O
P1	O
receptors	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
RPE	O
cells	O
.	O

A2	O
receptors	O
have	O
been	O
recognized	O
on	O
cultured	O
and	O
fresh	O
RPE	O
cells	O
for	O
some	O
time	O
[	O
26	O
,	O
27	O
]	O
,	O
with	O
in	O
situ	O
hybridization	O
confirming	O
the	O
presence	O
of	O
A2A	O
receptors	O
in	O
rat	B
RPE	O
[	O
28	O
]	O
.	O

Stimulation	O
of	O
A2	O
receptors	O
reduces	O
the	O
rate	O
of	O
rod	O
outer	O
segment	O
phagocytosis	O
by	O
RPE	O
cells	O
[	O
29	O
]	O
,	O
while	O
application	O
of	O
adenosine	O
to	O
the	O
apical	O
membrane	O
of	O
chick	O
RPE	O
cells	O
increases	O
the	O
basolateral	O
Cl-	O
conductance	O
,	O
the	O
transepithelial	O
potential	O
,	O
and	O
the	O
c	O
-	O
wave	O
,	O
and	O
decreases	O
the	O
hyperpolarization	O
of	O
the	O
basal	O
membrane	O
in	O
response	O
to	O
light	O
[	O
30	O
]	O
.	O

Although	O
adenosine	O
alone	O
does	O
not	O
increase	O
intracellular	O
Ca2	O
+	O
levels	O
[	O
31	O
]	O
,	O
adenosine	O
acts	O
synergistically	O
with	O
ATP	O
to	O
elevate	O
Ca2	O
+	O
levels	O
in	O
human	B
RPE	O
cells	O
by	O
stimulating	O
both	O
A1	O
and	O
A2A	O
receptors	O
[	O
32	O
,	O
33	O
]	O
.	O

Stimulation	O
of	O
A1	O
receptors	O
with	O
high	O
doses	O
of	O
NECA	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
while	O
activation	O
of	O
A2A	O
receptors	O
decreases	O
this	O
transport	O
,	O
and	O
by	O
extension	O
,	O
transport	O
of	O
the	O
ions	O
that	O
underlie	O
fluid	O
movement	O
[	O
34	O
]	O
.	O

Stimulation	O
of	O
A1	O
and	O
A2A	O
receptors	O
produces	O
analogous	O
increases	O
and	O
decreases	O
,	O
respectively	O
,	O
in	O
the	O
absorption	O
of	O
subretinal	O
fluid	O
blebs	O
.	O

This	O
is	O
consistent	O
with	O
the	O
negative	O
coupling	O
of	O
the	O
A1	O
receptor	O
and	O
the	O
positive	O
coupling	O
of	O
the	O
A2	O
receptors	O
to	O
adenylate	O
cyclase	O
,	O
as	O
increasing	O
cAMP	O
inhibits	O
the	O
transport	O
of	O
fluid	O
across	O
the	O
RPE	O
towards	O
the	O
choroid	O
[	O
35–37	O
]	O
.	O

The	O
agonist	O
2-Cl	O
adenosine	O
reverses	O
the	O
deficit	O
in	O
phosphoinositide	O
metabolism	O
found	O
in	O
diabetic	O
RPE	O
cells	O
[	O
38	O
]	O
,	O
suggesting	O
effects	O
on	O
metabolism	O
in	O
addition	O
to	O
transport	O
and	O
phagocytosis	O
.	O

Multiple	O
P2	O
receptors	O
have	O
been	O
localized	O
to	O
the	O
RPE	O
.	O

The	O
P2Y2	O
receptor	O
was	O
initially	O
characterized	O
in	O
cultured	O
human	B
RPE	O
[	O
31	O
]	O
,	O
with	O
subsequent	O
reports	O
localizing	O
transcript	O
for	O
P2Y1	O
,	O
P2Y2	O
,	O
P2Y4	O
,	O
and	O
P2Y6	O
in	O
the	O
rat	B
RPE	O
/	O
choroid	O
[	O
39	O
]	O
and	O
for	O
P2Y1	O
and	O
P2Y12	O
receptors	O
in	O
ARPE-19	O
cells	O
[	O
40	O
]	O
,	O
and	O
functionally	O
identifying	O
a	O
P2X	O
receptor	O
in	O
rat	B
RPE	O
cells	O
[	O
41	O
]	O
.	O

ATP	O
,	O
ADP	O
,	O
and	O
UTP	O
induce	O
numerous	O
effects	O
on	O
RPE	O
physiology	O
[	O
32	O
,	O
33	O
,	O
42	O
,	O
43	O
]	O
.	O

While	O
these	O
effects	O
likely	O
involve	O
multiple	O
different	O
receptor	O
types	O
,	O
the	O
contributions	O
of	O
the	O
P2Y2	O
receptor	O
have	O
been	O
explored	O
in	O
most	O
detail	O
to	O
date	O
.	O

The	O
P2Y2	O
receptor	O
has	O
been	O
specifically	O
localized	O
to	O
the	O
apical	O
membrane	O
of	O
fresh	O
bovine	B
RPE	O
cells	O
,	O
and	O
addition	O
of	O
ATP	O
to	O
this	O
membrane	O
transiently	O
elevates	O
Ca2	O
+	O
,	O
activates	O
a	O
basolateral	O
Cl-	O
conductance	O
,	O
inhibits	O
an	O
apical	O
K+	O
conductance	O
,	O
and	O
increases	O
the	O
apical	O
to	O
basolateral	O
flow	O
of	O
fluid	O
[	O
43	O
]	O
.	O

This	O
increased	O
absorption	O
of	O
fluid	O
from	O
the	O
subretinal	O
space	O
suggests	O
P2Y2	O
receptor	O
stimulation	O
could	O
reduce	O
the	O
excess	O
fluid	O
that	O
accumulates	O
in	O
retinal	O
edemas	O
,	O
and	O
several	O
reports	O
have	O
supported	O
this	O
theory	O
.	O

ATP	O
,	O
UTP	O
,	O
and	O
the	O
P2Y2	O
receptor	O
agonist	O
INS37217	O
decrease	O
the	O
size	O
of	O
subretinal	O
fluid	O
blebs	O
when	O
injected	O
into	O
subretinal	O
space	O
of	O
rats	B
[	O
44	O
]	O
.	O

In	O
both	O
normal	O
and	O
rds	O
+	O
/-	O
mice	B
with	O
experimentally	O
induced	O
detachment	O
,	O
INS31217	O
improves	O
the	O
ERG	O
recovery	O
and	O
decreased	O
cell	O
death	O
[	O
45	O
]	O
.	O

INS37217	O
also	O
reduces	O
subretinal	O
blebs	O
in	O
rabbits	B
[	O
46	O
]	O
.	O

Injection	O
of	O
another	O
P2Y2	O
agonist	O
,	O
INS542	O
,	O
increases	O
the	O
active	O
transport	O
of	O
fluorescein	O
across	O
the	O
RPE	O
,	O
consistent	O
with	O
this	O
upregulation	O
of	O
ion	O
and	O
fluid	O
transport	O
across	O
the	O
tissue	O
[	O
47	O
]	O
.	O

Together	O
these	O
experiments	O
emphasize	O
the	O
clinical	O
potential	O
of	O
treating	O
retinal	O
edema	O
with	O
P2Y2	O
agonists	O
.	O

Regulation	O
of	O
purine	O
levels	O
in	O
subretinal	O
space	O
While	O
synthesized	O
purinergic	O
agonists	O
may	O
prove	O
useful	O
in	O
treating	O
some	O
ocular	O
disorders	O
,	O
the	O
endogenous	O
activation	O
of	O
P1	O
and	O
P2	O
receptors	O
in	O
the	O
subretinal	O
microenvironment	O
will	O
ultimately	O
be	O
determined	O
by	O
availability	O
of	O
agonists	O
.	O

These	O
levels	O
are	O
largely	O
controlled	O
by	O
the	O
release	O
of	O
ATP	O
into	O
the	O
subretinal	O
space	O
,	O
its	O
conversion	O
into	O
other	O
purines	O
including	O
adenosine	O
,	O
and	O
the	O
manipulation	O
of	O
adenosine	O
by	O
enzymes	O
or	O
transporters	O
.	O

Recent	O
work	O
has	O
increased	O
our	O
understanding	O
of	O
both	O
the	O
stimuli	O
that	O
initiate	O
changes	O
in	O
subretinal	O
purine	O
levels	O
and	O
the	O
mechanisms	O
that	O
mediate	O
these	O
changes	O
.	O

Release	O
of	O
ATP	O
by	O
the	O
RPE	O
At	O
least	O
some	O
of	O
the	O
ATP	O
capable	O
of	O
stimulating	O
the	O
purinergic	O
receptors	O
on	O
RPE	O
cells	O
is	O
released	O
from	O
the	O
RPE	O
itself	O
.	O

The	O
resulting	O
autocrine	O
stimulation	O
ensures	O
local	O
delivery	O
,	O
and	O
control	O
,	O
of	O
purines	O
to	O
initiate	O
the	O
physiologic	O
changes	O
in	O
the	O
RPE	O
.	O

The	O
release	O
of	O
ATP	O
by	O
RPE	O
cells	O
is	O
triggered	O
by	O
multiple	O
stimuli	O
including	O
osmotic	O
stress	O
,	O
bFGF	O
,	O
UTP	O
,	O
NMDA	O
,	O
glutamate	O
,	O
and	O
ATP	O
[	O
39	O
,	O
40	O
,	O
48–51	O
]	O
.	O

The	O
ATP	O
release	O
following	O
activation	O
of	O
NMDA	O
receptors	O
by	O
glutamate	O
may	O
have	O
the	O
most	O
interesting	O
implications	O
for	O
communication	O
across	O
subretinal	O
space	O
,	O
given	O
that	O
glutamate	O
confers	O
the	O
light	O
signal	O
from	O
photoreceptors	O
to	O
the	O
rest	O
of	O
the	O
visual	O
system	O
.	O

Glutamate	O
and	O
the	O
specific	O
receptor	O
agonist	O
NMDA	O
triggers	O
ATP	O
release	O
from	O
ARPE-19	O
cells	O
,	O
with	O
the	O
release	O
inhibited	O
by	O
NMDA	O
antagonist	O
MK-801	O
,	O
and	O
by	O
DCKA	O
,	O
which	O
inhibits	O
the	O
glycine	O
B	O
binding	O
site	O
on	O
NMDA	O
receptors	O
[	O
51	O
,	O
52	O
]	O
.	O

Although	O
NMDA	O
raises	O
intracellular	O
Ca2	O
+	O
levels	O
,	O
this	O
increase	O
is	O
prevented	O
by	O
eliminating	O
ATP	O
with	O
apyrase	O
,	O
indicating	O
autostimulation	O
through	O
released	O
ATP	O
is	O
responsible	O
for	O
this	O
Ca2	O
+	O
signal	O
.	O

NMDA	O
also	O
triggers	O
a	O
release	O
of	O
ATP	O
when	O
applied	O
to	O
the	O
intact	O
bovine	B
RPE	O
eyecup	O
[	O
51	O
]	O
.	O

The	O
NMDA	O
receptors	O
and	O
the	O
ATP	O
release	O
sites	O
have	O
been	O
functionally	O
identified	O
to	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	B
RPE	O
,	O
suggesting	O
the	O
neurotransmitter	O
interactions	O
could	O
amplify	O
the	O
signal	O
from	O
any	O
glutamate	O
reaching	O
subretinal	O
space	O
.	O

The	O
ability	O
of	O
both	O
UTP	O
and	O
ATP	O
to	O
stimulate	O
release	O
of	O
ATP	O
from	O
the	O
RPE	O
supports	O
the	O
theory	O
that	O
the	O
system	O
acts	O
to	O
amplify	O
signals	O
.	O

When	O
applied	O
at	O
greater	O
than	O
1	O
μM	O
,	O
ATP	O
triggers	O
a	O
secondary	O
release	O
of	O
ATP	O
peaking	O
10	O
min	O
after	O
the	O
initial	O
stimuli	O
[	O
40	O
]	O
.	O

UTP	O
also	O
initiates	O
a	O
release	O
in	O
extracellular	O
ATP	O
with	O
a	O
similar	O
delay	O
[	O
48	O
]	O
.	O

The	O
rise	O
in	O
ATP	O
triggered	O
by	O
UTP	O
is	O
inhibited	O
by	O
the	O
Cl-	O
channel	O
blocker	O
NPPB	O
,	O
and	O
UDP	O
is	O
much	O
less	O
effective	O
at	O
triggering	O
release	O
than	O
UTP	O
;	O
both	O
observations	O
suggest	O
the	O
P2Y2	O
receptor	O
contributes	O
to	O
the	O
increase	O
in	O
ATP	O
more	O
than	O
diphosphokinase	O
,	O
although	O
influence	O
from	O
the	O
enzyme	O
can	O
not	O
be	O
ruled	O
out	O
[	O
53	O
]	O
.	O

Recent	O
evidence	O
suggests	O
that	O
ischemia	O
may	O
lead	O
to	O
the	O
release	O
of	O
ATP	O
from	O
RPE	O
cells	O
.	O

Chemical	O
ischemia	O
triggers	O
a	O
substantial	O
ATP	O
release	O
from	O
cardiac	O
myocytes	O
[	O
54	O
]	O
,	O
while	O
changes	O
in	O
oxygen	O
levels	O
trigger	O
ATP	O
release	O
in	O
central	O
chemoreceptors	O
[	O
55	O
]	O
.	O

We	O
found	O
that	O
exposure	O
to	O
sodium	O
cyanide	O
led	O
to	O
a	O
rapid	O
release	O
of	O
ATP	O
from	O
ARPE-19	O
cells	O
(	O
Fig.	O
2	O
)	O
.	O

As	O
hypoxic	O
and/or	O
ischemic	O
challenge	O
may	O
lead	O
to	O
changes	O
in	O
the	O
expression	O
of	O
growth	O
factors	O
in	O
RPE	O
cells	O
during	O
certain	O
ocular	O
disorders	O
such	O
as	O
macular	O
degeneration	O
[	O
56	O
]	O
,	O
and	O
as	O
purines	O
can	O
induce	O
expression	O
of	O
VEGF	O
in	O
other	O
cells	O
[	O
57	O
]	O
,	O
this	O
ATP	O
release	O
may	O
contribute	O
to	O
growth	O
factor	O
signaling	O
by	O
the	O
diseased	O
RPE	O
.	O

Fig.	O
2Chemical	O
ischemia	O
triggers	O
ATP	O
release	O
from	O
ARPE-19	O
cells	O
.	O

ATP	O
release	O
was	O
measured	O
in	O
the	O
bath	O
directly	O
from	O
cells	O
plated	O
in	O
96-well	O
plates	O
to	O
which	O
the	O
luciferin-	O
luciferase	O
reaction	O
mixture	O
was	O
added	O
[	O
51	O
]	O
.	O

Left	O
Levels	O
of	O
ATP	O
in	O
the	O
bath	O
after	O
addition	O
of	O
5	O
mM	O
NaCN	O
to	O
the	O
cells	O
.	O

Measurement	O
began	O
1	O
min	O
after	O
addition	O
of	O
NaCN	O
or	O
control	O
solution	O
to	O
wells	O
.	O

Right	O
Levels	O
of	O
ATP	O
measured	O
at	O
the	O
peak	O
,	O
3	O
min	O
after	O
addition	O
of	O
NaCN	O
(	O
n	O
=	O
12	O
)	O
.	O

Levels	O
were	O
normalized	O
to	O
concurrent	O
levels	O
in	O
control	O
(	O
n	O
=	O
14	O
)	O
.	O

Symbols	O
and	O
bars	O
represent	O
mean	O
±	O
SE	O
,	O
*	O
p	O
<	O
0.001	O
The	O
particular	O
conduit	O
for	O
ATP	O
release	O
varies	O
with	O
the	O
stimuli	O
.	O

The	O
release	O
in	O
response	O
to	O
hypotonic	O
challenge	O
is	O
largely	O
dependent	O
upon	O
CFTR	O
,	O
as	O
it	O
was	O
prevented	O
by	O
the	O
specific	O
CFTR	O
inhibitor	O
CFTR172	O
in	O
addition	O
to	O
the	O
more	O
general	O
blocker	O
glybenclamide	O
[	O
50	O
]	O
.	O

While	O
the	O
precise	O
mechanisms	O
by	O
which	O
CFTR	O
contributes	O
to	O
this	O
release	O
are	O
not	O
yet	O
known	O
,	O
a	O
role	O
for	O
CFTR	O
in	O
ATP	O
release	O
into	O
subretinal	O
space	O
is	O
consistent	O
with	O
the	O
reduction	O
of	O
certain	O
ERG	O
components	O
in	O
cftr	O
-	O
/	O
-	O
mice	B
[	O
58	O
]	O
and	O
with	O
the	O
ability	O
of	O
apical	O
ATP	O
to	O
activate	O
conductances	O
associated	O
with	O
these	O
ERG	O
components	O
[	O
43	O
]	O
.	O

The	O
release	O
of	O
ATP	O
is	O
also	O
largely	O
blocked	O
by	O
the	O
vesicular	O
transport	O
inhibitor	O
brefeldin	O
A	O
,	O
suggesting	O
the	O
two	O
processes	O
occurred	O
in	O
series	O
whereby	O
ATP	O
efflux	O
follows	O
the	O
insertion	O
of	O
vesicles	O
containing	O
CFTR	O
into	O
the	O
plasma	O
membrane	O
.	O

Although	O
the	O
Ca2	O
+	O
chelator	O
BAPTA	O
blocks	O
this	O
ATP	O
release	O
[	O
50	O
]	O
,	O
raising	O
Ca2	O
+	O
alone	O
with	O
ionophore	O
ionomycin	O
does	O
not	O
itself	O
initiate	O
release	O
[	O
48	O
]	O
.	O

This	O
necessary	O
but	O
not	O
sufficient	O
contribution	O
of	O
Ca2	O
+	O
also	O
supports	O
a	O
role	O
for	O
vesicular	O
insertion	O
.	O

In	O
contrast	O
to	O
the	O
release	O
following	O
hypotonic	O
challenge	O
,	O
the	O
ATP	O
release	O
in	O
response	O
to	O
NMDA	O
does	O
not	O
involve	O
CFTR	O
[	O
51	O
]	O
.	O

Release	O
is	O
blocked	O
by	O
NPPB	O
,	O
however	O
,	O
suggesting	O
another	O
type	O
of	O
anion	O
channel	O
could	O
serve	O
as	O
a	O
conduit	O
for	O
ATP	O
release	O
.	O

The	O
presence	O
of	O
parallel	O
mechanisms	O
coexisting	O
on	O
the	O
same	O
cell	O
for	O
ATP	O
release	O
triggered	O
by	O
either	O
agonists	O
or	O
by	O
cell	O
swelling	O
has	O
also	O
been	O
reported	O
in	O
astrocytes	O
[	O
59	O
]	O
and	O
may	O
reflect	O
the	O
multiple	O
roles	O
of	O
purinergic	O
signaling	O
within	O
a	O
given	O
tissue	O
.	O

As	O
both	O
stimuli	O
lead	O
to	O
release	O
across	O
the	O
apical	O
membrane	O
into	O
subretinal	O
space	O
,	O
both	O
are	O
expected	O
to	O
influence	O
signaling	O
in	O
the	O
microenvironment	O
.	O

Interconversion	O
of	O
purines	O
in	O
subretinal	O
space	O
The	O
interconversion	O
of	O
nucleotides	O
and	O
nucleosides	O
each	O
capable	O
of	O
stimulating	O
distinct	O
receptors	O
makes	O
the	O
purinergic	O
signaling	O
system	O
of	O
particular	O
interest	O
in	O
a	O
confined	O
region	O
such	O
as	O
the	O
subretinal	O
space	O
.	O

The	O
main	O
enzymes	O
responsible	O
for	O
dephosphorylating	O
extracellular	O
ATP	O
on	O
the	O
RPE	O
cells	O
have	O
been	O
analyzed	O
and	O
a	O
basic	O
understanding	O
of	O
their	O
regulation	O
has	O
begun	O
.	O

This	O
section	O
first	O
describes	O
the	O
enzymes	O
that	O
act	O
on	O
ATP	O
and	O
ADP	O
,	O
followed	O
by	O
enzymes	O
which	O
convert	O
AMP	O
into	O
adenosine	O
.	O

The	O
dephosphorylation	O
of	O
extracellular	O
ATP	O
by	O
RPE	O
cells	O
involves	O
enzymes	O
from	O
multiple	O
families	O
[	O
40	O
]	O
,	O
as	O
found	O
in	O
airway	O
epithelial	O
cells	O
[	O
60	O
]	O
.	O

Degradation	O
of	O
ATP	O
by	O
the	O
apical	O
membrane	O
of	O
the	O
fresh	O
bovine	B
eyecup	O
and	O
by	O
ARPE-19	O
cells	O
is	O
inhibited	O
by	O
ARL67156	O
or	O
βγmATP	O
.	O

Message	O
for	O
eNPP1	O
,	O
eNPP2	O
,	O
and	O
eNPP3	O
is	O
present	O
in	O
ARPE-19	O
cells	O
,	O
consistent	O
with	O
the	O
preference	O
of	O
βγmATP	O
for	O
members	O
of	O
the	O
eNPP	O
family	O
[	O
61	O
]	O
.	O

The	O
cells	O
also	O
express	O
NTPDase2	O
,	O
and	O
NTPDase3	O
,	O
although	O
the	O
intermittent	O
presence	O
of	O
NTPDase1	O
likely	O
reflects	O
a	O
regulated	O
process	O
[	O
40	O
]	O
.	O

Ecto	O
-	O
alkaline	O
phosphatase	O
has	O
no	O
effect	O
on	O
ATP	O
degradation	O
in	O
RPE	O
cells	O
,	O
in	O
contrast	O
to	O
its	O
considerable	O
contribution	O
in	O
airway	O
epithelium	O
[	O
62	O
]	O
.	O

The	O
putative	O
contribution	O
from	O
diphosphokinases	O
to	O
interconversion	O
of	O
subretinal	O
purines	O
is	O
presently	O
unknown	O
.	O

Extracellular	O
AMP	O
is	O
rapidly	O
dephosphorylated	O
into	O
adenosine	O
in	O
subretinal	O
space	O
.	O

The	O
production	O
of	O
adenosine	O
from	O
ATP	O
at	O
the	O
apical	O
membrane	O
of	O
the	O
bovine	B
RPE	O
eyecup	O
is	O
inhibited	O
by	O
the	O
ecto-5′-nucleotidase	O
inhibitor	O
αβmADP	O
,	O
confirming	O
a	O
role	O
for	O
this	O
enzyme	O
[	O
63	O
]	O
.	O

The	O
enzyme	O
is	O
localized	O
to	O
rat	B
RPE	O
and	O
ARPE-19	O
cells	O
immunohistochemically	O
.	O

Degradation	O
of	O
5′AMP	O
is	O
highest	O
near	O
the	O
subretinal	O
space	O
of	O
rat	B
retina	O
[	O
63	O
]	O
,	O
although	O
localization	O
in	O
mouse	B
indicated	O
larger	O
amounts	O
of	O
ecto-5′-nucleotidase	O
at	O
the	O
tips	O
of	O
adjacent	O
Müller	O
cells	O
[	O
64	O
]	O
.	O

Levamisole	O
does	O
not	O
inhibit	O
the	O
dephosphorylation	O
of	O
5′AMP	O
by	O
the	O
RPE	O
,	O
consistent	O
with	O
the	O
absence	O
of	O
substantial	O
ecto	O
-	O
alkaline	O
phosphatase	O
in	O
subretinal	O
space	O
.	O

The	O
presence	O
of	O
light	O
may	O
alter	O
the	O
levels	O
of	O
adenosine	O
in	O
subretinal	O
space	O
.	O

Epinephrine	O
is	O
released	O
at	O
the	O
onset	O
of	O
light	O
[	O
65	O
]	O
and	O
stimulation	O
of	O
the	O
RPE	O
with	O
epinephrine	O
can	O
decrease	O
activity	O
of	O
ecto-5′-nucleotidase	O
[	O
63	O
]	O
.	O

While	O
norepinephrine	O
and	O
phenylephrine	O
lead	O
to	O
similar	O
decreases	O
in	O
enzyme	O
activity	O
,	O
prazosin	O
and	O
corynanthine	O
block	O
the	O
effects	O
of	O
norepinephrine	O
,	O
implicating	O
the	O
α1	O
epinephrine	O
receptor	O
in	O
the	O
inhibition	O
of	O
ecto-5′-nucleotidase	O
[	O
63	O
]	O
.	O

The	O
kinetics	O
of	O
inhibition	O
are	O
consistent	O
with	O
cleavage	O
of	O
the	O
nucleotidase	O
from	O
its	O
GPI	O
anchor	O
.	O

The	O
phagocytosis	O
of	O
rod	O
outer	O
segments	O
is	O
maximal	O
shortly	O
after	O
light	O
onset	O
[	O
16	O
]	O
,	O
and	O
this	O
phagocytosis	O
is	O
inhibited	O
by	O
adenosine	O
[	O
29	O
]	O
.	O

The	O
ability	O
of	O
epinephrine	O
released	O
by	O
the	O
illuminated	O
retina	O
to	O
reduce	O
ecto-5′-nucleotidase	O
activity	O
and	O
consequently	O
adenosine	O
levels	O
may	O
relieve	O
this	O
inhibition	O
and	O
enhance	O
the	O
rate	O
of	O
phagocytosis	O
at	O
light	O
onset	O
.	O

Physiologic	O
effects	O
of	O
subretinal	O
purines	O
on	O
the	O
RPE	O
and	O
photoreceptors	O
The	O
number	O
of	O
purinergic	O
receptors	O
on	O
both	O
photoreceptor	O
and	O
RPE	O
membranes	O
suggests	O
purines	O
make	O
multiple	O
contributions	O
to	O
the	O
physiology	O
of	O
the	O
outer	O
retina	O
.	O

Our	O
increased	O
understanding	O
of	O
how	O
agonist	O
levels	O
in	O
subretinal	O
space	O
are	O
controlled	O
has	O
begun	O
to	O
indicate	O
how	O
and	O
when	O
this	O
contribution	O
may	O
occur	O
.	O

Future	O
research	O
will	O
involve	O
applying	O
these	O
findings	O
from	O
isolated	O
systems	O
to	O
intact	O
RPE	O
-	O
photoreceptor	O
models	O
,	O
and	O
pursuing	O
the	O
role	O
of	O
defective	O
purinergic	O
regulation	O
in	O
ocular	O
disease	O
.	O

While	O
it	O
is	O
unlikely	O
that	O
ATP	O
released	O
across	O
the	O
apical	O
membrane	O
of	O
the	O
RPE	O
can	O
diffuse	O
to	O
these	O
P2	O
receptors	O
in	O
the	O
outer	O
plexiform	O
layer	O
given	O
the	O
ecto	O
-	O
ATPase	O
activity	O
in	O
the	O
synaptic	O
clef	O
[	O
25	O
]	O
,	O
stimulation	O
of	O
receptors	O
elsewhere	O
on	O
the	O
photoreceptor	O
membrane	O
is	O
possible	O
.	O

It	O
would	O
be	O
interesting	O
to	O
determine	O
whether	O
ATP	O
released	O
from	O
the	O
RPE	O
and	O
converted	O
to	O
adenosine	O
by	O
ecto	O
-	O
nucleotidases	O
can	O
actually	O
modulate	O
the	O
response	O
to	O
light	O
by	O
stimulating	O
the	O
A2A	O
receptors	O
on	O
photoreceptor	O
outer	O
segments	O
.	O

The	O
impact	O
of	O
purinergic	O
signaling	O
on	O
chronic	O
ocular	O
diseases	O
is	O
also	O
of	O
interest	O
,	O
such	O
as	O
the	O
role	O
of	O
ischemia	O
-	O
driven	O
ATP	O
release	O
in	O
VEGF	O
production	O
.	O

While	O
the	O
small	O
size	O
of	O
subretinal	O
space	O
can	O
complicate	O
pharmacologic	O
manipulation	O
within	O
the	O
intact	O
RPE	O
-	O
photoreceptor	O
complex	O
,	O
molecular	O
approaches	O
may	O
provide	O
new	O
insight	O
into	O
how	O
endogenous	O
purines	O
in	O
subretinal	O
space	O
affect	O
the	O
physiology	O
,	O
and	O
pathophysiology	O
,	O
of	O
both	O
RPE	O
and	O
photoreceptors	O
.	O

Genomic	O
-	O
Bioinformatic	O
Analysis	O
of	O
Transcripts	O
Enriched	O
in	O
the	O
Third	O
-	O
Stage	O
Larva	O
of	O
the	O
Parasitic	O
Nematode	O
Ascaris	B
suum	I
Abstract	O
Differential	O
transcription	O
in	O
Ascaris	B
suum	I
was	O
investigated	O
using	O
a	O
genomic	O
-	O
bioinformatic	O
approach	O
.	O

A	O
cDNA	O
archive	O
enriched	O
for	O
molecules	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
of	O
A.	B
suum	I
was	O
constructed	O
by	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
and	O
a	O
subset	O
of	O
cDNAs	O
from	O
3075	O
clones	O
subjected	O
to	O
microarray	O
analysis	O
using	O
cDNA	O
probes	O
derived	O
from	O
RNA	O
from	O
different	O
developmental	O
stages	O
of	O
A.	B
suum	I
.	O

The	O
cDNAs	O
(	O
n	O
=	O
498	O
)	O
shown	O
by	O
microarray	O
analysis	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
were	O
sequenced	O
and	O
subjected	O
to	O
bioinformatic	O
analyses	O
using	O
a	O
semi	O
-	O
automated	O
pipeline	O
(	O
ESTExplorer	O
)	O
.	O

Using	O
gene	O
ontology	O
(	O
GO	O
)	O
,	O
235	O
of	O
these	O
molecules	O
were	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
68	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
50	O
)	O
,	O
or	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
117	O
)	O
.	O

Of	O
the	O
91	O
clusters	O
assembled	O
,	O
56	O
molecules	O
(	O
61.5	O
%	O
)	O
had	O
homologues	O
/	O
orthologues	O
in	O
the	O
free	O
-	O
living	O
nematodes	O
Caenorhabditis	B
elegans	I
and	O
C.	B
briggsae	I
and/or	O
other	O
organisms	O
,	O
whereas	O
35	O
(	O
38.5	O
%	O
)	O
had	O
no	O
significant	O
similarity	O
to	O
any	O
sequences	O
available	O
in	O
current	O
gene	O
databases	O
.	O

Transcripts	O
encoding	O
protein	O
kinases	O
,	O
protein	O
phosphatases	O
(	O
and	O
their	O
precursors	O
)	O
,	O
and	O
enolases	O
were	O
abundantly	O
represented	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
as	O
were	O
molecules	O
involved	O
in	O
cellular	O
processes	O
,	O
such	O
as	O
ubiquitination	O
and	O
proteasome	O
function	O
,	O
gene	O
transcription	O
,	O
protein	O
–	O
protein	O
interactions	O
,	O
and	O
function	O
.	O

In	O
silico	O
analyses	O
inferred	O
the	O
C.	B
elegans	I
orthologues	O
/	O
homologues	O
(	O
n	O
=	O
50	O
)	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Small	O
numbers	O
of	O
these	O
50	O
molecules	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
,	O
and/or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
them	O
were	O
predicted	O
to	O
be	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C.	B
elegans	I
,	O
the	O
majority	O
being	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58.8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23.5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
.	O

A	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
these	O
17	O
C.	B
elegans	I
orthologues	O
,	O
revealing	O
highly	O
significant	O
interactions	O
for	O
nine	O
molecules	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
66.9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
5.1	O
%	O
)	O
,	O
cellular	O
processing	O
and	O
signaling	O
(	O
15.2	O
%	O
)	O
,	O
metabolism	O
(	O
6.1	O
%	O
)	O
,	O
and	O
unknown	O
function	O
(	O
6.7	O
%	O
)	O
.	O

The	O
potential	O
roles	O
of	O
these	O
molecules	O
in	O
development	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
known	O
roles	O
of	O
their	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
and	O
some	O
other	O
nematodes	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
provide	O
a	O
basis	O
for	O
future	O
functional	O
genomic	O
studies	O
to	O
elucidate	O
molecular	O
aspects	O
governing	O
larval	O
developmental	O
processes	O
in	O
A.	B
suum	I
and/or	O
the	O
transition	O
to	O
parasitism	O
.	O

Introduction	O
Parasitic	O
nematodes	O
are	O
of	O
major	O
socio	O
-	O
economic	O
importance	O
in	O
animals	O
.	O

For	O
example	O
,	O
hundreds	O
of	O
millions	O
of	O
people	O
are	O
infected	O
with	O
geohelminths	O
(	O
soil	O
-	O
transmitted	O
worms	O
)	O
,	O
such	O
as	O
blood	O
-	O
feeding	O
hookworms	O
Ancylostoma	B
duodenale	I
and/or	O
Necator	B
americanus	I
,	O
Trichuris	B
trichiura	I
and	O
Ascaris	O
spp	O
.	O

[	O
1	O
]	O
,	O
causing	O
serious	O
adverse	O
effects	O
on	O
human	B
health	O
,	O
particularly	O
in	O
children	O
.	O

Similarly	O
,	O
parasitic	O
nematodes	O
of	O
livestock	O
,	O
such	O
as	O
pigs	B
,	O
also	O
cause	O
substantial	O
economic	O
losses	O
due	O
to	O
subclinical	O
and	O
clinical	O
diseases	O
,	O
with	O
billions	O
of	O
dollars	O
spent	O
annually	O
on	O
the	O
treatment	O
and	O
control	O
of	O
gastro	O
-	O
intestinal	O
nematodes	O
.	O

In	O
addition	O
to	O
the	O
socioeconomic	O
impact	O
that	O
these	O
parasites	O
have	O
,	O
there	O
is	O
potential	O
for	O
the	O
emergence	O
of	O
resistance	O
in	O
them	O
against	O
all	O
of	O
the	O
main	O
classes	O
of	O
(	O
nematocidal	O
)	O
compounds	O
used	O
to	O
treat	O
the	O
diseases	O
they	O
cause	O
[	O
2	O
]	O
–	O
[	O
5	O
]	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
significant	O
need	O
to	O
work	O
toward	O
discovering	O
new	O
compounds	O
to	O
control	O
these	O
parasites	O
.	O

Gaining	O
an	O
improved	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
parasite	O
development	O
provides	O
such	O
an	O
avenue	O
.	O

Compared	O
with	O
the	O
free	O
-	O
living	O
nematode	O
Caenorhabditis	B
elegans	I
,	O
there	O
is	O
very	O
little	O
information	O
on	O
fundamental	O
molecular	O
aspects	O
of	O
development	O
in	O
parasitic	O
nematodes	O
[	O
6	O
]	O
–	O
[	O
8	O
]	O
.	O

Since	O
the	O
genome	O
sequence	O
of	O
C.	B
elegans	I
was	O
published	O
in	O
1998	O
[	O
9	O
]	O
,	O
many	O
aspects	O
of	O
the	O
molecular	O
biology	O
of	O
this	O
nematode	O
have	O
been	O
elucidated	O
.	O

For	O
instance	O
,	O
microarray	O
analyses	O
have	O
been	O
used	O
to	O
examine	O
developmental	O
and	O
gender	O
-	O
enriched	O
gene	O
expression	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
,	O
and	O
the	O
functions	O
of	O
more	O
than	O
96	O
%	O
of	O
the	O
C.	B
elegans	I
genes	O
have	O
been	O
assessed	O
by	O
double	O
-	O
stranded	O
RNA	O
interference	O
(	O
RNAi	O
,	O
or	O
gene	O
silencing	O
;	O
[	O
12	O
]	O
)	O
[	O
13	O
]	O
–	O
[	O
18	O
]	O
.	O

Comparative	O
analyses	O
of	O
genetic	O
data	O
sets	O
have	O
shown	O
that	O
parasitic	O
nematodes	O
usually	O
share	O
∼50–70	O
%	O
of	O
genes	O
with	O
C.	B
elegans	I
(	O
e.g.	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
)	O
.	O

There	O
is	O
similarity	O
in	O
other	O
features	O
(	O
such	O
as	O
basic	O
body	O
plan	O
and	O
moulting	O
)	O
between	O
C.	B
elegans	I
and	O
parasitic	O
nematodes	O
,	O
suggesting	O
that	O
some	O
molecular	O
pathways	O
are	O
relatively	O
conserved	O
[	O
8	O
]	O
,	O
[	O
21	O
]	O
.	O

Understanding	O
the	O
pathways	O
linked	O
to	O
basic	O
nematode	O
biology	O
and	O
development	O
could	O
have	O
important	O
implications	O
for	O
finding	O
new	O
ways	O
of	O
disrupting	O
these	O
pathways	O
and	O
thus	O
facilitate	O
the	O
identification	O
of	O
new	O
drug	O
targets	O
.	O

Despite	O
the	O
advances	O
in	O
genomic	O
technologies	O
[	O
7	O
]	O
,	O
[	O
22	O
]	O
–	O
[	O
29	O
]	O
and	O
the	O
study	O
of	O
C.	B
elegans	I
,	O
there	O
is	O
a	O
paucity	O
of	O
information	O
on	O
the	O
genomics	O
of	O
parasitic	O
nematodes	O
of	O
animals	O
,	O
particularly	O
in	O
relation	O
to	O
development	O
.	O

Also	O
considering	O
the	O
major	O
socioeconomic	O
impact	O
of	O
Ascaris	O
and	O
ascariasis	O
in	O
humans	B
and	O
pigs	B
[	O
30	O
]	O
–	O
[	O
32	O
]	O
,	O
several	O
characteristics	O
,	O
including	O
the	O
large	O
size	O
of	O
the	O
adult	O
worm	O
(	O
providing	O
the	O
opportunity	O
of	O
investigating	O
individual	O
organ	O
systems	O
and	O
tissues	O
)	O
,	O
the	O
ability	O
to	O
maintain	O
Ascaris	O
in	O
the	O
pig	B
,	O
store	O
eggs	O
and	O
culture	O
larvae	O
in	O
vitro	O
for	O
relatively	O
long	O
periods	O
of	O
time	O
(	O
months	O
to	O
years	O
)	O
[	O
32	O
]	O
as	O
well	O
as	O
the	O
discovery	O
that	O
RNAi	O
achieves	O
""""	O
cross	O
-	O
species	O
""""	O
gene	O
silencing	O
for	O
a	O
selected	O
number	O
of	O
genes	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
and	O
the	O
imminent	O
genome	O
sequence	O
(	O
http://www.sanger.ac.uk/Projects/Helminths/	O
)	O
all	O
indicate	O
that	O
Ascaris	O
could	O
serve	O
as	O
a	O
powerful	O
model	O
system	O
for	O
investigating	O
reproductive	O
and	O
developmental	O
processes	O
in	O
nematodes	O
.	O

In	O
the	O
present	O
study	O
,	O
Ascaris	O
from	O
pigs	B
was	O
used	O
to	O
study	O
molecules	O
abundantly	O
transcribed	O
in	O
the	O
infective	O
third	O
-	O
stage	O
larva	O
(	O
L3	O
)	O
.	O

Following	O
the	O
oral	O
ingestion	O
of	O
Ascaris	O
eggs	O
by	O
the	O
host	O
(	O
human	B
or	O
pig	B
)	O
,	O
L3s	O
are	O
released	O
and	O
then	O
invade	O
/	O
penetrate	O
predominantly	O
the	O
caecal	O
wall	O
[	O
35	O
]	O
to	O
then	O
undergo	O
hepato	O
-	O
pulmonary	O
migration	O
,	O
after	O
which	O
ultimately	O
the	O
adult	O
females	O
and	O
males	O
establish	O
and	O
develop	O
in	O
the	O
small	O
intestine	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
molecular	O
mechanisms	O
linked	O
to	O
host	O
invasion	O
and	O
parasite	O
development	O
are	O
largely	O
unknown	O
.	O

Here	O
,	O
we	O
constructed	O
an	O
L3-enriched	O
cDNA	O
library	O
using	O
the	O
method	O
of	O
suppressive	O
-	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
,	O
explored	O
transcription	O
of	O
a	O
representative	O
subset	O
of	O
molecules	O
by	O
microarray	O
analysis	O
and	O
conducted	O
bioinformatic	O
analyses	O
to	O
characterize	O
these	O
molecules	O
,	O
map	O
them	O
to	O
biochemical	O
pathways	O
and	O
predict	O
genetic	O
interactions	O
based	O
on	O
comparisons	O
with	O
C.	B
elegans	I
and/or	O
other	O
organisms	O
.	O

Materials	O
and	O
Methods	O
Production	O
of	O
Different	O
Developmental	O
Stages	O
of	O
Ascaris	O
Experimental	O
pigs	B
(	O
8–12	O
weeks	O
of	O
age	O
)	O
were	O
purchased	O
from	O
and	O
maintained	O
in	O
the	O
Experimental	O
Animal	O
Center	O
of	O
South	O
China	O
Agricultural	O
University	O
.	O

These	O
pigs	B
were	O
treated	O
humanely	O
,	O
according	O
to	O
the	O
Animal	O
Ethics	O
procedures	O
and	O
guidelines	O
of	O
the	O
People	O
's	O
Republic	O
of	O
China	O
.	O

Adult	O
worms	O
(	O
males	O
and	O
females	O
)	O
of	O
A.	B
suum	I
were	O
collected	O
from	O
the	O
small	O
intestines	O
of	O
pigs	B
from	O
an	O
abattoir	O
in	O
Shenzhen	O
,	O
China	O
.	O

Infective	O
eggs	O
and	O
infective	O
L3s	O
of	O
A.	B
suum	I
were	O
produced	O
according	O
to	O
the	O
methods	O
described	O
previously	O
[	O
38	O
]	O
.	O

In	O
brief	O
,	O
eggs	O
from	O
the	O
uteri	O
of	O
adult	O
females	O
of	O
A.	B
suum	I
were	O
collected	O
and	O
incubated	O
at	O
28	O
°	O
C	O
for	O
28	O
days	O
to	O
allow	O
them	O
to	O
develop	O
to	O
infective	O
eggs	O
(	O
containing	O
infective	O
L3s	O
)	O
.	O

To	O
obtain	O
pure	O
infective	O
L3s	O
,	O
7.5	O
%	O
v	O
/	O
v	O
sodium	O
hypochlorite	O
was	O
used	O
to	O
treat	O
the	O
larvated	O
eggs	O
at	O
37	O
°	O
C	O
overnight	O
and	O
then	O
the	O
eggs	O
were	O
shaken	O
with	O
glass	O
-	O
beads	O
;	O
then	O
,	O
the	O
exsheathed	O
L3s	O
and	O
shells	O
were	O
separated	O
by	O
density	O
gradient	O
centrifugation	O
using	O
lymphocyte	O
separating	O
medium	O
(	O
LSM	O
)	O
[	O
38	O
]	O
.	O

Following	O
the	O
experimental	O
infection	O
of	O
helminth	O
-	O
free	O
pigs	B
with	O
infective	O
Ascaris	O
eggs	O
as	O
described	O
previously	O
[	O
39	O
]	O
,	O
the	O
L3s	O
from	O
livers	O
and	O
in	O
lungs	O
as	O
well	O
as	O
L4s	O
in	O
intestines	O
were	O
isolated	O
according	O
to	O
an	O
established	O
method	O
[	O
40	O
]	O
.	O

All	O
parasite	O
materials	O
were	O
snap	O
-	O
frozen	O
in	O
liquid	O
nitrogen	O
prior	O
to	O
storage	O
at	O
−70	O
°	O
C	O
.	O

Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O
Total	O
RNA	O
was	O
isolated	O
from	O
adult	O
females	O
and	O
males	O
,	O
different	O
larval	O
stages	O
or	O
eggs	O
of	O
A.	B
suum	I
using	O
TriPure	O
reagent	O
(	O
Roche	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

Equal	O
amounts	O
of	O
total	O
RNA	O
from	O
each	O
stage	O
or	O
sex	O
were	O
pooled	O
.	O

The	O
mRNA	O
was	O
isolated	O
using	O
the	O
Oligotex	O
mRNA	O
Kit	O
(	O
Qiagen	O
)	O
,	O
following	O
the	O
manufacturer	O
's	O
protocol	O
.	O

SSH	O
was	O
carried	O
out	O
using	O
the	O
PCR	O
-	O
Select	O
cDNA	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

In	O
brief	O
,	O
cDNA	O
synthesized	O
from	O
mRNAs	O
from	O
infective	O
L3s	O
was	O
subtracted	O
against	O
cDNA	O
synthesized	O
from	O
the	O
pooled	O
mRNA	O
from	O
all	O
other	O
stages	O
included	O
herein	O
.	O

The	O
SSH	O
library	O
was	O
constructed	O
using	O
infective	O
L3s	O
as	O
the	O
tester	O
and	O
pooled	O
cDNAs	O
from	O
all	O
other	O
stages	O
as	O
the	O
driver	O
.	O

The	O
effectiveness	O
of	O
this	O
subtraction	O
process	O
has	O
already	O
been	O
demonstrated	O
in	O
previous	O
studies	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

The	O
cDNA	O
obtained	O
following	O
SSH	O
was	O
cloned	O
into	O
the	O
pGEM	O
-	O
T	O
Easy	O
plasmid	O
vector	O
(	O
Promega	O
)	O
and	O
competent	O
Escherichia	B
coli	I
(	O
JM109	O
)	O
transformed	O
.	O

Positive	O
clones	O
,	O
picked	O
randomly	O
(	O
based	O
on	O
blue	O
/	O
white	O
selection	O
)	O
,	O
were	O
grown	O
overnight	O
in	O
Luria	O
Bertani	O
(	O
LB	O
)	O
medium	O
(	O
shaking	O
,	O
37	O
°	O
C	O
)	O
.	O

Individual	O
inserts	O
were	O
PCR	O
-	O
amplified	O
using	O
""""	O
nested	O
primers	O
""""	O
1	O
and	O
2R	O
from	O
the	O
Subtraction	O
kit	O
(	O
Clontech	O
)	O
and	O
examined	O
by	O
agarose	O
electrophoresis	O
.	O

Preparation	O
of	O
Microarray	O
Slides	O
Clones	O
(	O
n	O
=	O
3075	O
)	O
from	O
the	O
subtracted	O
library	O
were	O
picked	O
and	O
cultured	O
overnight	O
in	O
LB	O
containing	O
ampicillin	O
(	O
1000	O
IU	O
/	O
ml	O
)	O
in	O
sealed	O
96-well	O
blocks	O
.	O

Five	O
µl	O
of	O
culture	O
suspension	O
from	O
each	O
well	O
were	O
transferred	O
into	O
individual	O
wells	O
thermocycling	O
(	O
96-well	O
)	O
plates	O
and	O
the	O
inserts	O
PCR	O
-	O
amplified	O
using	O
primers	O
1	O
and	O
2R	O
.	O

Following	O
a	O
10	O
min	O
denaturation	O
step	O
at	O
94	O
°	O
C	O
,	O
the	O
amplification	O
proceeded	O
for	O
25	O
cycles	O
of	O
10	O
s	O
at	O
94	O
°	O
C	O
,	O
30	O
s	O
at	O
68	O
°	O
C	O
and	O
1.5	O
min	O
at	O
72	O
°	O
C	O
,	O
with	O
a	O
final	O
extension	O
for	O
5	O
min	O
at	O
72	O
°	O
C	O
.	O

Products	O
were	O
resolved	O
in	O
agarose	O
gels	O
,	O
ethanol	O
precipitated	O
,	O
re	O
-	O
suspended	O
in	O
16	O
µl	O
of	O
""""	O
spotting	O
solution	O
""""	O
(	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc	O
)	O
to	O
a	O
final	O
concentration	O
of	O
∼500	O
ng	O
per	O
µl	O
,	O
before	O
being	O
printed	O
on	O
to	O
glass	O
slides	O
(	O
in	O
duplicate	O
)	O
using	O
a	O
robotic	O
arrayer	O
.	O

Sixteen	O
blanks	O
(	O
using	O
spotting	O
solution	O
only	O
)	O
and	O
the	O
same	O
number	O
of	O
negative	O
(	O
irrelevant	O
cDNAs	O
with	O
no	O
relationship	O
to	O
Ascaris	O
)	O
were	O
also	O
printed	O
on	O
to	O
slides	O
and	O
served	O
as	O
negative	O
controls	O
;	O
β	O
-	O
actin	O
of	O
A.	B
suum	I
served	O
as	O
a	O
positive	O
control	O
to	O
assess	O
the	O
efficiency	O
of	O
labeling	O
and	O
hybridization	O
.	O

The	O
slides	O
were	O
air	O
-	O
dried	O
for	O
2	O
h	O
,	O
and	O
cDNA	O
in	O
the	O
spots	O
were	O
cross	O
-	O
linked	O
at	O
254	O
mJ.	O
The	O
printed	O
slides	O
were	O
stored	O
at	O
4	O
°	O
C	O
.	O

Labeling	O
of	O
cDNA	O
Probes	O
with	O
Fluorescent	O
Dyes	O
,	O
and	O
Microarray	O
Analysis	O
The	O
cDNAs	O
produced	O
from	O
total	O
RNA	O
from	O
A.	B
suum	I
eggs	O
,	O
infective	O
L3s	O
,	O
L3s	O
isolated	O
from	O
pig	B
liver	O
or	O
lung	O
,	O
fourth	O
-	O
stage	O
larvae	O
(	O
L4s	O
)	O
,	O
adult	O
males	O
or	O
females	O
[	O
as	O
described	O
in	O
the	O
section	O
'	O
Construction	O
of	O
the	O
cDNA	O
Library	O
by	O
Subtractive	O
-	O
Suppressive	O
Hybridization	O
(	O
SSH	O
)	O
'	O
]	O
were	O
labeled	O
with	O
cyanine	O
dyes	O
.	O

Cy3	O
or	O
Cy5-dCTP	O
was	O
incorporated	O
into	O
cDNA	O
produced	O
from	O
30	O
µg	O
of	O
total	O
RNA	O
by	O
direct	O
labeling	O
in	O
a	O
reverse	O
transcription	O
reaction	O
using	O
an	O
oligo	O
(	O
dT	O
)	O
primer	O
.	O

Labeled	O
cDNA	O
was	O
purified	O
using	O
DyeEx	O
columns	O
(	O
Qiagen	O
)	O
.	O

Microarray	O
slides	O
were	O
incubated	O
with	O
a	O
pre	O
-	O
hybridization	O
solution	O
[	O
5	O
×	O
SSC	O
,	O
1	O
%	O
bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
,	O
0.1	O
%	O
sodium	O
dodecyl	O
-	O
sulphate	O
(	O
SDS	O
)	O
]	O
for	O
6	O
h	O
at	O
42	O
°	O
C	O
.	O

After	O
pre	O
-	O
hybridization	O
,	O
the	O
microarray	O
slides	O
were	O
incubated	O
with	O
'	O
pooled	O
'	O
Cy3	O
and	O
Cy5-labeled	O
probes	O
in	O
hybridization	O
solution	O
(	O
5	O
×	O
SSC	O
,	O
1	O
%	O
BSA	O
,	O
0.1	O
%	O
SDS	O
)	O
,	O
in	O
the	O
dark	O
at	O
42	O
°	O
C	O
for	O
18	O
h	O
,	O
and	O
then	O
washed	O
in	O
solution	O
I	O
(	O
1	O
×	O
SSC	O
,	O
0.2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
,	O
followed	O
by	O
solution	O
II	O
(	O
0.1	O
×	O
SSC	O
,	O
0.2	O
%	O
SDS	O
)	O
for	O
10	O
min	O
at	O
60	O
°	O
C	O
,	O
according	O
to	O
the	O
protocols	O
provided	O
by	O
Shanghai	O
BioStar	O
Genechip	O
,	O
Inc.	O
A	O
""""	O
dye	O
flip	O
""""	O
was	O
carried	O
out	O
to	O
control	O
for	O
any	O
bias	O
in	O
hybridization	O
signal	O
between	O
the	O
Cy	O
-	O
labeled	O
cDNA	O
probes	O
(	O
produced	O
for	O
two	O
distinct	O
mRNA	O
populations	O
)	O
.	O

The	O
slides	O
were	O
dried	O
and	O
scanned	O
(	O
ScanArray	O
4000	O
scanner	O
)	O
using	O
image	O
acquisition	O
software	O
(	O
Shanghai	O
BioStar	O
Genechip	O
Inc.	O
)	O
and	O
a	O
range	O
of	O
laser	O
power	O
and	O
photo	O
-	O
multiplier	O
tube	O
intensities	O
.	O

The	O
mean	O
hybridization	O
signal	O
(	O
derived	O
from	O
four	O
replicates	O
of	O
the	O
same	O
array	O
)	O
were	O
corrected	O
for	O
background	O
,	O
normalized	O
[	O
43	O
]	O
,	O
log2-transformed	O
and	O
then	O
subjected	O
to	O
statistical	O
analysis	O
employing	O
the	O
students	O
t	O
-	O
test	O
in	O
a	O
spreadsheet	O
(	O
Excel	O
,	O
Microsoft	O
,	O
USA	O
)	O
.	O

The	O
microarray	O
data	O
were	O
analysed	O
for	O
differential	O
cDNA	O
hybridization	O
(	O
>	O
2.0-fold	O
to	O
114.3-fold	O
)	O
between	O
L3	O
and	O
each	O
of	O
the	O
other	O
stages	O
(	O
eggs	O
,	O
lung	O
and	O
liver	O
L3s	O
,	O
L4	O
,	O
adult	O
female	O
and	O
adult	O
male	O
)	O
.	O

Verification	O
of	O
Differential	O
Hybridization	O
by	O
Reverse	O
Transcription	O
-	O
Coupled	O
Polymerase	O
Chain	O
Reaction	O
(	O
RT	O
-	O
PCR	O
)	O
Analysis	O
For	O
a	O
subset	O
(	O
n	O
=	O
17	O
)	O
of	O
representative	O
ESTs	O
(	O
rESTs	O
)	O
,	O
RT	O
-	O
PCR	O
was	O
used	O
to	O
verify	O
the	O
differential	O
transcription	O
recorded	O
by	O
microarray	O
analysis	O
.	O

Double	O
-	O
stranded	O
cDNA	O
was	O
synthesized	O
from	O
total	O
RNA	O
(	O
separately	O
)	O
from	O
each	O
stage	O
or	O
sex	O
of	O
A.	B
suum	I
using	O
reverse	O
transcriptase	O
(	O
Superscript	O
III	O
,	O
Invitrogen	O
)	O
.	O

Briefly	O
,	O
5	O
µg	O
of	O
total	O
RNA	O
were	O
added	O
to	O
14	O
µl	O
of	O
H2O	O
and	O
1	O
µl	O
of	O
oligo	O
d	O
(	O
T	O
)	O
n	O
=	O
12–18	O
primer	O
(	O
0.5	O
µg	O
/	O
µl	O
)	O
,	O
heated	O
to	O
70	O
°	O
C	O
for	O
10	O
min	O
and	O
chilled	O
on	O
ice	O
.	O

First-	O
and	O
second	O
-	O
strand	O
cDNAs	O
were	O
synthesized	O
via	O
the	O
addition	O
of	O
4	O
µl	O
of	O
first	O
-	O
strand	O
cDNA	O
buffer	O
(	O
250	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
8.3	O
,	O
375	O
mM	O
KCl	O
and	O
15	O
mM	O
MgCl2	O
)	O
,	O
2	O
µl	O
of	O
0.1	O
M	O
dithiothreitol	O
,	O
and	O
1	O
µl	O
of	O
10	O
mM	O
of	O
each	O
dNTP	O
,	O
followed	O
by	O
an	O
incubation	O
at	O
25	O
°	O
C	O
(	O
10	O
min	O
)	O
,	O
42	O
°	O
C	O
(	O
50	O
min	O
)	O
and	O
70	O
°	O
C	O
(	O
15	O
min	O
)	O
.	O

One	O
-	O
tenth	O
of	O
each	O
double	O
-	O
stranded	O
cDNA	O
produced	O
was	O
then	O
used	O
as	O
a	O
template	O
in	O
the	O
PCR	O
.	O

The	O
transcripts	O
were	O
amplified	O
from	O
individual	O
cDNAs	O
by	O
PCR	O
using	O
oligonucleotide	O
primers	O
(	O
sequences	O
available	O
upon	O
request	O
)	O
designed	O
to	O
each	O
EST	O
.	O

The	O
PCR	O
amplification	O
of	O
a	O
portion	O
(	O
209	O
bp	O
)	O
of	O
the	O
β	O
-	O
actin	O
gene	O
(	O
accession	O
no.	O
BI594141	O
)	O
using	O
forward	O
primer	O
(	O
5′-CTCGAAACAAGAATACGATG-3′	O
)	O
and	O
reverse	O
primer	O
(	O
5′-	O
ACATGTGCCGTTGTATGATG-3′	O
)	O
,	O
previously	O
determined	O
to	O
be	O
present	O
in	O
all	O
developmental	O
stages	O
and	O
both	O
sexes	O
of	O
A.	B
suum	I
[	O
44	O
]	O
,	O
served	O
as	O
a	O
positive	O
control	O
.	O

Samples	O
without	O
template	O
(	O
no	O
-	O
DNA	O
controls	O
)	O
were	O
included	O
in	O
each	O
PCR	O
run	O
.	O

The	O
following	O
cycling	O
conditions	O
were	O
employed	O
:	O
one	O
cycle	O
at	O
94	O
°	O
C	O
(	O
5	O
min	O
)	O
,	O
94	O
°	O
C	O
(	O
30	O
s	O
)	O
,	O
60	O
°	O
C	O
(	O
30	O
s	O
)	O
and	O
72	O
°	O
C	O
(	O
30	O
s	O
)	O
for	O
30	O
cycles	O
,	O
followed	O
by	O
a	O
final	O
extension	O
of	O
70	O
°	O
C	O
(	O
7	O
min	O
)	O
.	O

Following	O
the	O
PCR	O
,	O
5	O
µl	O
of	O
individual	O
amplicons	O
were	O
resolved	O
in	O
ethidium	O
bromide	O
-	O
stained	O
agarose	O
gels	O
(	O
2	O
%	O
)	O
and	O
then	O
photographed	O
upon	O
transillumination	O
.	O

The	O
relative	O
band	O
intensities	O
were	O
analyzed	O
using	O
UVIsoft	O
Image	O
Acquisition	O
and	O
Analysis	O
software	O
(	O
UVITEC	O
)	O
.	O

The	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
were	O
confirmed	O
by	O
direct	O
sequencing	O
using	O
the	O
same	O
primers	O
(	O
separately	O
)	O
as	O
employed	O
for	O
their	O
amplification	O
.	O

Sequencing	O
and	O
Bioinformatics	O
Analyses	O
Clones	O
from	O
the	O
SSH	O
cDNA	O
library	O
with	O
increased	O
hybridization	O
in	O
microarray	O
analysis	O
to	O
the	O
infective	O
L3	O
compared	O
with	O
other	O
stages	O
were	O
sequenced	O
using	O
standard	O
technology	O
[	O
45	O
]	O
.	O

The	O
nucleotide	O
sequences	O
have	O
been	O
deposited	O
in	O
the	O
GenBank	O
database	O
under	O
accession	O
numbers	O
ES290984-ES291074	O
.	O

Following	O
the	O
processing	O
of	O
the	O
sequences	O
(	O
i.e.	O
,	O
removal	O
of	O
vector	O
sequences	O
,	O
quality	O
assurance	O
and	O
clustering	O
)	O
,	O
contigs	O
or	O
singletons	O
from	O
individual	O
clusters	O
were	O
subjected	O
to	O
BLASTx	O
(	O
NCBI	O
:	O
www.ncbi.nlm.nih.gov	O
)	O
and	O
BLASTn	O
(	O
EMBL	O
-	O
EBI	O
Parasite	O
Genome	O
Blast	O
Server	O
:	O
www.ebi.ac.uk	O
)	O
analysis	O
to	O
identify	O
putative	O
homologues	O
in	O
C.	B
elegans	I
,	O
other	O
nematodes	O
and	O
other	O
organisms	O
(	O
e	O
-	O
value	O
of	O
≤1e-05	O
)	O
.	O

Peptides	O
inferred	O
from	O
ESTs	O
were	O
classified	O
functionally	O
using	O
Interproscan	O
(	O
available	O
at	O
http://www.ebi.ac.uk/InterProScan/	O
)	O
employing	O
the	O
default	O
search	O
parameters	O
.	O

WormBase	O
(	O
www.wormbase.org	O
)	O
was	O
interrogated	O
extensively	O
for	O
relevant	O
information	O
on	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
,	O
including	O
RNAi	O
phenotypic	O
,	O
transcriptomic	O
,	O
proteomic	O
and	O
interactomic	O
data	O
.	O

ESTs	O
with	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
and	O
other	O
nematodes	O
were	O
also	O
subjected	O
to	O
analysis	O
employing	O
the	O
KEGG	O
Orthology	O
-	O
Based	O
Annotation	O
System	O
(	O
KOBAS	O
)	O
(	O
www.kobas.cbi.pku.edu.cn	O
)	O
,	O
which	O
predicts	O
the	O
biochemical	O
pathways	O
in	O
which	O
molecules	O
are	O
involved	O
.	O

The	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
inferred	O
from	O
selected	O
ESTs	O
with	O
orthologues	O
in	O
C.	B
elegans	I
were	O
also	O
subjected	O
to	O
""""	O
secretome	O
analysis	O
""""	O
using	O
the	O
program	O
SignalP	O
v.2.0	O
www.cbs.dtu.dk/services/SignalP/	O
)	O
,	O
employing	O
both	O
the	O
neural	O
network	O
and	O
hidden	O
Markov	O
models	O
to	O
predict	O
signal	O
peptides	O
and/or	O
anchors	O
[	O
46	O
]	O
–	O
[	O
48	O
]	O
.	O

Also	O
,	O
transmembrane	O
domains	O
were	O
predicted	O
using	O
the	O
program	O
TMHMM	O
(	O
www.cbs.dtu.dk/services/TMHMM/	O
;	O
[	O
49	O
]	O
–	O
[	O
51	O
]	O
)	O
,	O
and	O
subcellular	O
localization	O
inferred	O
employing	O
the	O
program	O
WoLF	O
PSORT	O
(	O
http://wolfpsort.org/	O
;	O
[	O
52	O
]	O
)	O
.	O

The	O
method	O
established	O
by	O
Zhong	O
and	O
Sternberg	O
[	O
53	O
]	O
was	O
used	O
to	O
predict	O
the	O
interactions	O
for	O
C.	B
elegans	I
orthologues	O
of	O
the	O
L3-enriched	O
molecules	O
from	O
Ascaris	O
.	O

In	O
brief	O
,	O
interaction	O
,	O
phenotypic	O
,	O
expression	O
and	O
gene	O
ontology	O
data	O
from	O
fruitfly	B
,	O
yeast	B
,	O
mouse	B
and	O
human	B
were	O
integrated	O
using	O
a	O
naïve	O
Bayesian	O
model	O
to	O
predict	O
genetic	O
interactions	O
among	O
C.	B
elegans	I
genes	O
(	O
[	O
45	O
]	O
,	O
[	O
53	O
]	O
;	O
Zhong	O
and	O
Sternberg	O
,	O
unpublished	O
)	O
.	O

The	O
predicted	O
networks	O
resulting	O
from	O
the	O
analyses	O
were	O
saved	O
in	O
a	O
graphic	O
display	O
file	O
(	O
gdf	O
)	O
format	O
and	O
examined	O
using	O
the	O
graph	O
exploration	O
system	O
available	O
at	O
http://graphexploration.cond.org/.	O
Images	O
were	O
labeled	O
and	O
saved	O
in	O
the	O
joint	O
photographic	O
experts	O
group	O
(	O
jpeg	O
)	O
format	O
.	O

Results	O
To	O
identify	O
molecules	O
transcribed	O
abundantly	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
an	O
enriched	O
cDNA	O
library	O
was	O
constructed	O
by	O
SSH	O
.	O

From	O
a	O
total	O
of	O
3075	O
clones	O
from	O
this	O
library	O
,	O
2921	O
(	O
95	O
%	O
)	O
were	O
shown	O
to	O
contain	O
an	O
insert	O
(	O
which	O
could	O
be	O
amplified	O
by	O
PCR	O
)	O
.	O

From	O
2671	O
(	O
92	O
%	O
)	O
of	O
these	O
clones	O
,	O
amplicons	O
representing	O
single	O
bands	O
of	O
∼400	O
to	O
600	O
bp	O
in	O
size	O
were	O
produced	O
.	O

These	O
latter	O
amplicons	O
were	O
arrayed	O
(	O
in	O
duplicate	O
)	O
on	O
to	O
slides	O
and	O
then	O
hybridized	O
with	O
Cy3-labeled	O
L3-cDNA	O
or	O
with	O
Cy5-labeled	O
cDNA	O
from	O
eggs	O
,	O
liver	O
/	O
lung	O
L3s	O
,	O
L4s	O
,	O
adult	O
female	O
or	O
adult	O
male	O
of	O
Ascaris	O
.	O

Dye	O
flip	O
was	O
conducted	O
to	O
verify	O
the	O
hybridization	O
data	O
.	O

Of	O
the	O
2671	O
(	O
duplicate	O
)	O
spots	O
,	O
1526	O
had	O
a	O
significant	O
difference	O
in	O
hybridization	O
between	O
infective	O
L3	O
cDNA	O
and	O
cDNAs	O
from	O
all	O
other	O
stages	O
or	O
sexes	O
of	O
A.	B
suum	I
,	O
of	O
which	O
515	O
had	O
a	O
>	O
2.0-fold	O
increased	O
hybridization	O
for	O
the	O
L3	O
.	O

In	O
order	O
to	O
independently	O
verify	O
the	O
hybridization	O
results	O
in	O
the	O
microarray	O
,	O
a	O
PCR	O
-	O
based	O
analysis	O
of	O
a	O
selected	O
subset	O
(	O
n	O
=	O
17	O
)	O
clones	O
was	O
conducted	O
using	O
specific	O
primer	O
pairs	O
.	O

Having	O
verified	O
the	O
specificity	O
and	O
identity	O
of	O
individual	O
amplicons	O
by	O
sequencing	O
,	O
PCR	O
results	O
were	O
reproducible	O
(	O
based	O
on	O
multiple	O
runs	O
on	O
different	O
days	O
)	O
and	O
∼94	O
%	O
(	O
16	O
of	O
17	O
)	O
concordant	O
with	O
those	O
of	O
the	O
microarray	O
analysis	O
(	O
not	O
shown	O
)	O
.	O

There	O
was	O
complete	O
concordance	O
for	O
representative	O
clones	O
associated	O
with	O
a	O
differential	O
signal	O
of	O
≥3.0-fold	O
in	O
the	O
microarray	O
.	O

The	O
clones	O
linked	O
to	O
the	O
515	O
spots	O
representing	O
increased	O
transcription	O
(	O
>	O
2.0-fold	O
)	O
in	O
infective	O
L3	O
compared	O
with	O
the	O
other	O
developmental	O
stages	O
or	O
sexes	O
included	O
were	O
subjected	O
to	O
sequencing	O
.	O

The	O
498	O
sequences	O
(	O
length	O
:	O
550±115	O
bp	O
)	O
determined	O
were	O
then	O
subjected	O
to	O
detailed	O
bioinformatic	O
analyses	O
.	O

There	O
were	O
91	O
unique	O
clusters	O
(	O
accession	O
numbers	O
ES290984-ES291074	O
)	O
,	O
of	O
which	O
55	O
were	O
singletons	O
(	O
sequences	O
determined	O
once	O
)	O
.	O

Of	O
56	O
molecules	O
(	O
61.5	O
%	O
)	O
with	O
significant	O
similarity	O
to	O
sequences	O
other	O
than	O
A.	B
suum	I
in	O
the	O
databases	O
interrogated	O
,	O
50	O
(	O
54.9	O
%	O
)	O
had	O
C.	B
elegans	I
or	O
C.	B
briggsae	I
homologues	O
,	O
and	O
six	O
had	O
similarity	O
to	O
ESTs	O
already	O
sequenced	O
from	O
ascaridoid	O
and/or	O
other	O
parasitic	O
nematodes	O
,	O
and/or	O
other	O
organisms	O
(	O
Table	O
1	O
)	O
.	O

A	O
significant	O
proportion	O
(	O
38.4	O
%	O
)	O
did	O
not	O
have	O
any	O
similarity	O
in	O
sequence	O
to	O
any	O
organisms	O
for	O
which	O
data	O
are	O
presently	O
available	O
.	O

Comparative	O
analysis	O
specifically	O
against	O
A.	B
suum	I
EST	O
data	O
sets	O
(	O
n∼42,000	O
)	O
available	O
in	O
public	O
databases	O
confirmed	O
independently	O
that	O
the	O
majority	O
of	O
molecules	O
(	O
>	O
60	O
%	O
)	O
were	O
present	O
exclusively	O
in	O
the	O
infective	O
L3	O
stage	O
or	O
were	O
orphans	O
.	O

As	O
gene	O
ontology	O
(	O
GO	O
)	O
provides	O
a	O
hierarchy	O
that	O
unifies	O
the	O
descriptions	O
of	O
biological	O
,	O
cellular	O
and	O
molecular	O
functions	O
[	O
54	O
]	O
,	O
this	O
approach	O
was	O
employed	O
to	O
predict	O
the	O
classification	O
and	O
gene	O
function	O
of	O
molecules	O
enriched	O
in	O
infective	O
L3	O
of	O
A.	B
suum	I
.	O

A	O
summary	O
of	O
the	O
GO	O
categories	O
of	O
these	O
molecules	O
is	O
displayed	O
in	O
Fig.	O
1	O
.	O

Of	O
the	O
91	O
contigs	O
,	O
32	O
(	O
35	O
%	O
)	O
could	O
be	O
functionally	O
assigned	O
to	O
'	O
biological	O
process	O
'	O
(	O
n	O
=	O
38	O
)	O
,	O
'	O
cellular	O
component	O
'	O
(	O
n	O
=	O
17	O
)	O
and	O
'	O
molecular	O
function	O
'	O
(	O
n	O
=	O
64	O
)	O
.	O

The	O
most	O
common	O
subcategories	O
were	O
gluconeogenesis	O
(	O
13	O
%	O
)	O
and	O
metabolic	O
process	O
(	O
13	O
%	O
)	O
within	O
'	O
biological	O
process	O
'	O
,	O
extracellular	O
region	O
(	O
24	O
%	O
)	O
within	O
'	O
cellular	O
component	O
'	O
,	O
and	O
catalytic	O
activity	O
(	O
11	O
%	O
)	O
and	O
phosphoenolpyruvate	O
carboxykinase	O
activity	O
(	O
8	O
%	O
)	O
within	O
'	O
molecular	O
function	O
'	O
(	O
Table	O
S1	O
)	O
.	O

A	O
focused	O
KOBAS	O
analysis	O
inferred	O
the	O
50	O
C.	B
elegans	I
orthologues	O
/	O
homologues	O
to	O
be	O
involved	O
in	O
apoptosis	O
and	O
insulin	O
signaling	O
(	O
2	O
%	O
)	O
,	O
ATP	O
synthesis	O
(	O
2	O
%	O
)	O
,	O
carbon	O
metabolism	O
(	O
6	O
%	O
)	O
,	O
fatty	O
acid	O
biosynthesis	O
(	O
2	O
%	O
)	O
,	O
gap	O
junction	O
(	O
2	O
%	O
)	O
,	O
glucose	O
metabolism	O
(	O
6	O
%	O
)	O
or	O
porphyrin	O
metabolism	O
(	O
2	O
%	O
)	O
,	O
although	O
34	O
(	O
68	O
%	O
)	O
of	O
them	O
could	O
not	O
be	O
mapped	O
to	O
a	O
specific	O
metabolic	O
pathway	O
(	O
Table	O
2	O
)	O
.	O

Of	O
these	O
50	O
molecules	O
,	O
small	O
numbers	O
were	O
predicted	O
to	O
be	O
secreted	O
(	O
10	O
%	O
)	O
,	O
anchored	O
(	O
2	O
%	O
)	O
and/or	O
transmembrane	O
(	O
12	O
%	O
)	O
proteins	O
(	O
Table	O
2	O
)	O
.	O

Functionally	O
,	O
17	O
(	O
34	O
%	O
)	O
of	O
the	O
50	O
molecules	O
were	O
associated	O
with	O
(	O
non	O
-	O
wild	O
-	O
type	O
)	O
RNAi	O
phenotypes	O
in	O
C.	B
elegans	I
,	O
the	O
majority	O
displaying	O
embryonic	O
lethality	O
(	O
Emb	O
)	O
(	O
13	O
types	O
;	O
58.8	O
%	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
(	O
23.5	O
%	O
)	O
and	O
larval	O
lethality	O
(	O
Lvl	O
)	O
(	O
47	O
%	O
)	O
(	O
Table	O
2	O
)	O
.	O

Extending	O
this	O
analysis	O
,	O
a	O
relatively	O
complex	O
genetic	O
interaction	O
network	O
was	O
predicted	O
for	O
the	O
17	O
C.	B
elegans	I
orthologues	O
(	O
i.e.	O
,	O
with	O
non	O
-	O
wild	O
-	O
type	O
RNAi	O
phenotypes	O
)	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Statistically	O
highly	O
significant	O
interactions	O
were	O
predicted	O
for	O
nine	O
of	O
the	O
C.	B
elegans	I
genes	O
;	O
the	O
top	O
five	O
interactors	O
are	O
displayed	O
in	O
Fig.	O
2	O
.	O

The	O
gene	O
ontology	O
categories	O
for	O
eight	O
selected	O
C.	B
elegans	I
genes	O
(	O
F33D11.10	O
,	O
F55A12.8	O
,	O
kin-2	O
,	O
mec-12	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
)	O
included	O
:	O
embryonic	O
development	O
,	O
egg	O
hatching	O
,	O
larval	O
development	O
and/or	O
growth	O
.	O

The	O
other	O
categories	O
included	O
:	O
positive	O
regulation	O
of	O
growth	O
rate	O
(	O
F55A12.8	O
,	O
kin-2	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
)	O
and	O
gamete	O
generation	O
and	O
locomotory	O
behaviour	O
(	O
kin-2	O
,	O
mup-2	O
,	O
pab-1	O
and	O
F55A12.8	O
,	O
kin-2	O
,	O
mup-2	O
,	O
respectively	O
)	O
.	O

The	O
C.	B
elegans	I
homologue	O
egl-3	O
was	O
predicted	O
to	O
be	O
involved	O
in	O
proteolysis	O
(	O
see	O
www.wormbase.org	O
)	O
.	O

All	O
nine	O
C.	B
elegans	I
orthologues	O
were	O
predicted	O
to	O
interact	O
directly	O
with	O
a	O
total	O
of	O
296	O
(	O
range	O
:	O
5–75	O
)	O
other	O
genes	O
and	O
,	O
in	O
particular	O
,	O
a	O
direct	O
genetic	O
interaction	O
was	O
predicted	O
between	O
pab-1	O
and	O
T21B10.2	O
(	O
Fig.	O
2	O
)	O
.	O

The	O
296	O
interactors	O
were	O
associated	O
with	O
embryonic	O
and	O
larval	O
development	O
(	O
n	O
=	O
198	O
;	O
66.9	O
%	O
)	O
,	O
information	O
storage	O
and	O
processing	O
(	O
n	O
=	O
15	O
;	O
5.1	O
%	O
)	O
,	O
cellular	O
processes	O
and	O
signalling	O
(	O
n	O
=	O
45	O
;	O
15.2	O
%	O
)	O
and	O
metabolism	O
(	O
n	O
=	O
18	O
;	O
6.1	O
%	O
)	O
;	O
the	O
precise	O
function	O
of	O
some	O
of	O
the	O
interactors	O
(	O
n	O
=	O
20	O
;	O
6.7	O
%	O
)	O
is	O
presently	O
unknown	O
(	O
Table	O
S2	O
)	O
.	O

Discussion	O
The	O
present	O
study	O
investigated	O
transcripts	O
in	O
infective	O
L3s	O
of	O
A.	B
suum	I
using	O
a	O
genomic	O
-	O
bioinformatic	O
platform	O
.	O

The	O
focus	O
was	O
on	O
comparisons	O
with	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
,	O
because	O
the	O
entire	O
genome	O
sequence	O
of	O
this	O
nematode	O
is	O
known	O
[	O
9	O
]	O
and	O
because	O
there	O
is	O
a	O
wealth	O
of	O
information	O
on	O
the	O
localization	O
and	O
functionality	O
of	O
its	O
molecules	O
(	O
www.wormbase.org	O
;	O
http://elegans.bcgsc.bc.ca/knockout.shtml	O
)	O
.	O

The	O
functions	O
of	O
most	O
genes	O
in	O
C.	B
elegans	I
have	O
been	O
assessed	O
using	O
RNAi	O
(	O
e.g.	O
,	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
55	O
]	O
,	O
[	O
56	O
]	O
)	O
in	O
the	O
hermaphroditic	O
stage	O
,	O
whereas	O
there	O
is	O
a	O
paucity	O
of	O
functional	O
information	O
available	O
for	O
Ascaris	O
and	O
other	O
parasitic	O
nematodes	O
of	O
animals	O
[	O
57	O
]	O
,	O
[	O
58	O
]	O
.	O

Following	O
the	O
microarray	O
analysis	O
of	O
>	O
2500	O
ESTs	O
from	O
the	O
SSH	O
library	O
,	O
498	O
cDNAs	O
inferred	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
,	O
based	O
on	O
hybridization	O
signal	O
,	O
were	O
sequenced	O
and	O
subjected	O
to	O
comprehensive	O
in	O
silico	O
analyses	O
.	O

Of	O
the	O
91	O
clusters	O
of	O
molecules	O
categorized	O
,	O
50	O
(	O
54.9	O
%	O
)	O
had	O
C.	B
elegans	I
homologues	O
/	O
orthologues	O
with	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
could	O
be	O
mapped	O
to	O
key	O
pathways	O
.	O

The	O
statistically	O
significant	O
genetic	O
interactions	O
predicted	O
for	O
9	O
of	O
the	O
50	O
C.	B
elegans	I
orthologues	O
[	O
namely	O
egl-3	O
,	O
F33D11.10	O
,	O
F55A12.8	O
,	O
kin-2	O
,	O
mec-12	O
,	O
mup-2	O
,	O
pab-1	O
,	O
rpl-22	O
and	O
T21B10.2	O
(	O
=	O
enol-1	O
)	O
]	O
and	O
the	O
interaction	O
network	O
included	O
genes	O
encoding	O
kinases	O
,	O
alpha	O
-	O
tubulins	O
,	O
enolases	O
,	O
troponin	O
and	O
other	O
named	O
and	O
unnamed	O
proteins	O
.	O

Eight	O
of	O
these	O
molecules	O
(	O
enol-1	O
,	O
pab-1	O
,	O
F33D11.10	O
,	O
rpl-22	O
,	O
F55A12.8	O
mec-12	O
,	O
mup-2	O
and	O
kin-2	O
)	O
have	O
known	O
or	O
predicted	O
roles	O
in	O
embryonic	O
and	O
larval	O
growth	O
and	O
development	O
,	O
gamete	O
generation	O
,	O
locomotory	O
behaviour	O
or	O
other	O
biological	O
processes	O
in	O
C.	B
elegans	I
(	O
see	O
www.wormbase.org	O
)	O
.	O

The	O
enolase	O
encoded	O
by	O
enol-1	O
is	O
predicted	O
to	O
play	O
a	O
role	O
in	O
glycolysis	O
,	O
gluconeogenesis	O
,	O
phenylalanine	O
,	O
tyrosine	O
and	O
tryptophan	O
biosynthesis	O
(	O
cf	O
.	O

[	O
59	O
]	O
)	O
.	O

Since	O
glucose	O
is	O
the	O
main	O
source	O
for	O
ATP	O
production	O
,	O
the	O
alteration	O
in	O
these	O
key	O
glycolytic	O
enzymes	O
may	O
lead	O
to	O
cellular	O
dysfunction	O
,	O
such	O
as	O
impaired	O
ion	O
-	O
motive	O
ATPase	O
required	O
to	O
maintain	O
potential	O
gradients	O
,	O
operate	O
pumps	O
and	O
maintain	O
membrane	O
lipid	O
asymmetry	O
[	O
60	O
]	O
.	O

Bioinformatic	O
analysis	O
for	O
transmembrane	O
helices	O
(	O
TMHMM	O
)	O
and	O
peptide	O
signal	O
sequences	O
(	O
SignalP	O
)	O
predicted	O
ENOL-1	O
to	O
be	O
a	O
non	O
-	O
secreted	O
protein	O
localized	O
to	O
the	O
cytoplasm	O
(	O
cf	O
.	O

Table	O
2	O
)	O
.	O

Nonetheless	O
,	O
enolases	O
are	O
often	O
detected	O
in	O
the	O
excretory	O
/	O
secretory	O
(	O
ES	O
)	O
products	O
of	O
parasitic	O
helminths	O
,	O
including	O
adult	O
A.	B
suum	I
[	O
61	O
]	O
,	O
and	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
triggering	O
of	O
nitric	O
oxide	O
production	O
by	O
host	O
cells	O
.	O

The	O
enol-1	O
orthologue	O
of	O
C.	B
elegans	I
has	O
been	O
predicted	O
to	O
interact	O
specifically	O
with	O
the	O
polyadenylate	O
binding	O
protein	O
gene	O
,	O
pab-1	O
,	O
inferred	O
to	O
be	O
involved	O
in	O
coordinated	O
gene	O
transcription	O
and	O
expression	O
during	O
normal	O
larval	O
development	O
[	O
16	O
]	O
.	O

Poly	O
(	O
A	O
)	O
-binding	O
proteins	O
(	O
PABPs	O
)	O
are	O
recognized	O
to	O
be	O
central	O
to	O
the	O
regulation	O
of	O
mRNA	O
translation	O
and	O
stability	O
[	O
62	O
]	O
.	O

Present	O
evidence	O
suggests	O
that	O
the	O
expression	O
of	O
PAB-1	O
is	O
regulated	O
by	O
an	O
oligo	O
-	O
pyrimidine	O
tract	O
in	O
response	O
to	O
cell	O
growth	O
and	O
relates	O
to	O
coordinated	O
growth	O
regulation	O
in	O
C.	B
elegans	I
[	O
62	O
]	O
.	O

Furthermore	O
,	O
gene	O
silencing	O
of	O
pab-1	O
and	O
its	O
selected	O
interactors	O
(	O
see	O
Fig.	O
2	O
)	O
leads	O
to	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
,	O
slow	O
growth	O
(	O
Slo	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
phenotypes	O
(	O
see	O
www.wormbase.org	O
)	O
.	O

Another	O
gene	O
(	O
F33D11.10	O
;	O
EST	O
code	O
4F10	O
;	O
see	O
Table	O
2	O
)	O
which	O
encodes	O
an	O
ATP	O
-	O
dependent	O
RNA	O
helicase	O
and	O
is	O
associated	O
with	O
embryonic	O
lethal	O
(	O
Emb	O
)	O
and	O
larval	O
lethal	O
(	O
Lvl	O
)	O
RNAi	O
phenotypes	O
,	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
infective	O
L3s	O
of	O
A.	B
suum	I
.	O

Helicases	O
are	O
involved	O
in	O
a	O
variety	O
of	O
RNA	O
metabolic	O
processes	O
,	O
including	O
translation	O
initiation	O
,	O
pre	O
-	O
mRNA	O
splicing	O
,	O
pre	O
-	O
rRNA	O
processing	O
,	O
rRNA	O
maturation	O
and	O
RNA	O
degradation	O
[	O
63	O
]	O
,	O
and	O
are	O
crucial	O
for	O
life	O
cycle	O
progression	O
,	O
sex	O
determination	O
and	O
early	O
embryogenesis	O
in	O
C.	B
elegans	I
[	O
60	O
]	O
.	O

The	O
high	O
transcription	O
levels	O
of	O
a	O
homologue	O
/	O
orthologue	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
might	O
suggest	O
a	O
similar	O
role	O
in	O
this	O
ascaridoid	O
.	O

Similarly	O
,	O
the	O
coordination	O
of	O
the	O
expression	O
of	O
a	O
large	O
number	O
of	O
genes	O
is	O
required	O
for	O
normal	O
growth	O
and	O
cell	O
proliferation	O
during	O
larval	O
development	O
.	O

The	O
high	O
transcription	O
level	O
for	O
the	O
ribosomal	O
protein	O
gene	O
homologue	O
rpl-22	O
(	O
large	O
subunit	O
family	O
member	O
;	O
EST	O
code	O
26G12	O
,	O
see	O
Table	O
2	O
)	O
in	O
the	O
infective	O
L3	O
of	O
A.	B
suum	I
compared	O
with	O
other	O
developmental	O
stages	O
is	O
likely	O
to	O
reflect	O
the	O
substantial	O
rate	O
of	O
cell	O
growth	O
in	O
this	O
stage	O
[	O
64	O
]	O
.	O

The	O
gene	O
(	O
F55A12.8	O
,	O
EST	O
code	O
4G11	O
;	O
see	O
Table	O
2	O
)	O
encoding	O
an	O
acetyl	O
-	O
transferase	O
with	O
a	O
putative	O
ATPase	O
domain	O
,	O
shown	O
to	O
be	O
enriched	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
,	O
was	O
predicted	O
to	O
interact	O
with	O
75	O
other	O
genes	O
all	O
involved	O
in	O
energy	O
production	O
and/or	O
RNA	O
processing	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Several	O
molecules	O
involved	O
in	O
ATP	O
synthesis	O
and	O
mitochondrial	O
pathways	O
(	O
e.g.	O
,	O
cytochrome	O
oxidase	O
c	O
subunits	O
1	O
,	O
2	O
and	O
3	O
,	O
ADP	O
/	O
ATP	O
translocases	O
,	O
NADH	O
dehydrogenases	O
,	O
ATPases	O
and	O
ATP	O
synthetases	O
)	O
have	O
been	O
reported	O
previously	O
to	O
be	O
highly	O
represented	O
in	O
the	O
L3	O
stage	O
of	O
Anisakis	B
simplex	I
[	O
65	O
]	O
,	O
thus	O
supporting	O
the	O
proposal	O
that	O
substantial	O
energy	O
is	O
required	O
for	O
larval	O
development	O
as	O
well	O
as	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
and	O
the	O
invasion	O
of	O
the	O
host	O
.	O

There	O
is	O
also	O
likely	O
to	O
be	O
a	O
substantial	O
energy	O
requirement	O
for	O
muscle	O
contraction	O
linked	O
to	O
larval	O
motility	O
in	O
A.	B
suum	I
,	O
as	O
the	O
L3s	O
penetrate	O
the	O
caecal	O
wall	O
in	O
the	O
porcine	O
host	O
,	O
before	O
undergoing	O
hepato	O
-	O
pulmonary	O
migration	O
[	O
35	O
]	O
.	O

Accordingly	O
,	O
genes	O
encoding	O
a	O
specialized	O
tubulin	O
expressed	O
in	O
mechanoreceptors	O
(	O
mec-12	O
,	O
EST	O
code	O
13E09	O
)	O
and	O
a	O
troponin	O
(	O
mup-2	O
,	O
EST	O
code	O
01G03	O
;	O
see	O
Table	O
2	O
)	O
,	O
both	O
predicted	O
to	O
interact	O
with	O
a	O
total	O
number	O
of	O
32	O
tubulin-	O
and	O
myosin	O
-	O
encoding	O
genes	O
,	O
also	O
supported	O
a	O
link	O
to	O
extensive	O
muscle	O
contraction	O
and	O
motility	O
in	O
A.	B
suum	I
L3s	O
.	O

Also	O
,	O
neuroactive	O
peptides	O
are	O
required	O
to	O
regulate	O
the	O
responsiveness	O
of	O
nematode	O
larvae	O
to	O
mechanical	O
stimuli	O
[	O
66	O
]	O
.	O

A	O
homologue	O
encoded	O
by	O
egl-3	O
was	O
shown	O
to	O
be	O
highly	O
transcribed	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
;	O
EGL-3	O
is	O
predicted	O
to	O
be	O
a	O
pro	O
-	O
hormone	O
convertase	O
involved	O
in	O
the	O
maturation	O
of	O
neuropeptides	O
and	O
could	O
be	O
associated	O
with	O
mechano	O
-	O
sensory	O
responses	O
and	O
touch	O
sensitivity	O
linked	O
to	O
the	O
host	O
invasion	O
.	O

A	O
regulatory	O
subunit	O
of	O
a	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
(	O
kin-2	O
,	O
EST	O
code	O
22H01	O
;	O
see	O
Table	O
2	O
)	O
was	O
predicted	O
to	O
interact	O
with	O
72	O
other	O
genes	O
all	O
involved	O
in	O
diverse	O
cellular	O
processes	O
,	O
such	O
as	O
nuclear	O
trafficking	O
,	O
and	O
DNA	O
replication	O
and	O
repair	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Based	O
on	O
gene	O
ontology	O
terms	O
,	O
kin-2	O
is	O
implicated	O
in	O
gamete	O
generation	O
,	O
growth	O
,	O
larval	O
development	O
,	O
post	O
-	O
embryonic	O
body	O
morphogenesis	O
,	O
signal	O
transduction	O
and/or	O
protein	O
amino	O
acid	O
phosphorylation	O
(	O
see	O
Table	O
S2	O
)	O
.	O

Gene	O
silencing	O
of	O
kin-2	O
in	O
C.	B
elegans	I
leads	O
to	O
phenotypes	O
,	O
such	O
as	O
larval	O
lethal	O
(	O
Lvl	O
)	O
,	O
larval	O
arrest	O
(	O
Lva	O
)	O
,	O
body	O
morphology	O
defect	O
(	O
Bmd	O
)	O
,	O
dumpy	O
(	O
Dpy	O
)	O
,	O
uncoordinated	O
(	O
Unc	O
)	O
and	O
sterile	O
progeny	O
(	O
Stp	O
)	O
(	O
www.wormbase.org	O
)	O
,	O
suggesting	O
that	O
its	O
homologue	O
in	O
A.	B
suum	I
is	O
central	O
to	O
larval	O
maturation	O
.	O

The	O
KOBAS	O
analysis	O
predicted	O
the	O
protein	O
KIN-2	O
to	O
be	O
involved	O
in	O
the	O
insulin	O
-	O
signaling	O
pathway	O
,	O
previously	O
implicated	O
in	O
controlling	O
the	O
exit	O
from	O
dauer	O
in	O
C.	B
elegans	I
and	O
the	O
activation	O
of	O
L3s	O
of	O
the	O
canine	B
hookworm	I
,	O
Ancylostoma	B
caninum	I
,	O
following	O
exsheathment	O
[	O
67	O
]	O
.	O

In	O
a	O
recent	O
study	O
,	O
Brand	O
and	O
Hawdon	O
[	O
68	O
]	O
were	O
able	O
to	O
inhibit	O
(	O
with	O
a	O
phosphoinositide-3-OH	O
-	O
kinase	O
inhibitor	O
)	O
the	O
activation	O
of	O
infective	O
L3s	O
of	O
both	O
of	O
the	O
hookworms	O
Ancylostoma	B
caninum	I
and	O
Ancylostoma	B
ceylanicum	I
via	O
the	O
insulin	O
signaling	O
pathway	O
,	O
thus	O
lending	O
some	O
credence	O
to	O
the	O
hypothesis	O
that	O
this	O
pathway	O
plays	O
an	O
critical	O
role	O
in	O
regulating	O
the	O
transition	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
[	O
68	O
]	O
.	O

Recently	O
,	O
it	O
has	O
been	O
proposed	O
that	O
transcriptional	O
and	O
feeding	O
responses	O
to	O
serum	O
-	O
stimulation	O
in	O
Ancylostoma	B
caninum	I
are	O
regulated	O
by	O
parallel	O
systems	O
,	O
with	O
the	O
insulin	O
signaling	O
pathway	O
playing	O
a	O
significant	O
role	O
in	O
the	O
'	O
resumption	O
of	O
feeding	O
'	O
in	O
activated	O
larvae	O
[	O
69	O
]	O
.	O

Protein	O
kinases	O
are	O
also	O
likely	O
to	O
be	O
involved	O
in	O
pathways	O
linked	O
to	O
sexual	O
maturation	O
in	O
developing	O
larvae	O
.	O

As	O
already	O
proposed	O
for	O
adult	O
stages	O
of	O
H.	B
contortus	I
[	O
45	O
]	O
,	O
the	O
protein	O
kinase	O
gene	O
cdk-1	O
is	O
predicted	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
germline	O
,	O
oogenesis	O
and	O
spermiogenesis	O
pathways	O
of	O
this	O
parasitic	O
nematode	O
.	O

Other	O
protein	O
kinases	O
,	O
such	O
as	O
PEPCK	O
,	O
and	O
phosphatases	O
,	O
were	O
shown	O
herein	O
to	O
be	O
transcribed	O
at	O
high	O
levels	O
in	O
the	O
L3	O
stage	O
compared	O
with	O
other	O
developmental	O
stages	O
of	O
A.	B
suum	I
(	O
see	O
Table	O
2	O
)	O
,	O
which	O
is	O
in	O
accordance	O
to	O
findings	O
reported	O
recently	O
for	O
Anisakis	B
simplex	I
[	O
65	O
]	O
.	O

Due	O
to	O
their	O
major	O
regulatory	O
effects	O
in	O
eukaryotic	O
signaling	O
events	O
and	O
regulatory	O
and	O
sensory	O
functions	O
,	O
protein	O
kinases	O
have	O
been	O
considered	O
interesting	O
targets	O
for	O
anti	O
-	O
parasitic	O
drugs	O
[	O
70	O
]	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
has	O
given	O
some	O
interesting	O
insights	O
into	O
early	O
molecular	O
processes	O
in	O
the	O
L3	O
of	O
A.	B
suum	I
.	O

Approximately	O
60	O
%	O
of	O
the	O
transcripts	O
enriched	O
in	O
the	O
L3	O
stage	O
of	O
A.	B
suum	I
have	O
homologues	O
/	O
orthologues	O
in	O
C.	B
elegans	I
.	O

The	O
bioinformatic	O
analyses	O
of	O
selected	O
molecules	O
suggest	O
that	O
a	O
complex	O
genetic	O
network	O
regulates	O
or	O
controls	O
larval	O
growth	O
and	O
development	O
in	O
A.	B
suum	I
L3s	O
,	O
and	O
some	O
of	O
these	O
might	O
be	O
involved	O
in	O
or	O
regulate	O
the	O
switch	O
from	O
the	O
free	O
-	O
living	O
to	O
the	O
parasitic	O
stage	O
.	O

Some	O
caution	O
is	O
warranted	O
in	O
drawing	O
conclusions	O
regarding	O
molecular	O
mechanisms	O
regulating	O
the	O
transition	O
to	O
parasitism	O
in	O
parasitic	O
nematodes	O
from	O
information	O
on	O
C.	B
elegans	I
,	O
as	O
latter	O
is	O
a	O
free	O
-	O
living	O
nematode	O
.	O

Also	O
,	O
while	O
the	O
method	O
of	O
data	O
integration	O
is	O
essential	O
for	O
the	O
reliable	O
prediction	O
of	O
genetic	O
interactions	O
,	O
it	O
might	O
limit	O
the	O
capacity	O
of	O
the	O
approach	O
somewhat	O
to	O
infer	O
nematode	O
-	O
specific	O
interactions	O
.	O

As	O
additional	O
datasets	O
of	O
genes	O
and	O
gene	O
functions	O
become	O
available	O
for	O
various	O
parasitic	O
nematodes	O
,	O
more	O
informed	O
inferences	O
can	O
be	O
made	O
regarding	O
the	O
functions	O
of	O
nematode	O
-	O
specific	O
genes	O
,	O
particularly	O
those	O
involved	O
in	O
the	O
transition	O
to	O
parasitism	O
.	O

The	O
imminent	O
genome	O
sequence	O
of	O
A.	B
suum	I
(	O
http://www.sanger.ac.uk/Projects/Helminths/	O
)	O
should	O
all	O
assist	O
in	O
this	O
endeavour	O
.	O

Also	O
,	O
functional	O
analysis	O
of	O
selected	O
molecules	O
representing	O
selected	O
ESTs	O
identified	O
herein	O
,	O
utilizing	O
gene	O
silencing	O
approaches	O
established	O
recently	O
[	O
33	O
]	O
,	O
[	O
34	O
]	O
,	O
could	O
provide	O
some	O
insights	O
into	O
developmental	O
processes	O
in	O
Ascaris	O
and	O
related	O
ascaridoid	O
nematodes	O
and	O
provide	O
avenues	O
for	O
the	O
development	O
of	O
novel	O
approaches	O
for	O
their	O
control	O
.	O

Supporting	O
Information	O

Emergence	O
of	O
Delayed	O
Methylmercury	O
Toxicity	O
after	O
Perinatal	O
Exposure	O
in	O
Metallothionein	O
-	O
Null	O
and	O
Wild	O
-	O
Type	O
C57BL	O
Mice	B
Abstract	O
Background	O
Although	O
a	O
long	O
latency	O
period	O
of	O
toxicity	O
after	O
exposure	O
to	O
methylmercury	O
(	O
MeHg	O
)	O
is	O
known	O
to	O
exist	O
in	O
humans	B
,	O
few	O
animal	O
studies	O
have	O
addressed	O
this	O
issue	O
.	O

Substantiation	O
of	O
delayed	O
MeHg	O
toxicity	O
in	O
animals	O
would	O
affect	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
.	O

Objectives	O
Our	O
goal	O
in	O
this	O
study	O
was	O
to	O
demonstrate	O
the	O
existence	O
of	O
a	O
latency	O
period	O
in	O
a	O
rodent	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
perinatal	O
MeHg	O
exposure	O
becomes	O
apparent	O
only	O
later	O
in	O
life	O
.	O

Our	O
study	O
included	O
metallothionein	O
(	O
MT	O
)	O
knockout	O
mice	B
because	O
studies	O
have	O
suggested	O
the	O
potential	O
susceptibility	O
of	O
this	O
strain	O
to	O
the	O
neurodevelopmental	O
toxicity	O
of	O
MeHg	O
.	O

Methods	O
Pregnant	O
MT	O
-	O
null	O
and	O
wild	O
-	O
type	O
C57Bl	O
/	O
6J	O
mice	B
were	O
exposed	O
to	O
MeHg	O
through	O
their	O
diet	O
containing	O
5	O
μg	O
Hg	O
/	O
g	O
during	O
gestation	O
and	O
early	O
lactation	O
.	O

We	O
examined	O
behavioral	O
functions	O
of	O
the	O
offspring	O
using	O
frequently	O
used	O
paradigms	O
,	O
including	O
open	O
field	O
behavior	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
the	O
Morris	O
water	O
maze	O
(	O
MM	O
)	O
,	O
at	O
ages	O
of	O
12–13	O
and	O
52–53	O
weeks	O
.	O

Results	O
At	O
12	O
weeks	O
of	O
age	O
,	O
behavioral	O
effects	O
of	O
MeHg	O
were	O
not	O
detected	O
,	O
except	O
for	O
OPF	O
performance	O
in	O
MeHg	O
-	O
exposed	O
MT	O
-	O
null	O
females	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
showed	O
poorer	O
performance	O
both	O
in	O
PA	O
and	O
MM	O
,	O
and	O
their	O
OPF	O
activity	O
differed	O
from	O
controls	O
.	O

These	O
effects	O
of	O
MeHg	O
appeared	O
exaggerated	O
in	O
the	O
MT	O
-	O
null	O
strain	O
.	O

The	O
brain	O
Hg	O
concentration	O
had	O
leveled	O
off	O
by	O
13	O
weeks	O
of	O
age	O
.	O

Conclusions	O
The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
long	O
latency	O
period	O
after	O
perinatal	O
exposure	O
to	O
low	O
-	O
level	O
MeHg	O
,	O
in	O
which	O
the	O
behavioral	O
effects	O
emerged	O
long	O
after	O
the	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
levels	O
.	O

Hence	O
,	O
the	O
initial	O
toxicologic	O
event	O
responsible	O
for	O
the	O
late	O
effects	O
should	O
have	O
occurred	O
before	O
this	O
leveling	O
-	O
off	O
of	O
brain	O
Hg	O
.	O

Methylmercury	O
(	O
MeHg	O
)	O
poses	O
serious	O
and	O
practical	O
concerns	O
for	O
human	B
populations	O
regarding	O
perinatal	O
exposure	O
.	O

Fish	O
,	O
especially	O
large	O
predator	O
(	O
carnivore	O
)	O
fish	O
species	O
,	O
accumulate	O
high	O
concentrations	O
of	O
MeHg	O
through	O
the	O
marine	O
food	O
chain	O
,	O
and	O
exposure	O
of	O
pregnant	O
women	O
to	O
MeHg	O
through	O
the	O
consumption	O
of	O
fish	O
has	O
evoked	O
widespread	O
concern	O
due	O
to	O
potential	O
effects	O
on	O
offspring	O
.	O

Two	O
large	O
-	O
scale	O
cohort	O
studies	O
in	O
fish	O
-	O
eating	O
populations	O
of	O
Seychelles	O
and	O
Faroe	O
islanders	O
are	O
being	O
conducted	O
;	O
although	O
the	O
former	O
has	O
not	O
found	O
consistent	O
adverse	O
developmental	O
effects	O
of	O
MeHg	O
(	O
Myers	O
et	O
al.	O
2007	O
)	O
,	O
the	O
latter	O
has	O
reported	O
adverse	O
effects	O
(	O
Debes	O
et	O
al.	O
2006	O
)	O
.	O

Fundamental	O
reasons	O
for	O
this	O
discrepancy	O
have	O
not	O
been	O
completely	O
elucidated	O
,	O
and	O
many	O
questions	O
remain	O
regarding	O
the	O
neurotoxicity	O
of	O
MeHg	O
,	O
despite	O
extensive	O
study	O
.	O

Among	O
the	O
unanswered	O
questions	O
is	O
whether	O
there	O
is	O
a	O
long	O
latency	O
period	O
for	O
behavioral	O
manifestations	O
after	O
exposure	O
to	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
Landrigan	O
et	O
al.	O
2005	O
;	O
Rice	O
1996	O
;	O
Weiss	O
et	O
al.	O
2005a	O
,	O
2005b	O
)	O
.	O

Typical	O
examples	O
of	O
latent	O
toxicity	O
in	O
humans	B
,	O
including	O
both	O
acute	O
and	O
chronic	O
MeHg	O
exposures	O
,	O
have	O
been	O
described	O
in	O
detail	O
elsewhere	O
(	O
Weiss	O
et	O
al.	O
2005a	O
)	O
.	O

Davidson	O
et	O
al.	O
(	O
2006	O
)	O
recently	O
suggested	O
that	O
effects	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
may	O
emerge	O
9	O
years	O
after	O
birth	O
in	O
the	O
Seychelles	O
cohort	O
.	O

Consequently	O
,	O
risk	O
assessments	O
of	O
MeHg	O
exposure	O
could	O
be	O
inaccurate	O
because	O
studies	O
(	O
human	B
or	O
animal	O
)	O
usually	O
do	O
not	O
focus	O
on	O
later	O
stages	O
of	O
life	O
and	O
therefore	O
could	O
miss	O
delayed	O
effects	O
.	O

The	O
possibility	O
of	O
delayed	O
toxicity	O
is	O
exemplified	O
by	O
the	O
expanded	O
Barker	O
hypothesis	O
,	O
which	O
posits	O
that	O
the	O
origin	O
of	O
some	O
neurodegenerative	O
diseases	O
such	O
as	O
Parkinson	O
and	O
Alzheimer	O
diseases	O
lies	O
in	O
early	O
exposure	O
to	O
environmental	O
chemicals	O
(	O
Landrigan	O
et	O
al.	O
2005	O
)	O
.	O

Although	O
epidemiologic	O
evidence	O
would	O
be	O
ideal	O
for	O
exploring	O
the	O
possibility	O
of	O
delayed	O
toxicity	O
(	O
and	O
,	O
indeed	O
,	O
data	O
from	O
epidemiologic	O
studies	O
form	O
the	O
basis	O
of	O
current	O
risk	O
assessment	O
for	O
developmental	O
toxicity	O
of	O
MeHg	O
)	O
,	O
considering	O
the	O
complex	O
effects	O
of	O
numerous	O
potential	O
confounders	O
and	O
the	O
existence	O
of	O
multiple	O
exposures	O
in	O
human	B
populations	O
,	O
animal	O
models	O
would	O
likely	O
make	O
important	O
contributions	O
to	O
this	O
field	O
.	O

Although	O
numerous	O
animal	O
studies	O
have	O
described	O
the	O
developmental	O
neurotoxicity	O
of	O
MeHg	O
(	O
Watanabe	O
and	O
Satoh	O
,	O
1996	O
)	O
,	O
few	O
have	O
addressed	O
the	O
latency	O
issue	O
.	O

Few	O
studies	O
have	O
evaluated	O
the	O
neurobehavioral	O
effects	O
in	O
rodents	O
longitudinally	O
beyond	O
6	O
months	O
after	O
perinatal	O
exposure	O
.	O

Spyker	O
(	O
1975	O
)	O
addressed	O
this	O
issue	O
in	O
her	O
pioneering	O
work	O
,	O
reporting	O
the	O
late	O
development	O
of	O
behavioral	O
toxicity	O
in	O
mice	B
prenatally	O
exposed	O
to	O
MeHg	O
;	O
it	O
appeared	O
,	O
however	O
,	O
that	O
the	O
substantial	O
mortality	O
and	O
retarded	O
growth	O
among	O
the	O
exposed	O
mice	B
were	O
apparent	O
before	O
weaning	O
,	O
indicating	O
that	O
the	O
doses	O
used	O
(	O
even	O
though	O
some	O
lower	O
dose	O
levels	O
were	O
included	O
)	O
exerted	O
severe	O
toxicity	O
.	O

Using	O
a	O
relatively	O
complex	O
schedule	O
-	O
controlled	O
operant	O
behavior	O
method	O
,	O
rats	B
whose	O
parents	O
were	O
exposed	O
to	O
MeHg	O
(	O
0.5	O
or	O
6.4	O
mg	O
/	O
L	O
)	O
from	O
4	O
weeks	O
before	O
mating	O
and	O
continuing	O
to	O
postnatal	O
day	O
(	O
PND	O
)	O
16	O
were	O
shown	O
to	O
be	O
less	O
sensitive	O
to	O
a	O
change	O
in	O
the	O
reinforcement	O
schedule	O
than	O
were	O
their	O
nonexposed	O
counterparts	O
at	O
28–32	O
months	O
of	O
age	O
(	O
Newland	O
et	O
al.	O
2004	O
)	O
.	O

Mice	B
that	O
were	O
perinatally	O
exposed	O
to	O
1	O
or	O
3	O
mg	O
/	O
L	O
MeHg	O
in	O
drinking	O
water	O
did	O
not	O
show	O
significant	O
deviation	O
from	O
controls	O
in	O
behavioral	O
performance	O
(	O
motor	O
performance	O
,	O
memory	O
,	O
and	O
learning	O
)	O
at	O
5	O
,	O
15	O
,	O
or	O
26	O
months	O
of	O
age	O
,	O
but	O
the	O
lifetime	O
-	O
exposed	O
groups	O
did	O
show	O
a	O
significant	O
deviation	O
(	O
Weiss	O
et	O
al.	O
2005c	O
)	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
(	O
i.e.	O
,	O
the	O
absence	O
of	O
effects	O
earlier	O
in	O
life	O
followed	O
by	O
the	O
emergence	O
of	O
effects	O
at	O
a	O
later	O
stage	O
of	O
life	O
)	O
has	O
not	O
been	O
demonstrated	O
in	O
any	O
rodent	O
study	O
.	O

In	O
nonhuman	O
primates	O
,	O
delayed	O
emergence	O
of	O
the	O
signs	O
of	O
neurotoxicity	O
was	O
observed	O
several	O
years	O
after	O
the	O
cessation	O
of	O
a	O
7-year	O
postnatal	O
exposure	O
(	O
Rice	O
1996	O
)	O
.	O

Metallothionein	O
(	O
MT	O
)	O
protects	O
against	O
the	O
toxicities	O
of	O
a	O
variety	O
of	O
metals	O
.	O

We	O
examined	O
the	O
neurotoxicity	O
and	O
developmental	O
toxicity	O
of	O
metallic	O
Hg	O
in	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	B
(	O
Yoshida	O
et	O
al.	O
2004	O
)	O
and	O
demonstrated	O
the	O
susceptibility	O
of	O
this	O
genetically	O
manipulated	O
strain	O
to	O
the	O
toxicity	O
of	O
metallic	O
Hg	O
.	O

In	O
contrast	O
to	O
metallic	O
Hg	O
,	O
MeHg	O
does	O
not	O
induce	O
MT	O
,	O
and	O
MT	O
would	O
not	O
substantially	O
influence	O
the	O
kinetics	O
of	O
MeHg	O
(	O
Yasutake	O
et	O
al.	O
1998	O
)	O
.	O

Several	O
reports	O
,	O
however	O
,	O
have	O
demonstrated	O
protective	O
effects	O
of	O
MT	O
against	O
MeHg	O
toxicity	O
,	O
which	O
was	O
ascribed	O
to	O
the	O
radical	O
scavenging	O
effect	O
of	O
MT	O
(	O
Yao	O
et	O
al.	O
2000	O
)	O
.	O

We	O
also	O
showed	O
that	O
perinatal	O
exposure	O
to	O
MeHg	O
results	O
in	O
altered	O
metabolism	O
of	O
thyroid	O
hormones	O
in	O
neonates	O
that	O
was	O
more	O
distinct	O
in	O
MT	O
-	O
null	O
strains	O
than	O
their	O
wild	O
-	O
type	O
counterparts	O
(	O
Mori	O
et	O
al.	O
2006	O
)	O
.	O

The	O
vulnerability	O
of	O
the	O
MT	O
-	O
null	O
strain	O
suggests	O
that	O
delayed	O
neurobehavioral	O
toxicity	O
due	O
to	O
MeHg	O
,	O
if	O
it	O
does	O
exist	O
,	O
might	O
be	O
more	O
distinctive	O
in	O
this	O
strain	O
.	O

By	O
utilizing	O
the	O
MT	O
-	O
null	O
strain	O
,	O
we	O
aimed	O
to	O
answer	O
the	O
following	O
two	O
questions	O
:	O
First	O
,	O
could	O
we	O
generate	O
a	O
model	O
in	O
which	O
the	O
toxicity	O
of	O
MeHg	O
would	O
emerge	O
or	O
at	O
least	O
become	O
exaggerated	O
later	O
in	O
life	O
as	O
opposed	O
to	O
earlier	O
in	O
life	O
(	O
i.e.	O
,	O
at	O
3–6	O
months	O
,	O
which	O
was	O
the	O
timing	O
for	O
most	O
of	O
the	O
earlier	O
studies	O
that	O
used	O
behavioral	O
evaluations	O
)	O
?	O

Second	O
,	O
would	O
the	O
MT	O
-	O
null	O
strain	O
be	O
affected	O
more	O
than	O
its	O
parent	O
C57BL	O
strain	O
?	O

Answering	O
either	O
of	O
these	O
questions	O
not	O
only	O
could	O
influence	O
the	O
risk	O
evaluation	O
of	O
MeHg	O
,	O
but	O
it	O
could	O
also	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
toxicity	O
for	O
perinatal	O
MeHg	O
exposure	O
.	O

To	O
address	O
these	O
issues	O
,	O
we	O
used	O
three	O
behavioral	O
paradigms	O
,	O
the	O
open	O
field	O
(	O
OPF	O
)	O
,	O
passive	O
avoidance	O
(	O
PA	O
)	O
,	O
and	O
Morris	O
(	O
water	O
)	O
maze	O
(	O
MM	O
)	O
tests	O
,	O
which	O
are	O
often	O
used	O
in	O
this	O
field	O
and	O
which	O
we	O
used	O
in	O
our	O
previous	O
studies	O
on	O
the	O
effects	O
of	O
Hg	O
vapor	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2006	O
)	O
.	O

Performances	O
in	O
the	O
MM	O
and	O
PA	O
are	O
said	O
to	O
be	O
the	O
most	O
sensitive	O
to	O
aging	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
.	O

We	O
used	O
a	O
dose	O
of	O
5	O
μg	O
MeHg	O
/	O
g	O
in	O
the	O
diet	O
,	O
which	O
resulted	O
in	O
a	O
brain	O
Hg	O
level	O
relevant	O
to	O
human	B
risk	O
assessment	O
.	O

We	O
evaluated	O
the	O
behavioral	O
end	O
points	O
twice	O
,	O
once	O
around	O
3	O
months	O
of	O
age	O
and	O
the	O
other	O
time	O
around	O
1	O
year	O
;	O
the	O
latter	O
time	O
roughly	O
corresponds	O
to	O
the	O
period	O
when	O
many	O
behavioral	O
performances	O
,	O
including	O
OPF	O
(	O
Acevedoa	O
et	O
al.	O
2006	O
;	O
Carrie	O
et	O
al.	O
1999	O
;	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
,	O
and	O
MM	O
(	O
Bach	O
et	O
al.	O
1999	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
show	O
alterations	O
in	O
this	O
mouse	B
strain	O
.	O

Materials	O
and	O
Methods	O
Animals	O
and	O
MeHg	O
exposure	O
OLA129	O
/	O
C57BL	O
/	O
6J	O
strain	O
mice	B
(	O
wild	O
type	O
)	O
and	O
MT	O
I	O
/	O
II	O
-	O
knockout	O
mice	B
(	O
MT	O
-	O
null	O
)	O
of	O
this	O
strain	O
were	O
provided	O
by	O
K.H.	O
Choo	O
of	O
the	O
Murdoch	O
Institute	O
,	O
Parkville	O
,	O
Australia	O
(	O
Michalska	O
and	O
Choo	O
1993	O
)	O
and	O
were	O
of	O
a	O
mixed	O
genetic	O
background	O
of	O
129	O
/	O
Ola	O
and	O
C57BL	O
/	O
6	O
strains	O
.	O

F1	O
hybrid	O
mice	B
were	O
mated	O
with	O
C57BL	O
/	O
6	O
mice	B
for	O
six	O
generations	O
at	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
(	O
Tsukuba	O
,	O
Japan	O
)	O
.	O

At	O
10	O
weeks	O
of	O
age	O
,	O
single	O
male	O
and	O
female	O
mice	B
were	O
allowed	O
to	O
cohabit	O
;	O
every	O
female	O
mouse	B
was	O
checked	O
each	O
morning	O
for	O
the	O
presence	O
of	O
a	O
vaginal	O
plug	O
.	O

When	O
a	O
plug	O
was	O
confirmed	O
,	O
the	O
day	O
was	O
designated	O
as	O
day	O
0	O
of	O
gestation	O
(	O
GD0	O
)	O
.	O

The	O
diet	O
,	O
NIH-07PLD	O
formula	O
(	O
CLEA	O
Japan	O
,	O
Inc.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
contained	O
vitamins	O
and	O
trace	O
elements	O
as	O
follows	O
(	O
per	O
kilogram	O
diet	O
)	O
:	O
3.2	O
mg	O
CuSO4	O
,	O
88	O
mg	O
FeSO4	O
,	O
149	O
mg	O
MnSO4	O
,	O
25	O
mg	O
ZnCO3	O
,	O
1.6	O
mg	O
Ca	O
(	O
IO3	O
)	O
2	O
,	O
11	O
mg	O
vitamin	O
B1	O
,	O
4.7	O
mg	O
vitamin	O
B2	O
,	O
1.9	O
mg	O
vitamin	O
B6	O
,	O
44	O
mg	O
vitamin	O
E	O
,	O
in	O
addition	O
to	O
5	O
μg	O
MeHg	O
/	O
g	O
.	O

This	O
diet	O
was	O
fed	O
to	O
the	O
pregnant	O
mice	B
starting	O
from	O
GD0	O
through	O
10	O
days	O
after	O
delivery	O
(	O
i.e.	O
,	O
PND10	O
)	O
.	O

Thereafter	O
,	O
we	O
switched	O
mice	B
to	O
a	O
diet	O
that	O
did	O
not	O
contain	O
MeHg	O
.	O

We	O
chose	O
GD0	O
as	O
the	O
beginning	O
of	O
exposure	O
because	O
exposures	O
that	O
started	O
before	O
conception	O
often	O
resulted	O
in	O
fairly	O
high	O
Hg	O
concentrations	O
in	O
fetal	O
/	O
neonatal	O
brains	O
(	O
Kakita	O
et	O
al.	O
2003	O
)	O
,	O
and	O
we	O
chose	O
PND10	O
to	O
cover	O
the	O
early	O
neonatal	O
period	O
,	O
in	O
which	O
considerable	O
brain	O
growth	O
occurs	O
.	O

In	O
our	O
experimental	O
setting	O
,	O
the	O
neonatal	O
mice	B
started	O
to	O
eat	O
from	O
the	O
diet	O
bucket	O
and	O
drink	O
from	O
the	O
water	O
bottle	O
from	O
PND10	O
onward	O
.	O

Control	O
mice	B
were	O
kept	O
on	O
the	O
same	O
diet	O
but	O
without	O
MeHg	O
(	O
<	O
0.01	O
μg	O
Hg	O
/	O
g	O
)	O
.	O

On	O
PND1	O
,	O
to	O
avoid	O
the	O
confounding	O
effects	O
due	O
to	O
different	O
litter	O
size	O
,	O
we	O
reduced	O
each	O
litter	O
to	O
six	O
pups	O
(	O
three	O
males	O
and	O
three	O
females	O
when	O
possible	O
)	O
,	O
and	O
on	O
PND10	O
,	O
two	O
males	O
and	O
two	O
females	O
from	O
each	O
litter	O
were	O
killed	O
for	O
chemical	O
analyses	O
.	O

The	O
remaining	O
male	O
and	O
female	O
offspring	O
per	O
litter	O
were	O
weaned	O
on	O
PND28	O
and	O
used	O
for	O
subsequent	O
behavioral	O
analyses	O
(	O
either	O
at	O
12–13	O
weeks	O
or	O
52–53	O
weeks	O
,	O
depending	O
on	O
the	O
litter	O
)	O
as	O
described	O
below	O
.	O

We	O
measured	O
body	O
weights	O
of	O
the	O
weaned	O
mice	B
every	O
2	O
weeks	O
.	O

Thus	O
,	O
four	O
experimental	O
groups	O
were	O
used	O
(	O
with	O
or	O
without	O
MeHg	O
exposure	O
for	O
two	O
strains	O
)	O
,	O
and	O
each	O
group	O
consisted	O
of	O
12–13	O
litters	O
.	O

For	O
half	O
of	O
the	O
litters	O
,	O
the	O
behavioral	O
analyses	O
were	O
conducted	O
at	O
12–13	O
weeks	O
of	O
age	O
,	O
and	O
upon	O
completion	O
of	O
the	O
behavioral	O
analyses	O
,	O
the	O
animals	O
were	O
killed	O
under	O
ether	O
anesthesia	O
.	O

We	O
then	O
dissected	O
the	O
organs	O
(	O
brain	O
,	O
liver	O
,	O
and	O
kidneys	O
)	O
for	O
Hg	O
analyses	O
.	O

For	O
the	O
remaining	O
half	O
of	O
the	O
litters	O
,	O
we	O
conducted	O
the	O
behavioral	O
tests	O
at	O
52–53	O
weeks	O
of	O
age	O
.	O

The	O
mice	B
were	O
treated	O
humanely	O
and	O
with	O
regard	O
to	O
alleviation	O
of	O
suffering	O
according	O
to	O
the	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
'	O
Guidelines	O
for	O
Animal	O
Welfare	O
and	O
the	O
guidelines	O
of	O
St.	O
Marianna	O
University	O
.	O

Behavioral	O
evaluations	O
The	O
details	O
of	O
each	O
behavioral	O
procedure	O
have	O
been	O
described	O
elsewhere	O
(	O
Yoshida	O
et	O
al.	O
2006	O
)	O
.	O

Brief	O
descriptions	O
follow	O
.	O

For	O
the	O
OPF	O
test	O
,	O
we	O
used	O
an	O
OPF	O
apparatus	O
(	O
Ohara	O
Co.	O
,	O
Ltd.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
with	O
a	O
60	O
×	O
60-cm	O
floor	O
surrounded	O
by	O
walls	O
60	O
cm	O
high	O
.	O

The	O
experimental	O
room	O
light	O
was	O
turned	O
off	O
,	O
and	O
a	O
dim	O
light	O
of	O
80	O
lux	O
was	O
lit	O
during	O
the	O
experiment	O
.	O

We	O
placed	O
a	O
mouse	B
in	O
the	O
center	O
of	O
the	O
floor	O
and	O
monitored	O
its	O
behavior	O
for	O
10	O
min	O
using	O
a	O
CCD	O
camera	O
connected	O
to	O
a	O
computer	O
.	O

The	O
position	O
of	O
the	O
center	O
of	O
gravity	O
was	O
calculated	O
by	O
image	O
-	O
analyzing	O
software	O
,	O
which	O
was	O
used	O
to	O
calculate	O
the	O
total	O
distance	O
traveled	O
by	O
the	O
mouse	B
as	O
well	O
as	O
the	O
positional	O
preference	O
(	O
either	O
center	O
or	O
peripheral	O
,	O
where	O
peripheral	O
was	O
defined	O
as	O
the	O
area	O
within	O
10	O
cm	O
from	O
the	O
wall	O
)	O
.	O

We	O
cleaned	O
the	O
OPF	O
apparatus	O
with	O
70	O
%	O
ethanol	O
between	O
trials	O
.	O

The	O
apparatus	O
for	O
the	O
PA	O
test	O
(	O
Ohara	O
Co.	O
Ltd.	O
)	O
consisted	O
of	O
a	O
light	O
compartment	O
that	O
illuminated	O
by	O
a	O
400-lux	O
light	O
and	O
a	O
dark	O
compartment	O
with	O
black	O
opaque	O
walls	O
and	O
lids	O
.	O

The	O
two	O
compartments	O
were	O
separated	O
by	O
a	O
mobile	O
guillotine	O
door	O
.	O

On	O
the	O
first	O
day	O
(	O
training	O
trial	O
)	O
,	O
we	O
placed	O
each	O
mouse	B
in	O
the	O
light	O
compartment	O
facing	O
away	O
from	O
the	O
guillotine	O
door	O
,	O
which	O
was	O
closed	O
.	O

After	O
30	O
sec	O
of	O
introduction	O
,	O
the	O
door	O
was	O
opened	O
;	O
when	O
the	O
mouse	B
entered	O
the	O
dark	O
compartment	O
,	O
a	O
brief	O
electric	O
shock	O
(	O
4	O
mA	O
for	O
2	O
sec	O
)	O
was	O
delivered	O
through	O
the	O
metal	O
grid	O
floor	O
.	O

This	O
would	O
force	O
the	O
mouse	B
back	O
to	O
the	O
light	O
component	O
.	O

The	O
interval	O
between	O
the	O
opening	O
of	O
the	O
door	O
and	O
the	O
entry	O
to	O
the	O
dark	O
room	O
(	O
in	O
seconds	O
)	O
was	O
recorded	O
and	O
defined	O
as	O
the	O
latency	O
.	O

On	O
the	O
next	O
day	O
,	O
the	O
same	O
procedure	O
was	O
repeated	O
,	O
but	O
without	O
the	O
electric	O
shock	O
(	O
retaining	O
trail	O
)	O
.	O

In	O
this	O
PA	O
paradigm	O
,	O
aversive	O
learning	O
was	O
assumed	O
to	O
be	O
established	O
in	O
the	O
training	O
trial	O
,	O
and	O
we	O
used	O
its	O
retention	O
in	O
the	O
retaining	O
trail	O
as	O
the	O
index	O
of	O
learning	O
.	O

Between	O
each	O
individual	O
trial	O
,	O
we	O
cleaned	O
the	O
apparatus	O
with	O
ethanol	O
.	O

The	O
cutoff	O
time	O
of	O
the	O
retention	O
session	O
was	O
300	O
sec.	O
The	O
MM	O
test	O
apparatus	O
(	O
Ohara	O
Co.	O
,	O
Ltd.	O
)	O
was	O
a	O
round	O
-	O
shaped	O
water	O
pool	O
with	O
a	O
diameter	O
of	O
120	O
cm	O
.	O

A	O
small	O
platform	O
was	O
submerged	O
in	O
the	O
water	O
,	O
which	O
provided	O
a	O
place	O
for	O
mice	B
to	O
escape	O
from	O
the	O
water	O
(	O
i.e.	O
,	O
an	O
aversive	O
stimulus	O
,	O
water	O
temperature	O
=	O
23	O
±	O
1	O
°	O
C	O
)	O
.	O

The	O
water	O
was	O
made	O
opaque	O
by	O
adding	O
white	O
paint	O
so	O
that	O
the	O
mouse	B
could	O
not	O
see	O
the	O
submerged	O
platform	O
.	O

In	O
each	O
trial	O
,	O
we	O
released	O
a	O
mouse	B
into	O
the	O
pool	O
from	O
a	O
determined	O
position	O
along	O
the	O
wall	O
,	O
and	O
the	O
performance	O
of	O
the	O
mouse	B
was	O
monitored	O
by	O
a	O
CCD	O
camera	O
/	O
image	O
analyzer	O
.	O

The	O
time	O
required	O
to	O
reach	O
the	O
platform	O
was	O
recorded	O
.	O

If	O
a	O
mouse	B
could	O
not	O
find	O
the	O
platform	O
within	O
60	O
sec	O
after	O
release	O
,	O
it	O
was	O
led	O
to	O
the	O
platform	O
and	O
placed	O
on	O
it	O
for	O
20	O
sec	O
before	O
being	O
removed	O
.	O

In	O
these	O
cases	O
,	O
a	O
latency	O
of	O
60	O
sec	O
was	O
recorded	O
.	O

We	O
conducted	O
the	O
trial	O
once	O
a	O
day	O
up	O
to	O
the	O
fifth	O
day	O
for	O
each	O
mouse	B
,	O
and	O
the	O
order	O
of	O
each	O
mouse	B
was	O
counterbalanced	O
across	O
the	O
day	O
.	O

On	O
the	O
sixth	O
day	O
,	O
a	O
transfer	O
test	O
(	O
or	O
probe	O
test	O
)	O
,	O
which	O
is	O
a	O
trial	O
without	O
the	O
platform	O
,	O
was	O
conducted	O
;	O
in	O
this	O
procedure	O
,	O
we	O
counted	O
the	O
number	O
of	O
times	O
that	O
the	O
mouse	B
crossed	O
the	O
position	O
where	O
the	O
platform	O
had	O
been	O
.	O

Tissue	O
Hg	O
concentration	O
The	O
tissue	O
samples	O
were	O
homogenized	O
(	O
10	O
%	O
weight	O
/	O
volume	O
)	O
in	O
distilled	O
water	O
using	O
a	O
Polytron	O
homogenizer	O
(	O
Kinematica	O
GmbH	O
,	O
Littau	O
,	O
Switzerland	O
)	O
.	O

We	O
determined	O
Hg	O
levels	O
in	O
the	O
homogenates	O
by	O
the	O
oxygen	O
combustion	O
–	O
gold	O
amalgamation	O
method	O
(	O
Ohkawa	O
et	O
al.	O
1977	O
)	O
using	O
an	O
atomic	O
absorption	O
Hg	O
detector	O
MD-1	O
(	O
Nippon	O
Instruments	O
,	O
Co.	O
Ltd.	O
,	O
Osaka	O
,	O
Japan	O
)	O
.	O

To	O
ensure	O
the	O
accuracy	O
of	O
the	O
measurement	O
,	O
we	O
included	O
reference	O
material	O
from	O
a	O
dogfish	O
(	O
DORM-2	O
;	O
National	O
Research	O
Council	O
of	O
Canada	O
,	O
Ottawa	O
,	O
Ontario	O
,	O
Canada	O
)	O
with	O
a	O
certified	O
value	O
of	O
4.64	O
±	O
0.26	O
μg	O
/	O
g	O
in	O
the	O
analyses	O
;	O
the	O
observed	O
values	O
fell	O
within	O
the	O
certified	O
range	O
.	O

The	O
detection	O
limit	O
of	O
the	O
measurement	O
was	O
0.1	O
ng	O
Hg	O
.	O

Statistics	O
We	O
analyzed	O
behavioral	O
data	O
for	O
OPF	O
and	O
PA	O
by	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
,	O
taking	O
sex	O
,	O
strain	O
,	O
and	O
MeHg	O
exposure	O
as	O
the	O
factors	O
.	O

All	O
the	O
interactions	O
among	O
these	O
factors	O
were	O
put	O
into	O
the	O
model	O
.	O

When	O
any	O
of	O
the	O
interactions	O
was	O
highly	O
significant	O
,	O
we	O
analyzed	O
the	O
data	O
separately	O
in	O
an	O
appropriate	O
way	O
;	O
for	O
example	O
,	O
if	O
sex	O
×	O
Hg	O
was	O
significant	O
,	O
the	O
data	O
for	O
males	O
and	O
females	O
were	O
separately	O
analyzed	O
for	O
the	O
effects	O
of	O
strain	O
and	O
Hg	O
.	O

Whenever	O
appropriate	O
,	O
ANOVAs	O
were	O
followed	O
by	O
Mann	O
-	O
Whitney	O
U	O
or	O
Student	O
's	O
t	O
-	O
tests	O
,	O
depending	O
on	O
the	O
nature	O
and	O
distribution	O
of	O
the	O
variables	O
.	O

We	O
analyzed	O
data	O
for	O
the	O
MM	O
by	O
repeated	O
-	O
measures	O
ANOVA	O
,	O
taking	O
the	O
exposure	O
as	O
between	O
-	O
group	O
and	O
trials	O
as	O
within	O
-	O
group	O
variables	O
.	O

The	O
test	O
was	O
performed	O
for	O
each	O
of	O
the	O
four	O
sex	O
and	O
strain	O
combinations	O
separately	O
.	O

The	O
significance	O
level	O
was	O
set	O
at	O
p	O
<	O
0.05	O
.	O

Results	O
Body	O
weight	O
Up	O
to	O
20	O
weeks	O
of	O
age	O
,	O
the	O
body	O
weight	O
values	O
of	O
the	O
control	O
and	O
MeHg	O
-	O
exposed	O
groups	O
were	O
not	O
different	O
,	O
regardless	O
of	O
strain	O
or	O
sex	O
.	O

After	O
28	O
weeks	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
female	O
groups	O
,	O
the	O
MeHg	O
-	O
exposed	O
groups	O
weighed	O
significantly	O
less	O
than	O
the	O
controls	O
(	O
Figure	O
1	O
)	O
.	O

OPF	O
At	O
12	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
of	O
the	O
locomotion	O
distance	O
revealed	O
that	O
only	O
strain	O
was	O
a	O
significant	O
factor	O
(	O
p	O
<	O
0.001	O
)	O
,	O
reflecting	O
the	O
longer	O
distance	O
traveled	O
by	O
the	O
MT	O
-	O
null	O
mice	B
(	O
Figure	O
2A	O
)	O
.	O

Strain	O
was	O
also	O
a	O
significant	O
factor	O
for	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
(	O
Figure	O
3A	O
)	O
,	O
and	O
Hg	O
exposure	O
marginally	O
affected	O
this	O
outcome	O
.	O

In	O
MT	O
-	O
null	O
females	O
,	O
the	O
proportion	O
of	O
central	O
-	O
area	O
locomotion	O
was	O
higher	O
in	O
MeHg	O
-	O
exposed	O
mice	B
than	O
in	O
the	O
controls	O
;	O
this	O
difference	O
was	O
not	O
observed	O
in	O
any	O
other	O
strain	O
–	O
sex	O
combination	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
the	O
strain	O
×	O
Hg	O
interaction	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
in	O
an	O
ANOVA	O
of	O
locomotion	O
distance	O
(	O
Figure	O
2B	O
)	O
;	O
MeHg	O
exposure	O
was	O
associated	O
with	O
decreased	O
locomotion	O
distance	O
in	O
wild	O
-	O
type	O
mice	B
and	O
with	O
increased	O
distance	O
in	O
MT	O
-	O
null	O
mice	B
.	O

A	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
(	O
with	O
sex	O
and	O
Hg	O
as	O
the	O
factors	O
)	O
revealed	O
that	O
only	O
Hg	O
was	O
significant	O
in	O
both	O
strains	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Regarding	O
the	O
proportion	O
of	O
the	O
central	O
-	O
area	O
locomotion	O
,	O
the	O
effects	O
of	O
MeHg	O
appeared	O
to	O
depend	O
on	O
sex	O
[	O
i.e.	O
,	O
sex	O
×	O
Hg	O
was	O
highly	O
significant	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
three	O
-	O
way	O
ANOVA	O
;	O
Figure	O
3B	O
]	O
.	O

Indeed	O
,	O
a	O
sex	O
-	O
wise	O
two	O
-	O
way	O
ANOVA	O
showed	O
significant	O
effects	O
of	O
Hg	O
only	O
in	O
females	O
(	O
p	O
<	O
0.001	O
)	O
.	O

PA	O
At	O
12	O
weeks	O
of	O
age	O
,	O
all	O
the	O
groups	O
showed	O
prolonged	O
latency	O
in	O
the	O
second	O
(	O
retention	O
)	O
trial	O
,	O
and	O
no	O
consistent	O
effect	O
of	O
MeHg	O
was	O
recognized	O
regardless	O
of	O
strain	O
or	O
sex	O
(	O
Figure	O
4A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
,	O
a	O
three	O
-	O
way	O
ANOVA	O
revealed	O
a	O
significant	O
interaction	O
between	O
strain	O
and	O
Hg	O
(	O
p	O
<	O
0.05	O
)	O
;	O
strain	O
-	O
wise	O
two	O
-	O
way	O
ANOVAs	O
revealed	O
a	O
significant	O
effect	O
of	O
Hg	O
on	O
learning	O
in	O
MT	O
-	O
null	O
mice	B
of	O
both	O
sexes	O
;	O
these	O
groups	O
of	O
mice	B
showed	O
significantly	O
shorter	O
(	O
less	O
than	O
half	O
)	O
latency	O
times	O
compared	O
to	O
control	O
mice	B
(	O
Figure	O
4B	O
)	O
.	O

A	O
notable	O
difference	O
between	O
the	O
results	O
at	O
52	O
weeks	O
of	O
age	O
and	O
those	O
at	O
12	O
weeks	O
was	O
that	O
many	O
of	O
the	O
tested	O
mice	B
exceeded	O
the	O
cutoff	O
time	O
in	O
the	O
retention	O
trials	O
at	O
52	O
weeks	O
,	O
except	O
for	O
the	O
MT	O
-	O
null	O
groups	O
.	O

MM	O
At	O
13	O
weeks	O
of	O
age	O
,	O
repeated	O
-	O
measures	O
ANOVA	O
did	O
not	O
indicate	O
any	O
effects	O
of	O
MeHg	O
(	O
Figure	O
5A	O
)	O
.	O

At	O
52	O
weeks	O
of	O
age	O
(	O
Figure	O
5B	O
)	O
,	O
wild	O
-	O
type	O
males	O
and	O
MT	O
-	O
null	O
females	O
shared	O
the	O
same	O
statistical	O
results	O
;	O
Hg	O
as	O
well	O
as	O
the	O
Hg	O
×	O
trial	O
interaction	O
were	O
statistically	O
significant	O
.	O

Thus	O
,	O
in	O
both	O
cases	O
,	O
the	O
MeHg	O
groups	O
showed	O
a	O
longer	O
latency	O
,	O
hampering	O
learning	O
performance	O
.	O

Tissue	O
Hg	O
concentration	O
At	O
PND10	O
,	O
which	O
was	O
immediately	O
after	O
the	O
exposure	O
,	O
brain	O
Hg	O
concentrations	O
of	O
the	O
neonatal	O
mice	B
were	O
approximately	O
≤	O
0.5	O
μg	O
/	O
g	O
(	O
Table	O
1	O
)	O
.	O

Although	O
the	O
MT	O
-	O
null	O
mice	B
and	O
females	O
showed	O
slightly	O
higher	O
brain	O
Hg	O
concentrations	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
group	O
and	O
males	O
,	O
respectively	O
,	O
neither	O
of	O
these	O
differences	O
was	O
significant	O
.	O

At	O
13	O
weeks	O
,	O
when	O
the	O
behavioral	O
tests	O
were	O
completed	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
comparable	O
to	O
the	O
control	O
(	O
nonexposed	O
)	O
level	O
(	O
approximately	O
5	O
ng	O
/	O
g	O
in	O
both	O
the	O
exposed	O
and	O
control	O
brains	O
)	O
.	O

Interestingly	O
,	O
MT	O
-	O
null	O
mice	B
had	O
a	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
than	O
the	O
corresponding	O
wild	O
-	O
type	O
groups	O
.	O

Discussion	O
Results	O
of	O
the	O
present	O
study	O
demonstrate	O
the	O
delayed	O
emergence	O
of	O
neurobehavioral	O
toxicity	O
due	O
to	O
perinatal	O
MeHg	O
exposure	O
,	O
which	O
presumably	O
developed	O
after	O
brain	O
MeHg	O
concentrations	O
had	O
leveled	O
off	O
.	O

This	O
emergent	O
toxicity	O
was	O
exaggerated	O
in	O
MT	O
-	O
null	O
mice	B
and	O
was	O
more	O
distinct	O
in	O
females	O
.	O

To	O
our	O
knowledge	O
,	O
our	O
findings	O
show	O
the	O
first	O
clear	O
-	O
cut	O
demonstrations	O
of	O
a	O
long	O
latency	O
period	O
of	O
MeHg	O
neurobehavioral	O
toxicity	O
in	O
rodents	O
and	O
possible	O
genetic	O
susceptibility	O
for	O
the	O
emergent	O
toxicity	O
.	O

The	O
exposure	O
level	O
should	O
be	O
considered	O
before	O
discussing	O
the	O
end	O
points	O
.	O

On	O
PND10	O
,	O
immediately	O
after	O
the	O
cessation	O
of	O
MeHg	O
exposure	O
,	O
the	O
brain	O
Hg	O
concentration	O
was	O
approximately	O
0.5	O
μg	O
/	O
g	O
,	O
regardless	O
of	O
the	O
strain	O
or	O
sex	O
.	O

In	O
a	O
previous	O
study	O
,	O
the	O
brain	O
Hg	O
concentration	O
in	O
mice	B
perinatally	O
exposed	O
to	O
6	O
mg	O
MeHg	O
/	O
L	O
(	O
via	O
water	O
)	O
peaked	O
between	O
PND0	O
and	O
PND4	O
and	O
was	O
approximately	O
three	O
times	O
higher	O
than	O
on	O
PND21	O
(	O
Goulet	O
et	O
al.	O
2003	O
)	O
.	O

Therefore	O
,	O
the	O
peak	O
brain	O
Hg	O
concentration	O
,	O
which	O
is	O
presumably	O
observed	O
around	O
birth	O
,	O
can	O
be	O
estimated	O
as	O
about	O
3-fold	O
higher	O
than	O
that	O
on	O
PND10	O
and	O
would	O
be	O
approximately	O
1.5	O
μg	O
/	O
g	O
(	O
0.5	O
μg	O
/	O
g	O
×	O
3	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
lowest	O
levels	O
among	O
recent	O
rodent	O
studies	O
.	O

As	O
shown	O
by	O
Sakamoto	O
et	O
al.	O
(	O
2002	O
)	O
in	O
their	O
Figure	O
2	O
,	O
prenatal	O
exposure	O
of	O
rats	B
to	O
MeHg	O
showed	O
a	O
peak	O
brain	O
Hg	O
concentration	O
around	O
PND1	O
that	O
was	O
four	O
to	O
five	O
times	O
greater	O
than	O
the	O
level	O
on	O
PND10	O
.	O

Also	O
,	O
Newland	O
and	O
Rasmussen	O
(	O
2000	O
)	O
reported	O
a	O
slight	O
alteration	O
of	O
a	O
complex	O
operant	O
behavior	O
in	O
rats	B
at	O
ages	O
<	O
2	O
years	O
at	O
brain	O
Hg	O
concentrations	O
as	O
low	O
as	O
0.5	O
μg	O
/	O
g	O
at	O
birth	O
,	O
although	O
statistical	O
significance	O
of	O
this	O
particular	O
effect	O
was	O
not	O
clear	O
.	O

It	O
should	O
be	O
noted	O
that	O
rats	B
have	O
different	O
Hg	O
kinetics	O
(	O
Hirayama	O
and	O
Yasutake	O
1986	O
;	O
Yasutake	O
and	O
Hirayama	O
1990	O
)	O
due	O
to	O
the	O
high	O
affinity	O
of	O
rat	O
hemoglobin	O
for	O
MeHg	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
)	O
.	O

The	O
most	O
important	O
observation	O
of	O
the	O
present	O
study	O
was	O
that	O
the	O
effects	O
of	O
low	O
-	O
level	O
MeHg	O
exposure	O
were	O
detected	O
only	O
at	O
later	O
stages	O
in	O
the	O
lives	O
of	O
the	O
mice	B
.	O

Except	O
for	O
the	O
central	O
-	O
area	O
occupancy	O
in	O
OPF	O
in	O
MT	O
-	O
null	O
females	O
,	O
no	O
statistically	O
significant	O
effects	O
of	O
MeHg	O
were	O
observed	O
in	O
any	O
of	O
the	O
three	O
behavioral	O
tests	O
at	O
12	O
weeks	O
of	O
age	O
.	O

In	O
contrast	O
,	O
significant	O
effects	O
were	O
observed	O
in	O
all	O
three	O
tests	O
at	O
52	O
weeks	O
of	O
age	O
.	O

The	O
brain	O
Hg	O
concentration	O
of	O
the	O
exposed	O
groups	O
had	O
leveled	O
off	O
and	O
was	O
not	O
distinguishable	O
from	O
the	O
non	O
-	O
exposed	O
group	O
at	O
13	O
weeks	O
of	O
age	O
,	O
immediately	O
after	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
testing	O
.	O

Therefore	O
,	O
in	O
the	O
present	O
study	O
,	O
there	O
was	O
a	O
latency	O
period	O
in	O
which	O
the	O
dose	O
and	O
effects	O
could	O
not	O
be	O
detected	O
,	O
although	O
effects	O
were	O
observed	O
9	O
months	O
later	O
.	O

Another	O
notable	O
observation	O
was	O
that	O
the	O
emergent	O
manifestation	O
of	O
toxicity	O
was	O
also	O
recognized	O
in	O
the	O
suppression	O
of	O
body	O
weight	O
(	O
except	O
for	O
wild	O
-	O
type	O
females	O
)	O
,	O
which	O
only	O
became	O
apparent	O
on	O
or	O
after	O
28	O
weeks	O
of	O
age	O
.	O

The	O
existence	O
of	O
a	O
latency	O
period	O
of	O
as	O
long	O
as	O
several	O
years	O
after	O
chronic	O
(	O
7	O
years	O
from	O
birth	O
)	O
,	O
low	O
-	O
level	O
exposure	O
to	O
MeHg	O
has	O
been	O
described	O
in	O
nonhuman	O
primates	O
(	O
Rice	O
1996	O
)	O
.	O

In	O
that	O
case	O
,	O
however	O
,	O
the	O
Hg	O
concentration	O
in	O
the	O
brain	O
remained	O
elevated	O
,	O
presumably	O
as	O
a	O
result	O
of	O
the	O
long	O
exposure	O
.	O

Indeed	O
,	O
Rice	O
(	O
1996	O
)	O
argued	O
that	O
the	O
minute	O
amount	O
of	O
residual	O
brain	O
Hg	O
could	O
have	O
caused	O
the	O
delayed	O
toxicity	O
.	O

This	O
was	O
clearly	O
not	O
the	O
case	O
in	O
the	O
present	O
study	O
because	O
the	O
Hg	O
concentration	O
leveled	O
off	O
around	O
the	O
time	O
of	O
the	O
first	O
phase	O
of	O
the	O
behavioral	O
study	O
.	O

The	O
absence	O
of	O
behavioral	O
effects	O
at	O
12	O
weeks	O
of	O
age	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
residual	O
behavioral	O
effects	O
were	O
due	O
to	O
elevated	O
Hg	O
early	O
in	O
life	O
.	O

Therefore	O
,	O
the	O
behavioral	O
toxicity	O
that	O
surfaced	O
at	O
52	O
weeks	O
of	O
age	O
must	O
have	O
had	O
its	O
origin	O
before	O
the	O
brain	O
Hg	O
concentration	O
leveled	O
off	O
(	O
at	O
or	O
before	O
13	O
weeks	O
of	O
age	O
)	O
,	O
although	O
the	O
redistribution	O
of	O
Hg	O
to	O
the	O
brain	O
from	O
other	O
sites	O
of	O
deposition	O
,	O
such	O
as	O
the	O
liver	O
,	O
can	O
not	O
be	O
completely	O
excluded	O
.	O

The	O
long	O
silent	O
period	O
before	O
the	O
manifestations	O
of	O
toxicity	O
emerged	O
suggests	O
that	O
a	O
slow	O
process	O
plays	O
a	O
role	O
in	O
this	O
latent	O
toxicity	O
.	O

Although	O
an	O
example	O
of	O
a	O
slow	O
process	O
is	O
aging	O
,	O
52	O
weeks	O
of	O
age	O
might	O
not	O
be	O
sufficiently	O
old	O
for	O
a	O
mouse	B
to	O
be	O
considered	O
aged	O
in	O
the	O
physiologic	O
sense	O
because	O
C57BL	O
/	O
6	O
mice	B
have	O
a	O
relatively	O
long	O
life	O
span	O
among	O
mouse	B
strains	O
[	O
median	O
survival	O
of	O
27–31	O
months	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
]	O
and	O
a	O
survival	O
rate	O
at	O
18–19	O
months	O
as	O
high	O
as	O
90	O
%	O
(	O
Institute	O
on	O
Aging	O
HP	O
)	O
(	O
National	O
Institute	O
on	O
Aging	O
2008	O
)	O
.	O

Nevertheless	O
,	O
various	O
behavioral	O
examinations	O
have	O
shown	O
age	O
-	O
related	O
changes	O
in	O
the	O
performance	O
of	O
mice	B
at	O
approximately	O
1	O
year	O
of	O
age	O
in	O
the	O
OPF	O
(	O
Acevedoa	O
et	O
al.	O
2006	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
MM	O
(	O
Bach	O
et	O
al.	O
1999	O
;	O
Carrie	O
et	O
al.	O
1999	O
)	O
,	O
and	O
PA	O
(	O
Gower	O
and	O
Lamberty	O
1993	O
)	O
tests	O
.	O

The	O
observed	O
effects	O
of	O
MeHg	O
,	O
including	O
the	O
deterioration	O
in	O
the	O
PA	O
and	O
MM	O
and	O
suppression	O
in	O
the	O
OPF	O
(	O
in	O
wild	O
-	O
type	O
mice	B
)	O
,	O
were	O
consistent	O
with	O
these	O
reported	O
effects	O
of	O
aging	O
on	O
behavioral	O
function	O
(	O
in	O
the	O
sense	O
described	O
above	O
)	O
,	O
except	O
for	O
the	O
increased	O
OPF	O
activity	O
in	O
the	O
MT	O
-	O
null	O
mice	B
.	O

Regardless	O
of	O
its	O
neural	O
basis	O
,	O
the	O
basis	O
of	O
neurobehavioral	O
toxicity	O
should	O
be	O
sought	O
in	O
early	O
life	O
stages	O
when	O
the	O
brain	O
Hg	O
concentration	O
is	O
highly	O
elevated	O
(	O
approximately	O
1.5	O
μg	O
/	O
g	O
at	O
its	O
peak	O
)	O
.	O

Some	O
in	O
vivo	O
experiments	O
have	O
demonstrated	O
several	O
candidate	O
mechanisms	O
of	O
perinatal	O
exposure	O
to	O
MeHg	O
,	O
including	O
abnormal	O
migration	O
of	O
neurons	O
and/or	O
glias	O
(	O
Kakita	O
et	O
al.	O
2003	O
;	O
Rodier	O
et	O
al.	O
1984	O
)	O
,	O
but	O
at	O
higher	O
Hg	O
concentrations	O
.	O

Using	O
exactly	O
the	O
same	O
exposure	O
protocol	O
as	O
the	O
present	O
study	O
,	O
we	O
found	O
suppressed	O
activity	O
of	O
type	O
III	O
iodo	O
-	O
thyronine	O
deiodinase	O
,	O
a	O
thyroid	O
hormone	O
-	O
metabolizing	O
enzyme	O
,	O
in	O
the	O
brains	O
of	O
PND10	O
mouse	B
neonates	O
(	O
Mori	O
et	O
al.	O
2006	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
study	O
of	O
higher	O
MeHg	O
doses	O
(	O
Watanabe	O
et	O
al.	O
1999	O
)	O
.	O

This	O
perturbation	O
could	O
be	O
one	O
of	O
the	O
candidate	O
mechanisms	O
responsible	O
for	O
the	O
later	O
anomalous	O
behaviors	O
because	O
even	O
a	O
transient	O
change	O
in	O
thyroid	O
hormones	O
during	O
the	O
critical	O
period	O
of	O
perinatal	O
life	O
exerts	O
long	O
-	O
term	O
consequences	O
(	O
Auso	O
et	O
al.	O
2004	O
)	O
.	O

The	O
effects	O
of	O
MeHg	O
at	O
52	O
weeks	O
of	O
age	O
were	O
influenced	O
by	O
two	O
potential	O
modifying	O
factors	O
,	O
sex	O
and	O
strain	O
.	O

In	O
the	O
OPF	O
,	O
while	O
the	O
locomotion	O
was	O
affected	O
in	O
both	O
strains	O
(	O
although	O
the	O
direction	O
was	O
opposite	O
)	O
,	O
center	O
occupancy	O
was	O
significantly	O
increased	O
only	O
in	O
the	O
MT	O
-	O
null	O
mice	B
.	O

In	O
addition	O
,	O
the	O
effects	O
on	O
PA	O
were	O
significant	O
only	O
in	O
MT	O
-	O
null	O
mice	B
,	O
whereas	O
MeHg	O
at	O
a	O
higher	O
dose	O
was	O
reported	O
to	O
worsen	O
PA	O
performance	O
in	O
rats	B
(	O
6–8	O
weeks	O
of	O
age	O
;	O
Sakamoto	O
et	O
al.	O
2002	O
)	O
.	O

In	O
addition	O
,	O
body	O
weight	O
gain	O
was	O
suppressed	O
in	O
both	O
male	O
and	O
female	O
MT	O
-	O
null	O
mice	B
,	O
whereas	O
in	O
wild	O
-	O
type	O
mice	B
the	O
suppression	O
was	O
observed	O
only	O
in	O
males	O
.	O

Taken	O
together	O
,	O
the	O
MT	O
-	O
null	O
strain	O
appeared	O
to	O
be	O
slightly	O
more	O
susceptible	O
to	O
the	O
late	O
-	O
emergent	O
effects	O
of	O
MeHg	O
.	O

Several	O
lines	O
of	O
evidence	O
have	O
shown	O
that	O
MT	O
-	O
I	O
,	O
II	O
is	O
protective	O
against	O
the	O
toxicity	O
of	O
MeHg	O
(	O
Leiva	O
-	O
Presa	O
et	O
al.	O
2004	O
;	O
Yao	O
et	O
al.	O
2000	O
)	O
,	O
and	O
the	O
present	O
results	O
were	O
basically	O
consistent	O
with	O
these	O
reports	O
.	O

We	O
have	O
also	O
reported	O
the	O
susceptibility	O
of	O
the	O
MT	O
-	O
null	O
strain	O
to	O
the	O
neurotoxic	O
effects	O
of	O
metallic	O
Hg	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2006	O
)	O
.	O

The	O
difference	O
in	O
the	O
susceptibility	O
to	O
MeHg	O
between	O
sexes	O
is	O
still	O
debated	O
(	O
Clarkson	O
and	O
Magos	O
2006	O
;	O
National	O
Research	O
Council	O
2000	O
;	O
Vahter	O
2007	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
some	O
responses	O
to	O
MeHg	O
were	O
different	O
between	O
the	O
sexes	O
,	O
including	O
OPF	O
performance	O
at	O
12	O
and	O
52	O
weeks	O
of	O
age	O
and	O
MM	O
performance	O
at	O
52	O
weeks	O
.	O

The	O
fact	O
that	O
the	O
MT	O
-	O
null	O
female	O
group	O
was	O
the	O
only	O
group	O
affected	O
by	O
MeHg	O
at	O
12	O
weeks	O
may	O
suggest	O
the	O
particular	O
susceptibility	O
of	O
females	O
in	O
this	O
strain	O
.	O

This	O
point	O
needs	O
to	O
be	O
clarified	O
in	O
further	O
experiments	O
.	O

The	O
question	O
remains	O
of	O
why	O
MT	O
-	O
null	O
mice	B
are	O
susceptible	O
to	O
the	O
delayed	O
neurotoxicity	O
of	O
perinatal	O
MeHg	O
.	O

Apparently	O
kinetics	O
play	O
only	O
a	O
minor	O
role	O
because	O
the	O
strain	O
did	O
not	O
show	O
distinct	O
effects	O
on	O
the	O
brain	O
Hg	O
concentration	O
at	O
PND10	O
.	O

The	O
significantly	O
lower	O
brain	O
Hg	O
concentration	O
in	O
MT	O
-	O
null	O
mice	B
compared	O
with	O
corresponding	O
wild	O
-	O
type	O
mice	B
at	O
13	O
weeks	O
of	O
age	O
indicated	O
that	O
MT	O
-	O
I	O
,	O
II	O
might	O
play	O
a	O
significant	O
role	O
in	O
the	O
retention	O
of	O
Hg	O
(	O
or	O
MeHg	O
)	O
.	O

This	O
is	O
consistent	O
with	O
the	O
results	O
of	O
studies	O
of	O
metallic	O
Hg	O
exposure	O
(	O
Yoshida	O
et	O
al.	O
2004	O
,	O
2005	O
)	O
;	O
a	O
lower	O
brain	O
Hg	O
concentration	O
may	O
not	O
guarantee	O
lower	O
toxicity	O
,	O
supporting	O
the	O
protective	O
role	O
of	O
the	O
protein	O
.	O

Earlier	O
studies	O
suggest	O
that	O
brain	O
MT	O
-	O
I	O
,	O
II	O
has	O
an	O
important	O
role	O
both	O
in	O
the	O
response	O
to	O
oxidative	O
injury	O
(	O
Potter	O
et	O
al.	O
2007	O
)	O
and	O
in	O
the	O
process	O
of	O
aging	O
(	O
Kojima	O
et	O
al.	O
1999	O
)	O
.	O

Therefore	O
,	O
the	O
lack	O
of	O
MT	O
can	O
exaggerate	O
the	O
toxicity	O
of	O
MeHg	O
by	O
enhancing	O
the	O
initial	O
effects	O
due	O
to	O
oxygen	O
radicals	O
and/or	O
by	O
accelerating	O
functional	O
aging	O
.	O

Apart	O
from	O
this	O
,	O
an	O
intriguing	O
possibility	O
is	O
that	O
the	O
brain	O
-	O
specific	O
isoform	O
,	O
MT	O
-	O
III	O
,	O
might	O
contribute	O
to	O
the	O
results	O
we	O
obtained	O
because	O
the	O
expression	O
of	O
MT	O
-	O
III	O
,	O
together	O
with	O
MT	O
-	O
I	O
,	O
is	O
increased	O
in	O
the	O
brain	O
of	O
old	O
rats	B
,	O
resulting	O
in	O
the	O
low	O
availability	O
of	O
free	O
zinc	O
for	O
synapses	O
(	O
Mocchegiani	O
et	O
al.	O
2004	O
)	O
.	O

The	O
age	O
-	O
dependent	O
expressions	O
of	O
MT	O
isoforms	O
might	O
be	O
modified	O
in	O
MT	O
-	O
null	O
mice	B
.	O

Results	O
of	O
the	O
present	O
study	O
might	O
allow	O
the	O
possibility	O
of	O
alternative	O
interpretations	O
due	O
to	O
some	O
potentially	O
confounding	O
factors	O
.	O

For	O
example	O
,	O
except	O
for	O
the	O
wild	O
-	O
type	O
females	O
,	O
we	O
observed	O
significant	O
differences	O
in	O
body	O
weight	O
between	O
MeHg	O
-	O
exposed	O
and	O
non	O
-	O
exposed	O
groups	O
.	O

Because	O
these	O
differences	O
only	O
became	O
clear	O
later	O
in	O
life	O
,	O
they	O
might	O
be	O
associated	O
with	O
the	O
toxicity	O
that	O
also	O
emerged	O
later	O
in	O
life	O
.	O

Manipulation	O
of	O
body	O
weight	O
in	O
rodents	O
alters	O
activity	O
levels	O
,	O
although	O
the	O
reported	O
results	O
are	O
not	O
always	O
consistent	O
with	O
each	O
other	O
(	O
Harrison	O
and	O
Archer	O
1987	O
;	O
Samuelsson	O
et	O
al.	O
2008	O
)	O
.	O

Also	O
,	O
the	O
differential	O
performance	O
in	O
PA	O
could	O
be	O
related	O
with	O
the	O
potential	O
effects	O
of	O
MeHg	O
on	O
(	O
electric	O
)	O
shock	O
sensitivity	O
,	O
which	O
we	O
did	O
not	O
examine	O
.	O

At	O
least	O
one	O
high	O
-	O
dose	O
study	O
with	O
adult	O
rats	B
showed	O
reduced	O
electric	O
sensitivity	O
due	O
to	O
mercury	O
exposure	O
(	O
Wu	O
et	O
al.	O
1985	O
)	O
.	O

These	O
possibilities	O
need	O
to	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

To	O
summarize	O
,	O
the	O
present	O
results	O
suggest	O
that	O
an	O
initial	O
(	O
or	O
triggering	O
)	O
toxicologic	O
event	O
occurs	O
before	O
the	O
brain	O
Hg	O
concentration	O
stabilizes	O
and	O
that	O
the	O
nature	O
of	O
this	O
event	O
should	O
be	O
either	O
an	O
acceleration	O
of	O
the	O
aging	O
process	O
or	O
interaction	O
with	O
the	O
aging	O
process	O
.	O

Thus	O
,	O
by	O
identifying	O
the	O
physiologic	O
events	O
associated	O
with	O
the	O
functional	O
aging	O
of	O
the	O
examined	O
behavioral	O
tasks	O
,	O
the	O
fundamental	O
toxicologic	O
scar	O
might	O
be	O
revealed	O
.	O

Potentiation	O
of	O
Nerve	O
Growth	O
Factor	O
-	O
Induced	O
Neurite	O
Outgrowth	O
by	O
Fluvoxamine	O
:	O
Role	O
of	O
Sigma-1	O
Receptors	O
,	O
IP3	O
Receptors	O
and	O
Cellular	O
Signaling	O
Pathways	O
Abstract	O
Background	O
Selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
been	O
widely	O
used	O
and	O
are	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

However	O
,	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
.	O

The	O
SSRI	O
fluvoxamine	O
,	O
with	O
sigma-1	O
receptor	O
agonism	O
,	O
is	O
shown	O
to	O
potentiate	O
nerve	O
-	O
growth	O
factor	O
(	O
NGF	O
)	O
-induced	O
neurite	O
outgrowth	O
in	O
PC	O
12	O
cells	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
and	O
molecular	O
mechanisms	O
underlying	O
potentiation	O
by	O
fluvoxamine	O
are	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
roles	O
of	O
cellular	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
sigma-1	O
receptor	O
agonists	O
.	O

Methods	O
and	O
Findings	O
The	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
and	O
three	O
sigma-1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
and	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
-sulfate	O
)	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
were	O
examined	O
.	O

Also	O
examined	O
were	O
the	O
effects	O
of	O
the	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
,	O
inositol	O
1,4,5-triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
,	O
and	O
specific	O
inhibitors	O
of	O
signaling	O
pathways	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
selective	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
.	O

Fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma-1	O
receptor	O
agonists	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulfate	O
significantly	O
potentiated	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

The	O
potentiation	O
by	O
fluvoxamine	O
and	O
the	O
three	O
sigma-1	O
receptor	O
agonists	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
,	O
suggesting	O
that	O
sigma-1	O
receptors	O
play	O
a	O
role	O
in	O
blocking	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Moreover	O
,	O
the	O
potentiation	O
by	O
SA4503	O
was	O
blocked	O
by	O
co	O
-	O
administration	O
of	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C.	O
In	O
addition	O
,	O
the	O
specific	O
inhibitors	O
of	O
phospholipase	O
C	O
(	O
PLC	O
-	O
γ	O
)	O
,	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
,	O
p38MAPK	O
,	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathways	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Conclusion	O
These	O
findings	O
suggest	O
that	O
stimulation	O
of	O
sigma-1	O
receptors	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
,	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38MAPK	O
,	O
JNK	O
,	O
and	O
the	O
Ras	O
/	O
Raf	O
/	O
MAPK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
mechanisms	O
of	O
action	O
of	O
sigma-1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
SA4503	O
.	O

Introduction	O
Selective	O
serotonin	O
(	O
5-HT	O
;	O
5-hydroxytryptamine	O
)	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
have	O
emerged	O
as	O
a	O
major	O
therapeutic	O
advance	O
in	O
psychopharmacology	O
.	O

SSRIs	O
are	O
the	O
treatment	O
of	O
choice	O
for	O
many	O
indications	O
,	O
including	O
major	O
depressive	O
disorder	O
,	O
dysthymia	O
,	O
panic	O
disorder	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
,	O
eating	O
disorders	O
,	O
and	O
premenstrual	O
dysphoric	O
disorder	O
.	O

In	O
contrast	O
,	O
it	O
is	O
well	O
known	O
that	O
their	O
pharmacology	O
is	O
quite	O
heterogeneous	O
,	O
although	O
all	O
of	O
them	O
block	O
5-HT	O
transporters	O
,	O
thus	O
increasing	O
5-HT	O
levels	O
throughout	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
[	O
1	O
]	O
–	O
[	O
9	O
]	O
.	O

Accumulating	O
evidence	O
suggests	O
that	O
sigma-1	O
receptors	O
,	O
which	O
are	O
intracellular	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
proteins	O
,	O
are	O
involved	O
in	O
both	O
the	O
neuroplasticity	O
and	O
pathophysiology	O
of	O
neuropsychiatric	O
diseases	O
such	O
as	O
major	O
depressive	O
disorder	O
,	O
anxiety	O
,	O
schizophrenia	O
,	O
and	O
Alzheimer	O
's	O
disease	O
[	O
10	O
]	O
–	O
[	O
18	O
]	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
some	O
SSRIs	O
possess	O
high	O
to	O
moderate	O
affinities	O
for	O
sigma-1	O
receptors	O
in	O
the	O
rat	B
brain	O
.	O

The	O
rank	O
order	O
of	O
SSRIs	O
affinities	O
for	O
sigma-1	O
receptors	O
is	O
fluvoxamine	O
(	O
Ki	O
=	O
36	O
nM	O
)	O
>sertraline	O
(	O
Ki	O
=	O
57	O
nM	O
)	O
>>paroxetine	O
(	O
Ki	O
=	O
1893	O
nM	O
)	O
[	O
19	O
]	O
.	O

Recently	O
,	O
we	O
reported	O
that	O
fluvoxamine	O
,	O
but	O
not	O
paroxetine	O
,	O
significantly	O
ameliorated	O
cognitive	O
deficits	O
in	O
mice	B
after	O
repeated	O
phencyclidine	O
administration	O
,	O
and	O
that	O
the	O
effects	O
of	O
fluvoxamine	O
were	O
antagonized	O
by	O
co	O
-	O
administration	O
of	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
[	O
20	O
]	O
,	O
suggesting	O
that	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
[	O
9	O
]	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
sigma-1	O
receptor	O
agonists	O
including	O
fluvoxamine	O
could	O
potentiate	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
NE-100	O
blocked	O
the	O
potentiation	O
by	O
sigma-1	O
receptor	O
agonists	O
,	O
suggesting	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
neuroplasticity	O
[	O
21	O
]	O
.	O

However	O
,	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
potentiation	O
by	O
sigma-1	O
receptor	O
agonists	O
are	O
not	O
fully	O
understood	O
[	O
13	O
]	O
,	O
[	O
21	O
]	O
.	O

It	O
is	O
therefore	O
of	O
great	O
interest	O
to	O
study	O
the	O
precise	O
cellular	O
mechanisms	O
underlying	O
the	O
enhancement	O
by	O
fluvoxamine	O
on	O
NGF	O
-	O
induced	O
neurite	O
sprouting	O
in	O
PC12	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
three	O
SSRIs	O
(	O
fluvoxamine	O
,	O
sertraline	O
,	O
paroxetine	O
)	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
a	O
sigma-1	O
receptor	O
agonist	O
(	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
,	O
dehydroepiandrosterone	O
-	O
sulphate	O
(	O
DHEA	O
)	O
-sulfate	O
)	O
[	O
9	O
]	O
,	O
[	O
22	O
]	O
–	O
[	O
28	O
]	O
and	O
the	O
selective	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
[	O
29	O
]	O
,	O
[	O
30	O
]	O
,	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
also	O
known	O
that	O
sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17,18	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE-100	O
and	O
xestospongin	O
C	O
(	O
a	O
selective	O
inositol	O
1,4,5-triphosphate	O
(	O
IP3	O
)	O
receptor	O
antagonist	O
)	O
[	O
31	O
]	O
in	O
order	O
to	O
investigate	O
the	O
roles	O
of	O
sigma-1	O
receptors	O
and	O
IP3	O
receptors	O
in	O
the	O
mechanisms	O
underlying	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
examined	O
the	O
effects	O
of	O
specific	O
inhibitors	O
of	O
several	O
cellular	O
signaling	O
targets	O
on	O
the	O
enhancement	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
since	O
several	O
signal	O
transduction	O
molecules	O
have	O
been	O
implicated	O
in	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
[	O
32	O
]	O
.	O

Materials	O
and	O
Methods	O
Drugs	O
The	O
drugs	O
were	O
obtained	O
from	O
the	O
following	O
sources	O
:	O
fluvoxamine	O
maleate	O
(	O
Solvay	O
Seiyaku	O
K.K.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
;	O
paroxetine	O
hydrochloride	O
,	O
dehydroepiandosterone	O
-	O
sulfate	O
(	O
DHEA	O
-	O
sulfate	O
)	O
,	O
LY294002	O
(	O
Sigma	O
-	O
Aldrich	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
;	O
sertraline	O
(	O
Toronto	O
Research	O
Chemicals	O
Inc.	O
,	O
North	O
York	O
,	O
ON	O
,	O
Canada	O
)	O
;	O
SA4503	O
(	O
M	O
's	O
Science	O
Corporation	O
,	O
Kobe	O
,	O
Japan	O
)	O
;	O
NGF	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
;	O
xestospongin	O
C	O
,	O
lovastatin	O
,	O
PD98059	O
,	O
GW5074	O
,	O
SB203580	O
,	O
MEK	O
1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
)	O
,	O
and	O
SP600125	O
(	O
Calbiochem	O
-	O
Novabiochem	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

The	O
selective	O
sigma-1	O
receptor	O
antagonists	O
NE-100	O
and	O
4-phenyl-1-	O
(	O
4-phenylbutyl	O
)	O
piperidine	O
(	O
PPBP	O
)	O
were	O
synthesized	O
in	O
our	O
laboratory	O
.	O

Other	O
drugs	O
were	O
purchased	O
from	O
commercial	O
sources	O
.	O

Cell	O
culture	O
PC12	O
sells	O
(	O
RIKEN	O
Cell	O
Bank	O
,	O
Tsukuba	O
,	O
Japan	O
)	O
were	O
cultured	O
at	O
37	O
°	O
C	O
,	O
5	O
%	O
CO2	O
with	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
5	O
%	O
heat	O
-	O
inactivated	O
fetal	O
bovine	B
serum	O
(	O
FBS	O
)	O
,	O
10	O
%	O
heat	O
-	O
inactivated	O
horse	B
serum	O
,	O
and	O
1	O
%	O
penicillin	O
.	O

The	O
medium	O
was	O
changed	O
two	O
or	O
three	O
times	O
a	O
week	O
.	O

PC12	O
cells	O
were	O
plated	O
onto	O
24-well	O
tissue	O
culture	O
plates	O
coated	O
with	O
poly	O
-	O
D	O
-	O
lysine	O
/	O
laminin	O
.	O

Cells	O
were	O
plated	O
at	O
relatively	O
low	O
density	O
(	O
0.25	O
×	O
104	O
cells	O
/	O
cm2	O
)	O
in	O
DMEM	O
medium	O
containing	O
0.5	O
%	O
FBS	O
,	O
1	O
%	O
penicillin	O
streptomycin	O
.	O

Medium	O
containing	O
a	O
minimal	O
level	O
of	O
serum	O
(	O
0.5	O
%	O
FBS	O
)	O
was	O
used	O
,	O
since	O
serum	O
is	O
known	O
to	O
contain	O
steroid	O
hormones	O
that	O
bind	O
to	O
sigma-1	O
receptors	O
[	O
21	O
]	O
.	O

First	O
,	O
we	O
examined	O
the	O
optimal	O
concentration	O
of	O
NGF	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

NGF	O
(	O
2.5	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
ng	O
/	O
ml	O
)	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
the	O
subsequent	O
studies	O
,	O
2.5	O
ng	O
/	O
ml	O
of	O
NGF	O
was	O
used	O
to	O
study	O
the	O
potentiating	O
effects	O
of	O
sigma-1	O
receptor	O
agonists	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
plating	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
DMEM	O
medium	O
containing	O
0.5	O
%	O
FBS	O
and	O
1	O
%	O
penicillin	O
streptomycin	O
with	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
several	O
drugs	O
.	O

Quantification	O
of	O
neurite	O
sprouting	O
Five	O
days	O
after	O
incubation	O
with	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
the	O
several	O
drugs	O
,	O
morphometric	O
analysis	O
was	O
performed	O
on	O
digitized	O
images	O
of	O
live	O
cells	O
taken	O
under	O
phase	O
-	O
contrast	O
illumination	O
with	O
an	O
inverted	O
microscope	O
linked	O
to	O
a	O
camera	O
.	O

Images	O
of	O
three	O
fields	O
per	O
well	O
were	O
taken	O
,	O
with	O
an	O
average	O
of	O
100	O
cells	O
per	O
field	O
.	O

Differentiated	O
cells	O
were	O
counted	O
by	O
visual	O
examination	O
of	O
the	O
field	O
;	O
only	O
cells	O
that	O
had	O
at	O
least	O
one	O
neurite	O
with	O
a	O
length	O
equal	O
to	O
the	O
cell	O
body	O
diameter	O
were	O
counted	O
,	O
and	O
were	O
then	O
expressed	O
as	O
a	O
percentage	O
of	O
the	O
total	O
cells	O
in	O
the	O
field	O
.	O

The	O
counting	O
was	O
performed	O
in	O
a	O
blinded	O
manner	O
.	O

Immunocytochemistry	O
Cells	O
were	O
fixed	O
for	O
30	O
min	O
at	O
room	O
temperature	O
with	O
4	O
%	O
paraformaldehyde	O
then	O
permeabilized	O
with	O
0.2	O
%	O
Triton	O
and	O
blocked	O
with	O
1.5	O
%	O
normal	O
goat	B
serum	O
,	O
0.1	O
%	O
bovine	B
serum	O
albumin	O
(	O
BSA	O
)	O
in	O
0.1	O
M	O
phosphate	O
-	O
buffer	O
saline	O
for	O
1	O
h	O
to	O
reduce	O
nonspecific	O
binding	O
.	O

Cells	O
were	O
incubated	O
overnight	O
at	O
4	O
°	O
C	O
with	O
anti	O
-	O
microtubule	O
-	O
associated	O
protein	O
2	O
(	O
MAP-2	O
)	O
antibodies	O
(	O
1∶1000	O
dilution	O
in	O
blocking	O
solution	O
,	O
Chemicon	O
International	O
,	O
Temecula	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
immunolabeling	O
was	O
visualized	O
with	O
secondary	O
antibodies	O
conjugated	O
to	O
Alexa-488	O
(	O
1∶1000	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
)	O
.	O

MAP-2	O
immuncytochemistry	O
was	O
visualized	O
with	O
a	O
fluorescence	O
microscope	O
(	O
Axiovert	O
200	O
,	O
Carl	O
Zeiss	O
,	O
Oberkocken	O
,	O
Germany	O
)	O
.	O

Statistical	O
analysis	O
Data	O
are	O
expressed	O
as	O
means±S.E.M.	O
Statistical	O
analysis	O
was	O
performed	O
by	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
and	O
the	O
post	O
hoc	O
Bonferroni	O
/	O
Dunn	O
test	O
.	O

P	O
values	O
less	O
than	O
0.05	O
were	O
considered	O
statistically	O
significant	O
.	O

Results	O
Effects	O
of	O
SSRIs	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
Fluvoxamine	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
2	O
and	O
4	O
)	O
.	O

In	O
contrast	O
,	O
sertraline	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
and	O
paroxetine	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
did	O
not	O
increase	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
.	O

A	O
higher	O
concentration	O
(	O
10	O
µM	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
significantly	O
decreased	O
the	O
number	O
of	O
cells	O
with	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
suggesting	O
the	O
cellular	O
toxicity	O
of	O
these	O
drugs	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
sigma-1	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
and	O
SA4503	O
The	O
selective	O
and	O
potent	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
(	O
0.01	O
,	O
0.1	O
,	O
or	O
1.0	O
µM	O
)	O
significantly	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
by	O
NGF	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
in	O
PC12	O
cells	O
,	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
and	O
4	O
)	O
.	O

In	O
addition	O
,	O
other	O
sigma-1	O
receptor	O
agonists	O
–	O
PPBP	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
[	O
22	O
]	O
–	O
[	O
26	O
]	O
and	O
DHEA	O
-	O
sulphate	O
(	O
0.1	O
,	O
1.0	O
,	O
or	O
10	O
µM	O
)	O
[	O
9	O
]	O
,	O
[	O
27	O
]	O
,	O
[	O
28	O
]	O
–significantly	O
increased	O
the	O
number	O
of	O
such	O
cells	O
,	O
also	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Figure	O
3	O
)	O
.	O

In	O
the	O
absence	O
of	O
NGF	O
,	O
sigma-1	O
receptor	O
agonists	O
did	O
not	O
produce	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
sigma-1	O
receptors	O
,	O
we	O
examined	O
the	O
effects	O
of	O
NE-100	O
(	O
a	O
selective	O
sigma-1	O
receptor	O
antagonist	O
)	O
on	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
fluvoxamine	O
,	O
SA4503	O
,	O
PPBP	O
,	O
and	O
DHEA	O
-	O
sulphate	O
.	O

Co	O
-	O
administration	O
of	O
NE-100	O
(	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
such	O
potentiation	O
by	O
fluvoxamine	O
(	O
10	O
µM	O
)	O
,	O
SA4503	O
(	O
1.0	O
µM	O
)	O
,	O
PPBP	O
(	O
10	O
µM	O
)	O
,	O
or	O
DHEA	O
-	O
sulphate	O
(	O
10	O
µM	O
)	O
(	O
Figure	O
2	O
and	O
3	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
NE-100	O
(	O
1.0	O
µM	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
2	O
)	O
.	O

Role	O
of	O
IP3	O
receptors	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
Sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
interact	O
with	O
IP3	O
receptors	O
(	O
17,18,33–35	O
)	O
.	O

To	O
investigate	O
the	O
role	O
of	O
IP3	O
receptors	O
in	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
,	O
we	O
examined	O
the	O
effects	O
of	O
xestospongin	O
C	O
(	O
a	O
selective	O
,	O
reversible	O
,	O
and	O
membrane	O
-	O
permeable	O
inhibitor	O
of	O
IP3	O
receptors	O
)	O
[	O
31	O
]	O
on	O
the	O
effects	O
of	O
SA4503	O
on	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Co	O
-	O
administration	O
of	O
xestospongin	O
C	O
(	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
5	O
)	O
.	O

Furthermore	O
,	O
administration	O
of	O
xestospongin	O
C	O
(	O
1.0	O
µM	O
)	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
5	O
)	O
.	O

Role	O
of	O
signaling	O
molecules	O
proximal	O
to	O
TrkA	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
the	O
specific	O
inhibitors	O
of	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38	O
MAPK	O
,	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
,	O
since	O
these	O
signaling	O
molecules	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
36	O
]	O
.	O

The	O
PLC	O
-	O
γ	O
inhibitor	O
(	O
U73122	O
;	O
1.0	O
µM	O
)	O
,	O
PI3	O
K	O
inhibitor	O
(	O
LY294002	O
;	O
1.0	O
µM	O
)	O
,	O
p38	O
MAPK	O
inhibitor	O
(	O
SB203580	O
;	O
1.0	O
µM	O
)	O
,	O
and	O
JNK	O
inhibitor	O
(	O
SP600125	O
;	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
6	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
6	O
)	O
.	O

Role	O
of	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
The	O
Raf	O
/	O
Ras	O
/	O
ERK	O
/	O
MAPK	O
pathway	O
is	O
known	O
to	O
be	O
involved	O
in	O
NGF	O
-	O
induced	O
outgrowth	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
effects	O
of	O
this	O
pathway	O
's	O
specific	O
inhibitors	O
.	O

The	O
Ras	O
inhibitor	O
(	O
GW5074	O
;	O
1.0	O
µM	O
)	O
,	O
Raf	O
inhibitor	O
(	O
lovastatin	O
;	O
1.0	O
µM	O
)	O
,	O
MEK1	O
/	O
2	O
inhibitor	O
(	O
SL327	O
;	O
1.0	O
µM	O
)	O
,	O
and	O
MAPK	O
inhibitor	O
(	O
PD98059	O
;	O
1.0	O
µM	O
)	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
(	O
1.0	O
µM	O
)	O
(	O
Figure	O
7	O
)	O
.	O

In	O
contrast	O
,	O
these	O
inhibitors	O
alone	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
(	O
Figure	O
7	O
)	O
.	O

Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
fluvoxamine	O
(	O
but	O
not	O
sertraline	O
or	O
paroxetine	O
)	O
and	O
the	O
sigma-1	O
receptor	O
agonists	O
(	O
SA4503	O
,	O
PPBP	O
,	O
DHEA	O
-	O
sulfate	O
)	O
could	O
potentiate	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
,	O
and	O
that	O
the	O
effects	O
of	O
these	O
drugs	O
were	O
blocked	O
by	O
co	O
-	O
incubation	O
with	O
the	O
selective	O
sigma-1	O
receptor	O
antagonist	O
NE-100	O
.	O

These	O
findings	O
suggest	O
that	O
agonism	O
at	O
sigma-1	O
receptors	O
for	O
these	O
drugs	O
is	O
involved	O
in	O
the	O
mechanisms	O
underlying	O
the	O
drugs	O
'	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

As	O
shown	O
in	O
Figure	O
1	O
,	O
NGF	O
increased	O
the	O
number	O
of	O
cells	O
with	O
neurite	O
outgrowth	O
in	O
PC12	O
,	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

To	O
examine	O
whether	O
or	O
not	O
the	O
NGF	O
levels	O
are	O
altered	O
by	O
incubation	O
with	O
sigma-1	O
receptor	O
agonists	O
,	O
we	O
measured	O
the	O
levels	O
of	O
NGF	O
in	O
PC12	O
cells	O
with	O
or	O
without	O
sigma-1	O
receptor	O
agonist	O
SA4503	O
.	O

No	O
differences	O
of	O
NGF	O
levels	O
were	O
shown	O
in	O
the	O
between	O
control	O
group	O
and	O
SA4503-treated	O
group	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
,	O
therefore	O
,	O
unlikely	O
that	O
the	O
potentaition	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
might	O
be	O
due	O
to	O
increased	O
levels	O
of	O
NGF	O
.	O

Unlike	O
fluvoxamine	O
,	O
sertraline	O
,	O
which	O
has	O
a	O
moderate	O
affinity	O
for	O
sigma-1	O
receptors	O
,	O
did	O
not	O
alter	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

The	O
reasons	O
underlying	O
this	O
discrepancy	O
between	O
these	O
two	O
SSRIs	O
are	O
currently	O
unclear	O
.	O

One	O
possibility	O
may	O
involve	O
the	O
difference	O
in	O
pharmacological	O
actions	O
(	O
agonist	O
vs.	O
antagonist	O
)	O
between	O
these	O
SSRIs	O
at	O
sigma-1	O
receptors	O
.	O

Interestingly	O
,	O
we	O
recently	O
found	O
that	O
,	O
in	O
a	O
novel	O
object	O
recognition	O
test	O
,	O
phencyclidine	O
-	O
induced	O
cognitive	O
deficits	O
could	O
be	O
significantly	O
improved	O
by	O
subsequent	O
subchronic	O
(	O
14	O
days	O
)	O
administration	O
of	O
fluvoxamine	O
,	O
but	O
not	O
of	O
sertraline	O
,	O
suggesting	O
that	O
sigma-1	O
receptor	O
agonism	O
is	O
involved	O
in	O
fluvoxamine	O
's	O
mechanism	O
of	O
action	O
[	O
9	O
]	O
,	O
Ishima	O
et	O
al.	O
,	O
submitted	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
fluvoxamine	O
and	O
sertraline	O
may	O
function	O
as	O
an	O
agonist	O
and	O
an	O
antagonist	O
at	O
sigma-1	O
receptors	O
,	O
respectively	O
,	O
although	O
further	O
study	O
is	O
necessary	O
.	O

Another	O
possibility	O
may	O
be	O
that	O
other	O
pharmacological	O
activities	O
of	O
sertraline	O
mask	O
the	O
effects	O
of	O
sigma-1	O
receptor	O
agonism	O
.	O

In	O
this	O
study	O
,	O
we	O
also	O
found	O
that	O
high	O
concentration	O
(	O
10	O
µM	O
)	O
of	O
paroxetine	O
and	O
sertraline	O
,	O
but	O
not	O
fluvoxamine	O
,	O
showed	O
cytotoxicity	O
in	O
PC12	O
cells	O
,	O
suggesting	O
that	O
fluvoxamine	O
may	O
be	O
a	O
safe	O
drug	O
than	O
paroxetine	O
and	O
sertraline	O
.	O

Sigma-1	O
receptors	O
have	O
been	O
shown	O
to	O
affect	O
intracellular	O
Ca2	O
+	O
signaling	O
,	O
although	O
the	O
precise	O
molecular	O
and	O
cellular	O
mechanisms	O
underlying	O
this	O
effect	O
are	O
unknown	O
.	O

Sigma-1	O
receptors	O
bind	O
to	O
IP3	O
receptors	O
in	O
ER	O
,	O
and	O
sigma-1	O
receptors	O
regulate	O
Ca2	O
+	O
release	O
from	O
intracellular	O
Ca2	O
+	O
storage	O
sites	O
[	O
12	O
]	O
.	O

Very	O
recently	O
,	O
Hayashi	O
and	O
Su	O
[	O
17	O
]	O
reported	O
that	O
sigma-1	O
receptors	O
function	O
as	O
novel	O
ligand	O
-	O
operated	O
chaperones	O
that	O
specifically	O
target	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
.	O

Furthermore	O
,	O
sigma-1	O
receptors	O
form	O
Ca2	O
+	O
-sensitive	O
chaperone	O
machinery	O
with	O
another	O
chaperone	O
,	O
BiP	O
,	O
and	O
prolong	O
Ca2	O
+	O
signaling	O
from	O
ER	O
into	O
mitochondria	O
by	O
stabilizing	O
IP3	O
receptors	O
at	O
mitochondrion	O
-	O
associated	O
ER	O
membrane	O
[	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
IP3	O
receptor	O
antagonist	O
xestospongin	O
C	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
the	O
role	O
of	O
IP3	O
receptors	O
on	O
sigma-1	O
receptor	O
-	O
mediated	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
stimulation	O
at	O
sigma-1	O
receptors	O
by	O
sigma-1	O
receptor	O
agonists	O
and	O
subsequent	O
interaction	O
with	O
IP3	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
.	O

NGF	O
binds	O
to	O
the	O
high	O
-	O
affinity	O
tyrosine	O
receptor	O
TrkA	O
,	O
initiating	O
several	O
signaling	O
pathways	O
affecting	O
both	O
morphological	O
and	O
transcriptional	O
targets	O
[	O
32	O
]	O
,	O
[	O
36	O
]	O
,	O
[	O
37	O
]	O
.	O

The	O
signaling	O
molecules	O
,	O
including	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38	O
MAPK	O
,	O
and	O
JNK	O
,	O
are	O
activated	O
upon	O
the	O
addition	O
of	O
NGF	O
[	O
38	O
]	O
.	O

PLC	O
-	O
γ	O
catalyzes	O
the	O
hydrolysis	O
of	O
phosphatidylinositol-4,5-bisphosphate	O
(	O
PIP2	O
)	O
to	O
diacylglycerol	O
(	O
DAG	O
)	O
and	O
inositol	O
triphosphate	O
(	O
IP3	O
)	O
.	O

DAG	O
activates	O
protein	O
kinase	O
C	O
,	O
and	O
IP3	O
promotes	O
transient	O
release	O
of	O
Ca2	O
+	O
from	O
the	O
ER	O
[	O
39	O
]	O
.	O

The	O
pathway	O
via	O
PLC	O
-	O
γ	O
is	O
responsible	O
for	O
NGF	O
-	O
induced	O
cell	O
differentiation	O
[	O
40	O
]	O
and	O
neurite	O
outgrowth	O
[	O
41	O
]	O
.	O

Furthermore	O
,	O
stimulation	O
of	O
PI3	O
K	O
is	O
reported	O
to	O
be	O
involved	O
in	O
the	O
promotion	O
of	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
[	O
42	O
]	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
the	O
PLC	O
-	O
γ	O
inhibitor	O
U73122	O
and	O
the	O
PI3	O
K	O
inhibitor	O
LY294002	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
both	O
the	O
p38MAPK	O
inhibitor	O
SB203580	O
and	O
the	O
JNK	O
inhibitor	O
SP600125	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
.	O

In	O
addition	O
,	O
it	O
is	O
also	O
interesting	O
that	O
neurite	O
outgrowth	O
induced	O
by	O
low	O
concentration	O
(	O
2.5	O
ng	O
/	O
ml	O
)	O
of	O
NGF	O
was	O
not	O
blocked	O
by	O
these	O
inihibitors	O
,	O
consistent	O
with	O
a	O
previous	O
report	O
[	O
43	O
]	O
,	O
[	O
44	O
]	O
,	O
suggesting	O
the	O
existence	O
of	O
novel	O
pathway	O
(	O
s	O
)	O
for	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
PLC	O
-	O
γ	O
,	O
PI3	O
K	O
,	O
p38MAPK	O
,	O
and	O
JNK	O
signaling	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
(	O
Figure	O
8)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
the	O
specific	O
inhibitors	O
for	O
the	O
Raf	O
/	O
Ras	O
/	O
MEK	O
/	O
MAPK	O
pathways	O
significantly	O
blocked	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
SA4503	O
,	O
suggesting	O
that	O
these	O
pathways	O
are	O
involved	O
in	O
the	O
potentiation	O
of	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
by	O
sigma-1	O
receptor	O
agonists	O
(	O
Figure	O
8)	O
.	O

Our	O
recent	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
study	O
demonstrated	O
that	O
,	O
after	O
a	O
single	O
oral	O
administration	O
,	O
fluvoxamine	O
bound	O
to	O
sigma-1	O
receptors	O
in	O
the	O
living	O
human	B
brain	O
[	O
45	O
]	O
.	O

This	O
finding	O
suggests	O
that	O
sigma-1	O
receptors	O
are	O
involved	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
fluvoxamine	O
in	O
the	O
human	B
brain	O
[	O
45	O
]	O
.	O

Taken	O
together	O
,	O
the	O
past	O
and	O
present	O
findings	O
suggest	O
that	O
,	O
unlike	O
paroxetine	O
and	O
sertraline	O
,	O
the	O
SSRI	O
fluvoxamine	O
,	O
with	O
its	O
sigma-1	O
receptor	O
agonistic	O
activity	O
,	O
might	O
be	O
a	O
unique	O
therapeutic	O
drug	O
for	O
neuropsychiatric	O
diseases	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
results	O
suggest	O
that	O
,	O
as	O
a	O
sigma-1	O
receptor	O
agonist	O
,	O
fluvoxamine	O
could	O
potentiate	O
the	O
NGF	O
-	O
induced	O
neurite	O
outgrowth	O
in	O
PC12	O
cells	O
.	O

Furthermore	O
,	O
it	O
is	O
likely	O
that	O
interaction	O
with	O
IP3	O
receptors	O
and	O
several	O
subsequent	O
signaling	O
molecules	O
are	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
pharmacological	O
action	O
of	O
sigma-1	O
receptor	O
agonists	O
.	O

Therefore	O
,	O
it	O
is	O
likely	O
that	O
sigma-1	O
receptor	O
agonists	O
such	O
as	O
fluvoxamine	O
and	O
DHEA	O
-	O
sulfate	O
,	O
which	O
are	O
available	O
around	O
the	O
world	O
,	O
would	O
be	O
unique	O
therapeutic	O
drugs	O
for	O
neuropsychiatric	O
diseases	O
.	O

A	O
Novel	O
Role	O
of	O
the	O
NRF2	O
Transcription	O
Factor	O
in	O
the	O
Regulation	O
of	O
Arsenite	O
-	O
Mediated	O
Keratin	O
16	O
Gene	O
Expression	O
in	O
Human	B
Keratinocytes	O
Abstract	O
Background	O
Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
and	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
skin	O
hyperkeratosis	O
and	O
cancer	O
.	O

Objectives	O
We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
keratin	O
16	O
(	O
K16	O
)	O
gene	O
by	O
iAs	O
in	O
the	O
human	B
keratinocyte	O
cell	O
line	O
HaCaT.	O
Methods	O
We	O
performed	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
,	O
luciferase	O
assays	O
,	O
Western	O
blots	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
to	O
determine	O
the	O
transcriptional	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
.	O

We	O
used	O
gene	O
overexpression	O
approaches	O
to	O
elucidate	O
the	O
nuclear	O
factor	O
erythroid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
involved	O
in	O
the	O
K16	O
induction	O
.	O

Results	O
iAs	O
induced	O
the	O
mRNA	O
and	O
protein	O
expression	O
of	O
K16	O
.	O

We	O
also	O
found	O
that	O
the	O
expression	O
of	O
K16	O
was	O
transcriptionally	O
induced	O
by	O
iAs	O
through	O
activator	O
protein-1–like	O
sites	O
and	O
an	O
antioxidant	O
response	O
element	O
(	O
ARE	O
)	O
in	O
its	O
gene	O
promoter	O
region	O
.	O

Treatment	O
with	O
iAs	O
also	O
enhanced	O
the	O
production	O
and	O
translocation	O
of	O
the	O
NRF2	O
transcription	O
factor	O
,	O
an	O
ARE	O
-	O
binding	O
protein	O
,	O
into	O
the	O
nucleus	O
without	O
modification	O
of	O
its	O
mRNA	O
expression	O
.	O

In	O
addition	O
,	O
iAs	O
elongated	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
.	O

When	O
overexpressed	O
in	O
HaCaT	O
cells	O
,	O
NRF2	O
was	O
also	O
directly	O
involved	O
in	O
not	O
only	O
the	O
up	O
-	O
regulation	O
of	O
the	O
detoxification	O
gene	O
thioredoxin	O
but	O
also	O
K16	O
gene	O
expression	O
.	O

Conclusions	O
Our	O
data	O
clearly	O
indicate	O
that	O
the	O
K16	O
gene	O
is	O
a	O
novel	O
target	O
of	O
NRF2	O
.	O

Furthermore	O
,	O
our	O
findings	O
also	O
suggest	O
that	O
NRF2	O
has	O
opposing	O
roles	O
in	O
the	O
cell	O
—	O
in	O
the	O
activation	O
of	O
detoxification	O
pathways	O
and	O
in	O
promoting	O
the	O
development	O
of	O
skin	O
disorders	O
.	O

Inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
)	O
,	O
a	O
ubiquitous	O
element	O
,	O
is	O
one	O
of	O
the	O
most	O
toxic	O
metals	O
present	O
in	O
the	O
natural	O
environment	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
)	O
.	O

Arsenicals	O
are	O
found	O
as	O
naturally	O
occurring	O
constituents	O
of	O
soil	O
,	O
food	O
,	O
and	O
drinking	O
water	O
(	O
Wu	O
et	O
al.	O
1989	O
;	O
Yoshida	O
et	O
al.	O
2004	O
)	O
,	O
and	O
exposure	O
to	O
iAs	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
disease	O
outcomes	O
,	O
including	O
disorders	O
of	O
the	O
skin	O
,	O
urinary	O
bladder	O
,	O
liver	O
,	O
and	O
lung	O
(	O
Tchounwou	O
et	O
al.	O
2004	O
)	O
.	O

In	O
particular	O
,	O
skin	O
hyperkeratosis	O
is	O
a	O
characteristic	O
dermatologic	O
lesion	O
associated	O
with	O
ingestion	O
of	O
arsenic	O
from	O
contaminated	O
groundwater	O
(	O
McLellan	O
2002	O
;	O
Yoshida	O
et	O
al.	O
2004	O
)	O
.	O

There	O
is	O
also	O
a	O
significant	O
association	O
between	O
hyperkeratosis	O
,	O
nonmelanoma	O
skin	O
cancer	O
(	O
e.g.	O
,	O
basal	O
cell	O
carcinoma	O
and	O
squamous	O
cell	O
carcinoma	O
)	O
,	O
and	O
Bowen	O
disease	O
(	O
Col	O
et	O
al.	O
1999	O
;	O
Rossman	O
et	O
al.	O
2004	O
)	O
.	O

Furthermore	O
,	O
the	O
pathologic	O
features	O
associated	O
with	O
arsenic	O
-	O
induced	O
hyperkeratosis	O
present	O
as	O
typical	O
acanthotic	O
types	O
of	O
psoriasis	O
-	O
like	O
keratosis	O
,	O
characterized	O
by	O
the	O
aberrant	O
proliferation	O
and	O
terminal	O
differentiation	O
of	O
epidermal	O
keratinocytes	O
(	O
Lee	O
et	O
al.	O
2006	O
)	O
.	O

Many	O
epidemiologic	O
studies	O
have	O
shown	O
that	O
hyperkeratoses	O
are	O
the	O
most	O
frequent	O
precursor	O
lesions	O
of	O
some	O
skin	O
cancers	O
(	O
Bagla	O
and	O
Kaiser	O
1996	O
;	O
Col	O
et	O
al.	O
1999	O
)	O
.	O

The	O
keratins	O
are	O
the	O
most	O
prominent	O
cytoskeletal	O
proteins	O
in	O
keratinocytes	O
and	O
comprise	O
a	O
large	O
family	O
of	O
proteins	O
that	O
form	O
intermediate	O
filament	O
networks	O
in	O
all	O
epithelial	O
cell	O
types	O
(	O
Moll	O
et	O
al.	O
1982	O
)	O
.	O

Keratin	O
16	O
(	O
K16	O
)	O
and	O
keratin	O
6	O
(	O
K6	O
)	O
genes	O
are	O
constitutively	O
expressed	O
in	O
a	O
number	O
of	O
stratified	O
epithelial	O
levels	O
,	O
including	O
the	O
palmar	O
and	O
plantar	O
epidermis	O
(	O
Moll	O
et	O
al.	O
1982	O
)	O
.	O

In	O
skin	O
diseases	O
characterized	O
by	O
aberrant	O
proliferation	O
and	O
differentiation	O
,	O
such	O
as	O
psoriasis	O
and	O
cancer	O
,	O
K16	O
is	O
detectable	O
at	O
higher	O
levels	O
compared	O
with	O
normal	O
tissue	O
(	O
Haider	O
et	O
al.	O
2006	O
)	O
.	O

Furthermore	O
,	O
the	O
tissue	O
-	O
specific	O
overexpression	O
of	O
wild	O
-	O
type	O
K16	O
in	O
the	O
epidermis	O
of	O
transgenic	O
mice	B
results	O
in	O
the	O
hyperproliferation	O
of	O
keratinocytes	O
and	O
aberrant	O
keratinization	O
of	O
cornified	O
layers	O
,	O
leading	O
to	O
hyperkeratosis	O
of	O
the	O
skin	O
(	O
Takahashi	O
et	O
al.	O
1994	O
)	O
.	O

Nuclear	O
factor	O
erythoid	O
-	O
derived	O
2	O
related	O
factor	O
2	O
(	O
NRF2	O
)	O
,	O
a	O
""""	O
cap	O
'	O
n	O
'	O
collar	O
""""	O
basic	O
leucine	O
zipper	O
transcription	O
factor	O
,	O
regulates	O
a	O
transcriptional	O
program	O
that	O
maintains	O
cellular	O
redox	O
homeostasis	O
and	O
protects	O
cells	O
from	O
oxidative	O
stress	O
and	O
xenobiotic	O
agents	O
(	O
Ishii	O
et	O
al.	O
2000	O
;	O
Moi	O
et	O
al.	O
1994	O
)	O
.	O

Several	O
detoxifying	O
and	O
antioxidant	O
genes	O
,	O
including	O
glutathione	O
-	O
S	O
-	O
transferases	O
(	O
GSTs	O
)	O
,	O
heme	O
oxygenase-1	O
(	O
HMOX1	O
)	O
,	O
and	O
thioredoxin	O
(	O
TXN	O
)	O
,	O
are	O
regulated	O
by	O
NRF2	O
through	O
the	O
antioxidant	O
responsive	O
element	O
(	O
ARE	O
)	O
in	O
the	O
respective	O
promoter	O
regions	O
of	O
these	O
genes	O
(	O
McMahon	O
et	O
al.	O
2001	O
;	O
Wakabayashi	O
et	O
al.	O
2004	O
)	O
.	O

NRF2	O
is	O
held	O
in	O
the	O
cytoplasm	O
by	O
a	O
cytoskeletal	O
-	O
associated	O
specific	O
inhibitory	O
protein	O
(	O
kelch	O
-	O
like	O
ECH	O
-	O
associated	O
protein	O
1	O
;	O
KEAP1	O
)	O
under	O
normal	O
cellular	O
redox	O
state	O
conditions	O
,	O
where	O
it	O
is	O
continuously	O
targeted	O
by	O
the	O
proteasomal	O
degradation	O
pathway	O
(	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Upon	O
exposure	O
of	O
the	O
cell	O
to	O
oxidative	O
stress	O
or	O
electrophiles	O
,	O
NRF2	O
can	O
escape	O
this	O
KEAP1-mediated	O
repression	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
activate	O
the	O
expression	O
of	O
its	O
target	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
;	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Recently	O
,	O
studies	O
of	O
Keap1–	O
/	O
–mice	O
have	O
shown	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
and	O
constitutively	O
activates	O
the	O
transcription	O
of	O
its	O
target	O
genes	O
,	O
even	O
in	O
the	O
absence	O
of	O
stress	O
signals	O
(	O
Wakabayashi	O
et	O
al.	O
2003	O
)	O
.	O

Most	O
interestingly	O
,	O
however	O
,	O
the	O
skin	O
,	O
esophagus	O
,	O
and	O
forestomach	O
of	O
Keap1-deficient	O
mice	B
show	O
cornified	O
layer	O
and	O
hyperkeratosis	O
phenotypes	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
have	O
also	O
shown	O
that	O
the	O
expression	O
of	O
NRF2	O
and	O
ARE	O
-	O
controlled	O
genes	O
is	O
induced	O
by	O
iAs	O
in	O
some	O
cell	O
types	O
(	O
Pi	O
et	O
al.	O
2003	O
;	O
Sakurai	O
et	O
al.	O
2005	O
)	O
.	O

Furthermore	O
,	O
histochemical	O
analyses	O
have	O
indicated	O
that	O
the	O
expression	O
of	O
K16	O
is	O
increased	O
in	O
Bowen	O
disease	O
,	O
basal	O
cell	O
carcinoma	O
,	O
and	O
squamous	O
cell	O
carcinoma	O
induced	O
by	O
arsenicals	O
(	O
Yu	O
et	O
al.	O
1993	O
)	O
.	O

However	O
,	O
it	O
remains	O
to	O
be	O
determined	O
whether	O
NRF2	O
can	O
regulate	O
the	O
transcriptional	O
activation	O
of	O
K16	O
upon	O
iAs	O
exposure	O
in	O
human	B
keratinocytes	O
.	O

Hence	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
-	O
induced	O
NRF2	O
mediation	O
.	O

Materials	O
and	O
Methods	O
Chemicals	O
and	O
reagents	O
A	O
purified	O
preparation	O
of	O
inorganic	O
sodium	O
arsenite	O
(	O
iAs	O
;	O
NaAsO2	O
;	O
Merck	O
,	O
Darmstadt	O
,	O
Germany	O
)	O
was	O
dissolved	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
and	O
added	O
directly	O
to	O
the	O
culture	O
medium	O
.	O

A	O
fresh	O
iAs	O
solution	O
was	O
prepared	O
for	O
each	O
new	O
experiment	O
.	O

Cycloheximide	O
(	O
CHX	O
)	O
,	O
dimethyl	O
-	O
sulfoxide	O
(	O
DMSO	O
)	O
,	O
and	O
a	O
protease	O
inhibitor	O
cocktail	O
were	O
purchased	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
.	O

CHX	O
was	O
dissolved	O
in	O
DMSO	O
and	O
stored	O
–20	O
°	O
C	O
until	O
use	O
.	O

Cells	O
and	O
culture	O
conditions	O
The	O
human	B
keratinocyte	O
HaCaT	O
cell	O
line	O
was	O
obtained	O
from	O
N.E.	O
Fusenig	O
(	O
German	O
Cancer	O
Research	O
Center	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

Cells	O
were	O
maintained	O
in	O
monolayer	O
cultures	O
in	O
95	O
%	O
air	O
and	O
5	O
%	O
CO2	O
at	O
37	O
°	O
C	O
in	O
Dulbecco	O
's	O
modified	O
Eagles	O
medium	O
(	O
DMEM	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
,	O
50	O
U	O
/	O
mL	O
penicillin	O
and	O
50	O
mg	O
/	O
mL	O
streptomycin	O
and	O
nonessential	O
amino	O
acids	O
(	O
Gibco	O
BRL	O
,	O
Paisley	O
,	O
UK	O
)	O
.	O

RNA	O
preparation	O
and	O
semiquantitative	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
analysis	O
We	O
determined	O
RNA	O
expression	O
levels	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al.	O
2004	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
from	O
HaCaT	O
cells	O
using	O
the	O
GeneElute	O
Mammalian	O
Total	O
RNA	O
Kit	O
(	O
Sigma	O
)	O
.	O

The	O
specific	O
primers	O
used	O
for	O
first	O
-	O
strand	O
cDNA	O
synthesis	O
and	O
PCR	O
were	O
as	O
follows	O
:	O
K16	O
[	O
forward	O
,	O
5′-GAT	O
GCT	O
TGC	O
TCT	O
GAG	O
AGG	O
TC-3′	O
,	O
and	O
reverse	O
,	O
5′-CCA	O
GCA	O
AGA	O
TCT	O
GGT	O
ACT	O
CC-3′	O
;	O
Gene	O
Bank	O
accession	O
no.	O
NM_005557	O
(	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
2007	O
)	O
]	O
;	O
c	O
-	O
Jun	O
(	O
forward	O
,	O
5′-CCT	O
GTT	O
GCG	O
GCC	O
CCG	O
AAA	O
CT-3′	O
,	O
and	O
reverse	O
,	O
5′-ACC	O
ATG	O
CCT	O
GCC	O
CCG	O
TTG	O
AC-3′	O
;	O
NM_002228	O
)	O
;	O
c	O
-	O
Fos	O
(	O
forward	O
,	O
5′-TTT	O
GCC	O
TAA	O
CCG	O
CCA	O
CGA	O
TGA	O
T-3′	O
,	O
and	O
reverse	O
,	O
5′-TTG	O
CCG	O
CTT	O
TCT	O
GCC	O
ACC	O
TC-3′	O
;	O
NM_005252	O
)	O
;	O
NRF2	O
(	O
forward	O
,	O
5′-AGA	O
TTC	O
ACA	O
GGC	O
CTT	O
TCT	O
CG-3′	O
,	O
and	O
reverse	O
,	O
5′-CAG	O
CTC	O
TCC	O
CTA	O
CCG	O
TTG	O
GA-3′	O
;	O
AF323119	O
)	O
;	O
KEAP1	O
(	O
forward	O
,	O
5′-CAG	O
AGG	O
TGG	O
TGG	O
TGT	O
TGC	O
TTA	O
T-3′	O
,	O
and	O
reverse	O
,	O
5′-AGC	O
TCG	O
TTC	O
ATG	O
ATG	O
CCA	O
AAG-3′	O
;	O
NM_012289	O
)	O
;	O
TXN	O
(	O
forward	O
,	O
5′-CAG	O
GGG	O
AAT	O
GAA	O
AGA	O
AAG	O
G-3′	O
,	O
and	O
reverse	O
,	O
5′-CAA	O
GGT	O
GAA	O
GCA	O
GAT	O
CG-3′	O
;	O
NM_003329	O
)	O
,	O
and	O
glyceraldehyde	O
3-phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
as	O
a	O
loading	O
control	O
(	O
forward	O
,	O
5′-ACC	O
ACA	O
GTC	O
CAT	O
GCC	O
ATC	O
AC-3′	O
,	O
and	O
reverse	O
,	O
5′-TCC	O
ACC	O
ACC	O
CTG	O
TTG	O
CTG	O
TA-3′	O
,	O
NM_002046	O
)	O
.	O

PCR	O
products	O
were	O
separated	O
on	O
a	O
1.8	O
%	O
agarose	O
gel	O
and	O
stained	O
with	O
ethidium	O
bromide	O
.	O

Western	O
blot	O
analysis	O
We	O
performed	O
Western	O
blot	O
analysis	O
as	O
described	O
previously	O
(	O
Sugioka	O
et	O
al.	O
2004	O
)	O
.	O

Briefly	O
,	O
nuclear	O
and	O
cytoplasmic	O
proteins	O
were	O
extracted	O
using	O
the	O
NE	O
-	O
PER	O
nuclear	O
and	O
cytoplasmic	O
extraction	O
kit	O
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

For	O
protein	O
extraction	O
,	O
the	O
cells	O
were	O
lysed	O
in	O
a	O
buffer	O
containing	O
complete	O
protease	O
inhibitor	O
cocktail	O
.	O

We	O
measured	O
protein	O
concentrations	O
using	O
the	O
DC	O
Protein	O
Assay	O
Kit	O
(	O
Bio	O
-	O
Rad	O
,	O
Richmond	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Equal	O
amounts	O
of	O
protein	O
were	O
then	O
resolved	O
by	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
(	O
SDS	O
-	O
PAGE	O
)	O
and	O
transferred	O
to	O
a	O
polyvinylidene	O
fluoride	O
membrane	O
(	O
Amersham	O
Biosciences	O
,	O
Bucks	O
,	O
UK	O
)	O
.	O

Immunoblotting	O
was	O
carried	O
out	O
with	O
specific	O
antibodies	O
in	O
Tris	O
-	O
buffered	O
saline	O
with	O
0.05	O
%	O
Tween	O
20	O
.	O

The	O
primary	O
antibodies	O
were	O
as	O
follows	O
:	O
K16	O
(	O
Neomarkers	O
,	O
Fremont	O
,	O
CA	O
,	O
USA	O
)	O
,	O
NRF2	O
and	O
KEAP1	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
,	O
USA	O
)	O
,	O
c	O
-	O
Jun	O
(	O
Cell	O
Signaling	O
,	O
Beverly	O
,	O
MA	O
,	O
USA	O
)	O
,	O
and	O
β	O
-	O
actin	O
(	O
Sigma	O
)	O
.	O

After	O
washing	O
,	O
the	O
membranes	O
were	O
probed	O
with	O
horseradish	B
peroxidase	O
-	O
conjugated	O
secondary	O
antibodies	O
and	O
developed	O
by	O
chemiluminescence	O
using	O
the	O
ECL	O
Plus	O
Detection	O
Kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Plasmids	O
,	O
transfections	O
,	O
and	O
luciferase	O
assays	O
Human	B
K16	O
promoter	O
regions	O
of	O
varying	O
lengths	O
(	O
pXK-1	O
,	O
3	O
,	O
4	O
,	O
5	O
-	O
1	O
,	O
and	O
5	O
-	O
2	O
)	O
were	O
provided	O
by	O
Y	O
-	O
N	O
Wang	O
(	O
National	O
Cheng	O
Kung	O
University	O
,	O
Taiwan	O
)	O
.	O

These	O
DNA	O
fragments	O
were	O
prepared	O
from	O
HaCaT	O
cells	O
and	O
were	O
ligated	O
into	O
the	O
pXP-1	O
luciferase	O
vector	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

The	O
p3xARE	O
/	O
Luc	O
vector	O
,	O
harboring	O
three	O
tandem	O
repeats	O
of	O
ARE	O
,	O
was	O
donated	O
by	O
X.L.	O
Chen	O
(	O
Discovery	O
Research	O
,	O
AtheroGenics	O
Inc.	O
,	O
Alpharetta	O
,	O
GA	O
,	O
USA	O
)	O
(	O
Chen	O
et	O
al.	O
2003	O
)	O
.	O

The	O
wild	O
-	O
type	O
NRF2	O
expression	O
vector	O
(	O
WT	O
-	O
NRF2	O
)	O
was	O
a	O
gift	O
from	O
H.S.	O

So	O
(	O
Wonkwang	O
University	O
School	O
of	O
Medicine	O
,	O
Korea	O
)	O
(	O
So	O
et	O
al.	O
2006	O
)	O
.	O

NRF2	O
cDNA	O
was	O
subcloned	O
into	O
a	O
pcDNA3.1	O
(	O
+	O
)	O
vector	O
(	O
Invitrogen	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
the	O
transfection	O
of	O
reporter	O
plasmids	O
,	O
we	O
seeded	O
HaCaT	O
cells	O
into	O
six	O
-	O
well	O
plates	O
at	O
a	O
density	O
of	O
80	O
%	O
the	O
previous	O
day	O
.	O

Cells	O
were	O
then	O
transfected	O
with	O
a	O
total	O
of	O
each	O
luciferase	O
reporter	O
construct	O
(	O
2.5	O
μg	O
)	O
using	O
LipofectAMINE	O
plus	O
(	O
Invitrogen	O
)	O
.	O

To	O
control	O
for	O
the	O
efficiency	O
of	O
transfection	O
,	O
Renilla	O
luciferase	O
gene	O
expression	O
was	O
monitored	O
using	O
either	O
the	O
pRL	O
-	O
CMV	O
or	O
pRL	O
-	O
TK	O
vectors	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
,	O
USA	O
)	O
.	O

For	O
overexpression	O
of	O
WT	O
-	O
NRF2	O
,	O
we	O
normalized	O
the	O
total	O
plasmid	O
concentration	O
using	O
the	O
pcDNA3.1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Thirty	O
-	O
six	O
hours	O
after	O
transfection	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
fresh	O
medium	O
containing	O
either	O
vehicle	O
(	O
PBS	O
)	O
or	O
iAs	O
for	O
6	O
hr	O
.	O

After	O
iAs	O
exposure	O
,	O
we	O
harvested	O
cells	O
and	O
analyzed	O
them	O
for	O
luciferase	O
activity	O
using	O
a	O
Dual	O
-	O
Luciferase	O
Reporter	O
Assay	O
System	O
(	O
Promega	O
)	O
.	O

For	O
the	O
investigation	O
of	O
the	O
role	O
of	O
NRF2	O
in	O
regulating	O
K16	O
gene	O
expression	O
,	O
transfection	O
of	O
an	O
NRF2	O
expression	O
plasmid	O
into	O
HaCaT	O
cells	O
was	O
carried	O
out	O
using	O
LipofectAMINE	O
2000	O
(	O
Invitrogen	O
)	O
.	O

Cells	O
were	O
cultured	O
in	O
100-mm	O
plates	O
24	O
hr	O
before	O
transfection	O
.	O

The	O
expression	O
plasmid	O
WT	O
-	O
NRF2	O
(	O
15	O
μg	O
)	O
was	O
then	O
transfected	O
into	O
the	O
cells	O
for	O
48–60	O
hr	O
.	O

As	O
a	O
negative	O
control	O
,	O
we	O
used	O
15	O
μg	O
of	O
the	O
pcDNA3.1	O
(	O
+	O
)	O
empty	O
vector	O
.	O

Electrophoretic	O
mobility	O
-	O
shift	O
assays	O
(	O
EMSA	O
)	O
We	O
extracted	O
and	O
measured	O
nuclear	O
proteins	O
as	O
described	O
above	O
.	O

Nuclear	O
protein	O
/	O
DNA	O
complexes	O
were	O
subjected	O
to	O
electrophoresis	O
in	O
nondenaturing	O
5	O
%	O
polyacrylamide	O
gels	O
containing	O
2	O
%	O
glycerol	O
in	O
0.25	O
%	O
Tris	O
-	O
borate	O
/	O
EDTA	O
buffer	O
and	O
transferred	O
to	O
Hybond	O
-	O
N+	O
nylon	O
transfer	O
membranes	O
(	O
Amersham	O
Biosciences	O
)	O
for	O
detection	O
using	O
the	O
Light	O
-	O
Shift	O
EMSA	O
kit	O
(	O
Pierce	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
,	O
with	O
minor	O
modifications	O
.	O

We	O
incubated	O
10-μg	O
aliquots	O
of	O
nuclear	O
extract	O
with	O
the	O
DNA	O
probe	O
in	O
a	O
binding	O
reaction	O
buffer	O
containing	O
10	O
mM	O
Tris	O
/	O
HCl	O
(	O
pH	O
7.6	O
)	O
,	O
50	O
mM	O
KCl	O
,	O
0.5	O
mM	O
dithiothreitol	O
,	O
0.25	O
mM	O
EDTA	O
,	O
5	O
%	O
glycerol	O
,	O
2.5	O
mM	O
MgCl2	O
,	O
0.05	O
%	O
NP-40	O
detergent	O
,	O
and	O
2	O
μg	O
of	O
poly	O
(	O
dI	O
-	O
dC	O
)	O
·poly	O
(	O
dI	O
-	O
dC	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

For	O
supershift	O
assays	O
,	O
2	O
μg	O
of	O
either	O
a	O
polyclonal	O
anti	O
-	O
NRF2	O
or	O
an	O
anti	O
-	O
c	O
-	O
Jun	O
antibody	O
(	O
Santa	O
Cruz	O
Biotechnology	O
)	O
was	O
added	O
with	O
the	O
nuclear	O
protein	O
for	O
2	O
hr	O
at	O
4	O
°	O
C	O
before	O
the	O
labeled	O
oligonucleotide	O
probe	O
was	O
added	O
.	O

Biotin	O
-	O
labeled	O
,	O
double	O
-	O
stranded	O
oligonucleotides	O
WT	O
-	O
K16ARE	O
(	O
–157	O
/	O
–132	O
,	O
5′-GGGGAACCTGGAGTCAGCAGT	O
-	O
TAGGA-3′	O
)	O
,	O
containing	O
an	O
ARE	O
site	O
(	O
–148	O
/	O
–140	O
,	O
underlined	O
)	O
in	O
the	O
human	B
K16	O
promoter	O
region	O
,	O
and	O
Mut	O
-	O
K16ARE	O
(	O
5′-GGGGAA	O
-	O
CCTGGAGTCAaaAGTTAGGA-3′	O
,	O
mutated	O
GC	O
box	O
in	O
the	O
ARE	O
)	O
were	O
prepared	O
by	O
Fasmac	O
(	O
Kanagawa	O
,	O
Japan	O
)	O
.	O

A	O
consensus	O
ARE	O
probe	O
was	O
purchased	O
from	O
Panomics	O
,	O
Inc.	O
(	O
Redwood	O
City	O
,	O
CA	O
,	O
USA	O
)	O
.	O

For	O
competition	O
binding	O
of	O
the	O
K16	O
ARE	O
-	O
complexes	O
,	O
we	O
used	O
an	O
unlabeled	O
AP-1	O
consensus	O
oligonucleotide	O
(	O
5′-TATC	O
-	O
GATAAGCTATGAGTCATCCGGG-3′	O
)	O
.	O

The	O
binding	O
specificity	O
was	O
confirmed	O
in	O
each	O
case	O
by	O
the	O
addition	O
of	O
a	O
100-fold	O
molar	O
excess	O
of	O
unlabeled	O
oligonucleotide	O
.	O

CHX	O
chase	O
experiment	O
We	O
investigated	O
the	O
posttranscriptional	O
regulation	O
of	O
both	O
the	O
steady	O
-	O
state	O
levels	O
and	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
by	O
CHX	O
chase	O
analysis	O
.	O

Cells	O
were	O
incubated	O
in	O
serum	O
-	O
free	O
medium	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
for	O
6	O
hr	O
.	O

The	O
culture	O
medium	O
was	O
then	O
replaced	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
CHX	O
(	O
100	O
μg	O
/	O
mL	O
)	O
.	O

We	O
prepared	O
cell	O
lysates	O
at	O
0	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
and	O
240	O
min	O
after	O
iAs	O
treatment	O
.	O

Whole	O
-	O
cell	O
lysates	O
were	O
resolved	O
by	O
SDS	O
-	O
PAGE	O
and	O
immunoblotted	O
with	O
antibodies	O
against	O
NRF2	O
.	O

Statistics	O
All	O
the	O
data	O
generated	O
from	O
at	O
least	O
three	O
independent	O
experiments	O
and	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
were	O
analyzed	O
by	O
the	O
Student	O
's	O
t	O
-	O
test	O
.	O

Statistical	O
comparisons	O
were	O
made	O
by	O
logarithmic	O
transformation	O
of	O
the	O
normalized	O
values	O
.	O

We	O
considered	O
p	O
-	O
values	O
<	O
0.01	O
to	O
be	O
statistically	O
significant	O
.	O

Results	O
K16	O
expression	O
is	O
induced	O
by	O
iAs	O
in	O
HaCaT	O
cells	O
We	O
wanted	O
to	O
determine	O
whether	O
the	O
K16	O
mRNA	O
is	O
transcriptionally	O
regulated	O
by	O
iAs	O
,	O
and	O
treated	O
HaCaT	O
cells	O
with	O
this	O
compound	O
for	O
various	O
time	O
periods	O
over	O
a	O
range	O
of	O
doses	O
.	O

After	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
1–20	O
μM	O
iAs	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
increased	O
compared	O
with	O
the	O
control	O
at	O
6	O
hr	O
(	O
Figure	O
1A	O
)	O
but	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

The	O
increase	O
in	O
the	O
K16	O
protein	O
levels	O
after	O
6	O
hr	O
of	O
iAs	O
exposure	O
was	O
just	O
detectable	O
at	O
10–20	O
μM	O
,	O
but	O
a	O
dose	O
-	O
dependent	O
increase	O
was	O
more	O
evident	O
at	O
10	O
hr	O
(	O
Figure	O
1B	O
)	O
.	O

This	O
enhancement	O
of	O
K16	O
expression	O
had	O
declined	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Identification	O
of	O
the	O
iAs	O
responsive	O
region	O
in	O
the	O
K16	O
gene	O
promoter	O
To	O
investigate	O
the	O
mechanisms	O
underlying	O
the	O
transactivation	O
of	O
the	O
K16	O
gene	O
by	O
iAs	O
,	O
we	O
first	O
examined	O
the	O
response	O
of	O
the	O
K16	O
regulatory	O
region	O
to	O
this	O
compound	O
using	O
a	O
luciferase	O
reporter	O
gene	O
assay	O
.	O

The	O
dose	O
-	O
dependent	O
activation	O
of	O
K16	O
transcription	O
after	O
iAs	O
treatment	O
was	O
observed	O
with	O
a	O
construct	O
containing	O
a	O
515-bp	O
fragment	O
of	O
the	O
K16	O
promoter	O
(	O
Figure	O
2A	O
)	O
.	O

To	O
further	O
elucidate	O
the	O
region	O
containing	O
the	O
iAs	O
responsive	O
element	O
,	O
we	O
examined	O
a	O
series	O
of	O
deletions	O
of	O
the	O
5′-flanking	O
region	O
of	O
K16	O
gene	O
.	O

The	O
ARE	O
sequence	O
in	O
the	O
pXK-5–1	O
vector	O
contains	O
an	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
–like	O
element	O
followed	O
by	O
a	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
2B	O
,	O
an	O
enhancement	O
in	O
the	O
reporter	O
activity	O
levels	O
was	O
observed	O
for	O
the	O
promoter	O
constructs	O
,	O
pXK-1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
-	O
1	O
,	O
in	O
response	O
to	O
20	O
μM	O
iAs	O
.	O

A	O
decline	O
in	O
reporter	O
activity	O
,	O
however	O
,	O
depended	O
on	O
the	O
number	O
of	O
AP-1–like	O
sites	O
,	O
and	O
the	O
results	O
for	O
the	O
pXK-5	O
-	O
1	O
construct	O
show	O
also	O
that	O
ARE	O
is	O
activated	O
by	O
iAs	O
.	O

In	O
contrast	O
,	O
no	O
significant	O
activation	O
was	O
observed	O
using	O
a	O
pXK-5	O
-	O
2	O
construct	O
in	O
response	O
to	O
20	O
μM	O
iAs	O
.	O

Expression	O
of	O
AP-1	O
transcriptions	O
factor	O
and	O
c	O
-	O
Jun	O
production	O
following	O
iAs	O
treatment	O
We	O
examined	O
AP-1	O
transcription	O
factors	O
c	O
-	O
Jun	O
and	O
c	O
-	O
Fos	O
expression	O
in	O
iAs	O
-	O
treated	O
HaCaT	O
cells	O
by	O
semiquantitative	O
RT	O
-	O
PCR	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
expression	O
was	O
observed	O
during	O
the	O
first	O
3	O
hr	O
after	O
treatment	O
(	O
data	O
not	O
shown	O
)	O
.	O

An	O
appreciable	O
induction	O
of	O
c	O
-	O
Jun	O
was	O
also	O
confirmed	O
after	O
6	O
hr	O
,	O
but	O
this	O
was	O
down	O
-	O
regulated	O
by	O
24	O
hr	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
c	O
-	O
Fos	O
was	O
only	O
transiently	O
detectable	O
at	O
3	O
hr	O
(	O
data	O
not	O
shown	O
)	O
but	O
was	O
not	O
observed	O
during	O
the	O
6–24	O
hr	O
period	O
of	O
this	O
experiment	O
.	O

As	O
shown	O
in	O
Figure	O
3B	O
,	O
iAs	O
-	O
enhanced	O
c	O
-	O
Jun	O
production	O
can	O
be	O
observed	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
at	O
6	O
hr	O
,	O
but	O
it	O
declines	O
from	O
10	O
to	O
24	O
hr	O
.	O

iAs	O
potently	O
induces	O
the	O
translocation	O
of	O
NRF2	O
and	O
activates	O
the	O
ARE	O
of	O
the	O
K16	O
promoter	O
The	O
results	O
of	O
our	O
reporter	O
assays	O
suggested	O
that	O
iAs	O
stimulates	O
not	O
only	O
the	O
AP-1–like	O
sites	O
but	O
also	O
the	O
ARE	O
site	O
within	O
the	O
K16	O
gene	O
promoter	O
in	O
HaCaT	O
cells	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
several	O
oxidative	O
stress	O
agents	O
and	O
toxic	O
chemicals	O
,	O
including	O
iAs	O
,	O
have	O
been	O
reported	O
to	O
induce	O
the	O
expression	O
of	O
ARE	O
-	O
dependent	O
genes	O
in	O
several	O
cell	O
types	O
(	O
Pi	O
et	O
al.	O
2003	O
;	O
Sakurai	O
et	O
al.	O
2005	O
)	O
.	O

On	O
the	O
basis	O
of	O
our	O
observations	O
and	O
some	O
recent	O
reports	O
,	O
we	O
thus	O
hypothesized	O
that	O
iAs	O
would	O
have	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
of	O
the	O
K16	O
gene	O
promoter	O
directly	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
.	O

To	O
confirm	O
that	O
the	O
K16	O
ARE	O
indeed	O
functions	O
as	O
an	O
iAs	O
-	O
responsive	O
transcriptional	O
control	O
element	O
,	O
we	O
performed	O
transient	O
transfections	O
of	O
HaCaT	O
cells	O
with	O
a	O
p3xARE	O
/	O
Luc	O
construct	O
and	O
then	O
subjected	O
these	O
cells	O
to	O
iAs	O
for	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
treatment	O
of	O
HaCaT	O
cells	O
with	O
iAs	O
results	O
in	O
a	O
dramatic	O
increase	O
in	O
ARE	O
-	O
driven	O
promoter	O
activity	O
.	O

Likewise	O
,	O
EMSA	O
using	O
a	O
consensus	O
ARE	O
probe	O
show	O
that	O
iAs	O
-	O
induced	O
ARE	O
-	O
binding	O
complexes	O
increase	O
markedly	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
(	O
Figure	O
4B	O
)	O
.	O

These	O
results	O
indicate	O
that	O
iAs	O
has	O
the	O
ability	O
to	O
activate	O
the	O
ARE	O
-	O
driven	O
genes	O
.	O

We	O
performed	O
further	O
EMSA	O
experiments	O
using	O
an	O
ARE	O
probe	O
specific	O
to	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
WT	O
-	O
K16ARE	O
)	O
and	O
found	O
that	O
K16ARE	O
–	O
nuclear	O
protein	O
complexes	O
formation	O
is	O
augmented	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
4C	O
)	O
.	O

Moreover	O
,	O
the	O
formation	O
of	O
these	O
complexes	O
is	O
specifically	O
inhibited	O
by	O
the	O
addition	O
of	O
excess	O
unlabeled	O
oligonucleotide	O
competitor	O
(	O
Figure	O
4B	O
,	O
C	O
)	O
,	O
whereas	O
an	O
excess	O
of	O
an	O
unlabeled	O
AP-1	O
probe	O
competes	O
only	O
marginally	O
for	O
K16ARE	O
binding	O
(	O
Figure	O
4C	O
)	O
.	O

The	O
NRF2	O
transcription	O
factor	O
has	O
been	O
shown	O
to	O
bind	O
to	O
AREs	O
upon	O
translocation	O
into	O
the	O
nucleus	O
,	O
resulting	O
in	O
the	O
induction	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Wakabayashi	O
et	O
al.	O
2004	O
)	O
.	O

To	O
examine	O
whether	O
iAs	O
induces	O
and	O
translocates	O
NRF2	O
into	O
the	O
nucleus	O
in	O
HaCaT	O
cells	O
,	O
we	O
treated	O
these	O
cells	O
with	O
iAs	O
for	O
either	O
3	O
or	O
6	O
hr	O
.	O

As	O
shown	O
in	O
Figure	O
4D	O
,	O
a	O
dose	O
-	O
dependent	O
accumulation	O
of	O
NRF2	O
protein	O
was	O
observed	O
in	O
the	O
nucleus	O
upon	O
treatment	O
with	O
iAs	O
for	O
6	O
hr	O
.	O

This	O
was	O
not	O
observed	O
in	O
the	O
parallel	O
experiment	O
performed	O
over	O
the	O
3-hr	O
time	O
course	O
.	O

Supershift	O
EMSA	O
analysis	O
using	O
an	O
NRF2	O
antibody	O
showed	O
that	O
the	O
iAs	O
-	O
induced	O
and	O
iAs	O
-	O
translocated	O
NRF2	O
protein	O
binds	O
to	O
the	O
WT	O
-	O
K16ARE	O
probe	O
containing	O
the	O
ARE	O
sequence	O
of	O
the	O
K16	O
proximal	O
promoter	O
region	O
(	O
5′-GGAGTCAGC-3′	O
)	O
that	O
comprises	O
an	O
AP-1–like	O
site	O
and	O
a	O
GC	O
box	O
,	O
whereas	O
the	O
supershift	O
of	O
c	O
-	O
Jun	O
was	O
not	O
observed	O
(	O
Figure	O
4E	O
)	O
.	O

To	O
identify	O
whether	O
the	O
GC	O
box	O
is	O
dispensable	O
for	O
the	O
iAs	O
-	O
stimulated	O
binding	O
activity	O
of	O
NRF2	O
,	O
we	O
next	O
performed	O
EMSA	O
analyses	O
with	O
either	O
WT-	O
or	O
a	O
Mut	O
-	O
K16ARE	O
probe	O
containing	O
an	O
intact	O
AP-1–like	O
element	O
but	O
a	O
mutated	O
GC	O
box	O
.	O

As	O
shown	O
in	O
Figure	O
4F	O
,	O
the	O
K16ARE	O
–	O
nuclear	O
protein	O
complexes	O
and	O
supershifted	O
bands	O
that	O
were	O
enhanced	O
by	O
iAs	O
treatment	O
were	O
largely	O
abolished	O
by	O
the	O
addition	O
of	O
the	O
Mut	O
-	O
K16ARE	O
probe	O
.	O

iAs	O
stabilizes	O
the	O
NRF2	O
protein	O
We	O
examined	O
the	O
effects	O
of	O
iAs	O
treatment	O
on	O
the	O
function	O
of	O
KEAP1	O
in	O
HaCaT	O
cells	O
.	O

Treatment	O
with	O
iAs	O
did	O
not	O
alter	O
the	O
expression	O
levels	O
of	O
KEAP1	O
mRNA	O
or	O
protein	O
over	O
either	O
a	O
3	O
or	O
6	O
hr	O
time	O
course	O
(	O
Figure	O
5A	O
)	O
.	O

Next	O
,	O
we	O
examined	O
the	O
effects	O
of	O
iAs	O
on	O
the	O
expression	O
of	O
NRF2	O
mRNA	O
in	O
HaCaT	O
cells	O
.	O

Exposure	O
to	O
iAs	O
did	O
not	O
significantly	O
alter	O
the	O
steady	O
-	O
state	O
levels	O
of	O
NRF2	O
mRNA	O
(	O
data	O
not	O
shown	O
)	O
.	O

Production	O
of	O
NRF2	O
protein	O
,	O
however	O
,	O
was	O
observed	O
to	O
increase	O
in	O
both	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
(	O
Figure	O
4D	O
)	O
.	O

To	O
further	O
examine	O
the	O
stabilization	O
of	O
NRF2	O
protein	O
by	O
iAs	O
,	O
we	O
monitored	O
the	O
decay	O
of	O
basal	O
and	O
iAs	O
-	O
induced	O
NRF2	O
proteins	O
after	O
inhibition	O
of	O
protein	O
synthesis	O
by	O
CHX	O
(	O
Figure	O
5B	O
)	O
.	O

The	O
results	O
of	O
this	O
analysis	O
revealed	O
that	O
the	O
NRF2	O
protein	O
levels	O
decrease	O
by	O
approximately	O
50	O
%	O
within	O
30	O
min	O
of	O
treatment	O
with	O
CHX	O
in	O
cells	O
that	O
had	O
not	O
been	O
exposed	O
to	O
iAs	O
.	O

Only	O
trace	O
amounts	O
of	O
NRF2	O
are	O
then	O
detectable	O
after	O
60	O
min	O
of	O
exposure	O
to	O
CHX	O
in	O
these	O
cells	O
.	O

The	O
HaCaT	O
cells	O
were	O
then	O
pretreated	O
with	O
iAs	O
for	O
6	O
hr	O
before	O
their	O
exposure	O
to	O
CHX	O
in	O
a	O
similar	O
timecourse	O
experiment	O
.	O

The	O
levels	O
of	O
NRF2	O
in	O
these	O
iAs	O
-	O
treated	O
cells	O
were	O
again	O
found	O
to	O
decrease	O
by	O
about	O
50	O
%	O
,	O
but	O
only	O
after	O
120	O
min	O
of	O
CHX	O
exposure	O
.	O

NRF2	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
in	O
HaCaT	O
cells	O
To	O
confirm	O
the	O
functional	O
role	O
of	O
NRF2	O
in	O
the	O
induction	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
of	O
K16	O
mRNA	O
is	O
induced	O
by	O
the	O
overexpression	O
of	O
NRF2	O
(	O
WT	O
-	O
NRF2	O
)	O
in	O
HaCaT	O
cells	O
.	O

We	O
also	O
investigated	O
the	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
which	O
is	O
highly	O
induced	O
by	O
a	O
variety	O
of	O
oxidative	O
stimuli	O
through	O
NRF2-mediated	O
ARE	O
transactivation	O
(	O
Kim	O
et	O
al.	O
2001	O
)	O
.	O

The	O
expression	O
of	O
TXN	O
gene	O
in	O
untransfected	O
cells	O
after	O
treatment	O
with	O
iAs	O
was	O
stronger	O
than	O
that	O
of	O
the	O
control	O
cells	O
(	O
Figure	O
6A	O
)	O
.	O

When	O
the	O
cells	O
were	O
transfected	O
with	O
WT	O
-	O
NRF2	O
and	O
then	O
treated	O
with	O
or	O
without	O
iAs	O
,	O
the	O
expression	O
of	O
TXN	O
mRNA	O
was	O
augmented	O
markedly	O
compared	O
with	O
the	O
empty	O
-	O
vector	O
control	O
.	O

Similarly	O
,	O
the	O
expression	O
of	O
K16	O
mRNA	O
was	O
also	O
induced	O
in	O
cells	O
transfected	O
with	O
WT	O
-	O
NRF2	O
in	O
the	O
absence	O
or	O
presence	O
of	O
iAs	O
.	O

We	O
next	O
performed	O
a	O
transient	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
the	O
pXK-5–1	O
luciferase	O
vector	O
together	O
with	O
the	O
WT	O
-	O
NRF2	O
vector	O
.	O

The	O
overexpression	O
of	O
NRF2	O
in	O
increasing	O
concentrations	O
resulted	O
in	O
significant	O
enhancement	O
of	O
the	O
ARE	O
-	O
mediated	O
K16	O
promoter	O
activation	O
(	O
Figure	O
6B	O
)	O
.	O

Discussion	O
In	O
the	O
present	O
study	O
,	O
we	O
showed	O
for	O
the	O
first	O
time	O
that	O
iAs	O
induces	O
the	O
transcriptional	O
activation	O
of	O
K16	O
in	O
the	O
human	B
keratinocyte	O
cell	O
line	O
,	O
HaCaT	O
,	O
through	O
the	O
ARE	O
present	O
in	O
its	O
gene	O
promoter	O
.	O

It	O
has	O
been	O
reported	O
previously	O
that	O
treatment	O
with	O
iAs	O
enhances	O
the	O
production	O
and	O
translocation	O
of	O
NRF2	O
into	O
the	O
nucleus	O
in	O
several	O
cell	O
types	O
.	O

However	O
,	O
until	O
now	O
it	O
has	O
remained	O
uncertain	O
whether	O
the	O
induction	O
of	O
NRF2	O
by	O
iAs	O
mediates	O
the	O
transcriptional	O
activation	O
of	O
the	O
K16	O
gene	O
in	O
keratinocytes	O
.	O

In	O
our	O
current	O
experiments	O
,	O
we	O
demonstrated	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
,	O
which	O
results	O
in	O
its	O
increased	O
expression	O
levels	O
.	O

Furthermore	O
,	O
this	O
iAs	O
-	O
induced	O
NRF2	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
the	O
ARE	O
sequences	O
in	O
the	O
promoter	O
region	O
of	O
the	O
K16	O
gene	O
.	O

Finally	O
,	O
by	O
overexpressing	O
NRF2	O
,	O
we	O
have	O
clarified	O
that	O
its	O
induction	O
is	O
involved	O
in	O
not	O
only	O
the	O
gene	O
expression	O
of	O
the	O
detoxification	O
gene	O
TXN	O
,	O
but	O
also	O
in	O
the	O
upregulation	O
of	O
K16	O
expression	O
in	O
HaCaT	O
cells	O
through	O
the	O
ARE	O
in	O
the	O
K16	O
gene	O
promoter	O
.	O

These	O
experiments	O
indicate	O
an	O
important	O
and	O
novel	O
function	O
for	O
NRF2	O
in	O
the	O
regulation	O
of	O
K16	O
in	O
keratinocytes	O
and	O
also	O
help	O
to	O
further	O
explain	O
the	O
molecular	O
mechanisms	O
underlying	O
arsenic	O
-	O
mediated	O
epidermal	O
hyperkeratosis	O
.	O

In	O
our	O
present	O
experiments	O
,	O
the	O
expression	O
levels	O
of	O
K16	O
mRNA	O
and	O
protein	O
were	O
indeed	O
found	O
to	O
be	O
enhanced	O
by	O
iAs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
Figure	O
1	O
)	O
.	O

In	O
addition	O
,	O
luciferase	O
assays	O
of	O
the	O
K16	O
promoter	O
revealed	O
that	O
iAs	O
enhances	O
its	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
,	O
which	O
is	O
stimulated	O
by	O
AP-1–like	O
sites	O
and	O
an	O
ARE	O
(	O
Figure	O
2	O
)	O
.	O

The	O
promoter	O
of	O
the	O
human	B
K16	O
gene	O
was	O
recently	O
cloned	O
and	O
sequenced	O
,	O
and	O
several	O
AP-1–like	O
sites	O
were	O
found	O
within	O
the	O
–515-bp	O
region	O
of	O
the	O
gene	O
(	O
Wang	O
and	O
Chang	O
2003	O
)	O
.	O

AP-1	O
transcription	O
factor	O
can	O
be	O
formed	O
by	O
the	O
dimerization	O
of	O
either	O
Jun	O
or	O
Jun	O
/	O
Fos	O
family	O
members	O
(	O
Eferl	O
and	O
Wagner	O
2003	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
increased	O
expression	O
of	O
c	O
-	O
Jun	O
,	O
but	O
not	O
c	O
-	O
Fos	O
was	O
evident	O
in	O
the	O
nuclei	O
of	O
HaCaT	O
cells	O
after	O
iAs	O
treatment	O
(	O
Figure	O
3	O
)	O
.	O

Our	O
findings	O
thus	O
suggest	O
that	O
the	O
activation	O
of	O
c	O
-	O
Jun	O
/	O
AP-1	O
is	O
one	O
of	O
the	O
essential	O
steps	O
in	O
the	O
regulation	O
of	O
K16	O
gene	O
expression	O
by	O
iAs	O
exposure	O
in	O
HaCaT	O
cells	O
.	O

It	O
has	O
been	O
well	O
documented	O
that	O
the	O
ARE	O
core	O
sequence	O
includes	O
an	O
AP-1–like	O
binding	O
site	O
(	O
TGAC	O
/	O
GTCA	O
)	O
,	O
followed	O
by	O
a	O
GC	O
box	O
(	O
Rushmore	O
et	O
al.	O
1991	O
;	O
Xie	O
et	O
al.	O
1995	O
)	O
.	O

We	O
have	O
found	O
in	O
our	O
current	O
analyses	O
that	O
the	O
AP-1–like	O
site	O
within	O
the	O
K16	O
promoter	O
region	O
from	O
–148	O
to	O
–140	O
bp	O
(	O
5′-GGAGTCAGC-3′	O
)	O
resembles	O
a	O
consensus	O
ARE	O
sequence	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
AREs	O
can	O
be	O
specifically	O
bound	O
by	O
complexes	O
of	O
several	O
basic	O
-	O
leucine	O
zipper	O
transcription	O
factors	O
,	O
including	O
NRF2	O
(	O
Ishii	O
et	O
al.	O
2000	O
;	O
Moi	O
et	O
al.	O
1994	O
)	O
.	O

NRF2	O
heterodimerizes	O
with	O
either	O
AP-1	O
or	O
small	O
MAF	O
(	O
MAFG	O
,	O
MAFK	O
,	O
and	O
MAFF	O
)	O
proteins	O
(	O
MAF	O
,	O
v	O
-	O
maf	O
musculoaponeurotic	O
fibrosarcoma	O
oncogene	O
homolog	O
)	O
and	O
binds	O
to	O
the	O
ARE	O
to	O
induce	O
the	O
transcription	O
of	O
ARE	O
-	O
mediated	O
genes	O
(	O
Motohashi	O
et	O
al.	O
2002	O
)	O
.	O

In	O
the	O
present	O
investigation	O
,	O
EMSA	O
and	O
supershift	O
assays	O
showed	O
that	O
the	O
NRF2	O
proteins	O
in	O
the	O
nuclei	O
bind	O
to	O
the	O
ARE	O
sequences	O
of	O
K16	O
promoter	O
region	O
after	O
iAs	O
exposure	O
.	O

iAs	O
-	O
induced	O
c	O
-	O
Jun	O
,	O
however	O
,	O
does	O
not	O
bind	O
to	O
this	O
ARE	O
(	O
Figure	O
4E	O
)	O
.	O

c	O
-	O
Jun	O
may	O
thus	O
act	O
on	O
other	O
AP-1	O
sites	O
within	O
the	O
K16	O
promoter	O
region	O
.	O

These	O
results	O
also	O
suggest	O
that	O
other	O
heterodimer	O
partners	O
of	O
NRF2	O
are	O
involved	O
in	O
the	O
ARE	O
regulation	O
of	O
K16	O
promoter	O
region	O
underlying	O
iAs	O
-	O
mediated	O
the	O
K16	O
gene	O
expression	O
.	O

Gel	O
shifts	O
with	O
an	O
K16Mut	O
-	O
ARE	O
probe	O
(	O
harboring	O
a	O
mutation	O
in	O
the	O
ARE	O
GC	O
box	O
)	O
clearly	O
show	O
that	O
the	O
ARE	O
sequence	O
in	O
the	O
K16	O
promoter	O
,	O
particularly	O
the	O
terminal	O
GC	O
dinucleotide	O
,	O
is	O
essential	O
for	O
mediating	O
iAs	O
-	O
induced	O
K16	O
transactivation	O
and	O
NRF2	O
binding	O
(	O
Figure	O
4F	O
)	O
.	O

Several	O
investigations	O
have	O
suggested	O
that	O
the	O
GC	O
nucleotides	O
within	O
the	O
ARE	O
are	O
essential	O
for	O
both	O
the	O
basal	O
and	O
oxidative	O
stress	O
–	O
induced	O
activities	O
of	O
the	O
ARE	O
-	O
related	O
genes	O
,	O
NAD	O
(	O
P	O
)	O
H	O
dehydrogenase	O
quinone	O
1	O
(	O
NQO1	O
)	O
and	O
glutamate	O
-	O
cysteine	O
ligase	O
catalytic	O
subunit	O
(	O
GCLC	O
)	O
(	O
Wasserman	O
and	O
Fahl	O
1997	O
;	O
Wild	O
et	O
al.	O
1998	O
)	O
.	O

Our	O
current	O
results	O
are	O
consistent	O
with	O
these	O
earlier	O
studies	O
in	O
showing	O
that	O
the	O
formation	O
of	O
the	O
iAs	O
-	O
responsive	O
NRF2	O
/	O
ARE	O
complexes	O
is	O
reduced	O
by	O
a	O
mutation	O
in	O
the	O
GC	O
box	O
.	O

Collectively	O
,	O
our	O
present	O
observations	O
reveal	O
a	O
new	O
molecular	O
mechanism	O
in	O
which	O
iAs	O
-	O
induced	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
activation	O
NRF2	O
/	O
ARE	O
pathways	O
.	O

It	O
has	O
been	O
widely	O
accepted	O
that	O
oxidative	O
stress	O
disrupts	O
sequestration	O
of	O
NRF2	O
by	O
KEAP1	O
,	O
permits	O
NRF2	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
transactivates	O
the	O
expression	O
of	O
various	O
NRF2-mediated	O
genes	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
;	O
McMahon	O
et	O
al.	O
2003	O
)	O
.	O

Our	O
present	O
study	O
showed	O
that	O
iAs	O
elongates	O
the	O
half	O
-	O
life	O
of	O
the	O
NRF2	O
protein	O
but	O
has	O
no	O
effects	O
upon	O
KEAP1	O
expression	O
(	O
Figure	O
5	O
)	O
.	O

Other	O
studies	O
have	O
also	O
demonstrated	O
that	O
the	O
production	O
of	O
NRF2	O
is	O
increased	O
by	O
various	O
inducers	O
via	O
posttranscriptional	O
control	O
(	O
Nguyen	O
et	O
al.	O
2003	O
;	O
Stewart	O
et	O
al.	O
2003	O
)	O
.	O

Several	O
earlier	O
reports	O
also	O
indicated	O
that	O
either	O
oxidative	O
stress	O
or	O
antioxidant	O
substances	O
stabilize	O
the	O
expression	O
of	O
the	O
NRF2	O
protein	O
,	O
either	O
by	O
directly	O
modifying	O
the	O
cysteine	O
residues	O
on	O
KEAP1	O
to	O
disrupt	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Dinkova	O
-	O
Kostova	O
et	O
al.	O
2002	O
)	O
or	O
by	O
facilitating	O
the	O
release	O
of	O
NRF2	O
through	O
the	O
phosphorylation	O
of	O
the	O
NRF2	O
/	O
KEAP1	O
complex	O
(	O
Bloom	O
and	O
Jaiswal	O
2003	O
)	O
.	O

These	O
findings	O
are	O
largely	O
consistent	O
with	O
our	O
present	O
finding	O
that	O
iAs	O
stabilizes	O
the	O
expression	O
of	O
NRF2	O
in	O
HaCaT	O
cells	O
by	O
elongating	O
the	O
protein	O
half	O
-	O
life	O
.	O

Recently	O
,	O
Wakabayashi	O
et	O
al.	O
(	O
2003	O
)	O
demonstrated	O
that	O
NRF2	O
accumulates	O
in	O
the	O
nucleus	O
at	O
constitutively	O
high	O
levels	O
and	O
produces	O
various	O
cytoprotective	O
genes	O
in	O
embryonic	O
fibroblast-	O
and	O
liver	O
-	O
derived	O
Keap1-null	O
mice	B
.	O

Surprisingly	O
,	O
these	O
Keap1-deficient	O
mice	B
also	O
show	O
a	O
thicker	O
stratum	O
corneum	O
epidermis	O
,	O
abnormal	O
keratinization	O
,	O
and	O
cornification	O
in	O
the	O
esophagus	O
and	O
forestomach	O
(	O
hyperkeratosis	O
)	O
.	O

K6	O
was	O
found	O
to	O
be	O
strongly	O
expressed	O
in	O
the	O
esophageal	O
epithelium	O
of	O
these	O
mice	B
.	O

These	O
results	O
indicate	O
that	O
K6	O
is	O
also	O
a	O
target	O
gene	O
of	O
NRF2	O
.	O

In	O
addition	O
,	O
the	O
promoter	O
of	O
the	O
K6	O
gene	O
bears	O
a	O
remarkable	O
sequence	O
similarity	O
to	O
the	O
K16	O
promoter	O
(	O
Jiang	O
et	O
al.	O
1993	O
)	O
.	O

Therefore	O
,	O
we	O
examined	O
whether	O
K16	O
gene	O
expression	O
is	O
also	O
regulated	O
by	O
NRF2	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
gene	O
expression	O
and	O
transactivation	O
of	O
K16	O
were	O
dramatically	O
induced	O
by	O
transfection	O
with	O
WT	O
-	O
NRF2	O
via	O
in	O
HaCaT	O
cells	O
,	O
clearly	O
demonstrating	O
that	O
NRF2	O
acts	O
as	O
a	O
direct	O
transcriptional	O
regulator	O
of	O
the	O
K16	O
gene	O
(	O
Figure	O
6	O
)	O
.	O

In	O
addition	O
,	O
we	O
also	O
showed	O
that	O
transfection	O
of	O
HaCaT	O
cells	O
with	O
WT	O
-	O
NRF2	O
induces	O
the	O
expression	O
of	O
detoxification	O
gene	O
TXN	O
(	O
Figure	O
6A	O
)	O
.	O

NRF2	O
may	O
thus	O
have	O
a	O
major	O
role	O
to	O
play	O
in	O
the	O
development	O
of	O
hyperkeratosis	O
,	O
whereas	O
the	O
expression	O
and	O
induction	O
of	O
NRF2	O
is	O
implicated	O
in	O
cell	O
protection	O
against	O
a	O
variety	O
of	O
genotoxic	O
and	O
cytotoxic	O
effects	O
.	O

Hence	O
,	O
based	O
on	O
these	O
results	O
and	O
on	O
the	O
findings	O
from	O
studies	O
of	O
Keap1	O
knockout	O
mice	B
,	O
iAs	O
may	O
both	O
cause	O
hyperkeratosis	O
and	O
induce	O
detoxification	O
enzymes	O
via	O
the	O
modification	O
of	O
NRF2	O
.	O

Given	O
that	O
there	O
are	O
both	O
beneficial	O
and	O
adverse	O
effects	O
of	O
NRF2	O
activity	O
,	O
caution	O
will	O
therefore	O
be	O
needed	O
when	O
using	O
antioxidants	O
for	O
prevention	O
and	O
therapy	O
.	O

Although	O
further	O
investigations	O
are	O
needed	O
,	O
we	O
believe	O
that	O
our	O
findings	O
provide	O
important	O
clues	O
for	O
the	O
design	O
of	O
future	O
therapies	O
for	O
arsenic	O
-	O
mediated	O
hyperkeratosis	O
and	O
for	O
treatments	O
involving	O
the	O
molecular	O
targeting	O
of	O
NRF2	O
.	O

Conclusion	O
Our	O
findings	O
clearly	O
demonstrate	O
that	O
the	O
induction	O
of	O
the	O
K16	O
gene	O
in	O
human	B
keratinocytes	O
by	O
iAs	O
depends	O
on	O
NRF2	O
activation	O
.	O

Our	O
results	O
thus	O
represent	O
a	O
valuable	O
initial	O
effort	O
to	O
elucidate	O
the	O
relationship	O
between	O
the	O
K16	O
gene	O
and	O
the	O
NRF2	O
transcription	O
factor	O
,	O
which	O
may	O
be	O
responsible	O
for	O
hyperkeratosis	O
.	O

Identification	O
and	O
Analysis	O
of	O
Co	O
-	O
Occurrence	O
Networks	O
with	O
NetCutter	O
Abstract	O
Background	O
Co	O
-	O
occurrence	O
analysis	O
is	O
a	O
technique	O
often	O
applied	O
in	O
text	O
mining	O
,	O
comparative	O
genomics	O
,	O
and	O
promoter	O
analysis	O
.	O

The	O
methodologies	O
and	O
statistical	O
models	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
association	O
between	O
co	O
-	O
occurring	O
entities	O
are	O
quite	O
diverse	O
,	O
however	O
.	O

Methodology	O
/	O
Principal	O
Findings	O
We	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
based	O
on	O
a	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
,	O
a	O
novel	O
co	O
-	O
occurrence	O
statistic	O
,	O
and	O
software	O
performing	O
co	O
-	O
occurrence	O
analysis	O
as	O
well	O
as	O
generation	O
and	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
show	O
that	O
the	O
overall	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
depends	O
critically	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
and	O
find	O
that	O
random	O
sampling	O
from	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
optimal	O
stringency	O
.	O

We	O
show	O
that	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
is	O
the	O
most	O
natural	O
co	O
-	O
occurrence	O
probability	O
distribution	O
when	O
vertex	O
degrees	O
of	O
the	O
bipartite	O
graph	O
are	O
variable	O
,	O
which	O
is	O
usually	O
the	O
case	O
.	O

Calculation	O
of	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
difficult	O
,	O
however	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
bi	O
-	O
binomial	O
approximation	O
for	O
calculation	O
of	O
P	O
-	O
values	O
and	O
show	O
that	O
this	O
statistic	O
is	O
superior	O
to	O
other	O
measures	O
of	O
association	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
.	O

Furthermore	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
more	O
than	O
two	O
entities	O
can	O
be	O
performed	O
using	O
the	O
same	O
statistical	O
model	O
,	O
which	O
leads	O
to	O
increased	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
,	O
robustness	O
towards	O
noise	O
,	O
and	O
the	O
identification	O
of	O
implicit	O
relationships	O
between	O
co	O
-	O
occurring	O
entities	O
.	O

Using	O
NetCutter	O
,	O
we	O
identify	O
a	O
novel	O
protein	O
biosynthesis	O
related	O
set	O
of	O
genes	O
that	O
are	O
frequently	O
coordinately	O
deregulated	O
in	O
human	B
cancer	O
related	O
gene	O
expression	O
studies	O
.	O

NetCutter	O
is	O
available	O
at	O
http://bio.ifom-ieo-campus.it/NetCutter/	O
)	O
.	O

Conclusion	O
Our	O
approach	O
can	O
be	O
applied	O
to	O
any	O
set	O
of	O
categorical	O
data	O
where	O
co	O
-	O
occurrence	O
analysis	O
might	O
reveal	O
functional	O
relationships	O
such	O
as	O
clinical	O
parameters	O
associated	O
with	O
cancer	O
subtypes	O
or	O
SNPs	O
associated	O
with	O
disease	O
phenotypes	O
.	O

The	O
stringency	O
of	O
our	O
approach	O
is	O
expected	O
to	O
offer	O
an	O
advantage	O
in	O
a	O
variety	O
of	O
applications	O
.	O

Introduction	O
Biological	O
research	O
has	O
experienced	O
a	O
paradigm	O
shift	O
in	O
the	O
last	O
decade	O
catalyzed	O
by	O
the	O
availability	O
of	O
genome	O
sequences	O
and	O
the	O
resulting	O
development	O
of	O
high	O
-	O
throughput	O
technologies	O
.	O

The	O
large	O
data	O
volumes	O
produced	O
by	O
these	O
novel	O
technologies	O
are	O
often	O
published	O
as	O
supplementary	O
material	O
and/or	O
stored	O
in	O
extensive	O
data	O
repositories	O
[	O
1	O
]	O
.	O

Functional	O
interpretation	O
of	O
these	O
data	O
is	O
an	O
ongoing	O
challenge	O
.	O

Co	O
-	O
occurrence	O
analysis	O
,	O
based	O
on	O
the	O
hypothesis	O
that	O
co	O
-	O
occurring	O
entities	O
are	O
functionally	O
linked	O
,	O
is	O
a	O
technique	O
that	O
has	O
been	O
used	O
in	O
three	O
main	O
areas	O
of	O
biological	O
research	O
:	O
Co	O
-	O
occurrence	O
of	O
genes	O
in	O
sequenced	O
genomes	O
relies	O
on	O
the	O
fact	O
that	O
proteins	O
do	O
not	O
function	O
in	O
isolation	O
and	O
are	O
dependent	O
on	O
other	O
proteins	O
,	O
either	O
as	O
direct	O
binding	O
partners	O
,	O
or	O
as	O
catalysts	O
of	O
substrates	O
.	O

Thus	O
,	O
when	O
two	O
proteins	O
significantly	O
co	O
-	O
occur	O
in	O
a	O
large	O
number	O
of	O
genomes	O
or	O
can	O
be	O
observed	O
as	O
fusion	O
proteins	O
in	O
a	O
subset	O
of	O
genomes	O
,	O
they	O
are	O
likely	O
to	O
be	O
binding	O
partners	O
or	O
enzymes	O
needed	O
for	O
a	O
specific	O
metabolic	O
pathway	O
.	O

Examples	O
of	O
those	O
studies	O
have	O
been	O
reported	O
by	O
[	O
2	O
]	O
–	O
[	O
7	O
]	O
.	O

Text	O
mining	O
is	O
a	O
quickly	O
evolving	O
field	O
that	O
aims	O
at	O
developing	O
technologies	O
helping	O
to	O
cope	O
with	O
the	O
functional	O
interpretation	O
of	O
large	O
volumes	O
of	O
publications	O
.	O

Co	O
-	O
occurrence	O
of	O
gene	O
names	O
in	O
publication	O
abstracts	O
,	O
entire	O
publications	O
,	O
or	O
other	O
gene	O
-	O
related	O
databases	O
has	O
been	O
used	O
to	O
derive	O
co	O
-	O
occurrence	O
networks	O
with	O
clear	O
evidence	O
that	O
edges	O
in	O
those	O
networks	O
are	O
reflecting	O
functionally	O
relevant	O
relationships	O
[	O
8	O
]	O
–	O
[	O
11	O
]	O
.	O

Gene	O
names	O
have	O
also	O
been	O
analyzed	O
for	O
co	O
-	O
occurrence	O
with	O
other	O
entities	O
such	O
as	O
mutations	O
[	O
12	O
]	O
,	O
chemical	O
compounds	O
[	O
13	O
]	O
,	O
and	O
disease	O
related	O
keywords	O
[	O
14	O
]	O
.	O

From	O
the	O
resulting	O
networks	O
,	O
hypotheses	O
about	O
candidate	O
genes	O
involved	O
in	O
inherited	O
diseases	O
and	O
drug	O
targets	O
can	O
be	O
derived	O
.	O

Clustering	O
of	O
gene	O
related	O
publications	O
using	O
keywords	O
has	O
been	O
applied	O
to	O
enhance	O
the	O
quality	O
of	O
gene	O
expression	O
clusters	O
[	O
15	O
]	O
,	O
[	O
16	O
]	O
.	O

More	O
general	O
(	O
non	O
gene	O
-	O
centric	O
)	O
approaches	O
try	O
to	O
organize	O
the	O
literature	O
into	O
functional	O
areas	O
based	O
on	O
co	O
-	O
occurrence	O
of	O
MeSH	O
terms	O
,	O
keywords	O
,	O
diseases	O
,	O
phenotypes	O
,	O
chemicals	O
,	O
and	O
similar	O
objects	O
of	O
biomedical	O
research	O
interest	O
[	O
17	O
]	O
–	O
[	O
21	O
]	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
transcription	O
factor	O
binding	O
motifs	O
has	O
been	O
carried	O
out	O
in	O
a	O
variety	O
of	O
slightly	O
differing	O
ways	O
in	O
a	O
wide	O
range	O
of	O
organisms	O
,	O
including	O
humans	B
.	O

[	O
22	O
]	O
–	O
[	O
33	O
]	O
.	O

The	O
underlying	O
hypothesis	O
is	O
that	O
co	O
-	O
regulated	O
genes	O
,	O
identified	O
usually	O
by	O
gene	O
expression	O
studies	O
,	O
should	O
contain	O
specific	O
combinations	O
of	O
transcription	O
factor	O
binding	O
motifs	O
in	O
their	O
upstream	O
regulatory	O
regions	O
,	O
the	O
identification	O
of	O
which	O
would	O
allow	O
the	O
reverse	O
-	O
engineering	O
of	O
transcription	O
regulatory	O
networks	O
[	O
34	O
]	O
.	O

We	O
have	O
recently	O
applied	O
co	O
-	O
occurrence	O
analysis	O
to	O
studying	O
published	O
gene	O
expression	O
signatures	O
and	O
showed	O
that	O
co	O
-	O
occurrence	O
patterns	O
of	O
genes	O
reflect	O
cancer	O
signaling	O
pathways	O
[	O
35	O
]	O
.	O

Although	O
co	O
-	O
occurrence	O
analysis	O
has	O
a	O
respectable	O
history	O
,	O
the	O
methodologies	O
used	O
in	O
the	O
studies	O
mentioned	O
above	O
could	O
not	O
be	O
easily	O
applied	O
to	O
studying	O
gene	O
expression	O
signatures	O
.	O

There	O
are	O
three	O
main	O
reasons	O
that	O
dictated	O
the	O
use	O
of	O
a	O
different	O
approach	O
.	O

First	O
,	O
gene	O
expression	O
signatures	O
can	O
vary	O
in	O
size	O
by	O
orders	O
of	O
magnitude	O
.	O

Obviously	O
,	O
the	O
larger	O
a	O
signature	O
the	O
more	O
likely	O
it	O
is	O
to	O
find	O
two	O
or	O
more	O
genes	O
co	O
-	O
occurring	O
in	O
that	O
signature	O
.	O

Thus	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
in	O
the	O
presence	O
of	O
considerable	O
heterogeneity	O
of	O
co	O
-	O
occurrence	O
probabilities	O
among	O
gene	O
lists	O
.	O

As	O
a	O
consequence	O
,	O
the	O
statistics	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
events	O
must	O
reflect	O
this	O
heterogeneity	O
.	O

In	O
particular	O
,	O
it	O
must	O
be	O
based	O
on	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
.	O

Second	O
,	O
in	O
the	O
vast	O
majority	O
of	O
previous	O
studies	O
,	O
co	O
-	O
occurrence	O
is	O
analyzed	O
for	O
pair	O
-	O
wise	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

We	O
found	O
that	O
the	O
resulting	O
stringency	O
of	O
this	O
approach	O
is	O
not	O
adequate	O
for	O
the	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Third	O
,	O
the	O
null	O
-	O
model	O
against	O
which	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
is	O
tested	O
does	O
not	O
work	O
well	O
for	O
gene	O
expression	O
signatures	O
.	O

A	O
common	O
procedure	O
is	O
to	O
use	O
generic	O
randomization	O
of	O
the	O
entire	O
data	O
set	O
under	O
analysis	O
or	O
to	O
select	O
subsets	O
of	O
data	O
entries	O
randomly	O
for	O
comparison	O
purposes	O
.	O

However	O
,	O
gene	O
expression	O
signatures	O
are	O
composed	O
of	O
distinct	O
gene	O
sets	O
and	O
the	O
null	O
-	O
model	O
must	O
maintain	O
this	O
property	O
,	O
which	O
is	O
not	O
guaranteed	O
using	O
these	O
approaches	O
.	O

Furthermore	O
,	O
the	O
list	O
-	O
specific	O
nature	O
of	O
co	O
-	O
occurrence	O
probabilities	O
can	O
not	O
be	O
dealt	O
with	O
properly	O
.	O

NetCutter	O
was	O
developed	O
to	O
address	O
these	O
challenges	O
and	O
to	O
provide	O
a	O
generic	O
tool	O
for	O
generating	O
and	O
analyzing	O
co	O
-	O
occurrence	O
networks	O
.	O

Although	O
NetCutter	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
gene	O
expression	O
signatures	O
,	O
it	O
is	O
based	O
on	O
abstract	O
concepts	O
that	O
make	O
it	O
applicable	O
to	O
a	O
wide	O
variety	O
of	O
problems	O
.	O

The	O
input	O
is	O
represented	O
by	O
a	O
bipartite	O
graph	O
that	O
is	O
composed	O
of	O
list	O
-	O
entry	O
pairs	O
,	O
which	O
are	O
stored	O
in	O
tab	O
-	O
separated	O
text	O
format	O
.	O

Co	O
-	O
occurrence	O
of	O
entries	O
in	O
lists	O
is	O
analyzed	O
using	O
pair	O
-	O
wise	O
or	O
higher	O
order	O
combinations	O
of	O
entries	O
.	O

The	O
significance	O
of	O
co	O
-	O
occurrence	O
is	O
tested	O
using	O
a	O
novel	O
bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
statistics	O
(	O
which	O
is	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
that	O
handles	O
list	O
-	O
length	O
-	O
heterogeneity	O
properly	O
and	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
that	O
is	O
found	O
to	O
be	O
superior	O
to	O
the	O
Jaccard	O
and	O
the	O
uncertainty	O
coefficients	O
.	O

Occurrence	O
probabilities	O
are	O
obtained	O
from	O
an	O
edge	O
-	O
swapping	O
procedure	O
that	O
maintains	O
vertex	O
degrees	O
in	O
the	O
underlying	O
bipartite	O
graph	O
and	O
distinct	O
sets	O
of	O
entries	O
per	O
list	O
.	O

As	O
we	O
shall	O
see	O
below	O
,	O
this	O
procedure	O
has	O
a	O
number	O
of	O
advantages	O
over	O
other	O
possible	O
null	O
-	O
models	O
and	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
near	O
maximum	O
stringency	O
.	O

Last	O
but	O
not	O
least	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
number	O
of	O
algorithms	O
for	O
the	O
identification	O
of	O
network	O
communities	O
,	O
vertex	O
ranking	O
,	O
and	O
convenience	O
tools	O
needed	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

We	O
illustrate	O
the	O
utility	O
of	O
NetCutter	O
in	O
the	O
identification	O
of	O
corresponding	O
clusters	O
of	O
genes	O
and	O
publications	O
from	O
the	O
PubLiME	O
data	O
set	O
.	O

PubLiME	O
(	O
Published	O
Lists	O
of	O
Microarray	O
Experiments	O
)	O
is	O
a	O
repository	O
of	O
published	O
cancer	O
related	O
gene	O
expression	O
signatures	O
(	O
http://bio.ifom-ieo-campus.it/Publime	O
)	O
.	O

The	O
concept	O
of	O
cluster	O
correspondence	O
follows	O
from	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Reversing	O
the	O
list	O
-	O
entry	O
order	O
in	O
the	O
bipartite	O
graph	O
permits	O
identifying	O
communities	O
of	O
entries	O
as	O
well	O
as	O
communities	O
of	O
lists	O
.	O

We	O
show	O
that	O
communities	O
of	O
publications	O
corresponding	O
to	O
communities	O
of	O
genes	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
used	O
to	O
generate	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
communities	O
.	O

Results	O
The	O
bipartite	O
graph	O
model	O
of	O
co	O
-	O
occurrence	O
analysis	O
Co	O
-	O
occurrence	O
analysis	O
using	O
NetCutter	O
is	O
based	O
on	O
the	O
abstraction	O
of	O
list	O
-	O
entry	O
pairs	O
.	O

Any	O
entity	O
that	O
co	O
-	O
occurs	O
with	O
some	O
other	O
entity	O
must	O
be	O
confined	O
to	O
some	O
sort	O
of	O
container	O
where	O
co	O
-	O
occurrence	O
is	O
observed	O
.	O

For	O
example	O
,	O
in	O
the	O
case	O
of	O
gene	O
name	O
co	O
-	O
occurrence	O
in	O
PubMed	O
abstracts	O
,	O
the	O
abstract	O
is	O
the	O
container	O
and	O
the	O
gene	O
names	O
are	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Similarly	O
,	O
co	O
-	O
occurrence	O
of	O
transcription	O
factor	O
binding	O
motifs	O
is	O
observed	O
in	O
gene	O
promoters	O
.	O

The	O
promoters	O
are	O
the	O
containers	O
where	O
motif	O
entities	O
co	O
-	O
occur	O
.	O

The	O
containers	O
generally	O
host	O
more	O
than	O
one	O
entity	O
(	O
otherwise	O
co	O
-	O
occurrence	O
would	O
be	O
impossible	O
)	O
and	O
can	O
be	O
conveniently	O
interpreted	O
as	O
lists	O
.	O

The	O
co	O
-	O
occurring	O
entities	O
are	O
the	O
list	O
entries	O
.	O

Lists	O
and	O
entries	O
form	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
of	O
the	O
graph	O
representing	O
lists	O
and	O
the	O
other	O
part	O
representing	O
entries	O
.	O

The	O
presence	O
of	O
a	O
given	O
entry	O
in	O
a	O
given	O
list	O
is	O
indicated	O
by	O
an	O
edge	O
between	O
the	O
corresponding	O
list	O
and	O
entry	O
vertices	O
.	O

It	O
is	O
required	O
that	O
each	O
entry	O
can	O
be	O
linked	O
to	O
the	O
same	O
list	O
only	O
once	O
.	O

Without	O
loss	O
of	O
generality	O
,	O
let	O
's	O
consider	O
genes	O
as	O
entries	O
and	O
PubMedID_listIDs	O
as	O
lists	O
in	O
the	O
following	O
,	O
unless	O
otherwise	O
specified	O
(	O
Fig.	O
1A	O
)	O
.	O

This	O
interpretation	O
of	O
lists	O
and	O
entries	O
has	O
been	O
applied	O
in	O
the	O
co	O
-	O
occurrence	O
analysis	O
of	O
published	O
gene	O
expression	O
signatures	O
[	O
35	O
]	O
.	O

Occurrence	O
probabilities	O
and	O
null	O
-	O
models	O
A	O
prerequisite	O
for	O
co	O
-	O
occurrence	O
analysis	O
is	O
the	O
availability	O
of	O
occurrence	O
probabilities	O
of	O
genes	O
per	O
list	O
.	O

The	O
occurrence	O
probabilities	O
can	O
be	O
derived	O
from	O
randomizing	O
the	O
bipartite	O
graph	O
and	O
are	O
dependent	O
on	O
the	O
choice	O
of	O
the	O
null	O
-	O
model	O
.	O

A	O
null	O
-	O
model	O
creates	O
an	O
occurrence	O
probability	O
matrix	O
where	O
the	O
occurrence	O
probability	O
for	O
each	O
list	O
–	O
gene	O
pair	O
is	O
listed	O
.	O

As	O
a	O
general	O
property	O
of	O
this	O
matrix	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
must	O
equal	O
the	O
number	O
of	O
edges	O
in	O
the	O
bipartite	O
graph	O
.	O

This	O
is	O
because	O
each	O
edge	O
is	O
linked	O
to	O
either	O
side	O
of	O
the	O
bipartite	O
graph	O
with	O
certainty	O
and	O
therefore	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
over	O
all	O
lists	O
(	O
which	O
can	O
be	O
calculated	O
as	O
the	O
row	O
sum	O
if	O
genes	O
are	O
listed	O
vertically	O
or	O
as	O
the	O
column	O
sum	O
if	O
genes	O
are	O
listed	O
horizontally	O
)	O
followed	O
by	O
summing	O
the	O
results	O
over	O
all	O
genes	O
must	O
be	O
1	O
for	O
every	O
edge	O
.	O

The	O
number	O
of	O
matrix	O
elements	O
is	O
given	O
by	O
#	O
genes*#lists	O
and	O
therefore	O
the	O
average	O
occurrence	O
probability	O
for	O
any	O
null	O
-	O
model	O
must	O
be	O
#	O
edges	O
/	O
(	O
#genes*#lists	O
)	O
.	O

As	O
a	O
consequence	O
,	O
different	O
null	O
-	O
models	O
will	O
only	O
be	O
distinguished	O
by	O
the	O
way	O
they	O
attribute	O
occurrence	O
probabilities	O
to	O
vertices	O
with	O
different	O
vertex	O
degrees	O
but	O
not	O
by	O
the	O
average	O
occurrence	O
probability	O
.	O

We	O
consider	O
six	O
different	O
strategies	O
to	O
randomize	O
the	O
bipartite	O
graph	O
.	O

First	O
,	O
we	O
could	O
reconnect	O
all	O
edges	O
of	O
the	O
graph	O
randomly	O
.	O

The	O
probability	O
of	O
being	O
connected	O
by	O
an	O
edge	O
for	O
a	O
given	O
list	O
-	O
gene	O
pair	O
is	O
given	O
by	O
(	O
1	O
/	O
#genes	O
)	O
*	O
(	O
1	O
/	O
#lists	O
)	O
.	O

Since	O
there	O
are	O
#	O
edges	O
edges	O
to	O
be	O
reconnected	O
,	O
the	O
occurrence	O
probability	O
for	O
a	O
single	O
list	O
-	O
gene	O
pair	O
is	O
#	O
edges	O
/	O
(	O
#genes*#lists	O
)	O
,	O
i.e.	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
.	O

Thus	O
,	O
this	O
model	O
provides	O
equal	O
occurrence	O
probabilities	O
for	O
all	O
gene	O
-	O
list	O
pairs	O
and	O
does	O
not	O
consider	O
vertex	O
degrees	O
.	O

We	O
call	O
this	O
model	O
the	O
generic	O
randomization	O
(	O
GR	O
)	O
model	O
in	O
the	O
following	O
.	O

Second	O
,	O
we	O
could	O
disconnect	O
the	O
edges	O
on	O
only	O
the	O
list	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
gene	O
vertex	O
would	O
be	O
given	O
by	O
(	O
gene	O
vertex	O
degree	O
)	O
/	O
#lists	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
lists	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
gene	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Thus	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
number	O
of	O
edges	O
,	O
as	O
required	O
.	O

Since	O
this	O
model	O
considers	O
gene	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
gene	O
vertex	O
degree	O
(	O
GVD	O
)	O
model	O
.	O

Third	O
,	O
we	O
disconnect	O
the	O
edges	O
on	O
the	O
gene	O
side	O
of	O
the	O
bipartite	O
graph	O
and	O
reconnect	O
them	O
randomly	O
.	O

The	O
probability	O
of	O
a	O
list	O
vertex	O
being	O
connected	O
to	O
a	O
gene	O
would	O
be	O
given	O
by	O
(	O
list	O
vertex	O
degree	O
)	O
/	O
#genes	O
.	O

The	O
sum	O
of	O
these	O
probabilities	O
over	O
all	O
genes	O
is	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
and	O
the	O
sum	O
of	O
all	O
list	O
vertex	O
degrees	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
equal	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Since	O
this	O
model	O
considers	O
list	O
vertex	O
degrees	O
,	O
we	O
call	O
it	O
the	O
list	O
vertex	O
degree	O
(	O
LVD	O
)	O
model	O
.	O

In	O
model	O
four	O
and	O
five	O
,	O
we	O
reconnect	O
edges	O
considering	O
both	O
gene	O
and	O
list	O
vertex	O
degrees	O
and	O
allow	O
multiple	O
edges	O
between	O
list	O
-	O
gene	O
pairs	O
.	O

The	O
occurrence	O
probabilities	O
in	O
model	O
four	O
are	O
calculated	O
according	O
to	O
the	O
binomial	O
distribution	O
.	O

We	O
calculate	O
the	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
for	O
being	O
connected	O
as	O
the	O
cumulative	O
binomial	O
probability	O
of	O
the	O
list	O
-	O
gene	O
pair	O
being	O
chosen	O
at	O
least	O
once	O
in	O
the	O
process	O
of	O
randomly	O
reconnecting	O
the	O
edges	O
.	O

This	O
can	O
be	O
achieved	O
by	O
setting	O
the	O
number	O
of	O
trials	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
probability	O
of	O
success	O
equal	O
to	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
edges	O
,	O
and	O
the	O
number	O
of	O
successes	O
equal	O
to	O
0	O
.	O

The	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
then	O
given	O
by	O
the	O
complement	O
of	O
this	O
probability	O
.	O

This	O
model	O
is	O
called	O
the	O
binomial	O
(	O
BN	O
)	O
model	O
.	O

In	O
model	O
five	O
,	O
we	O
calculate	O
occurrence	O
probabilities	O
according	O
to	O
the	O
hypergeometric	O
distribution	O
.	O

The	O
number	O
of	O
successes	O
in	O
the	O
sample	O
is	O
equal	O
to	O
0	O
,	O
the	O
sample	O
size	O
is	O
equal	O
to	O
the	O
gene	O
vertex	O
degree	O
,	O
the	O
number	O
of	O
successes	O
in	O
the	O
population	O
is	O
set	O
to	O
the	O
list	O
vertex	O
degree	O
,	O
and	O
the	O
population	O
size	O
is	O
the	O
total	O
number	O
of	O
edges	O
.	O

Again	O
,	O
the	O
occurrence	O
probability	O
of	O
a	O
list	O
-	O
gene	O
pair	O
is	O
obtained	O
as	O
the	O
complement	O
of	O
this	O
probability	O
.	O

We	O
call	O
this	O
model	O
the	O
hypergeometric	O
(	O
HG	O
)	O
model	O
.	O

Calculating	O
occurrence	O
probabilities	O
in	O
this	O
manner	O
does	O
not	O
guarantee	O
that	O
the	O
matrix	O
elements	O
add	O
up	O
to	O
the	O
total	O
number	O
of	O
edges	O
.	O

Therefore	O
,	O
the	O
matrices	O
are	O
normalized	O
such	O
that	O
this	O
condition	O
is	O
satisfied	O
by	O
multiplying	O
each	O
matrix	O
element	O
with	O
the	O
factor	O
#	O
edges	O
/	O
(	O
observed	O
matrix	O
sum	O
)	O
,	O
which	O
is	O
generally	O
quite	O
close	O
to	O
1	O
,	O
however	O
.	O

In	O
model	O
six	O
,	O
we	O
again	O
consider	O
vertex	O
degrees	O
,	O
but	O
we	O
require	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Thus	O
,	O
multiple	O
edges	O
are	O
forbidden	O
.	O

This	O
condition	O
is	O
satisfied	O
by	O
applying	O
an	O
edge	O
-	O
swapping	O
procedure	O
during	O
graph	O
randomization	O
.	O

Edge	O
-	O
swapping	O
works	O
by	O
randomly	O
choosing	O
two	O
list	O
-	O
gene	O
pairs	O
from	O
the	O
bipartite	O
graph	O
and	O
prior	O
to	O
performing	O
the	O
edge	O
-	O
swap	O
,	O
a	O
test	O
is	O
performed	O
to	O
ensure	O
that	O
the	O
two	O
genes	O
are	O
not	O
already	O
linked	O
to	O
the	O
respective	O
target	O
lists	O
.	O

This	O
procedure	O
is	O
performed	O
a	O
large	O
number	O
of	O
times	O
.	O

To	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
,	O
the	O
number	O
of	O
swaps	O
performed	O
should	O
be	O
significantly	O
larger	O
than	O
the	O
number	O
of	O
edges	O
.	O

After	O
performing	O
R	O
randomizations	O
of	O
the	O
graph	O
and	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
has	O
been	O
linked	O
to	O
a	O
particular	O
list	O
,	O
division	O
of	O
this	O
number	O
by	O
R	O
gives	O
the	O
occurrence	O
probability	O
of	O
a	O
gene	O
in	O
a	O
given	O
list	O
.	O

As	O
will	O
be	O
shown	O
below	O
,	O
edge	O
-	O
swapping	O
produces	O
occurrence	O
probabilities	O
that	O
closely	O
approximate	O
occurrence	O
probabilities	O
obtained	O
by	O
generating	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
,	O
counting	O
the	O
number	O
of	O
times	O
a	O
gene	O
is	O
found	O
part	O
of	O
a	O
list	O
,	O
and	O
dividing	O
this	O
number	O
by	O
the	O
total	O
number	O
of	O
permutations	O
.	O

In	O
the	O
permutation	O
model	O
,	O
the	O
sum	O
of	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
equals	O
the	O
gene	O
vertex	O
degree	O
(	O
see	O
below	O
)	O
and	O
thus	O
the	O
sum	O
of	O
all	O
matrix	O
elements	O
is	O
the	O
number	O
of	O
edges	O
.	O

Since	O
permutation	O
sets	O
of	O
bipartite	O
graphs	O
are	O
difficult	O
to	O
calculate	O
,	O
we	O
use	O
the	O
edge	O
-	O
swapping	O
procedure	O
as	O
a	O
close	O
approximation	O
and	O
call	O
this	O
model	O
the	O
edge	O
-	O
swapping	O
(	O
ES	O
)	O
model	O
.	O

Fig.	O
1	O
shows	O
the	O
occurrence	O
probabilities	O
of	O
the	O
different	O
null	O
-	O
models	O
for	O
the	O
bipartite	O
graph	O
shown	O
in	O
Fig.	O
1A	O
.	O

The	O
GR	O
model	O
yields	O
identical	O
occurrence	O
probabilities	O
for	O
all	O
list	O
-	O
gene	O
pairs	O
,	O
which	O
is	O
equal	O
to	O
the	O
average	O
occurrence	O
probability	O
in	O
all	O
models	O
.	O

In	O
the	O
other	O
models	O
,	O
the	O
occurrence	O
probabilities	O
deviate	O
to	O
varying	O
extent	O
from	O
the	O
average	O
occurrence	O
probability	O
as	O
a	O
function	O
of	O
vertex	O
degrees	O
.	O

In	O
the	O
GVD	O
model	O
,	O
the	O
deviations	O
are	O
a	O
function	O
of	O
gene	O
vertex	O
degree	O
and	O
in	O
the	O
LVD	O
model	O
the	O
deviations	O
are	O
dependent	O
on	O
list	O
vertex	O
degrees	O
.	O

In	O
the	O
remaining	O
models	O
,	O
the	O
deviations	O
are	O
functions	O
of	O
both	O
the	O
gene	O
and	O
the	O
list	O
vertex	O
degrees	O
.	O

In	O
all	O
cases	O
,	O
larger	O
than	O
average	O
occurrence	O
probabilities	O
are	O
obtained	O
for	O
larger	O
vertex	O
degrees	O
at	O
the	O
expense	O
of	O
smaller	O
than	O
average	O
occurrence	O
probabilities	O
for	O
smaller	O
vertex	O
degrees	O
.	O

From	O
these	O
data	O
,	O
it	O
is	O
difficult	O
to	O
choose	O
the	O
most	O
effective	O
null	O
-	O
model	O
.	O

A	O
hint	O
can	O
be	O
gleaned	O
from	O
gene1	O
,	O
however	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
.	O

Therefore	O
,	O
the	O
co	O
-	O
occurrence	O
probability	O
of	O
gene1	O
with	O
other	O
genes	O
,	O
which	O
is	O
calculated	O
by	O
multiplying	O
the	O
occurrence	O
probabilities	O
of	O
gene1	O
and	O
geneX	O
for	O
every	O
list	O
under	O
study	O
,	O
should	O
depend	O
only	O
on	O
the	O
occurrence	O
probability	O
of	O
this	O
other	O
gene	O
.	O

In	O
other	O
words	O
,	O
the	O
occurrence	O
probability	O
of	O
gene1	O
in	O
all	O
lists	O
should	O
be	O
1.0	O
.	O

Only	O
two	O
models	O
satisfy	O
this	O
constraint	O
:	O
The	O
GVD	O
and	O
the	O
ES	O
models	O
.	O

Since	O
the	O
GVD	O
model	O
does	O
not	O
consider	O
list	O
vertex	O
degrees	O
,	O
it	O
seems	O
that	O
the	O
ES	O
model	O
is	O
the	O
preferred	O
null	O
-	O
model	O
.	O

Expected	O
number	O
of	O
co	O
-	O
occurrences	O
As	O
a	O
general	O
criterion	O
for	O
comparing	O
the	O
effectiveness	O
of	O
different	O
null	O
-	O
models	O
,	O
we	O
have	O
to	O
compare	O
them	O
for	O
the	O
number	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
most	O
effective	O
null	O
-	O
model	O
will	O
be	O
the	O
one	O
that	O
maximizes	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

If	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
larger	O
,	O
an	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
real	O
bipartite	O
graph	O
will	O
be	O
less	O
significant	O
and	O
thus	O
such	O
a	O
null	O
-	O
model	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
higher	O
stringency	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
depends	O
in	O
an	O
obvious	O
fashion	O
on	O
the	O
list	O
vertex	O
degree	O
.	O

If	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
are	O
considered	O
,	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
in	O
a	O
list	O
of	O
vertex	O
degree	O
N	O
is	O
given	O
by	O
the	O
binomial	O
coefficient	O
N	O
over	O
2	O
.	O

Larger	O
lists	O
will	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
and	O
the	O
number	O
increases	O
quickly	O
with	O
list	O
vertex	O
degree	O
.	O

The	O
dependency	O
of	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
gene	O
vertex	O
degree	O
is	O
less	O
obvious	O
and	O
depends	O
strongly	O
on	O
the	O
null	O
-	O
model	O
.	O

A	O
gene	O
that	O
is	O
part	O
of	O
a	O
list	O
with	O
vertex	O
degree	O
N	O
will	O
give	O
rise	O
to	O
N-1	O
co	O
-	O
occurrences	O
in	O
that	O
list	O
.	O

The	O
null	O
-	O
model	O
permits	O
calculating	O
the	O
probability	O
to	O
find	O
this	O
gene	O
in	O
a	O
given	O
list	O
.	O

Thus	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
of	O
a	O
gene	O
is	O
given	O
by	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
where	O
for	O
a	O
single	O
list	O
the	O
expected	O
co	O
-	O
occurrences	O
are	O
given	O
by	O
(	O
Nl−1	O
)	O
*pl	O
.	O

Nl	O
is	O
the	O
list	O
vertex	O
degree	O
and	O
pl	O
is	O
the	O
occurrence	O
probability	O
of	O
the	O
gene	O
in	O
that	O
list	O
as	O
determined	O
by	O
the	O
null	O
-	O
model	O
.	O

We	O
used	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
to	O
calculate	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
with	O
different	O
null	O
-	O
models	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig	O
2A	O
.	O

The	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
was	O
calculated	O
for	O
all	O
genes	O
in	O
all	O
lists	O
using	O
all	O
null	O
-	O
models	O
and	O
the	O
sum	O
of	O
expected	O
co	O
-	O
occurrences	O
per	O
gene	O
is	O
shown	O
as	O
a	O
scatter	O
plot	O
with	O
the	O
gene	O
vertex	O
degree	O
on	O
the	O
x	O
-	O
axis	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
on	O
the	O
y	O
-	O
axis	O
.	O

The	O
results	O
in	O
Fig.	O
2A	O
suggest	O
the	O
following	O
ranking	O
of	O
null	O
-	O
models	O
:	O
GR	O
<	O
GVD	O
<	O
LVD	O
<	O
BN	O
=	O
HG	O
<	O
ES	O
.	O

The	O
BN	O
and	O
the	O
HG	O
models	O
perform	O
in	O
an	O
essentially	O
identical	O
way	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
largest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
.	O

The	O
results	O
are	O
also	O
in	O
line	O
with	O
the	O
intuitive	O
expectation	O
that	O
genes	O
with	O
higher	O
vertex	O
degree	O
give	O
rise	O
to	O
more	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
it	O
can	O
be	O
seen	O
that	O
this	O
is	O
not	O
true	O
for	O
all	O
null	O
-	O
models	O
.	O

In	O
particular	O
,	O
it	O
is	O
not	O
true	O
for	O
the	O
GR	O
and	O
the	O
LVD	O
models	O
,	O
which	O
do	O
not	O
consider	O
gene	O
vertex	O
degrees	O
.	O

As	O
outlined	O
above	O
,	O
it	O
is	O
expected	O
that	O
the	O
null	O
-	O
model	O
that	O
yields	O
the	O
highest	O
estimates	O
of	O
expected	O
co	O
-	O
occurrences	O
should	O
permit	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

In	O
Fig.	O
2B	O
,	O
this	O
hypothesis	O
is	O
tested	O
directly	O
again	O
using	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
.	O

For	O
all	O
null	O
-	O
models	O
,	O
co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
using	O
module	O
size	O
3	O
and	O
support	O
5	O
(	O
co	O
-	O
occurrence	O
modules	O
must	O
be	O
present	O
in	O
at	O
least	O
five	O
publications	O
)	O
.	O

The	O
choice	O
of	O
these	O
parameters	O
has	O
been	O
discussed	O
in	O
[	O
35	O
]	O
.	O

The	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
was	O
then	O
determined	O
that	O
have	O
a	O
Z	O
-	O
score	O
higher	O
or	O
equal	O
than	O
the	O
cut	O
-	O
off	O
shown	O
in	O
Fig.	O
2B	O
.	O

The	O
Z	O
-	O
score	O
is	O
calculated	O
from	O
the	O
mean	O
and	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
as	O
shown	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
and	O
published	O
in	O
[	O
35	O
]	O
.	O

More	O
details	O
on	O
the	O
probability	O
distribution	O
will	O
be	O
provided	O
below	O
.	O

The	O
GR	O
and	O
GVD	O
models	O
perform	O
very	O
poorly	O
and	O
identify	O
large	O
numbers	O
of	O
modules	O
with	O
high	O
Z	O
-	O
scores	O
.	O

The	O
LVD	O
model	O
performs	O
a	O
little	O
better	O
and	O
approximates	O
the	O
BN	O
and	O
HG	O
models	O
at	O
higher	O
Z	O
-	O
score	O
cut	O
-	O
offs	O
.	O

The	O
BN	O
and	O
HG	O
models	O
give	O
essentially	O
identical	O
results	O
.	O

However	O
,	O
the	O
ES	O
model	O
is	O
the	O
model	O
that	O
yields	O
the	O
fewest	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
and	O
is	O
thus	O
the	O
most	O
stringent	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
the	O
BN	O
and	O
HG	O
models	O
is	O
also	O
reflected	O
in	O
a	O
higher	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
calculated	O
as	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
divided	O
by	O
the	O
number	O
of	O
modules	O
found	O
in	O
a	O
randomized	O
bipartite	O
graph	O
(	O
Fig.	O
2C	O
)	O
.	O

The	O
reason	O
for	O
the	O
superior	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
all	O
other	O
models	O
can	O
be	O
explained	O
by	O
examining	O
the	O
average	O
occurrence	O
probability	O
per	O
gene	O
and	O
list	O
vertex	O
degree	O
.	O

Fig.	O
2D	O
and	O
E	O
show	O
the	O
average	O
occurrence	O
probability	O
of	O
genes	O
with	O
the	O
same	O
gene	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
the	O
gene	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
yields	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
with	O
higher	O
vertex	O
degrees	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
GR	O
and	O
LVD	O
models	O
,	O
gene	O
vertex	O
degrees	O
are	O
ignored	O
and	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
large	O
vertex	O
degree	O
are	O
very	O
small	O
,	O
which	O
is	O
compensated	O
by	O
larger	O
occurrence	O
probabilities	O
for	O
genes	O
with	O
small	O
vertex	O
degree	O
.	O

The	O
GVD	O
model	O
is	O
identical	O
to	O
the	O
ES	O
model	O
in	O
this	O
setting	O
.	O

Fig.	O
2E	O
shows	O
the	O
average	O
occurrence	O
probability	O
of	O
all	O
lists	O
with	O
the	O
same	O
vertex	O
degree	O
as	O
a	O
function	O
of	O
list	O
vertex	O
degree	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
ES	O
model	O
provides	O
higher	O
occurrence	O
probability	O
estimates	O
for	O
large	O
lists	O
as	O
compared	O
to	O
the	O
BN	O
and	O
HG	O
models	O
.	O

In	O
this	O
setting	O
,	O
the	O
LVD	O
model	O
performs	O
like	O
the	O
ES	O
model	O
while	O
the	O
GR	O
and	O
GVD	O
models	O
yield	O
small	O
occurrence	O
probabilities	O
for	O
large	O
lists	O
.	O

Since	O
it	O
has	O
been	O
shown	O
above	O
that	O
long	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degree	O
are	O
responsible	O
for	O
a	O
large	O
part	O
of	O
the	O
total	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
the	O
most	O
stringent	O
null	O
-	O
models	O
,	O
the	O
null	O
-	O
model	O
that	O
provides	O
larger	O
occurrence	O
probability	O
estimates	O
for	O
genes	O
and	O
lists	O
with	O
high	O
vertex	O
degree	O
at	O
the	O
expense	O
of	O
lower	O
estimates	O
for	O
smaller	O
degrees	O
will	O
be	O
the	O
most	O
stringent	O
because	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
and	O
thus	O
less	O
significant	O
.	O

By	O
these	O
criteria	O
,	O
the	O
ES	O
model	O
is	O
the	O
most	O
stringent	O
of	O
all	O
models	O
tested	O
.	O

The	O
ES	O
model	O
as	O
an	O
approximation	O
of	O
the	O
permutation	O
null	O
-	O
model	O
The	O
data	O
shown	O
above	O
have	O
revealed	O
that	O
the	O
ES	O
model	O
is	O
the	O
best	O
of	O
the	O
models	O
tested	O
.	O

One	O
may	O
wonder	O
,	O
however	O
,	O
whether	O
yet	O
more	O
effective	O
null	O
-	O
models	O
can	O
be	O
found	O
.	O

An	O
obvious	O
choice	O
would	O
be	O
the	O
permutation	O
model	O
.	O

In	O
the	O
permutation	O
model	O
,	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
is	O
created	O
such	O
that	O
each	O
list	O
is	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

The	O
number	O
of	O
graphs	O
where	O
a	O
gene	O
is	O
present	O
in	O
a	O
given	O
list	O
divided	O
by	O
the	O
total	O
number	O
of	O
permutations	O
then	O
provides	O
the	O
occurrence	O
probability	O
estimate	O
.	O

The	O
permutation	O
model	O
is	O
the	O
ideal	O
null	O
-	O
model	O
because	O
it	O
is	O
exhaustive	O
.	O

The	O
problem	O
is	O
that	O
a	O
complete	O
permutation	O
set	O
of	O
bipartite	O
graphs	O
of	O
some	O
complexity	O
is	O
very	O
time	O
consuming	O
to	O
calculate	O
.	O

For	O
example	O
,	O
the	O
simple	O
bipartite	O
graph	O
from	O
Fig.	O
1A	O
is	O
part	O
of	O
a	O
permutation	O
set	O
of	O
455	O
graphs	O
.	O

The	O
number	O
of	O
permutations	O
is	O
increasing	O
quickly	O
as	O
the	O
numbers	O
of	O
genes	O
and	O
lists	O
grow	O
.	O

However	O
,	O
since	O
edge	O
-	O
swapping	O
ensures	O
that	O
gene	O
lists	O
are	O
composed	O
of	O
distinct	O
sets	O
of	O
genes	O
,	O
each	O
edge	O
-	O
swap	O
produces	O
a	O
graph	O
that	O
is	O
part	O
of	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Edge	O
-	O
swapping	O
can	O
thus	O
be	O
viewed	O
as	O
a	O
random	O
sampling	O
procedure	O
from	O
the	O
permutation	O
set	O
of	O
the	O
bipartite	O
graph	O
.	O

Therefore	O
,	O
occurrence	O
probability	O
estimates	O
derived	O
by	O
edge	O
-	O
swapping	O
should	O
approximate	O
those	O
obtained	O
from	O
the	O
permutation	O
model	O
.	O

We	O
generated	O
a	O
complete	O
permutation	O
set	O
of	O
the	O
graph	O
shown	O
in	O
Fig.	O
1A	O
to	O
verify	O
this	O
hypothesis	O
.	O

The	O
results	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

Fig.	O
3A	O
shows	O
how	O
the	O
number	O
of	O
possible	O
permutations	O
can	O
be	O
calculated	O
.	O

Gene1	O
is	O
present	O
in	O
all	O
lists	O
and	O
does	O
not	O
have	O
an	O
impact	O
on	O
the	O
total	O
number	O
of	O
permutations	O
.	O

Gene2	O
,	O
having	O
vertex	O
degree	O
two	O
,	O
is	O
present	O
in	O
two	O
out	O
of	O
three	O
lists	O
in	O
one	O
out	O
of	O
three	O
possible	O
ways	O
.	O

The	O
remaining	O
genes	O
have	O
vertex	O
degree	O
1	O
and	O
can	O
be	O
freely	O
chosen	O
to	O
fill	O
the	O
empty	O
slots	O
.	O

We	O
can	O
now	O
count	O
exactly	O
how	O
many	O
times	O
a	O
gene	O
is	O
linked	O
to	O
a	O
list	O
and	O
divide	O
these	O
counts	O
by	O
455	O
,	O
the	O
size	O
of	O
the	O
permutation	O
set	O
,	O
to	O
obtain	O
exact	O
occurrence	O
probabilities	O
.	O

These	O
numbers	O
are	O
shown	O
in	O
graphical	O
form	O
in	O
Fig.	O
3B	O
and	O
in	O
numerical	O
form	O
in	O
Fig.	O
3C	O
.	O

Fig.	O
3B	O
also	O
shows	O
the	O
occurrence	O
probability	O
estimates	O
obtained	O
by	O
edge	O
-	O
swapping	O
side	O
-	O
by	O
-	O
side	O
to	O
the	O
exact	O
occurrence	O
probabilities	O
.	O

The	O
graph	O
in	O
Fig.	O
1A	O
was	O
subjected	O
to	O
edge	O
-	O
swapping	O
1000	O
times	O
and	O
the	O
number	O
of	O
times	O
a	O
gene	O
was	O
found	O
present	O
in	O
a	O
list	O
was	O
divided	O
by	O
1000	O
to	O
obtain	O
the	O
occurrence	O
probability	O
.	O

At	O
each	O
run	O
,	O
100	O
random	O
edge	O
swaps	O
were	O
performed	O
to	O
ensure	O
complete	O
randomization	O
of	O
the	O
graph	O
.	O

This	O
procedure	O
was	O
repeated	O
10	O
times	O
and	O
the	O
mean	O
and	O
standard	O
deviation	O
of	O
occurrence	O
probability	O
estimates	O
for	O
each	O
gene	O
in	O
each	O
list	O
are	O
shown	O
.	O

In	O
all	O
cases	O
,	O
the	O
mean	O
differs	O
from	O
the	O
real	O
probability	O
by	O
less	O
than	O
two	O
standard	O
deviations	O
,	O
in	O
most	O
cases	O
by	O
less	O
than	O
one	O
standard	O
deviation	O
.	O

Thus	O
,	O
edge	O
-	O
swapping	O
provides	O
reliable	O
estimates	O
of	O
exact	O
occurrence	O
probabilities	O
as	O
determined	O
from	O
a	O
complete	O
permutation	O
set	O
.	O

As	O
an	O
interesting	O
observation	O
,	O
we	O
provide	O
evidence	O
that	O
occurrence	O
probabilities	O
are	O
non	O
-	O
linear	O
functions	O
of	O
vertex	O
degrees	O
in	O
the	O
edge	O
-	O
swapping	O
model	O
.	O

This	O
is	O
illustrated	O
in	O
Fig.	O
3C	O
.	O

Individual	O
and	O
average	O
occurrence	O
probabilities	O
are	O
shown	O
as	O
a	O
function	O
of	O
gene	O
and	O
list	O
vertex	O
degrees	O
.	O

Non	O
-	O
linearity	O
of	O
individual	O
occurrence	O
probabilities	O
can	O
be	O
verified	O
from	O
the	O
counts	O
table	O
underneath	O
the	O
plots	O
.	O

However	O
,	O
the	O
average	O
occurrence	O
probability	O
is	O
found	O
to	O
depend	O
on	O
vertex	O
degrees	O
in	O
a	O
linear	O
fashion	O
instead	O
.	O

This	O
is	O
a	O
consequence	O
of	O
the	O
fact	O
that	O
occurrence	O
probabilities	O
of	O
a	O
gene	O
over	O
all	O
lists	O
add	O
up	O
to	O
the	O
gene	O
vertex	O
degree	O
and	O
that	O
the	O
occurrence	O
probabilities	O
of	O
all	O
genes	O
for	O
a	O
given	O
list	O
add	O
up	O
to	O
the	O
list	O
vertex	O
degree	O
.	O

At	O
the	O
same	O
time	O
,	O
since	O
the	O
most	O
stringent	O
permutation	O
based	O
null	O
-	O
model	O
predicts	O
non	O
-	O
linear	O
dependencies	O
of	O
individual	O
occurrence	O
probabilities	O
on	O
vertex	O
degrees	O
,	O
assuming	O
such	O
linearity	O
in	O
statistical	O
models	O
of	O
co	O
-	O
occurrence	O
will	O
be	O
linked	O
to	O
loss	O
of	O
stringency	O
.	O

We	O
conclude	O
that	O
the	O
ES	O
null	O
-	O
model	O
is	O
the	O
null	O
-	O
model	O
that	O
permits	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
among	O
the	O
models	O
tested	O
and	O
that	O
it	O
closely	O
approximates	O
occurrence	O
probabilities	O
derived	O
from	O
an	O
ideal	O
permutation	O
model	O
.	O

The	O
increased	O
stringency	O
of	O
the	O
ES	O
model	O
over	O
other	O
models	O
is	O
a	O
consequence	O
of	O
higher	O
occurrence	O
probabilities	O
for	O
genes	O
and	O
list	O
with	O
high	O
vertex	O
degrees	O
,	O
which	O
are	O
giving	O
rise	O
to	O
a	O
large	O
part	O
of	O
all	O
co	O
-	O
occurrences	O
in	O
the	O
bipartite	O
graph	O
.	O

Since	O
large	O
occurrence	O
probabilities	O
make	O
co	O
-	O
occurrence	O
more	O
likely	O
,	O
the	O
analysis	O
becomes	O
more	O
stringent	O
.	O

Co	O
-	O
occurrence	O
probabilities	O
Co	O
-	O
occurrence	O
analysis	O
can	O
be	O
thought	O
of	O
as	O
a	O
Bernoulli	O
experiment	O
with	O
a	O
binomial	O
outcome	O
(	O
a	O
given	O
combination	O
of	O
entries	O
is	O
either	O
present	O
or	O
not	O
present	O
in	O
a	O
given	O
list	O
)	O
.	O

Thus	O
,	O
the	O
Binomial	O
distribution	O
(	O
BD	O
)	O
is	O
a	O
natural	O
choice	O
for	O
judging	O
the	O
significance	O
of	O
the	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

However	O
,	O
the	O
BD	O
is	O
defined	O
for	O
a	O
probability	O
of	O
success	O
which	O
is	O
equal	O
in	O
all	O
trials	O
.	O

The	O
list	O
-	O
specific	O
nature	O
of	O
occurrence	O
probabilities	O
is	O
not	O
compatible	O
with	O
this	O
condition	O
(	O
analysis	O
of	O
each	O
list	O
represents	O
one	O
trial	O
)	O
,	O
which	O
means	O
that	O
co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
better	O
described	O
as	O
a	O
series	O
of	O
Poisson	O
trials	O
,	O
where	O
the	O
probability	O
of	O
success	O
varies	O
from	O
trial	O
to	O
trial	O
.	O

Therefore	O
,	O
the	O
significance	O
of	O
co	O
-	O
occurrences	O
must	O
be	O
evaluated	O
using	O
a	O
binomial	O
distribution	O
with	O
trial	O
-	O
specific	O
probabilities	O
,	O
i.e.	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
PBD	O
)	O
.	O

The	O
probability	O
of	O
success	O
in	O
a	O
single	O
Poisson	O
trial	O
can	O
be	O
calculated	O
by	O
multiplying	O
the	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
for	O
the	O
combination	O
of	O
genes	O
under	O
study	O
.	O

The	O
number	O
of	O
occurrence	O
probabilities	O
that	O
need	O
to	O
be	O
multiplied	O
is	O
equal	O
to	O
the	O
module	O
size	O
,	O
i.e.	O
the	O
number	O
of	O
genes	O
whose	O
combination	O
is	O
studied	O
.	O

An	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
a	O
combination	O
of	O
genes	O
can	O
then	O
be	O
evaluated	O
using	O
the	O
PBD	O
,	O
which	O
is	O
given	O
by	O
the	O
formula	O
[	O
36	O
]	O
:	O
(	O
18	O
)	O
The	O
structure	O
of	O
this	O
formula	O
is	O
very	O
similar	O
to	O
the	O
structure	O
of	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
binomial	O
distribution	O
,	O
except	O
that	O
multiplication	O
with	O
a	O
binomial	O
coefficient	O
is	O
replaced	O
by	O
summation	O
over	O
individual	O
terms	O
,	O
which	O
makes	O
calculation	O
of	O
P	O
-	O
values	O
using	O
(	O
18	O
)	O
inefficient	O
(	O
note	O
that	O
equation	O
numbering	O
starts	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
)	O
.	O

Here	O
,	O
Ak	O
denotes	O
the	O
kth	O
set	O
of	O
indices	O
of	O
the	O
i	O
lists	O
where	O
genes	O
are	O
co	O
-	O
occurring	O
(	O
""""	O
success	O
""""	O
)	O
.	O

There	O
are	O
possible	O
sets	O
and	O
summation	O
is	O
carried	O
out	O
accordingly	O
.	O

denotes	O
the	O
set	O
of	O
indices	O
of	O
N−i	O
lists	O
where	O
genes	O
are	O
not	O
co	O
-	O
occurring	O
(	O
""""	O
failure	O
""""	O
)	O
.	O

[	O
36	O
]	O
have	O
reported	O
two	O
fast	O
procedures	O
for	O
calculating	O
exact	O
PBD	O
P	O
-	O
values	O
.	O

However	O
,	O
both	O
procedures	O
work	O
with	O
probability	O
ratios	O
and	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
for	O
large	O
numbers	O
of	O
trials	O
.	O

NetCutter	O
uses	O
two	O
workarounds	O
to	O
circumvent	O
this	O
problem	O
.	O

One	O
is	O
based	O
on	O
using	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
,	O
which	O
can	O
be	O
calculated	O
very	O
easily	O
instead	O
(	O
see	O
below	O
)	O
.	O

The	O
other	O
relies	O
on	O
a	O
fast	O
approximation	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
,	O
which	O
we	O
call	O
bi	O
-	O
binomial	O
approximation	O
(	O
BBA	O
)	O
or	O
bi	O
-	O
binomial	O
distribution	O
(	O
BBD	O
)	O
.	O

Z	O
-	O
scores	O
and	O
P	O
-	O
values	O
of	O
BBD	O
Given	O
the	O
mean	O
μ	O
(	O
1	O
)	O
and	O
variance	O
σ2	O
(	O
2	O
)	O
of	O
PBD	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
the	O
Z	O
-	O
score	O
associated	O
with	O
a	O
given	O
number	O
of	O
co	O
-	O
occurrences	O
x	O
is	O
obtained	O
as:	O
(	O
19	O
)	O
Considering	O
the	O
structure	O
of	O
formulae	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
(	O
Materials	O
and	O
Methods	O
section	O
)	O
,	O
PBD	O
Z	O
-	O
scores	O
can	O
be	O
calculated	O
very	O
easily	O
and	O
provide	O
a	O
simple	O
estimate	O
of	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
modules	O
.	O

However	O
,	O
in	O
contrast	O
to	O
normally	O
distributed	O
Z	O
-	O
scores	O
,	O
binomial	O
and	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
sets	O
of	O
probabilities	O
of	O
success	O
.	O

To	O
see	O
this	O
,	O
calculate	O
for	O
example	O
the	O
probability	O
of	O
success	O
in	O
a	O
series	O
of	O
100	O
Bernoulli	O
trials	O
with	O
success	O
probability	O
0.1	O
and	O
0.9	O
for	O
the	O
expectation	O
of	O
10	O
and	O
90	O
successes	O
,	O
respectively	O
.	O

The	O
Z	O
-	O
score	O
will	O
be	O
0	O
in	O
both	O
cases	O
but	O
the	O
corresponding	O
cumulative	O
P	O
-	O
values	O
are	O
0.5832	O
and	O
0.5487	O
.	O

Therefore	O
,	O
exact	O
levels	O
of	O
significance	O
can	O
not	O
be	O
derived	O
from	O
Z	O
-	O
scores	O
alone	O
.	O

Thus	O
,	O
a	O
fast	O
and	O
reliable	O
procedure	O
for	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
is	O
needed	O
.	O

The	O
BBD	O
approximation	O
was	O
developed	O
to	O
solve	O
this	O
problem	O
.	O

The	O
BBD	O
approximation	O
of	O
PBD	O
P	O
-	O
values	O
follows	O
from	O
the	O
relationship	O
between	O
the	O
variance	O
of	O
PBD	O
and	O
the	O
population	O
variance	O
of	O
trial	O
-	O
specific	O
probabilities	O
of	O
success	O
.	O

This	O
relationship	O
is	O
shown	O
in	O
Materials	O
and	O
Methods	O
to	O
be	O
described	O
by	O
(	O
4	O
)	O
:	O
(	O
4	O
)	O
This	O
equation	O
shows	O
that	O
there	O
is	O
an	O
inverse	O
linear	O
relationship	O
between	O
the	O
population	O
variance	O
S2	O
of	O
the	O
N	O
trial	O
probabilities	O
and	O
the	O
variance	O
of	O
PBD	O
σ2	O
,	O
which	O
means	O
that	O
PBD	O
becomes	O
increasingly	O
narrow	O
as	O
the	O
variance	O
of	O
trial	O
probabilities	O
grows	O
.	O

It	O
also	O
shows	O
that	O
,	O
for	O
constant	O
mean	O
μ	O
and	O
number	O
of	O
trials	O
N	O
,	O
the	O
shape	O
of	O
PBD	O
depends	O
only	O
on	O
the	O
variance	O
of	O
trial	O
probabilities	O
.	O

Therefore	O
,	O
relationship	O
(	O
4	O
)	O
suggests	O
an	O
easy	O
way	O
to	O
approximate	O
PBD	O
P	O
-	O
values	O
.	O

The	O
P	O
-	O
value	O
can	O
be	O
obtained	O
by	O
constructing	O
a	O
set	O
of	O
trial	O
probabilities	O
with	O
equal	O
variance	O
as	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
,	O
which	O
,	O
however	O
,	O
are	O
not	O
all	O
different	O
.	O

In	O
other	O
words	O
,	O
the	O
series	O
of	O
Poisson	O
trials	O
can	O
be	O
replaced	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
with	O
trial	O
probabilities	O
p1	O
and	O
p2	O
constructed	O
such	O
that	O
the	O
variance	O
is	O
equal	O
to	O
the	O
original	O
set	O
of	O
trial	O
probabilities	O
.	O

This	O
strategy	O
is	O
illustrated	O
in	O
Fig.	O
4	O
and	O
explains	O
why	O
this	O
approximation	O
is	O
called	O
bi	O
-	O
binomial	O
.	O

The	O
details	O
on	O
how	O
to	O
obtain	O
the	O
values	O
of	O
the	O
two	O
sets	O
of	O
Bernoulli	O
trial	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
with	O
p1	O
and	O
p2	O
as	O
probabilities	O
of	O
success	O
are	O
provided	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

The	O
precision	O
of	O
the	O
BBD	O
approximation	O
is	O
discussed	O
in	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

In	O
order	O
to	O
evaluate	O
whether	O
BBD	O
P	O
-	O
values	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
offer	O
an	O
advantage	O
over	O
other	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
or	O
the	O
uncertainty	O
coefficient	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
of	O
two	O
genes	O
in	O
200	O
lists	O
with	O
and	O
without	O
list	O
-	O
length	O
-	O
heterogeneity	O
was	O
studied	O
(	O
Fig.	O
5	O
)	O
.	O

Each	O
gene	O
is	O
assumed	O
to	O
occur	O
in	O
100	O
lists	O
.	O

Therefore	O
,	O
the	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
over	O
all	O
200	O
lists	O
must	O
add	O
up	O
to	O
100	O
,	O
regardless	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

For	O
simplicity	O
,	O
occurrence	O
probabilities	O
of	O
both	O
genes	O
are	O
assumed	O
to	O
be	O
equal	O
in	O
any	O
particular	O
list	O
.	O

The	O
co	O
-	O
occurrence	O
probability	O
in	O
a	O
list	O
is	O
then	O
given	O
by	O
the	O
square	O
of	O
the	O
occurrence	O
probability	O
in	O
that	O
list	O
.	O

For	O
all	O
possible	O
co	O
-	O
occurrences	O
from	O
0	O
to	O
100	O
,	O
the	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
were	O
calculated	O
as	O
detailed	O
in	O
the	O
Materials	O
and	O
Methods	O
section	O
.	O

In	O
addition	O
,	O
cumulative	O
BBD	O
P	O
-	O
values	O
were	O
calculated	O
using	O
the	O
co	O
-	O
occurrence	O
probabilities	O
as	O
trial	O
probabilities	O
.	O

To	O
illustrate	O
the	O
advantage	O
of	O
BBD	O
over	O
BD	O
as	O
co	O
-	O
occurrence	O
probability	O
distribution	O
,	O
cumulative	O
BD	O
P	O
-	O
values	O
of	O
a	O
BD	O
with	O
the	O
same	O
mean	O
as	O
BBD	O
but	O
constant	O
trial	O
probabilities	O
is	O
shown	O
.	O

These	O
trial	O
probabilities	O
can	O
be	O
obtained	O
by	O
dividing	O
the	O
mean	O
of	O
BBD	O
by	O
the	O
number	O
of	O
lists	O
.	O

Three	O
different	O
cases	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
are	O
considered	O
in	O
Fig.	O
5	O
:	O
No	O
heterogeneity	O
(	O
standard	O
deviation	O
0	O
)	O
,	O
heterogeneity	O
with	O
standard	O
deviation	O
0.283	O
and	O
heterogeneity	O
with	O
standard	O
deviation	O
0.401	O
in	O
the	O
occurrence	O
probabilities	O
.	O

The	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
are	O
by	O
definition	O
insensitive	O
to	O
list	O
-	O
length	O
-	O
heterogeneity	O
because	O
differences	O
in	O
co	O
-	O
occurrence	O
probabilities	O
in	O
a	O
given	O
list	O
can	O
not	O
be	O
considered	O
in	O
their	O
calculation	O
.	O

This	O
is	O
because	O
both	O
coefficients	O
are	O
defined	O
by	O
the	O
counts	O
of	O
the	O
four	O
list	O
classes	O
:	O
both	O
genes	O
absent	O
,	O
both	O
genes	O
present	O
,	O
first	O
gene	O
absent	O
second	O
gene	O
present	O
,	O
and	O
first	O
gene	O
present	O
second	O
gene	O
absent	O
,	O
i.e.	O
by	O
the	O
corresponding	O
contingency	O
table	O
,	O
which	O
does	O
not	O
change	O
with	O
different	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

In	O
the	O
absence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
cumulative	O
P	O
-	O
values	O
of	O
BD	O
and	O
BBD	O
(	O
which	O
are	O
perfectly	O
overlapping	O
as	O
expected	O
)	O
assume	O
0.5	O
at	O
50	O
co	O
-	O
occurrences	O
,	O
which	O
corresponds	O
to	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
calculated	O
as	O
(	O
50	O
=	O
100	O
occurrences	O
per	O
gene	O
/	O
200	O
lists	O
)	O
ˆ2	O
*	O
200	O
lists	O
.	O

The	O
uncertainty	O
coefficient	O
is	O
found	O
to	O
be	O
0	O
and	O
the	O
Jaccard	O
coefficient	O
is	O
0.33333	O
at	O
that	O
point	O
.	O

When	O
there	O
is	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
standard	O
deviation	O
0.283	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifting	O
to	O
the	O
right	O
.	O

This	O
is	O
because	O
the	O
sum	O
of	O
squares	O
of	O
varying	O
occurrence	O
probabilities	O
(	O
i.e.	O
the	O
sum	O
of	O
co	O
-	O
occurrence	O
probabilities	O
used	O
as	O
trial	O
probabilities	O
,	O
which	O
is	O
equal	O
to	O
the	O
mean	O
of	O
BBD	O
)	O
is	O
always	O
larger	O
than	O
the	O
sum	O
of	O
squares	O
of	O
constant	O
occurrence	O
probabilities	O
with	O
the	O
same	O
average	O
occurrence	O
probability	O
(	O
0.5	O
)	O
.	O

The	O
corresponding	O
BD	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
obtained	O
by	O
dividing	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
by	O
the	O
total	O
number	O
of	O
lists	O
,	O
which	O
means	O
assuming	O
equal	O
co	O
-	O
occurrences	O
in	O
all	O
lists	O
.	O

This	O
visualization	O
is	O
shown	O
to	O
illustrate	O
how	O
BBD	O
(	O
which	O
is	O
narrower	O
than	O
the	O
corresponding	O
BD	O
)	O
gives	O
rise	O
to	O
a	O
steeper	O
cumulative	O
distribution	O
of	O
P	O
-	O
values	O
and	O
as	O
a	O
consequence	O
to	O
more	O
significant	O
P	O
-	O
values	O
for	O
numbers	O
of	O
co	O
-	O
occurrence	O
that	O
are	O
far	O
from	O
the	O
expectation	O
.	O

As	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
grows	O
(	O
standard	O
deviation	O
of	O
occurrence	O
probabilities	O
0.401	O
)	O
,	O
the	O
mean	O
of	O
BBD	O
is	O
shifted	O
even	O
further	O
to	O
the	O
right	O
and	O
BBD	O
P	O
-	O
values	O
are	O
distributed	O
in	O
a	O
still	O
steeper	O
fashion	O
as	O
compared	O
to	O
corresponding	O
BD	O
P	O
-	O
values	O
and	O
the	O
interval	O
of	O
non	O
-	O
significant	O
co	O
-	O
occurrences	O
is	O
shrinking	O
further	O
.	O

With	O
modest	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
66	O
,	O
which	O
is	O
associated	O
with	O
a	O
Jaccard	O
coefficient	O
of	O
0.49	O
and	O
an	O
uncertainty	O
coefficient	O
of	O
0.075	O
.	O

In	O
the	O
case	O
of	O
large	O
list	O
-	O
length	O
-	O
heterogeneity	O
,	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
82	O
with	O
J	O
=	O
0.69	O
and	O
UC	O
=	O
0.32	O
.	O

Taken	O
together	O
,	O
these	O
data	O
show	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
varies	O
strongly	O
with	O
the	O
level	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
and	O
that	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
is	O
associated	O
with	O
different	O
values	O
of	O
UC	O
and	O
J.	O
To	O
complicate	O
matters	O
further	O
,	O
66	O
co	O
-	O
occurrences	O
(	O
J	O
=	O
0.49	O
,	O
UC	O
=	O
0.075	O
)	O
represent	O
significant	O
positive	O
association	O
(	O
PBBD	O
=	O
0.996	O
)	O
with	O
equal	O
list	O
lengths	O
,	O
no	O
significant	O
association	O
with	O
modest	O
differences	O
in	O
list	O
length	O
(	O
PBBD	O
=	O
0.536	O
)	O
and	O
strongly	O
negative	O
association	O
(	O
meaning	O
one	O
gene	O
excludes	O
the	O
other	O
)	O
with	O
strong	O
list	O
-	O
length	O
-	O
heterogeneity	O
(	O
PBBD	O
=	O
0.00016	O
)	O
.	O

Thus	O
,	O
the	O
same	O
J	O
and	O
UC	O
association	O
measure	O
is	O
obtained	O
for	O
positive	O
,	O
negative	O
,	O
and	O
absence	O
of	O
association	O
.	O

Therefore	O
,	O
the	O
meaning	O
of	O
these	O
measures	O
can	O
not	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
the	O
co	O
-	O
occurring	O
entities	O
.	O

Furthermore	O
,	O
the	O
data	O
in	O
Fig.	O
5	O
also	O
show	O
that	O
neither	O
J	O
nor	O
UC	O
can	O
distinguish	O
between	O
positive	O
and	O
negative	O
association	O
while	O
this	O
is	O
easy	O
with	O
cumulative	O
BBD	O
P	O
-	O
values	O
:	O
Large	O
P	O
-	O
values	O
mean	O
positive	O
association	O
and	O
low	O
P	O
-	O
values	O
mean	O
negative	O
association	O
.	O

In	O
summary	O
,	O
we	O
conclude	O
that	O
BBD	O
provides	O
a	O
novel	O
association	O
measure	O
that	O
offers	O
a	O
number	O
of	O
advantages	O
over	O
the	O
existing	O
contingency	O
table	O
based	O
association	O
measures	O
Jaccard	O
coefficient	O
and	O
uncertainty	O
coefficient	O
.	O

The	O
results	O
in	O
Fig.	O
5	O
also	O
show	O
that	O
significance	O
of	O
association	O
depends	O
critically	O
on	O
the	O
specific	O
distribution	O
of	O
co	O
-	O
occurring	O
entities	O
over	O
lists	O
of	O
varying	O
length	O
(	O
because	O
this	O
distribution	O
determines	O
the	O
occurrence	O
probabilities	O
)	O
and	O
that	O
contingency	O
table	O
based	O
methods	O
(	O
which	O
can	O
not	O
capture	O
this	O
distribution	O
)	O
should	O
be	O
avoided	O
in	O
the	O
presence	O
of	O
significant	O
list	O
-	O
length	O
-	O
heterogeneity	O
.	O

Generation	O
of	O
co	O
-	O
occurrence	O
networks	O
and	O
the	O
identification	O
of	O
communities	O
The	O
procedures	O
outlined	O
above	O
allow	O
the	O
identification	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
any	O
type	O
of	O
bipartite	O
graph	O
.	O

Three	O
user	O
defined	O
parameters	O
have	O
an	O
impact	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
:	O
The	O
module	O
size	O
,	O
the	O
support	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
.	O

The	O
module	O
size	O
determines	O
how	O
many	O
entries	O
will	O
be	O
tested	O
for	O
co	O
-	O
occurrence	O
,	O
the	O
support	O
sets	O
a	O
lower	O
boundary	O
on	O
the	O
required	O
number	O
of	O
co	O
-	O
occurrences	O
,	O
and	O
the	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
sets	O
the	O
significance	O
threshold	O
.	O

In	O
general	O
,	O
higher	O
module	O
size	O
leads	O
to	O
more	O
stringent	O
co	O
-	O
occurrence	O
analysis	O
at	O
the	O
cost	O
of	O
computational	O
complexity	O
.	O

The	O
support	O
parameter	O
allows	O
limiting	O
this	O
complexity	O
by	O
filtering	O
out	O
co	O
-	O
occurrence	O
modules	O
which	O
co	O
-	O
occur	O
less	O
frequently	O
than	O
required	O
by	O
the	O
support	O
.	O

The	O
significance	O
cutoff	O
permits	O
adjusting	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
,	O
which	O
is	O
calculated	O
as	O
the	O
number	O
of	O
co	O
-	O
occurrence	O
modules	O
observed	O
in	O
the	O
real	O
versus	O
a	O
randomized	O
bipartite	O
graph	O
.	O

The	O
impact	O
of	O
these	O
parameters	O
on	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
has	O
been	O
reported	O
previously	O
for	O
the	O
PubLiME	O
data	O
set	O
[	O
35	O
]	O
and	O
is	O
illustrated	O
in	O
a	O
simulation	O
study	O
provided	O
as	O
supplementary	O
material	O
Simulation	O
S1	O
.	O

From	O
the	O
set	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
,	O
a	O
co	O
-	O
occurrence	O
network	O
is	O
generated	O
by	O
considering	O
each	O
entry	O
a	O
vertex	O
and	O
drawing	O
an	O
edge	O
between	O
any	O
two	O
vertices	O
,	O
which	O
have	O
been	O
part	O
of	O
the	O
same	O
significant	O
co	O
-	O
occurrence	O
module	O
[	O
35	O
]	O
.	O

An	O
important	O
question	O
in	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
regards	O
the	O
presence	O
of	O
network	O
communities	O
.	O

Communities	O
can	O
be	O
understood	O
as	O
groups	O
of	O
vertices	O
with	O
the	O
property	O
that	O
the	O
number	O
of	O
edges	O
running	O
within	O
groups	O
is	O
larger	O
than	O
expected	O
by	O
chance	O
and	O
that	O
the	O
number	O
of	O
edges	O
running	O
between	O
groups	O
is	O
lower	O
than	O
expected	O
by	O
chance	O
[	O
37	O
]	O
.	O

This	O
problem	O
of	O
partitioning	O
a	O
graph	O
is	O
often	O
referred	O
to	O
as	O
the	O
graph	O
-	O
cut	O
problem	O
(	O
hence	O
the	O
name	O
NetCutter	O
)	O
.	O

NetCutter	O
is	O
built	O
on	O
the	O
Java	O
Universal	O
Network	O
and	O
Graph	O
framework	O
(	O
JUNG	O
)	O
software	O
package	O
(	O
http://jung.sourceforge.net	O
)	O
,	O
which	O
provides	O
algorithms	O
for	O
solving	O
this	O
problem	O
.	O

In	O
particular	O
,	O
NetCutter	O
implements	O
the	O
Bicomponent	O
clustering	O
algorithm	O
[	O
38	O
]	O
,	O
the	O
Edge	O
-	O
Betweenness	O
clustering	O
algorithm	O
[	O
39	O
]	O
,	O
and	O
the	O
Exact	O
Flow	O
Community	O
algorithm	O
[	O
40	O
]	O
.	O

Furthermore	O
,	O
there	O
is	O
a	O
clustering	O
tool	O
that	O
is	O
not	O
part	O
of	O
the	O
JUNG	O
package	O
,	O
namely	O
an	O
algorithm	O
identifying	O
communities	O
using	O
eigenvectors	O
of	O
the	O
modularity	O
matrix	O
[	O
37	O
]	O
.	O

The	O
code	O
for	O
this	O
algorithm	O
was	O
kindly	O
provided	O
by	O
Mark	O
Newman	O
in	O
C++	O
and	O
ported	O
to	O
Java	O
.	O

In	O
addition	O
to	O
these	O
tools	O
,	O
NetCutter	O
provides	O
a	O
number	O
of	O
convenience	O
functions	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
such	O
as	O
testing	O
the	O
significance	O
of	O
lists	O
reporting	O
a	O
set	O
of	O
entries	O
making	O
up	O
a	O
network	O
community	O
,	O
ranking	O
of	O
vertices	O
,	O
random	O
graph	O
generators	O
for	O
topological	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
and	O
others	O
.	O

Details	O
on	O
all	O
functions	O
are	O
provided	O
in	O
the	O
NetCutter	O
software	O
documentation	O
.	O

One	O
of	O
the	O
possible	O
applications	O
of	O
NetCutter	O
is	O
illustrated	O
below	O
.	O

This	O
application	O
is	O
tightly	O
linked	O
to	O
the	O
bipartite	O
graph	O
representation	O
of	O
the	O
data	O
.	O

Namely	O
,	O
NetCutter	O
can	O
be	O
used	O
to	O
perform	O
co	O
-	O
occurrence	O
analysis	O
of	O
genes	O
or	O
list	O
derived	O
from	O
the	O
same	O
bipartite	O
graph	O
.	O

The	O
network	O
communities	O
identified	O
in	O
each	O
both	O
reflect	O
the	O
same	O
underlying	O
structure	O
of	O
the	O
bipartite	O
graph	O
.	O

In	O
the	O
case	O
of	O
gene	O
expression	O
signatures	O
stored	O
in	O
PubLiME	O
,	O
clusters	O
of	O
genes	O
correspond	O
to	O
clusters	O
of	O
publications	O
,	O
which	O
can	O
reveal	O
possible	O
functions	O
of	O
gene	O
clusters	O
.	O

Cluster	O
correspondence	O
and	O
association	O
studies	O
The	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
published	O
previously	O
[	O
35	O
]	O
identified	O
5	O
major	O
network	O
communities	O
of	O
genes	O
with	O
consistent	O
functional	O
annotations	O
that	O
are	O
deregulated	O
in	O
cancer	O
related	O
gene	O
expression	O
signatures	O
.	O

This	O
analysis	O
was	O
performed	O
by	O
considering	O
all	O
genes	O
mentioned	O
in	O
a	O
particular	O
publication	O
as	O
a	O
single	O
signature	O
,	O
even	O
though	O
they	O
might	O
have	O
been	O
part	O
of	O
different	O
tables	O
and	O
cluster	O
analyses	O
.	O

Here	O
we	O
present	O
an	O
advanced	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
where	O
each	O
table	O
and/or	O
cluster	O
identified	O
in	O
a	O
given	O
publication	O
is	O
considered	O
as	O
a	O
separate	O
signature	O
.	O

This	O
brings	O
the	O
total	O
number	O
of	O
signatures	O
to	O
be	O
analyzed	O
to	O
1015	O
comprising	O
a	O
total	O
of	O
7358	O
differentially	O
regulated	O
genes	O
derived	O
from	O
233	O
publications	O
reporting	O
cancer	O
related	O
signatures	O
derived	O
from	O
human	B
samples	O
.	O

We	O
use	O
this	O
analysis	O
to	O
illustrate	O
three	O
major	O
points	O
:	O
First	O
,	O
the	O
set	O
of	O
communities	O
reported	O
previously	O
is	O
reproduced	O
by	O
this	O
more	O
fine	O
-	O
grained	O
analysis	O
.	O

Second	O
,	O
the	O
set	O
of	O
gene	O
communities	O
corresponds	O
to	O
a	O
set	O
of	O
publication	O
communities	O
.	O

Third	O
,	O
associations	O
between	O
publications	O
and	O
gene	O
communities	O
can	O
be	O
calculated	O
with	O
higher	O
stringency	O
using	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
in	O
conjunction	O
with	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
statistics	O
.	O

The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
PubMedID_listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Co	O
-	O
occurrence	O
analysis	O
was	O
carried	O
out	O
in	O
two	O
ways	O
:	O
First	O
,	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
and	O
communities	O
of	O
co	O
-	O
occurring	O
genes	O
were	O
defined	O
by	O
edge	O
-	O
betweenness	O
clustering	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Second	O
,	O
co	O
-	O
occurrence	O
of	O
PubMedID_listIDs	O
was	O
analyzed	O
.	O

To	O
this	O
end	O
,	O
the	O
order	O
of	O
PubMedID_listID	O
-	O
gene	O
pairs	O
was	O
reversed	O
to	O
form	O
GENE	O
-	O
PUBMEDID_LISTID	O
pairs	O
.	O

Thus	O
,	O
the	O
lists	O
in	O
the	O
resulting	O
bipartite	O
graph	O
are	O
formed	O
by	O
genes	O
and	O
the	O
entries	O
are	O
the	O
PubMedID_listIDs	O
where	O
the	O
genes	O
are	O
reported	O
as	O
differentially	O
regulated	O
.	O

Occurrence	O
probabilities	O
for	O
the	O
reversed	O
bipartite	O
graph	O
can	O
be	O
obtained	O
by	O
transposing	O
the	O
occurrence	O
probability	O
matrix	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

Since	O
the	O
gene	O
communities	O
identified	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
reflect	O
the	O
structure	O
inherent	O
in	O
the	O
bipartite	O
graph	O
(	O
which	O
is	O
not	O
affected	O
by	O
reversing	O
the	O
list	O
-	O
entry	O
order	O
)	O
,	O
co	O
-	O
occurrence	O
analysis	O
of	O
the	O
reversed	O
bipartite	O
graph	O
will	O
result	O
in	O
PubMedID_listID	O
communities	O
that	O
reflect	O
the	O
same	O
underlying	O
structure	O
in	O
the	O
bipartite	O
graph	O
.	O

In	O
other	O
words	O
,	O
PubMedID_listID	O
communities	O
correspond	O
to	O
gene	O
communities	O
.	O

In	O
less	O
abstract	O
terms	O
,	O
the	O
PubMedID_listID	O
communities	O
should	O
correspond	O
to	O
sets	O
of	O
publications	O
that	O
report	O
similar	O
sets	O
of	O
genes	O
as	O
differentially	O
regulated	O
.	O

The	O
identification	O
of	O
communities	O
of	O
publications	O
can	O
help	O
the	O
researcher	O
to	O
easily	O
identify	O
publications	O
studying	O
genes	O
in	O
a	O
gene	O
community	O
that	O
is	O
of	O
interest	O
to	O
the	O
researcher	O
.	O

The	O
results	O
of	O
both	O
types	O
of	O
co	O
-	O
occurrence	O
analysis	O
are	O
displayed	O
in	O
Fig.	O
6	O
.	O

Fig.	O
6A	O
shows	O
the	O
gene	O
clusters	O
identified	O
.	O

The	O
clusters	O
are	O
named	O
after	O
significant	O
enrichments	O
of	O
gene	O
categories	O
as	O
determined	O
by	O
functional	O
category	O
enrichment	O
using	O
DAVID	O
[	O
41	O
]	O
.	O

The	O
P	O
-	O
values	O
shown	O
are	O
Benjamini	O
corrected	O
for	O
multiple	O
testing	O
as	O
reported	O
by	O
DAVID	O
.	O

The	O
clusters	O
are	O
very	O
similar	O
to	O
the	O
clusters	O
published	O
previously	O
[	O
35	O
]	O
.	O

There	O
is	O
one	O
new	O
cluster	O
that	O
is	O
strongly	O
enriched	O
for	O
ribosomal	O
proteins	O
(	O
""""	O
protein	O
biosynthesis	O
""""	O
cluster	O
)	O
,	O
which	O
has	O
not	O
reached	O
significance	O
in	O
our	O
previous	O
analysis	O
.	O

The	O
""""	O
surface	O
antigen	O
""""	O
cluster	O
contains	O
many	O
genes	O
that	O
had	O
been	O
reported	O
as	O
part	O
of	O
the	O
""""	O
signal	O
transduction	O
""""	O
cluster	O
.	O

Altogether	O
,	O
however	O
,	O
these	O
results	O
strongly	O
support	O
the	O
notion	O
that	O
the	O
gene	O
clusters	O
in	O
the	O
PubLiME	O
data	O
set	O
can	O
be	O
reproduced	O
by	O
the	O
more	O
fine	O
-	O
grained	O
analysis	O
that	O
considers	O
sublists	O
in	O
each	O
publication	O
as	O
separate	O
signatures	O
.	O

The	O
corresponding	O
clusters	O
of	O
PubMedID_listIDs	O
are	O
shown	O
in	O
Fig.	O
6B	O
.	O

There	O
are	O
five	O
clusters	O
,	O
which	O
have	O
been	O
named	O
after	O
their	O
corresponding	O
gene	O
cluster	O
.	O

Only	O
one	O
cluster	O
(	O
the	O
""""	O
extracellular	O
matrix	O
-	O
immune	O
response	O
cluster	O
""""	O
)	O
can	O
not	O
be	O
separated	O
by	O
edge	O
-	O
betweenness	O
clustering	O
at	O
the	O
point	O
of	O
maximal	O
graph	O
modularity	O
.	O

To	O
see	O
that	O
this	O
naming	O
is	O
indeed	O
justified	O
,	O
we	O
needed	O
to	O
investigate	O
how	O
strongly	O
a	O
given	O
PubMedID_listID	O
is	O
associated	O
with	O
a	O
given	O
gene	O
cluster	O
,	O
i.e.	O
how	O
significant	O
is	O
the	O
overlap	O
of	O
the	O
genes	O
reported	O
in	O
a	O
gene	O
cluster	O
and	O
the	O
genes	O
reported	O
in	O
a	O
PubMedID_listID	O
.	O

Binomial	O
or	O
hypergemetric	O
statistics	O
are	O
generally	O
used	O
to	O
calculate	O
this	O
significance	O
.	O

However	O
,	O
the	O
bipartite	O
graph	O
model	O
in	O
conjunction	O
with	O
the	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
offers	O
a	O
more	O
fine	O
-	O
grained	O
approach	O
based	O
on	O
bi	O
-	O
binomial	O
statistics	O
.	O

The	O
edge	O
-	O
swapping	O
null	O
-	O
model	O
determines	O
occurrence	O
probabilities	O
in	O
such	O
a	O
way	O
that	O
the	O
number	O
of	O
genes	O
in	O
a	O
given	O
PubMedID_listID	O
is	O
associated	O
with	O
insignificant	O
P	O
-	O
values	O
in	O
the	O
context	O
of	O
the	O
complete	O
bipartite	O
graph	O
.	O

However	O
,	O
when	O
a	O
subset	O
of	O
genes	O
is	O
analyzed	O
,	O
e.g.	O
all	O
the	O
genes	O
that	O
are	O
reported	O
in	O
a	O
particular	O
list	O
,	O
the	O
P	O
-	O
value	O
associated	O
with	O
the	O
number	O
of	O
genes	O
contained	O
in	O
this	O
list	O
will	O
likely	O
be	O
highly	O
significant	O
according	O
to	O
how	O
unlikely	O
it	O
is	O
to	O
obtain	O
all	O
the	O
genes	O
contained	O
in	O
a	O
given	O
list	O
in	O
a	O
random	O
draw	O
from	O
all	O
genes	O
present	O
in	O
the	O
bipartite	O
graph	O
.	O

Thus	O
,	O
PubMedID_listID	O
association	O
with	O
a	O
set	O
of	O
genes	O
in	O
the	O
bipartite	O
graph	O
model	O
can	O
be	O
calculated	O
in	O
the	O
following	O
way	O
:	O
The	O
set	O
of	O
genes	O
that	O
is	O
used	O
to	O
analyze	O
association	O
is	O
used	O
to	O
extract	O
a	O
subgraph	O
from	O
the	O
original	O
bipartite	O
graph	O
where	O
occurrence	O
probabilities	O
for	O
each	O
gene	O
-	O
PubMedID_listID	O
pair	O
are	O
identical	O
to	O
those	O
in	O
the	O
original	O
bipartite	O
graph	O
(	O
i.e.	O
they	O
are	O
not	O
recalculated	O
by	O
edge	O
-	O
swapping	O
)	O
.	O

The	O
vertex	O
degree	O
of	O
the	O
PubMedID_listID	O
vertices	O
in	O
the	O
subgraph	O
indicates	O
the	O
number	O
of	O
genes	O
contained	O
in	O
each	O
PubMedID_listID	O
overlapping	O
with	O
the	O
set	O
of	O
genes	O
used	O
to	O
extract	O
the	O
subgraph	O
.	O

From	O
the	O
occurrence	O
probabilities	O
of	O
the	O
genes	O
in	O
a	O
given	O
PubMedID_listID	O
,	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
can	O
then	O
be	O
calculated	O
for	O
every	O
list	O
vertex	O
degree	O
observed	O
in	O
the	O
subgraph	O
.	O

In	O
Fig.	O
7	O
,	O
the	O
significance	O
of	O
association	O
of	O
the	O
PubMedID_listIDs	O
(	O
see	O
Fig.	O
6B	O
)	O
with	O
the	O
cell	O
cycle	O
cluster	O
of	O
genes	O
(	O
Fig.	O
6A	O
)	O
is	O
calculated	O
.	O

For	O
comparison	O
,	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
are	O
also	O
shown	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
is	O
larger	O
than	O
the	O
binomial	O
and	O
hypergeometric	O
P	O
-	O
values	O
,	O
which	O
means	O
that	O
the	O
strength	O
of	O
association	O
is	O
evaluated	O
in	O
a	O
more	O
stringent	O
manner	O
using	O
BBD	O
statistics	O
(	O
see	O
Discussion	O
for	O
an	O
explanation	O
of	O
this	O
observation	O
)	O
.	O

The	O
analysis	O
of	O
significant	O
associations	O
between	O
PubMedID_listIDs	O
and	O
gene	O
clusters	O
now	O
permit	O
answering	O
the	O
question	O
whether	O
there	O
is	O
correspondence	O
between	O
gene	O
clusters	O
and	O
PubMedID_listID	O
clusters	O
.	O

The	O
naming	O
of	O
PubMedID_listID	O
clusters	O
shown	O
in	O
Fig.	O
6B	O
is	O
based	O
on	O
the	O
number	O
of	O
PubMedID_listID	O
that	O
are	O
significantly	O
associated	O
with	O
gene	O
clusters	O
shown	O
in	O
Fig.	O
6A	O
.	O

First	O
,	O
for	O
each	O
gene	O
cluster	O
,	O
all	O
the	O
PubMedID_listIDs	O
that	O
are	O
associated	O
with	O
that	O
cluster	O
with	O
more	O
than	O
95	O
%	O
confidence	O
(	O
i.e.	O
cumulative	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
>	O
=	O
0.95	O
)	O
were	O
identified	O
.	O

Second	O
,	O
the	O
number	O
of	O
significant	O
PubMedID_listIDs	O
in	O
each	O
PubMedID_listID	O
cluster	O
was	O
counted	O
for	O
every	O
gene	O
cluster	O
.	O

The	O
significance	O
of	O
this	O
number	O
was	O
then	O
calculated	O
using	O
binomial	O
statistics	O
.	O

The	O
results	O
of	O
this	O
analysis	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Negative	O
decadic	O
logarithms	O
of	O
the	O
binomial	O
P	O
-	O
value	O
are	O
displayed	O
.	O

It	O
is	O
apparent	O
that	O
each	O
PubMedID_listID	O
cluster	O
is	O
strongly	O
associated	O
with	O
at	O
least	O
one	O
gene	O
cluster	O
,	O
except	O
for	O
the	O
""""	O
extracellular	O
matrix	O
-	O
immune	O
response	O
""""	O
cluster	O
,	O
which	O
is	O
associated	O
with	O
two	O
gene	O
clusters	O
.	O

The	O
strength	O
of	O
these	O
associations	O
suggests	O
that	O
the	O
PubMedID_listID	O
clusters	O
are	O
indeed	O
corresponding	O
to	O
the	O
gene	O
clusters	O
and	O
that	O
both	O
the	O
gene	O
and	O
the	O
PubMedID_listID	O
clusters	O
reflect	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
representing	O
the	O
PubLiME	O
data	O
set	O
.	O

Details	O
about	O
all	O
the	O
lists	O
analyzed	O
are	O
attached	O
as	O
supplementary	O
material	O
Table	O
S2	O
.	O

Looking	O
at	O
these	O
lists	O
,	O
some	O
general	O
conclusions	O
about	O
the	O
gene	O
clusters	O
can	O
be	O
drawn	O
.	O

Cell	O
cycle	O
cluster	O
genes	O
have	O
been	O
found	O
deregulated	O
in	O
a	O
wide	O
variety	O
of	O
tumor	O
types	O
such	O
as	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
in	O
biliary	O
tract	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
gastric	O
cancer	O
,	O
prostate	O
cancer	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
glioma	O
,	O
acute	O
lymphoblastic	O
and	O
myeloblastic	O
leukemias	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
neuroblastoma	O
,	O
as	O
well	O
as	O
in	O
a	O
number	O
of	O
cellular	O
model	O
systems	O
in	O
response	O
to	O
different	O
stimuli	O
.	O

Thus	O
,	O
the	O
cell	O
cycle	O
cluster	O
seems	O
to	O
consist	O
of	O
genes	O
with	O
a	O
general	O
role	O
in	O
oncogenesis	O
.	O

The	O
surface	O
antigen	O
cluster	O
instead	O
seems	O
to	O
be	O
derived	O
preferentially	O
from	O
studies	O
on	O
leukemia	O
.	O

The	O
interferon	O
cluster	O
genes	O
are	O
found	O
deregulated	O
in	O
virus	O
induced	O
pathologies	O
such	O
as	O
papilloma	O
virus	O
induced	O
cervical	O
cancer	O
,	O
and	O
viral	O
hepatitis	O
.	O

Immune	O
response	O
cluster	O
genes	O
were	O
reported	O
as	O
differentially	O
regulated	O
in	O
inflammatory	O
conditions	O
such	O
as	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
,	O
and	O
Helicobacter	B
pylori	I
infections	O
.	O

Genes	O
of	O
the	O
extracellular	O
matrix	O
cluster	O
seem	O
to	O
be	O
associated	O
with	O
cancer	O
progression	O
studies	O
and	O
metastatic	O
potential	O
.	O

For	O
the	O
protein	O
biosynthesis	O
cluster	O
,	O
there	O
are	O
15	O
signatures	O
that	O
are	O
significantly	O
enriched	O
for	O
those	O
genes	O
.	O

The	O
cancers	O
studied	O
comprise	O
medulloblastoma	O
,	O
glioblastoma	O
,	O
pancreatic	O
cancer	O
,	O
soft	O
tissue	O
sarcoma	O
,	O
lung	O
carcinoma	O
,	O
breast	O
carcinoma	O
,	O
prostate	O
carcinoma	O
,	O
multiple	O
myeloma	O
,	O
and	O
lymphocytic	O
leukemia	O
.	O

The	O
genes	O
are	O
also	O
found	O
deregulated	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

Although	O
the	O
number	O
of	O
signatures	O
is	O
limited	O
,	O
the	O
variation	O
in	O
conditions	O
where	O
the	O
genes	O
are	O
deregulated	O
is	O
compatible	O
with	O
the	O
hypothesis	O
that	O
protein	O
biosynthesis	O
genes	O
,	O
as	O
cell	O
cycle	O
genes	O
,	O
are	O
deregulated	O
in	O
many	O
cancer	O
types	O
,	O
which	O
might	O
reflect	O
the	O
general	O
property	O
of	O
cancer	O
cells	O
to	O
divide	O
and	O
grow	O
in	O
an	O
uncontrolled	O
fashion	O
.	O

Discussion	O
Here	O
we	O
have	O
investigated	O
basic	O
aspects	O
of	O
co	O
-	O
occurrence	O
analysis	O
and	O
present	O
a	O
software	O
tool	O
,	O
NetCutter	O
,	O
which	O
can	O
be	O
used	O
to	O
identify	O
and	O
analyze	O
generic	O
co	O
-	O
occurrence	O
networks	O
.	O

In	O
NetCutter	O
,	O
a	O
co	O
-	O
occurrence	O
data	O
set	O
is	O
represented	O
as	O
a	O
bipartite	O
graph	O
with	O
one	O
part	O
representing	O
lists	O
and	O
the	O
other	O
part	O
list	O
entries	O
whose	O
co	O
-	O
occurrence	O
patterns	O
are	O
studied	O
.	O

The	O
bipartite	O
graph	O
representation	O
of	O
co	O
-	O
occurrence	O
data	O
sets	O
allows	O
the	O
efficacy	O
of	O
different	O
null	O
-	O
models	O
to	O
be	O
tested	O
systematically	O
.	O

We	O
have	O
shown	O
that	O
an	O
edge	O
-	O
swapping	O
procedure	O
used	O
to	O
randomize	O
the	O
bipartite	O
graph	O
generates	O
a	O
null	O
-	O
model	O
that	O
allows	O
co	O
-	O
occurrence	O
analysis	O
with	O
the	O
highest	O
stringency	O
.	O

The	O
other	O
null	O
-	O
models	O
tested	O
here	O
tend	O
to	O
underestimate	O
occurrence	O
probabilities	O
of	O
entries	O
per	O
list	O
for	O
lists	O
and	O
genes	O
with	O
high	O
vertex	O
degrees	O
,	O
i.e.	O
for	O
lists	O
and	O
genes	O
where	O
most	O
co	O
-	O
occurrences	O
are	O
observed	O
.	O

As	O
a	O
result	O
,	O
co	O
-	O
occurrences	O
are	O
judged	O
more	O
significant	O
than	O
they	O
really	O
are	O
.	O

Co	O
-	O
occurrence	O
data	O
sets	O
with	O
exactly	O
equal	O
lists	O
lengths	O
are	O
likely	O
to	O
be	O
the	O
exception	O
from	O
the	O
rule	O
.	O

It	O
can	O
be	O
assumed	O
that	O
some	O
list	O
-	O
length	O
-	O
heterogeneity	O
will	O
be	O
present	O
in	O
most	O
circumstances	O
.	O

An	O
important	O
consequence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
regards	O
the	O
co	O
-	O
occurrence	O
probability	O
distribution	O
used	O
to	O
evaluate	O
the	O
significance	O
of	O
the	O
observed	O
number	O
of	O
co	O
-	O
occurrences	O
.	O

Co	O
-	O
occurrence	O
analysis	O
in	O
the	O
presence	O
of	O
list	O
-	O
length	O
-	O
heterogeneity	O
is	O
best	O
performed	O
using	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
a	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
.	O

However	O
,	O
calculating	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
for	O
large	O
numbers	O
of	O
lists	O
is	O
difficult	O
using	O
existing	O
procedures	O
[	O
36	O
]	O
.	O

We	O
have	O
presented	O
an	O
approximation	O
to	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
called	O
bi	O
-	O
binomial	O
distribution	O
,	O
which	O
is	O
based	O
on	O
replacing	O
the	O
set	O
of	O
Poisson	O
trials	O
by	O
two	O
sets	O
of	O
Bernoulli	O
trials	O
.	O

The	O
resulting	O
distribution	O
reproduces	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
nearly	O
exactly	O
and	O
its	O
P	O
-	O
values	O
can	O
be	O
calculated	O
with	O
ease	O
even	O
for	O
thousands	O
of	O
lists	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
for	O
details	O
on	O
the	O
precision	O
of	O
BBD	O
)	O
.	O

Importantly	O
,	O
BBD	O
provides	O
a	O
novel	O
measure	O
of	O
association	O
,	O
which	O
is	O
shown	O
to	O
be	O
superior	O
to	O
existing	O
measures	O
such	O
as	O
the	O
Jaccard	O
coefficient	O
and	O
the	O
uncertainty	O
coefficient	O
,	O
whose	O
values	O
can	O
not	O
be	O
interpreted	O
properly	O
in	O
the	O
absence	O
of	O
knowledge	O
about	O
the	O
occurrence	O
probabilities	O
of	O
co	O
-	O
occurring	O
entities	O
.	O

It	O
is	O
worth	O
noting	O
that	O
Poisson	O
-	O
binomial	O
Z	O
-	O
scores	O
are	O
distinguished	O
from	O
Gaussian	O
Z	O
-	O
scores	O
by	O
the	O
fact	O
that	O
they	O
do	O
not	O
correspond	O
to	O
the	O
same	O
P	O
-	O
value	O
for	O
different	O
PBDs	O
,	O
BBDs	O
,	O
and	O
even	O
BDs	O
.	O

This	O
is	O
because	O
the	O
Z	O
-	O
score	O
is	O
an	O
explicit	O
part	O
of	O
the	O
function	O
defining	O
the	O
normal	O
probability	O
density	O
while	O
it	O
is	O
not	O
part	O
of	O
the	O
definitions	O
of	O
BD	O
,	O
PBD	O
,	O
and	O
BBD	O
densities	O
.	O

As	O
a	O
consequence	O
,	O
the	O
simple	O
Poisson	O
-	O
binomial	O
Z	O
-	O
score	O
based	O
approach	O
to	O
evaluating	O
significance	O
of	O
co	O
-	O
occurrence	O
must	O
be	O
complemented	O
with	O
the	O
BBD	O
to	O
approximate	O
Poisson	O
-	O
binomial	O
P	O
-	O
values	O
in	O
order	O
to	O
enable	O
multiple	O
testing	O
corrections	O
and	O
to	O
allow	O
calculation	O
of	O
confidence	O
levels	O
in	O
association	O
studies	O
precisely	O
.	O

However	O
,	O
NetCutter	O
is	O
equipped	O
with	O
a	O
bipartite	O
graph	O
randomization	O
tool	O
that	O
permits	O
measuring	O
the	O
number	O
of	O
false	O
positives	O
due	O
to	O
multiple	O
testing	O
directly	O
by	O
comparing	O
the	O
number	O
of	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
to	O
the	O
corresponding	O
number	O
in	O
a	O
randomized	O
version	O
thereof	O
.	O

Randomization	O
is	O
performed	O
by	O
edge	O
-	O
swapping	O
in	O
order	O
to	O
preserve	O
vertex	O
degrees	O
.	O

The	O
resulting	O
signal	O
-	O
to	O
-	O
noise	O
ratios	O
that	O
are	O
plotted	O
for	O
each	O
Z	O
-	O
score	O
/	O
P	O
-	O
value	O
cutoff	O
provide	O
a	O
highly	O
reliable	O
and	O
visually	O
intuitive	O
defense	O
mechanism	O
against	O
false	O
positives	O
(	O
see	O
also	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
.	O

In	O
the	O
vast	O
majority	O
of	O
co	O
-	O
occurrence	O
studies	O
,	O
pair	O
-	O
wise	O
co	O
-	O
occurrences	O
have	O
been	O
analyzed	O
using	O
different	O
statistical	O
models	O
.	O

We	O
have	O
observed	O
that	O
the	O
stringency	O
of	O
pair	O
-	O
wise	O
co	O
-	O
occurrence	O
analysis	O
is	O
far	O
below	O
the	O
stringency	O
of	O
co	O
-	O
occurrence	O
analysis	O
using	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entities	O
[	O
35	O
]	O
.	O

In	O
NetCutter	O
,	O
co	O
-	O
occurrence	O
analysis	O
is	O
preceded	O
by	O
occurrence	O
analysis	O
,	O
i.e.	O
the	O
occurrence	O
probability	O
of	O
each	O
entry	O
in	O
each	O
list	O
is	O
determined	O
.	O

Starting	O
from	O
occurrence	O
probabilities	O
,	O
co	O
-	O
occurrence	O
probabilities	O
for	O
any	O
size	O
of	O
co	O
-	O
occurrence	O
modules	O
under	O
study	O
can	O
be	O
obtained	O
by	O
multiplying	O
the	O
respective	O
list	O
-	O
specific	O
occurrence	O
probabilities	O
.	O

Given	O
the	O
list	O
-	O
specific	O
co	O
-	O
occurrence	O
probabilities	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
values	O
are	O
then	O
calculated	O
in	O
exactly	O
the	O
same	O
way	O
for	O
any	O
module	O
size	O
.	O

As	O
a	O
consequence	O
,	O
NetCutter	O
can	O
perform	O
co	O
-	O
occurrence	O
analysis	O
for	O
higher	O
order	O
combinations	O
of	O
co	O
-	O
occurring	O
entries	O
(	O
i.e.	O
larger	O
module	O
sizes	O
)	O
using	O
the	O
same	O
statistical	O
model	O
.	O

One	O
of	O
the	O
benefits	O
of	O
using	O
higher	O
module	O
sizes	O
is	O
robustness	O
of	O
the	O
analyses	O
in	O
the	O
presence	O
of	O
noise	O
.	O

This	O
is	O
because	O
each	O
edge	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
is	O
evaluated	O
many	O
times	O
since	O
every	O
pair	O
of	O
co	O
-	O
occurring	O
entries	O
can	O
be	O
part	O
of	O
many	O
higher	O
order	O
co	O
-	O
occurrence	O
modules	O
[	O
35	O
]	O
.	O

Another	O
advantage	O
is	O
that	O
implicit	O
relationships	O
between	O
entries	O
,	O
which	O
have	O
never	O
occurred	O
together	O
[	O
18	O
]	O
,	O
can	O
be	O
derived	O
as	O
a	O
natural	O
by	O
-	O
product	O
of	O
using	O
module	O
sizes	O
larger	O
than	O
2	O
.	O

As	O
shown	O
in	O
a	O
simulation	O
study	O
(	O
supplementary	O
material	O
Simulation	O
S1	O
)	O
,	O
the	O
result	O
is	O
a	O
dramatic	O
reduction	O
of	O
misclassifications	O
at	O
higher	O
module	O
sizes	O
.	O

NetCutter	O
can	O
be	O
used	O
to	O
calculate	O
the	O
strength	O
of	O
association	O
between	O
a	O
subset	O
of	O
entries	O
and	O
lists	O
reporting	O
those	O
entries	O
.	O

In	O
this	O
case	O
,	O
the	O
analysis	O
is	O
performed	O
on	O
a	O
subgraph	O
of	O
the	O
original	O
bipartite	O
graph	O
.	O

The	O
subgraph	O
can	O
correspond	O
to	O
communities	O
of	O
entries	O
in	O
the	O
co	O
-	O
occurrence	O
network	O
,	O
or	O
any	O
set	O
of	O
entries	O
of	O
interest	O
.	O

NetCutter	O
will	O
then	O
calculate	O
the	O
significance	O
of	O
observing	O
a	O
given	O
number	O
of	O
occurrences	O
of	O
an	O
entry	O
in	O
the	O
user	O
defined	O
subset	O
of	O
lists	O
using	O
bi	O
-	O
binomal	O
statistics	O
.	O

This	O
analysis	O
mode	O
corresponds	O
to	O
association	O
studies	O
with	O
the	O
advantage	O
that	O
the	O
structure	O
of	O
the	O
underlying	O
bipartite	O
graph	O
(	O
i.e.	O
list	O
length	O
heterogeneity	O
)	O
is	O
considered	O
and	O
handled	O
appropriately	O
using	O
the	O
bi	O
-	O
binomial	O
distribution	O
.	O

As	O
a	O
consequence	O
,	O
association	O
studies	O
can	O
be	O
performed	O
with	O
higher	O
stringency	O
.	O

This	O
result	O
can	O
be	O
understood	O
by	O
examining	O
the	O
occurrence	O
probability	O
matrix	O
that	O
is	O
implicitly	O
assumed	O
in	O
performing	O
binomial	O
or	O
hypergeometric	O
tests	O
for	O
the	O
significance	O
of	O
overlaps	O
.	O

In	O
both	O
tests	O
,	O
a	O
gene	O
is	O
assumed	O
to	O
have	O
an	O
equal	O
opportunity	O
to	O
be	O
present	O
in	O
a	O
list	O
.	O

Therefore	O
,	O
the	O
probability	O
of	O
success	O
for	O
a	O
gene	O
to	O
be	O
part	O
of	O
a	O
list	O
is	O
given	O
by	O
the	O
list	O
vertex	O
degree	O
divided	O
by	O
the	O
total	O
number	O
of	O
genes	O
.	O

In	O
other	O
words	O
,	O
both	O
tests	O
are	O
implicitly	O
based	O
on	O
the	O
list	O
vertex	O
degree	O
model	O
,	O
which	O
has	O
been	O
shown	O
previously	O
to	O
underestimate	O
the	O
occurrence	O
probability	O
and	O
the	O
expected	O
number	O
of	O
co	O
-	O
occurrences	O
for	O
genes	O
with	O
high	O
vertex	O
degree	O
(	O
see	O
Fig.	O
2A	O
)	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
calculated	O
from	O
the	O
ES	O
-	O
model	O
,	O
which	O
assigns	O
higher	O
occurrence	O
probabilities	O
to	O
genes	O
with	O
higher	O
vertex	O
degree	O
and	O
more	O
expected	O
co	O
-	O
occurrences	O
,	O
the	O
observed	O
number	O
of	O
overlaps	O
between	O
a	O
set	O
of	O
genes	O
of	O
interest	O
and	O
the	O
content	O
of	O
a	O
given	O
list	O
(	O
which	O
can	O
be	O
viewed	O
as	O
co	O
-	O
occurrence	O
of	O
the	O
overlapping	O
genes	O
in	O
that	O
list	O
)	O
will	O
be	O
judged	O
less	O
significant	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
high	O
vertex	O
degree	O
(	O
and	O
vice	O
versa	O
when	O
the	O
overlapping	O
genes	O
are	O
of	O
low	O
vertex	O
degree	O
)	O
as	O
compared	O
to	O
binomial	O
or	O
hypergeometric	O
tests	O
.	O

Since	O
the	O
BBD	O
P	O
-	O
values	O
are	O
derived	O
from	O
the	O
most	O
stringent	O
ES	O
null	O
-	O
model	O
,	O
BBD	O
P	O
-	O
values	O
provide	O
a	O
more	O
reliable	O
estimate	O
for	O
the	O
significance	O
of	O
overlap	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
data	O
represented	O
as	O
bipartite	O
graphs	O
permits	O
visualizing	O
the	O
structure	O
of	O
the	O
bipartite	O
graph	O
either	O
as	O
communities	O
of	O
list	O
entries	O
(	O
genes	O
)	O
or	O
as	O
communities	O
of	O
lists	O
(	O
PubMedID_ListID	O
)	O
in	O
co	O
-	O
occurrence	O
networks	O
.	O

We	O
have	O
analyzed	O
the	O
PubLiME	O
data	O
set	O
for	O
the	O
presence	O
of	O
corresponding	O
gene	O
and	O
list	O
clusters	O
.	O

In	O
addition	O
to	O
previously	O
published	O
clusters	O
of	O
genes	O
,	O
we	O
describe	O
a	O
novel	O
gene	O
cluster	O
that	O
is	O
composed	O
of	O
protein	O
biosynthesis	O
associated	O
genes	O
[	O
35	O
]	O
.	O

We	O
found	O
that	O
the	O
corresponding	O
clusters	O
of	O
PubMedID_ListID	O
(	O
gene	O
expression	O
signatures	O
)	O
are	O
in	O
general	O
strongly	O
enriched	O
for	O
genes	O
reported	O
in	O
the	O
corresponding	O
gene	O
cluster	O
and	O
that	O
interrogation	O
of	O
corresponding	O
clusters	O
can	O
be	O
used	O
to	O
deduct	O
hypotheses	O
about	O
the	O
putative	O
function	O
of	O
gene	O
clusters	O
.	O

In	O
addition	O
to	O
co	O
-	O
occurrence	O
analysis	O
,	O
NetCutter	O
offers	O
a	O
number	O
of	O
tools	O
for	O
the	O
analysis	O
of	O
co	O
-	O
occurrence	O
networks	O
,	O
or	O
any	O
undirected	O
graph	O
.	O

In	O
particular	O
,	O
community	O
identification	O
is	O
supported	O
by	O
four	O
different	O
community	O
identification	O
algorithms	O
.	O

NetCutter	O
also	O
offers	O
a	O
range	O
of	O
convenience	O
functions	O
that	O
are	O
of	O
help	O
in	O
network	O
analysis	O
.	O

Worthy	O
of	O
mentioning	O
are	O
the	O
random	O
graph	O
generators	O
that	O
can	O
provide	O
control	O
graphs	O
for	O
topological	O
studies	O
.	O

The	O
complete	O
set	O
of	O
options	O
is	O
described	O
in	O
the	O
software	O
documentation	O
.	O

In	O
summary	O
,	O
we	O
present	O
a	O
general	O
framework	O
for	O
co	O
-	O
occurrence	O
analysis	O
with	O
many	O
potential	O
applications	O
.	O

We	O
illustrate	O
a	O
number	O
of	O
advantages	O
of	O
using	O
the	O
bipartite	O
graph	O
representation	O
of	O
data	O
and	O
the	O
associated	O
statistics	O
.	O

In	O
particular	O
,	O
the	O
identification	O
of	O
corresponding	O
clusters	O
permits	O
the	O
identification	O
of	O
functional	O
subunits	O
such	O
as	O
gene	O
clusters	O
on	O
the	O
one	O
hand	O
,	O
and	O
the	O
generation	O
of	O
hypotheses	O
about	O
the	O
function	O
of	O
those	O
units	O
by	O
analyzing	O
the	O
corresponding	O
list	O
clusters	O
on	O
the	O
other	O
hand	O
.	O

Future	O
developments	O
will	O
be	O
directed	O
towards	O
the	O
analysis	O
of	O
data	O
sets	O
that	O
are	O
considerably	O
larger	O
than	O
the	O
data	O
sets	O
analyzed	O
so	O
far	O
.	O

For	O
example	O
,	O
co	O
-	O
occurrence	O
analysis	O
might	O
be	O
of	O
interest	O
for	O
the	O
analysis	O
of	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
data	O
sets	O
and	O
association	O
studies	O
of	O
genome	O
variability	O
with	O
disease	O
.	O

Each	O
patient	O
is	O
characterized	O
by	O
a	O
specific	O
range	O
of	O
SNPs	O
.	O

Co	O
-	O
occurrence	O
patterns	O
of	O
patients	O
according	O
to	O
their	O
SNPs	O
could	O
be	O
compared	O
to	O
clinical	O
parameters	O
with	O
the	O
aim	O
of	O
identifying	O
genomic	O
regions	O
associated	O
with	O
disease	O
.	O

The	O
increased	O
stringency	O
of	O
association	O
studies	O
offered	O
by	O
NetCutter	O
may	O
be	O
of	O
use	O
in	O
the	O
analysis	O
of	O
polygenic	O
diseases	O
where	O
conventional	O
methods	O
fail	O
.	O

For	O
being	O
useful	O
in	O
this	O
setting	O
,	O
NetCutter	O
must	O
be	O
capable	O
of	O
analyzing	O
bipartite	O
graphs	O
with	O
millions	O
instead	O
of	O
thousands	O
of	O
vertices	O
.	O

Materials	O
and	O
Methods	O
Implementation	O
of	O
NetCutter	O
NetCutter	O
is	O
written	O
in	O
Java	O
using	O
NetBeans6	O
software	O
(	O
http://www.netbeans.info/	O
)	O
and	O
tested	O
on	O
the	O
Java	O
Runtime	O
environment	O
1.6.0.0	O
.	O

on	O
a	O
Windows	O
XP	O
Professional	O
computer	O
.	O

The	O
Java	O
Runtime	O
environment	O
,	O
which	O
can	O
be	O
downloaded	O
from	O
http://java.sun.com/	O
,	O
must	O
be	O
installed	O
on	O
a	O
computer	O
that	O
is	O
intended	O
to	O
run	O
NetCutter	O
.	O

NetCutter	O
is	O
provided	O
as	O
a	O
single	O
jar	O
file	O
and	O
should	O
run	O
by	O
double	O
clicking	O
the	O
jar	O
file	O
,	O
provided	O
that	O
the	O
Java	O
runtime	O
environment	O
is	O
properly	O
installed	O
.	O

NetCutter	O
makes	O
use	O
of	O
the	O
following	O
software	O
packages	O
and	O
classes	O
:	O
JUNG	O
version	O
1.3	O
(	O
http://jung.sourceforge.net/download.html	O
)	O
,	O
Apache	O
Jakarta	O
Commons	O
Collections	O
3.1	O
(	O
http://jakarta.apache.org/commons/collections/	O
)	O
,	O
Cern	O
Colt	O
Scientific	O
Library	O
1.2.0	O
(	O
http://dsd.lbl.gov/hoschek/colt/	O
)	O
,	O
Xerces	O
(	O
http://xerces.apache.org/xerces2-j/index.html	O
)	O
,	O
Jama	O
(	O
http://math.nist.gov/javanumerics/jama/	O
)	O
,	O
Netlib	O
Java	O
LAPACK	O
(	O
http://www.netlib.org/lapack/	O
)	O
,	O
JFreeChart	O
(	O
http://www.jfree.org/jfreechart/	O
)	O
,	O
partition.java	O
(	O
http://astro.u-strasbg.fr/fmurtagh/mda-sw/java/partition.java	O
)	O
.	O

Bi	O
-	O
binomial	O
approximation	O
of	O
Poisson	O
-	O
binomial	O
distribution	O
The	O
Poisson	O
-	O
binomial	O
distribution	O
(	O
binomial	O
distribution	O
with	O
trial	O
specific	O
probabilities	O
)	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
statistic	O
that	O
properly	O
handles	O
largely	O
differing	O
sizes	O
of	O
gene	O
expression	O
signatures	O
in	O
meta	O
-	O
analysis	O
of	O
gene	O
expression	O
data	O
[	O
35	O
]	O
.	O

Z	O
-	O
scores	O
have	O
been	O
used	O
to	O
estimate	O
the	O
significance	O
of	O
co	O
-	O
occurrence	O
because	O
P	O
-	O
value	O
calculation	O
is	O
cumbersome	O
and	O
error	O
prone	O
.	O

Two	O
methods	O
reported	O
by	O
[	O
36	O
]	O
suffer	O
from	O
numerical	O
overflow	O
/	O
underflow	O
problems	O
when	O
large	O
numbers	O
of	O
Poisson	O
trials	O
with	O
probabilities	O
deviating	O
significantly	O
from	O
0.5	O
are	O
being	O
analyzed	O
.	O

Therefore	O
,	O
we	O
propose	O
a	O
fast	O
approximation	O
of	O
P	O
-	O
values	O
based	O
on	O
a	O
bi	O
-	O
binomial	O
distribution	O
.	O

The	O
bi	O
-	O
binomial	O
distribution	O
is	O
a	O
special	O
case	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
where	O
the	O
probability	O
of	O
success	O
can	O
assume	O
only	O
two	O
values	O
.	O

In	O
order	O
to	O
achieve	O
a	O
good	O
approximation	O
of	O
the	O
underlying	O
Poisson	O
-	O
binomial	O
distribution	O
,	O
the	O
values	O
of	O
these	O
two	O
probabilities	O
and	O
the	O
number	O
of	O
trials	O
where	O
they	O
are	O
assumed	O
must	O
be	O
determined	O
carefully	O
.	O

As	O
is	O
shown	O
in	O
the	O
following	O
,	O
the	O
values	O
of	O
the	O
two	O
trial	O
probabilities	O
and	O
their	O
number	O
of	O
occurrences	O
follow	O
from	O
the	O
formula	O
used	O
to	O
calculate	O
the	O
variance	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
and	O
from	O
the	O
formula	O
yielding	O
the	O
population	O
variance	O
of	O
trial	O
probabilities	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
to	O
be	O
approximated	O
.	O

The	O
mean	O
μ	O
and	O
the	O
variance	O
σ2	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
are	O
given	O
by	O
equation	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
respectively.	O
(	O
1	O
)	O
(	O
2	O
)	O
pi	O
is	O
the	O
trial	O
-	O
specific	O
probability	O
of	O
success	O
and	O
N	O
is	O
the	O
total	O
number	O
of	O
trials	O
.	O

For	O
the	O
sake	O
of	O
completeness	O
,	O
a	O
formal	O
proof	O
of	O
equation	O
(	O
1	O
)	O
is	O
reported	O
as	O
supplementary	O
material	O
Proof	O
S1	O
and	O
the	O
proof	O
of	O
equation	O
(	O
2	O
)	O
can	O
be	O
obtained	O
in	O
an	O
analogous	O
fashion	O
.	O

The	O
population	O
variance	O
S2	O
of	O
trial	O
probabilities	O
pi	O
is	O
given	O
by	O
equation	O
(	O
3	O
)	O
.	O
(	O
3	O
)	O
Rearranging	O
equation	O
(	O
3	O
)	O
considering	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
leads	O
to	O
(	O
4	O
)	O
and	O
(	O
5	O
)	O
,	O
where	O
pa	O
denotes	O
the	O
average	O
trial	O
probability	O
of	O
success	O
and	O
qa	O
its	O
complement.	O
(	O
4	O
)	O
(	O
5	O
)	O
Now	O
let	O
's	O
define	O
two	O
trial	O
probabilities	O
p1	O
and	O
p2	O
,	O
which	O
are	O
used	O
N1	O
and	O
N2	O
times	O
during	O
the	O
Poisson	O
trials	O
,	O
respectively	O
.	O

Thus	O
,	O
N1	O
and	O
N2	O
add	O
up	O
to	O
N.	O
(	O
6	O
)	O
Considering	O
(	O
1	O
)	O
,	O
the	O
average	O
trial	O
probability	O
pa	O
can	O
then	O
be	O
obtained	O
from	O
(	O
7	O
)	O
.	O
(	O
7	O
)	O
Using	O
(	O
7	O
)	O
,	O
p1	O
can	O
thus	O
be	O
calculated	O
as	O
(	O
8	O
)	O
.	O
(	O
8	O
)	O
Similarly	O
,	O
considering	O
(	O
2	O
)	O
,	O
the	O
variance	O
σ2	O
is	O
given	O
by	O
(	O
9	O
)	O
.	O
(	O
9	O
)	O
Substituting	O
p1	O
in	O
(	O
9	O
)	O
using	O
(	O
8)	O
followed	O
by	O
substituting	O
σ2	O
in	O
(	O
5	O
)	O
by	O
(	O
9	O
)	O
leads	O
to	O
a	O
quadratic	O
equation	O
for	O
p2	O
as	O
a	O
function	O
of	O
pa	O
,	O
N	O
,	O
and	O
S2	O
,	O
as	O
shown	O
in	O
equation	O
(	O
10	O
)	O
.	O
(	O
10	O
)	O
The	O
solution	O
to	O
(	O
10	O
)	O
is	O
given	O
by	O
(	O
11	O
)	O
.	O
(	O
11	O
)	O
Setting	O
p2	O
to	O
(	O
12	O
)	O
p1	O
can	O
be	O
obtained	O
from	O
(	O
8)	O
and	O
shown	O
to	O
be	O
given	O
by	O
formula	O
(	O
13	O
)	O
:	O
(	O
13	O
)	O
Choosing	O
p2	O
as	O
(	O
12a	O
)	O
leads	O
to	O
p1	O
(	O
13a	O
)	O
Comparing	O
(	O
13a	O
)	O
to	O
(	O
12	O
)	O
and	O
(	O
12a	O
)	O
to	O
(	O
13	O
)	O
,	O
it	O
can	O
be	O
seen	O
that	O
the	O
formulae	O
are	O
identical	O
except	O
for	O
the	O
fact	O
that	O
N1	O
and	O
N2	O
are	O
reversed	O
.	O

Since	O
the	O
assignment	O
of	O
which	O
set	O
of	O
trials	O
is	O
called	O
N1	O
and	O
which	O
set	O
of	O
trials	O
is	O
called	O
N2	O
is	O
completely	O
arbitrary	O
,	O
we	O
can	O
limit	O
the	O
remaining	O
analysis	O
on	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
without	O
loss	O
of	O
generality	O
.	O

Note	O
that	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
do	O
not	O
guarantee	O
that	O
p1	O
and	O
p2	O
are	O
always	O
confined	O
between	O
0	O
and	O
1	O
for	O
any	O
combination	O
of	O
N1	O
and	O
N2	O
.	O

While	O
probabilities	O
smaller	O
than	O
0	O
or	O
bigger	O
than	O
1	O
would	O
still	O
result	O
in	O
a	O
distribution	O
with	O
the	O
same	O
overall	O
variance	O
as	O
the	O
original	O
distribution	O
,	O
P	O
-	O
value	O
calculation	O
will	O
be	O
imprecise	O
because	O
the	O
tails	O
of	O
the	O
distribution	O
will	O
deviate	O
significantly	O
from	O
the	O
original	O
distribution	O
.	O

Thus	O
,	O
we	O
need	O
to	O
define	O
the	O
values	O
N1	O
and	O
N2	O
in	O
such	O
a	O
way	O
that	O
p2	O
<	O
=	O
1	O
and	O
p1	O
>	O
=	O
0	O
.	O

This	O
can	O
be	O
achieved	O
by	O
evaluating	O
(	O
12	O
)	O
and	O
(	O
13	O
)	O
.	O

Evaluating	O
(	O
12	O
)	O
for	O
the	O
condition	O
that	O
p2	O
<	O
=	O
1	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
and	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
σ2	O
,	O
we	O
obtain	O
(	O
14	O
)	O
.	O
(	O
14	O
)	O
Similarly	O
,	O
evaluating	O
(	O
13	O
)	O
for	O
the	O
condition	O
p1	O
>	O
=	O
0	O
,	O
solving	O
the	O
resulting	O
inequality	O
for	O
N2	O
,	O
considering	O
(	O
5	O
)	O
,	O
which	O
relates	O
S2	O
and	O
σ2	O
,	O
and	O
defining	O
μf	O
the	O
expected	O
number	O
of	O
failures	O
as	O
N	O
*	O
(	O
1−pa	O
)	O
(	O
15	O
)	O
,	O
(	O
15	O
)	O
we	O
obtain	O
(	O
16	O
)	O
(	O
16	O
)	O
The	O
meaning	O
of	O
these	O
boundaries	O
is	O
best	O
illustrated	O
by	O
considering	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
whose	O
variance	O
is	O
0	O
,	O
i.e.	O
that	O
assumes	O
1	O
at	O
X	O
=	O
μ	O
and	O
0	O
otherwise	O
.	O

In	O
this	O
case	O
(	O
14	O
)	O
requires	O
N2	O
<	O
=	O
μ	O
while	O
(	O
16	O
)	O
requires	O
N2	O
>	O
=	O
μ	O
.	O

These	O
conditions	O
can	O
only	O
be	O
fulfilled	O
contemporaneously	O
when	O
N2	O
is	O
set	O
to	O
μ	O
.	O

Intuitively	O
,	O
this	O
means	O
that	O
there	O
are	O
μ	O
trials	O
with	O
probability	O
of	O
success	O
1	O
and	O
N−μ	O
trials	O
with	O
probability	O
of	O
0	O
,	O
resulting	O
in	O
a	O
Poisson	O
-	O
binomial	O
distribution	O
with	O
variance	O
σ2	O
=	O
0	O
and	O
mean	O
μ	O
.	O

When	O
σ2	O
is	O
larger	O
than	O
0	O
,	O
the	O
choice	O
of	O
N1	O
and	O
N2	O
is	O
more	O
flexible	O
.	O

However	O
,	O
since	O
the	O
choice	O
of	O
N2	O
=	O
μ	O
is	O
valid	O
for	O
all	O
possible	O
values	O
of	O
σ2	O
,	O
this	O
is	O
how	O
NetCutter	O
determines	O
N1	O
and	O
N2	O
.	O

When	O
μ	O
is	O
not	O
an	O
integer	O
,	O
N2	O
is	O
set	O
to	O
the	O
integer	O
closest	O
to	O
μ	O
.	O

Having	O
determined	O
p2	O
(	O
12	O
)	O
and	O
p1	O
(	O
13	O
)	O
as	O
well	O
a	O
N1	O
and	O
N2	O
(	O
14	O
,	O
16	O
,	O
6	O
)	O
,	O
we	O
can	O
now	O
calculate	O
the	O
bi	O
-	O
binomial	O
approximation	O
of	O
the	O
Poisson	O
-	O
binomial	O
distribution	O
in	O
a	O
fashion	O
that	O
is	O
very	O
similar	O
to	O
calculate	O
the	O
binomial	O
P	O
-	O
value	O
.	O

With	O
q1	O
=	O
1−p1	O
and	O
q2	O
=	O
1−p2	O
we	O
obtain:	O
(	O
17	O
)	O
The	O
summation	O
is	O
necessary	O
because	O
i	O
successes	O
can	O
be	O
obtained	O
from	O
any	O
combination	O
of	O
j	O
p1	O
and	O
i−j	O
p2	O
trials	O
,	O
where	O
j	O
can	O
assume	O
any	O
value	O
from	O
0	O
to	O
i.	O
Calculating	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
For	O
the	O
purpose	O
of	O
comparing	O
the	O
efficacy	O
of	O
the	O
bi	O
-	O
binomial	O
distribution	O
as	O
a	O
significance	O
measure	O
of	O
co	O
-	O
occurrence	O
,	O
Jaccard	O
and	O
uncertainty	O
coefficients	O
(	O
which	O
are	O
also	O
called	O
measures	O
of	O
association	O
)	O
were	O
calculated	O
using	O
the	O
formulae	O
:	O
The	O
Jaccard	O
coefficient	O
J	O
is	O
calculated	O
as	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
divided	O
by	O
the	O
number	O
of	O
times	O
A	O
occurs	O
without	O
B	O
plus	O
the	O
number	O
of	O
times	O
B	O
occurs	O
without	O
A	O
plus	O
the	O
number	O
of	O
times	O
A	O
and	O
B	O
occur	O
together	O
[	O
42	O
]	O
.	O

The	O
uncertainty	O
coefficient	O
[	O
42	O
]	O
is	O
calculated	O
as	O
:	O
H	O
is	O
the	O
entropy	O
associated	O
with	O
A	O
,	O
B	O
,	O
and	O
AB	O
.	O

For	O
A	O
,	O
the	O
entropy	O
is	O
calculated	O
from	O
the	O
probabilities	O
of	O
A	O
occurring	O
in	O
n1	O
out	O
of	O
N	O
lists	O
(	O
n1	O
/	O
N	O
)	O
and	O
A	O
not	O
occurring	O
in	O
n2	O
out	O
of	O
N	O
lists	O
(	O
n2	O
/	O
N	O
)	O
.	O

Analogous	O
calculations	O
lead	O
to	O
the	O
entropy	O
associated	O
with	O
B.	O
For	O
H	O
(	O
A	O
,	O
B	O
)	O
,	O
the	O
probabilities	O
of	O
A	O
occurring	O
without	O
B	O
,	O
B	O
occurring	O
without	O
A	O
,	O
A	O
and	O
B	O
occurring	O
together	O
,	O
and	O
neither	O
A	O
nor	O
B	O
occurring	O
in	O
the	O
lists	O
are	O
used	O
.	O

Co	O
-	O
occurrence	O
analysis	O
of	O
the	O
PubLiME	O
data	O
set	O
The	O
bipartite	O
graph	O
to	O
be	O
analyzed	O
is	O
composed	O
of	O
27619	O
PubMedID_listID	O
-	O
gene	O
pairs	O
(	O
see	O
supplementary	O
material	O
Table	O
S1	O
)	O
.	O

Edge	O
-	O
swapping	O
(	O
1000	O
simulations	O
,	O
see	O
above	O
)	O
was	O
used	O
to	O
determine	O
occurrence	O
probabilities	O
and	O
gene	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
3	O
(	O
co	O
-	O
occurrence	O
of	O
three	O
genes	O
)	O
,	O
bi	O
-	O
binomial	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1.0E-5	O
,	O
and	O
support	O
5	O
.	O

Supplementary	O
material	O
Simulation	O
S1	O
provides	O
details	O
on	O
why	O
module	O
size	O
3	O
is	O
chosen	O
.	O

The	O
support	O
parameter	O
ensures	O
that	O
each	O
3-gene	O
co	O
-	O
occurrence	O
module	O
is	O
present	O
in	O
at	O
least	O
5	O
signatures	O
.	O

We	O
identified	O
1654	O
significant	O
modules	O
in	O
the	O
test	O
data	O
compared	O
to	O
5	O
modules	O
in	O
a	O
randomized	O
bipartite	O
graph	O
,	O
corresponding	O
to	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
331	O
.	O

The	O
co	O
-	O
occurrence	O
network	O
was	O
generated	O
from	O
the	O
significant	O
co	O
-	O
occurrence	O
modules	O
by	O
drawing	O
an	O
edge	O
between	O
each	O
pair	O
wise	O
combination	O
of	O
genes	O
that	O
are	O
part	O
of	O
the	O
same	O
co	O
-	O
occurrence	O
module	O
.	O

Gene	O
communities	O
were	O
identified	O
in	O
this	O
network	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
4	O
edges	O
,	O
which	O
resulted	O
in	O
a	O
maximal	O
network	O
modularity	O
of	O
0.63	O
.	O

Modularity	O
is	O
calculated	O
as	O
described	O
by	O
[	O
43	O
]	O
.	O

For	O
the	O
identification	O
of	O
PubMedID_listID	O
clusters	O
,	O
the	O
PubMedID_listID	O
-	O
gene	O
pairs	O
in	O
the	O
original	O
bipartite	O
graph	O
were	O
reversed	O
to	O
form	O
gene	O
-	O
PubMedID_listID	O
pairs	O
.	O

Occurrence	O
probabilities	O
were	O
obtained	O
by	O
transposing	O
the	O
original	O
occurrence	O
probability	O
matrix	O
determined	O
by	O
edge	O
-	O
swapping	O
as	O
described	O
above	O
.	O

PubMedID_listID	O
co	O
-	O
occurrence	O
was	O
analyzed	O
using	O
module	O
size	O
5	O
,	O
Z	O
-	O
score	O
cutoff	O
6	O
,	O
bi	O
-	O
binomial	O
P	O
-	O
value	O
cutoff	O
1.0E-5	O
,	O
and	O
support	O
3	O
.	O

Please	O
note	O
that	O
the	O
choice	O
of	O
these	O
parameters	O
is	O
dictated	O
by	O
the	O
parameters	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
.	O

The	O
reversal	O
of	O
the	O
bipartite	O
graph	O
necessitates	O
the	O
support	O
parameter	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
5	O
)	O
to	O
be	O
used	O
as	O
module	O
size	O
in	O
PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
and	O
the	O
module	O
size	O
used	O
in	O
gene	O
co	O
-	O
occurrence	O
analysis	O
(	O
3	O
)	O
to	O
be	O
used	O
as	O
the	O
support	O
parameter	O
in	O
PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
if	O
the	O
scope	O
of	O
the	O
analysis	O
is	O
the	O
identification	O
of	O
PubMedID_listID	O
clusters	O
that	O
correspond	O
to	O
gene	O
clusters	O
identified	O
before	O
.	O

The	O
significance	O
cutoffs	O
remain	O
unchanged	O
.	O

PubMedID_listID	O
co	O
-	O
occurrence	O
analysis	O
revealed	O
448	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
real	O
bipartite	O
graph	O
and	O
6	O
significant	O
co	O
-	O
occurrence	O
modules	O
in	O
the	O
randomized	O
bipartite	O
graph	O
with	O
a	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
of	O
75	O
.	O

Communities	O
in	O
the	O
resulting	O
co	O
-	O
occurrence	O
network	O
were	O
identified	O
by	O
edge	O
-	O
betweenness	O
clustering	O
removing	O
130	O
edges	O
.	O

The	O
resulting	O
maximal	O
network	O
modularity	O
was	O
found	O
to	O
be	O
0.47	O
.	O

Supporting	O
Information	O

Personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
in	O
a	O
deprived	O
urban	O
population	O
Abstract	O
Background	O
Environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
active	O
travel	O
(	O
walking	O
or	O
cycling	O
for	O
transport	O
)	O
.	O

However	O
,	O
most	O
studies	O
in	O
this	O
field	O
have	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
,	O
and	O
hypotheses	O
about	O
putative	O
correlates	O
should	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
sociospatial	O
contexts	O
.	O

We	O
therefore	O
examined	O
the	O
contribution	O
of	O
putative	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
in	O
deprived	O
urban	O
neighbourhoods	O
in	O
Glasgow	O
,	O
Scotland	O
as	O
part	O
of	O
the	O
baseline	O
for	O
a	O
longitudinal	O
study	O
of	O
the	O
effects	O
of	O
opening	O
a	O
new	O
urban	O
motorway	O
(	O
freeway	O
)	O
.	O

Methods	O
We	O
conducted	O
a	O
postal	O
survey	O
of	O
a	O
random	O
sample	O
of	O
residents	O
(	O
n	O
=	O
1322	O
)	O
,	O
collecting	O
data	O
on	O
socioeconomic	O
status	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
,	O
physical	O
activity	O
and	O
general	O
health	O
and	O
wellbeing	O
using	O
a	O
new	O
14-item	O
neighbourhood	O
rating	O
scale	O
,	O
a	O
travel	O
diary	O
,	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
and	O
the	O
SF-8	O
.	O

We	O
analysed	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
,	O
first	O
building	O
models	O
using	O
personal	O
(	O
individual	O
and	O
household	O
)	O
explanatory	O
variables	O
and	O
then	O
adding	O
environmental	O
variables	O
.	O

Results	O
Active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
personal	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
explained	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
identify	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Conclusion	O
Apart	O
from	O
access	O
to	O
local	O
amenities	O
,	O
environmental	O
characteristics	O
may	O
have	O
limited	O
influence	O
on	O
active	O
travel	O
in	O
deprived	O
urban	O
populations	O
characterised	O
by	O
a	O
low	O
level	O
of	O
car	O
ownership	O
,	O
in	O
which	O
people	O
may	O
have	O
less	O
capacity	O
for	O
making	O
discretionary	O
travel	O
choices	O
than	O
the	O
populations	O
studied	O
in	O
most	O
published	O
research	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
.	O

Background	O
Until	O
recently	O
,	O
research	O
on	O
correlates	O
of	O
physical	O
activity	O
was	O
dominated	O
by	O
studies	O
of	O
individual	O
demographic	O
and	O
psychosocial	O
characteristics	O
[	O
1	O
]	O
.	O

This	O
reflected	O
an	O
emphasis	O
on	O
promoting	O
sport	O
,	O
recreation	O
or	O
health	O
-	O
directed	O
exercise	O
using	O
techniques	O
to	O
encourage	O
individual	O
behaviour	O
change	O
[	O
2	O
]	O
.	O

However	O
,	O
there	O
is	O
little	O
evidence	O
that	O
such	O
approaches	O
are	O
effective	O
in	O
increasing	O
physical	O
activity	O
in	O
the	O
medium	O
-	O
to	O
-	O
long	O
term	O
[	O
3	O
]	O
.	O

If	O
habitual	O
patterns	O
of	O
behaviour	O
are	O
environmentally	O
cued	O
,	O
sustained	O
change	O
is	O
likely	O
to	O
require	O
a	O
supportive	O
environment	O
in	O
which	O
people	O
can	O
be	O
active	O
[	O
4,5	O
]	O
.	O

There	O
is	O
therefore	O
increasing	O
interest	O
in	O
the	O
influence	O
of	O
the	O
social	O
and	O
physical	O
environment	O
on	O
physical	O
activity	O
.	O

With	O
respect	O
to	O
the	O
physical	O
(	O
natural	O
or	O
built	O
)	O
environment	O
,	O
a	O
growing	O
body	O
of	O
evidence	O
suggests	O
that	O
certain	O
environmental	O
characteristics	O
may	O
be	O
associated	O
with	O
patterns	O
of	O
physical	O
activity	O
in	O
general	O
or	O
with	O
particular	O
types	O
of	O
physical	O
activity	O
such	O
as	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
[	O
4	O
-	O
10	O
]	O
.	O

Among	O
the	O
correlates	O
most	O
frequently	O
identified	O
in	O
such	O
reviews	O
–	O
some	O
ascertained	O
using	O
'	O
objective	O
'	O
measures	O
,	O
and	O
others	O
in	O
terms	O
of	O
people	O
's	O
perceptions	O
–	O
are	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
,	O
the	O
presence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
the	O
convenience	O
of	O
facilities	O
for	O
being	O
active	O
,	O
the	O
availability	O
of	O
green	O
space	O
,	O
access	O
to	O
amenities	O
(	O
destinations	O
)	O
within	O
walking	O
or	O
cycling	O
distance	O
,	O
safety	O
from	O
traffic	O
and	O
personal	O
attack	O
,	O
and	O
the	O
lack	O
of	O
heavy	O
traffic	O
.	O

Some	O
of	O
these	O
local	O
characteristics	O
reflect	O
higher	O
-	O
order	O
aspects	O
of	O
urban	O
design	O
and	O
spatial	O
policy	O
such	O
as	O
population	O
density	O
,	O
connectivity	O
and	O
mixed	O
land	O
use	O
[	O
6,8	O
]	O
.	O

Importantly	O
,	O
different	O
characteristics	O
may	O
be	O
associated	O
with	O
different	O
types	O
of	O
physical	O
activity	O
;	O
for	O
example	O
,	O
Owen	O
and	O
colleagues	O
found	O
that	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
was	O
associated	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
and	O
with	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
transport	O
,	O
whereas	O
perceptions	O
of	O
traffic	O
were	O
associated	O
with	O
walking	O
for	O
transport	O
and	O
walking	O
in	O
general	O
,	O
but	O
not	O
with	O
walking	O
for	O
exercise	O
or	O
recreation	O
[	O
5	O
]	O
.	O

Despite	O
the	O
growing	O
volume	O
of	O
published	O
studies	O
in	O
this	O
field	O
,	O
many	O
authors	O
remain	O
circumspect	O
in	O
their	O
interpretation	O
of	O
the	O
available	O
evidence	O
.	O

Giles	O
-	O
Corti	O
and	O
Donovan	O
have	O
described	O
access	O
to	O
a	O
supportive	O
physical	O
environment	O
as	O
a	O
necessary	O
,	O
but	O
insufficient	O
,	O
condition	O
for	O
an	O
increase	O
in	O
physical	O
activity	O
in	O
the	O
population	O
[	O
11	O
]	O
,	O
while	O
Handy	O
found	O
'	O
convincing	O
'	O
evidence	O
of	O
an	O
association	O
between	O
physical	O
activity	O
and	O
the	O
built	O
environment	O
in	O
general	O
but	O
'	O
less	O
convincing	O
'	O
evidence	O
as	O
to	O
which	O
specific	O
environmental	O
characteristics	O
were	O
most	O
strongly	O
associated	O
[	O
7	O
]	O
.	O

One	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
most	O
research	O
has	O
been	O
conducted	O
in	O
North	O
America	O
and	O
Australia	O
[	O
9,12	O
]	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
associations	O
observed	O
in	O
those	O
countries	O
are	O
generalisable	O
to	O
other	O
settings	O
with	O
different	O
aggregate	O
socioeconomic	O
characteristics	O
(	O
e.g.	O
wealth	O
or	O
access	O
to	O
private	O
cars	O
)	O
or	O
environmental	O
characteristics	O
(	O
e.g.	O
climate	O
,	O
patterns	O
of	O
land	O
use	O
,	O
or	O
availability	O
of	O
public	O
transport	O
)	O
.	O

For	O
example	O
,	O
North	O
American	O
researchers	O
are	O
often	O
interested	O
in	O
the	O
presence	O
or	O
absence	O
of	O
pavements	O
(	O
sidewalks	O
)	O
,	O
but	O
it	O
is	O
unusual	O
for	O
streets	O
in	O
the	O
United	O
Kingdom	O
(	O
UK	O
)	O
not	O
to	O
have	O
a	O
pavement	O
or	O
footpath	O
beside	O
them	O
.	O

Hypotheses	O
about	O
putative	O
environmental	O
correlates	O
of	O
physical	O
activity	O
therefore	O
need	O
to	O
be	O
tested	O
in	O
a	O
wider	O
range	O
of	O
settings	O
.	O

A	O
more	O
profound	O
limitation	O
of	O
the	O
available	O
evidence	O
is	O
that	O
identifying	O
a	O
relationship	O
between	O
,	O
for	O
example	O
,	O
urban	O
form	O
and	O
walking	O
for	O
transport	O
is	O
not	O
the	O
same	O
thing	O
as	O
showing	O
that	O
changing	O
the	O
built	O
environment	O
will	O
lead	O
to	O
a	O
change	O
in	O
behaviour	O
[	O
13	O
]	O
.	O

Few	O
researchers	O
have	O
taken	O
up	O
the	O
opportunity	O
(	O
or	O
challenge	O
)	O
presented	O
by	O
'	O
natural	O
experiments	O
'	O
to	O
investigate	O
the	O
effects	O
of	O
environmental	O
interventions	O
on	O
physical	O
activity	O
[	O
14	O
]	O
.	O

We	O
therefore	O
established	O
a	O
longitudinal	O
study	O
to	O
examine	O
changes	O
associated	O
with	O
the	O
opening	O
of	O
a	O
new	O
urban	O
section	O
of	O
the	O
M74	O
motorway	O
(	O
freeway	O
)	O
currently	O
under	O
construction	O
in	O
Glasgow	O
,	O
Scotland	O
.	O

The	O
rationale	O
and	O
design	O
for	O
this	O
study	O
have	O
been	O
described	O
previously	O
[	O
15	O
]	O
.	O

It	O
is	O
claimed	O
that	O
the	O
new	O
motorway	O
,	O
which	O
will	O
mostly	O
pass	O
through	O
or	O
close	O
to	O
densely	O
-	O
populated	O
urban	O
neighbourhoods	O
,	O
will	O
contribute	O
to	O
the	O
regeneration	O
of	O
a	O
region	O
which	O
includes	O
some	O
of	O
the	O
most	O
deprived	O
and	O
least	O
healthy	O
working	O
-	O
class	O
communities	O
in	O
Europe	O
[	O
16	O
]	O
.	O

It	O
is	O
also	O
claimed	O
that	O
the	O
new	O
motorway	O
will	O
divert	O
traffic	O
from	O
local	O
streets	O
,	O
reduce	O
traffic	O
noise	O
and	O
bring	O
new	O
local	O
employment	O
opportunities	O
,	O
thereby	O
improving	O
characteristics	O
of	O
the	O
local	O
environment	O
held	O
to	O
be	O
associated	O
with	O
active	O
travel	O
.	O

Others	O
claim	O
that	O
the	O
new	O
motorway	O
will	O
encourage	O
car	O
use	O
,	O
degrade	O
the	O
aesthetic	O
quality	O
of	O
the	O
surroundings	O
and	O
reduce	O
the	O
safety	O
and	O
attractiveness	O
of	O
routes	O
for	O
pedestrians	O
and	O
cyclists	O
across	O
the	O
line	O
of	O
the	O
motorway	O
–	O
all	O
changes	O
which	O
may	O
be	O
expected	O
to	O
discourage	O
active	O
travel	O
[	O
15	O
]	O
.	O

The	O
eventual	O
aim	O
of	O
the	O
M74	O
study	O
will	O
be	O
to	O
assess	O
the	O
effects	O
of	O
this	O
major	O
modification	O
to	O
the	O
urban	O
built	O
environment	O
and	O
transport	O
infrastructure	O
on	O
perceptions	O
of	O
the	O
local	O
environment	O
and	O
on	O
population	O
health	O
and	O
health	O
-	O
related	O
behaviour	O
,	O
the	O
primary	O
outcome	O
of	O
interest	O
being	O
a	O
change	O
in	O
the	O
quantity	O
of	O
'	O
active	O
travel	O
'	O
(	O
walking	O
and	O
cycling	O
for	O
transport	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
findings	O
from	O
the	O
cross	O
-	O
sectional	O
(	O
baseline	O
)	O
phase	O
of	O
the	O
study	O
which	O
contribute	O
evidence	O
on	O
the	O
environmental	O
correlates	O
of	O
physical	O
activity	O
in	O
this	O
comparatively	O
deprived	O
urban	O
population	O
.	O

We	O
focus	O
on	O
two	O
specific	O
hypotheses	O
:	O
first	O
,	O
that	O
levels	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
vary	O
with	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
but	O
not	O
necessarily	O
in	O
the	O
same	O
way	O
;	O
second	O
,	O
that	O
these	O
relationships	O
may	O
be	O
partly	O
explained	O
by	O
the	O
perceived	O
characteristics	O
of	O
the	O
local	O
environment	O
in	O
which	O
people	O
live	O
and	O
by	O
their	O
objectively	O
-	O
assessed	O
proximity	O
to	O
motorway	O
and	O
major	O
road	O
infrastructure	O
.	O

Methods	O
Delineation	O
of	O
study	O
areas	O
We	O
used	O
spatially	O
referenced	O
census	O
and	O
transport	O
infrastructure	O
data	O
held	O
and	O
analysed	O
in	O
a	O
geographical	O
information	O
system	O
(	O
GIS	O
)	O
,	O
combined	O
with	O
field	O
visits	O
,	O
to	O
delineate	O
three	O
study	O
areas	O
in	O
Glasgow	O
with	O
similar	O
aggregate	O
socioeconomic	O
characteristics	O
and	O
broadly	O
similar	O
topographical	O
characteristics	O
apart	O
from	O
their	O
proximity	O
to	O
urban	O
motorway	O
infrastructure	O
(	O
Table	O
1	O
,	O
Figure	O
1	O
)	O
.	O

All	O
three	O
study	O
areas	O
extended	O
from	O
inner	O
mixed	O
-	O
use	O
districts	O
close	O
to	O
the	O
city	O
centre	O
to	O
residential	O
suburbs	O
,	O
contained	O
major	O
arterial	O
roads	O
other	O
than	O
motorways	O
,	O
and	O
contained	O
a	O
mixture	O
of	O
housing	O
stock	O
including	O
traditional	O
high	O
-	O
density	O
tenements	O
,	O
high	O
-	O
rise	O
flats	O
and	O
new	O
housing	O
developments	O
(	O
Figure	O
2	O
)	O
.	O

Sampling	O
and	O
survey	O
administration	O
We	O
used	O
the	O
Royal	O
Mail	O
Postcode	O
Address	O
File	O
(	O
PAF	O
)	O
(	O
version	O
2005.3	O
)	O
to	O
identify	O
all	O
residential	O
addresses	O
whose	O
unit	O
postcode	O
(	O
zip	O
code	O
)	O
was	O
within	O
one	O
of	O
the	O
study	O
areas	O
(	O
total	O
n	O
=	O
35601	O
)	O
and	O
drew	O
a	O
random	O
sample	O
of	O
3000	O
households	O
from	O
each	O
area	O
.	O

Unit	O
postcodes	O
(	O
e.g.	O
G12	O
8RZ	O
)	O
are	O
the	O
smallest	O
available	O
unit	O
of	O
postal	O
geography	O
in	O
the	O
UK	O
;	O
residential	O
unit	O
postcodes	O
cover	O
about	O
15	O
addresses	O
on	O
average	O
.	O

We	O
sent	O
the	O
survey	O
to	O
all	O
households	O
(	O
total	O
n	O
=	O
9000	O
)	O
between	O
28	O
September	O
and	O
4	O
October	O
2005	O
and	O
resent	O
the	O
survey	O
to	O
all	O
non	O
-	O
responding	O
households	O
between	O
26	O
and	O
31	O
October	O
2005	O
.	O

We	O
alerted	O
households	O
to	O
the	O
survey	O
by	O
means	O
of	O
a	O
postcard	O
sent	O
a	O
few	O
days	O
in	O
advance	O
,	O
used	O
coloured	O
paper	O
for	O
some	O
of	O
the	O
survey	O
materials	O
,	O
and	O
posted	O
survey	O
packs	O
in	O
white	O
envelopes	O
printed	O
with	O
the	O
university	O
crest	O
;	O
these	O
techniques	O
have	O
been	O
shown	O
in	O
a	O
meta	O
-	O
analysis	O
to	O
be	O
associated	O
with	O
increased	O
response	O
rates	O
to	O
postal	O
surveys	O
[	O
17	O
]	O
.	O

We	O
asked	O
householders	O
to	O
ensure	O
that	O
the	O
questionnaire	O
was	O
completed	O
by	O
a	O
resident	O
aged	O
16	O
or	O
over	O
;	O
if	O
more	O
than	O
one	O
resident	O
was	O
eligible	O
,	O
we	O
asked	O
householders	O
to	O
select	O
the	O
person	O
with	O
the	O
most	O
recent	O
birthday	O
.	O

Respondents	O
who	O
consented	O
to	O
follow	O
-	O
up	O
were	O
entered	O
into	O
a	O
prize	O
draw	O
to	O
win	O
a	O
£	O
50	O
(	O
€	O
63	O
;	O
US$	O
92	O
)	O
gift	O
voucher	O
.	O

Responses	O
received	O
more	O
than	O
three	O
months	O
after	O
the	O
first	O
mailing	O
wave	O
were	O
disregarded	O
in	O
analysis	O
.	O

Data	O
collection	O
The	O
questionnaire	O
included	O
items	O
on	O
demographic	O
and	O
socioeconomic	O
characteristics	O
,	O
health	O
and	O
wellbeing	O
(	O
including	O
the	O
the	O
SF-8	O
scale	O
)	O
,	O
perceptions	O
of	O
the	O
local	O
environment	O
,	O
travel	O
behaviour	O
and	O
the	O
short	O
form	O
of	O
the	O
International	O
Physical	O
Activity	O
Questionnaire	O
(	O
IPAQ	O
)	O
(	O
Additional	O
file	O
1	O
)	O
.	O

We	O
developed	O
a	O
new	O
'	O
neighbourhood	O
scale	O
'	O
to	O
assess	O
perceptions	O
of	O
relevant	O
characteristics	O
of	O
the	O
local	O
environment	O
(	O
aesthetics	O
,	O
green	O
space	O
,	O
access	O
to	O
amenities	O
,	O
convenience	O
of	O
routes	O
,	O
traffic	O
,	O
road	O
safety	O
and	O
personal	O
safety	O
)	O
.	O

The	O
development	O
,	O
principal	O
components	O
analysis	O
and	O
reliability	O
of	O
the	O
items	O
in	O
this	O
scale	O
and	O
the	O
derivation	O
and	O
reliability	O
of	O
summary	O
variables	O
are	O
reported	O
in	O
an	O
accompanying	O
paper	O
[	O
18	O
]	O
.	O

Data	O
cleaning	O
and	O
derivation	O
of	O
variables	O
Demographic	O
and	O
socioeconomic	O
characteristics	O
We	O
excluded	O
from	O
analysis	O
all	O
respondents	O
who	O
failed	O
to	O
enter	O
their	O
age	O
or	O
sex	O
.	O

We	O
then	O
examined	O
the	O
distributions	O
of	O
all	O
raw	O
variables	O
and	O
carried	O
out	O
range	O
and	O
consistency	O
checks	O
to	O
identify	O
any	O
anomalous	O
values	O
or	O
variables	O
with	O
a	O
high	O
proportion	O
of	O
missing	O
responses	O
.	O

As	O
a	O
consequence	O
,	O
we	O
collapsed	O
responses	O
on	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
housing	O
tenure	O
,	O
car	O
access	O
and	O
working	O
situation	O
into	O
fewer	O
categories	O
by	O
merging	O
categories	O
with	O
small	O
numbers	O
of	O
responses	O
;	O
we	O
also	O
disregarded	O
household	O
composition	O
and	O
working	O
situation	O
of	O
spouse	O
or	O
partner	O
in	O
analysis	O
because	O
of	O
the	O
large	O
numbers	O
of	O
missing	O
values	O
for	O
these	O
variables	O
.	O

Health	O
and	O
wellbeing	O
We	O
calculated	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
by	O
converting	O
,	O
where	O
necessary	O
,	O
self	O
-	O
reported	O
heights	O
and	O
weights	O
from	O
imperial	O
to	O
metric	O
units	O
and	O
dividing	O
the	O
height	O
in	O
metres	O
by	O
the	O
square	O
of	O
the	O
weight	O
in	O
kilograms	O
;	O
we	O
also	O
categorised	O
respondents	O
into	O
quintiles	O
of	O
BMI	O
.	O

We	O
calculated	O
physical	O
(	O
PCS-8	O
)	O
and	O
mental	O
(	O
MCS-8	O
)	O
health	O
summary	O
scores	O
from	O
the	O
SF-8	O
data	O
and	O
scaled	O
these	O
to	O
population	O
norms	O
using	O
the	O
method	O
and	O
coefficients	O
given	O
in	O
the	O
SF-8	O
manual	O
[	O
19	O
]	O
.	O

Objective	O
environmental	O
characteristics	O
We	O
linked	O
each	O
record	O
to	O
the	O
unit	O
postcode	O
of	O
residence	O
.	O

We	O
then	O
constructed	O
concentric	O
buffers	O
at	O
100-metre	O
intervals	O
up	O
to	O
500	O
metres	O
around	O
the	O
routes	O
and	O
access	O
points	O
of	O
existing	O
and	O
planned	O
motorways	O
and	O
around	O
the	O
network	O
of	O
other	O
major	O
(	O
A-	O
and	O
B-	O
class	O
)	O
roads	O
,	O
and	O
assigned	O
each	O
respondent	O
to	O
a	O
category	O
of	O
proximity	O
to	O
each	O
type	O
of	O
road	O
infrastructure	O
(	O
within	O
100	O
metres	O
,	O
101–200	O
metres	O
,	O
etc	O
.	O
)	O

based	O
on	O
the	O
location	O
of	O
the	O
centroid	O
of	O
their	O
unit	O
postcode	O
.	O

Travel	O
behaviour	O
For	O
travel	O
time	O
analysis	O
we	O
included	O
travel	O
diaries	O
which	O
recorded	O
no	O
travel	O
at	O
all	O
,	O
but	O
we	O
disregarded	O
travel	O
data	O
from	O
respondents	O
who	O
had	O
not	O
been	O
at	O
home	O
on	O
the	O
day	O
of	O
the	O
travel	O
diary	O
,	O
whose	O
questionnaire	O
had	O
been	O
misprinted	O
such	O
that	O
the	O
travel	O
diary	O
pages	O
were	O
unusable	O
,	O
who	O
had	O
recorded	O
journeys	O
without	O
reporting	O
valid	O
quantitative	O
data	O
on	O
the	O
durations	O
of	O
those	O
journeys	O
,	O
or	O
whose	O
completed	O
travel	O
diary	O
appeared	O
implausible	O
.	O

We	O
also	O
disregarded	O
journeys	O
whose	O
purpose	O
was	O
not	O
stated	O
or	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
travel	O
diary	O
(	O
Additional	O
file	O
1	O
,	O
page	O
8)	O
.	O

We	O
summed	O
the	O
reported	O
travel	O
time	O
for	O
each	O
mode	O
of	O
transport	O
,	O
calculated	O
a	O
total	O
travel	O
time	O
by	O
active	O
modes	O
(	O
walking	O
plus	O
cycling	O
)	O
and	O
by	O
all	O
modes	O
combined	O
,	O
and	O
calculated	O
the	O
proportion	O
of	O
total	O
travel	O
time	O
contributed	O
by	O
each	O
mode	O
of	O
transport	O
.	O

Physical	O
activity	O
We	O
cleaned	O
and	O
analysed	O
IPAQ	O
data	O
in	O
accordance	O
with	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

We	O
therefore	O
disregarded	O
physical	O
activity	O
data	O
from	O
respondents	O
who	O
had	O
reported	O
more	O
than	O
16	O
hours	O
of	O
physical	O
activity	O
per	O
day	O
or	O
who	O
had	O
missing	O
or	O
internally	O
inconsistent	O
data	O
on	O
the	O
frequency	O
or	O
duration	O
of	O
any	O
of	O
the	O
three	O
categories	O
of	O
physical	O
activity	O
(	O
walking	O
,	O
moderate	O
-	O
intensity	O
activity	O
or	O
vigorous	O
activity	O
)	O
.	O

We	O
also	O
recoded	O
reported	O
durations	O
of	O
activity	O
of	O
less	O
than	O
ten	O
minutes	O
to	O
zero	O
,	O
and	O
of	O
greater	O
than	O
180	O
minutes	O
to	O
180	O
minutes	O
.	O

We	O
calculated	O
the	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
for	O
each	O
respondent	O
(	O
MET	O
-	O
min	O
/	O
week	O
)	O
and	O
used	O
a	O
combination	O
of	O
frequency	O
,	O
duration	O
and	O
total	O
energy	O
expenditure	O
to	O
assign	O
each	O
respondent	O
to	O
a	O
'	O
high	O
'	O
,	O
'	O
moderate	O
'	O
or	O
'	O
low	O
'	O
category	O
of	O
overall	O
physical	O
activity	O
in	O
accordance	O
with	O
the	O
prescribed	O
IPAQ	O
algorithm	O
.	O

The	O
'	O
high	O
'	O
category	O
corresponds	O
to	O
a	O
sufficient	O
level	O
of	O
physical	O
activity	O
to	O
meet	O
current	O
public	O
health	O
recommendations	O
for	O
adults	O
[	O
20	O
]	O
.	O

Analysis	O
We	O
considered	O
it	O
unlikely	O
that	O
the	O
statistical	O
assumptions	O
required	O
for	O
linear	O
regression	O
could	O
be	O
met	O
because	O
the	O
distributions	O
of	O
time	O
spent	O
walking	O
and	O
cycling	O
and	O
of	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
were	O
both	O
strongly	O
positively	O
skewed	O
and	O
dominated	O
by	O
a	O
large	O
number	O
of	O
zero	O
values	O
which	O
meant	O
that	O
the	O
data	O
were	O
not	O
amenable	O
to	O
log	O
-	O
transformation	O
.	O

We	O
therefore	O
modelled	O
the	O
correlates	O
of	O
active	O
travel	O
and	O
physical	O
activity	O
using	O
multivariate	O
logistic	O
regression	O
.	O

We	O
defined	O
'	O
active	O
travel	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
who	O
had	O
reported	O
at	O
least	O
30	O
minutes	O
of	O
travel	O
by	O
walking	O
,	O
cycling	O
or	O
both	O
in	O
their	O
travel	O
diary	O
,	O
reflecting	O
the	O
current	O
recommendation	O
that	O
adults	O
should	O
accumulate	O
at	O
least	O
30	O
minutes	O
of	O
moderate	O
-	O
intensity	O
physical	O
activity	O
on	O
most	O
days	O
of	O
the	O
week	O
[	O
20	O
]	O
,	O
and	O
we	O
defined	O
'	O
physical	O
activity	O
'	O
as	O
a	O
binary	O
condition	O
achieved	O
by	O
any	O
respondent	O
whose	O
overall	O
physical	O
activity	O
was	O
categorised	O
as	O
'	O
high	O
'	O
using	O
IPAQ	O
.	O

We	O
then	O
built	O
separate	O
multivariate	O
models	O
for	O
active	O
travel	O
and	O
physical	O
activity	O
following	O
the	O
method	O
of	O
Hosmer	O
and	O
Lemeshow	O
[	O
21	O
]	O
,	O
first	O
including	O
only	O
'	O
personal	O
'	O
(	O
individual	O
or	O
household	O
)	O
variables	O
and	O
then	O
adding	O
'	O
environmental	O
'	O
variables	O
(	O
Additional	O
file	O
2	O
)	O
.	O

Results	O
Response	O
We	O
received	O
1345	O
completed	O
questionnaires	O
.	O

After	O
subtracting	O
from	O
the	O
numerator	O
23	O
completed	O
questionnaires	O
with	O
missing	O
critical	O
demographic	O
data	O
(	O
age	O
or	O
sex	O
)	O
,	O
and	O
after	O
subtracting	O
from	O
the	O
denominator	O
676	O
addresses	O
from	O
which	O
survey	O
packs	O
were	O
returned	O
as	O
undeliverable	O
,	O
this	O
left	O
1322	O
valid	O
responses	O
to	O
be	O
entered	O
into	O
analysis	O
–	O
a	O
response	O
rate	O
of	O
1322	O
/	O
(	O
9000	O
-	O
676	O
)	O
=	O
15.9	O
%	O
.	O

Characteristics	O
of	O
study	O
participants	O
Demographic	O
and	O
socioeconomic	O
characteristics	O
Respondents	O
were	O
aged	O
between	O
16	O
and	O
89	O
years	O
(	O
median	O
age	O
48	O
years	O
)	O
.	O

804	O
(	O
61	O
%	O
)	O
were	O
women	O
.	O

Only	O
136	O
(	O
26	O
%	O
)	O
of	O
the	O
men	O
and	O
145	O
(	O
18	O
%	O
)	O
of	O
the	O
women	O
reported	O
having	O
access	O
to	O
a	O
bicycle	O
.	O

For	O
those	O
who	O
usually	O
travelled	O
to	O
a	O
place	O
of	O
work	O
or	O
study	O
,	O
the	O
median	O
reported	O
distance	O
was	O
3.5	O
miles	O
(	O
about	O
5.5	O
kilometres	O
)	O
.	O

Other	O
characteristics	O
of	O
study	O
participants	O
are	O
summarised	O
in	O
Table	O
2	O
.	O

Health	O
and	O
wellbeing	O
25	O
%	O
of	O
respondents	O
reported	O
difficulty	O
walking	O
for	O
a	O
quarter	O
of	O
a	O
mile	O
,	O
39	O
%	O
reported	O
a	O
long	O
-	O
term	O
health	O
problem	O
or	O
disability	O
,	O
and	O
50	O
%	O
were	O
overweight	O
(	O
median	O
BMI	O
25.1	O
kg	O
/	O
m2	O
)	O
.	O

The	O
median	O
mental	O
health	O
summary	O
score	O
(	O
MCS-8	O
)	O
was	O
significantly	O
lower	O
(	O
i.e.	O
poorer	O
)	O
than	O
the	O
population	O
norm	O
(	O
median	O
47.3	O
,	O
95	O
%	O
CI	O
46.4	O
to	O
48.1	O
)	O
;	O
the	O
median	O
physical	O
health	O
summary	O
score	O
(	O
PCS-8	O
)	O
was	O
not	O
significantly	O
different	O
from	O
the	O
population	O
norm	O
(	O
median	O
50.9	O
,	O
95	O
%	O
CI	O
49.6	O
to	O
51.7	O
)	O
.	O

Descriptive	O
data	O
on	O
travel	O
behaviour	O
and	O
physical	O
activity	O
Travel	O
behaviour	O
1099	O
travel	O
diaries	O
were	O
suitable	O
for	O
travel	O
time	O
analysis	O
.	O

Men	O
and	O
women	O
were	O
equally	O
likely	O
to	O
have	O
returned	O
usable	O
travel	O
time	O
data	O
,	O
but	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

On	O
average	O
,	O
respondents	O
recorded	O
about	O
an	O
hour	O
's	O
travel	O
per	O
day	O
(	O
mean	O
61.5	O
minutes	O
,	O
median	O
50.0	O
minutes	O
)	O
,	O
of	O
which	O
a	O
minority	O
was	O
spent	O
using	O
active	O
modes	O
of	O
transport	O
(	O
walking	O
or	O
cycling	O
:	O
mean	O
20.0	O
minutes	O
,	O
median	O
10.0	O
minutes	O
)	O
(	O
Table	O
3	O
)	O
.	O

304	O
respondents	O
(	O
28	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
active	O
travel	O
,	O
of	O
whom	O
294	O
(	O
97	O
%	O
)	O
recorded	O
at	O
least	O
30	O
minutes	O
of	O
walking	O
.	O

Physical	O
activity	O
833	O
respondents	O
returned	O
complete	O
physical	O
activity	O
data	O
suitable	O
for	O
analysis	O
.	O

Women	O
and	O
respondents	O
who	O
were	O
older	O
,	O
retired	O
,	O
or	O
living	O
in	O
social	O
rented	O
accommodation	O
or	O
who	O
did	O
not	O
have	O
access	O
to	O
a	O
car	O
were	O
less	O
likely	O
to	O
have	O
returned	O
usable	O
data	O
.	O

Respondents	O
reported	O
a	O
mean	O
of	O
318	O
minutes	O
'	O
walking	O
per	O
week	O
and	O
a	O
mean	O
estimated	O
total	O
physical	O
activity	O
energy	O
expenditure	O
of	O
3000	O
MET	O
-	O
minutes	O
per	O
week	O
(	O
Table	O
4	O
)	O
.	O

Only	O
316	O
respondents	O
(	O
38	O
%	O
)	O
were	O
categorised	O
as	O
having	O
achieved	O
a	O
'	O
high	O
'	O
(	O
i.e.	O
sufficient	O
)	O
level	O
of	O
physical	O
activity	O
.	O

Correlates	O
of	O
active	O
travel	O
Active	O
travel	O
was	O
significantly	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
more	O
than	O
four	O
miles	O
to	O
work	O
,	O
having	O
access	O
to	O
a	O
bicycle	O
,	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
active	O
travel	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
13.04	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.11	O
)	O
and	O
explained	O
nearly	O
one	O
-	O
fifth	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
18.7	O
%	O
)	O
(	O
Table	O
5	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
active	O
travel	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
10.61	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.23	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
active	O
travel	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
20.1	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

In	O
order	O
to	O
aid	O
interpretation	O
,	O
we	O
also	O
partitioned	O
the	O
dataset	O
into	O
two	O
strata	O
(	O
'	O
No	O
car	O
available	O
'	O
and	O
'	O
Car	O
available	O
'	O
)	O
and	O
refitted	O
the	O
final	O
model	O
separately	O
to	O
each	O
stratum	O
of	O
the	O
dataset	O
(	O
Table	O
6	O
)	O
.	O

This	O
showed	O
that	O
the	O
subset	O
of	O
respondents	O
with	O
no	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationship	O
between	O
active	O
travel	O
and	O
access	O
to	O
a	O
bicycle	O
,	O
whereas	O
those	O
with	O
access	O
to	O
a	O
car	O
accounted	O
for	O
the	O
significant	O
overall	O
relationships	O
with	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
and	O
perceptions	O
of	O
the	O
local	O
environment	O
.	O

The	O
relationship	O
with	O
difficulty	O
walking	O
was	O
also	O
stronger	O
in	O
this	O
group	O
than	O
in	O
those	O
without	O
access	O
to	O
a	O
car	O
.	O

Correlates	O
of	O
physical	O
activity	O
Physical	O
activity	O
was	O
significantly	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
not	O
being	O
overweight	O
,	O
and	O
the	O
absence	O
of	O
any	O
difficulty	O
walking	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
'	O
personal	O
'	O
correlates	O
of	O
physical	O
activity	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
3.89	O
,	O
df	O
=	O
7	O
;	O
P	O
=	O
0.89	O
)	O
and	O
explained	O
about	O
one	O
-	O
sixth	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
(	O
Nagelkerke	O
's	O
R2	O
=	O
15.9	O
%	O
)	O
(	O
Table	O
7	O
)	O
.	O

Adding	O
'	O
environmental	O
'	O
variables	O
to	O
the	O
model	O
showed	O
an	O
additional	O
significant	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
(	O
i.e.	O
respondents	O
who	O
perceived	O
there	O
to	O
be	O
a	O
higher	O
volume	O
of	O
traffic	O
were	O
more	O
likely	O
to	O
report	O
physical	O
activity	O
)	O
.	O

The	O
final	O
best	O
model	O
of	O
the	O
personal	O
and	O
environmental	O
correlates	O
of	O
physical	O
activity	O
also	O
provided	O
satisfactory	O
goodness	O
-	O
of	O
-	O
fit	O
(	O
Hosmer	O
and	O
Lemeshow	O
test	O
:	O
χ2	O
=	O
3.86	O
,	O
df	O
=	O
8	O
;	O
P	O
=	O
0.87	O
)	O
and	O
explained	O
slightly	O
more	O
of	O
the	O
total	O
variance	O
in	O
physical	O
activity	O
than	O
did	O
the	O
personal	O
model	O
alone	O
(	O
Nagelkerke	O
's	O
16.6	O
%	O
)	O
(	O
Figure	O
3	O
)	O
.	O

Discussion	O
Principal	O
findings	O
In	O
this	O
deprived	O
urban	O
population	O
,	O
the	O
likelihood	O
of	O
reporting	O
active	O
travel	O
was	O
associated	O
with	O
being	O
younger	O
,	O
living	O
in	O
owner	O
-	O
occupied	O
accommodation	O
,	O
not	O
having	O
to	O
travel	O
a	O
long	O
distance	O
to	O
work	O
and	O
not	O
having	O
access	O
to	O
a	O
car	O
,	O
whereas	O
overall	O
physical	O
activity	O
was	O
associated	O
with	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
and	O
not	O
being	O
overweight	O
.	O

After	O
adjusting	O
for	O
individual	O
and	O
household	O
characteristics	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
the	O
objective	O
proximity	O
of	O
respondents	O
'	O
homes	O
to	O
motorway	O
or	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
although	O
we	O
did	O
find	O
a	O
significant	O
positive	O
association	O
between	O
active	O
travel	O
and	O
perceived	O
proximity	O
to	O
shops	O
.	O

Representativeness	O
and	O
completeness	O
of	O
survey	O
data	O
Our	O
difficulty	O
in	O
obtaining	O
a	O
representative	O
sample	O
of	O
the	O
resident	O
population	O
is	O
not	O
unique	O
to	O
our	O
study	O
.	O

Although	O
our	O
final	O
response	O
rate	O
was	O
low	O
,	O
it	O
was	O
almost	O
identical	O
to	O
that	O
achieved	O
in	O
a	O
recent	O
population	O
-	O
based	O
intervention	O
study	O
elsewhere	O
in	O
Glasgow	O
[	O
22	O
]	O
.	O

Some	O
of	O
the	O
challenges	O
of	O
recruiting	O
research	O
participants	O
in	O
areas	O
of	O
deprivation	O
have	O
been	O
described	O
elsewhere	O
[	O
23	O
]	O
;	O
these	O
are	O
superimposed	O
on	O
a	O
downward	O
trend	O
in	O
participation	O
in	O
even	O
the	O
best	O
-	O
resourced	O
national	O
population	O
surveys	O
[	O
24	O
]	O
and	O
an	O
upward	O
(	O
and	O
socially	O
biased	O
)	O
trend	O
in	O
opt	O
-	O
outs	O
from	O
the	O
main	O
alternative	O
sampling	O
frame	O
,	O
the	O
edited	O
electoral	O
register	O
[	O
25	O
]	O
.	O

Although	O
our	O
achieved	O
sample	O
contained	O
a	O
higher	O
proportion	O
of	O
respondents	O
from	O
owner	O
-	O
occupied	O
and	O
car	O
-	O
owning	O
households	O
than	O
predicted	O
from	O
2001	O
census	O
data	O
for	O
the	O
same	O
census	O
output	O
areas	O
,	O
these	O
differences	O
may	O
be	O
partly	O
accounted	O
for	O
by	O
an	O
upward	O
background	O
trend	O
in	O
owner	O
occupation	O
and	O
car	O
access	O
between	O
2001	O
and	O
2005	O
.	O

Our	O
achieved	O
sample	O
is	O
still	O
clearly	O
disadvantaged	O
overall	O
,	O
in	O
terms	O
of	O
socioeconomic	O
and	O
health	O
status	O
,	O
compared	O
with	O
the	O
country	O
as	O
a	O
whole	O
.	O

It	O
also	O
contains	O
sufficient	O
heterogeneity	O
to	O
enable	O
us	O
to	O
examine	O
,	O
in	O
time	O
,	O
how	O
the	O
effects	O
of	O
the	O
intervention	O
are	O
distributed	O
between	O
socioeconomic	O
groups	O
.	O

We	O
therefore	O
consider	O
our	O
achieved	O
sample	O
fit	O
for	O
purpose	O
.	O

We	O
had	O
to	O
disregard	O
a	O
substantial	O
proportion	O
of	O
cases	O
in	O
analysis	O
because	O
respondents	O
had	O
returned	O
unusable	O
travel	O
time	O
data	O
or	O
had	O
returned	O
physical	O
activity	O
data	O
that	O
were	O
incomplete	O
,	O
internally	O
inconsistent	O
or	O
included	O
a	O
'	O
Do	O
n't	O
know	O
'	O
response	O
and	O
were	O
therefore	O
unacceptable	O
according	O
to	O
the	O
IPAQ	O
scoring	O
protocol	O
.	O

Most	O
published	O
studies	O
using	O
the	O
same	O
,	O
short	O
form	O
of	O
IPAQ	O
have	O
either	O
not	O
reported	O
the	O
distribution	O
of	O
the	O
continuous	O
summary	O
measures	O
or	O
have	O
not	O
reported	O
data	O
for	O
the	O
UK	O
separately	O
from	O
those	O
for	O
other	O
countries	O
where	O
higher	O
levels	O
of	O
physical	O
activity	O
are	O
reported	O
.	O

Despite	O
the	O
high	O
proportion	O
of	O
missing	O
physical	O
activity	O
data	O
in	O
our	O
dataset	O
,	O
however	O
,	O
the	O
aggregate	O
continuous	O
data	O
we	O
obtained	O
were	O
broadly	O
comparable	O
to	O
those	O
reported	O
in	O
Rütten	O
and	O
colleagues	O
'	O
study	O
of	O
a	O
random	O
sample	O
of	O
UK	O
adults	O
[	O
26	O
]	O
.	O

We	O
could	O
have	O
included	O
more	O
cases	O
in	O
physical	O
activity	O
analysis	O
by	O
,	O
for	O
example	O
,	O
imputing	O
missing	O
values	O
,	O
but	O
the	O
results	O
would	O
not	O
have	O
been	O
comparable	O
with	O
others	O
'	O
owing	O
to	O
the	O
substantial	O
deviations	O
from	O
the	O
scoring	O
protocol	O
which	O
would	O
have	O
been	O
required	O
.	O

The	O
frequency	O
of	O
unusable	O
responses	O
was	O
not	O
reported	O
in	O
the	O
international	O
multi	O
-	O
centre	O
study	O
which	O
originally	O
established	O
the	O
validity	O
and	O
reliability	O
of	O
IPAQ	O
[	O
27	O
]	O
.	O

It	O
is	O
possible	O
that	O
offering	O
a	O
'	O
Do	O
n't	O
know	O
'	O
option	O
in	O
the	O
self	O
-	O
completed	O
IPAQ	O
questionnaire	O
encourages	O
respondents	O
to	O
select	O
this	O
rather	O
than	O
to	O
enter	O
what	O
may	O
be	O
a	O
reasonably	O
precise	O
estimate	O
of	O
the	O
actual	O
time	O
spent	O
in	O
physical	O
activity	O
;	O
the	O
respondent	O
has	O
no	O
way	O
of	O
knowing	O
that	O
a	O
single	O
'	O
Do	O
n't	O
know	O
'	O
response	O
will	O
result	O
in	O
all	O
of	O
their	O
physical	O
activity	O
data	O
being	O
disregarded	O
in	O
analysis	O
.	O

This	O
should	O
be	O
considered	O
in	O
any	O
future	O
revision	O
of	O
the	O
IPAQ	O
questionnaire	O
and	O
scoring	O
protocol	O
.	O

Contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O
The	O
explanatory	O
variables	O
that	O
were	O
significantly	O
associated	O
with	O
active	O
travel	O
but	O
not	O
with	O
physical	O
activity	O
(	O
distance	O
to	O
place	O
of	O
work	O
or	O
study	O
,	O
access	O
to	O
a	O
bicycle	O
,	O
access	O
to	O
a	O
car	O
,	O
perceived	O
proximity	O
to	O
shops	O
,	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
)	O
all	O
have	O
an	O
obvious	O
intuitive	O
relationship	O
with	O
the	O
use	O
of	O
walking	O
or	O
cycling	O
as	O
modes	O
of	O
transport	O
.	O

That	O
they	O
were	O
not	O
significantly	O
associated	O
with	O
overall	O
physical	O
activity	O
suggests	O
either	O
that	O
active	O
travel	O
contributes	O
only	O
a	O
minority	O
of	O
respondents	O
'	O
overall	O
physical	O
activity	O
or	O
that	O
other	O
factors	O
not	O
measured	O
in	O
this	O
study	O
are	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
than	O
those	O
which	O
determine	O
active	O
travel	O
.	O

A	O
crude	O
comparision	O
of	O
the	O
quantity	O
of	O
active	O
travel	O
reported	O
in	O
the	O
one	O
-	O
day	O
travel	O
diaries	O
with	O
the	O
quantities	O
of	O
physical	O
activity	O
reported	O
using	O
IPAQ	O
suggests	O
that	O
on	O
average	O
,	O
active	O
travel	O
may	O
indeed	O
make	O
only	O
a	O
small	O
(	O
~15	O
%	O
)	O
contribution	O
to	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
population	O
.	O

However	O
,	O
the	O
real	O
contribution	O
may	O
be	O
substantially	O
greater	O
than	O
this	O
if	O
,	O
as	O
has	O
been	O
shown	O
previously	O
,	O
respondents	O
tend	O
to	O
over	O
-	O
report	O
their	O
physical	O
activity	O
using	O
IPAQ	O
[	O
28	O
]	O
.	O

There	O
can	O
be	O
little	O
doubt	O
that	O
active	O
travel	O
makes	O
a	O
substantial	O
contribution	O
to	O
the	O
total	O
quantity	O
of	O
walking	O
reported	O
in	O
this	O
study	O
population	O
.	O

Irrespective	O
of	O
the	O
true	O
contribution	O
of	O
active	O
travel	O
to	O
overall	O
physical	O
activity	O
,	O
however	O
,	O
it	O
remains	O
likely	O
that	O
other	O
unmeasured	O
personal	O
and	O
social	O
factors	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
may	O
be	O
more	O
important	O
correlates	O
of	O
overall	O
physical	O
activity	O
.	O

Socio	O
-	O
spatial	O
patterning	O
of	O
active	O
travel	O
and	O
overall	O
physical	O
activity	O
Respondents	O
living	O
in	O
owner	O
-	O
occupied	O
households	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
than	O
those	O
living	O
in	O
social	O
-	O
rented	O
accommodation	O
,	O
but	O
less	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

Since	O
neither	O
working	O
situation	O
nor	O
perceived	O
financial	O
situation	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
,	O
housing	O
tenure	O
and	O
car	O
access	O
are	O
the	O
remaining	O
explanatory	O
variables	O
in	O
this	O
dataset	O
which	O
can	O
be	O
interpreted	O
as	O
markers	O
of	O
socioeconomic	O
status	O
.	O

Although	O
having	O
access	O
to	O
a	O
car	O
clearly	O
reflects	O
the	O
possession	O
of	O
a	O
material	O
asset	O
,	O
it	O
has	O
been	O
argued	O
that	O
this	O
is	O
a	O
less	O
direct	O
marker	O
of	O
socioeconomic	O
status	O
than	O
some	O
other	O
markers	O
because	O
,	O
in	O
Scotland	O
at	O
least	O
,	O
access	O
to	O
a	O
car	O
is	O
a	O
more	O
-	O
or	O
-	O
less	O
essential	O
requirement	O
for	O
living	O
in	O
many	O
rural	O
areas	O
,	O
whereas	O
it	O
is	O
possible	O
to	O
live	O
in	O
a	O
dense	O
urban	O
settlement	O
such	O
as	O
Glasgow	O
without	O
using	O
a	O
car	O
.	O

In	O
the	O
final	O
models	O
in	O
this	O
study	O
,	O
therefore	O
,	O
housing	O
tenure	O
may	O
be	O
regarded	O
as	O
the	O
primary	O
marker	O
of	O
socioeconomic	O
status	O
.	O

The	O
findings	O
consequently	O
suggest	O
conflicting	O
socioeconomic	O
gradients	O
in	O
prevalence	O
:	O
more	O
advantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
active	O
travel	O
,	O
but	O
more	O
disadvantaged	O
respondents	O
were	O
more	O
likely	O
to	O
report	O
sufficient	O
overall	O
physical	O
activity	O
.	O

The	O
higher	O
prevalence	O
of	O
sufficient	O
overall	O
physical	O
activity	O
among	O
the	O
more	O
disadvantaged	O
despite	O
their	O
lower	O
propensity	O
for	O
active	O
travel	O
is	O
likely	O
to	O
reflect	O
higher	O
quantities	O
of	O
physical	O
activity	O
in	O
other	O
domains	O
,	O
particularly	O
occupational	O
and	O
domestic	O
activities	O
,	O
since	O
leisure	O
-	O
time	O
physical	O
activity	O
tends	O
to	O
be	O
higher	O
among	O
more	O
advantaged	O
groups	O
[	O
29	O
]	O
.	O

Environmental	O
characteristics	O
:	O
paradoxical	O
,	O
unmeasured	O
,	O
or	O
irrelevant	O
?	O

The	O
two	O
environmental	O
variables	O
that	O
emerged	O
as	O
significantly	O
associated	O
with	O
active	O
travel	O
,	O
particularly	O
among	O
those	O
without	O
access	O
to	O
a	O
car	O
,	O
were	O
perceived	O
proximity	O
to	O
shops	O
and	O
perceived	O
road	O
safety	O
for	O
cyclists	O
.	O

The	O
positive	O
association	O
with	O
perceived	O
proximity	O
to	O
shops	O
suggests	O
that	O
for	O
active	O
travel	O
to	O
be	O
undertaken	O
in	O
this	O
population	O
,	O
it	O
may	O
be	O
more	O
important	O
that	O
people	O
live	O
close	O
to	O
the	O
amenities	O
they	O
need	O
than	O
that	O
they	O
live	O
in	O
an	O
environment	O
with	O
more	O
favourable	O
subjective	O
or	O
discretionary	O
considerations	O
such	O
as	O
attractiveness	O
or	O
noise	O
.	O

This	O
would	O
be	O
consistent	O
with	O
an	O
understanding	O
that	O
walking	O
as	O
a	O
mode	O
of	O
transport	O
is	O
primarily	O
a	O
way	O
of	O
undertaking	O
journeys	O
which	O
have	O
to	O
be	O
made	O
anyway	O
,	O
as	O
opposed	O
to	O
more	O
discretionary	O
(	O
recreational	O
)	O
forms	O
of	O
walking	O
which	O
may	O
be	O
more	O
susceptible	O
to	O
the	O
influence	O
of	O
less	O
-	O
structural	O
characteristics	O
.	O

Although	O
the	O
negative	O
association	O
with	O
perceived	O
road	O
safety	O
for	O
cyclists	O
appears	O
counter	O
-	O
intuitive	O
,	O
similar	O
'	O
paradoxical	O
inverse	O
relationships	O
'	O
have	O
been	O
reported	O
elsewhere	O
,	O
for	O
example	O
by	O
Titze	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
the	O
correlates	O
of	O
cycling	O
among	O
students	O
[	O
30	O
]	O
and	O
by	O
Humpel	O
and	O
colleagues	O
in	O
a	O
study	O
of	O
correlates	O
of	O
walking	O
for	O
pleasure	O
[	O
31	O
]	O
.	O

Titze	O
and	O
colleagues	O
suggest	O
that	O
respondents	O
who	O
cycle	O
regularly	O
are	O
more	O
likely	O
to	O
be	O
aware	O
of	O
,	O
and	O
report	O
,	O
the	O
danger	O
posed	O
by	O
traffic	O
than	O
non	O
-	O
cyclists	O
or	O
infrequent	O
cyclists	O
.	O

A	O
similar	O
phenomenon	O
could	O
explain	O
the	O
negative	O
association	O
between	O
physical	O
activity	O
and	O
perception	O
of	O
traffic	O
volume	O
.	O

Overall	O
,	O
the	O
influence	O
of	O
the	O
putative	O
environmental	O
characteristics	O
examined	O
in	O
this	O
study	O
on	O
active	O
travel	O
and	O
physical	O
activity	O
appeared	O
small	O
compared	O
with	O
that	O
of	O
the	O
personal	O
characteristics	O
found	O
to	O
be	O
significant	O
,	O
and	O
including	O
environmental	O
characteristics	O
in	O
the	O
models	O
did	O
not	O
substantially	O
modify	O
the	O
influence	O
of	O
personal	O
characteristics	O
.	O

On	O
the	O
one	O
hand	O
,	O
this	O
could	O
reflect	O
an	O
artefact	O
of	O
the	O
research	O
methods	O
(	O
a	O
false	O
negative	O
error	O
)	O
,	O
which	O
could	O
have	O
arisen	O
in	O
various	O
ways	O
.	O

In	O
particular	O
,	O
the	O
'	O
wrong	O
'	O
environmental	O
exposure	O
may	O
have	O
been	O
measured	O
,	O
in	O
that	O
the	O
environmental	O
characteristics	O
examined	O
were	O
those	O
of	O
the	O
immediate	O
surroundings	O
of	O
respondents	O
'	O
homes	O
,	O
whereas	O
the	O
propensity	O
to	O
choose	O
active	O
modes	O
of	O
transport	O
may	O
be	O
more	O
strongly	O
influenced	O
by	O
the	O
characteristics	O
of	O
the	O
environment	O
elsewhere	O
on	O
their	O
routes	O
[	O
30	O
]	O
,	O
for	O
example	O
the	O
perceived	O
danger	O
of	O
cycling	O
in	O
the	O
city	O
centre	O
–	O
an	O
association	O
which	O
may	O
be	O
absent	O
,	O
or	O
at	O
least	O
diluted	O
,	O
when	O
the	O
'	O
exposure	O
'	O
examined	O
is	O
limited	O
to	O
the	O
residential	O
environment	O
.	O

It	O
could	O
also	O
be	O
argued	O
that	O
the	O
apparently	O
weak	O
influence	O
of	O
environmental	O
characteristics	O
in	O
this	O
study	O
reflects	O
a	O
reliance	O
on	O
respondents	O
'	O
perceptions	O
which	O
have	O
not	O
been	O
objectively	O
verified	O
and	O
may	O
therefore	O
be	O
a	O
weak	O
proxy	O
for	O
the	O
'	O
true	O
'	O
objectively	O
-	O
measured	O
characteristics	O
of	O
their	O
surroundings	O
.	O

However	O
,	O
as	O
recent	O
reviews	O
have	O
pointed	O
out	O
,	O
the	O
current	O
weight	O
of	O
evidence	O
for	O
objective	O
environmental	O
correlates	O
of	O
walking	O
is	O
no	O
greater	O
than	O
that	O
for	O
subjective	O
environmental	O
correlates	O
[	O
5	O
]	O
and	O
it	O
is	O
entirely	O
plausible	O
that	O
people	O
's	O
perceptions	O
of	O
their	O
environment	O
may	O
be	O
at	O
least	O
as	O
important	O
as	O
their	O
objective	O
conditions	O
in	O
influencing	O
their	O
behaviour	O
[	O
6	O
]	O
.	O

On	O
the	O
other	O
hand	O
,	O
we	O
may	O
have	O
demonstrated	O
a	O
real	O
absence	O
of	O
any	O
major	O
association	O
.	O

Although	O
at	O
first	O
sight	O
this	O
appears	O
at	O
odds	O
with	O
the	O
growing	O
body	O
of	O
review	O
-	O
level	O
evidence	O
for	O
environmental	O
correlates	O
of	O
physical	O
activity	O
,	O
Wendel	O
-	O
Vos	O
and	O
colleagues	O
noted	O
that	O
of	O
all	O
the	O
environmental	O
factors	O
examined	O
in	O
all	O
the	O
studies	O
included	O
in	O
their	O
review	O
,	O
analysis	O
showed	O
a	O
'	O
null	O
association	O
'	O
in	O
76	O
%	O
of	O
cases	O
[	O
9	O
]	O
,	O
and	O
our	O
finding	O
that	O
personal	O
factors	O
account	O
for	O
a	O
much	O
larger	O
proportion	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
physical	O
activity	O
than	O
is	O
accounted	O
for	O
by	O
environmental	O
factors	O
is	O
consistent	O
with	O
those	O
of	O
some	O
other	O
European	O
studies	O
[	O
32,33	O
]	O
.	O

In	O
the	O
particular	O
context	O
of	O
this	O
study	O
,	O
residents	O
may	O
simply	O
have	O
adapted	O
to	O
adverse	O
conditions	O
in	O
their	O
local	O
environment	O
in	O
the	O
ways	O
identified	O
by	O
Hedges	O
in	O
a	O
qualitative	O
study	O
of	O
people	O
living	O
close	O
to	O
new	O
roads	O
built	O
in	O
the	O
UK	O
in	O
the	O
1970s	O
[	O
34	O
]	O
–	O
particularly	O
by	O
attitudinal	O
adaptation	O
,	O
which	O
Hedges	O
characterises	O
as	O
developing	O
an	O
attitude	O
that	O
it	O
is	O
futile	O
to	O
resist	O
.	O

One	O
can	O
imagine	O
that	O
in	O
the	O
most	O
deprived	O
areas	O
of	O
Glasgow	O
,	O
people	O
may	O
have	O
become	O
resigned	O
to	O
the	O
nature	O
of	O
their	O
surroundings	O
,	O
seeing	O
them	O
as	O
inevitable	O
and	O
not	O
amenable	O
to	O
change	O
either	O
through	O
environmental	O
improvement	O
or	O
through	O
their	O
moving	O
to	O
another	O
area	O
.	O

Conclusion	O
After	O
demographic	O
and	O
socioeconomic	O
characteristics	O
were	O
taken	O
into	O
account	O
,	O
neither	O
perceptions	O
of	O
the	O
local	O
environment	O
nor	O
objective	O
proximity	O
to	O
major	O
road	O
infrastructure	O
appeared	O
to	O
explain	O
much	O
of	O
the	O
variance	O
in	O
active	O
travel	O
or	O
overall	O
physical	O
activity	O
in	O
this	O
study	O
.	O

Our	O
study	O
population	O
may	O
be	O
both	O
objectively	O
constrained	O
by	O
their	O
socioeconomic	O
circumstances	O
(	O
including	O
comparatively	O
limited	O
access	O
to	O
private	O
cars	O
)	O
and	O
adapted	O
to	O
living	O
in	O
conditions	O
which	O
others	O
would	O
consider	O
to	O
pose	O
a	O
barrier	O
to	O
active	O
travel	O
.	O

Under	O
these	O
circumstances	O
,	O
environmental	O
characteristics	O
which	O
have	O
been	O
found	O
to	O
influence	O
discretionary	O
active	O
travel	O
in	O
studies	O
in	O
other	O
,	O
more	O
affluent	O
populations	O
may	O
simply	O
be	O
irrelevant	O
in	O
a	O
population	O
which	O
is	O
more	O
captive	O
in	O
its	O
travel	O
choices	O
.	O

Environmental	O
correlates	O
of	O
active	O
travel	O
should	O
not	O
be	O
assumed	O
to	O
be	O
generalisable	O
between	O
populations	O
;	O
researchers	O
should	O
continue	O
to	O
test	O
hypotheses	O
about	O
putative	O
environmental	O
correlates	O
in	O
different	O
settings	O
,	O
and	O
policymakers	O
should	O
recognise	O
that	O
the	O
effects	O
of	O
interventions	O
to	O
change	O
the	O
environment	O
are	O
likely	O
to	O
vary	O
between	O
populations	O
and	O
between	O
socioeconomic	O
groups	O
within	O
populations	O
.	O

Competing	O
interests	O
This	O
paper	O
is	O
based	O
on	O
material	O
contained	O
in	O
the	O
first	O
author	O
's	O
PhD	O
thesis	O
.	O

Authors	O
'	O
contributions	O
DO	O
had	O
the	O
original	O
idea	O
for	O
the	O
study	O
,	O
designed	O
the	O
study	O
and	O
the	O
survey	O
materials	O
,	O
applied	O
for	O
ethical	O
approval	O
,	O
cleaned	O
and	O
coded	O
the	O
survey	O
data	O
,	O
carried	O
out	O
all	O
the	O
geographical	O
and	O
statistical	O
analyses	O
and	O
wrote	O
the	O
paper	O
.	O

MP	O
was	O
DO	O
's	O
PhD	O
supervisor	O
.	O

RM	O
,	O
NM	O
,	O
MP	O
and	O
SP	O
constituted	O
the	O
steering	O
group	O
for	O
the	O
study	O
,	O
contributed	O
to	O
and	O
advised	O
on	O
the	O
design	O
of	O
the	O
study	O
and	O
the	O
interpretation	O
of	O
the	O
emerging	O
findings	O
,	O
and	O
contributed	O
to	O
the	O
critical	O
revision	O
of	O
the	O
paper	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Supplementary	O
Material	O

TOPS++FATCAT	O
:	O
Fast	O
flexible	O
structural	O
alignment	O
using	O
constraints	O
derived	O
from	O
TOPS+	O
Strings	O
Model	O
Abstract	O
Background	O
Protein	O
structure	O
analysis	O
and	O
comparison	O
are	O
major	O
challenges	O
in	O
structural	O
bioinformatics	O
.	O

Despite	O
the	O
existence	O
of	O
many	O
tools	O
and	O
algorithms	O
,	O
very	O
few	O
of	O
them	O
have	O
managed	O
to	O
capture	O
the	O
intuitive	O
understanding	O
of	O
protein	O
structures	O
developed	O
in	O
structural	O
biology	O
,	O
especially	O
in	O
the	O
context	O
of	O
rapid	O
database	O
searches	O
.	O

Such	O
intuitions	O
could	O
help	O
speed	O
up	O
similarity	O
searches	O
and	O
make	O
it	O
easier	O
to	O
understand	O
the	O
results	O
of	O
such	O
analyses	O
.	O

Results	O
We	O
developed	O
a	O
TOPS++FATCAT	O
algorithm	O
that	O
uses	O
an	O
intuitive	O
description	O
of	O
the	O
proteins	O
'	O
structures	O
as	O
captured	O
in	O
the	O
popular	O
TOPS	O
diagrams	O
to	O
limit	O
the	O
search	O
space	O
of	O
the	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
in	O
the	O
flexible	O
alignment	O
of	O
protein	O
structures	O
performed	O
by	O
the	O
FATCAT	O
algorithm	O
.	O

The	O
TOPS++FATCAT	O
algorithm	O
is	O
faster	O
than	O
FATCAT	O
by	O
more	O
than	O
an	O
order	O
of	O
magnitude	O
with	O
a	O
minimal	O
cost	O
in	O
classification	O
and	O
alignment	O
accuracy	O
.	O

For	O
beta	O
-	O
rich	O
proteins	O
its	O
accuracy	O
is	O
better	O
than	O
FATCAT	O
,	O
because	O
the	O
TOPS+	O
strings	O
models	O
contains	O
important	O
information	O
of	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
patterns	O
between	O
the	O
beta	O
-	O
strand	O
SSEs	O
(	O
Secondary	O
Structural	O
Elements	O
)	O
.	O

We	O
show	O
that	O
the	O
TOPS++FATCAT	O
errors	O
,	O
rare	O
as	O
they	O
are	O
,	O
can	O
be	O
clearly	O
linked	O
to	O
oversimplifications	O
of	O
the	O
TOPS	O
diagrams	O
and	O
can	O
be	O
corrected	O
by	O
the	O
development	O
of	O
more	O
precise	O
secondary	O
structure	O
element	O
definitions	O
.	O

Software	O
Availability	O
The	O
benchmark	O
analysis	O
results	O
and	O
the	O
compressed	O
archive	O
of	O
the	O
TOPS++FATCAT	O
program	O
for	O
Linux	O
platform	O
can	O
be	O
downloaded	O
from	O
the	O
following	O
web	O
site	O
:	O
Conclusion	O
TOPS++FATCAT	O
provides	O
FATCAT	O
accuracy	O
and	O
insights	O
into	O
protein	O
structural	O
changes	O
at	O
a	O
speed	O
comparable	O
to	O
sequence	O
alignments	O
,	O
opening	O
up	O
a	O
possibility	O
of	O
interactive	O
protein	O
structure	O
similarity	O
searches	O
.	O

Background	O
Structural	O
biology	O
is	O
one	O
of	O
the	O
most	O
successful	O
fields	O
of	O
modern	O
biology	O
.	O

Over	O
50,000	O
solved	O
protein	O
structures	O
illustrate	O
details	O
of	O
many	O
specific	O
biological	O
processes	O
.	O

The	O
same	O
data	O
also	O
provide	O
us	O
with	O
information	O
about	O
the	O
global	O
features	O
of	O
protein	O
structure	O
space	O
and	O
can	O
be	O
studied	O
to	O
discover	O
the	O
evolutionary	O
,	O
physical	O
,	O
and	O
mathematical	O
rules	O
governing	O
them	O
.	O

How	O
many	O
fundamentally	O
different	O
protein	O
shapes	O
(	O
folds	O
)	O
are	O
there	O
?	O

How	O
do	O
protein	O
structures	O
evolve	O
?	O

How	O
do	O
new	O
structural	O
features	O
appear	O
,	O
and	O
if	O
they	O
are	O
coupled	O
with	O
changes	O
in	O
function	O
,	O
how	O
does	O
this	O
process	O
occur	O
?	O

Such	O
questions	O
can	O
be	O
studied	O
by	O
classifying	O
,	O
comparing	O
and	O
analyzing	O
known	O
protein	O
structures	O
.	O

Two	O
different	O
,	O
but	O
synergistic	O
strategies	O
are	O
typically	O
used	O
for	O
this	O
purpose	O
.	O

In	O
classification	O
systems	O
such	O
as	O
SCOP	O
[	O
1	O
]	O
or	O
CATH	O
[	O
2	O
]	O
,	O
human	B
intuition	O
is	O
used	O
to	O
simplify	O
the	O
description	O
of	O
protein	O
structures	O
to	O
a	O
manageable	O
size	O
,	O
and	O
a	O
human	B
eye	O
,	O
sometimes	O
supported	O
by	O
automated	O
analysis	O
,	O
can	O
recognize	O
patterns	O
and	O
types	O
of	O
structures	O
.	O

In	O
the	O
second	O
approach	O
,	O
specialized	O
comparison	O
algorithms	O
,	O
such	O
as	O
DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
,	O
or	O
FATCAT	O
[	O
5	O
]	O
can	O
be	O
used	O
to	O
calculate	O
a	O
distance	O
-	O
like	O
metric	O
in	O
the	O
protein	O
structure	O
space	O
.	O

This	O
in	O
turn	O
can	O
be	O
used	O
to	O
cluster	O
proteins	O
into	O
groups	O
.	O

Many	O
such	O
algorithms	O
have	O
been	O
developed	O
over	O
the	O
past	O
few	O
decades	O
and	O
have	O
been	O
mostly	O
used	O
for	O
the	O
classification	O
of	O
protein	O
structures	O
into	O
families	O
.	O

An	O
exact	O
solution	O
of	O
an	O
alignment	O
between	O
two	O
structures	O
is	O
formally	O
equivalent	O
to	O
a	O
threading	O
problem	O
and	O
is	O
therefore	O
NP	O
-	O
complete	O
[	O
6	O
]	O
.	O

However	O
,	O
a	O
practical	O
solution	O
can	O
be	O
obtained	O
by	O
heuristics	O
reducing	O
the	O
problem	O
to	O
a	O
manageable	O
size	O
[	O
7	O
]	O
.	O

In	O
human	B
classification	O
systems	O
,	O
the	O
protein	O
is	O
usually	O
reduced	O
to	O
a	O
set	O
of	O
several	O
structural	O
elements	O
,	O
which	O
obviously	O
involve	O
many	O
arbitrary	O
thresholds	O
.	O

Automated	O
algorithms	O
have	O
the	O
same	O
problem	O
and	O
also	O
suffer	O
from	O
inconsistencies	O
between	O
different	O
numerical	O
measures	O
of	O
protein	O
structure	O
similarity	O
[	O
8	O
]	O
.	O

Interestingly	O
,	O
despite	O
these	O
problems	O
,	O
results	O
of	O
different	O
approaches	O
are	O
broadly	O
similar	O
.	O

They	O
all	O
identify	O
approximately	O
a	O
few	O
hundred	O
general	O
classes	O
of	O
protein	O
structures	O
,	O
usually	O
called	O
folds	O
[	O
1	O
]	O
or	O
topologies	O
[	O
2	O
]	O
,	O
distinguished	O
by	O
how	O
the	O
main	O
chain	O
of	O
the	O
protein	O
folds	O
around	O
itself	O
in	O
the	O
three	O
-	O
dimensional	O
space	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
comparison	O
of	O
different	O
approaches	O
,	O
both	O
between	O
and	O
within	O
the	O
two	O
classes	O
,	O
shows	O
that	O
fold	O
/	O
topologies	O
(	O
or	O
cluster	O
)	O
definitions	O
are	O
somewhat	O
fuzzy	O
,	O
with	O
some	O
proteins	O
being	O
occasionally	O
difficult	O
to	O
classify	O
and	O
joining	O
different	O
groups	O
depending	O
on	O
various	O
assumptions	O
.	O

This	O
lead	O
some	O
to	O
question	O
the	O
concept	O
of	O
the	O
fold	O
[	O
9	O
]	O
,	O
but	O
practical	O
application	O
of	O
protein	O
structure	O
comparison	O
leaves	O
little	O
doubt	O
that	O
protein	O
structure	O
space	O
has	O
some	O
natural	O
granularity	O
that	O
overlaps	O
well	O
with	O
the	O
traditional	O
fold	O
classification	O
.	O

Comparison	O
and	O
classification	O
of	O
protein	O
structures	O
is	O
significantly	O
simplified	O
by	O
the	O
fact	O
that	O
proteins	O
have	O
naturally	O
modular	O
structures	O
,	O
being	O
mostly	O
composed	O
of	O
locally	O
regular	O
structures	O
:	O
alpha	O
helices	O
and	O
beta	O
strands	O
.	O

These	O
two	O
types	O
of	O
secondary	O
structures	O
constitute	O
a	O
little	O
over	O
50	O
%	O
of	O
an	O
average	O
protein	O
's	O
length	O
.	O

With	O
the	O
average	O
length	O
of	O
a	O
secondary	O
structure	O
being	O
around	O
10	O
amino	O
acids	O
,	O
this	O
makes	O
it	O
possible	O
to	O
describe	O
protein	O
structure	O
as	O
an	O
arrangement	O
of	O
a	O
much	O
smaller	O
number	O
of	O
elements	O
.	O

Protein	O
structures	O
are	O
often	O
visualized	O
in	O
a	O
simplified	O
form	O
,	O
with	O
the	O
so	O
-	O
called	O
ribbon	O
diagram	O
with	O
secondary	O
structures	O
shown	O
as	O
helices	O
and	O
arrows	O
being	O
the	O
most	O
popular	O
(	O
see	O
Figure	O
1	O
)	O
.	O

This	O
picture	O
can	O
be	O
simplified	O
further	O
by	O
showing	O
individual	O
secondary	O
structure	O
elements	O
as	O
simple	O
symbols	O
(	O
circles	O
or	O
boxes	O
/	O
triangles	O
)	O
.	O

These	O
depictions	O
,	O
called	O
fold	O
diagrams	O
,	O
originally	O
proposed	O
in	O
the	O
70s	O
[	O
10	O
-	O
12	O
]	O
are	O
best	O
captured	O
by	O
a	O
TOPS	O
(	O
Topology	O
of	O
Protein	O
Structures	O
)	O
algorithm	O
,	O
which	O
attempts	O
to	O
automate	O
the	O
process	O
of	O
creation	O
of	O
the	O
topology	O
cartoon	O
[	O
13	O
]	O
.	O

While	O
useful	O
in	O
protein	O
classification	O
,	O
such	O
simplified	O
descriptions	O
are	O
not	O
used	O
in	O
the	O
most	O
popular	O
automated	O
protein	O
structure	O
comparison	O
algorithms	O
such	O
as	O
DALI	O
[	O
3	O
]	O
or	O
CE	O
[	O
4	O
]	O
.	O

Kleywegt	O
and	O
Jones	O
developed	O
a	O
method	O
for	O
finding	O
similar	O
motifs	O
based	O
on	O
comparing	O
distance	O
matrices	O
that	O
are	O
constructed	O
by	O
representing	O
protein	O
as	O
a	O
set	O
of	O
SSEs	O
with	O
their	O
directional	O
vectors	O
and	O
angle	O
between	O
those	O
vectors	O
[	O
14	O
]	O
.	O

Programs	O
that	O
used	O
SSEs	O
either	O
for	O
structure	O
comparison	O
based	O
on	O
hierarchical	O
superposition	O
of	O
both	O
SSEs	O
and	O
atomic	O
representation	O
[	O
15	O
]	O
or	O
for	O
finding	O
common	O
substructures	O
in	O
the	O
comparison	O
process	O
based	O
on	O
subgraph	O
isomorphism	O
,	O
such	O
as	O
[	O
16,17	O
]	O
and	O
recent	O
applications	O
of	O
the	O
TOPS	O
diagram	O
[	O
18,19	O
]	O
,	O
usually	O
struggle	O
with	O
translating	O
the	O
comparison	O
results	O
from	O
the	O
secondary	O
structure	O
to	O
the	O
individual	O
residue	O
level	O
.	O

Although	O
the	O
SSM	O
method	O
uses	O
graph	O
-	O
matching	O
procedures	O
at	O
the	O
SSE	O
level	O
followed	O
by	O
an	O
interactive	O
3D	O
alignment	O
of	O
the	O
protein	O
C	O
-	O
alpha	O
atom	O
[	O
20	O
]	O
,	O
it	O
lacks	O
the	O
topological	O
relationships	O
between	O
the	O
SSEs	O
,	O
which	O
are	O
essential	O
features	O
in	O
identifying	O
common	O
scaffolds	O
in	O
distantly	O
related	O
proteins	O
.	O

A	O
TOPS	O
pattern	O
was	O
used	O
to	O
guide	O
the	O
sequence	O
alignment	O
,	O
for	O
instance	O
,	O
to	O
build	O
multiple	O
structural	O
alignments	O
of	O
the	O
distantly	O
related	O
family	O
of	O
beta	O
-	O
rich	O
protein	O
domains	O
[	O
21	O
]	O
.	O

The	O
Multiple	O
Sequence	O
Alignment	O
Tool	O
(	O
MSAT	O
)	O
automates	O
this	O
approach	O
,	O
merging	O
it	O
with	O
a	O
popular	O
ClustalW	O
program	O
[	O
22	O
]	O
.	O

DALI	O
[	O
3	O
]	O
,	O
CE	O
[	O
4	O
]	O
or	O
FATCAT	O
[	O
5	O
]	O
introduce	O
their	O
own	O
methods	O
of	O
decomposing	O
the	O
protein	O
structure	O
into	O
smaller	O
units	O
,	O
such	O
as	O
7	O
×	O
7	O
dense	O
distance	O
map	O
fragments	O
(	O
DALIs	O
)	O
or	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
(	O
CE	O
and	O
FATCAT	O
)	O
.	O

The	O
large	O
number	O
of	O
such	O
fragments	O
and	O
the	O
combinations	O
of	O
the	O
fragments	O
that	O
need	O
to	O
be	O
evaluated	O
by	O
structure	O
comparison	O
programs	O
is	O
the	O
main	O
reason	O
for	O
the	O
significant	O
computational	O
requirements	O
of	O
such	O
algorithms	O
.	O

However	O
,	O
more	O
importantly	O
,	O
TOPS+	O
method	O
is	O
used	O
here	O
to	O
enable	O
a	O
structural	O
comparison	O
that	O
takes	O
into	O
account	O
flexibility	O
in	O
protein	O
structures	O
and	O
not	O
only	O
classifies	O
the	O
differences	O
,	O
but	O
also	O
can	O
recognize	O
such	O
rearrangements	O
–	O
which	O
is	O
a	O
first	O
such	O
application	O
using	O
the	O
SSEs	O
language	O
.	O

In	O
this	O
contribution	O
,	O
we	O
explore	O
the	O
question	O
of	O
whether	O
it	O
would	O
be	O
possible	O
to	O
combine	O
insights	O
provided	O
by	O
topology	O
diagrams	O
into	O
automated	O
protein	O
structure	O
alignment	O
algorithms	O
,	O
focusing	O
on	O
the	O
FATCAT	O
program	O
developed	O
previously	O
in	O
our	O
group	O
.	O

Methods	O
Flexible	O
structure	O
alignment	O
method	O
FATCAT	O
FATCAT	O
[	O
5	O
]	O
is	O
a	O
unique	O
structure	O
alignment	O
method	O
that	O
allows	O
for	O
flexibility	O
in	O
the	O
structures	O
being	O
compared	O
.	O

It	O
builds	O
the	O
alignment	O
by	O
chaining	O
aligned	O
fragment	O
pairs	O
(	O
AFPs	O
)	O
[	O
23	O
]	O
together	O
using	O
a	O
unified	O
scoring	O
function	O
where	O
AFP	O
extensions	O
,	O
gaps	O
,	O
and	O
twists	O
each	O
have	O
their	O
specific	O
scores	O
(	O
Figure	O
2	O
)	O
.	O

Introducing	O
a	O
twist	O
into	O
the	O
alignment	O
is	O
penalized	O
,	O
but	O
this	O
penalty	O
may	O
be	O
compensated	O
for	O
by	O
the	O
gain	O
in	O
the	O
score	O
of	O
the	O
resulting	O
alignment	O
(	O
i.e.	O
,	O
longer	O
alignment	O
and/or	O
better	O
RMSD	O
)	O
.	O

Rigid	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
""""	O
rigid	O
""""	O
mode	O
and	O
""""	O
flexible	O
""""	O
(	O
default	O
)	O
mode	O
.	O

FATCAT	O
,	O
as	O
well	O
as	O
most	O
other	O
protein	O
structure	O
comparison	O
programs	O
,	O
is	O
very	O
slow	O
when	O
compared	O
to	O
sequence	O
alignments	O
.	O

The	O
computing	O
time	O
of	O
FATCAT	O
is	O
determined	O
by	O
the	O
size	O
of	O
the	O
collection	O
of	O
AFPs	O
detected	O
between	O
the	O
two	O
structures	O
being	O
compared	O
.	O

FATCAT	O
is	O
available	O
from	O
a	O
server	O
with	O
an	O
option	O
to	O
search	O
in	O
SCOP	O
or	O
PDB	O
databases	O
for	O
similar	O
structures	O
.	O

This	O
search	O
typically	O
takes	O
between	O
8	O
to	O
16	O
hours	O
of	O
CPU	O
time	O
,	O
and	O
this	O
is	O
the	O
main	O
obstacle	O
to	O
broader	O
use	O
of	O
this	O
option	O
.	O

FATCAT	O
has	O
been	O
used	O
to	O
construct	O
a	O
Flexible	O
Structure	O
Neighborhood	O
(	O
FSN	O
)	O
database	O
that	O
contains	O
pre	O
-	O
computed	O
results	O
of	O
structure	O
similarity	O
searches	O
and	O
it	O
takes	O
several	O
weeks	O
of	O
CPU	O
time	O
to	O
update	O
the	O
FSN	O
database	O
.	O

Other	O
protein	O
structure	O
comparison	O
resources	O
,	O
such	O
as	O
DALI	O
or	O
CE	O
have	O
very	O
similar	O
problems	O
.	O

TOPS	O
cartoons	O
and	O
TOPS	O
graph	O
models	O
As	O
discussed	O
in	O
the	O
Background	O
,	O
TOPS	O
cartoons	O
capture	O
the	O
simplified	O
,	O
fold	O
-	O
level	O
description	O
of	O
protein	O
structure	O
and	O
at	O
the	O
same	O
time	O
can	O
be	O
automated	O
[	O
24	O
]	O
.	O

The	O
TOPS	O
algorithm	O
uses	O
structural	O
features	O
such	O
as	O
hydrogen	O
bonds	O
and	O
chirality	O
of	O
the	O
beta	O
strands	O
to	O
provide	O
a	O
scoring	O
function	O
to	O
optimize	O
the	O
cartoon	O
(	O
see	O
Figure	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
TOPS	O
,	O
the	O
secondary	O
structural	O
elements	O
(	O
SSEs	O
)	O
are	O
derived	O
from	O
the	O
DSSP	O
program	O
[	O
25	O
]	O
.	O

Based	O
on	O
TOPS	O
cartoons	O
,	O
a	O
formal	O
graph	O
model	O
and	O
graph	O
-	O
based	O
definitions	O
of	O
protein	O
topology	O
and	O
pattern	O
discovery	O
and	O
comparison	O
methods	O
were	O
developed	O
[	O
26,27	O
]	O
.	O

The	O
TOPS	O
database	O
and	O
comparison	O
,	O
pattern	O
discovery	O
and	O
matching	O
programs	O
are	O
accessible	O
from	O
.	O

Novel	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
The	O
TOPS	O
model	O
was	O
further	O
enhanced	O
to	O
incorporate	O
features	O
such	O
as	O
protein	O
-	O
ligand	O
interaction	O
information	O
and	O
more	O
detailed	O
secondary	O
structural	O
segment	O
information	O
.	O

This	O
enhanced	O
model	O
is	O
called	O
TOPS+	O
model	O
(	O
see	O
Figure	O
3a	O
)	O
.	O

This	O
TOPS+	O
model	O
can	O
be	O
described	O
formally	O
in	O
a	O
TOPS+	O
strings	O
language	O
(	O
Figure	O
3b	O
)	O
at	O
a	O
reduced	O
linear	O
level	O
.	O

The	O
enhanced	O
TOPS+	O
strings	O
models	O
can	O
be	O
used	O
in	O
fast	O
string	O
-	O
based	O
structure	O
matching	O
and	O
comparison	O
,	O
at	O
the	O
same	O
time	O
avoiding	O
issues	O
of	O
NP	O
-	O
completeness	O
associated	O
with	O
graph	O
alignments	O
.	O

In	O
detail	O
,	O
each	O
node	O
(	O
SSE	O
segment	O
)	O
of	O
the	O
TOPS+	O
strings	O
is	O
described	O
by	O
its	O
type	O
,	O
orientation	O
,	O
PDB	O
start	O
number	O
,	O
segment	O
length	O
,	O
total	O
number	O
of	O
incoming	O
(	O
InArc	O
)	O
and	O
outgoing	O
(	O
OutArc	O
)	O
arcs	O
(	O
edges	O
)	O
,	O
total	O
number	O
of	O
ArcTypes	O
,	O
and	O
total	O
number	O
of	O
ligand	O
arcs	O
(	O
LigArc	O
)	O
.	O

The	O
type	O
of	O
the	O
segment	O
(	O
SSEType	O
)	O
could	O
be	O
one	O
of	O
[	O
E	O
,	O
e	O
,	O
H	O
,	O
h	O
,	O
U	O
,	O
u	O
]	O
,	O
where	O
,	O
""""	O
E	O
""""	O
and	O
""""	O
e	O
""""	O
represent	O
the	O
""""	O
"up""-"	O
and	O
""""	O
down	O
"""-"	O
oriented	O
beta	O
strands	O
;	O
""""	O
H	O
""""	O
and	O
""""	O
h	O
""""	O
indicate	O
the	O
""""	O
"up""-"	O
and	O
""""	O
down	O
"""-"	O
oriented	O
alpha	O
helices	O
;	O
and	O
""""	O
U	O
""""	O
and	O
""""	O
u	O
""""	O
represent	O
ligand	O
-	O
bound	O
and	O
ligand	O
-	O
free	O
loops	O
.	O

The	O
InArcType	O
can	O
be	O
classified	O
as	O
an	O
/	O
a	O
[	O
R	O
,	O
L	O
,	O
P	O
,	O
A	O
]	O
,	O
where	O
""""	O
R	O
""""	O
and	O
""""	O
L	O
""""	O
represent	O
right	O
and	O
left	O
chiralities	O
;	O
and	O
""""	O
P	O
""""	O
and	O
""""	O
A	O
""""	O
represent	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
bonds	O
,	O
respectively	O
.	O

The	O
OutArcType	O
is	O
represented	O
in	O
a	O
similar	O
manner	O
by	O
[	O
R	O
'	O
,	O
L	O
'	O
,	O
P	O
'	O
,	O
A	O
'	O
]	O
.	O

Ligand	O
arcs	O
are	O
indicated	O
by	O
LT	O
=	O
AA	O
,	O
where	O
LT	O
is	O
the	O
ligand	O
type	O
and	O
AA	O
is	O
the	O
PDB	O
number	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
a	O
)	O
and	O
3	O
(	O
b	O
)	O
contain	O
visual	O
representations	O
of	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
,	O
respectively	O
,	O
for	O
the	O
protein	O
domain	O
d1fnb_1	O
.	O

Here	O
the	O
triangles	O
represent	O
the	O
beta	O
strands	O
;	O
the	O
red	O
curve	O
represents	O
the	O
alpha	O
helix	O
;	O
gray	O
ellipsoids	O
indicate	O
loops	O
;	O
and	O
green	O
arcs	O
indicate	O
hydrogen	O
bonds	O
between	O
two	O
beta	O
strands	O
,	O
called	O
anti	O
-	O
parallel	O
beta	O
sheets	O
.	O

The	O
length	O
of	O
a	O
TOPS+	O
strings	O
model	O
is	O
defined	O
by	O
number	O
of	O
SSEs	O
;	O
thus	O
,	O
the	O
length	O
of	O
d1fnb_1	O
is	O
19	O
.	O

For	O
further	O
details	O
,	O
see	O
[	O
28	O
]	O
.	O

TOPS+	O
strings	O
comparison	O
method	O
TOPS+	O
is	O
a	O
comparison	O
method	O
that	O
computes	O
a	O
distance	O
between	O
TOPS+	O
strings	O
models	O
of	O
two	O
proteins	O
based	O
on	O
a	O
dynamic	O
programming	O
approach	O
and	O
identifies	O
the	O
longest	O
common	O
subsequence	O
(	O
LCS	O
)	O
,	O
consisting	O
of	O
the	O
list	O
of	O
the	O
topologically	O
equivalent	O
SSEs	O
between	O
two	O
proteins	O
.	O

For	O
example	O
,	O
Figure	O
3	O
(	O
c	O
)	O
shows	O
the	O
TOPS+	O
strings	O
alignment	O
between	O
Dihydropteridine	O
reductase	O
proteins	O
from	O
rat	O
(	O
1dhr	O
)	O
and	O
human	B
(	O
1hdr	O
)	O
.	O

The	O
TOPS+	O
strings	O
models	O
for	O
1dhr	O
and	O
1hdr	O
are	O
represented	O
by	O
a	O
linear	O
string	O
-	O
model	O
,	O
where	O
a	O
yellow	O
triangle	O
and	O
red	O
curves	O
indicate	O
the	O
beta	O
strands	O
and	O
alpha	O
helices	O
in	O
their	O
""""	O
up	O
""""	O
or	O
""""	O
down	O
""""	O
orientations	O
,	O
respectively	O
.	O

The	O
grey	O
line	O
and	O
purple	O
stubs	O
represent	O
the	O
loop	O
regions	O
and	O
the	O
NAD	O
ligand	O
interactions	O
,	O
respectively	O
.	O

Note	O
that	O
the	O
ligand	O
-	O
interaction	O
information	O
is	O
optional	O
and	O
in	O
this	O
work	O
we	O
have	O
not	O
used	O
it	O
.	O

The	O
incoming	O
and	O
outgoing	O
arcs	O
are	O
depicted	O
in	O
the	O
SSEs	O
(	O
top	O
and	O
bottom	O
of	O
the	O
beta	O
strands	O
)	O
,	O
where	O
red	O
and	O
green	O
arcs	O
represent	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
hydrogen	O
-	O
bond	O
interactions	O
that	O
show	O
beta	O
-	O
sheet	O
information	O
,	O
while	O
yellow	O
and	O
blue	O
arcs	O
indicate	O
the	O
right	O
and	O
left	O
chirality	O
relationships	O
between	O
the	O
SSEs	O
.	O

A	O
pink	O
arrow	O
between	O
the	O
TOPS+	O
strings	O
elements	O
indicates	O
the	O
conserved	O
SSE	O
.	O

The	O
dotted	O
arrows	O
indicate	O
the	O
conserved	O
alpha	O
helices	O
and	O
beta	O
strands	O
,	O
while	O
the	O
plain	O
arrows	O
indicate	O
the	O
conserved	O
loop	O
regions	O
.	O

TOPS++FATCAT	O
method	O
In	O
this	O
work	O
,	O
we	O
want	O
to	O
test	O
the	O
general	O
idea	O
of	O
pruning	O
the	O
search	O
space	O
of	O
the	O
FATCAT	O
comparison	O
process	O
using	O
topological	O
constraints	O
derived	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
.	O

Many	O
of	O
the	O
AFPs	O
considered	O
in	O
the	O
FATCAT	O
alignment	O
could	O
be	O
easily	O
eliminated	O
from	O
the	O
comparison	O
by	O
constraining	O
the	O
alignment	O
region	O
.	O

Here	O
we	O
explore	O
constraints	O
obtained	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
,	O
which	O
identifies	O
topologically	O
equivalent	O
secondary	O
structure	O
elements	O
(	O
alpha	O
helices	O
,	O
beta	O
strands	O
,	O
and	O
loops	O
)	O
for	O
this	O
purpose	O
.	O

Such	O
equivalences	O
define	O
blocks	O
that	O
restrict	O
the	O
alignment	O
region	O
;	O
AFPs	O
that	O
fall	O
outside	O
these	O
regions	O
are	O
simply	O
not	O
considered	O
(	O
see	O
Figure	O
4	O
(	O
b	O
)	O
)	O
.	O

We	O
introduce	O
a	O
parameter	O
r	O
to	O
control	O
the	O
strictness	O
of	O
constraints	O
by	O
TOPS+	O
strings	O
alignments	O
;	O
r	O
equals	O
0	O
if	O
the	O
alignment	O
region	O
is	O
strictly	O
restrained	O
by	O
TOPS+	O
strings	O
alignment	O
,	O
and	O
r	O
is	O
set	O
to	O
1	O
by	O
default	O
in	O
our	O
program	O
to	O
allow	O
certain	O
flexibility	O
to	O
the	O
constrained	O
alignment	O
region	O
(	O
Figure	O
4	O
(	O
c	O
)	O
)	O
.	O

We	O
then	O
can	O
speed	O
up	O
the	O
FATCAT	O
alignment	O
by	O
considering	O
only	O
the	O
AFPs	O
within	O
the	O
constrained	O
alignment	O
area	O
(	O
Figure	O
4	O
(	O
d	O
)	O
)	O
.	O

The	O
rigid	O
structural	O
alignment	O
can	O
be	O
treated	O
as	O
a	O
special	O
case	O
of	O
TOPS++FATCAT	O
,	O
in	O
which	O
no	O
twist	O
is	O
allowed	O
in	O
chaining	O
AFPs	O
.	O

However	O
,	O
the	O
TOPS++FATCAT	O
program	O
provides	O
alignment	O
in	O
both	O
,	O
""""	O
rigid	O
""""	O
mode	O
and	O
""""	O
flexible	O
""""	O
mode	O
(	O
default	O
)	O
.	O

Benchmarking	O
For	O
benchmarking	O
and	O
comparison	O
,	O
we	O
have	O
used	O
the	O
PDB40	O
dataset	O
of	O
1,901	O
protein	O
domain	O
pairs	O
(	O
DP	O
)	O
corresponding	O
to	O
SCOP	O
version	O
1.61	O
from	O
the	O
ASTRAL	O
database	O
[	O
29	O
]	O
.	O

Table	O
1	O
provides	O
the	O
SCOP	O
superfamily	O
level	O
homolog	O
versus	O
non	O
-	O
homolog	O
statistics	O
for	O
the	O
four	O
main	O
SCOP	O
classes	O
i.e.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha+beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
their	O
structural	O
classes	O
.	O

Evaluation	O
Analyses	O
We	O
performed	O
the	O
Receiver	O
Operating	O
Characteristics	O
(	O
ROC	O
)	O
curve	O
and	O
the	O
AUC	O
(	O
Area	O
Under	O
the	O
ROC	O
Curve	O
)	O
analyses	O
to	O
compare	O
the	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
with	O
the	O
original	O
FATCAT	O
method	O
,	O
using	O
SCOP	O
classification	O
at	O
the	O
superfamily	O
level	O
as	O
a	O
standard	O
of	O
comparison	O
[	O
30	O
]	O
.	O

Results	O
ROC	O
and	O
AUC	O
Analyses	O
We	O
have	O
compared	O
the	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
against	O
the	O
original	O
FATCAT	O
method	O
using	O
the	O
SCOP	O
classification	O
information	O
at	O
the	O
superfamily	O
level	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
based	O
on	O
P	O
-	O
values	O
obtained	O
from	O
the	O
FATCAT	O
and	O
the	O
TOPS++FATCAT	O
methods	O
.	O

We	O
have	O
plotted	O
the	O
ROC	O
curves	O
separately	O
for	O
the	O
main	O
SCOP	O
classes	O
,	O
i.e.	O
,	O
all	O
-	O
alpha	O
,	O
all	O
-	O
beta	O
,	O
alpha	O
/	O
beta	O
,	O
alpha+beta	O
,	O
and	O
all	O
proteins	O
regardless	O
of	O
the	O
class	O
they	O
belong	O
to	O
(	O
see	O
Figure	O
5	O
(	O
a	O
)	O
to	O
5	O
(	O
e	O
)	O
)	O
.	O

In	O
the	O
graph	O
,	O
the	O
x-	O
and	O
y	O
-	O
axes	O
represent	O
the	O
false	O
positive	O
and	O
true	O
positive	O
rates	O
of	O
the	O
performance	O
of	O
the	O
comparison	O
methods	O
respectively	O
.	O

In	O
the	O
legend	O
,	O
rF	O
-	O
pvalue	O
and	O
fF	O
-	O
pvalue	O
indicate	O
results	O
from	O
the	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
,	O
respectively	O
;	O
similarly	O
,	O
rT2F	O
-	O
pvalue	O
and	O
fT2F	O
-	O
pvalue	O
represent	O
the	O
rigid	O
and	O
flexible	O
TOPS++FATCAT	O
methods	O
,	O
respectively	O
.	O

We	O
have	O
calculated	O
the	O
AUC	O
values	O
for	O
all	O
the	O
SCOP	O
classes	O
based	O
on	O
ROC	O
curves	O
obtained	O
from	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
with	O
the	O
flexible	O
/	O
rigid	O
options	O
(	O
see	O
Table	O
2	O
)	O
.	O

For	O
all	O
protein	O
classes	O
,	O
the	O
rigid	O
FATCAT	O
performs	O
best	O
,	O
usually	O
followed	O
by	O
the	O
flexible	O
FATCAT	O
,	O
the	O
rigid	O
TOPS++FATCAT	O
,	O
and	O
the	O
flexible	O
TOPS++FATCAT	O
.	O

The	O
performance	O
of	O
all	O
four	O
methods	O
is	O
best	O
for	O
all	O
alpha	O
and	O
all	O
beta	O
proteins	O
,	O
and	O
all	O
four	O
perform	O
markedly	O
worse	O
(	O
but	O
similar	O
to	O
each	O
other	O
)	O
for	O
alpha	O
/	O
beta	O
proteins	O
.	O

Only	O
alpha+beta	O
proteins	O
show	O
a	O
clear	O
difference	O
between	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
the	O
TOPS+	O
strings	O
models	O
consider	O
the	O
parallel	O
and	O
anti	O
-	O
parallel	O
properties	O
of	O
the	O
beta	O
-	O
sheet	O
information	O
in	O
the	O
form	O
of	O
total	O
number	O
of	O
incoming	O
and	O
outgoing	O
arcs	O
with	O
their	O
ArcTypes	O
.	O

Thus	O
,	O
the	O
TOPS++FATCAT	O
method	O
discriminates	O
the	O
protein	O
domain	O
pairs	O
more	O
efficiently	O
compared	O
to	O
the	O
original	O
FATCAT	O
method	O
.	O

For	O
example	O
,	O
in	O
the	O
all	O
-	O
beta	O
protein	O
domain	O
pairs	O
,	O
both	O
the	O
flexible	O
and	O
the	O
rigid	O
TOPS++FATCAT	O
methods	O
perform	O
well	O
.	O

The	O
flexible	O
TOPS++FATCAT	O
method	O
covers	O
nearly	O
84	O
%	O
of	O
protein	O
domains	O
with	O
0	O
%	O
false	O
positives	O
,	O
but	O
the	O
flexible	O
and	O
rigid	O
FATCAT	O
methods	O
cover	O
only	O
76	O
%	O
and	O
49	O
%	O
of	O
the	O
true	O
positives	O
,	O
respectively	O
,	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
zoomed	O
-	O
in	O
version	O
of	O
the	O
ROC	O
curves	O
with	O
up	O
to	O
10	O
%	O
false	O
positives	O
for	O
all	O
-	O
beta	O
rich	O
protein	O
families	O
is	O
shown	O
in	O
Figure	O
5	O
(	O
f	O
)	O
;	O
where	O
both	O
the	O
rigid	O
TOPS++FATCAT	O
(	O
green	O
)	O
and	O
flexible	O
(	O
red	O
)	O
TOPS++FATCAT	O
methods	O
have	O
coverage	O
rates	O
of	O
82	O
%	O
and	O
84	O
%	O
true	O
positives	O
respectively	O
with	O
0	O
%	O
false	O
positives	O
.	O

The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS++FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3%–7	O
%	O
AUC	O
value	O
difference	O
(	O
see	O
Table	O
2	O
)	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10-fold	O
speedup	O
(	O
see	O
next	O
section	O
)	O
.	O

AFP	O
and	O
Runtime	O
Analyses	O
We	O
tested	O
both	O
the	O
FATCAT	O
and	O
TOPS++FATCAT	O
methods	O
using	O
the	O
Mac	O
OS	O
X	O
version	O
10.4.10	O
computer	O
system	O
with	O
a	O
2	O
×	O
2.66-GHz	O
Dual	O
-	O
Core	O
Intel	O
Xeon	O
processor	O
and	O
1-GB	O
667	O
MHz	O
memory	O
.	O

We	O
have	O
performed	O
runtime	O
analysis	O
on	O
1,901	O
protein	O
domain	O
pairs	O
and	O
counted	O
the	O
total	O
number	O
of	O
AFPs	O
and	O
the	O
corresponding	O
runtime	O
from	O
both	O
the	O
FATCAT	O
and	O
the	O
TOPS++FATCAT	O
methods	O
.	O

The	O
results	O
show	O
an	O
exponential	O
increase	O
in	O
AFPs	O
(	O
Figure	O
6	O
(	O
b	O
)	O
)	O
and	O
corresponding	O
runtime	O
(	O
Figure	O
6	O
(	O
a	O
)	O
)	O
for	O
the	O
FATCAT	O
method	O
as	O
compared	O
to	O
the	O
TOPS++FATCAT	O
method	O
(	O
see	O
Table	O
3	O
)	O
For	O
example	O
,	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
TOPS++FATCAT	O
method	O
is	O
530	O
,	O
but	O
the	O
average	O
number	O
of	O
AFPs	O
for	O
the	O
FATCAT	O
method	O
is	O
15,019	O
.	O

This	O
represents	O
the	O
number	O
of	O
average	O
AFPs	O
used	O
by	O
the	O
FATCAT	O
method	O
is	O
increased	O
by	O
a	O
factor	O
of	O
28	O
(	O
see	O
Table	O
3	O
)	O
.	O

This	O
result	O
leads	O
to	O
the	O
conclusion	O
that	O
TOPS++FATCAT	O
is	O
22	O
times	O
faster	O
compared	O
to	O
the	O
FATCAT	O
because	O
this	O
method	O
must	O
take	O
into	O
account	O
more	O
number	O
of	O
AFPs	O
in	O
the	O
comparison	O
process	O
(	O
see	O
Table	O
3	O
)	O
.	O

Case	O
Studies	O
While	O
the	O
overall	O
accuracy	O
of	O
both	O
rigid	O
and	O
flexible	O
FATCAT	O
methods	O
is	O
better	O
than	O
their	O
TOPS++FATCAT	O
equivalents	O
,	O
an	O
interesting	O
example	O
where	O
the	O
opposite	O
is	O
true	O
lies	O
in	O
the	O
comparison	O
of	O
two	O
proteins	O
,	O
d2trxa	O
_	O
(	O
108	O
aa	O
)	O
from	O
Escherichia	B
coli	I
and	O
d1kte	O
_	O
_	O
(	O
105	O
aa	O
)	O
from	O
Sus	B
scrofa	I
(	O
pig	B
)	O
from	O
the	O
thioredoxin	O
-	O
like	O
superfamily	O
.	O

For	O
this	O
pair	O
,	O
the	O
flexible_TOPS++FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
88	O
equivalent	O
positions	O
with	O
1.67	O
Å	O
chain	O
RMSD	O
and	O
3.06	O
Å	O
of	O
optimal	O
RMSD	O
without	O
any	O
twist	O
,	O
giving	O
the	O
alignment	O
with	O
10	O
%	O
sequence	O
identity	O
(	O
see	O
Table	O
4	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
flexible_FATCAT	O
method	O
provides	O
an	O
alignment	O
with	O
86	O
aligned	O
positions	O
using	O
a	O
twist	O
in	O
the	O
C	O
-	O
terminal	O
region	O
;	O
it	O
has	O
a	O
higher	O
chain	O
RMSD	O
of	O
5.14	O
Å	O
,	O
and	O
its	O
optimal	O
RMSD	O
is	O
3.48	O
Å.	O
For	O
more	O
information	O
regarding	O
the	O
chain	O
and	O
optimal	O
RMSDs	O
refer	O
[	O
5	O
]	O
.	O

The	O
flexible_FATCAT	O
method	O
uses	O
the	O
twist	O
to	O
align	O
a	O
helix	O
in	O
the	O
C	O
-	O
terminal	O
region	O
,	O
which	O
is	O
positioned	O
incorrectly	O
with	O
a	O
beta	O
-	O
sheet	O
core	O
(	O
see	O
Table	O
4	O
)	O
.	O

Figure	O
7	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d2trxa	O
_	O
(	O
gray	O
)	O
and	O
d1kte	O
_	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible_FATCAT	O
method	O
,	O
where	O
the	O
blue	O
color	O
indicates	O
the	O
d1kte	O
_	O
_	O
protein	O
domain	O
from	O
the	O
flexible_TOPS++FATCAT	O
method	O
.	O

The	O
incorrect	O
alignment	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
alpha	O
helix	O
of	O
the	O
d1kte	O
_	O
_	O
domain	O
(	O
orange	O
)	O
is	O
visible	O
in	O
the	O
core	O
of	O
the	O
beta	O
-	O
sheet	O
region	O
.	O

Figure	O
7	O
(	O
b	O
)	O
and	O
7	O
(	O
c	O
)	O
shows	O
the	O
AFPs	O
from	O
the	O
flexible_FATCAT	O
and	O
flexible_TOPS++FATCAT	O
methods	O
,	O
respectively	O
.	O

The	O
hinge	O
region	O
provides	O
a	O
twist	O
in	O
the	O
flexible_FATCAT	O
method	O
indicated	O
by	O
an	O
arrow	O
and	O
the	O
AFPs	O
represented	O
by	O
a	O
different	O
color	O
(	O
see	O
Figure	O
7	O
(	O
b	O
)	O
)	O
.	O

In	O
this	O
case	O
,	O
the	O
alignment	O
constraints	O
from	O
the	O
TOPS+	O
strings	O
alignment	O
allow	O
the	O
TOPS++FATCAT	O
method	O
to	O
avoid	O
a	O
spurious	O
alignment	O
.	O

The	O
Erythrocruorin	O
protein	O
domain	O
d1eca	O
_	O
_	O
(	O
136	O
aa	O
)	O
from	O
Chironomus	B
thummi	I
and	O
the	O
Phycocyanin	O
alpha	O
subunit	O
protein	O
domain	O
d1cpca	O
_	O
(	O
162	O
aa	O
)	O
from	O
Fremyella	B
diplosiphon	I
(	O
Cyanobacterium	O
)	O
belong	O
to	O
the	O
Globin	O
-	O
like	O
superfamily	O
.	O

For	O
these	O
protein	O
domain	O
pairs	O
,	O
the	O
FATCAT	O
method	O
provides	O
a	O
better	O
alignment	O
with	O
120	O
and	O
118	O
aligned	O
positions	O
with	O
the	O
chain	O
RMSD	O
of	O
4.02	O
Å	O
based	O
on	O
the	O
flexible	O
and	O
rigid	O
options	O
,	O
respectively	O
.	O

The	O
flexible_TOPS++FATCAT	O
method	O
gives	O
an	O
alignment	O
of	O
63	O
aligned	O
positions	O
with	O
the	O
3.23	O
Å	O
optimal	O
RMSD	O
and	O
the	O
6.28	O
Å	O
chain	O
RMSD	O
.	O

In	O
this	O
case	O
,	O
the	O
flexible_TOPS++FATCAT	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
helix	O
and	O
misaligns	O
some	O
helices	O
.	O

For	O
example	O
,	O
Figure	O
8	O
(	O
a	O
)	O
shows	O
the	O
superposition	O
of	O
d1eca	O
_	O
_	O
(	O
gray	O
)	O
and	O
d1cpca	O
_	O
(	O
orange	O
)	O
domains	O
from	O
the	O
flexible_FATCAT	O
method	O
,	O
while	O
d1cpca	O
_	O
(	O
blue	O
)	O
domain	O
is	O
from	O
the	O
flexible_TOPS++FATCAT	O
method	O
.	O

The	O
AFP	O
chaining	O
alignment	O
and	O
the	O
actual	O
alignment	O
from	O
FATCAT	O
are	O
shown	O
in	O
Figure	O
8	O
(	O
b	O
)	O
and	O
8	O
(	O
e	O
)	O
,	O
respectively	O
.	O

Figure	O
8	O
(	O
c	O
)	O
shows	O
the	O
AFP	O
alignment	O
from	O
TOPS++FATCAT	O
,	O
in	O
which	O
this	O
method	O
misses	O
the	O
N	O
-	O
terminal	O
region	O
and	O
incorrectly	O
aligns	O
some	O
of	O
the	O
C	O
-	O
terminal	O
regions	O
(	O
see	O
Figure	O
8	O
(	O
d	O
)	O
)	O
.	O

However	O
,	O
the	O
rigid_TOPS++FATCAT	O
method	O
produces	O
an	O
alignment	O
of	O
108	O
aligned	O
positions	O
with	O
optimal	O
and	O
chain	O
RMSDs	O
of	O
3.22	O
Å	O
and	O
6.28	O
Å	O
respectively	O
.	O

In	O
general	O
,	O
TOPS	O
comparison	O
does	O
not	O
work	O
well	O
for	O
alpha	O
-	O
rich	O
proteins	O
due	O
to	O
the	O
lack	O
of	O
hydrogen	O
bonds	O
between	O
SSEs	O
[	O
26	O
]	O
.	O

The	O
same	O
is	O
true	O
for	O
TOPS+	O
strings	O
comparison	O
to	O
some	O
extent	O
;	O
however	O
,	O
this	O
method	O
takes	O
advantage	O
of	O
ligand	O
-	O
interaction	O
information	O
to	O
compare	O
protein	O
domains	O
more	O
efficiently	O
;	O
for	O
example	O
the	O
DNA	O
binding	O
motifs	O
such	O
as	O
helix	O
-	O
turn	O
-	O
helix	O
and	O
helix	O
-	O
loop	O
-	O
helix	O
can	O
be	O
easily	O
recognized	O
[	O
28	O
]	O
.	O

However	O
,	O
we	O
have	O
not	O
explored	O
that	O
ligand	O
pattern	O
discovery	O
option	O
within	O
the	O
TOPS+	O
strings	O
comparison	O
in	O
this	O
paper	O
.	O

In	O
addition	O
,	O
the	O
TOPS+	O
strings	O
alignment	O
provides	O
only	O
a	O
basic	O
alignment	O
;	O
the	O
scoring	O
function	O
to	O
find	O
the	O
best	O
alignment	O
has	O
not	O
been	O
optimized	O
.	O

These	O
problems	O
can	O
be	O
addressed	O
in	O
future	O
development	O
by	O
considering	O
the	O
advanced	O
TOPS+	O
and	O
TOPS+	O
strings	O
models	O
based	O
on	O
helix	O
-	O
helix	O
packing	O
relationships	O
and	O
SSE	O
-	O
ligand	O
interaction	O
properties	O
together	O
with	O
the	O
right	O
and	O
left	O
chiralities	O
.	O

Furthermore	O
,	O
the	O
TOPS+	O
strings	O
comparison	O
can	O
be	O
optimized	O
in	O
both	O
the	O
comparison	O
process	O
as	O
well	O
as	O
in	O
the	O
alignment	O
process	O
in	O
order	O
to	O
take	O
into	O
account	O
indels	O
(	O
insertion	O
/	O
deletion	O
)	O
of	O
SSEs	O
which	O
exist	O
in	O
nature	O
across	O
the	O
different	O
members	O
of	O
the	O
protein	O
superfamilies	O
[	O
31	O
]	O
.	O

Discussion	O
and	O
conclusion	O
The	O
overall	O
results	O
for	O
all	O
protein	O
classes	O
show	O
that	O
TOPS++FATCAT	O
performance	O
is	O
only	O
slightly	O
lower	O
(	O
3%–7	O
%	O
AUC	O
value	O
difference	O
)	O
as	O
compared	O
to	O
FATCAT	O
while	O
providing	O
a	O
significant	O
,	O
more	O
than	O
10-fold	O
speedup	O
.	O

The	O
main	O
reason	O
for	O
the	O
discrepancies	O
is	O
that	O
TOPS+	O
strings	O
alignments	O
occasionally	O
misalign	O
the	O
secondary	O
structure	O
elements	O
and	O
subsequent	O
FATCAT	O
alignment	O
,	O
constrained	O
by	O
the	O
TOPS+	O
strings	O
alignment	O
,	O
can	O
not	O
overcome	O
the	O
earlier	O
errors	O
.	O

There	O
is	O
a	O
clear	O
trade	O
-	O
off	O
between	O
the	O
runtime	O
and	O
the	O
accuracy	O
;	O
limiting	O
the	O
pool	O
of	O
fragments	O
being	O
compared	O
speeds	O
up	O
the	O
algorithm	O
but	O
results	O
in	O
(	O
slightly	O
)	O
lower	O
accuracy	O
.	O

At	O
the	O
same	O
time	O
,	O
these	O
results	O
offer	O
clear	O
suggestions	O
for	O
future	O
development	O
.	O

Using	O
a	O
more	O
advanced	O
version	O
of	O
the	O
TOPS+	O
strings	O
comparison	O
method	O
would	O
remove	O
some	O
of	O
the	O
false	O
positives	O
might	O
be	O
at	O
a	O
cost	O
of	O
significantly	O
slowing	O
the	O
total	O
performance	O
of	O
the	O
TOPS++FATCAT	O
method	O
.	O

Authors	O
'	O
contributions	O
MV	O
developed	O
the	O
TOPS++FATCAT	O
algorithm	O
,	O
performed	O
the	O
calculations	O
and	O
prepared	O
the	O
figures	O
,	O
YY	O
provided	O
advice	O
and	O
oversight	O
in	O
the	O
project	O
,	O
verified	O
the	O
code	O
and	O
provided	O
FATCAT	O
results	O
for	O
comparison	O
,	O
AG	O
contributed	O
to	O
the	O
original	O
idea	O
and	O
to	O
writing	O
of	O
the	O
manuscript	O
.	O

A	O
life	O
threatening	O
uterine	O
inversion	O
and	O
massive	O
post	O
partum	O
hemorrhage	O
caused	O
by	O
placenta	O
accrete	O
during	O
Caesarean	O
section	O
in	O
a	O
primigravida	O
:	O
a	O
case	O
report	O
Abstract	O
Background	O
A	O
32-year	O
-	O
old	O
Caucasian	O
primigravida	O
was	O
admitted	O
for	O
elective	O
Caesarean	O
Section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

Case	O
presentation	O
Traction	O
of	O
the	O
umbilical	O
cord	O
after	O
delivery	O
of	O
a	O
healthy	O
baby	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Piecemeal	O
excision	O
of	O
the	O
placenta	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
was	O
then	O
performed	O
.	O

Conclusion	O
In	O
this	O
way	O
we	O
were	O
able	O
to	O
control	O
a	O
massive	O
post	O
partum	O
hemorrhage	O
and	O
preserve	O
the	O
fertility	O
of	O
the	O
patient	O
.	O

Background	O
Placenta	O
accreta	O
is	O
defined	O
as	O
abnormal	O
adherence	O
,	O
either	O
in	O
whole	O
or	O
in	O
part	O
of	O
the	O
afterbirth	O
to	O
the	O
underlying	O
uterine	O
wall	O
.	O

Placenta	O
accreta	O
and	O
other	O
pathological	O
placentations	O
(	O
such	O
as	O
increta	O
,	O
percreta	O
)	O
are	O
rare	O
complications	O
of	O
pregnancy	O
with	O
potential	O
life	O
threatening	O
and	O
fertility	O
threatening	O
consequences	O
.	O

The	O
incidence	O
of	O
placenta	O
accreta	O
has	O
increased	O
ten	O
times	O
over	O
the	O
last	O
fifteen	O
years	O
,	O
which	O
reflects	O
the	O
increase	O
in	O
the	O
rate	O
of	O
Caesarean	O
Sections	O
(	O
CS	O
)	O
[	O
1	O
]	O
.	O

Placenta	O
accreta	O
has	O
become	O
the	O
most	O
important	O
cause	O
of	O
peripartum	O
hysterectomy	O
.	O

A	O
life	O
threatening	O
acute	O
uterine	O
inversion	O
and	O
massive	O
PPH	O
can	O
be	O
caused	O
by	O
placenta	O
accreta	O
during	O
CS	O
but	O
seldom	O
in	O
a	O
primigravida	O
(	O
Figure	O
1	O
)	O
.	O

Case	O
presentation	O
A	O
32	O
year	O
old	O
,	O
primigravida	O
,	O
was	O
admitted	O
in	O
a	O
District	O
General	O
Hospital	O
for	O
elective	O
Caesarean	O
section	O
at	O
36	O
weeks	O
and	O
6	O
days	O
with	O
the	O
diagnosis	O
of	O
preeclampsia	O
.	O

She	O
had	O
two	O
antenatal	O
ultrasound	O
examinations	O
showing	O
a	O
healthy	O
fetus	O
and	O
posterior	O
fundal	O
placenta	O
.	O

The	O
patient	O
had	O
lower	O
segment	O
CS	O
of	O
a	O
healthy	O
male	O
infant	O
under	O
spinal	O
anesthesia	O
.	O

The	O
placenta	O
was	O
found	O
to	O
be	O
densely	O
adherent	O
to	O
the	O
posterior	O
uterine	O
wall	O
.	O

Traction	O
of	O
the	O
umbilical	O
cord	O
was	O
applied	O
and	O
subsequently	O
resulted	O
in	O
uterine	O
inversion	O
.	O

The	O
placenta	O
was	O
removed	O
by	O
'	O
piecemeal	O
'	O
excising	O
as	O
close	O
as	O
possible	O
to	O
the	O
uterine	O
lining	O
.	O

About	O
80	O
%	O
of	O
the	O
placental	O
tissue	O
was	O
removed	O
until	O
the	O
uterine	O
inversion	O
was	O
corrected	O
.	O

The	O
uterus	O
was	O
closed	O
in	O
two	O
layers	O
.	O

Two	O
intra	O
-	O
abdominal	O
drains	O
were	O
sited	O
.	O

The	O
estimated	O
blood	O
loss	O
was	O
2.5	O
litres	O
and	O
five	O
units	O
of	O
blood	O
were	O
transfused	O
together	O
with	O
2	O
units	O
of	O
FFP	O
during	O
intra	O
-	O
operative	O
and	O
post	O
-	O
operative	O
period	O
.	O

In	O
addition	O
,	O
the	O
patient	O
was	O
treated	O
with	O
intravenous	O
oxytocin	O
infusion	O
,	O
pr	O
misoprostol	O
and	O
antibiotics	O
.	O

On	O
the	O
second	O
post	O
partum	O
day	O
,	O
vaginal	O
Doppler	O
ultrasound	O
scan	O
showed	O
significant	O
amount	O
of	O
placental	O
tissues	O
with	O
increased	O
vascularity	O
measuring	O
2.7	O
×	O
6.6	O
×	O
6.8	O
cms	O
within	O
the	O
endometrial	O
cavity	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
was	O
discharged	O
on	O
the	O
fifth	O
post	O
-	O
operative	O
day	O
with	O
a	O
conservative	O
management	O
.	O

A	O
follow	O
up	O
Ultrasound	O
scan	O
after	O
two	O
weeks	O
showed	O
reduction	O
of	O
placental	O
mass	O
(	O
Figure	O
3	O
)	O
.	O

In	O
addition	O
,	O
there	O
was	O
significant	O
decrease	O
in	O
serum	O
beta	O
HCG	O
levels	O
from	O
2300	O
u	O
/	O
L	O
on	O
day	O
1	O
to	O
13	O
u	O
/	O
L	O
at	O
four	O
weeks	O
post	O
operatively	O
.	O

The	O
patient	O
remained	O
with	O
minimal	O
vaginal	O
bleeding	O
without	O
abdominal	O
pain	O
.	O

She	O
had	O
two	O
normal	O
periods	O
after	O
stopping	O
breastfeeding	O
and	O
was	O
feeling	O
well	O
.	O

She	O
was	O
discharged	O
from	O
the	O
early	O
pregnancy	O
unit	O
.	O

Discussion	O
A	O
life	O
-	O
threatening	O
uterine	O
inversion	O
can	O
be	O
rarely	O
caused	O
by	O
placenta	O
accreta	O
[	O
2	O
]	O
.	O

Placenta	O
accreta	O
classically	O
presents	O
with	O
retained	O
placenta	O
and	O
hemorrhage	O
.	O

The	O
association	O
between	O
uterine	O
inversion	O
and	O
placenta	O
accreta	O
is	O
unclear	O
,	O
however	O
,	O
strong	O
traction	O
on	O
the	O
umbilical	O
cord	O
with	O
fundal	O
placenta	O
,	O
excessive	O
fundal	O
pressure	O
,	O
relaxed	O
uterus	O
,	O
short	O
umbilical	O
cord	O
,	O
uterine	O
anomalies	O
and	O
antepartum	O
use	O
of	O
magnesium	O
sulphate	O
are	O
known	O
associated	O
factors	O
[	O
2	O
]	O
.	O

Uterine	O
inversion	O
and	O
retain	O
placenta	O
accreta	O
can	O
both	O
be	O
fatal	O
complications	O
[	O
3	O
]	O
.	O

In	O
the	O
case	O
described	O
the	O
placenta	O
accreta	O
was	O
complicated	O
by	O
uterine	O
inversion	O
and	O
subsequent	O
massive	O
post	O
partum	O
hemorrhage	O
,	O
significantly	O
increasing	O
the	O
risk	O
of	O
maternal	O
mortality	O
.	O

Massive	O
post	O
partum	O
hemorrhage	O
is	O
a	O
major	O
cause	O
of	O
maternal	O
mortality	O
in	O
the	O
United	O
Kingdom	O
(	O
why	O
women	O
die	O
latest	O
report	O
)	O
[	O
4	O
]	O
.	O

In	O
this	O
case	O
,	O
the	O
placenta	O
was	O
clamped	O
as	O
close	O
to	O
the	O
uterine	O
cavity	O
as	O
possible	O
and	O
cut	O
.	O

The	O
base	O
of	O
the	O
placenta	O
was	O
overrun	O
with	O
haemostatic	O
sutures	O
and	O
this	O
was	O
repeated	O
until	O
as	O
much	O
of	O
the	O
placenta	O
as	O
possible	O
was	O
removed	O
(	O
Figure	O
4	O
)	O
.	O

Placental	O
removal	O
enabled	O
correction	O
of	O
uterine	O
inversion	O
.	O

Despite	O
the	O
many	O
conditions	O
associated	O
with	O
uterine	O
inversion	O
risk	O
assessment	O
is	O
often	O
lacking	O
making	O
the	O
condition	O
usually	O
unexpected	O
at	O
the	O
time	O
of	O
presentation	O
.	O

The	O
association	O
between	O
abnormal	O
placentation	O
such	O
as	O
placenta	O
accreta	O
and	O
uterine	O
inversion	O
is	O
well	O
supported	O
[	O
2	O
]	O
.	O

Therefore	O
,	O
we	O
advocate	O
antenatal	O
evaluation	O
and	O
risk	O
assessment	O
for	O
placenta	O
accreta	O
[	O
5	O
]	O
.	O

Prenatal	O
Ultrasound	O
reported	O
sensitivity	O
of	O
94	O
%	O
and	O
specificity	O
of	O
79	O
%	O
for	O
placenta	O
accreta	O
,	O
but	O
offer	O
no	O
more	O
than	O
provisional	O
diagnostic	O
probability	O
statement	O
[	O
6	O
]	O
.	O

Moreover	O
,	O
because	O
45	O
%	O
of	O
placenta	O
accreta	O
cases	O
were	O
not	O
detected	O
by	O
ultrasound	O
,	O
it	O
is	O
important	O
to	O
consider	O
avoiding	O
manual	O
removal	O
of	O
placenta	O
if	O
there	O
were	O
intraoperative	O
signs	O
of	O
accreta	O
[	O
6	O
]	O
.	O

If	O
clinically	O
or	O
sonographically	O
the	O
patient	O
is	O
suspected	O
antenatally	O
to	O
be	O
at	O
risk	O
of	O
placenta	O
accreta	O
,	O
appropriate	O
management	O
options	O
should	O
be	O
considered	O
,	O
such	O
as	O
attempted	O
conservative	O
management	O
or	O
hysterectomy	O
and	O
counseling	O
provided	O
about	O
potential	O
sequelae	O
[	O
6	O
]	O
.	O

The	O
traditional	O
management	O
is	O
abdominal	O
hysterectomy	O
,	O
but	O
this	O
operation	O
terminates	O
fertility	O
and	O
may	O
have	O
devastating	O
psychological	O
effects	O
.	O

However	O
,	O
in	O
correct	O
circumstances	O
,	O
a	O
conservative	O
approach	O
may	O
be	O
suitable	O
.	O

Conservative	O
management	O
of	O
abnormally	O
invasive	O
placentation	O
can	O
be	O
effective	O
and	O
fertility	O
can	O
be	O
preserved	O
.	O

It	O
should	O
be	O
only	O
considered	O
in	O
highly	O
selected	O
cases	O
when	O
blood	O
loss	O
is	O
minimal	O
and	O
there	O
is	O
wish	O
for	O
fertility	O
preservation	O
[	O
7	O
]	O
.	O

For	O
women	O
who	O
want	O
to	O
preserve	O
their	O
fertility	O
the	O
placenta	O
should	O
be	O
left	O
intact	O
if	O
possible	O
after	O
caesarean	O
delivery	O
as	O
this	O
approach	O
lowers	O
the	O
risk	O
of	O
subsequent	O
hysterectomy	O
from	O
85	O
%	O
to	O
15	O
%	O
.	O

For	O
women	O
who	O
have	O
completed	O
their	O
family	O
,	O
hysterectomy	O
with	O
placenta	O
left	O
in	O
situ	O
is	O
preferable	O
to	O
lower	O
the	O
maternal	O
morbidity	O
rates	O
[	O
6	O
]	O
.	O

This	O
case	O
report	O
involved	O
conservative	O
management	O
.	O

Peripartum	O
hysterectomy	O
was	O
avoided	O
and	O
the	O
aim	O
was	O
to	O
preserve	O
fertility	O
.	O

Prophylactic	O
antibiotics	O
,	O
post	O
partum	O
oxytocics	O
and	O
the	O
use	O
of	O
misoprostol	O
post	O
operatively	O
helped	O
to	O
prevent	O
further	O
post	O
partum	O
hemorrhage	O
.	O

When	O
a	O
patient	O
isinitially	O
opted	O
for	O
conservative	O
management	O
,	O
the	O
possibility	O
of	O
recurrence	O
should	O
be	O
discussed	O
[	O
8	O
]	O
.	O

Furthermore	O
,	O
placentation	O
should	O
be	O
carefully	O
monitored	O
for	O
recurrence	O
in	O
any	O
subsequent	O
pregnancy	O
,	O
particularly	O
if	O
the	O
placenta	O
is	O
located	O
at	O
the	O
same	O
site	O
as	O
the	O
previous	O
placenta	O
accreta	O
.	O

Conservative	O
treatment	O
for	O
placenta	O
accreta	O
may	O
be	O
an	O
alternative	O
procedure	O
in	O
some	O
selected	O
cases	O
.	O

Conclusion	O
We	O
suggest	O
an	O
alternative	O
approach	O
for	O
managing	O
uterine	O
inversion	O
caused	O
by	O
placenta	O
accreta	O
that	O
involved	O
conservative	O
management	O
.	O

This	O
way	O
hysterectomy	O
was	O
avoided	O
and	O
fertility	O
was	O
preserved	O
.	O

Abbreviations	O
CS	O
:	O
Caesarean	O
Section	O
;	O
FFP	O
:	O

Fresh	O
Frozen	O
Plasma	O
Consent	O
Written	O
informed	O
consent	O
was	O
obtained	O
from	O
the	O
patient	O
for	O
publication	O
of	O
this	O
case	O
report	O
and	O
accompanying	O
images	O
.	O

A	O
copy	O
of	O
the	O
written	O
consent	O
is	O
available	O
for	O
review	O
by	O
the	O
Editor	O
–	O
in	O
Chief	O
of	O
this	O
journal	O
.	O

Competing	O
interests	O
The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
All	O
authors	O
have	O
made	O
substantial	O
contribution	O
to	O
concept	O
this	O
case	O
report	O
.	O

Neurogenin2	O
Directs	O
Granule	O
Neuroblast	O
Production	O
and	O
Amplification	O
while	O
NeuroD1	O
Specifies	O
Neuronal	O
Fate	O
during	O
Hippocampal	O
Neurogenesis	O
Abstract	O
The	O
specification	O
and	O
differentiation	O
of	O
dentate	O
gyrus	O
granule	O
neurons	O
in	O
the	O
hippocampus	O
require	O
temporally	O
and	O
spatially	O
coordinated	O
actions	O
of	O
both	O
intrinsic	O
and	O
extrinsic	O
molecules	O
.	O

The	O
basic	O
helix	O
-	O
loop	O
-	O
helix	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
and	O
NeuroD1	O
are	O
key	O
regulators	O
in	O
these	O
processes	O
.	O

Based	O
on	O
existing	O
classification	O
,	O
we	O
analyzed	O
the	O
molecular	O
events	O
occurring	O
during	O
hippocampal	O
neurogenesis	O
,	O
primarily	O
focusing	O
on	O
juvenile	O
animals	O
.	O

We	O
found	O
that	O
Ngn2	O
is	O
transiently	O
expressed	O
by	O
late	O
type-2a	O
amplifying	O
progenitors	O
.	O

The	O
Ngn2	O
progenies	O
mature	O
into	O
hippocampal	O
granule	O
neurons	O
.	O

Interestingly	O
,	O
the	O
loss	O
of	O
Ngn2	O
at	O
early	O
stages	O
of	O
development	O
leads	O
to	O
a	O
robust	O
reduction	O
in	O
neurogenesis	O
,	O
but	O
does	O
not	O
disturb	O
granule	O
neuron	O
maturation	O
per	O
se	O
.	O

We	O
found	O
that	O
the	O
role	O
of	O
Ngn2	O
is	O
to	O
maintain	O
progenitors	O
in	O
an	O
undifferentiated	O
state	O
,	O
allowing	O
them	O
to	O
amplify	O
prior	O
to	O
their	O
maturation	O
into	O
granule	O
neurons	O
upon	O
NeuroD1	O
induction	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
and	O
NeuroD1	O
in	O
vivo	O
,	O
we	O
found	O
NeuroD1	O
to	O
exhibit	O
a	O
more	O
pronounced	O
neuron	O
-	O
inductive	O
effect	O
,	O
leading	O
to	O
granule	O
neuron	O
commitment	O
,	O
than	O
that	O
displayed	O
by	O
Ngn2	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
all	O
markers	O
expressed	O
during	O
the	O
transcriptional	O
control	O
of	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
also	O
present	O
in	O
the	O
human	B
hippocampus	O
.	O

Taken	O
together	O
,	O
we	O
demonstrate	O
a	O
critical	O
role	O
of	O
for	O
Ngn2	O
and	O
NeuroD1	O
in	O
controlling	O
neuronal	O
commitment	O
and	O
hippocampal	O
granule	O
neuroblast	O
formation	O
,	O
both	O
during	O
embryonic	O
development	O
and	O
in	O
post	O
-	O
natal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Introduction	O
Neurons	O
are	O
born	O
not	O
only	O
during	O
development	O
of	O
the	O
central	O
nervous	O
system	O
,	O
but	O
neurogenesis	O
also	O
continues	O
into	O
adulthood	O
.	O

In	O
both	O
rodent	B
and	O
human	B
adult	O
brain	O
,	O
neurogenesis	O
is	O
active	O
in	O
two	O
distinct	O
zones	O
of	O
the	O
forebrain	O
:	O
the	O
subventricular	O
zone	O
(	O
SVZ	O
)	O
of	O
the	O
lateral	O
ventricle	O
and	O
the	O
subgranular	O
zone	O
(	O
SGZ	O
)	O
of	O
the	O
hippocampal	O
dentate	O
gyrus	O
(	O
DG	O
)	O
[	O
1	O
]	O
–	O
[	O
5	O
]	O
.	O

The	O
molecular	O
mechanism	O
underlying	O
neurogenesis	O
in	O
the	O
DG	O
is	O
not	O
fully	O
understood	O
.	O

Clearly	O
,	O
a	O
cascade	O
of	O
transcriptional	O
events	O
controls	O
the	O
specification	O
of	O
neuronal	O
identity	O
in	O
the	O
DG	O
[	O
3	O
]	O
,	O
[	O
6	O
]	O
–	O
[	O
8	O
]	O
,	O
but	O
details	O
of	O
the	O
expression	O
pattern	O
and	O
function	O
of	O
each	O
transcription	O
factor	O
remain	O
elusive	O
.	O

The	O
paired	O
-	O
box	O
homeodomain	O
transcription	O
factor	O
Pax6	O
and	O
the	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
NeuroD1	O
are	O
important	O
when	O
cells	O
acquire	O
a	O
pan	O
-	O
neuronal	O
character	O
and	O
a	O
specific	O
neuronal	O
subtype	O
[	O
9	O
]	O
,	O
[	O
10	O
]	O
.	O

In	O
the	O
developing	O
neocortex	O
,	O
Pax6	O
is	O
expressed	O
in	O
dividing	O
radial	O
glial	O
cells	O
at	O
the	O
ventricular	O
surface	O
[	O
9	O
]	O
.	O

In	O
the	O
adult	O
hippocampus	O
,	O
Pax6	O
is	O
expressed	O
in	O
astrocytes	O
in	O
the	O
SGZ	O
and	O
are	O
considered	O
to	O
be	O
the	O
true	O
stem	O
cells	O
[	O
9	O
]	O
,	O
[	O
11	O
]	O
.	O

Loss-	O
and	O
gain	O
-	O
of	O
-	O
function	O
studies	O
indicate	O
that	O
Pax6	O
is	O
involved	O
in	O
regulating	O
the	O
proliferation	O
of	O
neocortical	O
and	O
hippocampal	O
progenitors	O
[	O
9	O
]	O
,	O
[	O
12	O
]	O
–	O
[	O
16	O
]	O
.	O

During	O
neocorticogenesis	O
,	O
high	O
concentrations	O
of	O
Pax6	O
induce	O
the	O
expression	O
of	O
the	O
bHLH	O
transcription	O
factor	O
Neurogenin2	O
(	O
Ngn2	O
)	O
[	O
17	O
]	O
.	O

In	O
turn	O
,	O
Ngn2	O
causes	O
cell	O
cycle	O
exit	O
[	O
18	O
]	O
,	O
an	O
event	O
that	O
takes	O
place	O
when	O
NeuroD1	O
starts	O
to	O
be	O
expressed	O
[	O
19	O
]	O
.	O

In	O
the	O
developing	O
hippocampus	O
,	O
the	O
absence	O
of	O
Ngn2	O
leads	O
to	O
a	O
reduced	O
number	O
of	O
granule	O
neurons	O
[	O
20	O
]	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
essential	O
for	O
the	O
differentiation	O
and	O
survival	O
of	O
hippocampal	O
granule	O
neurons	O
[	O
10	O
]	O
.	O

Interestingly	O
,	O
in	O
the	O
absence	O
of	O
Ngn2	O
,	O
NeuroD1	O
can	O
still	O
be	O
activated	O
and	O
neuronal	O
differentiation	O
can	O
still	O
take	O
place	O
[	O
20	O
]	O
.	O

This	O
has	O
led	O
to	O
the	O
idea	O
that	O
the	O
primary	O
role	O
of	O
Ngn2	O
is	O
not	O
to	O
direct	O
neuronal	O
differentiation	O
.	O

Only	O
a	O
small	O
number	O
of	O
studies	O
have	O
addressed	O
the	O
role	O
of	O
Ngn2	O
and	O
NeuroD1	O
in	O
hippocampal	O
neurogenesis	O
[	O
10	O
]	O
,	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

Therefore	O
,	O
we	O
now	O
re	O
-	O
examine	O
their	O
roles	O
in	O
hippocampal	O
neurogenesis	O
in	O
detail	O
,	O
using	O
gain-	O
and	O
loss	O
-	O
of	O
-	O
function	O
experiments	O
.	O

We	O
first	O
establish	O
a	O
hierarchy	O
of	O
transcriptional	O
events	O
that	O
occur	O
during	O
neurogenesis	O
in	O
the	O
DG	O
and	O
then	O
define	O
the	O
place	O
that	O
Ngn2	O
,	O
NeuroD1	O
and	O
other	O
transcription	O
factors	O
have	O
in	O
this	O
cascade	O
.	O

We	O
find	O
that	O
a	O
lack	O
of	O
Ngn2	O
expression	O
result	O
in	O
a	O
markedly	O
smaller	O
hippocampus	O
and	O
an	O
almost	O
complete	O
absence	O
of	O
the	O
DG	O
.	O

We	O
show	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
.	O

Gain	O
-	O
of	O
-	O
function	O
of	O
NeuroD1	O
during	O
development	O
of	O
the	O
DG	O
results	O
in	O
an	O
efficient	O
generation	O
of	O
granule	O
neuroblasts	O
,	O
an	O
effect	O
that	O
we	O
do	O
not	O
observe	O
when	O
we	O
overexpress	O
Ngn2	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
cellular	O
markers	O
seen	O
in	O
mouse	B
and	O
rat	B
tissue	O
are	O
also	O
present	O
in	O
the	O
human	B
hippocampus	O
.	O

Results	O
Expression	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
define	O
different	O
phases	O
of	O
postnatal	O
hippocampal	O
granule	O
neuron	O
maturation	O
We	O
first	O
analyzed	O
in	O
detail	O
the	O
chronology	O
of	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cell	O
-	O
specific	O
markers	O
during	O
DG	O
granule	O
neuron	O
formation	O
and	O
correlated	O
our	O
findings	O
to	O
the	O
previously	O
established	O
classification	O
of	O
adult	O
hippocampal	O
neurogenesis	O
[	O
3	O
]	O
.	O

The	O
current	O
classification	O
describes	O
hippocampal	O
stem	O
cells	O
and	O
progenies	O
into	O
three	O
categories	O
(	O
type-1	O
,	O
-2	O
and	O
-3	O
cells	O
)	O
depending	O
on	O
the	O
markers	O
they	O
express	O
as	O
they	O
mature	O
.	O

In	O
the	O
adult	O
mouse	B
DG	O
,	O
only	O
a	O
very	O
small	O
proportion	O
of	O
cells	O
undergo	O
mitosis	O
at	O
any	O
one	O
given	O
time	O
[	O
22	O
]	O
.	O

Consequently	O
,	O
in	O
adult	O
animals	O
it	O
is	O
difficult	O
to	O
analyze	O
which	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
transition	O
phase	O
from	O
one	O
cell	O
category	O
to	O
the	O
next	O
.	O

Therefore	O
,	O
we	O
studied	O
2	O
week	O
-	O
old	O
rodents	O
which	O
have	O
higher	O
numbers	O
of	O
maturing	O
granule	O
neurons	O
in	O
the	O
DG	O
.	O

We	O
performed	O
triple	O
immunohistochemistry	O
for	O
all	O
markers	O
of	O
interest	O
and	O
compared	O
results	O
from	O
2	O
week-	O
and	O
2	O
month	O
-	O
old	O
mice	B
(	O
Figure	O
1	O
and	O
figure	O
S1	O
)	O
.	O

We	O
first	O
confirmed	O
that	O
stem	O
cells	O
in	O
the	O
SGZ	O
exhibit	O
characteristics	O
of	O
radial	O
glia	O
[	O
3	O
]	O
,	O
[	O
11	O
]	O
,	O
[	O
16	O
]	O
.	O

They	O
extend	O
radial	O
processes	O
from	O
the	O
SGZ	O
to	O
the	O
apex	O
of	O
the	O
subgranular	O
layer	O
(	O
SGL	O
)	O
and	O
the	O
basal	O
molecular	O
layer	O
.	O

Moreover	O
,	O
they	O
express	O
the	O
intermediate	O
filament	O
protein	O
nestin	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
and	O
glial	O
glutamate	O
transporter	O
(	O
GLAST	O
)	O
[	O
16	O
]	O
(	O
Figure	O
1A	O
and	O
B	O
and	O
figure	O
S1A	O
and	O
S1B	O
)	O
.	O

The	O
GFAP-	O
and	O
GLAST+	O
cells	O
are	O
defined	O
as	O
type-1	O
cells	O
[	O
3	O
]	O
.	O

They	O
also	O
express	O
the	O
paired	O
-	O
homeodomain	O
transcription	O
factor	O
Pax6	O
(	O
Figure	O
1B	O
)	O
.	O

These	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
divide	O
relatively	O
infrequently	O
,	O
and	O
are	O
believed	O
to	O
undergo	O
symmetric	O
division	O
(	O
giving	O
rise	O
to	O
two	O
identical	O
stem	O
cells	O
)	O
under	O
some	O
conditions	O
.	O

They	O
can	O
also	O
divide	O
asymmetrically	O
and	O
give	O
rise	O
to	O
a	O
new	O
stem	O
cell	O
and	O
one	O
neuronal	O
progenitor	O
,	O
which	O
usually	O
is	O
defined	O
as	O
a	O
type-2	O
cell	O
(	O
Figure	O
2B	O
)	O
[	O
3	O
]	O
.	O

Type-2	O
cells	O
are	O
divided	O
into	O
two	O
different	O
populations	O
:	O
type-2a	O
expressing	O
nestin	O
and	O
type-2b	O
co	O
-	O
expressing	O
nestin	O
and	O
doublecortin	O
(	O
Dcx	O
)	O
[	O
23	O
]	O
.	O

Based	O
on	O
a	O
previous	O
report	O
[	O
24	O
]	O
,	O
we	O
examined	O
the	O
expression	O
pattern	O
of	O
the	O
T	O
-	O
domain	O
transcription	O
factors	O
Tbr1	O
and	O
Tbr2	O
.	O

We	O
found	O
that	O
Tbr2	O
is	O
expressed	O
in	O
type-2a	O
cells	O
,	O
in	O
agreement	O
with	O
a	O
recent	O
report	O
[	O
25	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
mice	B
,	O
we	O
found	O
an	O
average	O
of	O
50–70	O
Tbr2	O
+	O
cells	O
per	O
30	O
µm	O
-	O
thick	O
section	O
throughout	O
the	O
rostro	O
-	O
caudal	O
axis	O
of	O
the	O
dorsal	O
hippocampus	O
.	O

This	O
number	O
was	O
reduced	O
by	O
35	O
%	O
in	O
2	O
month	O
-	O
old	O
mice	B
(	O
Figure	O
1C	O
with	O
figure	O
S1C	O
and	O
data	O
not	O
shown	O
)	O
.	O

As	O
opposed	O
to	O
Tbr1	O
(	O
Figure	O
1D	O
and	O
figure	O
S1D	O
)	O
,	O
Tbr2	O
+	O
cells	O
did	O
not	O
co	O
-	O
express	O
Dcx	O
or	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
1C	O
and	O
figure	O
S1C	O
)	O
.	O

We	O
observed	O
that	O
Tbr1-immuoreactivity	O
gradually	O
decreased	O
as	O
neurons	O
matured	O
and	O
started	O
to	O
express	O
NeuN	O
(	O
Figure	O
1H	O
and	O
figure	O
S1H	O
)	O
.	O

Thus	O
,	O
Tbr2	O
labels	O
type-2	O
cells	O
,	O
while	O
Tbr1	O
is	O
expressed	O
by	O
immature	O
granule	O
neurons	O
.	O

We	O
then	O
examined	O
the	O
molecular	O
phenotype	O
of	O
type-3	O
cells	O
,	O
a	O
cell	O
type	O
that	O
transiently	O
expresses	O
Calretinin	O
[	O
26	O
]	O
.	O

We	O
hypothesized	O
that	O
hippocampal	O
type-3	O
cells	O
might	O
also	O
express	O
the	O
bHLH	O
transcription	O
factor	O
NeuroD1	O
,	O
known	O
to	O
partially	O
overlap	O
with	O
Tbr2	O
and	O
Tbr1	O
in	O
different	O
brain	O
regions	O
[	O
24	O
]	O
.	O

We	O
found	O
that	O
NeuroD1	O
expression	O
in	O
the	O
hippocampus	O
starts	O
in	O
Tbr2	O
+	O
cells	O
and	O
extends	O
to	O
post	O
-	O
mitotic	O
Tbr1	O
+	O
cells	O
,	O
which	O
also	O
express	O
the	O
hippocampal	O
granule	O
identity	O
transcription	O
factor	O
Prox1	O
(	O
Figure	O
1	O
G	O
and	O
1I	O
and	O
figure	O
S1	O
G	O
and	O
S1I	O
)	O
.	O

While	O
Tbr1	O
expression	O
ceases	O
during	O
granule	O
maturation	O
,	O
that	O
of	O
NeuroD1	O
is	O
weakly	O
maintained	O
when	O
NeuN	O
expression	O
starts	O
(	O
Figure	O
1	O
G	O
and	O
1H	O
and	O
figure	O
S1	O
G	O
and	O
S1H	O
)	O
.	O

We	O
found	O
that	O
calretinin	O
expression	O
decreased	O
during	O
granule	O
neuron	O
maturation	O
,	O
before	O
NeuroD1	O
was	O
reduced	O
(	O
Figure	O
1F	O
)	O
.	O

Thus	O
NeuroD1	O
is	O
expressed	O
in	O
type-2b	O
and	O
type-3	O
cells	O
,	O
as	O
well	O
as	O
immature	O
granule	O
neurons	O
.	O

Finally	O
,	O
we	O
found	O
that	O
NeuroD2	O
starts	O
to	O
be	O
expressed	O
just	O
after	O
NeuroD1	O
and	O
,	O
unlike	O
NeuroD1	O
,	O
continues	O
to	O
be	O
highly	O
expressed	O
in	O
mature	O
neurons	O
(	O
Figure	O
1J	O
and	O
data	O
not	O
shown	O
)	O
.	O

Mash1	O
and	O
Ngn2	O
define	O
the	O
early	O
versus	O
late	O
type-2a	O
stage	O
in	O
2	O
weeks	O
old	O
mice	B
Having	O
established	O
the	O
hierarchy	O
of	O
transcription	O
factors	O
and	O
cellular	O
markers	O
appearing	O
during	O
hippocampal	O
neurogenesis	O
,	O
we	O
set	O
out	O
to	O
clarify	O
the	O
position	O
of	O
the	O
two	O
bHLH	O
transcription	O
factors	O
Ngn2	O
and	O
Mash1	O
,	O
in	O
this	O
process	O
.	O

We	O
found	O
that	O
more	O
than	O
90	O
%	O
of	O
Ngn2-immunoreactive	O
cells	O
are	O
Pax6	O
positive	O
(	O
Figure	O
2A	O
)	O
,	O
and	O
almost	O
all	O
co	O
-	O
express	O
Tbr2	O
(	O
Figure	O
2B	O
)	O
.	O

Thus	O
,	O
Ngn2	O
appears	O
to	O
be	O
expressed	O
by	O
type-2a	O
cells	O
.	O

As	O
our	O
antibodies	O
against	O
Ngn2	O
and	O
NeuroD1	O
were	O
made	O
in	O
the	O
same	O
species	O
,	O
we	O
could	O
not	O
determine	O
if	O
there	O
was	O
an	O
overlap	O
between	O
these	O
two	O
proteins	O
.	O

However	O
,	O
by	O
comparing	O
their	O
overlapping	O
expression	O
pattern	O
with	O
that	O
of	O
Tbr2	O
,	O
we	O
propose	O
that	O
some	O
Ngn2	O
+	O
cells	O
co	O
-	O
express	O
NeuroD1	O
,	O
and	O
that	O
they	O
appear	O
at	O
the	O
onset	O
of	O
NeuroD1	O
expression	O
and	O
downregulation	O
of	O
Ngn2	O
.	O

We	O
base	O
this	O
assumption	O
on	O
the	O
facts	O
that	O
more	O
than	O
50	O
%	O
of	O
the	O
Tbr2	O
+	O
cells	O
are	O
Ngn2	O
+	O
and	O
more	O
than	O
50	O
%	O
of	O
Tbr2	O
+	O
cells	O
also	O
express	O
NeuroD1	O
.	O

The	O
expression	O
of	O
Ngn2	O
in	O
adult	O
hippocampus	O
was	O
hard	O
to	O
detect	O
using	O
immunohistochemistry	O
due	O
to	O
the	O
low	O
expression	O
of	O
the	O
protein	O
(	O
data	O
not	O
shown	O
)	O
.	O

However	O
,	O
it	O
is	O
present	O
,	O
as	O
previously	O
described	O
using	O
reporter	O
mice	B
and	O
as	O
revealed	O
by	O
in	O
situ	O
hybridization	O
[	O
21	O
]	O
.	O

We	O
next	O
examined	O
the	O
expression	O
of	O
Mash1	O
and	O
compared	O
it	O
with	O
that	O
of	O
Ngn2	O
,	O
Pax6	O
and	O
Tbr2	O
.	O

We	O
found	O
some	O
Mash1	O
+	O
cells	O
(	O
10–20	O
cells	O
per	O
section	O
)	O
in	O
the	O
dorsal	O
hippocampus	O
.	O

Almost	O
all	O
of	O
them	O
co	O
-	O
expressed	O
Pax6	O
(	O
Figure	O
2C	O
)	O
.	O

Only	O
few	O
cells	O
co	O
-	O
expressed	O
Tbr2	O
(	O
Figure	O
2D	O
)	O
or	O
Ngn2	O
(	O
Figure	O
2E	O
)	O
,	O
suggesting	O
that	O
Mash1	O
is	O
downregulated	O
when	O
these	O
two	O
proteins	O
are	O
expressed	O
.	O

None	O
of	O
the	O
Mash1-expressing	O
cells	O
were	O
positive	O
for	O
NeuroD1	O
(	O
Figure	O
2F	O
)	O
.	O

Mash1	O
+	O
cells	O
were	O
still	O
undergoing	O
mitosis	O
(	O
Figure	O
2C	O
)	O
and	O
consequently	O
over	O
90	O
%	O
of	O
them	O
co	O
-	O
labeled	O
with	O
the	O
cell	O
-	O
cycle	O
marker	O
Ki67	O
(	O
Figure	O
S1J	O
)	O
.	O

Taken	O
together	O
,	O
we	O
show	O
that	O
Mash1	O
and	O
Ngn2	O
are	O
expressed	O
in	O
early	O
and	O
late	O
stages	O
of	O
maturation	O
of	O
type2a	O
progenitors	O
,	O
respectively	O
,	O
and	O
that	O
both	O
transcription	O
factors	O
are	O
co	O
-	O
expressed	O
briefly	O
when	O
cells	O
transit	O
from	O
early	O
to	O
late	O
phase	O
type2a	O
cells	O
.	O

Ngn2	O
progenies	O
become	O
hippocampal	O
granule	O
neurons	O
Previous	O
work	O
has	O
shown	O
that	O
in	O
Mash1	O
null	O
mutant	O
mice	B
hippocampal	O
neurogenesis	O
is	O
not	O
reduced	O
and	O
the	O
hippocampus	O
is	O
not	O
malformed	O
[	O
20	O
]	O
.	O

Therefore	O
we	O
focused	O
our	O
initial	O
analysis	O
on	O
the	O
role	O
of	O
Ngn2	O
in	O
hippocampal	O
neurogenesis	O
.	O

We	O
characterized	O
the	O
fate	O
of	O
Ngn2-expressing	O
cells	O
using	O
Ngn2	O
Knock	O
-	O
in	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
mice	B
(	O
Ngn2+	O
/	O
GFP	O
)	O
[	O
27	O
]	O
.	O

In	O
the	O
SGZ	O
of	O
2	O
week	O
-	O
old	O
hippocampi	O
,	O
we	O
found	O
bright	O
GFP	O
-	O
expressing	O
cells	O
that	O
were	O
positive	O
for	O
Tbr2	O
(	O
Figure	O
2H	O
)	O
,	O
the	O
immature	O
neuronal	O
marker	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
2I	O
)	O
and	O
NeuroD1	O
(	O
Figure	O
2J	O
)	O
.	O

Furthermore	O
,	O
Prox1	O
+	O
,	O
NeuroD2	O
+	O
and	O
calretinin+	O
cells	O
were	O
also	O
weakly	O
positive	O
for	O
GFP	O
.	O

We	O
made	O
similar	O
observations	O
in	O
2	O
month	O
-	O
old	O
mice	B
(	O
data	O
not	O
shown	O
)	O
confirming	O
earlier	O
published	O
results	O
[	O
21	O
]	O
)	O
.	O

We	O
did	O
not	O
observe	O
Mash1+	O
/	O
GFP+	O
and	O
NeuN+	O
/	O
GFP+	O
cells	O
(	O
Figure	O
2	O
G	O
)	O
.	O

These	O
data	O
from	O
Ngn2+	O
/	O
GFP	O
mice	B
are	O
entirely	O
consistent	O
with	O
our	O
earlier	O
observations	O
using	O
immunocytochemistry	O
to	O
label	O
Ngn2-expressing	O
cells	O
and	O
with	O
GFP	O
undergoing	O
slow	O
degradation	O
after	O
the	O
expression	O
of	O
Ngn2	O
has	O
ceased	O
.	O

Importantly	O
,	O
none	O
of	O
the	O
GFP	O
-	O
expressing	O
cells	O
,	O
including	O
those	O
only	O
weakly	O
fluorescent	O
,	O
residing	O
in	O
the	O
SGL	O
expressed	O
the	O
astrocytic	O
marker	O
GFAP	O
or	O
the	O
oligodendrocytic	O
markers	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Taken	O
together	O
,	O
the	O
data	O
show	O
that	O
Ngn2	O
progenies	O
become	O
neurons	O
and	O
never	O
generate	O
astrocytes	O
or	O
oligodendrocytes	O
.	O

Marked	O
reduction	O
of	O
hippocampal	O
granule	O
neurons	O
in	O
absence	O
of	O
Ngn2	O
To	O
determine	O
the	O
role	O
of	O
Ngn2	O
during	O
the	O
initiation	O
of	O
hippocampal	O
granule	O
neurogenesis	O
,	O
we	O
analyzed	O
the	O
hippocampus	O
of	O
mice	B
lacking	O
Ngn2	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
.	O

In	O
contrast	O
to	O
the	O
mice	B
use	O
by	O
Galichet	O
and	O
coworkers	O
,	O
our	O
mice	B
have	O
a	O
lifespan	O
of	O
only	O
2	O
weeks	O
after	O
birth	O
.	O

Therefore	O
,	O
we	O
analyzed	O
2	O
week	O
-	O
old	O
and	O
younger	O
mice	B
.	O

Consistent	O
with	O
previous	O
observations	O
[	O
20	O
]	O
,	O
the	O
hippocampus	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutants	O
is	O
clearly	O
malformed	O
(	O
Figure	O
3A	O
)	O
.	O

In	O
two	O
week	O
-	O
old	O
Ngn2GFP	O
/	O
GFP	O
mice	B
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
completely	O
absent	O
.	O

Already	O
on	O
postnatal	O
day	O
1–2	O
,	O
the	O
ventral	O
blade	O
of	O
the	O
DG	O
is	O
malformed	O
along	O
its	O
whole	O
rostro	O
-	O
caudal	O
axis	O
(	O
Figure	O
3B	O
)	O
.	O

As	O
neither	O
migration	O
defects	O
nor	O
cell	O
death	O
cause	O
the	O
reduced	O
number	O
of	O
hippocampal	O
neurons	O
in	O
Ngn2	O
null	O
mice	B
[	O
20	O
]	O
,	O
we	O
asked	O
if	O
Ngn2	O
is	O
necessary	O
for	O
production	O
of	O
hippocampal	O
granule	O
neuroblasts	O
.	O

We	O
first	O
injected	O
2	O
day	O
-	O
old	O
mouse	B
pups	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
allowing	O
us	O
to	O
evaluate	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
.	O

We	O
also	O
injected	O
BrdU	O
into	O
female	O
mice	B
on	O
their	O
final	O
day	O
of	O
pregnancy	O
and	O
examined	O
the	O
brains	O
of	O
their	O
pups	O
48	O
hours	O
later	O
(	O
corresponding	O
to	O
P1–P2	O
old	O
pups	O
)	O
.	O

This	O
allowed	O
us	O
to	O
assess	O
the	O
number	O
of	O
neurons	O
derived	O
from	O
the	O
last	O
day	O
of	O
intrauterine	O
development	O
.	O

Regardless	O
of	O
whether	O
the	O
mice	B
were	O
WT	O
or	O
hetero	O
/	O
homozygous	O
mutant	O
pups	O
,	O
we	O
found	O
cells	O
that	O
had	O
incorporated	O
BrdU	O
in	O
the	O
hippocampal	O
subventricular	O
zone	O
(	O
hSVZ	O
)	O
,	O
fimbria	O
and	O
the	O
DG	O
(	O
Figure	O
4A	O
and	O
B	O
;	O
[	O
28	O
]	O
)	O
,	O
suggesting	O
that	O
progenitors	O
originating	O
in	O
the	O
hSVZ	O
divide	O
while	O
migrating	O
towards	O
the	O
DG	O
.	O

Most	O
of	O
them	O
were	O
organized	O
in	O
chains	O
typical	O
of	O
migrating	O
cells	O
(	O
Figure	O
4A	O
and	O
B	O
and	O
figure	O
S2	O
)	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	B
injected	O
with	O
BrdU	O
2	O
hours	O
prior	O
to	O
sacrifice	O
,	O
we	O
observed	O
a	O
decrease	O
in	O
the	O
number	O
of	O
BrdU+	O
cells	O
compared	O
to	O
heterozygous	O
littermates	O
.	O

Thus	O
,	O
the	O
numbers	O
of	O
newborn	O
cells	O
were	O
reduced	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
133.3±7.5	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
69.7±5.0	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
132.0±9.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
42.6±2.2	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4C	O
and	O
D	O
)	O
.	O

We	O
also	O
examined	O
the	O
number	O
of	O
newborn	O
cells	O
differentiating	O
into	O
neurons	O
,	O
and	O
identified	O
them	O
by	O
the	O
co	O
-	O
expression	O
of	O
BrdU	O
and	O
NeuroD1	O
.	O

As	O
expected	O
,	O
they	O
were	O
relatively	O
few	O
in	O
numbers	O
because	O
the	O
short	O
delay	O
(	O
2	O
hours	O
)	O
between	O
BrdU	O
administration	O
and	O
sacrifice	O
in	O
this	O
first	O
experimental	O
paradigm	O
.	O

In	O
Ngn2GFP	O
/	O
GFP	O
null	O
mutants	O
,	O
we	O
found	O
the	O
number	O
of	O
cells	O
differentiating	O
into	O
neurons	O
to	O
be	O
reduced	O
by	O
60	O
%	O
and	O
71	O
%	O
in	O
the	O
hSVZ	O
/	O
fimbria	O
(	O
8.6±1.4	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
3.4±0.5	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
and	O
DG	O
(	O
9.7±1.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
2.8±0.6	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
,	O
respectively	O
,	O
(	O
Figure	O
4E	O
and	O
F	O
)	O
.	O

As	O
a	O
result	O
,	O
the	O
number	O
of	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
80	O
%	O
(	O
580.3±27.7	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
116.2±7.3	O
for	O
Ngn2GFP	O
/	O
GFP	O
;	O
Figure	O
4	O
G	O
)	O
.	O

We	O
obtained	O
similar	O
results	O
in	O
the	O
second	O
paradigm	O
,	O
i.e.	O
in	O
mice	B
that	O
we	O
sacrificed	O
48	O
hours	O
after	O
BrdU	O
administration	O
and	O
in	O
which	O
a	O
larger	O
number	O
of	O
the	O
newborn	O
cells	O
had	O
time	O
to	O
mature	O
into	O
neurons	O
.	O

In	O
this	O
case	O
,	O
the	O
number	O
of	O
BrdU+	O
/	O
NeuroD1	O
+	O
cells	O
in	O
the	O
DG	O
was	O
reduced	O
by	O
73	O
%	O
of	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
animals	O
(	O
91.5±24.1	O
for	O
Ngn2+	O
/	O
GFP	O
vs	O
26.4±3.3	O
for	O
Ngn2GFP	O
/	O
GFP	O
)	O
(	O
Figure	O
4J	O
)	O
.	O

We	O
found	O
no	O
differences	O
in	O
the	O
proportion	O
of	O
BrdU+	O
cells	O
that	O
expressed	O
NeuroD1	O
in	O
Ngn2+	O
/	O
GFP	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	B
(	O
14.2±1.0	O
%	O
and	O
17.4±1.8	O
%	O
respectively	O
;	O
Figure	O
4	O
K	O
)	O
.	O

This	O
shows	O
that	O
the	O
few	O
cells	O
that	O
manage	O
to	O
proliferate	O
in	O
the	O
Ngn2	O
null	O
mice	B
have	O
the	O
same	O
ability	O
to	O
differentiate	O
into	O
neurons	O
as	O
those	O
in	O
mice	B
with	O
one	O
Ngn2	O
allele	O
.	O

Interestingly	O
,	O
the	O
absence	O
of	O
Ngn2	O
did	O
not	O
alter	O
the	O
identity	O
of	O
neurons	O
in	O
the	O
DG	O
granule	O
layer	O
in	O
2	O
week	O
-	O
old	O
Ngn2	O
null	O
mice	B
.	O

The	O
maturing	O
granule	O
progenitors	O
sequentially	O
expressed	O
Pax6	O
,	O
Tbr2	O
(	O
Figure	O
S3A	O
and	O
S3B	O
)	O
,	O
NeuroD1	O
and	O
Calretinin	O
(	O
Figure	O
4L	O
)	O
,	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
4N	O
)	O
,	O
Tbr1	O
(	O
data	O
not	O
shown	O
)	O
and	O
Prox1	O
(	O
Figure	O
4	O
M	O
)	O
.	O

We	O
confirmed	O
that	O
the	O
same	O
transcriptional	O
cascade	O
is	O
active	O
in	O
the	O
20	O
%	O
(	O
compared	O
to	O
mice	B
with	O
one	O
Ngn2	O
allele	O
)	O
residual	O
granule	O
neurons	O
that	O
are	O
formed	O
two	O
day	O
-	O
old	O
in	O
Ngn2GFP	O
/	O
GFP	O
mice	B
(	O
Figure	O
S3D	O
–	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

We	O
next	O
investigated	O
if	O
the	O
cells	O
that	O
failed	O
to	O
develop	O
into	O
neurons	O
in	O
Ngn2GFP	O
/	O
GFP	O
mutant	O
mice	B
,	O
became	O
glial	O
cells	O
.	O

We	O
found	O
that	O
cells	O
expressing	O
GFP	O
never	O
co	O
-	O
labeled	O
with	O
the	O
astrocyte	O
marker	O
GFAP	O
(	O
Figure	O
4N	O
)	O
or	O
the	O
oligodendrocyte	O
marker	O
CNPase	O
(	O
data	O
not	O
shown	O
)	O
.	O

Altogether	O
,	O
our	O
results	O
show	O
that	O
Ngn2	O
plays	O
an	O
important	O
role	O
during	O
the	O
production	O
/	O
amplification	O
of	O
hippocampal	O
granule	O
neuroblasts	O
,	O
but	O
not	O
the	O
acquisition	O
of	O
the	O
granule	O
neuron	O
identity	O
(	O
Figure	O
S7	O
)	O
.	O

Ngn2	O
controls	O
the	O
amplification	O
of	O
granule	O
neuron	O
progenitors	O
We	O
next	O
monitored	O
the	O
mitogenic	O
activity	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
2	O
week	O
-	O
old	O
WT	O
mice	B
.	O

We	O
observed	O
that	O
over	O
50	O
%	O
of	O
Ngn2	O
+	O
cells	O
in	O
the	O
DG	O
of	O
WT	O
mice	B
co	O
-	O
expressed	O
the	O
mitosis	O
marker	O
Ki67	O
(	O
Figure	O
5A	O
)	O
.	O

Inspired	O
by	O
this	O
finding	O
,	O
we	O
injected	O
BrdU	O
into	O
2	O
week	O
-	O
old	O
WT	O
and	O
Ngn2GFP	O
/	O
GFP	O
mice	B
and	O
compared	O
cell	O
proliferation	O
in	O
the	O
DG	O
.	O

We	O
observed	O
92	O
%	O
reduction	O
in	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
SGZ	O
of	O
Ngn2	O
null	O
mutant	O
mice	B
(	O
6.7±0.5	O
)	O
compared	O
to	O
WT	O
(	O
83.6±1.2	O
)	O
and	O
heterozygotic	O
(	O
data	O
not	O
shown	O
)	O
littermates	O
(	O
Figure	O
5B	O
–	O
C	O
)	O
.	O

This	O
data	O
confirm	O
the	O
importance	O
of	O
Ngn2	O
during	O
the	O
amplification	O
of	O
granule	O
progenitor.s	O
.	O

To	O
further	O
explore	O
whether	O
Ngn2	O
+	O
cells	O
become	O
post	O
-	O
mitotic	O
or	O
still	O
proliferate	O
after	O
Ngn2	O
is	O
downregulated	O
,	O
we	O
performed	O
immunohistochemistry	O
on	O
sections	O
through	O
the	O
DG	O
of	O
Ngn2+	O
/	O
GFP	O
mice	B
.	O

We	O
stained	O
them	O
with	O
the	O
mitosis	O
marker	O
Phospho	O
-	O
histone	O
3	O
(	O
PH3	O
)	O
and	O
NeuroD1	O
,	O
which	O
is	O
downstream	O
of	O
Ngn2	O
in	O
the	O
transcriptional	O
cascade	O
controlling	O
neurogenesis	O
.	O

Thus	O
,	O
in	O
the	O
same	O
sections	O
we	O
could	O
identify	O
whether	O
cells	O
that	O
had	O
initiated	O
Ngn2	O
expression	O
(	O
GFP	O
labeled	O
)	O
,	O
continued	O
to	O
divide	O
(	O
PH3	O
+	O
)	O
or	O
committed	O
to	O
neuronal	O
differentiation	O
(	O
NeuroD1	O
+	O
)	O
.	O

We	O
observed	O
some	O
GFP+	O
cells	O
that	O
co	O
-	O
expressed	O
PH3	O
.	O

They	O
all	O
exhibited	O
morphological	O
characteristics	O
of	O
one	O
of	O
the	O
five	O
mitotic	O
phases	O
:	O
prophase	O
,	O
metaphase	O
,	O
anaphase	O
,	O
telophase	O
and	O
cytokinesis	O
(	O
Figure	O
5D	O
and	O
data	O
not	O
shown	O
)	O
.	O

Unexpectedly	O
,	O
cells	O
that	O
colabeled	O
for	O
GFP	O
,	O
PH3	O
and	O
NeuroD1	O
(	O
Figure	O
5E	O
and	O
figure	O
S4A	O
and	O
S4B	O
)	O
were	O
rare	O
.	O

This	O
indicates	O
that	O
Ngn2	O
+	O
cells	O
undergo	O
division	O
/	O
amplification	O
and	O
that	O
they	O
mature	O
into	O
post	O
-	O
mitotic	O
neurons	O
upon	O
NeuroD1	O
expression	O
.	O

In	O
mice	B
lacking	O
Ngn2	O
,	O
we	O
found	O
the	O
cells	O
expressing	O
GFP	O
localized	O
to	O
the	O
malformed	O
ventral	O
blade	O
of	O
the	O
DG	O
(	O
Figure	O
5F	O
and	O
G	O
)	O
.	O

All	O
of	O
these	O
cells	O
were	O
Ki67	O
+	O
and	O
they	O
only	O
very	O
rarely	O
expressed	O
PH3	O
(	O
Figure	O
5F	O
and	O
G	O
,	O
and	O
figure	O
S4C	O
)	O
in	O
the	O
absence	O
of	O
Ngn2	O
most	O
of	O
the	O
cells	O
are	O
arrested	O
in	O
the	O
cell	O
cycle	O
prior	O
to	O
entering	O
the	O
M	O
phase	O
and	O
their	O
mitosis	O
is	O
impaired	O
.	O

These	O
data	O
suggest	O
that	O
the	O
mechanism	O
of	O
action	O
of	O
Ngn2	O
is	O
conserved	O
from	O
development	O
of	O
the	O
DG	O
to	O
postnatal	O
hippocampal	O
neurogenesis	O
.	O

Our	O
findings	O
suggest	O
that	O
Ngn2	O
regulates	O
amplification	O
and	O
cell	O
cycle	O
exit	O
of	O
DG	O
granule	O
progenitors	O
.	O

To	O
examine	O
this	O
hypothesis	O
,	O
we	O
compared	O
the	O
effects	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
mitotic	O
activity	O
in	O
embryonic	O
cortico	O
-	O
hippocampal	O
neurosphere	O
-	O
derived	O
progenitors	O
,	O
5	O
days	O
upon	O
transduction	O
,	O
in	O
vitro	O
.	O

In	O
cultures	O
transduced	O
with	O
Ngn2	O
retrovirus	O
,	O
we	O
found	O
that	O
27.2	O
%	O
(	O
±4.1	O
%	O
)	O
of	O
the	O
PH3	O
+	O
cells	O
had	O
been	O
transduced	O
(	O
Figure	O
I1–J	O
)	O
.	O

These	O
cells	O
were	O
immunopositive	O
for	O
MAP2	O
(	O
Figure	O
5I1	O
and	O
I2	O
)	O
and	O
therefore	O
represented	O
dividing	O
neuroblasts	O
.	O

By	O
contrast	O
,	O
in	O
NeuroD1	O
transduced	O
cultures	O
,	O
only	O
7.3	O
%	O
of	O
PH3	O
+	O
cells	O
were	O
GFP+	O
(	O
Figure	O
5H1	O
,	O
H2	O
and	O
J	O
)	O
.	O

All	O
of	O
the	O
NeuroD1-transduced	O
cells	O
became	O
MAP2	O
+	O
(	O
Figure	O
5H	O
)	O
.	O

To	O
confirm	O
this	O
data	O
we	O
pulse	O
-	O
labeled	O
transduced	O
cultures	O
with	O
chlorodeoxyuridine	O
(	O
CldU	O
)	O
for	O
48	O
hours	O
,	O
five	O
days	O
after	O
differentiation	O
.	O

In	O
contrast	O
to	O
NeuroD1-transduced	O
cultures	O
,	O
we	O
observed	O
dividing	O
cells	O
transduced	O
with	O
Ngn2	O
retrovirus	O
that	O
were	O
positive	O
for	O
PH3	O
and	O
that	O
had	O
incorporated	O
CldU	O
(	O
Figure	O
5K	O
–	O
L2	O
)	O
.	O

As	O
the	O
number	O
of	O
cells	O
PH3+	O
/	O
CldU+	O
/	O
GFP+	O
we	O
observed	O
was	O
low	O
,	O
we	O
did	O
not	O
quantify	O
this	O
finding	O
.	O

Collectively	O
,	O
we	O
have	O
shown	O
that	O
Ngn2	O
is	O
required	O
for	O
granule	O
neuroblast	O
production	O
and	O
amplification	O
and	O
that	O
in	O
the	O
absence	O
of	O
Ngn2	O
the	O
progenitors	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

NeuroD1	O
,	O
on	O
the	O
other	O
hand	O
,	O
induces	O
cell	O
cycle	O
exit	O
and	O
promotes	O
rapid	O
neuronal	O
maturation	O
.	O

NeuroD1	O
directs	O
neuronal	O
differentiation	O
and	O
maturation	O
Based	O
on	O
our	O
previous	O
observations	O
we	O
proposed	O
that	O
Ngn2	O
primarily	O
controls	O
amplification	O
of	O
granule	O
neuroblasts	O
and	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
overexpressed	O
Ngn2	O
or	O
NeuroD1	O
in	O
E14.5	O
cortico	O
-	O
hippocampal	O
neurospheres	O
and	O
compared	O
their	O
effects	O
after	O
5	O
days	O
of	O
differentiation	O
of	O
the	O
progenitors	O
.	O

All	O
cortico	O
-	O
hippocampal	O
progenitors	O
expressed	O
Pax6	O
prior	O
to	O
differentiation	O
(	O
Figure	O
S5	O
)	O
.	O

After	O
5	O
days	O
,	O
both	O
factors	O
suppressed	O
Pax6	O
and	O
Sox2	O
(	O
Figure	O
S5	O
,	O
figure	O
6C	O
)	O
and	O
induced	O
expression	O
of	O
Tbr1	O
,	O
Map2	O
,	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6D	O
and	O
E	O
)	O
.	O

Interestingly	O
,	O
all	O
Ngn2-overexpressing	O
cells	O
co	O
-	O
expressed	O
NeuroD1	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
next	O
explored	O
whether	O
Ngn2	O
overexpression	O
induces	O
NeuroD1	O
expression	O
,	O
and	O
if	O
NeuroD1	O
in	O
turn	O
directs	O
neuronal	O
differentiation	O
.	O

We	O
compared	O
the	O
effects	O
of	O
both	O
transcription	O
factors	O
in	O
progenitors	O
that	O
either	O
do	O
or	O
do	O
not	O
normally	O
express	O
them	O
.	O

Thus	O
,	O
we	O
expressed	O
Ngn2	O
in	O
E14.5	O
neural	O
progenitors	O
isolated	O
from	O
three	O
different	O
brain	O
regions	O
:	O
cortex	O
/	O
hippocampus	O
,	O
lateral	O
ganglionic	O
eminence	O
(	O
LGE	O
)	O
and	O
ventral	O
mesencephalon	O
(	O
VM	O
)	O
.	O

Ngn2	O
expression	O
in	O
the	O
developing	O
forebrain	O
is	O
normally	O
limited	O
to	O
the	O
neocortex	O
,	O
and	O
it	O
does	O
not	O
appear	O
in	O
LGE	O
tissue	O
[	O
29	O
]	O
.	O

In	O
the	O
developing	O
VM	O
,	O
both	O
Ngn2	O
and	O
NeuroD1	O
are	O
expressed	O
,	O
but	O
not	O
when	O
neural	O
progenitors	O
from	O
this	O
region	O
are	O
cultured	O
in	O
vitro	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
our	O
experiments	O
,	O
cortico	O
-	O
hippocampal	O
progenitors	O
could	O
differentiate	O
into	O
neurons	O
,	O
although	O
they	O
did	O
not	O
normally	O
express	O
NeuroD1	O
(	O
Figure	O
6E	O
)	O
.	O

When	O
we	O
overexpressed	O
Ngn2	O
in	O
VM	O
and	O
LGE	O
progenitors	O
,	O
the	O
cells	O
started	O
to	O
express	O
both	O
NeuroD1	O
and	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6F	O
and	O
G	O
)	O
.	O

We	O
then	O
overexpressed	O
NeuroD1	O
in	O
the	O
same	O
types	O
of	O
cultured	O
progenitors	O
and	O
found	O
that	O
the	O
cells	O
became	O
immunoreactive	O
for	O
PSA	O
-	O
NCAM	O
(	O
Figure	O
6	O
G	O
and	O
data	O
not	O
shown	O
)	O
.	O

Thus	O
,	O
NeuroD1	O
is	O
sufficient	O
to	O
direct	O
neuronal	O
differentiation	O
in	O
cortico	O
-	O
hippocampal-	O
,	O
LGE-	O
and	O
VM	O
-	O
derived	O
progenitors	O
.	O

Our	O
results	O
from	O
in	O
vitro	O
cultures	O
and	O
the	O
analysis	O
of	O
the	O
DG	O
of	O
Ngn2	O
mutant	O
animals	O
collectively	O
show	O
the	O
neuron	O
-	O
inducing	O
effect	O
of	O
NeuroD1	O
in	O
hippocampal	O
granule	O
cell	O
progenitors	O
[	O
32	O
]	O
.	O

NeuroD1	O
directs	O
exclusive	O
neuronal	O
differentiation	O
of	O
hippocampal	O
granule	O
neuron	O
progenitors	O
As	O
the	O
next	O
step	O
,	O
we	O
tested	O
the	O
effects	O
of	O
NeuroD1	O
in	O
vivo	O
and	O
compared	O
them	O
with	O
those	O
of	O
Ngn2	O
.	O

We	O
injected	O
retroviruses	O
carrying	O
the	O
gene	O
for	O
either	O
Ngn2	O
[	O
33	O
]	O
or	O
NeuroD1	O
,	O
and	O
the	O
reporter	O
gene	O
eGFP	O
into	O
the	O
ventricles	O
E15.5	O
rat	B
embryos	O
,	O
in	O
utero	O
(	O
Figure	O
7A	O
)	O
.	O

Three	O
weeks	O
later	O
,	O
when	O
the	O
rats	B
were	O
about	O
two	O
weeks	O
old	O
,	O
we	O
examined	O
their	O
hippocampi	O
and	O
analyzed	O
the	O
eGFP+	O
cells	O
.	O

The	O
rats	B
injected	O
with	O
control	O
vector	O
exhibited	O
eGFP+	O
cells	O
within	O
the	O
hippocampus	O
that	O
were	O
either	O
star	O
-	O
shaped	O
,	O
progenitor	O
/	O
glial	O
-	O
like	O
cells	O
(	O
14.8±3.4	O
%	O
)	O
or	O
neuron	O
-	O
like	O
cells	O
with	O
long	O
neurites	O
(	O
85.3±3.4	O
%	O
)	O
(	O
Figure	O
7B	O
)	O
.	O

In	O
rats	B
that	O
we	O
had	O
injected	O
with	O
the	O
vector	O
encoding	O
Ngn2	O
,	O
the	O
eGFP	O
-	O
labeled	O
,	O
the	O
transduced	O
hippocampal	O
cells	O
were	O
composed	O
of	O
31.9	O
%	O
(	O
±5.7	O
%	O
)	O
progenitor	O
/	O
glia	O
-	O
like	O
cells	O
and	O
69.4	O
%	O
(	O
±6.1	O
%	O
)	O
neuron	O
-	O
like	O
cells	O
(	O
Figure	O
7B	O
)	O
.	O

The	O
glia	O
-	O
like	O
subpopulation	O
was	O
immunopositive	O
for	O
the	O
astrocytic	O
marker	O
GFAP	O
(	O
Figure	O
7C	O
–	O
D	O
)	O
.	O

In	O
contrast	O
,	O
virtually	O
all	O
of	O
the	O
transduced	O
cells	O
in	O
rats	B
injected	O
with	O
the	O
NeuroD1	O
vector	O
became	O
neuron	O
-	O
like	O
cells	O
(	O
99.9%±0.1	O
;	O
Figure	O
7B	O
)	O
.	O

None	O
of	O
these	O
cells	O
stained	O
for	O
GFAP	O
(	O
Figure	O
7E	O
and	O
F	O
)	O
.	O

They	O
were	O
positioned	O
in	O
the	O
external	O
layers	O
of	O
both	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
(	O
Figure	O
7B3	O
,	O
E	O
and	O
I	O
and	O
figure	O
S6A	O
)	O
.	O

When	O
we	O
examined	O
neuronal	O
maturation	O
of	O
Ngn2-	O
and	O
NeuroD1-transduced	O
cells	O
,	O
we	O
observed	O
that	O
only	O
a	O
few	O
of	O
those	O
transduced	O
with	O
the	O
NeuroD1	O
vector	O
expressed	O
the	O
early	O
mature	O
neuronal	O
marker	O
Tbr1	O
(	O
3.1±1.4	O
%	O
;	O
Figure	O
7I	O
and	O
J	O
)	O
.	O

They	O
were	O
located	O
within	O
the	O
basal	O
layers	O
,	O
near	O
the	O
SGL	O
,	O
of	O
the	O
ventral	O
and	O
dorsal	O
blades	O
of	O
the	O
DG	O
.	O

In	O
contrast	O
,	O
a	O
greater	O
proportion	O
of	O
the	O
cells	O
transduced	O
with	O
Ngn2	O
still	O
expressed	O
Tbr1	O
(	O
19.6%±3.3	O
%	O
;	O
Figure	O
7H	O
and	O
J	O
)	O
,	O
indicating	O
that	O
they	O
were	O
less	O
mature	O
than	O
the	O
vast	O
majority	O
of	O
the	O
NeuroD1-transduced	O
cells	O
.	O

Immunohistochemistry	O
for	O
NeuN	O
confirmed	O
these	O
data	O
(	O
Figure	O
7	O
M	O
and	O
O	O
,	O
and	O
figure	O
S6A	O
)	O
.	O

Indeed	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
the	O
proportion	O
of	O
hippocampal	O
progenitors	O
that	O
became	O
NeuN+	O
was	O
no	O
greater	O
than	O
in	O
rats	B
transduced	O
with	O
the	O
control	O
virus	O
(	O
Figure	O
7F	O
)	O
.	O

As	O
a	O
whole	O
,	O
our	O
in	O
utero	O
injection	O
experiments	O
confirm	O
that	O
NeuroD1	O
has	O
a	O
stronger	O
neuron	O
-	O
inducing	O
effect	O
than	O
Ngn2	O
when	O
overexpressed	O
in	O
hippocampal	O
progenitors	O
.	O

Involvement	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr	O
and	O
NeuroD	O
proteins	O
during	O
human	B
hippocampal	O
neurogenesis	O
Finally	O
,	O
we	O
examined	O
whether	O
the	O
transcription	O
factors	O
and	O
cellular	O
markers	O
that	O
are	O
expressed	O
in	O
rodents	O
are	O
also	O
expressed	O
in	O
human	B
hippocampus	O
.	O

We	O
performed	O
immunohistochemistry	O
on	O
aged	O
human	B
hippocampal	O
DG	O
and	O
found	O
GFAP-	O
,	O
Sox2-	O
,	O
Pax6-	O
,	O
Nestin-	O
,	O
Prox1-	O
and	O
NeuN	O
-	O
immunopositive	O
cells	O
.	O

This	O
indicates	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
,	O
neural	O
progenitors	O
and	O
mature	O
granule	O
neurons	O
are	O
present	O
in	O
the	O
aged	O
human	B
hippocampus	O
(	O
Figure	O
8A	O
–	O
E	O
)	O
.	O

While	O
Prox1	O
is	O
found	O
mainly	O
in	O
granule	O
neurons	O
,	O
Sox2	O
and	O
Pax6	O
are	O
exclusively	O
localized	O
to	O
cells	O
in	O
the	O
SGZ	O
(	O
Figure	O
8D	O
and	O
E	O
)	O
.	O

As	O
for	O
aged	O
rodents	O
,	O
we	O
did	O
not	O
observe	O
the	O
presence	O
of	O
Mash1	O
,	O
Ngn2	O
,	O
Tbr2	O
,	O
Tbr1	O
and	O
NeuroD1	O
proteins	O
in	O
aged	O
human	B
hippocampus	O
,	O
using	O
immunohistochemistry	O
.	O

However	O
,	O
we	O
could	O
identify	O
the	O
presence	O
of	O
the	O
transcripts	O
,	O
using	O
RT	O
-	O
PCR	O
(	O
Figure	O
8F	O
)	O
.	O

In	O
addition	O
,	O
we	O
detected	O
mRNA	O
for	O
Prox1	O
,	O
Calbindin1	O
and	O
Calbindin2	O
/	O
Calretinin	O
(	O
Figure	O
8F	O
)	O
.	O

Interestingly	O
,	O
we	O
also	O
observed	O
Sonic	O
Hedgehog	O
and	O
Wnt-3A	O
transcripts	O
,	O
indicating	O
that	O
they	O
are	O
present	O
in	O
the	O
human	B
DG	O
and	O
supporting	O
previous	O
claims	O
that	O
they	O
are	O
important	O
for	O
the	O
regulation	O
of	O
adult	O
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
)	O
.	O

Finally	O
,	O
we	O
also	O
found	O
mRNA	O
for	O
GLAST	O
,	O
Pax6	O
and	O
GFAP	O
which	O
suggests	O
that	O
radial	O
glia	O
-	O
like	O
stem	O
cells	O
are	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
,	O
and	O
may	O
play	O
a	O
role	O
in	O
adult	O
human	B
hippocampal	O
neurogenesis	O
(	O
Figure	O
8F	O
;	O
[	O
8	O
]	O
)	O
.	O

Overall	O
,	O
our	O
data	O
show	O
that	O
different	O
proteins	O
known	O
to	O
play	O
key	O
roles	O
in	O
rodent	B
hippocampal	O
granule	O
neurogenesis	O
are	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
.	O

Discussion	O
In	O
this	O
study	O
we	O
determine	O
the	O
functions	O
of	O
Ngn2	O
and	O
NeuroD1	O
during	O
hippocampal	O
neurogenesis	O
.	O

First	O
,	O
we	O
map	O
the	O
hierarchy	O
of	O
molecular	O
markers	O
of	O
neurogenesis	O
in	O
the	O
DG	O
.	O

Second	O
,	O
we	O
describe	O
that	O
Ngn2	O
is	O
necessary	O
for	O
granule	O
progenitor	O
production	O
/	O
amplification	O
.	O

Third	O
,	O
we	O
demonstrate	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
of	O
granule	O
progenitors	O
.	O

Finally	O
,	O
we	O
show	O
that	O
different	O
cellular	O
markers	O
expressed	O
during	O
hippocampal	O
neurogenesis	O
in	O
rodents	O
are	O
present	O
in	O
human	B
.	O

Sequential	O
expression	O
of	O
different	O
transcription	O
factors	O
and	O
cellular	O
markers	O
during	O
hippocampal	O
neurogenesis	O
We	O
clarified	O
the	O
pattern	O
of	O
expression	O
of	O
various	O
markers	O
expressed	O
during	O
postnatal	O
and	O
adult	O
hippocampal	O
granule	O
neurogenesis	O
in	O
detail	O
.	O

We	O
found	O
that	O
the	O
transcription	O
factor	O
Pax6	O
is	O
initially	O
expressed	O
by	O
both	O
radial	O
glia	O
stem	O
cells	O
(	O
type-1	O
)	O
and	O
early	O
amplifying	O
progenitors	O
(	O
type-2a	O
)	O
.	O

The	O
next	O
transcription	O
factor	O
to	O
appear	O
in	O
chronology	O
is	O
Mash1	O
.	O

Mash1	O
expression	O
characterizes	O
the	O
early	O
stage	O
of	O
hippocampal	O
progenitor	O
amplification	O
(	O
early	O
type-2a	O
)	O
.	O

The	O
role	O
of	O
Mash1	O
during	O
hippocampal	O
granule	O
neurogenesis	O
is	O
still	O
unclear	O
.	O

Mash1	O
null	O
mutant	O
mice	B
do	O
not	O
display	O
any	O
clear	O
malformation	O
of	O
the	O
DG	O
[	O
20	O
]	O
.	O

However	O
,	O
overexpression	O
of	O
Mash1	O
alone	O
in	O
the	O
DG	O
leads	O
to	O
the	O
generation	O
of	O
oligodendrocytes	O
[	O
36	O
]	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
hypothesize	O
that	O
Mash1-expressing	O
cells	O
are	O
not	O
yet	O
committed	O
towards	O
a	O
granule	O
cell	O
fate	O
.	O

They	O
may	O
still	O
have	O
the	O
potential	O
to	O
generate	O
both	O
neurons	O
and	O
oligodendrocytes	O
,	O
as	O
is	O
the	O
case	O
in	O
the	O
SVZ	O
[	O
37	O
]	O
.	O

In	O
agreement	O
with	O
different	O
developing	O
brain	O
regions	O
,	O
we	O
found	O
that	O
Ngn2	O
starts	O
to	O
be	O
expressed	O
in	O
Mash1-positive	O
transiently	O
amplifying	O
progenitors	O
,	O
i.e.	O
""""	O
late	O
type-2a	O
cells	O
""""	O
according	O
to	O
the	O
classification	O
we	O
propose	O
.	O

We	O
observed	O
that	O
Pax6	O
expression	O
persisted	O
longer	O
than	O
that	O
of	O
Mash1	O
,	O
in	O
Ngn2-expressing	O
cells	O
(	O
late	O
type-2a	O
cells	O
)	O
,	O
in	O
juvenile	O
but	O
not	O
adult	O
DG	O
(	O
Fig.	O
1	O
and	O
figure	O
S1	O
)	O
.	O

Later	O
on	O
,	O
Ngn2	O
is	O
downregulated	O
,	O
whilst	O
Tbr2	O
expression	O
persists	O
(	O
type-2b	O
cells	O
)	O
.	O

The	O
transition	O
from	O
amplifying	O
progenitor	O
to	O
neuroblast	O
is	O
defined	O
by	O
the	O
expression	O
of	O
NeuroD1	O
.	O

Thus	O
,	O
Ngn2	O
is	O
expressed	O
at	O
the	O
beginning	O
of	O
the	O
transiently	O
amplifying	O
progenitor	O
phase	O
while	O
NeuroD1	O
marks	O
the	O
end	O
of	O
that	O
period	O
.	O

This	O
applies	O
both	O
to	O
the	O
juvenile	O
and	O
adult	O
rat	B
brain	O
[	O
21	O
]	O
,	O
[	O
25	O
]	O
.	O

After	O
NeuroD1	O
is	O
turned	O
on	O
the	O
progenitors	O
leave	O
the	O
cell	O
cycle	O
,	O
gradually	O
mature	O
,	O
express	O
PSA	O
-	O
NCAM	O
,	O
NeuroD2	O
,	O
Calretinin	O
,	O
Prox1	O
,	O
Tbr1	O
and	O
,	O
finally	O
,	O
NeuN.	O
NeuroD1	O
expression	O
persists	O
at	O
low	O
levels	O
in	O
mature	O
neurons	O
(	O
Figure	O
9	O
;	O
[	O
10	O
]	O
)	O
.	O

We	O
found	O
the	O
sequential	O
expression	O
of	O
these	O
markers	O
conserved	O
in	O
juvenile	O
(	O
P2	O
and	O
2	O
weeks	O
)	O
and	O
adult	O
rodent	B
brains	O
.	O

Importantly	O
,	O
we	O
observed	O
that	O
the	O
same	O
transcription	O
factors	O
and	O
neuronal	O
markers	O
are	O
also	O
present	O
in	O
the	O
adult	O
human	B
hippocampus	O
and	O
arranged	O
spatially	O
in	O
a	O
manner	O
reminiscent	O
with	O
what	O
we	O
saw	O
in	O
rodents	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
some	O
of	O
these	O
markers	O
are	O
expressed	O
for	O
longer	O
or	O
shorter	O
periods	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
hippocampal	O
progenitor	O
maturation	O
.	O

Moreover	O
,	O
one	O
can	O
ask	O
to	O
which	O
extent	O
the	O
number	O
of	O
divisions	O
occurring	O
during	O
neuroblasts	O
maturation	O
is	O
conserved	O
at	O
postnatal	O
and	O
adult	O
stages	O
of	O
neurogenesis	O
.	O

A	O
new	O
function	O
for	O
Ngn2	O
in	O
maintenance	O
of	O
a	O
progenitor	O
state	O
for	O
granule	O
neuron	O
production	O
/	O
amplification	O
during	O
embryonic	O
and	O
postnatal	O
hippocampal	O
neurogenesis	O
In	O
agreement	O
with	O
earlier	O
work	O
,	O
we	O
confirm	O
that	O
Ngn2	O
is	O
indispensable	O
for	O
hippocampal	O
development	O
and	O
plays	O
a	O
vital	O
role	O
in	O
postnatal	O
hippocampal	O
granule	O
neurogenesis	O
.	O

Ngn2	O
null	O
mutant	O
animals	O
display	O
a	O
reduced	O
size	O
of	O
the	O
cornu	O
ammonis	O
and	O
a	O
malformed	O
DG	O
(	O
Figure	O
3	O
and	O
4	O
;	O
[	O
20	O
]	O
)	O
.	O

We	O
show	O
that	O
the	O
number	O
of	O
newborn	O
neurons	O
(	O
incorporated	O
BrdU	O
)	O
is	O
decreased	O
in	O
absence	O
of	O
Ngn2	O
,	O
but	O
hippocampal	O
granule	O
neuron	O
subtype	O
specification	O
is	O
not	O
affected	O
,	O
post	O
-	O
nataly	O
.	O

Likewise	O
,	O
neurons	O
from	O
other	O
brain	O
regions	O
,	O
e.g.	O
ventral	O
midbrain	O
dopamine	O
neurons	O
,	O
can	O
be	O
generated	O
in	O
the	O
absence	O
of	O
Ngn2	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

The	O
reduced	O
numbers	O
of	O
mature	O
neurons	O
in	O
the	O
hippocampus	O
and	O
ventral	O
midbrain	O
of	O
Ngn2	O
null	O
mutant	O
animals	O
does	O
not	O
appear	O
to	O
be	O
due	O
to	O
cell	O
death	O
or	O
migration	O
defects	O
[	O
20	O
]	O
,	O
[	O
31	O
]	O
.	O

Instead	O
it	O
may	O
be	O
due	O
to	O
a	O
defect	O
in	O
the	O
generation	O
and/or	O
amplification	O
of	O
neuronal	O
progenitors	O
.	O

Indeed	O
,	O
in	O
the	O
hippocampus	O
of	O
postnatal	O
animals	O
,	O
we	O
observed	O
that	O
cells	O
lacking	O
Ngn2	O
arrest	O
in	O
the	O
cell	O
cycle	O
,	O
maintain	O
Pax6	O
expression	O
and	O
cease	O
to	O
proliferate	O
.	O

When	O
overexpressed	O
in	O
neural	O
progenitors	O
in	O
vitro	O
,	O
Ngn2	O
lead	O
to	O
up	O
-	O
regulation	O
of	O
NeuroD1	O
and	O
caused	O
neuronal	O
differentiation	O
(	O
Figure	O
6	O
)	O
,	O
which	O
was	O
not	O
always	O
the	O
case	O
when	O
we	O
overexpressed	O
the	O
same	O
factor	O
in	O
vivo	O
(	O
Figure	O
7L	O
,	O
N	O
and	O
O	O
)	O
.	O

We	O
also	O
saw	O
that	O
Ngn2	O
does	O
not	O
always	O
efficiently	O
induce	O
cell	O
cycle	O
exit	O
.	O

Typically	O
some	O
mitotically	O
active	O
eGFP+	O
cells	O
were	O
present	O
in	O
the	O
DG	O
of	O
rats	B
injected	O
with	O
the	O
Ngn2	O
retrovirus	O
(	O
Figure	O
7P	O
)	O
,	O
and	O
we	O
observed	O
that	O
cultured	O
Ngn2-transduced	O
cells	O
are	O
still	O
capable	O
of	O
dividing	O
.	O

Thus	O
,	O
Ngn2	O
does	O
not	O
always	O
promote	O
cell	O
cycle	O
exit	O
and	O
neuronal	O
commitment	O
,	O
but	O
depending	O
on	O
the	O
state	O
of	O
the	O
cells	O
,	O
Ngn2	O
may	O
instead	O
promote	O
alternate	O
cellular	O
fates	O
[	O
38	O
]	O
–	O
[	O
40	O
]	O
.	O

Indeed	O
,	O
an	O
earlier	O
study	O
has	O
shown	O
that	O
Ngn2-overexpressing	O
progenitors	O
generate	O
oligodendrocytes	O
when	O
grafted	O
to	O
the	O
adult	O
spinal	O
cord	O
[	O
40	O
]	O
.	O

We	O
have	O
also	O
seen	O
that	O
Ngn2-overexpressing	O
neural	O
progenitors	O
from	O
the	O
embryonic	O
midbrain	O
form	O
astrocytes	O
when	O
grafted	O
to	O
the	O
striatum	O
(	O
unpublished	O
observations	O
)	O
.	O

Probably	O
,	O
Ngn2	O
can	O
not	O
influence	O
already	O
committed	O
cells	O
,	O
but	O
rather	O
would	O
control	O
neuroblasts	O
production	O
.	O

One	O
could	O
speculate	O
that	O
Ngn2	O
oscillates	O
during	O
granule	O
neuron	O
formation	O
,	O
as	O
recently	O
demonstrated	O
during	O
neocorticogenesis	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

NeuroD1	O
,	O
but	O
not	O
Ngn2	O
,	O
is	O
obligatory	O
for	O
granule	O
neuron	O
progenitor	O
differentiation	O
Hippocampal	O
granule	O
progenitors	O
can	O
mature	O
and	O
express	O
Tbr1	O
and	O
Prox1	O
,	O
both	O
during	O
the	O
development	O
and	O
postnatally	O
,	O
even	O
in	O
the	O
absence	O
of	O
Ngn2	O
.	O

Because	O
neuronal	O
differentiation	O
still	O
occurs	O
in	O
Ngn2	O
null	O
mice	B
,	O
it	O
is	O
clear	O
that	O
compensatory	O
,	O
Ngn2-independent	O
mechanisms	O
induce	O
NeuroD1	O
expression	O
.	O

One	O
candidate	O
is	O
Ngn1	O
,	O
which	O
is	O
expressed	O
during	O
neocorticogenesis	O
,	O
the	O
specification	O
of	O
olfactory	O
sensory	O
neurons	O
and	O
during	O
embryonic	O
rat	B
hippocampal	O
development	O
[	O
43	O
]	O
–	O
[	O
47	O
]	O
.	O

Both	O
Ngn1	O
and	O
Ngn2	O
regulate	O
NeuroD1	O
[	O
19	O
]	O
,	O
[	O
48	O
]	O
.	O

The	O
introduction	O
of	O
two	O
mutant	O
forms	O
of	O
Ngn1	O
,	O
a	O
deletion	O
of	O
the	O
basic	O
region	O
of	O
Ngn1	O
and	O
a	O
substitution	O
of	O
two	O
amino	O
acids	O
in	O
the	O
C	O
-	O
terminal	O
basic	O
region	O
,	O
prevents	O
NeuroD1	O
expression	O
and	O
neuronal	O
differentiation	O
[	O
48	O
]	O
.	O

The	O
double	O
null	O
Ngn1	O
/	O
Ngn2	O
mutant	O
displays	O
a	O
more	O
severe	O
phenotype	O
than	O
single	O
gene	O
(	O
Ngn1	O
or	O
Ngn2	O
)	O
mutant	O
mice	B
.	O

For	O
example	O
,	O
the	O
total	O
brain	O
size	O
of	O
the	O
double	O
mutants	O
is	O
much	O
smaller	O
[	O
10	O
]	O
,	O
[	O
32	O
]	O
.	O

If	O
the	O
role	O
of	O
Ngn1	O
during	O
hippocampal	O
neurogenesis	O
is	O
to	O
activate	O
NeuroD1	O
and	O
that	O
of	O
Ngn2	O
is	O
to	O
control	O
granule	O
neuroblasts	O
production	O
/	O
amplification	O
,	O
the	O
DG	O
of	O
double	O
Ngn1	O
/	O
Ngn2	O
knockout	O
mice	B
should	O
resemble	O
that	O
of	O
NeuroD1	O
null	O
mutant	O
mice	B
.	O

We	O
demonstrated	O
that	O
NeuroD1	O
directs	O
neuronal	O
differentiation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
progenitors	O
isolated	O
from	O
different	O
embryonic	O
brain	O
regions	O
and	O
cultured	O
in	O
vitro	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
NeuroD1	O
induced	O
neuronal	O
differentiation	O
.	O

The	O
neurons	O
generated	O
expressed	O
PSA	O
-	O
NCAM	O
,	O
Dcx	O
and	O
MAP2	O
.	O

After	O
in	O
utero	O
retroviral	O
vector	O
-	O
mediated	O
gene	O
delivery	O
,	O
virtually	O
all	O
cells	O
transduced	O
with	O
NeuroD1	O
became	O
neurons	O
.	O

In	O
contrast	O
,	O
progenitors	O
transduced	O
with	O
Ngn2	O
or	O
control	O
retroviruses	O
adopted	O
a	O
neuron	O
-	O
like	O
morphology	O
in	O
only	O
70–85	O
%	O
of	O
cases	O
.	O

Under	O
in	O
vitro	O
cell	O
culture	O
conditions	O
,	O
when	O
we	O
overexpressed	O
Ngn2	O
in	O
progenitors	O
derived	O
from	O
the	O
LGE	O
we	O
observed	O
robust	O
expression	O
of	O
NeuroD1	O
and	O
neuronal	O
differentiation	O
.	O

These	O
in	O
vitro	O
results	O
differ	O
from	O
those	O
we	O
obtained	O
when	O
we	O
transduced	O
the	O
embryonic	O
brain	O
with	O
a	O
viral	O
vector	O
expressing	O
Ngn2	O
.	O

In	O
this	O
latter	O
case	O
,	O
Ngn2	O
did	O
not	O
induce	O
neurons	O
and	O
the	O
transduced	O
cells	O
did	O
not	O
express	O
NeuroD1	O
.	O

Therefore	O
,	O
Ngn2	O
appears	O
to	O
direct	O
non	O
-	O
neuronal	O
cell	O
type	O
specification	O
in	O
vivo	O
[	O
38	O
]	O
–	O
[	O
40	O
]	O
.	O

Taken	O
together	O
,	O
we	O
have	O
confirmed	O
that	O
NeuroD1	O
plays	O
a	O
key	O
role	O
in	O
neuronal	O
differentiation	O
in	O
the	O
hippocampus	O
,	O
both	O
during	O
development	O
and	O
in	O
the	O
adult	O
brain	O
.	O

Concluding	O
remark	O
We	O
present	O
a	O
detailed	O
classification	O
of	O
different	O
stages	O
in	O
hippocampal	O
neurogenesis	O
.	O

Our	O
detailed	O
molecular	O
mapping	O
of	O
hippocampal	O
neurogenesis	O
allows	O
for	O
a	O
more	O
accurate	O
analysis	O
of	O
how	O
new	O
factors	O
stimulate	O
neurogenesis	O
at	O
different	O
steps	O
in	O
the	O
development	O
of	O
granule	O
neurons	O
.	O

Thereby	O
we	O
hope	O
to	O
facilitate	O
the	O
development	O
of	O
new	O
agents	O
,	O
which	O
stimulate	O
endogenous	O
progenitors	O
in	O
the	O
treatment	O
of	O
diseases	O
.	O

Materials	O
and	O
Methods	O
Animal	O
tissue	O
preparation	O
The	O
creation	O
of	O
the	O
Ngn2	O
transgenic	O
mice	B
was	O
reported	O
elsewhere	O
(	O
ref	O
guillemot	O
)	O
.	O

Heterozygote	O
male	O
and	O
female	O
mice	B
were	O
crossed	O
to	O
obtain	O
WT	O
,	O
heterozygote	O
(	O
Ngn2+	O
/	O
GFP	O
)	O
and	O
null	O
mutant	O
(	O
Ngn2GFP	O
/	O
GFP	O
)	O
animals	O
.	O

Tails	O
of	O
the	O
Ngn2	O
offspring	O
were	O
used	O
to	O
obtain	O
DNA	O
for	O
determination	O
of	O
the	O
genotype	O
using	O
a	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
assay	O
as	O
previously	O
reported	O
[	O
31	O
]	O
.	O

As	O
null	O
mutant	O
Ngn2GFP	O
/	O
GFP	O
do	O
not	O
survive	O
longer	O
than	O
2.5–3	O
weeks	O
after	O
birth	O
,	O
Ngn2GFP	O
/	O
GFP	O
and	O
their	O
littermates	O
were	O
sacrificed	O
at	O
the	O
postnatal	O
ages	O
of	O
two	O
days	O
(	O
P2	O
)	O
or	O
two	O
weeks	O
for	O
this	O
study	O
.	O

Neurogenesis	O
was	O
assessed	O
in	O
two	O
weeks	O
or	O
two	O
months	O
old	O
WT	O
mice	B
.	O

Sprague	O
Dawley	O
pregnant	O
rats	B
were	O
ordered	O
from	O
B&K	O
Universal	O
Ltd	O
,	O
Sollentuna	O
,	O
Sweden	O
(	O
hppt://www.bku.com	O
)	O
.	O

All	O
animals	O
were	O
housed	O
in	O
groups	O
with	O
ad	O
libitum	O
access	O
to	O
food	O
and	O
water	O
at	O
a	O
12-h	O
light	O
/	O
dark	O
cycle	O
.	O

All	O
experimental	O
procedures	O
conducted	O
in	O
this	O
study	O
had	O
been	O
approved	O
by	O
the	O
Ethical	O
Committee	O
at	O
Lund	O
University	O
.	O

For	O
immunohistochemical	O
analysis	O
,	O
mice	B
(	O
from	O
two	O
weeks	O
old	O
and	O
adult	O
stage	O
)	O
and	O
juvenile	O
rats	B
were	O
sacrificed	O
by	O
transcardial	O
perfusion	O
with	O
saline	O
for	O
5–10	O
minutes	O
,	O
followed	O
by	O
4	O
%	O
paraformaldehyde	O
(	O
PFA	O
)	O
for	O
10	O
minutes	O
.	O

Brains	O
were	O
kept	O
in	O
PFA	O
overnight	O
at	O
4	O
°	O
C	O
and	O
subsequently	O
cryopreserved	O
in	O
a	O
20–30	O
%	O
sucrose	O
/	O
0.1	O
M	O
phosphate	O
buffer	O
solution	O
until	O
sectioning	O
on	O
a	O
microtome	O
apparatus	O
(	O
30	O
µm	O
thickness	O
sections	O
,	O
Microm	O
Zeiss	O
)	O
.	O

Seven	O
series	O
of	O
coronal	O
sections	O
were	O
cut	O
throughout	O
the	O
brain	O
.	O

Free	O
-	O
floating	O
sections	O
were	O
preserved	O
in	O
antifreeze	O
solution	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Heads	O
of	O
postanatal	O
two	O
days	O
old	O
mice	B
were	O
decapitated	O
and	O
soaked	O
in	O
PFA	O
4	O
%	O
for	O
24	O
hours	O
,	O
at	O
4	O
°	O
C	O
and	O
transferred	O
into	O
sucrose	O
solution	O
until	O
sectioning	O
on	O
cryostat	O
apparatus	O
(	O
16	O
µm	O
thickness	O
;	O
Leica	O
CM3000	O
)	O
.	O

Sections	O
were	O
mounted	O
on	O
Superfrost	O
glass	O
slides	O
and	O
stored	O
at	O
−80	O
°	O
C	O
until	O
immunohistochemistry	O
was	O
performed	O
.	O

Cloning	O
,	O
subcloning	O
,	O
virus	O
production	O
and	O
titer	O
measurement	O
The	O
Moloney	O
leukemia	O
-	O
derived	O
retroviral	O
vectors	O
used	O
in	O
this	O
study	O
,	O
pCMMP	O
-	O
IRES2eGFP	O
-	O
WPRE	O
and	O
pCMMP	O
-	O
Ngn2-IRES2eGFP	O
-	O
WPRE	O
were	O
previously	O
described	O
[	O
40	O
]	O
,	O
[	O
49	O
]	O
.	O

To	O
generate	O
the	O
construct	O
pCMMP	O
-	O
NeuroD1-IRES2eGFP	O
-	O
WPRE	O
,	O
mouse	B
NeuroD1	O
cDNA	O
was	O
amplified	O
from	O
a	O
pCS2+mtNeuroD1	O
plasmid	O
(	O
kindly	O
provided	O
by	O
Professor	O
Jackie	O
Lee	O
,	O
Denver	O
university	O
,	O
Boulder	O
,	O
USA	O
)	O
by	O
PCR	O
to	O
introduce	O
the	O
restriction	O
sites	O
PmeI	O
in	O
5′	O
and	O
XhoI	O
in	O
3′.	O
Amplification	O
of	O
cDNA	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
construction	O
was	O
verified	O
by	O
enzymatic	O
restriction	O
and	O
by	O
DNA	O
sequencing	O
using	O
BigDye	O
3.1	O
(	O
ABI	O
)	O
.	O

All	O
infectious	O
particles	O
were	O
produced	O
using	O
the	O
producer	O
cell	O
line	O
293VSV	O
-	O
G	O
and	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
titer	O
of	O
each	O
retrovirus	O
was	O
measured	O
by	O
flow	O
-	O
cytometry	O
based	O
on	O
eGFP	O
expression	O
,	O
four	O
days	O
following	O
infection	O
of	O
HT1080	O
cells	O
and	O
ranged	O
from	O
0.5	O
×	O
109−2.1	O
×	O
109	O
TU	O
/	O
ml	O
(	O
All	O
details	O
on	O
how	O
to	O
produce	O
infectious	O
particles	O
can	O
be	O
provided	O
upon	O
request	O
)	O
.	O

Neurosphere	O
generation	O
,	O
transduction	O
and	O
differentiation	O
Pregnant	O
female	O
Sprague	B
-	I
Dawley	I
rats	I
(	O
B	O
&	O
K	O
Universal	O
,	O
Sollentuna	O
,	O
Sweden	O
)	O
were	O
terminally	O
anesthetized	O
by	O
an	O
overdose	O
of	O
sodium	O
pentobarbital	O
(	O
i.p	O
.	O
,	O
60	O
ng	O
/	O
ml	O
)	O
.	O

Embryos	O
at	O
stage	O
embryonic	O
day	O
E14.5	O
(	O
Plug	O
day	O
as	O
day	O
0	O
)	O
were	O
collected	O
and	O
cortical	O
-	O
hippocampal	O
neurospheres	O
were	O
generated	O
following	O
dissection	O
of	O
the	O
dorso	O
-	O
posterior	O
part	O
of	O
the	O
cortical	O
tissue	O
,	O
and	O
generated	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

In	O
this	O
study	O
,	O
second	O
passage	O
(	O
P2	O
)	O
neurospheres	O
were	O
used	O
to	O
study	O
the	O
effect	O
of	O
the	O
overexpression	O
of	O
Ngn2	O
and	O
NeuroD1	O
on	O
neuronal	O
differentiation	O
.	O

Each	O
well	O
,	O
containing	O
an	O
equal	O
starting	O
population	O
of	O
200,000	O
cells	O
/	O
ml	O
,	O
corresponding	O
to	O
15–25	O
neurospheres	O
,	O
was	O
transduced	O
independently	O
with	O
each	O
retrovirus	O
at	O
a	O
multiplicity	O
of	O
infection	O
(	O
MOI	O
)	O
of	O
1	O
,	O
in	O
proliferation	O
medium	O
supplemented	O
by	O
protamine	O
-	O
sulfate	O
(	O
4	O
mg	O
/	O
ml	O
,	O
Sigma	O
)	O
.	O

To	O
induce	O
differentiation	O
,	O
the	O
medium	O
was	O
replaced	O
with	O
normal	O
basic	O
differentiation	O
medium	O
two	O
days	O
post	O
-	O
transduction	O
and	O
subsequently	O
changed	O
every	O
other	O
day	O
until	O
fixation	O
.	O

Immunocytochemistry	O
,	O
immunohistochemistry	O
and	O
microscopy	O
The	O
antibodies	O
used	O
in	O
this	O
study	O
are	O
:	O
rabbit	B
anti	O
-	O
GFAP	O
(	O
1∶1000	O
;	O
DAKO	O
)	O
,	O
mouse	B
anti	O
-	O
Nestin	O
(	O
1∶100	O
;	O
BD	O
PharMingen	O
)	O
,	O
guinea	B
pig	I
anti	O
-	O
Glast	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Prox1	O
(	O
1∶1000	O
;	O
Covance	O
)	O
,	O
goat	B
anti	O
-	O
Ngn2	O
(	O
1∶20	O
;	O
Santa	O
Cruz	O
)	O
,	O
goat	B
anti	O
-	O
NeuroD1	O
(	O
1∶200	O
;	O
Santa	O
Cruz	O
)	O
,	O
rabbit	B
anti	O
-	O
Pax6	O
(	O
1∶150	O
;	O
Covance	O
)	O
,	O
rabbit	B
anti	O
-	O
Trb2	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Trb1	O
:	O
(	O
1∶1000	O
;	O
Chemicon	O
)	O
,	O
goat	B
anti	O
-	O
Dcx	O
:	O
(	O
1∶500	O
;	O
Santa	O
Cruz	O
)	O
,	O
mouse	B
anti	O
-	O
PSA	O
-	O
NCAM	O
:	O
(	O
1∶500	O
;	O
Chemicon	O
)	O
,	O
mouse	B
anti	O
-	O
NeuN	O
(	O
1∶300	O
;	O
Chemicon	O
)	O
,	O
rabbit	B
anti	O
-	O
Calretinin	O
(	O
1∶500	O
;	O
Swant	O
)	O
;	O
mouse	B
anti	O
-	O
Sox2	O
(	O
1∶100	O
;	O
R&D	O
systems	O
)	O
,	O
mouse	B
anti	O
-	O
Mash1	O
(	O
1∶100	O
;	O
BD	O
PharMingen	O
)	O
,	O
rabbit	B
anti	O
-	O
NeuroD2	O
(	O
1∶300	O
;	O
ABCAM	O
)	O
,	O
mouse	B
anti	O
-	O
MAP2	O
(	O
1∶500	O
;	O
Sigma	O
)	O
,	O
rabbit	B
anti	O
-	O
Ki67	O
(	O
1∶150	O
;	O
NovaCastra	O
)	O
and	O
rabbit	B
anti	O
-	O
phospho	O
-	O
Histone	O
H3	O
.	O

The	O
secondary	O
antibodies	O
(	O
1∶200	O
)	O
Cy2	O
,	O
FITC	O
,	O
Cy3	O
and	O
Cy5	O
were	O
from	O
Jackson	O
IR	O
laboratories	O
,	O
Alexa	O
-	O
fluor	O
488	O
,	O
568	O
,	O
595	O
and	O
647	O
from	O
Invitrogen	O
-	O
Molecular	O
Probes	O
.	O

DAPI	O
(	O
1∶1000	O
)	O
was	O
purchased	O
from	O
Sigma	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
five	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
a	O
blocking	O
solution	O
(	O
10	O
%	O
donkey	B
serum	O
,	O
0.25	O
%	O
TritonX100	O
in	O
PBS	O
)	O
for	O
1	O
hour	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

Specimen	O
analyses	O
were	O
performed	O
using	O
a	O
Leica	O
confocal	O
microscope	O
(	O
Leica	O
software	O
,	O
equipped	O
with	O
a	O
GreNe	O
and	O
a	O
HeNe	O
laser	O
,	O
using	O
the	O
following	O
lines	O
of	O
excitation	O
:	O
488	O
nm	O
,	O
594	O
nm	O
and	O
647	O
nm	O
)	O
.	O

Samples	O
were	O
analyzed	O
using	O
20	O
×	O
,	O
40	O
×	O
and	O
63	O
×	O
objectives	O
,	O
sometimes	O
zoomed	O
.	O

Figures	O
were	O
composed	O
in	O
CANVAS	O
-	O
X	O
software	O
.	O

Bromo	O
-	O
deoxyuridine	O
(	O
BrdU	O
)	O
and	O
Cloro	O
-	O
deoxyuridine	O
(	O
CldU	O
)	O
pulse	O
labeling	O
and	O
immunohisto-	O
and	O
immunocyto	O
-	O
chemistry	O
To	O
assess	O
cell	O
proliferation	O
and	O
ongoing	O
neurogenesis	O
in	O
vivo	O
,	O
animals	O
were	O
injected	O
with	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
,	O
Sigma	O
)	O
,	O
two	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
both	O
P2	O
and	O
two	O
weeks	O
old	O
Ngn2	O
mice	B
)	O
.	O

To	O
assess	O
neurogenesis	O
,	O
BrdU	O
(	O
100	O
mg	O
/	O
kg	O
)	O
was	O
injected	O
48	O
hours	O
prior	O
to	O
sacrifice	O
(	O
for	O
P2	O
animals	O
,	O
BrdU	O
was	O
injected	O
in	O
pregnant	O
dams	O
half	O
day	O
prior	O
to	O
give	O
birth	O
)	O
.	O

Immunohistochemistry	O
was	O
carried	O
on	O
as	O
described	O
above	O
using	O
a	O
rat	B
anti	O
-	O
CldU	O
/	O
BrdU	O
primary	O
antibody	O
(	O
1∶200	O
,	O
monoclonal	O
,	O
Immunologicalsdirect	O
,	O
Oxfordshire	O
,	O
UK	O
)	O
,	O
with	O
an	O
additional	O
denaturation	O
in	O
1	O
M	O
HCl	O
for	O
30	O
minutes	O
prior	O
to	O
pre	O
-	O
incubation	O
with	O
serum	O
.	O

To	O
assess	O
the	O
neuronal	O
-	O
inducing	O
activity	O
of	O
Ngn2	O
and	O
NeuroD1	O
,	O
transduced	O
cultures	O
were	O
incubated	O
with	O
CldU	O
(	O
20	O
µM	O
,	O
Sigma	O
)	O
for	O
2	O
days	O
,	O
after	O
a	O
period	O
of	O
differentiation	O
of	O
five	O
days	O
.	O

For	O
immunocytochemistry	O
,	O
cultures	O
were	O
fixed	O
with	O
4	O
%	O
paraformaldehyde	O
at	O
day	O
7	O
,	O
rinsed	O
with	O
PBS	O
three	O
times	O
,	O
treated	O
with	O
1	O
M	O
HCl	O
at	O
65	O
°	O
C	O
for	O
5–10	O
min	O
,	O
pre	O
-	O
incubated	O
and	O
then	O
incubated	O
with	O
a	O
rat	B
anti	O
-	O
CldU	O
/	O
BrdU	O
antibody	O
and	O
other	O
primary	O
antibodies	O
.	O

The	O
remainder	O
of	O
the	O
procedure	O
was	O
performed	O
according	O
to	O
the	O
protocol	O
for	O
immunohistochemistry	O
already	O
mentioned	O
.	O

In	O
utero	O
surgery	O
Timed	O
pregnant	O
female	O
Sprague	B
Dawley	I
rats	I
with	O
embryos	O
at	O
gestational	O
age	O
E15.5	O
were	O
anesthetized	O
with	O
halothane	O
.	O

The	O
mother	O
was	O
placed	O
in	O
the	O
lower	O
level	O
of	O
a	O
two	O
-	O
level	O
wooden	O
stage	O
.	O

The	O
abdomen	O
was	O
shaved	O
with	O
an	O
electric	O
razor	O
and	O
then	O
cleaned	O
with	O
70	O
%	O
alcohol	O
.	O

A	O
2–3	O
cm	O
midline	O
laparotomy	O
was	O
performed	O
.	O

Each	O
uterine	O
horn	O
was	O
carefully	O
taken	O
out	O
individually	O
and	O
the	O
number	O
of	O
embryos	O
recorded	O
.	O

One	O
horn	O
was	O
then	O
placed	O
back	O
inside	O
the	O
mother	O
,	O
whilst	O
the	O
other	O
horn	O
was	O
prepared	O
for	O
injection	O
.	O

The	O
embryos	O
were	O
kept	O
moist	O
with	O
constant	O
application	O
of	O
warm	O
saline	O
to	O
prevent	O
dehydration	O
.	O

Approximately	O
2	O
µl	O
of	O
viral	O
suspension	O
(	O
1	O
×	O
10∧9TU	O
/	O
ml	O
)	O
was	O
injected	O
into	O
the	O
lateral	O
ventricle	O
of	O
each	O
embryo	O
,	O
except	O
for	O
the	O
embryo	O
closest	O
to	O
the	O
vagina	O
.	O

After	O
the	O
injections	O
,	O
the	O
uterine	O
horns	O
were	O
placed	O
back	O
into	O
the	O
abdomen	O
.	O

The	O
abdominal	O
wall	O
and	O
the	O
overlying	O
skin	O
were	O
then	O
sutured	O
.	O

Care	O
was	O
taken	O
not	O
to	O
damage	O
abdominal	O
muscles	O
so	O
that	O
normal	O
delivery	O
of	O
the	O
pups	O
was	O
possible	O
at	O
term	O
.	O

The	O
entire	O
surgery	O
generally	O
took	O
about	O
45	O
minutes	O
to	O
one	O
hour	O
.	O

Each	O
mother	O
was	O
allowed	O
to	O
recover	O
in	O
her	O
cage	O
before	O
being	O
returned	O
to	O
the	O
animal	O
stable	O
.	O

Shredded	O
paper	O
was	O
added	O
to	O
each	O
cage	O
to	O
encourage	O
nesting	O
and	O
special	O
care	O
was	O
taken	O
not	O
to	O
stress	O
the	O
mothers	O
.	O

Following	O
normal	O
delivery	O
,	O
the	O
pups	O
were	O
allowed	O
to	O
develop	O
to	O
adulthood	O
up	O
to	O
two	O
weeks	O
.	O

Quantification	O
For	O
the	O
in	O
vivo	O
experiment	O
,	O
manual	O
cell	O
counting	O
was	O
performed	O
on	O
18	O
and	O
30	O
µm	O
thick	O
brain	O
sections	O
for	O
two	O
days	O
and	O
two	O
weeks	O
old	O
animals	O
,	O
respectively	O
.	O

The	O
brain	O
of	O
P2	O
animals	O
was	O
cut	O
into	O
10	O
series	O
of	O
coronal	O
sections	O
;	O
the	O
brain	O
of	O
two	O
-	O
weeks	O
old	O
animals	O
was	O
cut	O
into	O
7–8	O
series	O
of	O
coronal	O
sections	O
.	O

For	O
each	O
staining	O
,	O
one	O
-	O
two	O
series	O
from	O
three	O
to	O
five	O
different	O
individuals	O
were	O
analyzed	O
per	O
genotype	O
using	O
a	O
confocal	O
microscope	O
with	O
1	O
,	O
2	O
or	O
3	O
lines	O
of	O
excitation	O
,	O
in	O
sequential	O
scanning	O
in	O
order	O
to	O
avoid	O
false	O
positives	O
.	O

When	O
two	O
series	O
were	O
analyzed	O
,	O
only	O
one	O
series	O
was	O
counted	O
.	O

The	O
mean	O
number	O
of	O
cells	O
per	O
hippocampus	O
expressing	O
the	O
markers	O
of	O
interest	O
,	O
was	O
calculated	O
for	O
each	O
brain	O
,	O
based	O
on	O
the	O
analysis	O
of	O
6–8	O
consecutive	O
dorsal	O
hippocampal	O
sections	O
.	O

The	O
final	O
mean	O
number	O
of	O
cells	O
per	O
section	O
was	O
calculated	O
by	O
adding	O
the	O
mean	O
number	O
from	O
each	O
individual	O
.	O

We	O
expressed	O
the	O
data	O
as	O
the	O
mean	O
number	O
of	O
positive	O
cells±standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

In	O
this	O
study	O
,	O
more	O
than	O
25	O
Ngn2	O
null	O
,	O
>	O
45	O
Ngn2	O
heterozygotes	O
,	O
and	O
>	O
60	O
WT	O
individuals	O
(	O
including	O
rats	B
injected	O
with	O
retroviruses	O
)	O
were	O
analyzed	O
,	O
in	O
total	O
.	O

Statistical	O
comparison	O
was	O
performed	O
using	O
one	O
-	O
factor	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
with	O
transcription	O
factor	O
,	O
cellular	O
marker	O
,	O
genotype	O
or	O
time	O
as	O
variables	O
,	O
followed	O
by	O
post	O
-	O
hoc	O
analysis	O
when	O
significant	O
differences	O
were	O
observed	O
,	O
using	O
Statview	O
5.0	O
software	O
(	O
SAS	O
institute	O
Inc.	O
)	O
.	O

For	O
cell	O
culture	O
experiments	O
,	O
three	O
independent	O
experiments	O
were	O
performed	O
,	O
each	O
in	O
duplicate	O
.	O

The	O
counting	O
was	O
based	O
on	O
seven	O
randomly	O
chosen	O
different	O
fields	O
of	O
view	O
.	O

For	O
each	O
diagram	O
,	O
the	O
level	O
of	O
significance	O
(	O
p	O
-	O
value	O
)	O
is	O
represented	O
as	O
follows	O
:	O
P<0.05	O
=	O
*	O
;	O
P<0.001	O
=	O
*	O
*	O
;	O
P<0.0001	O
=	O
*	O
*	O
*	O
.	O

All	O
data	O
are	O
expressed	O
as±standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
.	O

Human	B
sample	O
and	O
RT	O
-	O
PCR	O
The	O
brain	O
from	O
a	O
64	O
year	O
-	O
old	O
male	O
was	O
provided	O
by	O
the	O
Harvard	O
Brain	O
Tissue	O
Resource	O
Center	O
.	O

The	O
individual	O
whose	O
brain	O
tissue	O
was	O
being	O
analyzed	O
gave	O
written	O
consent	O
for	O
storage	O
and	O
use	O
of	O
his	O
tissue	O
for	O
research	O
.	O

Five	O
millimeters	O
thick	O
fresh	O
human	B
hippocampal	O
tissue	O
sample	O
was	O
snap	O
frozen	O
.	O

The	O
frozen	O
tissue	O
block	O
was	O
cut	O
into	O
20	O
series	O
of	O
coronal	O
sections	O
,	O
using	O
a	O
cryostat	O
.	O

Every	O
10	O
sections	O
,	O
one	O
section	O
was	O
placed	O
in	O
an	O
Eppendorf	O
tube	O
,	O
on	O
dry	O
ice	O
.	O

Pooled	O
sections	O
were	O
used	O
for	O
RT	O
-	O
PCR	O
.	O

Total	O
RNA	O
was	O
prepared	O
using	O
Trizol	O
and	O
RNAeasy	O
,	O
supplemented	O
with	O
RNAGuard	O
as	O
previously	O
described	O
[	O
49	O
]	O
.	O

The	O
RNA	O
was	O
digested	O
with	O
shrimp	O
DNAse	O
before	O
cDNA	O
synthesis	O
,	O
which	O
was	O
performed	O
using	O
a	O
mix	O
of	O
oligo	O
-	O
dT	O
and	O
random	O
hexamer	O
primers	O
and	O
SuperscriptII	O
reverse	O
transcriptase	O
.	O

Advantage2	O
polymerase	O
mix	O
(	O
Clontech	O
/	O
BRL	O
)	O
was	O
used	O
for	O
PCR	O
,	O
with	O
the	O
following	O
cycling	O
conditions	O
:	O
10	O
cycles	O
of	O
94	O
°	O
C	O
for	O
30	O
seconds	O
,	O
68	O
°	O
C	O
for	O
2	O
minutes	O
,	O
30	O
cycles	O
of	O
94	O
°	O
C	O
for	O
30	O
seconds	O
,	O
60	O
°	O
C	O
for	O
1	O
minute	O
,	O
68	O
°	O
C	O
for	O
1	O
minute	O
and	O
30	O
seconds	O
,	O
one	O
cycle	O
of	O
68	O
°	O
C	O
for	O
2	O
minutes	O
,	O
soak	O
at	O
16	O
°	O
C	O
.	O

Primers	O
marked	O
*	O
were	O
designed	O
by	O
PrimerBank	O
.	O

hRPS18	O
(	O
sense	O
)	O
5′-GCCTTTGCCATCACTGCCATT	O
and	O
hRPS18	O
(	O
antisense	O
)	O
5′-GCCAGTGGTCTTGGTGTGCT	O
,	O
hPAX6	O
(	O
sense	O
)	O
5′-GCCCTGGAGAAAGAGTTTGAGAGAACCCATT	O
hPAX6	O
(	O
antisense	O
)	O
5′-GGGGAAATGAGTCCTGTTGAAGTGGTGC	O
,	O
hTBR1	O
(	O
sense	O
)	O
5′-GCGGACACCAATGTGCAAGGAAATCG	O
and	O
hTBR1	O
(	O
antisense	O
)	O
5′-CGAGGGGGTCAGGCGGTCCATGTCACAGC	O
,	O
hTBR2	O
(	O
sense	O
)	O
5′-GACCTGTGGCAAAGCCGACAATAACATGC	O
and	O
hTBR2	O
(	O
antisense	O
)	O
5′-GGGGGTGTCTCTATCCAAGAAGAGCCAAT	O
,	O
hPDHX	O
(	O
=	O
PROX1	O
)	O
(	O
sense	O
)	O
5′-GGGACACTACGGTTCCGTTTAAGTCCAGC	O
and	O
hPDHX	O
(	O
antisense	O
)	O
5′-CTCTCCATCCCAGCTTACATTAACATCTGGCATTTGT	O
,	O
hNGN2	O
(	O
sense	O
)	O
*	O
5′-CATCAAGAAGACCCGTAGACTGA	O
and	O
hNGN2	O
(	O
antisense	O
)	O
*	O
5′-CAACACTGCCTCGGAGAAG	O
,	O
hMASH1	O
(	O
sense	O
)	O
5′-CCTGGATCCGCATGGAAAGCTCTGCCAAGATGGAG	O
and	O
hMASH1	O
(	O
antisense	O
)	O
5′-CCTGGATCCCCCCTCAGAACCAGTTGGTGAAGTCGA	O
,	O
hNEUROD1	O
(	O
sense	O
)	O
5′-GCTCAGGACCTACTAACAACAAAGGAAATCGAAACATG	O
and	O
hNEUROD1	O
(	O
antisense	O
)	O
5′-CAAAGCGTCTGAACGAAGGAGACCAGGT	O
,	O
hGLAST	O
(	O
sense	O
)	O
5′-CATCAGGGAAGATGGGAATGCGAGCTGTAGTCTATTAT	O
and	O
hGLAST	O
(	O
antisense	O
)	O
5′-CCACGGGGGCATACCACATTATTACTGCTACC	O
,	O
hNEST	O
(	O
sense	O
)	O
5′-CAGGAGCGGCTGCGGGCTACTGAAAAGTTCC	O
and	O
hNEST	O
(	O
antisense	O
)	O
5′-CAGGGCTGAGGGGTGGTGCCAAGGAGG	O
,	O
hGFAP	O
(	O
sense	O
)	O
5′-CCACGAGGAGGAGGTTCGGGAACTCCAGGAGC	O
and	O
hGFAP	O
(	O
antisense	O
)	O
5-GGAATGGTGATCCGGTTCTCCTCGCCCTCTAGC	O
,	O
hCALB2	O
(	O
=	O
Calretinin	O
)	O
(	O
sense	O
)	O
5′-GGCTCTGGCATGATGTCAAAGAGTGACAACTTT	O
and	O
hCALB2	O
(	O
antisense	O
)	O
5′-GGGCATCCAGCTCATGCTCGTCAATGTAGCC	O
,	O
hCALB1	O
(	O
sense	O
)	O
5′-GCGAAAGAAGGCTGGATTGGAGTTATCACC	O
and	O
hCALB1	O
(	O
antisense	O
)	O
5′-CCCTCCATCCGACAAAGCCATTATGTTCTTCTTGTATG	O
,	O
hSOX2	O
(	O
sense	O
)	O
5′-GGAGAACCCCAAGATGCACAACTCGGAGAT	O
and	O
hSOX2	O
(	O
antisense	O
)	O
5′-GAGGAAGAGGTAACCACAGGGGGGCTGGAGC	O
,	O
hWNT3A	O
(	O
sense	O
)	O
5′-CCGAGGGCATCAAGATTGGCATCCAGGAGTGC	O
and	O
hWNT3A	O
(	O
antisense	O
)	O
5′-TCGGGTTGCGACCACCAGCATGTCTTCACCTC	O
,	O
hSHH	O
*	O
(	O
sense	O
)	O
5′-ACTCCGAGCGATTTAAGGAACT	O
and	O
hSHH	O
*	O
(	O
antisense	O
)	O
5′-CAGACGTGGTGATGTCCACTG	O
.	O

Supporting	O
Information	O

Organization	O
and	O
structure	O
of	O
the	O
mouse	B
interleukin-2	O
gene	O
.	O

Abstract	O
We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	O
interleukin-2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	B
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5'-flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	B
and	O
man	B
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
.	O

Images	O
Volume	O
12	O
Number	O
24	O
1984	O
Nucleic	O
Acids	O
Research	O
Organization	O
and	O
structure	O
of	O
the	O
mouse	B
interleukin-2	O
gene	O
Akira	O
Fuse	O

*	O
,	O
Takashi	O
Fujita	O
,	O
Hidetaro	O
Yasumitsu	O
,	O
Nobukazu	O
Kashima+	O
,	O
Katsushige	O
Hasegawa	O
and	O
Tadatsugu	O
Taniguchi	O
?	O

Department	O
of	O
Biochemistry	O
,	O
Cancer	O
Institute	O
,	O
Japanese	O
Foundation	O
for	O
Cancer	O
Research	O
,	O
Toshimaku	O
,	O
Tokyo	O
170	O
and	O
Institute	O
for	O
Molecular	O
and	O
Cellular	O
Biology	O
,	O
Osaka	O
University	O
,	O
Suita	O
-	O
shi	O
,	O

Osaka	O
565	O
,	O
Japan	O
Received	O
10	O
October	O
1984	O
;	O
Revised	O
and	O
Accepted	O
20	O
November	O
1984	O
ABSTRACT	O
We	O
have	O
cloned	O
a	O
chromosomal	O
DNA	O
segment	O
which	O
covers	O
the	O
entire	O
sequence	O
for	O
the	O
murine	O
interleukin-2	O
gene	O
and	O
analysed	O
the	O
structure	O
of	O
the	O
gene	O
.	O

The	O
coding	O
regions	O
are	O
separated	O
into	O
four	O
blocks	O
by	O
three	O
introns	O
each	O
of	O
which	O
is	O
located	O
similarly	O
to	O
the	O
corresponding	O
human	B
gene	O
.	O

The	O
exon	O
sequences	O
can	O
be	O
aligned	O
perfectly	O
with	O
the	O
previously	O
cloned	O
cDNA	O
sequence	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
sequences	O
within	O
the	O
5'flanking	O
region	O
which	O
are	O
highly	O
conserved	O
between	O
mouse	B
and	O
man	B
.	O

The	O
conserved	O
region	O
which	O
spans	O
more	O
than	O
400	O
base	O
pairs	O
may	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
.	O

INTRODUCTION	O
Interleukin-2	O
(	O
IL-2	O
)	O
is	O
a	O
lymphokine	O
produced	O
by	O
T	O
cells	O
upon	O
antigenic	O
or	O
mitogenic	O
stimulation	O
and	O
is	O
required	O
for	O
the	O
proliferation	O
of	O
T	O
cells	O
(	O
1,2	O
)	O
.	O

Several	O
other	O
biological	O
activities	O
of	O
IL-2	O
which	O
appear	O
to	O
be	O
crucial	O
in	O
the	O
immune	O
regulation	O
have	O
also	O
been	O
reported	O
(	O
3	O
,	O
4	O
.	O
5	O
.	O
6	O
.	O
7	O
.	O
)	O
.	O

We	O
previously	O
reported	O
isolation	O
and	O
sequence	O
analysis	O
of	O
the	O
cDNA	O
for	O
human	B
IL-2	O
(	O
8)	O
,	O
as	O
well	O
as	O
the	O
chromosomal	O
gene	O
(	O
9	O
)	O
.	O

More	O
recently	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
which	O
encodes	O
murine	O
IL-2	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
cDNA	O
contains	O
a	O
unique	O
tandem	O
repeat	O
of	O
CAG	O
sequence	O
which	O
would	O
encode	O
12	O
consecutive	O
glutamine	O
residues	O
in	O
the	O
active	O
IL-2	O
molecule	O
.	O

In	O
order	O
to	O
study	O
the	O
structure	O
of	O
the	O
murine	O
IL-2	O
chromosomal	O
gene	O
and	O
its	O
controlling	O
region	O
,	O
we	O
isolated	O
and	O
analysed	O
a	O
A	O
phage	O
clone	O
containing	O
the	O
gene	O
and	O
its	O
flanking	O
sequences	O
.	O

MATERIALS	O
AND	O
METHODS	O
Southern	O
blotting	O
of	O
total	O
mouse	B
DNA	O
Mouse	B
chromosomal	O
DNA	O
was	O
extracted	O
from	O
liver	O
of	O
BALB	O
/	O
c6	O
?	O

I	O
R	O
L	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O
Volume	O
12	O
Number	O
24	O
1984	O
9323	O
Nucleic	O
Acids	O
Research	O
mouse	B
as	O
described	O
before	O
(	O
10	O
)	O
.	O

High	O
molecular	O
genomic	O
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
enzymes	O
and	O
electrophoresed	O
on	O
0.8	O
%	O
agarose	O
gel	O
.	O

Blotting	O
analysis	O
of	O
DNA	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Southern	O
(	O
11	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
as	O
described	O
previously	O
and	O
filters	O
were	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
650C	O
(	O
lower	O
stringent	O
condition	O
)	O
or	O
in	O
0.1	O
x	O
SSC	O
at	O
650C	O
(	O
higher	O
stringent	O
condition	O
)	O
.	O

Screening	O
of	O
genomic	O
DNA	O
library	O
A	O
bacteriophage	O
XCharon	O
4A	O
/	O
mouse	B
genomic	O
DNA	O
library	O
prepared	O
with	O
partial	O
EcoRI	O
digests	O
of	O
mouse	B
DNA	O
from	O
MPC	O
11	O
plasmacytoma	O
cells	O
was	O
kindly	O
provided	O
by	O
Dr.	O
T.	O
Honjo	O
.	O

Mouse	B
IL-2-specific	O
clones	O
were	O
screened	O
by	O
the	O
method	O
of	O
Benton	O
and	O
Davis	O
(	O
12	O
)	O
,	O
using	O
700	O
bp	O
PstI	O
-	O
AccI	O
fragment	O
of	O
a	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
45	O
as	O
the	O
probe	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

Hybridization	O
was	O
performed	O
as	O
described	O
previously	O
(	O
13	O
)	O
.	O

Positive	O
clones	O
were	O
rescreened	O
at	O
least	O
twice	O
.	O

Subcloninq	O
and	O
sequencing	O
of	O
the	O
mouse	B
IL-2	O
gene	O
Two	O
EcoRI	O
fragments	O
of	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
from	O
the	O
positive	O
recombinant	O
X	O
phage	O
were	O
subcloned	O
into	O
EcoRI	O
site	O
of	O
plasmid	O
pBR322	O
.	O

DNA	O
segments	O
derived	O
from	O
subcloned	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
fragments	O
were	O
labelled	O
at	O
either	O
3	O
'	O
end	O
or	O
5	O
'	O
end	O
,	O
and	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
chemical	O
degradation	O
method	O
(	O
14	O
)	O
.	O

The	O
0.8	O
Kbp	O
EcoRI	O
fragment	O
from	O
the	O
same	O
X	O
phage	O
clone	O
was	O
directly	O
subjected	O
to	O
sequence	O
analysis	O
by	O
the	O
dideoxy	O
chain	O
termination	O
method	O
(	O
15	O
)	O
.	O

RESULTS	O
Total	O
DNA	O
blotting	O
analysis	O
In	O
order	O
to	O
study	O
structural	O
organization	O
of	O
the	O
mouse	B
IL-2	O
gene	O
,	O
we	O
first	O
subjected	O
total	O
mouse	B
DNA	O
to	O
the	O
blotting	O
analysis	O
by	O
using	O
various	O
probes	O
specific	O
for	O
IL-2	O
gene	O
.	O

When	O
mouse	B
DNA	O
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
and	O
then	O
probed	O
with	O
a	O
7	O
kb	O
human	B
chromosomal	O
DNA	O
segment	O
which	O
contains	O
the	O
human	B
IL-2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
Fig.	O
1	O
lane	O
1	O
-	O
8	O
,	O
ref	O
.	O

9	O
.	O
)	O
,	O
single	O
positive	O
band	O
appeared	O
at	O
lower	O
but	O
not	O
at	O
higher	O
stringent	O
condition	O
for	O
washing	O
the	O
filters	O
(	O
see	O
Figure	O
legend	O
)	O
.	O

Additional	O
bands	O
corresponding	O
to	O
those	O
observed	O
by	O
using	O
mouse	B
IL-2	O
cDNA	O
probes	O
(	O
lane	O
13	O
-	O
17	O
)	O
also	O
appeared	O
by	O
longer	O
9324	O
Nucleic	O
Acids	O
Research	O
M	O
1	O
2	O
3	O
4	O
M	O
5	O
6	O
7	O
8	O
M	O
9	O
101112	O
M	O
13	O
141516	O
17	O
a~	O
~	O
3	O
..	O

I	O
pMIL2	O
-	O
45	O
SacI	O
Acc	O
I	O
CZI~~1	O
1	O
t	O
L2-	O
20	O
Acc	O
I	O
1	O
00	O
tp	O
lX	O
i	O
Fig.	O
1	O
.	O

Blot	O
hybridization	O
analysis	O
of	O
mouse	B
chromosomal	O
DNA	O
.	O

High	O
molecular	O
DNA	O
prepared	O
from	O
Liver	O
BALB	O
/	O
C6	O
mouse	B
was	O
digested	O
with	O
various	O
restriction	O
endonucleases	O
(	O
BamHI	O
for	O
lanes	O
1	O
,	O
5	O
,	O
9	O
,	O
13	O
;	O
EcoRI	O
for	O
lanes	O
2	O
,	O
6	O
,	O
10	O
,	O
14	O
,	O
17	O
;	O
HindIII	O
for	O
lanes	O
3	O
,	O
7	O
,	O
11	O
,	O
15	O
;	O
XbaI	O
for	O
lanes	O
4	O
,	O
8	O
,	O
12	O
,	O
16	O
)	O
.	O

The	O
resulting	O
digests	O
were	O
fractionated	O
on	O
0.8	O
%	O
agarose	O
gel	O
and	O
transferred	O
to	O
a	O
nitrocellulose	O
filter	O
.	O

Filters	O
were	O
hybridized	O
by	O
the	O
published	O
procedure	O
(	O
13	O
)	O
either	O
with	O
the	O
nick	O
-	O
translated	O
chromosomal	O
DNA	O
containing	O
human	B
IL-2	O
gene	O
and	O
its	O
flanking	O
region	O
(	O
total	O
length	O
,	O
7.0	O
kb	O
,	O
ref	O
.	O

9	O
)	O
(	O
lane	O
1	O
-	O
8	O
)	O
or	O
with	O
the	O
nick	O
-	O
translated	O
cDNA	O
for	O
mouse	B
IL-2	O
(	O
see	O
figure	O
)	O
.	O

Filters	O
were	O
then	O
washed	O
either	O
in	O
3	O
x	O
SSC	O
at	O
65	O
%	O
(	O
lower	O
stringent	O
condition	O
)	O
(	O
lane	O
1	O
-	O
4	O
,	O
9	O
-	O
12	O
)	O
or	O
0.1	O
x	O
SSC	O
at	O
65	O
OC	O
(	O
higher	O
stringent	O
condition	O
)	O
(	O
lane	O
5	O
-	O
8	O
,	O
13	O
-	O
17	O
)	O
.	O

Lane	O
M	O
each	O
contains	O
7	O
size	O
markers	O
with	O
their	O
size	O
being	O
23.7	O
kb	O
,	O
9.5	O
kb	O
,	O
6.7	O
kb	O
,	O
4.3	O
kb	O
,	O
2.3	O
kb	O
,	O
2.0	O
kb	O
and	O
0.6	O
kb	O
,	O
respectively	O
.	O

Brief	O
restriction	O
endonuclease	O
cleavage	O
map	O
for	O
the	O
mouse	B
IL-2	O
cDNAs	O
is	O
presented	O
in	O
the	O
lower	O
part	O
of	O
the	O
figure	O
.	O

exposure	O
of	O
the	O
film	O
(	O
data	O
not	O
shown	O
)	O
.	O

Those	O
results	O
suggest	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
between	O
human	B
and	O
mouse	B
DNA	O
either	O
in	O
the	O
flanking	O
regions	O
or	O
in	O
the	O
introns	O
of	O
the	O
IL-2	O
gene	O
,	O
since	O
the	O
coding	O
regions	O
apparently	O
show	O
lower	O
degree	O
of	O
sequence	O
homology	O
as	O
evidenced	O
in	O
this	O
series	O
of	O
blotting	O
analysis	O
(	O
see	O
below	O
)	O
.	O

When	O
the	O
PstI	O
insert	O
of	O
a	O
mouse	B
IL-2	O
cDNA	O
clone	O
,	O
pMIL2	O
-	O
20	O
,	O
was	O
used	O
as	O
the	O
probe	O
,	O
a	O
simple	O
pattern	O
was	O
9325	O
Nucleic	O
Acids	O
Research	O
obtained	O
at	O
higher	O
stringent	O
condition	O
(	O
lane	O
13	O
-	O
17	O
)	O
.	O

While	O
the	O
EcoRI	O
-	O
digested	O
DNA	O
gave	O
rise	O
to	O
two	O
positive	O
bands	O
(	O
2.8	O
kb	O
and	O
0.8	O
kb	O
)	O
(	O
Fig	O
.	O

1	O
,	O
lane	O
14	O
)	O
by	O
this	O
analysis	O
,	O
one	O
additional	O
band	O
of	O
3.3	O
kb	O
also	O
appeared	O
when	O
the	O
same	O
DNA	O
was	O
probed	O
with	O
a	O
longer	O
cDNA	O
insert	O
from	O
another	O
clone	O
,	O
pMIL2	O
-	O
45	O
(	O
Fig.	O
1	O
,	O
lane	O
17	O
)	O
.	O

The	O
3.3	O
kb	O
band	O
was	O
similar	O
in	O
its	O
size	O
with	O
the	O
positive	O
band	O
which	O
became	O
detectable	O
by	O
probing	O
the	O
same	O
DNA	O
with	O
the	O
7.0	O
kb	O
human	B
DNA	O
probe	O
(	O
Fig.	O
1	O
,	O
lane	O
2	O
)	O
.	O

Since	O
this	O
band	O
appeared	O
with	O
the	O
cDNA	O
probe	O
extending	O
further	O
upstream	O
,	O
it	O
is	O
likely	O
that	O
the	O
5	O
'	O
region	O
of	O
the	O
gene	O
is	O
located	O
within	O
this	O
DNA	O
segment	O
(	O
see	O
below	O
)	O
.	O

Indeed	O
,	O
this	O
3.3	O
kb	O
band	O
did	O
not	O
appear	O
even	O
after	O
longer	O
exposure	O
of	O
lane	O
14	O
(	O
result	O
not	O
shown	O
)	O
.	O

BamHI	O
digest	O
of	O
the	O
mouse	B
DNA	O
(	O
Fig.	O
1	O
,	O
lane	O
1	O
,	O
13	O
)	O
constantly	O
gave	O
a	O
very	O
faint	O
signal	O
which	O
would	O
correspond	O
to	O
a	O
DNA	O
larger	O
than	O
15	O
kb	O
.	O

Taken	O
together	O
,	O
the	O
results	O
suggested	O
the	O
presence	O
of	O
a	O
single	O
copy	O
gene	O
for	O
murine	O
IL-2	O
.	O

On	O
the	O
other	O
hand	O
appearance	O
of	O
the	O
multiple	O
positive	O
bands	O
at	O
lower	O
stringent	O
washing	O
condition	O
(	O
lane	O
9	O
-	O
12	O
)	O
indicates	O
the	O
presence	O
of	O
IL-2	O
related	O
sequences	O
within	O
the	O
mouse	B
genome	O
.	O

Screening	O
of	O
recombinant	O
phaqe	O
libraries	O
We	O
next	O
screened	O
a	O
gene	O
library	O
from	O
partial	O
EcoRIdigested	O
DNA	O
from	O
MPC	O
11	O
cells	O
and	O
by	O
using	O
0.8	O
Kbp	O
SacI	O
-	O
AccI	O
cDNA	O
fragment	O
as	O
the	O
probe	O
and	O
isolated	O
14	O
positive	O
clones	O
containing	O
sequences	O
specific	O
to	O
the	O
mouse	B
IL-2	O
gene	O
.	O

Three	O
of	O
the	O
clones	O
analysed	O
all	O
contained	O
three	O
EcoRI	O
fragments	O
whose	O
size	O
is	O
in	O
agreement	O
with	O
the	O
result	O
of	O
blotting	O
analysis	O
of	O
the	O
chromosomal	O
DNA	O
as	O
shown	O
in	O
Fig.	O
1	O
(	O
lane	O
17	O
)	O
.	O

One	O
of	O
these	O
is	O
designated	O
MIL-2G70	O
.	O

Nucleotide	O
sequence	O
analysis	O
Two	O
DNA	O
fragments	O
of	O
3.3	O
Kbp	O
and	O
2.8	O
Kbp	O
were	O
excised	O
from	O
the	O
phage	O
clone	O
MIL-2G70	O
by	O
EcoRI	O
digestion	O
and	O
they	O
were	O
subcloned	O
into	O
pBR322	O
.	O

DNA	O
sequences	O
were	O
determined	O
for	O
selected	O
regions	O
of	O
both	O
inserts	O
and	O
compared	O
to	O
the	O
known	O
cDNA	O
sequences	O
(	O
Kashima	O
et	O
al.	O
,	O
submitted	O
for	O
publication	O
)	O
.	O

The	O
strategy	O
used	O
for	O
sequence	O
analysis	O
of	O
the	O
genomic	O
DNA	O
is	O
presented	O
in	O
Fig.	O
2	O
.	O

Comparison	O
of	O
the	O
mouse	B
genomic	O
IL-2	O
sequence	O
with	O
mouse	B
IL-2	O
cDNA	O
sequence	O
revealed	O
that	O
,	O
like	O
the	O
human	B
gene	O
,	O
the	O
gene	O
is	O
divided	O
into	O
four	O
exons	O
.	O

A	O
putative	O
9326	O
Nucleic	O
Acids	O
Research	O
E	O
E	O
E	O
E	O
E	O
500bp	O
s	O
7S	O
P	O
HBH	O
H	O
\A	O
200	O
bp	O

*	O
,	O
-	O
4	O
I	O
4	O
-	O
4	O
-	O
---	O

*	O
*	O
-	O
--4	O
Fig.	O
2	O
.	O

Restriction	O
map	O
and	O
sequencing	O
strategy	O
of	O
mouse	B
IL-2	O
gene	O
.	O

Horizontal	O
lines	O
indicate	O
the	O
length	O
of	O
mouse	B
DNA	O
inserted	O
into	O
the	O
X	O
phage	O
Charon	O
4A	O
or	O
plasmid	O
subclones	O
.	O

Filled	O
blocks	O
,	O
dashed	O
blocks	O
and	O
open	O
blocks	O
indicate	O
protein	O
coding	O
regions	O
,	O
untranslated	O
regions	O
and	O
introns	O
,	O
respectively	O
.	O

Horizontal	O
arrows	O
indicate	O
the	O
direction	O
and	O
extent	O
of	O
sequence	O
determination	O
without	O
ambiguity	O
.	O

Dashed	O
arrows	O
:	O
determination	O
was	O
done	O
by	O
the	O
chain	O
termination	O
method	O
(	O
15	O
)	O
after	O
subcloning	O
the	O
0.8	O
kb	O
fragment	O
into	O
M13	O
.	O

Rest	O
of	O
the	O
sequence	O
determination	O
was	O
carried	O
out	O
by	O
the	O
method	O
of	O
Maxam	O
and	O
Gilbert	O
(	O
14	O
)	O
.	O

A	O
AccI	O
site	O
,	O
B	O
;	O
BamHI	O
site	O
,	O
E	O
;	O
EcoRI	O
site	O
,	O
H	O
;	O
HindIII	O
site	O
,	O
P	O
;	O
PstI	O
site	O
,	O
S	O
;	O
SacI	O
site	O
.	O

capping	O
site	O
or	O
the	O
transcription	O
initiation	O
site	O
was	O
located	O
32	O
bp	O
downstream	O
from	O
a	O
TATAAA	O
consensus	O
promotor	O
sequence	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
first	O
ATG	O
triplet	O
was	O
located	O
79	O
bp	O
downstream	O
from	O
the	O
TATA	O
box	O
.	O

As	O
seen	O
also	O
in	O
the	O
murine	O
IL-2	O
cDNA	O
,	O
there	O
is	O
an	O
unusual	O
repeat	O
of	O
CAG	O
triplet	O
coding	O
for	O
12	O
glutamine	O
residues	O
in	O
a	O
row	O
in	O
the	O
first	O
exon	O
.	O

The	O
second	O
exon	O
(	O
60	O
bp	O
)	O
is	O
separated	O
from	O
the	O
first	O
exon	O
by	O
a	O
short	O
intron	O
consisting	O
of	O
97	O
bp	O
.	O

The	O
second	O
,	O
the	O
third	O
and	O
the	O
fourth	O
exons	O
are	O
interrupted	O
by	O
longer	O
introns	O
whose	O
size	O
is	O
about	O
2.3	O
Kbp	O
and	O
1.6	O
Kbp	O
,	O
respectively	O
.	O

As	O
far	O
as	O
the	O
available	O
sequence	O
data	O
are	O
concerned	O
,	O
it	O
seems	O
that	O
,	O
despite	O
their	O
identical	O
location	O
,	O
intron	O
sequences	O
are	O
distinctly	O
dissimilar	O
except	O
for	O
the	O
junction	O
regions	O
between	O
the	O
human	B
and	O
mouse	B
IL-2	O
genes	O
.	O

There	O
are	O
two	O
potential	O
poly	O
(	O
A	O
)	O
addition	O
signals	O
within	O
the	O
mouse	B
gene	O
(	O
nucleotide	O
positions	O
793	O
-	O
798	O
and	O
924	O
-	O
929	O
in	O
Fig.	O
3	O
)	O
and	O
,	O
based	O
on	O
our	O
sequence	O
data	O
for	O
various	O
cDNA	O
clones	O
,	O
both	O
signals	O
seem	O
to	O
function	O
and	O
give	O
rise	O
to	O
heterogeneous	O
termini	O
of	O
the	O
mRNA	O
in	O
the	O
LBRM-33	O
cells	O
(	O
16	O
)	O
.	O

We	O
have	O
also	O
determined	O
the	O
sequence	O
of	O
about	O
500	O
bp	O
of	O
5'-flanking	O
region	O
of	O
mouse	B
IL-2	O
gene	O
,	O
since	O
(	O
i	O
)	O
promoter	O
/	O
regulatory	O
sequences	O
are	O
located	O
in	O
this	O
region	O
in	O
many	O
other	O
genes	O
of	O
eukaryotes	O
and	O
(	O
ii	O
)	O
this	O
region	O
appeared	O
to	O
contain	O
sequences	O
which	O
show	O
strongest	O
cross	O
-	O
hybridization	O
between	O
human	B
and	O
mouse	B
DNA	O
around	O
the	O
IL-2	O
gene	O
(	O
Fig.	O
1	O
)	O
.	O

Comparison	O
of	O
the	O
nucleotide	O
sequences	O
for	O
the	O
5	O
'	O
flanking	O
region	O
9327	O
Nucleic	O
Acids	O
Research	O
-4.0	O
TAGGAGGTAAACCATCTCGAAACGGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAG	O
-400	O
-350	O
GATTTATTCTTTTCATCTATCTCCTCTTGCGCCCGTCCACCACAACAGGCTGCTTACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTT	O
-300	O
-250	O
CATGAGTTACTTTTGTGTCTCCACCCCAAAGAGGAAAATTTTGTTCATACGAAAGGCGTTCATTGTATGAATTAAAACTGCCACCTAAGAG	O
-200	O
-150	O
TGGGCTAACCCGACCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATATGGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAA	O
-100	O
-50	O
AAACAAAGGTAATACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTAATATGTAAAACATCGTGACACCCCCATATTATTTTTC	O
CAGCATTAACAGTATAAATTGCCTCCCATGCTGAAGAGCTGCC	O
TCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGC	O
50	O
100	O
ATG	O
TAC	O
AGC	O
ATG	O
CAG	O
CTC	O
GCA	O
TCC	O
TGT	O
GTC	O
ACA	O
TTG	O
ACA	O
CTT	O
GTG	O
CTC	O
CTT	O
GTC	O
AAC	O
AGC	O
GCA	O
CCC	O
ACT	O
Met	O
Tyr	O
Ser	O
Met	O
Gln	O
Leu	O
Ala	O
Ser	O
Cys	O

Val	O
Thr	O
Leu	O
Thr	O
Leu	O
Val	O
Leu	O
Leu	O
Val	O
Asn	O
Ser	O
Ala	O
Pro	O
Thr	O
150	O
TCA	O
AGC	O
TCC	O
ACT	O
TCA	O
AGC	O
TCT	O
ACA	O
GCG	O
GAA	O
GCA	O

CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
CAG	O
Ser	O
Ser	O
Ser	O
Thr	O
Ser	O
Ser	O
Ser	O
Thr	O
Ala	O
Glu	O
Ala	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
Gln	O
200	O
CAC	O
CTG	O
GAG	O
CAG	O
CTG	O
TTG	O
ATG	O
GAC	O
CTA	O
CAG	O
GAG	O
CTC	O
CTG	O
AGC	O
AGG	O
ATG	O
GAG	O
GTAAGTGCACAGCCATCCCATC	O

His	O
Leu	O
Glu	O
Gln	O
Leu	O
Leu	O
Met	O
Asp	O
Leu	O
Gln	O
Glu	O
Leu	O
Leu	O
Ser	O

Arg	O
Met	O
Glu	O

TATAGGCAATACCTTTAGCTTTCTTGCCAAAGGCTGTGTTTAATAACCTTTAATAATAATGTTACGCTTTCTCAG	O
AAT	O
TAC	O
AGG	O
AAC	O
lAsn	O
Tyr	O
Arg	O
Asn	O
250	O
CTG	O
AAA	O
CTC	O
CCC	O
AGG	O
ATG	O
CTC	O
ACC	O
TTC	O
AAA	O
TTT	O
TAC	O
TTG	O
CCC	O
AAG	O
CAG	O
GTGAGTGAGTTTCTGTTTAACTGGTGC	O
Leu	O
Lys	O
Leu	O

Pro	O
Arg	O
Met	O
Leu	O

Thr	O
Phe	O
Lys	O
Phe	O
Tyr	O
Leu	O
Pro	O
Lys	O
Gln	O
TCTAATG----------------------------------------------------------	O
_	O
_	O
?	O

_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
_	O
-----------------------	O
2000	O
bp	O
--------------------?----------------------------------------------------------	O
AATGTGAACCTTGTAGTTTCTTTGTAGATTGGAACAATAGTCTGAACTTGTGT	O
TATGCATTGGTAGAGAAACACAGACTTTTTACAAAGTCTAATGAAGCCAGAAGAGCTCACTAGAGTGGCCTAACAGTTAAGGTGACCCTTA	O
TGGTTGTGAGCTCTTGCTCTTCTAGATTTATGGCATCGATTACCTCAGTCCCCCTTTACAGAGGACAGGGAGTGGTAAAAGCTATGTGCTG	O
CCTTCTCTTGATTAGAGAGACTGCAGACTAACTTTCTGGCTCTTCAGTATGTGGTGAGCTGAGCTGATGGTTAAGCTTATTACTCCTCTAG	O
300	O
350	O
GCC	O
ACA	O
GAA	O
TTG	O
AAA	O
GAT	O
CTT	O
CAG	O
TGC	O
CTA	O
GAA	O
GAT	O
GAA	O
CTT	O
GGA	O
CCT	O
CTG	O
CGG	O
CAT	O
GTT	O
CTG	O
GAT	O
TTG	O
Ala	O
Thr	O
Glu	O
Leu	O
Lys	O
Asp	O
Leu	O
Gln	O
Cys	O
Leu	O
Glu	O
Asp	O
Glu	O
Leu	O

Gly	O
Pro	O
Leu	O

Arg	O

His	O
Val	O
Leu	O
Asp	O
Leu	O
490	O
ACT	O
CAA	O
AGC	O
AAA	O
AGC	O
TTT	O
CAA	O
TTG	O
GAA	O
GAT	O
GCT	O
GAG	O
AAT	O
TTC	O
ATC	O
AGC	O
AAT	O
ATC	O
AGA	O
GTA	O
ACT	O
GTT	O

GTA	O
Thr	O
Gln	O
Ser	O
Lys	O
Ser	O
Phe	O
Gln	O
Leu	O
Glu	O
Asp	O
Ala	O
Glu	O
Asn	O
Phe	O
Ile	O
Ser	O
Asn	O
Ile	O
Arg	O
Val	O
Thr	O
Val	O
Val	O
AAA	O
CTA	O
AAG	O
GTAAGGTGTTGCTTTATTTGCTAATCTGGAAATAAAATAGAGAAGAAATGCATTTTTAAGTGGCTTGCCATTTCTGGT	O
Lys	O
Leu	O
Lys	O
CTTTGATGGGTTCTGTGCATTTAGTCAACCAAAGTTTAAAGTCACTGTGCAAGTGAATCC	O
--------------------------------------------------------------------	O

-1000	O
bp	O
------	O
---------------------------------------------------------------	O

GAATTCTACAGAAGTGTTCAGTGTTCCCATCAAATGCTCGTTGGTAATCAACTCTGGAGAGCTT	O
TATTTTTTATGCTTTACCATTTGATATCATAATAAAACATAACCCAATAATTGTGATCATTTCAGAAATGTGAATGTTCAATATATTTAAC	O
CAGTGTTAAAATAAATGCCTAAAAGCTCCGTTGAAGAATAATTATATGCAAAGTAAGCTACCTTAGCCTACAATTTTATATTCTTTTTTAG	O
450	O
500	O
GGC	O
TCT	O
GAC	O
AAC	O
ACA	O
TTT	O
GAG	O
TGC	O
CAA	O
TTC	O
GAT	O
GAT	O
GAG	O
TCA	O
GCA	O
ACT	O
GTG	O
GTG	O

GAC	O
TTT	O
CTG	O
AGG	O
AGA	O
Gly	O
Ser	O
Asp	O
Asn	O
Thr	O
Phe	O
Glu	O
Cys	O
Gln	O
Phe	O
Asp	O
Asp	O
GlU	O
Ser	O
Ala	O
Thr	O
Val	O
Val	O
Asp	O
Phe	O
Leu	O
Arg	O

Arg	O
550	O
TGG	O
ATA	O
GCC	O
TTC	O
TGT	O
CAA	O
AGC	O
ATC	O
ATC	O
TCA	O
ACA	O
AGC	O
CCT	O
CAA	O
TAACTATGTACCTCCTGCTTACAACACATAAGGC	O
Trp	O
Ile	O
Ala	O
Phe	O
Cys	O
Gln	O
Ser	O
Ile	O
Ile	O
Ser	O
Thr	O
Ser	O
Pro	O
Gln	O

600	O

650	O
TCTCTATTTAT4TAAATATTTAACTTTAATTTATTTTTGGATGTATTGTTTACTATCTTTTGTAACTACTAGTCTTCAGATGATAAATATG	O
700	O
750	O
GATCTTTAAAGATTCTTTTTGTAAGCCCCAAGGGCTCAAAAATGTTTTAAACTATTTATCTGAAATTATT+ATTATATTGAATTGTTAAAT	O
<	O
4>800	O
850	O
ATCATGTGTAGGTAGACTcATTCA	O
TAAAAGTAmAGATGATTCAAATATAAATAAGCTCAGATGTCTGTCATTTTTAGGACAGCACAAAG	O
900	O
0	O
""""	O
TAAGCGCTAAAATAACTTCTCAGTTATTCCTGTGAACTcTATGTTAATCAGTGTTTTCAAGAAATAAAGCTCTCCTCT	O
AAA	O
GATGGCTTGTGGGAAAAGATCTCCTCTCCAGGGAGCTAACATCAGCTCAGAGTTTACTCAAGAATTC	O
Fig.	O
3	O
.	O
Nucleotide	O
sequence	O
of	O
mouse	B
IL-2	O
gene	O
.	O

Four	O
exons	O
are	O
framed	O
.	O

Numbers	O
refer	O
to	O
nucleotide	O
positions	O
of	O
exons	O
from	O
the	O
presumed	O
cap	O
site	O
.	O

Dots	O
and	O
open	O
circles	O
indicate	O
TATA	O
box	O
and	O
poly	O
A	O
additional	O
signals	O
,	O
respectively	O
.	O

9328	O
Nucleic	O
Acids	O
Research	O
-4	O
5	O
0	O
-400	O
TAGGAGGT	O
AAACCA	O
T	O
CTCGAAAC	O
GGAAACCAATATCCTTCCTGTCTAATCAACAAATCTAAAGGATTTATTCTTTTCATCTATCTCC	O
.0	O

*	O
.0	O

.-	O

*	O
.	O

*	O
..	O

*	O
--	O
.	O

--	O
.*-@	O
..	O
............	O
--	O
-*-	O
*	O
*	O
TAAAAAGGTAAAACCAGTTCT	O
GAAACAGGAAACCAATACACTTCCTGTTTAATCAACAAATCTAAA	O
CATTTATTCTTTTCATCTGTTTAC	O
-350	O
-300	O
TCTTGCGCCCGTCCACCACAACAGGCTGCT	O
T	O
ACAGGTTCAGGATGGTTTTGACAAAGAGAACATTTTCATGAGTTACTTTTGTGTCTC	O
TCTTGCTCTTGTTCACCACAATA	O
TGCTATTCACATGTTCAGTGTAGTTTTATGACAAAGAAAATTTTC	O
TGAGTTACTTTTGTATCCC	O
-250	O
CA	O
CCCC	O
AAAG	O
AGGAAAATTTGTTTCATACGAAAGGCGTTCATTGTATGAATTAAAACT	O
CCACCTAAGAGTGGGCTAACCCGA	O

*	O
~~~	O
~~	O
.....	O

*	O
.--	O

*	O
..	O

-	O
*	O
.--	O
.	O

*	O
*	O
.	O

*	O
-	O
.	O

--	O
.	O

*	O
-	O
*	O
-	O
-	O
-	O
*	O
-	O
0	O
@	O

*	O
--	O
0	O
..	O
.	O

CACCCCCTTAAAGAAAGGAGGAAAAACTGTTTCATACAGAAGGCGTTAATTGCATGAATTAGAGCTATCACCTAAGTGTGGGCTAATGTAA	O
-200	O
-150	O
CCAAGAGGGATTTCACCTAAATCCATTCAGTCAGTATAT	O
GGGGTTTAAACAAATTCCAGAGAGTCATCAGAAGAGGAAAAACAAAGGTAA	O
CAAAGAGGGATTTCACCTACATCCATTCAGTCAGTCTTTGGGGGTTTAAA	O
AAATTCCAAAGAGTCATCAGAAGAGGAAAAATGAAGGTAA	O
-100	O
-50	O
TACTTTCTGCCACACAGGTAGACTCTTTTGAAAATATGTGTXATATTAAAACATCGTGACACCCCCATATiXrTCCAGCATTAACAG	O
TGTTTTTT	O
CAGACAGGTAAAGTC	O
TTTGAAAATATGTGTAATATGTAAAACATTTTGACACCCCCATAATATTTTTCCAGAATTAACAG	O
ATAAGCCTCCCATGCTGAAGAGCTGCCTATCACCCTTGCTAATCACTCCTCACAGTGACCTCAAGTCCTGCAGGCATG	O
Mouse	B
rTATGCATCTCTTGTTCAAGAGTTCCCTATCACTCTCTTTAATCACTACACACAGTAACCTCAACTCCTGCCACTATG	O
Human	B
Fig.	O
4	O
.	O

Comparison	O
of	O
5'-flanking	O
regions	O
of	O
mouse	B
and	O
human	B
IL-2	O
genes	O
.	O

In	O
aligning	O
the	O
sequences	O
for	O
both	O
genes	O
,	O
gaps	O
were	O
introduced	O
to	O
maximize	O
homology	O
.	O

Dots	O
indicate	O
identical	O
nucleotide	O
sequences	O
.	O

Number	O
1	O
indicates	O
putative	O
transcription	O
initiation	O
site	O
.	O

Inverted	O
repeats	O
are	O
indicated	O
by	O
bars	O
and	O
dashed	O
lines	O
.	O

TATA	O
box	O
is	O
framed	O
.	O

of	O
both	O
genes	O
is	O
illustrated	O
in	O
Fig.	O
4	O
.	O

The	O
nucleotide	O
sequence	O
homology	O
from	O
the	O
TATA	O
box	O
to	O
-470	O
is	O
85	O
%	O
.	O

The	O
highest	O
region	O
of	O
homology	O
was	O
observed	O
between	O
the	O
TATA	O
box	O
and	O
position	O
-97	O
(	O
60	O
bp	O
matches	O
out	O
of	O
64	O
bp	O
)	O
of	O
both	O
genes	O
.	O

DISCUSSION	O
We	O
have	O
isolated	O
recombinant	O
clones	O
for	O
mouse	B
IL-2	O
gene	O
from	O
a	O
phage	O
Charon	O
4A	O
/	O
mouse	B
genomic	O
DNA	O
library	O
and	O
determined	O
the	O
entire	O
sequence	O
of	O
the	O
gene	O
except	O
for	O
the	O
sequence	O
of	O
the	O
internal	O
portion	O
of	O
the	O
second	O
and	O
third	O
introns	O
.	O

The	O
mouse	B
IL-2	O
cDNA	O
sequence	O
was	O
aligned	O
with	O
the	O
genomic	O
sequence	O
and	O
both	O
sequences	O
matched	O
completely	O
each	O
other	O
.	O

The	O
unusual	O
CAG	O
repeats	O
encoding	O
12	O
glutamines	O
which	O
was	O
found	O
previously	O
in	O
the	O
cloned	O
cDNA	O
was	O
shown	O
to	O
be	O
present	O
also	O
in	O
the	O
chromosomal	O
gene	O
.	O

This	O
finding	O
further	O
excludes	O
the	O
possibility	O
that	O
the	O
unique	O
repeat	O
is	O
generated	O
by	O
artifacts	O
during	O
the	O
cDNA	O
cloning	O
process	O
.	O

Although	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
for	O
the	O
deletion	O
of	O
this	O
sequence	O
in	O
the	O
human	B
IL-2	O
gene	O
,	O
it	O
is	O
more	O
likely	O
that	O
the	O
CAG	O
repeat	O
has	O
been	O
generated	O
in	O
the	O
mouse	B
genome	O
rather	O
recently	O
.	O

The	O
repeat	O
could	O
have	O
been	O
generated	O
either	O
by	O
a	O
direct	O
insertion	O
of	O
the	O
sequence	O
or	O
by	O
the	O
duplication	O
after	O
insertion	O
of	O
a	O
unit	O
sequence	O
.	O

9329	O
Nucleic	O
Acids	O
Research	O
Organization	O
of	O
the	O
mouse	B
IL-2	O
gene	O
resembles	O
to	O
that	O
of	O
the	O
human	B
gene	O
(	O
Fig.	O
2	O
.	O
,	O
ref	O
.	O

9	O
)	O
.	O

There	O
seems	O
to	O
be	O
little	O
sequence	O
homology	O
between	O
corresponding	O
introns	O
of	O
mouse	B
and	O
human	B
IL-2	O
genes	O
,	O
except	O
for	O
the	O
intron	O
-	O
exon	O
junctions	O
part	O
of	O
which	O
is	O
thought	O
to	O
be	O
necessary	O
for	O
the	O
RNA	O
splicing	O
(	O
17	O
,	O
18	O
)	O
.	O

Dissimilarity	O
of	O
the	O
intron	O
sequences	O
among	O
the	O
genes	O
which	O
are	O
derived	O
from	O
a	O
common	O
ancestor	O
has	O
been	O
reported	O
in	O
other	O
genes	O
(	O
19	O
,	O
20	O
)	O
.	O

In	O
spite	O
of	O
the	O
divergence	O
in	O
sequence	O
of	O
introns	O
,	O
the	O
size	O
and	O
position	O
of	O
the	O
introns	O
are	O
very	O
similar	O
between	O
the	O
murine	O
and	O
human	B
IL-2	O
genes	O
.	O

Of	O
particular	O
interests	O
is	O
the	O
presence	O
of	O
highly	O
conserved	O
sequences	O
in	O
the	O
5	O
'	O
-flanking	O
region	O
of	O
the	O
human	B
and	O
mouse	B
IL-2	O
gene	O
(	O
Fig.	O
4	O
)	O
.	O

Whereas	O
the	O
coding	O
region	O
shows	O
nucleotide	O
sequence	O
homology	O
of	O
72	O
%	O
between	O
the	O
two	O
genes	O
,	O
the	O
5	O
'	O
upstream	O
region	O
spanning	O
about	O
500	O
bp	O
(	O
Fig.	O
4	O
)	O
shows	O
85	O
%	O
homology	O
which	O
was	O
readily	O
detectable	O
by	O
the	O
blotting	O
analysis	O
(	O
Fig.	O
1	O
,	O
lane	O
1	O
-	O
4	O
)	O
.	O

Since	O
we	O
have	O
not	O
yet	O
determined	O
the	O
nucleotide	O
sequence	O
further	O
upstream	O
of	O
the	O
mouse	B
gene	O
,	O
we	O
do	O
not	O
know	O
whether	O
or	O
not	O
this	O
similarity	O
extends	O
further	O
.	O

It	O
is	O
likely	O
that	O
such	O
sequences	O
are	O
involved	O
in	O
the	O
controlled	O
expression	O
of	O
the	O
IL-2	O
genes	O
in	O
activated	O
T	O
-	O
lymphocytes	O
.	O

Work	O
is	O
in	O
progress	O
to	O
identify	O
such	O
DNA	O
sequences	O
by	O
introducing	O
the	O
cloned	O
genes	O
into	O
various	O
lymphocytic	O
cell	O
lines	O
.	O

Our	O
preliminary	O
results	O
indicate	O
that	O
the	O
5	O
'	O
-flanking	O
sequence	O
of	O
the	O
human	B
IL-2	O
gene	O
mediates	O
mitogen	O
induced	O
expression	O
of	O
the	O
gene	O
in	O
T	O
-	O
lymphocytic	O
cells	O
(	O
Fujita	O
&	O
Taniguchi	O
,	O
unpublished	O
observation	O
)	O
.	O

ACKNOWLEDGEMENTS	O
We	O
thank	O
Dr.	O
T.	O
Honjo	O
for	O
mouse	B
gene	O
library	O
.	O

We	O
are	O
also	O
indepted	O
to	O
Ms.	O
M.	O
Nagatsuka	O
for	O
typing	O
the	O
manuscript	O
.	O

This	O
work	O
was	O
supported	O
in	O
part	O
by	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Special	O
Project	O
Research	O
,	O
Cancer	O
-	O
Bioscience	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
and	O
Culture	O
,	O
Japan	O
.	O

?	O

To	O
whom	O
correspondence	O
should	O
be	O
addressed	O
*	O
Present	O
address	O
:	O
Department	O
of	O
Microbiology	O
,	O
School	O
of	O
Medicine	O
,	O
Chiba	O
University	O
,	O
Chiba	O
280	O
,	O
Japan	O
+	O
Present	O
address	O
:	O
Central	O
Research	O
Laboratory	O
,	O
Ajinomoto	O
Co.	O

Inc.	O
,	O
Totsuka	O
-	O
ku	O
,	O
Yokohama	O
244	O
,	O
Japan	O
9330	O
Nucleic	O
Acids	O
Research	O
REFERENCES	O
1	O
.	O

Morgan	O
,	O
D.	O
A.	O
,	O
Ruscetti	O
,	O
F.	O
W.	O
and	O
Gallo	O
,	O
R.	O
(	O
1976	O
)	O
Science	O
,	O
193	O
,	O
1007	O
-	O
1008	O
.	O

2	O
.	O

Gil	O
lis	O
,	O
S.	O
Ferm	O
,	O
M.	O
M.	O
,	O
Ou	O
,	O
W.	O
and	O
Smith	O
,	O
K.	O
(	O
1	O
978	O
)	O
J.	O
Immunol	O
.	O
,	O
120	O
,	O
2023	O
-	O
2027	O
.	O

3	O
.	O

Chen	O
,	O
B.	O
M.	O
and	O
Di	O
Sabato	O
,	O
G.	O
(	O
1976	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
22	O
,	O
211	O
224	O
.	O

4	O
.	O

Henney	O
,	O
C.	O
S.	O
,	O
Kuribayashi	O
,	O
K.	O
,	O
Kern	O
,	O
D.	O
E.	O
and	O
Gillis	O
,	O
S.	O
(	O
1981	O
)	O
Nature	O
,	O
291	O
,	O
335	O
-	O
338	O
.	O

5	O
.	O

Wagner	O
,	O
H.	O
,	O
Hardt	O
,	O
C.	O
,	O
Heeg	O
,	O
K.	O
,	O
Rollinghoff	O
,	O
M.	O
and	O
Pfizenmaier	O
,	O
K.	O
(	O
1980	O
)	O
Nature	O
,	O
284	O
,	O
278	O
-	O
280	O
.	O

6	O
.	O

Farrar	O
,	O
J.	O
J.	O
,	O
Benjamin	O
,	O
W.	O
R.	O
,	O
Hilfikr	O
M.	O
L.	O
,	O
Howard	O
,	O
M.	O
,	O
Farrar	O
,	O
W.	O
L.	O
and	O
Fuller	O
-	O
Farrar	O
,	O
J.	O
(	O
1982	O
)	O
Immunol	O
.	O

Rev.	O
63	O
,	O
129	O
-	O
166	O
.	O

7	O
.	O

Pearlstein	O
,	O
K.	O
,	O
Palladino	O
,	O
M.	O
A.	O
,	O
Welte	O
,	O
K.	O
and	O
Vilcek	O
,	O
J.	O
(	O
1983	O
)	O
Cell	O
.	O

Immunol	O
.	O
,	O
80	O
,	O
1	O
-	O
9	O
.	O

8	O
.	O

Taniguchi	O
,	O
T.	O
,	O
Matsui	O
,	O
H.	O
,	O
Fujita	O
,	O
T.	O
,	O
Takaoka	O
,	O
C.	O
,	O
Kashima	O
,	O
N.	O
,	O
Yoshimoto	O
,	O
R.	O
and	O
Hamuro	O
,	O
J.	O
(	O
1983	O
)	O
Nature	O
302	O
,	O
305	O
-	O
310	O
.	O

9	O
.	O

Fujita	O
,	O
T.,Takaoka	O
,	O
C.	O
,	O
Matsui	O
,	O
H.	O
and	O
Taniguchi	O
T.	O
(	O
1983	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
80	O
,	O
7437	O
-	O
7411	O
.	O

10	O
.	O

Ohno	O
,	O
S.	O
and	O
Taniguchi	O
,	O
T.	O
(	O
1982	O
)	O
Nucleic	O
Acids	O
Res	O
.	O

10	O
,	O
967	O
977	O
.	O

11	O
.	O

Southern	O
,	O
E.	O
M.	O
(	O
1975	O
)	O
J.	O
Mol	O
.	O

Biol	O
.	O

98	O
,	O
503	O
-	O
517	O
.	O

12	O
.	O

Benton	O
,	O
W.	O
D.	O
and	O
Davis	O
,	O
R.	O
W.	O
(	O
1977	O
)	O
Science	O
196	O
,	O
180	O
-	O
182	O
.	O

13	O
.	O

Ohno	O
,	O
S.	O
and	O
Taniguchi	O
,	O
T.	O
(	O
1981	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
78	O
,	O
5305	O
-	O
5309	O
.	O

14	O
.	O

Maxam	O
,	O
A.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1980	O
)	O
Meth	O
.	O

Enzymol	O
.	O
65	O
,	O
560	O
580	O
.	O

15	O
.	O

Sanger	O
,	O
F.	O
,	O
Nicklen	O
,	O
S.	O
and	O
Coulson	O
,	O
A.	O
R.	O
(	O
1977	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

16	O
.	O

Gillis	O
,	O
S.	O
,	O
Scheid	O
,	O
M.	O
and	O
Watson	O
,	O
J.	O
D.	O
(	O
1980	O
)	O
J.	O
Immunol	O
.	O

,	O
125	O
,	O
2570	O
-	O
2580	O
.	O

17	O
.	O

Breathnach	O
,	O
R.	O
,	O
Benoist	O
,	O
C.	O
,	O
O'Hare	O
,	O
K.	O
,	O
Gannon	O
,	O
F.	O
and	O
Chambon	O
,	O
P.	O
(	O
1978	O
)	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
,	O
75	O
,	O
4853	O
-	O
4857	O
.	O

18	O
.	O

Lerner	O
,	O
M.	O
R.	O
,	O
Boyle	O
,	O
J.	O
A.	O
,	O
Mount	O
,	O
S.	O
M.	O
,	O
Wolin	O
,	O
S.	O
L.	O
and	O
Steitz	O
,	O
J.	O
A.	O
(	O
1980	O
)	O
Nature	O
,	O
283	O
,	O
220	O
-	O
224	O
.	O

19	O
.	O

Van	O
Ooyen	O
,	O
A.	O
,	O
Van	O
den	O
Berg	O
,	O
J.	O
,	O
Mantei	O
,	O
N.	O
and	O
Weissmann	O
,	O
C.	O
(	O
1979	O
)	O
Science	O
,	O
206	O
,	O
337	O
-	O
344	O
.	O

20	O
.	O

Searle	O
,	O
P.	O
F.	O
,	O
Davison	O
,	O
B.	O
L.	O
,	O
Stuart	O
,	O
G.	O
W.	O
,	O
Wilkie	O
,	O
T.	O
M.	O
,	O
Norstedt	O
,	O
G.	O
and	O
Palmiter	O
,	O
R.	O
D.	O
(	O
1984	O
)	O
Mol	O
.	O

Cell	O
.	O

Biol	O
.	O

4	O
,	O
1221	O
-	O
1230	O
.	O

9331	O

Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
.	O

Abstract	O
An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polymer	O
supports	O
which	O
involves	O
condensing	O
5'-dimethoxytrityldeoxynucleoside	O
3'-methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O
treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
nN	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
nN.	O
The	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O
series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O
original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O

Images	O
Vlue1Nubr1193NcecAisRsah	O
Preparation	O
of	O
oligodeoxyribonucleoside	O
methylphosphonates	O
on	O
a	O
polystyrene	O
support	O
P.S.Miller	O
,	O
C.H.Agris	O
,	O
A.Murakami	O
,	O
P.M.Reddy	O
,	O
S.A.Spitz	O
and	O
P.O.P.Ts'o	O
Division	O
of	O
Biophysics	O
,	O
Johns	O
Hopkins	O
University	O
,	O
School	O
of	O
Hygiene	O
and	O
Public	O
Health	O
,	O
Baltimore	O
,	O
MD	O
21205	O
,	O
USA	O
Received	O
26	O
July	O
1983	O
;	O
Accepted	O
5	O
September	O
1983	O
ABSTRACT	O
An	O
efficient	O
procedure	O
is	O
described	O
for	O
synthesizing	O
deoxyribonucleoside	O
methylphosphonates	O
on	O
polystyrene	O
polyner	O
supports	O
which	O
involves	O
condensing	O
5'-dimethoxytrityldeoxynucleoside	O
3'-methylphosphonates	O
.	O

The	O
oligomers	O
are	O
removed	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
hydrolyzed	O
by	O
treatment	O
with	O
ethylenediamine	O
in	O
ethanol	O
,	O
which	O
avoids	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
.	O

Two	O
types	O
of	O
oligomers	O
were	O
synthesized	O
:	O
those	O
containing	O
only	O
methylphosphonate	O
linkages	O
,	O
d	O
-	O
Np	O
(	O
Np	O
)	O
N	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5	O
'	O
nucleotide	O
residue	O
,	O
dNp	O
(	O
Np	O
)	O
N	O
.-	O
J	O
he	O
latter	O
oligomers	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
,	O
and	O
are	O
separated	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
according	O
to	O
their	O
chain	O
length	O
.	O

Piperdine	O
randomly	O
cleaves	O
the	O
oligomer	O
methylphosphonate	O
linkages	O
and	O
generates	O
a	O
series	O
of	O
shorter	O
oligomers	O
whose	O
number	O
corresponds	O
to	O
the	O
length	O
of	O
the	O
original	O
oligomer	O
.	O

Apurinic	O
sites	O
introduced	O
by	O
acid	O
treatment	O
spontaneously	O
hydrolyze	O
to	O
give	O
oligomers	O
which	O
terminate	O
with	O
free	O
3	O
'	O
and	O
5	O
'	O
OH	O
groups	O
.	O

These	O
reactions	O
may	O
be	O
used	O
to	O
characterize	O
the	O
oligomers	O
.	O

INTRODUCTION	O
Oligonucleoside	O
methylphosphonates	O
have	O
been	O
used	O
to	O
st	O
-	O
udy	O
the	O
function	O
of	O
specific	O
RNA	O
sequences	O
in	O
biochemical	O
and	O
intact	O
cellular	O
systems	O
(	O
1,2	O
)	O
.	O

Since	O
these	O
nonionic	O
nucleic	O
acid	O
analogs	O
can	O
be	O
taken	O
up	O
intact	O
by	O
mammalian	O
cells	O
and	O
certain	O
bacterial	O
cells	O
in	O
culture	O
,	O
these	O
compounds	O
promise	O
to	O
be	O
useful	O
reagents	O
for	O
exploring	O
and	O
regulating	O
the	O
function	O
of	O
nucleic	O
acids	O
within	O
living	O
cells	O
.	O

In	O
order	O
to	O
carry	O
out	O
more	O
extensive	O
biochemical	O
and	O
biological	O
studies	O
,	O
an	O
efficient	O
method	O
for	O
synthesis	O
of	O
oligonucleoside	O
methylphosphonates	O
of	O
defined	O
sequence	O
is	O
needed	O
.	O

Previously	O
we	O
described	O
the	O
synthesis	O
of	O
methylphosphonate	O
analogs	O
on	O
a	O
silica	O
gel	O
support	O
(	O
3	O
)	O
.	O

Protected	O
nucleoside	O
3'-methylphosphonic	O
chlorides	O
or	O
tetrazolides	O
were	O
used	O
as	O
synthetic	O
intermediates	O
.	O

While	O
oligothymidine	O
methylphosphonates	O
could	O
be	O
efficiently	O
synthesized	O
by	O
this	O
procedure	O
,	O
low	O
yields	O
were	O
encountered	O
when	O
other	O
nucleosides	O
,	O
particularly	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
were	O
used	O
.	O

Recently	O
Sinha	O
et	O
al.	O
?	O
)	O

I	O
RL	O
Press	O
Limited	O
,	O
Oxford	O
,	O
England	O
.	O

Nucleic	O
Acids	O
Research	O
Volume	O
1	O
1	O
Number	O
18	O
1983	O
6225	O
Nucleic	O
Acids	O
Research	O
described	O
the	O
preparation	O
of	O
oligonucleoside	O
methylphosphophonates	O
on	O
a	O
glass	O
support	O
using	O
nucleoside	O
3'-methylphosphine	O
chlorides	O
as	O
reactive	O
intermediates	O
(	O
4	O
)	O
.	O

In	O
this	O
paper	O
we	O
describe	O
a	O
set	O
of	O
useful	O
methods	O
for	O
the	O
synthesis	O
and	O
analysis	O
of	O
these	O
analogs	O
.	O

The	O
synthesis	O
involves	O
condensation	O
of	O
protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammonium	O
salts	O
with	O
nucleosides	O
or	O
oligomers	O
linked	O
to	O
a	O
polystyrene	O
support	O
.	O

This	O
method	O
has	O
proven	O
to	O
be	O
easy	O
to	O
use	O
and	O
allows	O
relatively	O
rapid	O
synthesis	O
of	O
oligomers	O
of	O
defined	O
sequence	O
up	O
to	O
nine	O
nucleosides	O
in	O
length	O
.	O

We	O
have	O
also	O
developed	O
conditions	O
for	O
the	O
efficient	O
removal	O
of	O
base	O
protecting	O
groups	O
and	O
subsequent	O
purification	O
of	O
the	O
oligomers	O
.	O

A	O
novel	O
hydrolysis	O
reaction	O
which	O
can	O
be	O
used	O
as	O
a	O
basis	O
for	O
characterizing	O
and	O
sequencing	O
these	O
oligonucleotide	O
analogs	O
occurs	O
at	O
apurinic	O
sites	O
created	O
by	O
acid	O
treatment	O
of	O
the	O
oligomers	O
.	O

EXPERIMENTAL	O
Materials	O
and	O
Methods	O
Protected	O
nucleosides	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N	O
,	O
were	O
purchased	O
from	O
P.L.	O
Biochemicals	O
and	O
were	O
used	O
without	O
further	O
purification	O
.	O

Protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammoni	O
um	O
salts	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np*Et3NH	O
,	O
were	O
prepared	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

5-Dimethoxytrityl	O
protected	O
nucleosides	O
esterified	O
to	O
1	O
%	O
or	O
2	O
%	O
crosslinked	O
polystyrene	O
were	O
purchased	O
from	O
Chem	O
Genes	O

Inc.	O

The	O
nucleoside	O
loading	O
level	O
was	O
40	O
to	O
120	O
pmol	O
of	O
nucleoside	O
/	O
g	O
of	O
support	O
.	O

Mesitylenesulfonyl-3-nitrotriazole	O
(	O
MSNT	O
)	O
was	O
purchased	O
from	O
Vega	O
Biochemicals	O
.	O

Anhydrous	O
pyridine	O
was	O
prepared	O
by	O
refluxing	O
previously	O
purified	O
pyridine	O
(	O
5	O
)	O
over	O
calcium	O
hydride	O
chips	O
for	O
several	O
hours	O
followed	O
by	O
distillation	O
onto	O
calcium	O
hydride	O
chips	O
in	O
5	O
ml	O
V	O
-	O
vials	O
fitted	O
with	O
Teflon	O
-	O
lined	O
septum	O
caps	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

Lyophilized	O
spleen	O
phosphodiesterase	O
was	O
obtained	O
from	O
P.L.	O
Biochemicals	O
.	O

T-4	O
polynucleotide	O
kinase	O
and	O
[	O
y-32P	O
]	O
-ATP	O
were	O
obtained	O
from	O
New	O
England	O
Nuclear	O
.	O

Reversed	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
carried	O
out	O
on	O
Whatman	O
Inc.	O
C-18	O
(	O
ODS-3	O
)	O
columns	O
(	O
0.4	O
x	O
25	O
cm	O
)	O
.	O

Analytical	O
columns	O
were	O
eluted	O
with	O
50	O
ml	O
linear	O
gradients	O
of	O
acetonitrile	O
in	O
water	O
or	O
acetonitrile	O
in	O
0.1	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5.8	O
)	O
at	O
a	O
flow	O
rate	O
of	O
2.5	O
ml	O
/	O
min	O
.	O

The	O
eluate	O
was	O
monitored	O
at	O
254	O
nm	O
.	O

The	O
following	O
molar	O
extinction	O
coefficients	O
were	O
used	O
at	O
254	O
nm	O
:	O
d	O
-	O
T	O
7,250	O
,	O
dA	O
13,270	O
,	O
dC	O
6,260	O
,	O
dG	O
13,700	O
.	O

Unless	O
otherwise	O
noted	O
,	O
all	O
reactions	O
and	O
operations	O
were	O
carried	O
out	O
at	O
room	O
temperature	O
.	O

General	O
Procedure	O
for	O
Preparing	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O
following	O
procedure	O
represents	O
the	O
current	O
method	O
used	O
in	O
our	O
laboratory	O
to	O
6226	O
Nucleic	O
Acids	O
Research	O
synthesize	O
methylphosphonate	O
oligomers	O
.	O

Table	O
I	O
lists	O
some	O
of	O
the	O
oligomers	O
which	O
have	O
been	O
synthesized	O
on	O
polystyrene	O
supports	O
.	O

Oligomers	O
7	O
,	O
8	O
,	O
and	O
10	O
were	O
synthesized	O
as	O
described	O
below	O
.	O

The	O
other	O
oligomers	O
were	O
synthesized	O
in	O
essentially	O
the	O
same	O
manner	O
except	O
the	O
condensation	O
reactions	O
were	O
run	O
in	O
1	O
ml	O
V	O
-	O
vials	O
or	O
in	O
glass	O
reaction	O
columns	O
purchased	O
from	O
Bachem	O
Inc.	O

When	O
the	O
reactions	O
were	O
run	O
in	O
V	O
-	O
vials	O
,	O
the	O
support	O
was	O
dried	O
by	O
several	O
evaporations	O
with	O
anhydrous	O
pyridine	O
in	O
the	O
V	O
-	O
vial	O
(	O
3	O
)	O
.	O

When	O
the	O
reactions	O
were	O
run	O
in	O
the	O
glass	O
reaction	O
column	O
,	O
the	O
support	O
was	O
dried	O
by	O
a	O
single	O
evaporation	O
with	O
anhydrous	O
pyridine	O
overnight	O
at	O
room	O
temperature	O
.	O

Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

The	O
synthetic	O
reactions	O
are	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
col	O
umn	O
(	O
Bio	O
Rad	O
Econo	O
column	O
)	O
fitted	O
with	O
a	O
Teflon	O
3-way	O
valve	O
(	O
Bio	O
Rad	O
)	O
and	O
a	O
rubber	O
septum	O
cap	O
(	O
Wheaton	O
Scientific	O
)	O
.	O

During	O
washing	O
operations	O
,	O
the	O
septum	O
cap	O
is	O
removed	O
and	O
the	O
3-way	O
valve	O
is	O
connected	O
to	O
a	O
filter	O
flask	O
via	O
a	O
Luerer	O
adaptor	O
and	O
tubing	O
set	O
(	O
Bio	O
Rad	O
)	O
.	O

Generally	O
vacuum	O
is	O
not	O
required	O
to	O
wash	O
the	O
support	O
.	O

During	O
the	O
drying	O
step	O
,	O
one	O
port	O
of	O
the	O
3-way	O
valve	O
is	O
connected	O
to	O
a	O
cold	O
trap	O
and	O
vacuum	O
pump	O
via	O
the	O
barrel	O
of	O
a	O
1	O
ml	O
plastic	O
syringe	O
.	O

The	O
other	O
port	O
is	O
connected	O
to	O
a	O
Drierite	O
column	O
filled	O
with	O
dry	O
argon	O
.	O

A	O
reaction	O
cycle	O
consists	O
of	O
the	O
following	O
10	O
steps	O
:	O
1	O
)	O
The	O
support	O
(	O
60	O
mg	O
,	O
1	O
%	O
crosslinked	O
)	O
in	O
the	O
column	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
(	O
85:15	O
,	O
v	O
/	O
v	O
)	O
.	O

2	O
)	O
The	O
support	O
is	O
treated	O
with	O
2	O
ml	O
of	O
1	O
M	O
zinc	O
bromide	O
in	O
methylene	O
chloride	O
/	O
isopropanol	O
solution	O
.	O

Two	O
fiveminute	O
treatments	O
are	O
used	O
when	O
the	O
support	O
-	O
bound	O
nucleoside	O
is	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
or	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuG	O
,	O
while	O
four	O
treatments	O
are	O
used	O
when	O
the	O
nucleoside	O
is	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
or	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC.	O
After	O
each	O
treatment	O
the	O
orange	O
solution	O
is	O
collected	O
in	O
a	O
clean	O
flask	O
.	O

3	O
)	O
The	O
support	O
is	O
washed	O
with	O
two	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
and	O
the	O
washings	O
are	O
collected	O
in	O
same	O
flask	O
used	O
in	O
step	O
2	O
)	O
.	O

The	O
solution	O
is	O
diluted	O
to	O
50	O
ml	O
and	O
a	O
0.20	O
ml	O
aliquot	O
is	O
dissolved	O
in	O
0.80	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
absorbance	O
is	O
determined	O
at	O
500	O
nm	O
and	O
the	O
amount	O
of	O
trityl	O
cation	O
is	O
determined	O
using	O
a	O
molar	O
extinction	O
coefficient	O
of	O
89,000	O
.	O

4	O
)	O
The	O
column	O
is	O
attached	O
to	O
a	O
waste	O
flask	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
0.5	O
M	O
triethylammonium	O
acetate	O
in	O
dimethylformamide	O
;	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

5	O
)	O
The	O
column	O
is	O
fitted	O
with	O
the	O
septum	O
cap	O
and	O
set	O
up	O
in	O
the	O
drying	O
mode	O
under	O
house	O
vacuum	O
for	O
at	O
least	O
5	O
min	O
.	O

6	O
)	O
The	O
support	O
is	O
dried	O
by	O
adding	O
300	O
jl	O
of	O
anhydrous	O
pyridine	O
via	O
a	O
gas	O
tight	O
syringe	O
(	O
Hamilton	O
)	O
.	O

After	O
the	O
support	O
has	O
swollen	O
,	O
the	O
vacuum	O
(	O
oil	O
pump	O
)	O
is	O
applied	O
and	O
the	O
support	O
is	O
warmed	O
with	O
a	O
6227	O
Nucleic	O
Acids	O
Research	O
stream	O
of	O
air	O
from	O
a	O
hair	O
dryer	O
.	O

Evaporation	O
is	O
continued	O
for	O
10	O
min	O
.	O

Dry	O
argon	O
is	O
then	O
admitted	O
and	O
the	O
drying	O
operation	O
is	O
repeated	O
two	O
more	O
times	O
.	O

7	O
)	O
The	O
coupling	O
mixture	O
is	O
prepared	O
by	O
dissolving	O
0.20	O
mmol	O
of	O
MSNT	O
in	O
320	O
pl	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
is	O
then	O
transferred	O
to	O
the	O
vial	O
containing	O
0.06	O
mmol	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
-	O
Et3NH	O
.	O

The	O
nucleotide	O
is	O
dissolved	O
by	O
vortexing	O
and	O
the	O
coupling	O
solution	O
is	O
then	O
added	O
dropwise	O
to	O
the	O
support	O
.	O

It	O
is	O
important	O
to	O
add	O
the	O
solution	O
slowly	O
and	O
to	O
allow	O
the	O
support	O
to	O
swell	O
.	O

Trapped	O
gas	O
bubbles	O
may	O
be	O
removed	O
by	O
gently	O
tapping	O
the	O
column	O
.	O

This	O
entire	O
operation	O
is	O
carried	O
out	O
using	O
one	O
predried	O
syringe	O
.	O

The	O
syringe	O
is	O
left	O
in	O
the	O
V	O
-	O
vial	O
while	O
the	O
reagents	O
are	O
being	O
dissolved	O
.	O

8)	O
The	O
reaction	O
mixture	O
is	O
kept	O
at	O
room	O
temperature	O
for	O
two	O
hrs	O
.	O

9	O
)	O
The	O
column	O
is	O
set	O
up	O
in	O
the	O
washing	O
mode	O
and	O
the	O
support	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
.	O

The	O
solution	O
,	O
which	O
contains	O
unreacted	O
nucleoside	O
3'-methylphosphonate	O
and	O
MSNT	O
,	O
is	O
collected	O
in	O
a	O
separate	O
flask	O
.	O

A	O
50	O
%	O
aqueous	O
pyridine	O
solution	O
(	O
1	O
ml	O
)	O
is	O
added	O
and	O
the	O
solution	O
is	O
kept	O
at	O
40C	O
for	O
later	O
purification	O
and	O
recovery	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
Np	O
.	O

10	O
)	O
The	O
support	O
is	O
treated	O
with	O
a	O
solution	O
containing	O
2	O
ml	O
of	O
anhydrous	O
pyridine	O
,	O
1	O
ml	O
of	O
acetic	O
anhydride	O
and	O
20	O
mg	O
of	O
dimethylaminopyridine	O
for	O
30	O
min	O
.	O

(	O
This	O
step	O
was	O
not	O
included	O
for	O
the	O
synthesis	O
of	O
oligomer	O
10	O
)	O
.	O

11	O
)	O
Return	O
to	O
step	O
1	O
,	O
for	O
the	O
next	O
cycle	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
.	O

The	O
following	O
general	O
procedure	O
was	O
found	O
to	O
be	O
the	O
most	O
effective	O
method	O
for	O
cleaving	O
the	O
oligonucleotide	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
with	O
minimal	O
hydrolysis	O
of	O
the	O
phosphonate	O
backbone	O
.	O

The	O
following	O
steps	O
were	O
used	O
for	O
deprotecting	O
oligomers	O
7	O
,	O
8	O
and	O
10	O
.	O

Oligomer	O
9	O
was	O
deprotected	O
in	O
a	O
similar	O
fashion	O
except	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650C	O
for	O
3	O
hrs	O
.	O

For	O
oligomers	O
1	O
-	O
6	O
,	O
step	O
3	O
)	O
was	O
not	O
included	O
and	O
step	O
4	O
)	O
was	O
carried	O
out	O
at	O
650	O
for	O
3	O
hrs	O
.	O

1	O
)	O
After	O
the	O
final	O
condensation	O
step	O
the	O
support	O
(	O
60	O
mg	O
)	O
is	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
;	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
and	O
three	O
2	O
ml	O
portions	O
of	O
diethyl	O
ether	O
.	O

The	O
support	O
is	O
then	O
dried	O
under	O
house	O
vacuum	O
.	O

2	O
)	O
The	O
support	O
is	O
swollen	O
by	O
addition	O
of	O
2	O
ml	O
of	O
pyridine	O
and	O
the	O
excess	O
is	O
removed	O
under	O
house	O
vacuum	O
.	O

3	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
0.017	O
M	O
tetra	O
-	O
n	O
-	O
butylammonium	O
fluoride	O
in	O
tetrahydrofuran	O
/	O
pyridine	O
/	O
water	O
(	O
8:1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
40	O
hrs	O
at	O
room	O
temperature	O
.	O

No	O
shaking	O
is	O
required	O
.	O

The	O
support	O
is	O
then	O
washed	O
with	O
three	O
2	O
ml	O
portions	O
of	O
50	O
%	O
pyridine	O
/	O
water	O
;	O
three	O
2	O
ml	O
portions	O
of	O
pyridine	O
;	O
and	O
three	O
2	O
ml	O
portions	O
of	O
methylene	O
chloride	O
/	O
isopropanol	O
.	O

4	O
)	O
The	O
support	O
is	O
treated	O
with	O
3	O
ml	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O
6228	O
Nucleic	O
Acids	O
Research	O
without	O
shaking	O
.	O

The	O
solution	O
is	O
collected	O
and	O
the	O
support	O
is	O
washed	O
with	O
four	O
2	O
ml	O
portions	O
of	O
pyridine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
and	O
four	O
2	O
ml	O
portions	O
of	O
N	O
,	O
N	O
-	O
dimethylformamide	O
.	O

The	O
combined	O
eluate	O
and	O
washings	O
are	O
evaporated	O
at	O
250C	O
and	O
the	O
oily	O
residue	O
is	O
co	O
-	O
evaporated	O
several	O
time	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

For	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
(	O
1	O
-	O
6	O
)	O
,	O
the	O
residue	O
from	O
step	O
4	O
)	O
of	O
the	O
previous	O
section	O
is	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
solution	O
is	O
chromatographed	O
on	O
a	O
C-18	O
reversed	O
phase	O
column	O
(	O
0.46	O
cm	O
x	O
25	O
cm	O
for	O
100	O
A254	O
units	O
or	O
less	O
;	O
0.9	O
cm	O
x	O
50	O
cm	O
for	O
more	O
than	O
100	O
A254	O
units	O
)	O
using	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
(	O
8-mer	O
or	O
less	O
)	O
or	O
0	O
%	O
to	O
35	O
%	O
(	O
9	O
mer	O
)	O
acetonitrile	O
in	O
water	O
to	O
remove	O
non	O
-	O
tritylated	O
oligomers	O
.	O

The	O
desired	O
tritylated	O
oligomer	O
is	O
eluted	O
with	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
treated	O
with	O
1	O
ml	O
of	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
1	O
hr	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
repeatedly	O
evaporated	O
with	O
ethanol	O
to	O
ensure	O
complete	O
removal	O
of	O
acetic	O
acid	O
.	O

The	O
oligomer	O
is	O
then	O
purified	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

For	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
phosphodiester	O
linkage	O
(	O
7	O
-	O
10	O
)	O
the	O
residue	O
from	O
step	O
4	O
)	O
described	O
in	O
the	O
preceeding	O
section	O
is	O
treated	O
with	O
80	O
%	O
acetic	O
acid	O
in	O
water	O
for	O
15	O
min	O
at	O
room	O
temperature	O
.	O

After	O
removal	O
of	O
the	O
acetic	O
acid	O
by	O
evaporation	O
,	O
the	O
residue	O
is	O
dissolved	O
in	O
20	O
ml	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O
is	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
2.5	O
x	O
8	O
cm	O
,	O
bicarbonate	O
form	O
)	O
which	O
has	O
been	O
previously	O
washed	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
column	O
is	O
monitored	O
at	O
254	O
nm	O
and	O
washed	O
with	O
50	O
%	O
aqueous	O
ethanol	O
until	O
the	O
pen	O
returns	O
to	O
the	O
baseline	O
.	O

The	O
desired	O
oligomer	O
is	O
then	O
eluted	O
with	O
0.15	O
M	O
triethylammonium	O
bicarbonate	O
in	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
buffer	O
is	O
removed	O
by	O
evaporation	O
and	O
co	O
-	O
evaporated	O
with	O
50	O
%	O
aqueous	O
ethanol	O
.	O

The	O
oligomer	O
is	O
then	O
further	O
purified	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0.10	O
M	O
ammonium	O
acetate	O
(	O
pH	O
5.8	O
)	O
gradient	O
.	O

The	O
oligomer	O
is	O
freed	O
of	O
ammonium	O
acetate	O
by	O
desalting	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
column	O
(	O
1.5	O
x	O
20	O
cm	O
)	O
.	O

Removal	O
of	O
the	O
5'-Terminal	O
Nucleotide	O
Unit	O
.	O

Oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleotide	O
phosphodiester	O
may	O
be	O
converted	O
to	O
the	O
oligonucleoside	O
methylphosphonate	O
by	O
the	O
following	O
procedure	O
.	O

The	O
oligomer	O
(	O
3	O
A254	O
units	O
)	O
is	O
dissolved	O
in	O
40	O
pl	O
of	O
water	O
and	O
treated	O
at	O
370C	O
for	O
2	O
hrs	O
with	O
10	O
PI	O
(	O
1	O
-	O
2	O
units	O
)	O
of	O
spleen	O
phosphodiesterase	O
dissolved	O
in	O
water	O
.	O

The	O
completeness	O
of	O
the	O
reaction	O
is	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

The	O
solution	O
is	O
then	O
6229	O
Nucleic	O
Acids	O
Research	O
diluted	O
with	O
50	O
ul	O
of	O
water	O
and	O
passed	O
through	O
a	O
DEAE	O
cellulose	O
column	O
(	O
0.5	O
x	O
1	O
cm	O
)	O
.	O

The	O
column	O
is	O
washed	O
with	O
500	O
Pl	O
of	O
water	O
and	O
the	O
oligomer	O
is	O
recovered	O
by	O
lyophilization	O
.	O

Recovery	O
of	O
Protected	O
Nucleoside	O
3'-Methylphosphonates	O
.	O

The	O
aqueous	O
pyridine	O
solution	O
from	O
step	O
9	O
)	O
described	O
in	O
General	O
Procedure	O
for	O
Preparing	O
Oligonucleoside	O
Methylphosphonates	O
,	O
is	O
evaporated	O
after	O
addition	O
of	O
0.1	O
ml	O
of	O
triethylamine	O
.	O

The	O
residue	O
is	O
dissolved	O
in	O
50	O
ml	O
of	O
chloroform	O
and	O
the	O
solution	O
is	O
extracted	O
twice	O
with	O
50	O
ml	O
of	O
1	O
M	O
ammonium	O
bicarbonate	O
.	O

The	O
chloroform	O
layer	O
is	O
dried	O
over	O
anhydrous	O
sodium	O
sulfate	O
.	O

Several	O
drops	O
of	O
triethylamine	O
are	O
added	O
to	O
clarify	O
the	O
solution	O
.	O

After	O
filtration	O
the	O
solvents	O
are	O
evaporated	O
and	O
the	O
residue	O
is	O
evaporated	O
with	O
three	O
2	O
ml	O
portions	O
of	O
anhydrous	O
pyridine	O
on	O
an	O
oil	O
pump	O
.	O

The	O
foamy	O
residue	O
is	O
dissolved	O
in	O
2	O
ml	O
of	O
dry	O
methylene	O
chloride	O
and	O
the	O
solution	O
is	O
added	O
dropwise	O
to	O
a	O
stirred	O
solution	O
of	O
1	O
%	O
triethylamine	O
in	O
hexane	O
.	O

The	O
resulting	O
precipitate	O
is	O
collected	O
via	O
filtration	O
on	O
a	O
sintered	O
glass	O
filter	O
,	O
washed	O
with	O
hexane	O
and	O
dried	O
in	O
a	O
vacuum	O
desiccator	O
.	O

Removal	O
of	O
Base	O
Protecting	O
Groups	O
with	O
Ethylenediamine	O
.	O

Several	O
mg	O
of	O
d	O
-	O
I	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
and	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibu	O
G	O
were	O
each	O
dissolved	O
in	O
250	O
pl	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1,v	O
/	O
v	O
)	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
aliquots	O
were	O
chromatographed	O
on	O
silica	O
gel	O
TLC	O
plates	O
which	O
were	O
eluted	O
with	O
10	O
%	O
methanol	O
in	O
chloroform	O
.	O

The	O
spots	O
corresponding	O
to	O
the	O
starting	O
material	O
and	O
the	O
product	O
were	O
cut	O
out	O
and	O
treated	O
with	O
1.5	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
for	O
30	O
min	O
.	O

The	O
absorbance	O
of	O
each	O
solution	O
was	O
measured	O
at	O
500	O
nm	O
and	O
the	O
percent	O
reaction	O
was	O
determined	O
.	O

The	O
half	O
-	O
lives	O
of	O
the	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Removal	O
of	O
Protected-	O
Nucleosides	O
from	O
Polystyrene	O
Support	O
.	O

Five	O
mg	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
(	O
ED	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA	O
O?	O
(	O
1	O
%	O
crosslinked	O
)	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzC	O
(	O
?	O
)	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
and	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGcD	O
(	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
)	O
were	O
each	O
treated	O
with	O
500	O
ul	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
solution	O
at	O
room	O
temperature	O
.	O

At	O
various	O
times	O
,	O
10	O
pl	O
aliquots	O
were	O
removed	O
,	O
the	O
solvent	O
was	O
evaporated	O
and	O
the	O
residue	O
was	O
dissolved	O
in	O
1	O
ml	O
of	O
perchloric	O
acid	O
/	O
ethanol	O
solution	O
(	O
3:2	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
amount	O
of	O
dimethoxytrityl	O
cation	O
and	O
hence	O
the	O
amount	O
of	O
nucleoside	O
cleaved	O
from	O
the	O
support	O
was	O
determined	O
by	O
measuring	O
the	O
absorbance	O
at	O
500	O
nm	O
.	O

The	O
half	O
lives	O
of	O
the	O
cleavage	O
reactions	O
are	O
given	O
in	O
Table	O
II	O
.	O

Hydrolysis	O
of	O
the	O
Methylphosphonate	O
Linkage	O
by	O
Ethylenediamine	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
1.25	O
A254	O
units	O
each	O
)	O
were	O
treated	O
with	O
50	O
il	O
of	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
.	O

Aliquots	O
6230	O

Nucleic	O
Acids	O
Research	O
(	O
10	O
pl	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
the	O
solvents	O
were	O
evaporated	O
.	O

The	O
residue	O
was	O
dissolved	O
in	O
20	O
PI	O
of	O
50	O
%	O
aqueous	O
ethanol	O
and	O
the	O
solution	O
examined	O
by	O
C-18	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
mole	O
percent	O
of	O
starting	O
oligomer	O
remaining	O
after	O
100	O
hrs	O
of	O
treatment	O
is	O
given	O
in	O
Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
in	O
Acid	O
.	O

Six	O
A254	O
units	O
of	O
oligomer	O
were	O
dissolved	O
in	O
100	O
pl	O
of	O
0.01	O
M	O
hydrochloric	O
acid	O
solution	O
.	O

The	O
solution	O
was	O
heated	O
at	O
either	O
450	O
or	O
650C	O
.	O

Aliquots	O
(	O
10	O
Pil	O
)	O
were	O
withdrawn	O
at	O
various	O
times	O
and	O
added	O
to	O
10	O
pl	O
of	O
0.015	O
M	O
ammonium	O
hydroxide	O
at	O
0?C.	O
The	O
samples	O
were	O
then	O
injected	O
directly	O
onto	O
a	O
C-18	O
reversed	O
phase	O
column	O
which	O
was	O
eluted	O
with	O
50	O
ml	O
of	O
a	O
linear	O
gradient	O
of	O
0	O
%	O
to	O
25	O
%	O
acetonitrile	O
in	O
water	O
at	O
a	O
flow	O
rate	O
of	O
2.5	O
ml	O
/	O
min	O
.	O

The	O
products	O
of	O
the	O
reaction	O
were	O
determined	O
by	O
comparison	O
with	O
authentic	O
samples	O
.	O

Labeling	O
5'-End	O
of	O
Oligonucleoside	O
Methylphosphonates	O
with	O
T4-Polynucleotide	O
Kinase	O
.	O

Oligonucleoside	O
methylphosphonates	O
(	O
2	O
nmol	O
)	O
were	O
dissolved	O
in	O
a	O
buffer	O
solution	O
containing	O
50	O
mM	O
Tris	O
-	O
HC1	O
(	O
pH	O
9.0	O
)	O
,	O
10	O
mM	O
MgCl2	O
,	O
5	O
mM	O
dithiothreitol	O
,	O
20	O
pM	O
spermidine	O
,	O
and	O
[	O
y-32P	O
]	O
ATP	O
(	O
8	O
ljCi	O
,	O
4Ci	O
/	O
mmol	O
)	O
.	O

T4-polynucleotide	O
kinase	O
(	O
4	O
units	O
)	O
was	O
added	O
to	O
the	O
solution	O
,	O
which	O
was	O
made	O
up	O
to	O
50	O
ul	O
by	O
adding	O
water	O
.	O

The	O
solutions	O
were	O
incubated	O
at	O
370C	O
for	O
2	O
hrs	O
.	O

The	O
reaction	O
was	O
checked	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

The	O
PEI	O
-	O
cellulose	O
plate	O
(	O
12x2Ocm	O
,	O
Merck	O
)	O
was	O
preactivated	O
by	O
elution	O
with	O
1.2	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3.5	O
)	O
.	O

Small	O
aliquots	O
(	O
0.1	O
pl	O
)	O
of	O
PNK	O
reaction	O
solutions	O
were	O
applied	O
and	O
developed	O
with	O
1.5	O
M	O
pyridinium	O
formate	O
(	O
pH	O
3.5	O
)	O
.	O

The	O
TLC	O
plate	O
was	O
dried	O
and	O
autoradiographed	O
using	O
an	O
intensifying	O
screen	O
at	O
room	O
temperature	O
.	O

Gel	O
Electrophoresis	O
of	O
5'-Labeled	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Polyacrylamide	O
gels	O
were	O
prepared	O
by	O
polymerizing	O
a	O
solution	O
containing	O
18	O
%	O
(	O
w	O
/	O
v	O
)	O
acrylamide	O
,	O
0.8	O
%	O
(	O
w	O
/	O
v	O
)	O
N	O
,	O
N'-methylenebisacrylamide	O
.	O

7	O
M	O
urea	O
,	O
89	O
mM	O
Tris	O
-	O
borate	O
(	O
pH	O
8.2	O
)	O
,	O
2	O
mM	O
EDTA	O
,	O
0.07	O
%	O
(	O
w	O
/	O
v	O
)	O
ammonium	O
persulfate	O
,	O
in	O
the	O
presence	O
of	O
N	O
,	O
N	O
,	O
N',N'-tetramethylethylenediamine	O
(	O
20	O
Pil	O
/	O
20	O
ml	O
solution	O
)	O
.	O

The	O
solution	O
was	O
poured	O
into	O
a	O
0.75	O
x	O
140	O
x	O
150	O
mm	O
mold	O
and	O
allowed	O
to	O
polymerize	O
for	O
2	O
hrs	O
at	O
room	O
temperature	O
.	O

5'-Labeled	O
oligonucleoside	O
methylphosphonates	O
were	O
dissolved	O
in	O
10	O
%	O
aqueous	O
glycerol	O
solution	O
containing	O
0.04	O
%	O
bromophenol	O
blue	O
and	O
applied	O
to	O
the	O
gel	O
.	O

The	O
electrophoresis	O
was	O
run	O
using	O
89	O
mM	O
Tris	O
-	O
Borate	O
buffer	O
containing	O
10	O
mM	O
EDTA	O
.	O

After	O
electrophoresis	O
the	O
gel	O
was	O
dried	O
using	O
a	O
gel	O
-	O
dryer	O
and	O
autoradiographed	O
using	O
intensifying	O
screens	O
at	O
room	O
temperature	O
.	O

Pa	O
rti	O
al	O
Cl	O
eavage	O
of	O
01	O
i	O
gonucl	O
eosi	O
de	O
Methyl	O
phosphonates	O
wi	O
th	O
Hydrochl	O
ori	O
c	O
Aci	O
d	O
or	O
Piperidine	O
.	O

Aliquots	O
(	O
1	O
,	O
jl	O
)	O
from	O
the	O
polynucleotide	O
kinase	O
reaction	O
6231	O
Nucleic	O
Acids	O
Research	O
mixture	O
were	O
incubated	O
with	O
1	O
il	O
of	O
1	O
M	O
hydrochloric	O
acid	O
at	O
37?C	O
for	O
30	O
min	O
.	O

After	O
incubation	O
the	O
solution	O
was	O
neutralized	O
with	O
1	O
Pl	O
of	O
1	O
M	O
ammonium	O
hydroxide	O
and	O
then	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
10	O
min	O
before	O
cooling	O
to	O
00	O
.	O

Alternatively	O
,	O
aliquots	O
(	O
1	O
pl	O
)	O
from	O
the	O
phosphorylation	O
reaction	O
were	O
incubated	O
with	O
1	O
ul	O
of	O
1	O
M	O
aqueous	O
piperidine	O
at	O
370C	O
for	O
10	O
min	O
after	O
which	O
the	O
solution	O
was	O
cooled	O
to	O
0	O
?	O
and	O
evaporated	O
.	O

The	O
treated	O
samples	O
were	O
then	O
subjected	O
to	O
polyacrylamide	O
gel	O
electrophoresis	O
as	O
described	O
above	O
without	O
further	O
purification	O
.	O

RESULTS	O
AND	O
DISCUSSION	O
Synthesis	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Table	O
I	O
shows	O
some	O
of	O
the	O
protected	O
oligonucleoside	O
methylphosphonates	O
which	O
have	O
been	O
synthesized	O
on	O
aminomethyl	O
succinyl	O
-	O
derivatized	O
polystyrene	O
supports	O
.	O

The	O
basic	O
synthetic	O
steps	O
which	O
are	O
shown	O
in	O
Figure	O
1	O
are	O
described	O
in	O
detail	O
in	O
the	O
Experimental	O
section	O
.	O

These	O
steps	O
are	O
:	O
(	O
1	O
)	O
removal	O
of	O
the	O
dimethoxytrityl	O
group	O
with	O
1	O
M	O
zinc	O
bromide	O
solution	O
;	O
(	O
2	O
)	O
drying	O
the	O
support	O
via	O
co	O
-	O
evaporation	O
with	O
anhydrous	O
pyridine	O
;	O
(	O
3	O
)	O
reaction	O
of	O
the	O
support	O
-	O
bound	O
nucleoside	O
or	O
oligonucleotide	O
with	O
a	O
coupling	O
mixture	O
containing	O
0.15	O
to	O
0.2	O
M	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
-NpjEt3NH	O
and	O
0.3	O
to	O
0.6	O
M	O
mesitylenesulfonyl-3-nitrotriazole	O
in	O
anhydrous	O
pyridine	O
and	O
(	O
4	O
)	O
acetylation	O
of	O
unreacted	O
5'-OH	O
groups	O
with	O
acetic	O
anhydride	O
.	O

The	O
reactions	O
and	O
washing	O
steps	O
were	O
most	O
conveniently	O
carried	O
out	O
in	O
a	O
polypropylene	O
Econo	O
Column	O
fitted	O
with	O
a	O
septum	O
cap	O
and	O
a	O
3-way	O
Teflon	O
DMTrO	O
,	O
O	O
Figure	O
1	O
:	O
Preparation	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
on	O
a	O
1	O
T	O
o	O
w	O
Polystyrene	O
Support	O
0	O
H	O
BFvON	O
DlDTrOjO4B	O
U	O
)	O
I	O
CH3-gd	O
-	O
OEt	O
3NH	O
0	O
6232	O
Nucleic	O
Acids	O
Research	O
stopcock	O
.	O

Thus	O
no	O
transfers	O
of	O
the	O
support	O
are	O
required	O
using	O
this	O
apparatus	O
.	O

The	O
synthetic	O
procedure	O
is	O
analogous	O
to	O
the	O
phosphotriester	O
approach	O
used	O
to	O
prepared	O
protected	O
oligonucleotide	O
phosphotriesters	O
on	O
polystyrene	O
supports	O
(	O
6	O
)	O
.	O

However	O
,	O
we	O
found	O
the	O
methylphosrhonate	O
coupling	O
reaction	O
to	O
be	O
extremely	O
sensitive	O
to	O
moisture	O
.	O

Drying	O
procedures	O
such	O
as	O
washing	O
with	O
anhydrous	O
solvent	O
or	O
blowing	O
dry	O
nitrogen	O
gas	O
through	O
the	O
support	O
which	O
are	O
satisfactory	O
for	O
phosphotriester	O
synthesis	O
resulted	O
in	O
low	O
yields	O
of	O
the	O
methylphosphonates	O
.	O

The	O
best	O
yields	O
were	O
obtained	O
when	O
the	O
support	O
was	O
co	O
-	O
evaporated	O
with	O
anhydrous	O
pyridine	O
by	O
directly	O
attaching	O
the	O
reaction	O
column	O
to	O
a	O
vacuum	O
pump	O
and	O
dry	O
-	O
ice	O
trap	O
.	O

Three	O
10	O
min	O
co	O
-	O
evaporations	O
were	O
sufficient	O
to	O
render	O
the	O
support	O
anhydrous	O
.	O

The	O
protected	O
nucleoside	O
3'-methylphosphonate	O
triethylammonium	O
salts	O
used	O
in	O
the	O
coupling	O
reactions	O
were	O
prepared	O
from	O
their	O
cyanoethyl	O
ester	O
derivatives	O
(	O
3	O
)	O
.	O

These	O
monomers	O
were	O
recovered	O
after	O
each	O
coupling	O
step	O
and	O
were	O
freed	O
of	O
unreacted	O
MSNT	O
by	O
a	O
simple	O
extraction	O
step	O
.	O

After	O
precipitation	O
and	O
drying	O
,	O
the	O
monomers	O
could	O
be	O
reused	O
for	O
other	O
syntheses	O
.	O

The	O
ability	O
to	O
recover	O
the	O
unreacted	O
monomers	O
is	O
particularly	O
important	O
for	O
large	O
scale	O
synthesis	O
since	O
large	O
excesses	O
of	O
these	O
materials	O
are	O
employed	O
in	O
the	O
coupling	O
step	O
.	O

This	O
recovery	O
step	O
represents	O
a	O
potential	O
advantage	O
over	O
the	O
phosphine	O
synthetic	O
method	O
(	O
4	O
)	O
,	O
since	O
it	O
is	O
not	O
clear	O
that	O
nucleoside	O
3'-methylphosphine	O
chlorides	O
can	O
be	O
recovered	O
after	O
reaction	O
.	O

Two	O
types	O
of	O
methylphosphonate	O
oligomers	O
were	O
prepared	O
;	O
those	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
oligomers	O
1	O
-	O
6	O
,	O
and	O
those	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
3'-p	O
-	O
chlorophenyl	O
phosphotriester	O
moiety	O
,	O
oligomers	O
7	O
-	O
10	O
.	O

Oligomers	O
were	O
synthesized	O
on	O
both	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
supports	O
.	O

As	O
shown	O
in	O
Table	O
I	O
,	O
the	O
average	O
yield	O
per	O
coupling	O
step	O
which	O
was	O
determined	O
by	O
trityl	O
group	O
analysis	O
was	O
approximately	O
82	O
%	O
,	O
for	O
both	O
types	O
of	O
support	O
.	O

This	O
yield	O
is	O
adequate	O
to	O
allow	O
preparation	O
of	O
protected	O
octamers	O
or	O
nonamers	O
in	O
25	O
%	O
and	O
20	O
%	O
overall	O
yield	O
,	O
respectively	O
.	O

Deprotection	O
.	O

Our	O
previous	O
studies	O
(	O
1	O
)	O
and	O
those	O
of	O
Sinha	O
et	O
al.	O
(	O
4	O
)	O
show	O
that	O
methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
found	O
this	O
hydrolysis	O
reaction	O
to	O
depend	O
to	O
some	O
extent	O
upon	O
the	O
nucleoside	O
sequence	O
of	O
the	O
oligomer	O
.	O

Hydrolysis	O
of	O
methylphosphonate	O
linkages	O
by	O
concentrated	O
ammonium	O
hydroxide	O
in	O
pyridine	O
(	O
1:1	O
v	O
/	O
v	O
)	O
,	O
the	O
reagent	O
commonly	O
used	O
to	O
remove	O
oligonucleotide	O
base	O
protecting	O
groups	O
,	O
can	O
be	O
largely	O
suppressed	O
if	O
the	O
reactions	O
are	O
run	O
at	O
0?C	O
(	O
1	O
)	O
.	O

However	O
,	O
these	O
conditions	O
are	O
unsatisfactory	O
for	O
removal	O
of	O
oligonucleoside	O
methylphosphonates	O
from	O
the	O
polystyrene	O
6233	O
Nucleic	O
Acids	O
Research	O
Table	O
I.	O
Syntheses	O
of	O
Protected	O
Oligonucleoside	O
Methylphosphonates	O
on	O
Polystyrene	O
Supports	O
Support	O
Average	O
cross-	O
yield	O
Protected	O
oligomer	O
(	O
a	O
)	O
linking	O
per	O
(	O
%	O
)	O
coupling	O
step	O
(	O
%	O
)	O
1	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzCpbzApT	O
-	O
O	O
1	O
81	O
2	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ibuGpbzCpbzCpbzApT-	O
1	O
82	O
3	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCpbzApi	O
buGpi	O
buGpTpbzApbzA	O
-	O
G1i	O
2	O
83	O
4	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzCLpTpT	O
bzApbzCpbzCpTpibuG-	O
?	O

2	O
85	O
5	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpbzCpbzCpTpbzCpbzCpTpibuG-	O
(	O
?	O

2	O
86	O
6	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
TpTpTpbzApbzCpbzCpTpT-	O
?	O

1	O
83	O
7	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzA-	O
?	O

1	O
83	O
8	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzA4bzCpbzCpbzApT-	O
?	O

1	O
81	O
9	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApibuGpbzCpbzApbzApibuG-	O
(	O
2	O
74	O
10	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
bzApbzApbzApbzApibuGpbzCpbzApbzApibuG-	O
(	O
Q	O
1	O
86	O
(	O
a	O
)	O
p	O
=	O
methylphosphonate	O
linkage	O
T	O
=	O
p	O
-	O
chlorophenyl	O
phosphotriester	O
linkage	O
(	O
Q=	O
polystyrene	O
support	O
(	O
b	O
)	O
Determined	O
by	O
analysis	O
of	O
the	O
dimethoxytrityl	O
group	O
after	O
each	O
coupling	O
step	O
.	O

support	O
.	O

We	O
therefore	O
examined	O
other	O
deprotection	O
procedures	O
.	O

Recently	O
Barnett	O
and	O
Letsinger	O
described	O
removal	O
of	O
base	O
protecting	O
groups	O
from	O
oligonucleotide	O
B	O
,	O
B,0-trichloroethylphosphotriesters	O
using	O
a	O
mixture	O
of	O
ethylenediamine	O
in	O
phenol	O
(	O
7	O
)	O
.	O

We	O
have	O
found	O
ethylenediamine	O
in	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
rapidly	O
and	O
cleanly	O
removes	O
benzoyl	O
and	O
isobutyryl	O
protecting	O
groups	O
from	O
dA	O
,	O
dC	O
and	O
dG	O
nucleosides	O
.	O

This	O
reagent	O
is	O
particularly	O
attractive	O
since	O
it	O
can	O
be	O
easily	O
removed	O
by	O
evaporation	O
.	O

In	O
our	O
initial	O
investigations	O
,	O
ol	O
igonucleoside	O
methylphosphonates	O
were	O
cleaved	O
from	O
the	O
support	O
and	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
65?C	O
for	O
3	O
hrs	O
.	O

Although	O
preliminary	O
results	O
indicated	O
the	O
methylphosphonate	O
linkages	O
of	O
several	O
dimers	O
were	O
stable	O
to	O
these	O
conditions	O
,	O
we	O
later	O
found	O
that	O
the	O
linkages	O
of	O
onger	O
6234	O
Nucleic	O
Acids	O
Research	O
Table	O
II	O
.	O

Hydrolysis	O
of	O
Protected	O
Nucleosides	O
by	O
Ethylenediamine	O
at	O
220C	O
Protected	O
Time	O
required	O
to	O
Time	O
required	O
to	O
nucleoside	O
remove	O
50	O
%	O
of	O
the	O
cleave	O
50	O
%	O
of	O
the	O
base	O
protecting	O
nucleoside	O
from	O
the	O
groups	O
(	O
min	O
)	O
1	O
%	O
crosslinked	O
support	O
(	O
min	O
)	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
)	O
bzA	O
10	O
105	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
bzC	O
20	O
105	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
i	O
buG	O
40	O
54	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
T	O
_	O
105	O
oligomers	O
were	O
hydrolyzed	O
to	O
various	O
extents	O
by	O
this	O
procedure	O
.	O

This	O
of	O
course	O
resulted	O
in	O
loss	O
of	O
product	O
as	O
was	O
evidenced	O
by	O
the	O
presence	O
of	O
shorter	O
oligomers	O
in	O
amounts	O
greater	O
than	O
expected	O
based	O
upon	O
the	O
coupling	O
yields	O
.	O

To	O
circumvent	O
this	O
problem	O
we	O
examined	O
the	O
deprotection	O
reactions	O
at	O
lower	O
temperatures	O
and	O
found	O
they	O
could	O
be	O
run	O
effectively	O
at	O
room	O
temperature	O
.	O

Table	O
II	O
shows	O
the	O
half	O
-	O
lives	O
for	O
removing	O
the	O
base	O
protecting	O
groups	O
from	O
nucleosides	O
at	O
room	O
temperature	O
.	O

While	O
the	O
isobutryl	O
protecting	O
group	O
is	O
removed	O
at	O
the	O
slowest	O
rate	O
,	O
all	O
the	O
groups	O
are	O
completely	O
removed	O
within	O
240	O
min	O
.	O

The	O
sole	O
product	O
of	O
each	O
reaction	O
is	O
the	O
5'-O	O
-	O
dimethoxytritylnucleoside	O
as	O
shown	O
by	O
TLC	O
.	O

Table	O
II	O
also	O
shows	O
the	O
half	O
-	O
lives	O
for	O
cleavage	O
of	O
protected	O
nucleosides	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
.	O

The	O
deoxyguanosine	O
nucleoside	O
is	O
cleaved	O
most	O
rapidly	O
while	O
the	O
other	O
three	O
nucleosides	O
have	O
essentially	O
the	O
same	O
rates	O
of	O
hydrolysis	O
.	O

All	O
the	O
nucleosides	O
are	O
completely	O
removed	O
from	O
the	O
support	O
within	O
7	O
hrs	O
.	O

In	O
contrast	O
,	O
very	O
different	O
rates	O
were	O
observed	O
for	O
the	O
2	O
%	O
crosslinked	O
supports	O
.	O

In	O
these	O
cases	O
,	O
very	O
little	O
cleavage	O
occurred	O
during	O
the	O
first	O
4	O
hrs	O
of	O
incubation	O
after	O
which	O
increasing	O
amounts	O
of	O
nucleoside	O
were	O
released	O
over	O
a	O
24	O
hr	O
period	O
.	O

This	O
effect	O
may	O
be	O
due	O
to	O
the	O
slower	O
swelling	O
rate	O
of	O
the	O
2	O
%	O
crosslinked	O
support	O
versus	O
the	O
1	O
%	O
support	O
.	O

The	O
results	O
of	O
these	O
experiments	O
suggest	O
that	O
,	O
although	O
condensation	O
reactions	O
occur	O
with	O
equal	O
efficiencies	O
on	O
both	O
the	O
1	O
%	O
and	O
2	O
%	O
crosslinked	O
supports	O
,	O
the	O
1	O
%	O
support	O
is	O
preferred	O
for	O
syntheses	O
since	O
the	O
oligomers	O
can	O
be	O
removed	O
more	O
readily	O
under	O
mild	O
conditions	O
.	O

The	O
stability	O
of	O
the	O
methylphosphonate	O
linkage	O
in	O
a	O
number	O
of	O
oligomers	O
of	O
varying	O
chain	O
length	O
and	O
base	O
composition	O
was	O
examined	O
following	O
prolonged	O
exposure	O
to	O
ethylenediamine	O
/	O
ethanol	O
at	O
room	O
temperature	O
.	O

As	O
shown	O
in	O
Table	O
III	O
,	O
some	O
of	O
these	O
oligomers	O
,	O
most	O
notably	O
the	O
dimer	O
and	O
d	O
-	O
GpGpT	O
,	O
were	O
6235	O
Nucleic	O
Acids	O
Research	O
Table	O
III	O
.	O

Hydrolysis	O
of	O
Oligonucleoside	O
Methylphosphonates	O
by	O
Ethylenediamine	O
at	O
22?C	O
|	O
Oligomer	O
Mole	O
percent	O
of	O
oligomer	O
remaining	O
after	O
treatment	O
for	O
24	O
hrs	O
48	O
hrs	O
96	O
hrs	O
d	O
-	O
T	O
A	O
100	O
100	O
100	O
d	O
-	O
A5r	O
100	O
100	O
100	O
d	O
-	O
TpT	O
100	O
100	O
100	O
d	O
-	O
l	O
pT	O
95	O
97	O
91	O
d	O
-	O
qgG	O
{	O
T	O
100	O
100	O
100	O
d	O
-	O
ApApA	O
93	O
87	O
75	O
d	O
-	O
C	O
pC	O
ApT	O
92	O
83	O

67	O
completely	O
stable	O
over	O
a	O
96	O
hr	O
period	O
.	O

The	O
maximum	O
rate	O
of	O
hydrolysis	O
for	O
a	O
methylphosphonate	O
linkage	O
in	O
those	O
oligomers	O
which	O
were	O
hydrolyzed	O
is	O
estimated	O
to	O
be	O
0.13	O
mole	O
%	O
/hr	O
.	O

The	O
results	O
of	O
these	O
studies	O
show	O
that	O
the	O
oligonucleoside	O
methylphosphonates	O
could	O
be	O
cleaved	O
from	O
the	O
1	O
%	O
crosslinked	O
support	O
and	O
completely	O
freed	O
of	O
base	O
protecting	O
groups	O
with	O
little	O
or	O
no	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkage	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
room	O
temperature	O
for	O
7	O
hrs	O
.	O

These	O
conditions	O
were	O
subsequently	O
adopted	O
for	O
the	O
deprotection	O
step	O
.	O

Purification	O
of	O
Oligonucleoside	O
Methylphosphonates	O
.	O

Two	O
methods	O
were	O
employed	O
to	O
purify	O
oligomers	O
following	O
cleavage	O
from	O
the	O
support	O
.	O

For	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
,	O
the	O
tritylated	O
oligomer	O
was	O
isolated	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

This	O
separation	O
is	O
based	O
upon	O
the	O
greater	O
affinity	O
of	O
the	O
tritylated	O
oligomer	O
for	O
the	O
hydrophobic	O
C-18	O
matrix	O
of	O
the	O
column	O
.	O

Shorter	O
,	O
non	O
-	O
tritylated	O
oligomers	O
were	O
first	O
eluted	O
with	O
a	O
0	O
%	O
to	O
25	O
%	O
or	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
water	O
gradient	O
.	O

The	O
tritylated	O
product	O
was	O
then	O
eluted	O
with	O
a	O
step	O
gradient	O
of	O
50	O
%	O
acetonitrile	O
in	O
water	O
.	O

The	O
dimethoxytrityl	O
group	O
was	O
removed	O
from	O
the	O
material	O
in	O
the	O
50	O
%	O
acetonitrile	O
fraction	O
by	O
treatment	O
with	O
80	O
%	O
acetic	O
acid	O
at	O
room	O
temperature	O
.	O

Because	O
these	O
oligomers	O
were	O
originally	O
cleaved	O
from	O
the	O
support	O
by	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
at	O
65?C	O
,	O
we	O
usually	O
found	O
that	O
the	O
tritylated	O
oligomer	O
fraction	O
contained	O
shorter	O
oligomers	O
in	O
addition	O
to	O
the	O
desired	O
product	O
.	O

These	O
were	O
easily	O
separated	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

While	O
this	O
purification	O
procedure	O
is	O
qualitatively	O
satisfactory	O
,	O
recoveries	O
from	O
the	O
reversed	O
phase	O
columns	O
varied	O
from	O
50	O
%	O
to	O
90	O
%	O
.	O

These	O
losses	O
which	O
appeared	O
to	O
be	O
due	O
to	O
irreverisble	O
absorption	O
of	O
the	O
oligomers	O
to	O
the	O
column	O
varied	O
depending	O
on	O
the	O
base	O
composition	O
of	O
the	O
oligomers	O
.	O

6236	O
Nucleic	O
Acids	O
Research	O
Figure	O
2	O
:	O
Purification	O
of	O
d	O
-	O
ApApApApGpCpApApG.	O
(	O
a	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
support	O
wi	O
th	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
.	O

(	O
b	O
)	O
Ol	O
igomers	O
obtained	O
after	O
treatment	O
of	O
the	O
mixture	O
in	O
(	O
a	O
)	O
with	O
80	O
%	O
acetic	O
acid	O
.	O

(	O
c	O
)	O
Oligomers	O
eluted	O
from	O
DEAE	O
cellulose	O
column	O
with	O
0.15	O
M	O
triethylammonium	O
bicarbonate	O
.	O

(	O
d	O
)	O
Nonamer	O
obtained	O
after	O
preparative	O
reversed	O
phase	O
HPLC	O
.	O

Peaks	O
marked	O
with	O
the	O
symbol	O
(	O
X	O
)	O
are	O
derived	O
from	O
impurities	O
in	O
the	O
solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
polystyrene	O
support	O
.	O

d	O
""""	O
AAAGCAAGc	O
O	O
I	O
t10	O
15	O
20	O
25	O
Time	O
(	O
min	O
)	O
For	O
the	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-nucleoside	O
phosphotriester	O
group	O
,	O
the	O
support	O
was	O
first	O
treated	O
for	O
40	O
hrs	O
with	O
tetra	O
-	O
n	O
-	O
butylammonium	O
fluoride	O
(	O
8)	O
to	O
remove	O
the	O
p	O
-	O
chlorophenyl	O
protecting	O
group	O
.	O

These	O
oligomers	O
6237	O
b	O
Nucleic	O
Acids	O

Research	O
were	O
then	O
cleaved	O
from	O
the	O
support	O
and	O
the	O
base	O
protecting	O
groups	O
were	O
removed	O
by	O
treatment	O
with	O
ethylenediamine	O
/	O
ethanol	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
for	O
7	O
hrs	O
at	O
room	O
temperature	O
.	O

For	O
example	O
,	O
the	O
reversed	O
phase	O
HPLC	O
profile	O
for	O
products	O
obtained	O
after	O
cleavage	O
of	O
the	O
nonamer	O
,	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
ApAjApApGpCpApApG	O
,	O
is	O
shown	O
in	O
Figure	O
2a	O
.	O

The	O
peaks	O
marked	O
with	O
(	O
X	O
)	O
are	O
from	O
impurities	O
in	O
the	O
solvents	O
used	O
to	O
elute	O
the	O
oligomer	O
from	O
the	O
support	O
.	O

The	O
tritylated	O
nonamer	O
appears	O
at	O
22	O
min	O
in	O
the	O
chromatogram	O
and	O
is	O
eluted	O
with	O
50	O
%	O
aqueous	O
acetonitrile	O
.	O

After	O
removal	O
of	O
the	O
dimethoxytrityl	O
group	O
,	O
the	O
nonamer	O
elutes	O
at	O
15.2	O
min	O
(	O
Figure	O
2b	O
)	O
.	O

The	O
peaks	O
which	O
appear	O
between	O
19	O
and	O
25	O
min	O
are	O
shorter	O
oligomers	O
which	O
contain	O
a	O
5'-mesitylenesulfonate	O
group	O
.	O

At	O
this	O
stage	O
,	O
the	O
nonamer	O
was	O
partially	O
purified	O
by	O
ion	O
exchange	O
chromatography	O
on	O
a	O
DEAE	O
cellulose	O
column	O
.	O

This	O
step	O
,	O
which	O
resulted	O
in	O
84	O
%	O
recovery	O
of	O
material	O
loaded	O
onto	O
the	O
column	O
,	O
removed	O
most	O
of	O
the	O
shorter	O
oligomers	O
as	O
shown	O
in	O
Figure	O
2c	O
.	O

After	O
removal	O
of	O
the	O
buffer	O
,	O
the	O
nonamer	O
was	O
purified	O
by	O
preparative	O
reversed	O
phase	O
HPLC	O
using	O
a	O
0	O
%	O
to	O
30	O
%	O
acetonitrile	O
in	O
0.1	O
M	O
ammonium	O
acetate	O
gradient	O
.	O

The	O
recovery	O
of	O
material	O
from	O
the	O
column	O
(	O
84	O
%	O
)	O
appears	O
to	O
be	O
higher	O
when	O
ammonium	O
acetate	O
is	O
used	O
.	O

The	O
pure	O
nonamer	O
(	O
Figure	O
2d	O
)	O
was	O
obtained	O
in	O
10	O
%	O
overall	O
yield	O
based	O
on	O
the	O
amount	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2	O
Tr	O
]	O
ibuG	O
originally	O
bound	O
to	O
the	O
polystyrene	O
support	O
.	O

The	O
oligomer	O
was	O
desalted	O
on	O
a	O
Bio	O
-	O
Gel	O
P-2	O
gel	O
filtration	O
column	O
.	O

Similar	O
results	O
were	O
obtained	O
for	O
the	O
other	O
oligomers	O
purified	O
by	O
this	O
method	O
.	O

Thus	O
,	O
for	O
example	O
dApApA	O
and	O
d	O
-	O
ApCpCpApT	O
were	O
obtained	O
in	O
44	O
%	O
and	O
22	O
%	O
isolated	O
yields	O
respectively	O
based	O
upon	O
the	O
amount	O
of	O
d-	O
[	O
(	O
MeO	O
)	O
2Tr	O
]	O
N.	O
The	O
5'-terminal	O
nucleotide	O
may	O
be	O
removed	O
enzynatically	O
to	O
give	O
an	O
oligomer	O
which	O
contains	O
only	O
methylphosphonate	O
linkages	O
.	O

Thus	O
treatment	O
of	O
the	O
nonamer	O
,	O
d	O
-	O
ApApApApGpCpApApG	O
,	O
with	O
spleen	O
phosphodiesterase	O
gave	O
d	O
-	O
Ap	O
and	O
the	O
octamer	O
d	O
-	O
ApApApGpCpApApG	O
whose	O
retention	O
time	O
is	O
16.4	O
min	O
on	O
the	O
reversed	O
phase	O
column	O
.	O

The	O
noncharged	O
octamer	O
was	O
freed	O
of	O
d	O
-	O
Ap	O
and	O
enzyne	O
by	O
simply	O
passing	O
it	O
through	O
a	O
small	O
DEAE	O
cellulose	O
column	O
.	O

Characterization	O
.	O

Methylphosphonate	O
linkages	O
are	O
cleaved	O
by	O
base	O
.	O

We	O
have	O
found	O
piperdine	O
is	O
particularly	O
effective	O
.	O

The	O
cleavage	O
occurs	O
in	O
a	O
random	O
manner	O
giving	O
nucleosides	O
,	O
nucleoside	O
3'-	O
or	O
5'-methylphosphonates	O
and	O
nucleoside	O
3',5'-bis	O
-	O
methylphosphonates	O
.	O

This	O
hydrolysis	O
reaction	O
may	O
be	O
used	O
to	O
characterize	O
dimers	O
,	O
since	O
the	O
identity	O
and	O
ratio	O
of	O
the	O
products	O
formed	O
are	O
easily	O
determined	O
by	O
reversed	O
phase	O
HPLC	O
.	O

However	O
,	O
the	O
method	O
becomes	O
less	O
satisfactory	O
for	O
longer	O
oligomers	O
.	O

Purine	O
-	O
containing	O
oligonucleoside	O
methylphosphonates	O
may	O
be	O
depurinated	O
by	O
treatment	O
with	O
hydrochloric	O
acid	O
at	O
650	O
.	O

The	O
methylphosphonate	O
linkage	O
is	O
6238	O
Nucleic	O
Acids	O
Research	O
9	O
0	O
OH	O
cH3P	O
:	O
O	O
cH	O
CH3P	O
9	O
9	O
CH	O
-	O
P	O
:O	O
C	O
cH	O
:	O
0pO	O
O~~	O
~j4	O
HO	O
OP	O
3	O
0	O
H	O
0	O
0OH0	O
9	O
S	O
S	O
Figure	O
3	O
:	O
Hydrolysis	O
of	O
the	O
internucleoside	O
methylphsophonate	O
linkages	O
at	O
an	O
apurinic	O
site	O
produced	O
by	O
treatment	O
of	O
the	O
oligomer	O
with	O
hydrochloric	O
acid	O
at	O
pH	O
2	O
.	O

resistant	O
to	O
hydrolysis	O
by	O
these	O
conditions	O
as	O
shown	O
by	O
the	O
stability	O
of	O
d	O
-	O
TpT	O
and	O
d	O
-	O
TpTpT.	O
On	O
the	O
other	O
hand	O
,	O
dimers	O
or	O
trimers	O
containing	O
purine	O
bases	O
such	O
as	O
d	O
-	O
ApA	O
,	O
dApT	O
,	O
dTpA	O
or	O
d	O
-	O
ApApA	O
have	O
half	O
-	O
lives	O
between	O
92	O
and	O
144	O
min	O
in	O
0.01	O
M	O
hydrochloric	O
acid	O
.	O

Following	O
neutralization	O
with	O
ammonium	O
hydroxide	O
,	O
the	O
products	O
of	O
these	O
reactions	O
were	O
characterized	O
by	O
reversed	O
phase	O
HPLC	O
.	O

d	O
-	O
ApA	O
gave	O
adenine	O
,	O
while	O
both	O
d	O
-	O
ApT	O
and	O
d	O
-	O
TpA	O
gave	O
adenine	O
and	O
thymidine	O
as	O
the	O
sole	O
products	O
of	O
the	O
reaction	O
.	O

Adenine	O
and	O
d	O
-	O
ApA	O
were	O
the	O
only	O
products	O
observed	O
when	O
d	O
-	O
ApApA	O
was	O
partially	O
hydrolyzed	O
.	O

When	O
d	O
-	O
CpCpApT	O
was	O
completely	O
hydrolyzed	O
in	O
acid	O
three	O
products	O
,	O
d	O
-	O
CpC	O
,	O
adenine	O
and	O
thynidine	O
,	O
were	O
observed	O
in	O
a	O
molar	O
ratio	O
of	O
1:1:1	O
.	O

In	O
contrast	O
to	O
the	O
base	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
group	O
,	O
apurinic	O
sites	O
produced	O
by	O
acid	O
treatment	O
are	O
further	O
hydrolyzed	O
to	O
nucleosides	O
or	O
oligomers	O
with	O
free	O
5'-	O
and	O
3'-OH	O
groups	O
.	O

The	O
absence	O
of	O
terminal	O
phosphonate	O
residues	O
suggests	O
hydrolysis	O
occurs	O
as	O
shown	O
in	O
Figure	O
3	O
.	O

The	O
OH	O
group	O
on	O
the	O
4'-carbon	O
generated	O
by	O
opening	O
the	O
ribose	O
at	O
the	O
apurinic	O
site	O
may	O
participate	O
in	O
an	O
intramolecular	O
attack	O
on	O
the	O
adjacent	O
phosphonate	O
linkages	O
which	O
results	O
in	O
removal	O
of	O
the	O
phosphonate	O
residues	O
from	O
the	O
neighboring	O
nucleoside	O
hydroxyls	O
.	O

Previous	O
studies	O
by	O
Agarwal	O
and	O
Riftina	O
indicated	O
dithymidine	O
methyl-	O
or	O
phenylphosphonates	O
can	O
be	O
phosphorylated	O
by	O
polynucleotide	O
kinase	O
(	O
9	O
)	O
.	O

Sinha	O
et	O
al.	O
reported	O
that	O
dimers	O
but	O
not	O
trimers	O
or	O
tetramers	O
served	O
as	O
substrates	O
for	O
this	O
enzyme	O
(	O
4	O
)	O
.	O

We	O
were	O
unable	O
to	O
phosphorylate	O
tetramers	O
or	O
longer	O
oligomers	O
which	O
contain	O
only	O
methylphosphonate	O
linkages	O
.	O

However	O
,	O
those	O
oligomers	O
which	O
terminate	O
with	O
a	O
5'-dAp	O
-	O
residue	O
are	O
readily	O
6239	O
Nucleic	O
Acids	O
Research	O
a	O
ATP	O
1	O
1	O
2	O
3	O
4	O
b	O
6	O
mer	O
Mik	O
6	O
mer	O
go	O
3mer	O
a	O
a	O
a	O
X	O
2mer	O
do	O
ATP	O
411	O
12	O
w	O
34	O
1	O
2	O
3	O
4	O
5	O
6	O
Figure	O
4	O
:	O
(	O
a	O
)	O
PEI	O
-	O
cellulose	O
TLC	O
of	O
T4	O
polynucleotide	O
kinase	O
reactions	O
.	O

1	O
)	O
[	O
y-32p	O
]	O
ATP	O
;	O
2	O
)	O
d	O
-	O
ApApA	O
reaction	O
mixture	O
;	O
3	O
)	O
d	O
-	O
ApGpCpApApG	O
reaction	O
mixture	O
;	O
4	O
)	O
d	O
-	O
ApApApApG_pCpApAeG	O
reaction	O
mixture	O
.	O

The	O
chromatogram	O
was	O
eluted	O
wi	O
th1.5	O
M	O
pyridinium	O
formate	O
,	O
pH	O
3.5	O
.	O

(	O
b	O
)	O
Polyacrylamide	O
gel	O
electrophoresis	O
of	O
phosphoryljted	O
olihonucleoside	O
methylghosphonates	O
.	O

1	O
)	O
markers	O
:	O
d-	O
pTpT	O
(	O
2	O
mer	O
)	O
;	O
d-,3pApApA	O
(	O
3	O
mer	O
)	O
;	O
d-	O
2pApGpCpApApG	O
(	O
6	O
mer	O
)	O
;	O
d-32pApApApApGpCpApApG	O
(	O
9	O
mer	O
.	O

Lanes	O
2	O
-	O
4	O
:	O
products	O
obtained	O
after	O
partTaT	O
fy?rlysis	O
of	O
dl2pApApA	O
(	O
2	O
)	O
;	O
d-	O
2pApGpCpApApG	O
(	O
3	O
)	O
and	O
d-32pApARApApGpCpAZARG	O
;	O
(	O
4	O
)	O
with	O
0.5	O
M	O
piperidine	O
at	O
377C	O
for	O
10	O
min	O
Lanel	O
t	O
:	O
products	O
obtained	O
Wfter	O
partial	O
hydrolysis	O
of	O
d-3Kp	O
-	O
ApGRCpApApG	O
(	O
5	O
)	O
and	O
d-32p	O
-	O
ApApAppGpjCppAjG	O
(	O
6	O
)	O
with	O
0.5	O
M	O
HC1	O
at	O
371C	O
fCor30	O
min	O
.	O

Electrophoresis	O
was	O
carried	O
out	O
at	O
constant	O
voltage	O
(	O
800	O
v	O
)	O
until	O
the	O
bromphenol	O
blue	O
marker	O
dye	O
had	O
migrated	O
halfway	O
down	O
the	O
gel	O
.	O

phosphorylated	O
by	O
polynucleotide	O
kinase	O
.	O

The	O
phosphorylation	O
reaction	O
is	O
easily	O
followed	O
by	O
PEI	O
-	O
cellulose	O
TLC	O
.	O

As	O
shown	O
in	O
Figure	O
4a	O
,	O
the	O
phosphorylated	O
oligomers	O
have	O
a	O
higher	O
Rf	O
values	O
than	O
does	O
d	O
-	O
ATP	O
.	O

The	O
phosphorylated	O
methylphosphonate	O
oligomers	O
can	O
be	O
separated	O
according	O
to	O
their	O
chain	O
lengths	O
by	O
polyacrylamide	O
gel	O
electrophoresis	O
on	O
an	O
18	O
%	O
gel	O
containing	O
7	O
M	O
urea	O
as	O
shown	O
in	O
Figure	O
4	O
(	O
b	O
)	O
.	O

Lane	O
1	O
shows	O
the	O
separation	O
of	O
a	O
trimer	O
,	O
hexamer	O
and	O
nonamer	O
.	O

The	O
band	O
which	O
appears	O
directly	O
below	O
the	O
nonamer	O
may	O
arise	O
from	O
traces	O
of	O
contaminating	O
octamer	O
which	O
were	O
not	O
removed	O
during	O
the	O
purification	O
of	O
d	O
-	O
ApApApApGpCpApApG.	O
6240	O
Nucleic	O
Acids	O
Research	O
When	O
the	O
oligomers	O
were	O
partially	O
hydrolyzed	O
with	O
piperidine	O
,	O
a	O
series	O
of	O
new	O
bands	O
appears	O
corresponding	O
to	O
shorter	O
oligomers	O
produced	O
via	O
hydrolysis	O
of	O
the	O
methylphosphonate	O
linkages	O
(	O
Lanes	O
2	O
-	O
4	O
)	O
.	O

Because	O
of	O
the	O
random	O
nature	O
of	O
this	O
cleavage	O
reaction	O
,	O
the	O
oligomers	O
should	O
terminate	O
with	O
either	O
a	O
3'-OH	O
or	O
a	O
3'-methylphosphonate	O
group	O
.	O

In	O
the	O
case	O
of	O
the	O
trimer	O
,	O
32pApApA	O
,	O
hydrolysis	O
gives	O
two	O
bands	O
which	O
correspond	O
to	O
d-32pApA	O
and	O
d-32pApAp	O
(	O
Lane	O
2	O
)	O
.	O

The	O
same	O
products	O
are	O
observed	O
for	O
hydrolysis	O
of	O
the	O
nonamer	O
,	O
d-32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

A	O
similar	O
situation	O
is	O
observed	O
for	O
d32pApGpCpApApG	O
although	O
the	O
dimers	O
d-32pApG	O
and	O
d-32pApGp	O
have	O
somewhat	O
different	O
mobilities	O
(	O
Lane	O
3	O
)	O
.	O

These	O
dimers	O
can	O
not	O
be	O
separated	O
when	O
the	O
gel	O
is	O
run	O
in	O
the	O
absence	O
of	O
urea	O
.	O

It	O
is	O
possible	O
to	O
determine	O
the	O
chain	O
lengths	O
of	O
the	O
original	O
oligomers	O
by	O
counting	O
the	O
number	O
of	O
oligomers	O
produced	O
by	O
partial	O
piperidine	O
hydrolysis	O
.	O

For	O
example	O
,	O
starting	O
with	O
the	O
trimer	O
band	O
,	O
one	O
can	O
observe	O
3	O
bands	O
corresponding	O
to	O
tetramer	O
,	O
pentamer	O
and	O
hexamer	O
for	O
the	O
hydrolysis	O
products	O
of	O
d-32pApGpCpApApG	O
(	O
Lane	O
3	O
)	O
and	O
6	O
bands	O
corresponding	O
to	O
tetramer	O
,	O
pentamer	O
,	O
hexamer	O
,	O
heptamer	O
,	O
octamer	O
and	O
nonamer	O
for	O
the	O
hydrolysis	O
products	O
of	O
32pApApApApGpCpApApG	O
(	O
Lane	O
4	O
)	O
.	O

The	O
positions	O
of	O
the	O
oligomers	O
of	O
the	O
same	O
chain	O
length	O
appear	O
to	O
be	O
very	O
similar	O
which	O
suggests	O
that	O
the	O
mobilities	O
are	O
not	O
greatly	O
affected	O
by	O
base	O
composition	O
on	O
the	O
urea	O
-	O
containing	O
gel	O
.	O

This	O
procedure	O
thus	O
provides	O
a	O
rapid	O
and	O
convenient	O
method	O
for	O
characterizing	O
the	O
methyl	O
phosphonate	O
ol	O
i	O
gomers	O
.	O

Treatment	O
of	O
the	O
phosphorylated	O
oligomers	O
with	O
acid	O
produces	O
shorter	O
oligomers	O
which	O
result	O
from	O
chain	O
cleavage	O
at	O
apurinic	O
sites	O
.	O

In	O
this	O
case	O
the	O
oligomers	O
terminate	O
with	O
a	O
3'-OH	O
group	O
.	O

Treatment	O
of	O
32pApGpCpApALpG	O
produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
pentamer	O
,	O
d-32pApGjCpAjA	O
(	O
Lane	O
5	O
)	O
while	O
treatment	O
of	O
32pApApApApGpCpApApG	O
produces	O
an	O
intense	O
band	O
corresponding	O
to	O
the	O
octamer	O
d-32pApApAPApGpCpApA	O
and	O
fainter	O
bands	O
corresponding	O
to	O
the	O
heptamer	O
,	O
hexamer	O
,	O
tetramer	O
and	O
trimer	O
.	O

These	O
results	O
suggest	O
that	O
under	O
the	O
conditions	O
of	O
the	O
experiment	O
,	O
hydrolysis	O
occurs	O
preferentially	O
at	O
the	O
3'-terminal	O
G	O
residue	O
of	O
both	O
oligomers	O
.	O

It	O
should	O
be	O
possible	O
to	O
extend	O
this	O
methodology	O
to	O
other	O
base	O
specific	O
depurination	O
or	O
depyrimidination	O
reactions	O
similar	O
to	O
those	O
employed	O
in	O
the	O
Maxam	O
-	O
Gilbert	O
sequencing	O
method	O
(	O
10	O
)	O
.	O

Experiments	O
directed	O
toward	O
this	O
goal	O
are	O
currently	O
in	O
progress	O
and	O
will	O
be	O
reported	O
in	O
a	O
future	O
communication	O
.	O

ACKNOWLEDGEMENT	O
:	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
the	O
following	O
grants	O
from	O
the	O
National	O
Institutes	O
of	O
Health	O
:	O
GM	O
16066	O
(	O
P.O.P.T.	O
)	O
and	O
GM	O
31927	O
6241	O
Nucleic	O
Acids	O
Research	O
(	O
P.S.M.	O
)	O
,	O
and	O
from	O
a	O
grant	O
from	O
Association	O
for	O
International	O
Cancer	O
Research	O
.	O

REFERENCES	O
:	O
1	O
.	O

MTTITr	O
,	O
P.S.	O
,	O
McParland	O
,	O
K.B.	O
,	O
Jayaraman	O
,	O
K.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1981	O
)	O
Biochemistry	O
20	O
,	O
1874	O
-	O
1880	O
.	O

2	O
.	O

Jayaraman	O
,	O
K.	O
,	O
McParland	O
,	O
K.B.	O
,	O
Miller	O
,	O
P.S.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1981	O
)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O
78	O
,	O
1537	O
-	O
1541	O
.	O

3	O
.	O

Miller	O
,	O
P.S.	O
,	O
Agris	O
,	O
C.H.	O
,	O
Blandin	O
,	O
M.	O
,	O
Murakami	O
,	O
A.	O
,	O
Reddy	O
,	O
P.M.	O
,	O
Spitz	O
,	O
S.A.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1983	O
)	O
Nucleic	O
Acids	O
Res	O
.	O
,	O
submitted	O
for	O
publ	O
ication	O
.	O

4	O
.	O

Sinha	O
,	O
N.D.	O
Grossbruchaus	O
,	O
V.	O
and	O
Koester	O
,	O
H.	O
(	O
1983	O
)	O
Tetrahedron	O
Letters	O
24	O
,	O
877	O
-	O
880	O
.	O

5	O
.	O

Miller	O
,	O
P.S.	O
,	O
Cheng	O
,	O
D.M.	O
,	O
Dreon	O
,	O
N.	O
,	O
Jayaraman	O
,	O
K.	O
,	O
Kan	O
,	O
L	O
.-	O
S.	O
,	O
Leutzinger	O
,	O
E.E.	O
,	O
Pulford	O
,	O
S.M.	O
and	O
Ts'o	O
,	O
P.O.P.	O
(	O
1980	O
)	O
Biochemistry	O
19	O
,	O
4688	O
-	O
4698	O
.	O

6	O
.	O

Ito	O
,	O
H.	O
,	O
Ike	O
,	O
Y.	O
,	O
Ikuta	O
,	O
S.	O
and	O
Itakura	O
,	O
K.	O
,	O
(	O
1982	O
)	O

Nucleic	O
Acids	O
Res	O
10	O
,	O
1755	O
-	O
1769	O
.	O

7	O
.	O

Barnett	O
,	O
R.W.	O
and	O
Letsinger	O
,	O
R.L.	O
(	O
1981	O
)	O

Tetrahedron	O
Letters	O
22	O
,	O
991	O
-	O
994	O
.	O

6242	O

Enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O

Abstract	O
The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
base	O
-	O
specific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
,	O
phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O

Images	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3301	O
Enzymatic	O
multiplex	O
DNA	O
sequencing	O
Mark	O
Chee	O
Medical	O
Research	O
Council	O
Laboratory	O
of	O
Molecular	O
Biology	O
,	O
Hills	O
Road	O
,	O
Cambridge	O
CB2	O
20H	O
,	O
UK	O
Received	O
March	O
15	O
,	O
1991	O
;	O
Revised	O
and	O
Accepted	O
May	O
2	O
,	O
1991	O
ABSTRACT	O
The	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
has	O
been	O
reformulated	O
using	O
an	O
easily	O
implemented	O
,	O
multiplex	O
version	O
of	O
enzymatic	O
DNA	O
sequencing	O
.	O

By	O
utilizing	O
a	O
uniquely	O
tagged	O
primer	O
for	O
each	O
base	O
-	O
specific	O
sequencing	O
reaction	O
,	O
the	O
four	O
reactions	O
can	O
be	O
pooled	O
and	O
electrophoresed	O
in	O
a	O
single	O
lane	O
.	O

This	O
approach	O
has	O
been	O
previously	O
proposed	O
for	O
use	O
with	O
fluorescently	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
and	O
is	O
analogous	O
to	O
the	O
principle	O
used	O
in	O
four	O
-	O
dye	O
fluorescence	O
sequencing	O
except	O
that	O
the	O
signals	O
are	O
resolved	O
following	O
electrophoresis	O
(	O
2	O
)	O
.	O

After	O
transfer	O
to	O
a	O
nylon	O
membrane	O
,	O
images	O
are	O
obtained	O
separately	O
for	O
each	O
of	O
the	O
four	O
reactions	O
by	O
hybridization	O
using	O
oligonucleotide	O
probes	O
.	O

The	O
images	O
can	O
then	O
be	O
superimposed	O
to	O
reconstitute	O
a	O
complete	O
sequence	O
pattern	O
.	O

In	O
this	O
way	O
the	O
correction	O
of	O
gel	O
distortion	O
effects	O
and	O
accurate	O
band	O
registration	O
are	O
considerably	O
simplified	O
,	O
as	O
each	O
of	O
the	O
four	O
basespecific	O
ladders	O
require	O
very	O
similar	O
corrections	O
.	O

The	O
methods	O
therefore	O
provide	O
the	O
basis	O
for	O
a	O
second	O
generation	O
of	O
more	O
accurate	O
and	O
reliable	O
film	O
reading	O
programs	O
,	O
as	O
well	O
as	O
being	O
useful	O
for	O
conventional	O
multiplex	O
sequencing	O
.	O

Unlike	O
the	O
original	O
multiplex	O
protocol	O
(	O
3	O
)	O
,	O
the	O
approach	O
described	O
is	O
suitable	O
for	O
small	O
projects	O
,	O
as	O
multiple	O
cloning	O
vectors	O
are	O
not	O
used	O
.	O

Although	O
more	O
than	O
one	O
vector	O
can	O
be	O
utilized	O
,	O
only	O
a	O
library	O
of	O
fragments	O
cloned	O
into	O
any	O
single	O
phage	O
.	O

phagemid	O
or	O
plasmid	O
vector	O
is	O
actually	O
required	O
,	O
together	O
with	O
a	O
set	O
of	O
tagged	O
oligonucleotide	O
primers	O
.	O

INTRODUCTION	O
The	O
community	O
of	O
biologists	O
is	O
undertaking	O
the	O
sequencing	O
of	O
representative	O
genomes	O
of	O
various	O
free	O
-	O
living	O
organisms	O
,	O
ranging	O
in	O
size	O
from	O
Mycoplasma	O
(	O
800	O
kb	O
)	O
to	O
mammals	O
(	O
3	O
Gb	O
)	O
(	O
4	O
)	O
.	O

However	O
,	O
the	O
largest	O
contiguous	O
DNA	O
sequences	O
which	O
have	O
been	O
determined	O
so	O
far	O
are	O
the	O
genomes	O
of	O
several	O
dsDNA	O
eukaryotic	O
viruses	O
(	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
9	O
)	O
and	O
plant	O
chloroplasts	O
(	O
10	O
,	O
11	O
,	O
12	O
)	O
.	O

The	O
largest	O
of	O
these	O
is	O
the	O
229	O
kb	O
genome	O
of	O
human	B
cytomegalovirus	I
(	O
8)	O
.	O

The	O
difficulty	O
in	O
sequencing	O
millions	O
of	O
base	O
pairs	O
of	O
DNA	O
is	O
that	O
several	O
steps	O
in	O
the	O
methods	O
are	O
relatively	O
labour	O
intensive	O
,	O
although	O
the	O
sequencing	O
reactions	O
themselves	O
are	O
rapid	O
and	O
easily	O
performed	O
.	O

Two	O
limiting	O
steps	O
in	O
conventional	O
procedures	O
are	O
the	O
size	O
fractionation	O
of	O
sequencing	O
reaction	O
products	O
by	O
gel	O
electrophoresis	O
and	O
the	O
subsequent	O
reading	O
of	O
sequence	O
ladders	O
.	O

The	O
former	O
problem	O
can	O
be	O
overcome	O
by	O
multiplexing	O
,	O
which	O
theoretically	O
allows	O
an	O
enormous	O
amount	O
of	O
data	O
to	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
by	O
processing	O
clones	O
as	O
mixtures	O
rather	O
than	O
individually	O
(	O
3	O
)	O
.	O

Each	O
sequence	O
in	O
the	O
mixture	O
is	O
labelled	O
by	O
a	O
unique	O
short	O
oligonucleotide	O
'	O
tag	O
'	O
sequence	O
.	O

This	O
allows	O
the	O
mixture	O
to	O
be	O
resolved	O
following	O
electrophoresis	O
:	O
the	O
superimposed	O
sequence	O
ladders	O
are	O
blotted	O
from	O
the	O
gel	O
to	O
a	O
nylon	O
membrane	O
,	O
and	O
detected	O
one	O
at	O
a	O
time	O
by	O
hybridization	O
using	O
tag	O
-	O
specific	O
oligonucleotide	O
probes	O
.	O

In	O
practice	O
,	O
at	O
least	O
50	O
sets	O
of	O
sequences	O
can	O
be	O
obtained	O
from	O
a	O
single	O
gel	O
(	O
3	O
)	O
.	O

Unfortunately	O
,	O
a	O
bottleneck	O
in	O
the	O
multiplex	O
procedure	O
is	O
the	O
reading	O
of	O
sequence	O
films	O
.	O

In	O
previous	O
large	O
-	O
scale	O
sequencing	O
projects	O
this	O
task	O
has	O
been	O
performed	O
with	O
the	O
aid	O
of	O
a	O
sonic	O
digitizer	O
(	O
13	O
,	O
14	O
)	O
.	O

Although	O
film	O
reading	O
programs	O
have	O
been	O
under	O
development	O
for	O
some	O
time	O
(	O
15	O
)	O
,	O
and	O
some	O
programs	O
are	O
commercially	O
available	O
,	O
their	O
error	O
rates	O
are	O
presently	O
more	O
variable	O
and	O
unpredictable	O
than	O
that	O
of	O
a	O
skilled	O
person	O
and	O
the	O
accurate	O
interpretation	O
of	O
film	O
-	O
imaged	O
sequence	O
ladders	O
by	O
computer	O
programs	O
is	O
difficult	O
to	O
achieve	O
in	O
routine	O
practice	O
.	O

Programs	O
specifically	O
designed	O
to	O
read	O
multiplex	O
films	O
have	O
an	O
advantage	O
.	O

This	O
is	O
because	O
a	O
sequence	O
image	O
can	O
be	O
used	O
as	O
an	O
'	O
internal	O
standard	O
'	O
to	O
help	O
interpret	O
other	O
images	O
derived	O
from	O
the	O
same	O
membrane	O
(	O
3	O
)	O
.	O

However	O
,	O
the	O
original	O
implementation	O
of	O
the	O
multiplex	O
strategy	O
used	O
chemical	O
sequencing	O
(	O
16	O
)	O
,	O
which	O
yields	O
a	O
more	O
complex	O
sequence	O
ladder	O
than	O
the	O
enzymatic	O
dideoxynucleotide	O
chain	O
-	O
termination	O
method	O
(	O
17	O
)	O
.	O

Most	O
successful	O
large	O
scale	O
sequencing	O
projects	O
have	O
used	O
the	O
chaintermination	O
method	O
and	O
bacteriophage	B
M13	I
vectors	O
,	O
which	O
allows	O
the	O
routine	O
production	O
of	O
clean	O
and	O
easily	O
interpretable	O
sequences	O
(	O
18	O
)	O
.	O

It	O
was	O
therefore	O
decided	O
to	O
adapt	O
the	O
original	O
multiplex	O
protocol	O
for	O
use	O
with	O
enzymatic	O
sequencing	O
,	O
using	O
tagged	O
primers	O
.	O

MATERIALS	O
AND	O
METHODS	O
Eight	O
oligonucleotide	O
sequencing	O
primers	O
were	O
synthesized	O
,	O
each	O
37	O
nucleotides	O
in	O
length	O
.	O

The	O
3	O
'	O
end	O
of	O
each	O
primer	O
consists	O
of	O
the	O
17	O
nucleotide	O
M13	O
universal	O
priming	O
sequence	O
[	O
GTAAAACGACGGCCAGT3	O
'	O
]	O
.	O

The	O
5	O
'	O
ends	O
of	O
the	O
primers	O
bear	O
different	O
20mer	O
tag	O
sequences	O
(	O
Figure	O
1	O
)	O
.	O

In	O
four	O
of	O
the	O
primers	O
,	O
UEO1C	O
,	O
UPOIC	O
,	O
UE02C	O
and	O
UP02C	O
,	O
these	O
tags	O
are	O
complementary	O
to	O
the	O
EO1	O
,	O
PO1	O
,	O
E02	O
and	O
P02	O
probe	O
sequences	O
respectively	O
(	O
copied	O
from	O
the	O
original	O
'	O
plex	O
'	O
vectors	O
(	O
3	O
)	O
)	O
.	O

A	O
second	O
set	O
of	O
four	O
primers	O
,	O
UJOL14C	O
,	O
UJOL15C	O
,	O
UJOL16C	O
and	O
UJOL17C	O
,	O
have	O
the	O
following	O
tag	O
sequences	O
:	O
5	O
'	O
CAAGTTTGAAGGTACTCATT	O
,	O
TATCAATTAAATTGTllTGAC	O
,	O
GTGTTGCTACCCAAGAAGCA	O
,	O
and	O
TGTCACTAGAGCTGTCACTT	O
,	O
respectively	O
.	O

The	O
?	O
=)	O
1991	O
Oxford	O
University	O
Press	O
3302	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
oligonucleotides	O
were	O
gel	O
-	O
purified	O
(	O
19	O
)	O
and	O
used	O
to	O
sequence	O
ssDNA	O
templates	O
prepared	O
by	O
phenol	O
extraction	O
(	O
20	O
)	O
or	O
SDS	O
denaturation	O
(	O
21	O
)	O
.	O

Conventional	O
sequencing	O
reactions	O
were	O
performed	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

For	O
hybridization	O
experiments	O
,	O
radioactively	O
labelled	O
nucleotides	O
were	O
omitted	O
from	O
the	O
sequencing	O
reactions	O
.	O

Instead	O
,	O
the	O
21d	O
of	O
each	O
nucleotide	O
mix	O
added	O
to	O
the	O
reaction	O
mixture	O
consisted	O
of	O
the	O
following	O
:	O
'	O
A	O
'	O
mix	O
:	O
6.25MtM	O
dATP	O
,	O
62.5lM	O
ddATP	O
;	O
'	O
C	O
'	O
mix	O
:	O
6.25MM	O
dCTP	O
,	O
40MtM	O
ddCTP	O
;	O
'	O
G	O
'	O
mix	O
:	O
6.25MtM	O
dGTP	O
,	O
80MtM	O
ddGTP	O
;	O
'	O
T	O
'	O
mix	O
:	O
6.25MM	O
dTTP	O
,	O
250yM	O
ddTTP	O
;	O
as	O
well	O
as	O
125MM	O
of	O
each	O
of	O
the	O
three	O
other	O
dNTPs	O
in	O
each	O
mix	O
.	O

Apart	O
from	O
the	O
use	O
of	O
these	O
modified	O
mixes	O
,	O
no	O
changes	O
were	O
made	O
to	O
the	O
conventional	O
sequencing	O
procedure	O
(	O
20	O
)	O
.	O

Sequencing	O
reactions	O
were	O
pooled	O
and	O
ethanol	O
precipitated	O
as	O
appropriate	O
.	O

Precipitation	O
in	O
microtitre	O
trays	O
was	O
carried	O
out	O
as	O
follows	O
:	O
a	O
mixture	O
of	O
3.2M1	O
3	O
M	O
NaAc	O
pH	O
5.0	O
and	O
112Mi1	O
EtOH	O
was	O
dispensed	O
to	O
individual	O
wells	O
of	O
a	O
microtitre	O
plate	O
(	O
Falcon	O
3911	O
or	O
Corning	O
25855	O
)	O
using	O
an	O
8-channel	O
pipettor	O
.	O

Each	O
set	O
of	O
four	O
reactions	O
was	O
added	O
to	O
the	O
EtOH	O
/	O
NaAc	O
mixture	O
,	O
and	O
the	O
tray	O
sealed	O
using	O
a	O
Falcon	O
3073	O
plate	O
sealer	O
.	O

The	O
samples	O
were	O
mixed	O
by	O
inversion	O
and	O
stored	O
at	O
-20?C	O
for	O
30	O
minutes	O
.	O

The	O
DNA	O
was	O
collected	O
by	O
a	O
20	O
minute	O
centrifugation	O
at	O
4	O
000	O
rpm	O
in	O
an	O
IEC	O
Centra	O
3C	O
centrifuge	O
.	O

The	O
sealer	O
was	O
removed	O
,	O
and	O
the	O
plate	O
inverted	O
to	O
discard	O
the	O
supernatant	O
.	O

After	O
blotting	O
the	O
tray	O
on	O
tissue	O
paper	O
,	O
200MI	O
of	O
95	O
%	O
EtOH	O
was	O
added	O
to	O
each	O
well	O
.	O

The	O
plate	O
was	O
covered	O
with	O
a	O
plastic	O
lid	O
and	O
recentrifuged	O
for	O
2	O
minutes	O
.	O

The	O
EtOH	O
was	O
discarded	O
and	O
the	O
plate	O
inverted	O
for	O
several	O
minutes	O
on	O
tissue	O
paper	O
,	O
then	O
left	O
for	O
20	O
minutes	O
to	O
air	O
dry	O
.	O

Precipitated	O
samples	O
were	O
resuspended	O
in	O
6M1	O
deionized	O
water	O
by	O
vortexing	O
on	O
an	O
SMI	O
multi	O
-	O
tube	O
vortexer	O
for	O
1	O
minute	O
.	O

Samples	O
were	O
denatured	O
and	O
electrophoresed	O
on	O
6	O
%	O
polyacrylamide	O
buffer	O
gradient	O
gels	O
as	O
previously	O
described	O
(	O
20	O
)	O
.	O

Following	O
electrophoresis	O
,	O
the	O
gel	O
was	O
transferred	O
to	O
a	O
dry	O
piece	O
of	O
Whatman	O
3MM	O
blotting	O
paper	O
,	O
and	O
placed	O
on	O
a	O
second	O
sheet	O
of	O
blotting	O
paper	O
supported	O
on	O
a	O
glass	O
plate	O
and	O
saturated	O
in	O
4	O
x	O
SSC	O
(	O
SSC	O
:	O
150mM	O
NaCl	O
,	O
l5mM	O
trisodium	O
citrate	O
)	O
.	O

This	O
sheet	O
was	O
wicked	O
in	O
a	O
tray	O
containing	O
1	O
litre	O
of	O
4	O
x	O
SSC	O
.	O

The	O
DNA	O
was	O
transferred	O
to	O
a	O
nylon	O
membrane	O
(	O
Amersham	O
Hybond	O
N	O
)	O
by	O
capillary	O
blotting	O
overnight	O
(	O
22	O
)	O
.	O

DNA	O
was	O
fixed	O
to	O
the	O
membranes	O
by	O
U.V.	O
crosslinking	O
(	O
23	O
)	O
.	O

Plex	O
oligonucleotide	O
probes	O
were	O
a	O
kind	O
gift	O
of	O
Dr.	O

George	O
Church	O
.	O

Probes	O
were	O
tailed	O
at	O
their	O
3	O
'	O
ends	O
using	O
[	O
a-32p	O
]	O
dCTP	O
as	O
previously	O
described	O
(	O
3	O
)	O
.	O

For	O
the	O
preparation	O
of	O
digoxigenin	O
(	O
DIG	O
)	O
labelled	O
probes	O
,	O
identical	O
tailing	O
reactions	O
were	O
carried	O
out	O
substituting	O
I0pmols	O
of	O
DIG	O
-	O
II	O
dUTP	O
(	O
Boehringer	O
Mannheim	O
)	O
for	O
[	O
a-32P	O
]	O
dCTP	O
.	O

Membranes	O
were	O
prehybridized	O
for	O
at	O
least	O
10	O
minutes	O
in	O
4	O
x	O
SSC	O
,	O
5	O
x	O
Denhardts	O
'	O
(	O
0.1	O
%	O
(	O
w	O
/	O
v	O
)	O
each	O
of	O
BSA	O
(	O
heated	O
at	O
80?C	O
for	O
30	O
minutes	O
to	O
inactivate	O
any	O
alkaline	O
phosphatase	O
activity	O
)	O
,	O
Ficoll	O
(	O
Pharmacia	O
)	O
and	O
polyvinylpyrrolidone	O
)	O
,	O
0.5	O
%	O
(	O
w	O
/	O
v	O
)	O
SDS	O
,	O
5mM	O
NaHPO4	O
(	O
23	O
)	O
.	O

Hybridization	O
was	O
carried	O
out	O
in	O
25	O
-	O
50M1	O
of	O
prehybridization	O
buffer	O
per	O
cm2	O
of	O
membrane	O
.	O

The	O
probe	O
concentration	O
was	O
approximately	O
lnM.	O
After	O
lh	O
at	O
42?C	O
,	O
unbound	O
probe	O
was	O
removed	O
by	O
five	O
1	O
minute	O
washes	O
at	O
room	O
temperature	O
in	O
1	O
x	O
SSC	O
,	O
0.5	O
%	O
SDS	O
(	O
200MI	O
/	O
cm2	O
membrane	O
)	O
.	O

Radioactive	O
blots	O
were	O
covered	O
in	O
Saran	O
wrap	O
and	O
exposed	O
to	O
film	O
immediately	O
.	O

Detection	O
of	O
DIG	O
labelled	O
probes	O
used	O
an	O
anti	O
-	O
DIG	O
antibodyalkaline	O
phosphatase	O
conjugate	O
(	O
Boehringer	O
Mannheim	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
,	O
except	O
that	O
all	O
volumes	O
were	O
reduced	O
by	O
70	O
%	O
and	O
the	O
conjugate	O
was	O
used	O
at	O
a	O
1:10	O
000	O
dilution	O
.	O

Blots	O
were	O
developed	O
in	O
25M1	O
of	O
100mM	O
Tris	O
.	O

Cl	O
pH9.5	O
,	O
mantane4-methoxy4	O
(	O
3	O
""""	O
-phosphoryloxy	O
)	O
phenyl-1	O
,	O
2-dioxetane	O
)	O
;	O
Tropix	O
)	O
/	O
cm2	O
for	O
30	O
minutes	O
at	O
37?C	O
,	O
prior	O
to	O
exposure	O
to	O
film	O
.	O

Probes	O
and	O
dioxetane	O
were	O
stripped	O
from	O
the	O
membranes	O
by	O
two	O
10	O
minute	O
washes	O
at	O
700C	O
with	O
0.2	O
%	O
SDS	O
,	O
2mM	O
EDTA	O
(	O
200,ul	O
/	O
cm2	O
membrane	O
)	O
.	O

The	O
hybridization	O
and	O
washing	O
procedures	O
were	O
carried	O
out	O
in	O
plastic	O
bags	O
.	O

However	O
,	O
washing	O
steps	O
have	O
also	O
been	O
performed	O
with	O
gentle	O
agitation	O
in	O
a	O
perspex	O
tub	O
(	O
43	O
x	O
27	O
x	O
15	O
cm	O
)	O
mounted	O
on	O
a	O
reciprocal	O
shaker	O
,	O
with	O
equivalent	O
results	O
.	O

In	O
the	O
latter	O
case	O
a	O
minimum	O
wash	O
volume	O
of	O
500mls	O
was	O
used	O
.	O

The	O
use	O
of	O
a	O
tub	O
is	O
more	O
convenient	O
for	O
batch	O
processing	O
and	O
should	O
be	O
straightforward	O
to	O
automate	O
.	O

RESULTS	O
Autoradiograms	O
revealed	O
no	O
difference	O
in	O
sequence	O
quality	O
when	O
tagged	O
primers	O
were	O
used	O
instead	O
of	O
the	O
17mer	O
universal	O
primer	O
in	O
conventional	O
[	O
a-35S	O
]	O
dATP	O
labelled	O
sequencing	O
reactions	O
and	O
in	O
multiplex	O
hybridization	O
experiments	O
using	O
[	O
a-32P	O
]	O
dCTP	O
-	O
tailed	O
probes	O
(	O
results	O
not	O
shown	O
)	O
.	O

Experiments	O
were	O
then	O
conducted	O
to	O
determine	O
the	O
feasibility	O
of	O
pooling	O
the	O
four	O
base	O
reactions	O
for	O
each	O
clone	O
and	O
fractionating	O
them	O
in	O
a	O
single	O
lane	O
to	O
obtain	O
a	O
superimposed	O
but	O
interpretable	O
set	O
of	O
sequence	O
ladders	O
.	O

The	O
question	O
addressed	O
was	O
whether	O
or	O
not	O
difficulties	O
in	O
band	O
registration	O
might	O
arise	O
as	O
a	O
result	O
of	O
mobility	O
differences	O
between	O
the	O
different	O
primer	O
sequences	O
and/or	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
.	O

It	O
is	O
relevant	O
that	O
an	O
automated	O
film	O
reader	O
employing	O
an	O
internal	O
standard	O
requires	O
that	O
the	O
nylon	O
membrane	O
does	O
not	O
undergo	O
significant	O
distortions	O
between	O
probings	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
)	O
.	O

Clones	O
were	O
sequenced	O
using	O
the	O
four	O
tagged	O
primers	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
,	O
one	O
for	O
each	O
base	O
reaction	O
(	O
Figure	O
1	O
)	O
.	O

The	O
A	O
,	O
C	O
,	O
G	O
and	O
T	O
reactions	O
for	O
each	O
clone	O
were	O
pooled	O
,	O
and	O
processed	O
as	O
described	O
above	O
.	O

A	O
complete	O
set	O
of	O
sequence	O
autoradiograms	O
was	O
obtained	O
from	O
four	O
consecutive	O
rounds	O
of	O
probing	O
with	O
[	O
a-32P	O
]	O
dCTP	O
-	O
labelled	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
films	O
showed	O
that	O
sequence	O
-	O
specific	O
mobility	O
effects	O
and	O
distortion	O
of	O
the	O
membrane	O
between	O
probings	O
were	O
sufficiently	O
minor	O
to	O
allow	O
accurate	O
registration	O
of	O
the	O
bands	O
,	O
and	O
hence	O
accurate	O
reading	O
of	O
the	O
sequence	O
.	O

At	O
least	O
200	O
nucleotides	O
of	O
sequence	O
could	O
be	O
read	O
accurately	O
from	O
a	O
single	O
clone	O
by	O
simply	O
tracing	O
the	O
four	O
sets	O
of	O
bands	O
using	O
different	O
colours	O
,	O
overlaying	O
the	O
tracings	O
,	O
and	O
reading	O
the	O
bands	O
sequentially	O
.	O

In	O
order	O
to	O
assess	O
the	O
practicality	O
of	O
reading	O
the	O
sequences	O
by	O
machine	O
,	O
the	O
images	O
were	O
scanned	O
to	O
provide	O
optical	O
density	O
profiles	O
(	O
Figure	O
2	O
)	O
.	O

These	O
profiles	O
were	O
overlaid	O
,	O
and	O
were	O
found	O
to	O
be	O
sufficiently	O
in	O
register	O
to	O
allow	O
accurate	O
interpretation	O
of	O
the	O
sequence	O
for	O
at	O
least	O
300	O
nucleotides	O
.	O

This	O
was	O
essentially	O
the	O
limit	O
of	O
resolution	O
of	O
the	O
gel	O
for	O
accurate	O
manual	O
reading	O
.	O

In	O
order	O
to	O
ensure	O
that	O
the	O
relatively	O
minor	O
mobility	O
differences	O
observed	O
between	O
the	O
four	O
primers	O
were	O
not	O
coincidental	O
to	O
the	O
oligonucleotides	O
used	O
,	O
a	O
second	O
set	O
of	O
four	O
tagged	O
M13	O
universal	O
primers	O
was	O
synthesised	O
,	O
this	O
time	O
incorporating	O
20mer	O
sequences	O
derived	O
from	O
the	O
genome	O
of	O
murine	O
herpesvirus-68	O
(	O
UJOL14C	O
,	O
15C	O
,	O
16C	O
,	O
17C	O
)	O
.	O

Sequencing	O
reactions	O
were	O
performed	O
using	O
[	O
cx-35S	O
]	O
dATP	O
to	O
label	O
the	O
DNA	O
directly	O
.	O

Various	O
templates	O
were	O
sequenced	O
,	O
and	O
in	O
all	O
cases	O
correctly	O
ordered	O
sequence	O
ladders	O
were	O
obtained	O
following	O
conventional	O
electrophoresis	O
in	O
which	O
the	O
four	O
reactions	O
were	O
run	O
side	O
-	O
by	O
-	O
side	O
(	O
results	O
not	O
shown	O
)	O
.	O

Initial	O
hybridization	O
experiments	O
were	O
conducted	O
using	O
[	O
f	O
-32p	O
]	O
dCTP	O
tailed	O
oligonucleotide	O
probes	O
.	O

However	O
,	O
the	O
use	O
of	O
lOOmM	O
NaCl	O
,	O
5OmM	O
MgC12	O
,	O
0.15mM	O
AMPPD	O
(	O
[	O
3-	O
(	O
2'-ada	O

B	O
C	O
'	O
Ordinary	O
'	O
Plex	O
'	O
4-CJ3	O
4-rn	O
+	O
Primeir	O
Primer	O
""""	O
All	O
""""	O
C	O
""""	O
""""	O
G	O
""""	O
""""	O
T	O
""""	O
'	O
Plex	O
'	O
'	O
Ordinary	O
'	O
Pool	O
and	O
Vector	O
Vector	O
fractionate	O
Resolve	O
by	O
sequential	O
hybridizations	O
Sequencing	O
reactions	O
SequencingreactIo	O
product	O
Sequencing	O
reaction	O
product	O
-	O
n	O
;	O
=	O
=	O
-	O
=	O
-	O
n	O
:	O
=	O
Figure	O
1	O
.	O

Approaches	O
to	O
enzymatic	O
multiplex	O
DNA	O
sequencing	O
.	O

a	O
)	O
A	O
set	O
of	O
sequence	O
-	O
tagged	O
vectors	O
can	O
be	O
used	O
.	O

The	O
tag	O
site	O
is	O
shown	O
in	O
red	O
,	O
and	O
the	O
insert	O
to	O
be	O
sequenced	O
in	O
blue	O
.	O

However	O
,	O
the	O
original	O
plex	O
vectors	O
(	O
3	O
)	O
are	O
plasmids	O
,	O
and	O
therefore	O
amenable	O
only	O
to	O
dsDNA	O
sequencing	O
.	O

Sets	O
of	O
bacteriophage	B
M13	I
vectors	O
have	O
been	O
constructed	O
bearing	O
either	O
one	O
(	O
32	O
)	O
or	O
two	O
[	O
Chee	O
,	O
unpublished	O
]	O
of	O
the	O
plex	O
tag	O
sites	O
flanking	O
the	O
polylinker	O
,	O
which	O
can	O
be	O
used	O
for	O
this	O
approach	O
.	O

b	O
)	O
The	O
strategy	O
used	O
in	O
this	O
paper	O
.	O

In	O
this	O
case	O
the	O
tag	O
site	O
is	O
carried	O
on	O
the	O
primer	O
.	O

c	O
)	O
If	O
tagged	O
primers	O
are	O
used	O
,	O
there	O
is	O
no	O
practical	O
impediment	O
to	O
performing	O
each	O
base	O
reaction	O
using	O
a	O
different	O
primer	O
,	O
as	O
depicted	O
.	O

The	O
reactions	O
can	O
then	O
be	O
pooled	O
in	O
any	O
combination	O
desired	O
.	O

The	O
configuration	O
shown	O
,	O
in	O
which	O
the	O
four	O
reactions	O
are	O
electrophoresed	O
in	O
a	O
single	O
lane	O
,	O
is	O
designed	O
to	O
facilitate	O
accurate	O
band	O
registration	O
and	O
reading	O
by	O
an	O
automatic	O
film	O
reader	O
.	O

In	O
order	O
to	O
read	O
the	O
sequence	O
manually	O
,	O
base	O
reactions	O
would	O
be	O
run	O
side	O
-	O
by	O
-	O
side	O
.	O

The	O
logistics	O
of	O
processing	O
the	O
reactions	O
are	O
essentially	O
the	O
same	O
with	O
either	O
configuration	O
;	O
the	O
same	O
number	O
of	O
probings	O
are	O
required	O
.	O

Figure	O
2	O
.	O

Four	O
overlaid	O
one	O
-	O
dimensional	O
optical	O
density	O
profiles	O
for	O
a	O
single	O
clone	O
shown	O
in	O
two	O
overlapping	O
sections	O
.	O

The	O
optical	O
density	O
profiles	O
are	O
unprocessed	O
,	O
except	O
for	O
a	O
simple	O
transform	O
to	O
correct	O
for	O
the	O
relative	O
displacement	O
(	O
translation	O
and	O
rotation	O
)	O
of	O
the	O
four	O
images	O
from	O
which	O
they	O
are	O
extracted	O
.	O

The	O
profiles	O
read	O
5	O
'	O
to	O
3	O
'	O
from	O
right	O
to	O
left	O
.	O

Nucleotides	O
positions	O
66	O
to	O
214	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
are	O
shown	O
.	O

The	O
sequence	O
is	O
that	O
of	O
Bluescribe	O
M13	O
+	O
(	O
template	O
DNA	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
,	O
and	O
was	O
determined	O
using	O
the	O
primers	O
UEOIC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O
specific	O
reactions	O
respectively	O
.	O

Detection	O
was	O
by	O
autoradiography	O
following	O
hybridization	O
with	O
[	O
a-	O
32p	O
]	O
dCTP	O
tailed	O
plex	O
probes	O
.	O

A	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
3303	O
I	O
3304	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O

19	O
,	O
No.	O
12	O
a	O
)	O
175-	O
...	O

-w	O
.m	O
;	O
b	O
)	O
182	O
a	O
:	O
......	O

F.VW	O
an	O
-	O
w	O
-1	O
S	O
-	O
K~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~i	O
'	O
F	O
C	O
C	O
;	O
A	O
I1	O
'	O
CG	O
A	O
Figure	O
3	O
.	O

Four	O
separate	O
base	O
-	O
specific	O
reactions	O
imaged	O
from	O
a	O
single	O
lane	O
using	O
chemiluminescent	O
detection	O
.	O

The	O
clones	O
sequenced	O
are	O
:	O
a	O
)	O
Bluescribe	O
M13	O
+	O
(	O
obtained	O
by	O
rescue	O
with	O
M13K07	O
helper	O
phage	O
(	O
30	O
)	O
)	O
and	O
b	O
)	O
an	O
M13	O
recombinant	O
clone	O
prepared	O
in	O
a	O
microtitre	O
tray	O
(	O
21	O
)	O
(	O
a	O
kind	O
gift	O
of	O
Victoria	O
Smith	O
)	O
.	O

Nucleotide	O
positions	O
shown	O
on	O
the	O
figure	O
are	O
numbered	O
from	O
the	O
start	O
of	O
the	O
universal	O
priming	O
site	O
.	O

The	O
clones	O
were	O
sequenced	O
using	O
UEOlC	O
,	O
UPOIC	O
,	O
UE02C	O
,	O
and	O
UP02C	O
for	O
the	O
T	O
,	O
C	O
,	O
G	O
and	O
A	O
specific	O
reactions	O
respectively	O
.	O

The	O
blot	O
was	O
probed	O
with	O
corresponding	O
DIG-11-dUTP	O
labelled	O
oligonucleotides	O
.	O

radioactivity	O
on	O
the	O
scale	O
envisioned	O
for	O
a	O
large	O
sequencing	O
project	O
is	O
undesirable	O
for	O
reasons	O
of	O
safety	O
.	O

The	O
relatively	O
long	O
exposure	O
times	O
required	O
(	O
6	O
to	O
24	O
hours	O
)	O
and	O
the	O
short	O
half	O
lives	O
of	O
the	O
probes	O
might	O
also	O
be	O
inconvenient	O
.	O

It	O
has	O
been	O
shown	O
that	O
a	O
biotin	O
/	O
streptavidin	O
/	O
alkaline	O
phosphatase	O
based	O
detection	O
system	O
used	O
in	O
conjunction	O
with	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
overcomes	O
these	O
disadvantages	O
(	O
24	O
,	O
25	O
,	O
26	O
)	O
.	O

We	O
utilized	O
a	O
different	O
bridging	O
system	O
with	O
similar	O
results	O
.	O

Digoxigenin	O
(	O
DIG	O
)	O
labelled	O
oligonucleotide	O
probes	O
were	O
detected	O
using	O
anti	O
-	O
DIG	O
antibody	O
-	O
alkaline	O
phosphatase	O
conjugates	O
and	O
a	O
chemiluminescent	O
dioxetane	O
substrate	O
.	O

Exposure	O
times	O
of	O
10	O
to	O
15	O
minutes	O
were	O
typically	O
required	O
,	O
following	O
a	O
one	O
hour	O
preincubation	O
period	O
(	O
Figure	O
3	O
)	O
.	O

In	O
our	O
hands	O
the	O
DIG	O
bridging	O
system	O
was	O
similar	O
in	O
sensitivity	O
to	O
the	O
streptavidin	O
based	O
system	O
(	O
24	O
)	O
,	O
and	O
the	O
practical	O
lower	O
limit	O
of	O
template	O
ssDNA	O
required	O
in	O
order	O
to	O
obtain	O
an	O
easily	O
interpretable	O
sequencing	O
ladder	O
was	O
estimated	O
to	O
be	O
in	O
the	O
range	O
of	O
20	O
to	O
50fmols	O
per	O
reaction	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
detection	O
was	O
limited	O
only	O
by	O
enzymaticallytriggered	O
background	O
luminescence	O
,	O
and	O
not	O
by	O
the	O
level	O
of	O
signal	O
obtained	O
.	O

The	O
nonradioactive	O
methods	O
described	O
have	O
been	O
used	O
successfully	O
in	O
an	O
8-plex	O
system	O
.	O

DISCUSSION	O
Although	O
the	O
original	O
multiplex	O
protocol	O
was	O
based	O
on	O
a	O
set	O
of	O
tagged	O
vectors	O
(	O
3	O
)	O
,	O
tagged	O
primers	O
have	O
also	O
been	O
used	O
or	O
proposed	O
for	O
various	O
forms	O
of	O
multiplex	O
DNA	O
sequencing	O
(	O
George	O
Church	O
,	O
personal	O
communication	O
;	O
2	O
,	O
27	O
)	O
.	O

For	O
example	O
,	O
a	O
proposal	O
was	O
recently	O
put	O
forward	O
for	O
multiplex	O
sequencing	O
using	O
sequence	O
-	O
labelled	O
primers	O
and	O
fluorophor	O
-	O
labelled	O
probes	O
(	O
1	O
)	O
,	O
similar	O
in	O
principle	O
to	O
the	O
methods	O
used	O
here	O
.	O

However	O
,	O
we	O
use	O
tagged	O
primers	O
and	O
the	O
superposition	O
of	O
the	O
four	O
sequencing	O
reactions	O
to	O
address	O
the	O
problem	O
of	O
reading	O
DNA	O
sequence	O
films	O
;	O
a	O
part	O
of	O
this	O
solution	O
is	O
to	O
utilize	O
M13	O
dideoxynucleotide	O
sequencing	O
,	O
thereby	O
improving	O
the	O
quality	O
of	O
the	O
data	O
to	O
be	O
analyzed	O
.	O

In	O
addition	O
,	O
the	O
proposal	O
for	O
fluorophor	O
-	O
labelled	O
probes	O
does	O
not	O
take	O
into	O
consideration	O
any	O
of	O
the	O
practical	O
sequencing	O
problems	O
addressed	O
here	O
,	O
and	O
,	O
in	O
the	O
version	O
described	O
,	O
remains	O
a	O
promising	O
but	O
unproven	O
scheme	O
for	O
large	O
scale	O
DNA	O
sequencing	O
.	O

There	O
are	O
several	O
advantages	O
to	O
tagging	O
primers	O
instead	O
of	O
vectors	O
.	O

Firstly	O
,	O
there	O
is	O
no	O
need	O
to	O
prepare	O
multiple	O
libraries	O
of	O
clones	O
in	O
special	O
vectors	O
.	O

This	O
means	O
that	O
workers	O
can	O
use	O
vector	O
/	O
host	O
combinations	O
that	O
yield	O
good	O
results	O
in	O
their	O
hands	O
,	O
and	O
an	O
increased	O
depth	O
of	O
multiplexing	O
can	O
easily	O
be	O
accomodated	O
by	O
synthesizing	O
more	O
primers	O
.	O

This	O
should	O
make	O
multiplexing	O
more	O
accessible	O
to	O
workers	O
undertaking	O
smaller	O
projects	O
.	O

A	O
theoretical	O
disadvantage	O
of	O
tagged	O
primers	O
is	O
that	O
the	O
procedure	O
can	O
only	O
be	O
multiplexed	O
following	O
primer	O
annealing	O
(	O
1	O
)	O
,	O
or	O
following	O
the	O
sequencing	O
reactions	O
(	O
this	O
paper	O
;	O
in	O
practice	O
,	O
pooling	O
immediately	O
after	O
the	O
annealing	O
step	O
might	O
lead	O
to	O
increased	O
backgrounds	O
if	O
one	O
or	O
more	O
primers	O
were	O
present	O
in	O
excess	O
over	O
their	O
template	O
DNAs	O
)	O
.	O

This	O
is	O
a	O
relatively	O
late	O
stage	O
.	O

In	O
the	O
original	O
procedure	O
(	O
3	O
)	O
,	O
clones	O
were	O
pooled	O
prior	O
to	O
amplification	O
by	O
growth	O
,	O
an	O
early	O
step	O
.	O

However	O
,	O
we	O
do	O
not	O
believe	O
the	O
sacrifice	O
to	O
be	O
of	O
practical	O
importance	O
when	O
using	O
phage	O
vectors	O
.	O

In	O
our	O
experience	O
,	O
recombinant	O
M13	O
phage	O
have	O
variable	O
growth	O
rates	O
and	O
the	O
effects	O
of	O
competition	O
are	O
likely	O
to	O
severely	O
limit	O
the	O
number	O
of	O
clones	O
that	O
can	O
usefully	O
be	O
pooled	O
for	O
growth	O
.	O

In	O
contrast	O
,	O
by	O
growing	O
clones	O
individually	O
,	O
the	O
depth	O
of	O
multiplexing	O
is	O
only	O
really	O
limited	O
by	O
probe	O
sensitivity	O
.	O

We	O
have	O
not	O
investigated	O
the	O
factors	O
influencing	O
variability	O
in	O
phage	O
growth	O
rates	O
.	O

It	O
is	O
worth	O
noting	O
that	O
reliable	O
protocols	O
have	O
been	O
developed	O
for	O
growing	O
large	O
numbers	O
of	O
individual	O
M13	O
clones	O
and	O
preparing	O
high	O
quality	O
ssDNA	O
templates	O
in	O
microtitre	O
trays	O
(	O
28	O
,	O
21	O
)	O
.	O

It	O
is	O
relatively	O
simple	O
to	O
prepare	O
manually	O
two	O
microtitre	O
trays	O
of	O
ssDNA	O
templates	O
(	O
192	O
clones	O
)	O
in	O
a	O
day	O
.	O

Sufficient	O
clones	O
can	O
be	O
prepared	O
in	O
a	O
week	O
to	O
sequence	O
a	O
20	O
kb	O
fragment	O
to	O
a	O
redundancy	O
of	O
10	O
(	O
Victoria	O
Smith	O
,	O
personal	O
communication	O
)	O
.	O

In	O
this	O
laboratory	O
,	O
ssDNA	O
is	O
now	O
prepared	O
with	O
the	O
aid	O
of	O
a	O
commercially	O
available	O
robotic	O
workstation	O
(	O
21	O
)	O
.	O

As	O
sequencing	O
reactions	O
are	O
also	O
carried	O
out	O
in	O
microtitre	O
trays	O
,	O
manually	O
or	O
robotically	O
(	O
20	O
,	O
29	O
)	O
,	O
the	O
entire	O
M13-based	O
dideoxynucleotide	O
sequencing	O
procedure	O
is	O
amenable	O
to	O
automation	O
(	O
29	O
)	O
.	O

For	O
these	O
reasons	O
we	O
see	O
little	O
practical	O
advantage	O
in	O
pooling	O
clones	O
early	O
.	O

Finally	O
,	O
by	O
not	O
pooling	O
clones	O
early	O
,	O
the	O
ability	O
to	O
easily	O
retrieve	O
individual	O
clones	O
is	O
retained	O
,	O
which	O
may	O
facilitate	O
directed	O
sequencing	O
later	O
in	O
a	O
project	O
should	O
this	O
become	O
necessary	O
.	O

Multiplex	O
DNA	O
sequencing	O
is	O
currently	O
limited	O
by	O
the	O
lack	O
of	O
a	O
robust	O
computer	O
program	O
which	O
can	O
correct	O
for	O
the	O
large	O
variety	O
of	O
gel	O
and	O
sequencing	O
artefacts	O
that	O
are	O
normally	O
encountered	O
.	O

The	O
foundation	O
of	O
a	O
film	O
reading	O
program	O
is	O
the	O
ability	O
to	O
bring	O
into	O
register	O
precisely	O
vertical	O
arrays	O
of	O
base	O
-	O
specific	O
bands	O
.	O

This	O
requires	O
the	O
ability	O
to	O
track	O
lanes	O
,	O
correct	O
for	O
distortions	O
,	O
and	O
order	O
bands	O
based	O
on	O
their	O
relative	O
spacing	O
.	O

A	O
method	O
of	O
sequencing	O
which	O
has	O
successfully	O
overcome	O
the	O
problem	O
of	O
sequence	O
reading	O
uses	O
real	O
-	O
time	O
detection	O
of	O
fluorescently	O
labelled	O
DNA	O
samples	O
migrating	O
through	O
the	O
gel	O
(	O
2	O
)	O
.	O

This	O
system	O
also	O
utilizes	O
the	O
principle	O
of	O
running	O
the	O
four	O
base	O
reactions	O
down	O
the	O
same	O
lane	O
(	O
2	O
)	O
.	O

However	O
,	O
bands	O
are	O
detected	O
at	O
a	O
fixed	O
location	O
in	O
space	O
,	O
and	O
their	O
detection	O
is	O
separated	O
in	O
time	O
.	O

Hence	O
the	O
Nucleic	O
Acids	O
Research	O
,	O
Vol	O
.	O
19	O
,	O
No.	O
12	O
3305	O
problem	O
of	O
gel	O
distortion	O
is	O
essentially	O
avoided	O
,	O
although	O
corrections	O
for	O
the	O
different	O
mobilities	O
of	O
the	O
four	O
dyes	O
must	O
be	O
carried	O
out	O
.	O

In	O
contrast	O
,	O
we	O
utilize	O
the	O
advantages	O
of	O
single	O
lane	O
electrophoresis	O
to	O
address	O
the	O
problem	O
of	O
superimposing	O
four	O
relatively	O
large	O
and	O
complex	O
two	O
-	O
dimensional	O
images	O
.	O

Furthermore	O
,	O
by	O
using	O
sequence	O
-	O
tagged	O
oligonucleotides	O
which	O
are	O
detected	O
by	O
hybridization	O
,	O
a	O
much	O
greater	O
depth	O
of	O
multiplexing	O
can	O
realistically	O
be	O
achieved	O
than	O
by	O
real	O
-	O
time	O
detection	O
.	O

The	O
use	O
of	O
two	O
-	O
dimensional	O
colour	O
traces	O
to	O
depict	O
the	O
processed	O
output	O
of	O
a	O
film	O
reader	O
is	O
consistent	O
with	O
the	O
method	O
of	O
displaying	O
fluorescence	O
traces	O
,	O
and	O
should	O
facilitate	O
the	O
checking	O
and	O
editing	O
of	O
sequence	O
databases	O
in	O
which	O
both	O
kinds	O
of	O
data	O
have	O
been	O
entered	O
.	O

The	O
sequence	O
compilation	O
programs	O
used	O
in	O
this	O
laboratory	O
,	O
which	O
are	O
already	O
capable	O
of	O
handling	O
large	O
shotgun	O
databases	O
(	O
8	O
,	O
31	O
)	O
,	O
have	O
recently	O
undergone	O
extensive	O
improvements	O
(	O
Rodger	O
Staden	O
,	O
personal	O
communication	O
)	O
.	O

There	O
is	O
now	O
an	O
interactive	O
database	O
editor	O
which	O
allows	O
the	O
graphical	O
display	O
of	O
fluorescence	O
traces	O
,	O
and	O
it	O
is	O
envisaged	O
that	O
this	O
feature	O
could	O
be	O
extended	O
to	O
allow	O
the	O
handling	O
of	O
data	O
from	O
a	O
film	O
reader	O
when	O
a	O
suitable	O
machine	O
is	O
developed	O
.	O

ACKNOWLEDGEMENTS	O

I	O
am	O
particularly	O
grateful	O
to	O
George	O
Church	O
for	O
thought	O
-	O
provoking	O
discussions	O
and	O
gifts	O
of	O
vectors	O
and	O
oligonucleotide	O
probes	O
and	O
to	O
John	O
Sulston	O
for	O
advice	O
.	O

I	O
also	O
thank	O
Victoria	O
Smith	O
for	O
the	O
gift	O
of	O
DNA	O
samples	O
,	O
Bart	O
Barrell	O
for	O
long	O
-	O
term	O
support	O
,	O
Tom	O
O'Keefe	O
of	O
Milligen	O
/	O
Biosearch	O
for	O
lessons	O
in	O
multiplexing	O
and	O
Amersham	O
International	O
for	O
the	O
optical	O
density	O
overlays	O
shown	O
in	O
Figure	O
2	O
.	O

M.C.	O
is	O
supported	O
by	O
a	O
fellowship	O
from	O
Applied	O
Biosystems	O
.	O

12	O
.	O

Hiratsuka	O
,	O
J.	O
,	O
Shimada	O
,	O
H.	O
,	O
Whittier	O
,	O
R.	O
,	O
Ishibashi	O
,	O
T.	O
,	O
Sakamoto	O
,	O
M.	O
,	O
Mori	O
,	O
M.	O
,	O
Kondo	O
,	O
C.	O
,	O
Honju	O
,	O
Y.	O
,	O
Sun	O
,	O
C.	O
-R	O
,	O
Meng	O
,	O
B.	O
-Y	O
,	O
Li	O
,	O
Y.	O
-Q	O
,	O
Kanno	O
,	O
A.	O
,	O
Nisizawa	O
,	O
Y.	O
,	O
Hirai	O
,	O
A.	O
,	O
Shinozaki	O
,	O
K.	O
and	O
Sugiura	O
,	O
M.	O
(	O
1989	O
)	O
Molecular	O
and	O
General	O
Genetics	O
,	O
217	O
,	O
185	O
-	O
194	O
.	O

13	O
.	O

Komaromy	O
,	O
M.	O
and	O
Govan	O
,	O
H.	O
(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
675	O
-	O
678	O
.	O
14	O
.	O

Staden	O
,	O
R.	O
(	O
1984	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
12	O
,	O
499	O
-	O
503	O
.	O

15	O
.	O

Elder	O
,	O
J.	O
K.	O
,	O
Green	O
,	O
D.	O
K.	O
and	O
Southern	O
,	O
E.	O
M.	O
(	O
1986	O
)	O
Nucleic	O
Acids	O
Research	O
,	O
14	O
,	O
417	O
-	O
424	O
.	O

16	O
.	O

Maxam	O
,	O
A.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
74	O
,	O
560	O
-	O
564	O
.	O

17	O
.	O

Sanger	O
,	O
F.	O
,	O
Nicklen	O
,	O
S.	O
and	O
Coulson	O
,	O
A.	O
R.	O
(	O
1977	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
74	O
,	O
5463	O
-	O
5467	O
.	O

18	O
.	O

Sanger	O
,	O
F.	O
,	O
Coulson	O
,	O
A.	O
R.	O
,	O
Barrell	O
,	O
B.	O
G.	O
,	O
Smith	O
,	O
A.	O
J.	O
H.	O
and	O
Roe	O
,	O
B.	O
A.	O
(	O
1980	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
143	O
,	O
161	O
-	O
178	O
.	O

19	O
.	O

Applied	O
Biosystems	O
User	O
Bulletin	O
(	O
1987	O
)	O
13	O
,	O
11	O
-	O
16	O
.	O

20	O
.	O

Bankier	O
,	O
A.	O
T.	O
,	O
Weston	O
,	O
K.	O
M.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1987	O
)	O
Methods	O
in	O
Enzymology	O
,	O
155	O
,	O
51	O
-	O
93	O
.	O

21	O
.	O

Smith	O
,	O
V.	O
,	O
Brown	O
,	O
C.	O
M.	O
,	O
Bankier	O
,	O
A.	O
T.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1990	O
)	O
DNA	O
Sequence	O
,	O
1	O
,	O
73	O
-	O
78	O
.	O

22	O
.	O

Southern	O
,	O
E.	O
M.	O
(	O
1975	O
)	O
Journal	O
of	O
Molecular	O
Biology	O
,	O
98	O
,	O
503	O
-	O
517	O
.	O

23	O
.	O

Church	O
,	O
G.	O
M.	O
and	O
Gilbert	O
,	O
W.	O
(	O
1984	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
81	O
,	O
1991	O
-	O
1995	O
.	O

24	O
.	O

Beck	O
,	O
S.	O
,	O
O'Keefe	O
,	O
T.	O
,	O
Coull	O
,	O
J.	O
M.	O
and	O
Koster	O
,	O
H.	O
(	O
1989	O
)	O

Nucleic	O
Acids	O
Research	O
,	O
17	O
,	O
5115	O
-	O
5123	O
.	O

25	O
.	O

Tizard	O
,	O
R.	O
,	O
Cate	O
,	O
R.	O
L.	O
,	O
Ramachandran	O
,	O
K.	O
L.	O
,	O
Wysk	O
,	O
M.	O
,	O
Voyta	O
,	O
J.	O
C.	O
,	O
Murphy	O
,	O
0	O
.	O
J.	O
and	O
Bronstein	O
,	O
I.	O
(	O
1990	O
)	O
Proceedings	O
of	O
the	O
National	O
Academy	O
of	O
Sciences	O
,	O
U.S.A.	O
,	O
87	O
,	O
4514	O
-	O
4518	O
.	O

26	O
.	O

Beck	O
,	O
S.	O
and	O
Koster	O
,	O
H.	O
(	O
1990	O
)	O
Analytical	O
Chemistry	O
,	O
62	O
,	O
2558	O
-	O
2570	O
.	O

27	O
.	O

Jacobson	O
,	O
K.	O
B.	O
,	O
Arlinghaus	O
,	O
H.	O
F.	O
,	O
Schmitt	O
,	O
H.	O
W.	O
,	O
Sachleben	O
,	O
R.	O
A.	O
,	O
Brown	O
,	O
G.	O
M.	O
,	O
Thonnard	O
,	O
N.	O
,	O
Sloop	O
,	O
F.	O
V.	O
,	O
Foote	O
,	O
R.	O
S.	O
,	O
Larimer	O
,	O
F.	O
W.	O
,	O
Woychik	O
,	O
R.	O
P.	O
,	O
England	O
,	O
M.	O
W.	O
,	O
Burchett	O
,	O
K.	O
L.	O
and	O
Jacobson	O
,	O
D.	O
A.	O
(	O
1991	O
)	O
Genomics	O
,	O
9	O
,	O
51	O
-	O
59	O
.	O

28	O
.	O

Eperon	O
,	O
I.	O
C.	O
(	O
1986	O
)	O
Analytical	O
Biochemistry	O
,	O
56	O
,	O
406	O
-	O
412	O
.	O

29	O
.	O

Bankier	O
,	O
A.	O
T.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1989	O
)	O
In	O
Howe	O
,	O
C.	O
J.	O
and	O
Ward	O
,	O
E.	O
S.	O
(	O
ed	O
)	O
,	O
Nucleic	O
acids	O
sequencing	O
:	O
a	O
practical	O
approach	O
.	O

IRL	O
Press	O
,	O
Oxford	O
,	O
Vol	O
.	O

1	O
,	O
pp	O
.	O

37	O
-	O
78	O
.	O

30	O
.	O

Vieira	O
,	O
J.	O
and	O
Messing	O
,	O
J.	O
(	O
1987	O
)	O
Methods	O
in	O
Enzymology	O
,	O
153	O
,	O
3	O
-	O
11	O
.	O
31	O
.	O

Davison	O
,	O
A.	O
DNA	O
Sequence	O
,	O
in	O
press	O
.	O

32	O
.	O

Heller	O
,	O
C.	O
,	O
Radley	O
,	O
E.	O
,	O
Khurshid	O
,	O
F.	O
A.	O
and	O
Beck	O
,	O
S.	O
Gene	O
,	O
in	O
press	O
.	O

REFERENCES	O
1	O
.	O

Yang	O
,	O
M.	O
M.	O
and	O
Youvan	O
,	O
D.	O
C.	O
(	O
1989	O
)	O
Biotechnology	O
,	O
7	O
,	O
576	O
-	O
580	O
.	O

2	O
.	O

Smith	O
,	O
L.	O
M.	O
,	O
Sanders	O
,	O
J.	O
Z.	O
,	O
Kaiser	O
,	O
R.	O
J.	O
,	O
Hughes	O
,	O
P.	O
,	O
Dodd	O
,	O
C.	O
,	O
Connell	O
,	O
C.	O
R.	O
,	O
Heiner	O
,	O
C.	O
,	O
Kent	O
,	O
S.	O
B.	O
H.	O
and	O
Hood	O
,	O
L.	O
E.	O
(	O
1986	O
)	O
Nature	O
,	O
321	O
,	O
674	O
-	O
679	O
.	O

3	O
.	O

Church	O
,	O
G.	O
M.	O
and	O
Kieffer	O
-	O
Higgins	O
,	O
S.	O
(	O
1988	O
)	O
Science	O
,	O
240	O
,	O
185	O
-	O
188	O
.	O
4	O
.	O

Watson	O
,	O
J.	O
D.	O
(	O
1990	O
)	O
Science	O
,	O
248	O
,	O
44	O
-	O
49	O
.	O

5	O
.	O

Baer	O
,	O
R.	O
,	O
Bankier	O
,	O
A.	O
T.	O
,	O
Biggin	O
,	O
M.	O
D.	O
,	O
Deininger	O
,	O
P.	O
L.	O
,	O
Farrell	O
,	O
P.	O
J.	O
,	O
Gibson	O
,	O
T.	O
J.	O
,	O
Hatfull	O
,	O
G.	O
,	O
Hudson	O
,	O
G.	O
S.	O
,	O
Satchwell	O
,	O
S.	O
C.	O
,	O
Seguin	O
,	O
C.	O
,	O
Tuffnell	O
,	O
P.	O
S.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1984	O
)	O
Nature	O
,	O
310	O
,	O
207	O
-	O
211	O
.	O

6	O
.	O

Davison	O
,	O
A.	O
J.	O
and	O
Scott	O
,	O
J.	O
E.	O
(	O
1986	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
67	O
,	O
1759	O
-	O
1816	O
.	O

7	O
.	O

McGeoch	O
,	O
D.	O
J.	O
,	O
Dalrymple	O
,	O
M.	O
A.	O
,	O
Davison	O
,	O
A.	O
J.	O
,	O
Dolan	O
,	O
A.	O
,	O
Frame	O
,	O
M.	O
C.	O
,	O
McNab	O
,	O
D.	O
,	O
Perry	O
,	O
L.	O
J.	O
,	O
Scott	O
,	O
J.	O
E.	O
and	O
Taylor	O
,	O
P.	O
(	O
1988	O
)	O
Journal	O
of	O
General	O
Virology	O
,	O
69	O
,	O
1531	O
-	O
1574	O
.	O

8	O
.	O

Chee	O
,	O
M.	O
S.	O
,	O
Bankier	O
,	O
A.	O
T.	O
,	O
Beck	O
,	O
S.	O
,	O
Bohni	O
,	O
R.	O
,	O
Brown	O
,	O
C.	O
M.	O
,	O
Cerny	O
,	O
R.	O
,	O
Horsnell	O
,	O
T.	O
,	O
Hutchison	O
III	O
,	O
C.	O
A.	O
,	O
Kouzarides	O
,	O
T.	O
,	O
Martignetti	O
,	O
J.	O
A.	O
,	O
Satchwell	O
,	O
S.	O
C.	O
,	O
Tomlinson	O
,	O
P.	O
,	O
Weston	O
,	O
K.	O
M.	O
and	O
Barrell	O
,	O
B.	O
G.	O
(	O
1990	O
)	O
Current	O
Topics	O
in	O
Microbiology	O
and	O
Immunology	O
,	O
154	O
,	O
125	O
-	O
169	O
.	O

9	O
.	O

Goebel	O
,	O
S.	O
J.	O
,	O
Johnson	O
,	O
G.	O
P.	O
,	O
Perkus	O
,	O
M.	O
E.	O
,	O
Davis	O
,	O
S.	O
W.	O
,	O
Winslow	O
,	O
J.	O
P.	O
and	O
Paoletti	O
,	O
E.	O
(	O
1990	O
)	O
Virology	O
,	O
179	O
,	O
247	O
-	O
266	O
.	O

10	O
.	O

Ohyama	O
,	O
K.	O
,	O
Fukuzawa	O
,	O
H.	O
,	O
Kohchi	O
,	O
T.	O
,	O
Shirai	O
,	O
H.	O
,	O
Sano	O
,	O
T.	O
,	O
Sano	O
,	O
S.	O
,	O
Umesono	O
,	O
K.	O
,	O
Shiki	O
,	O
Y.	O
,	O
Takeuchi	O
,	O
M.	O
,	O
Chang	O
,	O
Z.	O
,	O
Aota	O
,	O
S.	O
-I	O
,	O
Inokuchi	O
,	O
H.	O
and	O
Ozeki	O
,	O
H.	O
(	O
1986	O
)	O
Nature	O
,	O
322	O
,	O
572	O
-	O
574	O
.	O

11	O
.	O

Shinozaki	O
,	O
K.	O
,	O
Ohme	O
,	O
M.	O
,	O
Tanaka	O
,	O
M.	O
,	O
Wakasugi	O
,	O
T.	O
,	O
Hayashida	O
,	O
N.	O
,	O
Matsubayashi	O
,	O
T.	O
,	O
Zaita	O
,	O
N.	O
,	O
Chunwongse	O
,	O
J.	O
,	O
Obokata	O
,	O
J.	O
,	O
YamaguchiShinozaki	O
,	O
K.	O
,	O
Ohto	O
,	O
C.	O
,	O
Torazawa	O
,	O
K.	O
,	O
Meng	O
,	O
B.	O
Y.	O
,	O
Sugita	O
,	O
M.	O
,	O
Deno	O
,	O
H.	O
,	O
Kamogashira	O
,	O
T.	O
,	O
Yamada	O
,	O
K.	O
,	O
Kusuda	O
,	O
J.	O
,	O
Takaiwa	O
,	O
F.	O
,	O
Kato	O
,	O
A.	O
,	O
Tohdoh	O
,	O
N.	O
,	O
Shimada	O
,	O
H.	O
and	O
Sugiura	O
,	O
M.	O
(	O
1986	O
)	O
EMBO	O
Journal	O
,	O
5	O
,	O
2043	O
-	O
2049	O
.	O

Down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF	O
-	O
II	O
receptor	O
increases	O
cell	O
proliferation	O
and	O
reduces	O
apoptosis	O
in	O
neonatal	O
rat	B
cardiac	O
myocytes	O
Abstract	O
Background	O
The	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
multi	O
-	O
functional	O
protein	O
that	O
has	O
been	O
implicated	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
,	O
and	O
cardiomyocyte	O
apoptosis	O
has	O
been	O
identified	O
in	O
a	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
such	O
as	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

However	O
,	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
the	O
pathogenesis	O
of	O
these	O
conditions	O
has	O
not	O
been	O
determined	O
.	O

Thus	O
,	O
the	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Results	O
We	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
rat	B
cardiac	O
myocytes	O
and	O
examined	O
the	O
effect	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Infection	O
of	O
neonatal	O
cardiomyocytes	O
with	O
an	O
adenovirus	O
expressing	O
a	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
significantly	O
reduced	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
as	O
determined	O
by	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

M6P	O
-	O
containing	O
protein	O
binding	O
and	O
endocytosis	O
as	O
well	O
as	O
the	O
M6P	O
/	O
IGF2R	O
-	O
mediated	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
were	O
lower	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
than	O
the	O
control	O
myocytes	O
,	O
indicating	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
the	O
ribozyme	O
treated	O
cells	O
was	O
reduced	O
.	O

Accordingly	O
,	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
reduced	O
cell	O
susceptibility	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
were	O
observed	O
in	O
the	O
ribozyme	O
-	O
treated	O
cells	O
.	O

Conclusions	O
These	O
findings	O
suggest	O
that	O
M6P	O
/	O
IGF2R	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
growth	O
and	O
apoptosis	O
.	O

Down	O
regulation	O
of	O
this	O
gene	O
in	O
cardiac	O
tissues	O
might	O
be	O
a	O
new	O
approach	O
to	O
prevention	O
of	O
cell	O
death	O
or	O
promotion	O
of	O
mitogenesis	O
for	O
certain	O
heart	O
diseases	O
.	O

Background	O
The	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
II	O
receptor	O
(	O
M6P	O
/	O
IGF2R	O
)	O
is	O
a	O
unique	O
protein	O
that	O
interacts	O
with	O
multiple	O
ligands	O
,	O
some	O
of	O
which	O
are	O
important	O
growth	O
regulatory	O
factors	O
[	O
1	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
participates	O
in	O
internalization	O
and	O
lysosomal	O
degradation	O
of	O
IGF	O
-	O
II	O
,	O
a	O
mitogen	O
normally	O
acting	O
through	O
the	O
IGF	O
-	O
I	O
receptor	O
to	O
stimulate	O
cell	O
proliferation	O
[	O
2	O
]	O
.	O

The	O
M6P	O
/	O
IGF2	O
receptor	O
is	O
required	O
for	O
the	O
activation	O
of	O
TGF	O
-	O
β	O
[	O
3	O
]	O
,	O
a	O
potent	O
growth	O
inhibitor	O
for	O
many	O
cell	O
types	O
.	O

This	O
receptor	O
is	O
also	O
involved	O
in	O
the	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
newly	O
-	O
synthesized	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
[	O
4,5	O
]	O
,	O
which	O
have	O
been	O
recently	O
implicated	O
in	O
the	O
induction	O
of	O
apoptosis	O
[	O
6	O
]	O
.	O

On	O
the	O
basis	O
of	O
these	O
functions	O
,	O
the	O
M6P	O
/	O
IGF2R	O
has	O
been	O
proposed	O
to	O
play	O
a	O
significant	O
role	O
in	O
regulation	O
of	O
cell	O
growth	O
and	O
apoptosis	O
[	O
7	O
]	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
is	O
a	O
tightly	O
regulated	O
process	O
used	O
to	O
remove	O
excess	O
,	O
hazardous	O
or	O
damaged	O
somatic	O
cells	O
,	O
and	O
is	O
crucial	O
for	O
the	O
development	O
,	O
maintenance	O
and	O
survival	O
of	O
an	O
organism	O
.	O

However	O
,	O
alterations	O
in	O
the	O
control	O
of	O
apoptosis	O
have	O
also	O
been	O
shown	O
to	O
contribute	O
to	O
human	B
diseases	O
.	O

In	O
fact	O
,	O
morphological	O
and	O
biochemical	O
markers	O
of	O
apoptosis	O
have	O
been	O
identified	O
in	O
a	O
wide	O
variety	O
of	O
cardiovascular	O
disorders	O
,	O
including	O
myocardial	O
infarction	O
and	O
heart	O
failure	O
.	O

This	O
suggests	O
that	O
activation	O
of	O
apoptotic	O
pathways	O
contributes	O
to	O
cardiomyocyte	O
loss	O
and	O
subsequent	O
cardiac	O
dysfunction	O
in	O
these	O
conditions	O
.	O

A	O
number	O
of	O
factors	O
involved	O
in	O
cardiomyocyte	O
apoptosis	O
are	O
currently	O
known	O
and	O
include	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
(	O
IGF	O
-	O
I	O
)	O
,	O
stress	O
-	O
activated	O
protein	O
kinases	O
(	O
SAPKs	O
)	O
and	O
the	O
anti	O
-	O
apoptotic	O
Bcl-2	O
family	O
[	O
8	O
]	O
.	O

There	O
are	O
indications	O
that	O
other	O
factors	O
may	O
be	O
involved	O
in	O
induction	O
and	O
regulation	O
of	O
cardiac	O
apoptosis	O
.	O

However	O
,	O
these	O
potential	O
factors	O
and	O
their	O
corresponding	O
mechanisms	O
have	O
not	O
been	O
identified	O
.	O

Several	O
lines	O
of	O
evidence	O
point	O
to	O
the	O
potential	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiac	O
myocyte	O
proliferation	O
and	O
apoptosis	O
.	O

Cardiac	O
myocytes	O
express	O
relatively	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
and	O
transgenic	O
mice	B
containing	O
a	O
homologous	O
deletion	O
of	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
manifest	O
ventricular	O
hyperplasia	O
due	O
to	O
an	O
increase	O
in	O
cell	O
number	O
[	O
9,10	O
]	O
,	O
suggesting	O
that	O
the	O
M6P	O
/	O
IGF2R	O
normally	O
acts	O
to	O
suppress	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TGF	O
-	O
β	O
,	O
a	O
potent	O
growth	O
suppressor	O
whose	O
activation	O
requires	O
the	O
binding	O
of	O
latent	O
TGF	O
-	O
β	O
to	O
M6P	O
/	O
IGF2R	O
[	O
3	O
]	O
,	O
is	O
commonly	O
upregulated	O
in	O
chronic	O
heart	O
failure	O
[	O
11	O
]	O
.	O

Additional	O
evidence	O
for	O
the	O
involvement	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
apoptosis	O
comes	O
from	O
studies	O
of	O
tumorigenesis	O
.	O

It	O
has	O
been	O
shown	O
that	O
M6P	O
/	O
IGF2R	O
expression	O
is	O
significantly	O
reduced	O
in	O
a	O
variety	O
of	O
tumors	O
and	O
loss	O
of	O
heterozygocity	O
(	O
LOH	O
)	O
at	O
the	O
M6P	O
/	O
IGF2R	O
gene	O
locus	O
6q26	O
have	O
been	O
found	O
in	O
breast	O
,	O
liver	O
cancers	O
and	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
[	O
12	O
-	O
15	O
]	O
.	O

Although	O
several	O
studies	O
have	O
examined	O
the	O
effect	O
of	O
M6P	O
/	O
IGF2R	O
over	O
-	O
expression	O
on	O
cell	O
growth	O
[	O
7	O
]	O
,	O
it	O
is	O
not	O
known	O
whether	O
down	O
-	O
regulation	O
of	O
this	O
receptor	O
protein	O
leads	O
to	O
cellular	O
protection	O
against	O
apoptosis	O
.	O

Ribozymes	O
are	O
catalytic	O
RNA	O
molecules	O
that	O
cleave	O
a	O
complementary	O
mRNA	O
sequence	O
[	O
16	O
]	O
,	O
thereby	O
inactivating	O
specific	O
mRNAs	O
and	O
suppressing	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
[	O
17,18	O
]	O
.	O

Ribozymes	O
have	O
been	O
shown	O
to	O
be	O
highly	O
specific	O
,	O
efficient	O
and	O
stable	O
.	O

They	O
can	O
be	O
packaged	O
into	O
viral	O
vectors	O
to	O
enhance	O
transfer	O
into	O
cells	O
and	O
to	O
achieve	O
longer	O
expression	O
compared	O
with	O
naked	O
oligonucleotides	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
employed	O
ribozyme	O
technology	O
to	O
study	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
regulation	O
of	O
cardiac	O
myocyte	O
cell	O
growth	O
.	O

A	O
hammerhead	O
ribozyme	O
against	O
the	O
M6P	O
/	O
IGF2R	O
mRNA	O
was	O
constructed	O
and	O
packaged	O
in	O
an	O
adenoviral	O
vector	O
.	O

We	O
then	O
examined	O
the	O
effect	O
of	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
on	O
cell	O
growth	O
and	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Results	O
Cleavage	O
reaction	O
of	O
the	O
ribozyme	O
in	O
vitro	O
The	O
M6P	O
/	O
IGF2R	O
ribozyme	O
we	O
constructed	O
has	O
13-bp	O
binding	O
arms	O
complementary	O
to	O
the	O
target	O
site	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
,	O
and	O
a	O
catalytic	O
core	O
(	O
Fig.	O
1A	O
)	O
.	O

To	O
evaluate	O
the	O
bioactivity	O
of	O
the	O
ribozyme	O
and	O
the	O
accessibility	O
of	O
the	O
target	O
site	O
,	O
a	O
cleavage	O
reaction	O
was	O
performed	O
in	O
vitro	O
.	O

The	O
substrates	O
,	O
[	O
α-32P	O
]	O
labeled	O
RNA	O
transcripts	O
containing	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
,	O
were	O
incubated	O
with	O
the	O
ribozyme	O
as	O
described	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
ribozyme	O
cleaved	O
only	O
the	O
specific	O
M6P	O
/	O
IGF2R	O
mRNA	O
into	O
the	O
expected	O
products	O
.	O

In	O
the	O
assay	O
of	O
time	O
course	O
,	O
the	O
hammerhead	O
ribozyme	O
was	O
able	O
to	O
cleave	O
24.2	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
10	O
minutes	O
of	O
incubation	O
,	O
50.3	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
within	O
40	O
minutes	O
of	O
incubation	O
,	O
and	O
by	O
640	O
minutes	O
,	O
80.8	O
%	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
was	O
converted	O
to	O
the	O
expected	O
products	O
(	O
Fig.	O
1B	O
)	O
.	O

This	O
ribozyme	O
did	O
not	O
digest	O
the	O
unmatched	O
sequence	O
(	O
Fig.	O
1B	O
)	O
.	O

These	O
results	O
indicate	O
a	O
high	O
efficiency	O
and	O
specificity	O
of	O
the	O
ribozyme	O
in	O
vitro	O
.	O

Ribozymes	O
down	O
-	O
regulate	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cardiac	O
myocytes	O
To	O
examine	O
the	O
ability	O
of	O
the	O
ribozyme	O
to	O
reduce	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
in	O
cultured	O
cardiac	O
myocytes	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
and	O
subjected	O
to	O
RT	O
-	O
PCR	O
using	O
M6P	O
/	O
IGF2R	O
-	O
specific	O
primers	O
.	O

Primers	O
specific	O
for	O
β	O
-	O
actin	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
serve	O
as	O
an	O
internal	O
standard	O
.	O

Cells	O
were	O
used	O
4	O
days	O
after	O
infection	O
,	O
with	O
average	O
infection	O
efficiency	O
of	O
70–80	O
%	O
(	O
for	O
which	O
a	O
viral	O
dose	O
used	O
had	O
minimal	O
cytotoxicity	O
)	O
.	O

The	O
RT	O
-	O
PCR	O
product	O
of	O
M6P	O
/	O
IGF2R	O
was	O
856	O
bp	O
,	O
and	O
the	O
β	O
-	O
actin	O
product	O
was	O
285	O
bp	O
.	O

As	O
shown	O
in	O
Fig.	O
2A	O
,	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
exhibited	O
a	O
significantly	O
lower	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
than	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
,	O
with	O
a	O
reduction	O
of	O
about	O
50	O
%	O
.	O

This	O
result	O
was	O
confirmed	O
by	O
ribonuclease	O
protection	O
assay	O
(	O
RPA	O
)	O
,	O
in	O
which	O
GAPDH	O
was	O
used	O
as	O
a	O
control	O
(	O
Fig.	O
2C	O
&	O
2D	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
level	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
between	O
Ad	O
-	O
GFP	O
-	O
infected	O
cells	O
and	O
uninfected	O
cells	O
(	O
data	O
not	O
shown	O
)	O
,	O
indicating	O
that	O
infection	O
with	O
the	O
adenovirus	O
itself	O
did	O
not	O
alter	O
the	O
endogenous	O
M6P	O
/	O
IGF2R	O
mRNA	O
level	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
ribozyme	O
was	O
highly	O
effective	O
in	O
suppressing	O
M6P	O
/	O
IGF2R	O
expression	O
in	O
cultured	O
cardiac	O
myocytes	O
.	O

Effect	O
of	O
ribozyme	O
expression	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O
To	O
determine	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
functional	O
activity	O
of	O
M6P	O
/	O
IGF2R	O
,	O
binding	O
and	O
internalization	O
of	O
exogenous	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
measured	O
in	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

As	O
shown	O
in	O
Fig.	O
3A	O
,	O
cells	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
showed	O
a	O
54	O
%	O
reduction	O
in	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O
when	O
compared	O
with	O
the	O
control	O
cells	O
(	O
infected	O
with	O
Ad	O
-	O
GFP	O
)	O
.	O

We	O
also	O
examined	O
the	O
effect	O
of	O
the	O
ribozyme	O
on	O
the	O
M6P	O
-	O
binding	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
using	O
the	O
M6P	O
-	O
bearing	O
lysosomal	O
enzyme	O
,	O
β	O
-	O
glucuronidase	O
,	O
as	O
a	O
probe	O
.	O

The	O
results	O
showed	O
that	O
the	O
maximal	O
M6P	O
-	O
binding	O
capacity	O
of	O
cells	O
treated	O
with	O
the	O
ribozyme	O
was	O
about	O
50	O
%	O
less	O
than	O
that	O
of	O
controls	O
(	O
Fig.	O
3B	O
)	O
.	O

Furthermore	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
cells	O
to	O
internalize	O
exogenous	O
β	O
-	O
glucuronidase	O
after	O
treatment	O
with	O
ribozyme	O
.	O

Similarly	O
,	O
the	O
M6P	O
-	O
inhibitable	O
endocytosis	O
of	O
β	O
-	O
glucuronidase	O
by	O
ribozyme	O
-	O
treated	O
cells	O
was	O
about	O
52	O
%	O
less	O
than	O
that	O
of	O
control	O
cells	O
(	O
Fig.	O
3C	O
)	O
.	O

These	O
results	O
confirm	O
that	O
the	O
number	O
of	O
functional	O
M6P	O
/	O
IGF2R	O
in	O
ribozyme	O
-	O
treated	O
cells	O
was	O
reduced	O
.	O

Adenoviral	O
delivery	O
of	O
ribozymes	O
increases	O
the	O
proliferation	O
of	O
cardiac	O
myocytes	O
We	O
examined	O
the	O
effects	O
of	O
the	O
ribozyme	O
on	O
the	O
growth	O
of	O
cultured	O
neonatal	O
rat	B
cardiac	O
myocytes	O
.	O

Morphological	O
evaluation	O
showed	O
a	O
remarkable	O
difference	O
in	O
growth	O
pattern	O
between	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
-	O
infected	O
cells	O
and	O
the	O
control	O
cells	O
:	O
the	O
ribozyme	O
-	O
expressing	O
cells	O
formed	O
larger	O
and	O
more	O
spread	O
colonies	O
(	O
Fig.	O
4	O
)	O
.	O

Assessment	O
of	O
cell	O
proliferative	O
activity	O
by	O
the	O
MTT	O
assay	O
and	O
counts	O
of	O
viable	O
cells	O
showed	O
that	O
the	O
number	O
of	O
cardiac	O
myocytes	O
in	O
ribozyme	O
-	O
expressing	O
cultures	O
was	O
significantly	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig.	O
5	O
)	O
.	O

These	O
results	O
indicate	O
that	O
treatment	O
with	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
can	O
promote	O
cardiac	O
myocyte	O
proliferation	O
.	O

Effect	O
of	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
expression	O
on	O
apoptosis	O
of	O
cardiac	O
myocytes	O
We	O
examined	O
the	O
effects	O
of	O
ribozyme	O
expression	O
on	O
TNF	O
-	O
α	O
and	O
hypoxia	O
-	O
induced	O
apoptosis	O
of	O
cultured	O
cardiac	O
myocytes	O
.	O

After	O
a	O
24	O
hr	O
challenge	O
with	O
hypoxia	O
,	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
M6P	O
/	O
IGF2R	O
-	O
Rz	O
expressing	O
cultures	O
was	O
38	O
%	O
lower	O
than	O
in	O
control	O
cultures	O
as	O
determined	O
by	O
Hoechst	O
staining	O
(	O
which	O
highlights	O
the	O
nuclei	O
of	O
apoptotic	O
cells	O
)	O
and	O
ELISA	O
(	O
Fig.	O
6A	O
,	O
7A	O
)	O
.	O

MTT	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
viable	O
cells	O
in	O
ribozyme	O
-	O
treated	O
cultures	O
was	O
40	O
%	O
higher	O
than	O
in	O
control	O
cultures	O
(	O
Fig.	O
7A	O
)	O
.	O

After	O
treatment	O
with	O
TNF	O
-	O
α	O
,	O
as	O
shown	O
in	O
Fig.	O
6B	O
,	O
a	O
large	O
number	O
of	O
control	O
cells	O
underwent	O
apoptosis	O
,	O
as	O
indicated	O
by	O
morphological	O
changes	O
(	O
small	O
round	O
shape	O
)	O
and	O
bright	O
blue	O
nuclear	O
staining	O
.	O

There	O
were	O
significantly	O
more	O
apoptotic	O
cells	O
in	O
control	O
cultures	O
than	O
in	O
cultures	O
expressing	O
the	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

The	O
number	O
of	O
apoptotic	O
cells	O
,	O
as	O
measured	O
by	O
the	O
cell	O
death	O
ELISA	O
assay	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
40	O
%	O
)	O
lower	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig.	O
7B	O
)	O
.	O

Accordingly	O
,	O
the	O
number	O
of	O
viable	O
cells	O
,	O
as	O
measured	O
by	O
MTT	O
analysis	O
,	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
was	O
significantly	O
(	O
about	O
45	O
%	O
)	O
higher	O
than	O
in	O
cultures	O
infected	O
with	O
Ad	O
-	O
GFP	O
(	O
Fig.	O
7B	O
)	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
decreasing	O
M6P	O
/	O
IGF2R	O
expression	O
by	O
ribozyme	O
treatment	O
can	O
reduce	O
cell	O
apoptosis	O
.	O

Discussion	O
Some	O
62,000,000	O
Americans	O
have	O
one	O
or	O
more	O
types	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
and	O
CVD	O
is	O
the	O
leading	O
cause	O
(	O
40.1	O
%	O
)	O
of	O
death	O
in	O
the	O
United	O
States	O
.	O

Myocardial	O
infarction	O
and	O
heart	O
failure	O
,	O
conditions	O
accompanied	O
by	O
cardiac	O
myocyte	O
apoptosis	O
,	O
represent	O
23	O
%	O
of	O
all	O
CVDs	O
and	O
are	O
a	O
growing	O
clinical	O
challenge	O
in	O
need	O
of	O
novel	O
therapeutic	O
strategies	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
M6P	O
/	O
IGF2R	O
as	O
a	O
potential	O
new	O
therapeutic	O
target	O
for	O
reduction	O
of	O
cardiac	O
apoptosis	O
and	O
cardiac	O
injury	O
in	O
these	O
conditions	O
.	O

Using	O
ribozyme	O
technology	O
we	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
the	O
M6P	O
/	O
IGF2R	O
in	O
neonatal	O
cardiac	O
myocytes	O
.	O

We	O
then	O
examined	O
cell	O
proliferation	O
and	O
apoptosis	O
under	O
normal	O
conditions	O
and	O
post	O
challenge	O
with	O
either	O
hypoxia	O
,	O
a	O
model	O
of	O
ischemia	O
-	O
reperfusion	O
,	O
or	O
TNF	O
-	O
α	O
,	O
a	O
cytokine	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
heart	O
failure	O
[	O
19	O
]	O
.	O

Our	O
results	O
demonstrate	O
an	O
association	O
of	O
a	O
decrease	O
in	O
the	O
expression	O
and	O
function	O
of	O
the	O
M6P	O
/	O
IGF2R	O
with	O
increased	O
cell	O
proliferation	O
and	O
decreased	O
cell	O
susceptibility	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

Expression	O
of	O
the	O
ribozyme	O
targeted	O
against	O
the	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocytes	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
,	O
as	O
measured	O
by	O
RT	O
-	O
PCR	O
and	O
RPA	O
,	O
and	O
of	O
M6P	O
/	O
IGF2R	O
function	O
,	O
as	O
indicated	O
by	O
a	O
decrease	O
in	O
internalization	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
,	O
and	O
β	O
-	O
glucuronidase	O
binding	O
and	O
endocytosis	O
.	O

MTT	O
analysis	O
and	O
viable	O
cell	O
counts	O
showed	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
cell	O
proliferation	O
of	O
cardiomyocytes	O
,	O
which	O
normally	O
express	O
high	O
levels	O
of	O
M6P	O
/	O
IGF2R	O
[	O
20	O
]	O
and	O
have	O
limited	O
proliferative	O
capabilities	O
[	O
21	O
]	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
findings	O
of	O
previous	O
knockout	O
studies	O
[	O
9,10	O
]	O
.	O

Since	O
the	O
M6P	O
/	O
IGF2R	O
has	O
multiple	O
actions	O
on	O
cell	O
growth	O
,	O
its	O
proliferative	O
effect	O
on	O
the	O
heart	O
cells	O
observed	O
in	O
this	O
study	O
might	O
involve	O
multiple	O
mechanisms	O
.	O

However	O
,	O
it	O
is	O
likely	O
that	O
unchecked	O
IGF	O
-	O
II	O
stimulation	O
plays	O
a	O
key	O
role	O
in	O
the	O
effect	O
.	O

Because	O
the	O
M6P	O
/	O
IGF2R	O
is	O
believed	O
to	O
sequester	O
and	O
degrade	O
IGF	O
-	O
II	O
[	O
2	O
]	O
,	O
a	O
decrease	O
in	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
could	O
result	O
in	O
decreased	O
degradation	O
and	O
hence	O
increased	O
bioavailability	O
of	O
IGF	O
-	O
II	O
to	O
the	O
IGF	O
-	O
I	O
receptor	O
,	O
which	O
mediates	O
the	O
growth	O
-	O
promoting	O
effect	O
of	O
IGF	O
-	O
II	O
.	O

Supporting	O
evidence	O
for	O
the	O
involvement	O
of	O
IGF	O
-	O
II	O
in	O
the	O
proliferative	O
effect	O
resulting	O
from	O
loss	O
of	O
M6P	O
/	O
IGF2R	O
function	O
comes	O
from	O
studies	O
of	O
M6P	O
/	O
IGF2R	O
knock	O
-	O
out	O
mice	B
.	O

M6P	O
/	O
IGF2R	O
-	O
null	O
mice	B
display	O
global	O
hyperplasia	O
that	O
coincides	O
with	O
elevated	O
levels	O
of	O
IGF	O
-	O
II	O
.	O

Most	O
importantly	O
,	O
however	O
,	O
the	O
lethal	O
nature	O
of	O
an	O
M6P	O
/	O
IGF2R	O
-	O
null	O
phenotype	O
is	O
reversed	O
in	O
an	O
IGF	O
-	O
II	O
-	O
null	O
background	O
[	O
9	O
]	O
.	O

Our	O
results	O
showing	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
lead	O
to	O
a	O
decrease	O
in	O
IGF	O
-	O
II	O
internalization	O
support	O
the	O
above	O
possibility	O
.	O

However	O
,	O
further	O
investigation	O
to	O
confirm	O
this	O
mechanism	O
is	O
warranted	O
.	O

More	O
importantly	O
,	O
our	O
results	O
also	O
showed	O
that	O
M6P	O
/	O
IGF2R	O
down	O
-	O
regulation	O
resulted	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
.	O

There	O
is	O
evidence	O
that	O
lysosomal	O
enzymes	O
,	O
such	O
as	O
cathepsins	O
B	O
and	O
D	O
contribute	O
to	O
hypoxia-	O
and	O
TNF	O
-	O
induced	O
apoptosis	O
in	O
vitro	O
[	O
22	O
-	O
25	O
]	O
and	O
in	O
vivo	O
[	O
26,27	O
]	O
.	O

The	O
M6P	O
/	O
IGF2R	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
binding	O
,	O
transport	O
and	O
activation	O
of	O
lysosomal	O
enzymes	O
,	O
including	O
cathepsins	O
[	O
4,5	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
down	O
-	O
regulation	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
improper	O
trafficking	O
and	O
activation	O
of	O
cathepsins	O
.	O

This	O
,	O
in	O
turn	O
would	O
eliminate	O
the	O
apoptotic	O
cascades	O
triggered	O
by	O
these	O
enzymes	O
under	O
hypoxia	O
and	O
TNF	O
stimulation	O
and	O
result	O
in	O
decreased	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
apoptosis	O
.	O

It	O
has	O
also	O
been	O
shown	O
that	O
TNF	O
stimulation	O
involves	O
the	O
activation	O
of	O
TGF	O
-	O
β	O
[	O
28	O
-	O
30	O
]	O
,	O
a	O
ligand	O
of	O
M6P	O
/	O
IGF2R	O
that	O
has	O
been	O
implicated	O
in	O
the	O
progression	O
of	O
chronic	O
heart	O
failure	O
[	O
11,31	O
]	O
.	O

Therefore	O
,	O
down	O
-	O
regulation	O
of	O
M6P	O
/	O
IGF2R	O
expression	O
could	O
also	O
lead	O
to	O
a	O
decreased	O
bioavailability	O
of	O
activated	O
TGF	O
-	O
β	O
,	O
thereby	O
decreasing	O
the	O
sensitivity	O
of	O
cardiomyocytes	O
to	O
the	O
TNF	O
/	O
TGF	O
-	O
β	O
apoptotic	O
pathway	O
.	O

The	O
detailed	O
mechanism	O
of	O
the	O
observed	O
effects	O
is	O
unknown	O
and	O
requires	O
further	O
investigation	O
.	O

Conclusions	O
The	O
present	O
study	O
demonstrates	O
that	O
ribozyme	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
expression	O
and	O
functional	O
activity	O
of	O
the	O
M6P	O
/	O
IGF2R	O
results	O
in	O
a	O
decrease	O
in	O
the	O
susceptibility	O
of	O
cardiac	O
myocytes	O
to	O
apoptotic	O
stimuli	O
.	O

These	O
findings	O
suggest	O
that	O
this	O
receptor	O
might	O
be	O
involved	O
in	O
cardiac	O
cell	O
growth	O
and	O
apoptosis	O
.	O

The	O
ability	O
of	O
the	O
M6P	O
/	O
IGF2R	O
ribozyme	O
to	O
reduce	O
M6P	O
/	O
IGF2R	O
expression	O
and	O
function	O
in	O
transfected	O
cells	O
verifies	O
the	O
utility	O
of	O
the	O
ribozyme	O
in	O
studying	O
the	O
role	O
of	O
M6P	O
/	O
IGF2R	O
in	O
cardiomyocyte	O
growth	O
and	O
apoptosis	O
.	O

In	O
addition	O
to	O
its	O
utility	O
as	O
a	O
research	O
tool	O
,	O
the	O
ribozyme	O
,	O
with	O
further	O
exploration	O
and	O
development	O
,	O
might	O
have	O
potential	O
application	O
as	O
a	O
therapeutic	O
agent	O
to	O
prevent	O
cell	O
death	O
or	O
promote	O
mitogenesis	O
for	O
certain	O
clinical	O
conditions	O
,	O
such	O
as	O
,	O
myocardial	O
infarction	O
and	O
chronic	O
heart	O
failure	O
.	O

Methods	O
Construction	O
of	O
recombinant	O
M6P	O
/	O
IGF2R	O
-	O
RZ	O
adenoviral	O
vector	O
The	O
nucleotide	O
numbers	O
of	O
the	O
rat	B
M6P	O
/	O
IGF2R	O
sequence	O
targeted	O
by	O
the	O
hammerhead	O
ribozyme	O
is	O
1147–1160	O
after	O
coding	O
site	O
(	O
exon	O
9	O
)	O
.	O

The	O
structure	O
of	O
the	O
M6P	O
/	O
IGF2R	O
hammerhead	O
ribozyme	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

A	O
49	O
bp	O
M6P	O
/	O
IGF2R	O
ribozyme	O
oligonucleotide	O
,	O
5'-GAATTCCCC	O
ACACTG	O
ATGAGCCGCTTCGGCGGCGAAACATTCAAC	O
GCGT-3	O
'	O
and	O
the	O
corresponding	O
reverse	O
complementary	O
strand	O
were	O
synthesized	O
.	O

The	O
fragments	O
were	O
subcloned	O
to	O
produce	O
a	O
plasmid	O
containing	O
a	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
.	O

For	O
construction	O
of	O
the	O
recombinant	O
adenovirus	O
containing	O
the	O
M6P	O
/	O
IGF2R	O
-	O
ribozyme	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
the	O
segments	O
containing	O
the	O
ribozymes	O
were	O
amplified	O
by	O
PCR	O
and	O
cloned	O
into	O
a	O
pAdTrack	O
-	O
CMV	O
vector	O
and	O
then	O
recombined	O
homologously	O
with	O
an	O
adenoviral	O
backbone	O
pAdEasy	O
1	O
vector	O
to	O
generate	O
(	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
)	O
,	O
following	O
the	O
protocol	O
described	O
by	O
He	O
et	O
al.	O
[	O
32	O
]	O
.	O

The	O
pAd	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
carries	O
both	O
the	O
IGF2R	O
-	O
Rz	O
and	O
GFP	O
(	O
as	O
reporter	O
)	O
genes	O
,	O
each	O
under	O
the	O
control	O
of	O
separate	O
cytomegalovirus	O
(	O
CMV	O
)	O
promoters	O
.	O

Another	O
viral	O
vector	O
,	O
pAd	O
-	O
GFP	O
,	O
which	O
carries	O
the	O
GFP	O
gene	O
only	O
under	O
the	O
control	O
of	O
the	O
CMV	O
promoter	O
,	O
was	O
generated	O
and	O
used	O
as	O
a	O
control	O
vector	O
.	O

The	O
adenoviral	O
vector	O
DNA	O
were	O
linerized	O
with	O
Pac	O
I	O
and	O
transfected	O
into	O
the	O
replication	O
-	O
permissive	O
293	O
cells	O
(	O
E1A	O
transcomplementing	O
cell	O
line	O
)	O
by	O
using	O
Lipofectamine	O
(	O
Life	O
Technologies	O
)	O
to	O
produce	O
E1-deleted	O
,	O
replication	O
-	O
defective	O
recombinant	O
adenovirus	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

Large	O
-	O
scale	O
amplification	O
of	O
recombinant	O
adenovirus	O
in	O
293	O
cells	O
was	O
followed	O
by	O
purification	O
using	O
a	O
discontinuous	O
CsCl	O
gradient	O
.	O

The	O
constructs	O
were	O
confirmed	O
by	O
enzymatic	O
digestion	O
and	O
DNA	O
sequencing	O
.	O

Transcription	O
and	O
cleavage	O
reaction	O
of	O
ribozyme	O
in	O
vitro	O
Plasmids	O
containing	O
the	O
ribozyme	O
or	O
the	O
substrate	O
(	O
either	O
45	O
bp	O
of	O
M6P	O
/	O
IGF2R	O
mRNA	O
or	O
an	O
unmatched	O
sequence	O
5'-GTGCTGTCTGTATG-3	O
'	O
)	O
were	O
linearized	O
with	O
MluI	O
,	O
respectively	O
.	O

All	O
transcripts	O
were	O
generated	O
with	O
T7	O
RNA	O
polymerase	O
(	O
Promega	O
)	O
.	O

Substrate	O
transcripts	O
were	O
labeled	O
by	O
incorporation	O
of	O
[	O
α-32P	O
]	O
UTP	O
(	O
NEN	O
Life	O
Science	O
Products	O
,	O
Inc.	O
)	O
.	O

Specific	O
activity	O
of	O
the	O
[	O
α-32P	O
]	O
UTP	O
(	O
10	O
μCi	O
/	O
μl	O
)	O
and	O
the	O
base	O
composition	O
of	O
each	O
substrate	O
molecule	O
were	O
used	O
to	O
calculate	O
the	O
substrate	O
concentration	O
.	O

Ribozyme	O
transcripts	O
were	O
quantified	O
spectrophotometrically	O
.	O

(	O
The	O
half	O
-	O
life	O
of	O
the	O
M6P	O
/	O
IGF2R	O
target	O
is	O
about	O
280	O
minutes	O
)	O
.	O

Cleavage	O
reaction	O
mixture	O
contained	O
substrate	O
RNA	O
(	O
40	O
nM	O
)	O
,	O
increasing	O
amounts	O
of	O
ribozyme	O
(	O
60	O
nM	O
)	O
,	O
20	O
mM	O
MgCl2	O
and	O
20	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH8.0	O
,	O
in	O
a	O
final	O
volume	O
of	O
10	O
μl	O
.	O

The	O
mixture	O
was	O
incubated	O
at	O
37	O
°	O
C	O
for	O
a	O
time	O
-	O
course	O
of	O
cleavage	O
reaction	O
from	O
0	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
80	O
,	O
160	O
,	O
320	O
,	O
to	O
640	O
minutes	O
and	O
the	O
cleavage	O
reaction	O
was	O
stopped	O
by	O
addition	O
of	O
loading	O
buffer	O
(	O
80	O
%	O
formamide	O
,	O
10	O
mM	O
Na2EDTA	O
,	O
pH	O
8.0	O
,	O
and	O
1	O
mg	O
/	O
ml	O
each	O
bromophenol	O
blue	O
and	O
xylene	O
cyanol	O
)	O
.	O

Cleavage	O
products	O
were	O
analyzed	O
on	O
a	O
15	O
%	O
polyacrylamide	O
and	O
8	O
M	O
urea	O
gel	O
.	O

Product	O
and	O
substrate	O
fragments	O
were	O
quantitated	O
by	O
using	O
NIH	O
Imager	O
.	O

Cell	O
cultures	O
and	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
Rz	O
-	O
IGF2R	O
and	O
Ad	O
-	O
GFP	O
Cardiac	O
myocytes	O
were	O
isolated	O
from	O
1-day	O
-	O
old	O
newborn	O
rats	B
using	O
the	O
Neonatal	O
Cardiomyocyte	O
Isolation	O
System	O
(	O
Worthington	O
)	O
.	O

The	O
isolated	O
cells	O
were	O
plated	O
in	O
6-well	O
plates	O
and	O
cultured	O
in	O
F-10	O
medium	O
containing	O
5	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
and	O
10	O
%	O
(	O
vol	O
/	O
vol	O
)	O
horse	B
serum	O
at	O
37	O
°	O
C	O
in	O
a	O
tissue	O
culture	O
incubator	O
with	O
5	O
%	O
CO2	O
and	O
98	O
%	O
relative	O
humidity	O
.	O

Cells	O
were	O
used	O
for	O
experiments	O
after	O
2–3	O
days	O
of	O
culture	O
.	O

Viral	O
infections	O
were	O
carried	O
out	O
by	O
adding	O
viral	O
particles	O
at	O
various	O
concentrations	O
(	O
usually	O
,	O
2	O
×	O
108	O
virus	O
particles	O
/	O
ml	O
)	O
to	O
culture	O
medium	O
containing	O
2	O
%	O
(	O
vol	O
/	O
vol	O
)	O
FBS	O
.	O

Initially	O
,	O
optimal	O
viral	O
concentration	O
was	O
determined	O
by	O
using	O
Ad	O
-	O
GFP	O
to	O
achieve	O
an	O
optimal	O
balance	O
of	O
high	O
gene	O
expression	O
and	O
low	O
viral	O
titer	O
to	O
minimize	O
cytotoxicity	O
.	O

After	O
24	O
hours	O
of	O
incubation	O
,	O
the	O
infection	O
medium	O
was	O
replaced	O
with	O
normal	O
(	O
15	O
%	O
vol	O
/	O
vol	O
serum	O
)	O
culture	O
medium	O
.	O

For	O
treatment	O
with	O
IGF	O
-	O
II	O
,	O
cells	O
were	O
incubated	O
with	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
after	O
24	O
hours	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
.	O

Four	O
days	O
after	O
infection	O
,	O
cells	O
were	O
used	O
for	O
analysis	O
of	O
gene	O
expression	O
of	O
M6P	O
/	O
IGF2R	O
and	O
its	O
effect	O
on	O
cell	O
growth	O
and	O
apoptosis	O
.	O

Analysis	O
of	O
gene	O
expression	O
in	O
cardiac	O
myocytes	O
The	O
M6P	O
/	O
IGF2R	O
transcripts	O
were	O
determined	O
by	O
both	O
RT	O
-	O
PCR	O
and	O
Ribonuclease	O
Protection	O
Assay	O
(	O
RPA	O
)	O
.	O

RT	O
-	O
PCR	O
was	O
performed	O
using	O
the	O
GeneAmp	O
EZ	O
rTth	O
RNA	O
PCR	O
kit	O
(	O
Roche	O
)	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
an	O
RNA	O
isolation	O
kit	O
(	O
Qiagen	O
,	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

M6P	O
/	O
IGF2R	O
transcripts	O
were	O
amplified	O
using	O
the	O
primers	O
(	O
5'-GACAGGCTCGTTCTGACTTA-3	O
'	O
)	O
and	O
(	O
5'-CTTCCACTCTTATCCACAGC-3	O
'	O
)	O
specific	O
to	O
the	O
M6P	O
/	O
IGF2R	O
.	O

Each	O
RT	O
-	O
PCR	O
assay	O
was	O
performed	O
in	O
triplicate	O
and	O
product	O
levels	O
varied	O
by	O
less	O
than	O
3.2	O
%	O
for	O
each	O
RNA	O
sample	O
.	O

Primers	O
specific	O
for	O
β	O
-	O
actin	O
cDNA	O
were	O
added	O
to	O
a	O
parallel	O
reaction	O
to	O
standardize	O
for	O
variations	O
in	O
PCR	O
between	O
samples	O
.	O

PCR	O
products	O
were	O
resolved	O
on	O
a	O
1.0	O
%	O
agarose	O
gel	O
,	O
visualized	O
under	O
UV	O
light	O
and	O
quantitated	O
using	O
NIH	O
Imager	O
.	O

RPA	O
was	O
performed	O
using	O
the	O
RPA	O
III	O
kit	O
(	O
Ambion	O
,	O
Austin	O
,	O
TX	O
)	O
.	O

Briefly	O
,	O
total	O
RNA	O
was	O
extracted	O
from	O
cultured	O
cells	O
using	O
a	O
total	O
RNA	O
isolation	O
reagent	O
(	O
TRIzol	O
,	O
Gibco	O
BRL	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

The	O
plasmid	O
containing	O
the	O
rat	B
M6P	O
/	O
IGF2R	O
gene	O
was	O
linearized	O
and	O
used	O
as	O
a	O
transcription	O
template	O
.	O

Antisense	O
RNA	O
probes	O
were	O
transcribed	O
in	O
vitro	O
using	O
[	O
33P	O
]	O
-UTP	O
,	O
T7	O
polymerase	O
(	O
Riboprobea	O
System	O
T7	O
kit	O
,	O
Promega	O
)	O
,	O
hybridized	O
with	O
the	O
total	O
RNA	O
extracted	O
from	O
the	O
rat	B
cardiomyocytes	O
,	O
and	O
digested	O
with	O
ribonuclease	O
to	O
remove	O
non	O
-	O
hybridized	O
RNA	O
and	O
probe	O
.	O

The	O
protected	O
RNA·RNA	O
was	O
resolved	O
on	O
a	O
denaturing	O
5	O
%	O
sequence	O
gel	O
and	O
subjected	O
to	O
autoradiography	O
.	O

A	O
probe	O
targeting	O
the	O
GAPDH	O
gene	O
was	O
used	O
as	O
an	O
internal	O
control	O
.	O

Measurement	O
of	O
125I	O
-	O
IGF	O
-	O
II	O
internalization	O
Cells	O
were	O
incubated	O
at	O
37	O
°	O
C	O
for	O
2	O
hrs	O
in	O
serum	O
-	O
free	O
F-10	O
culture	O
medium	O
containing	O
125I	O
-	O
labeled	O
IGF	O
-	O
II	O
(	O
0.5	O
ng	O
/	O
ml	O
)	O
with	O
or	O
without	O
excess	O
unlabeled	O
IGF	O
-	O
II	O
(	O
2	O
μg	O
/	O
ml	O
)	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
and	O
cell	O
-	O
associated	O
radioactivity	O
was	O
determined	O
by	O
a	O
γ	O
counter	O
.	O

Specific	O
internalized	O
125I	O
-	O
IGF	O
-	O
II	O
was	O
calculated	O
by	O
subtracting	O
the	O
count	O
of	O
samples	O
with	O
excessive	O
unlabeled	O
IGF	O
-	O
II	O
from	O
that	O
without	O
unlabeled	O
IGF	O
-	O
II	O
,	O
and	O
normalized	O
to	O
protein	O
contents	O
.	O

Beta	O
-	O
glucuronidase	O
binding	O
assay	O
Binding	O
of	O
β	O
-	O
glucuronidase	O
was	O
assayed	O
as	O
described	O
previously	O
[	O
34,35	O
]	O
.	O

Briefly	O
,	O
cells	O
were	O
permeabilized	O
with	O
0.25	O
%	O
saponin	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7.0	O
)	O
,	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.5	O
%	O
human	B
serum	O
albumin	O
,	O
and	O
10	O
mM	O
mannose-6-phosphate	O
(	O
M6P	O
)	O
for	O
30	O
minutes	O
on	O
ice	O
.	O

The	O
cells	O
were	O
washed	O
three	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0.05	O
%	O
saponin	O
.	O

They	O
were	O
incubated	O
with	O
20,000	O
units	O
/	O
ml	O
β	O
-	O
glucuronidase	O
from	O
bovine	B
liver	O
(	O
Sigma	O
)	O
in	O
50	O
mM	O
Hepes	O
(	O
pH	O
7.5	O
)	O
containing	O
150	O
mM	O
NaCl	O
,	O
5	O
mM	O
β	O
-	O
glycerophosphate	O
,	O
0.5	O
%	O
human	B
serum	O
albumin	O
,	O
0.5	O
%	O
saponin	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
overnight	O
on	O
ice	O
.	O

Cells	O
were	O
washed	O
five	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
containing	O
0.05	O
%	O
saponin	O
and	O
sonicated	O
in	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4.6	O
)	O
.	O

The	O
protein	O
concentration	O
of	O
solubilized	O
cell	O
extract	O
was	O
measured	O
and	O
enzyme	O
activity	O
was	O
assayed	O
as	O
follows	O
:	O
for	O
each	O
reaction	O
50	O
ul	O
cell	O
extract	O
were	O
added	O
to	O
500	O
ul	O
of	O
100	O
mM	O
sodium	O
acetate	O
(	O
pH	O
4.0	O
)	O
containing	O
1	O
mM	O
paranitrophenyl	O
(	O
PNP	O
)	O
-β	O
-	O
glucuronide	O
(	O
Sigma	O
)	O
as	O
substrate	O
.	O

After	O
an	O
incubation	O
period	O
of	O
3	O
hours	O
at	O
37	O
°	O
C	O
,	O
500	O
ul	O
1	O
M	O
Na2CO3	O
were	O
added	O
to	O
each	O
reaction	O
and	O
the	O
absorbance	O
was	O
measured	O
at	O
400	O
nm	O
.	O

Experimental	O
values	O
were	O
compared	O
to	O
a	O
standard	O
curve	O
that	O
was	O
constructed	O
using	O
1–100	O
nM	O
solutions	O
of	O
PNP	O
(	O
Sigma	O
)	O
in	O
500	O
ul	O
100	O
mM	O
sodium	O
acetate	O
and	O
500	O
u1	O
1	O
M	O
Na2CO3	O
.	O

Specific	O
activity	O
was	O
calculated	O
as	O
nM	O
of	O
PNP	O
produced	O
/	O
hour	O
/	O
mg	O
of	O
protein	O
.	O

Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O
Beta	O
-	O
glucuronidase	O
endocytosis	O
assay	O
was	O
carried	O
out	O
as	O
described	O
previously	O
[	O
36	O
]	O
.	O

Briefly	O
,	O
confluent	O
cell	O
cultures	O
were	O
washed	O
twice	O
with	O
pre	O
-	O
warmed	O
serum	O
-	O
free	O
DMEM	O
followed	O
by	O
incubation	O
with	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	B
serum	O
albumin	O
and	O
10	O
mM	O
M6P	O
for	O
20	O
minutes	O
.	O

Following	O
incubation	O
cells	O
were	O
washed	O
3	O
times	O
with	O
pre	O
-	O
warmed	O
DMEM	O
.	O

Cells	O
were	O
then	O
incubated	O
in	O
DMEM	O
containing	O
5	O
mg	O
/	O
ml	O
human	B
serum	O
albumin	O
alone	O
or	O
4000	O
units	O
β	O
-	O
glucuronidase	O
with	O
or	O
without	O
10	O
mM	O
M6P	O
for	O
2	O
hours	O
at	O
37	O
°	O
C	O
.	O

Following	O
the	O
incubation	O
,	O
the	O
cells	O
were	O
washed	O
5	O
times	O
with	O
ice	O
-	O
cold	O
PBS	O
and	O
subjected	O
to	O
enzyme	O
activity	O
assay	O
as	O
described	O
above	O
.	O

Cell	O
proliferation	O
assay	O
(	O
MTT	O
assay	O
and	O
cell	O
counts	O
)	O
Cardiac	O
myocytes	O
were	O
grown	O
in	O
culture	O
plates	O
(	O
tissue	O
culture	O
grade	O
,	O
12	O
wells	O
,	O
flat	O
bottom	O
)	O
in	O
a	O
final	O
volume	O
of	O
1	O
ml	O
serum	O
-	O
containing	O
culture	O
medium	O
per	O
well	O
,	O
in	O
a	O
humidified	O
atmosphere	O
(	O
37	O
°	O
C	O
and	O
5	O
%	O
C02	O
)	O
for	O
3	O
days	O
.	O

After	O
infection	O
with	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
or	O
Ad	O
-	O
GFP	O
,	O
cells	O
were	O
incubated	O
with	O
or	O
without	O
50	O
ng	O
/	O
ml	O
IGF	O
-	O
II	O
for	O
4	O
days	O
.	O

Following	O
supplementation	O
with	O
IGF	O
-	O
II	O
,	O
100	O
μl	O
MTT	O
labeling	O
reagent	O
(	O
Roche	O
)	O
were	O
added	O
to	O
each	O
well	O
and	O
cells	O
were	O
incubated	O
for	O
4	O
hours	O
,	O
followed	O
by	O
addition	O
of	O
1	O
ml	O
solubilization	O
solution	O
into	O
each	O
well	O
.	O

The	O
plate	O
was	O
placed	O
in	O
an	O
incubator	O
at	O
37	O
°	O
C	O
overnight	O
.	O

Spectrophotometrical	O
absorbency	O
of	O
the	O
samples	O
was	O
measured	O
using	O
an	O
UV	O
-	O
visible	O
Recording	O
Spectrophotometer	O
with	O
wavelength	O
of	O
550–690	O
nm	O
.	O

In	O
addition	O
,	O
the	O
total	O
number	O
of	O
viable	O
cells	O
in	O
each	O
treatment	O
was	O
counted	O
by	O
trypan	O
blue	O
exclusion	O
method	O
using	O
a	O
hemocytometer	O
.	O

Induction	O
and	O
analysis	O
of	O
cell	O
apoptosis	O
Cells	O
were	O
infected	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
.	O

Seventy	O
-	O
two	O
hours	O
post	O
infection	O
,	O
cells	O
were	O
treated	O
with	O
TNF	O
(	O
0.1	O
ng	O
/	O
ml	O
)	O
for	O
24	O
hrs	O
or	O
subjected	O
to	O
hypoxia	O
.	O

For	O
induction	O
of	O
apoptosis	O
by	O
hypoxia	O
,	O
cell	O
culture	O
medium	O
was	O
changed	O
to	O
serum	O
-	O
free	O
F-10	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
°	O
C	O
airtight	O
box	O
saturated	O
with	O
95	O
%	O
N2	O
/	O
5	O
%	O
CO2	O
for	O
24	O
hrs	O
.	O

For	O
normoxic	O
controls	O
,	O
culture	O
medium	O
was	O
changed	O
to	O
F-10	O
/	O
5%F	O
BS	O
/	O
10	O
%	O
HS	O
and	O
cells	O
were	O
placed	O
in	O
a	O
37	O
°	O
C	O
/	O
5	O
%	O
CO2	O
incubator	O
for	O
24	O
hrs	O
before	O
analysis	O
.	O

Apoptotic	O
cells	O
were	O
identified	O
by	O
Hoechst	O
staining	O
using	O
the	O
Vybrant	O
™	O
Apoptosis	O
Kit	O
#	O
5	O
(	O
Molecular	O
Probes	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

In	O
addition	O
,	O
after	O
infection	O
with	O
Ad	O
-	O
GFP	O
or	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
and	O
challenge	O
with	O
either	O
TNF	O
or	O
hypoxia	O
,	O
cell	O
viability	O
was	O
assessed	O
using	O
the	O
MTT	O
assay	O
Kit	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
and	O
cell	O
apoptosis	O
was	O
determined	O
using	O
the	O
Cell	O
Death	O
Detection	O
ELISA	O
Kit	O
assay	O
(	O
Roche	O
Molecular	O
Biochemicals	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

Statistical	O
analysis	O
Students	O
'	O
t	O
-	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
difference	O
between	O
two	O
values	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
three	O
times	O
.	O

Statistical	O
significance	O
was	O
accepted	O
at	O
the	O
level	O
of	O
p	O
<	O
0.05	O
.	O

List	O
of	O
abbreviations	O
used	O
Ad	O
-	O
GFP	O
,	O
adenovirus	O
carrying	O
GFP	O
gene	O
;	O
Ad	O
-	O
GFP	O
/	O
IGF2R	O
-	O
Rz	O
,	O
adenovirus	O
carrying	O
both	O
the	O
ribozyme	O
against	O
M6P	O
/	O
IGF2R	O
and	O
the	O
GFP	O
gene	O
;	O
GFP	O
,	O
green	O
fluorescent	O
protein	O
;	O
IGF	O
-	O
II	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
;	O
M6P	O
/	O
IGF2R	O
,	O
mannose	O
6-phosphate	O
/	O
insulin	O
-	O
like	O
growth	O
factor	O
II	O
receptor	O
;	O
Rz	O
,	O
ribozyme	O
.	O

Authors	O
'	O
contributions	O
ZC	O
carried	O
out	O
construction	O
of	O
the	O
ribozyme	O
,	O
production	O
of	O
the	O
viruses	O
,	O
cellular	O
experiments	O
,	O
biochemical	O
assays	O
and	O
data	O
analysis	O
.	O

YG	O
carried	O
out	O
the	O
RPA	O
assay	O
and	O
participated	O
in	O
the	O
molecular	O
biological	O
studies	O
.	O

JXK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
the	O
manuscript	O
.	O

Medicinal	O
herb	O
use	O
among	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
care	O
facility	O
in	O
Trinidad	O
Abstract	O
Background	O
There	O
is	O
an	O
increasing	O
prevalence	O
of	O
asthma	O
in	O
the	O
Caribbean	O
and	O
patients	O
remain	O
non	O
-	O
compliant	O
to	O
therapy	O
despite	O
the	O
development	O
of	O
guidelines	O
for	O
management	O
and	O
prevention	O
.	O

Some	O
patients	O
may	O
self	O
-	O
medicate	O
with	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
,	O
as	O
there	O
is	O
a	O
long	O
tradition	O
of	O
use	O
for	O
a	O
variety	O
of	O
ailments	O
.	O

The	O
study	O
assessed	O
the	O
prevalence	O
of	O
use	O
and	O
the	O
factors	O
affecting	O
the	O
decision	O
to	O
use	O
herbs	O
in	O
asthmatic	O
patients	O
attending	O
a	O
public	O
specialty	O
care	O
clinic	O
in	O
Trinidad	O
.	O

Methods	O
A	O
descriptive	O
,	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
between	O
June	O
and	O
July	O
2003	O
.	O

Results	O
Fifty	O
-	O
eight	O
out	O
of	O
191	O
patients	O
(	O
30.4	O
%	O
)	O
reported	O
using	O
herbal	O
remedies	O
for	O
symptomatic	O
relief	O
.	O

Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
and	O
asthma	O
severity	O
did	O
not	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
;	O
however	O
,	O
62.5	O
%	O
of	O
patients	O
with	O
tertiary	O
level	O
schooling	O
used	O
herbs	O
,	O
p	O
=	O
0.025	O
.	O

Thirty	O
-	O
four	O
of	O
these	O
58	O
patients	O
(	O
58.6	O
%	O
)	O
obtained	O
herbs	O
from	O
their	O
backyards	O
or	O
the	O
supermarket	O
;	O
only	O
14	O
patients	O
(	O
24.1	O
%	O
)	O
obtained	O
herbs	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Relatives	O
and	O
friends	O
were	O
the	O
sole	O
source	O
of	O
information	O
for	O
most	O
patients	O
(	O
70.7	O
%	O
)	O
,	O
and	O
only	O
10.3	O
%	O
consulted	O
an	O
herbalist	O
.	O

Ginger	B
,	O
garlic	B
,	O
aloes	O
,	O
shandileer	B
,	O
wild	O
onion	B
,	O
pepper	O
and	O
black	B
sage	I
were	O
the	O
most	O
commonly	O
used	O
herbs	O
.	O

Conclusions	O
Among	O
patients	O
attending	O
the	O
Chest	O
Clinic	O
in	O
Trinidad	O
the	O
use	O
of	O
herbal	O
remedies	O
in	O
asthma	O
is	O
relatively	O
common	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
.	O

It	O
is	O
therefore	O
becoming	O
imperative	O
for	O
healthcare	O
providers	O
to	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
to	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
.	O

Background	O
Recent	O
reports	O
from	O
the	O
Caribbean	O
suggest	O
that	O
the	O
incidence	O
of	O
asthma	O
is	O
following	O
the	O
global	O
trend	O
of	O
increasing	O
prevalence	O
.	O

In	O
Jamaica	O
,	O
a	O
prevalence	O
of	O
20.8	O
%	O
for	O
exercise	O
-	O
induced	O
asthma	O
was	O
estimated	O
in	O
a	O
cross	O
-	O
sectional	O
study	O
in	O
schoolchildren	O
[	O
1	O
]	O
.	O

About	O
one	O
in	O
ten	O
patients	O
attending	O
an	O
Accident	O
and	O
Emergency	O
Department	O
in	O
Trinidad	O
were	O
treated	O
for	O
acute	O
severe	O
asthma	O
[	O
2	O
]	O
and	O
over	O
15,000	O
patients	O
attended	O
four	O
A&E	O
departments	O
throughout	O
the	O
island	O
over	O
a	O
12-month	O
period	O
[	O
3	O
]	O
.	O

Inhaled	O
corticosteroids	O
as	O
prophylaxis	O
and	O
'	O
as	O
required	O
'	O
bronchodilator	O
for	O
symptomatic	O
relief	O
are	O
established	O
modalities	O
for	O
asthma	O
management	O
and	O
prevention	O
and	O
the	O
Commonwealth	O
Caribbean	O
Medical	O
Research	O
Council	O
/	O
Global	O
Initiative	O
for	O
Asthma	O
guidelines	O
were	O
adopted	O
in	O
the	O
Caribbean	O
in	O
1997	O
[	O
4	O
]	O
.	O

It	O
has	O
been	O
noted	O
that	O
inefficient	O
management	O
predisposes	O
patients	O
to	O
frequent	O
hospitalization	O
and	O
reduced	O
quality	O
of	O
life	O
.	O

In	O
Trinidad	O
,	O
non	O
-	O
compliance	O
and	O
inadequate	O
inhaler	O
technique	O
negatively	O
impact	O
on	O
effective	O
disease	O
management	O
[	O
5,6	O
]	O
.	O

The	O
frequent	O
unavailability	O
of	O
medication	O
at	O
public	O
health	O
facilities	O
and	O
the	O
prohibitive	O
cost	O
at	O
private	O
pharmacies	O
are	O
significantly	O
associated	O
with	O
non	O
-	O
compliance	O
and	O
consequently	O
poor	O
disease	O
control	O
.	O

In	O
these	O
studies	O
,	O
some	O
patients	O
indicated	O
their	O
use	O
of	O
herbal	O
remedies	O
as	O
an	O
alternative	O
to	O
conventional	O
medicines	O
.	O

Over	O
the	O
last	O
few	O
decades	O
,	O
a	O
global	O
resurgence	O
in	O
the	O
use	O
of	O
herbal	O
remedies	O
has	O
fuelled	O
the	O
growing	O
multi	O
-	O
billion	O
dollar	O
international	O
trade	O
of	O
botanical	O
products	O
.	O

Many	O
patients	O
,	O
dissatisfied	O
with	O
conventional	O
medicines	O
because	O
they	O
expect	O
permanent	O
cures	O
,	O
believe	O
that	O
herbal	O
remedies	O
are	O
'	O
natural	O
'	O
and	O
sometimes	O
self	O
-	O
medicate	O
without	O
informing	O
their	O
attending	O
physician	O
.	O

Although	O
there	O
is	O
a	O
long	O
history	O
of	O
traditional	O
use	O
of	O
medicinal	O
herbs	O
throughout	O
the	O
Caribbean	O
[	O
7,8	O
]	O
few	O
studies	O
were	O
done	O
to	O
assess	O
the	O
prevalence	O
of	O
use	O
.	O

Surveys	O
in	O
Jamaica	O
reported	O
an	O
almost	O
100	O
%	O
use	O
of	O
herbal	O
teas	O
and	O
remedies	O
by	O
respondents	O
throughout	O
the	O
island	O
[	O
9	O
]	O
and	O
71	O
%	O
in	O
paediatrics	O
inpatients	O
at	O
the	O
University	O
Hospital	O
[	O
10	O
]	O
.	O

These	O
studies	O
,	O
however	O
,	O
assessed	O
only	O
the	O
lifetime	O
use	O
of	O
medicinal	O
herbs	O
and	O
did	O
not	O
identify	O
their	O
use	O
for	O
any	O
particular	O
disease	O
.	O

In	O
Trinidad	O
and	O
Tobago	O
,	O
the	O
use	O
of	O
'	O
bush	O
medicine	O
'	O
in	O
diabetic	O
patients	O
attending	O
primary	O
healthcare	O
facilities	O
throughout	O
the	O
island	O
was	O
assessed	O
and	O
although	O
42	O
%	O
reportedly	O
used	O
herbs	O
,	O
only	O
24	O
%	O
used	O
this	O
healthcare	O
modality	O
for	O
self	O
-	O
management	O
of	O
diabetes	O
[	O
11	O
]	O
.	O

Another	O
survey	O
conducted	O
at	O
an	O
outpatient	O
surgical	O
facility	O
in	O
Trinidad	O
indicated	O
a	O
lifetime	O
prevalence	O
of	O
86	O
%	O
among	O
patients	O
[	O
12	O
]	O
for	O
any	O
healthcare	O
issue	O
.	O

This	O
study	O
was	O
undertaken	O
to	O
assess	O
the	O
extent	O
of	O
use	O
of	O
herbal	O
remedies	O
by	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
chest	O
clinic	O
in	O
Trinidad	O
for	O
symptomatic	O
relief	O
and	O
to	O
determine	O
the	O
factors	O
influencing	O
the	O
patient	O
's	O
decision	O
to	O
use	O
herbs	O
.	O

Methods	O
The	O
study	O
was	O
approved	O
by	O
the	O
Ethics	O
Committee	O
of	O
the	O
Faculty	O
of	O
Medical	O
Sciences	O
,	O
University	O
of	O
the	O
West	O
Indies	O
,	O
St.	O
Augustine	O
campus	O
and	O
permission	O
to	O
interview	O
patients	O
was	O
granted	O
by	O
the	O
Director	O
of	O
the	O
Chest	O
Clinic	O
of	O
the	O
Ministry	O
of	O
Health	O
,	O
Trinidad	O
and	O
Tobago	O
.	O

The	O
study	O
was	O
conducted	O
over	O
the	O
two	O
-	O
month	O
period	O
June	O
to	O
July	O
2003	O
.	O

Sample	O
and	O
setting	O
The	O
Chest	O
Clinic	O
was	O
chosen	O
as	O
the	O
source	O
of	O
subjects	O
as	O
this	O
is	O
the	O
only	O
national	O
tertiary	O
level	O
health	O
facility	O
specializing	O
in	O
the	O
management	O
of	O
respiratory	O
diseases	O
.	O

Patients	O
entering	O
the	O
study	O
were	O
physician	O
-	O
diagnosed	O
asthmatics	O
based	O
on	O
self	O
-	O
reporting	O
symptoms	O
of	O
wheezing	O
,	O
chest	O
tightness	O
and	O
nocturnal	O
coughing	O
in	O
the	O
previous	O
year	O
.	O

Patients	O
were	O
recruited	O
by	O
consecutive	O
sampling	O
and	O
the	O
nature	O
and	O
purpose	O
of	O
the	O
study	O
were	O
explained	O
on	O
an	O
individual	O
basis	O
.	O

Those	O
confirming	O
their	O
willingness	O
to	O
participate	O
signed	O
their	O
informed	O
consent	O
and	O
were	O
interviewed	O
using	O
a	O
de	O
novo	O
,	O
pilot	O
-	O
tested	O
,	O
researcher	O
-	O
administered	O
questionnaire	O
.	O

Interview	O
instrument	O
The	O
questionnaire	O
assessed	O
demographic	O
data	O
such	O
as	O
age	O
,	O
gender	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
education	O
,	O
employment	O
and	O
socioeconomic	O
status	O
.	O

Subjects	O
reported	O
their	O
disease	O
severity	O
as	O
intermittent	O
,	O
moderate	O
or	O
severe	O
as	O
determined	O
by	O
the	O
Global	O
Initiative	O
for	O
Asthma	O
(	O
GINA	O
)	O
guidelines	O
with	O
respect	O
to	O
symptom	O
frequency	O
[	O
4	O
]	O
.	O

Patients	O
also	O
reported	O
their	O
use	O
of	O
herbal	O
remedies	O
,	O
identified	O
the	O
herbs	O
used	O
,	O
the	O
frequency	O
of	O
use	O
,	O
source	O
of	O
herbal	O
medicines	O
and	O
the	O
reasons	O
for	O
the	O
use	O
of	O
herbs	O
.	O

Statistical	O
analysis	O
The	O
sample	O
size	O
was	O
calculated	O
as	O
185	O
patients	O
assuming	O
a	O
prevalence	O
of	O
86	O
%	O
[	O
13	O
]	O
with	O
a	O
confidence	O
level	O
of	O
95	O
%	O
.	O

Since	O
all	O
variables	O
were	O
categorical	O
,	O
χ2	O
tests	O
were	O
performed	O
to	O
determine	O
whether	O
there	O
were	O
statistically	O
significant	O
associations	O
between	O
the	O
use	O
of	O
herbs	O
and	O
these	O
variables	O
.	O

The	O
p	O
value	O
was	O
set	O
at	O
<	O
0.05	O
for	O
statistical	O
significance	O
.	O

The	O
data	O
was	O
analyzed	O
using	O
SPSS	O
for	O
Windows	O
(	O
Version	O
9.0	O
,	O
Chicago	O
,	O
IL	O
)	O
.	O

Results	O
Demography	O
During	O
the	O
study	O
period	O
one	O
hundred	O
and	O
ninety	O
one	O
patients	O
consented	O
to	O
participate	O
.	O

The	O
demographic	O
details	O
of	O
the	O
sample	O
are	O
given	O
in	O
Table	O
1	O
.	O

Patients	O
between	O
35	O
and	O
64	O
years	O
of	O
age	O
formed	O
the	O
largest	O
portion	O
of	O
the	O
sample	O
(	O
62.3	O
%	O
)	O
.	O

There	O
was	O
a	O
significant	O
gender	O
difference	O
with	O
females	O
outnumbering	O
males	O
by	O
a	O
2:1	O
ratio	O
,	O
p	O
<	O
0.01	O
.	O

Most	O
patients	O
were	O
of	O
Asian	O
Indian	O
origin	O
(	O
58.1	O
%	O
)	O
and	O
resided	O
in	O
suburban	O
areas	O
(	O
60.2	O
%	O
)	O
.	O

There	O
was	O
a	O
high	O
level	O
of	O
unemployment	O
(	O
30.4	O
%	O
)	O
;	O
this	O
could	O
be	O
correlated	O
to	O
primary	O
schooling	O
(	O
seven	O
or	O
less	O
years	O
of	O
formal	O
education	O
)	O
being	O
the	O
highest	O
educational	O
level	O
attained	O
in	O
52.9	O
%	O
and	O
no	O
formal	O
schooling	O
in	O
5.2	O
%	O
of	O
the	O
sample	O
population	O
.	O

Income	O
was	O
low	O
,	O
with	O
42.9	O
%	O
of	O
the	O
sample	O
population	O
earning	O
below	O
US$	O
4,000	O
per	O
year	O
.	O

Antiasthmatic	O
drug	O
use	O
The	O
GINA	O
guidelines	O
were	O
recently	O
adopted	O
in	O
the	O
Caribbean	O
and	O
asthmatic	O
patients	O
are	O
currently	O
treated	O
according	O
to	O
their	O
symptom	O
severity	O
.	O

In	O
our	O
sample	O
population	O
,	O
particularly	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
symptoms	O
,	O
corticosteroids	O
(	O
controllers	O
)	O
and	O
β2-agonists	O
(	O
relievers	O
)	O
were	O
prescribed	O
at	O
very	O
high	O
rates	O
,	O
Table	O
2	O
.	O

Almost	O
90	O
%	O
of	O
all	O
patients	O
with	O
moderate	O
symptoms	O
were	O
prescribed	O
drugs	O
in	O
these	O
classes	O
.	O

Almost	O
all	O
patients	O
with	O
severe	O
symptoms	O
were	O
prescribed	O
β2-agonists	O
.	O

This	O
high	O
level	O
of	O
prescription	O
and	O
use	O
of	O
β2-agonists	O
suggest	O
a	O
lack	O
of	O
symptomatic	O
control	O
in	O
our	O
sample	O
population	O
.	O

Theophylline	O
and	O
anticholinergics	O
were	O
prescribed	O
in	O
both	O
categories	O
of	O
patients	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Factors	O
influencing	O
the	O
use	O
of	O
herbal	O
remedies	O
Gender	O
,	O
age	O
,	O
ethnicity	O
,	O
residential	O
district	O
,	O
employment	O
status	O
,	O
income	O
and	O
asthma	O
severity	O
had	O
no	O
statistically	O
significant	O
effect	O
on	O
the	O
use	O
of	O
herbal	O
remedies	O
within	O
the	O
sample	O
population	O
,	O
Table	O
3	O
.	O

However	O
,	O
almost	O
two	O
-	O
thirds	O
(	O
62.5	O
%	O
)	O
of	O
patients	O
with	O
tertiary	O
education	O
used	O
herbal	O
remedies	O
for	O
asthma	O
,	O
p	O
=	O
0.025	O
.	O

Characteristics	O
of	O
patients	O
using	O
herbal	O
remedies	O
Most	O
patients	O
(	O
70.7	O
%	O
)	O
using	O
herbs	O
were	O
advised	O
by	O
a	O
relative	O
or	O
friend	O
and	O
only	O
10.3	O
%	O
sought	O
the	O
advice	O
of	O
an	O
herbalist	O
,	O
Table	O
4	O
.	O

A	O
cultural	O
/	O
traditional	O
basis	O
was	O
the	O
reason	O
for	O
herbal	O
remedy	O
usage	O
in	O
twenty	O
-	O
one	O
(	O
36.2	O
%	O
)	O
patients	O
and	O
another	O
twelve	O
(	O
20.7	O
%	O
)	O
patients	O
used	O
herbs	O
because	O
they	O
felt	O
that	O
were	O
either	O
'	O
natural	O
'	O
or	O
'	O
healthy	O
'	O
.	O

Twelve	O
(	O
20.7	O
%	O
)	O
patients	O
used	O
herbs	O
because	O
they	O
believed	O
that	O
their	O
physician	O
-	O
prescribed	O
allopathic	O
medicines	O
were	O
not	O
working	O
.	O

Most	O
patients	O
(	O
58.6	O
%	O
)	O
obtained	O
their	O
herbs	O
or	O
medicinal	O
plants	O
from	O
either	O
their	O
backyards	O
or	O
the	O
supermarket	O
.	O

Only	O
fourteen	O
(	O
24.1	O
%	O
)	O
obtained	O
their	O
herbal	O
supplies	O
from	O
an	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
.	O

Seventeen	O
(	O
29.3	O
%	O
)	O
of	O
these	O
patients	O
reported	O
using	O
herbs	O
within	O
the	O
last	O
week	O
and	O
most	O
these	O
patients	O
(	O
60.3	O
%	O
)	O
used	O
herbs	O
within	O
the	O
last	O
six	O
months	O
.	O

Many	O
of	O
these	O
patients	O
were	O
using	O
both	O
physician	O
-	O
prescribed	O
antiasthmatic	O
drugs	O
and	O
herbal	O
remedies	O
,	O
Table	O
5	O
.	O

No	O
patient	O
with	O
either	O
moderate	O
or	O
severe	O
symptoms	O
indicated	O
that	O
herbal	O
remedies	O
alone	O
were	O
sufficient	O
to	O
relieve	O
symptomatic	O
episodes	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
most	O
patients	O
with	O
moderate	O
symptoms	O
(	O
57.1	O
%	O
)	O
believed	O
that	O
concurrent	O
use	O
of	O
conventional	O
medications	O
and	O
herbs	O
gave	O
better	O
symptomatic	O
relieve	O
.	O

One	O
the	O
other	O
hand	O
,	O
most	O
patients	O
with	O
severe	O
symptoms	O
(	O
53.8	O
%	O
)	O
believed	O
that	O
physician	O
-	O
prescribed	O
medications	O
worked	O
better	O
than	O
herbal	O
remedies	O
,	O
while	O
23.1	O
%	O
believed	O
that	O
neither	O
relieved	O
their	O
symptoms	O
.	O

Herbs	O
used	O
in	O
asthma	O
Most	O
patients	O
in	O
the	O
sample	O
used	O
more	O
than	O
one	O
medicinal	O
herb	O
simultaneously	O
,	O
which	O
were	O
usually	O
prepared	O
and	O
administered	O
as	O
mixtures	O
in	O
teas	O
.	O

Almost	O
one	O
in	O
four	O
patients	O
using	O
medicinal	O
herbs	O
(	O
22.5	O
%	O
)	O
used	O
either	O
garlic	B
(	O
Allium	B
sativum	I
)	O
or	O
ginger	B
(	O
Zingiber	B
officinale	I
)	O
for	O
symptomatic	O
relief	O
of	O
asthma	O
,	O
Table	O
6	O
.	O

Aloes	O
(	O
Aloe	B
vera	I
)	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
,	O
wild	O
onion	B
(	O
Hymenocallis	B
tubiflora	I
)	O
,	O
pepper	O
(	O
Capsicum	O
spp	O
.	O
)	O

tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
,	O
black	B
sage	I
(	O
Cordia	B
curassavica	I
)	O
,	O
shadon	B
beni	I
(	O
Eryngium	B
foetidium	I
)	O
,	O
lemongrass	B
(	O
Cymbopogon	B
citratus	I
)	O
and	O
nutmeg	B
(	O
Myristica	B
fragrans	I
)	O
were	O
the	O
more	O
popular	O
traditional	O
indigenous	O
West	O
Indian	O
medicinal	O
plants	O
used	O
.	O

Two	O
patients	O
reported	O
using	O
marijuana	O
(	O
leaves	O
and	O
roots	O
)	O
.	O

Herbs	O
of	O
European	O
and	O
North	O
American	O
origin	O
,	O
identified	O
as	O
Echinacea	O
(	O
Echinacea	B
purpurea	I
)	O
,	O
Golden	B
Seal	I
(	O
Hydrastis	B
canadensis	I
)	O
and	O
Chamomile	B
(	O
Matricaria	B
chamomilla	I
)	O
were	O
less	O
frequently	O
used	O
.	O

Five	O
patients	O
reported	O
using	O
trade	O
name	O
imported	O
tablets	O
for	O
asthma	O
.	O

Effect	O
of	O
income	O
and	O
education	O
on	O
the	O
use	O
of	O
herbs	O
Patients	O
using	O
easily	O
accessible	O
herbs	O
such	O
as	O
ginger	B
(	O
Zingiber	B
officinale	I
)	O
and	O
aloes	O
(	O
Aloe	B
vera	I
)	O
,	O
and	O
traditional	O
indigenous	O
medicinal	O
herbs	O
such	O
as	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
and	O
tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
were	O
more	O
likely	O
to	O
be	O
earning	O
less	O
than	O
US$	O
12,000	O
,	O
Table	O
7	O
.	O

Herbs	O
of	O
European	O
or	O
North	O
American	O
origin	O
(	O
Echinacea	B
purpurea	I
and	O
Matricaria	B
chamomilla	I
)	O
were	O
more	O
likely	O
to	O
be	O
used	O
by	O
patients	O
earning	O
in	O
excess	O
of	O
US$	O
12,000	O
per	O
annum	O
.	O

Income	O
did	O
not	O
affect	O
the	O
use	O
of	O
either	O
garlic	B
or	O
cocoa	O
onion	B
.	O

Aloes	O
(	O
Aloe	B
vera	I
)	O
,	O
tulsi	B
(	O
Ocimum	B
gratissimum	I
)	O
and	O
golden	O
seal	O
were	O
preferred	O
in	O
patients	O
with	O
at	O
least	O
twelve	O
years	O
of	O
formal	O
education	O
,	O
Table	O
7	O
.	O

Garlic	B
and	O
Echinacea	B
were	O
the	O
preferred	O
herbal	O
medicines	O
in	O
patients	O
with	O
more	O
than	O
twelve	O
years	O
formal	O
education	O
.	O

Educational	O
level	O
did	O
not	O
affect	O
the	O
patients	O
'	O
decision	O
to	O
use	O
shandileer	B
(	O
Leonotis	B
nepetifolia	I
)	O
,	O
wild	O
onion	B
(	O
Hymenocallis	B
tubiflora	I
)	O
or	O
ginger	B
(	O
Zingibe	B
officinale	I
)	O
.	O

Discussion	O
This	O
is	O
the	O
first	O
study	O
of	O
its	O
kind	O
in	O
the	O
Caribbean	O
to	O
assess	O
the	O
use	O
of	O
medicinal	O
herbs	O
by	O
asthmatic	O
patients	O
attending	O
a	O
specialty	O
care	O
clinic	O
.	O

The	O
findings	O
of	O
this	O
study	O
are	O
instructive	O
as	O
the	O
use	O
of	O
medicinal	O
herbs	O
for	O
self	O
-	O
medication	O
in	O
disease	O
management	O
has	O
far	O
reaching	O
implications	O
on	O
the	O
quality	O
of	O
healthcare	O
delivery	O
[	O
14	O
]	O
.	O

We	O
report	O
a	O
prevalence	O
of	O
30.4	O
%	O
in	O
our	O
patient	O
sample	O
,	O
which	O
is	O
significantly	O
higher	O
than	O
that	O
in	O
the	O
UK	O
,	O
Denmark	O
,	O
Singapore	O
and	O
in	O
the	O
US	O
[	O
15	O
-	O
18	O
]	O
.	O

Most	O
patients	O
using	O
medicinal	O
herbs	O
relied	O
on	O
the	O
advice	O
of	O
relatives	O
and	O
friends	O
as	O
their	O
sole	O
source	O
of	O
information	O
,	O
as	O
were	O
caregivers	O
of	O
children	O
in	O
a	O
US	O
study	O
[	O
19	O
]	O
.	O

We	O
suggest	O
that	O
this	O
information	O
on	O
the	O
use	O
of	O
medicinal	O
plants	O
could	O
have	O
come	O
from	O
traditional	O
/	O
cultural	O
knowledge	O
,	O
anecdotal	O
evidence	O
or	O
from	O
the	O
greater	O
public	O
awareness	O
through	O
information	O
networks	O
such	O
as	O
the	O
internet	O
on	O
the	O
potential	O
medicinal	O
benefits	O
of	O
herbs	O
.	O

Asthma	O
is	O
an	O
emerging	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
and	O
we	O
suggest	O
that	O
the	O
traditional	O
knowledge	O
in	O
this	O
area	O
may	O
be	O
relatively	O
'	O
new	O
'	O
and	O
exist	O
in	O
relation	O
to	O
other	O
diseases	O
affecting	O
the	O
respiratory	O
tract	O
,	O
such	O
as	O
cough	O
,	O
the	O
common	O
cold	O
and	O
the	O
flu	O
.	O

This	O
may	O
be	O
one	O
of	O
the	O
reasons	O
for	O
the	O
low	O
prevalence	O
of	O
use	O
of	O
herbs	O
in	O
elderly	O
asthmatic	O
patients	O
,	O
as	O
a	O
strong	O
traditional	O
knowledge	O
may	O
not	O
have	O
existed	O
.	O

We	O
expected	O
a	O
higher	O
prevalence	O
of	O
herbal	O
use	O
in	O
individuals	O
living	O
in	O
rural	O
areas	O
as	O
these	O
districts	O
are	O
depots	O
for	O
traditional	O
knowledge	O
as	O
was	O
reported	O
in	O
Jamaica	O
where	O
rural	O
respondents	O
used	O
a	O
larger	O
variety	O
of	O
herbs	O
than	O
those	O
living	O
in	O
urban	O
areas	O
[	O
10	O
]	O
.	O

As	O
suggested	O
earlier	O
,	O
we	O
suspect	O
that	O
due	O
to	O
the	O
recent	O
emergence	O
of	O
asthma	O
as	O
a	O
chronic	O
disease	O
in	O
the	O
Caribbean	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
traditional	O
knowledge	O
in	O
the	O
management	O
of	O
this	O
disease	O
is	O
not	O
strong	O
and	O
our	O
results	O
are	O
indicative	O
of	O
this	O
.	O

We	O
suspected	O
that	O
employment	O
status	O
could	O
have	O
predicted	O
the	O
use	O
of	O
herbs	O
,	O
however	O
,	O
this	O
was	O
not	O
the	O
case	O
in	O
our	O
study	O
sample	O
.	O

Unemployed	O
patients	O
did	O
not	O
improvise	O
more	O
in	O
their	O
use	O
of	O
herbal	O
remedies	O
than	O
those	O
in	O
other	O
income	O
groups	O
,	O
even	O
though	O
most	O
of	O
the	O
herbs	O
used	O
were	O
relatively	O
common	O
,	O
readily	O
available	O
and	O
cheap	O
.	O

The	O
low	O
socioeconomic	O
status	O
of	O
the	O
majority	O
of	O
the	O
sample	O
may	O
have	O
prohibited	O
both	O
consultation	O
with	O
qualified	O
herbalists	O
and	O
the	O
purchase	O
of	O
imported	O
,	O
processed	O
herbs	O
that	O
would	O
have	O
incurred	O
additional	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
to	O
the	O
patient	O
.	O

What	O
we	O
noted	O
was	O
that	O
there	O
was	O
no	O
difference	O
in	O
the	O
use	O
of	O
herbs	O
across	O
the	O
income	O
ranges	O
and	O
that	O
in	O
fact	O
,	O
patients	O
earning	O
relatively	O
modest	O
annual	O
incomes	O
between	O
$	O
US12,000	O
and	O
$	O
US19,999	O
were	O
most	O
likely	O
to	O
use	O
herbs	O
,	O
although	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

Attaining	O
a	O
higher	O
education	O
positively	O
influence	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

We	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
traditional	O
knowledge	O
regarding	O
the	O
medicinal	O
use	O
of	O
herbs	O
for	O
asthma	O
,	O
a	O
higher	O
educational	O
level	O
may	O
predispose	O
an	O
individual	O
to	O
greater	O
access	O
to	O
general	O
knowledge	O
,	O
especially	O
with	O
greater	O
exposure	O
to	O
the	O
internet	O
and	O
other	O
sources	O
of	O
information	O
,	O
and	O
this	O
could	O
be	O
a	O
factor	O
in	O
positively	O
influencing	O
the	O
individual	O
's	O
decision	O
to	O
use	O
medicinal	O
herbs	O
.	O

The	O
availability	O
of	O
scientific	O
evidence	O
-	O
based	O
information	O
on	O
the	O
efficacy	O
of	O
herbs	O
for	O
diverse	O
healthcare	O
problems	O
may	O
be	O
particularly	O
significant	O
in	O
patients	O
with	O
the	O
resources	O
to	O
avail	O
themselves	O
to	O
such	O
information	O
,	O
particularly	O
those	O
with	O
higher	O
educational	O
and	O
income	O
levels	O
.	O

This	O
is	O
particularly	O
true	O
for	O
garlic	B
and	O
Echinacea	B
,	O
which	O
have	O
been	O
extensively	O
researched	O
and	O
furthermore	O
patients	O
with	O
higher	O
educational	O
and	O
income	O
levels	O
would	O
be	O
more	O
likely	O
be	O
at	O
an	O
advantage	O
to	O
access	O
information	O
via	O
literature	O
or	O
on	O
the	O
world	O
wide	O
web	O
regarding	O
the	O
use	O
of	O
these	O
medicinal	O
plants	O
.	O

Patients	O
using	O
imported	O
,	O
processed	O
,	O
and	O
obviously	O
more	O
expensive	O
herbal	O
medications	O
were	O
on	O
the	O
higher	O
end	O
of	O
the	O
socioeconomic	O
scale	O
and	O
were	O
more	O
likely	O
to	O
afford	O
these	O
medications	O
.	O

It	O
was	O
also	O
observed	O
that	O
garlic	B
and	O
Echinacea	B
were	O
the	O
herbs	O
of	O
choice	O
in	O
patients	O
with	O
higher	O
educational	O
levels	O
.	O

These	O
herbs	O
have	O
a	O
long	O
tradition	O
of	O
use	O
and	O
are	O
widely	O
researched	O
in	O
Europe	O
and	O
North	O
America	O
.	O

The	O
traditional	O
use	O
and	O
strong	O
scientific	O
evidence	O
to	O
support	O
their	O
therapeutic	O
efficacy	O
could	O
be	O
important	O
factors	O
influencing	O
the	O
patient	O
's	O
decision	O
.	O

It	O
has	O
been	O
suggested	O
elsewhere	O
that	O
patients	O
with	O
higher	O
educational	O
levels	O
also	O
tend	O
be	O
more	O
involved	O
in	O
the	O
management	O
of	O
their	O
health	O
;	O
they	O
tend	O
to	O
self	O
-	O
medicate	O
or	O
even	O
suggest	O
to	O
their	O
physicians	O
the	O
course	O
of	O
therapy	O
.	O

Although	O
one	O
in	O
five	O
patients	O
using	O
medicinal	O
herbs	O
stated	O
that	O
""""	O
conventional	O
medicines	O
were	O
not	O
working	O
""""	O
as	O
the	O
reason	O
for	O
using	O
this	O
alternative	O
healthcare	O
modality	O
,	O
we	O
noted	O
that	O
asthma	O
severity	O
does	O
not	O
affect	O
the	O
decision	O
to	O
use	O
herbs	O
.	O

In	O
previous	O
studies	O
,	O
poor	O
management	O
was	O
associated	O
with	O
non	O
-	O
compliance	O
with	O
prescribed	O
pharmacotherapy	O
and	O
poor	O
inhaler	O
technique	O
[	O
5,6	O
]	O
.	O

The	O
backyard	O
and	O
home	O
garden	O
were	O
major	O
sources	O
of	O
readily	O
available	O
herbs	O
such	O
as	O
aloes	O
,	O
shadon	B
beni	I
and	O
lemongrass	B
.	O

Wild	O
growing	O
'	O
weeds	O
'	O
such	O
as	O
shandileer	B
,	O
tulsi	B
,	O
cocoa	O
onion	B
and	O
black	B
sage	I
were	O
also	O
identified	O
.	O

The	O
supermarket	O
was	O
a	O
major	O
source	O
of	O
inexpensive	O
common	O
medicinal	O
herbs	O
such	O
as	O
garlic	B
,	O
ginger	B
and	O
nutmeg	B
.	O

The	O
identification	O
of	O
these	O
medicinal	O
herbs	O
provides	O
an	O
opportunity	O
to	O
investigate	O
West	O
Indian	O
plants	O
used	O
to	O
treat	O
asthma	O
to	O
determine	O
whether	O
they	O
possess	O
pharmacological	O
properties	O
.	O

Scientific	O
investigations	O
have	O
shown	O
that	O
some	O
of	O
these	O
herbs	O
possess	O
pharmacological	O
and	O
anti	O
-	O
inflammatory	O
properties	O
,	O
and	O
these	O
may	O
be	O
useful	O
in	O
suppressing	O
the	O
characteristic	O
exaggerated	O
immune	O
response	O
in	O
asthma	O
[	O
20	O
-	O
24	O
]	O
.	O

Pepper	O
and	O
bayleaf	B
have	O
also	O
been	O
shown	O
to	O
exhibit	O
anti	O
-	O
inflammatory	O
properties	O
[	O
[	O
25,26	O
]	O
27	O
]	O
.	O

There	O
is	O
an	O
imperative	O
to	O
commence	O
scientific	O
investigations	O
on	O
traditional	O
West	O
Indian	O
medicinal	O
plants	O
to	O
determine	O
their	O
therapeutic	O
efficacy	O
and	O
safety	O
.	O

The	O
survey	O
instrument	O
specifically	O
asked	O
questions	O
on	O
the	O
use	O
of	O
medicinal	O
herbs	O
in	O
asthma	O
and	O
did	O
not	O
inquire	O
about	O
the	O
use	O
of	O
herbs	O
as	O
customary	O
teas	O
or	O
tonics	O
.	O

We	O
therefore	O
did	O
not	O
determine	O
lifetime	O
prevalence	O
for	O
the	O
use	O
of	O
herbs	O
in	O
our	O
patient	O
sample	O
,	O
but	O
we	O
suppose	O
that	O
had	O
this	O
been	O
included	O
that	O
there	O
might	O
have	O
been	O
a	O
prevalence	O
similar	O
to	O
those	O
reported	O
in	O
the	O
Jamaica	O
[	O
10,11	O
]	O
and	O
Trinidad	O
[	O
13	O
]	O
surveys	O
.	O

The	O
survey	O
was	O
also	O
limited	O
in	O
that	O
by	O
electing	O
to	O
conduct	O
the	O
study	O
at	O
a	O
public	O
health	O
facility	O
we	O
obviously	O
had	O
a	O
bias	O
towards	O
patients	O
at	O
the	O
lower	O
rung	O
of	O
the	O
socioeconomic	O
ladder	O
,	O
with	O
lower	O
income	O
and	O
educational	O
status	O
.	O

As	O
a	O
consequence	O
,	O
the	O
results	O
reflected	O
patients	O
from	O
this	O
demographic	O
background	O
.	O

We	O
may	O
have	O
expected	O
a	O
different	O
outcome	O
in	O
asthmatic	O
patients	O
attending	O
private	O
institutions	O
,	O
where	O
their	O
characteristics	O
would	O
have	O
been	O
slightly	O
different	O
,	O
as	O
we	O
noted	O
that	O
even	O
in	O
our	O
sample	O
the	O
small	O
number	O
of	O
persons	O
with	O
higher	O
income	O
and	O
educational	O
status	O
tended	O
to	O
use	O
more	O
medicinal	O
herbs	O
for	O
symptomatic	O
relief	O
.	O

We	O
did	O
not	O
assess	O
whether	O
patients	O
informed	O
their	O
attending	O
physician	O
at	O
the	O
clinic	O
about	O
their	O
use	O
of	O
herbs	O
or	O
determined	O
whether	O
the	O
knowledge	O
or	O
attitudes	O
of	O
these	O
physicians	O
regarding	O
the	O
use	O
of	O
herbs	O
influenced	O
the	O
patients	O
'	O
decision	O
to	O
use	O
herbs	O
.	O

The	O
study	O
was	O
also	O
limited	O
in	O
that	O
we	O
did	O
not	O
ascertain	O
the	O
out	O
-	O
of	O
-	O
pocket	O
expense	O
for	O
herbal	O
remedies	O
by	O
patients	O
,	O
although	O
most	O
stated	O
that	O
herbal	O
medicines	O
(	O
which	O
we	O
supposed	O
were	O
processed	O
,	O
imported	O
products	O
)	O
were	O
more	O
expensive	O
than	O
conventional	O
medicines	O
.	O

We	O
assumed	O
that	O
an	O
additional	O
expense	O
would	O
have	O
only	O
been	O
incurred	O
by	O
those	O
patients	O
purchasing	O
processed	O
,	O
imported	O
herbs	O
obtained	O
from	O
a	O
herbalist	O
,	O
herbal	O
shop	O
or	O
pharmacy	O
(	O
24.1	O
%	O
)	O
and	O
who	O
actually	O
consulted	O
a	O
herbalist	O
(	O
10.3	O
%	O
)	O
.	O

We	O
also	O
reasoned	O
that	O
since	O
all	O
the	O
other	O
herbs	O
used	O
were	O
inexpensive	O
and	O
available	O
from	O
either	O
the	O
backyard	O
garden	O
or	O
supermarket	O
(	O
58.6	O
%	O
)	O
that	O
the	O
cost	O
to	O
patients	O
selecting	O
these	O
remedies	O
was	O
minimal	O
.	O

Conclusions	O
The	O
findings	O
of	O
this	O
study	O
are	O
important	O
in	O
that	O
local	O
medicinal	O
plants	O
in	O
Trinidad	O
have	O
been	O
identified	O
in	O
the	O
self	O
-	O
management	O
of	O
asthma	O
in	O
a	O
significant	O
number	O
of	O
patients	O
attending	O
the	O
specialty	O
clinic	O
.	O

These	O
identified	O
herbs	O
can	O
now	O
be	O
targeted	O
for	O
scientific	O
investigation	O
to	O
determine	O
whether	O
their	O
pharmacological	O
efficacy	O
will	O
assist	O
in	O
the	O
development	O
of	O
viable	O
healthcare	O
alternatives	O
in	O
a	O
developing	O
country	O
.	O

These	O
findings	O
are	O
also	O
important	O
for	O
policymakers	O
in	O
the	O
health	O
sector	O
who	O
are	O
given	O
the	O
mandate	O
to	O
regulate	O
issues	O
pertaining	O
to	O
the	O
public	O
's	O
health	O
.	O

We	O
are	O
also	O
becoming	O
more	O
aware	O
of	O
the	O
potential	O
for	O
critical	O
interplay	O
between	O
herbs	O
and	O
drugs	O
when	O
taken	O
concomitantly	O
to	O
produce	O
life	O
-	O
threatening	O
interactions	O
.	O

Since	O
herbs	O
are	O
here	O
to	O
stay	O
and	O
patients	O
will	O
continue	O
to	O
self	O
-	O
medicate	O
with	O
increasing	O
frequency	O
,	O
it	O
is	O
imperative	O
that	O
healthcare	O
providers	O
become	O
more	O
knowledgeable	O
on	O
this	O
modality	O
and	O
keep	O
abreast	O
with	O
the	O
latest	O
developments	O
in	O
herbal	O
therapy	O
.	O

Competing	O
interests	O
The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O
YNC	O
was	O
the	O
P.I.	O
in	O
this	O
study	O
.	O

He	O
was	O
responsible	O
for	O
the	O
study	O
concept	O
,	O
development	O
of	O
methodology	O
,	O
coordinating	O
the	O
research	O
activities	O
,	O
analyzing	O
the	O
data	O
,	O
and	O
writing	O
the	O
manuscript	O
.	O

AFW	O
was	O
responsible	O
for	O
data	O
input	O
and	O
analysis	O
.	O

DA	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
and	O
presentation	O
at	O
regional	O
conference	O
.	O

RC	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
,	O
data	O
input	O
and	O
analysis	O
.	O

NW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

RM	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

OS	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

DW	O
was	O
involved	O
in	O
methodological	O
development	O
,	O
data	O
collection	O
and	O
input	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Pre	O
-	O
publication	O
history	O
The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

Molecular	O
cloning	O
and	O
biochemical	O
characterization	O
of	O
a	O
truncated	O
,	O
secreted	O
member	O
of	O
the	O
human	B
family	O
of	O
Ca2	O
+	O
-activated	O
Cl-	O
channels	O
.	O

A	O
novel	O
family	O
of	O
chloride	O
channel	O
proteins	O
has	O
recently	O
been	O
discovered	O
including	O
two	O
bovine	B
(	O
Lu	O
-	O
ECAM-1	O
,	O
bCLCA1	O
)	O
,	O
one	O
murine	B
(	O
mCLCA1	O
)	O
,	O
and	O
two	O
human	B
(	O
hCLCA1	O
and	O
hCLCA2	O
)	O
members	O
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	O
,	O
expression	O
,	O
and	O
molecular	O
characterization	O
of	O
a	O
truncated	O
human	B
homolog	O
,	O
tentatively	O
named	O
hCLCA3	O
.	O

It	O
was	O
cloned	O
from	O
a	O
human	B
spleen	O
cDNA	O
library	O
and	O
is	O
expressed	O
in	O
numerous	O
tissues	O
including	O
lung	O
,	O
trachea	O
,	O
spleen	O
,	O
thymus	O
,	O
and	O
mammary	O
gland	O
as	O
determined	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
.	O

Unlike	O
all	O
previously	O
known	O
CLCA	O
family	O
members	O
which	O
consistently	O
encode	O
an	O
approximately	O
125-kDa	O
transmembrane	O
protein	O
that	O
is	O
cleaved	O
to	O
form	O
a	O
heterodimer	O
of	O
two	O
proteins	O
of	O
approximately	O
90	O
and	O
35	O
kDa	O
,	O
the	O
3.6-kb	O
hCLCA3	O
mRNA	O
encodes	O
a	O
37-kDa	O
glycoprotein	O
that	O
corresponds	O
to	O
the	O
N	O
-	O
terminal	O
extracellular	O
domain	O
of	O
its	O
homologs	O
.	O

Moreover	O
,	O
when	O
expressed	O
in	O
human	B
embryonic	O
kidney	O
293	O
or	O
Chinese	O
hamster	O
ovary	O
cells	O
,	O
this	O
37-kDa	O
glycoprotein	O
is	O
secreted	O
into	O
the	O
culture	O
supernatant	O
.	O

These	O
observations	O
suggest	O
that	O
hCLCA3	O
is	O
a	O
structurally	O
divergent	O
member	O
of	O
the	O
CLCA	O
family	O
of	O
proteins	O
and	O
that	O
it	O
does	O
not	O
act	O
as	O
a	O
channel	O
protein	O
but	O
has	O
distinct	O
,	O
yet	O
unidentified	O
functions	O
.	O

Yeast	B
mutants	O
affecting	O
possible	O
quality	O
control	O
of	O
plasma	O
membrane	O
proteins	O
.	O

Mutations	O
gef1	O
,	O
stp22	O
,	O
STP26	O
,	O
and	O
STP27	O
in	O
Saccharomyces	B
cerevisiae	I
were	O
identified	O
as	O
suppressors	O
of	O
the	O
temperature	O
-	O
sensitive	O
alpha	O
-	O
factor	O
receptor	O
(	O
mutation	O
ste2	O
-	O
3	O
)	O
and	O
arginine	O
permease	O
(	O
mutation	O
can1	O
(	O
ts	O
)	O
)	O
.	O

These	O
suppressors	O
inhibited	O
the	O
elimination	O
of	O
misfolded	O
receptors	O
(	O
synthesized	O
at	O
34	O
degrees	O
C	O
)	O
as	O
well	O
as	O
damaged	O
surface	O
receptors	O
(	O
shifted	O
from	O
22	O
to	O
34	O
degrees	O
C	O
)	O
.	O

The	O
stp22	O
mutation	O
(	O
allelic	O
to	O
vps23	O
[	O
M.	O
Babst	O
and	O
S.	O
Emr	O
,	O
personal	O
communication	O
]	O
and	O
the	O
STP26	O
mutation	O
also	O
caused	O
missorting	O
of	O
carboxypeptidase	O
Y	O
,	O
and	O
ste2	O
-	O
3	O
was	O
suppressed	O
by	O
mutations	O
vps1	O
,	O
vps8	O
,	O
vps10	O
,	O
and	O
vps28	O
but	O
not	O
by	O
mutation	O
vps3	O
.	O

In	O
the	O
stp22	O
mutant	O
,	O
both	O
the	O
mutant	O
and	O
the	O
wild	O
-	O
type	O
receptors	O
(	O
tagged	O
with	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]	O
)	O
accumulated	O
within	O
an	O
endosome	O
-	O
like	O
compartment	O
and	O
were	O
excluded	O
from	O
the	O
vacuole	O
.	O

GFP	O
-	O
tagged	O
Stp22p	O
also	O
accumulated	O
in	O
this	O
compartment	O
.	O

Upon	O
reaching	O
the	O
vacuole	O
,	O
cytoplasmic	O
domains	O
of	O
both	O
mutant	O
and	O
wild	O
-	O
type	O
receptors	O
appeared	O
within	O
the	O
vacuolar	O
lumen	O
.	O

Stp22p	O
and	O
Gef1p	O
are	O
similar	O
to	O
tumor	O
susceptibility	O
protein	O
TSG101	O
and	O
voltage	O
-	O
gated	O
chloride	O
channel	O
,	O
respectively	O
.	O

These	O
results	O
identify	O
potential	O
elements	O
of	O
plasma	O
membrane	O
quality	O
control	O
and	O
indicate	O
that	O
cytoplasmic	O
domains	O
of	O
membrane	O
proteins	O
are	O
translocated	O
into	O
the	O
vacuolar	O
lumen	O
.	O

Apg13p	O
and	O
Vac8p	O
are	O
part	O
of	O
a	O
complex	O
of	O
phosphoproteins	O
that	O
are	O
required	O
for	O
cytoplasm	O
to	O
vacuole	O
targeting	O
.	O

We	O
have	O
been	O
studying	O
protein	O
components	O
that	O
function	O
in	O
the	O
cytoplasm	O
to	O
vacuole	O
targeting	O
(	O
Cvt	O
)	O
pathway	O
and	O
the	O
overlapping	O
process	O
of	O
macroautophagy	O
.	O

The	O
Vac8	O
and	O
Apg13	O
proteins	O
are	O
required	O
for	O
the	O
import	O
of	O
aminopeptidase	O
I	O
(	O
API	O
)	O
through	O
the	O
Cvt	O
pathway	O
.	O

We	O
have	O
identified	O
a	O
protein	O
-	O
protein	O
interaction	O
between	O
Vac8p	O
and	O
Apg13p	O
by	O
both	O
two	O
-	O
hybrid	O
and	O
co	O
-	O
immunoprecipitation	O
analysis	O
.	O

Subcellular	O
fractionation	O
of	O
API	O
indicates	O
that	O
Vac8p	O
and	O
Apg13p	O
are	O
involved	O
in	O
the	O
vesicle	O
formation	O
step	O
of	O
the	O
Cvt	O
pathway	O
.	O

Kinetic	O
analysis	O
of	O
the	O
Cvt	O
pathway	O
and	O
autophagy	O
indicates	O
that	O
,	O
although	O
Vac8p	O
is	O
essential	O
for	O
Cvt	O
transport	O
,	O
it	O
is	O
less	O
important	O
for	O
autophagy	O
.	O

In	O
vivo	O
phosphorylation	O
experiments	O
demonstrate	O
that	O
both	O
Vac8p	O
and	O
Apg13p	O
are	O
phosphorylated	O
proteins	O
,	O
and	O
Apg13p	O
phosphorylation	O
is	O
regulated	O
by	O
changing	O
nutrient	O
conditions	O
.	O

Although	O
Apg13p	O
interacts	O
with	O
the	O
serine	O
/	O
threonine	O
kinase	O
Apg1p	O
,	O
this	O
protein	O
is	O
not	O
required	O
for	O
phosphorylation	O
of	O
either	O
Vac8p	O
or	O
Apg13p	O
.	O

Subcellular	O
fractionation	O
experiments	O
indicate	O
that	O
Apg13p	O
and	O
a	O
fraction	O
of	O
Apg1p	O
are	O
membrane	O
-	O
associated	O
.	O

Vac8p	O
and	O
Apg13p	O
may	O
be	O
part	O
of	O
a	O
larger	O
protein	O
complex	O
that	O
includes	O
Apg1p	O
and	O
additional	O
interacting	O
proteins	O
.	O

Together	O
,	O
these	O
components	O
may	O
form	O
a	O
protein	O
complex	O
that	O
regulates	O
the	O
conversion	O
between	O
Cvt	O
transport	O
and	O
autophagy	O
in	O
response	O
to	O
changing	O
nutrient	O
conditions	O
.	O

Mdv1p	O
is	O
a	O
WD	O
repeat	O
protein	O
that	O
interacts	O
with	O
the	O
dynamin	O
-	O
related	O
GTPase	O
,	O
Dnm1p	O
,	O
to	O
trigger	O
mitochondrial	O
division	O
.	O

Mitochondrial	O
fission	O
is	O
mediated	O
by	O
the	O
dynamin	O
-	O
related	O
GTPase	O
,	O
Dnm1p	O
,	O
which	O
assembles	O
on	O
the	O
mitochondrial	O
outer	O
membrane	O
into	O
punctate	O
structures	O
associated	O
with	O
sites	O
of	O
membrane	O
constriction	O
and	O
fission	O
.	O

We	O
have	O
identified	O
additional	O
nuclear	O
genes	O
required	O
for	O
mitochondrial	O
fission	O
,	O
termed	O
MDV	O
(	O
for	O
mitochondrial	O
division	O
)	O
.	O

MDV1	O
encodes	O
a	O
predicted	O
soluble	O
protein	O
,	O
containing	O
a	O
coiled	O
-	O
coil	O
motif	O
and	O
seven	O
COOH	O
-	O
terminal	O
WD	O
repeats	O
.	O

Genetic	O
and	O
two	O
-	O
hybrid	O
analyses	O
indicate	O
that	O
Mdv1p	O
interacts	O
with	O
Dnm1p	O
to	O
mediate	O
mitochondrial	O
fission	O
.	O

In	O
addition	O
,	O
Mdv1p	O
colocalizes	O
with	O
Dnm1p	O
in	O
fission	O
-	O
mediating	O
punctate	O
structures	O
on	O
the	O
mitochondrial	O
outer	O
membrane	O
.	O

Whereas	O
localization	O
of	O
Mdv1p	O
to	O
these	O
structures	O
requires	O
Dnm1p	O
,	O
localization	O
of	O
Mdv1p	O
to	O
mitochondrial	O
membranes	O
does	O
not	O
.	O

This	O
indicates	O
that	O
Mdv1p	O
possesses	O
a	O
Dnm1p	O
-	O
independent	O
mitochondrial	O
targeting	O
signal	O
.	O

Dnm1p	O
-	O
independent	O
targeting	O
of	O
Mdv1p	O
to	O
mitochondria	O
requires	O
MDV2	O
.	O

Our	O
data	O
indicate	O
that	O
MDV2	O
also	O
functions	O
separately	O
to	O
regulate	O
the	O
assembly	O
of	O
Dnm1p	O
into	O
punctate	O
structures	O
.	O

In	O
contrast	O
,	O
Mdv1p	O
is	O
not	O
required	O
for	O
the	O
assembly	O
of	O
Dnm1p	O
,	O
but	O
Dnm1p	O
-	O
containing	O
punctate	O
structures	O
lacking	O
Mdv1p	O
are	O
not	O
able	O
to	O
complete	O
division	O
.	O

Our	O
studies	O
suggest	O
that	O
mitochondrial	O
fission	O
is	O
a	O
multi	O
-	O
step	O
process	O
in	O
which	O
Mdv2p	O
regulates	O
the	O
assembly	O
of	O
Dnm1p	O
into	O
punctate	O
structures	O
and	O
together	O
with	O
Mdv1p	O
functions	O
later	O
during	O
fission	O
to	O
facilitate	O
Dnm1p	O
-	O
dependent	O
mitochondrial	O
membrane	O
constriction	O
and/or	O
division	O
.	O

PEX11alpha	O
is	O
required	O
for	O
peroxisome	O
proliferation	O
in	O
response	O
to	O
4-phenylbutyrate	O
but	O
is	O
dispensable	O
for	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
-	O
mediated	O
peroxisome	O
proliferation	O
.	O

The	O
PEX11	O
peroxisomal	O
membrane	O
proteins	O
promote	O
peroxisome	O
division	O
in	O
multiple	O
eukaryotes	O
.	O

As	O
part	O
of	O
our	O
effort	O
to	O
understand	O
the	O
molecular	O
and	O
physiological	O
functions	O
of	O
PEX11	O
proteins	O
,	O
we	O
disrupted	O
the	O
mouse	B
PEX11alpha	O
gene	O
.	O

Overexpression	O
of	O
PEX11alpha	O
is	O
sufficient	O
to	O
promote	O
peroxisome	O
division	O
,	O
and	O
a	O
class	O
of	O
chemicals	O
known	O
as	O
peroxisome	O
proliferating	O
agents	O
(	O
PPAs	O
)	O
induce	O
the	O
expression	O
of	O
PEX11alpha	O
and	O
promote	O
peroxisome	O
division	O
.	O

These	O
observations	O
led	O
to	O
the	O
hypothesis	O
that	O
PPAs	O
induce	O
peroxisome	O
abundance	O
by	O
enhancing	O
PEX11alpha	O
expression	O
.	O

The	O
phenotypes	O
of	O
PEX11alpha	O
(	O
-	O
/	O
-	O
)	O
mice	B
indicate	O
that	O
this	O
hypothesis	O
remains	O
valid	O
for	O
a	O
novel	O
class	O
of	O
PPAs	O
that	O
act	O
independently	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
(	O
PPARalpha	O
)	O
but	O
is	O
not	O
valid	O
for	O
the	O
classical	O
PPAs	O
that	O
act	O
as	O
activators	O
of	O
PPARalpha	O
.	O

Furthermore	O
,	O
we	O
find	O
that	O
PEX11alpha	O
(	O
-	O
/	O
-	O
)	O
mice	B
have	O
normal	O
peroxisome	O
abundance	O
and	O
that	O
cells	O
lacking	O
both	O
PEX11alpha	O
and	O
PEX11beta	O
,	O
a	O
second	O
mammalian	O
PEX11	O
gene	O
,	O
have	O
no	O
greater	O
defect	O
in	O
peroxisome	O
abundance	O
than	O
do	O
cells	O
lacking	O
only	O
PEX11beta	O
.	O

Finally	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
third	O
mammalian	O
PEX11	O
gene	O
,	O
PEX11gamma	O
,	O
and	O
show	O
that	O
it	O
too	O
encodes	O
a	O
peroxisomal	O
protein	O
.	O

Functional	O
proteomic	O
analysis	O
of	O
human	O
nucleolus	O
.	O

The	O
notion	O
of	O
a	O
""""	O
plurifunctional	O
""""	O
nucleolus	O
is	O
now	O
well	O
established	O
.	O

However	O
,	O
molecular	O
mechanisms	O
underlying	O
the	O
biological	O
processes	O
occurring	O
within	O
this	O
nuclear	O
domain	O
remain	O
only	O
partially	O
understood	O
.	O

As	O
a	O
first	O
step	O
in	O
elucidating	O
these	O
mechanisms	O
we	O
have	O
carried	O
out	O
a	O
proteomic	O
analysis	O
to	O
draw	O
up	O
a	O
list	O
of	O
proteins	O
present	O
within	O
nucleoli	O
of	O
HeLa	O
cells	O
.	O

This	O
analysis	O
allowed	O
the	O
identification	O
of	O
213	O
different	O
nucleolar	O
proteins	O
.	O

This	O
catalog	O
complements	O
that	O
of	O
the	O
271	O
proteins	O
obtained	O
recently	O
by	O
others	O
,	O
giving	O
a	O
total	O
of	O
approximately	O
350	O
different	O
nucleolar	O
proteins	O
.	O

Functional	O
classification	O
of	O
these	O
proteins	O
allowed	O
outlining	O
several	O
biological	O
processes	O
taking	O
place	O
within	O
nucleoli	O
.	O

Bioinformatic	O
analyses	O
permitted	O
the	O
assignment	O
of	O
hypothetical	O
functions	O
for	O
43	O
proteins	O
for	O
which	O
no	O
functional	O
information	O
is	O
available	O
.	O

Notably	O
,	O
a	O
role	O
in	O
ribosome	O
biogenesis	O
was	O
proposed	O
for	O
31	O
proteins	O
.	O

More	O
generally	O
,	O
this	O
functional	O
classification	O
reinforces	O
the	O
plurifunctional	O
nature	O
of	O
nucleoli	O
and	O
provides	O
convincing	O
evidence	O
that	O
nucleoli	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
gene	O
expression	O
.	O

Finally	O
,	O
this	O
analysis	O
supports	O
the	O
recent	O
demonstration	O
of	O
a	O
coupling	O
of	O
transcription	O
and	O
translation	O
in	O
higher	O
eukaryotes	O
.	O

Genomic	O
structure	O
,	O
gene	O
expression	O
,	O
and	O
promoter	O
analysis	O
of	O
human	B
multidrug	O
resistance	O
-	O
associated	O
protein	O
7	O
.	O

The	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
(	O
MRP	O
)	O
subfamily	O
transporters	O
associated	O
with	O
anticancer	O
drug	O
efflux	O
are	O
attributed	O
to	O
the	O
multidrug	O
-	O
resistance	O
of	O
cancer	O
cells	O
.	O

The	O
genomic	O
organization	O
of	O
human	B
multidrug	O
resistance	O
-	O
associated	O
protein	O
7	O
(	O
MRP7	O
)	O
was	O
identified	O
.	O

The	O
human	B
MRP7	O
gene	O
,	O
consisting	O
of	O
22	O
exons	O
and	O
21	O
introns	O
,	O
greatly	O
differs	O
from	O
other	O
members	O
of	O
the	O
human	B
MRP	O
subfamily	O
.	O

A	O
splicing	O
variant	O
of	O
human	B
MRP7	O
,	O
MRP7A	O
,	O
expressed	O
in	O
most	O
human	B
tissues	O
,	O
was	O
also	O
characterized	O
.	O

The	O
1.93-kb	O
promoter	O
region	O
of	O
MRP7	O
was	O
isolated	O
and	O
shown	O
to	O
support	O
luciferase	O
activity	O
at	O
a	O
level	O
4-	O
to	O
5-fold	O
greater	O
than	O
that	O
of	O
the	O
SV40	O
promoter	O
.	O

Basal	O
MRP7	O
gene	O
expression	O
was	O
regulated	O
by	O
2	O
regions	O
in	O
the	O
5'-flanking	O
region	O
at	O
-1,780	O
-	O
1,287	O
bp	O
,	O
and	O
at	O
-611	O
to	O
-208	O
bp	O
.	O

In	O
Madin	O
-	O
Darby	O
canine	O
kidney	O
(	O
MDCK	O
)	O
cells	O
,	O
MRP7	O
promoter	O
activity	O
was	O
increased	O
by	O
226	O
%	O
by	O
genotoxic	O
2-acetylaminofluorene	O
and	O
347	O
%	O
by	O
the	O
histone	O
deacetylase	O
inhibitor	O
,	O
trichostatin	O
A.	O
The	O
protein	O
was	O
expressed	O
in	O
the	O
membrane	O
fraction	O
of	O
transfected	O
MDCK	O
cells	O
.	O

YMR313c	O
/	O
TGL3	O
encodes	O
a	O
novel	O
triacylglycerol	O
lipase	O
located	O
in	O
lipid	O
particles	O
of	O
Saccharomyces	B
cerevisiae	I
.	O

Previous	O
work	O
from	O
our	O
laboratory	O
(	O
Athenstaedt	O
,	O
K.	O
,	O
Zweytick	O
,	O
D.	O
,	O
Jandrositz	O
,	O
A.	O
,	O
Kohlwein	O
,	O
S.	O
D.	O
,	O
and	O
Daum	O
,	O
G.	O
(	O
1999	O
)	O
J.	O
Bacteriol	O
.	O

181	O
,	O
6441	O
-	O
6448	O
)	O
showed	O
that	O
the	O
gene	O
product	O
of	O
YMR313c	O
(	O
named	O
Tgl3p	O
)	O
is	O
a	O
component	O
of	O
yeast	B
lipid	O
particles	O
,	O
and	O
deletion	O
of	O
this	O
gene	O
led	O
to	O
an	O
increase	O
in	O
the	O
cellular	O
level	O
of	O
triacylglycerols	O
(	O
TAG	O
)	O
.	O

These	O
observations	O
suggested	O
that	O
TGL3	O
may	O
encode	O
a	O
TAG	O
lipase	O
of	O
Saccharomyces	B
cerevisiae	I
.	O

Here	O
we	O
demonstrate	O
by	O
cell	O
fractionation	O
and	O
by	O
microscopic	O
inspection	O
of	O
a	O
strain	O
bearing	O
a	O
Tgl3p	O
-	O
GFP	O
hybrid	O
that	O
this	O
polypeptide	O
is	O
highly	O
enriched	O
in	O
the	O
lipid	O
particle	O
fraction	O
but	O
virtually	O
absent	O
from	O
other	O
organelles	O
.	O

The	O
entire	O
TAG	O
lipase	O
activity	O
of	O
lipid	O
particles	O
is	O
attributed	O
to	O
Tgl3p	O
,	O
because	O
the	O
activity	O
in	O
this	O
organelle	O
is	O
completely	O
absent	O
in	O
a	O
Deltatgl3	O
deletion	O
mutant	O
,	O
whereas	O
it	O
is	O
significantly	O
enhanced	O
in	O
a	O
strain	O
overexpressing	O
Tgl3p	O
.	O

A	O
His6-tagged	O
Tgl3p	O
hybrid	O
purified	O
close	O
to	O
homogeneity	O
from	O
a	O
yeast	B
strain	O
overexpressing	O
this	O
fusion	O
protein	O
exhibited	O
high	O
TAG	O
lipase	O
activity	O
.	O

Most	O
importantly	O
,	O
experiments	O
in	O
vivo	O
using	O
the	O
fatty	O
acid	O
synthesis	O
inhibitor	O
cerulenin	O
demonstrated	O
that	O
deletion	O
of	O
TGL3	O
resulted	O
in	O
a	O
decreased	O
mobilization	O
of	O
TAG	O
from	O
lipid	O
particles	O
.	O

The	O
amino	O
acid	O
sequence	O
deduced	O
from	O
the	O
open	O
reading	O
frame	O
YMR313c	O
contains	O
the	O
consensus	O
sequence	O
motif	O
GXSXG	O
typical	O
for	O
lipolytic	O
enzymes	O
.	O

Otherwise	O
,	O
Tgl3p	O
has	O
no	O
significant	O
sequence	O
homology	O
to	O
other	O
lipases	O
identified	O
so	O
far	O
.	O

In	O
summary	O
,	O
our	O
data	O
identified	O
Tgl3p	O
as	O
a	O
novel	O
yeast	B
TAG	O
lipase	O
at	O
the	O
molecular	O
level	O
and	O
by	O
function	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Biochemical	O
features	O
of	O
the	O
MHC	O
-	O
related	O
protein	O
1	O
consistent	O
with	O
an	O
immunological	O
function	O
.	O

MHC	O
-	O
related	O
protein	O
(	O
MR	O
)	O
1	O
is	O
an	O
MHC	O
class	O
I	O
-	O
related	O
molecule	O
encoded	O
on	O
chromosome	O
1	O
that	O
is	O
highly	O
conserved	O
among	O
mammals	O
and	O
is	O
more	O
closely	O
related	O
to	O
classical	O
class	O
I	O
molecules	O
than	O
are	O
other	O
nonclassical	O
class	O
I	O
family	O
members	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
both	O
mouse	B
and	O
human	B
MR1	O
molecules	O
can	O
associate	O
with	O
the	O
peptide	O
-	O
loading	O
complex	O
and	O
can	O
be	O
detected	O
at	O
low	O
levels	O
at	O
the	O
surface	O
of	O
transfected	O
cells	O
.	O

We	O
also	O
report	O
the	O
production	O
of	O
recombinant	O
human	B
MR1	O
molecules	O
in	O
insect	O
cells	O
using	O
highly	O
supplemented	O
media	O
and	O
provide	O
evidence	O
that	O
the	O
MR1	O
H	O
chain	O
can	O
assume	O
a	O
folded	O
conformation	O
and	O
is	O
stoichiometrically	O
associated	O
with	O
beta	O
(	O
2	O
)	O
-microglobulin	O
,	O
similar	O
to	O
class	O
I	O
molecules	O
.	O

Cumulatively	O
,	O
these	O
findings	O
demonstrate	O
that	O
surface	O
expression	O
of	O
MR1	O
is	O
possible	O
but	O
may	O
be	O
limited	O
by	O
a	O
specific	O
ligand	O
or	O
associated	O
molecule	O
.	O

BRL1	O
and	O
BRL3	O
are	O
novel	O
brassinosteroid	O
receptors	O
that	O
function	O
in	O
vascular	O
differentiation	O
in	O
Arabidopsis	B
.	O

Plant	O
steroid	O
hormones	O
,	O
brassinosteroids	O
(	O
BRs	O
)	O
,	O
are	O
perceived	O
by	O
the	O
plasma	O
membrane	O
-	O
localized	O
leucine	O
-	O
rich	O
-	O
repeat	O
-	O
receptor	O
kinase	O
BRI1	O
.	O

Based	O
on	O
sequence	O
similarity	O
,	O
we	O
have	O
identified	O
three	O
members	O
of	O
the	O
BRI1	O
family	O
,	O
named	O
BRL1	O
,	O
BRL2	O
and	O
BRL3	O
.	O

BRL1	O
and	O
BRL3	O
,	O
but	O
not	O
BRL2	O
,	O
encode	O
functional	O
BR	O
receptors	O
that	O
bind	O
brassinolide	O
,	O
the	O
most	O
active	O
BR	O
,	O
with	O
high	O
affinity	O
.	O

In	O
agreement	O
,	O
only	O
BRL1	O
and	O
BRL3	O
can	O
rescue	O
bri1	O
mutants	O
when	O
expressed	O
under	O
the	O
control	O
of	O
the	O
BRI1	O
promoter	O
.	O

While	O
BRI1	O
is	O
ubiquitously	O
expressed	O
in	O
growing	O
cells	O
,	O
the	O
expression	O
of	O
BRL1	O
and	O
BRL3	O
is	O
restricted	O
to	O
non	O
-	O
overlapping	O
subsets	O
of	O
vascular	O
cells	O
.	O

Loss	O
-	O
of	O
-	O
function	O
of	O
brl1	O
causes	O
abnormal	O
phloem	O
:	O
xylem	O
differentiation	O
ratios	O
and	O
enhances	O
the	O
vascular	O
defects	O
of	O
a	O
weak	O
bri1	O
mutant	O
.	O

bri1	O
brl1	O
brl3	O
triple	O
mutants	O
enhance	O
bri1	O
dwarfism	O
and	O
also	O
exhibit	O
abnormal	O
vascular	O
differentiation	O
.	O

Thus	O
,	O
Arabidopsis	B
contains	O
a	O
small	O
number	O
of	O
BR	O
receptors	O
that	O
have	O
specific	O
functions	O
in	O
cell	O
growth	O
and	O
vascular	O
differentiation	O
.	O

Molecular	O
cloning	O
,	O
expression	O
and	O
immunolocalization	O
of	O
a	O
novel	O
human	B
cementum	O
-	O
derived	O
protein	O
(	O
CP-23	O
)	O
.	O

Cementum	O
is	O
a	O
unique	O
mineralized	O
connective	O
tissue	O
that	O
covers	O
the	O
root	O
surfaces	O
of	O
the	O
teeth	O
.	O

The	O
cementum	O
is	O
critical	O
for	O
appropriate	O
maturation	O
of	O
the	O
periodontium	O
,	O
both	O
during	O
development	O
as	O
well	O
as	O
that	O
associated	O
with	O
regeneration	O
of	O
periodontal	O
tissues	O
,	O
IU	O
;	O
however	O
,	O
one	O
major	O
impediment	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
that	O
regulate	O
periodontal	O
regeneration	O
is	O
the	O
lack	O
of	O
cementum	O
markers	O
.	O

Here	O
we	O
report	O
on	O
the	O
identification	O
and	O
characterization	O
of	O
one	O
such	O
differentially	O
human	B
expressed	O
gene	O
,	O
termed	O
""""	O
cementum	O
protein-23	O
""""	O
(	O
CP-23	O
)	O
that	O
appears	O
to	O
be	O
periodontal	O
ligament	O
and	O
cementum	O
-	O
specific	O
.	O

We	O
screened	O
human	B
cementum	O
tumor	O
-	O
derived	O
cDNA	O
libraries	O
by	O
transient	O
expression	O
in	O
COS-7	O
cells	O
and	O
""""	O
panning	O
""""	O
with	O
a	O
rabbit	B
polyclonal	O
antibody	O
against	O
a	O
cementoblastoma	O
conditioned	O
media	O
-	O
derived	O
protein	O
(	O
CP	O
)	O
.	O

One	O
isolated	O
cDNA	O
,	O
CP-23	O
,	O
was	O
expressed	O
in	O
E.	B
coli	I
and	O
polyclonal	O
antibodies	O
against	O
the	O
recombinant	O
human	B
CP-23	O
were	O
produced	O
.	O

Expression	O
of	O
CP-23	O
protein	O
by	O
cells	O
of	O
the	O
periodontium	O
was	O
examined	O
by	O
Northern	O
blot	O
and	O
in	O
situ	O
hybridization	O
.	O

Expression	O
of	O
CP-23	O
transcripts	O
in	O
human	B
cementoblastoma	O
-	O
derived	O
cells	O
,	O
periodontal	O
ligament	O
cells	O
,	O
human	B
gingival	O
fibroblasts	O
and	O
alveolar	O
bone	O
-	O
derived	O
cells	O
was	O
determined	O
by	O
RT	O
-	O
PCR	O
.	O

Our	O
results	O
show	O
that	O
we	O
have	O
isolated	O
a	O
1374-bp	O
human	B
cDNA	O
containing	O
an	O
open	O
reading	O
frame	O
that	O
encodes	O
a	O
polypeptide	O
with	O
247	O
amino	O
acid	O
residues	O
,	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
25.9	O
kDa	O
that	O
represents	O
CP	O
species	O
.	O

The	O
recombinant	O
human	B
CP-23	O
protein	O
cross	O
-	O
reacted	O
with	O
antibodies	O
against	O
CP	O
and	O
type	O
X	O
collagen	O
.	O

Immunoscreening	O
of	O
human	B
periodontal	O
tissues	O
revealed	O
that	O
CP-23	O
gene	O
product	O
is	O
localized	O
to	O
the	O
cementoid	O
matrix	O
of	O
cementum	O
and	O
cementoblasts	O
throughout	O
the	O
entire	O
surface	O
of	O
the	O
root	O
,	O
cell	O
subpopulations	O
of	O
the	O
periodontal	O
ligament	O
as	O
well	O
as	O
cells	O
located	O
paravascularly	O
to	O
the	O
blood	O
vessels	O
into	O
the	O
periodontal	O
ligament	O
.	O

Furthermore	O
,	O
98	O
%	O
of	O
putative	O
cementoblasts	O
and	O
15	O
%	O
of	O
periodontal	O
ligament	O
cells	O
cultured	O
in	O
vitro	O
expressed	O
CP-23	O
gene	O
product	O
.	O

Cementoblastoma	O
cells	O
and	O
periodontal	O
ligament	O
cells	O
contained	O
a	O
5.0	O
kb	O
CP-23	O
mRNA	O
.	O

In	O
situ	O
hybridization	O
showed	O
strong	O
expression	O
of	O
CP-23	O
mRNA	O
on	O
cementoblast	O
,	O
cell	O
subpopulations	O
of	O
the	O
periodontal	O
ligament	O
and	O
cells	O
located	O
around	O
blood	O
vessels	O
into	O
the	O
periodontal	O
ligament	O
.	O

Our	O
results	O
demonstrate	O
that	O
CP-23	O
represents	O
a	O
novel	O
,	O
tissue	O
-	O
specific	O
-	O
gene	O
product	O
being	O
expressed	O
by	O
periodontal	O
ligament	O
subpopulations	O
and	O
cementoblasts	O
.	O

These	O
findings	O
offer	O
the	O
possibility	O
to	O
determine	O
the	O
cellular	O
and	O
molecular	O
events	O
that	O
regulate	O
the	O
cementogenesis	O
process	O
during	O
root	O
development	O
.	O

Furthermore	O
,	O
it	O
might	O
provide	O
new	O
venues	O
for	O
the	O
design	O
of	O
translational	O
studies	O
aimed	O
at	O
achieving	O
predictable	O
new	O
cementogenesis	O
and	O
regeneration	O
of	O
the	O
periodontal	O
tissues	O
.	O

Nuclear	O
localisation	O
of	O
endogenous	O
SUMO-1-modified	O
PDGF	O
-	O
C	O
in	O
human	B
thyroid	O
tissue	O
and	O
cell	O
lines	O
.	O

We	O
investigated	O
post	O
-	O
translational	O
modification	O
and	O
subcellular	O
localisation	O
of	O
endogenous	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
C	O
(	O
PDGF	O
-	O
C	O
)	O
in	O
human	B
thyroid	O
papillary	O
carcinomas	O
(	O
PTC	O
)	O
,	O
non	O
-	O
neoplastic	O
thyroid	O
tissues	O
,	O
and	O
a	O
selection	O
of	O
cultured	O
cell	O
lines	O
.	O

PDGF	O
-	O
C	O
expressed	O
nuclear	O
localisation	O
in	O
95	O
%	O
of	O
all	O
tested	O
cell	O
types	O
in	O
culture	O
and	O
in	O
10	O
%	O
of	O
the	O
thyrocytes	O
from	O
both	O
PTC	O
and	O
non	O
-	O
neoplastic	O
tissue	O
.	O

The	O
cell	O
lines	O
expressed	O
two	O
forms	O
of	O
full	O
-	O
length	O
PDGF	O
-	O
C	O
,	O
approximately	O
39	O
and	O
approximately	O
55	O
kDa	O
,	O
in	O
cell	O
membrane	O
and	O
cytosol	O
,	O
while	O
the	O
approximately	O
55	O
kDa	O
form	O
dominated	O
in	O
the	O
nucleus	O
where	O
it	O
was	O
partly	O
chromatin	O
-	O
associated	O
.	O

The	O
approximately	O
55	O
kDa	O
form	O
was	O
post	O
-	O
translationally	O
modified	O
by	O
SUMO-1	O
.	O

The	O
putative	O
PDGF	O
-	O
C	O
SUMOylation	O
site	O
is	O
the	O
surface	O
exposed	O
(	O
314	O
)	O
lysine	O
part	O
of	O
a	O
positively	O
charged	O
loop	O
(	O
(	O
312	O
)	O
RPKTGVRGLHK	O
(	O
322	O
)	O
)	O
with	O
characteristics	O
of	O
a	O
nuclear	O
localisation	O
signal	O
.	O

The	O
tissue	O
thyrocytes	O
expressed	O
a	O
non	O
-	O
SUMOylated	O
approximately	O
43	O
kDa	O
and	O
the	O
55	O
kDa	O
PDGF	O
-	O
C.	O

The	O
SUMO-1	O
modified	O
approximately	O
55	O
kDa	O
PDGF	O
-	O
C	O
expression	O
was	O
low	O
in	O
PTC	O
where	O
the	O
approximately	O
43	O
kDa	O
PDGF	O
-	O
C	O
dominated	O
.	O

This	O
is	O
in	O
contrast	O
to	O
non	O
-	O
neoplastic	O
tissue	O
and	O
cultured	O
cells	O
where	O
the	O
SUMOylated	O
approximately	O
55	O
kDa	O
PDGF	O
-	O
C	O
was	O
strongly	O
expressed	O
.	O

Our	O
data	O
provide	O
novel	O
evidence	O
for	O
nuclear	O
localisation	O
of	O
PDGF	O
-	O
C	O
,	O
post	O
-	O
translational	O
modification	O
by	O
SUMOylation	O
and	O
the	O
expression	O
of	O
a	O
novel	O
form	O
of	O
PDGF	O
-	O
C	O
in	O
human	B
papillary	O
thyroid	O
carcinomas	O
.	O

Shugoshin	O
collaborates	O
with	O
protein	O
phosphatase	O
2A	O
to	O
protect	O
cohesin	O
.	O

Sister	O
chromatid	O
cohesion	O
,	O
mediated	O
by	O
a	O
complex	O
called	O
cohesin	O
,	O
is	O
crucial	O
--	O
particularly	O
at	O
centromeres	O
--	O
for	O
proper	O
chromosome	O
segregation	O
in	O
mitosis	O
and	O
meiosis	O
.	O

In	O
animal	O
mitotic	O
cells	O
,	O
phosphorylation	O
of	O
cohesin	O
promotes	O
its	O
dissociation	O
from	O
chromosomes	O
,	O
but	O
centromeric	O
cohesin	O
is	O
protected	O
by	O
shugoshin	O
until	O
kinetochores	O
are	O
properly	O
captured	O
by	O
the	O
spindle	O
microtubules	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
shugoshin	O
-	O
dependent	O
protection	O
of	O
cohesin	O
is	O
unknown	O
.	O

Here	O
we	O
find	O
a	O
specific	O
subtype	O
of	O
serine	O
/	O
threonine	O
protein	O
phosphatase	O
2A	O
(	O
PP2A	O
)	O
associating	O
with	O
human	B
shugoshin	O
.	O

PP2A	O
colocalizes	O
with	O
shugoshin	O
at	O
centromeres	O
and	O
is	O
required	O
for	O
centromeric	O
protection	O
.	O

Purified	O
shugoshin	O
complex	O
has	O
an	O
ability	O
to	O
reverse	O
the	O
phosphorylation	O
of	O
cohesin	O
in	O
vitro	O
,	O
suggesting	O
that	O
dephosphorylation	O
of	O
cohesin	O
is	O
the	O
mechanism	O
of	O
protection	O
at	O
centromeres	O
.	O

Meiotic	O
shugoshin	O
of	O
fission	O
yeast	B
also	O
associates	O
with	O
PP2A	O
,	O
with	O
both	O
proteins	O
collaboratively	O
protecting	O
Rec8-containing	O
cohesin	O
at	O
centromeres	O
.	O

Thus	O
,	O
we	O
have	O
revealed	O
a	O
conserved	O
mechanism	O
of	O
centromeric	O
protection	O
of	O
eukaryotic	O
chromosomes	O
in	O
mitosis	O
and	O
meiosis	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
novel	O
zinc	O
finger	O
protein	O
(	O
HZF1	O
)	O
gene	O
and	O
its	O
function	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
of	O
K562	O
cells	O
.	O

A	O
novel	O
zinc	O
finger	O
protein	O
(	O
HZF1	O
)	O
gene	O
was	O
identified	O
and	O
characterized	O
by	O
screening	O
a	O
human	B
bone	O
marrow	O
cDNA	O
library	O
,	O
using	O
a	O
new	O
expression	O
sequence	O
tag	O
probe	O
that	O
contains	O
sequences	O
encoding	O
zinc	O
finger	O
motifs	O
.	O

There	O
are	O
at	O
least	O
three	O
transcripts	O
that	O
may	O
result	O
from	O
different	O
splicing	O
of	O
the	O
pre	O
-	O
mRNA	O
,	O
but	O
the	O
differences	O
among	O
them	O
are	O
only	O
involved	O
in	O
5	O
'	O
non	O
-	O
translation	O
region	O
of	O
HZF1	O
mRNA	O
.	O

HZF1	O
gene	O
contains	O
four	O
exons	O
and	O
three	O
introns	O
.	O

The	O
putative	O
protein	O
consists	O
of	O
670	O
amino	O
-	O
acid	O
residues	O
including	O
15	O
typical	O
C2H2	O
and	O
2	O
C2RH	O
zinc	O
finger	O
motifs	O
.	O

This	O
structure	O
characterization	O
of	O
HZF1	O
and	O
the	O
nuclear	O
location	O
of	O
the	O
protein	O
suggest	O
that	O
HZF1	O
may	O
function	O
as	O
a	O
transcription	O
factor	O
.	O

HZF1	O
mRNA	O
expression	O
was	O
detected	O
in	O
ubiquitous	O
tissues	O
and	O
various	O
hematopoietic	O
cell	O
lines	O
.	O

Increased	O
HZF1	O
mRNA	O
expression	O
was	O
observed	O
following	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
induced	O
by	O
hemin	O
or	O
megakaryocytic	O
differentiation	O
of	O
K562	O
cells	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

Both	O
of	O
the	O
antisense	O
method	O
and	O
RNA	O
interference	O
assay	O
revealed	O
that	O
repression	O
of	O
the	O
intrinsic	O
expression	O
of	O
HZF1	O
blocked	O
the	O
hemin	O
-	O
induced	O
erythroid	O
differentiation	O
and	O
reduced	O
the	O
PMA	O
-	O
induced	O
megakaryocytic	O
differentiation	O
of	O
K562	O
cells	O
,	O
which	O
suggested	O
that	O
HZF1	O
play	O
important	O
roles	O
in	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
.	O

Reversible	O
lysine	O
acetylation	O
controls	O
the	O
activity	O
of	O
the	O
mitochondrial	O
enzyme	O
acetyl	O
-	O
CoA	O
synthetase	O
2	O
.	O

We	O
report	O
that	O
human	B
acetyl	O
-	O
CoA	O
synthetase	O
2	O
(	O
AceCS2	O
)	O
is	O
a	O
mitochondrial	O
matrix	O
protein	O
.	O

AceCS2	O
is	O
reversibly	O
acetylated	O
at	O
Lys-642	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

The	O
mitochondrial	O
sirtuin	O
SIRT3	O
interacts	O
with	O
AceCS2	O
and	O
deacetylates	O
Lys-642	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Deacetylation	O
of	O
AceCS2	O
by	O
SIRT3	O
activates	O
the	O
acetyl	O
-	O
CoA	O
synthetase	O
activity	O
of	O
AceCS2	O
.	O

This	O
report	O
identifies	O
the	O
first	O
acetylated	O
substrate	O
protein	O
of	O
SIRT3	O
.	O

Our	O
findings	O
show	O
that	O
a	O
mammalian	O
sirtuin	O
directly	O
controls	O
the	O
activity	O
of	O
a	O
metabolic	O
enzyme	O
by	O
means	O
of	O
reversible	O
lysine	O
acetylation	O
.	O

Because	O
the	O
activity	O
of	O
a	O
bacterial	O
ortholog	O
of	O
AceCS2	O
,	O
called	O
ACS	O
,	O
is	O
controlled	O
via	O
deacetylation	O
by	O
a	O
bacterial	O
sirtuin	O
protein	O
,	O
our	O
observation	O
highlights	O
the	O
conservation	O
of	O
a	O
metabolic	O
regulatory	O
pathway	O
from	O
bacteria	O
to	O
humans	B
.	O

Detection	O
of	O
autoantibodies	O
to	O
the	O
BTB	O
-	O
kelch	O
protein	O
KLHL7	O
in	O
cancer	O
sera	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
search	O
for	O
novel	O
targets	O
of	O
autoantibodies	O
in	O
patients	O
with	O
paraneoplastic	O
neurological	O
syndromes	O
(	O
PNS	O
)	O
.	O

PNS	O
are	O
mediated	O
by	O
immune	O
reactions	O
against	O
autoantigen	O
(	O
s	O
)	O
shared	O
by	O
the	O
cancer	O
cells	O
and	O
the	O
nervous	O
system	O
.	O

By	O
serological	O
screening	O
of	O
a	O
rat	B
cerebellum	O
cDNA	O
expression	O
library	O
using	O
anti	O
-	O
Hu	O
-	O
positive	O
sera	O
from	O
three	O
patients	O
with	O
paraneoplastic	O
encephalomyelitis	O
(	O
PEM	O
)	O
,	O
we	O
identified	O
an	O
open	O
reading	O
frame	O
encoding	O
an	O
isoform	O
of	O
the	O
BTB	O
-	O
kelch	O
protein	O
KLHL7	O
.	O

Immunohistochemical	O
studies	O
demonstrated	O
that	O
the	O
KLHL7	O
protein	O
is	O
expressed	O
in	O
the	O
nuclei	O
of	O
neurones	O
,	O
but	O
not	O
in	O
other	O
tissues	O
including	O
various	O
cancers	O
.	O

However	O
,	O
the	O
KLHL7	O
protein	O
was	O
detected	O
in	O
the	O
nuclei	O
of	O
cancer	O
cell	O
lines	O
.	O

Antibodies	O
to	O
KLHL7	O
were	O
detected	O
by	O
an	O
immunoprecipitation	O
assay	O
in	O
sera	O
from	O
12	O
of	O
254	O
(	O
4.7	O
%	O
)	O
patients	O
with	O
various	O
cancers	O
and	O
2	O
of	O
170	O
blood	O
donors	O
(	O
1.2	O
%	O
)	O
.	O

None	O
of	O
50	O
sera	O
from	O
patients	O
with	O
multiple	O
sclerosis	O
were	O
positive	O
for	O
KLHL7	O
antibodies	O
.	O

Sixteen	O
patients	O
with	O
classical	O
PNS	O
and	O
anti	O
-	O
Hu	O
or	O
anti	O
-	O
Yo	O
antibodies	O
were	O
also	O
negative	O
for	O
KLHL7	O
antibodies	O
.	O

Seven	O
cancer	O
patients	O
with	O
KLHL7	O
antibodies	O
had	O
various	O
signs	O
of	O
neurological	O
disease	O
that	O
could	O
be	O
related	O
to	O
cancer	O
,	O
whereas	O
the	O
remaining	O
five	O
seropositive	O
cancer	O
patients	O
had	O
no	O
clinical	O
signs	O
of	O
possible	O
PNS	O
.	O

The	O
present	O
results	O
indicate	O
that	O
KLHL7	O
antibodies	O
are	O
associated	O
with	O
various	O
cancers	O
,	O
and	O
in	O
some	O
patients	O
also	O
with	O
neurological	O
disease	O
.	O

Whether	O
KLHL7	O
antibodies	O
can	O
be	O
used	O
as	O
paraneoplastic	O
markers	O
for	O
PNS	O
remains	O
to	O
be	O
determined	O
.	O

Quantitative	O
phosphoproteomics	O
of	O
early	O
elicitor	O
signaling	O
in	O
Arabidopsis	B
.	O

Perception	O
of	O
general	O
elicitors	O
by	O
plant	O
cells	O
initiates	O
signal	O
transduction	O
cascades	O
that	O
are	O
regulated	O
by	O
protein	O
phosphorylation	O
.	O

The	O
earliest	O
signaling	O
events	O
occur	O
within	O
minutes	O
and	O
include	O
ion	O
fluxes	O
across	O
the	O
plasma	O
membrane	O
,	O
activation	O
of	O
MAPKs	O
,	O
and	O
the	O
formation	O
of	O
reactive	O
oxygen	O
species	O
.	O

The	O
phosphorylation	O
events	O
that	O
regulate	O
these	O
signaling	O
cascades	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
present	O
a	O
mass	O
spectrometry	O
-	O
based	O
quantitative	O
phosphoproteomics	O
approach	O
that	O
identified	O
differentially	O
phosphorylated	O
sites	O
in	O
signaling	O
and	O
response	O
proteins	O
from	O
Arabidopsis	B
cells	O
treated	O
with	O
either	O
flg22	O
or	O
xylanase	O
.	O

Our	O
approach	O
was	O
sensitive	O
enough	O
to	O
quantitate	O
phosphorylation	O
on	O
low	O
abundance	O
signaling	O
proteins	O
such	O
as	O
calcium	O
-	O
dependent	O
protein	O
kinases	O
and	O
receptor	O
-	O
like	O
kinase	O
family	O
members	O
.	O

With	O
this	O
approach	O
we	O
identified	O
one	O
or	O
more	O
differentially	O
phosphorylated	O
sites	O
in	O
76	O
membrane	O
-	O
associated	O
proteins	O
including	O
a	O
number	O
of	O
defense	O
-	O
related	O
proteins	O
.	O

Our	O
data	O
on	O
phosphorylation	O
indicate	O
a	O
high	O
degree	O
of	O
complexity	O
at	O
the	O
level	O
of	O
post	O
-	O
translational	O
modification	O
as	O
exemplified	O
by	O
the	O
complex	O
modification	O
patterns	O
of	O
respiratory	O
burst	O
oxidase	O
protein	O
D.	O
Furthermore	O
the	O
data	O
also	O
suggest	O
that	O
protein	O
translocation	O
and	O
vesicle	O
traffic	O
are	O
important	O
aspects	O
of	O
early	O
signaling	O
and	O
defense	O
in	O
response	O
to	O
general	O
elicitors	O
.	O

Our	O
study	O
presents	O
the	O
largest	O
quantitative	O
Arabidopsis	B
phosphoproteomics	O
data	O
set	O
to	O
date	O
and	O
provides	O
a	O
new	O
resource	O
that	O
can	O
be	O
used	O
to	O
gain	O
novel	O
insight	O
into	O
plant	O
defense	O
signal	O
transduction	O
and	O
early	O
defense	O
response	O
.	O

An	O
endoplasmic	O
reticulum	O
transmembrane	O
prolyl	O
4-hydroxylase	O
is	O
induced	O
by	O
hypoxia	O
and	O
acts	O
on	O
hypoxia	O
-	O
inducible	O
factor	O
alpha	O
.	O

Prolyl	O
4-hydroxylases	O
(	O
P4Hs	O
)	O
act	O
on	O
collagens	O
(	O
C	O
-	O
P4Hs	O
)	O
and	O
the	O
oxygen	O
-	O
dependent	O
degradation	O
domains	O
(	O
ODDDs	O
)	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
alpha	O
subunits	O
(	O
HIF	O
-	O
P4Hs	O
)	O
leading	O
to	O
degradation	O
of	O
the	O
latter	O
.	O

We	O
report	O
data	O
on	O
a	O
human	B
P4H	O
possessing	O
a	O
transmembrane	O
domain	O
(	O
P4H	O
-	O
TM	O
)	O
.	O

Its	O
gene	O
is	O
also	O
found	O
in	O
zebrafish	B
but	O
not	O
in	O
flies	B
and	O
nematodes	B
.	O

Its	O
sequence	O
more	O
closely	O
resembles	O
those	O
of	O
the	O
C	O
-	O
P4Hs	O
than	O
the	O
HIF	O
-	O
P4Hs	O
,	O
but	O
it	O
lacks	O
the	O
peptide	O
substrate	O
-	O
binding	O
domain	O
of	O
the	O
C	O
-	O
P4Hs	O
.	O

P4H	O
-	O
TM	O
levels	O
in	O
cultured	O
cells	O
are	O
increased	O
by	O
hypoxia	O
,	O
and	O
P4H	O
-	O
TM	O
is	O
N	O
-	O
glycosylated	O
and	O
is	O
located	O
in	O
endoplasmic	O
reticulum	O
membranes	O
with	O
its	O
catalytic	O
site	O
inside	O
the	O
lumen	O
,	O
a	O
location	O
differing	O
from	O
those	O
of	O
the	O
HIF	O
-	O
P4Hs	O
.	O

Despite	O
this	O
,	O
P4H	O
-	O
TM	O
overexpression	O
in	O
cultured	O
neuroblastoma	O
cells	O
reduced	O
HIF	O
-	O
alpha	O
ODDD	O
reporter	O
construct	O
levels	O
,	O
and	O
its	O
small	O
interfering	O
RNA	O
increased	O
HIF-1alpha	O
protein	O
level	O
,	O
in	O
the	O
same	O
way	O
as	O
those	O
of	O
HIF	O
-	O
P4Hs	O
.	O

Furthermore	O
,	O
recombinant	O
P4H	O
-	O
TM	O
hydroxylated	O
the	O
two	O
critical	O
prolines	O
in	O
HIF-1alpha	O
ODDD	O
in	O
vitro	O
,	O
with	O
a	O
preference	O
for	O
the	O
C	O
-	O
terminal	O
proline	O
,	O
whereas	O
it	O
did	O
not	O
hydroxylate	O
any	O
prolines	O
in	O
recombinant	O
type	O
I	O
procollagen	O
chains	O
.	O

A	O
mechanism	O
for	O
asymmetric	O
segregation	O
of	O
age	O
during	O
yeast	B
budding	O
.	O

Ageing	O
and	O
the	O
mortality	O
that	O
ensues	O
are	O
sustainable	O
for	O
the	O
species	O
only	O
if	O
age	O
is	O
reset	O
in	O
newborns	O
.	O

In	O
budding	O
yeast	B
,	O
buds	O
are	O
made	O
young	O
whereas	O
ageing	O
factors	O
,	O
such	O
as	O
carbonylated	O
proteins	O
and	O
DNA	O
circles	O
,	O
remain	O
confined	O
to	O
the	O
ageing	O
mother	O
cell	O
.	O

The	O
mechanisms	O
of	O
this	O
confinement	O
and	O
their	O
relevance	O
are	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
a	O
septin	O
-	O
dependent	O
,	O
lateral	O
diffusion	O
barrier	O
forms	O
in	O
the	O
nuclear	O
envelope	O
and	O
limits	O
the	O
translocation	O
of	O
pre	O
-	O
existing	O
nuclear	O
pores	O
into	O
the	O
bud	O
.	O

The	O
retention	O
of	O
DNA	O
circles	O
within	O
the	O
mother	O
cell	O
depends	O
on	O
the	O
presence	O
of	O
the	O
diffusion	O
barrier	O
and	O
on	O
the	O
anchorage	O
of	O
the	O
circles	O
to	O
pores	O
mediated	O
by	O
the	O
nuclear	O
basket	O
.	O

In	O
accordance	O
with	O
the	O
diffusion	O
barrier	O
ensuring	O
the	O
asymmetric	O
segregation	O
of	O
nuclear	O
age	O
-	O
determinants	O
,	O
the	O
barrier	O
mutant	O
bud6Delta	O
fails	O
to	O
properly	O
reset	O
age	O
in	O
buds	O
.	O

Our	O
data	O
involve	O
septin	O
-	O
dependent	O
diffusion	O
barriers	O
in	O
the	O
confinement	O
of	O
ageing	O
factors	O
to	O
one	O
daughter	O
cell	O
during	O
asymmetric	O
cell	O
division	O
.	O

H2A.Bbd	O
:	O
an	O
X	O
-	O
chromosome	O
-	O
encoded	O
histone	O
involved	O
in	O
mammalian	O
spermiogenesis	O
.	O

Despite	O
the	O
identification	O
of	O
H2A.Bbd	O
as	O
a	O
new	O
vertebrate	O
-	O
specific	O
replacement	O
histone	O
variant	O
several	O
years	O
ago	O
,	O
and	O
despite	O
the	O
many	O
in	O
vitro	O
structural	O
characterizations	O
using	O
reconstituted	O
chromatin	O
complexes	O
consisting	O
of	O
this	O
variant	O
,	O
the	O
existence	O
of	O
H2A.Bbd	O
in	O
the	O
cell	O
and	O
its	O
location	O
has	O
remained	O
elusive	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
native	O
form	O
of	O
this	O
variant	O
is	O
present	O
in	O
highly	O
advanced	O
spermiogenic	O
fractions	O
of	O
mammalian	O
testis	O
at	O
the	O
time	O
when	O
histones	O
are	O
highly	O
acetylated	O
and	O
being	O
replaced	O
by	O
protamines	O
.	O

It	O
is	O
also	O
present	O
in	O
the	O
nucleosomal	O
chromatin	O
fraction	O
of	O
mature	O
human	B
sperm	O
.	O

The	O
ectopically	O
expressed	O
non	O
-	O
tagged	O
version	O
of	O
the	O
protein	O
is	O
associated	O
with	O
micrococcal	O
nuclease	O
-	O
refractory	O
insoluble	O
fractions	O
of	O
chromatin	O
and	O
in	O
mouse	B
(	O
20T1	O
/	O
2	O
)	O
cell	O
line	O
,	O
H2A.Bbd	O
is	O
enriched	O
at	O
the	O
periphery	O
of	O
chromocenters	O
.	O

The	O
exceedingly	O
rapid	O
evolution	O
of	O
this	O
unique	O
X	O
-	O
chromosome	O
-	O
linked	O
histone	O
variant	O
is	O
shared	O
with	O
other	O
reproductive	O
proteins	O
including	O
those	O
associated	O
with	O
chromatin	O
in	O
the	O
mature	O
sperm	O
(	O
protamines	O
)	O
of	O
many	O
vertebrates	O
.	O

This	O
common	O
rate	O
of	O
evolution	O
provides	O
further	O
support	O
for	O
the	O
functional	O
and	O
structural	O
involvement	O
of	O
this	O
protein	O
in	O
male	O
gametogenesis	O
in	O
mammals	O
.	O

HERC2	O
coordinates	O
ubiquitin	O
-	O
dependent	O
assembly	O
of	O
DNA	O
repair	O
factors	O
on	O
damaged	O
chromosomes	O
.	O

Regulatory	O
ubiquitylation	O
is	O
emerging	O
as	O
an	O
important	O
mechanism	O
to	O
protect	O
genome	O
integrity	O
in	O
cells	O
exposed	O
to	O
DNA	O
damage	O
.	O

However	O
,	O
the	O
spectrum	O
of	O
known	O
ubiquitin	O
regulators	O
of	O
the	O
DNA	O
damage	O
response	O
(	O
DDR	O
)	O
is	O
limited	O
and	O
their	O
functional	O
interplay	O
is	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
identify	O
HERC2	O
as	O
a	O
factor	O
that	O
regulates	O
ubiquitin	O
-	O
dependent	O
retention	O
of	O
repair	O
proteins	O
on	O
damaged	O
chromosomes	O
.	O

In	O
response	O
to	O
ionising	O
radiation	O
(	O
IR	O
)	O
,	O
HERC2	O
forms	O
a	O
complex	O
with	O
RNF8	O
,	O
a	O
ubiquitin	O
ligase	O
involved	O
in	O
the	O
DDR	O
.	O

The	O
HERC2-RNF8	O
interaction	O
requires	O
IR	O
-	O
inducible	O
phosphorylation	O
of	O
HERC2	O
at	O
Thr	O
4827	O
,	O
which	O
in	O
turn	O
binds	O
to	O
the	O
forkhead	O
-	O
associated	O
(	O
FHA	O
)	O
domain	O
of	O
RNF8	O
.	O

Mechanistically	O
,	O
we	O
provide	O
evidence	O
that	O
HERC2	O
facilitates	O
assembly	O
of	O
the	O
ubiquitin	O
-	O
conjugating	O
enzyme	O
Ubc13	O
with	O
RNF8	O
,	O
thereby	O
promoting	O
DNA	O
damage	O
-	O
induced	O
formation	O
of	O
Lys	O
63-linked	O
ubiquitin	O
chains	O
.	O

We	O
also	O
show	O
that	O
HERC2	O
interacts	O
with	O
,	O
and	O
maintains	O
the	O
levels	O
of	O
,	O
RNF168	O
,	O
another	O
ubiquitin	O
ligase	O
operating	O
downstream	O
of	O
RNF8	O
(	O
Refs	O
7	O
,	O
8)	O
.	O

Consequently	O
,	O
knockdown	O
of	O
HERC2	O
abrogates	O
ubiquitin	O
-	O
dependent	O
retention	O
of	O
repair	O
factors	O
such	O
as	O
53BP1	O
,	O
RAP80	O
and	O
BRCA1	O
.	O

Together	O
with	O
the	O
increased	O
radiosensitivity	O
of	O
HERC2-depleted	O
cells	O
,	O
these	O
results	O
uncover	O
a	O
regulatory	O
layer	O
in	O
the	O
orchestration	O
of	O
protein	O
interactions	O
on	O
damaged	O
chromosomes	O
and	O
they	O
underscore	O
the	O
role	O
of	O
ubiquitin	O
-	O
mediated	O
signalling	O
in	O
genome	O
maintenance	O
.	O

Characterization	O
of	O
a	O
putative	O
3-deoxy	O
-	O
D	O
-	O
manno-2-octulosonic	O
acid	O
(	O
Kdo	O
)	O
transferase	O
gene	O
from	O
Arabidopsis	B
thaliana	I
.	O

The	O
structures	O
of	O
the	O
pectic	O
polysaccharide	O
rhamnogalacturonan	O
II	O
(	O
RG	O
-	O
II	O
)	O
pectin	O
constituent	O
are	O
remarkably	O
evolutionary	O
conserved	O
in	O
all	O
plant	O
species	O
.	O

At	O
least	O
12	O
different	O
glycosyl	O
residues	O
are	O
present	O
in	O
RG	O
-	O
II	O
.	O

Among	O
them	O
is	O
the	O
seldom	O
eight	O
-	O
carbon	O
sugar	O
3-deoxy	O
-	O
d	O
-	O
manno	O
-	O
octulosonic	O
acid	O
(	O
Kdo	O
)	O
whose	O
biosynthetic	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
conserved	O
between	O
plants	O
and	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Kdo	O
is	O
formed	O
in	O
the	O
cytosol	O
by	O
the	O
condensation	O
of	O
phosphoenol	O
pyruvate	O
with	O
d	O
-	O
arabinose-5-P	O
and	O
then	O
activated	O
by	O
coupling	O
to	O
cytidine	O
monophosphate	O
(	O
CMP	O
)	O
prior	O
to	O
its	O
incorporation	O
in	O
the	O
Golgi	O
apparatus	O
by	O
a	O
Kdo	O
transferase	O
(	O
KDTA	O
)	O
into	O
the	O
nascent	O
polysaccharide	O
RG	O
-	O
II	O
.	O

To	O
gain	O
new	O
insight	O
into	O
RG	O
-	O
II	O
biosynthesis	O
and	O
function	O
,	O
we	O
isolated	O
and	O
characterized	O
null	O
mutants	O
for	O
the	O
unique	O
putative	O
KDTA	O
(	O
AtKDTA	O
)	O
encoded	O
in	O
the	O
Arabidopsis	B
genome	O
.	O

We	O
provide	O
evidence	O
that	O
,	O
in	O
contrast	O
to	O
mutants	O
affecting	O
the	O
RG	O
-	O
II	O
biosynthesis	O
,	O
the	O
extinction	O
of	O
the	O
AtKDTA	O
gene	O
expression	O
does	O
not	O
result	O
in	O
any	O
developmental	O
phenotype	O
in	O
the	O
AtkdtA	O
plants	O
.	O

Furthermore	O
,	O
the	O
structure	O
of	O
RG	O
-	O
II	O
from	O
the	O
null	O
mutants	O
was	O
not	O
altered	O
and	O
contained	O
wild	O
-	O
type	O
amount	O
of	O
Rha	O
-	O
alpha	O
(	O
1	O
-	O
5	O
)	O
Kdo	O
side	O
chain	O
.	O

The	O
cellular	O
localization	O
of	O
AtKDTA	O
was	O
investigated	O
by	O
using	O
laser	O
scanning	O
confocal	O
imaging	O
of	O
the	O
protein	O
fused	O
to	O
green	O
fluorescent	O
protein	O
.	O

In	O
agreement	O
with	O
its	O
cellular	O
prediction	O
,	O
the	O
fusion	O
protein	O
was	O
demonstrated	O
to	O
be	O
targeted	O
to	O
the	O
mitochondria	O
.	O

These	O
data	O
,	O
together	O
with	O
data	O
deduced	O
from	O
sequence	O
analyses	O
of	O
higher	O
plant	O
genomes	O
,	O
suggest	O
that	O
AtKDTA	O
encodes	O
a	O
putative	O
KDTA	O
involved	O
in	O
the	O
synthesis	O
of	O
a	O
mitochondrial	O
not	O
yet	O
identified	O
lipid	O
A	O
-	O
like	O
molecule	O
rather	O
than	O
in	O
the	O
synthesis	O
of	O
the	O
cell	O
wall	O
RG	O
-	O
II	O
.	O

Arginine	O
metabolism	O
in	O
Saccharomyces	B
cerevisiae	I
:	O
subcellular	O
localization	O
of	O
the	O
enzymes	O
.	O

Subcellular	O
localization	O
of	O
enzymes	O
of	O
arginine	O
metabolism	O
in	O
Saccharomyces	B
cerevisiae	I
was	O
studied	O
by	O
partial	O
fractionation	O
and	O
stepwise	O
homogenization	O
of	O
spheroplast	O
lysates	O
.	O

These	O
enzymes	O
could	O
clearly	O
be	O
divided	O
into	O
two	O
groups	O
.	O

The	O
first	O
group	O
comprised	O
the	O
five	O
enzymes	O
of	O
the	O
acetylated	O
compound	O
cycle	O
,	O
i.e.	O
,	O
acetylglutamate	O
synthase	O
,	O
acetylglutamate	O
kinase	O
,	O
acetylglutamyl	O
-	O
phosphate	O
reductase	O
,	O
acetylornithine	O
aminotransferase	O
,	O
and	O
acetylornithine	O
-	O
glutamate	O
acetyltransferase	O
.	O

These	O
enzymes	O
were	O
exclusively	O
particulate	O
.	O

Comparison	O
with	O
citrate	O
synthase	O
and	O
cytochrome	O
oxidase	O
,	O
and	O
results	O
from	O
isopycnic	O
gradient	O
analysis	O
,	O
suggested	O
that	O
these	O
enzymes	O
were	O
associated	O
with	O
the	O
mitochondria	O
.	O

By	O
contrast	O
,	O
enzymatic	O
activities	O
going	O
from	O
ornithine	O
to	O
arginine	O
,	O
i.e.	O
,	O
arginine	O
pathway	O
-	O
specific	O
carbamoylphosphate	O
synthetase	O
,	O
ornithine	O
carbamoyltransferase	O
,	O
argininosuccinate	O
synthetase	O
,	O
and	O
argininosuccinate	O
lyase	O
,	O
and	O
the	O
two	O
first	O
catabolic	O
enzymes	O
,	O
arginase	O
and	O
ornithine	O
aminotransferase	O
,	O
were	O
in	O
the	O
""""	O
soluble	O
""""	O
fraction	O
of	O
the	O
cell	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
missing	O
pyrimidine	O
reductase	O
in	O
the	O
plant	O
riboflavin	O
biosynthesis	O
pathway	O
.	O

Riboflavin	O
(	O
vitamin	O
B₂	O
)	O
is	O
the	O
precursor	O
of	O
the	O
flavin	O
coenzymes	O
flavin	O
mononucleotide	O
and	O
flavin	O
adenine	O
dinucleotide	O
.	O

In	O
Escherichia	B
coli	I
and	O
other	O
bacteria	O
,	O
sequential	O
deamination	O
and	O
reduction	O
steps	O
in	O
riboflavin	O
biosynthesis	O
are	O
catalyzed	O
by	O
RibD	O
,	O
a	O
bifunctional	O
protein	O
with	O
distinct	O
pyrimidine	O
deaminase	O
and	O
reductase	O
domains	O
.	O

Plants	O
have	O
two	O
diverged	O
RibD	O
homologs	O
,	O
PyrD	O
and	O
PyrR	O
;	O
PyrR	O
proteins	O
have	O
an	O
extra	O
carboxyl	O
-	O
terminal	O
domain	O
(	O
COG3236	O
)	O
of	O
unknown	O
function	O
.	O

Arabidopsis	B
(	O
Arabidopsis	B
thaliana	I
)	O
PyrD	O
(	O
encoded	O
by	O
At4g20960	O
)	O
is	O
known	O
to	O
be	O
a	O
monofunctional	O
pyrimidine	O
deaminase	O
,	O
but	O
no	O
pyrimidine	O
reductase	O
has	O
been	O
identified	O
.	O

Bioinformatic	O
analyses	O
indicated	O
that	O
plant	O
PyrR	O
proteins	O
have	O
a	O
catalytically	O
competent	O
reductase	O
domain	O
but	O
lack	O
essential	O
zinc	O
-	O
binding	O
residues	O
in	O
the	O
deaminase	O
domain	O
,	O
and	O
that	O
the	O
Arabidopsis	B
PyrR	O
gene	O
(	O
At3g47390	O
)	O
is	O
coexpressed	O
with	O
riboflavin	O
synthesis	O
genes	O
.	O

These	O
observations	O
imply	O
that	O
PyrR	O
is	O
a	O
pyrimidine	O
reductase	O
without	O
deaminase	O
activity	O
.	O

Consistent	O
with	O
this	O
inference	O
,	O
Arabidopsis	B
or	O
maize	B
(	O
Zea	B
mays	I
)	O
PyrR	O
(	O
At3g47390	O
or	O
GRMZM2G090068	O
)	O
restored	O
riboflavin	O
prototrophy	O
to	O
an	O
E.	B
coli	I
ribD	O
deletant	O
strain	O
when	O
coexpressed	O
with	O
the	O
corresponding	O
PyrD	O
protein	O
(	O
At4g20960	O
or	O
GRMZM2G320099	O
)	O
but	O
not	O
when	O
expressed	O
alone	O
;	O
the	O
COG3236	O
domain	O
was	O
unnecessary	O
for	O
complementing	O
activity	O
.	O

Furthermore	O
,	O
recombinant	O
maize	B
PyrR	O
mediated	O
NAD	O
(	O
P	O
)	O
H	O
-	O
dependent	O
pyrimidine	O
reduction	O
in	O
vitro	O
.	O

Import	O
assays	O
with	O
pea	B
(	O
Pisum	B
sativum	I
)	O
chloroplasts	O
showed	O
that	O
PyrR	O
and	O
PyrD	O
are	O
taken	O
up	O
and	O
proteolytically	O
processed	O
.	O

Ablation	O
of	O
the	O
maize	B
PyrR	O
gene	O
caused	O
early	O
seed	O
lethality	O
.	O

These	O
data	O
argue	O
that	O
PyrR	O
is	O
the	O
missing	O
plant	O
pyrimidine	O
reductase	O
,	O
that	O
it	O
is	O
plastid	O
localized	O
,	O
and	O
that	O
it	O
is	O
essential	O
.	O

The	O
role	O
of	O
the	O
COG3236	O
domain	O
remains	O
mysterious	O
;	O
no	O
evidence	O
was	O
obtained	O
for	O
the	O
possibility	O
that	O
it	O
catalyzes	O
the	O
dephosphorylation	O
that	O
follows	O
pyrimidine	O
reduction	O
.	O

Heptahelical	O
protein	O
PQLC2	O
is	O
a	O
lysosomal	O
cationic	O
amino	O
acid	O
exporter	O
underlying	O
the	O
action	O
of	O
cysteamine	O
in	O
cystinosis	O
therapy	O
.	O

Cystinosin	O
,	O
the	O
lysosomal	O
cystine	O
exporter	O
defective	O
in	O
cystinosis	O
,	O
is	O
the	O
founding	O
member	O
of	O
a	O
family	O
of	O
heptahelical	O
membrane	O
proteins	O
related	O
to	O
bacteriorhodopsin	O
and	O
characterized	O
by	O
a	O
duplicated	O
motif	O
termed	O
the	O
PQ	O
loop	O
.	O

PQ	O
-	O
loop	O
proteins	O
are	O
more	O
frequent	O
in	O
eukaryotes	O
than	O
in	O
prokaryotes	O
;	O
except	O
for	O
cystinosin	O
,	O
their	O
molecular	O
function	O
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
three	O
yeast	B
PQ	O
-	O
loop	O
proteins	O
of	O
unknown	O
function	O
,	O
Ypq1	O
,	O
Ypq2	O
,	O
and	O
Ypq3	O
,	O
localize	O
to	O
the	O
vacuolar	O
membrane	O
and	O
are	O
involved	O
in	O
homeostasis	O
of	O
cationic	O
amino	O
acids	O
(	O
CAAs	O
)	O
.	O

We	O
also	O
show	O
that	O
PQLC2	O
,	O
a	O
mammalian	O
PQ	O
-	O
loop	O
protein	O
closely	O
related	O
to	O
yeast	B
Ypq	O
proteins	O
,	O
localizes	O
to	O
lysosomes	O
and	O
catalyzes	O
a	O
robust	O
,	O
electrogenic	O
transport	O
that	O
is	O
selective	O
for	O
CAAs	O
and	O
strongly	O
activated	O
at	O
low	O
extracytosolic	O
pH.	O
Heterologous	O
expression	O
of	O
PQLC2	O
at	O
the	O
yeast	B
vacuole	O
rescues	O
the	O
resistance	O
phenotype	O
of	O
an	O
ypq2	O
mutant	O
to	O
canavanine	O
,	O
a	O
toxic	O
analog	O
of	O
arginine	O
efficiently	O
transported	O
by	O
PQLC2	O
.	O

Finally	O
,	O
PQLC2	O
transports	O
a	O
lysine	O
-	O
like	O
mixed	O
disulfide	O
that	O
serves	O
as	O
a	O
chemical	O
intermediate	O
in	O
cysteamine	O
therapy	O
of	O
cystinosis	O
,	O
and	O
PQLC2	O
gene	O
silencing	O
trapped	O
this	O
intermediate	O
in	O
cystinotic	O
cells	O
.	O

We	O
conclude	O
that	O
PQLC2	O
and	O
Ypq1	O
-	O
3	O
proteins	O
are	O
lysosomal	O
/	O
vacuolar	O
exporters	O
of	O
CAAs	O
and	O
suggest	O
that	O
small	O
-	O
molecule	O
transport	O
is	O
a	O
conserved	O
feature	O
of	O
the	O
PQ	O
-	O
loop	O
protein	O
family	O
,	O
in	O
agreement	O
with	O
its	O
distant	O
similarity	O
to	O
SWEET	O
sugar	O
transporters	O
and	O
to	O
the	O
mitochondrial	O
pyruvate	O
carrier	O
.	O

The	O
elucidation	O
of	O
PQLC2	O
function	O
may	O
help	O
improve	O
cysteamine	O
therapy	O
.	O

It	O
may	O
also	O
clarify	O
the	O
origin	O
of	O
CAA	O
abnormalities	O
in	O
Batten	O
disease	O
.	O

GOLPH3L	O
antagonizes	O
GOLPH3	O
to	O
determine	O
Golgi	O
morphology	O
.	O

GOLPH3	O
is	O
a	O
phosphatidylinositol-4-phosphate	O
(	O
PI4P	O
)	O
effector	O
that	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
Golgi	O
architecture	O
and	O
anterograde	O
trafficking	O
.	O

GOLPH3	O
does	O
so	O
through	O
its	O
ability	O
to	O
link	O
trans	O
-	O
Golgi	O
membranes	O
to	O
F	O
-	O
actin	O
via	O
its	O
interaction	O
with	O
myosin	O
18A	O
(	O
MYO18A	O
)	O
.	O

GOLPH3	O
also	O
is	O
known	O
to	O
be	O
an	O
oncogene	O
commonly	O
amplified	O
in	O
human	B
cancers	O
.	O

GOLPH3L	O
is	O
a	O
GOLPH3	O
paralogue	O
found	O
in	O
all	O
vertebrate	O
genomes	O
,	O
although	O
previously	O
it	O
was	O
largely	O
uncharacterized	O
.	O

Here	O
we	O
demonstrate	O
that	O
although	O
GOLPH3	O
is	O
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
,	O
GOLPH3L	O
is	O
present	O
in	O
only	O
a	O
subset	O
of	O
tissues	O
and	O
cell	O
types	O
,	O
particularly	O
secretory	O
tissues	O
.	O

We	O
show	O
that	O
,	O
like	O
GOLPH3	O
,	O
GOLPH3L	O
binds	O
to	O
PI4P	O
,	O
localizes	O
to	O
the	O
Golgi	O
as	O
a	O
consequence	O
of	O
its	O
PI4P	O
binding	O
,	O
and	O
is	O
required	O
for	O
efficient	O
anterograde	O
trafficking	O
.	O

Surprisingly	O
,	O
however	O
,	O
we	O
find	O
that	O
perturbations	O
of	O
GOLPH3L	O
expression	O
produce	O
effects	O
on	O
Golgi	O
morphology	O
that	O
are	O
opposite	O
to	O
those	O
of	O
GOLPH3	O
and	O
MYO18A	O
.	O

GOLPH3L	O
differs	O
critically	O
from	O
GOLPH3	O
in	O
that	O
it	O
is	O
largely	O
unable	O
to	O
bind	O
to	O
MYO18A	O
.	O

Our	O
data	O
demonstrate	O
that	O
despite	O
their	O
similarities	O
,	O
unexpectedly	O
,	O
GOLPH3L	O
antagonizes	O
GOLPH3	O
/	O
MYO18A	O
at	O
the	O
Golgi	O
.	O

Molecular	O
cloning	O
of	O
a	O
novel	O
human	B
cDNA	O
encoding	O
a	O
zinc	O
finger	O
protein	O
that	O
binds	O
to	O
the	O
interleukin-3	O
promoter	O
.	O

The	O
CT	O
/	O
GC	O
-	O
rich	O
region	O
(	O
-76	O
to	O
-47	O
)	O
is	O
one	O
transcriptional	O
regulatory	O
region	O
of	O
the	O
interleukin-3	O
(	O
IL-3	O
)	O
gene	O
which	O
confers	O
basic	O
transcriptional	O
activity	O
and	O
responds	O
to	O
trans	O
-	O
activation	O
by	O
human	B
T	O
-	O
cell	O
leukemia	O
virus	O
type	O
I	O
-	O
encoded	O
Tax	O
.	O

We	O
isolated	O
three	O
types	O
of	O
cDNAs	O
encoding	O
Cys2	O
/	O
His2-type	O
zinc	O
finger	O
proteins	O
that	O
bind	O
to	O
this	O
region	O
.	O

Two	O
were	O
identical	O
to	O
known	O
transcription	O
factors	O
,	O
EGR1	O
and	O
EGR2	O
,	O
and	O
the	O
other	O
clone	O
,	O
named	O
DB1	O
,	O
encoded	O
a	O
novel	O
protein	O
of	O
516	O
amino	O
acids	O
with	O
six	O
zinc	O
finger	O
motifs	O
.	O

DB1	O
mRNA	O
was	O
present	O
in	O
human	B
tissues	O
,	O
ubiquitously	O
.	O

Two	O
constitutive	O
transcripts	O
of	O
4.0	O
and	O
4.8	O
kb	O
in	O
length	O
were	O
present	O
in	O
Jurkat	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
with	O
specific	O
antibodies	O
,	O
showed	O
that	O
DB1	O
constitutively	O
binds	O
to	O
this	O
region	O
whereas	O
EGR1	O
binds	O
in	O
a	O
T	O
-	O
cell	O
activation	O
-	O
dependent	O
manner	O
.	O

Overexpression	O
of	O
DB1	O
in	O
Jurkat	O
cells	O
had	O
no	O
detectable	O
effect	O
on	O
the	O
transcription	O
activity	O
of	O
the	O
IL-3	O
promoter	O
,	O
in	O
a	O
transient	O
-	O
transfection	O
assay	O
.	O

EGR1	O
and	O
EGR2	O
increased	O
IL-3	O
promoter	O
activity	O
when	O
the	O
transfected	O
cells	O
were	O
stimulated	O
with	O
phorbol-12-myristate-13-acetate	O
and	O
A23187	O
.	O

When	O
DB1	O
was	O
cotransfected	O
with	O
a	O
Tax	O
expression	O
vector	O
,	O
transcription	O
activity	O
of	O
the	O
IL-3	O
promoter	O
induced	O
by	O
Tax	O
was	O
significantly	O
increased	O
,	O
while	O
EGR1	O
and	O
EGR2	O
were	O
without	O
effect	O
.	O

These	O
results	O
suggest	O
that	O
EGR1	O
has	O
a	O
role	O
in	O
inducible	O
transcription	O
of	O
the	O
IL-3	O
gene	O
,	O
while	O
DB1	O
sustains	O
basal	O
transcriptional	O
activity	O
and	O
also	O
cooperates	O
with	O
Tax	O
to	O
activate	O
the	O
IL-3	O
promoter	O
.	O

Sequence	O
analysis	O
of	O
203	O
kilobases	O
from	O
Saccharomyces	B
cerevisiae	I
chromosome	O
VII	O
.	O

The	O
nucleotide	O
sequences	O
of	O
five	O
major	O
regions	O
from	O
chromosome	O
VII	O
of	O
Saccharomyces	B
cerevisiae	I
have	O
been	O
determined	O
and	O
analysed	O
.	O

These	O
regions	O
represent	O
203	O
kilobases	O
corresponding	O
to	O
approximately	O
one	O
-	O
fifth	O
of	O
the	O
complete	O
yeast	B
chromosome	O
VII	O
.	O

Two	O
fragments	O
originate	O
from	O
the	O
left	O
arm	O
of	O
this	O
chromosome	O
.	O

The	O
first	O
one	O
of	O
about	O
15.8	O
kb	O
starts	O
approximately	O
75	O
kb	O
from	O
the	O
left	O
telomere	O
and	O
is	O
bordered	O
by	O
the	O
SK18	O
chromosomal	O
marker	O
.	O

The	O
second	O
fragment	O
covers	O
the	O
72.6	O
kb	O
region	O
between	O
the	O
chromosomal	O
markers	O
CYH2	O
and	O
ALG2	O
.	O

On	O
the	O
right	O
chromosomal	O
arm	O
three	O
regions	O
,	O
a	O
70.6	O
kb	O
region	O
between	O
the	O
MSB2	O
and	O
the	O
KSS1	O
chromosomal	O
markers	O
and	O
two	O
smaller	O
regions	O
dominated	O
by	O
the	O
KRE11	O
marker	O
and	O
another	O
one	O
in	O
the	O
vicinity	O
of	O
the	O
SER2	O
marker	O
were	O
sequenced	O
.	O

We	O
found	O
a	O
total	O
of	O
114	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
13	O
of	O
which	O
were	O
completely	O
overlapping	O
with	O
larger	O
ORFs	O
running	O
in	O
the	O
opposite	O
direction	O
.	O

A	O
total	O
of	O
44	O
yeast	B
genes	O
,	O
the	O
physiological	O
functions	O
of	O
which	O
are	O
known	O
,	O
could	O
be	O
precisely	O
mapped	O
on	O
this	O
chromosome	O
.	O

Of	O
the	O
remaining	O
57	O
ORFs	O
,	O
26	O
shared	O
sequence	O
homologies	O
with	O
known	O
genes	O
,	O
among	O
which	O
were	O
13	O
other	O
S.	B
cerevisiae	I
genes	O
and	O
five	O
genes	O
from	O
other	O
organisms	O
.	O

No	O
homology	O
with	O
any	O
sequence	O
in	O
the	O
databases	O
could	O
be	O
found	O
for	O
31	O
ORFs	O
.	O

Furthermore	O
,	O
five	O
Ty	O
elements	O
were	O
found	O
,	O
one	O
of	O
which	O
may	O
not	O
be	O
functional	O
due	O
to	O
a	O
frame	O
shift	O
in	O
its	O
Ty1B	O
amino	O
acid	O
sequence	O
.	O

The	O
five	O
chromosomal	O
regions	O
harboured	O
five	O
potential	O
ARS	O
elements	O
and	O
one	O
sigma	O
element	O
together	O
with	O
eight	O
tRNA	O
genes	O
and	O
two	O
snRNAs	O
,	O
one	O
of	O
which	O
is	O
encoded	O
by	O
an	O
intron	O
of	O
a	O
protein	O
-	O
coding	O
gene	O
.	O

A	O
single	O
precursor	O
protein	O
for	O
ferrochelatase	O
-	O
I	O
from	O
Arabidopsis	B
is	O
imported	O
in	O
vitro	O
into	O
both	O
chloroplasts	O
and	O
mitochondria	O
.	O

Ferrochelatase	O
is	O
the	O
last	O
enzyme	O
of	O
heme	O
biosynthesis	O
and	O
in	O
higher	O
plants	O
is	O
found	O
in	O
both	O
chloroplasts	O
and	O
mitochondria	O
.	O

We	O
have	O
isolated	O
cDNAs	O
for	O
two	O
isoforms	O
of	O
ferrochelatase	O
from	O
Arabidopsis	B
thaliana	I
,	O
both	O
of	O
which	O
are	O
imported	O
into	O
isolated	O
chloroplasts	O
.	O

In	O
this	O
paper	O
we	O
show	O
that	O
ferrochelatase	O
-	O
I	O
is	O
also	O
imported	O
into	O
isolated	O
pea	B
mitochondria	O
with	O
approximately	O
the	O
same	O
efficiency	O
as	O
into	O
chloroplasts	O
.	O

Processing	O
of	O
the	O
precursor	O
was	O
observed	O
with	O
both	O
chloroplast	O
stroma	O
and	O
mitochondrial	O
matrix	O
extracts	O
.	O

This	O
was	O
inhibited	O
by	O
EDTA	O
,	O
indicating	O
it	O
was	O
due	O
to	O
the	O
specific	O
processing	O
proteases	O
.	O

The	O
specificity	O
of	O
import	O
was	O
verified	O
by	O
the	O
fact	O
that	O
the	O
mitochondrial	O
preparation	O
did	O
not	O
import	O
the	O
precursor	O
of	O
the	O
light	O
-	O
harvesting	O
chlorophyll	O
a	O
/	O
b	O
protein	O
precursor	O
or	O
the	O
precursor	O
of	O
porphobilinogen	O
deaminase	O
,	O
an	O
earlier	O
enzyme	O
of	O
tetrapyrrole	O
biosynthesis	O
,	O
both	O
of	O
which	O
are	O
exclusively	O
chloroplast	O
-	O
located	O
.	O

Furthermore	O
,	O
import	O
of	O
ferrochelatase	O
-	O
I	O
precursor	O
into	O
mitochondria	O
was	O
inhibited	O
by	O
valinomycin	O
,	O
but	O
this	O
had	O
no	O
effect	O
on	O
its	O
import	O
into	O
chloroplasts	O
.	O

Thus	O
a	O
single	O
precursor	O
molecule	O
is	O
recognized	O
by	O
the	O
import	O
machinery	O
of	O
the	O
two	O
organelles	O
.	O

The	O
implications	O
for	O
the	O
targeting	O
of	O
ferrochelatase	O
in	O
a	O
possible	O
protective	O
role	O
against	O
photooxidative	O
stress	O
are	O
discussed	O
.	O

Screening	O
for	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-dependent	O
cell	O
wall	O
proteins	O
in	O
Saccharomyces	B
cerevisiae	I
.	O

Open	O
reading	O
frames	O
in	O
the	O
genome	O
of	O
Saccharomyces	B
cerevisiae	I
were	O
screened	O
for	O
potential	O
glycosylphosphatidylinositol	O
(	O
GPI	O
)	O
-attached	O
proteins	O
.	O

The	O
identification	O
of	O
putative	O
GPI	O
-	O
attached	O
proteins	O
was	O
based	O
on	O
three	O
criteria	O
:	O
the	O
presence	O
of	O
a	O
GPI	O
-	O
attachment	O
signal	O
sequence	O
,	O
a	O
signal	O
sequence	O
for	O
secretion	O
and	O
a	O
serine-	O
or	O
threonine	O
-	O
rich	O
sequence	O
.	O

In	O
all	O
,	O
53	O
ORFs	O
met	O
these	O
three	O
criteria	O
and	O
38	O
were	O
further	O
analyzed	O
as	O
follows	O
.	O

The	O
sequence	O
encoding	O
the	O
40	O
C	O
-	O
terminal	O
amino	O
acids	O
of	O
each	O
was	O
fused	O
with	O
the	O
structural	O
gene	O
for	O
a	O
reporter	O
protein	O
consisting	O
of	O
a	O
secretion	O
signal	O
,	O
alpha	O
-	O
galactosidase	O
and	O
a	O
hemagglutinin	O
(	O
HA	O
)	O
epitope	O
,	O
and	O
examined	O
for	O
the	O
ability	O
to	O
become	O
incorporated	O
into	O
the	O
cell	O
wall	O
.	O

On	O
this	O
basis	O
,	O
14	O
of	O
fusion	O
proteins	O
were	O
classified	O
as	O
GPI	O
-	O
dependent	O
cell	O
wall	O
proteins	O
because	O
cells	O
expressing	O
these	O
fusion	O
proteins	O
:	O
(	O
i	O
)	O
had	O
high	O
levels	O
of	O
alpha	O
-	O
galactosidase	O
activity	O
on	O
their	O
surface	O
;	O
(	O
ii	O
)	O
released	O
significant	O
amounts	O
of	O
the	O
fusion	O
proteins	O
from	O
the	O
membrane	O
on	O
treatment	O
with	O
phosphatidylinositol	O
-	O
specific	O
phospholipase	O
C	O
(	O
PI	O
-	O
PLC	O
)	O
;	O
and	O
(	O
iii	O
)	O
released	O
fusion	O
proteins	O
from	O
the	O
cell	O
wall	O
following	O
treatment	O
with	O
laminarinase	O
.	O

Of	O
the	O
14	O
identified	O
putative	O
GPI	O
-	O
dependent	O
cell	O
wall	O
proteins	O
,	O
12	O
had	O
novel	O
ORFs	O
adjacent	O
to	O
their	O
GPI	O
-	O
attachment	O
signal	O
sequence	O
.	O

Amino	O
acid	O
sequence	O
alignment	O
of	O
the	O
C	O
-	O
terminal	O
sequences	O
of	O
the	O
12	O
ORFs	O
,	O
together	O
with	O
those	O
of	O
known	O
cell	O
wall	O
proteins	O
,	O
reveals	O
some	O
sequence	O
similarities	O
among	O
them	O
.	O

This	O
can	O
translate	O
into	O
global	O
effects	O
on	O
cellular	O
health	O
and	O
differentiation	O
state	O
.	O

Recently	O
,	O
several	O
reports	O
have	O
identified	O
crucial	O
roles	O
for	O
miRNAs	O
in	O
controlling	O
the	O
production	O
,	O
differentiation	O
,	O
and	O
health	O
of	O
myelinating	O
cells	O
of	O
the	O
mammalian	O
nervous	O
system	O
.	O

As	O
single	O
miRNAs	O
are	O
often	O
predicted	O
to	O
target	O
up	O
to	O
hundreds	O
of	O
individual	O
transcripts	O
,	O
miRNAs	O
are	O
able	O
to	O
broadly	O
affect	O
the	O
overall	O
protein	O
expression	O
state	O
of	O
the	O
cell	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
discuss	O
how	O
individual	O
miRNAs	O
regulate	O
these	O
various	O
processes	O
,	O
and	O
also	O
how	O
miRNA	O
production	O
in	O
general	O
is	O
required	O
for	O
several	O
stages	O
of	O
myelin	O
generation	O
and	O
maintenance	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
small	O
(	O
approx	O
.	O
22	O
nt	O
)	O
noncoding	O
RNAs	O
that	O
are	O
capable	O
of	O
post	O
-	O
transcriptionally	O
silencing	O
mRNAs	O
that	O
contain	O
sequences	O
complementary	O
to	O
the	O
miRNAs	O
'	O
7-	O
to	O
8-bp	O
'	O
seed	O
'	O
sequence	O
.	O

MicroRNAs	O
in	O
oligodendrocyte	O
and	O
Schwann	O
cell	O
differentiation	O
.	O

Identification	O
of	O
blood	O
microRNAs	O
associated	O
to	O
Parkinsońs	O
disease	O
.	O

While	O
miR-1	O
,	O
miR-22	O
*	O
and	O
miR-29	O
expression	O
levels	O
allowed	O
to	O
distinguish	O
non	O
-	O
treated	O
PD	O
from	O
healthy	O
subjects	O
,	O
miR-16	O
-	O
2	O
*	O
,	O
miR-26a2	O
*	O
and	O
miR30a	O
differentiated	O
treated	O
from	O
untreated	O
patients	O
.	B

They	O
form	O
two	O
groups	O
according	O
to	O
their	O
expression	O
profile	O
in	O
control	O
,	O
non	O
-	O
treated	O
,	O
early	O
-	O
onset	O
and	O
treated	O
Parkinson	O
's	O
disease	O
subjects	O
.	O

A	O
set	O
of	O
six	O
differentially	O
expressed	O
microRNAs	O
were	O
identified	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
blood	O
samples	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
miRNA	O
identification	O
associated	O
to	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

This	O
study	O
is	O
innovative	O
in	O
contributing	O
to	O
the	O
development	O
of	O
effective	O
PD	O
biomarkers	O
.	O

Our	O
data	O
suggests	O
that	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
may	O
contribute	O
to	O
glioma	O
and	O
GBM	O
,	O
in	O
part	O
,	O
by	O
coordinately	O
up	O
-	O
regulating	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
,	O
resulting	O
in	O
the	O
proliferation	O
of	O
undifferentiated	O
GBM	O
cells	O
.	O

Addition	O
of	O
exogenous	O
miRNA-128	O
to	O
CRL-1690	O
and	O
CRL-2610	O
GBM	O
cell	O
lines	O
(	O
a	O
)	O
restored	O
'	O
homeostatic	O
'	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
expression	O
,	O
and	O
(	O
b	O
)	O
significantly	O
decreased	O
the	O
proliferation	O
of	O
CRL-1690	O
and	O
CRL-2610	O
cell	O
lines	O
.	O

Three	O
bioinformatics	O
-	O
verified	O
miRNA-128	O
targets	O
,	O
angiopoietin	O
-	O
related	O
growth	O
factor	O
protein	O
5	O
(	O
ARP5	O
;	O
ANGPTL6	O
)	O
,	O
a	O
transcription	O
suppressor	O
that	O
promotes	O
stem	O
cell	O
renewal	O
and	O
inhibits	O
the	O
expression	O
of	O
known	O
tumor	O
suppressor	O
genes	O
involved	O
in	O
senescence	O
and	O
differentiation	O
,	O
Bmi-1	O
,	O
and	O
a	O
transcription	O
factor	O
critical	O
for	O
the	O
control	O
of	O
cell	O
-	O
cycle	O
progression	O
,	O
E2F-3a	O
,	O
were	O
found	O
to	O
be	O
up	O
-	O
regulated	O
.	O

The	O
down	O
-	O
regulation	O
of	O
miRNA-128	O
was	O
found	O
to	O
inversely	O
correlate	O
with	O
WHO	O
tumor	O
grade	O
.	O

High	O
density	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
arrays	O
,	O
fluorescent	O
-	O
reporter	O
miRNA	O
assay	O
and	O
Northern	O
miRNA	O
dot	O
-	O
blot	O
analysis	O
show	O
that	O
a	O
brain	O
-	O
enriched	O
miRNA-128	O
is	O
significantly	O
down	O
-	O
regulated	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
and	O
in	O
GBM	O
cell	O
lines	O
when	O
compared	O
to	O
age	O
-	O
matched	O
controls	O
.	O

Micro	O
-	O
RNA-128	O
(	O
miRNA-128	O
)	O
down	O
-	O
regulation	O
in	O
glioblastoma	O
targets	O
ARP5	O
(	O
ANGPTL6	O
)	O
,	O
Bmi-1	O
and	O
E2F-3a	O
,	O
key	O
regulators	O
of	O
brain	O
cell	O
proliferation	O
.	O

This	O
reveals	O
a	O
previously	O
unrecognized	O
signaling	O
cascade	O
involved	O
in	O
meningioma	O
tumor	O
development	O
and	O
highlights	O
a	O
novel	O
molecular	O
interaction	O
between	O
miR-200a	O
and	O
Wnt	O
signaling	O
,	O
thereby	O
providing	O
insights	O
into	O
novel	O
therapies	O
for	O
meningiomas	O
.	O

A	O
direct	O
correlation	O
was	O
found	O
between	O
the	O
downregulation	O
of	O
miR-200a	O
and	O
the	O
upregulation	O
of	O
beta	O
-	O
catenin	O
in	O
human	B
meningioma	O
samples	O
.	O

Thus	O
,	O
miR-200a	O
appears	O
to	O
act	O
as	O
a	O
multifunctional	O
tumor	O
suppressor	O
miRNA	O
in	O
meningiomas	O
through	O
effects	O
on	O
the	O
E	O
-	O
cadherin	O
and	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
pathways	O
.	O

miR-200a	O
was	O
found	O
to	O
directly	O
target	O
beta	O
-	O
catenin	O
mRNA	O
,	O
thereby	O
inhibiting	O
its	O
translation	O
and	O
blocking	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
,	O
which	O
is	O
frequently	O
involved	O
in	O
cancer	O
.	O

Downregulation	O
of	O
miR-200a	O
in	O
meningiomas	O
and	O
arachnoidal	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
beta	O
-	O
catenin	O
and	O
cyclin	O
D1	O
involved	O
in	O
cell	O
proliferation	O
.	O

Upregulation	O
of	O
miR-200a	O
decreased	O
the	O
expression	O
of	O
transcription	O
factors	O
ZEB1	O
and	O
SIP1	O
,	O
with	O
consequent	O
increased	O
expression	O
of	O
E	O
-	O
cadherin	O
,	O
an	O
adhesion	O
protein	O
associated	O
with	O
cell	O
differentiation	O
.	O

Elevated	O
levels	O
of	O
miR-200a	O
inhibited	O
meningioma	O
cell	O
growth	O
in	O
culture	O
and	O
in	O
a	O
tumor	O
model	O
in	O
vivo	O
.	O

Meningiomas	O
,	O
one	O
of	O
the	O
most	O
common	O
human	B
brain	O
tumors	O
,	O
are	O
derived	O
from	O
arachnoidal	O
cells	O
associated	O
with	O
brain	O
meninges	O
,	O
are	O
usually	O
benign	O
,	O
and	O
are	O
frequently	O
associated	O
with	O
neurofibromatosis	O
type	O
2	O
.	O
Here	O
,	O
we	O
define	O
a	O
typical	O
human	B
meningioma	O
microRNA	O
(	O
miRNA	O
)	O
profile	O
and	O
characterize	O
the	O
effects	O
of	O
one	O
downregulated	O
miRNA	O
,	O
miR-200a	O
,	O
on	O
tumor	O
growth	O
.	O

Downregulated	O
microRNA-200a	O
in	O
meningiomas	O
promotes	O
tumor	O
growth	O
by	O
reducing	O
E	O
-	O
cadherin	O
and	O
activating	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
signaling	O
pathway	O
.	O

In	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
brain	O
miRNA	O
profiles	O
are	O
altered	O
;	O
thus	O
miRNA	O
dysfunction	O
could	O
be	O
both	O
a	O
cause	O
and	O
a	O
consequence	O
of	O
disease	O
.	O

These	O
small	O
non	O
-	O
coding	O
RNA	O
regulators	O
are	O
highly	O
enriched	O
in	O
brain	O
where	O
they	O
play	O
key	O
roles	O
in	O
neuronal	O
development	O
,	O
plasticity	O
and	O
disease	O
.	O

Normal	O
brain	O
development	O
and	O
function	O
depends	O
on	O
microRNA	O
(	O
miRNA	O
)	O
networks	O
to	O
fine	O
tune	O
the	O
balance	O
between	O
the	O
transcriptome	O
and	O
proteome	O
of	O
the	O
cell	O
.	O

Neuronal	O
microRNA	O
deregulation	O
in	O
response	O
to	O
Alzheimer	O
's	O
disease	O
amyloid	O
-	O
beta	O
.	O

Bioinformatic	O
analysis	O
predicts	O
that	O
the	O
deregulated	O
miRNAs	O
are	O
likely	O
to	O
affect	O
target	O
genes	O
present	O
in	O
prominent	O
neuronal	O
pathways	O
known	O
to	O
be	O
disrupted	O
in	O
AD	O
.	O
Remarkably	O
,	O
we	O
also	O
found	O
that	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
was	O
paralleled	O
in	O
vivo	O
by	O
a	O
deregulation	O
in	O
the	O
hippocampus	O
of	O
Abeta42-depositing	O
APP23	O
mice	B
,	O
at	O
the	O
onset	O
of	O
Abeta	O
plaque	O
formation	O
.	O

Time	O
-	O
course	O
assays	O
of	O
neuronal	O
Abeta	O
treatments	O
show	O
that	O
Abeta	O
is	O
in	O
fact	O
a	O
powerful	O
regulator	O
of	O
miRNA	O
levels	O
as	O
the	O
response	O
of	O
certain	O
mature	O
miRNAs	O
is	O
extremely	O
rapid	O
.	O

We	O
used	O
sensitive	O
TaqMan	O
low	O
density	O
miRNA	O
arrays	O
(	O
TLDA	O
)	O
on	O
murine	B
primary	O
hippocampal	O
cultures	O
to	O
show	O
that	O
about	O
half	O
of	O
all	O
miRNAs	O
tested	O
were	O
down	O
-	O
regulated	O
in	O
response	O
to	O
Abeta	O
peptides	O
.	O

Our	O
study	O
dissects	O
the	O
complexity	O
of	O
human	B
AD	O
pathology	O
,	O
and	O
addresses	O
the	O
hypothesis	O
that	O
amyloid	O
-	O
beta	O
(	O
Abeta	O
)	O
itself	O
,	O
a	O
known	O
causative	O
factor	O
of	O
AD	O
,	O
causes	O
neuronal	O
miRNA	O
deregulation	O
,	O
which	O
could	O
contribute	O
to	O
the	O
pathomechanisms	O
of	O
AD	O
.	O

In	O
addition	O
,	O
the	O
miRNA	O
deregulation	O
in	O
hippocampal	O
cultures	O
and	O
APP23	O
hippocampus	O
overlaps	O
with	O
those	O
obtained	O
in	O
human	B
AD	O
studies	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
neuronal	O
miRNA	O
deregulation	O
in	O
response	O
to	O
an	O
insult	O
by	O
Abeta	O
may	O
be	O
an	O
important	O
factor	O
contributing	O
to	O
the	O
cascade	O
of	O
events	O
leading	O
to	O
AD	O
.	O

Isolation	O
and	O
characterization	O
of	O
a	O
novel	O
pituitary	O
tumor	O
apoptosis	O
gene	O
.	O

We	O
report	O
the	O
isolation	O
of	O
a	O
novel	O
differentially	O
methylated	O
chromosome	O
22	O
CpG	O
island	O
-	O
associated	O
gene	O
(	O
C22orf3	O
)	O
.	O

To	O
determine	O
mechanisms	O
for	O
pituitary	O
neoplasia	O
we	O
used	O
methylation	O
-	O
sensitive	O
arbitrarily	O
primed	O
-	O
PCR	O
to	O
isolate	O
novel	O
genes	O
that	O
are	O
differentially	O
methylated	O
relative	O
to	O
normal	O
pituitary	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
individual	O
adenomas	O
showed	O
that	O
6	O
of	O
30	O
(	O
20	O
%	O
)	O
that	O
failed	O
to	O
express	O
pituitary	O
tumor	O
apoptosis	O
gene	O
(	O
PTAG	O
)	O
were	O
methylated	O
;	O
however	O
,	O
genetic	O
change	O
as	O
determined	O
by	O
loss	O
of	O
heterozygosity	O
and	O
sequence	O
analysis	O
was	O
not	O
apparent	O
in	O
the	O
remaining	O
tumors	O
that	O
failed	O
to	O
express	O
this	O
gene	O
.	O

Sodium	O
bisulfite	O
sequencing	O
of	O
pooled	O
tumor	O
cohorts	O
,	O
used	O
in	O
the	O
isolation	O
of	O
this	O
gene	O
,	O
showed	O
that	O
only	O
a	O
proportion	O
of	O
the	O
adenomas	O
within	O
the	O
pools	O
were	O
methylated	O
;	O
however	O
,	O
expression	O
analysis	O
by	O
quantitative	O
RT	O
-	O
PCR	O
of	O
individual	O
adenoma	O
irrespective	O
of	O
subtype	O
showed	O
the	O
majority	O
(	O
30	O
of	O
38	O
;	O
79	O
%	O
)	O
failed	O
to	O
express	O
this	O
gene	O
relative	O
to	O
normal	O
pituitary	O
.	O

Enforced	O
expression	O
of	O
C22orf3	O
in	O
AtT20	O
cells	O
had	O
no	O
measurable	O
effects	O
on	O
cell	O
proliferation	O
or	O
viability	O
;	O
however	O
,	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
(	O
10	O
-	O
40	O
microm	O
)	O
cells	O
expressing	O
this	O
gene	O
showed	O
a	O
significantly	O
augmented	O
apoptotic	O
response	O
as	O
determined	O
by	O
both	O
acridine	O
orange	O
staining	O
and	O
TUNEL	O
labeling	O
.	O

In	O
those	O
cases	O
where	O
the	O
CpG	O
island	O
of	O
these	O
genes	O
was	O
methylated	O
it	O
was	O
invariably	O
associated	O
with	O
loss	O
of	O
transcript	O
expression	O
.	O

In	O
addition	O
,	O
in	O
time	O
course	O
experiments	O
,	O
direct	O
measurement	O
of	O
active	O
caspases	O
by	O
fluorochrome	O
-	O
labeled	O
inhibition	O
of	O
caspases	O
,	O
showed	O
an	O
augmented	O
increase	O
(	O
approximately	O
2.4	O
fold	O
)	O
in	O
active	O
caspases	O
in	O
response	O
to	O
bromocriptine	O
challenge	O
in	O
cells	O
expressing	O
C22orf3	O
relative	O
to	O
those	O
harboring	O
an	O
empty	O
vector	O
control	O
.	O

The	O
apoptotic	O
response	O
to	O
bromocriptine	O
challenge	O
was	O
inhibited	O
in	O
coincubation	O
experiments	O
with	O
the	O
general	O
caspase	O
inhibitor	O
z	O
-	O
VAD	O
-	O
fmk	O
.	O

The	O
pituitary	O
tumor	O
derivation	O
and	O
its	O
role	O
in	O
apoptosis	O
of	O
this	O
gene	O
led	O
us	O
to	O
assign	O
the	O
acronym	O
PTAG	O
to	O
this	O
gene	O
and	O
its	O
protein	O
product	O
.	O

The	O
ability	O
of	O
cells	O
,	O
showing	O
reduced	O
expression	O
of	O
PTAG	O
,	O
to	O
evade	O
or	O
show	O
a	O
blunted	O
apoptotic	O
response	O
may	O
underlie	O
oncogenic	O
transformation	O
in	O
both	O
the	O
pituitary	O
and	O
other	O
tumor	O
types	O
.	O

It	O
has	O
been	O
recently	O
demonstrated	O
that	O
herpesviruses	O
encode	O
miRNAs	O
to	O
control	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
expression	O
from	O
their	O
own	O
genomes	O
and	O
possibly	O
that	O
of	O
their	O
host	O
,	O
thus	O
adding	O
an	O
additional	O
layer	O
of	O
complexity	O
to	O
the	O
physiological	O
cross	O
-	O
talk	O
between	O
host	O
and	O
pathogen	O
.	O

MicroRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
approximately	O
22	O
nt	O
long	O
that	O
modulate	O
gene	O
expression	O
in	O
animals	O
and	O
plants	O
.	O

Co	O
-	O
expression	O
of	O
host	O
and	O
viral	O
microRNAs	O
in	O
porcine	B
dendritic	O
cells	O
infected	O
by	O
the	O
pseudorabies	O
virus	O
.	O

Almost	O
95	O
%	O
of	O
reads	O
mapped	O
to	O
the	O
draft	O
pig	B
genome	O
sequence	O
and	O
pig	B
miRNAs	O
previously	O
annotated	O
in	O
dedicated	O
databases	O
were	O
detected	O
by	O
sequence	O
alignment	O
.	O

An	O
average	O
of	O
2	O
million	O
reads	O
per	O
sample	O
with	O
a	O
size	O
of	O
21	O
-	O
24	O
nucleotides	O
was	O
obtained	O
from	O
six	O
libraries	O
representing	O
three	O
biological	O
replicates	O
of	O
infected	O
and	O
mock	O
-	O
infected	O
DCs	O
.	O

A	O
catalogue	O
of	O
porcine	B
and	O
viral	O
miRNAs	O
,	O
expressed	O
eight	O
hours	O
post	O
-	O
infection	O
,	O
was	O
established	O
by	O
deep	O
sequencing	O
.	O

The	O
present	O
study	O
focussed	O
on	O
the	O
interactions	O
between	O
porcine	B
dendritic	O
cells	O
(	O
DCs	O
)	O
and	O
the	O
Pseudorabies	O
virus	O
(	O
PRV	O
)	O
,	O
an	O
alpha	O
-	O
herpesvirus	O
causing	O
Aujeszky	O
's	O
disease	O
in	O
pigs	B
.	O

In	O
silico	O
prediction	O
allowed	O
the	O
identification	O
of	O
unknown	O
porcine	B
as	O
well	O
as	O
of	O
five	O
miRNAs	O
transcribed	O
by	O
the	O
Large	O
Latency	O
Transcript	O
(	O
LLT	O
)	O
of	O
PRV	O
.	O

The	O
gene	O
target	O
prediction	O
of	O
the	O
viral	O
miRNAs	O
and	O
the	O
Ingenuity	O
Pathway	O
Analysis	O
of	O
differentially	O
expressed	O
pig	B
miRNAs	O
were	O
conducted	O
to	O
contextualize	O
the	O
identified	O
small	O
RNA	O
molecules	O
and	O
functionally	O
characterize	O
their	O
involvement	O
in	O
the	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
.	O

The	O
results	O
support	O
a	O
role	O
for	O
PRV	O
miRNAs	O
in	O
the	O
maintenance	O
of	O
the	O
host	O
cell	O
latency	O
state	O
through	O
the	O
down	O
-	O
regulation	O
of	O
immediate	O
-	O
early	O
viral	O
genes	O
which	O
is	O
similar	O
to	O
other	O
herpesviruses	O
.	O

The	O
differentially	O
expressed	O
swine	B
miRNAs	O
identified	O
a	O
unique	O
network	O
of	O
target	O
genes	O
with	O
highly	O
significant	O
functions	O
in	O
the	O
development	O
and	O
function	O
of	O
the	O
nervous	O
system	O
and	O
in	O
infectious	O
mechanisms	O
,	O
suggesting	O
that	O
the	O
modulation	O
of	O
both	O
host	O
and	O
viral	O
miRNAs	O
is	O
necessary	O
for	O
the	O
establishment	O
of	O
PRV	O
latency	O
.	O

The	O
RAKE	O
assay	O
is	O
theoretically	O
versatile	O
and	O
may	O
be	O
used	O
for	O
other	O
applications	O
,	O
such	O
as	O
viral	O
gene	O
profiling	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
can	O
be	O
isolated	O
and	O
profiled	O
from	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
which	O
opens	O
up	O
new	O
opportunities	O
for	O
analyses	O
of	O
small	O
RNAs	O
from	O
archival	O
human	B
tissue	O
.	O

RAKE	O
offers	O
unique	O
advantages	O
for	O
specificity	O
over	O
northern	O
blots	O
or	O
other	O
microarray	O
-	O
based	O
expression	O
profiling	O
platforms	O
.	O

We	O
show	O
that	O
the	O
RAKE	O
assay	O
is	O
sensitive	O
and	O
specific	O
for	O
miRNAs	O
and	O
is	O
ideally	O
suited	O
for	O
rapid	O
expression	O
profiling	O
of	O
all	O
known	O
miRNAs	O
.	O

We	O
used	O
RAKE	O
to	O
study	O
human	B
cell	O
lines	O
and	O
brain	O
tumors	O
.	O

The	O
technique	O
is	O
termed	O
the	O
RNA	O
-	O
primed	O
,	O
array	O
-	O
based	O
Klenow	O
enzyme	O
(	O
RAKE	O
)	O
assay	O
,	O
because	O
it	O
involves	O
on	O
-	O
slide	O
application	O
of	O
the	O
Klenow	O
fragment	O
of	O
DNA	O
polymerase	O
I	O
to	O
extend	O
unmodified	O
miRNAs	O
hybridized	O
to	O
immobilized	O
DNA	O
probes	O
.	O

We	O
describe	O
a	O
new	O
method	O
for	O
high	O
-	O
throughput	O
miRNA	O
detection	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
regulatory	O
RNAs	O
that	O
serve	O
fundamental	O
biological	O
roles	O
across	O
eukaryotic	O
species	O
.	O

Microarray	O
-	O
based	O
,	O
high	O
-	O
throughput	O
gene	O
expression	O
profiling	O
of	O
microRNAs	O
.	O

Brain	O
cells	O
maintain	O
distinct	O
populations	O
of	O
miRNAs	O
that	O
support	O
physiologically	O
normal	O
patterns	O
of	O
expression	O
,	O
however	O
,	O
certain	O
miRNA	O
abundances	O
are	O
significantly	O
altered	O
in	O
neurodegenerative	O
disorders	O
such	O
as	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Here	O
we	O
provide	O
evidence	O
in	O
human	B
neural	O
(	O
HN	O
)	O
cells	O
of	O
an	O
aluminum	O
-	O
sulfate-	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
-mediated	O
up	O
-	O
regulation	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
miRNA-146a	O
that	O
down	O
-	O
regulates	O
the	O
expression	O
of	O
complement	O
factor	O
H	O
(	O
CFH	O
)	O
,	O
an	O
important	O
repressor	O
of	O
inflammation	O
.	O

Characterization	O
of	O
an	O
NF	O
-	O
kappaB	O
-	O
regulated	O
,	O
miRNA-146a	O
-	O
mediated	O
down	O
-	O
regulation	O
of	O
complement	O
factor	O
H	O
(	O
CFH	O
)	O
in	O
metal	O
-	O
sulfate	O
-	O
stressed	O
human	B
brain	O
cells	O
.	O

Micro	O
RNAs	O
(	O
miRNAs	O
)	O
represent	O
a	O
family	O
of	O
small	O
ribonucleic	O
acids	O
(	O
RNAs	O
)	O
that	O
are	O
post	O
-	O
transcriptional	O
regulators	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
.	O

An	O
NF	O
-	O
kappaB	O
-	O
containing	O
miRNA-146a	O
-	O
promoter	O
-	O
luciferase	O
reporter	O
construct	O
transfected	O
into	O
HN	O
cells	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-146a	O
after	O
aluminum	O
-	O
sulfate	O
treatment	O
that	O
corresponded	O
to	O
decreased	O
CFH	O
gene	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
(	O
1	O
)	O
as	O
in	O
AD	O
brain	O
,	O
NF	O
-	O
kappaB	O
-	O
sensitive	O
,	O
miRNA-146a	O
-	O
mediated	O
,	O
modulation	O
of	O
CFH	O
gene	O
expression	O
may	O
contribute	O
to	O
inflammatory	O
responses	O
in	O
aluminum	O
-	O
stressed	O
HN	O
cells	O
,	O
and	O
(	O
2	O
)	O
underscores	O
the	O
potential	O
of	O
nanomolar	O
aluminum	O
to	O
drive	O
genotoxic	O
mechanisms	O
characteristic	O
of	O
neurodegenerative	O
disease	O
processes	O
.	O

This	O
NF	O
-	O
kappaB	O
-	O
miRNA-146a	O
-	O
CFH	O
signaling	O
circuit	O
is	O
known	O
to	O
be	O
similarly	O
affected	O
by	O
Abeta42	O
peptides	O
and	O
in	O
AD	O
brain	O
.	O

These	O
aluminum	O
-	O
sulfate	O
-	O
inducible	O
events	O
were	O
not	O
observed	O
in	O
parallel	O
experiments	O
using	O
iron-	O
,	O
magnesium-	O
,	O
or	O
zinc	O
-	O
sulfate	O
-	O
stressed	O
HN	O
cells	O
.	O

A	O
specific	O
subset	O
of	O
five	O
miRNAs	O
revealed	O
by	O
in	O
silico	O
target	O
prediction	O
was	O
significantly	O
overexpressed	O
in	O
NFA	O
samples	O
;	O
three	O
miRs	O
(	O
miR-128a	O
,	O
miR-155	O
,	O
and	O
miR-516a-3p	O
)	O
targeted	O
the	O
3'-untranslated	O
region	O
of	O
the	O
Wee1	O
transcript	O
,	O
and	O
exogenous	O
overexpression	O
of	O
these	O
miRs	O
inhibited	O
Wee1	O
protein	O
expression	O
and	O
HeLa	O
cell	O
proliferation	O
.	O

RESULTS	O
:	O
Wee1	O
protein	O
expression	O
was	O
decreased	O
in	O
NFAs	O
and	O
GH	O
-	O
producing	O
tumors	O
with	O
or	O
without	O
prolactin	O
production	O
,	O
but	O
no	O
change	O
in	O
mRNA	O
expression	O
was	O
observed	O
with	O
qRT	O
-	O
PCR	O
.	O

CONCLUSIONS	O
:	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
suggesting	O
that	O
regulation	O
of	O
Wee1	O
kinase	O
by	O
miRs	O
may	O
be	O
linked	O
to	O
pituitary	O
tumorigenesis	O
.	O

CONTEXT	O
:	O
The	O
tumorigenic	O
mechanisms	O
involved	O
in	O
pituitary	O
adenomas	O
,	O
especially	O
of	O
nonfunctional	O
pituitary	O
adenomas	O
(	O
NFAs	O
)	O
,	O
remains	O
unclear	O
.	O

Down	O
-	O
regulation	O
of	O
Wee1	O
kinase	O
by	O
a	O
specific	O
subset	O
of	O
microRNA	O
in	O
human	B
sporadic	O
pituitary	O
adenomas	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
examine	O
the	O
expression	O
of	O
Wee1	O
in	O
pituitary	O
tumors	O
and	O
to	O
identify	O
microRNAs	O
(	O
miRs	O
)	O
that	O
can	O
regulate	O
its	O
expression	O
.	O

Various	O
cell	O
cycle	O
inhibitors	O
have	O
been	O
found	O
to	O
be	O
underexpressed	O
in	O
pituitary	O
tumors	O
;	O
however	O
,	O
Wee1	O
kinase	O
,	O
a	O
nuclear	O
protein	O
that	O
delays	O
mitosis	O
and	O
was	O
recently	O
recognized	O
as	O
a	O
tumor	O
suppressor	O
gene	O
,	O
has	O
not	O
been	O
previously	O
investigated	O
in	O
pituitary	O
tumors	O
.	O

Identification	O
of	O
miRs	O
targeting	O
the	O
Wee1	O
3'-untranslated	O
region	O
was	O
performed	O
by	O
miR	O
array	O
followed	O
by	O
expression	O
analysis	O
of	O
identified	O
miRs	O
using	O
qRT	O
-	O
PCR	O
.	O

DESIGN	O
:	O
Expression	O
of	O
Wee1	O
was	O
examined	O
by	O
immunohistochemistry	O
and	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

PATIENTS	B
:	O
A	O
total	O
of	O
57	O
pituitary	O
tissue	O
samples	O
including	O
27	O
NFAs	O
,	O
15	O
GH	O
-	O
producing	O
adenomas	O
with	O
or	O
without	O
prolactin	O
overproduction	O
,	O
and	O
15	O
normal	O
pituitary	O
glands	O
were	O
analyzed	O
.	O

Dual	O
-	O
luciferase	O
assay	O
and	O
transient	O
transfection	O
of	O
miRs	O
into	O
Hela	O
cells	O
followed	O
by	O
immunoblot	O
analysis	O
of	O
Wee1	O
protein	O
and	O
cell	O
proliferation	O
analysis	O
were	O
carried	O
out	O
.	O

In	O
this	O
review	O
article	O
,	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
role	O
and	O
function	O
of	O
miRNAs	O
in	O
the	O
regulation	O
of	O
genes	O
involved	O
in	O
neurological	O
and	O
neurodegenerative	O
diseases	O
will	O
be	O
discussed	O
,	O
with	O
a	O
focus	O
on	O
the	O
fragile	O
X	O
syndrome	O
,	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
and	O
prion	O
disease	O
.	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

MicroRNAs	O
as	O
a	O
molecular	O
basis	O
for	O
mental	O
retardation	O
,	O
Alzheimer	O
's	O
and	O
prion	O
diseases	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
,	O
approximately	O
21-	O
to	O
23-nucleotide	O
(	O
nt	O
)	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
act	O
as	O
key	O
regulators	O
of	O
gene	O
expression	O
along	O
a	O
central	O
and	O
well	O
-	O
defined	O
cellular	O
process	O
known	O
as	O
RNA	O
silencing	O
,	O
and	O
involving	O
the	O
recognition	O
and	O
translational	O
control	O
of	O
specific	O
messenger	O
RNA	O
(	O
mRNAs	O
)	O
.	O

Generated	O
through	O
the	O
well	O
-	O
orchestrated	O
and	O
sequential	O
processing	O
of	O
miRNA	O
precursor	O
molecules	O
,	O
mature	O
miRNAs	O
are	O
subsequently	O
incorporated	O
into	O
miRNA	O
-	O
containing	O
ribonucleoprotein	O
effector	O
complexes	O
to	O
regulate	O
mRNA	O
translation	O
through	O
the	O
recognition	O
of	O
specific	O
binding	O
sites	O
of	O
imperfect	O
complementarity	O
located	O
mainly	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
.	O

Predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	B
,	O
miRNAs	O
may	O
thus	O
control	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	B
body	O
.	O

High	O
levels	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
also	O
significantly	O
correlated	O
with	O
the	O
proliferation	O
marker	O
Ki-67	O
(	O
P<0.0001	O
)	O
.	O

High	O
levels	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
were	O
more	O
frequently	O
observed	O
in	O
macroadenomas	O
than	O
in	O
microadenomas	O
(	O
P<0.05	O
)	O
.	O

Overexpression	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
was	O
observed	O
in	O
39	O
%	O
(	O
38	O
/	O
98	O
)	O
of	O
pituitary	O
adenomas	O
compared	O
with	O
normal	O
adenohypophysial	O
tissue	O
and	O
was	O
frequently	O
found	O
in	O
adenomas	O
including	O
prolactin	O
(	O
PRL	O
)	O
,	O
adrenocorticotrophic	O
hormone	O
,	O
or	O
follicle	O
-	O
stimulating	O
hormone	O
/	O
luteinizing	O
hormone	O
and	O
in	O
null	O
cell	O
adenomas	O
,	O
but	O
relatively	O
rare	O
in	O
growth	O
hormone	O
(	O
GH	O
)	O
and	O
mixed	O
GH	O
/	O
PRL	O
adenomas	O
.	O

High	O
-	O
mobility	O
group	O
A2	O
expression	O
was	O
significantly	O
associated	O
with	O
tumor	O
invasion	O
(	O
P<0.05	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
grade	O
IV	O
than	O
in	O
grades	O
I	O
,	O
II	O
,	O
and	O
III	O
adenomas	O
(	O
P<0.05	O
)	O
.	O

However	O
,	O
no	O
studies	O
have	O
investigated	O
the	O
clinical	O
significance	O
of	O
high	O
-	O
mobility	O
group	O
A2	O
and	O
its	O
relationship	O
to	O
the	O
let-7	O
miRNA	O
family	O
in	O
human	B
pituitary	O
adenomas	O
.	O

Using	O
immunohistochemistry	O
,	O
we	O
analyzed	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
with	O
respect	O
to	O
various	O
clinicopathologic	O
factors	O
in	O
98	O
pituitary	O
adenomas	O
.	O

Recent	O
studies	O
report	O
that	O
high	O
-	O
mobility	O
group	O
A2	O
is	O
negatively	O
regulated	O
by	O
the	O
let-7	O
microRNAs	O
(	O
miRNAs	O
)	O
family	O
in	O
vitro	O
.	O

The	O
development	O
of	O
pituitary	O
adenomas	O
in	O
high	O
-	O
mobility	O
group	O
A2	O
transgenic	B
mice	I
showed	O
that	O
high	O
-	O
mobility	O
group	O
A2	O
may	O
be	O
involved	O
in	O
pituitary	O
tumorigenesis	O
.	O

Overexpression	O
of	O
HMGA2	O
relates	O
to	O
reduction	O
of	O
the	O
let-7	O
and	O
its	O
relationship	O
to	O
clinicopathological	O
features	O
in	O
pituitary	O
adenomas	O
.	O

High	O
-	O
mobility	O
group	O
A2	O
is	O
highly	O
expressed	O
during	O
embryogenesis	O
and	O
in	O
various	O
benign	O
and	O
malignant	O
tumors	O
.	O

Real	O
-	O
time	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
was	O
carried	O
out	O
to	O
evaluate	O
the	O
expression	O
of	O
let-7	O
in	O
55	O
pituitary	O
adenomas	O
.	O

Subsequently	O
,	O
decreased	O
expression	O
of	O
let-7	O
was	O
confirmed	O
in	O
23	O
of	O
55	O
(	O
42	O
%	O
)	O
adenomas	O
and	O
was	O
correlated	O
with	O
high	O
-	O
grade	O
tumors	O
(	O
P<0.05	O
)	O
.	O

An	O
inverse	O
correlation	O
between	O
let-7	O
and	O
high	O
-	O
mobility	O
group	O
A2	O
expression	O
was	O
evident	O
(	O
R=-0.33	O
,	O
P<0.05	O
)	O
.	O

These	O
findings	O
support	O
a	O
causal	O
link	O
between	O
let-7	O
and	O
high	O
-	O
mobility	O
group	O
A2	O
whereby	O
loss	O
of	O
let-7	O
expression	O
induces	O
high	O
-	O
mobility	O
group	O
A2	O
upregulation	O
that	O
represents	O
an	O
important	O
mechanism	O
in	O
pituitary	O
tumorigenesis	O
and	O
progression	O
.	O

The	O
proliferation	O
inhibition	O
and	O
induced	O
apoptosis	O
by	O
this	O
recombinant	O
with	O
an	O
apoptosis	O
ratio	O
of	O
21.89	O
%	O
in	O
U87	O
cell	O
were	O
also	O
observed	O
.	O

The	O
results	O
of	O
Western	O
blot	O
indicated	O
the	O
expression	O
of	O
Flag	O
of	O
No	O
1	O
recombinant	O
plasmid	O
group	O
was	O
inhibited	O
heavily	O
with	O
a	O
34.3	O
%	O
expression	O
level	O
by	O
compared	O
with	O
control	O
group	O
.	O

The	O
expressed	O
Flag	O
protein	O
was	O
detected	O
by	O
Western	O
blot	O
to	O
evaluate	O
the	O
inhibition	O
effect	O
of	O
targeting	O
sequences	O
.	O

The	O
confirmed	O
pGCSIL	O
-	O
GFP	O
recombinants	O
by	O
combining	O
with	O
pEGFP	O
-	O
miR-221	O
were	O
transfected	O
into	O
293	O
T	O
cells	O
seperately	O
.	O

RESULTS	O
:	O
The	O
resulting	O
recombinants	O
were	O
confirmed	O
by	O
sequencing	O
which	O
demonstrated	O
that	O
the	O
recombinant	O
plasmids	O
contained	O
the	O
correct	O
sequences	O
of	O
designed	O
transcript	O
templates	O
.	O

Then	O
a	O
recombinant	O
with	O
the	O
highest	O
anti	O
-	O
miR-221	O
effect	O
was	O
screened	O
and	O
transfected	O
into	O
U87	O
glioma	O
cell	O
,	O
and	O
its	O
anti	O
-	O
tumor	O
effect	O
was	O
evaluated	O
by	O
MTT	O
and	O
FCM	O
.	O

[	O
Construction	O
and	O
screening	O
an	O
effective	O
anti	O
-	O
miR-221	O
RNAi	O
vector	O
in	O
vitro	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
construct	O
and	O
screen	O
an	O
effective	O
anti	O
-	O
miR-221	O
vector	O
of	O
siRNA	O
.	O

METHODS	O
:	O
Four	O
hairpin	O
structure	O
of	O
siRNA	O
transcript	O
templates	O
targeting	O
miR-221	O
and	O
a	O
negative	O
control	O
were	O
synthesized	O
,	O
then	O
ligated	O
with	O
pGCSIL	O
-	O
GFP	O
vector	O
and	O
a	O
pEGFP	O
-	O
miR-221	O
which	O
express	O
pre	O
-	O
miR-221	O
was	O
also	O
constructed	O
.	O

All	O
the	O
recombinants	O
were	O
sequenced	O
.	O

CONCLUSION	O
:	O
The	O
anti	O
-	O
miR-221	O
expression	O
siRNA	O
espression	O
recombinants	O
were	O
constructed	O
successfully	O
,	O
and	O
one	O
sequence	O
with	O
the	O
highest	O
inhibition	O
efficiency	O
was	O
screened	O
out	O
,	O
which	O
could	O
inhibit	O
U87	O
cell	O
proliferation	O
and	O
induce	O
cell	O
apoptosis	O
,	O
and	O
could	O
be	O
used	O
to	O
suppress	O
target	O
gene	O
for	O
further	O
study	O
in	O
tumor	O
biology	O
.	O

Expression	O
profiling	O
showed	O
strong	O
miRNA	O
and	O
isomiR	O
expression	O
deregulation	O
in	O
HD	O
,	O
most	O
being	O
common	O
to	O
both	O
FC	O
and	O
ST	O
.	O

Around	O
80	O
-	O
90	O
%	O
of	O
the	O
miRNAs	O
presented	O
modifications	O
in	O
the	O
3'-terminus	O
mainly	O
in	O
the	O
form	O
of	O
trimming	O
and/or	O
as	O
nucleotide	O
addition	O
variants	O
,	O
while	O
the	O
5'-terminus	O
of	O
the	O
miRNAs	O
was	O
specially	O
protected	O
from	O
changes	O
.	O

Deep	O
sequencing	O
revealed	O
length	O
and	O
sequence	O
heterogeneity	O
(	O
IsomiRs	O
)	O
for	O
the	O
vast	O
majority	O
of	O
miRNAs	O
.	O

More	O
than	O
80	O
%	O
of	O
the	O
small	O
-	O
RNAs	O
were	O
annotated	O
as	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
all	O
samples	O
.	O

We	O
have	O
applied	O
the	O
Illumina	O
massively	O
parallel	O
sequencing	O
to	O
deeply	O
analyze	O
the	O
small	O
RNA	O
populations	O
of	O
two	O
different	O
forebrain	O
areas	O
,	O
the	O
frontal	O
cortex	O
(	O
FC	O
)	O
and	O
the	O
striatum	O
(	O
ST	O
)	O
of	O
healthy	O
individuals	O
and	O
individuals	O
with	O
HD	O
.	O

Huntington	O
disease	O
(	O
HD	O
)	O
is	O
a	O
neurodegenerative	O
disorder	O
that	O
predominantly	O
affects	O
neurons	O
of	O
the	O
forebrain	O
.	O

A	O
myriad	O
of	O
miRNA	O
variants	O
in	O
control	O
and	O
Huntington	O
's	O
disease	O
brain	O
regions	O
detected	O
by	O
massively	O
parallel	O
sequencing	O
.	O

Our	O
results	O
show	O
that	O
miRNA	O
variability	O
is	O
a	O
ubiquitous	O
phenomenon	O
in	O
the	O
adult	O
human	B
brain	O
,	O
which	O
may	O
influence	O
gene	O
expression	O
in	O
physiological	O
and	O
pathological	O
conditions	O
.	O

The	O
putative	O
targets	O
of	O
deregulated	O
miRNAs	O
and	O
seed	O
-	O
region	O
IsomiRs	O
strongly	O
suggest	O
that	O
their	O
altered	O
expression	O
contributes	O
to	O
the	O
aberrant	O
gene	O
expression	O
in	O
HD	O
.	O

The	O
analysis	O
of	O
the	O
upstream	O
regulatory	O
regions	O
in	O
co	O
-	O
regulated	O
miRNAs	O
suggests	O
a	O
role	O
for	O
RE1-Silencing	O
Transcription	O
Factor	O
(	O
REST	O
)	O
and	O
P53	O
in	O
miRNAs	O
downregulation	O
in	O
HD	O
.	O

Moreover	O
,	O
LPS	O
stimulation	O
decreased	O
expression	O
of	O
microRNAs	O
(	O
miRNA	O
)	O
--miR-17	O
-	O
5	O
,	O
miR-20a	O
,	O
and	O
miR-93	O
-	O
-which	O
target	O
MICA	O
,	O
implicating	O
a	O
novel	O
role	O
for	O
miRNAs	O
in	O
NKG2D	O
ligand	O
expression	O
.	O

However	O
,	O
it	O
was	O
not	O
sufficient	O
for	O
surface	O
protein	O
expression	O
,	O
which	O
was	O
controlled	O
posttranscriptionally	O
via	O
a	O
separate	O
pathway	O
involving	O
the	O
ataxia	O
telangiectasia	O
mutated	O
/	O
ataxia	O
telangiectasia	O
and	O
Rad3	O
related	O
kinases	O
.	O

Thus	O
,	O
TLR	O
stimulation	O
allows	O
expression	O
of	O
NKG2D	O
ligands	O
through	O
multiple	O
pathways	O
,	O
including	O
downmodulation	O
of	O
specific	O
miRNAs	O
.	O

In	O
this	O
paper	O
,	O
we	O
clarify	O
that	O
LPS	O
,	O
which	O
ligates	O
TLR-4	O
,	O
preferentially	O
upregulated	O
MICA	O
and	O
not	O
MICB	O
;	O
CL097	O
,	O
which	O
ligates	O
TLR-7	O
/	O
8	O
,	O
upregulated	O
both	O
MICA	O
and	O
MICB	O
;	O
and	O
polyinosinic	O
-	O
polycytidylic	O
acid	O
,	O
which	O
ligates	O
TLR-3	O
,	O
upregulated	O
neither	O
.	O

However	O
,	O
NKG2D	O
ligands	O
can	O
also	O
be	O
induced	O
on	O
human	B
macrophages	O
by	O
TLR	O
stimulation	O
,	O
which	O
has	O
been	O
far	O
less	O
studied	O
.	O

This	O
finding	O
suggests	O
that	O
increased	O
levels	O
of	O
MICA	O
mRNA	O
following	O
LPS	O
stimulation	O
resulted	O
from	O
increased	O
transcription	O
.	O

To	O
probe	O
how	O
LPS	O
stimulation	O
triggers	O
MICA	O
expression	O
,	O
we	O
determined	O
that	O
the	O
stability	O
of	O
MICA	O
mRNA	O
was	O
much	O
longer	O
than	O
that	O
of	O
MICB	O
mRNA	O
,	O
but	O
neither	O
was	O
changed	O
by	O
LPS	O
stimulation	O
.	O

Multiple	O
mechanisms	O
downstream	O
of	O
TLR-4	O
stimulation	O
allow	O
expression	O
of	O
NKG2D	O
ligands	O
to	O
facilitate	O
macrophage	O
/	O
NK	O
cell	O
crosstalk	O
.	O

This	O
establishes	O
recognition	O
of	O
""""	O
induced	O
self	O
""""	O
as	O
an	O
important	O
strategy	O
for	O
surveillance	O
of	O
infections	O
or	O
tumor	O
transformation	O
.	O

The	O
activating	O
receptor	O
NKG2D	O
recognizes	O
proteins	O
that	O
are	O
not	O
normally	O
expressed	O
at	O
the	O
surface	O
of	O
most	O
cells	O
but	O
are	O
expressed	O
during	O
a	O
cellular	O
""""	O
stress	O
""""	O
response	O
(	O
e.g.	O
,	O
upon	O
induction	O
of	O
the	O
DNA	O
damage	O
pathway	O
)	O
.	O

MicroRNA	O
in	O
Situ	O
Hybridization	O
in	O
the	O
Human	B
Entorhinal	O
and	O
Transentorhinal	O
Cortex	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
key	O
roles	O
in	O
gene	O
expression	O
regulation	O
in	O
both	O
healthy	O
and	O
disease	O
brains	O
.	O

To	O
better	O
understand	O
those	O
roles	O
,	O
it	O
is	O
necessary	O
to	O
characterize	O
the	O
miRNAs	O
that	O
are	O
expressed	O
in	O
particular	O
cell	O
types	O
under	O
a	O
range	O
of	O
conditions	O
.	O

In	O
situ	O
hybridization	O
(	O
ISH	O
)	O
can	O
demonstrate	O
cell-	O
and	O
lamina	O
-	O
specific	O
patterns	O
of	O
miRNA	O
expression	O
that	O
would	O
be	O
lost	O
in	O
tissue	O
-	O
level	O
expression	O
profiling	O
.	O

In	O
the	O
present	O
study	O
,	O
ISH	O
was	O
performed	O
with	O
special	O
focus	O
on	O
the	O
human	B
entorhinal	O
cortex	O
(	O
EC	O
)	O
and	O
transentorhinal	O
cortex	O
(	O
TEC	O
)	O
.	O

The	O
TEC	O
is	O
the	O
area	O
of	O
the	O
cerebral	O
cortex	O
that	O
first	O
develops	O
neurofibrillary	O
tangles	O
in	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

However	O
,	O
the	O
reason	O
for	O
TEC	O
's	O
special	O
vulnerability	O
to	O
AD	O
-	O
type	O
pathology	O
is	O
unknown	O
.	O

MiRNA	O
ISH	O
was	O
performed	O
on	O
three	O
human	B
brains	O
with	O
well	O
-	O
characterized	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Locked	O
nucleic	O
acid	O
ISH	O
probes	O
were	O
used	O
referent	O
to	O
miR-107	O
,	O
miR-124	O
,	O
miR-125b	O
,	O
and	O
miR-320	O
.	O

In	O
order	O
to	O
correlate	O
the	O
ISH	O
data	O
with	O
AD	O
pathology	O
,	O
the	O
ISH	O
staining	O
was	O
compared	O
with	O
near	O
-	O
adjacent	O
slides	O
processed	O
using	O
Thioflavine	O
stains	O
.	O

MiRNA	O
ISH	O
is	O
among	O
the	O
first	O
methods	O
to	O
show	O
special	O
staining	O
characteristics	O
of	O
cells	O
and	O
laminae	O
of	O
the	O
human	B
TEC	O
.	O

As	O
with	O
other	O
areas	O
of	O
brain	O
,	O
the	O
TEC	O
and	O
EC	O
have	O
characteristic	O
miRNA	O
expression	O
patterns	O
.	O

Not	O
all	O
neurons	O
or	O
cortical	O
lamina	O
stain	O
with	O
equal	O
intensity	O
for	O
individual	O
miRNAs	O
.	O

Our	O
in	O
vitro	O
results	O
suggested	O
that	O
Aβ42	O
oligomer	O
-	O
induced	O
miR-106b	O
leads	O
to	O
impairment	O
in	O
TGF	O
-	O
β	O
signaling	O
through	O
TβR	O
II	O
,	O
concomitant	O
with	O
retinoic	O
acid	O
-	O
induced	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
.	O

These	O
results	O
show	O
that	O
TβR	O
II	O
is	O
a	O
functional	O
target	O
of	O
miR-106b	O
and	O
that	O
miR-106b	O
may	O
influence	O
TGF	O
-	O
β	O
signaling	O
,	O
thereby	O
contributing	O
to	O
the	O
pathogenesis	O
of	O
AD	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
abundantly	O
expressed	O
in	O
the	O
brain	O
and	O
play	O
an	O
important	O
role	O
in	O
disorders	O
of	O
the	O
brain	O
,	O
including	O
Alzheimer	O
's	O
diseases	O
(	O
AD	O
)	O
.	O

miR-106b	O
aberrantly	O
expressed	O
in	O
a	O
double	O
transgenic	B
mouse	I
model	O
for	O
Alzheimer	O
's	O
disease	O
targets	O
TGF	O
-	O
β	O
type	O
II	O
receptor	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
miRNAs	O
involved	O
in	O
AD	O
pathogenesis	O
by	O
regulating	O
TGF	O
-	O
β	O
signaling	O
.	O

Growing	O
body	O
of	O
evidence	O
suggests	O
that	O
the	O
TGF	O
-	O
β	O
signaling	O
pathway	O
plays	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
AD	O
.	O

Sequence	O
analysis	O
revealed	O
two	O
putative	O
binding	O
sites	O
for	O
miR-106b	O
in	O
the	O
3	O
'	O
UTR	O
of	O
the	O
TβR	O
II	O
mRNA	O
.	O

Here	O
we	O
found	O
that	O
miR-106b	O
and	O
TGF	O
-	O
β	O
type	O
II	O
receptor	O
(	O
TβR	O
II	O
)	O
were	O
aberrantly	O
expressed	O
in	O
APPswe	O
/	O
PS∆E9	O
mice	B
(	O
a	O
double	O
transgenic	B
mouse	I
model	O
for	O
AD	O
)	O
.	O

After	O
induced	O
neurodifferentiation	O
with	O
all	O
-	O
trans	O
retinoic	O
acid	O
,	O
we	O
observed	O
significant	O
neurodegeneration	O
in	O
SH	O
-	O
SY5Y	O
cells	O
stably	O
transfected	O
with	O
miR-106b	O
.	O

Our	O
results	O
showed	O
that	O
the	O
expression	O
of	O
miR-106b	O
was	O
inversely	O
correlated	O
with	O
TβR	O
II	O
protein	O
levels	O
and	O
miR-106b	O
can	O
directly	O
inhibit	O
the	O
TβR	O
II	O
translation	O
in	O
vitro	O
.	O

Exposure	O
of	O
SH	O
-	O
SY5Y	O
cells	O
to	O
Aβ42	O
oligomers	O
led	O
to	O
the	O
expression	O
of	O
miR-106b	O
was	O
first	O
increased	O
and	O
then	O
decreased	O
and	O
TβR	O
II	O
levels	O
reduced	O
.	O

Western	O
blot	O
analysis	O
revealed	O
unchanged	O
total	O
Smad2	O
/	O
3	O
protein	O
levels	O
,	O
but	O
reduced	O
phospho	O
-	O
Smad2	O
/	O
3	O
(	O
p	O
-	O
Smad2	O
/	O
3	O
)	O
and	O
increased	O
Smad6	O
/	O
7	O
protein	O
levels	O
in	O
the	O
miR-106b	O
stably	O
transfected	O
cell	O
line	O
.	O

Nuclear	O
factor	O
TDP-43	O
can	O
affect	O
selected	O
microRNA	O
levels	O
.	O

TDP-43	O
has	O
recently	O
been	O
described	O
as	O
the	O
major	O
component	O
of	O
the	O
inclusions	O
found	O
in	O
the	O
brain	O
of	O
patients	B
with	O
a	O
variety	O
of	O
neurodegenerative	O
diseases	O
,	O
such	O
as	O
frontotemporal	O
lobar	O
degeneration	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

Apart	O
from	O
its	O
involvement	O
in	O
transcription	O
,	O
splicing	O
and	O
mRNA	O
stability	O
,	O
TDP-43	O
has	O
also	O
been	O
described	O
as	O
a	O
Drosha	O
-	O
associated	O
protein	O
.	O

TDP-43	O
is	O
a	O
ubiquitous	O
protein	O
whose	O
specific	O
functions	O
are	O
probably	O
crucial	O
to	O
establishing	O
its	O
pathogenic	O
role	O
.	O

Here	O
we	O
report	O
for	O
the	O
first	O
time	O
which	O
changes	O
occur	O
in	O
the	O
total	O
miRNA	O
population	O
following	O
TDP-43	O
knockdown	O
in	O
culture	O
cells	O
.	O

However	O
,	O
our	O
knowledge	O
of	O
the	O
role	O
of	O
TDP-43	O
in	O
the	O
microRNA	O
(	O
miRNA	O
)	O
synthesis	O
pathway	O
is	O
limited	O
to	O
the	O
association	O
mentioned	O
above	O
.	O

Interestingly	O
,	O
both	O
miRNAs	O
are	O
capable	O
of	O
binding	O
directly	O
to	O
TDP-43	O
in	O
different	O
positions	O
:	O
within	O
the	O
miRNA	O
sequence	O
itself	O
(	O
let-7b	O
)	O
or	O
in	O
the	O
hairpin	O
precursor	O
(	O
miR-663	O
)	O
.	O

In	O
particular	O
,	O
we	O
have	O
observed	O
that	O
let-7b	O
and	O
miR-663	O
expression	O
levels	O
are	O
down-	O
and	O
upregulated	O
,	O
respectively	O
.	O

Using	O
microarray	O
data	O
and	O
real	O
-	O
time	O
PCR	O
we	O
have	O
also	O
identified	O
several	O
candidate	O
transcripts	O
whose	O
expression	O
levels	O
are	O
selectively	O
affected	O
by	O
these	O
TDP-43-miRNA	O
interactions	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
tissue	O
-	O
specific	O
miRNAs	O
may	O
serve	O
as	O
diagnostically	O
sensitive	O
plasma	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

The	O
miR-124	O
concentration	O
increased	O
in	O
the	O
plasma	O
of	O
rats	B
8	O
h	O
after	O
surgery	O
to	O
produce	O
brain	O
injury	O
and	O
peaked	O
at	O
24	O
h	O
,	O
while	O
the	O
miR-122	O
and	O
miR-133a	O
concentrations	O
remained	O
at	O
baseline	O
values	O
.	O

Furthermore	O
,	O
miR-122	O
exhibited	O
a	O
diagnostic	O
sensitivity	O
superior	O
to	O
that	O
of	O
ALT	O
when	O
the	O
results	O
were	O
correlated	O
to	O
the	O
liver	O
histopathologic	O
results	O
.	O

Plasma	O
MicroRNAs	O
as	O
sensitive	O
and	O
specific	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

BACKGROUND	O
:	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
,	O
small	O
noncoding	O
RNAs	O
.	O

Because	O
of	O
their	O
size	O
,	O
abundance	O
,	O
tissue	O
specificity	O
,	O
and	O
relative	O
stability	O
in	O
plasma	O
,	O
miRNAs	O
hold	O
promise	O
as	O
unique	O
accessible	O
biomarkers	O
to	O
monitor	O
tissue	O
injury	O
.	O

METHODS	O
:	O
We	O
investigated	O
the	O
use	O
of	O
liver-	O
,	O
muscle-	O
and	O
brain	O
-	O
specific	O
miRNAs	O
as	O
circulating	O
biomarkers	O
of	O
tissue	O
injury	O
.	O

We	O
used	O
a	O
highly	O
sensitive	O
quantitative	O
PCR	O
assay	O
to	O
measure	O
specific	O
miRNAs	O
(	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
)	O
in	O
plasma	O
samples	O
from	O
rats	B
treated	O
with	O
liver	O
or	O
muscle	O
toxicants	O
and	O
from	O
a	O
rat	B
surgical	O
model	O
of	O
stroke	O
.	O

RESULTS	O
:	O
We	O
observed	O
increases	O
in	O
plasma	O
concentrations	O
of	O
miR-122	O
,	O
miR-133a	O
,	O
and	O
miR-124	O
corresponding	O
to	O
injuries	O
in	O
liver	O
,	O
muscle	O
,	O
and	O
brain	O
,	O
respectively	O
.	O

miR-122	O
and	O
miR-133a	O
illustrated	O
specificity	O
for	O
liver	O
and	O
muscle	O
toxicity	O
,	O
respectively	O
,	O
because	O
they	O
were	O
not	O
detectable	O
in	O
the	O
plasma	O
of	O
animals	O
with	O
toxicity	O
to	O
the	O
other	O
organ	O
.	O

This	O
result	O
contrasted	O
with	O
the	O
results	O
for	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	O
aminotransferase	O
,	O
which	O
were	O
both	O
increased	O
with	O
either	O
organ	O
toxicity	O
.	O

Meanwhile	O
,	O
3NP	O
rats	B
showed	O
dynamic	O
changes	O
in	O
the	O
miRNA	O
profiles	O
during	O
disease	O
development	O
and	O
a	O
few	O
miRNAs	O
with	O
altered	O
expression	O
.	O

In	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	B
,	O
downregulation	O
was	O
dominant	O
in	O
the	O
miRNA	O
expressions	O
and	O
the	O
level	O
of	O
Drosha	O
decreased	O
concomitantly	O
.	O

Nine	O
miRNAs	O
(	O
miR-22	O
,	O
miR-29c	O
,	O
miR-128	O
,	O
miR-132	O
,	O
miR-138	O
,	O
miR-218	O
,	O
miR-222	O
,	O
miR-344	O
,	O
and	O
miR-674	O
*	O
)	O
were	O
commonly	O
down	O
-	O
regulated	O
in	O
both	O
the	O
12-month	O
-	O
old	O
YAC128	O
and	O
10-week	O
-	O
old	O
R6	O
/	O
2	O
mice	B
.	O

Concomitantly	O
,	O
the	O
expressions	O
of	O
Drosha	O
-	O
DGCR8	O
,	O
Exportin-5	O
,	O
and	O
Dcp1	O
were	O
increased	O
at	O
5months	O
,	O
and	O
the	O
expression	O
of	O
Dicer	O
was	O
decreased	O
at	O
12	O
months	O
.	O

YAC128	O
mice	B
showed	O
upregulation	O
-	O
dominant	O
miRNA	O
expressions	O
at	O
5	O
months	O
and	O
downregulation	O
-	O
dominant	O
expressions	O
at	O
12	O
months	O
.	O

After	O
characterizing	O
the	O
phenotypes	O
by	O
behavioral	O
tests	O
and	O
histological	O
analyses	O
,	O
we	O
profiled	O
striatal	O
miRNAs	O
using	O
a	O
miRNA	O
microarray	O
and	O
we	O
measured	O
the	O
key	O
molecules	O
involved	O
in	O
miRNA	O
biogenesis	O
and	O
function	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
miRNA	O
expression	O
and	O
miRNA	O
regulators	O
in	O
two	O
transgenic	O
models	O
of	O
HD	O
,	O
YAC128	O
and	O
R6	O
/	O
2	O
mice	B
,	O
and	O
in	O
a	O
3-nitropropionic	O
acid	O
(	O
3NP	O
)	O
-induced	O
striatal	O
degeneration	O
rat	B
model	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
short	O
RNA	O
molecules	O
regulating	O
gene	O
expression	O
,	O
and	O
are	O
implicated	O
in	O
a	O
variety	O
of	O
diseases	O
including	O
HD	O
.	O
However	O
,	O
the	O
profiles	O
and	O
regulation	O
of	O
miRNAs	O
in	O
HD	O
are	O
not	O
fully	O
understood	O
.	O

Huntington	O
's	O
disease	O
(	O
HD	O
)	O
is	O
a	O
genetic	O
neurodegenerative	O
disease	O
caused	O
by	O
abnormal	O
CAG	O
expansion	O
.	O

Altered	O
microRNA	O
regulation	O
in	O
Huntington	O
's	O
disease	O
models	O
.	O

This	O
information	O
should	O
aid	O
in	O
future	O
studies	O
on	O
therapeutic	O
application	O
of	O
miRNAs	O
in	O
HD	O
.	O

Our	O
results	O
show	O
that	O
transgenic	O
HD	O
mice	B
have	O
abnormal	O
miRNA	O
biogenesis	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
miRNA	O
profiles	O
in	O
A.	O
cantonensis	O
,	O
which	O
may	O
represent	O
a	O
new	O
platform	O
for	O
studying	O
regulation	O
of	O
genes	O
and	O
their	O
networks	O
in	O
A.	O
cantonensis	O
.	O

Nucleotide	O
bias	O
analysis	O
showed	O
that	O
uracil	O
was	O
the	O
prominent	O
nucleotide	O
,	O
particularly	O
at	O
positions	O
of	O
1	O
,	O
10	O
,	O
14	O
,	O
17	O
and	O
22	O
,	O
approximately	O
at	O
the	O
beginning	O
,	O
middle	O
and	O
the	O
end	O
of	O
the	O
conserved	O
miRNAs	O
.	O

No	O
new	O
miRNA	O
sequence	O
was	O
found	O
.	O

A	O
total	O
of	O
8861,260	O
and	O
10,957,957	O
high	O
quality	O
reads	O
with	O
20	O
and	O
23	O
conserved	O
miRNAs	O
were	O
obtained	O
in	O
females	O
and	O
males	O
,	O
respectively	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
and	O
characterize	O
miRNAs	O
of	O
female	O
and	O
male	O
adults	O
of	O
A.	O
cantonensis	O
by	O
Solexa	O
deep	O
sequencing	O
.	O

They	O
have	O
been	O
identified	O
in	O
a	O
diverse	O
range	O
of	O
organisms	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
non	O
-	O
coding	O
RNAs	O
that	O
play	O
crucial	O
roles	O
in	O
gene	O
expression	O
regulation	O
,	O
cellular	O
function	O
and	O
defense	O
,	O
homeostasis	O
and	O
pathogenesis	O
.	O

Angiostrongylus	O
cantonensis	O
causes	O
eosinophilic	O
meningitis	O
and	O
eosinophilic	O
pleocytosis	O
in	O
humans	B
and	O
is	O
of	O
significant	O
socio	O
-	O
economic	O
importance	O
globally	O
.	O

Angiostrongylus	O
cantonensis	O
:	O
Identification	O
and	O
characterization	O
of	O
microRNAs	O
in	O
male	O
and	O
female	O
adults	O
.	O

However	O
,	O
none	O
of	O
these	O
individuals	O
reported	O
here	O
have	O
epilepsy	O
,	O
although	O
two	O
have	O
an	O
abnormal	O
EEG	O
.	O

CONCLUSIONS	O
:	O
The	O
phenotype	O
of	O
chromosome	O
15q13.2q13.3	O
BP4-BP5	O
microdeletion	O
/	O
duplication	O
syndrome	O
may	O
include	O
features	O
of	O
autism	O
spectrum	O
disorder	O
,	O
a	O
variety	O
of	O
neuropsychiatric	O
disorders	O
,	O
and	O
cognitive	O
impairment	O
.	O

Recognition	O
of	O
this	O
broader	O
phenotype	O
has	O
implications	O
for	O
clinical	O
diagnostic	O
testing	O
and	O
efforts	O
to	O
understand	O
the	O
underlying	O
aetiology	O
of	O
this	O
syndrome	O
.	O

PATIENTS	B
:	O
DNA	O
samples	O
from	O
1445	O
unrelated	O
patients	B
submitted	O
consecutively	O
for	O
clinical	O
array	O
comparative	O
genomic	O
hybridisation	O
(	O
CGH	O
)	O
testing	O
at	O
Children	B
's	I
Hospital	O
Boston	O
and	O
DNA	O
samples	O
from	O
1441	O
individuals	O
with	O
autism	O
from	O
751	O
families	O
in	O
the	O
Autism	O
Genetic	O
Resource	O
Exchange	O
(	O
AGRE	O
)	O
repository	O
.	O

RESULTS	O
:	O
We	O
report	O
the	O
clinical	O
features	O
of	O
five	O
patients	B
with	O
a	O
BP4-BP5	O
deletion	O
,	O
three	O
with	O
a	O
BP4-BP5	O
duplication	O
,	O
and	O
two	O
with	O
an	O
overlapping	O
but	O
smaller	O
duplication	O
identified	O
by	O
whole	O
genome	O
high	O
resolution	O
oligonucleotide	O
array	O
CGH	O
.	O

Microdeletion	O
/	O
duplication	O
at	O
15q13.2q13.3	O
among	O
individuals	O
with	O
features	O
of	O
autism	O
and	O
other	O
neuropsychiatric	O
disorders	O
.	O

BACKGROUND	O
:	O
Segmental	O
duplications	O
at	O
breakpoints	O
(	O
BP4-BP5	O
)	O
of	O
chromosome	O
15q13.2q13.3	O
mediate	O
a	O
recurrent	O
genomic	O
imbalance	O
syndrome	O
associated	O
with	O
mental	O
retardation	O
,	O
epilepsy	O
,	O
and/or	O
electroencephalogram	O
(	O
EEG	O
)	O
abnormalities	O
.	O

BP4-BP5	O
covers	O
approximately	O
1.5	O
Mb	O
(	O
chr15:28.719	O
-	O
30.298	O
Mb	O
)	O
and	O
includes	O
six	O
reference	O
genes	O
and	O
1	O
miRNA	O
gene	O
,	O
while	O
the	O
smaller	O
duplications	O
cover	O
approximately	O
500	O
kb	O
(	O
chr15:28.902	O
-	O
29.404	O
Mb	O
)	O
and	O
contain	O
three	O
reference	O
genes	O
and	O
one	O
miRNA	O
gene	O
.	O

Cognitive	O
impairment	O
varied	O
from	O
moderate	O
mental	O
retardation	O
to	O
normal	O
IQ	O
with	O
learning	O
disability	O
.	O

These	O
BP4-BP5	O
deletion	O
cases	O
exhibit	O
minor	O
dysmorphic	O
features	O
,	O
significant	O
expressive	O
language	O
deficits	O
,	O
and	O
a	O
spectrum	O
of	O
neuropsychiatric	O
impairments	O
that	O
include	O
autism	O
spectrum	O
disorder	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
anxiety	O
disorder	O
,	O
and	O
mood	O
disorder	O
.	O

The	O
BP4-BP5	O
deletion	O
and	O
duplication	O
events	O
span	O
CHRNA7	O
,	O
a	O
candidate	O
gene	O
for	O
seizures	O
.	O

The	O
KIAA0226	O
gene	O
encodes	O
a	O
protein	O
that	O
we	O
named	O
rundataxin	O
,	O
with	O
two	O
conserved	O
domains	O
:	O
an	O
N	O
-	O
terminal	O
RUN	O
domain	O
and	O
a	O
C	O
-	O
terminal	O
domain	O
containing	O
a	O
diacylglycerol	O
binding	O
-	O
like	O
motif	O
.	O

Mutation	O
screening	O
of	O
all	O
coding	O
sequences	O
revealed	O
a	O
single	O
nucleotide	O
deletion	O
,	O
2927delC	O
,	O
in	O
exon	O
19	O
of	O
the	O
KIAA0226	O
gene	O
,	O
which	O
results	O
in	O
a	O
frame	O
shift	O
of	O
the	O
C	O
-	O
terminal	O
domain	O
(	O
p	O
.	O
Ala943ValfsX146	O
)	O
.	O

The	O
rundataxin	O
pathway	O
appears	O
therefore	O
distinct	O
from	O
the	O
ataxia	O
pathways	O
involving	O
deficiency	O
in	O
mitochondrial	O
or	O
nuclear	O
proteins	O
and	O
broadens	O
the	O
range	O
of	O
mechanisms	O
leading	O
to	O
recessive	O
ataxias	O
.	O

The	O
closest	O
paralogue	O
of	O
rundataxin	O
,	O
the	O
plekstrin	O
homology	O
domain	O
family	O
member	O
M1	O
,	O
has	O
been	O
shown	O
to	O
colocalize	O
with	O
Rab7	O
,	O
a	O
small	O
GTPase	O
associated	O
with	O
late	O
endosomes	O
/	O
lysosomes	O
,	O
suggesting	O
that	O
rundataxin	O
may	O
also	O
be	O
associated	O
with	O
vesicular	O
trafficking	O
and	O
signalling	O
pathways	O
through	O
its	O
RUN	O
and	O
diacylglycerol	O
binding	O
-	O
like	O
domains	O
.	O

The	O
three	O
patients	B
presented	O
with	O
childhood	O
onset	O
gait	O
and	O
limb	O
ataxia	O
,	O
dysarthria	O
and	O
had	O
limited	O
walking	O
without	O
aid	O
into	O
their	O
teenage	O
years	O
.	O

We	O
have	O
identified	O
a	O
novel	O
form	O
of	O
recessive	O
ataxia	O
that	O
segregates	O
in	O
three	O
children	B
of	O
a	O
large	O
consanguineous	O
Saudi	O
Arabian	O
family	O
.	O

Linkage	O
studies	O
allowed	O
us	O
to	O
identify	O
a	O
single	O
locus	O
that	O
segregated	O
with	O
the	O
disease	O
on	O
chromosome	O
3q28-qter	O
.	O

Two	O
patients	B
developed	I
epilepsy	O
at	O
7	O
months	O
without	O
relapse	O
after	O
treatment	O
,	O
and	O
mental	O
retardation	O
.	O

Rundataxin	O
,	O
a	O
novel	O
protein	O
with	O
RUN	O
and	O
diacylglycerol	O
binding	O
domains	O
,	O
is	O
mutant	O
in	O
a	O
new	O
recessive	O
ataxia	O
.	O

A	O
novel	O
microRNA	O
and	O
transcription	O
factor	O
mediated	O
regulatory	O
network	O
in	O
schizophrenia	O
.	O

Previous	O
studies	O
have	O
suggested	O
that	O
changes	O
in	O
gene	O
expression	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
schizophrenia	O
,	O
and	O
that	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
are	O
primary	O
regulators	O
of	O
this	O
gene	O
expression	O
.	O

BACKGROUND	O
:	O
Schizophrenia	O
is	O
a	O
complex	O
brain	O
disorder	O
with	O
molecular	O
mechanisms	O
that	O
have	O
yet	O
to	O
be	O
elucidated	O
.	O

We	O
hypothesized	O
that	O
miRNAs	O
and	O
TFs	O
might	O
play	O
combinatory	O
regulatory	O
roles	O
for	O
schizophrenia	O
genes	O
and	O
,	O
thus	O
,	O
explored	O
miRNA	O
-	O
TF	O
regulatory	O
networks	O
in	O
schizophrenia	O
.	O

So	O
far	O
,	O
several	O
miRNA	O
-	O
TF	O
mediated	O
regulatory	O
modules	O
have	O
been	O
verified	O
.	O

Our	O
evaluation	O
revealed	O
that	O
these	O
observed	O
FFLs	O
were	O
significantly	O
enriched	O
in	O
schizophrenia	O
genes	O
.	O

RESULTS	O
:	O
We	O
identified	O
32	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
among	O
our	O
compiled	O
schizophrenia	O
-	O
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
.	O

By	O
converging	O
the	O
FFLs	O
and	O
mutual	O
feedback	O
loops	O
,	O
we	O
constructed	O
a	O
novel	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
schizophrenia	O
.	O

Our	O
analysis	O
revealed	O
EGR3	O
and	O
hsa	O
-	O
miR-195	O
were	O
core	O
regulators	O
in	O
this	O
regulatory	O
network	O
.	O

We	O
next	O
proposed	O
a	O
model	O
highlighting	O
EGR3	O
and	O
miRNAs	O
involved	O
in	O
signaling	O
pathways	O
and	O
regulatory	O
networks	O
in	O
the	O
nervous	O
system	O
.	O

It	O
represents	O
the	O
first	O
investigation	O
of	O
a	O
miRNA	O
-	O
TF	O
regulatory	O
network	O
for	O
a	O
complex	O
disease	O
,	O
as	O
demonstrated	O
in	O
schizophrenia	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
provides	O
many	O
insights	O
on	O
the	O
regulatory	O
mechanisms	O
of	O
genes	O
involved	O
in	O
schizophrenia	O
.	O

Finally	O
,	O
we	O
suggested	O
several	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
located	O
on	O
miRNAs	O
,	O
their	O
target	O
sites	O
,	O
and	O
TFBSs	O
,	O
which	O
may	O
have	O
an	O
effect	O
in	O
schizophrenia	O
gene	O
regulation	O
.	O

MicroRNA	O
expression	O
in	O
ACTH	O
-	O
producing	O
pituitary	O
tumors	O
:	O
up	O
-	O
regulation	O
of	O
microRNA-122	O
and	O
-493	O
in	O
pituitary	O
carcinomas	O
.	O

Real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
were	O
used	O
to	O
confirm	O
and	O
independently	O
validate	O
miRNAs	O
that	O
were	O
significantly	O
up	O
-	O
regulated	O
or	O
down	O
-	O
regulated	O
between	O
the	O
pituitary	O
tissues	O
.	O

We	O
used	O
miRNA	O
profiling	O
with	O
1,145	O
probes	O
to	O
study	O
miRNA	O
expression	O
in	O
normal	O
anterior	O
pituitary	O
(	O
6	O
cases	O
)	O
,	O
adrenocorticotropin	O
(	O
ACTH	O
)	O
-producing	O
adenomas	O
(	O
8	O
cases	O
)	O
,	O
and	O
ACTH	O
-	O
producing	O
pituitary	O
carcinomas	O
(	O
two	O
cases	O
)	O
.	O

The	O
expression	O
of	O
miRNAs	O
in	O
pituitary	O
carcinomas	O
has	O
not	O
been	O
previously	O
examined	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
involved	O
in	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
,	O
and	O
can	O
function	O
as	O
tumor	O
suppressor	O
genes	O
or	O
oncogenes	O
.	O

MiRNA-493	O
was	O
also	O
up	O
-	O
regulated	O
in	O
carcinomas	O
compared	O
to	O
ACTH	O
adenomas	O
.	O

Analysis	O
of	O
genes	O
that	O
miRNA-493	O
interacts	O
with	O
included	O
LGALS3	O
and	O
RUNX2	O
(	O
http://microrna.sanger.ac.uk	O
)	O
both	O
of	O
which	O
have	O
been	O
shown	O
to	O
have	O
roles	O
in	O
pituitary	O
tumor	O
cell	O
growth	O
.	O

There	O
were	O
more	O
miRNAs	O
up-	O
(	O
188	O
)	O
or	O
down	O
-	O
regulated	O
(	O
160	O
)	O
between	O
adenomas	O
and	O
normal	O
pituitaries	O
compared	O
to	O
carcinomas	O
and	O
normal	O
pituitaries	O
(	O
92	O
up-	O
and	O
91	O
down	O
-	O
regulated	O
)	O
or	O
between	O
carcinomas	O
and	O
adenomas	O
(	O
46	O
up-	O
and	O
52	O
down	O
-	O
regulated	O
)	O
.	O

Both	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
and	O
in	O
situ	O
hybridization	O
showed	O
significant	O
up	O
-	O
regulation	O
of	O
miRNA-122	O
between	O
pituitary	O
carcinomas	O
and	O
adenomas	O
.	O

These	O
results	O
provide	O
information	O
about	O
marker	O
miRNAs	O
that	O
may	O
lead	O
to	O
further	O
insights	O
into	O
the	O
regulation	O
of	O
pituitary	O
tumor	O
growth	O
and	O
development	O
.	O

Vascular	O
injury	O
triggers	O
dedifferentiation	O
and	O
cytoskeletal	O
remodeling	O
of	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
,	O
culminating	O
in	O
vessel	O
occlusion	O
.	O

MicroRNAs	O
miR-143	O
and	O
miR-145	O
modulate	O
cytoskeletal	O
dynamics	O
and	O
responsiveness	O
of	O
smooth	O
muscle	O
cells	O
to	O
injury	O
.	O

Serum	O
response	O
factor	O
(	O
SRF	O
)	O
and	O
its	O
coactivator	O
,	O
myocardin	O
,	O
play	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
smooth	O
muscle	O
phenotypes	O
by	O
regulating	O
the	O
expression	O
of	O
cytoskeletal	O
genes	O
.	O

We	O
show	O
that	O
SRF	O
and	O
myocardin	O
regulate	O
a	O
cardiovascular	O
-	O
specific	O
microRNA	O
(	O
miRNA	O
)	O
cluster	O
encoding	O
miR-143	O
and	O
miR-145	O
.	O

To	O
assess	O
the	O
functions	O
of	O
these	O
miRNAs	O
in	O
vivo	O
,	O
we	O
systematically	O
deleted	O
them	O
singly	O
and	O
in	O
combination	O
in	O
mice	B
.	O

Mice	B
lacking	O
both	O
miR-143	O
and	O
miR-145	O
are	O
viable	O
and	O
do	O
not	O
display	O
overt	O
abnormalities	O
in	O
smooth	O
muscle	O
differentiation	O
,	O
although	O
they	O
show	O
a	O
significant	O
reduction	O
in	O
blood	O
pressure	O
due	O
to	O
reduced	O
vascular	O
tone	O
.	O

Remarkably	O
,	O
however	O
,	O
neointima	O
formation	O
in	O
response	O
to	O
vascular	O
injury	O
is	O
profoundly	O
impeded	O
in	O
mice	B
lacking	O
these	O
miRNAs	O
,	O
due	O
to	O
disarray	O
of	O
actin	O
stress	O
fibers	O
and	O
diminished	O
migratory	O
activity	O
of	O
SMCs	O
.	O

These	O
abnormalities	O
reflect	O
the	O
regulation	O
of	O
a	O
cadre	O
of	O
modulators	O
of	O
SRF	O
activity	O
and	O
actin	O
dynamics	O
by	O
miR-143	O
and	O
miR-145	O
.	O

Thus	O
,	O
miR-143	O
and	O
miR-145	O
act	O
as	O
integral	O
components	O
of	O
the	O
regulatory	O
network	O
whereby	O
SRF	O
controls	O
cytoskeletal	O
remodeling	O
and	O
phenotypic	O
switching	O
of	O
SMCs	O
during	O
vascular	O
disease	O
.	O

Plasma	O
concentrations	O
of	O
miR-124	O
were	O
significantly	O
elevated	O
at	O
6	O
h	O
,	O
and	O
remained	O
elevated	O
at	O
48	O
h	O
after	O
MCAO	O
introduction	O
.	O

Thus	O
,	O
plasma	O
concentration	O
of	O
miR-124	O
provides	O
a	O
promising	O
candidate	O
biomarker	O
for	O
early	O
detection	O
of	O
cerebral	O
infarction	O
.	O

In	O
this	O
study	O
,	O
miRNA	O
array	O
analysis	O
in	O
various	O
tissues	O
showed	O
that	O
miR-124	O
is	O
almost	O
exclusively	O
expressed	O
in	O
the	O
central	O
nervous	O
system	O
and	O
neuronal	O
cells	O
,	O
suggesting	O
that	O
it	O
might	O
be	O
useful	O
as	O
a	O
potential	O
biomarker	O
for	O
neurological	O
diseases	O
.	O

We	O
examined	O
whether	O
plasma	O
concentrations	O
of	O
brain	O
-	O
specific	O
miRNA	O
can	O
serve	O
as	O
a	O
biomarker	O
for	O
cerebral	O
infarction	O
,	O
where	O
the	O
cerebral	O
infarction	O
was	O
modeled	O
by	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
in	O
the	O
rat	B
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
small	O
RNAs	O
that	O
play	O
an	O
important	O
role	O
in	O
various	O
physiological	O
processes	O
by	O
downregulating	O
target	O
genes	O
.	O

Recently	O
,	O
plasma	O
miRNAs	O
have	O
been	O
investigated	O
as	O
biomarkers	O
for	O
various	O
diseases	O
.	O

Plasma	O
miR-124	O
as	O
a	O
biomarker	O
for	O
cerebral	O
infarction	O
.	O

METHODS	O
:	O
Surgical	O
outcome	O
data	O
were	O
prospectively	O
collected	O
for	O
2	O
to	O
11	O
years	O
in	O
161	O
consecutive	O
patients	B
with	O
MTLE	O
/	O
HS	O
.	O
Eighty	O
patients	B
underwent	O
an	O
ATL	O
and	O
81	O
an	O
SA	O
.	O
Seizure	O
control	O
achieved	O
with	O
each	O
technique	O
was	O
compared	O
using	O
the	O
Engel	O
classification	O
scheme	O
.	O

Postoperative	O
memory	O
testing	O
was	O
performed	O
in	O
86	O
patients	B
(	O
53	O
%	O
)	O
.	O

At	O
the	O
last	O
follow	O
up	O
,	O
72	O
%	O
of	O
the	O
patients	B
who	O
had	O
undergone	O
an	O
ATL	O
(	O
mean	O
follow	O
up	O
6.7	O
years	O
)	O
and	O
71	O
%	O
of	O
those	O
who	O
had	O
undergone	O
an	O
SA	O
(	O
mean	O
follow	O
up	O
4.5	O
years	O
)	O
were	O
seizure	O
free	O
(	O
Engle	O
Class	O
IA	O
)	O
.	O

Estimated	O
survival	O
in	O
patients	B
in	O
Engel	O
Classes	O
I	O
,	O
IA	O
,	O
and	O
I	O
and	O
II	O
combined	O
did	O
not	O
differ	O
between	O
the	O
two	O
surgical	O
techniques	O
.	O

Preoperatively	O
,	O
58	O
%	O
of	O
the	O
patients	B
had	O
verbal	O
memory	O
scores	O
one	O
standard	O
deviation	O
(	O
SD	O
)	O
below	O
the	O
normal	O
mean	O
.	O

One	O
third	O
of	O
the	O
patients	B
with	O
preoperative	O
scores	O
in	O
the	O
normal	O
range	O
worsened	O
after	O
surgery	O
,	O
although	O
this	O
outcome	O
was	O
not	O
related	O
to	O
the	O
surgical	O
technique	O
.	O

In	O
contrast	O
,	O
one	O
third	O
of	O
those	O
whose	O
preoperative	O
scores	O
were	O
less	O
than	O
-1	O
SD	O
experienced	O
improvement	O
after	O
surgery	O
.	O

Nine	O
(	O
18	O
%	O
)	O
of	O
the	O
50	O
patients	B
whose	O
left	O
side	O
had	O
been	O
surgically	O
treated	O
improved	O
their	O
verbal	O
memory	O
scores	O
by	O
more	O
than	O
one	O
SD	O
.	O
Seven	O
(	O
78	O
%	O
)	O
of	O
these	O
nine	O
underwent	O
an	O
SA	O
(	O
p	O
=	O
0.05	O
)	O
.	O

OBJECT	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
seizure	O
and	O
memory	O
outcome	O
in	O
patients	B
with	O
medically	O
refractory	O
mesial	O
temporal	O
lobe	O
epilepsy	O
due	O
to	O
hippocampal	O
sclerosis	O
(	O
MTLE	O
/	O
HS	O
)	O
treated	O
using	O
an	O
anterior	O
temporal	O
lobectomy	O
(	O
ATL	O
)	O
or	O
a	O
selective	O
amygdalohippocampectomy	O
(	O
SA	O
)	O
.	O

Seizure	O
and	O
memory	O
outcome	O
following	O
temporal	O
lobe	O
surgery	O
:	O
selective	O
compared	O
with	O
nonselective	O
approaches	O
for	O
hippocampal	O
sclerosis	O
.	O

Preliminary	O
data	O
suggest	O
that	O
postoperative	O
verbal	O
memory	O
scores	O
may	O
improve	O
in	O
patients	B
who	O
undergo	O
selective	O
resection	O
of	O
a	O
sclerotic	O
hippocampus	O
in	O
the	O
dominant	O
temporal	O
lobe	O
.	O

CONCLUSIONS	O
:	O
Both	O
ATL	O
and	O
SA	O
can	O
lead	O
to	O
similar	O
favorable	O
seizure	O
control	O
in	O
patients	B
with	O
MTLE	O
/	O
HS	O
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSV-1-induced	B
miRNA-146a	O
in	O
the	O
evasion	O
of	O
HSV-1	B
from	O
the	O
complement	O
system	O
,	O
and	O
the	O
activation	O
of	O
key	O
elements	O
of	O
the	O
arachidonic	O
acid	O
cascade	O
known	O
to	O
contribute	O
to	O
Alzheimer	O
-	O
type	O
neuropathological	O
change	O
.	O

A	O
known	O
miRNA-146a	O
target	O
in	O
the	O
brain	O
,	O
complement	O
factor	O
H	O
,	O
was	O
downregulated	O
.	O

Expression	O
of	O
cytoplasmic	O
phospholipase	O
A2	O
,	O
the	O
inducible	O
prostaglandin	O
synthase	O
cyclooxygenase-2	O
,	O
and	O
the	O
neuroinflammatory	O
cytokine	O
interleukin-1beta	O
were	O
each	O
upregulated	O
.	O

We	O
report	O
that	O
infection	O
of	O
human	B
primary	O
neural	O
cells	O
with	O
a	O
high	O
phenotypic	O
reactivator	O
HSV-1	B
(	O
17syn+	O
)	O
induces	O
upregulation	O
of	O
a	O
brain	O
-	O
enriched	O
microRNA	O
(	O
miRNA	O
)	O
-146a	O
that	O
is	O
associated	O
with	O
proinflammatory	O
signaling	O
in	O
stressed	O
brain	O
cells	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Herpes	B
simplex	I
virus	I
type-1	I
(	I
HSV-1	I
)	O
infection	O
of	O
human	B
brain	O
cells	O
induces	O
changes	O
in	O
gene	O
expression	O
favorable	O
to	O
the	O
propagation	O
of	O
the	O
infecting	O
agent	O
and	O
detrimental	O
to	O
the	O
function	O
of	O
the	O
host	O
cells	O
.	O

HSV-1	B
infection	O
of	O
human	B
brain	O
cells	O
induces	O
miRNA-146a	O
and	O
Alzheimer	O
-	O
type	O
inflammatory	O
signaling	O
.	O

This	O
study	O
reveals	O
the	O
occurrence	O
of	O
novel	O
mechanisms	O
of	O
HIF	O
regulation	O
,	O
which	O
might	O
contribute	O
to	O
developing	O
novel	O
strategies	O
for	O
therapeutic	O
intervention	O
of	O
HIF	O
-	O
related	O
pathologies	O
,	O
including	O
heart	O
attack	O
,	O
cancer	O
,	O
and	O
stroke	O
.	O

One	O
remarkable	O
hit	O
was	O
the	O
argonaute	O
1	O
(	O
ago1	O
)	O
gene	O
,	O
a	O
central	O
element	O
of	O
the	O
microRNA	O
(	O
miRNA	O
)	O
translational	O
silencing	O
machinery	O
.	O

Further	O
studies	O
confirmed	O
the	O
physiological	O
role	O
of	O
the	O
miRNA	O
machinery	O
in	O
HIF	O
-	O
dependent	O
transcription	O
.	O

After	O
3	O
rounds	O
of	O
selection	O
,	O
30	O
genes	O
emerged	O
as	O
critical	O
HIF	O
regulators	O
in	O
hypoxia	O
,	O
most	O
of	O
which	O
had	O
not	O
been	O
previously	O
associated	O
with	O
HIF	O
biology	O
.	O

The	O
list	O
of	O
genes	O
includes	O
components	O
of	O
chromatin	O
remodeling	O
complexes	O
,	O
transcription	O
elongation	O
factors	O
,	O
and	O
translational	O
regulators	O
.	O

Molecular	O
mechanisms	O
that	O
mediate	O
oxygen	O
-	O
dependent	O
HIF	O
regulation	O
operate	O
at	O
the	O
level	O
of	O
the	O
alpha	O
subunit	O
,	O
controlling	O
protein	O
stability	O
,	O
subcellular	O
localization	O
,	O
and	O
transcriptional	O
coactivator	O
recruitment	O
.	O

We	O
have	O
conducted	O
an	O
unbiased	O
genome	O
-	O
wide	O
RNA	O
interference	O
(	O
RNAi	O
)	O
screen	O
in	O
Drosophila	O
cells	O
aimed	O
to	O
the	O
identification	O
of	O
genes	O
required	O
for	O
HIF	O
activity	O
.	O

Drosophila	O
genome	O
-	O
wide	O
RNAi	O
screen	O
identifies	O
multiple	O
regulators	O
of	O
HIF	O
-	O
dependent	O
transcription	O
in	O
hypoxia	O
.	O

Hypoxia	O
-	O
inducible	O
factors	O
(	O
HIFs	O
)	O
are	O
a	O
family	O
of	O
evolutionary	O
conserved	O
alpha	O
-	O
beta	O
heterodimeric	O
transcription	O
factors	O
that	O
induce	O
a	O
wide	O
range	O
of	O
genes	O
in	O
response	O
to	O
low	O
oxygen	O
tension	O
.	O

Follow	O
up	O
functional	O
enrichment	O
analysis	O
of	O
these	O
FFLs	O
uncovered	O
some	O
functions	O
important	O
to	O
carcinogenesis	O
but	O
also	O
some	O
unique	O
functions	O
specific	O
to	O
the	O
FFLs	O
we	O
identified	O
.	O

Transcriptional	O
aberrations	O
may	O
play	O
a	O
vital	O
role	O
in	O
the	O
etiology	O
of	O
glioblastoma	O
,	O
which	O
might	O
be	O
caused	O
by	O
both	O
genomic	O
alterations	O
and	O
other	O
regulation	O
molecules	O
.	O

Illustrating	O
the	O
functions	O
being	O
disturbed	O
during	O
carcinogenesis	O
and	O
how	O
they	O
are	O
deregulated	O
is	O
very	O
important	O
for	O
us	O
to	O
understand	O
its	O
underlying	O
mechanism	O
.	O

We	O
searched	O
glioblastoma	O
-	O
specific	O
regulatory	O
networks	O
by	O
integrating	O
glioblastoma	O
related	O
miRNAs	O
,	O
TFs	O
and	O
genes	O
,	O
and	O
identified	O
54	O
feed	O
-	O
forward	O
loops	O
(	O
FFLs	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
possible	O
cooperative	O
deregulation	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
and	O
transcription	O
factors	O
(	O
TFs	O
)	O
in	O
glioblastoma	O
,	O
under	O
the	O
hypothesis	O
that	O
miRNAs	O
and	O
TFs	O
might	O
have	O
a	O
combinational	O
regulatory	O
effect	O
on	O
glioblastoma	O
genes	O
.	O

Glioblastoma	O
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
brain	O
tumour	O
in	O
humans	B
.	O

Gene	O
regulation	O
in	O
glioblastoma	O
:	O
a	O
combinatorial	O
analysis	O
of	O
microRNAs	O
and	O
transcription	O
factors	O
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
patterns	O
of	O
miRNA	O
expression	O
in	O
cortical	O
GM	O
may	O
contribute	O
to	O
AD	O
pathogenetically	O
,	O
because	O
the	O
aggregate	O
change	O
in	O
miRNA	O
expression	O
observed	O
early	O
in	O
the	O
disease	O
would	O
be	O
predicted	O
to	O
cause	O
profound	O
changes	O
in	O
gene	O
expression	O
.	O

Patterns	O
of	O
microRNA	O
expression	O
in	O
normal	O
and	O
early	O
Alzheimer	O
's	O
disease	O
human	B
temporal	O
cortex	O
:	O
white	O
matter	O
versus	O
gray	O
matter	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
was	O
assessed	O
in	O
human	B
cerebral	O
cortical	O
gray	O
matter	O
(	O
GM	O
)	O
and	O
white	O
matter	O
(	O
WM	O
)	O
in	O
order	O
to	O
provide	O
the	O
first	O
insights	O
into	O
the	O
difference	O
between	O
GM	O
and	O
WM	O
miRNA	O
repertoires	O
across	O
a	O
range	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
pathology	O
.	O

RNA	O
was	O
isolated	O
separately	O
from	O
GM	O
and	O
WM	O
portions	O
of	O
superior	O
and	O
middle	O
temporal	O
cerebral	O
cortex	O
(	O
N	O
=	O
10	O
elderly	O
females	O
,	O
postmortem	O
interval	O
<	O
4	O
h	O
)	O
.	O

miRNA	O
profiling	O
experiments	O
were	O
performed	O
using	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
Exiqon	O
(	O
©	O
)	O
LNA	O
-	O
microarrays	O
.	O

A	O
subset	O
of	O
miRNAs	O
that	O
appeared	O
to	O
be	O
strongly	O
expressed	O
according	O
to	O
the	O
microarrays	O
did	O
not	O
appear	O
to	O
be	O
conventional	O
miRNAs	O
according	O
to	O
Northern	O
blot	O
analyses	O
.	O

Some	O
well	O
-	O
characterized	O
miRNAs	O
were	O
substantially	O
enriched	O
in	O
WM	O
as	O
expected	O
.	O

However	O
,	O
most	O
of	O
the	O
miRNA	O
expression	O
variability	O
that	O
correlated	O
with	O
the	O
presence	O
of	O
early	O
AD	O
-	O
related	O
pathology	O
was	O
seen	O
in	O
GM	O
.	O

We	O
confirm	O
that	O
downregulation	O
of	O
a	O
set	O
of	O
miRNAs	O
in	O
GM	O
(	O
including	O
several	O
miR-15	O
/	O
107	O
genes	O
and	O
miR-29	O
paralogs	O
)	O
correlated	O
strongly	O
with	O
the	O
density	O
of	O
diffuse	O
amyloid	O
plaques	O
detected	O
in	O
adjacent	O
tissue	O
.	O

A	O
few	O
miRNAs	O
were	O
differentially	O
expressed	O
in	O
WM	O
,	O
including	O
miR-212	O
that	O
is	O
downregulated	O
in	O
AD	O
and	O
miR-424	O
which	O
is	O
upregulated	O
in	O
AD	O
.	O

The	O
expression	O
of	O
certain	O
miRNAs	O
correlates	O
with	O
other	O
miRNAs	O
across	O
different	O
cases	O
,	O
and	O
particular	O
subsets	O
of	O
miRNAs	O
are	O
coordinately	O
expressed	O
in	O
relation	O
to	O
AD	O
-	O
related	O
pathology	O
.	O

Leukodystrophy	O
and	O
gene	O
therapy	O
with	O
a	O
dimmer	O
switch	O
.	O

The	O
authors	O
reviewed	O
the	O
records	O
of	O
nineteen	O
consecutive	O
children	B
with	O
newly	O
diagnosed	O
IIH	O
in	O
order	O
to	O
compare	O
demographic	O
characteristics	O
,	O
clinical	O
pictures	O
and	O
ophthalmologic	O
aspects	O
as	O
optic	O
disc	O
evaluation	O
and	O
visual	O
field	O
evaluation	O
,	O
as	O
well	O
as	O
treatment	O
modalities	O
and	O
follow	O
up	O
.	O

Beside	O
obesity	O
and	O
female	O
gender	O
,	O
potential	O
alternative	O
risk	O
factors	O
remains	O
to	O
be	O
investigated	O
,	O
which	O
need	O
a	O
good	O
collaboration	O
between	O
neuro	O
-	O
ophthalmologists	O
and	O
pediatric	O
neurologists	O
.	O

Idiopathic	O
intracranial	O
hypertension	O
(	O
IIH	O
)	O
is	O
a	O
clinical	O
condition	O
characterized	O
by	O
elevated	O
intracranial	O
pressure	O
and	O
absence	O
of	O
clinical	O
,	O
laboratory	O
or	O
radiographic	O
evidence	O
of	O
central	O
nervous	O
system	O
infection	O
,	O
vascular	O
malformation	O
,	O
intracranial	O
space	O
occupying	O
lesion	O
or	O
hydrocephalus	O
.	O

In	O
the	O
last	O
years	O
the	O
raising	O
understanding	O
of	O
pediatric	O
IIH	O
,	O
especially	O
concerning	O
its	O
demographics	O
and	O
epidemiology	O
,	O
has	O
brought	O
up	O
to	O
a	O
redefinition	O
of	O
diagnostic	O
criteria	O
and	O
reevaluation	O
of	O
pathogenesis	O
and	O
treatment	O
.	O

Pediatric	O
idiopathic	O
intracranial	O
hypertension	O
:	O
clinical	O
and	O
demographic	O
features	O
.	O

Although	O
microRNAs	O
are	O
expressed	O
extensively	O
in	O
the	O
central	O
nervous	O
system	O
in	O
physiological	O
and	O
pathological	O
conditions	O
,	O
their	O
expression	O
in	O
neurological	O
disorder	O
of	O
epilepsy	O
has	O
not	O
been	O
well	O
characterized	O
.	O

Expression	O
profile	O
of	O
microRNAs	O
in	O
rat	B
hippocampus	O
following	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
.	O

Rat	B
MicroRNA	O
array	O
and	O
differential	O
analysis	O
had	O
detected	O
19	O
up	O
-	O
regulated	O
microRNAs	O
and	O
7	O
down	O
-	O
regulated	O
microRNAs	O
in	O
rat	B
hippocampus	O
,	O
and	O
four	O
randomly	O
selected	O
deregulated	O
microRNAs	O
(	O
microRNA-34a	O
,	O
microRNA-22	O
,	O
microRNA-125a	O
,	O
microRNA-21	O
)	O
were	O
confirmed	O
by	O
qRT	O
-	O
PCR	O
,	O
then	O
their	O
expression	O
alterations	O
in	O
rat	B
peripheral	O
blood	O
were	O
analyzed	O
.	O

Here	O
we	O
investigated	O
microRNA	O
expression	O
pattern	O
in	O
post	O
status	O
epilepticus	O
rats	B
(	O
24h	O
after	O
status	O
)	O
.	O

Thus	O
,	O
our	O
results	O
have	O
not	O
only	O
characterized	O
the	O
microRNA	O
expression	O
profile	O
in	O
post	O
status	O
epilepticus	O
rat	B
hippocampus	O
but	O
also	O
demonstrated	O
that	O
some	O
rat	B
hippocampal	O
microRNAs	O
were	O
probably	O
associated	O
with	O
rat	B
peripheral	O
blood	O
microRNAs	O
.	O

We	O
found	O
that	O
these	O
four	O
deregulated	O
microRNAs	O
were	O
also	O
differentially	O
expressed	O
in	O
rat	B
peripheral	O
blood	O
,	O
and	O
trends	O
for	O
their	O
blood	O
expression	O
alterations	O
were	O
just	O
the	O
same	O
as	O
their	O
counterparts	O
in	O
rat	B
hippocampus	O
.	O

Moreover	O
,	O
targets	O
of	O
these	O
deregulated	O
microRNAs	O
were	O
analyzed	O
using	O
bioinformatics	O
and	O
the	O
identified	O
enriched	O
MAPK	O
pathway	O
and	O
long	O
-	O
term	O
potentiation	O
pathway	O
might	O
have	O
been	O
involved	O
in	O
molecular	O
mechanisms	O
concerning	O
neuronal	O
death	O
,	O
inflammation	O
and	O
epileptogenesis	O
.	O

Remarks	O
are	O
also	O
provided	O
to	O
point	O
out	O
the	O
unanswered	O
questions	O
and	O
to	O
outline	O
the	O
new	O
directions	O
for	O
the	O
future	O
research	O
of	O
the	O
field	O
.	O

Speculations	O
on	O
the	O
development	O
of	O
miRNAs	O
as	O
potential	O
therapeutic	O
targets	O
are	O
also	O
presented	O
.	O

These	O
small	O
molecules	O
act	O
by	O
repressing	O
the	O
expression	O
of	O
either	O
the	O
proapoptotic	O
or	O
antiapoptotic	O
genes	O
to	O
produce	O
antiapoptotic	O
or	O
proapoptotic	O
effects	O
.	O

Appealing	O
evidence	O
has	O
been	O
accumulating	O
for	O
the	O
involvement	O
of	O
miRNAs	O
in	O
human	B
diseases	O
associated	O
with	O
apoptotic	O
cell	O
death	O
and	O
the	O
potential	O
of	O
miRNAs	O
as	O
novel	O
therapeutic	O
targets	O
for	O
the	O
treatment	O
of	O
the	O
diseases	O
.	O

The	O
importance	O
of	O
miRNAs	O
has	O
steadily	O
gained	O
appreciation	O
and	O
miRNA	O
biology	O
has	O
exploded	O
into	O
a	O
massive	O
swell	O
of	O
interest	O
with	O
enormous	O
range	O
and	O
potential	O
in	O
almost	O
every	O
biological	O
discipline	O
because	O
of	O
their	O
widespread	O
expression	O
and	O
diverse	O
functions	O
in	O
both	O
animals	O
and	O
humans	B
.	O

It	O
has	O
been	O
established	O
that	O
miRNAs	O
are	O
critical	O
regulators	O
of	O
apoptosis	O
of	O
various	O
cell	O
types	O
.	O

Tremendous	O
efforts	O
have	O
been	O
made	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
involved	O
in	O
apoptosistic	O
cell	O
death	O
.	O

Once	O
ignored	O
completely	O
or	O
overlooked	O
as	O
cellular	O
detritus	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
that	O
were	O
discovered	O
only	O
a	O
decade	O
ago	O
,	O
have	O
recently	O
taken	O
many	O
by	O
surprise	O
.	O

MicroRNA	O
:	O
A	O
matter	O
of	O
life	O
or	O
death	O
.	O

Progressive	O
cell	O
loss	O
due	O
to	O
apoptosis	O
is	O
a	O
pathological	O
hallmark	O
implicated	O
in	O
a	O
wide	O
spectrum	O
of	O
degenerative	O
diseases	O
such	O
as	O
heart	O
disease	O
,	O
atherosclerotic	O
arteries	O
and	O
hypertensive	O
vessels	O
,	O
Alzheimer	O
's	O
disease	O
and	O
other	O
neurodegenerative	O
disorders	O
.	O

This	O
editorial	O
aims	O
to	O
convey	O
this	O
message	O
and	O
to	O
boost	O
up	O
the	O
research	O
interest	O
by	O
providing	O
a	O
timely	O
,	O
comprehensive	O
overview	O
on	O
regulation	O
of	O
apoptosis	O
by	O
miRNAs	O
and	O
a	O
synopsis	O
on	O
the	O
pathophysiologic	O
implications	O
of	O
this	O
novel	O
regulatory	O
network	O
based	O
on	O
the	O
currently	O
available	O
data	O
in	O
the	O
literature	O
.	O

It	O
begins	O
with	O
a	O
brief	O
introduction	O
to	O
apoptosis	O
and	O
miRNAs	O
,	O
followed	O
by	O
the	O
description	O
of	O
the	O
fundamental	O
aspects	O
of	O
miRNA	O
biogenesis	O
and	O
action	O
,	O
and	O
the	O
role	O
of	O
miRNAs	O
in	O
regulating	O
apoptosis	O
of	O
cancer	O
cells	O
and	O
cardiovascular	O
cells	O
.	O

The	O
accurate	O
diagnosis	O
of	O
brain	O
malignancies	O
is	O
essential	O
for	O
selection	O
of	O
proper	O
treatment	O
.	O

A	O
recurring	O
challenge	O
for	O
brain	O
pathologists	O
is	O
to	O
diagnose	O
whether	O
a	O
brain	O
malignancy	O
is	O
a	O
primary	O
tumor	O
or	O
a	O
metastasis	O
from	O
some	O
other	O
tissue	O
.	O

MiR-92b	O
and	O
miR-9	O
/	O
9	O
*	O
are	O
specifically	O
expressed	O
in	O
brain	O
primary	O
tumors	O
and	O
can	O
be	O
used	O
to	O
differentiate	O
primary	O
from	O
metastatic	O
brain	O
tumors	O
.	O

These	O
microRNAs	O
thus	O
represent	O
excellent	O
biomarkers	O
for	O
brain	O
primary	O
tumors	O
.	O

By	O
considering	O
the	O
expression	O
of	O
only	O
these	O
two	O
microRNAs	O
,	O
it	O
is	O
possible	O
to	O
distinguish	O
between	O
primary	O
and	O
metastatic	O
brain	O
tumors	O
with	O
very	O
high	O
accuracy	O
.	O

Using	O
microRNA	O
expression	O
profiling	O
,	O
we	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
over	O
-	O
expressed	O
,	O
specifically	O
in	O
brain	O
primary	O
tumors	O
,	O
as	O
compared	O
to	O
primary	O
tumors	O
from	O
other	O
tissues	O
and	O
their	O
metastases	O
to	O
the	O
brain	O
.	O

MicroRNAs	O
are	O
a	O
class	O
of	O
small	O
non	O
-	O
coding	O
RNA	O
species	O
that	O
regulate	O
gene	O
expression	O
;	O
many	O
exhibit	O
tissue	O
-	O
specific	O
expression	O
and	O
are	O
misregulated	O
in	O
cancer	O
.	O

Previous	O
reports	O
have	O
found	O
that	O
hsa	O
-	O
miR-92b	O
and	O
hsa	O
-	O
miR-9	O
/	O
hsa	O
-	O
miR-9	O
*	O
are	O
expressed	O
more	O
strongly	O
in	O
developing	O
neurons	O
and	O
brain	O
than	O
in	O
adult	O
brain	O
.	O

Thus	O
,	O
their	O
specific	O
over	O
-	O
expression	O
in	O
brain	O
primary	O
tumors	O
supports	O
a	O
functional	O
role	O
for	O
these	O
microRNAs	O
or	O
a	O
link	O
between	O
neuronal	O
stem	O
cells	O
and	O
brain	O
tumorigenesis	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
that	O
levels	O
of	O
human	B
APP	O
can	O
be	O
regulated	O
by	O
miRNAs	O
.	O

Over	O
-	O
expression	O
of	O
these	O
miRNAs	O
,	O
but	O
not	O
control	O
miRNAs	O
,	O
results	O
in	O
translational	O
repression	O
of	O
APP	O
mRNA	O
and	O
significantly	O
reduces	O
APP	O
protein	O
levels	O
.	O

Here	O
we	O
test	O
the	O
hypothesis	O
that	O
APP	O
protein	O
levels	O
can	O
be	O
regulated	O
by	O
miRNAs	O
,	O
evolutionarily	O
conserved	O
small	O
noncoding	O
RNA	O
molecules	O
that	O
play	O
an	O
important	O
role	O
in	O
regulating	O
gene	O
expression	O
.	O

Utilizing	O
human	B
cell	O
lines	O
,	O
we	O
demonstrate	O
that	O
miRNAs	O
hsa	O
-	O
mir-106a	O
and	O
hsa	O
-	O
mir-520c	O
bind	O
to	O
their	O
predicted	O
target	O
sequences	O
in	O
the	O
APP	O
3'UTR	O
and	O
negatively	O
regulate	O
reporter	O
gene	O
expression	O
.	O

ABSTRACT	O
:	O
A	O
number	O
of	O
studies	O
have	O
shown	O
that	O
increased	O
APP	O
levels	O
,	O
resulting	O
from	O
either	O
a	O
genomic	O
locus	O
duplication	O
or	O
alteration	O
in	O
APP	O
regulatory	O
sequences	O
,	O
can	O
lead	O
to	O
development	O
of	O
early	O
-	O
onset	O
dementias	O
,	O
including	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Therefore	O
,	O
understanding	O
how	O
APP	O
levels	O
are	O
regulated	O
could	O
provide	O
valuable	O
insight	O
into	O
the	O
genetic	O
basis	O
of	O
AD	O
and	O
illuminate	O
novel	O
therapeutic	O
avenues	O
for	O
AD	O
.	O

MicroRNAs	O
can	O
regulate	O
human	B
APP	O
levels	O
.	O

MicroRNA	O
expression	O
profiling	O
for	O
molecular	O
classification	O
of	O
pediatric	O
brain	O
tumors	O
.	O

The	O
transcription	O
factor	O
REST	O
silences	O
neuronal	O
gene	O
expression	O
in	O
non	O
-	O
neuronal	O
cells	O
.	O

The	O
bifunctional	O
microRNA	O
miR-9	O
/	O
miR-9	O
*	O
regulates	O
REST	O
and	O
CoREST	O
and	O
is	O
downregulated	O
in	O
Huntington	O
's	O
disease	O
.	O

Polyglutamine	O
expansions	O
in	O
huntingtin	O
,	O
which	O
causes	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
abrogates	O
REST	O
-	O
huntingtin	O
binding	O
.	O

In	O
neurons	O
,	O
the	O
protein	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
in	O
part	O
through	O
binding	O
to	O
huntingtin	O
.	O

In	O
this	O
work	O
,	O
we	O
found	O
that	O
levels	O
of	O
several	O
microRNAs	O
(	O
miRNAs	O
)	O
with	O
upstream	O
RE1	O
sites	O
are	O
decreased	O
in	O
HD	O
patient	B
cortices	O
relative	O
to	O
healthy	O
controls	O
.	O

Consequently	O
,	O
REST	O
translocates	O
to	O
the	O
nucleus	O
,	O
occupies	O
RE1	O
repressor	O
sequences	O
and	O
decreases	O
neuronal	O
gene	O
expression	O
.	O

Interestingly	O
,	O
one	O
of	O
these	O
,	O
the	O
bifunctional	O
brain	O
enriched	O
miR-9	O
/	O
miR-9	O
*	O
,	O
targets	O
two	O
components	O
of	O
the	O
REST	O
complex	O
:	O
miR-9	O
targets	O
REST	O
and	O
miR-9	O
*	O
targets	O
CoREST	O
.	O

These	O
data	O
provide	O
evidence	O
for	O
a	O
double	O
negative	O
feedback	O
loop	O
between	O
the	O
REST	O
silencing	O
complex	O
and	O
the	O
miRNAs	O
it	O
regulates	O
.	O

Specificity	O
,	O
duplex	O
degradation	O
and	O
subcellular	O
localization	O
of	O
antagomirs	O
.	O

Finally	O
,	O
we	O
show	O
that	O
antagomirs	O
,	O
although	O
incapable	O
of	O
silencing	O
miRNAs	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
when	O
injected	O
systemically	O
,	O
efficiently	O
target	O
miRNAs	O
when	O
injected	O
locally	O
into	O
the	O
mouse	B
cortex	O
.	O

Our	O
data	O
further	O
validate	O
the	O
effectiveness	O
of	O
antagomirs	O
in	O
vivo	O
and	O
should	O
facilitate	O
future	O
studies	O
to	O
silence	O
miRNAs	O
for	O
functional	O
analysis	O
and	O
in	O
clinically	O
relevant	O
settings	O
.	O

We	O
demonstrate	O
that	O
antagomirs	O
harbor	O
optimized	O
phosphorothioate	O
modifications	O
,	O
require	O
>	O
19-nt	O
length	O
for	O
highest	O
efficiency	O
and	O
can	O
discriminate	O
between	O
single	O
nucleotide	O
mismatches	O
of	O
the	O
targeted	O
miRNA	O
.	O

Degradation	O
of	O
different	O
chemically	O
protected	O
miRNA	O
/	O
antagomir	O
duplexes	O
in	O
mouse	B
livers	O
and	O
localization	O
of	O
antagomirs	O
in	O
a	O
cytosolic	O
compartment	O
that	O
is	O
distinct	O
from	O
processing	O
(	O
P	O
)	O
-bodies	O
indicates	O
a	O
degradation	O
mechanism	O
independent	O
of	O
the	O
RNA	O
interference	O
(	O
RNAi	O
)	O
pathway	O
.	O

We	O
recently	O
demonstrated	O
silencing	O
miRNA	O
function	O
in	O
mice	B
using	O
chemically	O
modified	O
and	O
cholesterol	O
-	O
conjugated	O
RNAs	O
termed	O
'	O
antagomirs	O
'	O
.	O

Here	O
,	O
we	O
further	O
characterize	O
the	O
properties	O
and	O
function	O
of	O
antagomirs	O
in	O
mice	B
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
an	O
abundant	O
class	O
of	O
20	O
-	O
23-nt	O
long	O
regulators	O
of	O
gene	O
expression	O
.	O

The	O
study	O
of	O
miRNA	O
function	O
in	O
mice	B
and	O
potential	O
therapeutic	O
approaches	O
largely	O
depend	O
on	O
modified	O
oligonucleotides	O
.	O

Altered	O
microRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
:	O
miR-146a	O
targets	O
TBP	O
.	O

We	O
studied	O
expression	O
of	O
90	O
miRNAs	O
in	O
STHdh	O
(	O
Q111	O
)	O
/	O
Hdh	O
(	O
Q111	O
)	O
cells	O
,	O
a	O
model	O
for	O
Huntington	O
's	O
disease	O
and	O
compared	O
with	O
that	O
obtained	O
in	O
STHdh	O
(	O
Q7	O
)	O
/	O
Hdh	O
(	O
Q7	O
)	O
cells	O
.	O

Fifteen	O
miRNAs	O
were	O
down	O
regulated	O
and	O
12	O
miRNAs	O
were	O
up	O
regulated	O
more	O
than	O
2-fold	O
.	O

Such	O
changes	O
were	O
statistically	O
significant	O
.	O

One	O
hundred	O
and	O
forty	O
-	O
two	O
genes	O
are	O
experimentally	O
known	O
targets	O
of	O
these	O
altered	O
miRNAs	O
.	O

Using	O
luciferase	O
reporter	O
assays	O
with	O
3'-UTRs	O
of	O
TBP	O
,	O
over	O
-	O
expression	O
and	O
inhibition	O
of	O
miR-146a	O
,	O
we	O
showed	O
that	O
miR-146a	O
targets	O
TBP	O
.	O

It	O
has	O
been	O
predicted	O
that	O
miR-146a	O
may	O
target	O
Tata	O
Binding	O
Protein	O
(	O
TBP	O
)	O
.	O

Regulation	O
of	O
TBP	O
by	O
miR-146a	O
may	O
contribute	O
to	O
HD	O
pathogenesis	O
.	O

Many	O
of	O
these	O
pathways	O
were	O
first	O
identified	O
in	O
genetic	O
screens	O
in	O
Drosophila	B
and	O
other	O
lower	O
organisms	O
.	O

In	O
the	O
last	O
20	O
years	O
,	O
it	O
has	O
become	O
clear	O
that	O
developmental	O
genes	O
and	O
their	O
regulators	O
,	O
noncoding	O
RNAs	O
including	O
microRNAs	O
and	O
long	O
-	O
noncoding	O
RNAs	O
,	O
within	O
signaling	O
pathways	O
play	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
.	O

Genes	O
and	O
pathways	O
expressed	O
during	O
embryonic	O
development	O
,	O
including	O
the	O
Notch	O
,	O
Wnt	O
/	O
β	O
-	O
Catenin	O
,	O
TGF	O
-	O
β	O
/	O
BMP	O
,	O
Shh	O
/	O
Patched	O
,	O
and	O
Hippo	O
pathways	O
are	O
mutated	O
,	O
lost	O
,	O
or	O
aberrantly	O
regulated	O
in	O
a	O
wide	O
variety	O
of	O
human	B
cancers	O
,	O
including	O
skin	O
,	O
breast	O
,	O
blood	O
,	O
and	O
brain	O
cancers	O
,	O
including	O
medulloblastoma	O
.	O

Mammalian	O
orthologs	O
were	O
subsequently	O
identified	O
and	O
genes	O
within	O
the	O
pathways	O
cloned	O
and	O
found	O
to	O
regulate	O
cell	O
growth	O
.	O

Cerebellum	O
development	O
and	O
medulloblastoma	O
.	O

Medulloblastoma	O
,	O
the	O
most	O
common	O
malignant	O
nervous	O
system	O
tumor	O
in	O
childhood	O
,	O
are	O
thought	O
to	O
arise	O
from	O
disruptions	O
in	O
cerebellar	O
development	O
[	O
reviewed	O
by	O
Marino	O
,	O
S.	O
(	O
2005	O
)	O
]	O
.	O

These	O
biochemical	O
pathways	O
affect	O
cell	O
fate	O
determination	O
,	O
axis	O
formation	O
,	O
and	O
patterning	O
during	O
development	O
and	O
regulate	O
tissue	O
homeostasis	O
and	O
regeneration	O
in	O
adults	O
.	O

In	O
this	O
chapter	O
,	O
we	O
will	O
review	O
the	O
development	O
of	O
the	O
cerebellar	O
cortex	O
,	O
highlighting	O
signaling	O
pathways	O
of	O
potential	O
relevance	O
to	O
tumorigenesis	O
.	O

Defining	O
the	O
extracellular	O
cues	O
and	O
intracellular	O
signaling	O
pathways	O
that	O
control	O
cerebellar	O
neurogenesis	O
,	O
especially	O
granule	O
cell	O
progenitor	O
(	O
GCP	O
)	O
proliferation	O
and	O
differentiation	O
has	O
been	O
useful	O
for	O
developing	O
models	O
to	O
unravel	O
the	O
mechanisms	O
underlying	O
medulloblastoma	O
formation	O
and	O
growth	O
.	O

This	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
case	O
of	O
this	O
kind	O
found	O
in	O
Argentina	O
and	O
is	O
additional	O
evidence	O
that	O
HAM	O
/	O
TSP	O
solely	O
related	O
to	O
HTLV	O
-	O
II	O
infection	O
occurs	O
in	O
HTLV	O
-	O
I	O
-	O
negative	O
subjects	O
.	O

A	O
case	O
of	O
neurological	O
disease	O
featuring	O
human	B
T	O
lymphocyte	O
virus	O
-	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
was	O
diagnosed	O
by	O
serological	O
(	O
Western	O
blot	O
)	O
and	O
molecular	O
(	O
polymerase	O
chain	O
reaction	O
)	O
criteria	O
as	O
related	O
to	O
human	B
T	O
lymphocyte	O
virus	O
(	O
HTLV	O
)	O
-II	O
infection	O
.	O

A	O
possible	O
case	O
of	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
in	O
an	O
Argentinian	O
woman	B
with	O
human	B
T	O
lymphocyte	O
virus	O
type	O
II	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
directly	O
resulted	O
in	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	O
in	O
the	O
tested	O
cells	O
,	O
consequently	O
,	O
affects	O
their	O
growth	O
potential	O
by	O
reducing	O
a	O
G1	O
to	O
S	O
shift	O
in	O
the	O
cell	O
cycle	O
.	O

Consistently	O
,	O
miR-221	O
/	O
222	O
knocked	O
-	O
down	O
through	O
antisense	O
2'-OME	O
-	O
oligonucleotides	O
increased	O
p27Kip1	O
in	O
U251	O
glioma	O
subcutaneous	O
mice	B
and	O
strongly	O
reduced	O
tumor	O
growth	O
in	O
vivo	O
through	O
up	O
regulation	O
of	O
p27Kip1	O
.	O

Our	O
results	O
suggest	O
that	O
miR-221	O
/	O
222	O
is	O
a	O
regulator	O
of	O
the	O
tumor	O
suppressor	O
gene	O
p27Kip1	O
,	O
and	O
co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
expression	O
in	O
advanced	O
gliomas	O
may	O
inhibit	O
glioma	O
cell	O
proliferation	O
by	O
a	O
mechanism	O
involving	O
the	O
up	O
-	O
regulation	O
of	O
p27Kip1	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Co	O
-	O
suppression	O
of	O
miR-221	O
/	O
222	O
cluster	O
suppresses	O
human	B
glioma	O
cell	O
growth	O
by	O
targeting	O
p27kip1	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
are	O
short	O
regulatory	O
RNAs	O
that	O
negatively	O
modulate	O
protein	O
expression	O
at	O
a	O
post	O
-	O
transcriptional	O
level	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
altered	O
regulation	O
of	O
miRNA	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
several	O
types	O
of	O
cancers	O
.	O

In	O
the	O
current	O
study	O
,	O
an	O
inverse	O
relationship	O
between	O
the	O
expression	O
of	O
miR-221	O
/	O
miR-222	O
and	O
the	O
cell	O
cycle	O
inhibitor	O
p27Kip1	O
was	O
identified	O
in	O
U251	O
glioma	O
cells	O
.	O

The	O
mRNA	O
expression	O
of	O
the	O
RNases	O
Drosha	O
and	O
Dicer	O
,	O
cofactor	O
Pasha	O
,	O
and	O
the	O
pre	O
-	O
miRNA	O
transporter	O
exportin-5	O
,	O
which	O
modulate	O
miRNA	O
biogenesis	O
,	O
were	O
not	O
altered	O
after	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

Thus	O
,	O
the	O
present	O
studies	O
indicate	O
a	O
critical	O
role	O
of	O
miRNAs	O
in	O
controlling	O
mRNA	O
transcription	O
and	O
translation	O
in	O
the	O
postischemic	O
brain	O
.	O

Bioinformatics	O
analysis	O
indicated	O
a	O
correlation	O
between	O
miRNAs	O
altered	O
to	O
several	O
mRNAs	O
known	O
to	O
mediate	O
inflammation	O
,	O
transcription	O
,	O
neuroprotection	O
,	O
receptors	O
function	O
,	O
and	O
ionic	O
homeostasis	O
.	O

Of	O
those	O
,	O
17	O
showed	O
>	O
5	O
fold	O
change	O
.	O

In	O
silico	O
analysis	O
showed	O
sequence	O
complementarity	O
of	O
eight	O
miRNAs	O
induced	O
after	O
focal	O
ischemia	O
to	O
877	O
promoters	O
indicating	O
the	O
possibility	O
of	O
noncoding	O
RNA	O
-	O
induced	O
activation	O
of	O
gene	O
expression	O
.	O

Antagomir	O
-	O
mediated	O
prevention	O
of	O
mir-145	O
expression	O
led	O
to	O
an	O
increased	O
protein	O
expression	O
of	O
its	O
downstream	O
target	O
superoxide	O
dismutase-2	O
in	O
the	O
postischemic	O
brain	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
approximately	O
22	O
nucleotides	O
long	O
,	O
noncoding	O
RNAs	O
that	O
control	O
cellular	O
function	O
by	O
either	O
degrading	O
mRNAs	O
or	O
arresting	O
their	O
translation	O
.	O

Transient	O
focal	O
ischemia	O
induces	O
extensive	O
temporal	O
changes	O
in	O
rat	B
cerebral	O
microRNAome	O
.	O

Of	O
the	O
238	O
miRNAs	O
evaluated	O
,	O
8	O
showed	O
increased	O
and	O
12	O
showed	O
decreased	O
expression	O
at	O
least	O
at	O
4	O
out	O
of	O
5	O
reperfusion	O
time	O
points	O
studied	O
between	O
3	O
h	O
and	O
3	O
days	O
compared	O
with	O
sham	O
.	O

To	O
understand	O
their	O
functional	O
significance	O
in	O
ischemic	O
pathophysiology	O
,	O
we	O
profiled	O
miRNAs	O
in	O
adult	O
rat	B
brain	O
as	O
a	O
function	O
of	O
reperfusion	O
time	O
after	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
.	O

The	O
therapy	O
employed	O
,	O
in	O
a	O
single	O
baculoviral	O
vector	O
,	O
a	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
gene	O
promoter	O
and	O
the	O
repeated	O
target	O
sequences	O
of	O
three	O
miRNAs	O
that	O
are	O
enriched	O
in	O
astrocytes	O
but	O
downregulated	O
in	O
glioblastoma	O
cells	O
to	O
control	O
the	O
expression	O
of	O
the	O
herpes	O
simplex	O
virus	O
thymidine	O
kinase	O
(	O
HSVtk	O
)	O
gene	O
.	O

This	O
resulted	O
in	O
significantly	O
improved	O
in	O
vivo	O
selectivity	O
over	O
the	O
use	O
of	O
a	O
control	O
vector	O
without	O
miRNA	O
regulation	O
,	O
enabling	O
effective	O
elimination	O
of	O
human	B
glioma	O
xenografts	O
while	O
producing	O
negligible	O
toxic	O
effects	O
on	O
normal	O
astrocytes	O
.	O

In	O
the	O
context	O
of	O
cancer	O
suicide	O
gene	O
therapy	O
,	O
this	O
approach	O
may	O
lead	O
to	O
cytotoxic	O
effects	O
in	O
both	O
cancer	O
and	O
nontarget	O
normal	O
cells	O
.	O

Considering	O
microRNA	O
(	O
miRNA	O
)	O
function	O
in	O
post	O
-	O
transcriptional	O
regulation	O
of	O
gene	O
expression	O
,	O
we	O
have	O
developed	O
a	O
viral	O
vector	O
platform	O
combining	O
cellular	O
promoter	O
-	O
based	O
transcriptional	O
targeting	O
with	O
miRNA	O
regulation	O
for	O
a	O
glioma	O
suicide	O
gene	O
therapy	O
in	O
the	O
mouse	B
brain	O
.	O

Thus	O
,	O
incorporating	O
miRNA	O
regulation	O
into	O
a	O
transcriptional	O
targeting	O
vector	O
adds	O
an	O
extra	O
layer	O
of	O
security	O
to	O
prevent	O
off	O
-	O
target	O
transgene	O
expression	O
and	O
should	O
be	O
useful	O
for	O
the	O
development	O
of	O
gene	O
delivery	O
vectors	O
with	O
high	O
targeting	O
specificity	O
for	O
cancer	O
therapy	O
.	O

Transcriptional	O
targeting	O
using	O
a	O
tissue	O
-	O
specific	O
cellular	O
promoter	O
is	O
proving	O
to	O
be	O
a	O
powerful	O
means	O
for	O
restricting	O
transgene	O
expression	O
in	O
targeted	O
tissues	O
.	O

Combinatorial	O
control	O
of	O
suicide	O
gene	O
expression	O
by	O
tissue	O
-	O
specific	O
promoter	O
and	O
microRNA	O
regulation	O
for	O
cancer	O
therapy	O
.	O

The	O
possible	O
use	O
of	O
RNAi	O
in	O
the	O
treatment	O
of	O
spinocerebellar	O
ataxia	O
or	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
with	O
its	O
advantages	O
and	O
pitfalls	O
and	O
possible	O
extensions	O
to	O
other	O
diseases	O
are	O
discussed	O
.	O

RNAi	O
has	O
moved	O
from	O
a	O
purely	O
experimental	O
technique	O
to	O
the	O
stage	O
of	O
potential	O
clinical	O
applications	O
.	O

RNAi	O
utilises	O
cellular	O
machinery	O
associated	O
with	O
the	O
processing	O
of	O
naturally	O
occurring	O
micro	O
RNA	O
(	O
miRNAs	O
)	O
.	O

RNAi	O
has	O
both	O
admirers	O
and	O
detractors	O
,	O
but	O
is	O
undeniably	O
a	O
technique	O
with	O
great	O
potential	O
,	O
which	O
has	O
come	O
a	O
long	O
way	O
in	O
the	O
short	O
time	O
since	O
its	O
discovery	O
.	O

RNA	O
interference	O
has	O
become	O
the	O
tool	O
of	O
choice	O
to	O
analyse	O
the	O
loss	O
-	O
of	O
-	O
function	O
of	O
individual	O
genes	O
and	O
has	O
been	O
exploited	O
to	O
identify	O
complex	O
regulatory	O
pathways	O
following	O
genomic	O
screening	O
.	O

Design	O
of	O
shRNAs	O
for	O
RNAi	O
-	O
A	O
lesson	O
from	O
pre	O
-	O
miRNA	O
processing	O
:	O
possible	O
clinical	O
applications	O
.	O

The	O
cellular	O
processing	O
of	O
shRNAs	O
shares	O
common	O
features	O
with	O
the	O
biogenesis	O
of	O
naturally	O
occurring	O
miRNA	O
such	O
as	O
cleavage	O
by	O
nuclear	O
RNase	O
Drosha	O
,	O
export	O
from	O
the	O
nucleus	O
,	O
processing	O
by	O
a	O
cytoplasmic	O
RNase	O
Dicer	O
,	O
and	O
incorporation	O
into	O
the	O
RNA	O
-	O
induced	O
silencing	O
complex	O
(	O
RISC	O
)	O
.	O

Each	O
step	O
has	O
a	O
crucial	O
influence	O
on	O
the	O
efficiency	O
of	O
RNAi	O
and	O
their	O
consideration	O
should	O
be	O
a	O
part	O
of	O
a	O
standard	O
experimental	O
design	O
.	O

More	O
recently	O
an	O
introduction	O
of	O
short	O
approximately	O
22	O
nucleotide	O
RNA	O
duplexes	O
has	O
become	O
the	O
standard	O
in	O
short	O
-	O
term	O
experiments	O
,	O
but	O
is	O
insufficient	O
for	O
long	O
-	O
term	O
knock	O
-	O
down	O
assays	O
.	O

Long	O
-	O
term	O
expression	O
of	O
siRNAs	O
has	O
been	O
achieved	O
by	O
in	O
vivo	O
transcription	O
from	O
plasmids	O
coding	O
for	O
short	O
hairpin	O
RNAs	O
(	O
shRNAs	O
)	O
.	O

Effective	O
use	O
of	O
RNAi	O
requires	O
detailed	O
knowledge	O
of	O
the	O
individual	O
steps	O
and	O
the	O
proteins	O
involved	O
,	O
as	O
well	O
as	O
the	O
similarities	O
and	O
distinctions	O
between	O
miRNA	O
and	O
siRNA	O
pathways	O
.	O

RNAi	O
was	O
originally	O
induced	O
by	O
the	O
introduction	O
of	O
long	O
double	O
stranded	O
RNAs	O
(	O
dsRNAs	O
)	O
into	O
cells	O
in	O
which	O
the	O
RNA	O
was	O
cleaved	O
into	O
short	O
RNAs	O
which	O
effectively	O
interfered	O
with	O
a	O
transcription	O
of	O
cognate	O
mRNA	O
.	O

[	O
AD	O
-	O
FTLD	O
spectrum	O
--	O
new	O
findings	O
on	O
risk	O
genes	O
in	O
neurodegenerative	O
diseases	O
]	O
.	O

Our	O
microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	B
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
has	O
shown	O
that	O
some	O
microRNA	O
such	O
as	O
miR-21	O
could	O
be	O
involved	O
in	O
the	O
intricate	O
process	O
of	O
TBI	O
course	O
.	O

Furthermore	O
,	O
we	O
revealed	O
global	O
up	O
-	O
regulation	O
of	O
miR-21	O
expression	O
within	O
all	O
the	O
four	O
time	O
points	O
post	O
injury	O
.	O

Our	O
research	O
revealed	O
that	O
136	O
miRNAs	O
were	O
expressing	O
at	O
6	O
h	O
post	O
injury	O
,	O
in	O
which	O
13	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
14	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
118	O
miRNAs	O
were	O
expressing	O
at	O
24	O
h	O
post	O
injury	O
,	O
in	O
which	O
4	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
23	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
149	O
miRNAs	O
were	O
expressing	O
at	O
48	O
h	O
post	O
injury	O
,	O
in	O
which	O
16	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
11	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
;	O
and	O
203	O
miRNAs	O
were	O
expressing	O
at	O
72	O
h	O
post	O
injury	O
,	O
in	O
which	O
19	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
up	O
-	O
regulated	O
,	O
and	O
5	O
miRNAs	O
were	O
more	O
than	O
2-fold	O
down	O
-	O
regulated	O
.	O

The	O
qRT	O
-	O
PCR	O
results	O
indicated	O
good	O
consistency	O
with	O
the	O
results	O
of	O
the	O
microarray	O
method	O
.	O

Finally	O
,	O
we	O
utilized	O
qRT	O
-	O
PCR	O
methods	O
to	O
verify	O
the	O
microarray	O
results	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
very	O
important	O
regulators	O
of	O
biological	O
processes	O
such	O
as	O
development	O
,	O
cellular	O
differentiation	O
,	O
and	O
tumor	O
generation	O
.	O

MiRNA	O
microarray	O
has	O
been	O
found	O
to	O
be	O
a	O
high	O
throughput	O
global	O
analysis	O
tool	O
for	O
detecting	O
miRNA	O
expression	O
profiling	O
,	O
and	O
miRNA	O
expression	O
profiling	O
will	O
facilitate	O
the	O
study	O
of	O
the	O
biological	O
function	O
of	O
miRNAs	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
miRNA	O
expression	O
level	O
in	O
rat	B
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
using	O
microarray	O
method	O
.	O

We	O
choose	O
several	O
time	O
points	O
post	O
brain	O
injury	O
:	O
6	O
h	O
,	O
24	O
h	O
,	O
48	O
h	O
and	O
72	O
h	O
,	O
respectively	O
,	O
to	O
reveal	O
differential	O
expression	O
of	O
miRNAs	O
in	O
rat	B
brain	O
cortex	O
compared	O
with	O
control	O
groups	O
.	O

Microarray	O
based	O
analysis	O
of	O
microRNA	O
expression	O
in	O
rat	B
cerebral	O
cortex	O
after	O
traumatic	O
brain	O
injury	O
.	O

Ectopic	O
expression	O
of	O
miR-29b	O
decreased	O
hPGRN	O
expression	O
at	O
the	O
both	O
mRNA	O
and	O
protein	O
levels	O
.	O

To	O
examine	O
the	O
direct	O
effect	O
of	O
manipulating	O
endogenous	O
miR-29b	O
on	O
hPGRN	O
expression	O
,	O
we	O
established	O
a	O
stable	O
NIH3T3	O
cell	O
line	O
that	O
expresses	O
hPGRN	O
under	O
the	O
control	O
of	O
the	O
cytomegalovirus	O
promoter	O
.	O

Endogenous	O
hPGRN	O
in	O
HEK	O
293	O
cells	O
was	O
also	O
regulated	O
by	O
miR-29b	O
.	O

Conversely	O
,	O
knockdown	O
of	O
endogenous	O
miR-29b	O
with	O
locked	O
nucleic	O
acid	O
increased	O
the	O
production	O
and	O
secretion	O
of	O
hPGRN	O
in	O
NIH3T3	O
cells	O
.	O

How	O
progranulin	O
(	O
PGRN	O
)	O
expression	O
is	O
regulated	O
is	O
largely	O
unknown	O
.	O

Progranulin	O
deficiency	O
is	O
thought	O
to	O
cause	O
some	O
forms	O
of	O
frontotemporal	O
dementia	O
(	O
FTD	O
)	O
,	O
a	O
major	O
early	O
-	O
onset	O
age	O
-	O
dependent	O
neurodegenerative	O
disease	O
.	O

miR-29b	O
downregulates	O
the	O
expression	O
of	O
luciferase	O
through	O
hPGRN	O
or	O
mouse	B
PGRN	O
(	O
mPGRN	O
)	O
3'UTRs	O
,	O
and	O
the	O
regulation	O
was	O
abolished	O
by	O
mutations	O
in	O
the	O
miR-29b	O
binding	O
site	O
.	O

We	O
identified	O
an	O
evolutionarily	O
conserved	O
binding	O
site	O
for	O
microRNA-29b	O
(	O
miR-29b	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3'UTR	O
)	O
of	O
the	O
human	B
PGRN	O
(	O
hPGRN	O
)	O
mRNA	O
.	O

MicroRNA-29b	O
regulates	O
the	O
expression	O
level	O
of	O
human	B
progranulin	O
,	O
a	O
secreted	O
glycoprotein	O
implicated	O
in	O
frontotemporal	O
dementia	O
.	O

These	O
findings	O
identify	O
miR-29b	O
as	O
a	O
novel	O
posttranscriptional	O
regulator	O
of	O
PGRN	O
expression	O
,	O
raising	O
the	O
possibility	O
that	O
miR-29b	O
or	O
other	O
miRNAs	O
might	O
be	O
targeted	O
therapeutically	O
to	O
increase	O
hPGRN	O
levels	O
in	O
some	O
FTD	O
patients	B
.	O

We	O
studied	O
the	O
expression	O
of	O
selected	O
miRNAs	O
following	O
infection	O
of	O
CBA	O
mice	B
with	O
Plasmodium	O
berghei	O
ANKA	O
(	O
PbA	O
)	O
,	O
which	O
causes	O
cerebral	O
malaria	O
(	O
CM	O
)	O
,	O
or	O
Plasmodium	O
berghei	O
K173	O
(	O
PbK	O
)	O
,	O
which	O
causes	O
severe	O
malaria	O
but	O
without	O
cerebral	O
complications	O
,	O
termed	O
non	O
-	O
CM	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
posttranscriptional	O
regulatory	O
molecules	O
that	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
immune	O
responses	O
,	O
but	O
their	O
role	O
in	O
the	O
immune	O
response	O
to	O
Plasmodium	O
infection	O
is	O
unknown	O
.	O

Differential	O
MicroRNA	O
Expression	O
in	O
Experimental	O
Cerebral	O
and	O
Noncerebral	O
Malaria	O
.	O

To	O
investigate	O
the	O
involvement	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
in	O
CM	O
-	O
resistant	O
mice	B
,	O
we	O
assessed	O
the	O
expression	O
levels	O
in	O
gamma	O
interferon	O
knockout	O
(	O
IFN	O
-	O
γ	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	B
on	O
a	O
C57BL	O
/	O
6	O
genetic	O
background	O
.	O

In	O
contrast	O
,	O
no	O
miRNA	O
changes	O
were	O
detected	O
in	O
the	O
heart	O
,	O
an	O
organ	O
with	O
no	O
known	O
pathology	O
during	O
acute	O
malaria	O
.	O

We	O
identified	O
three	O
miRNAs	O
that	O
were	O
differentially	O
expressed	O
in	O
the	O
brain	O
of	O
PbA	O
-	O
infected	O
CBA	O
mice	B
:	O
let7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
.	O

The	O
differential	O
expression	O
profiles	O
of	O
selected	O
miRNAs	O
(	O
let-7i	O
,	O
miR-27a	O
,	O
miR-150	O
,	O
miR-126	O
,	O
miR-210	O
,	O
and	O
miR-155	O
)	O
were	O
analyzed	O
in	O
mouse	B
brain	O
and	O
heart	O
tissue	O
by	O
quantitative	O
reverse	O
transcription	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
the	O
CBA	O
mouse	B
at	O
least	O
,	O
miRNA	O
may	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
pathogenesis	O
of	O
severe	O
malaria	O
.	O

Overexpression	O
of	O
these	O
three	O
miRNAs	O
during	O
PbA	O
,	O
but	O
not	O
PbK	O
,	O
infection	O
in	O
WT	O
mice	B
may	O
be	O
critical	O
for	O
the	O
triggering	O
of	O
the	O
neurological	O
syndrome	O
via	O
regulation	O
of	O
their	O
potential	O
downstream	O
targets	O
.	O

The	O
expression	O
of	O
let-7i	O
,	O
miR-27a	O
,	O
and	O
miR-150	O
was	O
unchanged	O
in	O
both	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
IFN	O
-	O
γ	O
(	O
-	O
/	O
-	O
)	O
mice	B
following	O
infection	O
.	O

[	O
Genetic	O
and	O
molecular	O
abnormalities	O
of	O
glioblastomas	O
(	O
GBM	O
)	O
]	O
.	O

This	O
presentation	O
reports	O
a	O
series	O
of	O
data	O
dealing	O
with	O
recurrent	O
genetic	O
abnormalities	O
and	O
gene	O
expression	O
profiles	O
that	O
characterize	O
primary	O
glioblastomas	O
and	O
secondary	O
glioblastomas	O
resulting	O
from	O
the	O
transformation	O
of	O
low	O
grade	O
tumors	O
(	O
grade	O
II	O
and	O
III	O
astrocytomas	O
and	O
oligodendrogliomas	O
)	O
.	O

Finally	O
,	O
a	O
short	O
description	O
of	O
exosomes	O
as	O
vectors	O
of	O
tumor	O
information	O
will	O
be	O
presented	O
.	O

The	O
most	O
recent	O
aspects	O
of	O
the	O
concept	O
of	O
tumor	O
stem	O
cells	O
that	O
may	O
explain	O
the	O
relentless	O
growth	O
of	O
GBM	O
will	O
be	O
reported	O
.	O

Molecular	O
features	O
of	O
tumor	O
neoangiogenesis	O
will	O
be	O
described	O
.	O

Epigenetic	O
alterations	O
and	O
deregulation	O
of	O
gene	O
expression	O
by	O
microRNAs	O
(	O
miRs	O
)	O
will	O
be	O
also	O
included	O
.	O

Some	O
aspects	O
of	O
tumor	O
predisposition	O
will	O
be	O
also	O
discussed	O
.	O

In	O
an	O
effort	O
to	O
shed	O
light	O
on	O
consequences	O
mediated	O
by	O
p53	O
inactivation	O
in	O
gliomas	O
,	O
we	O
established	O
the	O
Tet	O
-	O
On	O
system	O
for	O
p53	O
in	O
the	O
LN	O
-	O
Z308	O
glioblastoma	O
cell	O
line	O
.	O

p53	O
is	O
activated	O
upon	O
various	O
kinds	O
of	O
cellular	O
stress	O
leading	O
to	O
apoptosis	O
or	O
cell	O
cycle	O
arrest	O
,	O
but	O
is	O
also	O
implicated	O
in	O
complex	O
biological	O
processes	O
such	O
as	O
inhibition	O
of	O
angiogenesis	O
and	O
metastasis	O
.	O

Oxygen	O
deprivation	O
,	O
an	O
important	O
cellular	O
stress	O
,	O
revealed	O
MIC-1	O
as	O
an	O
anoxia	O
responsive	O
gene	O
in	O
glioblastoma	O
cell	O
lines	O
.	O

The	O
macrophage	O
inhibitory	O
cytokine-1	O
(	O
MIC-1	O
)	O
gene	O
was	O
identified	O
as	O
a	O
most	O
prominent	O
p53	O
target	O
gene	O
upon	O
gene	O
expression	O
profiling	O
.	O

Furthermore	O
,	O
ectopic	O
expression	O
of	O
MIC-1	O
in	O
LN	O
-	O
Z308	O
cell	O
line	O
completely	O
abolished	O
its	O
inherent	O
tumorigenicity	O
in	O
nude	B
mice	I
,	O
while	O
proliferation	O
in	O
vitro	O
was	O
not	O
affected	O
.	O

MIC-1	O
up	O
-	O
regulation	O
by	O
anoxia	O
is	O
mediated	O
through	O
an	O
alternative	O
,	O
p53	O
and	O
hypoxia	O
inducible	O
factor	O
1	O
(	O
HIF-1	O
)	O
independent	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
MIC-1	O
is	O
an	O
important	O
downstream	O
mediator	O
of	O
p53	O
function	O
,	O
while	O
acting	O
itself	O
as	O
an	O
intercessor	O
of	O
cellular	O
stress	O
signaling	O
and	O
exerting	O
anti	O
-	O
tumorigenic	O
activities	O
.	O

In	O
the	O
present	O
experimental	O
model	O
MIC-1	O
may	O
exert	O
its	O
anti	O
-	O
tumorigenic	O
properties	O
via	O
a	O
paracrine	O
mechanism	O
mediated	O
by	O
host	O
cells	O
in	O
vivo	O
.	O

Human	B
astrocytic	O
brain	O
tumors	O
select	O
for	O
mutations	O
in	O
the	O
p53	O
tumor	O
suppressor	O
gene	O
early	O
in	O
malignant	O
progression	O
.	O

Anoxia	O
induces	O
macrophage	O
inhibitory	O
cytokine-1	O
(	O
MIC-1	O
)	O
in	O
glioblastoma	O
cells	O
independently	O
of	O
p53	O
and	O
HIF-1	O
.	O

Reduction	O
of	O
miR-21	O
induces	O
glioma	O
cell	O
apoptosis	O
via	O
activating	O
caspase	O
9	O
and	O
3	O
.	O
Extensive	O
data	O
indicate	O
that	O
miR-21	O
plays	O
a	O
critical	O
role	O
in	O
gliomagenesis	O
,	O
however	O
,	O
knowledge	O
is	O
limited	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
miR-21	O
,	O
including	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
migration	O
.	O

Moreover	O
,	O
reduction	O
of	O
miR-21	O
activated	O
caspase	O
9	O
and	O
3	O
,	O
which	O
may	O
be	O
mediated	O
by	O
modulating	O
multiple	O
potential	O
target	O
genes	O
,	O
such	O
as	O
TIMP3	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
miR-21	O
expression	O
by	O
antisense	O
oligonucleotides	O
inhibited	O
glioma	O
cell	O
proliferation	O
and	O
induced	O
cell	O
apoptosis	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
miR-21	O
plays	O
a	O
key	O
role	O
in	O
regulating	O
cell	O
apoptosis	O
in	O
gliomas	O
and	O
may	O
serve	O
as	O
a	O
target	O
for	O
effective	O
therapies	O
.	O

Membership	O
in	O
this	O
group	O
is	O
defined	O
based	O
on	O
sequence	O
similarity	O
near	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
end	O
:	O
all	O
include	O
the	O
sequence	O
AGCAGC	O
.	O

Here	O
we	O
provide	O
an	O
overview	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
the	O
evolution	O
of	O
miR-15	O
/	O
107	O
group	O
member	O
genes	O
;	O
(	O
2	O
)	O
the	O
expression	O
levels	O
of	O
miRNAs	O
in	O
mammalian	O
tissues	O
;	O
(	O
3	O
)	O
evidence	O
for	O
overlapping	O
gene	O
-	O
regulatory	O
functions	O
by	O
different	O
miRNAs	O
;	O
(	O
4	O
)	O
the	O
normal	O
biochemical	O
pathways	O
regulated	O
by	O
miR-15	O
/	O
107	O
group	O
miRNAs	O
;	O
and	O
(	O
5	O
)	O
the	O
roles	O
played	O
by	O
these	O
miRNAs	O
in	O
human	B
diseases	O
.	O

While	O
all	O
vertebrates	O
studied	O
to	O
date	O
express	O
miR-15a	O
,	O
miR-15b	O
,	O
miR-16	O
,	O
miR-103	O
,	O
and	O
miR-107	O
,	O
mammals	O
alone	O
are	O
known	O
to	O
express	O
miR-195	O
,	O
miR-424	O
,	O
miR-497	O
,	O
miR-503	O
,	O
and	O
miR-646	O
.	O

Phylogeny	O
of	O
this	O
group	O
of	O
miRNAs	O
is	O
incomplete	O
;	O
thus	O
,	O
a	O
definitive	O
taxonomic	O
classification	O
(	O
e.g.	O
,	O
designation	O
as	O
a	O
""""	O
superfamily	O
""""	O
)	O
is	O
currently	O
not	O
possible	O
.	O

We	O
present	O
data	O
on	O
the	O
expression	O
of	O
all	O
known	O
miR-15	O
/	O
107	O
group	O
members	O
in	O
human	B
cerebral	O
cortical	O
gray	O
matter	O
and	O
white	O
matter	O
using	O
new	O
miRNA	O
profiling	O
microarrays	O
.	O

Multiple	O
different	O
miRNAs	O
in	O
the	O
miR-15	O
/	O
107	O
group	O
are	O
expressed	O
at	O
moderate	O
to	O
high	O
levels	O
in	O
human	B
tissues	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
genes	O
:	O
evolutionary	O
biology	O
,	O
cellular	O
functions	O
,	O
and	O
roles	O
in	O
human	B
diseases	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
is	O
increasingly	O
appreciated	O
to	O
serve	O
key	O
functions	O
in	O
humans	B
.	O

These	O
miRNAs	O
regulate	O
gene	O
expression	O
involved	O
in	O
cell	O
division	O
,	O
metabolism	O
,	O
stress	O
response	O
,	O
and	O
angiogenesis	O
in	O
vertebrate	O
species	O
.	O

The	O
miR-15	O
/	O
107	O
group	O
has	O
also	O
been	O
implicated	O
in	O
human	B
cancers	O
,	O
cardiovascular	O
disease	O
and	O
neurodegenerative	O
disease	O
,	O
including	O
Alzheimer	O
's	O
disease	O
.	O

In	O
conclusion	O
,	O
the	O
miR-15	O
/	O
107	O
group	O
of	O
miRNA	O
genes	O
is	O
a	O
fascinating	O
topic	O
of	O
study	O
for	O
evolutionary	O
biologists	O
,	O
miRNA	O
biochemists	O
,	O
and	O
clinically	O
oriented	O
translational	O
researchers	O
alike	O
.	O

We	O
show	O
new	O
data	O
from	O
cultured	O
H4	O
cancer	O
cells	O
that	O
demonstrate	O
similarities	O
in	O
mRNAs	O
targeted	O
by	O
miR-16	O
and	O
miR-103	O
and	O
also	O
support	O
the	O
importance	O
of	O
the	O
mature	O
miRNAs	O
'	O
5	O
'	O
seed	O
region	O
in	O
mRNA	O
target	O
recognition	O
.	O

There	O
is	O
extensive	O
overlap	O
in	O
the	O
mRNAs	O
targeted	O
by	O
miR-15	O
/	O
107	O
group	O
members	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
small	O
noncoding	O
RNAs	O
comprising	O
21	O
-	O
23	O
nucleotides	O
that	O
regulate	O
gene	O
expression	O
by	O
transcriptionally	O
repressing	O
their	O
complementary	O
mRNAs	O
.	O

Let-7	O
microRNA	O
inhibits	O
the	O
proliferation	O
of	O
human	B
glioblastoma	O
cells	O
.	O

Transfection	O
of	O
let-7	O
miRNA	O
reduced	O
expression	O
of	O
pan	O
-	O
RAS	O
,	O
N	O
-	O
RAS	O
,	O
and	O
K	O
-	O
RAS	O
in	O
the	O
glioblastoma	O
cells	O
.	O

Human	B
glioblastoma	O
cells	O
(	O
U251	O
or	O
U87	O
cells	O
)	O
were	O
transfected	O
with	O
let-7	O
miRNA	O
and	O
assayed	O
for	O
in	O
-	O
vitro	O
proliferation	O
,	O
migration	O
,	O
and	O
in	O
-	O
vivo	O
tumor	O
formation	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
anti	O
-	O
tumorigenic	O
effect	O
of	O
let-7	O
miRNA	O
in	O
glioblastoma	O
cells	O
.	O

In	O
particular	O
,	O
let-7	O
miRNA	O
has	O
been	O
postulated	O
to	O
function	O
as	O
a	O
tumor	O
suppressor	O
in	O
various	O
cancer	O
cells	O
,	O
but	O
not	O
yet	O
in	O
glioblastoma	O
.	O

These	O
results	O
indicate	O
that	O
let-7	O
miRNA	O
has	O
an	O
anti	O
-	O
tumorigenic	O
effect	O
on	O
glioblastoma	O
cells	O
,	O
and	O
suggest	O
possible	O
use	O
of	O
let-7	O
miRNA	O
for	O
treating	O
glioblastoma	O
.	O

However	O
,	O
let-7	O
miRNA	O
exerted	O
no	O
effect	O
on	O
the	O
proliferation	O
of	O
normal	O
human	B
astrocytes	O
.	O

Let-7	O
miRNA	O
also	O
reduced	O
the	O
in	O
-	O
vitro	O
proliferation	O
and	O
migration	O
of	O
the	O
cells	O
,	O
and	O
reduced	O
the	O
sizes	O
of	O
the	O
tumors	O
produced	O
after	O
transplantation	O
into	O
nude	B
mice	I
.	O

MiRNAs	O
microarray	O
analysis	O
results	O
showed	O
that	O
125	O
miRNAs	O
were	O
detected	O
in	O
the	O
hippocampus	O
of	O
lithium	O
-	O
pilocarpine	O
-	O
induced	O
TLE	O
rats	B
and	O
normal	O
rats	B
.	O

To	O
understand	O
the	O
role	O
of	O
miRNAs	O
in	O
the	O
molecular	O
mechanisms	O
of	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
we	O
investigated	O
the	O
changes	O
in	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
profiles	O
of	O
chronic	O
TLE	O
rat	B
models	O
.	O

Temporal	O
lobe	O
epilepsy	O
induces	O
differential	O
expression	O
of	O
hippocampal	O
miRNAs	O
including	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
.	O

let-7e	O
was	O
detected	O
down	O
-	O
regulated	O
expression	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
2days	O
,	O
7days	O
,	O
50days	O
after	O
SE	O
and	O
up	O
-	O
regulated	O
expression	O
at	O
12h	O
,	O
24h	O
,	O
10days	O
,	O
30days	O
after	O
SE	O
,	O
which	O
was	O
significantly	O
up	O
-	O
regulated	O
expression	O
at	O
24h	O
after	O
SE	O
(	O
10.49	O
folds	O
,	O
P<0.01	O
)	O
.	O

miR-23a	O
/	O
b	O
was	O
detected	O
down	O
-	O
regulated	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
2days	O
,	O
7days	O
,	O
10days	O
,	O
30days	O
after	O
SE	O
and	O
significantly	O
up	O
-	O
regulated	O
at	O
24h	O
(	O
4.49	O
folds	O
P<0.01	O
)	O
,	O
50d	O
(	O
2.4	O
folds	O
,	O
P<0.01	O
)	O
after	O
SE	O
.	O
TLE	O
alters	O
the	O
expression	O
levels	O
of	O
a	O
subset	O
of	O
miRNAs	O
in	O
the	O
hippocampus	O
and	O
these	O
deregulated	O
miRNAs	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
epilepsy	O
directly	O
or	O
indirectly	O
.	O

Compared	O
with	O
normal	O
rats	B
(	O
control	O
group	O
)	O
,	O
23	O
of	O
the	O
125	O
miRNAs	O
were	O
expressed	O
differentially	O
in	O
TLE	O
rats	B
including	O
5	O
down	O
-	O
regulated	O
miRNAs	O
(	O
let-7e	O
included	O
)	O
and	O
18	O
up	O
-	O
regulated	O
miRNAs	O
(	O
miR-23a	O
/	O
b	O
included	O
)	O
.	O

Furthermore	O
,	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
analysis	O
in	O
rat	B
hippocampus	O
were	O
performed	O
by	O
real	O
-	O
time	O
quantitative	O
polymerase	O
chain	O
reaction	O
at	O
0h	O
,	O
1h	O
,	O
6h	O
,	O
12h	O
,	O
24h	O
,	O
2days	O
,	O
7days,10days	O
,	O
30days,50days	O
after	O
induction	O
of	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

Also	O
the	O
temporal	O
change	O
of	O
the	O
let-7e	O
and	O
miR-23a	O
/	O
b	O
expression	O
in	O
the	O
epileptogenesis	O
indicated	O
their	O
underlying	O
functions	O
on	O
TLE	O
.	O

The	O
findings	O
also	O
indicate	O
that	O
allopregnanolone	O
and	O
perhaps	O
other	O
neurosteroid	O
-	O
like	O
compounds	O
might	O
represent	O
potential	O
biomarkers	O
or	O
therapies	O
for	O
multiple	O
sclerosis	O
.	O

These	O
multi	O
-	O
platform	O
studies	O
point	O
to	O
impaired	O
neurosteroidogenesis	O
in	O
both	O
multiple	O
sclerosis	O
and	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Allopregnanolone	O
treatment	O
of	O
the	O
experimental	O
autoimmune	O
encephalomyelitis	O
mouse	B
model	O
limited	O
the	O
associated	O
neuropathology	O
,	O
including	O
neuroinflammation	O
,	O
myelin	O
and	O
axonal	O
injury	O
and	O
reduced	O
neurobehavioral	O
deficits	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Levels	O
of	O
important	O
neurosteroids	O
,	O
including	O
allopregnanolone	O
,	O
were	O
suppressed	O
in	O
the	O
white	O
matter	O
of	O
patients	B
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Induction	O
of	O
the	O
murine	B
micro	O
-	O
RNAs	O
,	O
miR-338	O
and	O
miR-155	O
,	O
accompanied	O
by	O
diminished	O
expression	O
of	O
neurosteroidogenic	O
enzymes	O
and	O
allopregnanolone	O
,	O
was	O
also	O
observed	O
in	O
the	O
brains	O
of	O
mice	B
with	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Analysis	O
of	O
the	O
neurosteroidogenic	O
pathways	O
targeted	O
by	O
micro	O
-	O
RNAs	O
revealed	O
suppression	O
of	O
enzyme	O
transcript	O
and	O
protein	O
levels	O
in	O
the	O
white	O
matter	O
of	O
patients	B
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

This	O
was	O
confirmed	O
by	O
firefly	O
/	O
Renilla	O
luciferase	O
micro	O
-	O
RNA	O
target	O
knockdown	O
experiments	O
(	O
P	O
<	O
0.05	O
)	O
and	O
detection	O
of	O
specific	O
micro	O
-	O
RNAs	O
by	O
in	O
situ	O
hybridization	O
in	O
the	O
brains	O
of	O
patients	B
with	O
or	O
without	O
multiple	O
sclerosis	O
.	O

These	O
observations	O
were	O
verified	O
using	O
the	O
in	O
vivo	O
multiple	O
sclerosis	O
model	O
,	O
experimental	O
autoimmune	O
encephalomyelitis	O
.	O

Brains	O
of	O
patients	B
with	O
or	O
without	O
multiple	O
sclerosis	O
demonstrated	O
differential	O
expression	O
of	O
multiple	O
micro	O
-	O
RNAs	O
,	O
but	O
expression	O
of	O
three	O
neurosteroid	O
synthesis	O
enzyme	O
-	O
specific	O
micro	O
-	O
RNAs	O
(	O
miR-338	O
,	O
miR-155	O
and	O
miR-491	O
)	O
showed	O
a	O
bias	O
towards	O
induction	O
in	O
patients	B
with	O
multiple	O
sclerosis	O
(	O
P	O
<	O
0.05	O
)	O
.	O

High	O
-	O
throughput	O
technologies	O
have	O
led	O
to	O
advances	O
in	O
the	O
recognition	O
of	O
disease	O
pathways	O
and	O
their	O
underlying	O
mechanisms	O
.	O

To	O
investigate	O
the	O
impact	O
of	O
micro	O
-	O
RNAs	O
on	O
the	O
disease	O
process	O
in	O
multiple	O
sclerosis	O
,	O
a	O
prototypic	O
inflammatory	O
neurological	O
disorder	O
,	O
we	O
examined	O
cerebral	O
white	O
matter	O
from	O
patients	B
with	O
or	O
without	O
the	O
disease	O
by	O
micro	O
-	O
RNA	O
profiling	O
,	O
together	O
with	O
confirmatory	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
immunoblotting	O
and	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Impaired	O
neurosteroid	O
synthesis	O
in	O
multiple	O
sclerosis	O
.	O

This	O
review	O
reports	O
the	O
current	O
knowledge	O
of	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
in	O
pituitary	O
adenomas	O
,	O
focusing	O
on	O
recent	O
microarray	O
data	O
.	O

Moreover	O
,	O
a	O
discussion	O
is	O
provided	O
concerning	O
the	O
possible	O
role	O
of	O
validated	O
and	O
putative	O
targets	O
of	O
the	O
most	O
dysregulated	O
miRNA	O
in	O
pituitary	O
adenoma	O
pathogenesis	O
.	O

MicroRNAs	O
and	O
possible	O
role	O
in	O
pituitary	O
adenoma	O
.	O

These	O
findings	O
indicate	O
that	O
miR-107	O
contributes	O
to	O
GRN	O
expression	O
regulation	O
with	O
implications	O
for	O
brain	O
disorders	O
.	O

In	O
brain	O
tissue	O
subjacent	O
to	O
1.0	O
mm	O
depth	O
controlled	O
cortical	O
impact	O
,	O
surviving	O
hippocampal	O
neurons	O
show	O
decreased	O
miR-107	O
with	O
augmentation	O
of	O
neuronal	O
GRN	O
expression	O
.	O

We	O
also	O
tested	O
a	O
mouse	B
model	O
where	O
miR-107	O
has	O
been	O
shown	O
to	O
be	O
down	O
-	O
regulated	O
.	O

However	O
,	O
GRN	O
regulation	O
expression	O
is	O
poorly	O
understood	O
.	O

A	O
high	O
-	O
throughput	O
experimental	O
microRNA	O
assay	O
showed	O
that	O
GRN	O
is	O
the	O
strongest	O
target	O
for	O
miR-107	O
in	O
human	B
H4	O
neuroglioma	O
cells	O
.	O

miR-107	O
has	O
been	O
implicated	O
in	O
Alzheimer	O
's	O
disease	O
pathogenesis	O
,	O
and	O
sequence	O
elements	O
in	O
the	O
open	O
reading	O
frame	O
-	O
rather	O
than	O
the	O
3	O
'	O
untranslated	O
region	O
-	O
of	O
GRN	O
mRNA	O
are	O
recognized	O
by	O
miR-107	O
and	O
are	O
highly	O
conserved	O
among	O
vertebrate	O
species	O
.	O

To	O
better	O
understand	O
the	O
mechanism	O
of	O
this	O
interaction	O
,	O
FLAG	O
-	O
tagged	O
Argonaute	O
constructs	O
were	O
used	O
following	O
miR-107	O
transfection	O
.	O

miR-107	O
regulates	O
granulin	O
/	O
progranulin	O
with	O
implications	O
for	O
traumatic	O
brain	O
injury	O
and	O
neurodegenerative	O
disease	O
.	O

Granulin	O
(	O
GRN	O
,	O
or	O
progranulin	O
)	O
is	O
a	O
protein	O
involved	O
in	O
wound	O
repair	O
,	O
inflammation	O
,	O
and	O
neoplasia	O
.	O

GRN	O
has	O
also	O
been	O
directly	O
implicated	O
in	O
frontotemporal	O
dementia	O
and	O
may	O
contribute	O
to	O
Alzheimer	O
's	O
disease	O
pathogenesis	O
.	O

GRN	O
mRNA	O
interacts	O
preferentially	O
with	O
Argonaute	O
2	O
.	O
In	O
vitro	O
and	O
in	O
vivo	O
studies	O
indicate	O
that	O
regulation	O
of	O
GRN	O
by	O
miR-107	O
may	O
be	O
functionally	O
important	O
.	O

Glucose	O
supplementation	O
in	O
cultured	O
cells	O
that	O
leads	O
to	O
increased	O
miR-107	O
levels	O
also	O
results	O
in	O
decreased	O
GRN	O
expression	O
,	O
including	O
changes	O
in	O
cell	O
compartmentation	O
and	O
decreased	O
secretion	O
of	O
GRN	O
protein	O
.	O

This	O
effect	O
was	O
eliminated	O
following	O
miR-107	O
transfection	O
.	O

Many	O
miRNA	O
targets	O
have	O
been	O
computationally	O
predicted	O
but	O
only	O
a	O
limited	O
number	O
of	O
these	O
were	O
experimentally	O
validated	O
.	O

However	O
,	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
are	O
complex	O
and	O
very	O
often	O
there	O
are	O
numerous	O
putative	O
miRNA	O
recognition	O
sites	O
in	O
mRNAs	O
.	O

Therefore	O
,	O
it	O
is	O
of	O
particular	O
interest	O
to	O
reliably	O
predict	O
potential	O
miRNA	O
targets	O
which	O
might	O
be	O
involved	O
in	O
these	O
diseases	O
.	O

Both	O
the	O
deregulation	O
of	O
genes	O
controlled	O
by	O
miRNAs	O
and	O
the	O
altered	O
miRNA	O
expression	O
have	O
been	O
linked	O
to	O
many	O
disorders	O
,	O
including	O
cancer	O
,	O
cardiovascular	O
,	O
metabolic	O
and	O
neurodegenerative	O
diseases	O
.	O

In	O
this	O
review	O
,	O
currently	O
available	O
and	O
frequently	O
used	O
computational	O
tools	O
for	O
miRNA	O
target	O
prediction	O
,	O
i.e.	O
,	O
PicTar	O
,	O
TargetScan	O
,	O
DIANA	O
-	O
microT	O
,	O
miRanda	O
,	O
rna22	O
and	O
PITA	O
are	O
outlined	O
and	O
various	O
practical	O
aspects	O
of	O
miRNA	O
target	O
analysis	O
are	O
extensively	O
discussed	O
.	O

Hence	O
,	O
finding	O
a	O
functional	O
miRNA	O
target	O
is	O
still	O
a	O
challenging	O
task	O
.	O

Although	O
a	O
variety	O
of	O
miRNA	O
target	O
prediction	O
algorithms	O
are	O
available	O
,	O
results	O
of	O
their	O
application	O
are	O
often	O
inconsistent	O
.	O

microRNAs	O
(	O
miRNAs	O
)	O
are	O
endogenous	O
non	O
-	O
coding	O
RNAs	O
that	O
control	O
gene	O
expression	O
at	O
the	O
posttranscriptional	O
level	O
.	O

These	O
small	O
regulatory	O
molecules	O
play	O
a	O
key	O
role	O
in	O
the	O
majority	O
of	O
biological	O
processes	O
and	O
their	O
expression	O
is	O
also	O
tightly	O
regulated	O
.	O

Practical	O
Aspects	O
of	O
microRNA	O
Target	O
Prediction	O
.	O

Moreover	O
,	O
the	O
performance	O
of	O
three	O
algorithms	O
(	O
PicTar	O
,	O
TargetScan	O
and	O
DIANA	O
-	O
microT	O
)	O
is	O
both	O
demonstrated	O
and	O
evaluated	O
by	O
performing	O
an	O
in	O
-	O
depth	O
analysis	O
of	O
miRNA	O
interactions	O
with	O
mRNAs	O
derived	O
from	O
genes	O
triggering	O
hereditary	O
neurological	O
disorders	O
known	O
as	O
trinucleotide	O
repeat	O
expansion	O
diseases	O
(	O
TREDs	O
)	O
,	O
such	O
as	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
,	O
a	O
number	O
of	O
spinocerebellar	O
ataxias	O
(	O
SCAs	O
)	O
,	O
and	O
myotonic	O
dystrophy	O
type	O
1	O
(	O
DM1	O
)	O
.	O

Our	O
study	O
shows	O
that	O
one	O
aspect	O
of	O
miR-155	O
function	O
is	O
the	O
promotion	O
of	O
T	O
cell	O
-	O
dependent	O
tissue	O
inflammation	O
,	O
suggesting	O
that	O
miR-155	O
might	O
be	O
a	O
promising	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
autoimmune	O
disorders	O
.	O

miR-155	O
functions	O
in	O
the	O
hematopoietic	O
compartment	O
to	O
promote	O
the	O
development	O
of	O
inflammatory	O
T	O
cells	O
including	O
the	O
T	O
helper	O
17	O
(	O
Th17	O
)	O
cell	O
and	O
Th1	O
cell	O
subsets	O
.	O

Furthermore	O
,	O
the	O
major	O
contribution	O
of	O
miR-155	O
to	O
EAE	O
was	O
CD4	O
(	O
+	O
)	O
T	O
cell	O
intrinsic	O
,	O
whereas	O
miR-155	O
was	O
also	O
required	O
for	O
optimum	O
dendritic	O
cell	O
production	O
of	O
cytokines	O
that	O
promoted	O
Th17	O
cell	O
formation	O
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
miR-155	O
during	O
an	O
autoimmune	O
inflammatory	O
disease	O
.	O

Consistent	O
with	O
a	O
positive	O
role	O
for	O
miR-155	O
in	O
mediating	O
inflammatory	O
responses	O
,	O
Mir155	O
(	O
-	O
/	O
-	O
)	O
mice	B
were	O
highly	O
resistant	O
to	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
.	O

MicroRNA-155	O
promotes	O
autoimmune	O
inflammation	O
by	O
enhancing	O
inflammatory	O
T	O
cell	O
development	O
.	O

Mammalian	O
noncoding	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
gene	O
regulators	O
that	O
have	O
been	O
linked	O
to	O
immune	O
system	O
function	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
in	O
cancer	O
:	O
discovery	O
,	O
function	O
and	O
future	O
perspectives	O
.	O

Expression	O
of	O
these	O
miRNAs	O
inhibits	O
cell	O
proliferation	O
,	O
promotes	O
apoptosis	O
of	O
cancer	O
cells	O
,	O
and	O
suppresses	O
tumorigenicity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
encoded	O
by	O
the	O
miR-15	O
/	O
16	O
cluster	O
are	O
known	O
to	O
act	O
as	O
tumor	O
suppressors	O
.	O

Down	O
-	O
regulation	O
of	O
these	O
miRNAs	O
has	O
been	O
reported	O
in	O
chronic	O
lymphocytic	O
lymphoma	O
(	O
CLL	O
)	O
,	O
pituitary	O
adenomas	O
,	O
and	O
prostate	O
carcinoma	O
.	O

miR-15a	O
and	O
miR-16	O
-	O
1	O
function	O
by	O
targeting	O
multiple	O
oncogenes	O
,	O
including	O
BCL2	O
,	O
MCL1	O
,	O
CCND1	O
,	O
and	O
WNT3A	O
.	O

This	O
review	O
summarizes	O
the	O
discovery	O
,	O
functions	O
,	O
and	O
clinical	O
relevance	O
of	O
these	O
miRNAs	O
in	O
cancer	O
,	O
particularly	O
CLL	O
.	O

During	O
experimental	O
autoimmune	O
encephalomyelitis	O
(	O
EAE	O
)	O
,	O
miR-124	O
was	O
downregulated	O
in	O
activated	O
microglia	O
.	O

Peripheral	O
administration	O
of	O
miR-124	O
in	O
EAE	O
caused	O
systemic	O
deactivation	O
of	O
macrophages	O
,	O
reduced	O
activation	O
of	O
myelin	O
-	O
specific	O
T	O
cells	O
and	O
marked	O
suppression	O
of	O
disease	O
.	O

Conversely	O
,	O
knockdown	O
of	O
miR-124	O
in	O
microglia	O
and	O
macrophages	O
resulted	O
in	O
activation	O
of	O
these	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

These	O
findings	O
identify	O
miR-124	O
both	O
as	O
a	O
key	O
regulator	O
of	O
microglia	O
quiescence	O
in	O
the	O
central	O
nervous	O
system	O
and	O
as	O
a	O
previously	O
unknown	O
modulator	O
of	O
monocyte	O
and	O
macrophage	O
activation	O
.	O

MicroRNA-124	O
promotes	O
microglia	O
quiescence	O
and	O
suppresses	O
EAE	O
by	O
deactivating	O
macrophages	O
via	O
the	O
C	O
/	O
EBP	O
-	O
α	O
-	O
PU.1	O
pathway	O
.	O

MicroRNAs	O
are	O
a	O
family	O
of	O
regulatory	O
molecules	O
involved	O
in	O
many	O
physiological	O
processes	O
,	O
including	O
differentiation	O
and	O
activation	O
of	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
found	O
that	O
brain	O
-	O
specific	O
miR-124	O
is	O
expressed	O
in	O
microglia	O
but	O
not	O
in	O
peripheral	O
monocytes	O
or	O
macrophages	O
.	O

When	O
overexpressed	O
in	O
macrophages	O
,	O
miR-124	O
directly	O
inhibited	O
the	O
transcription	O
factor	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
-	O
α	O
(	O
C	O
/	O
EBP	O
-	O
α	O
)	O
and	O
its	O
downstream	O
target	O
PU.1	O
,	O
resulting	O
in	O
transformation	O
of	O
these	O
cells	O
from	O
an	O
activated	O
phenotype	O
into	O
a	O
quiescent	O
CD45	O
(	O
low	O
)	O
,	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
(	O
low	O
)	O
phenotype	O
resembling	O
resting	O
microglia	O
.	O

Molecular	O
and	O
cellular	O
neurobiological	O
studies	O
of	O
the	O
miRNAs	O
in	O
neurodegeneration	O
represent	O
the	O
exploration	O
of	O
a	O
new	O
Frontier	O
of	O
miRNAs	O
biology	O
and	O
the	O
potential	O
development	O
of	O
new	O
diagnostic	O
tests	O
and	O
genetic	O
therapies	O
for	O
neurodegenerative	O
diseases	O
.	O

MiRNA	O
studies	O
in	O
neurobiology	O
showed	O
their	O
involvement	O
in	O
synaptic	O
plasticity	O
and	O
brain	O
diseases	O
.	O

In	O
this	O
review	O
,	O
correlations	O
between	O
miRNA	O
-	O
mediated	O
gene	O
silencing	O
and	O
Alzheimer	O
's	O
,	O
Parkinson	O
's	O
,	O
and	O
other	O
neurodegenerative	O
diseases	O
will	O
be	O
discussed	O
.	O

In	O
few	O
years	O
our	O
understanding	O
of	O
microRNA	O
(	O
miRNA	O
)	O
biogenesis	O
,	O
molecular	O
mechanisms	O
by	O
which	O
miRNAs	O
regulate	O
gene	O
expression	O
,	O
and	O
the	O
functional	O
roles	O
of	O
miRNAs	O
has	O
been	O
expanded	O
.	O

Interestingly	O
,	O
numerous	O
miRNAs	O
are	O
expressed	O
in	O
a	O
spatially	O
and	O
temporally	O
controlled	O
manner	O
in	O
the	O
nervous	O
system	O
,	O
suggesting	O
that	O
their	O
posttrascriptional	O
regulation	O
may	O
be	O
particularly	O
relevant	O
in	O
neural	O
development	O
and	O
function	O
.	O

Searching	O
for	O
MIND	O
:	O
microRNAs	O
in	O
neurodegenerative	O
diseases	O
.	O

In	O
gliomas	O
,	O
microRNA-21	O
(	O
miR-21	O
)	O
levels	O
have	O
been	O
reported	O
to	O
be	O
elevated	O
and	O
their	O
knockdown	O
is	O
associated	O
with	O
increased	O
apoptotic	O
activity	O
.	O

We	O
hypothesized	O
that	O
suppression	O
of	O
miR-21	O
might	O
sensitize	O
gliomas	O
for	O
cytotoxic	O
tumor	O
therapy	O
.	O

With	O
the	O
use	O
of	O
locked	O
nucleic	O
acid	O
(	O
LNA	O
)	O
-antimiR-21	O
oligonucleotides	O
,	O
bimodal	O
imaging	O
vectors	O
,	O
and	O
neural	O
precursor	O
cells	O
(	O
NPC	O
)	O
expressing	O
a	O
secretable	O
variant	O
of	O
the	O
cytotoxic	O
agent	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
S	O
-	O
TRAIL	O
)	O
,	O
we	O
show	O
that	O
the	O
combined	O
suppression	O
of	O
miR-21	O
and	O
NPC	O
-	O
S	O
-	O
TRAIL	O
leads	O
to	O
a	O
synergistic	O
increase	O
in	O
caspase	O
activity	O
and	O
significantly	O
decreased	O
cell	O
viability	O
in	O
human	B
glioma	O
cells	O
in	O
vitro	O
.	O

This	O
phenomenon	O
persists	O
in	O
vivo	O
,	O
as	O
we	O
observed	O
complete	O
eradication	O
of	O
LNA	O
-	O
antimiR-21-treated	O
gliomas	O
subjected	O
to	O
the	O
presence	O
of	O
NPC	O
-	O
S	O
-	O
TRAIL	O
in	O
the	O
murine	B
brain	O
.	O

Our	O
results	O
reveal	O
the	O
efficacy	O
of	O
miR-21	O
antagonism	O
in	O
murine	B
glioma	O
models	O
and	O
implicate	O
miR-21	O
as	O
a	O
target	O
for	O
therapeutic	O
intervention	O
.	O

Furthermore	O
,	O
our	O
findings	O
provide	O
the	O
basis	O
for	O
developing	O
combination	O
therapies	O
using	O
miRNA	O
modulation	O
and	O
cytotoxic	O
tumor	O
therapies	O
.	O

MicroRNA-21	O
knockdown	O
disrupts	O
glioma	O
growth	O
in	O
vivo	O
and	O
displays	O
synergistic	O
cytotoxicity	O
with	O
neural	O
precursor	O
cell	O
delivered	O
S	O
-	O
TRAIL	O
in	O
human	B
gliomas	O
.	O

Mounting	O
evidence	O
indicates	O
that	O
microRNAs	O
(	O
miRNA	O
)	O
might	O
play	O
a	O
fundamental	O
role	O
in	O
tumorigenesis	O
,	O
controlling	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Despite	O
the	O
development	O
of	O
new	O
glioma	O
therapies	O
that	O
allow	O
for	O
tumor	O
-	O
targeted	O
in	O
situ	O
delivery	O
of	O
cytotoxic	O
drugs	O
,	O
tumor	O
resistance	O
to	O
apoptosis	O
remains	O
a	O
key	O
impediment	O
to	O
effective	O
treatment	O
.	O

CONCLUSIONS	O
:	O
The	O
irregularity	O
of	O
prolactin	O
secretion	O
in	O
patients	B
with	O
NPG	O
is	O
not	O
dependant	O
on	O
the	O
presence	O
of	O
a	O
pituitary	O
tumour	O
which	O
suggests	O
that	O
a	O
hypothalamic	O
dysfunction	O
underlies	O
this	O
condition	O
.	O

An	O
irregular	O
secretion	O
and	O
a	O
higher	O
daily	O
mass	O
production	O
of	O
prolactin	O
in	O
patients	B
with	O
NPG	O
could	O
explain	O
both	O
galactorrhea	O
and	O
infertility	O
.	O

BACKGROUND	O
:	O
Abnormal	O
frequency	O
and	O
pulse	O
amplitud	O
of	O
prolactin	O
secretion	O
in	O
micro	O
and	O
macroprolactinomas	O
has	O
been	O
atributed	O
to	O
a	O
dysfunctional	O
tumoral	O
lactotrope	O
.	O

[	O
Irregular	O
secretion	O
of	O
prolactin	O
in	O
infertile	O
women	B
with	O
normoprolactinemic	O
galactorrhea	O
]	O
.	O

The	O
regularity	O
of	O
prolactin	O
secretion	O
has	O
not	O
been	O
studied	O
with	O
cuantitative	O
methods	O
in	O
patients	B
with	O
normoprolactinemic	O
galactorrhea	O
(	O
NPG	O
)	O
which	O
could	O
be	O
considered	O
an	O
entity	O
that	O
precedes	O
non	O
tumoral	O
and	O
tumoral	O
hyperprolactinemia	O
.	O

Previous	O
evidence	O
suggests	O
that	O
non	O
tumoral	O
hyperprolactinemia	O
is	O
caused	O
by	O
a	O
hypothalamic	O
dysfunction	O
.	O

PATIENTS	B
AND	O
METHODS	O
:	O
A	O
transversal	O
-	O
comparative	O
study	O
was	O
carried	O
out	O
in	O
6	O
infertile	O
women	B
with	O
normoprolactinemic	O
galactorrhea	O
and	O
4	O
healthy	O
women	B
as	O
controls	O
.	O

Objective	O
:	O
To	O
analyze	O
the	O
24-hour	O
prolactin	O
secretion	O
pattern	O
and	O
its	O
secretion	O
regularity	O
in	O
a	O
group	O
of	O
infertile	O
women	B
with	O
normoprolactinemic	O
galatorea	O
.	O

RESULTS	O
:	O
Blunting	O
of	O
the	O
nyctohemeral	O
rythm	O
and	O
nocturn	O
hyperprolactinaemia	O
occurred	O
in	O
patients	B
with	O
normoprolactinemic	O
galactorrhea	O
(	O
NPG	O
)	O
.	O

The	O
24	O
hour	O
prolactin	O
profile	O
,	O
the	O
ratio	O
night	O
time	O
mean	O
concentration	O
/	O
daytime	O
mean	O
concentrattion	O
(	O
NM	O
/	O
DM	O
ratio	O
)	O
and	O
apparent	O
entropy	O
(	O
Ap	O
En	O
,	O
Ap	O
En	O
ratio	O
)	O
were	O
compared	O
in	O
the	O
two	O
groups	O
.	O

Higher	O
irregularity	O
of	O
prolactin	O
secretion	O
was	O
found	O
in	O
patients	B
with	O
NPG	O
(	O
ApEn	O
:	O
0.853	O
+	O
/-	O
0.158	O
vs	O
0.608	O
+	O
/-	O
0.171	O
,	O
p=0.04	O
;	O
Ap	O
En	O
ratio	O
:	O
0.839	O
+	O
/-	O
0.11	O
vs	O
0.661	O
+	O
/-	O
0.14	O
;	O
p=0.04	O
)	O
.	O

NM	O
/	O
DM	O
ratio	O
was	O
lower	O
in	O
patients	B
with	O
NPG	O
than	O
in	O
controls	O
(	O
1.28	O
+	O
/-	O
0.25	O
vs.	O
1.75	O
+	O
/-	O
0.05	O
;	O
p=	O
0.01	O
)	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
whether	O
microRNA	O
targets	O
could	O
be	O
engineered	O
into	O
VSV	O
to	O
ameliorate	O
its	O
neuropathogenicity	O
.	O

Using	O
a	O
panel	O
of	O
recombinant	O
VSVs	O
incorporating	O
microRNA	O
target	O
sequences	O
corresponding	O
to	O
neuron	O
-	O
specific	O
or	O
control	O
microRNAs	O
(	O
in	O
forward	O
and	O
reverse	O
orientations	O
)	O
,	O
we	O
tested	O
viral	O
replication	O
kinetics	O
in	O
cell	O
lines	O
treated	O
with	O
microRNA	O
mimics	O
,	O
neurotoxicity	O
after	O
direct	O
intracerebral	O
inoculation	O
in	O
mice	B
,	O
and	O
antitumor	O
efficacy	O
.	O

Compared	O
to	O
picornaviruses	O
and	O
adenoviruses	O
,	O
the	O
engineered	O
VSVs	O
were	O
relatively	O
resistant	O
to	O
microRNA	O
-	O
mediated	O
inhibition	O
,	O
but	O
neurotoxicity	O
could	O
nevertheless	O
be	O
ameliorated	O
significantly	O
using	O
this	O
approach	O
,	O
without	O
compromise	O
to	O
antitumor	O
efficacy	O
.	O

Neurotoxicity	O
was	O
most	O
profoundly	O
reduced	O
in	O
a	O
virus	O
carrying	O
four	O
tandem	O
copies	O
of	O
a	O
neuronal	O
mir125	O
target	O
sequence	O
inserted	O
in	O
the	O
3'-untranslated	O
region	O
of	O
the	O
viral	O
polymerase	O
(	O
L	O
)	O
gene	O
.	O

Attenuation	O
of	O
vesicular	O
stomatitis	O
virus	O
encephalitis	O
through	O
microRNA	O
targeting	O
.	O

Vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
has	O
long	O
been	O
regarded	O
as	O
a	O
promising	O
recombinant	O
vaccine	O
platform	O
and	O
oncolytic	O
agent	O
but	O
has	O
not	O
yet	O
been	O
tested	O
in	O
humans	B
because	O
it	O
causes	O
encephalomyelitis	O
in	O
rodents	O
and	O
primates	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
specific	O
tropisms	O
of	O
several	O
viruses	O
could	O
be	O
eliminated	O
by	O
engineering	O
microRNA	O
target	O
sequences	O
into	O
their	O
genomes	O
,	O
thereby	O
inhibiting	O
spread	O
in	O
tissues	O
expressing	O
cognate	O
microRNAs	O
.	O

Alteration	O
of	O
miRNA	O
expression	O
by	O
disease	O
and	O
insult	O
also	O
holds	O
the	O
potential	O
for	O
improved	O
diagnostic	O
tools	O
.	O

Finally	O
,	O
miRNAs	O
have	O
been	O
shown	O
to	O
control	O
cellular	O
proliferation	O
and	O
specification	O
,	O
suggesting	O
that	O
manipulation	O
of	O
miRNAs	O
in	O
cultured	O
cells	O
could	O
result	O
in	O
more	O
convenient	O
generation	O
of	O
pure	O
cell	O
populations	O
for	O
transplantation	O
.	O

miRNAs	O
appear	O
to	O
be	O
dysregulated	O
in	O
a	O
number	O
of	O
neurodegenerative	O
diseases	O
,	O
developmental	O
disorders	O
,	O
and	O
as	O
a	O
result	O
of	O
stroke	O
.	O

MicroRNAS	O
(	O
miRNAs	O
)	O
have	O
been	O
suggested	O
to	O
play	O
important	O
roles	O
in	O
the	O
central	O
nervous	O
system	O
during	O
development	O
as	O
well	O
as	O
disease	O
.	O

The	O
therapeutic	O
potential	O
of	O
microRNAs	O
in	O
nervous	O
system	O
damage	O
,	O
degeneration	O
,	O
and	O
repair	O
.	O

Artificial	O
miRNAs	O
have	O
also	O
been	O
generated	O
for	O
the	O
repression	O
of	O
specific	O
transcripts	O
.	O

Both	O
viral	O
delivery	O
and	O
administration	O
of	O
modified	O
oligonucleotides	O
mimicking	O
or	O
inhibiting	O
specific	O
miRNAs	O
have	O
been	O
effective	O
in	O
model	O
systems	O
.	O

Recent	O
findings	O
suggest	O
that	O
it	O
may	O
eventually	O
be	O
possible	O
to	O
treat	O
some	O
neurological	O
disorders	O
by	O
restoring	O
or	O
inhibiting	O
miRNAs	O
altered	O
by	O
disease	O
pathology	O
.	O

Each	O
miRNA	O
has	O
the	O
ability	O
to	O
regulate	O
hundreds	O
of	O
messenger	O
RNA	O
transcripts	O
,	O
both	O
by	O
causing	O
degradation	O
of	O
the	O
mRNA	O
and	O
by	O
inhibition	O
of	O
protein	O
translation	O
.	O

MicroRNA-210	O
as	O
a	O
novel	O
blood	O
biomarker	O
in	O
acute	O
cerebral	O
ischemia	O
.	O

MicroRNA-210	O
(	O
miR-210	O
)	O
,	O
a	O
master	O
and	O
pleiotropic	O
hypoxia	O
-	O
microRNA	O
,	O
plays	O
multiple	O
roles	O
in	O
brain	O
ischemia	O
.	O

However	O
,	O
miR-210	O
expression	O
and	O
its	O
function	O
in	O
humans	B
have	O
not	O
been	O
explored	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
correlation	O
of	O
blood	O
miR-210	O
with	O
clinical	O
findings	O
in	O
acute	O
ischemic	O
stroke	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
stroke	O
patients	B
(	O
n=112	O
)	O
and	O
healthy	O
controls	O
(	O
n=	O
60	O
)	O
.	O

MiR-210	O
was	O
measured	O
at	O
within	O
3	O
,	O
7	O
and	O
14	O
days	O
after	O
stroke	O
using	O
a	O
quantitative	O
PCR	O
technique	O
.	O

Stroke	O
severity	O
and	O
clinical	O
outcome	O
were	O
evaluated	O
by	O
NIHSS	O
and	O
modified	O
Rankin	O
Score	O
.	O

Both	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	B
was	O
examined	O
and	O
the	O
correlation	O
was	O
investigated	O
.	O

Compared	O
to	O
healthy	O
controls	O
,	O
blood	O
miRNA-210	O
was	O
significantly	O
decreased	O
in	O
stroke	O
patients	B
(	O
0.93	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
,	O
especially	O
at	O
7	O
days	O
(	O
0.56	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
and	O
14	O
days	O
of	O
stroke	O
onset	O
(	O
0.50	O
vs.	O
1.36	O
;	O
P=0.001	O
)	O
.	O

The	O
cut	O
off	O
point	O
of	O
miR-210	O
in	O
diagnosis	O
was	O
0.505	O
with	O
88.3	O
per	O
cent	O
sensitivity	O
.	O

MiR-210	O
level	O
in	O
stroke	O
patients	B
with	O
good	O
outcome	O
was	O
significantly	O
higher	O
than	O
patients	B
with	O
poor	O
outcome	O
(	O
1.2	O
vs.	O
0.44	O
;	O
P=0.012	O
)	O
.	O

The	O
correlation	O
between	O
blood	O
and	O
brain	O
miR-210	O
in	O
ischemic	O
mice	B
was	O
positive	O
(	O
R2=0.57	O
,	O
P=0.001	O
)	O
.	O

Blood	O
miR-210	O
is	O
a	O
novel	O
sensitive	O
biomarker	O
for	O
clinical	O
diagnosis	O
and	O
prognosis	O
in	O
acute	O
cerebral	O
ischemia	O
.	O

Out	O
of	O
the	O
5	O
positive	O
samples	O
,	O
one	O
was	O
an	O
HTLV	O
,	O
three	O
HTLV-1	O
and	O
one	O
HTLV-2	O
.	O

These	O
blood	O
donors	O
were	O
residents	O
of	O
Posadas	O
,	O
Eldorado	O
and	O
Oberá	O
,	O
with	O
no	O
risk	O
antecedents	O
.	O

This	O
study	O
demonstrates	O
the	O
presence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
population	O
of	O
Misiones	O
with	O
a	O
prevalence	O
rate	O
similar	O
to	O
those	O
reported	O
among	O
blood	O
donors	O
from	O
non	O
-	O
endemic	O
areas	O
.	O

[	O
Seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
blood	O
donors	O
from	O
Misiones	O
Province	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
seroprevalence	O
of	O
HTLV-1	O
/	O
2	O
in	O
a	O
blood	O
donor	O
population	O
from	O
Misiones	O
province	O
.	O

They	O
are	O
transmitted	O
through	O
sex	O
contact	O
,	O
parenterally	O
and	O
from	O
mother	O
to	O
child	B
.	O

HTLV-1	O
/	O
2	O
screening	O
was	O
performed	O
with	O
ELISA	O
and	O
particle	O
agglutination	O
,	O
and	O
reactive	O
samples	O
were	O
confirmed	O
by	O
Western	O
Blot	O
.	O

A	O
total	O
of	O
6912	O
accepted	O
blood	O
donations	O
in	O
2008	O
were	O
analyzed	O
.	O

It	O
is	O
endemic	O
worldwide	O
,	O
including	O
the	O
North	O
of	O
Argentina	O
where	O
both	O
associated	O
diseases	O
have	O
also	O
been	O
detected	O
.	O

Human	B
T	O
-	O
cell	O
Lymphotropic	O
viruses	O
type	O
1	O
(	O
HTLV-1	O
)	O
,	O
the	O
first	O
human	B
oncoretrovirus	O
to	O
be	O
discovered	O
,	O
is	O
the	O
etiologic	O
agent	O
of	O
Adult	O
T	O
-	O
cell	O
Leukemia	O
(	O
ATL	O
)	O
and	O
HTLV-1	O
Associated	O
Mielopathy	O
or	O
Tropical	O
Spastic	O
Paraparesis	O
(	O
HAM	O
/	O
TSP	O
)	O
.	O

Both	O
retroviruses	O
are	O
endemic	O
in	O
native	O
populations	O
of	O
The	O
Americas	O
,	O
Africa	O
and	O
at	O
-	O
risk	O
populations	O
.	O

No	O
etiologic	O
role	O
has	O
been	O
described	O
for	O
HTLV-2	O
,	O
although	O
it	O
has	O
been	O
associated	O
with	O
HAM	O
/	O
TSP	O
-	O
like	O
neurologic	O
syndromes	O
.	O

From	O
the	O
total	O
,	O
5	O
samples	O
resulted	O
seropositive	O
with	O
a	O
final	O
prevalence	O
of	O
0.00072	O
.	O

Furthermore	O
,	O
in	O
patient	O
samples	O
expression	O
of	O
miR	O
124a	O
is	O
significantly	O
decreased	O
.	O

Our	O
data	O
strongly	O
indicate	O
that	O
CDK6	O
is	O
regulated	O
by	O
microRNA	O
124	O
in	O
medulloblastoma	O
and	O
that	O
miR	O
124	O
modulates	O
medulloblastoma	O
cell	O
growth	O
.	O

We	O
hypothesized	O
that	O
CDK6	O
expression	O
is	O
also	O
regulated	O
by	O
microRNAs	O
in	O
medulloblastoma	O
.	O

Genomic	O
amplification	O
accounts	O
for	O
some	O
,	O
but	O
not	O
all	O
of	O
the	O
CDK6	O
over	O
-	O
expression	O
.	O

Expression	O
of	O
miR	O
124a	O
was	O
significantly	O
decreased	O
in	O
medulloblastoma	O
cells	O
compared	O
to	O
normal	O
adult	O
cerebellum	O
.	O

We	O
identified	O
putative	O
miR	O
sites	O
in	O
the	O
CDK6	O
including	O
microRNA	O
124a	O
,	O
a	O
brain	O
enriched	O
microRNA	O
.	O

Additionally	O
,	O
re	O
-	O
expression	O
of	O
miR	O
124a	O
in	O
medulloblastoma	O
cells	O
decreased	O
expression	O
of	O
CDK6	O
protein	O
.	O

Functional	O
association	O
between	O
miR	O
124a	O
and	O
CDK6	O
in	O
medulloblastoma	O
was	O
established	O
using	O
luciferase	O
assays	O
.	O

Transfection	O
of	O
miR	O
124	O
significantly	O
decreases	O
medulloblastoma	O
cell	O
growth	O
but	O
does	O
not	O
alter	O
apoptosis	O
.	O

Regulation	O
of	O
cyclin	O
dependent	O
kinase	O
6	O
by	O
microRNA	O
124	O
in	O
medulloblastoma	O
.	O

Despite	O
recent	O
advances	O
in	O
treatment	O
medulloblastoma	O
continues	O
to	O
remain	O
a	O
vexing	O
problem	O
.	O

Recently	O
increased	O
expression	O
of	O
cyclin	O
dependent	O
kinase	O
6	O
(	O
CDK6	O
)	O
was	O
identified	O
as	O
an	O
adverse	O
prognostic	O
marker	O
in	O
medulloblastoma	O
.	O

CONCLUSIONS	O
:	O
The	O
study	O
suggests	O
that	O
spatial	O
orientation	O
memory	O
relies	O
on	O
the	O
integrity	O
of	O
the	O
right	O
hippocampus	O
.	O

Nevertheless	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
confirm	O
this	O
hypothesis	O
.	O

The	O
subjects	O
were	O
submitted	O
to	O
a	O
neuropsychologic	O
evaluation	O
through	O
the	O
Route	O
Learning	O
Test	O
and	O
the	O
Childhood	O
Home	O
Test	O
in	O
the	O
preoperative	O
period	O
.	O

The	O
statistical	O
analysis	O
was	O
performed	O
using	O
the	O
Kruskal	O
-	O
Wallis	O
,	O
analysis	O
of	O
variance	O
,	O
χ	O
,	O
and	O
Mann	O
-	O
Whitney	O
U	O
tests	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
performance	O
in	O
the	O
remote	O
visuospatial	O
memory	O
(	O
as	O
measured	O
by	O
the	O
Childhood	O
Home	O
Test	O
)	O
across	O
the	O
groups	O
(	O
LTLE	O
,	O
RTLE	O
,	O
and	O
control	O
)	O
.	O

Concerning	O
the	O
spatial	O
orientation	O
memory	O
,	O
however	O
,	O
there	O
was	O
a	O
significant	O
difference	O
between	O
the	O
LTLE	O
and	O
controls	O
as	O
compared	O
with	O
the	O
RTLE	O
group	O
(	O
P<0.001	O
)	O
,	O
the	O
latter	O
showing	O
a	O
poorer	O
performance	O
.	O

However	O
,	O
evaluations	O
of	O
the	O
right	O
hippocampal	O
functions	O
have	O
not	O
been	O
consistent	O
.	O

In	O
ablative	O
interventions	O
,	O
neuropsychologic	O
testing	O
of	O
memory	O
is	O
a	O
crucial	O
step	O
.	O

METHODS	O
:	O
A	O
controlled	O
study	O
of	O
patients	B
with	O
left	O
(	O
LTLE	O
)	O
or	O
right	O
(	O
RTLE	O
)	O
TLE	O
.	O

AIM	O
:	O
To	O
assess	O
the	O
hippocampal	O
function	O
in	O
remote	O
orientation	O
and	O
visuospatial	O
memory	O
in	O
patients	B
with	O
refractory	O
temporal	O
epilepsy	O
.	O

INTRODUCTION	O
:	O
In	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
,	O
about	O
30	O
%	O
of	O
the	O
patients	B
do	O
not	O
achieve	O
adequate	O
pharmacologic	O
control	O
of	O
refractory	O
crises	O
,	O
and	O
surgery	O
becomes	O
an	O
alternative	O
.	O

Route	O
Learning	O
Performance	O
:	O
Is	O
it	O
a	O
Hippocampus	O
Function	O
?	O

Thrombolytic	O
therapy	O
involving	O
recombinant	O
tissue	O
plasminogen	O
activator	O
(	O
rtPA	O
)	O
has	O
been	O
shown	O
to	O
be	O
beneficial	O
only	O
when	O
used	O
within	O
4.5	O
hours	O
of	O
onset	O
of	O
acute	O
ischemic	O
stroke	O
.	O

There	O
are	O
two	O
major	O
types	O
of	O
stroke	O
:	O
cerebral	O
ischemia	O
caused	O
by	O
obstruction	O
of	O
blood	O
vessels	O
in	O
the	O
brain	O
and	O
haemorrhagic	O
stroke	O
that	O
is	O
triggered	O
by	O
the	O
disruption	O
of	O
blood	O
vessels	O
.	O

Stroke	O
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
death	O
and	O
disability	O
worldwide	O
.	O

microRNAs	O
in	O
stroke	O
pathogenesis	O
.	O

Although	O
the	O
biochemistry	O
of	O
stroke	O
and	O
related	O
diseases	O
is	O
quite	O
well	O
understood	O
,	O
the	O
knowledge	O
on	O
the	O
molecular	O
mechanisms	O
underlying	O
these	O
diseases	O
is	O
still	O
at	O
its	O
infancy	O
.	O

microRNAs	O
that	O
form	O
a	O
unique	O
class	O
of	O
endogenous	O
riboregulators	O
of	O
gene	O
function	O
,	O
offer	O
tremendous	O
potential	O
in	O
unraveling	O
the	O
mechanisms	O
underlying	O
stroke	O
pathogenesis	O
.	O

rtPA	O
treatment	O
beyond	O
this	O
time	O
window	O
has	O
been	O
found	O
to	O
be	O
unsuitable	O
and	O
usually	O
resulting	O
in	O
haemorrhagic	O
transformation	O
.	O

Stroke	O
is	O
a	O
multifactorial	O
disease	O
that	O
forms	O
a	O
possible	O
end	O
state	O
for	O
majority	O
of	O
patients	B
suffering	O
from	O
diabetes	O
,	O
atherosclerosis	O
and	O
hypertension	O
which	O
are	O
known	O
risk	O
factors	O
.	O

microRNA	O
expression	O
also	O
reflects	O
the	O
response	O
of	O
individuals	O
to	O
drugs	O
and	O
therapy	O
.	O

Several	O
microRNAs	O
and	O
their	O
target	O
genes	O
,	O
known	O
to	O
be	O
involved	O
in	O
endothelial	O
dysfunction	O
,	O
dysregulation	O
of	O
neurovascular	O
integrity	O
,	O
edema	O
formation	O
,	O
pro	O
-	O
apoptosis	O
,	O
inflammation	O
and	O
extra	O
-	O
cellular	O
matrix	O
remodeling	O
contribute	O
to	O
the	O
critical	O
processes	O
in	O
the	O
pathogenesis	O
of	O
stroke	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
also	O
be	O
discussing	O
the	O
role	O
of	O
microRNAs	O
as	O
possible	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
as	O
well	O
as	O
potential	O
therapeutic	O
targets	O
in	O
stroke	O
pathogenesis	O
.	O

Mutations	O
in	O
ABHD12	O
cause	O
the	O
neurodegenerative	O
disease	O
PHARC	O
:	O
An	O
inborn	O
error	O
of	O
endocannabinoid	O
metabolism	O
.	O

Previously	O
,	O
we	O
mapped	O
this	O
Refsum	O
-	O
like	O
disorder	O
to	O
a	O
16	O
Mb	O
region	O
on	O
chromosome	O
20	O
.	O

Polyneuropathy	O
,	O
hearing	O
loss	O
,	O
ataxia	O
,	O
retinitis	O
pigmentosa	O
,	O
and	O
cataract	O
(	O
PHARC	O
)	O
is	O
a	O
neurodegenerative	O
disease	O
marked	O
by	O
early	O
-	O
onset	O
cataract	O
and	O
hearing	O
loss	O
,	O
retinitis	O
pigmentosa	O
,	O
and	O
involvement	O
of	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
,	O
including	O
demyelinating	O
sensorimotor	O
polyneuropathy	O
and	O
cerebellar	O
ataxia	O
.	O

Our	O
findings	O
show	O
that	O
ABHD12	O
performs	O
essential	O
functions	O
in	O
both	O
the	O
central	O
and	O
peripheral	O
nervous	O
systems	O
and	O
the	O
eye	O
.	O

Any	O
future	O
drug	O
-	O
mediated	O
interference	O
with	O
this	O
enzyme	O
should	O
consider	O
the	O
potential	O
risk	O
of	O
long	O
-	O
term	O
adverse	O
effects	O
.	O

Here	O
we	O
report	O
that	O
mutations	O
in	O
the	O
ABHD12	O
gene	O
cause	O
PHARC	O
disease	O
and	O
we	O
describe	O
the	O
clinical	O
manifestations	O
in	O
a	O
total	O
of	O
19	O
patients	B
from	O
four	O
different	O
countries	O
.	O

The	O
ABHD12	O
enzyme	O
was	O
recently	O
shown	O
to	O
hydrolyze	O
2-arachidonoyl	O
glycerol	O
(	O
2-AG	O
)	O
,	O
the	O
main	O
endocannabinoid	O
lipid	O
transmitter	O
that	O
acts	O
on	O
cannabinoid	O
receptors	O
CB1	O
and	O
CB2	O
.	O

Our	O
data	O
therefore	O
represent	O
an	O
example	O
of	O
an	O
inherited	O
disorder	O
related	O
to	O
endocannabinoid	O
metabolism	O
.	O

The	O
endocannabinoid	O
system	O
is	O
involved	O
in	O
a	O
wide	O
range	O
of	O
physiological	O
processes	O
including	O
neurotransmission	O
,	O
mood	O
,	O
appetite	O
,	O
pain	O
appreciation	O
,	O
addiction	O
behavior	O
,	O
and	O
inflammation	O
,	O
and	O
several	O
potential	O
drugs	O
targeting	O
these	O
pathways	O
are	O
in	O
development	O
for	O
clinical	O
applications	O
.	O

These	O
cellular	O
responses	O
are	O
mediated	O
by	O
augmented	O
expression	O
of	O
the	O
direct	O
targets	O
of	O
miR-10b	O
,	O
including	O
BCL2L11	O
/	O
Bim	O
,	O
TFAP2C	O
/	O
AP-2γ	O
,	O
CDKN1A	O
/	O
p21	O
,	O
and	O
CDKN2A	O
/	O
p16	O
,	O
which	O
normally	O
protect	O
cells	O
from	O
uncontrolled	O
growth	O
.	O

Analysis	O
of	O
The	O
Cancer	O
Genome	O
Atlas	O
expression	O
data	O
set	O
reveals	O
a	O
strong	O
positive	O
correlation	O
between	O
numerous	O
genes	O
sustaining	O
cellular	O
growth	O
and	O
miR-10b	O
levels	O
in	O
human	B
glioblastomas	O
,	O
while	O
proapoptotic	O
genes	O
anticorrelate	O
with	O
the	O
expression	O
of	O
miR-10b	O
.	O

Molecular	O
functions	O
of	O
these	O
miRNAs	O
in	O
gliomagenesis	O
are	O
mainly	O
unknown	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
miR-10b	O
,	O
a	O
miRNA	O
not	O
expressed	O
in	O
human	B
brain	O
and	O
strongly	O
upregulated	O
in	O
both	O
low	O
-	O
grade	O
and	O
high	O
-	O
grade	O
gliomas	O
,	O
reduces	O
glioma	O
cell	O
growth	O
by	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

Human	B
glioma	O
growth	O
is	O
controlled	O
by	O
microRNA-10b	O
.	O

MicroRNA	O
(	O
miRNA	O
)	O
expression	O
profiling	O
studies	O
revealed	O
a	O
number	O
of	O
miRNAs	O
dysregulated	O
in	O
the	O
malignant	O
brain	O
tumor	O
glioblastoma	O
.	O

Altogether	O
,	O
our	O
experiments	O
validate	O
an	O
important	O
role	O
of	O
miR-10b	O
in	O
gliomagenesis	O
,	O
reveal	O
a	O
novel	O
mechanism	O
of	O
miR-10b	O
-	O
mediated	O
regulation	O
,	O
and	O
suggest	O
the	O
possibility	O
of	O
its	O
future	O
use	O
as	O
a	O
therapeutic	O
target	O
in	O
gliomas	O
.	O

Furthermore	O
,	O
survival	O
of	O
glioblastoma	O
patients	B
expressing	O
high	O
levels	O
of	O
miR-10	O
family	O
members	O
is	O
significantly	O
reduced	O
in	O
comparison	O
to	O
patients	B
with	O
low	O
miR-10	O
levels	O
,	O
indicating	O
that	O
miR-10	O
may	O
contribute	O
to	O
glioma	O
growth	O
in	O
vivo	O
.	O

Finally	O
,	O
inhibition	O
of	O
miR-10b	O
in	O
a	O
mouse	B
model	O
of	O
human	B
glioma	O
results	O
in	O
significant	O
reduction	O
of	O
tumor	O
growth	O
.	O

MRI	O
scan	O
showed	O
an	O
area	O
of	O
encephalomalacia	O
in	O
the	O
left	O
temporal	O
lobe	O
,	O
as	O
well	O
as	O
post	O
-	O
surgical	O
changes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

He	O
presented	O
with	O
status	O
epilepticus	O
every	O
two	O
or	O
three	O
months	O
,	O
and	O
required	O
long	O
periods	O
of	O
hospitalization	O
on	O
each	O
occasion	O
for	O
post	O
-	O
ictal	O
confusion	O
and	O
aphasia	O
.	O

He	O
continued	O
to	O
have	O
frequent	O
seizures	O
despite	O
treatment	O
with	O
multiple	O
combinations	O
of	O
antiepileptic	O
medications	O
.	O

EEG	O
telemetry	O
recorded	O
multiple	O
seizures	O
,	O
all	O
with	O
a	O
clear	O
focus	O
in	O
the	O
left	O
temporal	O
area	O
.	O

Scalp	O
EEG	O
showed	O
continuous	O
spikes	O
and	O
polyspikes	O
and	O
persistent	O
slowing	O
in	O
the	O
left	O
temporal	O
area	O
,	O
as	O
well	O
as	O
spikes	O
in	O
the	O
left	O
frontal	O
area	O
.	O

CASE	O
REPORT	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
75-year	O
-	O
old	O
right	O
-	O
handed	O
man	B
who	O
underwent	O
a	O
left	O
fronto	O
-	O
temporal	O
craniotomy	O
for	O
resection	O
of	O
a	O
suprasellar	O
meningioma	O
in	O
2002	O
.	O

Immediately	O
following	O
hospital	O
discharge	O
,	O
he	O
began	O
to	O
experience	O
complex	O
partial	O
seizures	O
.	O

BACKGROUND	O
:	O
Epilepsy	O
surgery	O
is	O
increasingly	O
well	O
-	O
supported	O
as	O
an	O
effective	O
treatment	O
for	O
patients	B
with	O
intractable	O
epilepsy	O
.	O

It	O
is	O
most	O
often	O
performed	O
on	O
younger	O
patients	B
and	O
the	O
safety	O
and	O
efficacy	O
of	O
epilepsy	O
surgery	O
in	O
elderly	O
patients	B
are	O
not	O
frequently	O
described	O
.	O

Epilepsy	O
surgery	O
in	O
the	O
elderly	O
:	O
an	O
unusual	O
case	O
of	O
a	O
75-year	O
-	O
old	O
man	B
with	O
recurrent	O
status	O
epilepticus	O
.	O

In	O
addition	O
,	O
few	O
cases	O
with	O
such	O
a	O
malignant	O
evolution	O
of	O
temporal	O
lobe	O
epilepsy	O
have	O
been	O
described	O
in	O
this	O
age	O
group	O
.	O

A	O
left	O
anteromesial	O
temporal	O
lobectomy	O
was	O
performed	O
with	O
intraoperative	O
electrocorticography	O
.	O

Neuropsychological	O
testing	O
showed	O
bilateral	O
memory	O
impairment	O
with	O
no	O
significant	O
cognitive	O
decline	O
expected	O
after	O
unilateral	O
temporal	O
lobe	O
resection	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
one	O
of	O
the	O
oldest	O
patients	B
reported	O
in	O
the	O
literature	O
with	O
epilepsy	O
surgery	O
and	O
supports	O
the	O
possibility	O
of	O
epilepsy	O
surgery	O
in	O
elderly	O
patients	B
for	O
particular	O
cases	O
.	O

Since	O
surgery	O
,	O
the	O
patient	B
was	O
not	O
seizure	O
-	O
free	O
(	O
Engel	O
class	O
II	O
-	O
b	O
)	O
,	O
but	O
had	O
no	O
further	O
episodes	O
of	O
status	O
epilepticus	O
in	O
one	O
year	O
and	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Adult	O
-	O
onset	O
autosomal	O
dominant	O
leukodystrophy	O
:	O
linking	O
nuclear	O
envelope	O
to	O
myelin	O
.	O

Aberrant	O
expression	O
of	O
miRNAs	O
can	O
lead	O
to	O
diseases	O
,	O
including	O
cancer	O
.	O

Expression	O
of	O
many	O
miRNAs	O
in	O
the	O
de	O
-	O
differentiated	O
brain	O
tumor	O
cancer	O
stem	O
cells	O
resembles	O
that	O
of	O
neural	O
stem	O
cells	O
.	O

MicroRNAs	O
:	O
regulators	O
of	O
oncogenesis	O
and	O
stemness	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
essential	O
post	O
-	O
transcriptional	O
regulators	O
that	O
determine	O
cell	O
identity	O
and	O
fate	O
.	O

In	O
this	O
issue	O
of	O
BMC	O
Medicine	O
,	O
Silber	O
et	O
al	O
provide	O
evidence	O
of	O
the	O
expression	O
of	O
such	O
miRNAs	O
and	O
their	O
potential	O
to	O
mediate	O
differentiation	O
in	O
both	O
stem	O
cell	O
populations	O
.	O

In	O
this	O
commentary	O
,	O
we	O
discuss	O
the	O
known	O
functions	O
of	O
miRNAs	O
in	O
cancer	O
and	O
stem	O
cells	O
,	O
their	O
therapeutic	O
potential	O
and	O
how	O
the	O
findings	O
of	O
Silber	O
et	O
al	O
provide	O
insight	O
into	O
the	O
role	O
of	O
miR-124	O
/	O
miR-137	O
dysregulation	O
in	O
glioblastomas	O
.	O

The	O
emerging	O
role	O
of	O
epigenetics	O
in	O
stroke	O
:	O
II	O
.	O
RNA	O
regulatory	O
circuitry	O
.	O

These	O
non	O
-	O
protein	O
-	O
coding	O
RNAs	O
(	O
ncRNAs	O
)	O
include	O
subclasses	O
that	O
are	O
well	O
known	O
,	O
such	O
as	O
transfer	O
RNAs	O
and	O
ribosomal	O
RNAs	O
,	O
as	O
well	O
as	O
those	O
that	O
have	O
more	O
recently	O
been	O
characterized	O
,	O
such	O
as	O
microRNAs	O
,	O
small	O
nucleolar	O
RNAs	O
,	O
and	O
long	O
ncRNAs	O
.	O

In	O
this	O
review	O
,	O
we	O
examine	O
the	O
role	O
of	O
these	O
novel	O
ncRNAs	O
in	O
the	O
nervous	O
system	O
and	O
highlight	O
emerging	O
evidence	O
that	O
implicates	O
RNA	O
-	O
based	O
networks	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
stroke	O
.	O

Recent	O
scientific	O
advances	O
have	O
demonstrated	O
the	O
existence	O
of	O
extensive	O
RNA	O
-	O
based	O
regulatory	O
networks	O
involved	O
in	O
orchestrating	O
nearly	O
every	O
cellular	O
process	O
in	O
health	O
and	O
various	O
disease	O
states	O
.	O

This	O
previously	O
hidden	O
layer	O
of	O
functional	O
RNAs	O
is	O
derived	O
largely	O
from	O
non	O
-	O
protein	O
-	O
coding	O
DNA	O
sequences	O
that	O
constitute	O
more	O
than	O
98	O
%	O
of	O
the	O
genome	O
in	O
humans	B
.	O

These	O
novel	O
approaches	O
for	O
neural	O
cell-	O
and	O
tissue	O
-	O
selective	O
reprogramming	O
of	O
epigenetic	O
regulatory	O
mechanisms	O
are	O
likely	O
to	O
promote	O
more	O
effective	O
neuroprotective	O
and	O
neural	O
regenerative	O
responses	O
for	O
safeguarding	O
and	O
even	O
restoring	O
central	O
nervous	O
system	O
function	O
.	O

We	O
also	O
describe	O
RNA	O
editing	O
,	O
a	O
related	O
epigenetic	O
mechanism	O
that	O
is	O
partly	O
responsible	O
for	O
generating	O
the	O
exquisite	O
degrees	O
of	O
environmental	O
responsiveness	O
and	O
molecular	O
diversity	O
that	O
characterize	O
ncRNAs	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
development	O
of	O
future	O
therapeutic	O
strategies	O
for	O
locus	O
-	O
specific	O
and	O
genome	O
-	O
wide	O
regulation	O
of	O
genes	O
and	O
functional	O
gene	O
networks	O
through	O
the	O
modulation	O
of	O
RNA	O
transcription	O
,	O
posttranscriptional	O
RNA	O
processing	O
(	O
eg	O
,	O
RNA	O
modifications	O
,	O
quality	O
control	O
,	O
intracellular	O
trafficking	O
,	O
and	O
local	O
and	O
long	O
-	O
distance	O
intercellular	O
transport	O
)	O
,	O
and	O
RNA	O
translation	O
.	O

These	O
results	O
indicate	O
that	O
miRNAs	O
are	O
differentially	O
expressed	O
in	O
C.	B
elegans	I
PD	O
models	O
and	O
suggest	O
a	O
role	O
for	O
these	O
molecules	O
in	O
disease	O
pathogenesis	O
.	O

Here	O
,	O
we	O
show	O
that	O
12	O
specific	O
miRNAs	O
are	O
differentially	O
regulated	O
in	O
the	O
animals	O
overexpressing	O
alpha	O
-	O
synuclein	O
,	O
five	O
in	O
cat-1	O
,	O
and	O
three	O
in	O
the	O
pdr-1	O
mutants	O
.	O

The	O
family	O
of	O
miR-64	O
and	O
miR-65	O
are	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	O
-	O
synuclein	O
transgenic	O
and	O
cat-1	O
strains	O
,	O
and	O
members	O
of	O
let-7	O
family	O
co	O
-	O
underexpressed	O
in	O
the	O
alpha	O
-	O
synuclein	O
and	O
pdr-1	O
strains	O
;	O
mdl-1	O
and	O
ptc-1	O
genes	O
are	O
target	O
candidates	O
for	O
miR-64	O
and	O
miR-65	O
and	O
are	O
overexpressed	O
in	O
alpha	O
-	O
synuclein	O
transgenic	O
as	O
well	O
as	O
miR-64	O
/	O
65	O
(	O
tm3711	O
)	O
knockout	O
animals	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
play	O
an	O
important	O
role	O
in	O
human	B
brain	O
development	O
and	O
maintenance	O
.	O

To	O
search	O
for	O
miRNAs	O
that	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Parkinsons	O
disease	O
(	O
PD	O
)	O
,	O
we	O
utilized	O
miRNA	O
microarrays	O
to	O
identify	O
potential	O
gene	O
expression	O
changes	O
in	O
115	O
annotated	O
miRNAs	O
in	O
PD	O
-	O
associated	O
Caenorhabditis	B
elegans	I
models	O
that	O
either	O
overexpress	O
human	B
A53	O
T	O
alpha	O
-	O
synuclein	O
or	O
have	O
mutations	O
within	O
the	O
vesicular	O
catecholamine	O
transporter	O
(	O
cat-1	O
)	O
or	O
parkin	O
(	O
pdr-1	O
)	O
ortholog	O
.	O

Global	O
microRNA	O
expression	O
profiling	O
of	O
Caenorhabditis	B
elegans	I
Parkinson	O
's	O
disease	O
models	O
.	O

A	O
series	O
of	O
novel	O
and	O
established	O
medulloblastoma	O
defects	O
were	O
detected	O
(	O
MYC	O
amplification	O
(	O
n	O
=	O
4	O
)	O
,	O
17q21.31	O
high	O
-	O
level	O
gain	O
(	O
n	O
=	O
1	O
)	O
;	O
9p21.1-p21.3	O
(	O
n	O
=	O
1	O
)	O
and	O
6q23.1	O
(	O
n	O
=	O
1	O
)	O
homozygous	O
deletion	O
)	O
.	O

METHODOLOGY	O
/	O
PRINCIPAL	O
FINDINGS	O
:	O
We	O
performed	O
a	O
SNP	O
-	O
array	O
based	O
genome	O
-	O
wide	O
copy	O
number	O
analysis	O
in	O
medulloblastoma	O
cell	O
lines	O
,	O
to	O
identify	O
regions	O
of	O
genomic	O
amplification	O
and	O
homozygous	O
deletion	O
,	O
which	O
may	O
harbour	O
critical	O
disease	O
genes	O
.	O

Most	O
notably	O
,	O
a	O
novel	O
recurrent	O
region	O
of	O
genomic	O
amplification	O
at	O
8q24.22-q24.23	O
was	O
identified	O
(	O
n	O
=	O
2	O
)	O
,	O
and	O
selected	O
for	O
further	O
investigation	O
.	O

Amplification	O
and	O
overexpression	O
of	O
Hsa	O
-	O
miR-30b	O
,	O
Hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
at	O
8q24.22-q24.23	O
in	O
medulloblastoma	O
.	O

The	O
identification	O
of	O
critical	O
genes	O
involved	O
in	O
its	O
pathogenesis	O
will	O
be	O
central	O
to	O
advances	O
in	O
our	O
understanding	O
of	O
its	O
molecular	O
basis	O
,	O
and	O
the	O
development	O
of	O
improved	O
therapeutic	O
approaches	O
.	O

BACKGROUND	O
:	O
Medulloblastoma	O
is	O
the	O
most	O
common	O
malignant	O
brain	O
tumour	O
of	O
childhood	O
.	O

Of	O
these	O
,	O
only	O
expression	O
of	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
correlated	O
with	O
copy	O
number	O
status	O
,	O
and	O
all	O
three	O
of	O
these	O
transcripts	O
also	O
displayed	O
evidence	O
of	O
elevated	O
expression	O
in	O
sub	O
-	O
sets	O
of	O
primary	O
medulloblastomas	O
,	O
measured	O
relative	O
to	O
the	O
normal	O
cerebellum	O
.	O

Additional	O
analysis	O
by	O
interphase	O
fluorescence	O
in	O
situ	O
hybridisation	O
(	O
iFISH	O
)	O
,	O
PCR	O
-	O
based	O
mapping	O
and	O
SNP	O
-	O
array	O
revealed	O
this	O
novel	O
amplification	O
at	O
8q24.22-q24.23	O
is	O
independent	O
of	O
MYC	O
amplification	O
at	O
8q24.21	O
,	O
and	O
is	O
unique	O
to	O
medulloblastoma	O
in	O
over	O
800	O
cancer	O
cell	O
lines	O
assessed	O
from	O
different	O
tumour	O
types	O
,	O
suggesting	O
it	O
contains	O
key	O
genes	O
specifically	O
involved	O
in	O
medulloblastoma	O
development	O
.	O

Detailed	O
mapping	O
identified	O
a	O
3Mb	O
common	O
minimal	O
region	O
of	O
amplification	O
harbouring	O
3	O
coding	O
genes	O
(	O
ZFAT1	O
,	O
LOC286094	O
,	O
KHDRBS3	O
)	O
and	O
two	O
genes	O
encoding	O
micro	O
-	O
RNAs	O
(	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
)	O
.	O

Our	O
findings	O
suggest	O
critical	O
roles	O
for	O
these	O
genes	O
in	O
medulloblastoma	O
development	O
,	O
and	O
further	O
support	O
the	O
contribution	O
of	O
micro	O
-	O
RNA	O
species	O
to	O
medulloblastoma	O
pathogenesis	O
.	O

CONCLUSIONS	O
/	O
SIGNIFICANCE	O
:	O
These	O
data	O
implicate	O
hsa	O
-	O
miR-30b	O
,	O
hsa	O
-	O
miR-30d	O
and	O
KHDRBS3	O
as	O
putative	O
oncogenic	O
target	O
(	O
s	O
)	O
of	O
a	O
novel	O
recurrent	O
medulloblastoma	O
amplicon	O
at	O
8q24.22-q24.23	O
.	O

PURPOSE	O
Medulloblastomas	O
are	O
heterogeneous	O
tumors	O
that	O
collectively	O
represent	O
the	O
most	O
common	O
malignant	O
brain	O
tumor	O
in	O
children	B
.	O

Integrative	O
genomic	O
analysis	O
of	O
medulloblastoma	O
identifies	O
a	O
molecular	O
subgroup	O
that	O
drives	O
poor	O
clinical	O
outcome	O
.	O

We	O
reveal	O
the	O
relative	O
contribution	O
of	O
each	O
subgroup	O
to	O
clinical	O
outcome	O
as	O
a	O
whole	O
and	O
show	O
that	O
a	O
previously	O
unidentified	O
molecular	O
subgroup	O
,	O
characterized	O
genetically	O
by	O
c	O
-	O
MYC	O
copy	O
number	O
gains	O
and	O
transcriptionally	O
by	O
enrichment	O
of	O
photoreceptor	O
pathways	O
and	O
increased	O
miR-183∼96∼182	O
expression	O
,	O
is	O
associated	O
with	O
significantly	O
lower	O
rates	O
of	O
event	O
-	O
free	O
and	O
overall	O
survivals	O
.	O

Results	O
Identified	O
are	O
six	O
molecular	O
subgroups	O
of	O
medulloblastoma	O
,	O
each	O
with	O
a	O
unique	O
combination	O
of	O
numerical	O
and	O
structural	O
chromosomal	O
aberrations	O
that	O
globally	O
influence	O
mRNA	O
and	O
miRNA	O
expression	O
.	O

CONCLUSION	O
Our	O
results	O
detail	O
the	O
complex	O
genomic	O
heterogeneity	O
of	O
medulloblastomas	O
and	O
identify	O
a	O
previously	O
unrecognized	O
molecular	O
subgroup	O
with	O
poor	O
clinical	O
outcome	O
for	O
which	O
more	O
effective	O
therapeutic	O
strategies	O
should	O
be	O
developed	O
.	O

PATIENTS	B
AND	O
METHODS	O
We	O
profiled	O
the	O
mRNA	O
transcriptome	O
of	O
194	O
medulloblastomas	O
and	O
performed	O
high	O
-	O
density	O
single	O
nucleotide	O
polymorphism	O
array	O
and	O
miRNA	O
analysis	O
on	O
115	O
and	O
98	O
of	O
these	O
,	O
respectively	O
.	O

To	O
understand	O
the	O
molecular	O
characteristics	O
underlying	O
their	O
heterogeneity	O
and	O
to	O
identify	O
whether	O
such	O
characteristics	O
represent	O
risk	O
factors	O
for	O
patients	B
with	O
this	O
disease	O
,	O
we	O
performed	O
an	O
integrated	O
genomic	O
analysis	O
of	O
a	O
large	O
series	O
of	O
primary	O
tumors	O
.	O

We	O
additionally	O
validated	O
our	O
findings	O
in	O
three	O
previously	O
published	O
independent	O
medulloblastoma	O
data	O
sets	O
.	O

Non	O
-	O
negative	O
matrix	O
factorization	O
-	O
based	O
clustering	O
of	O
mRNA	O
expression	O
data	O
was	O
used	O
to	O
identify	O
molecular	O
subgroups	O
of	O
medulloblastoma	O
;	O
DNA	O
copy	O
number	O
,	O
miRNA	O
profiles	O
,	O
and	O
clinical	O
outcomes	O
were	O
analyzed	O
for	O
each	O
.	O

The	O
reason	O
why	O
a	O
mild	O
TBI	O
results	O
in	O
varying	O
clinical	O
symptoms	O
is	O
currently	O
unknown	O
.	O

Based	O
on	O
evidence	O
that	O
microRNA	O
species	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
may	O
reflect	O
molecular	O
alterations	O
in	O
neurodegenerative	O
disorders	O
,	O
it	O
can	O
be	O
hypothesized	O
that	O
at	O
early	O
,	O
preclinical	O
phases	O
of	O
the	O
disease	O
,	O
PBMC	O
may	O
provide	O
an	O
ideal	O
and	O
clinically	O
assessable	O
""""	O
window	O
""""	O
into	O
the	O
brain	O
.	O

Patients	B
who	O
have	O
sustained	O
a	O
mild	O
traumatic	O
brain	O
injury	O
(	O
TBI	O
)	O
from	O
both	O
civilian	O
and	O
military	O
populations	O
exhibit	O
clinical	O
symptoms	O
of	O
varying	O
severity	O
with	O
minimal	O
to	O
profound	O
impact	O
on	O
their	O
daily	O
functioning	O
.	O

Although	O
most	O
patients	B
make	O
a	O
full	O
recovery	O
,	O
a	O
subgroup	O
of	O
mild	O
TBI	O
patients	B
develop	O
cognitive	O
,	O
somatic	O
,	O
and	O
neurobehavioral	O
sequelae	O
that	O
generally	O
resolve	O
over	O
3	O
to	O
6	O
months	O
;	O
a	O
smaller	O
subgroup	O
develop	O
persisting	O
symptoms	O
.	O

Personalized	O
medicine	O
in	O
traumatic	O
brain	O
injury	O
.	O

Thus	O
,	O
it	O
is	O
conceivable	O
that	O
changes	O
in	O
the	O
expression	O
profile	O
of	O
clinically	O
accessible	O
biological	O
indices	O
(	O
biomarkers	O
)	O
,	O
such	O
as	O
microRNA	O
in	O
PBMC	O
,	O
may	O
reflect	O
molecular	O
alterations	O
following	O
TBI	O
that	O
contribute	O
to	O
the	O
onset	O
and	O
progression	O
of	O
TBI	O
phenotypes	O
including	O
chronic	O
traumatic	O
encephalopathy	O
.	O

It	O
is	O
possible	O
that	O
the	O
availability	O
of	O
TBI	O
biomarkers	O
may	O
provide	O
potential	O
elements	O
with	O
clinical	O
relevance	O
to	O
prevention	O
,	O
prognosis	O
,	O
and	O
treatment	O
of	O
postconcussive	O
disorders	O
.	O

This	O
opportunistic	O
mycosis	O
infection	O
presented	O
with	O
clinically	O
totally	O
nonspecific	O
signs	O
and	O
symptoms	O
of	O
CNS	O
affection	O
.	O

Therefore	O
,	O
we	O
suspected	O
affection	O
of	O
CNS	O
with	O
SLE	O
.	O

Even	O
though	O
all	O
diagnostic	O
procedures	O
were	O
made	O
on	O
time	O
and	O
that	O
adequate	O
antifungal	O
and	O
supportive	O
agents	O
were	O
applied	O
very	O
early	O
after	O
the	O
infection	O
onset	O
,	O
the	O
outcome	O
was	O
fatal	O
.	O

Because	O
of	O
infective	O
diathesis	O
in	O
patients	B
with	O
SLE	O
,	O
which	O
present	O
with	O
common	O
and	O
opportunistic	O
infections	O
,	O
and	O
due	O
to	O
high	O
mortality	O
rates	O
caused	O
by	O
these	O
infections	O
,	O
we	O
have	O
tried	O
to	O
emphasise	O
the	O
importance	O
of	O
taking	O
adequate	O
specimens	O
early	O
after	O
infection	O
outcome	O
for	O
these	O
rare	O
infective	O
agents	O
like	O
C.	O
neophormans	O
.	O

It	O
was	O
meningitis	O
caused	O
by	O
C.	O
neoformans	O
.	O

Reports	O
from	O
Europe	O
are	O
very	O
rare	O
,	O
and	O
this	O
case	O
is	O
the	O
one	O
of	O
that	O
kind	O
in	O
Croatia	O
.	O

In	O
recent	O
medical	O
literature	O
are	O
dominant	O
cases	O
reported	O
in	O
Asia	O
.	O

Systemic	O
erythematosus	O
lupus	O
(	O
SLE	O
)	O
is	O
a	O
disease	O
with	O
wide	O
range	O
of	O
clinical	O
manifestations	O
,	O
signs	O
and	O
symptoms	O
.	O

[	O
Cryptococcal	O
meningitis	O
as	O
a	O
diagnostic	O
problem	O
in	O
a	O
patient	B
with	O
SLE	O
--	O
case	O
report	O
]	O
.	O

Very	O
important	O
cause	O
of	O
death	O
in	O
patients	B
with	O
SLE	O
is	O
infection	O
.	O

Disease	O
outcome	O
depends	O
mostly	O
on	O
the	O
affection	O
of	O
kidneys	O
and	O
central	O
nervous	O
system	O
by	O
the	O
disease	O
.	O

During	O
one	O
of	O
the	O
disease	O
flares	O
the	O
patient	B
was	O
hospitalized	O
an	O
opportunistic	O
infection	O
developed	O
.	O

As	O
an	O
outcome	O
of	O
the	O
combined	O
effect	O
of	O
disease	O
and	O
immunosuppressive	O
agents	O
used	O
in	O
the	O
treatment	O
of	O
the	O
disease	O
,	O
the	O
patient	B
had	O
increased	O
infective	O
diathesis	O
(	O
repeated	O
infections	O
caused	O
by	O
S.	O
enteritidis	O
--	O
urinary	O
infections	O
and	O
sepsis	O
)	O
.	O

In	O
this	O
case	O
report	O
we	O
have	O
presented	O
a	O
patient	B
with	O
SLE	O
who	O
initially	O
had	O
severe	O
renal	O
affection	O
,	O
but	O
also	O
complications	O
of	O
immunosuppressive	O
therapy	O
that	O
was	O
administered	O
.	O

Infections	O
are	O
very	O
common	O
among	O
these	O
patients	B
due	O
to	O
aggressive	O
immunosuppressive	O
treatment	O
that	O
is	O
needed	O
for	O
the	O
disease	O
inflammatory	O
activity	O
control	O
.	O

Because	O
of	O
lupus	O
nephropathy	O
,	O
in	O
the	O
early	O
phase	O
of	O
the	O
disease	O
we	O
administered	O
aggressive	O
immunosuppressive	O
therapy	O
(	O
combined	O
parenteral	O
therapy	O
of	O
glucocorticoides	O
and	O
cyclophosphamide	O
)	O
.	O

Even	O
though	O
the	O
disease	O
was	O
accidentally	O
diagnosed	O
,	O
it	O
had	O
a	O
severe	O
clinical	O
progress	O
.	O

Isolation	O
and	O
characterization	O
of	O
MAT	O
genes	O
in	O
the	O
symbiotic	O
ascomycete	O
Tuber	B
melanosporum	I
.	O

*	O
The	O
genome	O
of	O
Tuber	B
melanosporum	I
has	O
recently	O
been	O
sequenced	O
.	O

Here	O
,	O
we	O
used	O
this	O
information	O
to	O
identify	O
genes	O
involved	O
in	O
the	O
reproductive	O
processes	O
of	O
this	O
edible	O
fungus	O
.	O

The	O
sequenced	O
strain	O
(	O
Mel28	O
)	O
possesses	O
only	O
one	O
of	O
the	O
two	O
master	O
genes	O
required	O
for	O
mating	O
,	O
that	O
is	O
,	O
the	O
gene	O
that	O
codes	O
for	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
transcription	O
factor	O
(	O
MAT1	O
-	O
2	O
-	O
1	O
)	O
,	O
whereas	O
it	O
lacks	O
the	O
gene	O
that	O
codes	O
for	O
the	O
protein	O
containing	O
the	O
alpha	O
-	O
box-	O
domain	O
(	O
MAT1	O
-	O
1	O
-	O
1	O
)	O
,	O
suggesting	O
that	O
this	O
fungus	O
is	O
heterothallic	O
.	O

*	O
A	O
PCR	O
-	O
based	O
approach	O
was	O
initially	O
employed	O
to	O
screen	O
truffles	O
for	O
the	O
presence	O
of	O
the	O
MAT1	O
-	O
2	O
-	O
1	O
gene	O
and	O
amplify	O
the	O
conserved	O
regions	O
flanking	O
the	O
mating	O
type	O
(	O
MAT	O
)	O
locus	O
.	O

The	O
MAT1	O
-	O
1	O
-	O
1	O
gene	O
was	O
finally	O
identified	O
using	O
primers	O
designed	O
from	O
the	O
conserved	O
regions	O
of	O
strains	O
that	O
lack	O
the	O
MAT1	O
-	O
2	O
-	O
1	O
gene	O
.	O

*	O
Mating	O
type	O
-	O
specific	O
primer	O
pairs	O
were	O
developed	O
to	O
screen	O
asci	O
and	O
gleba	O
from	O
truffles	O
of	O
different	O
origins	O
and	O
to	O
genotype	O
single	O
ascospores	O
within	O
the	O
asci	O
.	O

These	O
analyses	O
provided	O
definitive	O
evidence	O
that	O
T.	B
melanosporum	I
is	O
a	O
heterothallic	O
species	O
with	O
a	O
MAT	O
locus	O
that	O
is	O
organized	O
similarly	O
to	O
those	O
of	O
ancient	O
fungal	O
lineages	O
.	O

*	O
A	O
greater	O
understanding	O
of	O
the	O
reproductive	O
mechanisms	O
that	O
exist	O
in	O
Tuber	O
spp	O
.	O
allows	O
for	O
optimization	O
of	O
truffle	O
plantation	O
management	O
strategies	O
.	O

Microtubule	O
dynamics	O
in	O
mitosis	O
in	O
Aspergillus	B
nidulans	I
.	O

Mitosis	O
in	O
Aspergillus	B
nidulans	I
is	O
very	O
rapid	O
,	O
requiring	O
less	O
than	O
5	O
min	O
at	O
37	O
^0C	O
in	O
germlings	O
(	O
Bergen	O
and	O
Morris	O
,	O
1983	O
)	O
.	O

In	O
this	O
time	O
the	O
cytoplasmic	O
microtubules	O
(	O
MTs	O
)	O
must	O
disassemble	O
,	O
the	O
mitotic	O
spindle	O
assemble	O
,	O
function	O
and	O
disassemble	O
,	O
and	O
cytoplasmic	O
MTs	O
reassemble	O
.	O

It	O
follows	O
that	O
cytoplasmic	O
MTs	O
must	O
be	O
extremely	O
dynamic	O
in	O
this	O
period	O
and	O
we	O
were	O
interested	O
,	O
in	O
particular	O
,	O
in	O
examining	O
the	O
processes	O
of	O
MT	O
disassembly	O
in	O
prophase	O
and	O
reassembly	O
in	O
anaphase	O
and	O
telophase	O
.	O

We	O
observed	O
a	O
diploid	O
strain	O
that	O
expressed	O
GFP	O
-	O
alpha	O
-	O
tubulin	O
.	O

We	O
used	O
a	O
spinning	O
disk	O
confocal	O
microscope	O
that	O
allowed	O
rapid	O
image	O
capture	O
,	O
which	O
proved	O
necessary	O
because	O
microtubule	O
dynamics	O
were	O
extremely	O
rapid	O
.	O

We	O
found	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
microtubule	O
severing	O
occurs	O
in	O
prophase	O
in	O
a	O
filamentous	O
fungus	O
and	O
that	O
catastrophe	O
rather	O
than	O
nucleation	O
limits	O
astral	O
microtubule	O
growth	O
.	O

Morphological	O
redescriptions	O
of	O
four	O
marine	O
ciliates	O
(	O
Ciliophora	O
:	O
Cyrtophorida	O
:	O
Dysteriidae	O
)	O
from	O
Qingdao	O
,	O
China	O
.	O

The	O
morphology	O
and	O
infraciliature	O
of	O
four	O
marine	O
cyrtophorid	O
ciliates	O
isolated	O
from	O
Qingdao	O
,	O
China	O
,	O
were	O
investigated	O
.	O

Based	O
on	O
the	O
present	O
work	O
and	O
on	O
previous	O
data	O
,	O
improved	O
diagnoses	O
for	O
three	O
rarely	O
known	O
species	O
are	O
provided	O
:	O
(	O
1	O
)	O
Mirodysteria	O
decora	O
;	O
small	O
-	O
sized	O
marine	O
Mirodysteria	O
about	O
35	O
-	O
60	O
x	O
25	O
-	O
35	O
mum	O
in	O
vivo	O
,	O
oval	O
in	O
outline	O
;	O
body	O
surface	O
with	O
two	O
or	O
three	O
conspicuous	O
dorsal	O
spines	O
and	O
one	O
caudal	O
spine	O
;	O
three	O
right	O
kineties	O
,	O
the	O
rightmost	O
one	O
extending	O
dorso	O
-	O
apically	O
;	O
left	O
frontal	O
kineties	O
reduced	O
,	O
each	O
consisting	O
of	O
three	O
basal	O
bodies	O
only	O
;	O
podite	O
subcaudally	O
positioned	O
;	O
two	O
ventrally	O
located	O
contractile	O
vacuoles	O
.	O

(	O
2	O
)	O
Dysteria	O
legumen	O
;	O
body	O
oval	O
with	O
two	O
longitudinal	O
grooves	O
on	O
different	O
plates	O
;	O
six	O
right	O
kineties	O
,	O
the	O
rightmost	O
two	O
of	O
which	O
extend	O
dorso	O
-	O
apically	O
;	O
two	O
left	O
frontal	O
kineties	O
and	O
two	O
ventrally	O
located	O
contractile	O
vacuoles	O
.	O

(	O
3	O
)	O
Dysteria	O
proraefrons	O
;	O
body	O
about	O
60x35	O
mum	O
in	O
vivo	O
;	O
six	O
right	O
kineties	O
,	O
the	O
two	O
rightmost	O
of	O
which	O
extend	O
dorso	O
-	O
apically	O
and	O
the	O
leftmost	O
one	O
is	O
considerably	O
shortened	O
;	O
three	O
left	O
frontal	O
kineties	O
;	O
two	O
ventrally	O
located	O
contractile	O
vacuoles	O
.	O

A	O
population	O
of	O
D.	B
derouxi	I
with	O
eight	O
or	O
nine	O
right	O
kineties	O
is	O
also	O
briefly	O
described	O
.	O

The	O
current	O
investigation	O
further	O
demonstrates	O
high	O
diversity	O
and	O
cosmopolitan	O
distribution	O
of	O
this	O
highly	O
specialized	O
group	O
of	O
benthic	O
ciliates	O
.	O

Auxin	O
depletion	O
in	O
barley	B
plants	O
under	O
high	O
-	O
temperature	O
conditions	O
represses	O
DNA	O
proliferation	O
in	O
organelles	O
and	O
nuclei	O
via	O
transcriptional	O
alterations	O
.	O

Many	O
plant	O
species	O
are	O
susceptible	O
to	O
high	O
-	O
temperature	O
(	O
HT	O
)	O
injury	O
during	O
reproductive	O
development	O
.	O

We	O
recently	O
demonstrated	O
that	O
HT	O
represses	O
the	O
expression	O
of	O
YUCCA	O
auxin	O
biosynthesis	O
genes	O
and	O
reduces	O
endogenous	O
auxin	O
in	O
the	O
developing	O
anthers	O
of	O
barley	B
and	O
Arabidopsis	O
.	O

Here	O
,	O
we	O
show	O
that	O
DNA	O
proliferation	O
in	O
mitochondria	O
,	O
chloroplasts	O
and	O
nuclei	O
of	O
developing	O
panicles	O
is	O
inhibited	O
with	O
increasing	O
temperatures	O
in	O
barley	B
.	O

Following	O
DNA	O
proliferation	O
suppression	O
,	O
terminal	O
abnormalities	O
were	O
observed	O
in	O
the	O
organelles	O
of	O
anther	O
wall	O
cells	O
,	O
including	O
mitochondrial	O
swelling	O
and	O
overdevelopment	O
of	O
chloroplasts	O
.	O

Comprehensive	O
transcriptome	O
analyses	O
using	O
both	O
reproductive	O
organs	O
and	O
vegetative	O
tissues	O
showed	O
high	O
and	O
positive	O
pairwise	O
correlations	O
between	O
the	O
expression	O
profiles	O
of	O
auxin	O
-	O
induced	O
genes	O
,	O
DNA	O
replication	O
-	O
related	O
genes	O
and	O
mitochondrial	O
-	O
related	O
genes	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
profiles	O
of	O
auxin	O
-	O
repressed	O
protein	O
genes	O
and	O
photosynthesis-	O
/	O
chloroplast	O
-	O
related	O
genes	O
were	O
negatively	O
correlated	O
with	O
those	O
of	O
the	O
previously	O
mentioned	O
genes	O
.	O

Under	O
HT	O
conditions	O
,	O
the	O
former	O
was	O
repressed	O
and	O
the	O
latter	O
was	O
up	O
-	O
regulated	O
in	O
the	O
developing	O
panicles	O
.	O

Furthermore	O
,	O
application	O
of	O
exogenous	O
auxin	O
promoted	O
the	O
expression	O
of	O
DNA	O
replication	O
-	O
related	O
genes	O
under	O
HT	O
conditions	O
,	O
inducing	O
anther	O
cell	O
proliferation	O
.	O

These	O
suggest	O
that	O
compromised	O
auxin	O
biosynthesis	O
/	O
IAA	O
level	O
under	O
HT	O
condition	O
results	O
in	O
nuclear	O
and	O
organellar	O
DNA	O
proliferation	O
arrest	O
due	O
to	O
co	O
-	O
transcriptional	O
alterations	O
.	O

Separating	O
parental	O
environment	O
from	O
seed	O
size	O
effects	O
on	O
next	O
generation	O
growth	O
and	O
development	O
in	O
Arabidopsis	O
.	O

Plant	O
growth	O
and	O
development	O
is	O
profoundly	O
influenced	O
by	O
environmental	O
conditions	O
that	O
laboratory	O
experimentation	O
typically	O
attempts	O
to	O
control	O
.	O

However	O
,	O
growth	O
conditions	O
are	O
not	O
uniform	O
between	O
or	O
even	O
within	O
laboratories	O
and	O
the	O
extent	O
to	O
which	O
these	O
differences	O
influence	O
plant	O
growth	O
and	O
development	O
is	O
unknown	O
.	O

Experiments	O
with	O
wild	O
-	O
type	O
Arabidopsis	B
thaliana	I
were	O
designed	O
to	O
quantify	O
the	O
influences	O
of	O
parental	O
environment	O
and	O
seed	O
size	O
on	O
growth	O
and	O
development	O
in	O
the	O
next	O
generation	O
.	O

A	O
single	O
lot	O
of	O
seed	O
was	O
planted	O
in	O
six	O
environmental	O
chambers	O
and	O
grown	O
to	O
maturity	O
.	O

The	O
seed	O
produced	O
was	O
mechanically	O
sieved	O
into	O
small	O
and	O
large	O
size	O
classes	O
then	O
grown	O
in	O
a	O
common	O
environment	O
and	O
subjected	O
to	O
a	O
set	O
of	O
assays	O
spanning	O
the	O
life	O
cycle	O
.	O

Analysis	O
of	O
variance	O
demonstrated	O
that	O
seed	O
size	O
effects	O
were	O
particularly	O
significant	O
early	O
in	O
development	O
,	O
affecting	O
primary	O
root	O
growth	O
and	O
gravitropism	O
,	O
but	O
also	O
flowering	O
time	O
.	O

Parental	O
environment	O
affected	O
progeny	O
germination	O
time	O
,	O
flowering	O
and	O
weight	O
of	O
seed	O
the	O
progeny	O
produced	O
.	O

In	O
some	O
cases	O
,	O
the	O
parental	O
environment	O
affected	O
the	O
magnitude	O
of	O
(	O
interacted	O
with	O
)	O
the	O
observed	O
seed	O
size	O
effects	O
.	O

These	O
data	O
indicate	O
that	O
life	O
history	O
circumstances	O
of	O
the	O
parental	O
generation	O
can	O
affect	O
growth	O
and	O
development	O
throughout	O
the	O
life	O
cycle	O
of	O
the	O
next	O
generation	O
to	O
an	O
extent	O
that	O
should	O
be	O
considered	O
when	O
performing	O
genetic	O
studies	O
.	O

Minimum	O
hydraulic	O
safety	O
leads	O
to	O
maximum	O
water	O
-	O
use	O
efficiency	O
in	O
a	O
forage	O
grass	O
.	O

Understanding	O
how	O
water	O
-	O
use	O
regulation	O
relates	O
to	O
biomass	O
accumulation	O
is	O
imperative	O
for	O
improving	O
crop	O
production	O
in	O
water	O
-	O
limited	O
environments	O
.	O

Here	O
,	O
we	O
examine	O
how	O
the	O
vulnerability	O
of	O
xylem	O
to	O
water	O
stress	O
-	O
induced	O
cavitation	O
and	O
the	O
coordination	O
between	O
water	O
transport	O
capacity	O
and	O
assimilation	O
(	O
A	O
)	O
influences	O
diurnal	O
water	O
-	O
use	O
efficiency	O
(	O
WUE	O
)	O
and	O
dry	O
-	O
matter	O
production	O
in	O
Lolium	B
perenne	I
L.	O
-	O
a	O
commercial	O
forage	O
grass	O
.	O

Plants	O
were	O
exposed	O
to	O
a	O
range	O
of	O
water	O
stresses	O
,	O
causing	O
up	O
to	O
90	O
%	O
leaf	O
death	O
,	O
by	O
withholding	O
water	O
and	O
then	O
rewatering	O
to	O
observe	O
the	O
recovery	O
process	O
.	O

Leaf	O
hydraulic	O
conductance	O
(	O
K	O
(	O
leaf	O
)	O
)	O
declined	O
to	O
50	O
%	O
of	O
maximum	O
at	O
a	O
leaf	O
water	O
potential	O
(	O
psi	O
(	O
leaf	O
)	O
)	O
of	O
-1	O
MPa	O
,	O
whereas	O
complete	O
stomatal	O
closure	O
occurred	O
well	O
after	O
this	O
point	O
,	O
at	O
-2.35	O
MPa	O
,	O
providing	O
no	O
protection	O
against	O
hydraulic	O
dysfunction	O
.	O

Instantaneous	O
A	O
remained	O
maximal	O
until	O
>	O
70	O
%	O
of	O
hydraulic	O
conductivity	O
had	O
been	O
lost	O
.	O

Post	O
-	O
stress	O
rewatering	O
showed	O
that	O
95	O
%	O
loss	O
of	O
K	O
(	O
leaf	O
)	O
could	O
be	O
incurred	O
before	O
the	O
recovery	O
of	O
gas	O
exchange	O
exceeded	O
1	O
d	O
,	O
with	O
a	O
rapid	O
transition	O
to	O
leaf	O
death	O
after	O
this	O
point	O
.	O

Plants	O
exposed	O
to	O
sustained	O
soil	O
water	O
deficits	O
through	O
restricted	O
nightly	O
watering	O
regimes	O
did	O
not	O
suffer	O
cumulative	O
losses	O
in	O
K	O
(	O
leaf	O
)	O
;	O
instead	O
,	O
psi	O
(	O
leaf	O
)	O
and	O
gas	O
exchange	O
recovered	O
diurnally	O
.	O

The	O
effect	O
was	O
improved	O
WUE	O
during	O
the	O
day	O
and	O
optimal	O
psi	O
(	O
leaf	O
)	O
during	O
the	O
night	O
for	O
the	O
maintenance	O
of	O
growth	O
.	O

Cotterillia	B
bromelicola	I
nov.	I
gen.	I
,	I
nov.	I
spec	I
.	O
,	O
a	O
gonostomatid	O
ciliate	O
(	O
Ciliophora	O
,	O
Hypotricha	O
)	O
from	O
tank	O
bromeliads	O
(	O
Bromeliaceae	O
)	O
with	O
de	O
novo	O
originating	O
dorsal	O
kineties	O
.	O

Cotterillia	B
bromelicola	I
nov.	I
gen.	I
,	I
nov.	I
spec	I
.	O

was	O
discovered	O
in	O
the	O
tanks	O
of	O
the	O
Mexican	O
bromeliad	O
Tillandsia	B
heterophylla	I
.	O

Its	O
morphology	O
,	O
ontogenesis	O
,	O
and	O
18S	O
rDNA	O
were	O
studied	O
with	O
standard	O
methods	O
.	O

Cotterillia	B
has	O
many	O
cirral	O
rows	O
on	O
both	O
sides	O
of	O
the	O
body	O
.	O

Uniquely	O
,	O
and	O
thus	O
used	O
to	O
diagnose	O
the	O
new	O
genus	O
Cotterillia	B
,	O
it	O
has	O
dorsal	O
kineties	O
originating	O
de	O
novo	O
,	O
producing	O
neokinetal	O
waves	O
where	O
the	O
parental	O
dorsal	O
kineties	O
reorganize	O
to	O
""""	O
combined	O
rows	O
""""	O
,	O
consisting	O
of	O
dorsal	O
bristles	O
anteriorly	O
and	O
of	O
cirri	O
posteriorly	O
.	O

Thus	O
,	O
up	O
to	O
four	O
generations	O
of	O
bristles	O
and	O
cirri	O
occur	O
on	O
the	O
dorsal	O
body	O
surface	O
.	O

Cotterillia	O
bromelicola	B
has	I
a	I
gonostomatid	I
body	O
and	O
adoral	O
zone	O
of	O
membranelles	O
,	O
while	O
the	O
dense	O
ciliature	O
and	O
the	O
neokinetal	O
waves	O
resemble	O
kahliellid	O
hypotrichs	O
.	O

However	O
,	O
the	O
de	O
novo	O
origin	O
of	O
anlage	O
1	O
and	O
the	O
molecular	O
analyses	O
show	O
convincingly	O
that	O
Cotterillia	O
belongs	B
to	O
the	O
Gonostomatidae	O
Small	O
and	O
Lynn	O
,	O
1985	O
,	O
for	O
which	O
an	O
improved	O
diagnosis	O
is	O
provided	O
.	O

Thus	O
,	O
neokinetal	O
waves	O
originated	O
several	O
times	O
independently	O
.	O

The	O
molecular	O
differences	O
between	O
Trachelostyla	O
,	O
Gonostomum	O
,	O
and	O
Cotterillia	O
are	B
small	I
(=	O
<	O
5	O
%	O
)	O
compared	O
to	O
their	O
distinct	O
morphologies	O
and	O
ontogeneses	O
,	O
suggesting	O
that	O
the	O
18S	O
rDNA	O
underestimates	O
generic	O
diversity	O
.	O

Our	O
study	O
emphasizes	O
the	O
need	O
of	O
combined	O
morphological	O
,	O
ontogenetic	O
,	O
and	O
molecular	O
investigations	O
to	O
unravel	O
the	O
complex	O
phylogeny	O
and	O
evolution	O
of	O
hypotrich	O
ciliates	O
.	O

The	O
first	O
vitellogenin	O
receptor	O
from	O
a	O
Lepidopteran	O
insect	O
:	O
molecular	O
characterization	O
,	O
expression	O
patterns	O
and	O
RNA	O
interference	O
analysis	O
.	O

The	O
vitellogenin	O
receptor	O
(	O
VgR	O
)	O
belongs	O
to	O
the	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLR	O
)	O
superfamily	O
,	O
and	O
is	O
an	O
important	O
carrier	O
for	O
the	O
uptake	O
of	O
vitellogenin	O
(	O
Vg	O
)	O
into	O
developing	O
oocytes	O
of	O
all	O
oviparous	O
species	O
.	O

The	O
first	O
full	O
-	O
length	O
message	O
for	O
a	O
VgR	O
from	O
a	O
Lepidopteran	O
insect	O
was	O
cloned	O
and	O
sequenced	O
from	O
the	O
ovary	O
of	O
Spodoptera	B
litura	I
Fabricius	I
(	O
GenBank	O
accession	O
no.	O
GU983858	O
)	O
.	O

The	O
coding	O
region	O
consisted	O
of	O
5370	O
bp	O
flanked	O
by	O
a	O
49	O
bp	O
5'-untranslated	O
region	O
(	O
UTR	O
)	O
and	O
a	O
177	O
bp	O
3'-UTR	O
,	O
which	O
encoded	O
a	O
1798-residue	O
protein	O
with	O
a	O
predicted	O
molecular	O
weight	O
(	O
MW	O
)	O
of	O
201.69	O
kDa	O
.	O

S.	B
litura	I
VgR	O
(	O
SlVgR	O
)	O
comprised	O
two	O
ligand	O
binding	O
sites	O
with	O
four	O
LDLR	O
class	O
A	O
repeats	O
in	O
the	O
first	O
domain	O
and	O
seven	O
in	O
the	O
second	O
domain	O
,	O
an	O
epidermal	O
growth	O
factor	O
-	O
like	O
domain	O
containing	O
an	O
LDLR	O
class	O
B	O
repeat	O
and	O
a	O
YWXD	O
motif	O
,	O
a	O
transmembrane	O
domain	O
and	O
a	O
cytoplasmic	O
domain	O
.	O

A	O
phylogenetic	O
relationship	O
placed	O
SlVgR	O
as	O
a	O
separate	O
group	O
from	O
the	O
other	O
insects	O
.	O

SlVgR	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
was	O
specifically	O
expressed	O
in	O
the	O
ovarian	O
tissues	O
.	O

The	O
developmental	O
expression	O
patterns	O
showed	O
that	O
VgR	O
mRNA	O
was	O
first	O
transcribed	O
in	O
6	O
(	O
th	O
)	O
day	O
female	O
pupae	O
and	O
the	O
maximum	O
level	O
of	O
VgR	O
mRNA	O
appeared	O
in	O
36-h	O
-	O
old	O
adults	O
.	O

Immunoblot	O
analysis	O
detected	O
an	O
ovary	O
-	O
specific	O
VgR	O
protein	O
with	O
a	O
MW	O
of	O
-200	O
kDa	O
,	O
whose	O
development	O
profiles	O
were	O
consistent	O
with	O
VgR	O
mRNA	O
expression	O
patterns	O
.	O

RNA	O
inteference	O
(	O
RNAi	O
)	O
specifically	O
disrupted	O
the	O
VgR	O
gene	O
by	O
injection	O
of	O
3	O
or	O
5	O
mug	O
VgR	O
double	O
-	O
stranded	O
RNA	O
per	O
insect	O
in	O
4	O
(	O
th	O
)	O
or	O
6	O
(	O
th	O
)	O
day	O
pupae	O
.	O

RNAi	O
of	O
SlVgR	O
led	O
to	O
a	O
phenotype	O
characterized	O
by	O
high	O
Vg	O
accumulation	O
in	O
the	O
haemolymph	O
,	O
low	O
Vg	O
deposition	O
in	O
the	O
ovary	O
and	O
the	O
failure	O
of	O
insect	O
spawning	O
.	O

These	O
results	O
mean	O
that	O
VgR	O
is	O
critical	O
for	O
binding	O
Vg	O
and	O
transporting	O
it	O
into	O
the	O
oocytes	O
of	O
the	O
insect	O
ovary	O
,	O
thus	O
playing	O
an	O
important	O
role	O
in	O
insect	O
reproduction	O
.	O

Rapid	O
detection	O
of	O
Newcastle	B
disease	I
virus	I
replication	O
in	O
embryonated	O
chicken	B
eggs	O
using	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
.	O

Newcastle	B
disease	I
virus	I
(	O
NDV	B
)	O
,	O
an	O
avian	O
paramyxovirus	O
,	O
is	O
an	O
economically	O
important	O
disease	O
of	O
poultry	B
globally	O
.	O

Rapid	O
methods	O
to	O
detect	O
and	O
differentiate	O
the	O
virus	O
are	O
important	O
to	O
curtail	O
the	O
spread	O
of	O
this	O
virus	O
.	O

Nucleic	O
acid	O
based	O
detection	O
methods	O
are	O
routinely	O
employed	O
for	O
diagnosis	O
that	O
suffer	O
from	O
the	O
disadvantage	O
of	O
failure	O
to	O
discriminate	O
viable	O
virus	O
and	O
non	O
-	O
infectious	O
genome	O
.	O

However	O
,	O
virus	O
isolation	O
remains	O
the	O
gold	O
standard	O
for	O
diagnosis	O
of	O
field	O
outbreaks	O
.	O

The	O
sensitivity	O
of	O
virus	O
isolation	O
was	O
combined	O
with	O
nucleic	O
acid	O
based	O
detection	O
methods	O
so	O
that	O
the	O
time	O
taken	O
for	O
confirmatory	O
diagnosis	O
could	O
be	O
considerably	O
reduced	O
while	O
increasing	O
sensitivity	O
.	O

Quantitative	O
real	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
qRT	O
-	O
PCR	O
)	O
and	O
conventional	O
RT	O
-	O
PCR	O
techniques	O
were	O
compared	O
for	O
the	O
detection	O
of	O
NDV	B
genome	O
replication	O
in	O
9	O
-	O
11-day	O
-	O
old	O
embryonated	O
chicken	B
eggs	O
(	O
ECE	O
)	O
using	O
the	O
nucleoprotein	O
(	O
NP	O
)	O
gene	O
of	O
the	O
virus	O
as	O
a	O
target	O
.	O

The	O
results	O
suggest	O
that	O
at	O
least	O
two	O
to	O
fourfold	O
increase	O
in	O
cycle	O
threshold	O
(	O
C	O
(	O
t	O
)	O
)	O
values	O
over	O
the	O
baseline	O
C	O
(	O
t	O
)	O
value	O
of	O
samples	O
lacking	O
infectious	O
virus	O
,	O
would	O
indicate	O
live	O
NDV	B
replication	O
.	O

The	O
limit	O
of	O
detection	O
of	O
NDV	B
replication	O
using	O
qRT	O
-	O
PCR	O
was	O
1x10	O
(	O
4.0	O
)	O
mean	O
embryo	O
infective	O
doses	O
(	O
EID	O
(	O
50	O
)	O
)	O
.	O

The	O
earliest	O
time	O
point	O
when	O
live	O
virus	O
replication	O
was	O
detectable	O
by	O
qRT	O
-	O
PCR	O
or	O
RT	O
-	O
PCR	O
was	O
30h	O
post	O
-	O
inoculation	O
in	O
ECE	O
.	O

Ste50	O
adaptor	O
protein	O
governs	O
sexual	O
differentiation	O
of	O
Cryptococcus	B
neoformans	I
via	O
the	O
pheromone	O
-	O
response	O
MAPK	O
signaling	O
pathway	O
.	O

The	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathways	O
control	O
diverse	O
cellular	O
functions	O
in	O
pathogenic	O
fungi	O
,	O
including	O
sexual	O
differentiation	O
,	O
stress	O
response	O
,	O
and	O
maintenance	O
of	O
cell	O
wall	O
integrity	O
.	O

Here	O
we	O
characterized	O
a	O
Cryptococcus	B
neoformans	I
gene	O
,	O
which	O
is	O
homologous	O
to	O
the	O
yeast	O
Ste50	O
that	O
is	O
known	O
to	O
play	O
an	O
important	O
role	O
in	O
mating	O
pheromone	O
response	O
and	O
stress	O
response	O
as	O
an	O
adaptor	O
protein	O
to	O
the	O
Ste11	O
MAPK	O
kinase	O
kinase	O
in	O
Saccharomyces	B
cerevisiae	I
.	O

The	O
C.	B
neoformans	I
Ste50	O
was	O
not	O
involved	O
in	O
any	O
of	O
the	O
stress	O
responses	O
or	O
virulence	O
factor	O
production	O
(	O
capsule	O
and	O
melanin	O
)	O
that	O
are	O
controlled	O
by	O
the	O
HOG	O
and	O
Ras	O
/	O
cAMP	O
signaling	O
pathways	O
.	O

However	O
,	O
Ste50	O
was	O
required	O
for	O
mating	O
in	O
both	O
serotype	B
A	O
and	O
serotype	B
D	I
C.	I
neoformans	I
strains	O
.	O

The	O
ste50Delta	O
mutant	O
was	O
completely	O
defective	O
in	O
cell	O
-	O
cell	O
fusion	O
and	O
mating	O
pheromone	O
production	O
.	O

Double	O
mutation	O
of	O
the	O
STE50	O
gene	O
blocked	O
increased	O
production	O
of	O
pheromone	O
and	O
the	O
hyper	O
-	O
filamentation	O
phenotype	O
of	O
cells	O
deleted	O
of	O
the	O
CRG1	O
gene	O
,	O
which	O
encodes	O
the	O
RGS	O
protein	O
that	O
negatively	O
regulates	O
pheromone	O
responsive	O
G	O
-	O
protein	O
signaling	O
via	O
the	O
MAPK	O
pathway	O
.	O

Regardless	O
of	O
the	O
presence	O
of	O
the	O
basidiomycota	O
-	O
specific	O
SH3	O
domains	O
of	O
Ste50	O
that	O
are	O
known	O
to	O
be	O
required	O
for	O
full	O
virulence	O
of	O
Ustilago	B
maydis	I
,	O
Ste50	O
was	O
dispensable	O
for	O
virulence	O
of	O
C.	B
neoformans	I
in	O
a	O
murine	O
model	O
of	O
cryptococcosis	O
.	O

In	O
conclusion	O
,	O
the	O
Ste50	O
adaptor	O
protein	O
controls	O
sexual	O
differentiation	O
of	O
C.	B
neoformans	I
via	O
the	O
pheromone	O
-	O
responsive	O
MAPK	O
pathway	O
but	O
is	O
not	O
required	O
for	O
virulence	O
.	O

The	O
role	O
of	O
abscisic	O
acid	O
and	O
water	O
stress	O
in	O
root	O
herbivore	O
-	O
induced	O
leaf	O
resistance	O
.	O

*	O
Herbivore	O
-	O
induced	O
systemic	O
resistance	O
occurs	O
in	O
many	O
plants	O
and	O
is	O
commonly	O
assumed	O
to	O
be	O
adaptive	O
.	O

The	O
mechanisms	O
triggered	O
by	O
leaf	O
-	O
herbivores	O
that	O
lead	O
to	O
systemic	O
resistance	O
are	O
largely	O
understood	O
,	O
but	O
it	O
remains	O
unknown	O
how	O
and	O
why	O
root	O
herbivory	O
also	O
increases	O
resistance	O
in	O
leaves	O
.	O

*	O
To	O
resolve	O
this	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
the	O
root	O
herbivore	O
Diabrotica	B
virgifera	I
induces	O
resistance	O
against	O
lepidopteran	O
herbivores	O
in	O
the	O
leaves	O
of	O
Zea	B
mays	I
.	O

*	O
Diabrotica	B
virgifera	I
infested	O
plants	O
suffered	O
less	O
aboveground	O
herbivory	O
in	O
the	O
field	O
and	O
showed	O
reduced	O
growth	O
of	O
Spodoptera	B
littoralis	I
caterpillars	O
in	O
the	O
laboratory	O
.	O

Root	O
herbivory	O
did	O
not	O
lead	O
to	O
a	O
jasmonate	O
-	O
dependent	O
response	O
in	O
the	O
leaves	O
,	O
but	O
specifically	O
triggered	O
water	O
loss	O
and	O
abscisic	O
acid	O
(	O
ABA	O
)	O
accumulation	O
.	O

The	O
induction	O
of	O
ABA	O
by	O
itself	O
was	O
partly	O
responsible	O
for	O
the	O
induction	O
of	O
leaf	O
defenses	O
,	O
but	O
not	O
for	O
the	O
resistance	O
against	O
S.	B
littoralis	I
.	O

Root	O
-	O
herbivore	O
induced	O
hydraulic	O
changes	O
in	O
the	O
leaves	O
,	O
however	O
,	O
were	O
crucial	O
for	O
the	O
increase	O
in	O
insect	O
resistance	O
.	O

*	O
We	O
conclude	O
that	O
the	O
induced	O
leaf	O
resistance	O
after	O
root	O
feeding	O
is	O
the	O
result	O
of	O
hydraulic	O
changes	O
,	O
which	O
reduce	O
the	O
quality	O
of	O
the	O
leaves	O
for	O
chewing	O
herbivores	O
.	O

This	O
finding	O
calls	O
into	O
question	O
whether	O
root	O
-	O
herbivore	O
induced	O
leaf	O
-	O
resistance	O
is	O
an	O
evolved	O
response	O
.	O

Introduced	O
brown	B
trout	I
alter	O
native	O
acanthocephalan	O
infections	O
in	O
native	O
fish	O
.	O

1	O
.	O

Native	O
parasite	O
acquisition	O
provides	O
introduced	O
species	O
with	O
the	O
potential	O
to	O
modify	O
native	O
host	O
-	O
parasite	O
dynamics	O
by	O
acting	O
as	O
parasite	O
reservoirs	O
(	O
with	O
the	O
'	O
spillback	O
'	O
of	O
infection	O
increasing	O
the	O
parasite	O
burdens	O
of	O
native	O
hosts	O
)	O
or	O
sinks	O
(	O
with	O
the	O
'	O
dilution	O
'	O
of	O
infection	O
decreasing	O
the	O
parasite	O
burdens	O
of	O
native	O
hosts	O
)	O
of	O
infection	O
.	O

2	O
.	O

In	O
New	O
Zealand	O
,	O
negative	O
correlations	O
between	O
the	O
presence	O
of	O
introduced	O
brown	B
trout	I
(	O
Salmo	B
trutta	I
)	O
and	O
native	O
parasite	O
burdens	O
of	O
the	O
native	O
roundhead	B
galaxias	I
(	O
Galaxias	B
anomalus	I
)	O
have	O
been	O
observed	O
,	O
suggesting	O
that	O
parasite	O
dilution	O
is	O
occurring	O
.	O

3	O
.	O

We	O
used	O
a	O
multiple	O
-	O
scale	O
approach	O
combining	O
field	O
observations	O
,	O
experimental	O
infections	O
and	O
dynamic	O
population	O
modelling	O
to	O
investigate	O
whether	O
native	O
Acanthocephalus	O
galaxii	O
acquisition	O
by	O
brown	B
trout	I
alters	O
host	O
-	O
parasite	O
dynamics	O
in	O
native	O
roundhead	B
galaxias	I
.	O

4	O
.	O
Field	O
observations	O
demonstrated	O
higher	O
infection	O
intensity	O
in	O
introduced	O
trout	O
than	O
in	O
native	B
galaxias	I
,	O
but	O
only	O
small	O
,	O
immature	O
A.	O
galaxii	O
were	O
present	O
in	O
trout	B
.	O

Experimental	O
infections	O
also	O
demonstrated	O
that	O
A.	O
galaxii	O
does	O
not	O
mature	O
in	O
trout	B
,	O
although	O
parasite	O
establishment	O
and	O
initial	O
growth	O
were	O
similar	O
in	O
the	O
two	O
hosts	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
trout	B
may	O
serve	O
as	O
an	O
infection	O
sink	O
for	O
the	O
native	O
parasite	O
.	O

5	O
.	O

However	O
,	O
dynamic	O
population	O
modelling	O
predicts	O
that	O
A.	O
galaxii	O
infections	O
in	O
native	O
galaxias	B
should	O
at	O
most	O
only	O
be	O
slightly	O
reduced	O
by	O
dilution	O
in	O
the	O
presence	O
of	O
trout	B
.	O

Rather	O
,	O
model	O
exploration	O
indicates	O
parasite	O
densities	O
in	O
galaxias	B
are	O
highly	O
sensitive	O
to	O
galaxias	B
predation	O
on	O
infected	O
amphipods	O
,	O
and	O
to	O
relative	O
abundances	O
of	O
galaxias	B
and	O
trout	B
.	O

Hence	O
,	O
trout	B
presence	O
may	O
instead	O
reduce	O
parasite	O
burdens	O
in	O
galaxias	B
by	O
either	O
reducing	O
galaxias	B
density	O
or	O
by	O
altering	O
galaxias	B
foraging	O
behaviour	O
.	O

Host	O
phylogeography	O
and	O
beta	O
diversity	O
in	O
avian	O
haemosporidian	O
(	O
Plasmodiidae	O
)	O
assemblages	O
of	O
the	O
Lesser	O
Antilles	O
.	O

1	O
.	O

We	O
estimated	O
the	O
correlation	O
between	O
host	O
phylogeographical	O
structure	O
and	O
beta	O
diversity	O
of	O
avian	O
haemosporidian	O
assemblages	O
of	O
passerine	O
birds	O
to	O
determine	O
the	O
degree	O
to	O
which	O
parasite	O
communities	O
change	O
with	O
host	O
evolution	O
,	O
expressed	O
as	O
genetic	O
divergence	O
between	O
island	O
populations	O
,	O
and	O
we	O
investigated	O
whether	O
differences	O
among	O
islands	O
in	O
the	O
haemosporidia	O
of	O
a	O
particular	O
host	O
species	O
reflect	O
beta	O
diversity	O
in	O
the	O
entire	O
parasite	O
assemblage	O
,	O
beta	O
diversity	O
in	O
vectors	O
,	O
turnover	O
of	O
bird	O
species	O
and/or	O
geographical	O
distance	O
.	O

2	O
.	O

We	O
used	O
Mantel	O
tests	O
to	O
assess	O
the	O
significance	O
of	O
partial	O
correlations	O
between	O
host	O
nucleotide	O
difference	O
(	O
based	O
on	O
cytochrome	O
b	O
)	O
and	O
haemosporidian	O
(	O
Haemoproteus	O
spp	O
.	O
and	O
Plasmodium	O
spp	O
.	O
)	O
mitochondrial	O
lineage	O
beta	O
diversity	O
within	O
a	O
given	O
host	O
species	O
and	O
between	O
Plasmodium	O
mitochondrial	O
lineage	O
beta	O
diversity	O
and	O
mosquito	O
and	O
bird	O
species	O
beta	O
diversity	O
(	O
or	O
turnover	O
)	O
.	O

Three	O
abundant	O
and	O
widespread	O
host	O
species	O
(	O
Tiaris	B
bicolor	I
,	O
Coereba	B
flaveola	I
and	O
Loxigilla	B
noctis	I
/	O
barbadensis	B
)	O
were	O
included	O
in	O
the	O
study	O
.	O

Haemosporidian	O
lineage	O
beta	O
diversity	O
among	O
nine	O
islands	O
was	O
assessed	O
using	O
the	O
Chao	O
-	O
Jaccard	O
,	O
Chao	O
-	O
Sorensen	O
and	O
Morisita	O
-	O
Horn	O
indices	O
of	O
community	O
similarity	O
.	O

Beta	O
diversity	O
indices	O
of	O
mosquito	O
species	O
and	O
turnover	O
of	O
bird	O
species	O
were	O
calculated	O
from	O
data	O
in	O
published	O
records	O
and	O
field	O
guides	O
.	O

3	O
.	O

In	O
Loxigilla	O
spp	O
.	O
,	O
we	O
found	O
a	O
positive	O
correlation	O
with	O
geographical	O
distance	O
and	O
an	O
unexpected	O
negative	O
correlation	O
between	O
haemosporidian	O
beta	O
diversity	O
and	O
host	O
genetic	O
distance	O
.	O

Tiaris	B
bicolor	I
exhibited	O
a	O
significant	O
positive	O
correlation	O
between	O
haemosporidian	O
beta	O
diversity	O
and	O
beta	O
diversity	O
within	O
the	O
entire	O
parasite	O
assemblage	O
.	O

We	O
did	O
not	O
find	O
significant	O
correlations	O
between	O
parasite	O
beta	O
diversity	O
and	O
mosquito	O
beta	O
diversity	O
or	O
bird	O
species	O
turnover	O
.	O

4	O
.	O

Host	O
phylogeographical	O
structure	O
does	O
not	O
appear	O
to	O
drive	O
within	O
-	O
host	O
beta	O
diversity	O
of	O
haemosporidian	O
lineages	O
.	O

Instead	O
,	O
the	O
array	O
of	O
parasites	O
on	O
one	O
host	O
can	O
reflect	O
the	O
haemosporidian	O
assemblage	O
on	O
other	O
hosts	O
.	O

Analysis	O
of	O
expressed	O
sequence	O
tags	O
from	O
Maize	B
mosaic	I
rhabdovirus	I
-	O
infected	O
gut	O
tissues	O
of	O
Peregrinus	B
maidis	I
reveals	O
the	O
presence	O
of	O
key	O
components	O
of	O
insect	O
innate	O
immunity	O
.	O

The	O
corn	B
planthopper	I
,	O
Peregrinus	B
maidis	I
,	O
causes	O
direct	O
feeding	O
damage	O
to	O
plants	O
and	O
transmits	O
Maize	B
mosaic	I
rhabdovirus	I
(	I
MMV	I
)	O
in	O
a	O
persistent	O
-	O
propagative	O
manner	O
.	O

MMV	B
must	O
cross	O
several	O
insect	O
tissue	O
layers	O
for	O
successful	O
transmission	O
to	O
occur	O
,	O
and	O
the	O
gut	O
serves	O
as	O
an	O
important	O
barrier	O
for	O
rhabdovirus	O
transmission	O
.	O

In	O
order	O
to	O
facilitate	O
the	O
identification	O
of	O
proteins	O
that	O
may	O
interact	O
with	O
MMV	B
either	O
by	O
facilitating	O
acquisition	O
or	O
responding	O
to	O
virus	O
infection	O
,	O
we	O
generated	O
and	O
analysed	O
the	O
gut	O
transcriptome	O
of	O
P.	B
maidis	I
.	O

From	O
two	O
normalized	O
cDNA	O
libraries	O
,	O
we	O
generated	O
a	O
P.	B
maidis	I
gut	O
transcriptome	O
composed	O
of	O
20,771	O
expressed	O
sequence	O
tags	O
(	O
ESTs	O
)	O
.	O

Assembly	O
of	O
the	O
sequences	O
yielded	O
1860	O
contigs	O
and	O
14,032	O
singletons	O
,	O
and	O
biological	O
roles	O
were	O
assigned	O
to	O
5793	O
(	O
36	O
%	O
)	O
.	O

Comparison	O
of	O
P.	B
maidis	I
ESTs	O
with	O
other	O
insect	O
amino	O
acid	O
sequences	O
revealed	O
that	O
P.	B
maidis	I
shares	O
greatest	O
sequence	O
similarity	O
with	O
another	O
hemipteran	O
,	O
the	O
brown	B
planthopper	I
Nilaparvata	B
lugens	I
.	O

We	O
identified	O
202	O
P.	B
maidis	I
transcripts	O
with	O
putative	O
homology	O
to	O
proteins	O
associated	O
with	O
insect	O
innate	O
immunity	O
,	O
including	O
those	O
implicated	O
in	O
the	O
Toll	O
,	O
Imd	O
,	O
JAK	O
/	O
STAT	O
,	O
Jnk	O
and	O
the	O
small	O
-	O
interfering	O
RNA	O
-	O
mediated	O
pathways	O
.	O

Sequence	O
comparisons	O
between	O
our	O
P.	B
maidis	I
gut	O
EST	O
collection	O
and	O
the	O
currently	O
available	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
EST	O
database	O
collection	O
for	O
Ni	B
.	I

lugens	B
revealed	O
that	O
a	O
pathogen	O
recognition	O
receptor	O
in	O
the	O
Imd	O
pathway	O
,	O
peptidoglycan	O
recognition	O
protein	O
-	O
long	O
class	O
(	O
PGRP	O
-	O
LC	O
)	O
,	O
is	O
present	O
in	O
these	O
two	O
members	O
of	O
the	O
family	O
Delphacidae	O
;	O
however	O
,	O
these	O
recognition	O
receptors	O
are	O
lacking	O
in	O
the	O
model	O
hemipteran	O
Acyrthosiphon	B
pisum	I
.	O

In	O
addition	O
,	O
we	O
identified	O
sequences	O
in	O
the	O
P.	B
maidis	I
gut	O
transcriptome	O
that	O
share	O
significant	O
amino	O
acid	O
sequence	O
similarities	O
with	O
the	O
rhabdovirus	O
receptor	O
molecule	O
,	O
acetylcholine	O
receptor	O
(	O
AChR	O
)	O
,	O
found	O
in	O
other	O
hosts	O
.	O

This	O
EST	O
analysis	O
sheds	O
new	O
light	O
on	O
immune	O
response	O
pathways	O
in	O
hemipteran	O
guts	O
that	O
will	O
be	O
useful	O
for	O
further	O
dissecting	O
innate	O
defence	O
response	O
pathways	O
to	O
rhabdovirus	O
infection	O
.	O

Proteomics	O
of	O
cryoprotective	O
dehydration	O
in	O
Megaphorura	B
arctica	I
Tullberg	O
1876	O
(	O
Onychiuridae	O
:	O
Collembola	O
)	O
.	O

The	O
Arctic	B
springtail	I
,	O
Megaphorura	B
arctica	I
Tullberg	O
1876	O
(	O
Onychiuridae	O
:	O
Collembola	O
)	O
,	O
is	O
one	O
of	O
the	O
few	O
organisms	O
known	O
to	O
survive	O
the	O
extreme	O
stresses	O
of	O
its	O
environment	O
by	O
using	O
cryoprotective	O
dehydration	O
.	O

We	O
have	O
undertaken	O
a	O
proteomics	O
study	O
comparing	O
M.	B
arctica	I
,	O
acclimated	O
at	O
-2	O
^	O
0C	O
,	O
the	O
temperature	O
known	O
to	O
induce	O
the	O
production	O
of	O
the	O
anhydroprotectant	O
trehalose	O
in	O
this	O
species	O
,	O
and	O
-6	O
^	O
0C	O
,	O
the	O
temperature	O
at	O
which	O
trehalose	O
expression	O
plateaus	O
,	O
against	O
control	O
animals	O
acclimated	O
at	O
+	O
5	O
^	O
0C	O
.	O

Using	O
difference	O
gel	O
electrophoresis	O
,	O
and	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
,	O
we	O
identified	O
three	O
categories	O
of	O
differentially	O
expressed	O
proteins	O
with	O
specific	O
functions	O
,	O
up	O
-	O
regulated	O
in	O
both	O
the	O
-2	O
^	O
0C	O
and	O
-6	O
^	O
0C	O
animals	O
,	O
that	O
were	O
involved	O
in	O
metabolism	O
,	O
membrane	O
transport	O
and	O
protein	O
folding	O
.	O

Proteins	O
involved	O
in	O
cytoskeleton	O
organisation	O
were	O
only	O
up	O
-	O
regulated	O
in	O
the	O
-6	O
^	O
0C	O
animals	O
.	O

Genetic	O
analysis	O
of	O
the	O
xenobiotic	O
resistance	O
-	O
associated	O
ABC	O
gene	O
subfamilies	O
of	O
the	O
Lepidoptera	O
.	O

Some	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporters	O
of	O
subfamilies	O
B	O
,	O
C	O
and	O
G	O
confer	O
resistance	O
to	O
xenobiotics	O
including	O
insecticides	O
.	O

We	O
identified	O
genes	O
of	O
these	O
subfamilies	O
expressed	O
by	O
the	O
lepidopterans	O
Trichoplusia	B
ni	I
and	O
Bombyx	B
mori	I
.	O

The	O
B.	B
mori	I
genome	O
includes	O
eight	O
,	O
six	O
and	O
13	O
ABC	O
-	O
B	O
,	O
-C	O
and	O
-G	O
genes	O
,	O
respectively	O
,	O
which	O
encode	O
P	O
-	O
glycoprotein	O
,	O
multidrug	O
resistance	O
protein	O
,	O
MRP	O
,	O
and	O
breast	O
cancer	O
resistance	O
protein	O
,	O
BCRP	O
,	O
homologues	O
.	O

Among	O
the	O
ABC	O
-	O
C	O
and	O
-G	O
subfamilies	O
,	O
gene	O
duplication	O
contributes	O
to	O
protein	O
diversity	O
.	O

We	O
have	O
identified	O
three	O
ABC	O
-	O
B	O
and	O
two	O
ABC	O
-	O
C	O
T.	B
ni	I
genes	O
.	O

Analyses	O
of	O
the	O
T.	B
ni	I
MRP	O
(	O
TrnMRP	O
)	O
revealed	O
unique	O
features	O
,	O
including	O
the	O
potential	O
for	O
TrnMRP4	O
hyperglycosylation	O
and	O
the	O
alternative	O
splicing	O
of	O
TrnMRP1	O
.	O

Taken	O
together	O
,	O
these	O
attributes	O
of	O
moth	O
multidrug	O
resistance	O
-	O
associated	O
ABCs	O
may	O
confer	O
distinct	O
functional	O
capacities	O
to	O
xenobiotic	O
efflux	O
.	O

El	O
Nino	O
in	O
the	O
warm	O
tropics	O
:	O
local	O
sea	O
temperature	O
predicts	O
breeding	O
parameters	O
and	O
growth	O
of	O
blue	B
-	I
footed	I
boobies	I
.	O

1	O
.	O

There	O
is	O
increasing	O
interest	O
in	O
the	O
impacts	O
of	O
El	O
Nino	O
Southern	O
Oscillation	O
(	O
ENSO	O
)	O
on	O
reproduction	O
of	O
apical	O
predators	O
such	O
as	O
seabirds	O
and	O
marine	O
mammals	O
.	O

Long	O
-	O
term	O
studies	O
documenting	O
ENSO	O
effects	O
on	O
reproduction	O
of	O
seabirds	O
in	O
the	O
warm	O
tropics	O
are	O
scarce	O
,	O
and	O
differential	O
sensitivity	O
of	O
breeding	O
parameters	O
to	O
ENSO	O
has	O
rarely	O
been	O
explored	O
.	O

2	O
.	O
Analysis	O
of	O
18	O
years	O
of	O
breeding	O
data	O
from	O
a	O
colony	O
of	O
the	O
blue	B
-	I
footed	I
booby	I
Sula	B
nebouxii	I
(	O
Milne	O
-	O
Edwards	O
)	O
showed	O
a	O
delay	O
in	O
onset	O
of	O
breeding	O
when	O
the	O
global	O
Southern	O
Oscillation	O
Index	O
was	O
negative	O
;	O
each	O
unit	O
of	O
the	O
atmospheric	O
pressure	O
differential	O
(	O
hPa	O
)	O
across	O
the	O
Pacific	O
Ocean	O
meant	O
a	O
delay	O
of	O
7	O
days	O
.	O

3	O
.	O
ENSO	O
conditions	O
also	O
produced	O
declines	O
in	O
breeding	O
participation	O
,	O
clutch	O
size	O
,	O
brood	O
size	O
,	O
hatching	O
success	O
and	O
fledging	O
success	O
,	O
especially	O
when	O
surface	O
waters	O
surrounding	O
the	O
colony	O
were	O
warmer	O
during	O
winter	O
and	O
spring	O
.	O

Each	O
additional	O
degree	O
(	O
^0C	O
)	O
of	O
water	O
temperature	O
produced	O
a	O
reduction	O
of	O
0.45	O
fledglings	O
per	O
nest	O
.	O

Different	O
breeding	O
parameters	O
were	O
sensitive	O
to	O
ENSO	O
indices	O
in	O
different	O
blocks	O
of	O
months	O
.	O

4	O
.	O

Warming	O
of	O
local	O
waters	O
during	O
the	O
winter	O
was	O
associated	O
with	O
decline	O
in	O
ocean	O
productivity	O
in	O
the	O
current	O
year	O
and	O
the	O
following	O
year	O
,	O
consistent	O
with	O
ENSO	O
impacts	O
on	O
breeding	O
parameters	O
being	O
mediated	O
by	O
effects	O
on	O
local	O
productivity	O
and	O
prey	O
availability	O
.	O

However	O
,	O
there	O
was	O
no	O
evidence	O
of	O
lagged	O
effects	O
of	O
ENSO	O
on	O
any	O
breeding	O
parameter	O
.	O

5	O
.	O

Comparison	O
of	O
5	O
years	O
revealed	O
that	O
when	O
local	O
surface	O
waters	O
were	O
warm	O
,	O
chicks	O
grew	O
more	O
slowly	O
,	O
but	O
no	O
effects	O
of	O
ENSO	O
on	O
weight	O
and	O
size	O
of	O
eggs	O
were	O
evident	O
in	O
data	O
of	O
9	O
and	O
7	O
years	O
,	O
respectively	O
.	O

6	O
.	O

Our	O
findings	O
extend	O
evidence	O
of	O
impacts	O
of	O
ENSO	O
on	O
seabird	O
reproduction	O
to	O
the	O
eastern	O
tropical	O
Pacific	O
and	O
indicate	O
that	O
several	O
breeding	O
parameters	O
of	O
blue	B
-	I
footed	I
boobies	I
(	O
but	O
not	O
egg	O
size	O
)	O
are	O
affected	O
in	O
the	O
short	O
term	O
by	O
ENSO	O
conditions	O
,	O
particularly	O
by	O
local	O
anomalies	O
in	O
sea	O
surface	O
temperature	O
associated	O
with	O
decline	O
in	O
ocean	O
productivity	O
.	O

Amnibacterium	B
kyonggiense	I
gen.	I
nov.	I
,	I
sp.	I
nov.	I
,	O
a	O
new	O
member	O
of	O
the	O
family	O
Microbacteriaceae	O
.	O

A	O
Gram	O
-	O
positive	O
,	O
non	O
-	O
motile	O
bacterium	O
,	O
designated	O
KSL51201	B
-	I
037	I
(	I
T	I
)	O
,	O
was	O
isolated	O
from	O
Anyang	O
stream	O
,	O
Republic	O
of	O
Korea	O
,	O
and	O
was	O
characterized	O
using	O
a	O
polyphasic	O
taxonomic	O
approach	O
.	O

Comparative	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
showed	O
that	O
strain	O
KSL51201	B
-	I
037	I
(	I
T	I
)	O
belonged	O
to	O
the	O
family	O
Microbacteriaceae	O
of	O
the	O
class	O
Actinobacteria	O
and	O
exhibited	O
96.9	O
%	O
gene	O
sequence	O
similarity	O
to	O
Labedella	B
gwakjiensis	I
KSW2	I
-	I
17	I
(	I
T	I
)	O
,	O
96.0	O
%	O
to	O
Leifsonia	B
ginsengi	I
wged11	I
(	I
T	I
)	O
and	O
95.9	O
%	O
to	O
Microterricola	B
viridarii	I
KV-677	I
(	I
T	I
)	O
.	O

The	O
G+C	O
content	O
of	O
the	O
genomic	O
DNA	O
was	O
72.7	O
mol%	O
.	O

Strain	O
KSL51201	B
-	I
037	I
(	I
T	I
)	O
had	O
l-2,4-diaminobutyric	O
acid	O
as	O
the	O
diagnostic	O
cell	O
-	O
wall	O
diamino	O
acid	O
,	O
MK-11	O
and	O
MK-12	O
as	O
the	O
major	O
menaquinones	O
,	O
anteiso	O
-	O
C	O
(	O
15	O
:	O
0	O
)	O
(	O
47.8	O
%	O
)	O
and	O
iso	O
-	O
C	O
(	O
16	O
:	O
0	O
)	O
(	O
24.0	O
%	O
)	O
as	O
the	O
major	O
fatty	O
acids	O
and	O
phosphatidylglycerol	O
and	O
three	O
unknown	O
phospholipids	O
as	O
the	O
major	O
polar	O
lipids	O
.	O

On	O
the	O
basis	O
of	O
phenotypic	O
and	O
genotypic	O
properties	O
and	O
phylogenetic	O
distinctiveness	O
,	O
it	O
is	O
suggested	O
that	O
strain	O
KSL51201	B
-	I
037	I
(	I
T	I
)	O
represents	O
a	O
novel	O
species	O
of	O
a	O
new	O
genus	O
in	O
the	O
family	O
Microbacteriaceae	O
for	O
which	O
the	O
name	O
Amnibacterium	B
kyonggiense	I
gen.	I
nov.	I
,	I
sp.	I
nov.	I
is	O
proposed	O
.	O

The	O
type	O
strain	O
of	O
the	O
type	O
species	O
is	O
KSL51201	B
-	I
037	I
(	I
T	I
)	O
(	O
=	O
KEMC	O
51201	O
-	O
037	O
(	O
T	O
)	O
=JCM	O
16463	O
(	O
T	O
)	O
)	O
.	O

Nocardioides	B
caricicola	I
sp.	I
nov.	I
,	O
an	O
endophytic	O
bacterium	O
isolated	O
from	O
a	O
halophyte	O
,	O
Carex	B
scabrifolia	I
Steud	O
.	O

A	O
Gram	O
-	O
staining	O
-	O
positive	O
,	O
coccoid	O
to	O
rod	O
-	O
shaped	O
bacterium	O
,	O
designated	O
strain	O
YC6903	B
(	O
T	O
)	O
,	O
was	O
isolated	O
from	O
a	O
halophytic	O
plant	O
(	O
Carex	B
scabrifolia	I
Steud	O
.	O
)	O
collected	O
from	O
sand	O
dunes	O
at	O
Namhae	O
Island	O
,	O
Korea	O
,	O
and	O
its	O
taxonomic	O
position	O
was	O
investigated	O
by	O
using	O
a	O
polyphasic	O
approach	O
.	O

Strain	O
YC6903	B
(	O
T	O
)	O
grew	O
optimally	O
at	O
30	O
^0C	O
and	O
at	O
pH	O
8.0	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
indicated	O
that	O
strain	O
YC6903	B
(	O
T	O
)	O
belongs	O
to	O
the	O
genus	O
Nocardioides	O
in	O
the	O
family	O
Nocardioidaceae	O
.	O

Strain	O
YC6903	B
(	O
T	O
)	O
was	O
related	O
most	O
closely	O
to	O
Nocardioides	B
pyridinolyticus	I
OS4	I
(	O
T	O
)	O
(	O
97.0	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
)	O
,	O
Nocardioides	B
dokdonensis	I
FR1436	I
(	O
T	O
)	O
(	O
96.6	O
%	O
)	O
,	O
Nocardioides	B
aquiterrae	I
GW-9	I
(	O
T	O
)	O
(	O
96.6	O
%	O
)	O
and	O
Nocardioides	B
hankookensis	I
DS-30	I
(	O
T	O
)	O
(	O
96.6	O
%	O
)	O
.	O

The	O
cell	O
-	O
wall	O
peptidoglycan	O
contained	O
LL	O
-	O
diaminopimelic	O
acid	O
and	O
MK-8	O
(	O
H	O
(	O
4	O
)	O
)	O
was	O
the	O
major	O
respiratory	O
quinone	O
.	O

The	O
mean	O
(	O
+	O
/-SD	O
)	O
level	O
of	O
DNA	O
-	O
DNA	O
relatedness	O
between	O
strain	O
YC6903	B
(	O
T	O
)	O
and	O
N.	B
pyridinolyticus	I
OS4	I
(	O
T	O
)	O
was	O
53.5+	O
/	O
-5.5	O
%	O
.	O

The	O
predominant	O
cellular	O
fatty	O
acid	O
of	O
strain	O
YC6903	B
(	O
T	O
)	O
was	O
iso	O
-	O
C	O
(	O
16	O
:	O
0	O
)	O
(	O
28.9	O
%	O
)	O
.	O

The	O
DNA	O
G+C	O
content	O
was	O
71.7	O
mol%	O
.	O

Phenotypic	O
,	O
phylogenetic	O
and	O
chemotaxonomic	O
data	O
indicated	O
that	O
strain	O
YC6903	B
(	O
T	O
)	O
represents	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Nocardioides	O
,	O
for	O
which	O
the	O
name	O
Nocardioides	B
caricicola	I
sp.	I
nov.	I
is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
YC6903	B
(	O
T	O
)	O
(	O
=	O
KACC	O
13778	O
(	O
T	O
)	O
=	O
DSM	O
22177	O
(	O
T	O
)	O
)	O
.	O

Staphylococcus	B
aureus	I
ClpC	O
divergently	O
regulates	O
capsule	O
via	O
sae	O
and	O
codY	O
in	O
strain	O
newman	B
but	O
activates	O
capsule	O
via	O
codY	O
in	O
strain	O
UAMS-1	B
and	O
in	O
strain	O
Newman	B
with	O
repaired	O
saeS.	O
ClpC	O
is	O
an	O
ATPase	O
chaperone	O
found	O
in	O
most	O
Gram	O
-	O
positive	O
low	O
-	O
GC	O
bacteria	O
.	O

It	O
has	O
been	O
recently	O
reported	O
that	O
ClpC	O
affected	O
virulence	O
gene	O
expression	O
in	O
Staphylococcus	B
aureus	I
.	O

Here	O
we	O
report	O
that	O
ClpC	O
regulates	O
transcription	O
of	O
the	O
cap	O
operon	O
and	O
accumulation	O
of	O
capsule	O
,	O
a	O
major	O
virulence	O
factor	O
for	O
S.	B
aureus	I
.	O

As	O
virulence	O
genes	O
are	O
regulated	O
by	O
a	O
complex	O
regulatory	O
network	O
in	O
S.	B
aureus	I
,	O
we	O
have	O
used	O
capsule	O
as	O
a	O
model	O
to	O
understand	O
this	O
regulation	O
.	O

By	O
microarray	O
analyses	O
of	O
strain	O
Newman	B
,	O
we	O
found	O
that	O
ClpC	O
strongly	O
activates	O
transcription	O
of	O
the	O
sae	O
operon	O
,	O
whose	O
products	O
are	O
known	O
to	O
negatively	O
regulate	O
capsule	O
synthesis	O
in	O
this	O
strain	O
.	O

Further	O
studies	O
indicated	O
that	O
ClpC	O
repressed	O
capsule	O
production	O
by	O
activating	O
the	O
sae	O
operon	O
in	O
strain	O
Newman	B
.	O

Interestingly	O
,	O
the	O
clpC	O
gene	O
cloned	O
into	O
a	O
multiple	O
-	O
copy	O
plasmid	O
vector	O
exhibited	O
an	O
activation	O
phenotype	O
,	O
suggesting	O
that	O
ClpC	O
overexpression	O
has	O
a	O
net	O
positive	O
effect	O
.	O

In	O
the	O
absence	O
of	O
sae	O
function	O
,	O
by	O
either	O
deletion	O
or	O
correction	O
of	O
a	O
native	O
mutation	O
within	O
saeS	O
,	O
we	O
found	O
that	O
ClpC	O
had	O
a	O
positive	O
effect	O
on	O
capsule	O
production	O
.	O

Indeed	O
,	O
in	O
the	O
UAMS-1	B
strain	O
,	O
which	O
does	O
not	O
have	O
the	O
saeS	O
mutation	O
,	O
ClpC	O
functioned	O
as	O
an	O
activator	O
of	O
capsule	O
production	O
.	O

Our	O
microarray	O
analyses	O
of	O
strain	O
Newman	B
also	O
revealed	O
that	O
CodY	O
,	O
a	O
repressor	O
of	O
capsule	O
production	O
,	O
was	O
repressed	O
by	O
ClpC.	O
Using	O
genetic	O
approaches	O
,	O
we	O
showed	O
that	O
CodY	O
functioned	O
downstream	O
of	O
ClpC	O
,	O
leading	O
to	O
capsule	O
activation	O
both	O
in	O
Newman	B
and	O
in	O
UAMS-1	B
.	O

Thus	O
,	O
ClpC	O
functions	O
in	O
two	O
opposite	O
pathways	O
in	O
capsule	O
regulation	O
in	O
strain	O
Newman	B
but	O
functions	O
as	O
a	O
positive	O
activator	O
in	O
strain	O
UAMS-1	B
.	O

Characterizing	O
the	O
role	O
of	O
the	O
microtubule	O
binding	O
protein	O
Bim1	O
in	O
Cryptococcus	B
neoformans	I
.	O

During	O
sexual	O
development	O
the	O
human	B
fungal	O
pathogen	O
Cryptococcus	B
neoformans	I
undergoes	O
a	O
developmental	O
transition	O
from	O
yeast	O
-	O
form	O
growth	O
to	O
filamentous	O
growth	O
.	O

This	O
transition	O
requires	O
cellular	O
restructuring	O
to	O
form	O
a	O
filamentous	O
dikaryon	O
.	O

Dikaryotic	O
growth	O
also	O
requires	O
tightly	O
controlled	O
nuclear	O
migration	O
to	O
ensure	O
faithful	O
replication	O
and	O
dissemination	O
of	O
genetic	O
material	O
to	O
spore	O
progeny	O
.	O

Although	O
the	O
gross	O
morphological	O
changes	O
that	O
take	O
place	O
during	O
dikaryotic	O
growth	O
are	O
largely	O
known	O
,	O
the	O
molecular	O
underpinnings	O
that	O
control	O
this	O
process	O
are	O
uncharacterized	O
.	O

Here	O
we	O
identify	O
and	O
characterize	O
a	O
C.	B
neoformans	I
homolog	O
of	O
the	O
Saccharomyces	B
cerevisiae	I
BIM1	O
gene	O
,	O
and	O
establish	O
the	O
importance	O
of	O
BIM1	O
for	O
proper	O
filamentous	O
growth	O
of	O
C.	B
neoformans	I
.	O

Deletion	O
of	O
BIM1	O
leads	O
to	O
truncated	O
sexual	O
development	O
filaments	O
,	O
a	O
severe	O
defect	O
in	O
diploid	O
formation	O
,	O
and	O
a	O
block	O
in	O
monokaryotic	O
fruiting	O
.	O

Our	O
findings	O
lead	O
to	O
a	O
model	O
consistent	O
with	O
a	O
critical	O
role	O
for	O
BIM1	O
in	O
both	O
filament	O
integrity	O
and	O
nuclear	O
congression	O
that	O
is	O
mediated	O
through	O
the	O
microtubule	O
cytoskeleton	O
.	O

Improved	O
nitrogen	O
nutrition	O
enhances	O
root	O
uptake	O
,	O
root	O
-	O
to	O
-	O
shoot	O
translocation	O
and	O
remobilization	O
of	O
zinc	O
(	O
(	O
65	O
)	O
Zn	O
)	O
in	O
wheat	O
.	O

This	O
study	O
focussed	O
on	O
the	O
effect	O
of	O
increasing	O
nitrogen	O
(	O
N	O
)	O
supply	O
on	O
root	O
uptake	O
and	O
root	O
-	O
to	O
-	O
shoot	O
translocation	O
of	O
zinc	O
(	O
Zn	O
)	O
as	O
well	O
as	O
retranslocation	O
of	O
foliar	O
-	O
applied	O
Zn	O
in	O
durum	B
wheat	I
(	O
Triticum	B
durum	I
)	O
.	O

Nutrient	O
solution	O
experiments	O
were	O
conducted	O
to	O
examine	O
the	O
root	O
uptake	O
and	O
root	O
-	O
to	O
-	O
shoot	O
translocation	O
of	O
(	O
65	O
)	O
Zn	O
in	O
seedlings	O
precultured	O
with	O
different	O
N	O
supplies	O
.	O

In	O
additional	O
experiments	O
,	O
the	O
effect	O
of	O
varied	O
N	O
nutrition	O
on	O
retranslocation	O
of	O
foliar	O
-	O
applied	O
(	O
65	O
)	O
Zn	O
was	O
tested	O
at	O
both	O
the	O
vegetative	O
and	O
generative	O
stages	O
.	O

When	O
N	O
supply	O
was	O
increased	O
,	O
the	O
(	O
65	O
)	O
Zn	O
uptake	O
by	O
roots	O
was	O
enhanced	O
by	O
up	O
to	O
threefold	O
and	O
the	O
(	O
65	O
)	O
Zn	O
translocation	O
from	O
roots	O
to	O
shoots	O
increased	O
by	O
up	O
to	O
eightfold	O
,	O
while	O
plant	O
growth	O
was	O
affected	O
to	O
a	O
much	O
smaller	O
degree	O
.	O

Retranslocation	O
of	O
(	O
65	O
)	O
Zn	O
from	O
old	O
into	O
young	O
leaves	O
and	O
from	O
flag	O
leaves	O
to	O
grains	O
also	O
showed	O
marked	O
positive	O
responses	O
to	O
increasing	O
N	O
supply	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
N	O
-	O
nutritional	O
status	O
of	O
wheat	O
affects	O
major	O
steps	O
in	O
the	O
route	O
of	O
Zn	O
from	O
the	O
growth	O
medium	O
to	O
the	O
grain	O
,	O
including	O
its	O
uptake	O
,	O
xylem	O
transport	O
and	O
remobilization	O
via	O
phloem	O
.	O

Thus	O
,	O
N	O
is	O
a	O
critical	O
player	O
in	O
the	O
uptake	O
and	O
accumulation	O
of	O
Zn	O
in	O
plants	O
,	O
which	O
deserves	O
special	O
attention	O
in	O
biofortification	O
of	O
food	O
crops	O
with	O
Zn	O
.	O

UreA	O
,	O
the	O
major	O
urea	O
/	O
H+	O
symporter	O
in	O
Aspergillus	B
nidulans	I
.	O

We	O
report	O
here	O
the	O
characterization	O
of	O
UreA	O
,	O
a	O
high	O
-	O
affinity	O
urea	O
/	O
H+	O
symporter	O
of	O
Aspergillus	B
nidulans	I
.	O

The	O
deletion	O
of	O
the	O
encoding	O
gene	O
abolishes	O
urea	O
transport	O
at	O
low	O
substrate	O
concentrations	O
,	O
suggesting	O
that	O
in	O
these	O
conditions	O
UreA	O
is	O
the	O
sole	O
transport	O
system	O
specific	O
for	O
urea	O
in	O
A.	B
nidulans	I
.	O

The	O
ureA	O
gene	O
is	O
not	O
inducible	O
by	O
urea	O
or	O
its	O
precursors	O
,	O
but	O
responds	O
to	O
nitrogen	O
metabolite	O
repression	O
,	O
necessitating	O
for	O
its	O
expression	O
the	O
AreA	O
GATA	O
factor	O
.	O

In	O
contrast	O
to	O
what	O
was	O
observed	O
for	O
other	O
transporters	O
in	O
A.	B
nidulans	I
,	O
repression	O
by	O
ammonium	O
is	O
also	O
operative	O
during	O
the	O
isotropic	O
growth	O
phase	O
.	O

The	O
activity	O
of	O
UreA	O
is	O
down	O
-	O
regulated	O
post	O
-	O
translationally	O
by	O
ammonium	O
-	O
promoted	O
endocytosis	O
.	O

A	O
number	O
of	O
homologues	O
of	O
UreA	O
have	O
been	O
identified	O
in	O
A.	B
nidulans	I
and	O
other	O
Aspergilli	O
,	O
which	O
cluster	O
in	O
four	O
groups	O
,	O
two	O
of	O
which	O
contain	O
the	O
urea	O
transporters	O
characterized	O
so	O
far	O
in	O
fungi	O
and	O
plants	O
.	O

This	O
phylogeny	O
may	O
have	O
arisen	O
by	O
gene	O
duplication	O
events	O
,	O
giving	O
place	O
to	O
putative	O
transport	O
proteins	O
that	O
could	O
have	O
acquired	O
novel	O
,	O
still	O
unidentified	O
functions	O
.	O

Linking	O
disease	O
and	O
community	O
ecology	O
through	O
behavioural	O
indicators	O
:	O
immunochallenge	O
of	O
white	B
-	I
footed	I
mice	I
and	O
its	O
ecological	O
impacts	O
.	O

1	O
.	O

Pathogens	O
and	O
immune	O
challenges	O
can	O
induce	O
changes	O
in	O
host	O
phenotype	O
in	O
ways	O
that	O
indirectly	O
impact	O
important	O
community	O
interactions	O
,	O
including	O
those	O
that	O
affect	O
host	O
-	O
pathogen	O
interactions	O
.	O

2	O
.	O

To	O
explore	O
host	O
behavioural	O
response	O
to	O
immune	O
challenge	O
,	O
we	O
exposed	O
wild	O
white	B
-	I
footed	I
mice	I
(	O
Peromyscus	B
leucopus	I
)	O
to	O
an	O
immunogen	O
from	O
an	O
endemic	O
,	O
zoonotic	O
pathogen	O
,	O
the	O
spirochete	O
Borrelia	B
burgdorferi	I
.	O

White	B
-	I
footed	I
mice	I
are	O
a	O
major	O
reservoir	O
host	O
of	O
Lyme	O
disease	O
(	O
LD	O
)	O
spirochetes	O
in	O
northeastern	O
USA	O
and	O
an	O
abundant	O
member	O
of	O
forest	O
communities	O
.	O

The	O
activity	O
patterns	O
,	O
foraging	O
behaviour	O
,	O
and	O
space	O
use	O
of	O
white	B
-	I
footed	I
mice	I
have	O
implications	O
for	O
population	O
growth	O
rates	O
of	O
community	O
members	O
upon	O
which	O
mice	O
incidentally	O
prey	O
(	O
i.e.	O
gypsy	O
moths	O
and	O
native	O
thrushes	O
)	O
,	O
as	O
well	O
as	O
potentially	O
determining	O
host	O
-	O
vector	O
encounter	O
rates	O
and	O
human	B
risk	O
of	O
LD	O
.	O

3	O
.	O

Immunochallenge	O
led	O
to	O
specific	O
humoral	O
(	O
antibody	O
)	O
and	O
cellular	O
(	O
i.e.	O
elevated	O
neutrophils	O
and	O
eosinophils	O
)	O
immune	O
responses	O
,	O
supporting	O
use	O
of	O
the	O
immunogen	O
as	O
a	O
surrogate	O
for	O
pathogenic	O
infection	O
.	O

4	O
.	O

Immunochallenged	O
mice	O
had	O
reduced	O
wheel	O
-	O
running	O
activity	O
early	O
in	O
the	O
night	O
when	O
measured	O
in	O
the	O
lab	O
.	O

However	O
,	O
mouse	O
activity	O
,	O
as	O
measured	O
by	O
track	O
plates	O
in	O
natural	O
field	O
experiments	O
,	O
did	O
not	O
differ	O
between	O
mice	O
exposed	O
to	O
the	O
immunogen	O
and	O
unexposed	O
mice	O
.	O

5	O
.	O

Foraging	O
behaviour	O
of	O
wild	O
mice	O
in	O
the	O
field	O
-	O
assessed	O
with	O
giving	O
-	O
up	O
densities	O
of	O
seed	O
at	O
artificial	O
feeding	O
stations	O
-	O
was	O
affected	O
by	O
exposure	O
to	O
the	O
immunogen	O
.	O

Whereas	O
immunochallenge	O
did	O
not	O
influence	O
whether	O
foraging	O
mice	O
gained	O
information	O
on	O
patch	O
quality	O
while	O
foraging	O
,	O
it	O
led	O
to	O
reductions	O
in	O
predator	O
avoidance	O
during	O
foraging	O
,	O
suggesting	O
that	O
the	O
proportion	O
of	O
space	O
used	O
by	O
foraging	O
mice	O
may	O
be	O
greater	O
as	O
a	O
result	O
of	O
immunochallenge	O
.	O

This	O
increased	O
space	O
use	O
is	O
predicted	O
to	O
increase	O
encounter	O
rates	O
with	O
patchily	O
distributed	O
LD	O
vectors	O
(	O
ticks	O
)	O
and	O
with	O
incidental	O
prey	O
items	O
.	O

6	O
.	O

Thus	O
,	O
immunochallenge	O
in	O
white	B
-	I
footed	I
mice	I
,	O
and	O
potentially	O
pathogenic	O
infection	O
,	O
have	O
the	O
potential	O
to	O
indirectly	O
impact	O
community	O
interactions	O
,	O
including	O
those	O
important	O
for	O
pathogen	O
transmission	O
.	O

Regulation	O
and	O
function	O
of	O
Escherichia	B
coli	I
sugar	O
efflux	O
transporter	O
A	O
(	O
SetA	O
)	O
during	O
glucose	O
-	O
phosphate	O
stress	O
.	O

Accumulation	O
of	O
certain	O
nonmetabolizable	O
sugar	O
-	O
phosphates	O
(	O
including	O
alpha	O
-	O
methyl	O
glucoside-6-phosphate	O
)	O
in	O
Escherichia	O
coli	O
is	O
growth	O
inhibitory	O
and	O
elicits	O
the	O
glucose	O
-	O
phosphate	O
stress	O
response	O
.	O

The	O
transcription	O
factor	O
SgrR	O
activates	O
transcription	O
of	O
the	O
small	O
RNA	O
SgrS	O
under	O
stress	O
conditions	O
.	O

SgrS	O
represses	O
translation	O
of	O
mRNAs	O
encoding	O
sugar	O
transporters	O
.	O

The	O
sgrR	O
and	O
sgrS	O
genes	O
are	O
located	O
directly	O
upstream	O
of	O
setA	O
,	O
and	O
this	O
gene	O
organization	O
is	O
conserved	O
in	O
numerous	O
enteric	O
species	O
,	O
prompting	O
the	O
hypothesis	O
that	O
SetA	O
contributes	O
to	O
the	O
glucose	O
-	O
phosphate	O
stress	O
response	O
.	O

SetA	O
is	O
a	O
proton	O
motive	O
force	O
-	O
driven	O
efflux	O
pump	O
capable	O
of	O
transporting	O
various	O
sugars	O
and	O
sugar	O
analogs	O
in	O
vitro	O
.	O

This	O
study	O
demonstrates	O
that	O
setA	O
expression	O
is	O
induced	O
in	O
response	O
to	O
glucose	O
-	O
phosphate	O
stress	O
,	O
and	O
this	O
requires	O
SgrR.	O
Under	O
stress	O
conditions	O
,	O
setA	O
is	O
cotranscribed	O
with	O
sgrS	O
from	O
the	O
sgrS	O
promoter	O
.	O

A	O
setA	O
mutant	O
exhibits	O
a	O
growth	O
defect	O
under	O
stress	O
conditions	O
that	O
can	O
be	O
complemented	O
by	O
setA	O
in	O
trans	O
,	O
suggesting	O
that	O
SetA	O
contributes	O
to	O
the	O
optimal	O
cellular	O
recovery	O
from	O
stress	O
.	O

Despite	O
previous	O
in	O
vitro	O
evidence	O
that	O
SetA	O
can	O
promote	O
efflux	O
of	O
the	O
stress	O
-	O
causing	O
glucose	O
analog	O
alpha	O
-	O
methyl	O
glucoside	O
,	O
in	O
vivo	O
data	O
in	O
this	O
study	O
indicate	O
that	O
SetA	O
is	O
not	O
the	O
major	O
efflux	O
pump	O
responsible	O
for	O
removal	O
of	O
alpha	O
-	O
methyl	O
glucoside	O
under	O
stress	O
conditions	O
.	O

Functional	O
analysis	O
of	O
molybdopterin	O
biosynthesis	O
in	O
mycobacteria	O
identifies	O
a	O
fused	O
molybdopterin	O
synthase	O
in	O
Mycobacterium	B
tuberculosis	I
.	O

Most	O
mycobacterial	O
species	O
possess	O
a	O
full	O
complement	O
of	O
genes	O
for	O
the	O
biosynthesis	O
of	O
molybdenum	O
cofactor	O
(	O
MoCo	O
)	O
.	O

However	O
,	O
a	O
distinguishing	O
feature	O
of	O
members	O
of	O
the	O
Mycobacterium	O
tuberculosis	O
complex	O
is	O
their	O
possession	O
of	O
multiple	O
homologs	O
associated	O
with	O
the	O
first	O
two	O
steps	O
of	O
the	O
MoCo	O
biosynthetic	O
pathway	O
.	O

A	O
mutant	O
of	O
M.	B
tuberculosis	I
lacking	O
the	O
moaA1-moaD1	O
gene	O
cluster	O
and	O
a	O
derivative	O
in	O
which	O
moaD2	O
was	O
also	O
deleted	O
were	O
significantly	O
impaired	O
for	O
growth	O
in	O
media	O
containing	O
nitrate	O
as	O
a	O
sole	O
nitrogen	O
source	O
,	O
indicating	O
a	O
reduced	O
availability	O
of	O
MoCo	O
to	O
support	O
the	O
assimilatory	O
function	O
of	O
the	O
MoCo	O
-	O
dependent	O
nitrate	O
reductase	O
,	O
NarGHI	O
.	O

However	O
,	O
the	O
double	O
mutant	O
displayed	O
residual	O
respiratory	O
nitrate	O
reductase	O
activity	O
,	O
suggesting	O
that	O
it	O
retains	O
the	O
capacity	O
to	O
produce	O
MoCo	O
.	O

The	O
M.	B
tuberculosis	I
moaD	O
and	O
moaE	O
homologs	O
were	O
further	O
analyzed	O
by	O
expressing	O
these	O
genes	O
in	O
mutant	O
strains	O
of	O
M.	B
smegmatis	I
that	O
lacked	O
one	O
or	O
both	O
of	O
the	O
sole	O
molybdopterin	O
(	O
MPT	O
)	O
synthase	O
-	O
encoding	O
genes	O
,	O
moaD2	O
and	O
moaE2	O
,	O
and	O
were	O
unable	O
to	O
grow	O
on	O
nitrate	O
,	O
presumably	O
as	O
a	O
result	O
of	O
the	O
loss	O
of	O
MoCo	O
-	O
dependent	O
nitrate	O
assimilatory	O
activity	O
.	O

Expression	O
of	O
M.	B
tuberculosis	I
moaD2	O
in	O
the	O
M.	B
smegmatis	I
moaD2	O
mutant	O
and	O
of	O
M.	B
tuberculosis	I
moaE1	O
or	O
moaE2	O
in	O
the	O
M.	B
smegmatis	I
moaE2	O
mutant	O
restored	O
nitrate	O
assimilation	O
,	O
confirming	O
the	O
functionality	O
of	O
these	O
genes	O
in	O
MPT	O
synthesis	O
.	O

Expression	O
of	O
M.	B
tuberculosis	I
moaX	O
also	O
restored	O
MoCo	O
biosynthesis	O
in	O
M.	B
smegmatis	I
mutants	O
lacking	O
moaD2	O
,	O
moaE2	O
,	O
or	O
both	O
,	O
thus	O
identifying	O
MoaX	O
as	O
a	O
fused	O
MPT	O
synthase	O
.	O

By	O
implicating	O
multiple	O
synthase	O
-	O
encoding	O
homologs	O
in	O
MoCo	O
biosynthesis	O
,	O
these	O
results	O
suggest	O
that	O
important	O
cellular	O
functions	O
may	O
be	O
served	O
by	O
their	O
expansion	O
in	O
M.	B
tuberculosis	I
.	O

The	O
nodulation	O
of	O
alfalfa	O
by	O
the	O
acid	O
-	O
tolerant	O
Rhizobium	B
sp.	I
strain	I
LPU83	I
does	O
not	O
require	O
sulfated	O
forms	O
of	O
lipochitooligosaccharide	O
nodulation	O
signals	O
.	O

The	O
induction	O
of	O
root	O
nodules	O
by	O
the	O
majority	O
of	O
rhizobia	O
has	O
a	O
strict	O
requirement	O
for	O
the	O
secretion	O
of	O
symbiosis	O
-	O
specific	O
lipochitooligosaccharides	O
(	O
nodulation	O
factors	O
[	O
NFs	O
]	O
)	O
.	O

The	O
nature	O
of	O
the	O
chemical	O
substitution	O
on	O
the	O
NFs	O
depends	O
on	O
the	O
particular	O
rhizobium	O
and	O
contributes	O
to	O
the	O
host	O
specificity	O
imparted	O
by	O
the	O
NFs	O
.	O

We	O
present	O
here	O
a	O
description	O
of	O
the	O
genetic	O
organization	O
of	O
the	O
nod	O
gene	O
cluster	O
and	O
the	O
characterization	O
of	O
the	O
chemical	O
structure	O
of	O
the	O
NFs	O
associated	O
with	O
the	O
broad	O
-	O
host	O
-	O
range	O
Rhizobium	B
sp.	I
strain	I
LPU83	I
,	O
a	O
bacterium	O
capable	O
of	O
nodulating	O
at	O
least	O
alfalfa	B
,	O
bean	O
,	O
and	O
Leucena	B
leucocephala	I
.	O

The	O
nod	O
gene	O
cluster	O
was	O
located	O
on	O
the	O
plasmid	O
pLPU83b	O
.	O

The	O
organization	O
of	O
the	O
cluster	O
showed	O
synteny	O
with	O
those	O
of	O
the	O
alfalfa	B
-	O
nodulating	O
rhizobia	O
,	O
Sinorhizobium	B
meliloti	I
and	O
Sinorhizobium	B
medicae	I
.	O

Interestingly	O
,	O
the	O
strongest	O
sequence	O
similarity	O
observed	O
was	O
between	O
the	O
partial	O
nod	O
sequences	O
of	O
Rhizobium	B
mongolense	I
USDA	I
1844	I
and	O
the	O
corresponding	O
LPU83	B
nod	O
genes	O
sequences	O
.	O

The	O
phylogenetic	O
analysis	O
of	O
the	O
intergenic	O
region	O
nodEG	O
positions	O
strain	O
LPU83	B
and	O
the	O
type	O
strain	O
R.	B
mongolense	I
1844	I
in	O
the	O
same	O
branch	O
,	O
which	O
indicates	O
that	O
Rhizobium	B
sp.	I
strain	I
LPU83	I
might	O
represent	O
an	O
early	O
alfalfa	B
-	O
nodulating	O
genotype	O
.	O

The	O
NF	O
chemical	O
structures	O
obtained	O
for	O
the	O
wild	O
-	O
type	O
strain	O
consist	O
of	O
a	O
trimeric	O
,	O
tetrameric	O
,	O
and	O
pentameric	O
chitin	O
backbone	O
that	O
shares	O
some	O
substitutions	O
with	O
both	O
alfalfa-	O
and	O
bean	O
-	O
nodulating	O
rhizobia	O
.	O

Remarkably	O
,	O
while	O
in	O
strain	O
LPU83	B
most	O
of	O
the	O
NFs	O
were	O
sulfated	O
in	O
their	O
reducing	O
terminal	O
residue	O
,	O
none	O
of	O
the	O
NFs	O
isolated	O
from	O
the	O
nodH	O
mutant	O
LPU83-H	B
were	O
sulfated	O
.	O

The	O
evidence	O
obtained	O
supports	O
the	O
notion	O
that	O
the	O
sulfate	O
decoration	O
of	O
NFs	O
in	O
LPU83	B
is	O
not	O
necessary	O
for	O
alfalfa	B
nodulation	O
.	O

Plantazolicin	O
,	O
a	O
novel	O
microcin	O
B17	O
/	O
streptolysin	O
S	O
-	O
like	O
natural	O
product	O
from	O
Bacillus	B
amyloliquefaciens	I
FZB42	I
.	O

Here	O
we	O
report	O
on	O
a	O
novel	O
thiazole	O
/	O
oxazole	O
-	O
modified	O
microcin	O
(	O
TOMM	O
)	O
from	O
Bacillus	B
amyloliquefaciens	I
FZB42	I
,	O
a	O
Gram	O
-	O
positive	O
soil	O
bacterium	O
.	O

This	O
organism	O
is	O
well	O
known	O
for	O
stimulating	O
plant	O
growth	O
and	O
biosynthesizing	O
complex	O
small	O
molecules	O
that	O
suppress	O
the	O
growth	O
of	O
bacterial	O
and	O
fungal	O
plant	O
pathogens	O
.	O

Like	O
microcin	O
B17	O
and	O
streptolysin	O
S	O
,	O
the	O
TOMM	O
from	O
B.	B
amyloliquefaciens	I
FZB42	I
undergoes	O
extensive	O
posttranslational	O
modification	O
to	O
become	O
a	O
bioactive	O
natural	O
product	O
.	O

Our	O
data	O
show	O
that	O
the	O
modified	O
peptide	O
bears	O
a	O
molecular	O
mass	O
of	O
1,335	O
Da	O
and	O
displays	O
antibacterial	O
activity	O
toward	O
closely	O
related	O
Gram	O
-	O
positive	O
bacteria	O
.	O

A	O
cluster	O
of	O
12	O
genes	O
that	O
covers	O
-10	O
kb	O
is	O
essential	O
for	O
the	O
production	O
,	O
modification	O
,	O
export	O
,	O
and	O
self	O
-	O
immunity	O
of	O
this	O
natural	O
product	O
.	O

We	O
have	O
named	O
this	O
compound	O
plantazolicin	O
(	O
PZN	O
)	O
,	O
based	O
on	O
the	O
association	O
of	O
several	O
producing	O
organisms	O
with	O
plants	O
and	O
the	O
incorporation	O
of	O
azole	O
heterocycles	O
,	O
which	O
derive	O
from	O
Cys	O
,	O
Ser	O
,	O
and	O
Thr	O
residues	O
of	O
the	O
precursor	O
peptide	O
.	O

Mismatch	O
repair	O
modulation	O
of	O
MutY	O
activity	O
drives	O
Bacillus	B
subtilis	I
stationary	O
-	O
phase	O
mutagenesis	O
.	O

Stress	O
-	O
promoted	O
mutations	O
that	O
occur	O
in	O
nondividing	O
cells	O
(	O
adaptive	O
mutations	O
)	O
have	O
been	O
implicated	O
strongly	O
in	O
causing	O
genetic	O
variability	O
as	O
well	O
as	O
in	O
species	O
survival	O
and	O
evolutionary	O
processes	O
.	O

Oxidative	O
stress	O
-	O
induced	O
DNA	O
damage	O
has	O
been	O
associated	O
with	O
generation	O
of	O
adaptive	O
His	O
(	O
+	O
)	O
and	O
Met	O
(	O
+	O
)	O
but	O
not	O
Leu	O
(	O
+	O
)	O
revertants	O
in	O
strain	B
Bacillus	I
subtilis	I
YB955	I
(	I
hisC952	I
metB5	I
leuC427	I
)	O
.	O

Here	O
we	O
report	O
that	O
an	O
interplay	O
between	O
MutY	O
and	O
MutSL	O
(	O
mismatch	O
repair	O
system	O
[	O
MMR	O
]	O
)	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
production	O
of	O
adaptive	O
Leu	O
(	O
+	O
)	O
revertants	O
.	O

Essentially	O
,	O
the	O
genetic	O
disruption	O
of	O
MutY	O
dramatically	O
reduced	O
the	O
reversion	O
frequency	O
to	O
the	O
leu	O
allele	O
in	O
this	O
model	O
system	O
.	O

Moreover	O
,	O
the	O
increased	O
rate	O
of	O
adaptive	O
Leu	O
(	O
+	O
)	O
revertants	O
produced	O
by	O
a	O
MutSL	B
knockout	I
strain	I
was	O
significantly	O
diminished	O
following	O
mutY	O
disruption	O
.	O

Interestingly	O
,	O
although	O
the	O
expression	O
of	O
mutY	O
took	O
place	O
during	O
growth	O
and	O
stationary	O
phase	O
and	O
was	O
not	O
under	O
the	O
control	O
of	O
RecA	O
,	O
PerR	O
,	O
or	O
sigma	O
(	O
B	O
)	O
,	O
a	O
null	O
mutation	O
in	O
the	O
mutSL	O
operon	O
increased	O
the	O
expression	O
of	O
mutY	O
several	O
times	O
.	O

Thus	O
,	O
in	O
starved	O
cells	O
,	O
saturation	O
of	O
the	O
MMR	O
system	O
may	O
induce	O
the	O
expression	O
of	O
mutY	O
,	O
disturbing	O
the	O
balance	O
between	O
MutY	O
and	O
MMR	O
proteins	O
and	O
aiding	O
in	O
the	O
production	O
of	O
types	O
of	O
mutations	O
detected	O
by	O
reversion	O
to	O
leucine	O
prototrophy	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
MMR	O
regulation	O
of	O
the	O
mutagenic	O
/	O
antimutagenic	O
properties	O
of	O
MutY	O
promotes	O
stationary	O
-	O
phase	O
mutagenesis	O
in	O
B.	B
subtilis	I
cells	O
.	O

Structural	O
and	O
functional	O
analysis	O
of	O
the	O
type	O
III	O
secretion	O
system	O
from	O
Pseudomonas	B
fluorescens	I
Q8r1	I
-	I
96	I
.	O

Pseudomonas	B
fluorescens	I
Q8r1	I
-	I
96	I
represents	O
a	O
group	O
of	O
rhizosphere	O
strains	O
responsible	O
for	O
the	O
suppressiveness	O
of	O
agricultural	O
soils	O
to	O
take	O
-	O
all	O
disease	O
of	O
wheat	O
.	O

It	O
produces	O
the	O
antibiotic	O
2,4-diacetylphloroglucinol	O
and	O
aggressively	O
colonizes	O
the	O
roots	O
of	O
cereal	O
crops	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
the	O
genome	O
of	O
Q8r1	B
-	I
96	I
and	O
identified	O
a	O
type	O
III	O
protein	O
secretion	O
system	O
(	O
T3SS	O
)	O
gene	O
cluster	O
that	O
has	O
overall	O
organization	O
similar	O
to	O
that	O
of	O
the	O
T3SS	O
gene	O
cluster	O
of	O
the	O
plant	O
pathogen	O
Pseudomonas	B
syringae	I
.	O

We	O
also	O
screened	O
a	O
collection	O
of	O
30	O
closely	O
related	O
P.	B
fluorescens	I
strains	I
and	O
detected	O
the	O
T3SS	O
genes	O
in	O
all	O
but	O
one	O
of	O
them	O
.	O

The	O
Q8r1	B
-	I
96	I
genome	O
contained	O
ropAA	O
and	O
ropM	O
type	O
III	O
effector	O
genes	O
,	O
which	O
are	O
orthologs	O
of	O
the	O
P.	B
syringae	I
effector	O
genes	O
hopAA1	O
-	O
1	O
and	O
hopM1	O
,	O
as	O
well	O
as	O
a	O
novel	O
type	O
III	O
effector	O
gene	O
designated	O
ropB.	O
These	O
type	O
III	O
effector	O
genes	O
encoded	O
proteins	O
that	O
were	O
secreted	O
in	O
culture	O
and	O
injected	O
into	O
plant	O
cells	O
by	O
both	O
P.	B
syringae	I
and	O
Q8r1	B
-	I
96	I
T3SSs	O
.	O

The	O
Q8r1	B
-	I
96	I
T3SS	O
was	O
expressed	O
in	O
the	O
rhizosphere	O
,	O
but	O
mutants	O
lacking	O
a	O
functional	O
T3SS	O
were	O
not	O
altered	O
in	O
their	O
rhizosphere	O
competence	O
.	O

The	O
Q8r1	B
-	I
96	I
type	O
III	O
effectors	O
RopAA	O
,	O
RopB	O
,	O
and	O
RopM	O
were	O
capable	O
of	O
suppressing	O
the	O
hypersensitive	O
response	O
and	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
two	O
plant	O
immune	O
responses	O
.	O

A	O
cis	O
-	O
encoded	O
antisense	O
small	O
RNA	O
regulated	O
by	O
the	O
HP0165-HP0166	O
two	O
-	O
component	O
system	O
controls	O
expression	O
of	O
ureB	O
in	O
Helicobacter	B
pylori	I
.	O

Expression	O
of	O
urease	O
is	O
essential	O
for	O
gastric	O
colonization	O
by	O
Helicobacter	B
pylori	I
.	O

The	O
increased	O
level	O
of	O
urease	O
in	O
gastric	O
acidity	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
acid	O
activation	O
of	O
the	O
two	O
-	O
component	O
system	O
(	O
TCS	O
)	O
consisting	O
of	O
the	O
membrane	O
sensor	O
HP0165	O
and	O
its	O
response	O
regulator	O
,	O
HP0166	O
,	O
which	O
regulates	O
transcription	O
of	O
the	O
seven	O
genes	O
of	O
the	O
urease	O
gene	O
cluster	O
.	O

We	O
now	O
find	O
that	O
there	O
are	O
two	O
major	O
ureAB	O
transcripts	O
:	O
a	O
2.7-kb	O
full	O
-	O
length	O
ureAB	O
transcript	O
and	O
a	O
1.4-kb	O
truncated	O
transcript	O
lacking	O
3	O
'	O
ureB.	O
Acidic	O
pH	O
(	O
pH	O
4.5	O
)	O
results	O
in	O
a	O
significant	O
increase	O
in	O
transcription	O
of	O
ureAB	O
,	O
while	O
neutral	O
pH	O
(	O
pH	O
7.4	O
)	O
increases	O
the	O
truncated	O
1.4-kb	O
transcript	O
.	O

Northern	O
blot	O
analysis	O
with	O
sense	O
RNA	O
and	O
strand	O
-	O
specific	O
oligonucleotide	O
probes	O
followed	O
by	O
5	O
'	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
detects	O
an	O
antisense	O
small	O
RNA	O
(	O
sRNA	O
)	O
encoded	O
by	O
the	O
5	O
'	O
ureB	O
noncoding	O
strand	O
consisting	O
of	O
-290	O
nucleotides	O
(	O
5'ureB	O
-	O
sRNA	O
)	O
.	O

Deletion	O
of	O
HP0165	O
elevates	O
the	O
level	O
of	O
the	O
truncated	O
1.4-kb	O
transcript	O
along	O
with	O
that	O
of	O
the	O
5'ureB	O
-	O
sRNA	O
at	O
both	O
pH	O
7.4	O
and	O
pH	O
4.5	O
.	O

Overexpression	O
of	O
5'ureB	O
-	O
sRNA	O
increases	O
the	O
1.4-kb	O
transcript	O
,	O
decreases	O
the	O
2.7-kb	O
transcript	O
,	O
and	O
decreases	O
urease	O
activity	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
shows	O
that	O
unphosphorylated	O
HP0166	O
binds	O
specifically	O
to	O
the	O
5'ureB	O
-	O
sRNA	O
promoter	O
.	O

The	O
ability	O
of	O
the	O
HP0165-HP0166	O
TCS	O
to	O
both	O
increase	O
and	O
decrease	O
ureB	O
expression	O
at	O
low	O
and	O
high	O
pHs	O
,	O
respectively	O
,	O
facilitates	O
gastric	O
habitation	O
and	O
colonization	O
over	O
the	O
wide	O
range	O
of	O
intragastric	O
pHs	O
experienced	O
by	O
the	O
organism	O
.	O

Effects	O
of	O
deficiency	O
and	O
overdose	O
of	O
group	O
2	O
sigma	O
factors	O
in	O
triple	O
inactivation	O
strains	O
of	O
Synechocystis	B
sp.	I
strain	I
PCC	I
6803	I
.	O

Acclimation	O
of	O
cyanobacteria	O
to	O
environmental	O
changes	O
includes	O
major	O
changes	O
in	O
the	O
gene	O
expression	O
patterns	O
partly	O
orchestrated	O
by	O
the	O
replacement	O
of	O
a	O
particular	O
sigma	O
subunit	O
with	O
another	O
in	O
the	O
RNA	O
polymerase	O
holoenzyme	O
.	O

The	O
cyanobacterium	O
Synechocystis	B
sp.	I
strain	I
PCC	I
6803	I
encodes	O
nine	O
sigma	O
factors	O
,	O
all	O
belonging	O
to	O
the	O
sigma	O
(	O
70	O
)	O
family	O
.	O

Cyanobacteria	O
typically	O
encode	O
many	O
group	O
2	O
sigma	O
factors	O
that	O
closely	O
resemble	O
the	O
principal	O
sigma	O
factor	O
.	O

We	O
inactivated	O
three	O
out	O
of	O
the	O
four	O
group	O
2	O
sigma	O
factors	O
of	O
Synechocystis	O
simultaneously	O
in	O
all	O
possible	O
combinations	O
and	O
found	O
that	O
all	O
triple	O
inactivation	O
strains	O
grow	O
well	O
under	O
standard	O
conditions	O
.	O

Unlike	O
the	O
other	O
strains	O
,	O
the	O
DeltasigBCD	O
strain	O
,	O
which	O
contains	O
SigE	O
as	O
the	O
only	O
functional	O
group	O
2	O
sigma	O
factor	O
,	O
did	O
not	O
grow	O
faster	O
under	O
mixotrophic	O
than	O
under	O
autotrophic	O
conditions	O
.	O

The	O
SigB	O
and	O
SigD	O
factors	O
were	O
important	O
in	O
low	O
-	O
temperature	O
acclimation	O
,	O
especially	O
under	O
diurnal	O
light	O
rhythm	O
.	O

The	O
DeltasigBCD	O
,	O
DeltasigBCE	O
,	O
and	O
DeltasigBDE	O
strains	O
were	O
sensitive	O
to	O
high	O
-	O
light	O
-	O
induced	O
photoinhibition	O
,	O
indicating	O
a	O
central	O
role	O
of	O
the	O
SigB	O
factor	O
in	O
high	O
-	O
light	O
tolerance	O
.	O

Furthermore	O
,	O
the	O
DeltasigBCE	O
strain	O
(	O
SigD	O
is	O
the	O
only	O
functional	O
group	O
2	O
sigma	O
factor	O
)	O
appeared	O
to	O
be	O
locked	O
in	O
the	O
high	O
-	O
fluorescence	O
state	O
(	O
state	O
1	O
)	O
and	O
grew	O
slowly	O
in	O
blue	O
but	O
not	O
in	O
orange	O
or	O
white	O
light	O
.	O

Our	O
results	O
suggest	O
that	O
features	O
of	O
the	O
triple	O
inactivation	O
strains	O
can	O
be	O
categorized	O
as	O
(	O
i	O
)	O
direct	O
consequences	O
of	O
the	O
inactivation	O
of	O
a	O
particular	O
sigma	O
factor	O
(	O
s	O
)	O
and	O
(	O
ii	O
)	O
effects	O
resulting	O
from	O
the	O
higher	O
probability	O
that	O
the	O
remaining	O
group	O
2	O
sigma	O
factors	O
associate	O
with	O
the	O
RNA	O
polymerase	O
core	O
.	O

Effects	O
of	O
temperature	O
on	O
the	O
development	O
and	O
population	O
growth	O
of	O
the	O
sycamore	B
lace	I
bug	I
,	O
Corythucha	B
ciliata	I
.	O

The	O
sycamore	B
lace	I
bug	I
,	O
Corythucha	B
ciliata	I
(	O
Say	O
)	O
(	O
Hemiptera	O
:	O
Tingidae	O
)	O
,	O
is	O
an	O
important	O
invasive	O
exotic	O
pest	O
of	O
Platanus	O
(	O
Proteales	O
:	O
Platanaceae	O
)	O
trees	O
in	O
China	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effects	O
of	O
temperature	O
on	O
C.	B
ciliata	I
in	O
the	O
laboratory	O
so	O
that	O
forecasting	O
models	O
based	O
on	O
heat	O
accumulation	O
units	O
could	O
be	O
developed	O
for	O
the	O
pest	O
.	O

Development	O
and	O
fecundity	O
of	O
C.	B
ciliata	I
reared	O
on	O
leaves	O
of	O
London	B
plane	I
tree	I
(	O
Platanus	B
x	I
acerifolia	I
)	O
were	O
investigated	O
at	O
seven	O
constant	O
temperatures	O
(	O
16	O
,	O
19	O
,	O
22	O
,	O
26	O
,	O
30	O
,	O
33	O
,	O
and	O
36	O
^	O
0	O
C	O
)	O
and	O
at	O
a	O
relative	O
humidity	O
of	O
80	O
%	O
with	O
a	O
photoperiod	O
of	O
14:10	O
(	O
L	O
:	O
D	O
)	O
.	O

The	O
developmental	O
time	O
was	O
found	O
to	O
significantly	O
decrease	O
with	O
increasing	O
temperature	O
.	O

The	O
developmental	O
time	O
from	O
egg	O
hatching	O
to	O
adult	O
emergence	O
was	O
respectively	O
47.6	O
,	O
35.0	O
,	O
24.1	O
,	O
20.0	O
,	O
and	O
17.1	O
days	O
at	O
the	O
temperatures	O
of	O
19	O
,	O
22	O
,	O
26	O
,	O
30	O
,	O
and	O
33	O
^	O
0	O
C.	O
C.	B
ciliata	I
could	O
not	O
complete	O
full	O
development	O
at	O
16	O
^	O
0	O
and	O
36	O
^	O
0	O
C.	O
The	O
developmental	O
threshold	O
temperature	O
(	O
C	O
)	O
estimated	O
for	O
egg	O
-	O
to	O
-	O
adult	O
was	O
11.17	O
^	O
0	O
C	O
,	O
with	O
a	O
thermal	O
constant	O
of	O
(	O
K	O
)	O
370.57	O
degree	O
-	O
days	O
.	O

Longevity	O
of	O
females	O
was	O
found	O
to	O
be	O
the	O
shortest	O
,	O
17.7	O
days	O
at	O
33	O
^	O
0	O
C	O
and	O
the	O
longest	O
,	O
58.9	O
days	O
at	O
16	O
^	O
0	O
C	O
,	O
and	O
that	O
of	O
males	O
was	O
the	O
shortest	O
,	O
19.7	O
days	O
at	O
33	O
^	O
0	O
C	O
and	O
the	O
longest	O
,	O
59.7	O
days	O
at	O
16	O
^	O
0	O
C.	O
Fecundity	O
was	O
the	O
highest	O
at	O
30	O
^	O
0	O
C	O
,	O
being	O
286.8	O
eggs	O
per	O
female	O
over	O
an	O
oviposition	O
period	O
of	O
8.9	O
days	O
.	O

Female	O
lifetime	O
fecundity	O
was	O
reduced	O
at	O
other	O
temperatures	O
,	O
being	O
the	O
lowest	O
(	O
87.7	O
eggs	O
per	O
female	O
)	O
at	O
19	O
^	O
0	O
C.	O
The	O
population	O
trend	O
index	O
(	O
I	O
)	O
of	O
C.	B
ciliata	I
was	O
the	O
highest	O
(	O
130.1	O
)	O
at	O
30	O
^	O
0	O
C	O
and	O
the	O
lowest	O
(	O
24.9	O
)	O
at	O
19	O
^	O
0	O
C.	O
Therefore	O
,	O
the	O
optimal	O
developmental	O
temperature	O
for	O
C.	B
ciliata	I
was	O
determined	O
to	O
be	O
30	O
^	O
0	O
C.	O

Adaptation	O
of	O
a	O
Madin	O
-	O
Darby	O
canine	B
kidney	O
cell	O
line	O
to	O
suspension	O
growth	O
in	O
serum	O
-	O
free	O
media	O
and	O
comparison	O
of	O
its	O
ability	O
to	O
produce	O
avian	O
influenza	O
virus	O
to	O
Vero	O
and	O
BHK21	O
cell	O
lines	O
.	O

Madin	O
-	O
Darby	O
canine	B
kidney	O
(	O
MDCK	O
)	O
cells	O
are	O
currently	O
considered	O
for	O
influenza	O
vaccine	O
manufacturing	O
.	O

A	O
drawback	O
of	O
these	O
cells	O
is	O
their	O
anchorage	O
dependent	O
growth	O
,	O
which	O
greatly	O
complicates	O
process	O
scale	O
-	O
up	O
.	O

In	O
this	O
paper	O
a	O
novel	O
MDCK	O
cell	O
line	O
(	O
MDCK	O
-	O
SFS	O
)	O
is	O
described	O
that	O
grows	O
efficiently	O
in	O
suspension	O
and	O
retained	O
high	O
expression	O
levels	O
of	O
both	O
alpha-2,6	O
and	O
alpha-2,3	O
sialic	O
acid	O
receptors	O
,	O
which	O
bind	O
preferably	O
to	O
human	O
and	O
avian	O
influenza	O
viruses	O
,	O
respectively	O
.	O

The	O
production	O
of	O
avian	O
influenza	O
virus	O
by	O
BHK21	O
,	O
Vero	O
and	O
MDCK	O
-	O
SFS	O
cell	O
lines	O
was	O
compared	O
.	O

Although	O
BHK21	O
cells	O
consisted	O
of	O
two	O
populations	O
,	O
one	O
of	O
which	O
lacks	O
the	O
alpha-2,3	O
receptor	O
,	O
they	O
supported	O
the	O
replication	O
of	O
two	O
influenza	O
strains	O
to	O
high	O
titres	O
.	O

However	O
,	O
BHK21	O
cells	O
are	O
generally	O
not	O
applicable	O
for	O
influenza	O
production	O
since	O
they	O
supported	O
the	O
replication	O
of	O
six	O
further	O
strains	O
poorly	O
.	O

MDCK	O
-	O
SFS	O
cells	O
yielded	O
the	O
highest	O
infectious	O
virus	O
titres	O
and	O
virus	O
genome	O
equivalent	O
concentration	O
for	O
five	O
of	O
the	O
eight	O
influenza	O
strains	O
analyzed	O
and	O
the	O
highest	O
hemagglutination	O
activity	O
for	O
all	O
eight	O
virus	O
strains	O
.	O

Taken	O
together	O
with	O
their	O
suitability	O
for	O
suspension	O
growth	O
this	O
makes	O
the	O
MDCK	O
-	O
SFS	O
cell	O
line	O
potentially	O
useful	O
for	O
large	O
scale	O
influenza	O
virus	O
production	O
.	O

Novel	O
cultured	O
protists	O
identify	O
deep	O
-	O
branching	O
environmental	O
DNA	O
clades	O
of	O
cercozoa	O
:	O
New	O
Genera	O
Tremula	O
,	O
Micrometopion	O
,	O
Minimassisteria	O
,	O
Nudifila	O
,	O
Peregrinia	O
.	O

We	O
describe	O
three	O
new	O
orders	O
of	O
filosan	O
Cercozoa	O
,	O
five	O
new	O
deep	O
-	O
branching	O
genera	O
,	O
eight	O
new	O
species	O
of	O
Thaumatomonas	O
,	O
Reckertia	O
,	O
Spongomonas	O
,	O
Rhogostoma	O
,	O
Agitata	O
,	O
Neoheteromita	O
and	O
Paracercomonas	O
,	O
sequence	O
their	O
18S	O
rDNA	O
,	O
and	O
construct	O
18S	O
rDNA	O
trees	O
for	O
148	O
Cercozoa	O
.	O

Our	O
phylogeny	O
indicates	O
that	O
Filosa	O
were	O
ancestrally	O
gliding	O
flagellates	O
;	O
non	O
-	O
flagellate	O
filose	O
amoebae	O
evolved	O
from	O
them	O
five	O
times	O
independently	O
.	O

The	O
new	O
genera	O
are	O
more	O
closely	O
related	O
to	O
environmental	O
DNA	O
sequences	O
than	O
cultured	O
organisms	O
.	O

Tremula	B
longifila	I
,	O
a	O
zooflagellate	O
glider	O
on	O
both	O
flagella	O
(	O
unlike	O
other	O
Cercozoa	O
)	O
,	O
is	O
the	O
most	O
divergent	O
filosan	O
(	O
Tremulida	O
ord	O
.	O

n.	O
)	O
.	O

Micrometopion	B
nutans	I
is	O
a	O
eukaryote	O
-	O
eating	O
gliding	O
zooflagellate	O
like	O
Metopion	O
and	O
Metromonas	O
.	O

Minimassisteria	B
diva	I
is	O
a	O
widespread	O
trimorphic	O
marine	O
amoeboflagellate	O
granofilosan	O
.	O

Peregrinia	B
clavideferens	I
,	O
a	O
non	O
-	O
testate	O
,	O
scale	O
-	O
bearing	O
,	O
filose	O
amoeba	O
,	O
branches	O
deeply	O
in	O
Thaumatomonadida	O
,	O
which	O
are	O
probably	O
sisters	O
to	O
Spongomonadida	O
.	O

Nudifila	B
producta	I
is	O
a	O
filose	O
amoeboflagellate	O
related	O
to	O
Clautriavia	O
and	O
Marimonadida	O
(	O
ord	O
.	O

n.	O
,	O
e.g.	O
Pseudopirsonia	O
,	O
Auranticordis	O
)	O
.	O

We	O
substantially	O
revise	O
Imbricatea	O
,	O
now	O
including	O
Spongomonadida	O
,	O
and	O
Thecofilosea	O
to	O
include	O
Phaeodaria	O
.	O

Thecofilosea	O
and	O
Imbricatea	O
and	O
Thecofilosea	O
are	O
sisters	O
,	O
both	O
arguably	O
ancestrally	O
rigid	O
gliding	O
flagellates	O
with	O
ventral	O
pseudopod	O
-	O
emitting	O
grooves	O
.	O

Scale	O
-	O
free	O
Ovulinata	B
parva	I
is	O
sister	O
to	O
Paulinella	O
,	O
so	O
imbricate	O
silica	O
scales	O
can	O
be	O
lost	O
.	O

Internal	O
hollow	O
silica	O
skeletons	O
evolved	O
twice	O
in	O
Thecofilosea	O
(	O
Ebriida	O
,	O
Phaeodaria	O
)	O
or	O
were	O
multiply	O
lost	O
.	O

Protaspa	O
replaces	O
preoccupied	O
'	O
Protaspis	O
'	O
.	O

Functional	O
analysis	O
of	O
a	O
mitochondrial	O
phosphopantetheinyl	O
transferase	O
(	O
PPTase	O
)	O
gene	O
pptB	O
in	O
Aspergillus	B
fumigatus	I
.	O

The	O
mitochondrial	O
phosphopantetheinyl	O
transferase	O
gene	O
pptB	O
of	O
the	O
opportunistic	O
pathogen	O
Aspergillus	B
fumigatus	I
has	O
been	O
identified	O
and	O
characterised	O
.	O

Unlike	O
pptA	O
,	O
which	O
is	O
required	O
for	O
lysine	O
biosynthesis	O
,	O
secondary	O
metabolism	O
,	O
and	O
iron	O
assimilation	O
,	O
pptB	O
is	O
essential	O
for	O
viability	O
.	O

PptB	O
is	O
located	O
in	O
the	O
mitochondria	O
.	O

In	O
vitro	O
expression	O
of	O
pptA	O
and	O
pptB	O
has	O
shown	O
that	O
PptB	O
is	O
specific	O
for	O
the	O
mitochondrial	O
acyl	O
carrier	O
protein	O
AcpA.	O

The	O
second	O
face	O
of	O
a	O
known	O
player	O
:	O
Arabidopsis	B
silencing	O
suppressor	O
AtXRN4	O
acts	O
organ	O
-	O
specifically	O
.	O

Plant	O
viruses	O
exploit	O
the	O
symplastic	O
transport	O
pathway	O
provided	O
by	O
plasmodesmata	O
by	O
encoding	O
for	O
specialized	O
movement	O
proteins	O
,	O
which	O
interact	O
with	O
host	O
factors	O
to	O
enable	O
viral	O
intracellular	O
and	O
intercellular	O
spread	O
.	O

Stable	O
expression	O
of	O
the	O
Potato	B
leaf	I
roll	I
virus	I
movement	O
protein	O
MP17	O
in	O
Arabidopsis	B
results	O
in	O
a	O
carbohydrate	O
export	O
block	O
and	O
stunted	O
growth	O
.	O

To	O
identify	O
host	O
factors	O
essential	O
for	O
viral	O
infection	O
,	O
we	O
screened	O
a	O
progeny	O
population	O
of	O
EMS	O
(	O
ethyl	O
methanesulfonate	O
)	O
-mutagenized	O
Arabidopsis	B
expressing	O
a	O
MP17	O
:	O
GFP	O
fusion	O
for	O
suppressor	O
mutants	O
with	O
restored	O
wild	O
type	O
-	O
like	O
phenotype	O
.	O

Two	O
suppressor	O
mutants	O
showed	O
decreased	O
susceptibility	O
against	O
Turnip	B
mosaic	I
virus	I
and	O
post	O
-	O
transcriptional	O
silencing	O
of	O
MP17	O
:	O
GFP	O
RNA	O
in	O
source	O
leaves	O
.	O

Map	O
based	O
cloning	O
identified	O
in	O
both	O
lines	O
mutations	O
in	O
XRN4	O
(	O
Exoribonuclease	O
4	O
)	O
,	O
which	O
was	O
previously	O
described	O
as	O
a	O
suppressor	O
of	O
transgene	O
silencing	O
in	O
source	O
leaves	O
.	O

Importantly	O
,	O
silencing	O
of	O
MP17	O
:	O
GFP	O
was	O
not	O
present	O
in	O
cotyledons	O
and	O
roots	O
of	O
the	O
two	O
suppressor	O
mutants	O
,	O
which	O
was	O
confirmed	O
in	O
a	O
third	O
xrn4	O
T	O
-	O
DNA	O
knock	O
out	O
line	O
.	O

Subsequent	O
analysis	O
of	O
MP17	O
:	O
GFP	O
transcript	O
stability	O
in	O
xrn2	O
and	O
xrn3	O
mutants	O
indicated	O
an	O
essential	O
role	O
of	O
AtXRN2	O
for	O
silencing	O
suppression	O
in	O
roots	O
/	O
cotyledons	O
while	O
AtXRN3	O
appears	O
to	O
act	O
similar	O
to	O
AtXRN4	O
in	O
source	O
leaves	O
,	O
only	O
.	O

Overall	O
,	O
these	O
findings	O
point	O
towards	O
an	O
organ	O
-	O
specific	O
regulation	O
of	O
gene	O
silencing	O
in	O
Arabidopsis	B
.	O

Ecological	O
trade	O
-	O
offs	O
between	O
jasmonic	O
acid	O
-	O
dependent	O
direct	O
and	O
indirect	O
plant	O
defences	O
in	O
tritrophic	O
interactions	O
.	O

Recent	O
studies	O
on	O
plants	O
genetically	O
modified	O
in	O
jasmonic	O
acid	O
(	O
JA	O
)	O
signalling	O
support	O
the	O
hypothesis	O
that	O
the	O
jasmonate	O
family	O
of	O
oxylipins	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
direct	O
and	O
indirect	O
plant	O
defences	O
.	O

However	O
,	O
the	O
interaction	O
of	O
two	O
modes	O
of	O
defence	O
in	O
tritrophic	O
systems	O
is	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
preference	O
and	O
performance	O
of	O
a	O
herbivorous	O
leafminer	B
(	O
Liriomyza	B
huidobrensis	I
)	O
and	O
its	O
parasitic	O
wasp	B
(	O
Opius	B
dissitus	I
)	O
on	O
three	O
tomato	B
genotypes	O
:	O
a	O
wild	B
-	I
type	I
(	I
WT	I
)	I
plant	I
,	O
a	O
JA	B
biosynthesis	I
(	I
spr2	I
)	I
mutant	I
,	O
and	O
a	O
JA	B
-	I
overexpression	I
35S::prosys	I
plant	I
.	O

Their	O
proteinase	O
inhibitor	O
production	O
and	O
volatile	O
emission	O
were	O
used	O
as	O
direct	O
and	O
indirect	O
defence	O
factors	O
to	O
evaluate	O
the	O
responses	O
of	O
leafminers	B
and	O
parasitoids	O
.	O

Here	O
,	O
we	O
show	O
that	O
although	O
spr2	B
mutant	I
plants	I
are	O
compromised	O
in	O
direct	O
defence	O
against	O
the	O
larval	O
leafminers	B
and	O
in	O
attracting	O
parasitoids	O
,	O
they	O
are	O
less	O
attractive	O
to	O
adult	O
flies	O
compared	O
with	O
WT	B
plants	I
.	O

Moreover	O
,	O
in	O
comparison	O
to	O
other	O
genotypes	O
,	O
the	O
35S::prosys	B
plant	I
displays	O
greater	O
direct	O
and	O
constitutive	O
indirect	O
defences	O
,	O
but	O
reduced	O
success	O
of	O
parasitism	O
by	O
parasitoids	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
there	O
are	O
distinguished	O
ecological	O
trade	O
-	O
offs	O
between	O
JA	O
-	O
dependent	O
direct	O
and	O
indirect	O
defences	O
in	O
genetically	O
modified	O
plants	O
whose	O
fitness	O
should	O
be	O
assessed	O
in	O
tritrophic	O
systems	O
and	O
under	O
natural	O
conditions	O
.	O

Haplotype	O
analysis	O
of	O
the	O
genes	O
encoding	O
glutamine	O
synthetase	O
plastic	O
isoforms	O
and	O
their	O
association	O
with	O
nitrogen	O
-	O
use-	O
and	O
yield	O
-	O
related	O
traits	O
in	O
bread	B
wheat	I
.	O

Glutamine	O
synthetase	O
(	O
GS	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
growth	O
,	O
nitrogen	O
(	O
N	O
)	O
use	O
and	O
yield	O
potential	O
of	O
cereal	O
crops	O
.	O

Investigating	O
the	O
haplotype	O
variation	O
of	O
GS	O
genes	O
and	O
its	O
association	O
with	O
agronomic	O
traits	O
may	O
provide	O
useful	O
information	O
for	O
improving	O
wheat	B
N	O
-	O
use	O
efficiency	O
and	O
yield	O
.	O

We	O
isolated	O
the	O
promoter	O
and	O
coding	O
region	O
sequences	O
of	O
the	O
plastic	O
glutamine	O
synthetase	O
isoform	O
(	O
GS2	O
)	O
genes	O
located	O
on	O
chromosomes	O
2A	O
,	O
2B	O
and	O
2D	O
in	O
bread	B
wheat	I
.	O

By	O
analyzing	O
nucleotide	O
sequence	O
variations	O
of	O
the	O
coding	O
region	O
,	O
two	O
,	O
six	O
and	O
two	O
haplotypes	O
were	O
distinguished	O
for	O
TaGS2-A1	O
(	O
a	O
and	O
b	O
)	O
,	O
TaGS2-B1	O
(	O
a	O
-	O
f	O
)	O
and	O
TaGS2-D1	O
(	O
a	O
and	O
b	O
)	O
,	O
respectively	O
.	O

By	O
analyzing	O
the	O
frequency	O
data	O
of	O
different	O
haplotypes	O
and	O
their	O
association	O
with	O
N	O
use	O
and	O
agronomic	O
traits	O
,	O
four	O
major	O
and	O
favorable	O
TaGS2	O
haplotypes	O
(	O
A1b	O
,	O
B1a	O
,	O
B1b	O
,	O
D1a	O
)	O
were	O
revealed	O
.	O

These	O
favorable	O
haplotypes	O
may	O
confer	O
better	O
seedling	O
growth	O
,	O
better	O
agronomic	O
performance	O
,	O
and	O
improved	O
N	O
uptake	O
during	O
vegetative	O
growth	O
or	O
grain	O
N	O
concentration	O
.	O

Our	O
data	O
suggest	O
that	O
certain	O
TaGS2	O
haplotypes	O
may	O
be	O
valuable	O
in	O
breeding	O
wheat	B
varieties	O
with	O
improved	O
agronomic	O
performance	O
and	O
N	O
-	O
use	O
efficiency	O
.	O

High	O
homologous	O
gene	O
conservation	O
despite	O
extreme	O
autopolyploid	O
redundancy	O
in	O
sugarcane	B
.	O

Modern	O
sugarcane	B
(	O
Saccharum	B
spp	I
.	O
)	O
is	O
the	O
leading	O
sugar	O
crop	O
and	O
a	O
primary	O
energy	O
crop	O
.	O

It	O
has	O
the	O
highest	O
level	O
of	O
'	O
vertical	O
'	O
redundancy	O
(	O
2n=12x=120	O
)	O
of	O
all	O
polyploid	O
plants	O
studied	O
to	O
date	O
.	O

It	O
was	O
produced	O
about	O
a	O
century	O
ago	O
through	O
hybridization	O
between	O
two	O
autopolyploid	O
species	O
,	O
namely	O
S.	B
officinarum	I
and	O
S.	B
spontaneum	I
.	O

In	O
order	O
to	O
investigate	O
the	O
genome	O
dynamics	O
in	O
this	O
highly	O
polyploid	O
context	O
,	O
we	O
sequenced	O
and	O
compared	O
seven	O
hom	O
(	O
oe	O
)	O
ologous	O
haplotypes	O
(	O
bacterial	O
artificial	O
chromosome	O
clones	O
)	O
.	O

Our	O
analysis	O
revealed	O
a	O
high	O
level	O
of	O
gene	O
retention	O
and	O
colinearity	O
,	O
as	O
well	O
as	O
high	O
gene	O
structure	O
and	O
sequence	O
conservation	O
,	O
with	O
an	O
average	O
sequence	O
divergence	O
of	O
4	O
%	O
for	O
exons	O
.	O

Remarkably	O
,	O
all	O
of	O
the	O
hom	O
(	O
oe	O
)	O
ologous	O
genes	O
were	O
predicted	O
as	O
being	O
functional	O
(	O
except	O
for	O
one	O
gene	O
fragment	O
)	O
and	O
showed	O
signs	O
of	O
evolving	O
under	O
purifying	O
selection	O
,	O
with	O
the	O
exception	O
of	O
genes	O
within	O
segmental	O
duplications	O
.	O

By	O
contrast	O
,	O
transposable	O
elements	O
displayed	O
a	O
general	O
absence	O
of	O
colinearity	O
among	O
hom	O
(	O
oe	O
)	O
ologous	O
haplotypes	O
and	O
appeared	O
to	O
have	O
undergone	O
dynamic	O
expansion	O
in	O
Saccharum	O
,	O
compared	O
with	O
sorghum	O
,	O
its	O
close	O
relative	O
in	O
the	O
Andropogonea	O
tribe	O
.	O

These	O
results	O
reinforce	O
the	O
general	O
trend	O
emerging	O
from	O
recent	O
studies	O
indicating	O
the	O
diverse	O
and	O
nuanced	O
effect	O
of	O
polyploidy	O
on	O
genome	O
dynamics	O
.	O

Updated	O
hypothesis	O
on	O
the	O
evolution	O
of	O
oligotrichid	O
ciliates	O
(	O
Ciliophora	O
,	O
Spirotricha	O
,	O
Oligotrichida	O
)	O
based	O
on	O
somatic	O
ciliary	O
patterns	O
and	O
ontogenetic	O
data	O
.	O

The	O
two	O
recently	O
established	O
genera	O
Apostrombidium	O
Xu	O
et	O
al.	O
,	O
2009	O
and	O
Varistrombidium	O
Xu	O
et	O
al.	O
,	O
2009	O
and	O
the	O
analysis	O
of	O
ontogenetic	O
data	O
in	O
Strombidium	O
constrictum	O
,	O
S.	O
montagnesi	O
,	O
S.	O
wilberti	O
,	O
Omegastrombidium	B
elegans	I
,	O
and	O
Paratontonia	O
gracillima	O
necessitated	O
a	O
revision	O
of	O
the	O
hypothesis	O
about	O
the	O
somatic	O
ciliary	O
pattern	O
evolution	O
in	O
oligotrichid	O
ciliates	O
.	O

As	O
a	O
consequence	O
,	O
the	O
species	O
-	O
rich	O
genus	O
Strombidium	O
was	O
split	O
,	O
establishing	O
two	O
genera	O
for	O
species	O
with	O
a	O
horizontal	O
girdle	O
kinety	O
posterior	O
to	O
the	O
oral	O
primordium	O
:	O
Opisthostrombidium	O
nov.	O
gen.	O
with	O
the	O
extrusome	O
attachment	O
sites	O
along	O
the	O
anterior	O
margin	O
of	O
the	O
girdle	O
kinety	O
and	O
posterior	O
to	O
the	O
oral	O
primordium	O
and	O
Foissneridium	O
nov.	O
gen.	O
with	O
the	O
extrusome	O
attachment	O
sites	O
distinctly	O
apart	O
from	O
the	O
girdle	O
kinety	O
and	O
anterior	O
to	O
the	O
oral	O
primordium	O
.	O

The	O
ontogenetic	O
data	O
revealed	O
that	O
the	O
Omega	O
-	O
shaped	O
girdle	O
kinety	O
pattern	O
evolved	O
convergently	O
from	O
the	O
Pseudotontonia	O
pattern	O
with	O
its	O
horizontal	O
girdle	O
kinety	O
in	O
the	O
tailed	O
genus	O
Paratontonia	O
and	O
from	O
the	O
Novistrombidium	O
pattern	O
with	O
its	O
dextrally	O
spiralled	O
girdle	O
kinety	O
in	O
the	O
tailless	O
genus	O
Omegastrombidium	O
.	O

The	O
somatic	O
ciliary	O
pattern	O
of	O
the	O
latter	O
genus	O
probably	O
gave	O
rise	O
to	O
the	O
patterns	O
of	O
Apostrombidium	O
and	O
Varistrombidium	O
.	O

Identification	O
of	O
a	O
novel	O
mitochondrial	O
protein	O
,	O
short	O
postembryonic	O
roots	O
1	O
(	O
SPR1	O
)	O
,	O
involved	O
in	O
root	O
development	O
and	O
iron	O
homeostasis	O
in	O
Oryza	B
sativa	I
.	O

*	O
A	O
rice	B
mutant	O
,	O
Oryza	B
sativa	I
short	I
postembryonic	I
roots	I
1	O
(	O
Osspr1	B
)	O
,	O
has	O
been	O
characterized	O
.	O

It	O
has	O
short	O
postembryonic	O
roots	O
,	O
including	O
adventitious	O
and	O
lateral	O
roots	O
,	O
and	O
a	O
lower	O
iron	O
content	O
in	O
its	O
leaves	O
.	O

*	O
OsSPR1	B
was	O
identified	O
by	O
map	O
-	O
based	O
cloning	O
.	O

It	O
encodes	O
a	O
novel	O
mitochondrial	O
protein	O
with	O
the	O
Armadillo	O
-	O
like	O
repeat	O
domain	O
.	O

*	O
Osspr1	O
mutants	O
exhibited	O
decreased	O
root	O
cell	O
elongation	O
.	O

The	O
iron	O
content	O
of	O
the	O
mutant	O
shoots	O
was	O
significantly	O
altered	O
compared	O
with	O
that	O
of	O
wild	O
-	O
type	O
shoots	O
.	O

A	O
similar	O
pattern	O
of	O
alteration	O
of	O
manganese	O
and	O
zinc	O
concentrations	O
in	O
shoots	O
was	O
also	O
observed	O
.	O

Complementation	O
of	O
the	O
mutant	O
confirmed	O
that	O
OsSPR1	B
is	O
involved	O
in	O
post	O
-	O
embryonic	O
root	O
elongation	O
and	O
iron	O
homeostasis	O
in	O
rice	O
.	O

OsSPR1	B
was	O
found	O
to	O
be	O
ubiquitously	O
expressed	O
in	O
various	O
tissues	O
throughout	O
the	O
plant	O
.	O

The	O
transcript	O
abundance	O
of	O
various	O
genes	O
involved	O
in	O
iron	O
uptake	O
and	O
signaling	O
via	O
both	O
strategies	O
I	O
and	O
II	O
was	O
similar	O
in	O
roots	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
plants	O
,	O
but	O
was	O
higher	O
in	O
the	O
leaves	O
of	O
mutant	O
plants	O
.	O

*	O

Thus	O
,	O
a	O
novel	O
mitochondrial	O
protein	O
that	O
is	O
involved	O
in	O
root	O
elongation	O
and	O
plays	O
a	O
role	O
in	O
metal	O
ion	O
homeostasis	O
has	O
been	O
identified	O
.	O

Morphology	O
and	O
ultrastructure	O
of	O
multiple	O
life	O
cycle	O
stages	O
of	O
the	O
photosynthetic	O
relative	O
of	O
apicomplexa	O
,	O
Chromera	B
velia	I
.	O

Chromera	B
velia	I
is	O
a	O
photosynthetic	O
alga	O
with	O
a	O
secondary	O
plastid	O
that	O
represents	O
the	O
closest	O
known	O
photosynthetic	O
relative	O
of	O
the	O
apicomplexan	O
parasites	O
.	O

The	O
original	O
description	O
of	O
this	O
organism	O
was	O
based	O
on	O
brownish	O
,	O
immotile	O
coccoid	O
cells	O
,	O
which	O
is	O
the	O
predominating	O
stage	O
of	O
C.	B
velia	I
in	O
the	O
culture	O
.	O

Here	O
we	O
provide	O
a	O
detailed	O
light	O
and	O
electron	O
microscopy	O
description	O
of	O
coccoid	O
cells	O
of	O
C.	B
velia	I
and	O
a	O
previously	O
undocumented	O
bi	O
-	O
flagellated	O
stage	O
that	O
is	O
highly	O
motile	O
and	O
moves	O
in	O
a	O
characteristic	O
zig	O
-	O
zag	O
pattern	O
.	O

Transformation	O
from	O
a	O
coccoid	O
into	O
a	O
flagellate	O
stage	O
occurs	O
in	O
exponentially	O
growing	O
cultures	O
,	O
and	O
is	O
accelerated	O
by	O
exposure	O
to	O
light	O
.	O

The	O
C.	B
velia	I
cells	O
contain	O
a	O
pseudoconoid	O
,	O
which	O
is	O
likely	O
homologous	O
to	O
the	O
corresponding	O
structure	O
in	O
the	O
apical	O
complex	O
of	O
Apicomplexa	O
,	O
cortical	O
alveoli	O
subtended	O
by	O
subpellicular	O
microtubules	O
,	O
mitochondrion	O
with	O
tubular	O
cristae	O
,	O
a	O
micropyle	O
,	O
and	O
a	O
distinctive	O
chromerosome	O
,	O
an	O
apparently	O
novel	O
type	O
of	O
extrusion	O
organelle	O
.	O

Ultrastructural	O
analysis	O
of	O
the	O
flagellate	O
supports	O
its	O
close	O
association	O
with	O
colpodellids	O
and	O
apicomplexans	O
and	O
provides	O
important	O
insight	O
into	O
their	O
evolution	O
.	O

Constraints	O
on	O
host	O
choice	O
:	O
why	O
do	O
parasitic	O
birds	O
rarely	O
exploit	O
some	O
common	O
potential	O
hosts	O
?	O

1	O
.	O

Why	O
are	O
some	O
common	O
and	O
apparently	O
suitable	O
resources	O
avoided	O
by	O
potential	O
users	O
?	O

This	O
interesting	O
ecological	O
and	O
evolutionary	O
conundrum	O
is	O
vividly	O
illustrated	O
by	O
obligate	O
brood	O
parasites	O
.	O

Parasitic	O
birds	O
lay	O
their	O
eggs	O
into	O
nests	O
of	O
a	O
wide	O
range	O
of	O
host	O
species	O
,	O
including	O
many	O
rare	O
ones	O
,	O
but	O
do	O
not	O
parasitize	O
some	O
commonly	O
co	O
-	O
occurring	O
potential	O
hosts	O
.	O

2	O
.	O
Attempts	O
to	O
explain	O
the	O
absence	O
of	O
parasitism	O
in	O
common	O
potential	O
hosts	O
are	O
limited	O
and	O
typically	O
focused	O
on	O
single	O
-	O
factor	O
explanations	O
while	O
ignoring	O
other	O
potential	O
factors	O
.	O

We	O
tested	O
why	O
thrushes	O
Turdus	O
spp	O
.	O
are	O
extremely	O
rarely	O
parasitized	O
by	O
common	B
cuckoos	I
Cuculus	B
canorus	I
despite	O
breeding	O
commonly	O
in	O
sympatry	O
and	O
building	O
the	O
most	O
conspicuous	O
nests	O
among	O
forest	O
-	O
breeding	O
passerines	O
.	O

3	O
.	O

No	O
single	O
examined	O
factor	O
explained	O
cuckoo	B
avoidance	O
of	O
thrushes	O
.	O

Life	O
-	O
history	O
traits	O
of	O
all	O
six	O
European	O
thrush	O
species	O
and	O
the	O
10	O
most	O
frequently	O
used	O
cuckoo	B
hosts	O
in	O
Europe	O
were	O
similar	O
except	O
body	O
/	O
egg	O
size	O
,	O
nest	O
design	O
and	O
nestling	O
diet	O
.	O

4	O
.	O

Experiments	O
(	O
n	O
=	O
1211	O
)	O
in	O
several	O
populations	O
across	O
Europe	O
showed	O
that	O
host	O
defences	O
at	O
egg	O
-	O
laying	O
and	O
incubation	O
stages	O
did	O
not	O
account	O
for	O
the	O
lack	O
of	O
cuckoo	B
parasitism	O
in	O
thrushes	O
.	O

However	O
,	O
cross	O
-	O
fostering	O
experiments	O
disclosed	O
that	O
various	O
factors	O
during	O
the	O
nestling	O
period	O
prevent	O
cuckoos	B
from	O
successfully	O
parasitizing	O
thrushes	O
.	O

Specifically	O
,	O
in	O
some	O
thrush	O
species	O
,	O
the	O
nest	O
cup	O
design	O
forced	O
cuckoo	B
chicks	O
to	O
compete	O
with	O
host	O
chicks	O
with	O
fatal	O
consequences	O
for	O
the	O
parasite	O
.	O

Other	O
species	O
were	O
reluctant	O
to	O
care	O
even	O
for	O
lone	O
cuckoo	B
chicks	O
.	O

5	O
.	O

Importantly	O
,	O
in	O
an	O
apparently	O
phylogenetically	O
homogenous	O
group	O
of	O
hosts	O
,	O
there	O
were	O
interspecific	O
differences	O
in	O
factors	O
responsible	O
for	O
the	O
absence	O
of	O
cuckoo	B
parasitism	O
.	O

6	O
.	O

This	O
study	O
highlights	O
the	O
importance	O
of	O
considering	O
multiple	O
potential	O
factors	O
and	O
their	O
interactions	O
for	O
understanding	O
absence	O
of	O
parasitism	O
in	O
potential	O
hosts	O
of	O
parasitic	O
birds	O
.	O

In	O
the	O
present	O
study	O
,	O
comparative	O
and	O
experimental	O
procedures	O
are	O
integrated	O
,	O
which	O
represent	O
a	O
novel	O
approach	O
that	O
should	O
prove	O
useful	O
for	O
the	O
understanding	O
of	O
interspecific	O
ecological	O
relationships	O
in	O
general	O
.	O

Expression	O
and	O
functional	O
characterisation	O
of	O
TNC	O
,	O
a	O
high	O
-	O
affinity	O
nickel	O
transporter	O
from	O
Neurospora	B
crassa	I
.	O

Our	O
previous	O
in	O
silico	O
studies	O
identified	O
a	O
high	O
-	O
affinity	O
nickel	O
transporter	O
,	O
TNC	O
,	O
from	O
the	O
metal	O
transportome	O
of	O
Neurospora	B
crassa	I
.	O

A	O
knockout	O
mutant	O
of	O
the	O
tnc	O
gene	O
in	O
N.	B
crassa	I
failed	O
to	O
transport	O
nickel	O
,	O
showed	O
phenotypic	O
growth	O
defects	O
and	O
diminished	O
urease	O
activity	O
under	O
physiological	O
levels	O
of	O
nickel	O
.	O

Transport	O
assays	O
conducted	O
in	O
wild	O
type	O
and	O
knockout	O
mutant	O
strains	O
showed	O
that	O
TNC	O
transports	O
nickel	O
withhigh	O
affinity	O
but	O
exhibits	O
selectivity	O
for	O
other	O
transition	O
metal	O
ions	O
like	O
cobalt	O
.	O

Heterologous	O
complementation	O
of	O
Schizosaccharomyces	B
pombe	I
nickel	O
uptake	O
mutant	O
by	O
TNC	O
further	O
substantiates	O
its	O
nickel	O
transport	O
function	O
.	O

Transcriptional	O
analysis	O
of	O
the	O
nickel	O
transporter	O
encoding	O
gene	O
,	O
tnc	O
in	O
N.	B
crassa	I
by	O
qRT	O
-	O
PCR	O
showed	O
its	O
constitutive	O
expression	O
in	O
various	O
phases	O
of	O
its	O
life	O
cycle	O
.	O

However	O
,	O
levels	O
of	O
the	O
corresponding	O
protein	O
TNC	O
were	O
down	O
-	O
regulated	O
only	O
by	O
increasing	O
the	O
nickel	O
,	O
but	O
not	O
cobalt	O
concentration	O
in	O
the	O
media	O
.	O

Immunolocalisation	O
data	O
suggested	O
that	O
TNC	O
is	O
distributed	O
in	O
the	O
plasma	O
membrane	O
of	O
N.	B
crassa	I
.	O

Thus	O
,	O
the	O
present	O
study	O
establishes	O
TNC	O
as	O
a	O
functional	O
plasma	O
membrane	O
nickel	O
transporter	O
necessary	O
for	O
physiological	O
acquisition	O
of	O
nickel	O
in	O
the	O
multicellular	O
fungi	O
N.	B
crassa	I
.	O

An	O
Antarctic	O
hypotrichous	O
ciliate	O
,	O
Parasterkiella	B
thompsoni	I
(	O
Foissner	O
)	O
nov.	O
gen.	O
,	O
nov.	O
comb	O
.	O
,	O
recorded	O
in	O
Argentinean	O
peat	O
-	O
bogs	O
:	O
morphology	O
,	O
morphogenesis	O
,	O
and	O
molecular	O
phylogeny	O
.	O

The	O
ciliate	O
Parasterkiella	B
thompsoni	I
(	O
Foissner	O
,	O
1996	O
)	O
nov.	O
gen.	O
,	O
nov.	O
comb	O
.	O
was	O
originally	O
described	O
from	O
Antarctica	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
morphology	O
,	O
morphogenesis	O
during	O
cell	O
division	O
,	O
and	O
molecular	O
phylogeny	O
inferred	O
from	O
the	O
18S	O
-	O
rDNA	O
sequence	O
of	O
a	O
population	O
isolated	O
from	O
the	O
Rancho	O
Hambre	O
peat	O
bog	O
,	O
Tierra	O
del	O
Fuego	O
Province	O
(	O
Argentina	O
)	O
.	O

The	O
study	O
is	O
based	O
on	O
live	O
and	O
protargol	O
-	O
impregnated	O
specimens	O
.	O

Molecular	O
phylogeny	O
was	O
inferred	O
from	O
trees	O
constructed	O
by	O
means	O
of	O
the	O
maximum	O
parsimony	O
,	O
neighbor	O
joining	O
,	O
and	O
Bayesian	O
analyses	O
.	O

The	O
interphase	O
morphology	O
matches	O
the	O
original	O
description	O
of	O
the	O
species	O
.	O

During	O
the	O
cell	O
division	O
,	O
stomatogenesis	O
begins	O
with	O
the	O
de	O
novo	O
proliferation	O
of	O
two	O
fields	O
of	O
basal	O
bodies	O
,	O
each	O
one	O
left	O
of	O
the	O
postoral	O
ventral	O
cirri	O
and	O
of	O
transverse	O
cirri	O
,	O
which	O
later	O
unify	O
.	O

Primordia	O
IV	O
-	O
VI	O
of	O
the	O
proter	O
develop	O
from	O
disaggregation	O
of	O
cirrus	O
IV	O
/	O
3	O
,	O
while	O
primordium	O
IV	O
of	O
the	O
opisthe	O
develops	O
from	O
cirrus	O
IV	O
/	O
2	O
and	O
primordia	O
V	O
and	O
VI	O
from	O
cirrus	O
V	O
/	O
4	O
.	O

Dorsal	O
morphogenesis	O
occurs	O
in	O
the	O
Urosomoida	O
pattern	O
-	O
that	O
is	O
,	O
the	O
fragmentation	O
of	O
kinety	O
3	O
is	O
lacking	O
.	O

Three	O
macronuclear	O
nodules	O
are	O
generated	O
before	O
cytokinesis	O
.	O

Phylogenetic	O
analyses	O
consistently	O
placed	O
P.	B
thompsoni	I
within	O
the	O
stylonychines	O
.	O

New	O
data	O
on	O
the	O
morphogenesis	O
of	O
the	O
dorsal	O
ciliature	O
justifies	O
the	O
transference	O
of	O
Sterkiella	B
thompsoni	I
to	O
a	O
new	O
genus	O
Parasterkiella	O
.	O

A	O
nuclear	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
encoded	O
by	O
a	O
poxvirus	O
.	O

Poxviruses	O
have	O
evolved	O
various	O
strategies	O
to	O
inhibit	O
cytoplasmic	O
events	O
leading	O
to	O
activation	O
of	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
-	O
kappaB	O
)	O
signaling	O
pathway	O
,	O
with	O
individual	O
viruses	O
often	O
encoding	O
multiple	O
NF	O
-	O
kappaB	O
inhibitors	O
.	O

Here	O
,	O
the	O
novel	O
orf	B
virus	I
(	O
ORFV	B
)	O
-encoded	O
protein	O
ORFV002	B
was	O
shown	O
to	O
inhibit	O
nuclear	O
events	O
regulating	O
NF	O
-	O
kappaB	O
transcriptional	O
activity	O
.	O

ORFV002	O
expression	O
in	O
cell	O
cultures	O
significantly	O
decreased	O
wild	O
-	O
type	O
-	O
virus-	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
-	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
NF	O
-	O
kappaB	O
-	O
mediated	O
gene	O
expression	O
.	O

Expression	O
of	O
ORFV002	O
in	O
cells	O
,	O
while	O
not	O
affecting	O
phosphorylation	O
or	O
nuclear	O
translocation	O
of	O
NF	O
-	O
kappaB	O
-	O
p65	O
,	O
markedly	O
decreased	O
TNF	O
-	O
alpha-	O
and	O
wild	O
-	O
type	O
-	O
virus	O
-	O
induced	O
acetylation	O
of	O
NF	O
-	O
kappaB	O
-	O
p65	O
,	O
a	O
p300-mediated	O
nuclear	O
modification	O
of	O
NF	O
-	O
kappaB	O
-	O
p65	O
that	O
regulates	O
its	O
transactivating	O
activity	O
.	O

ORFV002	O
was	O
shown	O
to	O
colocalize	O
and	O
interact	O
with	O
NF	O
-	O
kappaB	O
-	O
p65	O
,	O
and	O
expression	O
of	O
ORFV002	O
in	O
cell	O
cultures	O
resulted	O
in	O
a	O
reduced	O
interaction	O
of	O
NF	O
-	O
kappaB	O
-	O
p65	O
with	O
p300	O
,	O
suggesting	O
that	O
ORFV002	O
interferes	O
with	O
NF	O
-	O
kappaB	O
-	O
p65	O
/	O
p300	O
association	O
.	O

Deletion	O
of	O
ORFV002	O
from	O
the	O
OV	O
-	O
IA82	O
genome	O
had	O
no	O
significant	O
effect	O
on	O
ORFV	O
pathogenesis	O
in	O
sheep	O
,	O
indicating	O
that	O
ORFV002	O
is	O
nonessential	O
for	O
virus	O
virulence	O
in	O
the	O
natural	O
host	O
.	O

This	O
represents	O
the	O
first	O
description	O
of	O
a	O
nuclear	O
inhibitor	O
of	O
NF	O
-	O
kappaB	O
encoded	O
by	O
a	O
poxvirus	O
.	O

Alphacoronavirus	O
transmissible	B
gastroenteritis	I
virus	I
nsp1	O
protein	O
suppresses	O
protein	O
translation	O
in	O
mammalian	O
cells	O
and	O
in	O
cell	O
-	O
free	O
HeLa	O
cell	O
extracts	O
but	O
not	O
in	O
rabbit	B
reticulocyte	O
lysate	O
.	O

The	O
nsp1	O
protein	O
of	O
transmissible	B
gastroenteritis	I
virus	I
(	O
TGEV	B
)	O
,	O
an	O
alphacoronavirus	O
,	O
efficiently	O
suppressed	O
protein	O
synthesis	O
in	O
mammalian	O
cells	O
.	O

Unlike	O
the	O
nsp1	O
protein	O
of	O
severe	B
acute	I
respiratory	I
syndrome	I
coronavirus	I
,	O
a	O
betacoronavirus	O
,	O
the	O
TGEV	B
nsp1	O
protein	O
was	O
unable	O
to	O
bind	O
40S	O
ribosomal	O
subunits	O
or	O
promote	O
host	O
mRNA	O
degradation	O
.	O

TGEV	B
nsp1	O
also	O
suppressed	O
protein	O
translation	O
in	O
cell	O
-	O
free	O
HeLa	O
cell	O
extract	O
;	O
however	O
,	O
it	O
did	O
not	O
affect	O
translation	O
in	O
rabbit	B
reticulocyte	O
lysate	O
(	O
RRL	O
)	O
.	O

Our	O
data	O
suggested	O
that	O
HeLa	O
cell	O
extracts	O
and	O
cultured	O
host	O
cells	O
,	O
but	O
not	O
RRL	O
,	O
contain	O
a	O
host	O
factor	O
(	O
s	O
)	O
that	O
is	O
essential	O
for	O
TGEV	B
nsp1-induced	O
translational	O
suppression	O
.	O

Modification	O
of	O
nonstructural	O
protein	O
1	O
of	O
influenza	B
A	I
virus	I
by	O
SUMO1	O
.	O

Nonstructural	O
protein	O
1	O
(	O
NS1	O
)	O
is	O
one	O
of	O
the	O
major	O
factors	O
resulting	O
in	O
the	O
efficient	O
infection	O
rate	O
and	O
high	O
level	O
of	O
virulence	O
of	O
influenza	B
A	I
virus	I
.	O

Although	O
consisting	O
of	O
only	O
approximately	O
230	O
amino	O
acids	O
,	O
NS1	O
has	O
the	O
ability	O
to	O
interfere	O
with	O
several	O
systems	O
of	O
the	O
host	O
viral	O
defense	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
NS1	O
of	O
the	O
highly	O
pathogenic	O
avian	O
influenza	B
A	B
/	I
Duck	I
/	I
Hubei	I
/	I
L-1	I
/	I
2004	I
(	I
H5N1	I
)	I
virus	I
interacts	O
with	O
human	B
Ubc9	O
,	O
which	O
is	O
the	O
E2	O
conjugating	O
enzyme	O
for	O
sumoylation	O
,	O
and	O
we	O
show	O
that	O
SUMO1	O
is	O
conjugated	O
to	O
H5N1	B
NS1	O
in	O
both	O
transfected	O
and	O
infected	O
cells	O
.	O

Furthermore	O
,	O
two	O
lysine	O
residues	O
in	O
the	O
C	O
terminus	O
of	O
NS1	O
were	O
identified	O
as	O
SUMO1	O
acceptor	O
sites	O
.	O

When	O
the	O
SUMO1	O
acceptor	O
sites	O
were	O
removed	O
by	O
mutation	O
,	O
NS1	O
underwent	O
rapid	O
degradation	O
.	O

Studies	O
of	O
different	O
influenza	B
A	I
virus	I
strains	O
of	O
human	B
and	O
avian	O
origin	O
showed	O
that	O
the	O
majority	O
of	O
viruses	O
possess	O
an	O
NS1	O
protein	O
that	O
is	O
modified	O
by	O
SUMO1	O
,	O
except	O
for	O
the	O
recently	O
emerged	O
swine	B
-	I
origin	I
influenza	I
A	I
virus	I
(	I
S	I
-	I
OIV	I
)	I
(	I
H1N1	I
)	O
.	O

Interestingly	O
,	O
growth	O
of	O
a	O
sumoylation	O
-	O
deficient	O
WSN	O
virus	O
mutant	O
was	O
retarded	O
compared	O
to	O
that	O
of	O
wild	O
-	O
type	O
virus	O
.	O

Together	O
,	O
these	O
results	O
indicate	O
that	O
sumoylation	O
enhances	O
NS1	O
stability	O
and	O
thus	O
promotes	O
rapid	O
growth	O
of	O
influenza	B
A	I
virus	I
.	O

Novel	O
mutations	O
reveal	O
two	O
important	O
regions	O
in	O
Aspergillus	B
nidulans	I
transcriptional	O
activator	O
MetR.	O
Expression	O
of	O
the	O
sulfur	O
assimilation	O
pathway	O
in	O
Aspergillus	B
nidulans	I
is	O
under	O
control	O
of	O
sulfur	O
metabolite	O
repression	O
,	O
which	O
is	O
composed	O
of	O
scon	O
genes	O
encoding	O
subunits	O
of	O
ubiquitin	O
ligase	O
and	O
the	O
metR	O
gene	O
coding	O
for	O
a	O
transcriptional	O
activator	O
.	O

In	O
this	O
paper	O
we	O
report	O
three	O
dominant	O
suppressors	O
of	O
methionine	O
requirement	O
isolated	O
from	O
a	O
metB3	O
diploid	O
strain	O
.	O

All	O
three	O
mutations	O
lead	O
to	O
the	O
substitution	O
of	O
phenylalanine	O
48	O
by	O
serine	O
or	O
leucine	O
in	O
the	O
conserved	O
N	O
-	O
terminal	O
region	O
of	O
the	O
MetR	O
protein	O
.	O

Strains	O
carrying	O
the	O
dominant	O
suppressor	O
mutations	O
exhibit	O
increased	O
activities	O
of	O
homocysteine	O
synthase	O
and	O
sulfur	O
assimilation	O
enzymes	O
as	O
well	O
as	O
elevated	O
levels	O
of	O
the	O
corresponding	O
transcripts	O
.	O

These	O
changes	O
are	O
observed	O
even	O
under	O
conditions	O
of	O
methionine	O
repression	O
,	O
which	O
suggests	O
that	O
the	O
mutated	O
MetR	O
protein	O
may	O
be	O
resistant	O
to	O
inactivation	O
or	O
degradation	O
mediated	O
by	O
sulfur	O
metabolite	O
repression	O
.	O

We	O
also	O
found	O
that	O
a	O
mutant	O
impaired	O
in	O
sulfite	O
reductase	O
activity	O
,	O
known	O
until	O
now	O
as	O
sG8	O
,	O
has	O
a	O
frameshift	O
which	O
changes	O
41	O
C	O
-	O
terminal	O
amino	O
acids	O
.	O

Therefore	O
,	O
it	O
is	O
now	O
designated	O
metR18	O
.	O

This	O
mutant	O
has	O
elevated	O
levels	O
of	O
MetR	O
-	O
regulated	O
transcripts	O
and	O
of	O
activities	O
of	O
sulfur	O
assimilation	O
enzymes	O
(	O
except	O
sulfite	O
reductase	O
)	O
,	O
which	O
can	O
be	O
repressed	O
to	O
the	O
wild	O
type	O
level	O
by	O
exogenous	O
methionine	O
.	O

Thus	O
,	O
metR18	O
and	O
the	O
three	O
dominant	O
suppressors	O
represent	O
new	O
types	O
of	O
mutations	O
affecting	O
different	O
parts	O
of	O
the	O
A.	B
nidulans	I
MetR	O
protein	O
.	O

Norovirus	O
GII.4	O
strain	O
antigenic	O
variation	O
.	O

Noroviruses	O
are	O
the	O
principal	O
cause	O
of	O
epidemic	O
gastroenteritis	O
worldwide	O
.	O

Multiple	O
reports	O
have	O
concluded	O
that	O
the	O
major	O
capsid	O
proteins	O
of	O
GII.4	O
strains	O
,	O
which	O
cause	O
80	O
%	O
of	O
norovirus	O
infections	O
worldwide	O
,	O
are	O
evolving	O
rapidly	O
,	O
resulting	O
in	O
new	O
epidemic	O
strains	O
.	O

Surrogate	O
neutralization	O
assays	O
using	O
sera	O
from	O
outbreaks	O
and	O
from	O
immunized	O
mice	O
suggest	O
that	O
,	O
as	O
with	O
influenza	B
virus	I
,	O
antigenic	O
variation	O
maintains	O
GII.4	O
persistence	O
in	O
the	O
face	O
of	O
human	B
population	O
herd	O
immunity	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
mice	O
were	O
hyperimmunized	O
with	O
virus	O
-	O
like	O
particles	O
(	O
VLPs	O
)	O
representing	O
an	O
early	O
(	O
GII.4	O
-	O
1987	O
)	O
and	O
a	O
contemporary	O
(	O
GII.4	O
-	O
2006	O
)	O
GII.4	O
strain	O
.	O

Anti	O
-	O
GII.4	O
-	O
1987	O
IgG	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
strongly	O
reacted	O
with	O
GII.4	O
VLPs	O
derived	O
between	O
only	O
1987	O
and	O
2002	O
.	O

Ligand	O
binding	O
blockade	O
was	O
more	O
efficient	O
with	O
GII.4	O
-	O
1987	O
and	O
GII.4	O
-	O
1997	O
VLPs	O
than	O
with	O
GII.4	O
-	O
2002	O
.	O

Anti	O
-	O
GII.4	O
-	O
2006	O
IgG	O
MAbs	O
recognized	O
either	O
a	O
broad	O
panel	O
of	O
GII.4	O
VLPs	O
(	O
1987	O
to	O
2006	O
)	O
or	O
a	O
subset	O
of	O
contemporary	O
(	O
2004	O
to	O
2006	O
)	O
VLPs	O
.	O

Most	O
2006	O
antibodies	O
did	O
not	O
recognize	O
or	O
only	O
poorly	O
recognized	O
GII.4	O
VLPs	O
of	O
2007	O
or	O
2008	O
,	O
documenting	O
rapid	O
antigenic	O
evolution	O
of	O
GII.4	O
capsids	O
.	O

Generally	O
,	O
2006	O
MAbs	O
blocked	O
homotypic	O
VLP	O
-	O
ligand	O
binding	O
but	O
were	O
unable	O
to	O
block	O
VLPs	O
representing	O
strains	O
primarily	O
circulating	O
during	O
or	O
earlier	O
than	O
2002	O
.	O

These	O
analyses	O
demonstrate	O
that	O
both	O
subtle	O
and	O
significant	O
evolutionary	O
change	O
has	O
occurred	O
within	O
antibody	O
epitopes	O
between	O
epidemic	O
strains	O
,	O
providing	O
direct	O
evidence	O
that	O
the	O
GII.4	O
noroviruses	O
are	O
undergoing	O
antigenic	O
variation	O
,	O
likely	O
in	O
response	O
to	O
herd	O
immunity	O
.	O

As	O
with	O
influenza	B
virus	I
,	O
HIV	O
,	O
and	O
hepatitis	B
C	I
virus	I
,	O
norovirus	O
antigenic	O
variation	O
will	O
significantly	O
influence	O
the	O
design	O
of	O
efficacious	O
vaccines	O
and	O
immunotherapeutics	O
against	O
these	O
important	O
human	B
pathogens	O
.	O

Cold	O
stress	O
contributes	O
to	O
aberrant	O
cytokinesis	O
during	O
male	O
meiosis	O
I	O
in	O
a	O
wheat	B
thermosensitive	O
genic	O
male	O
sterile	O
line	O
.	O

The	O
male	O
sterility	O
of	O
a	O
wheat	B
thermosensitive	O
genic	O
male	O
sterile	O
(	O
TGMS	O
)	O
line	O
is	O
strictly	O
controlled	O
by	O
temperature	O
.	O

When	O
the	O
TGMS	O
line	O
BS366	O
was	O
exposed	O
to	O
10	O
^0C	O
from	O
the	O
pollen	O
mother	O
cell	O
stage	O
to	O
the	O
meiosis	O
stage	O
,	O
a	O
few	O
pollen	O
grains	O
were	O
formed	O
and	O
devoid	O
of	O
starch	O
.	O

We	O
report	O
here	O
a	O
large	O
-	O
scale	O
transcriptomic	O
study	O
using	O
the	O
Affymetrix	O
wheat	B
GeneChip	O
to	O
follow	O
gene	O
expression	O
in	O
BS366	O
line	O
anthers	O
in	O
response	O
to	O
cold	O
stress	O
.	O

Notably	O
,	O
many	O
cytoskeletal	O
signaling	O
components	O
were	O
gradually	O
induced	O
in	O
response	O
to	O
cold	O
stress	O
in	O
BS366	O
line	O
anthers	O
.	O

However	O
,	O
the	O
cytoskeleton	O
-	O
associated	O
genes	O
that	O
play	O
key	O
roles	O
in	O
the	O
dynamic	O
organization	O
of	O
the	O
cytoskeleton	O
were	O
dramatically	O
repressed	O
.	O

Histological	O
studies	O
revealed	O
that	O
the	O
separation	O
of	O
dyads	O
occurred	O
abnormally	O
during	O
male	O
meiosis	O
I	O
,	O
indicating	O
defective	O
male	O
meiotic	O
cytokinesis	O
.	O

Fluorescence	O
labelling	O
and	O
subcellular	O
histological	O
observations	O
revealed	O
that	O
the	O
phragmoplast	O
was	O
defectively	O
formed	O
and	O
the	O
cell	O
plate	O
was	O
abnormally	O
assembled	O
during	O
meiosis	O
I	O
under	O
cold	O
stress	O
.	O

Based	O
on	O
the	O
transcriptomic	O
analysis	O
and	O
observations	O
of	O
characterized	O
histological	O
changes	O
,	O
our	O
results	O
suggest	O
that	O
cold	O
stress	O
repressed	O
transcription	O
of	O
cytoskeleton	O
dynamic	O
factors	O
and	O
subsequently	O
caused	O
the	O
defective	O
cytokinesis	O
during	O
meiosis	O
I.	O
The	O
results	O
may	O
explain	O
the	O
male	O
sterility	O
caused	O
by	O
low	O
temperature	O
in	O
wheat	O
TGMS	O
lines	O
.	O

Social	O
immunity	O
in	O
honeybees	B
(	O
Apis	B
mellifera	I
)	O
:	O
transcriptome	O
analysis	O
of	O
varroa	O
-	O
hygienic	O
behaviour	O
.	O

Honeybees	B
have	O
evolved	O
a	O
social	O
immunity	O
consisting	O
of	O
the	O
cooperation	O
of	O
individuals	O
to	O
decrease	O
disease	O
in	O
the	O
hive	O
.	O

We	O
identified	O
a	O
set	O
of	O
genes	O
involved	O
in	O
this	O
social	O
immunity	O
by	O
analysing	O
the	O
brain	O
transcriptome	O
of	O
highly	O
varroa	O
-	O
hygienic	O
bees	O
,	O
who	O
efficiently	O
detect	O
and	O
remove	O
brood	O
infected	O
with	O
the	O
Varroa	O
destructor	O
mite	O
.	O

The	O
function	O
of	O
these	O
candidate	O
genes	O
does	O
not	O
seem	O
to	O
support	O
a	O
higher	O
olfactory	O
sensitivity	O
in	O
hygienic	O
bees	O
,	O
as	O
previously	O
hypothesized	O
.	O

However	O
,	O
comparing	O
their	O
genomic	O
profile	O
with	O
those	O
from	O
other	O
behaviours	O
suggests	O
a	O
link	O
with	O
brood	O
care	O
and	O
the	O
highly	O
varroa	O
-	O
hygienic	O
Africanized	B
honeybees	I
.	O

These	O
results	O
represent	O
a	O
first	O
step	O
toward	O
the	O
identification	O
of	O
genes	O
involved	O
in	O
social	O
immunity	O
and	O
thus	O
provide	O
first	O
insights	O
into	O
the	O
evolution	O
of	O
social	O
immunity	O
.	O

Introns	O
,	O
alternative	O
splicing	O
,	O
spliced	O
leader	O
trans	O
-	O
splicing	O
and	O
differential	O
expression	O
of	O
pcna	O
and	O
cyclin	O
in	O
Perkinsus	B
marinus	I
.	O

To	O
gain	O
understanding	O
on	O
the	O
structure	O
and	O
regulation	O
of	O
growth	O
-	O
related	O
genes	O
of	O
the	O
parasitic	O
alveolate	O
Perkinsus	B
marinus	I
,	O
we	O
analyzed	O
genes	O
encoding	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
pcna	O
)	O
and	O
cyclins	O
(	O
cyclin	O
)	O
.	O

Comparison	O
of	O
the	O
full	O
-	O
length	O
cDNAs	O
with	O
the	O
corresponding	O
genomic	O
sequences	O
revealedtrans	O
-	O
splicing	O
of	O
the	O
mRNAs	O
of	O
these	O
genes	O
with	O
a	O
conserved	O
21	O
-	O
22	O
nt	O
spliced	O
leader	O
.	O

Over	O
10	O
copies	O
of	O
pcna	O
were	O
detected	O
,	O
with	O
identical	O
gene	O
structures	O
and	O
similar	O
nucleotide	O
(	O
nt	O
)	O
sequences	O
(	O
88	O
-	O
99	O
%	O
)	O
,	O
encoding	O
largely	O
identical	O
amino	O
acid	O
sequences	O
(	O
aa	O
)	O
.	O

Two	O
distinct	O
types	O
ofcyclin	O
(	O
Pmacyclin1	O
and	O
Pmacyclin2	O
)	O
were	O
identified	O
,	O
with	O
66	O
-	O
69	O
%	O
nt	O
and	O
81	O
-	O
85	O
%	O
aa	O
similarities	O
.	O

Pmacyclin2	O
was	O
organized	O
in	O
tandem	O
repeats	O
,	O
and	O
was	O
alternatively	O
spliced	O
,	O
giving	O
rise	O
to	O
five	O
subtypes	O
of	O
transcripts	O
.	O

For	O
both	O
pcna	O
and	O
cyclin	O
genes	O
,	O
6	O
-	O
10	O
introns	O
were	O
found	O
.	O

Quantitative	O
RT	O
-	O
PCR	O
assays	O
showed	O
that	O
pcna	O
and	O
Pmacyclin2	O
expression	O
levels	O
were	O
low	O
with	O
small	O
variations	O
during	O
a	O
28-h	O
time	O
course	O
,	O
whereas	O
Pmacyclin1	O
transcript	O
abundance	O
was	O
10	O
-	O
100	O
times	O
higher	O
,	O
and	O
increased	O
markedly	O
during	O
active	O
cell	O
division	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
mitoticcyclinand	O
can	O
be	O
a	O
useful	O
growth	O
marker	O
for	O
this	O
species	O
.	O

The	O
gene	O
structure	O
and	O
expression	O
features	O
along	O
with	O
phylogenetic	O
results	O
position	O
this	O
organism	O
between	O
dinoflagellates	O
and	O
apicomplexans	O
,	O
but	O
its	O
definitive	O
affiliation	O
among	O
alveolates	O
requires	O
further	O
studies	O
.	O

Development	O
Time	O
and	O
Body	O
Size	O
in	O
Eupolyphaga	B
sinensis	I
Along	O
a	O
Latitudinal	O
Gradient	O
From	O
China	O
.	O

The	O
responses	O
of	O
organisms	O
to	O
temperature	O
variations	O
may	O
be	O
via	O
short	O
term	O
responses	O
of	O
the	O
phenotype	O
(	O
phenotypic	O
plasticity	O
)	O
,	O
or	O
they	O
could	O
involve	O
long	O
-	O
term	O
evolutionary	O
change	O
and	O
adaptation	O
(	O
via	O
selection	O
)	O
to	O
the	O
genotype	O
.	O

These	O
could	O
involve	O
changes	O
to	O
the	O
mean	O
size	O
of	O
the	O
animal	O
or	O
to	O
the	O
thermal	O
reaction	O
norm	O
.	O

We	O
examined	O
the	O
effects	O
of	O
various	O
temperatures	O
(	O
of	O
22	O
,	O
25	O
,	O
28	O
,	O
and	O
31	O
^	O
0C	O
)	O
on	O
development	O
time	O
,	O
adult	O
body	O
size	O
and	O
preadult	O
survivorship	O
in	O
three	O
populations	O
of	O
the	O
cockroach	O
,	O
Eupolyphaga	B
sinensis	I
(	O
Walker	O
)	O
,	O
collected	O
at	O
different	O
latitudes	O
.	O

We	O
found	O
substantial	O
temperature	O
-	O
induced	O
plasticity	O
in	O
development	O
time	O
,	O
body	O
size	O
,	O
and	O
preadult	O
survivorship	O
,	O
indicating	O
that	O
developmental	O
temperatures	O
have	O
strong	O
impacts	O
on	O
growth	O
and	O
life	O
history	O
traits	O
of	O
E.	B
sinensis	I
.	O

Genetic	O
differences	O
for	O
development	O
time	O
,	O
body	O
size	O
,	O
and	O
preadult	O
survivorship	O
were	O
detected	O
among	O
populations	O
,	O
and	O
the	O
three	O
traits	O
exhibited	O
highly	O
significant	O
variations	O
in	O
the	O
responses	O
of	O
different	O
populations	O
to	O
various	O
temperature	O
conditions	O
,	O
indicating	O
genetic	O
differences	O
among	O
populations	O
in	O
terms	O
of	O
thermal	O
reaction	O
norms	O
.	O

We	O
also	O
found	O
that	O
two	O
populations	O
seem	O
to	O
support	O
the	O
beneficial	O
acclimation	O
hypothesis	O
whereas	O
the	O
third	O
mid	O
-	O
latitude	O
population	O
does	O
not	O
.	O

The	O
results	O
are	O
likely	O
because	O
of	O
differences	O
in	O
season	O
length	O
and	O
voltinism	O
,	O
indicating	O
that	O
not	O
only	O
temperature	O
regime	O
but	O
also	O
its	O
interactions	O
with	O
generation	O
time	O
(	O
and	O
development	O
time	O
)	O
,	O
voltinism	O
,	O
and	O
season	O
length	O
are	O
likely	O
to	O
have	O
considerable	O
effects	O
on	O
insect	O
development	O
time	O
and	O
body	O
size	O
.	O

Overall	O
,	O
changes	O
in	O
development	O
time	O
,	O
body	O
size	O
,	O
and	O
preadult	O
survivorship	O
in	O
E.	B
sinensis	I
can	O
all	O
be	O
regarded	O
as	O
adaptations	O
to	O
changing	O
thermal	O
regimes	O
.	O

Age	O
and	O
Sex	O
Related	O
Responsiveness	O
of	O
Tribolium	B
castaneum	I
(	O
Coleoptera	O
:	O
Tenebrionidae	O
)	O
in	O
Novel	O
Behavioral	O
Bioassays	O
.	O

The	O
hardiness	O
and	O
mobile	O
nature	O
of	O
Tribolium	B
castaneum	I
(	I
Herbst	I
)	O
make	O
them	O
easy	O
to	O
work	O
with	O
but	O
are	O
the	O
same	O
factors	O
that	O
make	O
their	O
responses	O
to	O
behavior	O
-	O
modifying	O
chemical	O
stimuli	O
difficult	O
to	O
evaluate	O
.	O

To	O
overcome	O
these	O
difficulties	O
two	O
bioassays	O
were	O
developed	O
:	O
a	O
two	O
-	O
choice	O
test	O
with	O
airflow	O
and	O
a	O
diffusion	O
-	O
based	O
test	O
to	O
evaluate	O
responses	O
to	O
chemical	O
stimuli	O
.	O

The	O
two	O
-	O
choice	O
assay	O
is	O
excellent	O
for	O
rapidly	O
comparing	O
two	O
stimuli	O
or	O
examining	O
the	O
response	O
to	O
one	O
stimulus	O
against	O
a	O
control	O
.	O

The	O
diffusion	O
assay	O
determines	O
differences	O
in	O
orientation	O
behavior	O
to	O
multiple	O
simultaneous	O
stimuli	O
and	O
can	O
examine	O
other	O
behaviors	O
during	O
exposure	O
.	O

Preparation	O
of	O
individuals	O
for	O
bioassay	O
is	O
also	O
important	O
,	O
because	O
disturbance	O
increases	O
the	O
activity	O
level	O
of	O
individual	O
beetles	O
beyond	O
the	O
duration	O
of	O
the	O
disturbance	O
.	O

The	O
age	O
and	O
the	O
sex	O
of	O
beetles	O
affect	O
responsiveness	O
to	O
chemical	O
cues	O
.	O

These	O
bioassays	O
and	O
a	O
better	O
understanding	O
of	O
T.	B
castaneum	I
's	O
activity	O
have	O
revealed	O
approaches	O
for	O
evaluating	O
its	O
responsiveness	O
to	O
behavior	O
-	O
modifying	O
chemicals	O
.	O

Monoclonal	O
antibody	O
-	O
based	O
triple	O
antibody	O
sandwich	O
-	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
immunocapture	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
for	O
Odontoglossum	B
ringspot	I
virus	I
detection	O
.	O

Odontoglossum	B
ringspot	I
virus	I
(	O
ORSV	B
)	O
infects	O
numerous	O
commercially	O
important	O
orchids	O
and	O
causes	O
significant	O
losses	O
worldwide	O
.	O

The	O
coat	O
protein	O
(	O
CP	O
)	O
gene	O
of	O
ORSV	B
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	B
coli	I
by	O
using	O
the	O
pET-32a	O
expression	O
vector	O
,	O
and	O
the	O
expression	O
of	O
recombinant	O
protein	O
was	O
confirmed	O
by	O
Western	O
blotting	O
using	O
anti	O
-	O
ORSV	B
antibodies	O
.	O

The	O
recombinant	O
protein	O
was	O
purified	O
using	O
Ni	O
-	O
NTA	O
agarose	O
,	O
and	O
the	O
purified	O
protein	O
was	O
used	O
as	O
an	O
immunogen	O
to	O
produce	O
monoclonal	O
antibodies	O
(	O
MAbs	O
)	O
and	O
polyclonal	O
antibodies	O
(	O
PAbs	O
)	O
.	O

Five	O
murine	O
MAbs	O
against	O
ORSV	B
CP	O
were	O
obtained	O
.	O

Among	O
them	O
,	O
two	O
MAbs	O
(	O
6B4	O
and	O
1D1	O
)	O
also	O
reacted	O
with	O
TMV	O
CP	O
.	O

The	O
triple	O
antibody	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
TAS	O
-	O
ELISA	O
)	O
and	O
immunocapture	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
(	O
IC	O
-	O
RT	O
-	O
PCR	O
)	O
methods	O
using	O
the	O
MAb	O
(	O
8A5	O
)	O
were	O
then	O
developed	O
for	O
sensitive	O
,	O
specific	O
,	O
and	O
rapid	O
detection	O
of	O
ORSV	B
.	O

TAS	O
-	O
ELISA	O
and	O
IC	O
-	O
RT	O
-	O
PCR	O
could	O
detect	O
ORSV	B
in	O
the	O
infected	O
leaf	O
saps	O
with	O
dilutions	O
of	O
1:10,240	O
and	O
1:81,920	O
(	O
w	O
/	O
v	O
,	O
g	O
mL	O
(	O
-1	O
)	O
)	O
,	O
respectively	O
.	O

TAS	O
-	O
ELISA	O
and	O
IC	O
-	O
RT	O
-	O
PCR	O
detections	O
indicated	O
that	O
ORSV	B
was	O
prevalent	O
in	O
orchids	O
in	O
the	O
Zhejiang	O
Province	O
of	O
China	O
.	O

A	O
review	O
of	O
the	O
implications	O
of	O
heterozygosity	O
and	O
inbreeding	O
on	O
germplasm	O
biodiversity	O
and	O
its	O
conservation	O
in	O
the	O
silkworm	B
,	O
Bombyx	B
mori	I
.	O

Abstract	O
Silkworm	B
genebanks	O
assume	O
paramount	O
importance	O
as	O
the	O
reservoirs	O
of	O
biodiversity	O
and	O
source	O
of	O
alleles	O
that	O
can	O
be	O
easily	O
retrieved	O
for	O
genetic	O
enhancement	O
of	O
popular	O
breeds	O
.	O

More	O
than	O
4000	O
Bombyx	B
mori	I
L	O
(	O
Lepidoptera	O
:	O
Bombycidae	O
)	O
strains	O
are	O
currently	O
available	O
and	O
these	O
strains	O
are	O
maintained	O
through	O
continuous	O
sibling	O
mating	O
.	O

This	O
repeated	O
sibling	O
mating	O
makes	O
the	O
populations	O
of	O
each	O
strain	O
more	O
homozygous	O
,	O
but	O
leads	O
to	O
loss	O
of	O
unique	O
and	O
valuable	O
genes	O
through	O
the	O
process	O
of	O
inbreeding	O
depression	O
.	O

Hence	O
,	O
it	O
is	O
essential	O
to	O
maintain	O
a	O
minimal	O
degree	O
of	O
heterozygosity	O
within	O
the	O
population	O
of	O
each	O
silkworm	B
strain	O
,	O
especially	O
in	O
the	O
traditional	O
geographic	O
strains	O
,	O
to	O
avoid	O
such	O
loss	O
.	O

As	O
a	O
result	O
,	O
accurate	O
estimation	O
of	O
genetic	O
diversity	O
is	O
becoming	O
more	O
important	O
in	O
silkworm	B
genetic	O
resources	O
conservation	O
.	O

Application	O
of	O
molecular	O
markers	O
help	O
estimate	O
genetic	O
diversity	O
much	O
more	O
accurately	O
than	O
that	O
of	O
morphological	O
traits	O
.	O

Since	O
a	O
minimal	O
amount	O
of	O
heterozygosity	O
in	O
each	O
silkworm	B
strain	O
is	O
essential	O
for	O
better	O
conservation	O
by	O
avoiding	O
inbreeding	O
depression	O
,	O
this	O
article	O
overviews	O
both	O
theoretical	O
and	O
practical	O
importance	O
of	O
heterozygosity	O
together	O
with	O
impacts	O
of	O
inbreeding	O
depression	O
and	O
the	O
merits	O
and	O
demerits	O
of	O
neutral	O
molecular	O
markers	O
for	O
measurements	O
of	O
both	O
heterozygosity	O
and	O
inbreeding	O
depression	O
in	O
the	O
silkworm	B
Bombyx	B
mori	I
.	O

Evidence	O
for	O
the	O
higher	O
importance	O
of	O
signal	O
size	O
over	O
body	O
size	O
in	O
aposematic	O
signaling	O
in	O
insects	O
.	O

To	O
understand	O
the	O
evolution	O
of	O
warning	O
coloration	O
,	O
it	O
is	O
important	O
to	O
distinguish	O
between	O
different	O
aspects	O
of	O
conspicuous	O
color	O
patterns	O
.	O

As	O
an	O
example	O
,	O
both	O
pattern	O
element	O
size	O
and	O
body	O
size	O
of	O
prey	O
have	O
been	O
shown	O
to	O
enhance	O
the	O
effectiveness	O
of	O
warning	O
signals	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
effect	O
of	O
body	O
size	O
is	O
merely	O
a	O
side	O
effect	O
of	O
proportionally	O
increasing	O
pattern	O
elements	O
,	O
or	O
if	O
there	O
is	O
an	O
effect	O
of	O
body	O
size	O
per	O
se	O
.	O

These	O
possibilities	O
were	O
evaluated	O
by	O
offering	O
different	O
sized	O
artificial	O
caterpillars	O
with	O
either	O
fixed	O
or	O
proportionally	O
increasing	O
aposematic	O
color	O
signal	O
elements	O
to	O
wild	O
great	B
tits	I
,	O
Parus	B
major	I
L.	I
(	O
Passeriformes	O
:	O
Paridae	O
)	O
.	O

The	O
birds	O
'	O
hesitation	O
time	O
to	O
attack	O
each	O
""""	O
caterpillar	O
""""	O
was	O
used	O
as	O
a	O
measure	O
of	O
the	O
warning	O
effect	O
.	O

The	O
hesitation	O
time	O
showed	O
a	O
significant	O
,	O
positive	O
size	O
-	O
dependence	O
with	O
the	O
caterpillars	O
whose	O
pattern	O
elements	O
increased	O
proportionally	O
with	O
their	O
body	O
size	O
.	O

In	O
contrast	O
,	O
no	O
size	O
dependence	O
was	O
found	O
in	O
the	O
larvae	O
with	O
fixed	O
-	O
size	O
signal	O
elements	O
.	O

Such	O
a	O
difference	O
in	O
mortality	O
curves	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
pattern	O
element	O
size	O
is	O
a	O
more	O
important	O
aspect	O
than	O
body	O
size	O
in	O
enhancing	O
a	O
warning	O
signal	O
.	O

Since	O
no	O
evidence	O
of	O
an	O
effect	O
of	O
body	O
size	O
per	O
se	O
on	O
signal	O
efficiency	O
was	O
found	O
,	O
this	O
study	O
does	O
not	O
support	O
the	O
hypothesis	O
that	O
aposematic	O
insects	O
gain	O
more	O
from	O
large	O
size	O
than	O
cryptic	O
ones	O
.	O

Post	O
-	O
egression	O
host	O
tissue	O
feeding	O
is	O
another	O
strategy	O
of	O
host	O
regulation	O
by	O
the	O
Koinobiont	O
wasp	O
,	O
Toxoneuron	B
nigriceps	I
.	O

Koinobiont	O
wasps	O
start	O
their	O
lives	O
as	O
hemolymph	O
feeders	O
inside	O
the	O
host	O
body	O
,	O
but	O
before	O
they	O
egress	O
from	O
the	O
host	O
many	O
become	O
tissue	O
predators	O
.	O

One	O
species	O
,	O
the	O
endoparasitoid	O
Toxoneuron	B
nigriceps	I
Viereck	O
(	O
Hymenoptera	O
:	O
Braconidae	O
)	O
,	O
exhibits	O
the	O
unusual	O
behavior	O
of	O
egressing	O
before	O
initiating	O
tissue	O
predation	O
.	O

After	O
egression	O
from	O
the	O
host	O
,	O
it	O
reinserts	O
its	O
head	O
into	O
the	O
host	O
body	O
to	O
begin	O
tissue	O
feeding	O
.	O

These	O
third	O
instar	O
T.	B
nigriceps	I
larvae	O
show	O
a	O
significant	O
increase	O
in	O
body	O
size	O
and	O
mass	O
after	O
post	O
-	O
egression	O
feeding	O
.	O

Through	O
this	O
project	O
the	O
importance	O
of	O
post	O
-	O
egression	O
feeding	O
in	O
the	O
development	O
of	O
T.	B
nigriceps	I
in	O
its	O
host	O
the	O
tobacco	B
budworm	I
,	O
Heliothis	B
virescens	I
Fabricius	O
(	O
Lepidoptera	O
:	O
Noctuidae	O
)	O
,	O
has	O
been	O
evaluated	O
.	O

The	O
study	O
was	O
conducted	O
by	O
preventing	O
the	O
egressed	O
third	O
instar	O
T.	B
nigriceps	I
larvae	O
from	O
feeding	O
on	O
host	O
tissue	O
and	O
observing	O
whether	O
they	O
could	O
undergo	O
further	O
development	O
.	O

Though	O
some	O
of	O
the	O
larvae	O
that	O
were	O
prevented	O
from	O
post	O
-	O
egression	O
feeding	O
did	O
undergo	O
cocoon	O
formation	O
,	O
pupation	O
,	O
and	O
adult	O
emergence	O
they	O
were	O
inferior	O
in	O
terms	O
of	O
size	O
,	O
body	O
mass	O
,	O
and	O
survival	O
to	O
those	O
that	O
developed	O
from	O
larvae	O
allowed	O
to	O
feeding	O
after	O
egression	O
.	O

Hence	O
,	O
it	O
is	O
concluded	O
that	O
post	O
-	O
egression	O
host	O
tissue	O
feeding	O
is	O
essential	O
for	O
the	O
normal	O
development	O
of	O
T.	B
nigriceps	I
,	O
as	O
the	O
prevention	O
of	O
feeding	O
resulted	O
in	O
significantly	O
lighter	O
and	O
smaller	O
larvae	O
,	O
cocoons	O
,	O
and	O
adults	O
as	O
well	O
as	O
deformed	O
adults	O
and	O
reduced	O
adult	O
survival	O
.	O

Post	O
-	O
egression	O
feeding	O
as	O
a	O
host	O
regulatory	O
strategy	O
is	O
discussed	O
.	O

Transcript	O
analysis	O
and	O
comparative	O
evaluation	O
of	O
shaker	O
and	O
slowmo	O
gene	O
homologues	O
from	O
the	O
European	B
corn	I
borer	I
,	O
Ostrinia	B
nubilalis	I
.	O

The	O
movement	O
and	O
dispersal	O
of	O
larval	O
Lepidoptera	O
impact	O
their	O
survival	O
and	O
distribution	O
within	O
the	O
natural	O
landscape	O
.	O

Homologues	O
of	O
the	O
Drosophila	O
behaviour	O
-	O
linked	O
genes	O
shaker	O
(	O
shkr	O
)	O
and	O
slowmo	O
(	O
slmo	O
)	O
were	O
identified	O
from	O
Ostrinia	B
nubilalis	I
(	O
Lepidoptera	O
:	O
Crambidae	O
)	O
.	O

Onshkr	O
was	O
isolated	O
as	O
a	O
1610-nucleotide	O
(	O
nt	O
)	O
constitutively	O
expressed	O
transcript	O
encoding	O
a	O
membrane	O
-	O
localized	O
469-amino	O
-	O
acid	O
(	O
aa	O
)	O
protein	O
with	O
a	O
conserved	O
tetramerization	O
domain	O
and	O
the	O
six	O
-	O
domain	O
architecture	O
necessary	O
for	O
the	O
molecule	O
to	O
fold	O
into	O
an	O
active	O
K	O
(	O
+	O
)	O
channel	O
.	O

Three	O
expressed	O
splice	O
variants	O
of	O
682	O
,	O
970	O
and	O
1604	O
nt	O
were	O
identified	O
for	O
the	O
Onslmo	O
gene	O
,	O
and	O
encode	O
predicted	O
141	O
and	O
228	O
aa	O
proteins	O
with	O
a	O
conserved	O
protein	O
of	O
relevant	O
evolutionary	O
and	O
lymphoid	O
interest	O
(	O
PRELI	O
)	O
domain	O
that	O
may	O
function	O
in	O
mitochondrial	O
protein	O
sorting	O
and	O
perinuclear	O
protein	O
localization	O
.	O

Onshkr	O
and	O
Onslmo	O
protein	O
sequences	O
aligned	O
within	O
monophyletic	O
lepidopteran	O
groups	O
.	O

Projectin	O
PEVK	O
domain	O
,	O
splicing	O
variants	O
and	O
domain	O
structure	O
in	O
basal	O
and	O
derived	O
insects	O
.	O

The	O
third	O
elastic	O
filament	O
of	O
striated	O
muscles	O
consists	O
of	O
giant	O
proteins	O
:	O
titin	O
(	O
in	O
vertebrates	O
)	O
and	O
kettin	O
/	O
projectin	O
(	O
in	O
insects	O
)	O
.	O

In	O
all	O
three	O
proteins	O
,	O
elasticity	O
is	O
at	O
least	O
partly	O
associated	O
with	O
the	O
so	O
-	O
called	O
PEVK	O
domain	O
.	O

The	O
projectin	O
PEVK	O
domains	O
of	O
diverse	O
insects	O
are	O
highly	O
divergent	O
compared	O
with	O
an	O
otherwise	O
conserved	O
protein	O
organization	O
.	O

We	O
present	O
the	O
characterization	O
of	O
the	O
PEVK	O
domain	O
in	O
two	O
dragonflies	O
and	O
in	O
human	B
lice	I
.	O

A	O
conserved	O
segment	O
at	O
the	O
end	O
of	O
the	O
PEVK	O
,	O
the	O
NH	O
(	O
2	O
)	O
-terminal	O
conserved	O
segment-1	O
(	O
NTCS-1	O
)	O
,	O
may	O
serve	O
as	O
an	O
anchor	O
point	O
for	O
projectin	O
to	O
either	O
myosin	O
or	O
actin	O
,	O
providing	O
a	O
mechanical	O
link	O
.	O

The	O
analysis	O
of	O
alternative	O
splicing	O
variants	O
identifies	O
the	O
shortest	O
PEVK	O
isoform	O
as	O
the	O
predominant	O
form	O
in	O
the	O
flight	O
muscles	O
of	O
several	O
insects	O
,	O
possibly	O
contributing	O
to	O
myofibrillar	O
stiffness	O
.	O

Clinical	O
management	O
of	O
Staphylococcus	B
aureus	I
bacteraemia	O
.	O

Staphylococcus	B
aureus	I
bacteraemia	O
is	O
one	O
of	O
the	O
most	O
common	O
serious	O
bacterial	O
infections	O
worldwide	O
.	O

In	O
the	O
UK	O
alone	O
,	O
around	O
12,500	O
cases	O
each	O
year	O
are	O
reported	O
,	O
with	O
an	O
associated	O
mortality	O
of	O
about	O
30	O
%	O
,	O
yet	O
the	O
evidence	O
guiding	O
optimum	O
management	O
is	O
poor	O
.	O

To	O
date	O
,	O
fewer	O
than	O
1500	O
patients	O
with	O
S	B
aureus	I
bacteraemia	O
have	O
been	O
recruited	O
to	O
16	O
controlled	O
trials	O
of	O
antimicrobial	O
therapy	O
.	O

Consequently	O
,	O
clinical	O
practice	O
is	O
driven	O
by	O
the	O
results	O
of	O
observational	O
studies	O
and	O
anecdote	O
.	O

Here	O
,	O
we	O
propose	O
and	O
review	O
ten	O
unanswered	O
clinical	O
questions	O
commonly	O
posed	O
by	O
those	O
managing	O
S	B
aureus	I
bacteraemia	O
.	O

Our	O
findings	O
define	O
the	O
major	O
areas	O
of	O
uncertainty	O
in	O
the	O
management	O
of	O
S	B
aureus	I
bacteraemia	O
and	O
highlight	O
just	O
two	O
key	O
principles	O
.	O

First	O
,	O
all	O
infective	O
foci	O
must	O
be	O
identified	O
and	O
removed	O
as	O
soon	O
as	O
possible	O
.	O

Second	O
,	O
long	O
-	O
term	O
antimicrobial	O
therapy	O
is	O
required	O
for	O
those	O
with	O
persistent	O
bacteraemia	O
or	O
a	O
deep	O
,	O
irremovable	O
focus	O
.	O

Beyond	O
this	O
,	O
the	O
best	O
drugs	O
,	O
dose	O
,	O
mode	O
of	O
delivery	O
,	O
and	O
duration	O
of	O
therapy	O
are	O
uncertain	O
,	O
a	O
situation	O
compounded	O
by	O
emerging	O
S	B
aureus	I
strains	O
that	O
are	O
resistant	O
to	O
old	O
and	O
new	O
antibiotics	O
.	O

We	O
discuss	O
the	O
consequences	O
on	O
clinical	O
practice	O
,	O
and	O
how	O
these	O
findings	O
define	O
the	O
agenda	O
for	O
future	O
clinical	O
research	O
.	O

A	O
new	O
model	O
of	O
Epstein	B
-	I
Barr	I
virus	I
infection	O
reveals	O
an	O
important	O
role	O
for	O
earlylytic	O
viral	O
protein	O
expression	O
in	O
the	O
development	O
of	O
lymphomas	O
.	O

Epstein	B
-	I
Barr	I
virus	I
(	O
EBV	B
)	O
infects	O
cells	O
in	O
latent	O
or	O
lytic	O
forms	O
,	O
but	O
the	O
roleof	O
lytic	O
infection	O
in	O
EBV	B
-	O
induced	O
lymphomas	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
have	O
used	O
anew	O
humanized	O
mouse	B
model	O
,	O
in	O
which	O
both	O
human	B
fetal	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
stemcells	O
and	O
thymus	O
/	O
liver	O
tissue	O
are	O
transplanted	O
,	O
to	O
compare	O
EBV	B
pathogenesis	O
andlymphoma	O
formation	O
following	O
infection	O
with	O
a	O
lytic	O
replication	O
-	O
defectiveBZLF1-deleted	O
(	O
Z	O
-	O
KO	O
)	O
virus	O
or	O
a	O
lytically	O
active	O
BZLF1	O
(	O
+	O
)	O
control	O
.	O

Both	O
thecontrol	O
and	O
Z	O
-	O
KO	O
viruses	O
established	O
long	O
-	O
term	O
viral	O
latency	O
in	O
all	O
infectedanimals	O
.	O

The	O
infection	O
appeared	O
well	O
controlled	O
in	O
some	O
animals	O
,	O
but	O
otherseventually	O
developed	O
CD20	O
(	O
+	O
)	O
diffuse	O
large	O
B	O
cell	O
lymphomas	O
(	O
DLBCL	O
)	O
.	O

Animalsinfected	O
with	O
the	O
control	O
virus	O
developed	O
tumors	O
more	O
frequently	O
than	O
Z	O
-	O
KOvirus	O
-	O
infected	O
animals	O
.	O

Specific	O
immune	O
responses	O
against	O
EBV	B
-	O
infected	O
B	O
cellswere	O
generated	O
in	O
mice	B
infected	O
with	O
either	O
the	O
control	O
virus	O
or	O
the	O
Z	O
-	O
KOvirus	O
.	O

In	O
both	O
cases	O
,	O
forms	O
of	O
viral	O
latency	O
(	O
type	O
I	O
and	O
type	O
IIB	O
)	O
wereobserved	O
that	O
are	O
less	O
immunogenic	O
than	O
the	O
highly	O
transforming	O
form	O
(	O
type	O
III	O
)	O
commonly	O
found	O
in	O
tumors	O
of	O
immunocompromised	O
hosts	O
,	O
suggesting	O
that	O
immunepressure	O
contributed	O
to	O
the	O
outcome	O
of	O
the	O
infection	O
.	O

These	O
results	O
point	O
to	O
animportant	O
role	O
for	O
lytic	O
EBV	B
infection	O
in	O
the	O
development	O
of	O
B	O
cell	O
lymphomasin	O
the	O
context	O
of	O
an	O
active	O
host	O
immune	O
response	O
.	O

Serine	O
-	O
threonine	O
ubiquitination	O
mediates	O
downregulation	O
of	O
BST-2	O
/	O
tetherin	O
and	O
relief	O
of	O
restricted	O
virion	O
release	O
by	O
HIV-1	B
Vpu	O
.	O

The	O
HIV-1	B
protein	O
Vpu	O
counteracts	O
the	O
antiviral	O
activity	O
of	O
the	O
innate	O
restriction	O
factor	O
BST-2	O
/	O
tetherin	O
by	O
a	O
mechanism	O
that	O
partly	O
depends	O
on	O
its	O
interaction	O
with	O
Beta	O
-	O
TrCP	O
,	O
a	O
substrate	O
adaptor	O
for	O
an	O
SCF	O
(	O
Skp	O
-	O
Cullin	O
1-F	O
box	O
)	O
E3	O
ubiquitin	O
ligase	O
complex	O
.	O

This	O
suggests	O
that	O
Vpu	O
stimulates	O
the	O
ubiquitination	O
of	O
BST-2	O
and	O
that	O
this	O
underlies	O
the	O
relief	O
of	O
restriction	O
.	O

Here	O
,	O
we	O
show	O
that	O
Vpu	O
stimulates	O
ubiquitination	O
of	O
BST-2	O
.	O

Mutation	O
of	O
all	O
potential	O
ubiquitination	O
sites	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
BST-2	O
,	O
including	O
lysines	O
,	O
cysteines	O
,	O
serines	O
,	O
and	O
threonines	O
,	O
abrogates	O
Vpu	O
-	O
mediated	O
ubiquitination	O
.	O

However	O
,	O
a	O
serine	O
-	O
threonine	O
-	O
serine	O
sequence	O
specifically	O
mediates	O
the	O
downregulation	O
of	O
BST-2	O
from	O
the	O
cell	O
surface	O
and	O
the	O
optimal	O
relief	O
of	O
restricted	O
virion	O
release	O
.	O

Serine	O
-	O
threonine	O
ubiquitination	O
of	O
BST-2	O
is	O
likely	O
part	O
of	O
the	O
mechanism	O
by	O
which	O
Vpu	O
counteracts	O
innate	O
defenses	O
.	O

Small	O
-	O
molecule	O
inhibition	O
of	O
human	B
immunodeficiency	I
virus	I
type	I
1	O
infection	O
by	O
virus	O
capsid	O
destabilization	O
.	O

Human	B
immunodeficiency	I
virus	I
type	I
1	O
(	O
HIV-1	B
)	O
infection	O
is	O
dependent	O
on	O
the	O
proper	O
disassembly	O
of	O
the	O
viral	O
capsid	O
,	O
or	O
""""	O
uncoating	O
,	O
""""	O
in	O
target	O
cells	O
.	O

The	O
HIV-1	O
capsid	O
consists	B
of	O
a	O
conical	O
multimeric	O
complex	O
of	O
the	O
viral	O
capsid	O
protein	O
(	O
CA	O
)	O
arranged	O
in	O
a	O
hexagonal	O
lattice	O
.	O

Mutations	O
in	O
CA	O
that	O
destabilize	O
the	O
viral	O
capsid	O
result	O
in	O
impaired	O
infection	O
owing	O
to	O
defects	O
in	O
reverse	O
transcription	O
in	O
target	O
cells	O
.	O

We	O
describe	O
here	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
small	O
molecule	O
HIV-1	O
inhibitor	O
,	O
PF-3450074	O
(	O
PF74	O
)	O
,	O
which	O
targets	O
CA	O
.	O

PF74	O
acts	O
at	O
an	O
early	O
stage	O
of	O
HIV-1	O
infection	O
and	O
inhibits	O
reverse	O
transcription	O
in	O
target	O
cells	O
.	O

We	O
show	O
that	O
PF74	O
binds	O
specifically	O
to	O
HIV-1	O
particles	O
,	O
and	O
substitutions	O
in	O
CA	O
that	O
confer	O
resistance	O
to	O
the	O
compound	O
prevent	O
binding	O
.	O

A	O
single	O
point	O
mutation	O
in	O
CA	O
that	O
stabilizes	O
the	O
HIV-1	O
core	O
also	B
conferred	O
strong	O
resistance	O
to	O
the	O
virus	O
without	O
inhibiting	O
compound	O
binding	O
.	O

Treatment	O
of	O
HIV-1	O
particles	O
or	O
purified	O
cores	O
with	O
PF74	O
destabilized	O
the	O
viral	O
capsid	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
compound	O
induced	O
the	O
rapid	O
dissolution	O
of	O
the	O
HIV-1	O
capsid	O
in	B
target	O
cells	O
.	O

PF74	O
antiviral	O
activity	O
was	O
promoted	O
by	O
binding	O
of	O
the	O
host	O
protein	O
cyclophilin	O
A	O
to	O
the	O
HIV-1	O
capsid	O
,	B
and	O
PF74	O
and	O
cyclosporine	O
exhibited	O
mutual	O
antagonism	O
.	O

Our	O
data	O
suggest	O
that	O
PF74	O
triggers	O
premature	O
HIV-1	O
uncoating	O
in	O
target	O
cells	O
,	O
thereby	O
mimicking	O
the	O
activity	O
of	O
the	O
retrovirus	O
restriction	O
factor	O
TRIM5alpha	O
.	O

This	O
study	O
highlights	O
uncoating	O
as	O
a	O
step	O
in	O
the	O
HIV-1	O
life	O
cycle	B
that	O
is	O
susceptible	O
to	O
small	O
molecule	O
intervention	O
.	O

Macaque	O
long	O
-	O
term	O
nonprogressors	O
resist	O
superinfection	O
with	O
multiple	O
CD8	O
+	O
T	O
cell	O
escape	O
variants	O
of	O
simian	B
immunodeficiency	I
virus	I
.	O

Human	B
immunodeficiency	I
virus	I
(	O
HIV	B
)	O
-positive	O
individuals	O
can	O
be	O
superinfected	O
with	O
different	O
virus	O
strains	O
.	O

Individuals	O
who	O
control	O
an	O
initial	O
HIV	B
infection	O
are	O
therefore	O
still	O
at	O
risk	O
for	O
subsequent	O
infection	O
with	O
divergent	O
viruses	O
,	O
but	O
the	O
barriers	O
to	O
such	O
superinfection	O
remain	O
unclear	O
.	O

Here	O
we	O
tested	O
long	O
-	O
term	O
nonprogressors	O
'	O
(	O
LTNPs	O
'	O
)	O
susceptibility	O
to	O
superinfection	O
using	O
Indian	B
rhesus	I
macaques	I
that	O
express	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
(	O
MHC	O
-	O
I	O
)	O
allele	O
Mamu	O
-	O
B	O
17	O
,	O
which	O
is	O
associated	O
with	O
control	O
of	O
the	O
pathogenic	O
AIDS	O
virus	B
SIVmac239	I
.	O

The	O
Mamu	O
-	O
B	O
17-restricted	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
repertoire	O
is	O
focused	O
almost	O
entirely	O
on	O
5	O
epitopes	O
.	O

We	O
engineered	O
a	O
series	O
of	O
SIVmac239	O
variants	O
bearing	O
mutations	O
in	O
3	O
,	O
4	O
,	O
or	O
all	O
5	O
of	O
these	O
epitopes	O
and	O
used	O
them	O
to	O
serially	O
challenge	O
2	O
Mamu	O
-	O
B	O
17-positive	O
LTNPs	O
.	O

None	O
of	O
the	O
escape	O
variants	O
caused	O
breakthrough	O
replication	O
in	O
LTNPs	O
,	O
although	O
they	O
readily	O
infected	O
Mamu	O
-	O
B	O
17-negative	O
naive	O
macaques	O
.	O

In	O
vitro	O
competing	O
coculture	O
assays	O
and	O
examination	O
of	O
viral	O
evolution	O
in	O
hosts	O
lacking	O
Mamu	O
-	O
B	O
17	O
suggested	O
that	O
the	O
mutant	O
viruses	O
had	O
negligible	O
defects	O
in	O
replicative	O
fitness	O
.	O

Both	O
LTNPs	O
maintained	O
robust	O
immune	O
responses	O
,	O
including	O
simian	B
immunodeficiency	I
virus	I
(	O
SIV	B
)	O
-specific	O
CD8	O
(	O
+	O
)	O
and	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
and	O
neutralizing	O
antibodies	O
.	O

Our	O
results	O
suggest	O
that	O
escape	O
mutations	O
in	O
epitopes	O
bound	O
by	O
""""	O
protective	O
""""	O
MHC	O
-	O
I	O
molecules	O
may	O
not	O
be	O
sufficient	O
to	O
establish	O
superinfection	O
in	O
LTNPs	O
.	O

Determinants	O
that	O
specify	O
the	O
integration	O
pattern	O
of	O
retrotransposon	O
Tf1	O
in	O
the	O
fbp1	O
promoter	O
of	O
Schizosaccharomyces	B
pombe	I
.	O

Long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
retrotransposons	O
are	O
closely	O
related	O
to	O
retroviruses	O
and	O
,	O
as	O
such	O
,	O
are	O
important	O
models	O
for	O
the	O
study	O
of	O
viral	O
integration	O
and	O
target	O
site	O
selection	O
.	O

The	O
transposon	O
Tf1	O
of	O
Schizosaccharomyces	B
pombe	I
integrates	O
with	O
a	O
strong	O
preference	O
for	O
the	O
promoters	O
of	O
polymerase	O
II	O
(	O
Pol	O
II	O
)	O
-transcribed	O
genes	O
.	O

Previous	O
work	O
in	O
vivo	O
with	O
plasmid	O
-	O
based	O
targets	O
revealed	O
that	O
the	O
patterns	O
of	O
insertion	O
were	O
promoter	O
specific	O
and	O
highly	O
reproducible	O
.	O

To	O
determine	O
which	O
features	O
of	O
promoters	O
are	O
recognized	O
by	O
Tf1	O
,	O
we	O
studied	O
integration	O
in	O
a	O
promoter	O
that	O
has	O
been	O
characterized	O
.	O

The	O
promoter	O
of	O
fbp1	O
has	O
two	O
upstream	O
activating	O
sequences	O
,	O
UAS1	O
and	O
UAS2	O
.	O

We	O
found	O
that	O
integration	O
was	O
targeted	O
to	O
two	O
windows	O
,	O
one	O
180	O
nucleotides	O
(	O
nt	O
)	O
upstream	O
and	O
the	O
other	O
30	O
to	O
40	O
nt	O
downstream	O
of	O
UAS1	O
.	O

A	O
series	O
of	O
deletions	O
in	O
the	O
promoter	O
showed	O
that	O
the	O
integration	O
activities	O
of	O
these	O
two	O
regions	O
functioned	O
autonomously	O
.	O

Integration	O
assays	O
of	O
UAS2	O
and	O
of	O
a	O
synthetic	O
promoter	O
demonstrated	O
that	O
strong	O
promoter	O
activity	O
alone	O
was	O
not	O
sufficient	O
to	O
direct	O
integration	O
.	O

The	O
factors	O
that	O
modulate	O
the	O
transcription	O
activities	O
of	O
UAS1	O
and	O
UAS2	O
include	O
the	O
activators	O
Atf1p	O
,	O
Pcr1p	O
,	O
and	O
Rst2p	O
as	O
well	O
as	O
the	O
repressors	O
Tup11p	O
,	O
Tup12p	O
,	O
and	O
Pka1p	O
.	O

Strains	O
lacking	O
each	O
of	O
these	O
proteins	O
revealed	O
that	O
Atf1p	O
alone	O
mediated	O
the	O
sites	O
of	O
integration	O
.	O

These	O
data	O
indicate	O
that	O
Atf1p	O
plays	O
a	O
direct	O
and	O
specific	O
role	O
in	O
targeting	O
integration	O
in	O
the	O
promoter	O
of	O
fbp1	O
.	O

Replicative	O
and	O
transcriptional	O
activities	O
of	O
hepatitis	B
B	I
virus	I
in	O
patients	O
coinfected	O
with	O
hepatitis	B
B	O
and	O
hepatitis	B
delta	I
viruses	I
.	O

Hepatitis	B
B	I
virus	I
(	O
HBV	B
)	O
and	O
hepatitis	B
delta	I
virus	I
(	O
HDV	B
)	O
interplay	O
was	O
investigated	O
by	O
examining	O
liver	O
and	O
serum	O
samples	O
from	O
21	O
coinfected	O
and	O
22	O
HBV	B
-	O
monoinfected	O
patients	O
with	O
chronic	O
liver	O
disease	O
.	O

Different	O
real	O
-	O
time	O
PCR	O
assays	O
were	O
applied	O
to	O
evaluate	O
intrahepatic	O
amounts	O
of	O
HBV	B
DNA	O
,	O
covalently	O
closed	O
circular	O
DNA	O
(	O
cccDNA	O
)	O
,	O
pregenomic	O
RNA	O
(	O
pgRNA	O
)	O
,	O
pre	O
-	O
S	O
/	O
S	O
RNAs	O
,	O
and	O
HDV	B
RNA	O
.	O

Besides	O
HBV	B
DNA	O
and	O
HDV	B
RNA	O
levels	O
,	O
HBsAg	O
concentrations	O
in	O
the	O
sera	O
were	O
also	O
determined	O
.	O

HDV	B
-	O
coinfected	O
cases	O
showed	O
significantly	O
lower	O
median	O
levels	O
of	O
serum	O
HBV	B
DNA	O
(	O
-5	O
log	O
)	O
,	O
intrahepatic	O
relaxed	O
-	O
circular	O
DNA	O
(	O
-2	O
log	O
)	O
,	O
and	O
cccDNA	O
(	O
-2	O
log	O
)	O
than	O
those	O
of	O
HBV	B
-	O
monoinfected	O
cases	O
.	O

Interestingly	O
,	O
pgRNA	O
and	O
pre	O
-	O
S	O
/	O
S	O
RNA	O
amounts	O
were	O
significantly	O
lower	O
(	O
both	O
-1	O
log	O
)	O
in	O
HDV	B
-	O
positive	O
patients	O
,	O
whereas	O
serum	O
HBsAg	O
concentrations	O
were	O
comparable	O
between	O
the	O
two	O
patient	O
groups	O
.	O

Pre	O
-	O
S	O
/	O
S	O
RNA	O
and	O
HBsAg	O
amounts	O
per	O
cccDNA	O
molecule	O
were	O
higher	O
in	O
HDV	B
-	O
positive	O
patients	O
(	O
3-fold	O
and	O
1	O
log	O
,	O
respectively	O
)	O
,	O
showing	O
that	O
HBV	B
replication	O
was	O
reduced	O
,	O
whereas	O
synthesis	O
of	O
envelope	O
proteins	O
was	O
not	O
specifically	O
decreased	O
.	O

The	O
ratios	O
of	O
cccDNA	O
to	O
intracellular	O
total	O
HBV	B
DNA	O
showed	O
a	O
larger	O
proportion	O
of	O
cccDNA	O
molecules	O
in	O
HDV	B
-	O
positive	O
cases	O
.	O

For	O
these	O
patients	O
,	O
both	O
intrahepatic	O
and	O
serum	O
HDV	B
RNA	O
amounts	O
were	O
associated	O
with	O
cccDNA	O
but	O
not	O
with	O
HBsAg	O
or	O
HBV	O
DNA	O
levels	O
.	O

Finally	O
,	O
HBV	O
genomes	O
with	O
large	O
deletions	O
in	O
the	O
basal	O
core	O
promoter	O
/	O
precore	O
region	O
were	O
detected	O
in	O
5	O
/	O
21	O
HDV	B
-	O
positive	O
patients	O
but	O
in	O
no	O
HDV	B
-	O
negative	O
patients	O
and	O
were	O
associated	O
with	O
lower	O
viremia	O
levels	O
.	O

These	O
findings	O
provide	O
significant	O
information	O
about	O
the	O
interference	O
exerted	O
by	O
HDV	O
on	O
HBV	B
replication	O
and	O
transcription	O
activities	O
in	O
the	O
human	B
liver	O
.	O

Lasting	O
effects	O
of	O
maternal	O
behaviour	O
on	O
the	O
distribution	O
of	O
a	O
dispersive	O
stream	O
insect	O
.	O

1	O
.	O

Predicting	O
population	O
dynamics	O
at	O
large	O
spatial	O
scales	O
requires	O
integrating	O
information	O
about	O
spatial	O
distribution	O
patterns	O
,	O
inter	O
-	O
patch	O
movement	O
rates	O
and	O
within	O
-	O
patch	O
processes	O
.	O

Advective	O
dispersal	O
of	O
aquatic	O
species	O
by	O
water	O
movement	O
is	O
considered	O
paramount	O
to	O
understanding	O
their	O
population	O
dynamics	O
.	O

Rivers	O
are	O
model	O
advective	O
systems	O
,	O
and	O
the	O
larvae	O
of	O
baetid	O
mayflies	O
are	O
considered	O
quintessential	O
dispersers	O
.	O

Egg	O
laying	O
of	O
baetids	O
along	O
channels	O
is	O
patchy	O
and	O
reflects	O
the	O
distribution	O
of	O
oviposition	O
sites	O
,	O
but	O
larvae	O
are	O
assumed	O
to	O
drift	O
frequently	O
and	O
far	O
,	O
thereby	O
erasing	O
patterns	O
created	O
during	O
oviposition	O
.	O

Dispersal	O
kernels	O
are	O
often	O
overestimated	O
,	O
however	O
,	O
and	O
empirical	O
tests	O
of	O
such	O
assumptions	O
are	O
warranted	O
because	O
of	O
the	O
pivotal	O
role	O
distribution	O
patterns	O
can	O
have	O
on	O
populations	O
.	O

2	O
.	O

We	O
tested	O
empirically	O
whether	O
the	O
egg	O
distribution	O
patterns	O
arising	O
from	O
oviposition	O
behaviours	O
persisted	O
and	O
were	O
reflected	O
in	O
the	O
distribution	O
patterns	O
of	O
larval	O
Baetis	B
rhodani	I
.	O

In	O
field	O
surveys	O
,	O
we	O
tested	O
for	O
associations	O
between	O
egg	O
mass	O
and	O
larval	O
densities	O
over	O
1	O
km	O
lengths	O
of	O
four	O
streams	O
.	O

A	O
control	O
species	O
,	O
the	O
mayfly	O
Ephemerella	O
ignita	O
,	O
was	O
employed	O
to	O
test	O
for	O
covarying	O
environmental	O
factors	O
.	O

We	O
estimated	O
drift	O
rates	O
directly	O
to	O
test	O
whether	O
larvae	O
dispersed	O
between	O
riffles	O
(	O
patches	O
of	O
high	O
egg	O
mass	O
density	O
)	O
and	O
whether	O
drift	O
rates	O
were	O
density	O
-	O
dependent	O
or	O
density	O
-	O
related	O
-	O
expected	O
outcomes	O
if	O
drift	O
erases	O
patterns	O
established	O
by	O
maternal	O
behaviours	O
.	O

3	O
.	O

Positive	O
associations	O
between	O
egg	O
masses	O
and	O
larval	O
benthic	O
densities	O
were	O
found	O
for	O
neonate	O
and	O
mid	O
-	O
stage	O
larvae	O
of	O
Baetis	O
,	O
but	O
not	O
the	O
control	O
species	O
,	O
suggesting	O
persistence	O
of	O
the	O
patchy	O
distribution	O
patterns	O
established	O
at	O
oviposition	O
.	O

Drift	O
rates	O
were	O
high	O
,	O
and	O
riffles	O
were	O
net	O
exporters	O
of	O
neonate	O
and	O
mid	O
-	O
stage	O
larvae	O
,	O
but	O
drift	O
rates	O
were	O
unrelated	O
to	O
benthic	O
densities	O
and	O
few	O
drifters	O
reached	O
the	O
next	O
riffle	O
.	O

Riffles	O
were	O
sinks	O
for	O
large	O
larvae	O
,	O
suggesting	O
ontogenetic	O
shifts	O
in	O
habitat	O
use	O
,	O
but	O
little	O
long	O
-	O
distance	O
dispersal	O
.	O

4	O
.	O

Overall	O
,	O
the	O
results	O
suggest	O
that	O
most	O
neonate	O
and	O
mid	O
-	O
stage	O
larvae	O
of	O
B.	B
rhodani	I
remain	O
close	O
to	O
the	O
natal	O
riffle	O
,	O
and	O
late	O
-	O
stage	O
larvae	O
disperse	O
shorter	O
distances	O
than	O
routinely	O
assumed	O
.	O

The	O
persistence	O
of	O
maternal	O
effects	O
on	O
distribution	O
patterns	O
well	O
into	O
juvenile	O
life	O
of	O
an	O
allegedly	O
iconic	O
disperser	O
suggests	O
that	O
traditional	O
models	O
of	O
how	O
dispersal	O
influences	O
the	O
population	O
dynamics	O
of	O
many	O
lotic	O
invertebrates	O
may	O
be	O
incorrect	O
.	O

Symbiotic	O
Chlorella	B
vulgaris	I
of	O
the	O
ciliate	O
Paramecium	B
bursaria	I
plays	O
an	O
important	O
role	O
in	O
maintaining	O
perialgal	O
vacuole	O
membrane	O
functions	O
.	O

Treatment	O
of	O
symbiotic	O
alga	O
-	O
bearing	O
Paramecium	B
bursaria	I
cells	O
with	O
a	O
protein	O
synthesis	O
inhibitor	O
,	O
cycloheximide	O
,	O
induces	O
synchronous	O
swelling	O
of	O
all	O
perialgal	O
vacuoles	O
at	O
about	O
24h	O
after	O
treatment	O
under	O
a	O
constant	O
light	O
condition	O
.	O

Subsequently	O
,	O
the	O
vacuoles	O
detach	O
from	O
the	O
host	O
cell	O
cortex	O
.	O

The	O
algae	O
in	O
the	O
vacuoles	O
are	O
digested	O
by	O
the	O
host	O
's	O
lysosomal	O
fusion	O
to	O
the	O
vacuoles	O
.	O

To	O
elucidate	O
the	O
timing	O
of	O
algal	O
degeneration	O
,	O
P.	B
bursaria	I
cells	O
were	O
treated	O
with	O
cycloheximide	O
under	O
a	O
constant	O
light	O
condition	O
.	O

Then	O
the	O
cells	O
were	O
observed	O
using	O
transmission	O
electron	O
microscopy	O
.	O

Results	O
show	O
that	O
algal	O
chloroplasts	O
and	O
nuclei	O
degenerated	O
within	O
9h	O
after	O
treatment	O
,	O
but	O
before	O
the	O
synchronous	O
swelling	O
of	O
the	O
perialgal	O
vacuole	O
and	O
appearance	O
of	O
acid	O
phosphatase	O
activity	O
in	O
the	O
perialgal	O
vacuole	O
by	O
lysosomal	O
fusion	O
.	O

Treatment	O
with	O
cycloheximide	O
under	O
a	O
constant	O
dark	O
condition	O
and	O
treatment	O
with	O
chloramphenicol	O
under	O
a	O
constant	O
light	O
condition	O
induced	O
neither	O
synchronous	O
swelling	O
of	O
the	O
vacuoles	O
nor	O
digestion	O
of	O
the	O
algae	O
inside	O
the	O
vacuoles	O
.	O

These	O
results	O
demonstrate	O
that	O
algal	O
proteins	O
synthesized	O
during	O
photosynthesis	O
are	O
necessary	O
to	O
maintain	O
chloroplastic	O
and	O
nuclear	O
structures	O
,	O
and	O
that	O
inhibition	O
of	O
protein	O
synthesis	O
induces	O
rapid	O
lysis	O
of	O
these	O
organelles	O
,	O
after	O
which	O
synchronous	O
swelling	O
of	O
the	O
perialgal	O
vacuole	O
and	O
fusion	O
occur	O
with	O
the	O
host	O
lysosomes	O
.	O

The	O
transcriptional	O
response	O
of	O
Saccharomyces	B
cerevisiae	I
to	O
proapoptotic	O
concentrations	O
of	O
Pichia	B
membranifaciens	I
killer	O
toxin	O
.	O

PMKT	O
(	O
Pichia	B
membranifaciens	I
killer	O
toxin	O
)	O
reportedly	O
has	O
antimicrobial	O
activity	O
against	O
yeasts	B
and	O
filamentous	O
fungi	O
.	O

In	O
previous	O
research	O
we	O
posited	O
that	O
high	O
PMKT	O
concentrations	O
pose	O
a	O
serious	O
challenge	O
for	O
cell	O
survival	O
by	O
disrupting	O
plasma	O
membrane	O
electrochemical	O
gradients	O
,	O
inducing	O
a	O
transcriptional	O
response	O
similar	O
to	O
that	O
of	O
certain	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
.	O

This	O
response	O
was	O
related	O
to	O
the	O
HOG	O
-	O
pathway	O
with	O
Hog1p	O
phosphorylation	O
and	O
a	O
transitional	O
increase	O
in	O
intracellular	O
glycerol	O
accumulation	O
.	O

Such	O
a	O
response	O
was	O
consistent	O
with	O
the	O
notion	O
that	O
the	O
effect	O
induced	O
by	O
high	O
PMKT	O
concentrations	O
lies	O
in	O
an	O
alteration	O
to	O
the	O
ionic	O
homeostasis	O
of	O
the	O
sensitive	O
cell	O
.	O

By	O
contrast	O
,	O
the	O
evidence	O
presented	O
here	O
shows	O
that	O
low	O
PMKT	O
doses	O
lead	O
to	O
a	O
cell	O
death	O
process	O
in	O
Saccharomyces	B
cerevisiae	I
accompanied	O
by	O
cytological	O
and	O
biochemical	O
indicators	O
of	O
apoptotic	O
programmed	O
cell	O
death	O
,	O
namely	O
,	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
,	O
DNA	O
strand	O
breaks	O
,	O
metacaspase	O
activation	O
and	O
cytochrome	O
c	O
release	O
.	O

Furthermore	O
,	O
dying	O
cells	O
progressed	O
from	O
an	O
apoptotic	O
state	O
to	O
a	O
secondary	O
necrotic	O
state	O
,	O
and	O
the	O
rate	O
at	O
which	O
this	O
change	O
occurred	O
was	O
proportional	O
to	O
the	O
intensity	O
of	O
the	O
stimulus	O
.	O

We	O
have	O
explored	O
the	O
global	O
gene	O
expression	O
response	O
of	O
S.	B
cerevisiae	I
during	O
that	O
stimulus	O
.	O

The	O
results	O
obtained	O
from	O
DNA	O
microarrays	O
indicate	O
that	O
genes	O
related	O
with	O
an	O
oxidative	O
stress	O
response	O
were	O
induced	O
in	O
response	O
to	O
proapoptotic	O
concentrations	O
of	O
PMKT	O
,	O
showing	O
that	O
the	O
coordinated	O
transcriptional	O
response	O
is	O
not	O
coincident	O
with	O
that	O
obtained	O
when	O
ionophoric	O
concentrations	O
of	O
PMKT	O
are	O
used	O
.	O

By	O
contrast	O
,	O
cwp2Delta	O
mutants	O
showed	O
no	O
signs	O
of	O
apoptosis	O
,	O
indicating	O
that	O
the	O
initial	O
steps	O
of	O
the	O
killer	O
mechanism	O
coincide	O
when	O
proapoptotic	O
(	O
low	O
)	O
or	O
ionophoric	O
(	O
high	O
)	O
PMKT	O
concentrations	O
are	O
used	O
.	O

Additionally	O
,	O
low	O
dosages	O
of	O
PMKT	O
promoted	O
Hog1p	O
phosphorylation	O
and	O
glycerol	O
accumulation	O
.	O

Real	O
time	O
PCR	O
method	O
for	O
simultaneous	O
detection	O
,	O
quantitation	O
and	O
differentiation	O
of	O
capripoxviruses	O
.	O

The	O
genus	O
Capripoxvirus	O
(	O
CaPV	O
)	O
comprises	O
three	O
members	O
namely	O
,	O
sheep	B
poxvirus	I
(	O
SPPV	B
)	O
,	O
goat	B
poxvirus	I
(	O
GTPV	B
)	O
and	O
lumpy	B
skin	I
disease	I
virus	I
(	O
LSDV	B
)	O
affecting	O
sheep	B
,	O
goats	B
and	O
cattle	B
,	O
respectively	O
.	O

CaPV	O
infections	O
produce	O
similar	O
symptoms	O
in	O
sheep	B
and	O
goats	B
,	O
and	O
the	O
three	O
viruses	O
can	O
not	O
be	O
distinguished	O
serologically	O
.	O

Since	O
there	O
are	O
conflicting	O
opinions	O
regarding	O
the	O
host	O
specificity	O
of	O
CaPVs	O
,	O
particularly	O
for	O
goatpox	B
and	O
sheeppox	B
viruses	I
,	O
the	O
development	O
of	O
rapid	O
genotyping	O
tools	O
will	O
facilitate	O
more	O
accurate	O
disease	O
diagnosis	O
and	O
surveillance	O
for	O
better	O
management	O
of	O
capripox	O
outbreaks	O
.	O

This	O
paper	O
describes	O
a	O
species	O
-	O
specific	O
,	O
real	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
based	O
on	O
unique	O
molecular	O
markers	O
that	O
were	O
found	O
in	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
chemokine	O
receptor	O
(	O
GPCR	O
)	O
gene	O
sequences	O
of	O
CaPVs	O
,	O
that	O
uses	O
dual	O
hybridization	O
probes	O
for	O
their	O
simultaneous	O
detection	O
,	O
quantitation	O
and	O
genotyping	O
.	O

The	O
assay	O
can	O
differentiate	O
between	O
CaPV	O
strains	O
based	O
on	O
differences	O
in	O
the	O
melting	O
point	O
temperature	O
(	O
Tm	O
)	O
obtained	O
after	O
fluorescence	O
melting	O
curve	O
analysis	O
(	O
FMCA	O
)	O
.	O

It	O
is	O
highly	O
sensitive	O
and	O
presents	O
low	O
intra-	O
and	O
inter	O
-	O
run	O
variation	O
.	O

This	O
real	O
time	O
PCR	O
assay	O
will	O
make	O
a	O
significant	O
contribution	O
to	O
CaPV	O
diagnosis	O
and	O
to	O
the	O
better	O
understanding	O
of	O
the	O
epidemiology	O
of	O
CaPVs	O
by	O
enabling	O
rapid	O
genotyping	O
and	O
gene	O
-	O
based	O
classification	O
of	O
viral	O
strains	O
and	O
unequivocal	O
identification	O
of	O
isolates	O
.	O

The	O
Perigord	B
black	I
truffle	I
responds	O
to	O
cold	O
temperature	O
with	O
an	O
extensive	O
reprogramming	O
of	O
its	O
transcriptional	O
activity	O
.	O

The	O
Tuber	B
melanosporum	I
genome	O
has	O
been	O
analysed	O
with	O
the	O
aim	O
of	O
identifying	O
and	O
characterizing	O
the	O
genes	O
involved	O
in	O
the	O
environmental	O
stress	O
response	O
.	O

A	O
whole	O
genome	O
array	O
(	O
7496	O
genes	O
/	O
probe	O
)	O
was	O
used	O
to	O
verify	O
the	O
fungal	O
transcriptional	O
profiling	O
upon	O
a	O
cold	O
temperature	O
period	O
(	O
7	O
days	O
at	O
4	O
^0C	O
)	O
.	O

A	O
total	O
of	O
423	O
genes	O
resulted	O
to	O
be	O
differentially	O
expressed	O
in	O
a	O
significant	O
manner	O
(	O
>	O
2.5-fold	O
;	O
p	O
-	O
value<0.05	O
)	O
in	O
the	O
mycelia	O
exposed	O
to	O
cold	O
,	O
compared	O
to	O
the	O
control	O
ones	O
:	O
187	O
of	O
these	O
genes	O
were	O
up	O
-	O
regulated	O
,	O
while	O
236	O
were	O
down	O
-	O
regulated	O
.	O

Sixty	O
-	O
six	O
and	O
fifty	O
-	O
one	O
percent	O
,	O
respectively	O
,	O
of	O
the	O
up-	O
or	O
down	O
-	O
regulated	O
transcripts	O
had	O
no	O
KOG	O
classification	O
and	O
were	O
clustered	O
as	O
unclassified	O
proteins	O
,	O
which	O
was	O
the	O
most	O
abundant	O
category	O
in	O
the	O
both	O
up-	O
and	O
down	O
-	O
regulated	O
genes	O
.	O

A	O
gene	O
subset	O
,	O
containing	O
a	O
range	O
of	O
biological	O
functions	O
,	O
was	O
chosen	O
to	O
validate	O
the	O
microarray	O
experiment	O
through	O
quantitative	O
real	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
.	O

The	O
analysis	O
confirmed	O
the	O
array	O
data	O
for	O
16	O
out	O
of	O
22	O
of	O
the	O
considered	O
genes	O
,	O
confirming	O
that	O
a	O
cold	O
temperature	O
period	O
influences	O
the	O
truffle	O
global	O
gene	O
expression	O
.	O

The	O
expressed	O
genes	O
,	O
which	O
mostly	O
resulted	O
to	O
be	O
genes	O
for	O
heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
and	O
genes	O
involved	O
in	O
cell	O
wall	O
and	O
lipid	O
metabolism	O
,	O
could	O
be	O
involved	O
in	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
fungal	O
adaptation	O
.	O

Since	O
truffle	O
ascomata	O
develop	O
during	O
the	O
winter	O
period	O
,	O
we	O
hypothesize	O
that	O
these	O
differentially	O
expressed	O
genes	O
may	O
help	O
the	O
truffle	O
to	O
adapt	O
to	O
low	O
temperatures	O
and/or	O
perceive	O
environmental	O
signals	O
that	O
regulate	O
the	O
fructification	O
.	O

The	O
rapid	O
production	O
of	O
high	O
-	O
titer	O
porcine	B
endogenous	I
retrovirus	I
(	O
PERV	O
)	O
-B	O
env	O
pseudotype	O
and	O
construction	O
of	O
an	O
EGFP	O
-	O
expressing	O
replication	O
competent	O
PERV	O
-	O
A	O
vector	O
.	O

Porcine	B
endogenous	I
retroviruses	I
(	O
PERVs	B
)	O
present	O
a	O
unique	O
concern	O
associated	O
with	O
xenotransplantation	O
because	O
they	O
have	O
been	O
shown	O
to	O
infect	O
certain	O
human	B
cells	O
in	O
vitro	O
and	O
it	O
is	O
also	O
difficult	O
to	O
generate	O
herds	O
of	O
pigs	B
free	O
of	O
PERVs	B
.	O

A	O
simple	O
system	O
for	O
the	O
production	O
of	O
high	O
-	O
titer	O
MoMLV	O
-	O
PERV	O
pseudotypes	O
is	O
reported	O
;	O
an	O
EGFP	O
-	O
expressing	O
replication	O
-	O
competent	O
molecular	O
clone	O
that	O
allows	O
direct	O
measurement	O
of	O
titer	O
was	O
also	O
constructed	O
.	O

To	O
improve	O
the	O
MLV	O
-	O
based	O
retroviral	B
vector	O
system	O
,	O
a	O
2.1-kb	O
PERV	B
-	O
B	O
env	O
product	O
was	O
amplified	O
from	O
PK-15	O
genomic	O
DNA	O
and	O
cloned	O
into	O
the	O
pCL	O
-	O
Eco	O
retroviral	O
vector	O
.	O

The	O
titer	O
of	O
lacZ	O
(	O
PERV	B
-	I
B	O
)	O
from	O
the	O
293	O
cells	O
was	O
about	O
1.0x10	O
(	O
4	O
)	O
CFU	O
/	O
ml	O
.	O

In	O
contrast	O
,	O
the	O
titer	O
of	O
lacZ	O
(	O
PERV	O
-	O
B	O
)	O
from	O
a	O
conventional	O
murine	O
retroviral	B
vector	O
(	O
split	O
genome	O
)	O
was	O
found	O
to	O
be	O
1.2x10	O
(	O
2	O
)	O
CFU	O
/	O
ml	O
when	O
the	O
PERV	B
-	I
B	O
env	O
expression	O
vector	O
was	O
transfected	O
into	O
TELCeB6	O
cells	O
,	O
which	O
harbor	O
MFGnlslacZ	O
and	O
the	O
gag	O
-	O
pol	O
-	O
expressing	O
vector	O
.	O

In	O
addition	O
,	O
an	O
infectious	O
PERV	B
-	I
A	O
clone	O
containing	O
enhanced	O
GFP	O
(	O
EGFP	O
)	O
by	O
using	O
a	O
PCR	O
-	O
based	O
method	O
was	O
developed	O
.	O

This	O
EGFP	O
-	O
expressing	O
PERV	O
-	O
A	O
-	O
IRES	O
-	O
EGFP	O
molecular	O
clone	O
was	O
found	O
to	O
be	O
stable	O
genetically	O
on	O
transfection	O
in	O
293	O
cells	O
.	O

Cross	O
-	O
talk	O
between	O
light	O
and	O
glucose	O
regulation	O
controls	O
toxin	O
production	O
and	O
morphogenesis	O
in	O
Aspergillus	B
nidulans	I
.	O

Light	O
is	O
a	O
major	O
environmental	O
stimulus	O
that	O
has	O
a	O
broad	O
effect	O
on	O
organisms	O
,	O
triggering	O
a	O
cellular	O
response	O
that	O
results	O
in	O
an	O
optimal	O
adaptation	O
enhancing	O
fitness	O
and	O
survival	O
.	O

In	O
fungi	O
,	O
light	O
affects	O
growth	O
,	O
and	O
causes	O
diverse	O
morphological	O
changes	O
such	O
as	O
those	O
leading	O
to	O
reproduction	O
.	O

Light	O
can	O
also	O
affect	O
fungal	O
metabolism	O
,	O
including	O
the	O
biosynthesis	O
of	O
natural	O
products	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
in	O
Aspergillus	B
nidulans	I
the	O
effect	O
of	O
light	O
on	O
the	O
production	O
of	O
the	O
sterigmatocystin	O
(	O
ST	O
)	O
toxin	O
depends	O
on	O
the	O
glucose	O
concentration	O
.	O

In	O
cultures	O
grown	O
with	O
1	O
%	O
glucose	O
and	O
exposed	O
to	O
light	O
,	O
ST	O
production	O
was	O
lower	O
than	O
when	O
grown	O
in	O
the	O
dark	O
.	O

This	O
lower	O
ST	O
production	O
coincided	O
with	O
an	O
elevated	O
rate	O
of	O
cellular	O
damage	O
with	O
partial	O
loss	O
of	O
nuclear	O
integrity	O
and	O
vacuolated	O
cytoplasm	O
.	O

However	O
,	O
in	O
cultures	O
grown	O
with	O
2	O
%	O
glucose	O
these	O
effects	O
were	O
reversed	O
and	O
light	O
enhanced	O
ST	O
production	O
.	O

Glucose	O
abundance	O
also	O
affected	O
the	O
light	O
-	O
dependent	O
subcellular	O
localization	O
of	O
the	O
VeA	O
(	O
velvet	O
)	O
protein	O
,	O
a	O
key	O
regulator	O
necessary	O
for	O
normal	O
light	O
-	O
dependent	O
morphogenesis	O
and	O
secondary	O
metabolism	O
in	O
Aspergilli	O
and	O
other	O
fungal	O
genera	O
.	O

The	O
role	O
of	O
other	O
VeA	O
-	O
associated	O
proteins	O
,	O
particularly	O
the	O
blue	O
-	O
light	O
-	O
sensing	O
proteins	O
LreA	O
and	O
LreB	O
(	O
WC-1	O
and	O
WC-2	O
orthologs	O
)	O
,	O
on	O
conidiation	O
could	O
also	O
be	O
modified	O
by	O
the	O
abundance	O
of	O
glucose	O
.	O

We	O
also	O
show	O
that	O
LreA	O
and	O
LreB	O
,	O
as	O
well	O
as	O
the	O
phytochrome	O
FphA	O
,	O
modulate	O
not	O
only	O
the	O
synthesis	O
of	O
sterigmatocystin	O
,	O
but	O
also	O
the	O
production	O
of	O
the	O
antibiotic	O
penicillin	O
.	O

Genome	O
-	O
wide	O
analysis	O
of	O
brain	O
transcriptional	O
changes	O
in	O
honey	B
bee	I
(	O
Apis	B
mellifera	I
L.	O
)	O
queens	O
exposed	O
to	O
carbon	O
dioxide	O
and	O
physical	O
manipulation	O
.	O

Mating	O
is	O
a	O
complex	O
process	O
causing	O
many	O
behavioural	O
and	O
physiological	O
changes	O
,	O
but	O
the	O
factors	O
triggering	O
them	O
and	O
the	O
underlying	O
molecular	O
processes	O
are	O
not	O
well	O
characterized	O
.	O

In	O
the	O
present	O
study	O
we	O
examine	O
the	O
effects	O
of	O
CO	O
(	O
2	O
)	O
(	O
a	O
commonly	O
used	O
anaesthetic	O
in	O
instrumental	O
insemination	O
that	O
causes	O
changes	O
similar	O
to	O
those	O
occurring	O
after	O
mating	O
)	O
and	O
physical	O
manipulation	O
(	O
which	O
may	O
mimic	O
certain	O
aspects	O
of	O
copulation	O
)	O
on	O
the	O
behavioural	O
,	O
physiological	O
and	O
brain	O
transcriptional	O
changes	O
in	O
honey	B
bee	I
queens	O
.	O

We	O
show	O
that	O
while	O
CO	O
(	O
2	O
)	O
causes	O
cessation	O
of	O
mating	O
flights	O
and	O
ovary	O
activation	O
,	O
physical	O
manipulation	O
has	O
additional	O
effects	O
on	O
ovary	O
activation	O
and	O
brain	O
transcriptional	O
changes	O
.	O

Comparisons	O
with	O
previous	O
studies	O
of	O
honey	B
bees	I
and	O
female	O
Drosophila	B
indicate	O
that	O
common	O
molecular	O
mechanisms	O
may	O
be	O
responsible	O
for	O
regulating	O
reproductive	O
changes	O
across	O
different	O
mating	O
regimes	O
and	O
insect	O
orders	O
.	O

Identification	O
and	O
expression	O
analysis	O
of	O
the	O
genes	O
involved	O
in	O
serotonin	O
biosynthesis	O
and	O
transduction	O
in	O
the	O
field	O
cricket	O
Gryllus	B
bimaculatus	I
.	O

Serotonin	O
(	O
5-HT	O
)	O
modulates	O
various	O
aspects	O
of	O
behaviours	O
such	O
as	O
aggressive	O
behaviour	O
and	O
circadian	O
behaviour	O
in	O
the	O
cricket	O
.	O

To	O
elucidate	O
the	O
molecular	O
basis	O
of	O
the	O
cricket	O
5-HT	O
system	O
,	O
we	O
identified	O
5-HT	O
-	O
related	O
genes	O
in	O
the	O
field	O
cricket	O
Gryllus	B
bimaculatus	I
DeGeer	I
.	O

Complementary	O
DNA	O
of	O
tryptophan	O
hydroxylase	O
and	O
phenylalanine	O
-	O
tryptophan	O
hydroxylase	O
,	O
which	O
convert	O
tryptophan	O
into	O
5-hydroxy	O
-	O
L	O
-	O
tryptophan	O
(	O
5-HTP	O
)	O
,	O
and	O
that	O
of	O
aromatic	O
L	O
-	O
amino	O
acid	O
decarboxylase	O
,	O
which	O
converts	O
5-HTP	O
into	O
5-HT	O
,	O
were	O
isolated	O
from	O
a	O
cricket	O
brain	O
cDNA	O
library	O
.	O

In	O
addition	O
,	O
four	O
5-HT	O
receptor	O
genes	O
(	O
5-HT	O
(	O
1A	O
)	O
,	O
5-HT	O
(	O
1B	O
)	O
,	O
5-HT	O
(	O
2alpha	O
)	O
,	O
and	O
5-HT	O
(	O
7	O
)	O
)	O
were	O
identified	O
.	O

Expression	O
analysis	O
of	O
the	O
tryptophan	O
hydroxylase	O
gene	O
TRH	O
and	O
phenylalanine	O
-	O
tryptophan	O
hydroxylase	O
gene	O
TPH	O
,	O
which	O
are	O
selectively	O
involved	O
in	O
neuronal	O
and	O
peripheral	O
5-HT	O
synthesis	O
in	O
Drosophila	O
,	O
suggested	O
that	O
two	O
5-HT	O
synthesis	O
pathways	O
co	O
-	O
exist	O
in	O
the	O
cricket	O
neuronal	O
tissues	O
.	O

The	O
four	O
5-HT	O
receptor	O
genes	O
were	O
expressed	O
in	O
various	O
tissues	O
at	O
differential	O
expression	O
levels	O
,	O
suggesting	O
that	O
the	O
5-HT	O
system	O
is	O
widely	O
distributed	O
in	O
the	O
cricket	O
.	O

Fungal	O
secondary	O
metabolites	O
-	O
strategies	O
to	O
activate	O
silent	O
gene	O
clusters	O
.	O

Filamentous	O
fungi	O
produce	O
a	O
multitude	O
of	O
low	O
molecular	O
weight	O
bioactive	O
compounds	O
.	O

The	O
increasing	O
number	O
of	O
fungal	O
genome	O
sequences	O
impressively	O
demonstrated	O
that	O
their	O
biosynthetic	O
potential	O
is	O
far	O
from	O
being	O
exploited	O
.	O

In	O
fungi	O
,	O
the	O
genes	O
required	O
for	O
the	O
biosynthesis	O
of	O
a	O
secondary	O
metabolite	O
are	O
clustered	O
.	O

Many	O
of	O
these	O
bioinformatically	O
newly	O
discovered	O
secondary	O
metabolism	O
gene	O
clusters	O
are	O
silent	O
under	O
standard	O
laboratory	O
conditions	O
.	O

Consequently	O
,	O
no	O
product	O
can	O
be	O
found	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
strategies	O
that	O
have	O
been	O
successfully	O
applied	O
during	O
the	O
last	O
years	O
to	O
activate	O
these	O
silent	O
gene	O
clusters	O
in	O
filamentous	O
fungi	O
,	O
especially	O
in	O
the	O
genus	O
Aspergillus	O
.	O

The	O
techniques	O
take	O
advantage	O
of	O
genome	O
mining	O
,	O
vary	O
from	O
the	O
simple	O
search	O
for	O
compounds	O
with	O
bioinformatically	O
predicted	O
physicochemical	O
properties	O
up	O
to	O
methods	O
that	O
exploit	O
a	O
probable	O
interaction	O
of	O
microorganisms	O
.	O

Until	O
now	O
,	O
the	O
majority	O
of	O
successful	O
approaches	O
have	O
been	O
based	O
on	O
molecular	O
biology	O
like	O
the	O
generation	O
of	O
gene	O
""""	O
knock	O
outs	O
""""	O
,	O
promoter	O
exchange	O
,	O
overexpression	O
of	O
transcription	O
factors	O
or	O
other	O
pleiotropic	O
regulators	O
.	O

Moreover	O
,	O
strategies	O
based	O
on	O
epigenetics	O
opened	O
a	O
new	O
avenue	O
for	O
the	O
elucidation	O
of	O
the	O
regulation	O
of	O
secondary	O
metabolite	O
formation	O
and	O
will	O
certainly	O
continue	O
to	O
play	O
a	O
significant	O
role	O
for	O
the	O
elucidation	O
of	O
cryptic	O
natural	O
products	O
.	O

The	O
conditions	O
under	O
which	O
a	O
given	O
gene	O
cluster	O
is	O
naturally	O
expressed	O
are	O
largely	O
unknown	O
.	O

One	O
technique	O
is	O
to	O
attempt	O
to	O
simulate	O
the	O
natural	O
habitat	O
by	O
co	O
-	O
cultivation	O
of	O
microorganisms	O
from	O
the	O
same	O
ecosystem	O
.	O

This	O
has	O
already	O
led	O
to	O
the	O
activation	O
of	O
silent	O
gene	O
clusters	O
and	O
the	O
identification	O
of	O
novel	O
compounds	O
in	O
Aspergillus	O
nidulans	B
.	I

These	B
simulation	I
strategies	O
will	O
help	O
discover	O
new	O
natural	O
products	O
in	O
the	O
future	O
,	O
and	O
may	O
also	O
provide	O
fundamental	O
new	O
insights	O
into	O
microbial	O
communication	O
.	O

The	O
genetic	O
basis	O
for	O
3-ADON	O
and	O
15-ADON	O
trichothecene	O
chemotypes	O
in	O
Fusarium	O
.	O

Certain	O
Fusarium	O
species	O
cause	O
head	O
blight	O
of	O
wheat	B
and	O
other	O
small	O
grains	O
worldwide	O
and	O
produce	O
trichothecene	O
mycotoxins	O
.	O

These	O
mycotoxins	O
can	O
induce	O
toxicoses	O
in	O
animals	O
and	O
humans	B
and	O
can	O
contribute	O
to	O
the	O
ability	O
of	O
some	O
fusaria	O
to	O
cause	O
plant	O
disease	O
.	O

Production	O
of	O
the	O
trichothecene	O
3-acetyldeoxynivalenol	O
(	O
3-ADON	O
)	O
versus	O
15-acetyldeoxynivalenol	O
(	O
15-ADON	O
)	O
is	O
an	O
important	O
phenotypic	O
difference	O
within	O
and	O
among	O
some	O
Fusarium	O
species	O
.	O

However	O
,	O
until	O
now	O
,	O
the	O
genetic	O
basis	O
for	O
this	O
difference	O
in	O
chemotype	O
has	O
not	O
been	O
identified	O
.	O

Here	O
,	O
we	O
identified	O
consistent	O
DNA	O
sequence	O
differences	O
in	O
the	O
coding	O
region	O
of	O
the	O
trichothecene	O
biosynthetic	O
gene	O
TRI8	O
in	O
3-ADON	O
and	O
15-ADON	O
strains	O
.	O

Functional	O
analyses	O
of	O
the	O
TRI8	O
enzyme	O
(	O
Tri8	O
)	O
in	O
F.	B
graminearum	I
,	O
the	O
predominant	O
cause	O
of	O
wheat	O
head	O
blight	O
in	O
North	O
America	O
and	O
Europe	O
,	O
revealed	O
that	O
Tri8	O
from	O
3-ADON	O
strains	O
catalyzes	O
deacetylation	O
of	O
the	O
trichothecene	O
biosynthetic	O
intermediate	O
3,15-diacetyldeoxynivalenol	O
at	O
carbon	O
15	O
to	O
yield	O
3-ADON	O
,	O
whereas	O
Tri8	O
from	O
15-ADON	O
strains	O
catalyzes	O
deacetylation	O
of	O
3,15-diacetyldeoxynivalenol	O
at	O
carbon	O
3	O
to	O
yield	O
15-ADON	O
.	O

Fusarium	O
strains	O
that	O
produce	O
the	O
trichothecene	O
nivalenol	O
have	O
a	O
Tri8	O
that	O
functions	O
like	O
that	O
in	O
15-ADON	O
strains	O
.	O

TRI3	O
,	O
which	O
encodes	O
a	O
trichothecene	O
carbon	O
15	O
acetyltransferase	O
,	O
was	O
found	O
to	O
be	O
functional	O
in	O
all	O
three	O
chemotypes	O
.	O

Together	O
,	O
our	O
data	O
indicate	O
that	O
differential	O
activity	O
of	O
Tri8	O
determines	O
the	O
3-ADON	O
and	O
15-ADON	O
chemotypes	O
in	O
Fusarium	O
.	O

Recovery	O
of	O
ectomycorrhiza	O
after	O
'	O
nitrogen	O
saturation	O
'	O
of	O
a	O
conifer	O
forest	O
.	O

Trees	O
reduce	O
their	O
carbon	O
(	O
C	O
)	O
allocation	O
to	O
roots	O
and	O
mycorrhizal	O
fungi	O
in	O
response	O
to	O
high	O
nitrogen	O
(	O
N	O
)	O
additions	O
,	O
which	O
should	O
reduce	O
the	O
N	O
retention	O
capacity	O
of	O
forests	O
.	O

The	O
time	O
needed	O
for	O
recovery	O
of	O
mycorrhizas	O
after	O
termination	O
of	O
N	O
loading	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
the	O
long	O
-	O
term	O
impact	O
of	O
N	O
loading	O
and	O
the	O
recovery	O
of	O
ectomycorrhiza	O
after	O
high	O
N	O
loading	O
on	O
a	O
Pinus	B
sylvestris	I
forest	O
.	O

We	O
analysed	O
the	O
N%	O
and	O
abundance	O
of	O
the	O
stable	O
isotope	O
(	O
15	O
)	O
N	O
in	O
tree	O
needles	O
and	O
soil	O
,	O
soil	O
microbial	O
fatty	O
acid	O
biomarkers	O
and	O
fungal	O
DNA	O
.	O

Needles	O
in	O
N	O
-	O
loaded	O
plots	O
became	O
enriched	O
in	O
(	O
15	O
)	O
N	O
,	O
reflecting	O
decreased	O
N	O
retention	O
by	O
mycorrhizal	O
fungi	O
and	O
isotopic	O
discrimination	O
against	O
(	O
15	O
)	O
N	O
during	O
loss	O
of	O
N.	O
Meanwhile	O
,	O
needles	O
in	O
N	O
-	O
limited	O
(	O
control	O
)	O
plots	O
became	O
depleted	O
in	O
(	O
15	O
)	O
N	O
,	O
reflecting	O
high	O
retention	O
of	O
(	O
15	O
)	O
N	O
by	O
mycorrhizal	O
fungi	O
.	O

N	O
loading	O
was	O
terminated	O
after	O
20yr	O
.	O

The	O
delta	O
(	O
15	O
)	O
N	O
and	O
N%	O
of	O
the	O
needles	O
decreased	O
6yr	O
after	O
N	O
loading	O
had	O
been	O
terminated	O
,	O
and	O
approached	O
values	O
in	O
control	O
plots	O
after	O
15yr	O
.	O

This	O
decrease	O
,	O
and	O
the	O
larger	O
contributions	O
compared	O
with	O
N	O
-	O
loaded	O
plots	O
of	O
a	O
fungal	O
fatty	O
acid	O
biomarker	O
and	O
ectomycorrhizal	O
sequences	O
,	O
suggest	O
recovery	O
of	O
ectomycorrhiza	O
.	O

High	O
N	O
loading	O
rapidly	O
decreased	O
the	O
functional	O
role	O
of	O
ectomycorrhiza	O
in	O
the	O
forest	O
N	O
cycle	O
,	O
but	O
significant	O
recovery	O
occurred	O
within	O
6	O
-	O
15yr	O
after	O
termination	O
of	O
N	O
loading	O
.	O

What	O
determines	O
variation	O
in	O
home	O
range	O
size	O
across	O
spatiotemporal	O
scales	O
in	O
a	O
large	O
browsing	O
herbivore	O
?	O

1	O
.	O

Most	O
studies	O
of	O
intraspecific	O
variation	O
in	O
home	O
range	O
size	O
have	O
investigated	O
only	O
a	O
single	O
or	O
a	O
few	O
factors	O
and	O
often	O
at	O
one	O
specific	O
scale	O
.	O

However	O
,	O
considering	O
multiple	O
spatial	O
and	O
temporal	O
scales	O
when	O
defining	O
a	O
home	O
range	O
is	O
important	O
as	O
mechanisms	O
that	O
affect	O
variation	O
in	O
home	O
range	O
size	O
may	O
differ	O
depending	O
on	O
the	O
scale	O
under	O
investigation	O
.	O

2	O
.	O

We	O
aim	O
to	O
quantify	O
the	O
relative	O
effect	O
of	O
various	O
individual	O
,	O
forage	O
and	O
climatic	O
determinants	O
of	O
variation	O
in	O
home	O
range	O
size	O
across	O
multiple	O
spatiotemporal	O
scales	O
in	O
a	O
large	O
browsing	O
herbivore	O
,	O
the	O
moose	O
(	O
Alces	B
alces	I
)	O
,	O
living	O
at	O
the	O
southern	O
limit	O
of	O
its	O
distribution	O
in	O
Norway	O
.	O

3	O
.	O

Total	O
home	O
range	O
size	O
and	O
core	O
home	O
range	O
areas	O
were	O
estimated	O
for	O
daily	O
to	O
monthly	O
scales	O
in	O
summer	O
and	O
winter	O
using	O
both	O
local	O
convex	O
hull	O
(	O
LoCoH	O
)	O
and	O
fixed	O
kernel	O
home	O
range	O
methods	O
.	O

Variance	O
in	O
home	O
range	O
size	O
was	O
analysed	O
using	O
linear	O
mixed	O
-	O
effects	O
models	O
for	O
repeated	O
measurements	O
.	O

4	O
.	O

Reproductive	O
status	O
was	O
the	O
most	O
influential	O
individual	O
-	O
level	O
factor	O
explaining	O
variance	O
in	O
moose	O
home	O
range	O
size	O
,	O
with	O
females	O
accompanied	O
by	O
a	O
calf	O
having	O
smaller	O
summer	O
ranges	O
across	O
all	O
scales	O
.	O

Variation	O
in	O
home	O
range	O
size	O
was	O
strongly	O
correlated	O
with	O
spatiotemporal	O
changes	O
in	O
quantity	O
and	O
quality	O
of	O
natural	O
food	O
resources	O
.	O

Home	O
range	O
size	O
decreased	O
with	O
increasing	O
browse	O
density	O
at	O
daily	O
scales	O
,	O
but	O
the	O
relationship	O
changed	O
to	O
positive	O
at	O
longer	O
temporal	O
scales	O
.	O

In	O
contrast	O
,	O
browse	O
quality	O
was	O
consistently	O
negatively	O
correlated	O
with	O
home	O
range	O
size	O
except	O
at	O
the	O
monthly	O
scale	O
during	O
winter	O
when	O
depletion	O
of	O
high	O
-	O
quality	O
forage	O
occurs	O
.	O

Local	O
climate	O
affected	O
total	O
home	O
range	O
size	O
more	O
than	O
core	O
areas	O
.	O

Temperature	O
,	O
precipitation	O
and	O
snow	O
depth	O
influenced	O
home	O
range	O
size	O
directly	O
at	O
short	O
temporal	O
scales	O
.	O

5	O
.	O

The	O
relative	O
effects	O
of	O
intrinsic	O
and	O
extrinsic	O
determinants	O
of	O
variation	O
in	O
home	O
range	O
size	O
differed	O
with	O
spatiotemporal	O
scale	O
,	O
providing	O
clear	O
evidence	O
that	O
home	O
range	O
size	O
is	O
scale	O
dependent	O
in	O
this	O
large	O
browser	O
.	O

Insight	O
into	O
the	O
behavioural	O
responses	O
of	O
populations	O
to	O
climatic	O
stochasticity	O
and	O
forage	O
variability	O
is	O
essential	O
in	O
view	O
of	O
current	O
and	O
future	O
climate	O
change	O
,	O
especially	O
for	O
populations	O
with	O
thermoregulatory	O
restrictions	O
living	O
at	O
the	O
southern	O
limit	O
of	O
their	O
distribution	O
.	O

Differential	O
responses	O
of	O
Bacillus	B
subtilis	I
rRNA	O
promoters	O
to	O
nutritional	O
stress	O
.	O

The	O
in	O
vivo	O
expression	O
levels	O
of	O
four	O
rRNA	O
promoter	O
pairs	O
(	O
rrnp	O
(	O
1	O
)	O
p	O
(	O
2	O
)	O
)	O
of	O
Bacillus	B
subtilis	I
were	O
determined	O
by	O
employing	O
single	O
-	O
copy	O
lacZ	O
fusions	O
integrated	O
at	O
the	O
amyE	O
locus	O
.	O

The	O
rrnO	O
,	O
rrnJ	O
,	O
rrnD	O
,	O
and	O
rrnB	O
promoters	O
displayed	O
unique	O
growth	O
rate	O
regulation	O
and	O
stringent	O
responses	O
.	O

Both	O
lacZ	O
activity	O
and	O
mRNA	O
levels	O
were	O
highest	O
for	O
rrnO	O
under	O
all	O
growth	O
conditions	O
tested	O
,	O
while	O
rrnJ	O
,	O
rrnB	O
,	O
and	O
rrnD	O
showed	O
decreasing	O
levels	O
of	O
activity	O
.	O

During	O
amino	O
acid	O
starvation	O
induced	O
by	O
serine	O
hydroxamate	O
(	O
SHX	O
)	O
,	O
only	O
the	O
strong	O
rrnO	O
and	O
rrnJ	O
promoters	O
demonstrated	O
stringent	O
responses	O
.	O

Under	O
the	O
growth	O
conditions	O
used	O
,	O
the	O
rrn	O
promoters	O
showed	O
responses	O
similar	O
to	O
the	O
responses	O
to	O
carbon	O
source	O
limitation	O
induced	O
by	O
alpha	O
-	O
methyl	O
glucoside	O
(	O
alpha	O
-	O
MG	O
)	O
.	O

The	O
ratio	O
of	O
P2	O
to	O
P1	O
transcripts	O
,	O
determined	O
by	O
primer	O
extension	O
analysis	O
,	O
was	O
high	O
for	O
the	O
strong	O
rrnO	O
and	O
rrnJ	O
promoters	O
,	O
while	O
only	O
P2	O
transcripts	O
were	O
detected	O
for	O
the	O
weak	O
rrnD	O
and	O
rrnB	O
promoters	O
.	O

Cloned	O
P1	O
or	O
P2	O
promoter	O
fragments	O
of	O
rrnO	O
or	O
rrnJ	O
were	O
differentially	O
regulated	O
.	O

In	O
wild	O
-	O
type	O
(	O
relA	O
(	O
+	O
)	O
)	O
and	O
suppressor	O
[	O
relA	O
(	O
S	O
)	O
]	O
strains	O
under	O
the	O
conditions	O
tested	O
,	O
only	O
P2	O
responded	O
to	O
carbon	O
source	O
limitation	O
by	O
a	O
decrease	O
in	O
RNA	O
synthesis	O
,	O
correlating	O
with	O
an	O
increase	O
in	O
(	O
p	O
)	O
ppGpp	O
levels	O
and	O
a	O
decrease	O
in	O
the	O
GTP	O
concentration	O
.	O

The	O
weak	O
P1	O
promoter	O
elements	O
remain	O
relaxed	O
in	O
the	O
three	O
genetic	O
backgrounds	O
[	O
relA	O
(	O
+	O
)	O
,	O
relA	O
,	O
relA	O
(	O
S	O
)	O
]	O
in	O
the	O
presence	O
of	O
alpha	O
-	O
MG	O
.	O

During	O
amino	O
acid	O
starvation	O
,	O
P2	O
was	O
stringently	O
regulated	O
in	O
relA	O
(	O
+	O
)	O
and	O
relA	O
(	O
S	O
)	O
cells	O
,	O
while	O
only	O
rrnJp	O
(	O
1	O
)	O
was	O
also	O
regulated	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
.	O

Both	O
the	O
relA	O
(	O
+	O
)	O
and	O
relA	O
(	O
S	O
)	O
strains	O
showed	O
(	O
p	O
)	O
ppGpp	O
accumulation	O
after	O
alpha	O
-	O
MG	O
treatment	O
but	O
not	O
after	O
SHX	O
treatment	O
.	O

These	O
data	O
reveal	O
the	O
complex	O
nature	O
of	O
B.	B
subtilis	I
rrn	O
promoter	O
regulation	O
in	O
response	O
to	O
stress	O
,	O
and	O
they	O
suggest	O
that	O
the	O
P2	O
promoters	O
may	O
play	O
a	O
more	O
prominent	O
role	O
in	O
the	O
stringent	O
response	O
.	O

Altered	O
regulation	O
of	O
the	O
OmpF	O
porin	O
by	O
Fis	O
in	O
Escherichia	B
coli	I
during	O
an	O
evolution	O
experiment	O
and	O
between	O
B	O
and	O
K-12	O
strains	O
.	O

The	O
phenotypic	O
plasticity	O
of	O
global	O
regulatory	O
networks	O
provides	O
bacteria	O
with	O
rapid	O
acclimation	O
to	O
a	O
wide	O
range	O
of	O
environmental	O
conditions	O
,	O
while	O
genetic	O
changes	O
in	O
those	O
networks	O
provide	O
additional	O
flexibility	O
as	O
bacteria	O
evolve	O
across	O
long	O
time	O
scales	O
.	O

We	O
previously	O
identified	O
mutations	O
in	O
the	O
global	O
regulator	O
-	O
encoding	O
gene	O
fis	O
that	O
enhanced	O
organismal	O
fitness	O
during	O
a	O
long	O
-	O
term	O
evolution	O
experiment	O
with	O
Escherichia	B
coli	I
.	O

To	O
gain	O
insight	O
into	O
the	O
effects	O
of	O
these	O
mutations	O
,	O
we	O
produced	O
two	O
-	O
dimensional	O
protein	O
gels	O
with	O
strains	O
carrying	O
different	O
fis	O
alleles	O
,	O
including	O
a	O
beneficial	O
evolved	O
allele	O
and	O
one	O
with	O
an	O
in	O
-	O
frame	O
deletion	O
.	O

We	O
found	O
that	O
Fis	O
controls	O
the	O
expression	O
of	O
the	O
major	O
porin	O
-	O
encoding	O
gene	O
ompF	O
in	O
the	O
E.	B
coli	I
B	O
-	O
derived	O
ancestral	O
strain	O
used	O
in	O
the	O
evolution	O
experiment	O
,	O
a	O
relationship	O
that	O
has	O
not	O
been	O
described	O
before	O
.	O

We	O
further	O
showed	O
that	O
this	O
regulatory	O
connection	O
evolved	O
over	O
two	O
different	O
time	O
scales	O
,	O
perhaps	O
explaining	O
why	O
it	O
was	O
not	O
observed	O
before	O
.	O

On	O
the	O
longer	O
time	O
scale	O
,	O
we	O
showed	O
that	O
this	O
regulation	O
of	O
ompF	O
by	O
Fis	O
is	O
absent	O
from	O
the	O
more	O
widely	O
studied	O
K-12	B
strain	I
and	O
thus	O
is	O
specific	O
to	O
the	O
B	B
strain	I
.	O

On	O
a	O
shorter	O
time	O
scale	O
,	O
this	O
regulatory	O
linkage	O
was	O
lost	O
during	O
20,000	O
generations	O
of	O
experimental	O
evolution	O
of	O
the	O
B	B
strain	I
.	O

Finally	O
,	O
we	O
mapped	O
the	O
Fis	O
binding	O
sites	O
in	O
the	O
ompF	O
regulatory	O
region	O
,	O
and	O
we	O
present	O
a	O
hypothetical	O
model	O
of	O
ompF	O
expression	O
that	O
includes	O
its	O
other	O
known	O
regulators	O
.	O

Fur	O
and	O
the	O
novel	O
regulator	O
YqjI	O
control	O
transcription	O
of	O
the	O
ferric	O
reductase	O
gene	O
yqjH	O
in	O
Escherichia	B
coli	I
.	O

Iron	O
acquisition	O
in	O
aerobic	O
habitats	O
is	O
complicated	O
by	O
the	O
low	O
solubility	O
of	O
ferric	O
hydroxides	O
.	O

Siderophores	O
that	O
bind	O
ferric	O
iron	O
with	O
high	O
affinity	O
are	O
used	O
to	O
mobilize	O
iron	O
.	O

The	O
reduction	O
of	O
ferric	O
iron	O
to	O
the	O
ferrous	O
form	O
can	O
be	O
coupled	O
to	O
the	O
release	O
of	O
iron	O
from	O
siderophores	O
.	O

Iron	O
is	O
also	O
stored	O
intracellularly	O
as	O
a	O
ferric	O
mineral	O
in	O
proteins	O
,	O
such	O
as	O
ferritin	O
,	O
and	O
must	O
be	O
reduced	O
during	O
release	O
.	O

In	O
Escherichia	B
coli	I
,	O
the	O
yqjH	O
gene	O
encodes	O
a	O
putative	O
ferric	O
siderophore	O
reductase	O
that	O
is	O
also	O
part	O
of	O
the	O
Fur	O
regulon	O
.	O

Here	O
we	O
show	O
that	O
YqjH	O
has	O
ferric	O
reductase	O
activity	O
and	O
is	O
required	O
for	O
iron	O
homeostasis	O
in	O
E.	B
coli	I
.	O

Divergently	O
transcribed	O
from	O
yqjH	O
is	O
the	O
yqjI	O
gene	O
,	O
which	O
encodes	O
a	O
novel	O
member	O
of	O
the	O
winged	O
-	O
helix	O
family	O
of	O
transcriptional	O
regulators	O
and	O
also	O
contains	O
an	O
N	O
-	O
terminal	O
extension	O
similar	O
to	O
the	O
Ni	O
(	O
2+	O
)	O
-binding	O
C	O
-	O
terminal	O
tail	O
of	O
SlyD.	O
Deletion	O
of	O
yqjI	O
leads	O
to	O
constitutive	O
high	O
-	O
level	O
activity	O
of	O
the	O
yqjH	O
and	O
yqjI	O
promoters	O
.	O

Purified	O
YqjI	O
binds	O
inverted	O
repeat	O
target	O
sequences	O
within	O
the	O
yqjH	O
and	O
yqjI	O
promoters	O
.	O

We	O
also	O
observed	O
that	O
YqjI	O
-	O
dependent	O
transcriptional	O
repression	O
is	O
reduced	O
when	O
cells	O
are	O
exposed	O
to	O
elevated	O
nickel	O
levels	O
,	O
resulting	O
in	O
increased	O
expression	O
of	O
yqjH	O
and	O
yqjI.	O
YqjI	O
binding	O
to	O
nickel	O
or	O
iron	O
reduces	O
YqjI	O
DNA	O
-	O
binding	O
activity	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
elevated	O
nickel	O
stress	O
levels	O
disrupt	O
iron	O
homeostasis	O
in	O
E.	B
coli	I
and	O
that	O
deletion	O
of	O
yqjH	O
increases	O
nickel	O
toxicity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
YqjI	O
protein	O
controls	O
expression	O
of	O
yqjH	O
to	O
help	O
maintain	O
iron	O
homeostasis	O
under	O
conditions	O
(	O
such	O
as	O
elevated	O
cellular	O
nickel	O
levels	O
)	O
that	O
disrupt	O
iron	O
metabolism	O
.	O

Identification	O
of	O
binary	O
interactions	O
between	O
human	B
cytomegalovirus	I
virion	O
proteins	O
.	O

Human	B
cytomegalovirus	I
(	O
HCMV	B
)	O
virions	O
are	O
composed	O
of	O
a	O
DNA	O
-	O
containing	O
nucleocapsid	O
surrounded	O
by	O
a	O
tegument	O
layer	O
and	O
host	O
-	O
derived	O
lipid	O
envelope	O
studded	O
with	O
virally	O
encoded	O
glycoproteins	O
.	O

These	O
complex	O
virions	O
are	O
estimated	O
to	O
be	O
composed	O
of	O
more	O
than	O
50	O
viral	O
proteins	O
.	O

Assembly	O
of	O
HCMV	B
virions	O
is	O
poorly	O
understood	O
,	O
especially	O
with	O
respect	O
to	O
acquisition	O
of	O
the	O
tegument	O
;	O
however	O
,	O
it	O
is	O
thought	O
to	O
involve	O
the	O
stepwise	O
addition	O
of	O
virion	O
components	O
through	O
protein	O
-	O
protein	O
interactions	O
.	O

We	O
sought	O
to	O
identify	O
interactions	O
among	O
HCMV	B
virion	O
proteins	O
using	O
yeast	B
two	O
-	O
hybrid	O
analysis	O
.	O

Using	O
33	O
known	O
capsid	O
and	O
tegument	O
proteins	O
,	O
we	O
tested	O
1,089	O
pairwise	O
combinations	O
for	O
binary	O
interaction	O
in	O
the	O
two	O
-	O
hybrid	O
assay	O
.	O

We	O
identified	O
24	O
interactions	O
among	O
HCMV	B
virion	O
proteins	O
,	O
including	O
13	O
novel	O
interactions	O
among	O
tegument	O
proteins	O
and	O
one	O
novel	O
interaction	O
between	O
capsid	O
proteins	O
.	O

Several	O
of	O
these	O
novel	O
interactions	O
were	O
confirmed	O
by	O
coimmunoprecipitation	O
of	O
protein	O
complexes	O
from	O
transfected	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
three	O
of	O
these	O
interactions	O
in	O
the	O
context	O
of	O
HCMV	B
infection	O
.	O

This	O
study	O
reveals	O
several	O
new	O
protein	O
-	O
protein	O
interactions	O
among	O
HCMV	B
tegument	O
proteins	O
,	O
some	O
of	O
which	O
are	O
likely	O
important	O
for	O
HCMV	B
replication	O
and	O
pathogenesis	O
.	O

Role	O
of	O
the	O
F1	O
region	O
in	O
the	O
Escherichia	B
coli	I
aerotaxis	O
receptor	O
Aer	O
.	O

In	O
Escherichia	B
coli	I
,	O
the	O
aerotaxis	O
receptor	O
Aer	O
is	O
an	O
atypical	O
receptor	O
because	O
it	O
senses	O
intracellular	O
redox	O
potential	O
.	O

The	O
Aer	O
sensor	O
is	O
a	O
cytoplasmic	O
,	O
N	O
-	O
terminal	O
PAS	O
domain	O
that	O
is	O
tethered	O
to	O
the	O
membrane	O
by	O
a	O
47-residue	O
F1	O
linker	O
.	O

Here	O
we	O
investigated	O
the	O
function	O
,	O
topology	O
,	O
and	O
orientation	O
of	O
F1	O
by	O
employing	O
random	O
mutagenesis	O
,	O
cysteine	O
scanning	O
,	O
and	O
disulfide	O
cross	O
-	O
linking	O
.	O

No	O
native	O
residue	O
was	O
obligatory	O
for	O
function	O
,	O
most	O
deleterious	O
substitutions	O
had	O
radically	O
different	O
side	O
chain	O
properties	O
,	O
and	O
all	O
F1	O
mutants	O
but	O
one	O
were	O
functionally	O
rescued	O
by	O
the	O
chemoreceptor	O
Tar	O
.	O

Cross	O
-	O
linking	O
studies	O
were	O
consistent	O
with	O
the	O
predicted	O
alpha	O
-	O
helical	O
structure	O
in	O
the	O
N	O
-	O
terminal	O
F1	O
region	O
and	O
demonstrated	O
trigonal	O
interactions	O
among	O
the	O
F1	O
linkers	O
from	O
three	O
Aer	O
monomers	O
,	O
presumably	O
within	O
trimer	O
-	O
of	O
-	O
dimer	O
units	O
,	O
as	O
well	O
as	O
binary	O
interactions	O
between	O
subunits	O
.	O

Using	O
heterodimer	O
analyses	O
,	O
we	O
also	O
demonstrated	O
the	O
importance	O
of	O
arginine	O
residues	O
near	O
the	O
membrane	O
interface	O
,	O
which	O
may	O
properly	O
anchor	O
the	O
Aer	O
protein	O
in	O
the	O
membrane	O
.	O

By	O
incorporating	O
these	O
data	O
into	O
a	O
homology	O
model	O
of	O
Aer	O
,	O
we	O
developed	O
a	O
model	O
for	O
the	O
orientation	O
of	O
the	O
Aer	O
F1	O
and	O
PAS	O
regions	O
in	O
an	O
Aer	O
lattice	O
that	O
is	O
compatible	O
with	O
the	O
known	O
dimensions	O
of	O
the	O
chemoreceptor	O
lattice	O
.	O

We	O
propose	O
that	O
the	O
F1	O
region	O
facilitates	O
the	O
orientation	O
of	O
PAS	O
and	O
HAMP	O
domains	O
during	O
folding	O
and	O
thereby	O
promotes	O
the	O
stability	O
of	O
the	O
PAS	O
and	O
HAMP	O
domains	O
in	O
Aer	O
.	O

Novel	O
Fusarium	O
head	O
blight	O
pathogens	O
from	O
Nepal	O
and	O
Louisiana	O
revealed	O
by	O
multilocus	O
genealogical	O
concordance	O
.	O

This	O
study	O
was	O
conducted	O
to	O
assess	O
evolutionary	O
relationships	O
,	O
species	O
diversity	O
and	O
trichothecene	O
toxin	O
potential	O
of	O
five	O
Fusarium	B
graminearum	I
complex	I
(	O
FGSC	B
)	O
isolates	O
identified	O
as	O
genetically	O
novel	O
during	O
prior	O
Fusarium	O
head	O
blight	O
(	O
FHB	O
)	O
surveys	O
in	O
Nepal	O
and	O
Louisiana	O
.	O

Results	O
of	O
a	O
multilocus	O
genotyping	O
(	O
MLGT	O
)	O
assay	O
for	O
B	O
-	O
trichothecene	O
species	O
determination	O
indicated	O
these	O
isolates	O
might	O
represent	O
novel	O
species	O
within	O
the	O
FGSC	B
.	O

GCPSR	O
-	O
based	O
phylogenetic	O
analyses	O
of	O
a	O
12-gene	O
dataset	O
,	O
comprising	O
portions	O
of	O
seven	O
loci	O
totaling	O
13.1	O
kb	O
of	O
aligned	O
DNA	O
sequence	O
data	O
,	O
provided	O
strong	O
support	O
for	O
the	O
genealogical	O
exclusivity	O
of	O
the	O
Nepalese	O
and	O
Louisianan	O
isolates	O
.	O

Accordingly	O
,	O
both	O
species	O
are	O
formally	O
recognized	O
herein	O
as	O
novel	O
FGSC	B
species	I
.	O

Fusarium	B
nepalense	I
was	O
resolved	O
as	O
the	O
sister	O
lineage	O
of	O
Fusarium	B
ussurianum+Fusarium	I
asiaticum	I
within	O
an	O
Asian	O
subclade	O
of	O
the	O
FGSC	B
.	O

Fusarium	B
louisianense	I
was	O
strongly	O
supported	O
as	O
a	O
reciprocally	O
monophyletic	O
sister	O
of	O
Fusarium	B
gerlachii+F.	I
graminearum	I
,	O
suggesting	O
that	O
this	O
subclade	O
might	O
be	O
endemic	O
to	O
North	O
America	O
.	O

Multilocus	O
Bayesian	O
species	O
tree	O
analyses	O
augment	O
these	O
results	O
and	O
provide	O
evidence	O
for	O
a	O
distinct	O
lineage	O
within	O
F.	B
graminearum	I
predominately	O
from	O
the	O
Gulf	O
Coast	O
of	O
Louisiana	O
.	O

As	O
predicted	O
by	O
the	O
MLGT	O
assay	O
,	O
mycotoxin	O
analyses	O
demonstrated	O
that	O
F.	B
nepalense	I
and	O
F.	B
louisianense	I
could	O
produce	O
15ADON	O
and	O
nivalenol	O
,	O
respectively	O
,	O
in	O
planta	O
.	O

In	O
addition	O
,	O
both	O
species	O
were	O
only	O
able	O
to	O
induce	O
mild	O
FHB	O
symptoms	O
on	O
wheat	O
in	O
pathogenicity	O
experiments	O
.	O

Host	O
plant	O
secondary	O
metabolite	O
profiling	O
shows	O
a	O
complex	O
,	O
strain	O
-	O
dependent	O
response	O
of	O
maize	B
to	O
plant	O
growth	O
-	O
promoting	O
rhizobacteria	O
of	O
the	O
genus	O
Azospirillum	O
.	O

Most	O
Azospirillum	O
plant	O
growth	O
-	O
promoting	O
rhizobacteria	O
(	O
PGPR	O
)	O
benefit	O
plant	O
growth	O
through	O
source	O
effects	O
related	O
to	O
free	O
nitrogen	O
fixation	O
and/or	O
phytohormone	O
production	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
potential	O
effects	O
on	O
plant	O
physiology	O
.	O

These	O
effects	O
were	O
assessed	O
by	O
comparing	O
the	O
early	O
impacts	O
of	O
three	O
Azospirillum	O
inoculant	O
strains	O
on	O
secondary	O
metabolite	O
profiles	O
of	O
two	O
different	O
maize	B
(	O
Zea	B
mays	I
)	O
cultivars	O
.	O

After	O
10d	O
of	O
growth	O
in	O
nonsterile	O
soil	O
,	O
maize	B
methanolic	O
extracts	O
were	O
analyzed	O
by	O
reverse	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
RP	O
-	O
HPLC	O
)	O
and	O
secondary	O
metabolites	O
identified	O
by	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
)	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
.	O

Seed	O
inoculation	O
resulted	O
in	O
increased	O
shoot	O
biomass	O
(	O
and	O
also	O
root	O
biomass	O
with	O
one	O
strain	O
)	O
of	O
hybrid	O
PR37Y15	O
but	O
had	O
no	O
stimulatory	O
effect	O
on	O
hybrid	O
DK315	O
.	O

In	O
parallel	O
,	O
Azospirillum	O
inoculation	O
led	O
to	O
major	O
qualitative	O
and	O
quantitative	O
modifications	O
of	O
the	O
contents	O
of	O
secondary	O
metabolites	O
,	O
especially	O
benzoxazinoids	O
,	O
in	O
the	O
maize	B
plants	O
.	O

These	O
modifications	O
depended	O
on	O
the	O
PGPR	O
strainxplant	O
cultivar	O
combination	O
.	O

Thus	O
,	O
Azospirillum	O
inoculation	O
resulted	O
in	O
early	O
,	O
strain	O
-	O
dependent	O
modifications	O
in	O
the	O
biosynthetic	O
pathways	O
of	O
benzoxazine	O
derivatives	O
in	O
maize	B
in	O
compatible	O
interactions	O
.	O

This	O
is	O
the	O
first	O
study	O
documenting	O
a	O
PGPR	O
effect	O
on	O
plant	O
secondary	O
metabolite	O
profiles	O
,	O
and	O
suggests	O
the	O
establishment	O
of	O
complex	O
interactions	O
between	O
Azospirillum	O
PGPR	O
and	O
maize	O
.	O

Carnivorous	O
planktonic	O
Difflugia	O
(	O
Protista	O
,	O
Amoebina	O
Testacea	O
)	O
and	O
their	O
predators	O
.	O

Four	O
planktonic	O
species	O
of	O
Difflugia	O
co	O
-	O
occurring	O
in	O
a	O
south	O
Chinese	O
reservoir	O
were	O
found	O
to	O
be	O
carnivorous	O
,	O
but	O
the	O
diet	O
was	O
widest	O
in	O
the	O
largest	O
species	O
(	O
D.	O
tuberspinifera	O
)	O
and	O
narrowest	O
in	O
the	O
smallest	O
(	O
D.	O
hydrostatica	O
)	O
.	O

It	O
included	O
rotifers	O
,	O
ciliates	O
,	O
dinoflagellates	O
,	O
floating	O
eggs	O
,	O
and	O
small	O
particles	O
associated	O
with	O
organic	O
debris	O
.	O

Scavenging	O
and	O
cannibalism	O
were	O
also	O
observed	O
.	O

Species	O
with	O
a	O
collared	O
test	O
(	O
D.	O
biwae	O
,	O
D.	O
mulanensis	O
)	O
showed	O
a	O
form	O
of	O
suction	O
-	O
feeding	O
,	O
while	O
species	O
with	O
teeth	O
on	O
the	O
pseudostome	O
used	O
these	O
,	O
together	O
with	O
their	O
pseudopods	O
,	O
as	O
""""	O
inverted	O
crown	O
corks	O
""""	O
,	O
providing	O
leverage	O
for	O
opening	O
the	O
lorica	O
of	O
their	O
(	O
rotifer	O
)	O
prey	O
.	O

Predators	O
of	O
Difflugia	O
included	O
cyclopoid	O
copepods	O
.	O

In	O
addition	O
,	O
the	O
rotifers	O
Asplanchna	O
priodonta	O
,	O
Ploesoma	O
hudsoni	O
and	B
,	I
occasionally	I
,	O
big	O
ciliates	O
(	O
Stentor	O
sp.	O
)	O
all	O
ingested	O
their	O
prey	O
as	O
a	O
whole	O
.	O

Ca	O
(	O
2+	O
)	O
-dependent	O
in	O
vivo	O
protein	O
phosphorylation	O
and	O
encystment	O
induction	O
in	O
the	O
ciliated	O
protozoan	O
Colpoda	B
cucullus	I
.	O

Encystment	O
induction	O
of	O
Colpoda	B
cucullus	I
is	O
promoted	O
by	O
an	O
increase	O
in	O
external	O
Ca	O
(	O
2	O
+	O
)	O
and	O
overpopulation	O
of	O
Colpoda	O
vegetative	O
cells	O
.	O

Using	O
phos	O
-	O
tag	O
detection	O
assays	O
,	O
the	O
present	O
study	O
revealed	O
that	O
the	O
in	O
vivo	O
phosphorylation	O
level	O
in	O
several	O
proteins	O
[	O
33	O
kDa	O
,	O
37	O
kDa	O
,	O
37.5	O
kDa	O
,	O
43	O
kDa	O
,	O
47	O
kDa	O
,	O
49	O
kDa	O
,	O
etc	O
.	O
]	O
was	O
raised	O
when	O
the	O
vegetative	O
cells	O
were	O
stimulated	O
by	O
overpopulation	O
to	O
encyst	O
in	O
a	O
medium	O
containing	O
0.1	O
mM	O
Ca	O
(	O
2	O
+	O
)	O
or	O
without	O
the	O
addition	O
of	O
Ca	O
(	O
2	O
+	O
)	O
.	O

Both	O
overpopulation	O
-	O
mediated	O
encystment	O
induction	O
and	O
protein	O
phosphorylation	O
were	O
suppressed	O
by	O
the	O
addition	O
of	O
EGTA	O
.	O

Ca	O
(	O
2+	O
)	O
/	O
overpopulation	O
-	O
stimulated	O
encystment	O
induction	O
and	O
protein	O
phosphorylation	O
were	O
also	O
suppressed	O
by	O
the	O
addition	O
of	O
BAPTA	O
-	O
AM	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Ca	O
(	O
2	O
+	O
)	O
inflow	O
promoted	O
by	O
cell	O
-	O
to	O
-	O
cell	O
stimulation	O
due	O
to	O
overpopulation	O
may	O
activate	O
signaling	O
pathways	O
involving	O
protein	O
phosphorylation	O
and	O
encystment	O
induction	O
.	O

In	O
the	O
presence	O
of	O
cAMP	O
-	O
AM	O
,	O
the	O
phosphorylation	O
levels	O
of	O
33	O
kDa	O
,	O
37	O
kDa	O
,	O
37.5	O
kDa	O
,	O
43	O
kDa	O
,	O
47	O
kDa	O
and	O
49	O
kDa	O
proteins	O
were	O
enhanced	O
,	O
and	O
encystment	O
induction	O
was	O
promoted	O
.	O

Enzyme	O
immunoassays	O
(	O
EIAs	O
)	O
showed	O
that	O
intracellular	O
cAMP	O
concentration	O
was	O
raised	O
prior	O
to	O
encystment	O
when	O
the	O
cells	O
were	O
stimulated	O
by	O
overpopulation	O
.	O

These	O
results	O
suggest	O
that	O
cAMP	O
/	O
PKA	O
-	O
dependent	O
protein	O
phosphorylation	O
,	O
which	O
is	O
an	O
event	O
on	O
Ca	O
(	O
2+	O
)	O
-triggered	O
signaling	O
pathways	O
,	O
may	O
be	O
involved	O
in	O
encystment	O
induction	O
.	O

Proposal	O
of	O
Mingxiaea	O
gen.	O
nov.	O
for	O
the	O
anamorphic	O
basidiomycetous	O
yeast	B
species	O
in	O
the	O
Bulleribasidium	O
clade	O
(	O
Tremellales	O
)	O
based	O
on	O
molecular	O
phylogenetic	O
analysis	O
,	O
with	O
six	O
new	O
combinations	O
and	O
four	O
novel	O
species	O
.	O

The	O
distinction	O
and	O
monophyletic	O
property	O
of	O
the	O
basidiomycetous	O
yeast	B
species	O
in	O
the	O
Bulleribasidium	O
clade	O
of	O
the	O
order	O
Tremellales	O
was	O
resolved	O
by	O
molecular	O
phylogenetic	O
analysis	O
based	O
on	O
the	O
combined	O
sequences	O
of	O
the	O
18S	O
rRNA	O
gene	O
,	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
region	O
including	O
5.8S	O
rRNA	O
gene	O
and	O
26S	O
rRNA	O
gene	O
D1	O
/	O
D2	O
domain	O
.	O

The	O
addition	O
to	O
the	O
clade	O
of	O
new	O
anamorphic	O
species	O
identified	O
among	O
ballistoconidium	O
-	O
forming	O
yeasts	B
isolated	O
from	O
China	O
confirmed	O
and	O
strengthened	O
the	O
separation	O
of	O
this	O
clade	O
from	O
other	O
clades	O
or	O
lineages	O
in	O
the	O
order	O
Tremellales	O
.	O

A	O
new	O
anamorphic	O
genus	O
,	O
Mingxiaea	O
gen.	O
nov.	O
(	O
type	O
species	O
Mingxiaea	O
variabilis	O
comb	O
.	O

nov.	O
)	O
is	O
therefore	O
proposed	O
to	O
accommodate	O
the	O
anamorphic	O
species	O
in	O
the	O
Bulleribasidium	O
clade	O
.	O

Six	O
new	O
combinations	O
are	O
proposed	O
for	O
the	O
described	O
species	O
of	O
this	O
clade	O
which	O
were	O
formerly	O
assigned	O
to	O
the	O
genus	O
Bullera	O
.	O

Four	O
novel	O
species	O
in	O
the	O
new	O
genus	O
were	O
identified	O
among	O
16	O
ballistoconidium	O
-	O
forming	O
yeast	B
strains	O
isolated	O
from	O
plant	O
leaves	O
collected	O
in	O
Hainan	O
province	O
,	O
southern	O
China	O
,	O
by	O
D1	O
/	O
D2	O
and	O
ITS	O
sequence	O
analyses	O
.	O

The	O
novel	O
species	O
are	O
described	O
as	O
Mingxiaea	O
sanyaensis	O
sp.	O
nov.	O
(	O
type	O
strain	O
SY-3.23	O
(	O
T	O
)	O
=	O
AS	O
2	O
.	O
3623	O
(	O
T	O
)	O
=	O
CBS	O
11408	O
(	O
T	O
)	O
)	O
,	O
Mingxiaea	O
hainanensis	O
(	O
type	O
strain	O
WZS-8.13	O
(	O
T	O
)	O
=	O
AS	O
2.4161	O
(	O
T	O
)	O
=	O
CBS	O
11409	O
(	O
T	O
)	O
)	O
,	O
Mingxiaea	O
foliicola	O
(	O
type	O
strain	O
WZS-8.14	O
(	O
T	O
)	O
=	O
AS	O
2.3518	O
(	O
T	O
)	O
=	O
CBS	O
11407	O
(	O
T	O
)	O
)	O
and	O
Mingxiaea	O
wuzhishanensis	O
(	O
type	O
strain	O
WZS-29.8	O
(	O
T	O
)	O
=	O
AS	O
2.4163	O
(	O
T	O
)	O
=	O
CBS	O
11411	O
(	O
T	O
)	O
)	O
.	O

Taxonomy	O
and	O
phylogeny	O
of	O
a	O
new	O
kleptoplastidal	O
dinoflagellate	O
,	O
Gymnodinium	B
myriopyrenoides	I
sp.	O
nov.	O
(	O
Gymnodiniales	O
,	O
Dinophyceae	O
)	O
,	O
and	O
its	O
cryptophyte	O
symbiont	O
.	O

A	O
new	O
kleptoplastidal	O
dinoflagellate	O
,	O
Gymnodinium	B
myriopyrenoides	I
sp.	O
nov.	O
,	O
was	O
described	O
using	O
light	O
microscopy	O
,	O
electron	O
microscopy	O
and	O
phylogengetic	O
analysis	O
based	O
on	O
partial	O
LSU	O
rDNA	O
sequences	O
.	O

Cells	O
were	O
dorsiventrally	O
flattened	O
,	O
elongate	O
-	O
elliptical	O
in	O
ventral	O
view	O
.	O

There	O
was	O
no	O
displacement	O
of	O
the	O
cingulum	O
encircling	O
the	O
anterior	O
part	O
of	O
the	O
cell	O
.	O

The	O
cingulum	O
was	O
curved	O
posteriorly	O
at	O
the	O
terminal	O
junction	O
with	O
the	O
sulcus	O
.	O

The	O
sulcus	O
was	O
generally	O
narrow	O
but	O
expanded	O
in	O
the	O
posterior	O
end	O
.	O

The	O
epicone	O
possessed	O
an	O
apical	O
groove	O
made	O
of	O
one	O
and	O
one	O
-	O
half	O
counterclockwise	O
revolutions	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
LSU	O
rDNA	O
showed	O
that	O
the	O
sequence	O
of	O
G.	B
myriopyrenoides	I
was	O
included	O
in	O
the	O
Gymnodiniales	O
sensu	O
stricto	O
clade	O
and	O
had	O
special	O
affinities	O
with	O
the	O
species	O
Amphidinium	B
poecilochroum	I
and	O
Gymnodinium	B
acidotum	I
,	O
which	O
also	O
harbor	O
kleptochloroplasts	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
plastid	O
-	O
encoded	O
SSU	O
rDNA	O
and	O
ultrastructural	O
observations	O
suggested	O
that	O
the	O
symbionts	O
of	O
G.	B
myriopyrenoides	I
were	O
cryptophytes	O
of	O
the	O
genus	O
Chroomonas	O
or	O
Hemiselmis	O
.	O

Organelles	O
including	O
the	O
nucleus	O
,	O
the	O
nucleomorph	O
,	O
mitochondria	O
,	O
Golgi	O
bodies	O
and	O
large	O
chloroplasts	O
remained	O
in	O
the	O
cytoplasm	O
of	O
the	O
symbionts	O
,	O
but	O
not	O
the	O
periplast	O
,	O
ejectosomes	O
or	O
flagellar	O
apparatus	O
.	O

The	O
symbiotic	O
level	O
of	O
G.	B
myriopyrenoides	I
was	O
estimated	O
to	O
be	O
a	O
relatively	O
early	O
stage	O
in	O
the	O
unarmored	O
kleptoplastidal	O
dinoflagellates	O
.	O

Unexpected	O
coregulator	O
range	O
for	O
the	O
global	O
regulator	O
Lrp	O
of	O
Escherichia	B
coli	I
and	O
Proteus	B
mirabilis	I
.	O

The	O
Lrp	O
/	O
AsnC	O
family	O
of	O
transcription	O
factors	O
links	O
gene	O
regulation	O
to	O
metabolism	O
in	O
bacteria	O
and	O
archaea	O
.	O

Members	O
of	O
this	O
family	O
,	O
collectively	O
,	O
respond	O
to	O
a	O
wide	O
range	O
of	O
amino	O
acids	O
as	O
coregulators	O
.	O

In	O
Escherichia	B
coli	I
,	O
Lrp	O
regulates	O
over	O
200	O
genes	O
directly	O
and	O
is	O
well	O
known	O
to	O
respond	O
to	O
leucine	O
and	O
,	O
to	O
a	O
somewhat	O
lesser	O
extent	O
,	O
alanine	O
.	O

We	O
focused	O
on	O
Lrp	O
from	O
Proteus	B
mirabilis	I
and	O
E.	B
coli	I
,	O
orthologs	O
with	O
98	O
%	O
identity	O
overall	O
and	O
identical	O
helix	O
-	O
turn	O
-	O
helix	O
motifs	O
,	O
for	O
which	O
a	O
previous	O
study	O
nevertheless	O
found	O
functional	O
differences	O
.	O

Sequence	O
differences	O
between	O
these	O
orthologs	O
,	O
within	O
and	O
adjacent	O
to	O
the	O
amino	O
acid	O
-	O
responsive	O
RAM	O
domain	O
,	O
led	O
us	O
to	O
test	O
for	O
differential	O
sensitivity	O
to	O
coregulatory	O
amino	O
acids	O
.	O

In	O
the	O
course	O
of	O
this	O
investigation	O
,	O
we	O
found	O
,	O
via	O
in	O
vivo	O
reporter	O
fusion	O
assays	O
and	O
in	O
vitro	O
electrophoretic	O
mobility	O
shift	O
experiments	O
,	O
that	O
E.	B
coli	I
Lrp	O
itself	O
responded	O
to	O
a	O
broader	O
range	O
of	O
amino	O
acids	O
than	O
was	O
previously	O
appreciated	O
.	O

In	O
particular	O
,	O
for	O
both	O
the	O
E.	B
coli	I
and	O
P.	B
mirabilis	I
orthologs	O
,	O
Lrp	O
responsiveness	O
to	O
methionine	O
was	O
similar	O
in	O
magnitude	O
to	O
that	O
to	O
leucine	O
.	O

Both	O
Lrp	O
orthologs	O
are	O
also	O
fairly	O
sensitive	O
to	O
Ile	O
,	O
His	O
,	O
and	O
Thr	O
.	O

These	O
observations	O
suggest	O
that	O
Lrp	O
ties	O
gene	O
expression	O
in	O
the	O
Enterobacteriaceae	O
rather	O
extensively	O
to	O
physiological	O
status	O
,	O
as	O
reflected	O
in	O
amino	O
acid	O
pools	O
.	O

These	O
findings	O
also	O
have	O
substantial	O
implications	O
for	O
attempts	O
to	O
model	O
regulatory	O
architecture	O
from	O
transcriptome	O
measurements	O
or	O
to	O
infer	O
such	O
architecture	O
from	O
genome	O
sequences	O
,	O
and	O
they	O
suggest	O
that	O
even	O
well	O
-	O
studied	O
regulators	O
deserve	O
ongoing	O
exploration	O
.	O

Contrasting	O
covariation	O
of	O
above-	O
and	O
belowground	O
invertebrate	O
species	O
across	O
plant	O
genotypes	O
.	O

1	O
.	O

Invertebrate	O
species	O
generally	O
do	O
not	O
respond	O
independently	O
to	O
genotypic	O
variation	O
in	O
plants	O
,	O
giving	O
rise	O
to	O
clusters	O
of	O
species	O
that	O
naturally	O
associate	O
with	O
or	O
avoid	O
certain	O
genotypes	O
.	O

This	O
covariation	O
causes	O
coevolution	O
to	O
be	O
diffuse	O
rather	O
than	O
pairwise	O
.	O

Studies	O
on	O
this	O
topic	O
,	O
however	O
,	O
have	O
never	O
considered	O
the	O
belowground	O
invertebrate	O
community	O
,	O
leaving	O
a	O
critical	O
gap	O
in	O
our	O
understanding	O
.	O

2	O
.	O

We	O
investigated	O
the	O
covariation	O
among	O
naturally	O
colonising	O
above-	O
and	O
belowground	O
invertebrate	O
species	O
across	O
six	O
genetically	O
distinct	O
populations	O
of	O
the	O
dune	O
grass	O
Ammophila	B
arenaria	I
.	O

After	O
having	O
grown	O
from	O
seed	O
in	O
a	O
common	O
garden	O
,	O
plants	O
were	O
randomised	O
in	O
a	O
single	O
field	O
site	O
to	O
exclude	O
all	O
but	O
broad	O
-	O
sense	O
genetic	O
variation	O
.	O

3	O
.	O
Strong	O
positive	O
covariation	O
across	O
genotypes	O
among	O
both	O
above-	O
and	O
belowground	O
invertebrates	O
was	O
detected	O
,	O
while	O
correlations	O
between	O
these	O
two	O
groups	O
were	O
negative	O
.	O

This	O
clustering	O
of	O
above-	O
and	O
belowground	O
species	O
matched	O
well	O
with	O
order	O
level	O
taxonomy	O
.	O

Host	O
range	O
,	O
trophic	O
level	O
and	O
food	O
type	O
on	O
the	O
other	O
hand	O
did	O
not	O
correspond	O
well	O
with	O
the	O
clusters	O
.	O

Within	O
the	O
cluster	O
of	O
aboveground	O
fauna	O
,	O
subsequent	O
groupings	O
were	O
not	O
related	O
to	O
any	O
phylogenetic	O
or	O
ecological	O
characteristic	O
,	O
although	O
correlations	O
within	O
these	O
subgroups	O
were	O
very	O
high	O
.	O

We	O
furthermore	O
demonstrated	O
significant	O
differences	O
in	O
multiple	O
invertebrate	O
species	O
occurrence	O
between	O
plant	O
genotypes	O
,	O
in	O
general	O
as	O
well	O
as	O
at	O
the	O
above-	O
and	O
belowground	O
level	O
.	O

4	O
.	O

The	O
observed	O
strong	O
covariation	O
suggests	O
diffuse	O
coevolution	O
between	O
A.	B
arenaria	I
and	O
its	O
associated	O
invertebrate	O
species	O
.	O

The	O
trade	O
-	O
off	O
between	O
root	O
and	O
shoot	O
invertebrates	O
could	O
however	O
hamper	O
directional	O
selection	O
on	O
resistance	O
to	O
either	O
group	O
.	O

5	O
.	O

Our	O
results	O
clearly	O
demonstrate	O
the	O
need	O
for	O
studies	O
of	O
plant	O
-	O
animal	O
interactions	O
to	O
include	O
the	O
belowground	O
fauna	O
,	O
as	O
this	O
might	O
drastically	O
alter	O
our	O
general	O
conception	O
of	O
how	O
plants	O
and	O
their	O
associated	O
animal	O
communities	O
interact	O
and	O
how	O
these	O
interactions	O
shape	O
the	O
process	O
of	O
evolution	O
.	O

Labeling	O
and	O
enzyme	O
studies	O
of	O
the	O
central	O
carbon	O
metabolism	O
in	O
Metallosphaera	B
sedula	I
.	O

Metallosphaera	B
sedula	I
(	O
Sulfolobales	O
,	O
Crenarchaeota	O
)	O
uses	O
the	O
3-hydroxypropionate	O
/	O
4-hydroxybutyrate	O
cycle	O
for	O
autotrophic	O
carbon	O
fixation	O
.	O

In	O
this	O
pathway	O
,	O
acetyl	O
-	O
coenzyme	O
A	O
(	O
CoA	O
)	O
and	O
succinyl	O
-	O
CoA	O
are	O
the	O
only	O
intermediates	O
that	O
can	O
be	O
considered	O
common	O
to	O
the	O
central	O
carbon	O
metabolism	O
.	O

We	O
addressed	O
the	O
question	O
of	O
which	O
intermediate	O
of	O
the	O
cycle	O
most	O
biosynthetic	O
routes	O
branch	O
off	O
.	O

We	O
labeled	O
autotrophically	O
growing	O
cells	O
by	O
using	O
4-hydroxy	O
[	O
1-^1	O
^	O
4C	O
]	O
butyrate	O
and	O
[	O
1,4-^1	O
^	O
3C1	O
]	O
succinate	O
,	O
respectively	O
,	O
as	O
precursors	O
for	O
biosynthesis	O
.	O

The	O
labeling	O
patterns	O
of	O
protein	O
-	O
derived	O
amino	O
acids	O
verified	O
the	O
operation	O
of	O
the	O
proposed	O
carbon	O
fixation	O
cycle	O
,	O
in	O
which	O
4-hydroxybutyrate	O
is	O
converted	O
to	O
two	O
molecules	O
of	O
acetyl	O
-	O
CoA.	O
The	O
results	O
also	O
showed	O
that	O
major	O
biosynthetic	O
flux	O
does	O
not	O
occur	O
via	O
acetyl	O
-	O
CoA	O
,	O
except	O
for	O
the	O
formation	O
of	O
building	O
blocks	O
that	O
are	O
directly	O
derived	O
from	O
acetyl	O
-	O
CoA.	O
Notably	O
,	O
acetyl	O
-	O
CoA	O
is	O
not	O
assimilated	O
via	O
reductive	O
carboxylation	O
to	O
pyruvate	O
.	O

Rather	O
,	O
our	O
data	O
suggest	O
that	O
the	O
majority	O
of	O
anabolic	O
precursors	O
are	O
derived	O
from	O
succinyl	O
-	O
CoA	O
,	O
which	O
is	O
removed	O
from	O
the	O
cycle	O
via	O
oxidation	O
to	O
malate	O
and	O
oxaloacetate	O
.	O

These	O
C4intermediates	O
yield	O
pyruvate	O
and	O
phosphoenolpyruvate	O
(	O
PEP	O
)	O
.	O

Enzyme	O
activities	O
that	O
are	O
required	O
for	O
forming	O
intermediates	O
from	O
succinyl	O
-	O
CoA	O
were	O
detected	O
,	O
including	O
enzymes	O
catalyzing	O
gluconeogenesis	O
from	O
PEP	O
.	O

This	O
study	O
completes	O
the	O
picture	O
of	O
the	O
central	O
carbon	O
metabolism	O
in	O
autotrophic	O
Sulfolobales	O
by	O
connecting	O
the	O
autotrophic	O
carbon	O
fixation	O
cycle	O
to	O
the	O
formation	O
of	O
central	O
carbon	O
precursor	O
metabolites	O
.	O

Density	O
-	O
dependent	O
population	O
dynamics	O
and	O
dispersal	O
in	O
heterogeneous	O
metapopulations	O
.	O

1	O
.	O

Metapopulation	O
microcosms	O
were	O
constructed	O
to	O
test	O
the	O
effect	O
of	O
four	O
different	O
types	O
of	O
habitat	O
heterogeneity	O
on	O
the	O
dynamics	O
and	O
dispersal	O
in	O
spatially	O
extended	O
systems	O
;	O
homogeneity	O
,	O
spatial	O
heterogeneity	O
,	O
temporal	O
heterogeneity	O
and	O
spatio	O
-	O
temporal	O
heterogeneity	O
.	O

Resources	O
were	O
distributed	O
across	O
discrete	O
habitat	O
patches	O
in	O
bruchid	O
beetle	O
(	O
Callosobruchus	B
maculatus	I
)	O
metapopulations	O
,	O
and	O
long	O
-	O
term	O
time	O
series	O
were	O
recorded	O
.	O

2	O
.	O

Mathematical	O
models	O
were	O
fitted	O
to	O
the	O
long	O
-	O
term	O
time	O
series	O
from	O
the	O
experimental	O
systems	O
using	O
a	O
maximum	O
likelihood	O
approach	O
.	O

Models	O
were	O
composed	O
of	O
separate	O
birth	O
,	O
death	O
,	O
emigration	O
and	O
immigration	O
terms	O
all	O
of	O
which	O
incorporated	O
stochasticity	O
drawn	O
from	O
different	O
probability	O
distributions	O
.	O

Models	O
with	O
density	O
-	O
dependent	O
and	O
density	O
-	O
independent	O
birth	O
,	O
death	O
and	O
emigration	O
terms	O
were	O
investigated	O
and	O
,	O
in	O
each	O
case	O
,	O
the	O
model	O
that	O
best	O
described	O
the	O
empirical	O
data	O
was	O
identified	O
.	O

3	O
.	O

At	O
the	O
local	O
scale	O
,	O
population	O
sizes	O
differed	O
between	O
patches	O
depending	O
on	O
the	O
type	O
of	O
heterogeneity	O
.	O

Larger	O
populations	O
were	O
associated	O
with	O
higher	O
resource	O
availabilities	O
.	O

As	O
a	O
result	O
of	O
this	O
,	O
the	O
variation	O
between	O
local	O
population	O
sizes	O
was	O
greatest	O
when	O
there	O
was	O
spatial	O
heterogeneity	O
in	O
which	O
mean	O
resource	O
abundance	O
varied	O
from	O
patch	O
to	O
patch	O
.	O

Variation	O
in	O
population	O
sizes	O
within	O
patches	O
was	O
largest	O
when	O
there	O
was	O
temporal	O
heterogeneity	O
.	O

4	O
.	O
Density	O
-	O
dependent	O
processes	O
leading	O
to	O
the	O
regulation	O
of	O
local	O
population	O
dynamics	O
in	O
our	O
experimental	O
systems	O
were	O
strongest	O
in	O
homogeneity	O
or	O
temporal	O
heterogeneity	O
treatments	O
.	O

Associated	O
with	O
this	O
,	O
we	O
found	O
that	O
these	O
systems	O
were	O
best	O
described	O
using	O
mathematical	O
models	O
with	O
density	O
dependence	O
acting	O
on	O
mortality	O
.	O

In	O
contrast	O
,	O
spatial	O
and	O
spatio	O
-	O
temporal	O
time	O
series	O
were	O
adequately	O
described	O
using	O
density	O
-	O
independent	O
population	O
processes	O
.	O

5	O
.	O
Experimental	O
metapopulations	O
showed	O
varying	O
degrees	O
of	O
density	O
-	O
dependent	O
dispersal	O
.	O

Local	O
net	O
dispersal	O
each	O
week	O
was	O
primarily	O
driven	O
by	O
the	O
local	O
population	O
size	O
and	O
secondarily	O
affected	O
by	O
neighbourhood	O
population	O
density	O
.	O

Mathematical	O
population	O
models	O
illustrated	O
the	O
importance	O
of	O
explicit	O
description	O
of	O
density	O
-	O
dependent	O
dispersal	O
in	O
all	O
systems	O
except	O
the	O
homogeneous	O
metapopulations	O
.	O

Predicting	O
diet	O
and	O
consumption	O
rate	O
differences	O
between	O
and	O
within	O
species	O
using	O
gut	O
ecomorphology	O
.	O

1	O
.	O

Rapid	O
environmental	O
changes	O
and	O
pressing	O
human	B
needs	O
to	O
forecast	O
the	O
consequences	O
of	O
environmental	O
change	O
are	O
increasingly	O
driving	O
ecology	O
to	O
become	O
a	O
predictive	O
science	O
.	O

The	O
need	O
for	O
effective	O
prediction	O
requires	O
both	O
the	O
development	O
of	O
new	O
tools	O
and	O
the	O
refocusing	O
of	O
existing	O
tools	O
that	O
may	O
have	O
previously	O
been	O
used	O
primarily	O
for	O
purposes	O
other	O
than	O
prediction	O
.	O

One	O
such	O
tool	O
that	O
historically	O
has	O
been	O
more	O
descriptive	O
in	O
nature	O
is	O
ecomorphology	O
(	O
the	O
study	O
of	O
relationships	O
between	O
ecological	O
roles	O
and	O
morphological	O
adaptations	O
of	O
species	O
and	O
individuals	O
)	O
.	O

2	O
.	O
Here	O
,	O
we	O
examine	O
relationships	O
between	O
diet	O
and	O
gut	O
morphology	O
for	O
15	O
species	O
of	O
brachyuran	O
crabs	O
,	O
a	O
group	O
of	O
pervasive	O
and	O
highly	O
successful	O
consumers	O
for	O
which	O
trophic	O
predictions	O
would	O
be	O
highly	O
valuable	O
.	O

3	O
.	O

We	O
show	O
that	O
patterns	O
in	O
crab	O
stomach	O
volume	O
closely	O
match	O
some	O
predictions	O
of	O
metabolic	O
theory	O
and	O
demonstrate	O
that	O
individual	O
diet	O
differences	O
and	O
associated	O
morphological	O
variation	O
reflect	O
,	O
at	O
least	O
in	O
some	O
instances	O
,	O
individual	O
choice	O
or	O
diet	O
specialization	O
.	O

4	O
.	O

We	O
then	O
present	O
examples	O
of	O
how	O
stomach	O
volume	O
can	O
be	O
used	O
to	O
predict	O
both	O
the	O
per	O
cent	O
herbivory	O
of	O
brachyuran	O
crabs	O
and	O
the	O
relative	O
consumption	O
rates	O
of	O
individual	O
crabs	O
.	O

Alcohol	O
dehydrogenase	O
and	O
hydrogenase	O
transcript	O
fluctuations	O
during	O
a	O
day	O
-	O
night	O
cycle	O
in	O
Chlamydomonas	B
reinhardtii	I
:	O
the	O
role	O
of	O
anoxia	O
.	O

*	O
The	O
unicellular	O
green	O
alga	O
Chlamydomonas	B
reinhardtii	I
contains	O
two	O
iron	O
(	O
Fe	O
)	O
-hydrogenases	O
which	O
are	O
responsible	O
for	O
hydrogen	O
production	O
under	O
anoxia	O
.	O

In	O
the	O
present	O
work	O
the	O
patterns	O
of	O
expression	O
of	O
alcohol	O
dehydrogenase	O
,	O
a	O
typical	O
anaerobic	O
gene	O
in	O
plants	O
,	O
of	O
the	O
hydrogenases	O
genes	O
(	O
HYD1	O
,	O
HYD2	O
)	O
and	O
of	O
the	O
genes	O
responsible	O
for	O
their	O
maturation	O
(	O
HYDEF	O
,	O
HYDG	O
)	O
,	O
were	O
analysed	O
.	O

*	O
The	O
expression	O
patterns	O
were	O
analysed	O
by	O
real	O
-	O
time	O
reverse	O
-	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
Chlamydomonas	O
cultures	O
during	O
the	O
day	O
-	O
night	O
cycle	O
,	O
as	O
well	O
as	O
in	O
response	O
to	O
oxygen	O
availability	O
.	O

*	O
The	O
results	O
indicated	O
that	O
ADH1	O
,	O
HYD1	O
,	O
HYD2	O
,	O
HYDEF	O
and	O
HYDG	O
were	O
expressed	O
following	O
precise	O
day	O
-	O
night	O
fluctuations	O
.	O

ADH1	O
and	O
HYD2	O
were	O
modulated	O
by	O
the	O
day	O
-	O
night	O
cycle	O
.	O

Low	O
oxygen	O
plays	O
an	O
important	O
role	O
for	O
the	O
induction	O
of	O
HYD1	O
,	O
HYDEF	O
and	O
HYDG	O
,	O
while	O
ADH1	O
and	O
HYD2	O
expression	O
was	O
relatively	O
insensitive	O
to	O
oxygen	O
availability	O
.	O

*	O
The	O
regulation	O
of	O
the	O
anaerobic	O
gene	O
expression	O
in	O
Chlamydomonas	O
is	O
only	O
partly	O
explained	O
by	O
responses	O
to	O
anoxia	O
.	O

The	O
cell	O
cycle	O
and	O
light	O
-	O
dark	O
cycles	O
are	O
equally	O
important	O
elements	O
in	O
the	O
regulatory	O
network	O
modulating	O
the	O
anaerobic	O
response	O
in	O
Chlamydomonas	O
.	O

Analysis	O
of	O
the	O
Fusarium	B
graminearum	I
species	I
complex	I
from	O
wheat	B
,	O
barley	B
and	O
maize	B
in	O
South	O
Africa	O
provides	O
evidence	O
of	O
species	O
-	O
specific	O
differences	O
in	O
host	O
preference	O
.	O

Species	O
identity	O
and	O
trichothecene	O
toxin	O
potential	O
of	O
560	O
members	O
of	O
the	O
Fusarium	B
graminearum	I
species	I
complex	I
(	O
FGSC	B
)	O
collected	O
from	O
diseased	O
wheat	B
,	O
barley	B
and	O
maize	B
in	O
South	O
Africa	O
was	O
determined	O
using	O
a	O
microsphere	O
-	O
based	O
multilocus	O
genotyping	O
assay	O
.	O

Although	O
three	O
trichothecene	O
types	O
(	O
3-ADON	O
,	O
15-ADON	O
and	O
NIV	O
)	O
were	O
represented	O
among	O
these	O
isolates	O
,	O
strains	O
with	O
the	O
15-ADON	O
type	O
predominated	O
on	O
all	O
three	O
hosts	O
.	O

A	O
significant	O
difference	O
,	O
however	O
,	O
was	O
identified	O
in	O
the	O
composition	O
of	O
FGSC	B
pathogens	O
associated	O
with	O
Gibberella	O
ear	O
rot	O
(	O
GER	O
)	O
of	O
maize	B
as	O
compared	O
to	O
Fusarium	O
head	O
blight	O
(	O
FHB	O
)	O
of	O
wheat	B
or	O
barley	B
(	O
P<0.001	O
)	O
.	O

F.	O
graminearum	B
accounted	I
for	O
more	O
than	O
85	O
%	O
of	O
the	O
FGSC	O
isolates	B
associated	O
with	O
FHB	O
of	O
wheat	O
and	B
barley	O
(	B
N=425	O
)	O
,	O
and	O
was	O
also	O
the	O
dominant	O
species	O
among	O
isolates	O
from	O
maize	O
roots	B
(	O
N=35	O
)	O
.	O

However	O
,	O
with	O
the	O
exception	O
of	O
a	O
single	O
isolate	O
identified	O
as	O
an	O
interspecific	O
hybrid	O
between	O
Fusariumboothii	O
and	B
F.	O
graminearum	B
,	I
GER	O
of	O
maize	O
(	B
N=100	O
)	O
was	O
exclusively	O
associated	O
with	O
F.	O
boothii	B
.	I

The	O
predominance	O
of	O
F.	O
graminearum	B
among	I
FHB	O
isolates	O
,	O
and	O
the	O
near	O
exclusivity	O
of	O
F.	O
boothii	B
among	I
GER	O
isolates	O
,	O
was	O
observed	O
across	O
all	O
cultivars	O
,	O
collection	O
dates	O
,	O
and	O
provinces	O
sampled	O
.	O

Because	O
these	O
results	O
suggest	O
a	O
difference	O
in	O
host	O
preference	O
among	O
species	O
of	O
the	O
FGSC	O
,	B
we	O
hypothesize	O
that	O
F.	O
graminearum	B
may	I
be	O
less	O
well	O
adapted	O
to	O
infect	O
maize	O
ears	B
than	O
other	O
members	O
of	O
the	O
FGSC	O
.	B

Molecular	O
structure	O
of	O
the	O
prothoracicotropic	O
hormone	O
gene	O
in	O
the	O
northern	B
house	I
mosquito	I
,	O
Culex	B
pipiens	I
,	O
and	O
its	O
expression	O
analysis	O
in	O
association	O
with	O
diapause	O
and	O
blood	O
feeding	O
.	O

We	O
cloned	O
the	O
gene	O
that	O
encodes	O
prothoracicotropic	O
hormone	O
(	O
PTTH	O
)	O
in	O
the	O
northern	B
house	I
mosquito	I
,	O
Culex	B
pipiens	I
,	O
and	O
investigated	O
its	O
expression	O
profile	O
in	O
short	O
-	O
day	O
(	O
diapause	O
-	O
destined	O
)	O
and	O
long	O
-	O
day	O
(	O
nondiapause	O
-	O
destined	O
)	O
individuals	O
from	O
the	O
fourth	O
-	O
instar	O
larval	O
stage	O
to	O
2	O
months	O
of	O
adulthood	O
,	O
as	O
well	O
as	O
after	O
a	O
blood	O
meal	O
.	O

The	O
deduced	O
C.	B
pipiens	I
PTTH	O
(	O
Cupip	O
-	O
PTTH	O
)	O
amino	O
acid	O
sequence	O
contains	O
seven	O
cysteines	O
with	O
a	O
specific	O
spacing	O
pattern	O
.	O

Sequence	O
alignment	O
suggests	O
that	O
Cupip	O
-	O
PTTH	O
is	O
23	O
%	O
identical	O
to	O
Drosophila	B
melanogaster	I
PTTH	O
,	O
but	O
is	O
>	O
=	O
59	O
%	O
identical	O
to	O
the	O
PTTHs	O
of	O
other	O
mosquitoes	O
.	O

Cupip	O
-	O
PTTH	O
has	O
structural	O
characteristics	O
similar	O
to	O
those	O
of	O
Bombyx	B
mori	I
PTTH	O
and	O
some	O
vertebrate	O
nerve	O
growth	O
factors	O
with	O
cysteine	O
-	O
knot	O
motifs	O
.	O

PTTH	O
transcripts	O
exhibit	O
a	O
daily	O
cycling	O
profile	O
during	O
the	O
final	O
(	O
fourth	O
)	O
larval	O
instar	O
,	O
with	O
peak	O
abundance	O
occurring	O
late	O
in	O
the	O
scotophase	O
.	O

The	O
fourth	O
-	O
larval	O
instar	O
stage	O
is	O
one	O
day	O
longer	O
in	O
short	O
-	O
day	O
larvae	O
than	O
in	O
long	O
-	O
day	O
larvae	O
,	O
resulting	O
in	O
larger	O
larvae	O
and	O
adults	O
.	O

This	O
additional	O
day	O
of	O
larval	O
development	O
is	O
associated	O
with	O
one	O
extra	O
PTTH	O
cycle	O
.	O

No	O
cycling	O
was	O
observed	O
in	O
pupae	O
,	O
but	O
PTTH	O
transcripts	O
were	O
slightly	O
higher	O
in	O
short	O
-	O
day	O
pupae	O
than	O
in	O
long	O
-	O
day	O
pupae	O
throughout	O
much	O
of	O
the	O
pupal	O
stage	O
.	O

PTTH	O
expression	O
persisted	O
at	O
a	O
nearly	O
constant	O
level	O
in	O
diapausing	O
adult	O
females	O
for	O
the	O
first	O
month	O
but	O
then	O
dropped	O
by	O
-50	O
%	O
,	O
while	O
expression	O
decreased	O
at	O
the	O
beginning	O
of	O
adulthood	O
in	O
nondiapausing	O
females	O
and	O
then	O
remained	O
at	O
a	O
low	O
level	O
as	O
long	O
as	O
the	O
females	O
were	O
denied	O
a	O
blood	O
meal	O
.	O

However	O
,	O
when	O
nondiapausing	O
females	O
were	O
offered	O
a	O
blood	O
meal	O
,	O
PTTH	O
transcripts	O
rose	O
approximately	O
7	O
fold	O
in	O
2	O
h	O
and	O
remained	O
elevated	O
for	O
24	O
h.	O
A	O
few	O
diapausing	O
females	O
(	O
-10	O
%	O
)	O
will	O
take	O
a	O
blood	O
meal	O
when	O
placed	O
in	O
close	O
proximity	O
to	O
a	O
host	O
,	O
but	O
much	O
of	O
the	O
blood	O
is	O
ejected	O
and	O
such	O
meals	O
do	O
not	O
result	O
in	O
mature	O
eggs	O
.	O

Yet	O
,	O
elevated	O
PTTH	O
mRNA	O
expression	O
was	O
also	O
observed	O
in	O
diapausing	O
females	O
that	O
were	O
force	O
fed	O
.	O

Our	O
results	O
thus	O
point	O
to	O
several	O
distinctions	O
in	O
PTTH	O
expression	O
between	O
short	O
-	O
day	O
and	O
long	O
-	O
day	O
mosquitoes	O
,	O
but	O
both	O
types	O
of	O
females	O
responded	O
to	O
a	O
blood	O
meal	O
by	O
elevating	O
levels	O
of	O
PTTH	O
mRNA	O
.	O

Phylloplane	O
location	O
of	O
glucosinolates	O
in	O
Barbarea	O
spp	O
.	O

(	O
Brassicaceae	O
)	O
and	O
misleading	O
assessment	O
of	O
host	O
suitability	O
by	O
a	O
specialist	O
herbivore	O
.	O

Glucosinolates	O
are	O
plant	O
secondary	O
metabolites	O
used	O
in	O
host	O
plant	O
recognition	O
by	O
insects	O
specialized	O
on	O
Brassicaceae	O
,	O
such	O
as	O
the	O
diamondback	B
moth	I
(	O
DBM	B
)	O
,	O
Plutella	B
xylostella	I
.	O

Their	O
perception	O
as	O
oviposition	O
cues	O
by	O
females	O
would	O
seem	O
to	O
require	O
their	O
occurrence	O
on	O
the	O
leaf	O
surface	O
,	O
yet	O
previous	O
studies	O
have	O
reached	O
opposite	O
conclusions	O
about	O
whether	O
glucosinolates	O
are	O
actually	O
present	O
on	O
the	O
surface	O
of	O
crucifer	O
leaves	O
.	O

DBM	B
oviposits	O
extensively	O
on	O
Barbarea	B
vulgaris	I
,	O
despite	O
its	O
larvae	O
not	O
being	O
able	O
to	O
survive	O
on	O
this	O
plant	O
because	O
of	O
its	O
content	O
of	O
feeding	O
-	O
deterrent	O
saponins	O
.	O

Glucosinolates	O
and	O
saponins	O
in	O
plant	O
tissue	O
and	O
mechanically	O
removed	O
surface	O
waxes	O
from	O
leaves	O
of	O
Barbarea	O
spp	O
.	O
were	O
analyzed	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
and	O
liquid	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
)	O
.	O

Surface	O
waxes	O
from	O
leaves	O
of	O
Barbarea	O
spp	O
.	O

contained	O
glucosinolates	O
,	O
but	O
not	O
feeding	O
-	O
deterrent	O
saponins	O
.	O

Our	O
research	O
is	O
the	O
first	O
to	O
show	O
that	O
glucosinolates	O
are	O
present	O
on	O
the	O
leaf	O
surface	O
of	O
Barbarea	O
spp	O
.	O
,	O
but	O
not	O
in	O
other	O
crucifers	O
investigated	O
,	O
resolving	O
some	O
conflicting	O
results	O
from	O
previous	O
studies	O
.	O

Our	O
research	O
is	O
also	O
the	O
first	O
to	O
quantify	O
glucosinolates	O
on	O
the	O
leaf	O
surface	O
of	O
a	O
crucifer	O
,	O
and	O
to	O
show	O
that	O
the	O
concentrations	O
of	O
glucosinolates	O
found	O
on	O
the	O
leaf	O
surface	O
of	O
Barbarea	O
spp	O
.	O
are	O
sufficient	O
to	O
be	O
perceived	O
by	O
ovipositing	O
DBM	B
.	O

Floret	O
initiation	O
,	O
tissue	O
expansion	O
and	O
carbon	O
availability	O
at	O
the	O
meristem	O
of	O
the	O
sunflower	B
capitulum	O
as	O
affected	O
by	O
water	O
or	O
light	O
deficits	O
.	O

*	O
The	O
co	O
-	O
ordination	O
between	O
floret	O
initiation	O
and	O
meristem	O
expansion	O
,	O
and	O
their	O
relationships	O
with	O
carbon	O
availability	O
,	O
were	O
studied	O
and	O
quantified	O
in	O
sunflower	B
(	O
Helianthus	B
annuus	I
)	O
plants	O
subjected	O
to	O
light	O
or	O
water	O
shortages	O
.	O

*	O
Meristem	O
size	O
,	O
number	O
of	O
floret	O
primordia	O
,	O
primordium	O
size	O
,	O
rate	O
of	O
plant	O
biomass	O
accumulation	O
,	O
leaf	O
area	O
,	O
photosynthetic	O
rate	O
,	O
and	O
soluble	O
sugar	O
content	O
in	O
the	O
capitulum	O
were	O
measured	O
until	O
completion	O
of	O
floret	O
initiation	O
.	O

*	O
Although	O
treatments	O
differentially	O
affected	O
tissue	O
expansion	O
and	O
biomass	O
acquisition	O
,	O
a	O
common	O
relationship	O
between	O
the	O
final	O
number	O
of	O
florets	O
and	O
the	O
rate	O
and	O
duration	O
of	O
meristem	O
expansion	O
was	O
conserved	O
.	O

In	O
the	O
absence	O
of	O
water	O
deficit	O
,	O
changes	O
in	O
relative	O
expansion	O
rate	O
in	O
the	O
meristem	O
paralleled	O
changes	O
in	O
soluble	O
sugar	O
content	O
.	O

Water	O
deficit	O
reduced	O
tissue	O
expansion	O
both	O
in	O
leaves	O
and	O
in	O
the	O
capitulum	O
,	O
and	O
induced	O
the	O
accumulation	O
of	O
soluble	O
sugars	O
in	O
the	O
meristem	O
.	O

Use	O
of	O
these	O
sugars	O
at	O
re	O
-	O
watering	O
was	O
associated	O
with	O
increased	O
meristem	O
growth	O
and	O
higher	O
floret	O
numbers	O
compared	O
with	O
control	O
plants	O
.	O

*	O
Floret	O
initiation	O
and	O
meristem	O
tissue	O
expansion	O
remained	O
strongly	O
co	O
-	O
ordinated	O
under	O
all	O
studied	O
circumstances	O
,	O
and	O
both	O
depended	O
on	O
local	O
carbon	O
availability	O
when	O
water	O
supply	O
was	O
unlimited	O
.	O

Transient	O
water	O
deficits	O
favoured	O
reproductive	O
meristem	O
growth	O
and	O
floret	O
production	O
.	O

Equations	O
accounting	O
for	O
these	O
results	O
constitute	O
a	O
framework	O
for	O
phenotyping	O
the	O
response	O
to	O
drought	O
.	O

Dynamic	O
behaviour	O
of	O
stationary	O
pronuclei	O
during	O
their	O
positioning	O
in	O
Paramecium	B
caudatum	I
.	O

During	O
conjugation	O
of	O
Paramecium	B
caudatum	I
,	O
there	O
are	O
two	O
well	O
-	O
known	O
stages	O
when	O
nuclear	O
migration	O
occurs	O
.	O

What	O
happens	O
to	O
the	O
nuclei	O
is	O
closely	O
related	O
to	O
their	O
localisations	O
in	O
cells	O
.	O

The	O
first	O
of	O
these	O
stages	O
is	O
the	O
entrance	O
of	O
one	O
meiotic	O
product	O
into	O
the	O
paroral	O
region	O
.	O

This	O
nucleus	O
survives	O
,	O
while	O
the	O
remaining	O
three	O
outside	O
this	O
area	O
degenerate	O
.	O

The	O
second	O
stage	O
is	O
the	O
antero	O
-	O
posterior	O
localisation	O
of	O
eight	O
synkaryon	O
division	O
products	O
.	O

Four	O
posterior	O
nuclei	O
are	O
differentiated	O
into	O
macronuclear	O
anlagen	O
,	O
whereas	O
four	O
anterior	O
nuclei	O
remain	O
as	O
the	O
presumptive	O
micronuclei	O
.	O

In	O
this	O
experiment	O
,	O
the	O
process	O
of	O
the	O
third	O
prezygotic	O
division	O
of	O
P.	B
caudatum	I
was	O
studied	O
with	O
the	O
help	O
of	O
protargol	O
staining	O
.	O

Here	O
,	O
a	O
third	O
nuclear	O
migration	O
was	O
discovered	O
.	O

By	O
two	O
spindle	O
turnings	O
and	O
two	O
spindle	O
elongations	O
,	O
stationary	O
pronuclei	O
were	O
positioned	O
near	O
migratory	O
pronuclei	O
.	O

This	O
positioning	O
of	O
stationary	O
pronuclei	O
could	O
shorten	O
the	O
distance	O
for	O
transferred	O
migratory	O
pronuclei	O
to	O
recognise	O
and	O
reach	O
the	O
stationary	O
pronuclei	O
.	O

This	O
fosters	O
the	O
synkaryon	O
formation	O
of	O
P.	B
caudatum	I
.	O

Adaptive	O
trade	O
-	O
offs	O
in	O
juvenile	O
salmonid	O
metabolism	O
associated	O
with	O
habitat	O
partitioning	O
between	O
coho	B
salmon	I
and	O
steelhead	B
trout	I
in	O
coastal	O
streams	O
.	O

1	O
.	O

Adaptive	O
trade	O
-	O
offs	O
are	O
fundamental	O
to	O
the	O
evolution	O
of	O
diversity	O
and	O
the	O
coexistence	O
of	O
similar	O
taxa	O
and	O
occur	O
when	O
complimentary	O
combinations	O
of	O
traits	O
maximize	O
efficiency	O
of	O
resource	O
exploitation	O
or	O
survival	O
at	O
different	O
points	O
on	O
environmental	O
gradients	O
.	O

2	O
.	O

Standard	O
metabolic	O
rate	O
(	O
SMR	O
)	O
is	O
a	O
key	O
physiological	O
trait	O
that	O
reflects	O
adaptations	O
to	O
baseline	O
metabolic	O
performance	O
,	O
whereas	O
active	O
metabolism	O
reflects	O
adaptations	O
to	O
variable	O
metabolic	O
output	O
associated	O
with	O
performance	O
related	O
to	O
foraging	O
,	O
predator	O
avoidance	O
,	O
aggressive	O
interactions	O
or	O
migratory	O
movements	O
.	O

Benefits	O
of	O
high	O
SMR	O
and	O
active	O
metabolism	O
may	O
change	O
along	O
a	O
resource	O
(	O
productivity	O
)	O
gradient	O
,	O
indicating	O
that	O
a	O
trade	O
-	O
off	O
exists	O
among	O
active	O
metabolism	O
,	O
resting	O
metabolism	O
and	O
energy	O
intake	O
.	O

3	O
.	O

We	O
measured	O
and	O
compared	O
SMR	O
,	O
maximal	O
metabolic	O
rate	O
(	O
MMR	O
)	O
,	O
aerobic	O
scope	O
(	O
AS	O
)	O
,	O
swim	O
performance	O
(	O
UCrit	O
)	O
and	O
growth	O
of	O
juvenile	O
hatchery	O
and	O
wild	O
steelhead	B
and	O
coho	B
salmon	I
held	O
on	O
high-	O
and	O
low	O
-	O
food	O
rations	O
in	O
order	O
to	O
better	O
understand	O
the	O
potential	O
significance	O
of	O
variation	O
in	O
SMR	O
to	O
growth	O
,	O
differentiation	O
between	O
species	O
,	O
and	O
patterns	O
of	O
habitat	O
use	O
along	O
a	O
productivity	O
gradient	O
.	O

4	O
.	O

We	O
found	O
that	O
differences	O
in	O
SMR	O
,	O
MMR	O
,	O
AS	O
,	O
swim	O
performance	O
and	O
growth	O
rate	O
between	O
steelhead	B
trout	I
and	O
coho	B
salmon	I
were	O
reduced	O
in	O
hatchery	O
-	O
reared	O
fish	O
compared	O
with	O
wild	O
fish	O
.	O

Wild	O
steelhead	B
had	O
a	O
higher	O
MMR	O
,	O
AS	O
,	O
swim	O
performance	O
and	O
growth	O
rate	O
than	O
wild	O
coho	B
,	O
but	O
adaptations	O
between	O
species	O
do	O
not	O
appear	O
to	O
involve	O
differences	O
in	O
SMR	O
or	O
to	O
trade	O
-	O
off	O
increased	O
growth	O
rate	O
against	O
lower	O
swim	O
performance	O
,	O
as	O
commonly	O
observed	O
for	O
high	O
-	O
growth	O
strains	O
.	O

Instead	O
,	O
we	O
hypothesize	O
that	O
wild	O
steelhead	B
may	O
be	O
trading	O
off	O
higher	O
growth	O
rate	O
for	O
lower	O
food	O
consumption	O
efficiency	O
,	O
similar	O
to	O
strategies	O
adopted	O
by	O
anadromous	O
vs.	O
resident	O
brook	B
trout	I
and	O
Atlantic	B
salmon	I
vs.	O
brook	B
trout	I
.	O

This	O
highlights	O
potential	O
differences	O
in	O
food	O
consumption	O
and	O
digestion	O
strategies	O
as	O
cryptic	O
adaptations	O
ecologically	O
differentiating	O
salmonid	O
species	O
.	O

5	O
.	O

We	O
hypothesize	O
that	O
divergent	O
digestive	O
strategies	O
,	O
which	O
are	O
common	O
and	O
well	O
documented	O
among	O
terrestrial	O
vertebrates	O
,	O
may	O
be	O
an	O
important	O
but	O
overlooked	O
aspect	O
of	O
adaptive	O
strategies	O
of	O
juvenile	O
salmonids	O
,	O
and	O
fish	O
in	O
general	O
.	O

Natal	O
conditions	O
alter	O
age	O
-	O
specific	O
reproduction	O
but	O
not	O
survival	O
or	O
senescence	O
in	O
a	O
long	O
-	O
lived	O
bird	O
of	O
prey	O
.	O

1	O
.	O

Natal	O
conditions	O
and	O
senescence	O
are	O
two	O
major	O
factors	O
shaping	O
life	O
-	O
history	O
traits	O
of	O
wild	O
animals	O
.	O

However	O
,	O
such	O
factors	O
have	O
rarely	O
been	O
investigated	O
together	O
,	O
and	O
it	O
remains	O
largely	O
unknown	O
whether	O
they	O
interact	O
to	O
affect	O
age	O
-	O
specific	O
performance	O
.	O

2	O
.	O

We	O
used	O
27	O
years	O
of	O
longitudinal	O
data	O
collected	O
on	O
tawny	B
owls	I
with	O
estimates	O
of	O
prey	O
density	O
(	O
field	O
voles	O
)	O
from	O
Kielder	O
Forest	O
(	O
UK	O
)	O
to	O
investigate	O
how	O
prey	O
density	O
at	O
birth	O
affects	O
ageing	O
patterns	O
in	O
reproduction	O
and	O
survival	O
.	O

3	O
.	O

Natal	O
conditions	O
experienced	O
by	O
tawny	B
owls	I
,	O
measured	O
in	O
terms	O
of	O
vole	O
density	O
,	O
dramatically	O
varied	O
among	O
cohorts	O
and	O
explained	O
87	O
%	O
of	O
the	O
deviance	O
in	O
first	O
-	O
year	O
apparent	O
survival	O
(	O
annual	O
estimates	O
ranging	O
from	O
0	O
*	O
07	O
to	O
0	O
*	O
33	O
)	O
.	O

4	O
.	O

We	O
found	O
evidence	O
for	O
senescence	O
in	O
survival	O
for	O
females	O
as	O
well	O
as	O
for	O
males	O
.	O

Model	O
-	O
averaged	O
estimates	O
showed	O
that	O
adult	O
survival	O
probability	O
declined	O
linearly	O
with	O
age	O
for	O
females	O
from	O
age	O
1	O
.	O

In	O
contrast	O
,	O
male	O
survival	O
probability	O
,	O
lower	O
on	O
average	O
than	O
for	O
female	O
,	O
declined	O
after	O
a	O
plateau	O
at	O
age	O
1	O
-	O
3	O
.	O
5	O
.	O

We	O
also	O
found	O
evidence	O
for	O
reproductive	O
senescence	O
(	O
number	O
of	O
offspring	O
)	O
.	O

For	O
females	O
,	O
reproductive	O
performance	O
increased	O
until	O
age	O
9	O
then	O
declined	O
.	O

Males	O
showed	O
an	O
earlier	O
decline	O
in	O
reproductive	O
performance	O
with	O
an	O
onset	O
of	O
senescence	O
at	O
age	O
3	O
.	O
6	O
.	O

Long	O
-	O
lasting	O
effects	O
of	O
natal	O
environmental	O
conditions	O
were	O
sex	O
specific	O
.	O

Female	O
reproductive	O
performance	O
was	O
substantially	O
related	O
to	O
natal	O
conditions	O
(	O
difference	O
of	O
0	O
*	O
24	O
fledgling	O
per	O
breeding	O
event	O
between	O
females	O
born	O
in	O
the	O
first	O
or	O
third	O
quartile	O
of	O
vole	O
density	O
)	O
,	O
whereas	O
male	O
performance	O
was	O
not	O
.	O

We	O
found	O
no	O
evidence	O
for	O
tawny	B
owls	I
born	O
in	O
years	O
with	O
low	O
prey	O
density	O
having	O
accelerated	O
rates	O
of	O
senescence	O
.	O

7	O
.	O

Our	O
results	O
,	O
combined	O
with	O
previous	O
findings	O
,	O
suggest	O
the	O
way	O
natal	O
environmental	O
conditions	O
affect	O
senescence	O
varies	O
not	O
only	O
across	O
species	O
but	O
also	O
within	O
species	O
according	O
to	O
gender	O
and	O
the	O
demographic	O
trait	O
considered	O
.	O

Linking	O
irradiance	O
-	O
induced	O
changes	O
in	O
pit	O
membrane	O
ultrastructure	O
with	O
xylem	O
vulnerability	O
to	O
cavitation	O
.	O

The	O
effect	O
of	O
shading	O
on	O
xylem	O
hydraulic	O
traits	O
and	O
xylem	O
anatomy	O
was	O
studied	O
in	O
hybrid	O
poplar	O
(	O
Populus	B
trichocarpa	I
x	I
deltoides	I
,	O
clone	O
H11	O
-	O
11	O
)	O
.	O

Hydraulic	O
measurements	O
conducted	O
on	O
stem	O
segments	O
of	O
3-month	O
-	O
old	O
saplings	O
grown	O
in	O
shaded	O
(	O
SH	O
)	O
or	O
control	O
light	O
(	O
C	O
)	O
conditions	O
indicated	O
that	O
shading	O
resulted	O
in	O
more	O
vulnerable	O
and	O
less	O
efficient	O
xylem	O
.	O

Air	O
is	O
thought	O
to	O
enter	O
vessels	O
through	O
pores	O
in	O
inter	O
-	O
vessel	O
pit	O
membranes	O
,	O
thereby	O
nucleating	O
cavitation	O
.	O

Therefore	O
,	O
we	O
tested	O
if	O
the	O
ultrastructure	O
and/or	O
chemistry	O
of	O
pit	O
membranes	O
differed	O
in	O
SH	O
and	O
C	O
plants	O
.	O

Transmission	O
electron	O
micrographs	O
revealed	O
that	O
pit	O
membranes	O
were	O
thinner	O
in	O
SH	O
,	O
which	O
was	O
paralleled	O
by	O
lower	O
compound	O
middle	O
lamella	O
thickness	O
.	O

Immunolabelling	O
with	O
JIM5	O
and	O
JIM7	O
monoclonal	O
antibodies	O
surprisingly	O
indicated	O
that	O
pectic	O
homogalacturonans	O
were	O
not	O
present	O
in	O
the	O
mature	O
pit	O
membrane	O
regardless	O
of	O
the	O
light	O
treatment	O
.	O

Porosity	O
measurements	O
conducted	O
with	O
scanning	O
electron	O
microscopy	O
were	O
significantly	O
affected	O
by	O
the	O
method	O
used	O
for	O
sample	O
dehydration	O
.	O

Drying	O
through	O
a	O
gradual	O
ethanol	O
series	O
seems	O
to	O
be	O
a	O
better	O
alternative	O
to	O
drying	O
directly	O
from	O
a	O
hydrated	O
state	O
for	O
pit	O
membrane	O
observations	O
in	O
poplar	O
.	O

Scanning	O
electron	O
microscopy	O
based	O
estimates	O
of	O
pit	O
membrane	O
porosity	O
probably	O
overestimated	O
real	O
porosity	O
as	O
suggested	O
by	O
the	O
results	O
from	O
the	O
'	O
rare	O
pit	O
'	O
model	O
.	O

Sensing	O
embolism	O
in	O
xylem	O
vessels	O
:	O
the	O
role	O
of	O
sucrose	O
as	O
a	O
trigger	O
for	O
refilling	O
.	O

Refilling	O
of	O
embolized	O
vessels	O
requires	O
a	O
source	O
of	O
water	O
and	O
the	O
release	O
of	O
energy	O
stored	O
in	O
xylem	O
parenchyma	O
cells	O
.	O

Past	O
evidence	O
suggests	O
that	O
embolism	O
presence	O
can	O
trigger	O
a	O
biological	O
response	O
that	O
is	O
switched	O
off	O
upon	O
successful	O
vessel	O
refilling	O
.	O

As	O
embolism	O
formation	O
is	O
a	O
purely	O
physical	O
process	O
and	O
most	O
biological	O
triggers	O
rely	O
on	O
chemical	O
sensors	O
,	O
we	O
hypothesized	O
that	O
accumulation	O
of	O
osmotic	O
compounds	O
in	O
walls	O
of	O
embolized	O
vessels	O
are	O
involved	O
in	O
the	O
embolism	O
sensing	O
mechanism	O
.	O

Analysis	O
of	O
Populus	B
trichocarpa	I
's	O
response	O
to	O
infiltration	O
of	O
sucrose	O
,	O
monosaccharides	O
,	O
polyethylene	O
glycol	O
and	O
potassium	O
chloride	O
into	O
the	O
xylem	O
revealed	O
that	O
only	O
presence	O
of	O
sucrose	O
resulted	O
in	O
a	O
simultaneous	O
physiological	O
and	O
molecular	O
response	O
similar	O
to	O
that	O
induced	O
by	O
embolism	O
.	O

This	O
response	O
included	O
reduction	O
of	O
the	O
starch	O
pool	O
in	O
xylem	O
parenchyma	O
cells	O
and	O
significant	O
correlation	O
of	O
gene	O
expression	O
from	O
aquaporins	O
,	O
amylases	O
and	O
sugar	O
transporter	O
families	O
.	O

The	O
work	O
provides	O
evidence	O
of	O
the	O
ability	O
of	O
plants	O
to	O
sense	O
embolism	O
and	O
suggests	O
that	O
sucrose	O
concentration	O
is	O
the	O
stimulus	O
that	O
allows	O
plants	O
to	O
trigger	O
a	O
biological	O
response	O
to	O
embolism	O
.	O

Light	O
exerts	O
multiple	O
levels	O
of	O
influence	O
on	O
the	O
Arabidopsis	B
wound	O
response	O
.	O

Light	O
plays	O
important	O
roles	O
in	O
modulating	O
plant	O
responses	O
to	O
attack	O
by	O
pests	O
and	O
pathogens	O
.	O

Here	O
,	O
we	O
test	O
the	O
hypothesis	O
that	O
darkness	O
modifies	O
the	O
response	O
to	O
wounding	O
,	O
and	O
examine	O
possible	O
mechanisms	O
for	O
such	O
an	O
effect	O
.	O

We	O
investigated	O
changes	O
in	O
the	O
Arabidopsis	B
transcriptome	O
following	O
a	O
light	O
-	O
dark	O
transition	O
and	O
the	O
response	O
to	O
wounding	O
either	O
in	O
the	O
light	O
or	O
in	O
the	O
dark	O
.	O

The	O
transcriptional	O
response	O
to	O
the	O
light	O
-	O
dark	O
transition	O
strongly	O
resembles	O
responses	O
associated	O
with	O
carbon	O
depletion	O
.	O

The	O
dark	O
shift	O
and	O
wound	O
responses	O
acted	O
largely	O
independently	O
,	O
but	O
more	O
complex	O
interactions	O
were	O
identified	O
at	O
a	O
number	O
of	O
levels	O
.	O

Darkness	O
attenuates	O
the	O
overall	O
transcriptional	O
response	O
to	O
wounding	O
,	O
and	O
we	O
identified	O
genes	O
and	O
physiological	O
processes	O
,	O
such	O
as	O
anthocyanin	O
accumulation	O
,	O
that	O
exhibit	O
light	O
-	O
dependent	O
wound	O
responses	O
.	O

Transcriptional	O
activation	O
of	O
light	O
-	O
dependent	O
wound	O
-	O
induced	O
genes	O
requires	O
a	O
chloroplast	O
-	O
derived	O
signal	O
originating	O
from	O
photosynthetic	O
electron	O
transport	O
.	O

We	O
also	O
present	O
evidence	O
of	O
a	O
role	O
for	O
the	O
circadian	O
clock	O
in	O
modifying	O
wound	O
responses	O
.	O

Our	O
results	O
show	O
that	O
darkness	O
impacts	O
on	O
the	O
wound	O
response	O
at	O
a	O
number	O
of	O
levels	O
,	O
which	O
may	O
imply	O
differences	O
in	O
induced	O
herbivore	O
defences	O
during	O
the	O
day	O
and	O
night	O
.	O

Parallel	O
evolution	O
of	O
cytochrome	O
b	O
mediated	O
bifenazate	O
resistance	O
in	O
the	O
citrus	B
red	I
mite	I
Panonychus	B
citri	I
.	O

Bifenazate	O
is	O
a	O
recently	O
developed	O
acaricide	O
that	O
is	O
mainly	O
used	O
to	O
control	O
spider	O
mites	O
on	O
a	O
variety	O
of	O
crops	O
.	O

Although	O
first	O
thought	O
to	O
be	O
a	O
neurotoxin	O
,	O
genetic	O
evidence	O
obtained	O
from	O
bifenazate	O
resistant	O
Tetranychus	B
urticae	I
strains	O
suggested	O
an	O
alternative	O
mode	O
of	O
action	O
as	O
a	O
Qo	O
pocket	O
inhibitor	O
of	O
the	O
mitochondrial	O
complex	O
III	O
.	O

In	O
this	O
study	O
,	O
we	O
reveal	O
how	O
bifenazate	O
resistance	O
in	O
strains	O
of	O
Panonychus	B
citri	I
is	O
maternally	O
inherited	O
and	O
can	O
confer	O
cross	O
-	O
resistance	O
to	O
the	O
known	O
Qo	O
inhibitor	O
acequinocyl	O
.	O

The	O
mitochondrial	O
genome	O
of	O
P.	B
citri	I
was	O
sequenced	O
and	O
Qo	O
pocket	O
mutations	O
were	O
shown	O
to	O
be	O
linked	O
with	O
the	O
resistant	O
trait	O
.	O

Parallel	O
evolution	O
of	O
cytochrome	O
b	O
mediated	O
bifenazate	O
resistance	O
corroborates	O
the	O
alternative	O
mode	O
of	O
action	O
and	O
yet	O
again	O
illustrates	O
that	O
care	O
should	O
be	O
taken	O
when	O
employing	O
Qo	O
inhibitors	O
as	O
crop	O
protection	O
compounds	O
.	O

European	O
guidelines	O
on	O
the	O
clinical	O
management	O
of	O
HIV-1	B
tropism	O
testing	O
.	O

Viral	O
tropism	O
is	O
the	O
ability	O
of	O
viruses	O
to	O
enter	O
and	O
infect	O
specific	O
host	O
cells	O
and	O
is	O
based	O
on	O
the	O
ability	O
of	O
viruses	O
to	O
bind	O
to	O
receptors	O
on	O
those	O
cells	O
.	O

Testing	O
for	O
HIV	B
tropism	O
is	O
recommended	O
before	O
prescribing	O
a	O
chemokine	O
receptor	O
blocker	O
.	O

In	O
most	O
European	O
countries	O
,	O
HIV	B
tropism	O
is	O
identified	O
with	O
tropism	O
phenotype	O
testing	O
.	O

New	O
data	O
support	O
genotype	O
analysis	O
of	O
the	O
HIV	B
third	O
hypervariable	O
loop	O
(	O
V3	O
)	O
for	O
the	O
identification	O
of	O
tropism	O
.	O

The	O
European	O
Consensus	O
Group	O
on	O
clinical	O
management	O
of	O
tropism	O
testing	O
was	O
established	O
to	O
make	O
recommendations	O
to	O
clinicians	O
and	O
clinical	O
virologists	O
.	O

The	O
panel	O
recommends	O
HIV	B
-	O
tropism	O
testing	O
for	O
the	O
following	O
groups	O
:	O
drug	O
-	O
naive	O
patients	O
in	O
whom	O
toxic	O
effects	O
are	O
anticipated	O
or	O
for	O
whom	O
few	O
treatment	O
options	O
are	O
available	O
;	O
patients	O
who	O
have	O
poor	O
tolerability	O
to	O
or	O
toxic	O
effects	O
from	O
current	O
treatment	O
or	O
who	O
have	O
CNS	O
pathology	O
;	O
and	O
patients	O
for	O
whom	O
therapy	O
has	O
failed	O
and	O
a	O
change	O
in	O
treatment	O
is	O
considered	O
.	O

In	O
general	O
,	O
an	O
enhanced	O
sensitivity	O
Trofile	O
assay	O
and	O
V3	O
population	O
genotyping	O
are	O
the	O
recommended	O
methods	O
.	O

Genotypic	O
methods	O
are	O
anticipated	O
to	O
be	O
used	O
more	O
frequently	O
in	O
the	O
clinical	O
setting	O
because	O
of	O
their	O
greater	O
accessibility	O
,	O
lower	O
cost	O
,	O
and	O
faster	O
turnaround	O
time	O
than	O
other	O
methods	O
.	O

For	O
the	O
interpretation	O
of	O
V3	O
loop	O
genotyping	O
,	O
clinically	O
validated	O
systems	O
should	O
be	O
used	O
when	O
possible	O
.	O

Laboratories	O
doing	O
HIV	B
tropism	O
tests	O
should	O
have	O
adequate	O
quality	O
assurance	O
measures	O
.	O

Similarly	O
,	O
close	O
collaboration	O
between	O
HIV	B
clinicians	O
and	O
virologists	O
is	O
needed	O
to	O
ensure	O
adequate	O
diagnostic	O
and	O
treatment	O
decisions	O
.	O

Effects	O
of	O
early	O
horn	O
growth	O
on	O
reproduction	O
and	O
hunting	O
mortality	O
in	O
female	O
chamois	B
.	O

1	O
.	O

Environmental	O
conditions	O
during	O
early	O
development	O
can	O
affect	O
the	O
growth	O
patterns	O
of	O
vertebrates	O
,	O
influencing	O
future	O
survival	O
and	O
reproduction	O
.	O

In	O
long	O
-	O
lived	O
mammals	O
,	O
females	O
that	O
experience	O
poor	O
environmental	O
conditions	O
early	O
in	O
life	O
may	O
delay	O
primiparity	O
.	O

In	O
female	O
bovids	O
,	O
annual	O
horn	O
growth	O
increments	O
may	O
provide	O
a	O
record	O
of	O
age	O
-	O
specific	O
reproduction	O
and	O
body	O
growth	O
.	O

Horn	O
length	O
,	O
however	O
,	O
may	O
also	O
be	O
a	O
criterion	O
used	O
by	O
hunters	O
in	O
selecting	O
animals	O
to	O
harvest	O
,	O
possibly	O
leading	O
to	O
artificial	O
selection	O
.	O

2	O
.	O

We	O
studied	O
three	O
populations	O
of	O
chamois	B
(	O
Rupicapra	B
rupicapra	I
)	O
in	O
the	O
western	O
Alps	O
to	O
explore	O
the	O
relationships	O
between	O
female	O
horn	O
length	O
and	O
early	O
growth	O
,	O
age	O
of	O
primiparity	O
and	O
age	O
-	O
specific	O
reproduction	O
.	O

We	O
also	O
compared	O
the	O
risk	O
of	O
harvest	O
to	O
reproductive	O
status	O
and	O
horn	O
length	O
.	O

3	O
.	O

Early	O
horn	O
growth	O
was	O
positively	O
correlated	O
with	O
body	O
mass	O
in	O
pre	O
-	O
reproductive	O
females	O
and	O
with	O
reproduction	O
in	O
very	O
young	O
and	O
senescent	O
adults	O
.	O

Females	O
with	O
strong	O
early	O
horn	O
growth	O
attained	O
primiparity	O
at	O
an	O
earlier	O
age	O
than	O
those	O
with	O
weak	O
early	O
growth	O
.	O

Horn	O
length	O
did	O
not	O
affect	O
hunter	O
selection	O
,	O
but	O
we	O
found	O
a	O
strong	O
hunter	O
preference	O
for	O
nonlactating	O
females	O
.	O

4	O
.	O

Our	O
research	O
highlights	O
the	O
persistent	O
effects	O
of	O
early	O
development	O
on	O
reproductive	O
performance	O
in	O
mammals	O
.	O

Moderate	O
sport	O
harvests	O
are	O
unlikely	O
to	O
affect	O
the	O
evolution	O
of	O
phenotypic	O
traits	O
and	O
reproductive	O
strategies	O
in	O
female	O
chamois	B
.	O

A	O
policy	O
of	O
penalizing	O
hunters	O
that	O
harvest	O
lactating	O
females	O
,	O
however	O
,	O
may	O
increase	O
the	O
harvest	O
of	O
2-year	O
-	O
old	O
females	O
,	O
which	O
have	O
high	O
reproductive	O
potential	O
.	O

Dissection	O
of	O
the	O
phytohormonal	O
regulation	O
of	O
trichome	O
formation	O
and	O
biosynthesis	O
of	O
the	O
antimalarial	O
compound	O
artemisinin	O
in	O
Artemisia	B
annua	I
plants	I
.	O

*	O
Biosynthesis	O
of	O
the	O
sesquiterpene	O
lactone	O
and	O
potent	O
antimalarial	O
drug	O
artemisinin	O
occurs	O
in	O
glandular	O
trichomes	O
of	O
Artemisia	B
annua	I
plants	I
and	O
is	O
subjected	O
to	O
a	O
strict	O
network	O
of	O
developmental	O
and	O
other	O
regulatory	O
cues	O
.	O

*	O
The	O
effects	O
of	O
three	O
hormones	O
,	O
jasmonate	O
,	O
gibberellin	O
and	O
cytokinin	O
,	O
were	O
studied	O
at	O
the	O
structural	O
and	O
molecular	O
levels	O
in	O
two	O
different	O
A.	B
annua	I
chemotypes	O
by	O
microscopic	O
analysis	O
of	O
gland	O
development	O
,	O
and	O
by	O
targeted	O
metabolite	O
and	O
transcript	O
profiling	O
.	O

Furthermore	O
,	O
a	O
genome	O
-	O
wide	O
cDNA	O
-	O
amplified	O
fragment	O
length	O
polymorphism	O
(	O
AFLP	O
)	O
-based	O
transcriptome	O
profiling	O
was	O
carried	O
out	O
of	O
jasmonate	O
-	O
elicited	O
leaves	O
at	O
different	O
developmental	O
stages	O
.	O

*	O
Although	O
cytokinin	O
and	O
gibberellin	O
positively	O
affected	O
at	O
least	O
one	O
aspect	O
of	O
gland	O
formation	O
,	O
these	O
two	O
hormones	O
did	O
not	O
stimulate	O
artemisinin	O
biosynthesis	O
.	O

Only	O
jasmonate	O
simultaneously	O
promoted	O
gland	O
formation	O
and	O
coordinated	O
transcriptional	O
activation	O
of	O
biosynthetic	O
gene	O
expression	O
,	O
which	O
ultimately	O
led	O
to	O
increased	O
sesquiterpenoid	O
accumulation	O
with	O
chemotype	O
-	O
dependent	O
effects	O
on	O
the	O
distinct	O
pathway	O
branches	O
.	O

Transcriptome	O
profiling	O
revealed	O
a	O
trichome	O
-	O
specific	O
fatty	O
acyl-	O
coenzyme	O
A	O
reductase	O
,	O
trichome	O
-	O
specific	O
fatty	O
acyl	O
-	O
CoA	O
reductase	O
1	O
(	O
TFAR1	O
)	O
,	O
the	O
expression	O
of	O
which	O
correlates	O
with	O
trichome	O
development	O
and	O
sesquiterpenoid	O
biosynthesis	O
.	O

*	O
TFAR1	O
is	O
potentially	O
involved	O
in	O
cuticular	O
wax	O
formation	O
during	O
glandular	O
trichome	O
expansion	O
in	O
leaves	O
and	O
flowers	O
of	O
A.	B
annua	I
plants	I
.	O

Analysis	O
of	O
phytohormone	O
-	O
modulated	O
transcriptional	O
regulons	O
provides	O
clues	O
to	O
dissect	O
the	O
concerted	O
regulation	O
of	O
metabolism	O
and	O
development	O
of	O
plant	O
trichomes	O
.	O

Accumulation	O
of	O
P	O
-	O
bodies	O
in	O
Candida	B
albicans	I
under	O
different	O
stress	O
and	O
filamentous	O
growth	O
conditions	O
.	O

Candida	B
albicans	I
is	O
an	O
opportunistic	O
fungal	O
pathogen	O
that	O
grows	O
as	O
budding	O
yeast	O
,	O
pseudohyphal	O
,	O
and	O
hyphal	O
forms	O
.	O

In	O
response	O
to	O
external	O
signals	O
,	O
C.	B
albicans	I
switches	O
rapidly	O
among	O
these	O
forms	O
.	O

mRNA	O
-	O
containing	O
cytoplasmic	O
granules	O
,	O
termed	O
processing	O
bodies	O
(	O
P	O
-	O
bodies	O
)	O
,	O
have	O
been	O
reported	O
to	O
accumulate	O
under	O
various	O
environmental	O
stress	O
conditions	O
in	O
diverse	O
species	O
from	O
yeast	B
to	O
mammals	O
.	O

Here	O
,	O
we	O
provide	O
the	O
first	O
microscopic	O
and	O
genetic	O
characterization	O
of	O
P	O
-	O
bodies	O
in	O
C.	B
albicans	I
.	O

The	O
core	O
components	O
of	O
P	O
-	O
bodies	O
,	O
including	O
the	O
decapping	O
machinery	O
(	O
Dcp2	O
and	O
Dhh1	O
)	O
,	O
5'-3	O
'	O
exoribonuclease	O
(	O
Kem1	O
/	O
Xrn1	O
)	O
,	O
and	O
the	O
P	O
-	O
body	O
scaffolding	O
protein	O
(	O
Edc3	O
)	O
,	O
were	O
identified	O
and	O
their	O
localizations	O
with	O
respect	O
to	O
P	O
-	O
bodies	O
were	O
demonstrated	O
.	O

Various	O
growth	O
conditions	O
,	O
including	O
glucose	O
deprivation	O
,	O
hyperosmotic	O
stress	O
,	O
and	O
heat	O
stress	O
,	O
stimulated	O
the	O
accumulation	O
of	O
P	O
-	O
bodies	O
.	O

In	O
addition	O
,	O
we	O
observed	O
P	O
-	O
body	O
aggregation	O
during	O
hyphal	O
development	O
.	O

The	O
deletion	O
mutant	O
strain	O
edc3	O
/	O
edc3	O
had	O
a	O
defect	O
in	O
filamentation	O
and	O
exhibited	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
P	O
-	O
bodies	O
.	O

These	O
results	O
suggest	O
that	O
Edc3	O
plays	O
an	O
essential	O
role	O
in	O
the	O
assembly	O
and	O
maintenance	O
of	O
P	O
-	O
bodies	O
in	O
C.	B
albicans	I
,	O
and	O
that	O
the	O
switch	O
to	O
filamentous	O
growth	O
appears	O
to	O
accompany	O
P	O
-	O
body	O
accumulation	O
.	O

A	O
heme	O
peroxidase	O
of	O
the	O
ascomyceteous	O
lichen	O
Leptogium	B
saturninum	I
oxidizes	O
high	O
-	O
redox	O
potential	O
substrates	O
.	O

Lichens	O
belonging	O
to	O
the	O
order	O
Peltigerales	O
display	O
strong	O
activity	O
of	O
multi	O
-	O
copper	O
oxidases	O
(	O
e.g.	O
tyrosinase	O
)	O
as	O
well	O
as	O
heme	O
-	O
containing	O
peroxidases	O
.	O

The	O
lichen	O
peroxidase	O
was	O
purified	O
to	O
homogeneity	O
from	O
the	O
thallus	O
of	O
Leptogium	B
saturninum	I
(	O
LsaPOX	O
)	O
by	O
fast	O
protein	O
liquid	O
chromatography	O
and	O
then	O
partially	O
characterized	O
.	O

The	O
oligomeric	O
protein	O
occurs	O
as	O
both	O
79kDa	O
dimeric	O
and	O
42kDa	O
monomeric	O
forms	O
,	O
and	O
displayed	O
broad	O
substrate	O
specificity	O
.	O

In	O
addition	O
to	O
an	O
ability	O
to	O
oxidize	O
classic	O
peroxidase	O
substrates	O
(	O
e.g.	O
2,6-dimethoxyphenol	O
)	O
,	O
the	O
enzyme	O
could	O
convert	O
recalcitrant	O
compounds	O
such	O
as	O
synthetic	O
dyes	O
(	O
e.g.	O
Azure	O
B	O
and	O
Reactive	O
Blue	O
5	O
)	O
,	O
4-nitrophenol	O
and	O
non	O
-	O
phenolic	O
methoxylated	O
aromatics	O
(	O
e.g.	O
veratryl	O
alcohol	O
)	O
.	O

Comparing	O
LsaPOX	O
with	O
a	O
basidiomycete	O
dye	O
-	O
decolorizing	O
(	O
DyP	O
)	O
-type	O
peroxidase	O
from	O
Auricularia	B
auricula	I
-	I
judae	I
showed	O
that	O
the	O
lichen	O
enzyme	O
has	O
a	O
high	O
-	O
redox	O
potential	O
,	O
with	O
oxidation	O
capabilities	O
ranging	O
between	O
those	O
of	O
known	O
plant	O
and	O
fungal	O
peroxidases	O
.	O

Internal	O
peptide	O
fragments	O
show	O
homology	O
(	O
up	O
to	O
60	O
%	O
)	O
with	O
putative	O
proteins	O
from	O
free	O
-	O
living	O
ascomycetes	O
(	O
e.g.	O
Penicillium	B
marneffei	I
and	O
Neosartorya	B
fischeri	I
)	O
,	O
but	O
not	O
to	O
sequences	O
of	O
algal	O
or	O
cyanobacterial	O
peptides	O
or	O
to	O
known	O
fungal	O
,	O
bacterial	O
or	O
plant	O
peroxidases	O
.	O

LsaPOX	O
is	O
the	O
first	O
heme	O
peroxidase	O
purified	O
from	O
an	O
ascomyceteous	O
lichen	O
that	O
may	O
help	O
the	O
organism	O
to	O
successfully	O
exploit	O
the	O
extreme	O
micro	O
-	O
environments	O
in	O
which	O
they	O
often	O
grow	O
.	O

Comparative	O
immunofluorescence	O
and	O
ultrastructural	O
analysis	O
of	O
microtubule	O
organization	O
in	O
Uronema	O
sp.	O
,	O
Klebsormidium	B
flaccidum	I
,	O
K.	B
subtilissimum	I
,	O
Stichococcus	B
bacillaris	I
and	O
S.	B
chloranthus	I
(	O
Chlorophyta	O
)	O
.	O

A	O
detailed	O
comparative	O
examination	O
of	O
microtubule	O
(	O
MT	O
)	O
organization	O
in	O
interphase	O
and	O
dividing	O
cells	O
of	O
Uronema	O
sp.	O
,	O
Klebsormidium	B
flaccidum	I
,	O
K.	B
subtilissimum	I
,	O
Stichococcus	B
bacillaris	I
and	O
S.	B
chloranthus	I
was	O
made	O
using	O
tubulin	O
immunofluorescence	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
.	O

During	O
interphase	O
all	O
the	O
species	O
bear	O
a	O
well	O
-	O
organized	O
cortical	O
MT	O
system	O
,	O
consisting	O
of	O
parallel	O
bundles	O
with	O
different	O
orientations	O
.	O

In	O
Uronema	O
sp.	O
the	O
cortical	O
MT	O
bundles	O
are	O
longitudinally	O
oriented	O
,	O
whereas	O
in	O
the	O
other	O
species	O
they	O
are	O
in	O
transverse	O
orientation	O
to	O
the	O
axis	O
of	O
the	O
cells	O
.	O

Considerable	O
differences	O
in	O
MT	O
organization	O
were	O
also	O
observed	O
during	O
stages	O
of	O
mitosis	O
,	O
mainly	O
preprophase	O
,	O
as	O
well	O
as	O
cytokinesis	O
.	O

In	O
Uronema	O
sp.	O
,	O
a	O
particular	O
radial	O
MT	O
assembly	O
is	O
organized	O
during	O
preprophase	O
-	O
early	O
prophase	O
,	O
which	O
was	O
not	O
observed	O
in	O
the	O
other	O
species	O
.	O

In	O
Stichococcus	O
a	O
fine	O
MT	O
ring	O
surrounded	O
the	O
nucleus	O
during	O
preprophase	O
and	O
prophase	O
.	O

An	O
MT	O
ring	O
,	O
together	O
with	O
single	O
cytoplasmic	O
MTs	O
,	O
was	O
also	O
found	O
associated	O
with	O
the	O
developing	O
diaphragm	O
during	O
cytokinesis	O
in	O
Stichococcus	O
.	O

A	O
phycoplast	O
participates	O
in	O
cytokinesis	O
in	O
Uronema	O
sp.	O
,	O
but	O
not	O
in	O
the	O
other	O
species	O
.	O

In	O
Uronema	O
sp.	O
the	O
centrosome	O
functions	O
as	O
a	O
microtubule	O
organizing	O
center	O
(	O
MTOC	O
)	O
during	O
mitosis	O
,	O
but	O
not	O
during	O
interphase	O
and	O
cytokinesis	O
.	O

The	O
phylogenetic	O
significance	O
of	O
these	O
differences	O
is	O
discussed	O
in	O
combination	O
with	O
SSU	O
/	O
ITS	O
sequencing	O
and	O
other	O
,	O
existing	O
molecular	O
data	O
.	O

Growth	O
and	O
reproductive	O
costs	O
of	O
larval	O
defence	O
in	O
the	O
aposematic	O
lepidopteran	O
Pieris	B
brassicae	I
.	O

1	O
.	O

Utilization	O
of	O
plant	O
secondary	O
compounds	O
for	O
antipredator	O
defence	O
is	O
common	O
in	O
immature	O
herbivorous	O
insects	O
.	O

Such	O
defences	O
may	O
incur	O
a	O
cost	O
to	O
the	O
animal	O
,	O
either	O
in	O
terms	O
of	O
survival	O
,	O
growth	O
rate	O
or	O
in	O
the	O
reproductive	O
success	O
.	O

2	O
.	O

A	O
common	O
defence	O
in	O
lepidopterans	O
is	O
the	O
regurgitation	O
of	O
semi	O
-	O
digested	O
material	O
containing	O
the	O
defensive	O
compounds	O
of	O
the	O
food	O
plant	O
,	O
a	O
defence	O
which	O
has	O
led	O
to	O
gut	O
specialization	O
in	O
this	O
order	O
.	O

Regurgitation	O
is	O
often	O
swift	O
in	O
response	O
to	O
cuticular	O
stimulation	O
and	O
deters	O
predators	O
from	O
consuming	O
or	O
parasitizing	O
the	O
larva	O
.	O

The	O
loss	O
of	O
food	O
and	O
other	O
gut	O
material	O
seems	O
likely	O
to	O
impact	O
on	O
fitness	O
,	O
but	O
evidence	O
is	O
lacking	O
.	O

3	O
.	O

Here	O
,	O
we	O
raised	O
larvae	O
of	O
the	O
common	O
crop	O
pest	O
Pieris	B
brassicae	I
on	O
commercial	O
cabbage	B
leaves	O
,	O
simulated	O
predator	O
attacks	O
throughout	O
the	O
larval	O
period	O
,	O
and	O
measured	O
life	O
-	O
history	O
responses	O
.	O

4	O
.	O

We	O
found	O
that	O
the	O
probability	O
of	O
survival	O
to	O
pupation	O
decreased	O
with	O
increasing	O
frequency	O
of	O
attacks	O
,	O
but	O
this	O
was	O
because	O
of	O
regurgitation	O
rather	O
than	O
the	O
stimulation	O
itself	O
.	O

There	O
was	O
a	O
growth	O
cost	O
to	O
the	O
defence	O
such	O
that	O
the	O
more	O
regurgitant	O
that	O
individuals	O
produced	O
over	O
the	O
growth	O
period	O
,	O
the	O
smaller	O
they	O
were	O
at	O
pupation	O
.	O

5	O
.	O

The	O
number	O
of	O
mature	O
eggs	O
in	O
adult	O
females	O
was	O
positively	O
related	O
to	O
pupal	O
mass	O
,	O
but	O
this	O
relationship	O
was	O
only	O
found	O
when	O
individuals	O
were	O
not	O
subjected	O
to	O
a	O
high	O
frequency	O
of	O
predator	O
simulation	O
.	O

This	O
suggests	O
that	O
there	O
might	O
be	O
cryptic	O
fitness	O
costs	O
to	O
common	O
defensive	O
responses	O
that	O
are	O
paid	O
despite	O
apparent	O
growth	O
rate	O
being	O
maintained	O
.	O

6	O
.	O

Our	O
results	O
demonstrate	O
a	O
clear	O
life	O
-	O
history	O
cost	O
of	O
an	O
antipredator	O
defence	O
in	O
a	O
model	O
pest	O
species	O
and	O
show	O
that	O
under	O
certain	O
conditions	O
,	O
such	O
as	O
high	O
predation	O
threat	O
,	O
the	O
expected	O
relationship	O
between	O
female	O
body	O
size	O
and	O
potential	O
fecundity	O
can	O
be	O
disrupted	O
.	O

Functions	O
of	O
the	O
mitotic	O
B	O
-	O
type	O
cyclins	O
CLB1	O
,	O
CLB2	O
,	O
and	O
CLB3	O
at	O
mitotic	O
exit	O
antagonized	O
by	O
the	O
CDC14	O
phosphatase	O
.	O

In	O
the	O
budding	O
yeast	B
Saccharomyces	B
cerevisiae	I
,	O
cell	O
cycle	O
progression	O
and	O
cytokinesis	O
at	O
mitotic	O
exit	O
are	O
proposed	O
to	O
be	O
linked	O
by	O
CDC14	O
phosphatase	O
antagonizing	O
the	O
function	O
of	O
mitotic	O
B	O
-	O
type	O
cyclin	O
(	O
CLBs	O
)	O
.	O

We	O
have	O
isolated	O
a	O
temperature	O
-	O
sensitive	O
mutant	O
,	O
cdc14	O
(	O
A280V	O
)	O
,	O
with	O
a	O
mutation	O
in	O
the	O
conserved	O
phosphatase	O
domain	O
.	O

Prolonged	O
arrest	O
in	O
the	O
cdc14	O
(	O
A280V	O
)	O
mutant	O
partially	O
uncoupled	O
cell	O
cycle	O
progression	O
from	O
the	O
completion	O
of	O
cytokinesis	O
as	O
measured	O
by	O
bud	O
re	O
-	O
emergence	O
,	O
in	O
the	O
form	O
of	O
elongated	O
apical	O
projections	O
,	O
and	O
DNA	O
re	O
-	O
replication	O
.	O

In	O
contrast	O
to	O
previous	O
mitotic	O
exit	O
mutants	O
,	O
cdc14	O
(	O
A280V	O
)	O
mutants	O
displayed	O
a	O
strong	O
bias	O
for	O
the	O
first	O
apical	O
projection	O
to	O
form	O
in	O
the	O
mother	O
cell	O
body	O
.	O

Using	O
cdc14	O
(	O
A280V	O
)	O
mutant	O
phenotypes	O
,	O
the	O
functions	O
of	O
the	O
B	O
-	O
type	O
cyclins	O
at	O
mitotic	O
exit	O
were	O
investigated	O
.	O

The	O
preference	O
in	O
mother	O
-	O
daughter	O
apical	O
projection	O
formation	O
was	O
observed	O
to	O
be	O
independent	O
of	O
any	O
individual	O
CLB	O
function	O
.	O

However	O
,	O
cdc14	O
(	O
A280V	O
)	O
clb1Delta	O
cells	O
displayed	O
a	O
pronounced	O
increase	O
in	O
apical	O
projections	O
,	O
while	O
cdc14	O
(	O
A280V	O
)	O
clb3Delta	O
cells	O
were	O
observed	O
to	O
form	O
round	O
cellular	O
chains	O
.	O

While	O
cdc14	O
(	O
A280V	O
)	O
cells	O
arrested	O
at	O
mitotic	O
exit	O
,	O
both	O
cdc14	O
(	O
A280V	O
)	O
clb1Delta	O
and	O
cdc14	O
(	O
A280V	O
)	O
clb3Delta	O
cells	O
completed	O
cytokinesis	O
,	O
but	O
failed	O
cell	O
separation	O
.	O

cdc14	O
(	O
A280V	O
)	O
clb2Delta	O
cells	O
displayed	O
a	O
defect	O
in	O
actin	O
ring	O
assembly	O
.	O

These	O
observations	O
differentiate	O
the	O
functions	O
of	O
CLB1	O
,	O
CLB2	O
,	O
and	O
CLB3	O
at	O
mitotic	O
exit	O
,	O
and	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
CLB	O
activities	O
are	O
antagonized	O
by	O
the	O
CDC14	O
phosphatase	O
in	O
order	O
to	O
couple	O
cell	O
cycle	O
progression	O
with	O
cytokinesis	O
at	O
mitotic	O
exit	O
.	O

PRP8	O
intein	O
in	O
Ajellomycetaceae	O
family	O
pathogens	O
:	O
sequence	O
analysis	O
,	O
splicing	O
evaluation	O
and	O
homing	O
endonuclease	O
activity	O
.	O

Inteins	O
are	O
intervening	O
sequences	O
that	O
are	O
transcribed	O
and	O
translated	O
with	O
flanking	O
host	O
protein	O
sequences	O
and	O
then	O
self	O
-	O
excised	O
by	O
protein	O
splicing	O
.	O

Bi	O
-	O
functional	O
inteins	O
also	O
contain	O
a	O
homing	O
endonuclease	O
responsible	O
for	O
their	O
genetic	O
mobility	O
.	O

The	O
PRP8	O
intein	O
,	O
the	O
most	O
widespread	O
among	O
fungi	O
,	O
occurs	O
in	O
important	O
pathogens	O
such	O
as	O
Histoplasma	B
capsulatum	I
and	O
Paracoccidioides	B
brasiliensis	I
,	O
from	O
the	O
Ajellomycetaceae	O
family	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
bi	O
-	O
functional	O
PRP8	O
intein	O
in	O
two	O
other	O
Ajellomycetacean	O
pathogens	O
,	O
Blastomyces	B
dermatitidis	I
and	O
Emmonsia	B
parva	I
.	O

Sequence	O
analysis	O
and	O
experimental	O
evidence	O
suggest	O
that	O
the	O
homing	O
endonuclease	O
from	O
PbrPRP8	O
is	O
inactive	O
.	O

The	O
splicing	O
activity	O
of	O
the	O
PRP8	O
intein	O
from	O
the	O
B.	B
dermatitidis	I
,	O
E.	B
parva	I
and	O
P.	B
brasiliensis	I
species	I
complex	I
was	O
demonstrated	O
in	O
a	O
non	O
-	O
native	O
protein	O
context	O
in	O
Escherichia	B
coli	I
.	O

Since	O
the	O
PRP8	O
intein	O
is	O
located	O
in	O
a	O
functionally	O
essential	O
nuclear	O
protein	O
,	O
it	O
can	O
be	O
considered	O
a	O
promising	O
therapeutic	O
target	O
for	O
anti	O
-	O
fungal	O
drugs	O
,	O
because	O
inhibition	O
of	O
intein	O
splicing	O
should	O
inhibit	O
proliferation	O
of	O
intein	O
-	O
containing	O
pathogens	O
.	O

Towards	O
a	O
conceptual	O
framework	O
to	O
support	O
one	O
-	O
health	O
research	O
for	O
policy	O
on	O
emerging	O
zoonoses	O
.	O

In	O
the	O
past	O
two	O
decades	O
there	O
has	O
been	O
a	O
growing	O
realisation	O
that	O
the	O
livestock	O
sector	O
was	O
in	O
a	O
process	O
of	O
change	O
,	O
resulting	O
from	O
an	O
expansion	O
of	O
intensive	O
animal	O
production	O
systems	O
and	O
trade	O
to	O
meet	O
a	O
globalised	O
world	O
's	O
increasing	O
demand	O
for	O
livestock	O
products	O
.	O

One	O
unintended	O
consequence	O
has	O
been	O
the	O
emergence	O
and	O
spread	O
of	O
transboundary	O
animal	O
diseases	O
and	O
,	O
more	O
specifically	O
,	O
the	O
resurgence	O
and	O
emergence	O
of	O
zoonotic	O
diseases	O
.	O

Concurrent	O
with	O
changes	O
in	O
the	O
livestock	O
sector	O
,	O
contact	O
with	O
wildlife	O
has	O
increased	O
.	O

This	O
development	O
has	O
increased	O
the	O
risk	O
of	O
transmission	O
of	O
infections	O
from	O
wildlife	O
to	O
human	B
beings	O
and	O
livestock	O
.	O

Two	O
overarching	O
questions	O
arise	O
with	O
respect	O
to	O
the	O
real	O
and	O
perceived	O
threat	O
from	O
emerging	O
infectious	O
diseases	O
:	O
why	O
are	O
these	O
problems	O
arising	O
with	O
increasing	O
frequency	O
,	O
and	O
how	O
should	O
we	O
manage	O
and	O
control	O
them	O
?	O

A	O
clear	O
conceptual	O
research	O
framework	O
can	O
provide	O
a	O
guide	O
to	O
ensure	O
a	O
research	O
strategy	O
that	O
coherently	O
links	O
to	O
the	O
overarching	O
goals	O
of	O
policy	O
makers	O
.	O

We	O
propose	O
such	O
a	O
new	O
framework	O
in	O
support	O
of	O
a	O
research	O
and	O
policy	O
-	O
generation	O
strategy	O
to	O
help	O
to	O
address	O
the	O
challenges	O
posed	O
by	O
emerging	O
zoonoses	O
.	O

The	O
ribonucleotide	O
reductase	O
large	O
subunit	O
(	O
RRM1	O
)	O
as	O
a	O
predictive	O
factor	O
in	O
patients	O
with	O
cancer	O
.	O

The	O
large	O
subunit	O
of	O
human	B
ribonucleotide	O
reductase	O
,	O
RRM1	O
,	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
,	O
cell	O
migration	O
,	O
tumour	O
and	O
metastasis	O
development	O
,	O
and	O
the	O
synthesis	O
of	O
deoxyribonucleotides	O
for	O
DNA	O
synthesis	O
.	O

It	O
is	O
also	O
a	O
cellular	O
target	O
for	O
the	O
chemotherapeutic	O
agent	O
,	O
gemcitabine	O
.	O

RRM1	O
has	O
been	O
studied	O
in	O
a	O
large	O
number	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	O
,	O
such	O
as	O
non	O
-	O
small	O
-	O
cell	O
lung	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
breast	O
cancer	O
,	O
and	O
biliary	O
tract	O
cancer	O
,	O
to	O
establish	O
its	O
prognostic	O
or	O
predictive	O
value	O
when	O
patients	O
were	O
treated	O
with	O
gemcitabine	O
,	O
and	O
mRNA	O
expression	O
and	O
genetic	O
variants	O
as	O
determined	O
by	O
genotyping	O
have	O
in	O
some	O
cases	O
been	O
associated	O
with	O
clinical	O
outcome	O
of	O
patients	O
with	O
cancer	O
.	O

Here	O
,	O
we	O
review	O
preclinical	O
and	O
clinical	O
studies	O
of	O
RRM1	O
assessment	O
and	O
discuss	O
the	O
further	O
steps	O
in	O
the	O
development	O
of	O
this	O
clinically	O
pertinent	O
biomarker	O
.	O

OsEDR1	O
negatively	O
regulates	O
rice	B
bacterial	O
resistance	O
via	O
activation	O
of	O
ethylene	O
biosynthesis	O
.	O

Rice	B
OsEDR1	O
is	O
a	O
sequence	O
ortholog	O
of	O
Arabidopsis	O
EDR1	O
.	O

However	O
,	O
its	O
molecular	O
function	O
is	O
unknown	O
.	O

We	O
show	O
here	O
that	O
OsEDR1-suppressing	O
/	O
knockout	O
(	O
KO	O
)	O
plants	O
,	O
which	O
developed	O
spontaneous	O
lesions	O
on	O
the	O
leaves	O
,	O
have	O
enhanced	O
resistance	O
to	O
Xanthomonas	B
oryzae	I
pv	I
.	I

oryzae	B
(	O
Xoo	B
)	O
causing	O
bacterial	O
blight	O
disease	O
.	O

This	O
resistance	O
was	O
associated	O
with	O
increased	O
accumulation	O
of	O
salicylic	O
acid	O
(	O
SA	O
)	O
and	O
jasmonic	O
acid	O
(	O
JA	O
)	O
,	O
induced	O
expression	O
of	O
SA-	O
and	O
JA	O
-	O
related	O
genes	O
and	O
suppressed	O
accumulation	O
of	O
1-aminocyclopropane-1-carboxylic	O
acid	O
(	O
ACC	O
)	O
,	O
the	O
direct	O
precursor	O
of	O
ethylene	O
,	O
and	O
expression	O
of	O
ethylene	O
-	O
related	O
genes	O
.	O

OsEDR1-KO	O
plants	O
also	O
showed	O
suppressed	O
production	O
of	O
ethylene	O
.	O

Knockout	O
of	O
OsEDR1	O
suppressed	O
the	O
ACC	O
synthase	O
(	O
ACS	O
)	O
gene	O
family	O
,	O
which	O
encodes	O
the	O
rate	O
-	O
limiting	O
enzymes	O
of	O
ethylene	O
biosynthesis	O
by	O
catalysing	O
the	O
formation	O
of	O
ACC	O
.	O

The	O
lesion	O
phenotype	O
and	O
enhanced	O
bacterial	O
resistance	O
of	O
the	O
OsEDR1-KO	O
plants	O
was	O
partly	O
complemented	O
by	O
the	O
treatment	O
with	O
ACC	O
.	O

ACC	O
treatment	O
was	O
associated	O
with	O
decreased	O
SA	O
and	O
JA	O
biosynthesis	O
in	O
OsEDR1-KO	O
plants	O
.	O

In	O
contrast	O
,	O
aminoethoxyvinylglycine	O
,	O
the	O
inhibitor	O
of	O
ethylene	O
biosynthesis	O
,	O
promoted	O
expression	O
of	O
SA	O
and	O
JA	O
synthesis	O
-	O
related	O
genes	O
in	O
OsEDR1-KO	O
plants	O
.	O

These	O
results	O
suggest	O
that	O
ethylene	O
is	O
a	O
negative	O
signalling	O
molecule	O
in	O
rice	B
bacterial	O
resistance	O
.	O

In	O
the	O
rice	B
-	O
Xoo	B
interaction	O
,	O
OsEDR1	O
transcriptionally	O
promotes	O
the	O
synthesis	O
of	O
ethylene	O
that	O
,	O
in	O
turn	O
,	O
suppresses	O
SA-	O
and	O
JA	O
-	O
associated	O
defence	O
signalling	O
.	O

Functional	O
test	O
of	O
the	O
influence	O
of	O
Wolbachia	O
genes	O
on	O
cytoplasmic	O
incompatibility	O
expression	O
in	O
Drosophila	B
melanogaster	I
.	O

Wolbachia	O
are	O
inherited	O
intracellular	O
bacteria	O
that	O
infect	O
a	O
broad	O
range	O
of	O
invertebrate	O
hosts	O
.	O

They	O
commonly	O
manipulate	O
host	O
reproduction	O
in	O
a	O
variety	O
of	O
ways	O
and	O
thereby	O
favour	O
their	O
invasion	O
into	O
host	O
populations	O
.	O

While	O
the	O
biology	O
of	O
Wolbachia	O
has	O
been	O
extensively	O
studied	O
at	O
the	O
ecological	O
and	O
phenotypic	O
level	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
interaction	O
between	O
Wolbachia	O
and	O
their	O
hosts	O
.	O

Recent	O
comparative	O
genomics	O
studies	O
of	O
Wolbachia	O
strains	O
have	O
revealed	O
putative	O
candidate	O
genes	O
involved	O
in	O
the	O
expression	O
of	O
cytoplasmic	O
incompatibility	O
(	O
CI	O
)	O
in	O
insects	O
.	O

However	O
the	O
functional	O
testing	O
of	O
these	O
genes	O
is	O
hindered	O
by	O
the	O
lack	O
of	O
available	O
genetic	O
tools	O
in	O
Wolbachia	O
.	O

To	O
circumvent	O
this	O
problem	O
we	O
generated	O
transgenic	O
Drosophila	O
lines	O
expressing	O
various	O
Wolbachia	O
CI	O
candidate	O
genes	O
under	O
the	O
control	O
of	O
the	O
GAL4	O
/	O
UAS	O
system	O
in	O
order	O
to	O
evaluate	O
their	O
possible	O
role	O
in	O
Wolbachia	O
-	O
related	O
phenotypes	O
in	O
Drosophila	O
.	O

The	O
expression	O
of	O
a	O
number	O
of	O
these	O
genes	O
in	O
Drosophila	B
melanogaster	I
failed	O
to	O
mimic	O
or	O
alter	O
CI	O
phenotypes	O
across	O
a	O
range	O
of	O
Wolbachia	O
backgrounds	O
or	O
in	O
the	O
absence	O
of	O
Wolbachia	O
.	O

Differential	O
transcription	O
of	O
two	O
highly	O
divergent	O
gut	O
-	O
expressed	O
Bm86	O
antigen	O
gene	O
homologues	O
in	O
the	O
tick	O
Rhipicephalus	B
appendiculatus	I
(	O
Acari	O
:	O
Ixodida	O
)	O
.	O

The	O
transcriptional	O
control	O
of	O
gene	O
expression	O
is	O
not	O
well	O
documented	O
in	O
the	O
Arthropoda	O
.	O

We	O
describe	O
transcriptional	O
analysis	O
of	O
two	O
exceptionally	O
divergent	O
homologues	O
(	O
Ra86	O
)	O
of	O
the	O
Bm86	O
gut	O
antigen	O
from	O
Rhipicephalus	B
appendiculatus	I
.	O

Bm86	O
forms	O
the	O
basis	O
of	O
a	O
commercial	O
vaccine	O
for	O
the	O
control	O
of	O
Rhipicephalus	B
(	I
Boophilus	I
)	I
microplus	I
.	O

The	O
R.	B
appendiculatus	I
Ra86	O
proteins	O
contain	O
654	O
and	O
693	O
amino	O
acids	O
,	O
with	O
only	O
80	O
%	O
amino	O
acid	O
sequence	O
identity	O
.	O

Reverse	O
-	O
transcription	O
PCR	O
of	O
gut	O
cDNA	O
showed	O
transcription	O
of	O
only	O
one	O
genotype	O
in	O
individual	O
female	O
ticks	O
.	O

PCR	O
amplification	O
of	O
3	O
'	O
untranslated	O
sequences	O
from	O
genomic	O
DNA	O
indicated	O
that	O
both	O
variants	O
could	O
be	O
encoded	O
within	O
a	O
single	O
genome	O
.	O

When	O
both	O
variants	O
were	O
present	O
,	O
one	O
of	O
the	O
two	O
Ra86	O
genotypes	O
was	O
transcriptionally	O
dominant	O
.	O

Surface	O
and	O
flagella	O
morphology	O
of	O
the	O
motile	O
form	O
of	O
Chromera	B
velia	I
revealed	O
by	O
field	O
-	O
emission	O
scanning	O
electron	O
microscopy	O
.	O

Chromera	B
velia	I
(	O
Chromerida	O
;	O
Alveolata	O
)	O
is	O
an	O
autotrophic	O
protist	O
isolated	O
from	O
stony	O
corals	O
.	O

Ch	B
.	I

velia	B
possesses	O
a	O
chloroplast	O
thought	O
to	O
be	O
most	O
closely	O
related	O
to	O
the	O
apicoplasts	O
of	O
non	O
-	O
photosynthetic	O
apicomplexa	O
.	O

Phylogenetic	O
analyses	O
place	O
Ch	B
.	I

velia	B
as	O
a	O
close	O
relative	O
of	O
parasitic	O
apicomplexa	O
and	O
predatory	O
colpodellids	O
.	O

We	O
have	O
used	O
field	O
-	O
emission	O
scanning	O
electron	O
microscopy	O
of	O
cells	O
sputter	O
-	O
coated	O
with	O
gold	O
or	O
chromium	O
and	O
non	O
-	O
coated	O
cells	O
to	O
characterise	O
the	O
surface	O
ultrastructure	O
of	O
the	O
motile	O
form	O
of	O
Ch	B
.	I

velia	B
.	O

In	O
overall	O
morphology	O
the	O
biflagellated	O
Ch	B
.	I

velia	B
cells	O
resemble	O
the	O
colpodellid	O
Colpodella	B
edax	I
,	O
but	O
with	O
some	O
notable	O
differences	O
.	O

The	O
ventral	O
side	O
of	O
the	O
flagellated	O
Ch	B
.	I

velia	B
cell	O
has	O
two	O
grooves	O
extending	O
from	O
the	O
anterior	O
flagella	O
insertion	O
point	O
with	O
a	O
ridge	O
rising	O
towards	O
the	O
anterior	O
apex	O
of	O
the	O
cell	O
.	O

The	O
anterior	O
flagellum	O
is	O
shorter	O
than	O
the	O
posterior	O
flagellum	O
and	O
possesses	O
a	O
distinct	O
,	O
small	O
curved	O
appendage	O
.	O

The	O
insertion	O
point	O
of	O
the	O
anterior	O
flagellum	O
is	O
partly	O
enclosed	O
by	O
a	O
flap	O
extending	O
from	O
the	O
cell	O
.	O

The	O
posterior	O
flagellum	O
is	O
approximately	O
four	O
times	O
the	O
length	O
of	O
the	O
cell	O
and	O
possesses	O
mastigonemes	O
.	O

The	O
combination	O
of	O
coating	O
techniques	O
proved	O
superior	O
to	O
the	O
commonly	O
used	O
gold	O
coating	O
to	O
determine	O
fine	O
surface	O
ultrastructure	O
.	O

This	O
new	O
ultrastructural	O
information	O
for	O
Ch	B
.	I

velia	B
allowed	O
us	O
to	O
emend	O
its	O
diagnosis	O
.	O

Genetic	O
and	O
molecular	O
characterization	O
of	O
a	O
blue	O
light	O
photoreceptor	O
MGWC-1	O
in	O
Magnaporth	B
oryzae	I
.	O

Three	O
key	O
factors	O
involved	O
in	O
successful	O
plant	O
disease	O
development	O
include	O
the	O
presence	O
of	O
a	O
susceptible	O
host	O
,	O
a	O
virulent	O
pathogen	O
,	O
and	O
a	O
disease	O
-	O
conducive	O
environment	O
.	O

Our	O
understanding	O
of	O
how	O
environmental	O
factors	O
influence	O
disease	O
-	O
conducive	O
or	O
disease	O
-	O
suppressive	O
conditions	O
,	O
and	O
how	O
a	O
pathogen	O
advantageously	O
capitalizes	O
on	O
them	O
,	O
is	O
quite	O
limited	O
.	O

Utilizing	O
the	O
model	O
pathosystem	O
Magnaporthe	B
oryzae	I
-	O
Oryza	B
sativa	I
,	O
we	O
found	O
a	O
significant	O
light	O
-	O
dependent	O
disease	O
suppression	O
.	O

Our	O
genetic	O
data	O
suggest	O
that	O
the	O
blue	O
-	O
light	O
receptor	O
MGWC-1	O
in	O
M.	B
oryzae	I
is	O
involved	O
in	O
light	O
-	O
dependent	O
disease	O
suppression	O
during	O
the	O
dark	O
-	O
phase	O
(	O
disease	O
-	O
conducive	O
light	O
condition	O
)	O
immediately	O
after	O
pathogen	O
-	O
host	O
contact	O
.	O

Sensing	O
""""	O
darkness	O
""""	O
is	O
accomplished	O
by	O
MGWC-1	O
,	O
a	O
blue	O
-	O
light	O
receptor	O
in	O
M.	O
oryzae	O
.	O

To	B
explore	I
the	O
potential	O
molecular	O
mechanisms	O
of	O
light	O
-	O
dependent	O
disease	O
suppression	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
microarray	O
experiment	O
and	O
identified	O
several	O
groups	O
of	O
gene	O
families	O
that	O
are	O
differentially	O
regulated	O
during	O
the	O
light	O
-	O
to	O
-	O
dark	O
transition	O
.	O

Our	O
genetic	O
and	O
molecular	O
data	O
provide	O
insights	O
into	O
how	O
a	O
fungal	O
pathogen	O
utilizes	O
ambient	O
light	O
signals	O
for	O
successful	O
disease	O
development	O
.	O

Determinants	O
of	O
reproductive	O
success	O
in	O
dominant	O
pairs	O
of	O
clownfish	O
:	O
a	O
boosted	O
regression	O
tree	O
analysis	O
.	O

1	O
.	O

Central	O
questions	O
of	O
behavioural	O
and	O
evolutionary	O
ecology	O
are	O
what	O
factors	O
influence	O
the	O
reproductive	O
success	O
of	O
dominant	O
breeders	O
and	O
subordinate	O
nonbreeders	O
within	O
animal	O
societies	O
?	O

A	O
complete	O
understanding	O
of	O
any	O
society	O
requires	O
that	O
these	O
questions	O
be	O
answered	O
for	O
all	O
individuals	O
.	O

2	O
.	O

The	O
clown	O
anemonefish	O
,	O
Amphiprion	B
percula	I
,	O
forms	O
simple	O
societies	O
that	O
live	O
in	O
close	O
association	O
with	O
sea	O
anemones	O
,	O
Heteractis	B
magnifica	I
.	O

Here	O
,	O
we	O
use	O
data	O
from	O
a	O
well	O
-	O
studied	O
population	O
of	O
A.	B
percula	I
to	O
determine	O
the	O
major	O
predictors	O
of	O
reproductive	O
success	O
of	O
dominant	O
pairs	O
in	O
this	O
species	O
.	O

3	O
.	O

We	O
analyse	O
the	O
effect	O
of	O
multiple	O
predictors	O
on	O
four	O
components	O
of	O
reproductive	O
success	O
,	O
using	O
a	O
relatively	O
new	O
technique	O
from	O
the	O
field	O
of	O
statistical	O
learning	O
:	O
boosted	O
regression	O
trees	O
(	O
BRTs	O
)	O
.	O

BRTs	O
have	O
the	O
potential	O
to	O
model	O
complex	O
relationships	O
in	O
ways	O
that	O
give	O
powerful	O
insight	O
.	O

4	O
.	O

We	O
show	O
that	O
the	O
reproductive	O
success	O
of	O
dominant	O
pairs	O
is	O
unrelated	O
to	O
the	O
presence	O
,	O
number	O
or	O
phenotype	O
of	O
nonbreeders	O
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
nonbreeders	O
do	O
not	O
help	O
or	O
hinder	O
breeders	O
in	O
any	O
way	O
,	O
confirming	O
and	O
extending	O
the	O
results	O
of	O
a	O
previous	O
study	O
.	O

5	O
.	O
Primarily	O
,	O
reproductive	O
success	O
is	O
negatively	O
related	O
to	O
male	O
growth	O
and	O
positively	O
related	O
to	O
breeding	O
experience	O
.	O

It	O
is	O
likely	O
that	O
these	O
effects	O
are	O
interrelated	O
because	O
males	O
that	O
grow	O
a	O
lot	O
have	O
little	O
breeding	O
experience	O
.	O

These	O
effects	O
are	O
indicative	O
of	O
a	O
trade	O
-	O
off	O
between	O
male	O
growth	O
and	O
parental	O
investment	O
.	O

6	O
.	O

Secondarily	O
,	O
reproductive	O
success	O
is	O
positively	O
related	O
to	O
female	O
growth	O
and	O
size	O
.	O

In	O
this	O
population	O
,	O
female	O
size	O
is	O
positively	O
related	O
to	O
group	O
size	O
and	O
anemone	O
size	O
,	O
also	O
.	O

These	O
positive	O
correlations	O
among	O
traits	O
likely	O
are	O
caused	O
by	O
variation	O
in	O
site	O
quality	O
and	O
are	O
suggestive	O
of	O
a	O
silver	O
-	O
spoon	O
effect	O
.	O

7	O
.	O

Noteworthily	O
,	O
whereas	O
reproductive	O
success	O
is	O
positively	O
related	O
to	O
female	O
size	O
,	O
it	O
is	O
unrelated	O
to	O
male	O
size	O
.	O

This	O
observation	O
provides	O
support	O
for	O
the	O
size	O
advantage	O
hypothesis	O
for	O
sex	O
change	O
:	O
both	O
individuals	O
maximize	O
their	O
reproductive	O
success	O
when	O
the	O
larger	O
individual	O
adopts	O
the	O
female	O
tactic	O
.	O

8	O
.	O

This	O
study	O
provides	O
the	O
most	O
complete	O
picture	O
to	O
date	O
of	O
the	O
factors	O
that	O
predict	O
the	O
reproductive	O
success	O
of	O
dominant	O
pairs	O
of	O
clown	O
anemonefish	O
and	O
illustrates	O
the	O
utility	O
of	O
BRTs	O
for	O
analysis	O
of	O
complex	O
behavioural	O
and	O
evolutionary	O
ecology	O
data	O
.	O

Multiplex	O
RT	O
-	O
PCR	O
for	O
rapid	O
detection	O
and	O
differentiation	O
of	O
class	B
I	O
and	O
class	B
II	I
Newcastle	I
disease	I
viruses	I
.	O

A	O
multiplex	O
RT	O
-	O
PCR	O
was	O
developed	O
for	O
detection	O
and	O
differentiation	O
of	O
class	B
I	O
and	O
class	B
II	I
strains	I
of	I
Newcastle	I
disease	I
virus	I
(	I
NDV	I
)	O
.	O

The	O
method	O
was	O
shown	O
to	O
have	O
high	O
specificity	O
and	O
sensitivity	O
.	O

The	O
results	O
obtained	O
from	O
the	O
multiplex	O
RT	O
-	O
PCR	O
for	O
a	O
total	O
of	O
67	O
NDV	B
field	O
isolates	O
obtained	O
in	O
2009	O
were	O
consistent	O
with	O
those	O
obtained	O
by	O
nucleotide	O
sequencing	O
and	O
phylogenetic	O
analysis	O
.	O

A	O
phylogenetic	O
tree	O
based	O
on	O
the	O
partial	O
sequences	O
of	O
the	O
F	O
gene	O
revealed	O
that	O
the	O
67	O
field	O
isolates	O
of	O
NDV	B
could	O
be	O
divided	O
into	O
two	O
classes	O
.	O

Twenty	O
-	O
seven	O
NDV	B
isolates	O
were	O
grouped	O
into	O
class	B
I	O
,	O
and	O
two	O
genotypes	O
were	O
identified	O
.	O

Most	O
of	O
the	O
class	B
I	O
isolates	O
were	O
determined	O
to	O
be	O
of	O
genotype	O
3	O
,	O
with	O
the	O
exception	O
of	O
isolate	O
NDV09	B
-	I
034	I
,	O
which	O
belonged	O
to	O
genotype	O
2	O
.	O

Forty	O
class	B
II	I
NDV	I
isolates	I
were	O
divided	O
into	O
three	O
genotypes	O
,	O
namely	O
genotype	O
VII	O
(	O
27	O
isolates	O
)	O
,	O
genotype	O
I	O
(	O
2	O
isolates	O
)	O
and	O
genotype	O
II	O
(	O
11	O
isolates	O
)	O
.	O

Isolates	O
of	O
genotypes	O
I	O
and	O
II	O
in	O
class	O
II	O
were	O
shown	O
to	O
be	O
related	O
to	O
commercial	O
vaccine	O
strains	O
used	O
commonly	O
in	O
China	O
.	O

All	O
isolates	O
of	O
genotype	O
VII	O
were	O
predicted	O
to	O
be	O
virulent	O
,	O
on	O
the	O
basis	O
of	O
the	O
sequence	O
motif	O
at	O
the	O
cleavage	O
site	O
of	O
the	O
F	O
gene	O
.	O

This	O
genotype	O
has	O
become	O
predominantly	O
responsible	O
for	O
most	O
outbreaks	O
of	O
ND	O
in	O
China	O
in	O
recent	O
years	O
.	O

In	O
conclusion	O
,	O
this	O
multiplex	O
RT	O
-	O
PCR	O
provides	O
a	O
new	O
assay	O
for	O
rapid	O
detection	O
and	O
differentiation	O
of	O
both	O
classes	O
of	O
NDV	B
isolates	I
.	O

Comparison	O
of	O
commercial	O
systems	O
for	O
extraction	O
of	O
nucleic	O
acids	O
from	O
DNA	O
/	O
RNA	O
respiratory	O
pathogens	O
.	O

This	O
study	O
compared	O
six	O
automated	O
nucleic	O
acid	O
extraction	O
systems	O
and	O
one	O
manual	O
kit	O
for	O
their	O
ability	O
to	O
recover	O
nucleic	O
acids	O
from	O
human	B
nasal	O
wash	O
specimens	O
spiked	O
with	O
five	O
respiratory	O
pathogens	O
,	O
representing	O
Gram	O
-	O
positive	O
bacteria	O
(	O
Streptococcus	B
pyogenes	I
)	O
,	O
Gram	O
-	O
negative	O
bacteria	O
(	O
Legionella	B
pneumophila	I
)	O
,	O
DNA	O
viruses	O
(	O
adenovirus	O
)	O
,	O
segmented	O
RNA	O
viruses	O
(	O
human	B
influenza	I
virus	I
A	O
)	O
,	O
and	O
non	O
-	O
segmented	O
RNA	O
viruses	O
(	O
respiratory	B
syncytial	I
virus	I
)	O
.	O

The	O
robots	O
and	O
kit	O
evaluated	O
represent	O
major	O
commercially	O
available	O
methods	O
that	O
are	O
capable	O
of	O
simultaneous	O
extraction	O
of	O
DNA	O
and	O
RNA	O
from	O
respiratory	O
specimens	O
,	O
and	O
included	O
platforms	O
based	O
on	O
magnetic	O
-	O
bead	O
technology	O
(	O
KingFisher	O
mL	O
,	O
Biorobot	O
EZ1	O
,	O
easyMAG	O
,	O
KingFisher	O
Flex	O
,	O
and	O
MagNA	O
Pure	O
Compact	O
)	O
or	O
glass	O
fiber	O
filter	O
technology	O
(	O
Biorobot	O
MDX	O
and	O
the	O
manual	O
kit	O
Allprep	O
)	O
.	O

All	O
methods	O
yielded	O
extracts	O
free	O
of	O
cross	O
-	O
contamination	O
and	O
RT	O
-	O
PCR	O
inhibition	O
.	O

All	O
automated	O
systems	O
recovered	O
L.	B
pneumophila	I
and	O
adenovirus	O
DNA	O
equivalently	O
.	O

However	O
,	O
the	O
MagNA	O
Pure	O
protocol	O
demonstrated	O
more	O
than	O
4-fold	O
higher	O
DNA	O
recovery	O
from	O
the	O
S.	B
pyogenes	I
than	O
other	O
methods	O
.	O

The	O
KingFisher	O
mL	O
and	O
easyMAG	O
protocols	O
provided	O
1-	O
to	O
3-log	O
wider	O
linearity	O
and	O
extracted	O
3-	O
to	O
4-fold	O
more	O
RNA	O
from	O
the	O
human	B
influenza	I
virus	I
and	O
respiratory	B
syncytial	I
virus	I
.	O

These	O
findings	O
suggest	O
that	O
systems	O
differed	O
in	O
nucleic	O
acid	O
recovery	O
,	O
reproducibility	O
,	O
and	O
linearity	O
in	O
a	O
pathogen	O
specific	O
manner	O
.	O

Detection	O
of	O
Tomato	B
black	I
ring	I
virus	I
by	O
real	O
-	O
time	O
one	O
-	O
step	O
RT	O
-	O
PCR	O
.	O

A	O
TaqMan	O
-	O
based	O
real	O
-	O
time	O
one	O
-	O
step	O
RT	O
-	O
PCR	O
assay	O
was	O
developed	O
for	O
the	O
rapid	O
detection	O
of	O
Tomato	B
black	I
ring	I
virus	I
(	O
TBRV	B
)	O
,	O
a	O
significant	O
plant	O
pathogen	O
which	O
infects	O
a	O
wide	O
range	O
of	O
economically	O
important	O
crops	O
.	O

Primers	O
and	O
a	O
probe	O
were	O
designed	O
against	O
existing	O
genomic	O
sequences	O
to	O
amplify	O
a	O
72	O
bp	O
fragment	O
from	O
RNA-2	O
.	O

The	O
assay	O
amplified	O
all	O
isolates	O
of	O
TBRV	B
tested	O
,	O
but	O
no	O
amplification	O
was	O
observed	O
from	O
the	O
RNA	O
of	O
other	O
nepovirus	O
species	O
or	O
healthy	O
host	O
plants	O
.	O

The	O
detection	O
limit	O
of	O
the	O
assay	O
was	O
estimated	O
to	O
be	O
around	O
nine	O
copies	O
of	O
the	O
TBRV	B
target	O
region	O
in	O
total	O
RNA	O
.	O

A	O
comparison	O
with	O
conventional	O
RT	O
-	O
PCR	O
and	O
ELISA	O
,	O
indicated	O
that	O
ELISA	O
,	O
the	O
current	O
standard	O
test	O
method	O
,	O
lacked	O
specificity	O
and	O
reacted	O
to	O
all	O
nepovirus	O
species	O
tested	O
,	O
while	O
conventional	O
RT	O
-	O
PCR	O
was	O
approximately	O
ten	O
-	O
fold	O
less	O
sensitive	O
than	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
.	O

Finally	O
,	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
assay	O
was	O
tested	O
using	O
five	O
different	O
RT	O
-	O
PCR	O
reagent	O
kits	O
and	O
was	O
found	O
to	O
be	O
robust	O
and	O
reliable	O
,	O
with	O
no	O
significant	O
differences	O
in	O
sensitivity	O
being	O
found	O
.	O

The	O
development	O
of	O
this	O
rapid	O
assay	O
should	O
aid	O
in	O
quarantine	O
and	O
post	O
-	O
border	O
surveys	O
for	O
regulatory	O
agencies	O
.	O

Scales	O
of	O
orientation	O
,	O
directed	O
walks	O
and	O
movement	O
path	O
structure	O
in	O
sharks	O
.	O

1	O
.	O

Animal	O
search	O
patterns	O
reflect	O
sensory	O
perception	O
ranges	O
combined	O
with	O
memory	O
and	O
knowledge	O
of	O
the	O
surrounding	O
environment	O
.	O

2	O
.	O

Random	O
walks	O
are	O
used	O
when	O
the	O
locations	O
of	O
resources	O
are	O
unknown	O
,	O
whereas	O
directed	O
walks	O
should	O
be	O
optimal	O
when	O
the	O
location	O
of	O
favourable	O
habitats	O
is	O
known	O
.	O

However	O
,	O
directed	O
walks	O
have	O
been	O
quantified	O
for	O
very	O
few	O
species	O
.	O

3	O
.	O

We	O
re	O
-	O
analysed	O
tracking	O
data	O
from	O
three	O
shark	O
species	O
to	O
determine	O
whether	O
they	O
were	O
using	O
directed	O
walks	O
,	O
and	O
if	O
so	O
,	O
over	O
which	O
spatial	O
scales	O
.	O

Fractal	O
analysis	O
was	O
used	O
to	O
quantify	O
how	O
movement	O
structure	O
varied	O
with	O
spatial	O
scale	O
and	O
determine	O
whether	O
the	O
sharks	O
were	O
using	O
patches	O
.	O

4	O
.	O
Tiger	O
sharks	O
performed	O
directed	O
walks	O
at	O
large	O
spatial	O
scales	O
(	O
at	O
least	O
6	O
-	O
8	O
km	O
)	O
.	O

Thresher	O
sharks	O
also	O
showed	O
directed	O
movement	O
(	O
at	O
scales	O
of	O
400	O
-	O
1900	O
m	O
)	O
,	O
and	O
adult	O
threshers	B
were	O
able	O
to	O
orient	O
at	O
greater	O
scales	O
than	O
juveniles	O
,	O
which	O
may	O
suggest	O
that	O
learning	O
improves	O
the	O
ability	O
to	O
perform	O
directed	O
walks	O
.	O

Blacktip	B
reef	I
sharks	I
had	O
small	O
home	O
ranges	O
,	O
high	O
site	O
fidelity	O
and	O
showed	O
no	O
evidence	O
of	O
oriented	O
movements	O
at	O
large	O
scales	O
.	O

5	O
.	O

There	O
were	O
inter-	O
and	O
intraspecific	O
differences	O
in	O
path	O
structure	O
and	O
patch	O
size	O
,	O
although	O
most	O
individuals	O
showed	O
scale	O
-	O
dependent	O
movements	O
.	O

Furthermore	O
,	O
some	O
individuals	O
of	O
each	O
species	O
performed	O
movements	O
similar	O
to	O
a	O
correlated	O
random	O
walk	O
.	O

6	O
.	O

Sharks	O
can	O
perform	O
directed	O
walks	O
over	O
large	O
spatial	O
scales	O
,	O
with	O
scales	O
of	O
movements	O
reflecting	O
site	O
fidelity	O
and	O
home	O
range	O
size	O
.	O

Understanding	O
when	O
and	O
where	O
directed	O
walks	O
occur	O
is	O
crucial	O
for	O
developing	O
more	O
accurate	O
population	O
-	O
level	O
dispersal	O
models	O
.	O

Fluorescent	O
proteins	O
illuminate	O
the	O
structure	O
and	O
function	O
of	O
the	O
hyphal	O
tip	O
apparatus	O
.	O

Fungal	O
hyphae	O
show	O
extreme	O
polarized	O
growth	O
at	O
the	O
tip	O
.	O

Electron	O
microscope	O
studies	O
have	O
revealed	O
a	O
apical	O
body	O
called	O
the	O
Spitzenkorper	O
that	O
is	O
thought	O
to	O
drive	O
polarized	O
growth	O
.	O

Studies	O
of	O
polarized	O
growth	O
in	O
S.	B
cerevisiae	I
have	O
identified	O
the	O
protein	O
components	O
of	O
the	O
polarized	O
growth	O
machinery	O
,	O
that	O
are	O
conserved	O
in	O
other	O
fungi	O
.	O

Fusion	O
of	O
these	O
proteins	O
to	O
GFP	O
and	O
its	O
variants	O
has	O
for	O
the	O
first	O
time	O
allowed	O
the	O
localization	O
of	O
these	O
proteins	O
in	O
real	O
time	O
to	O
the	O
hyphal	O
tip	O
without	O
the	O
need	O
for	O
drastic	O
fixation	O
procedures	O
.	O

Such	O
studies	O
showed	O
that	O
vesicle	O
-	O
associated	O
proteins	O
localize	O
to	O
the	O
Spitzenkorper	O
and	O
identified	O
a	O
second	O
compartment	O
located	O
at	O
the	O
tip	O
surface	O
composed	O
of	O
exocyst	O
and	O
other	O
proteins	O
that	O
mediate	O
the	O
fusion	O
of	O
secretory	O
vesicles	O
with	O
the	O
plasma	O
membrane	O
.	O

Galleria	B
mellonella	I
as	O
model	O
host	O
for	O
the	O
trans	O
-	O
kingdom	O
pathogen	O
Fusarium	B
oxysporum	I
.	O

Fusarium	B
oxysporum	I
,	O
the	O
causal	O
agent	O
of	O
vascular	O
wilt	O
disease	O
,	O
affects	O
a	O
wide	O
range	O
of	O
plant	O
species	O
and	O
can	O
produce	O
disseminated	O
infections	O
in	O
humans	B
.	O

F.	B
oxysporum	I
f.	I
sp.	I
lycopersici	I
isolate	I
FGSC	I
9935	I
causes	O
disease	O
both	O
on	O
tomato	B
plants	I
and	O
immunodepressed	O
mice	B
,	O
making	O
it	O
an	O
ideal	O
model	O
for	O
the	O
comparative	O
analysis	O
of	O
fungal	O
virulence	O
on	O
plant	O
and	O
animal	O
hosts	O
.	O

Here	O
we	O
tested	O
the	O
ability	O
of	O
FGSC	B
9935	I
to	O
cause	O
disease	O
in	O
the	O
greater	B
wax	I
moth	I
Galleria	B
mellonella	I
,	O
an	O
invertebrate	O
model	O
host	O
that	O
is	O
widely	O
used	O
for	O
the	O
study	O
of	O
microbial	O
human	B
pathogens	O
.	O

Injection	O
of	O
living	O
but	O
not	O
of	O
heat	O
-	O
killed	O
microconidia	O
into	O
the	O
hemocoel	O
of	O
G.	B
mellonella	I
larvae	O
resulted	O
in	O
dose	O
-	O
dependent	O
killing	O
both	O
at	O
30	O
^	O
0C	O
and	O
at	O
37	O
^	O
0C	O
.	O

Fluorescence	O
microscopy	O
of	O
larvae	O
inoculated	O
with	O
a	O
F.	B
oxysporum	I
transformant	I
expressing	O
GFP	O
revealed	O
hyphal	O
proliferation	O
within	O
the	O
hemocoel	O
,	O
interaction	O
with	O
G.	B
mellonella	I
hemocytes	O
,	O
and	O
colonization	O
of	O
the	O
killed	O
insects	O
by	O
the	O
fungus	O
.	O

Fungal	O
gene	O
knockout	O
mutants	O
previously	O
tested	O
in	O
the	O
tomato	B
and	O
immunodepressed	O
mouse	B
systems	O
displayed	O
a	O
good	O
correlation	O
in	O
virulence	O
between	O
the	O
Galleria	O
and	O
the	O
mouse	B
model	O
.	O

Thus	O
,	O
Galleria	O
represents	O
a	O
useful	O
non	O
-	O
vertebrate	O
infection	O
model	O
for	O
studying	O
virulence	O
mechanisms	O
of	O
F.	B
oxysporum	I
on	O
animal	O
hosts	O
.	O

Genome	O
-	O
wide	O
inventory	O
of	O
metal	O
homeostasis	O
-	O
related	O
gene	O
products	O
including	O
a	O
functional	O
phytochelatin	O
synthase	O
in	O
the	O
hypogeous	O
mycorrhizal	O
fungus	O
Tuber	B
melanosporum	I
.	O

Ectomycorrhizal	O
fungi	O
are	O
thought	O
to	O
enhance	O
mineral	O
nutrition	O
of	O
their	O
host	O
plants	O
and	O
to	O
confer	O
increased	O
tolerance	O
toward	O
toxic	O
metals	O
.	O

However	O
,	O
a	O
global	O
view	O
of	O
metal	O
homeostasis	O
-	O
related	O
genes	O
and	O
pathways	O
in	O
these	O
organisms	O
is	O
still	O
lacking	O
.	O

Building	O
upon	O
the	O
genome	O
sequence	O
of	O
Tuber	B
melanosporum	I
and	O
on	O
transcriptome	O
analyses	O
,	O
we	O
set	O
out	O
to	O
systematically	O
identify	O
metal	O
homeostasis	O
-	O
related	O
genes	O
in	O
this	O
plant	O
-	O
symbiotic	O
ascomycete	O
.	O

Candidate	O
gene	O
products	O
(	O
101	O
)	O
were	O
subdivided	O
into	O
three	O
major	O
functional	O
classes	O
:	O
(	O
i	O
)	O
metal	O
transport	O
(	O
58	O
)	O
;	O
(	O
ii	O
)	O
oxidative	O
stress	O
defence	O
(	O
32	O
)	O
;	O
(	O
iii	O
)	O
metal	O
detoxification	O
(	O
11	O
)	O
.	O

The	O
latter	O
class	O
includes	O
a	O
small	O
-	O
size	O
metallothionein	O
(	O
TmelMT	O
)	O
that	O
was	O
functionally	O
validated	O
in	O
yeast	B
,	O
and	O
phytochelatin	O
synthase	O
(	O
TmelPCS	O
)	O
,	O
the	O
first	O
enzyme	O
of	O
this	O
kind	O
to	O
be	O
described	O
in	O
filamentous	O
ascomycetes	O
.	O

Recombinant	O
TmelPCS	O
was	O
shown	O
to	O
support	O
GSH	O
-	O
dependent	O
,	O
metal	O
-	O
activated	O
phytochelatin	O
synthesis	O
in	O
vitro	O
and	O
to	O
afford	O
increased	O
Cd	O
/	O
Cu	O
tolerance	O
to	O
metal	O
hypersensitive	O
yeast	B
strains	O
.	O

Metal	O
transporters	O
,	O
especially	O
those	O
related	O
to	O
Cu	O
and	O
Zn	O
trafficking	O
,	O
displayed	O
the	O
highest	O
expression	O
levels	O
in	O
mycorrhizae	O
,	O
suggesting	O
extensive	O
translocation	O
of	O
both	O
metals	O
to	O
root	O
cells	O
as	O
well	O
as	O
to	O
fungal	O
metalloenzymes	O
(	O
e.g.	O
,	O
laccase	O
)	O
that	O
are	O
strongly	O
upregulated	O
in	O
symbiotic	O
hyphae	O
.	O

Predation	O
is	O
associated	O
with	O
variation	O
in	O
colour	O
pattern	O
,	O
but	O
not	O
body	O
shape	O
or	O
colour	O
reflectance	O
,	O
in	O
a	O
rainbowfish	B
(	O
Melanotaenia	B
australis	I
)	O
.	O

1	O
.	O

In	O
freshwater	O
fishes	O
,	O
inter	O
-	O
population	O
variation	O
in	O
male	O
phenotype	O
is	O
often	O
associated	O
with	O
differences	O
in	O
predation	O
intensity	O
,	O
but	O
these	O
effects	O
can	O
be	O
difficult	O
to	O
disentangle	O
from	O
environmental	O
influences	O
.	O

2	O
.	O

The	O
western	B
rainbowfish	I
Melanotaenia	B
australis	I
exhibits	O
marked	O
sexual	O
dimorphism	O
-	O
females	O
are	O
plain	O
with	O
a	O
slender	O
body	O
,	O
while	O
males	O
have	O
striking	O
coloration	O
and	O
are	O
deeper	O
in	O
the	O
body	O
.	O

Male	O
traits	O
differ	O
in	O
expression	O
among	O
populations	O
,	O
but	O
this	O
has	O
not	O
been	O
described	O
or	O
explored	O
in	O
the	O
literature	O
.	O

3	O
.	O

This	O
paper	O
describes	O
a	O
study	O
designed	O
to	O
test	O
for	O
geographic	O
structuring	O
of	O
male	O
phenotype	O
in	O
M.	B
australis	I
and	O
to	O
determine	O
whether	O
between	O
-	O
population	O
variation	O
in	O
male	O
phenotype	O
is	O
attributable	O
to	O
variation	O
in	O
predation	O
regime	O
,	O
after	O
accounting	O
for	O
environment	O
.	O

4	O
.	O

We	O
collected	O
data	O
describing	O
habitat	O
,	O
and	O
the	O
size	O
,	O
activity	O
and	O
abundance	O
of	O
predators	O
at	O
sites	O
containing	O
M.	B
australis	I
populations	O
.	O

We	O
then	O
used	O
photography	O
,	O
spectrometry	O
and	O
geometric	O
morphometrics	O
to	O
describe	O
colour	O
pattern	O
,	O
spectral	O
reflectance	O
and	O
body	O
shape	O
in	O
males	O
from	O
these	O
populations	O
.	O

Finally	O
,	O
we	O
used	O
permutation	O
-	O
based	O
multivariate	O
statistics	O
to	O
partition	O
variance	O
in	O
these	O
traits	O
according	O
to	O
environment	O
and	O
predation	O
regime	O
.	O

5	O
.	O

Downstream	O
environments	O
posed	O
higher	O
predation	O
risk	O
to	O
M.	B
australis	I
.	O

Furthermore	O
,	O
males	O
from	O
these	O
sites	O
consistently	O
exhibited	O
larger	O
cheek	O
spots	O
and	O
fewer	O
coloured	O
lateral	O
stripes	O
than	O
those	O
from	O
upstream	O
sites	O
.	O

Variation	O
in	O
predation	O
regime	O
accounted	O
for	O
a	O
significant	O
proportion	O
of	O
the	O
total	O
variance	O
in	O
these	O
traits	O
(	O
30	O
*	O
9	O
%	O
)	O
,	O
after	O
controlling	O
for	O
the	O
effects	O
of	O
environment	O
.	O

6	O
.	O

Variation	O
in	O
predation	O
regime	O
did	O
not	O
explain	O
variation	O
in	O
reflectance	O
or	O
shape	O
.	O

Environmental	O
variation	O
,	O
however	O
,	O
explained	O
a	O
significant	O
portion	O
of	O
the	O
total	O
variance	O
in	O
reflectance	O
(	O
74	O
*	O
9	O
%	O
)	O
,	O
and	O
there	O
was	O
a	O
strong	O
trend	O
towards	O
it	O
explaining	O
a	O
portion	O
of	O
the	O
total	O
variance	O
in	O
body	O
shape	O
(	O
34	O
*	O
9	O
%	O
)	O
.	O

7	O
.	O

We	O
conclude	O
that	O
natural	O
selection	O
by	O
predators	O
may	O
be	O
an	O
important	O
determinant	O
of	O
the	O
evolution	O
of	O
colour	O
pattern	O
variation	O
in	O
M.	B
australis	I
,	O
but	O
not	O
of	O
that	O
of	O
body	O
shape	O
or	O
colour	O
reflectance	O
.	O

8	O
.	O

Further	O
study	O
of	O
M.	B
australis	I
will	O
complement	O
existing	O
models	O
,	O
which	O
show	O
complex	O
relationships	O
between	O
predation	O
regime	O
,	O
environment	O
and	O
phenotype	O
.	O

Understanding	O
these	O
relationships	O
is	O
prerequisite	O
to	O
predicting	O
the	O
evolution	O
of	O
phenotypic	O
variation	O
in	O
natural	O
systems	O
.	O

Distribution	O
and	O
localization	O
of	O
microsatellites	O
in	O
the	O
Perigord	B
black	I
truffle	I
genome	O
and	O
identification	O
of	O
new	O
molecular	O
markers	O
.	O

The	O
level	O
of	O
genetic	O
diversity	O
and	O
genetic	O
structure	O
in	O
the	O
Perigord	B
black	I
truffle	I
(	O
Tuber	B
melanosporum	I
Vittad	I
.	O
)	O
has	O
been	O
debated	O
for	O
several	O
years	O
,	O
mainly	O
due	O
to	O
the	O
lack	O
of	O
appropriate	O
genetic	O
markers	O
.	O

Microsatellites	O
or	O
simple	O
sequence	O
repeats	O
(	O
SSRs	O
)	O
are	O
important	O
for	O
the	O
genome	O
organisation	O
,	O
phenotypic	O
diversity	O
and	O
are	O
one	O
of	O
the	O
most	O
popular	O
molecular	O
markers	O
.	O

In	O
this	O
study	O
,	O
we	O
surveyed	O
the	O
T.	B
melanosporum	I
genome	O
(	O
1	O
)	O
to	O
characterise	O
its	O
SSR	O
pattern	O
;	O
(	O
2	O
)	O
to	O
compare	O
it	O
with	O
SSR	O
patterns	O
found	O
in	O
48	O
other	O
fungal	O
and	O
three	O
oomycetes	O
genomes	O
and	O
(	O
3	O
)	O
to	O
identify	O
new	O
polymorphic	O
SSR	O
markers	O
for	O
population	O
genetics	O
.	O

The	O
T.	B
melanosporum	I
genome	O
is	O
rich	O
in	O
SSRs	O
with	O
22,425	O
SSRs	O
with	O
mono	O
-	O
nucleotides	O
being	O
the	O
most	O
frequent	O
motifs	O
.	O

SSRs	O
were	O
found	O
in	O
all	O
genomic	O
regions	O
although	O
they	O
are	O
more	O
frequent	O
in	O
non	O
-	O
coding	O
regions	O
(	O
introns	O
and	O
intergenic	O
regions	O
)	O
.	O

Sixty	O
out	O
of	O
135	O
PCR	O
-	O
amplified	O
mono-	O
,	O
di-	O
,	O
tri-	O
,	O
tetra	O
,	O
penta	O
,	O
and	O
hexa	O
-	O
nucleotides	O
were	O
polymorphic	O
(	O
44	O
%	O
)	O
within	O
black	B
truffle	I
populations	O
and	O
27	O
were	O
randomly	O
selected	O
and	O
analysed	O
on	O
139	O
T.	B
melanosporum	I
isolates	O
from	O
France	O
,	O
Italy	O
and	O
Spain	O
.	O

The	O
number	O
of	O
alleles	O
varied	O
from	O
2	O
to	O
18	O
and	O
the	O
expected	O
heterozygosity	O
from	O
0.124	O
to	O
0.815	O
.	O

One	O
hundred	O
and	O
thirty	O
-	O
two	O
different	O
multilocus	O
genotypes	O
out	O
of	O
the	O
139	O
T.	B
melanosporum	I
isolates	O
were	O
identified	O
and	O
the	O
genotypic	O
diversity	O
was	O
high	O
(	O
0.999	O
)	O
.	O

Polymorphic	O
SSRs	O
were	O
found	O
in	O
UTR	O
regulatory	O
regions	O
of	O
fruiting	O
bodies	O
and	O
ectomycorrhiza	O
regulated	O
genes	O
,	O
suggesting	O
that	O
they	O
may	O
play	O
a	O
role	O
in	O
phenotypic	O
variation	O
.	O

In	O
conclusion	O
,	O
SSRs	O
developed	O
in	O
this	O
study	O
were	O
highly	O
polymorphic	O
and	O
our	O
results	O
showed	O
that	O
T.	B
melanosporum	I
is	O
a	O
species	O
with	O
an	O
important	O
genetic	O
diversity	O
,	O
which	O
is	O
in	O
agreement	O
with	O
its	O
recently	O
uncovered	O
heterothallic	O
mating	O
system	O
.	O

Complete	O
genome	O
sequences	O
of	O
three	O
Erwinia	B
amylovora	I
phages	O
isolated	O
in	O
north	O
america	O
and	O
a	O
bacteriophage	O
induced	O
from	O
an	O
Erwinia	B
tasmaniensis	I
strain	O
.	O

Fire	O
blight	O
,	O
a	O
plant	O
disease	O
of	O
economic	O
importance	O
caused	O
by	O
Erwinia	B
amylovora	I
,	O
may	O
be	O
controlled	O
by	O
the	O
application	O
of	O
bacteriophages	O
.	O

Here	O
,	O
we	O
provide	O
the	O
complete	O
genome	O
sequences	O
and	O
the	O
annotation	O
of	O
three	O
E.	B
amylovora	I
-	O
specific	O
phages	O
isolated	O
in	O
North	O
America	O
and	O
genomic	O
information	O
about	O
a	O
bacteriophage	O
induced	O
by	O
mitomycin	O
C	O
treatment	O
of	O
an	O
Erwinia	B
tasmaniensis	I
strain	O
that	O
is	O
antagonistic	O
for	O
E.	B
amylovora	I
.	O

The	O
American	O
phages	O
resemble	O
two	O
already	O
-	O
described	O
viral	O
genomes	O
,	O
whereas	O
the	O
E.	B
tasmaniensis	I
phage	O
displays	O
a	O
singular	O
genomic	O
sequence	O
in	O
BLAST	O
searches	O
.	O

Prasinoderma	O
singularis	O
sp.	O
nov.	O
(	O
Prasinophyceae	O
,	O
Chlorophyta	O
)	O
,	O
a	O
solitary	O
coccoid	O
Prasinophyte	O
from	O
the	O
South	O
-	O
East	O
Pacific	O
Ocean	O
.	O

During	O
the	O
BIOSOPE	O
cruise	O
in	O
the	O
South	O
-	O
East	O
Pacific	O
Ocean	O
in	O
2004	O
,	O
several	O
unidentified	O
strains	O
of	O
prasinophytes	O
were	O
isolated	O
into	O
culture	O
.	O

Of	O
these	O
,	O
nine	O
strains	O
composed	O
a	O
group	O
for	O
which	O
the	O
partial	O
18S	O
rRNA	O
gene	O
sequence	O
was	O
related	O
to	O
Prasinoderma	B
coloniale	I
.	O

The	O
ultrastructure	O
,	O
morphology	O
,	O
division	O
process	O
,	O
pigment	O
composition	O
,	O
genome	O
size	O
and	O
molecular	O
genetic	O
phylogeny	O
of	O
these	O
nine	O
strains	O
were	O
investigated	O
,	O
using	O
P.	B
coloniale	I
as	O
a	O
reference	O
.	O

The	O
18S	O
rRNA	O
gene	O
sequence	O
of	O
P.	O
singularis	O
sp.	O
nov.	O
shares	O
only	O
96.9	O
%	O
of	O
identity	O
with	O
that	O
of	O
P.	B
coloniale	I
and	O
contains	O
a	O
conserved	O
insertion	O
of	O
567bp	O
length	O
not	O
recorded	O
in	O
P.	B
coloniale	I
.	O

When	O
compared	O
to	O
P.	B
coloniale	I
,	O
P.	O
singularis	O
sp.	O
nov.	O
is	O
morphologically	O
characterized	O
by	O
the	O
absence	O
of	O
colonies	O
,	O
smaller	O
cells	O
with	O
a	O
thinner	O
cell	O
wall	O
,	O
and	O
a	O
second	O
cell	O
type	O
with	O
a	O
different	O
cell	O
covering	O
.	O

Regulation	O
of	O
horizontal	O
gene	O
transfer	O
in	O
Bacillus	B
subtilis	I
by	O
activation	O
of	O
a	O
conserved	O
site	O
-	O
specific	O
protease	O
.	O

The	O
mobile	O
genetic	O
element	O
ICEBs1	O
is	O
an	O
integrative	O
and	O
conjugative	O
element	O
(	O
a	O
conjugative	O
transposon	O
)	O
found	O
in	O
Bacillus	B
subtilis	I
.	O

The	O
RecA	O
-	O
dependent	O
SOS	O
response	O
and	O
the	O
RapI	O
-	O
PhrI	O
cell	O
sensory	O
system	O
activate	O
ICEBs1	O
gene	O
expression	O
by	O
stimulating	O
cleavage	O
of	O
ImmR	O
,	O
the	O
ICEBs1	O
immunity	O
repressor	O
,	O
by	O
the	O
protease	O
ImmA.	O
We	O
found	O
that	O
increasing	O
the	O
amount	O
of	O
wild	O
-	O
type	O
ImmA	O
in	O
vivo	O
caused	O
partial	O
derepression	O
of	O
ICEBs1	O
gene	O
expression	O
.	O

However	O
,	O
during	O
RapI	O
-	O
mediated	O
derepression	O
of	O
ICEBs1	O
gene	O
expression	O
,	O
ImmA	O
levels	O
did	O
not	O
detectably	O
increase	O
,	O
indicating	O
that	O
RapI	O
likely	O
activates	O
the	O
protease	O
ImmA	O
by	O
increasing	O
its	O
specific	O
activity	O
.	O

We	O
also	O
isolated	O
and	O
characterized	O
mutations	O
in	O
immA	O
(	O
immA	O
(	O
h	O
)	O
)	O
that	O
cause	O
partial	O
derepression	O
of	O
ICEBs1	O
gene	O
expression	O
in	O
the	O
absence	O
of	O
inducing	O
signals	O
.	O

We	O
obtained	O
two	O
types	O
of	O
immA	O
(	O
h	O
)	O
mutations	O
:	O
one	O
type	O
caused	O
increased	O
amounts	O
of	O
the	O
mutant	O
proteins	O
in	O
vivo	O
but	O
no	O
detectable	O
effect	O
on	O
specific	O
activity	O
in	O
vitro	O
;	O
the	O
other	O
type	O
had	O
no	O
detectable	O
effect	O
on	O
the	O
amount	O
of	O
the	O
mutant	O
protein	O
in	O
vivo	O
but	O
caused	O
increased	O
specific	O
activity	O
of	O
the	O
protein	O
(	O
as	O
measured	O
in	O
vitro	O
)	O
.	O

Together	O
,	O
these	O
findings	O
indicate	O
that	O
derepression	O
of	O
ICEBs1	O
gene	O
expression	O
is	O
likely	O
caused	O
by	O
an	O
increase	O
in	O
the	O
specific	O
activity	O
of	O
ImmA.	O
Homologs	O
of	O
ImmA	O
and	O
ImmR	O
are	O
found	O
in	O
many	O
mobile	O
genetic	O
elements	O
,	O
so	O
the	O
mechanisms	O
that	O
regulate	O
ImmA	O
-	O
mediated	O
cleavage	O
of	O
ImmR	O
may	O
be	O
widely	O
conserved	O
.	O

Complete	O
genome	O
sequence	O
of	O
strain	O
HTCC2503	B
T	O
of	O
Parvularcula	B
bermudensis	I
,	O
the	O
type	O
species	O
of	O
the	O
order	O
Parvularculales	O
in	O
the	O
class	O
Alphaproteobacteria	O
.	O

The	O
order	O
Parvularculales	O
represents	O
the	O
seventh	O
order	O
in	O
the	O
class	O
Alphaproteobacteria	O
.	O

Parvularcula	B
bermudensis	I
,	O
the	O
type	O
species	O
of	O
the	O
order	O
,	O
was	O
isolated	O
from	O
the	O
Sargasso	O
Sea	O
using	O
dilution	O
-	O
to	O
-	O
extinction	O
culturing	O
.	O

We	O
present	O
here	O
the	O
complete	O
genome	O
sequence	O
of	O
Parvularcula	B
bermudensis	I
HTCC2503	I
(	I
T	I
)	O
,	O
which	O
contains	O
genes	O
for	O
carotenoid	O
biosynthesis	O
,	O
dimethylsulfoniopropionate	O
demethylase	O
,	O
and	O
transduction	O
-	O
like	O
gene	O
transfer	O
agents	O
.	O

argC	O
Orthologs	O
from	O
Rhizobiales	O
show	O
diverse	O
profiles	O
of	O
transcriptional	O
efficiency	O
and	O
functionality	O
in	O
Sinorhizobium	B
meliloti	I
.	O

Several	O
factors	O
can	O
influence	O
ortholog	O
replacement	O
between	O
closely	O
related	O
species	O
.	O

We	O
evaluated	O
the	O
transcriptional	O
expression	O
and	O
metabolic	O
performance	O
of	O
ortholog	O
substitution	O
complementing	O
a	O
Sinorhizobium	B
meliloti	I
argC	O
mutant	O
with	O
argC	O
from	O
Rhizobiales	O
(	O
Agrobacterium	B
tumefaciens	I
,	O
Rhizobium	B
etli	I
,	O
and	O
Mesorhizobium	B
loti	I
)	O
.	O

The	O
argC	O
gene	O
is	O
necessary	O
for	O
the	O
synthesis	O
of	O
arginine	O
,	O
an	O
amino	O
acid	O
that	O
is	O
central	O
to	O
protein	O
and	O
cellular	O
metabolism	O
.	O

Strains	O
were	O
obtained	O
carrying	O
plasmids	O
with	O
argC	O
orthologs	O
expressed	O
under	O
the	O
speB	O
and	O
argC	O
(	O
S.	B
meliloti	I
)	O
and	O
lac	O
(	O
Escherichia	B
coli	I
)	O
promoters	O
.	O

Complementation	O
analysis	O
was	O
assessed	O
by	O
growth	O
,	O
transcriptional	O
activity	O
,	O
enzymatic	O
activity	O
,	O
mRNA	O
levels	O
,	O
specific	O
detection	O
of	O
ArgC	O
proteomic	O
protein	O
,	O
and	O
translational	O
efficiency	O
.	O

The	O
argC	O
orthologs	O
performed	O
differently	O
in	O
each	O
complementation	O
,	O
reflecting	O
the	O
diverse	O
factors	O
influencing	O
gene	O
expression	O
and	O
the	O
ability	O
of	O
the	O
ortholog	O
product	O
to	O
function	O
in	O
a	O
foreign	O
metabolic	O
background	O
.	O

Optimal	O
complementation	O
was	O
directly	O
related	O
to	O
sequence	O
similarity	O
with	O
S.	B
meliloti	I
,	O
and	O
was	O
inversely	O
related	O
to	O
species	O
signature	O
,	O
with	O
M.	B
loti	I
argC	O
showing	O
the	O
poorest	O
performance	O
,	O
followed	O
by	O
R.	B
etli	I
and	O
A.	B
tumefaciens	I
.	O

Different	O
copy	O
numbers	O
of	O
genes	O
and	O
amounts	O
of	O
mRNA	O
and	O
protein	O
were	O
produced	O
,	O
even	O
with	O
genes	O
transcribed	O
from	O
the	O
same	O
promoter	O
,	O
indicating	O
that	O
coding	O
sequences	O
play	O
a	O
role	O
in	O
the	O
transcription	O
and	O
translation	O
processes	O
.	O

These	O
results	O
provide	O
relevant	O
information	O
for	O
further	O
genomic	O
analyses	O
and	O
suggest	O
that	O
orthologous	O
gene	O
substitutions	O
between	O
closely	O
related	O
species	O
are	O
not	O
completely	O
functionally	O
equivalent	O
.	O

Complete	O
genome	O
sequence	O
of	O
strain	O
HTCC2170	B
,	O
a	O
novel	O
member	O
of	O
the	O
genus	O
Maribacter	O
in	O
the	O
family	O
Flavobacteriaceae	O
.	O

Strain	O
HTCC2170	B
was	O
isolated	O
from	O
surface	O
waters	O
off	O
the	O
Oregon	O
coast	O
using	O
dilution	O
-	O
to	O
-	O
extinction	O
culturing	O
.	O

Here	O
,	O
we	O
present	O
the	O
finished	O
genome	O
sequence	O
of	O
a	O
marine	B
bacterium	I
,	O
Maribacter	B
sp.	I
strain	I
HTCC2170	I
.	O

Strain	O
sp.	O
HTCC2170	B
is	O
predicted	O
to	O
be	O
a	O
facultatively	O
aerobic	O
chemoorganotroph	O
that	O
,	O
based	O
on	O
genomic	O
sequence	O
analysis	O
,	O
is	O
capable	O
of	O
macromolecule	O
degradation	O
and	O
anaerobic	O
respiration	O
.	O

Flavobacterium	B
ponti	I
sp.	I
nov.	I
,	O
isolated	O
from	O
seawater	O
.	O

A	O
Gram	O
-	O
stain	O
-	O
negative	O
,	O
non	O
-	O
flagellated	O
,	O
non	O
-	O
gliding	O
,	O
yellow	O
-	O
pigmented	O
and	O
rod	O
-	O
shaped	O
bacterial	O
strain	O
,	O
designated	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
,	O
was	O
isolated	O
from	O
seawater	O
of	O
Geoje	O
Island	O
in	O
the	O
South	O
Sea	O
,	O
Korea	O
.	O

Strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
grew	O
optimally	O
at	O
25	O
^0C	O
,	O
at	O
pH	O
7.0	O
-	O
8.0	O
and	O
in	O
the	O
presence	O
of	O
2	O
%	O
(	O
w	O
/	O
v	O
)	O
NaCl	O
.	O

Phylogenetic	O
analyses	O
based	O
on	O
16S	O
rRNA	O
gene	O
sequences	O
showed	O
that	O
strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
belonged	O
to	O
the	O
genus	O
Flavobacterium	O
,	O
joining	O
Flavobacterium	B
gelidilacus	I
LMG	O
21477	O
(	O
T	O
)	O
by	O
a	O
bootstrap	O
resampling	O
value	O
of	O
100	O
%	O
.	O

Strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
exhibited	O
97.6	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
to	O
F.	B
gelidilacus	I
LMG	O
21477	O
(	O
T	O
)	O
and	O
similarities	O
of	O
91.2	O
-	O
95.2	O
%	O
to	O
other	O
members	O
of	O
the	O
genus	O
Flavobacterium	O
.	O

Strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
contained	O
MK-6	O
as	O
the	O
predominant	O
menaquinone	O
.	O

The	O
fatty	O
acid	O
profile	O
of	O
strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
was	O
similar	O
to	O
that	O
of	O
F.	B
gelidilacus	I
LMG	O
21477	O
(	O
T	O
)	O
.	O

The	O
DNA	O
G+C	O
content	O
of	O
strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
was	O
31.4	O
mol%	O
and	O
its	O
DNA	O
-	O
DNA	O
relatedness	O
with	O
F.	B
gelidilacus	I
LMG	O
21477	O
(	O
T	O
)	O
was	O
31	O
%	O
.	O

Strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
could	O
be	O
distinguished	O
from	O
F.	B
gelidilacus	I
and	O
the	O
other	O
species	O
of	O
the	O
genus	O
Flavobacterium	O
by	O
its	O
phylogenetic	O
and	O
genetic	O
distinctiveness	O
and	O
by	O
several	O
phenotypic	O
properties	O
.	O

On	O
the	O
basis	O
of	O
these	O
data	O
,	O
strain	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
is	O
considered	O
to	O
represent	O
a	O
novel	O
species	O
of	O
the	O
genus	O
Flavobacterium	O
,	O
for	O
which	O
the	O
name	O
Flavobacterium	B
ponti	I
sp.	I
nov.	I
is	O
proposed	O
;	O
the	O
type	O
strain	O
is	O
GSW	B
-	I
R14	I
(	O
T	O
)	O
(	O
=	O
KCTC	O
22802	O
(	O
T	O
)	O
=	O
CCUG	O
58402	O
(	O
T	O
)	O
)	O
.	O

The	O
small	O
GTPase	O
BcCdc42	O
affects	O
nuclear	O
division	O
,	O
germination	O
and	O
virulence	O
of	O
the	O
gray	O
mold	O
fungus	O
Botrytis	B
cinerea	I
.	O

The	O
small	O
GTPase	O
Cdc42	O
plays	O
a	O
central	O
role	O
in	O
various	O
processes	O
in	O
eukaryotic	O
cells	O
including	O
growth	O
,	O
differentiation	O
and	O
cytoskeleton	O
organization	O
.	O

Whereas	O
it	O
is	O
essential	O
in	O
the	O
yeast	B
Saccharomyces	B
cerevisiae	I
,	O
its	O
role	O
in	O
filamentous	O
fungi	O
differs	O
,	O
due	O
to	O
the	O
complementing	O
,	O
partly	O
overlapping	O
function	O
of	O
Rac	O
.	O

We	O
analyzed	O
the	O
role	O
of	O
the	O
Cdc42	O
homologue	O
in	O
the	O
necrotrophic	O
,	O
broad	O
host	O
range	O
pathogen	O
Botrytis	B
cinerea	I
.	O

Deletion	O
mutants	O
of	O
bccdc42	O
showed	O
various	O
growth	O
abnormalities	O
;	O
the	O
mutants	O
had	O
reduced	O
growth	O
rate	O
and	O
hyphal	O
branching	O
,	O
they	O
produced	O
fewer	O
conidia	O
,	O
which	O
were	O
enlarged	O
and	O
misshapen	O
and	O
had	O
germination	O
defects	O
.	O

Additionally	O
,	O
the	O
mutants	O
were	O
impaired	O
in	O
sclerotia	O
development	O
.	O

Cytological	O
studies	O
indicate	O
that	O
at	O
least	O
part	O
of	O
this	O
phenotype	O
could	O
be	O
attributed	O
to	O
disturbed	O
control	O
of	O
nuclear	O
division	O
:	O
conidia	O
and	O
hyphae	O
of	O
the	O
mutant	O
showed	O
twofold	O
higher	O
nucleus	O
/	O
cytoplasm	O
ratio	O
compared	O
to	O
wild	O
type	O
cells	O
.	O

Apart	O
from	O
these	O
effects	O
on	O
vegetative	O
growth	O
and	O
differentiation	O
,	O
Deltabccdc42	O
strains	O
were	O
attenuated	O
in	O
penetration	O
and	O
colonization	O
of	O
host	O
tissue	O
,	O
confirming	O
that	O
BcCdc42	O
-	O
though	O
being	O
not	O
essential	O
like	O
in	O
yeast	B
-	O
is	O
involved	O
in	O
important	O
developmental	O
processes	O
in	O
B.	B
cinerea	I
.	O

Human	B
resources	O
for	O
health	O
in	O
India	O
.	O

India	O
has	O
a	O
severe	O
shortage	O
of	O
human	B
resources	O
for	O
health	O
.	O

It	O
has	O
a	O
shortage	O
of	O
qualified	O
health	O
workers	O
and	O
the	O
workforce	O
is	O
concentrated	O
in	O
urban	O
areas	O
.	O

Bringing	O
qualified	O
health	O
workers	O
to	O
rural	O
,	O
remote	O
,	O
and	O
underserved	O
areas	O
is	O
very	O
challenging	O
.	O

Many	O
Indians	O
,	O
especially	O
those	O
living	O
in	O
rural	O
areas	O
,	O
receive	O
care	O
from	O
unqualified	O
providers	O
.	O

The	O
migration	O
of	O
qualified	O
allopathic	O
doctors	O
and	O
nurses	O
is	O
substantial	O
and	O
further	O
strains	O
the	O
system	O
.	O

Nurses	O
do	O
not	O
have	O
much	O
authority	O
or	O
say	O
within	O
the	O
health	O
system	O
,	O
and	O
the	O
resources	O
to	O
train	O
them	O
are	O
still	O
inadequate	O
.	O

Little	O
attention	O
is	O
paid	O
during	O
medical	O
education	O
to	O
the	O
medical	O
and	O
public	O
health	O
needs	O
of	O
the	O
population	O
,	O
and	O
the	O
rapid	O
privatisation	O
of	O
medical	O
and	O
nursing	O
education	O
has	O
implications	O
for	O
its	O
quality	O
and	O
governance	O
.	O

Such	O
issues	O
are	O
a	O
result	O
of	O
underinvestment	O
in	O
and	O
poor	O
governance	O
of	O
the	O
health	O
sector	O
--	O
two	O
issues	O
that	O
the	O
government	O
urgently	O
needs	O
to	O
address	O
.	O

A	O
comprehensive	O
national	O
policy	O
for	O
human	B
resources	O
is	O
needed	O
to	O
achieve	O
universal	O
health	O
care	O
in	O
India	O
.	O

The	O
public	O
sector	O
will	O
need	O
to	O
redesign	O
appropriate	O
packages	O
of	O
monetary	O
and	O
non	O
-	O
monetary	O
incentives	O
to	O
encourage	O
qualified	O
health	O
workers	O
to	O
work	O
in	O
rural	O
and	O
remote	O
areas	O
.	O

Such	O
a	O
policy	O
might	O
also	O
encourage	O
task	O
-	O
shifting	O
and	O
mainstreaming	O
doctors	O
and	O
practitioners	O
who	O
practice	O
traditional	O
Indian	O
medicine	O
(	O
ayurveda	O
,	O
yoga	O
and	O
naturopathy	O
,	O
unani	O
,	O
and	O
siddha	O
)	O
and	O
homoeopathy	O
to	O
work	O
in	O
these	O
areas	O
while	O
adopting	O
other	O
innovative	O
ways	O
of	O
augmenting	O
human	B
resources	O
for	O
health	O
.	O

At	O
the	O
same	O
time	O
,	O
additional	O
investments	O
will	O
be	O
needed	O
to	O
improve	O
the	O
relevance	O
,	O
quantity	O
,	O
and	O
quality	O
of	O
nursing	O
,	O
medical	O
,	O
and	O
public	O
health	O
education	O
in	O
the	O
country	O
.	O

Continuing	O
challenge	O
of	O
infectious	O
diseases	O
in	O
India	O
.	O

In	O
India	O
,	O
the	O
range	O
and	O
burden	O
of	O
infectious	O
diseases	O
are	O
enormous	O
.	O

The	O
administrative	O
responsibilities	O
of	O
the	O
health	O
system	O
are	O
shared	O
between	O
the	O
central	O
(	O
federal	O
)	O
and	O
state	O
governments	O
.	O

Control	O
of	O
diseases	O
and	O
outbreaks	O
is	O
the	O
responsibility	O
of	O
the	O
central	O
Ministry	O
of	O
Health	O
,	O
which	O
lacks	O
a	O
formal	O
public	O
health	O
department	O
for	O
this	O
purpose	O
.	O

Tuberculosis	O
,	O
malaria	O
,	O
filariasis	O
,	O
visceral	O
leishmaniasis	O
,	O
leprosy	O
,	O
HIV	B
infection	O
,	O
and	O
childhood	O
cluster	O
of	O
vaccine	O
-	O
preventable	O
diseases	O
are	O
given	O
priority	O
for	O
control	O
through	O
centrally	O
managed	O
vertical	O
programmes	O
.	O

Control	O
of	O
HIV	B
infection	O
and	O
leprosy	O
,	O
but	O
not	O
of	O
tuberculosis	O
,	O
seems	O
to	O
be	O
on	O
track	O
.	O

Early	O
success	O
of	O
malaria	O
control	O
was	O
not	O
sustained	O
,	O
and	O
visceral	O
leishmaniasis	O
prevalence	O
has	O
increased	O
.	O

Inadequate	O
containment	O
of	O
the	O
vector	O
has	O
resulted	O
in	O
recurrent	O
outbreaks	O
of	O
dengue	O
fever	O
and	O
re	O
-	O
emergence	O
of	O
Chikungunya	B
virus	I
disease	O
and	O
typhus	O
fever	O
.	O

Other	O
infectious	O
diseases	O
caused	O
by	O
faecally	O
transmitted	O
pathogens	O
(	O
enteric	O
fevers	O
,	O
cholera	O
,	O
hepatitis	B
A	O
and	O
E	B
viruses	I
)	O
and	O
zoonoses	O
(	O
rabies	O
,	O
leptospirosis	O
,	O
anthrax	O
)	O
are	O
not	O
in	O
the	O
process	O
of	O
being	O
systematically	O
controlled	O
.	O

Big	O
gaps	O
in	O
the	O
surveillance	O
and	O
response	O
system	O
for	O
infectious	O
diseases	O
need	O
to	O
be	O
addressed	O
.	O

Replication	O
of	O
the	O
model	O
of	O
vertical	O
single	O
-	O
disease	O
control	O
for	O
all	O
infectious	O
diseases	O
will	O
not	O
be	O
efficient	O
or	O
viable	O
.	O

India	O
needs	O
to	O
rethink	O
and	O
revise	O
its	O
health	O
policy	O
to	O
broaden	O
the	O
agenda	O
of	O
disease	O
control	O
.	O

A	O
comprehensive	O
review	O
and	O
redesign	O
of	O
the	O
health	O
system	O
is	O
needed	O
urgently	O
to	O
ensure	O
equity	O
and	O
quality	O
in	O
health	O
care	O
.	O

We	O
recommend	O
the	O
creation	O
of	O
a	O
functional	O
public	O
health	O
infrastructure	O
that	O
is	O
shared	O
between	O
central	O
and	O
state	O
governments	O
,	O
with	O
professional	O
leadership	O
and	O
a	O
formally	O
trained	O
public	O
health	O
cadre	O
of	O
personnel	O
who	O
manage	O
an	O
integrated	O
control	O
mechanism	O
of	O
diseases	O
in	O
districts	O
that	O
includes	O
infectious	O
and	O
non	O
-	O
infectious	O
diseases	O
,	O
and	O
injuries	O
.	O

Negotiating	O
a	O
noisy	O
,	O
information	O
-	O
rich	O
environment	O
in	O
search	O
of	O
cryptic	O
prey	O
:	O
olfactory	O
predators	O
need	O
patchiness	O
in	O
prey	O
cues	O
.	O

1	O
.	O

Olfactory	O
predator	O
search	O
processes	O
differ	O
fundamentally	O
to	O
those	O
based	O
on	O
vision	O
,	O
particularly	O
when	O
odour	O
cues	O
are	O
deposited	O
rather	O
than	O
airborne	O
or	O
emanating	O
from	O
a	O
point	O
source	O
.	O

When	O
searching	O
for	O
visually	O
cryptic	O
prey	O
that	O
may	O
have	O
moved	O
some	O
distance	O
from	O
a	O
deposited	O
odour	O
cue	O
,	O
cue	O
context	O
and	O
spatial	O
variability	O
are	O
the	O
most	O
likely	O
sources	O
of	O
information	O
about	O
prey	O
location	O
available	O
to	O
an	O
olfactory	O
predator	O
.	O

2	O
.	O

We	O
tested	O
whether	O
the	O
house	B
mouse	I
(	O
Mus	B
domesticus	I
)	O
,	O
a	O
model	O
olfactory	O
predator	O
,	O
would	O
use	O
cue	O
context	O
and	O
spatial	O
variability	O
when	O
searching	O
for	O
buried	O
food	O
items	O
;	O
specifically	O
,	O
we	O
tested	O
the	O
effect	O
of	O
varying	O
cue	O
patchiness	O
,	O
odour	O
strength	O
,	O
and	O
cue	O
-	O
prey	O
association	O
on	O
mouse	B
foraging	O
success	O
.	O

3	O
.	O

Within	O
mouse-	B
and	O
predator	O
-	O
proof	O
enclosures	O
,	O
we	O
created	O
grids	O
of	O
100	O
sand	O
-	O
filled	O
Petri	O
dishes	O
and	O
buried	O
peanut	B
pieces	O
in	O
a	O
set	O
number	O
of	O
these	O
patches	O
to	O
represent	O
visually	O
cryptic	O
'	O
prey	O
'	O
.	O

By	O
adding	O
peanut	B
oil	O
to	O
selected	O
dishes	O
,	O
we	O
varied	O
the	O
spatial	O
distribution	O
of	O
prey	O
odour	O
relative	O
to	O
the	O
distribution	O
of	O
prey	O
patches	O
in	O
each	O
grid	O
,	O
to	O
reflect	O
different	O
levels	O
of	O
cue	O
patchiness	O
(	O
Experiment	O
1	O
)	O
,	O
odour	O
strength	O
(	O
Experiment	O
2	O
)	O
and	O
cue	O
-	O
prey	O
association	O
(	O
Experiment	O
3	O
)	O
.	O

We	O
measured	O
the	O
overnight	O
foraging	O
success	O
of	O
individual	O
mice	B
(	O
percentage	O
of	O
searched	O
patches	O
containing	O
prey	O
)	O
,	O
as	O
well	O
as	O
their	O
foraging	O
activity	O
(	O
percentage	O
of	O
patches	O
searched	O
)	O
,	O
and	O
prey	O
survival	O
(	O
percentage	O
of	O
unsearched	O
prey	O
patches	O
)	O
.	O

4	O
.	O

Mouse	B
foraging	O
success	O
was	O
highest	O
where	O
odour	O
cues	O
were	O
patchy	O
rather	O
than	O
uniform	O
(	O
Experiment	O
1	O
)	O
,	O
and	O
where	O
cues	O
were	O
tightly	O
associated	O
with	O
prey	O
location	O
,	O
rather	O
than	O
randomly	O
or	O
uniformly	O
distributed	O
(	O
Experiment	O
3	O
)	O
.	O

However	O
,	O
when	O
cues	O
at	O
prey	O
patches	O
were	O
ten	O
times	O
stronger	O
than	O
a	O
uniformly	O
distributed	O
weak	O
background	O
odour	O
,	O
mice	B
did	O
not	O
improve	O
their	O
foraging	O
success	O
over	O
that	O
experienced	O
when	O
cues	O
were	O
of	O
uniform	O
strength	O
and	O
distribution	O
(	O
Experiment	O
2	O
)	O
.	O

5	O
.	O

These	O
results	O
suggest	O
that	O
spatial	O
variability	O
and	O
cue	O
context	O
are	O
important	O
means	O
by	O
which	O
olfactory	O
predators	O
can	O
use	O
deposited	O
odour	O
cues	O
to	O
locate	O
visually	O
cryptic	O
prey	O
.	O

They	O
also	O
indicate	O
that	O
chemical	O
crypsis	O
can	O
disrupt	O
these	O
search	O
processes	O
as	O
effectively	O
as	O
background	O
matching	O
in	O
visually	O
based	O
predator	O
-	O
prey	O
systems	O
.	O

Comparison	O
of	O
transgene	O
expression	O
in	O
Aedes	B
aegypti	I
generated	O
by	O
mariner	O
Mos1	O
transposition	O
and	O
PhiC31	O
site	O
-	O
directed	O
recombination	O
.	O

Transgenic	O
mosquitoes	O
generated	O
by	O
transposable	O
elements	O
(	O
TEs	O
)	O
often	O
poorly	O
express	O
transgenes	O
owing	O
to	O
position	O
effects	O
.	O

To	O
avoid	O
these	O
effects	O
,	O
the	O
PhiC31	O
site	O
-	O
directed	O
recombination	O
system	O
was	O
used	O
to	O
insert	O
transgenes	O
into	O
a	O
locus	O
favourable	O
for	O
gene	O
expression	O
in	O
Aedes	B
aegypti	I
.	O

We	O
describe	O
phenotypes	O
of	O
mariner	O
Mos1	O
TE	O
and	O
PhiC31	O
transgenic	O
mosquitoes	O
expressing	O
the	O
enhanced	O
green	O
fluorescent	O
protein	O
(	O
EGFP	O
)	O
reporter	O
in	O
midguts	O
of	O
blood	O
-	O
fed	O
females	O
.	O

Mosquitoes	O
of	O
nine	O
TE	O
-	O
generated	O
lines	O
[	O
estimated	O
transformation	O
frequency	O
(	O
TF	O
)	O
:	O
9.3	O
%	O
]	O
clearly	O
expressed	O
the	O
eye	O
-	O
specific	O
selection	O
marker	O
but	O
only	O
2	O
/	O
9	O
lines	O
robustly	O
expressed	O
the	O
EGFP	O
reporter	O
.	O

The	O
piggyBac	O
TE	O
-	O
generated	O
PhiC31	O
docking	O
strain	O
,	O
attP26	O
,	O
supported	O
recombination	O
with	O
attB	O
site	O
containing	O
donors	O
at	O
an	O
estimated	O
TF	O
of	O
1.7	O
-	O
4.9	O
%	O
.	O

Using	O
a	O
codon	O
-	O
optimized	O
PhiC31	O
integrase	O
mutant	O
instead	O
of	O
the	O
'	O
wild	O
-	O
type	O
'	O
enzyme	O
did	O
not	O
affect	O
TF	O
.	O

Site	O
-	O
directed	O
recombination	O
of	O
line	O
attP26	O
with	O
an	O
attB	O
-	O
containing	O
donor	O
expressing	O
EGFP	O
from	O
the	O
Ae	B
.	I

aegypti	B
carboxypeptidase	O
promoter	O
produced	O
one	O
transgenic	O
line	O
with	O
blood	O
-	O
fed	O
females	O
expressing	O
the	O
reporter	O
in	O
midgut	O
tissue	O
.	O

Docking	O
strain	O
attP26	O
also	O
supported	O
robust	O
expression	O
of	O
Flock	B
House	I
virus	I
B2	I
from	O
the	O
Ae	B
.	I

aegypti	B
polyubiquitin	O
promoter	O
.	O

Our	O
data	O
confirm	O
that	O
eye	O
-	O
specific	O
selection	O
marker	O
expression	O
alone	O
is	O
not	O
a	O
reliable	O
indicator	O
for	O
robust	O
gene	O
-	O
of	O
-	O
interest	O
expression	O
in	O
Ae	B
.	I

aegypti	B
and	O
that	O
the	O
PhiC31	O
system	O
can	O
ensure	O
predictable	O
transgene	O
expression	O
in	O
this	O
mosquito	O
species	O
.	O

Citrate	O
uptake	O
in	O
exchange	O
with	O
intermediates	O
in	O
the	O
citrate	O
metabolic	O
pathway	O
in	O
Lactococcus	B
lactis	I
IL1403	O
.	O

Carbohydrate	O
/	O
citrate	O
cometabolism	O
in	O
Lactococcus	B
lactis	I
results	O
in	O
the	O
formation	O
of	O
the	O
flavor	O
compound	O
acetoin	O
.	O

Resting	O
cells	O
of	O
strain	O
IL1403	B
(	O
pFL3	O
)	O
rapidly	O
consumed	O
citrate	O
while	O
producing	O
acetoin	O
when	O
substoichiometric	O
concentrations	O
of	O
glucose	O
or	O
l	O
-	O
lactate	O
were	O
present	O
.	O

A	O
proton	O
motive	O
force	O
was	O
generated	O
by	O
electrogenic	O
exchange	O
of	O
citrate	O
and	O
lactate	O
catalyzed	O
by	O
the	O
citrate	O
transporter	O
CitP	O
and	O
proton	O
consumption	O
in	O
decarboxylation	O
reactions	O
in	O
the	O
pathway	O
.	O

In	O
the	O
absence	O
of	O
glucose	O
or	O
l	O
-	O
lactate	O
,	O
citrate	O
consumption	O
was	O
biphasic	O
.	O

During	O
the	O
first	O
phase	O
,	O
hardly	O
any	O
citrate	O
was	O
consumed	O
.	O

In	O
the	O
second	O
phase	O
,	O
citrate	O
was	O
converted	O
rapidly	O
,	O
but	O
without	O
the	O
formation	O
of	O
acetoin	O
.	O

Instead	O
,	O
significant	O
amounts	O
of	O
the	O
intermediates	O
pyruvate	O
and	O
alpha	O
-	O
acetolactate	O
,	O
and	O
the	O
end	O
product	O
acetate	O
,	O
were	O
excreted	O
from	O
the	O
cells	O
.	O

It	O
is	O
shown	O
that	O
the	O
intermediates	O
and	O
acetate	O
are	O
excreted	O
in	O
exchange	O
with	O
the	O
uptake	O
of	O
citrate	O
catalyzed	O
by	O
CitP.	O
The	O
availability	O
of	O
exchangeable	O
substrates	O
in	O
the	O
cytoplasm	O
determines	O
both	O
the	O
rate	O
of	O
citrate	O
consumption	O
and	O
the	O
end	O
product	O
profile	O
.	O

It	O
follows	O
that	O
citrate	O
metabolism	O
in	O
L.	B
lactis	I
IL1403	O
(	O
pFL3	O
)	O
splits	O
up	O
in	O
two	O
routes	O
after	O
the	O
formation	O
of	O
pyruvate	O
,	O
one	O
the	O
well	O
-	O
characterized	O
route	O
yielding	O
acetoin	O
and	O
the	O
other	O
a	O
new	O
route	O
yielding	O
acetate	O
.	O

The	O
flux	O
distribution	O
between	O
the	O
two	O
branches	O
changes	O
from	O
85:15	O
in	O
the	O
presence	O
of	O
l	O
-	O
lactate	O
to	O
30:70	O
in	O
the	O
presence	O
of	O
pyruvate	O
.	O

The	O
proton	O
motive	O
force	O
generated	O
was	O
greatest	O
in	O
the	O
presence	O
of	O
l	O
-	O
lactate	O
and	O
zero	O
in	O
the	O
presence	O
of	O
pyruvate	O
,	O
suggesting	O
that	O
the	O
pathway	O
to	O
acetate	O
does	O
not	O
generate	O
proton	O
motive	O
force	O
.	O

OsHMA3	O
,	O
a	O
P1B	O
-	O
type	O
of	O
ATPase	O
affects	O
root	O
-	O
to	O
-	O
shoot	O
cadmium	O
translocation	O
in	O
rice	B
by	O
mediating	O
efflux	O
into	O
vacuoles	O
.	O

*	O
The	O
cadmium	O
(	O
Cd	O
)	O
over	O
-	O
accumulating	O
rice	B
(	O
Oryza	B
sativa	I
)	O
cv	B
Cho	I
-	I
Ko	I
-	I
Koku	I
was	O
previously	O
shown	O
to	O
have	O
an	O
enhanced	O
rate	O
of	O
root	O
-	O
to	O
-	O
shoot	O
Cd	O
translocation	O
.	O

This	O
trait	O
is	O
controlled	O
by	O
a	O
single	O
recessive	O
allele	O
located	O
at	O
qCdT7	O
.	O

*	O
In	O
this	O
study	O
,	O
using	O
positional	O
cloning	O
and	O
transgenic	O
strategies	O
,	O
heavy	O
metal	O
ATPase	O
3	O
(	O
OsHMA3	O
)	O
was	O
identified	O
as	O
the	O
gene	O
that	O
controls	O
root	O
-	O
to	O
-	O
shoot	O
Cd	O
translocation	O
rates	O
.	O

The	O
subcellular	O
localization	O
and	O
Cd	O
-	O
transporting	O
activity	O
of	O
the	O
gene	O
products	O
were	O
also	O
investigated	O
.	O

*	O
The	O
allele	O
of	O
OsHMA3	O
that	O
confers	O
high	O
root	O
-	O
to	O
-	O
shoot	O
Cd	O
translocation	O
rates	O
(	O
OsHMA3mc	O
)	O
encodes	O
a	O
defective	O
P	O
(	O
1B	O
)	O
-ATPase	O
transporter	O
.	O

OsHMA3	O
fused	O
to	O
green	O
fluorescent	O
protein	O
was	O
localized	O
to	O
vacuolar	O
membranes	O
in	O
plants	O
and	O
yeast	B
.	O

An	O
OsHMA3	O
transgene	O
complemented	O
Cd	O
sensitivity	O
in	O
a	O
yeast	B
mutant	O
that	O
lacks	O
the	O
ability	O
to	O
transport	O
Cd	O
into	O
vacuoles	O
.	O

By	O
contrast	O
,	O
OsHMA3mc	O
did	O
not	O
complement	O
the	O
Cd	O
sensitivity	O
of	O
this	O
yeast	B
mutant	O
,	O
indicating	O
that	O
the	O
OsHMA3mc	O
transport	O
function	O
was	O
lost	O
.	O

*	O
We	O
propose	O
that	O
the	O
root	O
cell	O
cytoplasm	O
of	O
Cd	O
-	O
overaccumulating	O
rice	B
plants	I
has	O
more	O
Cd	O
available	O
for	O
loading	O
into	O
the	O
xylem	O
as	O
a	O
result	O
of	O
the	O
lack	O
of	O
OsHMA3-mediated	O
transportation	O
of	O
Cd	O
to	O
the	O
vacuoles	O
.	O

This	O
defect	O
results	O
in	O
Cd	O
translocation	O
to	O
the	O
shoots	O
in	O
higher	O
concentrations	O
.	O

These	O
data	O
demonstrate	O
the	O
importance	O
of	O
vacuolar	O
sequestration	O
for	O
Cd	O
accumulation	O
in	O
rice	B
.	O

Functional	O
and	O
phylogenetic	O
analysis	O
of	O
ureD	O
in	O
Shiga	O
toxin	O
-	O
producing	O
Escherichia	B
coli	I
.	O

Enterohemorrhagic	O
Escherichia	B
coli	I
(	O
EHEC	B
)	O
is	O
a	O
food	O
-	O
borne	O
pathogen	O
that	O
can	O
cause	O
severe	O
health	O
complications	O
and	O
utilizes	O
a	O
much	O
lower	O
infectious	O
dose	O
than	O
other	O
E.	B
coli	I
pathotypes	O
.	O

Despite	O
having	O
an	O
intact	O
ure	O
locus	O
,	O
ureDABCEFG	O
,	O
the	O
majority	O
of	O
EHEC	B
strains	O
are	O
phenotypically	O
urease	O
negative	O
under	O
tested	O
conditions	O
.	O

Urease	O
activity	O
potentially	O
assists	O
with	O
survival	O
fitness	O
by	O
enhancing	O
acid	O
tolerance	O
during	O
passage	O
through	O
the	O
stomach	O
or	O
by	O
aiding	O
with	O
colonization	O
in	O
either	O
human	B
or	O
animal	O
reservoirs	O
.	O

Previously	O
,	O
in	O
the	O
EHEC	B
O157	I
:	I
H7	I
Sakai	O
strain	O
,	O
a	O
point	O
mutation	O
in	O
ureD	O
,	O
encoding	O
a	O
urease	O
chaperone	O
protein	O
,	O
was	O
identified	O
,	O
resulting	O
in	O
a	O
substitution	O
of	O
an	O
amber	O
stop	O
codon	O
for	O
glutamine	O
.	O

This	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
is	O
observed	O
in	O
the	O
majority	O
of	O
EHEC	B
O157	I
:	I
H7	I
isolates	O
and	O
correlates	O
with	O
a	O
negative	O
urease	O
phenotype	O
in	O
vitro	O
.	O

We	O
demonstrate	O
that	O
the	O
lack	O
of	O
urease	O
activity	O
in	O
vitro	O
is	O
not	O
solely	O
due	O
to	O
the	O
amber	O
codon	O
in	O
ureD.	O
Our	O
analysis	O
has	O
identified	O
two	O
additional	O
SNPs	O
in	O
ureD	O
affecting	O
amino	O
acid	O
positions	O
38	O
and	O
205	O
,	O
in	O
both	O
cases	O
determining	O
whether	O
the	O
encoded	O
amino	O
acid	O
is	O
leucine	O
or	O
proline	O
.	O

Phylogenetic	O
analysis	O
based	O
on	O
Ure	O
protein	O
sequences	O
from	O
a	O
variety	O
of	O
urease	O
-	O
encoding	O
bacteria	O
demonstrates	O
that	O
the	O
proline	O
at	O
position	O
38	O
is	O
highly	O
conserved	O
among	O
Gram	O
-	O
negative	O
bacteria	O
.	O

Experiments	O
reveal	O
that	O
the	O
L38P	O
substitution	O
enhances	O
urease	O
enzyme	O
activity	O
;	O
however	O
,	O
the	O
L205P	O
substitution	O
does	O
not	O
.	O

Multilocus	O
sequence	O
typing	O
analysis	O
for	O
a	O
variety	O
of	O
Shiga	O
toxin	O
-	O
producing	O
E.	B
coli	I
isolates	O
combined	O
with	O
the	O
ureD	O
sequence	O
reveals	O
that	O
except	O
for	O
a	O
subset	O
of	O
the	O
O157	B
:	I
H7	I
strains	O
,	O
neither	O
the	O
in	O
vitro	O
urease	O
-	O
positive	O
phenotype	O
nor	O
the	O
ureD	O
sequence	O
is	O
phylogenetically	O
restricted	O
.	O

Genome	O
-	O
wide	O
identification	O
of	O
Mycobacterium	B
tuberculosis	I
exported	O
proteins	O
with	O
roles	O
in	O
intracellular	O
growth	O
.	O

The	O
exported	O
proteins	O
of	O
Mycobacterium	B
tuberculosis	I
that	O
are	O
localized	O
at	O
the	O
bacterial	O
cell	O
surface	O
or	O
secreted	O
into	O
the	O
environment	O
are	O
ideally	O
situated	O
to	O
interact	O
with	O
host	O
factors	O
and	O
to	O
function	O
in	O
virulence	O
.	O

In	O
this	O
study	O
,	O
we	O
constructed	O
a	O
novel	O
Beta	O
-	O
lactamase	O
reporter	O
transposon	O
and	O
used	O
it	O
directly	O
in	O
M.	B
tuberculosis	I
for	O
genome	O
-	O
wide	O
identification	O
of	O
exported	O
proteins	O
.	O

From	O
177	O
Beta	O
-	O
lactam	O
-	O
resistant	O
transposon	O
mutants	O
,	O
we	O
identified	O
111	O
different	O
exported	O
proteins	O
.	O

The	O
majority	O
of	O
these	O
proteins	O
have	O
no	O
known	O
function	O
,	O
and	O
for	O
nearly	O
half	O
of	O
the	O
proteins	O
,	O
our	O
demonstration	O
that	O
they	O
are	O
exported	O
when	O
fused	O
to	O
a	O
Beta	O
-	O
lactamase	O
reporter	O
is	O
the	O
first	O
experimental	O
proof	O
of	O
their	O
extracytoplasmic	O
localization	O
.	O

The	O
transposon	O
mutants	O
in	O
our	O
banked	O
library	O
were	O
of	O
further	O
value	O
as	O
a	O
collection	O
of	O
mutants	O
lacking	O
individual	O
exported	O
proteins	O
.	O

By	O
individually	O
testing	O
each	O
of	O
111	O
mutants	O
for	O
growth	O
in	O
macrophages	O
,	O
six	O
attenuated	O
mutants	O
with	O
insertions	O
in	O
mce1A	O
,	O
mce1B	O
,	O
mce2F	O
,	O
rv0199	O
,	O
ctaC	O
,	O
and	O
lppX	O
were	O
identified	O
.	O

Given	O
that	O
much	O
of	O
the	O
M.	B
tuberculosis	I
genome	O
encodes	O
proteins	O
of	O
unknown	O
function	O
,	O
our	O
library	O
of	O
mapped	O
transposon	O
mutants	O
is	O
a	O
valuable	O
resource	O
for	O
efforts	O
in	O
functional	O
genomics	O
.	O

This	O
work	O
also	O
demonstrates	O
the	O
power	O
of	O
a	O
Beta	O
-	O
lactamase	O
reporter	O
transposon	O
that	O
could	O
be	O
applied	O
similarly	O
to	O
other	O
bacterial	O
pathogens	O
.	O

Infraciliature	O
of	O
eight	O
Triplumaria	O
species	O
(	O
Ciliophora	O
,	O
Entodiniomorphida	O
)	O
from	O
Asian	B
elephants	I
with	O
the	O
description	O
of	O
six	O
new	O
species	O
.	O

Intestinal	O
ciliates	O
excreted	O
in	O
the	O
feces	O
of	O
Asian	B
elephants	I
were	O
surveyed	O
.	O

Fourteen	O
species	O
in	O
the	O
order	O
Entodiniomorphida	O
were	O
detected	O
.	O

Nine	O
Triplumaria	O
species	O
in	O
the	O
family	O
Cycloposthiidae	O
were	O
found	O
.	O

Using	O
the	O
silver	O
impregnation	O
,	O
two	O
known	O
species	O
,	O
T.	O
antis	O
and	O
T.	O
dvoinosi	O
,	O
were	O
redescribed	O
and	O
six	O
new	O
species	O
,	O
T.	O
sukuna	O
n.	O

sp.	O
,	O
T.	O
zuze	O

n.	O
sp.	O
,	O
T.	O
solea	O

n.	O
sp.	O

,	O
T.	O
suwako	O
n.	O
sp.	O
,	O
T.	O
fulgora	O
n.	O
sp.	O
,	O
and	O
T.	O
harpagonis	O
n.	O
sp.	O
,	O
were	O
described	O
.	O

T.	O
sukuna	O
,	O
T.	O
zuze	O
,	O
T.	O
solea	O
,	O
and	O
T.	O
suwako	O
have	O
the	O
perivestibular	O
polybrachykinety	O
along	O
the	O
vestibular	O
opening	O
.	O

The	O
buccal	O
infraciliary	O
bands	O
of	O
T.	O
suwako	O
are	O
similar	O
to	O
those	O
of	O
T.	B
selenica	I
found	O
from	O
elephants	O
and	O
the	O
buccal	O
infraciliary	O
bands	O
of	O
T.	O
sukuna	O
,	O
T.	O
zuze	O
,	O
and	O
T.	O
solea	O
are	O
similar	O
to	O
those	O
of	O
T.	O
grypoclunis	O
described	O
from	O
rhinoceroses	O
.	O

T.	O
antis	O
,	O
T.	O
dvoinosi	O
,	O
T.	O
fulgora	O
,	O
and	O
T.	O
harpagonis	O
have	O
the	O
vestibular	O
polybrachykinety	O
extending	O
down	O
inside	O
the	O
vestibulum	O
as	O
found	O
in	O
rumen	O
ciliates	O
in	O
the	O
family	O
Ophryoscolecidae	O
.	O

The	O
caudalial	O
ciliary	O
zones	O
of	O
T.	O
dvoinosi	O
and	O
T.	O
fulgora	O
were	O
retractable	O
as	O
found	O
in	O
rumen	O
ophryoscolecids	O
.	O

Raabena	B
bella	I
and	O
Pseudoentodinium	O
elephantis	O
showed	O
high	O
composition	O
values	O
over	O
30	O
%	O
.	O

Ciliate	O
densities	O
in	O
the	O
three	O
fecal	O
samples	O
were	O
0.15	O
,	O
1.09	O
,	O
and	O
2.07x10	O
(	O
4	O
)	O
/	O
ml	O
.	O

Comparison	O
of	O
seasonal	O
variations	O
in	O
water	O
-	O
use	O
efficiency	O
calculated	O
from	O
the	O
carbon	O
isotope	O
composition	O
of	O
tree	O
rings	O
and	O
flux	O
data	O
in	O
a	O
temperate	O
forest	O
.	O

Tree	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
is	O
often	O
interpreted	O
in	O
terms	O
of	O
intrinsic	O
water	O
-	O
use	O
efficiency	O
(	O
WUE	O
)	O
using	O
a	O
carbon	O
isotope	O
discrimination	O
model	O
established	O
at	O
the	O
leaf	O
level	O
.	O

We	O
examined	O
whether	O
intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
could	O
be	O
used	O
to	O
assess	O
variations	O
in	O
intrinsic	O
WUE	O
(	O
W	O
(	O
g	O
)	O
,	O
the	O
ratio	O
of	O
carbon	O
assimilation	O
and	O
stomatal	O
conductance	O
to	O
water	O
)	O
and	O
variations	O
in	O
ecosystem	O
WUE	O
(	O
W	O
(	O
t	O
)	O
,	O
the	O
ratio	O
of	O
C	O
assimilation	O
and	O
transpiration	O
)	O
at	O
a	O
seasonal	O
scale	O
.	O

Intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
was	O
measured	O
in	O
30-	O
to	O
60-mum	O
-	O
thick	O
slices	O
in	O
eight	O
oak	O
trees	O
(	O
Quercus	B
petraea	I
)	O
.	O

Canopy	O
W	O
(	O
g	O
)	O
was	O
simulated	O
using	O
a	O
physiologically	O
process	O
-	O
based	O
model	O
.	O

High	O
between	O
-	O
tree	O
variability	O
was	O
observed	O
in	O
the	O
seasonal	O
variations	O
of	O
intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C.	O
Six	O
trees	O
showed	O
significant	O
positive	O
correlations	O
between	O
W	O
(	O
g	O
)	O
calculated	O
from	O
intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
and	O
canopy	O
W	O
(	O
g	O
)	O
averaged	O
over	O
several	O
days	O
during	O
latewood	O
formation	O
.	O

These	O
results	O
suggest	O
that	O
latewood	O
is	O
a	O
seasonal	O
recorder	O
of	O
W	O
(	O
g	O
)	O
trends	O
,	O
with	O
a	O
temporal	O
lag	O
corresponding	O
to	O
the	O
mixing	O
time	O
of	O
sugars	O
in	O
the	O
phloem	O
.	O

These	O
six	O
trees	O
also	O
showed	O
significant	O
negative	O
correlations	O
between	O
photosynthetic	O
discrimination	O
Delta	O
calculated	O
from	O
intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
,	O
and	O
ecosystem	O
W	O
(	O
t	O
)	O
,	O
during	O
latewood	O
formation	O
.	O

Despite	O
the	O
observed	O
between	O
-	O
tree	O
variability	O
,	O
these	O
results	O
indicate	O
that	O
intra	O
-	O
ring	O
delta	O
(	O
13	O
)	O
C	O
can	O
be	O
used	O
to	O
access	O
seasonal	O
variations	O
in	O
past	O
W	O
(	O
t	O
)	O
.	O

Neuropeptide	O
precursor	O
gene	O
discovery	O
in	O
the	O
Chagas	O
disease	O
vector	O
Rhodnius	B
prolixus	I
.	O

We	O
show	O
a	O
straightforward	O
workflow	O
combining	O
homology	O
search	O
in	O
Rhodnius	B
prolixus	I
genome	O
sequence	O
with	O
cloning	O
by	O
rapid	O
amplification	O
of	O
cDNA	O
ends	O
and	O
mass	O
spectrometry	O
.	O

We	O
have	O
identified	O
32	O
genes	O
and	O
their	O
transcripts	O
that	O
encode	O
a	O
number	O
of	O
neuropeptide	O
precursors	O
leading	O
to	O
194	O
putative	O
peptides	O
.	O

We	O
validated	O
by	O
mass	O
spectrometry	O
82	O
of	O
those	O
predicted	O
neuropeptides	O
in	O
the	O
brain	O
of	O
R.	B
prolixus	I
to	O
achieve	O
the	O
first	O
comprehensive	O
genomic	O
,	O
transcriptomic	O
and	O
neuropeptidomic	O
analysis	O
of	O
an	O
insect	O
disease	O
vector	O
.	O

Comparisons	O
of	O
available	O
insect	O
neuropeptide	O
sequences	O
revealed	O
that	O
the	O
R.	B
prolixus	I
genome	O
contains	O
most	O
of	O
the	O
conserved	O
neuropeptides	O
in	O
insects	O
,	O
many	O
of	O
them	O
displaying	O
specific	O
features	O
at	O
the	O
sequence	O
level	O
.	O

Some	O
gene	O
families	O
reported	O
here	O
are	O
identified	O
for	O
the	O
first	O
time	O
in	O
the	O
order	O
Hemiptera	O
,	O
a	O
highly	O
biodiverse	O
group	O
of	O
insects	O
that	O
includes	O
many	O
human	B
,	O
animal	O
and	O
plant	O
disease	O
agents	O
.	O

Resistance	O
and	O
recovery	O
of	O
soil	O
microbial	O
communities	O
in	O
the	O
face	O
of	O
Alliaria	B
petiolata	I
invasions	O
.	O

Invaders	O
can	O
gain	O
ecological	O
advantages	O
because	O
of	O
their	O
evolutionary	O
novelty	O
,	O
but	O
little	O
is	O
known	O
about	O
how	O
these	O
novel	O
advantages	O
will	O
change	O
over	O
time	O
as	O
the	O
invader	O
and	O
invaded	O
community	O
evolve	O
in	O
response	O
to	O
each	O
other	O
.	O

Invasive	O
plants	O
often	O
gain	O
such	O
an	O
advantage	O
through	O
alteration	O
of	O
soil	O
microbial	O
communities	O
.	O

In	O
soil	O
communities	O
sampled	O
from	O
sites	O
along	O
a	O
gradient	O
of	O
invasion	O
history	O
with	O
Alliaria	B
petiolata	I
,	O
microbial	O
richness	O
tended	O
to	O
decline	O
,	O
but	O
the	O
community	O
's	O
resistance	O
to	O
A.	B
petiolata	I
's	O
effects	O
generally	O
increased	O
with	O
increasing	O
history	O
of	O
invasion	O
.	O

However	O
,	O
sensitive	O
microbial	O
taxa	O
appeared	O
to	O
recover	O
in	O
the	O
two	O
oldest	O
sites	O
,	O
leading	O
to	O
an	O
increase	O
in	O
richness	O
,	O
but	O
consequent	O
decrease	O
in	O
resistance	O
.	O

This	O
may	O
be	O
because	O
of	O
evolutionary	O
changes	O
in	O
the	O
A.	B
petiolata	I
populations	O
,	O
which	O
tend	O
to	O
reduce	O
their	O
investment	O
to	O
allelopathic	O
compounds	O
over	O
time	O
.	O

These	O
results	O
show	O
that	O
,	O
over	O
time	O
,	O
microbial	O
communities	O
can	O
develop	O
resistance	O
to	O
an	O
invasive	O
plant	O
but	O
at	O
the	O
cost	O
of	O
lower	O
richness	O
.	O

However	O
,	O
over	O
longer	O
time	O
-	O
scales	O
evolution	O
in	O
the	O
invasive	O
species	O
may	O
allow	O
for	O
the	O
recovery	O
of	O
soil	O
microbial	O
communities	O
.	O

Streptococcus	B
ursoris	I
sp.	I
nov.	I
,	O
isolated	O
from	O
the	O
oral	O
cavities	O
of	O
bears	O
.	O

Three	O
Gram	O
-	O
positive	O
,	O
catalase	O
-	O
negative	O
,	O
coccus	O
-	O
shaped	O
organisms	O
were	O
isolated	O
from	O
the	O
oral	O
cavities	O
of	O
bears	O
.	O

The	O
isolates	O
were	O
tentatively	O
identified	O
as	O
a	O
streptococcal	O
species	O
based	O
on	O
the	O
results	O
of	O
biochemical	O
tests	O
.	O

Comparative	O
16S	O
rRNA	O
gene	O
sequencing	O
studies	O
confirmed	O
that	O
the	O
organisms	O
were	O
members	O
of	O
the	O
genus	O
Streptococcus	O
,	O
but	O
they	O
did	O
not	O
correspond	O
to	O
any	O
recognized	O
species	O
of	O
the	O
genus	O
.	O

The	O
nearest	O
phylogenetic	O
relative	O
of	O
the	O
new	O
isolates	O
was	O
Streptococcus	B
ratti	I
ATCC	I
19645	I
(	O
T	O
)	O
(	O
98.6	O
%	O
)	O
,	O
however	O
,	O
DNA	O
-	O
DNA	O
hybridization	O
analysis	O
showed	O
that	O
the	O
isolates	O
displayed	O
less	O
than	O
15	O
%	O
DNA	O
-	O
DNA	O
relatedness	O
with	O
the	O
type	O
strain	O
of	O
S.	B
ratti	I
.	O

Colonies	O
of	O
the	O
novel	O
strains	O
grown	O
on	O
mitis	O
salivarius	O
agar	O
showed	O
an	O
extracellular	O
polysaccharide	O
-	O
producing	O
colony	O
morphology	O
.	O

Based	O
on	O
phenotypic	O
and	O
phylogenetic	O
evidence	O
,	O
it	O
is	O
proposed	O
that	O
the	O
novel	O
isolates	O
are	O
classified	O
in	O
the	O
genus	O
Streptococcus	O
as	O
Streptococcus	B
ursoris	I
sp.	I
nov.	I
The	O
type	O
strain	O
of	O
S.	B
ursoris	I
is	O
NUM	B
1615	I
(	I
T	I
)	O
(	O
=	O
JCM	O
16316	O
(	O
T	O
)	O
=DSM	O
22768	O
(	O
T	O
)	O
)	O
.	O

Rarity	O
,	O
life	O
history	O
and	O
scaling	O
of	O
the	O
dynamics	O
in	O
time	O
and	O
space	O
of	O
British	O
birds	O
.	O

1	O
.	O

Many	O
patterns	O
in	O
macroecology	O
are	O
closely	O
related	O
to	O
the	O
total	O
abundance	O
of	O
a	O
species	O
in	O
a	O
region	O
.	O

Here	O
we	O
show	O
that	O
interspecific	O
differences	O
in	O
the	O
pattern	O
of	O
population	O
fluctuations	O
of	O
British	O
bird	O
species	O
can	O
be	O
predicted	O
from	O
knowledge	O
of	O
their	O
overall	O
abundance	O
and	O
some	O
basic	O
life	O
-	O
history	O
characteristics	O
.	O

2	O
.	O

We	O
identify	O
a	O
rarity	O
syndrome	O
that	O
arises	O
through	O
an	O
increased	O
stochastic	O
influence	O
on	O
population	O
fluctuations	O
with	O
decreasing	O
population	O
size	O
,	O
mainly	O
resulting	O
from	O
an	O
inverse	O
density	O
-	O
dependent	O
effect	O
of	O
demographic	O
stochasticity	O
.	O

This	O
syndrome	O
involves	O
an	O
increase	O
in	O
the	O
annual	O
changes	O
in	O
population	O
size	O
with	O
increasing	O
rarity	O
in	O
the	O
United	O
Kingdom	O
.	O

3	O
.	O

The	O
relationship	O
between	O
the	O
magnitude	O
of	O
temporal	O
variation	O
and	O
local	O
mean	O
population	O
size	O
differs	O
between	O
species	O
dependent	O
on	O
their	O
life	O
history	O
,	O
i.e.	O
species	O
with	O
larger	O
clutch	O
size	O
and	O
lower	O
survival	O
tended	O
to	O
have	O
larger	O
annual	O
changes	O
in	O
population	O
size	O
than	O
low	O
-	O
reproducing	O
long	O
-	O
lived	O
species	O
.	O

4	O
.	O

The	O
probability	O
of	O
local	O
disappearance	O
from	O
a	O
study	O
plot	O
depended	O
on	O
the	O
population	O
size	O
and	O
was	O
hence	O
closely	O
related	O
to	O
the	O
overall	O
abundance	O
of	O
the	O
species	O
in	O
UK	O
.	O

For	O
a	O
given	O
population	O
size	O
,	O
this	O
probability	O
was	O
also	O
related	O
to	O
species	O
-	O
specific	O
life	O
-	O
history	O
characteristics	O
,	O
being	O
higher	O
in	O
species	O
with	O
larger	O
clutch	O
sizes	O
and	O
smaller	O
survival	O
rates	O
.	O

5	O
.	O

Rareness	O
results	O
in	O
a	O
spatial	O
decoupling	O
of	O
the	O
temporal	O
variation	O
in	O
population	O
size	O
.	O

6	O
.	O

These	O
patterns	O
show	O
that	O
once	O
a	O
species	O
has	O
become	O
rare	O
,	O
e.g.	O
due	O
to	O
human	B
activities	O
,	O
key	O
population	O
dynamical	O
characteristics	O
will	O
change	O
because	O
of	O
density	O
-	O
dependent	O
stochastic	O
effects	O
,	O
which	O
in	O
turn	O
are	O
dependent	O
on	O
species	O
-	O
specific	O
life	O
-	O
history	O
characteristics	O
.	O

Influence	O
of	O
helix	O
12	O
of	O
Ultraspiracle	O
on	O
Drosophila	B
melanogaster	I
ecdysone	O
receptor	O
function	O
.	O

Although	O
it	O
has	O
no	O
ligand	O
,	O
helix	O
12	O
in	O
the	O
ligand	O
binding	O
domain	O
of	O
Ultraspiracle	O
(	O
USP	O
)	O
is	O
locked	O
in	O
an	O
antagonistic	O
position	O
.	O

To	O
investigate	O
whether	O
this	O
position	O
is	O
of	O
functional	O
importance	O
,	O
we	O
enhanced	O
the	O
flexibility	O
of	O
helix	O
12	O
by	O
mutating	O
two	O
amino	O
acids	O
(	O
259	O
,	O
located	O
in	O
L1	O
-	O
3	O
and	O
F491	O
in	O
helix	O
12	O
)	O
.	O

Mutated	O
USP	O
reduces	O
the	O
stability	O
of	O
USP	O
and	O
all	O
isoforms	O
of	O
the	O
ecdysone	O
receptor	O
(	O
EcR	O
)	O
and	O
impairs	O
nuclear	O
localization	O
and	O
DNA	O
binding	O
of	O
EcR	O
/	O
USP	O
(	O
L259A	O
/	O
F491	O
/	O
A	O
)	O
,	O
resulting	O
in	O
lower	O
levels	O
of	O
basal	O
transcriptional	O
activity	O
.	O

Although	O
the	O
affinity	O
of	O
the	O
ligand	O
ponasterone	O
A	O
to	O
EcR	O
/	O
USP	O
(	O
L259	O
/	O
F491	O
)	O
is	O
moderately	O
diminished	O
,	O
hormone	O
-	O
induced	O
stimulation	O
of	O
transcriptional	O
activity	O
is	O
normal	O
.	O

Potentiation	O
of	O
the	O
ecdysone	O
response	O
by	O
juvenile	O
hormone	O
(	O
JH	O
)	O
is	O
selectively	O
increased	O
in	O
mutated	O
heterodimers	O
with	O
EcR	O
-	O
B1	O
,	O
demonstrating	O
that	O
the	O
antagonistic	O
position	O
impairs	O
functional	O
interaction	O
of	O
the	O
EcR	O
complex	O
with	O
JHIII	O
.	O

The	O
rise	O
of	O
chronic	O
non	O
-	O
communicable	O
diseases	O
in	O
southeast	O
Asia	O
:	O
time	O
for	O
action	O
.	O

Southeast	O
Asia	O
faces	O
an	O
epidemic	O
of	O
chronic	O
non	O
-	O
communicable	O
diseases	O
,	O
now	O
responsible	O
for	O
60	O
%	O
of	O
deaths	O
in	O
the	O
region	O
.	O

The	O
problem	O
stems	O
from	O
environmental	O
factors	O
that	O
promote	O
tobacco	B
use	O
,	O
unhealthy	O
diet	O
,	O
and	O
inadequate	O
physical	O
activity	O
.	O

Disadvantaged	O
populations	O
are	O
the	O
hardest	O
hit	O
,	O
with	O
death	O
rates	O
inversely	O
proportional	O
to	O
a	O
country	O
's	O
gross	O
national	O
income	O
.	O

Families	O
shoulder	O
the	O
financial	O
burden	O
,	O
but	O
entire	O
economies	O
suffer	O
as	O
well	O
.	O

Although	O
attempts	O
to	O
control	O
non	O
-	O
communicable	O
diseases	O
are	O
increasing	O
,	O
more	O
needs	O
to	O
be	O
done	O
.	O

Health	O
-	O
care	O
systems	O
need	O
to	O
be	O
redesigned	O
to	O
deliver	O
chronic	O
care	O
that	O
is	O
founded	O
on	O
existing	O
primary	O
health	O
-	O
care	O
facilities	O
,	O
but	O
supported	O
by	O
good	O
referral	O
systems	O
.	O

Surveillance	O
of	O
key	O
modifiable	O
risk	O
factors	O
is	O
needed	O
to	O
monitor	O
the	O
magnitude	O
of	O
the	O
problem	O
and	O
to	O
study	O
the	O
effects	O
of	O
interventions	O
.	O

All	O
branches	O
of	O
government	O
and	O
all	O
sectors	O
of	O
society	O
have	O
to	O
get	O
involved	O
in	O
establishing	O
environments	O
that	O
are	O
conducive	O
to	O
healthy	O
living	O
.	O

The	O
Association	O
of	O
Southeast	O
Asian	O
Nations	O
is	O
in	O
a	O
unique	O
position	O
to	O
make	O
a	O
united	O
stand	O
against	O
chronic	O
non	O
-	O
communicable	O
diseases	O
in	O
the	O
region	O
.	O

Inaction	O
will	O
affect	O
millions	O
of	O
lives	O
-	O
often	O
,	O
the	O
lives	O
of	O
those	O
who	O
have	O
the	O
least	O
.	O

Health	O
-	O
financing	O
reforms	O
in	O
southeast	O
Asia	O
:	O
challenges	O
in	O
achieving	O
universal	O
coverage	O
.	O

In	O
this	O
sixth	O
paper	O
of	O
the	O
Series	O
,	O
we	O
review	O
health	O
-	O
financing	O
reforms	O
in	O
seven	O
countries	O
in	O
southeast	O
Asia	O
that	O
have	O
sought	O
to	O
reduce	O
dependence	O
on	O
out	O
-	O
of	O
-	O
pocket	O
payments	O
,	O
increase	O
pooled	O
health	O
finance	O
,	O
and	O
expand	O
service	O
use	O
as	O
steps	O
towards	O
universal	O
coverage	O
.	O

Laos	O
and	O
Cambodia	O
,	O
both	O
resource	O
-	O
poor	O
countries	O
,	O
have	O
mostly	O
relied	O
on	O
donor	O
-	O
supported	O
health	O
equity	O
funds	O
to	O
reach	O
the	O
poor	O
,	O
and	O
reliable	O
funding	O
and	O
appropriate	O
identification	O
of	O
the	O
eligible	O
poor	O
are	O
two	O
major	O
challenges	O
for	O
nationwide	O
expansion	O
.	O

For	O
Thailand	O
,	O
the	O
Philippines	O
,	O
Indonesia	O
,	O
and	O
Vietnam	O
,	O
social	O
health	O
insurance	O
financed	O
by	O
payroll	O
tax	O
is	O
commonly	O
used	O
for	O
formal	O
sector	O
employees	O
(	O
excluding	O
Malaysia	O
)	O
,	O
with	O
varying	O
outcomes	O
in	O
terms	O
of	O
financial	O
protection	O
.	O

Alternative	O
payment	O
methods	O
have	O
different	O
implications	O
for	O
provider	O
behaviour	O
and	O
financial	O
protection	O
.	O

Two	O
alternative	O
approaches	O
for	O
financial	O
protection	O
of	O
the	O
non	O
-	O
poor	O
outside	O
the	O
formal	O
sector	O
have	O
emerged	O
-	O
contributory	O
arrangements	O
and	O
tax	O
-	O
financed	O
schemes	O
-	O
with	O
different	O
abilities	O
to	O
achieve	O
high	O
population	O
coverage	O
rapidly	O
.	O

Fiscal	O
space	O
and	O
mobilisation	O
of	O
payroll	O
contributions	O
are	O
both	O
important	O
in	O
accelerating	O
financial	O
protection	O
.	O

Expanding	O
coverage	O
of	O
good	O
-	O
quality	O
services	O
and	O
ensuring	O
adequate	O
human	B
resources	O
are	O
also	O
important	O
to	O
achieve	O
universal	O
coverage	O
.	O

As	O
health	O
-	O
financing	O
reform	O
is	O
complex	O
,	O
institutional	O
capacity	O
to	O
generate	O
evidence	O
and	O
inform	O
policy	O
is	O
essential	O
and	O
should	O
be	O
strengthened	O
.	O

Implementation	O
and	O
validation	O
of	O
a	O
sensitive	O
PCR	O
detection	O
method	O
in	O
the	O
eradication	O
campaign	O
against	O
Aleutian	B
mink	I
disease	I
virus	I
.	O

Aleutian	B
mink	I
disease	I
virus	I
(	I
AMDV	I
)	O
is	O
a	O
severe	O
progressive	O
disease	O
causing	O
multiple	O
different	O
clinical	O
syndromes	O
in	O
mink	B
.	O

In	O
Denmark	O
,	O
the	O
disease	O
is	O
notifiable	O
and	O
under	O
official	O
control	O
.	O

The	O
control	O
programme	O
,	O
based	O
on	O
serological	O
screening	O
,	O
has	O
confined	O
successfully	O
AMDV	B
to	O
the	O
northern	O
part	O
of	O
Denmark	O
.	O

However	O
,	O
re	O
-	O
infections	O
and	O
new	O
introductions	O
of	O
virus	O
into	O
farms	O
require	O
a	O
confirmatory	O
virological	O
test	O
to	O
verify	O
the	O
positive	O
test	O
results	O
of	O
single	O
animals	O
and	O
ultimately	O
to	O
investigate	O
disease	O
transmission	O
.	O

A	O
one	O
step	O
PCR	O
amplifying	O
a	O
374-base	O
fragment	O
of	O
the	O
NS1	O
gene	O
of	O
AMDV	B
was	O
compared	O
to	O
the	O
counter	O
-	O
current	O
immune	O
electrophoresis	O
(	O
CIE	O
)	O
routinely	O
used	O
in	O
the	O
serological	O
screening	O
programme	O
.	O

Mink	B
organs	O
(	O
n=299	O
)	O
obtained	O
from	O
55	O
recently	O
infected	O
farms	O
and	O
8	O
non	O
-	O
infected	O
farms	O
from	O
2008	O
to	O
2010	O
were	O
tested	O
by	O
PCR	O
,	O
and	O
the	O
results	O
were	O
found	O
to	O
have	O
a	O
high	O
correlation	O
with	O
the	O
serological	O
status	O
of	O
the	O
mink	B
.	O

The	O
relative	O
diagnostic	O
sensitivity	O
of	O
the	O
PCR	O
was	O
94.7	O
%	O
,	O
and	O
the	O
relative	O
diagnostic	O
specificity	O
was	O
97.9	O
%	O
when	O
read	O
in	O
parallel	O
with	O
the	O
CIE	O
.	O

PCR	O
positive	O
samples	O
were	O
sequenced	O
and	O
phylogenetic	O
analysis	O
revealed	O
high	O
similarity	O
within	O
the	O
analysed	O
AMDV	B
strains	I
and	O
to	O
AMDV	B
strains	I
described	O
previously	O
.	O

Rapid	O
and	O
sensitive	O
detection	O
of	O
infectious	B
hypodermal	I
and	I
hematopoietic	I
necrosis	I
virus	I
by	O
loop	O
-	O
mediated	O
isothermal	O
amplification	O
combined	O
with	O
a	O
lateral	O
flow	O
dipstick	O
.	O

Infectious	B
hypodermal	I
and	I
hematopoietic	I
necrosis	I
virus	I
(	O
IHHNV	B
)	O
is	O
an	O
important	O
shrimp	O
pathogen	O
that	O
causes	O
mortality	O
in	O
Penaeus	B
stylirostris	I
and	O
stunting	O
(	O
called	O
runt	O
deformity	O
syndrome	O
or	O
RDS	O
)	O
in	O
Penaeus	B
vannamei	I
.	O

Loop	O
-	O
mediated	O
isothermal	O
amplification	O
(	O
LAMP	O
)	O
allows	O
rapid	O
amplification	O
of	O
nucleic	O
acids	O
under	O
isothermal	O
conditions	O
.	O

It	O
can	O
be	O
combined	O
with	O
a	O
chromatographic	O
lateral	O
flow	O
dipstick	O
(	O
LFD	O
)	O
for	O
highly	O
specific	O
,	O
rapid	O
and	O
simple	O
visual	O
detection	O
of	O
IHHNV	B
-	O
specific	O
amplicons	O
.	O

Using	O
this	O
protocol	O
,	O
a	O
30-min	O
amplification	O
followed	O
by	O
5	O
min	O
hybridization	O
with	O
an	O
FITC	O
-	O
labeled	O
DNA	O
probe	O
and	O
5	O
min	O
LFD	O
resulted	O
in	O
visualization	O
of	O
DNA	O
amplicons	O
trapped	O
at	O
the	O
LFD	O
test	O
line	O
.	O

Thus	O
,	O
10	O
min	O
for	O
rapid	O
DNA	O
extraction	O
followed	O
by	O
LAMP	O
combined	O
with	O
LFD	O
detection	O
resulted	O
in	O
a	O
total	O
assay	O
time	O
of	O
approximately	O
50	O
min	O
.	O

Detection	O
sensitivity	O
was	O
comparable	O
to	O
other	O
methods	O
used	O
commonly	O
for	O
nested	O
PCR	O
detection	O
of	O
IHHNV	B
but	O
had	O
the	O
additional	O
advantages	O
of	O
reduced	O
assay	O
time	O
,	O
confirmation	O
of	O
amplicon	O
identity	O
by	O
hybridization	O
and	O
elimination	O
of	O
electrophoresis	O
with	O
carcinogenic	O
ethidium	O
bromide	O
.	O

Methanobacterium	O
arcticum	O
sp.	O
nov.	O
,	O
a	O
methanogenic	O
archaeon	O
from	O
Holocene	O
Arctic	O
permafrost	O
.	O

A	O
mesophilic	O
,	O
non	O
-	O
motile	O
,	O
hydrogenotrophic	O
,	O
rod	O
-	O
shaped	O
methanogen	O
,	O
designated	O
M2	B
(	I
T	I
)	O
,	O
was	O
isolated	O
from	O
Holocene	O
permafrost	O
sediments	O
of	O
the	O
Kolyma	O
lowland	O
in	O
the	O
Russian	O
Arctic	O
.	O

Cells	O
were	O
3	O
-	O
6	O
mum	O
long	O
and	O
0.45	O
-	O
0.5	O
mum	O
wide	O
.	O

Strain	O
M2	B
(	I
T	I
)	O
grew	O
on	O
H	O
(	O
2	O
)	O
/	O
CO	O
(	O
2	O
)	O
and	O
formate	O
.	O

Optimum	O
conditions	O
for	O
growth	O
were	O
37	O
^	O
0C	O
,	O
pH	O
6.8	O
-	O
7.2	O
and	O
0.1	O
M	O
NaCl	O
.	O

The	O
DNA	O
G+C	O
content	O
was	O
38.1	O
mol%	O
.	O

On	O
the	O
basis	O
of	O
16S	O
rRNA	O
gene	O
sequence	O
comparison	O
with	O
known	O
methanogens	O
,	O
strain	O
M2	B
(	I
T	I
)	O
was	O
affiliated	O
with	O
the	O
genus	O
Methanobacterium	O
and	O
was	O
most	O
closely	O
related	O
to	O
Methanobacterium	B
veterum	I
MK4	I
(	I
T	I
)	O
and	O
Methanobacterium	B
bryantii	I
DSM	B
863	I
(	I
T	I
)	O
(	O
both	O
99	O
%	O
16S	O
rRNA	O
gene	O
sequence	O
similarity	O
)	O
.	O

However	O
,	O
no	O
significant	O
DNA	O
-	O
DNA	O
relatedness	O
was	O
observed	O
between	O
strain	O
M2	B
(	I
T	I
)	O
and	O
these	O
type	O
strains	O
.	O

We	O
propose	O
that	O
strain	O
M2	B
(	I
T	I
)	O
represents	O
a	O
novel	O
species	O
,	O
with	O
the	O
name	O
Methanobacterium	O
arcticum	O
sp.	O
nov.	O
,	O
with	O
type	O
strain	O
M2	B
(	I
T	I
)	O
(	O
=	O
DSM	O
19844	O
(	O
T	O
)	O
=	O
VKM	O
B-2371	O
(	O
T	O
)	O
)	O
.	O

PsOr1	O
,	O
a	O
potential	O
target	O
for	O
RNA	O
interference	O
-	O
based	O
pest	O
management	O
.	O

Insect	O
pests	O
cause	O
billions	O
of	O
dollars	O
in	O
agricultural	O
losses	O
,	O
and	O
attempts	O
to	O
kill	O
them	O
have	O
resulted	O
in	O
growing	O
threats	O
from	O
insecticide	O
resistance	O
,	O
dietary	O
pesticide	O
pollution	O
and	O
environmental	O
destruction	O
.	O

New	O
approaches	O
to	O
control	O
refractory	O
insect	O
pests	O
are	O
therefore	O
needed	O
.	O

The	O
host	O
-	O
plant	O
preferences	O
of	O
insect	O
pests	O
rely	O
on	O
olfaction	O
and	O
are	O
mediated	O
via	O
a	O
seven	O
transmembrane	O
-	O
domain	O
odorant	O
receptor	O
(	O
Or	O
)	O
family	O
.	O

The	O
present	O
study	O
reports	O
the	O
cloning	O
and	O
characterization	O
of	O
PsOr1	O
,	O
the	O
first	O
candidate	O
member	O
of	O
the	O
Or	O
gene	O
family	O
from	O
Phyllotreta	B
striolata	I
,	O
a	O
devastating	O
beetle	O
pest	O
that	O
causes	O
damage	O
worldwide	O
.	O

PsOr1	O
is	O
remarkably	O
well	O
conserved	O
with	O
respect	O
to	O
other	O
insect	O
orthologues	O
,	O
including	O
DmOr83b	O
from	O
Drosophila	B
melanogaster	I
.	O

These	O
insect	O
orthologues	O
form	O
an	O
essential	O
non	O
-	O
conventional	O
Or	O
sub	O
-	O
family	O
and	O
may	O
play	O
an	O
important	O
and	O
generalized	O
role	O
in	O
insect	O
olfaction	O
.	O

We	O
designed	O
double	O
-	O
stranded	O
(	O
ds	O
)	O
RNA	O
directly	O
against	O
the	O
PsOr1	O
gene	O
and	O
exploited	O
RNA	O
interference	O
(	O
RNAi	O
)	O
to	O
control	O
P.	B
striolata	I
.	O

The	O
chemotactic	O
behavioural	O
measurements	O
showed	O
that	O
adult	O
beetles	O
were	O
unable	O
to	O
sense	O
the	O
attractant	O
or	O
repellent	O
odour	O
stimulus	O
after	O
microinjection	O
of	O
dsRNA	O
against	O
PsOr1	O
.	O

Reverse	O
Transcription	O
(	O
RT	O
)	O
-PCR	O
analysis	O
showed	O
specific	O
down	O
-	O
regulation	O
of	O
mRNA	O
transcript	O
levels	O
for	O
this	O
gene	O
.	O

Furthermore	O
,	O
host	O
-	O
plant	O
preference	O
experiments	O
confirmed	O
that	O
silencing	O
PsOr1	O
by	O
RNAi	O
treatment	O
impaired	O
the	O
host	O
-	O
plant	O
preferences	O
of	O
P.	B
striolata	I
for	O
cruciferous	O
vegetables	O
.	O

These	O
results	O
demonstrate	O
that	O
this	O
insect	O
control	O
approach	O
of	O
using	O
RNAi	O
to	O
target	O
PsOr1	O
and	O
its	O
orthologues	O
might	O
be	O
effective	O
in	O
blocking	O
host	O
-	O
plant	O
-	O
seeking	O
behaviours	O
in	O
diverse	O
insect	O
pests	O
.	O

The	O
results	O
also	O
support	O
the	O
theory	O
that	O
this	O
unique	O
receptor	O
type	O
plays	O
an	O
essential	O
general	O
role	O
in	O
insect	O
olfaction	O
.	O

Effective	O
management	O
in	O
clusters	O
of	O
pneumococcal	B
disease	O
:	O
a	O
systematic	O
review	O
.	O

Outbreaks	O
of	O
serious	O
pneumococcal	B
disease	O
can	O
occur	O
with	O
high	O
attack	O
rates	O
in	O
certain	O
settings	O
.	O

We	O
systematically	O
reviewed	O
studies	O
of	O
interventions	O
implemented	O
in	O
pneumococcal	B
clusters	O
and	O
those	O
reporting	O
the	O
effect	O
of	O
antibiotics	O
on	O
carriage	O
reduction	O
to	O
assess	O
the	O
effectiveness	O
of	O
interventions	O
.	O

Evidence	O
was	O
graded	O
according	O
to	O
the	O
Scottish	O
Intercollegiate	O
Guidelines	O
Network	O
system	O
.	O

Of	O
28	O
identified	O
cluster	O
reports	O
,	O
one	O
showed	O
that	O
administration	O
of	O
antibiotics	O
to	O
close	O
contacts	O
reduced	O
risk	O
of	O
pneumococcal	B
disease	O
.	O

In	O
three	O
of	O
four	O
clusters	O
where	O
rifampicin	O
chemoprophylaxis	O
was	O
used	O
and	O
in	O
four	O
of	O
five	O
clusters	O
where	O
penicillin	O
was	O
used	O
no	O
further	O
cases	O
were	O
seen	O
after	O
intervention	O
.	O

In	O
clusters	O
where	O
pneumococcal	B
polysaccharide	O
vaccine	O
was	O
used	O
,	O
subsequent	O
cases	O
occurred	O
,	O
all	O
within	O
around	O
2	O
weeks	O
of	O
vaccination	O
,	O
which	O
suggests	O
delayed	O
benefit	O
with	O
this	O
approach	O
(	O
evidence	O
grade	O
D	O
)	O
.	O

Use	O
of	O
infection	O
control	O
measures	O
alone	O
was	O
reported	O
in	O
eight	O
clusters	O
,	O
with	O
no	O
further	O
cases	O
being	O
reported	O
in	O
seven	O
(	O
grade	O
D	O
)	O
.	O

From	O
21	O
selected	O
carriage	O
studies	O
,	O
large	O
carriage	O
reductions	O
were	O
observed	O
consistently	O
with	O
use	O
of	O
penicillin	O
and	O
azithromycin	O
,	O
with	O
median	O
values	O
being	O
90	O
%	O
and	O
73	O
%	O
,	O
respectively	O
(	O
grade	O
C	O
)	O
.	O

The	O
findings	O
were	O
presented	O
to	O
a	O
working	O
group	O
for	O
pneumococcal	B
cluster	O
guidelines	O
and	O
used	O
to	O
develop	O
key	O
recommendations	O
on	O
the	O
management	O
of	O
clusters	O
that	O
supported	O
prompt	O
use	O
of	O
amoxicillin	O
or	O
azithromycin	O
chemoprophylaxis	O
,	O
pneumococcal	B
vaccination	O
for	O
close	O
contacts	O
,	O
and	O
implementation	O
of	O
infection	O
control	O
measures	O
.	O

Bacillus	B
anthracis	I
sin	O
locus	O
and	O
regulation	O
of	O
secreted	O
proteases	O
.	O

Bacillus	B
anthracis	I
shares	O
many	O
regulatory	O
loci	O
with	O
the	O
nonpathogenic	O
Bacillus	O
species	O
Bacillus	B
subtilis	I
.	O

One	O
such	O
locus	O
is	O
sinIR	O
,	O
which	O
in	O
B.	B
subtilis	I
controls	O
sporulation	O
,	O
biofilm	O
formation	O
,	O
motility	O
,	O
and	O
competency	O
.	O

As	O
B.	B
anthracis	I
is	O
not	O
known	O
to	O
be	O
motile	O
,	O
to	O
be	O
naturally	O
competent	O
,	O
or	O
to	O
readily	O
form	O
biofilms	O
,	O
we	O
hypothesized	O
that	O
the	O
B.	B
anthracis	I
sinIR	O
regulon	O
is	O
distinct	O
from	O
that	O
of	O
B.	B
subtilis	I
.	O

A	O
genome	O
-	O
wide	O
expression	O
microarray	O
analysis	O
of	O
B.	B
anthracis	I
parental	O
and	O
sinR	O
mutant	O
strains	O
indicated	O
limited	O
convergence	O
of	O
the	O
B.	B
anthracis	I
and	O
B.	B
subtilis	I
SinR	O
regulons	O
.	O

The	O
B.	B
anthracis	I
regulon	O
includes	O
homologues	O
of	O
some	O
B.	B
subtilis	I
SinR	O
-	O
regulated	O
genes	O
,	O
including	O
the	O
signal	O
peptidase	O
gene	O
sipW	O
near	O
the	O
sinIR	O
locus	O
and	O
the	O
sporulation	O
gene	O
spoIIE	O
.	O

The	O
B.	B
anthracis	I
SinR	O
protein	O
also	O
negatively	O
regulates	O
transcription	O
of	O
genes	O
adjacent	O
to	O
the	O
sinIR	O
locus	O
that	O
are	O
unique	O
to	O
the	O
Bacillus	B
cereus	I
group	I
species	I
.	O

These	O
include	O
calY	O
and	O
inhA1	O
,	O
structural	O
genes	O
for	O
the	O
metalloproteases	O
camelysin	O
and	O
immune	O
inhibitor	O
A1	O
(	O
InhA1	O
)	O
,	O
which	O
have	O
been	O
suggested	O
to	O
be	O
associated	O
with	O
virulence	O
in	O
B.	B
cereus	I
and	O
B.	B
anthracis	I
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
direct	O
binding	O
of	O
B.	B
anthracis	I
SinR	O
to	O
promoter	O
DNA	O
from	O
strongly	O
regulated	O
genes	O
,	O
such	O
as	O
calY	O
and	O
sipW	O
,	O
but	O
not	O
to	O
the	O
weakly	O
regulated	O
inhA1	O
gene	O
.	O

Assessment	O
of	O
camelysin	O
and	O
InhA1	O
levels	O
in	O
culture	O
supernates	O
from	O
sinR-	O
,	O
inhA1-	O
,	O
and	O
calY	O
-	O
null	O
mutants	O
showed	O
that	O
the	O
concentration	O
of	O
InhA1	O
in	O
the	O
culture	O
supernatant	O
is	O
inversely	O
proportional	O
to	O
the	O
concentration	O
of	O
camelysin	O
.	O

Our	O
data	O
are	O
consistent	O
with	O
a	O
model	O
in	O
which	O
InhA1	O
protease	O
levels	O
are	O
controlled	O
at	O
the	O
transcriptional	O
level	O
by	O
SinR	O
and	O
at	O
the	O
posttranslational	O
level	O
by	O
camelysin	O
.	O

Npc1	O
is	O
involved	O
in	O
sterol	O
trafficking	O
in	O
the	O
filamentous	O
fungus	O
Fusarium	B
graminearum	I
.	O

The	O
ortholog	O
of	O
the	O
human	B
gene	O
NPC1	O
was	O
identified	O
in	O
the	O
plant	O
pathogenic	O
,	O
filamentous	O
fungus	O
Fusarium	B
graminearum	I
by	O
shared	O
amino	O
acid	O
sequence	O
,	O
protein	O
domain	O
structure	O
and	O
cellular	O
localization	O
of	O
the	O
mature	O
fungal	O
protein	O
.	O

The	O
FusariumNpc1	O
gene	O
shares	O
34	O
%	O
amino	O
acid	O
sequence	O
identity	O
and	O
51	O
%	O
similarity	O
to	O
the	O
human	B
gene	O
,	O
has	O
similar	O
domain	O
structure	O
and	O
is	O
constitutively	O
expressed	O
,	O
although	O
up	O
-	O
regulated	O
in	O
ungerminated	O
macroconidia	O
and	O
ascospores	O
.	O

GFP	O
-	O
tagged	O
Npc1p	O
localizes	O
to	O
the	O
fungal	O
vacuolar	O
membrane	O
.	O

Cultures	O
derived	O
from	O
a	O
Deltanpc1	O
mutant	O
strain	O
contain	O
significantly	O
more	O
ergosterol	O
than	O
cultures	O
of	O
the	O
wildtype	O
.	O

Staining	O
with	O
the	O
fluorescent	O
,	O
sterol	O
binding	O
dye	O
filipin	O
,	O
shows	O
that	O
ergosterol	O
accumulates	O
in	O
vacuoles	O
of	O
the	O
Deltanpc1	O
mutant	O
but	O
not	O
the	O
wildtype	O
strain	O
.	O

The	O
Deltanpc1	O
mutant	O
has	O
a	O
temperature	O
dependent	O
reduction	O
in	O
growth	O
and	O
greater	O
sensitivity	O
to	O
the	O
ergosterol	O
synthesis	O
inhibiting	O
fungicide	O
tebuconazole	O
compared	O
with	O
the	O
wildtype	O
strain	O
or	O
the	O
mutant	O
complemented	O
with	O
wildtype	O
Npc1	O
.	O

The	O
mutant	O
also	O
is	O
significantly	O
reduced	O
in	O
pathogenicity	O
to	O
wheat	B
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
Npc1p	O
is	O
important	O
for	O
normal	O
transport	O
of	O
ergosterol	O
from	O
the	O
vacuole	O
and	O
is	O
essential	O
for	O
proper	O
membrane	O
function	O
under	O
particular	O
environmental	O
conditions	O
.	O

Flavobacterium	B
johnsoniae	I
sprB	O
is	O
part	O
of	O
an	O
operon	O
spanning	O
the	O
additional	O
gliding	O
motility	O
genes	O
sprC	O
,	O
sprD	O
,	O
and	O
sprF.	O
Cells	O
of	O
Flavobacterium	B
johnsoniae	I
move	O
rapidly	O
over	O
surfaces	O
by	O
a	O
process	O
known	O
as	O
gliding	O
motility	O
.	O

Gld	O
proteins	O
are	O
thought	O
to	O
comprise	O
the	O
gliding	O
motor	O
that	O
propels	O
cell	O
surface	O
adhesins	O
,	O
such	O
as	O
the	O
669-kDa	O
SprB.	O
A	O
novel	O
protein	O
secretion	O
apparatus	O
called	O
the	O
Por	O
secretion	O
system	O
(	O
PorSS	O
)	O
is	O
required	O
for	O
assembly	O
of	O
SprB	O
on	O
the	O
cell	O
surface	O
.	O

Genetic	O
and	O
molecular	O
analyses	O
revealed	O
that	O
sprB	O
is	O
part	O
of	O
a	O
seven	O
-	O
gene	O
operon	O
spanning	O
29.3	O
kbp	O
of	O
DNA	O
.	O

In	O
addition	O
to	O
sprB	O
,	O
three	O
other	O
genes	O
of	O
this	O
operon	O
(	O
sprC	O
,	O
sprD	O
,	O
and	O
sprF	O
)	O
are	O
involved	O
in	O
gliding	O
.	O

Mutations	O
in	O
sprB	O
,	O
sprC	O
,	O
sprD	O
,	O
and	O
sprF	O
resulted	O
in	O
cells	O
that	O
failed	O
to	O
form	O
spreading	O
colonies	O
on	O
agar	O
but	O
that	O
exhibited	O
some	O
motility	O
on	O
glass	O
in	O
wet	O
mounts	O
.	O

SprF	O
exhibits	O
some	O
similarity	O
to	O
Porphyromonas	B
gingivalis	I
PorP	O
,	O
which	O
is	O
required	O
for	O
secretion	O
of	O
gingipain	O
protease	O
virulence	O
factors	O
via	O
the	O
P.	B
gingivalis	I
PorSS	O
.	O

F.	B
johnsoniae	I
sprF	O
mutants	O
produced	O
SprB	O
protein	O
but	O
were	O
defective	O
in	O
localization	O
of	O
SprB	O
to	O
the	O
cell	O
surface	O
,	O
suggesting	O
a	O
role	O
for	O
SprF	O
in	O
secretion	O
of	O
SprB.	O
The	O
F.	B
johnsoniae	I
PorSS	O
is	O
involved	O
in	O
secretion	O
of	O
extracellular	O
chitinase	O
in	O
addition	O
to	O
its	O
role	O
in	O
secretion	O
of	O
SprB.	O
SprF	O
was	O
not	O
needed	O
for	O
chitinase	O
secretion	O
and	O
may	O
be	O
specifically	O
required	O
for	O
SprB	O
secretion	O
by	O
the	O
PorSS	O
.	O

Cells	O
with	O
nonpolar	O
mutations	O
in	O
sprC	O
or	O
sprD	O
produced	O
and	O
secreted	O
SprB	O
and	O
propelled	O
it	O
rapidly	O
along	O
the	O
cell	O
surface	O
.	O

Multiple	O
paralogs	O
of	O
sprB	O
,	O
sprC	O
,	O
sprD	O
,	O
and	O
sprF	O
are	O
present	O
in	O
the	O
genome	O
,	O
which	O
may	O
explain	O
why	O
mutations	O
in	O
sprB	O
,	O
sprC	O
,	O
sprD	O
,	O
and	O
sprF	O
do	O
not	O
result	O
in	O
complete	O
loss	O
of	O
motility	O
and	O
suggests	O
the	O
possibility	O
that	O
semiredundant	O
SprB	O
-	O
like	O
adhesins	O
may	O
allow	O
movement	O
of	O
cells	O
over	O
different	O
surfaces	O
.	O

Evaluating	O
aggregation	O
membership	O
and	O
copulatory	O
success	O
in	O
the	O
stink	B
bug	I
,	O
Euschistus	O
conspersus	O
,	O
using	O
field	O
and	O
laboratory	O
experiments	O
.	O

The	O
aggregation	O
and	O
mating	O
behavior	O
of	O
the	O
stink	B
bug	I
,	O
Euschistus	O
conspersus	O
Uhler	O
(	O
Hemiptera	O
:	O
Pentatomidae	O
)	O
was	O
investigated	O
in	O
a	O
series	O
of	O
field	O
and	O
laboratory	O
experiments	O
.	O

Marking	O
of	O
E.	O
conspersus	O
mating	O
in	O
aggregations	O
in	O
the	O
field	O
demonstrated	O
that	O
both	O
sexes	O
mate	O
multiple	O
times	O
within	O
aggregations	O
on	O
successive	O
nights	O
and	O
with	O
different	O
partners	O
,	O
although	O
=	O
20	O
%	O
of	O
the	O
individuals	O
of	O
both	O
sexes	O
returned	O
to	O
aggregations	O
but	O
did	O
not	O
mate	O
.	O

Further	O
analysis	O
of	O
mating	O
patterns	O
in	O
caged	O
aggregations	O
revealed	O
that	O
heavy	O
males	O
and	O
light	O
females	O
mated	O
more	O
frequently	O
than	O
their	O
respective	O
counterparts	O
.	O

Data	O
are	O
interpreted	O
in	O
terms	O
of	O
elucidating	O
the	O
function	O
of	O
benefits	O
of	O
multiple	O
mating	O
within	O
aggregations	O
for	O
males	O
and	O
females	O
.	O

Ice	O
-	O
cover	O
effects	O
on	O
competitive	O
interactions	O
between	O
two	O
fish	O
species	O
.	O

1	O
.	O

Variations	O
in	O
the	O
strength	O
of	O
ecological	O
interactions	O
between	O
seasons	O
have	O
received	O
little	O
attention	O
,	O
despite	O
an	O
increased	O
focus	O
on	O
climate	O
alterations	O
on	O
ecosystems	O
.	O

Particularly	O
,	O
the	O
winter	O
situation	O
is	O
often	O
neglected	O
when	O
studying	O
competitive	O
interactions	O
.	O

In	O
northern	O
temperate	O
freshwaters	O
,	O
winter	O
implies	O
low	O
temperatures	O
and	O
reduced	O
food	O
availability	O
,	O
but	O
also	O
strong	O
reduction	O
in	O
ambient	O
light	O
because	O
of	O
ice	O
and	O
snow	O
cover	O
.	O

Here	O
,	O
we	O
study	O
how	O
brown	B
trout	I
[	O
Salmo	B
trutta	I
(	O
L.	O
)	O
]	O
respond	O
to	O
variations	O
in	O
ice	O
-	O
cover	O
duration	O
and	O
competition	O
with	O
Arctic	B
charr	I
[	O
Salvelinus	B
alpinus	I
(	O
L.	O
)	O
]	O
,	O
by	O
linking	O
laboratory	O
-	O
derived	O
physiological	O
performance	O
and	O
field	O
data	O
on	O
variation	O
in	O
abundance	O
among	O
and	O
within	O
natural	O
brown	B
trout	I
populations	O
.	O

2	O
.	O

Both	O
Arctic	B
charr	I
and	O
brown	B
trout	I
reduced	O
resting	O
metabolic	O
rate	O
under	O
simulated	O
ice	O
-	O
cover	O
(	O
darkness	O
)	O
in	O
the	O
laboratory	O
,	O
compared	O
to	O
no	O
ice	O
(	O
6-h	O
daylight	O
)	O
.	O

However	O
,	O
in	O
contrast	O
to	O
brown	B
trout	I
,	O
Arctic	B
charr	I
was	O
able	O
to	O
obtain	O
positive	O
growth	O
rate	O
in	O
darkness	O
and	O
had	O
higher	O
food	O
intake	O
in	O
tank	O
experiments	O
than	O
brown	B
trout	I
.	O

Arctic	B
charr	I
also	O
performed	O
better	O
(	O
lower	O
energy	O
loss	O
)	O
under	O
simulated	O
ice	O
-	O
cover	O
in	O
a	O
semi	O
-	O
natural	O
environment	O
with	O
natural	O
food	O
supply	O
.	O

3	O
.	O

When	O
comparing	O
brown	B
trout	I
biomass	O
across	O
190	O
Norwegian	O
lakes	O
along	O
a	O
climate	O
gradient	O
,	O
longer	O
ice	O
-	O
covered	O
duration	O
decreased	O
the	O
biomass	O
only	O
in	O
lakes	O
where	O
brown	B
trout	I
lived	O
together	O
with	O
Arctic	B
charr	I
.	O

We	O
were	O
not	O
able	O
to	O
detect	O
any	O
effect	O
of	O
ice	O
-	O
cover	O
on	O
brown	B
trout	I
biomass	O
in	O
lakes	O
where	O
brown	B
trout	I
was	O
the	O
only	O
fish	O
species	O
.	O

4	O
.	O

Similarly	O
,	O
a	O
25-year	O
time	O
series	O
from	O
a	O
lake	O
with	O
both	O
brown	B
trout	I
and	O
Arctic	B
charr	I
showed	O
that	O
brown	B
trout	I
population	O
growth	O
rate	O
depended	O
on	O
the	O
interaction	O
between	O
ice	O
breakup	O
date	O
and	O
Arctic	B
charr	I
abundance	O
.	O

High	O
charr	B
abundance	O
was	O
correlated	O
with	O
low	O
trout	O
population	O
growth	O
rate	O
only	O
in	O
combination	O
with	O
long	O
winters	O
.	O

5	O
.	O

In	O
conclusion	O
,	O
the	O
two	O
species	O
differed	O
in	O
performance	O
under	O
ice	O
,	O
and	O
the	O
observed	O
outcome	O
of	O
competition	O
in	O
natural	O
populations	O
was	O
strongly	O
dependent	O
on	O
duration	O
of	O
the	O
ice	O
-	O
covered	O
period	O
.	O

Our	O
study	O
shows	O
that	O
changes	O
in	O
ice	O
phenology	O
may	O
alter	O
species	O
interactions	O
in	O
Northern	O
aquatic	O
systems	O
.	O

Increased	O
knowledge	O
of	O
how	O
adaptations	O
to	O
winter	O
conditions	O
differ	O
among	O
coexisting	O
species	O
is	O
therefore	O
vital	O
for	O
our	O
understanding	O
of	O
ecological	O
impacts	O
of	O
climate	O
change	O
.	O

Prolixicin	O
:	O
a	O
novel	O
antimicrobial	O
peptide	O
isolated	O
from	O
Rhodnius	B
prolixus	I
with	O
differential	O
activity	O
against	O
bacteria	O
and	O
Trypanosoma	B
cruzi	I
.	O

We	O
identified	O
and	O
characterized	O
the	O
activity	O
of	O
prolixicin	O
,	O
a	O
novel	O
antimicrobial	O
peptide	O
(	O
AMP	O
)	O
isolated	O
from	O
the	O
hemipteran	O
insect	O
,	O
Rhodnius	B
prolixus	I
.	O

Sequence	O
analysis	O
reveals	O
one	O
region	O
of	O
prolixicin	O
that	O
may	O
be	O
related	O
to	O
the	O
diptericin	O
/	O
attacin	O
family	O
of	O
AMPs	O
.	O

Prolixicin	O
is	O
an	O
11-kDa	O
peptide	O
containing	O
a	O
putative	O
21	O
amino	O
acid	O
signal	O
peptide	O
,	O
two	O
putative	O
phosphorylation	O
sites	O
and	O
no	O
glycosylation	O
sites	O
.	O

It	O
is	O
produced	O
by	O
both	O
adult	O
fat	O
body	O
and	O
midgut	O
tissues	O
in	O
response	O
to	O
bacterial	O
infection	O
of	O
the	O
haemolymph	O
or	O
the	O
midgut	O
.	O

Unlike	O
most	O
insect	O
antibacterial	O
peptides	O
,	O
the	O
prolixicin	O
gene	O
does	O
not	O
seem	O
to	O
be	O
regulated	O
by	O
NF	O
-	O
kappaB	O
binding	O
sites	O
,	O
but	O
its	O
promoter	O
region	O
contains	O
several	O
GATA	O
sites	O
.	O

Recombinant	O
prolixicin	O
has	O
strong	O
activity	O
against	O
the	O
Gram	O
-	O
negative	O
bacterium	O
Escherichia	B
coli	I
and	O
differential	O
activity	O
against	O
several	O
Gram	O
-	O
negative	O
and	O
Gram	O
-	O
positive	O
bacteria	O
.	O

No	O
significant	O
toxicity	O
was	O
demonstrated	O
against	O
Trypanosoma	B
cruzi	I
,	O
the	O
human	B
parasite	O
transmitted	O
by	O
R.	B
prolixus	I
.	O

Amyotrophic	O
lateral	O
sclerosis	O
.	O

Amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
is	O
an	O
idiopathic	O
,	O
fatal	O
neurodegenerative	O
disease	O
of	O
the	O
human	B
motor	O
system	O
.	O

In	O
this	O
Seminar	O
,	O
we	O
summarise	O
current	O
concepts	O
about	O
the	O
origin	O
of	O
the	O
disease	O
,	O
what	O
predisposes	O
patients	O
to	O
develop	O
the	O
disorder	O
,	O
and	O
discuss	O
why	O
all	O
cases	O
of	O
ALS	O
are	O
not	O
the	O
same	O
.	O

In	O
the	O
150	O
years	O
since	O
Charcot	O
originally	O
described	O
ALS	O
,	O
painfully	O
slow	O
progress	O
has	O
been	O
made	O
towards	O
answering	O
these	O
questions	O
.	O

We	O
focus	O
on	O
what	O
is	O
known	O
about	O
ALS	O
and	O
where	O
research	O
is	O
heading	O
-	O
from	O
the	O
small	O
steps	O
of	O
extending	O
longevity	O
,	O
improving	O
therapies	O
,	O
undertaking	O
clinical	O
trials	O
,	O
and	O
compiling	O
population	O
registries	O
to	O
the	O
overarching	O
goals	O
of	O
establishing	O
the	O
measures	O
that	O
guard	O
against	O
onset	O
and	O
finding	O
the	O
triggers	O
for	O
this	O
neurodegenerative	O
disorder	O
.	O

Role	O
of	O
RNase	O
MRP	O
in	O
viral	O
RNA	O
degradation	O
and	O
RNA	O
recombination	O
.	O

RNA	O
degradation	O
,	O
together	O
with	O
RNA	O
synthesis	O
,	O
controls	O
the	O
steady	O
-	O
state	O
level	O
of	O
viral	O
RNAs	O
in	O
infected	O
cells	O
.	O

The	O
endoribonucleolytic	O
cleavage	O
of	O
viral	O
RNA	O
is	O
important	O
not	O
only	O
for	O
viral	O
RNA	O
degradation	O
but	O
for	O
RNA	O
recombination	O
as	O
well	O
,	O
due	O
to	O
the	O
participation	O
of	O
some	O
RNA	O
degradation	O
products	O
in	O
the	O
RNA	O
recombination	O
process	O
.	O

To	O
identify	O
host	O
endoribonucleases	O
involved	O
in	O
degradation	O
of	O
Tomato	B
bushy	I
stunt	I
virus	I
(	O
TBSV	B
)	O
in	O
a	O
Saccharomyces	B
cerevisiae	I
model	O
host	O
,	O
we	O
tested	O
eight	O
known	O
endoribonucleases	O
.	O

Here	O
we	O
report	O
that	O
downregulation	O
of	O
SNM1	O
,	O
encoding	O
a	O
component	O
of	O
the	O
RNase	O
MRP	O
,	O
and	O
a	O
temperature	O
-	O
sensitive	O
mutation	O
in	O
the	O
NME1	O
gene	O
,	O
coding	O
for	O
the	O
RNA	O
component	O
of	O
RNase	O
MRP	O
,	O
lead	O
to	O
reduced	O
production	O
of	O
the	O
endoribonucleolytically	O
cleaved	O
TBSV	B
RNA	O
in	O
yeast	B
.	O

We	O
also	O
show	O
that	O
the	O
highly	O
purified	O
yeast	B
RNase	O
MRP	O
cleaves	O
the	O
TBSV	B
RNA	O
in	O
vitro	O
,	O
resulting	O
in	O
TBSV	B
RNA	O
degradation	O
products	O
similar	O
in	O
size	O
to	O
those	O
observed	O
in	O
yeast	B
cells	O
.	O

Knocking	O
down	O
the	O
NME1	O
homolog	O
in	O
Nicotiana	B
benthamiana	I
also	O
led	O
to	O
decreased	O
production	O
of	O
the	O
cleaved	O
TBSV	B
RNA	O
,	O
suggesting	O
that	O
in	O
plants	O
,	O
RNase	O
MRP	O
is	O
involved	O
in	O
TBSV	B
RNA	O
degradation	O
.	O

Altogether	O
,	O
this	O
work	O
suggests	O
a	O
role	O
for	O
the	O
host	O
endoribonuclease	O
RNase	O
MRP	O
in	O
viral	O
RNA	O
degradation	O
and	O
recombination	O
.	O

Reverse	O
genetics	O
generation	O
of	O
chimeric	O
infectious	O
Junin	O
/	O
Lassa	O
virus	O
is	O
dependent	O
on	O
interaction	O
of	O
homologous	O
glycoprotein	O
stable	O
signal	O
peptide	O
and	O
G2	O
cytoplasmic	O
domains	O
.	O

The	O
Arenaviridae	O
are	O
a	O
diverse	O
and	O
globally	O
distributed	O
collection	O
of	O
viruses	O
that	O
are	O
maintained	O
primarily	O
by	O
rodent	O
reservoirs	O
.	O

Junin	B
virus	I
(	O
JUNV	B
)	O
and	O
Lassa	B
virus	I
(	O
LASV	B
)	O
can	O
both	O
cause	O
significant	O
outbreaks	O
of	O
severe	O
and	O
often	O
fatal	O
human	B
disease	O
throughout	O
their	O
respective	O
areas	O
of	O
endemicity	O
.	O

In	O
an	O
effort	O
to	O
improve	O
upon	O
the	O
existing	O
live	O
attenuated	O
JUNV	B
Candid1	O
vaccine	O
,	O
we	O
generated	O
a	O
genetically	O
homogenous	O
stock	O
of	O
this	O
virus	O
from	O
cDNA	O
copies	O
of	O
the	O
virus	O
S	O
and	O
L	O
segments	O
by	O
using	O
a	O
reverse	O
genetics	O
system	O
.	O

Further	O
,	O
these	O
cDNAs	O
were	O
used	O
in	O
combination	O
with	O
LASV	B
cDNAs	O
to	O
successfully	O
generate	O
two	O
recombinant	O
Candid1	O
JUNV	B
/	O
LASV	B
chimeric	O
viruses	O
(	O
via	O
envelope	O
glycoprotein	O
[	O
GPC	O
]	O
exchange	O
)	O
.	O

It	O
was	O
found	O
that	O
while	O
the	O
GPC	O
extravirion	O
domains	O
were	O
readily	O
exchangeable	O
,	O
homologous	O
stable	O
signal	O
peptide	O
(	O
SSP	O
)	O
and	O
G2	O
transmembrane	O
and	O
cytoplasmic	O
tail	O
domains	O
were	O
essential	O
for	O
correct	O
GPC	O
maturation	O
and	O
production	O
of	O
infectious	O
chimeric	O
viruses	O
.	O

The	O
switching	O
of	O
the	O
JUNV	B
and	O
LASV	B
G1	O
/	O
G2	O
ectodomains	O
within	O
the	O
Candid1	O
vaccine	O
background	O
did	O
not	O
alter	O
the	O
attenuated	O
phenotype	O
of	O
the	O
vaccine	O
strain	O
in	O
a	O
lethal	O
mouse	B
model	O
.	O

These	O
recombinant	O
chimeric	O
viruses	O
shed	O
light	O
on	O
the	O
fundamental	O
requirements	O
of	O
arenavirus	O
GPC	O
maturation	O
and	O
may	O
serve	O
as	O
a	O
strategy	O
for	O
the	O
development	O
of	O
bivalent	O
JUNV	B
and	O
LASV	B
vaccine	O
candidates	O
.	O

Titrating	O
the	O
cost	O
of	O
plant	O
toxins	O
against	O
predators	O
:	O
determining	O
the	O
tipping	O
point	O
for	O
foraging	O
herbivores	O
.	O

1	O
.	O

Foraging	O
herbivores	O
must	O
deal	O
with	O
plant	O
characteristics	O
that	O
inhibit	O
feeding	O
and	O
they	O
must	O
avoid	O
being	O
eaten	O
.	O

Principally	O
,	O
toxins	O
limit	O
food	O
intake	O
,	O
while	O
predation	O
risk	O
alters	O
how	O
long	O
animals	O
are	O
prepared	O
to	O
harvest	O
resources	O
.	O

Each	O
of	O
these	O
factors	O
strongly	O
affects	O
how	O
herbivores	O
use	O
food	O
patches	O
,	O
and	O
both	O
constraints	O
can	O
pose	O
immediate	O
proximate	O
costs	O
and	O
long	O
-	O
term	O
consequences	O
to	O
fitness	O
.	O

2	O
.	O
Using	O
a	O
generalist	O
mammalian	O
herbivore	O
,	O
the	O
common	B
brushtail	I
possum	I
(	O
Trichosurus	B
vulpecula	I
)	O
,	O
our	O
aim	O
was	O
to	O
quantitatively	O
compare	O
the	O
influence	O
of	O
plant	O
toxin	O
and	O
predation	O
risk	O
on	O
foraging	O
decisions	O
.	O

3	O
.	O

We	O
performed	O
a	O
titration	O
experiment	O
by	O
offering	O
animals	O
a	O
choice	O
between	O
non	O
-	O
toxic	O
food	O
at	O
a	O
risky	O
patch	O
paired	O
with	O
food	O
with	O
one	O
of	O
five	O
toxin	O
concentrations	O
at	O
a	O
safe	O
patch	O
.	O

This	O
allowed	O
us	O
to	O
identify	O
the	O
tipping	O
point	O
,	O
where	O
the	O
cost	O
of	O
toxin	O
in	O
the	O
safe	O
food	O
patch	O
was	O
equivalent	O
to	O
the	O
perceived	O
predation	O
risk	O
in	O
the	O
alternative	O
patch	O
.	O

4	O
.	O

At	O
low	O
toxin	O
concentration	O
,	O
animals	O
ate	O
more	O
from	O
the	O
safe	O
than	O
the	O
risky	O
patch	O
.	O

As	O
toxin	O
concentration	O
increased	O
at	O
the	O
safe	O
patch	O
,	O
intake	O
shifted	O
until	O
animals	O
ate	O
mainly	O
from	O
the	O
risky	O
patch	O
.	O

This	O
shift	O
was	O
associated	O
with	O
behavioural	O
changes	O
:	O
animals	O
spent	O
more	O
time	O
and	O
fed	O
longer	O
at	O
the	O
risky	O
patch	O
,	O
while	O
vigilance	O
increased	O
at	O
both	O
risky	O
and	O
safe	O
patches	O
.	O

5	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
variation	O
in	O
toxin	O
concentration	O
,	O
which	O
occurs	O
intraspecifically	O
among	O
plants	O
,	O
can	O
critically	O
influence	O
the	O
relative	O
cost	O
of	O
predation	O
risk	O
on	O
foraging	O
.	O

We	O
show	O
that	O
herbivores	O
quantify	O
,	O
compare	O
and	O
balance	O
these	O
two	O
different	O
but	O
proximate	O
costs	O
,	O
altering	O
their	O
foraging	O
patterns	O
in	O
the	O
process	O
.	O

This	O
has	O
potential	O
ecological	O
and	O
evolutionary	O
implications	O
for	O
the	O
production	O
of	O
plant	O
defence	O
compounds	O
in	O
relation	O
to	O
spatial	O
variation	O
in	O
predation	O
risk	O
to	O
herbivores	O
.	O

The	O
Role	O
of	O
Frass	O
and	O
Cocoon	O
Volatiles	O
in	O
Host	O
Location	O
by	O
Monodontomerus	O
aeneus	O
,	O
a	O
Parasitoid	O
of	O
Megachilid	O
Solitary	O
Bees	O
.	O

Monodontomerus	O
aeneus	O
(	O
Fonscolombe	O
)	O
is	O
a	O
parasitic	O
wasp	O
that	O
oviposits	O
on	O
the	O
prepupae	O
and	O
pupae	O
of	O
Osmia	B
cornuta	I
(	O
Latreille	O
)	O
and	O
other	O
solitary	O
bee	O
species	O
.	O

A	O
two	O
-	O
armed	O
olfactometer	O
was	O
used	O
to	O
test	O
the	O
olfactory	O
attractiveness	O
of	O
O.	B
cornuta	I
prepupae	O
,	O
cocoon	O
,	O
and	O
larval	O
frass	O
to	O
female	O
M.	O
aeneus	O
.	O

Both	O
cocoon	O
and	O
frass	O
attracted	O
the	O
female	O
parasitoids	O
,	O
but	O
frass	O
alone	O
was	O
more	O
attractive	O
than	O
the	O
cocoon	O
and	O
the	O
cocoon	O
with	O
frass	O
was	O
more	O
attractive	O
than	O
frass	O
alone	O
.	O

Female	O
parasitoids	O
were	O
not	O
attracted	O
by	O
the	O
host	O
prepupa	O
.	O

M33	O
(	O
methanol	O
)	O
was	O
the	O
organic	O
volatile	O
most	O
emitted	O
by	O
cocoons	O
and	O
m61	O
(	O
acetic	O
acid	O
)	O
was	O
the	O
compound	O
most	O
emitted	O
by	O
frass	O
.	O

However	O
,	O
cocoons	O
showed	O
higher	O
emission	O
for	O
almost	O
all	O
compounds	O
,	O
including	O
m61	O
(	O
acetic	O
acid	O
)	O
.	O

Although	O
acetic	O
acid	O
alone	O
attracted	O
M.	O
aeneus	O
,	O
a	O
complex	O
volatile	O
signal	O
is	O
probably	O
involved	O
in	O
the	O
attraction	O
process	O
because	O
the	O
ratio	O
of	O
acetic	O
acid	O
and	O
acetaldehyde	O
characteristic	O
of	O
the	O
frass	O
was	O
more	O
attractive	O
than	O
other	O
ratios	O
.	O

Individual	O
differences	O
in	O
reproductive	O
costs	O
examined	O
using	O
multi	O
-	O
state	O
methods	O
.	O

1	O
.	O

Trade	O
-	O
offs	O
among	O
life	O
-	O
history	O
traits	O
are	O
common	O
because	O
individuals	O
have	O
to	O
partition	O
limited	O
resources	O
between	O
multiple	O
traits	O
.	O

Reproductive	O
costs	O
are	O
generally	O
assumed	O
to	O
be	O
high	O
,	O
resulting	O
in	O
reduced	O
survival	O
and	O
fecundity	O
in	O
the	O
following	O
year	O
.	O

However	O
,	O
it	O
is	O
common	O
to	O
find	O
positive	O
rather	O
than	O
negative	O
correlations	O
between	O
life	O
-	O
history	O
traits	O
.	O

2	O
.	O
Here	O
,	O
we	O
use	O
a	O
data	O
set	O
from	O
the	O
individual	O
-	O
based	O
study	O
of	O
red	B
deer	I
on	O
the	O
Isle	O
of	O
Rum	O
to	O
examine	O
how	O
these	O
costs	O
vary	O
between	O
individuals	O
and	O
at	O
different	O
ages	O
,	O
using	O
multi	O
-	O
state	O
mark	O
-	O
recapture	O
methodology	O
.	O

3	O
.	O
Females	O
that	O
had	O
reproduced	O
frequently	O
in	O
the	O
past	O
incurred	O
lower	O
costs	O
of	O
reproduction	O
in	O
terms	O
of	O
survival	O
in	O
the	O
following	O
year	O
and	O
were	O
more	O
likely	O
to	O
reproduce	O
in	O
two	O
consecutive	O
years	O
.	O

Older	O
individuals	O
and	O
those	O
that	O
had	O
not	O
reproduced	O
frequently	O
exhibited	O
higher	O
costs	O
.	O

4	O
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
considering	O
heterogeneity	O
and	O
individual	O
quality	O
when	O
examining	O
trade	O
-	O
offs	O
and	O
demonstrate	O
the	O
effectiveness	O
of	O
using	O
detailed	O
long	O
-	O
term	O
data	O
sets	O
to	O
explore	O
life	O
-	O
history	O
strategies	O
using	O
multi	O
-	O
state	O
mark	O
-	O
recapture	O
models	O
.	O

Phr1p	O
,	O
a	O
glycosylphosphatidylinsitol	O
-	O
anchored	O
Beta	O
(	O
1,3	O
)	O
-glucanosyltransferase	O
critical	O
for	O
hyphal	O
wall	O
formation	O
,	O
localizes	O
to	O
the	O
apical	O
growth	O
sites	O
and	O
septa	O
in	O
Candida	B
albicans	I
.	O

Cell	O
wall	O
biogenesis	O
is	O
a	O
dynamic	O
process	O
relying	O
on	O
the	O
coordinated	O
activity	O
of	O
several	O
extracellular	O
enzymes	O
.	O

PHR1	O
is	O
a	O
pH	O
-	O
regulated	O
gene	O
of	O
Candida	B
albicans	I
encoding	O
a	O
glycosylphosphatidylinositol	O
-	O
anchored	O
Beta	O
(	O
1,3	O
)	O
-glucanosyltransferase	O
of	O
family	O
GH72	O
which	O
acts	O
as	O
a	O
cell	O
wall	O
remodelling	O
enzyme	O
and	O
is	O
crucial	O
for	O
morphogenesis	O
and	O
virulence	O
.	O

In	O
order	O
to	O
explore	O
the	O
function	O
of	O
Phr1p	O
,	O
we	O
obtained	O
a	O
green	O
fluorescent	O
protein	O
(	O
GFP	O
)	O
fusion	O
to	O
determine	O
its	O
localization	O
.	O

During	O
induction	O
of	O
vegetative	O
growth	O
,	O
Phr1p	O
-	O
GFP	O
was	O
concentrated	O
in	O
the	O
plasma	O
membrane	O
of	O
the	O
growing	O
bud	O
,	O
in	O
the	O
mother	O
-	O
bud	O
neck	O
,	O
and	O
in	O
the	O
septum	O
.	O

Phr1p	O
-	O
GFP	O
was	O
recovered	O
in	O
the	O
detergent	O
-	O
resistant	O
membranes	O
indicating	O
its	O
association	O
with	O
the	O
lipid	O
rafts	O
as	O
the	O
wild	O
type	O
Phr1p	O
.	O

Upon	O
induction	O
of	O
hyphal	O
growth	O
,	O
Phr1p	O
-	O
GFP	O
highly	O
concentrated	O
at	O
the	O
apex	O
of	O
the	O
germ	O
tubes	O
and	O
progressively	O
distributed	O
along	O
the	O
lateral	O
sides	O
of	O
the	O
hyphae	O
.	O

Phr1p	O
-	O
GFP	O
also	O
labelled	O
the	O
hyphal	O
septa	O
,	O
where	O
it	O
colocalized	O
with	O
chitin	O
.	O

Localization	O
to	O
the	O
hyphal	O
septa	O
was	O
perturbed	O
in	O
nocodazole	O
-	O
treated	O
cells	O
,	O
whereas	O
inhibition	O
of	O
actin	O
polymerization	O
hindered	O
the	O
apical	O
localization	O
.	O

Electron	O
Microscopy	O
analysis	O
of	O
the	O
hyphal	O
wall	O
ultrastructure	O
of	O
a	O
PHR1	O
null	O
mutant	O
showed	O
loss	O
of	O
compactness	O
and	O
irregular	O
organization	O
of	O
the	O
surface	O
layer	O
.	O

These	O
observations	O
indicate	O
that	O
Phr1p	O
plays	O
a	O
crucial	O
role	O
in	O
hyphal	O
wall	O
formation	O
,	O
a	O
highly	O
regulated	O
process	O
on	O
which	O
morphogenesis	O
and	O
virulence	O
rely	O
.	O

Hormone	O
receptor	O
-	O
like	O
in	O
96	O
and	O
Broad	O
-	O
Complex	O
modulate	O
phenobarbital	O
induced	O
transcription	O
of	O
cytochrome	O
P450	O
CYP6D1	O
in	O
Drosophila	B
S2	O
cells	O
.	O

Phenobarbital	O
(	O
PB	O
)	O
is	O
a	O
prototypical	O
inducer	O
for	O
studies	O
of	O
xenobiotic	O
responses	O
in	O
animals	O
.	O

In	O
mammals	O
,	O
the	O
nuclear	O
receptors	O
constitutive	O
androstane	O
receptor	O
(	O
CAR	O
)	O
and	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
have	O
been	O
identified	O
as	O
key	O
transcription	O
factors	O
regulating	O
PB	O
induced	O
transcription	O
of	O
xenobiotic	O
responsive	O
genes	O
.	O

In	O
insects	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
transcription	O
factors	O
involved	O
in	O
regulating	O
PB	O
induced	O
transcription	O
,	O
although	O
CAR	O
and	O
PXR	O
have	O
a	O
single	O
orthologue	O
hormone	O
receptor	O
-	O
like	O
in	O
96	O
(	O
HR96	O
)	O
in	O
Drosophila	B
melanogaster	I
.	O

Using	O
dual	O
luciferase	O
reporter	O
assays	O
in	O
Drosophila	B
Schneider	O
(	O
S2	O
)	O
cells	O
,	O
constructs	O
containing	O
variable	O
lengths	O
of	O
the	O
promoter	O
of	O
the	O
PB	O
inducible	O
cytochrome	O
P450	O
CYP6D1	O
were	O
evaluated	O
in	O
the	O
presence	O
and	O
absence	O
of	O
PB	O
.	O

The	O
promoter	O
region	O
between	O
-330	O
and	O
-280	O
(	O
relative	O
to	O
the	O
position	O
of	O
transcription	O
start	O
site	O
,	O
+	O
1	O
)	O
was	O
found	O
to	O
be	O
critical	O
for	O
PB	O
induction	O
.	O

Putative	O
binding	O
sites	O
for	O
Drosophila	B
Broad	O
-	O
Complex	O
(	O
BR	O
-	O
C	O
)	O
and	O
deformed	O
(	O
Dfd	O
)	O
were	O
identified	O
within	O
this	O
promoter	O
region	O
using	O
TFsearch	O
.	O

RNA	O
interference	O
(	O
RNAi	O
)	O
treatment	O
of	O
S2	O
cells	O
in	O
conjunction	O
with	O
CYP6D1	O
promoter	O
assays	O
showed	O
that	O
suppression	O
of	O
Drosophila	B
HR96	O
and	O
BR	O
-	O
C	O
transcription	O
in	O
S2	O
cells	O
resulted	O
in	O
a	O
significant	O
decrease	O
and	O
increase	O
,	O
respectively	O
,	O
of	O
PB	O
induction	O
.	O

Effects	O
of	O
HR96	O
and	O
BR	O
-	O
C	O
in	O
mediating	O
PB	O
induction	O
were	O
PB	O
specific	O
and	O
PB	O
dependent	O
.	O

This	O
represents	O
new	O
functional	O
evidence	O
that	O
Drosophila	B
HR96	O
and	O
BR	O
-	O
C	O
can	O
act	O
as	O
an	O
activator	O
and	O
repressor	O
,	O
respectively	O
,	O
in	O
regulating	O
PB	O
induced	O
transcription	O
in	O
insects	O
.	O

Nucleotide	O
parasitism	O
by	O
Simkania	B
negevensis	I
(	O
Chlamydiae	O
)	O
.	O

Intracellular	O
bacteria	O
live	O
in	O
an	O
environment	O
rich	O
in	O
most	O
essential	O
metabolites	O
but	O
need	O
special	O
mechanisms	O
to	O
access	O
these	O
substrates	O
.	O

Nucleotide	O
transport	O
proteins	O
(	O
NTTs	O
)	O
catalyze	O
the	O
import	O
of	O
ATP	O
and	O
other	O
nucleotides	O
from	O
the	O
eukaryotic	O
host	O
into	O
the	O
bacterial	O
cell	O
and	O
render	O
de	O
novo	O
synthesis	O
of	O
these	O
compounds	O
dispensable	O
.	O

The	O
draft	O
genome	O
sequence	O
of	O
Simkania	B
negevensis	I
strain	I
Z	O
,	O
a	O
chlamydial	O
organism	O
considered	O
a	O
newly	O
emerging	O
pathogen	O
,	O
revealed	O
four	O
genes	O
encoding	O
putative	O
nucleotide	O
transport	O
proteins	O
(	O
SnNTT1	O
to	O
SnNTT4	O
)	O
,	O
all	O
of	O
which	O
are	O
transcribed	O
during	O
growth	O
of	O
S.	B
negevensis	I
in	O
Acanthamoeba	O
host	O
cells	O
,	O
as	O
confirmed	O
by	O
reverse	O
transcription	O
-	O
PCR	O
.	O

Using	O
heterologous	O
expression	O
in	O
Escherichia	B
coli	I
,	O
we	O
could	O
show	O
that	O
SnNTT1	O
functions	O
as	O
an	O
ATP	O
/	O
ADP	O
antiporter	O
,	O
SnNTT2	O
as	O
a	O
guanine	O
nucleotide	O
/	O
ATP	O
/	O
H	O
(	O
+	O
)	O
symporter	O
driven	O
by	O
the	O
membrane	O
potential	O
,	O
and	O
SnNTT3	O
as	O
a	O
nucleotide	O
triphosphate	O
antiporter	O
.	O

In	O
addition	O
,	O
SnNTT3	O
is	O
able	O
to	O
transport	O
dCTP	O
,	O
which	O
has	O
not	O
been	O
shown	O
for	O
a	O
prokaryotic	O
transport	O
protein	O
before	O
.	O

No	O
substrate	O
could	O
be	O
identified	O
for	O
SnNTT4	O
.	O

Taking	O
these	O
data	O
together	O
,	O
S.	B
negevensis	I
employs	O
a	O
set	O
of	O
nucleotide	O
transport	O
proteins	O
to	O
efficiently	O
tap	O
its	O
host	O
's	O
energy	O
and	O
nucleotide	O
pools	O
.	O

Although	O
similar	O
to	O
other	O
chlamydiae	O
,	O
these	O
transporters	O
show	O
distinct	O
and	O
unique	O
adaptations	O
with	O
respect	O
to	O
substrate	O
specificities	O
and	O
mode	O
of	O
transport	O
.	O

Promoter	O
discrimination	O
at	O
class	O
I	O
MarA	O
regulon	O
promoters	O
mediated	O
by	O
glutamic	O
acid	O
89	O
of	O
the	O
MarA	O
transcriptional	O
activator	O
of	O
Escherichia	B
coli	I
.	O

Three	O
paralogous	O
transcriptional	O
activators	O
MarA	O
,	O
SoxS	O
,	O
and	O
Rob	O
,	O
activate	O
>	O
40	O
Escherichia	B
coli	I
promoters	O
.	O

To	O
understand	O
why	O
MarA	O
does	O
not	O
activate	O
certain	O
promoters	O
as	O
strongly	O
as	O
SoxS	O
,	O
we	O
compared	O
MarA	O
,	O
MarA	O
mutants	O
,	O
and	O
SoxS	O
for	O
their	O
abilities	O
to	O
activate	O
16	O
promoters	O
and	O
to	O
bind	O
their	O
cognate	O
marbox	O
binding	O
sites	O
.	O

Replacement	O
of	O
the	O
MarA	O
glutamic	O
acid	O
residue	O
89	O
with	O
alanine	O
greatly	O
increased	O
the	O
marbox	O
binding	O
and	O
activation	O
of	O
many	O
class	O
I	O
promoters	O
.	O

Like	O
cells	O
constitutive	O
for	O
SoxS	O
,	O
cells	O
expressing	O
the	O
MarA	O
with	O
the	O
E89A	O
mutation	O
were	O
more	O
resistant	O
to	O
superoxides	O
than	O
those	O
harboring	O
WT	O
MarA.	O
The	O
activities	O
of	O
several	O
other	O
E89	O
substitutions	O
ranked	O
as	O
follows	O
:	O
E89A	O
>	O
E89	O
G	O
>	O
E89V	O
>	O
WT	O
>	O
E89D	O
.	O

Increased	O
binding	O
and	O
activation	O
occurred	O
only	O
at	O
class	O
I	O
promoters	O
when	O
the	O
12th	O
base	O
of	O
the	O
promoter	O
's	O
marbox	O
(	O
a	O
position	O
at	O
which	O
there	O
is	O
no	O
known	O
interaction	O
between	O
the	O
marbox	O
and	O
MarA	O
)	O
was	O
not	O
a	O
T	O
residue	O
.	O

Furthermore	O
,	O
WT	O
MarA	O
binding	O
to	O
a	O
synthetic	O
marbox	O
in	O
vitro	O
was	O
enhanced	O
when	O
the	O
phosphate	O
group	O
between	O
positions	O
12	O
and	O
13	O
was	O
eliminated	O
on	O
one	O
strand	O
.	O

The	O
results	O
demonstrate	O
that	O
relatively	O
minor	O
changes	O
in	O
a	O
single	O
amino	O
acid	O
side	O
chain	O
(	O
e.g.	O
,	O
alanine	O
to	O
valine	O
or	O
glutamic	O
acid	O
to	O
aspartic	O
acid	O
)	O
can	O
strongly	O
influence	O
activity	O
despite	O
any	O
evidence	O
that	O
the	O
side	O
chain	O
is	O
involved	O
in	O
positive	O
interactions	O
with	O
either	O
DNA	O
or	O
RNA	O
polymerase	O
.	O

We	O
present	O
a	O
model	O
which	O
attributes	O
the	O
differences	O
in	O
binding	O
and	O
activation	O
to	O
the	O
interference	O
between	O
the	O
Beta-	O
and	O
gamma	O
-	O
carbons	O
of	O
the	O
amino	O
acid	O
at	O
position	O
89	O
and	O
the	O
phosphate	O
group	O
between	O
positions	O
12	O
and	O
13	O
.	O

The	O
Serengeti	O
food	O
web	O
:	O
empirical	O
quantification	O
and	O
analysis	O
of	O
topological	O
changes	O
under	O
increasing	O
human	B
impact	O
.	O

1	O
.	O

To	O
address	O
effects	O
of	O
land	O
use	O
and	O
human	B
overexploitation	O
on	O
wildlife	O
populations	O
,	O
it	O
is	O
essential	O
to	O
better	O
understand	O
how	O
human	B
activities	O
have	O
changed	O
species	O
composition	O
,	O
diversity	O
and	O
functioning	O
.	O

Theoretical	O
studies	O
modelled	O
how	O
network	O
properties	O
change	O
under	O
human	B
-	O
induced	O
,	O
non	O
-	O
random	O
species	O
loss	O
.	O

However	O
,	O
we	O
lack	O
data	O
on	O
realistic	O
species	O
-	O
loss	O
sequences	O
in	O
threatened	O
,	O
real	O
-	O
world	O
food	O
webs	O
to	O
parameterize	O
these	O
models	O
.	O

2	O
.	O
Here	O
,	O
we	O
present	O
a	O
first	O
size	O
-	O
structured	O
topological	O
food	O
web	O
of	O
one	O
of	O
the	O
most	O
pristine	O
terrestrial	O
ecosystems	O
in	O
the	O
world	O
,	O
the	O
Serengeti	O
ecosystem	O
(	O
Tanzania	O
)	O
.	O

The	O
food	O
web	O
consists	O
of	O
95	O
grouped	O
nodes	O
and	O
includes	O
both	O
invertebrates	O
and	O
vertebrates	O
ranging	O
from	O
body	O
masses	O
between	O
10	O
(	O
-7	O
)	O
and	O
10	O
(	O
4	O
)	O
kg	O
.	O

3	O
.	O

We	O
study	O
the	O
topological	O
changes	O
in	O
this	O
food	O
web	O
that	O
result	O
from	O
the	O
simulated	O
IUCN	O
-	O
based	O
species	O
-	O
loss	O
sequence	O
representing	O
current	O
species	O
vulnerability	O
to	O
human	B
disturbances	O
in	O
and	O
around	O
this	O
savanna	O
ecosystem	O
.	O

We	O
then	O
compare	O
this	O
realistic	O
extinction	O
scenario	O
with	O
other	O
extinction	O
sequences	O
based	O
on	O
body	O
size	O
and	O
connectance	O
and	O
perform	O
an	O
analysis	O
of	O
robustness	O
of	O
this	O
savanna	O
food	O
web	O
.	O

4	O
.	O

We	O
demonstrate	O
that	O
real	O
-	O
world	O
species	O
loss	O
in	O
this	O
case	O
starts	O
with	O
the	O
biggest	O
(	O
mega	O
)	O
herbivores	O
and	O
top	O
predators	O
,	O
causing	O
higher	O
predator	O
-	O
prey	O
mass	O
ratios	O
.	O

However	O
,	O
unlike	O
theoretically	O
modelled	O
linear	O
species	O
deletion	O
sequences	O
,	O
this	O
causes	O
poor	O
-	O
connected	O
species	O
to	O
be	O
lost	O
first	O
,	O
while	O
more	O
highly	O
connected	O
species	O
become	O
lost	O
as	O
human	B
impact	O
progresses	O
.	O

This	O
food	O
web	O
shows	O
high	O
robustness	O
to	O
decreasing	O
body	O
size	O
and	O
increasing	O
connectance	O
deletion	O
sequences	O
compared	O
with	O
a	O
high	O
sensitivity	O
to	O
the	O
decreasing	O
connectance	O
deletion	O
scenario	O
.	O

5	O
.	O

Furthermore	O
,	O
based	O
on	O
the	O
current	O
knowledge	O
of	O
the	O
Serengeti	O
ecosystem	O
,	O
we	O
discuss	O
how	O
the	O
focus	O
on	O
food	O
web	O
topology	O
alone	O
,	O
disregarding	O
nontrophic	O
interactions	O
,	O
may	O
lead	O
to	O
an	O
underestimation	O
of	O
human	B
impacts	O
on	O
wildlife	O
communities	O
,	O
with	O
the	O
number	O
of	O
trophic	O
links	O
affected	O
by	O
a	O
factor	O
of	O
two	O
.	O

6	O
.	O

This	O
study	O
underlines	O
the	O
importance	O
of	O
integrative	O
efforts	O
between	O
the	O
development	O
of	O
food	O
web	O
theory	O
and	O
basic	O
field	O
work	O
approaches	O
in	O
the	O
quantification	O
of	O
the	O
structure	O
of	O
interaction	O
networks	O
to	O
sustain	O
natural	O
ecosystems	O
in	O
a	O
changing	O
world	O
.	O

Activation	O
of	O
the	O
SoxR	O
regulon	O
in	O
Streptomyces	B
coelicolor	I
by	O
the	O
extracellular	O
form	O
of	O
the	O
pigmented	O
antibiotic	O
actinorhodin	O
.	O

The	O
redox	O
-	O
sensitive	O
transcription	O
factor	O
SoxR	O
in	O
enteric	O
bacteria	O
senses	O
and	O
regulates	O
the	O
cellular	O
response	O
to	O
superoxide	O
and	O
nitric	O
oxide	O
.	O

In	O
other	O
bacterial	O
groups	O
,	O
however	O
,	O
it	O
may	O
respond	O
to	O
redox	O
-	O
active	O
small	O
molecules	O
,	O
as	O
demonstrated	O
for	O
pyocyanin	O
sensing	O
in	O
pseudomonads	O
.	O

The	O
antibiotic	O
-	O
producing	O
soil	O
bacterium	O
Streptomyces	B
coelicolor	I
contains	O
a	O
gene	O
for	O
an	O
SoxR	O
homologue	O
(	O
SCO1697	O
)	O
whose	O
DNA	O
recognition	O
helix	O
is	O
identical	O
to	O
that	O
of	O
Escherichia	B
coli	I
SoxR.	O
Using	O
the	O
E.	B
coli	I
SoxR	O
binding	O
sequence	O
,	O
we	O
predicted	O
five	O
candidate	O
genes	O
of	O
the	O
SoxR	O
regulon	O
and	O
demonstrated	O
that	O
SoxR	O
binds	O
to	O
their	O
promoter	O
regions	O
and	O
activates	O
their	O
expression	O
concurrently	O
with	O
the	O
production	O
of	O
the	O
blue	O
antibiotic	O
actinorhodin	O
(	O
a	O
benzoisochromanequinone	O
)	O
.	O

These	O
genes	O
encode	O
a	O
probable	O
NADPH	O
-	O
dependent	O
flavin	O
reductase	O
(	O
SCO2478	O
)	O
,	O
an	O
NADPH	O
-	O
dependent	O
quinone	O
reductase	O
(	O
SCO4266	O
)	O
,	O
an	O
ABC	O
transporter	O
(	O
SCO7008	O
)	O
,	O
a	O
monooxygenase	O
(	O
SCO1909	O
)	O
,	O
and	O
a	O
hypothetical	O
protein	O
(	O
SCO1178	O
)	O
.	O

Addition	O
of	O
actinorhodin	O
to	O
exponentially	O
growing	O
cells	O
activated	O
the	O
expression	O
of	O
SoxR	O
target	O
genes	O
in	O
an	O
SoxR	O
-	O
dependent	O
manner	O
.	O

The	O
secreted	O
gamma	O
-	O
actinorhodin	O
was	O
over	O
10-fold	O
more	O
effective	O
in	O
activation	O
than	O
the	O
intracellular	O
form	O
of	O
actinorhodin	O
,	O
suggesting	O
that	O
SoxR	O
is	O
specified	O
to	O
respond	O
more	O
to	O
exogenous	O
signals	O
than	O
to	O
intracellular	O
metabolites	O
.	O

The	O
DeltasoxR	O
mutant	O
was	O
not	O
compromised	O
in	O
resistance	O
against	O
oxidants	O
but	O
was	O
slow	O
in	O
forming	O
aerial	O
mycelium	O
on	O
R2YE	O
medium	O
with	O
reduced	O
sporulation	O
,	O
and	O
its	O
production	O
of	O
actinorhodin	O
and	O
undecylprodigiosin	O
was	O
lowered	O
by	O
about	O
50	O
%	O
and	O
30	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
that	O
of	O
the	O
wild	O
type	O
.	O

These	O
results	O
support	O
the	O
proposal	O
that	O
SoxR	O
senses	O
redox	O
-	O
active	O
molecules	O
,	O
such	O
as	O
actinorhodin	O
in	O
S.	B
coelicolor	I
,	O
and	O
induces	O
a	O
protective	O
function	O
against	O
them	O
.	O

It	O
also	O
functions	O
to	O
ensure	O
that	O
cells	O
undergo	O
optimal	O
differentiation	O
and	O
secondary	O
metabolite	O
production	O
.	O

Aerobic	O
degradation	O
of	O
mercaptosuccinate	O
by	O
the	O
gram	O
-	O
negative	O
bacterium	O
Variovorax	B
paradoxus	I
strain	O
B4	O
.	O

The	O
Gram	O
-	O
negative	O
bacterium	O
Variovorax	B
paradoxus	I
strain	O
B4	O
was	O
isolated	O
from	O
soil	O
under	O
mesophilic	O
and	O
aerobic	O
conditions	O
to	O
elucidate	O
the	O
so	O
far	O
unknown	O
catabolism	O
of	O
mercaptosuccinate	O
(	O
MS	O
)	O
.	O

During	O
growth	O
with	O
MS	O
this	O
strain	O
released	O
significant	O
amounts	O
of	O
sulfate	O
into	O
the	O
medium	O
.	O

Tn5::mob	O
-	O
induced	O
mutagenesis	O
was	O
successfully	O
employed	O
and	O
yielded	O
nine	O
independent	O
mutants	O
incapable	O
of	O
using	O
MS	O
as	O
a	O
carbon	O
source	O
.	O

In	O
six	O
of	O
these	O
mutants	O
,	O
Tn5::mob	O
insertions	O
were	O
mapped	O
in	O
a	O
putative	O
gene	O
encoding	O
a	O
molybdenum	O
(	O
Mo	O
)	O
cofactor	O
biosynthesis	O
protein	O
(	O
moeA	O
)	O
.	O

In	O
two	O
further	O
mutants	O
the	O
Tn5::mob	O
insertion	O
was	O
mapped	O
in	O
the	O
gene	O
coding	O
for	O
a	O
putative	O
molybdopterin	O
(	O
MPT	O
)	O
oxidoreductase	O
.	O

In	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
these	O
eight	O
mutants	O
also	O
showed	O
no	O
growth	O
on	O
taurine	O
.	O

In	O
another	O
mutant	O
a	O
gene	O
putatively	O
encoding	O
a	O
3-hydroxyacyl	O
-	O
coenzyme	O
A	O
dehydrogenase	O
(	O
paaH2	O
)	O
was	O
disrupted	O
by	O
transposon	O
insertion	O
.	O

Upon	O
subcellular	O
fractionation	O
of	O
wild	O
-	O
type	O
cells	O
cultivated	O
with	O
MS	O
as	O
sole	O
carbon	O
and	O
sulfur	O
source	O
,	O
MPT	O
oxidoreductase	O
activity	O
was	O
detected	O
in	O
only	O
the	O
cytoplasmic	O
fraction	O
.	O

Cells	O
grown	O
with	O
succinate	O
,	O
taurine	O
,	O
or	O
gluconate	O
as	O
a	O
sole	O
carbon	O
source	O
exhibited	O
no	O
activity	O
or	O
much	O
lower	O
activity	O
.	O

MPT	O
oxidoreductase	O
activity	O
in	O
the	O
cytoplasmic	O
fraction	O
of	O
the	O
Tn5::mob	O
-	O
induced	O
mutant	O
Icr6	O
was	O
3-fold	O
lower	O
in	O
comparison	O
to	O
the	O
wild	O
type	O
.	O

Therefore	O
,	O
a	O
new	O
pathway	O
for	O
MS	O
catabolism	O
in	O
V.	B
paradoxus	I
strain	O
B4	O
is	O
proposed	O
:	O
(	O
i	O
)	O
MPT	O
oxidoreductase	O
catalyzes	O
the	O
conversion	O
of	O
MS	O
first	O
into	O
sulfinosuccinate	O
(	O
a	O
putative	O
organo	O
-	O
sulfur	O
compound	O
composed	O
of	O
succinate	O
and	O
a	O
sulfino	O
group	O
)	O
and	O
then	O
into	O
sulfosuccinate	O
by	O
successive	O
transfer	O
of	O
oxygen	O
atoms	O
,	O
(	O
ii	O
)	O
sulfosuccinate	O
is	O
cleaved	O
into	O
oxaloacetate	O
and	O
sulfite	O
,	O
and	O
(	O
iii	O
)	O
sulfite	O
is	O
oxidized	O
to	O
sulfate	O
.	O

